PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Jessen, C; Kress, JKC; Baluapuri, A; Hufnagel, A; Schmitz, W; Kneitz, S; Roth, S; Marquardt, A; Appenzeller, S; Ade, CP; Glutsch, V; Wobser, M; Friedmann-Angeli, JP; Mosteo, L; Goding, CR; Schilling, B; Geissinger, E; Wolf, E; Meierjohann, S				Jessen, Christina; Kress, Julia K. C.; Baluapuri, Apoorva; Hufnagel, Anita; Schmitz, Werner; Kneitz, Susanne; Roth, Sabine; Marquardt, Andre; Appenzeller, Silke; Ade, Carsten P.; Glutsch, Valerie; Wobser, Marion; Friedmann-Angeli, Jose Pedro; Mosteo, Laura; Goding, Colin R.; Schilling, Bastian; Geissinger, Eva; Wolf, Elmar; Meierjohann, Svenja			The transcription factor NRF2 enhances melanoma malignancy by blocking differentiation and inducing COX2 expression	ONCOGENE			English	Article							OXIDATIVE STRESS; INFLAMMATION; CANCER; MELANOCYTES; RESISTANCE; PATHWAY; GENE; SENESCENCE; MUTATIONS; PHENOTYPE	The transcription factor NRF2 is the major mediator of oxidative stress responses and is closely connected to therapy resistance in tumors harboring activating mutations in the NRF2 pathway. In melanoma, such mutations are rare, and it is unclear to what extent melanomas rely on NRF2. Here we show that NRF2 suppresses the activity of the melanocyte lineage marker MITF in melanoma, thereby reducing the expression of pigmentation markers. Intriguingly, we furthermore identified NRF2 as key regulator of immune-modulating genes, linking oxidative stress with the induction of cyclooxygenase 2 (COX2) in an ATF4-dependent manner. COX2 is critical for the secretion of prostaglandin E2 and was strongly induced by H(2)O(2)or TNF alpha only in presence of NRF2. Induction of MITF and depletion of COX2 and PGE2 were also observed in NRF2-deleted melanoma cells in vivo. Furthermore, genes corresponding to the innate immune response such asRSAD2andIFIH1were strongly elevated in absence of NRF2 and coincided with immune evasion parameters in human melanoma datasets. Even in vitro, NRF2 activation or prostaglandin E2 supplementation blunted the induction of the innate immune response in melanoma cells. Transcriptome analyses from lung adenocarcinomas indicate that the observed link between NRF2 and the innate immune response is not restricted to melanoma.	[Jessen, Christina; Kress, Julia K. C.; Hufnagel, Anita; Kneitz, Susanne; Meierjohann, Svenja] Univ Wurzburg, Dept Physiol Chem, Wurzburg, Germany; [Jessen, Christina; Kress, Julia K. C.; Hufnagel, Anita; Roth, Sabine; Marquardt, Andre; Geissinger, Eva; Meierjohann, Svenja] Univ Wurzburg, Inst Pathol, Wurzburg, Germany; [Baluapuri, Apoorva; Schmitz, Werner; Ade, Carsten P.; Wolf, Elmar] Univ Wurzburg, Dept Biochem & Mol Biol, Wurzburg, Germany; [Marquardt, Andre; Appenzeller, Silke; Schilling, Bastian; Geissinger, Eva; Meierjohann, Svenja] Univ Wurzburg, Comprehens Canc Ctr Mainfranken, Wurzburg, Germany; [Glutsch, Valerie; Wobser, Marion; Schilling, Bastian] Univ Hosp Wurzburg, Dept Dermatol Venereol & Allergol, Wurzburg, Germany; [Glutsch, Valerie; Wobser, Marion; Schilling, Bastian] Univ Hosp Wurzburg, Skin Canc Ctr, Wurzburg, Germany; [Friedmann-Angeli, Jose Pedro] Univ Wurzburg, Rudolf Virchow Ctr Integrat & Translat Bioimaging, Wurzburg, Germany; [Mosteo, Laura; Goding, Colin R.] Univ Oxford, Nuffield Dept Med, Ludwig Inst Canc Res, Oxford, England	University of Wurzburg; University of Wurzburg; University of Wurzburg; University of Wurzburg; University of Wurzburg; University of Wurzburg; University of Wurzburg; Ludwig Institute for Cancer Research; University of Oxford	Meierjohann, S (corresponding author), Univ Wurzburg, Dept Physiol Chem, Wurzburg, Germany.; Meierjohann, S (corresponding author), Univ Wurzburg, Inst Pathol, Wurzburg, Germany.; Meierjohann, S (corresponding author), Univ Wurzburg, Comprehens Canc Ctr Mainfranken, Wurzburg, Germany.	svenja.meierjohann@uni-wuerzburg.de	Wolf, Elmar/AAY-8493-2021; Schilling, Bastian/AAY-8646-2020; Marquardt, André/AAY-8844-2021; Baluapuri, Apoorva/AAF-4624-2020	Wolf, Elmar/0000-0002-5299-6335; Schilling, Bastian/0000-0001-8859-4103; Baluapuri, Apoorva/0000-0002-3723-7891; Marquardt, Andre/0000-0002-2425-7033; Ade, Carsten/0000-0001-7226-1179; Mosteo, Laura/0000-0002-4410-2370; Appenzeller, Silke/0000-0002-5472-8692; Schmitz, Werner/0000-0003-0485-7303	German Research Foundation [ME1899/4-1, ME1899/6-1, FR3746/3-1]; Interdisciplinary Center for Clinical Research, IZKF, University Hospital Wurzburg [Z-14]	German Research Foundation(German Research Foundation (DFG)); Interdisciplinary Center for Clinical Research, IZKF, University Hospital Wurzburg	This work was supported by the research grants ME1899/4-1 and ME1899/6-1 (German Research Foundation), as well as project Z-14 (Central Unit for Personalized Oncology) (Interdisciplinary Center for Clinical Research, IZKF, University Hospital Wurzburg). JPFA receives funding from FR3746/3-1 (German Research Foundation). We are furthermore grateful to Harald Wajant (Dept. of Molecular Internal Medicine, University Hospital Wurzburg) for providing TNF alpha. Where indicated, some results are based upon data generated by the TCGA Research Network.	Aguilera TA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13898; Appenzeller S, 2019, CANCER-AM CANCER SOC, V125, P586, DOI 10.1002/cncr.31843; Bottcher JP, 2018, CELL, V172, P1022, DOI 10.1016/j.cell.2018.01.004; Chang YL, 2015, J INVEST DERMATOL, V135, P807, DOI 10.1038/jid.2014.385; Corazzari M, 2015, CELL DEATH DIFFER, V22, P946, DOI 10.1038/cdd.2014.183; Corrales L, 2016, J CLIN INVEST, V126, P2404, DOI 10.1172/JCI86892; Cotter MA, 2007, CLIN CANCER RES, V13, P5952, DOI 10.1158/1078-0432.CCR-07-1187; COULIE PG, 1994, J EXP MED, V180, P35, DOI 10.1084/jem.180.1.35; Cristescu R, 2018, SCIENCE, V362, P197, DOI 10.1126/science.aar3593; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; de la Vega MR, 2018, CANCER CELL, V34, P21, DOI 10.1016/j.ccell.2018.03.022; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; DeNicola GM, 2015, NAT GENET, V47, P1475, DOI 10.1038/ng.3421; Dong ZY, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1356145; Falahat R, 2019, CANCER IMMUNOL RES, V7, P1837, DOI 10.1158/2326-6066.CIR-19-0229; Falletta P, 2017, GENE DEV, V31, P18, DOI 10.1101/gad.290940.116; Fassler M, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0523-2; Ferguson J, 2017, ONCOTARGET, V8, P32946, DOI 10.18632/oncotarget.16514; Frank R, 2018, CLIN CANCER RES, V24, P3087, DOI 10.1158/1078-0432.CCR-17-3416; Gunderstofte C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02101; Hintsala HR, 2016, ANTICANCER RES, V36, P1497; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Konno H, 2018, CELL REP, V23, P1112, DOI 10.1016/j.celrep.2018.03.115; Landsberg J, 2012, NATURE, V490, P412, DOI 10.1038/nature11538; Leikam C, 2014, ONCOGENE, V33, P771, DOI 10.1038/onc.2012.641; Leikam C, 2008, ONCOGENE, V27, P7070, DOI 10.1038/onc.2008.323; Li TW, 2017, CANCER RES, V77, pE108, DOI 10.1158/0008-5472.CAN-17-0307; Lokaj K, 2009, J PROTEOME RES, V8, P1818, DOI 10.1021/pr800578a; Markosyan N, 2019, J CLIN INVEST, V129, P3594, DOI 10.1172/JCI127755; Marloye M, 2019, PHARM PAT ANAL, V8, P87, DOI 10.4155/ppa-2019-0013; Meierjohann S, 2014, EUR J CELL BIOL, V93, P36, DOI 10.1016/j.ejcb.2013.11.005; Mitra D, 2012, NATURE, V491, P449, DOI 10.1038/nature11624; Muller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6712; Olagnier D, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05861-7; Park SH, 2018, FASEB J; Qu XL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00563; Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006; Riesenberg S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9755; Sander CS, 2004, INT J DERMATOL, V43, P326, DOI 10.1111/j.1365-4632.2004.02222.x; Schepsky A, 2006, MOL CELL BIOL, V26, P8914, DOI 10.1128/MCB.02299-05; Schmitt A, 2015, BIOCHEM J, V471, P267, DOI 10.1042/BJ20141204; Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420; Subbarayan V, 2001, CANCER RES, V61, P2720; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Tsoi J, 2018, CANCER CELL, V33, P890, DOI 10.1016/j.ccell.2018.03.017; Vivas-Garcia Y, 2020, MOL CELL, V77, P120, DOI 10.1016/j.molcel.2019.10.014; Widmer DS, 2013, J INVEST DERMATOL, V133, P2436, DOI 10.1038/jid.2013.115; Wiemer AJ, 2011, J IMMUNOL, V187, P3663, DOI 10.4049/jimmunol.1100103; Xia TL, 2016, CANCER RES, V76, P6747, DOI 10.1158/0008-5472.CAN-16-1404; Zelenay S, 2015, CELL, V162, P1257, DOI 10.1016/j.cell.2015.08.015; Zhu B, 2018, ONCOGENE, V37, P4941, DOI 10.1038/s41388-018-0314-0	52	33	33	2	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2020	39	44					6841	6855		10.1038/s41388-020-01477-8	http://dx.doi.org/10.1038/s41388-020-01477-8		SEP 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OH9QS	32978520	Green Published, Green Submitted, hybrid			2022-12-28	WOS:000572714000003
J	Wang, J; Wang, GW; Cheng, DM; Huang, S; Chang, AT; Tan, XM; Wang, Q; Zhao, SR; Wu, D; Liu, AT; Yang, S; Xiang, R; Sun, PQ				Wang, Juan; Wang, Guanwen; Cheng, Dongmei; Huang, Shan; Chang, Antao; Tan, Xiaoming; Wang, Qiong; Zhao, Shaorong; Wu, Dan; Liu, Andy T.; Yang, Shuang; Xiang, Rong; Sun, Peiqing			Her2 promotes early dissemination of breast cancer by suppressing the p38-MK2-Hsp27 pathway that is targetable by Wip1 inhibition	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR-SUPPRESSOR; CELL-ADHESION; E-CADHERIN; PHOSPHATASE; HSP27; GROWTH; METASTASIS; EXPRESSION	Cancer can metastasize from early lesions without detectable tumors. Despite extensive studies on metastasis in cancer cells from patients with detectable primary tumors, mechanisms for early metastatic dissemination are poorly understood. Her2 promotes breast cancer early dissemination by inhibiting p38, but the downstream pathway in this process was unknown. Using early lesion breast cancer models, we demonstrate that the effect of p38 suppression by Her2 on early dissemination is mediated by MK2 and heat shock protein 27 (Hsp27). The early disseminating cells in the MMTV-Her2 breast cancer model are Her2(high)p-p38(low)p-MK2(low)p-Hsp27(low), which also exist in human breast carcinoma tissues. Suppression of p38 and MK2 by Her2 reduces MK2-mediated Hsp27 phosphorylation, and unphosphorylated Hsp27 binds to beta-catenin and enhances its phosphorylation by Src, leading to beta-catenin activation and disseminating phenotypes in early lesion breast cancer cells. Pharmacological inhibition of MK2 promotes, while inhibition of a p38 phosphatase Wip1 suppresses, early dissemination in vivo. These findings identify Her2-mediated suppression of the p38-MK2-Hsp27 pathway as a novel mechanism for cancer early dissemination, and provide a basis for new therapies targeting early metastatic dissemination in Her2(+)breast cancer.	[Wang, Juan; Wang, Guanwen; Huang, Shan; Chang, Antao; Wang, Qiong; Zhao, Shaorong; Yang, Shuang; Xiang, Rong] Nankai Univ, Sch Med, Dept Immunol, Tianjin, Peoples R China; [Wang, Juan; Wang, Guanwen; Cheng, Dongmei; Huang, Shan; Chang, Antao; Tan, Xiaoming; Wu, Dan; Liu, Andy T.; Sun, Peiqing] Wake Forest Baptist Med Ctr, Dept Canc Biol, Winston Salem, NC 27006 USA; [Wang, Juan; Wang, Guanwen; Cheng, Dongmei; Huang, Shan; Chang, Antao; Tan, Xiaoming; Wu, Dan; Liu, Andy T.; Sun, Peiqing] Wake Forest Baptist Med Ctr, Comprehens Canc Ctr, Winston Salem, NC 27006 USA; [Tan, Xiaoming] Shanghai Jiao Tong Univ, Renji Hosp, Dept Resp Dis, Sch Med, South Campus, Shanghai, Peoples R China; [Liu, Andy T.] Univ N Carolina, Chapel Hill, NC 27515 USA	Nankai University; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Shanghai Jiao Tong University; University of North Carolina; University of North Carolina Chapel Hill	Xiang, R (corresponding author), Nankai Univ, Sch Med, Dept Immunol, Tianjin, Peoples R China.; Sun, PQ (corresponding author), Wake Forest Baptist Med Ctr, Dept Canc Biol, Winston Salem, NC 27006 USA.; Sun, PQ (corresponding author), Wake Forest Baptist Med Ctr, Comprehens Canc Ctr, Winston Salem, NC 27006 USA.	rxiang@nankai.edu.cn; psun@wakehealth.edu		Liu, Andy/0000-0002-9268-4272	NIH/NCI [CA131231, CA172115]; Bilateral Inter-Governmental S&T Cooperation Project grants from Ministry of Science and Technology of China [81972882, 2018YFE0114300]; Cell Engineering and Tumor Tissue and Pathology Shared Resources of WFBCCC - NCI's Cancer Center Support Grant [P30CA012197]; Anderson Oncology Research Professorship	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Bilateral Inter-Governmental S&T Cooperation Project grants from Ministry of Science and Technology of China; Cell Engineering and Tumor Tissue and Pathology Shared Resources of WFBCCC - NCI's Cancer Center Support Grant; Anderson Oncology Research Professorship	This study was supported by NIH/NCI grants CA131231, CA172115 (PS) and Bilateral Inter-Governmental S&T Cooperation Project grants from Ministry of Science and Technology of China (81972882 and 2018YFE0114300, RX), and by Cell Engineering and Tumor Tissue and Pathology Shared Resources of WFBCCC, supported by NCI's Cancer Center Support Grant (P30CA012197). PS is supported by the Anderson Oncology Research Professorship.	Brembeck FH, 2006, CURR OPIN GENET DEV, V16, P51, DOI 10.1016/j.gde.2005.12.007; Cardiff RD, 2001, MICROSC RES TECHNIQ, V52, P224, DOI 10.1002/1097-0029(20010115)52:2<224::AID-JEMT1007>3.3.CO;2-1; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen Z, 2016, SCI REP, P6; Collins NL, 2005, MOL CELL BIOL, V25, P5282, DOI 10.1128/MCB.25.12.5282-5291.2005; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; Cordonnier T, 2015, INT J CANCER, V136, pE496, DOI 10.1002/ijc.29122; Demidov ON, 2007, ONCOGENE, V26, P2502, DOI 10.1038/sj.onc.1210032; Di KJ, 2007, EXP CELL RES, V313, P3983, DOI 10.1016/j.yexcr.2007.08.023; Dietlein F, 2015, CELL, V162, P146, DOI 10.1016/j.cell.2015.05.053; ENGEL K, 1995, J BIOL CHEM, V270, P27213, DOI 10.1074/jbc.270.45.27213; Esfandiari A, 2016, MOL CANCER THER, V15, P379, DOI 10.1158/1535-7163.MCT-15-0651; Eyles J, 2010, J CLIN INVEST, V120, P2030, DOI 10.1172/JCI42002; Fry EA, 2017, INT J CANCER, V140, P495, DOI 10.1002/ijc.30399; Gavert N, 2007, J CELL BIOCHEM, V102, P820, DOI 10.1002/jcb.21505; Gilmartin AG, 2014, NAT CHEM BIOL, V10, P181, DOI [10.1038/nchembio.1427, 10.1038/NCHEMBIO.1427]; Goloudina AR, 2016, ONCOTARGET, V7, P31563, DOI 10.18632/oncotarget.7325; Greco FA, 2009, SEMIN ONCOL, V36, P6, DOI 10.1053/j.seminoncol.2008.10.007; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Haeger A, 2015, TRENDS CELL BIOL, V25, P556, DOI 10.1016/j.tcb.2015.06.003; Hajra KM, 2002, CANCER RES, V62, P1613; Han JH, 2007, TRENDS BIOCHEM SCI, V32, P364, DOI 10.1016/j.tibs.2007.06.007; Han YC, 2017, ONCOL REP, V38, P3574, DOI 10.3892/or.2017.6017; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harper KL, 2016, NATURE, V540, P588, DOI 10.1038/nature20609; Huang S, 2000, J BIOL CHEM, V275, P12266, DOI 10.1074/jbc.275.16.12266; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Katsogiannou M, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00346; Koniali Lola, 2020, Oncotarget, V11, P650, DOI 10.18632/oncotarget.27453; Lee JS, 2014, J DERMATOL SCI, V73, P125, DOI 10.1016/j.jdermsci.2013.09.003; Lee JW, 2008, EUR J CELL BIOL, V87, P377, DOI 10.1016/j.ejcb.2008.03.006; Liu Y, 2018, NAT COMMUN, P9; Lu XB, 2008, CANCER METAST REV, V27, P123, DOI 10.1007/s10555-008-9127-x; Malladi S, 2016, CELL, V165, P45, DOI 10.1016/j.cell.2016.02.025; Matsushima-Nishiwaki R, 2008, J BIOL CHEM, V283, P18852, DOI 10.1074/jbc.M801301200; Montero L, 1999, CANCER RES, V59, P5286; Mourey RJ, 2010, J PHARMACOL EXP THER, V333, P797, DOI 10.1124/jpet.110.166173; Neviere Z, 2020, THER ADV MED ONCOL, V12, DOI 10.1177/1758835919897530; Orsulic S, 1999, J CELL SCI, V112, P1237; Pantel K, 2008, NAT REV CANCER, V8, P329, DOI 10.1038/nrc2375; Paul C, 2002, MOL CELL BIOL, V22, P816, DOI 10.1128/MCB.22.3.816-834.2002; Pechackova S, 2016, ONCOTARGET, V7, P14458, DOI 10.18632/oncotarget.7363; Polakis P, 2000, GENE DEV, V14, P1837; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Rocchi P, 2006, BJU INT, V98, P1082, DOI 10.1111/j.1464-410X.2006.06425.x; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Sanchez-Tillo E, 2011, P NATL ACAD SCI USA, V108, P19204, DOI 10.1073/pnas.1108977108; Shi Y, 2002, BIOL CHEM, V383, P1519, DOI 10.1515/BC.2002.173; Shiota M, 2013, CANCER RES, V73, P3109, DOI 10.1158/0008-5472.CAN-12-3979; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Taneja P, 2010, CANCER RES, V70, P9084, DOI 10.1158/0008-5472.CAN-10-0159; Tian L, 2019, LIFE SCI, V239, DOI 10.1016/j.lfs.2019.117035; Wang SZE, 2007, J BIOL CHEM, V282, P5661, DOI 10.1074/jbc.M608499200; Xu L, 2006, ONCOGENE, V25, P2987, DOI 10.1038/sj.onc.1209337; Yamaguchi H, 2006, BIOCHEMISTRY-US, V45, P13193, DOI 10.1021/bi061356b; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257	58	4	4	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2020	39	40					6313	6326		10.1038/s41388-020-01437-2	http://dx.doi.org/10.1038/s41388-020-01437-2		AUG 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NV5JK	32848211	Green Accepted			2022-12-28	WOS:000563171800001
J	Chervo, MF; Russo, RIC; Petrillo, E; Izzo, F; De Martino, M; Bellora, N; Cenciarini, ME; Chiauzzi, VA; de la Parra, LS; Pereyra, MG; Guttlein, LN; Podhajcer, OL; Daniotti, JL; Dupont, A; Barchuk, S; Figurelli, S; Della Vecchia, DL; Roa, JC; Guzman, P; Proietti, CJ; Schillaci, R; Elizalde, PV				Chervo, Maria F.; Cordo Russo, Rosalia I.; Petrillo, Ezequiel; Izzo, Franco; De Martino, Mara; Bellora, Nicolas; Cenciarini, Mauro E.; Chiauzzi, Violeta A.; santa Maria de la Parra, Lucia; Pereyra, Matias G.; Guttlein, Leandro N.; Podhajcer, Osvaldo L.; Daniotti, Jose L.; Dupont, Agustina; Barchuk, Sabrina; Figurelli, Silvina; Lopez Della Vecchia, Daniel; Roa, Juan C.; Guzman, Pablo; Proietti, Cecilia J.; Schillaci, Roxana; Elizalde, Patricia V.			Canonical ErbB-2 isoform and ErbB-2 variant c located in the nucleus drive triple negative breast cancer growth	ONCOGENE			English	Article							PROGESTERONE-RECEPTOR; SPLICE VARIANT; EGF RECEPTOR; JUXTAMEMBRANE REGION; DOWN-REGULATION; BASAL-LIKE; HER2; ACTIVATION; EXPRESSION; DOMAIN	Triple negative breast cancer (TNBC) refers to tumors that do not express clinically significant levels of estrogen and progesterone receptors, and lack membrane overexpression or gene amplification of ErbB-2/HER2, a receptor tyrosine kinase. Transcriptome and proteome heterogeneity of TNBC poses a major challenge to precision medicine. Clinical biomarkers and targeted therapies for this disease remain elusive, so chemotherapy has been the standard of care for early and metastatic TNBC. Our present findings placed ErbB-2 in an unanticipated scenario: the nucleus of TNBC (NErbB-2). Our study on ErbB-2 alternative splicing events, using a PCR-sequencing approach combined with an RNA interference strategy, revealed that TNBC cells express either the canonical (wild-type) ErbB-2, encoded by transcript variant 1, or the non-canonical ErbB-2 isoform c, encoded by alternative variant 3 (RefSeq), or both. These ErbB-2 isoforms function in the nucleus as transcription factors. Evicting both from the nucleus or silencing isoform c only, blocks TN cell and tumor growth. This reveals not only NErbB-2 canonical and alternative isoforms role as targets of therapy in TNBC, but also isoform c dominant oncogenic potential. Furthermore, we validated our findings in the clinic and observed that NErbB-2 correlates with poor prognosis in primary TN tumors, disclosing NErbB-2 as a novel biomarker for TNBC. Our discoveries challenge the present scenario of drug development for personalized BC medicine that focuses on wild-type RefSeq proteins, which conserve the canonical domains and are located in their classical cellular compartments.	[Chervo, Maria F.; Cordo Russo, Rosalia I.; Izzo, Franco; De Martino, Mara; Cenciarini, Mauro E.; Chiauzzi, Violeta A.; santa Maria de la Parra, Lucia; Pereyra, Matias G.; Proietti, Cecilia J.; Schillaci, Roxana; Elizalde, Patricia V.] Consejo Nacl Invest Cient & Tecn, Inst Biol & Med Expt IBYME, Lab Mol Mech Carcinogenesis & Mol Endocrinol, Vuelta Obligado 2490,C1428ADN, Buenos Aires, DF, Argentina; [Petrillo, Ezequiel] Univ Buenos Aires UBA, Fac Ciencias Exactas & Nat, Dept Fisiol Biol Mol & Celular, C1428EHA, Buenos Aires, DF, Argentina; [Petrillo, Ezequiel] CONICET UBA, Inst Fisiol Biol Mol & Neurociencias IFIBYNE, C1428EHA, Buenos Aires, DF, Argentina; [Bellora, Nicolas] CONICET UNComahue, Inst Andinopatagon Tecnol Biol & Geoambientales I, Lab Microbiol Aplicada Biotecnol & Bioinformat Le, Quintral 1250, RA-8400 San Carlos De Bariloche, Rio Negro, Argentina; [Guttlein, Leandro N.; Podhajcer, Osvaldo L.] Consejo Nacl Invest Cient & Tecn, Leloir Inst, Lab Mol & Cellular Therapy, Ave Patricias Argentinas 435,C1405BWE, Buenos Aires, DF, Argentina; [Daniotti, Jose L.] Consejo Nacl Invest Cient & Tecn, CIQUIBIC, Ctr Invest Quim Biol Cordoba, Ciudad Univ,X5000HUA, Cordoba, Argentina; [Daniotti, Jose L.] Univ Nacl Cordoba, Fac Ciencias Quim, Dept Quim Biol Ranwel Caputto, Ciudad Univ,X5000HUA, Cordoba, Argentina; [Dupont, Agustina; Barchuk, Sabrina; Figurelli, Silvina; Lopez Della Vecchia, Daniel] Hosp Gen Agudos Juan A Fernandez, Unidad Patol Mamaria, C1425AGP, Buenos Aires, DF, Argentina; [Roa, Juan C.; Guzman, Pablo] Univ La Frontera, Dept Anat Patol BIOREN, Casilla 54-D, Temuco, Chile; [Roa, Juan C.] Pontificia Univ Catolica Chile, Sch Med, Dept Pathol, Santiago 8330024, Chile; [Roa, Juan C.] Pontificia Univ Catolica Chile, Adv Ctr Chron Dis ACCDIS, Santiago, Chile	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Institute of Biology & Experimental Medicine; University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Universidad Nacional del Comahue; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Leloir Institute; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Cordoba; University of Buenos Aires; Universidad de La Frontera; Pontificia Universidad Catolica de Chile; Pontificia Universidad Catolica de Chile	Elizalde, PV (corresponding author), Consejo Nacl Invest Cient & Tecn, Inst Biol & Med Expt IBYME, Lab Mol Mech Carcinogenesis & Mol Endocrinol, Vuelta Obligado 2490,C1428ADN, Buenos Aires, DF, Argentina.	patriciaelizalde@ibyme.conicet.gov.ar	Roa, Juan C./K-4749-2014; Russo, Rosalia Cordo/O-9149-2017; Bellora, Nicolas/E-6356-2014	Roa, Juan C./0000-0001-8313-8774; Russo, Rosalia Cordo/0000-0002-5984-9717; Santa Maria de la Parra, Lucia/0000-0002-4577-139X; De Martino, Mara/0000-0002-3049-6495; Bellora, Nicolas/0000-0001-6637-3465; Izzo, Franco/0000-0002-5813-6504; Chervo, Maria Florencia/0000-0001-8878-5591	National Agency of Scientific Promotion of Argentina [IDB/PICT 2012-668, PID 2012-066, PICT 2015-1587, PICT 2017-1072]; INC 2016 research grant from Nat. Cancer Institute of Argentina; Fondation Nelia et Amadeo Barletta Research Grant; Foundation Alberto J. Roemmers Research Grant	National Agency of Scientific Promotion of Argentina(ANPCyT); INC 2016 research grant from Nat. Cancer Institute of Argentina; Fondation Nelia et Amadeo Barletta Research Grant; Foundation Alberto J. Roemmers Research Grant	In memory of EH Charreau, our colleague and dear friend. We thank A Molinolo (UCSD, USA) and E Gil Deza (Instituto Oncologico Henry Moore, Argentina) for their advice. This work was supported by IDB/PICT 2012-668, PID 2012-066, PICT 2015-1587, PICT 2017-1072 from the National Agency of Scientific Promotion of Argentina, INC 2016 research grant from Nat. Cancer Institute of Argentina, and Fondation Nelia et Amadeo Barletta Research Grant, all awarded to PVE, and Foundation Alberto J. Roemmers Research Grant awarded to PVE and RICR.	Al-Ejeh F, 2014, ONCOTARGET, V5, P3145, DOI 10.18632/oncotarget.1865; Alajati A, 2013, CANCER RES, V73, P5320, DOI 10.1158/0008-5472.CAN-12-3186; Anido J, 2006, EMBO J, V25, P3234, DOI 10.1038/sj.emboj.7601191; Beguelin W, 2010, MOL CELL BIOL, V30, P5456, DOI 10.1128/MCB.00012-10; Brand TM, 2014, MOL CANCER THER, V13, P1356, DOI 10.1158/1535-7163.MCT-13-1021; Burstein MD, 2015, CLIN CANCER RES, V21, P1688, DOI 10.1158/1078-0432.CCR-14-0432; Castagnoli L, 2017, ONCOGENE, V36, P1721, DOI 10.1038/onc.2016.338; Castiglioni F, 2006, ENDOCR-RELAT CANCER, V13, P221, DOI 10.1677/erc.1.01047; Contessa JN, 2008, CANCER RES, V68, P3803, DOI 10.1158/0008-5472.CAN-07-6389; Russo RIC, 2015, ONCOGENE, V34, P3413, DOI 10.1038/onc.2014.272; Daemen A, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-0933-y; Flaque MCD, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3587; Flaque MCD, 2013, STEROIDS, V78, P559, DOI 10.1016/j.steroids.2012.11.003; Duarte HO, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112262; Elizalde PV, 2016, ENDOCR-RELAT CANCER, V23, pT243, DOI 10.1530/ERC-16-0360; Ferreira IG, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020580; Frei AP, 2012, NAT BIOTECHNOL, V30, P997, DOI 10.1038/nbt.2354; Garrido-Castro AC, 2019, CANCER DISCOV, V9, P176, DOI 10.1158/2159-8290.CD-18-1177; Gautrey H, 2015, RNA BIOL, V12, P1139, DOI 10.1080/15476286.2015.1076610; Giri DK, 2005, MOL CELL BIOL, V25, P11005, DOI 10.1128/MCB.25.24.11005-11018.2005; Grigoriadis A, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-619; Henderson IC, 1998, BREAST CANCER RES TR, V52, P261, DOI 10.1023/A:1006141703224; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Hsu YH, 2014, CANCER RES, V74, P4822, DOI 10.1158/0008-5472.CAN-14-0584; Ito K, 2016, CANCER RES, V76, P4406, DOI 10.1158/0008-5472.CAN-15-3445; Ortiz-Ruiz MJ, 2014, ONCOTARGET, V5, P11308, DOI 10.18632/oncotarget.2324; Jura N, 2011, MOL CELL, V42, P9, DOI 10.1016/j.molcel.2011.03.004; Jura N, 2009, CELL, V137, P1293, DOI 10.1016/j.cell.2009.04.025; Kelemen O, 2013, GENE, V514, P1, DOI 10.1016/j.gene.2012.07.083; Kim HM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004987; Kwong KY, 1998, MOL CARCINOGEN, V23, P62, DOI 10.1002/(SICI)1098-2744(199810)23:2<62::AID-MC2>3.0.CO;2-O; Le Du F, 2015, ONCOTARGET, V6, P12890, DOI 10.18632/oncotarget.3849; Lee CYF, 2014, CANCER RES, V74, P341, DOI 10.1158/0008-5472.CAN-13-1055; Lehmann BD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157368; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Li LY, 2011, CANCER RES, V71, P4269, DOI 10.1158/0008-5472.CAN-10-3504; Li X, 2012, J BIOL CHEM, V287, P83; LIN YZJ, 1991, ONCOGENE, V6, P639; Linggi B, 2006, ONCOGENE, V25, P160, DOI 10.1038/sj.onc.1209003; Menon R, 2014, J PROTEOME RES, V13, P212, DOI 10.1021/pr400773v; Mitra D, 2009, MOL CANCER THER, V8, P2152, DOI 10.1158/1535-7163.MCT-09-0295; Molina MA, 2002, CLIN CANCER RES, V8, P347; Paik S, 2008, NEW ENGL J MED, V358, P1409, DOI 10.1056/NEJMc0801440; Pal S, 2011, GENOME RES, V21, P1260, DOI 10.1101/gr.120535.111; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Prat A, 2013, BREAST CANCER RES TR, V142, P237, DOI 10.1007/s10549-013-2743-3; Prat A, 2013, ONCOLOGIST, V18, P123, DOI 10.1634/theoncologist.2012-0397; Proietti CJ, 2009, MOL CELL BIOL, V29, P1249, DOI 10.1128/MCB.00853-08; PUPA SM, 1993, ONCOGENE, V8, P2917; Red Brewer M, 2009, MOL CELL, V34, P641, DOI 10.1016/j.molcel.2009.04.034; Reyes A, 2018, NUCLEIC ACIDS RES, V46, P582, DOI 10.1093/nar/gkx1165; Ross JS, 2009, ONCOLOGIST, V14, P320, DOI 10.1634/theoncologist.2008-0230; Sasso Marianna, 2011, J NUCL ACIDS INVESTI, V2, pe9; Scaltriti M, 2007, J NATL CANCER I, V99, P628, DOI 10.1093/jnci/djk134; Schillaci R, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-74; Schmid P, 2018, NEW ENGL J MED, V379, P2108, DOI 10.1056/NEJMoa1809615; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Thiel KW, 2007, P NATL ACAD SCI USA, V104, P19238, DOI 10.1073/pnas.0703854104; Tilio M, 2016, CANCER LETT, V381, P76, DOI 10.1016/j.canlet.2016.07.028; Tryndyak VP, 2010, INT J CANCER, V126, P2575, DOI 10.1002/ijc.24972; Turpin J, 2016, ONCOGENE, V35, P6053, DOI 10.1038/onc.2016.129; Venturutti L, 2016, ONCOGENE, V35, P2208, DOI 10.1038/onc.2015.281; Wang SC, 2004, CANCER CELL, V6, P251, DOI 10.1016/j.ccr.2004.07.012; Warri AM, 1996, EUR J CANCER, V32A, P134, DOI 10.1016/0959-8049(95)00550-1; Watanabe M, 2013, ANAL BIOANAL CHEM, V405, P4289, DOI 10.1007/s00216-013-6771-y; Wood ER, 2008, P NATL ACAD SCI USA, V105, P2773, DOI 10.1073/pnas.0708281105; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yunokawa M, 2012, CANCER SCI, V103, P1665, DOI 10.1111/j.1349-7006.2012.02359.x; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013	70	4	4	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2020	39	39					6245	6262		10.1038/s41388-020-01430-9	http://dx.doi.org/10.1038/s41388-020-01430-9		AUG 2020	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NS8XO	32843720				2022-12-28	WOS:000562669100003
J	Zhu, YX; Li, JJ; Bo, H; He, D; Xiao, MQ; Xiang, L; Gong, L; Hu, Y; Zhang, YY; Cheng, YX; Deng, LP; Zhu, RR; Ma, YN; Cao, K				Zhu, Yuxing; Li, Jingjing; Bo, Hao; He, Dong; Xiao, Mengqing; Xiang, Liang; Gong, Lian; Hu, Yi; Zhang, Yeyu; Cheng, Yaxin; Deng, Liping; Zhu, Rongrong; Ma, Yanni; Cao, Ke			LINC00467 is up-regulated by TDG-mediated acetylation in non-small cell lung cancer and promotes tumor progression	ONCOGENE			English	Article								The long non-coding RNA (LncRNA) abnormally expresses in several cancers including non-small cell lung cancer (NSCLC). To better understand the role of key lncRNA involving cancer progress, we conduct a comprehensive data mining on LINC00467 and determine its molecular mechanisms. We identified LINC00467 was the up-regulated lncRNA that common significantly differentially expressed in NSCLC and CRC tissues from GEO database. LINC00467 highly expressed in NSCLC tissues and associated with advanced clinical stages and poor outcome. Knockdown of LINC00467 inhibited cell growth and metastasis via regulating the Akt signaling pathway. Finally, we demonstrated that TDG mediated acetylation is the key factor controlling LINC00467 expression. In conclusion, LINC00467 promotes NSCLC progression via Akt signal pathway. The identified LINC00467 may serve as a valuable diagnostic and prognostic biomarker as well as a therapeutic target for NSCLC.	[Zhu, Yuxing; Li, Jingjing; Xiao, Mengqing; Xiang, Liang; Gong, Lian; Hu, Yi; Zhang, Yeyu; Cheng, Yaxin; Deng, Liping; Zhu, Rongrong; Ma, Yanni; Cao, Ke] Cent South Univ, Dept Oncol, Xiangya Hosp 3, Changsha 410013, Peoples R China; [Li, Jingjing] Cent South Univ, Dept Plast Surg, Xiangya Hosp, Changsha 410008, Peoples R China; [Bo, Hao] Reprod & Genet Hosp CITIC Xiangya, Clin Res Ctr Reprod & Genet Hunan Prov, Changsha 410078, Peoples R China; [Bo, Hao] Cent South Univ, Key Lab Reprod & Stem Cell Engn, Natl Hlth & Family Planning Commiss, Inst Reprod & Stem Cell Engn,Basic Med Coll, Changsha 410078, Peoples R China; [He, Dong] Second Peoples Hosp Hunan Prov, Dept Resp, Chansha 410007, Peoples R China	Central South University; Central South University; Central South University; Central South University	Cao, K (corresponding author), Cent South Univ, Dept Oncol, Xiangya Hosp 3, Changsha 410013, Peoples R China.	csucaoke@163.com	Li, Jing/GYU-5036-2022	Cao, Ke/0000-0001-5392-2306	National Natural Science Foundation of China [81874137]; Outstanding Youth Foundation of Hunan Province [2018JJ1047]; Huxiang Young Talent Project [2016RS3022]; Hunan Province Science and technology talent promotion project [2019TJ-Q10]; Project of scientific research plan of health and Family Planning Commission of Hunan Province [c20180476]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Outstanding Youth Foundation of Hunan Province; Huxiang Young Talent Project; Hunan Province Science and technology talent promotion project; Project of scientific research plan of health and Family Planning Commission of Hunan Province	This work was supported by the National Natural Science Foundation of China (81874137), the Outstanding Youth Foundation of Hunan Province (2018JJ1047), the Huxiang Young Talent Project (2016RS3022). the Hunan Province Science and technology talent promotion project (2019TJ-Q10), the Project of scientific research plan of health and Family Planning Commission of Hunan Province (c20180476).	Chen J, 2019, INT J BIOL SCI, V15, P1802, DOI 10.7150/ijbs.34785; Chen TY, 2019, MOL GENET GENOM MED, V7, DOI 10.1002/mgg3.757; Chu Ci, 2012, J Vis Exp, DOI 10.3791/3912; Guan HY, 2019, P NATL ACAD SCI USA, V116, P14019, DOI 10.1073/pnas.1900997116; Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714; Herreros-Pomares A, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1898-1; Hirsch FR, 2016, LANCET, V388, P1012, DOI 10.1016/S0140-6736(16)31473-8; Hua JT, 2018, CELL, V174, P564, DOI 10.1016/j.cell.2018.06.014; Huang ZW, 2018, J CELL PHYSIOL, V233, P6768, DOI 10.1002/jcp.26530; Loewen G, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0090-4; Oka H, 2019, BMC GENOMICS, V20, DOI 10.1186/s12864-018-5375-5; Peterson AC, 2012, MOL CELL PROTEOMICS, V11, P1475, DOI 10.1074/mcp.O112.020131; Rizvi NA, 2017, NEW ENGL J MED, V377, P1986, DOI 10.1056/NEJMe1711430; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tini M, 2002, MOL CELL, V9, P265, DOI 10.1016/S1097-2765(02)00453-7; Wang XH, 2019, MOL MED REP, V20, P640, DOI 10.3892/mmr.2019.10292; Wei SQ, 2019, INT J IMMUNOPATH PH, V33, DOI 10.1177/2058738419859699; Xiong RF, 2019, BMC NEPHROL, V20, DOI 10.1186/s12882-019-1550-4; Xue YN, 2019, J CELL BIOCHEM, V120, P19087, DOI 10.1002/jcb.29232; Yang F, 2013, MOL CELL, V49, P1083, DOI 10.1016/j.molcel.2013.01.010; Yang JL, 2019, BIOCHEM BIOPH RES CO, V514, P118, DOI 10.1016/j.bbrc.2019.04.107; Yin DD, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0836-7; Zhu YX, 2019, ONCOGENE, V38, P6065, DOI 10.1038/s41388-019-0858-7	24	23	23	2	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2020	39	38					6071	6084		10.1038/s41388-020-01421-w	http://dx.doi.org/10.1038/s41388-020-01421-w		AUG 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NQ9JF	32796958				2022-12-28	WOS:000559718800001
J	Shu, Z; Li, Z; Huang, HH; Chen, Y; Fan, J; Yu, L; Wu, ZH; Tian, L; Qi, Q; Peng, S; Wei, CY; Xie, ZQ; Li, XB; Feng, Q; Sheng, H; Li, GQ; Wei, DP; Shan, CL; Chen, G				Shu, Zhen; Li, Zhen; Huang, Huanhuan; Chen, Yan; Fan, Jun; Yu, Li; Wu, Zhihui; Tian, Ling; Qi, Qi; Peng, Shuang; Wei, Changyong; Xie, Zhongqiu; Li, Xiaobo; Feng, Qi; Sheng, Hao; Li, Guangqiang; Wei, Dongping; Shan, Changliang; Chen, Guo			Cell-cycle-dependent phosphorylation of RRM1 ensures efficient DNA replication and regulates cancer vulnerability to ATR inhibition	ONCOGENE			English	Article							RIBONUCLEOTIDE REDUCTASE; GENOME INTEGRITY; SUBUNIT P53R2; S-PHASE; KINASE; ACTIVATION; STRESS; PROTEIN; SAMHD1; REPAIR	Ribonucleotide reductase (RNR) catalyzes the rate-limiting step of de novo synthesis of deoxyribonucleotide triphosphates (dNTPs) building blocks for DNA synthesis, and is a well-recognized target for cancer therapy. RNR is a heterotetramer consisting of two large RRM1 subunits and two small RRM2 subunits. RNR activity is greatly stimulated by transcriptional activation of RRM2 during S/G2 phase to ensure adequate dNTP supply for DNA replication. However, little is known about the cell-cycle-dependent regulation of RNR activity through RRM1. Here, we report that RRM1 is phosphorylated at Ser 559 by CDK2/cyclin A during S/G2 phase. And this S559 phosphorylation of RRM1enhances RNR enzymatic activity and is required for maintaining sufficient dNTPs during normal DNA replication. Defective RRM1 S559 phosphorylation causes DNA replication stress, double-strand break, and genomic instability. Moreover, combined targeting of RRM1 S559 phosphorylation and ATR triggers lethal replication stress and profound antitumor effects. Thus, this posttranslational phosphorylation of RRM1 provides an alternative mechanism to finely regulating RNR and therapeutic opportunities for cancer treatment.	[Shu, Zhen; Li, Zhen; Chen, Yan; Fan, Jun; Yu, Li; Wu, Zhihui; Tian, Ling; Chen, Guo] Jinan Univ, Sch Med, Dept Med Biochem & Mol Biol, Guangzhou 510632, Peoples R China; [Shu, Zhen; Wei, Changyong; Xie, Zhongqiu] Emory Univ, Dept Radiat Oncol, Sch Med, Atlanta, GA 30322 USA; [Li, Zhen; Feng, Qi; Sheng, Hao; Li, Guangqiang; Shan, Changliang] Jinan Univ, Biomed Translat Res Inst, Guangzhou 510632, Peoples R China; [Huang, Huanhuan; Wei, Dongping] Nanjing Med Univ, Nanjing Hosp 1, Dept Oncol, Nanjing 210006, Peoples R China; [Qi, Qi; Peng, Shuang] Jinan Univ, Sch Med, Dept Pathophysiol & Pharmacol, Guangzhou 510632, Peoples R China; [Li, Xiaobo] Tianjin Med Univ, Minist Educ, Key Lab Immune Microenvironm & Dis, Tianjin 300070, Peoples R China; [Shan, Changliang] Nankai Univ, Coll Pharm, State Key Lab Med Chem Biol, Tianjin 300350, Peoples R China; [Shan, Changliang] Nankai Univ, Tianjin Key Lab Mol Drug Res, Tianjin 300350, Peoples R China	Jinan University; Emory University; Jinan University; Nanjing Medical University; Jinan University; Tianjin Medical University; Nankai University; Nankai University	Chen, G (corresponding author), Jinan Univ, Sch Med, Dept Med Biochem & Mol Biol, Guangzhou 510632, Peoples R China.	gchen84@jnu.edu.cn	Peng, shuang/GPX-0999-2022; Chen, Guo/HGE-9902-2022; Xie, Zhongqiu/AAZ-9680-2020; Qi, Qi/J-3508-2013	Chen, Guo/0000-0001-8886-1873; Xie, Zhongqiu/0000-0002-2869-7669; Li, Guangqiang/0000-0003-2447-1803; Qi, Qi/0000-0003-4460-0713; Peng, Shuang/0000-0002-0163-9047	Natural Science Foundation of Guangdong Province of China [2019A1515011247]; Guangzhou Municipal Science and Technology Program of China [202002030451]; Fundamental Research Funds for the Central Universities [21620421]; National Natural Science Foundation of China [81472793, 81672895]	Natural Science Foundation of Guangdong Province of China(National Natural Science Foundation of Guangdong Province); Guangzhou Municipal Science and Technology Program of China; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by Natural Science Foundation of Guangdong Province of China (2019A1515011247 to GC), Guangzhou Municipal Science and Technology Program of China (202002030451 to GC), Fundamental Research Funds for the Central Universities (21620421 to GC) and National Natural Science Foundation of China (81472793 and 81672895 to DW).	Arnaoutov A, 2014, SCIENCE, V345, P1512, DOI 10.1126/science.1251550; Aye Y, 2015, ONCOGENE, V34, P2011, DOI 10.1038/onc.2014.155; Buckland RJ, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004846; Buisson R, 2015, MOL CELL, V59, P1011, DOI 10.1016/j.molcel.2015.07.029; Chabes A, 1999, J BIOL CHEM, V274, P36679, DOI 10.1074/jbc.274.51.36679; Chang LF, 2008, P NATL ACAD SCI USA, V105, P18519, DOI 10.1073/pnas.0803313105; Chen G, 2018, BIO-PROTOCOL, V8, DOI 10.21769/BioProtoc.2994; Chen Z, 2007, SCIENCE, V316, P1916, DOI 10.1126/science.1140958; Chung G, 2015, GENE DEV, V29, P1969, DOI 10.1101/gad.266056.115; Cribier A, 2013, CELL REP, V3, P1036, DOI 10.1016/j.celrep.2013.03.017; D'Angiolella V, 2012, CELL, V149, P1023, DOI 10.1016/j.cell.2012.03.043; De Bont R, 2004, MUTAGENESIS, V19, P169, DOI 10.1093/mutage/geh025; Flynn RL, 2011, TRENDS BIOCHEM SCI, V36, P133, DOI 10.1016/j.tibs.2010.09.005; Grinberg IR, 2018, J BIOL CHEM, V293, P15889, DOI 10.1074/jbc.RA118.004991; Grinberg IR, 2018, ELIFE, V7, DOI 10.7554/eLife.31529; Hakansson P, 2006, J BIOL CHEM, V281, P7834, DOI 10.1074/jbc.M512894200; Jackson DA, 1998, J CELL BIOL, V140, P1285, DOI 10.1083/jcb.140.6.1285; Le TM, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00221-3; Lin YF, 2018, NUCLEIC ACIDS RES, V46, P59; Liu PD, 2014, NATURE, V508, P541, DOI 10.1038/nature13079; Logan DT, 2011, NAT STRUCT MOL BIOL, V18, P251, DOI 10.1038/nsmb0311-251; Ma K, 2012, INT J MOL SCI, V13, P11974, DOI 10.3390/ijms130911974; Mailand N, 2005, CELL, V122, P915, DOI 10.1016/j.cell.2005.08.013; Maya-Mendoza A, 2018, NATURE, V559, P279, DOI 10.1038/s41586-018-0261-5; Minocherhomji S, 2015, NATURE, V528, P286, DOI 10.1038/nature16139; Pontarin G, 2012, P NATL ACAD SCI USA, V109, P13302, DOI 10.1073/pnas.1211289109; Puigvert JC, 2016, FEBS J, V283, P232, DOI 10.1111/febs.13574; Rajeshkumar NV, 2011, CLIN CANCER RES, V17, P2799, DOI 10.1158/1078-0432.CCR-10-2580; Schmidt TT, 2019, NUCLEIC ACIDS RES, V47, P237, DOI 10.1093/nar/gky1154; Schwab RA, 2010, EMBO J, V29, P806, DOI 10.1038/emboj.2009.385; Schwab RAV, 2011, JOVE-J VIS EXP, DOI 10.3791/3255; Sopko R, 2014, DEV CELL, V31, P114, DOI 10.1016/j.devcel.2014.07.027; Sorensen CS, 2012, NUCLEIC ACIDS RES, V40, P477, DOI 10.1093/nar/gkr697; Tanaka S, 2007, NATURE, V445, P328, DOI 10.1038/nature05465; Tang CX, 2015, J BIOL CHEM, V290, P26352, DOI 10.1074/jbc.M115.677435; Tuli R, 2019, EBIOMEDICINE, V40, P375, DOI 10.1016/j.ebiom.2018.12.060; Vassin VM, 2009, J CELL SCI, V122, P4070, DOI 10.1242/jcs.053702; von der Maase H, 2005, J CLIN ONCOL, V23, P4602, DOI 10.1200/JCO.2005.07.757; Wohlschlegel JA, 2002, MOL CELL, V9, P233, DOI 10.1016/S1097-2765(02)00456-2; Xie MH, 2014, CANCER RES, V74, P212, DOI 10.1158/0008-5472.CAN-13-1536-T; Yan JP, 2015, J BIOL CHEM, V290, P13279, DOI 10.1074/jbc.M115.646588; Zhang JF, 2018, NATURE, V553, P91, DOI 10.1038/nature25015; Zhao XL, 2001, EMBO J, V20, P3544, DOI 10.1093/emboj/20.13.3544; Zhao XL, 2002, P NATL ACAD SCI USA, V99, P3746, DOI 10.1073/pnas.062502299; Zhou BS, 2013, CANCER RES, V73, P6484, DOI 10.1158/0008-5472.CAN-13-1094; Zhu YH, 2004, MOL CELL BIOL, V24, P6268, DOI 10.1128/MCB.24.14.6268-6277.2004; Zimanyi CM, 2016, ELIFE, V5, DOI 10.7554/eLife.07141	47	10	11	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2020	39	35					5721	5733		10.1038/s41388-020-01403-y	http://dx.doi.org/10.1038/s41388-020-01403-y		JUL 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NF2QB	32712628				2022-12-28	WOS:000552667700001
J	Simoes, BM; Santiago-Gomez, A; Chiodo, C; Moreira, T; Conole, D; Lovell, S; Alferez, D; Eyre, R; Spence, K; Sarmiento-Castro, A; Kohler, B; Morisset, L; Lanzino, M; Ando, S; Marangoni, E; Sims, AH; Tate, EW; Howell, SJ; Clarke, RB				Simoes, Bruno M.; Santiago-Gomez, Angelica; Chiodo, Chiara; Moreira, Tiago; Conole, Daniel; Lovell, Scott; Alferez, Denis; Eyre, Rachel; Spence, Katherine; Sarmiento-Castro, Aida; Kohler, Bertram; Morisset, Ludivine; Lanzino, Marilena; Ando, Sebastiano; Marangoni, Elisabetta; Sims, Andrew H.; Tate, Edward W.; Howell, Sacha J.; Clarke, Robert B.			Targeting STAT3 signaling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer	ONCOGENE			English	Article							PROMOTES TAMOXIFEN RESISTANCE; THERAPY; MAMMOSPHERE; PROGRESSION; ESTROGEN; TUMORS; GENE	Estrogen receptor (ER) positive breast cancer is frequently sensitive to endocrine therapy. Multiple mechanisms of endocrine therapy resistance have been identified, including cancer stem-like cell (CSC) activity. Here we investigate SFX-01, a stabilised formulation of sulforaphane (SFN), for its effects on breast CSC activity in ER+ preclinical models. SFX-01 reduced mammosphere formation efficiency (MFE) of ER+ primary and metastatic patient samples. Both tamoxifen and fulvestrant increased MFE and aldehyde dehydrogenase (ALDH) activity of patient-derived xenograft (PDX) tumors, which was reversed by combination with SFX-01. SFX-01 significantly reduced tumor-initiating cell frequency in secondary transplants and reduced the formation of spontaneous lung micrometastases by PDX tumors in mice. Mechanistically, we establish that both tamoxifen and fulvestrant induce STAT3 phosphorylation. SFX-01 suppressed phospho-STAT3 and SFN directly bound STAT3 in patient and PDX samples. Analysis of ALDH+ cells from endocrine-resistant patient samples revealed activation of STAT3 target genesMUC1andOSMR, which were inhibited by SFX-01 in patient samples. Increased expression of these genes after 3 months' endocrine treatment of ER+ patients (n = 68) predicted poor prognosis. Our data establish the importance of STAT3 signaling in CSC-mediated resistance to endocrine therapy and the potential of SFX-01 for improving clinical outcomes in ER+ breast cancer.	[Simoes, Bruno M.; Santiago-Gomez, Angelica; Chiodo, Chiara; Moreira, Tiago; Alferez, Denis; Eyre, Rachel; Spence, Katherine; Sarmiento-Castro, Aida; Kohler, Bertram; Howell, Sacha J.; Clarke, Robert B.] Univ Manchester, Fac Biol Med & Hlth, Div Canc Sci, Breast Biol Grp,Manchester Breast Ctr, Manchester, Lancs, England; [Chiodo, Chiara; Lanzino, Marilena; Ando, Sebastiano] Univ Calabria, Dept Pharm, Arcavacata Di Rende, Italy; [Conole, Daniel; Lovell, Scott; Tate, Edward W.] Imperial Coll, Mol Sci Res Hub, London, England; [Morisset, Ludivine; Marangoni, Elisabetta] PSL Res Univ, Inst Curie, Translat Res Dept, Paris, France; [Sims, Andrew H.] Univ Edinburgh, Appl Bioinformat Canc Grp, Canc Res UK Ctr, Edinburgh, Midlothian, Scotland; [Howell, Sacha J.] Christie NHS Fdn Trust, Dept Med Oncol, Manchester, Lancs, England	University of Manchester; University of Calabria; Imperial College London; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Edinburgh; Christie NHS Foundation Trust	Simoes, BM; Howell, SJ; Clarke, RB (corresponding author), Univ Manchester, Fac Biol Med & Hlth, Div Canc Sci, Breast Biol Grp,Manchester Breast Ctr, Manchester, Lancs, England.; Howell, SJ (corresponding author), Christie NHS Fdn Trust, Dept Med Oncol, Manchester, Lancs, England.	bruno.simoes@manchester.ac.uk; sacha.howell@christie.nhs.uk; robert.clarke@manchester.ac.uk	Simoes, Bruno/AAB-2582-2019; Marangoni, Elisabetta/GSO-3945-2022; Conole, Daniel/ABA-6423-2021; Clarke, Robert/AAA-3442-2021	Simoes, Bruno/0000-0003-1253-6657; Marangoni, Elisabetta/0000-0002-3337-6448; Conole, Daniel/0000-0002-3389-8377; Clarke, Robert/0000-0001-5407-3123; Santiago Gomez, Angelica/0000-0002-2946-2669; Tate, Edward/0000-0003-2213-5814; Moreira, Tiago/0000-0003-3817-7103	National Centre for the Replacement, Refinement and Reduction of Animals in Research [NC/T001267/1] Funding Source: Medline	National Centre for the Replacement, Refinement and Reduction of Animals in Research(UK Research & Innovation (UKRI)National Centre for the Replacement, Refinement & Reduction of Animals in Research (NC3Rs))		Alam M, 2014, ONCOTARGET, V5, P2622, DOI 10.18632/oncotarget.1848; Alam M, 2013, J BIOL CHEM, V288, P30892, DOI 10.1074/jbc.M113.477158; Bui QT, 2017, CANCER LETT, V390, P115, DOI 10.1016/j.canlet.2017.01.014; Clarke JD, 2011, PHARM RES-DORDR, V28, P3171, DOI 10.1007/s11095-011-0500-z; Clulow JA, 2017, CHEM COMMUN, V53, P5182, DOI 10.1039/c6cc08797c; Cottu P, 2012, BREAST CANCER RES TR, V133, P595, DOI 10.1007/s10549-011-1815-5; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Dagan IDFA, 2008, Stabilized sulforaphane, VWO2008091608A1, A61K 31/70 (2006.01) A61K 8/00 (2006.01) A61K 31/40 (2006.01, Patent No. 2008091608; Domenici G, 2019, ONCOGENE, V38, P3151, DOI 10.1038/s41388-018-0656-7; Dustin D, 2019, CANCER-AM CANCER SOC, V125, P3714, DOI 10.1002/cncr.32345; Eyre R, 2016, J MAMMARY GLAND BIOL, V21, P99, DOI 10.1007/s10911-016-9361-8; Franklin SJ, 2014, DRUG DEV IND PHARM, V40, P494, DOI 10.3109/03639045.2013.768634; Fry DW, 2004, MOL CANCER THER, V3, P1427; Gaemers IC, 2001, J BIOL CHEM, V276, P6191, DOI 10.1074/jbc.M009449200; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hong F, 2005, CHEM RES TOXICOL, V18, P1917, DOI 10.1021/tx0502138; HOWELL SJ, 2019, ANN ONCOL, V30, pv122, DOI DOI 10.1093/annonc/mdz242.036; Kettner NM, 2019, CLIN CANCER RES, V25, P3996, DOI 10.1158/1078-0432.CCR-18-3274; Kharbanda A, 2013, MOL CANCER RES, V11, P714, DOI 10.1158/1541-7786.MCR-12-0668; Li YY, 2010, CLIN CANCER RES, V16, P2580, DOI 10.1158/1078-0432.CCR-09-2937; Lin L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082821; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Palmieri C, 2014, MOL CELL ENDOCRINOL, V382, P695, DOI 10.1016/j.mce.2013.08.001; Pan HC, 2017, NEW ENGL J MED, V377, P1836, DOI 10.1056/NEJMoa1701830; Parashar D, 2019, CELL REP, V29, P4389, DOI 10.1016/j.celrep.2019.11.085; Patnaik A, 2016, CANCER DISCOV, V6, P740, DOI 10.1158/2159-8290.CD-16-0095; Pearce D.A., 2018, CONTINUOUS BIOMARKER, DOI [10.1101/208660, DOI 10.1101/208660]; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Pitroda SP, 2009, P NATL ACAD SCI USA, V106, P5837, DOI 10.1073/pnas.0812029106; Piva M, 2014, EMBO MOL MED, V6, P66, DOI 10.1002/emmm.201303411; Sarmiento-Castro A, 2019, DORMANT SUBPOPULATIO, DOI [10.1101/821876, DOI 10.1101/821876]; Shaw FL, 2012, J MAMMARY GLAND BIOL, V17, P111, DOI 10.1007/s10911-012-9255-3; Simoes BM, 2015, CELL REP, V12, P1968, DOI 10.1016/j.celrep.2015.08.050; Simoes BM, 2011, BREAST CANCER RES TR, V129, P23, DOI 10.1007/s10549-010-1169-4; Tawara K, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-0971-5; Tripathy D, 2017, CLIN CANCER RES, V23, P5658, DOI 10.1158/1078-0432.CCR-17-1819; Turnbull AK, 2015, J CLIN ONCOL, V33, P2270, DOI 10.1200/JCO.2014.57.8963; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wei W, 2014, STEM CELLS, V32, P2571, DOI 10.1002/stem.1752; West NR, 2014, ONCOGENE, V33, P1485, DOI 10.1038/onc.2013.105; West NR, 2012, ENDOCR-RELAT CANCER, V19, P181, DOI 10.1530/ERC-11-0326	42	13	13	2	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 18	2020	39	25					4896	4908		10.1038/s41388-020-1335-z	http://dx.doi.org/10.1038/s41388-020-1335-z			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LZ3HT	32472077	hybrid, Green Published, Green Submitted			2022-12-28	WOS:000541119400009
J	Lorenzo-Martin, LF; Rodriguez-Fdez, S; Fabbiano, S; Abad, A; Garcia-Macias, MC; Dosil, M; Cuadrado, M; Robles-Valero, J; Bustelo, XR				Francisco Lorenzo-Martin, L.; Rodriguez-Fdez, Sonia; Fabbiano, Salvatore; Abad, Antonio; Garcia-Macias, Maria C.; Dosil, Mercedes; Cuadrado, Myriam; Robles-Valero, Javier; Bustelo, Xose R.			Vav2pharmaco-mimetic mice reveal the therapeutic value and caveats of the catalytic inactivation of a Rho exchange factor	ONCOGENE			English	Article							GTP-BINDING PROTEINS; SKIN TUMOR-FORMATION; RAC ACTIVATOR TIAM1; VAV FAMILY; PATHWAY; GTPASES; CANCER; INHIBITION; TARGETS; DOMAIN	The current paradigm holds that the inhibition of Rho guanosine nucleotide exchange factors (GEFs), the enzymes that stimulate Rho GTPases, can be a valuable therapeutic strategy to treat Rho-dependent tumors. However, formal validation of this idea using in vivo models is still missing. In this context, it is worth remembering that many Rho GEFs can mediate both catalysis-dependent and independent responses, thus raising the possibility that the inhibition of their catalytic activities might not be sufficient per se to block tumorigenic processes. On the other hand, the inhibition of these enzymes can trigger collateral side effects that could preclude the practical implementation of anti-GEF therapies. To address those issues, we have generated mouse models to mimic the effect of the systemic application of an inhibitor for the catalytic activity of the Rho GEF Vav2 at the organismal level. Our results indicate that lowering the catalytic activity of Vav2 below specific thresholds is sufficient to block skin tumor initiation, promotion, and progression. They also reveal that the negative side effects typically induced by the loss of Vav2 can be bypassed depending on the overall level of Vav2 inhibition achieved in vivo. These data underscore the pros and cons of anti-Rho GEF therapies for cancer treatment. They also support the idea that Vav2 could represent a viable drug target.	[Francisco Lorenzo-Martin, L.; Rodriguez-Fdez, Sonia; Fabbiano, Salvatore; Abad, Antonio; Garcia-Macias, Maria C.; Dosil, Mercedes; Cuadrado, Myriam; Robles-Valero, Javier; Bustelo, Xose R.] Univ Salamanca, Ctr Invest Canc, CSIC, Salamanca 37007, Spain; [Francisco Lorenzo-Martin, L.; Rodriguez-Fdez, Sonia; Fabbiano, Salvatore; Abad, Antonio; Garcia-Macias, Maria C.; Dosil, Mercedes; Cuadrado, Myriam; Robles-Valero, Javier; Bustelo, Xose R.] Univ Salamanca, Inst Biol Mol & Celular Canc, CSIC, Salamanca 37007, Spain; [Francisco Lorenzo-Martin, L.; Rodriguez-Fdez, Sonia; Abad, Antonio; Dosil, Mercedes; Cuadrado, Myriam; Robles-Valero, Javier; Bustelo, Xose R.] Univ Salamanca, Ctr Invest Biomed Red Canc CIBERONC, CSIC, Salamanca 37007, Spain; [Dosil, Mercedes] Univ Salamanca, Sch Pharm, Dept Bioquim & Biol Mol, Salamanca 37007, Spain; [Fabbiano, Salvatore] Cell Press Editorial Off, Cambridge, MA 02139 USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Consejo Superior de Investigaciones Cientificas (CSIC); University of Salamanca; University of Salamanca	Bustelo, XR (corresponding author), Univ Salamanca, Ctr Invest Canc, CSIC, Salamanca 37007, Spain.; Bustelo, XR (corresponding author), Univ Salamanca, Inst Biol Mol & Celular Canc, CSIC, Salamanca 37007, Spain.; Bustelo, XR (corresponding author), Univ Salamanca, Ctr Invest Biomed Red Canc CIBERONC, CSIC, Salamanca 37007, Spain.	xbustelo@usal.es	Rodriguez-Fdez, Sonia/AAD-9317-2021; Bustelo, Xose R./AAD-2081-2022; Robles-Valero, Javier/J-4069-2017; Dosil, Mercedes/A-9536-2016	Bustelo, Xose R./0000-0001-9398-6072; Abad de Blas, Antonio Luis/0000-0001-8019-2775; Fabbiano, Salvatore/0000-0003-0768-6028; Robles-Valero, Javier/0000-0001-5218-0187; Cuadrado, Myriam/0000-0001-9410-1205; Dosil, Mercedes/0000-0001-8119-8263; Lorenzo-Martin, L. Francisco/0000-0003-4717-9338; Rodriguez-Fdez, Sonia/0000-0001-5369-2969	Worldwide Cancer Research [14-1248]; Castilla-Leon Government [CSI252P18, CLC-2017-01]; Spanish Ministry of Science and Innovation (MSI) [RTI2018-096481-B-I00]; Spanish Association against Cancer [GC16173472GARC]; Programa de Apoyo a Planes Estrategicos de Investigacion de Estructuras de Investigacion de Excelencia of the Castilla-Leon autonomous government [CLC-2017-01]; MSI [BES-2010-031386, BES-2013-063573]; Spanish Ministry of Universities [CLC-2017-01, FPU13/02923]; CIBERONC; Spanish Association against Cancer; European Regional Development Fund	Worldwide Cancer Research; Castilla-Leon Government; Spanish Ministry of Science and Innovation (MSI)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Spanish Association against Cancer; Programa de Apoyo a Planes Estrategicos de Investigacion de Estructuras de Investigacion de Excelencia of the Castilla-Leon autonomous government; MSI; Spanish Ministry of Universities(Spanish Government); CIBERONC; Spanish Association against Cancer; European Regional Development Fund(European Commission)	We thank M. Blazquez for lab work and CIC facilities' personnel for technical assistance. XRB is supported by grants from Worldwide Cancer Research (14-1248), the Castilla-Leon Government (CSI252P18, CLC-2017-01), the Spanish Ministry of Science and Innovation (MSI) (RTI2018-096481-B-I00), and the Spanish Association against Cancer (GC16173472GARC). XRB's institution is supported by the Programa de Apoyo a Planes Estrategicos de Investigacion de Estructuras de Investigacion de Excelencia of the Castilla-Leon autonomous government (CLC-2017-01). SF, SR-F, and LFL-M contracts have been supported by funding from the MSI (SF, BES-2010-031386; SR-F, BES-2013-063573), the Spanish Ministry of Universities (LFL-M, FPU13/02923), and the CLC-2017-01 grant (SR-F and LFL-M). JR-V has been supported by the CIBERONC and, currently, by the Spanish Association against Cancer. Both Spanish and Castilla-Leon government-associated funding is partially supported by the European Regional Development Fund.	Abel EL, 2009, NAT PROTOC, V4, P1350, DOI 10.1038/nprot.2009.120; Amado-Azevedo J, 2014, CELL TISSUE RES, V355, P557, DOI 10.1007/s00441-014-1828-6; Arash EH, 2014, EMBO J, V33, P2997, DOI 10.15252/embj.201490230; Barreira M, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004993; Bouquier N, 2009, CHEM BIOL, V16, P391, DOI 10.1016/j.chembiol.2009.02.006; Bustelo XR, 2007, BIOESSAYS, V29, P356, DOI 10.1002/bies.20558; Bustelo XR, 2018, BIOCHEM SOC T, V46, P741, DOI 10.1042/BST20170531; Bustelo Xose R, 2014, Small GTPases, V5, P9, DOI 10.4161/21541248.2014.973757; Chrencik JE, 2008, J MOL BIOL, V380, P828, DOI 10.1016/j.jmb.2008.05.024; Citterio C, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002962; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1996, ONCOGENE, V13, P455; Cullis J, 2014, CANCER CELL, V25, P181, DOI 10.1016/j.ccr.2014.01.025; Doody GM, 2001, NAT IMMUNOL, V2, P542, DOI 10.1038/88748; Dotto GP, 2016, CANCER CELL, V29, P622, DOI 10.1016/j.ccell.2016.04.004; Dutting S, 2015, J THROMB HAEMOST, V13, P827, DOI 10.1111/jth.12861; Fabbiano S, 2014, MOL CELL BIOL, V34, P4404, DOI 10.1128/MCB.01066-14; Fine B, 2009, SCIENCE, V325, P1261, DOI 10.1126/science.1173569; Lorenzo-Martin LF, 2019, ONCOGENE, V38, P209, DOI 10.1038/s41388-018-0433-7; Fujikawa K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009050; Garcia-Mariscal A, 2018, ONCOGENE, V37, P847, DOI 10.1038/onc.2017.333; Garrett TA, 2007, EXP CELL RES, V313, P3285, DOI 10.1016/j.yexcr.2007.05.027; Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Huang YP, 2019, CELL DISCOV, V5, DOI 10.1038/s41421-019-0126-6; Hunter SG, 2006, MOL CELL BIOL, V26, P4830, DOI 10.1128/MCB.02215-05; Kawasaki Y, 2009, EMBO REP, V10, P1355, DOI 10.1038/embor.2009.233; Khanna N, 2013, P NATL ACAD SCI USA, V110, P15979, DOI 10.1073/pnas.1310434110; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Luch A, 2005, NAT REV CANCER, V5, P113, DOI 10.1038/nrc1546; Lyons LS, 2006, MOL ENDOCRINOL, V20, P1061, DOI 10.1210/me.2005-0346; Malliri A, 2006, J BIOL CHEM, V281, P543, DOI 10.1074/jbc.M507582200; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; Menacho-Marquez M, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001615; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Niebel B, 2013, BIOORGAN MED CHEM, V21, P6239, DOI 10.1016/j.bmc.2013.05.021; Que SKT, 2018, J AM ACAD DERMATOL, V78, P237, DOI 10.1016/j.jaad.2017.08.059; Rapley J, 2008, EMBO REP, V9, P655, DOI 10.1038/embor.2008.80; Robles-Valero Javier, 2020, Small GTPases, V11, P233, DOI 10.1080/21541248.2018.1423851; Robles-Valero J, 2017, CANCER CELL, V32, P608, DOI 10.1016/j.ccell.2017.10.004; Rodriguez-Fdez S, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050465; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Ruggiero C, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aal2464; Sauzeau V, 2006, NAT MED, V12, P841, DOI 10.1038/nm1426; Sauzeau V, 2007, MOL BIOL CELL, V18, P943, DOI 10.1091/mbc.E06-09-0877; Sauzeau V, 2010, J CLIN INVEST, V120, P315, DOI 10.1172/JCI38356; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Svensmark JH, 2019, ONCOGENE, V38, P7447, DOI 10.1038/s41388-019-0963-7; Thomas EK, 2007, CANCER CELL, V12, P467, DOI 10.1016/j.ccr.2007.10.015; Verma R, 2020, MOL CELL, V77, P446, DOI 10.1016/j.molcel.2020.01.010; Vigil D, 2010, NAT REV CANCER, V10, P842, DOI 10.1038/nrc2960; Wang Z, 2010, ONCOGENE, V29, P3362, DOI 10.1038/onc.2010.95; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Zandvakili I, 2017, ONCOGENE, V36, P3213, DOI 10.1038/onc.2016.473; Zugaza JL, 2002, J BIOL CHEM, V277, P45377, DOI 10.1074/jbc.M208039200	55	8	8	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	2020	39	28					5098	5111		10.1038/s41388-020-1353-x	http://dx.doi.org/10.1038/s41388-020-1353-x		JUN 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MH4RK	32528129	Green Accepted			2022-12-28	WOS:000539817600001
J	Pei, GS; Hu, RF; Dai, YL; Zhao, ZM; Jia, PL				Pei, Guangsheng; Hu, Ruifeng; Dai, Yulin; Zhao, Zhongming; Jia, Peilin			Decoding whole-genome mutational signatures in 37 human pan-cancers by denoising sparse autoencoder neural network	ONCOGENE			English	Article							DNA-DAMAGE; SEQUENCE; MECHANISMS; DISEASE; REPAIR; P53	Millions of somatic mutations have recently been discovered in cancer genomes. These mutations in cancer genomes occur due to internal and external mutagenesis forces. Decoding the mutational processes by examining their unique patterns has successfully revealed many known and novel signatures from whole exome data, but many still remain undiscovered. Here, we developed a deep learning approach, DeepMS, to decompose mutational signatures using 52,671,908 somatic mutations from 2780 highly curated cancer genomes with whole genome sequencing (WGS) in 37 cancer types/subtypes. With rigorous model training and comparison, we characterized 54 signatures for single base substitutions (SBSs), 11 for doublet base substitutions (DBSs) and 16 for small insertions and deletions (Indels). Compared to the previous methods, DeepMS could discover 37 SBS, 5 DBS, and 9 Indel new signatures, many of which represent associations with DNA mismatch or base excision repair and cisplatin therapy mechanisms. We further developed a regression-based model to estimate the correlation between signatures and clinical and demographical phenotypes. The first deep learning model DeepMS on WGS somatic mutational profiles enable us identify more comprehensive context-based mutational signatures than traditional NMF approaches. Our work substantially expands the landscape of the naturally occurring mutational signatures in cancer genomes, and provides new insights into cancer biology.	[Pei, Guangsheng; Hu, Ruifeng; Dai, Yulin; Zhao, Zhongming; Jia, Peilin] Univ Texas Hlth Sci Ctr Houston, Ctr Precis Hlth, Sch Biomed Informat, Houston, TX 77030 USA; [Zhao, Zhongming] Univ Texas Hlth Sci Ctr Houston, Human Genet Ctr, Sch Publ Hlth, Houston, TX 77030 USA; [Zhao, Zhongming] Univ Texas MD Anderson Canc Ctr, UTHlth Grad Sch Biomed Sci, Houston, TX 77030 USA; [Zhao, Zhongming] Vanderbilt Univ, Med Ctr, Dept Biomed Informat, Nashville, TN 37203 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; University of Texas System; UTMD Anderson Cancer Center; Vanderbilt University	Zhao, ZM; Jia, PL (corresponding author), Univ Texas Hlth Sci Ctr Houston, Ctr Precis Hlth, Sch Biomed Informat, Houston, TX 77030 USA.; Zhao, ZM (corresponding author), Univ Texas Hlth Sci Ctr Houston, Human Genet Ctr, Sch Publ Hlth, Houston, TX 77030 USA.; Zhao, ZM (corresponding author), Univ Texas MD Anderson Canc Ctr, UTHlth Grad Sch Biomed Sci, Houston, TX 77030 USA.; Zhao, ZM (corresponding author), Vanderbilt Univ, Med Ctr, Dept Biomed Informat, Nashville, TN 37203 USA.	zhongming.zhao@uth.tmc.edu; peilin.jia@uth.tmc.edu	Hu, Ruifeng/AAF-8619-2019	Hu, Ruifeng/0000-0001-5549-3082; dai, yulin/0000-0003-1874-7893; Pei, Guangsheng/0000-0003-1804-7598	Cancer Prevention and Research Institute of Texas [CPRIT RP180734]; National Institutes of Health [R01LM012806]	Cancer Prevention and Research Institute of Texas; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Cancer Prevention and Research Institute of Texas (CPRIT RP180734), National Institutes of Health (R01LM012806).	Alexandrov LB, 2020, NATURE, V578, P94, DOI 10.1038/s41586-020-1943-3; Alexandrov LB, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9683; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Alexandrov LB, 2013, CELL REP, V3, P246, DOI 10.1016/j.celrep.2012.12.008; Ardin M, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-1011-z; Bengio Y, 2013, IEEE T PATTERN ANAL, V35, P1798, DOI 10.1109/TPAMI.2013.50; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Blokzijl F, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0539-0; Boot A, 2018, GENOME RES, V28, P654, DOI 10.1101/gr.230219.117; Brash DE, 2015, PHOTOCHEM PHOTOBIOL, V91, P15, DOI 10.1111/php.12377; Ceccaldi R, 2016, TRENDS CELL BIOL, V26, P52, DOI 10.1016/j.tcb.2015.07.009; Chuzhanova NA, 2003, HUM MUTAT, V21, P28, DOI 10.1002/humu.10146; Cooper David N, 2010, Hum Genomics, V4, P406; Drost J, 2017, SCIENCE, V358, P234, DOI 10.1126/science.aao3130; Forbes SA, 2017, NUCLEIC ACIDS RES, V45, pD777, DOI 10.1093/nar/gkw1121; Garraway LA, 2013, CELL, V153, P17, DOI 10.1016/j.cell.2013.03.002; Gehring JS, 2015, BIOINFORMATICS, V31, P3673, DOI 10.1093/bioinformatics/btv408; Hainaut P, 2001, CARCINOGENESIS, V22, P367, DOI 10.1093/carcin/22.3.367; Haradhvala NJ, 2016, CELL, V164, P538, DOI 10.1016/j.cell.2015.12.050; Hatakeyama K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26967-4; Jia PL, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0489-9; Jia PL, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755-8794-7-11; Kelley DR, 2016, GENOME RES, V26, P990, DOI 10.1101/gr.200535.115; Krawczak M, 1998, AM J HUM GENET, V63, P474, DOI 10.1086/301965; Krizhevsky A., P 25 INT C NEUR INF, P1097; Kucab JE, 2019, CELL, V177, P821, DOI 10.1016/j.cell.2019.03.001; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Ollila J, 1996, FEBS LETT, V396, P119, DOI 10.1016/0014-5793(96)01075-7; Palles C, 2013, NAT GENET, V45, P136, DOI 10.1038/ng.2503; Pena-Diaz J, 2012, MOL CELL, V47, P669, DOI 10.1016/j.molcel.2012.07.006; Pfeifer GP, 2005, MUTAT RES-FUND MOL M, V571, P19, DOI 10.1016/j.mrfmmm.2004.06.057; Pfeifer GP, 2002, ONCOGENE, V21, P7435, DOI 10.1038/sj.onc.1205803; Pfeifer GP, 1997, PHOTOCHEM PHOTOBIOL, V65, P270, DOI 10.1111/j.1751-1097.1997.tb08560.x; Pilati C, 2017, J PATHOL, V242, P10, DOI 10.1002/path.4880; Rosenthal R, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0893-4; Thurau C, 2011, KNOWL INF SYST, V29, P457, DOI 10.1007/s10115-010-0352-6; Tomasetti C, 2017, SCIENCE, V355, P1330, DOI 10.1126/science.aaf9011; van der Maaten L, 2008, J MACH LEARN RES, V9, P2579; Viel A, 2017, EBIOMEDICINE, V20, P39, DOI 10.1016/j.ebiom.2017.04.022; Vincent E, 2008, INT CONF ACOUST SPEE, P109, DOI 10.1109/ICASSP.2008.4517558; Vincent P, 2010, J MACH LEARN RES, V11, P3371; Zhang JJ, 2019, NAT BIOTECHNOL, V37, P367, DOI 10.1038/s41587-019-0055-9	43	6	6	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 2	2020	39	27					5031	5041		10.1038/s41388-020-1343-z	http://dx.doi.org/10.1038/s41388-020-1343-z		JUN 2020	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ME5NL	32528130	Green Accepted			2022-12-28	WOS:000539817600003
J	Jiang, MM; Zhang, WW; Zhang, R; Liu, PP; Ye, YN; Yu, WW; Guo, XJ; Yu, JP				Jiang, Mengmeng; Zhang, Wenwen; Zhang, Rui; Liu, Pengpeng; Ye, Yingnan; Yu, Wenwen; Guo, Xiaojing; Yu, Jinpu			Cancer exosome-derived miR-9 and miR-181a promote the development of early-stage MDSCs via interfering with SOCS3 and PIAS3 respectively in breast cancer	ONCOGENE			English	Article							SUPPRESSOR-CELLS; EXPRESSION; MICRORNA-9; METHYLATION; METASTASIS; ACTIVATION; INFECTION; RESPONSES; INVASION	We previously identified that the development of early-stage myeloid-derived suppressor cells (eMDSCs) in breast cancer with high IL-6 (IL-6(high)) expression was correlated with the SOCS3 deficiency-dependent hyperactivation of the JAK/STAT signaling pathway. However, the regulatory mechanisms have not yet been elucidated. In this study, we aimed to investigate how the posttranscriptional regulation mediated by cancer exosome-derived miRNAs affected the JAK/STAT signaling pathway and the development of eMDSCs. Using miRNA microarray, we screened miR-9 and miR-181a which were exclusively upregulated in eMDSCs and inversely associated with SOCS3 expression. We found both miRNAs promoted the amplification of immature eMDSCs with the strong suppression on T-cell immunity in mice and humans. Furthermore, miR-9 and miR-181a promoted 4T1 tumor growth and immune escape via enhancing eMDSCs infiltration in situ. But miR-9 and miR-181a stimulated eMDSCs development by separately inhibiting SOCS3 and PIAS3, two crucial regulators in the negative feedback loop of the JAK/STAT signaling pathway. Elevated miR-9 and miR-181a in eMDSCs was derived from tumor-derived exosomes, and blocking the exosome release could fully attenuate the miRNA-mediated regulation on eMDSCs development. In summary, our findings indicated that tumor exosome-derived miR-9 and miR-181a activated the JAK/STAT signaling pathway via targeting SOCS3 and PIAS3, respectively, and thus promoted the expansion of eMDSCs which might provide potential therapeutic target for IL-6(high) breast cancer treatment.	[Jiang, Mengmeng; Zhang, Wenwen; Zhang, Rui; Liu, Pengpeng; Ye, Yingnan; Yu, Jinpu] Tianjin Med Univ Canc Inst & Hosp, Canc Mol Diagnost Core, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc,Key Lab Canc Prevent &, Tianjin, Peoples R China; [Jiang, Mengmeng] Tianjin Third Central Hosp, Dept Oncol, Tianjin, Peoples R China; [Zhang, Wenwen; Zhang, Rui; Liu, Pengpeng; Ye, Yingnan; Yu, Wenwen; Yu, Jinpu] Tianjin Med Univ Canc Inst & Hosp, Dept Immunol, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China; [Yu, Wenwen; Yu, Jinpu] Key Lab Canc Immunol & Biotherapy, Tianjin, Peoples R China; [Guo, Xiaojing] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Key Lab Breast Canc Breast Canc Prevent & Therapy, Dept Breast Pathol & Lab, Tianjin, Peoples R China	Tianjin Medical University; Tianjin Medical University; Tianjin Medical University	Yu, JP (corresponding author), Tianjin Med Univ Canc Inst & Hosp, Canc Mol Diagnost Core, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc,Key Lab Canc Prevent &, Tianjin, Peoples R China.; Yu, JP (corresponding author), Tianjin Med Univ Canc Inst & Hosp, Dept Immunol, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China.; Yu, JP (corresponding author), Key Lab Canc Immunol & Biotherapy, Tianjin, Peoples R China.	yujinpu@tjmuch.com			National Natural Science Foundation of China [81872143, 81472473, 81772840]; National Science and Technology Support Program of China [2015BAI12B15]; Project of Science and Technology of Tianjin [13ZCZCSY20300, 18JCQNJC82700]; Key Project of Tianjin Health and Family Planning Commission [16KG126]; National Science and Technology Major Project [2018ZX09201-015]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science and Technology Support Program of China; Project of Science and Technology of Tianjin; Key Project of Tianjin Health and Family Planning Commission; National Science and Technology Major Project	This work was supported by National Natural Science Foundation of China (Grant No.81872143, 81472473, 81772840), National Science and Technology Support Program of China (Grant No.2015BAI12B15), National Science and Technology Major Project (Grant No.2018ZX09201-015), Project of Science and Technology of Tianjin (Grant No.13ZCZCSY20300, 18JCQNJC82700) and Key Project of Tianjin Health and Family Planning Commission (Grant No.16KG126). We appreciate the efforts of Dr Juntian Liu and Dr Shixia Li of Department of Preventive Health Screening Center in sample collection. We thank Dr Xiubao Ren of Department of Biotherapy for support of Flow cytometry. We also thank Prof Weijia Zhang of Department of Medicine of Icahn School of Medicine at Mount Sinai for constructive comments to our manuscript.	Al-Mahmood S, 2018, DRUG DELIV TRANSL RE, V8, P1483, DOI 10.1007/s13346-018-0551-3; Arora T, 2003, J BIOL CHEM, V278, P21327, DOI 10.1074/jbc.C300119200; Baroni S, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.224; Bhatia A, 2014, EXPERT REV CLIN IMMU, V10, P41, DOI 10.1586/1744666X.2014.865519; Bjornetro T, 2019, J EXTRACELL VESICLES, V8, DOI 10.1080/20013078.2019.1567219; Boosani CS, 2015, MOL BIOL REP, V42, P853, DOI 10.1007/s11033-015-3860-3; Bronte V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12150; Cao Q, 2013, PHYSIOL GENOMICS, V45, P1206, DOI 10.1152/physiolgenomics.00122.2013; Dudda JC, 2013, IMMUNITY, V38, P742, DOI 10.1016/j.immuni.2012.12.006; Guo XF, 2018, ONCOGENE, V37, P4239, DOI 10.1038/s41388-018-0261-9; He B, 2003, P NATL ACAD SCI USA, V100, P14133, DOI 10.1073/pnas.2232790100; Isomoto H, 2009, DIGESTION, V79, P2, DOI 10.1159/000167859; Jang MH, 2017, HUM PATHOL, V68, P69, DOI 10.1016/j.humpath.2017.08.026; Jiang MM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01840; Jiang MM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00070; Khatibi S, 2017, GROWTH FACTORS, V35, P100, DOI 10.1080/08977194.2017.1363746; Lao MX, 2016, J IMMUNOL, V196, P596, DOI 10.4049/jimmunol.1403254; Liu B, 2001, P NATL ACAD SCI USA, V98, P3203, DOI 10.1073/pnas.051489598; Lu CM, 2011, BLOOD, V117, P4293, DOI 10.1182/blood-2010-12-322503; McClure C, 2017, IMMUNOL CELL BIOL, V95, P42, DOI 10.1038/icb.2016.63; Niu J, 2016, ONCOGENE, V35, P1302, DOI 10.1038/onc.2015.189; Orangi E, 2019, GENE, V687, P272, DOI 10.1016/j.gene.2018.11.036; Pu SM, 2016, SCI REP-UK, V6, DOI 10.1038/srep23115; Pyzer AR, 2016, INT J CANCER, V139, P1915, DOI 10.1002/ijc.30232; Ru Peng, 2011, Genes Cancer, V2, P720, DOI 10.1177/1947601911425832; Sade-Feldman M, 2016, CLIN CANCER RES, V22, P5661, DOI 10.1158/1078-0432.CCR-15-3104; Seif F, 2017, CELL COMMUN SIGNAL, V15, DOI 10.1186/s12964-017-0177-y; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; Sporn JC, 2019, J SURG RES, V233, P426, DOI 10.1016/j.jss.2018.08.020; Tian J, 2015, J IMMUNOL, V195, P1301, DOI 10.4049/jimmunol.1500209; Tischoff I, 2007, GUT, V56, P1047, DOI 10.1136/gut.2006.111633; Tussie-Luna MI, 2002, P NATL ACAD SCI USA, V99, P12807, DOI 10.1073/pnas.192464499; Xu Z, 2017, FEBS J, V284, P2410, DOI 10.1111/febs.14133; Yang L, 2018, J NEUROIMMUNE PHARM, V13, P330, DOI 10.1007/s11481-018-9779-4; Yu JP, 2014, J IMMUNOL, V193, P2574, DOI 10.4049/jimmunol.1400833; Yu JP, 2013, J IMMUNOL, V190, P3783, DOI 10.4049/jimmunol.1201449; Zhang WW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01699; Zhang X, 2014, J VIRAL HEPATITIS, V21, P264, DOI 10.1111/jvh.12137; Zhao Y, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1004983; Zhen J, 2019, BIOMED PHARMACOTHER, V116, DOI 10.1016/j.biopha.2019.109016; Zheng HB, 2015, INT J CLIN EXP MED, V8, P20263; Zhou ZP, 2010, STEM CELLS, V28, P620, DOI 10.1002/stem.301; Zhu KP, 2019, MOL THER, V27, P518, DOI 10.1016/j.ymthe.2019.01.001	43	46	46	3	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	24					4681	4694		10.1038/s41388-020-1322-4	http://dx.doi.org/10.1038/s41388-020-1322-4		MAY 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LY0HO	32398867				2022-12-28	WOS:000532103100002
J	Manjili, MH				Manjili, Masoud H.			The premise of personalized immunotherapy for cancer dormancy	ONCOGENE			English	Review							CIRCULATING TUMOR-CELLS; BREAST-CANCER; BONE-MARROW; NEOANTIGENS; EQUILIBRIUM; CARCINOMA; REVEALS; ENDOTHELIN-1; CHEMOTHERAPY; TRASTUZUMAB	Progress in cancer therapies has resulted in improved survival of patients with early stage breast cancer. However, mortality remains high in patients with distant recurrence of the disease after initially successful treatment of early stage breast cancer. To this end, tumor recurrences have been attributed to the presence of dormant tumor cells in breast cancer patients and cancer survivors. Current clinical practice guidelines recommend a "wait-and-watch" approach for tumor recurrence. This is because of our limited understanding of tumor dormancy. Dormant tumor cells are quiescent, and thus, do not respond to chemotherapies or radiation therapies, and they are not operable. Therefore, immunotherapy is the only option for the treatment of tumor dormancy. However, gaps in our knowledge as to dormancy-specific antigens prevent a relapse preventing vaccine design. Here, I provide a critical review of cancer immunotherapy, and discuss empirical evidence related to naturally occurring tumor dormancy and treatment-induced tumor dormancy at the site of primary tumor and in distant organs before and after cancer therapies. Finally, I suggest that personalized vaccines targeting dormancy-associated neoantigens, which can be given to patients with early stage disease after the completion of neoadjuvant therapies and tumor resection as well as to cancer survivors could eliminate relapse causing dormant cells and offer a cure for cancer.	[Manjili, Masoud H.] Massey Canc Ctr, VCU Sch Med, VCU Inst Mol Med, Dept Microbiol & Immunol, Richmond, VA 23298 USA	Virginia Commonwealth University	Manjili, MH (corresponding author), Massey Canc Ctr, VCU Sch Med, VCU Inst Mol Med, Dept Microbiol & Immunol, Richmond, VA 23298 USA.	masoud.manjili@vcuhealth.org			Office of the Assistant Secretary of Defense for Health Affairs through the Breast Cancer Research Program [W81XWH-14-1-0087]; VCU Massey Cancer Center; NIH-NCI Cancer Center Support Grant [P30 CA016059]	Office of the Assistant Secretary of Defense for Health Affairs through the Breast Cancer Research Program; VCU Massey Cancer Center; NIH-NCI Cancer Center Support Grant	This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Breast Cancer Research Program under Award No. W81XWH-14-1-0087 (MHM), pilot funding from the VCU Massey Cancer Center supported, in part, with funding from NIH-NCI Cancer Center Support Grant P30 CA016059.	Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Alspach E, 2019, NATURE, V574, P696, DOI 10.1038/s41586-019-1671-8; American Cancer Society, 2016, CANC TREATM SURV FAC; Aqbi Hussein F, 2018, Oncotarget, V9, P22113, DOI 10.18632/oncotarget.25197; Ascierto PA, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0798-3; Bai Y, 2018, METHODS MOL BIOL, V1802, P193, DOI 10.1007/978-1-4939-8546-3_13; Bartkowiak K, 2015, CANCER RES, V75, P5367, DOI 10.1158/0008-5472.CAN-14-3728; Bartkowiak K, 2010, J PROTEOME RES, V9, P3158, DOI 10.1021/pr100039d; Baxevanis CN, 2015, VACCINES-BASEL, V3, P597, DOI 10.3390/vaccines3030597; Bidard FC, 2018, JNCI-J NATL CANCER I, V110, P560, DOI 10.1093/jnci/djy018; Boegel S, 2012, GENOME MED, V4, DOI 10.1186/gm403; Butturini E, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174305; Cackowski FC, 2017, J CELL BIOCHEM, V118, P891, DOI 10.1002/jcb.25768; Cameron D, 2017, LANCET, V389, P1195, DOI 10.1016/S0140-6736(16)32616-2; Chen WY, 2018, J MATER CHEM B, V6, P327, DOI 10.1039/c7tb02608k; Clements ME, 2019, CURR OSTEOPOROS REP, V17, P353, DOI 10.1007/s11914-019-00532-y; Demicheli R, 2019, BREAST, V45, P61, DOI 10.1016/j.breast.2019.03.001; Dimco G, 2010, CELL CYCLE, V9, P4638, DOI 10.4161/cc.9.23.13955; Ebinger S, 2016, CANCER CELL, V30, P849, DOI 10.1016/j.ccell.2016.11.002; Eide N, 2019, PATHOL ONCOL RES, V25, P255, DOI 10.1007/s12253-017-0355-7; Emens LA, 2019, JAMA ONCOL, V5, P74, DOI 10.1001/jamaoncol.2018.4224; FELDMAN AR, 1986, NEW ENGL J MED, V315, P1394, DOI 10.1056/NEJM198611273152206; Folkman J, 2004, NATURE, V427, P787, DOI 10.1038/427787a; Francescangeli F, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-019-1505-4; Gil M, 2013, P NATL ACAD SCI USA, V110, pE1291, DOI 10.1073/pnas.1220580110; Gubin MM, 2015, J CLIN INVEST, V125, P3413, DOI 10.1172/JCI80008; HARACH HR, 1985, CANCER-AM CANCER SOC, V56, P531, DOI 10.1002/1097-0142(19850801)56:3<531::AID-CNCR2820560321>3.0.CO;2-3; Hellmann MD, 2017, IMMUNITY, V47, P221, DOI 10.1016/j.immuni.2017.08.001; Hilf N, 2019, NATURE, V565, P240, DOI 10.1038/s41586-018-0810-y; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Iyengar NM, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.16211; Jahanban-Esfahlan R, 2019, CANCERS, V11, DOI 10.3390/cancers11081207; Jiang T, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0787-5; Johanns TM, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2018.1561106; Kaplan MA, 2016, BREAST CARE, V11, P248, DOI 10.1159/000448186; Karagiannis GS, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan0026; Khazali AS, 2018, BRIT J CANCER, V118, P566, DOI 10.1038/bjc.2017.414; Kimura W, 1998, CANCER, V82, P1839, DOI 10.1002/(SICI)1097-0142(19980515)82:10<1839::AID-CNCR5>3.0.CO;2-I; Kiyotani K, 2017, J HUM GENET, V62, P397, DOI 10.1038/jhg.2016.141; Kodumudi KN, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01939; Koebel CM, 2007, NATURE, V450, P903, DOI 10.1038/nature06309; Kortylewski M, 2004, J INVEST DERMATOL, V122, P414, DOI 10.1046/j.0022-202X.2004.22237.x; Krall JA, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan3464; Kurppa KJ, 2020, CANCER CELL, V37, P104, DOI 10.1016/j.ccell.2019.12.006; Liang H, 2013, J IMMUNOL, V190, P5874, DOI 10.4049/jimmunol.1202612; Linette GP, 2017, TRENDS MOL MED, V23, P869, DOI 10.1016/j.molmed.2017.08.007; Linnemann C, 2015, NAT MED, V21, P81, DOI 10.1038/nm.3773; Liu YY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15207; Loi S, 2019, LANCET ONCOL, V20, P371, DOI 10.1016/S1470-2045(18)30812-X; Loi S, 2016, JAMA ONCOL, V2, P1040, DOI 10.1001/jamaoncol.2016.0339; Luo XL, 2018, CANCER RES, V78, P3532, DOI 10.1158/0008-5472.CAN-18-0134; Ma KY, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.121387; Magbanua MJM, 2019, CLIN CANCER RES, V25, P5388, DOI 10.1158/1078-0432.CCR-18-3888; Manjili MH, 2018, ADV CANCER RES, V137, P17, DOI 10.1016/bs.acr.2017.11.005; Manjili MH, 2017, CANCER RES, V77, P2564, DOI 10.1158/0008-5472.CAN-17-0068; Manser RL, 2005, RESP MED, V99, P501, DOI 10.1016/j.rmed.2004.08.017; Matsushita H, 2012, NATURE, V482, P400, DOI 10.1038/nature10755; Meng SD, 2004, CLIN CANCER RES, V10, P8152, DOI 10.1158/1078-0432.CCR-04-1110; Merlino G, 2016, PIGM CELL MELANOMA R, V29, P404, DOI 10.1111/pcmr.12475; Montagner M, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00037; Namjoshi P, 2016, ONCOTARGET, V10, P6006; Nariai N, 2015, BMC GENOMICS, V16, DOI 10.1186/1471-2164-16-S2-S7; Nelson J, 2003, NAT REV CANCER, V3, P110, DOI 10.1038/nrc990; Nelson JB, 2005, NEOPLASIA, V7, P631, DOI 10.1593/neo.04787; Nichols Erin E, 2017, Int Ophthalmol Clin, V57, P1; NIELSEN M, 1987, BRIT J CANCER, V56, P814, DOI 10.1038/bjc.1987.296; Ogba N, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0489-4; Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991; Pan RY, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/4325874; Payne KK, 2016, J LEUKOCYTE BIOL, V100, P625, DOI 10.1189/jlb.5A1215-580R; Perez EA, 2019, CANCER-AM CANCER SOC, V125, P3974, DOI 10.1002/cncr.32392; Planes-Laine G, 2019, CANCERS, V11, DOI 10.3390/cancers11071033; Ranganathan AC, 2006, CANCER RES, V66, P1702, DOI 10.1158/0008-5472.CAN-05-3092; Ren D, 2019, J EXP MED, V216, P428, DOI 10.1084/jem.20180661; Sanger N, 2011, INT J CANCER, V129, P2522, DOI 10.1002/ijc.25895; Satelli A, 2015, CLIN CHEM, V61, P259, DOI 10.1373/clinchem.2014.228122; Schardt JA, 2005, CANCER CELL, V8, P227, DOI 10.1016/j.ccr.2005.08.003; Schmitt MJ, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478-811X-10-41; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Shachaf CM, 2004, NATURE, V431, P1112, DOI 10.1038/nature03043; Shah SA, 2017, IMMUNOTHERAPY-UK, V9, P943, DOI 10.2217/imt-2017-0044; Sinha G, 2012, J NATL CANCER I, V104, P1693, DOI 10.1093/jnci/djs478; Spirig R, 2009, MOL IMMUNOL, V46, P3178, DOI 10.1016/j.molimm.2009.05.179; Szikriszt B, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0963-7; Tan SH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142466; Teng MWL, 2008, J LEUKOCYTE BIOL, V84, P988, DOI 10.1189/jlb.1107774; Thery L, 2019, JNCI CANCER SPECT, V3, DOI 10.1093/jncics/pkz026; Tjensvoll K, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6268-y; Tonnessen-Murray CA, 2019, J CELL BIOL, V218, P3827, DOI 10.1083/jcb.201904051; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tran E, 2017, NAT IMMUNOL, V18, P255, DOI 10.1038/ni.3682; Tran E, 2014, SCIENCE, V344, P641, DOI 10.1126/science.1251102; Triana-Martinez F, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9020346; Trujillo JA, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0780-0; Turajlic S, 2017, LANCET ONCOL, V18, P1009, DOI 10.1016/S1470-2045(17)30516-8; van Buuren MM, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.28836; van Maaren MC, 2019, INT J CANCER, V144, P263, DOI 10.1002/ijc.31914; Ward JP, 2016, ADV IMMUNOL, V130, P25, DOI 10.1016/bs.ai.2016.01.001; Zhang XN, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4295; Zhu GZ, 2017, ACS NANO, V11, P2387, DOI 10.1021/acsnano.7b00978; Zolkind P, 2017, ORAL ONCOL, V71, P169, DOI 10.1016/j.oraloncology.2016.09.010	102	9	9	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	22					4323	4330		10.1038/s41388-020-1295-3	http://dx.doi.org/10.1038/s41388-020-1295-3		APR 2020	8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LR9IT	32322001	Green Accepted			2022-12-28	WOS:000528504800001
J	Zhang, X; Huang, ZN; Guo, YY; Xiao, T; Tang, L; Zhao, S; Wu, LS; Su, J; Zeng, WQ; Huang, HB; Li, Z; Tao, J; Zhou, JD; Chen, X; Peng, C				Zhang, Xu; Huang, Zunnan; Guo, Yeye; Xiao, Ta; Tang, Ling; Zhao, Shuang; Wu, Lisha; Su, Juan; Zeng, Weiqi; Huang, Hongbin; Li, Zheng; Tao, Juan; Zhou, Jianda; Chen, Xiang; Peng, Cong			The phosphorylation of CD147 by Fyn plays a critical role for melanoma cells growth and metastasis	ONCOGENE			English	Article							GNT-V; PROLIFERATION; INVASION; MATRIX-METALLOPROTEINASE-9; METALLOPROTEINASES; PROGRESSION; EXPRESSION; ADHESION; 3-KINASE; DOMAINS	CD147, also known as extracellular matrix metalloproteinase inducer (EMMPRIN), is a transmembrane glycoprotein that is highly expressed in tumor cells, particularly melanoma cells, and plays critical roles in tumor cell metastasis through the regulation of matrix metalloprotease (MMP) expression. In this study, we identified Fyn as a novel interacting protein of CD147. Fyn is a member of the Src family of nonreceptor tyrosine kinases that regulates diverse physiological processes, such as T lymphocyte differentiation, through the TCR signaling pathway. Our findings demonstrated that Fyn directly phosphorylates CD147 at Y140 and Y183. Two phosphospecific antibodies against Y140 and Y183 were developed to validate the phosphorylation of CD147 by Fyn. Moreover, the CD147-FF (Y140F/Y183F) mutation impaired the interaction between CD147 and GnT-V, leading to decreased CD147 glycosylation and membrane recruitment. In addition, CD147-FF significantly blocked MMP-9 expression as well as cell migration. Moreover, we found that Fyn is overexpressed in clinical melanoma tissues as well as in melanoma cell lines. Knockdown of Fyn expression markedly attenuated the malignant phenotype of melanoma cells in vitro and in vivo through downregulation of CD147 phosphorylation, indicating that Fyn/CD147 is a potential target molecule in melanoma treatment. Finally, through virtual screening, we identified amodiaquine as a potential inhibitor targeting the Fyn/CD147 axis. Amodiaquine treatment dramatically inhibited the phosphorylation of CD147 by Fyn, thus attenuating melanoma cell growth and invasion in vitro and in vivo, suggesting that amodiaquine is a promising inhibitor for melanoma treatment.	[Zhang, Xu; Guo, Yeye; Xiao, Ta; Tang, Ling; Zhao, Shuang; Wu, Lisha; Su, Juan; Zeng, Weiqi; Chen, Xiang; Peng, Cong] Cent South Univ, Xiangya Hosp, Dept Dermatol, Changsha, Hunan, Peoples R China; [Zhang, Xu; Guo, Yeye; Xiao, Ta; Tang, Ling; Zhao, Shuang; Wu, Lisha; Su, Juan; Zeng, Weiqi; Chen, Xiang; Peng, Cong] Cent South Univ, Xiangya Hosp, Hunan Key Lab Skin Canc & Psoriasis, Changsha, Hunan, Peoples R China; [Zhang, Xu; Guo, Yeye; Xiao, Ta; Tang, Ling; Zhao, Shuang; Wu, Lisha; Su, Juan; Zeng, Weiqi; Chen, Xiang; Peng, Cong] Cent South Univ, Xiangya Hosp, Hunan Engn Res Ctr Skin Hlth & Dis, Changsha, Hunan, Peoples R China; [Huang, Zunnan; Huang, Hongbin] Guangdong Med Univ, Res Platform Serv Management Ctr, Key Lab Big Data Min & Precis Drug Design, Dongguan 523808, Guangdong, Peoples R China; [Li, Zheng] Cent South Univ, Xiangya Hosp, Chinese Minist Hlth, Key Lab Carcinogenesis, Changsha, Hunan, Peoples R China; [Tao, Juan] Huazhong Univ Sci & Technol, Tongji Med Coll, Affiliated Union Hosp, Dept Dermatol, Wuhan, Peoples R China; [Zhou, Jianda] Cent South Univ, Xiangya Hosp 3, Dept Plast Surg, Changsha, Peoples R China	Central South University; Central South University; Central South University; Guangdong Medical University; Central South University; Huazhong University of Science & Technology; Central South University	Chen, X; Peng, C (corresponding author), Cent South Univ, Xiangya Hosp, Dept Dermatol, Changsha, Hunan, Peoples R China.; Chen, X; Peng, C (corresponding author), Cent South Univ, Xiangya Hosp, Hunan Key Lab Skin Canc & Psoriasis, Changsha, Hunan, Peoples R China.; Chen, X; Peng, C (corresponding author), Cent South Univ, Xiangya Hosp, Hunan Engn Res Ctr Skin Hlth & Dis, Changsha, Hunan, Peoples R China.	chenxiangck@126.com; pengcongxy@csu.edu.cn	Huang, Zunnan/M-5214-2019; Wu, Lisha/ABG-2923-2021; wu, Xianrui/AAM-6540-2021; zhao, shuangling/HCI-6255-2022	Huang, Zunnan/0000-0002-5821-703X; Wu, Lisha/0000-0003-2847-1982; wu, Xianrui/0000-0003-4803-5934; Zhao, Shuang/0000-0001-7081-6177	Major Projects of International Cooperation and Exchanges NSFC [81620108024]; National Natural Science Foundation [81572679, 81773341, 31770774, 81572677, 81830096]; Strategy-Oriented Special Project of Central South University in China [ZLXD2017003]; Provincial Major Project of basic or Applied Research in Natural Science, Guangdong Provincial, Education Department [2016KZDXM038]; China Postdoctoral Science Foundation [2019M652808]	Major Projects of International Cooperation and Exchanges NSFC; National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Strategy-Oriented Special Project of Central South University in China; Provincial Major Project of basic or Applied Research in Natural Science, Guangdong Provincial, Education Department; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This work was financially supported by the Major Projects of International Cooperation and Exchanges NSFC Grant No. 81620108024; Grant No. 81572679, 81773341, 31770774, 81572677, 81830096 from the National Natural Science Foundation; the Strategy-Oriented Special Project of Central South University in China (ZLXD2017003); the Provincial Major Project of basic or Applied Research in Natural Science, Guangdong Provincial, Education Department (2016KZDXM038) and the China Postdoctoral Science Foundation (2019M652808).	Baillat G, 2008, BBA-MOL CELL RES, V1783, P2323, DOI 10.1016/j.bbamcr.2008.08.008; Cotignola J, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-10; Cui J, 2018, J PATHOL, V245, P41, DOI 10.1002/path.5054; Elias D, 2015, PHARMACOL RES, V100, P250, DOI 10.1016/j.phrs.2015.08.010; Fan JH, 2012, GLYCOCONJUGATE J, V29, P323, DOI 10.1007/s10719-012-9414-1; Gruszewska Ewa, 2013, Pol Merkur Lekarski, V34, P58; Huang BB, 2014, INT J ONCOL, V44, P849, DOI 10.3892/ijo.2014.2248; Huang BB, 2013, ONCOL REP, V29, P2392, DOI 10.3892/or.2013.2373; Huang W, 2013, BIOCHEM J, V449, P437, DOI 10.1042/BJ20120343; Kanekura T, 2002, INT J CANCER, V99, P520, DOI 10.1002/ijc.10390; Kanekura T, 2010, J DERMATOL SCI, V57, P149, DOI 10.1016/j.jdermsci.2009.12.008; Kato N, 2009, J AM SOC NEPHROL, V20, P1565, DOI 10.1681/ASN.2008090957; Kuphal S, 2009, J PATHOL, V219, P400, DOI 10.1002/path.2617; Lang V, 1999, J IMMUNOL, V162, P7224; Li B, 2016, MOL MED REP, V13, P469, DOI 10.3892/mmr.2015.4492; Li JH, 2016, SCI REP-UK, V6, DOI 10.1038/srep35210; Li K, 2018, ANN RHEUM DIS, V77, P935, DOI 10.1136/annrheumdis-2017-212658; Liang XQ, 2004, J BIOL CHEM, V279, P8133, DOI 10.1074/jbc.M311180200; Liao CG, 2011, MOL CELL BIOL, V31, P2591, DOI 10.1128/MCB.05160-11; Long TT, 2013, CANCER LETT, V339, P93, DOI 10.1016/j.canlet.2013.07.019; Mauris J, 2014, J CELL SCI, V127, P3141, DOI 10.1242/jcs.148510; Mehner C, 2014, ONCOTARGET, V5, P2736, DOI 10.18632/oncotarget.1932; Miyamoto Y, 2016, DATA BRIEF, V7, P1098, DOI 10.1016/j.dib.2016.03.096; Moro N, 2014, EUR J CELL BIOL, V93, P23, DOI 10.1016/j.ejcb.2014.01.002; RAAB M, 1995, P NATL ACAD SCI USA, V92, P8891, DOI 10.1073/pnas.92.19.8891; Rey MCW, 2011, AM J DERMATOPATH, V33, P413, DOI 10.1097/DAD.0b013e3181e2e8d6; Saito YD, 2010, CANCER-AM CANCER SOC, V116, P1629, DOI 10.1002/cncr.24879; Salmond RJ, 2009, IMMUNOL REV, V228, P9, DOI 10.1111/j.1600-065X.2008.00745.x; Schaeuble K, 2011, J IMMUNOL, V187, P5645, DOI 10.4049/jimmunol.1101850; Su J, 2016, ONCOTARGET, V7, P64778, DOI 10.18632/oncotarget.11415; Su J, 2009, CANCER LETT, V273, P140, DOI 10.1016/j.canlet.2008.07.034; Susa M, 1996, BIOCHEM BIOPH RES CO, V220, P729, DOI 10.1006/bbrc.1996.0472; Tang Y, 2018, BIOCHEM BIOPH RES CO, V503, P3142, DOI 10.1016/j.bbrc.2018.08.107; Villanueva J, 2008, CURR ONCOL REP, V10, P439, DOI 10.1007/s11912-008-0067-y; Vultur Adina, 2013, Cancer Cell, V23, P706, DOI 10.1016/j.ccr.2013.05.001; Watanabe A, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003086; Wu JB, 2015, INT J CLIN EXP PATHO, V8, P9901; Yadav V, 2011, MOL CARCINOGEN, V50, P346, DOI 10.1002/mc.20716; Yu XL, 2006, INT J BIOCHEM CELL B, V38, P1939, DOI 10.1016/j.biocel.2006.05.008; Zeng W, 2014, CURR MOL MED, V14, P163, DOI 10.2174/15665240113136660077; Zhang J, 2014, MOL MED REP, V10, P1084, DOI 10.3892/mmr.2014.2277; Zhou J, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-25	42	11	12	2	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	21					4183	4197		10.1038/s41388-020-1287-3	http://dx.doi.org/10.1038/s41388-020-1287-3		APR 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LQ2DH	32291412				2022-12-28	WOS:000526237900005
J	Saliakoura, M; Reynoso-Moreno, I; Pozzato, C; Sebastiano, MR; Galie, M; Gertsch, J; Konstantinidou, G				Saliakoura, Maria; Reynoso-Moreno, Ines; Pozzato, Chiara; Rossi Sebastiano, Matteo; Galie, Mirco; Gertsch, Jurg; Konstantinidou, Georgia			The ACSL3-LPIAT1 signaling drives prostaglandin synthesis in non-small cell lung cancer	ONCOGENE			English	Article							GENE-EXPRESSION; PHOSPHOLIPASE A(2); GROWTH-FACTOR; FATTY-ACIDS; CYCLOOXYGENASE-2; PHOSPHATIDYLINOSITOL; INDUCTION; LIPIDOME; BREAST; PROGRESSION	Enhanced prostaglandin production promotes the development and progression of cancer. Prostaglandins are generated from arachidonic acid (AA) by the action of cyclooxygenase (COX) isoenzymes. However, how cancer cells are able to maintain an elevated supply of AA for prostaglandin production remains unclear. Here, by using lung cancer cell lines and clinically relevant Kras(G12D)-driven mouse models, we show that the long-chain acyl-CoA synthetase (ACSL3) channels AA into phosphatidylinositols to provide the lysophosphatidylinositol-acyltransferase 1 (LPIAT1) with a pool of AA to sustain high prostaglandin synthesis. LPIAT1 knockdown suppresses proliferation and anchorage-independent growth of lung cancer cell lines, and hinders in vivo tumorigenesis. In primary human lung tumors, the expression of LPIAT1 is elevated compared with healthy tissue, and predicts poor patient survival. This study uncovers the ACSL3-LPIAT1 axis as a requirement for the sustained prostaglandin synthesis in lung cancer with potential therapeutic value.	[Saliakoura, Maria; Pozzato, Chiara; Rossi Sebastiano, Matteo; Konstantinidou, Georgia] Univ Bern, Inst Pharmacol, CH-3010 Bern, Switzerland; [Reynoso-Moreno, Ines; Gertsch, Jurg] Univ Bern, Inst Biochem & Mol Med, CH-3012 Bern, Switzerland; [Galie, Mirco] Univ Verona, Dept Neurosci Biomed & Movement, I-37134 Verona, Italy	University of Bern; University of Bern; University of Verona	Konstantinidou, G (corresponding author), Univ Bern, Inst Pharmacol, CH-3010 Bern, Switzerland.	georgia.konstantinidou@pki.unibe.ch	Konstantinidou, Georgia/O-9192-2016	Konstantinidou, Georgia/0000-0001-9513-0286; Saliakoura, Maria/0000-0001-9021-2151; Gertsch, Jurg/0000-0003-0978-1555; GALIE', Mirco/0000-0002-6441-8313; Rossi Sebastiano, Matteo/0000-0002-9925-1904; Reynoso Moreno, Ines del Carmen/0000-0001-7672-8282	Swiss National Science Foundation (SNSF) [PP00P3_163929]; Novartis Foundation for medical-biological research [16C190]; UniBern Forschungsstiftung; SNSF [163359]	Swiss National Science Foundation (SNSF)(Swiss National Science Foundation (SNSF)); Novartis Foundation for medical-biological research; UniBern Forschungsstiftung; SNSF(Swiss National Science Foundation (SNSF))	The authors wish to thank Prof. Hiroyuki Arai (University of Tokyo, Japan) for providing the LPIAT1 antibody [39]. The NSCLC cell lines were a kind gift from Prof. John D. Minna (University of Southwestern Medical Center at Dallas, Texas, USA). Human tissues were provided by the Tissue Bank Bern. We thank Dr. Alexis Traynor-Kaplan (University of Washington, Medicinal Chemistry Mass Spectrometry Center, Washington, USA) for help with MS analysis. This study was supported by the Swiss National Science Foundation (SNSF) professorship PP00P3_163929, Novartis Foundation for medical-biological research #16C190, UniBern Forschungsstiftung (to GK), and SNSF research grant #163359 (to JG).	Balsinde J, 2002, FEBS LETT, V531, P2, DOI 10.1016/S0014-5793(02)03413-0; Baratelli F, 2005, J IMMUNOL, V175, P1483, DOI 10.4049/jimmunol.175.3.1483; Blaine SA, 2001, J BIOL CHEM, V276, P42737, DOI 10.1074/jbc.M107773200; Borer JS, 2005, ARTHRITIS RES THER, V7, pS14, DOI 10.1186/ar1794; Cancer Genome Atlas Research Network, 2014, Nature, V511, P543, DOI [10.1038/s41586-018-0228-6, 10.1038/nature13385]; Chicca A, 2017, P NATL ACAD SCI USA, V114, pE5006, DOI 10.1073/pnas.1704065114; D'Souza K, 2014, BBA-BIOMEMBRANES, V1838, P1501, DOI 10.1016/j.bbamem.2013.10.003; Dannenberg AJ, 2003, CANCER CELL, V4, P431, DOI 10.1016/S1535-6108(03)00310-6; Ejsing CS, 2009, P NATL ACAD SCI USA, V106, P2136, DOI 10.1073/pnas.0811700106; Ferrer I, 2018, LUNG CANCER, V124, P53, DOI 10.1016/j.lungcan.2018.07.013; Goldman M, 2018, PREPRINT, DOI DOI 10.1101/326470V3; Harris R. E., 2009, Inflammopharmacology, V17, P55, DOI 10.1007/s10787-009-8049-8; Herzog R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029851; Herzog R, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-1-r8; HOLUB BJ, 1971, J LIPID RES, V12, P699; Howe LR, 2002, CANCER RES, V62, P5405; Huang M, 1998, CANCER RES, V58, P1208; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; JUNGALWALA FB, 1984, J LIPID RES, V25, P738; Kaminska K, 2014, FUTURE ONCOL, V10, P2177, DOI 10.2217/fon.14.152; Kamphorst JJ, 2013, P NATL ACAD SCI USA, V110, P8882, DOI 10.1073/pnas.1307237110; LANDS WEM, 1958, J BIOL CHEM, V231, P883; Lee HC, 2008, MOL BIOL CELL, V19, P1174, DOI 10.1091/mbc.E07-09-0893; Lee HC, 2012, MOL BIOL CELL, V23, P4689, DOI 10.1091/mbc.E12-09-0673; Marino S, 2000, GENE DEV, V14, P994; Mashek DG, 2007, FUTURE LIPIDOL, V2, P465, DOI 10.2217/17460875.2.4.465; Meehan TF, 2015, NUCLEIC ACIDS RES, V43, pD1171, DOI 10.1093/nar/gku1193; Oliver TG, 2010, GENE DEV, V24, P837, DOI 10.1101/gad.1897010; Padanad MS, 2016, CELL REP, V16, P1614, DOI 10.1016/j.celrep.2016.07.009; Park JY, 2006, CLIN IMMUNOL, V119, P229, DOI 10.1016/j.clim.2006.01.016; PATTON GM, 1982, J LIPID RES, V23, P190; Perez R, 2006, J LIPID RES, V47, P484, DOI 10.1194/jlr.M500397-JLR200; Phelps RM, 1996, J CELL BIOCHEM, P32; Poligone B, 2001, J BIOL CHEM, V276, P38658, DOI 10.1074/jbc.M106599200; Quach ND, 2014, BIOCHEM PHARMACOL, V90, P338, DOI 10.1016/j.bcp.2014.05.022; Sampaio JL, 2011, P NATL ACAD SCI USA, V108, P1903, DOI 10.1073/pnas.1019267108; Sheng HM, 1998, J BIOL CHEM, V273, P22120, DOI 10.1074/jbc.273.34.22120; Slatter DA, 2016, CELL METAB, V23, P930, DOI 10.1016/j.cmet.2016.04.001; Smakman N, 2005, CLIN CANCER RES, V11, P41; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Stolina M, 2000, J IMMUNOL, V164, P361, DOI 10.4049/jimmunol.164.1.361; Subbaramaiah K, 2002, J BIOL CHEM, V277, P18649, DOI 10.1074/jbc.M111415200; Surette ME, 1999, CARCINOGENESIS, V20, P757, DOI 10.1093/carcin/20.5.757; Tanaka T, 2003, EUR J BIOCHEM, V270, P1466, DOI 10.1046/j.1432-1033.2003.03512.x; Traynor-Kaplan A, 2017, BBA-MOL CELL BIOL L, V1862, P513, DOI 10.1016/j.bbalip.2017.02.002; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; Wang D, 2006, GUT, V55, P115, DOI 10.1136/gut.2004.047100; Wang DZ, 2010, NAT REV CANCER, V10, P181, DOI 10.1038/nrc2809; Wang Z, 2014, GASTROENT RES PRACT, V2014, DOI 10.1155/2014/132320; Wymann MP, 2008, NAT REV MOL CELL BIO, V9, P162, DOI 10.1038/nrm2335; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742	53	24	25	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	14					2948	2960		10.1038/s41388-020-1196-5	http://dx.doi.org/10.1038/s41388-020-1196-5		FEB 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KZ2VB	32034305	Green Published, hybrid			2022-12-28	WOS:000511752600003
J	Misek, SA; Appleton, KM; Dexheimer, TS; Lisabeth, EM; Lo, RS; Larsen, SD; Gallo, KA; Neubig, RR				Misek, S. A.; Appleton, K. M.; Dexheimer, T. S.; Lisabeth, E. M.; Lo, R. S.; Larsen, S. D.; Gallo, K. A.; Neubig, R. R.			Rho-mediated signaling promotes BRAF inhibitor resistance in de-differentiated melanoma cells	ONCOGENE			English	Article							SERUM RESPONSE FACTOR; GROWTH-FACTOR; TRANSCRIPTIONAL PATHWAY; ACQUIRED-RESISTANCE; DRIVES RESISTANCE; RAF INHIBITION; COILED-COIL; ACTIN; GTPASES; KINASE	Over half of cutaneous melanoma tumors have BRAF(V600E/K) mutations. Acquired resistance to BRAF inhibitors (BRAFi) remains a major hurdle in attaining durable therapeutic responses. In this study we demonstrate that 50-60% of melanoma cell lines with vemurafenib resistance acquired in vitro show activation of RhoA family GTPases. In BRAFi-resistant melanoma cell lines and tumors, activation of RhoA is correlated with decreased expression of melanocyte lineage genes. Using a machine learning approach, we built gene expression-based models to predict drug sensitivity for 265 common anticancer compounds. We then projected these signatures onto the collection of TCGA cutaneous melanoma and found that poorly differentiated tumors were predicted to have increased sensitivity to multiple Rho kinase (ROCK) inhibitors. Two transcriptional effectors downstream of Rho, MRTF and YAP1, are activated in the Rho(High) BRAFi-resistant cell lines, and resistant cells are more sensitive to inhibition of these transcriptional mechanisms. Taken together, these results support the concept of targeting Rho-regulated gene transcription pathways as a promising therapeutic approach to restore sensitivity to BRAFi-resistant tumors or as a combination therapy to prevent the onset of drug resistance.	[Misek, S. A.; Gallo, K. A.] Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA; [Appleton, K. M.; Dexheimer, T. S.; Lisabeth, E. M.; Neubig, R. R.] Michigan State Univ, Dept Pharmacol & Toxicol, E Lansing, MI 48824 USA; [Lo, R. S.] Univ Calif Los Angeles, Dept Med, Div Dermatol, Los Angeles, CA 90095 USA; [Lo, R. S.] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; [Lo, R. S.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; [Lo, R. S.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Larsen, S. D.] Univ Michigan, Dept Med Chem, Ann Arbor, MI 48109 USA; [Larsen, S. D.] Univ Michigan, Vahlteich Med Chem Core, Ann Arbor, MI 48109 USA; [Neubig, R. R.] Michigan State Univ, Coll Human Med, Dept Med, Div Dermatol, E Lansing, MI 48824 USA	Michigan State University; Michigan State University; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Michigan State University; Michigan State University College of Human Medicine	Neubig, RR (corresponding author), Michigan State Univ, Dept Pharmacol & Toxicol, E Lansing, MI 48824 USA.; Neubig, RR (corresponding author), Michigan State Univ, Coll Human Med, Dept Med, Div Dermatol, E Lansing, MI 48824 USA.	rneubig@msu.edu		Neubig, Richard/0000-0003-0501-0008	NIH [R01 AR066049, F31 CA232555]; MSU Gran Fondo Skin Cancer Research Fund; MSUFCU Aitch Foundation Fellowship	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MSU Gran Fondo Skin Cancer Research Fund; MSUFCU Aitch Foundation Fellowship	This work was supported by NIH R01 AR066049 (SDL), the MSU Gran Fondo Skin Cancer Research Fund (RRN), NIH F31 CA232555 (SAM), MSUFCU Aitch Foundation Fellowship (SAM).	Abel EV, 2013, J CLIN INVEST, V123, P2155, DOI 10.1172/JCI65780; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bell JL, 2013, BIOORG MED CHEM LETT, V23, P3826, DOI 10.1016/j.bmcl.2013.04.080; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Das Thakur M, 2013, NATURE, V494, P251, DOI 10.1038/nature11814; Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106; Esnault C, 2014, GENE DEV, V28, P943, DOI 10.1101/gad.239327.114; Fallahi-Sichani M, 2017, MOL SYST BIOL, V13, DOI 10.15252/msb.20166796; Fisher ML, 2017, ONCOTARGET, V8, P110257, DOI 10.18632/oncotarget.22628; Foster CT, 2017, GENE DEV, V31, P2361, DOI 10.1101/gad.304501.117; Fujisawa K, 1996, J BIOL CHEM, V271, P23022, DOI 10.1074/jbc.271.38.23022; Haak Andrew J., 2016, MOL CANCER THER, V16, P193; Hodge RG, 2016, NAT REV MOL CELL BIO, V17, P496, DOI 10.1038/nrm.2016.67; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Hong A, 2018, CANCER DISCOV, V8, P74, DOI 10.1158/2159-8290.CD-17-0682; Hugo W, 2015, CELL, V162, P1271, DOI 10.1016/j.cell.2015.07.061; Hutchings KM, 2017, BIOORG MED CHEM LETT, V27, P1744, DOI 10.1016/j.bmcl.2017.02.070; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Johnson DB, 2015, EUR J CANCER, V51, P2792, DOI 10.1016/j.ejca.2015.08.022; Kim MH, 2016, EMBO J, V35, P462, DOI 10.15252/embj.201592081; Klein RM, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-114; Konieczkowski DJ, 2014, CANCER DISCOV, V4, P816, DOI 10.1158/2159-8290.CD-13-0424; Lamar JM, 2019, J BIOL CHEM, V294, P2302, DOI 10.1074/jbc.RA118.004364; Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868; Licciulli S, 2011, AM J PATHOL, V178, P2397, DOI 10.1016/j.ajpath.2011.01.019; Licciulli S, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-5; Lin LP, 2015, NAT GENET, V47, P250, DOI 10.1038/ng.3218; Lisabeth EM, 2018, IDENTIFICATION PIRIN, DOI DOI 10.1101/458554V1; Liu XF, 2016, CELL REP, V14, P1169, DOI 10.1016/j.celrep.2015.12.104; Marinissen MJ, 2004, MOL CELL, V14, P29, DOI 10.1016/S1097-2765(04)00153-4; Medjkane S, 2009, NAT CELL BIOL, V11, P257, DOI 10.1038/ncb1833; Miyazaki I, 2010, NAT CHEM BIOL, V6, P667, DOI [10.1038/NCHEMBIO.423, 10.1038/nchembio.423]; Moriceau G, 2015, CANCER CELL, V27, P240, DOI 10.1016/j.ccell.2014.11.018; Mouilleron S, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001750; Mouilleron S, 2008, EMBO J, V27, P3198, DOI 10.1038/emboj.2008.235; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Nishimura EK, 2010, CELL STEM CELL, V6, P130, DOI 10.1016/j.stem.2009.12.010; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Pan M, 2016, NAT CELL BIOL, V18, P1090, DOI 10.1038/ncb3410; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Pich C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148095; Posern G, 2006, TRENDS CELL BIOL, V16, P588, DOI 10.1016/j.tcb.2006.09.008; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Ramsdale R, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aab1111; Robert C, 2015, NEW ENGL J MED, V372, P30, DOI 10.1056/NEJMoa1412690; Rosenbluh J, 2012, CELL, V151, P1457, DOI 10.1016/j.cell.2012.11.026; Routhier A, 2010, ONCOL REP, V23, P861, DOI 10.3892/or_00000708; Ruth MC, 2006, J INVEST DERMATOL, V126, P862, DOI 10.1038/sj.jid.5700211; Saei A, 2018, J EXP MED, V215, P1913, DOI 10.1084/jem.20171960; Seo J, 2018, BMB REP, V51, P151, DOI 10.5483/BMBRep.2018.51.3.012; Shaffer SM, 2017, NATURE, V546, P431, DOI 10.1038/nature22794; Shakhova O, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1004877; Shen CH, 2016, NAT MED, V22, P1056, DOI 10.1038/nm.4155; Shi HB, 2014, CANCER DISCOV, V4, P80, DOI 10.1158/2159-8290.CD-13-0642; Shi HB, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1727; Si Y, 2017, CANCER RES, V77, P4868, DOI 10.1158/0008-5472.CAN-17-0391; Sit ST, 2011, J CELL SCI, V124, P679, DOI 10.1242/jcs.064964; Song CY, 2017, CANCER DISCOV, V7, P1248, DOI 10.1158/2159-8290.CD-17-0401; Spiering D, 2011, CELL ADHES MIGR, V5, P170, DOI 10.4161/cam.5.2.14403; Su YP, 2017, P NATL ACAD SCI USA, V114, P13679, DOI 10.1073/pnas.1712064115; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Taglietti V, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.163956; Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501; Tsoi J, 2018, CANCER CELL, V33, P890, DOI 10.1016/j.ccell.2018.03.017; Van Allen EM, 2014, CANCER DISCOV, V4, P94, DOI 10.1158/2159-8290.CD-13-0617; van Dijk D, 2018, CELL, V174, P716, DOI 10.1016/j.cell.2018.05.061; Vega FM, 2011, J CELL BIOL, V193, P655, DOI 10.1083/jcb.201011038; Whittaker SR, 2013, CANCER DISCOV, V3, P350, DOI 10.1158/2159-8290.CD-12-0470; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Yang G, 2008, MOL CELL, V32, P554, DOI 10.1016/j.molcel.2008.11.002; Yang WJ, 2013, NUCLEIC ACIDS RES, V41, pD955, DOI 10.1093/nar/gks1111; Ye SA, 2018, CANCER RES, V78, P2705, DOI 10.1158/0008-5472.CAN-17-4052; Yin LM, 2007, MOL CANCER THER, V6, P1517, DOI 10.1158/1535-7163.MCT-06-0689; Yui OM, 2018, ONCOGENE, V37, P5492, DOI 10.1038/s41388-018-0301-5; Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216; Zuckerbraun BS, 2003, CIRCULATION, V108, P876, DOI 10.1161/01.CIR.0000081947.00070.07	78	24	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	7					1466	1483		10.1038/s41388-019-1074-1	http://dx.doi.org/10.1038/s41388-019-1074-1			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KL2WP	31659259	Green Accepted			2022-12-28	WOS:000513289600006
J	Wu, XQ; Zhang, X; Yu, L; Zhang, C; Ye, LP; Ren, D; Li, Y; Sun, XQ; Yu, LF; Ouyang, Y; Chen, XF; Song, LB; Liu, P; Lin, X				Wu, Xianqiu; Zhang, Xin; Yu, Liang; Zhang, Chen; Ye, Liping; Ren, Dong; Li, Yue; Sun, Xiaoqing; Yu, Lefan; Ouyang, Ying; Chen, Xiangfu; Song, Libing; Liu, Pian; Lin, Xi			Zinc finger protein 367 promotes metastasis by inhibiting the Hippo pathway in breast cancer	ONCOGENE			English	Article							CIRCULATING TUMOR-CELLS; YES-ASSOCIATED PROTEIN; YAP; ANOIKIS; MECHANISMS; SUPPRESSOR; DORMANCY	Circulating tumor cells (CTC) disseminating is an important cause of distant metastasis. However, the mechanism involved in increasing the numbers of CTCs in breast cancer is unclear. Herein, Zinc finger protein 367 (ZNF367) was identified as a potential prometastatic gene in an integrative breast cancer datasets. ZNF367 was upregulated in breast cancer tissues and cell lines, and significantly correlated with poorer metastasis-free and overall survivals in patients. ZNF367 promoted tumor metastasis accompanied with increase of CTC numbers. Mechanistically, ZNF367 interacted with chromatin remodeling protein BRG1 and transcriptionally activated CIT and TP53BP2, leading to the inhibition of the Hippo pathway and activation of YAP1, which gave rise to the resistance of anoikis and increased CTCs in the blood circulation. More importantly, administration of a YAP1 inhibitor Verteporfin resensitized ZNF367-overexpressing breast cancer cells to anoikis and abrogated metastasis. Our findings addressed the importance of ZNF367 in breast cancer as a prognostic biomarker and offered a potential therapeutic strategy for the treatment of a subset of metastatic breast cancer with ZNF367 overexpression.	[Wu, Xianqiu; Zhang, Xin; Ye, Liping; Li, Yue; Sun, Xiaoqing; Ouyang, Ying; Chen, Xiangfu; Song, Libing; Lin, Xi] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Expt Res,State Key Lab Oncol Southern China, Guangzhou 510060, Peoples R China; [Wu, Xianqiu] Sun Yat Sen Univ, Affiliated Jiangmen Hosp, Jiangmen Cent Hosp, Dept Gastrointestinal Surg, Jiangmen 529030, Peoples R China; [Zhang, Xin; Ren, Dong] Sun Yat Sen Univ, Affiliated Jiangmen Hosp, Jiangmen Cent Hosp, Clin Expt Ctr, Jiangmen 529030, Peoples R China; [Yu, Liang] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Vasc & Breast Surg, Guangzhou 510080, Guangdong, Peoples R China; [Zhang, Chen] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Hepatobiliary Surg, Wuhan 430022, Peoples R China; [Yu, Lefan] UCL, Inst Struct & Mol Biol, Div Biosci, London WC1E 6BT, England; [Liu, Pian] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan 430022, Peoples R China; [Lin, Xi] Sun Yat Sen Univ, Canc Ctr, Ultrason Dept, Guangzhou 510060, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Huazhong University of Science & Technology; University of London; Birkbeck University London; University College London; Huazhong University of Science & Technology; Sun Yat Sen University	Lin, X (corresponding author), Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Expt Res,State Key Lab Oncol Southern China, Guangzhou 510060, Peoples R China.; Liu, P (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan 430022, Peoples R China.; Lin, X (corresponding author), Sun Yat Sen Univ, Canc Ctr, Ultrason Dept, Guangzhou 510060, Peoples R China.	liupianamazing@126.com; linxi@sysucc.org.cn	Zhang, Xin/C-2464-2017; Song, LB/AAL-1968-2020	Zhang, Xin/0000-0001-6036-2685; Ye, Liping/0000-0002-2263-0631	National Natural Science Foundation of China [81772800]; Fundamental Research Funds for the Central Universities [2017KFYXJJ258]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	This work was supported by National Natural Science Foundation of China (No. 81772800); Fundamental Research Funds for the Central Universities (No. 2017KFYXJJ258).	Asano H, 2004, BIOCHEM J, V384, P647, DOI 10.1042/BJ20040394; Aslan B, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8351; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Calvo F, 2013, NAT CELL BIOL, V15, P637, DOI 10.1038/ncb2756; Chen DH, 2012, NAT MED, V18, P1511, DOI 10.1038/nm.2940; Cristofanilli M, 2005, J CLIN ONCOL, V23, P1420, DOI 10.1200/JCO.2005.08.140; Cristofanilli M, 2004, NEW ENGL J MED, V351, P781, DOI 10.1056/NEJMoa040766; de Groot AF, 2017, CANCER TREAT REV, V60, P130, DOI 10.1016/j.ctrv.2017.09.003; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Espanel X, 2001, J BIOL CHEM, V276, P14514, DOI 10.1074/jbc.M008568200; Gao Y, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0340-0; Gibault F, 2017, CHEMMEDCHEM, V12, P954, DOI 10.1002/cmdc.201700063; Giuliano M, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0440-8; Gomis RR, 2006, CANCER CELL, V10, P203, DOI 10.1016/j.ccr.2006.07.019; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Jain M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101423; Lamar JM, 2012, P NATL ACAD SCI USA, V109, pE2441, DOI 10.1073/pnas.1212021109; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lin E, 2018, ANNU REV BIOMED ENG, V20, P329, DOI 10.1146/annurev-bioeng-062117-120947; Lu C, 2017, NAT GENET, V49, P178, DOI 10.1038/ng.3779; Lucci A, 2012, LANCET ONCOL, V13, P688, DOI 10.1016/S1470-2045(12)70209-7; Maheswaran S, 2008, NEW ENGL J MED, V359, P366, DOI 10.1056/NEJMoa0800668; McCarthy N, 2014, NAT REV CANCER, V14, DOI 10.1038/nrc3746; McFall A, 2001, MOL CELL BIOL, V21, P5488, DOI 10.1128/MCB.21.16.5488-5499.2001; Meng ZP, 2016, GENE DEV, V30, P1, DOI 10.1101/gad.274027.115; Rack B, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju066; Ren CL, 2016, INT J CANCER, V138, P1586, DOI 10.1002/ijc.29679; Shachaf CM, 2004, NATURE, V431, P1112, DOI 10.1038/nature03043; Sinn HP, 2010, PATHOLOGE, V31, P361, DOI 10.1007/s00292-010-1307-0; Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793; Tseng LM, 2013, NEOPLASMA, V60, P290, DOI 10.4149/neo_2013_038; Vora SR, 2014, CANCER CELL, V26, P136, DOI 10.1016/j.ccr.2014.05.020; Wang WQ, 2014, MOL CELL PROTEOMICS, V13, P119, DOI 10.1074/mcp.M113.030049; Wong CW, 2001, CANCER RES, V61, P333; Yu SJ, 2013, CLIN CANCER RES, V19, P1389, DOI 10.1158/1078-0432.CCR-12-1959; Yuan M, 2008, CELL DEATH DIFFER, V15, P1752, DOI 10.1038/cdd.2008.108; Zhang X, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0717-5; Zhang XP, 2017, ONCOTARGET, V8, P38863, DOI 10.18632/oncotarget.16408; Zhang ZL, 2009, CANCER EPIDEM BIOMAR, V18, P2685, DOI 10.1158/1055-9965.EPI-09-0097	39	22	23	3	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	12					2568	2582		10.1038/s41388-020-1166-y	http://dx.doi.org/10.1038/s41388-020-1166-y		JAN 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KW4HU	31988454				2022-12-28	WOS:000509655100001
J	Cui, JJ; Quan, M; Xie, DC; Gao, Y; Guha, S; Fallon, MB; Chen, JD; Xie, KP				Cui, Jiujie; Quan, Ming; Xie, Dacheng; Gao, Yong; Guha, Sushovan; Fallon, Michael B.; Chen, Jingde; Xie, Keping			A novel KDM5A/MPC-1 signaling pathway promotes pancreatic cancer progression via redirecting mitochondrial pyruvate metabolism	ONCOGENE			English	Article							DEMETHYLASE KDM5A; H3K4 DEMETHYLASE; TCA CYCLE; PROLIFERATION; REPRESSION; SUBTYPES; CARRIER	Mitochondrial pyruvate carrier 1 (MPC-1) appears to be a tumor suppressor. In this study, we determined the regulation of MPC-1 expression by Lysine demethylase 5A (KDM5A) and critical impact of this novel KDM5A/MPC-1 signaling on PDA progression. TCGA database, paired PDA and adjacent normal pancreatic tissues, PDA tissue array and cell lines were used to determine the levels of MPC-1 and KDM5A expression, and their relationship with the clinicopathologic characteristics and overall survival (OS) of PDA patients. Both in vitro and in vivo models were used to determine biologic impacts of MPC-1 and KDM5A on PDA and mitochondrial pyruvate metabolism, and the mechanism underling reduced MPC-1 expression in PDA. The expression of MPC-1 was decreased in PDA cell lines and tissues, and negatively associated with tumor poorer differentiation, lymph nodes metastasis, higher TNM stages, and patients' overall survival (OS). Functional analysis revealed that restored expression of MPC-1 suppressed the growth, invasion, migration, stemness and tumorigenicity. Re-expression of MPC-1 stimulated the mitochondrial pyruvate metabolism and inhibited glycolysis, while MPC-1-specific inhibitor UK5099 attenuated these effects. Furthermore, KDM5A bound directly to MPC-1 promoter region and transcriptionally suppressed the expression of MPC-1 via demethylation H3K4. Consistently, KDM5A expression was elevated in PDA and promoted PDA cell proliferation in vitro and tumor growth in vivo via suppressing the expression of MPC-1. The expression of KDM5A was inversely correlated with that of MPC-1 in PDA. KDM5A/MPC-1 signaling promoted PDA growth, invasion, migration, and stemness via inhibiting mitochondrial pyruvate metabolism. Targeting KDM5A/MPC-1 signaling may be an effective therapeutic strategy for PDA.	[Cui, Jiujie] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Shanghai Canc Inst,Dept Med Oncol, Shanghai, Peoples R China; [Cui, Jiujie] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Shanghai Canc Inst,State Key Lab Oncogene & Relat, Shanghai, Peoples R China; [Quan, Ming; Xie, Dacheng; Gao, Yong; Chen, Jingde] Tongji Univ, Shanghai East Hosp, Dept Oncol, Sch Med, Shanghai, Peoples R China; [Quan, Ming; Xie, Dacheng; Gao, Yong; Chen, Jingde] Tongji Univ, Shanghai East Hosp, Tumor Inst, Sch Med, Shanghai, Peoples R China; [Guha, Sushovan; Fallon, Michael B.; Xie, Keping] Univ Arizona, Dept Med, Coll Med Phoenix, Phoenix, AZ 85004 USA; [Xie, Keping] Univ Arizona, Dept Interdisciplinary Oncol, Coll Med Phoenix, Phoenix, AZ 85004 USA	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Tongji University; Tongji University; University of Arizona; University of Arizona	Quan, M; Chen, JD (corresponding author), Tongji Univ, Shanghai East Hosp, Dept Oncol, Sch Med, Shanghai, Peoples R China.; Quan, M; Chen, JD (corresponding author), Tongji Univ, Shanghai East Hosp, Tumor Inst, Sch Med, Shanghai, Peoples R China.; Xie, KP (corresponding author), Univ Arizona, Dept Med, Coll Med Phoenix, Phoenix, AZ 85004 USA.; Xie, KP (corresponding author), Univ Arizona, Dept Interdisciplinary Oncol, Coll Med Phoenix, Phoenix, AZ 85004 USA.	mquan2015@163.com; nade@163.com; kepingxie@gmail.com			National Natural Science Foundation of China [81502018, 81502043, 81602051]; Shanghai "Rising Stars of Medical Talent" Youth Development Program [[2019]72]; Youth Medical Talents-Specialist Program [[2019]72]; Fundamental Research Funds for the Central Universities [22120180029]; Outstanding Clinical Discipline Project of Shanghai Pudong [PWYgy2018-02]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai "Rising Stars of Medical Talent" Youth Development Program; Youth Medical Talents-Specialist Program; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Outstanding Clinical Discipline Project of Shanghai Pudong	This work was supported by grants 81502018 (to JC), 81502043 (to MQ) and 81602051 (to DX) from National Natural Science Foundation of China; grant [2019]72 (to JC) from Shanghai "Rising Stars of Medical Talent" Youth Development Program, Youth Medical Talents-Specialist Program; Fundamental Research Funds for the Central Universities 22120180029 (to MQ); The Outstanding Clinical Discipline Project of Shanghai Pudong (Grant No. PWYgy2018-02).	Aguirre-Gamboa R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074250; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Beshiri ML, 2012, P NATL ACAD SCI USA, V109, P18499, DOI 10.1073/pnas.1216724109; Birsoy K, 2015, CELL, V162, P540, DOI 10.1016/j.cell.2015.07.016; Blair Lauren P, 2011, Cancers (Basel), V3, P1383, DOI 10.3390/cancers3011383; Bricker DK, 2012, SCIENCE, V337, P96, DOI 10.1126/science.1218099; Brivet M, 2003, MOL GENET METAB, V78, P186, DOI 10.1016/S1096-7192(03)00016-7; Collisson EA, 2011, NAT MED, V17, P500, DOI 10.1038/nm.2344; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; FLAVELL RB, 1971, NATURE, V230, P504, DOI 10.1038/230504a0; Gong F, 2017, J CELL BIOL, V216, P1959, DOI 10.1083/jcb.201611135; Herzig S, 2012, SCIENCE, V337, P93, DOI 10.1126/science.1218530; Howe FS, 2017, BIOESSAYS, V39, DOI 10.1002/bies.201600095; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Klose RJ, 2007, CELL, V128, P889, DOI 10.1016/j.cell.2007.02.013; Li XL, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2941-6; Li YQ, 2017, ONCOTARGET, V8, P1058, DOI 10.18632/oncotarget.13717; LOFRUMENTO NE, 1971, B SOC ITAL BIOL SPER, V47, P676; Lopez-Bigas N, 2008, MOL CELL, V31, P520, DOI 10.1016/j.molcel.2008.08.004; Mair B, 2014, TRENDS PHARMACOL SCI, V35, P136, DOI 10.1016/j.tips.2014.01.001; Martinez-Reyes I, 2016, MOL CELL, V61, P199, DOI 10.1016/j.molcel.2015.12.002; Pasini D, 2008, GENE DEV, V22, P1345, DOI 10.1101/gad.470008; Peng JC, 2009, CELL, V139, P1290, DOI 10.1016/j.cell.2009.12.002; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Schell JC, 2017, NAT CELL BIOL, V19, P1027, DOI 10.1038/ncb3593; Schell JC, 2014, MOL CELL, V56, P400, DOI 10.1016/j.molcel.2014.09.026; Shannon CE, 2017, FEBS J, V284, P451, DOI 10.1111/febs.13992; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sullivan LB, 2015, CELL, V162, P552, DOI 10.1016/j.cell.2015.07.017; Takaoka Y, 2019, CANCER SCI, V110, P1331, DOI 10.1111/cas.13980; Tu SJ, 2008, NAT STRUCT MOL BIOL, V15, P419, DOI 10.1038/nsmb.1400; Tzatsos A, 2013, J CLIN INVEST, V123, P727, DOI 10.1172/JCI64535; Varaljai R, 2015, GENE DEV, V29, P1817, DOI 10.1101/gad.264036.115; Wang CD, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.238; WARBURG O, 1956, SCIENCE, V124, P269; Yamamoto K, 2014, CARCINOGENESIS, V35, P2404, DOI 10.1093/carcin/bgu136; Yang CD, 2014, MOL CELL, V56, P414, DOI 10.1016/j.molcel.2014.09.025; Zhao DZ, 2016, CELL REP, V15, P288, DOI 10.1016/j.celrep.2016.03.035; Zou HB, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1324-8	39	19	20	0	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	5					1140	1151		10.1038/s41388-019-1051-8	http://dx.doi.org/10.1038/s41388-019-1051-8			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KI2VY	31641207				2022-12-28	WOS:000511209700014
J	Wegert, J; Zauter, L; Appenzeller, S; Otto, C; Bausenwein, S; Vokuhl, C; Ernestus, K; Furtwangler, R; Graf, N; Gessler, M				Wegert, Jenny; Zauter, Lisa; Appenzeller, Silke; Otto, Christoph; Bausenwein, Sabrina; Vokuhl, Christian; Ernestus, Karen; Furtwaengler, Rhoikos; Graf, Norbert; Gessler, Manfred			High-risk blastemal Wilms tumor can be modeled by 3D spheroid cultures in vitro	ONCOGENE			English	Article							STEM-CELLS; MUTATIONS; CANCER; PROGENITORS; MARKERS; KIDNEY; GENES; MOUSE; LINE	In vitro models represent a critical tool in cancer research to study tumor biology and to evaluate new treatment options. Unfortunately, there are no effective preclinical models available that represent Wilms tumor (WT) - the most common pediatric renal tumor. Especially the high-risk blastemal WT subtype is not represented by the few primary cell lines established until now. Here, we describe a new 3D approach for in vitro cultivation of blastemal WT cells, where primary cultures grown in suspension as spheroids could be propagated long-term. Besides blastemal cultures, we could generate spheroids representing epithelial and stromal WT. Spheroid cultures were analyzed by immunohistochemistry in comparison to corresponding tumor sections and were further characterized by RNA sequencing. Histological appearance of spheroids resembled the original tumor and they expressed marker genes characteristic of early renal development and blastemal WT elements. The cultures were amenable to genetic manipulation and they formed xenograft tumors, which resemble the primary human tumor. This collection of WT spheroids that carry different genetic drivers forms a long-sought tool for drug testing and in vitro modeling.	[Wegert, Jenny; Zauter, Lisa; Bausenwein, Sabrina; Gessler, Manfred] Univ Wurzburg, Theodor Boveri Inst, Dev Biochem, Bioctr, Wurzburg, Germany; [Appenzeller, Silke; Gessler, Manfred] Univ Wurzburg, Comprehens Canc Ctr Mainfranken, Wurzburg, Germany; [Otto, Christoph] Univ Hosp Wuerzburg, Dept Gen Visceral Vasc & Pediat Surg, Expt Surg, Wurzburg, Germany; [Vokuhl, Christian] Univ Hosp Kiel, Dept Pathol, Sect Pediat Pathol, Kiel Pediat Tumor Registry, Kiel, Germany; [Ernestus, Karen] Univ Wurzburg, Inst Pathol, Wurzburg, Germany; [Furtwaengler, Rhoikos; Graf, Norbert] Saarland Univ, Childrens Hosp, Pediat Oncol & Hematol, Homburg, Germany; [Furtwaengler, Rhoikos; Graf, Norbert] Saarland Univ, Med Ctr, Homburg, Germany	University of Wurzburg; University of Wurzburg; University of Wurzburg; University of Kiel; Schleswig Holstein University Hospital; University of Wurzburg; Universitatsklinikum des Saarlandes; Universitatsklinikum des Saarlandes	Gessler, M (corresponding author), Univ Wurzburg, Theodor Boveri Inst, Dev Biochem, Bioctr, Wurzburg, Germany.; Gessler, M (corresponding author), Univ Wurzburg, Comprehens Canc Ctr Mainfranken, Wurzburg, Germany.	gessler@biozentrum.uni-wuerzburg.de	Vokuhl, Christian/M-1511-2017; Furtwängler, Rhoikos/V-3519-2018; Graf, Norbert/H-1328-2011	Furtwängler, Rhoikos/0000-0002-1967-8343; Graf, Norbert/0000-0002-2248-323X; Gessler, Manfred/0000-0002-7915-6045; Appenzeller, Silke/0000-0002-5472-8692	Deutsche Forschungsgemeinschaft [DFG Ge539/13]; Wilhelm-Sander-Stiftung	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Wilhelm-Sander-Stiftung	We thank patients for participating in our research and the members of the GPOH WT study group for their efforts in collecting precious samples and data. This study was supported by the Deutsche Forschungsgemeinschaft (DFG Ge539/13) and the Wilhelm-Sander-Stiftung.	Alami J, 2003, INT J CANCER, V107, P365, DOI 10.1002/ijc.11429; Bhakta N, 2017, LANCET, V390, P2569, DOI 10.1016/S0140-6736(17)31610-0; BRESLOW N, 1993, MED PEDIATR ONCOL, V21, P172, DOI 10.1002/mpo.2950210305; Chagtai T, 2016, J CLIN ONCOL, V34, P3195, DOI 10.1200/JCO.2015.66.0001; Dome JS, 2015, J CLIN ONCOL, V33, P2999, DOI 10.1200/JCO.2015.62.1888; Drost J, 2018, NAT REV CANCER, V18, P407, DOI 10.1038/s41568-018-0007-6; Faussilion M, 2008, CANCER GENET CYTOGEN, V184, P22, DOI 10.1016/j.cancergencyto.2008.02.018; Gadd S, 2017, NAT GENET, V49, P1487, DOI 10.1038/ng.3940; GARVIN AJ, 1987, AM J PATHOL, V129, P353; Hochane M, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000152; Houghton PJ, 2007, PEDIATR BLOOD CANCER, V49, P928, DOI 10.1002/pbc.21078; Hu QH, 2011, J CLIN INVEST, V121, P174, DOI 10.1172/JCI43772; Huff V, 2011, NAT REV CANCER, V11, P111, DOI 10.1038/nrc3002; Kumar SV, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.172361; Li ZW, 2016, CELL STEM CELL, V19, P516, DOI 10.1016/j.stem.2016.07.016; Lindstrom NO, 2018, DEV CELL, V45, P651, DOI 10.1016/j.devcel.2018.05.010; Magella B, 2018, DEV BIOL, V434, P36, DOI 10.1016/j.ydbio.2017.11.006; Pode-Shakked N, 2013, EMBO MOL MED, V5, P18, DOI 10.1002/emmm.201201516; Royer-Pokora B, 2010, HUM MOL GENET, V19, P1651, DOI 10.1093/hmg/ddq042; Sachs N, 2014, CURR OPIN GENET DEV, V24, P68, DOI 10.1016/j.gde.2013.11.012; Sadak KT, 2013, NAT REV UROL, V10, P15, DOI 10.1038/nrurol.2012.218; Schutgens F, 2019, NAT BIOTECHNOL, V37, P303, DOI 10.1038/s41587-019-0048-8; Shukrun R, 2014, STEM CELL REP, V3, DOI 10.1016/j.stemcr.2014.05.013; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; Urbach A, 2014, GENE DEV, V28, P971, DOI 10.1101/gad.237149.113; Vujanic GM, 2018, NAT REV UROL, V15, P693, DOI 10.1038/s41585-018-0100-3; Walz AL, 2015, CANCER CELL, V27, P286, DOI 10.1016/j.ccell.2015.01.003; Wegert J, 2015, CANCER CELL, V27, P298, DOI 10.1016/j.ccell.2015.01.002; Wegert J, 2012, GENE CHROMOSOME CANC, V51, P92, DOI 10.1002/gcc.20936; Wittmann S, 2008, GENE CHROMOSOME CANC, V47, P386, DOI 10.1002/gcc.20544; Zweigerdt R, 2003, CYTOTHERAPY, V5, P399, DOI 10.1080/14653240310003062	31	9	10	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	4					849	861		10.1038/s41388-019-1027-8	http://dx.doi.org/10.1038/s41388-019-1027-8			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KF4EJ	31562394	Green Published, hybrid			2022-12-28	WOS:000509197200008
J	Xu, J; Brosseau, JP; Shi, HB				Xu, Jie; Brosseau, Jean-Philippe; Shi, Hubing			Targeted degradation of immune checkpoint proteins: emerging strategies for cancer immunotherapy	ONCOGENE			English	Review							CELL-INTRINSIC PD-1; LYSOSOMAL DEGRADATION; DOWN-REGULATION; HIV-1 NEF; OPPORTUNITIES; MOTIF	Cancer immunotherapy using immune-checkpoint blockade has displayed promising clinical effects, but prevalent antibody-based inhibitors face multiple challenges such as low response rate, acquired resistance, and adverse effects. The intracellular expression of PD-1/PD-L1 in recycling endosomes and their active trafficking to membrane highlight the importance of depleting rather than interfering with checkpoint proteins. Preclinical investigations on the therapeutic effects of lead compounds that function by degrading immune checkpoint ligands and receptors have reported highly promising results. By harnessing the degradation capabilities of the lysosome, proteasome and autophagosomes, different small molecules and peptides potently induced degradation of checkpoint proteins and enhanced anti-tumor immunity. Both in vitro and in vivo experiments support the therapeutic efficacy of these molecules. Thus, targeted degradation through endo-lysosomal, autophagic, proteasomal, or endoplasmic reticulum-related pathways may provide promising strategies for tackling the challenges in cancer immunotherapy.	[Xu, Jie] Fudan Univ, Inst Biomed Sci, Shanghai, Peoples R China; [Xu, Jie] Fudan Univ, Zhongshan Xuhui Hosp, Key Lab Epigenet & Metab, Shanghai, Peoples R China; [Brosseau, Jean-Philippe] Ctr Hosp Sherbrooke, Ctr Rech, Sherbrooke, PQ, Canada; [Brosseau, Jean-Philippe] Univ Sherbrooke, Dept Biochem & Funct Genom, Sherbrooke, PQ, Canada; [Shi, Hubing] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Lab Tumor Targeted & Immune Therapy,Clin Res Ctr, Chengdu, Peoples R China; [Shi, Hubing] Collaborat Innovat Ctr Biotherapy, Chengdu, Peoples R China	Fudan University; Fudan University; University of Sherbrooke; Sichuan University	Xu, J (corresponding author), Fudan Univ, Inst Biomed Sci, Shanghai, Peoples R China.; Xu, J (corresponding author), Fudan Univ, Zhongshan Xuhui Hosp, Key Lab Epigenet & Metab, Shanghai, Peoples R China.	jie_xu@fudan.edu.cn	Xu, Jie/K-3712-2019	Xu, Jie/0000-0001-9163-3898; Shi, Hubing/0000-0002-2926-3440	National Natural Science Foundation of China [82030104, 81874050, 81572326]; Basic Research Projects of Shanghai Science and Technology Innovation Action Plan [20JC1410700]; National Key R & D Program of China [2016YFC0906002]; Startup Research Funding of Fudan University	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Basic Research Projects of Shanghai Science and Technology Innovation Action Plan; National Key R & D Program of China; Startup Research Funding of Fudan University	This work was supported by National Natural Science Foundation of China (No: 82030104, 81874050, 81572326), Basic Research Projects of Shanghai Science and Technology Innovation Action Plan (20JC1410700); National Key R & D Program of China (2016YFC0906002, 2016YFC0906002), Tang Scholar (JX), and Startup Research Funding of Fudan University.	Baek K, 2020, NAT CHEM BIOL, V16, P2, DOI 10.1038/s41589-019-0414-3; Brosseau JP, 2020, ADV EXP MED BIOL, V1248, P251, DOI 10.1007/978-981-15-3266-5_11; Burr ML, 2017, NATURE, V549, P101, DOI 10.1038/nature23643; Cha JH, 2020, CSH PERSPECT MED, V10, DOI 10.1101/cshperspect.a036863; Cha JH, 2019, MOL CELL, V76, P359, DOI 10.1016/j.molcel.2019.09.030; Cha JH, 2018, MOL CELL, V71, P606, DOI 10.1016/j.molcel.2018.07.030; Chamberlain PP, 2019, NAT CHEM BIOL, V15, P937, DOI 10.1038/s41589-019-0362-y; Chen SL, 2019, CURR TOP MED CHEM, V19, P180, DOI 10.2174/1568026619666190308131805; Delport A, 2019, MOLECULES, V24, DOI 10.3390/molecules24183272; Deng SY, 2020, ADV EXP MED BIOL, V1248, P431, DOI 10.1007/978-981-15-3266-5_18; Dong PX, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00386; Dua P, 2015, NUCLEIC ACID THER, V25, P180, DOI 10.1089/nat.2014.0516; Dvela-Levitt M, 2019, CELL, V178, P521, DOI 10.1016/j.cell.2019.07.002; Endicott SJ, 2021, AUTOPHAGY, V17, P612, DOI 10.1080/15548627.2020.1725378; Esfahani K, 2019, NEW ENGL J MED, V380, P2375, DOI 10.1056/NEJMc1903064; Fan XL, 2014, NAT NEUROSCI, V17, P471, DOI 10.1038/nn.3637; Gao HY, 2020, ACS MED CHEM LETT, V11, P237, DOI 10.1021/acsmedchemlett.9b00597; Gao HL, 2013, SCI REP-UK, V3, DOI 10.1038/srep02534; Gomez-Navarro N, 2016, J CELL BIOL, V215, P769, DOI 10.1083/jcb.201610031; Greenberg M, 1998, CURR BIOL, V8, P1239, DOI 10.1016/S0960-9822(07)00518-0; Greillier L, 2018, TRANSL LUNG CANCER R, V7, P639, DOI 10.21037/tlcr.2018.10.08; Hakenberg OW, 2017, EXPERT OPIN BIOL TH, V17, P1309, DOI 10.1080/14712598.2017.1353076; Hsu JM, 2018, CANCER RES, V78, P6349, DOI 10.1158/0008-5472.CAN-18-1892; Johansen T, 2011, AUTOPHAGY, V7, P279, DOI 10.4161/auto.7.3.14487; Kiran S, 2020, CHEM COMMUN, V56, P285, DOI 10.1039/c9cc09131a; Kleffel S, 2015, CELL, V162, P1242, DOI 10.1016/j.cell.2015.08.052; Li H, 2017, HEPATOLOGY, V66, P1920, DOI 10.1002/hep.29360; Liang LX, 2018, CELL CHEM BIOL, V25, P761, DOI 10.1016/j.chembiol.2018.03.010; Liu Y, 2019, TRANSL LUNG CANCER R, V8, P1125, DOI 10.21037/tlcr.2019.11.26; Lyle C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56208-1; Meng XB, 2018, NATURE, V564, P130, DOI 10.1038/s41586-018-0756-0; Neklesa T, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.7_suppl.259; Pu N, 2019, CANCER LETT, V460, P42, DOI 10.1016/j.canlet.2019.06.013; Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168; Riggs NL, 1999, VIROLOGY, V258, P203, DOI 10.1006/viro.1999.9736; Santos R, 2017, NAT REV DRUG DISCOV, V16, P19, DOI 10.1038/nrd.2016.230; Steven B, 2019, LYSOSOME TARGETING C, V584, P291; Sun XY, 2019, SIGNAL TRANSDUCT TAR, V4, DOI 10.1038/s41392-019-0101-6; Theivanthiran B, 2020, J CLIN INVEST, V130, P2570, DOI 10.1172/JCI133055; Valdor R, 2019, P NATL ACAD SCI USA, V116, P20655, DOI 10.1073/pnas.1903542116; Verdura S, 2020, AGING-US, V12, P8, DOI 10.18632/aging.102646; Wang HB, 2020, ADV EXP MED BIOL, V1248, P325, DOI 10.1007/978-981-15-3266-5_14; Wang HB, 2019, NAT CHEM BIOL, V15, P42, DOI 10.1038/s41589-018-0161-x; Wang J, 2019, NAT MED, V25, P656, DOI 10.1038/s41591-019-0374-x; Wang XJ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1148-5; Wang Y, 2020, ACTA PHARMACOL SIN B, V10, P207, DOI 10.1016/j.apsb.2019.08.001; Wang YC, 2019, JAMA ONCOL, V5, P1008, DOI 10.1001/jamaoncol.2019.0393; Wang YG, 2020, CANCER BIOL MED, V17, P583, DOI 10.20892/j.issn.2095-3941.2020.0066; Wei Z, 2019, CELL REP, V28, P554, DOI 10.1016/j.celrep.2019.05.033; Wu JJ, 2018, CANCER MED-US, V7, P4004, DOI 10.1002/cam4.1675; Yang Q, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00447; Yao H, 2019, PALMITOYLATION IS CR; Yao H, 2020, ADV EXP MED BIOL, V1248, P295, DOI 10.1007/978-981-15-3266-5_13; Yao H, 2019, NAT BIOMED ENG, V3, P306, DOI 10.1038/s41551-019-0375-6; Yao H, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01774; Zhang JF, 2018, NATURE, V553, P91, DOI 10.1038/nature25015	56	10	10	3	41	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	2020	39	48					7106	7113		10.1038/s41388-020-01491-w	http://dx.doi.org/10.1038/s41388-020-01491-w		OCT 2020	8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PE1YE	33024277				2022-12-28	WOS:000575700700001
J	Bisteau, X; Lee, J; Srinivas, V; Lee, JHS; Niska-Blakie, J; Tan, GF; Yap, SYX; Hom, KW; Wong, CK; Chae, J; Wang, LC; Kim, J; Rancati, G; Sobota, RM; Tan, CSH; Kaldis, P				Bisteau, Xavier; Lee, Joann; Srinivas, Vinayaka; Lee, Joanna H. S.; Niska-Blakie, Joanna; Tan, Gifford; Yap, Shannon Y. X.; Hom, Kevin W.; Wong, Cheng Kit; Chae, Jeongjun; Wang, Loo Chien; Kim, Jinho; Rancati, Giulia; Sobota, Radoslaw M.; Tan, Chris S. H.; Kaldis, Philipp			The Greatwall kinase safeguards the genome integrity by affecting the kinome activity in mitosis	ONCOGENE			English	Article							CELL-CYCLE; PROTEIN-KINASE; MITOTIC EXIT; HOMOLOGOUS RECOMBINATION; NEK2 KINASE; BINDING PROTEIN; HISTONE H2AX; AURORA-A; PHOSPHORYLATION; DEPHOSPHORYLATION	Progression through mitosis is balanced by the timely regulation of phosphorylation and dephosphorylation events ensuring the correct segregation of chromosomes before cytokinesis. This balance is regulated by the opposing actions of CDK1 and PP2A, as well as the Greatwall kinase/MASTL. MASTL is commonly overexpressed in cancer, which makes it a potential therapeutic anticancer target. Loss ofMastlinduces multiple chromosomal errors that lead to the accumulation of micronuclei and multilobulated cells in mitosis. Our analyses revealed that loss ofMastlleads to chromosome breaks and abnormalities impairing correct segregation. Phospho-proteomic data forMastlknockout cells revealed alterations in proteins implicated in multiple processes during mitosis including double-strand DNA damage repair. In silico prediction of the kinases with affected activity unveiled NEK2 to be regulated in the absence ofMastl. We uncovered that, RAD51AP1, involved in regulation of homologous recombination, is phosphorylated by NEK2 and CDK1 but also efficiently dephosphorylated by PP2A/B55. Our results suggest thatMastlKOdisturbs the equilibrium of the mitotic phosphoproteome that leads to the disruption of DNA damage repair and triggers an accumulation of chromosome breaks even in noncancerous cells.	[Bisteau, Xavier; Lee, Joann; Lee, Joanna H. S.; Niska-Blakie, Joanna; Tan, Gifford; Yap, Shannon Y. X.; Hom, Kevin W.; Wang, Loo Chien; Sobota, Radoslaw M.; Tan, Chris S. H.; Kaldis, Philipp] ASTAR, Inst Mol & Cell Biol IMCB, Singapore 138673, Singapore; [Srinivas, Vinayaka] Duke NUS Grad Med Sch, Program Canc & Stem Cell Biol, Singapore 169857, Singapore; [Niska-Blakie, Joanna; Tan, Chris S. H.] ASTAR, Bioinformat Inst BII, Singapore 138671, Singapore; [Wong, Cheng Kit; Rancati, Giulia] ASTAR, Inst Med Biol, Singapore 138648, Singapore; [Chae, Jeongjun] Sungkyunkwan Univ, SAIHST, Dept Hlth Sci & Technol, Seoul 06351, South Korea; [Wang, Loo Chien; Sobota, Radoslaw M.] ASTAR, IMCB, Funct Prote Lab, Singapore 138673, Singapore; [Kim, Jinho] Samsung Med Ctr, Samsung Genome Inst, Seoul 06351, South Korea; [Kaldis, Philipp] Lund Univ, Clin Res Ctr CRC, Dept Clin Sci, Box 50332, S-20213 Malmo, Sweden; [Bisteau, Xavier] Univ Libre Bruxelles ULB, IRIBHM, Campus Erasme Blg C, Brussels, Belgium; [Lee, Joanna H. S.] Ewha Womans Univ, 52 Ewhayeodae Gil, Seoul, South Korea; [Tan, Chris S. H.] Southern Univ Sci & Technol, Coll Sci, Dept Chem, Shenzhen, Peoples R China	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Bioinformatics Institute (BII); Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB); Sungkyunkwan University (SKKU); Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Samsung; Sungkyunkwan University (SKKU); Samsung Medical Center; Lund University; Universite Libre de Bruxelles; Ewha Womans University; Southern University of Science & Technology	Bisteau, X; Kaldis, P (corresponding author), ASTAR, Inst Mol & Cell Biol IMCB, Singapore 138673, Singapore.; Kaldis, P (corresponding author), Lund Univ, Clin Res Ctr CRC, Dept Clin Sci, Box 50332, S-20213 Malmo, Sweden.; Bisteau, X (corresponding author), Univ Libre Bruxelles ULB, IRIBHM, Campus Erasme Blg C, Brussels, Belgium.	xbisteau@ulb.ac.be; philipp.kaldis@med.lu.se	Bisteau, Xavier/AAH-6744-2021; Bisteau, Xavier/Q-7239-2018; Kaldis, Philipp/G-2714-2010	Bisteau, Xavier/0000-0002-8896-5098; Kaldis, Philipp/0000-0002-7247-7591; Lee, Joanna/0000-0002-1941-935X	Biomedical Research Council (BMRC), Agency for Science, Technology and Research (A*STAR); Bomedial Research Council-Young investigator Grant 2016 [1610151039]; Bomedial Research Council-Young investigator Grant 2015; MSCA-IF-2018 [843107]; Innoviris BB2B-Attract [RBC/BFB1]; Biomedical Research Council-Joint Council Office Grant [1231AFG031]; National Medical Research Council Singapore, NMRC [NMRC/CBRG/0091/2015]; National Research Foundation Singapore [NRF2016-CRP001-103]; Faculty of Medicine, Lund University; Swedish Foundation for Strategic Research [IRC15-0067]; Swedish Research Council, Strategic Research Area EXODIAB [2009-1039]	Biomedical Research Council (BMRC), Agency for Science, Technology and Research (A*STAR)(Agency for Science Technology & Research (A*STAR)); Bomedial Research Council-Young investigator Grant 2016; Bomedial Research Council-Young investigator Grant 2015; MSCA-IF-2018; Innoviris BB2B-Attract(Innoviris); Biomedical Research Council-Joint Council Office Grant; National Medical Research Council Singapore, NMRC(National Medical Research Council, Singapore); National Research Foundation Singapore(National Research Foundation, Singapore); Faculty of Medicine, Lund University; Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research); Swedish Research Council, Strategic Research Area EXODIAB(Swedish Research Council)	This work is supported by the Biomedical Research Council (BMRC), Agency for Science, Technology and Research (A*STAR) to PK and RMS, by the Bomedial Research Council-Young investigator Grant 2016 (1610151039) to XB, and Young investigator Grant 2015 to RMS, by a MSCA-IF-2018 (843107) to XB, by a Innoviris BB2B-Attract (RBC/BFB1) to XB, by the Biomedical Research Council-Joint Council Office Grant (1231AFG031 to Sang Hyun Lee and PK); by the National Medical Research Council Singapore, NMRC (NMRC/CBRG/0091/2015) to PK, and by National Research Foundation Singapore Grant NRF2016-CRP001-103 to PK, the Faculty of Medicine, Lund University to PK, the Swedish Foundation for Strategic Research Dnr IRC15-0067, and Swedish Research Council, Strategic Research Area EXODIAB, Dnr 2009-1039.	Alexander J, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001796; Alvarez-Fernandez M, 2018, CELL DEATH DIFFER, V25, P828, DOI 10.1038/s41418-017-0024-0; Alvarez-Fernandez M, 2013, P NATL ACAD SCI USA, V110, P17374, DOI 10.1073/pnas.1310745110; Anania MC, 2015, ONCOTARGET, V6, P34629, DOI 10.18632/oncotarget.5282; Bahe S, 2005, J CELL BIOL, V171, P27, DOI 10.1083/jcb.200504107; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101; Bisteau X, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003546; Blethrow JD, 2008, P NATL ACAD SCI USA, V105, P1442, DOI 10.1073/pnas.0708966105; Boeing S, 2016, CELL REP, V15, P1597, DOI 10.1016/j.celrep.2016.04.047; Booth DG, 2017, TRENDS CELL BIOL, V27, P906, DOI 10.1016/j.tcb.2017.08.001; Breitwieser FP, 2013, J PROTEOMICS, V90, P77, DOI 10.1016/j.jprot.2013.02.022; Breitwieser FP, 2011, J PROTEOME RES, V10, P2758, DOI 10.1021/pr1012784; Burgess A, 2010, P NATL ACAD SCI USA, V107, P12564, DOI 10.1073/pnas.0914191107; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Byeon IJL, 2005, NAT STRUCT MOL BIOL, V12, P987, DOI 10.1038/nsmb1008; Castilho PV, 2009, MOL BIOL CELL, V20, P4777, DOI 10.1091/mbc.E09-07-0643; Cervenka I, 2016, P NATL ACAD SCI USA, V113, P9304, DOI 10.1073/pnas.1608783113; Cetti E, 2019, CANCER LETT, V442, P362, DOI 10.1016/j.canlet.2018.11.010; Charrasse S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00339-4; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Chen W, 2005, CANCER RES, V65, P8183, DOI 10.1158/0008-5472.CAN-05-1103; Chen YM, 2002, J BIOL CHEM, V277, P49408, DOI 10.1074/jbc.M207069200; Choi BK, 2018, P NATL ACAD SCI USA, V115, P10666, DOI 10.1073/pnas.1806643115; Cukras S, 2016, CELL CYCLE, V15, P2636, DOI 10.1080/15384101.2016.1209613; Cundell MJ, 2016, J CELL BIOL, V214, P539, DOI 10.1083/jcb.201606033; Cundell MJ, 2013, MOL CELL, V52, P393, DOI 10.1016/j.molcel.2013.09.005; Cuylen S, 2016, NATURE, V535, P308, DOI 10.1038/nature18610; Dephoure N, 2008, P NATL ACAD SCI USA, V105, P10762, DOI 10.1073/pnas.0805139105; Diril MK, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006310; Diril MK, 2012, P NATL ACAD SCI USA, V109, P3826, DOI 10.1073/pnas.1115201109; Domingo-Sananes MR, 2011, PHILOS T R SOC B, V366, P3584, DOI 10.1098/rstb.2011.0087; Dray E, 2010, NAT STRUCT MOL BIOL, V17, P1255, DOI 10.1038/nsmb.1916; Duan HQ, 2016, J BIOL CHEM, V291, P21123, DOI 10.1074/jbc.M116.745372; Fry AM, 1999, J BIOL CHEM, V274, P16304, DOI 10.1074/jbc.274.23.16304; Fry AM, 1998, J CELL BIOL, V141, P1563, DOI 10.1083/jcb.141.7.1563; FRY AM, 1995, J BIOL CHEM, V270, P12899, DOI 10.1074/jbc.270.21.12899; Fu GS, 2007, CELL RES, V17, P608, DOI 10.1038/cr.2007.55; Gelot C, 2015, GENES-BASEL, V6, P267, DOI 10.3390/genes6020267; Gerard C, 2009, P NATL ACAD SCI USA, V106, P21643, DOI 10.1073/pnas.0903827106; Gharbi-Ayachi A, 2010, SCIENCE, V330, P1673, DOI 10.1126/science.1197048; Godfrey M, 2017, MOL CELL, V65, P393, DOI 10.1016/j.molcel.2016.12.018; Grallert A, 2015, NATURE, V517, P94, DOI 10.1038/nature14019; Gutierrez A, 2014, J CLIN INVEST, V124, P644, DOI 10.1172/JCI65093; Hayashi Y, 2017, BIOCHEM BIOPH RES CO, V493, P1043, DOI 10.1016/j.bbrc.2017.09.092; Hegarat N, 2016, BIOESSAYS, V38, P627, DOI 10.1002/bies.201600057; Hegarat N, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004004; Hein JB, 2017, NAT CELL BIOL, V19, P1433, DOI 10.1038/ncb3634; Helps NR, 2000, BIOCHEM J, V349, P509, DOI 10.1042/0264-6021:3490509; Horn H, 2014, NAT METHODS, V11, P603, DOI 10.1038/nmeth.2968; Innocenti P, 2012, J MED CHEM, V55, P3228, DOI 10.1021/jm201683b; Jowsey P, 2007, DNA REPAIR, V6, P1536, DOI 10.1016/j.dnarep.2007.04.011; Julien E, 2004, MOL CELL, V14, P713, DOI 10.1016/j.molcel.2004.06.008; Julien E, 2003, EMBO J, V22, P2360, DOI 10.1093/emboj/cdg242; Kettenbach AN, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001497; Kovalenko OV, 1997, NUCLEIC ACIDS RES, V25, P4946, DOI 10.1093/nar/25.24.4946; Lara-Gonzalez P, 2019, DEV CELL, V51, P313, DOI 10.1016/j.devcel.2019.09.005; Lebraud H, 2014, ORG BIOMOL CHEM, V12, P141, DOI 10.1039/c3ob41806e; Liang FS, 2016, CELL REP, V15, P2118, DOI 10.1016/j.celrep.2016.05.007; Liu XS, 2010, EMBO REP, V11, P626, DOI 10.1038/embor.2010.90; Ma S, 2016, J CELL SCI, V129, P1329, DOI 10.1242/jcs.178855; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Mbom BC, 2014, MOL BIOL CELL, V25, P977, DOI 10.1091/mbc.E13-06-0349; McCloy RA, 2015, MOL CELL PROTEOMICS, V14, P2194, DOI 10.1074/mcp.M114.046938; Mi J, 2007, CANCER RES, V67, P1082, DOI 10.1158/0008-5472.CAN-06-3071; MINAMIDE LS, 1990, ANAL BIOCHEM, V190, P66, DOI 10.1016/0003-2697(90)90134-U; Mochida S, 2010, SCIENCE, V330, P1670, DOI 10.1126/science.1195689; Modesti M, 2007, MOL CELL, V28, P468, DOI 10.1016/j.molcel.2007.08.025; Morozumi Y, 2009, NUCLEIC ACIDS RES, V37, P4296, DOI 10.1093/nar/gkp298; Neviani P, 2013, J CLIN INVEST, V123, P4144, DOI 10.1172/JCI68951; O'Shea JP, 2013, NAT METHODS, V10, P1211, DOI [10.1038/NMETH.2646, 10.1038/nmeth.2646]; Olsen JV, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000475; Pachis ST, 2018, OPEN BIOL, V8, DOI 10.1098/rsob.180109; Pan WA, 2015, RNA BIOL, V12, P255, DOI 10.1080/15476286.2015.1017221; Park J, 2013, BIOCHEM BIOPH RES CO, V431, P302, DOI 10.1016/j.bbrc.2012.12.106; Parplys AC, 2014, DNA REPAIR, V24, P87, DOI 10.1016/j.dnarep.2014.09.007; Peng AM, 2010, CELL CYCLE, V9, P4364, DOI 10.4161/cc.9.21.13632; Pires E, 2017, DNA REPAIR, V59, P76, DOI 10.1016/j.dnarep.2017.09.008; Rajesh C, 2011, NUCLEIC ACIDS RES, V39, P132, DOI 10.1093/nar/gkq738; Rogers S, 2018, ONCOGENE, V37, P4518, DOI 10.1038/s41388-018-0295-z; Rogers S, 2016, J CELL SCI, V129, P1340, DOI 10.1242/jcs.179754; Sangodkar J, 2017, J CLIN INVEST, V127, P2081, DOI 10.1172/JCI89548; Santamaria D, 2007, NATURE, V448, P811, DOI 10.1038/nature06046; SCHULTZ SJ, 1994, CELL GROWTH DIFFER, V5, P625; Shim SY, 2015, J BIOL CHEM, V290, P9122, DOI 10.1074/jbc.M114.591545; Sobecki M, 2016, ELIFE, V5, DOI 10.7554/eLife.13722; Takagi M, 2001, J BIOL CHEM, V276, P25386, DOI 10.1074/jbc.M102227200; Tang X, 2008, MOL CELL BIOL, V28, P2559, DOI 10.1128/MCB.01711-07; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Tzelepis K, 2016, CELL REP, V17, P1193, DOI 10.1016/j.celrep.2016.09.079; van de Kooij B, 2019, ELIFE, V8, DOI 10.7554/eLife.44635; Vera J, 2015, ELIFE, V4, DOI 10.7554/eLife.10115; Vigneron S, 2011, MOL CELL BIOL, V31, P2262, DOI 10.1128/MCB.00753-10; Wagner SA, 2016, PROTEOMICS, V16, P402, DOI 10.1002/pmic.201500172; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Wei R, 2011, MOL BIOL CELL, V22, P3584, DOI 10.1091/mbc.E11-01-0012; Wiese C, 2007, MOL CELL, V28, P482, DOI 10.1016/j.molcel.2007.08.027; Wiredja DD, 2017, BIOINFORMATICS, V33, P3489, DOI 10.1093/bioinformatics/btx415; Wong J, 2008, MOL BIOL CELL, V19, P2083, DOI 10.1091/mbc.E07-10-1088; Wu JM, 2013, P NATL ACAD SCI USA, V110, pE1779, DOI 10.1073/pnas.1220523110; Wu JQ, 2009, NAT CELL BIOL, V11, P644, DOI 10.1038/ncb1871; Yu CTR, 2005, MOL CELL BIOL, V25, P5789, DOI 10.1128/MCB.25.14.5789-5800.2005; Yu JT, 2004, J CELL BIOL, V164, P487, DOI 10.1083/JCB.200310059	103	6	6	4	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2020	39	44					6816	6840		10.1038/s41388-020-01470-1	http://dx.doi.org/10.1038/s41388-020-01470-1		SEP 2020	25	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OH9QS	32978522	Green Published, hybrid			2022-12-28	WOS:000572714000006
J	Cho, C; Mukherjee, R; Peck, AR; Sun, YG; McBrearty, N; Katlinski, KV; Gui, J; Govindaraju, PK; Pure, E; Rui, H; Fuchs, SY				Cho, Christina; Mukherjee, Riddhita; Peck, Amy R.; Sun, Yunguang; McBrearty, Noreen; Katlinski, Kanstantsin V.; Gui, Jun; Govindaraju, Priya K.; Pure, Ellen; Rui, Hallgeir; Fuchs, Serge Y.			Cancer-associated fibroblasts downregulate type I interferon receptor to stimulate intratumoral stromagenesis	ONCOGENE			English	Article							ACTIVATION PROTEIN; TGF-BETA; TUMOR STROMA; GROWTH; FAP; IMMUNOTHERAPY; EXPRESSION; PROMOTES; IMMUNITY; CELLS	Activation of cancer-associated fibroblasts (CAFs) and ensuing desmoplasia play an important role in the growth and progression of solid tumors. Here we demonstrate that, within colon and pancreatic ductal adenocarcinoma tumors, efficient stromagenesis relies on downregulation of the IFNAR1 chain of the type I interferon (IFN1) receptor. Expression of the fibroblast activation protein (FAP) and accumulation of the extracellular matrix (ECM) was notably impaired in tumors grown in theIfnar1(S526A)(SA) knock-in mice, which are deficient in IFNAR1 downregulation. Primary fibroblasts from these mice exhibited elevated levels of Smad7, a negative regulator of the transforming growth factor-beta (TGF beta) pathway. Knockdown of Smad7 alleviated deficient ECM production in SA fibroblasts in response to TGF beta. Analysis of human colorectal cancers revealed an inverse correlation between IFNAR1 and FAP levels. Whereas growth of tumors in SA mice was stimulated by co-injection of wild type but not SA fibroblasts, genetic ablation of IFNAR1 in fibroblasts also accelerated tumor growth. We discuss how inactivation of IFNAR1 in CAFs acts to stimulate stromagenesis and tumor growth.	[Cho, Christina; Mukherjee, Riddhita; McBrearty, Noreen; Katlinski, Kanstantsin V.; Gui, Jun; Govindaraju, Priya K.; Pure, Ellen; Fuchs, Serge Y.] Univ Penn, Sch Vet Med, Dept Biomed Sci, Philadelphia, PA 19104 USA; [Peck, Amy R.; Sun, Yunguang; Rui, Hallgeir] Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA	University of Pennsylvania; Medical College of Wisconsin	Fuchs, SY (corresponding author), Univ Penn, Sch Vet Med, Dept Biomed Sci, Philadelphia, PA 19104 USA.	syfuchs@upenn.edu		Rui, Hallgeir/0000-0002-8778-261X; McBrearty, Noreen/0000-0002-2597-9441; Cho, Christina/0000-0001-5482-9533; Gui, Jun/0000-0002-8022-1203	NIH/NCI [CA092900, CA240814, P01 CA217805];  [T32 CA115299];  [T32 CA009140]	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ; 	This work was supported by the by the NIH/NCI R01 grants CA092900 (to SYF), CA240814 (to SYF and HR), and P01 CA217805 (to EP). Additional support from T32 CA115299 (to NM) and T32 CA009140 (to KVK) is also greatly appreciated. We would like to thank Dr. Ben Z. Stanger and Jinyang Li for generously gifting mouse PDA cells and advising us in the generation of PDAC subcutaneous tumors. We also thank Drs. Xin-Hua Feng and Yi Yu and for generously gifting the pLKO.1 plasmids, and providing the protocols for generating the aforementioned lentiviruses.	Alexander J, 2016, CURR OPIN CELL BIOL, V42, P80, DOI 10.1016/j.ceb.2016.05.002; Beacham DA, 2005, SEMIN CANCER BIOL, V15, P329, DOI 10.1016/j.semcancer.2005.05.003; Bhattacharya S, 2014, EMBO MOL MED, V6, P384, DOI 10.1002/emmm.201303236; Biffi G, 2019, CANCER DISCOV, V9, P282, DOI 10.1158/2159-8290.CD-18-0710; Calon A, 2014, SEMIN CANCER BIOL, V25, P15, DOI 10.1016/j.semcancer.2013.12.008; Castello-Cros Remedios, 2009, V522, P275, DOI 10.1007/978-1-59745-413-1_19; Chen H, 2009, EXP MOL PATHOL, V87, P189, DOI 10.1016/j.yexmp.2009.09.001; Erdogan B, 2017, BIOCHEM SOC T, V45, P229, DOI 10.1042/BST20160387; Feig C, 2013, P NATL ACAD SCI USA, V110, P20212, DOI 10.1073/pnas.1320318110; Fish EN, 2014, MOL CANCER RES, V12, P1691, DOI 10.1158/1541-7786.MCR-14-0450; Fuchs SY, 2013, J INTERF CYTOK RES, V33, P211, DOI 10.1089/jir.2012.0117; Gascard P, 2016, GENE DEV, V30, P1002, DOI 10.1101/gad.279737.116; Goetz JG, 2011, CELL, V146, P148, DOI 10.1016/j.cell.2011.05.040; Gui J, 2020, NAT CANCER, V1, P603, DOI 10.1038/s43018-020-0064-0; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Henry LR, 2007, CLIN CANCER RES, V13, P1736, DOI 10.1158/1078-0432.CCR-06-1746; HuangFu WC, 2012, ONCOGENE, V31, P161, DOI 10.1038/onc.2011.221; Katlinskaya YV, 2016, CELL REP, V15, P171, DOI 10.1016/j.celrep.2016.03.006; Katlinski KV, 2017, CANCER CELL, V31, P194, DOI 10.1016/j.ccell.2017.01.004; Kato T, 2018, CLIN CANCER RES, V24, P4820, DOI 10.1158/1078-0432.CCR-18-0205; Li JY, 2018, IMMUNITY, V49, P178, DOI 10.1016/j.immuni.2018.06.006; Lieberman A, 2019, CANCER RES, V79, P3928, DOI 10.1158/0008-5472.CAN-19-0056; Lo A, 2015, CANCER RES, V75, P2800, DOI 10.1158/0008-5472.CAN-14-3041; Ohlund D, 2017, J EXP MED, V214, P579, DOI 10.1084/jem.20162024; Ortiz A, 2019, CANCER CELL, V35, P33, DOI 10.1016/j.ccell.2018.12.001; Peck AR, 2016, MODERN PATHOL, V29, P1143, DOI 10.1038/modpathol.2016.112; Piehler J, 2012, IMMUNOL REV, V250, P317, DOI 10.1111/imr.12001; Pure E, 2016, CANCER IMMUNOL RES, V4, P269, DOI 10.1158/2326-6066.CIR-16-0011; Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568-019-0238-1; Santos AM, 2009, J CLIN INVEST, V119, P3613, DOI 10.1172/JCI38988; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Valkenburg KC, 2018, NAT REV CLIN ONCOL, V15, P366, DOI 10.1038/s41571-018-0007-1; Wang LCS, 2014, CANCER IMMUNOL RES, V2, P154, DOI 10.1158/2326-6066.CIR-13-0027; Webber J P, 2015, Oncogene, V34, P290, DOI 10.1038/onc.2013.560; Webber J, 2010, CANCER RES, V70, P9621, DOI 10.1158/0008-5472.CAN-10-1722; Wikberg ML, 2013, TUMOR BIOL, V34, P1013, DOI 10.1007/s13277-012-0638-2; Yu Y, 2017, P NATL ACAD SCI USA, V114, P10113, DOI 10.1073/pnas.1705755114; Zhang RS, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1435-2; Zheng H, 2011, BLOOD, V118, P4003, DOI 10.1182/blood-2011-06-359745	39	11	11	4	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2020	39	38					6129	6137		10.1038/s41388-020-01424-7	http://dx.doi.org/10.1038/s41388-020-01424-7		AUG 2020	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NQ9JF	32807917	Green Accepted			2022-12-28	WOS:000560274700001
J	Bartolome, RA; Pintado-Berninches, L; Jaen, M; de los Rios, V; Imbaud, JI; Casal, JI				Bartolome, Ruben A.; Pintado-Berninches, Laura; Jaen, Marta; de los Rios, Vivian; Imbaud, Juan Ignacio; Casal, J. Ignacio			SOSTDC1 promotes invasion and liver metastasis in colorectal cancer via interaction with ALCAM/CD166	ONCOGENE			English	Article							CELL-ADHESION MOLECULE; MORPHOGENETIC PROTEIN ANTAGONIST; STEM-CELLS; ACTIN CYTOSKELETON; PANCREATIC-CANCER; PROGNOSTIC MARKER; POOR SURVIVAL; EXPRESSION; MIGRATION; CD166	The mechanistic basis of liver metastasis in colorectal cancer remains poorly understood. We previously reported that the sclerostin domain containing-1 (SOSTDC1) protein is overexpressed in the secretome of metastatic colorectal cancer cells and can inhibit liver homing. Here, we investigated the mechanisms of SOSTDC1 for promoting invasiveness and progression of colorectal cancer liver metastasis. SOSTDC1 inhibition of BMP4 maintains the expression of cancer stem cell traits, including SOX2 and NANOG. Immunoprecipitation and mass spectrometry analyses reveal the association of SOSTDC1 with ALCAM/CD166, which was confirmed by confocal microscopy and competition ELISA. Interaction with ALCAM is mediated by the N-terminal region of SOSTDC1, which contains a sequence similar to the ALCAM-binding motif used by CD6. Knocking down either SOSTDC1 or ALCAM expression, or using blocking antibodies, reduces the invasive activity by inhibiting Src and PI3K/AKT signaling pathways. In addition, ALCAM interacts with the alpha 2ss1 and alpha 1ss1 integrins, providing a possible link to Src activation. Finally, inoculation of SOSTDC1-silenced metastatic cells increases mouse survival by inhibiting liver metastasis. In conclusion, SOSTDC1 promotes invasion and liver metastasis in colorectal cancer, by overcoming BMP4-specific antimetastatic signals and inducing ALCAM-mediated Src and PI3K/AKT activation. These experiments underscore the potential of SOSTDC1 as a therapeutic target in metastatic colorectal cancer.	[Bartolome, Ruben A.; Pintado-Berninches, Laura; Jaen, Marta; de los Rios, Vivian; Casal, J. Ignacio] CSIC, Ctr Invest Biol, Dept Mol Biomed, Ramiro de Maeztu 9, Madrid 28039, Spain; [Imbaud, Juan Ignacio] Prot Alternat SL, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Bartolome, RA; Casal, JI (corresponding author), CSIC, Ctr Invest Biol, Dept Mol Biomed, Ramiro de Maeztu 9, Madrid 28039, Spain.	rubenabc@cib.csic.es; icasal@cib.csic.es	Imbaud, Juan Ignacio/AAP-2121-2021; Casal, J. Ignacio/M-2312-2014; Bartolome, Ruben A/M-1873-2014	Imbaud, Juan Ignacio/0000-0002-6026-4265; Casal, J. Ignacio/0000-0003-1085-2840; Bartolome, Ruben A/0000-0002-3292-1491	Ministerio de Ciencia e Innovacion [BIO2015-66489-R, RTI2018-095055-B100]; Foundation Ramon Areces; PRB3 [ISCIII-SGEFI/FEDER-PT17/0019/0008]	Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Foundation Ramon Areces; PRB3	We thank Diego Laxalde, Alejandro Diaz, Jose Ramon Gutierrez, Marcos Rodriguez, Eva Calvino, and Gema Elvira for their contributions to the paper. This research was supported by grants from the Ministerio de Ciencia e Innovacion (BIO2015-66489-R, RTI2018-095055-B100), Foundation Ramon Areces and PRB3 (ISCIII-SGEFI/FEDER-PT17/0019/0008).	Barderas R, 2013, MOL CELL PROTEOMICS, V12, P1602, DOI 10.1074/mcp.M112.022848; Bartolome RA, 2014, ONCOGENE, V33, P1658, DOI 10.1038/onc.2013.117; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Blish KR, 2008, MOL BIOL CELL, V19, P457, DOI 10.1091/mbc.E07-05-0433; Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013; Chappell PE, 2015, STRUCTURE, V23, P1426, DOI 10.1016/j.str.2015.05.019; Chen GH, 2018, INT J MOL MED, V42, P3424, DOI 10.3892/ijmm.2018.3926; Clausen KA, 2011, BREAST CANCER RES TR, V129, P737, DOI 10.1007/s10549-010-1261-9; Cui YZ, 2019, AM J CANCER RES, V9, P2331; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Devis L, 2017, J PATHOL, V241, P475, DOI 10.1002/path.4851; Donizy P, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0331-z; Gao H, 2012, CELL, V150, P764, DOI 10.1016/j.cell.2012.06.035; Gilsanz A, 2013, CELL MOL LIFE SCI, V70, P475, DOI 10.1007/s00018-012-1132-0; Gopal G, 2013, CANCER GENET-NY, V206, P174, DOI 10.1016/j.cancergen.2013.04.005; Horst D, 2009, CANCER INVEST, V27, P844, DOI 10.1080/07357900902744502; Inaguma S, 2018, HUM PATHOL, V71, P1, DOI 10.1016/j.humpath.2017.04.032; Kahlert C, 2009, BRIT J CANCER, V101, P457, DOI 10.1038/sj.bjc.6605136; Kholmanskikh SS, 2003, J NEUROSCI, V23, P8673; Kim GR, 2015, ONCOL LETT, V9, P1641, DOI 10.3892/ol.2015.2918; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lintern KB, 2009, J BIOL CHEM, V284, P23159, DOI 10.1074/jbc.M109.025478; Liu L, 2016, CELL BIOSCI, V6, DOI 10.1186/s13578-016-0091-9; Lo FY, 2012, LUNG CANCER, V77, P585, DOI 10.1016/j.lungcan.2012.05.105; Lunter PC, 2005, CANCER RES, V65, P8801, DOI 10.1158/0008-5472.CAN-05-0378; MORIKAWA K, 1988, CANCER RES, V48, P1943; Nolan K, 2014, PROTEIN SCI, V23, P999, DOI 10.1002/pro.2485; Oskarsson T, 2014, CELL STEM CELL, V14, P306, DOI 10.1016/j.stem.2014.02.002; Piazza T, 2005, J CELL SCI, V118, P1515, DOI 10.1242/jcs.02280; Rauhala HE, 2013, ANTICANCER RES, V33, P45; Rawat A, 2014, CELL ONCOL, V37, P409, DOI 10.1007/s13402-014-0204-6; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Secondini C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016078; Tesfay L, 2015, CANCER RES, V75, P2254, DOI 10.1158/0008-5472.CAN-14-2465; Torres S, 2015, CLIN CANCER RES, V21, P4892, DOI 10.1158/1078-0432.CCR-14-3096; Tudor C, 2014, J BIOL CHEM, V289, P13445, DOI 10.1074/jbc.M113.546754; van Kilsdonk JWJ, 2008, CANCER RES, V68, P3671, DOI 10.1158/0008-5472.CAN-07-5767; von Lersner A, 2019, CLIN EXP METASTAS, V36, P87, DOI 10.1007/s10585-019-09957-2; Weichert W, 2004, J CLIN PATHOL, V57, P1160, DOI 10.1136/jcp.2004.016238; Weidle Ulrich H., 2010, Cancer Genomics & Proteomics, V7, P231; Yamaguchi H, 2007, BBA-MOL CELL RES, V1773, P642, DOI 10.1016/j.bbamcr.2006.07.001; Yan K, 2014, GENE DEV, V28, P1085, DOI 10.1101/gad.235515.113; Yanagita M, 2005, CYTOKINE GROWTH F R, V16, P309, DOI 10.1016/j.cytogfr.2005.02.007; Yanagita M, 2004, BIOCHEM BIOPH RES CO, V316, P490, DOI 10.1016/j.bbrc.2004.02.075; Young RA, 2011, CELL, V144, P940, DOI 10.1016/j.cell.2011.01.032; Zhou QY, 2017, MOL CELL BIOCHEM, V435, P87, DOI 10.1007/s11010-017-3059-0	46	15	15	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2020	39	38					6085	6098		10.1038/s41388-020-01419-4	http://dx.doi.org/10.1038/s41388-020-01419-4		AUG 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NQ9JF	32801337	Green Submitted			2022-12-28	WOS:000559940500001
J	Wolf, ER; Mabry, AR; Damania, B; Mayo, LD				Wolf, Eric R.; Mabry, Alexander R.; Damania, Blossom; Mayo, Lindsey D.			Mdm2-mediated neddylation of pVHL blocks the induction of antiangiogenic factors	ONCOGENE			English	Article							RENAL-CELL CARCINOMA; WILD-TYPE P53; TUMOR ANGIOGENESIS; HIF-ALPHA; VHL GENE; MDM2; HYPOXIA; EXPRESSION; BINDING; STABILIZATION	Mutations in the tumor suppressorTP53are rare in renal cell carcinomas. p53 is a key factor for inducing antiangiogenic genes and RCC are highly vascularized, which suggests that p53 is inactive in these tumors. One regulator of p53 is the Mdm2 oncogene, which is correlated with high-grade, metastatic tumors. However, the sole activity of Mdm2 is not just to regulate p53, but it can also function independent of p53 to regulate the early stages of metastasis. Here, we report that the oncoprotein Mdm2 can bind directly to the tumor suppressor VHL, and conjugate nedd8 to VHL within a region that is important for the p53-VHL interaction. Nedd8 conjugated VHL is unable to bind to p53 thereby preventing the induction of antiangiogenic factors. These results highlight a previously unknown oncogenic function of Mdm2 during the progression of cancer to promote angiogenesis through the regulation of VHL. Thus, the Mdm2-VHL interaction represents a pathway that impacts tumor angiogenesis.	[Wolf, Eric R.; Mabry, Alexander R.; Mayo, Lindsey D.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; [Damania, Blossom] Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; [Mayo, Lindsey D.] Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Indiana University System; Indiana University Bloomington	Mayo, LD (corresponding author), Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.; Mayo, LD (corresponding author), Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN 46202 USA.	ldmayo@iu.edu		Mayo, Lindsey/0000-0002-5997-5166; Mabry, Alex/0000-0003-1635-8800	NIH/NCI [CA172256]; Riley Children's Foundation	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Riley Children's Foundation	This research was supported by NIH/NCI CA172256 and the Riley Children's Foundation. We thank Dr. Ohh for the VHL expression plasmid, Dr. Bouck for the Thrombospondin reporter plasmid, and Dr. Ivan for the renal cell carcinoma cell lines to aid in this study.	An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Batuello CN, 2015, P NATL ACAD SCI USA, V112, P1749, DOI 10.1073/pnas.1416656112; Bohlman Stephen, 2014, Subcell Biochem, V85, P235, DOI 10.1007/978-94-017-9211-0_13; Chen DL, 2003, J BIOL CHEM, V278, P13595, DOI 10.1074/jbc.C200694200; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Ding XY, 2019, CELL DEATH DIFFER, V26, P1750, DOI 10.1038/s41418-018-0242-0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Ganguli G, 2003, MOL CANCER RES, V1, P1027; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Gurova KV, 2004, CANCER RES, V64, P1951, DOI 10.1158/0008-5472.CAN-03-1541; Haitel A, 2000, CLIN CANCER RES, V6, P1840; Hammond EM, 2002, MOL CELL BIOL, V22, P1834, DOI 10.1128/MCB.22.6.1834-1843.2002; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Hansson LO, 2002, P NATL ACAD SCI USA, V99, P10305, DOI 10.1073/pnas.122347199; Hauck PM, 2017, ONCOTARGET, V8, P104455, DOI 10.18632/oncotarget.22320; Hauck PM, 2017, MOL CANCER RES, V15, P1598, DOI 10.1158/1541-7786.MCR-17-0174; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jin YL, 2018, CLIN CANCER RES, V24, P3741, DOI 10.1158/1078-0432.CCR-17-1703; Joerger AC, 2016, ANNU REV BIOCHEM, V85, P375, DOI 10.1146/annurev-biochem-060815-014710; Joshi S, 2014, J BIOL CHEM, V289, P22785, DOI 10.1074/jbc.M114.587493; Kadakia M, 2001, DNA CELL BIOL, V20, P321, DOI 10.1089/10445490152122433; Kaelin WG, 2007, ANNU REV PATHOL-MECH, V2, P145, DOI 10.1146/annurev.pathol.2.010506.092049; Kamat CD, 2007, CANCER LETT, V249, P209, DOI 10.1016/j.canlet.2006.08.017; Kim WY, 2004, J CLIN ONCOL, V22, P4991, DOI 10.1200/JCO.2004.05.061; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Li AG, 2006, MOL CELL, V23, P575, DOI 10.1016/j.molcel.2006.06.028; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Miled C, 2005, CANCER RES, V65, P5096, DOI 10.1158/0008-5472.CAN-04-4232; MIYASHITA T, 1995, CELL, V80, P293; Mizuno S, 2011, AM J PHYSIOL-LUNG C, V300, pL753, DOI 10.1152/ajplung.00286.2010; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Nieminen AL, 2005, J CELL PHYSIOL, V204, P364, DOI 10.1002/jcp.20406; Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542; Noon AP, 2010, CANCER-AM CANCER SOC, V116, P780, DOI 10.1002/cncr.24841; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Pan Y, 2004, ONCOGENE, V23, P4975, DOI 10.1038/sj.onc.1207657; Patterson DM, 2011, ANGIOGENESIS, V14, P255, DOI 10.1007/s10456-011-9210-8; Rayburn E, 2005, CURR CANCER DRUG TAR, V5, P27, DOI 10.2174/1568009053332636; Reed SM, 2015, CANCERS, V7, P30, DOI 10.3390/cancers7010030; Roe JS, 2006, MOL CELL, V22, P395, DOI 10.1016/j.molcel.2006.04.006; Russell RC, 2008, EMBO REP, V9, P486, DOI 10.1038/embor.2008.19; Sanchez-Puig N, 2005, MOL CELL, V17, P11, DOI 10.1016/j.molcel.2004.11.019; Somasundaram K, 1999, ONCOGENE, V18, P6605, DOI 10.1038/sj.onc.1203284; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Stickle NH, 2004, MOL CELL BIOL, V24, P3251, DOI 10.1128/MCB.24.8.3251-3261.2004; Venkatesan T, 2018, CELLS, V7, P3; Wang XQ, 2001, CANCER RES, V61, P1598; Wolf ER, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aao4170; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xiong J, 2014, ANGIOGENESIS, V17, P37, DOI 10.1007/s10456-013-9376-3; Yao WT, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.21; Zbar B, 1996, HUM MUTAT, V8, P348, DOI 10.1002/(SICI)1098-1004(1996)8:4<348::AID-HUMU8>3.0.CO;2-3; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhou S, 2011, MOL CELL BIOL, V31, P4928, DOI 10.1128/MCB.06085-11; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051	59	6	6	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 16	2020	39	29					5228	5239		10.1038/s41388-020-1359-4	http://dx.doi.org/10.1038/s41388-020-1359-4		JUN 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ML6WO	32555333	Green Submitted, Green Accepted			2022-12-28	WOS:000545371000003
J	Gou, Q; Jiang, YD; Zhang, RY; Xu, Y; Xu, HH; Zhang, WB; Shi, JJ; Hou, YZ				Gou, Qian; Jiang, Yidan; Zhang, Runyun; Xu, Ying; Xu, Huihui; Zhang, Wenbo; Shi, Juanjuan; Hou, Yongzhong			PPAR delta is a regulator of autophagy by its phosphorylation	ONCOGENE			English	Article							CELL-DEATH; LIGAND ACTIVATION; TUMOR PROGRESSION; CANCER CELLS; LUNG-CANCER; EGFR; APOPTOSIS; GAMMA; INHIBITION; GROWTH	In response to nutrient deficiency, autophagy degrades cytoplasmic materials and organelles in lysosomes, which is nutrient recycling, whereas activation of EGFR mediates autophagy suppression in response to growth factors. It is unclear whether PPAR delta could be the regulator of autophagy in response to active EGFR. Here we found that EGFR induced PPAR delta phosphorylation at tyrosine-108 leading to increased binding of LC3 to PPAR delta by its LIR (LC3 interacting region) motif, consequently, inhibited autophagic flux. Conversely, EGFR inhibitor treatment reversed this event. Furthermore, EGFR-mediated PPAR delta phosphorylation at tyrosine-108 led to autophagy inhibition and tumor growth. These findings suggest that PPAR delta serves as a regulator of autophagy by its phosphorylation.	[Gou, Qian; Jiang, Yidan; Zhang, Runyun; Xu, Ying; Xu, Huihui; Zhang, Wenbo; Shi, Juanjuan; Hou, Yongzhong] Jiangsu Univ, Inst Life Sci, Zhenjiang 212013, Jiangsu, Peoples R China	Jiangsu University	Hou, YZ (corresponding author), Jiangsu Univ, Inst Life Sci, Zhenjiang 212013, Jiangsu, Peoples R China.	houyz@ujs.edu.cn		Hou, Yongzhong/0000-0003-2019-8686	National Natural Science Foundation of China [81672711, 81972618]; Postgraduate Research & Practice Innovation Program of Jiangsu Province [KYCX18_2218]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Postgraduate Research & Practice Innovation Program of Jiangsu Province	This work was supported by the National Natural Science Foundation of China (81672711, 81972618); Postgraduate Research & Practice Innovation Program of Jiangsu Province (KYCX18_2218).	Abu el Maaty MA, 2017, MOL CARCINOGEN, V56, P2486, DOI 10.1002/mc.22696; Ba MC, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317711952; Balakumaran BS, 2009, CANCER RES, V69, P7803, DOI 10.1158/0008-5472.CAN-09-0910; Bhatelia K, 2017, CELL SIGNAL, V35, P73, DOI 10.1016/j.cellsig.2017.03.024; Birgisdottir AB, 2013, J CELL SCI, V126, P3237, DOI 10.1242/jcs.126128; Burton LJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164115; Capizzi M, 2017, AUTOPHAGY, V13, P554, DOI 10.1080/15548627.2016.1269989; Chang CH, 2017, INT J ONCOL, V50, P873, DOI 10.3892/ijo.2017.3866; Chang CT, 2017, ARCH TOXICOL, V91, P3341, DOI 10.1007/s00204-017-1967-0; Chang SH, 2017, J DERMATOL SCI, V87, P138, DOI 10.1016/j.jdermsci.2017.04.011; Chung SJ, 2017, AUTOPHAGY, V13, P1386, DOI 10.1080/15548627.2017.1332565; Coelho MA, 2017, IMMUNITY, V47, P1083, DOI 10.1016/j.immuni.2017.11.016; Foreman JE, 2011, MOL CARCINOGEN, V50, P884, DOI 10.1002/mc.20757; Fung C, 2012, CANCER BIOL THER, V13, P1417, DOI 10.4161/cbt.22002; Gao JM, 2015, ONCOTARGET, V6, P44635, DOI 10.18632/oncotarget.5988; Gou Q, 2017, ONCOTARGET, V8, P60704, DOI 10.18632/oncotarget.19610; Han WD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018691; Han W, 2012, CANCER LETT, V318, P124, DOI 10.1016/j.canlet.2012.01.011; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hollingshead HE, 2008, CARCINOGENESIS, V29, P169, DOI 10.1093/carcin/bgm209; Hotchkiss RS, 2009, NEW ENGL J MED, V361, P1570, DOI 10.1056/NEJMra0901217; Hou Y, 2014, ONCOGENE, V33, P5619, DOI 10.1038/onc.2013.504; Hou YZ, 2007, J BIOL CHEM, V282, P9279, DOI 10.1074/jbc.M608523200; Hou YZ, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2270; Hou YZ, 2010, J BIOL CHEM, V285, P35497, DOI 10.1074/jbc.M109.066035; Kang MR, 2009, J PATHOL, V217, P702, DOI 10.1002/path.2509; Kaur J, 2015, NAT REV MOL CELL BIO, V16, P461, DOI 10.1038/nrm4024; Khozoie C, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-665; Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738; Li XQ, 2010, AUTOPHAGY, V6, P1066, DOI 10.4161/auto.6.8.13366; Lian JQ, 2010, AUTOPHAGY, V6, P1201, DOI [10.1038/cdd.2010.74, 10.4161/auto.6.8.13549]; Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007; Marin HE, 2006, CANCER RES, V66, P4394, DOI 10.1158/0008-5472.CAN-05-4277; Marmor MD, 2004, INT J RADIAT ONCOL, V58, P903, DOI 10.1016/j.ijrobp.2003.06.002; Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254; Mizushima N, 2007, ANNU REV NUTR, V27, P19, DOI 10.1146/annurev.nutr.27.061406.093749; Nazim UM, 2017, ONCOTARGET, V8, P26819, DOI 10.18632/oncotarget.15819; Oh S, 2011, CELL DEATH DIFFER, V18, P452, DOI 10.1038/cdd.2010.116; Park MA, 2008, AUTOPHAGY, V4, P513, DOI 10.4161/auto.5725; Peng Y, 2017, ONCOTARGET, V8, P52960, DOI 10.18632/oncotarget.17674; Peters Jeffrey M, 2011, Drug Discov Today Dis Mech, V8, pe85; Rautou PE, 2010, J HEPATOL, V53, P1123, DOI 10.1016/j.jhep.2010.07.006; Rodolfo C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167672; Venkatachalam G, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-S3-S5; Wang DZ, 2014, P NATL ACAD SCI USA, V111, P7084, DOI 10.1073/pnas.1324233111; Wei YJ, 2013, CELL, V154, P1269, DOI 10.1016/j.cell.2013.08.015; Xu Y, 2016, CARCINOGENESIS, V37, P215, DOI 10.1093/carcin/bgv252; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; You ML, 2018, J ONCOL, V2018, DOI 10.1155/2018/6458537; You ML, 2017, J CELL BIOCHEM, V118, P1556, DOI 10.1002/jcb.25817; You ML, 2015, CURR PHARM DESIGN, V21, P2956, DOI 10.2174/1381612821666150514104035; Yu JJ, 2020, CANCER LETT, V474, P23, DOI 10.1016/j.canlet.2020.01.004; Yuan SP, 2017, EVID-BASED COMPL ALT, V2017, DOI 10.1155/2017/3801976; Zhang WB, 2017, CARCINOGENESIS, V38, P748, DOI 10.1093/carcin/bgx035; Zhang Z, 2013, ONKOLOGIE, V36, P598, DOI 10.1159/000355328; Zhou DY, 2019, EUR J PHARMACOL, V842, P248, DOI 10.1016/j.ejphar.2018.10.050; Zhu B, 2014, ONCOGENE, V33, P5348, DOI 10.1038/onc.2013.477; Zuo XS, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju052	58	7	7	2	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 18	2020	39	25					4844	4853		10.1038/s41388-020-1329-x	http://dx.doi.org/10.1038/s41388-020-1329-x		MAY 2020	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LZ3HT	32439863				2022-12-28	WOS:000534735300001
J	Wolf, MM; Rathmell, WK; Beckermann, KE				Wolf, Melissa M.; Rathmell, W. Kimryn; Beckermann, Kathryn E.			Modeling clear cell renal cell carcinoma and therapeutic implications	ONCOGENE			English	Review							HYPOXIA-INDUCIBLE FACTORS; IN-VITRO; ANTIANGIOGENIC THERAPY; TUMOR ANGIOGENESIS; MAMMALIAN TARGET; XENOGRAFT MODELS; ORGANOID MODELS; GENETIC-BASIS; MOUSE MODELS; CANCER	Renal cell carcinoma (RCC) comprises a diverse group of malignancies arising from the nephron. The most prevalent type, clear cell renal cell carcinoma (ccRCC), is characterized by genetic mutations in factors governing the hypoxia signaling pathway, resulting in metabolic dysregulation, heightened angiogenesis, intratumoral heterogeneity, and deleterious tumor microenvironmental (TME) crosstalk. Identification of specific genetic variances has led to therapeutic innovation and improved survival for patients with ccRCC. Current barriers to effective long-term therapeutic success highlight the need for continued drug development using improved modeling systems. ccRCC preclinical models can be grouped into three broad categories: cell line, mouse, and 3D models. Yet, the breadth of important unanswered questions in ccRCC research far exceeds the accessibility of model systems capable of carrying them out. Accordingly, we review the strengths, weaknesses, and therapeutic implications of each model system that are relied upon today.	[Wolf, Melissa M.; Rathmell, W. Kimryn; Beckermann, Kathryn E.] Vanderbilt Univ, Dept Med, Div Hematol & Oncol, Med Ctr, Nashville, TN 37232 USA	Vanderbilt University	Beckermann, KE (corresponding author), Vanderbilt Univ, Dept Med, Div Hematol & Oncol, Med Ctr, Nashville, TN 37232 USA.	katy.beckermann@vumc.org		M Wolf, Melissa/0000-0003-2038-6978	NCI NIH HHS [K12 CA090625] Funding Source: Medline; U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute (NCI) [5K12CA090625-19] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute (NCI)		Bailey ST, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15770; Barata PC, 2017, CA-CANCER J CLIN, V67, P507, DOI 10.3322/caac.21411; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Baumans V, 2004, GENE THER, V11, pS64, DOI 10.1038/sj.gt.3302371; Beckermann KE, 2017, EXPERT REV CLIN IMMU, V13, P77, DOI 10.1080/1744666X.2016.1214575; Beksac AT, 2017, UROL ONCOL-SEMIN ORI, V35, P507, DOI 10.1016/j.urolonc.2017.05.006; Berlato C, 2017, J CLIN INVEST, V127, P801, DOI 10.1172/JCI82976; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Boj SF, 2015, CELL, V160, P324, DOI 10.1016/j.cell.2014.12.021; Bouchard M, 2002, GENE DEV, V16, P2958, DOI 10.1101/gad.240102; Bouchard M, 2004, GENESIS, V38, P105, DOI 10.1002/gene.20008; Brodaczewska KK, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0565-8; Brooks SA, 2014, EUR UROL, V66, P77, DOI 10.1016/j.eururo.2014.02.035; Bult CJ, 2019, NUCLEIC ACIDS RES, V47, pD801, DOI 10.1093/nar/gky1056; Capitanio U, 2016, LANCET, V387, P894, DOI 10.1016/S0140-6736(15)00046-X; Chappell JC, 2019, J CLIN INVEST, V129, P442, DOI 10.1172/JCI120855; Chen FJ, 2016, CELL REP, V14, P2476, DOI 10.1016/j.celrep.2016.02.024; Chen QF, 2019, TRANSL ONCOL, V12, P987, DOI 10.1016/j.tranon.2019.04.020; Cheval L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046876; Chiang YC, 2018, CANCER RES, V78, P3135, DOI 10.1158/0008-5472.CAN-17-3460; Clevers H, 2016, CELL, V165, P1586, DOI 10.1016/j.cell.2016.05.082; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Cuenod CA, 2006, ABDOM IMAGING, V31, P188, DOI 10.1007/s00261-005-0386-5; de Cubas AA, 2018, NAT REV UROL, V15, P599, DOI 10.1038/s41585-018-0052-7; de Velasco G, 2017, ONCOLOGIST, V22, P286, DOI 10.1634/theoncologist.2016-0078; Devaud C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108670; Dong, 2017, NAT COMMUN, V8; Dong YY, 2017, EUR UROL FOCUS, V3, P590, DOI 10.1016/j.euf.2016.08.005; Ebos JML, 2011, NAT REV CLIN ONCOL, V8, P210, DOI 10.1038/nrclinonc.2011.21; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; Espana-Agusti J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02245-1; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Finnberg NK, 2017, ONCOTARGET, V8, P66747, DOI 10.18632/oncotarget.19965; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Frew IJ, 2015, ANNU REV PATHOL-MECH, V10, P263, DOI 10.1146/annurev-pathol-012414-040306; Gerlinger M, 2014, NAT GENET, V46, P225, DOI 10.1038/ng.2891; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Ghatalia P, 2018, KIDNEY CANCER, V2, P23, DOI 10.3233/KCA-170021; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; Gioanni J, 1996, B CANCER, V83, P553; Grassi L, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1453-0; Grisanzio C, 2011, J PATHOL, V225, P212, DOI 10.1002/path.2929; Gu YF, 2017, CANCER DISCOV, V7, P900, DOI 10.1158/2159-8290.CD-17-0292; Haake SM, 2017, CANCER-AM CANCER SOC, V123, P200, DOI 10.1002/cncr.30314; Haake SM, 2016, MOL CANCER RES, V14, P589, DOI 10.1158/1541-7786.MCR-16-0115; Hakimi AA, 2013, CLIN CANCER RES, V19, P3259, DOI 10.1158/1078-0432.CCR-12-3886; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harlander S, 2017, NAT MED, V23, P869, DOI 10.1038/nm.4343; Harshman LC, 2014, CLIN GENITOURIN CANC, V12, P335, DOI 10.1016/j.clgc.2014.03.003; Hartmann JT, 1999, ANTICANCER RES, V19, P1541; Hsieh JJ, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.9; Huang B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068293; Hudes GR, 2009, CANCER, V115, P2313, DOI 10.1002/cncr.24239; Ideno N, 2019, LAB INVEST, V99, P1233, DOI 10.1038/s41374-018-0171-z; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Jonasch E, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4797; Karthaus WR, 2014, CELL, V159, P163, DOI 10.1016/j.cell.2014.08.017; Kersten K, 2017, EMBO MOL MED, V9, P137, DOI 10.15252/emmm.201606857; Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003; Kleymenova E, 2004, CARCINOGENESIS, V25, P309, DOI 10.1093/carcin/bgh017; Klinghammer K, 2017, CANCER TREAT REV, V55, P36, DOI 10.1016/j.ctrv.2017.02.009; Kobayashi A, 2008, CELL STEM CELL, V3, P169, DOI 10.1016/j.stem.2008.05.020; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Kondo K, 2001, INT J CANCER, V91, P219, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1034>3.0.CO;2-S; KORHONEN M, 1994, CANCER RES, V54, P4532; Kovacs G, 1997, J PATHOL, V183, P131, DOI 10.1002/(SICI)1096-9896(199710)183:2<131::AID-PATH931>3.0.CO;2-G; Kucejova B, 2011, MOL CANCER RES, V9, P1255, DOI 10.1158/1541-7786.MCR-11-0302; Lai YX, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0470-7; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Le Magnen C, 2016, NAT REV CANCER, V16, P187, DOI 10.1038/nrc.2016.1; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Lee CM, 2009, ONCOGENE, V28, P1694, DOI 10.1038/onc.2009.12; Lee CH, 2017, NAT REV NEPHROL, V13, P69, DOI 10.1038/nrneph.2016.194; Lee SH, 2018, CELL, V173, P515, DOI 10.1016/j.cell.2018.03.017; Liao LL, 2015, CANCER GENET-NY, V208, P206, DOI 10.1016/j.cancergen.2015.02.008; Linehan WM, 2003, J UROLOGY, V170, P2163, DOI 10.1097/01.ju.0000096060.92397.ed; Liu Y, 2012, MOL CANCER THER, V11, P1672, DOI 10.1158/1535-7163.MCT-12-0131; Lopez-Beltran A, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00456; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; Matano M, 2015, NAT MED, V21, P256, DOI 10.1038/nm.3802; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McDermott DF, 2018, NAT MED, V24, P749, DOI 10.1038/s41591-018-0053-3; Mitchell TJ, 2018, CELL, V173, P611, DOI 10.1016/j.cell.2018.02.020; Moch H, 2016, EUR UROL, V70, P93, DOI 10.1016/j.eururo.2016.02.029; Moore LE, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002312; Motzer RJ, 2018, NEW ENGL J MED, V378, P1277, DOI 10.1056/NEJMoa1712126; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; Motzer RJ, 1999, J CLIN ONCOL, V17, P2530, DOI 10.1200/JCO.1999.17.8.2530; Motzer RJ, 2019, NEW ENGL J MED, V380, P1103, DOI 10.1056/NEJMoa1816047; Nargund AM, 2017, CELL REP, V18, P2893, DOI 10.1016/j.celrep.2017.02.074; Neal JT, 2018, CELL, V175, P1972, DOI 10.1016/j.cell.2018.11.021; Nishimura H, 1999, IMMUNITY, V11, P141, DOI 10.1016/S1074-7613(00)80089-8; Patel A, 2019, TRANSL ANDROL UROL, V8, pS156, DOI 10.21037/tau.2018.11.04; Pavia-Jimenez A, 2014, NAT PROTOC, V9, P1848, DOI 10.1038/nprot.2014.108; Pena-LlopiS S, 2012, NAT GENET, V44, P751, DOI 10.1038/ng.2323; Pichler R, 2019, CANCERS, V11, DOI 10.3390/cancers11030422; Prasetyanti PR, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0600-4; PROCHAZKA M, 1992, P NATL ACAD SCI USA, V89, P3290, DOI 10.1073/pnas.89.8.3290; Rangarajan A, 2003, NAT REV CANCER, V3, P952, DOI 10.1038/nrc1235; Ricketts CJ, 2018, CELL REP, V23, P313, DOI [10.1016/j.celrep.2018.03.075, 10.1016/j.celrep.2018.06.032]; Rini B, 2015, LANCET ONCOL, V16, P676, DOI 10.1016/S1470-2045(15)70167-1; Rini BI, 2008, CLIN CANCER RES, V14, P1286, DOI 10.1158/1078-0432.CCR-07-4719; Rini BI, 2019, NEW ENGL J MED, V380, P2582, DOI 10.1056/NEJMc1905518; Rini BI, 2018, CLIN CANCER RES, V24, P4407, DOI 10.1158/1078-0432.CCR-18-0323; Rojas JD, 2019, IEEE T BIO-MED ENG, V66, P873, DOI 10.1109/TBME.2018.2860932; Sachs N, 2018, CELL, V172, P373, DOI 10.1016/j.cell.2017.11.010; Sanchez DJ, 2018, BBA-REV CANCER, V1870, P23, DOI 10.1016/j.bbcan.2018.06.003; SANCHEZ Y, 1994, P NATL ACAD SCI USA, V91, P3383, DOI 10.1073/pnas.91.8.3383; Santoni Matteo, 2018, Drugs Context, V7, P212528, DOI 10.7573/dic.212528; Schaaf MB, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0061-0; Schokrpur S, 2016, SCI REP-UK, V6, DOI 10.1038/srep29032; Schor-Bardach R, 2009, RADIOLOGY, V251, P731, DOI 10.1148/radiol.2521081059; Schuetz AN, 2005, J MOL DIAGN, V7, P206, DOI 10.1016/S1525-1578(10)60547-8; Shao XL, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000016444.90348.50; Shinojima T, 2007, CARCINOGENESIS, V28, P529, DOI 10.1093/carcin/bgl143; Shoemaker RH, 2006, NAT REV CANCER, V6, P813, DOI 10.1038/nrc1951; Shuch B, 2015, EUR UROL, V67, P85, DOI 10.1016/j.eururo.2014.04.029; Shvarts O, 2006, UROLOGY, V68, P1132, DOI 10.1016/j.urology.2006.08.1073; Sivanand S, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003643; Tate JG, 2019, NUCLEIC ACIDS RES, V47, pD941, DOI 10.1093/nar/gky1015; Thomas GV, 2006, NAT MED, V12, P122, DOI 10.1038/nm1337; Tiriac H, 2018, GASTROINTEST ENDOSC, V87, P1474, DOI 10.1016/j.gie.2017.12.032; Tratar UL, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00268; Turajlic S, 2018, CELL, V173, P595, DOI 10.1016/j.cell.2018.03.043; Turajlic S, 2018, CELL, V173, P581, DOI 10.1016/j.cell.2018.03.057; Vallon V, 2001, J AM SOC NEPHROL, V12, P2003, DOI 10.1681/ASN.V12102003; van de Wetering M, 2015, CELL, V161, P933, DOI 10.1016/j.cell.2015.03.053; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; WALLACE AC, 1972, CANCER, V29, P977, DOI 10.1002/1097-0142(197204)29:4<977::AID-CNCR2820290444>3.0.CO;2-P; Wang SS, 2014, P NATL ACAD SCI USA, V111, P16538, DOI 10.1073/pnas.1414789111; Wettersten HI, 2017, NAT REV NEPHROL, V13, P410, DOI 10.1038/nrneph.2017.59; Wiltrout RH, 1991, IMMUNOTHERAPY RENAL, P13; YAO M, 1988, CANCER RES, V48, P6753; Young MD, 2018, SCIENCE, V361, P594, DOI 10.1126/science.aat1699; Zhao CX, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0419-4; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028	137	52	52	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	17					3413	3426		10.1038/s41388-020-1234-3	http://dx.doi.org/10.1038/s41388-020-1234-3		MAR 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LH1YK	32123314	Green Accepted			2022-12-28	WOS:000517738400002
J	Fang, RP; Xu, FF; Shi, H; Wu, Y; Cao, C; Li, H; Ye, K; Zhang, YY; Liu, Q; Zhang, SQ; Zhang, WY; Ye, LH				Fang, Runping; Xu, Feifei; Shi, Hui; Wu, Yue; Cao, Can; Li, Hang; Ye, Kai; Zhang, Yingyi; Liu, Qian; Zhang, Shuqin; Zhang, Weiying; Ye, Lihong			LAMTOR5 raises abnormal initiation of O-glycosylation in breast cancer metastasis via modulating GALNT1 activity	ONCOGENE			English	Article							ONCOPROTEIN; GROWTH; HBXIP; PHOSPHORYLATION; ACTIVATION; LUNG; IDENTIFICATION; TRANSCRIPTION; EXPRESSION; PROGNOSIS	During malignancy, perturbed O-glycosylation confers global influence on cancer progression. As a hallmark of cancer metastasis, GalNAc-type O-glycosylation initiation is aberrantly raised, but the regulatory mechanism is still mysterious. Here, we show that LAMTOR5 raises abnormal initiation of O-glycosylation in breast cancer metastasis. LAMTOR5 was highly expressed in adenocarcinoma and correlated with Tn antigen, a product of O-glycosylation initiation, in both clinical metastatic breast cancer specimens and secondary metastasis mouse model. LAMTOR5-modulated O-glycosylation initiating enzyme GALNT1 conferred Tn accumulation and predicted poor survival. Mechanistically, LAMTOR5 stimulated transcriptions of GALNT1 through coactivating c-Jun, and triggered dislocation of GALNT1 in the endoplasmic reticulum (ER) via LAMTOR5 dependent-activation of c-Src. This unusual initiation of O-glycosylation resulted in the abundance of Tn modified glycoproteins, such as MUC1 and OPN. Collectively, our findings indicate that LAMTOR5/c-Jun/c-Src axis serves as the upstream regulator of abnormal O-glycosylation initiation and potential therapeutic targets in breast cancer metastasis.	[Fang, Runping; Xu, Feifei; Shi, Hui; Wu, Yue; Cao, Can; Li, Hang; Ye, Kai; Zhang, Yingyi; Liu, Qian; Zhang, Shuqin; Zhang, Weiying; Ye, Lihong] Nankai Univ, State Key Lab Med Chem Biol, Tianjin Key Lab Prot Sci, Dept Biochem,Coll Life Sci, Tianjin 300071, Peoples R China	Nankai University	Ye, LH (corresponding author), Nankai Univ, State Key Lab Med Chem Biol, Tianjin Key Lab Prot Sci, Dept Biochem,Coll Life Sci, Tianjin 300071, Peoples R China.	yelihong@nankai.edu.cn	Fang, Runping/AAF-6835-2020					Nguyen AT, 2017, CANCER CELL, V32, P639, DOI 10.1016/j.ccell.2017.10.001; Bar-Peled L, 2012, CELL, V150, P1196, DOI 10.1016/j.cell.2012.07.032; Baum LG, 1996, J BIOL CHEM, V271, P10793, DOI 10.1074/jbc.271.18.10793; Berger T, 2010, P NATL ACAD SCI USA, V107, P2995, DOI 10.1073/pnas.1000101107; Cummings R.D., 2015, ESSENTIALS GLYCOBIOL, P611; Desai PR, 2000, TRANSFUS MED REV, V14, P312, DOI 10.1053/tmrv.2000.16229; Farre D, 2003, NUCLEIC ACIDS RES, V31, P3651, DOI 10.1093/nar/gkg605; Finlin BS, 2003, P NATL ACAD SCI USA, V100, P14469, DOI 10.1073/pnas.2437756100; Gill DJ, 2013, P NATL ACAD SCI USA, V110, pE3152, DOI 10.1073/pnas.1305269110; Gill DJ, 2011, TRENDS CELL BIOL, V21, P149, DOI 10.1016/j.tcb.2010.11.004; Gill DJ, 2010, J CELL BIOL, V189, P843, DOI 10.1083/jcb.201003055; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Hofmann BT, 2014, CLIN CANCER RES, V20, P6117, DOI 10.1158/1078-0432.CCR-14-0716; Hu N, 2011, J BIOL CHEM, V286, P13714, DOI 10.1074/jbc.M110.204131; Ju TZ, 2011, ANGEW CHEM INT EDIT, V50, P1770, DOI 10.1002/anie.201002313; Kariya Y, 2014, BIOCHEM J, V463, P93, DOI 10.1042/BJ20140060; Korourian S, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-136; Laack E, 2002, AM J PATHOL, V160, P1001, DOI 10.1016/S0002-9440(10)64921-8; Lee TH, 2012, KOREAN J RADIOL S1, V13, pS12; Li C, 2016, CANCER RES, V76, P1273, DOI 10.1158/0008-5472.CAN-15-2309; Li C, 2014, CLIN CANCER RES, V20, P4001, DOI 10.1158/1078-0432.CCR-13-3397; Li H, 2015, J BIOL CHEM, V290, P22649, DOI 10.1074/jbc.M115.658468; Li YH, 2016, CANCER RES, V76, P293, DOI 10.1158/0008-5472.CAN-14-3607; Lu G, 2014, CANCER CELL, V26, P222, DOI 10.1016/j.ccr.2014.06.026; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; Milde-Langosch K, 2015, BREAST CANCER RES TR, V151, P515, DOI 10.1007/s10549-015-3425-0; Minai-Tehrani A, 2013, INT J MOL MED, V32, P1137, DOI 10.3892/ijmm.2013.1483; Miwa HE, 2010, J BIOL CHEM, V285, P1208, DOI 10.1074/jbc.M109.035436; Nath S, 2014, TRENDS MOL MED, V20, P332, DOI 10.1016/j.molmed.2014.02.007; Ooms LM, 2015, CANCER CELL, V28, P155, DOI 10.1016/j.ccell.2015.07.003; Pangeni RP, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0089-x; Park JH, 2010, CANCER RES, V70, P2759, DOI 10.1158/0008-5472.CAN-09-3911; Pinho SS, 2015, NAT REV CANCER, V15, P540, DOI 10.1038/nrc3982; Qiu YH, 2008, J PROTEOME RES, V7, P1693, DOI 10.1021/pr700706s; Remmers N, 2013, CLIN CANCER RES, V19, P1981, DOI 10.1158/1078-0432.CCR-12-2662; Ritchie S, 2000, J BIOL CHEM, V275, P847, DOI 10.1074/jbc.275.2.847; Rottger S, 1998, J CELL SCI, V111, P45; Seales EC, 2003, ONCOGENE, V22, P7137, DOI 10.1038/sj.onc.1206834; Singh R, 2007, CANCER BIOL THER, V6, P481, DOI 10.4161/cbt.6.4.4201; Song KH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13796; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Yue L, 2013, CARCINOGENESIS, V34, P927, DOI 10.1093/carcin/bgs399; Zhang YY, 2013, J BIOL CHEM, V288, P18961, DOI 10.1074/jbc.M113.458638; Zhao Y, 2016, CANCER RES, V76, P4696, DOI 10.1158/0008-5472.CAN-15-1734	45	14	14	5	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	11					2290	2304		10.1038/s41388-019-1146-2	http://dx.doi.org/10.1038/s41388-019-1146-2			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KU0ZS	31836847				2022-12-28	WOS:000519440400005
J	Yoe, J; Kim, D; Kim, S; Lee, Y				Yoe, Jeehyun; Kim, Donghyo; Kim, Sanguk; Lee, Yoontae			Capicua restricts cancer stem cell-like properties in breast cancer cells	ONCOGENE			English	Article							TRANSCRIPTION FACTORS; EXTRACELLULAR-MATRIX; GENE-EXPRESSION; MICE; ASSOCIATION; RESISTANCE; MUTATIONS; FUSION; FAMILY; LINKS	Cancer stem cells (CSCs) play a central role in cancer initiation, progression, therapeutic resistance, and recurrence in patients. Here we present Capicua (CIC), a developmental transcriptional repressor, as a suppressor of CSC properties in breast cancer cells. CIC deficiency critically enhances CSC self-renewal and multiple CSC subpopulations of breast cancer cells without altering their growth rate or invasiveness. Loss of CIC relieves repression of ETV4 and ETV5 expression, consequently promoting self-renewal capability, EpCAM(+)/CD44(+)/CD24(low/-) expression, and ALDH activity. In xenograft models, CIC deficiency significantly increases CSC frequency and drives tumor initiation through derepression of ETV4. Consistent with the experimental data, the CD44(high)/CD24(low) CSC-like feature is inversely correlated with CIC levels in breast cancer patients. We also identify SOX2 as a downstream target gene of CIC that partly promotes CSC properties. Taken together, our study demonstrates that CIC suppresses breast cancer formation via restricting cancer stemness and proposes CIC as a potential regulator of stem cell maintenance.	[Yoe, Jeehyun; Kim, Donghyo; Kim, Sanguk; Lee, Yoontae] Pohang Univ Sci & Technol POSTECH, Dept Life Sci, Pohang 37673, Gyeongbuk, South Korea; [Kim, Sanguk; Lee, Yoontae] Pohang Univ Sci & Technol POSTECH, Div Integrat Biosci & Biotechnol, Pohang 37673, Gyeongbuk, South Korea	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH)	Lee, Y (corresponding author), Pohang Univ Sci & Technol POSTECH, Dept Life Sci, Pohang 37673, Gyeongbuk, South Korea.; Lee, Y (corresponding author), Pohang Univ Sci & Technol POSTECH, Div Integrat Biosci & Biotechnol, Pohang 37673, Gyeongbuk, South Korea.	yoontael@postech.ac.kr		Kim, Sanguk/0000-0002-3449-3814	National Research Foundation (NRF) of Korea [2017R1A5A1015366, 2018R1A2B2004416]; BK21 Plus Program (Program of Bio-Molecular Function, POSTECH)	National Research Foundation (NRF) of Korea(National Research Foundation of Korea); BK21 Plus Program (Program of Bio-Molecular Function, POSTECH)	We thank the Lee lab members for helpful discussions on this study as well as helping to conduct the experiments. This work was supported by grants from the National Research Foundation (NRF) of Korea (2017R1A5A1015366 and 2018R1A2B2004416 to YL). JY and DK were supported by the BK21 Plus Program (Program of Bio-Molecular Function, POSTECH).	Ahmad ST, 2018, REGULATION NEURAL ST, DOI [10.1101/335984, DOI 10.1101/335984]; Akagi T, 2015, J BIOL CHEM, V290, P22460, DOI 10.1074/jbc.M115.675595; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bieche I, 2004, CARCINOGENESIS, V25, P405, DOI 10.1093/carcin/bgh024; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Charafe-Jauffret E, 2010, CLIN CANCER RES, V16, P45, DOI 10.1158/1078-0432.CCR-09-1630; Choi N, 2015, ONCOTARGET, V6, P23533, DOI 10.18632/oncotarget.4372; Chotteau-Lelievre A, 2004, CLIN CANCER RES, V10, P7297, DOI 10.1158/1078-0432.CCR-04-0593; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Colacino JA, 2018, STEM CELL REP, V10, P1596, DOI 10.1016/j.stemcr.2018.03.001; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733; Eleveld TF, 2018, CANCER RES, V78, P6297, DOI 10.1158/0008-5472.CAN-18-1045; Firlej V, 2008, J CELL SCI, V121, P3393, DOI 10.1242/jcs.027201; Fores M, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006622; Gattazzo F, 2014, BBA-GEN SUBJECTS, V1840, P2506, DOI 10.1016/j.bbagen.2014.01.010; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Graham C, 2012, HUM PATHOL, V43, P180, DOI 10.1016/j.humpath.2011.04.023; Han SK, 2016, ONCOTARGET, V7, P56147, DOI 10.18632/oncotarget.11269; Hess DA, 2006, BLOOD, V107, P2162, DOI 10.1182/blood-2005-06-2284; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Hyun KA, 2016, ONCOTARGET, V7, P24677, DOI 10.18632/oncotarget.8250; Jimenez G, 2012, J CELL SCI, V125, P1383, DOI 10.1242/jcs.092965; Kan ZY, 2010, NATURE, V466, P869, DOI 10.1038/nature09208; Kawamura-Saito M, 2006, HUM MOL GENET, V15, P2125, DOI 10.1093/hmg/ddl136; Kim E, 2018, HEPATOLOGY, V67, P2287, DOI 10.1002/hep.29738; Kim E, 2015, SCI REP-UK, V5, DOI 10.1038/srep08272; Kurpios NA, 2003, J MAMMARY GLAND BIOL, V8, P177, DOI 10.1023/A:1025948823955; LeBlanc VG, 2017, J PATHOL, V242, P206, DOI 10.1002/path.4894; Lee JS, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-1111-8; Lee Y, 2011, DEV CELL, V21, P746, DOI 10.1016/j.devcel.2011.08.017; Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Liu SL, 2014, STEM CELL REP, V2, P78, DOI 10.1016/j.stemcr.2013.11.009; Lobo NA, 2007, ANNU REV CELL DEV BI, V23, P675, DOI 10.1146/annurev.cellbio.22.010305.104154; Lu HC, 2017, NAT GENET, V49, P527, DOI 10.1038/ng.3808; Masui S, 2007, NAT CELL BIOL, V9, P625, DOI 10.1038/ncb1589; Nik-Zainal S, 2016, NATURE, V534, P47, DOI 10.1038/nature17676; Oh S, 2012, BBA-REV CANCER, V1826, P1, DOI 10.1016/j.bbcan.2012.02.002; Okimoto RA, 2017, NAT GENET, V49, P87, DOI 10.1038/ng.3728; Park S, 2019, HEPATOLOGY, V70, P358, DOI 10.1002/hep.30594; Park S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16037; Patel M, 2008, LUNG CANCER, V59, P340, DOI 10.1016/j.lungcan.2007.08.033; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Simon-Carrasco L, 2017, GENE DEV, V31, P1456, DOI 10.1101/gad.300244.117; Tan QM, 2018, P NATL ACAD SCI USA, V115, pE1511, DOI 10.1073/pnas.1716452115; Tanei T, 2009, CLIN CANCER RES, V15, P4234, DOI 10.1158/1078-0432.CCR-08-1479; Wong D, 2019, ONCOGENE, V38, P273, DOI 10.1038/s41388-018-0427-5; Yip S, 2012, J PATHOL, V226, P7, DOI 10.1002/path.2995; Yuan ZY, 2014, ONCOTARGETS THER, V7, P1733, DOI 10.2147/OTT.S66692	53	14	15	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	17					3489	3506		10.1038/s41388-020-1230-7	http://dx.doi.org/10.1038/s41388-020-1230-7		FEB 2020	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LH1YK	32108163				2022-12-28	WOS:000516891300001
J	Kato, H; Asamitsu, K; Sun, WD; Kitajima, S; Yoshizawa-Sugata, N; Okamoto, T; Masai, H; Poellinger, L				Kato, Hiroyuki; Asamitsu, Kaori; Sun, Wendi; Kitajima, Shojiro; Yoshizawa-Sugata, Naoko; Okamoto, Takashi; Masai, Hisao; Poellinger, Lorenz			Cancer-derived UTX TPR mutations G137V and D336G impair interaction with MLL3/4 complexes and affect UTX subcellular localization	ONCOGENE			English	Article							MAKE-UP SYNDROME; KABUKI-SYNDROME; DEMETHYLASE UTX; PROTEIN; KDM6A; MLL2; GENES; INACTIVATION; RETARDATION; METHYLATION	The ubiquitously transcribed tetratricopeptide repeat on X chromosome (UTX) is a major histone H3 lysine 27 (H3K27) demethylase and the mixed-lineage leukemia (MLL) proteins are the H3K4 methyltransferases. UTX is one of the major components of MLL3- and MLL4-containing (MlLL3/4) complexes and likely has functions within the complexes. Although UTX is frequently mutated in various types of cancer and is thought to play a crucial role as a tumor suppressor, the importance of UTX interaction with MLL3/4 complexes in cancer formation is poorly understood. Here, we analyzed the ability of cancer-derived UTX mutant proteins to interact with ASH2L, which is a common core component of all the MLL complexes, and MLL3/4-specific components PTIP and PA1, and found that several single-amino acid substitution mutations in the tetratricopeptide repeat (TPR) affect UTX interaction with these components. Interaction-compromised mutants G137V and D336G and a TPR-deleted mutant Delta 80-397 were preferentially localized to the cytoplasm, suggesting that UTX is retained in the nucleus by MLL3/4 complexes through their interaction with the TPR. Intriguingly, WT UTX suppressed colony formation in soft agar, whereas G137V failed. This suggests that interaction of UTX with MLL3/4 complex plays a crucial role in their tumor suppressor function. Preferential cytoplasmic localization was also observed for endogenous proteins of G137V and another mutant G137V Delta 138 in HCT116 created by CRISPR-Cas9 gene editing. Interestingly, expression levels of these mutants were low and MG312 stabilized both endogenous as well as exogenous G137V proteins. These results reveal a novel mechanism of UTX regulation and reinforce the importance of UTX interaction with MLL3/4 complexes in cancer formation.	[Kato, Hiroyuki; Sun, Wendi; Kitajima, Shojiro; Poellinger, Lorenz] Natl Univ Singapore, Canc Sci Inst Singapore, 14 Med Dr, Singapore 117599, Singapore; [Kato, Hiroyuki; Yoshizawa-Sugata, Naoko; Masai, Hisao] Tokyo Metropolitan Inst Med Sci, Dept Genome Med, Setagaya Ku, 2-1-6 Kamikitazawa, Tokyo 1568506, Japan; [Kato, Hiroyuki; Asamitsu, Kaori; Okamoto, Takashi] Nagoya City Univ, Dept Mol & Cellular Biol, Grad Sch Med Sci, Mizuho Ku, Nagoya, Aichi 467860, Japan; [Kitajima, Shojiro] Keio Univ, Inst Adv Biosci, Kakuganji 246-2, Tsuruoka, Yamagata 9970052, Japan; [Poellinger, Lorenz] Karolinska Inst, Dept Cell & Mol Biol, SE-17177 Stockholm, Sweden	National University of Singapore; Tokyo Metropolitan Institute of Medical Science; Nagoya City University; Keio University; Karolinska Institutet	Kato, H (corresponding author), Natl Univ Singapore, Canc Sci Inst Singapore, 14 Med Dr, Singapore 117599, Singapore.; Kato, H (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Genome Med, Setagaya Ku, 2-1-6 Kamikitazawa, Tokyo 1568506, Japan.; Kato, H (corresponding author), Nagoya City Univ, Dept Mol & Cellular Biol, Grad Sch Med Sci, Mizuho Ku, Nagoya, Aichi 467860, Japan.	csihkato@gmail.com		Yoshizawa-Sugata, Naoko/0000-0001-8792-8669; Masai, Hisao/0000-0003-1268-5302; Asamitsu, Kaori/0000-0001-5333-8011	Singapore National Research Foundation [R-713-005-014-271, R-713-000-162-511]; Singapore Ministry of Education; Singapore Ministry of Health's National Medical Research Council [NMRC/CIRG/1389/2014]; Japan Society for the Promotion of Science KAKENHI [17K08638, 23247031, 26251004]; Takeda Science Foundation	Singapore National Research Foundation(National Research Foundation, Singapore); Singapore Ministry of Education(Ministry of Education, Singapore); Singapore Ministry of Health's National Medical Research Council(National Medical Research Council, Singapore); Japan Society for the Promotion of Science KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Takeda Science Foundation(Takeda Science Foundation (TSF))	We thank all the LP lab members for technical assistance. This work was supported by grants from the Singapore National Research Foundation (R-713-005-014-271 and R-713-000-162-511), the Singapore Ministry of Education under the Research Centres of Excellence Programme, and the Singapore Ministry of Health's National Medical Research Council (Clinician Scientist Individual Research Grant, NMRC/CIRG/1389/2014) to LP, and Japan Society for the Promotion of Science KAKENHI (17K08638) to KA and (Scientific Research A, 23247031 and 26251004) to HM, and the Takeda Science Foundation to HM. In the midst of this project, Prof. Lorenz Poellinger passed away, to whom we dedicate this work.	Agger K, 2007, NATURE, V449, P731, DOI 10.1038/nature06145; Ahn J, 2016, ONCOTARGET, V7, P63252, DOI 10.18632/oncotarget.11207; Andricovich J, 2018, CANCER CELL, V33, P512, DOI 10.1016/j.ccell.2018.02.003; Banka S, 2015, CLIN GENET, V87, P252, DOI 10.1111/cge.12363; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Bouazzi H, 2015, CLIN CASE REP, V3, P604, DOI 10.1002/ccr3.301; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Cho YW, 2007, J BIOL CHEM, V282, P20395, DOI 10.1074/jbc.M701574200; D'Andrea LD, 2003, TRENDS BIOCHEM SCI, V28, P655, DOI 10.1016/j.tibs.2003.10.007; Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672; Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031; Greenfield A, 1998, HUM MOL GENET, V7, P737, DOI 10.1093/hmg/7.4.737; Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173; Gui YT, 2011, NAT GENET, V43, P875, DOI 10.1038/ng.907; Hannibal MC, 2011, AM J MED GENET A, V155A, P1511, DOI 10.1002/ajmg.a.34074; Hernandez-Ramirez LC, 2016, J CLIN ENDOCR METAB, V101, P3144, DOI 10.1210/jc.2016-1307; Herz HM, 2016, BIOESSAYS, V38, P1003, DOI 10.1002/bies.201600106; Hong SH, 2007, P NATL ACAD SCI USA, V104, P18439, DOI 10.1073/pnas.0707292104; Ijichi O, 1996, ACTA PAEDIATR JAPON, V38, P66; Issaeva I, 2007, MOL CELL BIOL, V27, P1889, DOI 10.1128/MCB.01506-06; Jankowska AM, 2011, BLOOD, V118, P3932, DOI 10.1182/blood-2010-10-311019; Jones DTW, 2012, NATURE, V488, P100, DOI 10.1038/nature11284; Kim DE, 2004, NUCLEIC ACIDS RES, V32, pW526, DOI 10.1093/nar/gkh468; Kim J, 2017, ANN CLIN LAB SCI, V47, P229; Kitajima S, 2017, ONCOTARGET, V8, P114481, DOI 10.18632/oncotarget.23010; Lan F, 2007, NATURE, V449, P689, DOI 10.1038/nature06192; Lederer D, 2012, AM J HUM GENET, V90, P119, DOI 10.1016/j.ajhg.2011.11.021; Lee MG, 2007, SCIENCE, V318, P447, DOI 10.1126/science.1149042; Ler LD, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai8312; Leusen JHW, 1996, J EXP MED, V184, P1243, DOI 10.1084/jem.184.4.1243; Lindgren AM, 2013, HUM GENET, V132, P537, DOI 10.1007/s00439-013-1263-x; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Mar BG, 2012, LEUKEMIA, V26, P1881, DOI 10.1038/leu.2012.56; Merks JHM, 2005, AM J MED GENET A, V134A, P132, DOI 10.1002/ajmg.a.30603; Micale L, 2014, HUM MUTAT, V35, P841, DOI 10.1002/humu.22547; Miyake N, 2013, AM J MED GENET A, V161, P2234, DOI 10.1002/ajmg.a.36072; Ng SB, 2010, NAT GENET, V42, P790, DOI 10.1038/ng.646; NIIKAWA N, 1988, AM J MED GENET, V31, P565, DOI 10.1002/ajmg.1320310312; NIIKAWA N, 1981, J PEDIATR-US, V99, P565, DOI 10.1016/S0022-3476(81)80255-7; Niranjan TS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116454; Patel SR, 2007, DEV CELL, V13, P580, DOI 10.1016/j.devcel.2007.09.004; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Robinson G, 2012, NATURE, V488, P43, DOI 10.1038/nature11213; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Scherer S, 2003, AM J MED GENET A, V122A, P76, DOI 10.1002/ajmg.a.20261; Shpargel KB, 2017, P NATL ACAD SCI USA, V114, pE9046, DOI 10.1073/pnas.1705011114; Shpargel KB, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002964; Su I, 2005, CELL, V121, P425, DOI 10.1016/j.cell.2005.02.029; Sun WD, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05685-3; Tumino M, 2010, AM J MED GENET A, V152A, P1536, DOI 10.1002/ajmg.a.33405; Van der Meulen J, 2014, EPIGENETICS-US, V9, P658, DOI 10.4161/epi.28298; van Haaften G, 2009, NAT GENET, V41, P521, DOI 10.1038/ng.349; Vandamme J, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002647; Walport LJ, 2014, J BIOL CHEM, V289, P18302, DOI 10.1074/jbc.M114.555052; Wang CC, 2012, P NATL ACAD SCI USA, V109, P15324, DOI 10.1073/pnas.1204166109; Wang JK, 2010, GENE DEV, V24, P327, DOI 10.1101/gad.1882610; Wang SP, 2017, MOL CELL, V67, P308, DOI 10.1016/j.molcel.2017.06.028; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Willems AP, 2017, J BIOL CHEM, V292, P12621, DOI 10.1074/jbc.M117.790097; Zhang SY, 2016, NATURE, V533, P260, DOI 10.1038/nature17973	62	9	9	2	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2020	39	16					3322	3335		10.1038/s41388-020-1218-3	http://dx.doi.org/10.1038/s41388-020-1218-3		FEB 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF9OJ	32071397				2022-12-28	WOS:000514262600001
J	Kennedy, SP; O'Neill, M; Cunningham, D; Morris, PG; Toomey, S; Blanco-Aparicio, C; Martinez, S; Pastor, J; Eustace, AJ; Hennessy, BT				Kennedy, Sean P.; O'Neill, Michael; Cunningham, Darren; Morris, Patrick G.; Toomey, Sinead; Blanco-Aparicio, Carmen; Martinez, Sonia; Pastor, Joaquin; Eustace, Alex J.; Hennessy, Bryan T.			Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer	ONCOGENE			English	Article							PIM KINASE INHIBITOR; PROTEIN-KINASE; DUAL INHIBITION; PROSTATE-CANCER; THERAPY; PATHWAY; POTENT; CELLS; PHOSPHORYLATION; RESISTANCE	The proviral integration of Moloney virus (PIM) family of protein kinases are overexpressed in many haematological and solid tumours. PIM kinase expression is elevated in PI3K inhibitor-treated breast cancer samples, suggesting a major resistance pathway for PI3K inhibitors in breast cancer, potentially limiting their clinical utility. IBL-302 is a novel molecule that inhibits both PIM and PI3K/AKT/mTOR signalling. We thus evaluated the preclinical activity of IBL-302, in a range of breast cancer models. Our results demonstrate in vitro efficacy of IBL-302 in a range of breast cancer cell lines, including lines with acquired resistance to trastuzumab and lapatinib. IBL-302 demonstrated single-agent, anti-tumour efficacy in suppression of pAKT, pmTOR and pBAD in the SKBR-3, BT-474 and HCC-1954 HER2+/PIK3CA-mutated cell lines. We have also shown the in vivo single-agent efficacy of IBL-302 in the subcutaneous BT-474 and HCC-1954 xenograft model in BALB/c nude mice. The combination of trastuzumab and IBL-302 significantly increased the anti-proliferative effect in HER2+ breast cancer cell line, and matched trastuzumab-resistant line, relative to testing either drug alone. We thus believe that the novel PIM and PI3K/mTOR inhibitor, IBL-302, represents an exciting new potential treatment option for breast cancer, and that it should be considered for clinical investigation.	[Kennedy, Sean P.; Morris, Patrick G.; Toomey, Sinead; Hennessy, Bryan T.] Royal Coll Surgeons Ireland, Dept Mol Med, Med Oncol Grp, Smurfit Bldg Beaumont Hosp, Dublin, Ireland; [O'Neill, Michael; Cunningham, Darren] Inflect Biosci, Anglesea House, Dublin, Ireland; [Morris, Patrick G.; Hennessy, Bryan T.] Beaumont Hosp, Canc Clin Trials & Res Unit, Dublin, Ireland; [Blanco-Aparicio, Carmen; Martinez, Sonia; Pastor, Joaquin] Spanish Natl Canc Res Ctr CNIO, Expt Therapeut Programme, Madrid, Spain; [Eustace, Alex J.] Dublin City Univ, Natl Inst Cellular Biotechnol, Mol Therapeut Canc Ireland, Dublin, Ireland; [Hennessy, Bryan T.] Canc Trials Ireland, Innovat House,Old Finglas Rd, Dublin, Ireland	Royal College of Surgeons - Ireland; Centro Nacional de Investigaciones Oncologicas (CNIO); Dublin City University	Kennedy, SP (corresponding author), Royal Coll Surgeons Ireland, Dept Mol Med, Med Oncol Grp, Smurfit Bldg Beaumont Hosp, Dublin, Ireland.	Seanpkennedy@rcsi.ie	Blanco-Aparicio, Carmen/I-3162-2015; Gonzalez, Sonia Martinez/I-4616-2015; Fernandez, Joaquin Pastor/I-4567-2015	Blanco-Aparicio, Carmen/0000-0002-3249-6595; Gonzalez, Sonia Martinez/0000-0003-2230-7794; Fernandez, Joaquin Pastor/0000-0003-0553-8021; Hennessy, Bryan/0000-0002-7871-6477	North East Cancer Research & Education Trust; Enterprise Ireland [IV-2017-2125]; Fox family; Kerins family	North East Cancer Research & Education Trust; Enterprise Ireland; Fox family; Kerins family	We are very grateful to Stephen Madden for his valuable input and statistical analysis. This research was supported by the North East Cancer Research & Education Trust, Fox and Kerins families and Enterprise Ireland (Voucher ID: IV-2017-2125).	Aziz AUR, 2018, BIOMOLECULES, V8, DOI 10.3390/biom8010007; Bachmann M, 2005, INT J BIOCHEM CELL B, V37, P726, DOI 10.1016/j.biocel.2004.11.005; Beier UH, 2007, INT J ONCOL, V30, P1381; Bhattacharya N, 2002, CHROMOSOMA, V111, P80, DOI 10.1007/s00412-002-0192-6; Bian CN, 2018, ONCOL LETT, V15, P9655, DOI 10.3892/ol.2018.8587; Braso-Maristany F, 2016, NAT MED, V22, P1303, DOI 10.1038/nm.4198; Burger MT, 2015, J MED CHEM, V58, P8373, DOI 10.1021/acs.jmedchem.5b01275; Cen B, 2014, MOL CELL BIOL, V34, P2517, DOI 10.1128/MCB.00147-14; Cen B, 2013, CANCER RES, V73, P3402, DOI 10.1158/0008-5472.CAN-12-4619; Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; Chapuis N, 2010, CLIN CANCER RES, V16, P5424, DOI 10.1158/1078-0432.CCR-10-1102; Chen LS, 2009, BLOOD, V114, P4150, DOI 10.1182/blood-2009-03-212852; Cobb M, 2017, CANCER RES, V77, DOI 10.1158/1538-7445.AM2017-524; Cortes J, 2018, BRIT J CANCER, V118, P1425, DOI 10.1038/s41416-018-0082-1; Dakin LA, 2012, BIOORG MED CHEM LETT, V22, P4599, DOI 10.1016/j.bmcl.2012.05.098; Doshi KA, 2015, CANCER RES, V75, DOI 10.1158/1538-7445.AM2015-5332; Elster N, 2015, BREAST CANCER RES TR, V149, P373, DOI 10.1007/s10549-014-3239-5; Elster N, 2018, THER ADV MED ONCOL, V10, DOI 10.1177/1758835918778297; Eustace AJ, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-53; Garcia PD, 2014, CLIN CANCER RES, V20, P1834, DOI 10.1158/1078-0432.CCR-13-2062; Haddach M, 2012, ACS MED CHEM LETT, V3, P135, DOI 10.1021/ml200259q; Herzog A, 2013, CLIN CANCER RES, V19, P3808, DOI 10.1158/1078-0432.CCR-12-2716; Hogan C, 2008, J BIOL CHEM, V283, P18012, DOI 10.1074/jbc.M709695200; Horiuchi D, 2016, NAT MED, V22, P1321, DOI 10.1038/nm.4213; Hua H, 2018, BIOMED PHARMACOTHER, V101, P115, DOI 10.1016/j.biopha.2018.02.031; Ilic N, 2011, P NATL ACAD SCI USA, V108, pE699, DOI 10.1073/pnas.1108237108; Isaac M, 2011, DRUG RESIST UPDATE, V14, P203, DOI 10.1016/j.drup.2011.04.002; Jin B, 2014, AGING CELL, V13, P879, DOI 10.1111/acel.12249; Keegan NM, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.1036; Keeton EK, 2014, BLOOD, V123, P905, DOI 10.1182/blood-2013-04-495366; Koblish H, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199108; Le XN, 2016, CANCER DISCOV, V6, P1134, DOI 10.1158/2159-8290.CD-16-0305; Liu PX, 2011, NAT MED, V17, P1116, DOI 10.1038/nm.2402; Liu WT, 2016, CELL CYCLE, V15, P886, DOI 10.1080/15384101.2016.1152428; Macdonald A, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-1; Malinen M, 2013, MOL CELL ENDOCRINOL, V365, P270, DOI 10.1016/j.mce.2012.10.028; Mcdermott MSJ, 2017, INT J ONCOL, V50, P2221, DOI 10.3892/ijo.2017.3976; McDermott MSJ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-157; Meja K, 2014, BRIT J HAEMATOL, V167, P69, DOI 10.1111/bjh.13013; Mohlin S, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201810058; Moody SE, 2015, ONCOGENE, V34, P2061, DOI 10.1038/onc.2014.153; Moore G, 2017, J THORAC ONCOL, V12, pS527, DOI 10.1016/j.jtho.2016.11.649; Musiani D, 2014, J PROTEOME RES, V13, P4970, DOI 10.1021/pr500651n; Narlik-Grassow M, 2014, MED RES REV, V34, P136, DOI 10.1002/med.21284; Nawijn MC, 2011, NAT REV CANCER, V11, P23, DOI 10.1038/nrc2986; Neil M, 2014, CANCER RES, V74, P4524; Paino T, 2017, CLIN CANCER RES, V23, P225, DOI 10.1158/1078-0432.CCR-16-0230; Rampal RK, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.634.634; Rebello Richard J., 2018, Advances in Biological Regulation, V67, P163, DOI 10.1016/j.jbior.2017.10.010; Reidy M, 2014, BLOOD, V124, DOI 10.1182/blood.V124.21.5713.5713; Roh M, 2003, CANCER RES, V63, P8079; Simioni C, 2014, ONCOTARGET, V5, P10034, DOI 10.18632/oncotarget.2490; Song JH, 2012, CANCER RES, V72, P294, DOI 10.1158/0008-5472.CAN-11-3240; Sourbier C, 2006, CANCER RES, V66, P5130, DOI 10.1158/0008-5472.CAN-05-1469; Tursynbay Y, 2016, BIOMED REP, V4, P140, DOI 10.3892/br.2015.561; Wang ZP, 2002, BBA-MOL CELL RES, V1593, P45, DOI 10.1016/S0167-4889(02)00347-6; Warfel NA, 2015, PHARMACOL THERAPEUT, V151, P41, DOI 10.1016/j.pharmthera.2015.03.001; White E, 2003, GENE DEV, V17, P1813, DOI 10.1101/gad.1123103; Wong PM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9048; Xia ZP, 2009, J MED CHEM, V52, P74, DOI 10.1021/jm800937p; Yang J, 2017, ONCOGENE, V36, P4828, DOI 10.1038/onc.2017.96; Zhang F, 2009, CANCER BIOL THER, V8, P846, DOI 10.4161/cbt.8.9.8210; Zhang RX, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16153-3; Zhang YD, 2007, MOL CANCER RES, V5, P909, DOI 10.1158/1541-7786.MCR-06-0388; Zhao B, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0348-9	65	14	14	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	14					3028	3040		10.1038/s41388-020-1202-y	http://dx.doi.org/10.1038/s41388-020-1202-y		FEB 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KZ2VB	32042115	Green Published, hybrid			2022-12-28	WOS:000512528200002
J	Hsu, BE; Roy, J; Mouhanna, J; Rayes, RF; Ramsay, L; Tabaries, S; Annis, MG; Watson, IR; Spicer, JD; Costantino, S; Siegel, PM				Hsu, Brian E.; Roy, Joannie; Mouhanna, Jack; Rayes, Roni F.; Ramsay, LeeAnn; Tabaries, Sebastien; Annis, Matthew G.; Watson, Ian R.; Spicer, Jonathan D.; Costantino, Santiago; Siegel, Peter M.			C3a elicits unique migratory responses in immature low-density neutrophils	ONCOGENE			English	Article							PARTICLE TRACKING; CHEMOTAXIS; C5A; RECEPTOR; ANAPHYLATOXIN; ANTAGONIST; EXPRESSION; LEUKOCYTES; LTB4	Neutrophils represent the immune system's first line of defense and are rapidly recruited into inflamed tissue. In cancer associated inflammation, phenotypic heterogeneity has been ascribed to this cell type, whereby neutrophils can manifest anti- or pro-metastatic functions depending on the cellular/micro-environmental context. Here, we demonstrate that pro-metastatic immature low-density neutrophils (iLDNs) more efficiently accumulate in the livers of mice bearing metastatic lesions compared with anti-metastatic mature high-density neutrophils (HDNs). Transcriptomic analyses reveal enrichment of a migration signature in iLDNs relative to HDNs. We find that conditioned media derived from liver-metastatic breast cancer cells, but not lung-metastatic variants, specifically induces chemotaxis of iLDNs and not HDNs. Chemotactic responses are due to increased surface expression of C3aR in iLDNs relative to HDNs. In addition, we detect elevated secretion of cancer-cell derived C3a from liver-metastatic versus lung-metastatic breast cancer cells. Perturbation of C3a/C3aR signaling axis with either a small molecule inhibitor, SB290157, or reducing the levels of secreted C3a from liver-metastatic breast cancer cells by short hairpin RNAs, can abrogate the chemotactic response of iLDNs both in vitro and in vivo, respectively. Together, these data reveal novel mechanisms through which iLDNs prefentially accumulate in liver tissue harboring metastases in response to tumor-derived C3a secreted from the liver-aggressive 4T1 breast cancer cells.	[Hsu, Brian E.; Ramsay, LeeAnn; Tabaries, Sebastien; Annis, Matthew G.; Watson, Ian R.; Siegel, Peter M.] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada; [Hsu, Brian E.; Siegel, Peter M.] McGill Univ, Dept Med, Montreal, PQ H3G 1Y6, Canada; [Roy, Joannie; Costantino, Santiago] Maisonneuve Rosemont Hosp, Res Ctr, Montreal, PQ H1T 2M4, Canada; [Roy, Joannie; Costantino, Santiago] Univ Montreal, Inst Biomed Engn, Montreal, PQ H3C 3T5, Canada; [Mouhanna, Jack; Rayes, Roni F.; Spicer, Jonathan D.] McGill Univ, Ctr Hlth, Res Inst, Dept Surg, Montreal, PQ H4A 3J1, Canada; [Watson, Ian R.; Siegel, Peter M.] McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University; Universite de Montreal; Universite de Montreal; McGill University; McGill University	Siegel, PM (corresponding author), McGill Univ, Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada.; Siegel, PM (corresponding author), McGill Univ, Dept Med, Montreal, PQ H3G 1Y6, Canada.; Siegel, PM (corresponding author), McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada.	peter.siegel@mcgill.ca	Costantino, Santiago/ABD-5472-2020	Costantino, Santiago/0000-0002-2454-2635; Watson, Ian/0000-0002-6025-3080; Rayes, Roni/0000-0001-7508-020X; Annis, Matthew/0000-0002-8776-004X	Cancer Research Society; Terry Fox Research Institute [242122]; Quebec Breast Cancer Foundation [242122]; NSERC; Genome Canada; FRQS; AATS; MGH foundation; Charlotte and Leo Karassik Foundation PhD Fellowship; Rolande and Marcel Gosselin Graduate Studentship	Cancer Research Society; Terry Fox Research Institute; Quebec Breast Cancer Foundation; NSERC(Natural Sciences and Engineering Research Council of Canada (NSERC)); Genome Canada(Genome Canada); FRQS; AATS; MGH foundation; Charlotte and Leo Karassik Foundation PhD Fellowship; Rolande and Marcel Gosselin Graduate Studentship	We acknowledge the Goodman Cancer Research Centre histology core facility (McGill University) for routine histological services, the Cell Vision Core Facility (McGill University) for providing routine cell sorting service and the Genetics Perturbation Service for shRNAs (McGill University). We thank Anie Monast and Cynthia Lavoie for technical support and members of the Siegel laboratory for their thoughtful discussions and critical reading of the manuscript. This work was supported by an operating grant to P.M.S. from the Cancer Research Society and the Terry Fox Research Institute and Quebec Breast Cancer Foundation (Grant #: 242122). S.C. acknowledges funding support from NSERC and Genome Canada and salary awarded from FRQS. J.D.S acknowledges funding support from AATS, MGH foundation and FRQS. BEH acknowledges support from the Charlotte and Leo Karassik Foundation PhD Fellowship and the Rolande and Marcel Gosselin Graduate Studentship. PMS is a McGill University William Dawson Scholar.	Afonso PV, 2012, DEV CELL, V22, P1079, DOI 10.1016/j.devcel.2012.02.003; Ames RS, 2001, J IMMUNOL, V166, P6341, DOI 10.4049/jimmunol.166.10.6341; Banda NK, 2012, J IMMUNOL, V188, P1469, DOI 10.4049/jimmunol.1102310; Bautsch W, 2000, J IMMUNOL, V165, P5401, DOI 10.4049/jimmunol.165.10.5401; Brandau S, 2011, J LEUKOCYTE BIOL, V89, P311, DOI 10.1189/jlb.0310162; Crocker JC, 1996, J COLLOID INTERF SCI, V179, P298, DOI 10.1006/jcis.1996.0217; DAFFERN PJ, 1995, J EXP MED, V181, P2119, DOI 10.1084/jem.181.6.2119; Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149; Foxman EF, 1997, J CELL BIOL, V139, P1349, DOI 10.1083/jcb.139.5.1349; Foxman EF, 1999, J CELL BIOL, V147, P577, DOI 10.1083/jcb.147.3.577; Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017; Guglietta S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11037; Hartmann K, 1997, BLOOD, V89, P2863, DOI 10.1182/blood.V89.8.2863; Heit B, 2002, J CELL BIOL, V159, P91, DOI 10.1083/jcb.200202114; Heit Bryan, 2003, Sci STKE, V2003, pPL5, DOI 10.1126/stke.2003.170.pl5; Hsu BE, 2019, CELL REP, V27, P3902, DOI 10.1016/j.celrep.2019.05.091; Hutamekalin P, 2010, J PHARMACOL SCI, V112, P56, DOI 10.1254/jphs.09180FP; Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399; KRAUSS AHP, 1994, J LEUKOCYTE BIOL, V55, P201, DOI 10.1002/jlb.55.2.201; Lammermann T, 2013, NATURE, V498, P371, DOI 10.1038/nature12175; Lim H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052666; Liu LH, 2010, DEV CELL, V19, P845, DOI 10.1016/j.devcel.2010.11.004; Lohman RJ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00414-w; Luo WJ, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-161; Majumdar R, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002336; MARDER SR, 1985, J IMMUNOL, V134, P3325; Mazzaferri J, 2015, BIOINFORMATICS, V31, P1279, DOI 10.1093/bioinformatics/btu793; Mishalian I, 2017, IMMUNOBIOLOGY, V222, P82, DOI 10.1016/j.imbio.2016.02.001; Mizutani N, 2009, J IMMUNOL, V183, P4039, DOI 10.4049/jimmunol.0901468; Mollnes TE, 2002, BLOOD, V100, P1869; NELSON RD, 1975, J IMMUNOL, V115, P1650; OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076; PALMBLAD J, 1981, BLOOD, V58, P658; Quell KM, 2017, J IMMUNOL, V199, P688, DOI 10.4049/jimmunol.1700318; Rink I, 2015, J IMMUNOL, V194, P5549, DOI 10.4049/jimmunol.1500148; Roy J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02993-6; Sadik CD, 2011, TRENDS IMMUNOL, V32, P452, DOI 10.1016/j.it.2011.06.008; Sagiv JY, 2015, CELL REP, V10, P562, DOI 10.1016/j.celrep.2014.12.039; Saha P, 2017, J IMMUNOL, V198, P4293, DOI 10.4049/jimmunol.1700261; Saunders CA, 2019, METHOD CELL BIOL, V149, P31, DOI 10.1016/bs.mcb.2018.09.002; Subramanian BC, 2018, J CELL SCI, V131, DOI 10.1242/jcs.217422; Tabaries S, 2011, ONCOGENE, V30, P1318, DOI 10.1038/onc.2010.518; Tabaries S, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0558-3; Takabayashi T, 1996, J IMMUNOL, V156, P3455; Talbot J, 2015, ARTHRITIS RHEUMATOL, V67, P1751, DOI 10.1002/art.39117; Wculek SK, 2015, NATURE, V528, P413, DOI 10.1038/nature16140; Wu MCL, 2013, P NATL ACAD SCI USA, V110, P9439, DOI 10.1073/pnas.1218815110	48	13	13	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	12					2612	2623		10.1038/s41388-020-1169-8	http://dx.doi.org/10.1038/s41388-020-1169-8		FEB 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KW4HU	32020055				2022-12-28	WOS:000511084200001
J	Chauhan, SS; Toth, RK; Jensen, CC; Casillas, AL; Kashatus, DF; Warfel, NA				Chauhan, Shailender S.; Toth, Rachel K.; Jensen, Corbin C.; Casillas, Andrea L.; Kashatus, David F.; Warfel, Noel A.			PIM kinases alter mitochondrial dynamics and chemosensitivity in lung cancer	ONCOGENE			English	Article							DEPENDENT PROTEIN-KINASE; CYTOCHROME-C; SMALL-CELL; FISSION; DRP1; PHOSPHORYLATION; FUSION; RESISTANCE; REGULATORS; SURVIVAL	Resistance to chemotherapy represents a major obstacle to the successful treatment of non-small-cell lung cancer (NSCLC). The goal of this study was to determine how PIM kinases impact mitochondrial dynamics, ROS production, and response to chemotherapy in lung cancer. Live-cell imaging and microscopy were used to determine the effect of PIM loss or inhibition on mitochondrial phenotype and ROS. Inhibition of PIM kinases caused excessive mitochondrial fission and significant upregulation of mitochondrial superoxide, increasing intracellular ROS. Mechanistically, we define a signaling axis linking PIM1 to Drp1 and mitochondrial fission in lung cancer. PIM inhibition significantly increased the protein levels and mitochondrial localization of Drp1, causing marked fragmentation of mitochondria. An inverse correlation between PIM1 and Drp1 was confirmed in NSCLC patient samples. Inhibition of PIM sensitized NSCLC cells to chemotherapy and produced a synergistic antitumor response in vitro and in vivo. Immunohistochemistry and transmission electron microscopy verified that PIM inhibitors promote mitochondrial fission and apoptosis in vivo. These data improve our knowledge about how PIM1 regulates mitochondria and provide justification for combining PIM inhibition with chemotherapy in NSCLC.	[Chauhan, Shailender S.; Warfel, Noel A.] Univ Arizona, Dept Cellular & Mol Med, Tucson, AZ 85721 USA; [Toth, Rachel K.; Warfel, Noel A.] Univ Arizona, Canc Ctr, Tucson, AZ 85721 USA; [Jensen, Corbin C.; Casillas, Andrea L.] Univ Arizona, Dept Canc Biol, Tucson, AZ USA; [Kashatus, David F.] Univ Virginia, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA USA; [Warfel, Noel A.] Levy Canc Ctr, Rm 0977,1515 N Campbell Ave, Tucson, AZ 85724 USA	University of Arizona; University of Arizona; University of Arizona; University of Virginia	Warfel, NA (corresponding author), Univ Arizona, Dept Cellular & Mol Med, Tucson, AZ 85721 USA.; Warfel, NA (corresponding author), Univ Arizona, Canc Ctr, Tucson, AZ 85721 USA.; Warfel, NA (corresponding author), Levy Canc Ctr, Rm 0977,1515 N Campbell Ave, Tucson, AZ 85724 USA.	warfelna@email.arizona.edu	Chauhan, Shailender Singh/AAM-5269-2020; Kashatus, David/D-8299-2012	Chauhan, Shailender Singh/0000-0002-1975-2734; Casillas, Andrea L/0000-0002-2059-3048; Kashatus, David/0000-0001-8007-0612	American Cancer Society [RSG-16-159-01-CDD]; American Lung Association [LCD-504131]; Department of Defense PCRP Award [W81XWH-19-1-0455]; Cancer Center Support Grant [P30CA023074]	American Cancer Society(American Cancer Society); American Lung Association; Department of Defense PCRP Award(United States Department of Defense); Cancer Center Support Grant	We would like to thank Donna Zhang (University of Arizona) for providing the H1299 Keap1<SUP>-/-</SUP>cell line and assistance with the acquisition and analysis of EPR results. We thank Adam R. Kohr for his assistance with graphic design. The research was supported by American Cancer Society grant RSG-16-159-01-CDD, American Lung Association grant LCD-504131, and Department of Defense PCRP Award (W81XWH-19-1-0455) to NAW. Cancer Center Support Grant P30CA023074 also provided support for this research.	Bordt EA, 2017, DEV CELL, V40, P583, DOI 10.1016/j.devcel.2017.02.020; Breckenridge DG, 2003, J CELL BIOL, V160, P1115, DOI 10.1083/jcb.200212059; Cao LJ, 2019, CANCER LETT, V444, P116, DOI 10.1016/j.canlet.2018.12.015; Chang CR, 2007, J BIOL CHEM, V282, P21583, DOI 10.1074/jbc.C700083200; Choi YM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135083; Cribbs JT, 2007, EMBO REP, V8, P939, DOI 10.1038/sj.embor.7401062; Cristofani R, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0866-5; Din S, 2013, P NATL ACAD SCI USA, V110, P5969, DOI 10.1073/pnas.1213294110; Estaquier J, 2007, CELL DEATH DIFFER, V14, P1086, DOI 10.1038/sj.cdd.4402107; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Jezek J, 2018, ANTIOXIDANTS-BASEL, V7, DOI 10.3390/antiox7010013; Joseph B, 1999, BIOCHEM BIOPH RES CO, V262, P381, DOI 10.1006/bbrc.1999.1191; Kashatus DF, 2011, NAT CELL BIOL, V13, P1108, DOI 10.1038/ncb2310; Kashatus JA, 2015, MOL CELL, V57, P537, DOI 10.1016/j.molcel.2015.01.002; Kong B, 2014, J BIOL CHEM, V289, P27134, DOI 10.1074/jbc.M114.594812; Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294; Li X, 2017, SCI REP-UK, V7, DOI 10.1038/srep42748; Lilly M, 1999, ONCOGENE, V18, P4022, DOI 10.1038/sj.onc.1202741; Lin JJ, 2016, TRENDS CANCER, V2, P350, DOI 10.1016/j.trecan.2016.05.010; Macdonald A, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-1; Mikkers H, 2004, MOL CELL BIOL, V24, P6104, DOI 10.1128/MCB.24.13.6104-6115.2004; Nagdas S, 2019, CELL REP, V28, P1845, DOI 10.1016/j.celrep.2019.07.031; Qian W, 2014, ONCOTARGET, V5, P4180, DOI 10.18632/oncotarget.1944; Rambold AS, 2011, P NATL ACAD SCI USA, V108, P10190, DOI 10.1073/pnas.1107402108; Roberts ER, 2013, COMPUT STRUCT BIOTEC, V6, DOI 10.5936/csbj.201303019; Senft D, 2016, CURR OPIN CELL BIOL, V39, P43, DOI 10.1016/j.ceb.2016.02.001; Song JH, 2015, ONCOGENE, V34, P3728, DOI 10.1038/onc.2014.306; Song Jin H, 2018, Mol Cancer Ther, V17, P2710, DOI 10.1158/1535-7163.MCT-18-0374; Song JH, 2016, ONCOTARGET, V7, P20152, DOI 10.18632/oncotarget.7918; Thomas KJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045319; Trotta AP, 2017, CELL MOL LIFE SCI, V74, P1999, DOI 10.1007/s00018-016-2451-3; Tu ML, 2011, LIFE SCI, V88, P233, DOI 10.1016/j.lfs.2010.12.001; von Eyss B, 2015, CANCER CELL, V28, P743, DOI 10.1016/j.ccell.2015.10.013; Wan J, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0665-1; Warfel NA, 2016, MOL CANCER THER, V15, P1637, DOI 10.1158/1535-7163.MCT-15-1018; Warfel NA, 2015, PHARMACOL THERAPEUT, V151, P41, DOI 10.1016/j.pharmthera.2015.03.001; Warfel NA, 2011, J BIOL CHEM, V286, P19777, DOI 10.1074/jbc.M111.237081; Westermann B, 2010, NAT REV MOL CELL BIO, V11, P872, DOI 10.1038/nrm3013; Xie LL, 2018, CANCER SCI, V109, P3686, DOI 10.1111/cas.13830; Zappa C, 2016, TRANSL LUNG CANCER R, V5, P288, DOI 10.21037/tlcr.2016.06.07; Zemskova M, 2008, J BIOL CHEM, V283, P20635, DOI 10.1074/jbc.M709479200; Zhao J, 2013, ONCOGENE, V32, P4814, DOI 10.1038/onc.2012.494	42	21	21	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	12					2597	2611		10.1038/s41388-020-1168-9	http://dx.doi.org/10.1038/s41388-020-1168-9		JAN 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KW4HU	31992853	Green Submitted, Green Accepted			2022-12-28	WOS:000509838800001
J	Pataer, A; Ozpolat, B; Shao, RP; Cashman, NR; Plotkin, SS; Samuel, CE; Lin, SH; Kabil, NN; Wang, J; Majidi, M; Fang, BL; Roth, JA; Vaporciyan, AA; Wistuba, II; Hung, MC; Swisher, SG				Pataer, Apar; Ozpolat, Bulent; Shao, RuPing; Cashman, Neil R.; Plotkin, Steven S.; Samuel, Charles E.; Lin, Steven H.; Kabil, Nashwa N.; Wang, Jing; Majidi, Mourad; Fang, Bingliang; Roth, Jack A.; Vaporciyan, Ara A.; Wistuba, Ignacio I.; Hung, Mien-Chie; Swisher, Stephen G.			Therapeutic targeting of the PI4K2A/PKR lysosome network is critical for misfolded protein clearance and survival in cancer cells	ONCOGENE			English	Article							KINASE PKR; PI4KII-ALPHA; MECHANISM; PHOSPHORYLATION; DEGRADATION; INITIATION; VIRUSES; IMPACT; GROWTH; DEATH	The role of RNA-dependent protein kinase R (PKR) and its association with misfolded protein expression in cancer cells are unclear. Herein we report that PKR regulates misfolded protein clearance by preventing it release through exosomes and promoting lysosomal degradation of misfolded prion proteins in cancer cells. We demonstrated that PKR contributes to the lysosome function and regulates misfolded prion protein clearance. We hypothesized that PKR-associated lysosome function is critical for cancer but not normal cell survival, representing an effective approach for highly targeted cancer therapy. In screening a compound library, we identified two PKR-associated compounds 1 and 2 (Pac 1 and 2) did not affect normal cells but selectively induced cell death in cancer cells depending on their PKR expression status. Pac 1 significantly inhibited the growth of human lung and breast xenograft tumors in mice with no toxicity. Pac 1 binds to PI4K2A and disrupts the PKR/PI4K2A-associated lysosome complex, contributing to destabilization of cancer cell lysosomes and triggering cell death. We observed that PKR and PI4K2A play significant prognostic roles in breast cancer patients. These results demonstrate that targeting of a PI4K2A/PKR lysosome complex may be an effective approach for cancer therapy.	[Pataer, Apar; Shao, RuPing; Majidi, Mourad; Fang, Bingliang; Roth, Jack A.; Vaporciyan, Ara A.; Swisher, Stephen G.] Univ Texas MD Anderson Canc Ctr, Dept Thorac, Houston, TX 77030 USA; [Pataer, Apar; Shao, RuPing; Majidi, Mourad; Fang, Bingliang; Roth, Jack A.; Vaporciyan, Ara A.; Swisher, Stephen G.] Univ Texas MD Anderson Canc Ctr, Dept Cardiovasc Surg, Houston, TX 77030 USA; [Ozpolat, Bulent; Kabil, Nashwa N.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Cashman, Neil R.] Univ British Columbia, Dept Med Neurol, Vancouver, BC, Canada; [Cashman, Neil R.] Brain Res Ctr, Vancouver Coastal Hlth Res Inst, Vancouver, BC, Canada; [Cashman, Neil R.] Amorfix Life Sci Ltd, Mississauga, ON, Canada; [Plotkin, Steven S.] Univ British Columbia, Dept Phys & Astron, Vancouver, BC, Canada; [Samuel, Charles E.] Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; [Lin, Steven H.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA; [Wang, Jing] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat, Houston, TX 77030 USA; [Wistuba, Ignacio I.] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [Hung, Mien-Chie] Univ Texas MD Anderson Canc Ctr, Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of British Columbia; Vancouver Coastal Health Research Institute; University of British Columbia; University of California System; University of California Santa Barbara; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Pataer, A (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Thorac, Houston, TX 77030 USA.; Pataer, A (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Cardiovasc Surg, Houston, TX 77030 USA.	apataer@mdanderson.org	Hung, Mien-Chie/ABD-5911-2021; Plotkin, Steven/AAO-3257-2020	Hung, Mien-Chie/0000-0003-4317-4740; Plotkin, Steven/0000-0001-8998-877X; Pataer, Apar/0000-0002-1960-3579; Ozpolat, Bulent/0000-0001-8602-7463	NIH/NCI [P30CA016672]; Homer Flower Gene Therapy Fund; Charles Rogers Gene Therapy Fund; Margaret W. Elkins Endowed Research Fund; Flora and Stuart Mason Lung Cancer Research Fund; Phalan Thoracic Gene Therapy Fund; George P. Sweeney Esophageal Research Fund	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Homer Flower Gene Therapy Fund; Charles Rogers Gene Therapy Fund; Margaret W. Elkins Endowed Research Fund; Flora and Stuart Mason Lung Cancer Research Fund; Phalan Thoracic Gene Therapy Fund; George P. Sweeney Esophageal Research Fund	This work was supported in part by the NIH/NCI under award number P30CA016672 and used and by the Homer Flower Gene Therapy Fund, the Charles Rogers Gene Therapy Fund, the Margaret W. Elkins Endowed Research Fund, the Flora and Stuart Mason Lung Cancer Research Fund, the Phalan Thoracic Gene Therapy Fund, and the George P. Sweeney Esophageal Research Fund (S.G. Swisher).	ALI A, 2011, PLOS ONE, V0006; Aronson LI, 2012, HAEMATOL-HEMATOL J, V97, P1119, DOI 10.3324/haematol.2012.064923; Balachandran S, 2004, NATURE, V432, P401, DOI 10.1038/nature03124; Balachandran Siddharth, 2007, V383, P277, DOI 10.1007/978-1-59745-335-6_18; Barber GN, 2001, CELL DEATH DIFFER, V8, P113, DOI 10.1038/sj.cdd.4400823; Baumlova A, 2014, EMBO REP, V15, P1085, DOI 10.15252/embr.201438841; Boya P, 2012, ANTIOXID REDOX SIGN, V17, P766, DOI 10.1089/ars.2011.4405; Chiti F, 2006, ANNU REV BIOCHEM, V75, P333, DOI 10.1146/annurev.biochem.75.101304.123901; Cohen FE, 2003, NATURE, V426, P905, DOI 10.1038/nature02265; Cortes Constanza J, 2013, Int J Cell Biol, V2013, P560421, DOI 10.1155/2013/560421; Craige B, 2008, MOL BIOL CELL, V19, P1415, DOI 10.1091/mbc.E07-12-1239; Davidson SM, 2017, ANNU REV PHARMACOL, V57, P481, DOI 10.1146/annurev-pharmtox-010715-103101; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Fasen K, 2008, TRAFFIC, V9, P251, DOI 10.1111/j.1600-0854.2007.00679.x; Fehrenbacher N, 2005, CANCER RES, V65, P2993, DOI 10.1158/0008-5472.CAN-05-0476; Fehrenbacher N, 2008, CANCER RES, V68, P6623, DOI 10.1158/0008-5472.CAN-08-0463; Galluzzi L, 2014, NAT CELL BIOL, V16, P728, DOI 10.1038/ncb3005; Garcia MA, 2006, MICROBIOL MOL BIOL R, V70, P1032, DOI 10.1128/MMBR.00027-06; Gregersen N, 2006, ANNU REV GENOM HUM G, V7, P103, DOI 10.1146/annurev.genom.7.080505.115737; Guo CC, 2015, ONCOTARGET, V6, P11114, DOI 10.18632/oncotarget.3573; Hamouda MA, 2014, ONCOTARGET, V5, P6252, DOI 10.18632/oncotarget.2193; Hugon J, 2009, EXPERT REV NEUROTHER, V9, P1455, DOI [10.1586/ern.09.92, 10.1586/ERN.09.92]; Jagus R, 1999, INT J BIOCHEM CELL B, V31, P123, DOI 10.1016/S1357-2725(98)00136-8; Kirkegaard T, 2010, NATURE, V463, P549, DOI 10.1038/nature08710; Kirkegaard T, 2009, BBA-MOL CELL RES, V1793, P746, DOI 10.1016/j.bbamcr.2008.09.008; Li J, 2010, ONCOGENE, V29, P2550, DOI 10.1038/onc.2010.14; Li JM, 2017, CANCER RES, V77, P6253, DOI 10.1158/0008-5472.CAN-17-0484; Marchal JA, 2014, FASEB J, V28, P1965, DOI 10.1096/fj.13-248294; Minogue Shane, 2012, Subcell Biochem, V58, P1, DOI 10.1007/978-94-007-3012-0_1; Morel M, 2009, J CELL MOL MED, V13, P1476, DOI 10.1111/j.1582-4934.2009.00849.x; Moreno-Gonzalez I, 2011, SEMIN CELL DEV BIOL, V22, P482, DOI 10.1016/j.semcdb.2011.04.002; Mouton-Liger F, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.552; Nakamura T, 2010, CELL, V140, P338, DOI 10.1016/j.cell.2010.01.001; Pataer A, 2008, MOL CANCER THER, V7, P2528, DOI 10.1158/1535-7163.MCT-08-0083; Piao SF, 2016, ANN NY ACAD SCI, V1371, P45, DOI 10.1111/nyas.12953; Robinson JW, 2014, BIOCHEM J, V464, P145, DOI 10.1042/BJ20140497; Rochet Jean-Christophe, 2007, Expert Reviews in Molecular Medicine, V9, DOI 10.1017/S1462399407000385; Samuel CE, 2012, CURR TOP MICROBIOL, V353, P163, DOI 10.1007/82_2011_148; Savina A, 2003, J BIOL CHEM, V278, P20083, DOI 10.1074/jbc.M301642200; Settembre C, 2013, NAT REV MOL CELL BIO, V14, P283, DOI 10.1038/nrm3565; Silva JL, 2013, BIOSCI REP, V33; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Soto C, 2018, NAT NEUROSCI, V21, P1332, DOI 10.1038/s41593-018-0235-9; Sukhai MA, 2013, J CLIN INVEST, V123, P315, DOI 10.1172/JCI64180; Vilchez D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6659; Waugh MG, 2012, CANCER LETT, V325, P125, DOI 10.1016/j.canlet.2012.06.009; Williams B R, 2001, Sci STKE, V2001, pre2, DOI 10.1126/stke.2001.89.re2; Zhang P, 2008, J VIROL, V82, P840, DOI 10.1128/JVI.01891-07; Zhang P, 2007, J VIROL, V81, P8192, DOI 10.1128/JVI.00426-07	49	9	9	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	4					801	813		10.1038/s41388-019-1010-4	http://dx.doi.org/10.1038/s41388-019-1010-4			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KF4EJ	31554935	hybrid, Green Accepted, Green Published			2022-12-28	WOS:000509197200005
J	Ouyang, HY; Luong, P; Frodin, M; Hansen, SH				Ouyang, Hanyue; Luong, Phi; Frodin, Morten; Hansen, Steen H.			p190A RhoGAP induces CDH1 expression and cooperates with E-cadherin to activate LATS kinases and suppress tumor cell growth	ONCOGENE			English	Article							GAP-ASSOCIATED PROTEINS; MESENCHYMAL TRANSITION; CONTACT INHIBITION; SIGNALING-PATHWAY; HIPPO PATHWAY; RAS-GAP; GTPASE; P190RHOGAP; YAP; MIGRATION	TheARHGAP35gene encoding p190A RhoGAP (p190A) is significantly altered by both mutation and allelic deletion in human cancer, but the functional implications of such alterations are not known. Here, we demonstrate for the first time that p190A is a tumor suppressor using a xenograft mouse model with carcinoma cells harboring definedARHGAP35alterations. In vitro, restoration of p190A expression in carcinoma cells promotes contact inhibition of proliferation (CIP) through activation of LATS kinases and phosphorylation of the proto-oncogenic transcriptional co-activator YAP. In contrast, p190A forms harboring recurrent cancer mutations exhibit loss of function in modulating the Hippo pathway, inducing CIP, as well as attenuated suppression of tumor growth in mice. We determine that p190A promotes mesenchymal to epithelial transition (MET) and elicits expression of a cassette of epithelial adherens junction-associated genes in a cell density-dependent manner. This cassette includesCDH1encoding E-cadherin, which amplifies p190A-mediated LATS activation and is necessary for CIP. Oppositely, we establish that p190A is obligatory for E-cadherin to activate LATS kinases and induce CIP. Collectively, this work defines a novel mechanism by which p190A and E-cadherin cooperate in modulating Hippo signaling to suppress tumor cell growth.	[Ouyang, Hanyue; Luong, Phi; Hansen, Steen H.] Boston Childrens Hosp, GI Cell Biol Lab, Boston, MA 02115 USA; [Ouyang, Hanyue; Luong, Phi; Hansen, Steen H.] Harvard Med Sch, Boston, MA 02115 USA; [Frodin, Morten] Univ Copenhagen, Biotech Res & Innovat Ctr BRIC, DK-2200 Copenhagen N, Denmark	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; University of Copenhagen	Hansen, SH (corresponding author), Boston Childrens Hosp, GI Cell Biol Lab, Boston, MA 02115 USA.; Hansen, SH (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	steen.hansen@childrens.harvard.edu		Frodin, Morten/0000-0003-3691-9820	Harvard Digestive Diseases Center (HDDC) [NIH P30DK034854]; NIH [R01CA205158]; Roy and Lynne Frank Foundation	Harvard Digestive Diseases Center (HDDC); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Roy and Lynne Frank Foundation	We are grateful to Suzanne L. White and Dr. Lay-Hong Ang, BIDMC confocal imaging and IHC core for assistance with histology procedures, and Dr. Olga Olstrup, Center for Genomic Medicine, Rigshospitalet, University of Copenhagen for assistance with CNV analysis, as well as to Dr. Michael Grey, Boston Children's Hospital for helpful suggestions. This work utilized Harvard Digestive Diseases Center (HDDC) core facilities (NIH P30DK034854) and was funded by NIH R01CA205158, as well as an endowment from the Roy and Lynne Frank Foundation (to SHH).	Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Asnaghi L, 2010, ONCOGENE, V29, P2760, DOI 10.1038/onc.2010.39; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Biname F, 2016, J CELL BIOL, V214, P859, DOI 10.1083/jcb.201601063; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; Brouns MR, 2000, DEVELOPMENT, V127, P4891; Burbelo PD, 1995, J BIOL CHEM, V270, P30919, DOI 10.1074/jbc.270.52.30919; Bustos RI, 2008, CURR BIOL, V18, P1606, DOI 10.1016/j.cub.2008.09.019; Campbell JD, 2016, NAT GENET, V48, P607, DOI 10.1038/ng.3564; CHANG JH, 1993, ONCOGENE, V8, P959; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; Frank SR, 2017, ONCOGENE, V36, P1816, DOI 10.1038/onc.2016.345; Frank SR, 2018, J CELL BIOL, V217, P3183, DOI 10.1083/jcb.201710058; Hajra KM, 2002, CANCER RES, V62, P1613; Heckman-Stoddard BM, 2011, DEV BIOL, V360, P1, DOI 10.1016/j.ydbio.2011.09.006; Hu KQ, 1997, EMBO J, V16, P473, DOI 10.1093/emboj/16.3.473; Jiang W, 2008, J BIOL CHEM, V283, P20978, DOI 10.1074/jbc.M802588200; Jiao S, 2014, CANCER CELL, V25, P166, DOI 10.1016/j.ccr.2014.01.010; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kapoor A, 2014, CELL, V158, P185, DOI 10.1016/j.cell.2014.06.003; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Kim NG, 2011, P NATL ACAD SCI USA, V108, P11930, DOI 10.1073/pnas.1103345108; Kulkarni SV, 2000, J CELL BIOL, V149, P457, DOI 10.1083/jcb.149.2.457; Kusama T, 2006, CANCER SCI, V97, P848, DOI 10.1111/j.1349-7006.2006.00242.x; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Lawson CD, 2018, J CELL BIOL, V217, P447, DOI 10.1083/jcb.201612069; Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874-07; Levay M, 2009, BIOCHEMISTRY-US, V48, P8615, DOI 10.1021/bi900667y; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Maatta AM, 2008, INT J CANCER, V123, P1704, DOI 10.1002/ijc.23646; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; Meng ZP, 2016, GENE DEV, V30, P1, DOI 10.1101/gad.274027.115; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; Notsuda H, 2013, INT J ONCOL, V43, P1569, DOI 10.3892/ijo.2013.2096; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Parasuraman P, 2017, J BIOL CHEM, V292, P2679, DOI 10.1074/jbc.M116.769216; Pullikuth AK, 2010, MOL CELL BIOL, V30, P3233, DOI 10.1128/MCB.01178-09; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; Shao DD, 2014, CELL, V158, P171, DOI 10.1016/j.cell.2014.06.004; Shen CH, 2008, CANCER RES, V68, P7779, DOI 10.1158/0008-5472.CAN-08-0997; Smith SA, 2019, J MED CHEM, V62, P1291, DOI 10.1021/acs.jmedchem.8b01402; Sordella R, 2003, CELL, V113, P147, DOI 10.1016/S0092-8674(03)00271-X; Stewart K, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005785; Su L, 2003, J CELL BIOL, V163, P571, DOI 10.1083/jcb.200308007; Sun Q, 2014, CELL RES, V24, P1288, DOI 10.1038/cr.2014.137; Tarazona S, 2011, GENOME RES, V21, P2213, DOI 10.1101/gr.124321.111; Tatsis N, 1998, J BIOL CHEM, V273, P34631, DOI 10.1074/jbc.273.51.34631; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403; Tikoo A, 2000, GENE, V257, P23, DOI 10.1016/S0378-1119(00)00387-5; Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601; Wang DZM, 1997, CANCER RES, V57, P2478; Wei J, 2005, MOL CELL, V17, P23, DOI 10.1016/j.molcel.2004.11.024; Wennerberg K, 2003, CURR BIOL, V13, P1106, DOI 10.1016/S0960-9822(03)00418-4; Wildenberg GA, 2006, CELL, V127, P1027, DOI 10.1016/j.cell.2006.09.046; Wolf RM, 2003, GENE DEV, V17, P476, DOI 10.1101/gad.1040003; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zebda N, 2013, J BIOL CHEM, V288, P18290, DOI 10.1074/jbc.M112.432757; Zhang ZZ, 2014, ACS MED CHEM LETT, V5, P993, DOI 10.1021/ml500160m; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zrihan-Licht S, 2000, ONCOGENE, V19, P1318, DOI 10.1038/sj.onc.1203422	69	6	6	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2020	39	33					5570	5587		10.1038/s41388-020-1385-2	http://dx.doi.org/10.1038/s41388-020-1385-2		JUL 2020	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NB0QV	32641858	hybrid, Green Published			2022-12-28	WOS:000546526000001
J	Borges, KS; Pignatti, E; Leng, S; Kariyawasam, D; Ruiz-Babot, G; Ramalho, FS; Taketo, MM; Carlone, DL; Breault, DT				Borges, Kleiton Silva; Pignatti, Emanuele; Leng, Sining; Kariyawasam, Dulanjalee; Ruiz-Babot, Gerard; Ramalho, Fernando Silva; Taketo, Makoto Mark; Carlone, Diana L.; Breault, David T.			Wnt/beta-catenin activation cooperates with loss of p53 to cause adrenocortical carcinoma in mice	ONCOGENE			English	Article							BETA-CATENIN; GENOMIC CHARACTERIZATION; MOUSE MODELS; FACTOR-I; CANCER; TUMORS; MUTATIONS; EXPRESSION; PATHWAY; CELLS	Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy with limited therapeutic options. The lack of mouse models that recapitulate the genetics of ACC has hampered progress in the field. We analyzed The Cancer Genome Atlas (TCGA) dataset for ACC and found that patients harboring alterations in both p53/Rb and Wnt/beta-catenin signaling pathways show a worse prognosis compared with patients that harbored alterations in only one. To model this, we utilized theCyp11b2(AS)(Cre)mouse line to generate mice with adrenocortical-specific Wnt/beta-catenin activation,Trp53deletion, or the combination of both. Mice with targeted Wnt/beta-catenin activation orTrp53deletion showed no changes associated with tumor formation. In contrast, alterations in both pathways led to ACC with pulmonary metastases. Similar to ACCs in humans, these tumors produced increased levels of corticosterone and aldosterone and showed a high proliferation index. Gene expression analysis revealed that mouse tumors exhibited downregulation ofStarandCyp11b1and upregulation ofEzh2, similar to ACC patients with a poor prognosis. Altogether, these data show that altering both Wnt/beta-catenin and p53/Rb signaling is sufficient to drive ACC in mouse. This autochthonous model of ACC represents a new tool to investigate the biology of ACC and to identify new treatment strategies.	[Borges, Kleiton Silva; Pignatti, Emanuele; Leng, Sining; Kariyawasam, Dulanjalee; Ruiz-Babot, Gerard; Carlone, Diana L.; Breault, David T.] Boston Childrens Hosp, Div Endocrinol, Boston, MA 02115 USA; [Borges, Kleiton Silva; Pignatti, Emanuele; Kariyawasam, Dulanjalee; Ruiz-Babot, Gerard; Carlone, Diana L.; Breault, David T.] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA; [Borges, Kleiton Silva] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pediat, Ribeirao Preto, Brazil; [Leng, Sining] Harvard Med Sch, Div Med Sci, Boston, MA 02115 USA; [Ramalho, Fernando Silva] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pathol, Ribeirao Preto, Brazil; [Taketo, Makoto Mark] Kyoto Univ, Grad Sch Med, Div Expt Therapeut, Kyoto 6068506, Japan; [Carlone, Diana L.; Breault, David T.] Harvard Stem Cell Inst, Cambridge, MA 02138 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Universidade de Sao Paulo; Universidade Federal de Sao Paulo (UNIFESP); Harvard University; Harvard Medical School; Universidade de Sao Paulo; Kyoto University; Harvard University	Breault, DT (corresponding author), Boston Childrens Hosp, Div Endocrinol, Boston, MA 02115 USA.; Breault, DT (corresponding author), Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA.; Breault, DT (corresponding author), Harvard Stem Cell Inst, Cambridge, MA 02138 USA.	david.breault@childrens.harvard.edu	Pignatti, Emanuele/AAF-2743-2021; Borges, Kleiton Silva/C-7214-2012; kariyawasam, dulanjalee/AAH-1867-2021; Ramalho, Fernando Silva/G-3817-2012; Breault, David/HDN-6048-2022; Borges, Kleiton/AAT-7336-2020	Borges, Kleiton Silva/0000-0003-0356-922X; Ramalho, Fernando Silva/0000-0002-7529-466X; Borges, Kleiton/0000-0003-0356-922X; breault, David/0000-0002-0402-4857; Pignatti, Emanuele/0000-0002-5372-5692	National Institutes of Health (NIH) [RO1 DK100653, R01 DK123694]; FundacAo de Amparo a Pesquisa do Estado de SAo Paulo scholarship [16/00862-0]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) [409711/2018-7, 151760/2018-7]	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); FundacAo de Amparo a Pesquisa do Estado de SAo Paulo scholarship; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This work was supported by National Institutes of Health (NIH) grants RO1 DK100653 and R01 DK123694 (D.T.B.). K.S.B. was supported by FundacAo de Amparo a Pesquisa do Estado de SAo Paulo scholarship 16/00862-0, Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), scholarship 409711/2018-7 and Grant 151760/2018-7. We thank Graziella Ribeiro Sousa for her technical assistance with IHC experiments.	Abiven G, 2006, J CLIN ENDOCR METAB, V91, P2650, DOI 10.1210/jc.2005-2730; Ahuja D, 2005, ONCOGENE, V24, P7729, DOI 10.1038/sj.onc.1209046; Assie G, 2014, NAT GENET, V46, P607, DOI 10.1038/ng.2953; Basham KJ, 2019, GENE DEV, V33, P209, DOI 10.1101/gad.317412.118; Basham KJ, 2016, MOL CELL ENDOCRINOL, V421, P82, DOI 10.1016/j.mce.2015.11.031; Batisse-Lignier M, 2017, ONCOGENE, V36, P4445, DOI 10.1038/onc.2017.54; Berthon A, 2010, HUM MOL GENET, V19, P1561, DOI 10.1093/hmg/ddq029; Bonnet-Serrano F, 2018, ENDOCR-RELAT CANCER, V25, pR131, DOI 10.1530/ERC-17-0361; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Drelon C, 2016, HUM MOL GENET, V25, P2789, DOI 10.1093/hmg/ddw136; Drelon C, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12751; Drelon C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044171; Else T, 2014, ENDOCR REV, V35, P282, DOI 10.1210/er.2013-1029; Else T, 2014, J CLIN ENDOCR METAB, V99, P455, DOI 10.1210/jc.2013-2856; Else T, 2012, MOL CELL ENDOCRINOL, V351, P66, DOI 10.1016/j.mce.2011.12.008; Fassnacht M, 2018, EUR J ENDOCRINOL, V179, pG1, DOI 10.1530/EJE-18-0608; Fassnacht M, 2013, J CLIN ENDOCR METAB, V98, P4551, DOI 10.1210/jc.2013-3020; Freedman BD, 2013, DEV CELL, V26, P666, DOI 10.1016/j.devcel.2013.07.016; Haluska P, 2010, CANCER CHEMOTH PHARM, V65, P765, DOI 10.1007/s00280-009-1083-9; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Heaton JH, 2012, AM J PATHOL, V181, P1017, DOI 10.1016/j.ajpath.2012.05.026; Jones RL, 2015, CLIN CANCER RES, V21, P693, DOI 10.1158/1078-0432.CCR-14-0265; Kastenhuber ER, 2017, CELL, V170, P1062, DOI 10.1016/j.cell.2017.08.028; Kim AC, 2008, DEVELOPMENT, V135, P2593, DOI 10.1242/dev.021493; Leal LF, 2011, J CLIN ENDOCR METAB, V96, P3106, DOI 10.1210/jc.2011-0363; Leccia F, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00093; Liang SH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15295-9; Lippert J, 2018, J CLIN ENDOCR METAB, V103, P4511, DOI 10.1210/jc.2018-01348; Mai PL, 2016, CANCER-AM CANCER SOC, V122, P3673, DOI 10.1002/cncr.30248; Marino S, 2000, GENE DEV, V14, P994; Mohan Dipika R, 2019, Curr Opin Endocr Metab Res, V8, P72, DOI 10.1016/j.coemr.2019.07.006; Mohan DR, 2018, J ENDOCR SOC, V2, P1259, DOI 10.1210/js.2018-00197; Mouat IC, 2019, ENDOCR-RELAT CANCER, V26, P217, DOI 10.1530/ERC-18-0385; Park JH, 2018, CANCER RES, V78, P5375, DOI 10.1158/0008-5472.CAN-18-0016; Pereira SS, 2018, EUR J ENDOCRINOL, V179, pR95, DOI 10.1530/EJE-17-0976; Pignatti E, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107524; Pinto EM, 2017, J CLIN ONCOL, V35, P3956, DOI 10.1200/JCO.2017.74.2460; Ragazzon B, 2010, CANCER RES, V70, P8276, DOI 10.1158/0008-5472.CAN-10-2014; Ribeiro RC, 2001, P NATL ACAD SCI USA, V98, P9330, DOI 10.1073/pnas.161479898; Sbiera S, 2010, J CLIN ENDOCR METAB, V95, pE161, DOI 10.1210/jc.2010-0653; Terzolo M, 2001, UROLOGY, V57, P176, DOI 10.1016/S0090-4295(00)00852-9; Tissier F, 2005, CANCER RES, V65, P7622, DOI 10.1158/0008-5472.CAN-05-0593; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; WALDMAN T, 1995, CANCER RES, V55, P5187; Wasserman JD, 2012, MOL CELL ENDOCRINOL, V351, P101, DOI 10.1016/j.mce.2011.09.010; WEISS LM, 1984, AM J SURG PATHOL, V8, P163, DOI 10.1097/00000478-198403000-00001; Zheng SY, 2016, CANCER CELL, V29, P723, DOI 10.1016/j.ccell.2016.04.002; Zsippai A, 2011, AM J CANCER RES, V1, P618	49	15	15	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 23	2020	39	30					5282	5291		10.1038/s41388-020-1358-5	http://dx.doi.org/10.1038/s41388-020-1358-5		JUN 2020	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MO5BV	32561853	hybrid, Green Published			2022-12-28	WOS:000541308400002
J	Meng, DF; Sun, R; Liu, GY; Peng, LX; Zheng, LS; Xie, P; Lin, ST; Mei, Y; Qiang, YY; Li, CZ; Xu, L; Peng, XS; Hu, H; Lang, YH; Liu, ZJ; Wang, MD; Guo, LL; Xie, DH; Shu, DT; Li, HF; Luo, FF; Niu, XT; Huang, BJ; Qian, CN				Meng, Dong-Fang; Sun, Rui; Liu, Guo-Ying; Peng, Li-Xia; Zheng, Li-Sheng; Xie, Ping; Lin, Si-Ting; Mei, Yan; Qiang, Yuan-Yuan; Li, Chang-Zhi; Xu, Liang; Peng, Xing-Si; Hu, Hao; Lang, Yan-Hong; Liu, Zhi-Jie; Wang, Ming-Dian; Guo, Ling-Ling; Xie, De-Huan; Shu, Di-Tian; Li, Hai-Feng; Luo, Fei-Fei; Niu, Xing-Tang; Huang, Bi-Jun; Qian, Chao-Nan			S100A14 suppresses metastasis of nasopharyngeal carcinoma by inhibition of NF-kB signaling through degradation of IRAK1	ONCOGENE			English	Article							KAPPA-B; BREAST-CANCER; PROMOTES METASTASIS; ACTIVATION; EXPRESSION; PROTEINS; KINASE; PELLINO; BINDING; CELLS	Nasopharyngeal carcinoma (NPC) is a unique head and neck cancer with highly aggressive and metastatic potential in which distant metastasis is the main reason for treatment failure. Till present, the underlying molecular mechanisms of NPC metastasis remains poorly understood. Here, we identified S100 calcium-binding protein A14 (S100A14) as a functional regulator suppressing NPC metastasis by inhibiting the NF-kB signaling pathway and reversing the epithelial-mesenchymal transition (EMT). S100A14 was found to be downregulated in highly metastatic NPC cells and tissues. Immunohistochemical staining of 202 NPC samples revealed that lower S100A14 expression was significantly correlated with shorter patient overall survival (OS) and distant metastasis-free survival (DMFS). S100A14 was also found as an independent prognostic factor for favorable survival. Gain- and loss-of-function studies confirmed that S100A14 suppressed the in vitro and in vivo motility of NPC cells. Mechanistically, S100A14 promoted the ubiquitin-proteasome-mediated degradation of interleukin-1 receptor-associated kinase 1 (IRAK1) to suppress NPC cellular migration. Moreover, S100A14 and IRAK1 established a feedback loop that could be disrupted by the IRAK1 inhibitor T2457. Overall, our findings showed that the S100A14-IRAK1 feedback loop could be a promising therapeutic target for NPC metastasis.	[Meng, Dong-Fang; Sun, Rui; Liu, Guo-Ying; Peng, Li-Xia; Zheng, Li-Sheng; Lin, Si-Ting; Mei, Yan; Li, Chang-Zhi; Peng, Xing-Si; Lang, Yan-Hong; Liu, Zhi-Jie; Wang, Ming-Dian; Guo, Ling-Ling; Xie, De-Huan; Shu, Di-Tian; Luo, Fei-Fei; Huang, Bi-Jun; Qian, Chao-Nan] Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, Guangzhou 510060, Peoples R China; [Meng, Dong-Fang; Sun, Rui; Liu, Guo-Ying; Peng, Li-Xia; Zheng, Li-Sheng; Lin, Si-Ting; Mei, Yan; Li, Chang-Zhi; Peng, Xing-Si; Lang, Yan-Hong; Liu, Zhi-Jie; Wang, Ming-Dian; Guo, Ling-Ling; Xie, De-Huan; Shu, Di-Tian; Luo, Fei-Fei; Huang, Bi-Jun; Qian, Chao-Nan] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Peoples R China; [Meng, Dong-Fang; Sun, Rui; Liu, Guo-Ying; Peng, Li-Xia; Zheng, Li-Sheng; Lin, Si-Ting; Mei, Yan; Li, Chang-Zhi; Peng, Xing-Si; Lang, Yan-Hong; Liu, Zhi-Jie; Wang, Ming-Dian; Guo, Ling-Ling; Xie, De-Huan; Shu, Di-Tian; Luo, Fei-Fei; Huang, Bi-Jun; Qian, Chao-Nan] Sun Yat Sen Univ, Canc Ctr, Guangdong Key Lab Nasopharyngeal Carcinoma Diag &, Guangzhou 510060, Peoples R China; [Meng, Dong-Fang; Sun, Rui; Liu, Guo-Ying; Peng, Li-Xia; Zheng, Li-Sheng; Lin, Si-Ting; Mei, Yan; Li, Chang-Zhi; Peng, Xing-Si; Lang, Yan-Hong; Liu, Zhi-Jie; Wang, Ming-Dian; Guo, Ling-Ling; Xie, De-Huan; Shu, Di-Tian; Luo, Fei-Fei; Huang, Bi-Jun; Qian, Chao-Nan] Sun Yat Sen Univ, Canc Ctr, Dept Nasopharyngeal Carcinoma, Guangzhou 510060, Peoples R China; [Meng, Dong-Fang] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan 250117, Peoples R China; [Xie, Ping] Xiamen Univ, Xiangan Hosp, Sch Med, Dept Radiat Oncol, Xiamen, Peoples R China; [Qiang, Yuan-Yuan] Ningxia Med Univ, Ningxia Key Lab Cerebrocran Dis, Yinchuan 750001, Ningxia, Peoples R China; [Xu, Liang] Sun Yat Sen Univ, Inst Gastroenterol, Affiliated Hosp 6, Guangzhou 510655, Guangdong, Peoples R China; [Hu, Hao] Sun Yat Sen Univ, Dept Tradit Chinese Med, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China; [Li, Hai-Feng] Sun Yat Sen Univ, Dept Med Oncol, Canc Ctr, Guangzhou 510060, Peoples R China; [Niu, Xing-Tang] Sun Yat Sen Univ, Dept Plast Surg, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China; [Qian, Chao-Nan] Guangzhou Concord Canc Ctr, Guangzhou, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Shandong First Medical University & Shandong Academy of Medical Sciences; Xiamen University; Ningxia Medical University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Qian, CN (corresponding author), Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, Guangzhou 510060, Peoples R China.; Qian, CN (corresponding author), Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Peoples R China.; Qian, CN (corresponding author), Sun Yat Sen Univ, Canc Ctr, Guangdong Key Lab Nasopharyngeal Carcinoma Diag &, Guangzhou 510060, Peoples R China.; Qian, CN (corresponding author), Sun Yat Sen Univ, Canc Ctr, Dept Nasopharyngeal Carcinoma, Guangzhou 510060, Peoples R China.; Qian, CN (corresponding author), Guangzhou Concord Canc Ctr, Guangzhou, Peoples R China.	qianchn@sysucc.org.cn	peng, li/GQH-5153-2022; HU, HAO/ABF-6803-2020; Huang, Bi-Jun/GSD-2430-2022	HU, HAO/0000-0002-4319-2706; 	National Natural Science Foundation of China [81872384, 81672872, 81472386, 81972785, 81773162, 81572901, 81902974]; Science and Technology Planning Project of Guangdong Province, China [2013B021800065]; Provincial Natural Science Foundation of Guangdong, China [2016A030311011, 2017A030313866]; Provincial Natural Science Foundation of Fujian, China [2019J05008]; Sun Yat-sen University [84000-18843409]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Planning Project of Guangdong Province, China; Provincial Natural Science Foundation of Guangdong, China; Provincial Natural Science Foundation of Fujian, China(Natural Science Foundation of Fujian Province); Sun Yat-sen University	This work was supported by grants from the National Natural Science Foundation of China (Nos. 81872384, 81672872, and 81472386 to C.Q., Nos. 81972785, 81773162, and 81572901 to B.H., No. 81902974 to P.X.), the Science and Technology Planning Project of Guangdong Province, China (No. 2013B021800065 to R.S.), the Provincial Natural Science Foundation of Guangdong, China (No. 2016A030311011 to C.Q., No. 2017A030313866 to B.H.), the Provincial Natural Science Foundation of Fujian, China (No. 2019J05008 to P.X.), and a research program from Sun Yat-sen University (No. 84000-18843409 to C.Q.).	Basnet Suyog, 2019, Oncotarget, V10, P2996, DOI 10.18632/oncotarget.26861; Bigelow RLH, 2009, BREAST CANCER RES TR, V117, P31, DOI 10.1007/s10549-008-0170-7; Blanchard P, 2015, LANCET ONCOL, V16, P645, DOI 10.1016/S1470-2045(15)70126-9; Brabletz T, 2018, NAT REV CANCER, V18, P128, DOI 10.1038/nrc.2017.118; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bresnick AR, 2015, NAT REV CANCER, V15, P96, DOI 10.1038/nrc3893; Bulk E, 2009, CLIN CANCER RES, V15, P22, DOI 10.1158/1078-0432.CCR-08-0953; Cao Su-Mei, 2011, Chin J Cancer, V30, P114; Chen HY, 2013, MOL CANCER RES, V11, P1542, DOI 10.1158/1541-7786.MCR-13-0317; Chen HY, 2009, CANCER RES, V69, P3451, DOI 10.1158/0008-5472.CAN-08-4231; Chen YP, 2019, LANCET, V394, P64, DOI 10.1016/S0140-6736(19)30956-0; Chou J, 2008, HEAD NECK-J SCI SPEC, V30, P946, DOI 10.1002/hed.20833; Colevas AD, 2018, J NATL COMPR CANC NE, V16, P479, DOI 10.6004/jnccn.2018.0026; DiDonato JA, 2012, IMMUNOL REV, V246, P379, DOI 10.1111/j.1600-065X.2012.01099.x; Donato R, 2013, CURR MOL MED, V13, P24, DOI 10.2174/156652413804486214; Dumbrepatil AB, 2019, J BIOL CHEM, V294, P6888, DOI 10.1074/jbc.RA119.007719; Feng RM, 2019, CANCER COMMUN, V39, DOI 10.1186/s40880-019-0368-6; Feng SS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192208; Filipek A, 2006, CHEMOTHERAPY, V52, P32, DOI 10.1159/000090240; Gallo LH, 2017, CELL CYCLE, V16, P634, DOI 10.1080/15384101.2017.1288326; Goh JY, 2017, NAT MED, V23, P1319, DOI 10.1038/nm.4405; Gottipati S, 2008, CELL SIGNAL, V20, P269, DOI 10.1016/j.cellsig.2007.08.009; Graczyk A, 2014, INT J BIOCHEM CELL B, V57, P135, DOI 10.1016/j.biocel.2014.10.007; Ichikawa M, 2011, MOL CANCER RES, V9, P133, DOI 10.1158/1541-7786.MCR-10-0394; Jin QE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019375; Knop J, 1999, FEBS LETT, V448, P81, DOI 10.1016/S0014-5793(99)00322-1; Kwon CH, 2013, MOL CELLS, V35, P226, DOI 10.1007/s10059-013-2269-x; Lesniak W, 2007, J INVEST DERMATOL, V127, P2307, DOI 10.1038/sj.jid.5700879; Lesniak W, 2011, CLIN EPIGENETICS, V2, P77, DOI 10.1007/s13148-011-0023-9; Li XJ, 2011, CANCER RES, V71, P3162, DOI 10.1158/0008-5472.CAN-10-3557; Li XX, 2001, P NATL ACAD SCI USA, V98, P4461, DOI 10.1073/pnas.071054198; Li YY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14121; Li ZY, 2015, J CLIN INVEST, V125, P1081, DOI 10.1172/JCI75821; Lindsey JC, 2007, BRIT J CANCER, V97, P267, DOI 10.1038/sj.bjc.6603852; Meng DF, 2018, J CANCER, V9, P92, DOI 10.7150/jca.21357; Meng DF, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-016-0483-z; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Ordureau A, 2008, BIOCHEM J, V409, P43, DOI 10.1042/BJ20071365; Qian CN, 2017, CHIN J CANCER, V36, DOI 10.1186/s40880-017-0206-7; Rhyasen GW, 2013, CANCER CELL, V24, P90, DOI 10.1016/j.ccr.2013.05.006; Sapkota D, 2012, ORAL ONCOL, V48, P219, DOI 10.1016/j.oraloncology.2011.10.001; Sapkota D, 2011, EUR J CANCER, V47, P600, DOI 10.1016/j.ejca.2010.10.012; Schauvliege R, 2006, FEBS LETT, V580, P4697, DOI 10.1016/j.febslet.2006.07.046; Schneider G, 2011, AMINO ACIDS, V41, P773, DOI 10.1007/s00726-010-0498-2; Smith H, 2009, P NATL ACAD SCI USA, V106, P4584, DOI 10.1073/pnas.0900774106; Srivastava R, 2012, CANCER RES, V72, P6209, DOI 10.1158/0008-5472.CAN-12-0337; Taniguchi K, 2018, NAT REV IMMUNOL, V18, P309, DOI 10.1038/nri.2017.142; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tsai WC, 2006, MOL CANCER RES, V4, P539, DOI 10.1158/1541-7786.MCR-05-0266; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wang XH, 2010, AM J PATHOL, V177, P586, DOI 10.2353/ajpath.2010.091217; Wee ZN, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9746; Windheim M, 2008, MOL CELL BIOL, V28, P1783, DOI 10.1128/MCB.02380-06; Xiong TF, 2019, MELANOMA RES, V29, P23, DOI 10.1097/CMR.0000000000000512; Xu CS, 2014, J BIOL CHEM, V289, P827, DOI 10.1074/jbc.M113.469718; Xu L, 2018, CANCER LETT, V431, P230, DOI 10.1016/j.canlet.2017.10.016; Yi M, 2018, J CELL PHYSIOL, V233, P5537, DOI 10.1002/jcp.26410; Zhang W, 2020, CANCER COMMUN, V40, P69, DOI 10.1002/cac2.12010; Zheng LS, 2017, CANCER RES, V77, P579, DOI 10.1158/0008-5472.CAN-16-1281; Zhu M, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.297	60	17	20	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 23	2020	39	30					5307	5322		10.1038/s41388-020-1363-8	http://dx.doi.org/10.1038/s41388-020-1363-8		JUN 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MO5BV	32555330				2022-12-28	WOS:000545371000001
J	Pancholi, S; Ribas, R; Simigdala, N; Schuster, E; Nikitorowicz-Buniak, J; Ressa, A; Gao, Q; Leal, MF; Bhamra, A; Thornhill, A; Morisset, L; Montaudon, E; Sourd, L; Fitzpatrick, M; Altelaar, M; Johnston, SR; Marangoni, E; Dowsett, M; Martin, LA				Pancholi, Sunil; Ribas, Ricardo; Simigdala, Nikiana; Schuster, Eugene; Nikitorowicz-Buniak, Joanna; Ressa, Anna; Gao, Qiong; Leal, Mariana Ferreira; Bhamra, Amandeep; Thornhill, Allan; Morisset, Ludivine; Montaudon, Elodie; Sourd, Laura; Fitzpatrick, Martin; Altelaar, Maarten; Johnston, Stephen R.; Marangoni, Elisabetta; Dowsett, Mitch; Martin, Lesley-Ann			Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities	ONCOGENE			English	Article							DEPENDENT KINASE 4/6; CELL-CYCLE; ADJUVANT TAMOXIFEN; TRANSCRIPTION; DEPRIVATION; INHIBITION; CYCLIN-D1; CDK7; AMPLIFICATION; TARGET	Combination of CDK4/6 inhibitors and endocrine therapy improves clinical outcome in advanced oestrogen receptor (ER)-positive breast cancer, however relapse is inevitable. Here, we show in model systems that other than loss of RB1 few gene-copy number (CN) alterations are associated with irreversible-resistance to endocrine therapy and subsequent secondary resistance to palbociclib. Resistance to palbociclib occurred as a result of tumour cell re-wiring leading to increased expression of EGFR, MAPK, CDK4, CDK2, CDK7, CCNE1 and CCNE2. Resistance altered the ER genome wide-binding pattern, leading to decreased expression of 'classical' oestrogen-regulated genes and was accompanied by reduced sensitivity to fulvestrant and tamoxifen. Persistent CDK4 blockade decreased phosphorylation of tuberous sclerosis complex 2 (TSC2) enhancing EGFR signalling, leading to the re-wiring of ER. Kinome-knockdown confirmed dependency on ERBB-signalling and G2/M-checkpoint proteins such as WEE1, together with the cell cycle master regulator, CDK7. Noteworthy, sensitivity to CDK7 inhibition was associated with loss of ER and RB1 CN. Overall, we show that resistance to CDK4/6 inhibitors is dependent on kinase re-wiring and the redeployment of signalling cascades previously associated with endocrine resistance and highlights new therapeutic networks that can be exploited upon relapse after CDK4/6 inhibition.	[Pancholi, Sunil; Ribas, Ricardo; Simigdala, Nikiana; Schuster, Eugene; Nikitorowicz-Buniak, Joanna; Leal, Mariana Ferreira; Dowsett, Mitch; Martin, Lesley-Ann] Inst Canc Res, Breast Canc Now Toby Robins Res Ctr, London SW7 3RP, England; [Ressa, Anna; Fitzpatrick, Martin; Altelaar, Maarten] Univ Utrecht, Bijvoet Ctr Biomol Res, Biomol Mass Spectrometry & Prote, NL-3584 CH Utrecht, Netherlands; [Ressa, Anna; Fitzpatrick, Martin; Altelaar, Maarten] Univ Utrecht, Utrecht Inst Pharmaceut Sci, NL-3584 CH Utrecht, Netherlands; [Gao, Qiong] Inst Canc Res, Bioinformat Cofacil, CRUK, Sutton SM2 5NG, Surrey, England; [Bhamra, Amandeep] Inst Canc Res, Prote Unit, Sutton SW7 3RP, Surrey, England; [Thornhill, Allan] Inst Canc Res, Ctr Canc Imaging, Sutton SM2 5NG, Surrey, England; [Morisset, Ludivine; Montaudon, Elodie; Sourd, Laura; Marangoni, Elisabetta] Inst Curie, Dept Translat Res, Paris, France; [Johnston, Stephen R.] Royal Marsden Hosp, Breast Unit, London SW3 6JJ, England; [Dowsett, Mitch] Royal Marsden Hosp, Ralph Lauren Ctr Breast Canc Res, London SW3 6JJ, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Utrecht University; Utrecht University; University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust	Martin, LA (corresponding author), Inst Canc Res, Breast Canc Now Toby Robins Res Ctr, London SW7 3RP, England.	lesley-ann.martin@icr.ac.uk	Marangoni, Elisabetta/GSO-3945-2022	Marangoni, Elisabetta/0000-0002-3337-6448; Ribas, Ricardo/0000-0002-8134-0036; Schuster, Eugene/0000-0001-5076-2810; Gao, Qiong/0000-0002-0406-1594; Pancholi, Sunil/0000-0002-0880-1588	Pfizer; NHS; Breast Cancer Now; Walk the Walk; Proteins@Work - Netherlands Organisation for Scientific Research (NWO) as part of the National Roadmap Large-scale Research Facilities of the Netherlands [184.032.201]; HighThroughput Genomics Group at the Wellcome Trust Centre for Human Genetics (Wellcome Trust) [090532/Z/09/Z]; Arthur Foundation	Pfizer(Pfizer); NHS; Breast Cancer Now; Walk the Walk; Proteins@Work - Netherlands Organisation for Scientific Research (NWO) as part of the National Roadmap Large-scale Research Facilities of the Netherlands(Netherlands Organization for Scientific Research (NWO)); HighThroughput Genomics Group at the Wellcome Trust Centre for Human Genetics (Wellcome Trust); Arthur Foundation	We also would like to thank Pfizer, for academic funding and NHS funding to the Royal Marsden Hospital's NIHR Biomedical Research Centre. This work was also supported by Breast Cancer Now, working in partnership with Walk the Walk; Proteins@Work, financed by the Netherlands Organisation for Scientific Research (NWO) as part of the National Roadmap Large-scale Research Facilities of the Netherlands (project number 184.032.201); HighThroughput Genomics Group at the Wellcome Trust Centre for Human Genetics (funded by Wellcome Trust grant reference 090532/Z/09/Z) for the generation of the Sequencing data and The Arthur Foundation.	Asghar U, 2015, NAT REV DRUG DISCOV, V14, P130, DOI 10.1038/nrd4504; Bhat-Nakshatri P, 2008, MOL CELL BIOL, V28, P7487, DOI 10.1128/MCB.00799-08; Bhinge K, 2017, ONCOTARGET, V8, P27155, DOI 10.18632/oncotarget.15676; Bosco EE, 2007, J CLIN INVEST, V117, P218, DOI 10.1172/JCI28803; Brough R, 2011, CANCER DISCOV, V1, P260, DOI 10.1158/2159-8290.CD-11-0107; Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; De Falco G, 2000, ONCOGENE, V19, P373, DOI 10.1038/sj.onc.1203305; de Leeuw R, 2018, CLIN CANCER RES, V24, P4201, DOI 10.1158/1078-0432.CCR-18-0410; DICKSON C, 1995, CANCER LETT, V90, P43, DOI 10.1016/0304-3835(94)03676-A; Finn RS, 2016, NEW ENGL J MED, V375, P1925, DOI 10.1056/NEJMoa1607303; Fisher RP, 2005, J CELL SCI, V118, P5171, DOI 10.1242/jcs.02718; Fry DW, 2004, MOL CANCER THER, V3, P1427; Gao Q, 2014, CLIN CANCER RES, V20, P2485, DOI 10.1158/1078-0432.CCR-13-2602; GILLETT C, 1994, CANCER RES, V54, P1812; Goel S, 2016, CANCER CELL, V29, P255, DOI 10.1016/j.ccell.2016.02.006; Goetz MP, 2017, J CLIN ONCOL, V35, P3638, DOI 10.1200/JCO.2017.75.6155; Grinstein E, 2002, ONCOGENE, V21, P1485, DOI 10.1038/sj.onc.1205211; Halaban R, 1998, INT J MOL MED, V1, P419; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Herrera-Abreu MT, 2016, CANCER RES, V76, P2301, DOI 10.1158/0008-5472.CAN-15-0728; Hortobagyi GN, 2016, NEW ENGL J MED, V375, P1738, DOI 10.1056/NEJMoa1609709; Jansen VM, 2017, CANCER RES, V77, P2488, DOI 10.1158/0008-5472.CAN-16-2653; Jirstrom K, 2005, CANCER RES, V65, P8009, DOI 10.1158/0008-5472.CAN-05-0746; Kettner NM, 2019, CLIN CANCER RES, V25, P3996, DOI 10.1158/1078-0432.CCR-18-3274; Kwiatkowski N, 2014, NATURE, V511, P616, DOI 10.1038/nature13393; Li B, 2017, CANCER RES, V77, P3834, DOI 10.1158/0008-5472.CAN-16-2546; Lundgren K, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3161; Lupien M, 2010, GENE DEV, V24, P2219, DOI 10.1101/gad.1944810; Ma CX, 2017, CLIN CANCER RES, V23, P4055, DOI 10.1158/1078-0432.CCR-16-3206; Martin M, 2017, NAT COMMUN, V8, DOI [10.1038/ncomms15127, 10.1038/s41467-017-01864-y]; Matheson CJ, 2016, TRENDS PHARMACOL SCI, V37, P872, DOI 10.1016/j.tips.2016.06.006; Michaloglou C, 2018, MOL CANCER THER, V17, P908, DOI 10.1158/1535-7163.MCT-17-0537; Miller TW, 2011, CANCER DISCOV, V1, P338, DOI 10.1158/2159-8290.CD-11-0101; Morandi A, 2013, CANCER RES, V73, P3783, DOI 10.1158/0008-5472.CAN-12-4265; Musgrove EA, 2011, NAT REV CANCER, V11, P558, DOI 10.1038/nrc3090; Narasimha AM, 2014, ELIFE, V3, DOI 10.7554/eLife.02872; O'Leary B, 2018, CANCER DISCOV, V8, P1390, DOI 10.1158/2159-8290.CD-18-0264; Patani N, 2014, MOL CELL ENDOCRINOL, V382, P683, DOI 10.1016/j.mce.2013.09.038; Patel H, 2018, MOL CANCER THER, V17, P1156, DOI 10.1158/1535-7163.MCT-16-0847; Paternot S, 2010, CELL CYCLE, V9, P689, DOI 10.4161/cc.9.4.10611; Raaijmakers LM, 2015, J PROTEOME RES, V14, P4332, DOI 10.1021/acs.jproteome.5b00529; Ressa A, 2019, J PROTEOME RES, V18, P576, DOI 10.1021/acs.jproteome.8b00576; Ribas R, 2015, MOL CANCER THER, V14, P2035, DOI 10.1158/1535-7163.MCT-15-0143; Rondon-Lagos M, 2014, MOL CYTOGENET, V7, DOI 10.1186/1755-8166-7-8; Rudas M, 2008, CLIN CANCER RES, V14, P1767, DOI 10.1158/1078-0432.CCR-07-4122; Rudolph JD, 2016, CELL SYST, V3, P585, DOI 10.1016/j.cels.2016.11.005; Schmidt D, 2009, METHODS, V48, P240, DOI 10.1016/j.ymeth.2009.03.001; Shaw AS, 2014, MOL CELL BIOL, V34, P1538, DOI 10.1128/MCB.00057-14; Simigdala N, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0713-5; Smith EJ, 1998, CELL GROWTH DIFFER, V9, P297; Stark R., 2011, R PACKAGE VERSION, V100, P1; Turner NC, 2015, NEW ENGL J MED, V373, P209, DOI 10.1056/NEJMoa1505270; Witzel II, 2010, BIOCHEM SOC T, V38, P217, DOI 10.1042/BST0380217; Yang C, 2017, ONCOGENE, V36, P2255, DOI 10.1038/onc.2016.379; Zacharek SJ, 2005, CANCER RES, V65, P11354, DOI 10.1158/0008-5472.CAN-05-2236; Zhou HJ, 2013, NAT PROTOC, V8, P461, DOI 10.1038/nprot.2013.010	56	30	30	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 18	2020	39	25					4781	4797		10.1038/s41388-020-1284-6	http://dx.doi.org/10.1038/s41388-020-1284-6		APR 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LZ3HT	32307447	Green Published, hybrid			2022-12-28	WOS:000527477100001
J	Qian, T; Liu, CM; Ding, YY; Guo, C; Cai, RW; Wang, XX; Wang, R; Zhang, K; Zhou, L; Deng, Y; Wu, CY; Sun, Y				Qian, Tao; Liu, Chengmin; Ding, Yanyan; Guo, Chen; Cai, Renwei; Wang, Xiaoxia; Wang, Rong; Zhang, Kuo; Zhou, Li; Deng, Yi; Wu, Chuanyue; Sun, Ying			PINCH-1 interacts with myoferlin to promote breast cancer progression and metastasis	ONCOGENE			English	Article							INTEGRIN-LINKED KINASE; CELL-MATRIX ADHESION; THERAPEUTIC TARGET; ADAPTER PROTEIN; EXPRESSION; ILK; GENE; ANGIOGENESIS; ENDOCYTOSIS; ACTIVATION	PINCH-1 is a cytoplasmic component of the cell-extracellular matrix (ECM) adhesion machine that is frequently overexpressed in cancer. The functions and mechanism of PINCH-1 in cancer, however, remain to be determined. Here, we show that PINCH-1 interacts with myoferlin, a transmembrane protein that is critical for cancer progression. High expression of both PINCH-1 and myoferlin correlates with poor clinical outcome in human breast cancer patients. Ablation of PINCH-1 from breast cancer cells diminished myoferlin level and suppressed breast cancer cell proliferation, migration, and endothelial cell tube formation in vitro and breast tumor growth, angiogenesis and metastasis in vivo. Mechanistically, PINCH-1 controls myoferlin level through its interaction with myoferlin and regulation of its ubiquitination and proteasome-dependent degradation. Functionally, re-expression of PINCH-1, but not that of a myoferlin-binding defective Delta LIM2 mutant, effectively reversed the inhibition of myoferlin expression and breast cancer progression induced by loss of PINCH-1. Finally, restoration of myoferlin expression was sufficient to reverse PINCH-1-deficiency induced inhibition on breast cancer progression. These results reveal a PINCH-1-myoferlin signaling axis that is critical for breast cancer progression and suggest a new strategy for therapeutic control of breast cancer.	[Qian, Tao; Liu, Chengmin; Ding, Yanyan; Guo, Chen; Cai, Renwei; Wang, Xiaoxia; Wang, Rong; Zhang, Kuo; Zhou, Li; Deng, Yi; Sun, Ying] Southern Univ Sci & Technol, Guangdong Prov Key Lab Cell Microenvironm & Dis R, Dept Biol, Shenzhen Key Lab Cell Microenvironm, Shenzhen 518055, Peoples R China; [Wu, Chuanyue] Univ Pittsburgh, Dept Pathol, Sch Med, Pittsburgh, PA 15260 USA; [Wu, Chuanyue] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15260 USA	Southern University of Science & Technology; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Sun, Y (corresponding author), Southern Univ Sci & Technol, Guangdong Prov Key Lab Cell Microenvironm & Dis R, Dept Biol, Shenzhen Key Lab Cell Microenvironm, Shenzhen 518055, Peoples R China.; Wu, CY (corresponding author), Univ Pittsburgh, Dept Pathol, Sch Med, Pittsburgh, PA 15260 USA.; Wu, CY (corresponding author), Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15260 USA.	carywu@pitt.edu; suny@sustech.edu.cn	ding, yy/HHS-9589-2022; Liu, Chengmin/GRO-0365-2022	Liu, Chengmin/0000-0002-0882-582X; kuo, zhang/0000-0003-2875-2581	National Natural Science Foundation of China [81772983, 81430068, 31471311]; Chinese Ministry of Science and Technology [2016YFC1302100]; Natural Science Foundation of Guangdong Province [1914050005629, 2017B030301018]; Shenzhen Innovation Committee of Science and Technology, China [JCYJ20170817104854302, ZDSYS20140509142721429, JCYJ20150831142427959]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese Ministry of Science and Technology(Ministry of Science and Technology, China); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Shenzhen Innovation Committee of Science and Technology, China	We thank Dr. Ruijun Tian of the Department of Chemistry, Southern University of Science and Technology, for help with nano-LC-MS/MS analysis; Dr. Jiahuai Han (Xiamen University, China) for the myoferlin cDNA; Drs. Jason D. Weber (Washington University) and Yandong Zhang (Southern University of Science and Technology) for the 3x Flag tagged pLVX-IRES-Hyg vector; Dr. Andrew Hutchins (Southern University of Science and Technology) for comments on the manuscript. This work was supported by the National Natural Science Foundation of China (81772983, 81430068, and 31471311), the Chinese Ministry of Science and Technology (2016YFC1302100), the Natural Science Foundation of Guangdong Province (1914050005629 and 2017B030301018), the Shenzhen Innovation Committee of Science and Technology, China (JCYJ20170817104854302, ZDSYS20140509142721429, and JCYJ20150831142427959).	Balkwill FR, 2012, J CELL SCI, V125, P5591, DOI 10.1242/jcs.116392; Barnhouse Victoria R, 2018, Oncotarget, V9, P19209, DOI 10.18632/oncotarget.24971; Bernatchez PN, 2007, J BIOL CHEM, V282, P30745, DOI 10.1074/jbc.M704798200; Bernatchez PN, 2009, AM J PHYSIOL-CELL PH, V297, pC484, DOI 10.1152/ajpcell.00498.2008; Blackstone BN, 2015, AM J PHYSIOL-CELL PH, V308, pC642, DOI 10.1152/ajpcell.00276.2014; Blomme A, 2017, ONCOGENE, V36, P2116, DOI 10.1038/onc.2016.369; Chen K, 2008, J BIOL CHEM, V283, P2508, DOI 10.1074/jbc.M707307200; Chen WD, 2016, ANAL CHEM, V88, P4864, DOI 10.1021/acs.analchem.6b00631; Cipta S, 2009, AM J PHYSIOL-CELL PH, V297, pC481, DOI 10.1152/ajpcell.00288.2009; Davis DB, 2000, HUM MOL GENET, V9, P217, DOI 10.1093/hmg/9.2.217; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Doherty KR, 2008, J BIOL CHEM, V283, P20252, DOI 10.1074/jbc.M802306200; Dong YY, 2014, CELL RES, V24, P1354, DOI 10.1038/cr.2014.129; Eke I, 2010, J CLIN INVEST, V120, P2516, DOI 10.1172/JCI41078; Fahmy K, 2016, INT J CANCER, V138, P652, DOI 10.1002/ijc.29820; Fukuda T, 2003, J BIOL CHEM, V278, P51324, DOI 10.1074/jbc.M309122200; Gkretsi V, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00145; Goodman SL, 2012, TRENDS PHARMACOL SCI, V33, P405, DOI 10.1016/j.tips.2012.04.002; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hamidi H, 2016, BRIT J CANCER, V115, P1017, DOI 10.1038/bjc.2016.312; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Harisi R, 2015, ONCOTARGETS THER, V8, P1387, DOI 10.2147/OTT.S48883; Hermanns C, 2017, ONCOGENE, V36, P3464, DOI 10.1038/onc.2016.496; Hu WB, 2017, ELIFE, V6, DOI 10.7554/eLife.28021; Humphries JD, 2019, CURR OPIN CELL BIOL, V56, P14, DOI 10.1016/j.ceb.2018.08.004; Kim MH, 2018, J PATHOL TRANSL MED, V52, P93, DOI 10.4132/jptm.2017.11.29; Kovalevich J, 2011, J CELL PHYSIOL, V226, P940, DOI 10.1002/jcp.22437; Kumar B, 2016, ONCOTARGET, V7, P18665, DOI 10.18632/oncotarget.7625; Legate KR, 2006, NAT REV MOL CELL BIO, V7, P20, DOI 10.1038/nrm1789; Leung C, 2013, AM J PATHOL, V182, P1900, DOI 10.1016/j.ajpath.2013.01.041; Li R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039766; Li SH, 2005, J CELL SCI, V118, P2913, DOI 10.1242/jcs.02422; Liang XQ, 2005, MOL CELL BIOL, V25, P3056, DOI 10.1128/MCB.25.8.3056-3062.2005; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Longmate Whitney, 2017, F1000Res, V6, P1612, DOI 10.12688/f1000research.11877.1; Loof J, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-103; Moon S, 2014, SCI REP-UK, V4, DOI 10.1038/srep04376; Qin J, 2012, CURR OPIN CELL BIOL, V24, P607, DOI 10.1016/j.ceb.2012.06.003; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Rademaker G, 2018, ONCOGENE, V37, P4398, DOI 10.1038/s41388-018-0287-z; Seager R J, 2017, Converg Sci Phys Oncol, V3, DOI 10.1088/2057-1739/aa7e86; Seguin L, 2015, TRENDS CELL BIOL, V25, P234, DOI 10.1016/j.tcb.2014.12.006; Song DH, 2016, ONCOL LETT, V11, P998, DOI 10.3892/ol.2015.3988; Sun Y, 2019, ONCOGENE, V38, P4856, DOI 10.1038/s41388-019-0762-1; Sun Y, 2017, J AM SOC NEPHROL, V28, P3545, DOI 10.1681/ASN.2016091021; Sun Y, 2012, J CELL SCI, V125, P4507, DOI 10.1242/jcs.105023; Tu YZ, 2001, J CELL BIOL, V153, P585, DOI 10.1083/jcb.153.3.585; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Turtoi A, 2013, CANCER RES, V73, P5438, DOI 10.1158/0008-5472.CAN-13-1142; Ungefroren H, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-18; Vakaloglou KM, 2016, CELL REP, V16, P596, DOI 10.1016/j.celrep.2016.06.079; Volakis LI, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086110; Wang MW, 2007, ONCOLOGY-BASEL, V72, P343, DOI 10.1159/000113064; Wang-Rodriguez J, 2002, CANCER-AM CANCER SOC, V95, P1387, DOI 10.1002/cncr.10878; Whittaker CA, 2006, DEV BIOL, V300, P252, DOI 10.1016/j.ydbio.2006.07.044; Wickstrom SA, 2010, EMBO J, V29, P281, DOI 10.1038/emboj.2009.376; Winograd-Katz SE, 2014, NAT REV MOL CELL BIO, V15, P273, DOI 10.1038/nrm3769; Wu CY, 2005, TRENDS CELL BIOL, V15, P460, DOI 10.1016/j.tcb.2005.07.002; Wu CY, 2004, BBA-MOL CELL RES, V1692, P55, DOI 10.1016/j.bbamcr.2004.01.006; Yu C, 2011, VASC PHARMACOL, V55, P26, DOI 10.1016/j.vph.2011.04.001; Zaidel-Bar R, 2007, NAT CELL BIOL, V9, P858, DOI 10.1038/ncb0807-858; Zhang TY, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02748-x; Zhang YJ, 2002, J CELL SCI, V115, P4777, DOI 10.1242/jcs.00166; Zhang YJ, 2002, J BIOL CHEM, V277, P38328, DOI 10.1074/jbc.M205576200; Zheng CC, 2019, AM J CANCER RES, V9, P186; Zhu ZL, 2008, DIS MARKERS, V25, P75, DOI 10.1155/2008/473860	67	9	9	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	10					2069	2087		10.1038/s41388-019-1135-5	http://dx.doi.org/10.1038/s41388-019-1135-5			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KS8UR	31801973				2022-12-28	WOS:000518584000004
J	Chen, PZ; Duan, XH; Li, XG; Li, JQ; Ba, Q; Wang, H				Chen, Peizhan; Duan, Xiaohua; Li, Xiaoguang; Li, Jingquan; Ba, Qian; Wang, Hui			HIPK2 suppresses tumor growth and progression of hepatocellular carcinoma through promoting the degradation of HIF-1 alpha	ONCOGENE			English	Article							PROTEIN; APOPTOSIS; GENE; P53; PHOSPHORYLATION; IDENTIFICATION; EPIDEMIOLOGY; CONTRIBUTES; METASTASIS; STABILITY	Aberrant angiogenesis of hepatocellular carcinoma (HCC) leads to tumor growth and local or distant metastasis. Uncovering the underlying mechanisms for the neoangiogenesis of HCC can provide novel potential therapeutic targets in the clinic. Here, we reported that serine/threonine homeodomain-interacting protein kinase 2 (HIPK2) was frequently downregulated in HCC tissues compared with the adjacent normal tissues, and patients with lower HIPK2 protein expression were associated with worse overall survival. Both in vitro and in vivo, HIPK2 inhibited the migration of HCC cells, as well as tumor growth and metastasis in xenograft and orthotopic syngeneic HCC mouse models. Furthermore, HIPK2 inhibited the angiogenesis in HCC tumors. Under the hypoxic condition, HIPK2 knockdown enhanced the angiogenesis and the key regulator, HIF-1 alpha signaling pathway; however, HIPK2 overexpression downregulated the tumoral angiogenesis and HIF-1 alpha signaling. In HCC cells, HIPK2 could directly bind to HIF-1 alpha and stimulate the ubiquitination of HIF-1 alpha for proteasomal degradation. HIF-1 alpha knockout partially rescued the promoting effect of HIPK2 depletion on angiogenesis and tumor growth. In conclusion, the downregulation of HIPK2 could enhance the angiogenesis in HCC through inducing the HIF-1 alpha pathway, and further contribute to tumor growth and metastasis, which may provide a novel therapeutic strategy for HCC.	[Chen, Peizhan; Li, Xiaoguang; Li, Jingquan; Ba, Qian; Wang, Hui] Shanghai Jiao Tong Univ, Sch Med, Sch Publ Hlth, State Key Lab Oncogenes & Related Genes,Ctr Singl, Shanghai 200025, Peoples R China; [Chen, Peizhan; Duan, Xiaohua; Wang, Hui] Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Inst Nutr & Hlth, CAS Key Lab Nutr Metab & Food Safety, Shanghai 200031, Peoples R China	Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institute of Nutrition & Health, CAS; Shanghai Institutes for Biological Sciences, CAS	Ba, Q; Wang, H (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Sch Publ Hlth, State Key Lab Oncogenes & Related Genes,Ctr Singl, Shanghai 200025, Peoples R China.; Wang, H (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Inst Nutr & Hlth, CAS Key Lab Nutr Metab & Food Safety, Shanghai 200031, Peoples R China.	qba@shsmu.edu.cn; huiwang@shsmu.edu.cn	Ba, Qian/AAZ-2623-2021	Ba, Qian/0000-0002-7253-7566	National Key R&D Program of China [2018YFC2000700, 2018ZX10302205, 2017YFC0907001]; National Natural Science Foundation of China [81630086, 81573161, 81973078, 81427805]; Science and Technology Commission of Shanghai Municipality [16391903700]; Shanghai Municipality Health Commission [20164Y0250, 2017YQ0059]; Major Science and Technology Innovation Program of Shanghai Municipal Education Commission [2019-01-07-00-01-E00059]; Chinese Academy of Sciences [ZDRW-ZS-2017-1]; Science and Technology Commission of Jiading Distinct [JDKW-2017-W09]; Shanghai Jiao Tong University [YG2017MS85]; Shanghai Municipal Human Resources and Social Security Bureau [2018060]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); Shanghai Municipality Health Commission; Major Science and Technology Innovation Program of Shanghai Municipal Education Commission; Chinese Academy of Sciences(Chinese Academy of Sciences); Science and Technology Commission of Jiading Distinct; Shanghai Jiao Tong University; Shanghai Municipal Human Resources and Social Security Bureau	This work was supported by grants from the National Key R&D Program of China (2018YFC2000700, 2018ZX10302205, and 2017YFC0907001), the National Natural Science Foundation of China (81630086, 81573161, 81973078, and 81427805), the Science and Technology Commission of Shanghai Municipality (16391903700), the Shanghai Municipality Health Commission (20164Y0250 and 2017YQ0059), the Major Science and Technology Innovation Program of Shanghai Municipal Education Commission (2019-01-07-00-01-E00059), the Key Research Program (ZDRW-ZS-2017-1) of the Chinese Academy of Sciences, Shanghai Municipal Human Resources and Social Security Bureau (2018060), Science and Technology Commission of Jiading Distinct (JDKW-2017-W09), and Shanghai Jiao Tong University (YG2017MS85).	Ba Q, 2017, J MOL CELL BIOL, V9, P209, DOI 10.1093/jmcb/mjx019; Bitomsky N, 2009, FEBS J, V276, P6074, DOI 10.1111/j.1742-4658.2009.07331.x; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cai JL, 2017, EBIOMEDICINE, V19, P18, DOI 10.1016/j.ebiom.2017.04.014; Calzado MA, 2009, NAT CELL BIOL, V11, P85, DOI 10.1038/ncb1816; Choi JR, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16489-w; Clark T, 2015, CURR PROBL DIAGN RAD, V44, P479, DOI 10.1067/j.cpradiol.2015.04.004; Di Stefana V, 2005, FEBS LETT, V579, P5473, DOI 10.1016/j.febslet.2005.09.008; Di Stefano V, 2004, ONCOGENE, V23, P5185, DOI 10.1038/sj.onc.1207656; Fang JM, 2001, CANCER RES, V61, P5731; Feng YY, 2017, ONCOTARGET, V8, P20452, DOI 10.18632/oncotarget.14723; Garufi A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048342; Guan Yong-Song, 2012, ISRN Gastroenterol, V2012, P480650, DOI 10.5402/2012/480650; Hofmann TG, 2000, BIOCHIMIE, V82, P1123, DOI 10.1016/S0300-9084(00)01196-2; Hu HY, 2019, INT J BIOL MACROMOL, V132, P470, DOI 10.1016/j.ijbiomac.2019.03.221; Kim CJ, 2004, ONCOGENE, V23, P8591, DOI 10.1038/sj.onc.1208113; Kim EJ, 2002, J BIOL CHEM, V277, P32020, DOI 10.1074/jbc.M200153200; Lazzari C, 2011, ONCOGENE, V30, P4802, DOI 10.1038/onc.2011.182; Lee Ji-Won, 2004, Experimental & Molecular Medicine, V36, P1; Li QX, 2007, CANCER RES, V67, P66, DOI 10.1158/0008-5472.CAN-06-1671; Li XG, 2017, GUT, V66, P157, DOI 10.1136/gutjnl-2015-310514; Lin JW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094040; Liu SP, 2012, J HEPATOL, V56, P389, DOI 10.1016/j.jhep.2011.08.008; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; McGlynn KA, 2011, CLIN LIVER DIS, V15, P223, DOI 10.1016/j.cld.2011.03.006; Moehlenbrink J, 2010, CANCER LETT, V292, P119, DOI 10.1016/j.canlet.2009.11.016; Morse MA, 2019, CLIN CANCER RES, V25, P912, DOI 10.1158/1078-0432.CCR-18-1254; Nardinocchi L, 2011, AGING-US, V3, P33, DOI 10.18632/aging.100254; Nardinocchi L, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-1; Nardinocchi L, 2009, BBA-MOL CELL RES, V1793, P368, DOI 10.1016/j.bbamcr.2008.10.013; Puca R, 2008, GYNECOL ONCOL, V109, P403, DOI 10.1016/j.ygyno.2008.02.018; Qin Y, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12603; Rinaldo C, 2007, MOL CELL, V25, P739, DOI 10.1016/j.molcel.2007.02.008; Tan MY, 2014, J CELL BIOCHEM, V115, P1762, DOI 10.1002/jcb.24842; Tan XY, 2018, J CELL BIOCHEM, V119, P5153, DOI 10.1002/jcb.26542; Upadhyay M, 2016, BIOCHEM BIOPH RES CO, V472, P580, DOI 10.1016/j.bbrc.2016.03.035; Wang SY, 2012, CLIN CANCER RES, V18, P2987, DOI 10.1158/1078-0432.CCR-11-2863; Wang Y, 2001, BMC Mol Biol, V2, P8, DOI 10.1186/1471-2199-2-8; Zhang N, 2018, J GENET, V97, P47, DOI 10.1007/s12041-018-0881-4; Zhang OH, 2003, CELL, V115, P177, DOI 10.1016/S0092-8674(03)00802-X; Zhang QH, 2005, P NATL ACAD SCI USA, V102, P2802, DOI 10.1073/pnas.0409373102; Zhang Z, 2018, EXP THER MED, V15, P1113, DOI 10.3892/etm.2017.5468; Zhou LH, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-747; Zhu AX, 2011, NAT REV CLIN ONCOL, V8, P292, DOI 10.1038/nrclinonc.2011.30	44	17	17	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	14					2863	2876		10.1038/s41388-020-1190-y	http://dx.doi.org/10.1038/s41388-020-1190-y		FEB 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KZ2VB	32034309				2022-12-28	WOS:000511752600002
J	Rebollido-Rios, R; Venton, G; Sanchez-Redondo, S; Felip, CII; Fournet, G; Gonzalez, E; Fernandez, WR; Escuela, DOB; Di Stefano, B; Penarroche-Diaz, R; Martin, G; Ceylan, I; Costello, R; Perez-Alea, M				Rebollido-Rios, Rocio; Venton, Geoffroy; Sanchez-Redondo, Sara; Iglesias i Felip, Carmela; Fournet, Guy; Gonzalez, Elena; Fernandez, Wilber Romero; Escuela, Dasiel Oscar Borroto; Di Stefano, Barbara; Penarroche-Diaz, Reinier; Martin, Guillaume; Ceylan, Ismail; Costello, Regis; Perez-Alea, Mileidys			Dual disruption of aldehyde dehydrogenases 1 and 3 promotes functional changes in the glutathione redox system and enhances chemosensitivity in nonsmall cell lung cancer	ONCOGENE			English	Article							STEM-CELLS; EXPRESSION; MECHANISM; 1A1; INHIBITORS; MARKER; APOPTOSIS; SUBSTRATE; REDUCTASE; ALDH1A3	Aldehyde dehydrogenases (ALDHs) are multifunctional enzymes that oxidize diverse endogenous and exogenous aldehydes. We conducted a meta-analysis based on The Cancer Genome Atlas and Gene Expression Omnibus data and detected genetic alterations in ALDH1A1, ALDH1A3, or ALDH3A1, 86% of which were gene amplification or mRNA upregulation, in 31% of nonsmall cell lung cancers (NSCLCs). The expression of these isoenzymes impacted chemoresistance and shortened survival times in patients. We hypothesized that these enzymes provide an oxidative advantage for the persistence of NSCLC. To test this hypothesis, we used genetic and pharmacological approaches with DIMATE, an irreversible inhibitor of ALDH1/3. DIMATE showed cytotoxicity in 73% of NSCLC cell lines tested and demonstrated antitumor activity in orthotopic xenografts via hydroxynonenal-protein adduct accumulation, GSTO1-mediated depletion of glutathione and increased H2O2. Consistent with this result, ALDH1/3 disruption synergized with ROS-inducing agents or glutathione synthesis inhibitors to trigger cell death. In lung cancer xenografts with high to moderate cisplatin resistance, combination treatment with DIMATE promoted strong synergistic responses with tumor regression. These results indicate that NSCLCs with increased expression of ALDH1A1, ALDH1A3, or ALDH3A1 may be targeted by strategies involving inhibitors of these isoenzymes as monotherapy or in combination with chemotherapy to overcome patient-specific drug resistance.	[Rebollido-Rios, Rocio] Univ Cologne, Fac Med, Dept Internal Med 1, Cologne, Germany; [Rebollido-Rios, Rocio] Univ Cologne, Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany; [Venton, Geoffroy; Costello, Regis] Ctr Hosp Univ La Conception, Serv Haematol & Cellular Therapy, Marseille, France; [Sanchez-Redondo, Sara] Spanish Natl Canc Res Ctr CNIO, Microenvironm & Metastasis Lab, Mol Oncol Programme, Madrid, Spain; [Iglesias i Felip, Carmela] Barcelona UAB, Dept Anat Pathol, Vall dHebron Hosp, Barcelona, Spain; [Fournet, Guy] Univ Claude Bernard Lyon1, Inst Chim & Biochim Mol & Supramol, CNRS, UMR 5246,Univ Lyon, Villeurbanne, France; [Gonzalez, Elena; Perez-Alea, Mileidys] Vall dHebron Res Inst, Oncol Res Program, Barcelona, Spain; [Fernandez, Wilber Romero; Escuela, Dasiel Oscar Borroto] Uppsala Univ, Dept Cell & Mol Biol, Computat Biol & Bioinformat, Uppsala, Sweden; [Di Stefano, Barbara] Univ Palermo, Dichirons Dept Surg, Lab Biol & Regenerat Med Plast Surg BIOPLAST, Oncol & Stomatol Sci, Palermo, Italy; [Penarroche-Diaz, Reinier] Reixmor, Barcelona, Spain; [Martin, Guillaume; Ceylan, Ismail; Perez-Alea, Mileidys] Adv Biodesign ABD, Unit Res Cellular & Mol Biol, St Priest, France	University of Cologne; University of Cologne; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Centro Nacional de Investigaciones Oncologicas (CNIO); Hospital Universitari Vall d'Hebron; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Institut National des Sciences Appliquees de Lyon - INSA Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Uppsala University; University of Palermo	Perez-Alea, M (corresponding author), Vall dHebron Res Inst, Oncol Res Program, Barcelona, Spain.; Perez-Alea, M (corresponding author), Adv Biodesign ABD, Unit Res Cellular & Mol Biol, St Priest, France.	mileidys.perez@gmail.com	Borroto-Escuela, Dasiel Oscar/F-3627-2014; Rebollido-Rios, Rocio/ABD-5458-2020; di stefano, anna barbara/K-1447-2016	Borroto-Escuela, Dasiel Oscar/0000-0002-5736-373X; Rebollido-Rios, Rocio/0000-0002-8910-867X; di stefano, anna barbara/0000-0003-4323-8564; fournet, guy/0000-0002-2478-4810; Romero-Fernandez, Wilber/0000-0001-9868-8074; PEREZ, Mileidys/0000-0002-8739-8087	La Marato TV3 Foundation program of Catalonia, Spain; Prometheus program of SENESCYT	La Marato TV3 Foundation program of Catalonia, Spain; Prometheus program of SENESCYT	The authors are grateful to Dr Gerard Quash, who has been a motivation and inspiration for this work. The authors also thank Alessandro Ventura for imaging support, Dr Alberto Indacochea for his advice and support in database analysis and Dr Yokota Jun for kindly providing the H441, H23, H2122, Hop62, and H829 cell lines. This work was partially funded by the La Marato TV3 Foundation program of Catalonia, Spain and the Prometheus program of SENESCYT.	AHMAD T, 1985, J LAB CLIN MED, V105, P464; Alamgeer M, 2013, THORAX, V68, P1095, DOI 10.1136/thoraxjnl-2012-203021; Alison MR, 2010, J PATHOL, V222, P335, DOI 10.1002/path.2772; [Anonymous], R LANG ENV STAT COMP; Ayala A, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/360438; Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193; Barta JA, 2019, ANN GLOB HEALTH, V85, DOI 10.5334/aogh.2419; Canino C, 2015, ONCOTARGET, V6, P12637, DOI 10.18632/oncotarget.3703; Castro JP, 2017, FREE RADICAL BIO MED, V111, P309, DOI 10.1016/j.freeradbiomed.2016.10.497; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Choi YM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135083; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Cvek B, 2011, CURR CANCER DRUG TAR, V11, P332, DOI 10.2174/156800911794519806; Eramo A, 2010, ONCOGENE, V29, P4625, DOI 10.1038/onc.2010.207; Fournet G, 2013, CURR MED CHEM, V20, P527; Franco R, 2009, CELL DEATH DIFFER, V16, P1303, DOI 10.1038/cdd.2009.107; Franklin CC, 2002, AM J PATHOL, V160, P1887, DOI 10.1016/S0002-9440(10)61135-2; Gene Expression Omnibus (GEO), GEN EXPR OMN GEO; GRIFFITH OW, 1982, J BIOL CHEM, V257, P13704; Gyorff B, 2019, KAPLAN MEIER PLOTTER; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Jackson Brian, 2011, Human Genomics, V5, P283; Jiang F, 2009, MOL CANCER RES, V7, P330, DOI 10.1158/1541-7786.MCR-08-0393; JONES P, 1968, BIOCHEM J, V110, P621, DOI 10.1042/bj1100621; Koppaka V, 2012, PHARMACOL REV, V64, P520, DOI 10.1124/pr.111.005538; Levi BP, 2009, BLOOD, V113, P1670, DOI 10.1182/blood-2008-05-156752; Li X, 2012, J THORAC ONCOL, V7, P1235, DOI 10.1097/JTO.0b013e318257cc6d; Ma I, 2011, STEM CELL REV REP, V7, P292, DOI 10.1007/s12015-010-9208-4; Mahmood T, 2012, N AM J MED SCI, V4, P429, DOI 10.4103/1947-2714.100998; Marcato P, 2011, CELL CYCLE, V10, P1378, DOI 10.4161/cc.10.9.15486; Marchitti SA, 2008, EXPERT OPIN DRUG MET, V4, P697, DOI [10.1517/17425255.4.6.697, 10.1517/17425255.4.6.697 ]; Marullo R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081162; MCKENNA R, 1983, J LAB CLIN MED, V102, P102; Mordant P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026073; Morgan CA, 2015, CHEM-BIOL INTERACT, V234, P18, DOI 10.1016/j.cbi.2014.12.008; Muller M, 2002, FREE RADICAL BIO MED, V33, P1527, DOI 10.1016/S0891-5849(02)01087-0; Oncomine Platform, 2015, ONCOMINE PLATFORM; Patel M, 2008, LUNG CANCER, V59, P340, DOI 10.1016/j.lungcan.2007.08.033; Perez-Alea M, 2017, ONCOGENE, V36, P5695, DOI 10.1038/onc.2017.160; Ponten F, 2011, J INTERN MED, V270, P428, DOI 10.1111/j.1365-2796.2011.02427.x; Pors K, 2014, DRUG DISCOV TODAY, V19, P1953, DOI 10.1016/j.drudis.2014.09.009; Postmus PE, 2017, ANN ONCOL, V28, P1, DOI 10.1093/annonc/mdx222; Quash G, 1999, ADV EXP MED BIOL, V463, P97; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Rodriguez-Torres M, 2016, CLIN EXP METASTAS, V33, P97, DOI 10.1007/s10585-015-9755-9; Shao CL, 2014, CLIN CANCER RES, V20, P4154, DOI 10.1158/1078-0432.CCR-13-3292; Shien K, 2012, LUNG CANCER, V77, P162, DOI 10.1016/j.lungcan.2012.02.006; Sies H, 1999, FREE RADICAL BIO MED, V27, P916, DOI 10.1016/S0891-5849(99)00177-X; Singh S, 2013, FREE RADICAL BIO MED, V56, P89, DOI 10.1016/j.freeradbiomed.2012.11.010; Sullivan JP, 2010, CANCER RES, V70, P9937, DOI 10.1158/0008-5472.CAN-10-0881; Tomita H, 2016, ONCOTARGET, V7, P11018, DOI 10.18632/oncotarget.6920; Vasiliou V, 2013, CHEM-BIOL INTERACT, V202, P2, DOI 10.1016/j.cbi.2012.10.026; Vassalli G, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/3904645; Wei D, 2015, HEART LUNG CIRC, V24, P780, DOI 10.1016/j.hlc.2015.03.021; Yang HT, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0909-x; Zhou L, 2019, CELL BIOL TOXICOL, V35, P161, DOI 10.1007/s10565-018-9444-y	56	20	20	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	13					2756	2771		10.1038/s41388-020-1184-9	http://dx.doi.org/10.1038/s41388-020-1184-9		FEB 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KX4EF	32015486	Green Published, hybrid			2022-12-28	WOS:000510820900001
J	Kim, YS; Vallur, PG; Jones, VM; Worley, BL; Shimko, S; Shin, DH; Crawford, LC; Chen, CW; Aird, KM; Abraham, T; Shepherd, TG; Warrick, JI; Lee, NY; Phaeton, R; Mythreye, K; Hempel, N				Kim, Yeon Soo; Vallur, Piyushi Gupta; Jones, Victoria M.; Worley, Beth L.; Shimko, Sara; Shin, Dong-Hui; Crawford, LaTaijah C.; Chen, Chi-Wei; Aird, Katherine M.; Abraham, Thomas; Shepherd, Trevor G.; Warrick, Joshua, I; Lee, Nam Y.; Phaeton, Rebecca; Mythreye, Karthikeyan; Hempel, Nadine			Context-dependent activation of SIRT3 is necessary for anchorage-independent survival and metastasis of ovarian cancer cells	ONCOGENE			English	Article							MANGANESE SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS; METABOLISM; ANTIOXIDANT; EXPRESSION; DEACETYLATES; PROGRESSION; ANOIKIS; GROWTH; SOD2	Tumor cells must alter their antioxidant capacity for maximal metastatic potential. Yet the antioxidant adaptations required for ovarian cancer transcoelomic metastasis, which is the passive dissemination of cells in the peritoneal cavity, remain largely unexplored. Somewhat contradicting the need for oxidant scavenging are previous observations that expression of SIRT3, a nutrient stress sensor and regulator of mitochondrial antioxidant defenses, is often suppressed in many primary tumors. We have discovered that this mitochondrial deacetylase is specifically upregulated in a context-dependent manner in cancer cells. SIRT3 activity and expression transiently increased following ovarian cancer cell detachment and in tumor cells derived from malignant ascites of high-grade serous adenocarcinoma patients. Mechanistically, SIRT3 prevents mitochondrial superoxide surges in detached cells by regulating the manganese superoxide dismutase (SOD2). This mitochondrial stress response is under dual regulation by SIRT3. SIRT3 rapidly increases SOD2 activity as an early adaptation to cellular detachment, which is followed by SIRT3-dependent increases in SOD2 mRNA during sustained anchorage-independence. In addition, SIRT3 inhibits glycolytic capacity in anchorage-independent cells thereby contributing to metabolic changes in response to detachment. While manipulation of SIRT3 expression has few deleterious effects on cancer cells in attached conditions, SIRT3 upregulation and SIRT3-mediated oxidant scavenging are required for anoikis resistance in vitro following matrix detachment, and both SIRT3 and SOD2 are necessary for colonization of the peritoneal cavity in vivo. Our results highlight the novel context-specific, pro-metastatic role of SIRT3 in ovarian cancer.	[Kim, Yeon Soo; Vallur, Piyushi Gupta; Jones, Victoria M.; Worley, Beth L.; Shimko, Sara; Shin, Dong-Hui; Crawford, LaTaijah C.; Hempel, Nadine] Penn State Univ, Coll Med, Dept Pharmacol, Hershey, PA 17033 USA; [Chen, Chi-Wei; Aird, Katherine M.] Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA USA; [Abraham, Thomas] Penn State Univ, Coll Med, Dept Neural & Behav Sci, Hershey, PA USA; [Shepherd, Trevor G.] Western Univ, Dept Obstet, Mary & John Knight Translat Ovarian Canc Res Unit, London, ON, Canada; [Shepherd, Trevor G.] Western Univ, Dept Gynecol Oncol, Mary & John Knight Translat Ovarian Canc Res Unit, London, ON, Canada; [Shepherd, Trevor G.] Western Univ, Dept Anat & Cell Biol, Mary & John Knight Translat Ovarian Canc Res Unit, London, ON, Canada; [Warrick, Joshua, I] Penn State Univ, Coll Med, Dept Pathol, Hershey, PA USA; [Lee, Nam Y.] Univ Arizona, Coll Med, Dept Pharmacol, Tucson, AZ 85724 USA; [Phaeton, Rebecca] Penn State Univ, Coll Med, Dept Obstet & Gynecol & Microbiol & Immunol, Hershey, PA USA; [Mythreye, Karthikeyan] Univ South Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA; [Mythreye, Karthikeyan] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Arizona; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of South Carolina System; University of South Carolina Columbia; University of Alabama System; University of Alabama Birmingham	Hempel, N (corresponding author), Penn State Univ, Coll Med, Dept Pharmacol, Hershey, PA 17033 USA.; Mythreye, K (corresponding author), Univ South Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA.; Mythreye, K (corresponding author), Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.	mythreye@uab.edu; nhempel@psu.edu	Abraham, Thomas/AAJ-7950-2020; Karthikeyan, Mythreye/ABC-7345-2020; Aird, Katherine/AAY-3300-2020	Karthikeyan, Mythreye/0000-0001-5478-0098; Chen, Chi-Wei/0000-0001-8658-055X; Kim, Yeon Soo/0000-0002-9677-374X; Hempel, Nadine/0000-0002-5574-8783; Vallur, Piyushi/0000-0002-1906-7497; Crawford, LaTaijah/0000-0002-5129-3355	NIH [R00CA143229, R01CA230628, S100D018124]; Rivkin Center for Ovarian Cancer; Agilent; Penn State Cancer Institute Developmental Fund Award; DoD Pilot award [W81XWH-16-1-0117]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Rivkin Center for Ovarian Cancer; Agilent; Penn State Cancer Institute Developmental Fund Award; DoD Pilot award	This work was supported by NIH grants R00CA143229 (NH), R01CA230628 (NH and KM), S100D018124 (TA), by the Rivkin Center for Ovarian Cancer (NH), an equipment grant from Agilent (NH), and the Penn State Cancer Institute Developmental Fund Award (NH). Collection of ascites was partially supported by DoD Pilot award W81XWH-16-1-0117 (NH).	Alhazzazi TY, 2011, BBA-REV CANCER, V1816, P80, DOI 10.1016/j.bbcan.2011.04.004; Alhazzazi TY, 2011, CANCER-AM CANCER SOC, V117, P1670, DOI 10.1002/cncr.25676; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; Bell EL, 2011, ONCOGENE, V30, P2986, DOI 10.1038/onc.2011.37; Cai Q, 2015, ONCOGENE, V34, P3315, DOI 10.1038/onc.2014.264; Chen YH, 2011, EMBO REP, V12, P534, DOI 10.1038/embor.2011.65; Connor KM, 2007, CANCER RES, V67, P10260, DOI 10.1158/0008-5472.CAN-07-1204; Correa RJM, 2012, CARCINOGENESIS, V33, P49, DOI 10.1093/carcin/bgr241; Davison CA, 2013, CANCER RES, V73, P3704, DOI 10.1158/0008-5472.CAN-12-2482; Desouki MM, 2014, HUM PATHOL, V45, P1071, DOI 10.1016/j.humpath.2014.01.004; Dier U, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098479; Dong XC, 2016, BIOCHEM BIOPH RES CO, V475, P245, DOI 10.1016/j.bbrc.2016.05.098; Emmings E, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010229; Finley LWS, 2011, CANCER CELL, V19, P416, DOI 10.1016/j.ccr.2011.02.014; Hemachandra LPMP, 2015, CANCER RES, V75, P4973, DOI 10.1158/0008-5472.CAN-14-3799; Hempel N, 2011, ANTI-CANCER AGENT ME, V11, P191, DOI 10.2174/187152011795255911; Hempel N, 2009, FREE RADICAL BIO MED, V46, P42, DOI 10.1016/j.freeradbiomed.2008.09.020; Hou J, 2018, CANCER RES, V78, P2503, DOI 10.1158/0008-5472.CAN-17-2618; Jiang L, 2016, NATURE, V532, P255, DOI 10.1038/nature17393; Jing EX, 2013, DIABETES, V62, P3404, DOI 10.2337/db12-1650; Kamarajan P, 2012, CANCER-AM CANCER SOC, V118, P5800, DOI 10.1002/cncr.27655; Kenny HA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7220; Kenny TC, 2017, ONCOGENE, V36, P4393, DOI 10.1038/onc.2017.52; Kenny TC, 2019, CELL REP, V27, P2292, DOI 10.1016/j.celrep.2019.04.095; Kim HS, 2010, CANCER CELL, V17, P41, DOI 10.1016/j.ccr.2009.11.023; Kim YS, 2017, ANTIOXIDANTS-BASEL, V6, DOI 10.3390/antiox6040086; Le Gal K, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad3740; Li M, 2019, CANCER CELL, V35, P916, DOI 10.1016/j.ccell.2019.05.002; McGlynn LM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131344; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Ozden O, 2014, FREE RADICAL BIO MED, V76, P163, DOI 10.1016/j.freeradbiomed.2014.08.001; Papa L, 2011, J CELL SCI, V124, P1396, DOI 10.1242/jcs.078220; Park HK, 2019, CANCER RES, V79, P1369, DOI 10.1158/0008-5472.CAN-18-2558; Peart TM, 2012, CLIN EXP METASTAS, V29, P293, DOI 10.1007/s10585-011-9451-3; Piskounova E, 2015, NATURE, V527, P186, DOI 10.1038/nature15726; Qiu XL, 2010, CELL METAB, V12, P662, DOI 10.1016/j.cmet.2010.11.015; Rangarajan P, 2015, NEUROSCIENCE, V311, P398, DOI 10.1016/j.neuroscience.2015.10.048; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Sehouli J, 2009, J SURG ONCOL, V99, P424, DOI 10.1002/jso.21288; Shepherd TG, 2006, NAT PROTOC, V1, P2643, DOI 10.1038/nprot.2006.328; Tan DSP, 2006, LANCET ONCOL, V7, P925, DOI 10.1016/S1470-2045(06)70939-1; Tao RD, 2010, MOL CELL, V40, P893, DOI 10.1016/j.molcel.2010.12.013; Torre LA, 2018, CA-CANCER J CLIN, V68, P284, DOI 10.3322/caac.21456; Wei Z, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06812-y; Worley BL, 2019, REDOX BIOL, V25, DOI 10.1016/j.redox.2018.11.009; Xiang XY, 2016, INT J ONCOL, V49, P773, DOI 10.3892/ijo.2016.3552; Yang B, 2014, BIOCHEM BIOPH RES CO, V443, P156, DOI 10.1016/j.bbrc.2013.11.068; Yu W, 2016, J BIOL CHEM, V291, P3268, DOI 10.1074/jbc.M115.702076; Zhang CZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051703; Zhou YP, 2018, ONCOTARGETS THER, V11, P2157, DOI 10.2147/OTT.S157836; Zou XH, 2017, CANCER RES, V77, P3990, DOI 10.1158/0008-5472.CAN-16-2393	51	22	22	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	8					1619	1633		10.1038/s41388-019-1097-7	http://dx.doi.org/10.1038/s41388-019-1097-7			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN6CG	31723239	Green Published, Green Accepted, Green Submitted			2022-12-28	WOS:000514923000001
J	Loveridge, CJ; Slater, S; Campbell, KJ; Nam, NA; Knight, J; Ahmad, I; Hedley, A; Lilla, S; Repiscak, P; Patel, R; Salji, M; Fleming, J; Mitchell, L; Nixon, C; Strathdee, D; Neilson, M; Ntala, C; Bryson, S; Zanivan, S; Edwards, J; Robson, CN; Goodyear, CS; Blyth, K; Leung, HY				Loveridge, Carolyn J.; Slater, Sarah; Campbell, Kirsteen J.; Nam, Noor A.; Knight, John; Ahmad, Imran; Hedley, Ann; Lilla, Sergio; Repiscak, Peter; Patel, Rachana; Salji, Mark; Fleming, Janis; Mitchell, Louise; Nixon, Colin; Strathdee, Douglas; Neilson, Matthew; Ntala, Chara; Bryson, Sheila; Zanivan, Sara; Edwards, Joanne; Robson, Craig N.; Goodyear, Carl S.; Blyth, Karen; Leung, Hing Y.			BRF1 accelerates prostate tumourigenesis and perturbs immune infiltration	ONCOGENE			English	Article							RNA-POLYMERASE III; MOUSE MODEL; CANCER; OVEREXPRESSION; COMPLEMENT	BRF1 is a rate-limiting factor for RNA Polymerase III-mediated transcription and is elevated in numerous cancers. Here, we report that elevated levels of BRF1 associate with poor prognosis in human prostate cancer. In vitro studies in human prostate cancer cell lines demonstrated that transient overexpression of BRF1 increased cell proliferation whereas the transient downregulation of BRF1 reduced proliferation and mediated cell cycle arrest. Consistent with our clinical observations, BRF1 overexpression in a Pten-deficient mouse (Pten(Delta/Delta)BRF1(Tg)) prostate cancer model accelerated prostate carcinogenesis and shortened survival. In Pten(Delta/Delta)BRF1(Tg) tumours, immune and inflammatory processes were altered, with reduced tumoral infiltration of neutrophils and CD4 positive T cells, which can be explained by decreased levels of complement factor D (CFD) and C7 components of the complement cascade, an innate immune pathway that influences the adaptive immune response. We tested if the secretome was involved in BRF1-driven tumorigenesis. Unbiased proteomic analysis on BRF1-overexpresing PC3 cells confirmed reduced levels of CFD in the secretome, implicating the complement system in prostate carcinogenesis. We further identify that expression of C7 significantly correlates with expression of CD4 and has the potential to alter clinical outcome in human prostate cancer, where low levels of C7 associate with poorer prognosis.	[Loveridge, Carolyn J.; Campbell, Kirsteen J.; Ahmad, Imran; Salji, Mark; Ntala, Chara; Zanivan, Sara; Edwards, Joanne; Leung, Hing Y.] Univ Glasgow, Coll Med Vet & Life Sci, Inst Canc Sci, Glasgow G61 1QH, Lanark, Scotland; [Loveridge, Carolyn J.; Slater, Sarah; Campbell, Kirsteen J.; Nam, Noor A.; Knight, John; Ahmad, Imran; Hedley, Ann; Lilla, Sergio; Repiscak, Peter; Patel, Rachana; Salji, Mark; Fleming, Janis; Mitchell, Louise; Nixon, Colin; Strathdee, Douglas; Neilson, Matthew; Ntala, Chara; Bryson, Sheila; Zanivan, Sara; Blyth, Karen; Leung, Hing Y.] CRUK Beatson Inst, Glasgow G61 1BD, Lanark, Scotland; [Robson, Craig N.] Newcastle Univ, Med Sch, Northern Inst Canc Res, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Goodyear, Carl S.] Univ Glasgow, Coll Med Vet & Life Sci, Inst Infect Immun & Inflammat, Glasgow G12 8TA, Lanark, Scotland; [Nam, Noor A.] Univ Sains Islam Malaysia, Fac Dent, Dept Basic Sci & Oral Biol, Kuala Lumpur, Malaysia	University of Glasgow; Beatson Institute; Newcastle University - UK; University of Glasgow; Universiti Sains Islam Malaysia	Leung, HY (corresponding author), Univ Glasgow, Coll Med Vet & Life Sci, Inst Canc Sci, Glasgow G61 1QH, Lanark, Scotland.; Leung, HY (corresponding author), CRUK Beatson Inst, Glasgow G61 1BD, Lanark, Scotland.	h.leung@beatson.gla.ac.uk	Edwards, Joanne/J-1903-2015; Zanivan, Sara/GOV-5505-2022; Knight, John/V-2922-2019; NAM, NOOR AKMAR/AAG-2571-2019	Edwards, Joanne/0000-0002-7192-6906; Knight, John/0000-0002-8771-5484; Ahmad, Imran/0000-0002-4404-1926; Zanivan, Sara/0000-0002-9880-9099; Loveridge, Carolyn/0000-0002-6237-8661; NAM, NOOR AKMAR/0000-0002-7703-2049; Campbell, Kirsteen/0000-0002-0201-8736; Repiscak, Peter/0000-0002-7335-8324	Cancer Research UK [A15151, A10419, A17196]; Prostate Cancer UK [PG10-10]; Medical Research Council Clinical Research Training Fellowship; Ministry of Higher Education, Malaysia; SLAI Fellowship from University of Malaya	Cancer Research UK(Cancer Research UK); Prostate Cancer UK; Medical Research Council Clinical Research Training Fellowship(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Ministry of Higher Education, Malaysia(Ministry of Education, Malaysia); SLAI Fellowship from University of Malaya	This work was funded by Cancer Research UK (A15151, A10419 and A17196; HYL) and Prostate Cancer UK (PG10-10; HYL). SS's PhD was supported by Medical Research Council Clinical Research Training Fellowship. NAN's PhD was sponsored by Ministry of Higher Education, Malaysia and SLAI Fellowship from University of Malaya. We thank the Cancer Research UK Beatson Institute core research services, including the biological services unit and the histology department. We acknowledge Arnaud Blomme for helpful discussions and commenting on the manuscript. We are grateful to Bob White for involvement and useful discussions in the initial stage of this project, and to Owen Sansom for general support in the development of the BRF1 mouse model.	Afshar-Kharghan V, 2017, J CLIN INVEST, V127, P780, DOI 10.1172/JCI90962; Arthurs C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186047; Birch J, 2016, BIOL OPEN, V5, P1371, DOI 10.1242/bio.019075; Bryant G, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071542; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Clarke CJ, 2016, CURR BIOL, V26, P755, DOI 10.1016/j.cub.2016.01.045; Fang Z, 2017, MOL ONCOL, V11, P1752, DOI 10.1002/1878-0261.12141; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Garcia-Hernandez MDLL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00563; Gingold H, 2014, CELL, V158, P1281, DOI 10.1016/j.cell.2014.08.011; Goodfellow SJ, 2006, EMBO J, V25, P1522, DOI 10.1038/sj.emboj.7601040; Graczyk D, 2015, MOL CELL BIOL, V35, P1848, DOI 10.1128/MCB.00990-14; Kourtzelis I, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.06.26; Lesche R, 2002, GENESIS, V32, P148, DOI 10.1002/gene.10036; Liko D, 2019, CELL DEATH DIFFER, V26, P2535, DOI 10.1038/s41418-019-0316-7; Loveridge CJ, 2017, CANCER RES, V77, P3158, DOI 10.1158/0008-5472.CAN-16-2565; Moschini M, 2017, EUR UROL, V72, P238, DOI 10.1016/j.eururo.2017.03.009; Ricklin D, 2013, J IMMUNOL, V190, P3831, DOI 10.4049/jimmunol.1203487; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Thakur Archana, 2013, Cancers (Basel), V5, P569, DOI 10.3390/cancers5020569; Uemura M, 2012, ONCOGENE, V31, P1254, DOI 10.1038/onc.2011.319; Wu XT, 2001, MECH DEVELOP, V101, P61, DOI 10.1016/S0925-4773(00)00551-7; Wurzner R, 2000, CLIN EXP IMMUNOL, V121, P8, DOI 10.1046/j.1365-2249.2000.01263.x; Zhang YY, 2018, AM J PATHOL, V188, P367, DOI 10.1016/j.ajpath.2017.10.010; Zhong Q, 2016, ONCOTARGET, V7, P6243, DOI 10.18632/oncotarget.6668	26	9	9	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	8					1797	1806		10.1038/s41388-019-1106-x	http://dx.doi.org/10.1038/s41388-019-1106-x			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN6CG	31740786	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000514923000013
J	Ma, XJ; Lu, JY; Moraru, A; Teleman, AA; Fang, JN; Qiu, Y; Liu, P; Xu, T				Ma, Xianjue; Lu, Jin-Yu; Moraru, Alexandra; Teleman, Aurelio A.; Fang, Jinan; Qiu, Yue; Liu, Peng; Xu, Tian			A novel regulator of ER Ca2+ drives Hippo-mediated tumorigenesis	ONCOGENE			English	Article							CELL-PROLIFERATION; DROSOPHILA HOMOLOG; SIGNALING PATHWAY; TUMOR-GROWTH; PROMOTES APOPTOSIS; JNK ACTIVATION; POSH; PROTEIN; CANCER; INVASION	Calcium ion (Ca2+) is a versatile second messenger that regulates various cellular and physiological functions. However, the in vivo molecular mechanisms by which Ca2+ alterations contribute to tumor growth remain poorly explored. Here we show that Emei is a novel ER Ca2+ regulator that synergizes with Ras(V12) to induce tumor growth via JNK-mediated Hippo signaling. Emei disruption reduces ER Ca2+ level and subsequently leads to JNK activation and Hippo inactivation. Importantly, genetically increasing cytosolic Ca2+ concentration cooperates with Ras(V12) to drive tumor growth via inactivating the Hippo pathway. Finally, we identify POSH as a crucial link that bridges cytosolic Ca2+ alteration with JNK activation and Hippo-mediated tumor growth. Together, our findings provide a novel mechanism of tumor growth that acts through intracellular Ca2+ levels to modulate JNK-mediated Hippo signaling.	[Ma, Xianjue; Fang, Jinan; Qiu, Yue; Liu, Peng; Xu, Tian] Westlake Univ, Sch Life Sci, Hangzhou, Peoples R China; [Ma, Xianjue; Lu, Jin-Yu; Xu, Tian] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; [Moraru, Alexandra; Teleman, Aurelio A.] German Canc Res Ctr, Heidelberg, Germany; [Teleman, Aurelio A.] Heidelberg Univ, D-69120 Heidelberg, Germany; [Teleman, Aurelio A.] Heidelberg Univ, CellNetworks Cluster Excellence, Heidelberg, Germany; [Lu, Jin-Yu] Baylor Coll Med, Hematol & Oncol, Houston, TX 77030 USA	Westlake University; Yale University; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Baylor College of Medicine	Ma, XJ; Xu, T (corresponding author), Westlake Univ, Sch Life Sci, Hangzhou, Peoples R China.; Ma, XJ; Xu, T (corresponding author), Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA.	maxianjue@westlake.edu.cn; xutian@westlake.edu.cn	Teleman, Aurelio/V-8470-2019; Teleman, Aurelio A/E-6864-2013	Teleman, Aurelio/0000-0002-4237-9368; Teleman, Aurelio A/0000-0002-4237-9368; Ma, Xianjue/0000-0003-4360-3947	Natural Science Foundation of China [31601024]; NIH [R01CA069408]; American Cancer Society; NCI-NRSA [F32CA132311]; Westlake University	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); NCI-NRSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Westlake University	We are thankful for Bloomington, VDRC and DGRC stock centers for providing fly stocks, Lei Xue for comments. This research was supported in part by Natural Science Foundation of China Grants 31601024 to XM. Work in the Xu lab was supported by NIH grant R01CA069408. J-Y Lu was supported by American Cancer Society, and NCI-NRSA (F32CA132311) postdoctoral fellowships. XM and TX are supported by Westlake University.	Bustos G, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00199; Cho E, 2006, NAT GENET, V38, P1142, DOI 10.1038/ng1887; Cong B, 2018, ONCOGENE, V37, P3088, DOI 10.1038/s41388-018-0201-8; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Enomoto M, 2018, ADV EXP MED BIOL, V1076, P173, DOI 10.1007/978-981-13-0529-0_10; Feng MY, 2010, CELL, V143, P84, DOI 10.1016/j.cell.2010.08.040; Giorgi C, 2018, TRENDS CELL BIOL, V28, P258, DOI 10.1016/j.tcb.2018.01.002; Groenendyk J, 2013, ANNU REV PHYSIOL, V75, P49, DOI 10.1146/annurev-physiol-030212-183707; Hamaratoglu F, 2006, NAT CELL BIOL, V8, P27, DOI 10.1038/ncb1339; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Igaki T, 2002, EMBO J, V21, P3009, DOI 10.1093/emboj/cdf306; Igaki T, 2006, CURR BIOL, V16, P1139, DOI 10.1016/j.cub.2006.04.042; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; Kukekov NV, 2006, J BIOL CHEM, V281, P15517, DOI 10.1074/jbc.M601056200; Lee TM, 2001, TRENDS NEUROSCI, V24, P251, DOI 10.1016/S0166-2236(00)01791-4; Ma X, 2017, ONCOGENE, V36, P3159, DOI 10.1038/onc.2016.463; Ma X, 2016, ONCOGENE, V35, P846, DOI 10.1038/onc.2015.137; Ma X, 2014, CELL DEATH DIFFER, V21, P407, DOI 10.1038/cdd.2013.154; Ma XJ, 2018, P NATL ACAD SCI USA, V115, P2150, DOI 10.1073/pnas.1715165115; Ma XJ, 2017, CELL REP, V19, P2657, DOI 10.1016/j.celrep.2017.05.092; Ma XJ, 2017, P NATL ACAD SCI USA, V114, P1934, DOI 10.1073/pnas.1621359114; Ma XJ, 2015, P NATL ACAD SCI USA, V112, P1065, DOI 10.1073/pnas.1415020112; McAndrew D, 2011, MOL CANCER THER, V10, P448, DOI 10.1158/1535-7163.MCT-10-0923; McEwen DG, 2005, DEVELOPMENT, V132, P3935, DOI 10.1242/dev.01949; Mirzoyan Z, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00051; Mo JS, 2014, EMBO REP, V15, P642, DOI 10.15252/embr.201438638; Monteith GR, 2017, NAT REV CANCER, V17, P367, DOI 10.1038/nrc.2017.18; Moraru A, 2017, DEV CELL, V41, P450, DOI 10.1016/j.devcel.2017.05.001; Moreno E, 2002, CURR BIOL, V12, P1263, DOI 10.1016/S0960-9822(02)00954-5; Neto-Silva RM, 2010, DEV CELL, V19, P507, DOI 10.1016/j.devcel.2010.09.009; Oh H, 2008, DEVELOPMENT, V135, P1081, DOI 10.1242/dev.015255; Ohsawa S, 2014, J BIOCHEM, V156, P129, DOI 10.1093/jb/mvu045; Ohsawa S, 2012, NATURE, V490, P547, DOI 10.1038/nature11452; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Pan DJ, 2007, GENE DEV, V21, P886, DOI 10.1101/gad.1536007; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Pantalacci S, 2003, NAT CELL BIOL, V5, P921, DOI 10.1038/ncb1051; Prasad V, 2005, CANCER RES, V65, P8655, DOI 10.1158/0008-5472.CAN-05-0026; Roderick HL, 2008, NAT REV CANCER, V8, P361, DOI 10.1038/nrc2374; Ryoo HD, 2007, EMBO J, V26, P242, DOI 10.1038/sj.emboj.7601477; Shibao K, 2010, CELL CALCIUM, V48, P315, DOI 10.1016/j.ceca.2010.09.005; Srivastava A, 2007, P NATL ACAD SCI USA, V104, P2721, DOI 10.1073/pnas.0611666104; Sun GP, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004324; Tsuda M, 2006, FEBS LETT, V580, P3296, DOI 10.1016/j.febslet.2006.05.005; Tuvia S, 2007, J CELL BIOL, V177, P51, DOI 10.1083/jcb.200611036; Udan RS, 2003, NAT CELL BIOL, V5, P914, DOI 10.1038/ncb1050; Uhlirova M, 2006, EMBO J, V25, P5294, DOI 10.1038/sj.emboj.7601401; Wu M, 2010, NATURE, V463, P545, DOI 10.1038/nature08702; Wu S, 2003, CELL, V114, P445, DOI 10.1016/S0092-8674(03)00549-X; XU TA, 1995, DEVELOPMENT, V121, P1053; Xu ZH, 2005, MOL CELL BIOL, V25, P9949, DOI 10.1128/MCB.25.22.9949-9959.2005; Xu ZH, 2003, EMBO J, V22, P252, DOI 10.1093/emboj/cdg021; Zhu H, 2014, ONCOTARGET, V5, P3455, DOI 10.18632/oncotarget.1903; Ziosi M, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001140	54	6	6	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	6					1378	1387		10.1038/s41388-019-1076-z	http://dx.doi.org/10.1038/s41388-019-1076-z			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE4UH	31649333				2022-12-28	WOS:000526714600015
J	Lee, PC; Chen, ST; Kuo, TC; Lino, TC; Lin, MC; Huang, J; Hung, JS; Hsu, CL; Juan, HF; Lee, PH; Huang, MC				Lee, Po-Chu; Chen, Syue-Ting; Kuo, Ting-Chun; Lino, Tzu-Chi; Lin, Mei-Chun; Huang, John; Hung, Ji-Shiang; Hsu, Chia-Lang; Juan, Hsueh-Fen; Lee, Po-Huang; Huang, Min-Chuan			C1GALT1 is associated with poor survival and promotes soluble Ephrin A1-mediated cell migration through activation of EPHA2 in gastric cancer	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; O-GLYCOSYLATION; RECEPTORS; MET; BIOMARKERS; LIGANDS; TARGETS; GROWTH	C1GALT1 controls the crucial step of GalNAc-type O-glycosylation and is associated with both physiologic and pathologic conditions, including cancers. EPH receptors comprise the largest family of receptor tyrosine kinases (RTKs) and modulate a diverse range of developmental processes and human diseases. However, the role of C1GALT1 in the signaling of EPH receptors remains largely overlooked. Here, we showed that C1GALT1 high expression in gastric adenocarcinomas correlated with adverse clinicopathologic features and is an independent prognostic factor for poor overall survival. Silencing or loss of C1GALT1 inhibited cell viability, migration, invasion, tumor growth and metastasis, as well as increased apoptosis and cytotoxicity of 5-fluorouracil in AGS and MKN45 cells. Phospho-RTK array and western blot analysis showed that C1GALT1 depletion suppressed tyrosine phosphorylation of EPHA2 induced by soluble Ephrin A1-Fc. O-glycans on EPHA2 were modified by C1GALT1 and both S277A and T429A mutants, which are O-glycosites on EPHA2, dramatically enhanced phosphorylation of Y588, suggesting that not only overall O-glycan structures but also site-specific O-glycosylation can regulate EPHA2 activity. Furthermore, depletion of C1GALT1 decreased Ephrin A1-Fc induced migration and reduced Ephrin A1 binding to cell surfaces. The effects of C1GALT1 knockdown or knockout on cell invasiveness in vitro and in vivo were phenocopied by EPHA2 knockdown in gastric cancer cells. These results suggest that C1GALT1 promotes phosphorylation of EPHA2 and enhances soluble Ephrin A1-mediated migration primarily by modifying EPHA2 O-glycosylation. Our study highlights the importance of GalNAc-type O-glycosylation in EPH receptor-regulated diseases and identifies C1GALT1 as a potential therapeutic target for gastric cancer.	[Lee, Po-Chu; Kuo, Ting-Chun; Huang, John; Hung, Ji-Shiang; Lee, Po-Huang] Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan; [Lee, Po-Chu; Kuo, Ting-Chun] Natl Taiwan Univ Hosp, Dept Traumatol, Taipei, Taiwan; [Lee, Po-Chu] Natl Taiwan Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan; [Chen, Syue-Ting; Kuo, Ting-Chun; Lino, Tzu-Chi; Huang, Min-Chuan] Natl Taiwan Univ, Coll Med, Grad Inst Anat & Cell Biol, Taipei, Taiwan; [Lin, Mei-Chun] Natl Taiwan Univ Hosp, Dept Otolaryngol, Taipei, Taiwan; [Hsu, Chia-Lang] Natl Taiwan Univ Hosp, Dept Med Res, Taipei, Taiwan; [Juan, Hsueh-Fen] Natl Taiwan Univ, Dept Life Sci, Taipei, Taiwan; [Lee, Po-Huang] E DA Hosp, Dept Surg, Kaohsiung, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; E-Da Hospital	Huang, MC (corresponding author), Natl Taiwan Univ, Coll Med, Grad Inst Anat & Cell Biol, Taipei, Taiwan.	mchuang@ntu.edu.tw	Hsu, Chia-Lang/O-1458-2013	Hsu, Chia-Lang/0000-0002-7447-8045; LEE, PO-HUANG/0000-0001-5831-035X; KUO, TING-CHUN/0000-0003-1960-1423; HUANG, MIN-CHUAN/0000-0002-0704-3447; Hung, Ji-Shiang/0000-0001-7392-5694; LEE, PO-CHU/0000-0001-5053-1895; JUAN, HSUEH-FEN/0000-0003-4876-3309	National Taiwan University Hospital [109-049]; Ministry of Science and Technology, Taiwan [108-2320-B-002-064-MY3]	National Taiwan University Hospital(National Taiwan University); Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan)	The authors thank Dr Shu-Yun Tung (Academia Sinica, Taiwan) for performing global gene expression analysis and Dr Chiung-Nien Chen and Dr I-Rue Lai (National Taiwan University Hospital, Taiwan) for providing gastric cancer cell lines. This study was supported by National Taiwan University Hospital (109-049) to PCL, and Ministry of Science and Technology, Taiwan (108-2320-B-002-064-MY3) to MCH.	Alford S, 2010, CANCER CELL INT, V10, DOI 10.1186/1475-2867-10-41; Beauchamp A, 2012, SEMIN CELL DEV BIOL, V23, P109, DOI 10.1016/j.semcdb.2011.10.019; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Boyd AW, 2014, NAT REV DRUG DISCOV, V13, P39, DOI 10.1038/nrd4175; Bradley CA, 2017, NAT REV CLIN ONCOL, V14, P562, DOI 10.1038/nrclinonc.2017.40; Campos D, 2015, MOL CELL PROTEOMICS, V14, P1616, DOI 10.1074/mcp.M114.046862; Chou CH, 2015, ONCOTARGET, V6, P6123, DOI 10.18632/oncotarget.3045; Chu ML, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19788-y; Cui XD, 2010, INT J CANCER, V126, P940, DOI 10.1002/ijc.24798; Deng NT, 2012, GUT, V61, P673, DOI 10.1136/gutjnl-2011-301839; Duarte HO, 2016, BIOMOLECULES, V6, DOI 10.3390/biom6030033; Fife CM, 2014, BRIT J PHARMACOL, V171, P5507, DOI 10.1111/bph.12704; Fuster MM, 2005, NAT REV CANCER, V5, P526, DOI 10.1038/nrc1649; Gill DJ, 2013, P NATL ACAD SCI USA, V110, pE3152, DOI 10.1073/pnas.1305269110; GOSEKI N, 1992, GUT, V33, P606, DOI 10.1136/gut.33.5.606; Gravalos C, 2008, ANN ONCOL, V19, P1523, DOI 10.1093/annonc/mdn169; Herath NI, 2010, INT J CANCER, V126, P2003, DOI 10.1002/ijc.25147; Ho WL, 2014, ONCOTARGET, V5, P12247, DOI 10.18632/oncotarget.2627; Huang J, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3875-3; Huang MJ, 2015, ONCOTARGET, V6, P5650, DOI 10.18632/oncotarget.3117; Hung JS, 2014, ONCOTARGET, V5, P2096, DOI 10.18632/oncotarget.1815; Ieguchi K, 2014, ONCOGENE, V33, P2179, DOI 10.1038/onc.2013.180; Ju TZ, 2002, P NATL ACAD SCI USA, V99, P16613, DOI 10.1073/pnas.262438199; Kania A, 2016, NAT REV MOL CELL BIO, V17, P240, DOI 10.1038/nrm.2015.16; Kudo T, 2013, BLOOD, V122, P1649, DOI 10.1182/blood-2012-12-471102; Lin MC, 2018, ONCOGENE, V37, P5780, DOI 10.1038/s41388-018-0375-0; Lisle JE, 2013, BBA-REV CANCER, V1835, P243, DOI 10.1016/j.bbcan.2013.01.003; Liu SY, 2016, ONCOTARGET, V7, P11251, DOI 10.18632/oncotarget.7081; Nakamura R, 2005, CANCER SCI, V96, P42, DOI 10.1111/j.1349-7006.2005.00007.x; Neill T, 2016, J CELL BIOL, V215, P687, DOI 10.1083/jcb.201603079; Ohtsu A, 2003, J CLIN ONCOL, V21, P54, DOI 10.1200/JCO.2003.04.130; Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806; Peng Z, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0092924, 10.1371/journal.pone.0084502, 10.1371/journal.pone.0085663]; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Sierra JC, 2018, GUT, V67, P1247, DOI 10.1136/gutjnl-2016-312888; Ten Hagen KG, 2003, GLYCOBIOLOGY, V13, p1R, DOI 10.1093/glycob/cwg007; Tian E, 2009, GLYCOCONJUGATE J, V26, P325, DOI 10.1007/s10719-008-9162-4; Tran DT, 2013, J BIOL CHEM, V288, P6921, DOI 10.1074/jbc.R112.418558; Tran Phu N, 2017, Gastrointest Cancer, V7, P1, DOI 10.2147/GICTT.S113525; Uchida Y, 2013, CANCER BIOL THER, V14, P127, DOI 10.4161/cbt.22634; Vaught D, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2207; Washington K, 2010, ANN SURG ONCOL, V17, P3077, DOI 10.1245/s10434-010-1362-z; Wen QC, 2017, ONCOTARGET, V8, P47998, DOI 10.18632/oncotarget.18208; Wu J, 2016, ONCOTARGET, V7, P25315, DOI 10.18632/oncotarget.8287; Wu YM, 2013, CANCER RES, V73, P5580, DOI 10.1158/0008-5472.CAN-13-0869; Wu YM, 2011, CANCER RES, V71, P7270, DOI 10.1158/0008-5472.CAN-11-1161; Wykosky J, 2008, MOL CANCER RES, V6, P1795, DOI 10.1158/1541-7786.MCR-08-0244; Xi HQ, 2012, J CELL MOL MED, V16, P2894, DOI 10.1111/j.1582-4934.2012.01612.x; Yao HP, 2013, NAT REV CANCER, V13, P466, DOI 10.1038/nrc3545; Yuan W, 2012, NEOPLASMA, V59, P105, DOI 10.4149/neo_2012_014; Yuan WJ, 2009, DIGEST DIS SCI, V54, P2410, DOI 10.1007/s10620-008-0649-4	51	17	17	1	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	13					2724	2740		10.1038/s41388-020-1178-7	http://dx.doi.org/10.1038/s41388-020-1178-7		JAN 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KX4EF	32005975	hybrid, Green Published			2022-12-28	WOS:000510346700005
J	Gu, L; Zhu, YH; Lin, X; Tan, XY; Lu, BJ; Li, YJ				Gu, Li; Zhu, Yahui; Lin, Xi; Tan, Xingyu; Lu, Bingjun; Li, Youjun			Stabilization of FASN by ACAT1-mediated GNPAT acetylation promotes lipid metabolism and hepatocarcinogenesis	ONCOGENE			English	Article							FATTY-ACID SYNTHASE; HEPATOCELLULAR-CARCINOMA; EXPRESSION; CELLS; AKT; PHOSPHORYLATION; PLASMALOGENS; INACTIVATION; RECRUITMENT; STABILITY	Metabolic alteration for adaptation of the local environment has been recognized as a hallmark of cancer. GNPAT dysregulation has been implicated in hepatocellular carcinoma (HCC). However, the precise posttranslational regulation of GNPAT is still undiscovered. Here we show that ACAT1 is upregulated in response to extra palmitic acid (PA). ACAT1 acetylates GNPAT at K128, which represses TRIM21-mediated GNPAT ubiquitination and degradation. Conversely, GNPAT deacetylation by SIRT4 antagonizes ACAT1's function. GNPAT represses TRIM21-mediated FASN degradation and promotes lipid metabolism. Furthermore, shRNA-mediated ACAT1 ablation and acetylation deficiency of GNPAT repress lipid metabolism and tumor progression in xenograft and DEN/CCl4-induced HCC. Otherwise, ACAT1 inhibitor combination with sorafenib enormously retards tumor formation in mice. Collectively, we demonstrate that stabilization of FASN by ACAT1-mediated GNPAT acetylation plays a critical role in hepatocarcinogenesis.	[Gu, Li; Zhu, Yahui; Lin, Xi; Tan, Xingyu; Lu, Bingjun; Li, Youjun] Wuhan Univ, Coll Life Sci, Hubei Key Lab Cell Homeostasis, Wuhan 430072, Peoples R China; [Gu, Li; Zhu, Yahui; Lin, Xi; Tan, Xingyu; Lu, Bingjun; Li, Youjun] Wuhan Univ, Sch Med, Med Res Inst, Wuhan 430071, Peoples R China	Wuhan University; Wuhan University	Gu, L; Li, YJ (corresponding author), Wuhan Univ, Coll Life Sci, Hubei Key Lab Cell Homeostasis, Wuhan 430072, Peoples R China.; Gu, L; Li, YJ (corresponding author), Wuhan Univ, Sch Med, Med Res Inst, Wuhan 430071, Peoples R China.	gulicherry@whu.edu.cn; liy7@whu.edu.cn			National Nature Science Foundation of China [81772609, 81902843]; Medical Science Advancement Program (Basic Medical Sciences) of Wuhan University [TFJC2018005]; China Postdoctoral Science Foundation [2019T120681, 2019M652702]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Medical Science Advancement Program (Basic Medical Sciences) of Wuhan University; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	We thank Profs Qunying Lei (Fudan University, Shanghai) for the SIRT family vectors and FASN plasmid, Yan Wang (Wuhan University, Wuhan, China) for the AAV8 vector, Ping Wang (East China Normal University, Shanghai, China) for pcDNA3.1(+)-5'flag Luc vector and Jinxiang Zhang (Wuhan Union Hospital, Wuahn, China) for providing the HCC samples. This work was supported by grants from the National Nature Science Foundation of China (81772609, 81902843), Medical Science Advancement Program (Basic Medical Sciences) of Wuhan University (TFJC2018005), and China Postdoctoral Science Foundation (2019T120681, 2019M652702).	Alo PL, 2007, ANTICANCER RES, V27, P2523; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Budhu A, 2013, GASTROENTEROLOGY, V144, P1066, DOI 10.1053/j.gastro.2013.01.054; Dorninger F, 2017, J NEUROCHEM, V143, P569, DOI 10.1111/jnc.14082; Facciotti F, 2012, NAT IMMUNOL, V13, P474, DOI 10.1038/ni.2245; Fan J, 2016, MOL CELL, V64, P859, DOI 10.1016/j.molcel.2016.10.014; Fan J, 2014, MOL CELL, V53, P534, DOI 10.1016/j.molcel.2013.12.026; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Furuta E, 2008, CANCER RES, V68, P1003, DOI 10.1158/0008-5472.CAN-07-2489; Gingold JA, 2018, TRENDS MOL MED, V24, P395, DOI 10.1016/j.molmed.2018.02.006; Gong XL, 2016, WORLD J GASTROENTERO, V22, P6582, DOI 10.3748/wjg.v22.i29.6582; Gonzalez-Guerrico AM, 2016, ONCOTARGET, V7, P71151, DOI 10.18632/oncotarget.9463; Graner E, 2004, CANCER CELL, V5, P253, DOI 10.1016/S1535-6108(04)00055-8; Gu L, 2018, CANCER RES, V78, P5808, DOI 10.1158/0008-5472.CAN-18-0340; Haapalainen AM, 2006, TRENDS BIOCHEM SCI, V31, P64, DOI 10.1016/j.tibs.2005.11.011; Han H, 2013, HEPATOLOGY, V57, P2378, DOI 10.1002/hep.26302; Hossain MS, 2017, J NEUROSCI, V37, P4074, DOI 10.1523/JNEUROSCI.3941-15.2017; Jin JL, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13594; Kim DW, 2017, J GASTROINTEST ONCOL, V8, P256, DOI 10.21037/jgo.2016.09.07; Knobloch M, 2013, NATURE, V493, P226, DOI 10.1038/nature11689; Komljenovic D, 2009, CELL TISSUE RES, V337, P281, DOI 10.1007/s00441-009-0809-7; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; Lee M, 2018, YONSEI MED J, V59, P1143, DOI 10.3349/ymj.2018.59.10.1143; Li L, 2016, J HEPATOL, V64, P333, DOI 10.1016/j.jhep.2015.10.004; Lin HP, 2016, CANCER RES, V76, P6924, DOI 10.1158/0008-5472.CAN-16-1597; Liu PD, 2013, NAT CELL BIOL, V15, P1340, DOI 10.1038/ncb2860; Lv L, 2011, MOL CELL, V42, P719, DOI 10.1016/j.molcel.2011.04.025; Ma C, 2016, NATURE, V531, P253, DOI 10.1038/nature16969; Malheiro AR, 2015, J INHERIT METAB DIS, V38, P111, DOI 10.1007/s10545-014-9795-3; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; O'Brien CA, 2012, CANCER CELL, V21, P777, DOI 10.1016/j.ccr.2012.04.036; Pan JA, 2016, MOL CELL, V61, P720, DOI 10.1016/j.molcel.2016.02.007; Rodemer C, 2003, HUM MOL GENET, V12, P1881, DOI 10.1093/hmg/ddg191; Souchek JJ, 2017, MOL CANCER THER, V16, P1819, DOI 10.1158/1535-7163.MCT-17-0013; Tesori V, 2015, SCI REP-UK, V5, DOI 10.1038/srep09149; Wang B, 2017, NATURE, V545, P365, DOI 10.1038/nature22344; Wei Z, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06812-y; Zaytseva YY, 2015, ONCOTARGET, V6, P18891, DOI 10.18632/oncotarget.3783; Zhang ZQ, 2013, NAT IMMUNOL, V14, P172, DOI 10.1038/ni.2492; Zhu YH, 2017, CELL DEATH DIFFER, V24, P2199, DOI 10.1038/cdd.2017.151	40	26	31	4	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	11					2437	2449		10.1038/s41388-020-1156-0	http://dx.doi.org/10.1038/s41388-020-1156-0		JAN 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KU0ZS	31974474				2022-12-28	WOS:000509037000002
J	Zhu, J; Li, X; Su, P; Xue, M; Zang, YF; Ding, YL				Zhu, Jian; Li, Xin; Su, Peng; Xue, Min; Zang, Yifeng; Ding, Yinlu			The ubiquitin ligase RNF181 stabilizes ER alpha and modulates breast cancer progression	ONCOGENE			English	Article							ESTROGEN-RECEPTOR-ALPHA; SHARPIN; IDENTIFICATION; COACTIVATOR; EXPRESSION; RESISTANCE; COMPONENT; P300	ER alpha positive breast cancer accounts for 70% of breast malignancies. Compared with ER alpha negative types, ER alpha positive breast cancer could be effective controlled by endocrine therapy. However, more than half of the patients will develop endocrine resistance, making it an important clinical issue for breast cancer therapy. Endocrine resistance might be caused by multiple alternations, including the components of ER alpha signaling, during tumor progression. Thus, it is urgent and necessary to uncover the molecular mechanisms that controls ER alpha expression and stability to improve breast cancer therapeutics. In our current study, we identifies that the ubiquitin ligase RNF181 stabilizes ER alpha and facilitates breast cancer progression. The expression of RNF181 is correlated with ER alpha level in human breast tumors and relates to poor survival in endocrine-treated patients. RNF181 depletion inhibits breast cancer progression in vivo and in vitro, reduces ER alpha protein level and its target gene expression, such as PS2 and GREB1. Unbiased RNA sequencing analysis indicates RNF181 is necessary for ER alpha signature gene expression in whole genomic level. Immuno-precipitation assays indicate that RNF181 associates with ER alpha and promotes its stability possibly via inducing ER alpha K63-linked poly-ubiquitination. In conclusion, our data implicate a non-genomic mechanism by RNF181 via stabilizing ER alpha protein controls ER alpha target gene expression linked to breast cancer progression.	[Zhu, Jian; Zang, Yifeng; Ding, Yinlu] Shandong Univ, Second Hosp, Dept Gen Surg, Cheeloo Coll Med, Jinan 250033, Peoples R China; [Li, Xin; Xue, Min] Xinxiang Med Univ, Xinxiang Key Lab Tumor Migrat Invas & Precis Med, Sch Lab Med, Henan Collaborat Innovat Ctr Mol Diag & Lab Med, Xinxiang 453003, Henan, Peoples R China; [Su, Peng] Shandong Univ, Qilu Hosp, Dept Pathol, Cheeloo Coll Med, Jinan 250033, Peoples R China	Shandong University; Xinxiang Medical University; Shandong University	Zhu, J; Ding, YL (corresponding author), Shandong Univ, Second Hosp, Dept Gen Surg, Cheeloo Coll Med, Jinan 250033, Peoples R China.	zhujian1204@yahoo.com; dingyinlu@126.com	zhu, jian/D-7361-2017	zhu, jian/0000-0003-3596-4339	National Natural Science Foundation of China [U1604190]; Key R&D programs in Shandong Province [2019gsf108229]; KI-SDU joint research program for 2020	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key R&D programs in Shandong Province; KI-SDU joint research program for 2020	The project was supported from Joint Fund of the National Natural Science Foundation of China (No.U1604190, JZ), The KI-SDU joint research program for 2020, and the Key R&D programs in Shandong Province (2019gsf108229, YD).	Abdel-Magid AF, 2017, ACS MED CHEM LETT, V8, P1129, DOI 10.1021/acsmedchemlett.7b00424; Ali S, 2000, J MAMMARY GLAND BIOL, V5, P271, DOI 10.1023/A:1009594727358; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brophy TM, 2008, BIOCHEM BIOPH RES CO, V369, P1088, DOI 10.1016/j.bbrc.2008.02.142; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Cai ZJ, 2021, SCI CHINA LIFE SCI, V64, P1017, DOI 10.1007/s11427-019-9816-1; Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI 10.1146/annurev.biochem.78.101807.093809; Eisenhaber B, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-3-209; Fan P, 2019, CANCER DRUG RESIST, V2, P198, DOI 10.20517/cdr.2019.13; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Haque MM, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00573; Ikeda F, 2011, NATURE, V471, P637, DOI 10.1038/nature09814; Jackisch C, 2019, LANCET ONCOL, V20, P1185, DOI 10.1016/S1470-2045(19)30500-5; Jin HW, 2016, J PROTEOMICS, V136, P77, DOI 10.1016/j.jprot.2015.12.012; Lei JT, 2019, BREAST, V48, pS26, DOI 10.1016/S0960-9776(19)31118-X; Liu ZH, 2018, J CELL MOL MED, V22, P4161, DOI 10.1111/jcmm.13694; Metzger MB, 2012, J CELL SCI, V125, P531, DOI 10.1242/jcs.091777; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Onitilo AA, 2009, CLIN MED RES, V7, P4, DOI 10.3121/cmr.2009.825; Pedersen SM, 2016, MOL CELL BIOL, V36, P794, DOI 10.1128/MCB.00876-15; Raab M, 2010, PROTEOMICS, V10, P2790, DOI 10.1002/pmic.200900621; Ranganathan P, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00708; Renaud J, 2005, J MED CHEM, V48, P364, DOI 10.1021/jm040858p; Renaud J, 2003, J MED CHEM, V46, P2945, DOI 10.1021/jm030086h; Shaaban AM, 2002, AM J PATHOL, V160, P597, DOI 10.1016/S0002-9440(10)64879-1; Tokunaga F, 2011, NATURE, V471, P633, DOI 10.1038/nature09815; Vaz-Luis I, 2014, J CLIN ONCOL, V32, P2142, DOI 10.1200/JCO.2013.53.1608; Wang CG, 2001, J BIOL CHEM, V276, P18375, DOI 10.1074/jbc.M100800200; Wang SL, 2017, BBA-MOL BASIS DIS, V1863, P1615, DOI 10.1016/j.bbadis.2017.02.011; Xue M, 2019, ONCOGENESIS, V8, DOI 10.1038/s41389-019-0139-x; Yang HJ, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0672-z; Yang HJ, 2017, NEOPLASIA, V19, P84, DOI 10.1016/j.neo.2016.12.002; Zhu J, 2014, ONCOGENE, V33, P4340, DOI 10.1038/onc.2013.573; Zhuang T, 2017, ONCOTARGET, V8, P77137, DOI 10.18632/oncotarget.20368	35	11	11	3	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2020	39	44					6776	6788		10.1038/s41388-020-01464-z	http://dx.doi.org/10.1038/s41388-020-01464-z		SEP 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OH9QS	32973333	hybrid, Green Published			2022-12-28	WOS:000572607300003
J	Talotta, F; Casalino, L; Verde, P				Talotta, Francesco; Casalino, Laura; Verde, Pasquale			The nuclear oncoprotein Fra-1: a transcription factor knocking on therapeutic applications' door	ONCOGENE			English	Review							EPITHELIAL-MESENCHYMAL TRANSITION; P53 SIGNALING PATHWAY; CANCER CELLS; COLORECTAL-CANCER; GENE-EXPRESSION; TUMOR MICROENVIRONMENT; DRUG-ADDICTION; UP-REGULATION; ALPHA-V; BREAST	Among the FOS-related members of the AP-1 dimeric complex, the transcription factor Fra-1, encoded by FOSL1, is crucially involved in human tumor progression and metastasis, thus representing a promising therapeutic target. Here we review the state of the art and discuss the emerging topics and perspectives on FOSL1 and its gene product. First, we summarize the present knowledge on the FOSL1 transcriptional and epigenetic controls, driving Fra-1 accumulation in a variety of human solid tumors. We also present a model on the regulatory interactions between Fra-1, p53, and miRNAs. Then, we outline the multiple roles of Fra-1 posttranslational modifications and transactivation mechanisms of select Fra-1 target genes. In addition to summarizing the Fra-1-dependent gene networks controlling proliferation, survival, and epithelial-mesenchymal transitions (EMT) in multiple cancer cell types, we highlight the roles played by Fra-1 in nonneoplastic cell populations recruited to the tumor microenvironment, and in mouse models of tumorigenesis. Next, we review the prognostic power of the Fra-1-associated gene signatures, and envisage potential strategies aimed at Fra-1 therapeutic inhibition. Finally, we discuss several recent reports showing the emerging roles of Fra-1 in the mechanisms of both resistance and addiction to targeted therapies.	[Talotta, Francesco; Casalino, Laura; Verde, Pasquale] CNR, Inst Genet & Biophys Adriano Buzzati Traverso, Naples, Italy; [Talotta, Francesco] ReiThera Srl, Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)	Verde, P (corresponding author), CNR, Inst Genet & Biophys Adriano Buzzati Traverso, Naples, Italy.	pasquale.verde@igb.cnr.it	Casalino, Laura/C-1506-2015	Casalino, Laura/0000-0002-2557-0443	Regione Campania Project POR-SATIN	Regione Campania Project POR-SATIN	We wish to thank all the authors whose work was not cited here owing to page limitation. We thank the former members of the lab for fruitful discussions, along with Valerio Costa and Ingram Iaccarino for critical feedback on the paper. We also thank the Regione Campania Project POR-SATIN for financial support.	Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Andreolas C, 2008, INT J CANCER, V122, P1745, DOI 10.1002/ijc.23309; Baker EK, 2015, SCI REP-UK, V5, DOI 10.1038/srep10120; Bakiri L, 2015, CELL DEATH DIFFER, V22, P336, DOI 10.1038/cdd.2014.157; Behan FM, 2019, NATURE, V568, P511, DOI 10.1038/s41586-019-1103-9; Bejjani F, 2019, BBA-REV CANCER, V1872, P11, DOI 10.1016/j.bbcan.2019.04.003; Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312; Belguise K, 2017, CANCER LETT, V385, P97, DOI 10.1016/j.canlet.2016.10.038; Blake DR, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aav7259; Blunsom NJ, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00063; Caramel J, 2013, CANCER CELL, V24, P466, DOI 10.1016/j.ccr.2013.08.018; Casalino L, 2003, MOL CELL BIOL, V23, P4401, DOI 10.1128/MCB.23.12.4401-4415.2003; Casalino L, 2007, EMBO J, V26, P1878, DOI 10.1038/sj.emboj.7601617; Chandran SS, 2019, IMMUNOL REV, V290, P127, DOI 10.1111/imr.12772; Cheng FF, 2016, CANCER LETT, V375, P274, DOI 10.1016/j.canlet.2016.03.010; Racca AC, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00544; Dardenne E, 2014, CELL REP, V7, P1900, DOI 10.1016/j.celrep.2014.05.010; Desmet CJ, 2013, P NATL ACAD SCI USA, V110, P5139, DOI 10.1073/pnas.1222085110; Dhillon AS, 2015, ONCOGENE, V34, P4421, DOI 10.1038/onc.2014.374; Diesch J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088950; Dikshit A, 2018, CANCER RES, V78, P6462, DOI 10.1158/0008-5472.CAN-18-1040; Ding XM, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003884; Dongre A, 2017, CANCER RES, V77, P3982, DOI 10.1158/0008-5472.CAN-16-3292; Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Elangovan IM, 2018, AM J RESP CELL MOL, V58, P625, DOI 10.1165/rcmb.2017-0164OC; Esnault C, 2017, MOL CELL, V65, P1081, DOI 10.1016/j.molcel.2017.02.005; Evellin S, 2013, MOL CELL BIOL, V33, P1198, DOI 10.1128/MCB.01054-12; Fleming JD, 2013, GENOME RES, V23, P1195, DOI 10.1101/gr.148080.112; Franco HL, 2018, GENOME RES, V28, P159, DOI 10.1101/gr.226019.117; Gallenne T, 2017, ONCOTARGET, V8, P20572, DOI 10.18632/oncotarget.16244; Gerdes MJ, 2006, CANCER RES, V66, P7578, DOI 10.1158/0008-5472.CAN-06-1247; Grimm J, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0082-2; Hasenfuss SC, 2014, CELL METAB, V19, P84, DOI 10.1016/j.cmet.2013.11.018; He H, 2019, ONCOGENE, V38, P5725, DOI 10.1038/s41388-019-0824-4; He JY, 2015, INT J ONCOL, V47, P1725, DOI 10.3892/ijo.2015.3146; Hong A, 2018, CANCER DISCOV, V8, P74, DOI 10.1158/2159-8290.CD-17-0682; Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065; Iaccarino I, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071497; Ibrahim Sherif Abd El-Fattah, 2018, Oncotarget, V9, P34259, DOI 10.18632/oncotarget.26047; Ishay-Ronen D, 2019, CANCER CELL, V35, P17, DOI 10.1016/j.ccell.2018.12.002; Iskit S, 2015, ONCOTARGET, V6, P43146, DOI 10.18632/oncotarget.6454; Jiang XY, 2020, MOL BIOL REP, V47, P737, DOI 10.1007/s11033-019-05123-9; Jin Y, 2011, J BIOL CHEM, V286, P40104, DOI 10.1074/jbc.C111.296707; Kamide D, 2016, CANCER SCI, V107, P666, DOI 10.1111/cas.12914; Kong XJ, 2017, NATURE, V550, P270, DOI 10.1038/nature24037; Kroger C, 2019, MICROBIOL RESOUR ANN, V8, DOI 10.1128/MRA.01700-18; Kurimchak AM, 2019, MOL CANCER RES, V17, P1721, DOI 10.1158/1541-7786.MCR-18-1332; Lau EYT, 2016, CELL REP, V15, P1175, DOI 10.1016/j.celrep.2016.04.019; Lee MH, 2020, AM J TRANSL RES, V12, P409; Leveille N, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7520; Li MM, 2012, MOL CELL, V46, P30, DOI 10.1016/j.molcel.2012.01.020; Liu H, 2015, CARCINOGENESIS, V36, P459, DOI 10.1093/carcin/bgv017; Liu WJ, 2017, SCI REP-UK, V7, DOI 10.1038/srep41737; Liu XF, 2016, CELL REP, V14, P1169, DOI 10.1016/j.celrep.2015.12.104; Lockwood WW, 2012, P NATL ACAD SCI USA, V109, P19408, DOI 10.1073/pnas.1216363109; Loven J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036; Luo YP, 2010, ONCOGENE, V29, P662, DOI 10.1038/onc.2009.308; Luo YP, 2003, P NATL ACAD SCI USA, V100, P8850, DOI 10.1073/pnas.1033132100; Luther J, 2011, J CELL SCI, V124, P1465, DOI 10.1242/jcs.079855; Maurus K, 2017, ONCOGENE, V36, P5110, DOI 10.1038/onc.2017.135; Moquet-Torcy G, 2014, NUCLEIC ACIDS RES, V42, P11011, DOI 10.1093/nar/gku814; Natoli G, 2012, ANNU REV GENET, V46, P1, DOI 10.1146/annurev-genet-110711-155459; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; Nikulenkov F, 2012, CELL DEATH DIFFER, V19, P1992, DOI 10.1038/cdd.2012.89; Obenauf AC, 2015, NATURE, V520, P368, DOI 10.1038/nature14336; Qiao YC, 2015, ONCOTARGET, V6, P7804, DOI 10.18632/oncotarget.3158; Ramos-Nino ME, 2008, AM J RESP CELL MOL, V38, P209, DOI 10.1165/rcmb.2007-0206OC; Ramos-Nino ME, 2003, CANCER RES, V63, P3539; Rattanasinchai C, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.44; Roman M, 2019, CANCER RES, V79, P625, DOI 10.1158/0008-5472.CAN-18-1479; Sayan AE, 2012, ONCOGENE, V31, P1493, DOI 10.1038/onc.2011.336; Shi J, 2014, CANCER CELL, V25, P210, DOI 10.1016/j.ccr.2014.01.028; Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020; Shin S, 2007, CANCER RES, V67, P7572, DOI 10.1158/0008-5472.CAN-06-4652; Stinson S, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001538; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Sundqvist A, 2013, ONCOGENE, V32, P3606, DOI 10.1038/onc.2012.370; Tam WL, 2013, CANCER CELL, V24, P347, DOI 10.1016/j.ccr.2013.08.005; Tolza C, 2019, MOL CANCER RES, V17, P1999, DOI 10.1158/1541-7786.MCR-19-0036; Toyozumi T, 2017, ANN SURG ONCOL, V24, P3446, DOI 10.1245/s10434-016-5666-5; Tulchinsky E, 2019, BBA-REV CANCER, V1871, P29, DOI 10.1016/j.bbcan.2018.10.003; Tulchinsky E, 2014, ONCOTARGET, V5, P1; Vallejo A, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14294; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Walia V, 2012, ONCOGENE, V31, P2237, DOI 10.1038/onc.2011.392; Walia V, 2009, CANCER RES, V69, P6624, DOI 10.1158/0008-5472.CAN-08-4101; Wang QS, 2010, CELL RES, V20, P701, DOI 10.1038/cr.2010.52; Wang TY, 2019, ONCOGENE, V38, P4932, DOI 10.1038/s41388-019-0763-0; Wu J, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0650-6; Wu JM, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.289; Wu JM, 2012, CARCINOGENESIS, V33, P519, DOI 10.1093/carcin/bgr304; Xiao SS, 2015, INT J ONCOL, V46, P1677, DOI 10.3892/ijo.2015.2873; Yang J, 2014, ONCOGENE, V33, P3014, DOI 10.1038/onc.2013.258; Yang LQ, 2006, CELL, V127, P139, DOI 10.1016/j.cell.2006.08.036; Yang S, 2013, ONCOGENE, V32, P4294, DOI 10.1038/onc.2012.432; Zanconato F, 2018, NAT MED, V24, P1599, DOI 10.1038/s41591-018-0158-8; Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216; Zhang K, 2017, ONCOGENE, V36, P5681, DOI 10.1038/onc.2017.177; Zhang L, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20160643; Zhang N, 2016, ONCOTARGETS THER, V9, P6597, DOI 10.2147/OTT.S114609; Zhang XL, 2016, ONCOTARGET, V7, P34371, DOI 10.18632/oncotarget.9110; Zhao CY, 2014, CANCER RES, V74, P3983, DOI 10.1158/0008-5472.CAN-13-3396; Zhong GW, 2016, ONCOL REP, V35, P447, DOI 10.3892/or.2015.4395; Zhou JH, 2017, NAT REV DRUG DISCOV, V16, P181, DOI 10.1038/nrd.2016.199; Zippo A, 2009, CELL, V138, P1122, DOI 10.1016/j.cell.2009.07.031	106	24	24	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	23					4491	4506		10.1038/s41388-020-1306-4	http://dx.doi.org/10.1038/s41388-020-1306-4		MAY 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LU5ZF	32385348				2022-12-28	WOS:000531151100001
J	Adamski, V; Hattermann, K; Kubelt, C; Cohrs, G; Lucius, R; Synowitz, M; Sebens, S; Held-Feindt, J				Adamski, Vivian; Hattermann, Kirsten; Kubelt, Carolin; Cohrs, Gesa; Lucius, Ralph; Synowitz, Michael; Sebens, Susanne; Held-Feindt, Janka			Entry and exit of chemotherapeutically-promoted cellular dormancy in glioblastoma cells is differentially affected by the chemokines CXCL12, CXCL16, and CX3CL1	ONCOGENE			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; INTRATUMOR HETEROGENEITY; ANGIOGENIC SWITCH; TUMOR DORMANCY; RECEPTOR CXCR7; TEMOZOLOMIDE; MECHANISMS; EXPRESSION; ESCAPE; PROLIFERATION	Glioblastoma multiforme (GBM) is a malignant brain tumor that evades therapy regimens. Since cellular dormancy is one strategy for surviving, and since chemokines determine the environmental conditions in which dormancy occurs, we investigated how chemokines affect temozolomide (TMZ)-promoted cellular dormancy entry and exit in GBM cells. TMZ administration over ten days promoted cellular dormancy entry, whereas discontinuing TMZ for a further 15 days resulted in resumption of proliferation. Co-administration of a chemokine cocktail containing CXCL12, CXCL16, and CX3CL1 resulted in both delayed entry and exit from cellular dormancy. A microarray-based transcriptome analysis in LN229 GBM cells revealed that cellular dormancy entry was characterized by an increased expression of CCL2 and SAA2, while THSD4, FSTL3, and VEGFC were upregulated during dormancy exit. Co-stimulation with the chemokine cocktail reduced upregulation of identified genes. After verifying the appearance of identified genes in human GBM primary cultures and ex vivo samples, we clarified whether each chemokine alone impacts cellular dormancy mechanisms using specific antagonists and selective CRISPR/Cas9 clones. While expression of CCL2 and SAA2 in LN229 cells was altered by the CXCL12-CXCR4-CXCR7 axis, CXCL16 and CX3CL1 contributed to reduced upregulation of THSD4 and, to a weaker extent, of VEGFC. The influence on FSTL3 expression depended on the entire chemokine cocktail. Effects of chemokines on dormancy entry and exit-associated genes were detectable in human GBM primary cells, too, even if in a more complex, cell-specific manner. Thus, chemokines play a significant role in the regulation of TMZ-promoted cellular dormancy in GBMs.	[Adamski, Vivian; Kubelt, Carolin; Cohrs, Gesa; Synowitz, Michael; Held-Feindt, Janka] Univ Med Ctr Schleswig Holstein UKSH, Dept Neurosurg, Campus Kiel, D-24105 Kiel, Germany; [Hattermann, Kirsten; Lucius, Ralph] Univ Kiel, Dept Anat, D-24118 Kiel, Germany; [Sebens, Susanne] Univ Kiel, Inst Expt Canc Res, Campus Kiel, D-24105 Kiel, Germany; [Sebens, Susanne] Univ Med Ctr Schleswig Holstein UKSH, Campus Kiel, D-24105 Kiel, Germany	University of Kiel; Schleswig Holstein University Hospital; University of Kiel; University of Kiel; University of Kiel; Schleswig Holstein University Hospital	Held-Feindt, J (corresponding author), Univ Med Ctr Schleswig Holstein UKSH, Dept Neurosurg, Campus Kiel, D-24105 Kiel, Germany.	Janka.Held-Feindt@uksh.de	Sebens, Susanne/C-1222-2010; Hattermann, Kirsten/E-8043-2010		German Research Foundation (DFG) as part of the Research Training Group "Materials4Brain" [RTG2154]; University Medical Center Schleswig-Holstein, UKSH ("Anschubforderung 2020"); Projekt DEAL	German Research Foundation (DFG) as part of the Research Training Group "Materials4Brain"(German Research Foundation (DFG)); University Medical Center Schleswig-Holstein, UKSH ("Anschubforderung 2020"); Projekt DEAL	We thank Fereshteh Ebrahim, Brigitte Rehmke, and Judith Becker for expert technical assistance. This work was funded by the German Research Foundation (DFG) as part of the Research Training Group "Materials4Brain" (RTG2154; P8) and a sponsorship of the University Medical Center Schleswig-Holstein, UKSH ("Anschubforderung 2020" given to JHF). Open access funding was provided by Projekt DEAL.	Adamski V, 2017, ONCOTARGET, V8, P108064, DOI 10.18632/oncotarget.22514; Adamski V, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071468; Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256; Almog N, 2010, CANCER LETT, V294, P139, DOI 10.1016/j.canlet.2010.03.004; Almog N, 2009, CANCER RES, V69, P836, DOI 10.1158/0008-5472.CAN-08-2590; Ammerpohl O., 2017, ECOLOGY EVOLUTION CA, P235, DOI [10.1016/B978-0-12-804310-3.00020-X, DOI 10.1016/B978-0-12-804310-3.00020-X]; Bai D, 2009, INT J CANCER, V125, P2863, DOI 10.1002/ijc.24748; Bartholin L, 2007, GENE, V393, P153, DOI 10.1016/j.gene.2007.02.007; Bonavia R, 2011, CANCER RES, V71, P4055, DOI 10.1158/0008-5472.CAN-11-0153; Bowman RL, 2014, IMMUNOTHERAPY-UK, V6, P663, DOI [10.2217/IMT.14.48, 10.2217/imt.14.48]; Bruyere C, 2011, INT J ONCOL, V38, P1453, DOI 10.3892/ijo.2011.964; Chen L, 2018, INT J OPHTHALMOL-CHI, V11, P216, DOI 10.18240/ijo.2018.02.06; Christofides A, 2015, CYTOKINE, V71, P377, DOI 10.1016/j.cyto.2014.09.008; Clark AM, 2017, LAB CHIP, V17, P156, DOI 10.1039/c6lc01171c; Cohen H, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0464-0; Coppola D, 2014, J GERIATR ONCOL, V5, P389, DOI 10.1016/j.jgo.2014.08.003; De Cock JM, 2016, CANCER RES, V76, P6778, DOI 10.1158/0008-5472.CAN-16-0608; DESBAILLETS I, 1994, INT J CANCER, V58, P240, DOI 10.1002/ijc.2910580216; Ehtesham M, 2013, J NEURO-ONCOL, V113, P153, DOI 10.1007/s11060-013-1108-4; Endaya BB, 2016, MOL ONCOL, V10, P126, DOI 10.1016/j.molonc.2015.09.001; Facci L, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1205-6; Goffart N, 2017, NEURO-ONCOLOGY, V19, P66, DOI 10.1093/neuonc/now136; Guo YC, 2017, AM J PATHOL, V187, P1736, DOI 10.1016/j.ajpath.2017.04.007; Hasan T, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1387-6; Hattermann K, 2008, MOL CELL NEUROSCI, V39, P133, DOI 10.1016/j.mcn.2008.03.009; Hattermann K, 2016, CELL COMMUN SIGNAL, V14, DOI 10.1186/s12964-016-0149-7; Hattermann K, 2016, ELIFE, V5, DOI 10.7554/eLife.10820; Hattermann K, 2013, J NEUROIMMUNOL, V260, P47, DOI 10.1016/j.jneuroim.2013.04.006; Hattermann K, 2012, ONCOL REP, V27, P1348, DOI 10.3892/or.2012.1674; Hattermann K, 2010, CANCER RES, V70, P3299, DOI 10.1158/0008-5472.CAN-09-3642; Held-Feindt J, 2006, INT J CANCER, V118, P55, DOI 10.1002/ijc.21258; Held-Feindt J, 2010, EXP CELL RES, V316, P1553, DOI 10.1016/j.yexcr.2010.02.018; Hirose Y, 2001, CANCER RES, V61, P1957; Jin X, 2017, CELL PHYSIOL BIOCHEM, V44, P1616, DOI 10.1159/000485759; Johnson BE, 2014, SCIENCE, V343, P189, DOI 10.1126/science.1239947; Khazali AS, 2018, BRIT J CANCER, V118, P566, DOI 10.1038/bjc.2017.414; Lacalle RA, 2017, INT REV CEL MOL BIO, V331, P181, DOI 10.1016/bs.ircmb.2016.09.011; Lee SY, 2016, GENES DIS, V3, P198, DOI 10.1016/j.gendis.2016.04.007; Li JH, 2017, CYTOKINE, V94, P45, DOI 10.1016/j.cyto.2017.04.010; Liu Y, 2015, ANTICANCER RES, V35, P53; Magnus N, 2013, J THROMB HAEMOST, V11, P1197, DOI 10.1111/jth.12242; Magnus N, 2014, THROMB RES, V133, pS1, DOI 10.1016/S0049-3848(14)50001-1; Magnus N, 2014, P NATL ACAD SCI USA, V111, P3544, DOI 10.1073/pnas.1314118111; Malle E, 2009, CELL MOL LIFE SCI, V66, P9, DOI 10.1007/s00018-008-8321-x; Nagarsheth N, 2017, NAT REV IMMUNOL, V17, P559, DOI 10.1038/nri.2017.49; Naumov GN, 2006, JNCI-J NATL CANCER I, V98, P316, DOI 10.1093/jnci/djj068; Nie E, 2019, ONCOGENE, V38, P2706, DOI 10.1038/s41388-018-0596-2; Nobutani K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130032; Oh JW, 2001, J IMMUNOL, V166, P2695, DOI 10.4049/jimmunol.166.4.2695; Perazzoli G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140131; Quail DF, 2017, CANCER CELL, V31, P326, DOI 10.1016/j.ccell.2017.02.009; Ray A, 2002, MOL CELL BIOL, V22, P1027, DOI 10.1128/MCB.22.4.1027-1035.2002; Resende R. R., 2013, TRENDS STEM CELL PRO, P339; Satchi-Fainaro R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044395; Schols D, 1997, J EXP MED, V186, P1383, DOI 10.1084/jem.186.8.1383; Senft D, 2016, PIGM CELL MELANOMA R, V29, P27, DOI 10.1111/pcmr.12432; Song YR, 2013, P NATL ACAD SCI USA, V110, P17933, DOI 10.1073/pnas.1317026110; Sosa MS, 2011, CLIN CANCER RES, V17, P5850, DOI 10.1158/1078-0432.CCR-10-2574; Sottoriva A, 2013, P NATL ACAD SCI USA, V110, P4009, DOI 10.1073/pnas.1219747110; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Tabouret E, 2015, ONCOTARGET, V6, P11664, DOI 10.18632/oncotarget.3256; Tiram G, 2018, FASEB J, V1, pfj201701568R; Tivari S, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0259-5; Tong LQ, 2018, ONCOL REP, V40, P463, DOI 10.3892/or.2018.6425; Vakilian A, 2017, NEUROCHEM INT, V103, P1, DOI 10.1016/j.neuint.2016.12.013; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Yao M, 2016, ADV CANCER RES, V132, P265, DOI 10.1016/bs.acr.2016.05.005; Yeh AC, 2015, CANCER RES, V75, P5014, DOI 10.1158/0008-5472.CAN-15-1370; Zeng LC, 2016, ONCOL LETT, V12, P815, DOI 10.3892/ol.2016.4690; Zhang ZJ, 2012, CELL MOL NEUROBIOL, V32, P1003, DOI 10.1007/s10571-012-9816-4	70	16	16	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	22					4421	4435		10.1038/s41388-020-1302-8	http://dx.doi.org/10.1038/s41388-020-1302-8		APR 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LR9IT	32346064	Green Published, hybrid			2022-12-28	WOS:000529462400001
J	Kim, M; Morales, LD; Lee, CJ; Olivarez, SA; Kim, WJ; Hernandez, J; Mummidi, S; Jenkinson, C; Tsin, AT; Jang, IS; Slaga, TJ; Kim, DJ				Kim, Mihwa; Morales, Liza D.; Lee, Cheol Jung; Olivarez, Serena A.; Kim, Woo Jin; Hernandez, Joselin; Mummidi, Srinivas; Jenkinson, Christopher; Tsin, Andrew T.; Jang, Ik-Soon; Slaga, Thomas J.; Kim, Dae Joon			Overexpression of TC-PTP in murine epidermis attenuates skin tumor formation	ONCOGENE			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; KERATINOCYTE SURVIVAL; CELL-CYCLE; ACTIVATION; STAT3; CARCINOGENESIS; EXPRESSION; APOPTOSIS; VARIANTS; PATHWAY	T-cell protein tyrosine phosphatase (TC-PTP), encoded by Ptpn2, has been shown to function as a tumor suppressor during skin carcinogenesis. In the current study, we generated a novel epidermal-specific TC-PTP-overexpressing (K5HA.Ptpn2) mouse model to show that TC-PTP contributes to the attenuation of chemically induced skin carcinogenesis through the synergistic regulation of STAT1, STAT3, STAT5, and PI3K/AKT signaling. We found overexpression of TC-PTP increased epidermal sensitivity to DMBA-induced apoptosis and it decreased TPA-mediated hyperproliferation, coinciding with reduced epidermal thickness. Inhibition of STAT1, STAT3, STAT5, or AKT reversed the effects of TC-PTP overexpression on epidermal survival and proliferation. Mice overexpressing TC-PTP in the epidermis developed significantly reduced numbers of tumors during skin carcinogenesis and presented a prolonged latency of tumor initiation. Examination of human papillomas and squamous cell carcinomas (SCCs) revealed that TC-PTP expression was significantly reduced and TC-PTP expression was inversely correlated with the increased grade of SCCs. Our findings demonstrate that TC-PTP is a potential therapeutic target for the prevention of human skin cancer given that it is a major negative regulator of oncogenic signaling.	[Kim, Mihwa; Lee, Cheol Jung; Olivarez, Serena A.; Tsin, Andrew T.; Kim, Dae Joon] Univ Texas Rio Grande Valley, Sch Med, Dept Mol Sci, Edinburg, TX 78541 USA; [Morales, Liza D.; Hernandez, Joselin; Mummidi, Srinivas; Jenkinson, Christopher; Kim, Dae Joon] Univ Texas Rio Grande Valley, Sch Med, Dept Human Genet, Edinburg, TX 78541 USA; [Kim, Woo Jin] Univ Texas Rio Grande Valley, Sch Math & Stat Sci, Coll Sci, Edinburg, TX USA; [Jang, Ik-Soon] Korea Basic Sci Inst, Div Bioconvergence Anal, Daejeon 305333, South Korea; [Slaga, Thomas J.] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, Dept Pharmacol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Rio Grande Valley; University of Texas System; University of Texas Rio Grande Valley; University of Texas System; University of Texas Rio Grande Valley; Korea Basic Science Institute (KBSI); University of Texas System; University of Texas Health San Antonio	Kim, DJ (corresponding author), Univ Texas Rio Grande Valley, Sch Med, Dept Mol Sci, Edinburg, TX 78541 USA.; Kim, DJ (corresponding author), Univ Texas Rio Grande Valley, Sch Med, Dept Human Genet, Edinburg, TX 78541 USA.	dae.kim@utrgv.edu	Kim, Mihwa/AAN-5784-2020	Hernandez Ruiz, Joselin/0000-0002-0571-2563; Morales, Liza/0000-0003-1056-9121; KIM, DAE/0000-0002-7977-9955	NIH/NIEHS [ES022250]; NIH/NIAID [AI119131]	NIH/NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank H. Lee for technical assistance. This work was supported by NIH/NIEHS ES022250 (to D.J. Kim) and NIH/NIAID AI119131 (to S. Mummidi).	Abel EL, 2009, NAT PROTOC, V4, P1350, DOI 10.1038/nprot.2009.120; Agrawal S, 2002, MOL CELL BIOL, V22, P1981, DOI 10.1128/MCB.22.7.1981-1992.2002; Baek M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0781-9; Bourdeau A, 2005, CURR OPIN CELL BIOL, V17, P203, DOI 10.1016/j.ceb.2005.02.001; Bozeman R, 2015, MOL CARCINOGEN, V54, P642, DOI 10.1002/mc.22132; Casaletto JB, 2012, NAT REV CANCER, V12, P386, DOI 10.1038/nrc3277; Chan KS, 2004, CANCER RES, V64, P2382, DOI 10.1158/0008-5472.CAN-03-3197; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; Cuppen E, 1999, J CELL SCI, V112, P3299; DeVries TA, 2004, J BIOL CHEM, V279, P45603, DOI 10.1074/jbc.M407448200; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; DLUGOSZ AA, 1995, METHOD ENZYMOL, V254, P3; Dube N, 2005, BBA-PROTEINS PROTEOM, V1754, P108, DOI 10.1016/j.bbapap.2005.07.030; Hendriks WJAJ, 2008, FEBS J, V275, P816, DOI 10.1111/j.1742-4658.2008.06249.x; Hendriks WJAJ, 2013, BBA-MOL BASIS DIS, V1832, P1673, DOI 10.1016/j.bbadis.2013.05.022; HENNINGS H, 1993, CARCINOGENESIS, V14, P2353, DOI 10.1093/carcin/14.11.2353; Hunter T, 2009, CURR OPIN CELL BIOL, V21, P140, DOI 10.1016/j.ceb.2009.01.028; Kamatkar S, 1996, J BIOL CHEM, V271, P26755, DOI 10.1074/jbc.271.43.26755; Karlsson E, 2015, BREAST CANCER RES TR, V153, P31, DOI 10.1007/s10549-015-3516-y; Kim DJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010290; Kim M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092708; Kim M, 2017, ONCOTARGET, V8, P90674, DOI 10.18632/oncotarget.21794; Kleppe M, 2010, NAT GENET, V42, P530, DOI 10.1038/ng.587; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Lee CF, 2009, WORLD J GASTROENTERO, V15, P356, DOI 10.3748/wjg.15.356; Lee H, 2017, SCI REP-UK, V7, DOI 10.1038/srep45077; Lee H, 2015, J BIOL CHEM, V290, P13, DOI 10.1074/jbc.M114.611681; Lim WA, 2010, CELL, V142, P661, DOI 10.1016/j.cell.2010.08.023; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Manguso RT, 2017, NATURE, V547, P413, DOI 10.1038/nature23270; Martini M, 2014, ANN MED, V46, P372, DOI 10.3109/07853890.2014.912836; MOSINGER B, 1992, P NATL ACAD SCI USA, V89, P499, DOI 10.1073/pnas.89.2.499; Shields BJ, 2013, MOL CELL BIOL, V33, P557, DOI 10.1128/MCB.01016-12; TILLMANN U, 1994, MOL CELL BIOL, V14, P3030, DOI 10.1128/MCB.14.5.3030; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Xu D, 2008, FRONT BIOSCI-LANDMRK, V13, P4925, DOI 10.2741/3051; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963; Zimmerman MA, 2012, CANCER RES, V72, P4724, DOI 10.1158/0008-5472.CAN-12-1347	38	6	6	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	21					4241	4256		10.1038/s41388-020-1282-8	http://dx.doi.org/10.1038/s41388-020-1282-8		APR 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LQ2DH	32286519	Green Submitted, Green Accepted			2022-12-28	WOS:000526237900004
J	Wang, HG; Zhang, S; Song, LY; Qu, M; Zou, ZH				Wang, Hongge; Zhang, Shan; Song, Liyan; Qu, Meng; Zou, Zhihua			Synergistic lethality between PARP-trapping and alantolactone-induced oxidative DNA damage in homologous recombination-proficient cancer cells	ONCOGENE			English	Article							REPAIR DEFECT; HISTONE H2AX; LUNG-CANCER; INHIBITION; STABILITY; APOPTOSIS; STRESS; METABOLISM; RESISTANCE; BRCA1	PARP1 and PARP2 play critical roles in regulating DNA repair and PARP inhibitors have been approved for the treatment of BRCA1/2-mutated ovarian and breast cancers. It has long been known that PARP inhibition sensitizes cancer cells to DNA-damaging cytotoxic agents independent of BRCA status, however, clinical use of PARP inhibitors in combination with DNA-damaging chemotherapy is limited by the more-than-additive cytotoxicity. The natural compound alantolactone (ATL) inhibits the thioredoxin reductase to induce ROS accumulation and oxidative DNA damage selectively in cancer cells. Here, we showed that nontoxic doses of ATL markedly synergized with the PARP inhibitor olaparib to result in synthetic lethality irrespective of homologous recombination status. Synergistic cytotoxicity was seen in cancer but not noncancerous cells and was reduced by the ROS inhibitor NAC or knockdown of OGG1, demonstrating that the cytotoxicity resulted from the repair of ATL-induced oxidative DNA damage. PARP1 knockdown suppressed the synergistic lethality and olaparib was much more toxic than veliparib when combined with ATL, suggesting PARP-trapping as the primary inducer of cytotoxicity. Consistently, combined use of ATL and olaparib caused intense signs of replication stress and formation of double strand DNA breaks, leading to S and G(2) arrest followed by apoptosis. In vivo, the combination effectively induced regression of tumor xenografts, while either agent alone had no effect. Hence, PARP trapping combined with specific pro-oxidative agents may provide safe and effective ways to broaden the therapeutic potential of PARP inhibitors.	[Wang, Hongge; Zhang, Shan; Song, Liyan; Qu, Meng; Zou, Zhihua] Jilin Univ, Sch Life Sci, Key Lab Mol Enzymol & Engn,Minist Educ, Dept Cell Biol & Biophys,Natl Engn Lab Aids Vacci, Changchun, Peoples R China	Jilin University	Zou, ZH (corresponding author), Jilin Univ, Sch Life Sci, Key Lab Mol Enzymol & Engn,Minist Educ, Dept Cell Biol & Biophys,Natl Engn Lab Aids Vacci, Changchun, Peoples R China.	zouzh@jlu.edu.cn	wang, hg/AAE-2324-2021		Key Research and Development Program of Jilin Province [20170204025YY]; Natural Science Foundation of Jilin Province [20180101237JC]	Key Research and Development Program of Jilin Province; Natural Science Foundation of Jilin Province	This work was supported by grants from the Key Research and Development Program of Jilin Province (20170204025YY) and the Natural Science Foundation of Jilin Province (20180101237JC).	Abbotts R, 2017, FREE RADICAL BIO MED, V107, P228, DOI 10.1016/j.freeradbiomed.2016.11.039; AbdulSalam SF, 2016, BIOCHEMISTRY-US, V55, P5341, DOI 10.1021/acs.biochem.6b00703; Brown JS, 2017, CANCER DISCOV, V7, P20, DOI 10.1158/2159-8290.CD-16-0860; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Bryant HE, 2009, EMBO J, V28, P2601, DOI 10.1038/emboj.2009.206; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Chaudhuri AR, 2017, NAT REV MOL CELL BIO, V18, P610, DOI 10.1038/nrm.2017.53; Chou T-C., 2018, SYNERGIE, V7, P49, DOI [DOI 10.1016/J.SYNRES.2018.04.001, 10.1016/j.synres.2018.04.001]; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Davalli P, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/2389523; de la Vega MR, 2018, CANCER CELL, V34, P21, DOI 10.1016/j.ccell.2018.03.022; de Murcia JMN, 2003, EMBO J, V22, P2255, DOI 10.1093/emboj/cdg206; Deben C, 2016, CANCER LETT, V375, P313, DOI 10.1016/j.canlet.2016.03.017; Ding YS, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040558; El-Khamisy SF, 2003, NUCLEIC ACIDS RES, V31, P5526, DOI 10.1093/nar/gkg761; Elstrodt F, 2006, CANCER RES, V66, P41, DOI 10.1158/0008-5472.CAN-05-2853; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Graeser M, 2010, CLIN CANCER RES, V16, P6159, DOI 10.1158/1078-0432.CCR-10-1027; Hans F, 2001, ONCOGENE, V20, P3021, DOI 10.1038/sj.onc.1204326; Hanzlikova H, 2019, TRENDS GENET, V35, P412, DOI 10.1016/j.tig.2019.03.008; Harris IS, 2015, CANCER CELL, V27, P211, DOI 10.1016/j.ccell.2014.11.019; He W, 2019, FREE RADICAL RES, V53, P104, DOI 10.1080/10715762.2018.1558448; Hsu PC, 2019, ONCOGENE, V38, P1166, DOI 10.1038/s41388-018-0506-7; Huang XM, 2016, CANCER CELL, V30, P940, DOI 10.1016/j.ccell.2016.11.006; Konstantinopoulos PA, 2015, CANCER DISCOV, V5, P1137, DOI 10.1158/2159-8290.CD-15-0714; Le Gal K, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad3740; Lee JY, 2016, BIOPHARM DRUG DISPOS, V37, P156, DOI 10.1002/bdd.2005; Liu JL, 2018, INT J MOL MED, V42, P1847, DOI 10.3892/ijmm.2018.3751; Liu Q, 2018, ONCOGENE, V37, P2793, DOI 10.1038/s41388-018-0130-6; Lord CJ, 2017, SCIENCE, V355, P1152, DOI 10.1126/science.aam7344; Lord CJ, 2016, NAT REV CANCER, V16, P110, DOI 10.1038/nrc.2015.21; Marcar L, 2019, CELL REP, V27, P3422, DOI 10.1016/j.celrep.2019.05.058; Markkanen E, 2017, DNA REPAIR, V59, P82, DOI 10.1016/j.dnarep.2017.09.007; Marzo T, 2017, ACS MED CHEM LETT, V8, P997, DOI 10.1021/acsmedchemlett.7b00162; Michels J, 2013, CANCER RES, V73, P2271, DOI 10.1158/0008-5472.CAN-12-3000; Moloney JN, 2018, SEMIN CELL DEV BIOL, V80, P50, DOI 10.1016/j.semcdb.2017.05.023; Murai J, 2014, J PHARMACOL EXP THER, V349, P408, DOI 10.1124/jpet.113.210146; Murai J, 2012, CANCER RES, V72, P5588, DOI 10.1158/0008-5472.CAN-12-2753; Nickoloff JA, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx059; PG P, 2019, CLIN CANCER RES, V25, P3759, DOI [10.1158/1078-0432.CCR-18-0968, DOI 10.1158/1078-0432.CCR-18-0968]; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Pilie PG, 2019, NAT REV CLIN ONCOL, V16, P81, DOI 10.1038/s41571-018-0114-z; Piskounova E, 2015, NATURE, V527, P186, DOI 10.1038/nature15726; Pommier Y, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf9246; Pulliam N, 2018, CLIN CANCER RES, V24, P3163, DOI 10.1158/1078-0432.CCR-18-0204; Reynolds P, 2015, NUCLEIC ACIDS RES, V43, P4028, DOI 10.1093/nar/gkv250; Ronson GE, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03159-2; Saikolappan S, 2019, CANCER LETT, V452, P132, DOI 10.1016/j.canlet.2019.03.020; Sarkaria JN, 2008, CLIN CANCER RES, V14, P2900, DOI 10.1158/1078-0432.CCR-07-1719; Sayin VI, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007653; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Struthers L, 1998, ANAL BIOCHEM, V255, P20, DOI 10.1006/abio.1997.2354; Toledo LI, 2013, CELL, V155, P1088, DOI 10.1016/j.cell.2013.10.043; Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009; Trucco C, 1998, NUCLEIC ACIDS RES, V26, P2644, DOI 10.1093/nar/26.11.2644; Venkitaraman AR, 2014, SCIENCE, V343, P1470, DOI 10.1126/science.1252230; Wang K, 2019, TRENDS BIOCHEM SCI, V44, P401, DOI 10.1016/j.tibs.2019.01.001; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Woodhouse BC, 2008, DNA REPAIR, V7, P932, DOI 10.1016/j.dnarep.2008.03.017; Xu XG, 2019, LIFE SCI, V227, P153, DOI 10.1016/j.lfs.2019.04.034; Yang YG, 2004, ONCOGENE, V23, P3872, DOI 10.1038/sj.onc.1207491; Yap Timothy A, 2019, Am Soc Clin Oncol Educ Book, V39, P185, DOI 10.1200/EDBK_238473; Yin CT, 2019, J CELL MOL MED, V23, P2194, DOI 10.1111/jcmm.14139; Zhang JM, 2016, BIOCHEM PHARMACOL, V102, P34, DOI 10.1016/j.bcp.2015.12.004; Zhao P, 2015, J BIOCHEM MOL TOXIC, V29, P199, DOI 10.1002/jbt.21685; Zhou BL, 2018, J CHROMATOGR B, V1072, P370, DOI 10.1016/j.jchromb.2017.11.039	67	29	29	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	14					2905	2920		10.1038/s41388-020-1191-x	http://dx.doi.org/10.1038/s41388-020-1191-x		FEB 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KZ2VB	32029902	hybrid, Green Published			2022-12-28	WOS:000511540800002
J	Castillo, L; Young, AIJ; Mawson, A; Schafranek, P; Steinmann, AM; Nessem, D; Parkin, A; Johns, A; Chou, A; Law, AMK; Lucas, MC; Murphy, KJ; Deng, N; Gallego-Ortega, D; Caldon, CE; Timpson, P; Pajic, M; Ormandy, CJ; Oakes, SR				Castillo, Lesley; Young, Adelaide I. J.; Mawson, Amanda; Schafranek, Pia; Steinmann, Angela M.; Nessem, Danielle; Parkin, Ashleigh; Johns, Amber; Chou, Angela; Law, Andrew M. K.; Lucas, Morghan C.; Murphy, Kendelle J.; Deng, Niantao; Gallego-Ortega, David; Caldon, Catherine E.; Timpson, Paul; Pajic, Marina; Ormandy, Christopher J.; Oakes, Samantha R.		Australian Pancreatic Canc Genome	MCL-1 antagonism enhances the anti-invasive effects of dasatinib in pancreatic adenocarcinoma	ONCOGENE			English	Article							SRC; CANCER; SURVIVAL; FAMILY; EXPRESSION; INHIBITOR; MIGRATION; THERAPY; BCL-2	Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest malignancies. It is phenotypically heterogeneous with a highly unstable genome and provides few common therapeutic targets. We found that MCL1, Cofilin1 (CFL1) and SRC mRNA were highly expressed by a wide range of these cancers, suggesting that a strategy of dual MCL-1 and SRC inhibition might be efficacious for many patients. Immunohistochemistry revealed that MCL-1 protein was present at high levels in 94.7% of patients in a cohort of PDACs from Australian Pancreatic Genome Initiative (APGI). High MCL1 and Cofilin1 mRNA expression was also strongly predictive of poor outcome in the TCGA dataset and in the APGI cohort. In culture, MCL-1 antagonism reduced the level of the cytoskeletal remodeling protein Cofilin1 and phosphorylated SRC on the active Y416 residue, suggestive of reduced invasive capacity. The MCL-1 antagonist S63845 synergized with the SRC kinase inhibitor dasatinib to reduce cell viability and invasiveness through 3D-organotypic matrices. In preclinical murine models, this combination reduced primary tumor growth and liver metastasis of pancreatic cancer xenografts. These data suggest that MCL-1 antagonism, while reducing cell viability, may have an additional benefit in increasing the antimetastatic efficacy of dasatinib for the treatment of PDAC.	[Castillo, Lesley; Young, Adelaide I. J.; Mawson, Amanda; Schafranek, Pia; Steinmann, Angela M.; Nessem, Danielle; Parkin, Ashleigh; Johns, Amber; Law, Andrew M. K.; Lucas, Morghan C.; Murphy, Kendelle J.; Deng, Niantao; Gallego-Ortega, David; Caldon, Catherine E.; Timpson, Paul; Pajic, Marina; Ormandy, Christopher J.; Oakes, Samantha R.] Garvan Inst Med Res, Canc Res Div, 384 Victoria St, Darlinghurst, NSW 2010, Australia; [Castillo, Lesley; Young, Adelaide I. J.; Mawson, Amanda; Schafranek, Pia; Steinmann, Angela M.; Nessem, Danielle; Parkin, Ashleigh; Johns, Amber; Law, Andrew M. K.; Lucas, Morghan C.; Murphy, Kendelle J.; Deng, Niantao; Gallego-Ortega, David; Caldon, Catherine E.; Timpson, Paul; Pajic, Marina; Ormandy, Christopher J.; Oakes, Samantha R.] Kinghorn Canc Ctr, 384 Victoria St, Darlinghurst, NSW 2010, Australia; [Johns, Amber; Deng, Niantao; Gallego-Ortega, David; Caldon, Catherine E.; Timpson, Paul; Pajic, Marina; Ormandy, Christopher J.; Oakes, Samantha R.] UNSW Med, St Vincents Clin Sch, 384 Victoria St, Kensington, NSW 2052, Australia; [Chou, Angela] Univ Sydney, Camperdown, NSW 2006, Australia	Garvan Institute of Medical Research; University of Sydney	Oakes, SR (corresponding author), Garvan Inst Med Res, Canc Res Div, 384 Victoria St, Darlinghurst, NSW 2010, Australia.; Oakes, SR (corresponding author), Kinghorn Canc Ctr, 384 Victoria St, Darlinghurst, NSW 2010, Australia.; Oakes, SR (corresponding author), UNSW Med, St Vincents Clin Sch, 384 Victoria St, Kensington, NSW 2052, Australia.	s.oakes@garvan.org.au	Lucas, Morghan C/Y-6452-2019; Gallego-Ortega, David/AAK-9067-2020	Lucas, Morghan C/0000-0001-7654-9137; Gallego-Ortega, David/0000-0002-2347-7835; Herrmann, David/0000-0002-9514-7501; Deng, Niantao/0000-0001-9717-2236; Ormandy, Christopher/0000-0002-2504-7919; Murphy, Angela/0000-0002-8910-7626; Young, Adelaide/0000-0002-5714-0501; Timpson, Paul/0000-0002-5514-7080; Pereira, Brooke/0000-0003-3513-1214; Murphy, Kendelle/0000-0002-3234-3812; Pajic, Marina/0000-0002-3871-3829; Chou, Angela/0000-0001-9212-6927; Oakes, Samantha/0000-0003-1838-2310	Cancer Council NSW; NHMRC Australia; National Breast Cancer Foundation; Cancer Institute NSW; Len Ainsworth Pancreatic Cancer Fellowship; Avner Pancreatic Cancer Foundation; Sutton Motor Pancreatic cancer fund	Cancer Council NSW(Cancer Council New South Wales); NHMRC Australia(National Health and Medical Research Council (NHMRC) of Australia); National Breast Cancer Foundation; Cancer Institute NSW; Len Ainsworth Pancreatic Cancer Fellowship; Avner Pancreatic Cancer Foundation; Sutton Motor Pancreatic cancer fund	This work was supported by grants from the Cancer Council NSW (SRO and CJO), NHMRC Australia (CJO, DGO, PT, MP, and SRO), National Breast Cancer Foundation (ND and CEC), Cancer Institute NSW (DGO, PT, MP), Sutton Motor Pancreatic cancer funding (PT), Len Ainsworth Pancreatic Cancer Fellowship (PT), Avner Pancreatic Cancer Foundation Grant (PT) as well as philanthropic support through the Mostyn Family Foundation (SRO) and Cue Clothing Co. (SRO), Estee Lauder Australia (SRO, DGO and CJO), RT Hall Trust (CJO). We thank Gillian Lehrbach for tissue culture support and Anaiis Zaratzian and Andrew Da Silva for histology services.	Abulwerdi F, 2014, MOL CANCER THER, V13, P565, DOI 10.1158/1535-7163.MCT-12-0767; Adams JM, 2007, CURR OPIN IMMUNOL, V19, P488, DOI 10.1016/j.coi.2007.05.004; Aguirre AJ, 2017, CANCER CELL, V32, P185, DOI 10.1016/j.ccell.2017.07.007; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Booy EP, 2011, ONCOGENE, V30, P2367, DOI 10.1038/onc.2010.616; Bravo-Cordero JJ, 2013, NAT REV MOL CELL BIO, V14, P405, DOI 10.1038/nrm3609; CARDIN DB, 2018, INVEST NEW DRUG, V36, P442, DOI DOI 10.1007/S10637-017-0519-Z; Chee CE, 2013, ONCOLOGIST, V18, P1091, DOI 10.1634/theoncologist.2013-0255; Chou A, 2018, GUT, V67, P2142, DOI 10.1136/gutjnl-2017-315144; Chowdry R.P., 2014, ONCOTARGET, P5, DOI [10.18632/oncotarget.7485, DOI 10.18632/ONCOTARGET.7485]; Creedon Helen, 2012, Critical Reviews in Oncogenesis, V17, P145; Donahue TR, 2012, CLIN CANCER RES, V18, P1352, DOI 10.1158/1078-0432.CCR-11-1539; Duxbury MS, 2004, CLIN CANCER RES, V10, P2307, DOI 10.1158/1078-0432.CCR-1183-3; Evans TRJ, 2017, ANN ONCOL, V28, P354, DOI 10.1093/annonc/mdw607; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Goodwin CM, 2015, CELL DEATH DIFFER, V22, P2098, DOI 10.1038/cdd.2015.73; Johns AL, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0430-4; Jones S, 2009, SCIENCE, V324, P217, DOI 10.1126/science.1171202; Kotschy A, 2016, NATURE, V538, P477, DOI 10.1038/nature19830; Law AMK, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15885-6; Leverson JD, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.561; Lutz MP, 1998, BIOCHEM BIOPH RES CO, V243, P503, DOI 10.1006/bbrc.1997.8043; Miyamoto Y, 1999, ONCOLOGY-BASEL, V56, P73, DOI 10.1159/000011933; Morton JP, 2010, GASTROENTEROLOGY, V139, P292, DOI 10.1053/j.gastro.2010.03.034; Opferman JT, 2016, FEBS J, V283, P2661, DOI 10.1111/febs.13472; Oser M, 2009, J CELL BIOCHEM, V108, P1252, DOI 10.1002/jcb.22372; Patel A, 2016, LIFE SCI, V157, P52, DOI 10.1016/j.lfs.2016.05.036; Quinn BA, 2011, EXPERT OPIN INV DRUG, V20, P1397, DOI 10.1517/13543784.2011.609167; Rawla P, 2019, WORLD J ONCOL, V10, P10, DOI 10.14740/wjon1166; Renouf Daniel J, 2012, Invest New Drugs, V30, P779, DOI 10.1007/s10637-010-9611-3; Strasser A, 2011, EMBO J, V30, P3667, DOI 10.1038/emboj.2011.307; Timpson P, 2011, JOVE-J VIS EXP, DOI 10.3791/3089; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Wang JT, 2015, NEUROSCIENCE, V292, P90, DOI 10.1016/j.neuroscience.2015.02.025; Wheeler DL, 2009, ONCOLOGIST, V14, P667, DOI 10.1634/theoncologist.2009-0009; Yamaguchi H, 2006, EUR J CELL BIOL, V85, P213, DOI 10.1016/j.ejcb.2005.10.004; Yamaguchi H, 2005, CURR OPIN CELL BIOL, V17, P559, DOI 10.1016/j.ceb.2005.08.002; Young AIJ, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0781-6; Zhang SY, 2012, TRENDS PHARMACOL SCI, V33, P122, DOI 10.1016/j.tips.2011.11.002	40	13	13	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	8					1821	1829		10.1038/s41388-019-1091-0	http://dx.doi.org/10.1038/s41388-019-1091-0			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN6CG	31735913	Green Published, hybrid			2022-12-28	WOS:000514923000015
J	Dengler, MA; Teh, CE; Thijssen, R; Gangoda, L; Lan, P; Herold, MJ; Gray, DH; Kelly, GL; Roberts, AW; Adams, JM				Dengler, Michael A.; Teh, Charis E.; Thijssen, Rachel; Gangoda, Lahiru; Lan, Ping; Herold, Marco J.; Gray, Daniel H.; Kelly, Gemma L.; Roberts, Andrew W.; Adams, Jerry M.			Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma	ONCOGENE			English	Article							BRUTON TYROSINE KINASE; PHASE-I; BCL-2; VENETOCLAX; APOPTOSIS; EXPRESSION; CANCER; MICROENVIRONMENT; MUTATIONS; IBRUTINIB	Apoptosis-regulating BCL-2 family members, which can promote malignant transformation and resistance to therapy, have become prime therapeutic targets, as illustrated by the striking efficacy in certain lymphoid malignancies of the BCL-2-specific inhibitor venetoclax. In other lymphoid malignancies, however, such as the aggressive mantle cell lymphoma (MCL), cell survival might rely instead or also on BCL-2 relative MCL-1. We have explored MCL-1 as a target for killing MCL cells by both genetic and pharmacologic approaches. In several MCL cell lines, MCL-1 knockout with an inducible CRISPR/Cas9 system triggered spontaneous apoptosis. Accordingly, most MCL cell lines proved sensitive to the specific MCL-1 inhibitor S63845, and MCL-1 inhibition also proved efficacious in an MCL xenograft model. Furthermore, its killing efficacy rose on combination with venetoclax, the BCL-X-L-specific inhibitor A-1331852, or Bruton's tyrosine kinase (BTK) inhibitor ibrutinib, which reduced pro-survival signals. We also tested the MCL-1 inhibitor in primary samples from 13 MCL patients, using CD40L-expressing feeder cells to model their microenvironmental support. Notably, all unstimulated primary MCL samples were very sensitive to S63845, but the CD40L stimulation attenuated their sensitivity. Mass cytometric analysis revealed that the stimulation likely conveyed protection by elevating BCL-X-L and MCL-1. Accordingly, sensitivity of the CD40L-stimulated cells to S63845 was substantially restored by co-treatment with venetoclax, the BCL-X-L-specific inhibitor or ibrutinib. Overall, our findings indicate that MCL-1 is very important for survival of MCL cells and that the MCL-1 inhibitor, both alone and together with ibrutinib, venetoclax or a BCL-X-L inhibitor, offers promise for novel improved MCL therapies.	[Dengler, Michael A.; Teh, Charis E.; Thijssen, Rachel; Gangoda, Lahiru; Lan, Ping; Herold, Marco J.; Gray, Daniel H.; Kelly, Gemma L.; Roberts, Andrew W.; Adams, Jerry M.] Walter & Eliza Hall Inst Med Res, 1G Royal Parade, Melbourne, Vic 3052, Australia; [Dengler, Michael A.; Teh, Charis E.; Thijssen, Rachel; Gangoda, Lahiru; Lan, Ping; Herold, Marco J.; Gray, Daniel H.; Kelly, Gemma L.; Roberts, Andrew W.; Adams, Jerry M.] Univ Melbourne, Dept Med Biol, Melbourne, Vic 3010, Australia; [Lan, Ping] Jinan Univ, Inst Adv & Appl Chem Synth, Zhuhai 519070, Guangdong, Peoples R China	Walter & Eliza Hall Institute; University of Melbourne; Jinan University	Adams, JM (corresponding author), Walter & Eliza Hall Inst Med Res, 1G Royal Parade, Melbourne, Vic 3052, Australia.; Adams, JM (corresponding author), Univ Melbourne, Dept Med Biol, Melbourne, Vic 3010, Australia.	adams@wehi.edu.au	Herold, Marco J/C-8039-2013; Adams, Jerry M/E-1199-2013; Dengler, Michael/AFR-3509-2022; Kelly, Gemma/AAG-6352-2020; Roberts, Andrew W./C-6736-2012; Thijssen, Rachel/AAE-7599-2022; Gray, Daniel/A-3293-2013	Herold, Marco J/0000-0001-7539-7581; Roberts, Andrew W./0000-0002-7341-5720; Thijssen, Rachel/0000-0002-4493-306X; Kelly, Gemma/0000-0002-6533-1201; Dengler, Michael/0000-0002-1693-1761; Adams, Jerry/0000-0002-4360-8628; Gangoda, Lahiru/0000-0003-1931-6809; Gray, Daniel/0000-0002-8457-8242	Metro South Health; CASS Foundation Science Medicine Grant [SM/18/7801]; National Health and Medical Research Council (NHMRC) [1016701, 1079560]; SCOR from the Leukemia and Lymphoma Society [7015-18, 5467-18]; NHMRC [1089072, 1090236]; Victorian Cancer Agency Fellowship [MCRF 17028]; Cancer Council of Victoria [1146518, 1147328]; Leukaemia Foundation Australia grant; Australian Government Independent Research Institute Infrastructure Support Scheme [9000220]; Victorian State Government Operational Infrastructure Support Program	Metro South Health; CASS Foundation Science Medicine Grant; National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); SCOR from the Leukemia and Lymphoma Society; NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Victorian Cancer Agency Fellowship; Cancer Council of Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); Leukaemia Foundation Australia grant; Australian Government Independent Research Institute Infrastructure Support Scheme(Australian Government); Victorian State Government Operational Infrastructure Support Program	We thank Naomi Sprigg (Royal Melbourne Hospital) for assistance with fresh clinical samples, Leonie Gibson and Tania Tan for excellent technical assistance, and Connie Li Wai Suen for statistical advice. We would like to acknowledge the Metro South Health Cancer Collaborative Biobank, Brisbane for the provision of hematologic malignancy samples for this project. The Cancer Collaborative Biobank is supported by Metro South Health funding. This work was supported by a CASS Foundation Science & Medicine Grant SM/18/7801 (to MAD); program grant 1016701 (to JMA) and Practitioner Fellowship 1079560 (to AWR) from the National Health and Medical Research Council (NHMRC); SCOR grant 7015-18 (to JMA and AWR) and Fellowship 5467-18 (to RT) from the Leukemia and Lymphoma Society; NHMRC Fellowship 1089072 (to CET), NHMRC Fellowship 1090236 (to DHG), Victorian Cancer Agency Fellowship MCRF 17028 (to GLK), Cancer Council of Victoria Grants-in-Aid 1146518 (to DHG) and 1147328 (to GLK), Leukaemia Foundation Australia grant (to GLK), and operational infrastructure grants through the Australian Government Independent Research Institute Infrastructure Support Scheme (9000220) and the Victorian State Government Operational Infrastructure Support Program. This work was performed in part at the Materials Characterization and Fabrication Platform at the University of Melbourne and the Victorian Node of the Australian National Fabrication Facility.	Adams JM, 2018, CELL DEATH DIFFER, V25, P27, DOI 10.1038/cdd.2017.161; Agarwal R, 2019, NAT MED, V25, P119, DOI 10.1038/s41591-018-0243-z; Amin HM, 2003, ARCH PATHOL LAB MED, V127, P424; Anderson MA, 2016, BLOOD, V127, P3215, DOI 10.1182/blood-2016-01-688796; Arbour N, 2008, J NEUROSCI, V28, P6068, DOI 10.1523/JNEUROSCI.4940-07.2008; Aubrey BJ, 2015, CELL REP, V10, P1422, DOI 10.1016/j.celrep.2015.02.002; Bea S, 2013, P NATL ACAD SCI USA, V110, P18250, DOI 10.1073/pnas.1314608110; Brennan MS, 2018, BLOOD, V132, P1573, DOI 10.1182/blood-2018-06-859405; Brien G, 2007, ONCOGENE, V26, P5828, DOI 10.1038/sj.onc.1210363; Burger JA, 2011, SEMIN CANCER BIOL, V21, P308, DOI 10.1016/j.semcancer.2011.09.006; Caenepeel S, 2018, CANCER DISCOV, V8, P1582, DOI 10.1158/2159-8290.CD-18-0387; Campo E, 2015, BLOOD, V125, P48, DOI 10.1182/blood-2014-05-521898; Camps J, 2006, LEUKEMIA RES, V30, P923, DOI 10.1016/j.leukres.2005.11.013; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chang BY, 2013, BLOOD, V122, P2412, DOI 10.1182/blood-2013-02-482125; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chiron D, 2016, BLOOD, V128, P2808, DOI 10.1182/blood-2016-06-720490; Chiron D, 2015, ONCOTARGET, V6, P8750, DOI 10.18632/oncotarget.3275; Czabotar PE, 2014, NAT REV MOL CELL BIO, V15, P49, DOI 10.1038/nrm3722; Davids MS, 2017, J CLIN ONCOL, V35, P826, DOI 10.1200/JCO.2016.70.4320; Dengler MA, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.552; Eyre TA, 2019, HAEMATOLOGICA, V104, pE68, DOI 10.3324/haematol.2018.198812; Fakhri B, 2017, THER ADV HEMATOL, V8, P223, DOI 10.1177/2040620717719616; Foucquier J, 2015, PHARMACOL RES PERSPE, V3, DOI 10.1002/prp2.149; Glaser SP, 2012, GENE DEV, V26, P120, DOI 10.1101/gad.182980.111; Gomez-Bougie P, 2018, BLOOD, V132, P2656, DOI 10.1182/blood-2018-03-836718; Gong JN, 2016, BLOOD, V128, P1834, DOI 10.1182/blood-2016-03-704908; Good Z, 2018, NAT MED, V24, P474, DOI 10.1038/nm.4505; Greaves G, 2019, CELL DEATH DIFFER, V26, P1037, DOI 10.1038/s41418-018-0183-7; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huang S, 2018, P IEEE SEMICOND THER, P8; Jares P, 2012, J CLIN INVEST, V122, P3416, DOI 10.1172/JCI61272; Kelly GL, 2014, GENE DEV, V28, P58, DOI 10.1101/gad.232009.113; Khoury JD, 2003, J PATHOL, V199, P90, DOI 10.1002/path.1254; Kotschy A, 2016, NATURE, V538, P477, DOI 10.1038/nature19830; Kurtova AV, 2009, BLOOD, V113, P4604, DOI 10.1182/blood-2008-10-185827; Leverson JD, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4642; Ma J, 2014, BRIT J HAEMATOL, V166, P849, DOI 10.1111/bjh.12974; Mason KD, 2007, CELL, V128, P1173, DOI 10.1016/j.cell.2007.01.037; Mestre-Escorihuela C, 2007, BLOOD, V109, P271, DOI 10.1182/blood-2006-06-026500; Montero J, 2018, CELL DEATH DIFFER, V25, P56, DOI 10.1038/cdd.2017.183; Moujalled DM, 2019, LEUKEMIA, V33, P905, DOI 10.1038/s41375-018-0261-3; Nagy B, 2003, BRIT J HAEMATOL, V120, P434, DOI 10.1046/j.1365-2141.2003.04121.x; PRICHARD MN, 1991, ANTIMICROB AGENTS CH, V35, P1060, DOI 10.1128/AAC.35.6.1060; Prukova D, 2019, CLIN CANCER RES, V25, P4455, DOI 10.1158/1078-0432.CCR-18-3275; Ramsey HE, 2018, CANCER DISCOV, V8, P1566, DOI 10.1158/2159-8290.CD-18-0140; Rauert-Wunderlich H, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0157-6; Roberts AW, 2016, NEW ENGL J MED, V374, P311, DOI 10.1056/NEJMoa1513257; Roberts AW, 2012, J CLIN ONCOL, V30, P488, DOI 10.1200/JCO.2011.34.7898; Rudolph C, 2004, CANCER GENET CYTOGEN, V153, P144, DOI 10.1016/j.cancergencyto.2004.01.006; Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048; Strasser A, 2011, EMBO J, V30, P3667, DOI 10.1038/emboj.2011.307; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Tagawa H, 2005, ONCOGENE, V24, P1348, DOI 10.1038/sj.onc.1208300; Tam CS, 2018, NEW ENGL J MED, V378, P1211, DOI 10.1056/NEJMoa1715519; Teh TC, 2018, LEUKEMIA, V32, P303, DOI 10.1038/leu.2017.243; Thomas RL, 2013, GENE DEV, V27, P1365, DOI 10.1101/gad.215871.113; Tucker CA, 2006, LEUKEMIA RES, V30, P449, DOI 10.1016/j.leukres.2005.08.016; Vick B, 2009, HEPATOLOGY, V49, P627, DOI 10.1002/hep.22664; Vogler M, 2012, CELL DEATH DIFFER, V19, P67, DOI 10.1038/cdd.2011.158; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Yecies D, 2010, BLOOD, V115, P3304, DOI 10.1182/blood-2009-07-233304	62	13	13	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	9					2009	2023		10.1038/s41388-019-1122-x	http://dx.doi.org/10.1038/s41388-019-1122-x			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KP9VM	31772331				2022-12-28	WOS:000516579800014
J	Yu, Y; Chen, L; Zhao, GP; Li, HC; Guo, QD; Zhu, ST; Li, P; Min, L; Zhang, ST				Yu, Yang; Chen, Lei; Zhao, Guiping; Li, Hengcun; Guo, Qingdong; Zhu, Shengtao; Li, Peng; Min, Li; Zhang, Shutian			RBBP8/CtIP suppresses P21 expression by interacting with CtBP and BRCA1 in gastric cancer	ONCOGENE			English	Article							CELL-CYCLE; TRANSCRIPTIONAL COREPRESSOR; CTIP; REQUIRES; PHOSPHORYLATION; IDENTIFICATION; RECURRENCE; INHIBITORS; RESECTION; PATTERNS	RB Binding Protein 8 (RBBP8) was previously reported being involved in DNA double-strand break (DSB) repair in cancers. However, there is no systematic study about the specific functions and related mechanisms of RBBP8 in gastric carcinogenesis. Through immunohistochemistry staining of paired gastric cancer (GC) tissues, adjacent high-grade intraepithelial neoplasia (HGIEN) tissues, and non-cancerous tissues, we found RBBP8 expression was upregulated in both HGIEN and GC tissues. Functional experiments showed the knockdown of RBBP8 inhibited cell proliferation and colony formation ability. This is mainly achieved through the role of RBBP8 in facilitating G1/S transition and promoting Cyclin D1 and CDK4 level. Then the interaction between RBBP8, BRCA1, and CtBP was revealed by co-immunoprecipitation (co-IP) and immunofluorescence confocal imaging. Moreover, we found RBBP8 acted as an adapter in this complex and RBBP8 overexpression enhanced the nucleus location of BRCA1. RBBP8 overexpression could inhibit P21 expression and HDAC (histone deacetylase) inhibitor Trichostatin A (TSA) eliminated this effect. The HDAC activity of CtBP-RBBP8-BRCA1 complex was also further verified by HDAC activity assay. Through Chromatin immunoprecipitation (ChIP), we found RBBP8 could induce P21 promoter histone deacetylation and inhibit P21 transcription. In conclusion, we found RBBP8 could promote the G1/S transition of GC cells by inhibiting P21 level. Moreover, we revealed the chromatin modification role of RBBP8, which could suppress the histone acetylation level of P21 promoter by recruiting CtBP co-repressor complex to BRCA1 binding site.	[Yu, Yang; Chen, Lei; Zhao, Guiping; Li, Hengcun; Guo, Qingdong; Zhu, Shengtao; Li, Peng; Min, Li; Zhang, Shutian] Capital Med Univ, Beijing Key Lab Precanc Les Digest Dis, Dept Gastroenterol,Beijing Digest Dis Ctr, Beijing Friendship Hosp,Natl Clin Res Ctr Digest, Beijing 100050, Peoples R China	Capital Medical University	Min, L; Zhang, ST (corresponding author), Capital Med Univ, Beijing Key Lab Precanc Les Digest Dis, Dept Gastroenterol,Beijing Digest Dis Ctr, Beijing Friendship Hosp,Natl Clin Res Ctr Digest, Beijing 100050, Peoples R China.	minli@ccmu.edu.cn; zhangshutian@ccmu.edu.cn	Min, Li/AAG-2088-2021	Min, Li/0000-0001-9595-5536	National Natural Science Foundation of China [81702314]; Funding Program for Excellent Talents of Beijing [2017000021469G212]; Digestive Medical Coordinated Development Center of Beijing Municipal Administration of Hospitals [XXZ0201]; Beijing Municipal Administration of Hospitals' Youth Programme [QML20180108]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Funding Program for Excellent Talents of Beijing; Digestive Medical Coordinated Development Center of Beijing Municipal Administration of Hospitals; Beijing Municipal Administration of Hospitals' Youth Programme	This work was completely supported by grants from the National Natural Science Foundation of China (81702314); Funding Program for Excellent Talents of Beijing (2017000021469G212); The Digestive Medical Coordinated Development Center of Beijing Municipal Administration of Hospitals (XXZ0201); Beijing Municipal Administration of Hospitals' Youth Programme (QML20180108).	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Bang Y, 2009, J CLIN ONCOL S, V27, P15; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chen X, 2003, MOL BIOL CELL, V14, P3208, DOI 10.1091/mbc.E02-12-0833; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Chinnadurai G, 2009, CANCER RES, V69, P731, DOI 10.1158/0008-5472.CAN-08-3349; Chinnadurai G, 2009, ATLAS GENET CYTOGENE, V13, P282; Cui JA, 2011, NUCLEIC ACIDS RES, V39, P1197, DOI 10.1093/nar/gkq960; D'Angelica M, 2004, ANN SURG, V240, P808, DOI 10.1097/01.sla.0000143245.28656.15; Deng CX, 2000, BIOESSAYS, V22, P728; Deroanne CF, 2002, ONCOGENE, V21, P427, DOI 10.1038/sj.onc.1205108; Gray S. G., 2001, Current Molecular Medicine (Hilversum), V1, P401, DOI 10.2174/1566524013363537; Huertas P, 2009, J BIOL CHEM, V284, P9558, DOI 10.1074/jbc.M808906200; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kim DH, 2003, J BIOCHEM MOL BIOL, V36, P110; Kuppuswamy M, 2008, MOL CELL BIOL, V28, P269, DOI 10.1128/MCB.01077-07; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Limbo O, 2007, MOL CELL, V28, P134, DOI 10.1016/j.molcel.2007.09.009; Liu D, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-1042-y; Lord CJ, 2017, SCIENCE, V355, P1152, DOI 10.1126/science.aam7344; Lu ML, 2000, ONCOGENE, V19, P6351, DOI 10.1038/sj.onc.1204025; Miao L, 2014, J GASTROENTEROL, V19, P618; Murai J, 2012, CANCER RES, V72, P5588, DOI 10.1158/0008-5472.CAN-12-2753; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Peterson SE, 2013, MOL CELL, V49, P657, DOI 10.1016/j.molcel.2012.11.020; Sartori AA, 2007, NATURE, V450, P509, DOI 10.1038/nature06337; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Wang YG, 2013, WORLD J GASTROENTERO, V19, P3226, DOI 10.3748/wjg.v19.i21.3226; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yoo CH, 2000, BRIT J SURG, V87, P236, DOI 10.1046/j.1365-2168.2000.01360.x; Yu X, 2000, J BIOL CHEM, V275, P18541, DOI 10.1074/jbc.M909494199; Yu XC, 2004, MOL CELL BIOL, V24, P9478, DOI 10.1128/MCB.24.21.9478-9486.2004; Zhang QH, 2006, P NATL ACAD SCI USA, V103, P9029, DOI 10.1073/pnas.0603269103; Zhu GJ, 2014, EXP THER MED, V8, P1501, DOI 10.3892/etm.2014.1982	36	10	10	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	6					1273	1289		10.1038/s41388-019-1060-7	http://dx.doi.org/10.1038/s41388-019-1060-7			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE4UH	31636387				2022-12-28	WOS:000526714600008
J	Bhagirath, D; Liston, M; Patel, N; Akoto, T; Lui, B; Yang, TL; To, DM; Majid, S; Dahiya, R; Tabatabai, ZL; Saini, S				Bhagirath, Divya; Liston, Michael; Patel, Nikhil; Akoto, Theresa; Lui, Byron; Yang, Thao Ly; To, Dat My; Majid, Shahana; Dahiya, Rajvir; Tabatabai, Z. Laura; Saini, Sharanjot			MicroRNA determinants of neuroendocrine differentiation in metastatic castration-resistant prostate cancer	ONCOGENE			English	Article							INCREASED SURVIVAL; ENZALUTAMIDE; ABIRATERONE; CELLS; IDENTIFICATION; COMMON; MEN; AR	Therapy-induced neuroendocrine prostate cancer (NEPC), an extremely aggressive variant of castration-resistant prostate cancer (CRPC), is increasing in incidence with the widespread use of highly potent androgen receptor (AR)-pathway inhibitors (APIs) such as Enzalutamide (ENZ) and Abiraterone and arises via a reversible trans-differentiation process, referred to as neuroendocrine differentiation (NED). The molecular basis of NED is not completely understood leading to a lack of effective molecular markers for its diagnosis. Here, we demonstrate for the first time, that lineage switching to NE states is accompanied by key miRNA alterations including downregulation of miR-106a similar to 363 cluster and upregulation of miR-301a and miR-375. To systematically investigate the key miRNAs alterations driving therapy-induced NED, we performed small RNA-NGS in a retrospective cohort of human metastatic CRPC clinical samples + PDX models with adenocarcinoma features (CRPC-adeno) vs those with neuroendocrine features (CRPC-NE). Further, with the application of machine learning algorithms to sequencing data, we trained a 'miRNA classifier' that could robustly classify 'CRPC-NE' from 'CRPC-Adeno' cases. The performance of classifier was validated in an additional cohort of mCRPC patients and publicly available PCa cohorts. Importantly, we demonstrate that miR-106a similar to 363 cluster pleiotropically regulate cardinal nodal proteins instrumental in driving NEPC including Aurora Kinase A, N-Myc, E2F1 and STAT3. Our study has important clinical implications and transformative potential as our 'miRNA classifier' can be used as a molecular tool to stratify mCRPC patients into those with/without NED and guide treatment decisions. Further, we identify novel miRNA NED drivers that can be exploited for NEPC therapeutic targeting.	[Bhagirath, Divya; Akoto, Theresa; Saini, Sharanjot] Augusta Univ, Dept Biochem & Mol Biol, Augusta, GA USA; [Liston, Michael; Lui, Byron; Yang, Thao Ly; To, Dat My; Majid, Shahana; Dahiya, Rajvir; Tabatabai, Z. Laura] Vet Affairs Med Ctr, San Francisco, CA 94121 USA; [Liston, Michael; Lui, Byron; Yang, Thao Ly; To, Dat My; Majid, Shahana; Dahiya, Rajvir; Tabatabai, Z. Laura] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Patel, Nikhil] Augusta Univ, Dept Pathol, Augusta, GA USA	University System of Georgia; Augusta University; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University System of Georgia; Augusta University	Saini, S (corresponding author), Augusta Univ, Dept Biochem & Mol Biol, Augusta, GA USA.	ssaini@augusta.edu	Patel, Nikhil/O-6072-2018	Patel, Nikhil/0000-0001-9335-0082	US Army Medical Research Acquisition Activity (USAMRAA) through the Idea Development Award [W81XWH-18-1-0303]; National Cancer Institute at the National Institutes of Health [RO1CA177984]; Prostate Cancer Biorepository Network (PCBN) [W81XWH-18-2-0013, W81XWH-18-2-0015, W81XWH-18-2-0016, W81XWH-18-2-0017, W81XWH-18-2-0018, W81XWH-18-2-0019]	US Army Medical Research Acquisition Activity (USAMRAA) through the Idea Development Award; National Cancer Institute at the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Prostate Cancer Biorepository Network (PCBN)	We sincerely thank Dr. Paul Jedlicka at University of Colorado, Denver for miR-106a-363 sponge and control constructs and Dr. Felix Feng at UCSF for LNCaP-AR-Enzalutamide resistant cell line. This work is supported by the US Army Medical Research Acquisition Activity (USAMRAA) through the Idea Development Award under Award No. W81XWH-18-1-0303. Additionally, supported by Award no. W81XWH-18-2-0013, W81XWH-18-2-0015, W81XWH-18-2-0016, W81XWH-18-2-0017, W81XWH-18-2-0018, and W81XWH-18-2-0019 Prostate Cancer Biorepository Network (PCBN). Funding support by the National Cancer Institute at the National Institutes of Health (Grant Number RO1CA177984) is also acknowledged. Opinions, interpretations, conclusions, and recommendations are those of the author and are not necessarily endorsed by the Department of Defense or the U.S. Army.	Aggarwal R, 2018, J CLIN ONCOL, V36, P2492, DOI 10.1200/JCO.2017.77.6880; Aggarwal R, 2014, J NATL COMPR CANC NE, V12, P719, DOI 10.6004/jnccn.2014.0073; Aggarwal RR, 2014, ONCOLOGY-NY, V28, P838; Alshalalfa M, 2019, INT J CANCER, V145, P3453, DOI 10.1002/ijc.32430; Antonarakis ES, 2017, J CLIN ONCOL, V35, P2149, DOI 10.1200/JCO.2016.70.1961; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Beltran H, 2019, CLIN CANCER RES, V25, P43, DOI 10.1158/1078-0432.CCR-18-1912; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; Berger A, 2019, J CLIN INVEST, V129, P3924, DOI 10.1172/JCI127961; Bhagirath D, 2019, CLIN CANCER RES, V25, P6532, DOI 10.1158/1078-0432.CCR-19-0498; Bishop JL, 2017, CANCER DISCOV, V7, P54, DOI 10.1158/2159-8290.CD-15-1263; Chen SY, 2019, AM J CLIN EXP UROL, V7, P327; Damodaran C, 2016, UROL ONCOL-SEMIN ORI, V34, DOI 10.1016/j.urolonc.2016.03.009; Dang Q, 2015, MOL ONCOL, V9, P1241, DOI 10.1016/j.molonc.2015.02.010; Dankert JT, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200472; Dardenne E, 2016, CANCER CELL, V30, P563, DOI 10.1016/j.ccell.2016.09.005; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Ding M, 2015, ONCOTARGET, V6, P7686, DOI 10.18632/oncotarget.3480; Dylla L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063032; Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079; Fernandes RC, 2019, ENDOCR-RELAT CANCER, V26, pR237, DOI 10.1530/ERC-18-0571; Gupta K, 2017, TRANSL CANCER RES, V6, pS104, DOI 10.21037/tcr.2017.01.20; HAYWARD SW, 1995, IN VITRO CELL DEV-AN, V31, P14; Hu CD, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00090; Hussain M, 2018, NEW ENGL J MED, V379, P1381, DOI 10.1056/NEJMc1810065; Hussain M, 2018, NEW ENGL J MED, V378, P2465, DOI 10.1056/NEJMoa1800536; Knudsen KE, 2009, CLIN CANCER RES, V15, P4792, DOI 10.1158/1078-0432.CCR-08-2660; Kojima S, 2017, J HUM GENET, V62, P25, DOI 10.1038/jhg.2016.69; Labrecque MP, 2019, J CLIN INVEST, V129, P4492, DOI 10.1172/JCI128212; LAI SL, 1995, ANTICANCER RES, V15, P225; Lee JK, 2016, CANCER CELL, V29, P536, DOI 10.1016/j.ccell.2016.03.001; Li Z, 2015, MOL CANCER RES, V13, P584, DOI 10.1158/1541-7786.MCR-14-0277-T; Liu B, 2019, CLIN CANCER RES, V25, P6839, DOI 10.1158/1078-0432.CCR-19-0317; Lotan TL, 2011, MODERN PATHOL, V24, P820, DOI 10.1038/modpathol.2011.7; Maina PK, 2016, ONCOTARGET, V7, P75585, DOI 10.18632/oncotarget.12310; Nam Robert K, 2018, Oncotarget, V9, P19159, DOI 10.18632/oncotarget.24937; Nam RK, 2016, PROSTATE, V76, P869, DOI 10.1002/pros.23177; Nam RK, 2015, J CANCER, V6, P1160, DOI 10.7150/jca.13397; Nguyen HM, 2017, PROSTATE, V77, P654, DOI 10.1002/pros.23313; Park JW, 2018, SCIENCE, V362, P91, DOI 10.1126/science.aat5749; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Sasaki T, 2005, EUR UROL, V48, P224, DOI 10.1016/j.eururo.2005.03.017; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Schlomm T, 2016, EUR UROL, V69, P1157, DOI 10.1016/j.eururo.2016.02.024; Selth LA, 2017, ONCOGENE, V36, P24, DOI 10.1038/onc.2016.185; Shen MM, 2010, GENE DEV, V24, P1967, DOI 10.1101/gad.1965810; TAKAYAMA K, 2017, CANCERS, V9; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Thieu W, 2014, UROL ONCOL-SEMIN ORI, V32, P517, DOI 10.1016/j.urolonc.2013.11.004; WANG Y, 2016, MOL CANCER, V15	51	15	15	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2020	39	49					7209	7223		10.1038/s41388-020-01493-8	http://dx.doi.org/10.1038/s41388-020-01493-8		OCT 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PB0GA	33037409	Green Accepted, Green Submitted			2022-12-28	WOS:000578440800003
J	Gan, T; Stevens, AT; Xiong, XP; Wen, YA; Farmer, TN; Li, AT; Stevens, PD; Golshani, S; Weiss, HL; Evers, BM; Gao, TY				Gan, Tong; Stevens, Ashley T.; Xiong, Xiaopeng; Wen, Yang-An; Farmer, Trevor N.; Li, Austin T.; Stevens, Payton D.; Golshani, Sanam; Weiss, Heidi L.; Mark Evers, B.; Gao, Tianyan			Inhibition of protein tyrosine phosphatase receptor type F suppresses Wnt signaling in colorectal cancer	ONCOGENE			English	Article							TUMOR-GROWTH; STEM-CELLS; EXPRESSION; LAR; PTPRF; GENES; CLATHRIN; COMPLEX; LRP6	Wnt signaling dysregulation promotes tumorigenesis in colorectal cancer (CRC). We investigated the role of PTPRF, a receptor-type tyrosine phosphatase, in regulating Wnt signaling in CRC. Knockdown of PTPRF decreased cell proliferation in patient-derived primary colon cancer cells and established CRC cell lines. In addition, the rate of proliferation as well as colony formation ability were significantly decreased in tumor organoids grown in 3D, whereas the number of differentiated tumor organoids were markedly increased. Consistently, knockdown of PTPRF resulted in a decrease in the expression of genes associated with cancer stem cells downstream of Wnt/beta-catenin signaling. Treating PTPRF knockdown cells with GSK3 inhibitor rescued the expression of Wnt target genes suggesting that PTPRF functions upstream of the beta-catenin destruction complex. PTPRF was found to interact with LRP6 and silencing PTPRF largely decreased the activation of LRP6. Interestingly, this PTPRF-mediated activation of Wnt signaling was blocked in cells treated with clathrin endocytosis inhibitor. Furthermore, knockdown of PTPRF inhibited xenograft tumor growth in vivo and decreased the expression of Wnt target genes. Taken together, our studies identify a novel role of PTPRF as an oncogenic protein phosphatase in supporting the activation of Wnt signaling in CRC.	[Gan, Tong; Mark Evers, B.] Univ Kentucky, Dept Surg, Lexington, KY 40536 USA; [Gan, Tong; Stevens, Ashley T.; Xiong, Xiaopeng; Wen, Yang-An; Farmer, Trevor N.; Stevens, Payton D.; Golshani, Sanam; Weiss, Heidi L.; Mark Evers, B.; Gao, Tianyan] Univ Kentucky, Markey Canc Ctr, Lexington, KY 40536 USA; [Stevens, Ashley T.; Stevens, Payton D.; Gao, Tianyan] Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; [Li, Austin T.] Paul Laurence Dunbar High Sch, Lexington, KY USA; [Stevens, Payton D.] Van Andel Res Inst, Ctr Canc & Cell Biol, Grand Rapids, MI 49503 USA	University of Kentucky; University of Kentucky; University of Kentucky; Van Andel Institute	Gao, TY (corresponding author), Univ Kentucky, Markey Canc Ctr, Lexington, KY 40536 USA.; Gao, TY (corresponding author), Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.	tianyan.gao@uky.edu		, Ashley Skaggs/0000-0001-6732-1640	National Science Foundation Graduate Research Fellowship Award [1839289]; Biospecimen Procurement and Translational Pathology and Biostatistics and Bioinformatics Shared Resource Facilities of the University of Kentucky Markey Cancer Center at the University of Kentucky [P30CA177558];  [R01CA133429];  [R01CA208343];  [T32CA160003];  [F31CA196219]	National Science Foundation Graduate Research Fellowship Award(National Science Foundation (NSF)); Biospecimen Procurement and Translational Pathology and Biostatistics and Bioinformatics Shared Resource Facilities of the University of Kentucky Markey Cancer Center at the University of Kentucky; ; ; ; 	This work was supported by funding grants R01CA133429 (TG), R01CA208343 (BME and TG), T32CA160003 (BME), and F31CA196219 (PDS). This material is based upon work supported by the National Science Foundation Graduate Research Fellowship Award (#1839289). The studies were conducted with support provided by the Biospecimen Procurement and Translational Pathology and Biostatistics and Bioinformatics Shared Resource Facilities of the University of Kentucky Markey Cancer Center (P30CA177558) at the University of Kentucky.	Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Barlan K, 2017, DEV CELL, V40, P467, DOI 10.1016/j.devcel.2017.02.003; Barr AJ, 2009, CELL, V136, P352, DOI 10.1016/j.cell.2008.11.038; Bera R, 2014, HEPATOLOGY, V59, P2238, DOI 10.1002/hep.27030; Bujko M, 2015, ONCOL LETT, V9, P2463, DOI 10.3892/ol.2015.3107; Chen MY, 2009, BIOCHEMISTRY-US, V48, P10267, DOI 10.1021/bi9009677; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; DaSilva JO, 2013, PROSTATE, V73, P801, DOI 10.1002/pros.22624; Du WW, 2013, J CELL SCI, V126, P1440, DOI 10.1242/jcs.118299; Flanagan DJ, 2019, CANCER RES, V79, P5901, DOI 10.1158/0008-5472.CAN-19-1362; Flanagan DJ, 2019, CANCER RES, V79, P970, DOI 10.1158/0008-5472.CAN-18-2095; Hagemann AIH, 2014, J CELL SCI, V127, P3970, DOI 10.1242/jcs.148767; HARDER KW, 1995, GENOMICS, V27, P552, DOI 10.1006/geno.1995.1092; Johnson KG, 2003, PHYSIOL REV, V83, P1, DOI 10.1152/physrev.00016.2002; Julien SG, 2011, NAT REV CANCER, V11, P35, DOI 10.1038/nrc2980; Kim I, 2013, J CELL BIOL, V200, P419, DOI 10.1083/jcb.201206096; Komiya Yuko, 2008, Organogenesis, V4, P68; Konishi N, 2003, BRIT J CANCER, V88, P1223, DOI 10.1038/sj.bjc.6600876; Kreso A, 2014, NAT MED, V20, P29, DOI 10.1038/nm.3418; LeVea CM, 2000, BREAST CANCER RES TR, V64, P221, DOI 10.1023/A:1006410509740; Li X, 2014, GASTROENTEROLOGY, V146, P1301, DOI 10.1053/j.gastro.2014.02.003; Liu J, 2009, ONCOGENE, V28, P994, DOI 10.1038/onc.2008.450; Mana G, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13546; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470; Nunes-Xavier CE, 2013, BBA-REV CANCER, V1836, P211, DOI 10.1016/j.bbcan.2013.06.001; Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016; O'Connell JB, 2004, AM J SURG, V187, P343, DOI 10.1016/j.amjsurg.2003.12.020; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Saito-Diaz K, 2018, DEV CELL, V44, P566, DOI 10.1016/j.devcel.2018.02.013; Schatoff EM, 2017, CURR COLORECT CANC R, V13, P101, DOI 10.1007/s11888-017-0354-9; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Smith RA, 2018, CA-CANCER J CLIN, V68, P297, DOI 10.3322/caac.21446; Soulieres D, 2015, J THORAC ONCOL, V10, P1364, DOI 10.1097/JTO.0000000000000624; Stamos JL, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a007898; Stevens PD, 2018, CANCER RES, V78, P4839, DOI 10.1158/0008-5472.CAN-17-3629; Stewart K, 2013, DEVELOPMENT, V140, P3413, DOI 10.1242/dev.094532; STREULI M, 1992, EMBO J, V11, P897, DOI 10.1002/j.1460-2075.1992.tb05128.x; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tian XX, 2018, ONCOTARGETS THER, V11, P7795, DOI 10.2147/OTT.S178152; Vermeulen L, 2013, SCIENCE, V342, P995, DOI 10.1126/science.1243148; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Virshup DM, 2009, MOL CELL, V33, P537, DOI 10.1016/j.molcel.2009.02.015; Voloshanenko O, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3610; Wang ZH, 2004, SCIENCE, V304, P1164, DOI 10.1126/science.1096096; Wen YA, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0330-6; Wen YA, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.21; Wu DQ, 2010, TRENDS BIOCHEM SCI, V35, P161, DOI 10.1016/j.tibs.2009.10.002; Yamamoto H, 2006, DEV CELL, V11, P213, DOI 10.1016/j.devcel.2006.07.003; Yang T, 1999, MOL CARCINOGEN, V25, P139, DOI 10.1002/(SICI)1098-2744(199906)25:2<139::AID-MC9>3.3.CO;2-K	50	11	11	2	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2020	39	44					6789	6801		10.1038/s41388-020-01472-z	http://dx.doi.org/10.1038/s41388-020-01472-z		SEP 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OH9QS	32973331	Green Accepted			2022-12-28	WOS:000572607300001
J	Ochieng, JK; Kundu, ST; Bajaj, R; Rodriguez, BL; Fradette, JJ; Gibbons, DL				Ochieng, Joshua Kapere; Kundu, Samrat T.; Bajaj, Rakhee; Rodriguez, B. Leticia; Fradette, Jared J.; Gibbons, Don L.			MBIP (MAP3K12 binding inhibitory protein) drives NSCLC metastasis by JNK-dependent activation of MMPs	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; OVARIAN-CANCER CELLS; MATRIX METALLOPROTEINASES; LUNG-CANCER; ACETYLTRANSFERASE COMPLEX; PROMOTES INVASION; EXPRESSION; PATHWAY; GENOME; TARGET	Metastasis is the cause for 90% of cancer-related mortalities. Identification of genetic drivers promoting dissemination of tumor cells may provide opportunities for novel therapeutic strategies. We previously reported an in vivo gain-of-function screen that identified similar to 30 genes with a functional role in metastasis promotion and characterized detailed mechanistic functions of two hits. In this study, we characterized the contribution of one of the identified genes, MBIP (MAP3K12 binding inhibitory protein), towards driving tumor invasion and metastasis. We demonstrate that expression of MBIP significantly enhances the cellular proliferation, migration and invasion of NSCLC cells in vitro and metastasis in vivo. We functionally characterized that MBIP mediates activation of the JNK pathway and induces expression of matrix metalloproteinases (MMPs), which are necessary for the invasive and metastatic phenotype. Our findings establish a novel mechanistic role of MBIP as a driver of NSCLC progression and metastasis.	[Ochieng, Joshua Kapere; Kundu, Samrat T.; Bajaj, Rakhee; Rodriguez, B. Leticia; Fradette, Jared J.; Gibbons, Don L.] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA; [Gibbons, Don L.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Kundu, ST; Gibbons, DL (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.; Gibbons, DL (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	skundu@mdanderson.org; dlgibbon@mdanderson.org		Gibbons, Don/0000-0003-2362-3094; Bajaj, Rakhee/0000-0002-9990-1655; Kundu, Samrat/0000-0002-0117-6986; Fradette, Jared/0000-0001-6712-2860; Kapere Ochieng, Joshua/0000-0001-5082-3353	DoD CDMRP Lung cancer research award [W81XWH-12-16294]; NIH/NCIK [K08 CA151651]; Jeane F Shelby Scholarship Fund; University of Texas MD Anderson Lung Cancer Moon Shots Program	DoD CDMRP Lung cancer research award; NIH/NCIK; Jeane F Shelby Scholarship Fund; University of Texas MD Anderson Lung Cancer Moon Shots Program	This work was supported by the DoD CDMRP Lung cancer research award W81XWH-12-16294 and NIH/NCIK K08 CA151651. DLG is an R. Lee Clark Fellow of the University of Texas MD Anderson Cancer Center, supported by the Jeane F Shelby Scholarship Fund. The work was also supported by the generous philanthropic contributions to The University of Texas MD Anderson Lung Cancer Moon Shots Program. We would like to thank Dr. Ignacio Wistuba's lab for technical support, Jared Fredette and Laura Gibson for technical assistance and the UTMDACC Department of Veterinary Medicine Facility.	Ahn YH, 2012, J CLIN INVEST, V122, P3170, DOI 10.1172/JCI63608; Bajaj R, 2020, ONCOGENE, V39, P5979, DOI 10.1038/s41388-020-01410-z; Basu S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123979; Cheng CY, 2012, STEM CELL RES, V9, P9, DOI 10.1016/j.scr.2012.02.005; Choi Y, 2016, WORLD J GASTROENTERO, V22, P9141, DOI 10.3748/wjg.v22.i41.9141; Conlon GA, 2019, J PATHOL, V247, P629, DOI 10.1002/path.5225; Fukuyama K, 2000, J BIOL CHEM, V275, P21247, DOI 10.1074/jbc.M001488200; Gazon H, 2018, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02686; Gibbons DL, 2009, GENE DEV, V23, P2140, DOI 10.1101/gad.1820209; Gibbons DL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005401; Grzeskowiak CL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04572-3; Guelman S, 2009, MOL CELL BIOL, V29, P1176, DOI 10.1128/MCB.01599-08; Harris T, 2011, CLIN CANCER RES, V17, P690, DOI 10.1158/1078-0432.CCR-10-1892; He WL, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4317-6; Inoue H, 2001, EMBO J, V20, P5421, DOI 10.1093/emboj/20.19.5421; Ispanovic E, 2006, AM J PHYSIOL-CELL PH, V291, pC579, DOI 10.1152/ajpcell.00300.2005; Jamal-Hanjani M, 2017, NEW ENGL J MED, V376, P2109, DOI 10.1056/NEJMoa1616288; Jendrzejewski J, 2016, THYROID, V26, P1276, DOI 10.1089/thy.2015.0665; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Kenny HA, 2008, J CLIN INVEST, V118, P1367, DOI 10.1172/JCI33775; Konen JM, 2019, CANCERS, V11, DOI 10.3390/cancers11040462; Lee YH, 2014, TUMOR BIOL, V35, P7699, DOI 10.1007/s13277-014-2027-5; Levin PA, 2016, J THORAC ONCOL, V11, P1357, DOI 10.1016/j.jtho.2016.04.015; Li M, 2018, CHIN J INTEGR MED, V24, P40, DOI 10.1007/s11655-017-2805-1; Liotta L A, 1990, Semin Cancer Biol, V1, P99; Liu D, 2007, LUNG CANCER, V58, P384, DOI 10.1016/j.lungcan.2007.07.005; Martinotti S, 2020, METHODS MOL BIOL, V2109, P225, DOI 10.1007/7651_2019_259; McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357-4310(00)01686-5; MCDONNELL S, 1991, MOL CARCINOGEN, V4, P527, DOI 10.1002/mc.2940040617; Naglich JG, 2001, CANCER RES, V61, P8480; Olaussen KA, 2006, NEW ENGL J MED, V355, P983, DOI 10.1056/NEJMoa060570; Peng DH, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaq1238; Sathyanesan A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05656-w; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sporn MB, 1996, LANCET, V347, P1377, DOI 10.1016/S0140-6736(96)91015-6; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; Stanciu AE, 2017, CLIN LAB, V63, P1613, DOI 10.7754/Clin.Lab.2017.170339; Suganuma T, 2008, NAT STRUCT MOL BIOL, V15, P364, DOI 10.1038/nsmb.1397; Suganuma T, 2010, CELL, V142, P726, DOI 10.1016/j.cell.2010.07.045; Sui XB, 2014, CANCER LETT, V344, P174, DOI 10.1016/j.canlet.2013.11.019; Sulminoe A, 2007, LEUKEMIA RES, V31, P1437, DOI 10.1016/j.leukres.2007.01.015; Vincenti M P, 2001, Methods Mol Biol, V151, P121; Wang FQ, 2005, INT J CANCER, V114, P19, DOI 10.1002/ijc.20697; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Zappa C, 2016, TRANSL LUNG CANCER R, V5, P288, DOI 10.21037/tlcr.2016.06.07; Zheng S, 2007, ONCOGENE, V26, P6896, DOI 10.1038/sj.onc.1210493; Zhu J, 2019, AM J TRANSL RES, V11, P3862	47	5	5	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2020	39	43					6719	6732		10.1038/s41388-020-01463-0	http://dx.doi.org/10.1038/s41388-020-01463-0		SEP 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OF2UT	32963352	Green Accepted			2022-12-28	WOS:000572030400003
J	Zhang, YH; Shi, WN; Wu, SH; Miao, RR; Sun, SY; Luo, DD; Wan, SB; Guo, ZK; Wang, WY; Yu, XF; Cui, SX; Qu, XJ				Zhang, Yu-Hang; Shi, Wen-Na; Wu, Shu-Hua; Miao, Rong-Rong; Sun, Shi-Yue; Luo, Dong-Dong; Wan, Sheng-Biao; Guo, Zhi-Kun; Wang, Wen-Yu; Yu, Xin-Feng; Cui, Shu-Xiang; Qu, Xian-Jun			SphK2 confers 5-fluorouracil resistance to colorectal cancer via upregulating H3K56ac-mediated DPD expression	ONCOGENE			English	Article							IN-VITRO; SPHINGOSINE KINASE-1; SPHINGOSINE-1-PHOSPHATE; CHEMOTHERAPY; INHIBITOR; ABC294640; FLUOROURACIL; SENSITIVITY; STRATEGIES; TOXICITY	Aberrant sphingolipid metabolism has been implicated in chemoresistance, but the underlying mechanisms are still poorly understood. Herein we revealed a previously unrecognized mechanism of 5-fluorouracil (5-FU) resistance contributed by high SphK2-upregulated dihydropyrimidine dehydrogenase (DPD) in colorectal cancer (CRC), which is evidenced from human CRC specimens, animal models, and cancer cell lines. TMA samples from randomly selected 60 CRC specimens firstly identified the clinical correlation between high SphK2 and increased DPD (p < 0.001). Then the regulatory mechanism was explored in CRC models of villin-SphK2 Tg mice,SphK2(-/-)mice, and human CRC cells xenografted nude mice. Assays of ChIP-Seq and luciferase reporter gene demonstrated that high SphK2 upregulated DPD through promoting the HDAC1-mediated H3K56ac, leading to the degradation of intracellular 5-FU into inactive alpha-fluoro-beta-alanine (FBAL). Lastly, inhibition of SphK2 by SLR080811 exhibited excellent inhibition on DPD expression and potently reversed 5-FU resistance in colorectal tumors of villin-SphK2 Tg mice. Overall, this study manifests that SphK2(high)conferred 5-FU resistance through upregulating tumoral DPD, which highlights the strategies of blocking SphK2 to overcome 5-FU resistance in CRC.	[Zhang, Yu-Hang; Miao, Rong-Rong; Sun, Shi-Yue; Wang, Wen-Yu; Yu, Xin-Feng; Qu, Xian-Jun] Capital Med Univ, Dept Pharmacol, Sch Basic Med Sci, Beijing, Peoples R China; [Shi, Wen-Na] Shandong First Med Univ & Shandong Acad Med Sci, Dept Pharm, Shandong Canc Hosp & Inst, Jinan, Peoples R China; [Wu, Shu-Hua] Hosp Binzhou Med Univ, Dept Pathol, Yantai, Shandong, Peoples R China; [Luo, Dong-Dong; Wan, Sheng-Biao] Ocean Univ China, Qingdao Natl Lab Marine Sci & Technol, Key Lab Marine Drugs, Lab Marine Drugs & Bioprod,Minist Educ,Sch Med &, Qingdao, Peoples R China; [Guo, Zhi-Kun; Cui, Shu-Xiang] Capital Med Univ, Dept Toxicol & Sanit Chem, Sch Publ Hlth, Beijing, Peoples R China	Capital Medical University; Shandong First Medical University & Shandong Academy of Medical Sciences; Binzhou Medical University; Ocean University of China; Qingdao National Laboratory for Marine Science & Technology; Capital Medical University	Qu, XJ (corresponding author), Capital Med Univ, Dept Pharmacol, Sch Basic Med Sci, Beijing, Peoples R China.; Cui, SX (corresponding author), Capital Med Univ, Dept Toxicol & Sanit Chem, Sch Publ Hlth, Beijing, Peoples R China.	sxccui@ccmu.edu.cn; qxj@ccmu.edu.cn		zhang, yuhang/0000-0001-9752-983X; luo, dongdong/0000-0001-6428-9729; Guo, Zhikun/0000-0003-1639-4342	National Natural Science Foundation of China [91629303/81673449/81872884/81973350]; Beijing Natural Science Foundation and Scientific Research Program of Municipal Commission of Education [KZ201710025020/KZ201810025033]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Natural Science Foundation and Scientific Research Program of Municipal Commission of Education	This work was supported by National Natural Science Foundation of China (91629303/81673449/81872884/81973350) and Beijing Natural Science Foundation and Scientific Research Program of Municipal Commission of Education (KZ201710025020/KZ201810025033).	Adjei AA, 2002, J CLIN ONCOL, V20, P1683, DOI 10.1200/JCO.20.6.1683; Afzal S, 2011, CLIN CANCER RES, V17, P3822, DOI 10.1158/1078-0432.CCR-11-0304; Amstutz U, 2018, CLIN PHARMACOL THER, V103, P210, DOI 10.1002/cpt.911; Britten CD, 2017, CLIN CANCER RES, V23, P4642, DOI 10.1158/1078-0432.CCR-16-2363; Camp ER, 2017, CANCER BIOL THER, V18, P640, DOI 10.1080/15384047.2017.1345396; Dovey OM, 2010, P NATL ACAD SCI USA, V107, P8242, DOI 10.1073/pnas.1000478107; Fitzpatrick Leo R., 2011, Inflammopharmacology, V19, P75, DOI 10.1007/s10787-010-0060-6; French KJ, 2010, J PHARMACOL EXP THER, V333, P129, DOI 10.1124/jpet.109.163444; Grassi S, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00807; Guillermet-Guibert J, 2009, MOL CANCER THER, V8, P809, DOI 10.1158/1535-7163.MCT-08-1096; Hait NC, 2009, SCIENCE, V325, P1254, DOI 10.1126/science.1176709; Hamajima N, 1996, GENE, V180, P157, DOI 10.1016/S0378-1119(96)00445-3; Kharel Y, 2012, BIOCHEM J, V447, P149, DOI 10.1042/BJ20120609; Kidder BL, 2011, NAT IMMUNOL, V12, P918, DOI 10.1038/ni.2117; Lee AM, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju298; Liang J, 2013, CANCER CELL, V23, P107, DOI 10.1016/j.ccr.2012.11.013; Maceyka M, 2012, TRENDS CELL BIOL, V22, P50, DOI 10.1016/j.tcb.2011.09.003; Manca A, 2012, VALUE HEALTH, V15, P22, DOI 10.1016/j.jval.2011.07.008; Micoli G, 2001, J CHROMATOGR B, V750, P25, DOI 10.1016/S0378-4347(00)00377-7; Min JX, 2005, EUKARYOT CELL, V4, P178, DOI 10.1128/EC.4.1.178-189.2005; O'Sullivan S, 2017, NEUROPHARMACOLOGY, V113, P597, DOI 10.1016/j.neuropharm.2016.11.006; Offer SM, 2013, CANCER RES, V73, P1958, DOI 10.1158/0008-5472.CAN-12-3858; Parang B, 2016, METHODS MOL BIOL, V1422, P297, DOI 10.1007/978-1-4939-3603-8_26; Peters GJ, 2002, BBA-MOL BASIS DIS, V1587, P194, DOI 10.1016/S0925-4439(02)00082-0; Rosa R, 2013, CLIN CANCER RES, V19, P138, DOI 10.1158/1078-0432.CCR-12-1050; Rosmarin D, 2015, GUT, V64, P111, DOI 10.1136/gutjnl-2013-306571; Salas A, 2011, BLOOD, V117, P5941, DOI 10.1182/blood-2010-08-300772; Sarkar S, 2005, FEBS LETT, V579, P5313, DOI 10.1016/j.febslet.2005.08.055; Seymour MT, 2007, LANCET, V370, P143, DOI 10.1016/S0140-6736(07)61087-3; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Sun CC, 2014, PATHOL RES PRACT, V210, P668, DOI 10.1016/j.prp.2014.06.016; Van Cutsem E, 2001, J CLIN ONCOL, V19, P4097, DOI 10.1200/JCO.2001.19.21.4097; Venant H, 2015, MOL CANCER THER, V14, P2744, DOI 10.1158/1535-7163.MCT-15-0279; Xun C, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0205-y	34	9	10	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 16	2020	39	29					5214	5227		10.1038/s41388-020-1352-y	http://dx.doi.org/10.1038/s41388-020-1352-y		JUN 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ML6WO	32546724				2022-12-28	WOS:000540679400001
J	Crawford, LJ; Campbell, DC; Morgan, JJ; Lawson, MA; Down, JM; Chauhan, D; McAvera, RM; Morris, TC; Hamilton, C; Krishnan, A; Rajalingam, K; Chantry, AD; Irvine, AE				Crawford, Lisa J.; Campbell, David C.; Morgan, Jonathan J.; Lawson, Michelle A.; Down, Jennifer M.; Chauhan, Dharminder; McAvera, Roisin M.; Morris, Treen C.; Hamilton, Claudia; Krishnan, Aswini; Rajalingam, Krishnaraj; Chantry, Andrew D.; Irvine, Alexandra E.			The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma	ONCOGENE			English	Article							UBIQUITIN LIGASES; DOWN-REGULATION; BORTEZOMIB; CANCER; CELLS; APOPTOSIS; GROWTH; ARF	Proteasome inhibitors have provided a significant advance in the treatment of multiple myeloma (MM). Consequently, there is increasing interest in developing strategies to target E3 ligases, de-ubiquitinases, and/or ubiquitin receptors within the ubiquitin proteasome pathway, with an aim to achieve more specificity and reduced side-effects. Previous studies have shown a role for the E3 ligase HUWE1 in modulating c-MYC, an oncogene frequently dysregulated in MM. Here we investigated HUWE1 in MM. We identified elevated expression of HUWE1 in MM compared with normal cells. Small molecule-mediated inhibition of HUWE1 resulted in growth arrest of MM cell lines without significantly effecting the growth of normal bone marrow cells, suggesting a favorable therapeutic index. Studies using a HUWE1 knockdown model showed similar growth inhibition. HUWE1 expression positively correlated with MYC expression in MM bone marrow cells and correspondingly, genetic knockdown and biochemical inhibition of HUWE1 reduced MYC expression in MM cell lines. Proteomic identification of HUWE1 substrates revealed a strong association of HUWE1 with metabolic processes in MM cells. Intracellular glutamine levels are decreased in the absence of HUWE1 and may contribute to MYC degradation. Finally, HUWE1 depletion in combination with lenalidomide resulted in synergistic anti-MM activity in both in vitro and in vivo models. Taken together, our data demonstrate an important role of HUWE1 in MM cell growth and provides preclinical rationale for therapeutic strategies targeting HUWE1 in MM.	[Crawford, Lisa J.; Campbell, David C.; Morgan, Jonathan J.; McAvera, Roisin M.; Morris, Treen C.; Hamilton, Claudia; Irvine, Alexandra E.] Queens Univ Belfast, Patrick G Johnston Ctr Canc Res, Belfast, Antrim, North Ireland; [Lawson, Michelle A.; Down, Jennifer M.; Chantry, Andrew D.] Univ Sheffield, Sch Med, Sheffield Myeloma Res Team, Dept Oncol & Metab, Sheffield, S Yorkshire, England; [Chauhan, Dharminder] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA; [Chauhan, Dharminder] Harvard Med Sch, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr, Boston, MA 02115 USA; [Krishnan, Aswini; Rajalingam, Krishnaraj] Univ Med Ctr Mainz, Cell Biol Unit, Mainz, Germany	Queens University Belfast; University of Sheffield; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Johannes Gutenberg University of Mainz	Crawford, LJ (corresponding author), Queens Univ Belfast, Patrick G Johnston Ctr Canc Res, Belfast, Antrim, North Ireland.	lisa.crawford@qub.ac.uk	Lawson, Michelle/M-6095-2019	Lawson, Michelle/0000-0002-5446-923X; Morgan, Jonathan/0000-0002-9062-1542; Crawford, Lisa/0000-0001-5162-1809; McAvera, Roisin/0000-0002-1222-3047	Blood Cancer UK; Leukemia Lymphoma NI	Blood Cancer UK; Leukemia Lymphoma NI	This work was supported by a grant from Blood Cancer UK and funding from Leukemia & Lymphoma NI.	Adhikary S, 2005, CELL, V123, P409, DOI 10.1016/j.cell.2005.08.016; Bankhead P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17204-5; Bosshard M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15380-y; Chang Xiu-Bao, 2011, Int J Biochem Mol Biol, V2, P287; Chauhan D, 2012, CANCER CELL, V22, P345, DOI 10.1016/j.ccr.2012.08.007; Choe KN, 2016, EMBO REP, V17, P874, DOI 10.15252/embr.201541685; Confalonieri S, 2009, ONCOGENE, V28, P2959, DOI 10.1038/onc.2009.156; Crawford LJ, 2016, ONCOTARGET, V7, P70481, DOI 10.18632/oncotarget.12026; Effenberger M, 2017, ONCOTARGET, V8, P85858, DOI 10.18632/oncotarget.20691; El Arfani C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041200; Groen K, 2019, CANCER MANAG RES, V11, P2663, DOI 10.2147/CMAR.S150653; Guerrero-Garcia TA, 2018, EXPERT REV PROTEOMIC, V15, P1033, DOI 10.1080/14789450.2018.1543595; Hao ZY, 2012, J EXP MED, V209, P173, DOI 10.1084/jem.20111363; Horenstein AL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00760; Inoue S, 2013, GENE DEV, V27, P1101, DOI 10.1101/gad.214577.113; Jang ER, 2014, MOL CELL BIOL, V34, P3579, DOI 10.1128/MCB.00811-14; Jovanovic KK, 2018, LEUKEMIA, V32, P1295, DOI 10.1038/s41375-018-0036-x; Kao SH, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929-018-0470-0; Krishnan A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15955-w; Lawson MA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119546; Lee HJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10374-y; Leleu X, 2019, CL LYMPH MYELOM LEUK, V19, P9, DOI 10.1016/j.clml.2018.08.016; Liu P, 2019, EPIGENET CHROMATIN, V12, DOI 10.1186/s13072-019-0322-5; Nguyen L, 2017, GENES-BASEL, V8, DOI 10.3390/genes8040116; Mansour MA, 2018, INT J BIOCHEM CELL B, V101, P80, DOI 10.1016/j.biocel.2018.06.001; Michel MA, 2017, MOL CELL, V68, P233, DOI 10.1016/j.molcel.2017.08.020; Moortgat S, 2018, EUR J HUM GENET, V26, P64, DOI 10.1038/s41431-017-0038-6; Myant KB, 2017, EMBO MOL MED, V9, P181, DOI 10.15252/emmm.201606684; Ohtake F, 2016, MOL CELL, V64, P251, DOI 10.1016/j.molcel.2016.09.014; Pandya RK, 2010, J BIOL CHEM, V285, P5664, DOI 10.1074/jbc.M109.051805; Peter S, 2014, EMBO MOL MED, V6, P1525, DOI 10.15252/emmm.201403927; Poulsen EG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050548; Qi CF, 2013, LEUKEMIA RES, V37, P1680, DOI 10.1016/j.leukres.2013.09.009; Qi CF, 2012, INT J MOL SCI, V13, P6204, DOI 10.3390/ijms13056204; Rajkumar SV, 2019, HEMATOL ONCOL, V37, P62, DOI 10.1002/hon.2586; Richardson PG, 2018, EXPERT OPIN PHARMACO, V19, P1949, DOI 10.1080/14656566.2018.1528229; Rizzieri D, 2019, J CANC METASTASIS TR, V5, P26, DOI 10.20517/2394-4722.2019.05; Sander B, 2017, ELIFE, V6, DOI 10.7554/eLife.21036; Song Y, 2017, ONCOGENE, V36, P5631, DOI 10.1038/onc.2017.172; Vaughan L, 2015, CELL REP, V10, P88, DOI 10.1016/j.celrep.2014.12.012; Velasco R, 2019, J PERIPHER NERV SYST, V24, pS52, DOI 10.1111/jns.12338; Walker BA, 2018, BLOOD, V132, P587, DOI 10.1182/blood-2018-03-840132; Wallington-Beddoe CT, 2018, BRIT J HAEMATOL, V182, P11, DOI 10.1111/bjh.15210; Wang D, 2017, CANCER METAST REV, V36, P683, DOI 10.1007/s10555-017-9703-z; Wang SSS, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.18; Yang D, 2018, THERANOSTICS, V8, P3517, DOI 10.7150/thno.24401; Yang D, 2017, CANCER RES, V77, P4773, DOI 10.1158/0008-5472.CAN-16-2597; Zaal EA, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00500; Zhang ZB, 2016, BLOOD, V127, P1676, DOI 10.1182/blood-2015-07-658203	49	14	15	3	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 2	2020	39	27					5001	5014		10.1038/s41388-020-1345-x	http://dx.doi.org/10.1038/s41388-020-1345-x		JUN 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ME5NL	32523091	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000539515400001
J	Yadav, S; Anbalagan, M; Baddoo, M; Chellamuthu, VK; Mukhopadhyay, S; Woods, C; Jiang, W; Moroz, K; Flemington, EK; Makridakis, N				Yadav, Santosh; Anbalagan, Muralidharan; Baddoo, Melody; Chellamuthu, Vinodh K.; Mukhopadhyay, Sudurika; Woods, Carol; Jiang, Wei; Moroz, Krzysztof; Flemington, Erik K.; Makridakis, Nick			Somatic mutations in the DNA repairome in prostate cancers in African Americans and Caucasians	ONCOGENE			English	Article							GENE-MUTATIONS; HUMAN BREAST; PATTERNS; DEFECTS; ORIGINS; CELLS; RISK	Most hereditary tumors show aberrations in DNA repair genes or their regulators. In contrast, only a minority of sporadic tumors show alterations in these genes. As a result, genomic instability is currently considered an enhancer of tumorigenesis rather than an obligatory event in this process. However, tumor heterogeneity presents a significant technical challenge for most cancer genomics studies performed at less than 100x mean resolution depth. To address the importance of genomic instability in prostate carcinogenesis and tumor progression, we performed ultrahigh depth exome sequencing of 124 DNA damage repair/response (repairome) genes in 63 tumors and matched normal tissue samples in African Americans and Caucasians. The average sequence depth was 712-fold for DNA isolated from normal tissue and 368-fold for FFPE tumors. We identified 671 somatic mutations in tumors from African Americans and 762 somatic mutations in tumors in Caucasians. The most frequently mutated DNA repairome genes were EXO1, ATR, POLQ, NEIL3, ERCC6, BRCA2, BRCA1, XPC, JAG1, RPA1, POLE, ATM, and LIG1 in African American men, and POLQ, NEIL3, POLB, BRCA2, EXO1, ERCC6, ATR, RBBP8, BRCA1, ATM, JAG1, XPC, and POLE in Caucasians. We found that 89% of tumors had at least one mutation in nucleotide excision repair pathway genes in African Americans, whereas >40% of tumors had mutations in base excision repair pathway genes in Caucasians. We further identified a marginal increase in mutation rate in tumors in African Americans with increasing age. Tumors in Caucasians did not show a correlation with age, but a progressive increase in the mutation rate was observed at higher Gleason scores. Our data reveal significant differences in the molecular signatures in the DNA repairome in prostate cancer between African Americans and Caucasians. These data also have substantial implications regarding the well-known health disparities in prostate cancer, such as the higher mortality in African Americans than Caucasians.	[Yadav, Santosh; Anbalagan, Muralidharan; Baddoo, Melody; Mukhopadhyay, Sudurika; Woods, Carol; Jiang, Wei; Flemington, Erik K.; Makridakis, Nick] Louisiana Canc Res Ctr, New Orleans, LA 70112 USA; [Yadav, Santosh] Tulane Univ, Dept Med, Tulane Ctr Aging, New Orleans, LA 70118 USA; [Anbalagan, Muralidharan] Tulane Univ, Dept Struct & Cellular Biol, New Orleans, LA 70118 USA; [Baddoo, Melody; Moroz, Krzysztof; Flemington, Erik K.] Tulane Univ, Dept Pathol, New Orleans, LA 70118 USA; [Chellamuthu, Vinodh K.] Dixie State Univ, Dept Math, St George, UT 84770 USA; [Makridakis, Nick] 1Globe Hlth Inst, Boston, MA 02062 USA	Tulane University; Tulane University; Tulane University; Utah System of Higher Education; Dixie State University	Yadav, S; Makridakis, N (corresponding author), Louisiana Canc Res Ctr, New Orleans, LA 70112 USA.; Yadav, S (corresponding author), Tulane Univ, Dept Med, Tulane Ctr Aging, New Orleans, LA 70118 USA.; Makridakis, N (corresponding author), 1Globe Hlth Inst, Boston, MA 02062 USA.	Syadav1@tulane.edu; NMakridakis@1Globe-USA.com	Chellamuthu, Vinodh Kumar/AAS-6906-2020; Yadav, Santosh/GQZ-7569-2022	Anbalagan, Muralidharan/0000-0001-5797-7558	NCI NIH HHS [R01 CA243793] Funding Source: Medline; NIGMS NIH HHS [P20 GM103518] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akalu A, 1999, GENET ANAL-BIOMOL E, V15, P229, DOI 10.1016/S1050-3862(99)00050-9; An CL, 2011, HUM MUTAT, V32, P415, DOI 10.1002/humu.21465; Athie A, 2019, CURR ONCOL REP, V21, DOI 10.1007/s11912-019-0790-6; Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279; Bostwick DG, 2004, CANCER-AM CANCER SOC, V101, P2371, DOI 10.1002/cncr.20408; Brown JS, 2017, CANCER DISCOV, V7, P20, DOI 10.1158/2159-8290.CD-16-0860; Burgers PMJ, 2017, ANNU REV BIOCHEM, V86, P417, DOI 10.1146/annurev-biochem-061516-044709; Caglayan M, 2015, DNA REPAIR, V35, P85, DOI 10.1016/j.dnarep.2015.09.010; Caronia D, 2009, PHARMACOGENOMICS J, V9, P347, DOI 10.1038/tpj.2009.19; Choi Y, 2015, BIOINFORMATICS, V31, P2745, DOI 10.1093/bioinformatics/btv195; Christenson ES, 2018, EXPERT OPIN EMERG DR, V23, P123, DOI 10.1080/14728214.2018.1459563; DeSantis CE, 2019, CA-CANCER J CLIN, V69, P211, DOI 10.3322/caac.21555; Dong XQ, 2009, J CLIN ONCOL, V27, P1592, DOI 10.1200/JCO.2008.20.1111; Eyler CE, 2008, J CLIN ONCOL, V26, P2839, DOI 10.1200/JCO.2007.15.1829; Fox EJ, 2013, CANCER METAST REV, V32, P353, DOI 10.1007/s10555-013-9426-8; Gaines AR, 2014, CANCER CAUSE CONTROL, V25, P1029, DOI 10.1007/s10552-014-0402-6; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Gronberg H, 2003, LANCET, V361, P859, DOI 10.1016/S0140-6736(03)12713-4; Hoeijmakers JHJ, 2009, NEW ENGL J MED, V361, P1475, DOI 10.1056/NEJMra0804615; Koboldt Daniel C, 2013, Curr Protoc Bioinformatics, V44, DOI 10.1002/0471250953.bi1504s44; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Lin PC, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40571-0; Loeb LA, 2003, P NATL ACAD SCI USA, V100, P776, DOI 10.1073/pnas.0334858100; Makridakis NM, 2009, HUM MUTAT, V30, P39, DOI 10.1002/humu.20810; Marx J, 2002, SCIENCE, V297, P544, DOI 10.1126/science.297.5581.544; Mateo J, 2015, NEW ENGL J MED, V373, P1697, DOI 10.1056/NEJMoa1506859; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Nelson WG, 2014, CANCER TREAT RES, V159, P51, DOI 10.1007/978-3-642-38007-5_4; Nogueira Guilherme Augusto Silva, 2018, Oncotarget, V9, P29538, DOI 10.18632/oncotarget.25268; Powell IJ, 2007, J UROLOGY, V177, P444, DOI 10.1016/j.juro.2006.09.024; Pritchard CC, 2016, NEW ENGL J MED, V375, P443, DOI 10.1056/NEJMoa1603144; Ross CA, 2017, NATURE, V541, P34, DOI 10.1038/nature21107; Schweizer MT, 2017, CLIN ADV HEMATOL ONC, V15, P785; Shi WW, 2018, CELL REP, V25, P1446, DOI 10.1016/j.celrep.2018.10.046; Stephens P, 2005, NAT GENET, V37, P590, DOI 10.1038/ng1571; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Wedge DC, 2018, NAT GENET, V50, P682, DOI 10.1038/s41588-018-0086-z; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Yadav S, 2015, HUM MUTAT, V36, P873, DOI 10.1002/humu.22820	41	17	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	21					4299	4311		10.1038/s41388-020-1280-x	http://dx.doi.org/10.1038/s41388-020-1280-x			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LQ2DH	32300177	hybrid, Green Published			2022-12-28	WOS:000534819000011
J	Li, WJ; Dai, Y; Shi, BY; Yue, F; Zou, J; Xu, GB; Jiang, XH; Wang, F; Zhou, XK; Liu, LY				Li, Wenjiao; Dai, Yuan; Shi, Boyun; Yue, Fei; Zou, Jing; Xu, Guibin; Jiang, Xianhan; Wang, Fen; Zhou, Xinke; Liu, Leyuan			LRPPRC sustains Yap-P27-mediated cell ploidy and P62-HDAC6-mediated autophagy maturation and suppresses genome instability and hepatocellular carcinomas	ONCOGENE			English	Article							MITOCHONDRIAL; PROTEIN; TUMORIGENESIS; MICROTUBULE; PATHWAY; RASSF1; LIVER; ASSOCIATION; ACTIVATION; ANEUPLOIDY	Mutants in the gene encoding mitochondrion-associated protein LRPPRC were found to be associated with French Canadian Type Leigh syndrome, a human disorder characterized with neurodegeneration and cytochrome c oxidase deficiency. LRPPRC interacts with one of microtubule-associated protein family MAP1S that promotes autophagy initiation and maturation to suppress genomic instability and tumorigenesis. Previously, although various studies have attributed LRPPRC nuclear acid-associated functions, we characterized that LRPPRC acted as an inhibitor of autophagy in human cancer cells. Here we show that liver-specific deletion of LRPPRC causes liver-specific increases of YAP and P27 and decreases of P62, leading to an increase of cell polyploidy and an impairment of autophagy maturation. The blockade of autophagy maturation and promotion of polyploidy caused by LRPPRC depletion synergistically enhances diethylnitrosamine-induced DNA damage, genome instability, and further tumorigenesis so that LRPPRC knockout mice develop more and larger hepatocellular carcinomas and survive a shorter lifespan. Therefore, LRPPRC suppresses genome instability and hepatocellular carcinomas and promotes survivals in mice by sustaining Yap-P27-mediated cell ploidy and P62-HDAC6-controlled autophagy maturation.	[Li, Wenjiao; Shi, Boyun; Xu, Guibin; Jiang, Xianhan; Zhou, Xinke; Liu, Leyuan] Guangzhou Med Univ, Affiliated Hosp 5, 621 Gangwan Rd, Guangzhou 710700, Guangdong, Peoples R China; [Li, Wenjiao; Dai, Yuan; Shi, Boyun; Yue, Fei; Zou, Jing; Xu, Guibin; Jiang, Xianhan; Wang, Fen; Liu, Leyuan] Texas A&M Univ, Inst Biosci & Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA; [Liu, Leyuan] Texas A&M Univ, Coll Med, Dept Mol & Cellular Med, College Stn, TX 77843 USA	Guangzhou Medical University; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station	Liu, LY (corresponding author), Guangzhou Med Univ, Affiliated Hosp 5, 621 Gangwan Rd, Guangzhou 710700, Guangdong, Peoples R China.; Liu, LY (corresponding author), Texas A&M Univ, Inst Biosci & Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.; Liu, LY (corresponding author), Texas A&M Univ, Coll Med, Dept Mol & Cellular Med, College Stn, TX 77843 USA.	liuleyuan@hotmail.com	Yue, Fei/N-1891-2018	Li, Wenjiao/0000-0003-1308-8489; Zou, Jing/0000-0002-0976-7078	National Natural Science Foundation of China [81772931]; NCI [R01CA142862]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Nils-Goran Larsson, Department of Mitochondrial Genetics, Max Planck Institute for Biology of Ageing, Cologne, Germany, for providing LRPPRCloxP/loxP mice to us as a gift. This work was supported by National Natural Science Foundation of China (81772931) and NCI R01CA142862 to Leyuan Liu.	Chen Q, 2015, J BIOL CHEM, V290, P26051, DOI 10.1074/jbc.M115.653568; Chen Q, 2008, BLOOD, V111, P4690, DOI 10.1182/blood-2007-09-112904; Chourasia AH, 2015, CANCER METAB, V3, DOI 10.1186/s40170-015-0130-8; Cuillerier A, 2017, HUM MOL GENET, V26, P3186, DOI 10.1093/hmg/ddx202; Hergovich A, 2012, BIOCHEM SOC T, V40, P124, DOI 10.1042/BST20110619; Jiang XH, 2018, PROSTATE, V78, P426, DOI 10.1002/pros.23487; Jiang XH, 2015, MOL CARCINOGEN, V54, P1194, DOI 10.1002/mc.22193; Jiang XH, 2014, CANCER-AM CANCER SOC, V120, P1228, DOI 10.1002/cncr.28551; Jimenez-Martinez M, 2019, CANCERS, V11, DOI 10.3390/cancers11111767; Johansen T, 2020, J MOL BIOL, V432, P80, DOI 10.1016/j.jmb.2019.07.016; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Lai D, 2011, CANCER RES, V71, P2728, DOI 10.1158/0008-5472.CAN-10-2711; Lamkanfi M, 2014, CELL, V157, P1013, DOI 10.1016/j.cell.2014.04.007; Lee YA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07338-z; Li M, 2010, P NATL ACAD SCI USA, V107, P14188, DOI 10.1073/pnas.1005960107; Li WJ, 2019, CELL DEATH DIFFER, V26, P1379, DOI 10.1038/s41418-018-0211-7; Li WJ, 2016, AGING CELL, V15, P370, DOI 10.1111/acel.12441; Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537; Liu LY, 2012, AUTOPHAGY, V8, P278, DOI 10.4161/auto.8.2.18939; Liu LJ, 2011, J BIOL CHEM, V286, P41253, DOI 10.1074/jbc.M111.276121; Liu LY, 2005, BIOCHEM BIOPH RES CO, V332, P670, DOI 10.1016/j.bbrc.2005.05.006; Liu LY, 2005, CANCER RES, V65, P4191, DOI 10.1158/0008-5472.CAN-04-3865; Liu LY, 2005, CANCER RES, V65, P1830, DOI 10.1158/0008-5472.CAN-04-3896; Liu LY, 2002, IN VITRO CELL DEV-AN, V38, P582; Liu LY, 2002, GENOMICS, V79, P124, DOI 10.1006/geno.2001.6679; Marino G, 2007, J BIOL CHEM, V282, P18573, DOI 10.1074/jbc.M701194200; Mili S, 2003, MOL CELL BIOL, V23, P4972, DOI 10.1128/MCB.23.14.4972-4982.2003; Mishra PK, 2009, FREE RADICAL RES, V43, P718, DOI 10.1080/10715760903037699; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mootha VK, 2003, P NATL ACAD SCI USA, V100, P605, DOI 10.1073/pnas.242716699; Nam M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01879-x; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Refolo G, 2019, HEPATOLOGY, V69, P34, DOI 10.1002/hep.30149; Ruzzenente B, 2012, EMBO J, V31, P443, DOI 10.1038/emboj.2011.392; Ryter Stefan W, 2014, Int J Cell Biol, V2014, P502676, DOI 10.1155/2014/502676; Schweitzer CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040537; Siira SJ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01221-z; Singh S, 2014, NAT REV GASTRO HEPAT, V11, P45, DOI 10.1038/nrgastro.2013.143; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211; Terman A, 2006, CHEM-BIOL INTERACT, V163, P29, DOI 10.1016/j.cbi.2006.04.013; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Vandin F, 2012, BIOCOMPUT-PAC SYM, P55; Xie R, 2011, CANCER RES, V71, P7537, DOI 10.1158/0008-5472.CAN-11-2170; Xie R, 2011, J BIOL CHEM, V286, P10367, DOI 10.1074/jbc.M110.206532; Xie R, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-89; Xu FH, 2012, BIOCHEM J, V441, P275, DOI 10.1042/BJ20110985; Xu GB, 2016, ONCOTARGET, V7, P6255, DOI 10.18632/oncotarget.6669; Yu JJ, 2014, P NATL ACAD SCI USA, V111, P15514, DOI 10.1073/pnas.1414859111; Yue F, 2017, CANCER RES, V77, P2938, DOI 10.1158/0008-5472.CAN-16-3462; Yue F, 2015, AGING-US, V7, P839, DOI 10.18632/aging.100818; Zhang SH, 2017, CANCER CELL, V31, P669, DOI 10.1016/j.ccell.2017.04.004; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zou J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094903; Zou J, 2013, BIOCHEM J, V454, P447, DOI 10.1042/BJ20130306	56	10	10	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	19					3879	3892		10.1038/s41388-020-1257-9	http://dx.doi.org/10.1038/s41388-020-1257-9		MAR 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LK4OF	32203162				2022-12-28	WOS:000519841000001
J	Yang, W; Khoury, E; Guo, QY; Prabhu, SA; Emond, A; Huang, F; Goncalves, C; Zhan, Y; Plourde, D; Nichol, JN; Dahabieh, MS; Miller, WH; del Rincon, SV				Yang, William; Khoury, Elie; Guo, Qianyu; Prabhu, Sathyen A.; Emond, Audrey; Huang, Fan; Goncalves, Christophe; Zhan, Yao; Plourde, Dany; Nichol, Jessica N.; Dahabieh, Michael S.; Miller Jr., Wilson H.; del Rincon, Sonia Victoria			MNK1 signaling induces an ANGPTL4-mediated gene signature to drive melanoma progression	ONCOGENE			English	Article							ACTIVATED RECEPTOR BETA/DELTA; MATRIX METALLOPROTEINASES; EIF4E; PHOSPHORYLATION; METASTASIS; INVASION; ANGPTL4; INHIBITION; RESISTANCE; CLUSTERIN	The BRAF(V600E) mutation occurs in more than 50% of cutaneous melanomas, and results in the constitutive activation of the mitogen-activated protein kinases (MAPK) pathway. MAP kinase-interacting serine/threonine-protein kinase 1 and 2 (MNK1/2) are downstream effectors of the activated MAPK pathway, and important molecular targets in invasive and metastatic cancer. Despite the well-known role of MNK1 in regulating mRNA translation, little is known concerning the impact of its aberrant activation on gene transcription. Here, we show that changes in the activity, or abundance, of MNK1 result in changes in the expression of pro-oncogenic and pro-invasive genes. Among the MNK1-upregulated genes, we identify Angiopoietin-like 4 (ANGPTL4), which in turn promotes an invasive phenotype via its ability to induce the expression of matrix metalloproteinases (MMPs). Using a pharmacologic inhibitor of MNK1/2, SEL201, we demonstrate that BRAF(V600E)-mutated cutaneous melanoma cells are reliant on MNK1/2 for invasion and lung metastasis.	[Yang, William; Khoury, Elie; Guo, Qianyu; Prabhu, Sathyen A.; Huang, Fan; Zhan, Yao; Dahabieh, Michael S.; Miller Jr., Wilson H.; del Rincon, Sonia Victoria] McGill Univ, Div Expt Med, Fac Med, Montreal, PQ, Canada; [Yang, William; Khoury, Elie; Guo, Qianyu; Prabhu, Sathyen A.; Emond, Audrey; Huang, Fan; Goncalves, Christophe; Zhan, Yao; Plourde, Dany; Nichol, Jessica N.; Dahabieh, Michael S.; Miller Jr., Wilson H.; del Rincon, Sonia Victoria] McGill Univ, Lady Davis Inst, Jewish Gen Hosp, Montreal, PQ, Canada; [Miller Jr., Wilson H.] McGill Univ, Rossy Canc Network, Montreal, PQ, Canada	McGill University; Lady Davis Institute; McGill University; McGill University	Miller, WH; del Rincon, SV (corresponding author), McGill Univ, Div Expt Med, Fac Med, Montreal, PQ, Canada.; Miller, WH; del Rincon, SV (corresponding author), McGill Univ, Lady Davis Inst, Jewish Gen Hosp, Montreal, PQ, Canada.; Miller, WH (corresponding author), McGill Univ, Rossy Canc Network, Montreal, PQ, Canada.	wmiller@ldi.jgh.mcgill.ca; sonia.delrincon@mcgill.ca	Yang, William/AAU-2275-2020	Huang, Fan/0000-0002-3850-5317; Emond, Audrey/0000-0001-8053-2784; Miller, Wilson H./0000-0002-7408-1574	Canadian Institutes for Health Research [MOP-142281 PJT-156269, PJT-162260]; Canadian Cancer Society [703811]; Rossy Cancer Network; National Centre for Research and Development, INNOTECH Program [INNOTECH-K1/HI1/I6/157438/NCBR/12]; Cole Foundation Ph.D. fellowship; MICRTP graduate studentships; McGill Integrated Cancer Research Training Program (MICRTP) graduate studentship; McGill Faculty of Medicine graduate studentship	Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Cancer Society(Canadian Cancer Society (CCS)); Rossy Cancer Network; National Centre for Research and Development, INNOTECH Program; Cole Foundation Ph.D. fellowship; MICRTP graduate studentships; McGill Integrated Cancer Research Training Program (MICRTP) graduate studentship; McGill Faculty of Medicine graduate studentship	This research is funded by the Canadian Institutes for Health Research (grants MOP-142281 PJT-156269 to WHM and SVDR, and grant PJT-162260 to SVDR) and the Canadian Cancer Society (grant 703811 WHM and SVDR). The research was further supported by the Rossy Cancer Network. Development of MNK1/2 inhibitors by Selvita S.A. has been co-financed by the National Centre for Research and Development, INNOTECH Program (INNOTECH-K1/HI1/I6/157438/NCBR/12). WY was endowed by MICRTP graduate studentships. QG was financed by a Cole Foundation Ph.D. fellowship, McGill Integrated Cancer Research Training Program (MICRTP) graduate studentship and a McGill Faculty of Medicine graduate studentship. FH was sponsored by MICRTP graduate studentships. We thank Shalom Chaim Spira for editing this manuscript.	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Ascierto PA, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-85; Baron V, 2006, CANCER GENE THER, V13, P115, DOI 10.1038/sj.cgt.7700896; Beyaz S, 2016, CLIN CANCER RES, V22, P5636, DOI 10.1158/1078-0432.CCR-16-0775; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Djeu JY, 2009, ADV CANCER RES, V105, P77, DOI 10.1016/S0065-230X(09)05005-2; Domingues B, 2018, IMMUNOTARGETS THER, V7, P35, DOI 10.2147/ITT.S134842; Fang L, 2016, PPAR RES, V2016, DOI 10.1155/2016/6042162; Geller Alan C, 2003, Semin Oncol Nurs, V19, P2, DOI 10.1053/sonu.2003.50000; Georgiadi A, 2010, CIRC RES, V106, P1712, DOI 10.1161/CIRCRESAHA.110.217380; Gialeli C, 2011, FEBS J, V278, P16, DOI 10.1111/j.1742-4658.2010.07919.x; Guo QY, 2019, CANCER RES, V79, P1646, DOI 10.1158/0008-5472.CAN-18-1602; Guo ZH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10397-9; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hu K, 2016, ONCOTARGET, V7, P7816, DOI 10.18632/oncotarget.6868; Joshi Sonali, 2014, World J Biol Chem, V5, P321, DOI 10.4331/wjbc.v5.i3.321; Kimura R, 2011, BBA-MOL CELL RES, V1813, P1543, DOI 10.1016/j.bbamcr.2011.04.008; Korneeva NL, 2010, MOL CANCER RES, V8, P1571, DOI 10.1158/1541-7786.MCR-10-0091; La Paglia L, 2017, PPAR RES, V2017, DOI 10.1155/2017/8187235; Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868; Liao YH, 2017, ONCOGENE, V36, P2228, DOI 10.1038/onc.2016.371; Liu L, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.419; Naruhn S, 2011, MOL PHARMACOL, V80, P828, DOI 10.1124/mol.111.074039; O'Loghlen A, 2007, BBA-MOL CELL RES, V1773, P1416, DOI 10.1016/j.bbamcr.2007.05.009; Pettersson F, 2015, CANCER RES, V75, P1102, DOI 10.1158/0008-5472.CAN-14-1996; Ramalingam S, 2014, ONCOTARGET, V5, P530, DOI 10.18632/oncotarget.1528; Redondo M, 2009, ADV CANCER RES, V105, P21, DOI 10.1016/S0065-230X(09)05002-7; Robert C, 2015, NEW ENGL J MED, V372, P30, DOI 10.1056/NEJMoa1412690; Robichaud N, 2015, ONCOGENE, V34, P2032, DOI 10.1038/onc.2014.146; Vella V, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00031; Wang JH, 2010, WORLD J GASTROENTERO, V16, P5642, DOI 10.3748/wjg.v16.i44.5642; Zhan Y, 2017, J CLIN INVEST, V127, P4179, DOI 10.1172/JCI91258	34	10	10	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	18					3650	3665		10.1038/s41388-020-1240-5	http://dx.doi.org/10.1038/s41388-020-1240-5		MAR 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LI5XR	32132651				2022-12-28	WOS:000518095100001
J	Janiszewska, M				Janiszewska, Michalina			The microcosmos of intratumor heterogeneity: the space-time of cancer evolution	ONCOGENE			English	Review							SINGLE-CELL ANALYSIS; BREAST-CANCER; BRANCHED EVOLUTION; IN-SITU; REVEALS; RESISTANCE; MUTATIONS; AMPLIFICATION; METASTASIS; RNA	The Cancer Genome Atlas consortium brought us terabytes of information about genetic alterations in different types of human tumors. While many cancer-driver genes have been identified through these efforts, interrogating cancer genomes has also shed new light on tumor complexity. Mutations were found to vary tremendously in their allelic frequencies within the same tumor. Based on those variant allelic frequencies grouping, an estimate of genetically distinct "clones" of cancer cells can be determined for each tumor. It was estimated that 4-8 clones are present in every human tumor. Presence of distinct clones, cells that differ in their genotype and/or phenotype, is one of the roots for the major challenge of effectively curing cancer patients. Any given treatment applied to a heterogeneous mixture of cancer cells will yield distinct responses in different cells and may be ineffective in killing particular clones. Moreover, in highly heterogeneous tumors, stochastically, there is a higher chance of presence of traits, such as point mutations in key receptor tyrosine kinases, that drive drug resistance. Thus, intratumor heterogeneity is like an arsenal, providing a variety of weapons for self-defense against cancer-targeted therapy. However, in this arsenal the supplies are constantly changing, as cancer cells are accumulating new mutations. What is also changing is the battlefield-the tumor microenvironment including all noncancerous cells within the tumor and surrounding tissue, which also contribute to the diversification of cancer's forces. In order to design more effective therapies that would target this ever-changing landscape, we need to learn more about the two elusive variables that shape the tumor ecosystem: the space-how could we exploit the organization of tumor microenvironment? and the time-how could we predict the changes in heterogeneous tumors?	[Janiszewska, Michalina] Scripps Res Inst, Dept Mol Med, Jupiter, FL 33458 USA	Scripps Research Institute	Janiszewska, M (corresponding author), Scripps Res Inst, Dept Mol Med, Jupiter, FL 33458 USA.	mjaniszewska@scripps.edu			NIH [R00 CA201606-01A1]; Scripps Research Institute	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Scripps Research Institute	I thank Dr Joseph Kissil (The Scripps Research Institute) and the Janiszewska lab members for insightful discussions. This work is supported by NIH R00 CA201606-01A1 and the startup funds provided by the Scripps Research Institute.	Aceto N, 2014, CELL, V158, P1110, DOI 10.1016/j.cell.2014.07.013; Andor N, 2016, NAT MED, V22, P105, DOI 10.1038/nm.3984; Angelo M, 2014, NAT MED, V20, P436, DOI 10.1038/nm.3488; Baker AM, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02295-5; Ben-David U, 2018, NATURE, V560, P325, DOI 10.1038/s41586-018-0409-3; Berglund E, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04724-5; Bhang HEC, 2015, NAT MED, V21, P440, DOI 10.1038/nm.3841; Brastianos PK, 2015, CANCER DISCOV, V5, P1164, DOI 10.1158/2159-8290.CD-15-0369; Carter SL, 2012, NAT BIOTECHNOL, V30, P413, DOI 10.1038/nbt.2203; Casasent AK, 2018, CELL, V172, P205, DOI 10.1016/j.cell.2017.12.007; Chevrier S, 2017, CELL, V169, P736, DOI 10.1016/j.cell.2017.04.016; Dawson SJ, 2013, NEW ENGL J MED, V368, P1199, DOI 10.1056/NEJMoa1213261; Flavahan WA, 2017, SCIENCE, V357, DOI 10.1126/science.aal2380; Gaiti F, 2019, NATURE, V569, P576, DOI 10.1038/s41586-019-1198-z; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Gerdes MJ, 2013, P NATL ACAD SCI USA, V110, P11982, DOI 10.1073/pnas.1300136110; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Giaretti W, 1996, AM J PATHOL, V149, P237; Giesen C, 2014, NAT METHODS, V11, P417, DOI [10.1038/NMETH.2869, 10.1038/nmeth.2869]; Haber DA, 2014, CANCER DISCOV, V4, P650, DOI 10.1158/2159-8290.CD-13-1014; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hernandez L, 2012, J PATHOL, V227, P42, DOI 10.1002/path.3990; Hinohara K, 2019, TRENDS CELL BIOL, V29, P569, DOI 10.1016/j.tcb.2019.03.003; Hinohara K, 2019, CANCER CELL, V35, P330, DOI 10.1016/j.ccell.2019.01.012; Janiszewska M, 2019, NAT CELL BIOL, V21, P879, DOI 10.1038/s41556-019-0346-x; Janiszewska M, 2015, NAT GENET, V47, P1212, DOI 10.1038/ng.3391; Jeselsohn R, 2015, NAT REV CLIN ONCOL, V12, P573, DOI 10.1038/nrclinonc.2015.117; Joshi K, 2019, NAT MED, V25, P1549, DOI 10.1038/s41591-019-0592-2; Khalil DN, 2016, NAT REV CLIN ONCOL, V13, P273, DOI 10.1038/nrclinonc.2016.25; KONISHI N, 1995, AM J PATHOL, V147, P1112; Lan XY, 2017, NATURE, V549, P227, DOI 10.1038/nature23666; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Lee CH, 2018, TRENDS IMMUNOL, V39, P536, DOI 10.1016/j.it.2018.04.005; Lee JH, 2014, SCIENCE, V343, P1360, DOI 10.1126/science.1250212; Lin JR, 2018, ELIFE, V7, DOI 10.7554/eLife.31657; Maley CC, 2006, NAT GENET, V38, P468, DOI 10.1038/ng1768; Martincorena I, 2015, SCIENCE, V348, P880, DOI 10.1126/science.aaa6806; Marusyk A, 2014, NATURE, V514, P54, DOI 10.1038/nature13556; McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490; Merlo LMF, 2006, NAT REV CANCER, V6, P924, DOI 10.1038/nrc2013; Miller AM, 2019, NATURE, V565, P654, DOI 10.1038/s41586-019-0882-3; Miller CA, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003665; Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156; Neftel C, 2019, CELL, V178, P835, DOI 10.1016/j.cell.2019.06.024; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; Prager BC, 2019, CELL STEM CELL, V24, P41, DOI 10.1016/j.stem.2018.12.009; Reeves MQ, 2018, NAT CELL BIOL, V20, DOI 10.1038/s41556-018-0109-0; Rodriques SG, 2019, SCIENCE, V363, P1463, DOI 10.1126/science.aaw1219; Rosenthal R, 2019, NATURE, V567, P479, DOI 10.1038/s41586-019-1032-7; Roth A, 2014, NAT METHODS, V11, P396, DOI [10.1038/nmeth.2883, 10.1038/NMETH.2883]; Rye IH, 2018, MOL ONCOL, V12, P1838, DOI 10.1002/1878-0261.12375; Seol H, 2012, MODERN PATHOL, V25, P938, DOI 10.1038/modpathol.2012.36; Shema E, 2019, NAT GENET, V51, P19, DOI 10.1038/s41588-018-0290-x; Siegel MB, 2018, J CLIN INVEST, V128, P1371, DOI 10.1172/JCI96153; Siravegna G, 2015, NAT MED, V21, P795, DOI 10.1038/nm.3870; Snuderl M, 2011, CANCER CELL, V20, P810, DOI 10.1016/j.ccr.2011.11.005; Soucheray M, 2015, CANCER RES, V75, P4372, DOI 10.1158/0008-5472.CAN-15-0377; Stachler MD, 2015, NAT GENET, V47, P1047, DOI 10.1038/ng.3343; Stahl PL, 2016, SCIENCE, V353, P78, DOI 10.1126/science.aaf2403; Sun RP, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a028381; Tanay A, 2017, NATURE, V541, P331, DOI 10.1038/nature21350; Thrane K, 2018, CANCER RES, V78, P5970, DOI 10.1158/0008-5472.CAN-18-0747; Tsujikawa T, 2017, CELL REP, V19, P203, DOI 10.1016/j.celrep.2017.03.037; Turajlic S, 2016, SCIENCE, V352, P169, DOI 10.1126/science.aaf2784; Vogelstein B, 2015, NEW ENGL J MED, V373, P1895, DOI 10.1056/NEJMp1508811; Yates LR, 2017, CANCER CELL, V32, P169, DOI 10.1016/j.ccell.2017.07.005; Yates LR, 2015, NAT MED, V21, P751, DOI 10.1038/nm.3886; Yizhak K, 2019, SCIENCE, V364, P970, DOI 10.1126/science.aaw0726; Zhang JJ, 2014, SCIENCE, V346, P256, DOI 10.1126/science.1256930	69	26	26	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	10					2031	2039		10.1038/s41388-019-1127-5	http://dx.doi.org/10.1038/s41388-019-1127-5			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KS8UR	31784650	Green Accepted			2022-12-28	WOS:000518584000001
J	Wang, Y; Liu, Y; Bailey, C; Zhang, HX; He, M; Sun, DX; Zhang, P; Parkin, B; Baer, MR; Zheng, P; Malek, SN; Liu, Y				Wang, Yin; Liu, Yan; Bailey, Christopher; Zhang, Huixia; He, Miao; Sun, Duxin; Zhang, Peng; Parkin, Brian; Baer, Maria R.; Zheng, Pan; Malek, Sami N.; Liu, Yang			Therapeutic targeting of TP53-mutated acute myeloid leukemia by inhibiting HIF-1 alpha with echinomycin	ONCOGENE			English	Article							MYELODYSPLASTIC SYNDROMES; P53 MUTATIONS; STEM-CELLS; TP53 GENE; SURVIVAL; PERMEABILITY; HIF1-ALPHA	TP53 mutation in acute myeloid leukemia (AML) is associated with poor prognosis. Since no targeted therapy is available to restore p53 function, it is of great interest to test whether other pathways activated by TP53 mutations can be therapeutically targeted. Here, we showed HIF-1 alpha target genes are enriched in TP53-mutated versus TP53-wild-type AML. To determine the role of this activation, we tested efficacy of HIF-1 alpha inhibitor echinomycin in TP53-mutated AML samples in vitro and in vivo. Echinomycin was broadly effective against a panel of primary AML blast cells, with low nanomolar IC(50)s and, based on colony-forming unit assay, was tenfold more effective in eliminating AML stem cells. Echinomycin selectively eliminated CD34(+)CD38(-) AML cells. To test the therapeutic efficacy of echinomycin, we established a xenograft model of TP53-mutated AML. Echinomycin was broadly effective against xenografts from multiple AML samples in vivo, and more effective than cytarabine + daunorubicin chemotherapy. Importantly, while cytarabine + daunorubicin enriched for AML stem cells, echinomycin nearly eliminated this population. Using TP53-mutated AML cell line THP1 and patient-derived AML cells, we tested a new echinomycin formulation with longer half-life and significantly improved therapeutic effect. Our data suggest a novel approach to treat AML with TP53 mutations.	[Wang, Yin; Liu, Yan; Bailey, Christopher; Zhang, Peng; Zheng, Pan; Liu, Yang] Univ Maryland, Sch Med, Dept Surg, Div Immunotherapy,Inst Human Virol, Baltimore, MD 21201 USA; [Wang, Yin; Liu, Yan; Bailey, Christopher; Zhang, Peng; Zheng, Pan; Liu, Yang] Univ Maryland, Sch Med, Ctr Comprehens Canc, Baltimore, MD 21201 USA; [Bailey, Christopher] George Washington Univ, Sch Med, Grad Program Integrated Biomed Res, Washington, DC 20052 USA; [Zhang, Huixia; He, Miao; Sun, Duxin] Univ Michigan, Dept Pharmaceut Sci, Ann Arbor, MI 48109 USA; [Parkin, Brian; Malek, Sami N.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; [Baer, Maria R.] Univ Maryland, Dept Med, Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA; [Zheng, Pan; Liu, Yang] OncoImmune Inc, Rockville, MD 20853 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; George Washington University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University System of Maryland; University of Maryland Baltimore	Wang, Y; Liu, Y (corresponding author), Univ Maryland, Sch Med, Dept Surg, Div Immunotherapy,Inst Human Virol, Baltimore, MD 21201 USA.; Wang, Y; Liu, Y (corresponding author), Univ Maryland, Sch Med, Ctr Comprehens Canc, Baltimore, MD 21201 USA.; Liu, Y (corresponding author), OncoImmune Inc, Rockville, MD 20853 USA.	yin.wang@ihv.umaryland.edu; yaliu@ihv.umaryland.edu	Sun, Duxin/AAA-1774-2022	Zhang, Peng/0000-0002-6218-1885	National Institutes of Health National Cancer Institute [CA171972, CA183030, CA164469]; OncoImmune, Inc.	National Institutes of Health National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OncoImmune, Inc.	This study was supported by grants from the National Institutes of Health National Cancer Institute [CA171972, CA183030 (YL) and CA164469 (YW)] and a grant from OncoImmune, Inc. Some of the studies were performed when the authors were at the Children's National Medical Center in Washington, DC.	Bally C, 2014, LEUKEMIA RES, V38, P751, DOI 10.1016/j.leukres.2014.03.012; Bejar R, 2014, J CLIN ONCOL, V32, P2691, DOI 10.1200/JCO.2013.52.3381; BenYehuda D, 1996, BLOOD, V88, P4296; Birner P, 2001, CLIN CANCER RES, V7, P1661; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; Cerqueira BBS, 2015, EUR J PHARM BIOPHARM, V97, P140, DOI 10.1016/j.ejpb.2015.10.007; Cheloni G, 2017, BLOOD, V130, P655, DOI 10.1182/blood-2016-10-745588; CORBAZ R, 1957, HELV CHIM ACTA, V40, P199, DOI 10.1002/hlca.19570400124; Haferlach C, 2008, LEUKEMIA, V22, P1539, DOI 10.1038/leu.2008.143; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hou HA, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.59; Huang J, 2009, J CLIN INVEST, V119, P3519, DOI 10.1172/JCI40572; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; Iyer AK, 2006, DRUG DISCOV TODAY, V11, P812, DOI 10.1016/j.drudis.2006.07.005; Kong DH, 2005, CANCER RES, V65, P9047, DOI 10.1158/0008-5472.CAN-05-1235; Kumar P, 2012, CRIT REV THER DRUG, V29, P355, DOI 10.1615/CritRevTherDrugCarrierSyst.v29.i5.10; Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5; Ok CY, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0139-z; Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008; Parkin B, 2010, BLOOD, V116, P4958, DOI 10.1182/blood-2010-01-266999; Ruckner FG, 2012, BLOOD, V119, P2114, DOI 10.1182/blood-2011-08-375758; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Shih AH, 2013, HAEMATOLOGICA, V98, P908, DOI 10.3324/haematol.2012.076729; Silverman JA, 2013, CANCER CHEMOTH PHARM, V71, P555, DOI 10.1007/s00280-012-2042-4; SUGIMOTO K, 1992, BLOOD, V79, P2378, DOI 10.1182/blood.V79.9.2378.2378; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Tyner JW, 2018, NATURE, V562, P526, DOI 10.1038/s41586-018-0623-z; Wang Y, 2014, BLOOD, V124, P1127, DOI 10.1182/blood-2013-12-544221; Wang Y, 2011, CELL STEM CELL, V8, P399, DOI 10.1016/j.stem.2011.02.006; WATTEL E, 1994, BLOOD, V84, P3148, DOI 10.1182/blood.V84.9.3148.3148; Welch JS, 2016, NEW ENGL J MED, V375, P2023, DOI 10.1056/NEJMoa1605949; Zhang HJ, 2012, BLOOD, V119, P2595, DOI 10.1182/blood-2011-10-387381	32	15	16	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	14					3015	3027		10.1038/s41388-020-1201-z	http://dx.doi.org/10.1038/s41388-020-1201-z		FEB 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KZ2VB	32060420	Green Accepted			2022-12-28	WOS:000513384400001
J	Kluz, PN; Kolb, R; Xie, Q; Borcherding, N; Liu, Q; Luo, YW; Kim, MC; Wang, LN; Zhang, YN; Li, W; Stipp, C; Gibson-Corley, KN; Zhao, C; Qi, HH; Bellizzi, A; Tao, AW; Sugg, S; Weigel, RJ; Zhou, DH; Shen, X; Zhang, WZ				Kluz, Paige N.; Kolb, Ryan; Xie, Qing; Borcherding, Nicholas; Liu, Qi; Luo, Yuewan; Kim, Myung-Chul; Wang, Linna; Zhang, Yinan; Li, Wei; Stipp, Christopher; Gibson-Corley, Katherine N.; Zhao, Chen; Qi, Hank H.; Bellizzi, Andrew; Tao, Andy W.; Sugg, Sonia; Weigel, Ronald J.; Zhou, Daohong; Shen, Xian; Zhang, Weizhou			Cancer cell-intrinsic function of CD177 in attenuating beta-catenin signaling	ONCOGENE			English	Article							MAMMARY-GLAND HYPERPLASIA; GENE-EXPRESSION; TRANSGENIC MICE; WNT PATHWAY; BREAST; CADHERIN; ACTIVATION; PROMOTES; METASTASIS; SURVIVAL	Aiming to identify immune molecules with a novel function in cancer pathogenesis, we found the cluster of differentiation 177 (CD177), a known neutrophil antigen, to be positively correlated with relapse-free, metastasis-free, or overall survival in breast cancer. In addition, CD177 expression is correlated with good prognosis in several other solid cancers including prostate, cervical, and lung. Focusing on breast cancer, we found that CD177 is expressed in normal breast epithelial cells and is significantly reduced in invasive cancers. Loss of CD177 leads to hyperproliferative mammary epithelium and contributes to breast cancer pathogenesis. Mechanistically, we found that CD177-deficiency is associated with an increase in beta-catenin signaling. Here we identified CD177 as a novel regulator of mammary epithelial proliferation and breast cancer pathogenesis likely via the modulation of Wnt/beta-catenin signaling pathway, a key signaling pathway involved in multiple cancer types.	[Kluz, Paige N.; Xie, Qing; Borcherding, Nicholas; Gibson-Corley, Katherine N.; Zhao, Chen; Bellizzi, Andrew] Univ Iowa, Coll Med, Dept Pathol, Iowa City, IA 52242 USA; [Kluz, Paige N.; Luo, Yuewan; Kim, Myung-Chul; Li, Wei] Univ Iowa, Coll Med, Free Rad & Radiat Biol Program, Iowa City, IA 52242 USA; [Kolb, Ryan; Zhang, Weizhou] Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL 32610 USA; [Borcherding, Nicholas] Univ Iowa, Coll Med, Med Sci Training Program, Iowa City, IA 52242 USA; [Liu, Qi; Qi, Hank H.] Univ Iowa, Coll Med, Dept Anat & Cell Biol, Iowa City, IA 52242 USA; [Wang, Linna; Tao, Andy W.] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA; [Zhang, Yinan] Nankai Univ, Coll Life Sci, Dept Biol, Tianjin 300071, Peoples R China; [Stipp, Christopher] Univ Iowa, Coll Med, Dept Biol, Iowa City, IA 52242 USA; [Stipp, Christopher; Gibson-Corley, Katherine N.; Bellizzi, Andrew; Sugg, Sonia; Weigel, Ronald J.] Univ Iowa, Coll Med, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA; [Sugg, Sonia; Weigel, Ronald J.] Univ Iowa, Coll Med, Dept Surg, Iowa City, IA 52242 USA; [Zhou, Daohong] Univ Florida, Coll Pharm, Dept Pharmacodynam, Gainesville, FL 32610 USA; [Shen, Xian] Wenzhou Med Univ, Div Gastrointestinal Surg, Affiliated Hosp 2, Wenzhou 325035, Zhejiang, Peoples R China; [Xie, Qing] Xinxiang Med Univ, Sch Basic Med Sci, Tumor Signaling & Transduct Lab, Xinxiang 453000, Henan, Peoples R China	University of Iowa; University of Iowa; State University System of Florida; University of Florida; University of Iowa; University of Iowa; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Nankai University; University of Iowa; University of Iowa; University of Iowa; State University System of Florida; University of Florida; Wenzhou Medical University; Xinxiang Medical University	Zhang, WZ (corresponding author), Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL 32610 USA.; Shen, X (corresponding author), Wenzhou Med Univ, Div Gastrointestinal Surg, Affiliated Hosp 2, Wenzhou 325035, Zhejiang, Peoples R China.	13968888872@126.com; zhangw@ufl.edu	Kluz, Paige/AAT-4892-2021	Borcherding, Nicholas/0000-0003-1427-6342; Weigel, Ronald/0000-0002-9249-0793; Luo, Yuewan/0000-0002-8964-5301; Bellizzi, Andrew/0000-0002-8264-6379; Sugg, Sonia/0000-0001-7530-8526	NIH [CA206255, CA200673, CA203834]; V Scholar award; American Cancer Society; Breast Cancer Research Award; Oberley Award (National Cancer Institute Award) from Holden Comprehensive Cancer Center at the University of Iowa, University of Iowa [P30CA086862]; National Natural Science Foundation of China [81502313]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); V Scholar award; American Cancer Society(American Cancer Society); Breast Cancer Research Award; Oberley Award (National Cancer Institute Award) from Holden Comprehensive Cancer Center at the University of Iowa, University of Iowa; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	W.Z. was supported by NIH grants CA200673 and CA203834, the V Scholar award, American Cancer Society seed grant, Breast Cancer Research Award and Oberley Award (National Cancer Institute Award P30CA086862) from Holden Comprehensive Cancer Center at the University of Iowa, University of Iowa. N.B. was supported by NIH CA206255. Q.X. was supported by the National Natural Science Foundation of China (No. 81502313). We thank Dr. Foekens for sharing the site-specific metastasis information related to GSE2034. We thank Dr. Shay for sharing the human colon epithelial cells.	Badders NM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006594; Blankenberg Daniel, 2010, Curr Protoc Mol Biol, VChapter 19, DOI 10.1002/0471142727.mb1910s89; Borcherding N, 2018, AM J PATHOL, V188, P1910, DOI 10.1016/j.ajpath.2018.05.003; Brisken C, 2000, GENE DEV, V14, P650; Bulut G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027243; Caruccio L, 2006, TRANSFUSION, V46, P441, DOI 10.1111/j.1537-2995.2006.00741.x; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen Q, 2014, ONCOTARGET, V5, P9092, DOI 10.18632/oncotarget.2377; Chiurillo MA, 2015, WORLD J EXP MED, V5, P84, DOI [10.5493/wjem.v5.i2.84, DOI 10.5493/wjem.v5.i2.84, DOI 10.5493/WJEM.V5.I2.84]; Chu EY, 2004, DEVELOPMENT, V131, P4819, DOI 10.1242/dev.01347; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Dalerba P, 2011, NAT BIOTECHNOL, V29, P1120, DOI 10.1038/nbt.2038; Eger A, 2000, J CELL BIOL, V148, P173, DOI 10.1083/jcb.148.1.173; Fagotto F, 1996, J CELL BIOL, V132, P1105, DOI 10.1083/jcb.132.6.1105; Feng Q, 2014, CELL RES, V24, P809, DOI 10.1038/cr.2014.71; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Geyer FC, 2011, MODERN PATHOL, V24, P209, DOI 10.1038/modpathol.2010.205; Giardine B, 2005, GENOME RES, V15, P1451, DOI 10.1101/gr.4086505; Goecks J, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r86; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hayes MJ, 2008, CLIN CANCER RES, V14, P4038, DOI 10.1158/1078-0432.CCR-07-4379; HEASMAN J, 1994, DEVELOPMENT, V120, P49; Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555; Incassati A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2723; Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125; Kissel K, 2001, EUR J IMMUNOL, V31, P1301, DOI 10.1002/1521-4141(200105)31:5<1301::AID-IMMU1301>3.0.CO;2-J; Koesters R, 1999, CANCER RES, V59, P3880; Kuphal F, 2006, EXP CELL RES, V312, P457, DOI 10.1016/j.yexcr.2005.11.007; Kypta RM, 2012, NAT REV UROL, V9, P418, DOI 10.1038/nrurol.2012.116; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Lindvall C, 2006, J BIOL CHEM, V281, P35081, DOI 10.1074/jbc.M607571200; Lindvall C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005813; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Matsuzawa A, 2008, SCIENCE, V321, P663, DOI 10.1126/science.1157340; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Nakashima N, 2012, LUNG CANCER, V76, P228, DOI 10.1016/j.lungcan.2011.10.007; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Orsulic S, 1999, J CELL SCI, V112, P1237; Ozaki S, 2005, ONCOL REP, V14, P1437; Passamonti F, 2004, BRIT J HAEMATOL, V126, P650, DOI 10.1111/j.1365-2141.2004.05098.x; Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007; Prasad CP, 2007, ONCOLOGY-BASEL, V73, P112, DOI 10.1159/000120999; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Stockinger A, 2001, J CELL BIOL, V154, P1185, DOI 10.1083/jcb.200104036; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Temerinac S, 2000, BLOOD, V95, P2569; Tepera SB, 2003, J CELL SCI, V116, P1137, DOI 10.1242/jcs.00334; Teuliere J, 2005, DEVELOPMENT, V132, P267, DOI 10.1242/dev.01583; Toyoda T, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-122; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Uematsu K, 2003, ONCOGENE, V22, P7218, DOI 10.1038/sj.onc.1206817; Uhlen M, 2017, SCIENCE, V357, P660, DOI 10.1126/science.aan2507; Veeman MT, 2003, CURR BIOL, V13, P680, DOI 10.1016/S0960-9822(03)00240-9; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Xie Q, 2015, PROTEIN CELL, V6, P117, DOI 10.1007/s13238-014-0109-1; Yokoyama NN, 2014, AM J CLIN EXP UROL, V2, P27; Zeng YA, 2010, CELL STEM CELL, V6, P568, DOI 10.1016/j.stem.2010.03.020; Zhang J, 2010, ONCOGENE, V29, P539, DOI 10.1038/onc.2009.339; Zhang YN, 2014, INT J CLIN EXP PATHO, V7, P3908	63	6	6	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	14					2877	2889		10.1038/s41388-020-1203-x	http://dx.doi.org/10.1038/s41388-020-1203-x		FEB 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KZ2VB	32042113	Green Accepted			2022-12-28	WOS:000512528200001
J	Yang, R; Li, XX; Wu, YA; Zhang, GH; Liu, XR; Li, YP; Bao, YH; Yang, WC; Cui, HJ				Yang, Rui; Li, Xiuxiu; Wu, Yanan; Zhang, Guanghui; Liu, Xiaoran; Li, Yanping; Bao, Yonghua; Yang, Wancai; Cui, Hongjuan			EGFR activates GDH1 transcription to promote glutamine metabolism through MEK/ERK/ELK1 pathway in glioblastoma	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; SIGNAL-TRANSDUCTION; THERAPEUTIC TARGET; REDOX HOMEOSTASIS; CELL BIOLOGY; CANCER; ELK-1; RESISTANCE; PROTEIN; GLYCOLYSIS	Cancer metabolism research has recently been revived and its focus expanded from glucose and the Warburg's effects on other nutrients, such as glutamine. The underlying mechanism of oncogenic alterations of glutaminolysis remains unclear. Genetic alterations of EGFR are observed in similar to 50% of glioblastoma (GBM) patients, and have been found to play important roles in the metabolic abnormalities of GBM. In this study, we found that glutamine metabolism was upregulated after EGFR activation in a GDH1 (glutamate dehydrogenase 1)-dependent manner. Knockdown of GDH1 significantly reduced the cell proliferation, colony formation and tumorigenesis abilities of glioblastoma cells. Furthermore, we showed that GDH1-mediated glutaminolysis was involved in EGF-promoted cell proliferation. EGFR triggered the phosphorylation of ELK1 at Ser 383 through activating MEK/ERK signaling. Phosphorylated ELK1 enriched in the promoter of GDH1 to activate the transcription of GDH1, which then promoted glutamine metabolism. In addition, EGFR activation did not accelerate glutaminolysis in ELK1 knockdown or ELK1 Ser383-mutated cells. Collectively, our findings indicate that EGFR phosphorylates ELK1 to activate GDH1 transcription and glutaminolysis through MEK/ERK pathway, providing new insight into oncogenic alterations of glutamine metabolism.	[Yang, Rui; Liu, Xiaoran; Li, Yanping; Bao, Yonghua; Yang, Wancai] Jining Med Univ, Inst Precis Med, Key Lab Precis Oncol Shandong Higher Educ, Jining, Peoples R China; [Yang, Rui; Wu, Yanan; Zhang, Guanghui; Cui, Hongjuan] Southwest Univ, State Key Lab Silkworm Genome Biol, Chongqing, Peoples R China; [Li, Xiuxiu] Second Peoples Hosp Liaocheng, Dept Pharm, Liaocheng, Shandong, Peoples R China; [Zhang, Guanghui; Cui, Hongjuan] Southwest Univ, Engn Res Ctr Canc Biomed & Translat Med, Ctr Canc, Med Res Inst, Chongqing, Peoples R China; [Yang, Wancai] Univ Illinois, Dept Pathol, Chicago, IL USA	Jining Medical University; Southwest University - China; Southwest University - China; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Yang, R (corresponding author), Jining Med Univ, Inst Precis Med, Key Lab Precis Oncol Shandong Higher Educ, Jining, Peoples R China.; Yang, R; Cui, HJ (corresponding author), Southwest Univ, State Key Lab Silkworm Genome Biol, Chongqing, Peoples R China.; Cui, HJ (corresponding author), Southwest Univ, Engn Res Ctr Canc Biomed & Translat Med, Ctr Canc, Med Res Inst, Chongqing, Peoples R China.	simply_yang@126.com; hcui@swu.edu.cn	Zhang, Guanghui/HHS-1240-2022	Zhang, Guanghui/0000-0002-6289-4965; Yang, Wancai/0000-0001-7437-9197; Yang, Rui/0000-0002-0525-1728	National Natural Science Foundation of China [81672502, 81872071]; National Natural Science Foundation Cultivation Project of Jining Medical University [600788002]; Jining Medical University [600788001]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation Cultivation Project of Jining Medical University; Jining Medical University	This research was supported by the National Natural Science Foundation of China (Nos. 81672502 and 81872071), the grant to the Key Laboratory of Higher Education Institutes of Shandong Province, the National Natural Science Foundation Cultivation Project of Jining Medical University (600788002) and Faculty Startup Fund for RY from Jining Medical University (600788001).	Agnihotri S, 2016, NEURO-ONCOLOGY, V18, P160, DOI 10.1093/neuonc/nov125; Altman BJ, 2016, NAT REV CANCER, V16, P619, DOI 10.1038/nrc.2016.71; Babic I, 2013, CELL METAB, V17, P1000, DOI 10.1016/j.cmet.2013.04.013; Bhutia YD, 2015, CANCER RES, V75, P1782, DOI 10.1158/0008-5472.CAN-14-3745; Boros J, 2009, GENOME RES, V19, P1963, DOI 10.1101/gr.093047.109; Chai YL, 2001, ONCOGENE, V20, P1357, DOI 10.1038/sj.onc.1204256; Craze ML, 2019, BREAST CANCER RES TR, V174, P79, DOI 10.1007/s10549-018-5060-z; DeBerardinis RJ, 2010, ONCOGENE, V29, P313, DOI 10.1038/onc.2009.358; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; Dittmer J, 1998, BBA-REV CANCER, V1377, pF1, DOI 10.1016/S0304-419X(97)00039-5; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Fan J, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.65; Felsberg J, 2017, CLIN CANCER RES, V23, P6846, DOI 10.1158/1078-0432.CCR-17-0890; Halatsch ME, 2006, CANCER TREAT REV, V32, P74, DOI 10.1016/j.ctrv.2006.01.003; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hatanpaa KJ, 2010, NEOPLASIA, V12, P675, DOI 10.1593/neo.10688; Hensley CT, 2013, J CLIN INVEST, V123, P3678, DOI 10.1172/JCI69600; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; Jameson KL, 2013, NAT MED, V19, P626, DOI 10.1038/nm.3165; Ji HT, 2016, P NATL ACAD SCI USA, V113, P644, DOI 10.1073/pnas.1517112113; Jiang L, 2016, NATURE, V532, P255, DOI 10.1038/nature17393; Jin LT, 2018, MOL CELL, V69, P87, DOI 10.1016/j.molcel.2017.11.025; Jin LT, 2015, CANCER CELL, V27, P257, DOI 10.1016/j.ccell.2014.12.006; KOVACEVIC Z, 1971, BIOCHEM J, V125, P757, DOI 10.1042/bj1250757; Lee JH, 2018, MOL CELL, V70, P197, DOI 10.1016/j.molcel.2018.03.018; Liu F, 2015, MOL CELL, V60, P307, DOI 10.1016/j.molcel.2015.09.002; Ma JL, 2017, CANCER LETT, V411, P117, DOI [10.1016/j.canlet.2017.09.041, 10.1016/j.canlet.2017.10.026]; Mai WX, 2017, NAT MED, V23, P1342, DOI 10.1038/nm.4418; Maicas M, 2013, ONCOGENE, V32, P2069, DOI 10.1038/onc.2012.222; Mayers JR, 2015, TRENDS BIOCHEM SCI, V40, P130, DOI 10.1016/j.tibs.2015.01.004; Michalak KP, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/964321; Nwosu ZC, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0872-6; Ohguchi H, 2017, LEUKEMIA, V31, P2661, DOI 10.1038/leu.2017.141; Ostrom QT, 2018, NEURO-ONCOLOGY, V20, P1, DOI 10.1093/neuonc/noy131; Shao NS, 1998, ONCOGENE, V17, P527, DOI 10.1038/sj.onc.1201931; Stehle P, 2017, CLIN NUTR ESPEN, V17, P75, DOI 10.1016/j.clnesp.2016.09.007; Tanaka K, 2015, J CLIN INVEST, V125, P1591, DOI 10.1172/JCI78239; Tateishi K, 2016, CLIN CANCER RES, V22, P4452, DOI 10.1158/1078-0432.CCR-15-2274; Wang RN, 2011, IMMUNITY, V35, P871, DOI 10.1016/j.immuni.2011.09.021; Wang YQ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02951-4; Yang R, 2016, MOL CANCER THER, V15, P421, DOI 10.1158/1535-7163.MCT-15-0709; Yeh HY, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-70; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036; Zhang XS, 2013, J BIOL CHEM, V288, P32742, DOI 10.1074/jbc.M113.478016	44	32	32	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	14					2975	2986		10.1038/s41388-020-1199-2	http://dx.doi.org/10.1038/s41388-020-1199-2		FEB 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KZ2VB	32034306				2022-12-28	WOS:000511752600006
J	Lok, TM; Wang, Y; Xu, WK; Xie, SW; Ma, HT; Poon, RYC				Lok, Tsun Ming; Wang, Yang; Xu, Wendy Kaichun; Xie, Siwei; Ma, Hoi Tang; Poon, Randy Y. C.			Mitotic slippage is determined by p31(comet) and the weakening of the spindle-assembly checkpoint	ONCOGENE			English	Article							CELL-CYCLE; AAA-ATPASE; PROTEIN; TRIP13; ACTIVATION; MAD2; MPS1; INACTIVATION; DEGRADATION; INHIBITION	Mitotic slippage involves cells exiting mitosis without proper chromosome segregation. Although degradation of cyclin B1 during prolonged mitotic arrest is believed to trigger mitotic slippage, its upstream regulation remains obscure. Whether mitotic slippage is caused by APC/C-CDC20 activity that is able to escape spindle-assembly checkpoint (SAC)-mediated inhibition, or is actively promoted by a change in SAC activity remains an outstanding issue. We found that a major culprit for mitotic slippage involves reduction of MAD2 at the kinetochores, resulting in a progressive weakening of SAC during mitotic arrest. A further level of control of the timing of mitotic slippage is through p31(comet)-mediated suppression of MAD2 activation. The loss of kinetochore MAD2 was dependent on APC/C-CDC20, indicating a feedback control of APC/C to SAC during prolonged mitotic arrest. The gradual weakening of SAC during mitotic arrest enables APC/C-CDC20 to degrade cyclin B1, cumulating in the cell exiting mitosis by mitotic slippage.	[Lok, Tsun Ming; Wang, Yang; Xu, Wendy Kaichun; Xie, Siwei; Ma, Hoi Tang; Poon, Randy Y. C.] Hong Kong Univ Sci & Technol, Ctr Canc Res, Div Life Sci, Clear Water Bay, Hong Kong, Peoples R China; [Lok, Tsun Ming; Wang, Yang; Xu, Wendy Kaichun; Xie, Siwei; Ma, Hoi Tang; Poon, Randy Y. C.] Hong Kong Univ Sci & Technol, State Key Lab Mol Neurosci, Clear Water Bay, Hong Kong, Peoples R China; [Xu, Wendy Kaichun] Univ Texas Austin, Dept Mol Biosci, Inst Cellular & Mol Biol, Austin, TX 78712 USA	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology; University of Texas System; University of Texas Austin	Poon, RYC (corresponding author), Hong Kong Univ Sci & Technol, Ctr Canc Res, Div Life Sci, Clear Water Bay, Hong Kong, Peoples R China.; Poon, RYC (corresponding author), Hong Kong Univ Sci & Technol, State Key Lab Mol Neurosci, Clear Water Bay, Hong Kong, Peoples R China.	rycpoon@ust.hk	Xu, Wendy Kaichun/AAO-3471-2021	Xu, Wendy Kaichun/0000-0002-5866-3523; Wang, Yang/0000-0001-5065-7412; MA, Hoi Tang/0000-0001-5876-0107	Research Grants Council [16100017, 16102919]; Health and Medical Research Fund [04153526]; Innovation and Technology Commission [ITCPD/17-9]	Research Grants Council(Hong Kong Research Grants Council); Health and Medical Research Fund; Innovation and Technology Commission	This work was supported in part by grants from the Research Grants Council (16100017 to HTM and 16102919 to RYCP), Health and Medical Research Fund (04153526 to HTM), and Innovation and Technology Commission (ITCPD/17-9 to RYCP).	Ausubel FM, 2012, CURRENT PROTOCOLS MO; Baek KH, 2005, ONCOL RES, V15, P161, DOI 10.3727/096504005776367906; Brito DA, 2006, CURR BIOL, V16, P1194, DOI 10.1016/j.cub.2006.04.043; Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100; Chow JPH, 2011, MOL CELL BIOL, V31, P1478, DOI 10.1128/MCB.00891-10; Cui YP, 2010, J BIOL CHEM, V285, P32988, DOI 10.1074/jbc.M110.140905; Domenech E, 2015, NAT CELL BIOL, V17, P1304, DOI 10.1038/ncb3231; Eytan E, 2014, P NATL ACAD SCI USA, V111, P12019, DOI 10.1073/pnas.1412901111; Garnett MJ, 2009, NAT CELL BIOL, V11, P1363, DOI 10.1038/ncb1983; Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002; Gascoigne KE, 2009, J CELL SCI, V122, P2579, DOI 10.1242/jcs.039719; Hashimoto T, 2008, GENES CELLS, V13, P609, DOI 10.1111/j.1365-2443.2008.01192.x; Hashimoto T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018449; Hiruma Y, 2015, SCIENCE, V348, P1264, DOI 10.1126/science.aaa4055; Howell BJ, 2001, J CELL BIOL, V155, P1159, DOI 10.1083/jcb.200105093; Hsu SL, 2006, APOPTOSIS, V11, P765, DOI 10.1007/s10495-006-5880-x; Huang HC, 2009, CANCER CELL, V16, P347, DOI 10.1016/j.ccr.2009.08.020; Ji ZJ, 2015, SCIENCE, V348, P1260, DOI 10.1126/science.aaa4029; Kim M, 2005, MOL CELL BIOL, V25, P9232, DOI 10.1128/MCB.25.21.9232-9248.2005; Lee K, 2011, MOL BIOL CELL, V22, P2470, DOI 10.1091/mbc.E11-03-0228; Ma HT, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkl1109; Ma HT, 2018, CELL REP, V22, P1439, DOI 10.1016/j.celrep.2018.01.027; Ma HT, 2017, METHODS MOL BIOL, V1524, P189, DOI 10.1007/978-1-4939-6603-5_12; Ma HT, 2016, CELL REP, V14, P1086, DOI 10.1016/j.celrep.2016.01.001; Ma HT, 2012, J BIOL CHEM, V287, P21561, DOI 10.1074/jbc.M112.364356; Ma HT, 2011, J BIOL CHEM, V286, P13052, DOI 10.1074/jbc.M110.201897; Ma HT, 2009, MOL CELL BIOL, V29, P6500, DOI 10.1128/MCB.00669-09; Manchado E, 2010, CANCER CELL, V18, P641, DOI 10.1016/j.ccr.2010.10.028; Mapelli M, 2006, EMBO J, V25, P1273, DOI 10.1038/sj.emboj.7601033; Musacchio A, 2015, CURR BIOL, V25, pR1002, DOI 10.1016/j.cub.2015.08.051; Natsume T, 2016, CELL REP, V15, P210, DOI 10.1016/j.celrep.2016.03.001; Ng LY, 2019, CELL CYCLE, V18, P238, DOI 10.1080/15384101.2018.1563395; Nilsson J, 2008, NAT CELL BIOL, V10, P1411, DOI 10.1038/ncb1799; Pesin JA, 2008, ANNU REV CELL DEV BI, V24, P475, DOI 10.1146/annurev.cellbio.041408.115949; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Riffell JL, 2011, MOL CANCER THER, V10, P839, DOI 10.1158/1535-7163.MCT-10-0909; Sakaue-Sawano A, 2008, CELL, V132, P487, DOI 10.1016/j.cell.2007.12.033; Siu WY, 1999, EXP CELL RES, V250, P131, DOI 10.1006/excr.1999.4551; Swe M, 2000, APOPTOSIS, V5, P29, DOI 10.1023/A:1009681408367; Wang KX, 2014, J BIOL CHEM, V289, P23928, DOI 10.1074/jbc.M114.585315; Wong PY, 2016, SCI REP-UK, V6, DOI 10.1038/srep22230; Yam CH, 2000, J BIOL CHEM, V275, P3158, DOI 10.1074/jbc.275.5.3158; Yang MJ, 2007, CELL, V131, P744, DOI 10.1016/j.cell.2007.08.048; Ye QZ, 2015, ELIFE, V4, DOI 10.7554/eLife.07367; Yu HT, 2006, J CELL BIOL, V173, P153, DOI 10.1083/jcb.200601172; Zeng X, 2010, CANCER CELL, V18, P382, DOI 10.1016/j.ccr.2010.08.010	46	10	10	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	13					2819	2834		10.1038/s41388-020-1187-6	http://dx.doi.org/10.1038/s41388-020-1187-6		FEB 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KX4EF	32029899	Green Published, hybrid			2022-12-28	WOS:000511540800001
J	Chen, LP; De Menna, M; Groenewoud, A; Thalmann, GN; Kruithof-de Julio, M; Snaar-Jagalska, BE				Chen, Lanpeng; De Menna, Marta; Groenewoud, Arwin; Thalmann, George N.; Kruithof-de Julio, Marianna; Snaar-Jagalska, B. Ewa			A NF-kappa B-Activin A signaling axis enhances prostate cancer metastasis	ONCOGENE			English	Article							TGF-BETA; BONE METASTASIS; GROWTH-FACTOR; SELF-RENEWAL; STEM-CELLS; ZEBRAFISH; MODEL; PROGRESSION; INHIBITION; BREAST	Metastasis is a main cause of death in prostate cancer (PCa). To dissect the molecular cues from cancer cell-microenvironment interaction that drive metastatic cascade, bone metastatic PCa cells were intravenously implanted into zebrafish embryos and mice tibia forming metastatic lesions. Transcriptomic analysis showed an elevated expression of stemness genes, pro-inflammatory cytokines and TGF-beta family member Activin A in the cancer cells at metastatic onset in both animal models. Consistently, analysis of clinical datasets revealed that the expression of Activin A is specifically elevated in metastases and correlates with poor prognosis in stratified high-risk PCa patients. It is further unveiled that the microenvironment induced Activin A expression by NF-kappa B activation. The elevated level of Activin A enhanced the invasive ALDH(hi) CSC-like phenotypes and PCa proliferation by activation of Smad and ERK1/2 signaling driving metastasis. Suppression of Activin A or Activin receptor significantly reduced the CSC-like subpopulation, invasion, metastatic growth, and bone lesion formation in zebrafish and mice xenografts, suggesting a functional role of NF-kappa B-dependent Activin A in PCa metastasis. Overall, our study demonstrates that human PCa cells can display a comparable response with the microenvironment in zebrafish and mice xenografts. Combining both animal models, we uncovered the microenvironment-dependent activin signaling as an essential driver in PCa metastasis with therapeutic potential.	[Chen, Lanpeng; Groenewoud, Arwin; Snaar-Jagalska, B. Ewa] Leiden Univ, Inst Biol, Leiden, Netherlands; [De Menna, Marta; Kruithof-de Julio, Marianna] Univ Bern, Dept BioMed Res, Urol Res Lab, Bern, Switzerland; [Thalmann, George N.] Inselspital Bern, Dept Urol, Bern, Switzerland	Leiden University; Leiden University - Excl LUMC; University of Bern; University of Bern; University Hospital of Bern	Snaar-Jagalska, BE (corresponding author), Leiden Univ, Inst Biol, Leiden, Netherlands.; Kruithof-de Julio, M (corresponding author), Univ Bern, Dept BioMed Res, Urol Res Lab, Bern, Switzerland.	marianna.kruithofdejulio@dbmr.unibe.ch; b.e.snaar-jagalska@biology.leidenuniv.nl		Kruithof-de Julio, Marianna/0000-0002-6085-7706; De Menna, Marta/0000-0002-6306-3485	Alpe D'HuZes (AdH)/KWF PROPER entitled "Near-patient prostate cancer models for the assessment of disease prognosis and therapy" [UL2014-7058]; SNF [31003A_169352]	Alpe D'HuZes (AdH)/KWF PROPER entitled "Near-patient prostate cancer models for the assessment of disease prognosis and therapy"; SNF	We thank Dr Gabriel van der Pluijm (Deportment of Urology, LUMC) for providing experimental material, Prof. Peter ten Dijke (Department of Molecular Cell Biology) for providing experimental material and critical scientific discussion and Guido de Roo from the Flow cytometry facility (Department of Hematology, LUMC) for technical support, Prof. Rob Hoeben and Martijn Rabelink (Department of Cell Biology, LUMC) for providing lentiviral shRNA vectors (Sigma-Aldrich). The present work was supported by a personalized medicine grant from Alpe D'HuZes (AdH)/KWF PROPER entitled "Near-patient prostate cancer models for the assessment of disease prognosis and therapy" (UL2014-7058) and SNF 31003A_169352.	Aguirre-Gamboa R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074250; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Bashir M, 2015, NPJ BREAST CANCER, V1, DOI 10.1038/npjbcancer.2015.7; Brown CW, 2003, MOL ENDOCRINOL, V17, P2404, DOI 10.1210/me.2003-0051; Byfield SD, 2004, MOL PHARMACOL, V65, P744, DOI 10.1124/mol.65.3.744; Chen L, 2017, METHOD CELL BIOL, V138, P471, DOI 10.1016/bs.mcb.2016.10.009; Clements M, 2011, CURR BIOL, V21, P1289, DOI 10.1016/j.cub.2011.06.048; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Cui C, 2011, METHOD CELL BIOL, V105, P273, DOI 10.1016/B978-0-12-381320-6.00012-6; Dai JL, 2016, BONEKEY REP, V5, DOI 10.1038/bonekey.2016.4; Dalkin AC, 1996, ENDOCRINOLOGY, V137, P5230, DOI 10.1210/en.137.12.5230; Dooley K, 2000, CURR OPIN GENET DEV, V10, P252, DOI 10.1016/S0959-437X(00)00074-5; Drabsch Y, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3573; Ellett F, 2011, BLOOD, V117, pE49, DOI 10.1182/blood-2010-10-314120; Fior R, 2017, P NATL ACAD SCI USA, V114, pE8234, DOI 10.1073/pnas.1618389114; Gold E, 2012, MOL CELL ENDOCRINOL, V359, P107, DOI 10.1016/j.mce.2011.07.005; Gray PC, 2012, FEBS LETT, V586, P1836, DOI 10.1016/j.febslet.2012.01.051; He SN, 2012, J PATHOL, V227, P431, DOI 10.1002/path.4013; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; Hofland J, 2012, ENDOCRINOLOGY, V153, P5726, DOI 10.1210/en.2011-2065; Hsu WK, 2008, J NUCL MED, V49, P414, DOI 10.2967/jnumed.107.045666; James D, 2005, DEVELOPMENT, V132, P1273, DOI 10.1242/dev.01706; Jemal A, 2010, CANC EPIDEMIOLOGY PR, P1055; Jin H, 2007, BLOOD, V109, P5208, DOI 10.1182/blood-2007-01-069005; Karkampouna S, 2018, J PATHOL, V245, P297, DOI 10.1002/path.5083; Lawson ND, 2002, DEV BIOL, V248, P307, DOI 10.1006/dbio.2002.0711; Leto G, 2006, CLIN EXP METASTAS, V23, P117, DOI 10.1007/s10585-006-9010-5; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Liu TL, 2018, SCIENCE, V360, DOI 10.1126/science.aaq1392; Lonardo E, 2011, CELL STEM CELL, V9, P433, DOI 10.1016/j.stem.2011.10.001; Loomans HA, 2015, CANCERS, V7, P70, DOI 10.3390/cancers7010070; Lu HH, 2014, NAT CELL BIOL, V16, P1105, DOI 10.1038/ncb3041; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; McKenzie S, 2006, J CELL BIOCHEM, V97, P18, DOI 10.1002/jcb.20634; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; Postlethwait JH, 1998, NAT GENET, V18, P345, DOI 10.1038/ng0498-345; Quail DF, 2014, ONCOGENE, V33, P461, DOI 10.1038/onc.2012.608; Sacco A, 2016, CANCER RES, V76, P463, DOI 10.1158/0008-5472.CAN-15-1926; Schier AF, 2000, NATURE, V403, P385, DOI 10.1038/35000126; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shiozawa Y, 2016, ONCOTARGET, V7, P41217, DOI 10.18632/oncotarget.9251; Shiozawa Y, 2011, J CLIN INVEST, V121, P1298, DOI 10.1172/JCI43414; Singh S, 2013, FREE RADICAL BIO MED, V56, P89, DOI 10.1016/j.freeradbiomed.2012.11.010; Strizzi L, 2005, ONCOGENE, V24, P5731, DOI 10.1038/sj.onc.1208918; Tamplin OJ, 2015, CELL, V160, P241, DOI 10.1016/j.cell.2014.12.032; THALMANN GN, 1994, CANCER RES, V54, P2577; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Tulotta C, 2016, DIS MODEL MECH, V9, P141, DOI 10.1242/dmm.023275; van den Hoogen C, 2010, CANCER RES, V70, P5163, DOI 10.1158/0008-5472.CAN-09-3806; Wamsley JJ, 2015, CANCER RES, V75, P426, DOI 10.1158/0008-5472.CAN-13-2702; Wang Q, 2012, MED ONCOL, V29, P77, DOI 10.1007/s12032-010-9766-y; White R, 2013, NAT REV CANCER, V13, P624, DOI 10.1038/nrc3589; Xiao L, 2006, STEM CELLS, V24, P1476, DOI 10.1634/stemcells.2005-0299; Zon LI, 2005, NAT REV DRUG DISCOV, V4, P35, DOI 10.1038/nrd1606; Zoni E, 2017, ONCOGENE, V36, P4739, DOI 10.1038/onc.2017.87	56	17	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	8					1634	1651		10.1038/s41388-019-1103-0	http://dx.doi.org/10.1038/s41388-019-1103-0			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN6CG	31740783				2022-12-28	WOS:000514923000002
J	Wang, Z; Li, YJ; Wu, DL; Yu, S; Wang, YL; Chan, FL				Wang, Zhu; Li, Youjia; Wu, Dinglan; Yu, Shan; Wang, Yuliang; Chan, Franky Leung			Nuclear receptor HNF4 alpha performs a tumor suppressor function in prostate cancer via its induction of p21-driven cellular senescence	ONCOGENE			English	Article							TRANSCRIPTION FACTOR; FACTOR 4-ALPHA; GENE-EXPRESSION; EPITHELIAL-CELLS; THERAPEUTIC TARGET; ANDROGEN RECEPTOR; FACTOR-4-ALPHA; PROLIFERATION; PROMOTES; GROWTH	Hepatocyte nuclear factor 4 alpha (HNF4 alpha, NR2A1) is a highly conserved member of the nuclear receptor superfamily. Recent advances reveal that it is a key transcriptional regulator of genes, broadly involved in xenobiotic and drug metabolism and also cancers of gastrointestinal tract. However, the exact functional roles of HNF4 alpha in prostate cancer progression are still not fully understood. In this study, we determined the functional significance of HNF4 alpha in prostate cancer. Our results showed that HNF4 alpha exhibited a reduced expression pattern in clinical prostate cancer tissues, prostate cancer cell lines and xenograft model of castration-relapse prostate cancer. Stable HNF4 alpha knockdown not only could promote cell proliferation and suppress doxorubicin (Dox)-induced cellular senescence in prostate cancer cells, but also confer resistance to paclitaxel treatment and enhance colony formation capacity and in vivo tumorigenicity of prostate cancer cells. On the contrary, ectopic overexpression of HNF4 alpha could significantly inhibit the cell proliferation of prostate cancer cells, induce cell-cycle arrest at G(2)/M phase and trigger the cellular senescence in prostate cancer cells by activation of p21 signal pathway in a p53-independent manner via its direct transactivation of CDKN1A. Together, our results show that HNF4 alpha performs a tumor suppressor function in prostate cancer via a mechanism of p21-driven cellular senescence.	[Wang, Zhu] Southern Med Univ, Peoples Hosp Longhua, Dept Urol, Shenzhen 518109, Guangdong, Peoples R China; [Wang, Zhu; Li, Youjia; Wu, Dinglan; Yu, Shan; Wang, Yuliang; Chan, Franky Leung] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Peoples R China	Southern Medical University - China; Chinese University of Hong Kong	Wang, YL; Chan, FL (corresponding author), Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Peoples R China.	yuliang.wang816@gmail.com; franky-chan@cuhk.edu.hk		Wang, Zhu/0000-0002-5457-3731; Wu, Dinglan/0000-0002-5057-9626	CUHK [2015.1.064]; Research Grants Council of Hong Kong [461012]; Shenzhen Science and Technology Program (Basic Research Project) [JCYJ20180228163919346]	CUHK(Chinese University of Hong Kong); Research Grants Council of Hong Kong(Hong Kong Research Grants Council); Shenzhen Science and Technology Program (Basic Research Project)	This work was supported by a Direct Grant for Research 2015-2016 from CUHK (grant no. 2015.1.064), a General Research Fund (project number 461012) from the Research Grants Council of Hong Kong (to Chan FL), and Shenzhen Science and Technology Program (Basic Research Project; project number JCYJ20180228163919346 to ZW)	Ahn SH, 2008, INFLAMM BOWEL DIS, V14, P908, DOI 10.1002/ibd.20413; Alimonti A, 2010, J CLIN INVEST, V120, P681, DOI 10.1172/JCI40535; Attard G, 2016, LANCET, V387, P70, DOI 10.1016/S0140-6736(14)61947-4; Barrett JC, 2009, NAT GENET, V41, P1330, DOI 10.1038/ng.483; Bonzo JA, 2012, J BIOL CHEM, V287, P7345, DOI 10.1074/jbc.M111.334599; Cairns P, 1997, CANCER RES, V57, P4997; CHARTIER FL, 1994, GENE, V147, P269, DOI 10.1016/0378-1119(94)90079-5; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Cheung CP, 2005, J CLIN ENDOCR METAB, V90, P1830, DOI 10.1210/jc.2004-1421; Chiba H, 2005, EXP CELL RES, V302, P11, DOI 10.1016/j.yexcr.2004.08.014; Chu JH, 2009, PROSTATE, V69, P428, DOI 10.1002/pros.20897; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; Darsigny M, 2010, CANCER RES, V70, P9423, DOI 10.1158/0008-5472.CAN-10-1697; Darsigny M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007609; Dhe-Paganon S, 2002, J BIOL CHEM, V277, P37973, DOI 10.1074/jbc.C200420200; Drewa T., 2010, Experimental Oncology, V32, P228; Duncan SA, 1997, DEVELOPMENT, V124, P279; Erdmann S, 2007, BIOL CHEM, V388, P91, DOI 10.1515/BC.2007.011; Grigo K, 2008, BIOL CHEM, V389, P179, DOI 10.1515/BC.2008.011; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; Hwang-Verslues WW, 2010, CURR OPIN PHARMACOL, V10, P698, DOI 10.1016/j.coph.2010.08.010; Lazarevich N, 2004, HEPATOLOGY, V39, P1038, DOI 10.1002/hep.20155; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li JX, 2000, GENE DEV, V14, P464; Loaiza N, 2016, BBA-REV CANCER, V1865, P155, DOI 10.1016/j.bbcan.2016.01.007; Lucas B, 2005, ONCOGENE, V24, P6418, DOI 10.1038/sj.onc.1208794; Marcil V, 2012, GENES IMMUN, V13, P556, DOI 10.1038/gene.2012.37; MIQUEROL L, 1994, J BIOL CHEM, V269, P8944; Moschini M, 2017, EUR UROL, V72, P238, DOI 10.1016/j.eururo.2017.03.009; Muller M, 2009, ANTIOXID REDOX SIGN, V11, P59, DOI 10.1089/ars.2008.2104; Nanni S, 2006, MOL CANCER RES, V4, P79, DOI 10.1158/1541-7786.MCR-05-0098; Ning BF, 2010, CANCER RES, V70, P7640, DOI 10.1158/0008-5472.CAN-10-0824; Olsen CL, 2002, ONCOGENE, V21, P6328, DOI 10.1038/sj.onc.1205780; Oshima T, 2007, PATHOL INT, V57, P82, DOI 10.1111/j.1440-1827.2006.02061.x; Parviz F, 2003, NAT GENET, V34, P292, DOI 10.1038/ng1175; Pihlajamaa P, 2014, EMBO J, V33, P312, DOI 10.1002/embj.201385895; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Rieck S, 2012, MOL ENDOCRINOL, V26, P1590, DOI 10.1210/me.2012-1019; Sel S, 1996, CANCER LETT, V101, P205, DOI 10.1016/0304-3835(96)04136-5; Sharma S, 2010, PATHOLOGY, V42, P507, DOI 10.3109/00313025.2010.508791; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STEPHENSON RA, 1992, J NATL CANCER I, V84, P951, DOI 10.1093/jnci/84.12.951; Sugai M, 2008, PATHOL INT, V58, P681, DOI 10.1111/j.1440-1827.2008.02293.x; Sugano M, 2013, AM J SURG PATHOL, V37, P211, DOI 10.1097/PAS.0b013e31826be303; Tanaka T, 2006, J PATHOL, V208, P662, DOI 10.1002/path.1928; Tang DG, 2001, SCIENCE, V291, P868, DOI 10.1126/science.1056780; THALMANN GN, 1994, CANCER RES, V54, P2577; Walesky C, 2013, HEPATOLOGY, V57, P2480, DOI 10.1002/hep.26251; Walesky C, 2013, AM J PHYSIOL-GASTR L, V304, pG26, DOI 10.1152/ajpgi.00064.2012; Wallace TA, 2008, CANCER RES, V68, P927, DOI 10.1158/0008-5472.CAN-07-2608; Wang Z, 2018, ENDOCR-RELAT CANCER, V25, P35, DOI 10.1530/ERC-17-0280; Wisely GB, 2002, STRUCTURE, V10, P1225, DOI 10.1016/S0969-2126(02)00829-8; Wu DL, 2015, J PATHOL, V236, P103, DOI 10.1002/path.4505; Xiang X, 2015, CANCER LETT, V359, P187, DOI 10.1016/j.canlet.2015.01.008; Xiao LJ, 2018, CANCER RES, V78, P2205, DOI 10.1158/0008-5472.CAN-17-2341; Xu L, 2001, CANCER RES, V61, P3176; Yamagata K, 2014, VITAM HORM, V95, P407, DOI 10.1016/B978-0-12-800174-5.00016-8; Yu S, 2008, ONCOGENE, V27, P3313, DOI 10.1038/sj.onc.1210986; Yu SA, 2007, CANCER RES, V67, P4904, DOI 10.1158/0008-5472.CAN-06-3855; Yu S, 2014, J PATHOL, V234, P514, DOI 10.1002/path.4413; Yu S, 2013, CANCER LETT, V328, P83, DOI 10.1016/j.canlet.2012.09.006; Yu S, 2009, BIOCHEM BIOPH RES CO, V382, P756, DOI 10.1016/j.bbrc.2009.03.110; Yusuf D, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-3-r24; Zou C, 2014, J PATHOL, V233, P61, DOI 10.1002/path.4329	66	17	17	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	7					1572	1589		10.1038/s41388-019-1080-3	http://dx.doi.org/10.1038/s41388-019-1080-3			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KL2WP	31695151	Green Published, hybrid			2022-12-28	WOS:000513289600013
J	Yang, R; Xu, JH; Hua, XH; Tian, ZX; Xie, QP; Li, JX; Jiang, GS; Cohen, M; Sun, H; Huang, CS				Yang, Rui; Xu, Jiheng; Hua, Xiaohui; Tian, Zhongxian; Xie, Qipeng; Li, Jingxia; Jiang, Guosong; Cohen, Mitchell; Sun, Hong; Huang, Chuanshu			Overexpressed miR-200a promotes bladder cancer invasion through direct regulating Dicer/miR-16/JNK2/MMP-2 axis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; MATRIX-METALLOPROTEINASE (MMP)-2; CELL-MIGRATION; UP-REGULATION; ISORHAPONTIGENIN ISO; TRANSCRIPTION FACTOR; MICRORNA MACHINERY; DICER EXPRESSION; REPRESSORS ZEB1; DOWN-REGULATION	Invasive bladder cancer (BC) is one of the most lethal malignant urological tumors. Although miR-200a has been reported as an onco-miRNA that targets the PTEN gene in endometrioid carcinoma, its biological significance in BC invasion has been poorly explored. In the current study, we found that miR-200a was markedly overexpressed in both human BC tissues and BBN-induced muscle-invasive BC tissues. We further showed that miR-200a overexpression specifically promoted human BC cell invasion, but not migration, via transcriptional upregulation of matrix metalloproteinase (MMP)-2. Mechanistic studies indicated that the increased phosphorylation of c-Jun mediated the increasing levels of MMP-2 mRNA transcription. Further investigation revealed that Dicer was decreased in miR-200a overexpressed BC cells; this resulted in inhibition of miR-16 maturation and consequently led to increased JNK2 protein translation and c-Jun activation. Taken together, the studies here showed that miR-200a overexpression inhibited Dicer expression, in turn, resulted in inhibition of miR-16 maturation, leading to upregulation of JNK2 expression, c-Jun phosphorylation, MMP-2 transcription and, ultimately, BC invasion. Collectively, these results demonstrate that miR-200a is an onco-miRNA that is a positive regulator for BC invasion. This finding could be very useful in the ongoing development of new strategies to treat invasive BC patients.	[Yang, Rui; Xu, Jiheng; Hua, Xiaohui; Tian, Zhongxian; Xie, Qipeng; Li, Jingxia; Jiang, Guosong; Cohen, Mitchell; Sun, Hong; Huang, Chuanshu] NYU, Dept Environm Med, Sch Med, 341 East 25th St, New York, NY 10010 USA	New York University	Huang, CS (corresponding author), NYU, Dept Environm Med, Sch Med, 341 East 25th St, New York, NY 10010 USA.	Chuanshu.huang@nyulangone.org	Yang, Rui/CAF-8397-2022; xie, qipeng/ABG-5941-2021; Xu, Jiheng/AAV-5732-2020	Yang, Rui/0000-0002-1737-7168; Xu, Jiheng/0000-0002-3538-3174; Huang, Chuanshu/0000-0003-4133-5096	NIH/NCI [CA217923, CA177665, CA165980, CA229234]; NIH/NIEHS [ES000260]	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The authors wish to thank Dr. Etty N. Benveniste (University of Alabama at Birmingham) for providing the Human MMP-2 promoter luciferase reporter. We also thank Ms. Emily Davison for her critical reading of the manuscript. This work was partially supported by Grants NIH/NCI CA217923, CA177665, CA165980, CA229234, and NIH/NIEHS ES000260.	Antoni S, 2017, EUR UROL, V71, P96, DOI 10.1016/j.eururo.2016.06.010; Becker LE, 2015, CARCINOGENESIS, V36, P2, DOI 10.1093/carcin/bgu202; Burger M, 2013, EUR UROL, V63, P234, DOI 10.1016/j.eururo.2012.07.033; Carmell MA, 2004, NAT STRUCT MOL BIOL, V11, P214, DOI 10.1038/nsmb729; Cheloufi S, 2010, NATURE, V465, P584, DOI 10.1038/nature09092; Chen JS, 2013, CARCINOGENESIS, V34, P10, DOI 10.1093/carcin/bgs274; Chen Y, 2017, EXP THER MED, V14, P10, DOI 10.3892/etm.2017.4488; Chen ZF, 2015, ONCOL LETT, V10, P329, DOI 10.3892/ol.2015.3179; Chiosea S, 2006, AM J PATHOL, V169, P1812, DOI 10.2353/ajpath.2006.060480; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Grelier G, 2009, BRIT J CANCER, V101, P673, DOI 10.1038/sj.bjc.6605193; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Hua XH, 2020, CELL DEATH DIFFER, V27, P632, DOI 10.1038/s41418-019-0377-7; Hua XH, 2018, CANCER LETT, V436, P38, DOI 10.1016/j.canlet.2018.08.013; Huang C, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-016-0376-9; Huang HS, 2017, MOL ONCOL, V11, P1579, DOI 10.1002/1878-0261.12132; Jakymiw A, 2010, GENE CHROMOSOME CANC, V49, P549, DOI 10.1002/gcc.20765; Jee D, 2018, MOL CELL, V69, P265, DOI 10.1016/j.molcel.2017.12.027; Jiang GS, 2016, CANCER PREV RES, V9, P567, DOI 10.1158/1940-6207.CAPR-15-0338; Jiang QQ, 2013, ASIAN PAC J CANCER P, V14, P4127, DOI 10.7314/APJCP.2013.14.7.4127; Jin HL, 2016, ONCOTARGET, V7, P56540, DOI 10.18632/oncotarget.10645; Jin HL, 2015, ONCOTARGET, V6, P522, DOI 10.18632/oncotarget.2680; Justus CR, 2014, JOVE-J VIS EXP, DOI 10.3791/51046; Karube Y, 2005, CANCER SCI, V96, P111, DOI 10.1111/j.1349-7006.2005.00015.x; Katoh Y, 2008, INT J MOL MED, V22, P271, DOI 10.3892/ijmm_00000019; Kaufman DS, 2009, LANCET, V374, P239, DOI 10.1016/S0140-6736(09)60491-8; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Li SP, 2016, ONCOTARGET, V7, P42431, DOI 10.18632/oncotarget.9883; Li XL, 2013, INT J ONCOL, V43, P793, DOI 10.3892/ijo.2013.1992; Liang YG, 2016, AUTOPHAGY, V12, P1229, DOI 10.1080/15548627.2016.1179403; Liu JY, 2010, J BIOL CHEM, V285, P26058, DOI 10.1074/jbc.M110.100271; Miao C, 2015, INT J CLIN EXP PATHO, V8, P10512; Nelson P, 2003, TRENDS BIOCHEM SCI, V28, P534, DOI 10.1016/j.tibs.2003.08.005; Pampalakis G, 2010, CLIN BIOCHEM, V43, P324, DOI 10.1016/j.clinbiochem.2009.09.014; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pectasides D, 2005, EUR UROL, V48, P60, DOI 10.1016/j.eururo.2005.03.025; Qin HW, 1999, J BIOL CHEM, V274, P29130, DOI 10.1074/jbc.274.41.29130; Ruvinsky I, 2006, TRENDS BIOCHEM SCI, V31, P342, DOI 10.1016/j.tibs.2006.04.003; Shen Y, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317705756; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Stenzl A, 2011, EUR UROL, V59, P1009, DOI 10.1016/j.eururo.2011.03.023; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Taki M, 2006, INT J ONCOL, V28, P487; Tao J, 2012, MOL MED REP, V5, P167, DOI 10.3892/mmr.2011.591; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; Tseng JH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03972-7; van Rhijn BWG, 2009, EUR UROL, V56, P430, DOI 10.1016/j.eururo.2009.06.028; van Zijl F, 2011, MUTAT RES-REV MUTAT, V728, P23, DOI 10.1016/j.mrrev.2011.05.002; Wiesen JL, 2009, MOL IMMUNOL, V46, P1222, DOI 10.1016/j.molimm.2008.11.012; Wu DY, 2012, MOL MED REP, V5, P695, DOI 10.3892/mmr.2011.711; Xie QP, 2016, ONCOTARGET, V7, P16636, DOI 10.18632/oncotarget.7674; Yan LM, 2010, INT J MOL SCI, V11, P4441, DOI 10.3390/ijms11114441; Zhang Z, 2015, TUMOR BIOL, V36, P5071, DOI 10.1007/s13277-015-3158-z; Zhu JL, 2017, NEOPLASIA, V19, P672, DOI 10.1016/j.neo.2017.06.002; Zhu JL, 2014, CANCER PREV RES, V7, P1270, DOI 10.1158/1940-6207.CAPR-14-0233; Zhuang WZ, 2015, STEM CELLS, V33, P1985, DOI 10.1002/stem.1989; Zuo W, 2014, INT J MOL SCI, V15, P14298, DOI 10.3390/ijms150814298	58	25	25	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	9					1983	1996		10.1038/s41388-019-1120-z	http://dx.doi.org/10.1038/s41388-019-1120-z			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KP9VM	31772330	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000516579800012
J	Liu, YT; Mao, C; Wang, M; Liu, N; Ouyang, LL; Liu, SP; Tang, HS; Cao, Y; Liu, S; Wang, X; Xiao, DS; Chen, CS; Shi, Y; Yan, Q; Tao, YG				Liu, Yating; Mao, Chao; Wang, Min; Liu, Na; Ouyang, Lianlian; Liu, Shouping; Tang, Haosheng; Cao, Ya; Liu, Shuang; Wang, Xiang; Xiao, Desheng; Chen, Ceshi; Shi, Ying; Yan, Qin; Tao, Yongguang			Cancer progression is mediated by proline catabolism in non-small cell lung cancer	ONCOGENE			English	Article							NF-KAPPA-B; MITOCHONDRIAL TUMOR-SUPPRESSOR; SUCCINATE-DEHYDROGENASE; METHYLATION PATTERNS; OXIDASE; P53; GENE; EXPRESSION; ALPHA; LSH	Dysregulated metabolism contributes to cancer initiation and progression, but the key drivers of these pathways are just being discovered. Here, we report a critical role for proline catabolism in non-small cell lung cancer (NSCLC). Proline dehydrogenase (PRODH) is activated to reduce proline levels by the chromatin remodeling factor lymphoid-specific helicase (LSH), an epigenetic driver of NSCLC. PRODH promotes NSCLC tumorigenesis by inducing epithelial to mesenchymal transition (EMT) and IKK alpha-dependent inflammatory genes, including CXCL1, LCN2, and IL17C. Consistently, proline addition promotes the expression of these inflammatory genes, as well as EMT, tumor cell proliferation, and migration in vitro and tumor growth in vivo, while the depletion or inhibition of PRODH blocks these phenotypes. In summary, we reveal an essential metabolic pathway amenable to targeting in NSCLC.	[Liu, Yating; Mao, Chao; Wang, Min; Liu, Na; Ouyang, Lianlian; Liu, Shouping; Tang, Haosheng; Cao, Ya; Shi, Ying; Tao, Yongguang] Cent South Univ, Xiangya Hosp, Dept Pathol, Key Lab Carcinogenesis & Canc Invas,Minist Educ, Changsha 410078, Hunan, Peoples R China; [Liu, Yating; Mao, Chao; Wang, Min; Liu, Na; Ouyang, Lianlian; Liu, Shouping; Tang, Haosheng; Shi, Ying; Tao, Yongguang] Cent South Univ, NHC Key Lab Carcinogenesis, Canc Res Inst, Changsha 410078, Hunan, Peoples R China; [Liu, Yating; Mao, Chao; Wang, Min; Liu, Na; Ouyang, Lianlian; Liu, Shouping; Tang, Haosheng; Shi, Ying; Tao, Yongguang] Cent South Univ, Sch Basic Med, Changsha 410078, Hunan, Peoples R China; [Liu, Shuang] Cent South Univ, Xiangya Hosp, Inst Med Sci, Dept Oncol, Changsha 410008, Hunan, Peoples R China; [Wang, Xiang; Tao, Yongguang] Cent South Univ, Xiangya Hosp 2, Dept Thorac Surg, Changsha 410011, Hunan, Peoples R China; [Xiao, Desheng] Cent South Univ, Sch Basic Med, Dept Pathol, Changsha 410008, Hunan, Peoples R China; [Xiao, Desheng] Cent South Univ, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China; [Chen, Ceshi] Chinese Acad Sci, Kunming Inst Zool, Collaborat Innovat Ctr Canc Med, Key Lab Anim Models & Human Dis Mech,Chinese Acad, Kunming 650223, Yunnan, Peoples R China; [Yan, Qin] Yale Sch Med, Dept Pathol, New Haven, CT 06520 USA	Central South University; Central South University; Central South University; Central South University; Central South University; Central South University; Central South University; Chinese Academy of Sciences; Kunming Institute of Zoology; Yale University	Shi, Y; Tao, YG (corresponding author), Cent South Univ, Xiangya Hosp, Dept Pathol, Key Lab Carcinogenesis & Canc Invas,Minist Educ, Changsha 410078, Hunan, Peoples R China.; Shi, Y; Tao, YG (corresponding author), Cent South Univ, NHC Key Lab Carcinogenesis, Canc Res Inst, Changsha 410078, Hunan, Peoples R China.; Shi, Y; Tao, YG (corresponding author), Cent South Univ, Sch Basic Med, Changsha 410078, Hunan, Peoples R China.; Tao, YG (corresponding author), Cent South Univ, Xiangya Hosp 2, Dept Thorac Surg, Changsha 410011, Hunan, Peoples R China.; Yan, Q (corresponding author), Yale Sch Med, Dept Pathol, New Haven, CT 06520 USA.	yingshi@csu.edu.cn; qin.yan@yale.edu; taoyong@csu.edu.cn	Mao, Chao/AAM-6358-2020	, chao/0000-0002-8685-8539	National Natural Science Foundation of China [81872285, 81728014, 81672787, 81672991, 81874139, 81672308, 81772496]; National Basic Research Program of China [2015CB553903]; Overseas Expertize Introduction Project for Discipline Innovation (111 Project) [111-2-12]; Hunan Provincial Key Area RD Programs [2019SK2253]; Fundamental Research Funds for the Central Universities [1502211723]; Open projects of Key Laboratory of Carcinogenesis and Invasion, Ministry of Education (Central South University) [201805]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China(National Basic Research Program of China); Overseas Expertize Introduction Project for Discipline Innovation (111 Project); Hunan Provincial Key Area RD Programs; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Open projects of Key Laboratory of Carcinogenesis and Invasion, Ministry of Education (Central South University)	This work was supported by the National Natural Science Foundation of China [81872285 (YS), 81728014 (YT), 81672787 (YT), 81672991, and 81874139 (SL), 81672308 (XW), 81772496 (DX)]; the National Basic Research Program of China [2015CB553903 (YT)], the Overseas Expertize Introduction Project for Discipline Innovation (111 Project, No. 111-2-12), Hunan Provincial Key Area R&D Programs [2019SK2253 (XW)], the Fundamental Research Funds for the Central Universities [1502211723 (YL)], and Open projects of Key Laboratory of Carcinogenesis and Invasion, Ministry of Education (Central South University) [201805, (CC and YT)].	Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Balgkouranidou I, 2013, BIOMARK MED, V7, P49, DOI [10.2217/BMM.12.111, 10.2217/bmm.12.111]; Bononi A, 2017, CELL DEATH DIFFER, V24, P1694, DOI 10.1038/cdd.2017.95; Carey BW, 2015, NATURE, V518, P413, DOI 10.1038/nature13981; Chen L, 2019, EPIGENET CHROMATIN, V12, DOI 10.1186/s13072-019-0302-9; Coffelt SB, 2015, NATURE, V522, P345, DOI 10.1038/nature14282; Colak D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063204; Dai C, 2010, TRENDS MOL MED, V16, P528, DOI 10.1016/j.molmed.2010.09.002; De Ingeniis J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045190; Diakos CI, 2014, LANCET ONCOL, V15, pE493, DOI 10.1016/S1470-2045(14)70263-3; Donald SP, 2001, CANCER RES, V61, P1810; Elia I, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15267; Fan T, 2003, CANCER RES, V63, P4677; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Gomez-Chou SB, 2017, CANCER RES, V77, P2647, DOI 10.1158/0008-5472.CAN-16-1986; Govindan R, 2012, CELL, V150, P1121, DOI 10.1016/j.cell.2012.08.024; Gut P, 2013, NATURE, V502, P489, DOI 10.1038/nature12752; Han F, 2015, SCI REP-UK, V5, DOI 10.1038/srep13630; He XZ, 2016, CANCER RES, V76, P5743, DOI 10.1158/0008-5472.CAN-16-0268; He YC, 2019, INT J BIOL SCI, V15, P1187, DOI 10.7150/ijbs.33496; He YC, 2017, BBA-REV CANCER, V1868, P359, DOI 10.1016/j.bbcan.2017.07.002; Herbst RS, 2018, NATURE, V553, P446, DOI 10.1038/nature25183; Hinz M, 2014, EMBO REP, V15, P46, DOI 10.1002/embr.201337983; Jia JT, 2016, ONCOTARGET, V7, P27280, DOI 10.18632/oncotarget.8465; Jiang YQ, 2017, CHIN J CANCER, V36, DOI 10.1186/s40880-017-0248-x; Jiang YQ, 2017, THERANOSTICS, V7, P3293, DOI 10.7150/thno.19988; Jones PA, 2016, NAT REV GENET, V17, P630, DOI 10.1038/nrg.2016.93; Jung M, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaf3241; Jungnickel C, 2017, ONCOGENE, V36, P4182, DOI 10.1038/onc.2017.28; Kastenhuber ER, 2017, CELL, V170, P1062, DOI 10.1016/j.cell.2017.08.028; Katada S, 2012, CELL, V148, P24, DOI 10.1016/j.cell.2012.01.001; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kruiswijk F, 2015, NAT REV MOL CELL BIO, V16, P393, DOI 10.1038/nrm4007; Lampropoulou V, 2016, CELL METAB, V24, P158, DOI 10.1016/j.cmet.2016.06.004; Li Q, 2006, J BIOL CHEM, V281, P37566, DOI 10.1074/jbc.M603643200; Liu S, 2014, BBA-GENE REGUL MECH, V1839, P592, DOI 10.1016/j.bbagrm.2014.05.017; Liu W, 2015, SCI REP-UK, V5, DOI 10.1038/srep17206; Liu W, 2012, BIOFACTORS, V38, P398, DOI 10.1002/biof.1036; Liu W, 2012, AUTOPHAGY, V8, P1407, DOI 10.4161/auto.21152; Liu W, 2012, CANCER RES, V72, P3677, DOI 10.1158/0008-5472.CAN-12-0080; Liu W, 2012, P NATL ACAD SCI USA, V109, P8983, DOI 10.1073/pnas.1203244109; Liu Y, 2008, ONCOGENE, V27, P6729, DOI 10.1038/onc.2008.322; Liu YM, 2009, CANCER RES, V69, P6414, DOI 10.1158/0008-5472.CAN-09-1223; Loayza-Puch F, 2016, NATURE, V530, P490, DOI 10.1038/nature16982; Mao C, 2018, AM J CANCER RES, V8, P1214; Mao C, 2018, CANCER RES, V78, P3484, DOI 10.1158/0008-5472.CAN-17-3454; Martinez-Outschoorn UE, 2017, NAT REV CLIN ONCOL, V14, P11, DOI 10.1038/nrclinonc.2016.60; McDoniels-Silvers AL, 2002, NEOPLASIA, V4, P141, DOI 10.1038/sj.neo.7900217; Mills EL, 2016, CELL, V167, P457, DOI 10.1016/j.cell.2016.08.064; Olivares O, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16031; Pang SS, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6048; Pao W, 2011, LANCET ONCOL, V12, P175, DOI 10.1016/S1470-2045(10)70087-5; Perez-Moreno P, 2012, CLIN CANCER RES, V18, P2443, DOI 10.1158/1078-0432.CCR-11-2370; Phang JM, 2019, ANTIOXID REDOX SIGN, V30, P635, DOI 10.1089/ars.2017.7350; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Raimondi I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069152; Ryu B, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000594; Seifert L, 2016, NATURE, V532, P245, DOI 10.1038/nature17403; Shi Y, 2012, CARCINOGENESIS, V33, P1468, DOI 10.1093/carcin/bgs171; Shi Y, 2018, CANCER LETT, V422, P81, DOI 10.1016/j.canlet.2018.02.028; Tang HQ, 2016, CELL REP, V17, P2837, DOI 10.1016/j.celrep.2016.11.038; Tao YG, 2011, P NATL ACAD SCI USA, V108, P5626, DOI 10.1073/pnas.1017000108; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Wang DZ, 2017, CANCER RES, V77, P3655, DOI 10.1158/0008-5472.CAN-16-3199; Willis A, 2004, ONCOGENE, V23, P2330, DOI 10.1038/sj.onc.1207396; Xiao DS, 2017, THERANOSTICS, V7, P132, DOI 10.7150/thno.17032; Xiao DS, 2016, ONCOTARGET, V7, P59049, DOI 10.18632/oncotarget.10011; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yan B, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0542-9; Yan YT, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0466-z; Yang R, 2019, ONCOGENE, V38, P7133, DOI 10.1038/s41388-019-0909-0; Yang R, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1276-y; Yu WS, 2014, GENOME RES, V24, P1613, DOI 10.1101/gr.172015.114; Yu WS, 2014, P NATL ACAD SCI USA, V111, P5890, DOI 10.1073/pnas.1320945111; Yuan J, 2010, CELL, V140, P384, DOI 10.1016/j.cell.2009.12.032; Zhang Y, 2011, CELL RES, V21, P373, DOI 10.1038/cr.2011.33; Zhang ZY, 2019, SIGNAL TRANSDUCT TAR, V4, DOI 10.1038/s41392-019-0074-5; Zhu JJ, 2016, P NATL ACAD SCI USA, V113, P9822, DOI 10.1073/pnas.1610387113	78	34	35	8	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	11					2358	2376		10.1038/s41388-019-1151-5	http://dx.doi.org/10.1038/s41388-019-1151-5		JAN 2020	19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KU0ZS	31911619				2022-12-28	WOS:000508154600001
J	Jung, JH; Lee, H; Cao, B; Liao, P; Zeng, SX; Lu, H				Jung, Ji Hoon; Lee, Hyemin; Cao, Bo; Liao, Peng; Zeng, Shelya X.; Lu, Hua			RNA-binding motif protein 10 induces apoptosis and suppresses proliferation by activating p53	ONCOGENE			English	Article							C-MYC; DEGRADATION; PATHWAY; LOOP; MDM2	RNA-binding motif protein 10 (RBM10) is an RNA-binding protein frequently deleted or mutated in lung cancer cells. Recent reports showed that the knockdown of RBM10 in human cancer cells enhances the growth of mouse tumor xenografts, suggesting that RBM10 acts as a tumor suppressor. RBM10 also regulates alternative splicing and controls cancer cell proliferation. However, the underlying molecular mechanisms for its tumor suppression role remain largely unclear. Here, we for the first time report that RBM10 can induce apoptosis and inhibit cancer cell proliferation by activating p53. Our analysis of cancer genomic databases showed that patients with wild-type RBM10 and p53 survive longer than do those with mutated p53 or less RBM10. RBM10 overexpression markedly inhibited mitochondrial respiration, cell migration and proliferation of various cancer cells that harbor wild-type p53. Also, RBM10 overexpression elongated p53's half-life by disrupting MDM2-p53 interaction and subsequently repressing p53 ubiquitination, whereas knockdown of RBM10 decreased p53 stability. Altogether, our results demonstrate that RBM10 inhibits cancer cell proliferation and induces apoptosis in part by blocking the MDM2-p53 feedback loop.	[Jung, Ji Hoon; Lee, Hyemin; Cao, Bo; Liao, Peng; Zeng, Shelya X.; Lu, Hua] Tulane Univ, Dept Biochem & Mol Biol, Sch Med, New Orleans, LA 70112 USA; [Jung, Ji Hoon; Lee, Hyemin; Cao, Bo; Liao, Peng; Zeng, Shelya X.; Lu, Hua] Tulane Univ, Tulane Canc Ctr, Sch Med, New Orleans, LA 70112 USA; [Jung, Ji Hoon] Kyung Hee Univ, Coll Korean Med, Seoul 02447, South Korea	Tulane University; Tulane University; Kyung Hee University	Lu, H (corresponding author), Tulane Univ, Dept Biochem & Mol Biol, Sch Med, New Orleans, LA 70112 USA.; Lu, H (corresponding author), Tulane Univ, Tulane Canc Ctr, Sch Med, New Orleans, LA 70112 USA.	hlu2@tulane.edu	Liao, Peng/Y-1896-2019; Jung, Jihoon/HHY-7803-2022; CAO, BO/F-6682-2015	Liao, Peng/0000-0002-8409-5574; CAO, BO/0000-0002-4933-6424	National Institutes of Health (NIH)-National Cancer Institute (NCI) [R01CA095441, R01CA172468, R01CA127724]	National Institutes of Health (NIH)-National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Juan Valcarcel for providing us with RBM10 plasmid, Yongbo Wang for providing us with GFP-RBM10, and Xiang Zhou as well as other members of the Lu laboratory for active discussion. This work was supported in part by National Institutes of Health (NIH)-National Cancer Institute (NCI) grants (R01CA095441, R01CA172468, and R01CA127724) to HL and SXZ.	Bechara EG, 2013, MOL CELL, V52, P720, DOI 10.1016/j.molcel.2013.11.010; Bonnal S, 2008, MOL CELL, V32, P81, DOI 10.1016/j.molcel.2008.08.008; Cao B, 2017, ONCOTARGET, V8, P90651, DOI 10.18632/oncotarget.21544; Collins KM, 2017, NUCLEIC ACIDS RES, V45, P6761, DOI 10.1093/nar/gkx225; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Giebler HA, 2000, MOL CELL BIOL, V20, P4849, DOI 10.1128/MCB.20.13.4849-4858.2000; Guan GF, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317691740; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hunziker A, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-94; Jung JH, 2015, CANCER BIOL THER, V16, P412, DOI 10.1080/15384047.2014.1002698; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lahav G, 2004, NAT GENET, V36, P147, DOI 10.1038/ng1293; Liao JM, 2014, ONCOGENE, V33, P4916, DOI 10.1038/onc.2013.430; Muller PAJ, 2011, J CELL BIOL, V192, P209, DOI 10.1083/jcb.201009059; Nag S, 2013, J BIOMED RES, V27, P254, DOI 10.7555/JBR.27.20130030; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Sharma N, 2010, DIFFERENTIATION, V79, P218, DOI 10.1016/j.diff.2010.02.001; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yang MX, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0646-0; Zhang YH, 2017, GENE DEV, V31, P1243, DOI 10.1101/gad.299388.117; Zhou X, 2013, ONCOGENE, V32, P388, DOI 10.1038/onc.2012.63; Zhou X, 2015, J MOL CELL BIOL, V7, P92, DOI 10.1093/jmcb/mjv014; Zilfou JT, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001883	24	19	20	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	5					1031	1040		10.1038/s41388-019-1034-9	http://dx.doi.org/10.1038/s41388-019-1034-9			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KI2VY	31591476	Green Accepted			2022-12-28	WOS:000511209700006
J	Sung, JS; Kang, CW; Kang, S; Jang, Y; Chae, YC; Kim, BG; Cho, NH				Sung, Jin Sol; Kang, Chan Woo; Kang, Suki; Jang, Yeonsue; Chae, Young Chan; Kim, Baek Gil; Cho, Nam Hoon			ITGB4-mediated metabolic reprogramming of cancer-associated fibroblasts	ONCOGENE			English	Article							AEROBIC GLYCOLYSIS; OXIDATIVE STRESS; MITOPHAGY; EXPRESSION; CAVEOLIN-1; AUTOPHAGY; CELLS; PROGRESSION; APOPTOSIS; WARBURG	Integrin beta 4 (ITGB4) overexpression in cancer cells contributes to cancer progression. However, the role of stromal ITGB4 expression in cancer progression remains poorly understood, despite stromal ITGB4 overexpression in malignant cancers. In our study, ITGB4-overexpressing triple negative breast cancer (TNBC) cells provided cancer-associated fibroblasts (CAFs) with ITGB4 proteins via exosomes, which induced BNIP3L-dependent mitophagy and lactate production in CAFs. In coculture assays, the ITGB4-induced mitophagy and glycolysis were suppressed in CAFs by knocking down ITGB4 or inhibiting exosome generation in MDA-MB-231, or blocking c-Jun or AMPK phosphorylation in CAFs. ITGB4-overexpressing CAF-conditioned medium promoted the proliferation, epithelial-to-mesenchymal transition, and invasion of breast cancer cells. In a co-transplant mouse model, MDA-MB-231 made a bigger tumor mass with CAFs than ITGB4 knockdown MDA-MB-231. Herein, we presented how TNBC-derived ITGB4 protein triggers glycolysis in CAFs via BNIP3L-dependent mitophagy and suggested the possibility that ITGB4-induced mitophagy could be targeted as a cancer therapy.	[Sung, Jin Sol; Kang, Chan Woo; Kim, Baek Gil; Cho, Nam Hoon] Yonsei Univ, Coll Med, Brain Korea 21 Plus Project Med Sci, Seoul, South Korea; [Kang, Suki; Jang, Yeonsue; Kim, Baek Gil; Cho, Nam Hoon] Yonsei Univ, Dept Pathol, Coll Med, Seoul, South Korea; [Kang, Suki; Cho, Nam Hoon] Yonsei Univ, SBSI, Coll Med, Seoul, South Korea; [Chae, Young Chan] Ulsan Natl Inst Sci & Technol, Sch Life Sci, Ulsan, South Korea; [Cho, Nam Hoon] Yonsei Univ, Global 5 5 10 Syst Biol, Seoul, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Ulsan National Institute of Science & Technology (UNIST); Yonsei University	Kim, BG; Cho, NH (corresponding author), Yonsei Univ, Coll Med, Brain Korea 21 Plus Project Med Sci, Seoul, South Korea.; Kim, BG; Cho, NH (corresponding author), Yonsei Univ, Dept Pathol, Coll Med, Seoul, South Korea.; Cho, NH (corresponding author), Yonsei Univ, SBSI, Coll Med, Seoul, South Korea.; Cho, NH (corresponding author), Yonsei Univ, Global 5 5 10 Syst Biol, Seoul, South Korea.	bbaekiri@yuhs.ac; cho1988@yuhs.ac		KANG, SUKI/0000-0002-9957-3479; kang, chan woo/0000-0001-5822-5235; Jang, Yeonsue/0000-0001-5683-0001; Sung, Jin Sol/0000-0002-7899-8814; jo, namhun/0000-0002-0045-6441; KIM, BAEK GIL/0000-0001-6270-1433	Mid-Career Researcher Program through a National Research Foundation of Korea [2019R1A2B5B01069934]; Challenges in Creative Research through a National Research Foundation of Korea [2019R1I1A1A01060549]; Health Fellowship Foundation - Yuhan Corporation; Medical Illustration & Design, a part of the Medical Research Support Services of Yonsei University College of Medicine	Mid-Career Researcher Program through a National Research Foundation of Korea(National Research Foundation of Korea); Challenges in Creative Research through a National Research Foundation of Korea(National Research Foundation of Korea); Health Fellowship Foundation - Yuhan Corporation; Medical Illustration & Design, a part of the Medical Research Support Services of Yonsei University College of Medicine	This study was supported by the Mid-Career Researcher Program (no. 2019R1A2B5B01069934; NHC) and Challenges in Creative Research (no. 2019R1I1A1A01060549; BGK) through a National Research Foundation of Korea grant, and The Health Fellowship Foundation grants funded by Yuhan Corporation. The authors thank Medical Illustration & Design, a part of the Medical Research Support Services of Yonsei University College of Medicine, for all artistic support related to this work.	Cicenas J, 2018, CANCERS, V10, DOI 10.3390/cancers10010001; Esteban-Martinez L, 2017, EMBO J, V36, P1688, DOI 10.15252/embj.201695916; Frank M, 2012, BBA-MOL CELL RES, V1823, P2297, DOI 10.1016/j.bbamcr.2012.08.007; Fu YJ, 2017, ONCOTARGET, V8, P57813, DOI 10.18632/oncotarget.18175; Jezek J, 2018, ANTIOXIDANTS-BASEL, V7, DOI 10.3390/antiox7010013; Ke HN, 2010, CANCER RES, V70, P3080, DOI 10.1158/0008-5472.CAN-09-2923; Kim BG, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.73; Kim BG, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3203; Kim BG, 2011, AM J PATHOL, V178, P373, DOI 10.1016/j.ajpath.2010.11.028; Kosgodage US, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00889; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Kubli DA, 2012, CIRC RES, V111, P1208, DOI 10.1161/CIRCRESAHA.112.265819; Li X, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00596-9; Liou GY, 2010, FREE RADICAL RES, V44, P479, DOI 10.3109/10715761003667554; Liu MH, 2016, CANCER METAB, V4, DOI 10.1186/s40170-016-0160-x; Liu SY, 2016, ONCOTARGET, V7, P16282, DOI 10.18632/oncotarget.7646; Martinez-Outschoorn UE, 2011, CELL CYCLE, V10, P2504, DOI 10.4161/cc.10.15.16585; Martins D, 2013, CELL CYCLE, V12, P2684, DOI 10.4161/cc.25794; Maycotte P, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317698391; McKeown SR, 2014, BRIT J RADIOL, V87, DOI 10.1259/bjr.20130676; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; Novak I, 2010, EMBO REP, V11, P45, DOI 10.1038/embor.2009.256; Pavlides S, 2012, ANTIOXID REDOX SIGN, V16, P1264, DOI 10.1089/ars.2011.4243; Pavlides S, 2009, CELL CYCLE, V8, P3984, DOI 10.4161/cc.8.23.10238; PETERKOFSKY B, 1982, CANCER RES, V42, P1809; Quelo I, 2004, J BIOL CHEM, V279, P43893, DOI 10.1074/jbc.M406310200; Ratnikov BI, 2017, ONCOGENE, V36, P147, DOI 10.1038/onc.2016.198; Renschler MF, 2004, EUR J CANCER, V40, P1934, DOI 10.1016/j.ejca.2004.02.031; Roach PJ, 2011, MOL CELL BIOL, V31, P3082, DOI 10.1128/MCB.05565-11; Schwarten M, 2009, AUTOPHAGY, V5, P690, DOI 10.4161/auto.5.5.8494; Sena LA, 2012, MOL CELL, V48, P158, DOI 10.1016/j.molcel.2012.09.025; Sheen JH, 2011, CANCER CELL, V19, P613, DOI 10.1016/j.ccr.2011.03.012; Takahashi A, 2006, NAT CELL BIOL, V8, P1291, DOI 10.1038/ncb1491; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Vallejo Abbe N, 2008, CSH Protoc, V2008, DOI 10.1101/pdb.prot4861; Witkiewicz AK, 2009, CANCER BIOL THER, V8, P1071, DOI 10.4161/cbt.8.11.8874; Wu KN, 2011, CELL CYCLE, V10, P4250, DOI 10.4161/cc.10.24.18551; Xiao B, 2017, J BIOL CHEM, V292, P16697, DOI 10.1074/jbc.M117.787739; Yang L, 2015, ONCOTARGET, V6, P25755, DOI 10.18632/oncotarget.4697	39	58	64	6	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	3					664	676		10.1038/s41388-019-1014-0	http://dx.doi.org/10.1038/s41388-019-1014-0			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG1RJ	31534187				2022-12-28	WOS:000509718300013
J	Wang, L; Zhao, HY; Li, J; Xu, YQ; Lan, YJ; Yin, WK; Liu, XQ; Yu, L; Lin, SH; Du, MYF; Li, X; Xiao, Y; Zhang, YP				Wang, Li; Zhao, Hongying; Li, Jing; Xu, Yingqi; Lan, Yujia; Yin, Wenkang; Liu, Xiaoqin; Yu, Lei; Lin, Shihua; Du, Michael Yifei; Li, Xia; Xiao, Yun; Zhang, Yunpeng			Identifying functions and prognostic biomarkers of network motifs marked by diverse chromatin states in human cell lines	ONCOGENE			English	Article							FACTOR-BINDING SITES; REGULATORY NETWORK; DNA-DAMAGE; LEUKEMIA; DYNAMICS; GENES; EGR1	Epigenetic modifications play critical roles in modulating gene expression, yet their roles in regulatory networks in human cell lines remain poorly characterized. We integrated multiomics data to construct directed regulatory networks with nodes and edges labeled with chromatin states in human cell lines. We observed extensive association of diverse chromatin states and network motifs. The gene expression analysis showed that diverse chromatin states of coherent type-1 feedforward loop (C1-FFL) and incoherent type-1 feedforward loops (I1-FFL) contributed to the dynamic expression patterns of targets. Notably, diverse chromatin state compositions could help C1- or I1-FFL to control a large number of distinct biological functions in human cell lines, such as four different types of chromatin state compositions cooperating with K562-associated C1-FFLs controlling "regulation of cytokinesis," "G1/S transition of mitotic cell cycle," "DNA recombination," and "telomere maintenance," respectively. Remarkably, we identified six chromatin state-marked C1-FFL instances (HCFC1-NFYA-ABL1, THAP1-USF1-BRCA2, ZNF263-USF1-UBA52, MYC-ATF1-UBA52, ELK1-EGR1-CCT4, and YY1-EGR1-INO80C) could act as prognostic biomarkers of acute myelogenous leukemia though influencing cancer-related biological functions, such as cell proliferation, telomere maintenance, and DNA recombination. Our results will provide novel insight for better understanding of chromatin state-mediated gene regulation and facilitate the identification of novel diagnostic and therapeutic biomarkers of human cancers.	[Wang, Li; Zhao, Hongying; Xu, Yingqi; Lan, Yujia; Yin, Wenkang; Liu, Xiaoqin; Yu, Lei; Lin, Shihua; Li, Xia; Xiao, Yun; Zhang, Yunpeng] Harbin Med Univ, Coll Bioinformat Sci & Technol, Harbin 150081, Peoples R China; [Li, Jing] Heilongjiang Univ Chinese Med, Affiliated Hosp 1, Dept Ultrason Med, Harbin 150040, Peoples R China; [Du, Michael Yifei] Weston High Sch Massachusetts, 444 Wellesley St, Weston, MA 02493 USA	Harbin Medical University; Heilongjiang University of Chinese Medicine	Li, X; Xiao, Y; Zhang, YP (corresponding author), Harbin Med Univ, Coll Bioinformat Sci & Technol, Harbin 150081, Peoples R China.	lixia@hrbmu.edu.cn; xiaoyun@ems.hrbmu.edu.cn; zyp19871208@126.com	Xiao, Yun/A-8359-2013	Li, Xia/0000-0002-9794-2648; Xu, Yingqi/0000-0001-6879-639X	National Natural Science Foundation of China [31801115, 61803129, 61603116, 61873075]; China Postdoctoral Science Foundation [2018M631943, 2018M641860]; China Postdoctoral Science Special Foundation [2019T120280]; Hei Long Jiang Postdoctoral Foundation [LBH-Z17110, LBH-Z17218]; General Program of Natural Science Foundation of Heilongjiang Province [H2016055]; Fundamental Research Funds for the Provincial Universities [2017JCZX54, 2017JCZX51]; Heilongjiang Provincial Health and Family Planning Commission of Science Foundation [2018476, 2018477]; Heilongjiang Provincial planning office key subjects [GBB1318066]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); China Postdoctoral Science Special Foundation; Hei Long Jiang Postdoctoral Foundation; General Program of Natural Science Foundation of Heilongjiang Province; Fundamental Research Funds for the Provincial Universities; Heilongjiang Provincial Health and Family Planning Commission of Science Foundation; Heilongjiang Provincial planning office key subjects	This work was financially supported by the National Natural Science Foundation of China (31801115, 61803129, 61603116, and 61873075), the China Postdoctoral Science Foundation (2018M631943 and 2018M641860), the China Postdoctoral Science Special Foundation (2019T120280), the Hei Long Jiang Postdoctoral Foundation (LBH-Z17110 and LBH-Z17218), General Program of Natural Science Foundation of Heilongjiang Province (H2016055) and Fundamental Research Funds for the Provincial Universities (2017JCZX54 and 2017JCZX51). Heilongjiang Provincial Health and Family Planning Commission of Science Foundation (2018476 and 2018477). Heilongjiang Provincial planning office key subjects (GBB1318066).	Alon U, 2007, NAT REV GENET, V8, P450, DOI 10.1038/nrg2102; [Anonymous], AM SOC CLIN ONCOL S; Arneson A, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0488-1; Bulut-Karslioglu A, 2012, NAT STRUCT MOL BIOL, V19, P1023, DOI 10.1038/nsmb.2382; Cancer Genome Atlas Research Network. Electronic address: wheeler@bcm.edu, 2017, Cell, V169, P1327, DOI 10.1016/j.cell.2017.05.046; Chepyala SR, 2016, SCI REP-UK, V6, DOI 10.1038/srep23607; Dasgupta Y, 2016, BLOOD, V127, P2131, DOI 10.1182/blood-2015-11-681171; de Hoon MJL, 2010, CURR BIOL, V20, pR735, DOI 10.1016/j.cub.2010.06.031; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Ernst J, 2012, NAT METHODS, V9, P215, DOI 10.1038/nmeth.1906; Feng JX, 2012, NAT PROTOC, V7, P1728, DOI 10.1038/nprot.2012.101; Gkountela S, 2014, STEM CELL REV REP, V10, P230, DOI 10.1007/s12015-013-9490-z; Gui R, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00600; Hoffmeyer K, 2012, SCIENCE, V336, P1549, DOI 10.1126/science.1218370; Hong J, 2018, ELIFE, V7, DOI 10.7554/eLife.32323; Hsu YL, 2013, ONCOGENE, V32, P4436, DOI 10.1038/onc.2012.444; Hu JL, 2017, MOLECULES, V22, DOI 10.3390/molecules22122194; Hyka-Nouspikel N, 2012, STEM CELLS, V30, P1901, DOI 10.1002/stem.1177; Jin YL, 2016, J CLIN INVEST, V126, P3961, DOI 10.1172/JCI85239; John S, 2011, NAT GENET, V43, P264, DOI 10.1038/ng.759; Kittisopikul M, 2010, P NATL ACAD SCI USA, V107, P13300, DOI 10.1073/pnas.1003975107; Krapf G, 2010, ONCOGENE, V29, P3307, DOI 10.1038/onc.2010.53; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Li XT, 2019, IEEE T CYBERNETICS, V49, P1680, DOI 10.1109/TCYB.2018.2817480; Libbrecht MW, 2015, GENOME RES, V25, P544, DOI 10.1101/gr.184341.114; Lu C, 2013, ONCOGENE, V32, P5602, DOI 10.1038/onc.2013.349; Luscombe NM, 2004, NATURE, V431, P308, DOI 10.1038/nature02782; Mahmoudi S, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2010.90; Maifrede S, 2017, MOL CANCER RES, V15, P967, DOI 10.1158/1541-7786.MCR-16-0468; Marco A, 2009, BIOINFORMATICS, V25, P2473, DOI 10.1093/bioinformatics/btp462; Milo R, 2004, SCIENCE, V303, P1538, DOI 10.1126/science.1089167; Ocone A, 2015, BIOINFORMATICS, V31, P89, DOI 10.1093/bioinformatics/btv257; Pan X, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0291-9; Plaisier CL, 2016, CELL SYST, V3, P172, DOI 10.1016/j.cels.2016.06.006; Prill RJ, 2005, PLOS BIOL, V3, P1881, DOI 10.1371/journal.pbio.0030343; Reavie L, 2013, CANCER CELL, V23, P362, DOI 10.1016/j.ccr.2013.01.025; Shizuka D, 2015, J R SOC INTERFACE, V12, DOI 10.1098/rsif.2015.0080; Sims D, 2014, NAT REV GENET, V15, P121, DOI 10.1038/nrg3642; Soshnev AA, 2016, MOL CELL, V62, P681, DOI 10.1016/j.molcel.2016.05.004; Steinbrecher D, 2018, LEUKEMIA LYMPHOMA, V59, P1614, DOI 10.1080/10428194.2017.1390236; Stoddart A, 2014, BLOOD, V123, P1069, DOI 10.1182/blood-2013-07-517953; Stuart JR, 2005, ONCOGENE, V24, P8085, DOI 10.1038/sj.onc.1208953; Sun LX, 2015, NUCLEIC ACIDS RES, V43, P6334, DOI 10.1093/nar/gkv598; Taher L, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r117; Thurman RE, 2012, NATURE, V489, P75, DOI 10.1038/nature11232; Wang L, 2019, INT J CANCER, V144, P1723, DOI 10.1002/ijc.31865; Weirick T, 2016, BRIEF BIOINFORM, V17, P678, DOI 10.1093/bib/bbv067; Wernicke S, 2006, BIOINFORMATICS, V22, P1152, DOI 10.1093/bioinformatics/btl038; Wong JJL, 2014, CANCER SCI, V105, P1457, DOI 10.1111/cas.12532; Wong K. -C., 2016, COMPUTATIONAL BIOL B, DOI 10.1201/b20026; Wu S, 2010, THEOR BIOL MED MODEL, V7, DOI 10.1186/1742-4682-7-18; Yevshin I, 2017, NUCLEIC ACIDS RES, V45, pD61, DOI 10.1093/nar/gkw951; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zhang S, 2013, FEBS LETT, V587, P645, DOI 10.1016/j.febslet.2013.01.019; Zhao HY, 2016, BBA-GEN SUBJECTS, V1860, P1475, DOI 10.1016/j.bbagen.2016.04.008; Zhao HY, 2015, SCI REP-UK, V5, DOI 10.1038/srep11938	57	8	9	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	3					677	689		10.1038/s41388-019-1005-1	http://dx.doi.org/10.1038/s41388-019-1005-1			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG1RJ	31537905	Green Published, hybrid			2022-12-28	WOS:000509718300014
J	Zhou, Y; Liu, HY; Wang, J; Wang, XL; Qian, LL; Xu, F; Song, WG; Wu, DB; Shen, Z; Feng, DQ; Ling, B; Xiao, WH; Shan, G; Chen, L				Zhou, Ying; Liu, Hanyuan; Wang, Juan; Wang, Xiaolin; Qian, Lili; Xu, Fei; Song, Weiguo; Wu, Dabao; Shen, Zhen; Feng, Dingqing; Ling, Bin; Xiao, Weihua; Shan, Ge; Chen, Liang			Delta Np63 alpha exerts antitumor functions in cervical squamous cell carcinoma	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; REGENERATIVE PROLIFERATION; BREAST-CANCER; DNA-BINDING; P63; EXPRESSION; CISPLATIN; PROTEIN; ACTIVATION; TARGET	The molecular basis underlying the aggressive nature and excessive proliferation of cervical squamous cancer cell remains unclear. Delta Np63 alpha is the predominant isotype of p63 expressed in the epithelia and regulates epithelial cell differentiation. The pro-/anti-tumor role of Delta Np63 alpha in different kinds of solid tumors remains controversial and the precise molecular mechanisms are still elusive. In this study, we uncovered the molecular functions of Delta Np63 alpha in cervical squamous cell carcinoma to clarify its roles as a tumor suppressor. We demonstrated that Delta Np63 alpha suppressed cell migration, invasiveness, and tumor growth in SiHa and ME-180 cells with both in vivo and in vitro assays. Mechanistic investigation via RNA-sequencing and chromatin immunoprecipitation-sequencing revealed that Delta Np63 alpha exerted its antitumor capacity via regulating the expression of a cohort of cell junction genes. Further, we showed that ZNF385B and CLDN1 were two direct Delta Np63 alpha targets with significant relevance to cervical squamous cell carcinoma examined in cell cultures, tumor xenografts, and clinic tumors. We also demonstrated that Delta Np63 alpha downregulated NFATC1 to reduce cisplatin resistance. These findings shed new lights on functions of Delta Np63 alpha in tumors and providing novel insights in targeted therapy of cervical cancers.	[Zhou, Ying; Qian, Lili; Wu, Dabao; Shen, Zhen; Chen, Liang] Univ Sci & Technol China, Anhui Prov Hosp, Affiliated Hosp 1, Dept Obstet & Gynecol, Hefei 230001, Anhui, Peoples R China; [Liu, Hanyuan; Wang, Juan; Xu, Fei; Song, Weiguo] Anhui Med Univ, Hefei 230001, Anhui, Peoples R China; [Wang, Xiaolin; Xiao, Weihua; Shan, Ge; Chen, Liang] Univ Sci & Technol China, Sch Life Sci, Div Mol Med, CAS Key Lab Innate Immun & Chron Dis,Hefei Natl L, Hefei 230027, Peoples R China; [Feng, Dingqing; Ling, Bin] Peking Union Med Coll & Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Obstet & Gynecol, Beijing 100730, Peoples R China; [Shan, Ge] Chinese Acad Sci, Ctr Excellence Mol Cell Sci, Shanghai Inst Biol Sci, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Anhui Medical University; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Chen, L (corresponding author), Univ Sci & Technol China, Anhui Prov Hosp, Affiliated Hosp 1, Dept Obstet & Gynecol, Hefei 230001, Anhui, Peoples R China.; Shan, G; Chen, L (corresponding author), Univ Sci & Technol China, Sch Life Sci, Div Mol Med, CAS Key Lab Innate Immun & Chron Dis,Hefei Natl L, Hefei 230027, Peoples R China.; Shan, G (corresponding author), Chinese Acad Sci, Ctr Excellence Mol Cell Sci, Shanghai Inst Biol Sci, Shanghai 200031, Peoples R China.	shange@ustc.edu.cn; anqingcl@ustc.edu.cn	钱, 钱丽丽/GWV-8162-2022	Zhou, Ying/0000-0001-8992-7897	National Natural Science Foundation of China [81872110, 31600657, 81272881, 8137277"9, 81372777, 31725016, 81902632]; National Key Research and Development Program [2018YFC1003903]; Anhui Provincial Key Research and Development Projects [1704a0802151]; Strategic Priority Research Program (Pilot study): "Biological basis of aging and therapeutic strategies" of the Chinese Academy of Sciences [XDPB10]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program; Anhui Provincial Key Research and Development Projects; Strategic Priority Research Program (Pilot study): "Biological basis of aging and therapeutic strategies" of the Chinese Academy of Sciences	We would like to thank Yuhui Miao, Huimin Liu, Lu Qi, Xu Liu, Shuai Wei, Jingxin Li in University of Science and Technology of China for their valuable comments during the preparation of the manuscript. This work was supported by the National Natural Science Foundation of China (No. 81872110, 31600657, 81272881, 8137277"9, 81372777, 31725016, and 81902632); National Key Research and Development Program (2018YFC1003903); Anhui Provincial Key Research and Development Projects (1704a0802151); the Strategic Priority Research Program (Pilot study): "Biological basis of aging and therapeutic strategies" of the Chinese Academy of Sciences (grant XDPB10).	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Candi E, 2008, CELL MOL LIFE SCI, V65, P3126, DOI 10.1007/s00018-008-8119-x; Chao YC, 2009, AM J RESP CRIT CARE, V179, P123, DOI 10.1164/rccm.200803-456OC; Chen L, 2015, P NATL ACAD SCI USA, V112, P10002, DOI 10.1073/pnas.1502159112; Chen YL, 2018, CELL MOL LIFE SCI, V75, P965, DOI 10.1007/s00018-017-2666-y; Chung J, 2010, EMBO REP, V11, P777, DOI 10.1038/embor.2010.125; Crotti TN, 2006, GENE, V372, P92, DOI 10.1016/j.gene.2005.12.012; Dang TT, 2015, CANCER RES, V75, P3925, DOI 10.1158/0008-5472.CAN-14-3363; DeYoung MP, 2007, ONCOGENE, V26, P5169, DOI 10.1038/sj.onc.1210337; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Eftang LL, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-586; Fisher ML, 2016, CANCER RES, V76, P7265, DOI 10.1158/0008-5472.CAN-16-2032; Flores ER, 2007, CELL CYCLE, V6, P300, DOI 10.4161/cc.6.3.3793; Gerald RC, 2002, CELL, V109, P67; Hoevel T, 2002, J CELL PHYSIOL, V191, P60, DOI 10.1002/jcp.10076; Hu SS, 2016, NAT STRUCT MOL BIOL, V23, P1011, DOI 10.1038/nsmb.3302; Im JY, 2016, BBA-MOL CELL RES, V1863, P40, DOI 10.1016/j.bbamcr.2015.10.011; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Katayama A, 2017, PATHOL INT, V67, P404, DOI 10.1111/pin.12560; Ko E, 2013, CLIN CANCER RES, V19, P1204, DOI 10.1158/1078-0432.CCR-12-2848; Koster MI, 2004, DIFFERENTIATION, V72, P364, DOI 10.1111/j.1432-0436.2004.07208002.x; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Le Bras GF, 2012, CELL ADHES MIGR, V6, P365, DOI 10.4161/cam.21326; Lee M, 2006, MOL CELLS, V22, P1; Lopardo T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002715; Lv J, 2017, MOL CELL BIOCHEM, V432, P91, DOI 10.1007/s11010-017-3000-6; Machado-Silva A, 2010, SEMIN CANCER BIOL, V20, P57, DOI 10.1016/j.semcancer.2010.02.005; Mangiulli M, 2009, NUCLEIC ACIDS RES, V37, P6092, DOI 10.1093/nar/gkp674; Martin TA, 2001, HISTOL HISTOPATHOL, V16, P1183, DOI 10.14670/HH-16.1183; Mills AA, 2006, CURR OPIN GENET DEV, V16, P38, DOI 10.1016/j.gde.2005.12.001; Minion LE, 2018, GYNECOL ONCOL, V148, P609, DOI 10.1016/j.ygyno.2018.01.009; National Research Council, 2011, GUIDE CARE USE LAB A; Ortt K, 2006, FEBS LETT, V580, P4544, DOI 10.1016/j.febslet.2006.07.004; Pflaumf J, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00285; Qian LL, 2017, CYTOKINE, V96, P114, DOI 10.1016/j.cyto.2017.04.001; Qian X, 2015, CRIT REV ONCOL HEMAT, V95, P337, DOI 10.1016/j.critrevonc.2015.03.009; Qiao Feng, 2005, Sci STKE, V2005, pre7, DOI 10.1126/stke.2862005re7; Ratovitski EA, 2013, FEBS LETT, V587, P3581, DOI 10.1016/j.febslet.2013.09.023; Rizzo JM, 2016, CELL DEATH DIFFER, V23, P1073, DOI 10.1038/cdd.2015.162; Rodriguez-Carunchio L, 2015, BJOG-INT J OBSTET GY, V122, P119, DOI 10.1111/1471-0528.13071; Rose PG, 1999, NEW ENGL J MED, V340, P1144, DOI 10.1056/NEJM199904153401502; Rusan M, 2015, CLIN CANCER RES, V21, P2009, DOI 10.1158/1078-0432.CCR-14-1101; Saladi SV, 2017, CANCER CELL, V31, P35, DOI 10.1016/j.ccell.2016.12.001; Salah Z, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.6; Sen T, 2011, CANCER RES, V71, P1167, DOI 10.1158/0008-5472.CAN-10-1481; Si H, 2016, ONCOGENE, V35, P5781, DOI 10.1038/onc.2016.112; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Sol ES, 2009, J GYNECOL ONCOL, V20, P28, DOI 10.3802/jgo.2009.20.1.28; Szymborska A, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a029223; Tran MN, 2013, J BIOL CHEM, V288, P3275, DOI 10.1074/jbc.M112.408104; Tsukita S, 2008, ONCOGENE, V27, P6930, DOI 10.1038/onc.2008.344; van Bokhoven H, 2002, AM J HUM GENET, V71, P1, DOI 10.1086/341450; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Ying HQ, 2005, MOL CELL BIOL, V25, P6154, DOI 10.1128/MCB.25.14.6154-6164.2005; Zhou Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022065; Zhou Y, 2011, CLIN INVEST MED, V34, pE184; Zhou Y, 2009, J INTERF CYTOK RES, V29, P695, DOI 10.1089/jir.2009.0003	57	8	8	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	4					905	921		10.1038/s41388-019-1033-x	http://dx.doi.org/10.1038/s41388-019-1033-x			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KF4EJ	31576015				2022-12-28	WOS:000509197200012
J	Vetter, G; Saumet, A; Moes, M; Vallar, L; Le Bechec, A; Laurini, C; Sabbah, M; Arar, K; Theillet, C; Lecellier, CH; Friederich, E				Vetter, G.; Saumet, A.; Moes, M.; Vallar, L.; Le Bechec, A.; Laurini, C.; Sabbah, M.; Arar, K.; Theillet, C.; Lecellier, C-H; Friederich, E.			RETRACTION: miR-661 expression in SNAI1-induced epithelial to mesenchymal transition contributes to breast cancer cell invasion by targeting Nectin-1 and StarD10 messengers (Retraction of vol 29, pg 4436, 2010)	ONCOGENE			English	Retraction													Theillet, Charles/O-7634-2018	Theillet, Charles/0000-0001-5555-2759; Vallar, Laurent/0000-0002-4404-1010				Vetter G, 2010, ONCOGENE, V29, P4436, DOI 10.1038/onc.2010.181	1	0	0	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2016	35	5					670	670		10.1038/onc.2015.265	http://dx.doi.org/10.1038/onc.2015.265			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC9NR	32667144	Green Published, Bronze			2022-12-28	WOS:000369548800014
J	Doheny, D; Sirkisoon, S; Carpenter, RL; Aguayo, NR; Regua, AT; Anguelov, M; Manore, SG; Arrigo, A; Abu Jalboush, S; Wong, GL; Yu, Y; Wagner, CJ; Chan, M; Ruiz, J; Thomas, A; Strowd, R; Lin, J; Lo, HW				Doheny, Daniel; Sirkisoon, Sherona; Carpenter, Richard L.; Aguayo, Noah Reeve; Regua, Angelina T.; Anguelov, Marlyn; Manore, Sara G.; Arrigo, Austin; Jalboush, Sara Abu; Wong, Grace L.; Yu, Yang; Wagner, Calvin J.; Chan, Michael; Ruiz, Jimmy; Thomas, Alexandra; Strowd, Roy; Lin, Jiayuh; Lo, Hui-Wen			Combined inhibition of JAK2-STAT3 and SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis	ONCOGENE			English	Article							SIGNALING PATHWAY; SONIC HEDGEHOG; THERAPEUTIC TARGET; GENE-EXPRESSION; FACTOR RECEPTOR; SPLICE VARIANT; UP-REGULATION; SELF-RENEWAL; STAT3; ACTIVATION	Triple-negative breast cancer (TNBC) and HER2-positive breast cancer are particularly aggressive and associated with unfavorable prognosis. TNBC lacks effective treatments. HER2-positive tumors have treatment options but often acquire resistance to HER2-targeted therapy after initial response. To address these challenges, we determined whether novel combinations of JAK2-STAT3 and SMO-GLI1/tGLI1 inhibitors synergistically target TNBC and HER2 breast cancer since these two pathways are concurrently activated in both tumor types and enriched in metastatic tumors. Herein, we show that novel combinations of JAK2 inhibitors (ruxolitinib and pacritinib) with SMO inhibitors (vismodegib and sonidegib) synergistically inhibited in vitro growth of TNBC and HER2-positive trastuzumab-resistant BT474-TtzmR cells. Synergy was also observed against breast cancer stem cells. To determine if the combination is efficacious in inhibiting metastasis, we treated mice with intracardially inoculated TNBC cells and found the combination to inhibit lung and liver metastases, and prolong host survival without toxicity. The combination inhibited orthotopic growth, VEGF-A expression, and tumor vasculature of both TNBC and HER2-positive trastuzumab-refractory breast cancer. Lung metastasis of orthotopic BT474-TtzmR xenografts was suppressed by the combination. Together, our results indicated that dual targeting of JAK2 and SMO resulted in synergistic suppression of breast cancer growth and metastasis, thereby supporting future clinical testing.	[Doheny, Daniel; Sirkisoon, Sherona; Carpenter, Richard L.; Aguayo, Noah Reeve; Regua, Angelina T.; Anguelov, Marlyn; Manore, Sara G.; Arrigo, Austin; Jalboush, Sara Abu; Wong, Grace L.; Yu, Yang; Wagner, Calvin J.; Lo, Hui-Wen] Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC 27103 USA; [Chan, Michael; Ruiz, Jimmy; Thomas, Alexandra; Strowd, Roy; Lo, Hui-Wen] Wake Forest Univ, Bowman Gray Sch Med, Wake Forest Comprehens Canc Ctr, Winston Salem, NC 27103 USA; [Chan, Michael] Wake Forest Univ, Bowman Gray Sch Med, Dept Radiat Oncol, Winston Salem, NC USA; [Ruiz, Jimmy; Thomas, Alexandra] Wake Forest Univ, Bowman Gray Sch Med, Dept Hematol & Oncol, Winston Salem, NC USA; [Strowd, Roy] Wake Forest Univ, Bowman Gray Sch Med, Dept Neurol, Winston Salem, NC 27103 USA; [Lin, Jiayuh] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; [Carpenter, Richard L.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, JH 308 1001 E 3rd St, Bloomington, IN 47405 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; University System of Maryland; University of Maryland Baltimore; Indiana University System; Indiana University Bloomington	Lo, HW (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC 27103 USA.; Lo, HW (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Wake Forest Comprehens Canc Ctr, Winston Salem, NC 27103 USA.	hlo@wakehealth.edu		Manore, Sara/0000-0003-1962-5505; Regua, Angelina/0000-0003-2595-8242; Doheny, Daniel/0000-0002-1455-3090	NIH [R01NS087169, T32CA079448, R01NS087169-3S1, 1T32CA247819-01, P30CA012197, 1R01CA228137-01A1]; DoD [W81XWH-17-1-0044, W81XWH-19-1-0072, W81XWH-19-1-0753, W81XWH-20-1-0044]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DoD(United States Department of Defense)	We would like to acknowledge the Massague laboratory for gifting the 231-BoM and 231-BrM breast cancer cell lines and Dr. Dihua Yu for gifting the BT474-TtzmR cell line. We acknowledge funding support for this project from NIH grants, R01NS087169 (HWL), T32CA079448 (RLC), R01NS087169-3S1 (HWL and SS), 1T32CA247819-01 (ATR), P30CA012197 (BP), 1R01CA228137-01A1 (HWL), as well as, DoD grants, W81XWH-17-1-0044 (HWL), W81XWH-19-1-0072 (HWL), W81XWH-19-1-0753 (HWL), and W81XWH-20-1-0044 (HWL and JL).	Ackerman Z, 2015, BIOL TRACE ELEM RES, V163, P169, DOI 10.1007/s12011-014-0110-9; Aditya Suruchi, 2013, Indian Dermatol Online J, V4, P365, DOI 10.4103/2229-5178.120685; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Al-Mahmood S, 2018, DRUG DELIV TRANSL RE, V8, P1483, DOI 10.1007/s13346-018-0551-3; Atwood SX, 2015, CANCER CELL, V27, P342, DOI 10.1016/j.ccell.2015.02.002; Balko JM, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad3001; Balko JM, 2014, CANCER DISCOV, V4, P232, DOI 10.1158/2159-8290.CD-13-0286; Baron JM, 2015, J ONCOL PHARM PRACT, V21, P132, DOI 10.1177/1078155214527144; Bigelow RLH, 2004, J BIOL CHEM, V279, P1197, DOI 10.1074/jbc.M310589200; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Bourguignon LYW, 2008, J BIOL CHEM, V283, P17635, DOI 10.1074/jbc.M800109200; Cao X, 2012, ONCOGENE, V31, P104, DOI 10.1038/onc.2011.219; Carpenter RL, 2015, ONCOTARGET, V6, P22653, DOI 10.18632/oncotarget.4248; Carpenter RL, 2014, CANCERS, V6, P897, DOI 10.3390/cancers6020897; Carpenter RL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078836; Carpenter RL, 2013, J CARCINOG MUTAGEN, P2013; Chen WW, 2011, P NATL ACAD SCI USA, V108, P9589, DOI 10.1073/pnas.1017945108; Choi HJ, 2012, BBA-MOL CELL RES, V1823, P1082, DOI 10.1016/j.bbamcr.2012.03.015; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Epstein EH, 2008, NAT REV CANCER, V8, P743, DOI 10.1038/nrc2503; Fan C, 2006, NEW ENGL J MED, V355, P560, DOI 10.1056/NEJMoa052933; Fernandez A, 2009, GENE DEV, V23, P2729, DOI 10.1101/gad.1824509; Fiaschi M, 2009, CANCER RES, V69, P4810, DOI 10.1158/0008-5472.CAN-08-3938; Foshay KM, 2008, STEM CELLS DEV, V17, P269, DOI 10.1089/scd.2007.0098; Gruber R, 2016, GASTROENTEROLOGY, V151, P526, DOI 10.1053/j.gastro.2016.05.006; Guo CC, 2012, P NATL ACAD SCI USA, V109, P17603, DOI 10.1073/pnas.1208807109; Han W, 2013, CANC HALLMARKS, V1, P28, DOI DOI 10.1166/CH.2013.1006; Hindley C, 2013, BIOCHEM J, V451, P135, DOI 10.1042/BJ20121627; Howie LJ, 2019, CLIN CANCER RES, V25, P2949, DOI 10.1158/1078-0432.CCR-18-3003; Howlader NNA, 2019, SEER CANC STAT REV 1, V2020, P1975; Hsu TH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04052-6; Jain S, 2017, ONCOTARGETS THER, V10, DOI 10.2147/OTT.S130910; Jiao X, 2012, GENE CHROMOSOME CANC, V51, P480, DOI 10.1002/gcc.21935; Johnson DE, 2018, NAT REV CLIN ONCOL, V15, P234, DOI 10.1038/nrclinonc.2018.8; Kameda C, 2009, ANTICANCER RES, V29, P871; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Kuba S, 2014, JPN J CLIN ONCOL, V44, P1025, DOI 10.1093/jjco/hyu126; Kusaba T, 2006, ONCOL REP, V15, P1445; Lebert JM, 2018, CURR ONCOL, V25, pS142, DOI 10.3747/co.25.3954; Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054; Lo HW, 2008, CLIN CANCER RES, V14, P6042, DOI 10.1158/1078-0432.CCR-07-4923; Lo HW, 2007, CANCER RES, V67, P9066, DOI 10.1158/0008-5472.CAN-07-0575; Lo HW, 2010, MOL CANCER RES, V8, P232, DOI 10.1158/1541-7786.MCR-09-0391; Lo HW, 2009, CANCER RES, V69, P6790, DOI 10.1158/0008-5472.CAN-09-0886; Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007; Loh CY, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00048; Machold R, 2003, NEURON, V39, P937, DOI 10.1016/S0896-6273(03)00561-0; Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745; Merchant AA, 2010, CLIN CANCER RES, V16, P3130, DOI 10.1158/1078-0432.CCR-09-2846; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Okumura F, 2011, BBA-MOL CELL RES, V1813, P1784, DOI 10.1016/j.bbamcr.2011.05.013; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; PAIK S, 1990, J CLIN ONCOL, V8, P103, DOI 10.1200/JCO.1990.8.1.103; Palmieri C, 2010, NAT REV CLIN ONCOL, V7, P561, DOI 10.1038/nrclinonc.2010.122; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Qin JJ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1206-z; Ramos A, 2012, TRENDS CELL BIOL, V22, P339, DOI 10.1016/j.tcb.2012.04.006; Rimkus TK, 2018, CANCER RES, V78, P2589, DOI 10.1158/0008-5472.CAN-17-2933; Rimkus TK, 2016, CANCERS, V8, DOI 10.3390/cancers8020022; Riobo-Del Galdo NA, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8040375; Ruiz-Borrego M, 2019, INVEST NEW DRUG, V37, P98, DOI 10.1007/s10637-018-0614-9; Ryan Q, 2008, ONCOLOGIST, V13, P1114, DOI 10.1634/theoncologist.2008-0816; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sirkisoon SR, 2020, ONCOGENE, V39, P64, DOI 10.1038/s41388-019-0959-3; Sirkisoon SR, 2018, ONCOGENE, V37, P2502, DOI 10.1038/s41388-018-0132-4; Snigdha K, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00085; Tavallai M, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00142; Teperino R, 2014, SEMIN CELL DEV BIOL, V33, P81, DOI 10.1016/j.semcdb.2014.05.007; Wang T, 2015, ONCOTARGET, V6, P44191, DOI 10.18632/oncotarget.6176; Wang Y, 2018, CANCER LETT, V415, P117, DOI 10.1016/j.canlet.2017.12.003; Xie JW, 1997, CANCER RES, V57, P2369; Zaidi AH, 2013, CANCER INVEST, V31, P480, DOI 10.3109/07357907.2013.820317; Zbinden M, 2010, EMBO J, V29, P2659, DOI 10.1038/emboj.2010.137; Zhang SY, 2011, NAT MED, V17, P461, DOI 10.1038/nm.2309; Zhu C, 2015, ACTA BIOCH BIOPH SIN, V47, P16, DOI 10.1093/abbs/gmu110; Zhu H, 2014, CANCER LETT, V343, P51, DOI 10.1016/j.canlet.2013.09.014	80	23	25	0	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 15	2020	39	42					6589	6605		10.1038/s41388-020-01454-1	http://dx.doi.org/10.1038/s41388-020-01454-1		SEP 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OA9HI	32929154	Green Accepted			2022-12-28	WOS:000569499000002
J	Kohvakka, A; Sattari, M; Shcherban, A; Annala, M; Urbanucci, A; Kesseli, J; Tammela, TLJ; Kivinummi, K; Latonen, L; Nykter, M; Visakorpi, T				Kohvakka, Annika; Sattari, Mina; Shcherban, Anastasia; Annala, Matti; Urbanucci, Alfonso; Kesseli, Juha; Tammela, Teuvo L. J.; Kivinummi, Kati; Latonen, Leena; Nykter, Matti; Visakorpi, Tapio			AR and ERG drive the expression of prostate cancer specific long noncoding RNAs	ONCOGENE			English	Article							ANDROGEN RECEPTOR CISTROME; TMPRSS2-ERG GENE FUSION; DNA ELEMENTS; OVEREXPRESSION; ENCYCLOPEDIA; PROGRESSION; BINDING; PTEN	Long noncoding RNAs (lncRNAs) play pivotal roles in cancer development and progression, and some function in a highly cancer-specific manner. However, whether the cause of their expression is an outcome of a specific regulatory mechanism or nonspecific transcription induced by genome reorganization in cancer remains largely unknown. Here, we investigated a group of lncRNAs that we previously identified to be aberrantly expressed in prostate cancer (PC), called TPCATs. Our high-throughput real-time PCR experiments were integrated with publicly available RNA-seq and ChIP-seq data and revealed that the expression of a subset of TPCATs is driven by PC-specific transcription factors (TFs), especially androgen receptor (AR) and ETS-related gene (ERG). Our in vitro validations confirmed that AR and ERG regulated a subset of TPCATs, most notably forEPCART. Knockout ofEPCARTwas found to reduce migration and proliferation of the PC cells in vitro. The high expression ofEPCARTand two other TPCATs (TPCAT-3-174133andTPCAT-18-31849) were also associated with the biochemical recurrence of PC in prostatectomy patients and were independent prognostic markers. Our findings suggest that the expression of numerous PC-associated lncRNAs is driven by PC-specific mechanisms and not by random cellular events that occur during cancer development. Furthermore, we report three prospective prognostic markers for the early detection of advanced PC and showEPCARTto be a functionally relevant lncRNA in PC.	[Kohvakka, Annika; Sattari, Mina; Shcherban, Anastasia; Annala, Matti; Kesseli, Juha; Tammela, Teuvo L. J.; Kivinummi, Kati; Nykter, Matti; Visakorpi, Tapio] Tampere Univ, Fac Med & Hlth Technol, Tampere, Finland; [Kohvakka, Annika; Sattari, Mina; Shcherban, Anastasia; Annala, Matti; Kesseli, Juha; Tammela, Teuvo L. J.; Kivinummi, Kati; Nykter, Matti; Visakorpi, Tapio] Tampere Univ Hosp, Tays Canc Ctr, Tampere, Finland; [Urbanucci, Alfonso] Oslo Univ Hosp, Inst Canc Res, Dept Tumor Biol, Oslo, Norway; [Tammela, Teuvo L. J.] Tampere Univ Hosp, Dept Urol, Tampere, Finland; [Latonen, Leena] Univ Eastern Finland, Inst Biomed, Kuopio, Finland; [Visakorpi, Tapio] Fimlab Labs Ltd, Tampere Univ Hosp, Tampere, Finland	Tampere University; Tampere University; Tampere University Hospital; University of Oslo; Tampere University; Tampere University Hospital; University of Eastern Finland; Tampere University; Tampere University Hospital	Visakorpi, T (corresponding author), Tampere Univ, Fac Med & Hlth Technol, Tampere, Finland.; Visakorpi, T (corresponding author), Tampere Univ Hosp, Tays Canc Ctr, Tampere, Finland.; Visakorpi, T (corresponding author), Fimlab Labs Ltd, Tampere Univ Hosp, Tampere, Finland.	tapio.visakorpi@tuni.fi	Urbanucci, Alfonso/S-4450-2019	Urbanucci, Alfonso/0000-0003-2931-3652; Nykter, Matti/0000-0001-6956-2843; Sattari, Mina/0000-0001-7358-616X	Academy of Finland [317755, 310829, 317871]; Sigrid Juselius Foundation; Cancer Society of Finland; Business Finland; Finnish Cultural Foundation; European Union [721746]; Norwegian Cancer Society [AU 198016-2018]; Research collegium of the University of Tampere/IASR	Academy of Finland(Academy of Finland); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Cancer Society of Finland; Business Finland; Finnish Cultural Foundation(Finnish Cultural FoundationFinnish IT center for science); European Union(European Commission); Norwegian Cancer Society(Norwegian Cancer Society); Research collegium of the University of Tampere/IASR	This study was supported by grants from the Academy of Finland (TV 317755, MN 310829, and LL 317871), Sigrid Juselius Foundation (TV and LL), Cancer Society of Finland, Business Finland, the Finnish Cultural Foundation (AK), the European Union's Horizon 2020 (MS, TransPot - 721746), Norwegian Cancer Society grant (AU 198016-2018), Research collegium of the University of Tampere/IASR (KK). The authors want to thank Jenni Jouppila, Paula Kosonen, Riina Kylatie, Paivi Martikainen, Hanna Selin, and Marika Vaha-Jaakkola for their technical assistance and Tampere Imaging Facility (TIF) for their service. The results published here are in part based upon data generated by The Cancer Genome Atlas project (dbGaP Study Accession: phs000178.v9.p8) established by the NCI and NHGRI. Information about TCGA can be found at http://cancergenome.nih.gov. We acknowledge ENCODE Consortium and the ENCODE production laboratories for generating the DNase-seq data.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Boormans JL, 2011, EUR UROL, V60, P183, DOI 10.1016/j.eururo.2011.03.028; Bottcher R, 2015, ONCOTARGET, V6, P4036; Carver BS, 2009, NAT GENET, V41, P619, DOI 10.1038/ng.370; Cerveira N, 2006, NEOPLASIA, V8, P826, DOI 10.1593/neo.06427; Chawla K, 2013, BIOINFORMATICS, V29, P2519, DOI 10.1093/bioinformatics/btt432; Chen Y, 2013, NAT MED, V19, P1023, DOI 10.1038/nm.3216; Chinnaiyan AM, 2008, NEOPLASIA, V10, P177, DOI 10.1593/neo.07822; Davis CA, 2018, NUCLEIC ACIDS RES, V46, pD794, DOI 10.1093/nar/gkx1081; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Hessels D, 2003, EUR UROL, V44, P8, DOI 10.1016/S0302-2838(03)00201-X; Kron KJ, 2017, NAT GENET, V49, P1336, DOI 10.1038/ng.3930; Linja MJ, 2001, CANCER RES, V61, P3550; Martens-Uzunova ES, 2014, EUR UROL, V65, P1140, DOI 10.1016/j.eururo.2013.12.003; Nam RK, 2007, CANCER BIOL THER, V6, P40, DOI 10.4161/cbt.6.1.3489; Perner S, 2007, AM J SURG PATHOL, V31, P882, DOI 10.1097/01.pas.0000213424.38503.aa; Perner S, 2006, CANCER RES, V66, P8337, DOI 10.1158/0008-5472.CAN-06-1482; Pomerantz MM, 2015, NAT GENET, V47, P1346, DOI 10.1038/ng.3419; Prensner JR, 2014, LANCET ONCOL, V15, P1469, DOI 10.1016/S1470-2045(14)71113-1; Prensner JR, 2011, NAT BIOTECHNOL, V29, P742, DOI 10.1038/nbt.1914; Sahu A, 2015, TRENDS CANCER, V1, P93, DOI 10.1016/j.trecan.2015.08.010; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Shukla S, 2016, NEOPLASIA, V18, P489, DOI 10.1016/j.neo.2016.07.001; Su XP, 2014, ONCOTARGET, V5, P9864, DOI 10.18632/oncotarget.2454; Takayama K, 2013, EMBO J, V32, P1665, DOI 10.1038/emboj.2013.99; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Urbanucci A, 2012, ONCOGENE, V31, P2153, DOI 10.1038/onc.2011.401; Waltering KK, 2009, CANCER RES, V69, P8141, DOI 10.1158/0008-5472.CAN-09-0919; Weischenfeldt J, 2013, CANCER CELL, V23, P159, DOI 10.1016/j.ccr.2013.01.002; White NM, 2017, EUR UROL, V71, P257, DOI 10.1016/j.eururo.2016.07.012; White NM, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0429-8; Yan XH, 2015, CANCER CELL, V28, P529, DOI 10.1016/j.ccell.2015.09.006; Yang LQ, 2013, NATURE, V500, P598, DOI 10.1038/nature12451; Ylipaa A, 2015, CANCER RES, V75, P4026, DOI 10.1158/0008-5472.CAN-15-0217; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Zhang A, 2015, CELL REP, V13, P209, DOI 10.1016/j.celrep.2015.08.069; Zhang YJ, 2018, NAT GENET, V50, P814, DOI 10.1038/s41588-018-0120-1	38	4	4	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 23	2020	39	30					5241	5251		10.1038/s41388-020-1365-6	http://dx.doi.org/10.1038/s41388-020-1365-6		JUN 2020	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MO5BV	32555329	Green Accepted			2022-12-28	WOS:000545371000005
J	Al-Zahrani, KN; Abou-Hamad, J; Cook, DP; Prycel, BR; Hodgins, JJ; Labreche, C; Robineau-Charette, P; de Souza, CT; Bell, JC; Auer, RC; Ardolino, M; Vanderhyden, BC; Sabourin, LA				Al-Zahrani, Khalid N.; Abou-Hamad, John; Cook, David P.; Prycel, Benjamin R.; Hodgins, Jonathan J.; Labreche, Cedrik; Robineau-Charette, Pascale; de Souza, Christiano T.; Bell, John C.; Auer, Rebecca C.; Ardolino, Michele; Vanderhyden, Barbara C.; Sabourin, Luc A.			Loss of the Ste20-like kinase induces a basal/stem-like phenotype in HER2-positive breast cancers	ONCOGENE			English	Article							MOUSE MODELS; SLK; ACTIVATION; CELLS; EXPRESSION; SOX10	HER2 is overexpressed in 20-30% of all breast cancers and is associated with an invasive disease and poor clinical outcome. The Ste20-like kinase (SLK) is activated downstream of HER2/Neu and is required for efficient epithelial-to-mesenchymal transition, cell cycle progression, and migration in the mammary epithelium. Here we show that loss of SLK in a murine model of HER2/Neu-positive breast cancers significantly accelerates tumor onset and decreases overall survival. Transcriptional profiling of SLK knockout HER2/Neu-derived tumor cells revealed a strong induction in the triple-negative breast cancer marker, Sox10, accompanied by an increase in mammary stem/progenitor activity. Similarly, we demonstrate that SLK and Sox10 expression are inversely correlated in patient samples, with the loss of SLK and acquisition of Sox10 marking the triple-negative subtype. Furthermore, pharmacological inhibition of AKT reduces SLK-null tumor growth in vivo and is rescued by ectopic Sox10 expression, suggesting that Sox10 is a critical regulator of tumor growth downstream of SLK/AKT. These findings highlight a role for SLK in negatively regulating HER2-induced mammary tumorigenesis and provide mechanistic insight into the regulation of Sox10 expression in breast cancer.	[Al-Zahrani, Khalid N.; Abou-Hamad, John; Cook, David P.; Prycel, Benjamin R.; Hodgins, Jonathan J.; Labreche, Cedrik; Robineau-Charette, Pascale; de Souza, Christiano T.; Bell, John C.; Auer, Rebecca C.; Ardolino, Michele; Vanderhyden, Barbara C.; Sabourin, Luc A.] Ottawa Hosp Res Inst, Ctr Canc Therapeut, Ottawa, ON K1H 8L6, Canada; [Al-Zahrani, Khalid N.; Abou-Hamad, John; Cook, David P.; Prycel, Benjamin R.; Labreche, Cedrik; Robineau-Charette, Pascale; Vanderhyden, Barbara C.; Sabourin, Luc A.] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada; [Hodgins, Jonathan J.; Bell, John C.; Auer, Rebecca C.; Ardolino, Michele] Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada; [Auer, Rebecca C.] Univ Ottawa, Dept Surg, Ottawa, ON K1H 8M5, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; University of Ottawa	Sabourin, LA (corresponding author), Ottawa Hosp Res Inst, Ctr Canc Therapeut, Ottawa, ON K1H 8L6, Canada.; Sabourin, LA (corresponding author), Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada.	lsabourin@ohri.ca		Al-Zahrani, Khalid/0000-0001-5771-7537; Ardolino, Michele/0000-0003-4114-0985; Cook, David/0000-0001-7639-6724; Abou-Hamad, John/0000-0003-0138-1821	Canadian Breast Cancer Foundation; Canadian Institutes of Health Research; Ontario Graduate Scholarship; Cancer Research Society; Canadian Cancer Society Research Institute	Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Ontario Graduate Scholarship(Ontario Graduate Scholarship); Cancer Research Society; Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS))	KNA-Z and BRP are funded by the Canadian Breast Cancer Foundation. JA-H, JJH, and DPC are funded by scholarships from the Canadian Institutes of Health Research. PR-C is funded by an Ontario Graduate Scholarship. This study was supported by grants from the Canadian Breast Cancer Foundation, the Cancer Research Society, the Canadian Institutes of Health Research and the Canadian Cancer Society Research Institute. This work was also supported in part by a generous donation from Mr Eugene Tasse.	Al-Zahrani Khalid N, 2018, Oncotarget, V9, P33348, DOI 10.18632/oncotarget.26072; Al-Zahrani KN, 2013, CELL ADHES MIGR, V7, P1, DOI 10.4161/cam.22495; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Burnett JP, 2015, SCI REP-UK, V5, DOI 10.1038/srep15821; Chan CT, 2005, BREAST CANCER RES TR, V91, P187, DOI 10.1007/s10549-004-7715-1; Chen ZY, 2014, DEVELOPMENT, V141, P2691, DOI 10.1242/dev.108944; Cimino-Mathews A, 2013, HUM PATHOL, V44, P959, DOI 10.1016/j.humpath.2012.09.005; Conway J, 2017, ONCOTARGET, V8, P98745, DOI 10.18632/oncotarget.21928; Cossu-Rocca P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141763; Costa RLB, 2018, BREAST CANCER RES TR, V169, P397, DOI 10.1007/s10549-018-4697-y; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; Dillon RL, 2009, CANCER RES, V69, P5057, DOI 10.1158/0008-5472.CAN-08-4287; Dravis C, 2018, CANCER CELL, V34, P466, DOI 10.1016/j.ccell.2018.08.001; Dravis C, 2015, CELL REP, V12, P2035, DOI 10.1016/j.celrep.2015.08.040; Guilluy C, 2008, CIRC RES, V102, P1265, DOI 10.1161/CIRCRESAHA.107.164764; Gullick WJ, 1998, BREAST CANCER RES TR, V52, P43, DOI 10.1023/A:1006107016969; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Hirschmann-Jax C, 2004, P NATL ACAD SCI USA, V101, P14228, DOI 10.1073/pnas.0400067101; Hutchinson JN, 2004, CANCER RES, V64, P3171, DOI 10.1158/0008-5472.CAN-03-3465; Kim SB, 2017, LANCET ONCOL, V18, P1360, DOI 10.1016/S1470-2045(17)30450-3; Korkaya H, 2012, MOL CELL, V47, P570, DOI 10.1016/j.molcel.2012.06.014; Liu H, 2018, CANCER DISCOV, V8, P354, DOI 10.1158/2159-8290.CD-17-0679; MANSOUR EG, 1994, CANCER, V74, P381, DOI 10.1002/cncr.2820741326; Menard S, 2000, J CELL PHYSIOL, V182, P150, DOI 10.1002/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-E; Neuzil J, 2007, BIOCHEM BIOPH RES CO, V355, P855, DOI 10.1016/j.bbrc.2007.01.159; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pryce BR, 2017, SKELET MUSCLE, V7, DOI 10.1186/s13395-016-0119-1; Roovers K, 2009, ONCOGENE, V28, P2839, DOI 10.1038/onc.2009.146; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Ursini-Siegel J, 2008, EMBO J, V27, P910, DOI 10.1038/emboj.2008.22; Wang K, 2018, NEOPLASMA, V65, P185, DOI 10.4149/neo_2018_170318N193; Wisinski KB, 2016, CLIN CANCER RES, V22, P2659, DOI 10.1158/1078-0432.CCR-15-2365; Wolff AC, 2007, ARCH PATHOL LAB MED, V131, P18, DOI 10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2; Zuo Y, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-0966-2	35	5	5	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	23					4592	4602		10.1038/s41388-020-1315-3	http://dx.doi.org/10.1038/s41388-020-1315-3		MAY 2020	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LU5ZF	32393835				2022-12-28	WOS:000531771800001
J	Pinato, DJ; Guerra, N; Fessas, P; Murphy, R; Mineo, T; Mauri, FA; Mukherjee, SK; Thursz, M; Wong, CN; Sharma, R; Rimassa, L				Pinato, David J.; Guerra, Nadia; Fessas, Petros; Murphy, Ravindhi; Mineo, Takashi; Mauri, Francesco A.; Mukherjee, Sujit K.; Thursz, Mark; Wong, Ching Ngar; Sharma, Rohini; Rimassa, Lorenza			Immune-based therapies for hepatocellular carcinoma	ONCOGENE			English	Review							REGULATORY T-CELLS; GROWTH-FACTOR-BETA; CHRONIC HEPATITIS-B; SUPPRESSOR-CELLS; DENDRITIC CELLS; TUMOR MICROENVIRONMENT; DOUBLE-BLIND; TGF-BETA; ADOPTIVE IMMUNOTHERAPY; LIVER-CANCER	Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer-related death. The immune-rich contexture of the HCC microenvironment makes this tumour an appealing target for immune-based therapies. Here, we discuss how the functional characteristics of the liver microenvironment can potentially be harnessed for the treatment of HCC. We will review the evidence supporting a therapeutic role for vaccines, cell-based therapies and immune-checkpoint inhibitors and discuss the potential for patient stratification in an attempt to overcome the series of failures that has characterised drug development in this disease area.	[Pinato, David J.; Fessas, Petros; Murphy, Ravindhi; Mauri, Francesco A.; Wong, Ching Ngar; Sharma, Rohini] Imperial Coll London, Hammersmith Hosp, Dept Surg & Canc, Du Cane Rd, London W12 0HS, England; [Guerra, Nadia] Imperial Coll London, Dept Life Sci, South Kensington Campus,Exhibit Rd, London SW7 2AZ, England; [Mineo, Takashi] Tokyo Med & Dent Univ, Tokyo, Japan; [Mukherjee, Sujit K.; Thursz, Mark] Imperial Coll London, Dept Metab Digest & Reprod, St Marys Hosp, Praed St, London, England; [Rimassa, Lorenza] Humanitas Clin & Res Ctr IRCCS, Med Oncol & Haematol Unit, Humanitas Canc Ctr, Via Manzoni 56, I-20089 Milan, Italy; [Rimassa, Lorenza] Humanitas Univ, Dept Biomed Sci, Via Rita Levi Montalcini, I-20090 Milan, Italy	Imperial College London; Imperial College London; Tokyo Medical & Dental University (TMDU); Imperial College London; Humanitas University	Pinato, DJ (corresponding author), Imperial Coll London, Hammersmith Hosp, Dept Surg & Canc, Du Cane Rd, London W12 0HS, England.	david.pinato@imperial.ac.uk	Rimassa, Lorenza/N-4884-2016; Pinato, David James/ABB-3719-2020	Rimassa, Lorenza/0000-0001-9957-3615; Mauri, Francesco/0000-0003-4818-8500; Thursz, Mark/0000-0002-8218-192X; Pinato, David James/0000-0002-3529-0103	Wellcome Trust Strategic Fund [PS3416]; Cancer Research UK [C57701/A26137]; Wellcome Trust	Wellcome Trust Strategic Fund; Cancer Research UK(Cancer Research UK); Wellcome Trust(Wellcome TrustEuropean Commission)	The authors would like to acknowledge the infrastructure support provided by Imperial Experimental Cancer Medicine Centre, Cancer Research UK Imperial Centre. DJP is supported by grant funding from the Wellcome Trust Strategic Fund (PS3416) and Cancer Research UK for the immune phenotyping of HCC (Postdoctoral Bursary Grant Ref. C57701/A26137). SJM is funded by a Wellcome Trust Clinical Research Training Fellowship.	Ahn E, 2018, P NATL ACAD SCI USA, V115, P4749, DOI 10.1073/pnas.1718217115; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Alissafi T, 2019, J AUTOIMMUN, V104, DOI 10.1016/j.jaut.2019.102310; An Y, 2018, WORLD J GASTROENTERO, V24, P2733, DOI 10.3748/wjg.v24.i25.2733; Anderson AC, 2014, CANCER IMMUNOL RES, V2, P393, DOI 10.1158/2326-6066.CIR-14-0039; Andre P, 2018, CELL, V175, P1731, DOI 10.1016/j.cell.2018.10.014; Ang Celina, 2019, Oncotarget, V10, P4018, DOI 10.18632/oncotarget.26998; Anguille S, 2015, PHARMACOL REV, V67, P731, DOI 10.1124/pr.114.009456; Arihara F, 2013, CANCER IMMUNOL IMMUN, V62, P1421, DOI 10.1007/s00262-013-1447-1; Belkaid Y, 2014, CELL, V157, P121, DOI 10.1016/j.cell.2014.03.011; Bertuccio P, 2017, J HEPATOL, V67, P302, DOI 10.1016/j.jhep.2017.03.011; Bilate AM, 2012, ANNU REV IMMUNOL, V30, P733, DOI 10.1146/annurev-immunol-020711-075043; BISSELL DM, 1995, J CLIN INVEST, V96, P447, DOI 10.1172/JCI118055; Bruix J, 2017, LANCET, V389, P56, DOI 10.1016/S0140-6736(16)32453-9; Budhu A, 2006, CANCER CELL, V10, P99, DOI 10.1016/j.ccr.2006.06.016; Buttner R, 2019, ESMO OPEN, V4, DOI 10.1136/esmoopen-2018-000442; Bunt SK, 2007, CANCER RES, V67, P10019, DOI 10.1158/0008-5472.CAN-07-2354; Butterfield LH, 2006, CLIN CANCER RES, V12, P2817, DOI 10.1158/1078-0432.CCR-05-2856; Chambers CA, 2001, ANNU REV IMMUNOL, V19, P565, DOI 10.1146/annurev.immunol.19.1.565; Chang H, 2017, APMIS, V125, P690, DOI 10.1111/apm.12703; Chen J, 2016, ANN ONCOL, V27, P409, DOI 10.1093/annonc/mdv615; Chen KJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024671; Chen YC, 2015, HEPATOLOGY, V61, P1591, DOI 10.1002/hep.27665; Chen YC, 2014, HEPATOLOGY, V59, P1435, DOI 10.1002/hep.26790; Cheng A., 2019, ANN ONCOL S9, V30, DOI DOI 10.1093/ANNONC/MDZ446; Chiou SH, 2005, J REPROD IMMUNOL, V67, P35, DOI 10.1016/j.jri.2005.06.002; Dapito DH, 2012, CANCER CELL, V21, P504, DOI 10.1016/j.ccr.2012.02.007; Ding W, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000013301; Dougall WC, 2017, IMMUNOL REV, V276, P112, DOI 10.1111/imr.12518; Duffy AG, 2017, J HEPATOL, V66, P545, DOI 10.1016/j.jhep.2016.10.029; Dunham RM, 2013, J IMMUNOL, V190, P2009, DOI 10.4049/jimmunol.1201937; El-Khoueiry AB, 2017, LANCET, V389, P2492, DOI 10.1016/S0140-6736(17)31046-2; Fabregat I, 2016, FEBS J, V283, P2219, DOI 10.1111/febs.13665; Fang L, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0076-7; Finn RS, 2020, J CLIN ONCOL, V38, P193, DOI 10.1200/JCO.19.01307; Finn RS, 2018, J HEPATOL, V69, P353, DOI 10.1016/j.jhep.2018.04.010; Flynn MJ, 2019, HEPATOLOGY, V69, P2258, DOI 10.1002/hep.30337; Gao Q, 2007, J CLIN ONCOL, V25, P2586, DOI 10.1200/JCO.2006.09.4565; Gao XH, 2017, HEPATOL RES, V47, P1061, DOI 10.1111/hepr.12831; George B, 2016, J THORAC ONCOL, V11, pS211, DOI 10.1016/j.jtho.2016.08.068; Ghadially H, 2017, BRIT J CANCER, V116, P1208, DOI 10.1038/bjc.2017.79; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Greten TF, 2019, J HEPATOL, V70, P999, DOI 10.1016/j.jhep.2019.01.027; Greten TF, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-209; Grosso JF, 2007, J CLIN INVEST, V117, P3383, DOI 10.1172/JCI31184; Guerra N, 1999, EUR CYTOKINE NETW, V10, P357; Guillot A, 2019, HEPATOL COMMUN, V3, P730, DOI 10.1002/hep4.1356; Hammers HJ, 2017, J CLIN ONCOL, V35, P3851, DOI 10.1200/JCO.2016.72.1985; Harmon C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01502; Harmon C, 2016, EUR J IMMUNOL, V46, P2111, DOI 10.1002/eji.201646559; Hellmann MD, 2018, NEW ENGL J MED, V378, P2093, DOI 10.1056/NEJMoa1801946; Heymann F, 2016, NAT REV GASTRO HEPAT, V13, P88, DOI 10.1038/nrgastro.2015.200; Heymann F, 2015, HEPATOLOGY, V62, P279, DOI 10.1002/hep.27793; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hoechst B, 2008, GASTROENTEROLOGY, V135, P234, DOI 10.1053/j.gastro.2008.03.020; Hochst B, 2013, J HEPATOL, V59, P528, DOI 10.1016/j.jhep.2013.04.033; Hokuto D, 2015, EUR J CANCER, V51, P157, DOI 10.1016/j.ejca.2014.11.004; Hudspeth K, 2016, J AUTOIMMUN, V66, P40, DOI 10.1016/j.jaut.2015.08.011; Jiang JW, 2019, HEPATOB PANCREAT DIS, V18, P19, DOI 10.1016/j.hbpd.2018.11.002; Jiang ZW, 2017, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00690; Jiaqiang, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0814-7; Jinushi M, 2003, INT J CANCER, V104, P354, DOI 10.1002/ijc.10966; Jung HI, 2017, CANCER RES TREAT, V49, P246, DOI 10.4143/crt.2016.066; Kahraman A, 2010, HEPATOLOGY, V51, P92, DOI 10.1002/hep.23253; Kamimura H, 2012, J HEPATOL, V56, P381, DOI 10.1016/j.jhep.2011.06.017; Karkampouna S, 2012, CURR PHARM DESIGN, V18, P4103, DOI 10.2174/138161212802430521; Kelley RK, 2019, J CLIN ONCOL S15, V35, P4072; Kelly AM, 2006, CYTOKINE, V35, P171, DOI 10.1016/j.cyto.2006.07.019; Kennedy PTF, 2008, J VIRAL HEPATITIS, V15, P901, DOI 10.1111/j.1365-2893.2008.01049.x; Kim D, 2019, HEPATOLOGY, V69, P1064, DOI 10.1002/hep.30161; KNOLLE P, 1995, J HEPATOL, V22, P226, DOI 10.1016/0168-8278(95)80433-1; Knolle PA, 1998, CLIN EXP IMMUNOL, V114, P427; Knolle PA, 1999, J IMMUNOL, V162, P1401; Kuang DM, 2009, J EXP MED, V206, P1327, DOI 10.1084/jem.20082173; Kudo M, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.4072; Kudo M, 2018, LANCET, V391, P1163, DOI 10.1016/S0140-6736(18)30207-1; Kudo M, 2017, LIVER CANCER, V6, P16, DOI 10.1159/000449343; Langhans B, 2019, CANCER IMMUNOL IMMUN, V68, P2055, DOI 10.1007/s00262-019-02427-4; Lanier LL, 2005, ANNU REV IMMUNOL, V23, P225, DOI 10.1146/annurev.immunol.23.021704.115526; Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Larmonier N, 2007, CANCER IMMUNOL IMMUN, V56, P48, DOI 10.1007/s00262-006-0160-8; Lee JH, 2015, GASTROENTEROLOGY, V148, P1383, DOI 10.1053/j.gastro.2015.02.055; Lee WC, 2005, J IMMUNOTHER, V28, P496, DOI 10.1097/01.cji.0000171291.72039.e2; Li F, 2018, CANCER MANAG RES, V10, P941, DOI 10.2147/CMAR.S162478; Liao HT, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00883; Liao Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060444; Liu XD, 2015, CANCER IMMUNOL RES, V3, P1017, DOI 10.1158/2326-6066.CIR-14-0244; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Llovet JM, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.TPS4152; Lohitesh K, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0538-7; Lu LC, 2019, LIVER CANCER, V8, P110, DOI 10.1159/000489021; Ma J, 2016, ONCOTARGETS THER, V9, P183, DOI 10.2147/OTT.S96999; Matson V, 2018, SCIENCE, V359, P104, DOI 10.1126/science.aao3290; Mazzaferro V, 2018, GASTROENTEROLOGY, V154, P128, DOI 10.1053/j.gastro.2017.09.025; Mehrfeld C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00635; Meyer T, 2017, LANCET GASTROENTEROL, V2, P565, DOI 10.1016/S2468-1253(17)30156-5; Michelet X, 2018, NAT IMMUNOL, V19, P1330, DOI 10.1038/s41590-018-0251-7; Mittal D, 2014, CURR OPIN IMMUNOL, V27, P16, DOI 10.1016/j.coi.2014.01.004; Mizukoshi E, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0742-5; Norris S, 1998, J HEPATOL, V28, P84, DOI 10.1016/S0168-8278(98)80206-7; Oliviero B, 2009, GASTROENTEROLOGY, V137, P1151, DOI 10.1053/j.gastro.2009.05.047; Palmer DH, 2009, HEPATOLOGY, V49, P124, DOI 10.1002/hep.22626; Pan ZY, 2018, CANCER IMMUNOL IMMUN, V67, P1621, DOI 10.1007/s00262-018-2221-1; Parry RV, 2005, MOL CELL BIOL, V25, P9543, DOI 10.1128/MCB.25.21.9543-9553.2005; Patsoukis N, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002796; Pedroza-Gonzalez A, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1008355; Pinato DJ, 2019, ANN ONCOL, V30, P288; Pinato DJ, 2019, BRIT J CANCER, V120, P1033, DOI 10.1038/s41416-019-0466-x; Pinato DJ, 2017, J HEPATOL, V66, P338, DOI 10.1016/j.jhep.2016.09.008; PISHVAIAN MJ, 2018, ANN ONCOL S8, V29, P718, DOI DOI 10.1093/ANNONC/MDY424.028; PISHVAIAN MJ, 2018, ANN ONCOL S8, V29; Prieto J, 2015, NAT REV GASTRO HEPAT, V12, P681, DOI 10.1038/nrgastro.2015.173; Qin SK, 2019, FUTURE ONCOL, V15, P1811, DOI 10.2217/fon-2019-0097; Qin SK., 2018, ANN ONCOL, V29, pVIII719, DOI [DOI 10.1093/ANNONC/MDY424.029, 10.1093/annonc/mdy424.029]; Ramjiawan RR, 2017, ANGIOGENESIS, V20, P185, DOI 10.1007/s10456-017-9552-y; Raulet DH, 2009, NAT REV IMMUNOL, V9, P568, DOI 10.1038/nri2604; Ren L, 2016, ONCOTARGET, V7, P75763, DOI 10.18632/oncotarget.12409; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Sabado RL, 2017, CELL RES, V27, P74, DOI 10.1038/cr.2016.157; Sakuishi K, 2010, J EXP MED, V207, P2187, DOI 10.1084/jem.20100643; Sanchez-Correa B, 2019, CANCERS, V11, DOI 10.3390/cancers11060877; Sangro B, 2013, J HEPATOL, V59, P81, DOI 10.1016/j.jhep.2013.02.022; Schaaf MB, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0061-0; Schadendorf D, 2015, J CLIN ONCOL, V33, P1889, DOI 10.1200/JCO.2014.56.2736; Schildberg FA, 2011, HEPATOLOGY, V54, P1108, DOI 10.1002/hep.24565; Schildberg FA, 2011, HEPATOLOGY, V54, P262, DOI 10.1002/hep.24352; Schmidt N, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.954919; Shen H, 1998, CELL, V92, P535, DOI 10.1016/S0092-8674(00)80946-0; Sheppard S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01808; Shetty S, 2018, NAT REV GASTRO HEPAT, V15, P555, DOI 10.1038/s41575-018-0020-y; Shevach EM, 2009, IMMUNITY, V30, P636, DOI 10.1016/j.immuni.2009.04.010; Shi FD, 2011, NAT REV IMMUNOL, V11, P658, DOI 10.1038/nri3065; Shimizu K, 2014, HUM VACC IMMUNOTHER, V10, P970, DOI 10.4161/hv.27678; Sia D, 2017, GASTROENTEROLOGY, V153, P812, DOI 10.1053/j.gastro.2017.06.007; Stegmann KA, 2016, SCI REP-UK, V6, DOI 10.1038/srep26157; Sun HY, 2019, HEPATOLOGY, V70, P168, DOI 10.1002/hep.30347; Tacke F, 2017, J HEPATOL, V66, P1300, DOI 10.1016/j.jhep.2017.02.026; Takayama T, 2000, LANCET, V356, P802, DOI 10.1016/S0140-6736(00)02654-4; Tauber Catrin, 2019, Oncotarget, V10, P5194, DOI 10.18632/oncotarget.27146; Thomas M, 2009, J GASTROENTEROL, V44, P136, DOI 10.1007/s00535-008-2252-z; Totoki Y, 2014, NAT GENET, V46, P1267, DOI 10.1038/ng.3126; Tray N, 2018, CANCER IMMUNOL RES, V6, P1122, DOI 10.1158/2326-6066.CIR-18-0214; Ugel S, 2015, J CLIN INVEST, V125, P3365, DOI 10.1172/JCI80006; Unitt E, 2005, HEPATOLOGY, V41, P722, DOI 10.1002/hep.20644; van Montfoort N, 2018, CELL, V175, P1744, DOI 10.1016/j.cell.2018.10.028; Varchetta S, 2012, HEPATOLOGY, V56, P841, DOI 10.1002/hep.25723; Varol C, 2015, ANNU REV IMMUNOL, V33, P643, DOI 10.1146/annurev-immunol-032414-112220; Vey Norbert, 2018, Oncotarget, V9, P17675, DOI 10.18632/oncotarget.24832; Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343; Wada Y, 1998, HEPATOLOGY, V27, P407, DOI 10.1002/hep.510270214; Wainberg ZA, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.4071; Wang XC, 2019, J HEPATOL, V71, P731, DOI 10.1016/j.jhep.2019.05.015; Yamamoto H, 2000, INT J ONCOL, V16, P543; Yan J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058006; Yarchoan M, 2017, NEW ENGL J MED, V377, P2500, DOI 10.1056/NEJMc1713444; Yau T, 2019, ANN ONCOL, V30, DOI DOI 10.1093/ANNONC/MDZ394.029; Yau T, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.4012; Yegin EG, 2016, HEPATOB PANCREAT DIS, V15, P234, DOI 10.1016/S1499-3872(16)60097-8; Yen C-J, 2017, ANN ONCOL, V28, piii54, DOI [DOI 10.1093/ANNONC/MDX261.139, 10.1093/annonc/mdx261.139]; Yoshimoto S, 2013, NATURE, V499, P97, DOI 10.1038/nature12347; Zhang C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09212-y; Zhang JP, 2009, J HEPATOL, V50, P980, DOI 10.1016/j.jhep.2008.12.033; Zhao F, 2012, J IMMUNOL, V188, P6055, DOI 10.4049/jimmunol.1102918; Zhao QY, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1254855; Zhao WX, 2011, INT J CANCER, V129, P2651, DOI 10.1002/ijc.25920; Zheng CH, 2017, CELL, V169, P1342, DOI 10.1016/j.cell.2017.05.035; Zheng Y, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0650-9; Zhou GY, 2017, GASTROENTEROLOGY, V153, P1107, DOI 10.1053/j.gastro.2017.06.017; Zhou YL, 2002, J IMMUNOTHER, V25, P289, DOI 10.1097/00002371-200207000-00001; Zhu AX, 2018, LANCET ONCOL, V19, P940, DOI 10.1016/S1470-2045(18)30351-6; Zucman-Rossi J, 2015, GASTROENTEROLOGY, V149, P1226, DOI 10.1053/j.gastro.2015.05.061	171	99	105	6	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	18					3620	3637		10.1038/s41388-020-1249-9	http://dx.doi.org/10.1038/s41388-020-1249-9		MAR 2020	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LI5XR	32157213	hybrid, Green Published			2022-12-28	WOS:000518886000005
J	Liu, YY; Wang, XP; Li, WS; Xu, YJ; Zhuo, YT; Li, MY; He, Y; Wang, XS; Guo, QL; Zhao, L; Qiang, L				Liu, Yunyao; Wang, Xiaoping; Li, Wenshu; Xu, Yujiao; Zhuo, Yating; Li, Mengyuan; He, Yuan; Wang, Xiaosheng; Guo, Qinglong; Zhao, Li; Qiang, Lei			Oroxylin A reverses hypoxia-induced cisplatin resistance through inhibiting HIF-1 alpha mediated XPC transcription	ONCOGENE			English	Article							NUCLEOTIDE EXCISION-REPAIR; DNA-DAMAGE RECOGNITION; CELL LUNG-CANCER; MULTIDRUG-RESISTANCE; INDUCIBLE FACTOR-1; TUMOR HYPOXIA; CHEMORESISTANCE; EXPRESSION; SENSITIVITY; PHOSPHORYLATION	Hypoxia is a key concern during the treatment of non-small cell lung cancer (NSCLC), and hypoxia-inducible factor 1 alpha (HIF-1 alpha) has been associated with increased tumor resistance to therapeutic modalities such as cisplatin. Compensatory activation of nucleotide excision repair (NER) pathway is the major mechanism that accounts for cisplatin resistance. In the present study, we suggest a novel strategy to improve the treatment of NSCLC and overcome the hypoxia-induced cisplatin resistance by cotreatment with Oroxylin A, one of the main bioactive flavonoids ofScutellariae radix. Based on the preliminary screening, we found that xeroderma pigmentosum group C (XPC), an important DNA damage recognition protein involved in NER, dramatically increased in hypoxic condition and contributed to hypoxia-induced cisplatin resistance. Further data suggested that Oroxylin A significantly reversed the hypoxia-induced cisplatin resistance through directly binding to HIF-1 alpha bHLH-PAS domain and blocking its binding to HRE3 transcription factor binding sites onXPCpromoter which is important to hypoxia-inducedXPCtranscription. Taken together, our findings not only demonstrate a crucial role of XPC dependent NER in hypoxia-induced cisplatin resistance, but also suggest a previously unrecognized tumor suppressive mechanism of Oroxylin A in NSCLC which through sensitization of cisplatin-mediated growth inhibition and apoptosis under hypoxia.	[Liu, Yunyao; Wang, Xiaoping; Li, Wenshu; Xu, Yujiao; Zhuo, Yating; He, Yuan; Guo, Qinglong; Qiang, Lei] China Pharmaceut Univ, Sch Basic Med & Clin Pharm, State Key Lab Nat Med, Nanjing, Peoples R China; [Li, Mengyuan; Wang, Xiaosheng] China Pharmaceut Univ, Sch Basic Med & Clin Pharm, Biomed Informat Res Lab, Nanjing, Peoples R China; [Zhao, Li] China Pharmaceut Univ, Sch Basic Med & Clin Pharm, Nanjing, Peoples R China	China Pharmaceutical University; China Pharmaceutical University; China Pharmaceutical University	Qiang, L (corresponding author), China Pharmaceut Univ, Sch Basic Med & Clin Pharm, State Key Lab Nat Med, Nanjing, Peoples R China.; Zhao, L (corresponding author), China Pharmaceut Univ, Sch Basic Med & Clin Pharm, Nanjing, Peoples R China.	zhaoli@cpu.edu.cn; lqiang@cpu.edu.cn	Qiang, Lei/B-2763-2012; Wang, Xiaosheng/AAN-6410-2020; Li, Mengyuan/GZM-6335-2022	Qiang, Lei/0000-0002-7164-3164; Wang, Xiaosheng/0000-0002-7199-7093; Li, Mengyuan/0000-0001-6856-6463	China Postdoctoral Science Foundation [2019M652035]; General Program of National Natural Science Foundation of China [81772911, 81974425, 81903648]; Natural Science Foundation of Jiangsu Province [BK20170744]; Six Talent Peaks Project in Jiangsu Province [SWYY-095]	China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); General Program of National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Six Talent Peaks Project in Jiangsu Province	This work was supported by the China Postdoctoral Science Foundation Grant (2019M652035); the General Program of National Natural Science Foundation of China (81772911, 81974425, and 81903648); the Natural Science Foundation of Jiangsu Province (BK20170744); the Six Talent Peaks Project in Jiangsu Province (SWYY-095).	Akanji MA, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/8547846; An HC, 2018, J MED CHEM, V61, P9266, DOI 10.1021/acs.jmedchem.8b00971; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brown LM, 2006, MOL PHARMACOL, V69, P411, DOI 10.1124/mol.105.015743; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Cam H, 2010, MOL CELL, V40, P509, DOI 10.1016/j.molcel.2010.10.030; Chang A, 2011, LUNG CANCER, V71, P3, DOI 10.1016/j.lungcan.2010.08.022; Chun YS, 2002, J KOREAN MED SCI, V17, P581, DOI 10.3346/jkms.2002.17.5.581; Deben C, 2016, CRIT REV ONCOL HEMAT, V99, P63, DOI 10.1016/j.critrevonc.2015.11.019; Furuta T, 2002, CANCER RES, V62, P4899; Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384; Gao HB, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00188; Ha J, 2012, BIOCHEM CELL BIOL, V90, P521, DOI [10.1139/O2012-005, 10.1139/o2012-005]; Hirsch FR, 2017, LANCET, V389, P299, DOI 10.1016/S0140-6736(16)30958-8; Hu LB, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00290; Jin J, 2018, BIOMED PHARMACOTHER, V97, P385, DOI 10.1016/j.biopha.2017.10.140; Jung YW, 2007, CHEM REV, V107, P1387, DOI 10.1021/cr068207j; Kaluz S, 2008, CLIN CHIM ACTA, V395, P6, DOI 10.1016/j.cca.2008.05.002; Kothari S, 2003, ONCOGENE, V22, P4734, DOI 10.1038/sj.onc.1206666; Kwon DY, 2015, J MED CHEM, V58, P7659, DOI 10.1021/acs.jmedchem.5b01220; Lai TC, 2011, ONCOL REP, V25, P1243, DOI 10.3892/or.2011.1184; Lee JY, 2016, EXP THER MED, V12, P151, DOI 10.3892/etm.2016.3320; Lee K, 2007, J MED CHEM, V50, P1675, DOI 10.1021/jm0610292; Li WJ, 2017, MOL CARCINOGEN, V56, P863, DOI 10.1002/mc.22540; Li ZH, 2019, J MED CHEM, V62, P5725, DOI 10.1021/acs.jmedchem.8b01596; Liu RY, 2011, ONCOGENE, V30, P4814, DOI 10.1038/onc.2011.189; Liu YB, 2012, CARCINOGENESIS, V33, P1187, DOI 10.1093/carcin/bgs142; Liu YB, 2018, CELL PHYSIOL BIOCHEM, V46, P1971, DOI 10.1159/000489418; Lu L, 2016, PHYTOTHER RES, V30, P1765, DOI 10.1002/ptr.5694; Martin LP, 2008, CLIN CANCER RES, V14, P1291, DOI 10.1158/1078-0432.CCR-07-2238; Masoud GN, 2015, ACTA PHARM SIN B, V5, P378, DOI 10.1016/j.apsb.2015.05.007; Mazumdar J, 2010, P NATL ACAD SCI USA, V107, P14182, DOI 10.1073/pnas.1001296107; Naik R, 2012, J MED CHEM, V55, P10564, DOI 10.1021/jm301419d; Nardinocchi L, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-1; Olcina MM, 2013, MOL CELL, V52, P758, DOI 10.1016/j.molcel.2013.10.019; Qiang L, 2016, AUTOPHAGY, V12, P357, DOI 10.1080/15548627.2015.1110667; Roberts AM, 2009, CANCER RES, V69, P9056, DOI 10.1158/0008-5472.CAN-09-1770; Selvakumaran M, 2003, CANCER RES, V63, P1311; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005; Shannon AM, 2003, CANCER TREAT REV, V29, P297, DOI 10.1016/S0305-7372(03)00003-3; Slyskova J, 2018, NUCLEIC ACIDS RES, V46, P9537, DOI 10.1093/nar/gky764; Song XR, 2006, CANCER CHEMOTH PHARM, V58, P776, DOI 10.1007/s00280-006-0224-7; Sowa T, 2017, CANCER MED-US, V6, P288, DOI 10.1002/cam4.991; Teng X, 2019, ONCOL REP, V41, P1875, DOI 10.3892/or.2019.6959; To KKW, 2006, EMBO J, V25, P4784, DOI 10.1038/sj.emboj.7601369; Vaupel P, 2007, CANCER METAST REV, V26, P225, DOI 10.1007/s10555-007-9055-1; Wei M, 2019, J CELL PHYSIOL, V234, P17392, DOI 10.1002/jcp.28361; Wirthner R, 2008, CARCINOGENESIS, V29, P2306, DOI 10.1093/carcin/bgn231; Wohlkoenig C, 2011, CANCER LETT, V308, P134, DOI 10.1016/j.canlet.2011.03.014; Wood RD, 2000, COLD SPRING HARB SYM, V65, P173, DOI 10.1101/sqb.2000.65.173; Xie XQ, 2019, J CANCER, V10, P1039, DOI 10.7150/jca.25814; Yang HY, 2012, MOL CARCINOGEN, V51, P185, DOI 10.1002/mc.20789; Yang SL, 2016, J HUAZHONG U SCI-MED, V36, P321, DOI 10.1007/s11596-016-1586-7; Yohena T, 2009, J THORAC ONCOL, V4, P284, DOI 10.1097/JTO.0b013e31819852d5; Zhou J, 2006, CANCER LETT, V237, P10, DOI 10.1016/j.canlet.2005.05.028; Zhu BB, 2012, TOXICOL APPL PHARM, V259, P387, DOI 10.1016/j.taap.2012.01.019; Zhu LT, 2013, TOXICOL LETT, V219, P107, DOI 10.1016/j.toxlet.2013.01.019	58	24	24	5	30	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 5	2020	39	45					6893	6905		10.1038/s41388-020-01474-x	http://dx.doi.org/10.1038/s41388-020-01474-x		SEP 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ON7IM	32978517				2022-12-28	WOS:000572714000001
J	Sun, Z; Xue, SL; Zhang, MY; Xu, H; Hu, XM; Chen, SH; Liu, YY; Guo, MZ; Cui, HM				Sun, Zhen; Xue, Songlei; Zhang, Meiying; Xu, Hui; Hu, Xuming; Chen, Shihao; Liu, Yangyang; Guo, Mingzhou; Cui, Hengmi			Aberrant NSUN2-mediated m(5)C modification of H19 lncRNA is associated with poor differentiation of hepatocellular carcinoma	ONCOGENE			English	Article							METHYLTRANSFERASE MISU NSUN2; NONCODING RNA; CELL-PROLIFERATION; CANCER METASTASIS; EXPRESSION; METHYLATION; PROTEIN; 5-METHYLCYTOSINE; OVEREXPRESSION; BINDING	RNA methylation is an important epigenetic modification. Recent studies on RNA methylation mainly focus on the m(6)A modification of mRNA, but very little is known about the m(5)C modification. NSUN2 is an RNA methyltransferase responsible for the m(5)C modification of multiple RNAs. In this study, we knocked down the NSUN2 gene in HepG2 cells by CRISPR/Cas9 technology and performed high-throughput RNA-BisSeq. An important tumor-related lncRNA H19 was identified to be targeted by NSUN2. Studies have shown that the expression ofH19lncRNA is abnormally elevated and has a carcinogenic effect in many types of tumors. Our results demonstrated that m(5)C modification ofH19lncRNA can increase its stability. Interestingly, m(5)C-modifiedH19lncRNA can be specifically bound by G3BP1, a well-known oncoprotein which further leads to MYC accumulation. This may be a novel mechanism by which lncRNA H19 exerts its oncogenic effect. Besides, both the m(5)C methylation level and the expression level ofH19lncRNA in hepatocellular carcinoma tissues were significantly higher than those in adjacent non-cancer tissues, which were closely associated with poor differentiation of hepatocellular carcinoma (HCC). In conclusion, we found thatH19RNA is a specific target for the NSUN2 modifier. The m(5)C-modifiedH19lncRNA may promote the occurrence and development of tumors by recruiting the G3BP1 oncoprotein. Our findings may provide a potential target and biomarker for the diagnosis and treatment of HCC.	[Sun, Zhen; Xue, Songlei; Xu, Hui; Hu, Xuming; Chen, Shihao; Liu, Yangyang; Cui, Hengmi] Yangzhou Univ, Inst Epigenet & Epigen, 48 East Wenhui Rd, Yangzhou 225009, Jiangsu, Peoples R China; [Sun, Zhen; Xue, Songlei; Xu, Hui; Hu, Xuming; Chen, Shihao; Liu, Yangyang; Cui, Hengmi] Yangzhou Univ, Coll Anim Sci & Technol, 48 East Wenhui Rd, Yangzhou 225009, Jiangsu, Peoples R China; [Zhang, Meiying; Guo, Mingzhou] Gen Hosp Peoples Liberat Army PLAGH, Beijing, Peoples R China; [Cui, Hengmi] Yangzhou Univ, Minist Educ China, Joint Int Res Lab Agr & Agriprod Safety, Yangzhou 225009, Jiangsu, Peoples R China; [Cui, Hengmi] Jiangsu Coinnovat Ctr Prevent & Control Important, Yangzhou 225009, Jiangsu, Peoples R China; [Cui, Hengmi] Yangzhou Univ, Inst Comparat Med, Yangzhou 225009, Jiangsu, Peoples R China; [Cui, Hengmi] Yangzhou Univ, Minist Educ, Key Lab Avian Prevent Med, Yangzhou 225009, Jiangsu, Peoples R China	Yangzhou University; Yangzhou University; Ministry of Education, China; Yangzhou University; Yangzhou University; Yangzhou University	Cui, HM (corresponding author), Yangzhou Univ, Inst Epigenet & Epigen, 48 East Wenhui Rd, Yangzhou 225009, Jiangsu, Peoples R China.; Cui, HM (corresponding author), Yangzhou Univ, Coll Anim Sci & Technol, 48 East Wenhui Rd, Yangzhou 225009, Jiangsu, Peoples R China.; Guo, MZ (corresponding author), Gen Hosp Peoples Liberat Army PLAGH, Beijing, Peoples R China.; Cui, HM (corresponding author), Yangzhou Univ, Minist Educ China, Joint Int Res Lab Agr & Agriprod Safety, Yangzhou 225009, Jiangsu, Peoples R China.; Cui, HM (corresponding author), Jiangsu Coinnovat Ctr Prevent & Control Important, Yangzhou 225009, Jiangsu, Peoples R China.; Cui, HM (corresponding author), Yangzhou Univ, Inst Comparat Med, Yangzhou 225009, Jiangsu, Peoples R China.; Cui, HM (corresponding author), Yangzhou Univ, Minist Educ, Key Lab Avian Prevent Med, Yangzhou 225009, Jiangsu, Peoples R China.	mzguo@hotmail.com; hmcui@yzu.edu.cn		Sun, Zhen/0000-0003-0144-3594	National Key Research and Development Program in China [2016YFC1303604, 2018YFA0208902]; National Natural Science Foundation of China [81773013, 91540117, U1604281]; Priority Academic Program Development of Jiangsu Higher Education Institutions (Animal Science and Veterinary Medicine)	National Key Research and Development Program in China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development of Jiangsu Higher Education Institutions (Animal Science and Veterinary Medicine)	This research was supported by the the National Key Research and Development Program in China (grant nos. 2016YFC1303604 and 2018YFA0208902), the National Natural Science Foundation of China (grant nos. 81773013, 91540117, and U1604281) and the Priority Academic Program Development of Jiangsu Higher Education Institutions (Animal Science and Veterinary Medicine).	Amort T, 2013, RNA BIOL, V10, P1003, DOI 10.4161/rna.24454; Barnes CJ, 2002, CANCER RES, V62, P1251; Barsyte-Lovejoy D, 2006, CANCER RES, V66, P5330, DOI 10.1158/0008-5472.CAN-06-0037; Bian ZH, 2016, SCI REP-UK, V6, DOI 10.1038/srep23892; Chen X, 2019, NAT CELL BIOL, V21, P978, DOI 10.1038/s41556-019-0361-y; Choe J, 2018, NATURE, V561, P556, DOI 10.1038/s41586-018-0538-8; Chu C, 2012, JOVE-J VIS EXP, DOI 10.3791/3912; Ding K, 2018, BIOCHEM BIOPH RES CO, V502, P194, DOI 10.1016/j.bbrc.2018.05.143; Dou N, 2016, AM J CANCER RES, V6, P2641; Edupuganti RR, 2017, NAT STRUCT MOL BIOL, V24, P870, DOI 10.1038/nsmb.3462; Frye M, 2006, CURR BIOL, V16, P971, DOI 10.1016/j.cub.2006.04.027; Han D, 2016, ONCOTARGET, V7, P22159, DOI 10.18632/oncotarget.8063; Huang T, 2019, NAT STRUCT MOL BIOL, V26, P380, DOI 10.1038/s41594-019-0218-x; Hussain S, 2013, CELL REP, V4, P255, DOI 10.1016/j.celrep.2013.06.029; Hussain S, 2009, J CELL BIOL, V186, P27, DOI 10.1083/jcb.200810180; Li Q, 2017, J CELL BIOCHEM, V118, P2587, DOI 10.1002/jcb.25957; Li SP, 2016, ONCOTARGET, V7, P42431, DOI 10.18632/oncotarget.9883; Li Y, 2018, CANCER LETT, V430, P57, DOI 10.1016/j.canlet.2018.05.013; Lin SB, 2016, MOL CELL, V62, P335, DOI 10.1016/j.molcel.2016.03.021; Liu YY, 2017, J BIOL CHEM, V292, P5624, DOI 10.1074/jbc.M116.769034; Lottin S, 2002, CARCINOGENESIS, V23, P1885, DOI 10.1093/carcin/23.11.1885; Luo M, 2013, CANCER LETT, V333, P213, DOI 10.1016/j.canlet.2013.01.033; Ma CC, 2014, TUMOR BIOL, V35, P9163, DOI 10.1007/s13277-014-2185-5; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Okamoto M, 2012, DNA CELL BIOL, V31, P660, DOI 10.1089/dna.2011.1446; Parker F, 1996, MOL CELL BIOL, V16, P2561; Shi Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086295; Shinoda S, 2019, NUCLEIC ACIDS RES, V47, P8734, DOI 10.1093/nar/gkz575; Squires JE, 2012, NUCLEIC ACIDS RES, V40, P5023, DOI 10.1093/nar/gks144; Sun Z, 2019, EPIGENOMICS-UK, V11, P439, DOI 10.2217/epi-2018-0169; Taketo K, 2018, INT J ONCOL, V52, P621, DOI 10.3892/ijo.2017.4219; Tenenbaum SA, 2002, METHODS, V26, P191, DOI 10.1016/S1046-2023(02)00022-1; Tourriere H, 2001, MOL CELL BIOL, V21, P7747, DOI 10.1128/MCB.21.22.7747-7760.2001; Tsang WP, 2010, CARCINOGENESIS, V31, P350, DOI 10.1093/carcin/bgp181; Tuorto F, 2012, NAT STRUCT MOL BIOL, V19, P900, DOI 10.1038/nsmb.2357; Wang XL, 2017, ONCOTARGET, V8, P98918, DOI 10.18632/oncotarget.22041; Wang Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0504-2; Winslow S, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-156; Xing JY, 2015, MOL CELL BIOL, V35, P4043, DOI 10.1128/MCB.00742-15; Yang X, 2017, CELL RES, V27, P606, DOI 10.1038/cr.2017.55; Yang YW, 2014, ELIFE, V3, DOI 10.7554/eLife.02046; Yi J, 2017, ONCOTARGET, V8, P20751, DOI 10.18632/oncotarget.10612; Zhang EB, 2016, TUMOR BIOL, V37, P5653, DOI 10.1007/s13277-015-4347-5; Zhang LN, 2019, J CELL PHYSIOL, V234, P20469, DOI 10.1002/jcp.28648; Zhang SC, 2017, CANCER CELL, V31, P591, DOI 10.1016/j.ccell.2017.02.013; Zhang XT, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1692; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40; Zhao XG, 2018, CANCER BIOMARK, V21, P859, DOI 10.3233/CBM-170791; Zhu L, 2013, BIOCHEM BIOPH RES CO, V432, P612, DOI 10.1016/j.bbrc.2013.02.036; Zhuang M, 2014, BIOCHEM BIOPH RES CO, V448, P315, DOI 10.1016/j.bbrc.2013.12.126	50	64	68	3	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 5	2020	39	45					6906	6919		10.1038/s41388-020-01475-w	http://dx.doi.org/10.1038/s41388-020-01475-w		SEP 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ON7IM	32978516	hybrid, Green Published			2022-12-28	WOS:000572714000008
J	Sabbagh, Q; Andre-Gregoire, G; Guevel, L; Gavard, J				Sabbagh, Quentin; Andre-Gregoire, Gwennan; Guevel, Laetitia; Gavard, Julie			Vesiclemia: counting on extracellular vesicles for glioblastoma patients	ONCOGENE			English	Review							CELL-DERIVED EXOSOMES; STEM-CELLS; TEMOZOLOMIDE RESISTANCE; GLIOMA-CELLS; RNA; MICROVESICLES; RECEPTOR; MEDIATE; GROWTH; IDENTIFICATION	Although rare, glioblastoma is a devastating tumor of the central nervous system characterized by a poor survival and an extremely dark prognosis, making its diagnosis, treatment, and monitoring highly challenging. Numerous studies have highlighted extracellular vesicles (EVs) as key players of tumor growth, invasiveness, and resistance, as they carry oncogenic material. Moreover, EVs have been shown to communicate locally in a paracrine way but also at remote throughout the organism. Indeed, recent reports demonstrated the presence of brain tumor-derived EVs into body fluids such as plasma and cerebrospinal fluid. Fluid-associated EVs have indeed been suspected to reflect quantitative and qualitative information about the status and fate of the tumor and can potentially act as a resource for noninvasive biomarkers that might assist in diagnosis, treatment, and follow-up of glioblastoma patients. Here, we coined the name vesiclemia to define the concentration of plasmatic EVs, an intuitive term to be directly transposed in the clinical jargon.	[Sabbagh, Quentin; Andre-Gregoire, Gwennan; Guevel, Laetitia; Gavard, Julie] Univ Nantes, CNRS, INSERM, CRCINA, Nantes, France; [Sabbagh, Quentin; Andre-Gregoire, Gwennan; Guevel, Laetitia; Gavard, Julie] SIRIC Iliad, Nantes, France; [Andre-Gregoire, Gwennan; Gavard, Julie] ICO, Integrated Ctr Oncol, St Herblain, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; UNICANCER; Institut de Cancerologie de l'Ouest (ICO)	Gavard, J (corresponding author), Univ Nantes, CNRS, INSERM, CRCINA, Nantes, France.; Gavard, J (corresponding author), SIRIC Iliad, Nantes, France.; Gavard, J (corresponding author), ICO, Integrated Ctr Oncol, St Herblain, France.	julie.gavard@inserm.fr	Sabbagh, Quentin/ABD-1358-2020; Gavard, Julie/I-5487-2012; Andre-Gregoire, Gwennan/K-9284-2015	Sabbagh, Quentin/0000-0003-4600-5387; Gavard, Julie/0000-0002-7985-9007; Andre-Gregoire, Gwennan/0000-0002-9167-8727; Guevel, Laetitia/0000-0002-0320-2615	Fondation pour la Recherche Medicale [DEQ20180339184]; Fondation ARC contre le Cancer [PJA20171206146, PJA20191209477, PGA1 RF20190208474]; INCa PLBIO [2019-151, 2019-291]; Ligue nationale contre le cancer comite de Loire-Atlantique; Ligue nationale contre le cancer comite de Maine et Loire; Ligue nationale contre le cancer comite de Vendee; Ligue nationale contre le cancer comite de Ille-et-Vilaine; SIRIC ILIAD [INCa-DGOS-Inserm_12558]; Region Pays de la Loire et Nantes Metropole under Connect Talent Grant; ITMO Cancer (Plan Cancer 2014-2019)	Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Fondation ARC contre le Cancer; INCa PLBIO; Ligue nationale contre le cancer comite de Loire-Atlantique; Ligue nationale contre le cancer comite de Maine et Loire; Ligue nationale contre le cancer comite de Vendee; Ligue nationale contre le cancer comite de Ille-et-Vilaine; SIRIC ILIAD; Region Pays de la Loire et Nantes Metropole under Connect Talent Grant; ITMO Cancer (Plan Cancer 2014-2019)	We thank SOAP team members (Nantes, France). The research from the team was funded by Fondation pour la Recherche Medicale (Equipe labellisee DEQ20180339184), Fondation ARC contre le Cancer (PJA20171206146, PJA20191209477, PGA1 RF20190208474), INCa PLBIO (2019-151, 2019-291), Ligue nationale contre le cancer comites de Loire-Atlantique, Maine et Loire, Vendee, Ille-et-Vilaine, SIRIC ILIAD (INCa-DGOS-Inserm_12558) and Region Pays de la Loire et Nantes Metropole under Connect Talent Grant. QS received Master internship fellowship from ITMO Cancer (Plan Cancer 2014-2019).	Akers JC, 2013, J NEURO-ONCOL, V113, P1, DOI 10.1007/s11060-013-1084-8; Al-Nedawi K, 2008, NAT CELL BIOL, V10, P619, DOI 10.1038/ncb1725; An JH, 2009, J PROTEOME RES, V8, P2873, DOI 10.1021/pr900020q; Andre-Gregoire G, 2018, BIOCHIMIE, V155, P11, DOI 10.1016/j.biochi.2018.02.007; Andre-Gregoire G, 2017, CELL ADHES MIGR, V11, P164, DOI 10.1080/19336918.2016.1247145; Bebawy M, 2009, LEUKEMIA, V23, P1643, DOI 10.1038/leu.2009.76; Bellingham SA, 2012, NUCLEIC ACIDS RES, V40, P10937, DOI 10.1093/nar/gks832; Berenguer J, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1446660; Bondy ML, 2008, CANCER-AM CANCER SOC, V113, P1953, DOI 10.1002/cncr.23741; Bronisz A, 2014, CANCER RES, V74, P738, DOI 10.1158/0008-5472.CAN-13-2650; Chandran VI, 2019, CLIN CANCER RES, V25, P3115, DOI 10.1158/1078-0432.CCR-18-2946; Chinot OL, 2014, NEW ENGL J MED, V370, P709, DOI 10.1056/NEJMoa1308345; Colangelo NW, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-019-0494-4; Cosset EC, 2012, INT J CANCER, V131, P601, DOI 10.1002/ijc.26415; de Vrij J, 2015, INT J CANCER, V137, P1630, DOI 10.1002/ijc.29521; Domenis R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169932; Dusoswa SA, 2019, J EXTRACELL VESICLES, V8, DOI 10.1080/20013078.2019.1648995; Ebrahimkhani S, 2018, NPJ PRECIS ONCOL, V2, DOI 10.1038/s41698-018-0071-0; Escola JM, 1998, J BIOL CHEM, V273, P20121, DOI 10.1074/jbc.273.32.20121; Evans SM, 2016, J NEURO-ONCOL, V127, P391, DOI 10.1007/s11060-015-2051-3; Figueroa J, 2017, CANCER RES, V77, P5808, DOI 10.1158/0008-5472.CAN-16-2524; Figueroa JM, 2017, NEURO-ONCOLOGY, V19, P1494, DOI 10.1093/neuonc/nox085; Friedman HS, 2009, J CLIN ONCOL, V27, P4733, DOI 10.1200/JCO.2008.19.8721; FU L, 2019, EBIOMEDICINE, V42, DOI DOI 10.1590/1678-4685-GMB-2018-0234; Gandham S, 2020, TRENDS BIOTECHNOL, V38, P1066, DOI 10.1016/j.tibtech.2020.05.012; Gardiner C, 2016, J EXTRACELL VESICLES, V5, DOI 10.3402/jev.v5.32945; Garnier D, 2018, NEURO-ONCOLOGY, V20, P236, DOI 10.1093/neuonc/nox142; Ghiaseddin Ashley, 2015, CNS Oncol, V4, P157, DOI 10.2217/cns.15.8; Gimple RC, 2019, GENE DEV, V33, P591, DOI 10.1101/gad.324301.119; Godlewski J, 2017, STEM CELL REP, V8, P1497, DOI 10.1016/j.stemcr.2017.04.024; Guo XF, 2019, INT J CANCER, V144, P3111, DOI 10.1002/ijc.32052; Hallal S, 2019, MOL NEUROBIOL, V56, P4566, DOI 10.1007/s12035-018-1385-1; Hallal S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134754; Himes BT, 2020, NEURO-ONCOLOGY, V22, P967, DOI 10.1093/neuonc/noaa029; Jain KK, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00419; Jeppesen DK, 2019, CELL, V177, P428, DOI 10.1016/j.cell.2019.02.029; Kucharzewska P, 2013, P NATL ACAD SCI USA, V110, P7312, DOI 10.1073/pnas.1220998110; Lan FM, 2018, CELL ONCOL, V41, P25, DOI 10.1007/s13402-017-0355-3; Lathia JD, 2015, GENE DEV, V29, P1203, DOI 10.1101/gad.261982.115; Laulagnier K, 2004, BIOCHEM J, V380, P161, DOI 10.1042/BJ20031594; Li DK, 2019, ONCOGENE, V38, P6898, DOI 10.1038/s41388-019-0903-6; Linos E, 2007, JNCI-J NATL CANCER I, V99, P1544, DOI 10.1093/jnci/djm170; Lu-Emerson C, 2015, J CLIN ONCOL, V33, P1197, DOI 10.1200/JCO.2014.55.9575; Lucero R, 2020, CELL REP, V30, P2065, DOI 10.1016/j.celrep.2020.01.073; Manda SV, 2018, J NEUROSURG, V128, P1091, DOI 10.3171/2016.11.JNS161187; Nolte-'t Hoen ENM, 2012, NUCLEIC ACIDS RES, V40, P9272, DOI 10.1093/nar/gks658; Osti D, 2019, CLIN CANCER RES, V25, P266, DOI 10.1158/1078-0432.CCR-18-1941; Oushy S, 2018, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0477; Pace KR, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20163982; PAN BT, 1985, J CELL BIOL, V101, P942, DOI 10.1083/jcb.101.3.942; Pavlyukov MS, 2018, CANCER CELL, V34, P119, DOI 10.1016/j.ccell.2018.05.012; Ramakrishnan V, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102736; Saugstad JA, 2017, J EXTRACELL VESICLES, V6, P1, DOI 10.1080/20013078.2017.1317577; Shao HL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7999; Simon T, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0878-x; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; Skotland T., 2020, ADV DRUG DELIV REV S, pS0169; Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Subra C, 2007, BIOCHIMIE, V89, P205, DOI 10.1016/j.biochi.2006.10.014; Tan SK, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0822-0; Thery C, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1535750; Treps L, 2016, ONCOGENE, V35, P2615, DOI 10.1038/onc.2015.317; Treps L, 2017, J EXTRACELL VESICLES, V6, DOI 10.1080/20013078.2017.1359479; van der Vos KE, 2016, NEURO-ONCOLOGY, V18, P58, DOI 10.1093/neuonc/nov244; Van Deun J, 2017, NAT METHODS, V14, P228, DOI 10.1038/nmeth.4185; Van Deun J, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.24858; van Niel G, 2018, NAT REV MOL CELL BIO, V19, P213, DOI 10.1038/nrm.2017.125; Vijapura C, 2017, RADIOGRAPHICS, V37, P258, DOI 10.1148/rg.2017160057; Weaver AM, 2020, CANCER RES, V80, P379, DOI 10.1158/0008-5472.CAN-19-2782; Williams C, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1442985; Wubbolts R, 2003, J BIOL CHEM, V278, P10963, DOI 10.1074/jbc.M207550200; Yang JK, 2017, J NEURO-ONCOL, V131, P255, DOI 10.1007/s11060-016-2308-5; Yekula A, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2019.1689784; Yu TF, 2018, CANCER LETT, V433, P210, DOI 10.1016/j.canlet.2018.06.041; Yue X, 2019, MOL THER, V27, P1939, DOI 10.1016/j.ymthe.2019.07.011; Zhang CZ, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-229; Zhang HY, 2019, NAT PROTOC, V14, P1027, DOI 10.1038/s41596-019-0126-x; Zhang HY, 2018, NAT CELL BIOL, V20, P332, DOI 10.1038/s41556-018-0040-4; Zhang ZOA, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1336-3	80	11	12	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2020	39	38					6043	6052		10.1038/s41388-020-01420-x	http://dx.doi.org/10.1038/s41388-020-01420-x		AUG 2020	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NQ9JF	32801336				2022-12-28	WOS:000559718800003
J	Zhou, Y; Liu, F; Xu, QY; Yang, BK; Li, X; Jiang, SH; Hu, LP; Zhang, XL; Zhu, LL; Li, Q; Zhu, XL; Shao, HF; Dai, M; Shen, YF; Ni, B; Wang, S; Zhang, ZG; Teng, YC				Zhou, Yang; Liu, Fei; Xu, Qinyang; Yang, Bikang; Li, Xiao; Jiang, Shuheng; Hu, Lipeng; Zhang, Xueli; Zhu, Lili; Li, Qing; Zhu, Xiaolu; Shao, Hongfang; Dai, Miao; Shen, Yifei; Ni, Bo; Wang, Shuai; Zhang, Zhigang; Teng, Yincheng			Inhibiting Importin 4-mediated nuclear import of CEBPD enhances chemosensitivity by repression of PRKDC-driven DNA damage repair in cervical cancer	ONCOGENE			English	Article							STRAND BREAK REPAIR; CONCURRENT CHEMOTHERAPY; RADIATION-THERAPY; TUMOR-SUPPRESSOR; BINDING-PROTEINS; PELVIC RADIATION; XPO1 INHIBITION; C/EBP-DELTA; CISPLATIN; CARCINOMA	Cervical cancer (CC) remains highest in the mortality of female reproductive system cancers, while cisplatin (CDDP) resistance is the one of main reasons for the lethality. Preceding evidence has supported that karyopherins are associated with chemoresistance. In this study, we simultaneously compared CDDP-incomplete responders with CDDP-complete responders of CC patients and CDDP-insensitive CC cell lines with CDDP-sensitive group. We finally identified that DNA-PKcs (PRKDC) was related to CDDP sensitivity after overlapping in CC sample tissues and CC cell lines. Further functional assay revealed that targeting PRKDC by shRNA and NU7026 (specific PRKDC inhibitor) could enhance CDDP sensitivity in vitro and in vivo, which was mediated by impairing DNA damage repair pathway in CC. Mechanistically, we found that PRKDC was transcriptionally upregulated by CCAAT/enhancer-binding protein delta (CEBPD), while intriguingly, CDDP treatment strengthened the transcriptional activity of CEBPD to PRKDC. We further disclosed that Importin 4 (IPO4) augmented the nuclear translocation of CEBPD through nuclear localization signals (NLS) to activate PRKDC-mediated DNA damage repair in response to CDDP. Moreover, we demonstrated that IPO4 and CEBPD knockdown improved CDDP-induced cytotoxicity in vitro and in vivo. Together, we shed the novel insight into the role of IPO4 in chemosensitivity and provide a clinical translational potential to enhance CC chemosensitivity since the IPO4-CEBPD-PRKDC axis is actionable via NU7026 (PRKDC inhibitor) or targeting IPO4 in combination with CDDP.	[Zhou, Yang; Liu, Fei; Xu, Qinyang; Yang, Bikang; Li, Xiao; Zhu, Xiaolu; Teng, Yincheng] Shanghai Jiao Tong Univ, Dept Gynecol & Obstet, Affiliated Peoples Hosp 6, 600 Yishan Rd, Shanghai 200233, Peoples R China; [Zhou, Yang; Teng, Yincheng] Jiangsu Univ, Shanghai Peoples Hosp 8, Dept Gynecol & Obstet, Shanghai 200233, Peoples R China; [Liu, Fei] Shanghai Henlius Biotech Inc, Global Clin Med Affairs GCMA, 7-F,Innov Tower,Zone A,1801 HongMei Rd, Shanghai 200233, Peoples R China; [Jiang, Shuheng; Hu, Lipeng; Zhang, Xueli; Zhu, Lili; Li, Qing; Zhang, Zhigang] Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst, Shanghai, Peoples R China; [Shao, Hongfang] Shanghai Jiao Tong Univ, Ctr Reprod Med, Affiliated Peoples Hosp 6, 600 Yishan Rd, Shanghai 200233, Peoples R China; [Dai, Miao] Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, Dept Gynecol Oncol,Hunan Canc Hosp, Changsha, Peoples R China; [Shen, Yifei] Shanghai Tongji Univ, Shanghai East Hosp, Sch Med, Dept Orthoped, Shanghai 200120, Peoples R China; [Ni, Bo] Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Gastrointestinal Surg, Shanghai 200217, Peoples R China; [Wang, Shuai] Jacobi Med Ctr, New York, NY 10461 USA	Shanghai Jiao Tong University; Jiangsu University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Central South University; Tongji University; Shanghai Jiao Tong University; Jacobi Medical Center	Teng, YC (corresponding author), Shanghai Jiao Tong Univ, Dept Gynecol & Obstet, Affiliated Peoples Hosp 6, 600 Yishan Rd, Shanghai 200233, Peoples R China.; Teng, YC (corresponding author), Jiangsu Univ, Shanghai Peoples Hosp 8, Dept Gynecol & Obstet, Shanghai 200233, Peoples R China.; Zhang, ZG (corresponding author), Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst, Shanghai, Peoples R China.	zzhang@shsci.org; ycteng@sjtu.edu.cn		Zhang, Zhi-gang/0000-0001-8965-223X	National Natural Science Foundation of China [81672565, 81702556]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from the National Natural Science Foundation of China (81672565 of YT and 81702556 of XZ).	Ahmad S, 2010, CHEM BIODIVERS, V7, P543, DOI 10.1002/cbdv.200800340; Angus L, 2014, CARCINOGENESIS, V35, P1121, DOI 10.1093/carcin/bgt491; Balamurugan K, 2013, INT J BIOL SCI, V9, P917, DOI 10.7150/ijbs.7224; Balamurugan K, 2010, EMBO J, V29, P4106, DOI 10.1038/emboj.2010.280; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Carden S, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-5044-8; Casagrande N, 2013, GYNECOL ONCOL, V131, P744, DOI 10.1016/j.ygyno.2013.08.041; Conforti F, 2017, CANCER RES, V77, P5614, DOI 10.1158/0008-5472.CAN-17-1323; Conforti F, 2015, CLIN CANCER RES, V21, P4508, DOI 10.1158/1078-0432.CCR-15-0408; Fitzmaurice C, 2019, JAMA ONCOL, V5, P1749, DOI 10.1001/jamaoncol.2019.2996; Friedrich B, 2006, MOL CELL BIOL, V26, P8697, DOI 10.1128/MCB.00708-06; Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384; Gao JK, 2014, ONCOTARGET, V5, P3444, DOI 10.18632/oncotarget.1813; Hazawa M, 2019, ONCOGENE, DOI [10.1038/s41388-41019-137-41383, DOI 10.1038/S41388-41019-137-41383]; Hour TC, 2010, BIOCHEM PHARMACOL, V80, P325, DOI 10.1016/j.bcp.2010.04.007; Hu H, 2017, BIOCHEM BIOPH RES CO, V483, P725, DOI 10.1016/j.bbrc.2016.12.074; Hu LP, 2019, CLIN CANCER RES, V25, P1318, DOI 10.1158/1078-0432.CCR-18-2297; Jette N, 2015, PROG BIOPHYS MOL BIO, V117, P194, DOI 10.1016/j.pbiomolbio.2014.12.003; Jiang SH, 2017, GASTROENTEROLOGY, V153, P277, DOI 10.1053/j.gastro.2017.03.008; Kau TR, 2004, NAT REV CANCER, V4, P106, DOI 10.1038/nrc1274; Koh WJ, 2019, J NATL COMPR CANC NE, V17, P64, DOI 10.6004/jnccn.2019.0001; Kosyna FK, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7110221; Kuo DYS, 2010, GYNECOL ONCOL, V116, P442, DOI 10.1016/j.ygyno.2009.10.082; Kuusisto HV, 2015, BBA-MOL CELL RES, V1853, P1870, DOI 10.1016/j.bbamcr.2015.05.002; Lin KC, 2018, THERANOSTICS, V8, P2477, DOI 10.7150/thno.24173; Liu F, 2018, ONCOGENE, V37, P2394, DOI 10.1038/s41388-017-0119-6; Lund E, 2004, SCIENCE, V303, P95, DOI 10.1126/science.1090599; Mah LJ, 2010, LEUKEMIA, V24, P679, DOI 10.1038/leu.2010.6; Mahipal A, 2016, PHARMACOL THERAPEUT, V164, P135, DOI 10.1016/j.pharmthera.2016.03.020; Martelli L, 2006, BIOCHEM PHARMACOL, V72, P693, DOI 10.1016/j.bcp.2006.06.008; Moore DH, 2004, J CLIN ONCOL, V22, P3113, DOI 10.1200/JCO.2004.04.170; Morris M, 1999, NEW ENGL J MED, V340, P1137, DOI 10.1056/NEJM199904153401501; Mukherjee B, 2009, CANCER RES, V69, P4252, DOI 10.1158/0008-5472.CAN-08-4853; Pectasides D, 2008, CANCER TREAT REV, V34, P603, DOI 10.1016/j.ctrv.2008.05.006; Peters WA, 2000, J CLIN ONCOL, V18, P1606, DOI 10.1200/JCO.2000.18.8.1606; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; Ranganathan P, 2016, CLIN CANCER RES, V22, P6142, DOI 10.1158/1078-0432.CCR-15-2885; Saenz-Ponces N, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aar7223; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shen YF, 2019, EBIOMEDICINE, V40, P210, DOI 10.1016/j.ebiom.2018.12.038; Shintani S, 2003, CANCER SCI, V94, P894, DOI 10.1111/j.1349-7006.2003.tb01372.x; Stronach EA, 2011, NEOPLASIA, V13, P1069, DOI 10.1593/neo.111032; Sun G, 2017, ONCOL REP, V37, P3536, DOI 10.3892/or.2017.5634; Takeiri M, 2012, ORG BIOMOL CHEM, V10, P3053, DOI 10.1039/c2ob07104e; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; Tran EJ, 2014, BBA-MOL CELL RES, V1843, P2784, DOI 10.1016/j.bbamcr.2014.08.003; Verrico A, 2020, ONCOGENE, V39, P454, DOI 10.1038/s41388-019-0989-x; Wang J, 2010, P NATL ACAD SCI USA, V107, P16131, DOI 10.1073/pnas.1002603107; Wang WJ, 2017, CLIN CANCER RES, V23, P503, DOI 10.1158/1078-0432.CCR-15-1169; Wen SY, 2015, ONCOGENE, V34, P717, DOI 10.1038/onc.2014.9; Whitney CW, 1999, J CLIN ONCOL, V17, P1339, DOI 10.1200/JCO.1999.17.5.1339; Wrobel K, 2016, MOL ENDOCRINOL, V30, P1029, DOI 10.1210/me.2016-1101; Wu SR, 2011, J BIOL CHEM, V286, P28662, DOI 10.1074/jbc.M111.270710; Xiang SS, 2019, ONCOGENE, V38, P1269, DOI 10.1038/s41388-018-0494-7; Xu X, 2019, J CELL BIOCHEM, V120, P12638, DOI 10.1002/jcb.28530; Zhang WJ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1290-0; Zheng M, 2010, OBSTET GYNECOL, V116, P884, DOI 10.1097/AOG.0b013e3181f104ce	57	7	7	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2020	39	34					5633	5648		10.1038/s41388-020-1384-3	http://dx.doi.org/10.1038/s41388-020-1384-3		JUL 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NE9FK	32661323	hybrid, Green Published			2022-12-28	WOS:000548100200001
J	Wang, MN; Long, KL; Li, EJ; Li, LL; Li, BH; Ci, SS; He, LF; Pan, FY; Hu, ZG; Guo, ZG				Wang, Meina; Long, Kaili; Li, Enjie; Li, Lulu; Li, Binghua; Ci, Shusheng; He, Lingfeng; Pan, Feiyan; Hu, Zhigang; Guo, Zhigang			DNA polymerase beta modulates cancer progression via enhancing CDH13 expression by promoter demethylation	ONCOGENE			English	Article							BASE EXCISION-REPAIR; ADHESION MOLECULES; BREAST-CANCER; T-CADHERIN; METASTASIS; MUTATION; METHYLATION; MIGRATION; INVASION; IMPAIRS	DNA polymerase beta (Pol beta) plays a critical role in DNA base excision repair (BER), which is involved in maintaining genomic stability and in the modulation of DNA demethylation. Numerous studies implicated deficiency of Pol beta in the genomic instability and dysregulation of genes expression, leading to affecting initiation of cancer. However, the role of Pol beta in cancer progression is still unclear. Here, we show that Pol beta depresses migratory and invasive capabilities of both breast and lung carcinomas, which were evident in human breast and lung cancer cells, as well as in mouse xenograft tumors. On the molecular basis, overexpression of Pol beta enhanced expression of CDH13, which show function on cell adhesion and migration. Knockdown of CDH13 restores the migratory, invasive capabilities and angiogenesis in tumor, which gets impaired by Pol beta. According to the function of BER on modulation of DNA demethylation, our studies on CDH13 expression and the DNA methylation levels of CDH13 promoter suggested that Pol beta promotes expression of CDH13 by augmenting DNA demethylation of CDH13 promoter. Our findings elucidated a novel possibility that Pol beta impair cancer cell metastasis during cancer progression and shed light on the role of Pol beta in cancer therapy.	[Wang, Meina; Long, Kaili; Li, Enjie; Li, Lulu; Ci, Shusheng; He, Lingfeng; Pan, Feiyan; Hu, Zhigang; Guo, Zhigang] Nanjing Normal Univ, Coll Life Sci, Jiangsu Key Lab Mol & Med Biotechnol, Nanjing 210023, Peoples R China; [Li, Binghua] Nanjing Univ, Dept Hepatobiliary Surg, Affiliated Drum Tower Hosp, Sch Med, Nanjing 210008, Peoples R China	Nanjing Normal University; Nanjing University	Hu, ZG; Guo, ZG (corresponding author), Nanjing Normal Univ, Coll Life Sci, Jiangsu Key Lab Mol & Med Biotechnol, Nanjing 210023, Peoples R China.	huzg_2000@126.com; guo@njnu.edu.cn	Wang, Meina/AAP-3020-2021	Li, Binghua/0000-0001-7209-2854; guo, zhigang/0000-0001-7771-1829	National Natural Science Foundation of China [81872284]; Natural Science Foundation of Colleges and Universities in Jiangsu Province [19KJA180010]; Priority Academic Program Development of Jiangsu Higher Education Institutions	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Colleges and Universities in Jiangsu Province; Priority Academic Program Development of Jiangsu Higher Education Institutions	The authors would like to thank Dr. Binghui Shen (Beckman Research Institute, City of Hope, Duarte, CA, USA) for the MEF cell lines. This work was supported by the National Natural Science Foundation of China (81872284), the Natural Science Foundation of Colleges and Universities in Jiangsu Province (19KJA180010), and the Priority Academic Program Development of Jiangsu Higher Education Institutions.	Abdel-Fatah TMA, 2014, MOL ONCOL, V8, P520, DOI 10.1016/j.molonc.2014.01.001; Andreeva AV, 2010, GENE CHROMOSOME CANC, V49, P775, DOI 10.1002/gcc.20787; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Bergoglio V, 2002, CANCER RES, V62, P3511; Broustas CG, 2014, RADIAT RES, V181, P111, DOI 10.1667/RR13515.1; Chan DW, 2008, INT J CANCER, V123, P1043, DOI 10.1002/ijc.23634; Chen F, 2016, BMC UROL, V16, DOI 10.1186/s12894-016-0171-5; Chen ZX, 2011, J BIOL CHEM, V286, P18347, DOI 10.1074/jbc.R110.205286; Choi EB, 2016, ONCOGENE, V35, P4569, DOI 10.1038/onc.2016.3; Eccles SA, 2007, LANCET, V369, P1742, DOI 10.1016/S0140-6736(07)60781-8; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Fletcher SC, 2018, NUCLEIC ACIDS RES, V46, P1834, DOI 10.1093/nar/gkx1291; Gugnoni M, 2017, ONCOGENE, V36, P667, DOI 10.1038/onc.2016.237; Guo ZG, 2009, NUCLEIC ACIDS RES, V37, P3431, DOI 10.1093/nar/gkp201; Hajkova P, 2010, SCIENCE, V329, P78, DOI 10.1126/science.1187945; He YF, 2011, SCIENCE, V333, P1303, DOI 10.1126/science.1210944; Ju JY, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00988-5; Kuphal S, 2009, PIGM CELL MELANOMA R, V22, P296, DOI 10.1111/j.1755-148X.2009.00568.x; Levy N, 2006, NUCLEIC ACIDS RES, V34, P32, DOI 10.1093/nar/gkj409; Li JF, 2012, AM J CANCER RES, V2, P699; Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147; Lu X, 2020, ONCOGENE, V39, P234, DOI 10.1038/s41388-019-0986-0; Makrilia N, 2009, CANCER INVEST, V27, P1023, DOI 10.3109/07357900902769749; Matakidou A, 2007, HUM MOL GENET, V16, P2333, DOI 10.1093/hmg/ddm190; Nicolay Nils H, 2012, Curr Mol Pharmacol, V5, P54; Nollet F, 2000, J MOL BIOL, V299, P551, DOI 10.1006/jmbi.2000.3777; PIGNATELLI M, 1994, HUM PATHOL, V25, P849, DOI 10.1016/0046-8177(94)90002-7; Rubina Kseniya, 2007, Angiogenesis, V10, P183, DOI 10.1007/s10456-007-9072-2; Rytelewski M, 2014, MOL ONCOL, V8, P1429, DOI 10.1016/j.molonc.2014.05.017; Schar P, 2011, PROG DRUG RES, V67, P51, DOI 10.1007/978-3-7643-8989-5_3; Sobol RW, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003086; Sun H, 2017, ONCOGENE, V36, P194, DOI 10.1038/onc.2016.188; Tan XH, 2016, J CANCER, V7, P1472, DOI 10.7150/jca.14844; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Vens C, 2002, NUCLEIC ACIDS RES, V30, P2995, DOI 10.1093/nar/gkf403; Walsh CP, 2006, CURR TOP MICROBIOL, V301, P283; Wang MN, 2019, MOL CANCER RES, V17, P2077, DOI 10.1158/1541-7786.MCR-19-0482; Weber AR, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10806; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; Weis SM, 2011, NAT MED, V17, P1359, DOI 10.1038/nm.2537; Wiegmans AP, 2014, ONCOTARGET, V5, P3261, DOI 10.18632/oncotarget.1923; Yamtich J, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003052; Yamtich J, 2010, BBA-PROTEINS PROTEOM, V1804, P1136, DOI 10.1016/j.bbapap.2009.07.008; Ye M, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005956; Zheng WL, 2018, LIFE SCI, V192, P270, DOI 10.1016/j.lfs.2017.11.011; Zhou T, 2016, ONCOTARGET, V7, P6902, DOI 10.18632/oncotarget.6849	46	9	9	3	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2020	39	33					5507	5519		10.1038/s41388-020-1386-1	http://dx.doi.org/10.1038/s41388-020-1386-1		JUL 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NB0QV	32641859				2022-12-28	WOS:000546526000002
J	Khan, S; He, YH; Zhang, X; Yuan, YX; Pu, SY; Kong, QP; Zheng, GR; Zhou, DH				Khan, Sajid; He, Yonghan; Zhang, Xuan; Yuan, Yaxia; Pu, Shaoyan; Kong, Qingpeng; Zheng, Guangrong; Zhou, Daohong			PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics	ONCOGENE			English	Review							RENAL-CELL CARCINOMA; PROTEIN-DEGRADATION; MEDIATED DEGRADATION; SMALL MOLECULES; RECEPTOR; UBIQUITINATION; KNOCKDOWN; GENE; IAP; VHL	Using PROteolysis TArgeting Chimeras (PROTACs) to degrade proteins that are important for tumorigenesis has emerged as a potential therapeutic strategy for cancer. PROTACs are heterobifunctional molecules consisting of one ligand for binding to a protein of interest (POI) and another to an E3 ubiquitin (E3) ligase, connected via a linker. PROTACs recruit the E3 ligase to the POI and cause proximity-induced ubiquitination and degradation of the POI by the ubiquitin-proteasome system (UPS). PROTACs have been developed to degrade a variety of cancer targets with unprecedented efficacy against a multitude of tumor types. To date, most of the PROTACs developed have utilized ligands to recruit E3 ligases that are ubiquitously expressed in both tumor and normal tissues. These PROTACs can cause on-target toxicities if the POIs are not tumor-specific. Therefore, identifying and recruiting the E3 ligases that are enriched in tumors with minimal expression in normal tissues holds the potential to develop tumor-specific/selective PROTACs. In this review, we will discuss the potential of PROTACs to become anticancer therapeutics, chemical and bioinformatics approaches for PROTAC design, and safety concerns with a special focus on the development of tumor-specific/selective PROTACs. In addition, the identification of tumor types in terms of solid versus hematological malignancies that can be best targeted with PROTAC approach will be briefly discussed.	[Khan, Sajid; He, Yonghan; Yuan, Yaxia; Zhou, Daohong] Univ Florida, Coll Pharm, Dept Pharmacodynam, Gainesville, FL 32610 USA; [Zhang, Xuan; Zheng, Guangrong] Univ Florida, Coll Pharm, Dept Med Chem, Gainesville, FL USA; [Pu, Shaoyan; Kong, Qingpeng] Chinese Acad Sci, Kunming Inst Zool, State Key Lab Genet Resources & Evolut, Kunming 650223, Yunnan, Peoples R China	State University System of Florida; University of Florida; State University System of Florida; University of Florida; Chinese Academy of Sciences; Kunming Institute of Zoology	Zhou, DH (corresponding author), Univ Florida, Coll Pharm, Dept Pharmacodynam, Gainesville, FL 32610 USA.	zhoudaohong@cop.ufl.edu	He, Yonghan/P-7271-2014; khan, sajid/HGE-2406-2022; Khan, Sajid/AAR-8954-2020; ZHANG, XUAN/L-4393-2017	He, Yonghan/0000-0003-4409-4590; Khan, Sajid/0000-0003-1331-8846; ZHANG, XUAN/0000-0001-6062-6708	US National Institutes of Health (NIH) [R01CA211963, R01CA219836, R01CA242003, R21CA223371]	US National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors would like to thank the members of the Zheng and Zhou laboratories for thoughtful discussion and assistance. We greatly acknowledge help from Ms. Janet S. Wiegand for grammatical corrections. This study was supported by US National Institutes of Health (NIH) grants R01CA211963 (DZ), R01CA219836 (DZ), R01CA242003 (DZ and GZ) and R21CA223371 (GZ).	Ardlie KG, 2015, SCIENCE, V348, P648, DOI 10.1126/science.1262110; Bai L., 2019, CANCER CELL, V36; Bassi ZI, 2018, ACS CHEM BIOL, V13, P2862, DOI 10.1021/acschembio.8b00705; Bondeson DP, 2018, CELL CHEM BIOL, V25, P78, DOI 10.1016/j.chembiol.2017.09.010; Bondeson DP, 2015, NAT CHEM BIOL, V11, P611, DOI [10.1038/NCHEMBIO.1858, 10.1038/nchembio.1858]; Brand M, 2019, CELL CHEM BIOL, V26, P300, DOI 10.1016/j.chembiol.2018.11.006; Buckley DL, 2012, ANGEW CHEM INT EDIT, V51, P11463, DOI 10.1002/anie.201206231; Buckley DL, 2012, J AM CHEM SOC, V134, P4465, DOI 10.1021/ja209924v; Buhimschi AD, 2018, BIOCHEMISTRY-US, V57, P3564, DOI 10.1021/acs.biochem.8b00391; Burslem G. M., 2018, CELL CHEM BIOL, V25, pe63; Burslem GM, 2019, CANCER RES, V79, P4744, DOI 10.1158/0008-5472.CAN-19-1236; Burslem GM, 2018, J AM CHEM SOC, V140, P16428, DOI 10.1021/jacs.8b10320; Clifford SC, 1999, GENE CHROMOSOME CANC, V26, P20, DOI 10.1002/(SICI)1098-2264(199909)26:1<20::AID-GCC3>3.3.CO;2-Y; Clifford SC, 1998, GENE CHROMOSOME CANC, V22, P200, DOI 10.1002/(SICI)1098-2264(199807)22:3<200::AID-GCC5>3.0.CO;2-#; Costales MG, 2020, J MED CHEM, V63, P8880, DOI 10.1021/acs.jmedchem.9b01927; Costales MG, 2020, P NATL ACAD SCI USA, V117, P2406, DOI 10.1073/pnas.1914286117; Crew AP, 2018, J MED CHEM, V61, P583, DOI 10.1021/acs.jmedchem.7b00635; Cromm PM, 2018, J AM CHEM SOC, V140, P17019, DOI 10.1021/jacs.8b08008; Daniels Danette L, 2019, Drug Discov Today Technol, V31, P61, DOI 10.1016/j.ddtec.2018.12.001; Demizu Y, 2016, BIOORG MED CHEM LETT, V26, P4865, DOI 10.1016/j.bmcl.2016.09.041; Dobrovolsky D, 2019, BLOOD, V133, P952, DOI 10.1182/blood-2018-07-862953; Donovan KA, 2018, ELIFE, V7, DOI 10.7554/eLife.38430; Eichhorn JM, 2014, EXP CELL RES, V322, P415, DOI 10.1016/j.yexcr.2014.02.010; Farnaby W, 2019, NAT CHEM BIOL, V15, P672, DOI 10.1038/s41589-019-0294-6; Gadd MS, 2017, NAT CHEM BIOL, V13, P514, DOI [10.1038/nchembio.2329, 10.1038/NCHEMBIO.2329]; Gechijian LN, 2018, NAT CHEM BIOL, V14, P405, DOI 10.1038/s41589-018-0010-y; Girardini M, 2019, BIOORGAN MED CHEM, V27, P2466, DOI 10.1016/j.bmc.2019.02.048; Gonzalez TL, 2020, BREAST CANCER RES TR, V180, P611, DOI 10.1007/s10549-020-05564-y; Han T, 2017, SCIENCE, V356, DOI 10.1126/science.aal3755; Han X, 2019, J MED CHEM, V62, P11218, DOI 10.1021/acs.jmedchem.9b01393; Han X, 2019, J MED CHEM, V62, P941, DOI 10.1021/acs.jmedchem.8b01631; Hines J, 2019, CANCER RES, V79, P251, DOI 10.1158/0008-5472.CAN-18-2918; Hines J, 2013, P NATL ACAD SCI USA, V110, P8942, DOI 10.1073/pnas.1217206110; Hsu JHR, 2020, CELL CHEM BIOL, V27, P41, DOI 10.1016/j.chembiol.2019.11.004; Ishoey M, 2018, ACS CHEM BIOL, V13, P553, DOI 10.1021/acschembio.7b00969; Ito T, 2010, SCIENCE, V327, P1345, DOI 10.1126/science.1177319; Itoh Y, 2011, BIOORGAN MED CHEM, V19, P3229, DOI 10.1016/j.bmc.2011.03.057; Itoh Y, 2010, J AM CHEM SOC, V132, P5820, DOI 10.1021/ja100691p; Jaime-Figueroa S, 2020, BIOORG MED CHEM LETT, V30, DOI 10.1016/j.bmcl.2019.126877; Jensen SM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02697; Jiang BS, 2019, ANGEW CHEM INT EDIT, V58, P6321, DOI 10.1002/anie.201901336; Kang CH, 2018, BIOCHEM BIOPH RES CO, V505, P542, DOI 10.1016/j.bbrc.2018.09.169; Khan S, 2019, NAT MED, V25, P1938, DOI 10.1038/s41591-019-0668-z; Kim MS, 2014, NATURE, V509, P575, DOI 10.1038/nature13302; Kregel S, 2020, NEOPLASIA, V22, P111, DOI 10.1016/j.neo.2019.12.003; Lai AC, 2016, ANGEW CHEM INT EDIT, V55, P807, DOI 10.1002/anie.201507634; Lebraud H, 2016, ACS CENTRAL SCI, V2, P927, DOI 10.1021/acscentsci.6b00280; Li YB, 2019, J MED CHEM, V62, P448, DOI 10.1021/acs.jmedchem.8b00909; Lindner S., 2019, JOVE-J VIS EXP, V147; Liu B, 2007, CANCER LETT, V250, P168, DOI 10.1016/j.canlet.2006.09.024; Liu B, 2017, DIABETES, V66, P689, DOI 10.2337/db16-1104; Liu BY, 2017, NAT IMMUNOL, V18, P214, DOI 10.1038/ni.3641; Liu J, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay5154; Lu J, 2015, CHEM BIOL, V22, P755, DOI 10.1016/j.chembiol.2015.05.009; Lu MC, 2018, EUR J MED CHEM, V146, P251, DOI 10.1016/j.ejmech.2018.01.063; Ma L, 2006, CELL DEATH DIFFER, V13, P2079, DOI 10.1038/sj.cdd.4401959; Ma XX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0644-4; Maniaci C, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00954-1; Mason KD, 2007, CELL, V128, P1173, DOI 10.1016/j.cell.2007.01.037; McCoull W, 2018, ACS CHEM BIOL, V13, P3131, DOI 10.1021/acschembio.8b00698; Mele M, 2015, SCIENCE, V348, P660, DOI 10.1126/science.aaa0355; Moreau K, 2020, BRIT J PHARMACOL, V177, P1709, DOI 10.1111/bph.15014; Moser SC, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01920; Nunes J, 2019, ACS MED CHEM LETT, V10, P1081, DOI 10.1021/acsmedchemlett.9b00219; Ohoka N, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.471; Ohoka N, 2019, CHEM PHARM BULL, V67, P203, DOI 10.1248/cpb.c18-00567; Ohoka N, 2018, J BIOL CHEM, V293, P6776, DOI 10.1074/jbc.RA117.001091; Okuhira K, 2013, CANCER SCI, V104, P1492, DOI 10.1111/cas.12272; Pettersson Mariell, 2019, Drug Discov Today Technol, V31, P15, DOI 10.1016/j.ddtec.2019.01.002; Pfaff P, 2019, ACS CENTRAL SCI, V5, P1682, DOI 10.1021/acscentsci.9b00713; Powell CE, 2018, J MED CHEM, V61, P4249, DOI 10.1021/acs.jmedchem.7b01655; Reynders M, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay5064; Riching KM, 2018, ACS CHEM BIOL, V13, P2758, DOI 10.1021/acschembio.8b00692; Robb CM, 2017, CHEM COMMUN, V53, P7577, DOI 10.1039/c7cc03879h; Sakamoto KM, 2003, MOL CELL PROTEOMICS, V2, P1350, DOI 10.1074/mcp.T300009-MCP200; Sakamoto KM, 2001, P NATL ACAD SCI USA, V98, P8554, DOI 10.1073/pnas.141230798; Salami J, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003-018-0105-8; Schapira M, 2019, NAT REV DRUG DISCOV, V18, P949, DOI 10.1038/s41573-019-0047-y; Schiedel M, 2018, J MED CHEM, V61, P482, DOI 10.1021/acs.jmedchem.6b01872; Schmitt C, 2002, APOPTOSIS, V7, P277, DOI 10.1023/A:1015372322419; Schneekloth AR, 2008, BIOORG MED CHEM LETT, V18, P5904, DOI 10.1016/j.bmcl.2008.07.114; Schneekloth JS, 2004, J AM CHEM SOC, V126, P3748, DOI 10.1021/ja039025z; Schoenwaelder SM, 2011, BLOOD, V118, P1663, DOI 10.1182/blood-2011-04-347849; Shibata N, 2018, J MED CHEM, V61, P543, DOI 10.1021/acs.jmedchem.7b00168; Shibata N, 2017, CANCER SCI, V108, P1657, DOI 10.1111/cas.13284; Smith BE, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08027-7; Song H, 2016, GENES-BASEL, V7, DOI 10.3390/genes7060025; Spradlin JN, 2019, NAT CHEM BIOL, V15, P747, DOI 10.1038/s41589-019-0304-8; Steinebach C, 2018, ACS CHEM BIOL, V13, P2771, DOI 10.1021/acschembio.8b00693; Su S, 2019, J MED CHEM, V62, P7575, DOI 10.1021/acs.jmedchem.9b00871; Sun YH, 2019, LEUKEMIA, V33, P2105, DOI 10.1038/s41375-019-0440-x; Testa A, 2020, ANGEW CHEM INT EDIT, V59, P1727, DOI 10.1002/anie.201914396; Vucic D, 2000, CURR BIOL, V10, P1359, DOI 10.1016/S0960-9822(00)00781-8; Wang Y, 2020, ACTA PHARMACOL SIN B, V10, P207, DOI 10.1016/j.apsb.2019.08.001; Ward CC, 2019, ACS CHEM BIOL, V14, P2430, DOI 10.1021/acschembio.8b01083; Winter GE, 2015, SCIENCE, V348, P1376, DOI 10.1126/science.aab1433; Xue G, 2019, J AM CHEM SOC, V141, P18370, DOI 10.1021/jacs.9b06422; Yaguchi H, 2012, J BIOL CHEM, V287, P12050, DOI 10.1074/jbc.M111.307678; Yang HY, 2019, CHEM COMMUN, V55, P14848, DOI 10.1039/c9cc08509b; Yang K, 2018, BIOORG MED CHEM LETT, V28, P2493, DOI 10.1016/j.bmcl.2018.05.057; Zengerle M, 2015, ACS CHEM BIOL, V10, P1770, DOI 10.1021/acschembio.5b00216; Zhang XY, 2019, NAT CHEM BIOL, V15, P737, DOI 10.1038/s41589-019-0279-5; Zhang X, 2020, EUR J MED CHEM, V192, DOI 10.1016/j.ejmech.2020.112186; Zhang X, 2019, CHEM COMMUN, V55, P14765, DOI 10.1039/c9cc07217a; Zhao QY, 2019, CHEM COMMUN, V55, P369, DOI 10.1039/c8cc07813k; Zhao QJ, 2019, J MED CHEM, V62, P9281, DOI 10.1021/acs.jmedchem.9b01264; Zhou HB, 2019, J MED CHEM, V62, P11280, DOI 10.1021/acs.jmedchem.9b01530; Zoppi V, 2019, J MED CHEM, V62, P699, DOI 10.1021/acs.jmedchem.8b01413; Zorba A, 2018, P NATL ACAD SCI USA, V115, pE7285, DOI 10.1073/pnas.1803662115	109	76	78	11	106	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 25	2020	39	26					4909	4924		10.1038/s41388-020-1336-y	http://dx.doi.org/10.1038/s41388-020-1336-y		MAY 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MQ2YO	32475992	Green Accepted			2022-12-28	WOS:000536741100001
J	Liu, C; Liu, L; Wang, K; Li, XF; Ge, LY; Ma, RZ; Fan, YD; Li, LC; Liu, ZF; Qiu, M; Hao, YC; Shi, ZF; Xia, CY; Straat, K; Huang, Y; Ma, LL; Xu, DW				Liu, Cheng; Liu, Li; Wang, Kun; Li, Xiao-Feng; Ge, Li-Yuan; Ma, Run-Zhuo; Fan, Yi-Dong; Li, Lu-Chao; Liu, Zheng-Fang; Qiu, Min; Hao, Yi-Chang; Shi, Zhen-Feng; Xia, Chuan-You; Straat, Klas; Huang, Yi; Ma, Lu-Lin; Xu, Dawei			VHL-HIF-2 alpha axis-induced SMYD3 upregulation drives renal cell carcinoma progression via direct trans-activation of EGFR	ONCOGENE			English	Article							FACTOR RECEPTOR PROTEIN; GROWTH; CANCER; EXPRESSION; PROMOTES; PROLIFERATION; TRANSCRIPTION; INHIBITION; SUPPRESSES; ACTIVATION	It has been well established that the von Hippel-Lindau/hypoxia-inducible factor alpha (VHL-HIF alpha) axis and epidermal growth factor receptor (EGFR) signaling pathway play a critical role in the pathogenesis and progression of renal cell carcinoma (RCC). However, few studies have addressed the relationship between the two oncogenic drivers in RCC. SET and MYND domain-containing protein 3 (SMYD3) is a histone methyltransferase involved in gene transcription and oncogenesis, but its expression and function in RCC remain unclear. In the present study, we found that SMYD3 expression was significantly elevated in RCC tumors and correlated with advanced tumor stage, histological and nuclear grade, and shorter survival. Depletion of SMYD3 inhibited RCC cell proliferation, colony numbers, and xenograft tumor formation, while promoted apoptosis. Mechanistically, SMYD3 cooperates with SP1 to transcriptionally promote EGFR expression, amplifying its downstream signaling activity. TCGA data analyses revealed a significantly increased SMYD3 expression in primary RCC tumors carrying the loss-of-function VHL mutations. We further showed that HIF-2 alpha can directly bind to the SMYD3 promoter and subsequently induced SMYD3 transcription and expression. Taken together, we identify the VHL/HIF-2 alpha/SMYD3 signaling cascade-mediated EGFR hyperactivity through which SMYD3 promotes RCC progression. Our study suggests that SMYD3 is a potential therapeutic target and prognostic factor in RCC.	[Liu, Cheng; Ge, Li-Yuan; Ma, Run-Zhuo; Qiu, Min; Hao, Yi-Chang; Huang, Yi; Ma, Lu-Lin] Peking Univ, Hosp 3, Dept Urol, Beijing, Peoples R China; [Liu, Li] Beijing Univ Chinese Med, Sch Nursing, Beijing, Peoples R China; [Wang, Kun] Tianjin Med Univ Canc Inst & Hosp, Dept Urol, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China; [Li, Xiao-Feng; Fan, Yi-Dong; Li, Lu-Chao; Liu, Zheng-Fang] Shandong Univ, Qilu Hosp, Dept Urol, Jinan, Peoples R China; [Ge, Li-Yuan; Shi, Zhen-Feng] Peoples Hosp Xinjiang Uyghur Autonomous Region, Dept Urol, Xinjiang, Peoples R China; [Xia, Chuan-You; Straat, Klas; Xu, Dawei] Karolinska Univ Hosp Solna, Karolinska Inst, Bioclinicum, Dept Med,Div Hematol, Stockholm, Sweden; [Xia, Chuan-You; Straat, Klas; Xu, Dawei] Karolinska Univ Hosp Solna, Karolinska Inst, Ctr Mol Med, Stockholm, Sweden; [Xu, Dawei] Shandong Univ, Karolinska Inst, Collaborat Lab Canc & Stem Cell Res, Jinan, Peoples R China	Peking University; Beijing University of Chinese Medicine; Tianjin Medical University; Shandong University; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Shandong University	Liu, C; Ma, LL (corresponding author), Peking Univ, Hosp 3, Dept Urol, Beijing, Peoples R China.	chengliu@bjmu.edu.cn; malulin@bjmu.edu.cn	Ma, Runzhuo/Y-3043-2019; Ma, Runzhuo/GXM-4966-2022; Ge, Li/T-3955-2018	Ge, Li/0000-0002-1824-8034; Xu, Dawei/0000-0003-3141-4524	Peking University Medicine Fund of Fostering Young Scholars' Scientific and Technological Innovation [BMU2018PY003]; National Natural Science Foundation of China [81711530048, 81572515, 81672522, 81972381]; Peking University Third Hospital Clinical Research Fund [BYSY2018062, BYSY2018012]; Fundamental Research funds for the Central Universities [2020-JYB-XJSJJ-031]; Swedish Cancer Society; Swedish Research Council; Cancer Society in Stockholm	Peking University Medicine Fund of Fostering Young Scholars' Scientific and Technological Innovation; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Peking University Third Hospital Clinical Research Fund; Fundamental Research funds for the Central Universities(Fundamental Research Funds for the Central Universities); Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Cancer Society in Stockholm	The study was funded by Peking University Medicine Fund of Fostering Young Scholars' Scientific and Technological Innovation BMU2018PY003; the National Natural Science Foundation of China (Nos: 81711530048, 81572515, 81672522, and 81972381); Peking University Third Hospital Clinical Research Fund BYSY2018062 and BYSY2018012; the Fundamental Research funds for the Central Universities (No. 2020-JYB-XJSJJ-031); the Swedish Cancer Society, the Swedish Research Council, and Cancer Society in Stockholm.	An JB, 2007, MOL CANCER THER, V6, P61, DOI 10.1158/1535-7163.MCT-06-0255; Bheda A, 2008, ONCOGENE, V27, P4315, DOI 10.1038/onc.2008.65; Chakraborty AA, 2017, SCI TRANSL MED, V36, P3533; Chappell JC, 2019, J CLIN INVEST, V129, P442, DOI 10.1172/JCI120855; CHEN F, 2015, TRANSL PSYCHIAT, V5, DOI DOI 10.1038/srep13470; Chu CL, 2018, J BUON, V23, P1097; Cohen D, 2007, CLIN GENITOURIN CANC, V5, P264, DOI 10.3816/CGC.2007.n.002; Coppin C, 2011, BJU INT, V108, P1556, DOI 10.1111/j.1464-410X.2011.10629.x; Cossu-Rocca P, 2016, AM J CANCER RES, V6, P71; Dehghani Mehdi, 2018, Oncotarget, V9, P26737, DOI 10.18632/oncotarget.25481; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Erfani P, 2015, EPIGENETICS-US, V10, P496, DOI 10.1080/15592294.2015.1042645; Feng ZH, 2017, CANCER SCI, V108, P1620, DOI 10.1111/cas.13297; Fenizia C, 2019, NUCLEIC ACIDS RES, V47, P1278, DOI 10.1093/nar/gky1221; Giakountis A, 2017, SEMIN CANCER BIOL, V42, P70, DOI 10.1016/j.semcancer.2016.08.008; Gong XH, 2018, CELL PHYSIOL BIOCHEM, V45, P523, DOI 10.1159/000487030; Guo JL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20431-z; Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151; Hsieh JJ, 2018, J CLIN ONCOL, V36, P3533, DOI 10.1200/JCO.2018.79.2549; Huang L, 2017, AM J TRANSL RES, V9, P1; Jamal-Hanjani M, 2017, NEW ENGL J MED, V376, P2109, DOI 10.1056/NEJMoa1616288; Johnson AC, 1996, J BIOL CHEM, V271, P3033; Kassouf Wassim, 2008, Eur Urol, V54, P853, DOI 10.1016/j.eururo.2008.01.011; Kim H, 2009, J BIOL CHEM, V284, P19867, DOI 10.1074/jbc.M109.021485; Kim JM, 2015, NUCLEIC ACIDS RES, V43, P8868, DOI 10.1093/nar/gkv874; Lin FJ, 2019, INFLAMM RES, V68, P739, DOI 10.1007/s00011-019-01257-5; Liu C, 2007, CANCER RES, V67, P2626, DOI 10.1158/0008-5472.CAN-06-4126; Liu C, 2013, JNCI-J NATL CANCER I, V105, P1719, DOI 10.1093/jnci/djt304; Liu F, 2018, ONCOTARGETS THER, V11, P6209, DOI 10.2147/OTT.S172803; Liu L, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317705337; Mazur PK, 2014, NATURE, V510, P283, DOI 10.1038/nature13320; Merseburger AS, 2005, ANTICANCER RES, V25, P1901; Minner S, 2012, CANCER-AM CANCER SOC, V118, P1268, DOI 10.1002/cncr.26436; Mizumoto A, 2015, J PHARMACOL EXP THER, V355, P152, DOI 10.1124/jpet.115.226639; Ravaud A, 2008, J CLIN ONCOL, V26, P2285, DOI 10.1200/JCO.2007.14.5029; Ricketts CJ, 2017, CANCER DISCOV, V7, P1221, DOI 10.1158/2159-8290.CD-17-0971; Sarris ME, 2016, CANCER CELL, V29, P354, DOI 10.1016/j.ccell.2016.01.013; Schodel J, 2016, EUR UROL, V69, P646, DOI 10.1016/j.eururo.2015.08.007; Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI [10.3322/caac.21601, 10.3322/caac.21590]; Smith K, 2005, CANCER RES, V65, P5221, DOI 10.1158/0008-5472.CAN-05-0169; Thomasson Marcus, 2012, BMC Res Notes, V5, P216, DOI 10.1186/1756-0500-5-216; Tsuge M, 2005, NAT GENET, V37, P1104, DOI 10.1038/ng1638; Turajlic S, 2018, CELL, V173, P595, DOI 10.1016/j.cell.2018.03.043; Van Aller GS, 2012, EPIGENETICS-US, V7, P340, DOI 10.4161/epi.19506; Wang AB, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1331-9; Wang GL, 2020, AGING-US, V12, P2030, DOI 10.18632/aging.102718; Yuan XT, 2019, ONCOGENE, V38, P6172, DOI 10.1038/s41388-019-0872-9; Zhang F, 2018, INT J CANCER, V142, P2543, DOI 10.1002/ijc.31278	48	15	15	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	21					4286	4298		10.1038/s41388-020-1291-7	http://dx.doi.org/10.1038/s41388-020-1291-7		APR 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LQ2DH	32291411				2022-12-28	WOS:000526237900003
J	Gong, C; Tsoi, H; Mok, KC; Cheung, J; Man, EPS; Fujino, K; Wong, AH; Lam, EWF; Khoo, US				Gong, Chun; Tsoi, Ho; Mok, Ka Chun; Cheung, Jenny; Man, Ellen P. S.; Fujino, Kazunari; Wong, Ashely; Lam, Eric W. F.; Khoo, Ui-Soon			Phosphorylation independent eIF4E translational reprogramming of selective mRNAs determines tamoxifen resistance in breast cancer	ONCOGENE			English	Article							TRANSCRIPTION FACTOR; INITIATION-FACTORS; PROTEIN-SYNTHESIS; ER-ALPHA; THERAPY; EXPRESSION; FOXM1; SENSITIVITY; MECHANISMS; RECEPTOR	Eukaryotic translation initiation factor 4E (eIF4E) selectively promotes translation of mRNAs with atypically long and structured 5 '-UTRs and has been implicated in drug resistance. Through genome-wide transcriptome and translatome analysis we revealed eIF4E overexpression could promote cellular activities mediated by ER alpha and FOXM1 signalling pathways. Whilst eIF4E overexpression could enhance the translation of both ER alpha and FOXM1, it also led to enhanced transcription of FOXM1. Polysome fractionation experiments confirmed eIF4E could modulate the translation of ER alpha and FOXM1 mRNA. The enhancement of FOXM1 transcription was contingent upon the presence of ER alpha, and it was the high levels of FOXM1 that conferred Tamoxifen resistance. Furthermore, tamoxifen resistance was conferred by phosphorylation independent eIF4E overexpression. Immunohistochemistry on 134 estrogen receptor (ER+) primary breast cancer samples confirmed that high eIF4E expression was significantly associated with increased ER alpha and FOXM1, and significantly associated with tamoxifen resistance. Our study uncovers a novel mechanism whereby phosphorylation independent eIF4E translational reprogramming in governing the protein synthesis of ER alpha and FOXM1 contributes to anti-estrogen insensitivity in ER+ breast cancer. In eIF4E overexpressing breast cancer, the increased ER alpha protein expression in turn enhances FOXM1 transcription, which together with its increased translation regulated by eIF4E, contributes to tamoxifen resistance. Coupled with eIF4E translational regulation, our study highlights an important mechanism conferring tamoxifen resistance via both ER alpha dependent and independent pathways.	[Gong, Chun; Tsoi, Ho; Mok, Ka Chun; Cheung, Jenny; Man, Ellen P. S.; Wong, Ashely; Khoo, Ui-Soon] Univ Hong Kong, Li Ka Shing Fac Med, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; [Gong, Chun; Fujino, Kazunari; Lam, Eric W. F.] Imperial Coll London, Dept Surg & Canc, Hammersmith Hosp Campus, London, England	University of Hong Kong; Imperial College London	Khoo, US (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, Dept Pathol, Hong Kong, Hong Kong, Peoples R China.; Lam, EWF (corresponding author), Imperial Coll London, Dept Surg & Canc, Hammersmith Hosp Campus, London, England.	eric.lam@imperial.ac.uk; uskhoo@pathology.hku.hk	Khoo, Ui Soon/C-4293-2009; Lam, Eric W-F/AAW-8566-2020	Khoo, Ui Soon/0000-0003-2200-7505; Lam, Eric W-F/0000-0003-1274-3576; tsoi, ho/0000-0003-2037-9575	Committee on Research and Conference Grants from the University of Hong Kong [201109176081, 201209176093, 201711159147]; MRC [MR/N012097/1]; CRUK [A12011]; Breast Cancer Now [2012MayPR070, 2012NovPhD016]; Cancer Research UK Imperial Centre; NIHR Imperial BRC; Imperial ECMC	Committee on Research and Conference Grants from the University of Hong Kong; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); CRUK(Cancer Research UK); Breast Cancer Now; Cancer Research UK Imperial Centre; NIHR Imperial BRC; Imperial ECMC	The study was supported by grants from the Committee on Research and Conference Grants from the University of Hong Kong Project numbers 201109176081, 201209176093 and 201711159147. We thank Dr Robert Clarke (Georgetown University Medical Center) for providing the cell lines. EW-FL work is supported by MRC (MR/N012097/1), CRUK (A12011), Breast Cancer Now (2012MayPR070; 2012NovPhD016), the Cancer Research UK Imperial Centre, Imperial ECMC and NIHR Imperial BRC.	Bilanges B, 2007, ONCOGENE, V26, P5973, DOI 10.1038/sj.onc.1210431; Burris HA, 2013, CANCER CHEMOTH PHARM, V71, P829, DOI 10.1007/s00280-012-2043-3; Busch S, 2015, CANCER RES, V75, P1457, DOI 10.1158/0008-5472.CAN-14-1583; Chen J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012293; Chimge NO, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3073; Chu J, 2016, TRENDS CELL BIOL, V26, P918, DOI 10.1016/j.tcb.2016.06.005; Culjkovic B, 2008, J CELL BIOL, V181, P51, DOI 10.1083/jcb.200707018; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Droog M, 2013, EUR J PHARMACOL, V717, P47, DOI 10.1016/j.ejphar.2012.11.071; DUNCAN R, 1983, J BIOL CHEM, V258, P7228; DUNCAN R, 1987, J BIOL CHEM, V262, P380; Fagan DH, 2017, HORM CANCER-US, V8, P219, DOI 10.1007/s12672-017-0296-3; Ferrari N, 2015, SCI REP-UK, V5, DOI 10.1038/srep15658; Geter PA, 2017, GENE DEV, V31, P2235, DOI 10.1101/gad.305631.117; Gong C, 2018, CLIN CANCER RES, V24, P3681, DOI 10.1158/1078-0432.CCR-17-2259; Halasi M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031761; Hassan MK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191377; HORWITZ KB, 1975, SCIENCE, V189, P726, DOI 10.1126/science.168640; Hou Y, 2015, NAT IMMUNOL, V16, P810, DOI 10.1038/ni.3204; Ilic N, 2011, P NATL ACAD SCI USA, V108, pE699, DOI 10.1073/pnas.1108237108; Ito Y, 2015, NAT REV CANCER, V15, P81, DOI 10.1038/nrc3877; Jordan VC, 2008, EUR J CANCER, V44, P30, DOI 10.1016/j.ejca.2007.11.002; Kamburov A, 2011, NUCLEIC ACIDS RES, V39, pD712, DOI 10.1093/nar/gkq1156; Karadedou CT, 2006, HIPPOKRATIA, V10, P128; Kevil C, 1995, ONCOGENE, V11, P2339; Kevil CG, 1996, INT J CANCER, V65, P785, DOI 10.1002/(SICI)1097-0215(19960315)65:6<785::AID-IJC14>3.0.CO;2-3; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; Leng N, 2013, BIOINFORMATICS, V29, P1035, DOI 10.1093/bioinformatics/btt087; Leppek K, 2018, NAT REV MOL CELL BIO, V19, P158, DOI 10.1038/nrm.2017.103; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Millour J, 2010, ONCOGENE, V29, P2983, DOI 10.1038/onc.2010.47; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Ruggero D, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a012336; SHANTZ LM, 1994, CANCER RES, V54, P2313; Siddiqui N, 2015, BIOCHEM SOC T, V43, P763, DOI 10.1042/BST20150126; Sonenberg N, 2007, MOL CELL, V28, P721, DOI 10.1016/j.molcel.2007.11.018; Uttam S, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00470; Zhang LD, 2013, CANCER RES, V73, P246, DOI 10.1158/0008-5472.CAN-12-2241; Zhu YH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03951-0; Zilli M, 2009, BBA-REV CANCER, V1795, P62, DOI 10.1016/j.bbcan.2008.08.003; Zindy P, 2011, CANCER RES, V71, P4068, DOI 10.1158/0008-5472.CAN-11-0420	42	9	9	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	15					3206	3217		10.1038/s41388-020-1210-y	http://dx.doi.org/10.1038/s41388-020-1210-y		FEB 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LB8NS	32066877	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000514052700005
J	Tian, LT; Yao, K; Liu, K; Han, B; Dong, HG; Zhao, W; Jiang, WB; Qiu, FB; Qu, LL; Wu, ZH; Zhou, B; Zhong, MY; Zhao, JB; Qiu, XF; Zhong, LF; Guo, XF; Shi, TL; Hong, XH; Lu, SC				Tian, Lantian; Yao, Ke; Liu, Kun; Han, Bing; Dong, Hanguang; Zhao, Wei; Jiang, Weibo; Qiu, Fabo; Qu, Linlin; Wu, Zehua; Zhou, Bin; Zhong, Mengya; Zhao, Jiabao; Qiu, Xingfeng; Zhong, Lifeng; Guo, Xiaofeng; Shi, Tianlu; Hong, Xuehui; Lu, Shichun			PLK1/NF-kappa B feedforward circuit antagonizes the mono-ADP-ribosyltransferase activity of PARP10 and facilitates HCC progression	ONCOGENE			English	Article							POLO-LIKE KINASE; HEPATOCELLULAR-CARCINOMA; PLK1; PHOSPHORYLATION; PROLIFERATION; RIBOSYLATION; REPLICATION; ACTIVATION; RESISTANCE	Dysregulation of PARP10 has been implicated in various tumor types and plays a vital role in delaying hepatocellular carcinoma (HCC) progression. However, the mechanisms controlling the expression and activity of PARP10 in HCC remain mostly unknown. The crosstalk between PLK1, PARP10, and NF-kappa B pathway in HCC was determined by performing different in vitro and in vivo assays, including mass spectrometry, kinase, MARylation, chromatin immunoprecipitation, and luciferase reporter measurements. Functional examination was performed by using small chemical drug, cell culture, and mice HCC models. Correlation between PLK1, NF-kappa B, and PARP10 expression was determined by analyzing clinical samples of HCC patients with using immunohistochemistry. PLK1, an important regulator for cell mitosis, directly interacts with and phosphorylates PARP10 at T601. PARP10 phosphorylation at T601 significantly decreases its binding to NEMO and disrupts its inhibition to NEMO ubiquitination, thereby enhancing the transcription activity of NF-kappa B toward multiple target genes and promoting HCC development. In turn, NF-kappa B transcriptionally inhibits the PARP10 promoter activity and leads to its downregulation in HCC. Interestingly, PLK1 is mono-ADP-ribosylated by PARP10 and the MARylation of PLK1 significantly inhibits its kinase activity and oncogenic function in HCC. Clinically, the expression levels of PLK1 and phosphor-p65 show an inverse correlation with PARP10 expression in human HCC tissues. These findings are the first to uncover a PLK1/PARP10/NF-kappa B signaling circuit that underlies tumorigenesis and validate PLK1 inhibitors, alone or with NF-kappa B antagonists, as potential effective therapeutics for PARP10-expressing HCC.	[Tian, Lantian; Han, Bing; Zhao, Wei; Jiang, Weibo; Qiu, Fabo; Qu, Linlin; Wu, Zehua; Zhou, Bin] Qingdao Univ, Affiliated Hosp, Dept Hepatopancreatobiliary Surg, Qingdao, Shandong, Peoples R China; [Tian, Lantian; Lu, Shichun] Chinese Peoples Liberat Army Gen Hosp, Clin Med Ctr 1, Dept Hepatobiliary Surg, Beijing, Peoples R China; [Yao, Ke] Qingdao Univ, Affiliated Hosp, Dept Obstet & Gynaecol, Qingdao, Shandong, Peoples R China; [Liu, Kun] PLA Navy, Hosp 971, Dept Gen Surg, Qingdao, Shandong, Peoples R China; [Dong, Hanguang] Shandong Univ, Dept Gen Surg, Qilu Hosp, Qingdao, Shandong, Peoples R China; [Zhong, Mengya; Zhao, Jiabao; Qiu, Xingfeng; Zhong, Lifeng; Hong, Xuehui] Xiamen Univ, Dept Gastrointestinal Surg, Zhongshan Hosp, Xiamen, Fujian, Peoples R China; [Zhong, Mengya; Zhao, Jiabao; Qiu, Xingfeng; Zhong, Lifeng; Hong, Xuehui] Xiamen Univ, Inst Gastrointestinal Oncol, Sch Med, Xiamen, Fujian, Peoples R China; [Guo, Xiaofeng] Zhongshan Univ, Affiliated Hosp, Dept Hepatopancreatobiliary Surg, Guangzhou, Guangdong, Peoples R China; [Shi, Tianlu] Univ Sci & Technol China, Affiliated Hosp 1, Div Life Sci & Med, Dept Pharm, Hefei, Anhui, Peoples R China	Qingdao University; Chinese People's Liberation Army General Hospital; Qingdao University; Sixth Medical Center of Chinese PLA General Hospital; Shandong University; Xiamen University; Xiamen University; Sun Yat Sen University; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Lu, SC (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Clin Med Ctr 1, Dept Hepatobiliary Surg, Beijing, Peoples R China.; Hong, XH (corresponding author), Xiamen Univ, Dept Gastrointestinal Surg, Zhongshan Hosp, Xiamen, Fujian, Peoples R China.; Hong, XH (corresponding author), Xiamen Univ, Inst Gastrointestinal Oncol, Sch Med, Xiamen, Fujian, Peoples R China.; Shi, TL (corresponding author), Univ Sci & Technol China, Affiliated Hosp 1, Div Life Sci & Med, Dept Pharm, Hefei, Anhui, Peoples R China.	tianlu828@163.com; hongxu@xmu.edu.cn; lushichun889@126.com	Zhong, Mengya/AAA-6082-2021		National Natural Science Foundation of China [81602149]; Natural Science Foundation of Fujian Province [2016J01619]; Training Program for Young Talents of Fujian Health System [2016-ZQN-85]; Fujian Provincial Funds for Distinguished Young Scientists [2018D0016]; Affiliated Hospital of Qingdao University	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Fujian Province(Natural Science Foundation of Fujian Province); Training Program for Young Talents of Fujian Health System; Fujian Provincial Funds for Distinguished Young Scientists; Affiliated Hospital of Qingdao University	The authors would like to thank the Affiliated Hospital of Qingdao University for providing clinical samples and the contributions and supports of the entire research team. This study was supported by National Natural Science Foundation of China (Grant No. 81602149), Natural Science Foundation of Fujian Province (Grant No. 2016J01619), Training Program for Young Talents of Fujian Health System (Grant No. 2016-ZQN-85), Fujian Provincial Funds for Distinguished Young Scientists (No. 2018D0016).	Almeida LO, 2014, FEBS OPEN BIO, V4, P96, DOI 10.1016/j.fob.2013.12.003; Chen YC, 2010, J BIOL CHEM, V285, P41244, DOI 10.1074/jbc.M110.155242; Chou HYE, 2006, J BIOL CHEM, V281, P15201, DOI 10.1074/jbc.M506745200; de Carcer G, 2011, CELL CYCLE, V10, P2255, DOI 10.4161/cc.10.14.16494; Dietrich P, 2018, ONCOTARGET, V9, P3605, DOI 10.18632/oncotarget.23188; Feijs KLH, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-5; Fu Z, 2017, CANCERS, V9, DOI 10.3390/cancers9100131; Gutteridge REA, 2016, MOL CANCER THER, V15, P1427, DOI 10.1158/1535-7163.MCT-15-0897; Hong XH, 2018, ELIFE, V7, DOI 10.7554/eLife.29511; Hong XH, 2014, GUT, V63, P1635, DOI 10.1136/gutjnl-2013-305302; Huang GL, 2010, WORLD J GASTROENTERO, V16, P2046, DOI 10.3748/wjg.v16.i16.2046; Kachaner D, 2012, MOL CELL, V45, P553, DOI 10.1016/j.molcel.2011.12.030; Lasek AL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150225; Li XY, 2017, CELL CYCLE, V16, P1933, DOI 10.1080/15384101.2017.1363942; Ling F, 2017, ONCOTARGET, V8, P72773, DOI 10.18632/oncotarget.20347; Liu XQ, 2015, TRANSL ONCOL, V8, P185, DOI 10.1016/j.tranon.2015.03.010; Lo J, 2015, HEPATOLOGY, V62, P534, DOI 10.1002/hep.27859; de Lima CDM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041772; Marton J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0187789; Paone G, 2006, J BIOL CHEM, V281, P17054, DOI 10.1074/jbc.M603042200; Qu C, 2016, J HEPATOL, V64, P1076, DOI 10.1016/j.jhep.2016.01.005; Schleicher EM, 2018, NUCLEIC ACIDS RES, V46, P8908, DOI 10.1093/nar/gky658; Sokolova O, 2017, TOXINS, V9, DOI 10.3390/toxins9040119; Song RP, 2014, HEPATOLOGY, V60, P1659, DOI 10.1002/hep.27312; Studach LL, 2009, HEPATOLOGY, V50, P414, DOI 10.1002/hep.22996; Teloni F, 2016, NUCLEIC ACIDS RES, V44, P993, DOI 10.1093/nar/gkv1383; Varol B, 2014, TUMOR BIOL, V35, P5575, DOI 10.1007/s13277-014-1735-1; Verheugd P, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2672; Wang G, 2013, J CELL SCI, V126, P1355, DOI 10.1242/jcs.114918; Wright G, 2017, ACS CHEM BIOL, V12, P1883, DOI 10.1021/acschembio.7b00147; Yau L, 2003, EUR J BIOCHEM, V270, P101, DOI 10.1046/j.1432-1033.2003.03366.x; Zhao YH, 2018, ONCOGENE, V37, P2921, DOI 10.1038/s41388-018-0168-5; Zhu Y., 2018, IEEE J SEL TOP QUANT, V24, P1	33	14	15	6	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	15					3145	3162		10.1038/s41388-020-1205-8	http://dx.doi.org/10.1038/s41388-020-1205-8		FEB 2020	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LB8NS	32060423				2022-12-28	WOS:000513384600002
J	Shoumariyeh, K; Schneider, N; Poggio, T; Veratti, P; Ehrenfeld, S; Redhaber, DM; Khan, R; Pfeifer, D; Klingeberg, C; Kreutmair, S; Rudelius, M; Quintanilla-Martinez, L; Fend, F; Illert, AL; Duyster, J; Miething, C				Shoumariyeh, Khalid; Schneider, Nicolas; Poggio, Teresa; Veratti, Pia; Ehrenfeld, Sophia; Redhaber, Desiree M.; Khan, Robin; Pfeifer, Dietmar; Klingeberg, Cathrin; Kreutmair, Stefanie; Rudelius, Martina; Quintanilla-Martinez, Leticia; Fend, Falko; Illert, Anna L.; Duyster, Justus; Miething, Cornelius			A novel conditional NPM-ALK-driven model of CD30+T-cell lymphoma mediated by a translational stop cassette	ONCOGENE			English	Article							LARGE-CELL LYMPHOMA; T-CELLS; GENE; EXPRESSION; MACROPHAGES; MECHANISMS; DISEASE	Targeted expression of transgenes is essential for the accurate representation of human disease in in vivo models. Current approaches to generate conditional transgenic mouse models are cumbersome and not amenable to high-throughput analysis since they require de novo generation and characterization of genetically modified mice. Here we describe a new system for lineage-restricted expression of transgenes based on a retroviral vector incorporating a translational stop cassette flanked by loxP recombination sites. Conditional transgene expression in chimeric mice is achieved by retroviral infection and transplantation of hematopoietic stem cells (HSC) derived from transgenic mice expressing Cre-recombinase from a lineage-specific promoter. For validation, we directed expression of NPM-ALK, the fusion oncogene driving a subset of anaplastic large cell lymphoma (ALCL), to T-cells by infecting hematopoietic stem cells from Lck-Cre-transgenic mice with a retroviral construct containing the NPM-ALK cDNA preceded by a translational stop cassette. These mice developed T-cell lymphomas within 12-16 weeks, featuring increased expression of the ALCL hallmark antigen CD30 as well as other cytotoxic T-cell markers, similar to the human disease. The new model represents a versatile tool for the rapid analysis of gene function in a defined lineage or in a developmental stage in vivo.	[Shoumariyeh, Khalid; Poggio, Teresa; Veratti, Pia; Ehrenfeld, Sophia; Redhaber, Desiree M.; Khan, Robin; Pfeifer, Dietmar; Klingeberg, Cathrin; Kreutmair, Stefanie; Illert, Anna L.; Duyster, Justus; Miething, Cornelius] Univ Freiburg, Fac Med, Med Ctr, Dept Hematol Oncol & Stem Cell Transplantat, D-79106 Freiburg, Germany; [Shoumariyeh, Khalid; Veratti, Pia; Ehrenfeld, Sophia; Redhaber, Desiree M.; Kreutmair, Stefanie; Illert, Anna L.; Duyster, Justus; Miething, Cornelius] German Canc Consortium DKTK, Partner Site Freiburg, D-79106 Freiburg, Germany; [Schneider, Nicolas] Tech Univ Munich, Klinikum Rechts Isar, Dept Hematol Oncol & Stem Cell Transplantat, D-81675 Munich, Germany; [Poggio, Teresa; Ehrenfeld, Sophia; Redhaber, Desiree M.] Albert Ludwigs Univ Freiburg, Fac Biol, D-79104 Freiburg, Germany; [Veratti, Pia; Ehrenfeld, Sophia; Redhaber, Desiree M.; Illert, Anna L.; Duyster, Justus; Miething, Cornelius] German Canc Res Ctr, D-69120 Heidelberg, Germany; [Rudelius, Martina] Ludwig Maximilians Univ Munchen, Inst Pathol, D-81377 Munich, Germany; [Quintanilla-Martinez, Leticia; Fend, Falko] Univ Hosp Tubingen, Dept Pathol, D-72076 Tubingen, Germany	University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ); Technical University of Munich; University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ); University of Munich; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Miething, C (corresponding author), Univ Freiburg, Fac Med, Med Ctr, Dept Hematol Oncol & Stem Cell Transplantat, D-79106 Freiburg, Germany.; Miething, C (corresponding author), German Canc Consortium DKTK, Partner Site Freiburg, D-79106 Freiburg, Germany.; Miething, C (corresponding author), German Canc Res Ctr, D-69120 Heidelberg, Germany.	cornelius.miething@uniklinik-freiburg.de	Kreutmair, Stefanie/AAE-6952-2022; Kreutmair, Stefanie/GOK-2757-2022; Shoumariyeh, Khalid/AAB-8421-2021	Kreutmair, Stefanie/0000-0001-8466-6675; Poggio, Teresa/0000-0003-2560-8488; Schneider, Nicolas/0000-0002-9044-446X	European Union [675712]; German Research Council (DFG) [TRR54, 34712712]	European Union(European Commission); German Research Council (DFG)(German Research Foundation (DFG))	This work was in part funded by the European Union Horizon 2020 Marie Sklodowska-Curie Innovative Training Network Grant No 675712 (ALI and TP) and by the German Research Council (DFG) TRR54 grant No 34712712 (JD).	Babendure JR, 2006, RNA, V12, P851, DOI 10.1261/rna.2309906; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; Brierley I, 2007, NAT REV MICROBIOL, V5, P598, DOI 10.1038/nrmicro1704; Chiarle R, 2003, BLOOD, V101, P1919, DOI 10.1182/blood-2002-05-1343; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; Deftos ML, 1998, IMMUNITY, V9, P777, DOI 10.1016/S1074-7613(00)80643-3; Dow LE, 2015, TRENDS MOL MED, V21, P609, DOI 10.1016/j.molmed.2015.07.006; Frese KK, 2007, NAT REV CANCER, V7, P645, DOI 10.1038/nrc2192; Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488; HANNA Z, 1994, MOL CELL BIOL, V14, P1084, DOI 10.1128/MCB.14.2.1084; Hanson G, 2018, NAT REV MOL CELL BIO, V19, P20, DOI 10.1038/nrm.2017.91; Hemann Michael, 2015, Cold Spring Harb Protoc, V2015, P725, DOI 10.1101/pdb.top069872; Hennet T, 1995, P NATL ACAD SCI USA, V92, P12070, DOI 10.1073/pnas.92.26.12070; Heyer J, 2010, NAT REV CANCER, V10, P470, DOI 10.1038/nrc2877; Jacob J, 1999, NATURE, V399, P593, DOI 10.1038/21208; Jager R, 2005, ANTICANCER RES, V25, P3191; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Lee PP, 2001, IMMUNITY, V15, P763, DOI 10.1016/S1074-7613(01)00227-8; Maresch R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10770; Matz MV, 1999, NAT BIOTECHNOL, V17, P969, DOI 10.1038/13657; Miething C, 2003, ONCOGENE, V22, P4642, DOI 10.1038/sj.onc.1206575; Mou HW, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0178-7; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Pfleger BF, 2005, BIOTECHNOL BIOENG, V92, P553, DOI 10.1002/bit.20630; Roth TL, 2018, NATURE, V559, P405, DOI 10.1038/s41586-018-0326-5; Sperschneider J, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq021; Stein H, 2000, BLOOD, V96, P3681; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Turner SD, 2003, ONCOGENE, V22, P7750, DOI 10.1038/sj.onc.1207048; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	31	2	2	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	9					1904	1913		10.1038/s41388-019-1058-1	http://dx.doi.org/10.1038/s41388-019-1058-1			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KP9VM	31754210				2022-12-28	WOS:000516579800006
J	Zhangyuan, GY; Wang, F; Zhang, HT; Jiang, RQ; Tao, XW; Yu, DC; Jin, KP; Yu, WW; Liu, Y; Yin, Y; Shen, JT; Xu, QF; Zhang, WJ; Sun, BC				Zhangyuan, Guangyan; Wang, Fei; Zhang, Haitian; Jiang, Runqiu; Tao, Xuewen; Yu, Decai; Jin, Kangpeng; Yu, WeiWei; Liu, Yang; Yin, Yin; Shen, Jintao; Xu, Qinfeng; Zhang, Wenjie; Sun, Beicheng			VersicanV1 promotes proliferation and metastasis of hepatocellular carcinoma through the activation of EGFR-PI3K-AKT pathway	ONCOGENE			English	Article							EXTRACELLULAR-MATRIX COMPONENTS; GROWTH-FACTOR RECEPTOR; STROMAL VERSICAN; CANCER; EXPRESSION; HYALURONAN; MIGRATION; CELLS; PROGRESSION; ATTACHMENT	Versican has been reported to participate in carcinogenesis in several malignant tumors. However, the accurate role of VersicanV1, a predominant isoform of Versican in liver, remains an enigma in hepatocellular carcinoma (HCC). The expression of VersicanV1 in HCC tissues and adjacent tissues was detected by Reverse Transcription-Polymerase Chain Reaction (RT-PCR), Western Blot (WB) and inmumohistochemistry (IHC). Gain and loss of function assays were performed to examine the role of VersicanV1 in proliferation and metastasis of HCC. Measurement of oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) in vitro and PET-CT (positron emission tomography/computed tomography) analysis in vivo were applied to evaluate the effects of VersicanV1 on glycolysis. RNA sequencing, Co-IP (Co-immunoprecipitation) and MS (mass spectrometry) were utilized to investigate the molecular mechanisms. Our current study reveals that VersicanV1, regulated by direct interaction with Linc01225, is significantly upregulated in HCC tissues and correlates with poor prognosis. Both in vitro and in vivo experiments show that knockdown of VersicanV1 in HCC cells attenuates cancer cells malignancy. Further studies identify the positive role of VersicanV1 in aerobic glycolysis. Mechanistic investigation discovers the activation of EGFR-PI3K-AKT pathway in HCC cells expressing high VersicanV1. Moreover, EGF-like motif is indispensable for VersicanV1 to promote Warburg effect of HCC cells and subsequently, proliferation, invasion, and metastasis ability via activation of EGFR-PI3K-AKT axis. In sum, our research highlights a novel role of VersicanV1 in the progression of HCC, suggesting that VersicanV1 is an indicator for prognosis and a potential therapeutic target of HCC.	[Zhangyuan, Guangyan; Wang, Fei; Zhang, Haitian; Jiang, Runqiu; Tao, Xuewen; Zhang, Wenjie; Sun, Beicheng] Nanjing Med Univ, Dept Hepatobiliary Surg, Drum Tower Clin Med Coll, Nanjing, Peoples R China; [Zhangyuan, Guangyan; Wang, Fei; Zhang, Haitian; Jiang, Runqiu; Tao, Xuewen; Yu, Decai; Jin, Kangpeng; Yu, WeiWei; Liu, Yang; Yin, Yin; Zhang, Wenjie; Sun, Beicheng] Nanjing Univ, Med Sch, Dept Hepatobiliary Surg, Affiliated Drum Tower Hosp, Nanjing, Jiangsu, Peoples R China; [Wang, Fei; Zhang, Haitian; Jiang, Runqiu; Jin, Kangpeng; Liu, Yang; Zhang, Wenjie; Sun, Beicheng] Nanjing Med Univ, Affiliated Hosp 1, Liver Transplantat Ctr, Nanjing, Jiangsu, Peoples R China; [Wang, Fei; Zhang, Haitian; Jiang, Runqiu; Jin, Kangpeng; Liu, Yang; Zhang, Wenjie; Sun, Beicheng] Nanjing Med Univ, State Key Lab Reprod Med, Nanjing, Jiangsu, Peoples R China; [Shen, Jintao; Xu, Qinfeng] Nanjing Univ, Med Sch, Affiliated Drum Tower Hosp, Dept Nucl Med, Nanjing, Jiangsu, Peoples R China	Nanjing Medical University; Nanjing University; Nanjing Medical University; Nanjing Medical University; Nanjing University	Zhang, WJ; Sun, BC (corresponding author), Nanjing Med Univ, Dept Hepatobiliary Surg, Drum Tower Clin Med Coll, Nanjing, Peoples R China.; Zhang, WJ; Sun, BC (corresponding author), Nanjing Univ, Med Sch, Dept Hepatobiliary Surg, Affiliated Drum Tower Hosp, Nanjing, Jiangsu, Peoples R China.; Zhang, WJ; Sun, BC (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Liver Transplantat Ctr, Nanjing, Jiangsu, Peoples R China.; Zhang, WJ; Sun, BC (corresponding author), Nanjing Med Univ, State Key Lab Reprod Med, Nanjing, Jiangsu, Peoples R China.	drzhangwj@163.com; sunbc@nju.edu.cn		Yin, Yin/0000-0001-8113-4278; Jiang, Runqiu/0000-0002-6995-9557; YU, Decai/0000-0002-3006-2531; Zhangyuan, Guangyan/0000-0002-6298-8304; Sun, Beicheng/0000-0002-8657-7024	National Key Research and Development Program of China [2016YFC0905900]; State Key Program of the National Natural Science Foundation [81430062]; Innovative Research Groups of the National Natural Science Foundation [81521004]; National Natural Science Foundation [81702344]; TianQing Liver Disease Research Fund [TQGB20180095]; Research Innovation Program for Postgraduate of Jiangsu Province [SJKY19_1379]	National Key Research and Development Program of China; State Key Program of the National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Innovative Research Groups of the National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); TianQing Liver Disease Research Fund; Research Innovation Program for Postgraduate of Jiangsu Province	This work was supported by grants from the National Key Research and Development Program of China (Grant Number 2016YFC0905900 to BS), State Key Program of the National Natural Science Foundation (Grant Number 81430062 to BS), Innovative Research Groups of the National Natural Science Foundation (Grant Number 81521004 to BS), National Natural Science Foundation (Grant Number 81702344 to WZ), TianQing Liver Disease Research Fund (Grant Number: TQGB20180095 to WZ) and the Research Innovation Program for Postgraduate of Jiangsu Province (Grant Number SJKY19_1379 to GZ). BS is Yangtze River Scholar of Distinguished Professor.	Asano K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17613-6; Bhattacharyya S, 2014, ONCOGENE, V33, P5467, DOI 10.1038/onc.2013.483; Buzzai M, 2005, ONCOGENE, V24, P4165, DOI 10.1038/sj.onc.1208622; Casey RC, 2003, CLIN EXP METASTAS, V20, P143, DOI 10.1023/A:1022670501667; Cattaruzza S, 2002, J BIOL CHEM, V277, P47626, DOI 10.1074/jbc.M206521200; Chen Y, 2005, J PROTEOME RES, V4, P998, DOI 10.1021/pr049754t; Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704; Desjardins M, 2014, J OVARIAN RES, V7, DOI 10.1186/1757-2215-7-70; Domenzain-Reyna C, 2009, J BIOL CHEM, V284, P12306, DOI 10.1074/jbc.M807108200; DOURSZIMMERMANN MT, 1994, J BIOL CHEM, V269, P32992; Du WW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013828; Edwards IJ, 2012, NAT REV UROL, V9, P196, DOI 10.1038/nrurol.2012.19; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Fanhchaksai K, 2016, INT J CANCER, V138, P630, DOI 10.1002/ijc.29804; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Gilkes DM, 2014, NAT REV CANCER, V14, P430, DOI 10.1038/nrc3726; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hope C, 2017, J IMMUNOL, V199, P1933, DOI 10.4049/jimmunol.1700529; Hope C, 2016, BLOOD, V128, P680, DOI 10.1182/blood-2016-03-705780; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kodama J, 2007, ANN ONCOL, V18, P269, DOI 10.1093/annonc/mdl370; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Mitsui Y, 2017, MOL CANCER RES, V15, P884, DOI 10.1158/1541-7786.MCR-16-0444; Nara Y, 1997, HISTOCHEM J, V29, P21, DOI 10.1023/A:1026460700592; Nikitovic D, 2006, IUBMB LIFE, V58, P47, DOI 10.1080/15216540500531713; Normanno N, 2006, GENE, V366, P2, DOI 10.1016/j.gene.2005.10.018; Onken J, 2014, J NEURO-ONCOL, V120, P73, DOI 10.1007/s11060-014-1545-8; Pappas AG, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2018.1537427; Paulus W, 1996, J NEUROPATH EXP NEUR, V55, P528, DOI 10.1097/00005072-199605000-00005; Pickup MW, 2014, EMBO REP, V15, P1243, DOI 10.15252/embr.201439246; Pukkila M, 2007, J CLIN PATHOL, V60, P267, DOI 10.1136/jcp.2005.034181; Ricciardelli C, 2002, CLIN CANCER RES, V8, P1054; Ricciardelli C, 1998, CLIN CANCER RES, V4, P963; Sakko AJ, 2003, CANCER RES, V63, P4786; Suwiwat S, 2004, CLIN CANCER RES, V10, P2491, DOI 10.1158/1078-0432.CCR-03-0146; Touab M, 2002, AM J PATHOL, V160, P549, DOI 10.1016/S0002-9440(10)64874-2; Voutilainen K, 2003, INT J CANCER, V107, P359, DOI 10.1002/ijc.11423; Wang RY, 2013, GASTROENTEROLOGY, V145, pe1431; Wang X, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.26; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Worns MA, 2014, NAT REV GASTRO HEPAT, V11, P447, DOI 10.1038/nrgastro.2014.10; Wu YJ, 2005, CELL RES, V15, P483, DOI 10.1038/sj.cr.7290318; Wu YJ, 2004, J CELL SCI, V117, P2227, DOI 10.1242/jcs.01057; Xia LM, 2014, HEPATOLOGY, V59, P958, DOI 10.1002/hep.26735; Xiang YY, 2006, J BIOL CHEM, V281, P19358, DOI 10.1074/jbc.M512980200; Yarden Y, 2007, CELL, V131, DOI 10.1016/j.cell.2007.11.013	47	30	33	3	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	6					1213	1230		10.1038/s41388-019-1052-7	http://dx.doi.org/10.1038/s41388-019-1052-7			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE4UH	31605014				2022-12-28	WOS:000526714600004
J	Salcher, S; Spoden, G; Hagenbuchner, J; Fuhrer, S; Kaserer, T; Tollinger, M; Huber-Cantonati, P; Gruber, T; Schuster, D; Gust, R; Zwierzina, H; Muller, T; Kiechl-Kohlendorfer, U; Ausserlechner, MJ; Obexer, P				Salcher, Stefan; Spoden, Gilles; Hagenbuchner, Judith; Fuehrer, Sebastian; Kaserer, Teresa; Tollinger, Martin; Huber-Cantonati, Petra; Gruber, Thomas; Schuster, Daniela; Gust, Ronald; Zwierzina, Heinz; Mueller, Thomas; Kiechl-Kohlendorfer, Ursula; Ausserlechner, Michael J.; Obexer, Petra			A drug library screen identifies Carbenoxolone as novel FOXO inhibitor that overcomes FOXO3-mediated chemoprotection in high-stage neuroblastoma	ONCOGENE			English	Article							TRANSCRIPTION FACTOR; NEURONAL APOPTOSIS; CELLS; CANCER; EXPRESSION; RESISTANCE; AXIS; DIFFERENTIATION; INDUCTION; REPRESSION	The transcription factor FOXO3 has been associated in different tumor entities with hallmarks of cancer, including metastasis, tumor angiogenesis, maintenance of tumor-initiating stem cells, and drug resistance. In neuroblastoma (NB), we recently demonstrated that nuclear FOXO3 promotes tumor angiogenesis in vivo and chemoresistance in vitro. Hence, inhibiting the transcriptional activity of FOXO3 is a promising therapeutic strategy. However, as no FOXO3 inhibitor is clinically available to date, we used a medium-throughput fluorescence polarization assay (FPA) screening in a drug-repositioning approach to identify compounds that bind to the FOXO3-DNA-binding-domain (DBD). Carbenoxolone (CBX), a glycyrrhetinic acid derivative, was identified as a potential FOXO3-inhibitory compound that binds to the FOXO3-DBD with a binding affinity of 19 mu M. Specific interaction of CBX with the FOXO3-DBD was validated by fluorescence-based electrophoretic mobility shift assay (FAM-EMSA). CBX inhibits the transcriptional activity of FOXO3 target genes, as determined by chromatin immunoprecipitation (ChIP), DEPP-, and BIM promoter reporter assays, and real-time RT-PCR analyses. In high-stage NB cells with functional TP53, FOXO3 triggers the expression of SESN3, which increases chemoprotection and cell survival. Importantly, FOXO3 inhibition by CBX treatment at pharmacologically relevant concentrations efficiently repressed FOXO3-mediated SESN3 expression and clonogenic survival and sensitized high-stage NB cells to chemotherapy in a 2D and 3D culture model. Thus, CBX might be a promising novel candidate for the treatment of therapy-resistant high-stage NB and other "FOXO-resistant" cancers.	[Salcher, Stefan; Hagenbuchner, Judith; Kiechl-Kohlendorfer, Ursula; Obexer, Petra] Med Univ Innsbruck, Dept Pediat 2, Innsbruck, Austria; [Salcher, Stefan; Spoden, Gilles; Huber-Cantonati, Petra; Obexer, Petra] Tyrolean Canc Res Inst, Innsbruck, Austria; [Fuehrer, Sebastian; Tollinger, Martin] Univ Innsbruck, CMBI, Inst Organ Chem, Innsbruck, Austria; [Kaserer, Teresa; Schuster, Daniela; Gust, Ronald] Univ Innsbruck, CMBI, Inst Pharm Pharmaceut Chem, Innsbruck, Austria; [Gruber, Thomas] Med Univ Innsbruck, Div Translat Cell Genet, Innsbruck, Austria; [Schuster, Daniela] Paracelsus Med Univ Salzburg, Inst Pharm, Dept Pharmaceut & Med Chem, Salzburg, Austria; [Zwierzina, Heinz] Med Univ Innsbruck, Dept Internal Med 5, Innsbruck, Austria; [Mueller, Thomas; Ausserlechner, Michael J.] Med Univ Innsbruck, Dept Pediat 1, Innsbruck, Austria	Medical University of Innsbruck; University of Innsbruck; University of Innsbruck; Medical University of Innsbruck; Paracelsus Private Medical University; Medical University of Innsbruck; Medical University of Innsbruck	Obexer, P (corresponding author), Med Univ Innsbruck, Dept Pediat 2, Innsbruck, Austria.; Obexer, P (corresponding author), Tyrolean Canc Res Inst, Innsbruck, Austria.; Ausserlechner, MJ (corresponding author), Med Univ Innsbruck, Dept Pediat 1, Innsbruck, Austria.	Michael.J.Ausserlechner@i-med.ac.at; Petra.Obexer@i-med.ac.at	Tollinger, Martin/E-5896-2011; Führer, Sebastian/AAG-2389-2021; Schuster, Daniela/C-1024-2014	Tollinger, Martin/0000-0002-2177-983X; Führer, Sebastian/0000-0002-6523-1307; Ausserlechner, Michael/0000-0002-1015-2302; Gruber, Thomas/0000-0002-5796-7090; Salcher, Stefan/0000-0003-2391-6954; Hagenbuchner, Judith/0000-0003-1396-3407; Kaserer, Teresa/0000-0003-0372-1885; Schuster, Daniela/0000-0002-9933-8938	COMET center of excellence ONCOTYROL; Kinderkrebshilfe fur Tirol und Vorarlberg; Sudtiroler Krebshilfe; Kinderkrebshilfe Sudtirol-Regenbogen; SVP-Frauen-Initiative; MFF-Tirol [296, 208]; Tirol-Kliniken GmbH; Tyrolean Cancer Society;  [FWF-I3089-B28]	COMET center of excellence ONCOTYROL; Kinderkrebshilfe fur Tirol und Vorarlberg; Sudtiroler Krebshilfe; Kinderkrebshilfe Sudtirol-Regenbogen; SVP-Frauen-Initiative; MFF-Tirol; Tirol-Kliniken GmbH; Tyrolean Cancer Society; 	We thank Andreas Villunger, Domenico Accili, and Joan Massague for providing plasmids. This work was supported by grants by the COMET center of excellence ONCOTYROL, by the "Kinderkrebshilfe fur Tirol und Vorarlberg", the "Sudtiroler Krebshilfe", the "Kinderkrebshilfe Sudtirol-Regenbogen", the "SVP-Frauen-Initiative", the "MFF-Tirol (Project Nr. 296 and 208)", and the FWF-I3089-B28. The Tyrolean Cancer Research Institute and this study are supported by the "Tirol-Kliniken GmbH" and the "Tyrolean Cancer Society".	Arrozi AP, 2017, APPL BIOCHEM BIOTECH, V183, P853, DOI 10.1007/s12010-017-2468-6; Ausserlechner MJ, 2012, NEUROBLASTOMA PRESEN, P325; Baar MP, 2017, CELL, V169, P132, DOI 10.1016/j.cell.2017.02.031; BARON JH, 1978, GUT, V19, P330, DOI 10.1136/gut.19.4.330; BERTACCINI G, 1985, DIGEST DIS SCI, V30, pS43, DOI 10.1007/BF01309384; Bingel C, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.398; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; Boura E, 2007, J BIOL CHEM, V282, P8265, DOI 10.1074/jbc.M605682200; Chen JR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013704; de Brachene AC, 2016, CELL MOL LIFE SCI, V73, P1159, DOI 10.1007/s00018-015-2112-y; Diep CH, 2013, CELL CYCLE, V12, P1433, DOI 10.4161/cc.24550; Du YH, 2006, J BIOMOL SCREEN, V11, P269, DOI 10.1177/1087057105284862; Du Yuhong, 2008, Curr Chem Genomics, V2, P40, DOI 10.2174/1875397300802010040; Grignani F, 1998, CANCER RES, V58, P14; GROSS N, 1992, INT J CANCER, V52, P85, DOI 10.1002/ijc.2910520116; Hagenbuchner Judith, 2016, Oncotarget, V7, P77591, DOI 10.18632/oncotarget.12728; Hagenbuchner J, 2012, J CELL SCI, V125, P1191, DOI 10.1242/jcs.092098; Harada Y, 2010, J EXP MED, V207, P1381, DOI 10.1084/jem.20100004; Hou J, 2015, LUMINESCENCE, V30, P780, DOI 10.1002/bio.2820; Hui RCY, 2008, MOL CELL BIOL, V28, P5886, DOI 10.1128/MCB.01265-07; Hui RCY, 2008, MOL CANCER THER, V7, P670, DOI 10.1158/1535-7163.MCT-07-0397; Hurtz C, 2011, J EXP MED, V208, P2163, DOI 10.1084/jem.20110304; Jiang JX, 2016, BMC CELL BIOL, V17, DOI 10.1186/s12860-016-0094-8; Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897; Karki S, 2015, ARTERIOSCL THROM VAS, V35, P1498, DOI 10.1161/ATVBAHA.114.305139; Komatsu N, 2003, J BIOL CHEM, V278, P6411, DOI 10.1074/jbc.M211562200; Kumazoe M, 2017, ONCOGENE, V36, P2643, DOI 10.1038/onc.2016.426; Kumazoe M, 2017, J BIOL CHEM, V292, P10813, DOI 10.1074/jbc.M116.772111; Li DY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132998; Li DY, 2009, J CEREBR BLOOD F MET, V29, P1903, DOI 10.1038/jcbfm.2009.102; Maiese Kenneth, 2016, J Transl Sci, V2, P241; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Matkar S, 2015, CANCER CELL, V28, P472, DOI 10.1016/j.ccell.2015.09.005; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Moosavi MA, 2011, DARU, V19, P455; Nagashima T, 2010, MOL PHARMACOL, V78, P961, DOI 10.1124/mol.110.065714; Naka K, 2010, CANCER SCI, V101, P1577, DOI 10.1111/j.1349-7006.2010.01584.x; Naka K, 2010, NATURE, V463, P676, DOI 10.1038/nature08734; Narath R, 2005, CYTOM PART A, V68A, P113, DOI 10.1002/cyto.a.20190; Nikolovska-Coleska Z, 2004, ANAL BIOCHEM, V332, P261, DOI 10.1016/j.ab.2004.05.055; O'Carroll SJ, 2013, METHODS MOL BIOL, V1037, P519, DOI 10.1007/978-1-62703-505-7_31; Obexer P, 2007, CELL DEATH DIFFER, V14, P534, DOI 10.1038/sj.cdd.4402017; Obsil T, 2008, ONCOGENE, V27, P2263, DOI 10.1038/onc.2008.20; Obsil T, 2011, BBA-MOL CELL RES, V1813, P1946, DOI 10.1016/j.bbamcr.2010.11.025; Opel D, 2007, CANCER RES, V67, P735, DOI 10.1158/0008-5472.CAN-06-2201; Osuka S, 2013, STEM CELLS, V31, P627, DOI 10.1002/stem.1328; Ouyang W, 2010, NAT IMMUNOL, V11, P618, DOI 10.1038/ni.1884; Pan CW, 2017, EMBO J, V36, P995, DOI 10.15252/embj.201695534; Pellicano F, 2014, STEM CELLS, V32, P2324, DOI 10.1002/stem.1748; Qian ZR, 2017, INT J CANCER, V140, P2792, DOI 10.1002/ijc.30690; Qin WP, 2008, ANN NY ACAD SCI, V1147, P335, DOI 10.1196/annals.1427.024; Rupp M, 2017, ONCOGENE, V36, P6190, DOI 10.1038/onc.2017.288; Saha P, 2015, MOL CELL NEUROSCI, V68, P203, DOI 10.1016/j.mcn.2015.08.002; Salcher S, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0661-4; Salcher S, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-224; Sandeep TC, 2004, P NATL ACAD SCI USA, V101, P6734, DOI 10.1073/pnas.0306996101; Sanna PP, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.13; Santamaria CM, 2009, LEUKEMIA RES, V33, P1706, DOI 10.1016/j.leukres.2009.04.024; Savai R, 2014, NAT MED, V20, P1289, DOI 10.1038/nm.3695; Shi C, 2016, J BIOENERG BIOMEMBR, V48, P189, DOI 10.1007/s10863-016-9645-0; Shi C, 2016, J CELL SCI, V129, P1815, DOI 10.1242/jcs.185009; Storz P, 2009, MOL CELL BIOL, V29, P4906, DOI 10.1128/MCB.00077-09; Sun LQ, 2018, BEHAV BRAIN RES, V337, P271, DOI 10.1016/j.bbr.2017.08.042; Sykes SM, 2011, CELL, V146, P697, DOI 10.1016/j.cell.2011.07.032; Takeuchi H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021050; Tan P, 2015, SCI REP, V5; Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772; Tsai KL, 2007, NUCLEIC ACIDS RES, V35, P6984, DOI 10.1093/nar/gkm703; van Boxtel R, 2013, CELL DEATH DIFFER, V20, P1219, DOI 10.1038/cdd.2013.81; Wilson MSC, 2011, CURR DRUG TARGETS, V12, P1256; Wolber G, 2005, J CHEM INF MODEL, V45, P160, DOI 10.1021/ci049885e; Wong HKA, 2013, HUM MOL GENET, V22, P3077, DOI 10.1093/hmg/ddt164; Xu K, 2017, ONCOL REP, V37, P2391, DOI 10.3892/or.2017.5459; Yoo KY, 2012, NEUROCHEM RES, V37, P588, DOI 10.1007/s11064-011-0648-2; Yu YY, 2016, ONCOTARGET, V7, P80888, DOI 10.18632/oncotarget.13105; Yulyana Y, 2013, STEM CELLS DEV, V22, P1870, DOI 10.1089/scd.2012.0529; Zeldich E, 2014, J BIOL CHEM, V289, P24700, DOI 10.1074/jbc.M114.567321; Zhou LQ, 2018, MOL MED REP, V17, P5684, DOI 10.3892/mmr.2018.8624; Zhou YP, 2018, IUBMB LIFE, V70, P276, DOI 10.1002/iub.1699; Zou P, 2014, CELL CYCLE, V13, P3759, DOI 10.4161/15384101.2014.965977	80	18	20	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	5					1080	1097		10.1038/s41388-019-1044-7	http://dx.doi.org/10.1038/s41388-019-1044-7			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KI2VY	31591479	Green Published, hybrid			2022-12-28	WOS:000511209700010
J	Singh, K; Pruski, MA; Polireddy, K; Jones, NC; Chen, QZ; Yao, J; Dar, WA; McAllister, F; Ju, C; Eltzschig, HK; Younes, M; Moran, C; Karmouty-Quintana, H; Ying, HQ; Bailey, JM				Singh, Kanchan; Pruski, Melissa A.; Polireddy, Kishore; Jones, Neal C.; Chen, Qingzheng; Yao, Jun; Dar, Wasim A.; McAllister, Florencia; Ju, Cynthia; Eltzschig, Holger K.; Younes, Mamoun; Moran, Cesar; Karmouty-Quintana, Harry; Ying, Haoqiang; Bailey, Jennifer M.			Mst1/2 kinases restrain transformation in a novel transgenic model of Ras driven non-small cell lung cancer	ONCOGENE			English	Article							YES-ASSOCIATED PROTEIN; TUMOR-ASSOCIATED MACROPHAGES; HIPPO SIGNALING PATHWAY; ONCOGENIC KRAS; CLINICAL-IMPLICATIONS; MOUSE MODELS; GROWTH; YAP; MUTATIONS; PROLIFERATION	Non-small cell lung cancer remains a highly lethal malignancy. Using the tamoxifen inducible Hnf1b:CreER(T2) (H) transgenic mouse crossed to the LsL-Kras(G12D) (K) transgenic mouse, we recently discovered that an Hnf1b positive cell type in the lung is sensitive to adenoma formation when expressing a mutant Kras(G12D) allele. In these mice, we observe adenoma formation over a time frame of three to six months. To study specificity of the inducible Hnf1b:CreER(T2) in the lung, we employed lineage tracing using an mTmG (G) reporter allele. This technique revealed recombined, GFP+ cells were predominantly SPC+. We further employed this technique in HKG mice to determine Hnf1b+ cells give rise to adenomas that express SPC and TTF1. Review of murine lung tissue confirmed a diagnosis of adenoma and early adenocarcinoma, a pathologic subtype of non-small cell lung cancer. Our expanded mouse model revealed loss of Mst1/2 promotes aggressive lung adenocarcinoma and large-scale proteomic analysis revealed upregulation of PKM2 in the lungs of mice with genetic deletion of Mst1/2. PKM2 is a known metabolic regulator in proliferating cells and cancer. Using a human lung adenocarcinoma cell line, we show pharmacologic inhibition of Mst1/2 increases the abundance of PKM2, indicating genetic loss or pharmacologic inhibition of Mst1/2 directly modulates the abundance of PKM2. In conclusion, here we report a novel model of non-small cell lung cancer driven by a mutation in Kras and deletion of Mst1/2 kinases. Tumor development is restricted to a subset of alveolar type II cells expressing Hnf1b. Our data show loss of Mst1/2 regulates levels of a potent metabolic regulator, PKM2.	[Singh, Kanchan; Pruski, Melissa A.; Polireddy, Kishore; Jones, Neal C.; Chen, Qingzheng; Bailey, Jennifer M.] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Internal Med, Div Gastroenterol Hepatol & Nutr, Houston, TX 77030 USA; [Yao, Jun; Ying, Haoqiang] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Dar, Wasim A.] Univ Texas Hlth Sci Ctr Houston, Dept Surg, Div Immunol & Organ Transplantat, Houston, TX 77030 USA; [McAllister, Florencia] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA; [Ju, Cynthia; Eltzschig, Holger K.] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Anesthesiol, Houston, TX 77030 USA; [Younes, Mamoun] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Pathol, Houston, TX 77030 USA; [Moran, Cesar] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Karmouty-Quintana, Harry] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Biochem, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston	Bailey, JM (corresponding author), Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Internal Med, Div Gastroenterol Hepatol & Nutr, Houston, TX 77030 USA.	Jennifer.M.Bailey@uth.tmc.edu	Karmouty-Quintana, Harry/ABC-9144-2020; Ying, Haoqiang/AAK-4325-2020	Karmouty-Quintana, Harry/0000-0003-4753-9823; Dar, Wasim/0000-0001-8095-248X; Bailey-Lundberg, Jennifer/0000-0002-4750-106X; Younes, Mamoun/0000-0001-9618-3451	AACR/Pancreatic Cancer Action Network Pathway to Leadership Award; NIH [T35 DK007676-22]; National Institute of Health Grants [R01 DK097075, POI-HL114457, R01-HL109233, R01-DK109574, R01-HL119837, R01-HL133900]	AACR/Pancreatic Cancer Action Network Pathway to Leadership Award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Health Grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We would like to thank Bingqian Hu and Junlan Zhang for assistance with lung perfusions. We also thank Naveen Manisundaram for intellectual insights and discussions. JMB is supported by the AACR/Pancreatic Cancer Action Network Pathway to Leadership Award. NCJ is supported by NIH T35 DK007676-22. HKE is supported by National Institute of Health Grants R01 DK097075, POI-HL114457, R01-HL109233, R01-DK109574, R01-HL119837, and R01-HL133900.	Abdulkareem FB, 2012, HISTOPATHOLOGY, V61, P74; Aguirre AJ, 2017, CANCER CELL, V32, P185, DOI 10.1016/j.ccell.2017.07.007; [Anonymous], CURR PROTOC PHARM; Bailey JM, 2016, ONCOGENE, V35, P4282, DOI 10.1038/onc.2015.441; Cancer Genome Atlas Research Network, 2014, Nature, V511, P543, DOI [10.1038/s41586-018-0228-6, 10.1038/nature13385]; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Chen HY, 2015, J CLIN ONCOL, V33, P2303, DOI 10.1200/JCO.2014.59.3590; Cinar B, 2007, EMBO J, V26, P4523, DOI 10.1038/sj.emboj.7601872; Ciuffreda L, 2014, CURR PHARM DESIGN, V20, P3944, DOI 10.2174/13816128113196660763; Clarke CN, 2017, ANN SURG ONCOL, V24, P4051, DOI 10.1245/s10434-017-6054-5; Collins MA, 2012, J CLIN INVEST, V122, P639, DOI 10.1172/JCI59227; Cooper WN, 2009, ONCOGENE, V28, P2988, DOI 10.1038/onc.2009.152; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; Creighton CJ, 2015, DRUG DES DEV THER, V9, P3519, DOI 10.2147/DDDT.S38375; De Vas MG, 2015, DEVELOPMENT, V142, P871, DOI 10.1242/dev.110759; Dong GC, 2016, ONCOL LETT, V11, P1980, DOI 10.3892/ol.2016.4168; Du Di, 2018, Oncotarget, V9, P19704, DOI 10.18632/oncotarget.24803; Ehmer U, 2016, MOL CANCER RES, V14, P127, DOI 10.1158/1541-7786.MCR-15-0305; Fritz JM, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00587; Gao YJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5629; Gomez Daniel Richard, 2018, Oncotarget, V9, P14268, DOI 10.18632/oncotarget.24361; Guo LW, 2015, INT J ONCOL, V46, P1444, DOI 10.3892/ijo.2015.2877; Halder G, 2011, DEVELOPMENT, V138, P9, DOI 10.1242/dev.045500; Hitosugi T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000431; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jeong H, 2019, CANCER RES, V79, P795, DOI 10.1158/0008-5472.CAN-18-2545; Johansson Leif, 2004, Ann Diagn Pathol, V8, P259, DOI 10.1016/j.anndiagpath.2004.07.001; Ju R, 2012, EUR J CANCER, V48, P1085, DOI 10.1016/j.ejca.2011.06.050; Kapoor A, 2014, CELL, V158, P185, DOI 10.1016/j.cell.2014.06.003; Kim HB, 2018, BMB REP, V51, P119, DOI 10.5483/BMBRep.2018.51.3.018; Kimmelman AC, 2015, CLIN CANCER RES, V21, P1828, DOI 10.1158/1078-0432.CCR-14-2425; Kwak I, 2004, ANNU REV PHYSIOL, V66, P647, DOI 10.1146/annurev.physiol.66.032102.134301; Li H, 2019, PATHOL RES PRACT, V215, DOI 10.1016/j.prp.2019.04.001; Li RZ, 2018, CHEM BIOL DRUG DES, V92, P1851, DOI 10.1111/cbdd.13354; Liu VM, 2015, BRAIN PATHOL, V25, P781, DOI 10.1111/bpa.12311; Lu L, 2010, P NATL ACAD SCI USA, V107, P1437, DOI 10.1073/pnas.0911427107; Lunt SY, 2015, MOL CELL, V57, P95, DOI 10.1016/j.molcel.2014.10.027; Ma YL, 2015, INT J CANCER, V137, P2275, DOI 10.1002/ijc.29073; MALKINSON AM, 1989, TOXICOLOGY, V54, P241, DOI 10.1016/0300-483X(89)90062-0; Meuwissen R, 2005, GENE DEV, V19, P643, DOI 10.1101/gad.1284505; MILLER MS, 1994, CHEM RES TOXICOL, V7, P471, DOI 10.1021/tx00040a001; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Polireddy K, 2019, CANCER LETT, V453, P122, DOI 10.1016/j.canlet.2019.03.047; Prior IA, 2012, CANCER RES, V72, P2457, DOI 10.1158/0008-5472.CAN-11-2612; Rizvi S, 2016, J BIOL CHEM, V291, P8031, DOI 10.1074/jbc.M115.698472; Romero R, 2017, NAT MED, V23, P1362, DOI 10.1038/nm.4407; Santinon G, 2016, TRENDS CELL BIOL, V26, P289, DOI 10.1016/j.tcb.2015.11.004; Schneider J, 2003, CANCER LETT, V193, P91, DOI 10.1016/S0304-3835(02)00720-6; Seidel C, 2007, MOL CARCINOGEN, V46, P865, DOI 10.1002/mc.20317; Steinhardt AA, 2008, HUM PATHOL, V39, P1582, DOI 10.1016/j.humpath.2008.04.012; Sutherland KD, 2014, P NATL ACAD SCI USA, V111, P4952, DOI 10.1073/pnas.1319963111; Teoh SL, 2017, CURR DRUG TARGETS, V18, P1880, DOI 10.2174/1389450117666160907153338; Tuveson DA, 1999, ONCOGENE, V18, P5318, DOI 10.1038/sj.onc.1203107; Vasan N, 2014, CLIN CANCER RES, V20, P3921, DOI 10.1158/1078-0432.CCR-13-1762; Wang R, 2011, LUNG CANCER, V74, P188, DOI 10.1016/j.lungcan.2011.04.009; Wang Y, 2010, CANCER SCI, V101, P1279, DOI 10.1111/j.1349-7006.2010.01511.x; Xu CM, 2013, CANCER GENE THER, V20, P453, DOI 10.1038/cgt.2013.40; Xu Chen, 2012, Chinese Journal of Pathology, V41, P667, DOI 10.3760/cma.j.issn.0529-5807.2012.10.005; Yang WW, 2013, CELL CYCLE, V12, P3154, DOI 10.4161/cc.26182; Ye S, 2016, PHARMACOL RES, V103, P270, DOI 10.1016/j.phrs.2015.11.025; Yeung B, 2016, INT J CANCER, V138, P533, DOI 10.1002/ijc.29457; Ying HQ, 2016, GENE DEV, V30, P355, DOI 10.1101/gad.275776.115; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zhang L, 2009, BIOINFORMATICS, V25, P650, DOI 10.1093/bioinformatics/btn663; Zhang X, 2011, ONCOGENE, V30, P2810, DOI 10.1038/onc.2011.8; Zhou DW, 2011, P NATL ACAD SCI USA, V108, pE1312, DOI 10.1073/pnas.1110428108; Zhou DW, 2009, CANCER CELL, V16, P425, DOI 10.1016/j.ccr.2009.09.026; Zhou JX, 2013, ANN ONCOL, V24, P1319, DOI 10.1093/annonc/mds626; Zou SS, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6696	73	10	11	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	5					1152	1164		10.1038/s41388-019-1031-z	http://dx.doi.org/10.1038/s41388-019-1031-z			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KI2VY	31570790				2022-12-28	WOS:000511209700015
J	Jin, GG; Yan, MY; Liu, KD; Yao, K; Chen, HY; Zhang, CJ; Yi, Y; Reddy, K; Gorja, DR; Laster, KV; Guo, ZP; Dong, ZG				Jin, Guoguo; Yan, Mingyang; Liu, Kangdong; Yao, Ke; Chen, Hanyong; Zhang, Chengjuan; Yi, Yang; Reddy, Kanamata; Gorja, Dhilli Rao; Laster, Kyle Vaughn; Guo, Zhiping; Dong, Zigang			Discovery of a novel dual-target inhibitor against RSK1 and MSK2 to suppress growth of human colon cancer	ONCOGENE			English	Article							RIBOSOMAL S6 KINASE; PROTEIN; ACTIVATION; FAMILY; PHOSPHORYLATION; MAPK	Colon cancer is the most aggressive tumor in both men and women globally. As many the chemotherapeutic regimens have adverse side effects and contribute to the resistance and recurrence, therefore, finding novel therapeutic targets and developing effective agents are urgent. Based on the TCGA and GTEx database analysis, RSK1 and MSK2 were found abnormal expressed in colon cancer. RSK1 and MSK2 were overexpressed in colon cancer tissues confirmed by western blot and IHC. After knocking down RSK1 or MSK2, cell proliferation and anchorage-independent cell growth were markedly inhibited. Using a computer docking model, we identified a novel dual-target inhibitor, APIO-EE-07, that could block both RSK1 and MSK2 kinase activity in a dose-dependent manner. APIO-EE-07 inhibited cell growth and induced apoptosis and also increased expression of Bax as well as cleaved caspase-3 and -PARP in colon cancer cells by downregulating RSK1 and MSK2 downstream targets, including CREB and ATF1. Furthermore, APIO-EE-07 decreased tumor volume and weight in human patient-derived xenografts tumors implanted in SCID mice. In summary, our results demonstrate that RSK1 and MSK2 are the potential targets for the treatment of colon cancer. APIO-EE-07, a novel dual-target inhibitor of RSK1 and MSK2, can suppress the growth of colon cancer by attenuating RSK1 and MSK2 signaling.	[Jin, Guoguo; Guo, Zhiping] Henan Luoyang Orthoped Hosp, Zhengzhou, Henan, Peoples R China; [Jin, Guoguo; Yan, Mingyang; Liu, Kangdong; Gorja, Dhilli Rao; Laster, Kyle Vaughn; Dong, Zigang] China US Henan Hormel Canc Inst, Zhengzhou, Peoples R China; [Jin, Guoguo; Liu, Kangdong] Zhengzhou Univ, Henan Prov Cooperat Innovat Ctr Canc Chemoprevent, Zhengzhou, Henan, Peoples R China; [Liu, Kangdong; Dong, Zigang] Zhengzhou Univ, Coll Med, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou, Henan, Peoples R China; [Yao, Ke; Chen, Hanyong; Reddy, Kanamata] Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA; [Zhang, Chengjuan] Zhengzhou Univ, Affiliated Tumor Hosp, Ctr Bio Repository, Zhengzhou, Henan, Peoples R China; [Yi, Yang] Henan Univ Chinese Med, Sch Basic Med Sci, Dept Pathol & Pathophysiol, Zhengzhou, Henan, Peoples R China	Zhengzhou University; Zhengzhou University; University of Minnesota System; Zhengzhou University; Henan University of Traditional Chinese Medicine	Guo, ZP (corresponding author), Henan Luoyang Orthoped Hosp, Zhengzhou, Henan, Peoples R China.; Dong, ZG (corresponding author), China US Henan Hormel Canc Inst, Zhengzhou, Peoples R China.; Dong, ZG (corresponding author), Zhengzhou Univ, Coll Med, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou, Henan, Peoples R China.	Zhiping74@hotmail.com; zgdong@hci-cn.org			Key Science and Technology Program of Henan Province, China [182102310125]; Key program of TCM research in Henan Province, China [2018ZY1016, 2019ZY1037]	Key Science and Technology Program of Henan Province, China; Key program of TCM research in Henan Province, China	This work was supported by the Key Science and Technology Program of Henan Province, China (182102310125) and the Key program of TCM research in Henan Province, China (2018ZY1016, 2019ZY1037).	Anjum R, 2008, NAT REV MOL CELL BIO, V9, P747, DOI 10.1038/nrm2509; [Anonymous], 2019, SCHROD SUIT 2019; Arthur JSC, 2004, J NEUROSCI, V24, P4324, DOI 10.1523/JNEUROSCI.5227-03.2004; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bode AM, 2018, NPJ PRECIS ONCOL, V2, DOI 10.1038/s41698-018-0055-0; Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031-10; Clark DE, 2005, CANCER RES, V65, P3108; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Doehn U, 2009, MOL CELL, V35, P511, DOI 10.1016/j.molcel.2009.08.002; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Giselle R, 2002, MOL CELL BIOL, V8, P2871; Hidalgo M, 2014, CANCER DISCOV, V4, P998, DOI 10.1158/2159-8290.CD-14-0001; Houles T, 2018, SEMIN CANCER BIOL, V48, P53, DOI 10.1016/j.semcancer.2017.04.016; Hutchinson L, 2011, NAT REV CLIN ONCOL, V8, P189, DOI [10.1038/nrclinonc.2010.204, 10.1038/nrclinonc.2011.34]; Jideh B, 2018, MED J AUSTRALIA, V208, P483, DOI 10.5694/mja18.00279; Jin GG, 2017, ONCOTARGET, V8, P53387, DOI 10.18632/oncotarget.18508; Lara R, 2013, CANCER RES, V73, P5301, DOI 10.1158/0008-5472.CAN-12-4448; Lee YT, 2018, EUR J PHARMACOL, V834, P188, DOI 10.1016/j.ejphar.2018.07.034; Liu HY, 2014, NEUROCHEM RES, V39, P2479, DOI 10.1007/s11064-014-1452-6; Liu KD, 2011, J BIOL CHEM, V286, P2057, DOI 10.1074/jbc.M110.147306; Ludwik KA, 2016, MOL CANCER THER, V15, P2598, DOI 10.1158/1535-7163.MCT-16-0106; Markad SB, 2014, ORG LETT, V16, P5470, DOI 10.1021/ol502721r; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Reyskens KMSE, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00056; Rodriguez-Antona C, 2010, ENDOCR-RELAT CANCER, V17, P7, DOI 10.1677/ERC-08-0304; Roig AI, 2010, GASTROENTEROLOGY, V138, P1012, DOI 10.1053/j.gastro.2009.11.052; Romeo Y, 2012, BIOCHEM J, V441, P553, DOI 10.1042/BJ20110289; Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395; Smith JA, 2005, CANCER RES, V65, P1027; Strelkov IS, 2002, CANCER RES, V62, P75; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; Xian W, 2009, CANCER RES, V69, P2244, DOI 10.1158/0008-5472.CAN-08-3398; Yao K, 2014, CANCER PREV RES, V7, P958, DOI 10.1158/1940-6207.CAPR-14-0126; Ye D, 2019, J MOL NEUROSCI, V68, P475, DOI 10.1007/s12031-019-01309-9	35	3	3	2	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2020	39	43					6733	6746		10.1038/s41388-020-01467-w	http://dx.doi.org/10.1038/s41388-020-01467-w		SEP 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OF2UT	32963350				2022-12-28	WOS:000572030400002
J	Yuan, JP; Song, YM; Pan, WT; Li, YK; Xu, YY; Xie, MY; Shen, Y; Zhang, NS; Liu, JD; Hua, H; Wang, BW; An, CM; Yang, M				Yuan, Jupeng; Song, Yemei; Pan, Wenting; Li, Yankang; Xu, Yeyang; Xie, Mengyu; Shen, Yue; Zhang, Nasha; Liu, Jiandong; Hua, Hui; Wang, Bowen; An, Changming; Yang, Ming			LncRNA SLC26A4-AS1 suppresses the MRN complex-mediated DNA repair signaling and thyroid cancer metastasis by destabilizing DDX5	ONCOGENE			English	Article							PENDRED-SYNDROME; COMMON VARIANTS; GENE; PAPILLARY; CARCINOMA; RISK; ASSOCIATION; ACTIVATION; E2F-1; FOXE1	Lymph node metastasis is the major adverse feature for recurrence and death of thyroid cancer patients. To identify lncRNAs involved in thyroid cancer metastasis, we systemically screened differentially expressed lncRNAs in lymph node metastasis, thyroid cancer, and normal tissues via RNAseq. We found that lncRNA SLC26A4-AS1 was continuously, significantly down-regulated in normal tissues, thyroid cancer, and lymph node metastasis specimens. Low SLC26A4-AS1 levels in tissues were significantly associated with poor prognosis of thyroid cancer patients. LncRNA SLC26A4-AS1 markedly inhibited migration, invasion, and metastasis capability of cancer cells in vitro and in vivo. Intriguingly, SLC26A4-AS1 could simultaneously interact with DDX5 and the E3 ligase TRIM25, which promoting DDX5 degradation through the ubiquitin-proteasome pathway. In particular, SLC26A4-AS1 inhibited expression of multiple DNA double-strand breaks (DSBs) repair genes, especially genes coding proteins in the MRE11/RAS50/NBS1 (MRN) complex. Enhanced interaction between DDX5 and transcriptional factor E2F1 due to silencing of SLC26A4-AS1 promoted binding of the DDX5-E2F1 complex at promoters of the MRN genes and, thus, stimulate the MRN/ATM dependent DSB signaling and thyroid cancer metastasis. Our study uncovered new insights into the biology driving thyroid cancer metastasis and highlights potentials of lncRNAs as future therapeutic targets again cancer metastasis.	[Yuan, Jupeng; Song, Yemei; Pan, Wenting; Li, Yankang; Xu, Yeyang; Xie, Mengyu; Shen, Yue; Zhang, Nasha; Liu, Jiandong; Hua, Hui; Wang, Bowen; Yang, Ming] Shandong First Med Univ, Shandong Canc Hosp & Inst, Canc Res Ctr, Shandong Prov Key Lab Radiat Oncol, Jinan, Shandong, Peoples R China; [Yuan, Jupeng; Song, Yemei; Pan, Wenting; Li, Yankang; Xu, Yeyang; Xie, Mengyu; Shen, Yue; Zhang, Nasha; Liu, Jiandong; Hua, Hui; Wang, Bowen; Yang, Ming] Shandong Acad Med Sci, Jinan, Shandong, Peoples R China; [Li, Yankang; Xu, Yeyang; Xie, Mengyu; Shen, Yue; Wang, Bowen] Shandong Univ, Cheeloo Coll Med, Jinan, Shandong, Peoples R China; [An, Changming] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Canc Hosp, Dept Head & Neck Surg, Beijing, Peoples R China	Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong First Medical University & Shandong Academy of Medical Sciences; University of Jinan; Shandong University; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College	Yang, M (corresponding author), Shandong First Med Univ, Shandong Canc Hosp & Inst, Canc Res Ctr, Shandong Prov Key Lab Radiat Oncol, Jinan, Shandong, Peoples R China.; Yang, M (corresponding author), Shandong Acad Med Sci, Jinan, Shandong, Peoples R China.; An, CM (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Canc Hosp, Dept Head & Neck Surg, Beijing, Peoples R China.	anchangming@cicams.ac.cn; aaryoung@yeah.net	Yang, Ming/G-4705-2012	Yang, Ming/0000-0002-7722-7487; Yuan, Jupeng/0000-0003-1817-7771	National Natural Science Foundation of China [31671300, 31871306, 81702276]; Taishan Scholars Program of Shandong Province [tsqn20161060]; Program of Science and Technology for the youth innovation team in universities of Shandong Province [2020KJL001]; Natural Science Foundation of Shandong Province [ZR2016HQ48, ZR2019LZL011]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Taishan Scholars Program of Shandong Province; Program of Science and Technology for the youth innovation team in universities of Shandong Province; Natural Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province)	This work was supported by National Natural Science Foundation of China (31671300, 31871306, 81702276); Taishan Scholars Program of Shandong Province (tsqn20161060); Program of Science and Technology for the youth innovation team in universities of Shandong Province (2020KJL001); Natural Science Foundation of Shandong Province (ZR2016HQ48, ZR2019LZL011). The authors would like to thank many individuals who participated in the study.	Anastasiadou E, 2018, NAT REV CANCER, V18, P5, DOI 10.1038/nrc.2017.99; Bian L, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1100-5; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Evans JR, 2016, J CLIN INVEST, V126, P2775, DOI 10.1172/JCI84421; Everett LA, 1997, NAT GENET, V17, P411, DOI 10.1038/ng1297-411; Figlioli G, 2014, J CLIN ENDOCR METAB, V99, pE2084, DOI 10.1210/jc.2014-1734; Gao P, 2018, CELL, V174, P576, DOI 10.1016/j.cell.2018.06.003; Gudmundsson J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14517; Gudmundsson J, 2012, NAT GENET, V44, P319, DOI 10.1038/ng.1046; Gudmundsson J, 2009, NAT GENET, V41, P460, DOI 10.1038/ng.339; Gugnoni M, 2021, THYROID, V31, P247, DOI 10.1089/thy.2020.0001; He HL, 2015, P NATL ACAD SCI USA, V112, P6128, DOI 10.1073/pnas.1506255112; He HL, 2015, J CLIN ENDOCR METAB, V100, pE164, DOI 10.1210/jc.2014-2147; Hua JT, 2018, CELL, V174, P564, DOI 10.1016/j.cell.2018.06.014; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; Hwangbo Y, 2018, J CLIN ENDOCR METAB, V103, P4384, DOI 10.1210/jc.2017-02439; Jendrzejewski J, 2019, INT J CANCER, V144, P503, DOI 10.1002/ijc.31933; Jendrzejewski J, 2012, P NATL ACAD SCI USA, V109, P8646, DOI 10.1073/pnas.1205654109; Kim SY, 2018, WORLD J SURG, V42, P123, DOI 10.1007/s00268-017-4158-5; Knoll M, 2015, NAT REV ENDOCRINOL, V11, P151, DOI 10.1038/nrendo.2014.229; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Li HJ, 2021, FEBS J, V288, P212, DOI 10.1111/febs.15325; Liang WW, 2019, PEERJ, V7, DOI 10.7717/peerj.7441; Liyanarachchi S, 2020, P NATL ACAD SCI USA, V117, P5997, DOI 10.1073/pnas.1919976117; Mao JX, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00265; Mazurek A, 2012, CANCER DISCOV, V2, P812, DOI 10.1158/2159-8290.CD-12-0116; Muhanhali D, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00360; Nyamao RM, 2019, BBA-REV CANCER, V1871, P85, DOI 10.1016/j.bbcan.2018.11.003; Onda M, 2004, J HUM GENET, V49, P312, DOI 10.1007/s10038-004-0146-3; Pan WT, 2018, J BIOL CHEM, V293, P17154, DOI 10.1074/jbc.RA118.003055; Rao YS, 2020, COMPUT MATH METHOD M, V2020, DOI 10.1155/2020/3651051; Raudvere U, 2019, NUCLEIC ACIDS RES, V47, pW191, DOI 10.1093/nar/gkz369; Reginato G, 2020, DNA REPAIR, V91-92, DOI 10.1016/j.dnarep.2020.102869; Ren YL, 2017, J BIOL CHEM, V292, P17939, DOI 10.1074/jbc.M116.773978; Saiz AD, 2002, J PATHOL, V198, P157, DOI 10.1002/path.1185; Son HY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15966; Swierniak M, 2016, CLIN CANCER RES, V22, P1111, DOI 10.1158/1078-0432.CCR-15-1746; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Wang DP, 2020, J CELL PHYSIOL, V235, P2403, DOI 10.1002/jcp.29145; Wang YQ, 2017, P NATL ACAD SCI USA, V114, P474, DOI 10.1073/pnas.1619917114; Xing MZ, 2003, CANCER RES, V63, P2312; Xu XQ, 2007, GENOME RES, V17, P1550, DOI 10.1101/gr.6783507; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; Yuan JP, 2015, J PATHOL, V235, P784, DOI 10.1002/path.4492; Zhu H, 2016, SCI REP-UK, V6, DOI 10.1038/srep31969	46	29	29	3	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2020	39	43					6664	6676		10.1038/s41388-020-01460-3	http://dx.doi.org/10.1038/s41388-020-01460-3		SEP 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OF2UT	32939012				2022-12-28	WOS:000570051900001
J	Bongiovanni, D; Tosello, V; Saccomani, V; Dalla Santa, S; Amadori, A; Zanovello, P; Piovan, E				Bongiovanni, Deborah; Tosello, Valeria; Saccomani, Valentina; Dalla Santa, Silvia; Amadori, Alberto; Zanovello, Paola; Piovan, Erich			Crosstalk between Hedgehog pathway and the glucocorticoid receptor pathway as a basis for combination therapy in T-cell acute lymphoblastic leukemia	ONCOGENE			English	Article							FLOOR PLATE; TRANSCRIPTION; ACTIVATION; MECHANISM; AGONISTS; ROLES; GLI2; HES1	Notwithstanding intensified therapy, a considerable fraction of T-cell acute lymphoblastic leukemia (T-ALL) patients face a dismal prognosis due to primary resistance to treatment and relapse, raising the need for more efficient and targeted therapies. Hedgehog (HH) signaling is a major developmental pathway frequently deregulated in cancer, for which a role in T-ALL is emerging. Mounting evidence suggests that ligand-independent activation of HH pathway occurs in cancer including T-ALL, emphasizing the necessity of dissecting the complex interplay between HH and other signaling pathways regulating activation. In this work, we present a therapeutically relevant crosstalk between HH signaling and the glucocorticoid receptor (NR3C1) pathway acting at the level of GLI1 transcription factor. GLI inhibitor GANT61 and dexamethasone were shown to exert a synergistic anti-leukemic effect in vitro in T-ALL cell lines and patient-derived xenografts. Mechanistically, dexamethasone-activated NR3C1 impaired GLI1 function by dynamically modulating the recruitment of PCAF acetyltransferase and HDAC1 deacetylase. Increased GLI1 acetylation was associated with compromised transcriptional activity and reduced protein stability. In summary, our study identifies a novel crosstalk between GLI1 and NR3C1 signaling pathway which could be exploited in HH-dependent malignancies to increase therapeutic efficacy.	[Bongiovanni, Deborah; Saccomani, Valentina; Dalla Santa, Silvia; Amadori, Alberto; Zanovello, Paola; Piovan, Erich] Univ Padua, Dipartimento Sci Chirurg Oncol & Gastroenterol, Padua, Italy; [Tosello, Valeria; Amadori, Alberto; Piovan, Erich] Ist Oncol Veneto IOV IRCCS, UOC Immunol & Diagnost Mol Oncol, Padua, Italy	University of Padua; IRCCS Istituto Oncologico Veneto (IOV)	Piovan, E (corresponding author), Univ Padua, Dipartimento Sci Chirurg Oncol & Gastroenterol, Padua, Italy.; Piovan, E (corresponding author), Ist Oncol Veneto IOV IRCCS, UOC Immunol & Diagnost Mol Oncol, Padua, Italy.	erich.piovan@unipd.it	Piovan, Erich/L-1444-2016	Piovan, Erich/0000-0002-4241-563X; Bongiovanni, Deborah/0000-0001-8693-4776	Italian Foundation for Cancer Research (Fondazione AIRC) [22233]; Progetto di Ricerca di Ateneo (Universita di Padova) [SID19_01]; Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR); Istituto Oncologico Veneto 5 x 1000 fund	Italian Foundation for Cancer Research (Fondazione AIRC); Progetto di Ricerca di Ateneo (Universita di Padova); Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR)(Ministry of Education, Universities and Research (MIUR)); Istituto Oncologico Veneto 5 x 1000 fund	This work was supported by the Italian Foundation for Cancer Research (Fondazione AIRC) grants to EP (IG2018#22233); Progetto di Ricerca di Ateneo (SID19_01; Universita di Padova) to EP. Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR) Ex 60% to EP; Istituto Oncologico Veneto 5 x 1000 fund to EP.	Amakye D, 2013, NAT MED, V19, P1410, DOI 10.1038/nm.3389; Belver L, 2016, NAT REV CANCER, V16, P494, DOI 10.1038/nrc.2016.63; Burns MA, 2018, LEUKEMIA, V32, P2126, DOI 10.1038/s41375-018-0097-x; Canettieri G, 2010, NAT CELL BIOL, V12, P132, DOI 10.1038/ncb2013; Chiang MY, 2008, J CLIN INVEST, V118, P3181, DOI 10.1172/JCI35090; Coni S, 2017, SCI REP-UK, V7, DOI 10.1038/srep44079; Coni S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065718; Crompton T, 2007, NAT REV IMMUNOL, V7, P726, DOI 10.1038/nri2151; Dagklis A, 2016, BLOOD, V128, P2642, DOI 10.1182/blood-2016-03-703454; Dagklis A, 2015, HAEMATOLOGICA, V100, pE102, DOI 10.3324/haematol.2014.119248; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Dierks C, 2007, NAT MED, V13, P944, DOI 10.1038/nm1614; Ding Q, 1998, DEVELOPMENT, V125, P2533; Fuccillo M, 2006, NAT REV NEUROSCI, V7, P772, DOI 10.1038/nrn1990; Gallet A, 2011, TRENDS CELL BIOL, V21, P238, DOI 10.1016/j.tcb.2010.12.005; Gruber W, 2018, INT J CANCER, V142, P968, DOI 10.1002/ijc.31117; Gulino A, 2012, VITAM HORM, V88, P211, DOI 10.1016/B978-0-12-394622-5.00009-2; Hegde GV, 2008, MOL CANCER RES, V6, P1928, DOI 10.1158/1541-7786.MCR-08-0142; Heine VM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002731; Heine VM, 2009, J CLIN INVEST, V119, P267, DOI 10.1172/JCI36376; HOECK W, 1989, J BIOL CHEM, V264, P14396; Hou XM, 2014, BIOCHIMIE, V101, P50, DOI 10.1016/j.biochi.2013.12.019; Hunger SP, 2015, NEW ENGL J MED, V373, P1541, DOI 10.1056/NEJMra1400972; Inaba H, 2010, LANCET ONCOL, V11, P1096, DOI 10.1016/S1470-2045(10)70114-5; Ingram WJ, 2008, ONCOGENE, V27, P1489, DOI 10.1038/sj.onc.1210767; Kassel O, 2007, MOL CELL ENDOCRINOL, V275, P13, DOI 10.1016/j.mce.2007.07.003; Malatesta M, 2013, CANCER RES, V73, P6323, DOI 10.1158/0008-5472.CAN-12-4660; Matise MP, 1998, DEVELOPMENT, V125, P2759; Newton R, 2007, MOL PHARMACOL, V72, P799, DOI 10.1124/mol.107.038794; Nieuwenhuis E, 2005, CLIN GENET, V67, P193, DOI 10.1111/j.1399-0004.2004.00360.x; Niewiadomski P, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8020147; Pak E, 2016, DEV CELL, V38, P333, DOI 10.1016/j.devcel.2016.07.026; Pandolfi S, 2015, EXPERT REV MOL MED, V17, DOI 10.1017/erm.2015.3; Persson M, 2002, GENE DEV, V16, P2865, DOI 10.1101/gad.243402; Petrova R, 2014, DEVELOPMENT, V141, P3445, DOI 10.1242/dev.083691; Pietrobono S, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00556; Ramsbottom SA, 2016, J DEV BIOL, V4, DOI 10.3390/jdb4030023; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Rubin LL, 2006, NAT REV DRUG DISCOV, V5, P1026, DOI 10.1038/nrd2086; SCHMIDT TJ, 1994, RECEPTOR, V4, P229; Schrappe M, 2011, BLOOD, V118, P2077, DOI 10.1182/blood-2011-03-338707; Schreck KC, 2010, CLIN CANCER RES, V16, P6060, DOI 10.1158/1078-0432.CCR-10-1624; Schwartz JR, 2010, MOL CELL ENDOCRINOL, V320, P76, DOI 10.1016/j.mce.2010.02.014; Tosello V, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7100160; Wang JB, 2011, VITAM HORM, V87, P207, DOI 10.1016/B978-0-12-386015-6.00030-5; Wang JB, 2010, P NATL ACAD SCI USA, V107, P9323, DOI 10.1073/pnas.0910712107; Wang Y, 2012, CHEM BIOL, V19, P972, DOI 10.1016/j.chembiol.2012.06.012; Wu FJ, 2017, CELL CHEM BIOL, V24, P252, DOI 10.1016/j.chembiol.2017.02.010; Ying LT, 2000, NAT NEUROSCI, V3, P979, DOI 10.1038/79916	49	4	4	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 15	2020	39	42					6544	6555		10.1038/s41388-020-01453-2	http://dx.doi.org/10.1038/s41388-020-01453-2		SEP 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OA9HI	32917954	Green Published			2022-12-28	WOS:000568475200003
J	Whitlock, NC; Trostel, SY; Wilkinson, S; Terrigino, NT; Hennigan, ST; Lake, R; Carrabba, NV; Atway, R; Walton, ED; Gryder, BE; Capaldo, BJ; Ye, HH; Sowalsky, AG				Whitlock, Nichelle C.; Trostel, Shana Y.; Wilkinson, Scott; Terrigino, Nicholas T.; Hennigan, S. Thomas; Lake, Ross; Carrabba, Nicole, V; Atway, Rayann; Walton, Elizabeth D.; Gryder, Berkley E.; Capaldo, Brian J.; Ye, Huihui; Sowalsky, Adam G.			MEIS1 down-regulation by MYC mediates prostate cancer development through elevated HOXB13 expression and AR activity	ONCOGENE			English	Article							GENE-EXPRESSION; C-MYC; ANDROGEN RECEPTOR; OVEREXPRESSION; CELL; DIFFERENTIATION; PROLIFERATION; ONCOGENE; PREDICTS; PROGRAMS	Localized prostate cancer develops very slowly in most men, with the androgen receptor (AR) and MYC transcription factors amongst the most well-characterized drivers of prostate tumorigenesis. Canonically, MYC up-regulation in luminal prostate cancer cells functions to oppose the terminally differentiating effects of AR. However, the effects of MYC up-regulation are pleiotropic and inconsistent with a poorly proliferative phenotype. Here we show that increased MYC expression and activity are associated with the down-regulation ofMEIS1, a HOX-family transcription factor. Using RNA-seq to profile a series of human prostate cancer specimens laser capture microdissected on the basis of MYC immunohistochemistry, MYC activity, andMEIS1expression were inversely correlated. Knockdown ofMYCexpression in prostate cancer cells increased the expression ofMEIS1and increased the occupancy of MYC at theMEIS1locus. Finally, we show in laser capture microdissected human prostate cancer samples and the prostate TCGA cohort thatMEIS1expression is inversely proportional to AR activity as well asHOXB13, a known interacting protein of both AR and MEIS1. Collectively, our data demonstrate that elevated MYC in a subset of primary prostate cancers functions in a negative role in regulatingMEIS1expression, and that this down-regulation may contribute to MYC-driven development and progression.	[Whitlock, Nichelle C.; Trostel, Shana Y.; Wilkinson, Scott; Terrigino, Nicholas T.; Hennigan, S. Thomas; Lake, Ross; Carrabba, Nicole, V; Atway, Rayann; Walton, Elizabeth D.; Capaldo, Brian J.; Sowalsky, Adam G.] NCI, Lab Genitourinary Canc Pathogenesis, NIH, Bethesda, MD 20892 USA; [Gryder, Berkley E.] NCI, Genet Branch, NIH, Bethesda, MD 20892 USA; [Ye, Huihui] Beth Israel Deaconess Med Ctr, Dept Pathol, 330 Brookline Ave, Boston, MA 02215 USA; [Ye, Huihui] Univ Calif Los Angeles, Dept Pathol, Los Angeles, CA 90095 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Beth Israel Deaconess Medical Center; University of California System; University of California Los Angeles	Sowalsky, AG (corresponding author), NCI, Lab Genitourinary Canc Pathogenesis, NIH, Bethesda, MD 20892 USA.	adam.sowalsky@nih.gov	Sowalsky, Adam/K-1485-2013	Sowalsky, Adam/0000-0003-2760-1853; Terrigino, Nicholas T./0000-0002-0829-8433; Carrabba, Nicole/0000-0003-4118-9690; Wilkinson, Scott/0000-0002-2613-8425	Prostate Cancer Foundation; Intramural Research Program of the NIH, National Cancer Institute	Prostate Cancer Foundation; Intramural Research Program of the NIH, National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the Prostate Cancer Foundation (Young Investigator Awards to SW, HY and AGS) and the Intramural Research Program of the NIH, National Cancer Institute.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Baena-Del Valle JA, 2018, J PATHOL, V244, P11, DOI 10.1002/path.4980; Bai SS, 2019, ONCOGENE, V38, P4977, DOI 10.1038/s41388-019-0768-8; Barfeld SJ, 2017, EBIOMEDICINE, V18, P83, DOI 10.1016/j.ebiom.2017.04.006; Barfeld SJ, 2015, ONCOTARGET, V6, P12587, DOI 10.18632/oncotarget.3494; Bhanvadia RR, 2018, CLIN CANCER RES, V24, P3668, DOI 10.1158/1078-0432.CCR-17-3673; Brechka H, 2017, GENES DIS, V4, P75, DOI 10.1016/j.gendis.2017.01.003; Calvo KR, 2002, ONCOGENE, V21, P4247, DOI 10.1038/sj.onc.1205516; Chen H, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-018-0008-7; Collins CT, 2016, CURR OPIN HEMATOL, V23, P354, DOI 10.1097/MOH.0000000000000245; Cui L, 2014, EXP CELL RES, V328, P58, DOI 10.1016/j.yexcr.2014.08.023; Cunningham D, 2015, J BIOL METHODS, V2; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Dang CV, 1999, MOL CELL BIOL, V19, P1; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Gallenne T, 2017, ONCOTARGET, V8, P20572, DOI 10.18632/oncotarget.16244; Gurel B, 2008, MODERN PATHOL, V21, P1156, DOI 10.1038/modpathol.2008.111; Hammarsten P, 2019, MODERN PATHOL, V32, P1310, DOI 10.1038/s41379-019-0260-6; Hawksworth D, 2010, PROSTATE CANCER P D, V13, P311, DOI 10.1038/pcan.2010.31; Johng D, 2019, PROSTATE, V79, P414, DOI 10.1002/pros.23747; Junttila MR, 2008, CELL CYCLE, V7, P592, DOI 10.4161/cc.7.5.5492; Koh CM, 2011, AM J PATHOL, V178, P1824, DOI 10.1016/j.ajpath.2010.12.040; Koh Cheryl M, 2010, Genes Cancer, V1, P617, DOI 10.1177/1947601910379132; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; Marcos S, 2015, DEVELOPMENT, V142, P3009, DOI 10.1242/dev.122176; Mendiratta P, 2009, J CLIN ONCOL, V27, P2022, DOI 10.1200/JCO.2008.17.2882; Neiman PE, 2001, P NATL ACAD SCI USA, V98, P6378, DOI 10.1073/pnas.111144898; Nie ZQ, 2012, CELL, V151, P68, DOI 10.1016/j.cell.2012.08.033; Norris JD, 2009, MOL CELL, V36, P405, DOI 10.1016/j.molcel.2009.10.020; Packer JR, 2016, BBA-MOL CELL RES, V1863, P1238, DOI 10.1016/j.bbamcr.2016.02.016; Park JW, 2016, P NATL ACAD SCI USA, V113, P4482, DOI 10.1073/pnas.1603645113; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Shaffer AL, 2006, IMMUNOL REV, V210, P67, DOI 10.1111/j.0105-2896.2006.00373.x; Sowalsky AG, 2018, CANCER RES, V78, P4716, DOI 10.1158/0008-5472.CAN-18-0610; Sowalsky AG, 2017, CLIN CANCER RES, V23, P3823, DOI 10.1158/1078-0432.CCR-16-2414; Takeda A, 2006, CANCER RES, V66, P6628, DOI 10.1158/0008-5472.CAN-06-0458; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tretiakova MS, 2016, PROSTATE CANCER P D, V19, P264, DOI 10.1038/pcan.2016.12; Trock BJ, 2016, MODERN PATHOL, V29, P764, DOI 10.1038/modpathol.2016.63; Varlakhanova N, 2011, EPIGENET CHROMATIN, V4, DOI 10.1186/1756-8935-4-20; Wang GG, 2005, BLOOD, V106, P254, DOI 10.1182/blood-2004-12-4664; Yang YA, 2015, GENES DIS, V2, P144, DOI 10.1016/j.gendis.2015.01.003; Yohe ME, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan4470	44	8	10	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2020	39	34					5663	5674		10.1038/s41388-020-01389-7	http://dx.doi.org/10.1038/s41388-020-01389-7		JUL 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NE9FK	32681068	Green Submitted, Green Published, hybrid			2022-12-28	WOS:000549696500001
J	Chen, J; Dang, YZ; Feng, WB; Qiao, CY; Liu, DF; Zhang, TY; Wang, YJ; Tian, D; Fan, DM; Nie, YZ; Wu, KC; Xia, LM				Chen, Jie; Dang, Yunzhi; Feng, Weibo; Qiao, Chenyang; Liu, Danfei; Zhang, Tongyue; Wang, Yijun; Tian, Dean; Fan, Daiming; Nie, Yongzhan; Wu, Kaichun; Xia, Limin			SOX18 promotes gastric cancer metastasis through transactivating MCAM and CCL7	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; COLORECTAL-CANCER; CARCINOMA; PROLIFERATION; EXPRESSION; INVASION; CHEMOKINES; MOLECULE; MELANOMA; CELLS	The therapeutic strategies for advanced gastric cancer (GC) remain unsatisfying and limited. Therefore, it is still imperative to fully elucidate the mechanisms underlying GC metastasis. Here, we report a novel role of SRY-box transcription factor 18 (SOX18), a member of the SOX family, in promoting GC metastasis. The elevated expression of SOX18 was positively correlated with distant metastasis, higher AJCC stage, and poor prognosis in human GC. SOX18 expression was an independent and significant risk factor for the recurrence and survival in GC patients. Up-regulation of SOX18 promoted GC invasion and metastasis, whereas down-regulation of SOX18 decreased GC invasion and metastasis. Melanoma cell adhesion molecule (MCAM) and C-C motif chemokine ligand 7 (CCL7) are direct transcriptional targets of SOX18. Knockdown of MCAM and CCL7 significantly decreased SOX18-mediated GC invasion and metastasis, while the stable overexpression of MCAM and CCL7 reversed the decrease in cell invasion and metastasis that was induced by the inhibition of SOX18. A mechanistic investigation indicated that the upregulation of SOX18 that was mediated by the CCL7-CCR1 pathway relied on the ERK/ELK1 pathway. SOX18 knockdown significantly reduced CCL7-enhanced GC invasion and metastasis. Furthermore, BX471, a specific CCR1 inhibitor, significantly reduced the SOX18-mediated GC invasion and metastasis. In human GC tissues, SOX18 expression was positively correlated with CCL7 and MCAM expression, and patients with positive coexpression of SOX18/CCL7 or SOX18/MCAM had the worst prognosis. In conclusion, we defined a CCL7-CCR1-SOX18 positive feedback loop that played a pivotal role in GC metastasis, and targeting this pathway may be a promising therapeutic option for the clinical management of GC.	[Chen, Jie; Liu, Danfei; Zhang, Tongyue; Wang, Yijun; Tian, Dean; Xia, Limin] Huazhong Univ Sci & Technol, Dept Gastroenterol, Inst Liver & Gastrointestinal Dis, Tongji Hosp,Tongji Med Coll, Wuhan 430030, Peoples R China; [Chen, Jie; Dang, Yunzhi; Feng, Weibo; Qiao, Chenyang; Fan, Daiming; Nie, Yongzhan; Wu, Kaichun; Xia, Limin] Fourth Mil Med Univ, Natl Clin Res Ctr Digest Dis, State Key Lab Canc Biol, Xian 710032, Peoples R China; [Chen, Jie; Dang, Yunzhi; Feng, Weibo; Qiao, Chenyang; Fan, Daiming; Nie, Yongzhan; Wu, Kaichun; Xia, Limin] Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xian 710032, Peoples R China	Huazhong University of Science & Technology; Air Force Military Medical University; Air Force Military Medical University	Xia, LM (corresponding author), Huazhong Univ Sci & Technol, Dept Gastroenterol, Inst Liver & Gastrointestinal Dis, Tongji Hosp,Tongji Med Coll, Wuhan 430030, Peoples R China.; Xia, LM (corresponding author), Fourth Mil Med Univ, Natl Clin Res Ctr Digest Dis, State Key Lab Canc Biol, Xian 710032, Peoples R China.; Xia, LM (corresponding author), Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xian 710032, Peoples R China.	xialimin@tjh.tjmu.edu.cn	Wang, Yijun/GXW-1763-2022		National Key Research and Development Program of China [2018YFC1312103]; National Natural Science Foundation of China [81972237, 81772623]	National Key Research and Development Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Research was supported by grants from the National Key Research and Development Program of China 2018YFC1312103 (L.X.), National Natural Science Foundation of China No. 81972237 (L.X.), and No. 81772623 (L.X.).	Barbarani G, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39926-4; Bie LY, 2019, ARTIF CELL NANOMED B, V47, P3180, DOI 10.1080/21691401.2019.1646751; Chang WJ, 2014, WORLD J GASTROENTERO, V20, P4586, DOI 10.3748/wjg.v20.i16.4586; Chen G, 2012, J BIOL CHEM, V287, P12132, DOI 10.1074/jbc.M111.302299; Chen L, 2015, CANCER RES, V75, P3832, DOI 10.1158/0008-5472.CAN-14-3690; Cheng JW, 2014, CYTOKINE, V69, P277, DOI 10.1016/j.cyto.2014.06.007; Dang YN, 2020, CELL SIGNAL, V66, DOI 10.1016/j.cellsig.2019.109430; Du F, 2020, ONCOGENE, V39, P3522, DOI 10.1038/s41388-020-1233-4; Du F, 2019, CANCER LETT, V452, P103, DOI 10.1016/j.canlet.2019.03.035; Duong T, 2012, CANCER RES, V72, P3105, DOI 10.1158/0008-5472.CAN-11-4026; Fontaine F, 2017, CELL CHEM BIOL, V24, P346, DOI 10.1016/j.chembiol.2017.01.003; Gladue RP, 2010, CURR TOP MED CHEM, V10, P1268; Greten FR, 2019, IMMUNITY, V51, P27, DOI 10.1016/j.immuni.2019.06.025; Grimm D, 2020, SEMIN CANCER BIOL, V67, P122, DOI 10.1016/j.semcancer.2019.03.004; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Higashijima Y, 2020, SEMIN CANCER BIOL, V67, P39, DOI 10.1016/j.semcancer.2019.09.008; Hwang TL, 2012, WORLD J GASTROENTERO, V18, P1249, DOI 10.3748/wjg.v18.i11.1249; Jethon A, 2015, INT J ONCOL, V46, P123, DOI 10.3892/ijo.2014.2698; Julian LM, 2017, CURR OPIN GENET DEV, V46, P24, DOI 10.1016/j.gde.2017.06.005; Jung DW, 2010, INT J CANCER, V127, P332, DOI 10.1002/ijc.25060; Kasza A, 2013, BBA-GENE REGUL MECH, V1829, P1026, DOI 10.1016/j.bbagrm.2013.05.004; Kitamura T, 2010, P NATL ACAD SCI USA, V107, P13063, DOI 10.1073/pnas.1002372107; Klaus M, 2016, NUCLEIC ACIDS RES, V44, P3922, DOI 10.1093/nar/gkw130; Kumar P, 2020, SEMIN CANCER BIOL, V67, P105, DOI 10.1016/j.semcancer.2019.06.016; Kuzuhara T, 2007, J CANCER RES CLIN, V133, P287, DOI 10.1007/s00432-006-0169-6; Lee HJ, 2014, WORLD J GASTROENTERO, V20, P1681, DOI 10.3748/wjg.v20.i7.1681; Lee YS, 2016, ONCOTARGET, V7, P36842, DOI 10.18632/oncotarget.9209; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; Levin AA, 2019, NEW ENGL J MED, V380, P57, DOI 10.1056/NEJMra1705346; Liang M, 2000, J BIOL CHEM, V275, P19000, DOI 10.1074/jbc.M001222200; Liu YY, 2018, PEERJ, V6, DOI 10.7717/peerj.4928; Man CH, 2015, BLOOD, V125, P3928, DOI 10.1182/blood-2014-06-580993; Miao ZH, 2018, ONCOTARGETS THER, V11, P8481, DOI 10.2147/OTT.S178916; Nagarsheth N, 2017, NAT REV IMMUNOL, V17, P559, DOI 10.1038/nri.2017.49; Overman J, 2017, ELIFE, V6, DOI 10.7554/eLife.21221; Pei XH, 2014, BIOCHEM BIOPH RES CO, V446, P322, DOI 10.1016/j.bbrc.2014.02.109; Pula B, 2014, ANTICANCER RES, V34, P4029; Qin YR, 2011, CLIN CANCER RES, V17, P46, DOI 10.1158/1078-0432.CCR-10-1155; Santos JC, 2016, CANCER RES, V76, P6735, DOI 10.1158/0008-5472.CAN-16-1120; SERS C, 1994, CANCER RES, V54, P5689; Tan DS, 2020, SEMIN CANCER BIOL, V67, P65, DOI 10.1016/j.semcancer.2019.08.008; Thrumurthy SG, 2015, NAT REV CLIN ONCOL, V12, P676, DOI 10.1038/nrclinonc.2015.132; Van Cutsem E, 2016, LANCET, V388, P2654, DOI 10.1016/S0140-6736(16)30354-3; Wang D, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0461-2; Wang GM, 2015, ONCOL REP, V34, P1121, DOI 10.3892/or.2015.4112; Wang J, 2016, ONCOGENE, V35, P1692, DOI 10.1038/onc.2015.234; Wang L, 2019, FASEB J, V33, P254, DOI 10.1096/fj.201701453RR; Wang ZQ, 2013, CANCER LETT, V330, P150, DOI 10.1016/j.canlet.2012.11.049; Wu GJ, 2001, GENE, V279, P17, DOI 10.1016/S0378-1119(01)00736-3; You JX, 2019, ONCOTARGETS THER, V12, P2465, DOI 10.2147/OTT.S197087; Zeng QQ, 2012, P NATL ACAD SCI USA, V109, P1127, DOI 10.1073/pnas.1111053108; Zhang JX, 2016, ONCOL REP, V35, P3721, DOI 10.3892/or.2016.4746; Zhang Y, 2009, CANCER LETT, V277, P29, DOI 10.1016/j.canlet.2008.11.014; Zhou HL, 2019, ONCOL LETT, V18, P599, DOI 10.3892/ol.2019.10387; Zhu Y, 2018, CANCER SCI, V109, P710, DOI 10.1111/cas.13487	55	12	12	3	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2020	39	33					5536	5552		10.1038/s41388-020-1378-1	http://dx.doi.org/10.1038/s41388-020-1378-1		JUL 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NB0QV	32616889				2022-12-28	WOS:000545059900002
J	Li, MC; Nopparat, J; Aguilar, BJ; Chen, YH; Zhang, J; Du, J; Ai, X; Luo, Y; Jiang, YG; Boykin, C; Lu, Q				Li, Mingchuan; Nopparat, Jongdee; Aguilar, Byron J.; Chen, Yan-hua; Zhang, Jiao; Du, Jie; Ai, Xin; Luo, Yong; Jiang, Yongguang; Boykin, Christi; Lu, Qun			Intratumor delta-catenin heterogeneity driven by genomic rearrangement dictates growth factor dependent prostate cancer progression	ONCOGENE			English	Article							ARMADILLO PROTEIN; E-CADHERIN; EXPRESSION; REDISTRIBUTION; IDENTIFICATION; P120-CATENIN; P190RHOGEF; CHALLENGES; INVASION; HYPOXIA	Only a small number of genes are bona fide oncogenes and tumor suppressors such as Ras, Myc, beta-catenin, p53, and APC. However, targeting these cancer drivers frequently fail to demonstrate sustained cancer remission. Tumor heterogeneity and evolution contribute to cancer resistance and pose challenges for cancer therapy due to differential genomic rearrangement and expression driving distinct tumor responses to treatments. Here we report that intratumor heterogeneity of Wnt/beta-catenin modulator delta-catenin controls individual cell behavior to promote cancer. The differential intratumor subcellular localization of delta-catenin mirrors its compartmentalization in prostate cancer xenograft cultures as result of mutation-rendered delta-catenin truncations. Wild-type and delta-catenin mutants displayed distinct protein interactomes that highlight rewiring of signal networks. Localization specific delta-catenin mutants influenced p120(ctn)-dependent Rho GTPase phosphorylation and shifted cells towards differential bFGF-responsive growth and motility, a known signal to bypass androgen receptor dependence. Mutant delta-catenin promoted Myc-induced prostate tumorigenesis while increasing bFGF-p38 MAP kinase signaling, beta-catenin-HIF-1 alpha expression, and the nuclear size. Therefore, intratumor delta-catenin heterogeneity originated from genetic remodeling promotes prostate cancer expansion towards androgen independent signaling, supporting a neomorphism model paradigm for targeting tumor progression.	[Li, Mingchuan; Nopparat, Jongdee; Aguilar, Byron J.; Chen, Yan-hua; Zhang, Jiao; Boykin, Christi; Lu, Qun] East Carolina Univ, Brody Sch Med, Dept Anat & Cell Biol, Greenville, NC 27834 USA; [Li, Mingchuan; Luo, Yong; Jiang, Yongguang] Capital Med Univ, Beijing An Zhen Hosp, Dept Urol Surg, Beijing 100029, Peoples R China; [Nopparat, Jongdee] Prince Songkla Univ, Dept Anat, Hat Yai 90110, Thailand; [Du, Jie] Capital Med Univ, Beijing An Zhen Hosp, Beijing Inst Heart Lung & Blood Vessel Dis, Beijing 100029, Peoples R China; [Ai, Xin] Peoples Liberat Army Gen Hosp, Med Ctr 7, Dept Urol, Beijing 100029, Peoples R China; [Lu, Qun] East Carolina Univ, Brody Sch Med, Harriet & John Wooten Lab Alzheimers & Neurodegen, Greenville, NC 27834 USA	University of North Carolina; East Carolina University; Capital Medical University; Prince of Songkla University; Capital Medical University; Chinese People's Liberation Army General Hospital; University of North Carolina; East Carolina University	Lu, Q (corresponding author), East Carolina Univ, Brody Sch Med, Dept Anat & Cell Biol, Greenville, NC 27834 USA.; Lu, Q (corresponding author), East Carolina Univ, Brody Sch Med, Harriet & John Wooten Lab Alzheimers & Neurodegen, Greenville, NC 27834 USA.	luq@ecu.edu	Nopparat, Jongdee/AAX-1690-2020; , Proteomics Core UNC/AFQ-7201-2022; , Proteomics Core UNC/AAH-3777-2022	Nopparat, Jongdee/0000-0003-3532-1405; 	USA National Cancer Institute [CA111891, CA165202, P30 CA016086]; Harriet and John Wooten Foundation for Alzheimer's and Neurodegenerative Diseases Research; Chinese Beijing Natural Science Foundation [7172068]	USA National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Harriet and John Wooten Foundation for Alzheimer's and Neurodegenerative Diseases Research; Chinese Beijing Natural Science Foundation(Beijing Natural Science Foundation)	We thank George W. Lanford and William Guiler for technical assistance. This work was supported in part by grants from USA National Cancer Institute CA111891 (QL), CA165202 (QL), the Harriet and John Wooten Foundation for Alzheimer's and Neurodegenerative Diseases Research (QL), and Chinese Beijing Natural Science Foundation 7172068 (YGJ). This research is based in part upon work conducted using the UNC Proteomics Core Facility, which is supported in part by USA National Cancer Institute P30 CA016086 Cancer Center Core Support Grant to the UNC Lineberger Comprehensive Cancer Center.	Anastasiadis PZ, 2001, CURR OPIN CELL BIOL, V13, P604, DOI 10.1016/S0955-0674(00)00258-1; Bailey MH, 2018, CELL, V173, P371, DOI [10.1016/j.cell.2018.02.060, 10.1016/j.cell.2018.07.034]; Bensinger SJ, 2012, SEMIN CELL DEV BIOL, V23, P352, DOI 10.1016/j.semcdb.2012.02.003; Bluemn EG, 2017, CANCER CELL, V32, P474, DOI 10.1016/j.ccell.2017.09.003; Chaffer CL, 2016, CANCER METAST REV, V35, P645, DOI 10.1007/s10555-016-9648-7; Dang CV, 2008, NAT REV CANCER, V8, P51, DOI 10.1038/nrc2274; DeBusk LM, 2010, J EXP MED, V207, P669, DOI 10.1084/jem.2009109722610c; Dohn MR, 2009, J CELL BIOL, V184, P437, DOI 10.1083/jcb.200807096; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Fang YY, 2012, J CANCER RES CLIN, V138, P1769, DOI 10.1007/s00432-012-1257-4; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huang F, 2018, ONCOL REP, V39, P809, DOI 10.3892/or.2017.6140; Ip CKM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06949-w; Israely I, 2004, CURR BIOL, V14, P1657, DOI 10.1016/j.cub.2004.08.065; Iwata T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009427; Jones SB, 2004, J NEUROSCI, V24, P8510, DOI 10.1523/JNEUROSCI.1264-04.2004; Jones SB, 2002, NEUROSCIENCE, V115, P1009, DOI 10.1016/S0306-4522(02)00532-8; Kim H, 2008, J BIOL CHEM, V283, P977, DOI 10.1074/jbc.M707158200; Kim H, 2012, BBA-MOL BASIS DIS, V1822, P509, DOI 10.1016/j.bbadis.2011.12.015; Kim H, 2008, BIOCHEM BIOPH RES CO, V377, P636, DOI 10.1016/j.bbrc.2008.10.030; Kim K, 2002, EXP CELL RES, V275, P171, DOI 10.1006/excr.2002.5503; Kosik KS, 2005, TRENDS CELL BIOL, V15, P172, DOI 10.1016/j.tcb.2005.01.004; Liu Y, 2009, CANCER SCI, V100, P441, DOI 10.1111/j.1349-7006.2008.01067.x; Lu Q, 2005, HUM PATHOL, V36, P1037, DOI 10.1016/j.humpath.2005.07.012; Lu Q, 1999, J CELL BIOL, V144, P519, DOI 10.1083/jcb.144.3.519; Lu Q, 2016, HUM GENET, V135, P1107, DOI 10.1007/s00439-016-1705-3; Lu Q, 2010, J PATHOL, V222, P119, DOI 10.1002/path.2755; Maere S, 2005, BIOINFORMATICS, V21, P3448, DOI 10.1093/bioinformatics/bti551; McCrea PD, 2007, BBA-MOL CELL RES, V1773, P17, DOI 10.1016/j.bbamcr.2006.06.009; Nopparat J, 2015, ONCOGENE, V34, P1542, DOI 10.1038/onc.2014.89; Olson Michael F, 2018, Small GTPases, V9, P203, DOI 10.1080/21541248.2016.1218407; Paffenholz R, 1997, DIFFERENTIATION, V61, P293, DOI 10.1046/j.1432-0436.1997.6150293.x; Patiar S, 2006, ENDOCR-RELAT CANCER, V13, pS61, DOI 10.1677/erc.1.01290; Podar K, 2010, CELL CYCLE, V9, P1722, DOI 10.4161/cc.9.9.11358; Poon E, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001173; Powis G, 2004, MOL CANCER THER, V3, P647; Suhovskih AV, 2017, CELL ADHES MIGR, V11, P39, DOI 10.1080/19336918.2016.1182292; Swanton C, 2012, CANCER RES, V72, P4875, DOI 10.1158/0008-5472.CAN-12-2217; Tai S, 2011, PROSTATE, V71, P1668, DOI 10.1002/pros.21383; Takiar V, 2017, ONCOGENE, V36, P1607, DOI 10.1038/onc.2016.312; Viswanathan SR, 2018, NAT GENET, V50, P937, DOI 10.1038/s41588-018-0155-3; Westbrook TF, 2005, CELL, V121, P837, DOI 10.1016/j.cell.2005.03.033; Wolf A, 2006, NAT CELL BIOL, V8, P1432, DOI 10.1038/ncb1504; Wu YM, 2018, CELL, V173, P1770, DOI 10.1016/j.cell.2018.04.034; Yanagisawa M, 2008, J BIOL CHEM, V283, P18344, DOI 10.1074/jbc.M801192200; Zeng Y, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-19; Zhang GA, 2006, PROTEOMICS, V6, P571, DOI 10.1002/pmic.200500267; Zhang J, 2010, FUTURE ONCOL, V6, P587, DOI [10.2217/fon.10.15, 10.2217/FON.10.15]; Zhang J, 2008, DEVELOPMENT, V135, P3611, DOI 10.1242/dev.025361; Zhang Y, 2018, FRONT MED-PRC, V12, P361, DOI 10.1007/s11684-018-0656-6; Zheng JY, 2003, J MEMBRANE BIOL, V194, P187, DOI 10.1007/s00232-003-2038-4	51	5	5	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	22					4358	4374		10.1038/s41388-020-1281-9	http://dx.doi.org/10.1038/s41388-020-1281-9		APR 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LR9IT	32313227				2022-12-28	WOS:000527509300002
J	Chen, K; Cai, YX; Cheng, C; Zhang, JQ; Lv, F; Xu, GF; Duan, PW; Wu, YM; Wu, ZX				Chen, Kai; Cai, Yuanxia; Cheng, Cheng; Zhang, Junqi; Lv, Fan; Xu, Guofeng; Duan, Peiwen; Wu, Yeming; Wu, Zhixiang			MYT1 attenuates neuroblastoma cell differentiation by interacting with the LSD1/CoREST complex	ONCOGENE			English	Article							FINGER TRANSCRIPTION FACTORS; HISTONE DEACETYLASE; RETINOIC ACID; NEURONAL DIFFERENTIATION; NERVOUS-SYSTEM; INHIBITION; EXPRESSION; THERAPY; FAMILY; COREST	Impaired neuronal differentiation is a feature of neuroblastoma tumorigenesis, and the differentiation grade of neuroblastoma tumors is associated with patient prognosis. Detailed understanding of the molecular mechanisms underlying neuroblastoma differentiation will facilitate the development of effective treatment strategies. Recent studies have shown that myelin transcription factor 1 (MYT1) promotes vertebrate neurogenesis by regulating gene expression. We performed quantitative analysis of neuroblastoma samples, which revealed that MYT1 was differentially expressed among neuroblastoma patients with different pathological diagnoses. Analysis of clinical data showed that MYT1 overexpression was associated with a significantly shorter 3-year overall survival rate and poor differentiation in neuroblastoma specimens. MYT1 knockdown inhibited proliferation and promoted the expression of multiple differentiation-associated proteins. Integrated omics data indicated that many genes involved in neuro-differentiation were regulated by MYT1. Interestingly, many of these genes are targets of the REST complex; therefore, we further identified the physical interaction of MYT1 with LSD1/CoREST. Depletion of LSD1 or inhibition of LSD1 by ORY-1001 decreased MYT1 expression, providing an alternative approach to target MYT1. Taken together, our results indicate that MYT1 significantly attenuates cell differentiation by interacting with the LSD1/CoREST complex. MYT1 is, therefore, a promising therapeutic target for enhancing the neurite-inducing effect of retinoic acid and for inhibiting the growth of neuroblastoma.	[Chen, Kai; Cai, Yuanxia; Cheng, Cheng; Lv, Fan; Duan, Peiwen; Wu, Yeming; Wu, Zhixiang] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Pediat Surg, Shanghai 200092, Peoples R China; [Chen, Kai; Cai, Yuanxia; Cheng, Cheng; Lv, Fan; Duan, Peiwen; Wu, Yeming; Wu, Zhixiang] Shanghai Inst Pediat Res, Div Pediat Oncol, Shanghai 200092, Peoples R China; [Zhang, Junqi; Xu, Guofeng] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Pediat Urol,Natl Key Clin Specialty,Shanghai, Shanghai 200092, Peoples R China; [Lv, Fan; Wu, Yeming; Wu, Zhixiang] Soochow Univ, Dept Pediat Surg, Childrens Hosp, Suzhou 215003, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Soochow University - China	Wu, YM; Wu, ZX (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Pediat Surg, Shanghai 200092, Peoples R China.; Wu, YM; Wu, ZX (corresponding author), Shanghai Inst Pediat Res, Div Pediat Oncol, Shanghai 200092, Peoples R China.; Wu, YM; Wu, ZX (corresponding author), Soochow Univ, Dept Pediat Surg, Childrens Hosp, Suzhou 215003, Peoples R China.	wuyeming@xinhuamed.com.cn; wuzhixiang@xinhuamed.com.cn		Wu, Zhixiang/0000-0002-3947-2035; Chen, Kai/0000-0002-8845-1820	Natural Science Foundation of China [81672488, 81572918, 81402478]; Suzhou Clinical Medicine Innovation Team Introduction Project [SZYJTD201706]; Shanghai Jiao Tong University School of Medicine Doctoral Innovation Fund [BXJ201826]; Shanghai Rising-Star Program [16QA1402900]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Suzhou Clinical Medicine Innovation Team Introduction Project; Shanghai Jiao Tong University School of Medicine Doctoral Innovation Fund; Shanghai Rising-Star Program	This work is supported by the Natural Science Foundation of China (No. 81572918) and Suzhou Clinical Medicine Innovation Team Introduction Project (SZYJTD201706) to YW, Shanghai Jiao Tong University School of Medicine Doctoral Innovation Fund (No. BXJ201826) to KC, Natural Science Foundation of China (No. 81402478), Shanghai Rising-Star Program (16QA1402900) to ZW, and Natural Science Foundation of China (No. 81672488) to GX. We thank Lisa Kreiner, PhD, from Liwen Bianji, Edanz Editing China (www.liwenbianji.cn/ac), for editing the English text of a draft of this paper.	Ambros PF, 2009, BRIT J CANCER, V100, P1471, DOI 10.1038/sj.bjc.6605014; ANDERSON DJ, 1986, CELL, V47, P1079, DOI 10.1016/0092-8674(86)90823-8; ANDERSON DJ, 1991, J NEUROSCI, V11, P3507; Andres ME, 1999, P NATL ACAD SCI USA, V96, P9873, DOI 10.1073/pnas.96.17.9873; ARMSTRONG RC, 1995, GLIA, V14, P303, DOI 10.1002/glia.440140407; Ballas N, 2005, CELL, V121, P645, DOI 10.1016/j.cell.2005.03.013; Bellefroid EJ, 1996, CELL, V87, P1191, DOI 10.1016/S0092-8674(00)81815-2; Camarda R, 2016, NAT MED, V22, P427, DOI 10.1038/nm.4055; Chen K, 2018, PEDIATR BLOOD CANCER, V65, DOI 10.1002/pbc.27229; Chen K, 2016, ONCOTARGET, V7, P75968, DOI 10.18632/oncotarget.12513; Cho HS, 2011, CANCER RES, V71, P655, DOI 10.1158/0008-5472.CAN-10-2446; Cohn SL, 2009, J CLIN ONCOL, V27, P289, DOI 10.1200/JCO.2008.16.6785; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Gu YT, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0931-z; Huang J, 2007, NATURE, V449, P105, DOI 10.1038/nature06092; Huang YF, 1999, NAT NEUROSCI, V2, P867, DOI 10.1038/13165; Hudson LD, 2011, TRANSGENIC RES, V20, P951, DOI 10.1007/s11248-010-9470-x; Jiang YH, 1996, J BIOL CHEM, V271, P10723, DOI 10.1074/jbc.271.18.10723; Lee JY, 2017, ONCOGENE, V36, P5512, DOI 10.1038/onc.2017.158; Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021; Li LF, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00702-5; Louis CU, 2015, ANNU REV MED, V66, P49, DOI 10.1146/annurev-med-011514-023121; Mall M, 2017, NATURE, V544, P245, DOI 10.1038/nature21722; Manukyan A, 2018, J CELL BIOCHEM, V119, P4644, DOI 10.1002/jcb.26636; Matsushita F, 2014, DEV DYNAM, V243, P588, DOI 10.1002/dvdy.24091; Matthay KK, 2009, J CLIN ONCOL, V27, P1007, DOI 10.1200/JCO.2007.13.8925; Pandey GK, 2014, CANCER CELL, V26, P722, DOI 10.1016/j.ccell.2014.09.014; Qadeer ZA, 2019, CANCER CELL, V36, P512, DOI 10.1016/j.ccell.2019.09.002; Reynolds CP, 2003, CANCER LETT, V197, P185, DOI 10.1016/S0304-3835(03)00108-3; Romm E, 2005, J NEUROCHEM, V93, P1444, DOI 10.1111/j.1471-4159.2005.03131.x; Schor NF, 2013, J CHILD NEUROL, V28, P765, DOI 10.1177/0883073813483173; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; SIDELL N, 1982, J NATL CANCER I, V68, P589; Singh A, 2011, CANCER-AM CANCER SOC, V117, P5189, DOI 10.1002/cncr.26145; Vasconcelos FF, 2016, CELL REP, V17, P469, DOI 10.1016/j.celrep.2016.09.024; Wang S, 2007, MECH DEVELOP, V124, P898, DOI 10.1016/j.mod.2007.08.004; Wang Y, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0581-6; Xu GF, 2013, CELL PHYSIOL BIOCHEM, V31, P854, DOI 10.1159/000350103; Yokoyama A, 2014, J BIOL CHEM, V289, P18152, DOI 10.1074/jbc.M114.566448; You A, 2001, P NATL ACAD SCI USA, V98, P1454, DOI 10.1073/pnas.98.4.1454; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118	41	6	6	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	21					4212	4226		10.1038/s41388-020-1268-6	http://dx.doi.org/10.1038/s41388-020-1268-6		APR 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LQ2DH	32251364				2022-12-28	WOS:000523950600001
J	Yang, XT; Hu, F; Liu, JA; Yu, S; Cheung, MPL; Liu, XL; Ng, IOL; Guan, XY; Wong, KKW; Sharma, R; Lung, HL; Jiao, YF; Lee, LTO; Cheung, M				Yang, Xintao; Hu, Feng; Liu, Jessica Aijia; Yu, Shan; Cheung, May Pui Lai; Liu, Xuelai; Ng, Irene Oi-Lin; Guan, Xin-Yuan; Wong, Kelvin K. W.; Sharma, Rakesh; Lung, Hong Lok; Jiao, Yufei; Lee, Leo Tsz On; Cheung, Martin			Nuclear DLC1 exerts oncogenic function through association with FOXK1 for cooperative activation of MMP9 expression in melanoma	ONCOGENE			English	Article							TUMOR-SUPPRESSOR PROTEIN; NEURAL CREST; TRANSCRIPTIONAL CONTROL; METASTASIS SUPPRESSOR; CELL INVASION; CANCER; PROMOTES; LIVER; GENE; PROLIFERATION	A Rho GTPase-activating protein (RhoGAP), deleted in liver cancer 1 (DLC1), is known to function as a tumor suppressor in various cancer types; however, whether DLC1 is a tumor-suppressor gene or an oncogene in melanoma remains to be clarified. Here we revealed that high DLC1 expression was detected in most of the melanoma tissues where it was localized in both the nuclei and the cytoplasm. Functional studies unveiled that DLC1 was both required and sufficient for melanoma growth and metastasis. These tumorigenic events were mediated by nuclear-localized DLC1 in a RhoGAP-independent manner. Mechanistically, mass spectrometry analysis identified a DLC1-associated protein, FOXK1 transcription factor, which mediated oncogenic events in melanoma by translocating and retaining DLC1 into the nucleus. RNA-sequencing profiling studies further revealed MMP9 as a direct target of FOXK1 through DLC1-regulated promoter occupancy for cooperative activation of MMP9 expression to promote melanoma invasion and metastasis. Concerted action of DLC1-FOXK1 in MMP9 gene regulation was further supported by their highly correlated expression in melanoma patients' samples and cell lines. Together, our results not only unravel a mechanism by which nuclear DLC1 functions as an oncogene in melanoma but also suggest an unexpected role of RhoGAP protein in transcriptional regulation.	[Yang, Xintao; Hu, Feng; Cheung, May Pui Lai; Cheung, Martin] Univ Hong Kong, Shenzhen Inst Res & Innovat HKU SIRI, Shenzhen, Peoples R China; [Yang, Xintao; Hu, Feng; Cheung, May Pui Lai; Cheung, Martin] Univ Hong Kong, Sch Biomed Sci, Li Ka Shing Fac Med, Hong Kong, Peoples R China; [Liu, Jessica Aijia] Univ Hong Kong, Li Ka Shing Fac Med, Dept Anaesthesiol, Hong Kong, Peoples R China; [Yu, Shan; Lee, Leo Tsz On] Univ Macau, Canc Ctr, Fac Hlth Sci, Taipa, Macau, Peoples R China; [Liu, Xuelai] Hebei Med Univ, Dept Pediat Surg, Hosp 2, Shijiazhuang, Hebei, Peoples R China; [Ng, Irene Oi-Lin] Univ Hong Kong, Li Ka Shing Fac Med, State Key Lab Liver Res, Hong Kong, Peoples R China; [Ng, Irene Oi-Lin] Univ Hong Kong, Li Ka Shing Fac Med, Dept Pathol, Hong Kong, Peoples R China; [Guan, Xin-Yuan] Univ Hong Kong, Li Ka Shing Fac Med, Dept Clin Oncol, Hong Kong, Peoples R China; [Wong, Kelvin K. W.; Sharma, Rakesh] Univ Hong Kong, Li Ka Shing Fac Med, Ctr PanorOm Sci, Prote & Metab Core Facil, Hong Kong, Peoples R China; [Lung, Hong Lok] Hong Kong Baptist Univ, Dept Biol, Fac Sci, Hong Kong, Peoples R China; [Jiao, Yufei] Harbin Med Univ, Dept Pathol, Affiliated Hosp 2, Harbin, Peoples R China; [Lee, Leo Tsz On] Univ Macau, Ctr Reprod Dev & Aging, Fac Hlth Sci, Taipa, Macau, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Macau; Hebei Medical University; University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Hong Kong; Hong Kong Baptist University; Harbin Medical University; University of Macau	Cheung, M (corresponding author), Univ Hong Kong, Shenzhen Inst Res & Innovat HKU SIRI, Shenzhen, Peoples R China.; Cheung, M (corresponding author), Univ Hong Kong, Sch Biomed Sci, Li Ka Shing Fac Med, Hong Kong, Peoples R China.	mcheung9@hku.hk	Lee, Leo T.O./AAB-1581-2021; Cheung, Martin Chi Hang/C-4235-2009	Sharma, Rakesh/0000-0002-5306-3457; Yang, Xintao/0000-0003-0364-9377; Ng, Irene Oi-lin/0000-0001-7532-2029; Liu, Jessica Aijia/0000-0002-9307-2235; Cheung, Martin Chi Hang/0000-0002-3471-8534; Hu, Feng/0000-0001-9605-7594	Research Grants Council of Hong Kong [GRF_17110715, GRF_17123016, GRF_17114817]; University Grants Council of Hong Kong [GRF_17110715, GRF_17123016, GRF_17114817]; National Natural Science Foundation of China [81972588]; University of Hong Kong [201409176166, 201611159243]; Government Matching Grant Scheme (6th Phase)	Research Grants Council of Hong Kong(Hong Kong Research Grants Council); University Grants Council of Hong Kong; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); University of Hong Kong(University of Hong Kong); Government Matching Grant Scheme (6th Phase)	This work was supported by grants from the Research Grants Council and University Grants Council of Hong Kong (GRF_17110715, GRF_17123016, GRF_17114817), National Natural Science Foundation of China (81972588) as well as Small Project Fund (201409176166), Seed Fund for Basic Research (201611159243) from the University of Hong Kong, and Government Matching Grant Scheme (6th Phase).	Bailey CM, 2012, PIGM CELL MELANOMA R, V25, P573, DOI 10.1111/j.1755-148X.2012.01025.x; Barras D, 2014, CANCER METAST REV, V33, P87, DOI 10.1007/s10555-013-9458-0; Chan LK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025547; Cheung M, 2005, DEV CELL, V8, P179, DOI 10.1016/j.devcel.2004.12.010; Cronin JC, 2013, CANCER RES, V73, P5709, DOI 10.1158/0008-5472.CAN-12-4620; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Durkin ME, 2007, J CELL MOL MED, V11, P1185, DOI 10.1111/j.1582-4934.2007.00098.x; Goodison S, 2005, CANCER RES, V65, P6042, DOI 10.1158/0008-5472.CAN-04-3043; Graf SA, 2014, J INVEST DERMATOL, V134, P2212, DOI 10.1038/jid.2014.128; Harris ML, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003644; Hill VK, 2013, ANNU REV GENOM HUM G, V14, P257, DOI 10.1146/annurev-genom-091212-153429; Huang XT, 2018, CELL PHYSIOL BIOCHEM, V47, P590, DOI 10.1159/000490015; Kaufman CK, 2016, SCIENCE, V351, DOI 10.1126/science.aad2197; Khan A, 2018, NUCLEIC ACIDS RES, V46, pD1284, DOI 10.1093/nar/gkx1188; Kim T, 2009, CANCER METAST REV, V28, P77, DOI 10.1007/s10555-008-9167-2; Kulesa PM, 2013, CELLS TISSUES ORGANS, V198, P12, DOI 10.1159/000348418; Lahoz A, 2008, GENE DEV, V22, P1724, DOI 10.1101/gad.1691408; Liao YC, 2008, INT J BIOCHEM CELL B, V40, P843, DOI 10.1016/j.biocel.2007.04.008; Liu JA, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01107-0; Liu JA, 2016, DEV BIOL, V419, P199, DOI 10.1016/j.ydbio.2016.09.006; Low JSW, 2011, ONCOGENE, V30, P1923, DOI 10.1038/onc.2010.576; Monsonego-Ornan E, 2012, DEV BIOL, V364, P162, DOI 10.1016/j.ydbio.2012.01.028; Park H, 2015, P NATL ACAD SCI USA, V112, P12492, DOI 10.1073/pnas.1507491112; Peng Y, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.225; Pohl BS, 2004, DEV GENES EVOL, V214, P200, DOI 10.1007/s00427-004-0391-7; Popescu NC, 2014, MOL DIAGN THER, V18, P293, DOI 10.1007/s40291-014-0086-3; Potterf SB, 2001, DEV BIOL, V237, P245, DOI 10.1006/dbio.2001.0372; Scholz RP, 2009, J CELL SCI, V122, P92, DOI 10.1242/jcs.036251; Shakhova O, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1004877; Shakhova O, 2012, NAT CELL BIOL, V14, P882, DOI 10.1038/ncb2535; Shi H, 2014, MELANOMA RES, V24, P99, DOI 10.1097/CMR.0000000000000043; Sjoestroem C, 2014, MODERN PATHOL, V27, P1203, DOI 10.1038/modpathol.2013.223; Tang ZY, 2013, CELL BIOL INT, V37, P849, DOI 10.1002/cbin.10107; Torres-Collado AX, 2018, CANCERS, V10, DOI 10.3390/cancers10060157; Tripathi BK, 2017, J CELL BIOL, V216, P4255, DOI 10.1083/jcb.201703105; Tripathi V, 2014, ONCOGENE, V33, P724, DOI 10.1038/onc.2013.7; Tripathi V, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-27; Wang DR, 2016, ONCOTARGET, V7, P45144, DOI 10.18632/oncotarget.9266; Wang WQ, 2015, DEV CELL, V32, P707, DOI 10.1016/j.devcel.2015.01.031; Wang YF, 2014, J CLIN INVEST, V124, P1646, DOI 10.1172/JCI71812; Wong CM, 2003, CANCER RES, V63, P7646; Wong CM, 2005, CANCER RES, V65, P8861, DOI 10.1158/0008-5472.CAN-05-1318; Wu M, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.68; Xu HT, 2018, EXP THER MED, V15, P3108, DOI 10.3892/etm.2018.5732; Yang XT, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-018-0998-6; Yuan BZ, 2007, EXP CELL RES, V313, P3868, DOI 10.1016/j.yexcr.2007.08.009	46	7	8	3	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	20					4061	4076		10.1038/s41388-020-1274-8	http://dx.doi.org/10.1038/s41388-020-1274-8		MAR 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LN3GC	32214200	Green Published, hybrid			2022-12-28	WOS:000521526300001
J	Lai, SH; Zervoudakis, G; Chou, JS; Gurney, ME; Quesnelle, KM				Lai, Samuel Hsien; Zervoudakis, Guston; Chou, Jesse; Gurney, Mark E.; Quesnelle, Kelly M.			PDE4 subtypes in cancer	ONCOGENE			English	Review							PROTEIN-KINASE-A; PHOSPHODIESTERASE 4B; PROSTATE-CANCER; CELL-DEATH; ESOPHAGEAL ADENOCARCINOMA; INTEGRATED ANALYSIS; THERAPEUTIC TARGET; SELECTIVE PDE4B; BREAST-CANCER; IN-VITRO	Cyclic nucleotide phosphodiesterases (PDE) break down cyclic nucleotides such as cAMP and cGMP, reducing the signaling of these important intracellular second messengers. Several unique families of phosphodiesterases exist, and certain families are clinically important modulators of vasodilation. In the current work, we have summarized the body of literature that describes an emerging role for the PDE4 subfamily of phosphodiesterases in malignancy. We have systematically investigated PDE4A, PDE4B, PDE4C, and PDE4D isoforms and found evidence associating them with several cancer types including hematologic malignancies and lung cancers, among others. In this review, we compare the evidence examining the functional role of each PDE4 subtype across malignancies, looking for common signaling themes, signaling pathways, and establishing the case for PDE4 subtypes as a potential therapeutic target for cancer treatment.	[Lai, Samuel Hsien; Zervoudakis, Guston; Chou, Jesse; Quesnelle, Kelly M.] Western Michigan Univ, Homer Stryker MD Sch Med, Dept Biomed Sci, Kalamazoo, MI 49008 USA; [Gurney, Mark E.] Tetra Therapeut, Grand Rapids, MI USA	Western Michigan University	Quesnelle, KM (corresponding author), Western Michigan Univ, Homer Stryker MD Sch Med, Dept Biomed Sci, Kalamazoo, MI 49008 USA.	kelly.quesnelle@med.wmich.edu	Quesnelle, Kelly/AAJ-2580-2021	Lai, Samuel/0000-0003-0187-4255	NIMH NIH HHS [R43 MH107077, R43 MH091791] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Agostini A, 2018, INT J CANCER, V143, P1379, DOI 10.1002/ijc.31418; Araujo T, 2018, WORLD J GASTROENTERO, V24, P5338, DOI 10.3748/wjg.v24.i47.5338; Babu RV, 2013, ORG BIOMOL CHEM, V11, P6680, DOI 10.1039/c3ob41504j; Bao ZS, 2014, ONCOL REP, V32, P250, DOI 10.3892/or.2014.3176; Baty F, 2015, J BIOMED INFORM, V58, P175, DOI 10.1016/j.jbi.2015.10.002; Bodelon C, 2017, INT J CANCER, V140, P825, DOI 10.1002/ijc.30512; Bottcher R, 2016, ONCOTARGET, V7, P70669, DOI 10.18632/oncotarget.12204; Bogunovic D, 2009, P NATL ACAD SCI USA, V106, P20429, DOI 10.1073/pnas.0905139106; Bolger GB, 2016, ENDOCR-RELAT CANCER, V23, P419, DOI 10.1530/ERC-15-0205; Burgin AB, 2010, NAT BIOTECHNOL, V28, P63, DOI 10.1038/nbt.1598; Bye H, 2012, CARCINOGENESIS, V33, P2155, DOI 10.1093/carcin/bgs262; Cao B, 2016, ELIFE, V5, DOI 10.7554/eLife.15978; Chamseddine AN, 2016, CL LYMPH MYELOM LEUK, V16, pS67, DOI 10.1016/j.clml.2016.02.026; Chen L, 2018, AM J CANCER RES, V8, P2387; Cokic VP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135463; Cooney JD, 2018, CLIN CANCER RES, V24, P1103, DOI 10.1158/1078-0432.CCR-17-2218; Das A, 2015, PHARMACOL THERAPEUT, V147, P12, DOI 10.1016/j.pharmthera.2014.10.003; Delyon J, 2017, ONCOGENE, V36, P3252, DOI 10.1038/onc.2016.469; Dong HL, 2010, BIOCHEM PHARMACOL, V79, P321, DOI 10.1016/j.bcp.2009.09.001; Dong PX, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1306-9; Fernandez-Araujo A, 2015, TOXICOL IN VITRO, V29, P1545, DOI 10.1016/j.tiv.2015.05.013; Floor SL, 2015, MOL CELL ENDOCRINOL, V411, P1, DOI 10.1016/j.mce.2015.04.001; Fox D, 2014, CELL SIGNAL, V26, P657, DOI 10.1016/j.cellsig.2013.12.003; Garritano S, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.15; Ge XC, 2015, ELIFE, V4, DOI [10.7554/eLife.07068.001, 10.7554/eLife.07068]; Geybels MS, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0161-6; Goldhoff P, 2008, CLIN CANCER RES, V14, P7717, DOI 10.1158/1078-0432.CCR-08-0827; Gu JA, 2010, CANCER PREV RES, V3, P1176, DOI 10.1158/1940-6207.CAPR-09-0265; Gurney ME, 2019, J MED CHEM, V62, P4884, DOI 10.1021/acs.jmedchem.9b00193; Haddad SA, 2016, CARCINOGENESIS, V37, P870, DOI 10.1093/carcin/bgw067; Hagen TJ, 2014, BIOORG MED CHEM LETT, V24, P4031, DOI 10.1016/j.bmcl.2014.06.002; He N, 2014, MOL CANCER THER, V13, P2463, DOI 10.1158/1535-7163.MCT-14-0297; He RQ, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3646-1; Henderson DJP, 2014, BRIT J CANCER, V110, P1278, DOI 10.1038/bjc.2014.22; Henderson DJP, 2019, CLIN SCI, V133, P269, DOI 10.1042/CS20180519; Holloway DT, 2008, BIOL DIRECT, V3, DOI 10.1186/1745-6150-3-24; Houslay MD, 2010, TRENDS BIOCHEM SCI, V35, P91, DOI 10.1016/j.tibs.2009.09.007; Jiang Xin, 1998, Cell Biochemistry and Biophysics, V28, P135, DOI 10.1007/BF02737809; Kang TW, 2014, SCI REP-UK, V4, DOI 10.1038/srep05546; Karachaliou N, 2015, SCI REP-UK, V5, DOI 10.1038/srep17499; Kashiwagi E, 2012, PROSTATE, V72, P741, DOI 10.1002/pros.21478; Kelly K, 2017, CLIN CANCER RES, V23, P1186, DOI 10.1158/1078-0432.CCR-16-1207; Khaled M, 2010, GENE DEV, V24, P2276, DOI 10.1101/gad.1937710; Kim DH, 1998, BLOOD, V92, P2484, DOI 10.1182/blood.V92.7.2484.2484_2484_2494; Kim DU, 2019, ONCOL LETT, V17, P3589, DOI 10.3892/ol.2019.9996; Kim DU, 2019, BIOCHEM BIOPH RES CO, V508, P825, DOI 10.1016/j.bbrc.2018.12.004; Kim J, 2015, GENE, V558, P173, DOI 10.1016/j.gene.2015.01.001; Kim SW, 2011, CLIN CANCER RES, V17, P6723, DOI 10.1158/1078-0432.CCR-11-0770; Kim SW, 2009, BLOOD, V113, P6153, DOI 10.1182/blood-2009-02-206128; Knobloch TJ, 2019, METABOLITES, V9, DOI 10.3390/metabo9070140; Kolosionek E, 2009, MOL BIOL CELL, V20, P4751, DOI 10.1091/mbc.E09-01-0019; Lapa GB, 2016, CHEM BIOL DRUG DES, V87, P575, DOI 10.1111/cbdd.12691; Li H, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01048; Liu S, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1322-z; Mahmood B, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2980-z; Mareddy J, 2013, BIOORG MED CHEM LETT, V23, P6721, DOI 10.1016/j.bmcl.2013.10.035; Maurice DH, 2014, NAT REV DRUG DISCOV, V13, P290, DOI 10.1038/nrd4228; McEwan DG, 2007, CANCER RES, V67, P5248, DOI 10.1158/0008-5472.CAN-07-0097; Miklos W, 2016, ONCOTARGET, V7, P84556, DOI 10.18632/oncotarget.11821; Milinkovic V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082108; Mishra RR, 2018, CLIN CANCER RES, V24, P1987, DOI 10.1158/1078-0432.CCR-17-2776; Moon EY, 2012, LIFE SCI, V90, P373, DOI 10.1016/j.lfs.2011.12.010; Naganuma K, 2009, BIOORG MED CHEM LETT, V19, P3174, DOI 10.1016/j.bmcl.2009.04.121; Nagy ZS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057326; Nanayakkara S, 2018, AM J CARDIOL, V122, P1017, DOI 10.1016/j.amjcard.2018.06.009; Nancarrow DJ, 2008, CANCER RES, V68, P4163, DOI 10.1158/0008-5472.CAN-07-6710; Narita M, 2007, ONCOL REP, V17, P1133; Natrajan R, 2012, J PATHOL, V227, P29, DOI 10.1002/path.4003; Nishi K, 2017, ANTICANCER RES, V37, P3833, DOI 10.21873/anticanres.11762; Obernolte R, 1997, BBA-GENE STRUCT EXPR, V1353, P287, DOI 10.1016/S0167-4781(97)00080-8; Peng QP, 2018, CELL MOL BIOL, V64, P62, DOI 10.14715/cmb/2017.64.15.10; Peng YH, 2018, J CANCER, V9, P2389, DOI 10.7150/jca.24079; Persani L, 2000, J CLIN ENDOCR METAB, V85, P2872, DOI 10.1210/jc.85.8.2872; Pleiman JK, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007611; Powers GL, 2015, MOL CANCER RES, V13, P149, DOI 10.1158/1541-7786.MCR-14-0110; Praveena KSS, 2014, BIOORG CHEM, V53, P8, DOI 10.1016/j.bioorg.2013.12.002; Pullamsetti SS, 2013, ONCOGENE, V32, P1121, DOI 10.1038/onc.2012.136; Qiang Z, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0971-4; Rahrmann EP, 2009, CANCER RES, V69, P4388, DOI 10.1158/0008-5472.CAN-08-3901; Ramezani S, 2019, LIFE SCI, V239, DOI 10.1016/j.lfs.2019.116880; Ramezani S, 2017, LIFE SCI, V173, P11, DOI 10.1016/j.lfs.2017.02.005; Rickles RJ, 2010, BLOOD, V116, P593, DOI 10.1182/blood-2009-11-252668; Sakkas LI, 2017, CURR MED CHEM, V24, P3054, DOI 10.2174/0929867324666170530093902; Sarfati M, 2003, BLOOD, V101, P265, DOI 10.1182/blood-2002-01-0075; Shah MS, 2011, PHYSIOL GENOMICS, V43, P640, DOI 10.1152/physiolgenomics.00213.2010; Smith PG, 2005, BLOOD, V105, P308, DOI 10.1182/blood-2004-01-0240; Suhasini AN, 2016, LEUKEMIA, V30, P617, DOI 10.1038/leu.2015.302; Tiwari S, 2005, BIOCHEM PHARMACOL, V69, P473, DOI 10.1016/j.bcp.2004.10.009; Toledo RA, 2010, CLINICS, V65, P407, DOI 10.1590/S1807-59322010000400010; Tsunoda T, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-46; van Strijp D, 2019, PROSTATE CANCER, V2019, DOI 10.1155/2019/8107807; Wang HC, 2007, BIOCHEM J, V408, P193, DOI 10.1042/BJ20070970; Wang YF, 2018, BIOCHEM BIOPH RES CO, V501, P313, DOI 10.1016/j.bbrc.2018.05.024; Warrington NM, 2010, CANCER RES, V70, P5717, DOI 10.1158/0008-5472.CAN-09-3769; Wittliff JL, 2017, HORM CANCER-US, V8, P298, DOI 10.1007/s12672-017-0309-2; Xu T, 2014, ONCOL LETT, V8, P2110, DOI 10.3892/ol.2014.2422; Yang JJ, 2012, BLOOD, V120, P4197, DOI 10.1182/blood-2012-07-440107; Zebda R, 2018, J AM ACAD DERMATOL, V78, pS43, DOI 10.1016/j.jaad.2017.11.056; Zhang C, 2017, SCI REP-UK, V7, DOI 10.1038/srep40115; Zhang LZ, 2008, P NATL ACAD SCI USA, V105, P19532, DOI 10.1073/pnas.0806152105	100	30	30	6	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	19					3791	3802		10.1038/s41388-020-1258-8	http://dx.doi.org/10.1038/s41388-020-1258-8		MAR 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LK4OF	32203163	Green Accepted			2022-12-28	WOS:000520614000001
J	Huang, PB; Xu, QD; Yan, YC; Lu, YJ; Hu, ZG; Ou, B; Zhang, HY; Mao, K; Zhang, JL; Wang, J; Xiao, ZY				Huang, Pinbo; Xu, Qiaodong; Yan, Yongcong; Lu, Yingjuan; Hu, Zhigang; Ou, Bing; Zhang, Heyun; Mao, Kai; Zhang, Jianlong; Wang, Jie; Xiao, Zhiyu			HBx/ER alpha complex-mediated LINC01352 downregulation promotes HBV-related hepatocellular carcinoma via the miR-135b-APC axis	ONCOGENE			English	Article							LONG NONCODING RNA; HEPATITIS-B-VIRUS; GENETIC ALTERATIONS; ESTROGEN-RECEPTOR; LIVER-CANCER; METASTASIS; PROTEIN; PROLIFERATION; CONTRIBUTES; EXPRESSION	Hepatitis B virus (HBV) infection plays an important role in hepatocarcinogenesis, especially in hepatocellular carcinoma (HCC). Long non-coding RNAs (lncRNAs) have emerged as crucial biomarkers and regulators in many cancers. Novel lncRNAs involved in the initiation and progression of HBV-related hepatocellular carcinoma (HCC) need to be investigated. Here, we report that the long non-coding RNA LINC01352 is markedly downregulated by HBV/HBx (HBV X protein) in HCC cells and clinical samples. The LINC01352 expression level in HCC is an independent prognostic factor for survival. We found that HBx suppresses LINC01352 promoter activity by forming a complex with the estrogen receptor (ER alpha). Furthermore, using a combination of in vitro and in vivo studies, we confirmed that HBx promotes HCC cell growth and metastasis by inhibiting LINC01352 expression. Further investigation revealed that the downregulation of LINC01352, which acts as an endogenous sponge, increases the expression of miR-135b, leading to the reduced production of adenomatous polyposis coli (APC), consequently activating Wnt/beta-catenin signalling to facilitate tumour progression. These findings strongly suggest that the LINC01352-miR-135b-APC axis regulated by the HBx/ER alpha complex acts as an important pathogenic factor for tumour progression, which may help provide a theoretical basis for the identification of new therapeutic targets for HBV-related HCC.	[Huang, Pinbo; Yan, Yongcong; Hu, Zhigang; Zhang, Heyun; Mao, Kai; Zhang, Jianlong; Wang, Jie; Xiao, Zhiyu] Sun Yat Sen Univ, Dept Hepatobiliary Surg, Sun Yat Sen Mem Hosp, Guangzhou 510120, Peoples R China; [Huang, Pinbo; Yan, Yongcong; Hu, Zhigang; Xiao, Zhiyu] Sun Yat Sen Univ, Med Res Ctr, Sun Yat Sen Mem Hosp, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou 510120, Peoples R China; [Xu, Qiaodong] Shantou Univ, Dept Biliary Pancreat Minimally Invas Surg, Affiliated Hosp 1, Coll Med, Shantou 515041, Peoples R China; [Lu, Yingjuan] Sun Yat Sen Univ, Dept Stomatol, Sun Yat Sen Mem Hosp, Guangzhou 510120, Peoples R China; [Ou, Bing] Sun Yat Sen Univ, Dept Ultrasonog, Sun Yat Sen Mem Hosp, Guangzhou 510120, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Shantou University; Sun Yat Sen University; Sun Yat Sen University	Wang, J; Xiao, ZY (corresponding author), Sun Yat Sen Univ, Dept Hepatobiliary Surg, Sun Yat Sen Mem Hosp, Guangzhou 510120, Peoples R China.; Xiao, ZY (corresponding author), Sun Yat Sen Univ, Med Res Ctr, Sun Yat Sen Mem Hosp, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou 510120, Peoples R China.	jiewsysu@163.com; xzysurgeon@163.com			National Natural Science Foundation of China [81702404, 81572407, 81672405, 81372565]; Natural Science Foundation of Guangdong Province, China [2016A030311051, 2017A030313536]; Guangzhou Science Research Project [201607010225]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province, China(National Natural Science Foundation of Guangdong Province); Guangzhou Science Research Project	This work was supported by the National Natural Science Foundation of China (No. 81702404, 81572407, 81672405 and 81372565), the Natural Science Foundation of Guangdong Province, China (No. 2016A030311051 and 2017A030313536) and the Guangzhou Science Research Project (No. 201607010225).	Cesana M, 2011, CELL, V147, P358, DOI 10.1016/j.cell.2011.09.028; Chen LL, 2016, TRENDS BIOCHEM SCI, V41, P761, DOI 10.1016/j.tibs.2016.07.003; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Daud M, 2017, ARCH VIROL, V162, P2937, DOI 10.1007/s00705-017-3462-6; Ding J, 2014, CANCER LETT, V346, P17, DOI 10.1016/j.canlet.2013.12.024; Du YM, 2012, J BIOL CHEM, V287, P26302, DOI 10.1074/jbc.M112.342113; EISENFELD AJ, 1976, SCIENCE, V191, P862, DOI 10.1126/science.175442; El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061; Guichard C, 2012, NAT GENET, V44, P694, DOI 10.1038/ng.2256; Han JQ, 2006, NUCLEIC ACIDS RES, V34, P3095, DOI 10.1093/nar/gkl389; He Y, 2014, CANCER LETT, V344, P20, DOI 10.1016/j.canlet.2013.10.021; Hou ZH, 2017, AM J CANCER RES, V7, P845; Hu JJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep23521; Huang JF, 2013, HEPATOLOGY, V57, P1882, DOI 10.1002/hep.26195; Huang PB, 2015, CLIN CANCER RES, V21, P4420, DOI 10.1158/1078-0432.CCR-14-2067; Klingenberg M, 2018, HEPATOLOGY, V68, P1817, DOI 10.1002/hep.30102; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Lau SH, 2005, ACTA PHARMACOL SIN, V26, P659, DOI 10.1111/j.1745-7254.2005.00126.x; Laurent-Puig P, 2006, ONCOGENE, V25, P3778, DOI 10.1038/sj.onc.1209547; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Levrero M, 2016, J HEPATOL, V64, pS84, DOI 10.1016/j.jhep.2016.02.021; Li T, 2016, ONCOGENE, V35, P1575, DOI 10.1038/onc.2015.223; Liu F, 2016, ONCOGENE, V35, P5422, DOI 10.1038/onc.2016.80; Liu XH, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-92; Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521; Ng SA, 2011, J GASTROENTEROL, V46, P974, DOI 10.1007/s00535-011-0415-9; Park NH, 2006, POSTGRAD MED J, V82, P507, DOI 10.1136/pgmj.2006.047431; PATERLINI P, 1995, HEPATOLOGY, V21, P313, DOI 10.1002/hep.1840210208; PORTER LE, 1983, GASTROENTEROLOGY, V84, P704; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Schulze K, 2015, NAT GENET, V47, P505, DOI 10.1038/ng.3252; Serghiou S, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0535-1; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Villanueva A, 2014, NAT REV CLIN ONCOL, V11, P73, DOI [10.1038/nrclinonc.2013.227, 10.1038/nrclinonc.2013.243]; VITVITSKITREPO L, 1990, HEPATOLOGY, V12, P1278, DOI 10.1002/hep.1840120605; Wang JY, 2010, NUCLEIC ACIDS RES, V38, P5366, DOI 10.1093/nar/gkq285; Wang K, 2014, CIRC RES, V114, P1377, DOI 10.1161/CIRCRESAHA.114.302476; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R; Xie JJ, 2018, GASTROENTEROLOGY, V154, P2137, DOI 10.1053/j.gastro.2018.02.018; Xu LB, 2014, J HEPATOL, V60, P590, DOI 10.1016/j.jhep.2013.10.028; Yang F, 2013, MOL CELL, V49, P1083, DOI 10.1016/j.molcel.2013.01.010; Zhang H, 2015, CANCER RES, V75, P2363, DOI 10.1158/0008-5472.CAN-14-2928; Zhang L, 2013, CARCINOGENESIS, V34, P577, DOI 10.1093/carcin/bgs381	43	25	25	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	18					3774	3789		10.1038/s41388-020-1254-z	http://dx.doi.org/10.1038/s41388-020-1254-z		MAR 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LI5XR	32157216				2022-12-28	WOS:000518886000001
J	Li, Y; Zhang, HB; Fan, L; Mou, JH; Yin, Y; Peng, C; Chen, YX; Lu, HL; Zhao, LT; Tao, ZT; Chen, J; Wang, YZ; Qi, XM; Huang, RM; Ren, J				Li, Yu; Zhang, Huibiao; Fan, Lei; Mou, Jiahui; Yin, Yue; Peng, Chao; Chen, Yuxiang; Lu, Henglei; Zhao, Liting; Tao, Zhouteng; Chen, Jing; Wang, Yizheng; Qi, Xinming; Huang, Ruimin; Ren, Jin			MiR-629-5p promotes the invasion of lung adenocarcinoma via increasing both tumor cell invasion and endothelial cell permeability	ONCOGENE			English	Article							UP-REGULATION; CANCER; METASTASIS; EXPRESSION; TARGETS; GROWTH; CELSR1; ANGIOGENESIS; SUPPRESSES; MIGRATION	Tumor invasion underlies further metastasis, the leading cause for cancer-related deaths. Deregulation of microRNAs has been identified associated with the malignant behavior of various cancers, including lung adenocarcinoma (LUAD), the major subtype of lung cancer. Here, we showed the significantly positive correlation between miR-629-5p level and tumor invasion in LUAD specimens (n = 49). In a human LUAD metastasis mouse model, H1650 cells (high level of miR-629-5p) were more aggressive than A549 cells (low level of miR-629-5p) in vivo, including higher incidence of vascular invasion and pulmonary colonization. Ectopic expression of miR-629-5p in A549 cells also increased their invasive capability. Then we identified that miR-629-5p promotes LUAD invasion in a mode of dual regulation via tumor cells invasion and endothelial cells permeability, respectively. In tumor cells, miR-629-5p enhanced motility and invasiveness of tumor cells by directly targeting PPWD1 (a cyclophilin), which clinically related to tumor invasion in LUAD specimens. Restoring PPWD1 protein significantly attenuated the invasion-promoting effects of miR-629-5p. Besides, exosomal-miR-629-5p secreted from tumor cells could be transferred to endothelial cells and increased endothelial monolayers permeability by suppressing CELSR1 (a nonclassic-type cadherin), which had a low level in the endothelial cells of invasive LUAD specimens. Activating the expression of CELSR1 in endothelial cells markedly blocked the effect of miR-629-5p. Our study suggests the dual roles of miR-629-5p in tumor cells and endothelial cells for LUAD invasion, implying a therapeutic option to targeting miR-629-5p using the "one stone, two birds" strategy in LUAD.	[Li, Yu; Fan, Lei; Mou, Jiahui; Chen, Yuxiang; Lu, Henglei; Tao, Zhouteng; Chen, Jing; Qi, Xinming; Ren, Jin] Chinese Acad Sci, Shanghai Inst Mat Med, Ctr Drug Safety Evaluat & Res, State Key Lab Drug Res, Shanghai 201203, Peoples R China; [Li, Yu; Fan, Lei; Mou, Jiahui; Tao, Zhouteng; Chen, Jing; Qi, Xinming; Huang, Ruimin; Ren, Jin] Univ Chinese Acad Sci, Beijing 100049, Peoples R China; [Zhang, Huibiao] Fudan Univ, Huadong Hosp, Dept Thorac Surg, Shanghai 200040, Peoples R China; [Yin, Yue] Natl Facil Prot Sci Shanghai, Zhangjiang Lab, Shanghai 201210, Peoples R China; [Peng, Chao] Chinese Acad Sci, Shanghai Sci Res Ctr, Shanghai 201204, Peoples R China; [Lu, Henglei] Shanghai Univ Chinese Med, Shanghai 201203, Peoples R China; [Zhao, Liting] Fudan Univ, Huadong Hosp, Dept Nursing, Shanghai 200040, Peoples R China; [Wang, Yizheng] Beijing Inst Basic Med Sci, Brain Sci Ctr, Beijing 100730, Peoples R China; [Huang, Ruimin] Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China	Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Fudan University; Chinese Academy of Sciences; Shanghai University of Traditional Chinese Medicine; Fudan University; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS	Ren, J (corresponding author), Chinese Acad Sci, Shanghai Inst Mat Med, Ctr Drug Safety Evaluat & Res, State Key Lab Drug Res, Shanghai 201203, Peoples R China.; Huang, RM; Ren, J (corresponding author), Univ Chinese Acad Sci, Beijing 100049, Peoples R China.; Huang, RM (corresponding author), Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China.	rmhuang@simm.ac.cn; jren@cdser.simm.ac.cn		yin, yue/0000-0002-7693-3910	National Science & Technology Major Project "Key New Drug Creation and Manufacturing Program," China [2018ZX09101001-003-007, 2018ZX09711002-010-001]; National Natural Science Foundation of china [91859106]; One Hundred Talent Program of Chinese Academy of Sciences; State Key Laboratory of Drug Research; Shanghai Committee of Science and Technology, China [18DZ2290200]	National Science & Technology Major Project "Key New Drug Creation and Manufacturing Program," China; National Natural Science Foundation of china(National Natural Science Foundation of China (NSFC)); One Hundred Talent Program of Chinese Academy of Sciences(Chinese Academy of Sciences); State Key Laboratory of Drug Research; Shanghai Committee of Science and Technology, China(Shanghai Science & Technology Committee)	This work was supported by the National Science & Technology Major Project "Key New Drug Creation and Manufacturing Program," China (2018ZX09101001-003-007 and 2018ZX09711002-010-001), "the National Natural Science Foundation of china (91859106)," One Hundred Talent Program of Chinese Academy of Sciences, the Fundamental and Open Research Funds from the State Key Laboratory of Drug Research, and the grant from Shanghai Committee of Science and Technology, China (Grant No.: 18DZ2290200). We thank the Electron Microscopy System and Animal Facility at the National Facility for Protein Science in Shanghai (NFPS), Zhangjiang Lab, China, and the Institutional Technology Service Center of Shanghai Institute of Materia Medica, Chinese Academy of Sciences for technical supports.	Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850; Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Aurrand-Lions M, 2001, J BIOL CHEM, V276, P2733, DOI 10.1074/jbc.M005458200; Bica-Pop C, 2018, CELL MOL LIFE SCI, V75, P3539, DOI 10.1007/s00018-018-2877-x; Bielenberg DR, 2015, CANCER J, V21, P267, DOI 10.1097/PPO.0000000000000138; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brzoska HL, 2016, KIDNEY INT, V90, P1274, DOI 10.1016/j.kint.2016.07.011; Chang TH, 2017, CANCER LETT, V402, P190, DOI 10.1016/j.canlet.2017.06.002; Chen LM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6241; Chorti Angeliki, 2018, Microrna, V7, P167, DOI 10.2174/2211536607666180525073302; Davis TL, 2008, FEBS J, V275, P2283, DOI 10.1111/j.1742-4658.2008.06381.x; Duncan JS, 2017, DEV BIOL, V423, P126, DOI 10.1016/j.ydbio.2017.01.020; Faict S, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408-018-0139-7; Goffinet AM, 2017, SEMIN CELL DEV BIOL, V69, P102, DOI 10.1016/j.semcdb.2017.07.014; Graner MW, 2018, SEMIN IMMUNOPATHOL, V40, P505, DOI 10.1007/s00281-018-0689-6; Han ML, 2016, ONCOL REP, V35, P73, DOI 10.3892/or.2015.4360; Ito M, 2014, BLOOD, V123, P1499, DOI 10.1182/blood-2013-09-527739; Jenkinson EM, 2018, CLIN GENET, V93, P228, DOI 10.1111/cge.13025; Jin K, 2017, J PATHOL, V241, P567, DOI 10.1002/path.4871; Jingushi K, 2015, MOL CANCER RES, V13, P565, DOI 10.1158/1541-7786.MCR-14-0300; Kaemmerer D, 2014, CLIN EXP METASTAS, V31, P817, DOI 10.1007/s10585-014-9672-3; Kang YY, 2018, NATURE, V558, P553, DOI 10.1038/s41586-018-0215-y; Lee SW, 2009, INT J MOL MED, V23, P279, DOI 10.3892/ijmm_00000128; Lin SB, 2015, NAT REV CANCER, V15, P321, DOI 10.1038/nrc3932; Liu K, 2016, CHINESE MED J-PEKING, V129, P442, DOI 10.4103/0366-6999.176076; Lu J, 2018, BIOSCIENCE REP, V38; Maishi N, 2017, CANCER SCI, V108, P1921, DOI 10.1111/cas.13336; Miao LL, 2016, BBA-GENE REGUL MECH, V1859, P650, DOI 10.1016/j.bbagrm.2016.02.016; Myers D. J., 2019, CANC LUNG ADENOCARCI; Nagao Y, 2012, MODERN PATHOL, V25, P112, DOI 10.1038/modpathol.2011.142; Naik MU, 2006, J CELL SCI, V119, P490, DOI 10.1242/jcs.02771; Paliouras AR, 2018, CANCER LETT, V421, P152, DOI 10.1016/j.canlet.2018.02.029; Poel D, 2018, EXP MOL MED, V50, DOI 10.1038/emm.2017.288; Posorski N, 2011, CLIN EXP METASTAS, V28, P637, DOI 10.1007/s10585-011-9397-5; Pu MF, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006896; Qi LQ, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-163; Rajiv C, 2018, BIOMOLECULES, V8, DOI 10.3390/biom8040161; Riihimaki M, 2014, LUNG CANCER, V86, P78, DOI 10.1016/j.lungcan.2014.07.020; Shao LP, 2017, DNA CELL BIOL, V36, P1108, DOI 10.1089/dna.2017.3904; Singleton PA, 2014, ADV CANCER RES, V123, P191, DOI 10.1016/B978-0-12-800092-2.00007-1; Tan XH, 2014, J CUTAN PATHOL, V41, P630, DOI 10.1111/cup.12332; Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30; Tornavaca O, 2015, J CELL BIOL, V208, P821, DOI 10.1083/jcb.201404140; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; van Zijl F, 2011, MUTAT RES-REV MUTAT, V728, P23, DOI 10.1016/j.mrrev.2011.05.002; Wang T, 2017, ONCOGENE, V36, P3240, DOI 10.1038/onc.2016.468; Wen J, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317705761; Yan HJ, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.525; Yan LX, 2016, INT J ONCOL, V48, P471, DOI 10.3892/ijo.2015.3287; Yang H, 2013, HEPATOLOGY, V58, P205, DOI 10.1002/hep.26315; Yang L, 2012, CARCINOGENESIS, V33, P338, DOI 10.1093/carcin/bgr272; Yang N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.358; Yu SJ, 2018, BMC CANCER, V18, DOI 10.1186/s12885-017-3930-0; Zeng ZC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07810-w; Zhan YH, 2016, BIOCHEMISTRY-MOSCOW+, V81, P591, DOI 10.1134/S0006297916060055; Zhang BG, 2012, ONCOL REP, V27, P1019, DOI 10.3892/or.2012.1645; Zhao YJ, 2015, CANCER METAST REV, V34, P265, DOI 10.1007/s10555-015-9553-5; Zhou WY, 2014, CANCER CELL, V25, P501, DOI 10.1016/j.ccr.2014.03.007; Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24; Zhuang BF, 2019, MOL MED REP, V19, P3933, DOI 10.3892/mmr.2019.9990	60	18	19	5	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	17					3473	3488		10.1038/s41388-020-1228-1	http://dx.doi.org/10.1038/s41388-020-1228-1		FEB 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LH1YK	32108166				2022-12-28	WOS:000516891300003
J	Shao, AW; Lang, Y; Wang, MD; Qin, C; Kuang, Y; Mei, YD; Lin, DG; Zhang, S; Tang, J				Shao, Anwen; Lang, Yue; Wang, Mengdong; Qin, Chao; Kuang, Yu; Mei, Yide; Lin, Degui; Zhang, Shuo; Tang, Jun			Bclaf1 is a direct target of HIF-1 and critically regulates the stability of HIF-1 alpha under hypoxia	ONCOGENE			English	Article							INDUCIBLE FACTORS; MESSENGER-RNA; PROTEINS; ALPHA; DEATH; CELLS; DESTABILIZATION; TRANSCRIPTION; DEGRADATION; METABOLISM	Hypoxic stress is intimately connected with tumor progression, with hypoxia-inducible factor-1 alpha (HIF-1 alpha) being a critical regulator in this process. HIF-1 alpha is stabilized in response to hypoxia, which is required for the induction of gene transcriptions important for hypoxic adaptation. Bclaf1 is a multifunctional protein involved in tumorigenesis, however, its role in this process is not well characterized. Here we report Bclaf1 is a direct transcriptional target of HIF-1 and upregulated in multiple cell lines during hypoxia. Importantly, we found Bclaf1 is involved in the stabilization of HIF-1 alpha during long-term hypoxic treatments. Compared with the control cells, the protein level and stability of HIF-1 alpha in Bclaf1 knockdown or knockout cells is greatly compromised after long-term hypoxic treatments, concomitant with the impaired inductions of HIF-1 target gene transcription. Bclaf1 knockout HeLa cells exhibit a reduced tumor growth in mice xenografts, in which the expressions of HIF-1 alpha and its target genes are also decreased. Bclaf1 binds to HIF-1 alpha in the nucleus, and this interaction is required for Bclaf1 to stabilize HIF-1 alpha in hypoxic condition. These results uncover a positive feedback loop, HIF-1-Bclaf1, that sustains HIF-1 activity during long-term hypoxic conditions by binding to and protecting HIF-1 alpha from degradation, and suggest that Bclaf1 may promote tumor progression by enhancing HIF-1 alpha stability.	[Shao, Anwen; Lang, Yue; Wang, Mengdong; Qin, Chao; Kuang, Yu; Tang, Jun] China Agr Univ, Coll Vet Med, Dept Basic Vet Med, Beijing 100193, Peoples R China; [Mei, Yide] Univ Sci & Technol China, Sch Life Sci, Hefei 230026, Anhui, Peoples R China; [Lin, Degui; Zhang, Shuo] China Agr Univ, Coll Vet Med, Dept Clin Vet Med, Beijing 100193, Peoples R China	China Agricultural University; Chinese Academy of Sciences; University of Science & Technology of China, CAS; China Agricultural University	Tang, J (corresponding author), China Agr Univ, Coll Vet Med, Dept Basic Vet Med, Beijing 100193, Peoples R China.	jtang@cau.edu.cn	Mei, Yide/M-4468-2013		National Natural Science Foundation of China [31671488, 31872834]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (31671488 and 31872834).	Bertout JA, 2008, NAT REV CANCER, V8, P967, DOI 10.1038/nrc2540; Bracken CP, 2008, CANCER RES, V68, P7621, DOI 10.1158/0008-5472.CAN-08-1217; Caceres JF, 1997, J CELL BIOL, V138, P225, DOI 10.1083/jcb.138.2.225; Cavadas MAS, 2015, SCI REP-UK, V5, DOI 10.1038/srep17851; Chamboredon S, 2011, MOL BIOL CELL, V22, P3366, DOI 10.1091/mbc.E10-07-0617; Cheng J, 2007, CELL, V131, P584, DOI 10.1016/j.cell.2007.08.045; Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468; Ginouves A, 2008, P NATL ACAD SCI USA, V105, P4745, DOI 10.1073/pnas.0705680105; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Kaelin WG, 2005, ANNU REV BIOCHEM, V74, P115, DOI 10.1146/annurev.biochem.74.082803.133142; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kasof GM, 1999, MOL CELL BIOL, V19, P4390; Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019; Kim Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10347; Koh MY, 2008, MOL CELL BIOL, V28, P7081, DOI 10.1128/MCB.00773-08; Kong SY, 2011, J BIOL CHEM, V286, P16967, DOI 10.1074/jbc.M111.218206; Lamy L, 2013, CANCER CELL, V23, P435, DOI 10.1016/j.ccr.2013.02.017; Lee SH, 2012, P NATL ACAD SCI USA, V109, P9575, DOI 10.1073/pnas.1207496109; Lee YY, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.76; Liu H, 2007, MOL CELL BIOL, V27, P8480, DOI 10.1128/MCB.01126-07; Liu J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01947-w; Luo WB, 2018, CELL MOL LIFE SCI, V75, P1043, DOI 10.1007/s00018-017-2684-9; Luo WB, 2010, J BIOL CHEM, V285, P3651, DOI 10.1074/jbc.M109.068577; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; McPherson JP, 2009, CELL DEATH DIFFER, V16, P331, DOI 10.1038/cdd.2008.167; Montagner M, 2012, NATURE, V487, P380, DOI 10.1038/nature11207; Qin C, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007559; Sarras H, 2010, THESCIENTIFICWORLDJO, V10, P1450, DOI 10.1100/tsw.2010.132; Savage KI, 2014, MOL CELL, V54, P445, DOI 10.1016/j.molcel.2014.03.021; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shao AW, 2016, CELL DEATH DIFFER, V23, P865, DOI 10.1038/cdd.2015.150; Shih JW, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0358-4; Stiehl DP, 2006, J BIOL CHEM, V281, P23482, DOI 10.1074/jbc.M601719200; Uchida T, 2004, J BIOL CHEM, V279, P14871, DOI 10.1074/jbc.M400461200; Vohhodina J, 2017, NUCLEIC ACIDS RES, V45, DOI 10.1093/nar/gkx1046; Wen Y, 2019, ONCOGENE, V38, P1845, DOI 10.1038/s41388-018-0552-1; Yang F, 2014, MOL CELL, V53, P88, DOI 10.1016/j.molcel.2013.11.004; Zhou XX, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5581; Ziegelbauer JM, 2009, NAT GENET, V41, P130, DOI 10.1038/ng.266	41	6	7	3	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	13					2807	2818		10.1038/s41388-020-1185-8	http://dx.doi.org/10.1038/s41388-020-1185-8		FEB 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KX4EF	32029898				2022-12-28	WOS:000511540800003
J	Xiao, Y; Liu, GD; Sun, Y; Gao, Y; Ouyang, XW; Chang, CS; Gong, LS; Yeh, SY				Xiao, Yao; Liu, Guodong; Sun, Yin; Gao, Yuan; Ouyang, Xiwu; Chang, Chawnshang; Gong, Liansheng; Yeh, Shuyuan			Targeting the estrogen receptor alpha (ER alpha)-mediated circ-SMG1.72/miR-141-3p/Gelsolin signaling to better suppress the HCC cell invasion	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; CIRCULAR RNA; GENDER DISPARITY; CANCER; PROLIFERATION; GELSOLIN; EXPRESSION; GROWTH; OVEREXPRESSION; MECHANISMS	Early studies indicated that estrogen receptor alpha (ER alpha) might impact the progression of hepatocellular carcinoma (HCC). However, the detailed mechanisms, especially its linkage to the gelsolin (GSN)-mediated cell invasion, remain unclear. Here we found that ER alpha could decrease HCC cell invasion via suppressing the circular RNA-SMG1.72 (circRNA-SMG1.72) expression via transcriptional regulation through directly binding to the 5 ' promoter region of its host gene SMG1, We showed that ER alpha-suppressed circ-SMG1.72 could sponge and inhibit the expression of the microRNA (miRNA, miR), miR-141-3p, which could then result in increasing the GSN messenger RNA translation via reduced miR binding to its 3 ' untranslated region (3 ' UTR). The preclinical study using an in vivo mouse model with orthotopic xenografts of HCC cells confirmed the in vitro data, and the human HCC clinical sample survey and tissue staining also confirmed the linkage of ER alpha/miR-141-3p/GSN signaling to the HCC progression. Together, our findings suggest that ER alpha can suppress HCC cell invasion via altering the ER alpha/circRNA-SMG1.72/miR-141-3p/GSN signaling, and targeting this newly identified signaling with small molecules may help in the development of novel therapies to better suppress the HCC progression.	[Xiao, Yao; Liu, Guodong; Gong, Liansheng] Cent South Univ, Xiangya Hosp, Dept Hepatobiliary & Pancreat Surg, Changsha 410008, Peoples R China; [Xiao, Yao; Liu, Guodong; Sun, Yin; Gao, Yuan; Ouyang, Xiwu; Chang, Chawnshang; Yeh, Shuyuan] Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Urol, Rochester, NY 14642 USA; [Xiao, Yao; Liu, Guodong; Sun, Yin; Gao, Yuan; Ouyang, Xiwu; Chang, Chawnshang; Yeh, Shuyuan] Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, Rochester, NY 14642 USA; [Xiao, Yao; Liu, Guodong; Sun, Yin; Gao, Yuan; Ouyang, Xiwu; Chang, Chawnshang; Yeh, Shuyuan] Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Radiat Oncol, Rochester, NY 14642 USA; [Xiao, Yao; Liu, Guodong; Sun, Yin; Gao, Yuan; Ouyang, Xiwu; Chang, Chawnshang; Yeh, Shuyuan] Univ Rochester, Med Ctr, Wilmot Canc Ctr Inst, Rochester, NY 14642 USA	Central South University; University of Rochester; University of Rochester; University of Rochester; University of Rochester	Gong, LS (corresponding author), Cent South Univ, Xiangya Hosp, Dept Hepatobiliary & Pancreat Surg, Changsha 410008, Peoples R China.; Yeh, SY (corresponding author), Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Urol, Rochester, NY 14642 USA.; Yeh, SY (corresponding author), Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, Rochester, NY 14642 USA.; Yeh, SY (corresponding author), Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Radiat Oncol, Rochester, NY 14642 USA.; Yeh, SY (corresponding author), Univ Rochester, Med Ctr, Wilmot Canc Ctr Inst, Rochester, NY 14642 USA.	gongliansheng8280@163.com; Shuyuan_Yeh@URMC.Rochester.edu	Xiao, Yao/AEX-1775-2022	Xiao, Yao/0000-0002-4638-4148; Liu, Guodong/0000-0003-1922-2538; Chang, Chawnshang/0000-0001-8510-3516	George Whipple Professorship Endowment; National Natural Science Foundation of China [81903004]; The 12th Five-year Key Discipline Construction in Hunan Province (Biomedical Engineering)	George Whipple Professorship Endowment; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); The 12th Five-year Key Discipline Construction in Hunan Province (Biomedical Engineering)	This work was supported by George Whipple Professorship Endowment, National Natural Science Foundation of China (81903004) and The 12th Five-year Key Discipline Construction in Hunan Province (Biomedical Engineering). We thank Karen Wolf for help preparing the manuscript.	Ahlbory-Dieker DL, 2009, MOL ENDOCRINOL, V23, P1544, DOI 10.1210/me.2009-0045; Bai RX, 2018, CARBOHYD POLYM, V190, P255, DOI 10.1016/j.carbpol.2018.02.059; Chen CF, 2010, HEPATOLOGY, V52, P1690, DOI 10.1002/hep.23847; Chen JJ, 2015, ONCOL REP, V33, P792, DOI 10.3892/or.2014.3647; Chen P, 1996, J CELL BIOL, V134, P689, DOI 10.1083/jcb.134.3.689; Chen Q, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.142; Chow PKH, 2002, HEPATOLOGY, V36, P1221, DOI 10.1053/jhep.2002.36824; Deng BA, 2015, GENE, V571, P292, DOI 10.1016/j.gene.2015.06.083; Deng L, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0248-0; Deng RZ, 2015, ONCOL LETT, V9, P2129, DOI 10.3892/ol.2015.3002; Ding M, 2018, J CELL BIOCHEM, V119, P9974, DOI 10.1002/jcb.27326; Du WW, 2016, NUCLEIC ACIDS RES, V44, P2846, DOI 10.1093/nar/gkw027; El-Serag HB, 2001, HEPATOLOGY, V33, P62, DOI 10.1053/jhep.2001.21041; Fu LY, 2017, ONCOTARGET, V8, P58405, DOI 10.18632/oncotarget.16881; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Gu J, 2018, CELL PHYSIOL BIOCHEM, V48, P194, DOI 10.1159/000491718; Gu J, 2018, CANCER LETT, V434, P1, DOI 10.1016/j.canlet.2018.06.039; Han D, 2017, HEPATOLOGY, V66, P1151, DOI 10.1002/hep.29270; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jiang SY, 1995, J HEPATOL, V23, P712, DOI 10.1016/0168-8278(95)80038-7; Kavoosi Fraidoon, 2016, Adv Biomed Res, V5, P133, DOI 10.4103/2277-9175.187395; Kramer MC, 2015, GENE DEV, V29, P2168, DOI 10.1101/gad.270421.115; Lader AS, 2005, EXP CELL RES, V307, P153, DOI 10.1016/j.yexcr.2005.03.001; Li GH, 2012, MED RES REV, V32, P999, DOI 10.1002/med.20231; Li Z, 2012, CELL, V148, P72, DOI 10.1016/j.cell.2011.11.026; Liao CJ, 2011, GYNECOL ONCOL, V120, P135, DOI 10.1016/j.ygyno.2010.10.005; Liu CH, 2018, MOL THER, V26, P2267, DOI 10.1016/j.ymthe.2018.06.019; Liu CH, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0619-z; Liu WH, 2009, GASTROENTEROLOGY, V136, P683, DOI 10.1053/j.gastro.2008.10.029; Maynadier M, 2008, FASEB J, V22, P671, DOI 10.1096/fj.07-9322com; Megger DA, 2013, MOL CELL PROTEOMICS, V12, P2006, DOI 10.1074/mcp.M113.028027; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Nathan S, 2017, BREAST CANCER RES TR, V166, P681, DOI 10.1007/s10549-017-4442-y; Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485; Njei B, 2018, OBES SURG, V28, P3880, DOI 10.1007/s11695-018-3431-5; SANGER HL, 1976, P NATL ACAD SCI USA, V73, P3852, DOI 10.1073/pnas.73.11.3852; Sayeed A, 2007, CANCER RES, V67, P7746, DOI 10.1158/0008-5472.CAN-06-3724; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179; Tang YY, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0825-x; Tian MQ, 2018, J CLIN LAB ANAL, V32, DOI 10.1002/jcla.22281; Treiber T, 2012, THROMB HAEMOSTASIS, V107, P605, DOI 10.1160/TH11-12-0836; Villa E, 2002, MOL CELL ENDOCRINOL, V193, P65, DOI 10.1016/S0303-7207(02)00097-7; Wang SH, 2015, J GASTROEN HEPATOL, V30, P1237, DOI 10.1111/jgh.12934; Wang SH, 2012, GASTROENTEROLOGY, V142, P989, DOI 10.1053/j.gastro.2011.12.045; Wu H, 2017, J HEPATOL, V66, P1193, DOI 10.1016/j.jhep.2017.01.030; Yang W, 2016, ONCOGENE, V35, P3919, DOI 10.1038/onc.2015.460; Yin WB, 2018, CLIN CHIM ACTA, V487, P363, DOI 10.1016/j.cca.2017.10.011; Yu MW, 2003, HEPATOLOGY, V38, P1393, DOI 10.1016/j.hep.2003.09.041; Zhou JC, 2013, ONCOL REP, V30, P1622, DOI 10.3892/or.2013.2610; Zlotorynski E, 2015, NAT REV MOL CELL BIO, V16, DOI 10.1038/nrm4079; Zuo QF, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.573	54	26	26	5	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	12					2493	2508		10.1038/s41388-019-1150-6	http://dx.doi.org/10.1038/s41388-019-1150-6		JAN 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KW4HU	31996784				2022-12-28	WOS:000510136400001
J	Zhang, HW; Zhu, D; Zhang, ZB; Kaluz, S; Yu, B; Devi, NS; Olson, JJ; Van Meir, EG				Zhang, Hanwen; Zhu, Dan; Zhang, Zhaobin; Kaluz, Stefan; Yu, Bing; Devi, Narra S.; Olson, Jeffrey J.; Van Meir, Erwin G.			EZH2 targeting reduces medulloblastoma growth through epigenetic reactivation of the BAI1/p53 tumor suppressor pathway	ONCOGENE			English	Article							BRAIN; P53; ANGIOGENESIS; PROTEINS; GENE	Medulloblastoma (MB) is a malignant pediatric brain tumor for which new therapies are urgently needed. We demonstrate that treatment with EPZ-6438 (Tazemetostat), an enhancer of zeste homolog 2 (EZH2) inhibitor approved for clinical trials, blocks MB cell growth in vitro and in vivo, and prolongs survival in orthotopic xenograft models. We show that the therapeutic effect is dependent on epigenetic reactivation of adhesion G-protein-coupled receptor B1 (BAI1/ADGRB1), a tumor suppressor that controls p53 stability by blocking Mdm2. Histone 3 trimethylated on lysine 27 (H3K27me3), a marker of silent chromatin conformation is present at the ADGRB1 promoter, and inhibition of EZH2, the catalytic component of the Polycomb Repressive complex 2 (PRC2) that methylates H3K27, switches the gene into an active chromatin status and reactivates BAI1 expression. Mechanistically, targeting EZH2 promotes transition from H3K27me3 to H3K27ac at the promoter, recruits the C/EBP beta (CREB-binding protein) and CBP transcription factors and activates ADGRB1 gene transcription. Taken together, our results identify key molecular players that regulate ADGRB1 gene expression in MB, demonstrate that reactivation of BAI1 expression underlies EPZ-6438 antitumorigenic action, and provide preclinical proof-of-principle evidence for targeting EZH2 in patients with MB.	[Zhang, Hanwen; Zhu, Dan; Zhang, Zhaobin; Kaluz, Stefan; Yu, Bing; Devi, Narra S.; Olson, Jeffrey J.; Van Meir, Erwin G.] Emory Univ, Sch Med, Dept Neurosurg & Hematol & Med Oncol, Lab Mol Neurooncol, Atlanta, GA 30322 USA; [Zhang, Hanwen] Cent S Univ, Xiangya Hosp, Dept Neurosurg, Changsha 410013, Peoples R China; [Zhang, Hanwen] Cent S Univ, Sch Med, Changsha 410013, Peoples R China; [Olson, Jeffrey J.; Van Meir, Erwin G.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA; [Van Meir, Erwin G.] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA; [Van Meir, Erwin G.] UAB, Dept Neurosurg, WTI 520E,1720 2nd Ave, South Birmingham, AL 35294 USA; [Van Meir, Erwin G.] UAB, ONeal Comprehens Canc Ctr, WTI 520E,1720 2nd Ave, South Birmingham, AL 35294 USA	Emory University; Central South University; Central South University; Emory University; Emory University	Van Meir, EG (corresponding author), Emory Univ, Sch Med, Dept Neurosurg & Hematol & Med Oncol, Lab Mol Neurooncol, Atlanta, GA 30322 USA.; Van Meir, EG (corresponding author), Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.; Van Meir, EG (corresponding author), Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA.; Van Meir, EG (corresponding author), UAB, Dept Neurosurg, WTI 520E,1720 2nd Ave, South Birmingham, AL 35294 USA.; Van Meir, EG (corresponding author), UAB, ONeal Comprehens Canc Ctr, WTI 520E,1720 2nd Ave, South Birmingham, AL 35294 USA.	evanmeir@uab.edu	Zhang, Hanwen/AFK-2928-2022; Zhang, Hanwen/AAG-1299-2022	Zhang, Hanwen/0000-0001-8955-7494; Zhang, Hanwen/0000-0001-8955-7494; Van Meir, Erwin G./0000-0003-2444-7707	NIH [CA163722, CA235162, NS096236, CA138292]; CURE Childhood Cancer Foundation; St. Baldrick's Foundation	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CURE Childhood Cancer Foundation; St. Baldrick's Foundation	This work was supported by grants from the NIH CA163722, CA235162, and NS096236 (to EGVM), CA138292 (to Winship Cancer Institute), the CURE Childhood Cancer Foundation and the St. Baldrick's Foundation.	Aust G, 2016, HANDB EXP PHARMACOL, V234, P369, DOI 10.1007/978-3-319-41523-9_17; Chan HM, 2001, J CELL SCI, V114, P2363; Helming KC, 2014, CANCER CELL, V26, P309, DOI 10.1016/j.ccr.2014.07.018; Jin X, 2017, NAT MED, V23, P1352, DOI 10.1038/nm.4415; Kaur B, 2003, AM J PATHOL, V162, P19, DOI 10.1016/S0002-9440(10)63794-7; Kaur B, 2009, CANCER RES, V69, P1212, DOI 10.1158/0008-5472.CAN-08-1166; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; Mohammad F, 2017, NAT MED, V23, P483, DOI 10.1038/nm.4293; Naidu SR, 2009, ONCOGENE, V28, P2492, DOI 10.1038/onc.2009.121; Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542; Northcott PA, 2017, NATURE, V547, P311, DOI 10.1038/nature22973; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; Robinson G, 2012, NATURE, V488, P43, DOI 10.1038/nature11213; Schwartz C, 2003, EMBO J, V22, P882, DOI 10.1093/emboj/cdg076; Smits M, 2012, CLIN CANCER RES, V18, P4048, DOI 10.1158/1078-0432.CCR-12-0399; Van Meir EG, 1997, INT J CANCER, V71, P310; Vo BT, 2017, CELL REP, V18, P2907, DOI 10.1016/j.celrep.2017.02.073; Yan WJ, 2016, EPIGENOMICS-UK, V8, P119, DOI 10.2217/epi.15.84; Zhang P, 2015, INT J CANCER, V137, P2007, DOI 10.1002/ijc.29566; Zhu D, 2018, CANCER CELL, V33, P1004, DOI 10.1016/j.ccell.2018.05.006; Zhu D, 2011, CANCER RES, V71, P5859, DOI 10.1158/0008-5472.CAN-11-1157	21	19	19	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	5					1041	1048		10.1038/s41388-019-1036-7	http://dx.doi.org/10.1038/s41388-019-1036-7			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KI2VY	31582835	Green Accepted			2022-12-28	WOS:000511209700007
J	He, Q; Lin, ZY; Wang, ZH; Huang, WJ; Tian, D; Liu, M; Xia, LM				He, Qin; Lin, Zhuoying; Wang, Zhihui; Huang, Wenjie; Tian, Dean; Liu, Mei; Xia, Limin			SIX4 promotes hepatocellular carcinoma metastasis through upregulating YAP1 and c-MET	ONCOGENE			English	Article							HEPATOCYTE GROWTH-FACTOR; THERAPEUTIC TARGET; CANCER; INHIBITOR; YAP/TAZ; THERAPIES; PROTEIN; EGFR; SIZE; AXIS	Metastasis is the main reason for high mortality in hepatocellular carcinoma (HCC) patients and the molecular mechanism remains unclear. Therefore, it is important to elucidate the mechanism underlying HCC metastasis. Here, we report a novel role of SIX homeobox 4 (SIX4), one of the SIX gene family, in promoting HCC metastasis. The elevated expression of SIX4 was positively correlated with loss of tumor encapsulation, microvascular invasion, higher TNM stage, and poor prognosis in human HCC. SIX4 expression was an independent and significant risk factor for the recurrence and survival in HCC patients. Upregulation of SIX4 promoted HCC invasion and metastasis, whereas downregulation of SIX4 decreased HCC invasion and metastasis. SIX4 transactivated Yes1 associated transcriptional regulator (YAP1) and MET proto-oncogene, receptor tyrosine kinase (MET) expression through directly binding to their promoters. Knockdown of YAP1 and c-MET inhibited SIX4-medicated HCC metastasis, while the stable overexpression of YAP1 and c-MET reversed the decreased metastasis induced by SIX4 knockdown. Hepatocyte growth factor (HGF), the specific ligand of c-MET, upregulated SIX4 expression through ERK/NF-kappa B pathway. Knockdown of SIX4 significantly decreased HGF-enhanced HCC metastasis. In human HCC tissues, SIX4 expression was positively correlated with nuclear YAP1, c-MET and HGF expression. Patients with positive coexpression of SIX4/ nuclear YAP1, SIX4/c-MET or HGF/SIX4 had the poorest prognosis. Moreover, the combination treatment of YAP1 inhibitor Verteporfin and c-MET inhibitor Capmatinib significantly suppressed SIX4-mediated HCC metastasis. In conclusion, SIX4 is a prognostic biomarker in HCC patients and targeting the HGF-SIX4-c-MET positive feedback loop may provide a promising strategy for the treatment of SIX4-driven HCC metastasis.	[He, Qin; Lin, Zhuoying; Wang, Zhihui; Tian, Dean; Liu, Mei; Xia, Limin] Huazhong Univ Sci & Technol, Dept Gastroenterol, Inst Liver & Gastrointestinal Dis, Tongji Hosp,Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China; [Huang, Wenjie] Huazhong Univ Sci & Technol, Hepat Surg Ctr, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China; [Huang, Wenjie] Clin Med Res Ctr Hepat Surg Hubei Prov, Wuhan 430030, Hubei, Peoples R China; [Huang, Wenjie] Minist Educ, Key Lab Organ Transplantat, Wuhan 430030, Hubei, Peoples R China; [Huang, Wenjie] Minist Publ Hlth, Wuhan 430030, Hubei, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology	Liu, M; Xia, LM (corresponding author), Huazhong Univ Sci & Technol, Dept Gastroenterol, Inst Liver & Gastrointestinal Dis, Tongji Hosp,Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China.	fliumei@126.com; xialimin@tjh.tjmu.edu.cn		He, Qin/0000-0002-9887-9388; Xia, Limin/0000-0002-6327-6034	National Key Research and Development Program of China [2018YFC1312103]; National Natural Science Foundation of China [81871911, 81972237, 81772623]	National Key Research and Development Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Research was supported by grants from the National Key Research and Development Program of China 2018YFC1312103 (LX), National Natural Science Foundation of China No. 81871911 (WH), No. 81972237 (LX), and No. 81772623 (LX).	Bardelli A, 2013, CANCER DISCOV, V3, P658, DOI 10.1158/2159-8290.CD-12-0558; Bisso A, 2020, HEPATOLOGY, V72, P1430, DOI 10.1002/hep.31120; Bladt F, 2014, CANCERS, V6, P1736, DOI 10.3390/cancers6031736; Bouattour M, 2018, HEPATOLOGY, V67, P1132, DOI 10.1002/hep.29496; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chen J, 2020, HEPATOLOGY, V71, P1712, DOI 10.1002/hep.30951; Chen RC, 2018, HEPATOLOGY, V67, P1823, DOI 10.1002/hep.29663; Christensen KL, 2008, ADV CANCER RES, V101, P93, DOI 10.1016/S0065-230X(08)00405-3; Coletta RD, 2004, P NATL ACAD SCI USA, V101, P6478, DOI 10.1073/pnas.0401139101; Comoglio PM, 2018, NAT REV CANCER, V18, P341, DOI 10.1038/s41568-018-0002-y; Craig AJ, 2020, NAT REV GASTRO HEPAT, V17, P139, DOI 10.1038/s41575-019-0229-4; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Dong QZ, 2019, CANCER RES, V79, P819, DOI 10.1158/0008-5472.CAN-18-1273; Faivre S, 2020, J HEPATOL, V72, P342, DOI 10.1016/j.jhep.2019.09.010; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Forner A, 2018, LANCET, V391, P1301, DOI 10.1016/S0140-6736(18)30010-2; Garcia-Vilas JA, 2018, WORLD J GASTROENTERO, V24, P3695, DOI 10.3748/wjg.v24.i33.3695; Gavini J, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1989-z; Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205; Gibault F, 2017, CHEMMEDCHEM, V12, P954, DOI 10.1002/cmdc.201700063; Giordano S, 2014, J HEPATOL, V60, P442, DOI 10.1016/j.jhep.2013.09.009; Hu CT, 2017, CANCERS, V9, DOI 10.3390/cancers9060058; Lau EYT, 2016, CELL REP, V15, P1175, DOI 10.1016/j.celrep.2016.04.019; Li GD, 2017, PEERJ, V5, DOI 10.7717/peerj.3394; Li H, 2019, GASTROENTEROLOGY, V156, P1849, DOI 10.1053/j.gastro.2019.01.252; Li L, 2018, CANCER CELL, V33, P368, DOI 10.1016/j.ccell.2018.01.010; Liu XD, 2011, CLIN CANCER RES, V17, P7127, DOI 10.1158/1078-0432.CCR-11-1157; Liu Z, 2019, J DENT RES, V98, P572, DOI 10.1177/0022034519835204; McCoy EL, 2009, J CLIN INVEST, V119, P2663, DOI 10.1172/JCI37691; Mizuguchi T, 2009, J GASTROINTEST SURG, V13, P325, DOI 10.1007/s11605-008-0711-8; Oliphant MUJ, 2019, CANCER RES, V79, P720, DOI 10.1158/0008-5472.CAN-18-1791; Ono H, 2012, ONCOGENE, V31, P4923, DOI 10.1038/onc.2011.646; Ou SHI, 2017, J THORAC ONCOL, V12, P145, DOI 10.1016/j.jtho.2016.09.131; Papaccio F, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113595; Patel SH, 2017, GASTROENTEROLOGY, V152, P533, DOI 10.1053/j.gastro.2016.10.047; Shah AM, 2020, DIS MODEL MECH, V13, DOI 10.1242/dmm.043489; Shi C, 2018, REDOX BIOL, V14, P59, DOI 10.1016/j.redox.2017.08.013; Sun XL, 2020, AM J CANCER RES, V10, P224; Tang XP, 2019, BIOCHEM BIOPH RES CO, V516, P851, DOI 10.1016/j.bbrc.2019.06.114; Vejchapipat P, 2004, J GASTROENTEROL, V39, P1182, DOI 10.1007/s00535-004-1469-8; Wang CA, 2012, J CLIN INVEST, V122, P1895, DOI 10.1172/JCI59858; Wang HY, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00055; Xiang CA, 2017, CANCERS, V9, DOI 10.3390/cancers9050044; Xu MZ, 2009, CANCER-AM CANCER SOC, V115, P4576, DOI 10.1002/cncr.24495; Yang JD, 2019, NAT REV GASTRO HEPAT, V16, P589, DOI 10.1038/s41575-019-0186-y; Yang X, 2014, HEPATOLOGY, V59, P1874, DOI 10.1002/hep.26941; Yu YL, 2004, NAT MED, V10, P175, DOI 10.1038/nm966; Yu ZB, 2020, ONCOGENE, V39, P3163, DOI 10.1038/s41388-020-1206-7; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zhang SH, 2019, CURR OPIN CELL BIOL, V61, P64, DOI 10.1016/j.ceb.2019.07.006; Zhang XD, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0892-2; Zhang YZ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0796-y; Zheng Y, 2018, THERANOSTICS, V8, P972, DOI 10.7150/thno.22328	54	15	15	1	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2020	39	50					7279	7295		10.1038/s41388-020-01500-y	http://dx.doi.org/10.1038/s41388-020-01500-y		OCT 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PD4HE	33046796				2022-12-28	WOS:000578784100001
J	Zhang, LL; Qin, YQ; Wu, G; Wang, JY; Cao, JW; Wang, YQ; Wu, D; Yang, KY; Zhao, ZG; He, LC; Lyu, JX; Li, HZ; Gu, HH				Zhang, Lingling; Qin, Yaqian; Wu, Guang; Wang, Jieyi; Cao, Jiawei; Wang, Yaqi; Wu, Du; Yang, Kaiyan; Zhao, Zhiguang; He, Licai; Lyu, Jianxin; Li, Hongzhi; Gu, Haihua			PRRG4 promotes breast cancer metastasis through the recruitment of NEDD4 and downregulation of Robo1	ONCOGENE			English	Article							FOCAL ADHESION KINASE; MESENCHYMAL TRANSITION; AXON GUIDANCE; WAGR SYNDROME; PROTEINS; ROUNDABOUT; MIGRATION; PATHWAY; BINDING; FAMILY	Metastasis is responsible for the death of most breast cancer patients. Robo1 has been implicated as a tumor suppressor for various cancers including breast cancer. However, it is not well understood how Robo1 expression is regulated during tumorigenesis. In this study, we uncovered that the transmembrane proline rich gamma-carboxyglutamic acid protein 4 (PRRG4) promotes breast cancer metastasis by downregulating Robo1. Analysis of mRNA expression data in The Cancer Genome Atlas and immunohistochemistry assay on breast tumor samples showed that PRRG4 expression was higher in breast tumors than in normal breast tissues. Experiments with PRRG4 knockdown and overexpression revealed that PRRG4 promoted migration and invasion of breast cancer cells, and enhanced metastasis in an experimental metastasis model. Mechanistically, we found that PRRG4 via its LPSY and PPPY motifs recruited the E3 ubiquitin ligase NEDD4, which induced ubiquitination and degradation of Robo1, thus contributing to migration and invasion of breast cancer cells. In addition, PRRG4 interacted with and enhanced protein tyrosine kinase Src and FAK activation. Overall, our data support a model that PRRG4 via NEDD4 downregulates the Robo1, resulting in the activation of Src and FAK and promoting breast cancer metastasis. PRRG4 may be a novel target for treating metastatic breast cancer.	[Zhang, Lingling; Qin, Yaqian; Wu, Guang; Wang, Jieyi; Cao, Jiawei; Wang, Yaqi; Wu, Du; He, Licai; Lyu, Jianxin; Li, Hongzhi; Gu, Haihua] Wenzhou Med Univ, Sch Lab Med & Life Sci, Key Lab Lab Med, Minist Educ, Wenzhou 325035, Peoples R China; [Yang, Kaiyan] Wenzhou Med Univ, Dept Pathol, Affiliated Hosp 1, Wenzhou 325035, Peoples R China; [Zhao, Zhiguang] Wenzhou Med Univ, Dept Pathol, Affiliated Hosp 2, Wenzhou 325000, Peoples R China	Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical University	Lyu, JX; Li, HZ; Gu, HH (corresponding author), Wenzhou Med Univ, Sch Lab Med & Life Sci, Key Lab Lab Med, Minist Educ, Wenzhou 325035, Peoples R China.	jxlu313@163.com; lhz@wmu.edu.cn; haihuagu@wmu.edu.cn	zhang, lingling/HDM-2189-2022	Wang, Jieyi/0000-0001-7444-0656; Cao, Jiawei/0000-0001-6268-5912	National Natural Science Foundation of China [81972463, 81772819]; Natural Science Foundation of Zhejiang Province, China [LY20C080001, LY18H080003]; Wenzhou Medical University Startup funds; Key Discipline of Zhejiang Province in Medical Technology (First Class, Category A)	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Zhejiang Province, China(Natural Science Foundation of Zhejiang Province); Wenzhou Medical University Startup funds; Key Discipline of Zhejiang Province in Medical Technology (First Class, Category A)	We thank Dr. Weibao Jiao (Kunming Institute of Zoology, Academia Sinica) for kindly providing us the MDA-MB-231-luciferase cells, and Helen Gu (Department of Economics, Massachusetts Institute of Technology) for proofreading the paper. This work was supported by grants (81972463 and 81772819) from the National Natural Science Foundation of China, and grants (LY20C080001 and LY18H080003) from Natural Science Foundation of Zhejiang Province, China, and was supported in part by Wenzhou Medical University Startup funds and the Key Discipline of Zhejiang Province in Medical Technology (First Class, Category A).	Nieto MA, 2011, ANNU REV CELL DEV BI, V27, P347, DOI 10.1146/annurev-cellbio-092910-154036; Ballard MS, 2012, ADV CANCER RES, V114, P187, DOI 10.1016/B978-0-12-386503-8.00005-3; Bhattacharya R, 2016, J GENET, V95, P551, DOI 10.1007/s12041-016-0678-2; Blockus H, 2016, DEVELOPMENT, V143, P3037, DOI 10.1242/dev.132829; Blockus H, 2014, CURR OPIN NEUROBIOL, V27, P82, DOI 10.1016/j.conb.2014.03.003; Boase NA, 2015, GENE, V557, P113, DOI 10.1016/j.gene.2014.12.020; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Juarez-Cruz JC, 2019, ENDOCR CONNECT, V8, P1539, DOI 10.1530/EC-19-0442; Chang PH, 2012, CANCER RES, V72, P4652, DOI 10.1158/0008-5472.CAN-12-0877; Dallol A, 2002, ONCOGENE, V21, P3020, DOI 10.1038/sj.onc.1205421; Dickinson RE, 2010, REPRODUCTION, V139, P697, DOI 10.1530/REP-10-0017; Diepenbruck M, 2014, J CELL SCI, V127, P1523, DOI 10.1242/jcs.139865; Fang ZH, 2019, EXP CELL RES, V382, DOI 10.1016/j.yexcr.2019.06.007; Fitzmaurice C, 2021, JAMA ONCOL, DOI 10.1001/jamaoncol.2020.8307; Gara RK, 2015, DRUG DISCOV TODAY, V20, P156, DOI 10.1016/j.drudis.2014.09.008; Gilestro GF, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003798; Gorla M, 2019, CELL REP, V26, P3298, DOI 10.1016/j.celrep.2019.02.080; HE L, 2017, SCI REP UK, V7; Justice ED, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006865; Kanelis V, 2006, STRUCTURE, V14, P543, DOI 10.1016/j.str.2005.11.018; Ke H, 2018, P NATL ACAD SCI USA, V115, pE3426, DOI 10.1073/pnas.1714573115; Keleman K, 2002, CELL, V110, P415, DOI 10.1016/S0092-8674(02)00901-7; Kong RR, 2015, J CLIN INVEST, V125, P4407, DOI 10.1172/JCI81673; Kulman JD, 1997, P NATL ACAD SCI USA, V94, P9058, DOI 10.1073/pnas.94.17.9058; Kulman JD, 2001, P NATL ACAD SCI USA, V98, P1370, DOI 10.1073/pnas.98.4.1370; Lu W, 2019, DEV CELL, V49, P361, DOI 10.1016/j.devcel.2019.04.010; Marlow R, 2008, CANCER RES, V68, P7819, DOI 10.1158/0008-5472.CAN-08-1357; Myat A, 2002, NEURON, V35, P447, DOI 10.1016/S0896-6273(02)00795-X; Nakatsukasa K, 2008, CELL, V132, P101, DOI 10.1016/j.cell.2007.11.023; Naser R, 2018, CANCERS, V10, DOI 10.3390/cancers10060196; Nayar U, 2019, NAT GENET, V51, P207, DOI 10.1038/s41588-018-0287-5; Ngan E, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15059; Ottinger EA, 1998, J BIOL CHEM, V273, P729, DOI 10.1074/jbc.273.2.729; Patel A, 2016, LIFE SCI, V157, P52, DOI 10.1016/j.lfs.2016.05.036; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; Qin F, 2015, SCI REP-UK, V5, DOI 10.1038/srep09977; Schmid BC, 2007, BREAST CANCER RES TR, V106, P333, DOI 10.1007/s10549-007-9504-0; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; Timms JF, 1998, MOL CELL BIOL, V18, P3838, DOI 10.1128/MCB.18.7.3838; Waks Adrienne G, 2019, JAMA, V321, P288, DOI 10.1001/jama.2018.19323; Wallace AG, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.168724; Wang Jing, 2011, Zhonghua Zhong Liu Za Zhi, V33, P447; Wang SZ, 2013, J NEUROSCI, V33, P12242, DOI 10.1523/JNEUROSCI.5736-12.2013; Whitford KL, 2002, NEURON, V33, P47, DOI 10.1016/S0896-6273(01)00566-9; Wong K, 2001, CELL, V107, P209, DOI 10.1016/S0092-8674(01)00530-X; Xia YW, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12606; Xu S, 2008, CYTOGENET GENOME RES, V122, P181, DOI 10.1159/000172086; Yamamoto T, 2014, AM J MED GENET A, V164, P634, DOI 10.1002/ajmg.a.36325; Yang N, 2012, CELL CYCLE, V11, P2922, DOI 10.4161/cc.21386; Yazicioglu MN, 2013, J BIOL CHEM, V288, P25908, DOI 10.1074/jbc.M113.484683; Yip KT, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-128; Yuan TC, 2017, BIOCHEM BIOPH RES CO, V488, P439, DOI 10.1016/j.bbrc.2017.04.072; Yuasa-Kawada J, 2009, P NATL ACAD SCI USA, V106, P14530, DOI 10.1073/pnas.0801262106; Zhao X, 2011, ADV DRUG DELIVER REV, V63, P610, DOI 10.1016/j.addr.2010.11.001	54	10	10	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2020	39	49					7196	7208		10.1038/s41388-020-01494-7	http://dx.doi.org/10.1038/s41388-020-01494-7		OCT 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PB0GA	33037408				2022-12-28	WOS:000578440800002
J	Azad, AK; Zhabyeyev, P; Vanhaesebroeck, B; Eitzen, G; Oudit, GY; Moore, RB; Murray, AG				Azad, Abul K.; Zhabyeyev, Pavel; Vanhaesebroeck, Bart; Eitzen, Gary; Oudit, Gavin Y.; Moore, Ronald B.; Murray, Allan G.			Inactivation of endothelial cell phosphoinositide 3-kinase beta inhibits tumor angiogenesis and tumor growth	ONCOGENE			English	Article							ANTIANGIOGENIC AGENT SUNITINIB; VASCULAR DEVELOPMENT; MEDIATES RESISTANCE; P110-ALPHA ISOFORM; THERAPY; CARCINOMA; PATHWAY; OXYGENATION; METASTASIS; EXPRESSION	Angiogenesis inhibitors, such as the receptor tyrosine kinase (RTK) inhibitor sunitinib, target vascular endothelial growth factor (VEGF) signaling in cancers. However, only a fraction of patients respond, and most ultimately develop resistance to current angiogenesis inhibitor therapies. Activity of alternative pro-angiogenic growth factors, acting via RTK or G-protein coupled receptors (GPCR), may mediate VEGF inhibitor resistance. The phosphoinositide 3-kinase (PI3K)beta isoform is uniquely coupled to both RTK and GPCRs. We investigated the role of endothelial cell (EC) PI3K beta in tumor angiogenesis. Pro-angiogenic GPCR ligands were expressed by patient-derived renal cell carcinomas (PD-RCC), and selective inactivation of PI3K beta reduced PD-RCC-stimulated EC spheroid sprouting. EC-specific PI3K beta knockout (Epsilon C-beta KO) in mice potentiated the sunitinib-induced reduction in subcutaneous growth of LLC1 and B16F10, and lung metastasis of B16F10 tumors. Compared to single-agent sunitinib treatment, tumors in sunitinib-treated Epsilon C-beta KO mice showed a marked decrease in microvessel density, and reduced new vessel formation. The fraction of perfused mature tumor microvessels was increased in Epsilon C-beta KO mice suggesting immature microvessels were most sensitive to combined sunitinib and PI3K beta inactivation. Taken together, EC PI3K beta inactivation with sunitinib inhibition reduces microvessel turnover and decreases heterogeneity of the tumor microenvironment, hence PI3K beta inhibition may be a useful adjuvant antiangiogenesis therapy with sunitinib.	[Azad, Abul K.; Zhabyeyev, Pavel; Oudit, Gavin Y.; Murray, Allan G.] Univ Alberta, Dept Med, Edmonton, AB, Canada; [Zhabyeyev, Pavel; Oudit, Gavin Y.] Univ Alberta, Dept Physiol, Edmonton, AB, Canada; [Vanhaesebroeck, Bart] UCL, UCL Canc Inst, London, England; [Eitzen, Gary] Univ Alberta, Dept Cell Biol, Edmonton, AB, Canada; [Moore, Ronald B.] Univ Alberta, Dept Oncol, Edmonton, AB, Canada	University of Alberta; University of Alberta; University of London; University College London; University of Alberta; University of Alberta	Murray, AG (corresponding author), Univ Alberta, Dept Med, Edmonton, AB, Canada.	allan.murray@ualberta.ca	Moore, Ronald Brian/AET-3015-2022		Translational Research Fellowship award from the Department of Medicine at the University of Alberta; Canadian Cancer Society Research Institute	Translational Research Fellowship award from the Department of Medicine at the University of Alberta; Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS))	AKA was supported by a Translational Research Fellowship award from the Department of Medicine at the University of Alberta. Operating funding was provided by the Canadian Cancer Society Research Institute to AGM. The authors acknowledge the technical assistance of Jessica DesAulniers.	Abramsson A, 2003, J CLIN INVEST, V112, P1142, DOI 10.1172/JCI200318549; Ackah E, 2005, J CLIN INVEST, V115, P2119, DOI 10.1172/JCI24726; Nieto MA, 2017, NAT CELL BIOL, V19, P416, DOI 10.1038/ncb3520; Bergerot P, 2019, MOL CANCER THER, V18, P2185, DOI 10.1158/1535-7163.MCT-18-1399; Bilanges B, 2019, NAT REV MOL CELL BIO, V20, P515, DOI 10.1038/s41580-019-0129-z; Brabletz T, 2018, NAT REV CANCER, V18, P128, DOI 10.1038/nrc.2017.118; Bridgeman VL, 2017, J PATHOL, V241, P362, DOI 10.1002/path.4845; Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005; Charo DN, 2009, AM J PHYSIOL-HEART C, V297, pH1904, DOI 10.1152/ajpheart.00686.2009; Choueiri TK, 2017, NEW ENGL J MED, V376, P354, DOI 10.1056/NEJMra1601333; de Palma M, 2017, NAT REV CANCER, V17, P457, DOI 10.1038/nrc.2017.51; del Toro R, 2010, BLOOD, V116, P4025, DOI 10.1182/blood-2010-02-270819; Ebos JML, 2007, P NATL ACAD SCI USA, V104, P17069, DOI 10.1073/pnas.0708148104; Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Gougis P, 2017, CRIT REV ONCOL HEMAT, V119, P75, DOI 10.1016/j.critrevonc.2017.08.010; Graupera M, 2008, NATURE, V453, P662, DOI 10.1038/nature06892; Grepin R, 2012, ONCOGENE, V31, P1683, DOI 10.1038/onc.2011.360; Grepin R, 2014, CANCER RES, V74, P873, DOI 10.1158/0008-5472.CAN-13-1267; Grunstein J, 1999, CANCER RES, V59, P1592; Haddad G, 2014, BLOOD, V124, P2142, DOI 10.1182/blood-2014-02-557975; Hamada K, 2005, GENE DEV, V19, P2054, DOI 10.1101/gad.1308805; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huang D, 2010, CANCER RES, V70, P1063, DOI 10.1158/0008-5472.CAN-09-3965; Huang JH, 2002, J BIOL CHEM, V277, P10760, DOI 10.1074/jbc.M110219200; Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838; Jackson SP, 2005, NAT MED, V11, P507, DOI 10.1038/nm1232; Jahangiri A, 2013, CLIN CANCER RES, V19, P1773, DOI 10.1158/1078-0432.CCR-12-1281; Jimenez-Valerio G, 2016, CURR DRUG TARGETS, V17, P1728, DOI 10.2174/1389450117666160301101425; Kasai A, 2008, ARTERIOSCL THROM VAS, V28, P1717, DOI 10.1161/ATVBAHA.108.163402; Kryczek I, 2005, CANCER RES, V65, P465; Lyons YA, 2017, ONCOTARGET, V8, P96496, DOI [10.19632/oncotarget.20410, 10.18632/oncotarget.20410]; Ma Shaolin, 2018, F1000Res, V7, P326, DOI 10.12688/f1000research.11771.1; Mancuso MR, 2006, J CLIN INVEST, V116, P2610, DOI 10.1172/JCI24612; Mastrella G, 2019, CANCER RES, V79, P2298, DOI 10.1158/0008-5472.CAN-18-0881; Mateo J, 2017, CLIN CANCER RES, V23, P5981, DOI 10.1158/1078-0432.CCR-17-0725; Matsumoto S, 2011, CANCER RES, V71, P6350, DOI 10.1158/0008-5472.CAN-11-2025; McDermott DF, 2018, NAT MED, V24, P749, DOI 10.1038/s41591-018-0053-3; Nowak-Sliwinska P, 2018, ANGIOGENESIS, V21, P425, DOI 10.1007/s10456-018-9613-x; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Phung TL, 2006, CANCER CELL, V10, P159, DOI 10.1016/j.ccr.2006.07.003; Seaman S, 2007, CANCER CELL, V11, P539, DOI 10.1016/j.ccr.2007.04.017; Sennino B, 2012, NAT REV CANCER, V12, P699, DOI 10.1038/nrc3366; Shojaei F, 2010, CANCER RES, V70, P10090, DOI 10.1158/0008-5472.CAN-10-0489; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Soler A, 2013, J EXP MED, V210, P1937, DOI 10.1084/jem.20121571; Stockmann C, 2008, NATURE, V456, P814, DOI 10.1038/nature07445; Strasser GA, 2010, BLOOD, V115, P5102, DOI 10.1182/blood-2009-07-230284; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Terry S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103044; Thomas JS, 2015, CRIT REV ONCOL HEMAT, V96, P527, DOI 10.1016/j.critrevonc.2015.07.009; Vanhaesebroeck B, 2016, J MOL MED, V94, P5, DOI 10.1007/s00109-015-1352-5; Winkler F, 2004, CANCER CELL, V6, P553, DOI 10.1016/j.ccr.2004.10.011; Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765; Zhao L, 2008, ONCOGENE, V27, P5486, DOI 10.1038/onc.2008.244; Zhou L, 2016, ONCOGENE, V35, P2687, DOI 10.1038/onc.2015.343	57	8	8	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2020	39	41					6480	6492		10.1038/s41388-020-01444-3	http://dx.doi.org/10.1038/s41388-020-01444-3		SEP 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OA1JL	32879446	Green Submitted			2022-12-28	WOS:000565482600001
J	Ranzuglia, V; Lorenzon, I; Pellarin, I; Sonego, M; Dall'Acqua, A; D'Andrea, S; Lovisa, S; Segatto, I; Coan, M; Polesel, J; Serraino, D; Sabatelli, P; Spessotto, P; Belletti, B; Baldassarre, G; Schiappacassi, M				Ranzuglia, Valentina; Lorenzon, Ilaria; Pellarin, Ilenia; Sonego, Maura; Dall'Acqua, Alessandra; D'Andrea, Sara; Lovisa, Sara; Segatto, Ilenia; Coan, Michela; Polesel, Jerry; Serraino, Diego; Sabatelli, Patrizia; Spessotto, Paola; Belletti, Barbara; Baldassarre, Gustavo; Schiappacassi, Monica			Serum- and glucocorticoid- inducible kinase 2, SGK2, is a novel autophagy regulator and modulates platinum drugs response in cancer cells	ONCOGENE			English	Article							OVARIAN-CANCER; CISPLATIN RESISTANCE; DUAL ROLE; PROTEIN; TARGET; ACTIVATION; ATPASE; AKT; MECHANISMS; INHIBITION	For many tumor types chemotherapy still represents the therapy of choice and many standard treatments are based on the use of platinum (PT) drugs. However, de novo or acquired resistance to platinum is frequent and leads to disease progression. In Epithelial Ovarian Cancer (EOC) patients, PT-resistant recurrences are very common and improving the response to treatment still represents an unmet clinical need. To identify new modulators of PT-sensitivity, we performed a loss-of-function screening targeting 680 genes potentially involved in the response of EOC cells to platinum. We found that SGK2 (Serum-and Glucocorticoid-inducible kinase 2) plays a key role in PT-response. We show here that EOC cells relay on the induction of autophagy to escape PT-induced death and that SGK2 inhibition increases PT sensitivity inducing a block in the autophagy cascade due to the impairment of lysosomal acidification. Mechanistically we demonstrate that SGK2 controls autophagy in a kinase-dependent manner by binding and inhibiting the V-ATPase proton pump. Accordingly, SGK2 phosphorylates the subunit V1H (ATP6V1H) of V-ATPase and silencing or chemical inhibition of SGK2, affects the normal autophagic flux and sensitizes EOC cells to platinum. Hence, we identified a new pathway that links autophagy to the survival of cancer cells under platinum treatment in which the druggable kinase SGK2 plays a central role. Our data suggest that blocking autophagy via SGK2 inhibition could represent a novel therapeutic strategy to improve patients' response to platinum.	[Ranzuglia, Valentina; Lorenzon, Ilaria; Pellarin, Ilenia; Sonego, Maura; Dall'Acqua, Alessandra; D'Andrea, Sara; Lovisa, Sara; Segatto, Ilenia; Coan, Michela; Spessotto, Paola; Belletti, Barbara; Baldassarre, Gustavo; Schiappacassi, Monica] IRCCS, Ctr Riferimento Oncol Aviano CRO, Div Mol Oncol, I-33081 Aviano, Italy; [Polesel, Jerry; Serraino, Diego] IRCCS, Ctr Riferimento Oncol Aviano CRO, Epidemiol, I-33081 Aviano, Italy; [Sabatelli, Patrizia] CNR, Inst Mol Genet, Bologna, Italy; [Sabatelli, Patrizia] Rizzoli Orthoped Inst, Bologna, Italy	IRCCS Aviano (CRO); IRCCS Aviano (CRO); Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); IRCCS Istituto Ortopedico Rizzoli	Baldassarre, G; Schiappacassi, M (corresponding author), IRCCS, Ctr Riferimento Oncol Aviano CRO, Div Mol Oncol, I-33081 Aviano, Italy.	gbaldassarre@cro.it; mschiappacassi@cro.it	Serraino, Diego/J-3915-2018; Lorenzon, Ilaria/AAY-6372-2020; Baldassarre, Gustavo/K-1350-2016; Spessotto, Paola/K-5005-2012; Segatto, Ilenia/AAX-5513-2020; Belletti, Barbara/J-2028-2018; Lovisa, Sara/AAB-1141-2020; Schiappacassi, Monica/AAX-5505-2020; Dall'Acqua, Alessandra/ABF-8020-2020; Pellarin, Ilenia/AAY-2238-2020; Sonego, Maura/AAX-5529-2020	Serraino, Diego/0000-0003-0565-8920; Lorenzon, Ilaria/0000-0001-6336-4678; Baldassarre, Gustavo/0000-0002-9750-8825; Spessotto, Paola/0000-0002-3033-404X; Segatto, Ilenia/0000-0001-5282-1028; Belletti, Barbara/0000-0003-2249-0285; Lovisa, Sara/0000-0001-7776-2896; Schiappacassi, Monica/0000-0003-4804-4291; Dall'Acqua, Alessandra/0000-0003-2297-1361; Pellarin, Ilenia/0000-0002-1041-1722; Sonego, Maura/0000-0002-9505-9771	Ministero della Salute [RF-2010-2309704, RF-2016-02361040, RF-2016-02361041]; Regione Friuli Venezia Giulia (Tichep Grant); 5x1000 CRO; AIRC biannual Fellowship [18171]	Ministero della Salute(Ministry of Health, Italy); Regione Friuli Venezia Giulia (Tichep Grant); 5x1000 CRO; AIRC biannual Fellowship	We thank Dr William Hahn and David Root for SGK2 vector (through Addgene), Dr Tamotsu Yoshimori for ptfLC3 vectors (through Addgene), Dr Roberta Maestro for pLPC vector and Laura Cesaratto and Sara Benevol for technical support. We are grateful to all members of our lab for helpful and stimulating discussions. This work was supported by grants from Ministero della Salute (RF-2010-2309704 and RF-2016-02361040), Regione Friuli Venezia Giulia (Tichep Grant) and 5x1000 CRO to GB; grants from 5x1000 CRO Intramural Young Investigator and from Ministero della Salute (RF-2016-02361041) to MSo. IS was supported by an AIRC biannual Fellowship (# 18171). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arencibia JM, 2013, BBA-PROTEINS PROTEOM, V1834, P1302, DOI 10.1016/j.bbapap.2013.03.010; Bago R, 2016, EMBO J, V35, P2263, DOI 10.15252/embj.201670010; Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Berton S, 2014, CELL CYCLE, V13, P3100, DOI 10.4161/15384101.2014.949512; Biazik J, 2015, METHODS, V75, P44, DOI 10.1016/j.ymeth.2014.11.013; Bruhn Maressa A, 2013, Cancer Manag Res, V5, P281, DOI 10.2147/CMAR.S35178; Bruhn MA, 2010, GROWTH FACTORS, V28, P394, DOI 10.3109/08977194.2010.518616; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Castel P, 2016, CANCER CELL, V30, P229, DOI 10.1016/j.ccell.2016.06.004; Cotter K, 2015, TRENDS BIOCHEM SCI, V40, P611, DOI 10.1016/j.tibs.2015.08.005; Dall'Acqua A, 2017, EMBO MOL MED, V9, P1415, DOI 10.15252/emmm.201607012; Deans AJ, 2011, NAT REV CANCER, V11, P467, DOI 10.1038/nrc3088; Dikic I, 2018, NAT REV MOL CELL BIO, V19, P349, DOI 10.1038/s41580-018-0003-4; Eskelinen EL, 2005, AUTOPHAGY, V1, P1, DOI 10.4161/auto.1.1.1270; Eskelinen EL, 2011, CURR OPIN PHARMACOL, V11, P294, DOI 10.1016/j.coph.2011.03.009; Galluzzi L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.428; Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384; Galluzzi L, 2017, EMBO J, V36, P1811, DOI 10.15252/embj.201796697; Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784; Gatti L, 2015, DRUG RESIST UPDATE, V20, P1, DOI 10.1016/j.drup.2015.04.001; He PJ, 2011, MOL BIOL CELL, V22, P3812, DOI 10.1091/mbc.E11-04-0328; Henke G, 2002, KIDNEY BLOOD PRESS R, V25, P370, DOI 10.1159/000068699; Holmes D, 2015, NATURE, V527, P219; Holmes D, 2015, NATURE, V527, pS217, DOI 10.1038/527S217a; Imai H, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-0929-3; Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71; Jayson GC, 2014, LANCET, V384, P1376, DOI 10.1016/S0140-6736(13)62146-7; Kang X, 2015, CANCER BIOL MED, V12, P362, DOI 10.7497/j.issn.2095-3941.2015.0063; Katayama H, 2008, CELL STRUCT FUNCT, V33, P1, DOI 10.1247/csf.07011; Kimmelman AC, 2017, CELL METAB, V25, P1037, DOI 10.1016/j.cmet.2017.04.004; Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451; Klionsky DJ, 2011, AUTOPHAGY, V7, P1, DOI 10.4161/auto.7.1.14130; Kobayashi T, 1999, BIOCHEM J, V344, P189, DOI 10.1042/0264-6021:3440189; Kulshrestha A, 2016, MOL ONCOL, V10, P789, DOI 10.1016/j.molonc.2016.01.003; Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53; Liu DL, 2011, MED ONCOL, V28, P105, DOI 10.1007/s12032-009-9397-3; Lo Russo G, 2017, CURR DRUG TARGETS, V18, P341, DOI 10.2174/1389450117666160502152331; Loos B, 2014, AUTOPHAGY, V10, P2087, DOI 10.4161/15548627.2014.973338; Lu ZN, 2017, CANCER CHEMOTH PHARM, V80, P925, DOI 10.1007/s00280-017-3426-2; Machiels JPH, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-473; Marshansky V, 2008, CURR OPIN CELL BIOL, V20, P415, DOI 10.1016/j.ceb.2008.03.015; Massarelli E, 2015, ANN ONCOL, V26, P1476, DOI 10.1093/annonc/mdv194; Mauvezin C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8007; Mindell JA, 2012, ANNU REV PHYSIOL, V74, P69, DOI 10.1146/annurev-physiol-012110-142317; Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; O'Keeffe BA, 2013, BIOCHIMIE, V95, P1258, DOI 10.1016/j.biochi.2013.01.019; Pao AC, 2007, AM J PHYSIOL-RENAL, V292, pF1741, DOI 10.1152/ajprenal.00027.2007; Pao AC, 2012, CURR OPIN NEPHROL HY, V21, P534, DOI 10.1097/MNH.0b013e32835571be; Pao AC, 2010, AM J PHYSIOL-RENAL, V299, pF1496, DOI 10.1152/ajprenal.00075.2010; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Patch AM, 2015, NATURE, V521, P489, DOI 10.1038/nature14410; Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822; Pellarin I, 2020, ONCOGENE, V39, P4390, DOI 10.1038/s41388-020-1292-6; Ren JH, 2010, CANCER BIOTHER RADIO, V25, P75, DOI 10.1089/cbr.2009.0701; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802; Rybstein MD, 2018, NAT CELL BIOL, V20, P243, DOI 10.1038/s41556-018-0042-2; Sherk AB, 2008, CANCER RES, V68, P7475, DOI 10.1158/0008-5472.CAN-08-1047; Singh SS, 2018, ONCOGENE, V37, P1142, DOI 10.1038/s41388-017-0046-6; Sonego M, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav3235; Sonego M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07005-1; Sonego M, 2013, EMBO MOL MED, V5, P707, DOI 10.1002/emmm.201201504; Song T, 2017, CANCER RES TREAT, V49, P595, DOI 10.4143/crt.2016.034; Thome MP, 2016, J CELL SCI, V129, P4622, DOI 10.1242/jcs.195057; Vasudevan KM, 2009, CANCER CELL, V16, P21, DOI 10.1016/j.ccr.2009.04.012; Vaughan S, 2011, NAT REV CANCER, V11, P719, DOI 10.1038/nrc3144; Yu H, 2011, EUR J CANCER, V47, P1585, DOI 10.1016/j.ejca.2011.01.019	69	7	7	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2020	39	40					6370	6386		10.1038/s41388-020-01433-6	http://dx.doi.org/10.1038/s41388-020-01433-6		AUG 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NV5JK	32848212	hybrid, Green Published			2022-12-28	WOS:000563171700001
J	Esposito, M; Akman, HB; Giron, P; Ceregido, MA; Schepers, R; Paez, LRC; La Monaca, E; De Greve, J; Coux, O; De Trez, C; Lindon, C; Gutierrez, GJ				Esposito, Mara; Akman, H. Begum; Giron, Philippe; Ceregido, M. Angeles; Schepers, Rogier; Ramos Paez, Luis C.; La Monaca, Esther; De Greve, Jacques; Coux, Olivier; De Trez, Carl; Lindon, Catherine; Gutierrez, Gustavo J.			USP13 controls the stability of Aurora B impacting progression through the cell cycle	ONCOGENE			English	Article							TUMOR-SUPPRESSOR CYLD; MITOTIC KINASE; OVEREXPRESSION; ANEUPLOIDY; PHOSPHORYLATION; DEGRADATION; EXPRESSION; PREDICTION; REGULATOR; SEQUENCE	Aurora B kinase plays essential roles in mitosis. Its protein levels increase before the onset of mitosis and sharply decrease during mitosis exit. The latter decrease is due to a balance between the actions of the E3 ubiquitin ligase anaphase-promoting complex or cyclosome (activated by the Cdh1 adapter), and the deubiquitinating enzyme USP35. Aurora B also executes important functions in interphase. Abnormal modulation of Aurora B in interphase leads to cell cycle defects often linked to aberrant chromosomal condensation and segregation. Very little is however known about how Aurora B levels are regulated in interphase. Here we found that USP13-associates with and stabilizes Aurora B in cells, especially before their entry into mitosis. In order for USP13 to exert its stabilizing effect on Aurora B, their association is promoted by the Aurora B-mediated phosphorylation of USP13 at Serine 114. We also present evidence that USP13 instigates Aurora B deubiquitination and/or protect it from degradation in a non-catalytic manner. In addition, we report that genetic or chemical modulation of the cellular levels/activity of USP13 affects unperturbed cell-cycle progression. Overall our study unveils the molecular and cellular connections of the USP13-Aurora B axis, which potentially participates in the rewiring of the cell cycle happening in cancer cells.	[Esposito, Mara; Giron, Philippe; Ceregido, M. Angeles; Schepers, Rogier; Ramos Paez, Luis C.; La Monaca, Esther; Gutierrez, Gustavo J.] Vrije Univ Brussel, Fac Sci & Bioengn Sci, Dept Biol, Lab Pathophysiol Cell Signaling, Pl Laan 2, B-1050 Brussels, Belgium; [Akman, H. Begum; Lindon, Catherine] Univ Cambridge, Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1PD, England; [Giron, Philippe; De Greve, Jacques] Vrije Univ Brussel, Fac Med & Pharm, Lab Mol & Med Oncol, Laarbeeklaan 103, B-1090 Brussels, Belgium; [Coux, Olivier] CNRS, CRBM, 1919 Route Mende, F-34293 Montpellier, France; [De Trez, Carl] Vrije Univ Brussel, Fac Sci & Bioengn Sci, Dept Bioengn, Lab Cellular & Mol Immunol, Pl Laan 2, B-1050 Brussels, Belgium; [Ceregido, M. Angeles] GlaxoSmithKline, Ave Pascal 2-4-6, B-1300 Wavre, Belgium; [Schepers, Rogier] VIB KU Leuven, Ctr Canc Biol, Campus Gasthuisberg,Herestr 49-B912, Leuven, Belgium; [Ramos Paez, Luis C.] Ablynx NV, Technol Pk 21, B-9052 Ghent, Belgium; [La Monaca, Esther] Janssen Pharmaceut NV, Turnhoutseweg 30, B-2340 Beerse, Belgium; [Gutierrez, Gustavo J.] Galapagos NV, Generaal Wittelaan L11 A3, B-2800 Mechelen, Belgium	Vrije Universiteit Brussel; University of Cambridge; Vrije Universiteit Brussel; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Vrije Universiteit Brussel; GlaxoSmithKline; Flanders Institute for Biotechnology (VIB); KU Leuven; Johnson & Johnson; Janssen Pharmaceuticals; Galapagos NV	Gutierrez, GJ (corresponding author), Vrije Univ Brussel, Fac Sci & Bioengn Sci, Dept Biol, Lab Pathophysiol Cell Signaling, Pl Laan 2, B-1050 Brussels, Belgium.; Gutierrez, GJ (corresponding author), Galapagos NV, Generaal Wittelaan L11 A3, B-2800 Mechelen, Belgium.	ggutierr@vub.be	Akman, H. Begum/F-8427-2012; Coux, Olivier/P-6847-2019; Gutierrez, Gustavo/AAO-9957-2021; De Greve, Jacques/J-4939-2012	Akman, H. Begum/0000-0003-4646-4225; Coux, Olivier/0000-0001-8455-3849; Gutierrez, Gustavo/0000-0001-8652-972X; De Trez, Carl/0000-0002-3899-1968; Giron, Philippe/0000-0002-1331-1890; De Greve, Jacques/0000-0002-2389-0742	FWO [G0C7514N]; BELSPO Interuniversity Attraction Poles [IAP-P7 - 07]; VUB (starting ZAP credit & Interdisciplinary Research Program for Excellence on Cancer Research); Innoviris (BB2B program); COST-EU program (Proteostasis); BBSRC [BB/R004137/1] Funding Source: UKRI; MRC [MR/M01102X/1] Funding Source: UKRI	FWO(FWO); BELSPO Interuniversity Attraction Poles; VUB (starting ZAP credit & Interdisciplinary Research Program for Excellence on Cancer Research); Innoviris (BB2B program); COST-EU program (Proteostasis); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Research in GJG's laboratory was funded by grants from FWO (G0C7514N), BELSPO Interuniversity Attraction Poles (IAP-P7 - 07), VUB (starting ZAP credit & Interdisciplinary Research Program for Excellence on Cancer Research), and Innoviris (BB2B program). The collaboration between the laboratories of GJG and CL included a short-term scientific mission (ME) supported by the COST-EU program (Proteostasis). We are indebted to Yvon Elkrim for technical assistance with the flow cytometry analyses, and to Professors Luc Leyns and Peter Tompa (VUB- and VIB- Brussels, Belgium, respectively) for allowing access to some of their laboratories' equipment.	Bassermann F, 2014, BBA-MOL CELL RES, V1843, P150, DOI 10.1016/j.bbamcr.2013.02.028; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Bonet C, 2012, J BIOL CHEM, V287, P29887, DOI 10.1074/jbc.M112.371682; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Carmena M, 2012, NAT REV MOL CELL BIO, V13, P789, DOI 10.1038/nrm3474; Chen BB, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.271; Chen MF, 2011, P NATL ACAD SCI USA, V108, P9119, DOI 10.1073/pnas.1100028108; Chen YJ, 2009, VIRCHOWS ARCH, V455, P431, DOI 10.1007/s00428-009-0838-3; Darling S, 2017, BIOCHEM SOC T, V45, P1125, DOI 10.1042/BST20170087; Fang XG, 2017, J EXP MED, V214, P245, DOI 10.1084/jem.20151673; Floyd S, 2013, J CELL SCI, V126, P2845, DOI 10.1242/jcs.123232; Fournane Sadek, 2012, Genes Cancer, V3, P697, DOI 10.1177/1947601912473477; Ganem NJ, 2007, CURR OPIN GENET DEV, V17, P157, DOI 10.1016/j.gde.2007.02.011; Gilberto S, 2017, J CELL BIOL, V216, P2259, DOI 10.1083/jcb.201703170; Gonzalez-Loyola A, 2015, MOL CELL BIOL, V35, P3566, DOI 10.1128/MCB.01286-14; Gully CP, 2012, P NATL ACAD SCI USA, V109, pE1513, DOI 10.1073/pnas.1110287109; Han C, 2016, NAT COMMUN, V7; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; Hayashi-Takanaka Y, 2009, J CELL BIOL, V187, P781, DOI 10.1083/jcb.200904137; Jiao QJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027646; Komander D, 2012, ANNU REV BIOCHEM, V81, P203, DOI 10.1146/annurev-biochem-060310-170328; Krenn V, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00225; Li L, 2019, EBIOMEDICINE, V45, P553, DOI 10.1016/j.ebiom.2019.06.011; Li Y, 2017, NAT COMMUN, V8; Lindon C, 2016, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00307; Liu JL, 2011, CELL, V147, P223, DOI 10.1016/j.cell.2011.08.037; Liu Y, 2014, ELIFE, V3; Maerki S, 2009, J CELL BIOL, V187, P791, DOI 10.1083/jcb.200906117; Man XJ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1262-4; Mayya V, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000007; McCloy RA, 2014, CELL CYCLE, V13, P1400, DOI 10.4161/cc.28401; Morgan D. O., 2006, CELL CYCLE PRINCIPLE; Munoz-Barrera M, 2014, P NATL ACAD SCI USA, V111, pE3996, DOI 10.1073/pnas.1408017111; Nguyen HG, 2005, MOL CELL BIOL, V25, P4977, DOI 10.1128/MCB.25.12.4977-4992.2005; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Ota T, 2002, CANCER RES, V62, P5168; Otto T, 2017, NAT REV CANCER, V17, P93, DOI 10.1038/nrc.2016.138; Park J, 2018, BMB REP, V51, P261, DOI 10.5483/BMBRep.2018.51.6.110; Pinto-Fernandez A, 2019, FRONT CHEM, V7, DOI 10.3389/fchem.2019.00592; Ruchaud S, 2007, NAT REV MOL CELL BIO, V8, P798, DOI 10.1038/nrm2257; Sahtoe DD, 2015, TRENDS BIOCHEM SCI, V40, P456, DOI 10.1016/j.tibs.2015.05.002; Scortegagna M, 2011, J BIOL CHEM, V286, P27333, DOI 10.1074/jbc.M111.218214; Song CG, 2017, CELL PHYSIOL BIOCHEM, V42, P965, DOI 10.1159/000478679; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Staibano S, 2003, HISTOPATHOLOGY, V43, P254, DOI 10.1046/j.1365-2559.2003.01706.x; Stegmeier F, 2007, P NATL ACAD SCI USA, V104, P8869, DOI 10.1073/pnas.0703268104; Sumara I, 2007, DEV CELL, V12, P887, DOI 10.1016/j.devcel.2007.03.019; Sun H, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15534; Sun L, 2010, J PATHOL, V221, P425, DOI 10.1002/path.2723; Tatsuka M, 1998, CANCER RES, V58, P4811; Teng CL, 2012, CELL CYCLE, V11, P4059, DOI 10.4161/cc.22381; van der Waal MS, 2012, EXP CELL RES, V318, P1407, DOI 10.1016/j.yexcr.2012.03.015; van Leuken RJ, 2008, CELL CYCLE, V7, P2710, DOI 10.4161/cc.7.17.6553; Vischioni B, 2006, MOL CANCER THER, V5, P2905, DOI 10.1158/1535-7163.MCT-06-0301; Wu Y, 2019, BIOMED PHARMACOTHER, V114, DOI 10.1016/j.biopha.2019.108831; Xie X, 2018, J CELL SCI, V131, DOI 10.1242/jcs.210856; Yeh HM, 2013, J IMMUNOL, V191, P3328, DOI 10.4049/jimmunol.1300225; Zeng WFF, 2007, J CLIN PATHOL, V60, P218, DOI 10.1136/jcp.2006.036806; Zhang JS, 2013, NAT CELL BIOL, V15, P1486, DOI 10.1038/ncb2874; Zhang SY, 2018, INT CONF BIG DATA, P1, DOI 10.1109/BigComp.2018.00010; Zhao XS, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1421; Zhou QX, 2020, J EXP MED, V217, DOI 10.1084/jem.20191779	62	10	10	1	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2020	39	37					6009	6023		10.1038/s41388-020-01396-8	http://dx.doi.org/10.1038/s41388-020-01396-8		AUG 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NM2OY	32772043				2022-12-28	WOS:000557315300001
J	Cai, J; Liu, WF; Wong, CW; Zhu, WB; Lin, Y; Hu, J; Xu, WC; Zhang, JF; Sander, M; Wang, Z; Dan, J; Zhang, JY; Liu, Y; Guo, L; Qin, Z; Liu, XC; Liu, Y; Yan, GM; Wu, SH; Liang, JK				Cai, Jing; Liu, Wenfeng; Wong, Chun Wa; Zhu, Wenbo; Lin, Yuan; Hu, Jun; Xu, Wencang; Zhang, Jifu; Sander, Max; Wang, Zhuo; Dan, Jia; Zhang, Jiayu; Liu, Yang; Guo, Li; Qin, Zhen; Liu, Xincheng; Liu, Ying; Yan, Guangmei; Wu, Sihan; Liang, Jiankai			Zinc-finger antiviral protein acts as a tumor suppressor in colorectal cancer	ONCOGENE			English	Article							MULTIPLE INTESTINAL NEOPLASIA; VIRAL MESSENGER-RNAS; ZAP; TRAIL; INTERFERONS; INHIBITION; RECEPTOR; EXPRESSION; INFECTION; CASPASE-8	Avoiding immune destruction is essential for tumorigenesis. Current research into the interaction between tumor and immunological niches complement tumor pathology beyond cancer genetics. Intrinsic host defense immunity is a specialized innate immunity component to restrict viral infection. However, whether intrinsic immunity participates in tumor pathology is unclear. Previously, we identified a zinc-finger antiviral protein ZAP that is commonly downregulated in a panel of clinical cancer specimens. However, whether ZAP has an impact on tumor development was unknown. Here we report ZAP as a genuine tumor suppressor. Pan-caner analysis with TCGA data from 712 patients and large-scale immunohistochemistry in tissue microarrays from 1552 patients reveal that ZAP is prevalently downregulated, and associated with poor survival in liver, colon, and bladder cancer patients. Ectopic over-expression of ZAP inhibits the malignant phenotypes of colorectal tumor by cell cycle arrest. Using RNA immunoprecipitation and RNA decay assays, we demonstrate that ZAP directly and specifically binds to and degrades the transcript of TRAILR4, which in turn represses TRAILR4 expression and inhibits the aggressiveness of colorectal cancer cells. Furthermore, our CRISPR-engineered mice models show that loss-of-function of ZAP synergizes with APC-deficiency to drive malignant colorectal cancer in vivo. Overall, we identify a previously unknown function of the antiviral factor ZAP in colorectal tumorigenesis, linking intrinsic immunity to tumor pathogenetics.	[Cai, Jing; Liu, Wenfeng; Wong, Chun Wa; Zhu, Wenbo; Lin, Yuan; Hu, Jun; Dan, Jia; Zhang, Jiayu; Liu, Yang; Guo, Li; Qin, Zhen; Liu, Xincheng; Yan, Guangmei; Liang, Jiankai] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Pharmacol, Guangzhou 510080, Peoples R China; [Xu, Wencang; Zhang, Jifu; Sander, Max] Guangzhou Virotech Pharmaceut Co Ltd, Guangzhou 510663, Peoples R China; [Wang, Zhuo] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pathol, Guangzhou 510080, Peoples R China; [Liu, Ying] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Infect Dis, Guangzhou 510630, Peoples R China; [Wu, Sihan] Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Ludwig Institute for Cancer Research; University of California System; University of California San Diego	Liang, JK (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Pharmacol, Guangzhou 510080, Peoples R China.; Wu, SH (corresponding author), Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA.	siw048@ucsd.edu; liangjk5@mail.sysu.edu.cn	Wu, Sihan/AAB-6812-2020	Wu, Sihan/0000-0001-8329-7492; Lin, Yuan/0000-0002-7152-0965; Wong, Chun-wa/0000-0003-3476-9283	National Natural Science Foundation of China [81872887, 81902809, 81872886, 81773751, 81973342, 81973347]; Fundamental Research Funds for the Central Universities [18ykpy37]; National Major Scientific and Technological Special Project for "Significant New Drugs Development" [2018ZXO9733002]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); National Major Scientific and Technological Special Project for "Significant New Drugs Development"	JC: the National Natural Science Foundation of China (No. 81902809) and the Fundamental Research Funds for the Central Universities (No. 18ykpy37). WZ: the National Natural Science Foundation of China (No. 81872886). JH: the National Natural Science Foundation of China (No. 81773751). JL: the National Natural Science Foundation of China (No. 81973342). YL: the National Natural Science Foundation of China (No. 81973347). GY: the National Natural Science Foundation of China (No. `81872887) and the National Major Scientific and Technological Special Project for "Significant New Drugs Development" during the 13th Five-Year Plan Period (No. 2018ZXO9733002).	Bick MJ, 2003, J VIROL, V77, P11555, DOI 10.1128/JVI.77.21.11555-11562.2003; Charron G, 2013, P NATL ACAD SCI USA, V110, P11085, DOI 10.1073/pnas.1302564110; Chen SD, 2012, NAT STRUCT MOL BIOL, V19, P430, DOI 10.1038/nsmb.2243; Chiu HP, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007166; Dunn GP, 2006, NAT REV IMMUNOL, V6, P836, DOI 10.1038/nri1961; Feng MY, 2019, NAT REV CANCER, V19, P568, DOI 10.1038/s41568-019-0183-z; Gao GX, 2002, SCIENCE, V297, P1703, DOI 10.1126/science.1074276; Guo XM, 2004, J VIROL, V78, P12781, DOI 10.1128/JVI.78.23.12781-12787.2004; Guo XM, 2007, P NATL ACAD SCI USA, V104, P151, DOI 10.1073/pnas.0607063104; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huang Z, 2010, PROTEIN CELL, V1, P752, DOI 10.1007/s13238-010-0096-9; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Lee H, 2013, P NATL ACAD SCI USA, V110, P12379, DOI 10.1073/pnas.1310604110; Leung AKL, 2011, MOL CELL, V42, P489, DOI 10.1016/j.molcel.2011.04.015; Li S, 2016, NAT IMMUNOL, V17, P241, DOI 10.1038/ni.3311; Lin Y, 2014, P NATL ACAD SCI USA, V111, pE4504, DOI 10.1073/pnas.1408759111; Liu CH, 2015, P NATL ACAD SCI USA, V112, P14048, DOI 10.1073/pnas.1509745112; MacDonald MR, 2007, J VIROL, V81, P13509, DOI 10.1128/JVI.00402-07; Mao RC, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003494; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Merino D, 2006, MOL CELL BIOL, V26, P7046, DOI 10.1128/MCB.00520-06; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Muller S, 2007, J VIROL, V81, P2391, DOI 10.1128/JVI.01601-06; Munoz-Fontela C, 2016, NAT REV IMMUNOL, V16, P741, DOI 10.1038/nri.2016.99; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Parker BS, 2016, NAT REV CANCER, V16, P131, DOI 10.1038/nrc.2016.14; Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060; Ribas A, 2015, CANCER DISCOV, V5, P915, DOI 10.1158/2159-8290.CD-15-0563; Saito Y, 2016, SCI REP, V6; Smyth MJ, 2003, IMMUNITY, V18, P1, DOI 10.1016/S1074-7613(02)00502-2; Snell LM, 2017, TRENDS IMMUNOL, V38, P542, DOI 10.1016/j.it.2017.05.005; Spranger S, 2018, NAT REV CANCER, V18, P139, DOI 10.1038/nrc.2017.117; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Textor S, 2011, CANCER RES, V71, P5998, DOI 10.1158/0008-5472.CAN-10-3211; Thorsson V, 2018, IMMUNITY, V48, P812, DOI [10.1016/j.immuni.2018.03.023, 10.1016/j.immuni.2019.08.004]; Todorova T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6362; von Karstedt S, 2017, NAT REV CANCER, V17, P352, DOI 10.1038/nrc.2017.28; Vyas S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3240; Wang XS, 2019, GENOMICS, V111, P1464, DOI 10.1016/j.ygeno.2018.09.020; Xuan YF, 2012, J VIROL, V86, P12431, DOI 10.1128/JVI.01514-12; Yoon KW, 2015, SCIENCE, V349, DOI 10.1126/science.1261669; Zhu YP, 2012, EMBO J, V31, P4236, DOI 10.1038/emboj.2012.271; Zhu YP, 2011, P NATL ACAD SCI USA, V108, P15834, DOI 10.1073/pnas.1101676108; Zitvogel L, 2015, NAT REV IMMUNOL, V15, P405, DOI 10.1038/nri3845	45	6	7	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2020	39	37					5995	6008		10.1038/s41388-020-01416-7	http://dx.doi.org/10.1038/s41388-020-01416-7		AUG 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NM2OY	32770142				2022-12-28	WOS:000557117100001
J	Shi, X; Liu, TT; Yu, XN; Balakrishnan, A; Zhu, HR; Guo, HY; Zhang, GC; Bilegsaikhan, E; Sun, JL; Song, GQ; Weng, SQ; Dong, L; Ott, M; Zhu, JM; Shen, XZ				Shi, Xuan; Liu, Tao-Tao; Yu, Xiang-Nan; Balakrishnan, Asha; Zhu, Hai-Rong; Guo, Hong-Ying; Zhang, Guang-Cong; Bilegsaikhan, Enkhnaran; Sun, Jia-Lei; Song, Guang-Qi; Weng, Shu-Qiang; Dong, Ling; Ott, Michael; Zhu, Ji-Min; Shen, Xi-Zhong			microRNA-93-5p promotes hepatocellular carcinoma progression via a microRNA-93-5p/MAP3K2/c-Jun positive feedback circuit	ONCOGENE			English	Article							C-JUN; PATHWAY; JNK; PROLIFERATION; PATHOGENESIS; EXPRESSION; REPRESSION; APOPTOSIS; DATABASE; MAP3K2	Cumulative evidence suggests that microRNAs (miRNAs) promote gene expression in cancers. However, the pathophysiologic relevance of miRNA-mediated RNA activation in hepatocellular carcinoma (HCC) remains to be established. Our previous miRNA expression profiling in seven-paired HCC specimens revealed miR-93-5p as an HCC-related miRNA. In this study, miR-93-5p expression was assessed in HCC tissues and cell lines by quantitative real-time PCR and fluorescence in situ hybridization. The correlation of miR-93-5p expression with survival and clinicopathological features of HCC was determined by statistical analysis. The function and potential mechanism of miR-93-5p in HCC were further investigated by a series of gain- or loss-of-function experiments in vitro and in vivo. We identified that miR-93-5p, overexpressed in HCC specimens and cell lines, leads to poor outcomes in HCC cases and promotes proliferation, migration, and invasion in HCC cell lines. Mechanistically, rather than decreasing target mRNA levels as expected, miR-93-5p binds to the 3 '-untranslated region (UTR) of mitogen-activated protein kinase kinase kinase 2 (MAP3K2) to directly upregulate its expression and downstream p38 and c-Jun N-terminal kinase (JNK) pathway, thereby leading to cell cycle progression in HCC. Notably, we also demonstrated that c-Jun, a downstream effector of the JNK pathway, enhances miR-93-5p transcription by targeting its promoter region. Besides, downregulation of miR-93-5p significantly retarded tumor growth, while overexpression of miR-93-5p accelerated tumor growth in the HCC xenograft mouse model. Altogether, we revealed a miR-93-5p/MAP3K2/c-Jun positive feedback loop to promote HCC progression in vivo and in vitro, representing an RNA-activating role of miR-93-5p in HCC development.	[Shi, Xuan; Liu, Tao-Tao; Yu, Xiang-Nan; Zhu, Hai-Rong; Guo, Hong-Ying; Zhang, Guang-Cong; Bilegsaikhan, Enkhnaran; Sun, Jia-Lei; Song, Guang-Qi; Weng, Shu-Qiang; Dong, Ling; Zhu, Ji-Min; Shen, Xi-Zhong] Fudan Univ, Dept Gastroenterol & Hepatol, Zhongshan Hosp, 180 Fenglin Rd, Shanghai 200032, Peoples R China; [Shi, Xuan; Liu, Tao-Tao; Yu, Xiang-Nan; Zhu, Hai-Rong; Guo, Hong-Ying; Zhang, Guang-Cong; Bilegsaikhan, Enkhnaran; Sun, Jia-Lei; Song, Guang-Qi; Weng, Shu-Qiang; Dong, Ling; Zhu, Ji-Min; Shen, Xi-Zhong] Fudan Univ, Shanghai Inst Liver Dis, 180 Fenglin Rd, Shanghai 200032, Peoples R China; [Balakrishnan, Asha; Ott, Michael] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Carl Neuberg Str 1, D-30625 Hannover, Germany; [Balakrishnan, Asha; Ott, Michael] TWINCORE, Ctr Expt & Clin Infect Res, Feodor Lynen Str 7, D-30625 Hannover, Germany; [Shen, Xi-Zhong] Fudan Univ, Shanghai Med Coll, Key Lab Med Mol Virol, 130 Dongan Rd, Shanghai 200032, Peoples R China	Fudan University; Fudan University; Hannover Medical School; Helmholtz Association; Helmholtz-Center for Infection Research; Fudan University	Zhu, JM; Shen, XZ (corresponding author), Fudan Univ, Dept Gastroenterol & Hepatol, Zhongshan Hosp, 180 Fenglin Rd, Shanghai 200032, Peoples R China.; Zhu, JM; Shen, XZ (corresponding author), Fudan Univ, Shanghai Inst Liver Dis, 180 Fenglin Rd, Shanghai 200032, Peoples R China.; Shen, XZ (corresponding author), Fudan Univ, Shanghai Med Coll, Key Lab Med Mol Virol, 130 Dongan Rd, Shanghai 200032, Peoples R China.	zhu.jimin@zs-hospital.sh.cn; shen.xizhong@zs-hospital.sh.cn	liu, taotao/GSI-7460-2022; zhu, jimin/HDN-1451-2022	Song, Guangqi/0000-0002-2409-0771; Zhu, Ji-Min/0000-0002-2150-473X	National Natural Science Foundation of China [81402273, 81672720, 81672334, 81700550]; National Clinical Key Special Subject of China	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Clinical Key Special Subject of China	This work was partly supported by the National Natural Science Foundation of China (grant numbers 81402273, 81672720, 81672334, and 81700550), and by the National Clinical Key Special Subject of China.	Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chaluvally-Raghavan P, 2016, CELL REP, V15, P1493, DOI 10.1016/j.celrep.2016.04.034; Chen CY, 2019, CLIN RES HEPATOL GAS, V43, P436, DOI 10.1016/j.clinre.2018.11.008; Chen X, 2015, MOL CANCER, V14, P11; Das M, 2007, P NATL ACAD SCI USA, V104, P15759, DOI 10.1073/pnas.0707782104; Delire B, 2015, EUR J CLIN INVEST, V45, P609, DOI 10.1111/eci.12441; Du L, 2014, ONCOGENE, V33, P4307, DOI 10.1038/onc.2013.381; Fallmann J, 2016, NUCLEIC ACIDS RES, V44, pD90, DOI 10.1093/nar/gkv1238; Fang L, 2011, ONCOGENE, V30, P806, DOI 10.1038/onc.2010.465; Gong C, 2015, ONCOGENE, V34, P84, DOI 10.1038/onc.2013.525; Guarnieri AL, 2018, ONCOGENE, V37, P3879, DOI 10.1038/s41388-018-0239-7; He Y, 2017, EXP THER MED, V13, P2003, DOI 10.3892/etm.2017.4204; Huang V, 2012, NUCLEIC ACIDS RES, V40, P1695, DOI 10.1093/nar/gkr934; Ji CM, 2017, BIOTECHNOL LETT, V39, P1621, DOI 10.1007/s10529-017-2403-5; Johnson JM, 2005, TRENDS GENET, V21, P93, DOI 10.1016/j.tig.2004.12.009; Kim EK, 2010, BBA-MOL BASIS DIS, V1802, P396, DOI 10.1016/j.bbadis.2009.12.009; Lee SY, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53561-z; Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248; Li N, 2017, CELL DEATH DIS, V8; Li Y, 2009, CANCER SCI, V100, P1234, DOI 10.1111/j.1349-7006.2009.01164.x; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Nahand JS, 2019, J CELL PHYSIOL, V234, P12188, DOI 10.1002/jcp.27956; Niu Y, 2018, ONCOGENE, V37, P1743, DOI 10.1038/s41388-017-0082-2; Ohta K, 2015, ONCOTARGET, V6, P3211, DOI 10.18632/oncotarget.3085; Orom UA, 2008, MOL CELL, V30, P460, DOI 10.1016/j.molcel.2008.05.001; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Pichon X, 2012, CURR PROTEIN PEPT SC, V13, P294, DOI 10.2174/138920312801619475; POLISENO L, 2010, SCI SIGNAL, V3, P29, DOI DOI 10.1126/SCISIGNAL.2000594; Schwabe RF, 2003, HEPATOLOGY, V37, P824, DOI 10.1053/jhep.2003.50135; Seki E, 2012, GASTROENTEROLOGY, V143, P307, DOI 10.1053/j.gastro.2012.06.004; Sun Q, 2019, CELL DEATH DIS, V10; Vasaikar SV, 2018, NUCLEIC ACIDS RES, V46, pD956, DOI 10.1093/nar/gkx1090; Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wang C., 2016, UROL ONCOL, V34, pe23; Wang CH, 2000, BIOCHEM BIOPH RES CO, V270, P303, DOI 10.1006/bbrc.2000.2422; Wong CCL, 2011, GASTROENTEROLOGY, V140, P322, DOI 10.1053/j.gastro.2010.10.006; Wu J, 2017, BIOCHEM BIOPH RES CO, V483, P10, DOI 10.1016/j.bbrc.2017.01.023; Xiao M, 2017, RNA BIOL, V14, P1326, DOI 10.1080/15476286.2015.1112487; Xue XF, 2018, BIOCHEM BIOPH RES CO, V502, P515, DOI 10.1016/j.bbrc.2018.05.208; Yang JH, 2011, NUCLEIC ACIDS RES, V39, pD202, DOI 10.1093/nar/gkq1056; Yang Z, 2019, AUTOPHAGY, V15, P668, DOI 10.1080/15548627.2018.1539590; Yu J, 2015, AM J CANCER RES, V5, P802; Yu XN, 2020, ACS APPL MATER INTER, V12, P17193, DOI 10.1021/acsami.0c00375; Yu XN, 2020, ANN SURG ONCOL, V27, P1546, DOI 10.1245/s10434-020-08263-6; Zhu HR, 2018, TOHOKU J EXP MED, V245, P89, DOI 10.1620/tjem.245.89	46	17	18	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2020	39	35					5768	5781		10.1038/s41388-020-01401-0	http://dx.doi.org/10.1038/s41388-020-01401-0		JUL 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NF2QB	32719439				2022-12-28	WOS:000552933000001
J	Zhang, X; Zegar, T; Lucas, A; Morrison-Smith, C; Knox, T; French, CA; Knapp, S; Muller, S; Siveke, JT				Zhang, Xin; Zegar, Tim; Lucas, Anais; Morrison-Smith, Chevaun; Knox, Tatiana; French, Christopher A.; Knapp, Stefan; Muller, Susanne; Siveke, Jens T.			Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinoma	ONCOGENE			English	Article							BROMODOMAIN INHIBITOR; CBP/P300 BROMODOMAIN; THYMIC CARCINOMA; BET; REARRANGEMENT	Nuclear protein of the testis (NUT) midline carcinoma (NMC), is a rare and highly aggressive form of undifferentiated squamous cell carcinoma. NMC is molecularly characterized by chromosomal rearrangement of the NUT gene to another gene, most commonly the bromodomain and extraterminal domain (BET) gene BRD4, forming the BRD4-NUT fusion oncogene. Therefore, inhibiting BRD4-NUT oncogenic function directly by BET inhibitors represents an attractive therapeutic approach but toxicity may limit the use of pan-BET inhibitors treating this cancer. We thus performed a drug screening approach using a library consisting of epigenetic compounds and 'Donated Chemical Probes' collated by the Structural Genomics Consortium (SGC) and identified the p300/CBP HAT inhibitor A-485, in addition to the well-known BET inhibitor JQ1, to be the most active candidate for NMC treatment. In contrast to JQ1, A-485 was selectively potent in NMC compared to other cell lines tested. Mechanistically, A-485 inhibited p300-mediated histone acetylation, leading to disruption of BRD4-NUT binding to hyperacetylated megadomains. Consistently, BRD4-NUT megadomain-associated genes MYC, CCAT1 and TP63 were downregulated by A-485. A-485 strongly induced squamous differentiation, cell cycle arrest and apoptosis. Combined inhibition of p300/CBP and BET showed synergistic effects. In summary, we identified the p300/CBP HAT domain as a putative therapeutic target in highly therapy-resistant NMC.	[Zhang, Xin; Zegar, Tim; Siveke, Jens T.] Univ Hosp Essen, West German Canc Ctr, Inst Dev Canc Therapeut, Essen, Germany; [Zhang, Xin; Zegar, Tim; Siveke, Jens T.] German Canc Consortium DKTK, Partner Site Essen, Div Solid Tumor Translat Oncol, Heidelberg, Germany; [Zhang, Xin; Zegar, Tim; Siveke, Jens T.] DKFZ, German Canc Res Ctr, Heidelberg, Germany; [Lucas, Anais; Knapp, Stefan; Muller, Susanne] Goethe Univ Frankfurt, Buchmann Inst Life Sci, Struct Genom Consortium, D-60438 Frankfurt, Germany; [Lucas, Anais; Knapp, Stefan; Muller, Susanne] Goethe Univ Frankfurt, Inst Pharmaceut Chem, D-60438 Frankfurt, Germany; [Lucas, Anais; Knapp, Stefan] German Canc Consortium DKTK, Partner Site Frankfurt Mainz, D-60438 Frankfurt, Germany; [Lucas, Anais; Knapp, Stefan] Frankfurt Canc Inst FCI, D-60438 Frankfurt, Germany; [Morrison-Smith, Chevaun; Knox, Tatiana; French, Christopher A.] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA	University of Duisburg Essen; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Goethe University Frankfurt; Goethe University Frankfurt; Helmholtz Association; German Cancer Research Center (DKFZ); Harvard University; Brigham & Women's Hospital; Harvard Medical School	Siveke, JT (corresponding author), Univ Hosp Essen, West German Canc Ctr, Inst Dev Canc Therapeut, Essen, Germany.; Siveke, JT (corresponding author), German Canc Consortium DKTK, Partner Site Essen, Div Solid Tumor Translat Oncol, Heidelberg, Germany.; Siveke, JT (corresponding author), DKFZ, German Canc Res Ctr, Heidelberg, Germany.	jens.siveke@uk-essen.de	Knapp, Stefan/AAG-2347-2019; Siveke, Jens/AAQ-6170-2021	Knapp, Stefan/0000-0001-5995-6494; Muller-Knapp, Susanne/0000-0003-2402-4157; Siveke, Jens/0000-0002-8772-4778	AbbVie; Bayer Pharma AG; SGC [1097737]; Boehringer Ingelheim; Canada Foundation for Innovation; Eshelman Institute for Innovation; Genome Canada through Ontario Genomics Institute [OGI-055]; Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant] [115766]; Janssen; Merck KGaA; MSD; Novartis Pharma AG; Ontario Ministry of Research, Innovation and Science (MRIS); Pfizer; Sao Paulo Research Foundation-FAPESP; Takeda; Wellcome Trust; German Cancer Aid (PIPAC consortium) [70112505]; German Cancer Consortium (DKTK); Deutsche Forschungsgemeinschaft (DFG) [SI1549/3-1]; Deutsche Forschungsgemeinschaft (DFG) through Collaborative Research Center SFB824; Projekt DEAL	AbbVie(AbbVie); Bayer Pharma AG; SGC; Boehringer Ingelheim(Boehringer Ingelheim); Canada Foundation for Innovation(Canada Foundation for InnovationCGIAR); Eshelman Institute for Innovation; Genome Canada through Ontario Genomics Institute(Genome Canada); Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant]; Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Merck KGaA; MSD; Novartis Pharma AG; Ontario Ministry of Research, Innovation and Science (MRIS); Pfizer(Pfizer); Sao Paulo Research Foundation-FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Takeda(Takeda Pharmaceutical Company Ltd); Wellcome Trust(Wellcome TrustEuropean Commission); German Cancer Aid (PIPAC consortium); German Cancer Consortium (DKTK); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Deutsche Forschungsgemeinschaft (DFG) through Collaborative Research Center SFB824(German Research Foundation (DFG)); Projekt DEAL	We are grateful for support by the SGC, a registered charity (no. 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, Sao Paulo Research Foundation-FAPESP, Takeda, and the Wellcome Trust. JTS and SK are supported by the German Cancer Aid (grant no. 70112505; PIPAC consortium). JTS is supported by the German Cancer Consortium (DKTK) and the Deutsche Forschungsgemeinschaft (DFG) through grant SI1549/3-1 (Clinical Research Unit KFO337) and Collaborative Research Center SFB824 (project C4). Open access funding provided by Projekt DEAL.	Alekseyenko AA, 2015, GENE DEV, V29, P1507, DOI 10.1101/gad.267583.115; Bauer DE, 2012, CLIN CANCER RES, V18, P5773, DOI 10.1158/1078-0432.CCR-12-1153; Brooks N, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.SABCS18-3826; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Fong CY, 2015, NATURE, V525, P538, DOI 10.1038/nature14888; French CA, 2003, CANCER RES, V63, P304; French CA, 2001, AM J PATHOL, V159, P1987, DOI 10.1016/S0002-9440(10)63049-0; GILES F, 2018, ANN ONCOL S8, V29, P279, DOI DOI 10.1093/annonc/mdy279.416; Hammitzsch A, 2015, P NATL ACAD SCI USA, V112, P10768, DOI 10.1073/pnas.1501956112; Haruki N, 2005, J MED GENET, V42, P558, DOI 10.1136/jmg.2004.029686; Ianevski A, 2017, BIOINFORMATICS, V33, P2413, DOI 10.1093/bioinformatics/btx162; IGUCHI H, 1990, CANCER RES, V50, P3691; KEES UR, 1991, AM J PEDIAT HEMATOL, V13, P459; Kimura H, 2010, CHEM BIOL, V17, P1282, DOI 10.1016/j.chembiol.2010.10.011; KUZUME T, 1992, INT J CANCER, V50, P259, DOI 10.1002/ijc.2910500216; Lasko LM, 2017, NATURE, V550, P128, DOI 10.1038/nature24028; Lewin J, 2018, J CLIN ONCOL, V36, P3007, DOI 10.1200/JCO.2018.78.2292; Matzuk MM, 2012, CELL, V150, P673, DOI 10.1016/j.cell.2012.06.045; Muller S, 2018, ELIFE, V7, DOI 10.7554/eLife.34311; O'Dwyer PJ, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.AM2016-CT014; Picaud S, 2015, CANCER RES, V75, P5106, DOI 10.1158/0008-5472.CAN-15-0236; Reynoird N, 2010, EMBO J, V29, P2943, DOI 10.1038/emboj.2010.176; Scheer S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07905-4; Stathis A, 2018, CANCER DISCOV, V8, P24, DOI 10.1158/2159-8290.CD-17-0605; Stathis A, 2016, CANCER DISCOV, V6, P492, DOI 10.1158/2159-8290.CD-15-1335; Syntichaki P, 2000, NATURE, V404, P414, DOI 10.1038/35006136; Toretsky JA, 2003, AM J CLIN ONCOL-CANC, V26, P300, DOI 10.1097/00000421-200306000-00019; Wu Q, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09672-2; Xiang JF, 2014, CELL RES, V24, P513, DOI 10.1038/cr.2014.35; Yan JP, 2011, J BIOL CHEM, V286, P27663, DOI 10.1074/jbc.M111.246975; Yan YQ, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.7_suppl.62	32	17	19	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	24					4770	4779		10.1038/s41388-020-1301-9	http://dx.doi.org/10.1038/s41388-020-1301-9		MAY 2020	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LY0HO	32366905	Green Published, hybrid			2022-12-28	WOS:000530271400001
J	Roh, E; Han, YP; Reddy, K; Zykova, TA; Lee, MH; Yao, K; Bai, RH; Curiel-Lewandrowski, C; Dong, ZG				Roh, Eunmiri; Han, Yaping; Reddy, Kanamata; Zykova, Tatyana A.; Lee, Mee Hyun; Yao, Ke; Bai, Ruihua; Curiel-Lewandrowski, Clara; Dong, Zigang			Suppression of the solar ultraviolet-induced skin carcinogenesis by TOPK inhibitor HI-TOPK-032	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMA; C-JUN; CANCER; KINASE; POPULATION; ACTIVATION; RADIATION; MELANOMA; GROWTH; JNK1	Nonmelanoma skin cancer (NMSC) such as cutaneous squamous cell carcinoma (cSCC) is caused by solar ultraviolet (SUV) exposure and is the most common cancer in the United States. T-LAK cell-originated protein kinase (TOPK), a serine-threonine kinase is activated by SUV irradiation and involved in skin carcinogenesis. Strategies with research focusing on the TOPK signaling pathway and targeted therapy in skin carcinogenesis may helpful for the discovery of additional treatments against skin cancer. In this study, we found that TOPK can directly bind to and phosphorylate c-Jun (as one of the core member of AP-1) at Ser63 and Ser73 after SSL exposure in a JNKs-independent manner. TOPK knocking down, or HI-TOPK-032 (TOPK specific inhibitor) attenuated colony formation and cell proliferation of skin cancer cells. Phosphorylated levels of c-Jun were overexpressed in human AK and cSCC compared with normal skin tissues, and HI-TOPK-032 inhibited the phosphorylation of c-Jun in SCC cell line in a dose-dependent manner. Furthermore, HI-TOPK-032 decreased SSL-induced AP-1 transactivation activity. Moreover, acute SSL-induced inflammation was attenuated by the topical application of HI-TOPK-032 in SKH1 hairless mice. Importantly, HI-TOPK-032 suppressed chronic SSL-induced skin carcinogenesis and c-Jun phosphorylation levels in SKH1 hairless mice. Our results demonstrate that TOPK can phosphorylate and activate c-Jun at Ser63 and Ser73 in the process of skin carcinogenesis and HI-TOPK-032 could be used as a potential chemopreventive drug against cSCC development.	[Roh, Eunmiri; Han, Yaping; Reddy, Kanamata; Zykova, Tatyana A.; Yao, Ke; Bai, Ruihua; Dong, Zigang] Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA; [Lee, Mee Hyun] China US Henan Hormel Canc Inst, Zhengzhou 450008, Henan, Peoples R China; [Lee, Mee Hyun] Zhengzhou Univ, Sch Basic Med Sci, Zhengzhou 450001, Henan, Peoples R China; [Curiel-Lewandrowski, Clara] Univ Arizona, Canc Ctr, Tucson, AZ 85719 USA; [Dong, Zigang] Zhengzhou Univ, Coll Med, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou 450001, Henan, Peoples R China	University of Minnesota System; Zhengzhou University; University of Arizona; Zhengzhou University	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.; Dong, ZG (corresponding author), Zhengzhou Univ, Coll Med, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou 450001, Henan, Peoples R China.	dongzg@zzu.edu.cn		Roh, Eunmiri/0000-0003-4385-2046	Hormel Foundation; National institutes of Health [CA229112]	Hormel Foundation; National institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Dr Richard Flavell (Yale University School of Medicine, New Haven, CT) for providing JNK1<SUP>-/-</SUP> and JNK2<SUP>-/-</SUP> mice, and Dr Dirk Bohmann (European Molecular Biology Laboratory, Germany) for providing His6-tagged c-Jun expression plasmid. This work was supported by The Hormel Foundation and National institutes of Health grants (CA229112).	Behrens A, 2002, EMBO J, V21, P1782, DOI 10.1093/emboj/21.7.1782; Bode Ann M, 2003, Sci STKE, V2003, pRE2, DOI 10.1126/stke.2003.167.re2; Burton KA, 2016, AM J CLIN DERMATOL, V17, P491, DOI 10.1007/s40257-016-0207-3; D'Orazio J, 2013, INT J MOL SCI, V14, P12222, DOI 10.3390/ijms140612222; Decean HP, 2018, J ENVIRON PATHOL TOX, V37, P261, DOI 10.1615/JEnvironPatholToxicolOncol.2018027009; Edlund K, 2012, P NATL ACAD SCI USA, V109, P9551, DOI 10.1073/pnas.1200019109; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Gao G, 2017, MOL CANCER THER, V16, P1843, DOI 10.1158/1535-7163.MCT-17-0212; Gassmann P, 2008, CLIN EXP METASTAS, V25, P171, DOI 10.1007/s10585-007-9130-6; Gaudet S, 2000, P NATL ACAD SCI USA, V97, P5167, DOI 10.1073/pnas.090102397; Hess J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589; Jin JY, 2011, J INVEST DERMATOL, V131, P1149, DOI 10.1038/jid.2011.1; Katiyar SK, 2007, TOXICOL APPL PHARM, V224, P220, DOI 10.1016/j.taap.2006.11.017; Kim DJ, 2012, CANCER RES, V72, P3060, DOI 10.1158/0008-5472.CAN-11-3851; Kim JE, 2016, ONCOGENE, V35, P4091, DOI 10.1038/onc.2015.471; Koh HK, 1996, ARCH DERMATOL, V132, P436, DOI 10.1001/archderm.132.4.436; Li GC, 2003, DEV CELL, V4, P865, DOI 10.1016/S1534-5807(03)00159-X; Li Y, 2016, ONCOTARGET, V7, P6748, DOI 10.18632/oncotarget.6826; Liu J, 2004, MOL CELL BIOL, V24, P10844, DOI 10.1128/MCB.24.24.10844-10856.2004; Liu KD, 2013, CANCER RES, V73, P2181, DOI 10.1158/0008-5472.CAN-12-3408; Loyo M, 2013, HEAD NECK-J SCI SPEC, V35, P454, DOI 10.1002/hed.23100; Matsumura Y, 2004, TOXICOL APPL PHARM, V195, P298, DOI 10.1016/j.taap.2003.08.019; Oh SM, 2007, CANCER RES, V67, P5186, DOI 10.1158/0008-5472.CAN-06-4506; Rogers HW, 2015, JAMA DERMATOL, V151, P1081, DOI 10.1001/jamadermatol.2015.1187; Roh E, 2018, ONCOGENE, V37, P5633, DOI 10.1038/s41388-018-0350-9; Sabapathy K, 2004, MOL CELL, V15, P713, DOI 10.1016/j.molcel.2004.08.028; Shain AH, 2018, CANCER CELL, V34, P45, DOI 10.1016/j.ccell.2018.06.005; Stern RS, 2010, ARCH DERMATOL, V146, P279, DOI 10.1001/archdermatol.2010.4; Trifan OC, 2003, J CELL MOL MED, V7, P207, DOI 10.1111/j.1582-4934.2003.tb00222.x; Wang LJ, 2019, ANTI-CANCER AGENT ME, V19, P1029, DOI 10.2174/1871520619666190301123131; Wiser I, 2016, ISR MED ASSOC J, V18, P275; Xue PP, 2017, ONCOTARGET, V8, P27093, DOI 10.18632/oncotarget.15636; Yamamoto H, 2017, J INVEST DERMATOL, V137, P1322, DOI 10.1016/j.jid.2016.12.026; Yin Q, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09844-0; Yokogawa M, 2013, MOL CARCINOGEN, V52, P760, DOI 10.1002/mc.21901; Zhu F, 2007, GASTROENTEROLOGY, V133, P219, DOI 10.1053/j.gastro.2007.04.048	36	9	9	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	21					4170	4182		10.1038/s41388-020-1286-4	http://dx.doi.org/10.1038/s41388-020-1286-4		APR 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LQ2DH	32277233	Green Accepted			2022-12-28	WOS:000524959200001
J	Gao, QZ; Zhou, R; Meng, Y; Duan, RF; Wu, L; Li, R; Deng, FL; Lin, C; Zhao, L				Gao, Qingzu; Zhou, Rui; Meng, Yuan; Duan, Rongfei; Wu, Ling; Li, Rui; Deng, Fengliu; Lin, Chuang; Zhao, Liang			Long noncoding RNA CMPK2 promotes colorectal cancer progression by activating the FUBP3-c-Myc axis	ONCOGENE			English	Article							FAR UPSTREAM ELEMENT; C-MYC; TRANSCRIPTION; PROTEINS; LNCRNA; LIM	Long noncoding RNAs (lncRNAs) have been shown to play crucial roles in cancer long noncoding RNAs (lncRNAs) have been known to play crucial roles in cancer development and progression by regulating chromatin dynamics and gene expression. However, only a few lncRNAs with annotated functions in the progression of colorectal cancer (CRC) have been identified to date. In the present study, the expression of lncCMPK2 was upregulated in CRC tissues and positively correlated with clinical stages and lymphatic metastasis. The overexpression of lncCMPK2 promoted the proliferation and cell cycle transition of CRC cells. Conversely, the silencing of lncCMPK2 restricted cell proliferation both in vitro and in vivo. lncCMPK2 was localized to the nucleus of CRC cells, bound to far upstream element binding protein 3 (FUBP3), and guided FUBP3 to the far upstream element (FUSE) of the c-Myc gene to activate transcription. lncCMPK2 also stabilized FUBP3. These results provide novel insights into the functional mechanism of lncCMPK2 in CRC progression and highlight its potential as a biomarker of advanced CRC and therapeutic target.	[Gao, Qingzu; Zhou, Rui; Meng, Yuan; Wu, Ling; Li, Rui; Deng, Fengliu; Lin, Chuang; Zhao, Liang] Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou, Peoples R China; [Gao, Qingzu] Xinxiang Med Univ, Dept Pathol, Affiliated Hosp 1, Xinxiang, Henan, Peoples R China; [Gao, Qingzu; Zhou, Rui; Wu, Ling; Li, Rui; Deng, Fengliu; Zhao, Liang] Southern Med Univ, Sch Basic Med Sci, Dept Pathol, Guangzhou, Peoples R China; [Meng, Yuan] Second Peoples Hosp Longgang Dist, Dept Pathol, Shenzhen, Peoples R China; [Duan, Rongfei] Xinxiang Med Univ, Dept Endocrinol, Affiliated Hosp 1, Guangzhou, Peoples R China	Southern Medical University - China; Xinxiang Medical University; Southern Medical University - China; Xinxiang Medical University	Zhao, L (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou, Peoples R China.; Zhao, L (corresponding author), Southern Med Univ, Sch Basic Med Sci, Dept Pathol, Guangzhou, Peoples R China.	liangsmu@foxmail.com			National Natural Science Foundation of China [81572813, 81773082, 81702903, 81872423]; Guangdong Natural Science Foundation [2016A030313626, 2017A030310038, 2018B030311036]; Fork Ying Tung Education Foundation [161035]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Natural Science Foundation(National Natural Science Foundation of Guangdong Province); Fork Ying Tung Education Foundation	This work was supported by the National Natural Science Foundation of China (nos. 81572813, 81773082, 81702903, and 81872423), Guangdong Natural Science Foundation (2016A030313626, 2017A030310038, 2018B030311036), and Fork Ying Tung Education Foundation (161035).	Arab K, 2014, MOL CELL, V55, P604, DOI 10.1016/j.molcel.2014.06.031; Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912; AVIGAN MI, 1990, J BIOL CHEM, V265, P18538; Beckedorff FC, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003705; Bhan A, 2014, CHEMMEDCHEM, V9, P1932, DOI 10.1002/cmdc.201300534; Chen Q, 2018, CLIN CANCER RES, V24, P684, DOI 10.1158/1078-0432.CCR-17-0605; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; DavisSmyth T, 1996, J BIOL CHEM, V271, P31679, DOI 10.1074/jbc.271.49.31679; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Gilkes DM, 2014, NAT REV CANCER, V14, P430, DOI 10.1038/nrc3726; Gonzalez V, 2010, ANNU REV PHARMACOL, V50, P111, DOI 10.1146/annurev.pharmtox.48.113006.094649; Gu J, 2018, CELL PHYSIOL BIOCHEM, V48, P194, DOI 10.1159/000491718; Hajjari M, 2015, CANCER BIOL MED, V12, P1, DOI 10.7497/j.issn.2095-3941.2015.0006; Han QR, 2019, ONCOGENE, V38, P3019, DOI 10.1038/s41388-018-0614-4; Huang HI, 2016, PROTEOMICS, V16, P2351, DOI 10.1002/pmic.201600098; Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040; Hung T, 2011, NAT GENET, V43, P621, DOI 10.1038/ng.848; Kambara H, 2014, NUCLEIC ACIDS RES, V42, P10668, DOI 10.1093/nar/gku713; Kopp F, 2018, CELL, V172, P393, DOI 10.1016/j.cell.2018.01.011; Kortlever RM, 2017, CELL, V171, P1301, DOI 10.1016/j.cell.2017.11.013; Ling H, 2013, GENOME RES, V23, P1446, DOI 10.1101/gr.152942.112; Liu JH, 2017, FRONT BIOSCI-LANDMRK, V22, P66, DOI 10.2741/4472; Liu TY, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0873-2; Ma YL, 2016, GUT, V65, P1494, DOI 10.1136/gutjnl-2014-308392; Malakar P, 2019, CANCER RES, V79, P2480, DOI 10.1158/0008-5472.CAN-18-1432; Mariotti B, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00100; Munschauer M, 2018, NATURE, V561, P132, DOI 10.1038/s41586-018-0453-z; Naxerova K, 2017, SCIENCE, V357, P55, DOI 10.1126/science.aai8515; Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209; Quinn LM, 2017, TRANSCR-AUSTIN, V8, P185, DOI 10.1080/21541264.2017.1293595; Ren J, 2018, THERANOSTICS, V8, P3932, DOI 10.7150/thno.25541; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Silva JM, 2011, RNA BIOL, V8, P496, DOI 10.4161/rna.8.3.14800; Wang H, 2014, CLIN CANCER RES, V20, P5835, DOI 10.1158/1078-0432.CCR-14-0485; Wang ZH, 2018, CANCER CELL, V33, P706, DOI 10.1016/j.ccell.2018.03.006; Weber A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-369; Zhao LA, 2010, GUT, V59, P1226, DOI 10.1136/gut.2009.202739; Zheng P, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0216-3; Zubaidah RM, 2008, PROTEOMICS, V8, P5086, DOI 10.1002/pmic.200800322	41	27	27	0	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	19					3926	3938		10.1038/s41388-020-1266-8	http://dx.doi.org/10.1038/s41388-020-1266-8		MAR 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LK4OF	32203166				2022-12-28	WOS:000520826900001
J	Wenzel, J; Rose, K; Haghighi, EB; Lamprecht, C; Rauen, G; Freihen, V; Kesselring, R; Boerries, M; Hecht, A				Wenzel, Janna; Rose, Katja; Haghighi, Elham Bavafaye; Lamprecht, Constanze; Rauen, Gilles; Freihen, Vivien; Kesselring, Rebecca; Boerries, Melanie; Hecht, Andreas			Loss of the nuclear Wnt pathway effector TCF7L2 promotes migration and invasion of human colorectal cancer cells	ONCOGENE			English	Article							WNT/BETA-CATENIN PATHWAY; EPHB3 TUMOR-SUPPRESSOR; BETA-CATENIN; HUMAN COLON; COMPETITIVE DISPLACEMENT; ACTIVATION DOMAIN; FEEDBACK LOOP; HUMAN BREAST; STEM-CELLS; TRANSCRIPTION	The transcription factor TCF7L2 is indispensable for intestinal tissue homeostasis where it transmits mitogenic Wnt/beta-Catenin signals in stem and progenitor cells, from which intestinal tumors arise. Yet, TCF7L2 belongs to the most frequently mutated genes in colorectal cancer (CRC), and tumor-suppressive functions of TCF7L2 were proposed. This apparent paradox warrants to clarify the role of TCF7L2 in colorectal carcinogenesis. Here, we investigated TCF7L2 dependence/independence of CRC cells and the cellular and molecular consequences of TCF7L2 loss-of-function. By genome editing we achieved complete TCF7L2 inactivation in several CRC cell lines without loss of viability, showing that CRC cells have widely lost the strict requirement for TCF7L2. TCF7L2 deficiency impaired G1/S progression, reminiscent of the physiological role of TCF7L2. In addition, TCF7L2-negative cells exhibited morphological changes, enhanced migration, invasion, and collagen adhesion, albeit the severity of the phenotypic alterations manifested in a cell-line-specific fashion. To provide a molecular framework for the observed cellular changes, we performed global transcriptome profiling and identified gene-regulatory networks in which TCF7L2 positively regulates the proto-oncogene MYC, while repressing the cell cycle inhibitors CDKN2C/CDKN2D. Consistent with its function in curbing cell motility and invasion, TCF7L2 directly suppresses the pro-metastatic transcription factor RUNX2 and impinges on the expression of cell adhesion molecules. Altogether, we conclude that the proliferation-stimulating activity of TCF7L2 persists in CRC cells. In addition, TCF7L2 acts as invasion suppressor. Despite its negative impact on cell cycle progression, TCF7L2 loss-of-function may thereby increase malignancy, which could explain why TCF7L2 is mutated in a sizeable fraction of colorectal tumors.	[Wenzel, Janna; Rose, Katja; Freihen, Vivien; Hecht, Andreas] Univ Freiburg, Fac Med, Inst Mol Med & Cell Res, Stefan Meier Str 17, D-79104 Freiburg, Germany; [Wenzel, Janna; Rauen, Gilles; Hecht, Andreas] Univ Freiburg, Fac Biol, Schanzlestr 1, D-79104 Freiburg, Germany; [Haghighi, Elham Bavafaye; Boerries, Melanie] Univ Freiburg, Inst Med Bioinformat & Syst Med, Med Ctr, Fac Med, Breisacherstr 153, D-79104 Freiburg, Germany; [Lamprecht, Constanze] Univ Freiburg, Inst Phys, Hermann Herder Str 3a, D-79104 Freiburg, Germany; [Lamprecht, Constanze; Rauen, Gilles; Hecht, Andreas] Univ Freiburg, BIOSS Ctr Biol Signalling Studies, Schanzlestr 18, D-79104 Freiburg, Germany; [Lamprecht, Constanze] Univ Freiburg, Freiburg Ctr Interact Mat & Bioinspired Technol F, Georges Kohler Allee 105, D-79110 Freiburg, Germany; [Kesselring, Rebecca] Univ Freiburg, Dept Gen & Visceral Surg, Ctr Surg, Med Ctr,Fac Med, Hugstetter Str 55, D-79106 Freiburg, Germany; [Boerries, Melanie] German Canc Consortium DKTK, Hugstetter Str 55, D-79106 Freiburg, Germany; [Boerries, Melanie] German Canc Res Ctr, Neuenheimer Feld 280, D-69120 Heidelberg, Germany	University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Hecht, A (corresponding author), Univ Freiburg, Fac Med, Inst Mol Med & Cell Res, Stefan Meier Str 17, D-79104 Freiburg, Germany.; Hecht, A (corresponding author), Univ Freiburg, Fac Biol, Schanzlestr 1, D-79104 Freiburg, Germany.; Hecht, A (corresponding author), Univ Freiburg, BIOSS Ctr Biol Signalling Studies, Schanzlestr 18, D-79104 Freiburg, Germany.	andreas.hecht@mol-med.uni-freiburg.de	Boerries, Melanie/AAM-2602-2021	Lamprecht, Constanze/0000-0002-6005-6239	Deutsche Forschungsgemeinschaft (DFG) [DFG HE2004/11-1, CRC-850, KE2164/2-1, 322977937/GRK2344]; German Federal Ministry of Education and Research (BMBF) [FKZ 01ZX1708F]; Carl-Zeiss-Foundation [Az. 0563-2.8/685/4]; Deutsche Forschungsgemeinschaft Research Training Group GRK2344 "MeInBio-BioInMe"; Projekt DEAL	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); Carl-Zeiss-Foundation; Deutsche Forschungsgemeinschaft Research Training Group GRK2344 "MeInBio-BioInMe"(German Research Foundation (DFG)); Projekt DEAL	The authors express their gratitude to K. Geiger, D. Herchenbach, J. Bodinek, and A. Schmitt for exquisite technical assistance, and to the team of the Genomics and Proteomics Core Facility, German Cancer Research Center/DKFZ, Heidelberg, Germany, for sequencing services. The studies reported herein were financially supported by the Deutsche Forschungsgemeinschaft (DFG) (DFG HE2004/11-1 to AH; CRC-850 subprojects B5 to AH, C11 to RK [KE2164/2-1] and Z1 to MB; 322977937/GRK2344 subprojects B02 to MB and B03 to AH), and by the German Federal Ministry of Education and Research (BMBF) within the framework of the e:Med research and funding concept CoNfirm (FKZ 01ZX1708F to MB). CL received a fellowship from the Carl-Zeiss-Foundation (Postdoc Program 2017, Az. 0563-2.8/685/4). JW was additionally supported by the Deutsche Forschungsgemeinschaft Research Training Group GRK2344 "MeInBio-BioInMe". Open access funding provided by Projekt DEAL.	Albers J, 2015, J CLIN INVEST, V125, P1603, DOI 10.1172/JCI79743; Anders Simon, 2010, Genome Biol, V11, pR106, DOI 10.1186/gb-2010-11-10-r106; Angus-Hill ML, 2011, P NATL ACAD SCI USA, V108, P4914, DOI 10.1073/pnas.1102300108; Arrigoni L, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv1495; Atcha FA, 2003, J BIOL CHEM, V278, P16169, DOI 10.1074/jbc.M213218200; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Berg KCG, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0691-y; Beumer J, 2016, DEVELOPMENT, V143, P3639, DOI 10.1242/dev.133132; Beyes S, 2019, ONCOGENE, V38, P6647, DOI 10.1038/s41388-019-0905-4; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Bormann F, 2018, CELL REP, V23, P3407, DOI 10.1016/j.celrep.2018.05.045; Cadigan KM, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007906; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chai J, 2018, AM J CANCER RES, V8, P538; Clevers H, 2013, CELL, V154, P274, DOI 10.1016/j.cell.2013.07.004; Dang DT, 2003, ONCOGENE, V22, P3424, DOI 10.1038/sj.onc.1206413; de Lau W, 2007, FRONT BIOSCI-LANDMRK, V12, P471, DOI 10.2741/2076; de Sousa e Melo F, 2011, CELL STEM CELL, V9, P476, DOI 10.1016/j.stem.2011.10.008; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; Farley FW, 2000, GENESIS, V28, P106, DOI 10.1002/1526-968X(200011/12)28:3/4<106::AID-GENE30>3.0.CO;2-T; Fisher RA, 1922, J R STAT SOC, V85, P87, DOI 10.2307/2340521; Fox J., 2019, R COMPANION APPL REG; Freihen V, 2020, INT J CANCER, V146, P2229, DOI 10.1002/ijc.32644; Frietze S, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-9-r52; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Geoghegan G, 2019, MOL METAB, V24, P44, DOI 10.1016/j.molmet.2019.03.003; Giakountis A, 2016, CELL REP, V15, P2588, DOI 10.1016/j.celrep.2016.05.038; Guo ZJ, 2016, ONCOTARGET, V7, P20999, DOI 10.18632/oncotarget.8236; Hecht A, 2003, J BIOL CHEM, V278, P3776, DOI 10.1074/jbc.M210081200; Holmberg J, 2006, CELL, V125, P1151, DOI 10.1016/j.cell.2006.04.030; Hoverter NP, 2014, NUCLEIC ACIDS RES, V42, P13615, DOI 10.1093/nar/gku1186; Hrckulak D, 2018, GENES-BASEL, V9, DOI 10.3390/genes9090439; Hrckulak D, 2016, CANCERS, V8, DOI 10.3390/cancers8070070; Jagle S, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1007109; Jagle S, 2014, P NATL ACAD SCI USA, V111, P4886, DOI 10.1073/pnas.1314523111; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Kadem LF, 2016, ADV MATER, V28, P1799, DOI 10.1002/adma.201504394; Koo BK, 2012, NATURE, V488, P665, DOI 10.1038/nature11308; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Koshizuka K, 2017, CANCER SCI, V108, P1681, DOI 10.1111/cas.13298; Kranz A, 2010, GENESIS, V48, P512, DOI 10.1002/dvg.20641; Leung JY, 2002, J BIOL CHEM, V277, P21657, DOI 10.1074/jbc.M200139200; Li XQ, 2015, CANCER RES, V75, P3302, DOI 10.1158/0008-5472.CAN-15-0240; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Lv HQ, 2016, ONCOL RES, V23, P283, DOI 10.3727/096504016X14562725373833; Mokry M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015092; Mouradov D, 2014, CANCER RES, V74, P3238, DOI 10.1158/0008-5472.CAN-14-0013; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Neri P, 2011, BLOOD, V117, P6202, DOI 10.1182/blood-2010-06-292243; Ramovs V, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1146-8; Rodilla V, 2009, P NATL ACAD SCI USA, V106, P6315, DOI 10.1073/pnas.0813221106; Ronsch K, 2015, MOL ONCOL, V9, P335, DOI 10.1016/j.molonc.2014.08.016; Ronsch K, 2011, EPIGENETICS-US, V6, P610, DOI 10.4161/epi.6.5.15300; Rosenbluh J, 2012, CELL, V151, P1457, DOI 10.1016/j.cell.2012.11.026; Sabates-Beliver J, 2007, MOL CANCER RES, V5, P1263, DOI 10.1158/1541-7786.MCR-07-0267; Sadanandam A, 2013, NAT MED, V19, P619, DOI 10.1038/nm.3175; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Schnappauf O, 2016, BBA-GENE REGUL MECH, V1859, P1353, DOI 10.1016/j.bbagrm.2016.08.002; Schuijers J, 2015, CELL STEM CELL, V16, P158, DOI 10.1016/j.stem.2014.12.006; Seebauer CT, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1242543; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937; Tang W, 2014, BRIT J CANCER, V110, P450, DOI 10.1038/bjc.2013.724; Tang W, 2008, P NATL ACAD SCI USA, V105, P9697, DOI 10.1073/pnas.0804709105; Tuupanen S, 2009, NAT GENET, V41, P885, DOI 10.1038/ng.406; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; van der Flier LG, 2009, CELL, V136, P903, DOI 10.1016/j.cell.2009.01.031; van Es JH, 2012, MOL CELL BIOL, V32, P1918, DOI 10.1128/MCB.06288-11; Varnat F, 2010, EMBO MOL MED, V2, P440, DOI 10.1002/emmm.201000098; Wen DC, 2017, BIOMED PHARMACOTHER, V95, P1314, DOI 10.1016/j.biopha.2017.09.044; Wickham H, 2009, GGPLOT2; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Xiang JF, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0367-6; Yochum GS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018966; Yochum GS, 2008, MOL CELL BIOL, V28, P7368, DOI 10.1128/MCB.00744-08; Zhang Y, 2012, J BIOL CHEM, V287, P32494, DOI 10.1074/jbc.M112.368282	79	24	24	2	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	19					3893	3909		10.1038/s41388-020-1259-7	http://dx.doi.org/10.1038/s41388-020-1259-7		MAR 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LK4OF	32203164	Green Published, hybrid			2022-12-28	WOS:000520614000003
J	Zhang, GJ; Tang, X; Liang, L; Zhang, WF; Li, DW; Li, XY; Zhao, DC; Zheng, YQ; Chen, YH; Hao, BT; Wang, K; Tang, N; Ding, KY				Zhang, Guiji; Tang, Xia; Liang, Li; Zhang, Wanfeng; Li, Dewei; Li, Xiaoyuan; Zhao, Dachun; Zheng, Yaqiu; Chen, Yanhong; Hao, Bingtao; Wang, Kai; Tang, Ni; Ding, Keyue			DNA and RNA sequencing identified a novel oncogene VPS35 in liver hepatocellular carcinoma	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR-3; RETROMER COMPLEX; RECURRENT MUTATIONS; TRAFFICKING; EXPRESSION; PREVENTION; SECRETION; TARGETS; GENE; RAS	Liver hepatocellular carcinoma (LIHC) is the second leading cause of cancer mortality worldwide. Although cancer driver genes identified so far have been considered to be saturated or nearly saturated, challenges remain in discovering novel genes underlying carcinogenesis due to significant tumor heterogeneity. Here, in a small cohort of hepatitis B virus (HBV)-associated LIHC, we investigated the transcriptional patterns of tumor-mutated alleles using both whole-exome and RNA sequencing data. A graph clustering of the transcribed tumor-mutated alleles characterized overlapped functional clusters, and thus prioritized potentially novel oncogenes. We validated the function of the potentially novel oncogenes in vitro and in vivo. We showed that a component of the retromer complex-the vacuolar protein sorting-associated protein 35 (VPS35)-promoted the proliferation of hepatoma cell through the PI3K/AKT signaling pathway. In VPS35-knockout hepatoma cells, a significantly reduced distribution of membrane fibroblast growth factor receptor 3 (FGFR3) demonstrated the effects of VPS35 on sorting and trafficking of transmembrane receptor. This study provides insight into the roles of the retromer complex on carcinogenesis and has important implications for the development of personalized therapeutic strategies for LIHC.	[Zhang, Guiji; Tang, Xia; Liang, Li; Zheng, Yaqiu; Wang, Kai; Tang, Ni] Chongqing Med Univ, Affiliated Hosp 2, Inst Viral Hepatitis, Key Lab Mol Biol Infect Dis,Minist Educ,Dept Infe, Chongqing, Peoples R China; [Tang, Xia; Zhang, Wanfeng; Ding, Keyue] Chongqing Med Univ, Sch Basic Med, Dept Bioinformat, Chongqing, Peoples R China; [Li, Dewei] Chongqing Med Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Chongqing, Peoples R China; [Li, Xiaoyuan] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Oncol, Beijing, Peoples R China; [Zhao, Dachun] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Pathol, Beijing, Peoples R China; [Chen, Yanhong; Hao, Bingtao] Henan Univ, Med Genet Inst Henan Prov, Henan Prov Key Lab Genet Dis & Funct Genom, Zhengzhou Univ,Henan Prov Peoples Hosp,Peoples Ho, Zhengzhou, Henan, Peoples R China	Chongqing Medical University; Chongqing Medical University; Chongqing Medical University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital; Henan University; Zhengzhou University	Wang, K; Tang, N (corresponding author), Chongqing Med Univ, Affiliated Hosp 2, Inst Viral Hepatitis, Key Lab Mol Biol Infect Dis,Minist Educ,Dept Infe, Chongqing, Peoples R China.; Ding, KY (corresponding author), Chongqing Med Univ, Sch Basic Med, Dept Bioinformat, Chongqing, Peoples R China.	wangkai@cqmu.edu.cn; nitang@cqmu.edu.cn; ding.keyue@gmail.com	Ding, Keyue/AAH-7228-2019; Wang, Kai/U-3552-2019; Hao, Bingtao/G-6648-2011	Ding, Keyue/0000-0002-3496-6415; Wang, Kai/0000-0002-0137-1247; Hao, Bingtao/0000-0003-1997-9338	China National Natural Science Foundation [81672780, 81872270, 81572683, 81602417]; Major National ST program [2017ZX10202203-004]; Recruitment Program of Global Youth Experts in China; program of Artificial Intelligence in Medicine of CQ CSTC [ZHYX2019004]; Natural Science Foundation Project of CQ CSTC [cstc2018jcyjAX0254]; Program for Innovation Team of Higher Education in Chongqing [CXTDX201601015]; Leading Talent Program of CQ CSTC [CSTCCXLJRC201719]; Talent Development Program of CQMU for Postgraduate [BJRC201728]	China National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Major National ST program; Recruitment Program of Global Youth Experts in China; program of Artificial Intelligence in Medicine of CQ CSTC; Natural Science Foundation Project of CQ CSTC(Natural Science Foundation Project of CQ CSTC); Program for Innovation Team of Higher Education in Chongqing; Leading Talent Program of CQ CSTC; Talent Development Program of CQMU for Postgraduate	This work was funded by the China National Natural Science Foundation (no. 81672780, KD, nos. 81872270 and 81572683, NT, and 81602417, KW), the Major National S&T program (2017ZX10202203-004 to NT), the Recruitment Program of Global Youth Experts in China (KD), the program of Artificial Intelligence in Medicine of CQ CSTC (ZHYX2019004, KD), Natural Science Foundation Project of CQ CSTC (cstc2018jcyjAX0254 to NT), the Program for Innovation Team of Higher Education in Chongqing (grant no. CXTDX201601015), the Leading Talent Program of CQ CSTC (grant no. CSTCCXLJRC201719 to NT) and Talent Development Program of CQMU for Postgraduate (grant no. BJRC201728).	Ahn SM, 2014, HEPATOLOGY, V60, P1972, DOI 10.1002/hep.27198; Babu SD, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-10; Bailey MH, 2018, CELL, V173, P371, DOI [10.1016/j.cell.2018.02.060, 10.1016/j.cell.2018.07.034]; Belenkaya TY, 2008, DEV CELL, V14, P120, DOI 10.1016/j.devcel.2007.12.003; Cancer Genome Atlas Research Network. Electronic address: wheeler@bcm.edu, 2017, Cell, V169, P1327, DOI 10.1016/j.cell.2017.05.046; Caruso S, 2019, GASTROENTEROLOGY, V157, P760, DOI 10.1053/j.gastro.2019.05.001; Chen KE, 2019, TRAFFIC, V20, P465, DOI 10.1111/tra.12649; Chin CH, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752-0509-8-S4-S11; Cho JY, 2004, P NATL ACAD SCI USA, V101, P609, DOI 10.1073/pnas.2237184100; Cleary SP, 2013, HEPATOLOGY, V58, P1693, DOI 10.1002/hep.26540; Creixell P, 2015, NAT METHODS, V12, P615, DOI [10.1038/nmeth.3440, 10.1038/NMETH.3440]; Cui Y, 2019, J CELL BIOL, V218, P615, DOI 10.1083/jcb.201806153; Deng H, 2013, MOVEMENT DISORD, V28, P569, DOI 10.1002/mds.25430; DING K, 2015, SCI REP UK, V5; Ding L, 2014, NAT REV GENET, V15, P556, DOI 10.1038/nrg3767; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Farmer T, 2019, MOL BIOL CELL, V30, P1138, DOI 10.1091/mbc.E19-01-0044; Farmer T, 2017, J CELL SCI, V130, P2359, DOI 10.1242/jcs.204537; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Franch-Marro X, 2008, NAT CELL BIOL, V10, P170, DOI 10.1038/ncb1678; Fujimoto A, 2012, NAT GENET, V44, P760, DOI 10.1038/ng.2291; Fuse A, 2015, FEBS LETT, V589, P1430, DOI 10.1016/j.febslet.2015.04.040; Gao QZ, 2017, CANCER SCI, V108, P1328, DOI 10.1111/cas.13277; Hanawalt PC, 2008, NAT REV MOL CELL BIO, V9, P958, DOI 10.1038/nrm2549; Haugsten EM, 2005, J CELL SCI, V118, P3869, DOI 10.1242/jcs.02509; Hoshida Y, 2014, J HEPATOL, V61, pS79, DOI 10.1016/j.jhep.2014.07.010; Hsiehchen D, 2018, J HUM GENET, V63, P941, DOI 10.1038/s10038-018-0481-4; Huang J, 2012, NAT GENET, V44, P1117, DOI 10.1038/ng.2391; Huang WY, 2015, NUCLEIC ACIDS RES, V43, pD856, DOI 10.1093/nar/gku1151; Javidi-Sharifi N, 2015, CANCER RES, V75, P880, DOI 10.1158/0008-5472.CAN-14-0573; Kan ZY, 2013, GENOME RES, V23, P1422, DOI 10.1101/gr.154492.113; Kasprzak A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061288; Lee YI, 2000, ONCOGENE, V19, P3717, DOI 10.1038/sj.onc.1203694; Liang L, 2016, ONCOTARGET, V7, P38440, DOI 10.18632/oncotarget.9540; McGough IJ, 2014, CURR BIOL, V24, P1670, DOI 10.1016/j.cub.2014.06.024; McLaren W, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0974-4; Nepusz T, 2012, NAT METHODS, V9, P471, DOI [10.1038/nmeth.1938, 10.1038/NMETH.1938]; Pan Q, 2016, ONCOTARGET, V7, P38487, DOI 10.18632/oncotarget.9555; Paur J, 2015, HEPATOLOGY, V62, P1767, DOI 10.1002/hep.28023; Qiu WH, 2005, WORLD J GASTROENTERO, V11, P5266, DOI 10.3748/wjg.v11.i34.5266; Rao CV, 2017, CARCINOGENESIS, V38, P2, DOI 10.1093/carcin/bgw118; Schulze K, 2016, J HEPATOL, V65, P1031, DOI 10.1016/j.jhep.2016.05.035; Schulze K, 2015, NAT GENET, V47, P505, DOI 10.1038/ng.3252; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Shibata T, 2014, NAT REV GASTRO HEPAT, V11, DOI 10.1038/nrgastro.2014.6; Small SA, 2005, ANN NEUROL, V58, P909, DOI 10.1002/ana.20667; Sondka Z, 2018, NAT REV CANCER, V18, P696, DOI 10.1038/s41568-018-0060-1; Sung WK, 2012, NAT GENET, V44, P765, DOI 10.1038/ng.2295; TANG X, 2019, SCI REP UK, V9; Temkin P, 2017, NEURON, V94, P74, DOI 10.1016/j.neuron.2017.03.020; Totoki Y, 2011, NAT GENET, V43, P464, DOI 10.1038/ng.804; Villanueva A, 2019, NEW ENGL J MED, V380, P1450, DOI 10.1056/NEJMra1713263; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Wang JX, 2015, IEEE ACM T COMPUT BI, V12, P815, DOI 10.1109/TCBB.2014.2361348; Wang J, 2018, TRAFFIC, V19, P578, DOI 10.1111/tra.12574; Yang PT, 2008, DEV CELL, V14, P140, DOI 10.1016/j.devcel.2007.12.004; Zaki N, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-163; Zhang J, 2011, DATA DATABASE, V1, P10; Zheng J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200776; Zhou Mo, 2019, Small GTPases, V10, P20, DOI 10.1080/21541248.2016.1263380; Zhou M, 2016, J CELL BIOL, V214, P445, DOI 10.1083/jcb.201604061	61	21	21	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2020	39	16					3229	3244		10.1038/s41388-020-1215-6	http://dx.doi.org/10.1038/s41388-020-1215-6		FEB 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF9OJ	32071398				2022-12-28	WOS:000514262700002
J	Ray, A; Song, Y; Du, T; Chauhan, D; Anderson, KC				Ray, Arghya; Song, Yan; Du, Ting; Chauhan, Dharminder; Anderson, Kenneth C.			Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma	ONCOGENE			English	Article							DRUG-RESISTANCE; IMMUNE; INHIBITOR; THERAPIES; HYPOXIA; CELLS; CYTOTOXICITY; GROWTH; OXYGEN; MODEL	Bone marrow plasmacytoid dendritic cells (pDCs) in patients with multiple myeloma (MM) promote tumor growth, survival, drug resistance, and immune suppression. Understanding the molecular signaling crosstalk among the tumor cells, pDCs and immune cells will identify novel therapeutic approaches to enhance anti-MM immunity. Using oligonucleotide arrays, we found that pDC-MM interactions induce metabolic enzyme Alpha-Enolase (ENO1) in both pDCs and MM cells. Analysis of MM patient gene expression profiling database showed that ENO1 expression inversely correlates with overall survival. Protein expression analysis showed that ENO1 is expressed in pDC and MM cells; and importantly, that pDC-MM coculture further increases ENO1 expression in both MM cells and pDCs. Using our coculture models of patient autologous pDC-T-NK-MM cells, we examined whether targeting ENO1 can enhance anti-MM immunity. Biochemical inhibition of ENO1 with ENO1 inhibitor (ENO1i) activates pDCs, as well as increases pDC-induced MM-specific CD8(+) CTL and NK cell activity against autologous tumor cells. Combination of ENO1i and anti-PD-L1 Ab or HDAC6i ACY-241 enhances autologous MM-specific CD8(+) CTL activity. Our preclinical data therefore provide the basis for novel immune-based therapeutic approaches targeting ENO1, alone or in combination with anti-PD-L1 Ab or ACY241, to restore anti-MM immunity, enhance MM cytotoxicity, and improve patient outcome.	[Ray, Arghya; Song, Yan; Du, Ting; Chauhan, Dharminder; Anderson, Kenneth C.] Harvard Med Sch, Dept Med Oncol, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA; [Ray, Arghya; Song, Yan; Du, Ting; Chauhan, Dharminder; Anderson, Kenneth C.] Harvard Med Sch, Jerome Lipper Myeloma Ctr, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Chauhan, D; Anderson, KC (corresponding author), Harvard Med Sch, Dept Med Oncol, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA.; Chauhan, D; Anderson, KC (corresponding author), Harvard Med Sch, Jerome Lipper Myeloma Ctr, Dana Farber Canc Inst, Boston, MA 02115 USA.	Dharminder_Chauhan@dfci.harvard.edu; Kenneth_Anderson@dfci.harvard.edu			Dr. Miriam and Sheldon Adelson Medical Research Foundation; National Institutes of Health Specialized Programs of Research Excellence (SPORE) grant [P50100707, R01CA207237, R01 CA050947]	Dr. Miriam and Sheldon Adelson Medical Research Foundation; National Institutes of Health Specialized Programs of Research Excellence (SPORE) grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The grant supports for this investigation were provided by "Dr. Miriam and Sheldon Adelson Medical Research Foundation", and by the National Institutes of Health Specialized Programs of Research Excellence (SPORE) grant P50100707, R01CA207237, and R01 CA050947. KCA is an American Cancer Society Clinical Research Professor.	Ader I, 2008, CANCER RES, V68, P8635, DOI 10.1158/0008-5472.CAN-08-0917; Anderson KC, 2018, J ONCOL PRACT, V14, P411, DOI 10.1200/JOP.18.00311; Anderson KC, 2013, J NATL COMPR CANC NE, V11, P676, DOI 10.6004/jnccn.2013.0199; Anderson KC, 2012, J CLIN ONCOL, V30, P445, DOI 10.1200/JCO.2011.37.8919; Bae J, 2018, LEUKEMIA, V32, P1932, DOI 10.1038/s41375-018-0062-8; Barlogie B, 2006, NEW ENGL J MED, V354, P1021, DOI 10.1056/NEJMoa053583; Bi EG, 2018, J CLIN INVEST, V128, P4821, DOI 10.1172/JCI121421; Cappello P, 2017, FRONT BIOSCI-LANDMRK, V22, P944, DOI 10.2741/4526; Cappello P, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1112940; Chauhan D, 2003, BLOOD, V101, P3606, DOI 10.1182/blood-2002-10-3146; Chauhan D, 2009, CANCER CELL, V16, P309, DOI 10.1016/j.ccr.2009.08.019; Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490; de Broek IV, 2006, HAEMATOL-HEMATOL J, V91, P200; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Granchi C, 2014, BIOORG MED CHEM LETT, V24, P4915, DOI 10.1016/j.bmcl.2014.09.041; Gu ZM, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0392-4; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Heuck CJ, 2014, LEUKEMIA, V28, P2410, DOI 10.1038/leu.2014.232; Ikeda S, 2018, BLOOD ADV, V2, P323, DOI 10.1182/bloodadvances.2017008847; Jung DW, 2013, ACS CHEM BIOL, V8, P1271, DOI 10.1021/cb300687k; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Li WB, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071616; Liberti MV, 2016, NAT CHEM BIOL, V12, P577, DOI 10.1038/nchembio.2133; Lu CC, 2014, J CHROMATOGR A, V1372, P34, DOI 10.1016/j.chroma.2014.10.098; Maiso P, 2015, CANCER RES, V75, P2071, DOI 10.1158/0008-5472.CAN-14-3400; Manasanch EE, 2019, BLOOD ADV, V3, P2400, DOI 10.1182/bloodadvances.2019000300; Milosevic A, 2004, SEMIN RADIAT ONCOL, V14, P249, DOI 10.1016/j.semradonc.2004.04.006; Muller FL, 2012, NATURE, V488, P337, DOI 10.1038/nature11331; Pacella I, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01889; Qorraj M, 2017, LEUKEMIA, V31, P470, DOI 10.1038/leu.2016.214; Ray A, 2018, LEUKEMIA, V32, P843, DOI 10.1038/leu.2017.322; Ray A, 2015, LEUKEMIA, V29, P1441, DOI 10.1038/leu.2015.11; Ray A, 2014, LEUKEMIA, V28, P1716, DOI 10.1038/leu.2014.46; Ray A, 2020, LEUKEMIA, V34, P567, DOI 10.1038/s41375-019-0558-x; Ryans K, 2017, BMC IMMUNOL, V18, DOI 10.1186/s12865-017-0212-1; Shaughnessy JD, 2007, BLOOD, V109, P2276, DOI 10.1182/blood-2006-07-038430; Shin YC, 2008, CANCER RES, V68, P1751, DOI 10.1158/0008-5472.CAN-07-2766; Stessman HAF, 2013, MOL CANCER THER, V12, P1140, DOI 10.1158/1535-7163.MCT-12-1151; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Zhao MY, 2015, ONCOTARGET, V6, P15610, DOI 10.18632/oncotarget.3639; Zhu XH, 2015, EXP CELL RES, V335, P216, DOI 10.1016/j.yexcr.2015.05.020	41	17	19	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	13					2786	2796		10.1038/s41388-020-1172-0	http://dx.doi.org/10.1038/s41388-020-1172-0		FEB 2020	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KX4EF	32024967	Green Accepted			2022-12-28	WOS:000511273600001
J	Cluzet, V; Devillers, MM; Petit, F; Chauvin, S; Francois, CM; Giton, F; Genestie, C; di Clemente, N; Cohen-Tannoudji, J; Guigon, CJ				Cluzet, Victoria; Devillers, Marie M.; Petit, Florence; Chauvin, Stephanie; Francois, Charlotte M.; Giton, Frank; Genestie, Catherine; di Clemente, Nathalie; Cohen-Tannoudji, Joelle; Guigon, Celine J.			Aberrant granulosa cell-fate related to inactivated p53/Rb signaling contributes to granulosa cell tumors and to FOXL2 downregulation in the mouse ovary	ONCOGENE			English	Article							ANTI-MULLERIAN HORMONE; FOLLICULAR DEVELOPMENT; EXPRESSION; GENE; MUTATIONS; PROTEIN; PROLIFERATION; RECEPTOR; LOCALIZATION; INHIBITION	Ovarian granulosa cell tumors (GCTs) are indolent tumors of the ovary affecting women at all ages and potentially displaying late recurrence. Even if there is still little information regarding the mechanisms involved in GCT development and progression, FOXL2 would be a major tumor suppressor gene in granulosa cells. We analyzed the mechanisms underlying GCT initiation and progression by using mice with targeted expression of SV40 large T-antigen in granulosa cells (AT mouse), which develop GCTs. Consistent with patients, AT mice with developing GCTs displayed increased levels in circulating anti-Mullerian hormone (AMH), estradiol and androgens, as well as decreased FOXL2 protein abundance. Very few mice developed metastases (1 out of 30). In situ analyses revealed that GCT initiation resulted from both increased granulosa cell survival and proliferation in large antral follicles. Tumorigenesis was associated with the combined inactivation of p53 and Rb pathways, as shown by the impaired expression of respective downstream targets regulating cell apoptosis and proliferation, i.e., Bax, Bak, Gadd45a, Ccna2, Ccne1, E2f1, and Orc1. Importantly, the expression of FOXL2 was still present in newly developed GCTs and its downregulation only started during GCT growth. Collectively, our experiments provide evidence that disrupted p53/Rb signaling can drive tumor initiation and growth. This model challenges the current paradigm that impaired FOXL2 signaling is a major switch of granulosa cell tumorigenesis, albeit possibly contributing to tumor growth.	[Cluzet, Victoria; Devillers, Marie M.; Petit, Florence; Chauvin, Stephanie; Francois, Charlotte M.; Cohen-Tannoudji, Joelle; Guigon, Celine J.] Univ Paris Diderot, Physiol Axe Gonadotrope U1133, Biol Fonct & Adaptat UMR 8251, INSERM,Sorbonne Paris Cite, Paris, France; [Giton, Frank] Inserm IMRB U955 Eq07, Pole Biol Pathol Henri Mondor, AP HP, Creteil, France; [Genestie, Catherine] Inst Gustave Roussy, Dept Pathol, Villejuif, France; [di Clemente, Nathalie] Sorbonne Univ, CRSA, IHU ICAN, INSERM, Paris, France; [Guigon, Celine J.] Unite Biol Fonct & Adaptat, 4 Rue MA Lagroua Weill Halle,Case Courrier 7007, F-75013 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Cite	Guigon, CJ (corresponding author), Univ Paris Diderot, Physiol Axe Gonadotrope U1133, Biol Fonct & Adaptat UMR 8251, INSERM,Sorbonne Paris Cite, Paris, France.; Guigon, CJ (corresponding author), Unite Biol Fonct & Adaptat, 4 Rue MA Lagroua Weill Halle,Case Courrier 7007, F-75013 Paris, France.	celine.guigon@univ-paris-diderot.fr	; guigon, celine/L-3518-2017	Chauvin, Stephanie/0000-0002-8439-1453; GITON, Frank/0000-0002-4959-1214; guigon, celine/0000-0002-4489-4304; di Clemente, Nathalie/0000-0001-9087-3486; PETIT, Florence/0000-0002-0363-280X	Ligue contre le Cancer Ile-de-France; Projet Fondation ARC [PJA 20151203391]; GEFLUC Paris-Ile de France; "Institut National de la Sante & de la Recherche Medicale" (Inserm), "Center National de la Recherche Scientifique" (CNRS), University Paris Diderot; Ecole Doctorale Bio-SPC	Ligue contre le Cancer Ile-de-France; Projet Fondation ARC; GEFLUC Paris-Ile de France; "Institut National de la Sante & de la Recherche Medicale" (Inserm), "Center National de la Recherche Scientifique" (CNRS), University Paris Diderot; Ecole Doctorale Bio-SPC	We wish to thank Pr. R Veitia, Dr. AL Todeschini (Institut Jacques Monod, Paris, France), and Dr. S Bouret (Institut du Cerveau et de la Moelle, Paris, France) for valuable discussions regarding this work. They acknowledge the technical assistance of M. Surenaud for gonadotropin assays (IMRB-INSERM U955, Hopital Henri Mondor, France), and Dr. B. Querat and Dr. D. L'hote (University Paris 7, BFA unit, France) for providing p53 antibody and Foxl2 primers. They also thank the technical help of Dr. M. Pannetier (INRA, Jouy en Josas, France) for the detection of FOXL2 by Western blots. They thank O. Trassard (UMS-32 INSERM, Hopital du Kremlin Bicetre, France) for his kind help in scanning histological slides. They acknowledge the great help of the technicians of the Buffon Animal Facility (University Paris Diderot, France). This work was supported by Ligue contre le Cancer Ile-de-France (attributed to NC), Projet Fondation ARC (PJA 20151203391, attributed to CJG) and GEFLUC Paris-Ile de France (CJG). It was also funded by "Institut National de la Sante & de la Recherche Medicale" (Inserm), "Center National de la Recherche Scientifique" (CNRS), University Paris Diderot, and by fellowships from Ecole Doctorale Bio-SPC (VC, MMD, CMF).	Ahuja D, 2005, ONCOGENE, V24, P7729, DOI 10.1038/sj.onc.1209046; Alexander BM, 2007, ANAT REC, V290, P59, DOI 10.1002/ar.20409; Alexiadis M, 2019, MOL CANCER RES, V17, P177, DOI 10.1158/1541-7786.MCR-18-0359; Andreu-Vieyra C, 2008, MOL ENDOCRINOL, V22, P2141, DOI 10.1210/me.2008-0033; Anttonen M, 2011, LAB INVEST, V91, P1605, DOI 10.1038/labinvest.2011.116; Arcellana-Panlilio MY, 2002, GENE CHROMOSOME CANC, V35, P176, DOI 10.1002/gcc.10108; Auguste A, 2015, HUM MOL GENET, V24, P6687, DOI 10.1093/hmg/ddv373; Batisse-Lignier M, 2017, ONCOGENE, V36, P4445, DOI 10.1038/onc.2017.54; Batista F, 2007, P NATL ACAD SCI USA, V104, P3330, DOI 10.1073/pnas.0611326104; Benayoun BA, 2011, HUM MOL GENET, V20, P1673, DOI 10.1093/hmg/ddr042; Benayoun BA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008789; Bessiere L, 2015, EBIOMEDICINE, V2, P421, DOI 10.1016/j.ebiom.2015.03.002; BUKOVSKY A, 1995, BIOL REPROD, V52, P776, DOI 10.1095/biolreprod52.4.776; Caburet S, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1283-0; Chu S, 2002, MOL HUM REPROD, V8, P426, DOI 10.1093/molehr/8.5.426; De Cian MC, 2017, ONCOGENE, V36, P208, DOI 10.1038/onc.2016.191; Devillers MM, 2019, J ENDOCRINOL, V240, P215, DOI 10.1530/JOE-18-0313; Dutertre M, 2001, ENDOCRINOLOGY, V142, P4040, DOI 10.1210/en.142.9.4040; Engelmann D, 2012, CANCER RES, V72, P571, DOI 10.1158/0008-5472.CAN-11-2575; Fan HY, 2009, CANCER RES, V69, P6463, DOI 10.1158/0008-5472.CAN-08-3363; Fischer M, 2017, ONCOGENE, V36, P3943, DOI 10.1038/onc.2016.502; Fleming NI, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014389; Francois CM, 2017, SCI REP-UK, V7, DOI 10.1038/srep46222; Francois CM, 2015, CARCINOGENESIS, V36, P564, DOI 10.1093/carcin/bgv041; Fuller PJ, 2017, CLIN GENET, V91, P285, DOI 10.1111/cge.12917; Georges A, 2014, J MOL ENDOCRINOL, V52, pR17, DOI 10.1530/JME-13-0159; Georges A, 2014, ELIFE, V3, DOI 10.7554/eLife.04207; Gershon R, 2011, GYNECOL ONCOL, V122, P580, DOI 10.1016/j.ygyno.2011.05.008; Goulvent T, 2016, HISTOPATHOLOGY, V68, P279, DOI 10.1111/his.12747; Guigon CJ, 2010, CARCINOGENESIS, V31, P1284, DOI 10.1093/carcin/bgq059; Hafner A, 2019, NAT REV MOL CELL BIO, V20, P199, DOI 10.1038/s41580-019-0110-x; Hillman RT, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04950-x; Jamieson S, 2012, ENDOCR REV, V33, P109, DOI 10.1210/er.2011-0014; Kalfa N, 2006, J CLIN ENDOCR METAB, V91, P1842, DOI 10.1210/jc.2005-2710; Kalfa N, 2007, FERTIL STERIL, V87, P896, DOI 10.1016/j.fertnstert.2006.11.016; Kalfa N, 2009, GYNECOL ENDOCRINOL, V25, P299, DOI 10.1080/09513590802630153; Kim JH, 2011, ONCOGENE, V30, P1653, DOI 10.1038/onc.2010.541; L'Hote D, 2012, HUM MOL GENET, V21, P3264, DOI 10.1093/hmg/dds170; Lague MN, 2008, CARCINOGENESIS, V29, P2062, DOI 10.1093/carcin/bgn186; Ligtenberg MJ, 1999, J CLIN ENDOCR METAB, V84, P2233, DOI 10.1210/jc.84.6.2233; Liu ZL, 2015, MOL ENDOCRINOL, V29, P1006, DOI 10.1210/me.2015-1103; Makrigiannakis A, 2000, J CLIN ENDOCR METAB, V85, P449, DOI 10.1210/jc.85.1.449; Mayr D, 2002, MODERN PATHOL, V15, P951, DOI 10.1097/01.MP.0000024290.55261.14; McGee EA, 2000, ENDOCR REV, V21, P200, DOI 10.1210/er.21.2.200; Merras-Salmio L, 2002, PEDIATR HEMAT ONCOL, V19, P145, DOI 10.1080/088800102753541297; Nogales FF, 2004, MODERN PATHOL, V17, P868, DOI 10.1038/modpathol.3800133; Ogawa T, 2003, MOL CELL ENDOCRINOL, V210, P31, DOI 10.1016/j.mce.2003.08.008; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; Pannetier M, 2016, SEX DEV, V10, P167, DOI 10.1159/000448667; Pectasides D, 2008, CANCER TREAT REV, V34, P1, DOI 10.1016/j.ctrv.2007.08.007; Rey RA, 1996, AM J OBSTET GYNECOL, V174, P958, DOI 10.1016/S0002-9378(96)70333-2; Shah SP, 2009, NEW ENGL J MED, V360, P2719, DOI 10.1056/NEJMoa0902542; Sirotkin AV, 2008, REPRODUCTION, V136, P611, DOI 10.1530/REP-08-0229; TILLY KI, 1995, ENDOCRINOLOGY, V136, P1394, DOI 10.1210/en.136.4.1394; Uhlenhaut NH, 2009, CELL, V139, P1130, DOI 10.1016/j.cell.2009.11.021; Zhao HL, 2013, CANCER CELL, V24, P645, DOI 10.1016/j.ccr.2013.09.021	57	8	9	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	9					1875	1890		10.1038/s41388-019-1109-7	http://dx.doi.org/10.1038/s41388-019-1109-7			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KP9VM	31745296				2022-12-28	WOS:000516579800004
J	Dai, K; Tanaka, M; Kamiyoshi, A; Sakurai, T; Ichikawa-Shindo, Y; Kawate, H; Cui, NQ; Wei, YX; Tanaka, M; Kakihara, S; Matsui, S; Shindo, T				Dai, Kun; Tanaka, Megumu; Kamiyoshi, Akiko; Sakurai, Takayuki; Ichikawa-Shindo, Yuka; Kawate, Hisaka; Cui, Nanqi; Wei, Yangxuan; Tanaka, Masaaki; Kakihara, Shinji; Matsui, Shuhei; Shindo, Takayuki			Deficiency of the adrenomedullin-RAMP3 system suppresses metastasis through the modification of cancer-associated fibroblasts	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; SQUAMOUS-CELL CARCINOMAS; PANCREATIC-CANCER; POOR-PROGNOSIS; VASCULAR INTEGRITY; BREAST-CANCER; UP-REGULATION; PODOPLANIN; EXPRESSION; INVASION	Tumor metastasis is a primary source of morbidity and mortality in cancer. Adrenomedullin (AM) is a multifunctional peptide regulated by receptor activity-modifying proteins (RAMPs). We previously reported that the AM-RAMP2 system is involved in tumor angiogenesis, but the function of the AM-RAMP3 system remains largely unknown. Here, we investigated the actions of the AM-RAMP2 and 3 systems in the tumor microenvironment and their impact on metastasis. PAN02 pancreatic cancer cells were injected into the spleens of mice, leading to spontaneous liver metastasis. Tumor metastasis was enhanced in vascular endothelial cell-specific RAMP2 knockout mice (DI-E-RAMP2-/-). By contrast, metastasis was suppressed in RAMP3-/- mice, where the number of podoplanin (PDPN)-positive cancer-associated fibroblasts (CAFs) was reduced in the periphery of tumors at metastatic sites. Because PDPN-positive CAFs are a hallmark of tumor malignancy, we assessed the regulation of PDPN and found that Src/Cas/PDPN signaling is mediated by RAMP3. In fact, RAMP3 deficiency CAFs suppressed migration, proliferation, and metastasis in co-cultures with tumor cells in vitro and in vivo. Moreover, the activation of RAMP2 in RAMP3-/- mice suppressed both tumor growth and metastasis. Based on these results, we suggest that the upregulation of PDPN in DI-E-RAMP2-/- mice increases malignancy, while the downregulation of PDPN in RAMP3-/- mice reduces it. Selective activation of RAMP2 and inhibition of RAMP3 would therefore be expected to suppress tumor metastasis. This study provides the first evidence that understanding and targeting to AM-RAMP systems could contribute to the development of novel therapeutics against metastasis.	[Dai, Kun; Tanaka, Megumu; Kamiyoshi, Akiko; Sakurai, Takayuki; Ichikawa-Shindo, Yuka; Kawate, Hisaka; Cui, Nanqi; Wei, Yangxuan; Tanaka, Masaaki; Kakihara, Shinji; Matsui, Shuhei; Shindo, Takayuki] Shinshu Univ, Interdisciplinary Cluster Cutting Edge Res, Inst Biomed Sci, Dept Life Innovat, Matsumoto, Nagano 3908621, Japan; [Dai, Kun; Tanaka, Megumu; Kamiyoshi, Akiko; Sakurai, Takayuki; Ichikawa-Shindo, Yuka; Kawate, Hisaka; Cui, Nanqi; Wei, Yangxuan; Shindo, Takayuki] Shinshu Univ, Sch Med, Dept Cardiovasc Res, Matsumoto, Nagano 3908621, Japan; [Tanaka, Masaaki; Kakihara, Shinji] Shinshu Univ, Sch Med, Dept Ophthalmol, Matsumoto, Nagano 3908621, Japan; [Matsui, Shuhei] Shinshu Univ, Sch Med, Dept Anesthesiol, Matsumoto, Nagano 3908621, Japan	Shinshu University; Shinshu University; Shinshu University; Shinshu University	Shindo, T (corresponding author), Shinshu Univ, Interdisciplinary Cluster Cutting Edge Res, Inst Biomed Sci, Dept Life Innovat, Matsumoto, Nagano 3908621, Japan.; Shindo, T (corresponding author), Shinshu Univ, Sch Med, Dept Cardiovasc Res, Matsumoto, Nagano 3908621, Japan.	tshindo@shinshu-u.ac.jp	Kakihara, Shinji/AAR-1855-2021	Kakihara, Shinji/0000-0002-8433-8169	Core Research for Evolutionary Science and Technology (CREST) of Japan Science and Technology Agency (JST); Japan Agency for Medical Research and Development (AMED); Bristol-Myers Squibb Company; Japan Foundation for Applied Enzymology; Naito Foundation; Public Foundation of Chubu Science and Technology Center; Yamaguchi Endocrine Research Foundation; Hoyu Science Foundation; Takahashi Industrial and Economic Research Foundation; Akaeda Medical Research Foundation; Shinshu Public Utility Foundation for Promotion of Medial Sciences; Japan Heart Foundation; Otsuka Toshimi Scholarship Foundation	Core Research for Evolutionary Science and Technology (CREST) of Japan Science and Technology Agency (JST)(Japan Science & Technology Agency (JST)); Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Bristol-Myers Squibb Company(Bristol-Myers Squibb); Japan Foundation for Applied Enzymology; Naito Foundation(Naito Memorial Foundation); Public Foundation of Chubu Science and Technology Center; Yamaguchi Endocrine Research Foundation; Hoyu Science Foundation; Takahashi Industrial and Economic Research Foundation; Akaeda Medical Research Foundation; Shinshu Public Utility Foundation for Promotion of Medial Sciences; Japan Heart Foundation; Otsuka Toshimi Scholarship Foundation(Otsuka Pharmaceutical)	This study was supported by Grants-in-Aid for Scientific Research (KAKENHI) from the Core Research for Evolutionary Science and Technology (CREST) of Japan Science and Technology Agency (JST) and the Japan Agency for Medical Research and Development (AMED), and research grants from Bristol-Myers Squibb Company, Japan Foundation for Applied Enzymology, the Naito Foundation, the Public Foundation of Chubu Science and Technology Center, Yamaguchi Endocrine Research Foundation, Hoyu Science Foundation, Takahashi Industrial and Economic Research Foundation, Akaeda Medical Research Foundation, Shinshu Public Utility Foundation for Promotion of Medial Sciences, and Japan Heart Foundation. KD received a scholarship from Otsuka Toshimi Scholarship Foundation. The authors are grateful to Prof. Sachie Hiratsuka for valuable comments and tumor cells.	Aoki M, 2011, BRIT J CANCER, V104, P714, DOI 10.1038/sj.bjc.6606075; Berenguer-Daize C, 2013, CLIN CANCER RES, V19, P6138, DOI 10.1158/1078-0432.CCR-13-0691; Breiteneder-Geleff S, 1999, AM J PATHOL, V154, P385, DOI 10.1016/S0002-9440(10)65285-6; Conner MT, 2010, BIOCHEMISTRY-US, V49, P821, DOI 10.1021/bi902068b; Dauer P, 2018, CANCER RES, V78, P1321, DOI 10.1158/0008-5472.CAN-17-2320; Desmouliere A, 2004, INT J DEV BIOL, V48, P509, DOI 10.1387/ijdb.041802ad; Desmouliere A, 2003, LAB INVEST, V83, P1689, DOI 10.1097/01.LAB.0000101911.53973.90; Friedman SL, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004700; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hikosaka T, 2011, PEPTIDES, V32, P1825, DOI 10.1016/j.peptides.2011.07.012; Hinz B, 2001, MOL BIOL CELL, V12, P2730, DOI 10.1091/mbc.12.9.2730; Hirabayashi K, 2019, AM J PATHOL, V189, P449, DOI 10.1016/j.ajpath.2018.10.021; Hiratsuka S, 2008, NAT CELL BIOL, V10, P1349, DOI 10.1038/ncb1794; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Hirayama K, 2018, SURG TODAY, V48, P110, DOI 10.1007/s00595-017-1559-x; Iesato Y, 2013, AM J PATHOL, V182, P2380, DOI 10.1016/j.ajpath.2013.02.015; Iimuro S, 2004, CIRC RES, V95, P415, DOI 10.1161/01.RES.0000138018.61065.d1; Inoue H, 2012, J ORAL SCI, V54, P241, DOI 10.2334/josnusd.54.241; Kaafarani I, 2009, FASEB J, V23, P3424, DOI 10.1096/fj.08-127852; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Komohara Y, 2017, J PATHOL, V241, P313, DOI 10.1002/path.4824; Koukourakis MI, 2017, LAB INVEST, V97, P1321, DOI 10.1038/labinvest.2017.79; Koyama T, 2013, CIRCULATION, V127, P842, DOI 10.1161/CIRCULATIONAHA.112.000756; Lau EYT, 2016, CELL REP, V15, P1175, DOI 10.1016/j.celrep.2016.04.019; Liu T, 2018, PEPTIDES, V110, P10, DOI 10.1016/j.peptides.2018.10.006; Martin-Villar E, 2006, J CELL SCI, V119, P4541, DOI 10.1242/jcs.03218; Marusyk A, 2016, CANCER RES, V76, P6495, DOI 10.1158/0008-5472.CAN-16-1457; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Miller MJ, 1996, J BIOL CHEM, V271, P23345; Murakami S, 2005, AM J RESP CRIT CARE, V172, P581, DOI 10.1164/rccm.200409-1280OC; Nakashima Y, 2013, CANCER SCI, V104, P1718, DOI 10.1111/cas.12286; Neesse A, 2015, GUT, V64, P1476, DOI 10.1136/gutjnl-2015-309304; Neri S, 2015, INT J CANCER, V137, P784, DOI 10.1002/ijc.29464; Nojiri T, 2015, P NATL ACAD SCI USA, V112, P4086, DOI 10.1073/pnas.1417273112; Nouguerede E, 2013, CANCER MED-US, V2, P196, DOI 10.1002/cam4.51; Ohlund D, 2014, J EXP MED, V211, P1503, DOI 10.1084/jem.20140692; Peacock JG, 2007, MOL BIOL CELL, V18, P3860, DOI 10.1091/mbc.E07-01-0075; Prakash J, 2017, ADV DRUG DELIVER REV, V121, P1, DOI 10.1016/j.addr.2017.11.008; Qi LS, 2016, ONCOTARGET, V7, P74015, DOI 10.18632/oncotarget.12187; Ramachandran V, 2007, CANCER RES, V67, P2666, DOI 10.1158/0008-5472.CAN-06-3362; Ramachandran V, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007502; Raof NA, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-015-2267-9; Ren Y, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0758-4; Schacht V, 2005, AM J PATHOL, V166, P913, DOI 10.1016/S0002-9440(10)62311-5; Schoppmann SF, 2012, BREAST CANCER RES TR, V134, P237, DOI 10.1007/s10549-012-1984-x; Sexton PM, 2006, ANN NY ACAD SCI, V1070, P90, DOI 10.1196/annals.1317.076; Sexton PM, 2001, CELL SIGNAL, V13, P73, DOI 10.1016/S0898-6568(00)00143-1; Shindo K, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-168; Shindo T, 2001, CIRCULATION, V104, P1964, DOI 10.1161/hc4101.097111; Shindo T, 2019, PEPTIDES, V111, P55, DOI 10.1016/j.peptides.2018.04.004; Siclari VA, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0458-y; Singhal PK, 2016, P NATL ACAD SCI USA, V113, P122, DOI 10.1073/pnas.1522401112; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Suchanski J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184970; Tanaka M, 2016, CARDIOVASC RES, V111, P398, DOI 10.1093/cvr/cvw166; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Ugorski M, 2016, AM J CANCER RES, V6, P370; Wicki A, 2006, CANCER CELL, V9, P261, DOI 10.1016/j.ccr.2006.03.010; Yamauchi A, 2014, J MOL CELL CARDIOL, V77, P73, DOI 10.1016/j.yjmcc.2014.09.017; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yazdani S, 2017, ADV DRUG DELIVER REV, V121, P101, DOI 10.1016/j.addr.2017.07.010; Ye L, 2010, CANCER SCI, V101, P2137, DOI 10.1111/j.1349-7006.2010.01648.x; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Yoshida T, 2015, CLIN CANCER RES, V21, P642, DOI 10.1158/1078-0432.CCR-14-0846; Zhang DX, 2018, CANCER RES, V78, P1700, DOI 10.1158/0008-5472.CAN-17-1366; Zhang XHF, 2013, CELL, V154, P1060, DOI 10.1016/j.cell.2013.07.036; Zou GY, 2018, CANCER SCI, V109, P3416, DOI 10.1111/cas.13780	67	7	7	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	9					1914	1930		10.1038/s41388-019-1112-z	http://dx.doi.org/10.1038/s41388-019-1112-z			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KP9VM	31754214	Green Submitted			2022-12-28	WOS:000516579800007
J	Yu, CY; Han, JX; Zhang, JF; Jiang, PL; Shen, CQ; Guo, FF; Tang, JY; Yan, TT; Tian, XL; Zhu, XQ; Ma, D; Hu, Y; Xie, YH; Du, W; Zhong, M; Chen, JX; Liu, Q; Sun, DF; Chen, YX; Zou, WP; Hong, J; Chen, HY; Fang, JY				Yu, Chen-Yang; Han, Ji-Xuan; Zhang, Junfang; Jiang, Penglei; Shen, Chaoqin; Guo, Fangfang; Tang, Jiayin; Yan, Tingting; Tian, Xianglong; Zhu, Xiaoqiang; Ma, Dan; Hu, Ye; Xie, Yuanhong; Du, Wan; Zhong, Ming; Chen, Jinxian; Liu, Qiang; Sun, Danfeng; Chen, Yingxuan; Zou, Weiping; Hong, Jie; Chen, Haoyan; Fang, Jing-Yuan			A 16q22.1 variant confers susceptibility to colorectal cancer as a distal regulator of ZFP90	ONCOGENE			English	Article							GENOME-WIDE ASSOCIATION; RISK; EXPRESSION; LOCI; STATISTICS; RS6983267; GENETICS; BINDING; COHORTS	Genome-wide association studies (GWASs) implicate 16q22.1 locus in risk for colorectal cancer (CRC). However, the underlying oncogenic mechanisms remain unknown. Here, through comprehensive filtration, we prioritized rs7198799, a common SNP in the second intron of the CDH1, as the putative causal variant. In addition, we found an association of CRC-risk allele C of rs7198799 with elevated transcript level of biological plausible candidate gene ZFP90 via expression quantitative trait loci analysis. Mechanistically, causal variant rs7198799 resides in an enhancer element and remotely regulate ZFP90 expression by targeting the transcription factor NFATC2. Remarkably, CRISPR/Cas9-guided single-nucleotide editing demonstrated the direct effect of rs7198799 on ZFP90 expression and CRC cellular malignant phenotype. Furthermore, ZFP90 affects several oncogenic pathways, including BMP4, and promotes carcinogenesis in patients and in animal models with ZFP90 specific genetic manipulation. Taken together, these findings reveal a risk SNP-mediated long-range regulation on the NFATC2-ZFP90-BMP4 pathway underlying the initiation of CRC.	[Yu, Chen-Yang; Han, Ji-Xuan; Shen, Chaoqin; Guo, Fangfang; Tang, Jiayin; Yan, Tingting; Tian, Xianglong; Zhu, Xiaoqiang; Ma, Dan; Hu, Ye; Xie, Yuanhong; Du, Wan; Sun, Danfeng; Chen, Yingxuan; Hong, Jie; Chen, Haoyan; Fang, Jing-Yuan] Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Key Lab Gastroenterol & Hepatol,Minist Hlth,Div G, Shanghai Inst Digest Dis,Renji Hosp,Sch Med, 145 Middle Shandong Rd, Shanghai 200001, Peoples R China; [Zhang, Junfang; Jiang, Penglei] Shanghai Ocean Univ, Coll Fishery & Life Sci, Minist Educ, Key Lab Aquacultural Resources & Utilizat, Shanghai 201306, Peoples R China; [Du, Wan; Sun, Danfeng; Zou, Weiping] Univ Michigan, Ctr Excellence Canc Immunol & Immunotherapy, Grad Programs Immunol & Canc Biol, Rogel Canc Ctr,Sch Med,Dept Surg, Ann Arbor, MI 48109 USA; [Du, Wan; Sun, Danfeng; Zou, Weiping] Univ Michigan, Ctr Excellence Canc Immunol & Immunotherapy, Grad Programs Immunol & Canc Biol, Rogel Canc Ctr,Sch Med,Dept Pathol, Ann Arbor, MI 48109 USA; [Zhong, Ming; Chen, Jinxian] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Div Gastrointestinal Surg, 145 Middle Shandong Rd, Shanghai 200001, Peoples R China; [Liu, Qiang] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Pathol, 145 Middle Shandong Rd, Shanghai 200001, Peoples R China	Shanghai Jiao Tong University; Shanghai Ocean University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Hong, J; Chen, HY; Fang, JY (corresponding author), Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Key Lab Gastroenterol & Hepatol,Minist Hlth,Div G, Shanghai Inst Digest Dis,Renji Hosp,Sch Med, 145 Middle Shandong Rd, Shanghai 200001, Peoples R China.	jiehong97@sjtu.edu.cn; haoyanchen@sjtu.edu.cn; jingyuanfang@sjtu.edu.cn	Liu, Qiang/HHZ-3181-2022; Tang, Jiayin/AAJ-5473-2021; jiang, penglei/GPX-0521-2022	Tang, Jiayin/0000-0002-2510-6448; 	National Natural Science Foundation of China [81421001, 81530072, 81320108024, 81830081, 81522008, 81874159, 81871901, 31371273, 81770165]; Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning [201268]; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant [20152512, 20161309]; Chenxing Project of Shanghai Jiao Tong University; "Shu Guang" project [17CG17]; Program for Professor of Special Appointment (2015 Youth Eastern Scholar) at Shanghai Institutions of Higher Learning [QD2015003]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant; Chenxing Project of Shanghai Jiao Tong University; "Shu Guang" project(Chinese Academy of Sciences); Program for Professor of Special Appointment (2015 Youth Eastern Scholar) at Shanghai Institutions of Higher Learning	This work was supported by National Natural Science Foundation of China (81421001, 81530072, 81320108024, 81830081, 81522008, 81874159, 81871901, and 31371273,81770165), the Program for Professor of Special Appointment (Eastern Scholar No. 201268 and 2015 Youth Eastern Scholar No. QD2015003) at Shanghai Institutions of Higher Learning, the Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant (no. 20152512 and 20161309), the Chenxing Project of Shanghai Jiao Tong University to HC, and "Shu Guang" project (17CG17) to JH. Funding for open access charge: National Natural Science Foundation of China (81421001).	Abuli A, 2010, GASTROENTEROLOGY, V139, P788, DOI 10.1053/j.gastro.2010.05.072; Ardlie KG, 2015, SCIENCE, V348, P648, DOI 10.1126/science.1262110; Ay F, 2014, GENOME RES, V24, P999, DOI 10.1101/gr.160374.113; Azofeifa JG, 2018, GENOME RES, V28, P334, DOI 10.1101/gr.225755.117; Buckley M, 2016, NAT PROTOC, V11, P46, DOI 10.1038/nprot.2015.136; Carvajal-Carmona LG, 2011, HUM MOL GENET, V20, P2879, DOI 10.1093/hmg/ddr190; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Claussnitzer M, 2014, CELL, V156, P343, DOI 10.1016/j.cell.2013.10.058; Cookson W, 2009, NAT REV GENET, V10, P184, DOI 10.1038/nrg2537; Couzin J, 2007, SCIENCE, V316, P820, DOI 10.1126/science.316.5826.820; de Volo CPB, 2012, GENE, V498, P328, DOI 10.1016/j.gene.2012.01.028; Dixon AL, 2007, NAT GENET, V39, P1202, DOI 10.1038/ng2109; Du MM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157521; Duque J, 2005, J BIOL CHEM, V280, P8686, DOI 10.1074/jbc.M413076200; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Freedman ML, 2011, NAT GENET, V43, P513, DOI 10.1038/ng.840; Gerlach K, 2012, CANCER RES, V72, P4340, DOI 10.1158/0008-5472.CAN-11-4155; Goring HHH, 2007, NAT GENET, V39, P1208, DOI 10.1038/ng2119; Hata L, 2011, J MOL CELL CARDIOL, V50, P972, DOI 10.1016/j.yjmcc.2011.01.017; Heintzman ND, 2009, CURR OPIN GENET DEV, V19, P541, DOI 10.1016/j.gde.2009.09.006; Houlston RS, 2008, NAT GENET, V40, P1426, DOI 10.1038/ng.262; Kilpinen H, 2013, SCIENCE, V342, P744, DOI 10.1126/science.1242463; Kumar MS, 2012, CELL, V149, P642, DOI 10.1016/j.cell.2012.02.059; Lai F, 2014, CURR OPIN GENET DEV, V25, P38, DOI 10.1016/j.gde.2013.11.017; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; Lu Y, 2019, GASTROENTEROLOGY, V156, P1455, DOI 10.1053/j.gastro.2018.11.066; Manolio TA, 2010, NEW ENGL J MED, V363, P166, DOI 10.1056/NEJMra0905980; McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630; Montgomery SB, 2010, NATURE, V464, P773, DOI 10.1038/nature08903; Neufert C, 2007, NAT PROTOC, V2, P1998, DOI 10.1038/nprot.2007.279; Nishizaki SS, 2017, TRENDS GENET, V33, P34, DOI 10.1016/j.tig.2016.10.008; Peters U, 2015, GUT, V64, P1623, DOI 10.1136/gutjnl-2013-306705; Pomerantz MM, 2009, NAT GENET, V41, P882, DOI 10.1038/ng.403; Rockman MV, 2006, NAT REV GENET, V7, P862, DOI 10.1038/nrg1964; Schadt EE, 2005, NAT GENET, V37, P710, DOI 10.1038/ng1589; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Smith CG, 2015, CLIN CANCER RES, V21, P3453, DOI 10.1158/1078-0432.CCR-14-3136; Spisak S, 2015, NAT MED, V21, P1357, DOI 10.1038/nm.3975; Stadhouders R, 2013, NAT PROTOC, V8, P509, DOI 10.1038/nprot.2013.018; Tuupanen S, 2009, NAT GENET, V41, P885, DOI 10.1038/ng.406	41	10	12	3	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	6					1347	1360		10.1038/s41388-019-1055-4	http://dx.doi.org/10.1038/s41388-019-1055-4			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE4UH	31641208	Green Published, hybrid			2022-12-28	WOS:000526714600013
J	Champagne, J; Linares, LK; Maurel, B; Zampieri, A; Moreno, M; Fuentes, I; Dubois, E; Severac, D; Decorsiere, A; Bienvenu, F				Champagne, Julien; Linares, Laetitia K.; Maurel, Benjamin; Zampieri, Alexandre; Moreno, Maeva; Fuentes, Ivanna; Dubois, Emeric; Severac, Dany; Decorsiere, Adrien; Bienvenu, Frederic			TAG-RNAi overcomes off-target effects in cancer models	ONCOGENE			English	Article							CYCLIN D1; TRANSCRIPTIONAL ROLE; LARGE-SCALE; INTERFERENCE; REVEALS; DRIVE	RNA interference offers therapeutic opportunities for the clinical targeting of otherwise undruggable oncogenes. However RNAi can have off-target effects that considerably increase treatment risks. To manage these side effects and allow an easy subtraction of their activity in healthy tissues, we present here the TAG-RNAi approach where cells that are not designated targets do not have the mRNA tag. Using TAG-RNAi we first established the off-target signatures of three different siRNAs specific to the Cyclin D1 oncogene by RNA-sequencing of cultured cancer cells expressing a FLAG-HA-tagged-Cyclin D1. Then, by symmetrical allografts of tagged-cancer cells and untagged controls on the left and right flanks of model mice, we demonstrate that TAG-RNAi is a reliable approach to study the functional impact of any oncogene without off-target bias. Finally we show, as examples, that mutation-specific TAG-RNAi can be applied to downregulate two oncogenic mutants, KRAS-G12V or BRAF-V600E, while sparing the expression of the wild-type proteins. TAG-RNAi will thus avoid the traditional off-target limitations of RNAi in future experimental approaches.	[Champagne, Julien; Maurel, Benjamin; Zampieri, Alexandre; Moreno, Maeva; Fuentes, Ivanna; Decorsiere, Adrien; Bienvenu, Frederic] CNRS, Inst Genom Fonct, UMR 5203, F-34094 Montpellier, France; [Champagne, Julien; Maurel, Benjamin; Zampieri, Alexandre; Moreno, Maeva; Fuentes, Ivanna; Decorsiere, Adrien; Bienvenu, Frederic] INSERM, U1191, F-34094 Montpellier, France; [Champagne, Julien; Maurel, Benjamin; Zampieri, Alexandre; Moreno, Maeva; Fuentes, Ivanna; Decorsiere, Adrien; Bienvenu, Frederic] Univ Montpellier, UMR 5203, F-34094 Montpellier, France; [Linares, Laetitia K.] Univ Montpellier, IRCM, INSERM U896, Inst Reg Canc Montpellier, F-34298 Montpellier, France; [Dubois, Emeric; Severac, Dany] Inst Genom Fonct, MGX Montpellier GenomiX, 141 Rue Cardonille, F-34094 Montpellier 5, France; [Bienvenu, Frederic] Lab Excellence Genome & Epigenome Mol Med EpiGenM, F-34094 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UNICANCER; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM)	Bienvenu, F (corresponding author), CNRS, Inst Genom Fonct, UMR 5203, F-34094 Montpellier, France.; Bienvenu, F (corresponding author), INSERM, U1191, F-34094 Montpellier, France.; Bienvenu, F (corresponding author), Univ Montpellier, UMR 5203, F-34094 Montpellier, France.; Bienvenu, F (corresponding author), Lab Excellence Genome & Epigenome Mol Med EpiGenM, F-34094 Montpellier, France.	frederic.bienvenu@igf.cnrs.fr	Linares, Laetitia LKL/F-9901-2018	Linares, Laetitia LKL/0000-0003-1661-2119; Dubois, Emeric/0000-0002-6052-4178; bienvenu, frederic/0000-0003-2914-4051; decorsiere, adrien/0000-0002-5716-6154; CHAMPAGNE, Julien/0000-0001-8460-858X	Atip-Avenir program [RSE11003FSA]; Merieux Research Grant [060805]; FP7 Marie-Curie European IRG [277118]; EpiGenMed LabEx ("investissements d'avenir") [ANR-10-LABX-12-01]; Fondation pour la Recherche Medicale; Ligue Nationale contre le Cancer; University of Montpellier; SATT AxLR; Montpellier SIRIC; Canceropole GSO; Ligue Regionale contre le Cancer	Atip-Avenir program; Merieux Research Grant; FP7 Marie-Curie European IRG; EpiGenMed LabEx ("investissements d'avenir")(French National Research Agency (ANR)); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); University of Montpellier; SATT AxLR; Montpellier SIRIC; Canceropole GSO; Ligue Regionale contre le Cancer(Ligue nationale contre le cancer)	This work was supported by the Atip-Avenir program (RSE11003FSA), the Merieux Research Grant (060805), the FP7 Marie-Curie European IRG (277118), the EpiGenMed LabEx ("investissements d'avenir" reference ANR-10-LABX-12-01), the Fondation pour la Recherche Medicale, the Ligue Nationale and Regionale contre le Cancer, the University of Montpellier, the SATT AxLR, the Montpellier SIRIC, and the Canceropole GSO, all to FB. JC is the recipient of a Ligue Nationale contre le Cancer Ph.D. fellowship.	Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Anderson KR, 2018, NAT METHODS, V15, P512, DOI 10.1038/s41592-018-0011-5; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Bienvenu F, 2010, NATURE, V463, P374, DOI 10.1038/nature08684; Birmingham A, 2006, NAT METHODS, V3, P199, DOI 10.1038/NMETH854; Cantwell-Dorris ER, 2011, MOL CANCER THER, V10, P385, DOI 10.1158/1535-7163.MCT-10-0799; Casimiro MC, 2012, J CLIN INVEST, V122, P833, DOI 10.1172/JCI60256; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Guo RL, 2017, TRANSCRIPTOMICS, P5; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Iribe H, 2017, ACS OMEGA, V2, P2055, DOI 10.1021/acsomega.7b00291; Jackson AL, 2010, NAT REV DRUG DISCOV, V9, P57, DOI 10.1038/nrd3010; Kanasty R, 2013, NAT MATER, V12, P967, DOI [10.1038/NMAT3765, 10.1038/nmat3765]; Khan AA, 2009, NAT BIOTECHNOL, V27, P549, DOI 10.1038/nbt.1543; Kirk R., 2011, NAT REV CLIN ONCOL, V8, P691; Kok FO, 2015, DEV CELL, V32, P97, DOI 10.1016/j.devcel.2014.11.018; Lander E, 2019, NATURE, V567, P165, DOI 10.1038/d41586-019-00726-5; Lehmann S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088797; McDonald ER, 2017, CELL, V170, P577, DOI 10.1016/j.cell.2017.07.005; McFarland JM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06916-5; Mohr SE, 2014, NAT REV MOL CELL BIO, V15, P591, DOI 10.1038/nrm3860; Morrison C, 2018, NAT REV DRUG DISCOV, V17, P156, DOI 10.1038/nrd.2018.20; Pasquinelli AE, 2012, NAT REV GENET, V13, P271, DOI 10.1038/nrg3162; Prenen H, 2010, CLIN CANCER RES, V16, P2921, DOI 10.1158/1078-0432.CCR-09-2029; Rossi A, 2015, NATURE, V524, P230, DOI 10.1038/nature14580; Setten RL, 2019, NAT REV DRUG DISCOV, V18, P421, DOI 10.1038/s41573-019-0017-4; Sheridan C., 2019, NAT BIOTECHNOL; Stainier DYR, 2015, DEV CELL, V32, P7, DOI 10.1016/j.devcel.2014.12.012; Tabernero J, 2013, CANCER DISCOV, V3, P406, DOI 10.1158/2159-8290.CD-12-0429; Tsherniak A, 2017, CELL, V170, P564, DOI 10.1016/j.cell.2017.06.010; Wu SY, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008362; Xue W, 2014, P NATL ACAD SCI USA, V111, pE3553, DOI 10.1073/pnas.1412686111; Yin H, 2019, NAT REV CLIN ONCOL, V16, P281, DOI 10.1038/s41571-019-0166-8; Yu QY, 2006, CANCER CELL, V9, P23, DOI 10.1016/j.ccr.2005.12.012; Yu QY, 2005, ONCOGENE, V24, P7114, DOI 10.1038/sj.onc.1208853; Zampieri A, 2015, SCI REP-UK, V5, DOI 10.1038/srep15739; Zhou CY, 2019, NATURE, V571, P275, DOI 10.1038/s41586-019-1314-0; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	38	3	4	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	4					935	945		10.1038/s41388-019-1020-2	http://dx.doi.org/10.1038/s41388-019-1020-2			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KF4EJ	31558799				2022-12-28	WOS:000509197200014
J	Weinberg, F; Griffin, R; Frohlich, M; Heining, C; Braun, S; Spohr, C; Iconomou, M; Hollek, V; Roring, M; Horak, P; Kreutzfeldt, S; Warsow, G; Hutter, B; Uhrig, S; Neumann, O; Reuss, D; Heiland, DH; von Kalle, C; Weichert, W; Stenzinger, A; Brors, B; Glimm, H; Frohling, S; Brummer, T				Weinberg, Florian; Griffin, Ricarda; Froehlich, Martina; Heining, Christoph; Braun, Sandra; Spohr, Corinna; Iconomou, Mary; Hollek, Viola; Roering, Michael; Horak, Peter; Kreutzfeldt, Simon; Warsow, Gregor; Hutter, Barbara; Uhrig, Sebastian; Neumann, Olaf; Reuss, David; Heiland, Dieter Henrik; von Kalle, Christof; Weichert, Wilko; Stenzinger, Albrecht; Brors, Benedikt; Glimm, Hanno; Froehling, Stefan; Brummer, Tilman			Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domains	ONCOGENE			English	Article							RAF INHIBITOR RESISTANCE; B-RAF; TWEETY FAMILY; MAPK PATHWAY; TARGETED THERAPY; GENE FUSIONS; IN-VIVO; KINASE; CANCER; DIMERIZATION	Fusion proteins involving the BRAF serine/threonine kinase occur in many cancers. The oncogenic potential of BRAF fusions has been attributed to the loss of critical N-terminal domains that mediate BRAF autoinhibition. We used whole-exome and RNA sequencing in a patient with glioblastoma multiforme to identify a rearrangement between TTYH3, encoding a membrane-resident, calcium-activated chloride channel, and BRAF intron 1, resulting in a TTYH3-BRAF fusion protein that retained all features essential for BRAF autoinhibition. Accordingly, the BRAF moiety of the fusion protein alone, which represents full-length BRAF without the amino acids encoded by exon 1 (BRAF(Delta E1)), did not induce MEK/ERK phosphorylation or transformation. Likewise, neither the TTYH3 moiety of the fusion protein nor full-length TTYH3 provoked ERK pathway activity or transformation. In contrast, TTYH3-BRAF displayed increased MEK phosphorylation potential and transforming activity, which were caused by TTYH3-mediated tethering of near-full-length BRAF to the (endo)membrane system. Consistent with this mechanism, a synthetic approach, in which BRAF(Delta E1) was tethered to the membrane by fusing it to the cytoplasmic tail of CD8 also induced transformation. Furthermore, we demonstrate that TTYH3-BRAF signals largely independent of a functional RAS binding domain, but requires an intact BRAF dimer interface and activation loop phosphorylation sites. Cells expressing TTYH3-BRAF exhibited increased MEK/ERK signaling, which was blocked by clinically achievable concentrations of sorafenib, trametinib, and the paradox breaker PLX8394. These data provide the first example of a fully autoinhibited BRAF protein whose oncogenic potential is dictated by a distinct fusion partner and not by a structural change in BRAF itself.	[Weinberg, Florian; Griffin, Ricarda; Braun, Sandra; Spohr, Corinna; Iconomou, Mary; Hollek, Viola; Roering, Michael; Brummer, Tilman] Univ Freiburg, Fac Med, Inst Mol Med & Cell Res, Freiburg, Germany; [Weinberg, Florian; Braun, Sandra] Univ Freiburg, Ctr Biol Signalling Studies BIOSS, Freiburg, Germany; [Froehlich, Martina; Hutter, Barbara; Uhrig, Sebastian; Brors, Benedikt] German Canc Res Ctr, Div Appl Bioinformat, Heidelberg, Germany; [Froehlich, Martina; Hutter, Barbara; Uhrig, Sebastian; Brors, Benedikt] Natl Ctr Tumor Dis NCT, Heidelberg, Germany; [Heining, Christoph; Glimm, Hanno] NCT Dresden, Dept Translat Med Oncol, Heidelberg, Germany; [Heining, Christoph; Horak, Peter; Kreutzfeldt, Simon; von Kalle, Christof; Glimm, Hanno; Froehling, Stefan; Brummer, Tilman] DKFZ, Heidelberg, Germany; [Heining, Christoph; Glimm, Hanno] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dresden, Germany; [Heining, Christoph; Glimm, Hanno] German Canc Consortium DKTK, Dresden, Germany; [Spohr, Corinna] Univ Freiburg, Fac Biol, Freiburg, Germany; [Spohr, Corinna] Univ Freiburg, Spemann Grad Sch Biol & Med SGBM, Freiburg, Germany; [Horak, Peter; Kreutzfeldt, Simon; Froehling, Stefan] NCT Heidelberg, Dept Translat Med Oncol, Heidelberg, Germany; [Horak, Peter; Kreutzfeldt, Simon; Neumann, Olaf; Reuss, David; Stenzinger, Albrecht; Brors, Benedikt; Froehling, Stefan] DKTK, Heidelberg, Germany; [Warsow, Gregor] DKFZ, Omics IT & Data Management Core Facil, Heidelberg, Germany; [Warsow, Gregor] DKFZ, Div Theoret Bioinformat, Heidelberg, Germany; [Uhrig, Sebastian] Heidelberg Univ, Fac Biosci, Heidelberg, Germany; [Neumann, Olaf; Stenzinger, Albrecht] Heidelberg Univ Hosp, Inst Pathol, Heidelberg, Germany; [Reuss, David] Heidelberg Univ Hosp, Inst Pathol, Dept Neuropathol, Heidelberg, Germany; [Reuss, David] German Canc Res Ctr, German Consortium Translat Canc Res DKTK, Clin Cooperat Unit Neuropathol, Heidelberg, Germany; [Heiland, Dieter Henrik] Univ Freiburg, Fac Med, Med Ctr, Dept Neurosurg, Freiburg, Germany; [Heiland, Dieter Henrik] Univ Freiburg, Fac Med, Med Ctr, Translat NeuroOncol Res Grp, Freiburg, Germany; [von Kalle, Christof] NCT Heidelberg, Dept Translat Oncol, Heidelberg, Germany; [Weichert, Wilko] Tech Univ Munich, Inst Pathol, Munich, Germany; [Weichert, Wilko] DKTK, Munich, Germany; [Brummer, Tilman] Univ Freiburg, Comprehens Canc Ctr Freiburg, Freiburg, Germany; [Brummer, Tilman] DKTK Partner Site Freiburg, Heidelberg, Germany	University of Freiburg; University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Technische Universitat Dresden; Carl Gustav Carus University Hospital; Helmholtz Association; German Cancer Research Center (DKFZ); University of Freiburg; University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); University of Freiburg; University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Technical University of Munich; University of Freiburg	Brummer, T (corresponding author), Univ Freiburg, Fac Med, Inst Mol Med & Cell Res, Freiburg, Germany.; Frohling, S (corresponding author), NCT Heidelberg, Dept Translat Med Oncol, Heidelberg, Germany.; Frohling, S (corresponding author), DKTK, Heidelberg, Germany.; Brummer, T (corresponding author), Univ Freiburg, Comprehens Canc Ctr Freiburg, Freiburg, Germany.; Brummer, T (corresponding author), DKTK Partner Site Freiburg, Heidelberg, Germany.	stefan.froehling@nct-heidelberg.de; tilman.brummer@mol-med.uni-freiburg.de	Brummer, Tilman/AAA-9428-2020; Heiland, Dieter Henrik/ABE-8856-2020; Neumann, Olaf/GSO-3538-2022; Brummer, Tilman/B-6218-2016; Horak, Peter/ABC-1587-2021; Brors, Benedikt/E-5620-2013	Brummer, Tilman/0000-0003-4387-7905; Heiland, Dieter Henrik/0000-0002-9258-3033; Neumann, Olaf/0000-0003-2684-9187; Brummer, Tilman/0000-0003-4387-7905; Horak, Peter/0000-0003-4536-9306; Brors, Benedikt/0000-0001-5940-3101; Griffin, Ricarda/0000-0003-1368-2832; von Kalle, Christof/0000-0001-9221-3297; Hollek, Viola/0000-0001-9768-5568	German Research Foundation (DFG) [BR3662/4-1, SFB 850 B04, EXC 294 BIOSS]; DKFZ-Heidelberg Center for Personalized Oncology [021]; DFG	German Research Foundation (DFG)(German Research Foundation (DFG)); DKFZ-Heidelberg Center for Personalized Oncology; DFG(German Research Foundation (DFG))	This work was supported by the German Research Foundation (DFG) by BR3662/4-1, SFB 850 B04, and EXC 294 BIOSS to TB, and by grant 021 from the DKFZ-Heidelberg Center for Personalized Oncology to HG and SF, TB is the recipient of a Heisenberg Professorship from the DFG. CS is supported in part by the DFG-funded Spemann Graduate School of Biology and Medicine (SGBM, GSC 4). We thank the DKFZ-HIPO Sample Processing Laboratory, the DKFZ Genomics and Proteomics Core Facility, the Omics IT and Data Management Core Facility for technical support. We also thank D. Richter, K. Beck, K. Willmund, R. Eils, and P. Lichter for infrastructure and program development within DKFZ-HIPO.	Aoki Y, 2008, HUM MUTAT, V29, P992, DOI 10.1002/humu.20748; Behling F, 2019, CANCERS, V11, DOI 10.3390/cancers11060794; Bender S, 2016, NAT MED, V22, P1314, DOI 10.1038/nm.4204; Berghoff AS, 2014, CURR OPIN NEUROL, V27, P689, DOI 10.1097/WCO.0000000000000146; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Caunt CJ, 2015, NAT REV CANCER, V15, P577, DOI 10.1038/nrc4000; Chen SH, 2016, CANCER DISCOV, V6, P300, DOI 10.1158/2159-8290.CD-15-0896; Chmielecki J, 2014, CANCER DISCOV, V4, P1398, DOI 10.1158/2159-8290.CD-14-0617; Cin H, 2011, ACTA NEUROPATHOL, V121, P763, DOI 10.1007/s00401-011-0817-z; Dankner M, 2018, ONCOGENE, V37, P3183, DOI 10.1038/s41388-018-0171-x; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Diedrich B, 2017, EMBO J, V36, P646, DOI 10.15252/embj.201694732; Eisenhardt AE, 2016, ONCOTARGET, V7, P26628, DOI 10.18632/oncotarget.8427; Eisenhardt AE, 2011, INT J CANCER, V129, P2297, DOI 10.1002/ijc.25893; Fan QW, 2013, CANCER CELL, V24, P438, DOI 10.1016/j.ccr.2013.09.004; Fangusaro J, 2019, LANCET ONCOL, V20, P1011, DOI 10.1016/S1470-2045(19)30277-3; Fehrenbacher N, 2009, MOL ONCOL, V3, P297, DOI 10.1016/j.molonc.2009.06.004; Frattini V, 2013, NAT GENET, V45, P1141, DOI 10.1038/ng.2734; Freeman AK, 2013, MOL CELL, V49, P751, DOI 10.1016/j.molcel.2012.12.018; Galabova-Kovacs G, 2008, J CELL BIOL, V180, P947, DOI 10.1083/jcb.200709069; Girotti MR, 2015, CANCER CELL, V27, P85, DOI 10.1016/j.ccell.2014.11.006; Han YE, 2019, EXP NEUROBIOL, V28, P183, DOI 10.5607/en.2019.28.2.183; He YW, 2008, J BIOL CHEM, V283, P24000, DOI 10.1074/jbc.M803361200; He YW, 2008, BIOCHEM J, V412, P45, DOI 10.1042/BJ20071722; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; HENNECKE S, 1993, J BIOL CHEM, V268, P26607; Herr R, 2018, ONCOGENE, V37, P1576, DOI 10.1038/s41388-017-0063-5; Horak P, 2017, INT J CANCER, V141, P877, DOI 10.1002/ijc.30828; Hu JC, 2013, CELL, V154, P1036, DOI 10.1016/j.cell.2013.07.046; Hutchinson KE, 2013, CLIN CANCER RES, V19, P6696, DOI 10.1158/1078-0432.CCR-13-1746; Iodice L, 2001, J BIOL CHEM, V276, P28920, DOI 10.1074/jbc.M103558200; Isaacson AL, 2019, CSH MOL CASE STUD, V5, DOI 10.1101/mcs.a003848; Jain P, 2017, ONCOGENE, V36, P6348, DOI 10.1038/onc.2017.276; Jang JS, 2015, SCI REP-UK, V5, DOI 10.1038/srep09755; Jones DTW, 2009, ONCOGENE, V28, P2119, DOI 10.1038/onc.2009.73; Jones DTW, 2008, CANCER RES, V68, P8673, DOI 10.1158/0008-5472.CAN-08-2097; Jung E, 2017, J NEUROSCI, V37, P6837, DOI 10.1523/JNEUROSCI.3532-16.2017; Karajannis MA, 2014, NEURO-ONCOLOGY, V16, P1408, DOI 10.1093/neuonc/nou059; Karoulia Z, 2017, NAT REV CANCER, V17, P676, DOI 10.1038/nrc.2017.79; Kim HS, 2017, ONCOGENE, V36, P3334, DOI 10.1038/onc.2016.486; Kohler M, 2016, EMBO J, V35, P143, DOI 10.15252/embj.201592097; Kordes M, 2016, LEUKEMIA, V30, P937, DOI 10.1038/leu.2015.319; Lavoie H, 2015, NAT REV MOL CELL BIO, V16, P281, DOI 10.1038/nrm3979; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LITTMAN DR, 1985, CELL, V40, P237, DOI 10.1016/0092-8674(85)90138-2; Lu HY, 2017, CANCER RES, V77, P3502, DOI 10.1158/0008-5472.CAN-16-2745; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Masilamani AP, 2017, ONCOGENE, V36, P3562, DOI 10.1038/onc.2016.507; McEvoy CR, 2019, J CLIN INVEST, V129, P1940, DOI 10.1172/JCI123089; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Ng PKS, 2018, CANCER CELL, V33, P450, DOI 10.1016/j.ccell.2018.01.021; Nicolaides TP, 2011, CLIN CANCER RES, V17, P7595, DOI 10.1158/1078-0432.CCR-11-1456; Palanisamy N, 2010, NAT MED, V16, P793, DOI 10.1038/nm.2166; Papin C, 1998, J BIOL CHEM, V273, P24939, DOI 10.1074/jbc.273.38.24939; Phuchareon J, 2015, P NATL ACAD SCI USA, V112, pE3855, DOI 10.1073/pnas.1510733112; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Pratilas CA, 2009, P NATL ACAD SCI USA, V106, P4519, DOI 10.1073/pnas.0900780106; Ramis G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038770; Ricklefs FL, 2019, J EXTRACELL VESICLES, V8, DOI 10.1080/20013078.2019.1588555; Ritt DA, 2010, MOL CELL BIOL, V30, P806, DOI 10.1128/MCB.00569-09; Robinson JP, 2010, ONCOGENE, V29, P335, DOI 10.1038/onc.2009.333; Roring M, 2012, EMBO J, V31, P2629, DOI 10.1038/emboj.2012.100; Ross JS, 2016, INT J CANCER, V138, P881, DOI 10.1002/ijc.29825; Rushworth LK, 2006, MOL CELL BIOL, V26, P2262, DOI 10.1128/MCB.26.6.2262-2272.2006; Selt F, 2017, ONCOTARGET, V8, P11460, DOI 10.18632/oncotarget.14004; Selt F, 2016, BRAIN PATHOL, V26, P506, DOI 10.1111/bpa.12326; Sievert AJ, 2013, P NATL ACAD SCI USA, V110, P5957, DOI 10.1073/pnas.1219232110; Stefaniuk M, 2010, J NEUROCHEM, V115, P1183, DOI 10.1111/j.1471-4159.2010.07023.x; Strumberg D, 2005, J CLIN ONCOL, V23, P965, DOI 10.1200/JCO.2005.06.124; Sun MH, 2010, P NATL ACAD SCI USA, V107, P15547, DOI 10.1073/pnas.1009652107; Suzuki M, 2004, J BIOL CHEM, V279, P22461, DOI 10.1074/jbc.M313813200; Terai K, 2006, EMBO J, V25, P3556, DOI 10.1038/sj.emboj.7601241; Terrell Elizabeth M., 2018, COLD SPRING HARB PER, V9, pa033746; Tien AC, 2012, DEVELOPMENT, V139, P2477, DOI 10.1242/dev.077214; Turski ML, 2016, MOL CANCER THER, V15, P533, DOI 10.1158/1535-7163.MCT-15-0643; Yao Z, 2019, NAT MED, V25, P284, DOI 10.1038/s41591-018-0274-5; Yao Z, 2015, CANCER CELL, V28, P370, DOI 10.1016/j.ccell.2015.08.001; Yu J, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3248-y; Yuan JM, 2018, ONCOGENE, V37, P5719, DOI 10.1038/s41388-018-0365-2; Zhang C, 2015, NATURE, V526, P583, DOI 10.1038/nature14982	80	13	13	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	4					814	832		10.1038/s41388-019-1021-1	http://dx.doi.org/10.1038/s41388-019-1021-1			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KF4EJ	31558800				2022-12-28	WOS:000509197200006
J	Karra, L; Romero-Moya, D; Ksionda, O; Krush, M; Gu, ZH; Mues, M; Depeille, P; Mullighan, C; Roose, JP				Karra, Laila; Romero-Moya, Damia; Ksionda, Olga; Krush, Milana; Gu, Zhaohui; Mues, Marsilius; Depeille, Philippe; Mullighan, Charles; Roose, Jeroen P.			Increased baseline RASGRP1 signals enhance stem cell fitness during native hematopoiesis	ONCOGENE			English	Article							DEVELOPMENTAL DISORDERS; CONDITIONAL EXPRESSION; NOTCH1 MUTATIONS; RAS ACTIVATION; ONCOGENIC NRAS; SELF-RENEWAL; LEUKEMIA; DISTINCT; CANCER; MTOR	Oncogenic mutations inRASgenes, likeKRAS(G12D)orNRAS(G12D), trap Ras in the active state and cause myeloproliferative disorder and T cell leukemia (T-ALL) when induced in the bone marrow viaMx1CRE. The RAS exchange factor RASGRP1 is frequently overexpressed in T-ALL patients. In T-ALL cell lines overexpression of RASGRP1 increases flux through the RASGTP/RasGDP cycle. Here we expandedRASGRP1expression surveys in pediatric T-ALL and generated aRoLoRiGmouse model crossed toMx1CREto determine the consequences of induced RASGRP1 overexpression in primary hematopoietic cells. RASGRP1-overexpressing, GFP-positive cells outcompeted wild type cells and dominated the peripheral blood compartment over time. RASGRP1 overexpression bestows gain-of-function colony formation properties to bone marrow progenitors in medium containing limited growth factors. RASGRP1 overexpression enhances baseline mTOR-S6 signaling in the bone marrow, but not in vitro cytokine-induced signals. In agreement with these mechanistic findings, hRASGRP1-ires-EGFP enhances fitness of stem- and progenitor- cells, but only in the context of native hematopoiesis. RASGRP1 overexpression is distinct fromKRAS(G12D)orNRAS(G12D), does not cause acute leukemia on its own, and leukemia virus insertion frequencies predict that RASGRP1 overexpression can effectively cooperate with lesions in many other genes to cause acute T-ALL.	[Karra, Laila; Romero-Moya, Damia; Ksionda, Olga; Krush, Milana; Mues, Marsilius; Depeille, Philippe; Roose, Jeroen P.] Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; [Gu, Zhaohui; Mullighan, Charles] St Jude Childrens Res Hosp, Dept Pathol, 332 N Lauderdale St, Memphis, TN 38105 USA; [Gu, Zhaohui; Mullighan, Charles] St Jude Childrens Res Hosp, Hematol Malignancies Program, 332 N Lauderdale St, Memphis, TN 38105 USA; [Ksionda, Olga] Univ Auckland, Liggins Inst, Auckland, New Zealand; [Mues, Marsilius] Miltenyi Biotec GmbH, Friedrich Ebert Str 68, D-51429 Bergisch Gladbach, Germany	University of California System; University of California San Francisco; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Auckland; Miltenyi Biotec	Roose, JP (corresponding author), Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA.	jeroen.roose@ucsf.edu	Mullighan, Charles/H-3253-2011	Mullighan, Charles/0000-0002-1871-1850; Krush, Milana/0000-0003-4833-8564; Karra, Laila/0000-0001-5503-2809; Roose, Jeroen/0000-0003-4746-2811; Romero-Moya, Damia/0000-0001-9947-3577	Alex' Lemonade Stand Foundation Innovator Award; NIH/NCI [R01 - CA187318]; NIH/NHLBI [R01 - HL120724]; Leukemia & Lymphoma Society; Rothschild Fellowship for postdoctoral fellows in the Natural, Exact or Life Sciences and Engineering; Mark Foundation for Cancer Research; NCI [CA021765]; NCI R35 Outstanding Investigator Award [R35 CA197695]; St. Baldrick's Foundation Robert J. Arceci Innovation award; DRC Center Grant [NIH P30 DK063720]	Alex' Lemonade Stand Foundation Innovator Award; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Leukemia & Lymphoma Society(Leukemia and Lymphoma Society); Rothschild Fellowship for postdoctoral fellows in the Natural, Exact or Life Sciences and Engineering; Mark Foundation for Cancer Research; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI R35 Outstanding Investigator Award; St. Baldrick's Foundation Robert J. Arceci Innovation award; DRC Center Grant	This work was supported by an Alex' Lemonade Stand Foundation Innovator Award, the NIH/NCI (R01 - CA187318), and the NIH/NHLBI (R01 - HL120724) (all to JPR). Further support came from a Leukemia & Lymphoma Society grant (to MM) and the Rothschild Fellowship for postdoctoral fellows in the Natural, Exact or Life Sciences and Engineering (to LK), and PD is a Mark Foundation Momentum Fellow supported by a fellowship from the Mark Foundation for Cancer Research; and by NCI grants CA021765 (St Jude Comprehensive Cancer Center Support Grant), an NCI R35 Outstanding Investigator Award (R35 CA197695) and a St. Baldrick's Foundation Robert J. Arceci Innovation award. We thank the members of the Roose lab and the Heme-Onc community at UCSF for useful suggestions and comments. We thank UCSF flow cytometry facility and DRC Center Grant NIH P30 DK063720. We thank Emmanuelle Passague and her lab for kindly providing us Mx1-CRE mice.	Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Beck-Engeser GB, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-4; Bowen DT, 2005, BLOOD, V106, P2113, DOI 10.1182/blood-2005-03-0867; Braun BS, 2004, P NATL ACAD SCI USA, V101, P597, DOI 10.1073/pnas.0307203101; Chan IT, 2004, J CLIN INVEST, V113, P528, DOI 10.1172/JCI200420476; Downward J, 2006, NATURE, V439, P274, DOI 10.1038/439274a; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Hartzell C, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003848; Herault A, 2017, NATURE, V544, P53, DOI 10.1038/nature21693; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jun JE, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00239; Kalaitzidis D, 2012, CELL STEM CELL, V11, P429, DOI 10.1016/j.stem.2012.06.009; Kentsis A, 2012, CELL STEM CELL, V11, P281, DOI 10.1016/j.stem.2012.08.007; Kindler T, 2008, BLOOD, V112, P3373, DOI 10.1182/blood-2008-03-147587; Klinger MB, 2005, ONCOGENE, V24, P2695, DOI 10.1038/sj.onc.1208334; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kortum RL, 2012, MOL CELL BIOL, V32, P2748, DOI 10.1128/MCB.00317-12; Ksionda O, 2016, ONCOGENE, V35, P3658, DOI 10.1038/onc.2015.431; Ksionda O, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193849; Ksionda Olga, 2013, Front Biol (Beijing), V8, P508; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Li Q, 2013, NATURE, V504, P143, DOI 10.1038/nature12830; Li Q, 2011, BLOOD, V117, P2022, DOI 10.1182/blood-2010-04-280750; Liu Y, 2017, NAT GENET, V49, P1211, DOI 10.1038/ng.3909; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Magee JA, 2012, CELL STEM CELL, V11, P415, DOI 10.1016/j.stem.2012.05.026; Montes R, 2014, LEUKEMIA, V28, P666, DOI 10.1038/leu.2013.346; Morrison SJ, 2014, NATURE, V505, P327, DOI 10.1038/nature12984; Mues Marsilius, 2017, Small GTPases, V8, P20, DOI 10.1080/21541248.2016.1187323; Myers DR, 2019, IMMUNOL REV, V291, P134, DOI 10.1111/imr.12796; Myers DR, 2019, CELL REP, V27, P1858, DOI 10.1016/j.celrep.2019.04.037; Norment AM, 2003, J IMMUNOL, V170, P1141, DOI 10.4049/jimmunol.170.3.1141; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Oki T, 2012, LEUKEMIA, V26, P1038, DOI 10.1038/leu.2011.328; Oki-Idouchi CE, 2007, CANCER RES, V67, P276, DOI 10.1158/0008-5472.CAN-06-3080; Pietras EM, 2015, CELL STEM CELL, V17, P35, DOI 10.1016/j.stem.2015.05.003; Priatel JJ, 2002, IMMUNITY, V17, P617, DOI 10.1016/S1074-7613(02)00451-X; Romero-Moya D, 2013, HAEMATOLOGICA, V98, P1022, DOI 10.3324/haematol.2012.079244; Roose JP, 2003, PLOS BIOL, V1, P271, DOI 10.1371/journal.pbio.0000053; Sabnis AJ, 2009, PLOS BIOL, V7, P537, DOI 10.1371/journal.pbio.1000059; Sanjuan-Pla A, 2016, STEM CELLS DEV, V25, P259, DOI 10.1089/scd.2015.0309; Sanjuan-Pla A, 2015, BLOOD, V126, P2676, DOI 10.1182/blood-2015-09-667378; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; Schubbert S, 2007, CURR OPIN GENET DEV, V17, P15, DOI 10.1016/j.gde.2006.12.004; Seita J, 2010, WIRES SYST BIOL MED, V2, P640, DOI 10.1002/wsbm.86; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Stine RR, 2013, TRENDS CELL BIOL, V23, P357, DOI 10.1016/j.tcb.2013.03.001; Sun CC, 2017, ONCOTARGET, V8, P35445, DOI 10.18632/oncotarget.16367; Sun JL, 2014, NATURE, V514, P322, DOI 10.1038/nature13824; Terwilliger T, 2017, BLOOD CANCER J, V7, DOI 10.1038/bcj.2017.53; Vigil D, 2010, NAT REV CANCER, V10, P842, DOI 10.1038/nrc2960; von Lintig FC, 2000, CLIN CANCER RES, V6, P1804; Wang JY, 2013, BLOOD, V121, P5203, DOI 10.1182/blood-2012-12-475863; Wang JY, 2010, BLOOD, V116, P5991, DOI 10.1182/blood-2010-04-281527; Wilson A, 2006, NAT REV IMMUNOL, V6, P93, DOI 10.1038/nri1779; Winter SS, 2018, J CLIN ONCOL, V36, P2926, DOI 10.1200/JCO.2018.77.7250; Xu ZF, 2009, LEUKEMIA RES, V33, P891, DOI 10.1016/j.leukres.2009.01.041; Zhang CC, 2008, CURR OPIN HEMATOL, V15, P307, DOI 10.1097/MOH.0b013e3283007db5; Zhang YF, 2018, TRENDS CELL BIOL, V28, P976, DOI 10.1016/j.tcb.2018.06.001	59	0	0	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 5	2020	39	45					6920	6934		10.1038/s41388-020-01469-8	http://dx.doi.org/10.1038/s41388-020-01469-8		SEP 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ON7IM	32989257	Green Submitted, Green Accepted			2022-12-28	WOS:000573446900003
J	Qian, KY; Wang, G; Ju, LG; Liu, JY; Luo, YW; Wang, YP; Peng, TC; Chen, FJ; Zhang, Y; Xiao, Y; Wang, XH				Qian, Kaiyu; Wang, Gang; Ju, Lingao; Liu, Jiyan; Luo, Yongwen; Wang, Yejinpeng; Peng, Tianchen; Chen, Fangjin; Zhang, Yi; Xiao, Yu; Wang, Xinghuan			A novel germline EGFR variant p.R831H causes predisposition to familial CDK12-mutant prostate cancer with tandem duplicator phenotype	ONCOGENE			English	Article							MUTATION	5-10% of total prostate cancer (PCa) cases are hereditary. Particularly, immune checkpoint inhibitor-sensitive tandem duplicator phenotype (TDP) accounts for 6.9% of PCa cases, whereas genetic susceptibility genes remain completely unknown. We identified a Chinese family with two PCa patients, in which the PCa phenotype co-segregated with a rare germline variant EGFR(R831H). Patient-derived conditionally reprogrammed cells (CRC) exhibited increased EGFR and AKT phosphorylation, and a sensitivity to EGFR antagonist Afatinib in migration assays, suggesting the EGFR allele was constitutively active. Both EGFR(R831H)-mutant tumours contained biallelic CDK12 inactivation, together with prominent tandem duplication across the genome. These somatic mutations could be detected in urine before surgery. Analysis of public databases showed a significant correlation between the mutation status of EGFR and CDK12. Taken together, our genetic and functional analyses identified a previously undescribed link between EGFR and PCa.	[Qian, Kaiyu; Luo, Yongwen; Wang, Yejinpeng; Peng, Tianchen; Xiao, Yu; Wang, Xinghuan] Wuhan Univ, Dept Urol, Zhongnan Hosp, Wuhan, Peoples R China; [Qian, Kaiyu; Wang, Gang; Ju, Lingao; Xiao, Yu] Wuhan Univ, Zhongnan Hosp, Dept Biol Repositories, Wuhan, Peoples R China; [Qian, Kaiyu; Wang, Gang; Ju, Lingao; Xiao, Yu] Human Genet Resources Preservat Ctr Hubei Prov, Wuhan, Peoples R China; [Wang, Gang; Ju, Lingao; Xiao, Yu] Wuhan Univ, Zhongnan Hosp, Lab Precis Med, Wuhan, Peoples R China; [Liu, Jiyan] Sichuan Univ, West China Hosp, Canc Ctr, Dept Biotherapy, Chengdu, Peoples R China; [Chen, Fangjin; Zhang, Yi] Peking Univ, Ctr Life Sci, Beijing, Peoples R China; [Zhang, Yi] Euler Technol, Beijing, Peoples R China; [Wang, Xinghuan] Wuhan Univ, Med Res Inst, Wuhan, Peoples R China	Wuhan University; Wuhan University; Wuhan University; Sichuan University; Peking University; Wuhan University	Wang, XH (corresponding author), Wuhan Univ, Dept Urol, Zhongnan Hosp, Wuhan, Peoples R China.; Zhang, Y (corresponding author), Peking Univ, Ctr Life Sci, Beijing, Peoples R China.; Zhang, Y (corresponding author), Euler Technol, Beijing, Peoples R China.; Wang, XH (corresponding author), Wuhan Univ, Med Res Inst, Wuhan, Peoples R China.	zy@eulertechnology.com; wangxinghuan@whu.edu.cn	Wang, Xinghuan/AAB-3192-2021; Ju, Lingao/ADP-8482-2022; Xiao, Yu/AGA-4786-2022	Wang, Xinghuan/0000-0003-3497-0024; Ju, Lingao/0000-0003-0813-3628; Xiao, Yu/0000-0003-1377-9685; Qian, Kaiyu/0000-0003-4153-1265; Zhang, Yi/0000-0001-5388-1276	Health commission of Hubei Province scientific research project [WJ2019H080]; Chinese Central Special Fund for Local Science and Technology Development of Hubei Province [2018ZYYD023]; Science and Technology Department of Hubei Province Key Project [2018ACA159]; Wuhan Science and Technology Bureau Key Project [2018061005132294]	Health commission of Hubei Province scientific research project; Chinese Central Special Fund for Local Science and Technology Development of Hubei Province; Science and Technology Department of Hubei Province Key Project; Wuhan Science and Technology Bureau Key Project	This study was supported in part by grants from the Health commission of Hubei Province scientific research project (WJ2019H080), Chinese Central Special Fund for Local Science and Technology Development of Hubei Province (2018ZYYD023), Science and Technology Department of Hubei Province Key Project (2018ACA159), and Wuhan Science and Technology Bureau Key Project (2018061005132294). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Armenia J, 2018, NAT GENET, V50, P645, DOI 10.1038/s41588-018-0078-z; Attard G, 2016, LANCET, V387, P70, DOI 10.1016/S0140-6736(14)61947-4; Frank C, 2017, EUR UROL, V71, P162, DOI 10.1016/j.eururo.2016.07.031; Giri VN, 2019, PROSTATE, V79, P333, DOI 10.1002/pros.23739; Giri VN, 2016, SEMIN ONCOL, V43, P560, DOI 10.1053/j.seminoncol.2016.08.001; Liu W, 2020, CLIN TRANSL MED, V10, DOI 10.1002/ctm2.95; Liu XF, 2017, NAT PROTOC, V12, P439, DOI 10.1038/nprot.2016.174; Lu S, 2019, J THORAC ONCOL, V14, P732, DOI 10.1016/j.jtho.2018.12.006; Luo YW, 2020, CLIN TRANSL MED, V10, P294, DOI 10.1002/ctm2.36; Lynch HT, 2016, INT J CANCER, V138, P2579, DOI 10.1002/ijc.29949; Matsushima S, 2014, J THORAC ONCOL, V9, P1377, DOI 10.1097/JTO.0000000000000241; Menghi F, 2018, CANCER CELL, V34, P197, DOI 10.1016/j.ccell.2018.06.008; Pilie PG, 2017, CANCER-AM CANCER SOC, V123, P3925, DOI 10.1002/cncr.30817; Tonon L, 2019, EUR UROL, V75, P11, DOI 10.1016/j.eururo.2018.08.026; Wagner A, 2018, JCO PRECIS ONCOL, V2, P1; Wu YM, 2018, CELL, V173, P1770, DOI 10.1016/j.cell.2018.04.034; Yu HA, 2014, J THORAC ONCOL, V9, P554, DOI 10.1097/JTO.0000000000000052; Yuan YQ, 2020, J CANCER, V11, P3762, DOI 10.7150/jca.42314	18	2	2	3	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2020	39	44					6871	6878		10.1038/s41388-020-01476-9	http://dx.doi.org/10.1038/s41388-020-01476-9		SEP 2020	8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OH9QS	32978518	Green Submitted			2022-12-28	WOS:000572714000005
J	Martin-Padron, J; Boyero, L; Rodriguez, MI; Andrades, A; Diaz-Cano, I; Peinado, P; Balinas-Gavira, C; Alvarez-Perez, JC; Coira, IF; Farez-Vidal, ME; Medina, PP				Martin-Padron, Joel; Boyero, Laura; Isabel Rodriguez, Maria; Andrades, Alvaro; Diaz-Cano, Ines; Peinado, Paola; Balinas-Gavira, Carlos; Carlos Alvarez-Perez, Juan; Coira, Isabel F.; Esther Farez-Vidal, Maria; Medina, Pedro P.			Plakophilin 1 enhances MYC translation, promoting squamous cell lung cancer	ONCOGENE			English	Article							PROTEINS; CARCINOMA; MUTATIONS; IDENTIFY; ADHESION; EGFR	Plakophilin 1 (PKP1) is a member of the arm-repeat (armadillo) and plakophilin gene families and it is an essential component of the desmosomes. Although desmosomes have generally been associated with tumor suppressor functions, we have consistently observed that PKP1 is among the top overexpressed proteins in squamous cell lung cancer. To explore this paradox, we developed in vivo and in vitro functional models of PKP1 gain/loss in squamous cell lung cancer. CRISPR-Cas9 PKP1 knockout severely impaired cell proliferation, but it increased cell dissemination. In addition, PKP1 overexpression increased cell proliferation, cell survival, and in vivo xenograft engraftment. We further investigated the molecular mechanism of the mainly oncogenic function of PKP1 by combining transcriptomics, proteomics, and protein-nucleic acid interaction assays. Interestingly, we found that PKP1 enhancesMYCtranslation in collaboration with the translation initiation complex by binding to the 5 '-UTR ofMYCmRNA. We propose PKP1 as an oncogene in SqCLC and a novel posttranscriptional regulator of MYC. PKP1 may be a valuable diagnostic biomarker and potential therapeutic target for SqCLC. Importantly, PKP1 inhibition may indirectly target MYC, a primary anticancer target.	[Martin-Padron, Joel; Boyero, Laura; Isabel Rodriguez, Maria; Andrades, Alvaro; Diaz-Cano, Ines; Peinado, Paola; Balinas-Gavira, Carlos; Carlos Alvarez-Perez, Juan; Coira, Isabel F.; Medina, Pedro P.] Ctr Genom & Oncol Res GENYO, Granada, Spain; [Martin-Padron, Joel; Boyero, Laura; Diaz-Cano, Ines; Esther Farez-Vidal, Maria] Univ Granada, Dept Biochem & Mol Biol 3, Granada, Spain; [Martin-Padron, Joel; Diaz-Cano, Ines; Esther Farez-Vidal, Maria; Medina, Pedro P.] Univ Granada, Inst Biomed Res Ibs Granada, Univ Hosp Complex Granada, Granada, Spain; [Isabel Rodriguez, Maria; Andrades, Alvaro; Peinado, Paola; Balinas-Gavira, Carlos; Carlos Alvarez-Perez, Juan; Coira, Isabel F.; Medina, Pedro P.] Univ Granada, Dept Biochem & Mol Biol 1, Granada, Spain	University of Granada; Instituto de Investigacion Biosanitaria IBS Granada; University of Granada; University of Granada	Medina, PP (corresponding author), Ctr Genom & Oncol Res GENYO, Granada, Spain.; Farez-Vidal, ME (corresponding author), Univ Granada, Dept Biochem & Mol Biol 3, Granada, Spain.; Farez-Vidal, ME; Medina, PP (corresponding author), Univ Granada, Inst Biomed Res Ibs Granada, Univ Hosp Complex Granada, Granada, Spain.; Medina, PP (corresponding author), Univ Granada, Dept Biochem & Mol Biol 1, Granada, Spain.	efarez@ugr.es; pedromedina@ugr.es	Boyero Corral, Laura/AAA-5316-2020; Lara, María Isabel Rodríguez/A-1961-2017; Perez, Juan c Alvarez/J-8294-2016; Baliñas Gavira, Carlos/AAQ-2507-2021; Andrades, Álvaro/A-6890-2017; Perez, Juan Carlos Alvarez/AAE-4518-2021; Vico, Pedro Pablo Medina/D-1688-2013; Coira, Isabel F./N-4002-2014	Boyero Corral, Laura/0000-0002-2603-399X; Lara, María Isabel Rodríguez/0000-0002-2270-0070; Perez, Juan c Alvarez/0000-0001-6396-311X; Baliñas Gavira, Carlos/0000-0002-7535-5426; Andrades, Álvaro/0000-0001-9042-8964; Perez, Juan Carlos Alvarez/0000-0001-6396-311X; Vico, Pedro Pablo Medina/0000-0002-7834-7093; Coira, Isabel F./0000-0003-3368-4691; Peinado Fernandez, Paola/0000-0003-2484-928X				Alatas ET, 2017, INDIAN J DERMATOL VE, V83, P476, DOI 10.4103/ijdvl.IJDVL_411_16; Angulo B, 2008, J PATHOL, V214, P347, DOI 10.1002/path.2267; Bender E, 2014, NATURE, V513, pS2, DOI 10.1038/513S2a; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Budczies J, 2015, ONCOTARGET, V6, P570, DOI 10.18632/oncotarget.2677; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Dusek RL, 2011, NAT REV CANCER, V11, P317, DOI 10.1038/nrc3051; Furukawa C, 2005, CANCER RES, V65, P7102, DOI 10.1158/0008-5472.CAN-04-1877; Gomez-Morales M, 2013, HISTOPATHOLOGY, V63, P103, DOI 10.1111/his.12126; Hatzfeld M, 2000, J CELL BIOL, V149, P209, DOI 10.1083/jcb.149.1.209; Hatzfeld M, 2007, BBA-MOL CELL RES, V1773, P69, DOI 10.1016/j.bbamcr.2006.04.009; Hou J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010312; Kim HR, 2012, CANCER-AM CANCER SOC, V118, P729, DOI 10.1002/cncr.26311; Krunic AL, 1998, BRIT J CANCER, V77, P1275, DOI 10.1038/bjc.1998.213; Kundu ST, 2008, INT J CANCER, V123, P2303, DOI 10.1002/ijc.23797; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653; McGrath JA, 1997, NAT GENET, V17, P240, DOI 10.1038/ng1097-240; Molina JR, 2008, MAYO CLIN PROC, V83, P584, DOI 10.4065/83.5.584; Munoz WA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086784; Perez-Moreno P, 2012, CLIN CANCER RES, V18, P2443, DOI 10.1158/1078-0432.CCR-11-2370; Pirity M, 2006, CURR TOP MICROBIOL, V302, P205; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; RICHARDSON GE, 1993, SEMIN ONCOL, V20, P105; Rietscher K, 2016, J INVEST DERMATOL, V136, P1471, DOI 10.1016/j.jid.2016.03.021; Sanchez-Palencia A, 2011, INT J CANCER, V129, P355, DOI 10.1002/ijc.25704; Schmidt A, 1997, CELL TISSUE RES, V290, P481, DOI 10.1007/s004410050956; Whitfield JR, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00010	30	10	10	5	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2020	39	32					5479	5493		10.1038/s41388-019-1129-3	http://dx.doi.org/10.1038/s41388-019-1129-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW4DS	31822797				2022-12-28	WOS:000556990300006
J	Roh, JI; Lee, J; Sung, YH; Oh, J; Hyeon, D; Kim, Y; Lee, S; Devkota, S; Kim, HJ; Park, B; Nam, T; Song, Y; Kim, Y; Hwang, D; Lee, HW				Roh, Jae-il; Lee, Jaehoon; Sung, Young-Hoon; Oh, Jahyun; Hyeon, Do Young; Kim, Yujin; Lee, Seungeon; Devkota, Sushil; Kim, Hye Jeong; Park, Bomin; Nam, Taewook; Song, Yaechan; Kim, Yonghwan; Hwang, Daehee; Lee, Han-Woong			Impaired AKT signaling and lung tumorigenesis by PIERCE1 ablation in KRAS-mutant non-small cell lung cancer	ONCOGENE			English	Article							ER STRESS; PI3K/AKT/MTOR PATHWAY; INDUCIBLE GENE; ACTIVATION; EXPRESSION; SURVIVAL; PHOSPHORYLATION; PROLIFERATION; METABOLISM; INHIBITORS	KRAS-mutant non-small cell lung cancer (NSCLC) is a major lung cancer subtype that leads to many cancer-related deaths worldwide. Although numerous studies on KRAS-mutant type NSCLC have been conducted, new oncogenic or tumor suppressive genes need to be detected because a large proportion of NSCLC patients does not respond to currently used therapeutics. Here, we show the tumor-promoting function of a cell cycle-related protein, PIERCE1, in KRAS-mutant NSCLC. Mechanistically, PIERCE1 depletion inhibits cell growth and AKT phosphorylation (pAKT) at S473, which is particularly observed in KRAS-mutant lung cancers. Analyses of AKT-related genes using microarray, immunoblotting, and real-time quantitative PCR indicated that PIERCE1 negatively regulates the gene expression of the AKT suppressor, TRIB3, through the CHOP pathway, which is a key regulatory pathway for TRIB3 expression. Similarly, in vivo analyses of PIERCE1 depletion in the KRAS mutation-related lung cancer mouse models revealed the suppressive effect of PIERCE1 knockout in urethane- and KRAS(G12D)-induced lung tumorigenesis with decreased pAKT levels observed in the tumors. Tissue microarrays of human lung cancers indicated the expression of PIERCE1 in 83% of lung cancers and its correlation with pAKT expression. Thus, we illustrate how PIERCE1 depletion may serve as a therapeutic strategy against KRAS-mutant NSCLC and propose the clinical benefit of PIERCE1.	[Roh, Jae-il; Lee, Jaehoon; Oh, Jahyun; Kim, Yujin; Lee, Seungeon; Kim, Hye Jeong; Park, Bomin; Nam, Taewook; Song, Yaechan; Lee, Han-Woong] Yonsei Univ, Dept Biochem, Coll Life Sci & Biotechnol, Seoul, South Korea; [Sung, Young-Hoon] Univ Ulsan, Coll Med, Dept Convergence Med, Seoul, South Korea; [Hyeon, Do Young; Hwang, Daehee] Seoul Natl Univ, Dept Biol Sci, Seoul, South Korea; [Devkota, Sushil] Univ Calif San Diego, Dept Cell & Dev Biol, San Diego, CA 92093 USA; [Kim, Yonghwan] Sookmyung Womens Univ, Dept Life Syst, Seoul, South Korea	Yonsei University; University of Ulsan; Seoul National University (SNU); University of California System; University of California San Diego; Sookmyung Women's University	Lee, HW (corresponding author), Yonsei Univ, Dept Biochem, Coll Life Sci & Biotechnol, Seoul, South Korea.	hwl@yonsei.ac.kr			National Research Foundation of the Republic of Korea [2018R1A2A1A05022746, 2017R1A4A1015328]; Brain Korea 21 (BK21) PLUS program	National Research Foundation of the Republic of Korea(National Research Foundation of Korea); Brain Korea 21 (BK21) PLUS program	This work was supported by the National Research Foundation of the Republic of Korea (grants 2018R1A2A1A05022746 and 2017R1A4A1015328) and in part by Brain Korea 21 (BK21) PLUS program.	Abeyrathna P, 2015, VASC PHARMACOL, V74, P38, DOI 10.1016/j.vph.2015.05.008; Barkauskas CE, 2017, DEVELOPMENT, V144, P986, DOI 10.1242/dev.140103; Bi L, 1999, J BIOL CHEM, V274, P10963, DOI 10.1074/jbc.274.16.10963; Bitting RL, 2013, ENDOCR-RELAT CANCER, V20, pR83, DOI 10.1530/ERC-12-0394; Bittner N, 2014, PATHOL ONCOL RES, V20, P11, DOI 10.1007/s12253-013-9719-9; Carew JS, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.259; Chia S, 2015, CURR ONCOL, V22, P33, DOI 10.3747/co.22.2393; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Daga Aditi, 2015, Asian Pac J Cancer Prev, V16, P4147; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Erazo T, 2016, CLIN CANCER RES, V22, P2508, DOI 10.1158/1078-0432.CCR-15-1808; Eser S, 2014, BRIT J CANCER, V111, P817, DOI 10.1038/bjc.2014.215; Furic L, 2010, P NATL ACAD SCI USA, V107, P14134, DOI 10.1073/pnas.1005320107; Gangloff YG, 2004, MOL CELL BIOL, V24, P9508, DOI 10.1128/MCB.24.21.9508-9516.2004; Ghosh AP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039586; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Hung JY, 2010, LUNG CANCER, V68, P355, DOI 10.1016/j.lungcan.2009.07.017; Iurlaro R, 2016, FEBS J, V283, P2640, DOI 10.1111/febs.13598; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Kim JY, 2016, MOL CANCER RES, V14, P1019, DOI 10.1158/1541-7786.MCR-15-0506; Lanczky A, 2016, BREAST CANCER RES TR, V160, P439, DOI 10.1007/s10549-016-4013-7; Lawlor MA, 2001, J CELL SCI, V114, P2903; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Ohoka N, 2005, EMBO J, V24, P1243, DOI 10.1038/sj.emboj.7600596; Ord D, 2016, BBA-MOL CELL RES, V1863, P2668, DOI 10.1016/j.bbamcr.2016.08.003; Ord T, 2017, CURR PROTEIN PEPT SC, V18, P819, DOI 10.2174/1389203718666170406124547; Ramadori G, 2015, CELL METAB, V21, P117, DOI 10.1016/j.cmet.2014.11.020; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Rock JR, 2011, P NATL ACAD SCI USA, V108, pE1475, DOI 10.1073/pnas.1117988108; Roh JI, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193182; Roman M, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0789-x; Salazar M, 2015, CELL DEATH DIFFER, V22, P131, DOI 10.1038/cdd.2014.133; Salazar M, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723556.2014.980134; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.03.035, 10.1016/j.cell.2017.02.004]; Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; SPERANZA G, 2012, J CLIN ONCOL S, V30; Stathopoulos GT, 2007, P NATL ACAD SCI USA, V104, P18514, DOI 10.1073/pnas.0705316104; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sung YH, 2007, MOL CELLS, V24, P409; Sung YH, 2016, SCI REP-UK, V6, DOI 10.1038/srep27932; Sung YH, 2010, CANCER RES, V70, P10454, DOI 10.1158/0008-5472.CAN-10-0031; Tomasini P, 2016, ONCOLOGIST, V21, P1450, DOI 10.1634/theoncologist.2015-0084; Toschi A, 2009, MOL CELL BIOL, V29, P1411, DOI 10.1128/MCB.00782-08; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Walter DM, 2019, NATURE, V569, P423, DOI 10.1038/s41586-019-1172-9; Wang R, 2015, ONCOTARGET, V6, P34300, DOI 10.18632/oncotarget.5549; Wang Z, 2015, ONCOGENE, V34, P4975, DOI 10.1038/onc.2014.426; Westcott PMK, 2015, NATURE, V517, P489, DOI 10.1038/nature13898; Wu KH, 2012, INT J MOL SCI, V13, P11471, DOI 10.3390/ijms130911471; Yu JSL, 2016, DEVELOPMENT, V143, P3050, DOI 10.1242/dev.137075; Zappa C, 2016, TRANSL LUNG CANCER R, V5, P288, DOI 10.21037/tlcr.2016.06.07; Zhang C, 2017, PLOS ONE, V12	55	5	5	0	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2020	39	36					5876	5887		10.1038/s41388-020-01399-5	http://dx.doi.org/10.1038/s41388-020-01399-5		JUL 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NJ1HO	32728173	hybrid, Green Published			2022-12-28	WOS:000553757600001
J	Kohno, S; Linn, P; Nagatani, N; Watanabe, Y; Kumar, S; Soga, T; Takahashi, C				Kohno, Susumu; Linn, Paing; Nagatani, Naoko; Watanabe, Yoshihiro; Kumar, Sharad; Soga, Tomoyoshi; Takahashi, Chiaki			Pharmacologically targetable vulnerability in prostate cancer carrying RB1-SUCLA2 deletion	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; MUTATIONAL LANDSCAPE; COLLATERAL LETHALITY; RB; CELLS; EXPRESSION; SUCLA2; ENCEPHALOMYOPATHY; DIFFERENTIATION; DEFICIENCY	RB1gene is often homozygously deleted or mutated in prostate adenocarcinomas following acquirement of castration resistance and/or metastatic ability. We found thatSUCLA2gene is frequently involved in the deletion of theRB1gene region in advanced prostate cancer. SUCLA2 constitutes the beta-subunit of succinate CoA ligase heterodimer that reversibly converts succinyl CoA into succinate. We sought the possibility that deletion ofSUCLA2gives rise to a metabolic vulnerability that could be targeted therapeutically. We found a significant metabolic shift inSUCLA2-deleted prostate cancer cells, including lower mitochondrial respiratory activity. By screening a number of libraries for compounds that induce cell death selectively inSUCLA2-deficient prostate cancer cells, we identified thymoquinone (2-isopropyl-5-methylbenzo-1,4-quinone) and PMA (phorbol-12-myristate-13-acetate) from a natural compound library. These findings indicate that the metabolic vulnerability inSUCLA2-deficient prostate cancer cells is pharmacologically targetable.	[Kohno, Susumu; Linn, Paing; Nagatani, Naoko; Takahashi, Chiaki] Kanazawa Univ, Canc Res Inst, Div Oncol & Mol Biol, Kakuma Machi, Kanazawa, Ishikawa 9201192, Japan; [Watanabe, Yoshihiro] Kanazawa Univ Hosp, iCREK, 13-1 Takara Machi, Kanazawa, Ishikawa 9208641, Japan; [Kumar, Sharad] Univ South Australia, Ctr Canc Biol, Adelaide, SA 5001, Australia; [Soga, Tomoyoshi] Keio Univ, Inst Adv Biosci, Tsuruoka, Yamagata 9970052, Japan	Kanazawa University; Kanazawa University; Centre for Cancer Biology; University of South Australia; Keio University	Kohno, S; Takahashi, C (corresponding author), Kanazawa Univ, Canc Res Inst, Div Oncol & Mol Biol, Kakuma Machi, Kanazawa, Ishikawa 9201192, Japan.	skohno@staff.kanazawa-u.ac.jp; chtakaha@staff.kanazawa-u.ac.jp	Kumar, Sharad/AAX-7787-2020	Kumar, Sharad/0000-0001-7126-9814; Linn, Paing/0000-0001-9525-7041; Takahashi, Chiaki/0000-0003-3390-9563	Funding Program for Next Generation World-Leading Researchers from cabinet office of Japan [LS049]; MEXT [17H03576, 17K19586, 19K22555, 17K14992, 20K07612]; Japan Agency for Medical Research and Development (AMED) [19cm0106164h0001]; Daiichi-Sankyo Co. Ltd. [C1010568, C1010818]; National Health & Medical Research Council of Australia [GNT 1103006]	Funding Program for Next Generation World-Leading Researchers from cabinet office of Japan; MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Daiichi-Sankyo Co. Ltd.(Daiichi Sankyo Company Limited); National Health & Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	We thank Drs. Y. Hirota and S. Tsutsumi for the substantial contribution to the initiation of work, Dr. A. Mizokami for helpful discussion, and Dr. Y. Watanabe for suggestion on research direction. This study was supported by Funding Program for Next Generation World-Leading Researchers (LS049) from cabinet office of Japan, Grant-in-Aid for Scientific Research (17H03576, 17K19586 and 19K22555 to CT, and 17K14992 and 20K07612 to SK) from MEXT, Project for Cancer Research and Therapeutic (P-CREATE) (19cm0106164h0001) from Japan Agency for Medical Research and Development (AMED), and TaNeDS (C1010568) and a collaborative research fund (C1010818) from Daiichi-Sankyo Co. Ltd. SK was supported by a Senior Principal Research Fellowship from the National Health & Medical Research Council of Australia (GNT 1103006).	Abida W, 2019, P NATL ACAD SCI USA, V116, P11428, DOI 10.1073/pnas.1902651116; Abou-Kheir WG, 2010, STEM CELLS, V28, P2129, DOI 10.1002/stem.538; Al-Amri A. M., 2009, Shiraz E Medical Journal, V10, P107; Aparicio A, 2011, NAT REV UROL, V8, P562, DOI 10.1038/nrurol.2011.107; Barbieri CE, 2013, EUR UROL, V64, P567, DOI 10.1016/j.eururo.2013.05.029; Beltran H, 2013, EUR UROL, V63, P920, DOI 10.1016/j.eururo.2012.08.053; Besse A, 2015, CELL METAB, V21, P417, DOI 10.1016/j.cmet.2015.02.008; Bignell GR, 2010, NATURE, V463, P893, DOI 10.1038/nature08768; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BOUTAGY NE, 2015, JOVE J VIS EXP OCT, V105, DOI DOI 10.3791/53216; Brough R, 2018, ONCOGENE, V37, P5701, DOI 10.1038/s41388-018-0368-z; Carrozzo R, 2007, BRAIN, V130, P862, DOI 10.1093/brain/awl389; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; Crumbaker M, 2017, CANCERS, V9, DOI 10.3390/cancers9040034; Dey P, 2017, NATURE, V542, P119, DOI 10.1038/nature21052; Dobolyi A, 2015, BRAIN STRUCT FUNCT, V220, P135, DOI 10.1007/s00429-013-0643-2; Donti TR, 2014, DIS MODEL MECH, V7, P271, DOI 10.1242/dmm.013466; Dyson NJ, 2016, GENE DEV, V30, P1492, DOI 10.1101/gad.282145.116; El-Hattab A, 2013, NEUROTHERAPEUTICS, V10, P186, DOI 10.1007/s13311-013-0177-6; Frank Sander, 2018, F1000Res, V7, DOI 10.12688/f1000research.14499.1; Frezza C, 2007, NAT PROTOC, V2, P287, DOI 10.1038/nprot.2006.478; Frezza C, 2011, NATURE, V477, P225, DOI 10.1038/nature10363; Gao S, 2016, CELL REP, V17, P966, DOI 10.1016/j.celrep.2016.09.064; Gong XQ, 2019, CANCER DISCOV, V9, P248, DOI 10.1158/2159-8290.CD-18-0469; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; HECKER E, 1967, NATURWISSENSCHAFTEN, V54, P282, DOI 10.1007/BF00620887; Hirotsu T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118699; Huang L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088893; Huang YQ, 2018, ONCOL LETT, V15, P6063, DOI 10.3892/ol.2018.8123; Huggins C, 1943, SCIENCE, V97, P541, DOI 10.1126/science.97.2529.541; Johnson JD, 1998, J BIOL CHEM, V273, P27580, DOI 10.1074/jbc.273.42.27580; Jones RA, 2016, J CLIN INVEST, V126, P3739, DOI 10.1172/JCI81568; Kadota K, 2008, ALGORITHM MOL BIOL, V3, DOI 10.1186/1748-7188-3-8; Kirby M, 2011, INT J CLIN PRACT, V65, P1180, DOI 10.1111/j.1742-1241.2011.02799.x; Knudsen Erik S, 2018, Oncotarget, V9, P30940, DOI 10.18632/oncotarget.25797; Kundu J, 2014, FOOD CHEM TOXICOL, V65, P18, DOI 10.1016/j.fct.2013.12.015; Li FK, 2019, CANCER RES, V79, P3903, DOI 10.1158/0008-5472.CAN-18-3604; Manning AL, 2012, NAT REV CANCER, V12, P220, DOI 10.1038/nrc3216; Matilainen S, 2015, EUR J HUM GENET, V23, P325, DOI 10.1038/ejhg.2014.128; Miller C, 2011, BBA-MOL BASIS DIS, V1812, P625, DOI 10.1016/j.bbadis.2011.01.013; Mostofa AGM, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00295; Muller FL, 2015, TRENDS CANCER, V1, P161, DOI 10.1016/j.trecan.2015.10.002; Muller FL, 2012, NATURE, V488, P337, DOI 10.1038/nature11331; Nicolay BN, 2015, GENE DEV, V29, P1875, DOI 10.1101/gad.264127.115; Ohmiya H, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-269; Oser MG, 2019, CANCER DISCOV, V9, P230, DOI 10.1158/2159-8290.CD-18-0389; Patel AB, 2005, P NATL ACAD SCI USA, V102, P5588, DOI 10.1073/pnas.0501703102; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Salah M, 2016, MOL CARCINOGEN, V55, P1974, DOI 10.1002/mc.22444; SALOMI MJ, 1991, NUTR CANCER, V16, P67, DOI 10.1080/01635589109514142; Sankaran VG, 2008, GENE DEV, V22, P463, DOI 10.1101/gad.1627208; Scime A, 2005, CELL METAB, V2, P283, DOI 10.1016/j.cmet.2005.10.002; Sharma A, 2010, J CLIN INVEST, V120, P4478, DOI 10.1172/JCI44239; Soga T, 2006, J BIOL CHEM, V281, P16768, DOI 10.1074/jbc.M601876200; Soga T, 2009, ANAL CHEM, V81, P6165, DOI 10.1021/ac900675k; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tort F, 2006, CANCER RES, V66, P10258, DOI 10.1158/0008-5472.CAN-06-2178; Ueda Yuji, 2019, Oncotarget, V10, P5412, DOI 10.18632/oncotarget.27124; VANDUUREN BL, 1969, PROG EXP TUMOR RES, V11, P31; Varaljai R, 2015, GENE DEV, V29, P1817, DOI 10.1101/gad.264036.115; Witkiewicz AK, 2018, CELL REP, V22, P1185, DOI 10.1016/j.celrep.2018.01.022; Yi TF, 2008, MOL CANCER THER, V7, P1789, DOI 10.1158/1535-7163.MCT-08-0124; Zacksenhaus E, 2018, MOL CELL ONCOL, V5, DOI 10.1080/23723556.2018.1481814; Zhang LD, 2016, ONCOL LETT, V12, P2840, DOI 10.3892/ol.2016.4971; Zhao YJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05168-5; Zhou ZX, 2006, CANCER RES, V66, P7889, DOI 10.1158/0008-5472.CAN-06-0486	66	3	3	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2020	39	34					5690	5707		10.1038/s41388-020-1381-6	http://dx.doi.org/10.1038/s41388-020-1381-6		JUL 2020	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NE9FK	32694611				2022-12-28	WOS:000551055100001
J	He, SW; Xu, C; Li, YQ; Li, YQ; Zhao, Y; Zhang, PP; Lei, Y; Liang, YL; Li, JY; Li, Q; Chen, Y; Huang, SY; Ma, J; Liu, N				He, Shi-Wei; Xu, Cheng; Li, Ying-Qing; Li, Ying-Qin; Zhao, Yin; Zhang, Pan-Pan; Lei, Yuan; Liang, Ye-Lin; Li, Jun-Yan; Li, Qian; Chen, Yang; Huang, Sheng-Yan; Ma, Jun; Liu, Na			AR-induced long non-coding RNA LINC01503 facilitates proliferation and metastasis via the SFPQ-FOSL1 axis in nasopharyngeal carcinoma	ONCOGENE			English	Article							SFPQ; PROGNOSIS; INVASION; LNCRNA	Increasing evidence indicates that long non-coding RNAs (lncRNAs) play vital roles in the tumorigenesis and progression of cancers. However, the functions and regulatory mechanisms of lncRNAs in nasopharyngeal carcinoma (NPC) are still largely unknown. Our previous lncRNA expression profiles identified that LINC01503 was overexpressed in NPC. Here, we verified that LINC01503 was highly expressed in NPC and correlated with poor prognosis. LINC01503 promoted NPC cell proliferation, migration, and invasion in vitro, and facilitated tumor growth and metastasis in vivo. Mechanistically, LINC01503 recruited splicing factor proline-and glutamine-rich (SFPQ) to activate Fos like 1 (FOSL1) transcription, and ectopic expression of FOSL1 reversed the suppressive effect of LINC01503 knockdown on NPC progression. Moreover, androgen receptor (AR)-mediated transcription activation was responsible for the overexpression of LINC01503, and AR ligand-dependent cell growth, migration, and invasion in NPC cells. Taken together, our findings reveal that AR-induced LINC01503 can promote NPC progression through the SFPQ-FOSL1 axis, which represents a novel prognostic biomarker and therapeutic target for NPC patients.	[He, Shi-Wei; Xu, Cheng; Li, Ying-Qing; Li, Ying-Qin; Zhao, Yin; Zhang, Pan-Pan; Lei, Yuan; Liang, Ye-Lin; Li, Jun-Yan; Li, Qian; Chen, Yang; Huang, Sheng-Yan; Ma, Jun; Liu, Na] Sun Yat Sen Univ, Guangdong Key Lab Nasopharyngeal Carcinoma Diag &, Collaborat Innovat Ctr Canc Med, Canc Ctr,State Key Lab Oncol South China, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University	Liu, N (corresponding author), Sun Yat Sen Univ, Guangdong Key Lab Nasopharyngeal Carcinoma Diag &, Collaborat Innovat Ctr Canc Med, Canc Ctr,State Key Lab Oncol South China, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China.	liun1@sysucc.org.cn	lei, yuan/GXW-0547-2022	Zhao, Yin/0000-0001-7007-2999; Ma, Jun/0000-0002-1137-9349	Key-Area Research and Development Program of Guangdong Province [2019B020230002]; Natural Science Foundation of Guangdong Province [2017A030312003]; Health and Medical Collaborative Innovation Project of Guangzhou City, China [201803040003]; Innovation Team Development Plan of the Ministry of Education [IRT_17R110]; Overseas Expertise Introduction Project for Discipline Innovation (111 Project) [B14035]; National Natural Science Foundation of China [8200110172, 81773229]	Key-Area Research and Development Program of Guangdong Province; Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Health and Medical Collaborative Innovation Project of Guangzhou City, China; Innovation Team Development Plan of the Ministry of Education; Overseas Expertise Introduction Project for Discipline Innovation (111 Project); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank all the patients from the Sun Yat-sen University Cancer Center, who were involved in this study. This study was supported by grants from the National Natural Science Foundation of China (8200110172, CX; 81773229, NL), Key-Area Research and Development Program of Guangdong Province (2019B020230002, JM), Natural Science Foundation of Guangdong Province (2017A030312003, JM), Health and Medical Collaborative Innovation Project of Guangzhou City, China (201803040003, JM), Innovation Team Development Plan of the Ministry of Education (IRT_17R110, JM), and Overseas Expertise Introduction Project for Discipline Innovation (111 Project, B14035, JM). The raw data of this paper have been uploaded onto the Research Data Deposit (RDD) with an RDD number of RDDB2020000912.	Au KH, 2018, ORAL ONCOL, V77, P16, DOI 10.1016/j.oraloncology.2017.12.004; Bai SS, 2019, ONCOGENE, V38, P4977, DOI 10.1038/s41388-019-0768-8; Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen XW, 2018, J CELL BIOCHEM, V119, P4945, DOI 10.1002/jcb.26739; Chen YG, 2017, NAT IMMUNOL, V18, P962, DOI 10.1038/ni.3771; Chen YP, 2019, LANCET, V394, P64, DOI 10.1016/S0140-6736(19)30956-0; Chen YP, 2018, CLIN CANCER RES, V24, P1824, DOI 10.1158/1078-0432.CCR-17-2656; Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606; Geisler S, 2013, NAT REV MOL CELL BIO, V14, P699, DOI 10.1038/nrm3679; Han Y, 2019, J CELL PHYSIOL, V234, P3598, DOI 10.1002/jcp.27048; He SW, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0175-4; He Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0265-y; Hirose T, 2014, MOL BIOL CELL, V25, P169, DOI 10.1091/mbc.E13-09-0558; Huang WH, 2018, PROSTATE, V78, P1248, DOI 10.1002/pros.23700; Hui EP, 2018, CLIN CANCER RES, V24, P1030, DOI 10.1158/1078-0432.CCR-17-1667; Imamura K, 2014, MOL CELL, V53, P393, DOI 10.1016/j.molcel.2014.01.009; Jain AK, 2016, MOL CELL, V64, P967, DOI 10.1016/j.molcel.2016.10.039; Jiang XM, 2020, AGING-US, V12, P1237, DOI 10.18632/aging.102680; Knott GJ, 2016, NUCLEIC ACIDS RES, V44, P3989, DOI 10.1093/nar/gkw271; Lee AWM, 2015, J CLIN ONCOL, V33, P3356, DOI 10.1200/JCO.2015.60.9347; Lee MW, 2015, NUCLEIC ACIDS RES, V43, P3826, DOI 10.1093/nar/gkv156; Li G, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2755-6; Liu TY, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0873-2; Liu YW, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0588-9; Lu SR, 2018, EXP THER MED, V16, P4879, DOI 10.3892/etm.2018.6775; Misawa A, 2016, J BIOL CHEM, V291, P17861, DOI 10.1074/jbc.M116.718536; Mitani Y, 2020, CLIN CANCER RES, V26, P1175, DOI 10.1158/1078-0432.CCR-19-1603; Parolia A, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0314-4; Peng H, 2019, CLIN CANCER RES, V25, P4271, DOI 10.1158/1078-0432.CCR-18-3065; Qu YK, 2019, EUR REV MED PHARMACO, V23, P6445, DOI 10.26355/eurrev_201908_18526; Ransohoff JD, 2018, NAT REV MOL CELL BIO, V19, P143, DOI 10.1038/nrm.2017.104; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Tan BS, 2019, ONCOGENE, V38, P5612, DOI 10.1038/s41388-019-0812-8; Tosetti V, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180579; Wang FW, 2019, J CLIN INVEST, V129, P727, DOI 10.1172/JCI122478; Wang H, 2019, EUR REV MED PHARMACO, V23, P1600, DOI 10.26355/eurrev_201902_17119; Wang YY, 2015, CELL STEM CELL, V16, P413, DOI 10.1016/j.stem.2015.03.003; Wen X, 2018, THERANOSTICS, V8, P5676, DOI 10.7150/thno.28538; Wen X, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111956; Xie JJ, 2018, GASTROENTEROLOGY, V154, P2137, DOI 10.1053/j.gastro.2018.02.018; Yao RW, 2019, NAT CELL BIOL, V21, P542, DOI 10.1038/s41556-019-0311-8; Yu WW, 2019, ONCOGENE, V38, P1225, DOI 10.1038/s41388-018-0463-1; Zhang W, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008325; Zhang YJ, 2018, NAT GENET, V50, P814, DOI 10.1038/s41588-018-0120-1; Zhang Y, 2019, NEW ENGL J MED, V381, P1124, DOI 10.1056/NEJMoa1905287; Zheng ZQ, 2019, CANCER RES, V79, P4612, DOI 10.1158/0008-5472.CAN-19-0799	47	17	17	2	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2020	39	34					5616	5632		10.1038/s41388-020-01388-8	http://dx.doi.org/10.1038/s41388-020-01388-8		JUL 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NE9FK	32661324	hybrid, Green Published			2022-12-28	WOS:000548100200002
J	Sun, T; Wu, ZK; Wang, XF; Wang, YL; Hu, XY; Qin, WY; Lu, SX; Xu, DP; Wu, YT; Chen, QC; Ding, XY; Guo, H; Li, YL; Wang, YH; Fu, BS; Yao, WF; Wei, MJ; Wu, HZ				Sun, Tong; Wu, Zhikun; Wang, Xiufang; Wang, Yilin; Hu, Xiaoyun; Qin, Wenyan; Lu, Senxu; Xu, Dongping; Wu, Yutong; Chen, Qiuchen; Ding, Xiangyu; Guo, Hao; Li, Yalun; Wang, Yuanhe; Fu, Boshi; Yao, Weifan; Wei, Minjie; Wu, Huizhe			LNC942 promoting METTL14-mediated m(6)A methylation in breast cancer cell proliferation and progression	ONCOGENE			English	Article							RNA METHYLATION; MESSENGER-RNA; NONCODING RNAS; SUPPRESSES	Increasing evidence supports that long noncoding RNAs (lncRNAs) act as master regulators involved in tumorigenesis and development at theN6-methyladenine (m(6)A) epigenetic modification level. However, the underlying regulatory mechanism in breast cancer (BRCA) remains elusive. Here, we unveil that LINC00942 (LNC942) exerts its functions as an oncogene in promoting METTL14-mediated m(6)A methylation and regulating the expression and stability of its target genes CXCR4 and CYP1B1 in BRCA initiation and progression. Specifically, LNC942 and METTL14 were significantly upregulated accompanied with the upregulation of m(6)A levels in BRCA cells and our included BRCA cohorts (n = 150). Functionally, LNC942 elicits potent oncogenic effects on promoting cell proliferation and colony formation and inhibiting cell apoptosis, subsequently elevating METTL14-mediated m(6)A methylation levels and its associated mRNA stability and protein expression of CXCR4 and CYP1B1 in BRCA cells. Mechanistically, LNC942 directly recruits METTL14 protein by harboring the specific recognize sequence (+176-+265), thereby stabilized the expression of downstream targets of LNC942 including CXCR4 and CYP1B1 through posttranscriptional m(6)A methylation modification in vitro and in vivo. Therefore, our results uncover a novel LNC942-METTL14-CXCR4/CYP1B1 signaling axis, which provides new targets and crosstalk m(6)A epigenetic modification mechanism for BRCA prevention and treatment.	[Sun, Tong; Wu, Zhikun; Wang, Xiufang; Wang, Yilin; Hu, Xiaoyun; Qin, Wenyan; Lu, Senxu; Xu, Dongping; Wu, Yutong; Chen, Qiuchen; Ding, Xiangyu; Guo, Hao; Fu, Boshi; Yao, Weifan; Wei, Minjie; Wu, Huizhe] China Med Univ, Sch Pharm, Dept Pharmacol, Shenyang 110122, Peoples R China; [Sun, Tong; Wu, Zhikun; Wang, Xiufang; Wang, Yilin; Hu, Xiaoyun; Qin, Wenyan; Lu, Senxu; Xu, Dongping; Wu, Yutong; Chen, Qiuchen; Ding, Xiangyu; Guo, Hao; Fu, Boshi; Yao, Weifan; Wei, Minjie; Wu, Huizhe] China Med Univ, Liaoning Key Lab Mol Targeted Antitumor Drug Dev, Shenyang 110122, Peoples R China; [Sun, Tong; Wu, Zhikun; Wang, Xiufang; Wang, Yilin; Hu, Xiaoyun; Qin, Wenyan; Lu, Senxu; Xu, Dongping; Wu, Yutong; Chen, Qiuchen; Ding, Xiangyu; Guo, Hao; Fu, Boshi; Yao, Weifan; Wei, Minjie; Wu, Huizhe] China Med Univ, Liaoning Canc Immune Peptide Drug Engn Technol Re, Shenyang 110122, Peoples R China; [Sun, Tong; Wu, Zhikun; Wang, Xiufang; Wang, Yilin; Hu, Xiaoyun; Qin, Wenyan; Lu, Senxu; Xu, Dongping; Wu, Yutong; Chen, Qiuchen; Ding, Xiangyu; Guo, Hao; Fu, Boshi; Yao, Weifan; Wei, Minjie; Wu, Huizhe] China Med Univ, Key Lab Precis Diag & Treatment Gastrointestinal, Minist Educ, Shenyang 110122, Peoples R China; [Li, Yalun] China Med Univ, Dept Anorectal Surg, Hosp 1, Shenyang 110001, Peoples R China; [Wang, Yuanhe] China Med Univ, Liaoning Canc Hosp & Inst, Dept Med Oncol, Canc Hosp, Shenyang 110042, Peoples R China	China Medical University; China Medical University; China Medical University; China Medical University; China Medical University; China Medical University	Wei, MJ; Wu, HZ (corresponding author), China Med Univ, Sch Pharm, Dept Pharmacol, Shenyang 110122, Peoples R China.; Wei, MJ; Wu, HZ (corresponding author), China Med Univ, Liaoning Key Lab Mol Targeted Antitumor Drug Dev, Shenyang 110122, Peoples R China.; Wei, MJ; Wu, HZ (corresponding author), China Med Univ, Liaoning Canc Immune Peptide Drug Engn Technol Re, Shenyang 110122, Peoples R China.; Wei, MJ; Wu, HZ (corresponding author), China Med Univ, Key Lab Precis Diag & Treatment Gastrointestinal, Minist Educ, Shenyang 110122, Peoples R China.	mjwei@cmu.edu.cn; wuhz@cmu.edu.cn		Wu, Huizhe/0000-0001-7964-1342	National Natural Science Foundation of China [31828005, 81872905, 81673475, U1608281]; National Natural Science Foundation of Liaoning [U1608281]; Liaoning Revitalization Talents Program [XLYC1807155]; China Postdoctoral Science Foundation [2019M661180]; Special Foundation of China postdoctoral science foundation [2019T120225]; Shenyang ST Projects [19-109-4-09]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation of Liaoning; Liaoning Revitalization Talents Program; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Special Foundation of China postdoctoral science foundation; Shenyang ST Projects	This work was supported by grants from the National Natural Science Foundation of China [No. 31828005, 81872905, and 81673475], National Natural Science Foundation of China and Liaoning joint fund key program [No. U1608281], Liaoning Revitalization Talents Program [XLYC1807155], China Postdoctoral Science Foundation (Grant No. 2019M661180), Special Foundation of China postdoctoral science foundation (Grant No. 2019T120225), and Shenyang S&T Projects (19-109-4-09).	Adhikari S, 2016, RNA BIOL, V13, P756, DOI 10.1080/15476286.2016.1201628; Anastasiadou E, 2018, NAT REV CANCER, V18, P5, DOI 10.1038/nrc.2017.99; Ashouri A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13197; Chen S, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-1105-6; Cui Q, 2017, CELL REP, V18, P2622, DOI 10.1016/j.celrep.2017.02.059; Deng XL, 2018, CELL RES, V28, P507, DOI 10.1038/s41422-018-0034-6; Dominissini D, 2012, NATURE, V485, P201, DOI 10.1038/nature11112; Du H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12626; Golmohammadzadeh Golpar, 2019, Open Access Maced J Med Sci, V7, P2488, DOI 10.3889/oamjms.2019.667; Gong DK, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1223-y; Gu CH, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1084-1; Huang HL, 2020, CANCER CELL, V37, P270, DOI 10.1016/j.ccell.2020.02.004; Jin D, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0830-6; Kashyap D, 2020, LIFE SCI, V246, DOI 10.1016/j.lfs.2020.117417; Lang FC, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007796; Li FX, 2019, CANCER RES, V79, P5785, DOI 10.1158/0008-5472.CAN-18-2868; Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248; Li ZJ, 2017, CANCER CELL, V31, P127, DOI 10.1016/j.ccell.2016.11.017; Liu J, 2018, NAT CELL BIOL, V20, P1074, DOI 10.1038/s41556-018-0174-4; Liu N, 2015, NATURE, V518, P560, DOI 10.1038/nature14234; Liu N, 2013, RNA, V19, P1848, DOI 10.1261/rna.041178.113; Ma JZ, 2017, HEPATOLOGY, V65, P529, DOI 10.1002/hep.28885; Mathieu J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08020-0; Matsui M, 2017, NAT REV DRUG DISCOV, V16, P167, DOI 10.1038/nrd.2016.117; Mego M, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2143-2; Meyer KD, 2012, CELL, V149, P1635, DOI 10.1016/j.cell.2012.05.003; Ni W, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1079-y; Niu Yamei, 2013, Genomics Proteomics & Bioinformatics, V11, P8, DOI 10.1016/j.gpb.2012.12.002; Pan YT, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0590-8; Panneerdoss S, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aar8263; Patil DP, 2016, NATURE, V537, P369, DOI 10.1038/nature19342; Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI [10.3322/caac.21601, 10.3322/caac.21590]; Sun T, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.108613; Tao Y, 2019, INT J LAB MED, V40, P1541; Wang X, 2019, AM J TRANSL RES, V11, P4909; Weng HY, 2018, CELL STEM CELL, V22, P191, DOI 10.1016/j.stem.2017.11.016; Yan JJ, 2020, BIOCHEM BIOPH RES CO, V521, P887, DOI 10.1016/j.bbrc.2019.11.016; Yang DD, 2018, NUCLEIC ACIDS RES, V46, P3906, DOI 10.1093/nar/gky130; Yang F, 2019, CANCER RES, V79, P735, DOI 10.1158/0008-5472.CAN-18-0620; Yang X, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1146-4; Yao QJ, 2018, CELL RES, V28, P952, DOI 10.1038/s41422-018-0062-2; Yu AM, 2020, APPL MICROBIOL BIOT, V104, P1927, DOI 10.1007/s00253-020-10350-3; Yue B, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1065-4; Zhang C, 2019, CANCER MED-US, V8, P4766, DOI 10.1002/cam4.2360; Zhang SC, 2017, CANCER CELL, V31, P591, DOI 10.1016/j.ccell.2017.02.013; Zhi H, 2018, ADV EXP MED BIOL, V1094, P49, DOI 10.1007/978-981-13-0719-5_6; Zhu KP, 2019, MOL THER, V27, P518, DOI 10.1016/j.ymthe.2019.01.001	47	89	89	5	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 30	2020	39	31					5358	5372		10.1038/s41388-020-1338-9	http://dx.doi.org/10.1038/s41388-020-1338-9		JUN 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MT1TS	32576970				2022-12-28	WOS:000542510500001
J	Shang, CW; Zhou, HY; Liu, W; Shen, T; Luo, Y; Huang, SL				Shang, Chaowei; Zhou, Hongyu; Liu, Wang; Shen, Tao; Luo, Yan; Huang, Shile			Iron chelation inhibits mTORC1 signaling involving activation of AMPK and REDD1/Bnip3 pathways	ONCOGENE			English	Article							PROTEIN-KINASE; ANTITUMOR-ACTIVITY; MAMMALIAN TARGET; UPSTREAM KINASE; PHOSPHATASE 2A; ENERGY-SENSOR; GENE-PRODUCTS; CELL-GROWTH; TGF-BETA; CANCER	The mammalian target of rapamycin (mTOR) functions as two complexes (mTORC1 and mTORC2), regulating cell growth and metabolism. Aberrant mTOR signaling occurs frequently in cancers, so mTOR has become an attractive target for cancer therapy. Iron chelators have emerged as promising anticancer agents. However, the mechanisms underlying the anticancer action of iron chelation are not fully understood. Particularly, reports on the effects of iron chelation on mTOR complexes are inconsistent or controversial. Here, we found that iron chelators consistently inhibited mTORC1 signaling, which was blocked by pretreatment with ferrous sulfate. Mechanistically, iron chelation-induced mTORC1 inhibition was not related to ROS induction, copper chelation, or PP2A activation. Instead, activation of AMPK pathway mainly and activation of both HIF-1/REDD1 and Bnip3 pathways partially contribute to iron chelation-induced mTORC1 inhibition. Our findings indicate that iron chelation inhibits mTORC1 via multiple pathways and iron is essential for mTORC1 activation.	[Shang, Chaowei; Zhou, Hongyu; Liu, Wang; Shen, Tao; Luo, Yan; Huang, Shile] Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; [Shang, Chaowei; Shen, Tao; Huang, Shile] Louisiana State Univ, Hlth Sci Ctr, Feist Weiller Canc Ctr, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Huang, SL (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA.; Huang, SL (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Feist Weiller Canc Ctr, Shreveport, LA 71130 USA.	shuan1@lsuhsc.edu	Huang, Shile/I-1632-2019	Huang, Shile/0000-0002-3239-1072; Zhou, Hongyu/0000-0001-5852-3953	National Institutes of Health [CA115414]; American Cancer Society [RSG-08-135-01-CNE]; Feist-Weiller Cancer Center Idea Award; Carroll Feist Predoctoral Fellowship; Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center in Shreveport, LA	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Feist-Weiller Cancer Center Idea Award; Carroll Feist Predoctoral Fellowship; Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center in Shreveport, LA	We thank Michael N. Hall for reading the manuscript and helpful discussions, and Yu Jiang for generously providing Rheb-Q64L plasmid. This work was supported by the National Institutes of Health (CA115414; SH), American Cancer Society (RSG-08-135-01-CNE; SH), Feist-Weiller Cancer Center Idea Award (SH), and Carroll Feist Predoctoral Fellowship (CS and TS), Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center in Shreveport, LA.	Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Bystrom LM, 2015, FREE RADICAL BIO MED, V79, P337, DOI 10.1016/j.freeradbiomed.2014.04.035; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; Coombs GS, 2012, ONCOGENE, V31, P213, DOI 10.1038/onc.2011.228; Davies SP, 1995, FEBS LETT, V377, P421, DOI 10.1016/0014-5793(95)01368-7; Dennis MD, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005103; DeYoung MP, 2008, GENE DEV, V22, P239, DOI 10.1101/gad.1617608; Dixon KM, 2013, BRIT J CANCER, V108, P409, DOI 10.1038/bjc.2012.582; DONFRANCESCO A, 1990, CANCER RES, V50, P4929; Eberhard Y, 2009, BLOOD, V114, P3064, DOI 10.1182/blood-2009-03-209965; ESTROV Z, 1987, BLOOD, V69, P757; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Glick D, 2012, MOL CELL BIOL, V32, P2570, DOI 10.1128/MCB.00167-12; Guo K, 2001, CELL DEATH DIFFER, V8, P367, DOI 10.1038/sj.cdd.4400810; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Heberle AM, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723548.2014.970489; Huang X, 2003, MUTAT RES-FUND MOL M, V533, P153, DOI 10.1016/j.mrfmmm.2003.08.023; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Kalinowski DS, 2005, PHARMACOL REV, V57, P547, DOI 10.1124/pr.57.4.2; Kazyken D, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aav3249; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kovacevic Z, 2013, ANTIOXID REDOX SIGN, V18, P874, DOI 10.1089/ars.2011.4273; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Lane DJR, 2014, BBA-REV CANCER, V1845, P166, DOI 10.1016/j.bbcan.2014.01.005; Lee J, 1996, P NATL ACAD SCI USA, V93, P6043, DOI 10.1073/pnas.93.12.6043; Li Y, 2007, J BIOL CHEM, V282, P35803, DOI 10.1074/jbc.M705231200; Lin A, 2014, ONCOGENE, V33, P3183, DOI 10.1038/onc.2013.273; Linden T, 2003, FASEB J, V17, P761, DOI 10.1096/fj.02-0586fje; Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053; Lovejoy DB, 2011, CANCER RES, V71, P5871, DOI 10.1158/0008-5472.CAN-11-1218; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Ohyashiki JH, 2009, CANCER SCI, V100, P970, DOI 10.1111/j.1349-7006.2009.01131.x; Pinnix ZK, 2010, SCI TRANSL MED, V2, DOI [10.1126/scitranslmed.3001127, 10.1126/scisignal.3001127]; Rao VA, 2009, CANCER RES, V69, P948, DOI 10.1158/0008-5472.CAN-08-1437; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.03.035, 10.1016/j.cell.2017.02.004]; Shackelford DB, 2013, CANCER CELL, V23, P143, DOI 10.1016/j.ccr.2012.12.008; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shen T, 2016, CURR PHARM DESIGN, V22, P4443, DOI 10.2174/1381612822666160530151209; Shimobayashi M, 2014, NAT REV MOL CELL BIO, V15, P155, DOI 10.1038/nrm3757; Siddiqui N, 2015, BIOCHEM SOC T, V43, P763, DOI 10.1042/BST20150126; Singh M, 2011, APPL IMMUNOHISTO M M, V19, P417, DOI 10.1097/PAI.0b013e318209716e; Song S, 2011, CANCER RES, V71, P7628, DOI 10.1158/0008-5472.CAN-11-2745; Sowter HM, 2001, CANCER RES, V61, P6669; Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Torti SV, 2013, NAT REV CANCER, V13, P342, DOI 10.1038/nrc3495; Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547; VAUGHN CB, 1987, CANCER INVEST, V5, P7, DOI 10.3109/07357908709020300; Voss M, 2011, CELL SIGNAL, V23, P114, DOI 10.1016/j.cellsig.2010.08.010; WANG GL, 1993, BLOOD, V82, P3610; Wang LF, 2007, J BIOL CHEM, V282, P20036, DOI 10.1074/jbc.M702376200; Watson A, 2016, CELL SIGNAL, V28, P412, DOI 10.1016/j.cellsig.2016.01.014; Whitnall M, 2006, P NATL ACAD SCI USA, V103, P14901, DOI 10.1073/pnas.0604979103; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; Xie M, 2006, P NATL ACAD SCI USA, V103, P17378, DOI 10.1073/pnas.0604708103; Yu JS, 1998, J BIOCHEM, V124, P225, DOI 10.1093/oxfordjournals.jbchem.a022084; Yuan J, 2004, BLOOD, V104, P1450, DOI 10.1182/blood-2004-03-0868; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999; Zhou HY, 2016, BIOCHEM PHARMACOL, V116, P39, DOI 10.1016/j.bcp.2016.07.005; Zhou HY, 2014, ONCOTARGET, V5, P10140, DOI 10.18632/oncotarget.2471; Zhou HY, 2010, INT J CANCER, V127, P2467, DOI 10.1002/ijc.25255	76	13	13	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 16	2020	39	29					5201	5213		10.1038/s41388-020-1366-5	http://dx.doi.org/10.1038/s41388-020-1366-5		JUN 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ML6WO	32541839	Green Published, hybrid, Green Accepted			2022-12-28	WOS:000540391900001
J	Li, W; Wang, QX; Qi, XY; Guo, YY; Lu, HM; Chen, YH; Lu, ZM; Yan, Q; Zhu, XF; Jung, JU; Tosato, OAN; Gao, SJ; Lu, C				Li, Wan; Wang, Qingxia; Qi, Xiaoyu; Guo, Yuanyuan; Lu, Hongmei; Chen, Yuheng; Lu, Zhongmou; Yan, Qin; Zhu, Xiaofei; Jung, Jae U.; Tosato, Giovanna; Gao, Shou-Jiang; Lu, Chun			Viral interleukin-6 encoded by an oncogenic virus promotes angiogenesis and cellular transformation by enhancing STAT3-mediated epigenetic silencing of caveolin 1	ONCOGENE			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; KAPOSIS-SARCOMA; HIV-1 NEF; STAT3; GENE; ACTIVATION; TRANSCRIPTION; PROTEIN; VIL-6; IL-6	Kaposi's sarcoma (KS) caused by oncogenic Kaposi's sarcoma-associated herpesvirus (KSHV) is a highly angiogenic and invasive vascular tumor and the most common AIDS-associated cancer. KSHV-encoded viral interleukin-6 (vIL-6) is implicated in the development of KSHV-induced malignancies; however, the mechanisms underlying vIL-6-induced angiogenesis and tumorigenesis remain undefined. Here, we show that vIL-6 promotes angiogenesis, cell proliferation, and invasion by downregulating caveolin 1 (CAV1) that plays a pivotal and versatile role in multiple cancer-associated processes. Mechanistically, vIL-6 signaling led to the phosphorylation and acetylation of STAT3 that targeted DNA methyltransferase 1 (DNMT1) in a sequential manner. Specifically, the vIL-6-induced phosphorylated form of STAT3 transcriptionally activated DNMT1 expression. Furthermore, vIL-6-induced acetylated form of STAT3 interacted with DNMT1 to form a transcription factor complex that bound to and methylated the CAV1 promoter, leading to CAV1 expression silencing. In fact, downregulation of CAV1 expression resulted in the activation of AKT signaling, promoting cell invasion, and growth transformation induced by KSHV. Finally, genetic deletion of vIL-6 from the KSHV genome abolished KSHV-induced cellular transformation and impaired angiogenesis. Our results reveal that vIL-6 epigenetically silences CAV1 expression to promote angiogenesis and tumorigenesis by regulating the formation of STAT3-DNMT1 complex. These novel findings define a mechanism by which KSHV inhibits the CAV1 pathway and establish the scientific basis for targeting this pathway to treat KSHV-associated cancers.	[Li, Wan; Wang, Qingxia; Qi, Xiaoyu; Chen, Yuheng; Lu, Zhongmou; Yan, Qin; Lu, Chun] Nanjing Med Univ, Dept Microbiol, Nanjing 211166, Peoples R China; [Li, Wan; Lu, Chun] Nanjing Med Univ, Womens Hosp, Nanjing Matern & Child Hlth Hosp, Dept Gynecol, Nanjing 210029, Peoples R China; [Li, Wan; Lu, Chun] Nanjing Med Univ, Key Lab Pathogen Biol Jiangsu Prov, Nanjing 211166, Peoples R China; [Guo, Yuanyuan] Nanjing Univ Chinese Med, Coll Med & Life Sci, Nanjing 210023, Peoples R China; [Lu, Hongmei] Nanjing Med Univ, Dept Obstet, Affiliated Hosp 1, Nanjing 210036, Peoples R China; [Zhu, Xiaofei] Nanjing Univ Chinese Med, Dept Lab Med, Affiliated Hosp, Nanjing 210029, Peoples R China; [Jung, Jae U.] Univ Southern Calif, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA; [Tosato, Giovanna] NCI, Ctr Canc Res, Bethesda, MD 20892 USA; [Gao, Shou-Jiang] Univ Pittsburgh, UPMC Hillman Canc Ctr, Dept Microbiol & Mol Genet, Pittsburgh, PA 15232 USA	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing University of Chinese Medicine; Nanjing Medical University; Nanjing University of Chinese Medicine; University of Southern California; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lu, C (corresponding author), Nanjing Med Univ, Dept Microbiol, Nanjing 211166, Peoples R China.; Lu, C (corresponding author), Nanjing Med Univ, Womens Hosp, Nanjing Matern & Child Hlth Hosp, Dept Gynecol, Nanjing 210029, Peoples R China.; Lu, C (corresponding author), Nanjing Med Univ, Key Lab Pathogen Biol Jiangsu Prov, Nanjing 211166, Peoples R China.; Zhu, XF (corresponding author), Nanjing Univ Chinese Med, Dept Lab Med, Affiliated Hosp, Nanjing 210029, Peoples R China.	zxfyxjy@163.com; clu@njmu.edu.cn		Tosato, Giovanna/0000-0003-1663-3227; Lu, Chun/0000-0002-6078-9352; Gao, Shou-Jiang/0000-0001-6194-1742	National Natural Science Foundation of China [81730062, 81761128003, 31800148, 81503368]; Natural Science Foundation of Jiangsu Province [BK20180681]; Nanjing Medical University [KY101RC1710]; NIH [R01CA213275, CA200422, AI073099, AI116585, AI129496, AI140718, AI140705, DE023926, DE027888, DE028521]; Fletcher Jones Foundation	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Nanjing Medical University; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Fletcher Jones Foundation	This work was supported by grants from National Natural Science Foundation of China (81730062, 81761128003, 31800148, and 81503368), Natural Science Foundation of Jiangsu Province (BK20180681), Nanjing Medical University (KY101RC1710), a grant from NIH (R01CA213275), and grants (CA200422, AI073099, AI116585, AI129496, AI140718, AI140705, DE023926, DE027888, DE028521 and Fletcher Jones Foundation).	Aoki Y, 1999, BLOOD, V93, P4034, DOI 10.1182/blood.V93.12.4034.412k38_4034_4043; Aoki Y, 2001, BLOOD, V97, P2173, DOI 10.1182/blood.V97.7.2173; Belo Y, 2019, BBA-GEN SUBJECTS, V1863, P1343, DOI 10.1016/j.bbagen.2019.05.019; Bhatt AP, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00401; Boshoff C, 2001, ANNU REV MED, V52, P453, DOI 10.1146/annurev.med.52.1.453; Brulois KF, 2012, J VIROL, V86, P9708, DOI 10.1128/JVI.01019-12; Chandriani S, 2010, J VIROL, V84, P5565, DOI 10.1128/JVI.02723-09; Cousins E, 2013, J VIROL, V87, P10816, DOI 10.1128/JVI.02047-13; Cui J, 2001, PROSTATE, V46, P249, DOI 10.1002/1097-0045(20010215)46:3<249::AID-PROS1030>3.0.CO;2-#; Ding XY, 2019, CELL DEATH DIFFER, V26, P1970, DOI 10.1038/s41418-018-0268-3; Dourmishev LA, 2003, MICROBIOL MOL BIOL R, V67, P175, DOI 10.1128/MMBR.67.2.175-212.2003; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Fullwood RA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204947; Giffin L, 2015, MBIO, V6, DOI 10.1128/mBio.01499-15; Goetz JG, 2008, CANCER METAST REV, V27, P715, DOI 10.1007/s10555-008-9160-9; Gruffaz M, 2017, CANCER RES, V77, P7094, DOI 10.1158/0008-5472.CAN-17-2321; Gu XW, 2017, PROG RETIN EYE RES, V56, P84, DOI 10.1016/j.preteyeres.2016.09.005; Hu F, 2006, J VIROL, V80, P10874, DOI 10.1128/JVI.00767-06; Hu MM, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005171; Jones T, 2014, CELL CYCLE, V13, P845, DOI 10.4161/cc.27758; Jones T, 2012, J CLIN INVEST, V122, P1076, DOI 10.1172/JCI58530; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Lamaze C, 2017, CURR OPIN CELL BIOL, V47, P117, DOI 10.1016/j.ceb.2017.02.014; Lee H, 2012, P NATL ACAD SCI USA, V109, P7765, DOI 10.1073/pnas.1205132109; Lee MS, 2016, MBIO, V7, DOI 10.1128/mBio.02109-15; Lee MS, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004412; Li TT, 2019, J VIROL, V93, DOI 10.1128/JVI.01599-18; Li W, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007578; Li W, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005605; Magnaudeix A, 2016, ACTA BIOMATER, V38, P179, DOI 10.1016/j.actbio.2016.04.039; Mergia A, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9060129; Molden J, 1997, J BIOL CHEM, V272, P19625, DOI 10.1074/jbc.272.31.19625; Moody R, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003857; Morris VA, 2008, J VIROL, V82, P8771, DOI 10.1128/JVI.00766-08; Morris VA, 2012, VIROLOGY, V428, P112, DOI 10.1016/j.virol.2012.03.013; Nwosu ZC, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0558-7; Punjabi AS, 2007, J VIROL, V81, P2449, DOI 10.1128/JVI.01769-06; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Senetta R, 2013, J CELL MOL MED, V17, P325, DOI 10.1111/jcmm.12030; Stary CM, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00393; Suthaus J, 2012, BLOOD, V119, P5173, DOI 10.1182/blood-2011-09-377705; Syeed N, 2012, ASIAN PAC J CANCER P, V13, P371, DOI 10.7314/APJCP.2012.13.1.371; Tischer BK, 2010, METHODS MOL BIOL, V634, P421, DOI 10.1007/978-1-60761-652-8_30; Tischer BK, 2006, BIOTECHNIQUES, V40, P191, DOI 10.2144/000112096; Uldrick TS, 2010, CLIN INFECT DIS, V51, P350, DOI 10.1086/654798; Wake MS, 2015, FEBS J, V282, P2600, DOI 10.1111/febs.13285; Wang R, 2005, J BIOL CHEM, V280, P11528, DOI 10.1074/jbc.M413930200; Wen KW, 2010, CANCER LETT, V289, P140, DOI 10.1016/j.canlet.2009.07.004; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093478; Xia H, 2010, AM J PATHOL, V176, P2626, DOI 10.2353/ajpath.2010.091117; Xu HP, 2017, ONCOTARGET, V8, P76165, DOI 10.18632/oncotarget.19191; Xue M, 2014, NUCLEIC ACIDS RES, V42, P9862, DOI 10.1093/nar/gku583; Yao SH, 2015, NUCLEIC ACIDS RES, V43, P9362, DOI 10.1093/nar/gkv988; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; Zhang Q, 2006, BLOOD, V108, P1058, DOI 10.1182/blood-2005-08-007377; Zhou F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053145; Zhu X, 2014, ONCOGENE, V33, P1986, DOI 10.1038/onc.2013.136; Zhu Y, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005648	59	8	9	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	23					4603	4618		10.1038/s41388-020-1317-1	http://dx.doi.org/10.1038/s41388-020-1317-1		MAY 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LU5ZF	32393833	Green Accepted			2022-12-28	WOS:000531771800002
J	Lartigue, L; Merle, C; Lagarde, P; Delespaul, L; Lesluyes, T; Le Guellec, S; Perot, G; Leroy, L; Coindre, JM; Chibon, F				Lartigue, Lydia; Merle, Candice; Lagarde, Pauline; Delespaul, Lucile; Lesluyes, Tom; Le Guellec, Sophie; Perot, Gaelle; Leroy, Laura; Coindre, Jean-Michel; Chibon, Frederic			Genome remodeling upon mesenchymal tumor cell fusion contributes to tumor progression and metastatic spread	ONCOGENE			English	Article							MALIGNANT FIBROUS HISTIOCYTOMAS; CHROMOSOME INSTABILITY; CANCER; ANEUPLOIDY; MODEL; MECHANISMS; SARCOMAS; DNA; CONSEQUENCES; ONCOGENESIS	Cell fusion in tumor progression mostly refers to the merging of a cancer cell with a cell that has migration and immune escape capabilities such as macrophages. Here we show that spontaneous hybrids made from the fusion of transformed mesenchymal cells with partners from the same lineage undergo nonrecurrent large-scale genomic rearrangements, leading to the creation of highly aneuploid cells with novel phenotypic traits, including metastatic spreading capabilities. Moreover, in contrast to their parents, hybrids were the only cells able to recapitulate in vivo all features of human pleomorphic sarcomas, a rare and genetically complex mesenchymal tumor. Hybrid tumors not only displayed specific mesenchymal markers, but also combined a complex genetic profile with a highly metastatic behavior, like their human counterparts. Finally, we provide evidence that patient-derived pleomorphic sarcoma cells are inclined to spontaneous cell fusion. The resulting hybrids also gain in aggressiveness, exhibiting superior growth capacity in mouse models. Altogether, these results indicate that cell fusion has the potential to promote cancer progression by increasing growth and/or metastatic capacities, regardless of the nature of the companion cell. Moreover, such events likely occur upon sarcoma development, paving the way for better understanding of the biology, and aggressiveness of these tumors.	[Lartigue, Lydia; Lagarde, Pauline; Coindre, Jean-Michel; Chibon, Frederic] INSERM, U1218, 229 Cours Argonne, F-33076 Bordeaux, France; [Lartigue, Lydia; Lagarde, Pauline; Coindre, Jean-Michel] Bordeaux Univ, 146 Rue Leo Saignat, F-33000 Bordeaux, France; [Merle, Candice; Delespaul, Lucile; Lesluyes, Tom; Le Guellec, Sophie; Perot, Gaelle; Leroy, Laura; Chibon, Frederic] CRCT, INSERM, U1037, F-31037 Toulouse, France; [Merle, Candice] Univ Toulouse 3 Paul Sabatier, 118 Route Narbonne, F-31062 Toulouse 9, France; [Lagarde, Pauline; Coindre, Jean-Michel; Chibon, Frederic] Bergonie Inst, Dept Biopathol, 229 Cours Argonne, F-33076 Bordeaux, France; [Le Guellec, Sophie; Perot, Gaelle; Leroy, Laura; Chibon, Frederic] Inst Claudius Regaud, IUCT Oncopole, Dept Pathol, Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; UNICANCER; Institut Bergonie; UNICANCER; Institut Claudius Regaud	Chibon, F (corresponding author), INSERM, U1218, 229 Cours Argonne, F-33076 Bordeaux, France.; Chibon, F (corresponding author), CRCT, INSERM, U1037, F-31037 Toulouse, France.; Chibon, F (corresponding author), Bergonie Inst, Dept Biopathol, 229 Cours Argonne, F-33076 Bordeaux, France.; Chibon, F (corresponding author), Inst Claudius Regaud, IUCT Oncopole, Dept Pathol, Toulouse, France.	frederic.chibon@inserm.fr	Lesluyes, Tom/GSD-4621-2022; Lesluyes, Tom/AAB-6229-2019; Pérot, Gaëlle/W-8038-2019; Delespaul, Lucile/AAZ-1073-2021; leroy, laura/ABE-2798-2021	Lesluyes, Tom/0000-0003-2251-5884; Lesluyes, Tom/0000-0003-2251-5884; Leroy, Laura/0000-0002-6804-2245; Delespaul, Lucile/0000-0002-9509-6425	Fondation ARC pour la recherche contre le cancer; "Fondation pour la recherche medicale" (FRM); association "Phil'Anthrope"; association "Pour Corentin"	Fondation ARC pour la recherche contre le cancer; "Fondation pour la recherche medicale" (FRM)(Fondation pour la Recherche Medicale); association "Phil'Anthrope"; association "Pour Corentin"	This work was supported by the "Fondation ARC pour la recherche contre le cancer", "the Fondation pour la recherche medicale" (FRM), and the associations "Phil'Anthrope" and "Pour Corentin".	Aichel O, 1911, ZELLVERSCHMELZUNG QU; Berndt Benjamin, 2013, Critical Reviews in Oncogenesis, V18, P97; Broncy L, 2018, J LAB PRECIS MED, V3; Chakraborty A, 2004, BONE MARROW TRANSPL, V34, P183, DOI 10.1038/sj.bmt.1704547; Chibon F, 2003, CANCER GENET CYTOGEN, V141, P75, DOI 10.1016/S0165-4608(02)00664-7; Chibon F, 2002, CANCER GENET CYTOGEN, V139, P24, DOI 10.1016/S0165-4608(02)00614-3; Chibon F, 2010, NAT MED, V16, P781, DOI 10.1038/nm.2174; Cooke MS, 2003, FASEB J, V17, P1195, DOI 10.1096/fj.02-0752rev; Davoli T, 2013, CELL, V155, P948, DOI 10.1016/j.cell.2013.10.011; Delespaul L, 2019, ONCOGENE; Dittmar T, 2015, INT J MOL SCI, V16, P30362, DOI 10.3390/ijms161226240; Dittmar T, 2011, CLIN EXP METASTAS, V28, P75, DOI 10.1007/s10585-010-9359-3; Dodd Rebecca D, 2015, Methods Mol Biol, V1267, P283, DOI 10.1007/978-1-4939-2297-0_13; Dodd RD, 2010, DIS MODEL MECH, V3, P557, DOI 10.1242/dmm.005223; Duelli D, 2003, CANCER CELL, V3, P445, DOI 10.1016/S1535-6108(03)00114-4; Duelli DM, 2005, J CELL BIOL, V171, P493, DOI 10.1083/jcb.200507069; Duelli DM, 2007, CURR BIOL, V17, P431, DOI 10.1016/j.cub.2007.01.049; Durrieu-Gaillard S, 2018, CELL CYCLE, V17, P605, DOI 10.1080/15384101.2017.1405881; Gao RL, 2016, NAT GENET, V48, P1119, DOI 10.1038/ng.3641; Garvin S, 2018, J CANCER RES CLIN, V144, P1253, DOI 10.1007/s00432-018-2646-0; Gast CE, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aat7828; Gibault L, 2011, J PATHOL, V223, P64, DOI 10.1002/path.2787; Glinsky GV, 2004, J CLIN INVEST, V113, P913, DOI 10.1172/JCI200420032; Goldenberg DM, 2012, EXPERT OPIN BIOL TH, V12, pS133, DOI 10.1517/14712598.2012.671807; Gordon DJ, 2012, NAT REV GENET, V13, P189, DOI 10.1038/nrg3123; Guillou L, 2010, VIRCHOWS ARCH, V456, P201, DOI 10.1007/s00428-009-0853-4; Gupta PB, 2005, COLD SH Q B, V70, P291, DOI 10.1101/sqb.2005.70.033; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Han ZY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10421; Haurie V, 2010, P NATL ACAD SCI USA, V107, P4176, DOI 10.1073/pnas.0914980107; Hernando E, 2007, NAT MED, V13, P748, DOI 10.1038/nm1560; Jemaa M, 2017, ONCOTARGET, V8, P16669, DOI 10.18632/oncotarget.14291; Jiang EH, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/5013592; JOHNSON RT, 1970, NATURE, V226, P717, DOI 10.1038/226717a0; KERBEL RS, 1983, MOL CELL BIOL, V3, P523, DOI 10.1128/MCB.3.4.523; Kirsch DG, 2007, NAT MED, V13, P992, DOI 10.1038/nm1602; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Laberge GS, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8020170; LaBerge GS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0168581; Lagarde P., 2015, AUSTIN J GENET GENOM, V2, P1014; Lagarde P, 2013, J CLIN ONCOL, V31, P608, DOI 10.1200/JCO.2012.46.0147; Lagarde P, 2012, CLIN CANCER RES, V18, P826, DOI 10.1158/1078-0432.CCR-11-1610; Lartigue L, 2015, EUR J CANCER, V51, P75, DOI 10.1016/j.ejca.2014.10.014; Lazar AJ, 2017, CELL, V171, P950, DOI 10.1016/j.cell.2017.10.014; Lazebnik Y, 2014, CELL CYCLE, V13, P2323, DOI 10.4161/cc.29704; Lazova R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066731; Lu X, 2009, CANCER RES, V69, P8536, DOI 10.1158/0008-5472.CAN-09-2159; Magdalou I, 2014, SEMIN CELL DEV BIOL, V30, P154, DOI 10.1016/j.semcdb.2014.04.035; Mairal A, 1999, CANCER GENET CYTOGEN, V111, P134, DOI 10.1016/S0165-4608(98)00227-1; Massague J, 2017, MOL ONCOL, V11, P3, DOI 10.1002/1878-0261.12024; Melzer C, 2019, CANCERS, V11, DOI 10.3390/cancers11020185; Mitelman F, 2007, NAT REV CANCER, V7, P233, DOI 10.1038/nrc2091; Mohr M, 2015, METHODS MOL BIOL, P21, DOI 10.1007/978-1-4939-2703-6_2; Notta F, 2016, NATURE, V538, P378, DOI 10.1038/nature19823; Pachmayr E, 2017, VISC MED, V33, P11, DOI 10.1159/000454696; Powell AE, 2011, CANCER RES, V71, P1497, DOI 10.1158/0008-5472.CAN-10-3223; Rachkovsky M, 1998, CLIN EXP METASTAS, V16, P299; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; Rarnanathan A, 2005, P NATL ACAD SCI USA, V102, P5992, DOI 10.1073/pnas.0502267102; Riggi N, 2018, ANNU REV PATHOL-MECH, V13, P117, DOI 10.1146/annurev-pathol-020117-044127; Rizvi AZ, 2006, P NATL ACAD SCI USA, V103, P6321, DOI 10.1073/pnas.0508593103; Searles Stephen C, 2018, Oncotarget, V9, P6156, DOI 10.18632/oncotarget.23715; Seyfried Thomas N., 2013, Critical Reviews in Oncogenesis, V18, P43; Shabo I, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1935-0; Steele CD, 2019, CANCER CELL, V35, P441, DOI 10.1016/j.ccell.2019.02.002; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Turajlic S, 2019, NAT REV GENET, V20, P404, DOI 10.1038/s41576-019-0114-6; Turajlic S, 2018, CELL, V173, P581, DOI 10.1016/j.cell.2018.03.057; van de Vijver MJ, 2009, GENE EXPRESSION SIGN, DOI [10.1056/NEJMoa021967, DOI 10.1056/NEJMOA021967]; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wang RX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042653; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Weimann JM, 2003, NAT CELL BIOL, V5, P959, DOI 10.1038/ncb1053; Xue JG, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1780-1; Yilmaz Y, 2005, BONE MARROW TRANSPL, V35, P1021, DOI 10.1038/sj.bmt.1704939; Zhang S, 2014, ONCOGENE, V33, P116, DOI 10.1038/onc.2013.96; Zhou XF, 2015, AM J PATHOL, V185, P2049, DOI 10.1016/j.ajpath.2015.03.014	79	12	12	3	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	21					4198	4211		10.1038/s41388-020-1276-6	http://dx.doi.org/10.1038/s41388-020-1276-6		APR 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LQ2DH	32242148				2022-12-28	WOS:000522996500002
J	Tian, Q; Yuan, P; Quan, CT; Li, MY; Xiao, JJ; Zhang, L; Lu, H; Ma, TF; Zou, L; Wang, F; Xue, PP; Ni, XF; Wang, W; Liu, L; Wang, Z; Zhu, F; Duan, QH				Tian, Qin; Yuan, Ping; Quan, Chuntao; Li, Mingyang; Xiao, Juanjuan; Zhang, Lu; Lu, Hui; Ma, Tengfei; Zou, Ling; Wang, Fei; Xue, Peipei; Ni, Xiaofang; Wang, Wei; Liu, Lin; Wang, Zhe; Zhu, Feng; Duan, Qiuhong			Phosphorylation of BCKDK of BCAA catabolism at Y246 by Src promotes metastasis of colorectal cancer	ONCOGENE			English	Article							AMINO-ACID-METABOLISM; HEPATOCELLULAR-CARCINOMA; MESENCHYMAL TRANSITION; CELL-PROLIFERATION; TYROSINE KINASES; FAMILY KINASES; TARGETING SRC; GROWTH; PROGRESSION; ACTIVATION	Branched-chain alpha-keto acid dehydrogenase kinase (BCKDK), the key enzyme of branched-chain amino acids (BCAAs) metabolism, has been reported to promote colorectal cancer (CRC) tumorigenesis by upregulating the MEK-ERK signaling pathway. However, the profile of BCKDK in metastatic colorectal cancer (mCRC) remains unknown. Here, we report a novel role of BCKDK in mCRC. BCKDK is upregulated in CRC tissues. Increased BCKDK expression was associated with metastasis and poor clinical prognosis in CRC patients. Knockdown of BCKDK decreased CRC cell migration and invasion ex vivo, and lung metastasis in vivo. BCKDK promoted the epithelial mesenchymal transition (EMT) program, by decreasing the expression of E-cadherin, epithelial marker, and increasing the expression of N-cadherin and Vimentin, which are mesenchymal markers. Moreover, BCKDK-knockdown experiments in combination with phosphoproteomics analysis revealed the potent role of BCKDK in modulating multiple signal transduction pathways, including EMT and metastasis. Src phosphorylated BCKDK at the tyrosine 246 (Y246) site in vitro and ex vivo. Knockdown and knockout of Src downregulated the phosphorylation of BCKDK. Importantly, phosphorylation of BCKDK by Src enhanced the activity and stability of BCKDK, thereby promoting the migration, invasion, and EMT of CRC cells. In summary, the identification of BCKDK as a novel prometastatic factor in human CRC will be beneficial for further diagnostic biomarker studies and suggests novel targeting opportunities.	[Tian, Qin; Yuan, Ping; Xiao, Juanjuan; Zhang, Lu; Lu, Hui; Ma, Tengfei; Zou, Ling; Wang, Fei; Ni, Xiaofang; Wang, Wei; Liu, Lin; Zhu, Feng; Duan, Qiuhong] Huazhong Univ Sci & Technol, Sch Basic Med, Dept Biochem & Mol Biol, Wuhan 430030, Hubei, Peoples R China; [Quan, Chuntao] Huazhong Univ Sci & Technol, Tongji Sch Pharm, Wuhan 430030, Hubei, Peoples R China; [Li, Mingyang; Wang, Zhe] Fourth Mil Med Univ, Xijing Hosp, Dept Pathol, State Key Lab Canc Biol, Xian 710032, Peoples R China; [Li, Mingyang; Wang, Zhe] Fourth Mil Med Univ, Sch Basic Med, Xian 710032, Peoples R China; [Xiao, Juanjuan; Zhu, Feng] Guilin Med Univ, Affiliated Hosp, Canc Res Inst, Guilin 541000, Guangxi, Peoples R China; [Xue, Peipei] Populat & Family Planning Sci & Technol Res Inst, Key Lab Birth Defects & Reprod Hlth, Natl Hlth & Family Planning Commiss, Chongqing 400020, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Air Force Military Medical University; Air Force Military Medical University; Guilin Medical University	Zhu, F; Duan, QH (corresponding author), Huazhong Univ Sci & Technol, Sch Basic Med, Dept Biochem & Mol Biol, Wuhan 430030, Hubei, Peoples R China.; Wang, Z (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Pathol, State Key Lab Canc Biol, Xian 710032, Peoples R China.; Wang, Z (corresponding author), Fourth Mil Med Univ, Sch Basic Med, Xian 710032, Peoples R China.; Zhu, F (corresponding author), Guilin Med Univ, Affiliated Hosp, Canc Res Inst, Guilin 541000, Guangxi, Peoples R China.	zhwang@fmmu.edu.cn; fengzhu@hust.edu.cn; duanqhwz@hust.edu.cn	Li, Mingyang/C-2324-2018	Li, Mingyang/0000-0003-1766-7867	National Natural Science Foundation of China [81972762, 81672936, 81672739, 81902849, 81503105]; Independent innovation project of Huazhong University of Science and Technology [2018KFYYXJJ084, 2016YXZD034]; Hubei Province Health and Family Planning Scientific Research Project [WJ2019M109]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Independent innovation project of Huazhong University of Science and Technology; Hubei Province Health and Family Planning Scientific Research Project	This study was supported by the National Natural Science Foundation of China (Nos. 81972762, 81672936, 81672739, 81902849, and 81503105). The Independent innovation project of Huazhong University of Science and Technology (Nos. 2018KFYYXJJ084 and 2016YXZD034). Hubei Province Health and Family Planning Scientific Research Project (Nos. WJ2019M109).	Allgayer H, 2002, CANCER, V94, P344, DOI 10.1002/cncr.10221; Ananieva EA, 2018, CURR OPIN CLIN NUTR, V21, P64, DOI 10.1097/MCO.0000000000000430; Antoni S, 2016, B WORLD HEALTH ORGAN, V94, P174, DOI 10.2471/BLT.15.164384; Beaudet AL, 2012, SCIENCE, V338, P342, DOI 10.1126/science.1229178; Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9; Burrage LC, 2014, HUM MOL GENET, V23, pR1, DOI 10.1093/hmg/ddu123; Cao H, 2015, PATHOL RES PRACT, V211, P557, DOI 10.1016/j.prp.2015.05.010; Montero JC, 2011, CLIN CANCER RES, V17, P5546, DOI 10.1158/1078-0432.CCR-10-2616; Cheon S, 2019, P NATL ACAD SCI USA, V116, P3662, DOI 10.1073/pnas.1818751116; Christofk HR, 2008, NATURE, V452, P181, DOI 10.1038/nature06667; Dey P, 2017, NATURE, V542, P119, DOI 10.1038/nature21052; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harris RA, 2005, J NUTR, V135, p1527S, DOI 10.1093/jn/135.6.1527S; Hattori A, 2017, NATURE, V545, P500, DOI 10.1038/nature22314; Katagiri R, 2018, GASTROENTEROLOGY, V155, P1474, DOI 10.1053/j.gastro.2018.07.033; Kim JY, 2013, P NATL ACAD SCI USA, V110, P12414, DOI 10.1073/pnas.1220674110; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lieu C, 2010, CLIN COLORECTAL CANC, V9, P89, DOI 10.3816/CCC.2010.n.012; Liu KA, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-6; Martinez-Perez J, 2017, HUM PATHOL, V67, P119, DOI 10.1016/j.humpath.2017.05.025; Matysiak M, 2017, ARCH GYNECOL OBSTET, V295, P817, DOI 10.1007/s00404-017-4304-1; Mayers JR, 2017, CANCER RES, V77, P3131, DOI 10.1158/0008-5472.CAN-17-0165; Mayers JR, 2016, SCIENCE, V353, P1161, DOI 10.1126/science.aaf5171; Mochel F, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000647; Nelson ER, 2013, SCIENCE, V342, P1094, DOI 10.1126/science.1241908; Olea-Flores M, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8101133; Panosyan EH, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3148-1; Patra KC, 2013, CANCER CELL, V24, P213, DOI 10.1016/j.ccr.2013.06.014; Polonio-Vallon T, 2014, CELL CYCLE, V13, P115, DOI 10.4161/cc.26857; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; Schwartz D, 2005, NAT BIOTECHNOL, V23, P1391, DOI 10.1038/nbt1146; Seeber A, 2016, ONCOL RES TREAT, V39, P796, DOI 10.1159/000453027; Shiozawa S, 2016, J NIPPON MED SCH, V83, P248, DOI 10.1272/jnms.83.248; Singh V, 2017, PROTEIN J, V36, P1, DOI 10.1007/s10930-017-9696-z; Suryawan A, 1998, AM J CLIN NUTR, V68, P72, DOI 10.1093/ajcn/68.1.72; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Tauriello DVF, 2017, MOL ONCOL, V11, P97, DOI 10.1002/1878-0261.12018; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Tonjes M, 2013, NAT MED, V19, P901, DOI 10.1038/nm.3217; Tso SC, 2014, J BIOL CHEM, V289, P20583, DOI 10.1074/jbc.M114.569251; Varkaris A, 2014, CANCER METAST REV, V33, P595, DOI 10.1007/s10555-013-9481-1; Wang TJ, 2011, NAT MED, V17, P448, DOI 10.1038/nm.2307; Wang ZQ, 2015, ONCOTARGET, V6, P31522, DOI 10.18632/oncotarget.5159; White PJ, 2018, CELL METAB, V27, P1281, DOI 10.1016/j.cmet.2018.04.015; Xue PP, 2017, EBIOMEDICINE, V20, P50, DOI 10.1016/j.ebiom.2017.05.001; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Yi TF, 2014, P NATL ACAD SCI USA, V111, P11223, DOI 10.1073/pnas.1411381111; Yoo PS, 2006, CLIN COLORECTAL CANC, V6, P202, DOI 10.3816/CCC.2006.n.036; Zhang L, 2017, BIOCHEM BIOPH RES CO, V486, P224, DOI 10.1016/j.bbrc.2017.02.101; Zhang SY, 2012, TRENDS PHARMACOL SCI, V33, P122, DOI 10.1016/j.tips.2011.11.002; Zhang SY, 2011, NAT MED, V17, P461, DOI 10.1038/nm.2309; Zheng YH, 2016, LIVER INT, V36, P1836, DOI 10.1111/liv.13178	55	14	14	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	20					3980	3996		10.1038/s41388-020-1262-z	http://dx.doi.org/10.1038/s41388-020-1262-z		APR 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LN3GC	32238881	Green Published, hybrid			2022-12-28	WOS:000522804800001
J	De Piano, M; Manuelli, V; Zadra, G; Otte, J; Edqvist, PHD; Ponten, F; Nowinski, S; Niaouris, A; Grigoriadis, A; Loda, M; Van Hemelrijck, M; Wells, CM				De Piano, Mario; Manuelli, Valeria; Zadra, Giorgia; Otte, Jonathan; Edqvist, Per-Henrik D.; Ponten, Fredrik; Nowinski, Salpie; Niaouris, Athanasios; Grigoriadis, Anita; Loda, Massimo; Van Hemelrijck, Mieke; Wells, Claire M.			Lipogenic signalling modulates prostate cancer cell adhesion and migration via modification of Rho GTPases	ONCOGENE			English	Article							FATTY-ACID SYNTHASE; CDC42; EXPRESSION	Fatty acid synthase (FASN) is commonly overexpressed in prostate cancer and associated with tumour progression. FASN is responsible for de novo synthesis of the fatty acid palmitate; the building block for protein palmitoylation. Recent work has suggested that alongside its established role in promoting cell proliferation FASN may also promote invasion. We now find depletion of FASN expression increases prostate cancer cell adhesiveness, impairs HGF-mediated cell migration and reduces 3D invasion. These changes in motility suggest that FASN can mediate actin cytoskeletal remodelling; a process known to be downstream of Rho family GTPases. Here, we demonstrate that modulation of FASN expression specifically impacts on the palmitoylation of the atypical GTPase RhoU. Impaired RhoU activity in FASN depleted cells leads to reduced adhesion turnover downstream of paxillin serine phosphorylation, which is rescued by addition of exogenous palmitate. Moreover, canonical Cdc42 expression is dependent on the palmitoylation status of RhoU. Thus we uncover a novel relationship between FASN, RhoU and Cdc42 that directly influences cell migration potential. These results provide compelling evidence that FASN activity directly promotes cell migration and supports FASN as a potential therapeutic target in metastatic prostate cancer.	[De Piano, Mario; Manuelli, Valeria; Nowinski, Salpie; Niaouris, Athanasios; Grigoriadis, Anita; Van Hemelrijck, Mieke; Wells, Claire M.] Kings Coll London, Sch Canc & Pharmaceut Sci, London SE1 1UL, England; [Zadra, Giorgia; Loda, Massimo] Harvard Med Sch, Dana Farber Canc Inst, Dept Oncol Pathol, Boston, MA 02215 USA; [Zadra, Giorgia; Loda, Massimo] Harvard Med Sch, Dana Farber Canc Inst, Dept Pathol, Boston, MA 02215 USA; [Zadra, Giorgia; Loda, Massimo] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02215 USA; [Otte, Jonathan] Uppsala Univ, Dept Surg Sci, Uppsala, Sweden; [Edqvist, Per-Henrik D.; Ponten, Fredrik] Uppsala Univ, Dept Immunol Genet & Pathol, Uppsala, Sweden	University of London; King's College London; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Uppsala University; Uppsala University	Wells, CM (corresponding author), Kings Coll London, Sch Canc & Pharmaceut Sci, London SE1 1UL, England.	claire.wells@kcl.ac.uk		Van Hemelrijck, Mieke/0000-0002-7317-0858; Grigoriadis, Anita/0000-0003-3434-201X; Ponten, Fredrik/0000-0003-0703-3940; Wells, Claire/0000-0003-1926-6282	Prostate UK [S12-008]; Medical Research Council; U-CAN; DoD [PC150263]; Claudia Adams Barr Award in Innovative Basic Cancer Research	Prostate UK; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); U-CAN; DoD(United States Department of Defense); Claudia Adams Barr Award in Innovative Basic Cancer Research	MDP was supported by Prostate UK (S12-008). VM is supported by the Medical Research Council. This study was supported by U-CAN. GZ is a recipient of the DoD Idea Development Award for New Investigators (PC150263) and a Claudia Adams Barr Award in Innovative Basic Cancer Research.	Alinezhad S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155901; American Cancer Society, 2016, SURV RAT PROST CANC; Baenke F, 2013, DIS MODEL MECH, V6, P1353, DOI 10.1242/dmm.011338; Berzat AC, 2005, J BIOL CHEM, V280, P33055, DOI 10.1074/jbc.M507362200; Bright RK, 1997, CANCER RES, V57, P995; Coleman DT, 2009, MOL CANCER THER, V8, P214, DOI 10.1158/1535-7163.MCT-08-0722; Czuchra A, 2005, MOL BIOL CELL, V16, P4473, DOI 10.1091/mbc.E05-01-0061; Dart AE, 2015, J CELL BIOL, V211, P863, DOI 10.1083/jcb.201501072; Dasgupta Subhamoy, 2012, J Carcinog, V11, P4, DOI 10.4103/1477-3163.93001; De Piano M, 2017, STANDARD SUPER RESOL, P173; Flavin R, 2010, FUTURE ONCOL, V6, P551, DOI [10.2217/fon.10.11, 10.2217/FON.10.11]; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Glimelius B, 2018, ACTA ONCOL, V57, P187, DOI 10.1080/0284186X.2017.1337926; Hodge Richard G, 2020, Small GTPases, V11, P8, DOI 10.1080/21541248.2017.1362495; Kampf C, 2012, JOVE-J VIS EXP, V63; Lawson CD, 2017, J CELL BIOL, P2; Li N, 2012, NUTR CANCER, V64, P864, DOI 10.1080/01635581.2012.701704; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; NC I, CANC GEN ATL; Pascual G, 2017, NATURE, V541, P41, DOI 10.1038/nature20791; Reymond N, 2012, J CELL BIOL, V199, P653, DOI 10.1083/jcb.201205169; Swinnen JV, 2002, INT J CANCER, V98, P19, DOI 10.1002/ijc.10127; Team RC, 2015, LANG ENV STAT COMP; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Van de Sande T, 2005, J PATHOL, V206, P214, DOI 10.1002/path.1760; Wen SM, 2016, MOL CARCINOGEN, V55, P2278, DOI 10.1002/mc.22468; Whale AD, 2013, ONCOGENE, V32, P2114, DOI 10.1038/onc.2012.233; Zadra G, 2019, P NATL ACAD SCI USA, V116, P631, DOI 10.1073/pnas.1808834116; Zhang BL, 1998, J BIOL CHEM, V273, P25728, DOI 10.1074/jbc.273.40.25728	29	20	20	5	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	18					3666	3679		10.1038/s41388-020-1243-2	http://dx.doi.org/10.1038/s41388-020-1243-2		MAR 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LI5XR	32139877	Green Published, hybrid			2022-12-28	WOS:000518240300001
J	Voringer, S; Schreyer, L; Nadolni, W; Meier, MA; Woerther, K; Mittermeier, C; Ferioli, S; Singer, S; Holzer, K; Zierler, S; Chubanov, V; Liebl, B; Gudermann, T; Muehlich, S				Voringer, Sandra; Schreyer, Laura; Nadolni, Wiebke; Meier, Melanie A.; Woerther, Katharina; Mittermeier, Constanze; Ferioli, Silvia; Singer, Stephan; Holzer, Kerstin; Zierler, Susanna; Chubanov, Vladimir; Liebl, Bernhard; Gudermann, Thomas; Muehlich, Susanne			Inhibition of TRPM7 blocks MRTF/SRF-dependent transcriptional and tumorigenic activity	ONCOGENE			English	Article							SERUM RESPONSE FACTOR; KINASE-ACTIVITY; ACTIN DYNAMICS; CELL; RHOA; PHOSPHORYLATION; GROWTH	Myocardin-related transcription factors A and B (MRTFs) are coactivators of Serum Response Factor (SRF) that mediates the expression of genes involved in cell proliferation, migration and differentiation. There is mounting evidence that MRTFs and SRF represent promising targets for hepatocellular carcinoma (HCC) growth. Since MRTF-A nuclear localization is a prerequisite for its transcriptional activity and oncogenic properties, we searched for pharmacologically active compounds able to redistribute MRTF-A to the cytoplasm. We identified NS8593, a negative gating modulator of the transient receptor potential cation channel TRPM7, as a novel inhibitor of MRTF-A nuclear localization and transcriptional activity. Using a pharmacological approach and targeted genome editing, we investigated the functional contribution of TRPM7, a unique ion channel containing a serine-threonine kinase domain, to MRTF transcriptional and tumorigenic activity. We found that TRPM7 function regulates RhoA activity and subsequently actin polymerization, MRTF-A-Filamin A complex formation and MRTF-A/SRF target gene expression. Mechanistically, TRPM7 signaling relies on TRPM7 channel-mediated Mg2+ influx and phosphorylation of RhoA by TRPM7 kinase. Pharmacological blockade of TRPM7 results in oncogene-induced senescence of hepatocellular carcinoma (HCC) cells in vitro and in vivo in HCC xenografts. Hence, inhibition of the TRPM7/MRTF axis emerges as a promising strategy to curb HCC growth.	[Voringer, Sandra; Schreyer, Laura; Nadolni, Wiebke; Meier, Melanie A.; Woerther, Katharina; Mittermeier, Constanze; Ferioli, Silvia; Zierler, Susanna; Chubanov, Vladimir; Gudermann, Thomas; Muehlich, Susanne] Ludwig Maximilians Univ Munchen, Walther Straub Inst Pharmacol & Toxicol, Munich, Germany; [Singer, Stephan; Holzer, Kerstin] Univ Med Greifswald, Inst Pathol, Greifswald, Germany; [Liebl, Bernhard] LGL Bayer Landesamt Gesundheit & Lebensmittelsich, Oberschleissheim, Germany; [Schreyer, Laura; Meier, Melanie A.; Muehlich, Susanne] Friedrich Alexander Univ Erlangen Nurnberg, Dept Chem & Pharm Mol & Clin Pharm, Erlangen, Germany	University of Munich; Greifswald Medical School; Bavarian Health & Food Safety Authority; University of Erlangen Nuremberg	Muehlich, S (corresponding author), Ludwig Maximilians Univ Munchen, Walther Straub Inst Pharmacol & Toxicol, Munich, Germany.; Muehlich, S (corresponding author), Friedrich Alexander Univ Erlangen Nurnberg, Dept Chem & Pharm Mol & Clin Pharm, Erlangen, Germany.	susanne.muehlich@fau.de	Zierler, Susanna/E-2070-2012	Zierler, Susanna/0000-0002-4684-0385				Baarlink C, 2013, SCIENCE, V340, P864, DOI 10.1126/science.1235038; Bae JS, 2014, INT J ONCOL, V44, P129, DOI 10.3892/ijo.2013.2154; Blomen VA, 2015, SCIENCE, V350, P1092, DOI 10.1126/science.aac7557; Chen WL, 2015, ONCOTARGET, V6, P16321, DOI 10.18632/oncotarget.3872; Chubanov V, 2012, BRIT J PHARMACOL, V166, P1357, DOI 10.1111/j.1476-5381.2012.01855.x; Chubanov V, 2007, J BIOL CHEM, V282, P7656, DOI 10.1074/jbc.M611117200; Chubanov V, 2017, CELL CALCIUM, V67, P166, DOI 10.1016/j.ceca.2017.03.004; Chubanov V, 2016, ELIFE, V5, DOI 10.7554/eLife.20914; Clark K, 2006, EMBO J, V25, P290, DOI 10.1038/sj.emboj.7600931; Clark K, 2008, J MOL BIOL, V378, P790, DOI 10.1016/j.jmb.2008.02.057; Deason-Towne F, 2012, CELL SIGNAL, V24, P2070, DOI 10.1016/j.cellsig.2012.06.015; Dorovkov MV, 2011, BIOCHEMISTRY-US, V50, P2187, DOI 10.1021/bi101963h; Ellerbroek SM, 2003, J BIOL CHEM, V278, P19023, DOI 10.1074/jbc.M213066200; Essletzbichler P, 2014, GENOME RES, V24, P2059, DOI 10.1101/gr.177220.114; Evelyn CR, 2007, MOL CANCER THER, V6, P2249, DOI 10.1158/1535-7163.MCT-06-0782; Fleig A, 2014, HANDB EXP PHARMACOL, V222, P521, DOI 10.1007/978-3-642-54215-2_21; Hampl V, 2013, EMBO MOL MED, V5, P1367, DOI 10.1002/emmm.201202406; Hayashi K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089016; Hermanns C, 2017, ONCOGENE, V36, P3464, DOI 10.1038/onc.2016.496; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; Huang JH, 2017, CELL COMMUN SIGNAL, V15, DOI 10.1186/s12964-017-0187-9; Jin J, 2012, P NATL ACAD SCI USA, V109, pE225, DOI 10.1073/pnas.1120033109; Kaitsuka T, 2014, SCI REP-UK, V4, DOI 10.1038/srep05718; Kim BJ, 2008, CANCER SCI, V99, P2502, DOI 10.1111/j.1349-7006.2008.00982.x; Kircher P, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aad2959; Krapivinsky G, 2014, CELL, V157, P1061, DOI 10.1016/j.cell.2014.03.046; Krishnamoorthy M, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aah6692; Kwon CY, 2010, INT J ONCOL, V37, P837, DOI 10.3892/ijo_00000734; Londono MC, 2015, J HEPATOL, V62, P1196, DOI 10.1016/j.jhep.2015.01.028; Lundquist MR, 2014, CELL, V156, P563, DOI 10.1016/j.cell.2013.12.035; Matsushita M, 2005, J BIOL CHEM, V280, P20793, DOI 10.1074/jbc.M413671200; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Mittermeier L, 2019, P NATL ACAD SCI USA, V116, P4706, DOI 10.1073/pnas.1810633116; Muehlich S, 2012, ONCOGENE, V31, P3913, DOI 10.1038/onc.2011.560; Nadler MJS, 2001, NATURE, V411, P590, DOI 10.1038/35079092; Ohrnberger S, 2015, HEPATOLOGY, V61, P979, DOI 10.1002/hep.27539; Olson EN, 2010, NAT REV MOL CELL BIO, V11, P353, DOI 10.1038/nrm2890; Perraud AL, 2011, CELL SIGNAL, V23, P586, DOI 10.1016/j.cellsig.2010.11.011; Prevarskaya N, 2010, TRENDS MOL MED, V16, P107, DOI 10.1016/j.molmed.2010.01.005; Rolli-Derkinderen M, 2005, CIRC RES, V96, P1152, DOI 10.1161/01.RES.0000170084.88780.ea; Romagnani A, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01960-z; Ryazanova LV, 2004, J BIOL CHEM, V279, P3708, DOI 10.1074/jbc.M308820200; Rybarczyk P, 2017, NEOPLASIA, V19, P288, DOI 10.1016/j.neo.2017.01.004; Schmitz C, 2003, CELL, V114, P191, DOI 10.1016/S0092-8674(03)00556-7; Su LT, 2011, BIOCHEM J, V434, P513, DOI 10.1042/BJ20101678; Thompson AI, 2015, BMC GASTROENTEROL, V15, DOI 10.1186/s12876-015-0291-5; Tong JF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147103; Wang ZY, 2015, HISTOCHEM CELL BIOL, V144, P39, DOI 10.1007/s00418-015-1311-9; Winkles JA, 1998, PROG NUCLEIC ACID RE, V58, P41; Yee NS, 2017, PHARMACEUTICALS-BASE, V10, DOI 10.3390/ph10020039; Yee Nelson S, 2014, Cells, V3, P751, DOI 10.3390/cells3030751; Yee NS, 2012, SCIENTIFICA, V2012, DOI 10.6064/2012/415158; Yu-Wai-Man C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00212-w	53	17	17	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	11					2328	2344		10.1038/s41388-019-1140-8	http://dx.doi.org/10.1038/s41388-019-1140-8			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KU0ZS	31844251				2022-12-28	WOS:000519440400007
J	Lucia, K; Wu, YH; Garcia, JM; Barlier, A; Buchfelder, M; Saeger, W; Renner, U; Stalla, GK; Theodoropoulou, M				Lucia, Kristin; Wu, Yonghe; Garcia, Jose Monteserin; Barlier, Anne; Buchfelder, Michael; Saeger, Wolfgang; Renner, Ulrich; Stalla, Guenter K.; Theodoropoulou, Marily			Hypoxia and the hypoxia inducible factor 1 alpha activate protein kinase A by repressing RII beta subunit transcription	ONCOGENE			English	Article							REGULATORY SUBUNIT; CATALYTIC SUBUNIT; GENE-EXPRESSION; DNA-BINDING; DIFFERENTIAL EXPRESSION; GROWTH-HORMONE; LUNG-CANCER; CELL-GROWTH; I-ALPHA; PHOSPHORYLATION	Overactivation of the cAMP signal transduction pathway plays a central role in the pathogenesis of endocrine tumors. Genetic aberrations leading to increased intracellular cAMP or directly affecting PKA subunit expression have been identified in inherited and sporadic endocrine tumors, but are rare indicating the presence of nongenomic pathological PKA activation. In the present study, we examined the impact of hypoxia on PKA activation using human growth hormone (GH)-secreting pituitary tumors as a model of an endocrine disease displaying PKA-CREB overactivation. We show that hypoxia activates PKA and enhances CREB transcriptional activity and subsequently GH oversecretion. This is due to a previously uncharacterized ability of HIF-1 alpha to suppress the transcription of the PKA regulatory subunit 2B (PRKAR2B) by sequestering Sp1 from the PRKAR2B promoter. The present study reveals a novel mechanism through which the transcription factor HIF-1 alpha transduces environmental signals directly onto PKA activity, without affecting intracellular cAMP concentrations. By identifying a point of interaction between the cellular microenvironment and intracellular enzyme activation, neoplastic, and nonneoplastic diseases involving overactivated PKA pathway may be more efficiently targeted.	[Lucia, Kristin; Garcia, Jose Monteserin; Renner, Ulrich; Stalla, Guenter K.; Theodoropoulou, Marily] Max Planck Inst Psychiat, Dept Endocrinol, Munich, Germany; [Lucia, Kristin; Stalla, Guenter K.; Theodoropoulou, Marily] Ludwig Maximilians Univ Munchen, Med Klin & Poliklin 4, Munich, Germany; [Lucia, Kristin; Wu, Yonghe] Deutsch Krebsforschungszentrum, Div Mol Genet, Heidelberg, Germany; [Barlier, Anne] Ctr Rech Neurobiol & Neurophysiol Marseille, Marseille, France; [Buchfelder, Michael] Klinikum Univ Erlangen, Dept Neurosurg, Erlangen, Germany; [Saeger, Wolfgang] Univ Hamburg, Dept Neuropathol, Hamburg, Germany; [Lucia, Kristin] Charite, Dept Neurosurg, Berlin, Germany	Max Planck Society; University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ); UDICE-French Research Universities; Aix-Marseille Universite; University of Erlangen Nuremberg; University of Hamburg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Theodoropoulou, M (corresponding author), Max Planck Inst Psychiat, Dept Endocrinol, Munich, Germany.; Theodoropoulou, M (corresponding author), Ludwig Maximilians Univ Munchen, Med Klin & Poliklin 4, Munich, Germany.	marily.theodoropoulou@med.uni-muechen.de	Wu, Yonghe/N-2269-2019; Monteserin-Garcia, Jose Luis/AAC-7052-2020; Theodoropoulou, Marily/S-9546-2017; Barlier, Anne/G-2398-2015	Wu, Yonghe/0000-0001-9667-8198; Monteserin-Garcia, Jose Luis/0000-0002-4508-6771; Theodoropoulou, Marily/0000-0002-7378-4374; Barlier, Anne/0000-0002-3740-6173	Projekt DEAL	Projekt DEAL	Open access funding provided by Projekt DEAL.	ADAMS JA, 1992, BIOCHEMISTRY-US, V31, P8516, DOI 10.1021/bi00151a019; Amieux PS, 1997, J BIOL CHEM, V272, P3993, DOI 10.1074/jbc.272.7.3993; ARZT E, 1993, ENDOCRINOLOGY, V132, P459, DOI 10.1210/en.132.1.459; Barlier A, 1998, J CLIN ENDOCR METAB, V83, P1604, DOI 10.1210/jc.83.5.1604; Barry S, 2019, ONCOGENE, V38, P5381, DOI 10.1038/s41388-019-0779-5; Basso F, 2014, HORM METAB RES, V46, P883, DOI 10.1055/s-0034-1389951; BERTHERAT J, 1995, MOL ENDOCRINOL, V9, P777, DOI 10.1210/me.9.7.777; Bertout JA, 2008, NAT REV CANCER, V8, P967, DOI 10.1038/nrc2540; Beuschlein F, 2014, NEW ENGL J MED, V370, P1019, DOI 10.1056/NEJMoa1310359; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; Brandon EP, 1998, J NEUROSCI, V18, P3639; Bullen JW, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaf0583; Canettieri G, 2003, NAT STRUCT BIOL, V10, P175, DOI 10.1038/nsb895; Carlucci A, 2008, EMBO J, V27, P1073, DOI 10.1038/emboj.2008.33; Cheong HI, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.90240; Elliott MR, 2003, J IMMUNOL, V171, P3636, DOI 10.4049/jimmunol.171.7.3636; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Ezzat S, 2005, MOL ENDOCRINOL, V19, P1004, DOI 10.1210/me.2004-0432; Finger EC, 2015, P NATL ACAD SCI USA, V112, P4441, DOI 10.1073/pnas.1418164112; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HANDSCHIN JC, 1979, FEBS LETT, V106, P301, DOI 10.1016/0014-5793(79)80519-0; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hayward BE, 2001, J CLIN INVEST, V107, pR31, DOI 10.1172/JCI11887; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Katznelson L, 2014, J CLIN ENDOCR METAB, V99, P3933, DOI 10.1210/jc.2014-2700; Kietzmann T, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00011; Kim C, 2007, CELL, V130, P1032, DOI 10.1016/j.cell.2007.07.018; Kirschner LS, 2000, NAT GENET, V26, P89, DOI 10.1038/79238; Kitagawa K, 2007, FEBS J, V274, P3210, DOI 10.1111/j.1742-4658.2007.05890.x; Koshiji M, 2005, MOL CELL, V17, P793, DOI 10.1016/j.molcel.2005.02.015; Krishnamachary B, 2006, CANCER RES, V66, P2725, DOI 10.1158/0008-5472.CAN-05-3719; KURTEN RC, 1992, MOL ENDOCRINOL, V6, P536, DOI 10.1210/me.6.4.536; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; Melmed S, 2009, J CLIN INVEST, V119, P3189, DOI 10.1172/JCI39375; Michael LF, 2000, MOL CELL BIOL, V20, P1596, DOI 10.1128/MCB.20.5.1596-1603.2000; Michel G, 2002, BBA-GENE STRUCT EXPR, V1578, P73, DOI 10.1016/S0167-4781(02)00484-0; Mole DR, 2009, J BIOL CHEM, V284, P16767, DOI 10.1074/jbc.M901790200; Nesterova M, 1996, EUR J BIOCHEM, V235, P486, DOI 10.1111/j.1432-1033.1996.00486.x; Pagotto U, 2000, CANCER RES, V60, P6794; Prabu SK, 2006, J BIOL CHEM, V281, P2061, DOI 10.1074/jbc.M507741200; Pullamsetti SS, 2013, ONCOGENE, V32, P1121, DOI 10.1038/onc.2012.136; Ronchi CL, 2016, EUR J ENDOCRINOL, V174, P363, DOI 10.1530/EJE-15-1064; Ryan HE, 2000, CANCER RES, V60, P4010; Sandrini F, 2002, GENE CHROMOSOME CANC, V35, P182, DOI 10.1002/gcc.10112; Sandrini F, 2002, J Med Genet, V39, pe78, DOI 10.1136/jmg.39.12.e78; Seagroves TN, 2001, MOL CELL BIOL, V21, P3436, DOI 10.1128/MCB.21.10.3436-3444.2001; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 2017, EMBO J, V36, P252, DOI 10.15252/embj.201695204; Semenza GL, 2013, J CLIN INVEST, V123, P3664, DOI 10.1172/JCI67230; Shaikh D, 2012, CELL SIGNAL, V24, P2396, DOI 10.1016/j.cellsig.2012.08.007; Skalhegg BS, 2000, FRONT BIOSCI-LANDMRK, V5, pD678, DOI 10.2741/Skalhegg; STALLA GK, 1989, ENDOCRINOLOGY, V125, P699, DOI 10.1210/endo-125-2-699; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; Taylor SS, 2004, BBA-PROTEINS PROTEOM, V1697, P259, DOI 10.1016/j.bbapap.2003.11.029; Taylor SS, 2012, NAT REV MOL CELL BIO, V13, P646, DOI 10.1038/nrm3432; Theodoropoulou M, 2004, ENDOCR-RELAT CANCER, V11, P333, DOI 10.1677/erc.0.0110333; Theodoropoulou M, 2006, CANCER RES, V66, P1576, DOI 10.1158/0008-5472.CAN-05-1189; Toffoli S, 2007, BBA-MOL CELL RES, V1773, P1558, DOI 10.1016/j.bbamcr.2007.06.002; TORTORA G, 1994, ONCOGENE, V9, P3233; Tsigginou A, 2012, ENDOCR-RELAT CANCER, V19, P457, DOI 10.1530/ERC-11-0328; Turner HE, 2000, J CLIN ENDOCR METAB, V85, P1159, DOI 10.1210/jc.85.3.1159; Valimaki N, 2015, J CLIN ENDOCR METAB, V100, P3918, DOI 10.1210/jc.2015-3129; Vitali E, 2014, MOL CELL ENDOCRINOL, V383, P193, DOI 10.1016/j.mce.2013.12.006; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; Zhong H, 1999, CANCER RES, V59, P5830	71	11	11	2	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2020	39	16					3367	3380		10.1038/s41388-020-1223-6	http://dx.doi.org/10.1038/s41388-020-1223-6		FEB 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF9OJ	32111982	Green Published, hybrid			2022-12-28	WOS:000517049100001
J	Wang, JQ; He, CX; Gao, P; Wang, SQ; Lv, RT; Zhou, HH; Zhou, QD; Zhang, K; Sun, J; Fan, CB; Ding, GX; Lan, F				Wang, Jianqing; He, Chenxi; Gao, Peng; Wang, Siqing; Lv, Ruitu; Zhou, Huihui; Zhou, Qidong; Zhang, Ke; Sun, Jian; Fan, Caibin; Ding, Guanxiong; Lan, Fei			HNF1B-mediated repression of SLUG is suppressed by EZH2 in aggressive prostate cancer	ONCOGENE			English	Article							GENOME-WIDE ASSOCIATION; GROUP PROTEIN EZH2; E-CADHERIN; TRANSCRIPTION FACTORS; STEM-CELLS; POLYCOMB; GENE; LOCI; RISK; EXPRESSION	Prostate cancer is the most common malignancy in men in developed countries. Overexpression of enhancer of zeste homolog 2 (EZH2), the major histone H3 lysine 27 methyltransferase, has been connected to prostate cancer malignancy. However, its downstream genes and pathways have not been well established. Here, we show tumor suppressor Hepatocyte Nuclear Factor 1 beta (HNF1B) as a direct downstream target of EZH2. EZH2 binds HNF1B locus and suppresses HNF1B expression in prostate cancer cell lines, which is further supported by the reverse correlation between EZH2 and HNF1B expression in clinical samples. Consistently, restored HNF1B expression significantly suppresses EZH2-mediated overgrowth and EMT processes, including migration and invasion of prostate cancer cell lines. Mechanistically, we find that HNF1B primarily binds the promoters of thousands of target genes, and differentially regulates the expression of 876 genes. We also identify RBBP7/RbAP46 as a HNF1B interacting protein which is required for HNF1B-mediated repression of SLUG expression and EMT process. Importantly, we find that higher HNF1B expression strongly predicts better prognosis of prostate cancer, alone or together with lower EZH2 expression. Taken together, we have established a previously underappreciated axis of EZH2-HNF1B-SLUG in prostate cancer, and also provide evidence supporting HNF1B as a potential prognosis marker for metastatic prostate cancer.	[Wang, Jianqing; Zhang, Ke; Sun, Jian; Fan, Caibin] Nanjing Med Univ, Affiliated Suzhou Hosp, Dept Urol, Suzhou 215002, Jiangsu, Peoples R China; [He, Chenxi; Wang, Siqing; Lv, Ruitu; Lan, Fei] Fudan Univ, Inst Biomed Sci, Key Lab Epigenet & Metab, Minist Sci & Technol, Shanghai 200032, Peoples R China; [He, Chenxi; Wang, Siqing; Lv, Ruitu; Lan, Fei] Fudan Univ, Key Lab Carcinogenesis & Canc Invas, Minist Educ, Liver Canc Inst,Zhongshan Hosp, Shanghai 200032, Peoples R China; [Gao, Peng; Zhou, Qidong; Ding, Guanxiong] Fudan Univ, Huashan Hosp, Dept Urol, Shanghai, Peoples R China; [Zhou, Huihui] Qingdao Univ, Affiliated Yuhuangding Hosp, Dept Pathol, Qingdao 266071, Shandong, Peoples R China	Nanjing Medical University; Fudan University; Fudan University; Fudan University; Qingdao University	Wang, JQ (corresponding author), Nanjing Med Univ, Affiliated Suzhou Hosp, Dept Urol, Suzhou 215002, Jiangsu, Peoples R China.; Lan, F (corresponding author), Fudan Univ, Inst Biomed Sci, Key Lab Epigenet & Metab, Minist Sci & Technol, Shanghai 200032, Peoples R China.; Lan, F (corresponding author), Fudan Univ, Key Lab Carcinogenesis & Canc Invas, Minist Educ, Liver Canc Inst,Zhongshan Hosp, Shanghai 200032, Peoples R China.; Ding, GX (corresponding author), Fudan Univ, Huashan Hosp, Dept Urol, Shanghai, Peoples R China.	jqwang14@fudan.edu.cn; dingguanxiong1981@126.com; fei_lan@fudan.edu.cn	Wang, Siqing/K-6662-2019; Lyu, Ruitu/ABU-6220-2022; Lyu, Ruitu/ABG-1437-2021	Wang, Siqing/0000-0002-6665-298X; Lyu, Ruitu/0000-0003-4597-1604; Lyu, Ruitu/0000-0003-4597-1604	National Natural Science Foundation of China [81802565, 81773014]; Natural Science Foundation of Jiangsu Province [BK20180216]; Key Project of the Scientific Research Project of Nanjing Medical University Affiliated Suzhou Hospital [szslyy2017005]; Shanghai Municipal Science and Technology Major Project [2017SHZDZX01]; National Key Research and Development program of China [2018YFA0108700]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Key Project of the Scientific Research Project of Nanjing Medical University Affiliated Suzhou Hospital; Shanghai Municipal Science and Technology Major Project; National Key Research and Development program of China	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: this study was supported by National Natural Science Foundation of China (81802565 to JW and 81773014 to FL), Natural Science Foundation of Jiangsu Province (BK20180216 to JW), Key Project of the Scientific Research Project of Nanjing Medical University Affiliated Suzhou Hospital (szslyy2017005 to JW), Shanghai Municipal Science and Technology Major Project (2017SHZDZX01 to FL), and National Key Research and Development program of China (2018YFA0108700 to FL).	BERNDTSON WE, 1991, J ANIM SCI, V69, P67; Brabletz T, 2018, NAT REV CANCER, V18, P128, DOI 10.1038/nrc.2017.118; Bryant RJ, 2007, PROSTATE, V67, P547, DOI 10.1002/pros.20550; Bubancova I, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020474; Byles V, 2012, ONCOGENE, V31, P4619, DOI 10.1038/onc.2011.612; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chang CJ, 2012, BRIT J CANCER, V106, P243, DOI 10.1038/bjc.2011.551; Chen H, 2005, J BIOL CHEM, V280, P22437, DOI 10.1074/jbc.M501379200; Dardenne E, 2016, CANCER CELL, V30, P563, DOI 10.1016/j.ccell.2016.09.005; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Fu JJ, 2011, CELL RES, V21, P275, DOI 10.1038/cr.2010.118; Gudmundsson J, 2007, NAT GENET, V39, P977, DOI 10.1038/ng2062; Gudmundsson J, 2009, NAT GENET, V41, P1122, DOI 10.1038/ng.448; Guo R, 2014, MOL CELL, V56, P298, DOI 10.1016/j.molcel.2014.08.022; Heliot C, 2013, DEVELOPMENT, V140, P873, DOI 10.1242/dev.086538; Hiesberger T, 2005, J BIOL CHEM, V280, P10578, DOI 10.1074/jbc.M414121200; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kong LC, 2016, NUCLEIC ACIDS RES, V44, P8682, DOI 10.1093/nar/gkw529; Koyanagi M, 2005, J BIOL CHEM, V280, P31470, DOI 10.1074/jbc.M504766200; Ku SY, 2017, SCIENCE, V355, P78, DOI 10.1126/science.aah4199; Lan F, 2007, NATURE, V448, P718, DOI 10.1038/nature06034; Li HJ, 2016, ONCOGENE, V35, P2266, DOI 10.1038/onc.2015.289; Li M, 2010, J BIOL CHEM, V285, P6285, DOI 10.1074/jbc.M109.057943; Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784; Martin TA, 2005, ANN SURG ONCOL, V12, P488, DOI 10.1245/ASO.2005.04.010; Mei SL, 2017, NUCLEIC ACIDS RES, V45, pD658, DOI 10.1093/nar/gkw983; Michaelis M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019705; Mikami S, 2011, LAB INVEST, V91, P1443, DOI 10.1038/labinvest.2011.111; Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100; Ren G, 2012, CANCER RES, V72, P3091, DOI 10.1158/0008-5472.CAN-11-3546; Rhodes DR, 2003, J NATL CANCER I, V95, P661, DOI 10.1093/jnci/95.9.661; Ross-Adams H, 2016, ONCOTARGET, V7, P74734, DOI 10.18632/oncotarget.12543; Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002; Schumacher FR, 2011, HUM MOL GENET, V20, P3867, DOI 10.1093/hmg/ddr295; Sellers WR, 2002, CANCER CELL, V2, P349, DOI 10.1016/S1535-6108(02)00187-3; Shen L, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-284; Shihara N, 2004, DIABETOLOGIA, V47, P1128, DOI 10.1007/s00125-004-1402-y; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sun J, 2008, NAT GENET, V40, P1153, DOI 10.1038/ng.214; Sun MN, 2017, CANCER RES, V77, P5313, DOI 10.1158/0008-5472.CAN-17-0986; Takata R, 2010, NAT GENET, V42, P751, DOI 10.1038/ng.635; Thomas G, 2008, NAT GENET, V40, P310, DOI 10.1038/ng.91; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Wang J, 2017, TUMOR BIOL, V39, p1010428317704821; Xu JF, 2012, NAT GENET, V44, P1231, DOI 10.1038/ng.2424; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Yu J, 2007, CANCER CELL, V12, P419, DOI 10.1016/j.ccr.2007.10.016; Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498; Yusa K, 2009, NAT METHODS, V6, P363, DOI [10.1038/NMETH.1323, 10.1038/nmeth.1323]	52	19	19	2	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	6					1335	1346		10.1038/s41388-019-1065-2	http://dx.doi.org/10.1038/s41388-019-1065-2			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE4UH	31636385	Green Published, hybrid			2022-12-28	WOS:000526714600012
J	Lattier, JM; De, A; Chen, ZH; Morales, JE; Lang, FF; Huse, JT; McCarty, JH				Lattier, John M.; De, Arpan; Chen, Zhihua; Morales, John E.; Lang, Frederick F.; Huse, Jason T.; McCarty, Joseph H.			Megalencephalic leukoencephalopathy with subcortical cysts 1 (MLC1) promotes glioblastoma cell invasion in the brain microenvironment	ONCOGENE			English	Article							DYSTROPHIN-GLYCOPROTEIN COMPLEX; STEM-LIKE CELLS; GLIALCAM MUTATIONS; PROTEIN; ASTROCYTES; CHANNEL; INTERACTS; SUBUNIT; GROWTH; DEFECT	Glioblastoma (GBM), or grade IV astrocytoma, is a malignant brain cancer that contains subpopulations of proliferative and invasive cells that coordinately drive primary tumor growth, progression, and recurrence after therapy. Here, we have analyzed functions for megalencephalic leukoencephalopathy with subcortical cysts 1 (Mlc1), an eight-transmembrane protein normally expressed in perivascular brain astrocyte end feet that is essential for neurovascular development and physiology, in the pathogenesis of GBM. We show that Mlc1 is expressed in human stem-like GBM cells (GSCs) and is linked to the development of primary and recurrent GBM. Genetically inhibiting MLC1 in GSCs using RNAi-mediated gene silencing results in diminished growth and invasion in vitro as well as impaired tumor initiation and progression in vivo. Biochemical assays identify the receptor tyrosine kinase Axl and its intracellular signaling effectors as important for MLC1 control of GSC invasive growth. Collectively, these data reveal key functions for MLC1 in promoting GSC growth and invasion, and suggest that targeting the Mlc1 protein or its associated signaling effectors may be a useful therapy for blocking tumor progression in patients with primary or recurrent GBM.	[Lattier, John M.; De, Arpan; Chen, Zhihua; Morales, John E.; Lang, Frederick F.; McCarty, Joseph H.] Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; [Huse, Jason T.] Univ Texas MD Anderson Canc Ctr, Translat Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	McCarty, JH (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA.	jhmccarty@mdanderson.org	De, Arpan/AAG-8512-2020	De, Arpan/0000-0001-8237-6703; Lattier, John/0000-0002-7680-668X	Cancer Prevention and Research Institute of Texas [RP180220]; National Institutes of Health [R01NS087635, R21NS103841, P50CA127001]; Brockman Foundation; Terry L. Chandler Foundation; NCI	Cancer Prevention and Research Institute of Texas; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Brockman Foundation; Terry L. Chandler Foundation; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the various members of the McCarty laboratory for insightful comments on the paper. This work was supported, in part, by grants to JHM from the Cancer Prevention and Research Institute of Texas (RP180220), the National Institutes of Health (R01NS087635, R21NS103841, and P50CA127001), the Brockman Foundation, and the Terry L. Chandler Foundation. The following NCI-funded Cancer Center Support Grant (CCSG) Core Facilities were instrumental in data acquisition: the shRNA and ORFeome Core, the Research Histopathology Facility, the Flow Cytometry and Cellular Imaging Facility, and the Sequencing and Microarray Facility.	Ambrosini E, 2008, MOL CELL NEUROSCI, V37, P480, DOI 10.1016/j.mcn.2007.11.003; Amiry-Moghaddam M, 2003, NAT REV NEUROSCI, V4, P991, DOI 10.1038/nrn1252; Amiry-Moghaddam M, 2019, CANCER RES, V79, P2810, DOI 10.1158/0008-5472.CAN-19-1185; Antony J, 2017, CANCER RES, V77, P3725, DOI 10.1158/0008-5472.CAN-17-0392; Antony J, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaf8175; Balasubramaniyan V, 2015, ONCOTARGET, V6, P31007, DOI 10.18632/oncotarget.5219; Boor I, 2007, ACTA NEUROPATHOL, V114, P403, DOI 10.1007/s00401-007-0247-0; Boor PKI, 2005, J NEUROPATH EXP NEUR, V64, P412; Brignone MS, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00106; Brignone MS, 2011, HUM MOL GENET, V20, P90, DOI 10.1093/hmg/ddq435; Capdevila-Nortes X, 2015, J PHYSIOL-LONDON, V593, P4165, DOI 10.1113/JP270467; Chen ZH, 2018, CANCER RES, V78, P3809, DOI 10.1158/0008-5472.CAN-18-0085; Dundar B, 2020, GLIA, V68, P2173, DOI 10.1002/glia.23813; Elorza-Vidal X, 2020, HUM MOL GENET, V29, P1107, DOI 10.1093/hmg/ddaa009; Gaitan-Penas H, 2017, J PHYSIOL-LONDON, V595, P6993, DOI 10.1113/JP275087; Garcia J, 2020, CANCER TREAT REV, V86, DOI 10.1016/j.ctrv.2020.102017; Gilbert A, 2019, BRAIN STRUCT FUNCT, V224, P1267, DOI 10.1007/s00429-019-01832-w; Guerrero PA, 2017, ONCOGENE, V36, P6568, DOI 10.1038/onc.2017.248; Hara A, 2019, J ONCOL, V2019, DOI 10.1155/2019/2964783; Hoegg-Beiler MB, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4475; Hwang J, 2019, MOL BRAIN, V12, DOI 10.1186/s13041-019-0540-6; Jeworutzki E, 2012, NEURON, V73, P951, DOI 10.1016/j.neuron.2011.12.039; Jhaveri N, 2016, CANCER LETT, V380, P545, DOI 10.1016/j.canlet.2014.12.028; Lanciotti A, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9061425; Lanciotti A, 2016, HUM MOL GENET, V25, P1543, DOI 10.1093/hmg/ddw032; Lanciotti A, 2012, HUM MOL GENET, V21, P2166, DOI 10.1093/hmg/dds032; Lathia JD, 2015, GENE DEV, V29, P1203, DOI 10.1101/gad.261982.115; Leegwater PAJ, 2002, HUM GENET, V110, P279, DOI 10.1007/s00439-002-0682-x; Leegwater PAJ, 2001, AM J HUM GENET, V68, P831, DOI 10.1086/319519; Leventoux N, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-62145-1; Lewis-Tuffin LJ, 2015, MOL ONCOL, V9, P1783, DOI 10.1016/j.molonc.2015.06.001; Lopez-Hernandez T, 2011, HUM MOL GENET, V20, P3266, DOI 10.1093/hmg/ddr238; Lopez-Hernandez T, 2011, AM J HUM GENET, V88, P422, DOI 10.1016/j.ajhg.2011.02.009; Ma W, 2015, MOL MED REP, V12, P1050, DOI 10.3892/mmr.2015.3492; McCarty JH, 2020, J CELL SCI, V133, DOI 10.1242/jcs.239434; Minata M, 2019, CELL REP, V26, P1893, DOI 10.1016/j.celrep.2019.01.076; Muir M, 2020, EXPERT OPIN THER TAR, V24, P605, DOI 10.1080/14728222.2020.1762568; Nishizuka SS, 2016, DRUG METAB PHARMACOK, V31, P35, DOI 10.1016/j.dmpk.2015.11.009; Onken J, 2017, ONCOTARGET, V8, P50403, DOI 10.18632/oncotarget.18468; Peglion F, 2019, CURR OPIN CELL BIOL, V60, P121, DOI 10.1016/j.ceb.2019.05.002; Rao L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16061-7; Reyes SB, 2013, MOL BIOL CELL, V24, P474, DOI 10.1091/mbc.E12-07-0521; Sadahiro H, 2018, CANCER RES, V78, P3002, DOI 10.1158/0008-5472.CAN-17-2433; Turner KL, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0095; van der Knaap MS, 2012, LANCET NEUROL, V11, P973, DOI 10.1016/S1474-4422(12)70192-8; van der Knaap MS, 2010, ANN NEUROL, V67, P834, DOI 10.1002/ana.21980; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Waite A, 2012, TRENDS NEUROSCI, V35, P487, DOI 10.1016/j.tins.2012.04.004; Wen PY, 2020, NEURO-ONCOLOGY, V22, P1073, DOI 10.1093/neuonc/noaa106	49	4	4	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2020	39	50					7253	7264		10.1038/s41388-020-01503-9	http://dx.doi.org/10.1038/s41388-020-01503-9		OCT 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PD4HE	33040087	Green Accepted			2022-12-28	WOS:000576626800001
J	Zhang, JL; Wong, CC; Leung, KT; Wu, F; Zhou, YH; Tong, JHM; Chan, RCK; Li, H; Wang, YF; Yan, H; Liu, LP; Wu, WKK; Chan, MWY; Cheng, ASL; Yu, J; Wong, NA; Lo, KW; To, KF; Kang, W				Zhang, Jinglin; Wong, Chi Chun; Leung, Kam Tong; Wu, Feng; Zhou, Yuhang; Tong, Joanna H. M.; Chan, Ronald C. K.; Li, Hui; Wang, Yifei; Yan, Huan; Liu, Liping; Wu, William K. K.; Chan, Michael W. Y.; Cheng, Alfred S. L.; Yu, Jun; Wong, Nathalie; Lo, Kwok Wai; To, Ka Fai; Kang, Wei			FGF18-FGFR2 signaling triggers the activation of c-Jun-YAP1 axis to promote carcinogenesis in a subgroup of gastric cancer patients and indicates translational potential	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; GENE AMPLIFICATION; FGFR2 GENE; CROSS-TALK; PATHWAYS; AZD4547; OVEREXPRESSION; EFFICACY; HEDGEHOG; WNT	Fibroblast growth factor receptor type 2 (FGFR2) has emerged as a key oncogenic factor that regulates gastric cancer (GC) progression, but the underlying mechanism of FGF-FGFR2 signaling pathway remains largely unknown. To identify the potential molecular mechanisms of the oncogenic FGFR2 in gastric carcinogenesis and convey a novel therapeutic strategy, we profiled the FGFR alterations and analyzed their clinical associations in TCGA and Hong Kong GC cohorts. We found that FGFR2 overexpression in GC cell lines and primary tumors predicted poor survival and was associated with advanced stages of GC. Functionally, growth abilities and cell cycle progression of GC were inhibited by inactivation of ERK-MAPK signal transduction after FGFR2 knockdown, while apoptosis was promoted. Meanwhile, the first-line anti-cancer drug sensitivity was enhanced. RNA-seq analysis further revealed that YAP1 signaling serves as a significant downstream modulator and mediates the oncogenic signaling of FGFR2. When stimulating FGFR2 by rhFGF18, we observed intensified F-actin, nuclear accumulation of YAP1, and overexpression of YAP1 targets, but these effects were attenuated by either FGFR2 depletion or AZD4547 administration. Additionally, the FGF18-FGFR2 signaling upregulated YAP1 expression through activating c-Jun, an effector of MAPK signaling. In our cohort, 28.94% of GC cases were characterized as FGFR2, c-Jun, and YAP1 co-positive and demonstrated worse clinical outcomes. Remarkably, we also found that co-targeting FGFR2 and YAP1 by AZD4547 and Verteporfin synergistically enhanced the antitumor effects in vitro and in vivo. In conclusion, we have identified the oncogenic FGF-FGFR2 regulates YAP1 signaling in GC. The findings also highlight the translational potential of FGFR2-c-Jun-YAP1 axis, which may serve as a prognostic biomarker and therapeutic target for GC.	[Zhang, Jinglin; Wu, Feng; Zhou, Yuhang; Tong, Joanna H. M.; Chan, Ronald C. K.; Li, Hui; Wang, Yifei; Yan, Huan; Lo, Kwok Wai; To, Ka Fai; Kang, Wei] Chinese Univ Hong Kong, Prince Wales Hosp, State Key Lab Translat Oncol, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China; [Zhang, Jinglin; Wong, Chi Chun; Zhou, Yuhang; Tong, Joanna H. M.; Li, Hui; Wang, Yifei; Yan, Huan; Yu, Jun; To, Ka Fai; Kang, Wei] Chinese Univ Hong Kong, State Key Lab Digest Dis, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China; [Zhang, Jinglin; Zhou, Yuhang; Tong, Joanna H. M.; Li, Hui; Wang, Yifei; Yan, Huan; Wong, Nathalie; Lo, Kwok Wai; To, Ka Fai; Kang, Wei] Chinese Univ Hong Kong, Sir YK Pao Canc Ctr, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China; [Leung, Kam Tong] Chinese Univ Hong Kong, Dept Pediat, Hong Kong, Peoples R China; [Liu, Liping] Jinan Univ, Clin Med Coll 2, Shenzhen Peoples Hosp, Dept Hepatobiliary & Pancreat Surg, Shenzhen, Guangdong, Peoples R China; [Wu, William K. K.] Chinese Univ Hong Kong, Dept Anaesthesia & Intens Care, Hong Kong, Hong Kong, Peoples R China; [Chan, Michael W. Y.] Natl Chung Cheng Univ, Dept Life Sci, Chiayi, Taiwan; [Cheng, Alfred S. L.] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China; [Yu, Jun] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China; [Wong, Nathalie] Chinese Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Jinan University; Chinese University of Hong Kong; National Chung Cheng University; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong	To, KF; Kang, W (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, State Key Lab Translat Oncol, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China.; To, KF; Kang, W (corresponding author), Chinese Univ Hong Kong, State Key Lab Digest Dis, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China.; To, KF; Kang, W (corresponding author), Chinese Univ Hong Kong, Sir YK Pao Canc Ctr, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China.	kfto@cuhk.edu.hk; weikang@cuhk.edu.hk	Leung, Kam Tong/I-8569-2017; wu, william/HII-5817-2022; KANG, Wei/C-5451-2016; Wu, William K.K./A-3277-2009	Leung, Kam Tong/0000-0002-7695-2513; KANG, Wei/0000-0002-4651-677X; Wu, William K.K./0000-0002-5662-5240; Chan, Michael/0000-0003-0314-2437; , Huan/0000-0003-3370-0479; Wong, Chi Chun/0000-0003-1362-3541	Research Grants Council of the Hong Kong Special Administrative Region, China [CUHK 14100019, 14118518]; CUHK Direct Grant for Research from The Chinese University of Hong Kong [2019.001]	Research Grants Council of the Hong Kong Special Administrative Region, China(Hong Kong Research Grants Council); CUHK Direct Grant for Research from The Chinese University of Hong Kong	We thank the TCGA Research Network (http://ca ncergenome.nih.gov/), The UCSC Cancer Genomics Browser (https:// genome-cancer.ucsc.edu/), NCI Center for Cancer Genomics Office (http://gdc.nci.nih.gov/), and JASPAR 2020 database (http://jaspar.genereg.net/) for the gastric cancer dataset and analysis. We also appreciate the technical support from Core Utilities of Cancer Genomics and Pathobiology of Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong. The manuscript is under the support of Research Grants Council of the Hong Kong Special Administrative Region, China [Project No.: CUHK 14100019 and 14118518 (for GRF projects)], and CUHK Direct Grant for Research (2019.001) from The Chinese University of Hong Kong.	Ahn S, 2016, MODERN PATHOL, V29, P1095, DOI 10.1038/modpathol.2016.96; Babina IS, 2017, NAT REV CANCER, V17, P318, DOI 10.1038/nrc.2017.8; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Bosetti C, 2008, ANN ONCOL, V19, P631, DOI 10.1093/annonc/mdm597; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brooks AN, 2012, CLIN CANCER RES, V18, P1855, DOI 10.1158/1078-0432.CCR-11-0699; Chang JJ, 2015, ONCOTARGET, V6, P2009, DOI 10.18632/oncotarget.2987; Dey JH, 2010, CANCER RES, V70, P4151, DOI 10.1158/0008-5472.CAN-09-4479; Dienstmann R, 2014, ANN ONCOL, V25, P552, DOI 10.1093/annonc/mdt419; Dudka AA, 2010, CANCER RES, V70, P3391, DOI 10.1158/0008-5472.CAN-09-3033; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Farre D, 2003, NUCLEIC ACIDS RES, V31, P3651, DOI 10.1093/nar/gkg605; Fornes O, 2020, NUCLEIC ACIDS RES, V48, pD87, DOI 10.1093/nar/gkz1001; Haugsten EM, 2010, MOL CANCER RES, V8, P1439, DOI 10.1158/1541-7786.MCR-10-0168; Helsten T, 2016, CLIN CANCER RES, V22, P259, DOI 10.1158/1078-0432.CCR-14-3212; Hu B, 2012, J GASTROINTEST ONCOL, V3, P251, DOI 10.3978/j.issn.2078-6891.2012.021; Huang TT, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0493-7; Jang J, 2017, TRANSL ONCOL, V10, P469, DOI 10.1016/j.tranon.2017.03.001; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kang W, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0134-0; Kang W, 2011, CLIN CANCER RES, V17, P2130, DOI 10.1158/1078-0432.CCR-10-2467; Karolchik D, 2004, NUCLEIC ACIDS RES, V32, pD493, DOI 10.1093/nar/gkh103; Katoh M, 2006, INT J ONCOL, V29, P163; Katoh M, 2006, CANCER BIOL THER, V5, P1059, DOI 10.4161/cbt.5.9.3151; Kim HS, 2019, J CANCER, V10, P20, DOI 10.7150/jca.28204; Lau WM, 2018, MOL CANCER THER, V17, P232, DOI 10.1158/1535-7163.MCT-17-0367; Leung WK, 2018, GASTROENTEROLOGY, V155, P67, DOI 10.1053/j.gastro.2018.03.028; Liao RG, 2013, CANCER RES, V73, P5195, DOI 10.1158/0008-5472.CAN-12-3950; Matsuda Y, 2012, MOL CANCER THER, V11, P2010, DOI 10.1158/1535-7163.MCT-12-0243; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; Mi HY, 2019, NUCLEIC ACIDS RES, V47, pD419, DOI 10.1093/nar/gky1038; Mitsuno Y, 2001, GUT, V49, P18, DOI 10.1136/gut.49.1.18; Ohta H, 2009, BRIT J CANCER, V100, P389, DOI 10.1038/sj.bjc.6604846; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; Shoji H, 2015, ANTICANCER RES, V35, P5055; Su X, 2014, BRIT J CANCER, V110, P967, DOI 10.1038/bjc.2013.802; Sun D, 2016, ONCOTARGET, V7, P81062, DOI 10.18632/oncotarget.13188; Thisse B, 2005, DEV BIOL, V287, P390, DOI 10.1016/j.ydbio.2005.09.011; Tsang Michael, 2004, Sci STKE, V2004, ppe17, DOI 10.1126/stke.2282004pe17; Turner N, 2010, ONCOGENE, V29, P2013, DOI 10.1038/onc.2009.489; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Van Cutsem E, 2017, ANN ONCOL, V28, P1316, DOI 10.1093/annonc/mdx107; Xie L, 2013, CLIN CANCER RES, V19, P2572, DOI 10.1158/1078-0432.CCR-12-3898; Yanai K, 2008, CANCER LETT, V263, P145, DOI 10.1016/j.canlet.2007.12.030; Zhang CY, 2009, CLIN CANCER RES, V15, P4017, DOI 10.1158/1078-0432.CCR-08-2824; Zhang JL, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8060637; Zhang JL, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071576; Zhang JL, 2019, ONCOGENE, V38, P33, DOI 10.1038/s41388-018-0430-x	48	14	16	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2020	39	43					6647	6663		10.1038/s41388-020-01458-x	http://dx.doi.org/10.1038/s41388-020-01458-x		SEP 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OF2UT	32934314	hybrid, Green Published			2022-12-28	WOS:000571179500001
J	Han, H; Wang, S; Meng, J; Lyu, G; Ding, G; Hu, Y; Wang, L; Wu, L; Yang, W; Lv, Y; Jia, S; Zhang, L; Ji, J				Han, H.; Wang, S.; Meng, J.; Lyu, G.; Ding, G.; Hu, Y.; Wang, L.; Wu, L.; Yang, W.; Lv, Y.; Jia, S.; Zhang, L.; Ji, J.			Long noncoding RNA PART1 restrains aggressive gastric cancer through the epigenetic silencing of PDGFBviathe PLZF-mediated recruitment of EZH2	ONCOGENE			English	Article							CELL-PROLIFERATION; PROSTATE-CANCER; RECEPTOR-BETA; METASTASIS; EXPRESSION; PROMOTES; GROWTH; GENE; SUPPRESSION; APOPTOSIS	Current reports refer to the role of long noncoding RNA (lncRNA) prostate androgen-regulated transcript 1 (PART1) as a tumor suppressor in some types of cancer but as an oncogene in other kinds of cancer. In gastric cancer, it had been reported to be downregulated. However, the clinical significance and underlying mechanism of PART1 function in gastric cancer remains undefined. Here, seven differential expression levels of noncoding RNAs (DE-lncRNAs) were screened from gastric cancer through a probe reannotation of a human exon array. PART1 was selected for further study because of its high fold change number. In our cohort, PART1 was identified as a significant downregulated lncRNA in gastric cancer tissues by qPCR and in situ hybridization (ISH), and its low expression was significantly correlated with postoperative metastasis and short overall survival time after surgery. Through the results of gain-of-function experiments, PART1 was confirmed as a tumor suppressor that can decrease not only cell viability, migration, and invasion in vitro but also tumorigenesis and tumor metastasis in vivo. Mechanistically, RNA pull-down and RNA-binding protein immunoprecipitation (RIP) showed that PART1 interacts with androgen receptor (AR), and then, promyelocytic leukemia zinc finger (PLZF) is upregulated in an androgen-independent manner. In a chain reaction, chromatin immunoprecipitation (ChIP) assay additionally illustrated that PLZF upregulation increased the enrichment of EZH2 and H3K27 trimethylation in the platelet-derived growth factor (PDGFB) promotor, thereby inhibition of PDGFB and the subsequent PDGFR beta/PI3K/Akt signaling pathway. Based on these findings, we showed PART1 plays a tumor suppressor rolebypromoting PLZF expression followed by recruitment of EZH2 to mediate epigenetic PDGFB silencing and downstream PI3K/Akt inhibition, suggesting that PART1 has a key role in restraining the aggressive ability of GC cells and providing a novel perspective on lncRNAs in GC progression.	[Han, H.; Ding, G.; Hu, Y.] Peking Univ, Canc Hosp & Inst, Dept Biobank, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing, Peoples R China; [Wang, S.; Meng, J.; Wang, L.; Yang, W.; Lv, Y.] Peking Univ, Dept Clin Lab, Canc Hosp & Inst, Beijing, Peoples R China; [Lyu, G.] Peking Univ, Dept Gastrointestinal Surg, Shenzhen Hosp, Shenzhen, Peoples R China; [Wu, L.] Peking Univ, Dept Cent Lab, Canc Hosp & Inst, Beijing, Peoples R China; [Jia, S.] Peking Univ, Dept Mol Diagnost, Canc Hosp & Inst, Beijing, Peoples R China; [Zhang, L.; Ji, J.] Peking Univ, Dept Gastrointestinal Surg, Canc Hosp & Inst, Beijing, Peoples R China	Peking University; Peking University; Peking University; Peking University; Peking University; Peking University	Jia, S (corresponding author), Peking Univ, Dept Mol Diagnost, Canc Hosp & Inst, Beijing, Peoples R China.; Zhang, L; Ji, J (corresponding author), Peking Univ, Dept Gastrointestinal Surg, Canc Hosp & Inst, Beijing, Peoples R China.	shuqin_jia@hsc.pku.edu.cn; lianhaizhang@bjcancer.org; jijiafu@hsc.pku.edu.cn		Meng, Jialin/0000-0002-4622-833X	National Natural Science Foundation of China [81772632, 81802943]; Science Foundation of Peking University Cancer Hospital [2020-9]; Beijing outstanding talent training program [2018000021469G268]; interdisciplinary medicine Seed Fund of Peking University [BMU2018MX019]; Special funds of the Ministry of Finance for Reform and Development; 'San Ming' Project of Shenzhen city [SZSM 201612051]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science Foundation of Peking University Cancer Hospital; Beijing outstanding talent training program; interdisciplinary medicine Seed Fund of Peking University; Special funds of the Ministry of Finance for Reform and Development; 'San Ming' Project of Shenzhen city	This work was supported by grants from the National Natural Science Foundation of China (81772632, 81802943), Science Foundation of Peking University Cancer Hospital 2020-9, Beijing outstanding talent training program (No. 2018000021469G268), the interdisciplinary medicine Seed Fund of Peking University (No. BMU2018MX019), Special funds of the Ministry of Finance for Reform and Development and 'San Ming' Project of Shenzhen city (no. SZSM 201612051).	Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cao WJ, 2013, WORLD J GASTROENTERO, V19, P3658, DOI 10.3748/wjg.v19.i23.3658; Chen S, 2017, CELL PHYSIOL BIOCHEM, V44, P215, DOI 10.1159/000484648; Chen X, 2018, CLIN CANCER RES, V24, P2002, DOI 10.1158/1078-0432.CCR-17-2376; Cher ML, 1996, CANCER RES, V56, P3091; Dong Y, 2018, EUR REV MED PHARMACO, V22, P1307, DOI 10.26355/eurrev_201803_14472; Fei ZH, 2016, TUMOR BIOL, V37, P1983, DOI 10.1007/s13277-015-3979-9; Feng RM, 2019, CANCER COMMUN, V39, DOI 10.1186/s40880-019-0368-6; Gu L, 2018, CANCER MED-US, V7, P1253, DOI 10.1002/cam4.1310; Gu W, 2019, MOL MED REP, V20, P2209, DOI 10.3892/mmr.2019.10478; Guo HF, 2015, J GENET GENOMICS, V42, P343, DOI 10.1016/j.jgg.2015.03.003; Guo Y, 2013, WSPOLCZESNA ONKOL, V17, P150, DOI 10.5114/wo.2013.34618; He XJ, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-218; Hsieh CL, 2015, CANCER RES, V75, P1944, DOI 10.1158/0008-5472.CAN-14-3602; Hu L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0322-6; Hu XW, 2018, CURR OPIN GENET DEV, V48, P8, DOI 10.1016/j.gde.2017.10.004; Hu YB, 2017, BIOCHEM BIOPH RES CO, V490, P317, DOI 10.1016/j.bbrc.2017.06.042; Izumi K, 2012, INT J ONCOL, V41, P1587, DOI 10.3892/ijo.2012.1593; Jiang F, 2004, PROSTATE, V59, P426, DOI 10.1002/pros.20000; Jin Y, 2017, ONCOTARGET, V8, P71317, DOI 10.18632/oncotarget.19813; Kodama M, 2010, CANCER SCI, V101, P1984, DOI 10.1111/j.1349-7006.2010.01639.x; Kominea A, 2004, J CANCER RES CLIN, V130, P253, DOI 10.1007/s00432-003-0531-x; Koubi M, 2018, NUCLEIC ACIDS RES, V46, P3339, DOI 10.1093/nar/gky080; Li H, 2014, ONCOTARGET, V5, P2318, DOI 10.18632/oncotarget.1913; Li JJ, 2017, CANCER CELL INT, V17, DOI 10.1186/s12935-017-0408-8; Li M, 2017, J CANCER, V8, P1795, DOI 10.7150/jca.18848; Li QL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033379; Li Y, 2017, CANCER LETT, V395, P31, DOI 10.1016/j.canlet.2017.02.035; Lin BY, 2000, CANCER RES, V60, P858; Lin CR, 2018, TRENDS CELL BIOL, V28, P287, DOI 10.1016/j.tcb.2017.11.008; Liu J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0246-6; Liu TM, 2015, STEM CELLS DAYT OHIO, V34, P277; Ma HW, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20171193; Ozen M, 1998, CANCER GENET CYTOGEN, V106, P105, DOI 10.1016/S0165-4608(98)00051-X; Peng Y, 2014, BIOSCIENCE REP, V34, P247, DOI 10.1042/BSR20140020; Sugano K, 2015, BEST PRACT RES CL GA, V29, P895, DOI 10.1016/j.bpg.2015.09.013; Sun M, 2018, BIOL CHEM, V399, P387, DOI 10.1515/hsz-2017-0255; Thomassen I, 2014, INT J CANCER, V134, P622, DOI 10.1002/ijc.28373; Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020; Wang GH, 2019, BIOMED PHARMACOTHER, V111, P1334, DOI 10.1016/j.biopha.2019.01.023; Wang JB, 2019, ONCOL REP, V41, P1007, DOI 10.3892/or.2018.6866; Wang Y, 2018, CELL BIOL INT, V42, P1358, DOI 10.1002/cbin.11020; Wen W, 2012, HEPATOLOGY, V55, P1787, DOI 10.1002/hep.25596; Wu Q, 2018, MOL ONCOL, V12, P799, DOI 10.1002/1878-0261.12187; Xia N, 2019, J PATHOL, V248, P304, DOI 10.1002/path.5257; Xu WR, 2018, BIOSCI BIOTECH BIOCH, V82, P456, DOI 10.1080/09168451.2018.1431518; Xue M, 2018, GASTRIC CANCER, V21, P756, DOI 10.1007/s10120-018-0801-6; Yang F, 2012, FEBS J, V279, P3159, DOI 10.1111/j.1742-4658.2012.08694.x; Yu YC, 2017, J CELL MOL MED, V21, P955, DOI 10.1111/jcmm.13035; Zhang XQ, 2013, NEUROBIOL DIS, V58, P123, DOI 10.1016/j.nbd.2013.05.011; Zhang Y, 2018, ASIAN J ANDROL, V20, P511, DOI 10.4103/aja.aja_36_18; Zhang ZZ, 2015, MOL CANCER THER, V14, P1162, DOI 10.1158/1535-7163.MCT-14-0695; Zhao Y, 2014, ONCOL REP, V31, P358, DOI 10.3892/or.2013.2850; Zhou TC, 2020, INT J BIOCHEM CELL B, V118, DOI 10.1016/j.biocel.2019.105637; Zhu DY, 2019, CANCER MED-US, V8, P6064, DOI 10.1002/cam4.2494; Zong L, 2016, LANCET, V388, P2606, DOI 10.1016/S0140-6736(16)32226-7	56	19	19	2	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 15	2020	39	42					6513	6528		10.1038/s41388-020-01442-5	http://dx.doi.org/10.1038/s41388-020-01442-5		SEP 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OA9HI	32901105				2022-12-28	WOS:000567639400001
J	Ko, CJ; Hsu, TW; Wu, SR; Lan, SW; Hsiao, TF; Lin, HY; Lin, HH; Tu, HF; Lee, CF; Huang, CC; Chen, MJM; Hsiao, PW; Huang, HP; Lee, MS				Ko, Chun-Jung; Hsu, Ting-Wei; Wu, Shang-Ru; Lan, Shao-Wei; Hsiao, Ting-Feng; Lin, Hsin-Ying; Lin, Hsin-Hsien; Tu, Hsin-Fang; Lee, Cheng-Fan; Huang, Cheng-Chung; Chen, Mei-Ju May; Hsiao, Pei-Wen; Huang, Hsiang-Po; Lee, Ming-Shyue			Inhibition of TMPRSS2 by HAI-2 reduces prostate cancer cell invasion and metastasis	ONCOGENE			English	Article							HEPATOCYTE GROWTH-FACTOR; FACTOR ACTIVATOR INHIBITOR; ANCHORED SERINE-PROTEASE; PERICELLULAR PROTEOLYSIS; SWISS-MODEL; MATRIPTASE; EXPRESSION; CLUSPRO; TISSUE; MET	TMPRSS2 is an important membrane-anchored serine protease involved in human prostate cancer progression and metastasis. A serine protease physiologically often comes together with a cognate inhibitor for execution of proteolytically biologic function; however, TMPRSS2's cognate inhibitor is still elusive. To identify the cognate inhibitor of TMPRSS2, in this study, we applied co-immunoprecipitation and LC/MS/MS analysis and isolated hepatocyte growth factor activator inhibitors (HAIs) to be potential inhibitor candidates for TMPRSS2. Moreover, the recombinant HAI-2 proteins exhibited a better inhibitory effect on TMPRSS2 proteolytic activity than HAI-1, and recombinant HAI-2 proteins had a high affinity to form a complex with TMPRSS2. The immunofluorescence images further showed that TMPRSS2 was co-localized to HAI-2. Both KD1 and KD2 domain of HAI-2 showed comparable inhibitory effects on TMPRSS2 proteolytic activity. In addition, HAI-2 overexpression could suppress the induction effect of TMPRSS2 on pro-HGF activation, extracellular matrix degradation and prostate cancer cell invasion. We further determined that the expression levels of TMPRSS2 were inversely correlated with HAI-2 levels during prostate cancer progression. In orthotopic xenograft animal model, TMPRSS2 overexpression promoted prostate cancer metastasis, and HAI-2 overexpression efficiently blocked TMPRSS2-induced metastasis. In summary, the results together indicate that HAI-2 can function as a cognate inhibitor for TMPRSS2 in human prostate cancer cells and may serve as a potential factor to suppress TMPRSS2-mediated malignancy.	[Ko, Chun-Jung; Hsu, Ting-Wei; Wu, Shang-Ru; Lan, Shao-Wei; Lin, Hsin-Ying; Lin, Hsin-Hsien; Tu, Hsin-Fang; Lee, Cheng-Fan; Huang, Cheng-Chung; Lee, Ming-Shyue] Natl Taiwan Univ, Coll Med, Dept Biochem & Mol Biol, Taipei, Taiwan; [Ko, Chun-Jung] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; [Hsiao, Ting-Feng] Chang Gung Univ, Coll Med, Grad Inst Biomed Sci, Taoyuan, Taiwan; [Hsiao, Ting-Feng] Chang Gung Univ, Mol Med Res Ctr, Taoyuan, Taiwan; [Chen, Mei-Ju May] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Hsiao, Pei-Wen] Acad Sinica, Agr Biotechnol Res Ctr, Taipei, Taiwan; [Huang, Hsiang-Po] Natl Taiwan Univ, Coll Med, Grad Inst Med Genom & Prote, Taipei, Taiwan	National Taiwan University; University of Texas System; UTMD Anderson Cancer Center; Chang Gung University; Chang Gung University; University of Texas System; UTMD Anderson Cancer Center; Academia Sinica - Taiwan; National Taiwan University	Lee, MS (corresponding author), Natl Taiwan Univ, Coll Med, Dept Biochem & Mol Biol, Taipei, Taiwan.	mslee2006@ntu.edu.tw	Ko, Chun-Jung/AAA-6187-2022; Tu, Hsin-Fang/HGA-9284-2022	Ko, Chun-Jung/0000-0001-6565-7060; HUANG, HSIANG-PO/0000-0002-3382-305X; Hsiao, Ting-Feng/0000-0003-4074-9019	Ministry of Science and Technology [MOST 104-2320-B-002-044-MY3, MOST 105-2911-I-002-521, MOST 106-2320-B-002-046-MY3, MOST 108-2320-B-002-024-MY3]; National Health Research Institutes Grant [NHRI-EX106-10401BI, NHRI-EX109-10725BI]; National Taiwan University [NTU-CESRP-104R7602C4, NTU105R89612, NYU107L890504]	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); National Health Research Institutes Grant; National Taiwan University(National Taiwan University)	This study was supported by Ministry of Science and Technology Grants MOST 104-2320-B-002-044-MY3, MOST 105-2911-I-002-521, MOST 106-2320-B-002-046-MY3 and MOST 108-2320-B-002-024-MY3, National Health Research Institutes Grant NHRI-EX106-10401BI and NHRI-EX109-10725BI, and National Taiwan University Grant NTU-CESRP-104R7602C4, NTU105R89612 and NYU107L890504 to M.S. Lee. We appreciate the service of the First Core Laboratory of National Taiwan University College of Medicine. We thank Dr. Chen-Yong Lin at the Georgetown University for his gifts of antibodies. We would like to acknowledge Dr. Chia-Jung Yu (Chang Gung University, Taoyuan, Taiwan; Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan) and the Proteomics Core Laboratory of Chang Gung University for providing proteomics technical support.	Aalinkeel R, 2004, CANCER RES, V64, P5311, DOI 10.1158/0008-5472.CAN-2506-2; Benaud CM, 2002, CLIN EXP METASTAS, V19, P639, DOI 10.1023/A:1020985632550; Biasini Marco, 2014, Nucleic Acids Res, V42, pW252, DOI 10.1093/nar/gku340; Bugge TH, 2009, J BIOL CHEM, V284, P23177, DOI 10.1074/jbc.R109.021006; Chen YW, 2010, AM J PATHOL, V176, P2986, DOI 10.2353/ajpath.2010.090665; Chou FP, 2013, AM J PATHOL, V183, P1306, DOI 10.1016/j.ajpath.2013.06.024; Comeau SR, 2004, BIOINFORMATICS, V20, P45, DOI 10.1093/bioinformatics/btg371; Comeau SR, 2004, NUCLEIC ACIDS RES, V32, pW96, DOI 10.1093/nar/gkh354; Debes JD, 2004, NEW ENGL J MED, V351, P1488, DOI 10.1056/NEJMp048178; Delaria KA, 1997, J BIOL CHEM, V272, P12209, DOI 10.1074/jbc.272.18.12209; Dozmorov MG, 2009, PROSTATE, V69, P1077, DOI 10.1002/pros.20960; Eder T, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091458; Fan B, 2005, J BIOL CHEM, V280, P34513, DOI 10.1074/jbc.M502119200; Garten W, 2015, EUR J CELL BIOL, V94, P375, DOI 10.1016/j.ejcb.2015.05.013; Herter S, 2005, BIOCHEM J, V390, P125, DOI 10.1042/BJ20041955; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Humphrey PA, 2006, CLIN GENITOURIN CANC, V4, P269, DOI 10.3816/CGC.2006.n.006; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jin JS, 2007, HISTOL HISTOPATHOL, V22, P305, DOI 10.14670/HH-22.305; Kang JY, 2003, CANCER RES, V63, P1101; Kawaguchi M, 2014, CANCERS, V6, P1890, DOI 10.3390/cancers6041890; Kawaguchi T, 1997, J BIOL CHEM, V272, P27558, DOI 10.1074/jbc.272.44.27558; Kirchhofer D, 2005, FEBS LETT, V579, P1945, DOI 10.1016/j.febslet.2005.01.085; Ko CJ, 2015, CANCER RES, V75, P2949, DOI 10.1158/0008-5472.CAN-14-3297; Kozakov D, 2006, PROTEINS, V65, P392, DOI 10.1002/prot.21117; Kozakov D, 2017, NAT PROTOC, V12, P255, DOI 10.1038/nprot.2016.169; Kozakov D, 2013, PROTEINS, V81, P2159, DOI 10.1002/prot.24403; Kumar D, 2018, CANCER RES, V78, P3769, DOI 10.1158/0008-5472.CAN-17-1076; Lai YS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127293; Lam DK, 2015, PAIN, V156, P923, DOI 10.1097/j.pain.0000000000000130; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237; Lin CY, 1999, J BIOL CHEM, V274, P18231, DOI 10.1074/jbc.274.26.18231; Lopez-Otin C, 2008, J BIOL CHEM, V283, P30433, DOI 10.1074/jbc.R800035200; Lucas J, 2008, J PATHOL, V215, P118, DOI 10.1002/path.2330; Lucas JM, 2014, CANCER DISCOV, V4, P1310, DOI 10.1158/2159-8290.CD-13-1010; Maurer E, 2013, BIOCHEM J, V450, P583, DOI 10.1042/BJ20121518; Mestres J, 2008, NAT BIOTECHNOL, V26, P983, DOI 10.1038/nbt0908-983; Mierke CT, 2013, EUR J CELL BIOL, V92, P89, DOI 10.1016/j.ejcb.2012.12.002; Miyazawa K, 2010, FEBS J, V277, P2208, DOI 10.1111/j.1742-4658.2010.07637.x; Oberst MD, 2005, AM J PHYSIOL-CELL PH, V289, pC462, DOI 10.1152/ajpcell.00076.2005; Pietras K, 2010, EXP CELL RES, V316, P1324, DOI 10.1016/j.yexcr.2010.02.045; PISTERS LL, 1995, J UROLOGY, V154, P293, DOI 10.1016/S0022-5347(01)67297-5; Qin L, 1998, FEBS LETT, V436, P111, DOI 10.1016/S0014-5793(98)01105-3; Roversi FM, 2018, BIOMED PHARMACOTHER, V101, P278, DOI 10.1016/j.biopha.2018.02.100; Russo AL, 2009, CLIN CANCER RES, V15, P4292, DOI 10.1158/1078-0432.CCR-09-0599; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Seth A, 2005, EUR J CANCER, V41, P2462, DOI 10.1016/j.ejca.2005.08.013; Sevenich L, 2014, GENE DEV, V28, P2331, DOI 10.1101/gad.250647.114; Shen CA-SaMM, 2000, GENE DEV, V14, P26; Shimomura T, 1997, J BIOL CHEM, V272, P6370, DOI 10.1074/jbc.272.10.6370; Stowell SR, 2015, ANNU REV PATHOL-MECH, V10, P473, DOI 10.1146/annurev-pathol-012414-040438; Tao LL, 2017, ONCOL LETT, V14, P2611, DOI 10.3892/ol.2017.6497; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tsai CH, 2014, ONCOGENE, V33, P4643, DOI 10.1038/onc.2013.412; Vogel LK, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-176; Wilson S, 2005, BIOCHEM J, V388, P967, DOI 10.1042/BJ20041066; Wu SR, 2019, BRIT J CANCER, V120, P499, DOI 10.1038/s41416-019-0400-2	58	15	15	5	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2020	39	37					5950	5963		10.1038/s41388-020-01413-w	http://dx.doi.org/10.1038/s41388-020-01413-w		AUG 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NM2OY	32778768	Green Published, Bronze			2022-12-28	WOS:000558201400002
J	Green, D; Eyre, H; Singh, A; Taylor, JT; Chu, J; Jeys, L; Sumathi, V; Coonar, A; Rassl, D; Babur, M; Forster, D; Alzabin, S; Ponthan, F; McMahon, A; Bigger, B; Reekie, T; Kassiou, M; Williams, K; Dalmay, T; Fraser, WD; Finegan, KG				Green, Darrell; Eyre, Heather; Singh, Archana; Taylor, Jessica T.; Chu, Jason; Jeys, Lee; Sumathi, Vaiyapuri; Coonar, Aman; Rassl, Doris; Babur, Muhammad; Forster, Duncan; Alzabin, Saba; Ponthan, Frida; McMahon, Adam; Bigger, Brian; Reekie, Tristan; Kassiou, Michael; Williams, Kaye; Dalmay, Tamas; Fraser, William D.; Finegan, Katherine G.			Targeting the MAPK7/MMP9 axis for metastasis in primary bone cancer	ONCOGENE			English	Article							OSTEOSARCOMA CELL; LUNG METASTASIS; ERK5; EXPRESSION; GROWTH; INFLAMMATION; PERFORMANCE; INHIBITOR; INVASION	Metastasis is the leading cause of cancer-related death. This multistage process involves contribution from both tumour cells and the tumour stroma to release metastatic cells into the circulation. Circulating tumour cells (CTCs) survive circulatory cytotoxicity, extravasate and colonise secondary sites effecting metastatic outcome. Reprogramming the transcriptomic landscape is a metastatic hallmark, but detecting underlying master regulators that drive pathological gene expression is a key challenge, especially in childhood cancer. Here we used whole tumour plus single-cell RNA-sequencing in primary bone cancer and CTCs to perform weighted gene co-expression network analysis to systematically detect coordinated changes in metastatic transcript expression. This approach with comparisons applied to data collected from cell line models, clinical samples and xenograft mouse models revealed mitogen-activated protein kinase 7/matrix metallopeptidase 9 (MAPK7/MMP9) signalling as a driver for primary bone cancer metastasis. RNA interference knockdown ofMAPK7reduces proliferation, colony formation, migration, tumour growth, macrophage residency/polarisation and lung metastasis. Parallel to these observations were reduction of activated interleukinsIL1B,IL6,IL8plus mesenchymal markersVIMandVEGFin response toMAPK7loss. Our results implicate a newly discovered, multidimensional MAPK7/MMP9 signalling hub in primary bone cancer metastasis that is clinically actionable.	[Green, Darrell; Fraser, William D.] Univ East Anglia, Norwich Med Sch, Norwich, Norfolk, England; [Eyre, Heather; Taylor, Jessica T.; Chu, Jason; Babur, Muhammad; Bigger, Brian; Williams, Kaye; Finegan, Katherine G.] Univ Manchester, Fac Biol Med & Hlth, Manchester, Lancs, England; [Singh, Archana] Earlham Inst, Digital Biol, Norwich, Norfolk, England; [Jeys, Lee] Royal Orthopaed Hosp, Orthopaed Oncol, Birmingham, W Midlands, England; [Sumathi, Vaiyapuri] Royal Orthopaed Hosp, Musculoskeletal Pathol, Birmingham, W Midlands, England; [Coonar, Aman] Royal Papworth Hosp, Thorac Surg, Cambridge, England; [Rassl, Doris] Royal Papworth Hosp, Pathol, Cambridge, England; [Forster, Duncan; McMahon, Adam] Univ Manchester, Wolfson Mol Imaging Ctr, Manchester, Lancs, England; [Alzabin, Saba; Ponthan, Frida] Epistem Ltd, Manchester, Lancs, England; [Reekie, Tristan; Kassiou, Michael] Univ Sydney, Sch Chem, Sydney, NSW, Australia; [Dalmay, Tamas] Univ East Anglia, Sch Biol Sci, Norwich, Norfolk, England; [Fraser, William D.] Norfolk & Norwich Univ Hosp, Clin Biochem, Norwich, Norfolk, England; [Fraser, William D.] Norfolk & Norwich Univ Hosp, Diabet & Endocrinol, Norwich, Norfolk, England	University of East Anglia; University of Manchester; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Earlham Institute; Royal Orthopaedic Hospital; Royal Orthopaedic Hospital; Papworth Hospital; Papworth Hospital; University of Manchester; University of Sydney; University of East Anglia; Norfolk & Norwich University Hospitals NHS Foundation Trust; Norfolk & Norwich University Hospital; Norfolk & Norwich University Hospitals NHS Foundation Trust; Norfolk & Norwich University Hospital	Fraser, WD (corresponding author), Univ East Anglia, Norwich Med Sch, Norwich, Norfolk, England.; Finegan, KG (corresponding author), Univ Manchester, Fac Biol Med & Hlth, Manchester, Lancs, England.; Fraser, WD (corresponding author), Norfolk & Norwich Univ Hosp, Clin Biochem, Norwich, Norfolk, England.; Fraser, WD (corresponding author), Norfolk & Norwich Univ Hosp, Diabet & Endocrinol, Norwich, Norfolk, England.	w.fraser@uea.ac.uk; k.g.finegan@manchester.ac.uk	williams, kaye/HHN-5342-2022; McMahon, Adam/C-3660-2018	McMahon, Adam/0000-0002-6130-2008; Green, Darrell/0000-0002-0217-3322; Archana, Archana/0000-0002-5027-4582; Kassiou, Michael/0000-0002-6655-0529; Eyre, Heather/0000-0001-9932-3595; Finegan, Katie/0000-0003-2885-0122; Alzabin, Saba/0000-0003-3474-1846; Taylor, Jessica/0000-0001-8565-8589	Humane Research Trust; Paget's Association; BBSRC [BBS/E/T/000PR9819] Funding Source: UKRI	Humane Research Trust; Paget's Association; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This work was supported by The Humane Research Trust, Friends of Rosie, Big C and Paget's Association. We thank Teresa Brodie, Dionne Wortley, Emma Bruce, Jenny Ledwidge, Jennifer Gill, Joanne Taylor, Sukhpal Singh and staff at the FBMH Research Facilities: Histology and Bioimaging for technical support. We also thank Dr. Luisa Martinez-Pomares for the MR antibody. We are indebted to the patients for their contribution to this study.	Anderson ND, 2018, SCIENCE, V361, DOI 10.1126/science.aam8419; Behjati S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15936; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Binnewies M, 2018, NAT MED, V24, P541, DOI 10.1038/s41591-018-0014-x; Bray NL, 2016, NAT BIOTECHNOL, V34, P888, DOI 10.1038/nbt0816-888d; Campbell PJ, 2020, NATURE, V578, P82, DOI 10.1038/s41586-020-1969-6; Campeau E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006529; Chen X, 2014, CELL REP, V7, P104, DOI 10.1016/j.celrep.2014.03.003; Farina AR, 2014, CANCERS, V6, P240, DOI 10.3390/cancers6010240; Finegan KG, 2015, CANCER RES, V75, P742, DOI 10.1158/0008-5472.CAN-13-3043; Finegan KG, 2010, CANCER RES, V70, P5797, DOI 10.1158/0008-5472.CAN-09-3669; Gerrand C, 2016, CLIN SARCOMA RES, V6, DOI 10.1186/s13569-016-0047-1; Giurisato E, 2018, P NATL ACAD SCI USA, V115, pE2801, DOI 10.1073/pnas.1707929115; Green D, 2019, PATHOLOGY, V51, P113, DOI 10.1016/j.pathol.2018.08.014; Green D, 2017, ENDOCR-RELAT CANCER, V24, pL27, DOI 10.1530/ERC-16-0487; Harbour JW, 2010, SCIENCE, V330, P1410, DOI 10.1126/science.1194472; Heymann MF, 2017, CELL IMMUNOL, V343, P1; Hosseini H, 2016, NATURE, V540, P552, DOI 10.1038/nature20785; Jalili A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069064; Javaid S, 2015, MOL CANCER RES, V13, P934, DOI 10.1158/1541-7786.MCR-14-0604; Katz Y, 2015, BIOINFORMATICS, V31, P2400, DOI 10.1093/bioinformatics/btv034; Kim SM, 2012, J ORTHOP RES, V30, P1040, DOI 10.1002/jor.22025; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Lin ECK, 2016, P NATL ACAD SCI USA, V113, P11865, DOI 10.1073/pnas.1609019113; Lochhead PA, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15031-3; Lopez-Nieva P, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4304-y; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Matsui J, 2008, CLIN CANCER RES, V14, P5459, DOI 10.1158/1078-0432.CCR-07-5270; Mohorianu I, 2011, PLANT J, V67, P232, DOI 10.1111/j.1365-313X.2011.04586.x; Pearson AJ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030929; Pertea M, 2016, NAT PROTOC, V11, P1650, DOI 10.1038/nprot.2016.095; Rausch T, 2012, CELL, V148, P59, DOI 10.1016/j.cell.2011.12.013; Sachdev D, 2007, MOL CANCER THER, V6, P1, DOI 10.1158/1535-7163.MCT-06-0080; Shaw B, 2019, P NATL ACAD SCI USA, V116, P10463, DOI 10.1073/pnas.1820556116; Shen SH, 2014, P NATL ACAD SCI USA, V111, pE5593, DOI 10.1073/pnas.1419161111; Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800; Tesser-Gamba F, 2016, MOL CARCINOGEN, V55, P1700, DOI 10.1002/mc.22420; Tesser-Gamba F, 2012, HUM PATHOL, V43, P994, DOI 10.1016/j.humpath.2011.08.003; Tome Y, 2013, ANTICANCER RES, V33, P3623; Vasiliadou I, 2013, J BONE ONCOL, V2, P158, DOI 10.1016/j.jbo.2013.07.002; Wang J, 2014, CLIN CHIM ACTA, V433, P225, DOI 10.1016/j.cca.2014.03.023; Waschkau B, 2013, CONTRAST MEDIA MOL I, V8, P1, DOI 10.1002/cmmi.1486; Weekes D, 2016, ONCOGENE, V35, P2852, DOI 10.1038/onc.2015.344; Wellenstein MD, 2019, NATURE, V572, P538, DOI 10.1038/s41586-019-1450-6; Winer A, 2018, MOL CANCER THER, V17, P1147, DOI 10.1158/1535-7163.MCT-17-0646; Yue B, 2014, EUR REV MED PHARMACO, V18, P2640; Zhao W, 2010, J BIOPHARM STAT, V20, P281, DOI 10.1080/10543400903572753; Zheng JZ, 2016, MOL IMAGING BIOL, V18, P127, DOI 10.1007/s11307-015-0877-x; Zheng Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14344; Zhong ZY, 2016, CELL, V166, P288, DOI 10.1016/j.cell.2016.05.051; Zhou J, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000013051	52	9	9	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2020	39	33					5553	5569		10.1038/s41388-020-1379-0	http://dx.doi.org/10.1038/s41388-020-1379-0		JUL 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NB0QV	32655131	Green Accepted, hybrid, Green Published			2022-12-28	WOS:000547821000001
J	Meyer-Schaller, N; Tiede, S; Ivanek, R; Diepenbruck, M; Christofori, G				Meyer-Schaller, Nathalie; Tiede, Stefanie; Ivanek, Robert; Diepenbruck, Maren; Christofori, Gerhard			A dual role of Irf1 in maintaining epithelial identity but also enabling EMT and metastasis formation of breast cancer cells	ONCOGENE			English	Article							REGULATORY FACTOR-I; INTERFERON; INDUCTION; PATHWAY; FAMILY; TARGET	An epithelial to mesenchymal transition (EMT) is an embryonic dedifferentiation program which is aberrantly activated in cancer cells to acquire cellular plasticity. This plasticity increases the ability of breast cancer cells to invade into surrounding tissue, to seed metastasis at distant sites and to resist to chemotherapy. In this study, we have observed a higher expression of interferon-related factors in basal-like and claudin-low subtypes of breast cancer in patients, known to be associated with EMT. Notably, Irf1 exerts essential functions during the EMT process, yet it is also required for the maintenance of an epithelial differentiation status of mammary gland epithelial cells: RNAi-mediated ablation of Irf1 in mammary epithelial cells results in the expression of mesenchymal factors and Smad transcriptional activity. Conversely, ablation of Irf1 during TGF beta-induced EMT prevents a mesenchymal transition and stabilizes the expression of E-cadherin. In the basal-like murine breast cancer cell line 4T1, RNAi-mediated ablation of Irf1 reduces colony formation and cell migration in vitro and shedding of circulating tumor cells and metastasis formation in vivo. This context-dependent dual role of Irf1 in the regulation of epithelial-mesenchymal plasticity provides important new insights into the functional contribution and therapeutic potential of interferon-regulated factors in breast cancer.	[Meyer-Schaller, Nathalie; Tiede, Stefanie; Ivanek, Robert; Diepenbruck, Maren; Christofori, Gerhard] Univ Basel, Dept Biomed, CH-4058 Basel, Switzerland; [Ivanek, Robert] Swiss Inst Bioinformat, CH-4058 Basel, Switzerland	University of Basel; Swiss Institute of Bioinformatics	Meyer-Schaller, N; Christofori, G (corresponding author), Univ Basel, Dept Biomed, CH-4058 Basel, Switzerland.	nathalie.meyer-schaller@unibas.ch; gerhard.christofori@unibas.ch			Swiss National Science Foundation [310030B_163471]; SystemsX.ch RTD Cellplasticity; Swiss Cancer League [KFS-3479-08-2014]; Krebsliga Beider Basel [03-2013]; Marie-Heim Vogtlin grant from the Swiss National Science Foundation	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); SystemsX.ch RTD Cellplasticity; Swiss Cancer League; Krebsliga Beider Basel; Marie-Heim Vogtlin grant from the Swiss National Science Foundation	We thank Petra Schmidt for technical assistance with immunoblotting and quantitative RT-PCR, Helena Antoniadis for help with mouse work, Christian Beisel and the D-BSSE sequencing facility for RNA-sequencing, Pascal Lorenz and the DBM Mattenstrasse microscopy facility for microscopy and image quantification support. This work was supported by the Swiss National Science Foundation (310030B_163471), the SystemsX.ch RTD Cellplasticity, the Swiss Cancer League (KFS-3479-08-2014), the Krebsliga Beider Basel (03-2013) (all GC) and by a Marie-Heim Vogtlin grant from the Swiss National Science Foundation (NM-S).	Alsamman K, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20171672; Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Bouker KB, 2005, CARCINOGENESIS, V26, P1527, DOI 10.1093/carcin/bgi113; Bouker KB, 2004, CANCER RES, V64, P4030, DOI 10.1158/0008-5472.CAN-03-3602; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dror N, 2007, MOL IMMUNOL, V44, P338, DOI 10.1016/j.molimm.2006.02.026; Dvinge H, 2013, NATURE, V497, P378, DOI 10.1038/nature12108; Garcia-Diaz A, 2017, CELL REP, V19, P1189, DOI 10.1016/j.celrep.2017.04.031; Guerrero Michael S, 2012, Genes Cancer, V3, P371, DOI 10.1177/1947601912458585; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; Honda K, 2006, IMMUNITY, V25, P349, DOI 10.1016/j.immuni.2006.08.009; Huang RYJ, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.442; Irudayam JI, 2015, STEM CELL RES, V15, P354, DOI 10.1016/j.scr.2015.08.003; Jiang L, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1186-z; Jiang YY, 2020, CANCER LETT, V468, P72, DOI 10.1016/j.canlet.2019.10.013; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lehembre F, 2008, EMBO J, V27, P2603, DOI 10.1038/emboj.2008.178; Lotz-Jenne C, 2016, ONCOTARGET, V7, P25983, DOI 10.18632/oncotarget.8418; Maeda M, 2005, J CELL SCI, V118, P873, DOI 10.1242/jcs.01634; Meyer-Schaller N, 2019, DEV CELL, V48, P539, DOI 10.1016/j.devcel.2018.12.023; Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586-018-0040-3; Pavan S, 2018, ONCOGENE, V37, P4197, DOI 10.1038/s41388-018-0270-8; Pavan S, 2013, EUR J CANCER, V49, P964, DOI 10.1016/j.ejca.2012.09.024; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Stemmler MP, 2019, NAT CELL BIOL, V21, P102, DOI 10.1038/s41556-018-0196-y; Waldmeier L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048651; Yanai H, 2012, ONCOIMMUNOLOGY, V1, P1376, DOI 10.4161/onci.22475; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; You FP, 2013, NAT IMMUNOL, V14, P1237, DOI 10.1038/ni.2756; Yu M, 2017, INT J ONCOL, V50, P975, DOI 10.3892/ijo.2017.3852	34	3	3	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	24					4728	4740		10.1038/s41388-020-1326-0	http://dx.doi.org/10.1038/s41388-020-1326-0		MAY 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LY0HO	32404986				2022-12-28	WOS:000532807900001
J	Wu, PK; Hong, SK; Starenki, D; Oshima, K; Shao, H; Gestwicki, JE; Tsai, SS; Park, JI				Wu Pui-Kei; Hong, Seung-Keun; Starenki, Dmytro; Oshima, Kiyoko; Shao Hao; Gestwicki, Jason E.; Tsai, Susan; Park, Jong-In			Mortalin/HSPA9 targeting selectively induces KRAS tumor cell death by perturbing mitochondrial membrane permeability	ONCOGENE			English	Article							ADENINE-NUCLEOTIDE TRANSLOCASE; PANCREATIC-CANCER; TRANSITION PORE; UP-REGULATION; MKT-077; HSP70; P53; INHIBITOR; PROTEINS; BINDING	The mitochondrial HSP70 chaperone mortalin (HSPA9/GRP75) is often upregulated and mislocalized in MEK/ERK-deregulated tumors. Here, we show that mortalin depletion can selectively induce death of immortalized normal fibroblasts IMR90E1A when combined with K-Ras(G12V) expression, but not with wild-type K-Ras expression, and that K-Ras(G12V)-driven MEK/ERK activity is necessary for this lethality. This cell death was attenuated by knockdown or inhibition of adenine nucleotide translocase (ANT), cyclophilin D (CypD), or mitochondrial Ca2+ uniporter (MCU), which implicates a mitochondria-originated death mechanism. Indeed, mortalin depletion increased mitochondrial membrane permeability and induced cell death in KRAS-mutated human pancreatic ductal adenocarcinoma (PDAC) and colon cancer lines, which were attenuated by knockdown or inhibition of ANT, CypD, or MCU, and occurred independently of TP53 and p21(CIP1). Intriguingly, JG-98, an advanced MKT-077 derivative, phenocopied the lethal effects of mortalin depletion in K-Ras(G12V)-expressing IMR90E1A and KRAS-mutated tumor cell lines in vitro. Moreover, JG-231, a JG-98 analog with improved microsomal stability effectively suppressed the xenograft of MIA PaCa-2, a K-Ras(G12C)-expressing human PDAC line, in athymic nude mice. These data demonstrate that oncogenic KRAS activity sensitizes cells to the effects of mortalin depletion, suggesting that mortalin has potential as a selective therapeutic target for KRAS-mutated tumors.	[Wu Pui-Kei; Hong, Seung-Keun; Starenki, Dmytro; Park, Jong-In] Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; [Oshima, Kiyoko] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21287 USA; [Shao Hao; Gestwicki, Jason E.] Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94158 USA; [Tsai, Susan] Med Coll Wisconsin, LaBahn Pancreat Canc Program, Milwaukee, WI 53226 USA; [Tsai, Susan] Med Coll Wisconsin, Dept Surg, 8700 W Wisconsin Ave, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Johns Hopkins University; University of California System; University of California San Francisco; Medical College of Wisconsin; Medical College of Wisconsin	Park, JI (corresponding author), Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA.	jipark@mcw.edu	Oshima, Kiyoko/CAF-1543-2022	Wu, Pui Kei/0000-0002-8734-2657; Park, Jong-In/0000-0001-7248-4735	NIH/National Cancer Institute grant [R01CA138441]; NIH [R01NS059690]	NIH/National Cancer Institute grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by NIH/National Cancer Institute grant (R01CA138441) to JP. Development of HSP70 modulators was funded by NIH R01NS059690 to JG.	Bailey JM, 2016, ONCOGENE, V35, P4282, DOI 10.1038/onc.2015.441; Bonora M, 2015, ONCOGENE, V34, P1475, DOI 10.1038/onc.2014.96; Bonora M, 2019, TRENDS BIOCHEM SCI, V44, P559, DOI 10.1016/j.tibs.2019.04.009; BROEKEMEIER KM, 1994, MOL CELL BIOCHEM, V139, P33, DOI 10.1007/BF00944201; Bryant KL, 2014, TRENDS BIOCHEM SCI, V39, P91, DOI 10.1016/j.tibs.2013.12.004; Canon J, 2019, NATURE, V575, P217, DOI 10.1038/s41586-019-1694-1; Chevrollier A, 2011, BBA-BIOENERGETICS, V1807, P562, DOI 10.1016/j.bbabio.2010.10.008; Crompton M, 2002, BIOCHIMIE, V84, P143, DOI 10.1016/S0300-9084(02)01368-8; Cui XL, 2017, HUM PATHOL, V64, P171, DOI 10.1016/j.humpath.2017.03.015; Daugaard M, 2007, FEBS LETT, V581, P3702, DOI 10.1016/j.febsiet.2007.05.039; Green DR, 2014, SCIENCE, V345, P1466, DOI 10.1126/science.1250256; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; Halestrap AP, 2003, CURR MED CHEM, V10, P1507, DOI 10.2174/0929867033457278; Halestrap AP, 1997, MOL CELL BIOCHEM, V174, P167, DOI 10.1023/A:1006879618176; Haq R, 2013, CANCER CELL, V23, P302, DOI 10.1016/j.ccr.2013.02.003; He JY, 2017, P NATL ACAD SCI USA, V114, P3409, DOI 10.1073/pnas.1702357114; Hong SK, 2018, CELL SIGNAL, V42, P11, DOI 10.1016/j.cellsig.2017.10.001; Hong SK, 2009, J BIOL CHEM, V284, P33006, DOI 10.1074/jbc.M109.012591; Hoshino A, 2019, NATURE, V575, P375, DOI 10.1038/s41586-019-1667-4; Humpton TJ, 2019, CANCER DISCOV, V9, P1268, DOI 10.1158/2159-8290.CD-18-1409; Hurst S, 2019, J BIOL CHEM, V294, P10807, DOI 10.1074/jbc.RA118.006443; Karkhanis M, 2015, CELL SIGNAL, V27, P479, DOI 10.1016/j.cellsig.2015.01.005; Karoulia Z, 2017, NAT REV CANCER, V17, P676, DOI 10.1038/nrc.2017.79; Kaul SC, 2007, EXP GERONTOL, V42, P263, DOI 10.1016/j.exger.2006.10.020; Khalil AA, 2011, BBA-REV CANCER, V1816, P89, DOI 10.1016/j.bbcan.2011.05.001; Kidger AM, 2018, PHARMACOL THERAPEUT, V187, P45, DOI 10.1016/j.pharmthera.2018.02.007; Konieczkowski DJ, 2018, CANCER CELL, V33, P801, DOI 10.1016/j.ccell.2018.03.025; Koya K, 1996, CANCER RES, V56, P538; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Leanza L, 2014, ONCOGENE, V33, P5569, DOI 10.1038/onc.2013.578; Lee AS, 2014, NAT REV CANCER, V14, P263, DOI 10.1038/nrc3701; Lu WJ, 2011, CELL DEATH DIFFER, V18, P1046, DOI 10.1038/cdd.2010.177; Maruta H, 1999, ANN NY ACAD SCI, V886, P283, DOI 10.1111/j.1749-6632.1999.tb09437.x; Miyata Y, 2013, ACS CHEM NEUROSCI, V4, P930, DOI 10.1021/cn300210g; Modica-Napolitano JS, 2001, ADV DRUG DELIVER REV, V49, P63, DOI 10.1016/S0169-409X(01)00125-9; Na Y, 2016, CANCER RES, V76, P2754, DOI 10.1158/0008-5472.CAN-15-2704; Nagdas S, 2019, CELL REP, V28, P1845, DOI 10.1016/j.celrep.2019.07.031; Neginskaya MA, 2019, CELL REP, V26, P11, DOI 10.1016/j.celrep.2018.12.033; Ostrem JM, 2013, NATURE, V503, P548, DOI 10.1038/nature12796; Rosen A, 1997, J CELL BIOCHEM, V64, P50, DOI 10.1002/(SICI)1097-4644(199701)64:1<50::AID-JCB8>3.0.CO;2-Z; Rousaki A, 2011, J MOL BIOL, V411, P614, DOI 10.1016/j.jmb.2011.06.003; Rozenberg P, 2013, INT J CANCER, V133, P514, DOI 10.1002/ijc.28029; Sale MJ, 2014, BIOCHEM SOC T, V42, P776, DOI 10.1042/BST20140129; Santo-Domingo J, 2007, BRIT J PHARMACOL, V151, P647, DOI 10.1038/sj.bjp.0707260; Shao H, 2018, J MED CHEM, V61, P6163, DOI 10.1021/acs.jmedchem.8b00583; Starenki D, 2015, ONCOGENE, V34, P4624, DOI 10.1038/onc.2014.392; Starenki D, 2013, J CLIN ENDOCR METAB, V98, P1529, DOI 10.1210/jc.2012-3671; SUN J, 2017, TUMOR BIOL, V39, DOI DOI 10.1177/1010428317695918; Utkina-Sosunova IV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062448; Vasan N, 2019, NATURE, V575, P299, DOI 10.1038/s41586-019-1730-1; Vaseva AV, 2012, CELL, V149, P1536, DOI 10.1016/j.cell.2012.05.014; Viale A, 2014, NATURE, V514, P628, DOI 10.1038/nature13611; Wadhwa R, 2005, BIOCHEM J, V391, P185, DOI 10.1042/BJ20050861; Wadhwa R, 1998, J BIOL CHEM, V273, P29586, DOI 10.1074/jbc.273.45.29586; Wadhwa R, 2000, CANCER RES, V60, P6818; Wadhwa R, 2006, INT J CANCER, V118, P2973, DOI 10.1002/ijc.21773; Weaver JGR, 2005, J CLIN INVEST, V115, P1828, DOI 10.1172/JCI22954; Wu PK, 2020, SCI SIGNAL, V13, DOI 10.1126/scisignal.aay1478; Wu PK, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00061-17; Wu PK, 2013, MOL CELL BIOL, V33, P4051, DOI 10.1128/MCB.00021-13; Xu M, 2019, GENE, V696, P63, DOI 10.1016/j.gene.2019.02.033; Yu M, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.125166; Yun CO, 2017, SCI REP-UK, V7, DOI 10.1038/srep42016	63	13	14	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	21					4257	4270		10.1038/s41388-020-1285-5	http://dx.doi.org/10.1038/s41388-020-1285-5		APR 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LQ2DH	32291414	Green Accepted, Green Submitted			2022-12-28	WOS:000526237900001
J	Neeli, PK; Gollavilli, PN; Mallappa, S; Hari, SG; Kotamraju, S				Neeli, Praveen Kumar; Gollavilli, Paradesi Naidu; Mallappa, Sreevidya; Hari, Sai Gayathri; Kotamraju, Srigiridhar			A novel metadherin Delta 7 splice variant enhances triple negative breast cancer aggressiveness by modulating mitochondrial function via NF & x138;B-SIRT3 axis	ONCOGENE			English	Article							ASTROCYTE-ELEVATED GENE-1; MANGANESE SUPEROXIDE-DISMUTASE; ACTIVATION POTENTIAL ROLE; NITRIC-OXIDE; EXPRESSION; SIRT3; PROGRESSION; PROLIFERATION; KNOCKDOWN; DOXORUBICIN	Metadherin (MTDH) expression inversely correlates with prognosis of several cancers including mammary carcinomas. In this work, we identified a novel splice variant of MTDH with exon7 skipping (MTDH Delta 7) and its levels were found significantly high in triple negative breast cancer (TNBC) cells and in patients diagnosed with TNBC. Selective overexpression of MTDH Delta 7 in MDA-MB-231 and BT-549 cells enhanced proliferation, invasion, and epithelial-to-mesenchymal (EMT) transition markers in comparison to its wildtype counterpart. In contrast, knockdown of MTDH Delta 7 induced antiproliferative/antiinvasive effects. Mechanistically, MTDH-NF & x138;B-p65 complex activated SIRT3 transcription by binding to its promoter that in turn enhanced MnSOD levels and promoted EMT in TNBC cells. Intriguingly, mitochondrial OCR through Complex-I and -IV, and glycolytic rate (ECAR) were significantly high in MDA-MB-231 cells stably expressing MTDH Delta 7. While depletion of SIRT3 inhibited MTDH-Wt/Delta 7-induced OCR and ECAR, knockdown of MnSOD inhibited only ECAR. In addition, MTDH-Wt/Delta 7-mediated pro-proliferative/-invasive effects were greatly obviated with either siSIRT3 or siMnSOD in these cells. The functional relevance of MTDH Delta 7 was further proved under in vivo conditions in an orthotopic mouse model of breast cancer. Mice bearing labeled MDA-MB-231 cells stably expressing MTDH Delta 7 showed significantly more tumor growth and metastatic ability to various organs in comparison to MTDH-Wt bearing mice. Taken together, MTDH Delta 7 promotes TNBC aggressiveness through enhanced mitochondrial biogenesis/function, which perhaps serves as a biomarker.	[Neeli, Praveen Kumar; Gollavilli, Paradesi Naidu; Mallappa, Sreevidya; Kotamraju, Srigiridhar] CSIR Indian Inst Chem Technol, Dept Appl Biol, Uppal Rd, Hyderabad 500007, Telangana, India; [Neeli, Praveen Kumar; Gollavilli, Paradesi Naidu; Mallappa, Sreevidya; Kotamraju, Srigiridhar] Acad Sci & Innovat Res Training & Dev Complex, Chennai 600113, Tamil Nadu, India; [Hari, Sai Gayathri] Osmania Univ, Dept Genet, Hyderabad, Telangana, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Technology (IICT); Academy of Scientific & Innovative Research (AcSIR); Osmania University	Kotamraju, S (corresponding author), CSIR Indian Inst Chem Technol, Dept Appl Biol, Uppal Rd, Hyderabad 500007, Telangana, India.; Kotamraju, S (corresponding author), Acad Sci & Innovat Res Training & Dev Complex, Chennai 600113, Tamil Nadu, India.	giridhar@iict.res.in	Neeli, Praveen Kumar/AFK-2292-2022; Neeli, Praveen/AAF-9573-2022; Neeli, Praveen/AGG-9798-2022	Neeli, Praveen Kumar/0000-0002-4291-6223; Neeli, Praveen/0000-0002-4291-6223; 	Department of Biotechnology; Department of Science and Technology; Council of Scientific and Industrial Research, India; ICMR; UGC; CSIR; CSIR-IICT [IICT/Pubs/2019/186]	Department of Biotechnology; Department of Science and Technology(Department of Science & Technology (India)); Council of Scientific and Industrial Research, India(Council of Scientific & Industrial Research (CSIR) - India); ICMR(Indian Council of Medical Research (ICMR)); UGC(University Grants Commission, India); CSIR(Council of Scientific & Industrial Research (CSIR) - India); CSIR-IICT	This work was supported by grants from the Department of Biotechnology, Department of Science and Technology, and Council of Scientific and Industrial Research, India. PKN, PNG and SM acknowledge ICMR, UGC and CSIR, for the award of a research fellowship. The authors thank Dr Madhusudhana Kuncha, Ms Sravya Panangipalli, Mr Subbarao Tulimilli, Mr Kanaka Raju Yellusani, and Mr Suresh Yerramsetty for their excellent technical support during animal experimentation, IVIS live imaging, and cell cycle analysis. We thank Dr Nishant Jain for helping in the generation of lentiviral constructs. We thank Dr Mahesh Kumar Jerald for helping in tissue mitotic index analysis and quantification. We also thank Prof. Vishnupriya Satti and Dr Sandhya Annamaneni for providing human breast cancer tissues samples. We thank Director, CSIR-IICT (Ms. No. IICT/Pubs/2019/186) for providing all the required facilities to carry out the work.	Alhazzazi TY, 2011, CANCER-AM CANCER SOC, V117, P1670, DOI 10.1002/cncr.25676; Brown DM, 2004, CANCER CELL, V5, P365, DOI 10.1016/S1535-6108(04)00079-0; Climente-Gonzalez H, 2017, CELL REP, V20, P2215, DOI 10.1016/j.celrep.2017.08.012; Cui Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129834; Dhar SK, 2011, CANCER RES, V71, P6684, DOI 10.1158/0008-5472.CAN-11-1233; Emdad L, 2006, CANCER RES, V66, P1509, DOI 10.1158/0008-5472.CAN-05-3029; Emdad L, 2009, P NATL ACAD SCI USA, V106, P21300, DOI 10.1073/pnas.0910936106; Fernandez-Marcos PJ, 2012, SCI REP-UK, V2, DOI 10.1038/srep00425; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Gollavilli PN, 2015, FEBS J, V282, P3971, DOI 10.1111/febs.13391; Hart PC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7053; Haug S, 2015, INT J CANCER, V136, P2328, DOI 10.1002/ijc.29289; He SZ, 2014, CELL PHYSIOL BIOCHEM, V34, P2061, DOI 10.1159/000366401; He WJ, 2012, TRENDS ENDOCRIN MET, V23, P467, DOI 10.1016/j.tem.2012.07.004; Huang JY, 2010, BBA-PROTEINS PROTEOM, V1804, P1645, DOI 10.1016/j.bbapap.2009.12.021; Kanugula AK, 2014, FEBS J, V281, P3719, DOI 10.1111/febs.12893; Karnewar S, 2018, BBA-MOL BASIS DIS, V1864, P1115, DOI 10.1016/j.bbadis.2018.01.018; Kenny TC, 2017, ONCOGENE, V36, P4393, DOI 10.1038/onc.2017.52; Kikuno N, 2007, ONCOGENE, V26, P7647, DOI 10.1038/sj.onc.1210572; Kim HS, 2010, CANCER CELL, V17, P41, DOI 10.1016/j.ccr.2009.11.023; Kotamraju S, 2007, CANCER RES, V67, P7386, DOI 10.1158/0008-5472.CAN-07-0993; Li C, 2011, J SURG ONCOL, V103, P184, DOI 10.1002/jso.21788; Li J, 2008, CLIN CANCER RES, V14, P3319, DOI 10.1158/1078-0432.CCR-07-4054; Li MX, 2017, ONCOL LETT, V13, P2385, DOI 10.3892/ol.2017.5695; Liang YJ, 2015, CANCER RES, V75, P3672, DOI 10.1158/0008-5472.CAN-15-0930; Liu HY, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-19; Liu R, 2015, MOL CANCER THER, V14, P2090, DOI 10.1158/1535-7163.MCT-15-0017; Liu XQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017582; Loo SY, 2016, ANTIOXID REDOX SIGN, V25, P283, DOI 10.1089/ars.2015.6524; Mallappa S, 2019, MOL CARCINOGEN, V58, P1118, DOI 10.1002/mc.22996; Meng X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019877; Muccioli M, 2011, JOVE-J VIS EXP, DOI 10.3791/2785; Penney ME, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5346-5; Redig AJ, 2013, J INTERN MED, V274, P113, DOI 10.1111/joim.12084; Sarkar D, 2008, CANCER RES, V68, P1478, DOI 10.1158/0008-5472.CAN-07-6164; Sarkar D, 2009, CANCER RES, V69, P8529, DOI 10.1158/0008-5472.CAN-09-1846; Spinazzi M, 2012, NAT PROTOC, V7, P1235, DOI 10.1038/nprot.2012.058; Tao RD, 2014, ANTIOXID REDOX SIGN, V20, P1646, DOI 10.1089/ars.2013.5482; Tao RD, 2010, MOL CELL, V40, P893, DOI 10.1016/j.molcel.2010.12.013; Thorsen K, 2008, MOL CELL PROTEOMICS, V7, P1214, DOI 10.1074/mcp.M700590-MCP200; Tokunaga E, 2014, BREAST CANCER-TOKYO, V21, P341, DOI 10.1007/s12282-012-0398-2; Travis RC, 2010, LANCET, V375, P2143, DOI 10.1016/S0140-6736(10)60636-8; Vasamsetti SB, 2015, DIABETES, V64, P2028, DOI 10.2337/db14-1225; Vaupel P, 2012, INT J BIOCHEM CELL B, V44, P1477, DOI 10.1016/j.biocel.2012.05.019; Wagner BA, 2005, ARCH BIOCHEM BIOPHYS, V440, P181, DOI 10.1016/j.abb.2005.06.015; Yang L, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-1042-7; Zhao Y, 2013, ANN DIAGN PATHOL, V17, P483, DOI 10.1016/j.anndiagpath.2013.06.001; Zhou CX, 2016, ONCOTARGET, V7, P1288, DOI 10.18632/oncotarget.6339	48	12	13	3	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	10					2088	2102		10.1038/s41388-019-1126-6	http://dx.doi.org/10.1038/s41388-019-1126-6			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KS8UR	31806873				2022-12-28	WOS:000518584000005
J	Liu, K; Wang, BJ; Han, WW; Chi, CH; Gu, C; Wang, Y; Fu, XH; Huang, W; Liu, ZG; Song, XL				Liu, Kai; Wang, Ben-Jun; Han, WeiWei; Chi, Chun-Hua; Gu, Chao; Wang, Yu; Fu, Xiaohai; Huang, Wei; Liu, Zhiguo; Song, Xilin			CFIm25-regulated lncRNA acv3UTR promotes gastric tumorigenesis via miR-590-5p/YAP1 axis	ONCOGENE			English	Article							COMPETING ENDOGENOUS RNA; MONOCYTE/MACROPHAGE DIFFERENTIATION; POSTTRANSCRIPTIONAL REGULATION; CANCER CELLS; CERNA; EXPRESSION; INVASION; ACTIVIN; PROLIFERATION; PHOSPHORYLATION	Accumulating evidences indicate that 3MODIFIER LETTER PRIMEUTR of the coding gene can act as crucial regulators in gastric cancer (GC). However, the detailed mechanisms and responsive targets are not well established. Here, we found that acvr1b gene 3MODIFIER LETTER PRIMEUTR (acv3UTR) was elevated in GC tissue, the expression of which was significantly correlated with advanced pTNM-stage and poor outcome in clinical patients. Forced expression of acv3UTR promoted GC cells growth in vitro and in vivo. Mechanistically, our results suggested that acv3UTR functioned as an oncogenic competing endogenous RNA via sponging miR-590-5p and enhancing YAP1 level. Tumor suppressor miR-590-5p was a molecular module in acv3UTR regulatory axis, the forced expression of which led to impairing of oncogenic potential of acv3UTR. The positive correlation of acv3UTR and YAP1 expression, and the negative correlation of acv3UTR and miR-590-5p expression, were verified in GC patients. Moreover, CFIm25 was identified as a key regulator contributing to acv3UTR aberrant expression in GC binding to UGUA-264 motif. Overall, our finding defines a mechanism for understanding the potential role of acv3UTR transcription in GC tumorigenesis, and indicates a correlation between 3MODIFIER LETTER PRIMEUTR trans-regulatory effect and GC development.	[Liu, Kai; Song, Xilin] Shandong Canc Hosp & Inst, Dept Gastrointestinal Surg, Jinan, Peoples R China; [Wang, Ben-Jun; Han, WeiWei; Chi, Chun-Hua; Gu, Chao] Shandong Univ Tradit Chinese Med, Affiliated Hosp, Dept Anorectal Surg, Jinan 250014, Shandong, Peoples R China; [Wang, Yu] Shandong Univ Tradit Chinese Med, Affiliated Hosp, Dept Radiol, Jinan 250014, Shandong, Peoples R China; [Fu, Xiaohai] Shouguang Peoples Hosp, Dept Intens Care Unit, Shouguang, Shandong, Peoples R China; [Huang, Wei] Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Peoples R China; [Liu, Zhiguo] Shandong Canc Hosp & Inst, PET CT Ctr, Jinan, Peoples R China	Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University of Traditional Chinese Medicine; Shandong University of Traditional Chinese Medicine; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong First Medical University & Shandong Academy of Medical Sciences	Song, XL (corresponding author), Shandong Canc Hosp & Inst, Dept Gastrointestinal Surg, Jinan, Peoples R China.	xilin_song1980@163.com			National Natural Science Foundation of China [81773232, 81601554]; Natural Science Foundation of Shandong Province [ZR2013H1109, ZR2013HM43]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province)	This study was supported by the National Natural Science Foundation of China (81773232 and 81601554) and Natural Science Foundation of Shandong Province (ZR2013H1109 and ZR2013HM43).	Abdelmohsen K, 2010, WIRES RNA, V1, P214, DOI 10.1002/wrna.4; Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005; Arun Kanagaraj, 2018, Oncotarget, V9, P18386, DOI 10.18632/oncotarget.24841; Briata P, 2011, FRONT BIOSCI-LANDMRK, V16, P1787, DOI 10.2741/3821; Chen MT, 2015, MOL CELL BIOL, V35, P3212, DOI 10.1128/MCB.00429-15; Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233; Ergun S, 2015, TUMOR BIOL, V36, P3129, DOI 10.1007/s13277-015-3346-x; Ferro A, 2014, EUR J CANCER, V50, P1330, DOI 10.1016/j.ejca.2014.01.029; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Gao SM, 2016, J MOL HISTOL, V47, P135, DOI 10.1007/s10735-016-9659-2; Gratacos FM, 2010, WIRES RNA, V1, P457, DOI 10.1002/wrna.26; Hanninen UA, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007200; Hao YW, 2008, J BIOL CHEM, V283, P5496, DOI 10.1074/jbc.M709037200; Harrison CA, 2003, J BIOL CHEM, V278, P21129, DOI 10.1074/jbc.M302015200; Hellman LM, 2007, NAT PROTOC, V2, P1849, DOI 10.1038/nprot.2007.249; Hu-Lowe DD, 2011, CANCER RES, V71, P1362, DOI 10.1158/0008-5472.CAN-10-1451; Jiang XF, 2012, MOL CELLS, V33, P545, DOI 10.1007/s10059-012-2267-4; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; Kang W, 2011, CLIN CANCER RES, V17, P2130, DOI 10.1158/1078-0432.CCR-10-2467; Karimi P, 2014, CANCER EPIDEM BIOMAR, V23, P700, DOI 10.1158/1055-9965.EPI-13-1057; Karreth FA, 2015, CELL, V161, P319, DOI 10.1016/j.cell.2015.02.043; Levy D, 2008, MOL CELL, V29, P350, DOI 10.1016/j.molcel.2007.12.022; Li FX, 2018, MED SCI MONITOR, V24, P37, DOI 10.12659/MSM.905410; Lin HS, 2014, J LEUKOCYTE BIOL, V96, P1023, DOI 10.1189/jlb.1A0514-240R; Liu X, 2013, ONCOGENE, V32, P1266, DOI 10.1038/onc.2012.147; Lu MH, 2016, ONCOGENE, V35, P3524, DOI 10.1038/onc.2015.413; Mahoney S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152010; Masamha CP, 2014, NATURE, V510, P412, DOI 10.1038/nature13261; Mayr C, 2009, CELL, V138, P673, DOI 10.1016/j.cell.2009.06.016; Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007; Mercer TR, 2011, NUCLEIC ACIDS RES, V39, P2393, DOI 10.1093/nar/gkq1158; Mitchell D, 2010, MOL CANCER THER, V9, P379, DOI 10.1158/1535-7163.MCT-09-0650; Mizuno Y, 2009, FEBS LETT, V583, P2263, DOI 10.1016/j.febslet.2009.06.006; Morlando M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020570; Nomura M, 2013, BIOCHEM BIOPH RES CO, V430, P340, DOI 10.1016/j.bbrc.2012.11.011; Ogilvie RL, 2005, J IMMUNOL, V174, P953, DOI 10.4049/jimmunol.174.2.953; Ou CL, 2017, CANCER LETT, V399, P53, DOI 10.1016/j.canlet.2017.04.011; Peleteiro B, 2014, EUR J CANCER PREV, V23, P524, DOI 10.1097/CEJ.0b013e328364f2b6; Qiu WL, 2016, GASTROENTEROLOGY, V150, P218, DOI 10.1053/j.gastro.2015.09.013; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Sandberg R, 2008, SCIENCE, V320, P1643, DOI 10.1126/science.1155390; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Song M, 2012, ANTICANCER RES, V32, P3827; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; TENDIJKE P, 1993, ONCOGENE, V8, P2879; Thomson DW, 2016, NAT REV GENET, V17, P272, DOI 10.1038/nrg.2016.20; Togashi Y, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-126; Vislovukh Andrii, 2014, World J Biol Chem, V5, P40, DOI 10.4331/wjbc.v5.i1.40; Wan XC, 2018, ONCOTARGET, V9, P4798, DOI 10.18632/oncotarget.23219; Xiao XC, 2012, ONCOL RES, V20, P537, DOI 10.3727/096504013X13775486749335; Xu J, 2015, NUCLEIC ACIDS RES, V43, P8169, DOI 10.1093/nar/gkv853; Xu Y, 2018, CELL PHYSIOL BIOCHEM, V46, P2445, DOI 10.1159/000489651; Yang Q, 2011, STRUCTURE, V19, P368, DOI 10.1016/j.str.2010.12.021; Zanconato F, 2019, NAT REV CANCER, V19, P454, DOI 10.1038/s41568-019-0168-y; Zhang G, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0829-6; Zhang JL, 2019, ONCOGENE, V38, P33, DOI 10.1038/s41388-018-0430-x; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810; Zhao J, 2015, CELL CYCLE, V14, P3112, DOI 10.1080/15384101.2015.1078034; Zheng LF, 2018, EUR J CELL BIOL, V97, P23, DOI 10.1016/j.ejcb.2017.11.002; Zhu Y, 2018, MOL CELL, V69, P62, DOI 10.1016/j.molcel.2017.11.031	60	6	6	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	15					3075	3088		10.1038/s41388-020-1213-8	http://dx.doi.org/10.1038/s41388-020-1213-8		FEB 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LB8NS	32066878	hybrid, Green Published			2022-12-28	WOS:000514052700001
J	Struve, N; Binder, ZA; Stead, LF; Brend, T; Bagley, SJ; Faulkner, C; Ott, L; Muller-Goebel, J; Weik, AS; Hoffer, K; Krug, L; Rieckmann, T; Bussmann, L; Henze, M; Morrissette, JJD; Kurian, KM; Schuller, U; Petersen, C; Rothkamm, K; O'Rourke, DM; Short, SC; Kriegs, M				Struve, Nina; Binder, Zev A.; Stead, Lucy F.; Brend, Tim; Bagley, Stephen J.; Faulkner, Claire; Ott, Leonie; Mueller-Goebel, Justus; Weik, Anna-Sophie; Hoffer, Konstantin; Krug, Leonie; Rieckmann, Thorsten; Bussmann, Lara; Henze, Marvin; Morrissette, Jennifer J. D.; Kurian, Kathreena M.; Schueller, Ulrich; Petersen, Cordula; Rothkamm, Kai; O'Rourke, Donald M.; Short, Susan C.; Kriegs, Malte			EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; VARIANT III EGFRVIII; PROGNOSTIC-SIGNIFICANCE; ADJUVANT TEMOZOLOMIDE; PAIRED PRIMARY; EXPRESSION; GENE; MUTATIONS; THERAPY; CELLS	The oncogene epidermal growth factor receptor variant III (EGFRvIII) is frequently expressed in glioblastomas (GBM) but its impact on therapy response is still under controversial debate. Here we wanted to test if EGFRvIII influences the sensitivity towards the alkylating agent temozolomide (TMZ). Therefore, we retrospectively analyzed the survival of 336 GBM patients, demonstrating that under standard treatment, which includes TMZ, EGFRvIII expression is associated with prolonged survival, but only in patients with O6-methylguanine-DNA methyltransferase (MGMT) promoter methylated tumors. Using isogenic GBM cell lines with endogenous EGFRvIII expression we could demonstrate that EGFRvIII increases TMZ sensitivity and results in enhanced numbers of DNA double-strand breaks and a pronounced S/G2-phase arrest after TMZ treatment. We observed a higher expression of DNA mismatch repair (MMR) proteins in EGFRvIII+ cells and patient tumor samples, which was most pronounced for MSH2 and MSH6. EGFRvIII-specific knockdown reduced MMR protein expression thereby increasing TMZ resistance. Subsequent functional kinome profiling revealed an increased activation of p38- and ERK1/2-dependent signaling in EGFRvIII expressing cells, which regulates MMR protein expression downstream of EGFRvIII. In summary, our results demonstrate that the oncoprotein EGFRvIII sensitizes a fraction of GBM to current standard of care treatment through the upregulation of DNA MMR.	[Struve, Nina; Ott, Leonie; Mueller-Goebel, Justus; Weik, Anna-Sophie; Hoffer, Konstantin; Krug, Leonie; Rieckmann, Thorsten; Bussmann, Lara; Henze, Marvin; Petersen, Cordula; Rothkamm, Kai; Kriegs, Malte] Univ Med Ctr Hamburg Eppendorf, Univ Canc Ctr Hamburg, Hubertus Wald Tumorzentrum, Lab Radiobiol & Expt Radiat Oncol, Hamburg, Germany; [Binder, Zev A.; O'Rourke, Donald M.] Univ Penn, Perelman Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; [Stead, Lucy F.; Brend, Tim; Short, Susan C.] St James Univ Hosp, Leeds Inst Med Res St Jamess, Wellcome Trust Brenner Bldg, Leeds, W Yorkshire, England; [Bagley, Stephen J.] Univ Penn, Dept Med, Perelman Sch Med, Div Hematol Oncol, Philadelphia, PA 19104 USA; [Faulkner, Claire] Southmead Hosp, Bristol Genet Lab, Bristol, Avon, England; [Krug, Leonie; Rieckmann, Thorsten; Bussmann, Lara] Univ Med Ctr Hamburg Eppendorf, Dept Otorhinolaryngol & Head & Neck Surg, Hamburg, Germany; [Henze, Marvin; Petersen, Cordula] Univ Med Ctr Hamburg Eppendorf, Dept Radiotherapy & Radiooncol, Hamburg, Germany; [Morrissette, Jennifer J. D.] Hosp Univ Penn, Dept Pathol & Lab Med, Div Precis & Computat Diagnost, 3400 Spruce St, Philadelphia, PA 19104 USA; [Kurian, Kathreena M.] Univ Bristol, Bristol Brain Tumour Res Ctr, Bristol, Avon, England; [Schueller, Ulrich] Childrens Canc Ctr Hamburg, Res Inst, Hamburg, Germany; [Schueller, Ulrich] Univ Med Ctr Hamburg Eppendorf, Inst Neuropathol, Hamburg, Germany; [Schueller, Ulrich] Univ Med Ctr Hamburg Eppendorf, Dept Pediat Hematol & Oncol, Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Pennsylvania; Pennsylvania Medicine; Saint James's University Hospital; University of Pennsylvania; Pennsylvania Medicine; Southmead Hospital; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Pennsylvania; Pennsylvania Medicine; University of Bristol; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf	Struve, N (corresponding author), Univ Med Ctr Hamburg Eppendorf, Univ Canc Ctr Hamburg, Hubertus Wald Tumorzentrum, Lab Radiobiol & Expt Radiat Oncol, Hamburg, Germany.	ni.struve@uke.de	O'Rourke, Donald/AAC-3376-2021; Petersen, Cordula/AAW-9789-2020; Ott, Leonie/ABA-2973-2020; Rothkamm, Kai/A-2164-2014	Brend, Tim/0000-0001-9703-7042; Kurian, Kathreena/0000-0003-0303-3716; Bussmann, Lara/0000-0001-6302-0859; Stead, Lucy/0000-0002-9550-4150; Short, Susan/0000-0003-4423-7256; Rothkamm, Kai/0000-0001-7414-5729; Rieckmann, Thorsten/0000-0001-8426-107X	Brigitte and Dr. Konstanze Wegener-Stiftung; Wilhelm-Sander-Stiftung; Forschungsforderungsfonds des Fachbereichs Medizin des Universitatsklinikums Hamburg-Eppendorf; Federal Ministry of Education and Research (BMBF) [02NUK032]; Cancer Research UK [CRUK/21600]; Brain Tumour Charity [TBTC13/192]; Medical Research Council [MR/K015214/1]; University of Leeds Academic Fellowship; Templeton Family Research Fund; Maria and Gabriele Troiano Brain Cancer Immunotherapy Fund; National Institutes of Health [NIH 2R01-NS042645-11A1]; Fordergemeinschaft Kinderkrebs-Zentrum Hamburg; Projekt DEAL	Brigitte and Dr. Konstanze Wegener-Stiftung; Wilhelm-Sander-Stiftung; Forschungsforderungsfonds des Fachbereichs Medizin des Universitatsklinikums Hamburg-Eppendorf; Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); Cancer Research UK(Cancer Research UK); Brain Tumour Charity; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); University of Leeds Academic Fellowship; Templeton Family Research Fund; Maria and Gabriele Troiano Brain Cancer Immunotherapy Fund; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Fordergemeinschaft Kinderkrebs-Zentrum Hamburg; Projekt DEAL	This work was supported by the Brigitte and Dr. Konstanze Wegener-Stiftung (MK), Wilhelm-Sander-Stiftung (MK), Forschungsforderungsfonds des Fachbereichs Medizin des Universitatsklinikums Hamburg-Eppendorf (NS) and the Federal Ministry of Education and Research (BMBF grant 02NUK032; MK, KR), Cancer Research UK (CRUK/21600; SCS, TB), The Brain Tumour Charity (TBTC13/192; SCS, TB), Medical Research Council (MR/K015214/1; SCS, TB), University of Leeds Academic Fellowship (LFS), The Templeton Family Research Fund (ZAB), The Maria and Gabriele Troiano Brain Cancer Immunotherapy Fund (ZAB, DOR) and the National Institutes of Health (NIH 2R01-NS042645-11A1; DOR). U.S. is supported by the Fordergemeinschaft Kinderkrebs-Zentrum Hamburg. Open access funding provided by Projekt DEAL.	Arni S, 2017, ONCOTARGET, V8, P68599, DOI 10.18632/oncotarget.19803; Bienkowski M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065444; Binder ZA, 2018, CANCER CELL, V34, P163, DOI 10.1016/j.ccell.2018.06.006; Boyd PS, 2016, NANOSCALE, V8, P20037, DOI 10.1039/c6nr05880a; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Brown PD, 2008, J CLIN ONCOL, V26, P5603, DOI 10.1200/JCO.2008.18.0612; Cominelli M, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv041; D'Atri S, 1998, MOL PHARMACOL, V54, P334, DOI 10.1124/mol.54.2.334; Dosch J, 1998, CARCINOGENESIS, V19, P567, DOI 10.1093/carcin/19.4.567; Dunn J, 2009, BRIT J CANCER, V101, P124, DOI 10.1038/sj.bjc.6605127; Fan QW, 2013, CANCER CELL, V24, P438, DOI 10.1016/j.ccr.2013.09.004; Faulkner C, 2015, BRIT J NEUROSURG, V29, P23, DOI 10.3109/02688697.2014.950631; Felsberg J, 2017, CLIN CANCER RES, V23, P6846, DOI 10.1158/1078-0432.CCR-17-0890; Felsberg J, 2011, INT J CANCER, V129, P659, DOI 10.1002/ijc.26083; Gan HK, 2009, J CLIN NEUROSCI, V16, P748, DOI 10.1016/j.jocn.2008.12.005; Gazzoli I, 2003, MOL CELL BIOL, V23, P7992, DOI 10.1128/MCB.23.22.7992-8007.2003; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Heimberger AB, 2005, CLIN CANCER RES, V11, P1462, DOI 10.1158/1078-0432.CCR-04-1737; Ito M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062351; Kaina B, 2002, INT J CLIN PHARM TH, V40, P354; Kaina B, 2001, PROG NUCLEIC ACID RE, V68, P41; Kriegs M, 2015, RADIOTHER ONCOL, V115, P120, DOI 10.1016/j.radonc.2015.02.018; Lei XF, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh098; Li G, 2012, J NEURO-ONCOL, V108, P395, DOI 10.1007/s11060-012-0842-3; Liu L, 2005, J MOL MED, V83, P917, DOI 10.1007/s00109-005-0700-2; McFaline-Figueroa JL, 2015, CANCER RES, V75, P3127, DOI 10.1158/0008-5472.CAN-14-3616; Mojas N, 2007, GENE DEV, V21, P3342, DOI 10.1101/gad.455407; Montano N, 2011, NEOPLASIA, V13, P1113, DOI 10.1593/neo.111338; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; Mukherjee B, 2009, CANCER RES, V69, P4252, DOI 10.1158/0008-5472.CAN-08-4853; Nasrallah MP, 2019, ACAD PATHOL, V6, DOI 10.1177/2374289519848353; O'Rourke DM, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaa0984; Peereboom DM, 2010, J NEURO-ONCOL, V98, P93, DOI 10.1007/s11060-009-0067-2; Portnow J, 2009, CLIN CANCER RES, V15, P7092, DOI 10.1158/1078-0432.CCR-09-1349; Qi ST, 2011, ONCOL REP, V26, P1479, DOI 10.3892/or.2011.1428; Quiros S, 2010, CELL CYCLE, V9, P168, DOI 10.4161/cc.9.1.10363; Reardon DA, 2017, NEURO-ONCOLOGY, V19, P965, DOI 10.1093/neuonc/now257; Riedel M, 2016, ONCOTARGET, V7, P61988, DOI 10.18632/oncotarget.11328; Sanson M, 2009, J CLIN ONCOL, V27, P4150, DOI 10.1200/JCO.2009.21.9832; Scherer SJ, 2000, J BIOL CHEM, V275, P37469, DOI 10.1074/jbc.M006990200; Shinojima N, 2003, CANCER RES, V63, P6962; Smrdel U, 2016, RADIOL ONCOL, V50, P394, DOI 10.1515/raon-2015-0041; Struve N, 2015, ONCOTARGET, V6, P33867, DOI 10.18632/oncotarget.5293; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Tanaka K, 2011, CANCER DISCOV, V1, P524, DOI 10.1158/2159-8290.CD-11-0124; van den Bent M, 2017, CANCER CHEMOTH PHARM, V80, P1209, DOI 10.1007/s00280-017-3451-1; van den Bent MJ, 2015, NEURO-ONCOLOGY, V17, P935, DOI 10.1093/neuonc/nov013; Wachsberger PR, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00013; Weller M, 2017, LANCET ONCOL, V18, P1373, DOI 10.1016/S1470-2045(17)30517-X; Weller M, 2014, INT J CANCER, V134, P2437, DOI 10.1002/ijc.28576; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; Yip S, 2009, CLIN CANCER RES, V15, P4622, DOI 10.1158/1078-0432.CCR-08-3012; Zheng QF, 2014, NEURO-ONCOLOGY, V16, P1229, DOI 10.1093/neuonc/nou046	53	27	27	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	15					3041	3055		10.1038/s41388-020-1208-5	http://dx.doi.org/10.1038/s41388-020-1208-5		FEB 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LB8NS	32066879	hybrid, Green Published			2022-12-28	WOS:000514052700003
J	Yu, ZB; Feng, JB; Wang, W; Deng, ZY; Zhang, Y; Xiao, L; Wang, ZY; Liu, CH; Liu, Q; Chen, S; Wu, MH				Yu, Zhibin; Feng, Jianbo; Wang, Wei; Deng, Zhiyong; Zhang, Yan; Xiao, Lan; Wang, Zeyou; Liu, Changhong; Liu, Qing; Chen, Shuai; Wu, Minghua			The EGFR-ZNF263 signaling axis silences SIX3 in glioblastoma epigenetically	ONCOGENE			English	Article							INTEGRATED GENOMIC ANALYSIS; TUMOR-SUPPRESSOR; C-MYC; MUTATION; REPRESSION; EXPRESSION; FAMILY; EGFR; IDH1; METHYLATION	The homeotic protein SIX3 is a transcription factor vital for neurogenesis and has a bivalent promoter. We previously showed that SIX3 can be transcriptionally silenced by DNA hypermethylation, functions as a tumor suppressor gene, and inhibits human glioblastoma transcriptionally. Here, we show that the activation of epidermal growth factor (EGFR) induces DNA methylation of SIX3 promoter through the MAPK pathway. ERK, when activated, binds with ZNF263, consequently abrogating the ubiquitination of ZNF263 and leading to its stabilization. ZNF263 binds to the core promoter region of SIX3 and recruits the KAP1/HATS/DNMT corepressor complex to induce transcriptional silencing of SIX3 through H3K27me3 and methylation of SIX3 promoter. Activation of the EGFR-ZNF263 signaling axis in phenotypically normal astrocytes or glioblastoma cells triggers or enhances tumorigenic activities, while elevated expression of the EGFR-ZNF263 signaling components in glioblastoma tissues is associated with poor prognosis of the patients. Together, our findings demonstrate that epigenetic silencing of SIX3 is controlled by a sophisticated and highly ordered oncogenic signaling pathway and therefore provide new insights into initiation and progression of glioblastoma.	[Yu, Zhibin; Feng, Jianbo; Deng, Zhiyong; Zhang, Yan; Liu, Changhong; Chen, Shuai; Wu, Minghua] Cent South Univ, Xiangya Med Sch, Hunan Prov Tumor Hosp, Changsha 410013, Hunan, Peoples R China; [Yu, Zhibin; Feng, Jianbo; Deng, Zhiyong; Zhang, Yan; Liu, Changhong; Chen, Shuai; Wu, Minghua] Cent South Univ, Xiangya Med Sch, Affiliated Tumor Hosp, Changsha 410013, Hunan, Peoples R China; [Yu, Zhibin; Feng, Jianbo; Zhang, Yan; Xiao, Lan; Liu, Changhong; Wu, Minghua] Cent South Univ, Sch Basic Med Sci, Canc Res Inst,Minist Hlth, Key Lab Carcinogenesis & Canc Invas,Minist Educ,K, Changsha 410078, Hunan, Peoples R China; [Yu, Zhibin; Feng, Jianbo] Shanghai Jiao Tong Univ, Yale Inst Immune Metab, Sch Med, Shanghai 200025, Peoples R China; [Wang, Wei] Jining Med Univ, Dept Pathol, Affiliated Hosp, Jining 272000, Shandong, Peoples R China; [Wang, Zeyou] Cent South Univ, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China; [Liu, Qing] Cent South Univ, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China	Central South University; Central South University; Central South University; Shanghai Jiao Tong University; Jining Medical University; Central South University; Central South University	Chen, S; Wu, MH (corresponding author), Cent South Univ, Xiangya Med Sch, Hunan Prov Tumor Hosp, Changsha 410013, Hunan, Peoples R China.; Chen, S; Wu, MH (corresponding author), Cent South Univ, Xiangya Med Sch, Affiliated Tumor Hosp, Changsha 410013, Hunan, Peoples R China.; Wu, MH (corresponding author), Cent South Univ, Sch Basic Med Sci, Canc Res Inst,Minist Hlth, Key Lab Carcinogenesis & Canc Invas,Minist Educ,K, Changsha 410078, Hunan, Peoples R China.	chenshuai16@139.com; wuminghua554@aliyun.com			National Natural Science Foundation of China [81874850, 81502185]; Graduate Student Research Innovation Project in Hunan Province [2019zzts084]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Graduate Student Research Innovation Project in Hunan Province	This work was supported by the National Natural Science Foundation of China (Grant No. 81874850, 81502185) and Graduate Student Research Innovation Project in Hunan Province (2019zzts084).	Arnold HK, 2006, MOL CELL BIOL, V26, P2832, DOI 10.1128/MCB.26.7.2832-2844.2006; Bierhoff H, 2014, MOL CELL, V54, P675, DOI 10.1016/j.molcel.2014.03.032; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Carl M, 2002, DEVELOPMENT, V129, P4057; Carlin D, 2012, DEVELOPMENT, V139, P2614, DOI 10.1242/dev.076018; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chan KM, 2013, GENE DEV, V27, P985, DOI 10.1101/gad.217778.113; Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; De Carvalho DD, 2012, CANCER CELL, V21, P655, DOI 10.1016/j.ccr.2012.03.045; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Dingar D, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05660-0; Ecco G, 2017, DEVELOPMENT, V144, P2719, DOI 10.1242/dev.132605; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Forloni M, 2016, CELL REP, V16, P457, DOI 10.1016/j.celrep.2016.05.087; Frattini V, 2013, NAT GENET, V45, P1141, DOI 10.1038/ng.2734; Gazin C, 2007, NATURE, V449, P1073, DOI 10.1038/nature06251; Ge YZ, 2004, J BIOL CHEM, V279, P25447, DOI 10.1074/jbc.M312296200; Geng X, 2016, DEVELOPMENT, V143, P4462, DOI 10.1242/dev.132142; He YF, 2011, SCIENCE, V333, P1303, DOI 10.1126/science.1210944; Helin K, 2013, NATURE, V502, P480, DOI 10.1038/nature12751; Hernandez-Hernandez A, 2006, EMBO J, V25, P3264, DOI 10.1038/sj.emboj.7601228; Jeon Y, 2011, CELL, V146, P119, DOI 10.1016/j.cell.2011.06.026; Koh KH, 2016, METHODS MOL BIOL, V1366, P41, DOI 10.1007/978-1-4939-3127-9_5; Lagutin OV, 2003, GENE DEV, V17, P368, DOI 10.1101/gad.1059403; Lengler J, 2001, BIOCHEM BIOPH RES CO, V287, P372, DOI 10.1006/bbrc.2001.5605; Li QJ, 2003, EMBO J, V22, P281, DOI 10.1093/emboj/cdg028; Lidke DS, 2010, J BIOL CHEM, V285, DOI 10.1074/jbc.M109.064972; Lupo A, 2013, CURR GENOMICS, V14, P268, DOI 10.2174/13892029113149990002; Lv DG, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01731-w; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Ozawa T, 2014, CANCER CELL, V26, P288, DOI 10.1016/j.ccr.2014.06.005; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pasquier L, 2000, EUR J HUM GENET, V8, P797, DOI 10.1038/sj.ejhg.5200540; Pasquier L, 2005, J MED GENET, V42, DOI 10.1136/jmg.2004.023416; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; Riso V, 2016, NUCLEIC ACIDS RES, V44, P8165, DOI 10.1093/nar/gkw505; Roy DM, 2014, PROTEIN CELL, V5, P265, DOI 10.1007/s13238-014-0031-6; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Serra RW, 2014, ELIFE, V3, DOI 10.7554/eLife.02313; Simon JM, 2012, NAT PROTOC, V7, P256, DOI 10.1038/nprot.2011.444; Stupp R, 2014, ANN ONCOL, V25, P93, DOI 10.1093/annonc/mdu050; Thillainadesan G, 2012, MOL CELL, V46, P636, DOI 10.1016/j.molcel.2012.03.027; Thoresen SB, 2014, NAT CELL BIOL, V16, P547, DOI 10.1038/ncb2959; Tsai WB, 2012, CANCER RES, V72, P2622, DOI 10.1158/0008-5472.CAN-11-3605; Turcan S, 2012, NATURE, V483, P479, DOI 10.1038/nature10866; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wajapeyee N, 2013, GENE DEV, V27, P2221, DOI 10.1101/gad.227413.113; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; You JS, 2012, CANCER CELL, V22, P9, DOI 10.1016/j.ccr.2012.06.008; Yu ZB, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0483-2; Zhu CQC, 2002, DEVELOPMENT, V129, P2835; Zhu H, 2009, P NATL ACAD SCI USA, V106, P2712, DOI 10.1073/pnas.0813314106	54	13	14	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	15					3163	3178		10.1038/s41388-020-1206-7	http://dx.doi.org/10.1038/s41388-020-1206-7		FEB 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LB8NS	32051553	Green Published, hybrid			2022-12-28	WOS:000513108700001
J	Yoshimi, A; Trippett, TM; Zhang, N; Chen, XY; Penson, AV; Arcila, ME; Pichardo, J; Baik, J; Sigler, A; Harada, H; Fajgenbaum, DC; Dogan, A; Abdel-Wahab, O; Xiao, WB				Yoshimi, Akihide; Trippett, Tanya M.; Zhang, Nan; Chen, Xueyan; Penson, Alexander, V; Arcila, Maria E.; Pichardo, Janine; Baik, Jeeyeon; Sigler, Allison; Harada, Hironori; Fajgenbaum, David C.; Dogan, Ahmet; Abdel-Wahab, Omar; Xiao, Wenbin			Genetic basis for iMCD-TAFRO	ONCOGENE			English	Article							PLATELET DISORDER; DISEASE; THROMBOCYTOPENIA; PREDISPOSITION; ANASARCA; MUTATION	TAFRO syndrome, a clinical subtype of idiopathic multicentric Castleman disease (iMCD), consists of a constellation of symptoms/signs including thrombocytopenia, anasarca, fever, reticulin fibrosis/renal dysfunction, and organomegaly. The etiology of iMCD-TAFRO and the basis for cytokine hypersecretion commonly seen in iMCD-TAFRO patients has not been elucidated. Here, we identified a somatic MEK2(P128L) mutation and a germline RUNX1(G60C) mutation in two patients with iMCD-TAFRO, respectively. The MEK2(P128L) mutation, which has been identified previously in solid tumor and histiocytosis patients, caused hyperactivated MAP kinase signaling, conferred IL-3 hypersensitivity and sensitized the cells to various MEK inhibitors. The RUNX1(G60C) mutation abolished the transcriptional activity of wild-type RUNX1 and functioned as a dominant negative form of RUNX1, resulting in enhanced self-renewal activity in hematopoietic stem/progenitor cells. Interestingly, ERK was heavily activated in both patients, highlighting a potential role for activation of MAPK signaling in iMCD-TAFRO pathogenesis and a rationale for exploring inhibition of the MAPK pathway as a therapy for iMCD-TAFRO. Moreover, these data suggest that iMCD-TAFRO might share pathogenetic features with clonal inflammatory disorders bearing MEK and RUNX1 mutations such as histiocytoses and myeloid neoplasms.	[Yoshimi, Akihide; Penson, Alexander, V; Abdel-Wahab, Omar; Xiao, Wenbin] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA; [Trippett, Tanya M.] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10065 USA; [Zhang, Nan] SUNY Buffalo, Dept Pathol, Buffalo Gen Med Ctr, Buffalo, NY 14206 USA; [Chen, Xueyan] Univ Washington, Dept Lab Med, Seattle, WA 98109 USA; [Penson, Alexander, V] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA; [Arcila, Maria E.; Pichardo, Janine; Baik, Jeeyeon; Sigler, Allison; Dogan, Ahmet; Xiao, Wenbin] Mem Sloan Kettering Canc Ctr, Dept Pathol, Hematopathol Serv, New York, NY 10065 USA; [Arcila, Maria E.] Mem Sloan Kettering Canc Ctr, Dept Pathol, Diagnost Mol Lab, New York, NY 10065 USA; [Harada, Hironori] Tokyo Univ Pharm & Life Sci, Sch Life Sci, Lab Oncol, Tokyo 1920392, Japan; [Fajgenbaum, David C.] Castleman Dis Collaborat Network, Philadelphia, PA USA; [Abdel-Wahab, Omar] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY 10065 USA; [Zhang, Nan] Rochester Gen Hosp, Dept Pathol, Rochester, NY 14621 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Buffalo General Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University of Washington; University of Washington Seattle; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Tokyo University of Pharmacy & Life Sciences; Memorial Sloan Kettering Cancer Center; Rochester General Hospital	Xiao, WB (corresponding author), Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA.; Xiao, WB (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Pathol, Hematopathol Serv, New York, NY 10065 USA.	xiaow@mskcc.org	Yoshimi, Akihide/I-3792-2019; Arcila, Maria/ABE-2235-2021	Yoshimi, Akihide/0000-0002-0664-7281; 	NIH/NCI Cancer Center Support Grant [P30 CA008748]; Aplastic Anemia and MDS International Foundation (AAMDSIF); Lauri Strauss Leukemia Foundation; Leukemia and Lymphoma Society Special Fellow Award; JSPS Overseas Research Fellowships; NIH/NHLBI [R01 HL128239]; Department of Defense Bone Marrow Failure Research Program [W81XWH-16-1-0059]; Starr Foundation [I8-A8-075]; Henry & Marilyn Taub Foundation; Edward P. Evans Foundation; Josie Robertson Investigator Program; Leukemia and Lymphoma Society; Pershing Square Sohn Cancer Research Alliance; Castleman's Awareness and Research Effort/Castleman Disease Collaborative Network	NIH/NCI Cancer Center Support Grant; Aplastic Anemia and MDS International Foundation (AAMDSIF); Lauri Strauss Leukemia Foundation; Leukemia and Lymphoma Society Special Fellow Award(Leukemia and Lymphoma Society); JSPS Overseas Research Fellowships; NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Department of Defense Bone Marrow Failure Research Program; Starr Foundation; Henry & Marilyn Taub Foundation; Edward P. Evans Foundation; Josie Robertson Investigator Program; Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); Pershing Square Sohn Cancer Research Alliance(Pershing Square Sohn Cancer Research Alliance); Castleman's Awareness and Research Effort/Castleman Disease Collaborative Network	This study was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748. AY is a Special Fellow of The Leukemia and Lymphoma Society and supported by grants from the Aplastic Anemia and MDS International Foundation (AA&MDSIF), the Lauri Strauss Leukemia Foundation, the Leukemia and Lymphoma Society Special Fellow Award, and JSPS Overseas Research Fellowships. OA-W is supported by grants from NIH/NHLBI (R01 HL128239), the Department of Defense Bone Marrow Failure Research Program (W81XWH-16-1-0059), the Starr Foundation (I8-A8-075), the Henry & Marilyn Taub Foundation, the Edward P. Evans Foundation, the Josie Robertson Investigator Program, the Leukemia and Lymphoma Society, and the Pershing Square Sohn Cancer Research Alliance. WX is supported by a grant from Castleman's Awareness and Research Effort/Castleman Disease Collaborative Network.	Abelson S, 2018, NATURE, V559, P400, DOI 10.1038/s41586-018-0317-6; Baker TS, 2018, BLOOD ADV, V2, P2959, DOI 10.1182/bloodadvances.2018023911; Bolze A, 2010, AM J HUM GENET, V87, P873, DOI 10.1016/j.ajhg.2010.10.028; Cheng DT, 2015, J MOL DIAGN, V17, P251, DOI 10.1016/j.jmoldx.2014.12.006; Fajgenbaum DC, 2017, BLOOD, V129, P1646, DOI 10.1182/blood-2016-10-746933; Inoue M, 2013, J CLIN EXP HEMATOP, V53, P95, DOI 10.3960/jslrt.53.95; Iwaki N, 2017, SCI REP-UK, V7, DOI 10.1038/srep42316; Iwaki N, 2016, AM J HEMATOL, V91, P220, DOI 10.1002/ajh.24242; Jaiswal S, 2014, NEW ENGL J MED, V371, P2488, DOI 10.1056/NEJMoa1408617; Kawabata H, 2013, J CLIN EXP HEMATOP, V53, P57, DOI 10.3960/jslrt.53.57; Li ZM, 2019, LEUKEMIA, V33, P1035, DOI 10.1038/s41375-018-0323-6; Liu AY, 2016, LANCET HAEMATOL, V3, pE163, DOI 10.1016/S2352-3026(16)00006-5; Michaud J, 2002, BLOOD, V99, P1364, DOI 10.1182/blood.V99.4.1364; Nagy A, 2018, BLOOD ADV, V2, P481, DOI 10.1182/bloodadvances.2017009654; Ozkaya N, 2018, MODERN PATHOL, V31, P581, DOI 10.1038/modpathol.2017.160; Pierson SK, 2018, AM J HEMATOL, V93, P902, DOI 10.1002/ajh.25123; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Wang F, 2012, J MOL DIAGN, V14, P22, DOI 10.1016/j.jmoldx.2011.08.002; Yoshimi A, 2016, ANN ONCOL, V27, P887, DOI 10.1093/annonc/mdw066; Yoshimi A, 2019, NATURE, V574, P273, DOI 10.1038/s41586-019-1618-0; Yoshimi A, 2011, BLOOD, V117, P3617, DOI 10.1182/blood-2009-12-261602	21	9	9	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	15					3218	3225		10.1038/s41388-020-1204-9	http://dx.doi.org/10.1038/s41388-020-1204-9		FEB 2020	8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LB8NS	32051554	Green Accepted			2022-12-28	WOS:000513108500001
J	Crupi, MJF; Maritan, SM; Reyes-Alvarez, E; Lian, EY; Hyndman, BD; Rekab, AN; Moodley, S; Antonescu, CN; Mulligan, LM				Crupi, Mathieu J. F.; Maritan, Sarah M.; Reyes-Alvarez, Eduardo; Lian, Eric Y.; Hyndman, Brandy D.; Rekab, Aisha N.; Moodley, Serisha; Antonescu, Costin N.; Mulligan, Lois M.			GGA3-mediated recycling of the RET receptor tyrosine kinase contributes to cell migration and invasion	ONCOGENE			English	Article							AKT PHOSPHORYLATION; ISOFORMS; CLATHRIN; ROLES; ARF6; TRAFFICKING; ACTIVATION; BINDING; GGA3; INTERNALIZATION	The RET receptor tyrosine kinase plays important roles in regulating cellular proliferation, migration, and survival in the normal development of neural crest derived tissues. However, aberrant activation of RET, through oncogenic mutations or overexpression, can contribute to tumourigenesis, regional invasion, and metastasis of several human cancers. RET is expressed as two main isoforms with unique C-terminal sequences that differ in protein interactions and subcellular trafficking in response to RET activation, and which also have distinct oncogenic potentials. The long isoform, termed RET51, is internalized from the membrane in response to stimulation by its ligand, GDNF, but is known to recycle back to the surface via RAB11 endosomes. However, the mechanisms regulating this process and its cellular effects have not been defined. Here, we show that recycling of RET51 requires a multicomponent complex that includes the endosomal-sorting protein GGA3, which mediates GDNF-dependent slow recycling of RET51 receptors to the plasma membrane. Our data show that the GRB2 adapter associates with RET51 through interactions with its C-terminal sequences, facilitating recruitment of active ARF6 and GGA3 interaction, and that depletion of GGA3 or ARF6 reduced RET51 recycling. Further, GGA3 knockdown accelerated RET51 degradation and also attenuated RET-mediated AKT activation. Finally, we showed that recycling of RET51 to the cell surface through association with GGA3 and ARF6 contributes to RET51-dependent cell motility, migration, and invasion. Our data establish RET recycling as a mechanism coordinating location and duration of RET signals in order to direct cell movement and invasion.	[Crupi, Mathieu J. F.; Maritan, Sarah M.; Reyes-Alvarez, Eduardo; Lian, Eric Y.; Hyndman, Brandy D.; Rekab, Aisha N.; Moodley, Serisha; Mulligan, Lois M.] Queens Univ, Canc Res Inst, Div Canc Biol & Genet, Kingston, ON K7L 3N6, Canada; [Crupi, Mathieu J. F.; Maritan, Sarah M.; Reyes-Alvarez, Eduardo; Lian, Eric Y.; Hyndman, Brandy D.; Rekab, Aisha N.; Moodley, Serisha; Mulligan, Lois M.] Queens Univ, Dept Pathol & Mol Med, Kingston, ON K7L 3N6, Canada; [Antonescu, Costin N.] Ryerson Univ, Dept Chem & Biol, Toronto, ON M5B 2K3, Canada	Queens University - Canada; McMaster University; Queens University - Canada; Toronto Metropolitan University	Mulligan, LM (corresponding author), Queens Univ, Canc Res Inst, Div Canc Biol & Genet, Kingston, ON K7L 3N6, Canada.; Mulligan, LM (corresponding author), Queens Univ, Dept Pathol & Mol Med, Kingston, ON K7L 3N6, Canada.	mulligal@queensu.ca	Mulligan, Lois/D-1893-2010	Mulligan, Lois/0000-0002-9308-8245; Antonescu, Costin/0000-0001-9192-6340; Reyes-Alvarez, Eduardo/0000-0003-3093-3859; Maritan, Sarah/0000-0002-9703-7429; /0000-0003-4096-0922	Canadian Institutes of Health Research (CIHR) [MOP-142303, PJT-156355]; Queen Elizabeth II Graduate Scholarship in Science and Technology; Terry Fox Research Institute Training Program in Transdisciplinary Cancer Research; Ontario Graduate Scholarships; Mitacs Globalink Research Graduate Fellowship; Queen's Research Opportunities Fund; CIHR Post-doctoral Fellowships; Master's CIHR award; CONACyT; Journal of Cell Science Travelling Fellowship from The Company of Biologists	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Queen Elizabeth II Graduate Scholarship in Science and Technology; Terry Fox Research Institute Training Program in Transdisciplinary Cancer Research; Ontario Graduate Scholarships(Ontario Graduate Scholarship); Mitacs Globalink Research Graduate Fellowship; Queen's Research Opportunities Fund; CIHR Post-doctoral Fellowships(Canadian Institutes of Health Research (CIHR)); Master's CIHR award; CONACyT(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); Journal of Cell Science Travelling Fellowship from The Company of Biologists	This work was supported by operating grants from the Canadian Institutes of Health Research (CIHR) (MOP-142303, LMM; PJT-156355, CNA), a Queen Elizabeth II Graduate Scholarship in Science and Technology (MJFC), studentships from the Terry Fox Research Institute Training Program in Transdisciplinary Cancer Research (MJFC, SMM, ER-A, EYL, ANR), and by Ontario Graduate Scholarships (SMM, EYL), a Mitacs Globalink Research Graduate Fellowship (ER-A), Queen's Research Opportunities Fund and CIHR Post-doctoral Fellowships (SM), a Master's CIHR award (SMM), CONACyT (ER-A), as well as a Journal of Cell Science Travelling Fellowship from The Company of Biologists (MJFC).	AGARD DA, 1983, NATURE, V302, P676, DOI 10.1038/302676a0; Alberti L, 1998, ONCOGENE, V17, P1079, DOI 10.1038/sj.onc.1202046; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Bhinge K, 2017, ONCOTARGET, V8, P27155, DOI 10.18632/oncotarget.15676; Crupi MJF, 2015, TRAFFIC, V16, P1155, DOI 10.1111/tra.12315; Crupi Mathieu J. F., 2014, METHOD MOL BIOL, P91; D'Souza-Schorey C, 2006, NAT REV MOL CELL BIO, V7, P347, DOI 10.1038/nrm1910; Doray B, 2002, SCIENCE, V297, P1700, DOI 10.1126/science.1075327; Frankel EB, 2018, SEMIN CELL DEV BIOL, V74, P4, DOI 10.1016/j.semcdb.2017.08.020; Garay C, 2015, MOL BIOL CELL, V26, P3504, DOI 10.1091/mbc.E14-09-1412; Goh LK, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a017459; Gong XW, 2018, EMBO J, V37, DOI 10.15252/embj.201898994; Gorelik R, 2014, NAT PROTOC, V9, P1931, DOI 10.1038/nprot.2014.131; Haines E, 2014, J BIOL CHEM, V289, P5687, DOI 10.1074/jbc.M113.516047; Hashimoto S, 2004, P NATL ACAD SCI USA, V101, P6647, DOI 10.1073/pnas.0401753101; Haugsten EM, 2014, TRAFFIC, V15, P665, DOI 10.1111/tra.12168; Hu ZZ, 2013, EXP CELL RES, V319, P1932, DOI 10.1016/j.yexcr.2013.05.028; Hung MC, 2016, CANCER CELL, V30, P374, DOI 10.1016/j.ccell.2016.08.014; Hyndman BD, 2017, J CELL SCI, V130, P3282, DOI 10.1242/jcs.203885; Le Hir H, 2000, ONCOLOGY-BASEL, V58, P311, DOI 10.1159/000012118; Li R, 2017, LIFE SCI, V182, P80, DOI 10.1016/j.lfs.2017.06.008; Li XZ, 2015, MOL BIOL CELL, V26, P4412, DOI 10.1091/mbc.E15-02-0087; Lian EY, 2017, ENDOCR-RELAT CANCER, V24, P53, DOI 10.1530/ERC-16-0393; Liang C, 2017, CANCER LETT, V388, P303, DOI 10.1016/j.canlet.2016.12.014; Lucarelli S, 2017, METHODS MOL BIOL, V1652, P191, DOI 10.1007/978-1-4939-7219-7_15; Maritan SM, 2017, JOVE-J VIS EXP, DOI 10.3791/55544; Matsumoto Y, 2017, HEAD NECK-J SCI SPEC, V39, P476, DOI 10.1002/hed.24626; Mulligan LM, 2018, ENDOCR RELAT CANCER, V25, pT189, DOI 10.1530/ERC-18-0141; Mulligan LM, 2019, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01873; Mulligan LM, 2014, NAT REV CANCER, V14, P173, DOI 10.1038/nrc3680; Mutch LJ, 2014, TRAFFIC, V15, P648, DOI 10.1111/tra.12165; Oka S, 2014, ONCOLOGY-BASEL, V86, P263, DOI 10.1159/000360089; Orth JD, 2002, P NATL ACAD SCI USA, V99, P167, DOI 10.1073/pnas.012607899; Parachoniak CA, 2011, DEV CELL, V20, P751, DOI 10.1016/j.devcel.2011.05.007; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Pinilla-Macua I, 2016, P NATL ACAD SCI USA, V113, P2122, DOI 10.1073/pnas.1520301113; Plaza-Menacho I, 2016, CELL REP, V17, P3319, DOI 10.1016/j.celrep.2016.11.061; Puertollano R, 2004, NAT CELL BIOL, V6, P244, DOI 10.1038/ncb1106; Rainero E, 2012, J CELL BIOL, V196, P277, DOI 10.1083/jcb.201109112; Ratcliffe CDH, 2016, TRAFFIC, V17, P670, DOI 10.1111/tra.12390; Ren XF, 2010, EMBO J, V29, P1045, DOI 10.1038/emboj.2010.6; Richardson DS, 2006, ONCOGENE, V25, P3206, DOI 10.1038/sj.onc.1209349; Richardson DS, 2012, MOL BIOL CELL, V23, P3838, DOI 10.1091/mbc.E12-02-0114; Schmid SL, 2017, J CELL BIOL, V216, P2623, DOI 10.1083/jcb.201705017; Sorkin A, 2015, RECEPTOR TYROSINE KI; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; TAHIRA T, 1990, ONCOGENE, V5, P97; Tsui-Pierchala BA, 2002, J BIOL CHEM, V277, P34618, DOI 10.1074/jbc.M203580200; Wandinger-Ness A, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a022616; Yamauchi Yohei, 2017, Advances in Biological Regulation, V63, P115, DOI 10.1016/j.jbior.2016.10.004; Ye QH, 2016, CANCER CELL, V30, P444, DOI 10.1016/j.ccell.2016.07.017	51	11	11	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	6					1361	1377		10.1038/s41388-019-1068-z	http://dx.doi.org/10.1038/s41388-019-1068-z			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE4UH	31645646				2022-12-28	WOS:000526714600014
J	Guan, CJ; He, L; Chang, ZY; Gu, XJ; Liang, J; Liu, R				Guan, Chengjian; He, Lin; Chang, Zhenyu; Gu, Xinjin; Liang, Jing; Liu, Rong			ZNF774 is a potent suppressor of hepatocarcinogenesis through dampening the NOTCH2 signaling	ONCOGENE			English	Article							BILE-DUCT DEVELOPMENT; HEPATOCELLULAR-CARCINOMA; GAMMA-SECRETASE; CANCER; CELLS; INACTIVATION; INHIBITORS; PATHWAY; GROWTH; EMT	Discerning oncogenic drivers from passengers remain a major effort in understanding of the essence of the initiation and development of hepatocellular carcinoma (HCC), which is the most common primary liver malignancy and the third leading cause of cancer mortality worldwide. Here we report that ZNF774, a novel zinc-finger protein, inhibits the proliferation and invasion of HCC cells. Molecular characterization of this protein indicated that ZNF774 acts as a transcription repressor, and interrogation of ZNF774 interactome by affinity purification-coupled mass spectrometry revealed that ZNF774 is physically associated with the Mi-2/nucleosome remodeling and deacetylase (NuRD) complex in cells. Genome-wide identification of the transcriptional targets of the ZNF774/NuRD complex by ChIP-seq indicated that ZNF774 represses a cohort of genes including NOTCH2 that are critically involved in the growth and mobility of HCC. We demonstrated that the ZNF774/NuRD complex inhibits the proliferation and invasion of HCC cells in vitro and suppresses HCC growth and metastasis in vivo. Importantly, the expression of ZNF774 is significantly downregulated in HCC, and low ZNF774 expression strongly correlated with high NOTCH2 expression, advanced pathological stages, and poor overall survival of the patients. Together, these results uncover a key role for the ZNF774/NuRD-NOTCH2 axis in hepatocarcinogenesis.	[Guan, Chengjian] Capital Med Univ, Beijing Friendship Hosp, Gen Surg Dept, Beijing 100050, Peoples R China; [Guan, Chengjian; Chang, Zhenyu; Gu, Xinjin; Liu, Rong] Chinese Peoples Liberat Army, Med Sch, Beijing 100853, Peoples R China; [Guan, Chengjian; Chang, Zhenyu; Gu, Xinjin; Liu, Rong] Chinese Peoples Liberat Army Gen Hosp, Dept Hepatobiliary & Pancreat Surg Oncol, Beijing 100853, Peoples R China; [He, Lin; Liang, Jing] Peking Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Hlth Sci Ctr,Minist Educ,Key Lab Carcinogenesis &, Beijing 100191, Peoples R China	Capital Medical University; Chinese People's Liberation Army General Hospital; Peking University	Liu, R (corresponding author), Chinese Peoples Liberat Army, Med Sch, Beijing 100853, Peoples R China.; Liu, R (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Dept Hepatobiliary & Pancreat Surg Oncol, Beijing 100853, Peoples R China.	liurong301@126.com			Capital Health Research and Special Development [2016-1-1111]; National Key Technologies RD Program [2015BAI13B09]; Beijing Municipal Administration of Hospitals Incubator Program [PX2016001, PX2019004]; Miaopu" Innovation Foundation of the Chinese PLA General Hospital [17KMM07]	Capital Health Research and Special Development; National Key Technologies RD Program(National Key Technology R&D Program); Beijing Municipal Administration of Hospitals Incubator Program; Miaopu" Innovation Foundation of the Chinese PLA General Hospital	This paper was supported by Capital Health Research and Special Development (No. 2016-1-1111), National Key Technologies R&D Program (No. 2015BAI13B09), Beijing Municipal Administration of Hospitals Incubator Program (No. PX2016001 and No. PX2019004) and "Miaopu" Innovation Foundation of the Chinese PLA General Hospital (No. 17KMM07).	Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Beel AJ, 2008, CELL MOL LIFE SCI, V65, P1311, DOI 10.1007/s00018-008-7462-2; Brabletz T, 2018, NAT REV CANCER, V18, P128, DOI 10.1038/nrc.2017.118; Cai QY, 2014, NAT GENET, V46, P886, DOI 10.1038/ng.3041; Capra JA, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2013.0025; Dill MT, 2013, HEPATOLOGY, V57, P1607, DOI 10.1002/hep.26165; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Forner A, 2018, LANCET, V391, P1301, DOI 10.1016/S0140-6736(18)30010-2; Gebelein B, 1998, J CLIN INVEST, V102, P1911, DOI 10.1172/JCI1919; Geisler F, 2008, HEPATOLOGY, V48, P607, DOI 10.1002/hep.22381; Geisler F, 2015, HEPATOLOGY, V61, P382, DOI 10.1002/hep.27268; Goriki A, 2018, NAT REV UROL, V15, P345, DOI 10.1038/s41585-018-0005-1; Hayashi T, 2016, CLIN CANCER RES, V22, P2981, DOI 10.1158/1078-0432.CCR-15-2360; He L, 2018, CELL RES, V28, P934, DOI 10.1038/s41422-018-0079-6; Hori K, 2013, J CELL SCI, V126, P2135, DOI 10.1242/jcs.127308; Hubmann R, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00319; Huntzicker EG, 2015, HEPATOLOGY, V61, P942, DOI 10.1002/hep.27566; Jung KH, 2016, HEPATOLOGY, V63, P864, DOI 10.1002/hep.28367; Klinakis A, 2011, NATURE, V473, P230, DOI 10.1038/nature09999; KNIGHT RD, 2001, GENOME BIOL, V2; Koch U, 2007, CELL MOL LIFE SCI, V64, P2746, DOI 10.1007/s00018-007-7164-1; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Krushkal J, 1999, CIRCULATION, V99, P1407, DOI 10.1161/01.CIR.99.11.1407; Li WJ, 2017, J CLIN INVEST, V127, P3427, DOI 10.1172/JCI94233; Lorsch ZS, 2019, NAT NEUROSCI, V22, P1413, DOI 10.1038/s41593-019-0462-8; Lovisa S, 2015, NAT MED, V21, P998, DOI 10.1038/nm.3902; McCright B, 2001, DEVELOPMENT, V128, P491; Ong HT, 2013, J HEPATOL, V59, P999, DOI 10.1016/j.jhep.2013.07.010; Riccio O, 2008, EMBO REP, V9, P377, DOI 10.1038/embor.2008.7; Ringelhan M, 2018, NAT IMMUNOL, V19, P222, DOI 10.1038/s41590-018-0044-z; Schulze K, 2015, NAT GENET, V47, P505, DOI 10.1038/ng.3252; Serra H, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8935; Shih IM, 2007, CANCER RES, V67, P1879, DOI 10.1158/0008-5472.CAN-06-3958; Si WZ, 2015, CANCER CELL, V27, P822, DOI 10.1016/j.ccell.2015.04.011; Siebel C, 2017, PHYSIOL REV, V97, P1235, DOI 10.1152/physrev.00005.2017; Suzuki IK, 2018, CELL, V173, P1370, DOI 10.1016/j.cell.2018.03.067; Totaro A, 2018, TRENDS CELL BIOL, V28, P560, DOI 10.1016/j.tcb.2018.03.001; Totoki Y, 2014, NAT GENET, V46, P1267, DOI 10.1038/ng.3126; Urrutia R, 2003, GENOME BIOL, V4, DOI [10.1186/gb-2003-1184-1110-1231, DOI 10.1186/GB-2003-1184-1110-1231]; van Es JH, 2005, NATURE, V435, P959, DOI 10.1038/nature03659; Wang JX, 2018, ONCOGENE, V37, P3229, DOI 10.1038/s41388-018-0188-1; Wu N, 2017, LAB INVEST, V97, P843, DOI 10.1038/labinvest.2017.29; Wu Y, 2010, NATURE, V464, P1052, DOI 10.1038/nature08878; Xiao W, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0507-3	45	9	9	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	8					1665	1680		10.1038/s41388-019-1075-0	http://dx.doi.org/10.1038/s41388-019-1075-0			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN6CG	31659254				2022-12-28	WOS:000514923000004
J	Sinha, S; Dwivedi, N; Tao, SX; Jamadar, A; Kakade, VR; O'Neil, M; Weiss, RH; Enders, J; Calvet, JP; Thomas, SM; Rao, R				Sinha, Sonali; Dwivedi, Nidhi; Tao, Shixin; Jamadar, Abeda; Kakade, Vijayakumar R.; O'Neil, Maura; Weiss, Robert H.; Enders, Jonathan; Calvet, James P.; Thomas, Sufi M.; Rao, Reena			Targeting the vasopressin type-2 receptor for renal cell carcinoma therapy	ONCOGENE			English	Article							BREAST-CANCER CELLS; PROTEIN-KINASE-A; LUNG-CANCER; CYCLIC-AMP; SIGNALING PATHWAYS; MITOGENIC ACTION; ORAL TOLVAPTAN; INDUCED GROWTH; V-2 RECEPTOR; TUMOR-GROWTH	Arginine vasopressin (AVP) and its type-2 receptor (V2R) play an essential role in the regulation of salt and water homeostasis by the kidneys. V2R activation also stimulates proliferation of renal cell carcinoma (RCC) cell lines in vitro. The current studies investigated V2R expression and activity in human RCC tumors, and its role in RCC tumor growth. Examination of the cancer genome atlas (TCGA) database, and analysis of human RCC tumor tissue microarrays, cDNA arrays and tumor biopsy samples demonstrated V2R expression and activity in clear cell RCC (ccRCC). In vitro, V2R antagonists OPC31260 and Tolvaptan, or V2R gene silencing reduced wound closure and cell viability of 786-O and Caki-1 human ccRCC cell lines. Similarly in mouse xenograft models, Tolvaptan and OPC31260 decreased RCC tumor growth by reducing cell proliferation and angiogenesis, while increasing apoptosis. In contrast, the V2R agonist dDAVP significantly increased tumor growth. High intracellular cAMP levels and ERK1/2 activation were observed in human ccRCC tumors. In mouse tumors and Caki-1 cells, V2R agonists reduced cAMP and ERK1/2 activation, while dDAVP treatment had the reverse effect. V2R gene silencing in Caki-1 cells also reduced cAMP and ERK1/2 activation. These results provide novel evidence for a pathogenic role of V2R signaling in ccRCC, and suggest that inhibitors of the AVP-V2R pathway, including the FDA-approved drug Tolvaptan, could be utilized as novel ccRCC therapeutics.	[Sinha, Sonali; Dwivedi, Nidhi; Tao, Shixin; Jamadar, Abeda; Kakade, Vijayakumar R.; Calvet, James P.; Rao, Reena] Univ Kansas, Med Ctr, Jared Grantham Kidney Inst, Kansas City, KS 66103 USA; [Sinha, Sonali; Dwivedi, Nidhi; Tao, Shixin; Jamadar, Abeda; Kakade, Vijayakumar R.; Rao, Reena] Univ Kansas, Med Ctr, Dept Internal Med, Kansas City, KS 66103 USA; [O'Neil, Maura] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66103 USA; [Weiss, Robert H.] Univ Calif Davis, Div Nephrol, Davis, CA 95616 USA; [Weiss, Robert H.] Univ Calif Davis, Comprehens Canc Ctr, Davis, CA 95616 USA; [Weiss, Robert H.] VA Northern Calif Hlth Care Syst, Med Serv, Sacramento, CA USA; [Enders, Jonathan] Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66103 USA; [Calvet, James P.] Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66103 USA; [Calvet, James P.; Thomas, Sufi M.; Rao, Reena] Univ Kansas, Med Ctr, Dept Canc Biol, Kansas City, KS 66103 USA; [Thomas, Sufi M.] Univ Kansas, Med Ctr, Dept Otolaryngol, Kansas City, KS 66103 USA	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of California System; University of California Davis; University of California System; University of California Davis; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center	Rao, R (corresponding author), Univ Kansas, Med Ctr, Jared Grantham Kidney Inst, Kansas City, KS 66103 USA.; Rao, R (corresponding author), Univ Kansas, Med Ctr, Dept Internal Med, Kansas City, KS 66103 USA.; Rao, R (corresponding author), Univ Kansas, Med Ctr, Dept Canc Biol, Kansas City, KS 66103 USA.	rrao@kumc.edu	Jamadar, Abeda/AAL-4581-2021; DWIVEDI, NIDHI/AAE-8717-2019; Thomas, Sufi Mary/AFR-1642-2022	Jamadar, Abeda/0000-0002-0887-4613; DWIVEDI, NIDHI/0000-0002-7520-5030; Thomas, Sufi Mary/0000-0001-5370-0842; Wallace, Darren/0000-0003-4616-7669	NIH [R01-DK083525]; KU Cancer Center; PKD Research and Translation Core Center [P30-DK106912]; KU Biomedical Research and Training Program; American Heart Association	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); KU Cancer Center; PKD Research and Translation Core Center; KU Biomedical Research and Training Program; American Heart Association(American Heart Association)	This study was supported by NIH R01-DK083525, a private donation from the Watts family and a Pilot and Feasibility Grant from the KU Cancer Center and PKD Research and Translation Core Center P30-DK106912 to RR. ND is supported by Postdoctoral Fellowship Grants from the KU Biomedical Research and Training Program and American Heart Association.	Aihara M, 2014, J PHARMACOL EXP THER, V349, P258, DOI 10.1124/jpet.114.213256; Alonso DF, 1999, BREAST CANCER RES TR, V57, P271, DOI 10.1023/A:1006291607871; Bellmunt J, 2014, EUR UROL, V65, P731, DOI 10.1016/j.eururo.2013.10.057; BEPLER G, 1987, CANCER RES, V47, P2371; Berl T, 2010, J AM SOC NEPHROL, V21, P705, DOI 10.1681/ASN.2009080857; Bolignano D, 2010, UROL ONCOL-SEMIN ORI, V28, P642, DOI 10.1016/j.urolonc.2008.12.014; Boone M, 2008, PFLUG ARCH EUR J PHY, V456, P1005, DOI 10.1007/s00424-008-0498-1; BUNN PA, 1994, CANCER RES, V54, P3602; BUNN PA, 1992, CANCER RES, V52, P24; Burst V, 2017, SUPPORT CARE CANCER, V25, P2275, DOI 10.1007/s00520-017-3638-3; Cai Q, 2007, AM J PHYSIOL-RENAL, V293, pF1858, DOI 10.1152/ajprenal.00068.2007; Chang YS, 2007, CANCER CHEMOTH PHARM, V59, P561, DOI 10.1007/s00280-006-0393-4; Chebib FT, 2018, J AM SOC NEPHROL, V29, P2458, DOI 10.1681/ASN.2018060590; Chen FJ, 2016, CELL REP, V14, P2476, DOI 10.1016/j.celrep.2016.02.024; CHOCHUNG YS, 1992, BIOCHEM SOC T, V20, P425, DOI 10.1042/bst0200425; CHOOI KF, 1994, CANCER RES, V54, P6434; Davis CF, 2014, CANCER CELL, V26, P319, DOI 10.1016/j.ccr.2014.07.014; Dicitore A, 2016, ENDOCRINE, V51, P101, DOI 10.1007/s12020-015-0597-7; Dremier S, 2002, ANN NY ACAD SCI, V968, P106, DOI 10.1111/j.1749-6632.2002.tb04330.x; Garona J, 2019, CANCER RES TREAT, V51, P438, DOI 10.4143/crt.2018.040; Garona J, 2015, INT J ONCOL, V46, P2335, DOI 10.3892/ijo.2015.2952; Giron S, 2002, J SURG ONCOL, V81, P38, DOI 10.1002/jso.10141; Gralla RJ, 2017, CANCER MED-US, V6, P723, DOI 10.1002/cam4.805; Gunaratne R, 2010, P NATL ACAD SCI USA, V107, P15653, DOI 10.1073/pnas.1007424107; Heasley LE, 2001, ONCOGENE, V20, P1563, DOI 10.1038/sj.onc.1204183; Hsieh JJ, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.9; Huang D, 2008, CANCER RES, V68, P81, DOI 10.1158/0008-5472.CAN-07-5311; Iannucci NB, 2011, FUTURE MED CHEM, V3, P1987, DOI [10.4155/FMC.11.152, 10.4155/fmc.11.152]; Jeppesen AN, 2010, BRIT J CANCER, V102, P867, DOI 10.1038/sj.bjc.6605563; Kakade VR, 2016, J MOL CELL BIOL, V8, P464, DOI 10.1093/jmcb/mjw022; Kane RC, 2006, CLIN CANCER RES, V12, P7271, DOI 10.1158/1078-0432.CCR-06-1249; Keegan BP, 2006, BREAST CANCER RES TR, V95, P265, DOI 10.1007/s10549-005-9024-8; Khan MI, 2017, RES REP TROP MED, V8, P37, DOI 10.2147/RRTM.S97309; Kim SN, 2001, INT J CANCER, V93, P33, DOI 10.1002/ijc.1308; Kondo K, 1999, BIOORGAN MED CHEM, V7, P1743, DOI 10.1016/S0968-0896(99)00101-7; MacKinnon AC, 2005, BRIT J CANCER, V92, P522, DOI 10.1038/sj.bjc.6602366; North WG, 1998, CANCER RES, V58, P1866; North WG, 2000, EXP PHYSIOL, V85, p27S, DOI 10.1111/j.1469-445X.2000.tb00005.x; North WG, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00016; North WG, 2011, BREAST CANCER RES TR, V127, P631, DOI 10.1007/s10549-010-1009-6; Onitilo AA, 2007, CLIN MED RES, V5, P228, DOI 10.3121/cmr.2007.762; Pantziarka P, 2014, ECANCERMEDICALSCIENC, V8, DOI 10.3332/ecancer.2014.442; Pequeux C, 2004, ENDOCR-RELAT CANCER, V11, P871, DOI 10.1677/erc.1.00803; Pifano M, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00011; Prasad SR, 2007, BRIT J RADIOL, V80, P593, DOI 10.1259/bjr/20129205; R Development Core Team, 2009, R LANG ENV STAT COMP; Rao R, 2010, J AM SOC NEPHROL, V21, P428, DOI 10.1681/ASN.2009060672; Ricketts CJ, 2018, CELL REP, V23, P313, DOI [10.1016/j.celrep.2018.03.075, 10.1016/j.celrep.2018.06.032]; Ripoll GV, 2013, BREAST CANCER RES TR, V142, P9, DOI 10.1007/s10549-013-2724-6; Rocha AS, 2008, MOL BIOL CELL, V19, P4814, DOI 10.1091/mbc.E08-06-0617; Rodrigues AL, 2018, LIFE SCI, V192, P144, DOI 10.1016/j.lfs.2017.11.040; Ryan MB, 2015, TRENDS CANCER, V1, P183, DOI 10.1016/j.trecan.2015.10.001; Santarpia L, 2012, EXPERT OPIN THER TAR, V16, P103, DOI 10.1517/14728222.2011.645805; Sarmiento JM, 2005, KIDNEY INT, V68, P487, DOI 10.1111/j.1523-1755.2005.00426.x; Schwindt TT, 2003, BIOCHEMISTRY-US, V42, P2116, DOI 10.1021/bi026807g; Seeger-Nukpezah T, 2015, NAT REV NEPHROL, V11, P515, DOI 10.1038/nrneph.2015.46; Seo EJ, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01030; SETHI T, 1991, CANCER RES, V51, P3621; Shaw TJ, 2002, EXP CELL RES, V273, P95, DOI 10.1006/excr.2001.5426; Shi PP, 2007, AM J PHYSIOL-RENAL, V292, pF1334, DOI 10.1152/ajprenal.00308.2006; Shoaf SE, 2012, EUR J CLIN PHARMACOL, V68, P1595, DOI 10.1007/s00228-012-1295-5; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Singh SP, 2015, DIS MODEL MECH, V8, P931, DOI 10.1242/dmm.020511; STARZEC AB, 1994, J CELL PHYSIOL, V161, P31, DOI 10.1002/jcp.1041610105; Takahashi H, 2004, ARCH DERMATOL RES, V296, P74, DOI 10.1007/s00403-004-0478-z; Tao SX, 2015, KIDNEY INT, V87, P1164, DOI 10.1038/ki.2014.427; TAYLOR AH, 1990, CANCER RES, V50, P7882; Thibonnier M, 2000, AM J PHYSIOL-HEART C, V279, pH2529, DOI 10.1152/ajpheart.2000.279.5.H2529; Tierney T, 2002, J ENDOCRINOL, V175, P435, DOI 10.1677/joe.0.1750435; Torres VE, 2017, NEW ENGL J MED, V377, P1930, DOI 10.1056/NEJMoa1710030; Vitali E, 2014, MOL CELL ENDOCRINOL, V383, P193, DOI 10.1016/j.mce.2013.12.006; WALLACE AC, 1972, CANCER, V29, P977, DOI 10.1002/1097-0142(197204)29:4<977::AID-CNCR2820290444>3.0.CO;2-P; Watkins PB, 2015, DRUG SAFETY, V38, P1103, DOI 10.1007/s40264-015-0327-3; Yamaguchi T, 2004, J BIOL CHEM, V279, P40419, DOI 10.1074/jbc.M405079200; YAMAMURA Y, 1992, BRIT J PHARMACOL, V105, P787, DOI 10.1111/j.1476-5381.1992.tb09058.x; ZAORAL M, 1985, INT J PEPT PROT RES, V25, P561; Zhu XY, 1998, BIOCHEMISTRY-US, V37, P15773, DOI 10.1021/bi981162z; Zivadinovic D, 2005, BREAST CANCER RES, V7, pR101, DOI 10.1186/bcr958	78	18	19	2	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	6					1231	1245		10.1038/s41388-019-1059-0	http://dx.doi.org/10.1038/s41388-019-1059-0			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE4UH	31616061	Green Accepted, Green Submitted			2022-12-28	WOS:000526714600005
J	Li, XJ; Ding, JY; Wang, XY; Cheng, ZN; Zhu, QB				Li, Xiaojing; Ding, Junyao; Wang, Xueying; Cheng, Zeneng; Zhu, Qubo			NUDT21 regulates circRNA cyclization and ceRNA crosstalk in hepatocellular carcinoma	ONCOGENE			English	Article							CIRCULAR RNA; POLYADENYLATION; IDENTIFICATION	Circular RNAs (circRNAs) are a novel class of RNAs, which involve in many physiological processes and participate in many diseases, especially in cancer. Previous reports showed circRNAs were globally downregulated in hepatocellular carcinoma (HCC) and a lot of circRNAs involved in the tumorigenesis and metastasis of HCC. To understand the underlying mechanism of circRNAs' reduction, we explored the relationship between circRNA biogenesis and NUDT21, which was a RNA splice factor downregulated in HCC, and we found that NUDT21 elevated the formation of circRNA, and the UGUA sequences were critical for the cyclization of circRNA. Knockdown of NUDT21 disrupted the competitive endogenous RNA (ceRNA) pathway of circRNA-miRNA-mRNA, and overexpression of the downregulated circRNA could assist the NUDT21-mediated tumor suppression in HCC cells. In conclusion, the loss of NUDT21 prevented the cyclization of circRNA in HCC; without circRNA absorption, miRNAs were released to suppress the tumor-suppressor genes, leading to the uncontrolled cell proliferation.	[Li, Xiaojing; Ding, Junyao; Wang, Xueying; Cheng, Zeneng; Zhu, Qubo] Cent S Univ, Xiangya Sch Pharmaceut Sci, Changsha 410013, Hunan, Peoples R China	Central South University	Zhu, QB (corresponding author), Cent S Univ, Xiangya Sch Pharmaceut Sci, Changsha 410013, Hunan, Peoples R China.	qubozhu@csu.edu.cn	Zhu, Qubo/ACT-7180-2022		National Natural Science Foundation of China [C0709-31201056]; Hunan Provincial Natural Science Foundation of China [2018JJ2493]; Hunan Provincial Innovation Foundation for Postgraduate [CX20190244]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Hunan Provincial Natural Science Foundation of China(Natural Science Foundation of Hunan Province); Hunan Provincial Innovation Foundation for Postgraduate	We thank the KangChen Bio-tech (Shanghai, China) for providing RNA sequencing and data analysis and the Molecular Medical Center in the Xiangya Hospital (Changsha, China) for the confocal microscopy. We thank Shifu Luo for data analysis. We also thank Dr Wang for kindly supplying the IRES-drived pCircGFP reporter. This research is supported by the National Natural Science Foundation of China (C0709-31201056), the Hunan Provincial Natural Science Foundation of China (2018JJ2493) and the Hunan Provincial Innovation Foundation for Postgraduate (CX20190244).	Ashwal-Fluss R, 2014, MOL CELL, V56, P55, DOI 10.1016/j.molcel.2014.08.019; Bachmayr-Heyda A, 2015, SCI REP-UK, V5, DOI 10.1038/srep08057; Brown KM, 2003, MOL CELL, V12, P1467, DOI 10.1016/S1097-2765(03)00453-2; Conn SJ, 2015, CELL, V160, P1125, DOI 10.1016/j.cell.2015.02.014; Ding JY, 2019, BIOL CHEM, V400, P247, DOI 10.1515/hsz-2018-0232; El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683; Enuka Y, 2016, NUCLEIC ACIDS RES, V44, P1370, DOI 10.1093/nar/gkv1367; Fu LY, 2017, ONCOTARGET, V8, P58405, DOI 10.18632/oncotarget.16881; Gao B, 2014, BIOMED PHARMACOTHER, V68, P143, DOI 10.1016/j.biopha.2013.09.005; Greene J, 2017, FRONT MOL BIOSCI, V4, DOI 10.3389/fmolb.2017.00038; Han D, 2017, HEPATOLOGY, V66, P1151, DOI 10.1002/hep.29270; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Kelly S, 2015, J MOL BIOL, V427, P2414, DOI 10.1016/j.jmb.2015.02.018; Kramer MC, 2015, GENE DEV, V29, P2168, DOI 10.1101/gad.270421.115; Kristensen LS, 2018, ONCOGENE, V37, P555, DOI 10.1038/onc.2017.361; Kubo T, 2006, NUCLEIC ACIDS RES, V34, P6264, DOI 10.1093/nar/gkl794; Li P, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0473-z; Liang DM, 2017, MOL CELL, V68, P940, DOI 10.1016/j.molcel.2017.10.034; Lin XM, 2018, MED SCI MONIT BASIC, V24, P70, DOI 10.12659/MSMBR.909737; Lin YF, 2012, NUCLEIC ACIDS RES, V40, P8460, DOI 10.1093/nar/gks637; Meng XW, 2017, BIOINFORMATICS, V33, P3314, DOI 10.1093/bioinformatics/btx446; Park HJ, 2018, NAT GENET, V50, P783, DOI 10.1038/s41588-018-0118-8; Qu SB, 2015, CANCER LETT, V365, P141, DOI 10.1016/j.canlet.2015.06.003; Song CL, 2019, J CELL PHYSIOL, V234, P2460, DOI 10.1002/jcp.26764; Sun M, 2017, CANCER LETT, V410, P158, DOI 10.1016/j.canlet.2017.09.026; Tan S, 2018, ONCOGENE, V37, P4887, DOI 10.1038/s41388-018-0280-6; Verheijen BM, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00412; Wang Y, 2015, RNA, V21, P172, DOI 10.1261/rna.048272.114; Wilusz JE, 2013, SCIENCE, V340, P440, DOI 10.1126/science.1238522; Xia Z, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6274; Xu S, 2018, PEERJ, V6, DOI 10.7717/peerj.5503; Yang Q, 2011, STRUCTURE, V19, P368, DOI 10.1016/j.str.2010.12.021; Yao RZ, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00332; Yu J, 2018, J HEPATOL, V68, P1214, DOI 10.1016/j.jhep.2018.01.012; Zhang H, 2015, CANCER LETT, V367, P49, DOI 10.1016/j.canlet.2015.07.010; Zhang XW, 2018, ONCOTARGETS THER, V11, P2853, DOI 10.2147/OTT.S158008; Zhang XO, 2014, CELL, V159, P134, DOI 10.1016/j.cell.2014.09.001; Zhong YX, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0827-8	38	60	60	3	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	4					891	904		10.1038/s41388-019-1030-0	http://dx.doi.org/10.1038/s41388-019-1030-0			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KF4EJ	31570791				2022-12-28	WOS:000509197200011
J	Veschi, V; Mangiapane, LR; Nicotra, A; Di Franco, S; Scavo, E; Apuzzo, T; Sardina, DS; Fiori, M; Benfante, A; Colorito, ML; Cocorullo, G; Giuliante, F; Cipolla, C; Pistone, G; Bongiorno, MR; Rizzo, A; Tate, CM; Wu, XH; Rowlinson, S; Stancato, LF; Todaro, M; De Maria, R; Stassi, G				Veschi, Veronica; Mangiapane, Laura R.; Nicotra, Annalisa; Di Franco, Simone; Scavo, Emanuela; Apuzzo, Tiziana; Sardina, Davide S.; Fiori, Micol; Benfante, Antonina; Colorito, Maria L.; Cocorullo, Gianfranco; Giuliante, Felice; Cipolla, Calogero; Pistone, Giuseppe; Bongiorno, Maria Rita; Rizzo, Aroldo; Tate, Courtney M.; Wu, Xiaohua; Rowlinson, Scott; Stancato, Louis F.; Todaro, Matilde; De Maria, Ruggero; Stassi, Giorgio			Targeting chemoresistant colorectal cancer via systemic administration of a BMP7 variant	ONCOGENE			English	Article							BONE MORPHOGENETIC PROTEIN; EPITHELIAL-MESENCHYMAL TRANSITION; CONSENSUS MOLECULAR SUBTYPES; STEM-CELLS; COLON-CANCER; MICROSATELLITE-INSTABILITY; EXPRESSION PATTERNS; JUVENILE POLYPOSIS; TGF-BETA; DIFFERENTIATION	Despite intense research and clinical efforts, patients affected by advanced colorectal cancer (CRC) have still a poor prognosis. The discovery of colorectal (CR) cancer stem cell (CSC) as the cell compartment responsible for tumor initiation and propagation may provide new opportunities for the development of new therapeutic strategies. Given the reduced sensitivity of CR-CSCs to chemotherapy and the ability of bone morphogenetic proteins (BMP) to promote colonic stem cell differentiation, we aimed to investigate whether an enhanced variant of BMP7 (BMP7v) could sensitize to chemotherapy-resistant CRC cells and tumors. Thirty-five primary human cultures enriched in CR-CSCs, including four from chemoresistant metastatic lesions, were used for in vitro studies and to generate CR-CSC-based mouse avatars to evaluate tumor growth and progression upon treatment with BMP7v alone or in combination with standard therapy or PI3K inhibitors. BMP7v treatment promotes CR-CSC differentiation and recapitulates the cell differentiation-related gene expression profile by suppressing Wnt pathway activity and reducing mesenchymal traits and survival of CR-CSCs. Moreover, in CR-CSC-based mouse avatars, BMP7v exerts an antiangiogenic effect and sensitizes tumor cells to standard chemotherapy regardless of the mutational, MSI, and CMS profiles. Of note, tumor harboring PIK3CA mutations were affected to a lower extent by the combination of BMP7v and chemotherapy. However, the addition of a PI3K inhibitor to the BMP7v-based combination potentiates PIK3CA-mutant tumor drug response and reduces the metastatic lesion size. These data suggest that BMP7v treatment may represent a useful antiangiogenic and prodifferentiation agent, which renders CSCs sensitive to both standard and targeted therapies.	[Veschi, Veronica; Mangiapane, Laura R.; Nicotra, Annalisa; Di Franco, Simone; Scavo, Emanuela; Apuzzo, Tiziana; Sardina, Davide S.; Benfante, Antonina; Colorito, Maria L.; Cocorullo, Gianfranco; Cipolla, Calogero; Stassi, Giorgio] Univ Palermo, Dept Surg Oncol & Stomatol Sci DICHIRONS, I-90127 Palermo, Italy; [Fiori, Micol] Ist Super Sanita, Dept Oncol & Mol Med, Rome, Italy; [Giuliante, Felice; De Maria, Ruggero] Univ Cattolica Sacro Cuore, Ist Patol Gen, I-00168 Rome, Italy; [Giuliante, Felice; De Maria, Ruggero] Fdn Policlin Univ A Gemelli, IRCCS, I-00168 Rome, Italy; [Pistone, Giuseppe; Bongiorno, Maria Rita; Todaro, Matilde] Univ Palermo, Dept Hlth Promot Sci Internal Med & Med Specialti, I-90127 Palermo, Italy; [Rizzo, Aroldo] Osped Riuniti Villa Sofia Cervello, Pathol Unit, Palermo, Italy; [Tate, Courtney M.; Wu, Xiaohua; Rowlinson, Scott; Stancato, Louis F.] Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA	University of Palermo; Istituto Superiore di Sanita (ISS); Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Palermo; Eli Lilly	Stassi, G (corresponding author), Univ Palermo, Dept Surg Oncol & Stomatol Sci DICHIRONS, I-90127 Palermo, Italy.; De Maria, R (corresponding author), Univ Cattolica Sacro Cuore, Ist Patol Gen, I-00168 Rome, Italy.; De Maria, R (corresponding author), Fdn Policlin Univ A Gemelli, IRCCS, I-00168 Rome, Italy.	ruggero.demaria@unicatt.it; giorgio.stassi@unipa.it	di franco, simone/M-3714-2019; Sardina, Davide Stefano/AAI-9559-2020; Fiori, Micol Eleonora/J-7295-2016; Veschi, Veronica/K-4143-2018; Stassi, Giorgio/AAC-1175-2022; Fiori, Micol E/J-4043-2014; todaro, matilde/AAC-1003-2022; Cipolla, Calogero/H-2568-2018; Cocorullo, Gianfranco/L-3744-2016	di franco, simone/0000-0002-6217-2161; Sardina, Davide Stefano/0000-0003-1161-3016; Fiori, Micol Eleonora/0000-0002-1813-7035; Veschi, Veronica/0000-0002-6379-7366; Fiori, Micol E/0000-0002-1813-7035; todaro, matilde/0000-0001-8686-8043; Cipolla, Calogero/0000-0003-4396-3563; Giuliante, Felice/0000-0003-2087-2589; Mangiapane, Laura Rosa/0000-0003-4186-0157; Cocorullo, Gianfranco/0000-0003-2660-6724	AIRC [5x1000 (9979)]	AIRC(Fondazione AIRC per la ricerca sul cancro)	We are thankful to Alessandro Gorgone for technical support, Francesco Calo' for graphics and Tatiana Terranova for editing the manuscript. The research leading to these results has received funding from AIRC under 5x1000 (9979) project-P.I. SG and RDM.	Arends JW, 2000, J PATHOL, V190, P412; Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409; Beck SE, 2006, AM J PHYSIOL-GASTR L, V291, pG135, DOI 10.1152/ajpgi.00482.2005; Brosens LAA, 2011, WORLD J GASTROENTERO, V17, P4839, DOI 10.3748/wjg.v17.i44.4839; Buijs JT, 2007, CANCER RES, V67, P8742, DOI 10.1158/0008-5472.CAN-06-2490; Caja L, 2018, ONCOGENE, V37, P2515, DOI 10.1038/s41388-018-0136-0; CASTAIGNE S, 1990, BLOOD, V76, P1704; Chen D, 1998, J CELL BIOL, V142, P295, DOI 10.1083/jcb.142.1.295; Clevers H, 2013, CELL, V154, P274, DOI 10.1016/j.cell.2013.07.004; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Fruman DA, 2017, CELL, V170, P605, DOI 10.1016/j.cell.2017.07.029; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Haramis APG, 2004, SCIENCE, V303, P1684, DOI 10.1126/science.1093587; He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430; Hemminki A, 2000, GASTROENTEROLOGY, V119, P921, DOI 10.1053/gast.2000.18161; Ianevski A, 2017, BIOINFORMATICS, V33, P2413, DOI 10.1093/bioinformatics/btx162; Irshad S, 2017, J PATHOL, V242, P178, DOI 10.1002/path.4891; Jover R, 2006, GUT, V55, P1819, DOI 10.1136/gut.2006.105627; Kobayashi A, 2011, J EXP MED, V208, P2641, DOI 10.1084/jem.20110840; Kodach LL, 2008, GASTROENTEROLOGY, V134, P1332, DOI 10.1053/j.gastro.2008.02.059; Kosinski C, 2007, P NATL ACAD SCI USA, V104, P15418, DOI 10.1073/pnas.0707210104; Laurila R, 2013, INT J CLIN EXP PATHO, V6, P1400; Linnekamp JF, 2018, CELL DEATH DIFFER, V25, P616, DOI 10.1038/s41418-017-0011-5; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Lombardo Y, 2011, GASTROENTEROLOGY, V140, P297, DOI 10.1053/j.gastro.2010.10.005; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marcucci F, 2016, NAT REV DRUG DISCOV, V15, P311, DOI 10.1038/nrd.2015.13; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Medema JP, 2011, NATURE, V474, P318, DOI 10.1038/nature10212; Miyazono K, 2010, J BIOCHEM, V147, P35, DOI 10.1093/jb/mvp148; Qi Z, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13824; Ribic CM, 2003, NEW ENGL J MED, V349, P247, DOI 10.1056/NEJMoa022289; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Rider CC, 2010, BIOCHEM J, V429, P1, DOI 10.1042/BJ20100305; Rodon J, 2013, NAT REV CLIN ONCOL, V10, P143, DOI 10.1038/nrclinonc.2013.10; Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395; Sneddon JB, 2006, P NATL ACAD SCI USA, V103, P14842, DOI 10.1073/pnas.0606857103; Song N, 2016, JAMA ONCOL, V2, P1162, DOI 10.1001/jamaoncol.2016.2314; Swenckl-Underwood B, 2008, PROTEIN EXPRES PURIF, V57, P312, DOI 10.1016/j.pep.2007.09.016; Tate CM, 2012, CELL DEATH DIFFER, V19, P1644, DOI 10.1038/cdd.2012.44; Tate CM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125697; Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001; Todaro M, 2014, CELL STEM CELL, V14, P342, DOI 10.1016/j.stem.2014.01.009; Valent P, 2012, NAT REV CANCER, V12, P767, DOI 10.1038/nrc3368; Vermeulen L, 2014, NAT REV CANCER, V14, P468, DOI 10.1038/nrc3744; Vitale I, 2017, MOL CELL, V66, P306, DOI 10.1016/j.molcel.2017.04.006; Zeng YH, 2017, ONCOL REP, V38, P456, DOI 10.3892/or.2017.5662; Zeuner A, 2014, CELL STEM CELL, V15, P692, DOI 10.1016/j.stem.2014.11.012	51	21	22	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	5					987	1003		10.1038/s41388-019-1047-4	http://dx.doi.org/10.1038/s41388-019-1047-4			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KI2VY	31591478	hybrid, Green Published			2022-12-28	WOS:000511209700003
J	Williams, CB; Phelps-Polirer, K; Dingle, IP; Williams, CJ; Rhett, MJ; Eblen, ST; Armeson, K; Hill, EG; Yeh, ES				Williams, Carly B.; Phelps-Polirer, Kendall; Dingle, Ivan P.; Williams, Christina J.; Rhett, Matthew J.; Eblen, Scott T.; Armeson, Kent; Hill, Elizabeth G.; Yeh, Elizabeth S.			HUNK phosphorylates EGFR to regulate breast cancer metastasis	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTORS; MAMMARY-TUMOR; EXPRESSION; KINASE; SNAIL; OVEREXPRESSION; SUBPOPULATIONS; INTRAVASATION; HETEROGENEITY; SURVIVAL	Epidermal growth factor receptor (EGFR) is commonly over-expressed in metastatic breast cancer yet metastatic breast cancer is generally resistant to anti-EGFR therapies, and the mechanism for resistance to EGFR inhibitors in this setting is not fully understood. Hormonally up-regulated neu-associated kinase (HUNK) kinase is up-regulated in aggressive breast cancers and is thought to play a role in breast cancer metastasis. However, no studies have been conducted to examine a relationship between EGFR and HUNK in breast cancer metastasis. We performed a kinase substrate screen and identified that EGFR is phosphorylated by HUNK. Our studies show that HUNK phosphorylates EGFR at T654, enhancing receptor stability and downstream signaling. We found that increased phosphorylation of T654 EGFR correlates with increased epithelial to mesenchymal, migration and invasion, and metastasis. In addition, we found that HUNK expression correlates with overall survival and distant metastasis free survival. This study shows that HUNK directly phosphorylates EGFR at T654 to promote metastasis and is the first study to show that the phosphorylation of this site in EGFR regulates metastasis.	[Williams, Carly B.; Phelps-Polirer, Kendall; Dingle, Ivan P.; Williams, Christina J.; Rhett, Matthew J.; Eblen, Scott T.; Yeh, Elizabeth S.] Med Univ South Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut, 173 Ashley Ave,BSB 358,MSC509, Charleston, SC 29425 USA; [Armeson, Kent; Hill, Elizabeth G.] Med Univ South Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA; [Yeh, Elizabeth S.] Indiana Univ Sch Med, Simon Canc Ctr, Dept Pharmacol & Toxicol, Indianapolis, IN 46220 USA	Medical University of South Carolina; Medical University of South Carolina; Indiana University System; Indiana University Bloomington	Yeh, ES (corresponding author), Med Univ South Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut, 173 Ashley Ave,BSB 358,MSC509, Charleston, SC 29425 USA.; Yeh, ES (corresponding author), Indiana Univ Sch Med, Simon Canc Ctr, Dept Pharmacol & Toxicol, Indianapolis, IN 46220 USA.	esyeh@iu.edu	Williams-Scalise, Carly Bess/D-7095-2016	Williams-Scalise, Carly Bess/0000-0002-7612-7791	South Carolina Clinical and Translational Research (SCTR) Institute [TL1 TR001451, UL1 TR001450]; Concern Foundation Conquer Cancer Now Award; American Cancer Society Institutional Research Grant at Hollings Cancer Center [IRG-97-219-14]; Department of Defense BRIDGE Award at Hollings Cancer Center [W81XWH-11-2-0229]; Biostatistics Shared Resource, Hollings Cancer Center, Medical University of South Carolina [P30 CA138313]; Medical University of South Carolina;  [R01CA187304]	South Carolina Clinical and Translational Research (SCTR) Institute; Concern Foundation Conquer Cancer Now Award; American Cancer Society Institutional Research Grant at Hollings Cancer Center(American Cancer Society); Department of Defense BRIDGE Award at Hollings Cancer Center(United States Department of Defense); Biostatistics Shared Resource, Hollings Cancer Center, Medical University of South Carolina; Medical University of South Carolina; 	This work was supported by TL1 TR001451 and UL1 TR001450 through the South Carolina Clinical and Translational Research (SCTR) Institute, with an academic home at the Medical University of South Carolina (CBW). This work was also supported by R01CA187304 (ESY) as well as past funding from a Concern Foundation Conquer Cancer Now Award (ESY), American Cancer Society Institutional Research Grant (IRG-97-219-14) at Hollings Cancer Center, and a Department of Defense BRIDGE Award (W81XWH-11-2-0229) at Hollings Cancer Center. These studies were also supported by the Biostatistics Shared Resource, Hollings Cancer Center, Medical University of South Carolina (P30 CA138313).	Ali R, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2016.42; Appert-Collin A, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00283; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Bao J, 2000, J BIOL CHEM, V275, P26178, DOI 10.1074/jbc.M002367200; Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Buchanan BW, 2016, JOVE-J VIS EXP, DOI 10.3791/53975; Carey LA, 2012, J CLIN ONCOL, V30, P2615, DOI 10.1200/JCO.2010.34.5579; Davis MI, 2011, NAT BIOTECHNOL, V29, P1046, DOI 10.1038/nbt.1990; Dickler MN, 2009, BREAST CANCER RES TR, V115, P115, DOI 10.1007/s10549-008-0055-9; Ettenberg SA, 1999, ONCOGENE, V18, P1855, DOI 10.1038/sj.onc.1202499; Feigin ME, 2009, EXP CELL RES, V315, P707, DOI 10.1016/j.yexcr.2008.10.034; Hauck CR, 2001, CANCER RES, V61, P7079; HEPPNER GH, 1978, CANCER RES, V38, P3758; Heppner GH, 2000, BREAST CANCER RES, V2, P331; Hipp S, 2009, J CELL MOL MED, V13, P3858, DOI 10.1111/j.1582-4934.2008.00526.x; Lanczky A, 2016, BREAST CANCER RES TR, V160, P439, DOI 10.1007/s10549-016-4013-7; Liu SV, 2014, EXPERT OPIN EMERG DR, V19, P51, DOI 10.1517/14728214.2014.873403; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Iglesias JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077281; Martin TA, 2005, ANN SURG ONCOL, V12, P488, DOI 10.1245/ASO.2005.04.010; Masuda H, 2012, BREAST CANCER RES TR, V136, P331, DOI 10.1007/s10549-012-2289-9; MILLER FR, 1983, INVAS METAST, V3, P22; Park HS, 2014, MODERN PATHOL, V27, P1212, DOI 10.1038/modpathol.2013.251; Phelps-Polirer K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153025; Pulaski B A, 2001, Curr Protoc Immunol, VChapter 20, DOI 10.1002/0471142735.im2002s39; Quintela-Fandino M, 2010, P NATL ACAD SCI USA, V107, P2622, DOI 10.1073/pnas.0914492107; Reed KR, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1087-2; SAINSBURY JRC, 1987, LANCET, V1, P1398; SAINSBURY JRC, 1985, LANCET, V1, P364; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Tischkowitz M, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-134; Turner T, 1996, CLIN EXP METASTAS, V14, P409, DOI 10.1007/BF00123400; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Wendt MK, 2010, ONCOGENE, V29, P6485, DOI 10.1038/onc.2010.377; Wertheim GBW, 2009, P NATL ACAD SCI USA, V106, P15855, DOI 10.1073/pnas.0906993106; Williams CB, 2015, ADV CANCER RES, V127, P253, DOI 10.1016/bs.acr.2015.04.008; Xue CS, 2006, CANCER RES, V66, P1418, DOI 10.1158/0008-5472.CAN-05-0550; Xue CS, 2006, CANCER RES, V66, P192, DOI 10.1158/0008-5472.CAN-05-1242; Yeh ES, 2015, BREAST CANCER RES TR, V149, P91, DOI 10.1007/s10549-014-3227-9; Yeh ES, 2011, J CLIN INVEST, V121, P866, DOI 10.1172/JCI42928; Yue P, 2012, ONCOGENE, V31, P2309, DOI 10.1038/onc.2011.409; Zambrano Joelle N, 2018, Oncotarget, V9, P35962, DOI 10.18632/oncotarget.26311	43	9	10	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	5					1112	1124		10.1038/s41388-019-1046-5	http://dx.doi.org/10.1038/s41388-019-1046-5			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KI2VY	31597954	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000511209700012
J	Xie, Y; Liu, J; Jiang, HM; Wang, JY; Li, X; Wang, JJ; Zhu, S; Guo, J; Li, T; Zhong, YP; Zhang, QG; Liu, ZQ				Xie, Ying; Liu, Jing; Jiang, Hongmei; Wang, Jingya; Li, Xin; Wang, Jingjing; Zhu, Shuai; Guo, Jing; Li, Tao; Zhong, Yuping; Zhang, Qiguo; Liu, Zhiqiang			Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma	ONCOGENE			English	Article							PHASE-II TRIAL	Multiple myeloma (MM) is still incurable despite the successful application of proteasome inhibitors in clinic. Bortezomib represents the most common chemotherapy for MM, whereas acquired drug resistance and eventually developed relapse remain the major obstruction. In the current study, we established bortezomib-resistant myeloma cell lines and screened gene expression profiles using single cell RNA-sequencing. Resistant MM cells exhibited increased clonogenic potential, specific metabolic, and epigenetic signatures, along with the self-renewal signaling characteristic of MM stem-like cells. Aberrant activation of hedgehog (Hh) signaling was correlated with drug resistance and stem cell-like transcriptional program. The key transcriptional factor GLI2 of the Hh pathway was restricted in the high acetylation and low ubiquitination states in bortezomib-resistant myeloma cells. Further investigation revealed that SIRT1 deacetylates and stabilizes GLI2 protein at lysine 757 and consequentially activates the Hh signaling, and itself serves as a direct target of Hh signaling to format a positive regulating loop. Using combination screening with an epigenetic compound library, we identified the SIRT1 specific inhibitor S1541 and S2804 had very obvious synergetic antimyeloma effect. Sirt1 inhibition could partially impeded the Hh pathway and conferred bortezomib sensitivity in vitro and in vivo. Notably, elevated SIRT1 level was also a prominent hallmark for the resistant myeloma cells, and this expression pattern was confirmed in myeloma patients, but independent of RAS/RAF mutations. Clinically, SIRT1 expression in patients with complete response was suppressed but elevated in relapsed patients, and retrospective analysis showed patients with higher SIRT1 expression had poorer outcomes. In conclusion, the cooperation of SIRT1 and Hh is an important mechanism of drug resistance in myeloma, and therapeutics combining SIRT1 inhibitors will sensitize myeloma cells to proteasome inhibitors.	[Xie, Ying; Liu, Jing; Jiang, Hongmei; Wang, Jingya; Li, Xin; Wang, Jingjing; Zhu, Shuai; Guo, Jing; Liu, Zhiqiang] Tianjin Med Univ, Sch Basic Med Sci, Dept Physiol & Pathophysiol, Tianjin 300070, Peoples R China; [Li, Tao] Hunan Normal Univ, Sch Med, Changsha 410006, Hunan, Peoples R China; [Zhong, Yuping] Capital Med Univ, Beijing Chao Yang Hosp, Myeloma Res Ctr Beijing, Dept Hematol, Beijing 100020, Peoples R China; [Zhang, Qiguo] Nanjing Univ, Nanjing Drum Tower Hosp, Dept Hematol, Nanjing 210008, Jiangsu, Peoples R China	Tianjin Medical University; Hunan Normal University; Capital Medical University; Nanjing University	Liu, ZQ (corresponding author), Tianjin Med Univ, Sch Basic Med Sci, Dept Physiol & Pathophysiol, Tianjin 300070, Peoples R China.	zhiqiangliu@tmu.edu.cn	wang, jing/GRS-7509-2022; Wang, Jin/GYA-2019-2022; wang, jing/GVT-8700-2022; WANG, JINGYI/GSJ-1241-2022; Liu, Zhiqiang/E-6950-2014	Liu, Zhiqiang/0000-0002-0677-8097; Xie, Ying/0000-0003-1197-3222; Liu, Jing/0000-0002-2112-2416	National Natural Science Foundation of China [81670201, 81870161]; Natural Science Foundation of Tianjin [16JCYBJC42600]; Talent Project of Tianjin Medical University [11601501/2016KJ0317]; Nanjing Key Medical Science and Technology Development Project [ZKX18023]; Chuzhou Science and Technology Development Project [2018zd004]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Tianjin(Natural Science Foundation of Tianjin); Talent Project of Tianjin Medical University; Nanjing Key Medical Science and Technology Development Project; Chuzhou Science and Technology Development Project	This work was supported by the National Natural Science Foundation of China (81670201, 81870161, ZL), the Natural Science Foundation of Tianjin (16JCYBJC42600, ZL), the Talent Project of Tianjin Medical University (11601501/2016KJ0317, ZL), the Nanjing Key Medical Science and Technology Development Project (ZKX18023, QZ), and the Chuzhou Science and Technology Development Project (2018zd004, QZ).	Amodio N, 2016, MOL CANCER THER, V15, P1364, DOI [10.1158/1535-7163.MCT-15-0985-T, 10.1158/1535-7163.MCT-15-0985]; Armas-Lopez L, 2017, ONCOTARGET, V8, P60684, DOI 10.18632/oncotarget.19527; Avigan D, 2014, NEW ENGL J MED, V371, P961, DOI 10.1056/NEJMe1407442; Canettieri G, 2010, NAT CELL BIOL, V12, P132, DOI 10.1038/ncb2013; Cappellacci L, 2018, CURR MED CHEM, V25, P1; Chauhan D, 2002, BLOOD, V100, P2187, DOI 10.1182/blood-2002-02-0376; Chauhan D, 2011, BRIT J HAEMATOL, V155, P588, DOI 10.1111/j.1365-2141.2011.08888.x; Delcuve GP, 2012, CLIN EPIGENETICS, V4, DOI 10.1186/1868-7083-4-5; Delude C, 2011, NATURE, V480, pS43, DOI 10.1038/480S43a; Gulino A, 2012, VITAM HORM, V88, P211, DOI 10.1016/B978-0-12-394622-5.00009-2; Harada T, 2017, LEUKEMIA, V31, P2670, DOI 10.1038/leu.2017.144; Hatayama M, 2012, VITAM HORM, V88, P73, DOI 10.1016/B978-0-12-394622-5.00004-3; Islam S, 2019, ONCOL LETT, V17, P729, DOI 10.3892/ol.2018.9722; Kumar SK, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.46; Laubach JP, 2017, EXPERT REV HEMATOL, V10, P229, DOI 10.1080/17474086.2017.1280388; Li BZ, 2015, J BIOL CHEM, V290, P29854, DOI 10.1074/jbc.M115.664953; Liu H, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad8949; Liu Z, 2014, ONCOGENE, V33, P65, DOI 10.1038/onc.2012.544; Liu ZQ, 2015, ONCOTARGET, V6, P34329, DOI 10.18632/oncotarget.6020; Liu ZQ, 2014, BLOOD, V124, P2061, DOI 10.1182/blood-2014-03-557298; Niewiadomski P, 2014, CELL REP, V6, P168, DOI 10.1016/j.celrep.2013.12.003; Nunes T, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19124036; Ohguchi H, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408-018-0119-y; Ok CY, 2012, AM J PATHOL, V180, P2, DOI 10.1016/j.ajpath.2011.09.009; Robak P, 2018, CANCER TREAT REV, V70, P199, DOI 10.1016/j.ctrv.2018.09.001; Sari IN, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7110208; Simmons GE, 2015, INT J MOL SCI, V16, P950, DOI 10.3390/ijms16010950; Wallington-Beddoe CT, 2018, BRIT J HAEMATOL, V182, P11, DOI 10.1111/bjh.15210; Wolf JL, 2012, LEUKEMIA LYMPHOMA, V53, P1820, DOI 10.3109/10428194.2012.661175; Yazbeck V, 2018, CL LYMPH MYELOM LEUK, V18, P569, DOI 10.1016/j.clml.2018.05.023; Zaal EA, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00500	31	18	20	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	4					922	934		10.1038/s41388-019-1037-6	http://dx.doi.org/10.1038/s41388-019-1037-6			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KF4EJ	31576013				2022-12-28	WOS:000509197200013
J	Shen, H; Wang, GC; Li, X; Ge, X; Wang, M; Shi, ZM; Bhardwaj, V; Wang, ZX; Zinner, RG; Peiper, SC; Aplin, AE; Jiang, BH; He, J				Shen, Hua; Wang, Gao-Chan; Li, Xiang; Ge, Xin; Wang, Meng; Shi, Zhu-Mei; Bhardwaj, Vikas; Wang, Zi-Xuan; Zinner, Ralph G.; Peiper, Stephen C.; Aplin, Andrew E.; Jiang, Bing-Hua; He, Jun			S6K1 blockade overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer	ONCOGENE			English	Article							TYROSINE KINASE INHIBITORS; DRUG-RESISTANCE; P70S6K1 ACTIVATION; MAMMALIAN TARGET; BREAST-CANCER; GROWTH; MDM2; EXPRESSION; GEFITINIB; PROMOTES	The development of resistance to EGFR Tyrosine kinase inhibitors (TKIs) in NSCLC with activating EGFR mutations is a critical limitation of this therapy. In addition to genetic alterations such as EGFR secondary mutation causing EGFR-TKI resistance, compensatory activation of signaling pathways without interruption of genome integrity remains to be defined. In this study, we identified S6K1/MDM2 signaling axis as a novel bypass mechanism for the development of EGFR-TKI resistance. The observation of S6K1 as a candidate mechanism for resistance to EGFR TKI therapy was investigated by interrogation of public databases and a clinical cohort to establish S6K1 expression as a prognostic/predictive biomarker. The role of S6K1 in TKI resistance was determined in in vitro gain-and-loss of function studies and confirmed in subcutaneous and orthotopic mouse lung cancer models. Blockade of S6K1 by a specific inhibitor PF-4708671 synergistically enhanced the efficacy of TKI without showing toxicity. The mechanistic study showed the inhibition of EGFR caused nuclear translocation of S6K1 for binding with MDM2 in resistant cells. MDM2 is a downstream effector of S6K1-mediated TKI resistance. Taken together, we present evidence for the reversal of resistance to EGFR TKI by the addition of small molecule S6K1/MDM2 antagonists that could have clinical benefit.	[Shen, Hua] Nanjing Med Univ, Sir Run Run Hosp, Dept Oncol, Nanjing, Peoples R China; [Shen, Hua] Nanjing Med Univ, Dept Oncol, Affiliated Hosp 1, Nanjing, Peoples R China; [Wang, Gao-Chan; Li, Xiang; Wang, Meng; Wang, Zi-Xuan; Peiper, Stephen C.; He, Jun] Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA; [Li, Xiang] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Thorac Surg, Xian, Peoples R China; [Ge, Xin; Shi, Zhu-Mei] Nanjing Med Univ, State Key Lab Reprod Med, Dept Pathol, Nanjing, Peoples R China; [Bhardwaj, Vikas] Thomas Jefferson Univ, Coll Pharm, Philadelphia, PA 19107 USA; [Zinner, Ralph G.] Thomas Jefferson Univ, Dept Med Oncol, Philadelphia, PA 19107 USA; [Aplin, Andrew E.] Thomas Jefferson Univ, Dept Canc Biol, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA; [Jiang, Bing-Hua] Univ Iowa, Dept Pathol, Carver Coll Med, Iowa City, IA USA	Nanjing Medical University; Nanjing Medical University; Jefferson University; Xi'an Jiaotong University; Nanjing Medical University; Jefferson University; Jefferson University; Jefferson University; University of Iowa	He, J (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA.	Jun.he@jefferson.edu		He, Jun/0000-0002-5162-6041; Bhardwaj, Vikas/0000-0003-3364-8711	National Cancer Institute [R00 CA 215316, R01 CA232587, R01 CA160495]; Natural Science Foundation of China [81874230]; Jiangsu Social Development Project (China) [BE2018726]; Natural Science Foundation of Jiangsu Province [BK20171484]; Project of Invigorating Health Care through Science, Technology, and Education (Jiangsu Provincial Medical Youth Talent) [QNRC2016856]; Summit of the Six Top Talents Program of Jiangsu Province [2017WSN-179]; NCI of the NIH [P30CA056036]	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jiangsu Social Development Project (China); Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Project of Invigorating Health Care through Science, Technology, and Education (Jiangsu Provincial Medical Youth Talent); Summit of the Six Top Talents Program of Jiangsu Province; NCI of the NIH	This work was supported by National Cancer Institute (R00 CA 215316, R01 CA232587, R01 CA160495), Natural Science Foundation of China (No. 81874230), Jiangsu Social Development Project (China, BE2018726), the Natural Science Foundation of Jiangsu Province (Grants No. BK20171484), the Project of Invigorating Health Care through Science, Technology, and Education (Jiangsu Provincial Medical Youth Talent QNRC2016856), the Summit of the Six Top Talents Program of Jiangsu Province (2017WSN-179). Research reported in this publication utilized the Flow Cytometry Facility at Sidney Kimmel Cancer Center at Jefferson Health, which was supported by the NCI of the NIH (P30CA056036).	Ashton JC, 2015, CANCER RES, V75, P2400, DOI 10.1158/0008-5472.CAN-14-3763; Bilanges Benoit, 2010, Biochem J, V431, pe1, DOI 10.1042/BJ20101445; Bostner J, 2015, ENDOCR-RELAT CANCER, V22, P331, DOI 10.1530/ERC-14-0513; Boulares AH, 1999, J BIOL CHEM, V274, P22932, DOI 10.1074/jbc.274.33.22932; Cappuzzo F, 2009, J CLIN ONCOL, V27, P1667, DOI 10.1200/JCO.2008.19.1635; de Bruin EC, 2014, CANCER DISCOV, V4, P606, DOI 10.1158/2159-8290.CD-13-0741; Desbois-Mouthon C, 2006, INT J CANCER, V119, P2557, DOI 10.1002/ijc.22221; Donev IS, 2011, CLIN CANCER RES, V17, P2260, DOI 10.1158/1078-0432.CCR-10-1993; Eischen CM, 2017, J MOL CELL BIOL, V9, P69, DOI 10.1093/jmcb/mjw052; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Fang J, 2006, J CELL PHYSIOL, V209, P261, DOI 10.1002/jcp.20749; Feeley KP, 2017, CANCER RES, V77, P3823, DOI 10.1158/0008-5472.CAN-17-0809; Fenton TR, 2011, INT J BIOCHEM CELL B, V43, P47, DOI 10.1016/j.biocel.2010.09.018; Fujita Y, 2012, J THORAC ONCOL, V7, P1640, DOI 10.1097/JTO.0b013e3182653d7f; Grasso S, 2014, NEOPLASIA, V16, P845, DOI 10.1016/j.neo.2014.08.011; Gray JE, 2019, CLIN CANCER RES, V25, P6644, DOI 10.1158/1078-0432.CCR-19-1126; Guix M, 2008, J CLIN INVEST, V118, P2609, DOI 10.1172/JCI34588; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hollebecque A, 2014, EUR J CANCER, V50, P876, DOI 10.1016/j.ejca.2013.12.006; Ip CKM, 2014, ONCOTARGET, V5, P9133; Jacobsen K, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00450-6; Jiang BH, 2008, DRUG RESIST UPDATE, V11, P63, DOI 10.1016/j.drup.2008.03.001; Jiang XH, 2009, BIOCHEM BIOPH RES CO, V387, P521, DOI 10.1016/j.bbrc.2009.07.060; Ju LX, 2010, J CELL BIOCHEM, V111, P1565, DOI 10.1002/jcb.22888; Juchum M, 2015, DRUG RESIST UPDATE, V20, P12, DOI 10.1016/j.drup.2015.05.002; Khotskaya YB, 2014, AM J TRANSL RES, V6, P361; Koizumi F, 2005, INT J CANCER, V116, P36, DOI 10.1002/ijc.20985; Lai KP, 2010, EMBO J, V29, P2994, DOI 10.1038/emboj.2010.166; Leonetti A, 2019, BRIT J CANCER, V121, P725, DOI 10.1038/s41416-019-0573-8; Lu QJ, 2015, ONCOL LETT, V10, P277, DOI 10.3892/ol.2015.3228; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; McIlwain DR, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008656; Oxnard GR, 2011, CLIN CANCER RES, V17, P5530, DOI 10.1158/1078-0432.CCR-10-2571; Park HS, 2014, INT J CLIN ONCOL, V19, P842, DOI 10.1007/s10147-013-0639-1; Pearce LR, 2010, BIOCHEM J, V431, P245, DOI 10.1042/BJ20101024; Phuchareon J, 2015, P NATL ACAD SCI USA, V112, pE3855, DOI 10.1073/pnas.1510733112; Qi HW, 2011, EXP THER MED, V2, P1091, DOI 10.3892/etm.2011.324; Qiu ZX, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147185; Rolfo C, 2014, CANCER TREAT REV, V40, P990, DOI 10.1016/j.ctrv.2014.05.009; Romaniello D, 2018, CLIN CANCER RES, V24, P5610, DOI 10.1158/1078-0432.CCR-18-0450; Shangary S, 2008, P NATL ACAD SCI USA, V105, P3933, DOI 10.1073/pnas.0708917105; Shin S, 2011, P NATL ACAD SCI USA, V108, pE1204, DOI 10.1073/pnas.1110195108; Tavares MR, 2015, LIFE SCI, V131, P1, DOI 10.1016/j.lfs.2015.03.001; Tolcher A, 2014, EUR J CANCER, V50, P867, DOI 10.1016/j.ejca.2013.11.039; Valovka T, 2003, MOL CELL BIOL, V23, P852, DOI 10.1128/MCB.23.3.852-863.2003; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Wan X, 2007, ONCOGENE, V26, P1932, DOI 10.1038/sj.onc.1209990; Wang W, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6086; Wang Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0922-0; Wao H, 2013, SYST REV-LONDON, V2, DOI 10.1186/2046-4053-2-10; Wykosky J, 2015, CANCER RES, V75, P394, DOI 10.1158/0008-5472.CAN-14-2004; Yu HA, 2018, CLIN CANCER RES, V24, P3108, DOI 10.1158/1078-0432.CCR-17-2961; Zhang CH, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-184; Zhang Y, 2015, MOL CANCER THER, V14, P799, DOI 10.1158/1535-7163.MCT-14-0648; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330	55	4	4	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2020	39	49					7181	7195		10.1038/s41388-020-01497-4	http://dx.doi.org/10.1038/s41388-020-01497-4		OCT 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PB0GA	33037411	Green Accepted			2022-12-28	WOS:000578440800004
J	Angom, RS; Mondal, SK; Wang, F; Madamsetty, VS; Wang, EF; Dutta, SK; Gulani, Y; Sarabia-Estrada, R; Sarkaria, JN; Quinones-Hinojosa, A; Mukhopadhyay, D				Angom, Ramcharan Singh; Mondal, Sujan Kumar; Wang, Fei; Madamsetty, Vijay Sagar; Wang, Enfeng; Dutta, Shamit K.; Gulani, Yash; Sarabia-Estrada, Rachel; Sarkaria, Jann N.; Quinones-Hinojosa, Alfredo; Mukhopadhyay, Debabrata			Ablation of neuropilin-1 improves the therapeutic response in conventional drug-resistant glioblastoma multiforme	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; N-CADHERIN EXPRESSION; CANCER STEM-CELLS; GLIOMA PROGRESSION; C-MET; SURVIVAL; OVEREXPRESSION; ANGIOGENESIS; TUMORS; TUMORIGENICITY	Glioblastoma multiforme (GBM) is a highly proliferative and locally invasive cancer with poor prognosis and a high recurrence rate. Although anti-VEGF (vascular endothelial growth factor) therapy offers short-term benefit to GBM patients, this approach fails as the tumor develops into a more invasive and drug-resistant phenotype and ultimately recurs. Recently, both glioma stemlike cells (GSCs) and brain tumor-initiating cells (BTICs) have been implicated in GBM recurrence and its resistance to therapy. We observed that patient-derived GBM cells expressing shRNAs of VEGF or neuropilin-1 (NRP-1) attenuate cancer stem cell markers, inhibit the tumor-initiating cell's neurosphere-forming capacity, and migration. Furthermore, both VEGF and NRP-1 knockdown inhibit the growth of patient-derived GBM xenografts in both zebrafish and mouse models. Interestingly, NRP-1-depleted patient-derived GBM xenografts substantially prolonged survival in mice compared to that of VEGF depletion. Our results also demonstrate that NRP-1 ablation of patient-derived GBM cells improves the sensitivity of TMZ and enhances the overall survival of the respective tumor-bearing mice. This improved outcome may provide insight into the inhibition of GBM progression and effective treatment strategies by targeting NRP-1 in addition to chemotherapy and radiotherapy.	[Angom, Ramcharan Singh; Wang, Fei; Madamsetty, Vijay Sagar; Wang, Enfeng; Dutta, Shamit K.; Gulani, Yash; Mukhopadhyay, Debabrata] Mayo Clin, Coll Med & Sci, Dept Biochem & Mol Biol, Jacksonville, FL 32224 USA; [Mondal, Sujan Kumar; Sarabia-Estrada, Rachel; Quinones-Hinojosa, Alfredo] Mayo Clin, Coll Med & Sci, Dept Neurosurg, Jacksonville, FL 32224 USA; [Sarkaria, Jann N.] Mayo Clin, Coll Med & Sci, Dept Radiat Oncol, Rochester, MN USA; [Mondal, Sujan Kumar] Univ Pittsburgh, Med Ctr, Dept Pathol, UPMC Hillman Ctr, Pittsburgh, PA USA; [Wang, Fei] Inner Mongolia Med Univ, Affiliated Hosp, Dept Neurosurg, Hohhot 010050, Inner Mongolia, Peoples R China	Mayo Clinic; Mayo Clinic; Mayo Clinic; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Inner Mongolia Medical University	Mukhopadhyay, D (corresponding author), Mayo Clin, Coll Med & Sci, Dept Biochem & Mol Biol, Jacksonville, FL 32224 USA.; Quinones-Hinojosa, A (corresponding author), Mayo Clin, Coll Med & Sci, Dept Neurosurg, Jacksonville, FL 32224 USA.	Quinones-Hinojosa.Alfredo@mayo.edu; Mukhopadhyay.Debabrata@mayo.edu	Mondal, Sujan K./AAI-3850-2020; Madamsetty, Vijay Sagar/AAF-4804-2019; Angom, Ramcharan/ABH-2691-2021	Mondal, Sujan K./0000-0003-3241-2504; Madamsetty, Vijay Sagar/0000-0001-9883-190X; ANGOM, RAMCHARAN/0000-0002-5894-1108; Gulani, Yash/0000-0002-8053-8702	NIH [DM R01CA 78383, RO1HL140411, R01CA150190, R43CA221490, R01CA200399, R01CA195503, R01CA216855]; Florida Department of Health Cancer Research Chair Fund Florida [3J]; Mayo Clinic Professorship; Florida Department of Health Cancer Research Chair Fund	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Florida Department of Health Cancer Research Chair Fund Florida; Mayo Clinic Professorship; Florida Department of Health Cancer Research Chair Fund	The authors thank Dr Leonard Zon, Children's Hospital, Boston, Massachusetts, for providing the Casper zebrafish strain, and Dr Ying Wang, Mayo Clinic, Jacksonville, for assistance with lentiviral preparation. The work was supported by the NIH Grant to DM R01CA 78383, RO1HL140411, R01CA150190, Florida Department of Health Cancer Research Chair Fund Florida #3J. AQH was supported by the Mayo Clinic Professorship and a Clinician Investigator award, the Florida Department of Health Cancer Research Chair Fund, and the NIH (R43CA221490, R01CA200399, R01CA195503, and R01CA216855).	An ZY, 2018, ONCOGENE, V37, P1561, DOI 10.1038/s41388-017-0045-7; Andaloussi-Saghir K, 2011, N AM J MED SCI, V3, P527, DOI 10.4297/najms.2011.3527; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Beck B, 2011, NATURE, V478, P399, DOI 10.1038/nature10525; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Cantanhede IG, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15045-w; Cao Y, 2008, CANCER RES, V68, P8667, DOI 10.1158/0008-5472.CAN-08-2614; Cao Y, 2012, CANCER RES, V72, P3912, DOI 10.1158/0008-5472.CAN-11-4058; Chaichana KL, 2014, NEURO-ONCOLOGY, V16, P113, DOI 10.1093/neuonc/not137; Chaichana KL, 2011, J NEUROSURG, V114, P587, DOI 10.3171/2010.8.JNS1081; Chaudhry IH, 2001, HISTOPATHOLOGY, V39, P409, DOI 10.1046/j.1365-2559.2001.01230.x; Chen WJ, 2015, INT J CLIN EXP MED, V8, P8709; Chung AS, 2011, ANNU REV CELL DEV BI, V27, P563, DOI 10.1146/annurev-cellbio-092910-154002; Dirkse A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09853-z; Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Gamble JT, 2018, BIOCHEM BIOPH RES CO, V506, P833, DOI 10.1016/j.bbrc.2018.10.076; Gong CF, 2018, NEURO-ONCOLOGY, V20, P131; Grun D, 2016, ONCOGENE, V35, P4379, DOI 10.1038/onc.2015.507; Hamerlik P, 2012, J EXP MED, V209, P507, DOI 10.1084/jem.20111424; Han JF, 2015, AM J CANCER RES, V5, P945; Hattermann K, 2016, INT J ONCOL, V49, P1899, DOI 10.3892/ijo.2016.3682; Her NG, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0825-1; Holland EC, 2000, P NATL ACAD SCI USA, V97, P6242, DOI 10.1073/pnas.97.12.6242; Hou HL, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0937-4; Hu B, 2007, ONCOGENE, V26, P5577, DOI 10.1038/sj.onc.1210348; Ikushima H, 2009, CELL STEM CELL, V5, P504, DOI 10.1016/j.stem.2009.08.018; Kim YJ, 2017, ONCOGENE, V36, P2543, DOI 10.1038/onc.2016.407; Kitange GJ, 2012, CLIN CANCER RES, V18, P4070, DOI 10.1158/1078-0432.CCR-12-0560; Kwak Y, 2015, INT J CLIN EXP PATHO, V8, P14932; Kwiatkowski SC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185065; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Liu TR, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05982-z; Lobo NA, 2007, ANNU REV CELL DEV BI, V23, P675, DOI 10.1146/annurev.cellbio.22.010305.104154; Lu KV, 2012, CANCER CELL, V22, P21, DOI 10.1016/j.ccr.2012.05.037; Maire CL, 2014, NEURO-ONCOLOGY, V16, pviii1, DOI 10.1093/neuonc/nou294; McCarty JH, 2013, CLIN CANCER RES, V19, P1631, DOI 10.1158/1078-0432.CCR-13-0051; Mercurio AM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030490; Mukhopadhyay D, 2004, SEMIN CANCER BIOL, V14, P123, DOI 10.1016/j.semcancer.2003.09.019; Noh MG, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3591-z; Oka N, 2007, BIOCHEM BIOPH RES CO, V360, P553, DOI 10.1016/j.bbrc.2007.06.094; Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P1, DOI 10.1093/neuonc/nou223; Peglion F, 2012, CELL ADHES MIGR, V6, P327, DOI 10.4161/cam.20855; Peng KW, 2019, DRUG DISCOV TODAY, V24, P656, DOI 10.1016/j.drudis.2018.10.004; Petterson SA, 2015, J NEURO-ONCOL, V122, P517, DOI 10.1007/s11060-015-1723-3; Rizzolio S, 2018, J CLIN INVEST, V128, P3976, DOI 10.1172/JCI99257; Ruffini F, 2017, ONCOTARGET, V8, P66833, DOI 10.18632/oncotarget.18706; Seymour T, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00159; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Singh SK, 2003, CANCER RES, V63, P5821; Soker S, 2002, J CELL BIOCHEM, V85, P357, DOI 10.1002/jcb.10140; Song WS, 2016, J CHIN MED ASSOC, V79, P538, DOI 10.1016/j.jcma.2016.03.010; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Tilghman J, 2014, CANCER RES, V74, P3168, DOI 10.1158/0008-5472.CAN-13-2103; Tomida C, 2018, INT J ONCOL, V52, P1350, DOI 10.3892/ijo.2018.4291; Treps L, 2017, J EXTRACELL VESICLES, V6, DOI 10.1080/20013078.2017.1359479; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wang P, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2016.105; Xu CS, 2013, SCI WORLD J, DOI 10.1155/2013/417413; Yuan XP, 2004, ONCOGENE, V23, P9392, DOI 10.1038/sj.onc.1208311; Zhao D, 2015, ONCOGENE, V34, P3107, DOI 10.1038/onc.2014.257; Zhao JX, 2018, APPL IMMUNOHISTO M M, V26, P337, DOI 10.1097/PAI.0000000000000420	62	8	8	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	2020	39	48					7114	7126		10.1038/s41388-020-01462-1	http://dx.doi.org/10.1038/s41388-020-01462-1		OCT 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PE1YE	33005016				2022-12-28	WOS:000574356500001
J	Murray, AS; Hyland, TE; Sala-Hamrick, KE; Mackinder, JR; Martin, CE; Tanabe, LM; Varela, FA; List, K				Murray, Andrew S.; Hyland, Thomas E.; Sala-Hamrick, Kimberley E.; Mackinder, Jacob R.; Martin, Carly E.; Tanabe, Lauren M.; Varela, Fausto A.; List, Karin			The cell-surface anchored serine protease TMPRSS13 promotes breast cancer progression and resistance to chemotherapy	ONCOGENE			English	Article							HEPATOCYTE GROWTH-FACTOR; BARRIER FUNCTION; PROSTASIN; EXPRESSION; MATRIPTASE; CHEMOSENSITIVITY; LOCALIZATION; INVASION; CASCADE; ZYMOGEN	Breast cancer progression is accompanied by increased expression of extracellular and cell-surface proteases capable of degrading the extracellular matrix as well as cleaving and activating downstream targets. The type II transmembrane serine proteases (TTSPs) are a family of cell-surface proteases that play critical roles in numerous types of cancers. Therefore, the aim of this study was to identify novel and uncharacterized TTSPs with differential expression in breast cancer and to determine their potential roles in progression. Systematic in silico data analysis followed by immunohistochemical validation identified increased expression of the TTSP family member, TMPRSS13 (transmembrane protease, serine 13), in invasive ductal carcinoma patient tissue samples compared to normal breast tissue. To test whether loss of TMPRSS13 impacts tumor progression, TMPRSS13 was genetically ablated in the oncogene-induced transgenic MMTV-PymT tumor model. TMPRSS13 deficiency resulted in a significant decrease in overall tumor burden and growth rate, as well as a delayed formation of detectable mammary tumors, thus suggesting a causal relationship between TMPRSS13 expression and the progression of breast cancer. Complementary studies using human breast cancer cell culture models revealed that siRNA-mediated silencing of TMPRSS13 expression decreases proliferation, induces apoptosis, and attenuates invasion. Importantly, targeting TMPRSS13 expression renders aggressive triple-negative breast cancer cell lines highly responsive to chemotherapy. At the molecular level, knockdown of TMPRSS13 in breast cancer cells led to increased protein levels of the tumor-suppressive protease prostasin. TMPRSS13/prostasin co-immunoprecipitation and prostasin zymogen activation experiments identified prostasin as a potential novel target for TMPRSS13. Regulation of prostasin levels may be a mechanism that contributes to the pro-oncogenic properties of TMPRSS13 in breast cancer. TMPRSS13 represents a novel candidate for targeted therapy in combination with standard of care chemotherapy agents in patients with hormone receptor-negative breast cancer or in patients with tumors refractory to endocrine therapy.	[Murray, Andrew S.; Hyland, Thomas E.; Sala-Hamrick, Kimberley E.; Mackinder, Jacob R.; Martin, Carly E.; Tanabe, Lauren M.; Varela, Fausto A.; List, Karin] Wayne State Univ, Dept Pharmacol, Detroit, MI 48201 USA; [Murray, Andrew S.; Martin, Carly E.; List, Karin] Wayne State Univ, Dept Oncol, Detroit, MI 48202 USA	Wayne State University; Wayne State University	List, K (corresponding author), Wayne State Univ, Dept Pharmacol, Detroit, MI 48201 USA.; List, K (corresponding author), Wayne State Univ, Dept Oncol, Detroit, MI 48202 USA.	klist@med.wayne.edu		List, Karin/0000-0002-5847-5637; Murray, Andrew/0000-0002-2899-4970	NIH/NCI [R01CA160565, R01CA160565-04S, R01CA222359, F31CA217148]; NIGMS/NIH [R25 GM 058905-15]; NIH Ruth L. Kirschstein National Research Service Award [T32-CA009531]; DeRoy Testamentary Foundation	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIH Ruth L. Kirschstein National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DeRoy Testamentary Foundation	This work was supported by NIH/NCI R01CA160565 grant (KL), NIH/NCI R01CA160565-04S grant (KL, FAV), NIH/NCI R01CA222359 (KL), NIH/NCI F31CA217148 (FAV), NIGMS/NIH grant R25 GM 058905-15 (FAV), NIH Ruth L. Kirschstein National Research Service Award T32-CA009531 (ASM and CEM) and The DeRoy Testamentary Foundation (ASM).	Amundson SA, 2000, CANCER RES, V60, P6101; Antalis TM, 2011, PROG MOL BIOL TRANSL, V99, P1, DOI 10.1016/S1877-1173(11)99001-2; Antalis TM, 2010, BIOCHEM J, V428, P325, DOI 10.1042/BJ20100046; Bao YH, 2019, ONCOGENE, V38, P497, DOI 10.1038/s41388-018-0453-3; Bao YH, 2016, ONCOTARGET, V7, P28540, DOI 10.18632/oncotarget.8677; Bao YH, 2016, ONCOTARGET, V7, P26780, DOI 10.18632/oncotarget.8511; Bugge TH, 2009, J BIOL CHEM, V284, P23177, DOI 10.1074/jbc.R109.021006; Chen LM, 2006, AM J PHYSIOL-RENAL, V291, pF567, DOI 10.1152/ajprenal.00047.2006; Chen LM, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-377; Chen LM, 2001, J BIOL CHEM, V276, P21434, DOI 10.1074/jbc.M011423200; Chen LM, 2001, PROSTATE, V48, P93, DOI 10.1002/pros.1085; Chen LM, 2004, PROSTATE, V59, P1, DOI 10.1002/pros.10346; Chen LM, 2002, INT J CANCER, V97, P323, DOI 10.1002/ijc.1601; Chen M, 2008, BBA-MOL CELL RES, V1783, P896, DOI 10.1016/j.bbamcr.2007.10.019; Chen MQ, 2007, BBA-MOL CELL RES, V1773, P1133, DOI 10.1016/j.bbamcr.2007.04.013; Chen MQ, 2010, MOL CELL BIOCHEM, V337, P259, DOI 10.1007/s11010-009-0307-y; Dai XF, 2017, J CANCER, V8, P3131, DOI 10.7150/jca.18457; Friis S, 2016, J BIOL CHEM, V291, P2577, DOI 10.1074/jbc.C115.706721; Friis S, 2013, J BIOL CHEM, V288, P19028, DOI 10.1074/jbc.M113.469932; Goswami CP, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-970; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hashimoto T, 2010, FEBS J, V277, P4888, DOI 10.1111/j.1742-4658.2010.07894.x; Hollestelle A, 2010, BREAST CANCER RES TR, V121, P53, DOI 10.1007/s10549-009-0460-8; Hooper JD, 2001, J BIOL CHEM, V276, P857, DOI 10.1074/jbc.R000020200; Kido H, 2008, FRONT BIOSCI-LANDMRK, V13, P754, DOI 10.2741/2717; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Leyvraz C, 2005, J CELL BIOL, V170, P487, DOI 10.1083/jcb.200501038; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; List K, 2006, AM J PATHOL, V168, P1513, DOI 10.2353/ajpath.2006.051071; List K, 2005, GENE DEV, V19, P1934, DOI 10.1101/gad.1300705; List K, 2006, MOL MED, V12, P1, DOI 10.2119/2006-00022.List; Madsen DH, 2014, BIOCHEM J, V461, P487, DOI 10.1042/BJ20140337; Martin CE, 2019, CANCER METAST REV, V38, P357, DOI 10.1007/s10555-019-09811-7; Murray AS, 2017, J BIOL CHEM, V292, P14867, DOI 10.1074/jbc.M117.775999; Murray AS, 2016, BIOL CHEM, V397, P815, DOI 10.1515/hsz-2016-0131; Netzel-Arnett S, 2003, CANCER METAST REV, V22, P237, DOI 10.1023/A:1023003616848; Netzel-Arnett S, 2006, J BIOL CHEM, V281, P32941, DOI 10.1074/jbc.C600208200; Okumura Y, 2010, J VIROL, V84, P5089, DOI 10.1128/JVI.02605-09; Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325; Peters DE, 2014, J BIOL CHEM, V289, P14740, DOI 10.1074/jbc.M113.541318; Quinn JE, 2003, CANCER RES, V63, P6221; Sakashita K, 2008, J SURG ONCOL, V98, P559, DOI 10.1002/jso.21158; Selzer-Plon J, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-201; Shipway A, 2004, BIOCHEM BIOPH RES CO, V324, P953, DOI 10.1016/j.bbrc.2004.09.123; Szabo R, 2008, INT J BIOCHEM CELL B, V40, P1297, DOI 10.1016/j.biocel.2007.11.013; Takahashi S, 2003, PROSTATE, V54, P187, DOI 10.1002/pros.10178; Tanabe LM, 2017, FEBS J, V284, P1421, DOI 10.1111/febs.13971; Tassone P, 2003, BRIT J CANCER, V88, P1285, DOI 10.1038/sj.bjc.6600859; Trecesson SD, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01079-1; Wahba HA, 2015, CANCER BIOL MED, V12, P106, DOI 10.7497/j.issn.2095-3941.2015.0030; Wang J, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0661-5; Wei G, 2012, CANCER CELL, V21, P547, DOI 10.1016/j.ccr.2012.02.028; Yamamoto Koji, 2018, Oncotarget, V9, P11691, DOI 10.18632/oncotarget.24450; Yan BX, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.523; Yang HY, 2017, ONCOL RES, V25, P923, DOI 10.3727/096504016X14798241682647; YU JX, 1995, J BIOL CHEM, V270, P13483, DOI 10.1074/jbc.270.22.13483; YU JX, 1994, J BIOL CHEM, V269, P18843; Zmora P, 2014, J VIROL, V88, P12087, DOI 10.1128/JVI.01427-14; Zoratti GL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7776	59	9	9	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2020	39	41					6421	6436		10.1038/s41388-020-01436-3	http://dx.doi.org/10.1038/s41388-020-01436-3		AUG 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OA1JL	32868877	Green Accepted			2022-12-28	WOS:000564507300001
J	Prendergast, L; Hong, E; Safina, A; Poe, D; Gurova, K				Prendergast, Laura; Hong, Erin; Safina, Alfiya; Poe, Dante; Gurova, Katerina			Histone chaperone FACT is essential to overcome replication stress in mammalian cells	ONCOGENE			English	Article							CHROMATIN TRANSCRIPTION FACT; FUNCTIONAL COOPERATION; MCM-HELICASE; DNA-DAMAGE; COMPLEX; NUCLEOSOME; PROTEIN; MECHANISM; SPT16; YEAST	The histone chaperone FACT is upregulated during mammary tumorigenesis and necessary for the viability and growth of breast tumor cells. We established that only proliferating tumor cells are sensitive to FACT knockdown, suggesting that FACT functions during DNA replication in tumor cells but not in normal cells. We hypothesized that the basal level of replication stress defines the FACT dependence of cells. Using genetic and chemical tools, we demonstrated that FACT is needed to overcome replication stress. In the absence of FACT during replication stress, the MCM2-7 helicase dissociates from chromatin, resulting in the absence of ssDNA accumulation, RPA binding, and activation of the ATR/CHK1 checkpoint response. Without this response, stalled replication forks are not stabilized, and new origin firing cannot be prevented, leading to the accumulation of DNA damage and cell death. Thus, we propose a novel role for FACT as a factor preventing helicase dissociation from chromatin during replication stress.	[Prendergast, Laura; Hong, Erin; Safina, Alfiya; Poe, Dante; Gurova, Katerina] Roswell Pk Comprehens Canc Ctr, Dept Cell Stress Biol, Buffalo, NY 14263 USA		Gurova, K (corresponding author), Roswell Pk Comprehens Canc Ctr, Dept Cell Stress Biol, Buffalo, NY 14263 USA.	katerina.gurova@roswellpark.org		Prendergast, Laura/0000-0003-0467-657X; Poe, Dante/0000-0002-4813-3035; Gurova, Katerina/0000-0001-9189-0712	NCI NIH HHS [P30 CA016056, R01 CA197967] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe T, 2011, J BIOL CHEM, V286, P30504, DOI 10.1074/jbc.M111.264721; Attwood K, 2017, BREAST CANCER-TARGET, V9, P301, DOI 10.2147/BCTT.S126390; Byun TS, 2005, GENE DEV, V19, P1040, DOI 10.1101/gad.1301205; Carter DR, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab1803; Cha RS, 2002, SCIENCE, V297, P602, DOI 10.1126/science.1071398; Corpet A, 2011, EMBO J, V30, P480, DOI 10.1038/emboj.2010.335; Dermawan JKT, 2016, CANCER RES, V76, P2432, DOI 10.1158/0008-5472.CAN-15-2162; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Ekholm-Reed S, 2004, J CELL BIOL, V165, P789, DOI 10.1083/jcb.200404092; Fleyshman D, 2017, ONCOTARGET, V8, P20525, DOI 10.18632/oncotarget.15656; Forment JV, 2015, NAT PROTOC, V10, P1297, DOI 10.1038/nprot.2015.066; Garcia H, 2013, CELL REP, V4, P159, DOI 10.1016/j.celrep.2013.06.013; Garcia H, 2011, ONCOTARGET, V2, P783; Gasparian AV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002530; Groth A, 2005, MOL CELL, V17, P301, DOI 10.1016/j.molcel.2004.12.018; Gurova K, 2018, BBA-GENE REGUL MECH, V1861, P892, DOI 10.1016/j.bbagrm.2018.07.008; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Herrera-Moyano E, 2014, GENE DEV, V28, P735, DOI 10.1101/gad.234070.113; Hertel L, 1999, EXP CELL RES, V250, P313, DOI 10.1006/excr.1999.4495; Hoek M, 2003, P NATL ACAD SCI USA, V100, P12183, DOI 10.1073/pnas.1635158100; Kim ST, 1999, J BIOL CHEM, V8, P49; Klusmann I, 2016, CELL REP, V17, P1845, DOI 10.1016/j.celrep.2016.10.036; Koman IE, 2012, CANCER PREV RES, V5, P1025, DOI 10.1158/1940-6207.CAPR-11-0529; Kulaeva OI, 2013, BBA-GENE REGUL MECH, V1829, P76, DOI 10.1016/j.bbagrm.2012.08.015; Kurat CF, 2017, MOL CELL, V65, P117, DOI 10.1016/j.molcel.2016.11.016; Liu Y, 2020, NATURE, V577, P426, DOI 10.1038/s41586-019-1820-0; Lolas IB, 2010, PLANT J, V61, P686, DOI 10.1111/j.1365-313X.2009.04096.x; Lolis AA, 2013, J BIOL CHEM, V288, P7676, DOI 10.1074/jbc.M112.426718; Mejlvang J, 2014, J CELL BIOL, V204, P29, DOI 10.1083/jcb.201305017; Mylonas C, 2018, LIFE SCI ALLIANCE, V1, DOI 10.26508/lsa.201800085; O'Donnell AF, 2004, NUCLEIC ACIDS RES, V32, P5894, DOI 10.1093/nar/gkh922; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Prado F, 2017, GENES-BASEL, V8, DOI 10.3390/genes8020049; Qiu ZJ, 2018, RADIOTHER ONCOL, V126, P450, DOI 10.1016/j.radonc.2017.09.043; Safina A, 2013, CELL CYCLE, V12, P2423, DOI 10.4161/cc.25452; Sandlesh P, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101177; Sandlesh P, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199785; Schlesinger MB, 2000, GENETICS, V155, P1593; Shen ZL, 2018, STEM CELLS DEV, V27, P1693, DOI 10.1089/scd.2018.0150; SOULE HD, 1990, CANCER RES, V50, P6075; Spiesser TW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010203; Tan BCM, 2006, EMBO J, V25, P3975, DOI 10.1038/sj.emboj.7601271; Tan BCM, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-11; Toledo L, 2017, MOL CELL, V66, P735, DOI 10.1016/j.molcel.2017.05.001; True JD, 2016, J BIOL CHEM, V291, P15307, DOI 10.1074/jbc.M116.735134; Tsunaka Y, 2016, GENE DEV, V30, P673, DOI 10.1101/gad.274183.115; VanDemark AP, 2006, MOL CELL, V22, P363, DOI 10.1016/j.molcel.2006.03.025; Voth WP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084092; Wang T, 2018, LIFE SCI ALLIANCE, V1, DOI 10.26508/lsa.201800107; Wittmeyer J, 1999, BIOCHEMISTRY-US, V38, P8961, DOI 10.1021/bi982851d; Wittmeyer J, 1997, MOL CELL BIOL, V17, P4178, DOI 10.1128/MCB.17.7.4178; Yang JY, 2016, CELL REP, V14, P1128, DOI 10.1016/j.celrep.2015.12.096; YARBRO JW, 1992, SEMIN ONCOL, V19, P1; Ye XF, 2003, MOL CELL, V11, P341, DOI 10.1016/S1097-2765(03)00037-6; Yeo CQX, 2016, CELL REP, V15, P132, DOI 10.1016/j.celrep.2016.03.011; Zeman MK, 2014, NAT CELL BIOL, V16, P2, DOI 10.1038/ncb2897	56	10	10	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	2020	39	28					5124	5137		10.1038/s41388-020-1346-9	http://dx.doi.org/10.1038/s41388-020-1346-9			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MH4RK	32533099	Green Published, hybrid			2022-12-28	WOS:000546718100004
J	Lundberg, A; Lindstrom, LS; Parker, JS; Loverli, E; Perou, CM; Bergh, J; Tobin, NP				Lundberg, Arian; Lindstrom, Linda S.; Parker, Joel S.; Loverli, Elinor; Perou, Charles M.; Bergh, Jonas; Tobin, Nicholas P.			A pan-cancer analysis of the frequency of DNA alterations across cell cycle activity levels	ONCOGENE			English	Article							GENE-EXPRESSION SIGNATURES; MOLECULAR CLASSIFICATION; DIVISION CYCLE; RESOURCE	Pan-cancer genomic analyses based on the magnitude of pathway activity are currently lacking. Focusing on the cell cycle, we examined the DNA mutations and chromosome arm-level aneuploidy within tumours with low, intermediate and high cell-cycle activity in 9515 pan-cancer patients with 32 different tumour types. Boxplots showed that cell-cycle activity varied broadly across and within all cancers.TP53andPIK3CAmutations were common in all cell cycle score (CCS) tertiles but with increasing frequency as cell-cycle activity levels increased (P < 0.001). Mutations inBRAFand gains in 16p were less frequent in CCS High tumours (P < 0.001). In Kaplan-Meier analysis, patients whose tumours were CCS Low had a longer Progression Free Interval (PFI) relative to Intermediate or High (P < 0.001) and this significance remained in multivariable analysis (CCS Intermediate: HR = 1.37; 95% CI 1.17-1.60, CCS High: 1.54; 1.29-1.84, CCS Low = Ref). These results demonstrate that whilst similar DNA alterations can be found at all cell-cycle activity levels, some notable exceptions exist. Moreover, independent prognostic information can be derived on a pan-cancer level from a simple measure of cell-cycle activity.	[Lundberg, Arian; Loverli, Elinor; Bergh, Jonas; Tobin, Nicholas P.] Karolinska Inst, Dept Oncol & Pathol, Stockholm, Sweden; [Lundberg, Arian; Lindstrom, Linda S.; Loverli, Elinor; Bergh, Jonas; Tobin, Nicholas P.] Univ Hosp, Stockholm, Sweden; [Lundberg, Arian] Stanford Sch Med, Dept Radiat Oncol, Stanford, CA 94305 USA; [Lindstrom, Linda S.] Karolinska Inst, Dept Biosci & Nutr, Stockholm, Sweden; [Parker, Joel S.; Perou, Charles M.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Genet, Chapel Hill, NC 27515 USA; [Perou, Charles M.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pathol & Lab Med, Chapel Hill, NC 27515 USA; [Bergh, Jonas] Univ Oxford, Dept Publ Hlth, Oxford, England	Karolinska Institutet; Stanford University; Karolinska Institutet; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Oxford	Tobin, NP (corresponding author), Karolinska Inst, Dept Oncol & Pathol, Stockholm, Sweden.; Tobin, NP (corresponding author), Univ Hosp, Stockholm, Sweden.	nick.tobin@ki.se	Perou, Charles M/H-9934-2014; Lundberg, Arian/AAD-2244-2022; Lundberg, Arian/AAX-7213-2021	Perou, Charles M/0000-0001-9827-2247; Lundberg, Arian/0000-0002-6630-2787; Tobin, Nicholas/0000-0003-2343-9772; Bergh, Jonas/0000-0001-5526-1847	Iris, Stig och Gerry Castenbacks Stiftelse for cancer research; King Gustaf V Jubilee Foundation; BRECT; Swedish Cancer Society; Cancer Society in Stockholm Personalised Cancer Medicine (PCM); Swedish Breast Cancer Association (BRO); Swedish Research Council; NCI Breast SPORE program [P50-CA58223-09A1]; Susan G. Komen [SAC-160074]; Breast Cancer Research Foundation;  [R01-CA195754-01]	Iris, Stig och Gerry Castenbacks Stiftelse for cancer research; King Gustaf V Jubilee Foundation; BRECT; Swedish Cancer Society(Swedish Cancer Society); Cancer Society in Stockholm Personalised Cancer Medicine (PCM); Swedish Breast Cancer Association (BRO); Swedish Research Council(Swedish Research CouncilEuropean Commission); NCI Breast SPORE program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Susan G. Komen(Susan G. Komen Breast Cancer Foundation); Breast Cancer Research Foundation; 	This work was supported by the Iris, Stig och Gerry Castenbacks Stiftelse for cancer research (to NPT), the King Gustaf V Jubilee Foundation (NPT and JB), BRECT, the Swedish Cancer Society, the Cancer Society in Stockholm Personalised Cancer Medicine (PCM), the King Gustaf V Jubilee Foundation, the Swedish Breast Cancer Association (BRO) and the Swedish Research Council (J. Bergh). CMP was supported by funds from the NCI Breast SPORE program (P50-CA58223-09A1), by R01-CA195754-01, by the Susan G. Komen (SAC-160074) and the Breast Cancer Research Foundation.	Asp M, 2020, BIOESSAYS, V42, DOI 10.1002/bies.201900221; Bailey MH, 2018, CELL, V173, P371, DOI [10.1016/j.cell.2018.02.060, 10.1016/j.cell.2018.07.034]; Carter SL, 2012, NAT BIOTECHNOL, V30, P413, DOI 10.1038/nbt.2203; Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824; Chen JD, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026104; Desmedt C, 2008, CLIN CANCER RES, V14, P5158, DOI 10.1158/1078-0432.CCR-07-4756; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; Gray KA, 2015, NUCLEIC ACIDS RES, V43, pD1079, DOI 10.1093/nar/gku1071; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; Hoadley KA, 2018, CELL, V173, P291, DOI 10.1016/j.cell.2018.03.022; Hoadley KA, 2014, CELL, V158, P929, DOI 10.1016/j.cell.2014.06.049; Kanehisa M, 2016, NUCLEIC ACIDS RES, V44, pD457, DOI 10.1093/nar/gkv1070; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; Liu JF, 2018, CELL, V173, P400, DOI 10.1016/j.cell.2018.02.052; Lundberg A, 2017, CLIN CANCER RES, V23, P7512, DOI 10.1158/1078-0432.CCR-17-1535; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035; Santos A, 2015, NUCLEIC ACIDS RES, V43, pD1140, DOI 10.1093/nar/gku1092; Sotiriou C, 2009, NEW ENGL J MED, V360, P790, DOI 10.1056/NEJMra0801289; Sparano JA, 2019, NEW ENGL J MED, V380, P2395, DOI 10.1056/NEJMoa1904819; Taylor AM, 2018, CANCER CELL, V33, P676, DOI 10.1016/j.ccell.2018.03.007; Team RC., 2022, LANG ENV STAT COMP; Tobin NP, 2017, CLIN CANCER RES, V23, P7225, DOI 10.1158/1078-0432.CCR-17-2301; Tobin NP, 2014, MOL ONCOL, V8, P741, DOI 10.1016/j.molonc.2014.02.007; Turner NC, 2019, J CLIN ONCOL, V37, P1169, DOI 10.1200/JCO.18.00925	27	5	5	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2020	39	32					5430	5440		10.1038/s41388-020-1367-4	http://dx.doi.org/10.1038/s41388-020-1367-4		JUN 2020	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW4DS	32581248	Green Submitted, Green Accepted			2022-12-28	WOS:000543161100001
J	Shepard, A; Kissil, JL				Shepard, Alyssa; Kissil, Joseph L.			The use of non-traditional models in the study of cancer resistance-the case of the naked mole rat	ONCOGENE			English	Review							LONGEST-LIVING RODENT; HEAT-SHOCK PROTEINS; AGE-RELATED-CHANGES; TUMOR-SUPPRESSOR; HETEROCEPHALUS-GLABER; OXIDATIVE STRESS; DNA-REPAIR; NEGLIGIBLE SENESCENCE; CONTACT INHIBITION; RIBOSOMAL-RNA	Non-traditional model organisms are typically defined as any model the deviates from the typical laboratory animals, such as mouse, rat, and worm. These models are becoming increasingly important in human disease research, such as cancer, as they often display unusual biological features. Naked mole rats (NMRs) are currently one of the most popular non-traditional model, particularly in the longevity and cancer research fields. NMRs display an exceptionally long lifespan (similar to 30 years), yet have been observed to display a low incidence of cancer, making them excellent candidates for understanding endogenous cancer resistance mechanisms. Over the past decade, many potential resistance mechanisms have been characterized. These include unique biological mechanisms involved in genome stability, protein stability, oxidative metabolism, and other cellular mechanisms such as cell cycle regulation and senescence. This review aims to summarize the many identified cancer resistance mechanisms to understand some of the main hypotheses that have thus far been generated. Many of these proposed mechanisms remain to be fully characterized or confirmed in vivo, giving the field a direction to grow and further understand the complex biology displayed by the NMR.	[Shepard, Alyssa; Kissil, Joseph L.] Scripps Res Inst, Dept Mol Med, Jupiter, FL 33458 USA	Scripps Research Institute	Kissil, JL (corresponding author), Scripps Res Inst, Dept Mol Med, Jupiter, FL 33458 USA.	jkissil@scripps.edu						ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Anastasiou D, 2012, NAT CHEM BIOL, V8, P839, DOI 10.1038/NCHEMBIO.1060; Andziak B, 2005, MECH AGEING DEV, V126, P1206, DOI 10.1016/j.mad.2005.06.009; Andziak B, 2006, AGING CELL, V5, P463, DOI 10.1111/j.1474-9726.2006.00237.x; Azpurua J, 2013, P NATL ACAD SCI USA, V110, P17350, DOI 10.1073/pnas.1313473110; Bailey KL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176096; Ballal RD, 2009, J BIOL CHEM, V284, P36083, DOI 10.1074/jbc.M109.025825; Ben-David U, 2011, NAT REV CANCER, V11, P268, DOI 10.1038/nrc3034; Bens M, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-015-2349-8; Bleeker FE, 2010, ACTA NEUROPATHOL, V119, P487, DOI 10.1007/s00401-010-0645-6; Bowers LW, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00077; Brites P, 2004, BBA-MOL CELL BIOL L, V1636, P219, DOI 10.1016/j.bbalip.2003.12.010; Buffenstein R, 2005, J GERONTOL A-BIOL, V60, P1369, DOI 10.1093/gerona/60.11.1369; BUFFENSTEIN R, 1991, J ENDOCRINOL, V129, P21, DOI 10.1677/joe.0.1290021; Buffenstein R, 2008, J COMP PHYSIOL B, V178, P439, DOI 10.1007/s00360-007-0237-5; Buffenstein Rochelle, 2002, Sci Aging Knowledge Environ, V2002, ppe7, DOI 10.1126/sageke.2002.21.pe7; Cellarier E, 2003, CANCER TREAT REV, V29, P489, DOI 10.1016/S0305-7372(03)00118-X; Cheng JS, 2017, ONCOTARGET, V8, P96924, DOI 10.18632/oncotarget.19661; Cole JE, 2020, J VET DIAGN INVEST, V32, P132, DOI 10.1177/1040638719894985; Cong W, 2018, BMC MICROBIOL, V18, DOI 10.1186/s12866-018-1226-4; Cvijovic I, 2018, GENETICS, V209, P1235, DOI 10.1534/genetics.118.301058; Davies KTJ, 2015, MOL BIOL EVOL, V32, P3089, DOI 10.1093/molbev/msv175; De Waal EM, 2013, BIOCHEM BIOPH RES CO, V434, P815, DOI 10.1016/j.bbrc.2013.04.019; Debebe T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10287-0; Debebe T, 2016, GUT PATHOG, V8, DOI 10.1186/s13099-016-0107-3; Delaney MA, 2016, VET PATHOL, V53, P691, DOI 10.1177/0300985816630796; Delaney MA, 2013, VET PATHOL, V50, P607, DOI 10.1177/0300985812471543; Deuker MM, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64009-0; Djojosubroto MW, 2003, MOL CELLS, V15, P164; Du W, 2013, ONCOGENE, V32, P3319, DOI 10.1038/onc.2012.359; Evdokimov A, 2018, AGING-US, V10, P1454, DOI 10.18632/aging.101482; Evfratov SA, 2014, ACTA NATURAE, V6, P41, DOI 10.32607/20758251-2014-6-2-41-47; Fang XD, 2014, CELL REP, V8, P1354, DOI 10.1016/j.celrep.2014.07.030; FAULKES CG, 1990, J REPROD FERTIL, V89, P317; Faulkes CG, 2015, BIOL LETTERS, V11, DOI 10.1098/rsbl.2015.0185; Gelfond JA, 2015, STAT APPL GENET MOL, V14, P507, DOI 10.1515/sagmb-2014-0056; Gorbunova V, 2012, P NATL ACAD SCI USA, V109, P19392, DOI 10.1073/pnas.1217211109; Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173; Guan CQ, 2013, J CELL BIOCHEM, V114, P1343, DOI 10.1002/jcb.24475; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Heinze I, 2018, BMC BIOL, V16, DOI 10.1186/s12915-018-0547-y; Hensen SMM, 2013, BIOCHIMIE, V95, P1245, DOI 10.1016/j.biochi.2013.01.017; Hetz C, 2015, NAT CELL BIOL, V17, P829, DOI 10.1038/ncb3184; HILL W. C., 1957, PROC ZOOL SOC LONDON, V128, P455; Hilton HG, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000528; Hulbert AJ, 2007, PHYSIOL REV, V87, P1175, DOI 10.1152/physrev.00047.2006; Hulbert AJ, 2006, J GERONTOL A-BIOL, V61, P1009, DOI 10.1093/gerona/61.10.1009; JARVIS JUM, 1981, SCIENCE, V212, P571, DOI 10.1126/science.7209555; Jiang JJ, 2016, EPIGENET CHROMATIN, V9, DOI 10.1186/s13072-016-0101-5; KANUI TI, 1990, COMP BIOCHEM PHYS C, V96, P131, DOI 10.1016/0742-8413(90)90057-G; Keane M, 2014, BIOINFORMATICS, V30, P3558, DOI 10.1093/bioinformatics/btu579; Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046; Kim EB, 2011, NATURE, V479, P223, DOI 10.1038/nature10533; Kosova AA, 2019, AGING-US, V11, P2852, DOI 10.18632/aging.101959; Kowalczyk A, 2020, ELIFE, V9, DOI 10.7554/eLife.51089; Kurz S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189514; Lambert MJ, 2017, AGING-US, V9, P573, DOI 10.18632/aging.101180; Lee BP, 2020, GEROSCIENCE, V42, P633, DOI 10.1007/s11357-019-00150-7; Lee SG, 2017, STEM CELL REP, V9, P1706, DOI 10.1016/j.stemcr.2017.09.013; Lee S, 2019, NAT CELL BIOL, V21, P94, DOI 10.1038/s41556-018-0249-2; Lewis KN, 2018, GEROSCIENCE, V40, P105, DOI 10.1007/s11357-018-0014-2; Lewis KN, 2015, P NATL ACAD SCI USA, V112, P3722, DOI 10.1073/pnas.1417566112; Lewis KN, 2012, GERONTOLOGY, V58, P453, DOI 10.1159/000335966; Lewis KN, 2010, INTEGR COMP BIOL, V50, P829, DOI 10.1093/icb/icq034; Liang ST, 2010, AGING CELL, V9, P626, DOI 10.1111/j.1474-9726.2010.00588.x; Lindner I, 2010, CANCER RES, V70, P277, DOI 10.1158/0008-5472.CAN-09-1462; Ma Q, 2013, ANNU REV PHARMACOL, V53, P401, DOI 10.1146/annurev-pharmtox-011112-140320; MacRae SL, 2015, AGING-US, V7, P1171, DOI 10.18632/aging.100866; MacRae SL, 2015, AGING CELL, V14, P288, DOI 10.1111/acel.12314; Manov I, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-91; Mao ZY, 2011, SCIENCE, V332, P1443, DOI 10.1126/science.1202723; Melen GJ, 1999, EMBO J, V18, P3107, DOI 10.1093/emboj/18.11.3107; Millet C, 2007, CRIT REV EUKAR GENE, V17, P281, DOI 10.1615/CritRevEukarGeneExpr.v17.i4.30; Mitchell TW, 2007, EXP GERONTOL, V42, P1053, DOI 10.1016/j.exger.2007.09.004; Miyawaki S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11471; Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207; Morgan CC, 2013, BMC EVOL BIOL, V13, DOI 10.1186/1471-2148-13-251; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Munro D, 2019, AGING CELL, V18, DOI 10.1111/acel.12916; Nevo Y, 2012, NUCLEIC ACIDS RES, V40, P10980, DOI 10.1093/nar/gks834; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; O'Connor TP, 2002, COMP BIOCHEM PHYS A, V133, P835, DOI 10.1016/S1095-6433(02)00198-8; Ozenne P, 2010, INT J CANCER, V127, P2239, DOI 10.1002/ijc.25511; Pace C N, 1986, Methods Enzymol, V131, P266; Pawaria S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050365; Perez VI, 2009, P NATL ACAD SCI USA, V106, P3059, DOI 10.1073/pnas.0809620106; Populo H, 2012, INT J MOL SCI, V13, P1886, DOI 10.3390/ijms13021886; Pride H, 2015, BIOCHEM BIOPH RES CO, V457, P669, DOI 10.1016/j.bbrc.2015.01.046; Rodriguez KA, 2016, CELL STRESS CHAPERON, V21, P453, DOI 10.1007/s12192-016-0672-x; Rodriguez KA, 2014, BBA-MOL BASIS DIS, V1842, P2060, DOI 10.1016/j.bbadis.2014.07.005; Ruby JG, 2018, ELIFE, V7, DOI 10.7554/eLife.31157; Ruppell E, 1845, RUPPELL MUS SENCKENB, V3, P99; Sabeti PC, 2006, SCIENCE, V312, P1614, DOI 10.1126/science.1124309; Sahm A, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007272; Salmon AB, 2008, J GERONTOL A-BIOL, V63, P232, DOI 10.1093/gerona/63.3.232; Seim I, 2014, AGING-US, V6, P879, DOI 10.18632/aging.100699; Seluanov A, 2007, AGING CELL, V6, P45, DOI 10.1111/j.1474-9726.2006.00262.x; Seluanov A, 2009, P NATL ACAD SCI USA, V106, P19352, DOI 10.1073/pnas.0905252106; Seluanov A, 2008, AGING CELL, V7, P813, DOI 10.1111/j.1474-9726.2008.00431.x; Sgambato A, 2000, J CELL PHYSIOL, V183, P18, DOI 10.1002/(SICI)1097-4652(200004)183:1<18::AID-JCP3>3.0.CO;2-S; Shebzukhov Y, 2019, EUR J IMMUNOL, V49, P2103, DOI 10.1002/eji.201948124; Stewart DJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt356; Stocker S, 2018, NAT CHEM BIOL, V14, P148, DOI 10.1038/nchembio.2536; Sulak M, 2016, ELIFE, V5, DOI [10.7554/eLife.11994, 10.7554/eLife.24307]; Takahashi K, 2003, NATURE, V423, P541, DOI 10.1038/nature01646; Takai KK, 2011, MOL CELL, V44, P647, DOI 10.1016/j.molcel.2011.08.043; Tan L, 2017, STEM CELL REP, V9, P1721, DOI 10.1016/j.stemcr.2017.10.001; Tang JS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167851; Tang PMK, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14677; Taylor KR, 2017, J GERONTOL A-BIOL, V72, P38, DOI 10.1093/gerona/glw047; Thieme R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130470; Tian X, 2019, CELL, V177, P622, DOI 10.1016/j.cell.2019.03.043; Tian X, 2015, P NATL ACAD SCI USA, V112, P1053, DOI 10.1073/pnas.1418203112; Tian X, 2013, NATURE, V499, P346, DOI 10.1038/nature12234; Triplett JC, 2015, BBA-MOL BASIS DIS, V1852, P2213, DOI 10.1016/j.bbadis.2015.08.002; Triplett JC, 2015, J NEUROCHEM, V134, P538, DOI 10.1111/jnc.13149; Viltard M, 2019, AGING-US, V11, P4783, DOI 10.18632/aging.102116; Vina J, 2013, ANTIOXID REDOX SIGN, V19, P779, DOI 10.1089/ars.2012.5111; Vyssokikh MY, 2020, P NATL ACAD SCI USA, V117, P6491, DOI 10.1073/pnas.1916414117; Wada H, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54442-1; Wei HT, 2016, GENOM PROTEOM BIOINF, V14, P131, DOI 10.1016/j.gpb.2016.05.001; Went P, 2006, BRIT J CANCER, V94, P128, DOI 10.1038/sj.bjc.6602924; Whitley D, 1999, J VASC SURG, V29, P748, DOI 10.1016/S0741-5214(99)70329-0; Wu JM, 2017, TRENDS PHARMACOL SCI, V38, P226, DOI 10.1016/j.tips.2016.11.009; Yang ZY, 2015, GENE, V572, P101, DOI 10.1016/j.gene.2015.07.004; Yang ZY, 2013, BMC SYST BIOL, V7, DOI 10.1186/1752-0509-7-S2-S5; Yu CF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026729; YUAN PM, 1981, MECH AGEING DEV, V17, P151, DOI 10.1016/0047-6374(81)90081-6; Zhao SM, 2016, ONCOTARGET, V7, P84839, DOI 10.18632/oncotarget.13321; Zhao SM, 2014, CELL PHYSIOL BIOCHEM, V34, P463, DOI 10.1159/000363015; Zhao SM, 2014, CELL PHYSIOL BIOCHEM, V33, P321, DOI 10.1159/000356672; Zhao Y, 2018, P NATL ACAD SCI USA, V115, P1801, DOI 10.1073/pnas.1721160115; Zhao YF, 2019, ONCOGENE, V38, P4297, DOI 10.1038/s41388-019-0719-4	133	15	15	2	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	2020	39	28					5083	5097		10.1038/s41388-020-1355-8	http://dx.doi.org/10.1038/s41388-020-1355-8		JUN 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MH4RK	32535616				2022-12-28	WOS:000539953300002
J	An, PP; Chen, F; Li, ZH; Ling, YY; Peng, YX; Zhang, HS; Li, JX; Chen, ZJ; Wang, HS				An, Panpan; Chen, Feng; Li, Zihan; Ling, Yuyi; Peng, Yanxi; Zhang, Haisheng; Li, Jiexin; Chen, Zhuojia; Wang, Hongsheng			HDAC8 promotes the dissemination of breast cancer cells via AKT/GSK-3 beta/Snail signals	ONCOGENE			English	Article							CARDIAC HYPERTROPHIC RESPONSE; GLYCOGEN-SYNTHASE KINASE-3; HISTONE DEACETYLASE; MESENCHYMAL TRANSITION; PROTEIN; SNAIL; PHOSPHORYLATION; ACETYLATION; INHIBITION; SUPPRESSES	The mechanistic action of histone deacetylase 8 (HDAC8) in cancer motility, including epithelial-mesenchymal transition (EMT), remains largely undefined. We found that the expression of HDAC8 was upregulated in breast cancer (BC) cells and tissues as compared to the controls. Further, BC tissues had the highest values of HDAC8 expression among 31 kinds of cancers. Cellular study indicated that HDAC8 can positively regulate the dissemination and EMT of BC cells. It increased the protein stability of Snail, an important regulator of EMT, by phosphorylation of its motif 2 in serine-rich regions. There are 21 factors that have been reported to regulate the protein stability of Snail. Among them, HDAC8 can decrease the expression of GSK-3 beta through increasing its Ser9-phosphorylation. Mass spectrum analysis indicated that HDAC8 interact with AKT1 to decrease its acetylation while increase its phosphorylation, which further increased Ser9-phosphorylation of GSK-3 beta. The C-terminal of AKT1 was responsible for the interaction between HDAC8 and AKT1. Further, Lys426 was the key residue for HDAC8-regulated deacetylation of AKT1. Moreover, HDAC8/Snail axis acted as adverse prognosis factors for in vivo progression and overall survival (OS) rate of BC patients. Collectively, we found that HDAC8 can trigger the dissemination of BC cells via AKT/GSK-3 beta/Snail signals, which imposed that inhibition of HDAC8 is a potential approach for BC treatment.	[An, Panpan; Chen, Feng; Li, Zihan; Ling, Yuyi; Peng, Yanxi; Zhang, Haisheng; Li, Jiexin; Wang, Hongsheng] Sun Yat Sen Univ, Guangdong Key Lab Chiral Mol & Drug Discovery, Sch Pharmaceut Sci, Guangzhou 510006, Guangdong, Peoples R China; [Chen, Zhuojia] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Peoples R China	Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University	Wang, HS (corresponding author), Sun Yat Sen Univ, Guangdong Key Lab Chiral Mol & Drug Discovery, Sch Pharmaceut Sci, Guangzhou 510006, Guangdong, Peoples R China.; Chen, ZJ (corresponding author), Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Peoples R China.	chenzhj@sysucc.org.cn; whongsh@mail.sysu.edu.cn		Wang, Hong-Sheng/0000-0001-5729-6074	National Natural Science Foundation of China [81973343, 81673454, 81672608, 31801197]; Fundamental Research Funds for the Central Universities (Sun Yat-sen University) [19ykzd24, 19ykpy130]; Guangdong Provincial Key Laboratory of Construction Foundation [2017B030314030]; Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery [2019B030301005]; Natural Science Foundation of Guangdong Province [2020A1515010291]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities (Sun Yat-sen University); Guangdong Provincial Key Laboratory of Construction Foundation; Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery; Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province)	This research was supported by the National Natural Science Foundation of China (Grant Nos. 81973343, 81673454, 81672608, and 31801197), the Fundamental Research Funds for the Central Universities (Sun Yat-sen University) (19ykzd24, 19ykpy130), the Guangdong Provincial Key Laboratory of Construction Foundation (No. 2017B030314030), the Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery (2019B030301005), and the Natural Science Foundation of Guangdong Province (No. 2020A1515010291).	Balasubramanian S, 2008, LEUKEMIA, V22, P1026, DOI 10.1038/leu.2008.9; Beurel E, 2015, PHARMACOL THERAPEUT, V148, P114, DOI 10.1016/j.pharmthera.2014.11.016; Chang R, 2017, THORAC CANCER, V8, P131, DOI 10.1111/1759-7714.12408; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; Deardorff MA, 2012, NATURE, V489, P313, DOI 10.1038/nature11316; Domoto T, 2016, CANCER SCI, V107, P1363, DOI 10.1111/cas.13028; Du C, 2010, CANCER RES, V70, P7810, DOI 10.1158/0008-5472.CAN-09-4481; Ecker Jonas, 2013, CNS Oncol, V2, P359, DOI 10.2217/cns.13.24; Gupta M, 2009, BLOOD, V114, P2926, DOI 10.1182/blood-2009-05-220889; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Haberland M, 2009, GENE DEV, V23, P1625, DOI 10.1101/gad.1809209; Higuchi T, 2013, BLOOD, V121, P3640, DOI 10.1182/blood-2012-07-441022; Hojfeldt JW, 2013, NAT REV DRUG DISCOV, V12, P917, DOI 10.1038/nrd4154; Hsu DSS, 2014, CANCER CELL, V26, P534, DOI 10.1016/j.ccell.2014.09.002; Hu E, 2000, J BIOL CHEM, V275, P15254, DOI 10.1074/jbc.M908988199; Hua WK, 2017, BLOOD, V130, P2619, DOI 10.1182/blood-2017-03-771386; Iaconelli J, 2017, ACS CHEM BIOL, V12, P2139, DOI 10.1021/acschembio.6b01014; Kvaratskhelia Mamuka, 2008, V488, P213, DOI 10.1007/978-1-60327-475-3_15; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lee H, 2006, MOL CELL BIOL, V26, P5259, DOI 10.1128/MCB.01971-05; Lin XY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09865-9; Liu Q, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0654-3; Long J, 2017, LEUKEMIA, V31, P2761, DOI 10.1038/leu.2017.130; Lopez JE, 2017, J AM CHEM SOC, V139, P16222, DOI 10.1021/jacs.7b07603; Lu LL, 2020, CELL DEATH DIFFER, V27, P255, DOI 10.1038/s41418-019-0353-2; Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346; Narita T, 2019, NAT REV MOL CELL BIO, V20, P156, DOI 10.1038/s41580-018-0081-3; Nieuwenhuis J, 2019, TRENDS CELL BIOL, V29, P80, DOI 10.1016/j.tcb.2018.08.003; Oehme I, 2009, CLIN CANCER RES, V15, P91, DOI 10.1158/1078-0432.CCR-08-0684; Pallet N, 2012, J TRANSPLANT, V2012, DOI 10.1155/2012/348604; Park SY, 2011, ONCOL REP, V25, P1677, DOI 10.3892/or.2011.1236; Qi J, 2015, CELL STEM CELL, V17, P597, DOI 10.1016/j.stem.2015.08.004; Rodriguez MI, 2011, ONCOGENE, V30, P4365, DOI 10.1038/onc.2011.153; Somoza JR, 2004, STRUCTURE, V12, P1325, DOI 10.1016/j.str.2004.04.012; Sundaresan NR, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001465; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Trivedi CM, 2007, NAT MED, V13, P324, DOI 10.1038/nm1552; Vannini A, 2007, EMBO REP, V8, P879, DOI 10.1038/sj.embor.7401047; Vasaikar SV, 2018, NUCLEIC ACIDS RES, V46, pD956, DOI 10.1093/nar/gkx1090; von Burstin J, 2009, GASTROENTEROLOGY, V137, P361, DOI 10.1053/j.gastro.2009.04.004; Yan MW, 2015, CARDIOVASC RES, V105, P340, DOI 10.1093/cvr/cvu254; Yan W, 2013, ONCOGENE, V32, P599, DOI 10.1038/onc.2012.81; Zhang K, 2013, NAT CELL BIOL, V15, P677, DOI 10.1038/ncb2743; Zhang K, 2012, EMBO J, V31, P29, DOI 10.1038/emboj.2011.357; Zheng HQ, 2014, CANCER CELL, V26, P358, DOI 10.1016/j.ccr.2014.07.022; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173; Zhou Y, 2019, CELL DEATH DIFFER, V26, P1442, DOI 10.1038/s41418-018-0222-4	48	19	20	3	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 25	2020	39	26					4956	4969		10.1038/s41388-020-1337-x	http://dx.doi.org/10.1038/s41388-020-1337-x		JUN 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MQ2YO	32499521				2022-12-28	WOS:000537994200001
J	Lu, YF; Xu, XP; Lu, XP; Zhu, Q; Liu, G; Bao, YT; Wen, H; Li, YL; Gu, W; Zhu, WG				Lu, Ya-Fei; Xu, Xiao-Peng; Lu, Xiao-Peng; Zhu, Qian; Liu, Ge; Bao, Yan-Tao; Wen, He; Li, Ying-Lu; Gu, Wei; Zhu, Wei-Guo			SIRT7 activates p53 by enhancing PCAF-mediated MDM2 degradation to arrest the cell cycle	ONCOGENE			English	Article							PROMOTES; ACETYLATION; INHIBITION; STRESS; PHOSPHORYLATION; UBIQUITINATION; METABOLISM; PATHWAY; DIFFERENTIATION; BIOSYNTHESIS	Sirtuin 7 (SIRT7), an NAD(+)-dependent deacetylase, plays vital roles in energy sensing, but the underlying mechanisms of action remain less clear. Here, we report that SIRT7 is required for p53-dependent cell-cycle arrest during glucose deprivation. We show that SIRT7 directly interacts with p300/CBP-associated factor (PCAF) and the affinity for this interaction increases during glucose deprivation. Upon binding, SIRT7 deacetylates PCAF at lysine 720 (K720), which augments PCAF binding to murine double minute (MDM2), the p53 E3 ubiquitin ligase, leading to accelerated MDM2 degradation. This effect results in upregulated expression of the cell-cycle inhibitor, p21(Waf1/Cip1), which further leads to cell-cycle arrest and decreased cell viability. These data highlight the importance of the SIRT7-PCAF interaction in regulating p53 activity and cell-cycle progression during conditions of glucose deprivation. This axis may represent a new avenue to design effective therapeutics based on tumor starvation.	[Lu, Ya-Fei; Xu, Xiao-Peng; Lu, Xiao-Peng; Zhu, Qian; Liu, Ge; Bao, Yan-Tao; Wen, He; Zhu, Wei-Guo] Shenzhen Univ, Dept Biochem & Mol Biol, Guangdong Key Lab Genome Instabil & Human Dis, Int Canc Ctr,Sch Med, Shenzhen 518055, Peoples R China; [Li, Ying-Lu; Gu, Wei] Columbia Univ, Coll Phys & Surg, Inst Canc Genet, New York, NY 10032 USA; [Zhu, Wei-Guo] Peking Univ, Beijing Key Lab Prot Posttranslat Modificat & Cel, Key Lab Carcinogenesis & Translat Res,Minist Educ, Dept Biochem & Mol Biol,Sch Basic Med Sci,Hlth Sc, Beijing 100191, Peoples R China; [Zhu, Wei-Guo] Peking Univ Tsinghua Univ Ctr Life Sci, Beijing 100871, Peoples R China	Shenzhen University; Columbia University; Peking University; Peking University	Zhu, WG (corresponding author), Shenzhen Univ, Dept Biochem & Mol Biol, Guangdong Key Lab Genome Instabil & Human Dis, Int Canc Ctr,Sch Med, Shenzhen 518055, Peoples R China.; Li, YL (corresponding author), Columbia Univ, Coll Phys & Surg, Inst Canc Genet, New York, NY 10032 USA.; Zhu, WG (corresponding author), Peking Univ, Beijing Key Lab Prot Posttranslat Modificat & Cel, Key Lab Carcinogenesis & Translat Res,Minist Educ, Dept Biochem & Mol Biol,Sch Basic Med Sci,Hlth Sc, Beijing 100191, Peoples R China.; Zhu, WG (corresponding author), Peking Univ Tsinghua Univ Ctr Life Sci, Beijing 100871, Peoples R China.	yl4187@cumc.columbia.edu; zhuweiguo@szu.edu.cn	Wen, He/GZL-8825-2022; Li, Yinglu/GWC-7573-2022; Bao, Yantao/AAK-6146-2021	Gu, Wei/0000-0002-1480-2368	National Key R&D Program of China [2017YFA0503900]; NFSC [81720108027, 81530074]; Science and Technology Program of Guangdong Province in China [2017B030301016]; Shenzhen Municipal Commission of Science and Technology Innovation [JCYJ20170818092450901]; Discipline Construction of Shenzhen [(2016)1452]	National Key R&D Program of China; NFSC(National Natural Science Foundation of China (NSFC)); Science and Technology Program of Guangdong Province in China; Shenzhen Municipal Commission of Science and Technology Innovation; Discipline Construction of Shenzhen	The authors thank K. F. Chua for providing SIRT7 plasmids. The authors also appreciate Ye Zhang for sharing PCAF plasmids. Finally, the authors are grateful to Dr Jessica Tamanini (Shenzhen University) for proofreading the manuscript. This work was supported by National Key R&D Program of China [2017YFA0503900]; NFSC [81720108027, 81530074]; Science and Technology Program of Guangdong Province in China [2017B030301016]; Shenzhen Municipal Commission of Science and Technology Innovation [JCYJ20170818092450901]; and Discipline Construction Funding of Shenzhen [(2016)1452].	Barber MF, 2012, NATURE, V487, P114, DOI 10.1038/nature11043; Ben Sahra I, 2010, CANCER RES, V70, P2465, DOI 10.1158/0008-5472.CAN-09-2782; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813; Chalkiadaki A, 2012, NAT REV ENDOCRINOL, V8, P287, DOI 10.1038/nrendo.2011.225; Chen SF, 2013, MOL CELL, V52, P303, DOI 10.1016/j.molcel.2013.10.010; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Finkel T, 2009, NATURE, V460, P587, DOI 10.1038/nature08197; Gai X, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.76; Gannon HS, 2012, CANCER CELL, V21, P668, DOI 10.1016/j.ccr.2012.04.011; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Gregoire S, 2007, MOL CELL BIOL, V27, P1280, DOI 10.1128/MCB.00882-06; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; He HQ, 2017, CELL REP, V20, P2010, DOI 10.1016/j.celrep.2017.08.016; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hu HG, 2017, HEPATOLOGY, V65, P515, DOI 10.1002/hep.28887; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jiang L, 2017, J BIOL CHEM, V292, P13296, DOI 10.1074/jbc.M117.780130; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Kopeina GS, 2017, BBA-REV CANCER, V1867, P29, DOI 10.1016/j.bbcan.2016.11.002; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lee IH, 2012, SCIENCE, V336, P225, DOI 10.1126/science.1218395; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Li L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12235; Li TT, 2014, J BIOL CHEM, V289, P3775, DOI 10.1074/jbc.M113.531640; Li YL, 2018, NUCLEIC ACIDS RES, V46, P7716, DOI 10.1093/nar/gky568; Lin RT, 2013, MOL CELL, V51, P506, DOI 10.1016/j.molcel.2013.07.002; Linares LK, 2007, NAT CELL BIOL, V9, P331, DOI 10.1038/ncb1545; Linares LK, 2003, P NATL ACAD SCI USA, V100, P12009, DOI 10.1073/pnas.2030930100; Liu L, 1999, MOL CELL BIOL, V19, P1202; Michishita E, 2005, MOL BIOL CELL, V16, P4623, DOI 10.1091/mbc.E05-01-0033; Mohrin M, 2015, SCIENCE, V347, P1374, DOI 10.1126/science.aaa2361; Nihira NT, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aai8026; Pediconi N, 2009, MOL CELL BIOL, V29, P1989, DOI 10.1128/MCB.00552-08; Pelicano H, 2006, ONCOGENE, V25, P4633, DOI 10.1038/sj.onc.1209597; Qi H, 2018, J BIOL CHEM, V293, P17769, DOI 10.1074/jbc.RA118.003629; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Revollo JR, 2004, J BIOL CHEM, V279, P50754, DOI 10.1074/jbc.M408388200; Santos-Rosa H, 2003, NUCLEIC ACIDS RES, V31, P4285, DOI 10.1093/nar/gkg655; Sen N, 2011, MOL CELL, V44, P621, DOI 10.1016/j.molcel.2011.08.044; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shin JY, 2013, CELL REP, V5, P654, DOI 10.1016/j.celrep.2013.10.007; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Sun C, 2014, CELL REP, V9, P2250, DOI 10.1016/j.celrep.2014.11.029; Sun LH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12497; Sunami Y, 2017, J BIOL CHEM, V292, P2815, DOI 10.1074/jbc.M116.745398; Tang M, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav1118; Tang XL, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00396-9; Vakhrusheva O, 2008, CIRC RES, V102, P703, DOI 10.1161/CIRCRESAHA.107.164558; Vazquez BN, 2016, EMBO J, V35, P1488, DOI 10.15252/embj.201593499; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang XJ, 2004, FEBS LETT, V561, P195, DOI 10.1016/S0014-5793(04)00168-1; Wu D, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00652; Yan WW, 2018, EMBO REP, V19, DOI 10.15252/embr.201846377; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yoshizawa T, 2014, CELL METAB, V19, P712, DOI 10.1016/j.cmet.2014.03.006; Yu J, 2017, CELL REP, V18, P1229, DOI 10.1016/j.celrep.2017.01.009; Zhang P, 2016, STEM CELLS, V34, P2332, DOI 10.1002/stem.2424; Zheng X, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-96; Zhu WG, 2004, J BIOL CHEM, V279, P15161, DOI 10.1074/jbc.M311703200	64	18	18	5	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	24					4650	4665		10.1038/s41388-020-1305-5	http://dx.doi.org/10.1038/s41388-020-1305-5		MAY 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LY0HO	32404984	Green Published, hybrid			2022-12-28	WOS:000532808000002
J	Cheng, R; Billet, S; Liu, CX; Haldar, S; Choudhury, D; Tripathi, M; Hav, M; Merchant, A; Hu, T; Huang, HY; Zhou, HM; Bhowmick, NA				Cheng, Ran; Billet, Sandrine; Liu, Chuanxia; Haldar, Subhash; Choudhury, Diptiman; Tripathi, Manisha; Hav, Monirath; Merchant, Akil; Hu, Tao; Huang, Haiyun; Zhou, Hongmei; Bhowmick, Neil A.			Periodontal inflammation recruits distant metastatic breast cancer cells by increasing myeloid-derived suppressor cells	ONCOGENE			English	Article							T-CELLS; IL-1-BETA; CORRELATE; DISEASE; MICE; IL-1	Periodontal diseases can lead to chronic inflammation affecting the integrity of the tooth supporting tissues. Recently, a striking association has been made between periodontal diseases and primary cancers in the absence of a mechanistic understanding. Here we address the effect of periodontal inflammation (PI) on tumor progression, metastasis, and possible underlining mechanisms. We show that an experimental model of PI in mice can promote lymph node (LN) micrometastasis, as well as head and neck metastasis of 4T1 breast cancer cells, both in early and late stages of cancer progression. The cervical LNs had a greater tumor burden and infiltration of MDSC and M2 macrophages compared with LNs at other sites. Pyroptosis and the resultant IL-1 beta production were detected in patients with PI, mirrored in mouse models. Anakinra, IL-1 receptor antagonist, limited metastasis, and MDSC recruitment at early stages of tumor progression, but failed to reverse established metastatic tumors. PI and the resulting production of IL-1 beta was found to promote CCL5, CXCL12, CCL2, and CXCL5 expression. These chemokines recruit MDSC and macrophages, finally enabling the generation of a premetastatic niche in the inflammatory site. These findings support the idea that periodontal inflammation promotes metastasis of breast cancer by recruiting MDSC in part by pyroptosis-induced IL-1 beta generation and downstream CCL2, CCL5, and CXCL5 signaling in the early steps of metastasis. These studies define the role for IL-1 beta in the metastatic progression of breast cancer and highlight the need to control PI, a pervasive inflammatory condition in older patients.	[Cheng, Ran; Liu, Chuanxia; Zhou, Hongmei] Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu, Sichuan, Peoples R China; [Cheng, Ran; Billet, Sandrine; Liu, Chuanxia; Haldar, Subhash; Choudhury, Diptiman; Tripathi, Manisha; Hav, Monirath; Merchant, Akil; Bhowmick, Neil A.] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA; [Hu, Tao] Sichuan Univ, West China Hosp Stomatol, Dept Prevent Dent, Chengdu, Sichuan, Peoples R China; [Huang, Haiyun] Sichuan Univ, West China Hosp Stomatol, Dept Periodontol, Chengdu, Sichuan, Peoples R China; [Bhowmick, Neil A.] Greater Los Angeles Vet Adm, Dept Res, Los Angeles, CA 90073 USA	Sichuan University; Cedars Sinai Medical Center; Sichuan University; Sichuan University	Zhou, HM (corresponding author), Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu, Sichuan, Peoples R China.; Bhowmick, NA (corresponding author), Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA.; Bhowmick, NA (corresponding author), Greater Los Angeles Vet Adm, Dept Res, Los Angeles, CA 90073 USA.	zhouhm@scu.edu.cn; Neil.Bhowmick@cshs.org		Haldar, Subhash/0000-0002-1230-1770; , Ran/0000-0001-5590-3395; Zhou, Hongmei/0000-0003-2985-3536; Choudhury, Diptiman/0000-0003-1080-4558	National Cancer Institute [R01CA108646, P01CA098912]; Veterans Administration [BX001040]; National Nature Science Foundation of China [81772898, 81272962]	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veterans Administration(US Department of Veterans Affairs); National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the National Cancer Institute (R01CA108646, P01CA098912) and Veterans Administration (BX001040) to NAB and the National Nature Science Foundation of China (No. 81772898 and 81272962) to HZ.	Abais JM, 2015, ANTIOXID REDOX SIGN, V22, P1111, DOI 10.1089/ars.2014.5994; Achberger S, 2014, MOL IMMUNOL, V58, P182, DOI 10.1016/j.molimm.2013.11.018; Bar D, 2004, FASEB J, V18, P161, DOI 10.1096/fj.03-0483fje; Bode KA, 2009, J IMMUNOL, V182, P2176, DOI 10.4049/jimmunol.0802560; Casella G, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0596-5; Castellarin M, 2012, GENOME RES, V22, P299, DOI 10.1101/gr.126516.111; Cheng R, 2018, BBA-MOL BASIS DIS, V1864, P226, DOI 10.1016/j.bbadis.2017.10.025; Cheng R, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00474; Condamine T, 2015, ANNU REV MED, V66, P97, DOI 10.1146/annurev-med-051013-052304; Correa Pelayo, 2011, US Gastroenterol Hepatol Rev, V7, P59; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Eke PI, 2015, J PERIODONTOL, V86, P611, DOI 10.1902/jop.2015.140520; Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175; Garlanda C, 2013, IMMUNITY, V39, P1003, DOI 10.1016/j.immuni.2013.11.010; Gholizadeh P, 2017, BIOMED PHARMACOTHER, V89, P918, DOI 10.1016/j.biopha.2017.02.102; Gomes FIF, 2016, J ORAL MAXILLOFAC RE, V7, pe2; Guo BC, 2016, SCI REP-UK, V6, DOI 10.1038/srep36107; Haldar S, 2016, SCI REP-UK, V6, DOI 10.1038/srep39257; Haldar S, 2015, J BIOL CHEM, V290, P6574, DOI 10.1074/jbc.M114.617886; Han Y W, 2014, Adv Dent Res, V26, P47, DOI 10.1177/0022034514528334; Higgins SC, 2003, J IMMUNOL, V171, P3119, DOI 10.4049/jimmunol.171.6.3119; Huang A, 2013, CANCER IMMUNOL IMMUN, V62, P1439, DOI 10.1007/s00262-013-1450-6; Huang GN, 2017, TOXICOL APPL PHARM, V332, P138, DOI 10.1016/j.taap.2017.04.009; Kaplan RN, 2006, CANCER RES, V66, P11089, DOI 10.1158/0008-5472.CAN-06-2407; Kruger M, 2013, CASE REP DENT, V2013, DOI 10.1155/2013/262410; Kshirsagar AV, 2005, AM J KIDNEY DIS, V45, P650, DOI 10.1053/j.ajkd.2004.12.009; Kumar V, 2016, TRENDS IMMUNOL, V37, P208, DOI 10.1016/j.it.2016.01.004; Linden G, 2007, J CLIN PERIODONTOL, V34, P461, DOI 10.1111/j.1600-051X.2007.01075.x; Lukens JR, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00315; Moergel M, 2013, HEAD FACE MED, V9, DOI 10.1186/1746-160X-9-39; Mora J, 2016, BIOL CHEM, V397, P1125, DOI 10.1515/hsz-2016-0215; Nagy KN, 1998, ORAL ONCOL, V34, P304, DOI 10.1016/S1368-8375(98)80012-2; Pendyala Gowri, 2013, Dent Res J (Isfahan), V10, P704; Ray A, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00052; Saijo Y, 2002, J IMMUNOL, V169, P469, DOI 10.4049/jimmunol.169.1.469; Sampson TR, 2016, CELL, V167, P1469, DOI 10.1016/j.cell.2016.11.018; Schapiro D, 2017, NAT METHODS, V14, P873, DOI [10.1038/NMETH.4391, 10.1038/nmeth.4391]; Schugar RC, 2018, ADIPOCYTE, V7, P49, DOI 10.1080/21623945.2017.1398295; Song XP, 2003, J IMMUNOL, V171, P6448, DOI 10.4049/jimmunol.171.12.6448; Su LK, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.00213-17; Thi HTH, 2017, J CANCER PREV, V22, P62, DOI 10.15430/JCP.2017.22.2.62; Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100; Yao QW, 2014, TUMOR BIOL, V35, P7073, DOI 10.1007/s13277-014-1951-8; Yokoyama M, 2011, J PERIODONTAL RES, V46, P464, DOI 10.1111/j.1600-0765.2011.01362.x; Youn JI, 2008, J IMMUNOL, V181, P5791, DOI 10.4049/jimmunol.181.8.5791; Yu JP, 2013, J IMMUNOL, V190, P3783, DOI 10.4049/jimmunol.1201449; Zeng XT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079017; Zhang Y, 2013, CELL RES, V23, P394, DOI 10.1038/cr.2012.178	48	34	35	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	7					1543	1556		10.1038/s41388-019-1084-z	http://dx.doi.org/10.1038/s41388-019-1084-z			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KL2WP	31685946	Green Published, hybrid			2022-12-28	WOS:000513289600011
J	Wang, XW; Wang, YD; Li, L; Xue, XT; Xie, H; Shi, HX; Hu, Y				Wang, Xingwen; Wang, Yudong; Li, Li; Xue, Xuting; Xie, Hui; Shi, Huaxing; Hu, Ying			A lncRNA coordinates with Ezh2 to inhibit HIF-1 alpha transcription and suppress cancer cell adaption to hypoxia	ONCOGENE			English	Article							REPRESSIVE COMPLEX 2; LONG NONCODING RNAS; GROUP PROTEIN EZH2; INDUCIBLE FACTORS; DRUG-RESISTANCE; PROLIFERATION; PROGRESSION; EXPRESSION; PHOSPHORYLATION; INACTIVATION	Hypoxia is a salient feature of the tumor microenvironment. HIF-1 alpha is a master regulator of hypoxic adaption. The polycomb repressor complex 2 (PRC2) molecule Ezh2 is known to play roles in essential cellular processes of cell fate decisions. However, how PRC2-mediated epigenetic dynamic changes take part in hypoxic adaption is not completely understood. Recently, we identified a long non-coding RNA (lncRNA) named HITT (HIF-1 alpha inhibitor at translation levels) that plays roles in modulating hypoxia-mediated angiogenesis and tumor growth in vivo. In this study, we reveal an important activity of HITT in evading hypoxia-induced apoptosis by coordinating with PRC2 activity to regulate HIF-1 alpha transcription. Genetic or chemical inhibition of PRC2 significantly elevates HIF-1 alpha mRNA levels. The occupancy of Ezh2 and its substrate H3K27me3 on the HIF-1 alpha promoter is detected under normoxia, and is reduced by hypoxia. Restoring hypoxia-inhibited HITT expression rescues the association between Ezh2/H3K27me3 and the HIF-1 alpha promoter, which also simultaneously abrogates hypoxia-induced HIF-1 alpha mRNA transcription. Further mechanistic studies revealed that HITT inhibits HIF-1 alpha transcription by guiding Ezh2 through the formation of an RNA-DNA triplex with the HIF-1 alpha promoter. Importantly, HITT/Ezh2-regulated HIF-1 alpha transcription leads to alerted HIF-1 alpha protein output and elicits a significant effect to evade hypoxia-induced apoptosis. Importantly, a close association between HIF-1 alpha mRNA and HITT was further verified in human colon cancer tissues in vivo. Collectively, these findings suggest a model for the epigenetic regulation of hypoxia-induced HIF-1 alpha transcription modulated by lncRNA HITT, which provides important insights into how tumor cells sense and adapt to hypoxic stress.	[Wang, Xingwen; Wang, Yudong; Xue, Xuting; Hu, Ying] Harbin Inst Technol, Sch Life Sci & Technol, Harbin 150001, Heilongjiang, Peoples R China; [Li, Li] Harbin Med Univ, Affiliated Tumor Hosp, Harbin 150001, Heilongjiang, Peoples R China; [Xie, Hui] Harbin Inst Technol, State Key Lab Robot & Syst, 2 Yikuang, Harbin 150001, Peoples R China; [Shi, Huaxing] Harbin Inst Technol, Sch Comp Sci & Technol, 2 Yikuang, Harbin 150001, Peoples R China; [Hu, Ying] Harbin Inst Technol, Shenzhen Grad Sch, Shenzhen 518055, Peoples R China	Harbin Institute of Technology; Harbin Medical University; Harbin Institute of Technology; Harbin Institute of Technology; Harbin Institute of Technology; University Town of Shenzhen	Hu, Y (corresponding author), Harbin Inst Technol, Sch Life Sci & Technol, Harbin 150001, Heilongjiang, Peoples R China.; Hu, Y (corresponding author), Harbin Inst Technol, Shenzhen Grad Sch, Shenzhen 518055, Peoples R China.	huying@hit.edu.cn	Hu, Ying/ABG-2935-2021; Xie, Hui/J-6999-2012; xuting, xue/ABD-5584-2020	Hu, Ying/0000-0003-2469-5604; Xie, Hui/0000-0003-4299-2776; xuting, xue/0000-0002-0654-3263; Wang, Xingwen/0000-0001-7416-142X	National Nature Science Foundation of China [31301131, 31741084, 31871389]; Basic Science Fundation of Science and technology innovation Commission in Shenzhen [JCYJ20170811154452255]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Basic Science Fundation of Science and technology innovation Commission in Shenzhen	This work was funded by the National Nature Science Foundation of China (No. 31301131, 31741084 and 31871389) and Basic Science Fundation of Science and technology innovation Commission in Shenzhen (No. JCYJ20170811154452255).	Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180; Battistelli C, 2017, ONCOGENE, V36, P942, DOI 10.1038/onc.2016.260; BelAiba RS, 2007, MOL BIOL CELL, V18, P4691, DOI 10.1091/mbc.E07-04-0391; Buske FA, 2012, GENOME RES, V22, P1372, DOI 10.1101/gr.130237.111; Cai BZ, 2020, CELL DEATH DIFFER, V27, P2158, DOI 10.1038/s41418-020-0492-5; Campbell S, 2013, CELL CYCLE, V12, P2675, DOI 10.4161/cc.25795; Chen S, 2016, CANCER LETT, V383, P73, DOI 10.1016/j.canlet.2016.09.027; Cheng YH, 2013, MOL CELL BIOL, V33, P3365, DOI 10.1128/MCB.00438-13; Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533; Comet I, 2016, NAT REV CANCER, V16, P803, DOI 10.1038/nrc.2016.83; Flavahan WA, 2017, SCIENCE, V357, DOI 10.1126/science.aal2380; Grote P, 2013, DEV CELL, V24, P206, DOI 10.1016/j.devcel.2012.12.012; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Guttman M, 2012, NATURE, V482, P339, DOI 10.1038/nature10887; Holoch D, 2017, TRENDS BIOCHEM SCI, V42, P531, DOI 10.1016/j.tibs.2017.04.003; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; Iyer MK, 2015, NAT GENET, V47, P199, DOI 10.1038/ng.3192; Kikuchi J, 2015, J CLIN INVEST, V125, P4375, DOI 10.1172/JCI80325; Kim E, 2013, CANCER CELL, V23, P839, DOI 10.1016/j.ccr.2013.04.008; Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036; Kinnaird A, 2016, NAT REV CANCER, V16, P694, DOI 10.1038/nrc.2016.82; Li ZW, 2017, CELL DEATH DIFFER, V24, P59, DOI 10.1038/cdd.2016.95; Mahara S, 2016, P NATL ACAD SCI USA, V113, pE3735, DOI 10.1073/pnas.1602079113; Mahmoud F, 2016, CANCER BIOL THER, V17, P579, DOI 10.1080/15384047.2016.1167291; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; Mazure NM, 2010, CURR OPIN CELL BIOL, V22, P177, DOI 10.1016/j.ceb.2009.11.015; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; Mondal T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8743; Ntziachristos P, 2012, NAT MED, V18, P298, DOI 10.1038/nm.2651; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; Pang B, 2016, ONCOTARGET, V7, P45134, DOI 10.18632/oncotarget.9761; Perez-Perri JI, 2011, INT J MOL SCI, V12, P4705, DOI 10.3390/ijms12074705; Piunti A, 2016, SCIENCE, V352, DOI 10.1126/science.aad9780; Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209; Pruszko M, 2017, EMBO REP, V18, P1331, DOI 10.15252/embr.201643370; Rohwer N, 2011, DRUG RESIST UPDATE, V14, P191, DOI 10.1016/j.drup.2011.03.001; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005; Sperandio S, 2009, MOL CARCINOGEN, V48, P38, DOI 10.1002/mc.20454; Su I, 2005, CELL, V121, P425, DOI 10.1016/j.cell.2005.02.029; Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Weikert S, 2005, INT J MOL MED, V16, P349; Wen Y, 2019, ONCOGENE, V38, P1845, DOI 10.1038/s41388-018-0552-1; Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064; Zhang YY, 2016, NAT STRUCT MOL BIOL, V23, P522, DOI 10.1038/nsmb.3211; Zhao J, 2008, SCIENCE, V322, P750, DOI 10.1126/science.1163045	49	24	25	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	9					1860	1874		10.1038/s41388-019-1123-9	http://dx.doi.org/10.1038/s41388-019-1123-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KP9VM	31784651				2022-12-28	WOS:000516579800003
J	Xu, GL; Feng, DJ; Yao, Y; Li, PP; Sun, H; Yang, H; Li, CX; Jiang, RQ; Sun, BC; Chen, Y				Xu, Guolong; Feng, Dongju; Yao, Yao; Li, Peipei; Sun, Hua; Yang, Hong; Li, Changxian; Jiang, Runqiu; Sun, Beicheng; Chen, Yun			Listeria-based hepatocellular carcinoma vaccine facilitates anti-PD-1 therapy by regulating macrophage polarization	ONCOGENE			English	Article							PD-1/PD-L1 BLOCKADE; TUMOR MICROENVIRONMENT; COLORECTAL-CANCER; T-CELLS; AUTOPHAGY; ACTIVATION; IMMUNOTHERAPY; MECHANISMS; BGJ398; GROWTH	Recently, patients with advanced cancers have been benefited greatly from immune checkpoint blockade immunotherapy. However, immune checkpoint blockade is still suboptimal in HCC treatment and more immune modifications are needed to achieve an efficient therapeutic goal. Here, we investigated the combined administration of a Listeria-based HCC vaccine, Lmdd-MPFG, and the anti-PD-1 immune checkpoint blockade antibody. We found that Lmdd-MPFG promoted the expression of PD-L1 in HCC cells but resensitized the tumor local T cell to respond to the anti-PD-1 immunotherapy. Mechanistically, the Lmdd-MPFG vaccine activates the NF-kappa B pathway in the tumor-associated macrophages (TAMs) through the TLR2 and MyD88 pathway, and recruits p62 to activate the autophagy pathway. The overall effect is skewing the TAMs from M2-polarized TAMs into the M1-polarized TAMs. Most importantly, it skewed the cytokine profiles into antitumor one in the tumor microenvironment (TME). This change restores the T-cell reactivity to the anti-PD-1 blockade. Our results suggested that Lmdd-MPFG combined with PD-1 blockade exerted synergistic antitumor effects through modifying TAMs in the TME and removing T-cell inhibitory signals, thereby providing a new potential strategy for HCC treatment.	[Xu, Guolong; Feng, Dongju; Li, Peipei; Yang, Hong; Chen, Yun] Nanjing Med Univ, Dept Immunol, Key Lab Immune Microenvironm & Dis, Nanjing 211166, Jiangsu, Peoples R China; [Xu, Guolong; Li, Peipei; Chen, Yun] Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing 211166, Jiangsu, Peoples R China; [Yao, Yao; Chen, Yun] Jiangsu Canc Hosp, Res Ctr Clin Oncol, Dept Head & Neck Surg, Nanjing 210018, Jiangsu, Peoples R China; [Yao, Yao; Chen, Yun] Jiangsu Inst Canc Res, Nanjing 210018, Jiangsu, Peoples R China; [Yao, Yao; Chen, Yun] Nanjing Med Univ, Canc Hosp, Nanjing 210018, Jiangsu, Peoples R China; [Sun, Hua] Univ Texas Hlth Sci Ctr Houston, Inst Mol Med, Dept Immunol, Houston, TX 77030 USA; [Li, Changxian] Nanjing Med Univ, Liver Transplantat Ctr, Affiliated Hosp 1, Guangzhou Rd 300, Nanjing 210029, Jiangsu, Peoples R China; [Jiang, Runqiu; Sun, Beicheng] Nanjing Univ, Affiliated Drum Tower Hosp, Dept Hepatobiliary Surg, Med Sch, Nanjing 210093, Jiangsu, Peoples R China	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; University of Texas System; University of Texas Health Science Center Houston; Nanjing Medical University; Nanjing University	Chen, Y (corresponding author), Nanjing Med Univ, Dept Immunol, Key Lab Immune Microenvironm & Dis, Nanjing 211166, Jiangsu, Peoples R China.; Chen, Y (corresponding author), Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing 211166, Jiangsu, Peoples R China.; Chen, Y (corresponding author), Jiangsu Canc Hosp, Res Ctr Clin Oncol, Dept Head & Neck Surg, Nanjing 210018, Jiangsu, Peoples R China.; Chen, Y (corresponding author), Jiangsu Inst Canc Res, Nanjing 210018, Jiangsu, Peoples R China.; Chen, Y (corresponding author), Nanjing Med Univ, Canc Hosp, Nanjing 210018, Jiangsu, Peoples R China.	chenyun@njmu.edu.cn		Xu, Guolong/0000-0002-0425-2040; Sun, Beicheng/0000-0002-8657-7024	National Natural Science Foundation [81772602, 9174210027, 81902780]; Qing Lan Project; Six Talent Peaks Project [JY-018]; Jiangsu Provincial key research development program of China [BE2018750]; "333" project	National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Qing Lan Project(Jiangsu Polytech Institute); Six Talent Peaks Project; Jiangsu Provincial key research development program of China; "333" project(Natural Science Foundation of Jiangsu Province)	This work was supported by grants from the National Natural Science Foundation (Grant Number: 81772602, 9174210027 to YC, 81902780 to YY). The Qing Lan Project, the Six Talent Peaks Project (JY-018), the "333" project, Jiangsu Provincial key research development program of China (BE2018750 to YC).	Atkins MB, 2017, ANN ONCOL, V28, P1484, DOI 10.1093/annonc/mdx151; Ayers M, 2019, CLIN CANCER RES, V25, P1564, DOI 10.1158/1078-0432.CCR-18-1316; Balkwill FR, 2012, J CELL SCI, V125, P5591, DOI 10.1242/jcs.116392; Bel S, 2017, SCIENCE, V357, P1047, DOI 10.1126/science.aal4677; Chen PW, 2014, AUTOPHAGY, V10, P192, DOI 10.4161/auto.26927; Chen Y, 2012, ONCOGENE, V31, P2140, DOI 10.1038/onc.2011.395; Christopher MJ, 2018, NEW ENGL J MED, V379, P2330, DOI 10.1056/NEJMoa1808777; Concha-Benavente F, 2016, CANCER RES, V76, P1031, DOI 10.1158/0008-5472.CAN-15-2001; Conway KL, 2013, GASTROENTEROLOGY, V145, P1347, DOI 10.1053/j.gastro.2013.08.035; Doria A, 2013, NEW ENGL J MED, V368, P1845, DOI [10.1056/NEJMc1303158, 10.1056/NEJMra1205406]; Drolia R, 2018, CELL HOST MICROBE, V23, P470, DOI 10.1016/j.chom.2018.03.004; Dunai C, 2018, J CLIN INVEST, V128, P4251, DOI 10.1172/JCI123121; El-Khoueiry AB, 2017, LANCET, V389, P2492, DOI 10.1016/S0140-6736(17)31046-2; Forner A, 2018, LANCET, V391, P1301, DOI 10.1016/S0140-6736(18)30010-2; Galdiero MR, 2013, IMMUNOBIOLOGY, V218, P1402, DOI 10.1016/j.imbio.2013.06.003; Garris CS, 2018, IMMUNITY, V49, P1148, DOI 10.1016/j.immuni.2018.09.024; Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133; Javle M, 2018, J CLIN ONCOL, V36, P276, DOI 10.1200/JCO.2017.75.5009; Jung C, 2012, J CLIN INVEST, V122, P2239, DOI 10.1172/JCI58147; Kroemer G, 2015, J CLIN INVEST, V125, P1, DOI 10.1172/JCI78652; Ktistakis NT, 2016, TRENDS CELL BIOL, V26, P624, DOI 10.1016/j.tcb.2016.03.006; Landais I, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004881; Lane RS, 2018, J EXP MED, V215, P3057, DOI 10.1084/jem.20180654; Lin PL, 2017, CANCER MED-US, V6, P2052, DOI 10.1002/cam4.1143; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Lo Russo G, 2019, CLIN CANCER RES, V25, P989, DOI 10.1158/1078-0432.CCR-18-1390; Lu X, 2017, NATURE, V543, P728, DOI 10.1038/nature21676; Makarova-Rusher OV, 2015, J HEPATOL, V62, P1420, DOI 10.1016/j.jhep.2015.02.038; Martini DJ, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0273-y; Motzer RJ, 2015, J CLIN ONCOL, V33, P1430, DOI 10.1200/JCO.2014.59.0703; Murray PJ, 2017, ANNU REV PHYSIOL, V79, P541, DOI 10.1146/annurev-physiol-022516-034339; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Nogova L, 2017, J CLIN ONCOL, V35, P157, DOI 10.1200/JCO.2016.67.2048; Ouyang ZX, 2019, BIOMATERIALS, V205, P50, DOI 10.1016/j.biomaterials.2019.03.018; Ruffell B, 2015, CANCER CELL, V27, P462, DOI 10.1016/j.ccell.2015.02.015; Sheng CJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06756-3; Shi XJ, 2017, CANCER LETT, V406, P27, DOI 10.1016/j.canlet.2017.07.029; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Siu EHL, 2018, TRANSL GASTROENT HEP, V3, DOI 10.21037/tgh.2018.10.16; Sorbara MT, 2018, CELL HOST MICROBE, V23, P644, DOI 10.1016/j.chom.2018.04.008; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Vareki SM, 2017, CRIT REV ONCOL HEMAT, V116, P116, DOI 10.1016/j.critrevonc.2017.06.001; Wallecha A, 2013, J IMMUNOTHER, V36, P468, DOI 10.1097/CJI.0000000000000000; Webster JA, 2010, J PATHOL, V222, P158, DOI 10.1002/path.2738; Wu SP, 2018, J THORAC ONCOL, V13, P521, DOI 10.1016/j.jtho.2017.11.132; Yanik EL, 2017, JAMA ONCOL, V3, P974, DOI 10.1001/jamaoncol.2017.0115; Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008; Zhao S, 2019, CANCER IMMUNOL RES, V7, P630, DOI 10.1158/2326-6066.CIR-17-0640; Zhong J, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.102; Zhong ZY, 2016, CELL, V164, P896, DOI 10.1016/j.cell.2015.12.057	50	33	35	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	7					1429	1444		10.1038/s41388-019-1072-3	http://dx.doi.org/10.1038/s41388-019-1072-3			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KL2WP	31659256				2022-12-28	WOS:000513289600004
J	Moreno-Lama, L; Galindo-Campos, MA; Martinez, C; Comerma, L; Vazquez, I; Vernet-Tomas, M; Ampurdanes, C; Lutfi, N; Martin-Caballero, J; Dantzer, F; Quintela-Fandino, M; Ali, SO; Jimeno, J; Yelamos, J				Moreno-Lama, Lucia; Galindo-Campos, Miguel A.; Martinez, Carlos; Comerma, Laura; Vazquez, Ivonne; Vernet-Tomas, Maria; Ampurdanes, Coral; Lutfi, Nura; Martin-Caballero, Juan; Dantzer, Francoise; Quintela-Fandino, Miguel; Ali, Syed O.; Jimeno, Jaime; Yelamos, Jose			Coordinated signals from PARP-1 and PARP-2 are required to establish a proper T cell immune response to breast tumors in mice	ONCOGENE			English	Article							CANCER; EXPRESSION; REVEALS	Poly(ADP-ribose)-polymerase (PARP)-1 and PARP-2 play an essential role in the DNA damage response. Based on this effect of PARP in the tumor cell itself, PARP inhibitors have emerged as new therapeutic tools both approved and in clinical trials. However, the interactome of multiple other cell types, particularly T cells, within the tumor microenvironment are known to either favor or limit tumorigenesis. Here, we bypassed the embryonic lethality of dually PARP-1/PARP-2-deficient mice by using a PARP-1-deficient mouse with a Cd4-promoter-driven deletion of PARP-2 in T cells to investigate the understudied role of these PARPs in the modulation of T cell responses against AT-3-induced breast tumors. We found that dual PARP-1/PARP-2-deficiency in T cells promotes tumor growth while single deficiency of each protein limited tumor progression. Analysis of tumor-infiltrating cells in dual PARP-1/PARP-2-deficiency host-mice revealed a global change in immunological profile and impaired recruitment and activation of T cells. Conversely, single PARP-1 and PARP-2-deficiency tends to produce an environment with an active and partially upregulated immune response. Our findings pinpoint opposite effects of single and dual PARP-1 and PARP-2-deficiency in modulating the antitumor response with an impact on tumor progression, and will have implications for the development of more selective PARP-centered therapies.	[Moreno-Lama, Lucia; Galindo-Campos, Miguel A.; Ampurdanes, Coral; Lutfi, Nura; Yelamos, Jose] Hosp del Mar Med Res Inst IMIM, Canc Res Program, Barcelona, Spain; [Martinez, Carlos] IMIB LAIB Arrixaca, Expt Pathol Unit, Murcia, Spain; [Comerma, Laura; Vazquez, Ivonne; Yelamos, Jose] Hosp del Mar, Dept Pathol, Barcelona, Spain; [Vernet-Tomas, Maria] Hosp del Mar Med Res Inst IMIM, Dept Obstet & Gynecol, Barcelona, Spain; [Martin-Caballero, Juan] Barcelona Biomed Res Pk PRBB, Barcelona, Spain; [Dantzer, Francoise] ESBS, Lab Excellence Medalis, Biotechnol & Cell Signaling, UMR7242 CNRS, Illkirch Graffenstaden, France; [Quintela-Fandino, Miguel] CNIO, Breast Canc Clin Res Unit, Madrid, Spain; [Ali, Syed O.] NHS, Oxford Univ Hosp, Oxford, England; [Jimeno, Jaime] Hosp Univ Marques Valdecilla, Dept Gen Surg, Breast Unit, Santander, Spain	Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Pompeu Fabra University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Centro Nacional de Investigaciones Oncologicas (CNIO); Oxford University Hospitals NHS Foundation Trust; Hospital Universitario Marques de Valdecilla (HUMV)	Yelamos, J (corresponding author), Hosp del Mar Med Res Inst IMIM, Canc Res Program, Barcelona, Spain.; Yelamos, J (corresponding author), Hosp del Mar, Dept Pathol, Barcelona, Spain.	jyelamos@imim.es	Blesa, Laura Comerma/AAQ-9455-2020; Vernet-Tomas, Maria/AAE-6363-2021; Yelamos, Jose/N-2842-2016; Moreno Lama, Lucia/CAC-3410-2022; Martinez, Carlos M./E-4986-2016	Blesa, Laura Comerma/0000-0002-0249-4636; Moreno Lama, Lucia/0000-0003-3900-1388; Martinez, Carlos M./0000-0003-3307-1326; Vazquez, Ivonne/0000-0002-5305-1560; Galindo Campos, Miguel Alejandro/0000-0002-0650-8660; Yelamos, Jose/0000-0003-1195-1496; Dantzer, Francoise/0000-0003-0945-8483	Spanish Ministerio de Economia, Industria y Competitividad [SAF2017-83565-R]; Fundacion Cientifica de la Asociacion Espanola Contra el Cancer (AECC); LABEX, Strasbourg University, CNRS [ANR-10-LABX-0034_Medalis]	Spanish Ministerio de Economia, Industria y Competitividad; Fundacion Cientifica de la Asociacion Espanola Contra el Cancer (AECC); LABEX, Strasbourg University, CNRS	We thank Dr. Abrams Scott for giving us the AT-3 cell line, Mary Hensen for assistance with the AT-3 cell line, Gemma Torres-Sotodosos and Laura Regue for technical assistance, and Xavi Duran for statistical assistance. The Yelamos's lab is funded by the Spanish Ministerio de Economia, Industria y Competitividad (grant SAF2017-83565-R) and The Fundacion Cientifica de la Asociacion Espanola Contra el Cancer (AECC). The Dantzer's lab is supported by LABEX ANR-10-LABX-0034_Medalis, Strasbourg University, CNRS.	Ashworth A, 2018, NAT REV CLIN ONCOL, V15, P564, DOI 10.1038/s41571-018-0055-6; Badoual C, 2013, CANCER RES, V73, P128, DOI 10.1158/0008-5472.CAN-12-2606; Bai P, 2015, MOL CELL, V58, P947, DOI 10.1016/j.molcel.2015.01.034; Baumeister SH, 2016, ANNU REV IMMUNOL, V34, P539, DOI 10.1146/annurev-immunol-032414-112049; Bock FJ, 2015, MOL CELL, V58, P911, DOI 10.1016/j.molcel.2015.06.012; Broz ML, 2014, CANCER CELL, V26, P638, DOI 10.1016/j.ccell.2014.09.007; Cohen MS, 2018, NAT CHEM BIOL, V14, P236, DOI [10.1038/NCHEMBIO.2568, 10.1038/nchembio.2568]; Dantzer F, 2006, P NATL ACAD SCI USA, V103, P14854, DOI 10.1073/pnas.0604252103; Darvin P, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0191-1; de Murcia JMN, 2003, EMBO J, V22, P2255, DOI 10.1093/emboj/cdg206; Farres J, 2015, CELL DEATH DIFFER, V22, P1144, DOI 10.1038/cdd.2014.202; Farres J, 2013, BLOOD, V122, P44, DOI 10.1182/blood-2012-12-472845; Gibson BA, 2016, SCIENCE, V353, P45, DOI 10.1126/science.aaf7865; Hinshaw DC, 2019, CANCER RES, V79, P4557, DOI 10.1158/0008-5472.CAN-18-3962; Hui EF, 2017, SCIENCE, V355, P1428, DOI 10.1126/science.aaf1292; Lee KM, 2003, J IMMUNOL, V170, P4881, DOI 10.4049/jimmunol.170.10.4881; Luo XR, 2015, J BIOL CHEM, V290, P28675, DOI 10.1074/jbc.M115.661611; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Martinez-Lostao L, 2015, CLIN CANCER RES, V21, P5047, DOI 10.1158/1078-0432.CCR-15-0685; Muntasell A, 2019, CLIN CANCER RES, V25, P1535, DOI 10.1158/1078-0432.CCR-18-2365; Navarro J, 2017, SCI REP-UK, V7, DOI 10.1038/srep41962; Nicolas L, 2010, ONCOGENE, V29, P2877, DOI 10.1038/onc.2010.11; O'Connor MJ, 2015, MOL CELL, V60, P547, DOI 10.1016/j.molcel.2015.10.040; Robson M, 2017, NEW ENGL J MED, V377, P523, DOI 10.1056/NEJMoa1706450; Saenz L, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-171; Schalper KA, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju435; Silva-Santos B, 2019, NAT REV CANCER, V19, P392, DOI 10.1038/s41568-019-0153-5; Simon S, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1364828; Sonnenblick A, 2015, NAT REV CLIN ONCOL, V12, P27, DOI 10.1038/nrclinonc.2014.163; Stewart RA, 2018, CANCER RES, V78, P6717, DOI 10.1158/0008-5472.CAN-18-2652; Stewart TJ, 2007, J IMMUNOL, V179, P2851, DOI 10.4049/jimmunol.179.5.2851; Valdor R, 2008, MOL IMMUNOL, V45, P1863, DOI 10.1016/j.molimm.2007.10.044; Veglia F, 2017, CURR OPIN IMMUNOL, V45, P43, DOI 10.1016/j.coi.2017.01.002; Wahlberg E, 2012, NAT BIOTECHNOL, V30, P283, DOI 10.1038/nbt.2121; Wang BF, 2011, BMC IMMUNOL, V12, DOI 10.1186/1471-2172-12-43; Yelamos J, 2006, EMBO J, V25, P4350, DOI 10.1038/sj.emboj.7601301; Yelamos J, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1065370; Yelamos J, 2011, AM J CANCER RES, V1, P328; Yokosuka T, 2012, J EXP MED, V209, P1201, DOI 10.1084/jem.20112741; Zhang P, 2013, BLOOD, V122, P2224, DOI 10.1182/blood-2013-05-503250	40	13	14	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	13					2835	2843		10.1038/s41388-020-1175-x	http://dx.doi.org/10.1038/s41388-020-1175-x		JAN 2020	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KX4EF	32001817				2022-12-28	WOS:000510328400003
J	Wang, DM; Cheng, XH; Li, Y; Guo, MW; Zhao, WJ; Qiu, J; Zheng, Y; Meng, MY; Ping, XD; Chen, X; Wang, S; Luo, J; Luo, QQ; Ma, XR; Xu, LY				Wang, Dongmei; Cheng, Xinghua; Li, Yu; Guo, Mingwei; Zhao, Wenjun; Qiu, Jin; Zheng, Ying; Meng, Meiyao; Ping, Xiaodan; Chen, Xin; Wang, Shu; Luo, Jian; Luo, Qingquan; Ma, Xinran; Xu, Lingyan			C/EBP delta-Slug-Lox1 axis promotes metastasis of lung adenocarcinoma via oxLDL uptake	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; FATTY-ACID SYNTHASE; TRANSCRIPTIONAL REGULATION; C/EBP-DELTA; STEM-CELLS; CANCER; RECEPTOR; BINDING; LOX-1; METABOLISM	Cancer cells undergo significant lipid metabolic reprogramming to ensure sufficient energy supply for survival and progression. However, how cancer cells integrate lipid metabolic signaling with cancer progression is not well understood. In the present study, we demonstrated that C/EBP delta, a critical lipid metabolic regulator, is a TGF-beta 1 downstream gene and promotes lung adenocarcinoma metastasis. Importantly, C/EBP delta caused significant oscillations in both lipid metabolic and epithelial to mesenchymal transition (EMT) gene networks. Mechanistically, we demonstrated that C/EBP delta recruited oncogene NCOA3 to transcriptionally activate Slug, a canonical EMT transcription factor, which in turn induced oxLDL receptor-1 (Lox1) expression and enhanced oxLDL uptake to promote cancer metastasis, which could be blocked with LOX1 neutralizing antibody. In summary, our results unveiled a previously unappreciated interplay between lipid metabolic and metastatic program, as well as the existence of a pivotal C/EBP delta-Slug-Lox1 transcription axis to promote oxLDL levels and cancer metastasis.	[Wang, Dongmei; Li, Yu; Guo, Mingwei; Zhao, Wenjun; Qiu, Jin; Zheng, Ying; Meng, Meiyao; Ping, Xiaodan; Chen, Xin; Luo, Jian; Ma, Xinran; Xu, Lingyan] East China Normal Univ, Inst Biomed Sci, Shanghai Key Lab Regulatory Biol, 500 Dong Chuan Rd, Shanghai 200241, Peoples R China; [Wang, Dongmei; Li, Yu; Guo, Mingwei; Zhao, Wenjun; Qiu, Jin; Zheng, Ying; Meng, Meiyao; Ping, Xiaodan; Chen, Xin; Luo, Jian; Ma, Xinran; Xu, Lingyan] East China Normal Univ, Sch Life Sci, 500 Dong Chuan Rd, Shanghai 200241, Peoples R China; [Cheng, Xinghua; Luo, Qingquan] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Pulm Tumor Med Ctr, Dept Oncol, 241 West Huai Hai Rd, Shanghai 200030, Peoples R China; [Wang, Shu; Ma, Xinran; Xu, Lingyan] Shanghai Jiao Tong Univ, Rui Jin Hosp, Shanghai Clin Ctr Endocrine & Metab Dis, Sch Med,Dept Endocrinol & Metab, 197 Rui Jin 2nd Rd, Shanghai 200025, Peoples R China	East China Normal University; East China Normal University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Ma, XR; Xu, LY (corresponding author), East China Normal Univ, Inst Biomed Sci, Shanghai Key Lab Regulatory Biol, 500 Dong Chuan Rd, Shanghai 200241, Peoples R China.; Ma, XR; Xu, LY (corresponding author), East China Normal Univ, Sch Life Sci, 500 Dong Chuan Rd, Shanghai 200241, Peoples R China.; Ma, XR; Xu, LY (corresponding author), Shanghai Jiao Tong Univ, Rui Jin Hosp, Shanghai Clin Ctr Endocrine & Metab Dis, Sch Med,Dept Endocrinol & Metab, 197 Rui Jin 2nd Rd, Shanghai 200025, Peoples R China.	xrma@bio.ecnu.edu.cn; lyxu@ecnu.edu.cn			National Natural Science Foundation of China [31770840, 31800989, 81902980, 81502480]; Shanghai Pujiang Program [17PJ1402600, 17PJ1402700]; Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning [TP2017042]; Shanghai Young Top Notch Talents; China Postdoctoral Science Foundation [2017M611499]; ECNU public platform for Innovation [011]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Pujiang Program(Shanghai Pujiang Program); Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning; Shanghai Young Top Notch Talents; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); ECNU public platform for Innovation	We are thankful to Dr Yan Lu (Zhongshan Hospital, Shanghai) and Zhenfei Li (SIBS, Shanghai) for reading the paper and for discussions throughout the project. This project is supported by funds from the National Natural Science Foundation of China (31770840 to XM, 31800989 to LX, 81902980 to DW, and 81502480 to XC), Shanghai Pujiang Program (17PJ1402600 to XM and 17PJ1402700 to LX), the Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning (TP2017042 to XM), Shanghai Young Top Notch Talents (to XM), the China Postdoctoral Science Foundation (2017M611499 to DW), and ECNU public platform for Innovation (011).	Ackerman D, 2014, TRENDS CELL BIOL, V24, P472, DOI 10.1016/j.tcb.2014.06.001; Nieto MA, 2011, ANNU REV CELL DEV BI, V27, P347, DOI 10.1146/annurev-cellbio-092910-154036; Perez-Mancera PA, 2007, HUM MOL GENET, V16, P2972, DOI 10.1093/hmg/ddm278; Balamurugan K, 2019, ONCOGENE, V38, P3765, DOI 10.1038/s41388-018-0516-5; Balamurugan K, 2013, INT J BIOL SCI, V9, P917, DOI 10.7150/ijbs.7224; Balzan S, 2018, LIFE SCI, V198, P79, DOI 10.1016/j.lfs.2018.02.024; Currie E, 2013, CELL METAB, V18, P153, DOI 10.1016/j.cmet.2013.05.017; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Deshmukh A, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0555-x; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Garcia MR, 2017, CELL METAB, V26, P842, DOI 10.1016/j.cmet.2017.09.018; Gonzalez-Chavarria I, 2018, CANCER LETT, V414, P34, DOI 10.1016/j.canlet.2017.10.035; Hou SD, 2017, AM J PATHOL, V187, P954, DOI 10.1016/j.ajpath.2017.01.009; HUNT JE, 1993, P NATL ACAD SCI USA, V90, P2141, DOI 10.1073/pnas.90.6.2141; Kobayashi K, 2003, J LIPID RES, V44, P716, DOI 10.1194/jlr.M200329-JLR200; Li Z, 2017, CELL METAB, V25, P228, DOI 10.1016/j.cmet.2017.01.016; Lin HP, 2016, CANCER RES, V76, P6924, DOI 10.1158/0008-5472.CAN-16-1597; Louet JF, 2006, P NATL ACAD SCI USA, V103, P17868, DOI 10.1073/pnas.0608711103; Lu JJ, 2011, ANTIOXID REDOX SIGN, V15, P2301, DOI 10.1089/ars.2010.3792; Lue HW, 2017, GENE DEV, V31, P2067, DOI 10.1101/gad.305292.117; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; Mendoza-Villanueva D, 2016, ONCOGENE, V35, P6166, DOI 10.1038/onc.2016.156; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; Mittal V, 2018, ANNU REV PATHOL-MECH, V13, P395, DOI 10.1146/annurev-pathol-020117-043854; Nishimura S, 2004, OSTEOARTHR CARTILAGE, V12, P568, DOI 10.1016/j.joca.2004.04.005; Noto A, 2017, ONCOGENE, V36, P4573, DOI [10.1038/onc.2017.75, 10.1038/onc.2017.212]; Pascual G, 2017, NATURE, V541, P41, DOI 10.1038/nature20791; Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586-018-0040-3; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; Rosen ED, 2000, GENE DEV, V14, P1293; Samet JM, 2009, CLIN CANCER RES, V15, P5626, DOI 10.1158/1078-0432.CCR-09-0376; Sawamura T, 1997, NATURE, V386, P73, DOI 10.1038/386073a0; Schoors S, 2015, NATURE, V520, P192, DOI 10.1038/nature14362; Schug ZT, 2015, CANCER CELL, V27, P57, DOI 10.1016/j.ccell.2014.12.002; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Tregnago C, 2016, LEUKEMIA, V30, P1887, DOI 10.1038/leu.2016.98; Wang JY, 2013, MOL CELL, V51, P211, DOI 10.1016/j.molcel.2013.05.013; Wang WJ, 2017, CLIN CANCER RES, V23, P503, DOI 10.1158/1078-0432.CCR-15-1169; Wang YW, 2014, J INVEST DERMATOL, V134, P2016, DOI 10.1038/jid.2014.84; Ye HB, 2016, CELL STEM CELL, V19, P23, DOI 10.1016/j.stem.2016.06.001; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897	41	11	11	2	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	4					833	848		10.1038/s41388-019-1015-z	http://dx.doi.org/10.1038/s41388-019-1015-z			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KF4EJ	31562393				2022-12-28	WOS:000509197200007
J	Xu, Y; Surman, DR; Diggs, L; Xi, SC; Gao, SJ; Gurusamy, D; McLoughlin, K; Drake, J; Feingold, P; Brown, K; Wangsa, D; Wangsa, D; Zhang, X; Ried, T; Davis, JL; Hernandez, J; Hoang, CD; Souza, RF; Schrump, DS; Ripley, RT				Xu, Yuan; Surman, Deborah R.; Diggs, Laurence; Xi, Sichuan; Gao, Shaojian; Gurusamy, Devikala; McLoughlin, Kaitlin; Drake, Justin; Feingold, Paul; Brown, Kate; Wangsa, Danny; Wangsa, Darawalee; Zhang, Xi; Ried, Thomas; Davis, Jeremy L.; Hernandez, Jonathan; Hoang, Chuong D.; Souza, Rhonda F.; Schrump, David S.; Ripley, R. Taylor			Bile acid-induced "Minority MOMP" promotes esophageal carcinogenesis while maintaining apoptotic resistance via Mcl-1	ONCOGENE			English	Article							CAUSES DNA-DAMAGE; ADENOCARCINOMA INCIDENCE; BARRETTS-ESOPHAGUS; CANCER-CELLS; MITOCHONDRIAL; ROS; INSTABILITY; EXPRESSION; SURVIVAL; BCL-2	Barrett's esophagus (BE) is associated with reflux and is implicated the development of esophageal adenocarcinoma (EAC). Apoptosis induces cell death through mitochondrial outer membrane permeabilization (MOMP), which is considered an irreversible step in apoptosis. Activation of MOMP to levels that fail to reach the apoptotic threshold may paradoxically promote cancer-a phenomenon called "Minority MOMP." We asked whether reflux-induced esophageal carcinogenesis occurred via minority MOMP and whether compensatory resistance mechanisms prevented cell death during this process. We exposed preneoplastic, hTERT-immortalized Barrett's cell, CP-C and CP-A, to the oncogenic bile acid, deoxycholic acid (DCA), for 1 year. Induction of minority MOMP was tested via comet assay, CyQuant, annexin V, JC-1, cytochrome C subcellular localization, caspase 3 activation, and immunoblots. We used bcl-2 homology domain-3 (BH3) profiling to test the mitochondrial apoptotic threshold. One-year exposure of Barrett's cells to DCA induced a malignant phenotype noted by clone and tumor formation. DCA promoted minority MOMP noted by minimal release of cytochrome C and limited caspase 3 activation, which resulted in DNA damage without apoptosis. Upregulation of the antiapoptotic protein, Mcl-1, ROS generation, and NF-kappa B activation occurred in conjunction with minority MOMP. Inhibition of ROS blocked minority MOMP and Mcl-1 upregulation. Knockdown of Mcl-1 shifted minority MOMP to complete MOMP as noted by dynamic BH3 profiling and increased apoptosis. Minority MOMP contributes to DCA induced carcinogenesis in preneoplastic BE. Mcl-1 provided a balance within the mitochondria that induced resistance complete MOMP and cell death. Targeting Mcl-1 may be a therapeutic strategy in EAC.	[Xu, Yuan; Surman, Deborah R.; Diggs, Laurence; Xi, Sichuan; Gao, Shaojian; McLoughlin, Kaitlin; Drake, Justin; Feingold, Paul; Brown, Kate; Davis, Jeremy L.; Hernandez, Jonathan; Hoang, Chuong D.; Schrump, David S.; Ripley, R. Taylor] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Surman, Deborah R.; Ripley, R. Taylor] Baylor Coll Med, Michael E DeBakey Dept Gen Surg, Div Gen Thorac Surg, Houston, TX 77030 USA; [Gurusamy, Devikala] NCI, Surg Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Wangsa, Danny; Wangsa, Darawalee; Ried, Thomas] NCI, Genet Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Zhang, Xi; Souza, Rhonda F.] Baylor Univ, Med Ctr, Ctr Esophageal Dis, Dept Med, Dallas, TX USA; [Wangsa, Danny; Wangsa, Darawalee; Ried, Thomas] Baylor Scott & White Res Inst, Ctr Esophageal Res, Dallas, TX USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Baylor University; Baylor University Medical Center; Baylor Health Care System; Baylor University Medical Center	Ripley, RT (corresponding author), NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.; Ripley, RT (corresponding author), Baylor Coll Med, Michael E DeBakey Dept Gen Surg, Div Gen Thorac Surg, Houston, TX 77030 USA.	R.Taylor.Ripley@bcm.edu	Davis, Jeremy/GLT-7151-2022; Davis, Jeremy/GQA-5941-2022; Gurusamy, Devikala/T-3410-2019	Davis, Jeremy/0000-0002-6334-6936; Davis, Jeremy/0000-0002-6334-6936; DRAKE, JUSTIN/0000-0002-2500-7044; Gurusamy, Devikala/0000-0002-1727-8653				Araghi RR, 2018, P NATL ACAD SCI USA, V115, pE886, DOI 10.1073/pnas.1712952115; Bajpai M, 2012, MOL CYTOGENET, V5, DOI 10.1186/1755-8166-5-43; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Byun JY, 2009, MOL PHARMACOL, V76, P734, DOI 10.1124/mol.109.056259; Chong J, 2018, NUCLEIC ACIDS RES, V46, pW486, DOI 10.1093/nar/gky310; Ertel F, 2013, EMBO REP, V14, P328, DOI 10.1038/embor.2013.20; Gillies LA, 2014, J CELL BIOCHEM, V115, P632, DOI 10.1002/jcb.24709; Gyori BM, 2014, REDOX BIOL, V2, P457, DOI 10.1016/j.redox.2013.12.020; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hormi-Carver K, 2009, CANCER RES, V69, P672, DOI 10.1158/0008-5472.CAN-08-3703; Huo XF, 2011, AM J PHYSIOL-GASTR L, V301, pG278, DOI 10.1152/ajpgi.00092.2011; Hur C, 2013, CANCER-AM CANCER SOC, V119, P1149, DOI 10.1002/cncr.27834; Ichim G, 2015, MOL CELL, V57, P860, DOI 10.1016/j.molcel.2015.01.018; Kim MJ, 2013, CANCER LETT, V339, P15, DOI 10.1016/j.canlet.2013.07.027; Kong CY, 2014, CANCER EPIDEM BIOMAR, V23, P997, DOI 10.1158/1055-9965.EPI-13-1233; Kotschy A, 2016, NATURE, V538, P477, DOI 10.1038/nature19830; Kwong JQ, 2007, J CELL BIOL, V179, P1163, DOI 10.1083/jcb.200704059; Li DC, 2004, CANCER SCI, V95, P644, DOI 10.1111/j.1349-7006.2004.tb03323.x; Liu XJ, 2015, MOL CELL, V58, P284, DOI 10.1016/j.molcel.2015.03.003; Lovric MM, 2010, ONCOGENE, V29, P5048, DOI 10.1038/onc.2010.242; Palanca-Wessels MC, 1998, GASTROENTEROLOGY, V114, P295, DOI 10.1016/S0016-5085(98)70480-9; Perciavalle RM, 2013, TRENDS CELL BIOL, V23, P22, DOI 10.1016/j.tcb.2012.08.011; Potter DS, 2016, COLD SH Q B, V81, P131, DOI 10.1101/sqb.2016.81.030841; Runge TM, 2015, GASTROENTEROL CLIN N, V44, P203, DOI 10.1016/j.gtc.2015.02.001; Ryan J, 2016, BIOL CHEM, V397, P671, DOI 10.1515/hsz-2016-0107; Sabharwal SS, 2014, NAT REV CANCER, V14, P709, DOI 10.1038/nrc3803; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Sobieraj DM, 2011, AM J MANAG CARE, V17, pE449; Spencer SL, 2011, CELL, V144, P926, DOI 10.1016/j.cell.2011.03.002; Tait SWG, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008706; Tait SWG, 2010, NAT REV MOL CELL BIO, V11, P621, DOI 10.1038/nrm2952; Tang HL, 2012, MOL BIOL CELL, V23, P2240, DOI 10.1091/mbc.E11-11-0926; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Westphal D, 2011, BBA-MOL CELL RES, V1813, P521, DOI 10.1016/j.bbamcr.2010.12.019; Williams MM, 2017, MOL CANCER RES, V15, P259, DOI 10.1158/1541-7786.MCR-16-0280-T; Xu Y, 2017, ONCOTARGET, V8, P101057; Yadav N, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.305; Yen CJ, 2008, CANCER RES, V68, P2632, DOI 10.1158/0008-5472.CAN-07-5460; Yi XL, 2003, J BIOL CHEM, V278, P16992, DOI 10.1074/jbc.M300039200	39	12	13	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	4					877	890		10.1038/s41388-019-1029-6	http://dx.doi.org/10.1038/s41388-019-1029-6			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KF4EJ	31570787	Green Accepted			2022-12-28	WOS:000509197200010
J	Chu, YJ; Chen, YP; Guo, HD; Li, MK; Wang, BC; Shi, DY; Cheng, XL; Guan, JX; Wang, XM; Xue, CH; Cheng, T; Shi, J; Yuan, WP				Chu, Yajing; Chen, Yangpeng; Guo, Huidong; Li, Mengke; Wang, Bichen; Shi, Deyang; Cheng, Xuelian; Guan, Jinxia; Wang, Xiaomin; Xue, Chenghai; Cheng, Tao; Shi, Jun; Yuan, Weiping			SUV39H1 regulates the progression ofMLL-AF9-induced acute myeloid leukemia	ONCOGENE			English	Article							HISTONE METHYLTRANSFERASE SUV39H1; STEM-CELL; NONSPECIFIC INHIBITOR; H3K79 METHYLATION; GENE-EXPRESSION; TARGET; CANCER; IDENTIFICATION; CHAETOCIN; PROTEINS	Epigenetic regulations play crucial roles in leukemogenesis and leukemia progression. SUV39H1 is the dominant H3K9 methyltransferase in the hematopoietic system, and its expression declines with aging. However, the role of SUV39H1 via its-mediated repressive modification H3K9me3 in leukemogenesis/leukemia progression remains to be explored. We found thatSUV39H1was down-regulated in a variety of leukemias, includingMLL-r AML, as compared with normal individuals. Decreased levels ofSuv39h1expression and genomic H3K9me3 occupancy were observed in LSCs fromMLL-r-induced AML mouse models in comparison with that of hematopoietic stem/progenitor cells.Suv39h1overexpression increased leukemia latency and decreased the frequency of LSCs inMLL-rAML mouse models, whileSuv39h1knockdown accelerated disease progression with increased number of LSCs. IncreasedSuv39h1expression led to the inactivation ofHoxb13andSix1, as well as reversion of Hoxa9/Meis1 downstream target genes, which in turn decelerated leukemia progression. Interestingly,Hoxb13expression is up-regulated inMLL-AF9-induced AML cells, while knockdown ofHoxb13inMLL-AF9leukemic cells significantly prolonged the survival of leukemic mice with reduced LSC frequencies. Our data revealed that SUV39H1 functions as a tumor suppressor inMLL-AF9-induced AML progression. These findings provide the direct link of SUV39H1 to AML development and progression.	[Chu, Yajing; Chen, Yangpeng; Guo, Huidong; Li, Mengke; Wang, Bichen; Shi, Deyang; Cheng, Xuelian; Wang, Xiaomin; Cheng, Tao; Shi, Jun; Yuan, Weiping] Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Expt Hematol, Natl Clin Res Ctr Hematol Dis, Inst Hematol, Tianjin 300020, Peoples R China; [Chu, Yajing; Chen, Yangpeng; Guo, Huidong; Li, Mengke; Wang, Bichen; Shi, Deyang; Cheng, Xuelian; Wang, Xiaomin; Cheng, Tao; Shi, Jun; Yuan, Weiping] Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, Tianjin 300020, Peoples R China; [Guan, Jinxia; Xue, Chenghai] My Hlth Gene Technol Co Ltd, Serv Ctr Tianjin Chentang Sci & Technol Commercia, Tianjin 300220, Peoples R China; [Guo, Huidong] Peking Univ, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Inst Hematol, Natl Clin Res Ctr Hematol Dis,Peoples Hosp, Beijing 100044, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Hematology & Blood Diseases Hospital - CAMS; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Hematology & Blood Diseases Hospital - CAMS; Peking Union Medical College; Peking University	Chu, YJ; Shi, J; Yuan, WP (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Expt Hematol, Natl Clin Res Ctr Hematol Dis, Inst Hematol, Tianjin 300020, Peoples R China.; Chu, YJ; Shi, J; Yuan, WP (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, Tianjin 300020, Peoples R China.	chuyajing@ihcams.ac.cn; shijun@ihcams.ac.cn; wpyuan@ihcams.ac.cn	Chu, Yajing/HDN-8398-2022	Guo, Huidong/0000-0003-3851-3656; Mengke, Li/0000-0001-7748-5307; Cheng, Tao/0000-0002-5925-2769	Ministry of Science and Technology of China [2017YFA0103402, 2018YFA0107801]; CAMS Innovation Fund for Medical Sciences [2016-I2M-1-017, 2017-I2M-3-015, 2017-I2M-3-018]; National Natural Science Foundation of China [81600136, 81670120, 81629001, 81770105]	Ministry of Science and Technology of China(Ministry of Science and Technology, China); CAMS Innovation Fund for Medical Sciences; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Drs Peng Wu and Xiaowei Xie for their assistance with the bioinformatics analysis of RNA-seq. We would also like to thank the experimental pathology cell bank facility for the storage of human patient samples of SKLEH from IHBD. This work was partially supported by the funds from the Ministry of Science and Technology of China (2017YFA0103402 and 2018YFA0107801), CAMS Innovation Fund for Medical Sciences (2016-I2M-1-017, 2017-I2M-3-015 and 2017-I2M-3-018), National Natural Science Foundation of China (81600136, 81670120, 81629001, and 81770105).	Alharbi RA, 2013, LEUKEMIA, V27, P1000, DOI 10.1038/leu.2012.356; Bagger FO, 2016, NUCLEIC ACIDS RES, V44, pD917, DOI 10.1093/nar/gkv1101; Balgobind BV, 2009, HAEMATOL-HEMATOL J, V94, P1033, DOI 10.3324/haematol.2008.004564; Beebe-Dimmer JL, 2015, CANCER EPIDEM BIOMAR, V24, P1366, DOI 10.1158/1055-9965.EPI-15-0247; Bernt KM, 2011, CANCER CELL, V20, P66, DOI 10.1016/j.ccr.2011.06.010; Bertoli C, 2013, NAT REV MOL CELL BIO, V14, P518, DOI 10.1038/nrm3629; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Carbone R, 2006, MOL CELL BIOL, V26, P1288, DOI 10.1128/MCB.26.4.1288-1296.2006; Caslini C, 2007, CANCER RES, V67, P7275, DOI 10.1158/0008-5472.CAN-06-2369; Chaib H, 2012, LEUKEMIA, V26, P662, DOI 10.1038/leu.2011.271; Chen CW, 2015, NAT MED, V21, P335, DOI 10.1038/nm.3832; Cheng H, 2015, BLOOD, V126, P1302, DOI 10.1182/blood-2015-01-623645; Cherblanc FL, 2013, J MED CHEM, V56, P8616, DOI 10.1021/jm401063r; Cherblanc FL, 2013, NAT CHEM BIOL, V9, P136, DOI 10.1038/nchembio.1187; Chu YJ, 2019, CANCER SCI, V110, P2200, DOI 10.1111/cas.14033; Djeghloul D, 2016, STEM CELL REP, V6, P970, DOI 10.1016/j.stemcr.2016.05.007; Fong CY, 2014, HAEMATOLOGICA, V99, P1772, DOI 10.3324/haematol.2013.092007; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Fritsch L, 2010, MOL CELL, V37, P46, DOI 10.1016/j.molcel.2009.12.017; Goyama S, 2010, LEUKEMIA, V24, P81, DOI 10.1038/leu.2009.202; Greiner D, 2005, NAT CHEM BIOL, V1, P143, DOI 10.1038/nchembio721; Greiner D, 2013, NAT CHEM BIOL, V9, P137, DOI 10.1038/nchembio.1188; Guo HD, 2017, INT J CANCER, V141, P324, DOI 10.1002/ijc.30739; Harris WJ, 2012, CANCER CELL, V21, P473, DOI 10.1016/j.ccr.2012.03.014; Hess JL, 2006, BLOOD, V108, P297, DOI 10.1182/blood-2005-12-5014; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Jo SY, 2011, BLOOD, V117, P4759, DOI 10.1182/blood-2010-12-327668; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Krivtsov AV, 2008, CANCER CELL, V14, P355, DOI 10.1016/j.ccr.2008.10.001; Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253; Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980; Lai YS, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.37; Li L, 2018, CANCER CELL, V33, P368, DOI 10.1016/j.ccell.2018.01.010; Li YY, 2014, CELL, V159, P558, DOI 10.1016/j.cell.2014.09.049; Mizuno H, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-18; Monaghan L, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00705; Muller-Tidow C, 2010, BLOOD, V116, P3564, DOI 10.1182/blood-2009-09-240978; Muntean AG, 2012, ANNU REV PATHOL-MECH, V7, P283, DOI 10.1146/annurev-pathol-011811-132434; Okada Y, 2005, CELL, V121, P167, DOI 10.1016/j.cell.2005.02.020; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Petti E, 2015, CELL CYCLE, V14, P1438, DOI 10.1080/15384101.2015.1021517; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Reimann M, 2010, CANCER CELL, V17, P262, DOI 10.1016/j.ccr.2009.12.043; Ropa J, 2020, HAEMATOLOGICA, V105, P2273, DOI 10.3324/haematol.2019.223883; Ropa James, 2018, Oncotarget, V9, P22123, DOI 10.18632/oncotarget.25204; Slany RK, 2009, HAEMATOL-HEMATOL J, V94, P984, DOI 10.3324/haematol.2008.002436; Somervaille TCP, 2006, CANCER CELL, V10, P257, DOI 10.1016/j.ccr.2006.08.020; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun DQ, 2014, CELL STEM CELL, V14, P673, DOI 10.1016/j.stem.2014.03.002; Tsai CT, 2017, ONCOGENE, V36, P1753, DOI 10.1038/onc.2016.315; Wang QF, 2011, BLOOD, V117, P6895, DOI 10.1182/blood-2010-12-324699; Williams TM, 2005, DEV BIOL, V277, P457, DOI 10.1016/j.ydbio.2004.10.004; Wong SHK, 2015, CANCER CELL, V28, P198, DOI 10.1016/j.ccell.2015.06.003; Yang YJ, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.98; Yang YJ, 2010, NUCLEIC ACIDS RES, V38, P382, DOI 10.1093/nar/gkp991; Yokoyama A, 2008, CANCER CELL, V14, P36, DOI 10.1016/j.ccr.2008.05.003; Zeisig Bernd B, 2012, Cancer Cell, V22, P698, DOI 10.1016/j.ccr.2012.10.017; Zheng Y, 2016, LEUKEMIA, V30, P2373, DOI 10.1038/leu.2016.112; Zhu XF, 2014, NAT GENET, V46, P287, DOI 10.1038/ng.2894	59	7	10	7	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2020	39	50					7239	7252		10.1038/s41388-020-01495-6	http://dx.doi.org/10.1038/s41388-020-01495-6		OCT 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PD4HE	33037410	Green Published, hybrid			2022-12-28	WOS:000578440800001
J	Qian, WL; Li, Q; Wu, XL; Li, WG; Li, QW; Zhang, J; Li, MY; Zhang, D; Zhao, HX; Zou, XQ; Jia, H; Zhang, LQ; Yang, XD; Hou, ZY				Qian, Wenli; Li, Qi; Wu, Xinglong; Li, Wenguo; Li, Qiwei; Zhang, Jie; Li, Mengying; Zhang, Dan; Zhao, Hongxia; Zou, Xiuqun; Jia, Hao; Zhang, Lingqiang; Yang, Xiao-Dong; Hou, Zhaoyuan			Deubiquitinase USP29 promotes gastric cancer cell migration by cooperating with phosphatase SCP1 to stabilize Snail protein	ONCOGENE			English	Article							TERMINAL DOMAIN PHOSPHATASE; E-CADHERIN REPRESSION; DNA-REPLICATION; GENE; TRANSCRIPTION; PHOSPHORYLATION; RECRUITMENT; METASTASIS; DROSOPHILA; DISTINCT	Snail is a master inducer of epithelial-mesenchymal transition (EMT) and metastasis, however, Snail protein is labile and is quickly degraded through the predominate ubiquitination-mediated proteasome pathway. Deubiquitinases (DUBs) can counteract the Snail degradation process to maintain high level of Snail protein in cancer cells. In this study, we screened a cDNA library containing 79 DUBs, and discovered that a panel of DUBs consisting of USP13, USP28, USP29, USP37, OTUD6A, and DUB3 can markedly stabilize Snail protein, with USP29 displaying the strongest activity to prevent Snail degradation. Mechanistically, USP29 enhances the interaction of Snail and SCP1, resulting in simultaneous dephosphorylation and deubiquitination of Snail and thereafter cooperative prevention of Snail degradation. Biologically, ectopic expression of USP29 promotes gastric cancer cell migration, and depletion of Snail abolishes USP29-mediated cell migration; and USP29 can be induced by major EMT and metastatic inducing factors such as TGF beta, TNF alpha, and hypoxia. More importantly, high expression levels of Snail, USP29, and SCP1 are associated with poor survival and prognosis. Collectively, these data indicate that Snail is a crucial substrate for USP29 to promote cell migration and USP29/SCP1 complex may be new therapeutic targets to treat metastatic cancer.	[Qian, Wenli; Li, Qi; Zhang, Jie; Li, Mengying; Zhang, Dan; Zou, Xiuqun; Jia, Hao; Hou, Zhaoyuan] Shanghai Jiao Tong Univ, Hongqiao Inst Med, Tongren Hosp, Fac Basic Med,Sch Med, Shanghai 200025, Peoples R China; [Li, Qi] Chinese Acad Sci, Shanghai Inst Mat Med, Drug Discovery & Design Ctr, State Key Lab Drug Res, Shanghai 201203, Peoples R China; [Wu, Xinglong; Hou, Zhaoyuan] Lanling Peoples Hosp, Cent Clin Lab, Lanling Cty 277700, Shandong, Peoples R China; [Li, Wenguo; Yang, Xiao-Dong] Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Immunol, Dept Immunol & Microbiol, Shanghai 200025, Peoples R China; [Li, Wenguo; Yang, Xiao-Dong] Shanghai Jiao Tong Univ, Sch Med, Minist Educ, Key Lab Cell Death & Differentiat, Shanghai 200025, Peoples R China; [Li, Qiwei] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Biliary Pancreat Surg, Shanghai 200127, Peoples R China; [Zhao, Hongxia] Univ Helsinki, Fac Biol & Environm Sci, Helsinki, Finland; [Zhang, Lingqiang] Beijing Inst Life, Natl Ctr Prot Sci Beijing, State Key Lab Prote, Beijing 100850, Peoples R China; [Hou, Zhaoyuan] Shanghai Jiao Tong Univ, Dept Biochem & Mol Cell Biol, Shanghai Key Lab Tumor Microenvironm & Inflammat, Sch Med, Shanghai 200025, Peoples R China	Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Chinese Academy of Sciences; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; University of Helsinki; Shanghai Jiao Tong University	Hou, ZY (corresponding author), Shanghai Jiao Tong Univ, Hongqiao Inst Med, Tongren Hosp, Fac Basic Med,Sch Med, Shanghai 200025, Peoples R China.; Hou, ZY (corresponding author), Lanling Peoples Hosp, Cent Clin Lab, Lanling Cty 277700, Shandong, Peoples R China.; Yang, XD (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Immunol, Dept Immunol & Microbiol, Shanghai 200025, Peoples R China.; Yang, XD (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Minist Educ, Key Lab Cell Death & Differentiat, Shanghai 200025, Peoples R China.; Zhang, LQ (corresponding author), Beijing Inst Life, Natl Ctr Prot Sci Beijing, State Key Lab Prote, Beijing 100850, Peoples R China.; Hou, ZY (corresponding author), Shanghai Jiao Tong Univ, Dept Biochem & Mol Cell Biol, Shanghai Key Lab Tumor Microenvironm & Inflammat, Sch Med, Shanghai 200025, Peoples R China.	zhanglq@nic.bmi.ac.cn; xdyang@shsmu.edu.cn; houzy@sjtu.edu.cn		YANG, XIAO-DONG/0000-0001-6895-0713	National Natural Science Foundation of China [81872131, 31671415, 31570770, 31770818]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from the National Natural Science Foundation of China to ZH (81872131 and 31671415) and to XDY (31570770 and 31770818).	ALBERGA A, 1991, DEVELOPMENT, V111, P983; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carver EA, 2001, MOL CELL BIOL, V21, P8184, DOI 10.1128/MCB.21.23.8184-8188.2001; Chen JZ, 2014, CANCER RES, V74, P4353, DOI 10.1158/0008-5472.CAN-14-0181; Clague MJ, 2013, PHYSIOL REV, V93, P1289, DOI 10.1152/physrev.00002.2013; Deep G, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-37; Do Kim J, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-108; Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349; Hou ZY, 2008, MOL CELL BIOL, V28, P3198, DOI 10.1128/MCB.01435-07; Hsu DSS, 2014, CANCER CELL, V26, P534, DOI 10.1016/j.ccell.2014.09.002; Huang Z, 2019, SCI CHINA LIFE SCI, V62, P544, DOI 10.1007/s11427-018-9469-4; Kim J, 2000, GENOME RES, V10, P1138, DOI 10.1101/gr.10.8.1138; Kim J, 2003, HUM MOL GENET, V12, P233, DOI 10.1093/hmg/ddg028; Knockaert M, 2006, P NATL ACAD SCI USA, V103, P11940, DOI 10.1073/pnas.0605133103; Komander D, 2009, NAT REV MOL CELL BIO, V10, P550, DOI 10.1038/nrm2731; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Lee JH, 2017, NAT CELL BIOL, V19, P1260, DOI 10.1038/ncb3609; Li Q, 2016, CELL DEATH DIFFER, V23, P158, DOI 10.1038/cdd.2015.83; Liu JH, 2011, EMBO J, V30, P846, DOI 10.1038/emboj.2011.11; Martin Y, 2015, ONCOGENE, V34, P1058, DOI 10.1038/onc.2014.38; Meinhart A, 2005, GENE DEV, V19, P1401, DOI 10.1101/gad.1318105; Mevissen TET, 2017, ANNU REV BIOCHEM, V86, P159, DOI 10.1146/annurev-biochem-061516-044916; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Nesti E, 2014, P NATL ACAD SCI USA, V111, pE3929, DOI 10.1073/pnas.1414770111; NIETO MA, 1992, DEVELOPMENT, V116, P227; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Park SY, 2010, EMBO J, V29, P3787, DOI 10.1038/emboj.2010.254; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Rehman SAA, 2016, MOL CELL, V63, P146, DOI 10.1016/j.molcel.2016.05.009; Reyes-Turcu FE, 2009, ANNU REV BIOCHEM, V78, P363, DOI 10.1146/annurev.biochem.78.082307.091526; Sapkota G, 2006, J BIOL CHEM, V281, P40412, DOI 10.1074/jbc.M610172200; Vinas-Castells R, 2014, NUCLEIC ACIDS RES, V42, P1079, DOI 10.1093/nar/gkt935; Vinas-Castells R, 2010, J BIOL CHEM, V285, P3794, DOI 10.1074/jbc.M109.065995; Wrighton KH, 2006, J BIOL CHEM, V281, P38365, DOI 10.1074/jbc.M607246200; Wu YD, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14228; Wu YD, 2009, J BIOL CHEM, V284, P640, DOI 10.1074/jbc.M806916200; Xu BH, 2019, NUCLEIC ACIDS RES, V47, P2322, DOI 10.1093/nar/gky1306; Yeo M, 2003, J BIOL CHEM, V278, P26078, DOI 10.1074/jbc.M301791200; Yeo M, 2005, SCIENCE, V307, P596, DOI 10.1126/science.1100801; Yuan L, 2015, NAT CELL BIOL, V17, P1169, DOI 10.1038/ncb3218; Zhang MM, 2010, PROTEIN SCI, V19, P974, DOI 10.1002/pro.375; Zhang YH, 2019, CELL DEATH DIFFER, V26, P565, DOI 10.1038/s41418-018-0147-y; Zheng HQ, 2014, CANCER CELL, V26, P358, DOI 10.1016/j.ccr.2014.07.022; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173; Zhou HH, 2018, ONCOGENE, V37, P3356, DOI 10.1038/s41388-018-0224-1	46	23	25	3	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2020	39	44					6802	6815		10.1038/s41388-020-01471-0	http://dx.doi.org/10.1038/s41388-020-01471-0		SEP 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OH9QS	32973332				2022-12-28	WOS:000572607300002
J	Huang, QB; Sun, Y; Zhai, W; Ma, X; Shen, DL; Du, SL; You, BS; Niu, YJ; Huang, CP; Zhang, X; Chang, C				Huang, Qingbo; Sun, Yin; Zhai, Wei; Ma, Xin; Shen, Donglai; Du, Songliang; You, Bosen; Niu, Yuanjie; Huang, Chi-Ping; Zhang, Xu; Chang, Chawnshang			Androgen receptor modulates metastatic routes of VHL wild-type clear cell renal cell carcinoma in an oxygen-dependent manner	ONCOGENE			English	Article							HYPOXIA-INDUCIBLE FACTORS; TUMOR-SUPPRESSOR PROTEIN; CANCER; PROGRESSION; AXIS	Recent studies indicated that the androgen receptor (AR) plays important roles in modulating metastasis of VHL-mutant clear cell renal cell carcinoma (ccRCC). However, the precise mechanisms of AR roles in VHL wild-type (VHL-wt) ccRCC, remain unclear. Here we found that AR interacted with VHL to modulate the metastasis of VHL-wt ccRCC via an oxygen-dependent manner. Mechanism dissection revealed that AR could transcriptionally suppress the miR-185-5p expression in the presence of functional VHL-wt protein under a normoxic condition, which might then result in increasing the expression of VEGF-A and VEGF-C via targeting the 3 ' UTR of mRNAs at a post-transcriptional level. In contrast, under a hypoxic condition, AR could increase miR-185-5p expression to suppress VEGF-C expression, yet this miR-185-5p effect on VEGF-A was reversed via AR's positive regulation on the HIF2 alpha-increased VEGF-A expression that resulted in increasing VEGF-A in the VHL-wt RCC cells. These distinct AR functions under different oxygen conditions may involve the VHL-impacted ubiquitination and nuclear localization of AR. The differential regulation of VEGF-A vs VEGF-C by AR may then result in differential impacts on the ccRCC metastatic destinations of VHL-wt ccRCC cells under different oxygen conditions. These finer mechanisms may help in the development of a novel therapy to better suppress the ccRCC progression under different oxygenization conditions.	[Huang, Qingbo; Ma, Xin; Shen, Donglai; Du, Songliang; Zhang, Xu] Chinese Peoples Liberat Army Gen Hosp, Dept Urol, Beijing 100853, Peoples R China; [Huang, Qingbo; Sun, Yin; Zhai, Wei; You, Bosen; Niu, Yuanjie; Chang, Chawnshang] Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; [Huang, Qingbo; Sun, Yin; Zhai, Wei; You, Bosen; Niu, Yuanjie; Chang, Chawnshang] Univ Rochester, Med Ctr, Dept Urol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; [Huang, Qingbo; Sun, Yin; Zhai, Wei; You, Bosen; Niu, Yuanjie; Chang, Chawnshang] Univ Rochester, Med Ctr, Dept Radiat Oncol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; [Huang, Qingbo; Sun, Yin; Zhai, Wei; You, Bosen; Niu, Yuanjie; Chang, Chawnshang] Univ Rochester, Med Ctr, Wilmot Canc Inst, Rochester, NY 14642 USA; [Zhai, Wei] Jiao Tong Univ, Renji Hosp, Dept Urol, Shanghai 200127, Peoples R China; [Huang, Chi-Ping; Chang, Chawnshang] China Med Univ Hosp, Dept Urol, Sex Hormone Res Ctr, Taichung 404, Taiwan	Chinese People's Liberation Army General Hospital; University of Rochester; University of Rochester; University of Rochester; University of Rochester; Shanghai Jiao Tong University; China Medical University Taiwan; China Medical University Hospital - Taiwan	Zhang, X (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Dept Urol, Beijing 100853, Peoples R China.; Chang, C (corresponding author), Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA.; Chang, C (corresponding author), Univ Rochester, Med Ctr, Dept Urol, George Whipple Lab Canc Res, Rochester, NY 14642 USA.; Chang, C (corresponding author), Univ Rochester, Med Ctr, Dept Radiat Oncol, George Whipple Lab Canc Res, Rochester, NY 14642 USA.; Chang, C (corresponding author), Univ Rochester, Med Ctr, Wilmot Canc Inst, Rochester, NY 14642 USA.; Chang, C (corresponding author), China Med Univ Hosp, Dept Urol, Sex Hormone Res Ctr, Taichung 404, Taiwan.	xzhang@foxmail.com; chang@urmc.rochester.edu	zhang, xu/GYE-3558-2022; You, Bosen/AHC-2523-2022	Chang, Chawnshang/0000-0001-8510-3516; Huang, Qingbo/0000-0003-2894-0187; Zhai, Wei/0000-0001-6274-6404	George Whipple Professorship Endowment; Beijing Natural Science Foundation [7194319]; National Nature Science Foundation [81972389]	George Whipple Professorship Endowment; Beijing Natural Science Foundation(Beijing Natural Science Foundation); National Nature Science Foundation(National Natural Science Foundation of China (NSFC))	This work was supported by George Whipple Professorship Endowment, and Beijing Natural Science Foundation (No. 7194319), and National Nature Science Foundation (No. 81972389).	Arjumand W, 2012, TUMOR BIOL, V33, P9, DOI 10.1007/s13277-011-0257-3; Baran N, 2017, CLIN CANCER RES, V23, P2382, DOI 10.1158/1078-0432.CCR-16-0895; Bosson AD, 2014, MOL CELL, V56, P347, DOI 10.1016/j.molcel.2014.09.018; Bukowski RM, 1997, CANCER-AM CANCER SOC, V80, P1198, DOI 10.1002/(SICI)1097-0142(19971001)80:7<1198::AID-CNCR3>3.0.CO;2-H; Chen SL, 2013, BIOCHEM J, V456, P55, DOI 10.1042/BJ20121711; Chen Y, 2015, ONCOTARGET, V6, P31203, DOI 10.18632/oncotarget.4522; Chymkowitch P, 2011, EMBO J, V30, P468, DOI 10.1038/emboj.2010.337; Coffey K, 2012, J ENDOCRINOL, V215, P221, DOI 10.1530/JOE-12-0238; Gossage L, 2010, NAT REV CLIN ONCOL, V7, P277, DOI 10.1038/nrclinonc.2010.42; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; He DL, 2014, CANCER RES, V74, P4420, DOI 10.1158/0008-5472.CAN-13-2681; Huang QB, 2014, ONCOTARGET, V5, P3066, DOI 10.18632/oncotarget.1827; Huang QB, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00701-6; Kim W, 2003, CURR OPIN GENET DEV, V13, P55, DOI 10.1016/S0959-437X(02)00010-2; Kim WY, 2004, J CLIN ONCOL, V22, P4991, DOI 10.1200/JCO.2004.05.061; Linehan WM, 2010, NAT REV UROL, V7, P277, DOI 10.1038/nrurol.2010.47; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Oudard S, 2007, ANN ONCOL, V18, P25, DOI 10.1093/annonc/mdm411; Petrova V, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-017-0011-9; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Qi JF, 2013, CANCER CELL, V23, P332, DOI 10.1016/j.ccr.2013.02.016; Qu B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041504; Sayeed A, 2012, J CELL PHYSIOL, V227, P751, DOI 10.1002/jcp.22784; Shen C, 2013, SEMIN CANCER BIOL, V23, P18, DOI 10.1016/j.semcancer.2012.06.001; Tomasetti C, 2015, SCIENCE, V347, P78, DOI 10.1126/science.1260825; Wang J, 2014, MOL ENDOCRINOL, V28, P239, DOI 10.1210/me.2013-1258; Wong SC, 2018, MOL CANCER THER, V17, P140, DOI 10.1158/1535-7163.MCT-17-0471; Xu KX, 2009, CANCER CELL, V15, P270, DOI 10.1016/j.ccr.2009.02.021; Yang OCY, 2013, KIDNEY INT, V84, P667, DOI 10.1038/ki.2013.245; Zhai W, 2016, ONCOGENE, V35, P4866, DOI 10.1038/onc.2016.19	31	3	3	4	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2020	39	43					6677	6691		10.1038/s41388-020-01455-0	http://dx.doi.org/10.1038/s41388-020-01455-0		SEP 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OF2UT	32943729				2022-12-28	WOS:000571161500002
J	Yang, RS; Zhao, YL; Gu, Y; Yang, Y; Gao, X; Yuan, Y; Xiao, LM; Zhang, J; Sun, C; Yang, H; Qin, JH; Li, J; Zhang, F; Zhang, LJ; Jing,				Yang, Risheng; Zhao, Yuanlin; Gu, Yu; Yang, Ying; Gao, Xing; Yuan, Yuan; Xiao, Liming; Zhang, Jin; Sun, Chao; Yang, Han; Qin, Junhui; Li, Jing; Zhang, Feng; Zhang, Lijun; Ye, Jing			Isocitrate dehydrogenase 1 mutation enhances 24(S)-hydroxycholesterol production and alters cholesterol homeostasis in glioma	ONCOGENE			English	Article							CENTRAL-NERVOUS-SYSTEM; BRAIN CHOLESTEROL; IDH1 MUTATION; RECEPTOR LXR; METABOLISM; CANCER; 24S-HYDROXYCHOLESTEROL; TURNOVER; 24-HYDROXYLASE; EXPRESSION	Isocitrate dehydrogenase (IDH) mutation is the most important initiating event in gliomagenesis, and the increasing evidence shows that IDH mutation is associated with the metabolic reprogramming in the tumor. Dysregulated cholesterol metabolism is a hallmark of tumor cells, but the cholesterol homeostasis in IDH-mutated glioma is still unknown. In this study, we found that astrocyte-specific mutant IDH1(R132H) knockin reduced the cholesterol contents and damaged the structure of myelin in mouse brains. In U87 and U251 cells, the expression of mutant IDH1 consistently reduced the cholesterol levels. Furthermore, we found that IDH1 mutation enhanced the production of 24(S)-hydroxycholesterol (24-OHC), which is not only the metabolite of cholesterol elimination, but also functions as an endogenous ligand for the liver X receptors (LXRs). In IDH1-mutant glioma cells, the elevated 24-OHC activated LXRs, which consequently accelerated the low-density lipoprotein receptor (LDLR) degradation by upregulating the inducible degrader of the LDLR (IDOL). The reduced LDLR expressions in IDH1-mutant glioma cells abated the uptakes of low-density lipoprotein (LDL) to decrease the cholesterol influx. In addition, the activated LXRs also promoted the cholesterol efflux by elevating the ATP-binding cassette transporter A1 (ABCA1), ABCG1, and apolipoprotein E (ApoE) in both IDH1-mutant astrocytes and glioma cells. As a feedback, the reduced cholesterol levels stimulated the cholesterol biosynthesis, which made IDH1-mutated glioma cells more sensitive to atorvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase. The altered cholesterol homeostasis regulated by mutant IDH provides a pivotal therapeutical strategy for the IDH-mutated gliomas.	[Yang, Risheng; Zhao, Yuanlin; Gu, Yu; Yang, Ying; Gao, Xing; Yuan, Yuan; Xiao, Liming; Yang, Han; Qin, Junhui; Li, Jing; Zhang, Feng; Ye, Jing] Fourth Mil Med Univ, Xijing Hosp, Dept Pathol, State Key Lab Canc Biol, Xian 710032, Shaanxi, Peoples R China; [Yang, Risheng; Zhao, Yuanlin; Gu, Yu; Yang, Ying; Gao, Xing; Yuan, Yuan; Xiao, Liming; Yang, Han; Qin, Junhui; Li, Jing; Zhang, Feng; Ye, Jing] Fourth Mil Med Univ, Sch Basic Med, Xian 710032, Shaanxi, Peoples R China; [Zhang, Jin] Army Med Univ, Inst Canc, Xinqiao Hosp, Chongqing 400037, Peoples R China; [Sun, Chao] Fourth Mil Med Univ, Tangdu Hosp, Dept Neurol, Xian 710038, Shaanxi, Peoples R China; [Zhang, Lijun] Fourth Mil Med Univ, Tangdu Hosp, Dept Clin Diag, Xian 710038, Shaanxi, Peoples R China	Air Force Military Medical University; Air Force Military Medical University; Army Medical University; Air Force Military Medical University; Air Force Military Medical University	Jing, (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Pathol, State Key Lab Canc Biol, Xian 710032, Shaanxi, Peoples R China.; Jing, (corresponding author), Fourth Mil Med Univ, Sch Basic Med, Xian 710032, Shaanxi, Peoples R China.; Zhang, LJ (corresponding author), Fourth Mil Med Univ, Tangdu Hosp, Dept Clin Diag, Xian 710038, Shaanxi, Peoples R China.	zhanglijun_fmmu@163.com; yejing@fmmu.edu.cn		Yang, Risheng/0000-0001-6663-6114	National Natural Science Foundation of China [81972342, 81772659, 81670792]; State Key Laboratory of Cancer Biology of China [CBSKL2017Z20]; Natural Science Basic Research Plan in Shaanxi Province [2020JZ-29, 2020JQ-462]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); State Key Laboratory of Cancer Biology of China; Natural Science Basic Research Plan in Shaanxi Province	The research work was supported by the National Natural Science Foundation of China (81972342, 81772659 to JY, 81670792 to LZ), State Key Laboratory of Cancer Biology of China (CBSKL2017Z20 to YG), and Natural Science Basic Research Plan in Shaanxi Province (2020JZ-29 to JY, 2020JQ-462 to XG).	Adaikalakoteswari A, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0046-8; An ZY, 2016, CANCER CELL, V30, P653, DOI 10.1016/j.ccell.2016.10.011; Bjorkhem I, 2006, J INTERN MED, V260, P493, DOI 10.1111/j.1365-2796.2006.01725.x; Bjorkhem I, 2004, ARTERIOSCL THROM VAS, V24, P806, DOI 10.1161/01.ATV.0000120374.59826.1b; Bjorkhem I, 1998, J LIPID RES, V39, P1594; Bjorkhem I, 1997, J BIOL CHEM, V272, P30178, DOI 10.1074/jbc.272.48.30178; Bogdanovic E, 2015, BBA-GEN SUBJECTS, V1850, P1781, DOI 10.1016/j.bbagen.2015.04.014; Bovenga F, 2015, CELL METAB, V21, P517, DOI 10.1016/j.cmet.2015.03.002; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Clendening JW, 2012, ONCOGENE, V31, P4967, DOI 10.1038/onc.2012.6; de Nigris F, 2018, JAMA CARDIOL, V3, P1184, DOI 10.1001/jamacardio.2018.3546; Dietschy JM, 2001, CURR OPIN LIPIDOL, V12, P105, DOI 10.1097/00041433-200104000-00003; Dietschy JM, 2004, J LIPID RES, V45, P1375, DOI 10.1194/jlr.R400004-JLR200; Dietschy JM, 2009, BIOL CHEM, V390, P287, DOI 10.1515/BC.2009.035; Ferris JS, 2012, INT J CANCER, V131, pE1031, DOI 10.1002/ijc.27536; Fujiyoshi M, 2007, J NEUROCHEM, V100, P968, DOI 10.1111/j.1471-4159.2006.04240.x; Gallagher EJ, 2017, ONCOGENE, V36, P6462, DOI 10.1038/onc.2017.247; Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022; Guillaumond F, 2015, P NATL ACAD SCI USA, V112, P2473, DOI 10.1073/pnas.1421601112; Guo DL, 2011, CANCER DISCOV, V1, P442, DOI 10.1158/2159-8290.CD-11-0102; Iannelli F, 2018, RECENT PAT ANTI-CANC, V13, P184, DOI 10.2174/1574892812666171129141211; Izquierdo-Garcia JL, 2015, CANCER RES, V75, P2999, DOI 10.1158/0008-5472.CAN-15-0840; Korade Z, 2008, NEUROPHARMACOLOGY, V55, P1265, DOI 10.1016/j.neuropharm.2008.02.019; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Leonardi R, 2012, J BIOL CHEM, V287, P14615, DOI 10.1074/jbc.C112.353946; Lokody I, 2014, NAT REV CANCER, V14, P706, DOI 10.1038/nrc3840; Lu C, 2012, NATURE, V483, P474, DOI 10.1038/nature10860; Lund EG, 1999, P NATL ACAD SCI USA, V96, P7238, DOI 10.1073/pnas.96.13.7238; Lund EG, 2003, J BIOL CHEM, V278, P22980, DOI 10.1074/jbc.M303415200; Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; Miyata S, 2013, NEUROL MED-CHIR, V53, P645, DOI 10.2176/nmc.oa2012-0409; Peterse EFP, 2018, BRIT J CANCER, V118, P1074, DOI 10.1038/s41416-018-0050-9; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Saher G, 2005, NAT NEUROSCI, V8, P468, DOI 10.1038/nn1426; Sasaki M, 2012, NATURE, V488, P656, DOI 10.1038/nature11323; Silvente-Poirot S, 2014, SCIENCE, V343, P1445, DOI 10.1126/science.1252787; Strickland M, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00043; Tateishi K, 2015, CANCER CELL, V28, P773, DOI 10.1016/j.ccell.2015.11.006; Turcan S, 2012, NATURE, V483, P479, DOI 10.1038/nature10866; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Venur VA, 2015, CANCER TREAT RES, V163, P103, DOI 10.1007/978-3-319-12048-5_7; Villa GR, 2016, CANCER CELL, V30, P683, DOI 10.1016/j.ccell.2016.09.008; Viswanath P, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2015.1077922; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Zelcer N, 2009, SCIENCE, V325, P100, DOI 10.1126/science.1168974; Zhang J, 2019, LIPIDS HEALTH DIS, V18, DOI 10.1186/s12944-019-1022-7; Zhu ZY, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/2710693	49	10	10	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2020	39	40					6340	6353		10.1038/s41388-020-01439-0	http://dx.doi.org/10.1038/s41388-020-01439-0		AUG 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NV5JK	32855525				2022-12-28	WOS:000565020000001
J	Shin, SH; Kim, I; Lee, JE; Lee, M; Park, JW				Shin, Seung-Hyun; Kim, Iljin; Lee, Jae Eun; Lee, Mingyu; Park, Jong-Wan			Loss of EGR3 is an independent risk factor for metastatic progression in prostate cancer	ONCOGENE			English	Article							TRANSCRIPTION FACTOR; POOR-PROGNOSIS; GROWTH; EXPRESSION; PTEN; IDENTIFICATION; INFLAMMATION; GADD45-BETA; MECHANISMS; CARCINOMA	Identification of pro-metastatic genomic alterations is urgently needed to help understand and prevent the fatal course of prostate cancer. Here, we found that the transcription factorEGR3, located at chromosome 8p21.3, is a critical metastasis suppressor. Aberrant deletion ofEGR3was found in up to 59.76% (deep deletions, 16.87%; shallow deletions, 42.89%) of prostate cancer patients. In informatics analysis,EGR3loss was associated with prostate cancer progression and low survival rates.EGR3expression inversely correlated with the expressions of epithelial-to-mesenchymal transition (EMT) and metastasis-related gene sets in prostate cancer tissues. In prostate cancer cells, EGR3 blocked the EMT process and suppressed cell migration and invasion. In a mouse model for cancer metastasis, EGR3 overexpression significantly suppressed bone metastases of PC3 and 22Rv1 prostate cancer cells. Mechanistically, EGR3 transcriptionally activatedZFP36,GADD45B, andSOCS3genes by directly binding to their promoter regions. The EMT-inhibitory and tumor-suppressive roles of the EGR3 downstream genes were identified through in vitro and in silico analyses. Together, our results showed that EGR3 may be a biomarker to predict clinical outcomes and that it plays an important role in the metastatic progression of prostate cancer.	[Shin, Seung-Hyun; Kim, Iljin; Lee, Jae Eun; Lee, Mingyu; Park, Jong-Wan] Seoul Natl Univ, Dept Biomed Sci, Coll Med, Seoul, South Korea; [Shin, Seung-Hyun; Kim, Iljin; Lee, Jae Eun; Lee, Mingyu; Park, Jong-Wan] Seoul Natl Univ, Dept Pharmacol, Coll Med, Seoul, South Korea; [Shin, Seung-Hyun; Kim, Iljin; Lee, Jae Eun; Lee, Mingyu; Park, Jong-Wan] Seoul Natl Univ, Canc Res Inst, Coll Med, Seoul, South Korea; [Kim, Iljin; Lee, Mingyu; Park, Jong-Wan] Seoul Natl Univ, Ischem Hypox Dis Inst, Coll Med, Seoul, South Korea; [Lee, Mingyu] Seoul Natl Univ, Obstruct Upper Airway Res OUaR Lab, Coll Med, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU)	Park, JW (corresponding author), Seoul Natl Univ, Dept Biomed Sci, Coll Med, Seoul, South Korea.; Park, JW (corresponding author), Seoul Natl Univ, Dept Pharmacol, Coll Med, Seoul, South Korea.; Park, JW (corresponding author), Seoul Natl Univ, Canc Res Inst, Coll Med, Seoul, South Korea.; Park, JW (corresponding author), Seoul Natl Univ, Ischem Hypox Dis Inst, Coll Med, Seoul, South Korea.	parkjw@snu.ac.kr		Park, Jong-Wan/0000-0003-4676-5191	National Research Foundation of Korea [2019R1A2B5B03069677, 2020R1A4A2002903]	National Research Foundation of Korea(National Research Foundation of Korea)	The authors acknowledge the contribution of all the investigators at the participating study sites. This work was supported by the National Research Foundation of Korea (2019R1A2B5B03069677 and 2020R1A4A2002903).	Adamson E, 2003, CANCER BIOL THER, V2, P617; Adamson ED, 2002, TUMOR BIOL, V23, P93, DOI 10.1159/000059711; Baron VT, 2015, BRIT J CANCER, V112, P755, DOI 10.1038/bjc.2014.622; BOVA GS, 1993, CANCER RES, V53, P3869; Brawley OW, 2012, WORLD J UROL, V30, P195, DOI 10.1007/s00345-012-0824-2; Brooks SA, 2013, BBA-GENE REGUL MECH, V1829, P666, DOI 10.1016/j.bbagrm.2013.02.003; Buttigliero C, 2015, CANCER TREAT REV, V41, P884, DOI 10.1016/j.ctrv.2015.08.002; Chandran UR, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-64; Choi YJ, 2019, SCI REP, V9; Decker EL, 2003, NUCLEIC ACIDS RES, V31, P911, DOI 10.1093/nar/gkg186; Demichelis F, 2013, NAT MED, V19, P966, DOI 10.1038/nm.3285; El Gammal AT, 2010, CLIN CANCER RES, V16, P56, DOI 10.1158/1078-0432.CCR-09-1423; Eldredge LC, 2008, DEVELOPMENT, V135, P2949, DOI 10.1242/dev.023960; Gandhi J, 2018, PROSTATE CANCER P D, V21, P22, DOI 10.1038/s41391-017-0023-8; Gitenay D, 2009, FUTURE ONCOL, V5, P993, DOI 10.2217/FON.09.67; Gomez-Martin D, 2010, AUTOIMMUN REV, V9, P454, DOI 10.1016/j.autrev.2009.12.006; Huang H, 2018, PROSTATE, V78, P327, DOI 10.1002/pros.23469; Jamaspishvili T, 2018, NAT REV UROL, V15, P222, DOI 10.1038/nrurol.2018.9; Kim SH, 2015, PLOS ONE, V10; Kirby M, 2011, INT J CLIN PRACT, V65, P1180, DOI 10.1111/j.1742-1241.2011.02799.x; Kluth M, 2017, ONCOTARGET, V8, P108923, DOI 10.18632/oncotarget.22408; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Li SL, 2012, IMMUNITY, V37, P685, DOI 10.1016/j.immuni.2012.08.001; Liao F, 2013, J MOL HISTOL, V44, P463, DOI 10.1007/s10735-013-9493-8; Logothetis CJ, 2013, CANCER DISCOV, V3, P849, DOI 10.1158/2159-8290.CD-12-0460; Michaelis KA, 2011, ENDOCRINOLOGY, V152, P3603, DOI 10.1210/en.2011-0109; O'Donovan KJ, 2000, J NEUROCHEM, V75, P1352, DOI 10.1046/j.1471-4159.2000.0751352.x; Ou DL, 2010, CANCER RES, V70, P9309, DOI 10.1158/0008-5472.CAN-10-1033; Park JM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113384; Parker C, 2015, ANN ONCOL, V26, pV69, DOI 10.1093/annonc/mdv222; Pio R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054096; Reid AHM, 2010, BRIT J CANCER, V102, P678, DOI 10.1038/sj.bjc.6605554; Safford M, 2005, NAT IMMUNOL, V6, P472, DOI 10.1038/ni1193; Sartor O, 2018, NEW ENGL J MED, V378, P645, DOI 10.1056/NEJMra1701695; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Suzuki T, 2007, ENDOCR-RELAT CANCER, V14, P279, DOI 10.1677/ERC-06-0005; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tourtellotte WG, 1998, NAT GENET, V20, P87, DOI 10.1038/1757; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; Vlietstra RJ, 1998, CANCER RES, V58, P2720; Wang GC, 2018, GENE DEV, V32, P1105, DOI 10.1101/gad.315739.118; Wendt MK, 2014, JAK STAT, V3; Yoon NA, 2016, ONCOTARGET, V7, P8931, DOI 10.18632/oncotarget.7094; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158	44	8	8	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2020	39	36					5839	5854		10.1038/s41388-020-01418-5	http://dx.doi.org/10.1038/s41388-020-01418-5		AUG 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NJ1HO	32796959				2022-12-28	WOS:000559718800002
J	Chi, HC; Tsai, CY; Wang, CS; Yang, HY; Lo, CH; Wang, WJ; Lee, KF; Lai, LY; Hong, JH; Chang, YF; Tsai, MM; Yeh, CT; Wu, CH; Hsieh, CC; Wang, LH; Chen, WJ; Lin, KH				Chi, Hsiang-Cheng; Tsai, Chung-Ying; Wang, Chia-Siu; Yang, Huang-Yu; Lo, Chien-Hui; Wang, Won-Jing; Lee, Kam-Fai; Lai, Li-Yin; Hong, Ji-Hong; Chang, Yen-Fang; Tsai, Ming-Ming; Yeh, Chau-Ting; Wu, Cheng Heng; Hsieh, Ching-Chuan; Wang, Lu-Hai; Chen, Wei-Jan; Lin, Kwang-Huei			DOCK6 promotes chemo- and radioresistance of gastric cancer by modulating WNT/beta-catenin signaling and cancer stem cell traits	ONCOGENE			English	Article							BETA-CATENIN; RAC1; EXPRESSION; MIGRATION; CARCINOMA; COMPLEX	Gastric cancer (GC) is the third leading cause of cancer-related mortality worldwide and prognosis after potentially curative gastrectomy remains poor. Administration of GC-targeting molecules in combination with adjuvant chemo- or radiotherapy following surgical resection has been proposed as a potentially effective treatment option. Here, we have identified DOCK6, a guanine nucleotide exchange factor (GEF) for Rac1 and CDC42, as an independent biomarker for GC prognosis. Clinical findings indicate the positive correlation of higher DOCK6 expression with tumor size, depth of invasion, lymph node metastasis, vascular invasion, and pathological stage. Furthermore, elevated DOCK6 expression was significantly associated with shorter cumulative survival in both univariate and multivariate analyses. Gene ontology analysis of three independent clinical GC cohorts revealed significant involvement of DOCK6-correlated genes in the WNT/beta-catenin signaling pathway. Ectopic expression of DOCK6 promoted GC cancer stem cell (CSC) characteristics and chemo- or radioresistance concomitantly through Rac1 activation. Conversely, depletion of DOCK6 suppressed CSC phenotypes and progression of GC, further demonstrating the pivotal role of DOCK6 in GC progression. Our results demonstrate a novel mechanistic link between DOCK6, Rac1, and beta-catenin in GCCSC for the first time, supporting the utility of DOCK6 as an independent marker of GC	[Chi, Hsiang-Cheng] Chang Gung Univ, Chang Gung Mem Hosp, Inst Radiol Res, Radiat Biol Res Ctr, Taoyuan, Taiwan; [Chi, Hsiang-Cheng; Wu, Cheng Heng; Lin, Kwang-Huei] Chang Gung Univ, Dept Biochem, Coll Med, Taoyuan, Taiwan; [Chi, Hsiang-Cheng; Wang, Lu-Hai] China Med Univ, Grad Inst Integrated Med, Taichung, Taiwan; [Tsai, Chung-Ying] Chang Gung Mem Hosp, Dept Nephrol, Kidney Res Ctr, Taoyuan, Taiwan; [Wang, Chia-Siu; Tsai, Ming-Ming; Hsieh, Ching-Chuan] Chang Gung Mem Hosp, Dept Gen Surg, Chiayi, Taiwan; [Yang, Huang-Yu] Chang Gung Univ, Chang Gung Mem Hosp, Coll Med, Kidney Res Inst,Nephrol Dept, Taoyuan, Taiwan; [Yang, Huang-Yu; Chang, Yen-Fang] Chang Gung Univ, Grad Inst Biomed Sci, Coll Med, Taoyuan, Taiwan; [Yang, Huang-Yu] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA; [Lo, Chien-Hui; Wang, Won-Jing] Natl Yang Ming Univ, Inst Biochem & Mol Biol, Coll Life Sci, Taipei, Taiwan; [Lo, Chien-Hui; Wang, Won-Jing] Natl Yang Ming Univ, Taiwan Int Grad Program TIGP Mol Med, Taipei, Taiwan; [Lo, Chien-Hui; Wang, Won-Jing] Acad Sinica, Taipei, Taiwan; [Lee, Kam-Fai] Chang Gung Mem Hosp, Dept Pathol, Chiayi, Taiwan; [Lai, Li-Yin] Natl Taiwan Univ, Dept Microbiol & Internal Med, Taipei, Taiwan; [Hong, Ji-Hong] Chang Gung Mem Hosp Linkou, Inst Radiol Res, Dept Radiat Oncol, Taoyuan, Taiwan; [Tsai, Ming-Ming] Chang Gung Univ Sci & Technol, Dept Nursing, Taoyuan, Taiwan; [Tsai, Ming-Ming; Lin, Kwang-Huei] Chang Gung Univ Sci & Technol, Coll Human Ecol, Res Ctr Chinese Herbal Med, Taoyuan, Taiwan; [Yeh, Chau-Ting; Lin, Kwang-Huei] Chang Gung Mem Hosp, Liver Res Ctr, Taoyuan, Taiwan; [Wang, Lu-Hai] Natl Hlth Res Inst, Inst Mol & Genom Med, Zhunan, Miaoli County, Taiwan; [Chen, Wei-Jan] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Div Cardiol, Taoyuan, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; Chang Gung University; China Medical University Taiwan; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Academia Sinica - Taiwan; Chang Gung Memorial Hospital; National Taiwan University; Chang Gung Memorial Hospital; Chang Gung University of Science & Technology; Chang Gung University of Science & Technology; Chang Gung Memorial Hospital; National Health Research Institutes - Taiwan; Chang Gung Memorial Hospital; Chang Gung University	Lin, KH (corresponding author), Chang Gung Univ, Dept Biochem, Coll Med, Taoyuan, Taiwan.; Wang, LH (corresponding author), China Med Univ, Grad Inst Integrated Med, Taichung, Taiwan.; Lin, KH (corresponding author), Chang Gung Univ Sci & Technol, Coll Human Ecol, Res Ctr Chinese Herbal Med, Taoyuan, Taiwan.; Lin, KH (corresponding author), Chang Gung Mem Hosp, Liver Res Ctr, Taoyuan, Taiwan.; Wang, LH (corresponding author), Natl Hlth Res Inst, Inst Mol & Genom Med, Zhunan, Miaoli County, Taiwan.; Chen, WJ (corresponding author), Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Div Cardiol, Taoyuan, Taiwan.	lu-hai.wang@nhri.org.tw; wjchen@adm.cgmh.org.tw; khlin@mail.cgu.edu.tw	Lai, Li-Yin/ABD-8471-2021	Lai, Li-Yin/0000-0003-0244-6834; Tsai, Chung-Ying/0000-0002-1444-5647; Chi, Hsiang Cheng/0000-0001-5691-2453; Wang, Won-Jing/0000-0001-9733-0839; YANG, HUANG-YU/0000-0001-6826-9717	Chang Gung Memorial Hospital, Taoyuan, Taiwan [CMRPD1H0631-0632, CMRPD1G0421-0423, CMRPD1J0051, NMRPD1G0942, NMRPD1G0951, CMRPG6F0621-0623, NMRPG6G0051]; Ministry of Science and Technology of the Republic of China [MOST 106-2320-B-182-031-MY3, 106-2320-B-182-032-MY3, 106-2314-B-182A-130, MOST 105-2321-B-182 -002-MY3, 107-2320-B-182-025]	Chang Gung Memorial Hospital, Taoyuan, Taiwan(Chang Gung Memorial Hospital); Ministry of Science and Technology of the Republic of China(Ministry of Science and Technology, Taiwan)	This work was supported by grants from Chang Gung Memorial Hospital, Taoyuan, Taiwan (CMRPD1H0631-0632, CMRPD1G0421-0423, CMRPD1J0051, NMRPD1G0942, and NMRPD1G0951 to K-HL; CMRPG6F0621-0623 and NMRPG6G0051 to C-SW) and the Ministry of Science and Technology of the Republic of China (MOST 106-2320-B-182-031-MY3 and 106-2320-B-182-032-MY3 to K-HL, 106-2314-B-182A-130 to C-SW, and MOST 105-2321-B-182 -002-MY3 and 107-2320-B-182-025 to H-CC).	Al-Hajj M, 2007, CURR OPIN ONCOL, V19, P61; Baniak N, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0969-3; Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013; Bravo-Cordero JJ, 2012, CURR OPIN CELL BIOL, V24, P277, DOI 10.1016/j.ceb.2011.12.004; Buongiorno P, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-73; Chahdi A, 2013, J BIOL CHEM, V288, P34019, DOI 10.1074/jbc.M113.480103; Chen G, 2018, BIO-PROTOCOL, V8, DOI 10.21769/BioProtoc.2994; Chen X, 2003, MOL BIOL CELL, V14, P3208, DOI 10.1091/mbc.E02-12-0833; Chi HC, 2017, ONCOGENE, V36, P5274, DOI 10.1038/onc.2017.136; Chi HC, 2016, AUTOPHAGY, V12, P2271, DOI 10.1080/15548627.2016.1230583; Chi HC, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.227; Cho JY, 2011, CLIN CANCER RES, V17, P1850, DOI 10.1158/1078-0432.CCR-10-2180; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; D'Errico M, 2009, EUR J CANCER, V45, P461, DOI 10.1016/j.ejca.2008.10.032; Dalerba P, 2007, ANNU REV MED, V58, P267, DOI 10.1146/annurev.med.58.062105.204854; Debruyne DN, 2018, ONCOGENE, V37, P241, DOI 10.1038/onc.2017.323; Gadea G, 2014, EUR J CELL BIOL, V93, P466, DOI 10.1016/j.ejcb.2014.06.003; Gilles C, 2003, CANCER RES, V63, P2658; Gotoh K, 2008, BLOOD, V111, P2973, DOI 10.1182/blood-2007-09-112169; Han ME, 2011, CELL MOL LIFE SCI, V68, P3589, DOI 10.1007/s00018-011-0672-z; Hoey T, 2009, CELL STEM CELL, V5, P168, DOI 10.1016/j.stem.2009.05.019; Jamieson C, 2015, J CELL SCI, V128, P3933, DOI 10.1242/jcs.167742; Japanese Gastric Cancer Association, 1998, GASTRIC CANCER, V1, P10, DOI [DOI 10.1007/PL00011681, DOI 10.1007/S101209800016]]; Kwon KJ, 2014, GASTRIC CANCER, V17, P43, DOI 10.1007/s10120-013-0234-1; Li XW, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0729-z; Lou H, 2007, ONCOGENE, V26, P1357, DOI 10.1038/sj.onc.1210200; Mao J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.515; McNiven MA, 2004, FRONT BIOSCI-LANDMRK, V9, P1944, DOI 10.2741/1348; Miyamoto Y, 2007, EXP CELL RES, V313, P791, DOI 10.1016/j.yexcr.2006.11.017; Notani D, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000296; O'Dwyer D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027718; Polakis P, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008052; Saegusa M, 2005, LAB INVEST, V85, P768, DOI 10.1038/labinvest.3700273; Schlessinger K, 2009, GENE DEV, V23, P265, DOI 10.1101/gad.1760809; Shaheen R, 2011, AM J HUM GENET, V89, P328, DOI 10.1016/j.ajhg.2011.07.009; Shi Lei, 2013, Commun Integr Biol, V6, pe26839, DOI 10.4161/cib.26839; Stamos JL, 2013, COLD SPRING HARB PER, V5, DOI DOI 10.1101/CSHPERSPECT.A007898; Takaishi S, 2009, STEM CELLS, V27, P1006, DOI 10.1002/stem.30; Tsai CY, 2018, FASEB J, V32, P2601, DOI 10.1096/fj.201700094R; Tsai MM, 2016, EUR J CANCER, V64, P137, DOI 10.1016/j.ejca.2016.05.007; Upadhyay G, 2008, ONCOGENE, V27, P5845, DOI 10.1038/onc.2008.202; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Vojnits K, 2015, SCI REP-UK, V5, DOI 10.1038/srep17355; Wang Q, 2012, MED ONCOL, V29, P77, DOI 10.1007/s12032-010-9766-y; Wu XM, 2008, CELL, V133, P340, DOI 10.1016/j.cell.2008.01.052; Yamauchi J, 2008, J CELL BIOL, V181, P351, DOI 10.1083/jcb.200709033; Yoon CH, 2011, FEBS LETT, V585, P2331, DOI 10.1016/j.febslet.2011.05.070	47	14	14	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2020	39	37					5933	5949		10.1038/s41388-020-01390-0	http://dx.doi.org/10.1038/s41388-020-01390-0		AUG 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NM2OY	32753649				2022-12-28	WOS:000555747100002
J	Qi, L; Wang, ZY; Shao, XR; Li, M; Chen, SN; Liu, XQ; Yan, S; Zhang, B; Zhang, XD; Li, X; Zhao, WX; Pan, JA; Zhao, B; Zhang, XD				Qi, Lin; Wang, Zhong-Yong; Shao, Xin-Rong; Li, Miao; Chen, Shu-Na; Liu, Xue-Qi; Yan, Shi; Zhang, Bo; Zhang, Xu-Dong; Li, Xin; Zhao, Wenxue; Pan, Ji-An; Zhao, Bo; Zhang, Xing-Ding			ISL2 modulates angiogenesis through transcriptional regulation of ANGPT2 to promote cell proliferation and malignant transformation in oligodendroglioma	ONCOGENE			English	Article							GRADE II; RADIOTHERAPY; TEMOZOLOMIDE; PROGRESSION; MECHANISMS; CYTOKINE; SURVIVAL; GLIOMAS; GROWTH; CANCER	Oligodendroglioma is an important type of lower-grade glioma (LGG), which is a slowly progressing brain tumor. Many LGGs eventually transform into a more aggressive or malignant type. Enhanced angiogenesis is a characteristic of malignantly transformed oligodendroglioma (m-oligodendroglioma). However, the pathogenesis and signaling pathways associated with angiogenesis and proliferation in m-oligodendroglioma are not well understood. In this study, we identified that Insulin Gene Enhancer Protein (ISL2) and its angiogenic capacity were inversely related to survival according to LGG patient data from an online database, and this was further confirmed with pathological LGG patient samples, including malignantly transformed samples, by detecting the expression of ISL2, the angiogenic markers vascular endothelial growth factor (VEGFA) and CD31 and the proliferation marker Ki-67. We then established novel oligodendroglioma patient tumor-derived orthotopic xenograft mouse models and cell lines to verify the role of ISL2 in regulating angiogenesis to promote oligodendroglioma growth and malignant transformation. Furthermore, ISL2 regulated ANGPT2 transcription by binding to the ANGPT2 promoter. Then, ANGPT2, a downstream gene, activated angiogenesis through VEGFA to promote oligodendroglioma malignant transformation. Finally, combining AAV-ISL2-shRNA with temozolomide suppressed oligodendroglioma progression more effectively than either monotherapy in vivo and in vitro. Thus, hypoxia-induced ISL2 regulated ANGPT2, which subsequently induced angiogenesis to promote oligodendroglioma growth and malignant transformation. Malignancy was accompanied by worsened hypoxia inside the tumor mass, creating a positive feedback loop. In conclusion, this study suggests that ISL2 is a biomarker for oligodendroglioma progression and that anti-ISL2 therapy may offer a potential clinical strategy for treating m-oligodendroglioma.	[Qi, Lin; Shao, Xin-Rong; Li, Miao; Chen, Shu-Na; Liu, Xue-Qi; Zhang, Xu-Dong; Li, Xin; Zhao, Wenxue; Pan, Ji-An; Zhao, Bo; Zhang, Xing-Ding] Sun Yat Sen Univ, Sch Med, Dept Pharmacol, Mol Canc Res Ctr, Shenzhen, Peoples R China; [Qi, Lin] Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL 60611 USA; [Wang, Zhong-Yong] Soochow Univ, Affiliated Hosp 2, Dept Neurosurg, Suzhou, Peoples R China; [Yan, Shi] Univ Vet Med Vienna, Inst Parasitol, Dept Pathobiol, Vienna, Austria; [Zhang, Bo] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Intervent Radiol, Guangzhou, Peoples R China	Sun Yat Sen University; Northwestern University; Feinberg School of Medicine; Soochow University - China; University of Veterinary Medicine Vienna; Sun Yat Sen University	Qi, L; Zhang, XD (corresponding author), Sun Yat Sen Univ, Sch Med, Dept Pharmacol, Mol Canc Res Ctr, Shenzhen, Peoples R China.; Qi, L (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL 60611 USA.	qilin23@mail.sysu.edu.cn; zhangxd39@mail.sysu.edu.cn	zhang, xu/GRX-9733-2022; zhang, xian/GYA-0290-2022; Zhao, Bo/GVT-7665-2022; Zhang, xiaoyu/GXA-3206-2022; zhang, xu/GYE-3558-2022; Li, Xin/A-4137-2011; Yan, Shi/H-9091-2013	Zhao, Bo/0000-0002-2163-6484; WANG, ZHONGYONG/0000-0003-1131-3849; Li, Xin/0000-0001-8328-4894; Yan, Shi/0000-0003-4949-9140; Liu, Xueqi/0000-0002-8295-032X	National Natural Science Foundation of China [81970191, 31971161, 31971224, 81301978]; Guangdong Natural Science Foundation of China [2018A0303130090, 2019A1515011332]; Youth Medical Doctors Project of Jiangsu Province of China [QNRC2016870]; Fundamental Research Funds for the Central Universities of China [19ykpy149]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Natural Science Foundation of China(National Natural Science Foundation of Guangdong Province); Youth Medical Doctors Project of Jiangsu Province of China; Fundamental Research Funds for the Central Universities of China(Fundamental Research Funds for the Central Universities)	This work was supported in part by the National Natural Science Foundation of China (grant nos. 81970191, 31971161, 31971224, and 81301978), the Guangdong Natural Science Foundation of China (grant nos. 2018A0303130090 and 2019A1515011332), the Youth Medical Doctors Project of Jiangsu Province of China (QNRC2016870), and the Fundamental Research Funds for the Central Universities of China (grant no. 19ykpy149).	Alfonso JCL, 2017, J R SOC INTERFACE, V14, DOI 10.1098/rsif.2017.0490; Bachy I, 2002, NEUROREPORT, V13, pA23, DOI 10.1097/00001756-200202110-00002; Chaudhry IH, 2001, HISTOPATHOLOGY, V39, P409, DOI 10.1046/j.1365-2559.2001.01230.x; Chen Z, 2016, GUT, V65, P925, DOI 10.1136/gutjnl-2014-308416; Chinot OL, 2014, NEW ENGL J MED, V370, P709, DOI 10.1056/NEJMoa1308345; Eckel-Passow JE, 2015, NEW ENGL J MED, V372, P2499, DOI 10.1056/NEJMoa1407279; Edqvist PHD, 2006, EUR J HISTOCHEM, V50, P147; Esencay M, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-347; Feller C, 2020, ACTA NEUROPATHOL, V139, P211, DOI 10.1007/s00401-019-02096-8; Fischer I, 2005, BRAIN PATHOL, V15, P297; Fuchs Q, 2020, CANCERS, V12, DOI 10.3390/cancers12040979; Gagliardi F, 2020, NEUROBIOL DIS, V134, DOI 10.1016/j.nbd.2019.104705; Gill Gordon N, 2003, Trans Am Clin Climatol Assoc, V114, P179; Heindryckx F, 2015, WORLD J HEPATOL, V7, P165, DOI 10.4254/wjh.v7.i2.165; Karamysheva AF, 2008, BIOCHEMISTRY-MOSCOW+, V73, P751, DOI 10.1134/S0006297908070031; Kaur B, 2005, NEURO-ONCOLOGY, V7, P134, DOI 10.1215/S1152851704001115; Kay RB, 2017, FRONT NEURAL CIRCUIT, V11, DOI 10.3389/fncir.2017.00073; Krenzlin H, 2019, J CLIN INVEST, V129, P1671, DOI 10.1172/JCI123375; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Martinez-Gonzalez A, 2016, ADV EXP MED BIOL, V936, P11, DOI 10.1007/978-3-319-42023-3_2; Ohgaki H, 2013, CLIN CANCER RES, V19, P764, DOI 10.1158/1078-0432.CCR-12-3002; Onishi M, 2011, BRAIN TUMOR PATHOL, V28, P13, DOI 10.1007/s10014-010-0007-z; Osterberg N, 2016, NEURO-ONCOLOGY, V18, P939, DOI 10.1093/neuonc/now005; Podbielska M, 2016, J LIPID RES, V57, P2028, DOI 10.1194/jlr.M070664; POST GR, 1992, MOL CHEM NEUROPATHOL, V16, P303, DOI 10.1007/BF03159976; Qi L, 2015, PLOS ONE, V10; Reyes-Botero G, 2018, ONCOLOGIST, V23, P524, DOI 10.1634/theoncologist.2017-0689; Schiffer D, 2018, NEUROL SCI, V39, P1161, DOI 10.1007/s10072-018-3408-0; Scholz A, 2015, ANN NY ACAD SCI, V1347, P45, DOI 10.1111/nyas.12726; Seano G, 2020, ANGIOGENESIS, V23, P9, DOI 10.1007/s10456-019-09691-z; Shim WSN, 2007, MOL CANCER RES, V5, P655, DOI 10.1158/1541-7786.MCR-07-0072; Shirasaki R, 2002, ANNU REV NEUROSCI, V25, P251, DOI 10.1146/annurev.neuro.25.112701.142916; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Suzuki H, 2015, NAT GENET, V47, P458, DOI 10.1038/ng.3273; Swanson KR, 2011, CANCER RES, V71, P7366, DOI 10.1158/0008-5472.CAN-11-1399; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Vallee A, 2018, REV NEUROSCIENCE, V29, P71, DOI 10.1515/revneuro-2017-0032; van den Bent MJ, 2018, LANCET ONCOL, V19, P1170, DOI 10.1016/S1470-2045(18)30362-0; van den Bent MJ, 2018, NEUROL CLIN, V36, P467, DOI 10.1016/j.ncl.2018.04.005; Wang ML, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0533-1; Wang X, 2014, ONCOL REP, V31, P1975, DOI 10.3892/or.2014.3112; Weller M, 2017, LANCET ONCOL, V18, pE315, DOI 10.1016/S1470-2045(17)30194-8; Weller M, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.17; Wesseling P, 2015, ACTA NEUROPATHOL, V129, P809, DOI 10.1007/s00401-015-1424-1; Yazdani Yasaman, 2016, Asian Pac J Cancer Prev, V17, P5303; Zhang XD, 2016, CANCER CELL, V29, P639, DOI 10.1016/j.ccell.2016.03.026	46	9	9	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2020	39	37					5964	5978		10.1038/s41388-020-01411-y	http://dx.doi.org/10.1038/s41388-020-01411-y		AUG 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NM2OY	32753650				2022-12-28	WOS:000555747100004
J	Guterres, AN; Villanueva, J				Guterres, Adam N.; Villanueva, Jessie			Targeting telomerase for cancer therapy	ONCOGENE			English	Review							TERT PROMOTER MUTATIONS; REVERSE-TRANSCRIPTASE; INHIBITOR IMETELSTAT; PEPTIDE VACCINE; BETA-1L ISOFORM; LUNG-CANCER; IN-VIVO; RECRUITMENT; LENGTH; CELLS	Telomere maintenance via telomerase reactivation is a nearly universal hallmark of cancer cells which enables replicative immortality. In contrast, telomerase activity is silenced in most adult somatic cells. Thus, telomerase represents an attractive target for highly selective cancer therapeutics. However, development of telomerase inhibitors has been challenging and thus far there are no clinically approved strategies exploiting this cancer target. The discovery of prevalent mutations in theTERTpromoter region in many cancers and recent advances in telomerase biology has led to a renewed interest in targeting this enzyme. Here we discuss recent efforts targeting telomerase, including immunotherapies and direct telomerase inhibitors, as well as emerging approaches such as targetingTERTgene expression driven byTERTpromoter mutations. We also address some of the challenges to telomerase-directed therapies including potential therapeutic resistance and considerations for future therapeutic applications and translation into the clinical setting. Although much work remains to be done, effective strategies targeting telomerase will have a transformative impact for cancer therapy and the prospect of clinically effective drugs is boosted by recent advances in structural models of human telomerase.	[Guterres, Adam N.; Villanueva, Jessie] Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, 3601 Spruce St, Philadelphia, PA 19104 USA; [Villanueva, Jessie] Wistar Inst Anat & Biol, Melanoma Res Ctr, 3601 Spruce St, Philadelphia, PA 19104 USA	The Wistar Institute; The Wistar Institute	Villanueva, J (corresponding author), Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, 3601 Spruce St, Philadelphia, PA 19104 USA.; Villanueva, J (corresponding author), Wistar Inst Anat & Biol, Melanoma Res Ctr, 3601 Spruce St, Philadelphia, PA 19104 USA.	jvillanueva@wistar.org			NIH [R01CA215733, R01CA226888, P01CA114046, P50CA174523, P30CA010815]; Department of Defense Melanoma Research Program [W81XWH-20-1-0356]; PA Department of Health; Martha W. Rogers Trust	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense Melanoma Research Program; PA Department of Health; Martha W. Rogers Trust	L Work in our laboratory is supported by NIH grants R01CA215733, R01CA226888, P01CA114046, P50CA174523, P30CA010815, the Department of Defense Melanoma Research Program (W81XWH-20-1-0356), the PA Department of Health and Martha W. Rogers Trust.	Akincilar SC, 2016, CANCER DISCOV, V6, P1276, DOI 10.1158/2159-8290.CD-16-0177; Armanios M, 2015, NEW ENGL J MED, V373, P965, DOI 10.1056/NEJMe1508740; Asai A, 2003, CANCER RES, V63, P3931; Atkinson SP, 2005, CANCER RES, V65, P7585, DOI 10.1158/0008-5472.CAN-05-1715; Aviv A, 2017, TRENDS CANCER, V3, P253, DOI 10.1016/j.trecan.2017.02.005; Baell JB, 2016, J NAT PROD, V79, P616, DOI 10.1021/acs.jnatprod.5b00947; Baena-Del Valle JA, 2018, J PATHOL, V244, P11, DOI 10.1002/path.4980; Baerlocher GM, 2015, NEW ENGL J MED, V373, P920, DOI 10.1056/NEJMoa1503479; Bandaria JN, 2016, CELL, V164, P735, DOI 10.1016/j.cell.2016.01.036; Barthel FP, 2017, NAT GENET, V49, P349, DOI 10.1038/ng.3781; Bejarano L, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201910292; Bell RJA, 2015, SCIENCE, V348, P1036, DOI 10.1126/science.aab0015; Biffi G, 2013, NAT CHEM, V5, P182, DOI [10.1038/NCHEM.1548, 10.1038/nchem.1548]; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bryan C, 2015, STRUCTURE, V23, P1934, DOI 10.1016/j.str.2015.08.006; Bullock M, 2019, THYROID, V29, P1623, DOI 10.1089/thy.2018.0314; Cao Y, 2008, CANCER SCI, V99, P1092, DOI 10.1111/j.1349-7006.2008.00815.x; Chen L, 2018, CELL, V174, P218, DOI 10.1016/j.cell.2018.04.039; Chiappori AA, 2015, ANN ONCOL, V26, P354, DOI 10.1093/annonc/mdu550; Chiba K, 2017, SCIENCE, V357, P1416, DOI 10.1126/science.aao0535; Chiba K, 2015, ELIFE, V4, DOI 10.7554/eLife.07918; Cong YS, 2000, J BIOL CHEM, V275, P35665, DOI 10.1074/jbc.C000637200; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; Dilley RL, 2015, TRENDS CANCER, V1, P145, DOI 10.1016/j.trecan.2015.07.007; Drosopoulos WC, 2015, J CELL BIOL, V210, P191, DOI 10.1083/jcb.201410061; Duperret EK, 2018, MOL THER, V26, P435, DOI 10.1016/j.ymthe.2017.11.010; El-Daly H, 2005, BLOOD, V105, P1742, DOI 10.1182/blood-2003-12-4322; Gabler L, 2019, ACTA NEUROPATHOL COM, V7, DOI 10.1186/s40478-019-0775-6; Garcia-Beccaria M, 2015, EMBO MOL MED, V7, P930, DOI 10.15252/emmm.201404497; Gillis AJ, 2008, NATURE, V455, P633, DOI 10.1038/nature07283; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Griewank KG, 2014, JNCI-J NATL CANCER I, V106, P949; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hackett JA, 2003, MOL CELL BIOL, V23, P8450, DOI 10.1128/MCB.23.23.8450-8461.2003; Haycock PC, 2017, JAMA ONCOL, V3, P636, DOI 10.1001/jamaoncol.2016.5945; Hayward NK, 2017, NATURE, V545, P175, DOI 10.1038/nature22071; Heaphy CM, 2011, AM J PATHOL, V179, P1608, DOI 10.1016/j.ajpath.2011.06.018; Hemann MT, 2000, NUCLEIC ACIDS RES, V28, P4474, DOI 10.1093/nar/28.22.4474; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; Henson JD, 2005, CLIN CANCER RES, V11, P217; Hu J, 2012, CELL, V148, P651, DOI 10.1016/j.cell.2011.12.028; Huang FW, 2013, SCIENCE, V339, P957, DOI 10.1126/science.1229259; Huppert JL, 2005, NUCLEIC ACIDS RES, V33, P2908, DOI 10.1093/nar/gki609; Jacobs JJL, 2004, CURR BIOL, V14, P2302, DOI 10.1016/j.cub.2004.12.025; Jiang JS, 2018, CELL, V173, P1179, DOI 10.1016/j.cell.2018.04.038; Kanaya N, 2018, CANCER RES, V78, DOI 10.1158/1538-7445.AM2018-2744; Kawashima T, 2004, CLIN CANCER RES, V10, P285, DOI 10.1158/1078-0432.CCR-1075-3; Killela PJ, 2013, P NATL ACAD SCI USA, V110, P6021, DOI 10.1073/pnas.1303607110; Kim NW, 1994, SCIENCE, P266; Kim W, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.2000016; Kinde I, 2013, CANCER RES, V73, P7162, DOI 10.1158/0008-5472.CAN-13-2498; Koh CM, 2015, J CLIN INVEST, V125, P2109, DOI 10.1172/JCI79134; Labussiere M, 2014, NEUROLOGY, V83, P1200, DOI 10.1212/WNL.0000000000000814; Lai TP, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01291-z; Lee DD, 2019, J CLIN INVEST, V129, P223, DOI 10.1172/JCI121303; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; Li YH, 2016, P NATL ACAD SCI USA, V113, P14402, DOI 10.1073/pnas.1611106113; Li YH, 2015, NAT CELL BIOL, V17, P1327, DOI 10.1038/ncb3240; Lilleby W, 2017, CANCER IMMUNOL IMMUN, V66, P891, DOI 10.1007/s00262-017-1994-y; Liu RY, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03033-1; Liu W, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04254-0; Ludlow AT, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05582-x; Makowski MM, 2016, PROTEOMICS, V16, P417, DOI 10.1002/pmic.201500327; Mancini A, 2018, CANCER CELL, V34, P513, DOI 10.1016/j.ccell.2018.08.003; Masutomi K, 2005, P NATL ACAD SCI USA, V102, P8222, DOI 10.1073/pnas.0503095102; McKerlie M, 2012, NUCLEIC ACIDS RES, V40, P3975, DOI 10.1093/nar/gks035; Mender I, 2018, NEOPLASIA, V20, P826, DOI 10.1016/j.neo.2018.06.002; Mender I, 2015, CANCER DISCOV, V5, P82, DOI 10.1158/2159-8290.CD-14-0609; Middleton G, 2014, LANCET ONCOL, V15, P829, DOI 10.1016/S1470-2045(14)70236-0; Min J, 2017, NUCLEIC ACIDS RES, V45, P2615, DOI 10.1093/nar/gkw1295; Mitchell TJ, 2018, CELL, V173, P611, DOI 10.1016/j.cell.2018.02.020; Morrison SJ, 1996, IMMUNITY, V5, P207, DOI 10.1016/S1074-7613(00)80316-7; Moye AL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8643; Mukherjee J, 2018, CANCER RES, V78, P2966, DOI 10.1158/0008-5472.CAN-17-2269; Nakashima M, 2013, J BIOL CHEM, V288, P33171, DOI 10.1074/jbc.M113.518175; Nandakumar J, 2012, NATURE, V492, P285, DOI 10.1038/nature11648; Napier CE, 2015, ONCOTARGET, V6, P16543, DOI 10.18632/oncotarget.3846; Nault JC, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3218; Nemunaitis J, 2010, MOL THER, V18, P429, DOI 10.1038/mt.2009.262; Nitta E, 2011, BLOOD, V117, P4169, DOI 10.1182/blood-2010-08-297390; Notaro R, 1997, P NATL ACAD SCI USA, V94, P13782, DOI 10.1073/pnas.94.25.13782; O'Sullivan RJ, 2014, NAT STRUCT MOL BIOL, V21, P167, DOI 10.1038/nsmb.2754; Oh S, 2000, ONCOGENE, V19, P1485, DOI 10.1038/sj.onc.1203439; Ouellette MM, 2000, J BIOL CHEM, V275, P10072, DOI 10.1074/jbc.275.14.10072; Perera ON, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav4409; Peto R, 2016, INT J EPIDEMIOL, V45, P621, DOI 10.1093/ije/dyv199; Ramamoorthy M, 2015, CANCER CELL, V28, P357, DOI 10.1016/j.ccell.2015.08.003; Raval A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131722; Reyes-Uribe P, 2018, ONCOGENE, V37, P4058, DOI 10.1038/s41388-018-0247-7; Ristevski S, 2004, MOL CELL BIOL, V24, P5844, DOI 10.1128/MCB.24.13.5844-5849.2004; Sahm F, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv377; Sandri S, 2016, CANCER RES, V76, P2540, DOI 10.1158/0008-5472.CAN-15-2318; Sauerwald A, 2013, NAT STRUCT MOL BIOL, V20, P454, DOI 10.1038/nsmb.2530; Sayed ME, 2019, ONCOGENE, V38, P2937, DOI 10.1038/s41388-018-0639-8; Schmidt JC, 2015, GENE DEV, V29, P1095, DOI 10.1101/gad.263863.115; Seidel JA, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00086; Sengupta S, 2018, MOL CANCER THER, V17, P1504, DOI 10.1158/1535-7163.MCT-17-0792; Shain AH, 2015, NEW ENGL J MED, V373, P1926, DOI 10.1056/NEJMoa1502583; Shain AH, 2018, CANCER CELL, V34, pe4; Song YS, 2019, ENDOCR-RELAT CANCER, V26, P629, DOI 10.1530/ERC-17-0562; Spahr H, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04388-1; Spiegl-Kreinecker S, 2018, NEURO-ONCOLOGY, V20, P1584, DOI 10.1093/neuonc/noy104; Stern JL, 2012, MOL CELL BIOL, V32, P2384, DOI 10.1128/MCB.00379-12; Stern JL, 2015, GENE DEV, V29, P2219, DOI 10.1101/gad.269498.115; Sun CK, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-180; Tauchi T, 2006, ONCOGENE, V25, P5719, DOI 10.1038/sj.onc.1209577; Tefferi A, 2015, NEW ENGL J MED, V373, P908, DOI 10.1056/NEJMoa1310523; Nguyen THD, 2018, NATURE, V557, P190, DOI 10.1038/s41586-018-0062-x; Thompson PA, 2013, CLIN CANCER RES, V19, P6578, DOI 10.1158/1078-0432.CCR-13-1117; Tong AS, 2015, CELL REP, V13, P1633, DOI 10.1016/j.celrep.2015.10.041; Ugel S, 2010, BLOOD, V115, P1374, DOI 10.1182/blood-2009-07-233270; Vallarelli AF, 2016, ONCOTARGET, V7, P53127, DOI 10.18632/oncotarget.10634; Venteicher AS, 2009, SCIENCE, V323, P644, DOI 10.1126/science.1165357; Vinagre J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3185; Vonderheide RH, 2002, ONCOGENE, V21, P674, DOI 10.1038/sj.onc.1205074; Weinhold N, 2014, NAT GENET, V46, P1160, DOI 10.1038/ng.3101; Xue HH, 2008, MOL CELL BIOL, V28, P4300, DOI 10.1128/MCB.01855-07; Yamaguchi H, 2005, NEW ENGL J MED, V352, P1413, DOI 10.1056/NEJMoa042980; Yuan XT, 2019, ONCOGENE, V38, P965, DOI 10.1038/s41388-018-0483-x; Zanetti M, 2017, NAT REV CLIN ONCOL, V14, P115, DOI 10.1038/nrclinonc.2016.67; Zeng XH, 2018, CELL REP, V23, P3031, DOI 10.1016/j.celrep.2018.05.020; Zhang CA, 2015, HUM MOL GENET, V24, P5356, DOI 10.1093/hmg/ddv252; Zhang G, 2018, CLIN CANCER RES, V24, P4771, DOI 10.1158/1078-0432.CCR-17-2773; Zhu X, 2016, SCI REP, V6, P518	127	51	51	12	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2020	39	36					5811	5824		10.1038/s41388-020-01405-w	http://dx.doi.org/10.1038/s41388-020-01405-w		JUL 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NJ1HO	32733068	Green Accepted			2022-12-28	WOS:000557084000002
J	Wang, YC; Liu, YN; Deng, WF; Fu, FX; Yan, SS; Yang, HW; Liu, RM; Geng, J; Xu, J; Wu, YH; Ma, JF; Zhou, JP; Liu, N; Jin, Y; Xia, RF; Elias, N; Lee, RJ; Feldman, AS; Blute, ML; Colvin, RB; Wu, CL; Miao, Y				Wang, Yuchen; Liu, Yanna; Deng, Wenfeng; Fu, Fangxiang; Yan, Susha; Yang, Hongwei; Liu, Rumin; Geng, Jian; Xu, Jian; Wu, Yihan; Ma, Junfeng; Zhou, Jiapeng; Liu, Na; Jin, Yu; Xia, Renfei; Elias, Nahel; Lee, Richard J.; Feldman, Adam S.; Blute, Michael L.; Colvin, Robert B.; Wu, Chin-Lee; Miao, Yun			Viral integration in BK polyomavirus-associated urothelial carcinoma in renal transplant recipients: multistage carcinogenesis revealed by next-generation virome capture sequencing	ONCOGENE			English	Article							CANCER; VIRUS; GENOME; END	BK polyomavirus (BKPyV)-associated cancer after transplantation has gained increasing attention. However, the role of BKPyV integration on oncogenesis is still unclear. In this study, next-generation virome capture sequencing of primary and metastatic tumors were performed in three patients with BKPyV-associated urothelial carcinoma after renal transplantation. As a result, a total of 332 viral integration sites were identified in the six tumors. Integration of BKPyV in both primary and metastatic tumors followed the mechanism of microhomology-mediated end joining mostly, since microhomologies between human and BKPyV genomes were significantly enriched in flanking regions of 84% of the integration sites. Viral DNA breakpoints were nonrandom and tended to assemble in large T gene, small T gene and viral protein 2 gene. There were three, one and one consensus integration sites between the primary and metastatic tumors, which affectedLINC01924,eIF3c, andNEIL2genes in the three cases respectively. Thus, we concluded that integration of BKPyV was a continuous process occurring in both primary and metastatic tumors, generating heterogenous tumor cell populations. Through this ongoing process, certain cell populations might have gained growth advantage or metastatic potential, as a result of viral integration either affecting the cellular genes where the viral DNA integrated to or altering the expression or function of the viral genes.	[Wang, Yuchen; Liu, Yanna; Deng, Wenfeng; Fu, Fangxiang; Yan, Susha; Yang, Hongwei; Liu, Rumin; Xu, Jian; Wu, Yihan; Jin, Yu; Xia, Renfei; Miao, Yun] Southern Med Univ, Nanfang Hosp, Dept Organ Transplantat, Guangzhou, Peoples R China; [Geng, Jian] Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou, Peoples R China; [Ma, Junfeng; Zhou, Jiapeng; Liu, Na] Mygenostics Co, Beijing, Peoples R China; [Elias, Nahel] Harvard Med Sch, Massachusetts Gen Hosp, Dept Surg, Boston, MA 02115 USA; [Lee, Richard J.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Boston, MA 02115 USA; [Feldman, Adam S.; Blute, Michael L.; Wu, Chin-Lee] Harvard Med Sch, Massachusetts Gen Hosp, Dept Urol, Boston, MA 02115 USA; [Colvin, Robert B.; Wu, Chin-Lee] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02115 USA	Southern Medical University - China; Southern Medical University - China; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Miao, Y (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Organ Transplantat, Guangzhou, Peoples R China.; Wu, CL (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Urol, Boston, MA 02115 USA.; Wu, CL (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02115 USA.	cwu2@mgh.harvard.edu; miaoyunecho@126.com		Elias, Nahel/0000-0001-6466-7347	Natural Science Foundation of Guangdong Province [2020A1515010674]; National Natural Science Foundation of China [81500573]; Science and Technology Planning Project of Guangzhou [201803010109]; President Funding of Nanfang Hospital [2018B009, 2018C003]	Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Planning Project of Guangzhou; President Funding of Nanfang Hospital	The work was funded by Natural Science Foundation of Guangdong Province [grant number 2020A1515010674], National Natural Science Foundation of China [grant number 81500573], Science and Technology Planning Project of Guangzhou [grant number 201803010109] and President Funding of Nanfang Hospital [grant number 2018B009, 2018C003]. And we thanked Dr. Min-Hua Luo (Wuhan Institute of Virology, Wuhan, China) for her assisstant in the study design and critical revision of the manuscript.	Anzivino E, 2016, CANCER GENOM PROTEOM, V13, P499, DOI 10.21873/cgp.20013; Borchert S, 2014, J VIROL, V88, P3144, DOI 10.1128/JVI.02916-13; BRUGGE JS, 1975, J VIROL, V15, P619, DOI 10.1128/JVI.15.3.619-635.1975; CICALA C, 1993, AM J PATHOL, V142, P1524; Delbue Serena, 2014, Oncoscience, V1, P296; Egli A, 2009, J INFECT DIS, V199, P837, DOI 10.1086/597126; Ferber MJ, 2003, ONCOGENE, V22, P7233, DOI 10.1038/sj.onc.1207006; Fu FX, 2018, CLIN SCI, V132, P1753, DOI 10.1042/CS20180443; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Houben R, 2013, J INVEST DERMATOL, V133, P2453, DOI 10.1038/jid.2013.169; Hu JX, 2019, CANCER INVEST, V37, P199, DOI 10.1080/07357907.2019.1618322; Javorka P, 2019, PLANT DIRECT, V3, DOI 10.1002/pld3.146; Jin Y, 2019, AM J TRANSPLANT, V19, P1158; Kenan DJ, 2017, AM J TRANSPLANT, V17, P1674, DOI 10.1111/ajt.14191; Kenan DJ, 2015, J PATHOL, V237, P379, DOI 10.1002/path.4584; Knowles WA, 2003, J MED VIROL, V71, P115, DOI 10.1002/jmv.10450; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; LI J, 1993, J MED VIROL, V41, P11, DOI 10.1002/jmv.1890410104; Masutani M, 2007, EMBO J, V26, P3373, DOI 10.1038/sj.emboj.7601765; Merid SK, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-308; Moens U, 2005, VIROLOGY, V331, P209, DOI 10.1016/j.virol.2004.10.021; Mouw KW, 2017, CANCER DISCOV, V7, P675, DOI 10.1158/2159-8290.CD-17-0226; Muller DC, 2018, J PATHOL, V244, P265, DOI 10.1002/path.5012; Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865; Schwarz A, 2012, TRANSPLANTATION, V94, P396, DOI 10.1097/TP.0b013e31825a505d; Starrett GJ, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-00727-4; Starrett GJ, 2019, CURR OPIN VIROL, V39, P8, DOI 10.1016/j.coviro.2019.06.009; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Wei H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038533; Zeitouni B, 2010, BIOINFORMATICS, V26, P1895, DOI 10.1093/bioinformatics/btq293; Zhao LH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12992	31	7	8	3	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2020	39	35					5734	5742		10.1038/s41388-020-01398-6	http://dx.doi.org/10.1038/s41388-020-01398-6		JUL 2020	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NF2QB	32724161				2022-12-28	WOS:000553333400003
J	Liu, Y; Zhang, YY; Wang, SQ; Li, M; Long, YH; Li, YF; Liu, YK; Li, YH; Wang, YQ; Mi, JS; Yu, CH; Li, DY; Zhang, JH; Zhang, XJ				Liu, Yan; Zhang, Yuan-Yue; Wang, Shu-Qing; Li, Min; Long, Yue-Hong; Li, Yu-Feng; Liu, Yan-Kun; Li, Yu-Hui; Wang, Ya-Qi; Mi, Jiang-Sheng; Yu, Cheng-Hua; Li, De-Yan; Zhang, Jing-Hua; Zhang, Xiao-Jun			WSTF acetylation by MOF promotes WSTF activities and oncogenic functions	ONCOGENE			English	Article							SYNDROME TRANSCRIPTION FACTOR; HISTONE H3; CANCER CELLS; TARGETS; PROTEIN; COMPLEXES	Williams syndrome transcription factor (WSTF) is a transcription factor and tyrosine kinase. WSTF overexpression promotes migration and proliferation of various cancers, and Ser158 (WSTFS158) phosphorylation plays an important role in this process. However, the role of the other posttranslational modifications of WSTF is unknown. Here, we report that lysine (K) 426 on WSTF is acetylated by MOF and deacetylated by SIRT1. Mechanistically, male-specific lethal (MSL) 1v1 interaction with WSTF facilitates its interaction with MOF for WSTF acetylation, which in turn promotes WSTF(S158)phosphorylation. The kinase and transcriptional regulatory activity of WSTF were enhanced by acetylation. WSTF(K426ac)levels positively and significantly correlated with tumor size, histological grade, and age. Moreover, we demonstrated that acetylated WSTF promotes cancer cell proliferation, migration, invasion, and tumor formation. In conclusion, we identified the enzymes regulating WSTF K426 acetylation, and demonstrated an acetylation-dependent mechanism that modulates the activities of WSTF and contributes to tumorigenesis. Our findings provide new clues to study WSTF-mediated normal development and disease.	[Liu, Yan; Zhang, Yuan-Yue; Long, Yue-Hong] North China Univ Sci & Technol, Coll Life Sci, Tangshan, Peoples R China; [Liu, Yan; Zhang, Yuan-Yue; Li, Yu-Feng; Liu, Yan-Kun; Wang, Ya-Qi; Zhang, Jing-Hua] North China Univ Sci & Technol, Affiliated Tangshan Peoples Hosp, Canc Inst, Tangshan, Peoples R China; [Zhang, Yuan-Yue] North China Univ Sci & Technol, Grad Sch, Tangshan, Peoples R China; [Wang, Shu-Qing] Hosp North China Univ Sci & Technol, Tangshan, Peoples R China; [Li, Min] North China Univ Sci & Technol, Affiliated Hosp, Orthopaed Surg, Tangshan, Peoples R China; [Li, Yu-Hui] North China Univ Sci & Technol, Affiliated Tangshan Peoples Hosp, Neurosurg, Tangshan, Peoples R China; [Mi, Jiang-Sheng; Yu, Cheng-Hua; Li, De-Yan; Zhang, Xiao-Jun] Zunhua Peoples Hosp, Zunhua, Peoples R China	North China University of Science & Technology; North China University of Science & Technology; North China University of Science & Technology; North China University of Science & Technology; North China University of Science & Technology	Li, YF; Zhang, JH (corresponding author), North China Univ Sci & Technol, Affiliated Tangshan Peoples Hosp, Canc Inst, Tangshan, Peoples R China.; Zhang, XJ (corresponding author), Zunhua Peoples Hosp, Zunhua, Peoples R China.	yfli_renmin@qq.com; jhzhang_te@163.com; tech_ol@foxmail.com	zhang, jin/GXV-9154-2022; Li, yu/HHZ-5236-2022		National Natural Science Foundation of China [81772834]; Natural Science Foundation of Hebei Province [H2019105034]; Science Fund for Distinguished Young Scholars of North China University of Science and Technology [JQ201704]; Doctoral Research Project of North China University of Science and Technology; Program for Innovation Research Team (in Science and Technology) of Tangshan [17130205D]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Hebei Province(Natural Science Foundation of Hebei Province); Science Fund for Distinguished Young Scholars of North China University of Science and Technology; Doctoral Research Project of North China University of Science and Technology; Program for Innovation Research Team (in Science and Technology) of Tangshan	This work was supported by the National Natural Science Foundation of China (grant number 81772834); Natural Science Foundation of Hebei Province (grant number H2019105034); Science Fund for Distinguished Young Scholars of North China University of Science and Technology (JQ201704); Doctoral Research Project of North China University of Science and Technology; the Program for Innovation Research Team (in Science and Technology) of Tangshan (17130205D).	Barnett C, 2011, BIOCHEM CELL BIOL, V89, P12, DOI 10.1139/O10-114; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; Cook PJ, 2009, NATURE, V458, P591, DOI 10.1038/nature07849; Das C, 2009, NATURE, V459, P113, DOI 10.1038/nature07861; Guo JP, 2019, NAT CELL BIOL, V21, P226, DOI 10.1038/s41556-018-0261-6; Kahali B, 2014, ONCOGENE, V33, P653, DOI 10.1038/onc.2012.613; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Li XZ, 2009, MOL CELL, V36, P290, DOI 10.1016/j.molcel.2009.07.031; Liu Y, 2019, ONCOGENE, V38, P980, DOI 10.1038/s41388-018-0466-y; Liu Y, 2016, ONCOTARGET, V7, P53153, DOI 10.18632/oncotarget.10625; Liu Y, 2014, FEBS J, V281, P3315, DOI 10.1111/febs.12863; Liu Y, 2013, FEBS LETT, V587, P847, DOI 10.1016/j.febslet.2013.02.023; Liu Y, 2012, J BIOL CHEM, V287, P41469, DOI 10.1074/jbc.M112.367847; Lundqvist J, 2018, J STEROID BIOCHEM, V177, P171, DOI 10.1016/j.jsbmb.2017.06.003; Meng J, 2016, CELL SIGNAL, V28, P1673, DOI 10.1016/j.cellsig.2016.07.008; Pfister S, 2008, INT J CANCER, V122, P1207, DOI 10.1002/ijc.23283; Su JM, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010099; Wan JH, 2016, NUCLEIC ACIDS RES, V44, P10662, DOI 10.1093/nar/gkw808; Wang YQ, 2016, INT J CLIN EXP PATHO, V9, P1668; Xiao A, 2009, NATURE, V457, P57, DOI 10.1038/nature07668; Yang XJ, 2004, NUCLEIC ACIDS RES, V32, P959, DOI 10.1093/nar/gkh252	21	7	7	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 2	2020	39	27					5056	5067		10.1038/s41388-020-1350-0	http://dx.doi.org/10.1038/s41388-020-1350-0		JUN 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ME5NL	32518374				2022-12-28	WOS:000539201700001
J	Tsai, CN; Yu, SC; Lee, CW; Pang, JHS; Wu, CH; Lin, SE; Chung, YH; Tsai, CL; Hsieh, SY; Yu, MC				Tsai, Chi-Neu; Yu, Shu-Chuan; Lee, Chao-Wei; Pang, Jong-Hwei Su; Wu, Chun-Hsin; Lin, Sey-En; Chung, Yi-Hsiu; Tsai, Chia-Lung; Hsieh, Sen-Yung; Yu, Ming-Chin			SOX4 activates CXCL12 in hepatocellular carcinoma cells to modulate endothelial cell migration and angiogenesis in vivo	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; EXPRESSION; HCC; CXCR4; LIVER; GENE; METASTASIS; MANAGEMENT; CHEMOKINES; SORAFENIB	The overexpression of SOX4 in various kinds of cancer cells was associated with poor prognosis for patients. The role of SOX4 in angiogenesis and tumor microenvironment modulation was recently documented in breast cancer but remains unclear in hepatocellular carcinoma (HCC). In our study, the clinical relevance of SOX4 overexpression in HCC and its role in the tumor microenvironment were investigated. The overexpression of SOX4 (SOX4(high)) in tumor lesions was associated with higher microvessel density (P = 0.012), tumor thrombosis formation (P = 0.012), distant metastasis (P < 0.001), and an independent prognostic factor for disease-free survival in HCC patients (P = 0.048). Endogenous SOX4 knockout in Hep3B cells by the CRISPR/cas9 system reduced the expression of CXCL12, which, in turn, attenuated chemotaxis in human umbilical vein endothelial cells, tube formation in vitro, reduced tumor growth, reticular fiber production, and angiogenesis in vivo in a xenograft mouse model. Treatment with an antagonist targeting CXCR4 (AMD3100), a receptor of CXCL12, inhibited chemotaxis and tube formation in endothelial cells in vitro. The CXCL12 promoter was activated by ectopic expression of a Flag-tagged SOX4 plasmid, endogenous SOX4 knockdown abolished promoter activity of CXCL12 as shown by luciferase assays, and an association with the CXCL12 promoter was identified via chromatin immunoprecipitation in HCC cells. In conclusion, SOX4 modulates the CXCL12 promoter in HCC cells. The secretory CXCL12, in turn, modulates CXCR4 in endothelial cells, reticular fibers to regulate the tumor microenvironment and modulate neovascularization, which might contribute to the distant metastasis of tumors.	[Tsai, Chi-Neu; Lee, Chao-Wei; Pang, Jong-Hwei Su] Chang Gung Univ, Grad Inst Clin Med Sci, Taoyuan 33302, Taiwan; [Tsai, Chi-Neu; Yu, Shu-Chuan; Lee, Chao-Wei; Wu, Chun-Hsin; Yu, Ming-Chin] Chang Gung Mem Hosp, Dept Surg, Linkou Branch, Taoyuan 33305, Taiwan; [Lin, Sey-En] Wan Fang Hosp, Dept Pathol, Taipei 11696, Taiwan; [Lin, Sey-En] Taipei Med Univ, Coll Med, Sch Med, Dept Pathol, Taipei 11031, Taiwan; [Chung, Yi-Hsiu] Chang Gung Mem Hosp, Ctr Adv Mol Imaging & Translat CAMIT, Taoyuan 33305, Taiwan; [Tsai, Chia-Lung] Chang Gung Mem Hosp, Linkou Branch, Genom Med Core Lab, Taoyuan 33305, Taiwan; [Hsieh, Sen-Yung] Chang Gung Mem Hosp, Dept Gastroenterol & Hepatol, Linkou Branch, Taoyuan 33305, Taiwan; [Yu, Ming-Chin] Xiamen Chang Gung Hosp, Dept Surg, Xiamen 361028, Peoples R China	Chang Gung University; Chang Gung Memorial Hospital; Taipei Municipal WanFang Hospital; Taipei Medical University; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital	Yu, MC (corresponding author), Chang Gung Mem Hosp, Dept Surg, Linkou Branch, Taoyuan 33305, Taiwan.; Yu, MC (corresponding author), Xiamen Chang Gung Hosp, Dept Surg, Xiamen 361028, Peoples R China.	mingchin2000@gmail.com	Tsai, Chi-Neu/AAZ-2558-2020; Tsai, Chi neu/C-3373-2011; Yu, Ming-Chin/D-4464-2018	Tsai, Chi-Neu/0000-0002-5940-0696; Tsai, Chi neu/0000-0002-5940-0696; Lin, Sey-En/0000-0002-8994-9452; Yu, Ming-Chin/0000-0002-6980-7123	Chang Gung Medical Foundation in Taiwan [CMRPD1G0611, CMRPD1H0661, CORPG1G0021, CMRPG1J0061]; Ministry of Science and Technology [MOST 103-2314-B-182A-082-MY1-3, MOST 106-2314-B-182A-113]	Chang Gung Medical Foundation in Taiwan; Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea)	Financial support by Chang Gung Medical Foundation in Taiwan: CMRPD1G0611 and CMRPD1H0661 for Dr CN Tsai, CORPG1G0021 and CMRPG1J0061 for Dr MC Yu and Ministry of Science and Technology: MOST 103-2314-B-182A-082-MY1-3 and MOST 106-2314-B-182A-113 for Dr MC Yu.	Boogerd CJJ, 2011, CELL MOL LIFE SCI, V68, P3949, DOI 10.1007/s00018-011-0693-7; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7; Cheung M, 2000, MOL BRAIN RES, V79, P180, DOI 10.1016/S0169-328X(00)00109-1; Choi C, 2014, LIVER CANCER, V3, P405, DOI 10.1159/000343861; Chun YS, 2018, ANN SURG ONCOL, V25, P845, DOI 10.1245/s10434-017-6025-x; Chung YH, 2017, MOLECULES, V22, DOI 10.3390/molecules22111946; Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143; Dong YY, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0795-5; Fang CL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052804; Fang JH, 2019, HEPATOLOGY, V70, P824, DOI 10.1002/hep.30366; Fong ZV, 2014, CANCER-AM CANCER SOC, V120, P2824, DOI 10.1002/cncr.28730; Foronda M, 2014, CELL REP, V8, P486, DOI 10.1016/j.celrep.2014.06.031; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Ghanem I, 2014, AM J TRANSL RES, V6, P340; Gores GJ, 2014, NAT REV GASTRO HEPAT, V11, P645, DOI 10.1038/nrgastro.2014.157; Griffith JW, 2014, ANNU REV IMMUNOL, V32, P659, DOI 10.1146/annurev-immunol-032713-120145; Guo F, 2016, ONCOGENE, V35, P816, DOI 10.1038/onc.2015.139; Hanley KL, 2015, HEPATOLOGY, V62, P343, DOI 10.1002/hep.27860; Hasegawa S, 2016, INT J ONCOL, V48, P145, DOI 10.3892/ijo.2015.3258; Huang DW, 2007, NUCLEIC ACIDS RES, V35, pW169, DOI 10.1093/nar/gkm415; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Inoue H, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2090-y; Janssens R, 2018, CELL MOL IMMUNOL, V15, P299, DOI 10.1038/cmi.2017.107; Jin PP, 2018, JPN J CLIN ONCOL, V48, P1058, DOI 10.1093/jjco/hyy138; Kasagi Y, 2016, CANCER RES, V76, P347, DOI 10.1158/0008-5472.CAN-15-1563; Keating GM, 2017, TARGET ONCOL, V12, P243, DOI 10.1007/s11523-017-0484-7; Kee BL, 2014, BLOOD, V123, P4009, DOI 10.1182/blood-2014-05-574178; Koumangoye RB, 2015, MOL CANCER, V14, DOI 10.1186/s12943-014-0284-y; Kow AWC, 2012, ANN SURG ONCOL, V19, P2246, DOI 10.1245/s10434-012-2260-3; Lai YH, 2011, BMC CELL BIOL, V12, DOI 10.1186/1471-2121-12-50; Liao YL, 2008, ONCOGENE, V27, P5578, DOI 10.1038/onc.2008.168; Liu H, 2008, CELL MOL IMMUNOL, V5, P373, DOI 10.1038/cmi.2008.46; Mantovani A, 2010, CYTOKINE GROWTH F R, V21, P27, DOI 10.1016/j.cytogfr.2009.11.007; Medina PP, 2009, HUM MOL GENET, V18, P1343, DOI 10.1093/hmg/ddp034; Nagarsheth N, 2017, NAT REV IMMUNOL, V17, P559, DOI 10.1038/nri.2017.49; Pan X, 2006, BIOCHEM BIOPH RES CO, V344, P727, DOI 10.1016/j.bbrc.2006.03.194; Parvani JG, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3466; Polimeno MN, 2015, CELL MOL IMMUNOL, V12, P474, DOI 10.1038/cmi.2014.102; Sartorius K, 2015, CANCER EPIDEMIOL, V39, P284, DOI 10.1016/j.canep.2015.04.006; Schrader J, 2011, HEPATOLOGY, V53, P1192, DOI 10.1002/hep.24108; Semaan A, 2017, VIRCHOWS ARCH, V470, P185, DOI 10.1007/s00428-016-2051-5; Sethi A, 2011, INVEST OPHTH VIS SCI, V52, P5240, DOI 10.1167/iovs.11-7287; Shah AD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142337; Shibuta K, 2002, JPN J CANCER RES, V93, P789, DOI 10.1111/j.1349-7006.2002.tb01321.x; Sinner D, 2007, MOL CELL BIOL, V27, P7802, DOI 10.1128/MCB.02179-06; Sun XQ, 2010, CANCER METAST REV, V29, P709, DOI 10.1007/s10555-010-9256-x; Tadeo I, 2016, BRIT J CANCER, V115, P480, DOI 10.1038/bjc.2016.210; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Vervoort SJ, 2018, ELIFE, V7, DOI 10.7554/eLife.27706; Wang BC, 2016, TUMOR BIOL, V37, P9131, DOI 10.1007/s13277-015-4756-5; Wang L, 2014, PROSTATE, V74, P647, DOI 10.1002/pros.22783; Xu J, 2017, CLIN CANCER RES, V23, P4482, DOI 10.1158/1078-0432.CCR-16-2131; You Y, 2016, ONCOTARGET, V7, P32221, DOI 10.18632/oncotarget.8515; Zhang JC, 2012, CANCER RES, V72, P4597, DOI 10.1158/0008-5472.CAN-12-1045	55	17	17	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	24					4695	4710		10.1038/s41388-020-1319-z	http://dx.doi.org/10.1038/s41388-020-1319-z		MAY 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LY0HO	32404985				2022-12-28	WOS:000532808000001
J	Sierra, JC; Piazuelo, MB; Luis, PB; Barry, DP; Allaman, MM; Asim, M; Sebrell, TA; Finley, JL; Rose, KL; Hill, S; Holshouser, SL; Casero, RA; Cleveland, JL; Woster, PM; Schey, KL; Bimczok, D; Schneider, C; Gobert, AP; Wilson, KT				Sierra, Johanna C.; Piazuelo, M. Blanca; Luis, Paula B.; Barry, Daniel P.; Allaman, Margaret M.; Asim, Mohammad; Sebrell, Thomas A.; Finley, Jordan L.; Rose, Kristie L.; Hill, Salisha; Holshouser, Steven L.; Casero, Robert A.; Cleveland, John L.; Woster, Patrick M.; Schey, Kevin L.; Bimczok, Diane; Schneider, Claus; Gobert, Alain P.; Wilson, Keith T.			Spermine oxidase mediates Helicobacter pylori-induced gastric inflammation, DNA damage, and carcinogenic signaling	ONCOGENE			English	Article							BETA-CATENIN; ORNITHINE-DECARBOXYLASE; MACROPHAGE ACTIVATION; NITRIC-OXIDE; CANCER RISK; INFECTION; POLYAMINES; APOPTOSIS; PATHWAY; EGFR	Helicobacter pylori infection is the main risk factor for the development of gastric cancer, the third leading cause of cancer death worldwide. H. pylori colonizes the human gastric mucosa and persists for decades. The inflammatory response is ineffective in clearing the infection, leading to disease progression that may result in gastric adenocarcinoma. We have shown that polyamines are regulators of the host response to H. pylori, and that spermine oxidase (SMOX), which metabolizes the polyamine spermine into spermidine plus H2O2, is associated with increased human gastric cancer risk. We now used a molecular approach to directly address the role of SMOX, and demonstrate that Smox-deficient mice exhibit significant reductions of gastric spermidine levels and H. pylori-induced inflammation. Proteomic analysis revealed that cancer was the most significantly altered functional pathway in Smox(-/-) gastric organoids. Moreover, there was also less DNA damage and beta-catenin activation in H. pylori-infected Smox(-/-) mice or gastric organoids, compared to infected wild-type animals or gastroids. The link between SMOX and beta-catenin activation was confirmed in human gastric organoids that were treated with a novel SMOX inhibitor. These findings indicate that SMOX promotes H. pylori-induced carcinogenesis by causing inflammation, DNA damage, and activation of beta-catenin signaling.	[Sierra, Johanna C.; Piazuelo, M. Blanca; Barry, Daniel P.; Allaman, Margaret M.; Asim, Mohammad; Finley, Jordan L.; Gobert, Alain P.; Wilson, Keith T.] Vanderbilt Univ, Med Ctr, Dept Med, Div Gastroenterol Hepatol & Nutr, Nashville, TN 37232 USA; [Sierra, Johanna C.; Piazuelo, M. Blanca; Schneider, Claus; Gobert, Alain P.; Wilson, Keith T.] Vanderbilt Univ, Med Ctr, Ctr Mucosal Inflammat & Canc, Nashville, TN 37232 USA; [Luis, Paula B.; Schneider, Claus] Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; [Sebrell, Thomas A.; Bimczok, Diane] Montana State Univ, Dept Microbiol & Immunol, Bozeman, MT 59717 USA; [Rose, Kristie L.; Hill, Salisha; Schey, Kevin L.] Vanderbilt Univ, Med Ctr, Dept Biochem, Mass Spectrometry Res Ctr, Nashville, TN 37232 USA; [Holshouser, Steven L.; Woster, Patrick M.] Med Univ South Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA; [Casero, Robert A.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21287 USA; [Cleveland, John L.] H Lee Moffitt Canc Ctr & Res Inst, Dept Tumor Biol, Tampa, FL 33612 USA; [Wilson, Keith T.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA; [Wilson, Keith T.] Vet Affairs Tennessee Valley Healthcare Syst, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Montana State University System; Montana State University Bozeman; Vanderbilt University; Medical University of South Carolina; Johns Hopkins University; Johns Hopkins Medicine; H Lee Moffitt Cancer Center & Research Institute; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Wilson, KT (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Div Gastroenterol Hepatol & Nutr, Nashville, TN 37232 USA.; Wilson, KT (corresponding author), Vanderbilt Univ, Med Ctr, Ctr Mucosal Inflammat & Canc, Nashville, TN 37232 USA.; Wilson, KT (corresponding author), Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA.; Wilson, KT (corresponding author), Vet Affairs Tennessee Valley Healthcare Syst, Nashville, TN 37232 USA.	keith.wilson@vumc.org	Allaman, Margaret/GNO-9854-2022; Gobert, Alain P/AHB-1368-2022	Allaman, Margaret M./0000-0002-2803-1365; Finley, Jordan/0000-0002-5600-4292	NIH [R01CA190612, P01CA116087, P01CA028842, R21AI142042, R01AT006896, R03DK107960, R01GM131408, R01CA204345, R01CA235863, R01CA100603, P30DK058404]; Veterans Affairs Merit Review grant [I01BX001453]; Department of Defense [W81XWH-18-1-0301]; Thomas F. Frist Sr. Endowment; Vanderbilt Center for Mucosal Inflammation and Cancer; NCI Comprehensive Cancer Grant [P30CA76292]; Cortner-Couch Endowed Chair for Cancer Research from the University of South Florida; American Heart Association [16POST27250138]; Vanderbilt Ingram Cancer Center support grant [P30CA068485]; Vanderbilt Digestive Disease Research Center; Vanderbilt University Medical Center Digestive Disease Research Center - NIH [P30DK058404]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Veterans Affairs Merit Review grant(US Department of Veterans Affairs); Department of Defense(United States Department of Defense); Thomas F. Frist Sr. Endowment; Vanderbilt Center for Mucosal Inflammation and Cancer; NCI Comprehensive Cancer Grant; Cortner-Couch Endowed Chair for Cancer Research from the University of South Florida; American Heart Association(American Heart Association); Vanderbilt Ingram Cancer Center support grant; Vanderbilt Digestive Disease Research Center; Vanderbilt University Medical Center Digestive Disease Research Center - NIH	This work was funded by NIH grants R01CA190612 (K.T.W.), P01CA116087 (K.T.W.), P01CA028842 (K.T.W.), and R21AI142042 (K.T.W.); Veterans Affairs Merit Review grant I01BX001453 (K.T.W.); Department of Defense grant W81XWH-18-1-0301 (K.T.W.); the Thomas F. Frist Sr. Endowment (K.T.W.); and the Vanderbilt Center for Mucosal Inflammation and Cancer (K.T.W.). This work was also supported by NIH grants R01AT006896 (C.S.), R03DK107960 (D.B.), R01GM131408 (D.B.), R01CA204345 (R.A.C. and P.M.W.), R01CA235863 (R.A.C.), and R01CA100603 (J.L.C.). J.L.C. was also supported by the Cortner-Couch Endowed Chair for Cancer Research from the University of South Florida (J.L.C.) and NCI Comprehensive Cancer Grant P30CA76292 to the H. Lee Moffitt Cancer Center and Research Institute. P.B.L. was supported by a postdoctoral fellowship award from the American Heart Association (16POST27250138). Mass spectrometry analyses were supported in part by Core Scholarships from the Vanderbilt University Medical Center Digestive Disease Research Center funded by NIH grant P30DK058404, and the Vanderbilt Ingram Cancer Center support grant P30CA068485. Immunofluorescence confocal imaging was performed in the Vanderbilt Cell Imaging Shared Resource, supported by the Vanderbilt Digestive Disease Research Center and NIH grant P30DK058404.	Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chaturvedi R, 2015, ONCOGENE, V34, P3429, DOI 10.1038/onc.2014.273; Chaturvedi R, 2004, J BIOL CHEM, V279, P40161, DOI 10.1074/jbc.M401370200; Chaturvedi R, 2014, GASTROENTEROLOGY, V146, P1739, DOI 10.1053/j.gastro.2014.02.005; Chaturvedi R, 2011, GASTROENTEROLOGY, V141, P1696, DOI 10.1053/j.gastro.2011.07.045; Chaturvedi R, 2010, GASTROENTEROLOGY, V139, P1686, DOI 10.1053/j.gastro.2010.06.060; Clements WM, 2002, CANCER RES, V62, P3503; CORREA P, 1988, CANCER RES, V48, P3554; Ebert MPA, 2002, CARCINOGENESIS, V23, P87, DOI 10.1093/carcin/23.1.87; Franco AT, 2005, P NATL ACAD SCI USA, V102, P10646, DOI 10.1073/pnas.0504927102; Gobert AP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01242; Goodwin AC, 2011, P NATL ACAD SCI USA, V108, P15354, DOI 10.1073/pnas.1010203108; Guo X, 2002, AM J PHYSIOL-CELL PH, V283, pC722, DOI 10.1152/ajpcell.00054.2002; Hardbower DM, 2017, P NATL ACAD SCI USA, V114, pE751, DOI 10.1073/pnas.1614958114; Hardbower DM, 2016, J CLIN INVEST, V126, P3296, DOI 10.1172/JCI83585; Hardbower DM, 2013, GUT MICROBES, V4, P475, DOI 10.4161/gmic.25583; Holshouser S, 2019, MEDCHEMCOMM, V10, P778, DOI 10.1039/c8md00610e; Hooi JKY, 2017, GASTROENTEROLOGY, V153, P420, DOI 10.1053/j.gastro.2017.04.022; Jaiswal M, 2001, AM J PHYSIOL-GASTR L, V281, pG626, DOI 10.1152/ajpgi.2001.281.3.G626; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Lewis ND, 2011, J IMMUNOL, V186, P3632, DOI 10.4049/jimmunol.1003431; Malfertheiner P, 2012, GUT, V61, P646, DOI 10.1136/gutjnl-2012-302084; Mera RM, 2018, GUT, V67, P1239, DOI 10.1136/gutjnl-2016-311685; Morgan DR, 2013, JAMA-J AM MED ASSOC, V309, P578, DOI 10.1001/jama.2013.311; Murata-Kamiya N, 2007, ONCOGENE, V26, P4617, DOI 10.1038/sj.onc.1210251; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PATCHETT SE, 1995, GUT, V37, P13, DOI 10.1136/gut.37.1.13; Pegg AE, 2016, J BIOL CHEM, V291, P14904, DOI 10.1074/jbc.R116.731661; Radulescu S, 2013, ONCOGENE, V32, P2048, DOI 10.1038/onc.2012.224; Sebrell TA, 2018, CELL TISSUE RES, V371, P293, DOI 10.1007/s00441-017-2726-5; Sierra JC, 2019, P NATL ACAD SCI USA, V116, P5077, DOI 10.1073/pnas.1814497116; Sierra JC, 2018, GUT, V67, P1247, DOI 10.1136/gutjnl-2016-312888; Toller IM, 2011, P NATL ACAD SCI USA, V108, P14944, DOI 10.1073/pnas.1100959108; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Vujcic S, 2002, BIOCHEM J, V367, P665, DOI 10.1042/BJ20020720; Wang YL, 2001, CANCER RES, V61, P5370; Xu HX, 2004, CANCER RES, V64, P8521, DOI 10.1158/0008-5472.CAN-04-3511; Xue JF, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7156; Yong X, 2016, CANCER LETT, V374, P292, DOI 10.1016/j.canlet.2016.02.032	40	25	25	3	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	22					4465	4474		10.1038/s41388-020-1304-6	http://dx.doi.org/10.1038/s41388-020-1304-6		APR 2020	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LR9IT	32350444	Green Accepted			2022-12-28	WOS:000529589900001
J	Sundqvist, A; Vasilaki, E; Voytyuk, O; Bai, Y; Morikawa, M; Moustakas, A; Miyazono, K; Heldin, CH; ten Dijke, P; van Dam, H				Sundqvist, Anders; Vasilaki, Eleftheria; Voytyuk, Oleksandr; Bai, Yu; Morikawa, Masato; Moustakas, Aristidis; Miyazono, Kohei; Heldin, Carl-Henrik; ten Dijke, Peter; van Dam, Hans			TGF beta and EGF signaling orchestrates the AP-1-and p63 transcriptional regulation of breast cancer invasiveness	ONCOGENE			English	Article							NETWORK; TARGET; CELLS; FRA-1; CHEMOSENSITIVITY; EVOLUTION; PATHWAYS; PROTEIN; FOS	Activator protein (AP)-1 transcription factors are essential elements of the pro-oncogenic functions of transforming growth factor-beta (TGF beta)-SMAD signaling. Here we show that in multiple HER2+ and/or EGFR+ breast cancer cell lines these AP-1-dependent tumorigenic properties of TGF beta critically rely on epidermal growth factor receptor (EGFR) activation and expression of the Delta N isoform of transcriptional regulator p63. EGFR and Delta Np63 enabled and/or potentiated the activation of a subset of TGF beta-inducible invasion/migration-associated genes, e.g., ITGA2, LAMB3, and WNT7A/B, and enhanced the recruitment of SMAD2/3 to these genes. The TGF beta- and EGF-induced binding of SMAD2/3 and JUNB to these gene loci was accompanied by p63-SMAD2/3 and p63-JUNB complex formation. p63 and EGFR were also found to strongly potentiate TGF beta induction of AP-1 proteins and, in particular, FOS family members. Ectopic overexpression of FOS could counteract the decrease in TGF beta-induced gene activation after p63 depletion. p63 is also involved in the transcriptional regulation of heparin binding (HB)-EGF and EGFR genes, thereby establishing a self-amplification loop that facilitates and empowers the pro-invasive functions of TGF beta. These cooperative pro-oncogenic functions of EGFR, AP-1, p63, and TGF beta were efficiently inhibited by clinically relevant chemical inhibitors. Our findings may, therefore, be of importance for therapy of patients with breast cancers with an activated EGFR-RAS-RAF pathway.	[Sundqvist, Anders; Vasilaki, Eleftheria; Voytyuk, Oleksandr; Bai, Yu; Moustakas, Aristidis; Miyazono, Kohei; Heldin, Carl-Henrik; ten Dijke, Peter] Uppsala Univ, Sci Life Lab, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden; [Morikawa, Masato; Miyazono, Kohei] Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Tokyo 1130033, Japan; [ten Dijke, Peter; van Dam, Hans] Leiden Univ, Med Ctr, Oncode Inst, Dept Cell & Chem Biol, NL-2300 RC Leiden, Netherlands	Uppsala University; University of Tokyo; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Sundqvist, A (corresponding author), Uppsala Univ, Sci Life Lab, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden.; van Dam, H (corresponding author), Leiden Univ, Med Ctr, Oncode Inst, Dept Cell & Chem Biol, NL-2300 RC Leiden, Netherlands.	anders.sundqvist@imbim.uu.se; vdam@lumc.nl	Dijke, Peter ten/AAG-4660-2021; Vasilaki, Eleftheria/AAY-6392-2020; Morikawa, Masato/D-1932-2011	Dijke, Peter ten/0000-0002-7234-342X; Morikawa, Masato/0000-0002-6191-7176; van Dam, Hans/0000-0002-8307-4325	Swedish Cancer Foundation [2016/468, 2018/439]; Swedish Research Council [2015-02757]; European Research Council [787472]; Cancer Genomics Centre Netherlands (CGC.NL)	Swedish Cancer Foundation; Swedish Research Council(Swedish Research CouncilEuropean Commission); European Research Council(European Research Council (ERC)European Commission); Cancer Genomics Centre Netherlands (CGC.NL)	S We thank our colleagues, in particular Maria Tsioumpekou, for valuable discussion. David Baker and David van IJzendoorn for the Flag-FOS lentiviral vector. The HCC-1954 cells were kindly provided by Otavia L. Caballero and Andrew J.G. Simpson, Ludwig Cancer Research, New York, USA, and the HCC1937 and HCC202 cells by SE Le Devedec, Leiden Academic Center for Drug Research, Leiden, the Netherlands. This work was supported by the Swedish Cancer Foundation (2016/468 to PtD, 2018/439 to KM); Swedish Research Council (2015-02757 to C-HH); European Research Council (787472 to C-HH); and Cancer Genomics Centre Netherlands (CGC.NL to PtD).	Akhurst RJ, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aad0416; Ali R, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2016.42; Baan B, 2010, MOL CELL PROTEOMICS, V9, P1982, DOI 10.1074/mcp.M110.000943; Bakiri L, 2015, CELL DEATH DIFFER, V22, P336, DOI 10.1038/cdd.2014.157; Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312; Bhola NE, 2013, J CLIN INVEST, V123, P1348, DOI 10.1172/JCI65416; Buckley NE, 2011, CANCER RES, V71, P1933, DOI 10.1158/0008-5472.CAN-10-2717; Carroll DK, 2006, NAT CELL BIOL, V8, P551, DOI 10.1038/ncb1420; Chen YL, 2018, CELL MOL LIFE SCI, V75, P965, DOI 10.1007/s00018-017-2666-y; Chow A, 2011, J MAMMARY GLAND BIOL, V16, P81, DOI 10.1007/s10911-011-9206-4; David CJ, 2018, NAT REV MOL CELL BIO, V19, P419, DOI 10.1038/s41580-018-0007-0; Dawson PJ, 1996, AM J PATHOL, V148, P313; Derynck R, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aav5183; Desmet CJ, 2013, P NATL ACAD SCI USA, V110, P5139, DOI 10.1073/pnas.1222085110; Dhillon AS, 2015, ONCOGENE, V34, P4421, DOI 10.1038/onc.2014.374; Durchdewald M, 2009, HISTOL HISTOPATHOL, V24, P14451, DOI 10.14670/HH-24.1451; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143; Gatti V, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112683; Gatti V, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0073-3; Hess J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589; Hill CS, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a022079; Hu LS, 2017, P NATL ACAD SCI USA, V114, pE3964, DOI 10.1073/pnas.1617816114; Huang F, 2018, CANCER RES, V78, P6073, DOI 10.1158/0008-5472.CAN-18-0136; Huang SD, 2012, CELL, V151, P937, DOI 10.1016/j.cell.2012.10.035; Ikushima H, 2012, CELL TISSUE RES, V347, P37, DOI 10.1007/s00441-011-1179-5; Katsuno Y, 2013, CURR OPIN ONCOL, V25, P76, DOI 10.1097/CCO.0b013e32835b6371; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Koinuma D, 2009, MOL CELL BIOL, V29, P172, DOI 10.1128/MCB.01038-08; Kurrey NK, 2009, STEM CELLS, V27, P2059, DOI 10.1002/stem.154; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Leong CO, 2007, J CLIN INVEST, V117, P1370, DOI 10.1172/JCI30866; Lopez-Bergami P, 2010, NAT REV CANCER, V10, P65, DOI 10.1038/nrc2681; Lu D, 2012, CANCER RES, V72, P3451, DOI 10.1158/0008-5472.CAN-11-2536; Madrigal P, 2018, TRENDS CELL BIOL, V28, P509, DOI 10.1016/j.tcb.2018.04.009; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Moses HL, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021865; Ozanne BW, 2007, ONCOGENE, V26, P1, DOI 10.1038/sj.onc.1209759; ROBERTS AB, 1982, NATURE, V295, P417, DOI 10.1038/295417a0; Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2010, CELL SIGNAL, V22, P894, DOI 10.1016/j.cellsig.2009.12.008; SOULE HD, 1990, CANCER RES, V50, P6075; Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017; Subramanian D, 2015, J BIOL CHEM, V290, P18636, DOI 10.1074/jbc.M115.636548; Sundqvist A, 2013, ONCOGENE, V32, P3606, DOI 10.1038/onc.2012.370; Sundqvist A, 2018, NUCLEIC ACIDS RES, V46, P1180, DOI 10.1093/nar/gkx1190; Sundqvist A, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3066; Tam WL, 2013, CANCER CELL, V24, P347, DOI 10.1016/j.ccr.2013.08.005; van IJzendoorn DGP, 2017, J BIOL CHEM, V292, P21282, DOI 10.1074/jbc.C117.815845; van Staalduinen J, 2018, ONCOGENE, V37, P6195, DOI 10.1038/s41388-018-0378-x; Vasilaki E, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aag3232; Vierbuchen T, 2017, MOL CELL, V68, P1067, DOI 10.1016/j.molcel.2017.11.026; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wiercinska E, 2011, BREAST CANCER RES TR, V128, P657, DOI 10.1007/s10549-010-1147-x; Wilson CA, 2005, BREAST CANCER RES, V7, pR1058, DOI 10.1186/bcr1343; Xue Z, 2018, CELL RES, V28, P719, DOI 10.1038/s41422-018-0044-4; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	59	32	33	3	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	22					4436	4449		10.1038/s41388-020-1299-z	http://dx.doi.org/10.1038/s41388-020-1299-z		APR 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LR9IT	32350443	Green Published, hybrid			2022-12-28	WOS:000529589900002
J	Li, ZY; Philip, M; Ferrell, PB				Li, Zhuoyan; Philip, Mary; Ferrell, P. Brent			Alterations of T-cell-mediated immunity in acute myeloid leukemia	ONCOGENE			English	Review							ISOCITRATE DEHYDROGENASE MUTATIONS; INDOLEAMINE 2,3-DIOXYGENASE; CD200 EXPRESSION; SPONTANEOUS REMISSION; INCREASED FREQUENCY; PROGNOSTIC-FACTOR; PERIPHERAL-BLOOD; POOR-PROGNOSIS; PROLIFERATION; IMMUNOCOMPETENCE	Acute myeloid leukemia (AML) is a systemic, heterogeneous hematologic malignancy with poor overall survival. While some malignancies have seen improvements in clinical outcomes with immunotherapy, success of these agents in AML remains elusive. Despite limited progress, stem cell transplantation and donor lymphocyte infusions show that modulation of the immune system can improve overall survival of AML patients. Understanding the causes of immune evasion and disease progression will identify potential immune-mediated targets in AML. This review explores immunosuppressive mechanisms that alter T-cell-mediated immunity in AML.	[Li, Zhuoyan; Philip, Mary; Ferrell, P. Brent] Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol & Oncol, Nashville, TN 37232 USA	Vanderbilt University	Ferrell, PB (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol & Oncol, Nashville, TN 37232 USA.	brent.ferrell@vumc.org		Li, Zhuoyan/0000-0003-2658-9071	 [K23HL138291];  [T32CA217834]	; 	The authors are supported by K23HL138291(PBF) and T32CA217834 (ZL).	Almosailleakh M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020453; Arandi N, 2018, BLOOD RES, V53, P294, DOI 10.5045/br.2018.53.4.294; Austin R, 2016, CRIT REV ONCOL HEMAT, V103, P62, DOI 10.1016/j.critrevonc.2016.04.020; Barosi G, 2014, CURR HEMATOL MALIG R, V9, P331, DOI 10.1007/s11899-014-0227-0; Boddu P, 2018, LEUKEMIA LYMPHOMA, V59, P790, DOI 10.1080/10428194.2017.1344905; Buggins AGS, 2001, J IMMUNOL, V167, P6021, DOI 10.4049/jimmunol.167.10.6021; Bunse L, 2018, NAT MED, V24, P1192, DOI 10.1038/s41591-018-0095-6; Cerrano M, 2019, CURR ONCOL REP, V21, DOI 10.1007/s11912-019-0764-8; Chalmers ZR, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0424-2; Chamuleau MED, 2008, HAEMATOL-HEMATOL J, V93, P1894, DOI 10.3324/haematol.13113; Christopher MJ, 2018, NEW ENGL J MED, V379, P2330, DOI 10.1056/NEJMoa1808777; Coles SJ, 2012, LEUKEMIA, V26, P2146, DOI 10.1038/leu.2012.75; Coles SJ, 2012, LEUKEMIA, V26, P2148, DOI 10.1038/leu.2012.77; Corm S, 2009, LEUKEMIA RES, V33, P490, DOI 10.1016/j.leukres.2008.06.014; Curti A, 2007, LEUKEMIA, V21, P353, DOI 10.1038/sj.leu.2404485; Curti A, 2007, BLOOD, V109, P2871, DOI 10.1182/blood-2006-07-036863; Dama P, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0611-3; Damiani D, 2015, ONCOTARGET, V6, P30212, DOI 10.18632/oncotarget.4901; Daver N, 2019, CANCER DISCOV, V9, P370, DOI 10.1158/2159-8290.CD-18-0774; Deng M, 2018, NATURE, V562, P605, DOI 10.1038/s41586-018-0615-z; DiNardo CD, 2013, BLOOD, V121, P4917, DOI 10.1182/blood-2013-03-493197; Dobrowolska H, 2013, CYTOM PART B-CLIN CY, V84B, P21, DOI 10.1002/cyto.b.21050; Ersvaer Elisabeth, 2010, BMC Immunol, V11, P38, DOI 10.1186/1471-2172-11-38; Fozza C, 2016, CRIT REV ONCOL HEMAT, V107, P90, DOI 10.1016/j.critrevonc.2016.08.016; Frumento G, 2002, J EXP MED, V196, P459, DOI 10.1084/jem.20020121; Fukuno K, 2015, LEUKEMIA LYMPHOMA, V56, P1398, DOI 10.3109/10428194.2014.953150; Han YX, 2014, CANCER SCI, V105, P933, DOI 10.1111/cas.12459; Hasegawa K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144594; HERSH EM, 1974, J CLIN INVEST, V54, P401, DOI 10.1172/JCI107775; HERSH EM, 1971, NEW ENGL J MED, V285, P1211, DOI 10.1056/NEJM197111252852201; HOROWITZ MM, 1990, BLOOD, V75, P555; Howlader N, 2011, SEER CANC STAT REV 1; Jia B, 2019, CANC RES; Jia B, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408-018-0069-4; Kanakry CG, 2011, BLOOD, V117, P608, DOI 10.1182/blood-2010-04-277939; Kang XL, 2016, CELL CYCLE, V15, P25, DOI 10.1080/15384101.2015.1121324; Kawasaki BT, 2008, TRENDS IMMUNOL, V29, P464, DOI 10.1016/j.it.2008.07.005; Kelderman S, 2014, MOL ONCOL, V8, P1132, DOI 10.1016/j.molonc.2014.07.011; Kittang AO, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1062208; Klco JM, 2014, CANCER CELL, V25, P379, DOI 10.1016/j.ccr.2014.01.031; Knaus HA, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120974; Kretz-Rommel A, 2007, J IMMUNOL, V178, P5595, DOI 10.4049/jimmunol.178.9.5595; LaBelle JL, 2002, BLOOD, V99, P2146, DOI 10.1182/blood.V99.6.2146; Lamble AJ, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00213; Le Dieu R, 2009, BLOOD, V114, P3909, DOI 10.1182/blood-2009-02-206946; Lee JB, 2019, BLOOD REV, V35, P18, DOI 10.1016/j.blre.2019.02.001; Lichtenegger FS, 2014, LEUKEMIA RES, V38, P964, DOI 10.1016/j.leukres.2014.05.014; Liu YX, 2019, BLOOD REV, V34, P67, DOI 10.1016/j.blre.2018.12.001; Losman JA, 2013, SCIENCE, V339, P1621, DOI 10.1126/science.1231677; Masarova L, 2018, ADV EXP MED BIOL, V995, P97, DOI 10.1007/978-3-030-02505-2_4; Medeiros BC, 2017, LEUKEMIA, V31, P272, DOI 10.1038/leu.2016.275; Menter T, 2018, BRIT J HAEMATOL, V182, P581, DOI 10.1111/bjh.14819; Moreaux J, 2008, BIOCHEM BIOPH RES CO, V366, P117, DOI 10.1016/j.bbrc.2007.11.103; Moreaux J, 2006, BLOOD, V108, P4194, DOI 10.1182/blood-2006-06-029355; Muller-Schmah C, 2012, ANN HEMATOL, V91, P27, DOI 10.1007/s00277-011-1332-y; Mussai F, 2019, INT J CANCER, V145, P2201, DOI 10.1002/ijc.32028; Mussai F, 2013, BLOOD, V122, P749, DOI 10.1182/blood-2013-01-480129; Musuraca G, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0590-1; Orleans-Lindsay JK, 2001, CLIN EXP IMMUNOL, V126, P403, DOI 10.1046/j.1365-2249.2001.01692.x; Paley MA, 2012, SCIENCE, V338, P1220, DOI 10.1126/science.1229620; Papaemmanuil E, 2016, NEW ENGL J MED, V374, P2209, DOI 10.1056/NEJMoa1516192; Philip M, 2017, NATURE, V545, P452, DOI 10.1038/nature22367; Pollyea DA, 2018, HEMATOL-AM SOC HEMAT, P45, DOI 10.1182/asheducation-2018.1.45; Radpour R, 2019, LEUKEMIA, V33, P2379, DOI 10.1038/s41375-019-0441-9; Rashidi A, 2015, LEUKEMIA LYMPHOMA, V56, P1727, DOI 10.3109/10428194.2014.970545; Schnorfeil FM, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0189-2; Sun YX, 2014, HUM IMMUNOL, V75, P113, DOI 10.1016/j.humimm.2013.11.014; Szczepanski MJ, 2009, CLIN CANCER RES, V15, P3325, DOI 10.1158/1078-0432.CCR-08-3010; Teague RM, 2013, J IMMUNOTHER CANCER, V1, DOI 10.1186/2051-1426-1-13; Tian T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131761; Tian T, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/915873; Tikhonova AN, 2019, NATURE, V569, P222, DOI 10.1038/s41586-019-1104-8; Tonks A, 2007, LEUKEMIA, V21, P566, DOI 10.1038/sj.leu.2404559; Ustun C, 2011, BLOOD, V118, P5084, DOI 10.1182/blood-2011-07-365817; van Galen P, 2019, CELL, V176, P1265, DOI 10.1016/j.cell.2019.01.031; Wang MJ, 2018, CLIN IMMUNOL, V190, P64, DOI 10.1016/j.clim.2017.08.021; Wang XB, 2005, EUR J HAEMATOL, V75, P468, DOI 10.1111/j.1600-0609.2005.00537.x; Wherry EJ, 2011, NAT IMMUNOL, V12, P492, DOI 10.1038/ni.2035; Williams M, 2018, CANCERS, V10, DOI 10.3390/cancers10050129; Wouters BJ, 2016, BLOOD, V127, P42, DOI 10.1182/blood-2015-07-604512; Wu C, 2009, CLIN EXP IMMUNOL, V158, P199, DOI 10.1111/j.1365-2249.2009.04011.x; Xu T, 2017, NATURE, V548, P228, DOI 10.1038/nature23475; Zahran AM, 2018, CANCER BIOMARK, V22, P587, DOI 10.3233/CBM-181368; Zhang LJ, 2018, CLIN CANCER RES, V24, P5381, DOI 10.1158/1078-0432.CCR-17-3855; Zhang L, 2013, J CLIN INVEST, V123, P1999, DOI 10.1172/JCI63980; Zhang SH, 2011, INT J CANCER, V129, P1373, DOI 10.1002/ijc.25791; Zhou Q, 2011, BLOOD, V117, P4501, DOI 10.1182/blood-2010-10-310425; Zhou Q, 2009, BLOOD, V114, P3793, DOI 10.1182/blood-2009-03-208181; Zou WP, 2006, NAT REV IMMUNOL, V6, P295, DOI 10.1038/nri1806	89	24	24	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	18					3611	3619		10.1038/s41388-020-1239-y	http://dx.doi.org/10.1038/s41388-020-1239-y		MAR 2020	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LI5XR	32127646	Green Accepted			2022-12-28	WOS:000517861800001
J	Li, LN; Liu, J; Xue, HS; Li, CX; Liu, Q; Zhou, YT; Wang, T; Wang, HJ; Qian, HL; Wen, T				Li, Lina; Liu, Jian; Xue, Hongsheng; Li, Chunxiao; Liu, Qun; Zhou, Yantong; Wang, Ting; Wang, Haijuan; Qian, Haili; Wen, Tao			A TGF-beta-MTA1-SOX4-EZH2 signaling axis drives epithelial-mesenchymal transition in tumor metastasis	ONCOGENE			English	Article							TGF-BETA; HEPATOCELLULAR-CARCINOMA; SOX4 EXPRESSION; POOR-PROGNOSIS; CANCER CELLS; MTA1; PROTEIN; EZH2; CONTRIBUTES; PROGRESSION	MTA1, SOX4, EZH2, and TGF-beta are all potent inducers of epithelial-mesenchymal transition (EMT) in cancer; however, the signaling relationship among these molecules in EMT is poorly understood. Here, we investigated the function of MTA1 in cancer cells and demonstrated that MTA1 overexpression efficiently activates EMT. This activation resulted in a significant increase in the migratory and invasive properties of three different cancer cell lines through a common mechanism involving SOX4 activation, screened from a gene expression profiling analysis. We showed that both SOX4 and MTA1 are induced by TGF-beta and both are indispensable for TGF-beta-mediated EMT. Further investigation identified that MTA1 acts upstream of SOX4 in the TGF-beta pathway, emphasizing a TGF-beta-MTA1-SOX4 signaling axis in EMT induction. The histone methyltransferase EZH2, a component of the polycomb (PcG) repressive complex 2 (PRC2), was identified as a critical responsive gene of the TGF-beta-MTA1-SOX4 signaling in three different epithelial cancer cell lines, suggesting that this signaling acts broadly in cancer cells in vitro. The MTA1-SOX4-EZH2 signaling cascade was further verified in TCGA pan-cancer patient samples and in a colon cancer cDNA microarray, and activation of genes in this signaling pathway predicted an unfavorable prognosis in colon cancer patients. Collectively, our data uncover a SOX4-dependent EMT-inducing mechanism underlying MTA1-driven cancer metastasis and suggest a widespread TGF-beta-MTA1-SOX4-EZH2 signaling axis that drives EMT in various cancers. We propose that this signaling may be used as a common therapeutic target to control epithelial cancer metastasis.	[Li, Lina; Liu, Jian; Wen, Tao] Capital Med Univ, Beijing Chao Yang Hosp, Med Res Ctr, Beijing 100020, Peoples R China; [Xue, Hongsheng] Dalian Univ, Dept Thorac Surg, Affiliated Zhongshan Hosp, Dalian 116001, Peoples R China; [Li, Chunxiao; Zhou, Yantong; Wang, Ting; Wang, Haijuan; Qian, Haili] Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Mol Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing 100021, Peoples R China; [Liu, Qun] Capital Med Univ, Beijing Anzhen Hosp, Dept Obstet & Gynaecol, Beijing 100029, Peoples R China	Capital Medical University; Dalian University; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College; Capital Medical University	Liu, J; Wen, T (corresponding author), Capital Med Univ, Beijing Chao Yang Hosp, Med Res Ctr, Beijing 100020, Peoples R China.; Qian, HL (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Mol Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing 100021, Peoples R China.	liujian2004811@126.com; qianhaili001@163.com; wentao5281@163.com	wang, tingting/AAK-2640-2020; Liu, Jian/GQZ-6995-2022	Liu, Jian/0000-0002-8969-8446; qian, haili/0000-0003-0652-4801	National Natural Science Foundation of China [81502384, 81572842, 81672459, 81872280, 81672338]; National Basic Research Program of China (973 Program) [2015CB553904]; CAMS Innovation Fund for Medical Sciences (CIFMS) [2016-I2M-1-001, 2019-I2M-1-003]; Nonprofit Central Research Institute Fund of Chinese Academy of Medical Sciences [2017PT31029]; Open Issue of State Key Laboratory of Molecular Oncology [SKL-KF-2017-16]; Independent Issue of State Key Laboratory of Molecular Oncology [SKL-2017-16]; Dalian Science and Technology Project [2015E12SF117]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China (973 Program)(National Basic Research Program of China); CAMS Innovation Fund for Medical Sciences (CIFMS); Nonprofit Central Research Institute Fund of Chinese Academy of Medical Sciences; Open Issue of State Key Laboratory of Molecular Oncology; Independent Issue of State Key Laboratory of Molecular Oncology; Dalian Science and Technology Project	This work was financially supported by grants from the National Natural Science Foundation of China (Nos 81502384, 81572842, 81672459, 81872280, 81672338), the National Basic Research Program of China (973 Program) (No. 2015CB553904), the CAMS Innovation Fund for Medical Sciences (CIFMS) (No. 2016-I2M-1-001, 2019-I2M-1-003), the Nonprofit Central Research Institute Fund of Chinese Academy of Medical Sciences (No. 2017PT31029), the Open Issue of State Key Laboratory of Molecular Oncology (No. SKL-KF-2017-16), the Independent Issue of State Key Laboratory of Molecular Oncology (No. SKL-2017-16) and Dalian Science and Technology Project (No. 2015E12SF117).	Bin Cho K, 2010, CANCER LETT, V293, P230, DOI 10.1016/j.canlet.2010.01.013; David CJ, 2016, CELL, V164, P1015, DOI 10.1016/j.cell.2016.01.009; De Sousa E Melo F, 2013, NAT MED, V19, P614, DOI 10.1038/nm.3174; Deng L, 2017, ONCOGENE, V36, P3976, DOI 10.1038/onc.2016.491; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Gan L, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-017-0547-3; Guan XM, 2015, ACTA PHARM SIN B, V5, P402, DOI 10.1016/j.apsb.2015.07.005; Hasegawa S, 2016, INT J ONCOL, V48, P145, DOI 10.3892/ijo.2015.3258; Jafarnejad SM, 2010, AM J PATHOL, V177, P2741, DOI 10.2353/ajpath.2010.100377; Jin YJ, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0903-5; Kim IK, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42501-6; Koumangoye RB, 2015, MOL CANCER, V14, DOI 10.1186/s12943-014-0284-y; Kuwahara M, 2012, NAT IMMUNOL, V13, P778, DOI 10.1038/ni.2362; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Li DQ, 2011, P NATL ACAD SCI USA, V108, P8791, DOI 10.1073/pnas.1018389108; Li ZW, 2017, CELL DEATH DIFFER, V24, P59, DOI 10.1038/cdd.2016.95; Lin L, 2016, TUMOR BIOL, V37, P15719, DOI 10.1007/s13277-016-5339-9; Liu J, 2014, CANCER METAST REV, V33, P843, DOI 10.1007/s10555-014-9511-7; Liu J, 2014, ONCOTARGET, V5, P5153, DOI 10.18632/oncotarget.2095; Ma JJ, 2016, TUMOR BIOL, V37, P9077, DOI 10.1007/s13277-015-4555-z; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Pakala SB, 2011, ONCOGENE, V30, P2230, DOI 10.1038/onc.2010.608; Parvani JG, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3466; Sen N, 2014, CANCER METAST REV, V33, P879, DOI 10.1007/s10555-014-9515-3; Shen H, 2015, INT J BIOL SCI, V11, P1363, DOI 10.7150/ijbs.13240; Shi S, 2015, DIS MARKERS, V2015, DOI 10.1155/2015/658141; Song QC, 2019, EXP CELL RES, V382, DOI 10.1016/j.yexcr.2019.05.031; Talmadge JE, 2010, CANCER RES, V70, P5649, DOI 10.1158/0008-5472.CAN-10-1040; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Theriault C, 2011, GYNECOL ONCOL, V121, P434, DOI 10.1016/j.ygyno.2011.02.020; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020; Toh Y, 2014, CANCER METAST REV, V33, P891, DOI 10.1007/s10555-014-9516-2; Trimboli AJ, 2008, CANCER RES, V68, P937, DOI 10.1158/0008-5472.CAN-07-2148; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Wang H, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0680-1; Wang L, 2013, PROSTATE CANCER P D, V16, P301, DOI 10.1038/pcan.2013.25; Wang YF, 2013, CURR CANCER DRUG TAR, V13, P963, DOI 10.2174/15680096113136660102; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Xue HS, 2015, ONCOL REP, V33, P885, DOI 10.3892/or.2014.3671; Yamaguchi H, 2014, CANCER RES TREAT, V46, P209, DOI 10.4143/crt.2014.46.3.209; Yoo YG, 2008, ONCOGENE, V27, P3405, DOI 10.1038/sj.onc.1211000; Yoo YG, 2006, EMBO J, V25, P1231, DOI 10.1038/sj.emboj.7601025; Zhang JC, 2012, CANCER RES, V72, P4597, DOI 10.1158/0008-5472.CAN-12-1045; Zhang WC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116634; Zhang XY, 2005, P NATL ACAD SCI USA, V102, P13968, DOI 10.1073/pnas.0502330102; Zheng LS, 2017, CANCER RES, V77, P579, DOI 10.1158/0008-5472.CAN-16-1281	48	32	32	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	10					2125	2139		10.1038/s41388-019-1132-8	http://dx.doi.org/10.1038/s41388-019-1132-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KS8UR	31811272				2022-12-28	WOS:000518584000008
J	Farhat, D; Ghayad, SE; Icard, P; Le Romancer, M; Hussein, N; Lincet, H				Farhat, Diana; Ghayad, Sandra E.; Icard, Philippe; Le Romancer, Muriel; Hussein, Nader; Lincet, Hubert			Lipoic acid-induced oxidative stress abrogates IGF-1R maturation by inhibiting the CREB/furin axis in breast cancer cell lines	ONCOGENE			English	Article							INDUCED APOPTOSIS; FURIN EXPRESSION; GROWTH; PROLIFERATION; ACTIVATION; TUMORS	The beneficial effects of lipoic acid (LA) in cancer treatment have been well documented in the last decade. Indeed, LA exerts crucial antiproliferative effects by reducing breast cancer cell viability, cell cycle progression and the epithelial-to-mesenchymal transition (EMT). However, the mechanisms of action (MOA) underlying these antiproliferative effects remain to be elucidated. Recently, we demonstrated that LA decreases breast cancer cell proliferation by inhibiting IGF-1R maturation via the downregulation of the proprotein convertase furin. The aim of the present study was to investigate the MOA by which LA inhibits furin expression in estrogen receptor alpha (ER alpha) (+) and (-) breast cancer cell lines. We unveil that LA exerts a pro-oxidant effect on these cell lines, the resulting reactive oxygen species (ROS) generated being responsible for the reduction in the expression of the major (CREB) protein. This transcription factor is overexpressed in many types of cancers and regulates the expression of furin in breast cancer cells independently of ER alpha, as evidenced herein by the inhibition of furin expression following CREB silencing. Consequently, our findings expose for the first time the complete MOA of LA via the CREB/furin axis leading to inhibition of breast cancer cell proliferation.	[Farhat, Diana; Le Romancer, Muriel; Lincet, Hubert] Univ Lyon 1, Lyon, France; [Farhat, Diana; Le Romancer, Muriel; Lincet, Hubert] CRCL, INSERM, U1052, Lyon, France; [Farhat, Diana; Le Romancer, Muriel; Lincet, Hubert] CRCL, CNRS, UMR5286, Lyon, France; [Farhat, Diana; Hussein, Nader] Lebanese Univ, Fac Sci, Canc Biol Stem Cells & Mol Immunol, Hadath Beirut, Lebanon; [Ghayad, Sandra E.] Lebanese Univ, Fac Sci 2, Dept Biol, Fanar, Lebanon; [Icard, Philippe] Normandie Univ, UNICAEN, CHU Caen Normandie, Unite Rech,BioTICLA,INSERM,U119, F-14000 Caen, France; [Icard, Philippe] Hop Cochin, Hop Univ Paris Ctr, Serv Chirurg Thorac, Paris, France; [Lincet, Hubert] Fac Pharm, ISPB, Lyon, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; Centre de Recherche en cancerologie (CRCL); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UNICANCER; Centre Leon Berard; Centre de Recherche en cancerologie (CRCL); Lebanese University; Lebanese University; CHU de Caen NORMANDIE; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Caen Normandie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Lincet, H (corresponding author), Univ Lyon 1, Lyon, France.; Lincet, H (corresponding author), CRCL, INSERM, U1052, Lyon, France.; Lincet, H (corresponding author), CRCL, CNRS, UMR5286, Lyon, France.; Lincet, H (corresponding author), Fac Pharm, ISPB, Lyon, France.	hubert.lincet@univ-lyon1.fr		Le Romancer, Muriel/0000-0002-8491-4015	National Council for Scientific Research in Lebanon CNRS-L; Lebanese University; Canceropole Lyon Auvergne Rhone-Alpes (CLARA); CNRS-L	National Council for Scientific Research in Lebanon CNRS-L; Lebanese University; Canceropole Lyon Auvergne Rhone-Alpes (CLARA); CNRS-L	This project has been jointly supported by the National Council for Scientific Research in Lebanon CNRS-L and Lebanese University and Canceropole Lyon Auvergne Rhone-Alpes (CLARA). DF was the recipient of a fellowship from the CNRS-L and Lebanese University.	Bassi DE, 2001, P NATL ACAD SCI USA, V98, P10326, DOI 10.1073/pnas.191199198; Bassi DE, 2001, MOL CARCINOGEN, V31, P224, DOI 10.1002/mc.1057; Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; Cheng M, 2001, J MOL ENDOCRINOL, V26, P95, DOI 10.1677/jme.0.0260095; Choi SY, 2009, ANN NY ACAD SCI, V1171, P149, DOI 10.1111/j.1749-6632.2009.04708.x; Farhat D, 2020, BBA-REV CANCER, V1873, DOI 10.1016/j.bbcan.2019.188317; Farhat D, 2020, BRIT J CANCER, V122, P885, DOI 10.1038/s41416-020-0729-6; Fu XH, 2019, MOL MED REP, V19, P3649, DOI 10.3892/mmr.2019.10027; Ireland L, 2018, ONCOGENE, V37, P2022, DOI 10.1038/s41388-017-0115-x; Jaaks P, 2017, INT J CANCER, V141, P654, DOI 10.1002/ijc.30714; Jaaks P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161396; Jeon MJ, 2016, MOL CELL ENDOCRINOL, V419, P113, DOI 10.1016/j.mce.2015.10.005; Kafara P, 2015, J OVARIAN RES, V8, DOI 10.1186/s13048-015-0165-z; Kono Y, 2012, EXPERT OPIN THER TAR, V16, pS103, DOI 10.1517/14728222.2011.640320; Lapierre M, 2007, CANCER RES, V67, P9030, DOI 10.1158/0008-5472.CAN-07-0807; Lee HS, 2010, NUTR RES, V30, P403, DOI 10.1016/j.nutres.2010.06.009; MASSAGUE J, 1982, J BIOL CHEM, V257, P5038; Moungjaroen J, 2006, J PHARMACOL EXP THER, V319, P1062, DOI 10.1124/jpet.106.110965; Na MH, 2009, NUTR RES PRACT, V3, P265, DOI 10.4162/nrp.2009.3.4.265; Riedemann J, 2006, ENDOCR-RELAT CANCER, V13, pS33, DOI 10.1677/erc.1.01280; Sachdev D, 2004, J BIOL CHEM, V279, P5017, DOI 10.1074/jbc.M305403200; Selvakumar E, 2008, J HEMATOL ONCOL, V1, DOI 10.1186/1756-8722-1-4; Shi DY, 2008, FEBS LETT, V582, P1667, DOI 10.1016/j.febslet.2008.04.021; Simbula G, 2007, APOPTOSIS, V12, P113, DOI 10.1007/s10495-006-0487-9; Smyth IM, 2019, SEMIN CELL DEV BIOL, V91, P84, DOI 10.1016/j.semcdb.2018.11.003; Steven A, 2016, ONCOTARGET, V7, P35454, DOI 10.18632/oncotarget.7721; Tripathy J, 2018, LIFE SCI, V207, P15, DOI 10.1016/j.lfs.2018.05.039; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; Wang BY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047053; Ward CW, 2001, J CLIN PATHOL-MOL PA, V54, P125; Wenzel U, 2005, APOPTOSIS, V10, P359, DOI 10.1007/s10495-005-0810-x; Yang XK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0050479; Zhou Z, 2014, PLACENTA, V35, P907, DOI 10.1016/j.placenta.2014.07.017; ZIEGLER D, 1995, DIABETOLOGIA, V38, P1425, DOI 10.1007/BF00400603	34	7	7	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	17					3604	3610		10.1038/s41388-020-1211-x	http://dx.doi.org/10.1038/s41388-020-1211-x		FEB 2020	7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LH1YK	32060422				2022-12-28	WOS:000513384600003
J	Dong, KS; Chen, Y; Yang, G; Liao, ZB; Zhang, HW; Liang, HF; Chen, XP; Dong, HH				Dong, Ke-shuai; Chen, Yan; Yang, Guang; Liao, Zhi-bin; Zhang, Hong-wei; Liang, Hui-fang; Chen, Xiao-ping; Dong, Han-hua			TGF-beta 1 accelerates the hepatitis B virus X-induced malignant transformation of hepatic progenitor cells by upregulating miR-199a-3p	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; CANCER STEM-CELLS; TUMOR-INITIATING CELLS; HEPATOCELLULAR-CARCINOMA; TGF-BETA; HUMAN LIVER; ACTIVATION; MECHANISMS; MICRORNA; IDENTIFICATION	Increasing evidence has suggested that liver cancer arises partially from transformed hepatic progenitor cells (HPCs). However, the detailed mechanisms underlying HPC transformation are poorly understood. In this study, we provide evidence linking the coexistence of hepatitis B virus X protein (HBx) and transforming growth factor beta 1 (TGF-beta 1) with miR-199a-3p in the malignant transformation of HPCs. The examination of liver cancer specimens demonstrated that HBx and TGF-beta 1 expression was positively correlated with epithelial cell adhesion molecule (EpCAM) and cluster of differentiation 90 (CD90). Importantly, EpCAM and CD90 expression was much higher in the specimens expressing both high HBx and high TGF-beta 1 than in those with high HBx or high TGF-beta 1 and the double-low-expression group. HBx and TGF-beta 1 double-high expression was significantly associated with poor prognosis in primary liver cancer. We also found that HBx and TGF-beta 1 induced the transformation of HPCs into hepatic cancer stem cells and promoted epithelial-mesenchymal transformation, which was further enhanced by concomitant HBx and TGF-beta 1 exposure. Moreover, activation of the c-Jun N-terminal kinase (JNK)/c-Jun pathway was involved in the malignant transformation of HPCs. miR-199a-3p was identified as a significantly upregulated microRNA in HPCs upon HBx and TGF-beta 1 exposure, which were shown to promote miR-199a-3p expression via c-Jun-mediated activation. Finally, we found that miR-199a-3p was responsible for the malignant transformation of HPCs. In conclusion, our results provide evidence that TGF-beta 1 cooperates with HBx to promote the malignant transformation of HPCs through a JNK/c-Jun/miR-199a-3p-dependent pathway. This may open new avenues for therapeutic interventions targeting the malignant transformation of HPCs in treating liver cancer.	[Dong, Ke-shuai; Yang, Guang; Liao, Zhi-bin; Zhang, Hong-wei; Liang, Hui-fang; Chen, Xiao-ping; Dong, Han-hua] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr,Dept Hepat Surg, Wuhan, Peoples R China; [Dong, Ke-shuai] Wuhan Univ, Renmin Hosp, Dept Hepatobiliary & Laparoscop Surg, Hubei Key Lab Digest Syst Dis, Wuhan, Peoples R China; [Chen, Yan] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Gen Surg, Wuhan, Peoples R China	Huazhong University of Science & Technology; Wuhan University; Huazhong University of Science & Technology	Dong, HH (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr,Dept Hepat Surg, Wuhan, Peoples R China.	hanhua_dong@hotmail.com		Liao, Zhibin/0000-0003-0305-2079	National Natural Science Foundation of China [81402410, 81802767]; Edanz Group China	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Edanz Group China	This work was supported by the National Natural Science Foundation of China (Grant No. 81402410, 81802767). We thank Sarah Williams, PhD, from Liwen Bianji, Edanz Group China (www.liwenbianji.cn), for editing the English text of a draft of this manuscript.	Alemdehy MF, 2015, BLOOD, V125, P3937, DOI 10.1182/blood-2014-11-612507; Alvarez-Garcia I, 2005, DEVELOPMENT, V132, P4653, DOI 10.1242/dev.02073; Arzumanyan A, 2011, CANCER RES, V71, P3701, DOI 10.1158/0008-5472.CAN-10-3951; Celia-Terrassa T, 2017, NAT CELL BIOL, V19, P711, DOI 10.1038/ncb3533; Chen J, 2016, J CLIN INVEST, V126, P527, DOI 10.1172/JCI80937; Deng XG, 2014, LIVER INT, V34, P281, DOI 10.1111/liv.12239; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Drabsch Y, 2012, CANCER METAST REV, V31, P553, DOI 10.1007/s10555-012-9375-7; Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0; Gao Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep11365; Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Henkler F, 1996, J VIRAL HEPATITIS, V3, P109, DOI 10.1111/j.1365-2893.1996.tb00001.x; Hou J, 2011, CANCER CELL, V19, P232, DOI 10.1016/j.ccr.2011.01.001; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Iredale JP, 2007, J CLIN INVEST, V117, P539, DOI 10.1172/JCI30542; Jung KH, 2016, STEM CELLS, V34, P1284, DOI 10.1002/stem.2283; Kuo KK, 2016, STEM CELLS, V34, P2613, DOI 10.1002/stem.2447; Lee DK, 2001, GENE DEV, V15, P455, DOI 10.1101/gad.856201; Lee JS, 2006, NAT MED, V12, P410, DOI 10.1038/nm1377; Levrero M, 2016, J HEPATOL, V64, pS84, DOI 10.1016/j.jhep.2016.02.021; Li CH, 2011, CANCER LETT, V311, P1, DOI 10.1016/j.canlet.2011.05.035; Liu FY, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.46; Liu JL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076651; Liu Y, 2016, ONCOTARGET, V7, P33125, DOI 10.18632/oncotarget.8884; Ma S, 2007, GASTROENTEROLOGY, V132, P2542, DOI 10.1053/j.gastro.2007.04.025; Ma S, 2010, CELL STEM CELL, V7, P694, DOI 10.1016/j.stem.2010.11.010; Majumdar A, 2012, NAT REV GASTRO HEPAT, V9, P530, DOI 10.1038/nrgastro.2012.114; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Matsumoto T, 2017, CANCER RES, V77, P6131, DOI 10.1158/0008-5472.CAN-17-1800; Michalopoulos GK, 2015, GASTROENTEROLOGY, V149, P876, DOI 10.1053/j.gastro.2015.08.004; Mikhail S, 2011, INT J HEPATOL, V2011, DOI 10.4061/2011/486954; Mishra L, 2005, SCIENCE, V310, P68, DOI 10.1126/science.1118389; Motavaf M, 2013, ACTA VIROL, V57, P389, DOI 10.4149/av_2013_04_389; Murata M, 2009, HEPATOLOGY, V49, P1203, DOI 10.1002/hep.22765; Oikawa T, 2016, HEPATOLOGY, V64, P645, DOI 10.1002/hep.28485; Pencheva N, 2012, CELL, V151, P1068, DOI 10.1016/j.cell.2012.10.028; Sia D, 2017, GASTROENTEROLOGY, V152, P745, DOI 10.1053/j.gastro.2016.11.048; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Singh M, 2018, PHARMACOL THERAPEUT, V182, P80, DOI 10.1016/j.pharmthera.2017.08.009; Song WQ, 2014, CANCER RES, V74, P2444, DOI 10.1158/0008-5472.CAN-13-2136; Tanaka Y, 2006, ONCOGENE, V25, P633, DOI 10.1038/sj.onc.1209093; Teng CF, 2018, MOL ONCOL, V12, P1175, DOI 10.1002/1878-0261.12318; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Tummala KS, 2017, CELL REP, V19, P584, DOI 10.1016/j.celrep.2017.03.059; Wang C, 2012, HEPATOLOGY, V55, P108, DOI 10.1002/hep.24675; Weng HL, 2009, HEPATOLOGY, V50, P230, DOI 10.1002/hep.22934; Wu K, 2012, HEPATOLOGY, V56, P2255, DOI 10.1002/hep.26007; Wu QH, 2019, MED RES REV, V39, P2082, DOI 10.1002/med.21574; Wu Y, 2018, BIOCHIMIE, V148, P87, DOI 10.1016/j.biochi.2018.03.003; Xie X, 2017, ONCOGENE, V36, P2599, DOI 10.1038/onc.2016.417; Yamashita T, 2013, J CLIN INVEST, V123, P1911, DOI 10.1172/JCI66024; Yamashita T, 2009, GASTROENTEROLOGY, V136, P1012, DOI 10.1053/j.gastro.2008.12.004; Yang ZF, 2008, CANCER CELL, V13, P153, DOI 10.1016/j.ccr.2008.01.013; Yoo YD, 1996, J CLIN INVEST, V97, P388, DOI 10.1172/JCI118427; Zhou SJ, 2017, CELL DEATH DIFFER, V24, P1577, DOI 10.1038/cdd.2017.87	58	9	10	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	8					1807	1820		10.1038/s41388-019-1107-9	http://dx.doi.org/10.1038/s41388-019-1107-9			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN6CG	31740785	hybrid, Green Published			2022-12-28	WOS:000514923000014
J	Franke, CM; Gu, VW; Grimm, BG; Cassady, VC; White, JR; Weigel, RJ; Kulak, MV				Franke, Christopher M.; Gu, Vivian W.; Grimm, Benjamin G.; Cassady, Victoria C.; White, Jeffrey R.; Weigel, Ronald J.; Kulak, Mikhail, V			TFAP2C regulates carbonic anhydrase XII in human breast cancer	ONCOGENE			English	Article							GENE-EXPRESSION; ISOZYME-XII; CELL-LINES; CLASSIFICATION; ENHANCER; SUBTYPES; IDENTIFICATION; PROMOTER; TARGET; IX	The expression of carbonic anhydrase XII (CA12) is associated with the expression of estrogen receptor alpha (ER alpha) in breast cancer and is linked to a good prognosis with a lower risk of metastasis. Transcription Factor Activator Protein 2 gamma (TFAP2C, AP-2 gamma) governs luminal breast cancer phenotype through direct and indirect regulation of ER alpha and ER alpha-associated genes, GATA3, FOXA1, EGFR, CDH1, DSP, KRT7, FBP1, MYB, RET, KRT8, MUC1, and ERBB2-genes which are responsible for the luminal signature in breast cancer. Herein, utilizing chromatin immunoprecipitation and direct sequencing (ChIP-seq), we show that CA12 is regulated by AP-2 gamma through binding with its promoter region in luminal breast cancer cell lines and indirectly through a distal estrogen-responsive region in ER alpha-positive cell lines by upregulation of ER alpha. CA12 is transcriptionally silenced in basal breast cancer cell lines through histone deacetylation and CpG methylation of the promoter region and can be re-activated with Trichostatin A (histone deacetylase inhibitor) and/or 5-aza-dC (an inhibitor of DNA methylation). Strong concordance in co-expression of CA12 and ESR1 (R-2 = 0.1128, p = 0486) and TFAP2C (R-2 = 0.1823, p = 0.0105) was found using a panel of primary breast tumor samples (n = 35), supporting a synergetic role of AP-2 gamma and ER alpha in activation of CA12. Our results highlight the essential role of AP-2 gamma in maintaining the luminal breast cancer phenotype and provide evidence that epigenetic mechanisms silence luminal gene expression in the basal phenotype. Additional studies to decipher mechanisms that drive epigenetic silencing of AP-2 gamma target genes are a critical area for further research.	[Franke, Christopher M.; Gu, Vivian W.; Grimm, Benjamin G.; Cassady, Victoria C.; White, Jeffrey R.; Weigel, Ronald J.; Kulak, Mikhail, V] Univ Iowa, Dept Surg, Iowa City, IA 52242 USA; [Weigel, Ronald J.] Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Kulak, MV (corresponding author), Univ Iowa, Dept Surg, Iowa City, IA 52242 USA.	mikhail-kulak@uiowa.edu		Kulak, Mikhail/0000-0002-4307-5868; Weigel, Ronald/0000-0002-9249-0793; Grimm, Benjamin/0000-0002-9604-1266; White, Jeffrey/0000-0003-3146-9605				Barnett DH, 2008, CANCER RES, V68, P3505, DOI 10.1158/0008-5472.CAN-07-6151; Brenton JD, 2005, J CLIN ONCOL, V23, P7350, DOI 10.1200/JCO.2005.03.3845; Cyr AR, 2015, ONCOGENE, V34, P436, DOI 10.1038/onc.2013.569; Dai XF, 2017, J CANCER, V8, P3131, DOI 10.7150/jca.18457; De Andrade JP, 2016, MOL CANCER THER, V15, P503, DOI 10.1158/1535-7163.MCT-15-0548-T; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Haapasalo J, 2008, NEURO-ONCOLOGY, V10, P131, DOI 10.1215/15228517-2007-065; Hynninen P, 2006, HISTOPATHOLOGY, V49, P594, DOI 10.1111/j.1365-2559.2006.02523.x; Ilie MI, 2011, INT J CANCER, V128, P1614, DOI 10.1002/ijc.25491; Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146; Kivela A, 2000, AM J PATHOL, V156, P577, DOI 10.1016/S0002-9440(10)64762-1; Kivela AJ, 2005, WORLD J GASTROENTERO, V11, P2616, DOI 10.3748/wjg.v11.i17.2616; Kopecka J, 2016, ONCOTARGET, V7, P85861, DOI 10.18632/oncotarget.13040; Kopecka J, 2015, ONCOTARGET, V6, P6776, DOI 10.18632/oncotarget.2882; Kulak MV, 2013, ONCOGENE, V32, P4043, DOI 10.1038/onc.2012.400; Lacroix M, 2004, ONCOL REP, V12, P701; Liu Q, 2018, ONCOGENE, V37, P687, DOI 10.1038/onc.2017.382; Masood S, 2016, WOMENS HEALTH, V12, P103, DOI 10.2217/whe.15.99; McPherson LA, 1999, NUCLEIC ACIDS RES, V27, P4040, DOI 10.1093/nar/27.20.4040; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Nordfors K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-148; O'Brien KM, 2010, CLIN CANCER RES, V16, P6100, DOI 10.1158/1078-0432.CCR-10-1533; Palmer MB, 2007, CANCER RES, V67, P6113, DOI 10.1158/0008-5472.CAN-06-4256; Parkkila S, 2000, J HISTOCHEM CYTOCHEM, V48, P1601, DOI 10.1177/002215540004801203; Riaz M, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3415; SLY WS, 1995, ANNU REV BIOCHEM, V64, P375, DOI 10.1146/annurev.bi.64.070195.002111; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sotiriou C, 2009, NEW ENGL J MED, V360, P790, DOI 10.1056/NEJMra0801289; Spanheimer PM, 2013, ANN SURG ONCOL, V20, P2204, DOI 10.1245/s10434-012-2570-5; Supuran CT, 2008, CURR PHARM DESIGN, V14, P603, DOI 10.2174/138161208783877884; TASHIAN RE, 1989, BIOESSAYS, V10, P186, DOI 10.1002/bies.950100603; U.S. Cancer Statistics Working Group. U.S. Department of Health and Human Services C.f.D.C.a.P.a.N.C.I., US CANC STAT DAT VIS; von Neubeck B, 2018, INT J CANCER, V143, P2065, DOI 10.1002/ijc.31607; Waheed A, 2017, GENE, V623, P33, DOI 10.1016/j.gene.2017.04.027; Watson PH, 2003, BRIT J CANCER, V88, P1065, DOI 10.1038/sj.bjc.6600796; Weigelt B, 2010, J PATHOL, V220, P263, DOI 10.1002/path.2648; Woodfield GW, 2007, CANCER RES, V67, P8439, DOI 10.1158/0008-5472.CAN-07-2293; Woodfield GW, 2010, GENE CHROMOSOME CANC, V49, P948, DOI 10.1002/gcc.20807; Woodfield GW, 2009, CLIN CANCER RES, V15, P3672, DOI 10.1158/1078-0432.CCR-08-2343; Wykoff CC, 2001, AM J PATHOL, V158, P1011, DOI 10.1016/S0002-9440(10)64048-5; Yau C, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2753; Yersal O, 2014, WORLD J CLIN ONCOL, V5, P412, DOI 10.5306/wjco.v5.i3.412	42	7	7	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	6					1290	1301		10.1038/s41388-019-1062-5	http://dx.doi.org/10.1038/s41388-019-1062-5			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE4UH	31636386				2022-12-28	WOS:000526714600009
J	Kim, JY; Kim, JK; Kim, H				Kim, Jung Yun; Kim, Jun-Kyum; Kim, Hyunggee			ABCB7 simultaneously regulates apoptotic and non-apoptotic cell death by modulating mitochondrial ROS and HIF1 alpha-driven NF kappa B signaling	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; INDUCIBLE FACTOR-I; UP-REGULATION; HYPOXIA; CANCER; METABOLISM; IDENTIFICATION; PROLIFERATION; GLIOBLASTOMA; HOMEOSTASIS	Most of the mechanisms governing apoptotic and non-apoptotic cell death are regulated independently. However, cells may experience various stresses that lead to both apoptotic and non-apoptotic cell death. In particular, cancer cells require a program that simultaneously avoids these forms of cell death, but the mechanism by which they are able to do so is currently unclear. Here, we show that ABC transporter subfamily B member 7 (ABCB7), one of the mitochondrial iron transporters, induces the hypoxia-independent accumulation of hypoxia-inducible factor 1 alpha by controlling intracellular iron homeostasis and inhibits both apoptotic and non-apoptotic cell death. Mechanistically, ABCB7 mitigates non-apoptotic cell death by reducing levels of mitochondrial reactive oxygen species. ABCB7 also suppresses apoptosis by inhibiting the expression of leucine zipper downregulated in cancer 1, an inhibitor of nuclear factor-kappa B signaling. Therefore, our results support that ABCB7 is crucial in controlling both apoptotic and non-apoptotic cell death and indicate that the fine-tuning of intracellular iron homeostasis may be a novel anticancer strategy.	[Kim, Jung Yun; Kim, Jun-Kyum; Kim, Hyunggee] Korea Univ, Sch Life Sci & Biotechnol, Dept Biotechnol, Seoul 02841, South Korea; [Kim, Jung Yun; Kim, Jun-Kyum; Kim, Hyunggee] Korea Univ, Inst Anim Mol Biotechnol, Seoul 02841, South Korea; [Kim, Hyunggee] Korea Univ, Dept Med Engn, Coll Med, Seoul 02841, South Korea	Korea University; Korea University; Korea University; Korea University Medicine (KU Medicine)	Kim, H (corresponding author), Korea Univ, Sch Life Sci & Biotechnol, Dept Biotechnol, Seoul 02841, South Korea.; Kim, H (corresponding author), Korea Univ, Inst Anim Mol Biotechnol, Seoul 02841, South Korea.; Kim, H (corresponding author), Korea Univ, Dept Med Engn, Coll Med, Seoul 02841, South Korea.	hg-kim@korea.ac.kr			National Research Foundation (NRF) [2015R1A5A1009024, 2017R1E1A1A01074205, 2017M3A9A8031425]; School of Life Sciences and Biotechnology for BK21 Plus, Korea University	National Research Foundation (NRF); School of Life Sciences and Biotechnology for BK21 Plus, Korea University	The authors thank the members of the Cancer Growth Regulation Laboratory for their discussions and technical assistance. This work was supported by grants to Hyunggee Kim from the National Research Foundation (NRF) [grant numbers 2015R1A5A1009024, 2017R1E1A1A01074205 and 2017M3A9A8031425], and the School of Life Sciences and Biotechnology for BK21 Plus, Korea University.	Andreyev AI, 2005, BIOCHEMISTRY-MOSCOW+, V70, P200, DOI 10.1007/s10541-005-0102-7; Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200; Bagnall J, 2014, J BIOL CHEM, V289, P5549, DOI 10.1074/jbc.M113.500405; Behan FM, 2019, NATURE, V568, P511, DOI 10.1038/s41586-019-1103-9; Benita Y, 2009, NUCLEIC ACIDS RES, V37, P4587, DOI 10.1093/nar/gkp425; Bhat KPL, 2013, CANCER CELL, V24, P331, DOI 10.1016/j.ccr.2013.08.001; Bratic I, 2010, BBA-BIOENERGETICS, V1797, P961, DOI 10.1016/j.bbabio.2010.01.004; Chen L, 2012, MOL CELL BIOCHEM, V365, P263, DOI 10.1007/s11010-012-1267-1; Chirasani SR, 2009, J MOL MED, V87, P153, DOI 10.1007/s00109-008-0414-3; Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R; Depoix CL, 2017, MOL HUM REPROD, V23, P199, DOI 10.1093/molehr/gax002; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Drummen GPC, 2002, FREE RADICAL BIO MED, V33, P473, DOI 10.1016/S0891-5849(02)00848-1; Eales KL, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.50; Eruslanov E, 2010, METHODS MOL BIOL, V594, P57, DOI 10.1007/978-1-60761-411-1_4; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Frost J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13312; Glassford AJ, 2007, AM J PHYSIOL-ENDOC M, V293, pE1590, DOI 10.1152/ajpendo.00490.2007; Glavinas Hristos, 2004, Current Drug Delivery, V1, P27, DOI 10.2174/1567201043480036; Glickstein H, 2005, BLOOD, V106, P3242, DOI 10.1182/blood-2005-02-0460; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hentze MW, 2010, CELL, V142, P24, DOI 10.1016/j.cell.2010.06.028; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Huang JY, 2013, FASEB J, V27, P2845, DOI 10.1096/fj.12-216929; Hung HI, 2013, J BIOL CHEM, V288, P677, DOI 10.1074/jbc.M112.422667; Inoue H, 2014, CELL DEATH DIFFER, V21, P39, DOI 10.1038/cdd.2013.84; Joseph JV, 2015, CANCER LETT, V359, P107, DOI 10.1016/j.canlet.2015.01.010; Kang TB, 2004, J IMMUNOL, V173, P2976, DOI 10.4049/jimmunol.173.5.2976; Kaur D, 2009, FREE RADICAL BIO MED, V46, P593, DOI 10.1016/j.freeradbiomed.2008.11.012; Lee G, 2016, MOL CANCER THER, V15, P3064, DOI 10.1158/1535-7163.MCT-15-0675; Letai A, 2015, CLIN CANCER RES, V21, P5015, DOI 10.1158/1078-0432.CCR-15-1204; Li CW, 2012, CANCER RES, V72, P1290, DOI 10.1158/0008-5472.CAN-11-3123; Li W, 2016, DRUG RESIST UPDATE, V27, P14, DOI 10.1016/j.drup.2016.05.001; Mao P, 2013, P NATL ACAD SCI USA, V110, P8644, DOI 10.1073/pnas.1221478110; Mukhopadhyay P, 2007, BIOCHEM BIOPH RES CO, V358, P203, DOI 10.1016/j.bbrc.2007.04.106; Munoz LE, 2013, AUTOIMMUNITY, V46, P336, DOI 10.3109/08916934.2012.755960; Nagasaki K, 2003, INT J CANCER, V105, P454, DOI 10.1002/ijc.11122; Nagasaki K, 1999, CANCER LETT, V140, P227, DOI 10.1016/S0304-3835(99)00087-7; Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412; Paul VD, 2015, BBA-MOL CELL RES, V1853, P1528, DOI 10.1016/j.bbamcr.2014.12.018; Piret JP, 2002, ANN NY ACAD SCI, V973, P443, DOI 10.1111/j.1749-6632.2002.tb04680.x; Puliyappadamba VT, 2014, MOL CELL ONCOL, V1, DOI 10.4161/23723548.2014.963478; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Schaedler TA, 2015, BIOCHEM SOC T, V43, P943, DOI 10.1042/BST20150118; Schonberg DL, 2015, CANCER CELL, V28, P441, DOI 10.1016/j.ccell.2015.09.002; Shah YM, 2014, GASTROENTEROLOGY, V146, P630, DOI 10.1053/j.gastro.2013.12.031; Sparreboom A, 2003, DRUG RESIST UPDATE, V6, P71, DOI 10.1016/S1368-7646(03)00005-0; Tang N, 2004, CANCER CELL, V6, P485, DOI 10.1016/j.ccr.2004.09.026; Tenopoulou M, 2007, BIOCHEM J, V403, P261, DOI 10.1042/BJ20061840; Trnka J, 2009, FREE RADICAL RES, V43, P4, DOI 10.1080/10715760802582183; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev; Wu Y, 2009, CANCER CELL, V15, P416, DOI 10.1016/j.ccr.2009.03.016; Xia YF, 2014, CANCER IMMUNOL RES, V2, P823, DOI 10.1158/2326-6066.CIR-14-0112; Xie Y, 2016, CELL DEATH DIFFER, V23, P369, DOI 10.1038/cdd.2015.158; Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010; Yin F, 2014, ANTIOXID REDOX SIGN, V20, P353, DOI 10.1089/ars.2012.4774; Zutz A, 2009, BBA-BIOENERGETICS, V1787, P681, DOI 10.1016/j.bbabio.2009.02.009	58	12	12	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	9					1969	1982		10.1038/s41388-019-1118-6	http://dx.doi.org/10.1038/s41388-019-1118-6			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KP9VM	31772327				2022-12-28	WOS:000516579800011
J	Kumarasamy, V; Ruiz, A; Nambiar, R; Witkiewicz, AK; Knudsen, ES				Kumarasamy, Vishnu; Ruiz, Amanda; Nambiar, Ram; Witkiewicz, Agnieszka K.; Knudsen, Erik S.			Chemotherapy impacts on the cellular response to CDK4/6 inhibition: distinct mechanisms of interaction and efficacy in models of pancreatic cancer	ONCOGENE			English	Article							GEMCITABINE; REPLICATION; SUPPRESSION; PROGRESSION; RESISTANCE; APOPTOSIS; PATHWAY; REPAIR; CELLS; E2F	Pancreatic ductal adenocarcinoma (PDAC) is a therapy recalcitrant disease characterized by the aberrations in multiple genes that drive pathogenesis and limit therapeutic response. While CDK4/6 represents a downstream target of both KRAS mutation and loss of the CDKN2A tumor suppressor in PDAC, clinical and preclinical studies indicate that pharmacological CDK4/6 inhibitors are only modestly effective. Since chemotherapy represents the established backbone of PDAC treatment we evaluated the interaction of CDK4/6 inhibitors with gemcitabine and taxanes that are employed in the treatment of PDAC. Herein, we demonstrate that the difference in mechanisms of actions of chemotherapeutic agents elicit distinct effects on the cellular response to CDK4/6 inhibition. Gemcitabine largely ablates the function of CDK4/6 inhibition in S-phase arrested cells when administered contemporaneously; although, when cells recover from S-phase block they exhibit sensitivity to CDK4/6 inhibition. In contrast, pharmacological inhibition of CDK4/6 yields a cooperative cytostatic effect in combination with docetaxel and prevents adaptation and cell cycle re-entry, which is a common basis for resistance to such agents. Importantly, using organoid and PDX models we could confirm the cooperative effects between chemotherapy and CDK4/6 inhibition in vivo. These data indicate that the combination of cytotoxic and cytostatic agents could represent an important modality in those tumor types that are relatively resistant to CDK4/6 inhibitors.	[Kumarasamy, Vishnu; Nambiar, Ram; Witkiewicz, Agnieszka K.; Knudsen, Erik S.] Roswell Park Canc Inst, Ctr Personalized Med, Buffalo, NY 14263 USA; [Kumarasamy, Vishnu; Nambiar, Ram; Knudsen, Erik S.] Roswell Park Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA; [Ruiz, Amanda] Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA; [Witkiewicz, Agnieszka K.] Roswell Park Canc Inst, Dept Pathol, Buffalo, NY 14263 USA	Roswell Park Cancer Institute; Roswell Park Cancer Institute; Arizona Center Cancer Care; University of Arizona; Roswell Park Cancer Institute	Witkiewicz, AK; Knudsen, ES (corresponding author), Roswell Park Canc Inst, Ctr Personalized Med, Buffalo, NY 14263 USA.; Knudsen, ES (corresponding author), Roswell Park Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA.; Witkiewicz, AK (corresponding author), Roswell Park Canc Inst, Dept Pathol, Buffalo, NY 14263 USA.	Agnieszka.Witkiewicz@Roswellpark.org; Erik.Knudsen@roswellpark.org	Kumarasamy, Vishnu/AAV-8896-2021		National Cancer Institute (NCI)	National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The author thanks all members of the laboratory group and colleagues in the discussion and preparation of the manuscript. The research was supported by a grant to AKW and ESK from National Cancer Institute (NCI).	ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu, 2017, Cancer Cell, V32, P185, DOI 10.1016/j.ccell.2017.07.007; Cao J, 2019, ONCOGENE, V38, P4125, DOI 10.1038/s41388-019-0708-7; Cappella P, 2001, INT J CANCER, V93, P401, DOI 10.1002/ijc.1351.abs; Cheema AR, 2016, SURG CLIN N AM, V96, P1391, DOI 10.1016/j.suc.2016.07.011; Chou A, 2018, GUT, V67, P2142, DOI 10.1136/gutjnl-2017-315144; Clark AS, 2019, CLIN CANCER RES, V25, P2072, DOI 10.1158/1078-0432.CCR-18-0790; Cowan RW, 2014, CANCER J, V20, P80, DOI 10.1097/PPO.0000000000000011; Dean JL, 2012, J BIOL CHEM, V287, P29075, DOI 10.1074/jbc.M112.365494; Duronio Robert J, 2013, Cold Spring Harb Perspect Biol, V5, pa008904, DOI 10.1101/cshperspect.a008904; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Ewald B, 2007, MOL CANCER THER, V6, P1239, DOI 10.1158/1535-7163.MCT-06-0633; Francis AM, 2017, MOL CANCER THER, V16, P1751, DOI 10.1158/1535-7163.MCT-17-0040; Franco J, 2014, ONCOTARGET, V5, P6512, DOI 10.18632/oncotarget.2270; Haines Eric, 2018, Oncotarget, V9, P31572, DOI 10.18632/oncotarget.25803; He SH, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3986; HEINEMANN V, 1995, SEMIN ONCOL, V22, P11; Hernandez-Vargas H, 2007, ONCOGENE, V26, P2902, DOI 10.1038/sj.onc.1210102; Herrera-Abreu MT, 2016, CANCER RES, V76, P2301, DOI 10.1158/0008-5472.CAN-15-0728; Hidalgo M, 2015, PANCREATOLOGY, V15, P8, DOI 10.1016/j.pan.2014.10.001; Hoskins EE, 2008, ONCOGENE, V27, P4798, DOI 10.1038/onc.2008.121; Iyengar Mangala, 2018, Oncotarget, V9, P15658, DOI 10.18632/oncotarget.24585; Jansen VM, 2017, CANCER RES, V77, P2488, DOI 10.1158/0008-5472.CAN-16-2653; Johnson SM, 2010, J CLIN INVEST, V120, P2528, DOI 10.1172/JCI41402; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Knudsen ES, 2019, ONCOGENE, V38, P3355, DOI 10.1038/s41388-018-0650-0; Knudsen ES, 2018, GUT, V67, P508, DOI 10.1136/gutjnl-2016-313133; Knudsen ES, 2016, GASTROENTEROLOGY, V150, P48, DOI 10.1053/j.gastro.2015.08.056; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; McClendon AK, 2012, CELL CYCLE, V11, P2747, DOI 10.4161/cc.21127; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; O'Hayer KM, 2016, DISCOV MED, V21, P117; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; Pienta KJ, 2001, SEMIN ONCOL, V28, P3, DOI 10.1053/sonc.2001.26892; Pontano LL, 2009, CELL CYCLE, V8, P824, DOI 10.4161/cc.8.6.7889; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Schutte M, 1997, CANCER RES, V57, P3126; Shangguan WJ, 2014, ONCOL REP, V31, P305, DOI 10.3892/or.2013.2815; Shen H, 2010, J BIOL CHEM, V285, P23103, DOI 10.1074/jbc.M110.124990; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Taylor-Harding B, 2015, ONCOTARGET, V6, P696, DOI 10.18632/oncotarget.2673; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Witkiewicz AK, 2018, CELL REP, V22, P1185, DOI 10.1016/j.celrep.2018.01.022; Witkiewicz AK, 2015, ONCOTARGET, V6, P15788, DOI 10.18632/oncotarget.3819; Witkiewicz AK, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7744	48	20	20	1	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	9					1831	1845		10.1038/s41388-019-1102-1	http://dx.doi.org/10.1038/s41388-019-1102-1			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KP9VM	31745297	Green Accepted			2022-12-28	WOS:000516579800001
J	Li, YM; Zhou, Y; Li, BF; Chen, F; Shen, WY; Lu, YS; Zhong, CL; Zhang, C; Xie, H; Katanaev, VL; Jia, L				Li, Yumei; Zhou, Yu; Li, Bifei; Chen, Fan; Shen, Weiyu; Lu, Yusheng; Zhong, Chunlian; Zhang, Chen; Xie, Huanzhang; Katanaev, Vladimir L.; Jia, Lee			WDR74 modulates melanoma tumorigenesis and metastasis through the RPL5-MDM2-p53 pathway	ONCOGENE			English	Article							NUCLEOLAR AAA-ATPASE; RIBOSOMAL-PROTEINS; P53; GROWTH; PROLIFERATION; BIOGENESIS; MUTATIONS; REGULATOR; CANCER	The key molecules and underlying mechanisms of melanoma metastasis remain poorly understood. Using isobaric tag for relative and absolute quantitation (iTRAQ) proteomic screening, probing of patients' samples, functional verification, and mechanistic validation, we identified the important role of the WD repeat-containing protein 74 (WDR74) in melanoma progression and metastasis. Through gain- and loss-of-function approaches, WDR74 was found to promote cell proliferation, apoptosis resistance, and aggressive behavior in vitro. Moreover, WDR74 contributed to melanoma growth and metastasis in vivo. Mechanistically, WDR74 modulates RPL5 protein levels and consequently regulates MDM2 and insulates the ubiquitination degradation of p53 by MDM2. Our study is the first to reveal the oncogenic role of WDR74 in melanoma progression and the regulatory effect of WDR74 on the RPL5-MDM2-p53 pathway. Collectively, WDR74 can serve as a candidate target for the prevention and treatment of melanoma in the clinic.	[Li, Yumei; Zhou, Yu; Li, Bifei; Chen, Fan; Shen, Weiyu; Jia, Lee] Fuzhou Univ, Coll Chem, Canc Metastasis Alert & Prevent Ctr, Fujian Prov Key Lab Canc Metastasis Chemoprevent, Fuzhou 350116, Fujian, Peoples R China; [Lu, Yusheng; Zhong, Chunlian; Zhang, Chen; Xie, Huanzhang; Katanaev, Vladimir L.; Jia, Lee] Minjiang Univ, Inst Oceanog, Fuzhou 350116, Fujian, Peoples R China; [Katanaev, Vladimir L.] Far Eastern Fed Univ, Sch Biomed, Nat Prod Drug Discovery Lab, Vladivostok, Russia; [Katanaev, Vladimir L.] Univ Geneva, Fac Med, Translat Res Ctr Oncohaematol, Dept Cell Physiol & Metab, Geneva, Switzerland	Fuzhou University; Minjiang University; Far Eastern Federal University; University of Geneva	Jia, L (corresponding author), Fuzhou Univ, Coll Chem, Canc Metastasis Alert & Prevent Ctr, Fujian Prov Key Lab Canc Metastasis Chemoprevent, Fuzhou 350116, Fujian, Peoples R China.; Katanaev, VL; Jia, L (corresponding author), Minjiang Univ, Inst Oceanog, Fuzhou 350116, Fujian, Peoples R China.; Katanaev, VL (corresponding author), Far Eastern Fed Univ, Sch Biomed, Nat Prod Drug Discovery Lab, Vladivostok, Russia.; Katanaev, VL (corresponding author), Univ Geneva, Fac Med, Translat Res Ctr Oncohaematol, Dept Cell Physiol & Metab, Geneva, Switzerland.	Vladimir.Katanaev@unige.ch; cmapcjia1234@163.com	Katanaev, Vladimir/F-9480-2014	Katanaev, Vladimir/0000-0002-7909-5617; Lu, Yusheng/0000-0003-2341-4487; Li, Yumei/0000-0002-7910-6515; Zhang, Chen/0000-0002-5080-9321; JIA, LEE/0000-0001-6839-5545; Chen, Fan/0000-0003-3873-7094	National Natural Science Foundation of China [81961138017, 81773063, U1505225]; Ministry of Science and Technology of China [2015CB931804]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China)	This work was supported by the grants from National Natural Science Foundation of China (81961138017, 81773063, U1505225); Ministry of Science and Technology of China (2015CB931804).	Azim HA, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0538-7; Bedrosian I, 2000, ANN SURG ONCOL, V7, P262, DOI 10.1007/s10434-000-0262-z; Brentnall M, 2013, BMC CELL BIOL, V14, DOI 10.1186/1471-2121-14-32; Chen XX, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-018-1188-3; Chen XX, 2018, AGING-US, V10, P3421, DOI 10.18632/aging.101656; Cheng YL, 2018, INT J ONCOL, V53, P2590, DOI 10.3892/ijo.2018.4582; Chin L, 2006, GENE DEV, V20, P2149, DOI 10.1101/gad.1437206; Cox J, 2011, J PROTEOME RES, V10, P1794, DOI 10.1021/pr101065j; Damsky WE, 2014, ONCOGENE, V33, P2413, DOI 10.1038/onc.2013.194; de Marval PLM, 2011, ONCOTARGET, V2, P234; Engeland K, 2018, CELL DEATH DIFFER, V25, P114, DOI 10.1038/cdd.2017.172; Fahraeus R, 2014, ONCOGENE, V33, P4365, DOI 10.1038/onc.2013.410; Han Y, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.O111.014076; Hayward NK, 2017, NATURE, V545, P175, DOI 10.1038/nature22071; Hiraishi N, 2018, BIOCHEM BIOPH RES CO, V495, P116, DOI 10.1016/j.bbrc.2017.10.148; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Kardos GR, 2014, PIGM CELL MELANOMA R, V27, P801, DOI 10.1111/pcmr.12259; Kitatani K, 2016, ONCOGENE, V35, P2801, DOI 10.1038/onc.2015.330; Kressler D, 2010, BBA-MOL CELL RES, V1803, P673, DOI 10.1016/j.bbamcr.2009.10.009; Krol M, 2010, J APPL GENET, V51, P37, DOI 10.1007/BF03195709; Li BF, 2019, ONCOTARGETS THER, V12, P3207, DOI 10.2147/OTT.S195703; Liang W, 2018, P NATL ACAD SCI USA, V115, P11060, DOI 10.1073/pnas.1811717115; Lin CP, 2019, ENVIRON TOXICOL, V34, P303, DOI 10.1002/tox.22685; Little EG, 2012, DERMATOL CLIN, V30, P355, DOI 10.1016/j.det.2012.04.001; Liu JQ, 2018, J GENET GENOMICS, V45, P639, DOI 10.1016/j.jgg.2018.08.005; Liu S, 2017, ONCOGENE, V36, P1374, DOI 10.1038/onc.2016.301; Liu Y, 2016, TRENDS CANCER, V2, P191, DOI 10.1016/j.trecan.2016.03.002; Lo YH, 2017, STRUCTURE, V25, P762, DOI 10.1016/j.str.2017.03.008; Lozano G, 2007, CURR OPIN GENET DEV, V17, P66, DOI 10.1016/j.gde.2006.12.003; Maserati M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022516; Murphy JF, 2001, FASEB J, V15, P1667, DOI 10.1096/fj.00-0757fje; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Ossio R, 2017, NAT REV CANCER, V17, P393, DOI 10.1038/nrc.2017.43; Owens, 2020, NATURE, V515, pS109; Ozdemir E, 2000, EUR UROL, V38, P230, DOI 10.1159/000020284; Paradiso V, 2018, J MOL DIAGN, V20, P836, DOI 10.1016/j.jmoldx.2018.07.003; Pelletier J, 2018, NAT REV CANCER, V18, P51, DOI 10.1038/nrc.2017.104; Srivastava SK, 2015, BRIT J CANCER, V113, P1694, DOI 10.1038/bjc.2015.400; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; uri Reimand, 2017, CANC RES S, V77, DOI [10.1158/1538-7445.AM2017-385, DOI 10.1158/1538-7445.AM2017-385]; Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430; Wang SY, 2018, CANCER LETT, V439, P78, DOI 10.1016/j.canlet.2018.09.026; Wang W, 2015, MED RES REV, V35, P225, DOI 10.1002/med.21327; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Weinhold N, 2014, NAT GENET, V46, P1160, DOI 10.1038/ng.3101; Yoshikatsu Y, 2015, BIOCHEM BIOPH RES CO, V464, P780, DOI 10.1016/j.bbrc.2015.07.032; ZETTER BR, 1993, SEMIN CANCER BIOL, V4, P219; Zhang F, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.NONRNA15-PR06; Zhang Q, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1156-5; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zheng N, 2017, MOL CARCINOGEN, V56, P1896, DOI 10.1002/mc.22645; Zheng N, 2017, BIOMED PHARMACOTHER, V90, P339, DOI 10.1016/j.biopha.2017.03.076	52	12	12	3	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	13					2741	2755		10.1038/s41388-020-1179-6	http://dx.doi.org/10.1038/s41388-020-1179-6		JAN 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KX4EF	32005977				2022-12-28	WOS:000510346700002
J	Naert, T; Dimitrakopoulou, D; Tulkens, D; Demuynck, S; Carron, M; Noelanders, R; Eeckhout, L; Van Isterdael, G; Deforce, D; Vanhove, C; Van Dorpe, J; Creytens, D; Vleminckx, K				Naert, Thomas; Dimitrakopoulou, Dionysia; Tulkens, Dieter; Demuynck, Suzan; Carron, Marjolein; Noelanders, Rivka; Eeckhout, Liza; Van Isterdael, Gert; Deforce, Dieter; Vanhove, Christian; Van Dorpe, Jo; Creytens, David; Vleminckx, Kris			RBL1 (p107) functions as tumor suppressor in glioblastoma and small-cell pancreatic neuroendocrine carcinoma in Xenopus tropicalis	ONCOGENE			English	Article							RETINOBLASTOMA PROTEIN; GENOMIC PROFILES; HIGH-GRADE; BETA-CELL; P53; INACTIVATION; TP53; DELETION; MICE; PRB	Alterations of the retinoblastoma and/or the p53 signaling network are associated with specific cancers such as high-grade astrocytoma/glioblastoma, small-cell lung cancer (SCLC), choroid plexus tumors, and small-cell pancreatic neuroendocrine carcinoma (SC-PaNEC). However, the intricate functional redundancy between RB1 and the related pocket proteins RBL1/p107 and RBL2/p130 in suppressing tumorigenesis remains poorly understood. Here we performed lineage-restricted parallel inactivation of rb1 and rbl1 by multiplex CRISPR/Cas9 genome editing in the true diploid Xenopus tropicalis to gain insight into this in vivo redundancy. We show that while rb1 inactivation is sufficient to induce choroid plexus papilloma, combined rb1 and rbl1 inactivation is required and sufficient to drive SC-PaNEC, retinoblastoma and astrocytoma. Further, using a novel Li-Fraumeni syndrome-mimicking tp53 mutant X. tropicalis line, we demonstrate increased malignancy of rb1/rbl1-mutant glioma towards glioblastoma upon concomitant inactivation of tp53. Interestingly, although clinical SC-PaNEC samples are characterized by abnormal p53 expression or localization, in the current experimental models, the tp53 status had little effect on the establishment and growth of SC-PaNEC, but may rather be essential for maintaining chromosomal stability. SCLC was only rarely observed in our experimental setup, indicating requirement of additional or alternative oncogenic insults. In conclusion, we used CRISPR/Cas9 to delineate the tumor suppressor properties of Rbl1, generating new insights in the functional redundancy within the retinoblastoma protein family in suppressing neuroendocrine pancreatic cancer and glioma/glioblastoma.	[Naert, Thomas; Dimitrakopoulou, Dionysia; Tulkens, Dieter; Demuynck, Suzan; Carron, Marjolein; Noelanders, Rivka; Eeckhout, Liza; Vleminckx, Kris] Univ Ghent, Dept Biomed Mol Biol, Ghent, Belgium; [Naert, Thomas; Dimitrakopoulou, Dionysia; Tulkens, Dieter; Vanhove, Christian; Van Dorpe, Jo; Creytens, David; Vleminckx, Kris] Canc Res Inst Ghent, Ghent, Belgium; [Carron, Marjolein; Vleminckx, Kris] Univ Ghent, Ctr Med Genet, Ghent, Belgium; [Van Isterdael, Gert] VIB, VIB Ctr Inflammat Res, Ghent, Belgium; [Deforce, Dieter] Univ Ghent, Lab Pharmaceut Biotechnol, Ghent, Belgium; [Vanhove, Christian] Ghent Univ Hosp, Infin Lab, Ghent, Belgium; [Van Dorpe, Jo; Creytens, David] Univ Ghent, Dept Pathol, Ghent, Belgium; [Van Dorpe, Jo; Creytens, David] Ghent Univ Hosp, Ghent, Belgium	Ghent University; Ghent University; Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University; Ghent University; Ghent University Hospital; Ghent University; Ghent University; Ghent University Hospital	Vleminckx, K (corresponding author), Univ Ghent, Dept Biomed Mol Biol, Ghent, Belgium.; Vleminckx, K (corresponding author), Canc Res Inst Ghent, Ghent, Belgium.; Vleminckx, K (corresponding author), Univ Ghent, Ctr Med Genet, Ghent, Belgium.	kris.vleminckx@irc.UGent.be	Deforce, Dieter LD/J-4725-2013; Vleminckx, Kris/AAZ-4170-2020	Deforce, Dieter LD/0000-0002-0635-661X; Vanhove, Christian/0000-0002-3988-5980; Tulkens, Dieter/0000-0003-1688-5619	Research Foundation-Flanders (FWO-Vlaanderen) [G0A1515N, G029413N]; Belgian Science Policy (Interuniversity Attraction Poles) [IAP7/07]; Concerted Research Actions from Ghent University [BOF15/GOA/011]; Hercules Foundation, Flanders [AUGE/11/14]; Desmoid Tumor Research Foundation; "Kom op tegen Kanker" (Stand up to Cancer); Flemish cancer society; VLAIO-HERMES; Research Foundation-Flanders (FWO-Vlaanderen); NIH [R24 AI059830]; VIB BioImaging Core	Research Foundation-Flanders (FWO-Vlaanderen)(FWO); Belgian Science Policy (Interuniversity Attraction Poles); Concerted Research Actions from Ghent University; Hercules Foundation, Flanders; Desmoid Tumor Research Foundation; "Kom op tegen Kanker" (Stand up to Cancer); Flemish cancer society; VLAIO-HERMES; Research Foundation-Flanders (FWO-Vlaanderen)(FWO); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); VIB BioImaging Core	Research in the authors' laboratory is supported by the Research Foundation-Flanders (FWO-Vlaanderen) (grants G0A1515N and G029413N), by the Belgian Science Policy (Interuniversity Attraction Poles-IAP7/07) and by the Concerted Research Actions from Ghent University (BOF15/GOA/011). Further support was obtained by the Hercules Foundation, Flanders (grant AUGE/11/14) and the Desmoid Tumor Research Foundation. TN is funded by "Kom op tegen Kanker" (Stand up to Cancer), the Flemish cancer society and previously held PhD fellowship with VLAIO-HERMES during the course of this work. DT and MC have a PhD fellowship from the Research Foundation-Flanders (FWO-Vlaanderen). We thank the Xenopus laevis Resource for Immunobiology (Rochester, NY, NIH R24 AI059830) for the kind gift of monoclonal antibody AM20 (10A91, CD8). We are indebted to Tim Deceuninck for animal care, Kelly Lemeire for technical assistance with TUNEL staining. We would like to thank the VIB BioImaging Core, and in particular Chris Guerin, Eef Parthoens, and Anneke Kremer, for access to the instrument park, training, and support.	Abou-El-Ardat K, 2017, NEURO-ONCOLOGY, V19, P546, DOI 10.1093/neuonc/now231; Anzalone AV, 2019, NATURE, V576, P149, DOI 10.1038/s41586-019-1711-4; Basturk O, 2015, AM J SURG PATHOL, V39, P683, DOI 10.1097/PAS.0000000000000408; Berghmans S, 2005, P NATL ACAD SCI USA, V102, P407, DOI 10.1073/pnas.0406252102; Boel A, 2016, SCI REP-UK, V6, DOI 10.1038/srep30330; Bougeard G, 2015, J CLIN ONCOL, V33, P2345, DOI 10.1200/JCO.2014.59.5728; Cai EP, 2014, DIABETOLOGIA, V57, P2555, DOI 10.1007/s00125-014-3381-y; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Chow LML, 2011, CANCER CELL, V19, P305, DOI 10.1016/j.ccr.2011.01.039; Chow RD, 2017, NAT NEUROSCI, V20, P1329, DOI 10.1038/nn.4620; Costa C, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00307; Dannenberg JH, 2004, GENE DEV, V18, P2952, DOI 10.1101/gad.322004; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eischen CM, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026096; George J, 2015, NATURE, V524, P47, DOI 10.1038/nature14664; Glenn ST, 2014, ONCOGENE, V33, P5706, DOI 10.1038/onc.2013.514; Hann CL, 2008, ONCOLOGY-NY, V22, P1486; Harb G, 2009, DIABETES, V58, P1852, DOI 10.2337/db08-0759; Ignatius MS, 2018, ELIFE, V7, DOI 10.7554/eLife.37202; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jiang Z, 2010, J CLIN INVEST, V120, P3296, DOI 10.1172/JCI41490; Konukiewitz B, 2017, MODERN PATHOL, V30, P587, DOI 10.1038/modpathol.2016.217; Liu F, 2014, ONCOGENE, V33, P4813, DOI 10.1038/onc.2013.428; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Lu XD, 2001, MOL CELL BIOL, V21, P6017, DOI 10.1128/MCB.21.17.6017-6030.2001; Manning AL, 2014, ONCOGENE, V33, P2487, DOI 10.1038/onc.2013.201; Maresch R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10770; Marino S, 2000, GENE DEV, V14, P994; McEvoy J, 2011, CANCER CELL, V20, P260, DOI 10.1016/j.ccr.2011.07.005; Moreno-Mateos MA, 2015, NAT METHODS, V12, P982, DOI [10.1038/NMETH.3543, 10.1038/nmeth.3543]; Naert T, 2019, CRISPR NSID IN VIVO, DOI DOI 10.1101/595769V1; Naert Thomas, 2018, Drug Discov Today Technol, V28, P41, DOI 10.1016/j.ddtec.2018.07.001; Naert T, 2018, METHODS MOL BIOL, V1865, P33, DOI 10.1007/978-1-4939-8784-9_3; Naert T, 2017, GENESIS, V55, DOI 10.1002/dvg.23005; Naert T, 2016, SCI REP-UK, V6, DOI 10.1038/srep35264; Neely HR, 2018, EUR J IMMUNOL, V48, P430, DOI 10.1002/eji.201747260; Pan D, 2017, ONCOTARGET, V8, P4422, DOI 10.18632/oncotarget.12647; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; Schaffer BE, 2010, CANCER RES, V70, P3877, DOI 10.1158/0008-5472.CAN-09-4228; Schmid RS, 2016, NEURO-ONCOLOGY, V18, P962, DOI 10.1093/neuonc/nov321; Shi ZY, 2019, FASEB J, V33, P6962, DOI 10.1096/fj.201802661R; Shim J, 2017, ONCOTARGET, V8, P55280, DOI 10.18632/oncotarget.19424; Solin SL, 2015, SCI REP-UK, V5, DOI 10.1038/srep13745; Steed TC, 2016, ONCOTARGET, V7, P24899, DOI 10.18632/oncotarget.8551; Strecker J, 2019, SCIENCE, V365, P48, DOI 10.1126/science.aax9181; Tabori U, 2010, J CLIN ONCOL, V28, P1995, DOI 10.1200/JCO.2009.26.8169; Tong YA, 2015, CANCER CELL, V27, P712, DOI 10.1016/j.ccell.2015.04.005; Vanderluit JL, 2007, J CELL BIOL, V178, P129, DOI 10.1083/jcb.200703176; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; VANZOEST ID, 1989, GEN COMP ENDOCR, V76, P19, DOI 10.1016/0016-6480(89)90028-2; Vasavada RC, 2007, DIABETES, V56, P57, DOI 10.2337/db06-0517; Vitucci M, 2017, NEURO-ONCOLOGY, V19, P1237, DOI 10.1093/neuonc/nox050; Ward JM, 1999, LAB INVEST, V79, P3; Wiedemeyer WR, 2010, P NATL ACAD SCI USA, V107, P11501, DOI 10.1073/pnas.1001613107; Wojton J, 2013, MOL THER, V21, P1517, DOI 10.1038/mt.2013.114; Xiao A, 2002, CANCER CELL, V1, P157, DOI 10.1016/S1535-6108(02)00029-6; Yachida S, 2012, AM J SURG PATHOL, V36, P173, DOI 10.1097/PAS.0b013e3182417d36	57	6	6	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	13					2692	2706		10.1038/s41388-020-1173-z	http://dx.doi.org/10.1038/s41388-020-1173-z		JAN 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KX4EF	32001819	Green Submitted			2022-12-28	WOS:000510328400001
J	Xu, ZZ; Li, XM; Li, HX; Nie, C; Liu, WC; Li, SW; Liu, ZL; Wang, WB; Wang, JD				Xu, Zhanzhan; Li, Xiaoman; Li, Hanxiao; Nie, Chen; Liu, Wanchang; Li, Shiwei; Liu, Zelin; Wang, Weibin; Wang, Jiadong			Suppression of DDX39B sensitizes ovarian cancer cells to DNA-damaging chemotherapeutic agents via destabilizing BRCA1 mRNA	ONCOGENE			English	Article							STRAND-BREAK REPAIR; DEXH/D BOX PROTEIN; NUCLEAR EXPORT; UAP56; TREX; COMPLEX; MRE11; EXPRESSION; MUTATIONS; COMPONENT	Multiple RNA processing events including transcription, mRNA splicing, and export are delicately coordinated by the TREX complex. As one of the essential subunits, DDX39B couples the splicing and export machineries by recruiting ALYREF onto mRNA. In this study, we further explore the functions of DDX39B in handling damaged DNA, and unexpectedly find that DDX39B facilitates DNA repair by homologous recombination through upregulating BRCA1. Specifically, DDX39B binds to and stabilizes BRCA1 mRNA. DDX39B ensures ssDNA formation and RAD51 accumulation at DSB sites by maintaining BRCA1 levels. Without DDX39B being present, ovarian cancer cells exhibit hypersensitivity to DNA-damaging chemotherapeutic agents like platinum or PARPi. Moreover, DDX39B-deficient mice show embryonic lethality or developmental retardation, highly reminiscent of those lacking BRCA1. High DDX39B expression is correlated with worse survival in ovarian cancer patients. Thus, DDX39B suppression represents a rational approach for enhancing the efficacy of chemotherapy in BRCA1-proficient ovarian cancers.	[Xu, Zhanzhan; Li, Xiaoman; Li, Hanxiao; Nie, Chen; Liu, Wanchang; Li, Shiwei; Wang, Weibin; Wang, Jiadong] Peking Univ, Hlth Sci Ctr, Sch Basic Med Sci, Dept Radiat Med,Inst Syst Biomed, Beijing 100191, Peoples R China; [Liu, Zelin] Peking Univ, Hlth Sci Ctr, Sch Basic Med Sci, Dept Med Bioinformat,Inst Syst Biomed, Beijing 100191, Peoples R China	Peking University; Peking University	Wang, WB; Wang, JD (corresponding author), Peking Univ, Hlth Sci Ctr, Sch Basic Med Sci, Dept Radiat Med,Inst Syst Biomed, Beijing 100191, Peoples R China.	weibinwang@bjmu.edu.cn; wangjd@bjmu.edu.cn	Liu, Zelin/AAR-6795-2021	Liu, Zelin/0000-0002-3516-3999; Wang, Weibin/0000-0003-3087-7973; Nie, Chen/0000-0002-4221-4643	National Key R&D Program of China [2017YFA0503900, 2016YFC1302100]; National Natural Science Foundation of China [81672981, 81872282, 81903255, 81972608]; Beijing Municipal Natural Science Foundation [7182082]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Municipal Natural Science Foundation(Beijing Natural Science Foundation)	We are grateful to members of the Wang laboratory for insightful discussions and technical assistance. This study was supported by grants from the National Key R&D Program of China (2017YFA0503900 and 2016YFC1302100), the National Natural Science Foundation of China (81672981, 81872282, 81903255, and 81972608), and Beijing Municipal Natural Science Foundation (7182082).	Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033; Buis J, 2012, NAT STRUCT MOL BIOL, V19, P246, DOI 10.1038/nsmb.2212; Chang CT, 2013, EMBO J, V32, P473, DOI 10.1038/emboj.2012.342; Choi JH, 2010, P NATL ACAD SCI USA, V107, P13660, DOI 10.1073/pnas.1007856107; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dufu K, 2010, GENE DEV, V24, P2043, DOI 10.1101/gad.1898610; Evers B, 2006, ONCOGENE, V25, P5885, DOI 10.1038/sj.onc.1209871; Fan J, 2018, NUCLEIC ACIDS RES, V46, P8404, DOI 10.1093/nar/gky650; Gatfield D, 2001, CURR BIOL, V11, P1716, DOI 10.1016/S0960-9822(01)00532-2; Gyorffy B, 2012, ENDOCR-RELAT CANCER, V19, P197, DOI 10.1530/ERC-11-0329; Hautbergue GM, 2009, CURR BIOL, V19, P1918, DOI 10.1016/j.cub.2009.09.041; He YJ, 2018, NATURE, V563, P522, DOI 10.1038/s41586-018-0670-5; Hennessy BTJ, 2010, J CLIN ONCOL, V28, P3570, DOI 10.1200/JCO.2009.27.2997; Houseley J, 2009, CELL, V136, P763, DOI 10.1016/j.cell.2009.01.019; Huang C, 2018, GENE DEV, V32, P639, DOI 10.1101/gad.314856.118; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang M, 2018, NUCLEIC ACIDS RES, V46, P4560, DOI 10.1093/nar/gky220; Jensen RB, 2010, NATURE, V467, P678, DOI 10.1038/nature09399; Jiang QQ, 2015, J BIOL CHEM, V290, P17724, DOI 10.1074/jbc.R115.667931; Kapadia F, 2006, GENE, V384, P37, DOI 10.1016/j.gene.2006.07.010; Katahira J, 2009, RNA BIOL, V6, P149, DOI 10.4161/rna.6.2.8046; Konstantinopoulos PA, 2010, J CLIN ONCOL, V28, P3555, DOI 10.1200/JCO.2009.27.5719; Kriege M, 2012, CANCER-AM CANCER SOC, V118, P899, DOI 10.1002/cncr.26351; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Luo MJ, 2001, NATURE, V413, P644, DOI 10.1038/35098106; Mavaddat N, 2013, JNCI-J NATL CANCER I, V105, P812, DOI 10.1093/jnci/djt095; Mirza MR, 2016, NEW ENGL J MED, V375, P2154, DOI 10.1056/NEJMoa1611310; Pryor A, 2004, NUCLEIC ACIDS RES, V32, P1857, DOI 10.1093/nar/gkh347; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Scully R, 2019, NAT REV MOL CELL BIO, V20, P698, DOI 10.1038/s41580-019-0152-0; Shen JP, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M702304200; Strasser K, 2002, NATURE, V417, P304, DOI 10.1038/nature746; Swisher EM, 2017, LANCET ONCOL, V18, P75, DOI [10.1016/S1470-2045(16)30559-9, 10.1016/s1470-2045(16)30559-9]; Sy SMH, 2009, P NATL ACAD SCI USA, V106, P7155, DOI 10.1073/pnas.0811159106; Thakurta AG, 2007, J BIOL CHEM, V282, P17507, DOI 10.1074/jbc.M609727200; Wang WD, 2007, NAT REV GENET, V8, P735, DOI 10.1038/nrg2159; Xu GT, 2015, NATURE, V521, P541, DOI 10.1038/nature14328; Yamazaki T, 2010, MOL BIOL CELL, V21, P2953, DOI 10.1091/mbc.E09-10-0913; Yu ZB, 2012, CELL RES, V22, P305, DOI 10.1038/cr.2011.128; Yun MH, 2009, NATURE, V459, P460, DOI 10.1038/nature07955; Zhao WX, 2017, NATURE, V550, P360, DOI 10.1038/nature24060	41	9	9	3	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	2020	39	47					7051	7062		10.1038/s41388-020-01482-x	http://dx.doi.org/10.1038/s41388-020-01482-x		SEP 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OT7KA	32989256				2022-12-28	WOS:000573446900004
J	Mehner, C; Miller, E; Hockla, A; Coban, M; Weroha, SJ; Radisky, DC; Radisky, ES				Mehner, Christine; Miller, Erin; Hockla, Alexandra; Coban, Mathew; Weroha, S. John; Radisky, Derek C.; Radisky, Evette S.			Targeting an autocrine IL-6-SPINK1 signaling axis to suppress metastatic spread in ovarian clear cell carcinoma	ONCOGENE			English	Article							INHIBITOR KAZAL TYPE-1; TRYPSIN-INHIBITOR; MONOCLONAL-ANTIBODY; ANOIKIS RESISTANCE; INTERLEUKIN-6; SPINK1; CANCER; EXPRESSION; PROGNOSIS; IL-6	A major clinical challenge of ovarian cancer is the development of malignant ascites accompanied by widespread peritoneal metastasis. In ovarian clear cell carcinoma (OCCC), a challenging subtype of ovarian cancer, this problem is compounded by near-universal primary chemoresistance; patients with advanced stage OCCC thus lack effective therapies and face extremely poor survival rates. Here we show that tumor-cell-expressed serine protease inhibitor Kazal type 1 (SPINK1) is a key driver of OCCC progression and metastasis. Using cell culture models of human OCCC, we find that shRNA silencing of SPINK1 sensitizes tumor cells to anoikis and inhibits proliferation. Knockdown of SPINK1 in OCCC cells also profoundly suppresses peritoneal metastasis in mouse implantation models of human OCCC. We next identify a novel autocrine signaling axis in OCCC cells whereby tumor-cell-produced interleukin-6 (IL-6) regulates SPINK1 expression to stimulate a common protumorigenic gene expression pattern leading to anoikis resistance and proliferation of OCCC cells. We further demonstrate that this signaling pathway can be successfully interrupted with the IL-6R alpha inhibitor tocilizumab, sensitizing cells to anoikis in vitro and reducing metastasis in vivo. These results suggest that clinical trials of IL-6 pathway inhibitors in OCCC may be warranted, and that SPINK1 might offer a candidate predictive biomarker in this population.	[Mehner, Christine] Mayo Clin, Grad Sch Biomed Sci, Rochester, MN USA; [Mehner, Christine; Miller, Erin; Hockla, Alexandra; Coban, Mathew; Radisky, Derek C.; Radisky, Evette S.] Mayo Clin, Dept Canc Biol, Ctr Comprehens Canc, Jacksonville, FL 32224 USA; [Weroha, S. John] Mayo Clin, Div Med Oncol, Rochester, MN USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Radisky, ES (corresponding author), Mayo Clin, Dept Canc Biol, Ctr Comprehens Canc, Jacksonville, FL 32224 USA.	radisky.evette@mayo.edu	Coban, Matt/AAH-7053-2019	Coban, Matt/0000-0001-6396-6759; Radisky, Evette/0000-0003-3121-109X	NCI NIH HHS [R21 CA226302, P50 CA136393, R21 CA177865, R01 CA154387] Funding Source: Medline; U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute (NCI) [R01CA154387, P50CA136393, R21CA177865] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute (NCI)		Ahmed N, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00256; Al-Quteimat OM, 2014, J ONCOL PHARM PRACT, V20, P369, DOI 10.1177/1078155213506244; Angevin E, 2014, CLIN CANCER RES, V20, P2192, DOI 10.1158/1078-0432.CCR-13-2200; Anglesio MS, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0072162, 10.1371/annotation/ffcaf179-872f-470b-8bb6-f06d8ba6d03a]; Anglesio MS, 2011, CLIN CANCER RES, V17, P2538, DOI 10.1158/1078-0432.CCR-10-3314; Ateeq B, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001498; Cepeda D, 2013, EMBO MOL MED, V5, P1067, DOI 10.1002/emmm.201202341; Chan JK, 2008, GYNECOL ONCOL, V109, P370, DOI 10.1016/j.ygyno.2008.02.006; Chandler RL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7118; Chen F, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06860-4; Cichon MA, 2015, CANCER INFORM, V14, P1, DOI 10.4137/CIN.S18965; Coward J, 2011, CLIN CANCER RES, V17, P6083, DOI 10.1158/1078-0432.CCR-11-0945; del Carmen MG, 2012, GYNECOL ONCOL, V126, P481, DOI 10.1016/j.ygyno.2012.04.021; Dijkgraaf EM, 2015, ANN ONCOL, V26, P2141, DOI 10.1093/annonc/mdv309; du Bois A, 2003, JNCI-J NATL CANCER I, V95, P1320, DOI 10.1093/jnci/djg036; HALILA H, 1987, BRIT J CANCER, V56, P153, DOI 10.1038/bjc.1987.175; Hirano G, 2011, INT J ONCOL, V38, P893, DOI 10.3892/ijo.2011.938; Howlader NNA, 2020, SEER CANC STAT REV; HUHTALA ML, 1982, J BIOL CHEM, V257, P13713; Hunter CA, 2015, NAT IMMUNOL, V16, P448, DOI 10.1038/ni.3153; Itkonen O, 2014, CLIN CHIM ACTA, V431, P260, DOI 10.1016/j.cca.2014.02.014; Kawabata A, 2017, GYNECOL ONCOL, V146, P609, DOI 10.1016/j.ygyno.2017.06.027; Kereszturi E, 2009, GUT, V58, P545, DOI 10.1136/gut.2008.164947; Kipps E, 2013, NAT REV CANCER, V13, P273, DOI 10.1038/nrc3432; Lamontagne J, 2010, J VIROL, V84, P907, DOI 10.1128/JVI.01249-09; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Lu XY, 2008, APOPTOSIS, V13, P483, DOI 10.1007/s10495-008-0193-x; Ma H, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38362-0; Marzec K, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00162; Mehner C, 2015, ONCOTARGET, V6, P35737, DOI 10.18632/oncotarget.5927; Mitra AK, 2016, TUMOR METASTASIS, P43, DOI 10.5772/64700; Nilsson MB, 2005, CANCER RES, V65, P10794, DOI 10.1158/0008-5472.CAN-05-0623; Paju A, 2004, CLIN CANCER RES, V10, P4761, DOI 10.1158/1078-0432.CCR-0204-03; Pectasides D, 2006, ONCOLOGIST, V11, P1089, DOI 10.1634/theoncologist.11-10-1089; Portolano N, 2014, JOVE-J VIS EXP, DOI 10.3791/51897; Rasanen K, 2016, MOL CARCINOGEN, V55, P2010, DOI 10.1002/mc.22447; Rasanen K, 2016, CLIN CHEM, V62, P449, DOI 10.1373/clinchem.2015.241513; RINDERKNECHT H, 1986, DIGEST DIS SCI, V31, P314, DOI 10.1007/BF01318124; Simpson CD, 2008, CANCER LETT, V272, P177, DOI 10.1016/j.canlet.2008.05.029; Soon WW, 2011, EMBO MOL MED, V3, P451, DOI 10.1002/emmm.201100150; Stany MP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021121; Stenman UH, 2002, CLIN CHEM, V48, P1206; Stenman UH, 2011, ASIAN J ANDROL, V13, P628, DOI 10.1038/aja.2011.45; Sugiyama T, 1998, CANCER LETT, V128, P211, DOI 10.1016/S0304-3835(98)00065-2; Sugiyama T, 2000, CANCER, V88, P2584, DOI 10.1002/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5; Takano M, 2006, BRIT J CANCER, V94, P1369, DOI 10.1038/sj.bjc.6603116; Taniguchi K, 2014, SEMIN IMMUNOL, V26, P54, DOI 10.1016/j.smim.2014.01.001; Tomlins SA, 2008, CANCER CELL, V13, P519, DOI 10.1016/j.ccr.2008.04.016; WATSON JM, 1990, CANCER RES, V50, P6959; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433; Yanaihara N, 2016, MOL CARCINOGEN, V55, P832, DOI 10.1002/mc.22325; YASUDA T, 1993, GENE, V131, P275; YASUDA T, 1990, BIOL CHEM H-S, V371, P95; Yuniati L, 2019, J CELL PHYSIOL, V234, P5379, DOI 10.1002/jcp.27407	54	8	8	2	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 15	2020	39	42					6606	6618		10.1038/s41388-020-01451-4	http://dx.doi.org/10.1038/s41388-020-01451-4		SEP 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OA9HI	32929152	Green Accepted			2022-12-28	WOS:000569499000001
J	Wei, QY; Qian, Y; Yu, J; Wong, CC				Wei, Qinyao; Qian, Yun; Yu, Jun; Wong, Chi Chun			Metabolic rewiring in the promotion of cancer metastasis: mechanisms and therapeutic implications	ONCOGENE			English	Review							EPITHELIAL-MESENCHYMAL TRANSITION; HYPOXIA-INDUCIBLE FACTORS; PREDICTS POOR-PROGNOSIS; CELL LUNG-CANCER; COA SYNTHETASE 2; TUMOR PROGRESSION; GLUCOSE-METABOLISM; COLORECTAL-CANCER; SIGNALING PATHWAY; HEPATOCELLULAR-CARCINOMA	Tumor metastasis is the major cause of mortality from cancer. Metabolic rewiring and the metastatic cascade are highly intertwined, co-operating to promote multiple steps of cancer metastasis. Metabolites generated by cancer cells influence the metastatic cascade, encompassing epithelial-mesenchymal transition (EMT), survival of cancer cells in circulation, and metastatic colonization at distant sites. A variety of molecular mechanisms underlie the prometastatic effect of tumor-derived metabolites, such as epigenetic deregulation, induction of matrix metalloproteinases (MMPs), promotion of cancer stemness, and alleviation of oxidative stress. Conversely, metastatic signaling regulates expression and activity of rate-limiting metabolic enzymes to generate prometastatic metabolites thereby reinforcing the metastasis cascade. Understanding the complex interplay between metabolism and metastasis could unravel novel molecular targets, whose intervention could lead to improvements in the treatment of cancer. In this review, we summarized the recent discoveries involving metabolism and tumor metastasis, and emphasized the promising molecular targets, with an update on the development of small molecule or biologic inhibitors against these aberrant situations in cancer.	[Wei, Qinyao; Yu, Jun; Wong, Chi Chun] Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Peoples R China; [Wei, Qinyao; Yu, Jun; Wong, Chi Chun] Chinese Univ Hong Kong, State Key Lab Digest Dis, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut,CUHK Shenzhen Res Inst, Hong Kong, Peoples R China; [Qian, Yun] Shenzhen Univ, Dept Gastroenterol & Hepatol, Gen Hosp, Shenzhen, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Shenzhen University	Wong, CC (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Peoples R China.; Wong, CC (corresponding author), Chinese Univ Hong Kong, State Key Lab Digest Dis, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut,CUHK Shenzhen Res Inst, Hong Kong, Peoples R China.	chichunwong@cuhk.edu.hk	; Jun, Yu/D-8569-2015	Wong, Chi Chun/0000-0003-1362-3541; Jun, Yu/0000-0001-5008-2153	National Natural Science Foundation of China (NSFC) [81772501]; Research Grants Council-General Research Fund (RGC-GRF), Hong Kong [14101917, 14108718, 14163817, 14110819]; Heath and Medical Research Fund (HMRF) [06170686]; Science and Technology Program Grant Shenzhen [JCYJ20170413161534162]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Research Grants Council-General Research Fund (RGC-GRF), Hong Kong; Heath and Medical Research Fund (HMRF); Science and Technology Program Grant Shenzhen	This project was supported by funds from National Natural Science Foundation of China (NSFC; 81772501); Research Grants Council-General Research Fund (RGC-GRF; 14101917, 14108718, 14163817 and 14110819), Hong Kong; Heath and Medical Research Fund (HMRF) (06170686); Science and Technology Program Grant Shenzhen (JCYJ20170413161534162).	Al Tameemi W, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00004; Nguyen AT, 2017, CANCER CELL, V32, P639, DOI 10.1016/j.ccell.2017.10.001; Aspuria PJP, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-21; Atlante S, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0802-8; Bae JM, 2017, MODERN PATHOL, V30, P267, DOI 10.1038/modpathol.2016.172; Bauerle T, 2011, INT J CANCER, V128, P2453, DOI 10.1002/ijc.25563; Baillie GS, 2019, NAT REV DRUG DISCOV, V18, P770, DOI 10.1038/s41573-019-0033-4; Belkaid A, 2006, CANCER CELL INT, V6, DOI 10.1186/1475-2867-6-7; Boon L, 2016, BIOCHEM J, V473, P1471, DOI 10.1042/BJ20151154; Brunetti L, 2019, J MED CHEM, V62, P10995, DOI 10.1021/acs.jmedchem.9b00885; Brusselmans K, 2005, CANCER RES, V65, P6719, DOI 10.1158/0008-5472.CAN-05-0571; Bu PC, 2018, CELL METAB, V27, P1249, DOI 10.1016/j.cmet.2018.04.003; Butti R, 2018, MOL CANCER, V17; Cantelmo AR, 2016, CANCER CELL, V30, P968, DOI 10.1016/j.ccell.2016.10.006; Carbonneau M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12700; Caunt CJ, 2015, NAT REV CANCER, V15, P577, DOI 10.1038/nrc4000; Celia-Terrassa T, 2018, NAT CELL BIOL, V20, P868, DOI 10.1038/s41556-018-0145-9; Cen B, 2020, GASTROENTEROLOGY, V158, P971, DOI 10.1053/j.gastro.2019.11.013; Chen M, 2018, NAT GENET, V50, P206, DOI 10.1038/s41588-017-0027-2; Cheng CX, 2011, HELL J NUCL MED, V14, P15; Cheng G, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10042-1; Cheng TY, 2018, ONCOGENE, V37, P1730, DOI 10.1038/s41388-017-0086-y; Chugh S, 2018, GASTROENTEROLOGY, V155, P1608, DOI 10.1053/j.gastro.2018.08.007; Claesson-Welsh L, 2013, J INTERN MED, V273, P114, DOI 10.1111/joim.12019; Colvin H, 2016, SCI REP-UK, V6, DOI 10.1038/srep36289; Conradi LC, 2017, ANGIOGENESIS, V20, P599, DOI 10.1007/s10456-017-9573-6; Crea F, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-40; de la Vega MR, 2018, CANCER CELL, V34, P21, DOI 10.1016/j.ccell.2018.03.022; Dinndorf PA, 2007, ONCOLOGIST, V12, P991, DOI 10.1634/theoncologist.12-8-991; Dong Z, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143577; Fallah J, 2019, CURR ONCOL REP, V21, DOI 10.1007/s11912-019-0752-z; Frezza C, 2011, NATURE, V477, P225, DOI 10.1038/nature10363; Gan L, 2018, ONCOGENE, V37, P744, DOI 10.1038/onc.2017.363; Garcia MR, 2017, CELL METAB, V26, P842, DOI 10.1016/j.cmet.2017.09.018; Grassian AR, 2012, J BIOL CHEM, V287, P42180, DOI 10.1074/jbc.M112.417832; Gulati S, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav4322; Hah YS, 2019, ONCOL REP, V42, P1805, DOI 10.3892/or.2019.7315; Ham SA, 2014, AM J CANCER RES, V4, P674; Hay N, 2016, NAT REV CANCER, V16, P635, DOI 10.1038/nrc.2016.77; Hu B, 2019, BIOCHEM BIOPH RES CO, V509, P373, DOI 10.1016/j.bbrc.2018.12.127; Huang R, 2017, CRIT REV ONCOL HEMAT, V115, P13, DOI 10.1016/j.critrevonc.2017.04.005; Hung JS, 2014, ONCOTARGET, V5, P2096, DOI 10.18632/oncotarget.1815; Hur H, 2015, J SURG ONCOL, V112, P585, DOI 10.1002/jso.24043; Incio J, 2016, CLIN CANCER RES, V22, P2993, DOI 10.1158/1078-0432.CCR-15-1839; Ji RC, 2014, CANCER LETT, V346, P6, DOI 10.1016/j.canlet.2013.12.001; Jiang SY, 2019, CANCER RES, V79, P3063, DOI 10.1158/0008-5472.CAN-18-3295; Jin UH, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-498; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kim JH, 2013, BIOCHEM PHARMACOL, V86, P1285, DOI 10.1016/j.bcp.2013.08.022; Kiuru M, 2004, CURR MOL MED, V4, P869, DOI 10.2174/1566524043359638; Klutzny S, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0202-5; Knott SRV, 2018, NATURE, V554, P378, DOI 10.1038/nature25465; Kolli-Bouhafs K, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.329; Krock Bryan L, 2011, Genes Cancer, V2, P1117, DOI 10.1177/1947601911423654; Kumazoe M, 2017, ONCOGENE, V36, P2643, DOI 10.1038/onc.2016.426; Kumazoe M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02162-9; Kuo YL, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46439-7; Kutil Z, 2018, ACS CHEM BIOL, V13, P685, DOI 10.1021/acschembio.7b00942; Laezza C, 2012, EUR J CANCER, V48, P3112, DOI 10.1016/j.ejca.2012.02.062; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lang LW, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0623-3; Lee CK, 2019, SCIENCE, V363, P644, DOI 10.1126/science.aav0173; Lee SY, 2012, CANCER RES, V72, P3607, DOI 10.1158/0008-5472.CAN-12-0006; Leslie PL, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12222-5; Letouze E, 2013, CANCER CELL, V23, P739, DOI 10.1016/j.ccr.2013.04.018; Li HM, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-016-0481-1; Li J, 2016, ONCOGENE, V35, P6378, DOI 10.1038/onc.2016.168; Li QG, 2017, CELL PHYSIOL BIOCHEM, V42, P397, DOI 10.1159/000477484; Li WL, 2018, ONCOGENE, V37, P4903, DOI 10.1038/s41388-018-0341-x; Li XX, 2018, MOL CELL, V69, P480, DOI 10.1016/j.molcel.2018.01.001; Lim JCW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19102860; Lim SH, 2015, BRIT J CANCER, V113, P1421, DOI 10.1038/bjc.2015.371; Lin LC, 2014, CLIN EXP METASTAS, V31, P881, DOI 10.1007/s10585-014-9677-y; Lincet H, 2015, ONCOGENE, V34, P3751, DOI 10.1038/onc.2014.320; Liu NH, 2016, CANCER LETT, V378, P38, DOI 10.1016/j.canlet.2016.05.010; Liu P, 2020, HEPATOL RES, V50, P246, DOI 10.1111/hepr.13433; Liu WS, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-0953-7; Lomelino CL, 2017, J BIOL CHEM, V292, P19952, DOI 10.1074/jbc.R117.819060; Lu M, 2019, CELL METAB, V29, P886, DOI 10.1016/j.cmet.2018.12.019; Luo M, 2018, CELL METAB, V27, P947, DOI 10.1016/j.cmet.2018.04.012; Luo XJ, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0646-3; Lyons TR, 2014, J CLIN INVEST, V124, P3901, DOI 10.1172/JCI73777; McDonald PC, 2019, GASTROENTEROLOGY, V157, P823, DOI 10.1053/j.gastro.2019.05.004; Migita T, 2008, CANCER RES, V68, P8547, DOI 10.1158/0008-5472.CAN-08-1235; Mishra D, 2019, CANCERS, V11, DOI 10.3390/cancers11060750; Montagner A, 2014, EMBO MOL MED, V6, P80, DOI 10.1002/emmm.201302666; Morris JP, 2019, NATURE, V573, P595, DOI 10.1038/s41586-019-1577-5; Nagarajan A, 2016, TRENDS CANCER, V2, P365, DOI 10.1016/j.trecan.2016.06.002; Palmieri EM, 2017, CELL REP, V20, P1654, DOI 10.1016/j.celrep.2017.07.054; Papa S, 2019, ONCOGENE, V38, P2223, DOI 10.1038/s41388-018-0582-8; Pascual G, 2017, NATURE, V541, P41, DOI 10.1038/nature20791; Pastushenko I, 2019, TRENDS CELL BIOL, V29, P212, DOI 10.1016/j.tcb.2018.12.001; Pavlova NN, 2018, CELL METAB, V27, P428, DOI 10.1016/j.cmet.2017.12.006; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Peng MX, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1475-7; Peters JM, 2012, NAT REV CANCER, V12, P181, DOI 10.1038/nrc3214; Piskounova E, 2015, NATURE, V527, P186, DOI 10.1038/nature15726; Pozza ED, 2020, SEMIN CELL DEV BIOL, V98, P4, DOI 10.1016/j.semcdb.2019.04.013; Punekar Salman, 2019, Am Soc Clin Oncol Educ Book, V39, pe79, DOI 10.1200/EDBK_238499; Qian XC, 2015, INT J CLIN EXP MED, V8, P7855; Qiu GZ, 2017, TRENDS PHARMACOL SCI, V38, P669, DOI 10.1016/j.tips.2017.05.002; Rankin EB, 2016, SCIENCE, V352, P175, DOI 10.1126/science.aaf4405; Rey S, 2017, TRENDS CANCER, V3, P529, DOI 10.1016/j.trecan.2017.05.002; Saha SK, 2014, NATURE, V513, P110, DOI 10.1038/nature13441; Sahin M, 2010, CANCER METAST REV, V29, P655, DOI 10.1007/s10555-010-9253-0; Sasaki M, 2012, NATURE, V488, P656, DOI 10.1038/nature11323; Schild T, 2018, CANCER CELL, V33, P347, DOI 10.1016/j.ccell.2018.02.001; Sciacovelli M, 2016, NATURE, V537, P544, DOI 10.1038/nature19353; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Shaul YD, 2014, CELL, V158, P1094, DOI 10.1016/j.cell.2014.07.032; Shen B, 2012, BRIT J CANCER, V106, P1486, DOI 10.1038/bjc.2012.130; Steeg PS, 2016, NAT REV CANCER, V16, P201, DOI 10.1038/nrc.2016.25; Sun L, 2017, CANCER SCI, V108, P1338, DOI 10.1111/cas.13252; Sundberg TB, 2014, P NATL ACAD SCI USA, V111, P12468, DOI 10.1073/pnas.1412308111; Svensson RU, 2016, NAT MED, V22, P1108, DOI 10.1038/nm.4181; Tahanian E, 2010, CHEM BIOL DRUG DES, V75, P481, DOI 10.1111/j.1747-0285.2010.00961.x; Tai LH, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1431082; Taras D, 2007, J HEPATOL, V46, P69, DOI 10.1016/j.jhep.2006.06.015; Tian HN, 2015, MOL CARCINOGEN, V54, P1159, DOI 10.1002/mc.22186; Tripathi SC, 2019, CANCER REP-US, V2, DOI 10.1002/cnr2.1131; Tzeng SF, 2018, FASEB J, V32, P6869, DOI 10.1096/fj.201800687; Vatrinet R, 2017, CANCER METAB, V5, DOI 10.1186/s40170-017-0165-0; Waitkus MS, 2018, CANCER CELL, V34, P186, DOI 10.1016/j.ccell.2018.04.011; Wang DZ, 2015, GASTROENTEROLOGY, V149, P1884, DOI 10.1053/j.gastro.2015.07.064; Wang HY, 2016, TRANSL ONCOL, V9, P512, DOI 10.1016/j.tranon.2016.09.009; Wang SJ, 2018, ONCOGENE, V37, P4164, DOI 10.1038/s41388-018-0252-x; Wang T, 2020, ONCOGENE, V39, P3179, DOI 10.1038/s41388-020-1207-6; Wang ZY, 2019, TRENDS CANCER, V5, P30, DOI 10.1016/j.trecan.2018.11.003; Warburg O, 1924, BIOCHEM Z, V152, P309; Wei Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14041; Wen H, 2019, BBA-MOL CELL BIOL L, V1864, P413, DOI 10.1016/j.bbalip.2018.06.005; Wen J, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1391-9; Wigerup C, 2016, PHARMACOL THERAPEUT, V164, P152, DOI 10.1016/j.pharmthera.2016.04.009; Wolfer A, 2011, CANCER RES, V71, P2034, DOI 10.1158/0008-5472.CAN-10-3776; Wong CC, 2017, ONCOGENE, V36, P3359, DOI 10.1038/onc.2016.485; Xie H, 2014, CELL METAB, V19, P795, DOI 10.1016/j.cmet.2014.03.003; Xu LH, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008455; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yakes FM, 2011, MOL CANCER THER, V10, P2298, DOI 10.1158/1535-7163.MCT-11-0264; Yang J, 2017, SCI REP-UK, V7, DOI 10.1038/srep43864; Yang L, 2015, ONCOTARGET, V6, P25755, DOI 10.18632/oncotarget.4697; Yang MH, 2008, CELL CYCLE, V7, P2090, DOI 10.4161/cc.7.14.6324; Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691; Yang Y, 2019, CANCER LETT, V453, P170, DOI 10.1016/j.canlet.2019.03.054; Yao L, 2018, CELL PHYSIOL BIOCHEM, V45, P984, DOI 10.1159/000487293; Yin YF, 2018, CANCER LETT, V426, P14, DOI 10.1016/j.canlet.2018.04.001; Zhang J, 2016, MOL CELL BIOCHEM, V411, P331, DOI 10.1007/s11010-015-2595-8; Zhang WC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116634; Zhang XD, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0892-2; Zhao WN, 2016, CANCER RES, V76, P2037, DOI 10.1158/0008-5472.CAN-15-1970; Zhou YF, 2013, MOL CANCER THER, V12, P2782, DOI 10.1158/1535-7163.MCT-13-0098; Zhu WP, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0098-0; Zuo XS, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.91419	154	57	57	1	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2020	39	39					6139	6156		10.1038/s41388-020-01432-7	http://dx.doi.org/10.1038/s41388-020-01432-7		AUG 2020	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NS8XO	32839493	hybrid, Green Published			2022-12-28	WOS:000562336400001
J	Liu, Y; Yang, L; Liao, F; Wang, W; Wang, ZF				Liu, Yu; Yang, Liang; Liao, Fan; Wang, Wei; Wang, Zhi-Fei			MiR-450a-5p strengthens the drug sensitivity of gefitinib in glioma chemotherapy via regulating autophagy by targeting EGFR	ONCOGENE			English	Article							CELL LUNG-CANCER; KINASE INHIBITORS; WIPI PROTEINS; RESISTANCE; GROWTH; TEMOZOLOMIDE; MUTANT; CHEMORESISTANCE; IDENTIFICATION; CONTRIBUTES	Glioma reported to be refractory to EGFR tyrosine kinase inhibitor is the most common malignant tumor in central nervous system. Our research showed the low expression of miR-450a-5p and high expression of EGFR in glioma tissues. MiR-450a-5p was also observed to synergize with gefitinib to inhibit the proliferation, migration and invasion and induce the apoptosis and autophagy of glioma cells. Furthermore, miR-450a-5p was demonstrated to target 3 ' UTR of EGFR, and regulated EGFR-induced PI3K/AKT/mTOR signaling pathway. Moreover, the above effects induced by miR-450a-5p in glioma cells were reversed by WIPI1 silencing. The inhibition role of miR-450a-5p on glioma growth was also confirmed in vivo by subcutaneous and intracranial tumor xenografts. Therefore, we conclude that miR-450a-5p synergizes with gefitinib to inhibit the glioma tumorigenesis through inducing autophagy by regulating the EGFR-induced PI3K/AKT/mTOR signaling pathway, thereby enhancing the drug sensitivity of gefitinib.	[Liu, Yu; Yang, Liang; Liao, Fan; Wang, Zhi-Fei] Cent South Univ, Xiangya Hosp 3, Dept Neurosurg, Changsha 410013, Peoples R China; [Wang, Wei] Cent South Univ, Xiangya Hosp 2, Dept Neurol, Changsha 410011, Peoples R China	Central South University; Central South University	Wang, ZF (corresponding author), Cent South Univ, Xiangya Hosp 3, Dept Neurosurg, Changsha 410013, Peoples R China.	doctorwangzhifei@163.com			New Xiangya Talent Project of the Third Xiangya Hospital of Central South University [JY201711]	New Xiangya Talent Project of the Third Xiangya Hospital of Central South University	This work was supported by the New Xiangya Talent Project of the Third Xiangya Hospital of Central South University (No. JY201711).	Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Chang CY, 2014, EXP CELL RES, V327, P102, DOI 10.1016/j.yexcr.2014.05.011; Chen XR, 2017, CANCER RES, V77, P4998, DOI 10.1158/0008-5472.CAN-17-1139; Chistiakov DA, 2017, EUR J PHARMACOL, V810, P70, DOI 10.1016/j.ejphar.2017.05.064; Cho YH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58237-7; Davis ME, 2016, CLIN J ONCOL NURS, V20, P2, DOI 10.1188/16.CJON.S1.2-8; Detassis S, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00086; Dhillon S, 2015, TARGET ONCOL, V10, P153, DOI 10.1007/s11523-015-0358-9; Gharwan H, 2016, NAT REV CLIN ONCOL, V13, P209, DOI 10.1038/nrclinonc.2015.213; Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697; Gump JM, 2011, TRENDS CELL BIOL, V21, P387, DOI 10.1016/j.tcb.2011.03.007; Han J, 2016, INT J ONCOL, V48, P1855, DOI 10.3892/ijo.2016.3401; Han J, 2015, INT J CLIN EXP PATHO, V8, P12698; Hassan B, 2013, SURG ONCOL CLIN N AM, V22, P641, DOI 10.1016/j.soc.2013.06.008; Jendrossek V, 2003, EXPERT OPIN INV DRUG, V12, P1899, DOI 10.1517/13543784.12.12.1899; Jutten B, 2014, CELL CYCLE, V13, P42, DOI 10.4161/cc.27518; Koperski L, 2017, ONCOTARGET, V8, P49191, DOI 10.18632/oncotarget.16788; Lan FM, 2015, J NEUROCHEM, V134, P811, DOI 10.1111/jnc.13174; Learn CA, 2004, CLIN CANCER RES, V10, P3216, DOI 10.1158/1078-0432.CCR-03-0521; Li H, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0618-0; Li YH, 2014, INT J MOL MED, V34, P491, DOI 10.3892/ijmm.2014.1813; Ma W, 2017, EXP THER MED, V14, P2853, DOI 10.3892/etm.2017.4847; Ma YH, 2017, ONCOTARGET, V8, P88529, DOI 10.18632/oncotarget.19874; Muller AJ, 2015, FEBS LETT, V589, P1546, DOI 10.1016/j.febslet.2015.05.008; Nakada M, 2014, BRAIN TUMOR PATHOL, V31, P198, DOI 10.1007/s10014-013-0174-9; Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P896, DOI 10.1093/neuonc/nou087; Paquette M, 2018, CANCERS, V10, DOI 10.3390/cancers10010018; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pedersen MW, 2005, BRIT J CANCER, V93, P915, DOI 10.1038/sj.bjc.6602793; Peng Y, 2016, SIGNAL TRANSDUCT TAR, V1, DOI 10.1038/sigtrans.2015.4; Proikas-Cezanne T, 2015, J CELL SCI, V128, P207, DOI 10.1242/jcs.146258; Rich JN, 2004, J CLIN ONCOL, V22, P133, DOI 10.1200/JCO.2004.08.110; Sarkaria JN, 2008, CLIN CANCER RES, V14, P2900, DOI 10.1158/1078-0432.CCR-07-1719; Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350; Touat M, 2017, ANN ONCOL, V28, P1457, DOI 10.1093/annonc/mdx106; Wang SH, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0210-9; Wu H, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000-014-0173-0; Yamaoka T, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112420; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; YUN SH, 2018, COCHRANE DB SYST REV, V16, DOI DOI 10.3390/MD16040123; Zhou KC, 2017, FRONT MOL BIOSCI, V4, DOI 10.3389/fmolb.2017.00046	41	15	15	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2020	39	39					6190	6202		10.1038/s41388-020-01422-9	http://dx.doi.org/10.1038/s41388-020-01422-9		AUG 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NS8XO	32820249	hybrid, Green Published			2022-12-28	WOS:000561253800005
J	Helbing, DL; Schulz, A; Morrison, H				Helbing, Dario-Lucas; Schulz, Alexander; Morrison, Helen			Pathomechanisms in schwannoma development and progression	ONCOGENE			English	Review							VESTIBULAR SCHWANNOMA; NEUROFIBROMATOSIS TYPE-2; WALLERIAN DEGENERATION; CELL PROLIFERATION; PLASMA-MEMBRANE; PHASE-II; GROWTH; NEUREGULIN-1; MERLIN; REGENERATION	Schwannomas are tumors of the peripheral nervous system, consisting of different cell types. These include tumorigenic Schwann cells, axons, macrophages, T cells, fibroblasts, blood vessels, and an extracellular matrix. All cell types involved constitute an intricate "tumor microenvironment" and play relevant roles in the development and progression of schwannomas. AlthoughNf2tumor suppressor gene-deficient Schwann cells are the primary tumorigenic element and principle focus of current research efforts, evidence is accumulating regarding the contributory roles of other cell types in schwannoma pathology. In this review, we aim to provide an overview of intra- and intercellular mechanisms contributing to schwannoma formation.	[Helbing, Dario-Lucas; Schulz, Alexander; Morrison, Helen] Fritz Lipmann Inst, Leibniz Inst Aging, D-07745 Jena, Germany; [Helbing, Dario-Lucas] Friedrich Schiller Univ Jena, Inst Mol Cell Biol, Jena Univ Hosp, D-07745 Jena, Germany; [Schulz, Alexander] MVZ Human Genet, D-99084 Erfurt, Germany	Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI); Friedrich Schiller University of Jena	Morrison, H (corresponding author), Fritz Lipmann Inst, Leibniz Inst Aging, D-07745 Jena, Germany.	Helen.Morrison@leibniz-fli.de	Helbing, Dario/GYU-0930-2022; Morrison, Helen/F-9748-2014	Morrison, Helen/0000-0003-4938-1409; Helbing, Dario Lucas/0000-0001-6051-559X	Projekt DEAL	Projekt DEAL	We would like to thank Prof. Steffen Rosahl, Helios Clinic Erfurt, Department of Neurosurgery and Dr. Michael Brodhun, Helios Clinic Erfurt, Department of Pathology for providing tumor samples and performing histochemical stainings. Furthermore, we would like to thank Birgit Perner for help in setting up an imaging protocol for the Axio Scan.Z1 device and Leonie Karoline Stabenow for critical reading and editing of the manuscript. Open access funding provided by Projekt DEAL.	Abe M, 2000, Brain Tumor Pathol, V17, P35, DOI 10.1007/BF02478916; Alanin MC, 2015, EUR ARCH OTO-RHINO-L, V272, P3627, DOI 10.1007/s00405-014-3398-3; Ammoun S, 2014, ONCOGENE, V33, P336, DOI 10.1038/onc.2012.587; Arthur-Farraj PJ, 2012, NEURON, V75, P633, DOI 10.1016/j.neuron.2012.06.021; Asthagiri AR, 2009, LANCET, V373, P1974, DOI 10.1016/S0140-6736(09)60259-2; Baumer P, 2013, J NEUROL, V260, P38, DOI 10.1007/s00415-012-6581-8; Birchmeier C, 2008, GLIA, V56, P1491, DOI 10.1002/glia.20753; Cattin AL, 2015, CELL, V162, P1127, DOI 10.1016/j.cell.2015.07.021; Caye-Thomasen P, 2005, OTOL NEUROTOL, V26, P98, DOI 10.1097/00129492-200501000-00017; Chen PW, 2015, ACTA NEUROPATHOL, V130, P605, DOI 10.1007/s00401-015-1482-4; Cui Y, 2019, ONCOGENE, V38, P6370, DOI 10.1038/s41388-019-0883-6; de Vries M, 2013, OTOL NEUROTOL, V34, P347, DOI 10.1097/MAO.0b013e31827c9fbf; de Vries M, 2012, VIRCHOWS ARCH, V460, P629, DOI 10.1007/s00428-012-1236-9; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Fricker FR, 2011, FUTUR NEUROL, V6, P809, DOI 10.2217/FNL.11.45; Fry EJ, 2007, NEURON, V53, P649, DOI 10.1016/j.neuron.2007.02.009; Fuse MA, 2019, NEURO-ONCOLOGY, V21, P486, DOI 10.1093/neuonc/noz002; Gao RL, 2010, J AM COLL CARDIOL, V55, P1907, DOI 10.1016/j.jacc.2009.12.044; Giovannini M, 2014, NEURO-ONCOLOGY, V16, P493, DOI 10.1093/neuonc/not242; Gomez-Sanchez JA, 2015, J CELL BIOL, V210, P153, DOI 10.1083/jcb.201503019; Gorzelany JA, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005007; Gosk J, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/547926; Hilton DA, 2014, BRAIN PATHOL, V24, P205, DOI 10.1111/bpa.12125; Hobson MI, 2000, J ANAT, V197, P591, DOI 10.1046/j.1469-7580.2000.19740591.x; Hochart A, 2015, J NEURO-ONCOL, V124, P229, DOI 10.1007/s11060-015-1828-8; Hours M, 2009, OCCUP ENVIRON MED, V66, P480, DOI 10.1136/oem.2008.042101; Italiani P, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00514; Kandathil CK, 2014, OTOL NEUROTOL, V35, P353, DOI 10.1097/MAO.0000000000000189; Karajannis MA, 2012, NEURO-ONCOLOGY, V14, P1163, DOI 10.1093/neuonc/nos146; Lallemand D, 2009, ONCOGENE, V28, P854, DOI 10.1038/onc.2008.427; Lewis D, 2019, NEURO-ONCOLOGY, V21, P314, DOI 10.1093/neuonc/noy177; Li W, 2010, CELL, V140, P477, DOI 10.1016/j.cell.2010.01.029; Lutz AB, 2017, P NATL ACAD SCI USA, V114, pE8072, DOI 10.1073/pnas.1710566114; Mautner VF, 1996, NEUROSURGERY, V38, P880, DOI 10.1097/00006123-199605000-00004; Mendes-Ferreira P, 2013, DRUG DISCOV TODAY, V18, P836, DOI 10.1016/j.drudis.2013.01.010; Michailov GV, 2004, SCIENCE, V304, P700, DOI 10.1126/science.1095862; Mindos T, 2017, J CELL BIOL, V216, P495, DOI 10.1083/jcb.201606052; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Morrison H, 2007, CANCER RES, V67, P520, DOI 10.1158/0008-5472.CAN-06-1608; Neff BA, 2012, LARYNGOSCOPE, V122, P2269, DOI 10.1002/lary.23472; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Papiez J, 2014, INT J CLIN EXP PATHO, V7, P4032; Pathmanaban ON, 2020, NEUROONCOL ADV, P2; Petrilli AM, 2016, ONCOGENE, V35, P537, DOI 10.1038/onc.2015.125; Plotkin SR, 2012, OTOL NEUROTOL, V33, P1046, DOI 10.1097/MAO.0b013e31825e73f5; SALZER JL, 1980, J CELL BIOL, V84, P739, DOI 10.1083/jcb.84.3.739; SAMII M, 1995, J NEUROSURG, V82, P711, DOI 10.3171/jns.1995.82.5.0711; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.03.035, 10.1016/j.cell.2017.02.004]; Schlehofer B, 2007, EUR J CANCER, V43, P1741, DOI 10.1016/j.ejca.2007.05.008; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; Schulte E, 2018, PROMETHEUS KOPF HALS; Schulz A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159718; Schulz A, 2016, ACTA NEUROPATHOL, V132, P289, DOI 10.1007/s00401-016-1583-8; Schulz A, 2014, BRAIN, V137, P420, DOI 10.1093/brain/awt327; Shaw RJ, 1998, J BIOL CHEM, V273, P7757, DOI 10.1074/jbc.273.13.7757; SIAN CS, 1981, HUM PATHOL, V12, P145, DOI 10.1016/S0046-8177(81)80102-5; Stassart RM, 2013, NAT NEUROSCI, V16, P48, DOI 10.1038/nn.3281; Svennigsen AF, 2013, BRAIN SCI, V3, P1182, DOI 10.3390/brainsci3031182; Tagoe T, 2014, J NEUROSCI, V34, P2684, DOI 10.1523/JNEUROSCI.3977-13.2014; Tamaskovic R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11672; Tikoo R, 2000, J NEUROSCI, V20, P4627, DOI 10.1523/JNEUROSCI.20-12-04627.2000; Truong K, 2018, NEUROSCIENCE, V374, P205, DOI 10.1016/j.neuroscience.2018.01.054; Vargas ME, 2007, ANNU REV NEUROSCI, V30, P153, DOI 10.1146/annurev.neuro.30.051606.094354; Wang SY, 2018, J NEURO-ONCOL, V138, P183, DOI 10.1007/s11060-018-2788-6; Wippold FJ, 2007, AM J NEURORADIOL, V28, P1633, DOI 10.3174/ajnr.A0682; Yin F, 2013, CELL, V154, P1342, DOI 10.1016/j.cell.2013.08.025; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Zhang LW, 2009, CLIN NEUROL NEUROSUR, V111, P261, DOI 10.1016/j.clineuro.2008.10.014	68	15	17	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2020	39	32					5421	5429		10.1038/s41388-020-1374-5	http://dx.doi.org/10.1038/s41388-020-1374-5		JUL 2020	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW4DS	32616891	hybrid, Green Published			2022-12-28	WOS:000545059900004
J	Hyslop, SR; Alexander, M; Thai, AA; Kersbergen, A; Kueh, AJ; Herold, MJ; Corbin, J; Gangatirkar, P; Ng, AP; Solomon, BJ; Alexander, WS; Sutherland, KD; Josefsson, EC				Hyslop, Stephanie R.; Alexander, Marliese; Thai, Alesha A.; Kersbergen, Ariena; Kueh, Andrew J.; Herold, Marco J.; Corbin, Jason; Gangatirkar, Pradnya; Ng, Ashley P.; Solomon, Benjamin J.; Alexander, Warren S.; Sutherland, Kate D.; Josefsson, Emma C.			Targeting platelets for improved outcome inKRAS-driven lung adenocarcinoma	ONCOGENE			English	Article							CANCER; METASTASIS; THROMBOCYTOSIS; SUPPRESSION; PROGRESSION; TUMORS; CELLS	Elevated platelet count is associated with poor survival in certain solid cancers, including lung cancer. In addition, experimental transplantation of cancer cell lines has uncovered a role for platelets in blood-borne metastasis. These studies, however, do not account for heterogeneity between lung cancer subtypes. Subsequently, the role of platelets in the major subtypes of non-small cell lung cancer (adenocarcinoma (ADC) and squamous cell carcinoma (SqCC)) is not fully understood. We utilised an autochthonousKras(LSL-G12D/+);p53(flox/flox)mouse model of lung ADC together with genetic models of thrombocytopenia to interrogate the role of platelets in lung cancer growth and progression. While thrombocytopenia failed to impact primary tumour growth, in experimental metastatic models however, thrombocytopenic mice displayed significantly extended survival. Utilising a novel thrombocytopenic immunocompromised mouse, the importance of platelets in metastatic dissemination was confirmed with humanKRAS-mutant ADC cell lines. Finally, retrospective analysis of a NSCLC patient cohort revealed thrombocytosis was predictive of poor survival in ADC patients with metastatic disease. Interestingly, this association was not apparent in SqCC patients. Overall, these data highlight the possibility of patient stratification using thrombocytosis as a biomarker, and indicates opportunities for potential novel treatment strategies that combine anti-platelet and lung cancer therapies.	[Hyslop, Stephanie R.; Kersbergen, Ariena; Corbin, Jason; Gangatirkar, Pradnya; Sutherland, Kate D.; Josefsson, Emma C.] Walter & Eliza Hall Inst Med Res, ACRF Canc Biol & Stem Cells Div, Melbourne, Vic, Australia; [Hyslop, Stephanie R.; Kueh, Andrew J.; Herold, Marco J.; Ng, Ashley P.; Alexander, Warren S.; Josefsson, Emma C.] Univ Melbourne, Dept Med Biol, Melbourne, Vic, Australia; [Alexander, Marliese] Univ Melbourne, Peter MacCallum Canc Ctr, Pharm Dept, Parkville, Vic, Australia; [Alexander, Marliese; Solomon, Benjamin J.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic, Australia; [Thai, Alesha A.; Solomon, Benjamin J.] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia; [Kueh, Andrew J.; Herold, Marco J.; Ng, Ashley P.; Alexander, Warren S.] Walter & Eliza Hall Inst Med Res, Blood Cells & Blood Canc Div, Melbourne, Vic, Australia	University of Melbourne; Peter Maccallum Cancer Center; University of Melbourne; Peter Maccallum Cancer Center; University of Melbourne; Peter Maccallum Cancer Center	Josefsson, EC (corresponding author), Walter & Eliza Hall Inst Med Res, ACRF Canc Biol & Stem Cells Div, Melbourne, Vic, Australia.; Josefsson, EC (corresponding author), Univ Melbourne, Dept Med Biol, Melbourne, Vic, Australia.	josefsson@wehi.edu.au	Ng, Ashley/D-3842-2011; Josefsson, Emma/CAF-4970-2022; Herold, Marco J/C-8039-2013	Ng, Ashley/0000-0001-9690-0879; Herold, Marco J/0000-0001-7539-7581; Alexander, Marliese/0000-0001-5782-7912; Solomon, Benjamin/0000-0003-3059-5730; Hyslop, Stephanie Rose/0000-0001-5006-1627; Josefsson, Emma/0000-0001-6478-5204	Australian National Health and Medical Research Council [1079250, 1113577, 1122783, 1159658, 1058344, 1156095]; Independent Research Institutes Infrastructure Support Scheme Grant [9000220]; Victorian State Government Operational Infrastructure Support Grant; Lorenzo and Pamela Galli Charitable Trust; Australian Postgraduate Award from the University of Melbourne; Victorian Cancer Agency Mid-Career Fellowship [MCRF18003]; Peter and Julie Alston Centenary Fellowship; Australian Phenomics Network; Leukemia and Lymphoma Society [LLS SCOR 7001-13 MJH]; Australian Government through the National Collaborative Research Infrastructure Strategy program	Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Independent Research Institutes Infrastructure Support Scheme Grant; Victorian State Government Operational Infrastructure Support Grant; Lorenzo and Pamela Galli Charitable Trust; Australian Postgraduate Award from the University of Melbourne; Victorian Cancer Agency Mid-Career Fellowship; Peter and Julie Alston Centenary Fellowship; Australian Phenomics Network; Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); Australian Government through the National Collaborative Research Infrastructure Strategy program(Australian GovernmentDepartment of Industry, Innovation and Science)	We thank Prof Benjamin Kile for generously providing Bcl-x<SUP>Plt20</SUP> mice and A/Prof Marie-Liesse Asselin-Labat for kindly sharing cell lines. We thank Janelle Lochland, Dr Amanda Au, Nicole Lynch, Stephanie Bound, Keti Stoev, Rebekah Meeny and Shannon Oliver for outstanding assistance and Prof Doug Hilton for helpful discussions. Ann Officer facilitated data collection for the Thoracic Malignancies Cohort Study and Him Ahmad assisted with patient pathology data collation. This work was supported by Australian National Health and Medical Research Council Project, Ideas, and Program Grants (1079250 ECJ, 1113577, 1122783 APN, 1186575 MJH, 1159658 MJH), Fellowships (1058344 WSA, 1156095 MJH), an Independent Research Institutes Infrastructure Support Scheme Grant (9000220), and a Victorian State Government Operational Infrastructure Support Grant. ECJ is the recipient of a fellowship from the Lorenzo and Pamela Galli Charitable Trust. SRH is the recipient of an Australian Postgraduate Award from the University of Melbourne. KDS is supported by a Victorian Cancer Agency Mid-Career Fellowship (MCRF18003) and the Peter and Julie Alston Centenary Fellowship. The generation of the NSG Mpl-/-mice was supported by the Australian Phenomics Network, the Leukemia and Lymphoma Society (LLS SCOR 7001-13 MJH), and the Australian Government through the National Collaborative Research Infrastructure Strategy program.	Alexander WS, 1996, BLOOD, V87, P2162, DOI 10.1182/blood.V87.6.2162.bloodjournal8762162; Chen Z, 2014, NAT REV CANCER, V14, P535, DOI 10.1038/nrc3775; Cho MS, 2012, BLOOD, V120, P4869, DOI 10.1182/blood-2012-06-438598; Coenen DM, 2017, BLOOD, V130, P2819, DOI 10.1182/blood-2017-04-780825; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Gay LJ, 2011, CANCER CELL, V20, P553, DOI 10.1016/j.ccr.2011.11.001; Gay LJ, 2011, NAT REV CANCER, V11, P123, DOI 10.1038/nrc3004; Han R, 2020, MOL ONCOL, V14, P1152, DOI 10.1002/1878-0261.12682; Hu X, 2018, ONCOL LETT, V16, P2715, DOI 10.3892/ol.2018.8956; Hyslop SR, 2017, TRENDS CANCER, V3, P235, DOI 10.1016/j.trecan.2017.01.006; Izaguirre-Avila R, 2002, CLIN APPL THROMB-HEM, V8, P169, DOI 10.1177/107602960200800214; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; JAIN R, 1983, SOUTHERN MED J, V76, P1380, DOI 10.1097/00007611-198311000-00013; Kopp HG, 2009, CANCER RES, V69, P7775, DOI 10.1158/0008-5472.CAN-09-2123; Labelle M, 2011, CANCER CELL, V20, P576, DOI 10.1016/j.ccr.2011.09.009; Lebois M, 2016, J THROMB HAEMOST, V14, P1882, DOI 10.1111/jth.13397; LEVIN J, 1964, ARCH INTERN MED, V114, P497, DOI 10.1001/archinte.1964.03860100079008; Lucotti S, 2019, J CLIN INVEST, V129, P1845, DOI 10.1172/JCI121985; Malhotra J, 2017, TRANSL LUNG CANCER R, V6, P196, DOI 10.21037/tlcr.2017.03.01; Mammadova-Bach E, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.88245; Mason KD, 2007, CELL, V128, P1173, DOI 10.1016/j.cell.2007.01.037; McNeil JJ, 2018, NEW ENGL J MED, V379, P1519, DOI 10.1056/NEJMoa1803955; Michael JV, 2017, BLOOD, V130, P567, DOI 10.1182/blood-2016-11-751099; Miyata K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04324-1; Niki M, 2017, LUNG CANCER-TARGETS, V8, P91, DOI 10.2147/LCTT.S138887; Osmani L, 2018, SEMIN CANCER BIOL, V52, P103, DOI 10.1016/j.semcancer.2017.11.019; Pedersen LM, 1996, EUR RESPIR J, V9, P1826; Plantureux L, 2020, CANCER RES, V80, P291, DOI 10.1158/0008-5472.CAN-19-1181; Pucci F, 2016, CELL REP, V17, P1764, DOI 10.1016/j.celrep.2016.10.031; Rachidi S, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aai7911; Riesenberg BP, 2019, J IMMUNOL, V203, P1105, DOI 10.4049/jimmunol.1900594; Roselli M, 2004, CLIN CANCER RES, V10, P610, DOI 10.1158/1078-0432.CCR-0348-03; Roselli M, 2002, INT J BIOL MARKER, V17, P56, DOI 10.1177/172460080201700107; Rothwell PM, 2011, LANCET, V377, P31, DOI 10.1016/S0140-6736(10)62110-1; Schumacher D, 2013, CANCER CELL, V24, P130, DOI 10.1016/j.ccr.2013.05.008; Spiro SG, 2005, CURR OPIN PULM MED, V11, P287, DOI 10.1097/01.mcp.0000166590.03042.56; Takagi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073609; Tomita Masaki, 2008, Interact Cardiovasc Thorac Surg, V7, P613, DOI 10.1510/icvts.2007.174391; Wang JJ, 2019, TECHNOL CANCER RES T, V18, DOI 10.1177/1533033819837261; Winslow MM, 2011, NATURE, V473, P101, DOI 10.1038/nature09881; Yu LX, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6256; Zhang H, 2015, AM J SURG, V210, P526, DOI 10.1016/j.amjsurg.2015.03.022; Zhang X, 2015, INT J CLIN EXP MED, V8, P5379	44	2	2	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 16	2020	39	29					5177	5186		10.1038/s41388-020-1357-6	http://dx.doi.org/10.1038/s41388-020-1357-6		JUN 2020	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ML6WO	32535617				2022-12-28	WOS:000539953300001
J	Okumura, K; Saito, M; Yoshizawa, Y; Ito, Y; Isogai, E; Araki, K; Wakabayashi, Y				Okumura, Kazuhiro; Saito, Megumi; Yoshizawa, Yasuhiro; Ito, Yuki; Isogai, Eriko; Araki, Kimi; Wakabayashi, Yuichi			Pak1 maintains epidermal stem cells by regulating Langerhans cells and is required for skin carcinogenesis	ONCOGENE			English	Article							P21-ACTIVATED KINASES; CHEMICAL CARCINOGENESIS; TUMOR PROGRESSION; CANCER; RECEPTOR; MICE; MECHANISMS; INHIBITION; ALPHA	Pak1 (serine/threonine p21-activated kinases) was previously reported to have oncogenic activity in several cancers. However, its roles in the cancer microenvironment are poorly understood. We demonstrated that Pak1 expression in Langerhans cells (LCs) is essential for the maintenance of epidermal stem cells and skin tumor development. We found that PAK1 is localized in LCs by immunohistochemistry. Furthermore, the number of LCs significantly decreased in MSM/Ms Pak1 homozygous knockout mice (MSM/Ms-Pak1(-/-)). F-1 hybrid (FVB/NxMSM/Ms) Pak1 heterozygous knockout mice (F-1-Pak1(+/-)) had increased numbers of Th17 cells in the skin. Therefore, Pak1 knockdown cells were prepared using LC-derived XS52 cells (XS52-Pak1KD) and co-cultured with keratinocyte-derived C5N cells. As a result, XS52-Pak1KD cell supernatants promoted C5N cell proliferation. We then carried out DMBA/TPA skin carcinogenesis experiments using F-1-Pak1(+/-) mice. Of note, F-1-Pak1(+/-) mice exhibited stronger resistance to skin tumors than control mice. F-1-Pak1(+/-) mice had fewer epidermal stem cells in the skin bulge. Our study suggested that Pak1 regulates the epidermal stem cell number by changing the properties of LCs and functions in skin carcinogenesis. We clarified a novel role of Pak1 in regulating LCs as a potential therapeutic target in skin immune disease and carcinogenesis.	[Okumura, Kazuhiro; Saito, Megumi; Yoshizawa, Yasuhiro; Ito, Yuki; Isogai, Eriko; Wakabayashi, Yuichi] Chiba Canc Ctr, Res Inst, Dept Carcinogenesis Res, Div Expt Anim Res,Chuo Ku, 666-2 Nitonacho, Chiba 2608717, Japan; [Araki, Kimi] Inst Resource Dev & Anal, Div Dev Genet, Chuo Ku, 2-2-1 Honjo, Kumamoto 8600811, Japan	Chiba Cancer Center	Wakabayashi, Y (corresponding author), Chiba Canc Ctr, Res Inst, Dept Carcinogenesis Res, Div Expt Anim Res,Chuo Ku, 666-2 Nitonacho, Chiba 2608717, Japan.	yuichi_wakabayashi@chiba-cc.jp			JSPS KAKENHI grant [JP19K07494, JP15K06817]	JSPS KAKENHI grant(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The authors thank Dr. Naoki Okada of Osaka university and Dr. Akira Takashima for providing XS52 and NS47 cells, and Dr. Allan Balmain of University of California, San Francisco for providing C5N cells. The authors also thank Mrs. Sakura Katori and Mrs. Akemi Hongu for their technical assistance. This study was supported by JSPS KAKENHI grant number JP19K07494. This work was supported by JSPS KAKENHI Grant Number JP15K06817 (AdAMS).	Abel EL, 2009, NAT PROTOC, V4, P1350, DOI 10.1038/nprot.2009.120; Allen JD, 2009, BLOOD, V113, P2695, DOI 10.1182/blood-2008-06-160861; Aoto Y, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31349-x; Araki K, 2009, MAMM GENOME, V20, P14, DOI 10.1007/s00335-008-9160-7; Beesetti S, 2019, J CELL PHYSIOL, V234, P969, DOI 10.1002/jcp.26925; Cataisson C, 2012, J EXP MED, V209, P1689, DOI 10.1084/jem.20101355; Chow HY, 2012, CANCER RES, V72, P5966, DOI 10.1158/0008-5472.CAN-12-2246; Cipolat S, 2014, ELIFE, V3, DOI 10.7554/eLife.01888; Clausen BE, 2015, J INVEST DERMATOL, V135, P1218, DOI 10.1038/jid.2014.520; Di Cesare A, 2009, J INVEST DERMATOL, V129, P1339, DOI 10.1038/jid.2009.59; Eaton LH, 2018, BRIT J DERMATOL, V178, P1364, DOI 10.1111/bjd.16172; Forcales SV, 2012, EMBO J, V31, P301, DOI 10.1038/emboj.2011.391; Gan JF, 2016, P NATL ACAD SCI USA, V113, P14745, DOI 10.1073/pnas.1618582114; Garcia-Garcia E, 2002, J LEUKOCYTE BIOL, V72, P107; Go C, 1999, CANCER RES, V59, P2861; Gonzalez-Villasana V, 2015, CLIN CANCER RES, V21, P2127, DOI 10.1158/1078-0432.CCR-14-2279; Gorelik L, 2001, NAT MED, V7, P1118, DOI 10.1038/nm1001-1118; Guo FK, 2010, P NATL ACAD SCI USA, V107, P18505, DOI 10.1073/pnas.1010249107; Guo YX, 2017, J PATHOL, V243, P208, DOI 10.1002/path.4940; He H, 2013, BBA-MOL CELL RES, V1833, P33, DOI 10.1016/j.bbamcr.2012.10.015; Huynh N, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3432-0; Huynh N, 2016, CANCER BIOL THER, V17, P813, DOI 10.1080/15384047.2016.1195045; Jagadeeshan S, 2016, ANN ONCOL, V27, P1546, DOI 10.1093/annonc/mdw184; Jantschitsch C, 2012, J INVEST DERMATOL, V132, P1479, DOI 10.1038/jid.2011.469; Jensen KB, 2010, NAT PROTOC, V5, P898, DOI 10.1038/nprot.2010.39; Kaplan DH, 2017, NAT IMMUNOL, V18, P1068, DOI 10.1038/ni.3815; Kelly Mollie L, 2012, Cell Logist, V2, P84; Kemp CJ, 2005, SEMIN CANCER BIOL, V15, P460, DOI 10.1016/j.semcancer.2005.06.003; Kim E, 2014, CANCER RES, V74, P5520, DOI 10.1158/0008-5472.CAN-14-0735; Kumar R, 2017, GENE, V605, P20, DOI 10.1016/j.gene.2016.12.014; Langowski JL, 2006, NATURE, V442, P461, DOI 10.1038/nature04808; Lewis JM, 2015, J INVEST DERMATOL, V135, P1405, DOI 10.1038/jid.2014.411; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luckashenak N, 2013, J IMMUNOL, V190, P27, DOI 10.4049/jimmunol.1201082; Modi BG, 2012, SCIENCE, V335, P104, DOI 10.1126/science.1211600; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Morris RJ, 2004, NAT BIOTECHNOL, V22, P411, DOI 10.1038/nbt950; Muller G, 2020, AUTOPHAGY, V16, P1380, DOI 10.1080/15548627.2019.1686728; Nagao K, 2012, NAT IMMUNOL, V13, P744, DOI 10.1038/ni.2353; Nardinocchi L, 2015, EUR J IMMUNOL, V45, P922, DOI 10.1002/eji.201445052; Okumura K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097201; Okumura K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102111; Ong CC, 2011, P NATL ACAD SCI USA, V108, P7177, DOI 10.1073/pnas.1103350108; Ortner D, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1260215; Schwarz T, 2011, EUR J CELL BIOL, V90, P560, DOI 10.1016/j.ejcb.2010.09.011; Seoane J, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022277; Singh A, 2016, CARCINOGENESIS, V37, P72, DOI 10.1093/carcin/bgv162; Tran G, 2018, J AM ACAD DERMATOL, V78, P579, DOI 10.1016/j.jaad.2017.09.022; van de Ven R, 2011, BLOOD, V118, P2502, DOI 10.1182/blood-2011-03-344838; Wang A, 2020, J DERMATOL, V47, P104, DOI 10.1111/1346-8138.15184; Wang K, 2018, INT J ONCOL, V52, P261, DOI 10.3892/ijo.2017.4193; Wang L, 2010, CANCER RES, V70, P10112, DOI 10.1158/0008-5472.CAN-10-0775; Wong LLY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068843; XU S, 1995, J IMMUNOL, V154, P2697; Yeo D, 2015, PANCREAS, V44, P363, DOI 10.1097/MPA.0000000000000276; Yi CL, 2008, CANCER RES, V68, P7932, DOI 10.1158/0008-5472.CAN-08-0866; YUSPA SH, 1994, J INVEST DERMATOL, V103, pS90, DOI 10.1111/1523-1747.ep12399255; Zhang W, 2015, CELL DEATH DIFFER, V22, P287, DOI 10.1038/cdd.2014.142; Zhu G, 2012, ONCOGENE, V31, P1001, DOI 10.1038/onc.2011.294; Zoumpourlis V, 2003, CARCINOGENESIS, V24, P1159, DOI 10.1093/carcin/bgg067	60	4	4	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	24					4756	4769		10.1038/s41388-020-1323-3	http://dx.doi.org/10.1038/s41388-020-1323-3		MAY 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LY0HO	32427988				2022-12-28	WOS:000534491700001
J	Cassandri, M; Butera, A; Amelio, I; Lena, AM; Montanaro, M; Mauriello, A; Anemona, L; Candi, E; Knight, RA; Agostini, M; Melino, G				Cassandri, Matteo; Butera, Alessio; Amelio, Ivano; Lena, Anna Maria; Montanaro, Manuela; Mauriello, Alessandro; Anemona, Lucia; Candi, Eleonora; Knight, Richard A.; Agostini, Massimiliano; Melino, Gerry			ZNF750 represses breast cancer invasion via epigenetic control of prometastatic genes	ONCOGENE			English	Article							COMPREHENSIVE MOLECULAR PORTRAITS; CELL-MIGRATION; EXPRESSION; P63; CHROMOSOME-17; LAMININ-332; METASTASIS; COMPLEX; HEAD; KLF4	Breast cancer is the second leading cause of cancer-related deaths among women, largely due to the progression of a significant fraction of primary tumours to the metastatic stage. Here, we show that zinc-finger protein 750 (ZNF750) opposes the migration and invasion of breast cancer cells by repressing a prometastatic transcriptional programme, which includes genes involved in focal adhesion and extracellular matrix interactions, such as LAMB3 and CTNNAL1. Mechanistically, ZNF750 recruits the epigenetic modifiers KDM1A and HDAC1 to the promoter regions of LAMB3 and CTNNAL1, influencing histone marks and transactivating these genomic sites. Gene expression analysis in cancer patient datasets indicated that ZNF750 and its targets were negative prognostic factors in breast cancer. Together, our findings shed light on the molecular mechanism by which ZNF750 regulates cell migration and invasion, suggesting a role in breast cancer metastasis.	[Cassandri, Matteo; Butera, Alessio; Amelio, Ivano; Lena, Anna Maria; Montanaro, Manuela; Mauriello, Alessandro; Anemona, Lucia; Candi, Eleonora; Agostini, Massimiliano; Melino, Gerry] Univ Roma Tor Vergata, TOR, Dept Expt Med, I-00133 Rome, Italy; [Amelio, Ivano; Knight, Richard A.; Melino, Gerry] Univ Cambridge, MRC Toxicol Unit, Dept Pathol, Tennis Court Rd, Cambridge CB2 1QP, England; [Candi, Eleonora] IRCCS, IDI, Via Monti Creta 106, I-00166 Rome, Italy; [Cassandri, Matteo] Bambino Gesu Pediat Hosp, Dept Oncohematol, I-00146 Rome, Italy	University of Rome Tor Vergata; University of Cambridge; IRCCS Istituto Dermopatico dell'Immacolata (IDI); IRCCS Bambino Gesu	Agostini, M; Melino, G (corresponding author), Univ Roma Tor Vergata, TOR, Dept Expt Med, I-00133 Rome, Italy.; Melino, G (corresponding author), Univ Cambridge, MRC Toxicol Unit, Dept Pathol, Tennis Court Rd, Cambridge CB2 1QP, England.	m.agostini@med.uniroma2.it; gm614@mrc-tox.cam.ac.uk	Cassandri, Matteo/AAB-3730-2019; Anemona, lucia/AAB-3491-2022; Agostini, Massimiliano/G-9579-2014	Cassandri, Matteo/0000-0002-2919-676X; Anemona, lucia/0000-0002-3711-2714; Montanaro, Manuela/0000-0001-8441-3731; Lena, Anna Maria/0000-0001-6285-9927; Amelio, Ivano/0000-0002-9126-5391; Butera, Alessio/0000-0001-7196-4235; Agostini, Massimiliano/0000-0003-3124-2072	Medical Research Council UK; Associazione Italiana per la Ricerca contro il Cancro (AIRC) [20473]; AIRC [22206, 23219]; Ministero Salute, IDI-IRCCS; Italian Ministry of Foreign Affairs and International Cooperation; Regione Lazio through the LazioInnova Progetto Gruppo di Ricerca [85-2017-14986]	Medical Research Council UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Associazione Italiana per la Ricerca contro il Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); AIRC(Fondazione AIRC per la ricerca sul cancro); Ministero Salute, IDI-IRCCS; Italian Ministry of Foreign Affairs and International Cooperation(Ministry of Foreign Affairs and International Cooperation (Italy)); Regione Lazio through the LazioInnova Progetto Gruppo di Ricerca	We would like to thank Dr Annalisa Conti for helpful comments and suggestions and K. Dudek and C. Jones for assistance in gene microarray analysis. This work has been supported by the Medical Research Council (to GM) UK, the Associazione Italiana per la Ricerca contro il Cancro (AIRC) (to GM; IG#20473 (2018-2022)), the AIRC (to EC; IG#22206 (2019-2023)), the AIRC (Start-Up to IA; ID 23219), the Ministero Salute, IDI-IRCCS (RC to EC), and the Italian Ministry of Foreign Affairs and International Cooperation (to EC). The work has also been supported by Regione Lazio through the LazioInnova Progetto Gruppo di Ricerca n 85-2017-14986 (to GM).	Aubrey BJ, 2018, CELL DEATH DIFFER, V25, P104, DOI 10.1038/cdd.2017.169; Boxer LD, 2014, GENE DEV, V28, P2013, DOI 10.1101/gad.246579.114; Cassandri M, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2017.71; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chalcrabarti R, 2014, NAT CELL BIOL, V16, P1004, DOI 10.1038/ncb3040; Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033; Courjal F, 1997, CANCER RES, V57, P4368; Engeland K, 2018, CELL DEATH DIFFER, V25, P114, DOI 10.1038/cdd.2017.172; Fan LC, 2011, ONCOGENE, V30, P2610, DOI 10.1038/onc.2010.637; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Hazawa M, 2017, ONCOGENE, V36, P2243, DOI 10.1038/onc.2016.377; Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96; Jain N, 2009, INT J BIOCHEM CELL B, V41, P72, DOI 10.1016/j.biocel.2008.10.006; Jia Yuping, 2016, J Carcinog, V15, P3, DOI 10.4103/1477-3163.182809; Jiang P, 2009, CANCER LETT, V284, P122, DOI 10.1016/j.canlet.2009.02.034; Kaiser AM, 2018, CELL DEATH DIFFER, V25, P93, DOI 10.1038/cdd.2017.171; Kinoshita T, 2012, ONCOTARGET, V3, P1386, DOI 10.18632/oncotarget.709; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kreiseder B, 2013, INT J CANCER, V132, P521, DOI 10.1002/ijc.27698; Kwon OH, 2011, BIOCHEM BIOPH RES CO, V406, P539, DOI 10.1016/j.bbrc.2011.02.082; Lin DC, 2014, NAT GENET, V46, P467, DOI 10.1038/ng.2935; Marinkovich MP, 2007, NAT REV CANCER, V7, P370, DOI 10.1038/nrc2089; Maziveyi M, 2017, ONCOTARGET, V8, P48471, DOI 10.18632/oncotarget.17265; Memmi EM, 2015, P NATL ACAD SCI USA, V112, P3499, DOI 10.1073/pnas.1500762112; Millarte V, 2012, SCI WORLD J, DOI 10.1100/2012/498278; Orsetti B, 2004, CANCER RES, V64, P6453, DOI 10.1158/0008-5472.CAN-04-0756; Polyak K, 2007, J CLIN INVEST, V117, P3155, DOI 10.1172/JCI33295; Sen GL, 2012, DEV CELL, V22, P669, DOI 10.1016/j.devcel.2011.12.001; Su X, 2017, ONCOGENE, V36, P2377, DOI 10.1038/onc.2016.388; SUGIMOTO Y, 1987, MOL CELL BIOL, V7, P4549, DOI 10.1128/MCB.7.12.4549; Sullivan KD, 2018, CELL DEATH DIFFER, V25, P133, DOI 10.1038/cdd.2017.174; Sweeney C, 2014, CANCER EPIDEM BIOMAR, V23, P714, DOI 10.1158/1055-9965.EPI-13-1023; Tucci P, 2012, P NATL ACAD SCI USA, V109, P15312, DOI 10.1073/pnas.1110977109; Wang XL, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0053938, 10.1371/journal.pone.0050627]; Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050; Ye X, 2015, TRENDS CELL BIOL, V25, P675, DOI 10.1016/j.tcb.2015.07.012; Yeo SK, 2017, TRENDS CANCER, V3, P753, DOI 10.1016/j.trecan.2017.09.001; Zhang H, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1320-z; Zhang PP, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1224-3; Zhang W, 2011, INT J MOL SCI, V12, P5672, DOI 10.3390/ijms12095672; Zhang Z, 2016, TUMOR BIOL, V37, P1671, DOI 10.1007/s13277-015-3901-5	41	14	15	3	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	22					4331	4343		10.1038/s41388-020-1277-5	http://dx.doi.org/10.1038/s41388-020-1277-5		APR 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LR9IT	32313225				2022-12-28	WOS:000527509300003
J	Zhao, CG; Yang, LH; Zhou, F; Yu, Y; Du, XJ; Xiang, YQ; Li, CL; Huang, XY; Xie, CY; Liu, ZG; Lin, JY; Wang, LX; Liang, G; Cui, R				Zhao, Chengguang; Yang, Lehe; Zhou, Feng; Yu, Yun; Du, Xiaojing; Xiang, Youqun; Li, Chenglong; Huang, Xiaoying; Xie, Congying; Liu, Zhiguo; Lin, Jiayuh; Wang, Liangxing; Liang, Guang; Cui, Ri			Feedback activation of EGFR is the main cause for STAT3 inhibition-irresponsiveness in pancreatic cancer cells	ONCOGENE			English	Article							DRUG-RESISTANCE; TUMOR-GROWTH; PROMOTES; THERAPY; MEK; NAPABUCASIN; LIGANDS; PATHWAY	Pancreatic cancer is one of the world's leading causes of cancer-related death. Activation of STAT3 has been reported as a major contributor in pancreatic cancer tumorigenesis and chemoresistance. However, treatment of advanced pancreatic cancer patients with STAT3 inhibitors often meets drug resistance and heterogeneous response. We found that EGFR activation is a main cause for resistance to STAT3 inhibitors in pancreatic cancer cells, regardless of KRAS mutation status. Mechanistically, inhibition of STAT3 promotes STAT1- and STAT4-mediated TGF-alpha expression, leading to activation of the EGFR pathway. Combined treatment of pancreatic cancer cells with EGFR and STAT3 inhibitors persistently blocks EGFR and STAT3 signaling, and exerts synergistic antitumor activity both in vitro and in vivo, with or without KRAS mutation. Our results indicate that reciprocal cross-talk between STAT3 and EGFR pathways is a key molecular mechanism leading to resistance in pancreatic cancer cells. Furthermore, the study shows that combined inhibition of both EGFR and STAT3 might overcome drug resistance encountered during treatment with single agent alone. This study suggests an improved therapeutic strategy, through combined treatment with STAT3 and EGFR inhibitors, for pancreatic cancer patients.	[Zhao, Chengguang; Yang, Lehe; Zhou, Feng; Yu, Yun; Liu, Zhiguo; Liang, Guang; Cui, Ri] Wenzhou Med Univ, Sch Pharmaceut Sci, Canc & Anticanc Drug Res Ctr, Wenzhou 325035, Zhejiang, Peoples R China; [Zhao, Chengguang; Yang, Lehe; Zhou, Feng; Du, Xiaojing; Xiang, Youqun; Huang, Xiaoying; Xie, Congying; Liu, Zhiguo; Wang, Liangxing; Cui, Ri] Wenzhou Med Univ, Affiliated Hosp 1, Wenzhou 325000, Zhejiang, Peoples R China; [Zhao, Chengguang; Liang, Guang; Cui, Ri] Wenzhou Univ Wenzhou Med Univ Collaborat Innovat, Wenzhou 325035, Zhejiang, Peoples R China; [Yang, Lehe; Lin, Jiayuh] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; [Li, Chenglong] Univ Florida, Coll Pharm, Gainesville, FL 32610 USA	Wenzhou Medical University; Wenzhou Medical University; University System of Maryland; University of Maryland Baltimore; State University System of Florida; University of Florida	Liang, G; Cui, R (corresponding author), Wenzhou Med Univ, Sch Pharmaceut Sci, Canc & Anticanc Drug Res Ctr, Wenzhou 325035, Zhejiang, Peoples R China.; Wang, LX; Cui, R (corresponding author), Wenzhou Med Univ, Affiliated Hosp 1, Wenzhou 325000, Zhejiang, Peoples R China.; Liang, G; Cui, R (corresponding author), Wenzhou Univ Wenzhou Med Univ Collaborat Innovat, Wenzhou 325035, Zhejiang, Peoples R China.	wzyxywlx@163.com; wzmcliangguang@163.com; wzmucuiri@163.com	Zhao, Chengguang/AAK-2981-2021		National Natural Science Foundation of China [81672305, 81773579]; Natural Science Foundation of Zhejiang Province [LY17B020008, LY18H160047]; Medical Scientific Research Fund of Zhejiang Province [2019322308]; Wenzhou science and technology project [Y20190179]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Zhejiang Province(Natural Science Foundation of Zhejiang Province); Medical Scientific Research Fund of Zhejiang Province; Wenzhou science and technology project	This research was supported by National Natural Science Foundation of China (81672305 and 81773579), Natural Science Foundation of Zhejiang Province (LY17B020008 and LY18H160047), Medical Scientific Research Fund of Zhejiang Province (2019322308) and Wenzhou science and technology project (Y20190179).	Bai LC, 2019, CANCER CELL, V36, P498, DOI 10.1016/j.ccell.2019.10.002; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Bressy C, 2018, CANCER RES, V78, P909, DOI 10.1158/0008-5472.CAN-15-2790; Choi S, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1018-y; Delgoffe Greg M, 2013, JAKSTAT, V2, pe23060, DOI 10.4161/jkst.23060; Engle DD, 2019, SCIENCE, V364, P1156, DOI 10.1126/science.aaw3145; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Ho HH, 2006, J BIOL CHEM, V281, P14111, DOI 10.1074/jbc.M511797200; Hong D, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac5272; Hubbard JM, 2017, DRUGS, V77, P1091, DOI 10.1007/s40265-017-0759-4; Jiang H, 2020, GUT, V69, P122, DOI 10.1136/gutjnl-2018-317424; Johnson DE, 2018, NAT REV CLIN ONCOL, V15, P234, DOI 10.1038/nrclinonc.2018.8; Jonker DJ, 2018, LANCET GASTROENTEROL, V3, P263, DOI 10.1016/S2468-1253(18)30009-8; Laklai H, 2016, NAT MED, V22, P497, DOI 10.1038/nm.4082; Lankadasari MB, 2018, THERANOSTICS, V8, P3824, DOI 10.7150/thno.25308; Lee HJ, 2014, CANCER CELL, V26, P207, DOI 10.1016/j.ccr.2014.05.019; Lee JW, 2019, NATURE, V567, P249, DOI 10.1038/s41586-019-1004-y; Ligorio M, 2019, CELL, V178, P160, DOI 10.1016/j.cell.2019.05.012; Maretzky T, 2011, ONCOGENE, V30, P611, DOI 10.1038/onc.2010.443; Milagrel CS, 2015, CANCER RES, V75, P1255, DOI 10.1158/0008-5472.CAN-14-1801; Nagathihalli NS, 2018, CANCER RES, V78, P6235, DOI 10.1158/0008-5472.CAN-18-0634; Nagathihalli NS, 2014, CANCER RES, V74, P2062, DOI 10.1158/0008-5472.CAN-13-2329; Rath KS, 2014, CANCER RES, V74, P2316, DOI 10.1158/0008-5472.CAN-13-2433; Sahu N, 2017, MOL CANCER THER, V16, P1729, DOI 10.1158/1535-7163.MCT-17-0009; Shi Y, 2019, NATURE, V569, P131, DOI 10.1038/s41586-019-1130-6; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sun C, 2014, TRENDS BIOCHEM SCI, V39, P465, DOI 10.1016/j.tibs.2014.08.010; Van Schaeybroeck S, 2014, CELL REP, V7, P1940, DOI 10.1016/j.celrep.2014.05.032; Wang XC, 2016, ONCOTARGET, V7, P21496, DOI 10.18632/oncotarget.7452; Wormann SM, 2016, GASTROENTEROLOGY, V151, P180, DOI 10.1053/j.gastro.2016.03.010; Wu P, 2015, TRENDS PHARMACOL SCI, V36, P422, DOI 10.1016/j.tips.2015.04.005; Xiao H, 2015, J BIOL CHEM, V290, P3418, DOI 10.1074/jbc.M114.616748; Yang LH, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-018-1015-9; Yu WY, 2013, J MED CHEM, V56, P4402, DOI 10.1021/jm400080c; Zhang ZK, 2017, CANCER LETT, V402, P213, DOI 10.1016/j.canlet.2017.05.006; Zhang ZL, 2016, CANCER LETT, V382, P53, DOI 10.1016/j.canlet.2016.08.023; Zhao CG, 2016, TRENDS PHARMACOL SCI, V37, P47, DOI 10.1016/j.tips.2015.10.001; Zhao CG, 2015, ONCOTARGET, V6, P14472, DOI 10.18632/oncotarget.3991; Zhao CG, 2010, EUR J MED CHEM, V45, P5773, DOI 10.1016/j.ejmech.2010.09.037; Zheng HL, 2019, MOL CARCINOGEN, V58, P565, DOI 10.1002/mc.22951	40	18	18	4	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	20					3997	4013		10.1038/s41388-020-1271-y	http://dx.doi.org/10.1038/s41388-020-1271-y		APR 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LN3GC	32242147				2022-12-28	WOS:000522996500001
J	Chandrashekar, DS; Chakravarthi, BVSK; Robinson, AD; Anderson, JC; Agarwal, S; Balasubramanya, SAH; Eich, ML; Bajpai, AK; Davuluri, S; Guru, MS; Guru, AS; Naik, G; Della Manna, DL; Acharya, KK; Carskadon, S; Manne, U; Crossman, DK; Ferguson, JE; Grizzle, WE; Palanisamy, N; Willey, CD; Crowley, MR; Netto, GJ; Yang, ES; Varambally, S; Sonpavde, G				Chandrashekar, Darshan S.; Chakravarthi, Balabhadrapatruni V. S. K.; Robinson, Alyncia D.; Anderson, Joshua C.; Agarwal, Sumit; Balasubramanya, Sai Akshaya Hodigere; Eich, Marie-Lisa; Bajpai, Akhilesh Kumar; Davuluri, Sravanthi; Guru, Maya S.; Guru, Arjun S.; Naik, Gurudatta; Della Manna, Deborah L.; Acharya, Kshitish K.; Carskadon, Shannon; Manne, Upender; Crossman, David K.; Ferguson, James E.; Grizzle, William E.; Palanisamy, Nallasivam; Willey, Christopher D.; Crowley, Michael R.; Netto, George J.; Yang, Eddy S.; Varambally, Sooryanarayana; Sonpavde, Guru			Therapeutically actionable PAK4 is amplified, overexpressed, and involved in bladder cancer progression	ONCOGENE			English	Article							METASTATIC UROTHELIAL CARCINOMA; CISPLATIN-INELIGIBLE PATIENTS; GENE-EXPRESSION; BREAST-CANCER; TUMOR-GROWTH; SINGLE-ARM; CELLS; SURVIVAL; PROLIFERATION; CHEMOTHERAPY	Muscle-invasive bladder carcinomas (MIBCs) are aggressive genitourinary malignancies. Metastatic urothelial carcinoma of the bladder is generally incurable by current chemotherapy and leads to early mortality. Recent studies have identified molecular subtypes of MIBCs with different sensitivities to frontline therapy, suggesting tumor heterogeneity. We have performed multi-omic profiling of the kinome in bladder cancer patients with the goal of identify therapeutic targets. Our analyses revealed amplification, overexpression, and elevated kinase activity of P21 (RAC1) activated kinase 4 (PAK4) in a subset of Bladder cancer (BLCA). Using bladder cancer cells, we confirmed the role of PAK4 in BLCA cell proliferation and invasion. Furthermore, we observed that a PAK4 inhibitor was effective in curtailing growth of BLCA cells. Transcriptomic analyses identified elevated expression of another kinase, protein tyrosine kinase 6 (PTK6), upon treatment with a PAK4 inhibitor and RNA interference of PAK4. Treatment with a combination of kinase inhibitors (vandetanib and dasatinib) showed enhanced sensitivity compared with either drug alone. Thus, PAK4 may be therapeutically actionable for a subset of MIBC patients with amplified and/or overexpressed PAK4 in their tumors. Our results also indicate that combined inhibition of PAK4 and PTK6 may overcome resistance to PAK4. These observations warrant clinical investigations with selected BLCA patients.	[Chandrashekar, Darshan S.; Chakravarthi, Balabhadrapatruni V. S. K.; Robinson, Alyncia D.; Agarwal, Sumit; Balasubramanya, Sai Akshaya Hodigere; Eich, Marie-Lisa; Manne, Upender; Grizzle, William E.; Netto, George J.; Varambally, Sooryanarayana] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; [Anderson, Joshua C.; Della Manna, Deborah L.; Willey, Christopher D.; Yang, Eddy S.] Univ Alabama Birmingham, Dept Radiat Oncol, Birmingham, AL USA; [Bajpai, Akhilesh Kumar; Davuluri, Sravanthi; Acharya, Kshitish K.] Shodhaka Life Sci Private Ltd, Bengaluru, India; [Guru, Maya S.; Guru, Arjun S.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; [Naik, Gurudatta] Univ Alabama Birmingham, Div Hematol & Oncol, Birmingham, AL USA; [Naik, Gurudatta; Manne, Upender; Netto, George J.; Yang, Eddy S.; Varambally, Sooryanarayana] Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Birmingham, AL 35294 USA; [Acharya, Kshitish K.] Inst Bioinformat & Appl Biotechnol, Biotech Pk, Bengaluru 560100, Karnataka, India; [Carskadon, Shannon; Palanisamy, Nallasivam] Henry Ford Hlth Syst, Dept Urol, Vattikuti Urol Inst, Detroit, MI 48202 USA; [Crossman, David K.; Crowley, Michael R.] Univ Alabama Birmingham, Dept Genet, Birmingham, AL USA; [Ferguson, James E.; Grizzle, William E.; Willey, Christopher D.] Univ Alabama Birmingham, Dept Urol, Birmingham, AL USA; [Varambally, Sooryanarayana] Univ Alabama Birmingham, Informat Inst, Birmingham, AL 35294 USA; [Sonpavde, Guru] Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Henry Ford Health System; Henry Ford Hospital; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Harvard University; Dana-Farber Cancer Institute	Varambally, S (corresponding author), Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.; Varambally, S (corresponding author), Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Birmingham, AL 35294 USA.; Varambally, S (corresponding author), Univ Alabama Birmingham, Informat Inst, Birmingham, AL 35294 USA.; Sonpavde, G (corresponding author), Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA.	svarambally@uabmc.edu; GuruP_Sonpavde@DFCI.HARVARD.EDU	Palanisamy, Nallasivam/ABC-8844-2020; naik, Gurudatta/O-7284-2015	Palanisamy, Nallasivam/0000-0002-0633-9772; naik, Gurudatta/0000-0001-7265-6605; Anderson, Joshua/0000-0002-6977-9054; Netto, George/0000-0003-3915-9134	Department of Pathology of the University of Alabama at Birmingham; School of Medicine of the University of Alabama at Birmingham; Department of IT, BT and S&T, Government of Karnataka, India	Department of Pathology of the University of Alabama at Birmingham; School of Medicine of the University of Alabama at Birmingham; Department of IT, BT and S&T, Government of Karnataka, India	This study was supported in part by institutional funds (Department of Pathology and School of Medicine of the University of Alabama at Birmingham) awarded to SV. IBAB is supported by the Department of IT, BT and S&T, Government of Karnataka, India. The authors thank Dr Donald Hill for critical reading and editing of this manuscript.	Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005; Anders Simon, 2010, Genome Biol, V11, pR106, DOI 10.1186/gb-2010-11-10-r106; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Anderson JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139267; [Anonymous], 2018, Cancer Discov, V8, pOF6, DOI 10.1158/2159-8290.CD-NB2018-085; Antoni S, 2017, EUR UROL, V71, P96, DOI 10.1016/j.eururo.2016.06.010; Balar AV, 2017, LANCET ONCOL, V18, P1483, DOI 10.1016/S1470-2045(17)30616-2; Balar AV, 2017, LANCET, V389, P67, DOI 10.1016/S0140-6736(16)32455-2; Bandiera S, 2015, J HEPATOL, V62, P448, DOI 10.1016/j.jhep.2014.10.004; Bellmunt J, 2017, NEW ENGL J MED, V376, P1015, DOI 10.1056/NEJMoa1613683; Bellmunt J, 2015, EUR UROL, V68, P547, DOI 10.1016/j.eururo.2015.04.025; Bennett RD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062347; Brooks MD, 2013, INT J DENT, V2013, DOI 10.1155/2013/592843; Callegari E, 2018, MOL THER-NUCL ACIDS, V11, P485, DOI 10.1016/j.omtn.2018.04.002; Chakravarthi BVSK, 2018, NEOPLASIA, V20, P894, DOI 10.1016/j.neo.2018.07.006; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Chen CJ, 2019, MOL MED REP, V19, P3477, DOI 10.3892/mmr.2019.10055; Chen J, 2009, NUCLEIC ACIDS RES, V37, pW305, DOI 10.1093/nar/gkp427; Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009; Choudhury NJ, 2016, J CLIN ONCOL, V34, P2165, DOI 10.1200/JCO.2015.66.3047; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Conrad C, 2019, CLIN SCI, V133, P83, DOI 10.1042/CS20180906; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Francis NJ, 2001, NAT REV MOL CELL BIO, V2, P409, DOI 10.1038/35073039; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385; Griffiths G, 2011, J CLIN ONCOL, V29, P2171, DOI 10.1200/JCO.2010.32.3139; Grizzle W.E., 2005, MOL DIAGNOSTICS, V33, P421; Grossman HB, 2003, NEW ENGL J MED, V349, P859, DOI 10.1056/NEJMoa022148; Han H, 2018, NUCLEIC ACIDS RES, V46, pD380, DOI 10.1093/nar/gkx1013; Hao JQ, 2008, CHINESE MED J-PEKING, V121, P602, DOI 10.1097/00029330-200804010-00006; He LF, 2017, ONCOTARGET, V8, P17573, DOI 10.18632/oncotarget.7466; Huang XH, 2011, J PATHOL, V225, P463, DOI 10.1002/path.2877; Iguchi Y, 2015, CELL STRUCT FUNCT, V40, P61, DOI 10.1247/csf.15001; Iyer G, 2012, SCIENCE, V338, P221, DOI 10.1126/science.1226344; Jacobs JJL, 1999, SEMIN CELL DEV BIOL, V10, P227, DOI 10.1006/scdb.1999.0304; Jian B, 2016, TUMOR BIOL, V37, P8941, DOI 10.1007/s13277-015-4727-x; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Kimmelman AC, 2008, P NATL ACAD SCI USA, V105, P19372, DOI 10.1073/pnas.0809966105; Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111; Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109; Li H, 2011, BIOINFORMATICS, V27, P2987, DOI 10.1093/bioinformatics/btr509; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Li N, 2019, CLIN CANCER RES, V25, P369, DOI 10.1158/1078-0432.CCR-18-1776; Li SQ, 2015, IUBMB LIFE, V67, P768, DOI 10.1002/iub.1433; Li YS, 2019, ONCOGENE, V38, P808, DOI 10.1038/s41388-018-0456-0; Loriot Y, 2019, NEW ENGL J MED, V381, P338, DOI 10.1056/NEJMoa1817323; Mahlamaki EH, 2004, NEOPLASIA, V6, P432, DOI 10.1593/neo.04130; Mao K, 2017, INT J ONCOL, V51, P1521, DOI 10.3892/ijo.2017.4122; McConkey DJ, 2015, HEMATOL ONCOL CLIN N, V29, P377, DOI 10.1016/j.hoc.2014.11.003; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29; Park JJ, 2018, ONCOGENE, V37, P5147, DOI 10.1038/s41388-018-0327-8; Petrylak DP, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.7_suppl.TPS497; Phatak Pornima, 2018, Oncotarget, V9, P28391, DOI 10.18632/oncotarget.25375; Puvirajesinghe TM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10318; Ravipaty Shobha, 2017, J Mol Biomark Diagn, V8, DOI 10.4172/2155-9929.1000323; Ricciardelli C, 2017, ONCOTARGET, V8, P17819, DOI 10.18632/oncotarget.14867; Robert C, 2015, NEW ENGL J MED, V372, P30, DOI 10.1056/NEJMoa1412690; Robertson AG, 2017, CELL, V171, P540, DOI 10.1016/j.cell.2017.09.007; Rogers Michael S., 1999, Neoplasia (New York), V1, P220, DOI 10.1038/sj.neo.7900029; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Sonpavde G, 2017, NEW ENGL J MED, V376, P1073, DOI 10.1056/NEJMe1701182; Sonpavde G, 2015, HEMATOL ONCOL CLIN N, V29, P361, DOI 10.1016/j.hoc.2014.10.008; Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937; Thillai K, 2018, FUTURE ONCOL, V14, P579, DOI 10.2217/fon-2017-0458; Tyagi N, 2014, ONCOTARGET, V5, P8778, DOI 10.18632/oncotarget.2398; von der Maase H, 2005, J CLIN ONCOL, V23, P4602, DOI 10.1200/JCO.2005.07.757; Wang HY, 2019, PATHOL RES PRACT, V215, DOI 10.1016/j.prp.2019.152559; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Wang Y, 2016, AM J TRANSL RES, V8, P3056; Xiao J, 2017, ONCOTARGET, V8, P71759, DOI 10.18632/oncotarget.17606; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Xu HT, 2016, CANCER RES, V76, P5732, DOI 10.1158/0008-5472.CAN-15-3373; Xu XL, 2017, J CANCER, V8, P3464, DOI 10.7150/jca.21318; Ye LP, 2018, INT J CANCER, V143, P2602, DOI 10.1002/ijc.31766; Yu W, 2009, CANCER GENET CYTOGEN, V193, P29, DOI 10.1016/j.cancergencyto.2009.03.017; Zeng B, 2018, BMC CANCER, V18, DOI 10.1186/s12885-017-3949-2; Zhang HS, 2016, ARCH BIOCHEM BIOPHYS, V598, P50, DOI 10.1016/j.abb.2016.03.031	79	12	13	2	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	20					4077	4091		10.1038/s41388-020-1275-7	http://dx.doi.org/10.1038/s41388-020-1275-7		MAR 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LN3GC	32231273	Green Submitted			2022-12-28	WOS:000522380700002
J	Zhao, YN; Zhang, JL; Cheng, ASL; Yu, J; To, KF; Kang, W				Zhao, Yanan; Zhang, Jinglin; Cheng, Alfred S. L.; Yu, Jun; To, Ka Fai; Kang, Wei			Gastric cancer: genome damaged by bugs	ONCOGENE			English	Review							EPSTEIN-BARR-VIRUS; HELICOBACTER-PYLORI INFECTION; IN-SITU DETECTION; EPITHELIAL-CELLS; INCREASED RISK; INTERLEUKIN-1 POLYMORPHISMS; CELLULAR MIGRATION; MOLECULAR ANALYSIS; DNA METHYLATION; CARCINOMA CELLS	Gastric cancer (GC) is one of the leading causes of cancer-related death worldwide. The role of the microorganisms in gastric tumorigenesis attracts much attention in recent years. These microorganisms include bacteria, virus, and fungi. Among them, Helicobacter pylori (H. pylori) infection is by far the most important risk factor for GC development, with special reference to the early-onset cases. H. pylori targets multiple cellular components by utilizing various virulence factors to modulate the host proliferation, apoptosis, migration, and inflammatory response. Epstein-Barr virus (EBV) serves as another major risk factor in gastric carcinogenesis. The virus protein, EBER noncoding RNA, and EBV miRNAs contribute to the tumorigenesis by modulating host genome methylation and gene expression. In this review, we summarized the related reports about the colonized microorganism in the stomach and discussed their specific roles in gastric tumorigenesis. Meanwhile, we highlighted the therapeutic significance of eradicating the microorganisms in GC treatment.	[Zhao, Yanan; Zhang, Jinglin; To, Ka Fai; Kang, Wei] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, State Key Lab Translat Oncol, Hong Kong, Peoples R China; [Zhao, Yanan; Zhang, Jinglin; Yu, Jun; To, Ka Fai; Kang, Wei] Chinese Univ Hong Kong, Inst Digest Dis, State Key Lab Digest Dis, Hong Kong, Peoples R China; [Zhao, Yanan; Zhang, Jinglin; To, Ka Fai; Kang, Wei] Chinese Univ Hong Kong, Sir YK Pao Canc Ctr, Li Ka Shing Inst Hlth Sci, Hong Kong, Peoples R China; [Cheng, Alfred S. L.] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Peoples R China; [Yu, Jun] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong	To, KF; Kang, W (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, State Key Lab Translat Oncol, Hong Kong, Peoples R China.; To, KF; Kang, W (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis, State Key Lab Digest Dis, Hong Kong, Peoples R China.; To, KF; Kang, W (corresponding author), Chinese Univ Hong Kong, Sir YK Pao Canc Ctr, Li Ka Shing Inst Hlth Sci, Hong Kong, Peoples R China.	kfto@cuhk.edu.hk; weikang@cuhk.edu.hk	Yu, Jun/D-8569-2015; KANG, Wei/C-5451-2016	Yu, Jun/0000-0001-5008-2153; KANG, Wei/0000-0002-4651-677X	Research Grants Council of the Hong Kong Special Administrative Region, China [CUHK 14100019, 14118518]; CUHK Direct Grant for Research from The Chinese University of Hong Kong [2018.002]	Research Grants Council of the Hong Kong Special Administrative Region, China(Hong Kong Research Grants Council); CUHK Direct Grant for Research from The Chinese University of Hong Kong	The current manuscript is supported by Research Grants Council of the Hong Kong Special Administrative Region, China [Project nos.: CUHK 14100019, 14118518 (for GRF projects)], and CUHK Direct Grant for Research (2018.002) from The Chinese University of Hong Kong.	Akhiani AA, 2004, J IMMUNOL, V172, P5024, DOI 10.4049/jimmunol.172.8.5024; Akhiani AA, 2002, J IMMUNOL, V169, P6977, DOI 10.4049/jimmunol.169.12.6977; Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; Alm RA, 2000, INFECT IMMUN, V68, P4155, DOI 10.1128/IAI.68.7.4155-4168.2000; Ando T, 2009, INT J CANCER, V125, P2595, DOI 10.1002/ijc.24666; Banerjee AS, 2013, VIROLOGY, V443, P294, DOI 10.1016/j.virol.2013.05.020; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Beales ILP, 1997, EUR J GASTROEN HEPAT, V9, P451, DOI 10.1097/00042737-199705000-00008; Bik EM, 2006, P NATL ACAD SCI USA, V103, P732, DOI 10.1073/pnas.0506655103; Bimczok D, 2010, MUCOSAL IMMUNOL, V3, P260, DOI 10.1038/mi.2010.10; Blaser MJ, 2006, EMBO REP, V7, P956, DOI 10.1038/sj.embor.7400812; Bronte-Tinkew DM, 2009, CANCER RES, V69, P632, DOI 10.1158/0008-5472.CAN-08-1191; BURKE AP, 1990, MODERN PATHOL, V3, P377; Camargo MC, 2018, CANCERS, V10, DOI 10.3390/cancers10090284; Camargo MC, 2014, GUT, V63, P236, DOI 10.1136/gutjnl-2013-304531; Cantalupo PG, 2018, VIROLOGY, V513, P208, DOI 10.1016/j.virol.2017.10.017; Cardenas-Mondragon MG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062850; Cheng TC, 2010, INT J ONCOL, V36, P151, DOI 10.3892/ijo_00000486; Chesnokova LS, 2011, J VIROL, V85, P13214, DOI 10.1128/JVI.05580-11; Chesnokova LS, 2009, P NATL ACAD SCI USA, V106, P20464, DOI 10.1073/pnas.0907508106; Cho J, 2016, J GASTRIC CANCER, V16, P1, DOI 10.5230/jgc.2016.16.1.1; Cho SO, 2010, DIGEST DIS SCI, V55, P988, DOI 10.1007/s10620-009-0828-y; Choy EYW, 2008, J EXP MED, V205, P2551, DOI 10.1084/jem.20072581; Coker OO, 2018, GUT, V67, P1024, DOI 10.1136/gutjnl-2017-314281; Colquhoun A, 2015, GUT, V64, P1881, DOI 10.1136/gutjnl-2014-308915; Cristescu R, 2015, NAT MED, V21, P449, DOI 10.1038/nm.3850; de Martel C, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70137-7; Delgado S, 2013, MICROB ECOL, V65, P763, DOI 10.1007/s00248-013-0192-5; DElios MM, 1997, J IMMUNOL, V158, P962; Delyria ES, 2009, GASTROENTEROLOGY, V136, P247, DOI 10.1053/j.gastro.2008.09.017; Derks S, 2016, ONCOTARGET, V7, P32925, DOI 10.18632/oncotarget.9076; Dong M, 2016, HUM PATHOL, V53, P25, DOI 10.1016/j.humpath.2016.02.007; Eaton KA, 2001, J IMMUNOL, V166, P7456, DOI 10.4049/jimmunol.166.12.7456; Eaton KA, 2001, INFECT IMMUN, V69, P1025, DOI 10.1128/IAI.69.2.1025-1031.2001; El-Omar EM, 2003, GASTROENTEROLOGY, V124, P1193, DOI 10.1016/S0016-5085(03)00157-4; El-Omar EM, 2000, NATURE, V404, P398, DOI 10.1038/35006081; Engstrand L, 2013, BEST PRACT RES CL GA, V27, P39, DOI 10.1016/j.bpg.2013.03.016; Enroth H, 2000, CANCER EPIDEM BIOMAR, V9, P981; Fallone CA, 2016, GASTROENTEROLOGY, V151, P51, DOI 10.1053/j.gastro.2016.04.006; Farrell PJ, 2019, ANNU REV PATHOL-MECH, V14, P29, DOI 10.1146/annurev-pathmechdis-012418-013023; Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027; Ferro A, 2014, EUR J CANCER, V50, P1330, DOI 10.1016/j.ejca.2014.01.029; Franco AT, 2008, CANCER RES, V68, P379, DOI 10.1158/0008-5472.CAN-07-0824; Fukuda M, 2004, J VIROL, V78, P1697, DOI 10.1128/JVI.78.4.1697-1705.2004; Fukuda M, 2007, J VIROL, V81, P9299, DOI 10.1128/JVI.00537-07; Gao JJ, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00202; Geddert H, 2011, CELL ONCOL, V34, P209, DOI 10.1007/s13402-011-0028-6; Gulley ML, 1996, HUM PATHOL, V27, P20, DOI 10.1016/S0046-8177(96)90133-1; Hafsi N, 2004, J IMMUNOL, V173, P1249, DOI 10.4049/jimmunol.173.2.1249; HARN HJ, 1995, HUM PATHOL, V26, P267, DOI 10.1016/0046-8177(95)90056-X; He D, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0525-y; Higashi H, 2004, J BIOL CHEM, V279, P17205, DOI 10.1074/jbc.M309964200; Hino R, 2008, CANCER RES, V68, P1427, DOI 10.1158/0008-5472.CAN-07-3027; Hino R, 2009, CANCER RES, V69, P2766, DOI 10.1158/0008-5472.CAN-08-3070; Hooykaas MJG, 2017, J IMMUNOL, V198, P4062, DOI 10.4049/jimmunol.1501605; Huang JQ, 2003, GASTROENTEROLOGY, V125, P1636, DOI 10.1053/j.gastro.2003.08.033; Hutt-Fletcher LM, 2017, J VIROL, V91, DOI 10.1128/JVI.01677-16; Hwang IR, 2002, GASTROENTEROLOGY, V123, P1793, DOI 10.1053/gast.2002.37043; Ichimura T, 2016, HUM PATHOL, V56, P74, DOI 10.1016/j.humpath.2016.06.002; Imai S, 1998, J VIROL, V72, P4371, DOI 10.1128/JVI.72.5.4371-4378.1998; IMAI S, 1994, P NATL ACAD SCI USA, V91, P9131, DOI 10.1073/pnas.91.19.9131; Iwakiri D, 2003, CANCER RES, V63, P7062; Jackson CB, 2007, J PATHOL, V213, P140, DOI 10.1002/path.2218; Kamboj AK, 2017, MAYO CLIN PROC, V92, P599, DOI 10.1016/j.mayocp.2016.11.017; Kang GH, 2002, AM J PATHOL, V160, P787, DOI 10.1016/S0002-9440(10)64901-2; Kawazoe A, 2019, GASTRIC CANCER, V22, P69, DOI 10.1007/s10120-018-0843-9; Khan G, 2014, INFECT AGENTS CANCER, V9, DOI 10.1186/1750-9378-9-38; Khosravi Y, 2014, SCI WORLD J, DOI 10.1155/2014/610421; Kim H, 2015, CANCER LETT, V356, P733, DOI 10.1016/j.canlet.2014.10.023; Kim JY, 2019, GASTRIC CANCER, V22, P1164, DOI 10.1007/s10120-019-00974-4; Kim MY, 2019, MOL CELLS, V42, P448, DOI 10.14348/molcells.2019.2395; Kim ST, 2018, NAT MED, V24, P1449, DOI 10.1038/s41591-018-0101-z; Kim SM, 2017, BIOCHEM BIOPH RES CO, V494, P550, DOI 10.1016/j.bbrc.2017.10.095; Kim SY, 2015, GASTROENTEROLOGY, V148, P137, DOI 10.1053/j.gastro.2014.09.020; Kim TS, 2019, AM J SURG PATHOL, V43, P851, DOI 10.1097/PAS.0000000000001253; Knorr J, 2019, TRENDS MICROBIOL, V27, P731, DOI 10.1016/j.tim.2019.04.010; Koemans WJ, 2019, CANCER LETT, V442, P279, DOI 10.1016/j.canlet.2018.11.001; Kwok T, 2007, NATURE, V449, P862, DOI 10.1038/nature06187; Lamb A, 2013, J CELL BIOCHEM, V114, P491, DOI 10.1002/jcb.24389; Lamps LW, 2014, ADV ANAT PATHOL, V21, P217, DOI 10.1097/PAP.0000000000000016; LEONCINI L, 1993, INT J CANCER, V53, P898; Leung WK, 2006, CLIN CANCER RES, V12, P3216, DOI 10.1158/1078-0432.CCR-05-2442; Li XX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007985; Liang QY, 2014, GASTROENTEROLOGY, V147, P1350, DOI 10.1053/j.gastro.2014.08.036; Lieberman PM, 2014, SCIENCE, V343, P1323, DOI 10.1126/science.1252786; Lieberman PM, 2013, NAT REV MICROBIOL, V11, P863, DOI 10.1038/nrmicro3135; Liu XS, 2011, GASTROENT RES PRACT, V2011, DOI 10.1155/2011/182832; Louafi F, 2010, J BIOL CHEM, V285, P41328, DOI 10.1074/jbc.M110.146852; Lu SL, 2020, APPL IMMUNOHISTO M M, V28, P360, DOI 10.1097/PAI.0000000000000761; Lundgren A, 2003, INFECT IMMUN, V71, P1755, DOI 10.1128/IAI.71.4.1755-1762.2003; Luo B, 2005, WORLD J GASTROENTERO, V11, P629, DOI 10.3748/wjg.v11.i5.629; Maldonado-Contreras A, 2011, ISME J, V5, P574, DOI 10.1038/ismej.2010.149; Malfertheiner P., 2017, Gut, V66, P6, DOI [10.1136/gutjnl-2016-312288, DOI 10.1136/GUTJNL-2016-312288]; Marquitz AR, 2014, J VIROL, V88, P1389, DOI 10.1128/JVI.02662-13; Marquitz AR, 2012, P NATL ACAD SCI USA, V109, P9593, DOI 10.1073/pnas.1202910109; Marquitz AR, 2011, VIROLOGY, V412, P392, DOI 10.1016/j.virol.2011.01.028; Matsusaka K, 2011, CANCER RES, V71, P7187, DOI 10.1158/0008-5472.CAN-11-1349; Menheniott TR, 2015, CELL MICROBIOL, V17, P1570, DOI 10.1111/cmi.12518; Minamitani T, 2015, P NATL ACAD SCI USA, V112, P11612, DOI 10.1073/pnas.1514484112; Mishima S, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0514-3; Murata-Kamiya N, 2007, ONCOGENE, V26, P4617, DOI 10.1038/sj.onc.1210251; Murphy G, 2009, GASTROENTEROLOGY, V137, P824, DOI 10.1053/j.gastro.2009.05.001; Murray PG, 1996, J PATHOL, V178, P44, DOI 10.1002/(SICI)1096-9896(199601)178:1<44::AID-PATH471>3.0.CO;2-0; Nagy TA, 2009, J INFECT DIS, V199, P641, DOI 10.1086/596660; Nakayama M, 2009, J BIOL CHEM, V284, P1612, DOI 10.1074/jbc.M806981200; Namba-Fukuyo H, 2016, ONCOTARGET, V7, P81512, DOI 10.18632/oncotarget.13130; Nanbo A, 2016, J GEN VIROL, V97, P2989, DOI 10.1099/jgv.0.000605; Nardone G, 2015, UNITED EUR GASTROENT, V3, P255, DOI 10.1177/2050640614566846; Niwa T, 2010, CANCER RES, V70, P1430, DOI 10.1158/0008-5472.CAN-09-2755; Ohnishi N, 2008, P NATL ACAD SCI USA, V105, P1003, DOI 10.1073/pnas.0711183105; Okada T, 2013, CANCER SCI, V104, P1309, DOI 10.1111/cas.12228; OTT G, 1994, HISTOPATHOLOGY, V25, P323, DOI 10.1111/j.1365-2559.1994.tb01350.x; Pal AD, 2015, VIROLOGY, V484, P22, DOI 10.1016/j.virol.2015.05.007; Pal AD, 2014, CARCINOGENESIS, V35, P1592, DOI 10.1093/carcin/bgu069; Panda Anshuman, 2018, J Natl Cancer Inst, V110, P316, DOI 10.1093/jnci/djx213; Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731; Parsonnet J, 1997, GUT, V40, P297, DOI 10.1136/gut.40.3.297; Perry S, 2006, EMERG INFECT DIS, V12, P1701, DOI 10.3201/eid1211.060086; Plummer M, 2016, LANCET GLOB HEALTH, V4, pE609, DOI 10.1016/S2214-109X(16)30143-7; Qiu MZ, 2020, INT J CANCER, V146, P272, DOI 10.1002/ijc.32490; Robinson K, 2008, GUT, V57, P1375, DOI 10.1136/gut.2007.137539; ROWLANDS DC, 1993, BRIT J CANCER, V68, P1014, DOI 10.1038/bjc.1993.472; Rudi J, 1997, DIGEST DIS SCI, V42, P1652, DOI 10.1023/A:1018849112533; Saiki Y, 1996, LAB INVEST, V75, P67; Saito R, 2017, MODERN PATHOL, V30, P427, DOI 10.1038/modpathol.2016.202; Saju P, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.26, 10.1038/nmicrobiol.2016.26]; Sasaki S, 2019, GASTRIC CANCER, V22, P486, DOI 10.1007/s10120-018-0880-4; Schulze J, 2009, DTSCH ARZTEBL INT, V106, P837, DOI 10.3238/arztebl.2009.0837; Schuster V, 1996, BLOOD, V87, P1579, DOI 10.1182/blood.V87.4.1579.bloodjournal8741579; SCOTT BB, 1982, GUT, V23, P137, DOI 10.1136/gut.23.2.137; SHIBATA D, 1992, AM J PATHOL, V140, P769; SHIBATA D, 1993, CANCER EPIDEM BIOMAR, V2, P213; Shikata K, 2008, AM J EPIDEMIOL, V168, P1409, DOI 10.1093/aje/kwn276; Shikata K, 2006, INT J CANCER, V119, P196, DOI 10.1002/ijc.21822; Shinozaki A, 2010, CANCER RES, V70, P4719, DOI 10.1158/0008-5472.CAN-09-4620; Shinozaki-Ushiku A, 2015, J VIROL, V89, P5581, DOI 10.1128/JVI.03639-14; Sidagis J, 1997, INT J CANCER, V72, P72, DOI 10.1002/(SICI)1097-0215(19970703)72:1&lt;72::AID-IJC11&gt;3.0.CO;2-C; Sivachandran N, 2012, J VIROL, V86, P60, DOI 10.1128/JVI.05623-11; Sokal EM, 2007, J INFECT DIS, V196, P1749, DOI 10.1086/523813; Song HJ, 2010, GASTROENTEROLOGY, V139, P84, DOI 10.1053/j.gastro.2010.04.002; Stoicov C, 2004, GENE, V341, P1, DOI 10.1016/j.gene.2004.07.023; Stoicov C, 2009, J IMMUNOL, V183, P642, DOI 10.4049/jimmunol.0900511; Strong MJ, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003341; Sugiura M, 1996, BRIT J CANCER, V74, P625, DOI 10.1038/bjc.1996.412; Suzuki M, 2009, CELL HOST MICROBE, V5, P23, DOI 10.1016/j.chom.2008.11.010; Tan MP, 2007, APPL ENVIRON MICROB, V73, P1010, DOI 10.1128/AEM.01675-06; TOKUNAGA M, 1993, AM J PATHOL, V143, P1250; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Tsai CY, 2017, J GASTROEN HEPATOL, V32, P82, DOI 10.1111/jgh.13432; Tsutsumi R, 2006, MOL CELL BIOL, V26, P261, DOI 10.1128/MCB.26.1.261-276.2006; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Ushiku T, 2007, INT J CANCER, V120, P60, DOI 10.1002/ijc.22275; van Beek J, 2006, AM J SURG PATHOL, V30, P59, DOI 10.1097/01.pas.0000176428.06629.1e; Van Cutsem E, 2016, LANCET, V388, P2654, DOI 10.1016/S0140-6736(16)30354-3; Vinasco K, 2019, BBA-REV CANCER, V1872, DOI 10.1016/j.bbcan.2019.07.004; Virgin HW, 2014, CELL, V157, P142, DOI 10.1016/j.cell.2014.02.032; von Rosenvinge EC, 2013, ISME J, V7, P1354, DOI 10.1038/ismej.2013.33; Wang J, 2019, J BIOL CHEM, V294, P4854, DOI 10.1074/jbc.RA118.006853; Wang JY, 2019, VIROLOGY, V534, P87, DOI 10.1016/j.virol.2019.06.006; Wang ZK, 2014, ALIMENT PHARM THER, V39, P751, DOI 10.1111/apt.12665; WOLFE RR, 1990, AM J CLIN NUTR, V51, P248, DOI 10.1093/ajcn/51.2.248; Wong BCY, 2004, JAMA-J AM MED ASSOC, V291, P187, DOI 10.1001/jama.291.2.187; Wroblewski LE, 2010, CLIN MICROBIOL REV, V23, P713, DOI 10.1128/CMR.00011-10; Xiang T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07308-5; Xing XF, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1356144; Xiong D, 2015, P NATL ACAD SCI USA, V112, P11036, DOI 10.1073/pnas.1513359112; Yamaoka Y, 2000, P NATL ACAD SCI USA, V97, P7533, DOI 10.1073/pnas.130079797; Yamaoka Y, 2002, GASTROENTEROLOGY, V123, P414, DOI 10.1053/gast.2002.34781; Yamaoka Y, 1999, J CLIN PATHOL, V52, P215, DOI 10.1136/jcp.52.3.215; Yamaoka Y, 2010, NAT REV GASTRO HEPAT, V7, P629, DOI 10.1038/nrgastro.2010.154; Yamashita S, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0789-8; Yanai H, 1997, GASTROINTEST ENDOSC, V45, P236, DOI 10.1016/S0016-5107(97)70265-7; Ye G, 1997, J CLIN INVEST, V99, P1628, DOI 10.1172/JCI119325; Yu J, 2017, ONCOGENE, V36, P182, DOI 10.1038/onc.2016.187; Yu PC, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011387; YUEN ST, 1994, AM J SURG PATHOL, V18, P1158, DOI 10.1097/00000478-199411000-00010; Zhang H, 2018, NAT MICROBIOL, V3, P164, DOI 10.1038/s41564-017-0080-8; Zhang NN, 2015, SCI REP-UK, V5, DOI 10.1038/srep18057; Zhao J, 2013, BRIT J CANCER, V108, P2557, DOI 10.1038/bjc.2013.263; Zhao JH, 2013, CANCER-AM CANCER SOC, V119, P304, DOI 10.1002/cncr.27724; Zheng X, 2018, J VIROL, V92, DOI 10.1128/JVI.01022-18; Zhuang YA, 2011, IMMUNOBIOLOGY, V216, P200, DOI 10.1016/j.imbio.2010.05.005; Zwolinska-Wcislo M, 2001, MED SCI MONITOR, V7, P266	183	19	20	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	17					3427	3442		10.1038/s41388-020-1241-4	http://dx.doi.org/10.1038/s41388-020-1241-4		MAR 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LH1YK	32123313	hybrid, Green Published			2022-12-28	WOS:000517738400003
J	Filippou, PS; Karagiannis, GS; Constantinidou, A				Filippou, Panagiota S.; Karagiannis, George S.; Constantinidou, Anastasia			Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target	ONCOGENE			English	Review							EPITHELIAL-MESENCHYMAL TRANSITION; EMBRYONAL CARCINOMA-CELLS; ANGIOGENIC FACTOR MIDKINE; ACID-RESPONSIVE GENE; WILMS-TUMOR; HEPATOCELLULAR-CARCINOMA; CLINICAL-SIGNIFICANCE; BIOLOGICAL-ACTIVITIES; MIDGESTATION PERIOD; ALTERED EXPRESSION	Midkine is a heparin-binding growth factor, originally reported as the product of a retinoic acid-responsive gene during embryogenesis, but currently viewed as a multifaceted factor contributing to both normal tissue homeostasis and disease development. Midkine is abnormally expressed at high levels in various human malignancies and acts as a mediator for the acquisition of critical hallmarks of cancer, including cell growth, survival, metastasis, migration, and angiogenesis. Several studies have investigated the role of midkine as a cancer biomarker for the detection, prognosis, and management of cancer, as well as for monitoring the response to cancer treatment. Moreover, several efforts are also being made to elucidate its underlying mechanisms in therapeutic resistance and immunomodulation within the tumor microenvironment. We hereby summarize the current knowledge on midkine expression and function in cancer development and progression, and highlight its promising potential as a cancer biomarker and as a future therapeutic target in personalized cancer medicine.	[Filippou, Panagiota S.] Teesside Univ, Sch Hlth & Life Sci, Middlesbrough TS1 3BX, Cleveland, England; [Filippou, Panagiota S.] Teesside Univ, Natl Horizons Ctr, 38 John Dixon Ln, Darlington DL1 1HG, Durham, England; [Karagiannis, George S.] Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10467 USA; [Karagiannis, George S.] Albert Einstein Coll Med, Integrated Imaging Program, Bronx, NY 10467 USA; [Karagiannis, George S.] Albert Einstein Coll Med, Gruss Lipper Biophoton Ctr, Bronx, NY 10467 USA; [Constantinidou, Anastasia] Univ Cyprus, Med Sch, Nicosia, Cyprus; [Constantinidou, Anastasia] Bank Cyprus Oncol Ctr, Nicosia, Cyprus; [Constantinidou, Anastasia] Cyprus Canc Res Inst, Nicosia, Cyprus	University of Teesside; University of Teesside; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Cyprus	Filippou, PS (corresponding author), Teesside Univ, Sch Hlth & Life Sci, Middlesbrough TS1 3BX, Cleveland, England.; Filippou, PS (corresponding author), Teesside Univ, Natl Horizons Ctr, 38 John Dixon Ln, Darlington DL1 1HG, Durham, England.	P.Philippou@tees.ac.uk	Filippou, Panagiota S./ABF-1969-2021	Filippou, Panagiota/0000-0003-3974-988X; CONSTANTINIDOU, ANASTASIA/0000-0001-5316-7574				Adachi Y, 1996, ONCOGENE, V13, P2197; [Anonymous], 2013, ISRN ONCOL; ARIDOME K, 1995, JPN J CANCER RES, V86, P655, DOI 10.1111/j.1349-7006.1995.tb02449.x; Bellmunt J, 2017, NEW ENGL J MED, V376, P1015, DOI 10.1056/NEJMoa1613683; Cheng Yen-Po, 2014, Surg Neurol Int, V5, P78, DOI 10.4103/2152-7806.133205; Choudhuri R, 1997, CANCER RES, V57, P1814; Cohen S, 2014, BRIT J PHARMACOL, V171, P888, DOI 10.1111/bph.12419; Cohen S, 2012, J IMMUNOL, V188, P259, DOI 10.4049/jimmunol.1101468; Couch G, 2016, CANCER PREV RES, V9, P558, DOI 10.1158/1940-6207.CAPR-15-0379; Dai LC, 2007, WORLD J GASTROENTERO, V13, P1208, DOI 10.3748/wjg.v13.i8.1208; Van DV, 2016, ONCOL LETT, V12, P3143, DOI 10.3892/ol.2016.5040; Erdogan S, 2017, AM J MED SCI, V354, P299, DOI 10.1016/j.amjms.2017.04.019; Erguven M, 2011, CANCER CELL INT, V11, DOI 10.1186/1475-2867-11-18; FABRI L, 1993, J CHROMATOGR, V646, P213, DOI 10.1016/S0021-9673(99)87023-X; Fernandez-Calle R, 2018, NEUROSCI LETT, V662, P213, DOI 10.1016/j.neulet.2017.10.038; Filippou PS, 2017, BIOCHEM J, V474, P2417, DOI 10.1042/BCJ20170174; Filippou PS, 2016, CRIT REV CL LAB SCI, V53, P277, DOI 10.3109/10408363.2016.1154643; Fischer V, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19072070; GARVER RI, 1994, CANCER, V74, P1584, DOI 10.1002/1097-0142(19940901)74:5<1584::AID-CNCR2820740514>3.0.CO;2-V; GARVER RI, 1993, AM J RESP CELL MOL, V9, P463, DOI 10.1165/ajrcmb/9.5.463; Gela A, 2014, BRIT J PHARMACOL, V171, P859, DOI 10.1111/bph.12402; Geng XC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186847; Grupp K, 2018, EXP MOL PATHOL, V104, P109, DOI 10.1016/j.yexmp.2018.01.005; Gungor C, 2014, BRIT J PHARMACOL, V171, P849, DOI 10.1111/bph.12401; Gungor C, 2011, CANCER RES, V71, P5009, DOI 10.1158/0008-5472.CAN-11-0036; Gustavsson H, 2008, PROSTATE, V68, P161, DOI 10.1002/pros.20672; Haddada M, 2018, BIOL CHEM, V399, P1099, DOI 10.1515/hsz-2017-0339; Haffner-Luntzer M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0116282; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hao HF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071093; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; Hovanessian AG, 2006, CELL RES, V16, P174, DOI 10.1038/sj.cr.7310024; Hu RH, 2010, INT J HEMATOL, V92, P105, DOI 10.1007/s12185-010-0613-x; Huang Y, 2008, CELL CYCLE, V7, P1613, DOI 10.4161/cc.7.11.5952; Ibusuki M, 2009, CANCER SCI, V100, P1735, DOI 10.1111/j.1349-7006.2009.01233.x; Ikematsu S, 2000, BRIT J CANCER, V83, P701, DOI 10.1054/bjoc.2000.1339; Ikematsu S, 2003, BIOCHEM BIOPH RES CO, V306, P329, DOI 10.1016/S0006-291X(03)00984-7; Ikematsu S, 2008, CANCER SCI, V99, P2070, DOI 10.1111/j.1349-7006.2008.00957.x; Inazumi T, 1997, ARCH DERMATOL RES, V289, P471, DOI 10.1007/s004030050223; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jia HL, 2007, CLIN CANCER RES, V13, P1133, DOI 10.1158/1078-0432.CCR-06-1025; Jin Z, 2008, CLIN CANCER RES, V14, P5033, DOI 10.1158/1078-0432.CCR-08-0092; Jing X, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180511; Jones DR, 2014, BRIT J PHARMACOL, V171, P2925, DOI 10.1111/bph.12601; Jono Hirofumi, 2010, Cancers (Basel), V2, P624, DOI 10.3390/cancers2020624; KADOMATSU K, 1990, J CELL BIOL, V110, P607, DOI 10.1083/jcb.110.3.607; KADOMATSU K, 1988, BIOCHEM BIOPH RES CO, V151, P1312, DOI 10.1016/S0006-291X(88)80505-9; Kadomatsu K, 2013, J BIOCHEM, V153, P511, DOI 10.1093/jb/mvt035; Kadomatsu KJ, 2004, CANCER LETT, V204, P127, DOI 10.1016/S0304-3835(03)00450-6; Kaifi JT, 2007, J CANCER RES CLIN, V133, P431, DOI 10.1007/s00432-006-0180-y; KANAME T, 1993, GENOMICS, V17, P514, DOI 10.1006/geno.1993.1359; Kang HC, 2004, CLIN CANCER RES, V10, P272, DOI 10.1158/1078-0432.CCR-1025-3; Kaplan F, 2003, AM J RESP CELL MOL, V28, P33, DOI 10.1165/rcmb.2002-0047OC; Karaman S, 2017, DEV CELL, V42, P205, DOI 10.1016/j.devcel.2017.07.015; Kato M, 2000, ARCH PATHOL LAB MED, V124, P848; Katsuno Y, 2013, CURR OPIN ONCOL, V25, P76, DOI 10.1097/CCO.0b013e32835b6371; Kawai H, 2004, AM J PATHOL, V165, P1603, DOI 10.1016/S0002-9440(10)63417-7; Kerzerho J, 2013, J BIOL CHEM, V288, P13370, DOI 10.1074/jbc.M112.427302; Kerzerho J, 2010, J IMMUNOL, V185, P418, DOI 10.4049/jimmunol.0901014; Kishida S, 2014, BRIT J PHARMACOL, V171, P896, DOI 10.1111/bph.12442; Kohno S, 2004, ONCOL REP, V12, P73; Konishi N, 1999, ONCOLOGY-BASEL, V57, P253, DOI 10.1159/000012039; Kurosawa N, 2001, GLYCOCONJUGATE J, V18, P499, DOI 10.1023/A:1016042303253; Lautz T, 2018, EBIOMEDICINE, V27, P237, DOI 10.1016/j.ebiom.2017.11.020; Lee SH, 2012, J CELL PHYSIOL, V227, P1731, DOI 10.1002/jcp.22897; Liedert A, 2011, BONE, V48, P945, DOI 10.1016/j.bone.2010.12.019; Lorente M, 2011, CELL DEATH DIFFER, V18, P959, DOI 10.1038/cdd.2010.170; Lorente M, 2011, AUTOPHAGY, V7, P1071, DOI 10.4161/auto.7.9.15866; Lu YL, 2018, INT J MOL MED, V41, P2003, DOI 10.3892/ijmm.2018.3399; Ma JY, 2014, J CLIN NEUROSCI, V21, P1885, DOI 10.1016/j.jocn.2014.02.020; Maeda N, 1999, J BIOL CHEM, V274, P12474, DOI 10.1074/jbc.274.18.12474; Maeda S, 2007, BRIT J CANCER, V97, P405, DOI 10.1038/sj.bjc.6603879; Mashour GA, 2001, ONCOGENE, V20, P97, DOI 10.1038/sj.onc.1204026; MATSUBARA S, 1990, J BIOL CHEM, V265, P9441; Matsuda Y, 1996, BIOCHEM BIOPH RES CO, V228, P176, DOI 10.1006/bbrc.1996.1635; Maza S, 2018, BIOORGAN MED CHEM, V26, P1076, DOI 10.1016/j.bmc.2018.01.022; Meng K, 2000, P NATL ACAD SCI USA, V97, P2603, DOI 10.1073/pnas.020487997; Mirkin BL, 2005, ONCOGENE, V24, P4965, DOI 10.1038/sj.onc.1208671; Mishima K, 1997, NEUROSCI LETT, V233, P29, DOI 10.1016/S0304-3940(97)00619-8; Mitchell MS, 2007, CANCER IMMUNOL IMMUN, V56, P287, DOI 10.1007/s00262-006-0191-1; MITSIADIS TA, 1995, DEVELOPMENT, V121, P37; Miyashiro I, 1997, BREAST CANCER RES TR, V43, P1, DOI 10.1023/A:1005748728351; Miyauchi M, 1999, JPN J CANCER RES, V90, P469, DOI 10.1111/j.1349-7006.1999.tb00771.x; Muramaki M, 2003, CLIN CANCER RES, V9, P5152; MURAMATSU H, 1991, BIOCHEM BIOPH RES CO, V177, P652, DOI 10.1016/0006-291X(91)91838-4; Muramatsu H, 2004, J CELL SCI, V117, P5405, DOI 10.1242/jcs.01423; MURAMATSU H, 1993, DEV BIOL, V159, P392, DOI 10.1006/dbio.1993.1250; Muramatsu H, 2000, BIOCHEM BIOPH RES CO, V270, P936, DOI 10.1006/bbrc.2000.2549; Muramatsu H, 1996, J BIOCHEM-TOKYO, V119, P1171; Muramatsu T, 2002, J BIOCHEM, V132, P359, DOI 10.1093/oxfordjournals.jbchem.a003231; Muramatsu T, 2014, BRIT J PHARMACOL, V171, P814, DOI 10.1111/bph.12353; Muramatsu T, 2014, BRIT J PHARMACOL, V171, P811, DOI 10.1111/bph.12571; Muramatsu T, 2011, CURR PHARM DESIGN, V17, P410, DOI 10.2174/138161211795164167; Muramatsu T, 2010, P JPN ACAD B-PHYS, V86, P410, DOI 10.2183/pjab.86.410; Murasugi A, 2003, PROTEIN EXPRES PURIF, V27, P244, DOI 10.1016/S1046-5928(02)00587-9; Music M, 2018, CRIT REV CL LAB SCI, V55, P466, DOI 10.1080/10408363.2018.1499706; Nakamura E, 1998, GENES CELLS, V3, P811, DOI 10.1046/j.1365-2443.1998.00231.x; Nordin SL, 2013, AM J RESP CELL MOL, V49, P935, DOI 10.1165/rcmb.2013-0106OC; NOVOTNY WF, 1993, ARTERIOSCLER THROMB, V13, P1798, DOI 10.1161/01.ATV.13.12.1798; OBrien T, 1996, CANCER RES, V56, P2515; Ohgake S, 2009, PROG NEURO-PSYCHOPH, V33, P541, DOI 10.1016/j.pnpbp.2009.02.005; Ohhashi S, 2009, DIGEST DIS SCI, V54, P811, DOI 10.1007/s10620-008-0434-4; Ohuchida T, 2004, CANCER-AM CANCER SOC, V100, P2430, DOI 10.1002/cncr.20266; Olive KP, 2015, CLIN CANCER RES, V21, P3366, DOI 10.1158/1078-0432.CCR-15-0416; Olmeda D, 2017, NATURE, V546, P676, DOI 10.1038/nature22977; Ota T, 2012, ONCOL REP, V27, P1674, DOI 10.3892/or.2012.1684; Owada K, 1999, J Med Dent Sci, V46, P45; Paley PJ, 2001, CURR OPIN ONCOL, V13, P399, DOI 10.1097/00001622-200109000-00015; Papageorgis P, 2015, J ONCOL, V2015, DOI 10.1155/2015/587193; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Paul S, 2001, CANCER LETT, V163, P245, DOI 10.1016/S0304-3835(00)00696-0; PEDRAZA C, 1995, J BIOCHEM-TOKYO, V117, P845; Poon RTP, 2002, ANN SURG, V235, P373, DOI 10.1097/00000658-200203000-00009; Qi MS, 2001, J BIOL CHEM, V276, P15868, DOI 10.1074/jbc.M005911200; Qi MS, 2000, J BIOCHEM, V127, P269, DOI 10.1093/oxfordjournals.jbchem.a022604; Raave R, 2018, J CONTROL RELEASE, V274, P1, DOI 10.1016/j.jconrel.2018.01.029; Rakha EA, 2010, BREAST CANCER RES TR, V120, P293, DOI 10.1007/s10549-010-0746-x; Rawnaq T, 2014, MOL CANCER RES, V12, P670, DOI 10.1158/1541-7786.MCR-13-0467; Rebbaa A, 2001, MOL MED, V7, P393, DOI 10.1007/BF03402185; Ren YJ, 2006, WORLD J GASTROENTERO, V12, P2006, DOI 10.3748/wjg.v12.i13.2006; Reynolds PR, 2004, J BIOL CHEM, V279, P37124, DOI 10.1074/jbc.M405254200; Rice GE, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-62; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Sandra F, 2004, ORAL ONCOL, V40, P274, DOI 10.1016/j.oraloncology.2003.08.011; Shimada H, 2003, CANCER SCI, V94, P628, DOI 10.1111/j.1349-7006.2003.tb01494.x; Shimwell NJ, 2013, BRIT J CANCER, V108, P1854, DOI 10.1038/bjc.2013.157; Soukup V, 2015, UROL INT, V95, P56, DOI 10.1159/000368166; Stoica GE, 2002, J BIOL CHEM, V277, P35990, DOI 10.1074/jbc.M205749200; Sueyoshi T, 2012, CANCER LETT, V316, P23, DOI 10.1016/j.canlet.2011.10.013; Takei Y, 2002, J BIOL CHEM, V277, P23800, DOI 10.1074/jbc.M112100200; Tang SL, 2015, INT J CLIN EXP MED, V8, P12644; Tao P, 2007, CANCER LETT, V253, P60, DOI 10.1016/j.canlet.2007.01.019; Tazzyman S, 2009, INT J EXP PATHOL, V90, P222, DOI 10.1111/j.1365-2613.2009.00641.x; Tian WY, 2017, ONCOL REP, V38, P745, DOI 10.3892/or.2017.5743; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Torres A, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5556-x; Toyoda E, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-30; TSUTSUI J, 1993, CANCER RES, V53, P1281; Vongsuvanh R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155800; Wang QL, 2007, J BIOMED SCI, V14, P783, DOI 10.1007/s11373-007-9192-0; Weckbach LT, 2014, BLOOD, V123, P1887, DOI 10.1182/blood-2013-06-510875; Weckbach LT, 2012, AM J PHYSIOL-HEART C, V303, pH429, DOI 10.1152/ajpheart.00934.2011; Weckbach LT, 2011, THESCIENTIFICWORLDJO, V11, P2491, DOI 10.1100/2011/517152; Wu XQ, 2015, AM J CANCER RES, V5, P629; Xia X, 2016, ONCOTARGET, V7, P87462, DOI 10.18632/oncotarget.13865; Xu YY, 2012, TUMOR BIOL, V33, P1543, DOI 10.1007/s13277-012-0406-3; Ye C, 1999, BRIT J CANCER, V79, P179, DOI 10.1038/sj.bjc.6690030; Yin Zhengfeng, 2002, Zhonghua Zhongliu Zazhi, V24, P27; Yu L, 2004, EUR J CANCER, V40, P1787, DOI 10.1016/j.ejca.2004.04.014; Yu YJ, 2015, J BIOL CHEM, V290, P17762, DOI 10.1074/jbc.M115.643551; Yuan KH, 2015, ARCH MED RES, V46, P635, DOI 10.1016/j.arcmed.2015.11.006; Zhang DY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13431-y; Zhang Luo, 2018, Oncotarget, V9, P24821, DOI 10.18632/oncotarget.23892; Zhao GF, 2012, MOL ENDOCRINOL, V26, P1304, DOI 10.1210/me.2012-1028; Zhao JJ, 2017, CELL PHYSIOL BIOCHEM, V43, P589, DOI 10.1159/000480531; Zheng W, 2014, J CLIN INVEST, V124, P878, DOI 10.1172/JCI71603; Zou P, 2006, LAB INVEST, V86, P645, DOI 10.1038/labinvest.3700428	157	62	63	4	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	10					2040	2054		10.1038/s41388-019-1124-8	http://dx.doi.org/10.1038/s41388-019-1124-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KS8UR	31801970	Bronze, Green Submitted			2022-12-28	WOS:000518584000002
J	Suzuki, N; Idogawa, M; Tange, S; Ohashi, T; Sasaki, Y; Nakase, H; Tokino, T				Suzuki, Natsumi; Idogawa, Masashi; Tange, Shoichiro; Ohashi, Tomoko; Sasaki, Yasushi; Nakase, Hiroshi; Tokino, Takashi			p53-induced ARVCF modulates the splicing landscape and supports the tumor suppressive function of p53	ONCOGENE			English	Article							TRANSCRIPTIONAL TARGET; APOPTOSIS	p53 is one of the most important tumor suppressor genes, and the exploration of p53-target genes is important for elucidation of its functional mechanisms. In this study, we identified Armadillo Repeat gene deleted in Velo-Cardio-Facial syndrome (ARVCF) as a direct target of p53 through ChIP-sequencing analysis. Activated p53 protein was found to bind to two distinct sites in the ARVCF gene, resulting in induction of ARVCF expression at both the mRNA and protein levels. We revealed that the knockdown of ARVCF inhibited p53-induced apoptosis. Interestingly, ARVCF interacted with hnRNPH2, which is involved in pre-mRNA splicing, and ARVCF knockdown induced dynamic changes in alternative splicing patterns. These results suggest that p53-induced ARVCF indirectly, but not directly, regulates p53 target selectivity through splicing alterations of specific genes. Thus, we demonstrated that the induction of ARVCF expression contributed to the tumor suppressive function of p53. Recently, it has been reported that many tumors have thousands of alternative splicing events that are not detectable in normal samples. ARVCF may play a role in alternative splicing events in cancer and may provide clues to explore novel approaches for cancer diagnosis and therapy.	[Suzuki, Natsumi; Idogawa, Masashi; Tange, Shoichiro; Ohashi, Tomoko; Tokino, Takashi] Sapporo Med Univ, Res Inst Frontier Med, Dept Med Genome Sci, Sch Med, Sapporo, Hokkaido, Japan; [Idogawa, Masashi; Nakase, Hiroshi] Sapporo Med Univ, Dept Gastroenterol & Hepatol, Sch Med, Sapporo, Hokkaido, Japan; [Sasaki, Yasushi] Sapporo Med Univ, Ctr Med Educ, Dept Liberal Arts & Sci, Biol, Sapporo, Hokkaido, Japan	Sapporo Medical University; Sapporo Medical University; Sapporo Medical University	Idogawa, M; Tokino, T (corresponding author), Sapporo Med Univ, Res Inst Frontier Med, Dept Med Genome Sci, Sch Med, Sapporo, Hokkaido, Japan.; Idogawa, M (corresponding author), Sapporo Med Univ, Dept Gastroenterol & Hepatol, Sch Med, Sapporo, Hokkaido, Japan.	idogawa@sapmed.ac.jp; tokino@sapmed.ac.jp	Tokino, Takashi/AAI-9887-2021; Tange, Shoichiro/AAJ-5265-2020; Idogawa, Masashi/B-5208-2008; Nakase, Hiroshi/AAZ-4425-2020	Tange, Shoichiro/0000-0002-2126-6938; Idogawa, Masashi/0000-0002-8507-1726; Sasaki, Yasushi/0000-0002-3500-8059	JSPS KAKENHI [19K08372, 19K07645, 16K09285, 16K07122]; Takeda Science Foundation	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Takeda Science Foundation(Takeda Science Foundation (TSF))	This work was supported by JSPS KAKENHI (grant numbers: 19K08372, 19K07645, 16K09285, and 16K07122) and Takeda Science Foundation.	Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Chang GS, 2014, CELL REP, V8, P513, DOI 10.1016/j.celrep.2014.06.030; Fischer M, 2017, ONCOGENE, V36, P3943, DOI 10.1038/onc.2016.502; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Idogawa M, 2019, J ONCOL, V2019, DOI 10.1155/2019/4368068; Idogawa M, 2017, INT J CANCER, V140, P2785, DOI 10.1002/ijc.30689; Idogawa M, 2014, ONCOTARGET, V5, P7540, DOI 10.18632/oncotarget.2272; Idogawa M, 2014, HUM MOL GENET, V23, P2847, DOI 10.1093/hmg/ddt673; Idogawa M, 2009, CLIN CANCER RES, V15, P3725, DOI 10.1158/1078-0432.CCR-08-2396; Kahles A, 2018, CANCER CELL, V34, P211, DOI 10.1016/j.ccell.2018.07.001; Katz Y, 2010, NAT METHODS, V7, P1009, DOI 10.1038/NMETH.1528; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; McCrea PD, 2007, BBA-MOL CELL RES, V1773, P17, DOI 10.1016/j.bbamcr.2006.06.009; Ohashi T, 2017, CANCER LETT, V390, P58, DOI 10.1016/j.canlet.2016.12.034; Ohashi T, 2013, MOL CANCER RES, V11, P1554, DOI 10.1158/1541-7786.MCR-13-0330-T; Olsson A, 2007, CELL DEATH DIFFER, V14, P1561, DOI 10.1038/sj.cdd.4402196; Rappe U, 2014, J BIOL CHEM, V289, P12421, DOI 10.1074/jbc.M113.530717; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang B, 2014, CELL DEATH DIFFER, V21, P521, DOI 10.1038/cdd.2013.132; Zhang D, 2015, MOL CARCINOGEN, V54, pE185, DOI 10.1002/mc.22281	21	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	10					2202	2211		10.1038/s41388-019-1133-7	http://dx.doi.org/10.1038/s41388-019-1133-7			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KS8UR	31827232				2022-12-28	WOS:000518584000013
J	Saksouk, N; Hajdari, S; Perez, Y; Pratlong, M; Barrachina, C; Graber, C; Gregoire, D; Zavoriti, A; Sarrazin, A; Pirot, N; Noel, JY; Khellaf, L; Fabbrizio, E; Julien, E; Cammas, FM				Saksouk, Nehme; Hajdari, Shefqet; Perez, Yannick; Pratlong, Marine; Barrachina, Celia; Graber, Celine; Gregoire, Damien; Zavoriti, Aliki; Sarrazin, Amelie; Pirot, Nelly; Noel, Jean-Yohan; Khellaf, Lakhdar; Fabbrizio, Eric; Julien, Eric; Cammas, Florence M.			The mouse HP1 proteins are essential for preventing liver tumorigenesis	ONCOGENE			English	Article							HISTONE H3 LYSINE-9; REGULATE GENE-EXPRESSION; HEPATOCELLULAR-CARCINOMA; HETEROCHROMATIN; METHYLATION; METHYLTRANSFERASE; DEREGULATION; DROSOPHILA; TRIM24; LEADS	Chromatin organization is essential for appropriate interpretation of the genetic information. Here, we demonstrated that the chromatin-associated proteins HP1 are dispensable for hepatocytes survival but are essential within hepatocytes to prevent liver tumor development in mice with HP1 beta being pivotal in these functions. Yet, we found that the loss of HP1 per se is not sufficient to induce cell transformation but renders cells more resistant to specific stress such as the expression of oncogenes and thus in fine, more prone to cell transformation. Molecular characterization of HP1-Triple KO premalignant livers and BMEL cells revealed that HP1 are essential for the maintenance of heterochromatin organization and for the regulation of specific genes with most of them having well characterized functions in liver functions and homeostasis. We further showed that some specific retrotransposons get reactivated upon loss of HP1, correlating with overexpression of genes in their neighborhood. Interestingly, we found that, although HP1-dependent genes are characterized by enrichment H3K9me3, this mark does not require HP1 for its maintenance and is not sufficient to maintain gene repression in absence of HP1. Finally, we demonstrated that the loss of TRIM28 association with HP1 recapitulated several phenotypes induced by the loss of HP1 including the reactivation of some retrotransposons and the increased incidence of liver cancer development. Altogether, our findings indicate that HP1 proteins act as guardians of liver homeostasis to prevent tumor development by modulating multiple chromatin-associated events within both the heterochromatic and euchromatic compartments, partly through regulation of the corepressor TRIM28 activity.	[Saksouk, Nehme; Hajdari, Shefqet; Perez, Yannick; Zavoriti, Aliki; Pirot, Nelly; Noel, Jean-Yohan; Fabbrizio, Eric; Julien, Eric; Cammas, Florence M.] IRCM, F-34298 Montpellier, France; [Saksouk, Nehme; Hajdari, Shefqet; Perez, Yannick; Zavoriti, Aliki; Pirot, Nelly; Noel, Jean-Yohan; Fabbrizio, Eric; Julien, Eric; Cammas, Florence M.] INSERM, U1194, F-34298 Montpellier, France; [Saksouk, Nehme; Hajdari, Shefqet; Perez, Yannick; Zavoriti, Aliki; Pirot, Nelly; Noel, Jean-Yohan; Fabbrizio, Eric; Julien, Eric; Cammas, Florence M.] Univ Montpellier, F-34090 Montpellier, France; [Saksouk, Nehme; Hajdari, Shefqet; Perez, Yannick; Zavoriti, Aliki; Pirot, Nelly; Noel, Jean-Yohan; Khellaf, Lakhdar; Fabbrizio, Eric; Julien, Eric; Cammas, Florence M.] Inst Reg Canc Montpellier, F-34298 Montpellier, France; [Pratlong, Marine; Barrachina, Celia] Univ Montpellier, MGX, Biocampus Montpellier, CNRS,INSERM, Montpellier, France; [Graber, Celine; Sarrazin, Amelie] IGBMC, Illkirch Graffenstaden, France; [Gregoire, Damien; Fabbrizio, Eric; Julien, Eric; Cammas, Florence M.] CNRS, Route Mende, Montpellier, France; [Gregoire, Damien] Univ Montpellier, CNRS, Inst Genet Mol Montpellier, Montpellier, France; [Sarrazin, Amelie] Univ Montpellier, MRI, BioCampus Montpellier, CNRS,INSERM, Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UNICANCER; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Cammas, FM (corresponding author), IRCM, F-34298 Montpellier, France.; Cammas, FM (corresponding author), INSERM, U1194, F-34298 Montpellier, France.; Cammas, FM (corresponding author), Univ Montpellier, F-34090 Montpellier, France.; Cammas, FM (corresponding author), Inst Reg Canc Montpellier, F-34298 Montpellier, France.; Cammas, FM (corresponding author), CNRS, Route Mende, Montpellier, France.	Florence.cammas@inserm.fr	SAKSOUK, NEHME/ABA-4057-2021	SAKSOUK, NEHME/0000-0001-5592-6298; cammas, florence/0000-0003-4117-8182; JULIEN, ERIC/0000-0003-2976-666X	French National Research Agency [ANR-10-INBS-04]; Center National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (INSERM); University of Montpellier; Institut regional de Cancerologie de Montpellier (ICM); SIRIC Montpellier Cancer [INCa_Inserm_DGOS_12553]; Erasmus Ph.D. fellowship; Ministry of Education, Science and Technology of the Republic of Kosovo; ANR [ANR 2009 BLAN 021 91, ANR-16CE15-0018-03]; INCa [PLBIO13-146]; ARC [PJA20131200357]; La ligue Regionale contre le Cancer [128-R13021FF-RAB13006FFA]	French National Research Agency(French National Research Agency (ANR)); Center National de la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS)); Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); University of Montpellier; Institut regional de Cancerologie de Montpellier (ICM); SIRIC Montpellier Cancer; Erasmus Ph.D. fellowship; Ministry of Education, Science and Technology of the Republic of Kosovo; ANR(French National Research Agency (ANR)); INCa(Institut National du Cancer (INCA) France); ARC(Australian Research Council); La ligue Regionale contre le Cancer	We thank P. Chambon, C. Sardet, T. Forne, D. Fisher, and C. Grimaud for helpful discussions and critical reading of the paper. We thank F. Bernex and L. LeCam, C. Keime, and B. Jost for fruitful discussions. We thank L. Papon, H. Fontaine, and C. Bonhomme for technical assistance and M. Oulad-Abdelghani and the IGBMC for the anti-HP1 and TRIM28 antibodies. We also thank the RHEM technical facility and particularly J. Simony for histological analysis and the IGBMC/ICS transgenic and animal facility for the initial establishment of the HP1 and TRIM28 mouse models. We thank C. Vincent and the IRCM animal core facility for the day to day care of the animal models. Finally, we thank S. Chamroeun for counting positive cells on TMA. We acknowledge the imaging facility MRI, member of the national infrastructure France-BioImaging and supported by the French National Research Agency (ANR-10-INBS-04, "Investments for the future"). This work was supported by funds from the Center National de la Recherche Scientifique (CNRS), the Institut National de la Sante et de la Recherche Medicale (INSERM), the University of Montpellier and the Institut regional de Cancerologie de Montpellier (ICM),) and SIRIC Montpellier Cancer, Grant INCa_Inserm_DGOS_12553. SH was funded by an Erasmus Ph.D. fellowship. We also thank the Ministry of Education, Science and Technology of the Republic of Kosovo for a scholarships to support SH. FC was supported by grants from ANR (ANR 2009 BLAN 021 91; ANR-16CE15-0018-03), INCa (PLBIO13-146), ARC (PJA20131200357), and La ligue Regionale contre le Cancer (128-R13021FF-RAB13006FFA). Sequencing was performed by the MGX facility. Montpellier, France.	Allan RS, 2012, NATURE, V487, P249, DOI 10.1038/nature11173; Bhattacharyya S, 2014, CURR DRUG METAB, V15, P719, DOI 10.2174/1389200215666141125121659; Bishayee A, 2014, ADV EXP MED BIOL, V816, P401, DOI 10.1007/978-3-0348-0837-8_16; Bojkowska K, 2012, HEPATOLOGY, V56, P1279, DOI 10.1002/hep.25767; Bosch-Presegue L, 2017, CELL REP, V21, P2048, DOI 10.1016/j.celrep.2017.10.092; Bregnard C, 2016, EBIOMEDICINE, V8, P184, DOI 10.1016/j.ebiom.2016.05.005; Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199; Brustel J, 2017, EMBO J, V36, P2726, DOI 10.15252/embj.201796541; Camacho OV, 2017, ELIFE, V6, DOI 10.7554/eLife.25293; Cammas F, 2000, DEVELOPMENT, V127, P2955; Cizkova K, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/656428; Del Campo JA, 2018, WORLD J HEPATOL, V10, P1, DOI 10.4254/wjh.v10.i1.1; Dialynas GK, 2008, MUTAT RES-FUND MOL M, V647, P13, DOI 10.1016/j.mrfmmm.2008.09.007; Dinant C, 2009, MOL CELL BIOL, V29, P6335, DOI 10.1128/MCB.01048-09; Du Q, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08302-1; Ecco G, 2017, DEVELOPMENT, V144, P2719, DOI 10.1242/dev.132605; Ecco G, 2016, DEV CELL, V36, P611, DOI 10.1016/j.devcel.2016.02.024; EISSENBERG JC, 1992, GENETICS, V131, P345; Eissenberg JC, 2014, TRENDS GENET, V30, P103, DOI 10.1016/j.tig.2014.01.002; Fan DNY, 2013, HEPATOLOGY, V57, P637, DOI 10.1002/hep.26083; Fanti L, 2008, CURR OPIN GENET DEV, V18, P169, DOI 10.1016/j.gde.2008.01.009; Fausto N, 2006, HEPATOLOGY, V43, pS45, DOI 10.1002/hep.20969; Guengerich FP, 2019, J BIOL CHEM, V294, P1671, DOI 10.1074/jbc.TM118.004144; Hardy T, 2016, GUT, V65, P1895, DOI 10.1136/gutjnl-2015-311292; Herquel B, 2013, NAT STRUCT MOL BIOL, V20, P339, DOI 10.1038/nsmb.2496; Herquel B, 2011, P NATL ACAD SCI USA, V108, P8212, DOI 10.1073/pnas.1101544108; Herzog M, 2011, DEV BIOL, V350, P548, DOI 10.1016/j.ydbio.2010.12.014; Huang CY, 2017, GENE DEV, V31, P241, DOI 10.1101/gad.292169.116; Jacobs FMJ, 2014, NATURE, V516, P242, DOI 10.1038/nature13760; JAMES TC, 1986, MOL CELL BIOL, V6, P3862, DOI 10.1128/MCB.6.11.3862; Janssen A, 2018, ANNU REV CELL DEV BI, V34, P265, DOI 10.1146/annurev-cellbio-100617-062653; Jorgensen S, 2013, NUCLEIC ACIDS RES, V41, P2797, DOI 10.1093/nar/gkt012; Kato M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04132-9; Khetchoumian K, 2007, NAT GENET, V39, P1500, DOI 10.1038/ng.2007.15; Koschmann C, 2017, CANCER RES, V77, P227, DOI 10.1158/0008-5472.CAN-16-2301; Kuo LJ, 2008, IN VIVO, V22, P305; Kurinna S, 2011, INT J BIOCHEM CELL B, V43, P189, DOI 10.1016/j.biocel.2010.03.013; Lee DH, 2013, BIOCHEM BIOPH RES CO, V434, P820, DOI 10.1016/j.bbrc.2013.04.020; Lee Young-Ho, 2015, J Nat Sci, V1, pe127; Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9; Lomberk G, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-7-228; Mai S, 2019, GENE CHROMOSOME CANC, V58, P462, DOI 10.1002/gcc.22720; Matsui T, 2010, NATURE, V464, P927, DOI 10.1038/nature08858; Mattout A, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0760-8; Mirabella AC, 2016, CHROMOSOMA, V125, P75, DOI 10.1007/s00412-015-0530-0; Nishibuchi G, 2014, J BIOCHEM, V156, P11, DOI 10.1093/jb/mvu032; Niu ZS, 2016, WORLD J GASTROENTERO, V22, P9069, DOI 10.3748/wjg.v22.i41.9069; O'Geen H, 2007, PLOS GENET, V3, P916, DOI 10.1371/journal.pgen.0030089; Paik YH, 2014, ANTIOXID REDOX SIGN, V20, P2854, DOI 10.1089/ars.2013.5619; Park JW, 2014, BIOCHEM J, V464, P241, DOI 10.1042/BJ20140787; Piacentini L, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000670; Pogribny IP, 2006, CARCINOGENESIS, V27, P1180, DOI 10.1093/carcin/bgi364; Pogribny IP, 2014, CANCER LETT, V342, P223, DOI 10.1016/j.canlet.2012.01.038; Poleshko A, 2013, CELL REP, V5, P292, DOI 10.1016/j.celrep.2013.09.024; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Prakash K, 2018, BIOSYSTEMS, V164, P49, DOI 10.1016/j.biosystems.2017.11.005; Schott S, 2006, DEV BIOL, V298, P176, DOI 10.1016/j.ydbio.2006.06.039; Shi S, 2008, NAT CELL BIOL, V10, P491, DOI 10.1038/ncb1713; Strick-Marchand H, 2002, HEPATOLOGY, V36, P794, DOI 10.1053/jhep.2002.36123; Stunnenberg R, 2015, EMBO J, V34, P2789, DOI 10.15252/embj.201591320; Takaki A, 2015, WORLD J HEPATOL, V7, P968, DOI 10.4254/wjh.v7.i7.968; Towbin BD, 2012, CELL, V150, P934, DOI 10.1016/j.cell.2012.06.051; Vad-Nielsen J, 2015, CANCER BIOL THER, V16, P189, DOI 10.1080/15384047.2014.1001277; Vakoc CR, 2005, MOL CELL, V19, P381, DOI 10.1016/j.molcel.2005.06.011; Weisend CM, 2009, GENESIS, V47, P789, DOI 10.1002/dvg.20568; Wolf G, 2015, GENE DEV, V29, P538, DOI 10.1101/gad.252767.114; Yang P, 2017, TRENDS GENET, V33, P871, DOI 10.1016/j.tig.2017.08.006	67	10	10	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	13					2676	2691		10.1038/s41388-020-1177-8	http://dx.doi.org/10.1038/s41388-020-1177-8		FEB 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KX4EF	32020053	Green Submitted			2022-12-28	WOS:000511084200003
J	Chan, YC; Chang, YC; Chuang, HH; Yang, YC; Lin, YF; Huang, MS; Hsiao, M; Yang, CJ; Hua, KT				Chan, Yung-Chieh; Chang, Yu-Chan; Chuang, Hsiang-Hao; Yang, Yi-Chieh; Lin, Yuan-Feng; Huang, Ming-Shyan; Hsiao, Michael; Yang, Chih-Jen; Hua, Kuo-Tai			Overexpression of PSAT1 promotes metastasis of lung adenocarcinoma by suppressing the IRF1-IFN gamma axis	ONCOGENE			English	Article							L-SERINE BIOSYNTHESIS; NEU-LAXOVA SYNDROME; PYRUVATE-KINASE M2; PHOSPHOSERINE AMINOTRANSFERASE; PHOSPHORYLATED PATHWAY; DNA METHYLATION; BREAST; EXPRESSION; DEFICIENCY; CELLS	An increasing number of enzymes involved in serine biosynthesis have been identified and correlated with malignant evolution in various types of cancer. Here we showed that the overexpression of phosphoserine aminotransferase 1 (PSAT1) is widely found in lung cancer tissues compared with nontumor tissues and predicts a poorer prognosis in patients with lung adenocarcinoma. PSAT1 expression was examined in a tissue microarray by immunohistochemistry. The data show that the knockdown of PSAT1 dramatically inhibits the in vitro and in vivo metastatic potential of highly metastatic lung cancer cells; conversely, the enforced expression of exogenous PSAT1 predominantly enhances the metastatic potential of lung cancer cells. Importantly, manipulating PSAT1 expression regulates the in vivo tumor metastatic abilities in lung cancer cells. Adjusting the glucose and glutamine concentrations did not alter the PSAT1-driven cell invasion properties, indicating that this process might not rely on the activation of its enzymatic function. RNA microarray analysis of transcriptional profiling from PSAT1 alternation in CL1-5 and CL1-0 cells demonstrated that interferon regulatory factor 1 (IRF1) acts as a crucial regulator of PSAT1-induced gene expression upon metastatic progression. Decreasing the IRF1-IFIH1 axis compromised the PSAT1-prompted transcriptional reprogramming in cancer cells. Our results identify PSAT1 as a key regulator by a novel PSAT1/IRF1 axis in lung cancer progression, which may serve as a potential biomarker and therapeutic target for the treatment of lung cancer patients.	[Chan, Yung-Chieh] Show Chwan Mem Hosp, Innovat Ctr, Changhua, Taiwan; [Chang, Yu-Chan; Hsiao, Michael] Acad Sinica, Genom Res Ctr, Taipei, Taiwan; [Chuang, Hsiang-Hao; Yang, Chih-Jen] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Div Pulm & Crit Care Med, Kaohsiung, Taiwan; [Yang, Yi-Chieh] Tungs Taichung MetroHarbor Hosp, Dept Med Res, Taichung, Taiwan; [Yang, Yi-Chieh; Lin, Yuan-Feng] Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan; [Huang, Ming-Shyan] E DA Canc Hosp, Dept Internal Med, Div Pulm & Crit Care Med, Kaohsiung, Taiwan; [Huang, Ming-Shyan] I Shou Univ, Sch Med, Kaohsiung, Taiwan; [Hsiao, Michael] Kaohsiung Med Univ, Coll Med, Dept Biochem, Kaohsiung, Taiwan; [Yang, Chih-Jen] Kaohsiung Med Univ, Kaohsiung Municipal Ta Tung Hosp, Dept Internal Med, Kaohsiung, Taiwan; [Hua, Kuo-Tai] Natl Taiwan Univ, Coll Med, Grad Inst Toxicol, Taipei, Taiwan	Show Chwan Memorial Hospital; Academia Sinica - Taiwan; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Tungs' Taichung MetroHarbor Hospital; Taipei Medical University; E-Da Hospital; I Shou University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Municipal Ta-Tung Hospital; National Taiwan University	Yang, CJ (corresponding author), Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Div Pulm & Crit Care Med, Kaohsiung, Taiwan.; Yang, CJ (corresponding author), Kaohsiung Med Univ, Kaohsiung Municipal Ta Tung Hosp, Dept Internal Med, Kaohsiung, Taiwan.; Hua, KT (corresponding author), Natl Taiwan Univ, Coll Med, Grad Inst Toxicol, Taipei, Taiwan.	chjeya@cc.kmu.edu.tw; kthua@ntu.edu.tw	Chuang, Hsiang-Hao/AFR-5829-2022; Chang, Yu-Chan/W-3582-2019; Hsiao, Michael/U-6238-2019; Chan, yung-chieh/E-4091-2012	Chuang, Hsiang-Hao/0000-0002-3590-5622; Chang, Yu-Chan/0000-0003-0474-9935; Hsiao, Michael/0000-0001-8529-9213; Hua, Kuo-Tai/0000-0002-8468-4977	Ministry of Science and Technology [MOST 104-0210-01-09-02, MOST 105-0210-01-13-01, MOST 106-0210-01-15-02, MOST 108-2628-B-002-014]; Academia Sinica	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Academia Sinica(Academia Sinica - Taiwan)	This study is supported by grants from Academia Sinica and Ministry of Science and Technology grants (MOST 104-0210-01-09-02, MOST 105-0210-01-13-01, MOST 106-0210-01-15-02, and MOST 108-2628-B-002-014). We like to thank Miss Tracy Tsai for her assists in immunohistochemistry works. And also like to thank the GRC Instrument Core Facilities for their support for the Affymetrix microarray, IVIS spectrum, and Aperio digital pathology analyses.	Acuna-Hidalgo R, 2014, AM J HUM GENET, V95, P285, DOI 10.1016/j.ajhg.2014.07.012; Anastasiou D, 2011, SCIENCE, V334, P1278, DOI 10.1126/science.1211485; Bachmann SB, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-125; Baek JY, 2003, BIOCHEM J, V373, P191, DOI 10.1042/BJ20030144; Basurko MJ, 1999, IUBMB LIFE, V48, P525, DOI 10.1080/713803557; Bouker KB, 2005, CARCINOGENESIS, V26, P1527, DOI 10.1093/carcin/bgi113; Bu DW, 2013, CANCER EPIDEM BIOMAR, V22, P2212, DOI 10.1158/1055-9965.EPI-13-0208; Chen FF, 2013, ONCOL LETT, V5, P417, DOI 10.3892/ol.2012.1051; Cheng TY, 2018, ONCOGENE, V37, P1730, DOI 10.1038/s41388-017-0086-y; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; De Koning TJ, 2003, BIOCHEM J, V371, P653, DOI 10.1042/BJ20021785; Gromova I, 2015, MOL ONCOL, V9, P1636, DOI 10.1016/j.molonc.2015.05.003; Hanley Matthew P, 2015, Curr Pharmacol Rep, V1, P197; Harrison C, 2012, THER ADV HEMATOL, V3, P341, DOI 10.1177/2040620712459746; Hart CE, 2007, AM J HUM GENET, V80, P931, DOI 10.1086/517888; Hu Y, 2014, APOPTOSIS, V19, P1627, DOI 10.1007/s10495-014-1030-z; Jaeken J, 1996, J INHERIT METAB DIS, V19, P223, DOI 10.1007/BF01799435; KNOX WE, 1969, ARCH BIOCHEM BIOPHYS, V132, P397, DOI 10.1016/0003-9861(69)90381-6; Ksienzyk A, 2012, ONCOIMMUNOLOGY, V1, DOI 10.4161/onci.19405; Ksienzyk A, 2011, CANCER RES, V71, P6410, DOI 10.1158/0008-5472.CAN-11-1565; Kwon JE, 2014, NEOPLASMA, V61, P566, DOI 10.4149/neo_2014_069; LEE YC, 1985, JPN J CLIN ONCOL, V15, P637; Liu JL, 2013, J NEURO-ONCOL, V111, P245, DOI 10.1007/s11060-012-1018-x; Locasale JW, 2011, NAT GENET, V43, P869, DOI 10.1038/ng.890; LUND K, 1985, ARCH BIOCHEM BIOPHYS, V237, P186, DOI 10.1016/0003-9861(85)90268-1; Ma B, 2016, SCI REP-UK, V6, DOI 10.1038/srep26299; Ma L, 2013, CELL, V152, P599, DOI 10.1016/j.cell.2012.12.028; Maddocks ODK, 2013, NATURE, V493, P542, DOI 10.1038/nature11743; Martens JWM, 2005, CANCER RES, V65, P4101, DOI 10.1158/0008-5472.CAN-05-0064; Mehrmohamadi M, 2014, CELL REP, V9, P1507, DOI 10.1016/j.celrep.2014.10.026; Mizuno H, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-18; Nilsson R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4128; Noh S, 2014, TUMOR BIOL, V35, P4457, DOI 10.1007/s13277-013-1588-z; Pamment J, 2002, ONCOGENE, V21, P7776, DOI 10.1038/sj.onc.1205981; Pollari S, 2011, BREAST CANCER RES TR, V125, P421, DOI 10.1007/s10549-010-0848-5; Quezada SA, 2014, NAT IMMUNOL, V15, P703, DOI 10.1038/ni.2945; Ranoa DRE, 2016, ONCOTARGET, V7, P26496, DOI 10.18632/oncotarget.8420; Shaheen R, 2014, AM J HUM GENET, V94, P898, DOI 10.1016/j.ajhg.2014.04.015; Szasz AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337; Tabatabaie L, 2010, MOL GENET METAB, V99, P256, DOI 10.1016/j.ymgme.2009.10.012; Tisserand J, 2011, J BIOL CHEM, V286, P33369, DOI 10.1074/jbc.M111.225680; Vie N, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-14; Wang N, 2015, MOL CANCER THER, V14, P982, DOI 10.1158/1535-7163.MCT-14-0751; Yang Y, 2015, INT J CANCER, V136, pE39, DOI 10.1002/ijc.29150; Ye JB, 2012, P NATL ACAD SCI USA, V109, P6904, DOI 10.1073/pnas.1204176109; Yin K, 2015, ONCOTARGETS THER, V8, P1069, DOI 10.2147/OTT.S82433; Yu XF, 2016, CANCER RES, V76, P2166, DOI 10.1158/0008-5472.CAN-15-2142; Yuan L, 2015, CANCER LETT, V359, P136, DOI 10.1016/j.canlet.2015.01.003; Zhang WC, 2012, CELL, V148, P259, DOI 10.1016/j.cell.2011.11.050	49	15	17	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	12					2509	2522		10.1038/s41388-020-1160-4	http://dx.doi.org/10.1038/s41388-020-1160-4		JAN 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KW4HU	31988456				2022-12-28	WOS:000509655100005
J	Ricci, B; Millner, TO; Pomella, N; Zhang, XY; Guglielmi, L; Badodi, S; Ceric, D; Gemma, C; Cognolato, E; Zhang, Y; Brandner, S; Barnes, MR; Marino, S				Ricci, Barbara; Millner, Thomas O.; Pomella, Nicola; Zhang, Xinyu; Guglielmi, Loredana; Badodi, Sara; Ceric, Dario; Gemma, Carolina; Cognolato, Erica; Zhang, Ying; Brandner, Sebastian; Barnes, Michael R.; Marino, Silvia			Polycomb-mediated repression of EphrinA5 promotes growth and invasion of glioblastoma	ONCOGENE			English	Article							GENE-EXPRESSION; MESENCHYMAL TRANSFORMATION; MALIGNANT GLIOMA; SELF-RENEWAL; STEM-CELLS; BMI1; TUMOR; PROLIFERATION; MUTATIONS; NETWORK	Glioblastoma (GBM) is the most common and most aggressive intrinsic brain tumour in adults. Integrated transcriptomic and epigenomic analyses of glioblastoma initiating cells (GIC) in a mouse model uncovered a novel epigenetic regulation of EfnA5. In this model, Bmi1 enhances H3K27me3 at the EfnA5 locus and reinforces repression of selected target genes in a cellular context-dependent fashion. EfnA5 mediates Bmi1-dependent proliferation and invasion in vitro and tumour formation in an allograft model. Importantly, we show that this novel Polycomb feed-forward loop is also active in human GIC and we provide pre-clinical evidence of druggability of the EFNA5 signalling pathway in GBM xenografts overexpressing Bmi1.	[Ricci, Barbara; Millner, Thomas O.; Pomella, Nicola; Zhang, Xinyu; Guglielmi, Loredana; Badodi, Sara; Ceric, Dario; Cognolato, Erica; Marino, Silvia] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, 4 Newark St, London E1 2AT, England; [Gemma, Carolina] Imperial Coll London, Dept Surg & Canc, Hammersmith Hosp Campus, London W12 0NN, England; [Zhang, Ying; Brandner, Sebastian] Univ Coll London Hosp NHS Fdn, Natl Hosp Neurol & Neurosurg, Div Neuropathol, Queen Sq, London WC1N 3BG, England; [Barnes, Michael R.] Queen Mary Univ London, Barts & London Sch Med & Dent, William Harvey Res Inst, Ctr Translat Bioinformat, London EC1M 6BQ, England	University of London; Queen Mary University London; Imperial College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; Queen Mary University London	Marino, S (corresponding author), Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, 4 Newark St, London E1 2AT, England.	s.marino@qmul.ac.uk	Brandner, Sebastian/J-4562-2014; Badodi, Sara/GNH-3404-2022	Brandner, Sebastian/0000-0002-9821-0342; Millner, Thomas/0000-0001-5638-3918; Marino, Silvia/0000-0002-9612-2883; Pomella, Nicola/0000-0003-0028-4878; Gemma, Carolina/0000-0002-4890-9972; Badodi, Sara/0000-0002-8407-8336; Zhang, Ying/0000-0003-2194-7116	MRC [1365533]; Brain Tumour Charity [BTC 8/128, GN-000389]; Barts Charity; Brain Tumour Research (Centre of Excellence award); UCL-ORS; UCLH; National Institute of Health Research; Medical Research Council [1365533] Funding Source: researchfish	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Brain Tumour Charity; Barts Charity; Brain Tumour Research (Centre of Excellence award); UCL-ORS; UCLH; National Institute of Health Research(National Institute for Health Research (NIHR)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work is funded by grants from the MRC (1365533.studentship to BR), The Brain Tumour Charity (GN-000389 clinical research training fellowship to TM and BTC 8/128 to SB), Barts Charity (project and programme grants to SM) and Brain Tumour Research (Centre of Excellence award to SM); YZ was supported by a PhD Overseas research scholarship, UCL-ORS and UCLH Trustees. This research also forms a part of the research themes contributing to the translational research portfolio of Barts and the London Biomedical Research Centre, which is supported and funded by the National Institute of Health Research. LC-MS measurements of doxazosin were carried out by Dr Roberto Buccafusca, SBCS Mass Spectrometry Facility, QMUL. All xenograft tumour histology was performed by IQPath, UCLH, London.	Abdouh M, 2009, J NEUROSCI, V29, P8884, DOI 10.1523/JNEUROSCI.0968-09.2009; Acquati S, 2013, STEM CELLS, V31, P190, DOI 10.1002/stem.1274; Agger K, 2007, NATURE, V449, P731, DOI 10.1038/nature06145; Blackledge NP, 2015, NAT REV MOL CELL BIO, V16, P643, DOI 10.1038/nrm4067; Boyd AW, 2014, NAT REV DRUG DISCOV, V13, P39, DOI 10.1038/nrd4175; Bruggeman SWM, 2007, CANCER CELL, V12, P328, DOI 10.1016/j.ccr.2007.08.032; Burgold T, 2012, CELL REP, V2, P1244, DOI 10.1016/j.celrep.2012.09.013; Burgold T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003034; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Chen J, 1998, J BIOL CHEM, V273, P24670, DOI 10.1074/jbc.273.38.24670; Danussi C, 2013, CANCER RES, V73, P5140, DOI 10.1158/0008-5472.CAN-13-1168-T; Darmanis S, 2017, CELL REP, V21, P1399, DOI 10.1016/j.celrep.2017.10.030; Day BW, 2014, BRIT J CANCER, V111, P1255, DOI 10.1038/bjc.2014.73; De Santa F, 2009, EMBO J, V28, P3341, DOI 10.1038/emboj.2009.271; Ene CI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051407; Entrevan M, 2016, TRENDS CELL BIOL, V26, P511, DOI 10.1016/j.tcb.2016.04.009; Fasano CA, 2007, CELL STEM CELL, V1, P87, DOI 10.1016/j.stem.2007.04.001; Ferluga S, 2016, ONCOTARGET, V7, P59860, DOI 10.18632/oncotarget.10978; Frattini V, 2013, NAT GENET, V45, P1141, DOI 10.1038/ng.2734; Gargiulo G, 2013, CANCER CELL, V23, P660, DOI 10.1016/j.ccr.2013.03.030; Gil J, 2014, TRENDS CELL BIOL, V24, P632, DOI 10.1016/j.tcb.2014.06.005; Godlewski J, 2008, CANCER RES, V68, P9125, DOI 10.1158/0008-5472.CAN-08-2629; Gucciardo E, 2014, CELL MOL LIFE SCI, V71, P3685, DOI 10.1007/s00018-014-1633-0; Hashizume R, 2014, NAT MED, V20, P1394, DOI 10.1038/nm.3716; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Henrich CJ, 2007, MOL CANCER THER, V6, P3271, DOI 10.1158/1535-7163.MCT-07-0352; Himanen JP, 2010, P NATL ACAD SCI USA, V107, P10860, DOI 10.1073/pnas.1004148107; Hu BL, 2016, CELL, V167, P1281, DOI 10.1016/j.cell.2016.10.039; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacques TS, 2010, EMBO J, V29, P222, DOI 10.1038/emboj.2009.327; Jin X, 2017, NAT MED, V23, P1352, DOI 10.1038/nm.4415; KAYE B, 1986, BRIT J CLIN PHARMACO, V21, pS19, DOI 10.1111/j.1365-2125.1986.tb02849.x; Kim E, 2013, CANCER CELL, V23, P839, DOI 10.1016/j.ccr.2013.04.008; Kuang SQ, 2010, BLOOD, V115, P2412, DOI 10.1182/blood-2009-05-222208; Kyprianou N, 2000, CANCER RES, V60, P4550; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Li JJ, 2009, ONCOGENE, V28, P1759, DOI 10.1038/onc.2009.15; Lin Fan, 2013, CNS Oncol, V2, P271, DOI 10.2217/cns.13.15; Lisabeth EM, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a009159; Mohammad F, 2017, NAT MED, V23, P483, DOI 10.1038/nm.4293; Morey L, 2013, CELL REP, V3, P60, DOI 10.1016/j.celrep.2012.11.026; Overman JJ, 2012, P NATL ACAD SCI USA, V109, pE2230, DOI 10.1073/pnas.1204386109; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; Petty A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042120; Pollak J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172884; Rheinbay E, 2013, CELL REP, V3, P1567, DOI 10.1016/j.celrep.2013.04.021; Robey RW, 2003, BRIT J CANCER, V89, P1971, DOI 10.1038/sj.bjc.6601370; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Segerman A, 2016, CELL REP, V17, P2994, DOI 10.1016/j.celrep.2016.11.056; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; Sturm D, 2012, CANCER CELL, V22, P425, DOI 10.1016/j.ccr.2012.08.024; Subkhankulova T, 2010, MOL CELL NEUROSCI, V45, P151, DOI 10.1016/j.mcn.2010.06.006; Testa G, 2011, BIOESSAYS, V33, P519, DOI 10.1002/bies.201100021; Timp W, 2013, NAT REV CANCER, V13, P497, DOI 10.1038/nrc3486; Tu YY, 2013, CANCER RES, V73, P6046, DOI 10.1158/0008-5472.CAN-13-0358; van den Boom V, 2016, CELL REP, V14, P332, DOI 10.1016/j.celrep.2015.12.034; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Voncken JW, 1999, J CELL SCI, V112, P4627; Walker-Daniels J, 2003, AM J PATHOL, V162, P1037, DOI 10.1016/S0002-9440(10)63899-0; Wozniak MA, 2004, BBA-MOL CELL RES, V1692, P103, DOI 10.1016/j.bbamcr.2004.04.007; Xie Y, 2015, EBIOMEDICINE, V2, P1351, DOI 10.1016/j.ebiom.2015.08.026; Yadirgi G, 2011, STEM CELLS, V29, P700, DOI 10.1002/stem.614; Yan Y, 2015, FEBS LETT, V589, P756, DOI 10.1016/j.febslet.2015.02.005; Yu CH, 2009, DIGEST DIS SCI, V54, P2362, DOI 10.1007/s10620-008-0629-8; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhong CL, 1997, MOL BIOL CELL, V8, P2329, DOI 10.1091/mbc.8.11.2329	66	9	10	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	12					2523	2538		10.1038/s41388-020-1161-3	http://dx.doi.org/10.1038/s41388-020-1161-3		JAN 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KW4HU	31988455	Green Published, Green Submitted, hybrid			2022-12-28	WOS:000509655100004
J	Broustas, CG; Duval, AJ; Chaudhary, KR; Friedman, RA; Virk, RK; Lieberman, HB				Broustas, Constantinos G.; Duval, Axel J.; Chaudhary, Kunal R.; Friedman, Richard A.; Virk, Renu K.; Lieberman, Howard B.			Targeting MEK5 impairs nonhomologous end-joining repair and sensitizes prostate cancer to DNA damaging agents	ONCOGENE			English	Article							SIGNAL-REGULATED KINASE-5; H2AX PHOSPHORYLATION; ERK ACTIVATION; HISTONE H2AX; EXPRESSION; INHIBITION; CELLS; RADIATION; RADIOSENSITIZATION; MEK5-ALPHA	Radiotherapy is commonly used to treat a variety of solid human tumors, including localized prostate cancer. However, treatment failure often ensues due to tumor intrinsic or acquired radioresistance. Here we find that the MEK5/ERK5 signaling pathway is associated with resistance to genotoxic stress in aggressive prostate cancer cells. MEK5 knockdown by RNA interference sensitizes prostate cancer cells to ionizing radiation (IR) and etoposide treatment, as assessed by clonogenic survival and short-term proliferation assays. Mechanistically, MEK5 downregulation impairs phosphorylation of the catalytic subunit of DNA-PK at serine 2056 in response to IR or etoposide treatment. Although MEK5 knockdown does not influence the initial appearance of radiation- and etoposide-induced gamma H2AX and 53BP1 foci, it markedly delays their resolution, indicating a DNA repair defect. A cell-based assay shows that nonhomologous end joining (NHEJ) is compromised in cells with ablated MEK5 protein expression. Finally, MEK5 silencing combined with focal irradiation causes strong inhibition of tumor growth in mouse xenografts, compared with MEK5 depletion or radiation alone. These findings reveal a convergence between MEK5 signaling and DNA repair by NHEJ in conferring resistance to genotoxic stress in advanced prostate cancer and suggest targeting MEK5 as an effective therapeutic intervention in the management of this disease.	[Broustas, Constantinos G.; Duval, Axel J.; Chaudhary, Kunal R.; Lieberman, Howard B.] Columbia Univ, Ctr Radiol Res, Vagelos Coll Phys & Surg, Irving Med Ctr, New York, NY 10032 USA; [Friedman, Richard A.] Columbia Univ, Herbert Irving Comprehens Canc Ctr, Biomed Informat Shared Resource, Irving Med Ctr, New York, NY USA; [Friedman, Richard A.] Columbia Univ, Dept Biomed Informat, Irving Med Ctr, New York, NY USA; [Virk, Renu K.] Columbia Univ, Dept Pathol & Cell Biol, Irving Med Ctr, New York, NY USA; [Lieberman, Howard B.] Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY USA	Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Columbia University	Broustas, CG (corresponding author), Columbia Univ, Ctr Radiol Res, Vagelos Coll Phys & Surg, Irving Med Ctr, New York, NY 10032 USA.	cgb2117@cumc.columbia.edu	Chaudhary, Kunal/AAF-7187-2021	Chaudhary, Kunal/0000-0001-5423-3174; Broustas, Constantinos/0000-0001-7169-807X	Department of Defense Prostate Cancer Research Program [W81XWH-15-1-0296];  [P30CA013696]	Department of Defense Prostate Cancer Research Program(United States Department of Defense); 	This work is supported by the Department of Defense Prostate Cancer Research Program, W81XWH-15-1-0296 (CGB). This study also used the resources of the Herbert Irving Comprehensive Cancer Center Flow Cytometry, Radiation Research, and Confocal and Specialized Microscopy Shared Resources funded in part through Center Grant P30CA013696. We thank Theresa Swayne and Laura Munteanu from the Confocal and Specialized Microscopy Shared Resource of the Irving Cancer Research Center (ICRC) and Drs. Siu-Hong Ho, Wei Wang, and Caisheng Lu from the Flow Cytometry Shared Resource of the Herbert Irving Comprehensive Cancer Center at Columbia University Irving Medical Center for their help in performing the immunofluorescence and flow cytometry experiments.	Adachi N, 2003, J BIOL CHEM, V278, P35897, DOI 10.1074/jbc.M306500200; Arnoux V, 2008, MOL BIOL CELL, V19, P4738, DOI 10.1091/mbc.E07-10-1078; Banath JP, 2004, CANCER RES, V64, P7144, DOI 10.1158/0008-5472.CAN-04-1433; Benito-Jardon L, 2019, CANCER RES, V79, P2244, DOI 10.1158/0008-5472.CAN-18-2762; Bolla M, 2010, LANCET ONCOL, V11, P1066, DOI 10.1016/S1470-2045(10)70223-0; Bouchaert P, 2012, INT J RADIAT ONCOL, V84, P1179, DOI 10.1016/j.ijrobp.2012.02.014; Brenner JC, 2011, CANCER CELL, V19, P664, DOI 10.1016/j.ccr.2011.04.010; Cameron SJ, 2004, J BIOL CHEM, V279, P1506, DOI 10.1074/jbc.M308755200; Chao TH, 1999, J BIOL CHEM, V274, P36035, DOI 10.1074/jbc.274.51.36035; Chen BPC, 2005, J BIOL CHEM, V280, P14709, DOI 10.1074/jbc.M408827200; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Collis SJ, 2003, CANCER RES, V63, P1550; Davis AJ, 2014, DNA REPAIR, V17, P21, DOI 10.1016/j.dnarep.2014.02.020; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; Estrada-Bernal A, 2015, CELL CYCLE, V14, P3713, DOI 10.1080/15384101.2015.1104437; Filippo JS, 2008, ANNU REV BIOCHEM, V77, P229, DOI 10.1146/annurev.biochem.77.061306.125255; Ghosh AK, 2005, J BIOL CHEM, V280, P14325, DOI 10.1074/jbc.M413313200; Golding SE, 2007, CANCER RES, V67, P1046, DOI 10.1158/0008-5472.CAN-06-2371; Goodwin JF, 2013, CANCER DISCOV, V3, P1254, DOI 10.1158/2159-8290.CD-13-0108; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; Jiang WW, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0209-3; Kim MR, 2015, MOL CANCER RES, V13, P319, DOI 10.1158/1541-7786.MCR-14-0098-T; Lieber MR, 2008, J BIOL CHEM, V283, P1, DOI 10.1074/jbc.R700039200; Loveridge CJ, 2017, CANCER RES, V77, P3158, DOI 10.1158/0008-5472.CAN-16-2565; McCracken SRC, 2008, ONCOGENE, V27, P2978, DOI 10.1038/sj.onc.1210963; Mehta PB, 2003, ONCOGENE, V22, P1381, DOI 10.1038/sj.onc.1206154; Ni XH, 2011, J CLIN INVEST, V121, P2383, DOI 10.1172/JCI45109; Nyati MK, 2006, CANCER RES, V66, P11554, DOI 10.1158/0008-5472.CAN-06-1935; Olive PL, 2004, INT J RADIAT ONCOL, V58, P331, DOI 10.1016/j.ijrobp.2003.09.028; Palacios DA, 2013, BMC UROL, V13, DOI 10.1186/1471-2490-13-4; Panier S, 2013, NAT REV MOL CELL BIO, V14, P661, DOI 10.1038/nrm3659; Pavan S, 2018, ONCOGENE, V37, P4197, DOI 10.1038/s41388-018-0270-8; Polkinghorn WR, 2013, CANCER DISCOV, V3, P1245, DOI 10.1158/2159-8290.CD-13-0172; Ramsay AK, 2011, BRIT J CANCER, V104, P664, DOI 10.1038/sj.bjc.6606062; Regan CP, 2002, P NATL ACAD SCI USA, V99, P9248, DOI 10.1073/pnas.142293999; Schweppe RE, 2006, J BIOL CHEM, V281, P20993, DOI 10.1074/jbc.M604208200; Seyfried J, 2005, MOL CELL BIOL, V25, P9820, DOI 10.1128/MCB.25.22.9820-9828.2005; Shibata A, 2011, EMBO J, V30, P1079, DOI 10.1038/emboj.2011.27; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Sun WY, 2001, J BIOL CHEM, V276, P5093, DOI 10.1074/jbc.M003719200; Suzaki Y, 2002, J BIOL CHEM, V277, P9614, DOI 10.1074/jbc.M111790200; Taneja N, 2004, J BIOL CHEM, V279, P2273, DOI 10.1074/jbc.M310030200; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Tusa I, 2018, ONCOGENE, V37, DOI 10.1038/s41388-018-0164-9; Wang HC, 2006, CANCER RES, V66, P1391, DOI 10.1158/0008-5472.CAN-05-3270; Wei FX, 2013, BBA-MOL CELL RES, V1833, P90, DOI 10.1016/j.bbamcr.2012.10.016; Wu CC, 2017, INT J RADIAT ONCOL, V99, P191, DOI 10.1016/j.ijrobp.2017.05.016; Yan Lijun, 2003, BMC Dev Biol, V3, P11, DOI 10.1186/1471-213X-3-11; Zhou CH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2210; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	50	7	7	2	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	12					2467	2477		10.1038/s41388-020-1163-1	http://dx.doi.org/10.1038/s41388-020-1163-1		JAN 2020	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KW4HU	31980741	Green Accepted, Green Submitted			2022-12-28	WOS:000509176900001
J	Liang, Y; Hou, LD; Li, LJ; Li, L; Zhu, LM; Wang, Y; Huang, X; Hou, YC; Zhu, DX; Zou, HM; Gu, Y; Weng, XL; Wang, YY; Li, Y; Wu, TQ; Yao, MF; Gross, I; Gaiddon, C; Luo, M; Wang, JH; Meng, XJ				Liang, Yu; Hou, Lidan; Li, Linjing; Li, Lei; Zhu, Liming; Wang, Yu; Huang, Xin; Hou, Yichao; Zhu, Danxi; Zou, Huimin; Gu, Yan; Weng, Xiaoling; Wang, Yingying; Li, Yue; Wu, Tianqi; Yao, Mengfei; Gross, Isabelle; Gaiddon, Christian; Luo, Meng; Wang, Jianhua; Meng, Xiangjun			Dichloroacetate restores colorectal cancer chemosensitivity through the p53/miR-149-3p/PDK2-mediated glucose metabolic pathway	ONCOGENE			English	Article							PYRUVATE-DEHYDROGENASE; DRUG-RESISTANCE; INHIBITION; MICRORNAS; APOPTOSIS; GLYCOLYSIS; AXIS; DCA; FLUOROURACIL; STATISTICS	The development of chemoresistance remains a major challenge that accounts for colorectal cancer (CRC) lethality. Dichloroacetate (DCA) was originally used as a metabolic regulator in the treatment of metabolic diseases; here, DCA was assayed to identify the mechanisms underlying the chemoresistance of CRC. We found that DCA markedly enhanced chemosensitivity of CRC cells to fluorouracil (5-FU), and reduced the colony formation due to high levels of apoptosis. Using the microarray assay, we noted that miR-149-3p was involved in the chemoresistance of CRC, which was modulated by wild-type p53 after DCA treatment. In addition, PDK2 was identified as a direct target of miR-149-3p. Mechanistic analyses showed that overexpression of miR-149-3p enhanced 5-FU-induced apoptosis and reduced glucose metabolism, similar to the effects of PDK2 knockdown. In addition, overexpression of PDK2 partially reversed the inhibitory effect of miR-149-3p on glucose metabolism. Finally, both DCA treatment and miR-149-3p overexpression in 5-FU-resistant CRC cells were found to markedly sensitize the chemotherapeutic effect of 5-FU in vivo, and this effect was also validated in a small retrospective cohort of CRC patients. Taken together, we determined that the p53/miR-149-3p/PDK2 signaling pathway can potentially be targeted with DCA treatment to overcome chemoresistant CRC.	[Liang, Yu; Hou, Lidan; Li, Linjing; Li, Lei; Zhu, Liming; Wang, Yu; Huang, Xin; Hou, Yichao; Zhu, Danxi; Zou, Huimin; Meng, Xiangjun] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Gastroenterol, Sch Med, Shanghai, Peoples R China; [Gu, Yan; Luo, Meng] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Gen Surg, Sch Med, Shanghai, Peoples R China; [Weng, Xiaoling; Wu, Tianqi; Yao, Mengfei; Wang, Jianhua] Fudan Univ, Inst Canc, Shanghai Canc Ctr, Shanghai, Peoples R China; [Weng, Xiaoling] Ningbo Aitagene Technol Co LTD, Shanghai, Peoples R China; [Wang, Yingying] Shanghai Jiao Tong Univ, Dept Biochem & Mol Cell Biol, Sch Med, Shanghai, Peoples R China; [Li, Yue] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Pathol Ctr, Sch Med, Shanghai, Peoples R China; [Gross, Isabelle] INSERM, UMR S1113, F-67200 Strasbourg, France; [Gross, Isabelle] Univ Strasbourg, FMTS, F-67000 Strasbourg, France; [Gaiddon, Christian] Univ Strasbourg, INSERM, UMR S1113, IRFAC,Lab Stress Response & Innovat Therapy Strei, F-67200 Strasbourg, France; [Gaiddon, Christian] CLCC Paul Strauss, Strasbourg, France	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Fudan University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UNICANCER; Centre Paul Strauss	Meng, XJ (corresponding author), Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Gastroenterol, Sch Med, Shanghai, Peoples R China.; Luo, M (corresponding author), Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Gen Surg, Sch Med, Shanghai, Peoples R China.; Wang, JH (corresponding author), Fudan Univ, Inst Canc, Shanghai Canc Ctr, Shanghai, Peoples R China.	luotysy@sina.com; jianhuaw2007@qq.com; meng_xiangjun@yahoo.com	Gross, Isabelle/P-9859-2019; Gaiddon, Christian/F-7321-2012	Gross, Isabelle/0000-0002-2783-8773; Gaiddon, Christian/0000-0003-4315-3851	National Natural Science Foundation of China [81272745, 81872419, 81272404]; Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning	This work was supported by the National Natural Science Foundation of China (81272745, 81872419, and 81272404) and the Program for Professor of Special Appointment (Eastern Scholar to JW) at Shanghai Institutions of Higher Learning. We thank Dr Yanhong Gu for providing the 5-FU resistant HCT116 cell lines and Dr Hua Lu for providing the p53 plasmid.	Abbot EL, 2005, FEBS J, V272, P3004, DOI 10.1111/j.1742-4658.2005.04713.x; Adekola K, 2012, CURR OPIN ONCOL, V24, P650, DOI 10.1097/CCO.0b013e328356da72; Allen KT, 2015, FREE RADICAL BIO MED, V89, P263, DOI 10.1016/j.freeradbiomed.2015.08.006; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bellazzo A, 2018, CELL DEATH DIFFER, V25, P1224, DOI 10.1038/s41418-018-0088-5; Benci JL, 2016, CELL, V167, P1540, DOI 10.1016/j.cell.2016.11.022; Bertoli G, 2015, THERANOSTICS, V5, P1122, DOI 10.7150/thno.11543; Bhattacharya B, 2014, BRIT J PHARMACOL, V171, P3255, DOI 10.1111/bph.12668; Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020; Bowker-Kinley MM, 1998, BIOCHEM J, V329, P191, DOI 10.1042/bj3290191; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Cao DH, 2016, ONCOTARGET, V7, P71960, DOI 10.18632/oncotarget.12443; Chen D, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00502; Chen WQ, 2014, ANN TRANSL MED, V2, DOI 10.3978/j.issn.2305-5839.2014.04.05; Chu QSC, 2015, INVEST NEW DRUG, V33, P603, DOI 10.1007/s10637-015-0221-y; Contractor T, 2012, CANCER RES, V72, P560, DOI 10.1158/0008-5472.CAN-11-1215; Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Gnanapradeepan K, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00124; GUDI R, 1995, J BIOL CHEM, V270, P28989, DOI 10.1074/jbc.270.48.28989; Guo WJ, 2015, HEPATOLOGY, V62, P1132, DOI 10.1002/hep.27929; Hammond WA, 2016, THER ADV MED ONCOL, V8, P57, DOI 10.1177/1758834015614530; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hlouschek J, 2018, CANCER LETT, V439, P24, DOI 10.1016/j.canlet.2018.09.002; Huang SL, 2010, PROTEIN CELL, V1, P916, DOI 10.1007/s13238-010-0116-9; Hulse M, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007394; Iacopetta B, 2003, HUM MUTAT, V21, P271, DOI 10.1002/humu.10175; Kankotia S, 2014, BBA-REV CANCER, V1846, P617, DOI 10.1016/j.bbcan.2014.08.005; Kato M, 2007, STRUCTURE, V15, P992, DOI 10.1016/j.str.2007.07.001; Kim JW, 2006, CANCER RES, V66, P8927, DOI 10.1158/0008-5472.CAN-06-1501; Kimmelman AC, 2017, CELL METAB, V25, P1037, DOI 10.1016/j.cmet.2017.04.004; Kluza J, 2012, CANCER RES, V72, P5035, DOI 10.1158/0008-5472.CAN-12-0979; Li G, 2017, ONCOGENE, V36, P989, DOI 10.1038/onc.2016.265; Madhok BM, 2010, BRIT J CANCER, V102, P1746, DOI 10.1038/sj.bjc.6605701; Michelakis ED, 2008, BRIT J CANCER, V99, P989, DOI 10.1038/sj.bjc.6604554; Michelakis ED, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000677; Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349; Morgan RA, 2010, MOL THER, V18, P843, DOI 10.1038/mt.2010.24; Papandreou I, 2011, INT J CANCER, V128, P1001, DOI 10.1002/ijc.25728; Qiu ZP, 2015, GASTROENTEROLOGY, V149, P1587, DOI 10.1053/j.gastro.2015.07.050; Roh JL, 2016, CANCER LETT, V371, P20, DOI 10.1016/j.canlet.2015.11.023; Saltz LB, 2000, NEW ENGL J MED, V343, P905, DOI 10.1056/NEJM200009283431302; Shahrzad S, 2010, CANCER LETT, V297, P75, DOI 10.1016/j.canlet.2010.04.027; Shaw RJ, 2006, CURR OPIN CELL BIOL, V18, P598, DOI 10.1016/j.ceb.2006.10.005; Shen YC, 2013, BRIT J CANCER, V108, P72, DOI 10.1038/bjc.2012.559; Shroads AL, 2008, J PHARMACOL EXP THER, V324, P1163, DOI 10.1124/jpet.107.134593; Si LL, 2017, BRIT J PHARMACOL, V174, P553, DOI 10.1111/bph.13718; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Stacpoole PW, 2003, J CLIN PHARMACOL, V43, P683, DOI 10.1177/0091270003254637; STACPOOLE PW, 1989, METABOLISM, V38, P1124, DOI 10.1016/0026-0495(89)90051-6; Sugden MC, 2003, AM J PHYSIOL-ENDOC M, V284, pE855, DOI 10.1152/ajpendo.00526.2002; Sutendra G, 2013, ONCOGENE, V32, P1638, DOI 10.1038/onc.2012.198; Van Dang C, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-1; Vazquez A, 2008, NAT REV DRUG DISCOV, V7, P979, DOI 10.1038/nrd2656; Velpula KK, 2013, CANCER RES, V73, P7277, DOI 10.1158/0008-5472.CAN-13-1868; Xu RH, 2005, CANCER RES, V65, P613; Xuan Y, 2014, EXP CELL RES, V321, P219, DOI 10.1016/j.yexcr.2013.12.009; Zhang Y, 2017, BIOL CHEM, V398, P929, DOI 10.1515/hsz-2016-0308; Zhao Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.60	60	53	55	2	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	2					469	485		10.1038/s41388-019-1035-8	http://dx.doi.org/10.1038/s41388-019-1035-8			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KD3JY	31597953	Green Published, hybrid			2022-12-28	WOS:000507766400016
J	Ying, Y; Wang, YJ; Huang, XY; Sun, YM; Zhang, JB; Li, MQ; Zeng, JH; Wang, ML; Xiao, WJ; Zhong, L; Xu, B; Li, LL; Tao, Q; Wang, XM; Shu, XS				Ying, Ying; Wang, Yejun; Huang, Xiaoyan; Sun, Yanmei; Zhang, Junbao; Li, Meiqi; Zeng, Junhui; Wang, Maolin; Xiao, Wenjun; Zhong, Lan; Xu, Bo; Li, Lili; Tao, Qian; Wang, Xiaomei; Shu, Xing-sheng			Oncogenic HOXB8 is driven by MYC-regulated super-enhancer and potentiates colorectal cancer invasiveness via BACH1	ONCOGENE			English	Article							OXIDATIVE STRESS-RESPONSE; LONG-RANGE INTERACTION; TRANSCRIPTION FACTORS; CELL DEVELOPMENT; GENES; DIFFERENTIATION; DEREGULATION; METASTASIS; INHIBITION; EXPRESSION	Aberrant activation of Homeobox genes in human cancers has long been documented, whereas the mechanisms underlying remain largely obscure. Super-enhancers (SEs) act as key regulatory elements for both cell identity genes and cancer genes. Herein, we reported that SE-associated HOXB gene cluster represented a common feature of colorectal cancer (CRC) cell lines and multiple HOXB genes within this cluster were overexpressed in CRC. Among them, we found that HOXB8 was oncogenic and its activation in CRC was driven by SE instead of genetic alteration. We further demonstrated that the master transcription factor MYC preferentially occupied SEs over TEs (typical enhancers) and regulated HOXB8 transcription by binding to the active elements of its SE. HOXB8 silencing induced reversal of transcriptional signatures associated with malignant phenotypes of CRC. Mechanistically, HOXB8 interacted with a key metastasis regulator BACH1 and instigated BACH1-mediated transcriptional cascade by directly occupying and activating BACH1 gene transcription together with BACH1 itself. Lastly, the relevance of HOXB8 activation in clinical settings was strengthened by its close association with prognostic outcomes of CRC patients.	[Ying, Ying; Wang, Yejun; Huang, Xiaoyan; Sun, Yanmei; Zhang, Junbao; Li, Meiqi; Zeng, Junhui; Wang, Maolin; Xiao, Wenjun; Wang, Xiaomei; Shu, Xing-sheng] Shenzhen Univ, Hlth Sci Ctr, Sch Med, Dept Physiol, Shenzhen 518060, Peoples R China; [Zhong, Lan] Sichuan Univ, West China Hosp 2, Dept Gynecol & Obstet, Chengdu 610041, Peoples R China; [Xu, Bo] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjin 300070, Peoples R China; [Li, Lili; Tao, Qian] Chinese Univ Hong Kong, Sir YK Pao Ctr Canc, Dept Clin Oncol, Canc Epigenet Lab, Hong Kong 00000, Peoples R China	Shenzhen University; Sichuan University; Tianjin Medical University; Chinese University of Hong Kong	Shu, XS (corresponding author), Shenzhen Univ, Hlth Sci Ctr, Sch Med, Dept Physiol, Shenzhen 518060, Peoples R China.	shu@szu.edu.cn	Li, Lili/Q-5750-2018	Li, Lili/0000-0002-0292-5889	Shenzhen Commission of Science and Innovation Programs [JCYJ20170817101008912, JCYJ20170818143305472, JCYJ20160331114230843]; National Key Projects of Research and Development of China [2016YFC0904600]; Natural Science Foundation of Shenzhen University for Overseas High-Caliber Personnel [827000111]; National Natural Science Foundation of China [81670760]; Guangdong Health Committee [B2019104]	Shenzhen Commission of Science and Innovation Programs; National Key Projects of Research and Development of China; Natural Science Foundation of Shenzhen University for Overseas High-Caliber Personnel; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Health Committee	This work was supported by Shenzhen Commission of Science and Innovation Programs [JCYJ20170817101008912, JCYJ20170818143305472, JCYJ20160331114230843], National Key Projects of Research and Development of China [2016YFC0904600], Natural Science Foundation of Shenzhen University for Overseas High-Caliber Personnel [827000111], National Natural Science Foundation of China [81670760] and grant from Guangdong Health Committee [B2019104]. We thank technical support from Instrumental Analysis Center of Shenzhen University (Xili Campus), and thank Mr Shikang Liu, and Ms Danhong Qiu for technical assistance.	Ahmadiyeh N, 2010, P NATL ACAD SCI USA, V107, P9742, DOI 10.1073/pnas.0910668107; Akhtar-Zaidi B, 2012, SCIENCE, V336, P736, DOI 10.1126/science.1217277; Alharbi RA, 2013, LEUKEMIA, V27, P1000, DOI 10.1038/leu.2012.356; Banerjee-Basu S, 2001, NUCLEIC ACIDS RES, V29, P3258, DOI 10.1093/nar/29.15.3258; BLATT C, 1992, CELL GROWTH DIFFER, V3, P671; Bradner JE, 2017, CELL, V168, P629, DOI 10.1016/j.cell.2016.12.013; Cohen AJ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14400; Ding WJ, 2017, J CANCER RES CLIN, V143, P385, DOI 10.1007/s00432-016-2283-4; Grier DG, 2005, J PATHOL, V205, P154, DOI 10.1002/path.1710; Groschel S, 2014, CELL, V157, P369, DOI 10.1016/j.cell.2014.02.019; Herranz D, 2014, NAT MED, V20, P1130, DOI 10.1038/nm.3665; Hnisz D, 2013, CELL, V155, P934, DOI 10.1016/j.cell.2013.09.053; Igarashi K, 2006, ANTIOXID REDOX SIGN, V8, P107, DOI 10.1089/ars.2006.8.107; Igarashi K, 2017, NAT REV IMMUNOL, V17, P437, DOI 10.1038/nri.2017.26; Itoh-Nakadai A, 2014, NAT IMMUNOL, V15, P1171, DOI 10.1038/ni.3024; Ke LR, 2017, P NATL ACAD SCI USA, V114, P9683, DOI 10.1073/pnas.1705236114; Knoepfler PS, 2001, ONCOGENE, V20, P5440, DOI 10.1038/sj.onc.1204710; Lambert SA, 2018, CELL, V172, P650, DOI 10.1016/j.cell.2018.01.029; Liang YJ, 2012, J BIOL CHEM, V287, P33533, DOI 10.1074/jbc.M112.392332; Loven J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036; Mallo M, 2013, DEVELOPMENT, V140, P3951, DOI 10.1242/dev.068346; Mansour MR, 2014, SCIENCE, V346, P1373, DOI 10.1126/science.1259037; McCleland ML, 2016, J CLIN INVEST, V126, P639, DOI 10.1172/JCI83265; McFarland JM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06916-5; Merlos-Suarez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020; Northcott PA, 2014, NATURE, V511, P428, DOI 10.1038/nature13379; Pearson JC, 2005, NAT REV GENET, V6, P893, DOI 10.1038/nrg1726; Pomerantz MM, 2009, NAT GENET, V41, P882, DOI 10.1038/ng.403; Redecke V, 2013, NAT METHODS, V10, P795, DOI [10.1038/nmeth.2510, 10.1038/NMETH.2510]; Sengupta S, 2017, TRENDS CANCER, V3, P269, DOI 10.1016/j.trecan.2017.03.006; Shah N, 2010, NAT REV CANCER, V10, P361, DOI 10.1038/nrc2826; Shajari N, 2018, ARTIF CELL NANOMED B, V46, P1495, DOI 10.1080/21691401.2017.1374284; Shin HJ, 2009, BIOINFORMATICS, V25, P2605, DOI 10.1093/bioinformatics/btp479; Shlyueva D, 2014, NAT REV GENET, V15, P272, DOI 10.1038/nrg3682; Shu XS, 2018, J PATHOL, V244, P36, DOI 10.1002/path.4986; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sur I, 2016, NAT REV CANCER, V16, P483, DOI 10.1038/nrc.2016.62; Thakore PI, 2015, NAT METHODS, V12, P1143, DOI 10.1038/nmeth.3630; Vider BZ, 1997, BIOCHEM BIOPH RES CO, V232, P742, DOI 10.1006/bbrc.1997.6364; Warnatz HJ, 2011, J BIOL CHEM, V286, P23521, DOI 10.1074/jbc.M111.220178; Whyte WA, 2013, CELL, V153, P307, DOI 10.1016/j.cell.2013.03.035; Xiong X, 2017, ACS SYNTH BIOL, V6, P1034, DOI 10.1021/acssynbio.6b00358; Zhang XY, 2018, CANCER DISCOV, V8, P108, DOI 10.1158/2159-8290.CD-17-0532; Zhang XY, 2016, NAT GENET, V48, P176, DOI 10.1038/ng.3470; Zhu GD, 2018, BIOCHEM BIOPH RES CO, V499, P120, DOI 10.1016/j.bbrc.2018.02.178	45	29	29	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	5					1004	1017		10.1038/s41388-019-1013-1	http://dx.doi.org/10.1038/s41388-019-1013-1			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KI2VY	31591481				2022-12-28	WOS:000511209700004
J	Wang, GW; Wang, J; Chang, AT; Cheng, DM; Huang, S; Wu, D; Sirkisoon, S; Yang, S; Lin, HK; Lo, HW; Xiang, R; Sun, PQ				Wang, Guanwen; Wang, Juan; Chang, Antao; Cheng, Dongmei; Huang, Shan; Wu, Dan; Sirkisoon, Sherona; Yang, Shuang; Lin, Hui-Kuan; Lo, Hui-Wen; Xiang, Rong; Sun, Peiqing			Her2 promotes early dissemination of breast cancer by suppressing the p38 pathway through Skp2-mediated proteasomal degradation of Tpl2	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; MAP KINASE; CELL DISSEMINATION; CATENIN COMPLEX; BETA-CATENIN; ACTIVATION; PHOSPHORYLATION; INVASION; TUMORIGENESIS; PROGRESSION	While mechanisms for metastasis were extensively studied in cancer cells from patients with detectable tumors, pathways underlying metastatic dissemination from early lesions before primary tumors appear are poorly understood. Her2 promotes breast cancer early dissemination by suppressing p38, but how Her2 downregulates p38 is unclear. Here, we demonstrate that in early lesion breast cancer models, Her2 inhibits p38 by inducing Skp2 through Akt-mediated phosphorylation, which promotes ubiquitination and proteasomal degradation of Tpl2, a p38 MAP3K. The early disseminating cells are Her2(+)Skp2(high)Tpl2(low)p-p38(low)E-cadherin(low)in the MMTV-Her2 breast cancer model. In human breast carcinoma, high Skp2 and low Tpl2 expression are associated with the Her2(+)status; Tpl2 expression positively correlates with that of activated p38; Skp2 expression negatively correlates with that of Tpl2 and activated p38. Moreover, the Her2-Akt-Skp2-Tpl2-p38 axis plays a key role in the disseminating phenotypes in early lesion breast cancer cells; inhibition of Tpl2 enhances early dissemination in vivo. These findings identify the Her2-Akt-Skp2-Tpl2-p38 cascade as a novel mechanism mediating breast cancer early dissemination and a potential target for novel therapies targeting early metastatic dissemination.	[Wang, Guanwen; Wang, Juan; Chang, Antao; Cheng, Dongmei; Huang, Shan; Wu, Dan; Sirkisoon, Sherona; Lin, Hui-Kuan; Lo, Hui-Wen; Sun, Peiqing] Nankai Univ, Sch Med, Dept Immunol, Tianjin, Peoples R China; [Wang, Guanwen; Wang, Juan; Chang, Antao; Huang, Shan; Yang, Shuang; Xiang, Rong] Wake Forest Baptist Med Ctr, Dept Canc Biol, Winston Salem, NC 27157 USA; [Wang, Guanwen; Wang, Juan; Chang, Antao; Huang, Shan; Yang, Shuang; Xiang, Rong] Wake Forest Baptist Med Ctr, Ctr Comprehens Canc, Winston Salem, NC USA	Nankai University; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Sun, PQ (corresponding author), Nankai Univ, Sch Med, Dept Immunol, Tianjin, Peoples R China.; Xiang, R (corresponding author), Wake Forest Baptist Med Ctr, Dept Canc Biol, Winston Salem, NC 27157 USA.	rxiang@nankai.edu.cn; psun@wakehealth.edu		Lo, Hui-Wen/0000-0002-0681-7914; Lin, Hui-Kuan/0000-0002-3501-2410	NIH/NCI [CA131231, CA172115, P30CA012197]; Bilateral Inter-Governmental S&T Cooperation Project grants from Ministry of Science and Technology of China [81972882, 2018YFE0114300]; Cell Engineering Shared Resource of WFBCCC; Tumor Tissue and Pathology Shared Resource of WFBCCC	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Bilateral Inter-Governmental S&T Cooperation Project grants from Ministry of Science and Technology of China; Cell Engineering Shared Resource of WFBCCC; Tumor Tissue and Pathology Shared Resource of WFBCCC	We thank Cell Engineering and Tumor Tissue and Pathology Shared Resources of WFBCCC for support. This study was supported by NIH/NCI grants CA131231, CA172115, and P30CA012197 (PS) and Bilateral Inter-Governmental S&T Cooperation Project grants from Ministry of Science and Technology of China (81972882 and 2018YFE0114300) (RX). PS is an Anderson Oncology Research Professor.	ABBRUZZESE JL, 1994, J CLIN ONCOL, V12, P1272, DOI 10.1200/JCO.1994.12.6.1272; Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Anwar T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05078-8; Barrantes ID, 2012, BIOCHEM SOC T, V40, P79, DOI 10.1042/BST20110676; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Beinke S, 2004, MOL CELL BIOL, V24, P9658, DOI 10.1128/MCB.24.21.9658-9667.2004; Bulavin DV, 2004, ADV CANCER RES, V92, P95, DOI 10.1016/S0065-230X(04)92005-2; Candas D, 2014, CANCER RES, V74, P7498, DOI 10.1158/0008-5472.CAN-14-0844; Chan CH, 2012, CELL, V149, P1098, DOI 10.1016/j.cell.2012.02.065; Chan CH, 2010, THESCIENTIFICWORLDJO, V10, P1001, DOI 10.1100/tsw.2010.89; Cho J, 2005, J BIOL CHEM, V280, P20442, DOI 10.1074/jbc.M413554200; Cuadrado A, 2010, BIOCHEM J, V429, P403, DOI 10.1042/BJ20100323; DeCicco-Skinner KL, 2011, ONCOGENE, V30, P389, DOI 10.1038/onc.2010.447; Dodhiawala PB, 2020, J CLIN INVEST, V130, P4771, DOI 10.1172/JCI137660; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Ellinger-Ziegelbauer H, 1999, MOL CELL BIOL, V19, P3857; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Eyles J, 2010, J CLIN INVEST, V120, P2030, DOI 10.1172/JCI42002; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Gantke T, 2012, IMMUNOL REV, V246, P168, DOI 10.1111/j.1600-065X.2012.01104.x; Gao DM, 2009, NAT CELL BIOL, V11, P397, DOI 10.1038/ncb1847; Gkirtzimanaki K, 2013, P NATL ACAD SCI USA, V110, pE1470, DOI 10.1073/pnas.1215938110; Gong J, 2019, HEPATOLOGY, V69, P524, DOI 10.1002/hep.29820; Han YC, 2017, ONCOL REP, V38, P3574, DOI 10.3892/or.2017.6017; Harper KL, 2016, NATURE, V540, P588, DOI 10.1038/nature20609; Huang S, 2000, J BIOL CHEM, V275, P12266, DOI 10.1074/jbc.275.16.12266; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Kang YB, 2013, CANCER CELL, V23, P573, DOI 10.1016/j.ccr.2013.04.017; Kato H, 2020, ONCOGENE, V39, P3322, DOI 10.1038/s41388-020-1218-3; Kim G, 2015, MOL CARCINOGEN, V54, P440, DOI 10.1002/mc.22112; Kim K, 2014, CARCINOGENESIS, V35, P1352, DOI 10.1093/carcin/bgu044; Krcova Z, 2008, BIOMED PAP, V152, P21, DOI 10.5507/bp.2008.003; Lin HK, 2009, NAT CELL BIOL, V11, P420, DOI 10.1038/ncb1849; Lopez-Lazaro Miguel, 2015, Oncoscience, V2, P467; Mamillapalli R, 2001, CURR BIOL, V11, P263, DOI 10.1016/S0960-9822(01)00065-3; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Narod SA, 2015, JAMA ONCOL, V1, P888, DOI 10.1001/jamaoncol.2015.2510; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Pantel K, 2004, NAT REV CANCER, V4, P448, DOI 10.1038/nrc1370; Pattison MJ, 2016, BIOCHEM J, V473, P2845, DOI 10.1042/BCJ20160502; Riethmuller G, 2001, SEMIN CANCER BIOL, V11, P307, DOI 10.1006/scbi.2001.0386; Ruiz-Saenz A, 2018, CANCER RES, V78, P3645, DOI 10.1158/0008-5472.CAN-18-0430; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; Senger K, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aah4273; She QB, 2001, CANCER RES, V61, P1604; Shi Y, 2002, BIOL CHEM, V383, P1519, DOI 10.1515/BC.2002.173; Slack DN, 2001, J BIOL CHEM, V276, P16491, DOI 10.1074/jbc.M010966200; Sosa MS, 2011, CLIN CANCER RES, V17, P5850, DOI 10.1158/1078-0432.CCR-10-2574; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wei W, 2016, CANCER CELL, V29, P563, DOI 10.1016/j.ccell.2016.03.012; Weidensdorfer D, 2009, RNA, V15, P104, DOI 10.1261/rna.1175909; Wen HC, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001684; Wisinski KB, 2016, CLIN CANCER RES, V22, P2659, DOI 10.1158/1078-0432.CCR-15-2365; Wu MZ, 2015, CANCER RES, V75, P3912, DOI 10.1158/0008-5472.CAN-14-3208; Xu L, 2006, ONCOGENE, V25, P2987, DOI 10.1038/sj.onc.1209337; Yan MH, 2019, IMMUNOBIOLOGY, V224, P383, DOI 10.1016/j.imbio.2019.02.010; Zheng H, 2013, MOL CELL, V50, P699, DOI 10.1016/j.molcel.2013.04.013	59	6	6	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	2020	39	47					7034	7050		10.1038/s41388-020-01481-y	http://dx.doi.org/10.1038/s41388-020-01481-y		SEP 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OT7KA	32989258	Green Accepted			2022-12-28	WOS:000573446900005
J	Lin, SR; Wen, YC; Yeh, HL; Jiang, KC; Chen, WH; Mokgautsi, N; Huang, J; Chen, WY; Liu, YN				Lin, Shian-Ren; Wen, Yu-Ching; Yeh, Hsiu-Lien; Jiang, Kuo-Ching; Chen, Wei-Hao; Mokgautsi, Ntlotlang; Huang, Jiaoti; Chen, Wei-Yu; Liu, Yen-Nien			EGFR-upregulated LIFR promotes SUCLG2-dependent castration resistance and neuroendocrine differentiation of prostate cancer	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; MITOCHONDRIAL-DNA CONTENT; ANDROGEN RECEPTOR; STEM-CELLS; EXPRESSION; ACTIVATION; MECHANISMS; STAT3; ADENOCARCINOMAS; LOCALIZATION	Neuroendocrine (NE) differentiation is a well-recognized phenotypic change of prostate cancer after androgen deprivation therapy (ADT), and it ultimately develops into an aggressive subset of this disease. However, the contribution of signaling pathways that lead to metabolic disorders and NE differentiation of prostate cancer remains unclear. In this study, we identified that ADT induced upregulation of the succinate-CoA ligase GDP-forming beta subunit (SUCLG2), which regulates succinate metabolism and NE differentiation of prostate cancer. We demonstrated a connection that upregulation of epidermal growth factor receptor (EGFR)-leukemia inhibitory factor receptor (LIFR) signaling induced SUCLG2 expression in prostate cancer cells. The LIFR is upregulated by nuclear EGFR, which acts as a transcriptional regulator, directly binds to theLIFRpromoter, and drives NE differentiation and glycolysis of prostate cancer. LIFR upregulation is associated with SUCLG2, which increased succinate synthesis and enzymatic activities of mitochondrial nucleoside diphosphate kinase (NDPK) in prostate cancer cells. Knockdown of SUCLG2 suppressed NE differentiation in cultured cells and reduced prostate tumor growth in a xenograft model. Analysis of prostate tissue samples showed increased intensity of nuclear EGFR associated with the LIFR and SUCLG2 in castration-resistant prostate cancer tumors. Our study provides a mechanism whereby ADT upregulates EGFR-LIFR signaling that activates SUCLG2, which subsequently stimulates the metabolic changes associated with NE differentiation and aggressive prostate cancer phenotype.	[Lin, Shian-Ren; Jiang, Kuo-Ching; Chen, Wei-Hao; Mokgautsi, Ntlotlang; Liu, Yen-Nien] Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, Coll Med Sci & Technol, Taipei, Taiwan; [Wen, Yu-Ching] Taipei Med Univ, Wan Fang Hosp, Dept Urol, Taipei, Taiwan; [Wen, Yu-Ching] Taipei Med Univ, Sch Med, Dept Urol, Coll Med, Taipei, Taiwan; [Yeh, Hsiu-Lien] Natl Tsing Hua Univ, Inst Informat Syst & Applicat, Hsinchu, Taiwan; [Huang, Jiaoti; Liu, Yen-Nien] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; [Chen, Wei-Yu] Taipei Med Univ, Wan Fang Hosp, Dept Pathol, Taipei, Taiwan; [Chen, Wei-Yu] Taipei Med Univ, Sch Med, Dept Pathol, Coll Med, Taipei, Taiwan	Taipei Medical University; Taipei Medical University; Taipei Municipal WanFang Hospital; Taipei Medical University; National Tsing Hua University; Duke University; Taipei Medical University; Taipei Municipal WanFang Hospital; Taipei Medical University	Liu, YN (corresponding author), Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, Coll Med Sci & Technol, Taipei, Taiwan.; Liu, YN (corresponding author), Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA.; Chen, WY (corresponding author), Taipei Med Univ, Wan Fang Hosp, Dept Pathol, Taipei, Taiwan.; Chen, WY (corresponding author), Taipei Med Univ, Sch Med, Dept Pathol, Coll Med, Taipei, Taiwan.	1047@tmu.edu.tw; liuy@tmu.edu.tw	Lin, Shian-Ren/AAR-6238-2020; Liu, Yen-Nien/AAW-4698-2021	Lin, Shian-Ren/0000-0002-4160-2361; 	Ministry of Science and Technology of Taiwan [MOST108-2320-B-038-047, MOST 109-2314-B-038-105, MOST109-2326-B-038-001-MY3]; Taipei Medical University-Wan Fang Hospital [109TMU-WFH-01]; National Health Research Institute of Taiwan [NHRI-EX109-10702BI]	Ministry of Science and Technology of Taiwan(Ministry of Science and Technology, Taiwan); Taipei Medical University-Wan Fang Hospital; National Health Research Institute of Taiwan(National Health Research Institutes - Taiwan)	This work was jointly supported by grants from the Ministry of Science and Technology of Taiwan (MOST108-2320-B-038-047) to WYC, (MOST 109-2314-B-038-105) to YCW, and (MOST109-2326-B-038-001-MY3) to YNL, Taipei Medical University-Wan Fang Hospital (109TMU-WFH-01) to WYC, and the National Health Research Institute of Taiwan (NHRI-EX109-10702BI) to YNL.	Aggarwal R, 2018, J CLIN ONCOL, V36, P2492, DOI 10.1200/JCO.2017.77.6880; Cortes MA, 2012, CARCINOGENESIS, V33, P1169, DOI 10.1093/carcin/bgs139; Angelescu R, 2013, ENDOSC ULTRASOUND, V2, P86, DOI [10.4103/2303-9027.117692, 10.7178/eus.05.005]; Beltran H, 2019, CLIN CANCER RES, V25, P6916, DOI 10.1158/1078-0432.CCR-19-1423; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Brand TM, 2013, RADIOTHER ONCOL, V108, P370, DOI 10.1016/j.radonc.2013.06.010; Brand TM, 2011, DISCOV MED, V12, P419; Bressy C, 2018, CANCER RES, V78, P909, DOI 10.1158/0008-5472.CAN-15-2790; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Cai CM, 2009, CANCER RES, V69, P5202, DOI 10.1158/0008-5472.CAN-09-0026; Chang YS, 2015, CANCER RES, V75, P3077, DOI 10.1158/0008-5472.CAN-14-3380; Chen L, 2020, GUT, V69, P630, DOI 10.1136/gutjnl-2019-318325; Chiarugi P, 2014, SEMIN ONCOL, V41, P267, DOI 10.1053/j.seminoncol.2014.03.004; Chicas A, 2010, CANCER CELL, V17, P376, DOI 10.1016/j.ccr.2010.01.023; Choueiri TK, 2009, CANCER, V115, P981, DOI 10.1002/cncr.24064; Chua CY, 2016, ONCOGENE, V35, P738, DOI 10.1038/onc.2015.131; Dai C, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a030452; Day KC, 2017, CANCER RES, V77, P74, DOI 10.1158/0008-5472.CAN-16-1656; DISANTAGNESE PA, 1992, HUM PATHOL, V23, P287; Dobolyi A, 2015, J BIOENERG BIOMEMBR, V47, P33, DOI 10.1007/s10863-014-9586-4; Dobolyi A, 2015, BRAIN STRUCT FUNCT, V220, P135, DOI 10.1007/s00429-013-0643-2; Dziennis S, 2008, REV NEUROSCIENCE, V19, P341; Egan Kathryn, 2010, J Clin Med Res, V2, P225, DOI 10.4021/jocmr443w; Faraco CCF, 2018, J STRUCT BIOL, V202, P61, DOI 10.1016/j.jsb.2017.12.007; Gagliano-Juca T, 2018, J CLIN ENDOCR METAB, V103, P3900, DOI 10.1210/jc.2018-01068; Heidenreich A, 2014, EUR UROL, V65, P467, DOI 10.1016/j.eururo.2013.11.002; Hoshino M, 2007, PATHOBIOLOGY, V74, P15, DOI 10.1159/000101047; Hsing AW, 2007, AM J CLIN NUTR, V86, p843S, DOI 10.1093/ajcn/86.3.843S; Huang JT, 2006, PROSTATE, V66, P1399, DOI 10.1002/pros.20434; Humez S, 2006, ENDOCR-RELAT CANCER, V13, P181, DOI 10.1677/erc.1.01079; Kharmate G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154967; Kim J, 2019, CELL METAB, V30, P434, DOI 10.1016/j.cmet.2019.08.013; Kim MM, 2004, CLIN CANCER RES, V10, P8512, DOI 10.1158/1078-0432.CCR-04-0734; LI M, 1995, NATURE, V378, P724, DOI 10.1038/378724a0; Li QH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06067-7; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Liu YN, 2019, CLIN CANCER RES, V25, P4128, DOI 10.1158/1078-0432.CCR-18-3239; Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007; Madshus IH, 2009, J CELL SCI, V122, P3433, DOI 10.1242/jcs.050260; Mahdavi A, 2007, PLOS COMPUT BIOL, V3, P1257, DOI 10.1371/journal.pcbi.0030130; Marcoux N, 2019, J CLIN ONCOL, V37, P278, DOI 10.1200/JCO.18.01585; Martin-Orozco RM, 2007, NEOPLASIA, V9, P614, DOI 10.1593/neo.07337; Miller C, 2011, BBA-MOL BASIS DIS, V1812, P625, DOI 10.1016/j.bbadis.2011.01.013; Mizumachi T, 2008, PROSTATE, V68, P408, DOI 10.1002/pros.20697; Mosquera JM, 2013, NEOPLASIA, V15, P1, DOI 10.1593/neo.121550; Nelson PS, 2002, P NATL ACAD SCI USA, V99, P11890, DOI 10.1073/pnas.182376299; Nicola NA, 2015, CYTOKINE GROWTH F R, V26, P533, DOI 10.1016/j.cytogfr.2015.07.001; Onishi K, 2015, DEVELOPMENT, V142, P2230, DOI 10.1242/dev.117598; Papouchado B, 2005, MODERN PATHOL, V18, P1329, DOI 10.1038/modpathol.3800427; Peraldo-Neia C, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-31; Read J, 2017, EUR J CANCER, V70, P62, DOI 10.1016/j.ejca.2016.10.017; Rimawi MF, 2010, CANCER-AM CANCER SOC, V116, P1234, DOI 10.1002/cncr.24816; Rooney JP, 2015, METHODS MOL BIOL, V1241, P23, DOI 10.1007/978-1-4939-1875-1_3; Sasaki T, 2018, J CLIN MED, V7, DOI 10.3390/jcm7120565; Scaltriti M, 2006, CLIN CANCER RES, V12, P5268, DOI 10.1158/1078-0432.CCR-05-1554; Schindelin J, 2015, MOL REPROD DEV, V82, P518, DOI 10.1002/mrd.22489; Shah T, 2006, J NEUROENDOCRINOL, V18, P355, DOI 10.1111/j.1365-2826.2006.01425.x; Shao JL, 2019, CANCER LETT, V451, P110, DOI 10.1016/j.canlet.2019.02.042; Spiotto MT, 2000, PROSTATE, V42, P88, DOI 10.1002/(SICI)1097-0045(20000201)42:2<88::AID-PROS2>3.0.CO;2-P; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tanaka T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016295; Thomas R, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00800; Timofeeva OA, 2012, J BIOL CHEM, V287, P14192, DOI 10.1074/jbc.M111.323899; Traish AM, 2009, BRIT J CANCER, V101, P1949, DOI 10.1038/sj.bjc.6605376; Tsai YC, 2017, CANCER LETT, V384, P1, DOI 10.1016/j.canlet.2016.10.014; Vlachostergios PJ, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00006; Wang G, 2006, ONCOGENE, V25, P7311, DOI 10.1038/sj.onc.1209715; Wang Y, 2006, BRIT J CANCER, V95, P1087, DOI 10.1038/sj.bjc.6603377; Williamson SR, 2011, MODERN PATHOL, V24, P1120, DOI 10.1038/modpathol.2011.56; Wu HX, 2018, BBA-MOL BASIS DIS, V1864, P2769, DOI 10.1016/j.bbadis.2018.05.004; Xu RH, 2005, CANCER RES, V65, P613; Xue Y, 1997, AM J PATHOL, V151, P1759; Zhang XQ, 2003, ONCOGENE, V22, P6704, DOI 10.1038/sj.onc.1206764	73	15	15	2	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2020	39	44					6757	6775		10.1038/s41388-020-01468-9	http://dx.doi.org/10.1038/s41388-020-01468-9		SEP 2020	19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OH9QS	32963351				2022-12-28	WOS:000572030400001
J	Goodsell, DS; Burley, SK				Goodsell, David S.; Burley, Stephen K.			RCSB Protein Data Bank tools for 3D structure-guided cancer research: human papillomavirus (HPV) case study	ONCOGENE			English	Review							CRYSTAL-STRUCTURES; MECHANISM; VALIDATION	Atomic-level three-dimensional (3D) structure data for biological macromolecules often prove critical to dissecting and understanding the precise mechanisms of action of cancer-related proteins and their diverse roles in oncogenic transformation, proliferation, and metastasis. They are also used extensively to identify potentially druggable targets and facilitate discovery and development of both small-molecule and biologic drugs that are today benefiting individuals diagnosed with cancer around the world. 3D structures of biomolecules (including proteins, DNA, RNA, and their complexes with one another, drugs, and other small molecules) are freely distributed by the open-access Protein Data Bank (PDB). This global data repository is used by millions of scientists and educators working in the areas of drug discovery, vaccine design, and biomedical and biotechnology research. The US Research Collaboratory for Structural Bioinformatics Protein Data Bank (RCSB PDB) provides an integrated portal to the PDB archive that streamlines access for millions of worldwide PDB data consumers worldwide. Herein, we review online resources made available free of charge by the RCSB PDB to basic and applied researchers, healthcare providers, educators and their students, patients and their families, and the curious public. We exemplify the value of understanding cancer-related proteins in 3D with a case study focused on human papillomavirus.	[Goodsell, David S.; Burley, Stephen K.] Rutgers State Univ, Res Collaboratory Struct Bioinformat Prot Data Ba, Piscataway, NJ 08854 USA; [Goodsell, David S.; Burley, Stephen K.] Rutgers State Univ, Inst Quantitat Biomed, Piscataway, NJ 08854 USA; [Goodsell, David S.] Scripps Res Inst, Dept Integrat Struct & Computat Biol, La Jolla, CA 92037 USA; [Burley, Stephen K.] Rutgers State Univ, Dept Chem & Chem Biol, Piscataway, NJ 08854 USA; [Burley, Stephen K.] Univ Calif San Diego, San Diego Supercomp Ctr, Res Collaboratory Struct Bioinformat Prot Data Ba, La Jolla, CA 92093 USA; [Burley, Stephen K.] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA; [Burley, Stephen K.] Rutgers State Univ, Rutgers Canc Inst New Jersey, New Brunswick, NJ 08903 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Scripps Research Institute; Rutgers State University New Brunswick; University of California System; University of California San Diego; University of California System; University of California San Diego; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Goodsell, DS; Burley, SK (corresponding author), Rutgers State Univ, Res Collaboratory Struct Bioinformat Prot Data Ba, Piscataway, NJ 08854 USA.; Goodsell, DS; Burley, SK (corresponding author), Rutgers State Univ, Inst Quantitat Biomed, Piscataway, NJ 08854 USA.; Goodsell, DS (corresponding author), Scripps Res Inst, Dept Integrat Struct & Computat Biol, La Jolla, CA 92037 USA.; Burley, SK (corresponding author), Rutgers State Univ, Dept Chem & Chem Biol, Piscataway, NJ 08854 USA.; Burley, SK (corresponding author), Univ Calif San Diego, San Diego Supercomp Ctr, Res Collaboratory Struct Bioinformat Prot Data Ba, La Jolla, CA 92093 USA.; Burley, SK (corresponding author), Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA.; Burley, SK (corresponding author), Rutgers State Univ, Rutgers Canc Inst New Jersey, New Brunswick, NJ 08903 USA.	David.Goodsell@rcsb.org; Stephen.Burley@rcsb.org		Burley, Stephen K./0000-0002-2487-9713	National Science Foundation [DBI-1832184]; US Department of Energy [DE-SC0019749]; National Cancer Institute of the National Institutes of Health [R01GM133198]; National Institute of General Medical Sciences of the National Institutes of Health [R01GM133198]; National Institute of Allergy and Infectious Diseases of the National Institutes of Health [R01GM133198]	National Science Foundation(National Science Foundation (NSF)); US Department of Energy(United States Department of Energy (DOE)); National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of General Medical Sciences of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); National Institute of Allergy and Infectious Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We gratefully acknowledge discussions with Drs. X.F. Steven Zheng and Shridar Ganesan and other members of the Rutgers Cancer Institute of New Jersey, and contributions from all members of the RCSB PDB and our wwPDB partners around the world. RCSB PDB is jointly funded by grants to SKB from the National Science Foundation (DBI-1832184), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.	Adams PD, 2019, ACTA CRYSTALLOGR D, V75, P451, DOI 10.1107/S2059798319004522; [Anonymous], 2017, Wkly Epidemiol Rec, V92, P241; [Anonymous], 2018, DATABASE; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bishop B, 2007, J BIOL CHEM, V282, P31803, DOI 10.1074/jbc.M706380200; Burley SK, 2019, NUCLEIC ACIDS RES, V47, pD464, DOI 10.1093/nar/gky1004; Burley SK, 2019, NUCLEIC ACIDS RES, V47, pD520, DOI 10.1093/nar/gky949; Cardone G, 2014, MBIO, V5, DOI 10.1128/mBio.01104-14; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; Castellano GM, 2019, J THORAC ONCOL, V14, P1982, DOI 10.1016/j.jtho.2019.06.015; Charbonnier S, 2011, J MOL BIOL, V406, P745, DOI 10.1016/j.jmb.2011.01.015; Dasgupta J, 2011, J BIOL CHEM, V286, P2617, DOI 10.1074/jbc.M110.160184; Dutta S, 2010, J APPL CRYSTALLOGR, V43, P1224, DOI 10.1107/S002188981002371X; Enemark EJ, 2006, NATURE, V442, P270, DOI 10.1038/nature04943; Goddard TD, 2018, PROTEIN SCI, V27, P14, DOI 10.1002/pro.3235; Goodsell DS, 2020, PROTEIN SCI, V29, P52, DOI 10.1002/pro.3730; Goodsell DS, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002140; Gore S, 2017, STRUCTURE, V25, P1916, DOI 10.1016/j.str.2017.10.009; Graham SV, 2010, FUTURE MICROBIOL, V5, P1493, DOI 10.2217/FMB.10.107; Guan J, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9120374; Guiley KZ, 2015, GENE DEV, V29, P961, DOI 10.1101/gad.257568.114; Hanson RM, 2010, J APPL CRYSTALLOGR, V43, P1250, DOI 10.1107/S0021889810030256; Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KENDREW JC, 1958, NATURE, V181, P662, DOI 10.1038/181662a0; Kobayashi K, 2018, J CLIN MED, V7, DOI 10.3390/jcm7090241; Korkmaz S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197176; LIDDINGTON RC, 1991, NATURE, V354, P278, DOI 10.1038/354278a0; Martinez-Zapien D, 2016, NATURE, V529, P541, DOI 10.1038/nature16481; McBride AA, 2017, BIOL CHEM, V398, P919, DOI 10.1515/hsz-2017-0113; Mittal S, 2017, MUTAT RES-REV MUTAT, V772, P23, DOI 10.1016/j.mrrev.2016.08.001; RAO ST, 1973, J MOL BIOL, V76, P241, DOI 10.1016/0022-2836(73)90388-4; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Sehnal D, 2018, WORKSH MOL GRAPH VIS, P29, DOI [/10.5555/3293503.3293509, DOI 10.5555/3293503.3293509]; Shao CH, 2017, STRUCTURE, V25, P458, DOI 10.1016/j.str.2017.01.013; Watson H.C., 1969, PROGR STEREOCHEM, V4, P229; Westbrook JD, 2020, DRUG DISCOV TODAY, V25, P837, DOI 10.1016/j.drudis.2020.02.002; Westbrook JD, 2019, STRUCTURE, V27, P211, DOI 10.1016/j.str.2018.11.007; Wilkinson MD, 2016, SCI DATA, V3, DOI 10.1038/sdata.2016.18; Young JY, 2017, STRUCTURE, V25, P536, DOI 10.1016/j.str.2017.01.004	41	3	3	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2020	39	43					6623	6632		10.1038/s41388-020-01461-2	http://dx.doi.org/10.1038/s41388-020-01461-2		SEP 2020	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OF2UT	32939013	Green Published, hybrid			2022-12-28	WOS:000570051900002
J	Sun, QQ; Ye, Z; Qin, Y; Fan, GX; Ji, SR; Zhuo, QF; Xu, WY; Liu, WS; Hu, QS; Liu, MQ; Zhang, Z; Xu, XW; Yu, XJ				Sun, Qiqing; Ye, Zeng; Qin, Yi; Fan, Guixiong; Ji, Shunrong; Zhuo, Qifeng; Xu, Wenyan; Liu, Wensheng; Hu, Qiangsheng; Liu, Mengqi; Zhang, Zheng; Xu, Xiaowu; Yu, Xianjun			Oncogenic function of TRIM2 in pancreatic cancer by activating ROS-related NRF2/ITGB7/FAK axis	ONCOGENE			English	Article							E3 LIGASE; TRANSCRIPTION FACTOR; CELL-PROLIFERATION; GLUCOSE-METABOLISM; SIGNALING PATHWAY; GENE-EXPRESSION; DOWN-REGULATION; NRF2; GROWTH; INHIBITION	Evidence suggests that tripartite motif-containing 2 (TRIM2) is associated with carcinogenic effects in several malignancies. However, the expression patterns and roles of TRIM2 in pancreatic cancer are rarely studied. Our study demonstrated that TRIM2 was expressed in a high percentage of pancreatic tumors. High TRIM2 expression was negatively correlated with the outcome of pancreatic cancer. TRIM2 silencing significantly inhibited the proliferation, migration, invasion, and in vivo tumorigenicity of pancreatic cancer cells. Regarding the mechanism involved, TRIM2 activated ROS-related E2-related factor 2 (NRF2)/antioxidant response element (ARE) signaling and the integrin/focal adhesion kinase (FAK) pathway. Treatment of pancreatic cancer cells with the antioxidant N-acetyl-L-cysteine decreased ROS activity and expression level of NRF2 and ITGB7. Increased translocation of NRF2 protein into nucleus further rescued the inhibited ITGB7 transcription. Moreover, NRF2 bound to the potential ARE on the promoter region and enhanced the transcriptional activity ofITGB7, indicating the bridging effect of NRF2 between the two signaling pathways. In summary, our study provides evidence that upregulated TRIM2 in pancreatic cancer predicts short survival for pancreatic cancer patients. TRIM2 accelerates pancreatic cancer progression via the ROS-related NRF2/ITGB7/FAK axis.	[Sun, Qiqing; Ye, Zeng; Qin, Yi; Fan, Guixiong; Ji, Shunrong; Zhuo, Qifeng; Xu, Wenyan; Liu, Wensheng; Hu, Qiangsheng; Liu, Mengqi; Zhang, Zheng; Xu, Xiaowu; Yu, Xianjun] Fudan Univ, Shanghai Canc Ctr, Dept Pancreat Surg, Shanghai 200032, Peoples R China; [Sun, Qiqing; Ye, Zeng; Qin, Yi; Fan, Guixiong; Ji, Shunrong; Zhuo, Qifeng; Xu, Wenyan; Liu, Wensheng; Hu, Qiangsheng; Liu, Mengqi; Zhang, Zheng; Xu, Xiaowu; Yu, Xianjun] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China; [Sun, Qiqing; Ye, Zeng; Qin, Yi; Fan, Guixiong; Ji, Shunrong; Zhuo, Qifeng; Xu, Wenyan; Liu, Wensheng; Hu, Qiangsheng; Liu, Mengqi; Zhang, Zheng; Xu, Xiaowu; Yu, Xianjun] Fudan Univ, Pancreat Canc Inst, Shanghai 200032, Peoples R China; [Sun, Qiqing; Ye, Zeng; Qin, Yi; Fan, Guixiong; Ji, Shunrong; Zhuo, Qifeng; Xu, Wenyan; Liu, Wensheng; Hu, Qiangsheng; Liu, Mengqi; Zhang, Zheng; Xu, Xiaowu; Yu, Xianjun] Shanghai Pancreat Canc Inst, Shanghai 200032, Peoples R China	Fudan University; Fudan University; Fudan University	Xu, XW; Yu, XJ (corresponding author), Fudan Univ, Shanghai Canc Ctr, Dept Pancreat Surg, Shanghai 200032, Peoples R China.; Xu, XW; Yu, XJ (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China.; Xu, XW; Yu, XJ (corresponding author), Fudan Univ, Pancreat Canc Inst, Shanghai 200032, Peoples R China.; Xu, XW; Yu, XJ (corresponding author), Shanghai Pancreat Canc Inst, Shanghai 200032, Peoples R China.	xuxiaowu@fudanpci.org; yuxianjun@fudanpci.org	liu, wen/HGE-3071-2022; Liu, Meng/GRF-0962-2022		National Natural Science Foundation of China (CN) [81871950, 81972250]; China National Funds for Distinguished Young Scientists (CN) [81625016]; Scientific Innovation Project of Shanghai Education Committee [2019-01-07-00-07-E00057]	National Natural Science Foundation of China (CN)(National Natural Science Foundation of China (NSFC)); China National Funds for Distinguished Young Scientists (CN); Scientific Innovation Project of Shanghai Education Committee	This work was supported by the National Natural Science Foundation of China (CN) (81871950 and 81972250); the China National Funds for Distinguished Young Scientists (CN) (81625016); the Scientific Innovation Project of Shanghai Education Committee (2019-01-07-00-07-E00057).	Abukhdeir Abde M., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000744; Arlt A, 2013, ONCOGENE, V32, P4825, DOI 10.1038/onc.2012.493; Balastik M, 2008, P NATL ACAD SCI USA, V105, P12016, DOI 10.1073/pnas.0802261105; Bellezza I, 2018, BBA-MOL CELL RES, V1865, P721, DOI 10.1016/j.bbamcr.2018.02.010; Bui CB, 2011, BIOCHEM BIOPH RES CO, V412, P347, DOI 10.1016/j.bbrc.2011.07.101; Cao H, 2019, SCAND J GASTROENTERO, V54, P210, DOI 10.1080/00365521.2019.1575463; Caratozzolo MF, 2012, CELL CYCLE, V11, P511, DOI 10.4161/cc.11.3.19008; Chai ZH, 2019, ONCOTARGETS THER, V12, P10415, DOI 10.2147/OTT.S228631; Chen XB, 2015, GYNECOL ONCOL, V139, P513, DOI 10.1016/j.ygyno.2015.10.008; Chen X, 2018, CELL PHYSIOL BIOCHEM, V50, P1201, DOI 10.1159/000494547; Chio IIC, 2016, CELL, V166, P963, DOI 10.1016/j.cell.2016.06.056; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Dinkova-Kostova AT, 2015, FREE RADICAL BIO MED, V88, P179, DOI 10.1016/j.freeradbiomed.2015.04.036; Duong HQ, 2014, INT J ONCOL, V44, P959, DOI 10.3892/ijo.2013.2229; Farrow B, 2003, J GASTROINTEST SURG, V7, P864, DOI 10.1016/S1091-255X(03)00142-2; Ge WJ, 2017, CANCER CELL, V32, P561, DOI 10.1016/j.ccell.2017.09.008; Hamada S, 2017, CARCINOGENESIS, V38, P661, DOI 10.1093/carcin/bgx043; Hamidi H, 2018, NAT REV CANCER, V18, P532, DOI 10.1038/s41568-018-0038-z; Hatakeyama S, 2011, NAT REV CANCER, V11, P792, DOI 10.1038/nrc3139; Hayes AJ, 2015, INT J BIOCHEM CELL B, V65, P288, DOI 10.1016/j.biocel.2015.06.017; Hedrick E, 2017, MOL CARCINOGEN, V56, P2066, DOI 10.1002/mc.22662; Duong HQ, 2017, ANTIOXIDANTS-BASEL, V6, DOI 10.3390/antiox6030052; Hu QS, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12456; Hu QS, 2017, ONCOL REP, V38, P2069, DOI 10.3892/or.2017.5856; Jazag A, 2005, ONCOGENE, V24, P662, DOI 10.1038/sj.onc.1208102; Ji SR, 2016, CLIN CANCER RES, V22, P3950, DOI 10.1158/1078-0432.CCR-15-2380; Ji SR, 2015, CELL RES, V25, P561, DOI 10.1038/cr.2015.30; Jiang H, 2016, NAT MED, V22, P851, DOI 10.1038/nm.4123; Kielosto M, 2009, INT J CANCER, V125, P1065, DOI 10.1002/ijc.24391; Kim H, 2010, J BIOL CHEM, V285, P34419, DOI 10.1074/jbc.M110.126839; Krajka-Kuzniak V, 2017, PHARMACOL REP, V69, P393, DOI 10.1016/j.pharep.2016.12.011; Kuninty PR, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax2770; Lee DF, 2009, MOL CELL, V36, P131, DOI 10.1016/j.molcel.2009.07.025; Lin Z, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01407-4; Lister A, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-37; Logsdon CD, 2003, CANCER RES, V63, P2649; Lu YB, 2016, ONCOTARGETS THER, V9, P99, DOI 10.2147/OTT.S92758; Martinez-Useros J, 2017, J CLIN MED, V6, DOI 10.3390/jcm6030029; Masuda Y, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8299; Meng QC, 2018, ONCOGENE, V37, P5843, DOI 10.1038/s41388-018-0392-z; Meng XL, 2020, BOSNIAN J BASIC MED, V20, P106, DOI 10.17305/bjbms.2019.4255; Midha S, 2016, CANCER LETT, V381, P269, DOI 10.1016/j.canlet.2016.07.022; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Moore Alexandra, 2019, JAMA, V322, P1426, DOI 10.1001/jama.2019.14699; Nateri AS, 2004, SCIENCE, V303, P1374, DOI 10.1126/science.1092880; Neri P, 2011, BLOOD, V117, P6202, DOI 10.1182/blood-2010-06-292243; Niture SK, 2014, J BIOL CHEM, V289, P11568, DOI 10.1074/jbc.A110.175802; Ough M, 2005, CANCER BIOL THER, V4, P95; Qi ZX, 2016, J NEURO-ONCOL, V126, P19, DOI 10.1007/s11060-015-1897-8; Qin Y, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964-019-0344-4; Qin Y, 2018, INT J ONCOL, V53, P1643, DOI 10.3892/ijo.2018.4494; Reigan P, 2007, BIOCHEMISTRY-US, V46, P5941, DOI 10.1021/bi700008y; Sato T, 2012, J CELL SCI, V125, P1544, DOI 10.1242/jcs.095273; Schonrock N, 2012, J MOL NEUROSCI, V46, P324, DOI 10.1007/s12031-011-9587-2; Shibata T, 2010, CANCER RES, V70, P9095, DOI 10.1158/0008-5472.CAN-10-0384; Siegel RL, 2018, CA-CANCER J CLIN, V68, P30; Sies H, 2020, NAT REV MOL CELL BIO, V21, P363, DOI 10.1038/s41580-020-0230-3; Soini Y, 2014, PATHOL RES PRACT, V210, P35, DOI 10.1016/j.prp.2013.10.001; Sporn MB, 2012, NAT REV CANCER, V12, P564, DOI 10.1038/nrc3278; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taguchi K, 2011, GENES CELLS, V16, P123, DOI 10.1111/j.1365-2443.2010.01473.x; Theodore M, 2008, J BIOL CHEM, V283, P8984, DOI 10.1074/jbc.M709040200; Thompson S, 2011, J BIOL CHEM, V286, P19331, DOI 10.1074/jbc.M110.197707; Tomar D, 2015, FREE RADICAL BIO MED, V89, P1036, DOI 10.1016/j.freeradbiomed.2015.10.425; Venuto S, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050510; Wakabayashi N, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000762; Wang LD, 2019, GENE DEV, V33, P641, DOI 10.1101/gad.323303.118; Wang LD, 2014, CANCER RES, V74, P1778, DOI 10.1158/0008-5472.CAN-13-2289; Wang LD, 2009, CANCER CELL, V15, P207, DOI 10.1016/j.ccr.2009.01.018; Watanabe M, 2017, J BIOCHEM, V161, P135, DOI 10.1093/jb/mvw087; Watanabe M, 2009, BIOCHEM BIOPH RES CO, V388, P422, DOI 10.1016/j.bbrc.2009.08.028; Wei L, 2019, NEUROCHEM RES, V44, P2182, DOI 10.1007/s11064-019-02857-7; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Xiao W, 2018, CANCER MANAG RES, V10, P5951, DOI 10.2147/CMAR.S185270; Xiong H, 2008, NEOPLASIA, V10, P287, DOI 10.1593/neo.07971; Yin H, 2017, INT J ONCOL, V51, P1191, DOI 10.3892/ijo.2017.4117; You A, 2011, ARCH BIOCHEM BIOPHYS, V507, P356, DOI 10.1016/j.abb.2010.12.034; Zhang WY, 2014, CANCER LETT, V355, P273, DOI 10.1016/j.canlet.2014.09.031; ZHANG YY, 2019, J IMMUNOTHER CANCER, V7; Zoranovic Tamara, 2013, JAKSTAT, V2, pe25408, DOI 10.4161/jkst.25408	80	10	10	4	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 15	2020	39	42					6572	6588		10.1038/s41388-020-01452-3	http://dx.doi.org/10.1038/s41388-020-01452-3		SEP 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OA9HI	32929153				2022-12-28	WOS:000569499000003
J	Ge, ML; Li, D; Qiao, Z; Sun, Y; Kang, T; Zhu, SH; Wang, SF; Xiao, H; Zhao, CJ; Shen, SH; Xu, ZS; Liu, H				Ge, Maolin; Li, Dan; Qiao, Zhi; Sun, Yan; Kang, Ting; Zhu, Shouhai; Wang, Shifen; Xiao, Hua; Zhao, Chunjun; Shen, Shuhong; Xu, Zhenshu; Liu, Han			Restoring MLL reactivates latent tumor suppression-mediated vulnerability to proteasome inhibitors	ONCOGENE			English	Article							MULTIPLE-MYELOMA; METHYLTRANSFERASE ACTIVITY; FAMILY PROTEINS; CANCER; CELLS; GENE; BORTEZOMIB; MONOUBIQUITINATION; TRANSCRIPTION; DEGRADATION	MLL undergoes multiple distinct chromosomal translocations to yield aggressive leukemia with dismal outcomes. Besides their well-established role in leukemogenesis, MLL fusions also possess latent tumor-suppressive activity, which can be exploited as effective cancer treatment strategies using pharmacological means such as proteasome inhibitors (PIs). Here, using MLL-rearranged xenografts and MLL leukemic cells as models, we show that wild-type MLL is indispensable for the latent tumor-suppressive activity of MLL fusions. MLL dysfunction, shown as loss of the chromatin accumulation and subsequent degradation of MLL, compromises the latent tumor suppression of MLL-AF4 and is instrumental for the acquired PI resistance. Mechanistically, MLL dysfunction is caused by chronic PI treatment-induced epigenetic reprogramming through the H2Bub-ASH2L-MLL axis and can be specifically restored by histone deacetylase (HDAC) inhibitors, which induce histone acetylation and recruits MLL on chromatin to promote cell cycle gene expression. Our findings not only demonstrate the mechanism underlying the inevitable acquisition of PI resistance in MLL leukemic cells, but also illustrate that preventing the emergence of PI-resistant cells constitutes a novel rationale for combination therapy with PIs and HDAC inhibitors in MLL leukemias.	[Ge, Maolin; Li, Dan; Sun, Yan; Zhu, Shouhai; Zhao, Chunjun; Liu, Han] Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Hematol,Ruijin Hosp, State Key Lab Med Genom,Natl Res Ctr Translat Med, Shanghai 200025, Peoples R China; [Qiao, Zhi; Xiao, Hua] Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, State Key Lab Microbial Metab, Shanghai 200240, Peoples R China; [Kang, Ting] Shanghai Jiao Tong Univ, Sch Med, Xin Hua Hosp, Dept Oncol, Shanghai 200092, Peoples R China; [Wang, Shifen; Xu, Zhenshu] Fujian Med Univ, Union Hosp, Fujian Inst Hematol, Fujian Prov Key Lab Hematol, Fuzhou 350001, Peoples R China; [Shen, Shuhong] Shanghai Jiao Tong Univ, Key Lab Pediat Hematol & Oncol, Minist Hlth,Dept Hematol & Oncol,Sch Med, Pediat Translat Med Inst,Shanghai Childrens Med C, Shanghai 200127, Peoples R China	Chinese Academy of Sciences; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Fujian Medical University; Shanghai Jiao Tong University	Liu, H (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Hematol,Ruijin Hosp, State Key Lab Med Genom,Natl Res Ctr Translat Med, Shanghai 200025, Peoples R China.; Xu, ZS (corresponding author), Fujian Med Univ, Union Hosp, Fujian Inst Hematol, Fujian Prov Key Lab Hematol, Fuzhou 350001, Peoples R China.; Shen, SH (corresponding author), Shanghai Jiao Tong Univ, Key Lab Pediat Hematol & Oncol, Minist Hlth,Dept Hematol & Oncol,Sch Med, Pediat Translat Med Inst,Shanghai Childrens Med C, Shanghai 200127, Peoples R China.	shenshuhong@scmc.com.cn; zhenshuxu@yahoo.com; liuhan68@sjtu.edu.cn	Xiao, Hua/I-7429-2013	Xiao, Hua/0000-0002-2831-0436; Liu, Han/0000-0002-0022-1861	National Key Research and Development Program of China [2018YFA0107802]; National Natural Science Foundation of China [81973996, 81570119]; Shanghai Municipal Education Commission Gaofeng Clinical Medicine Grant [20161304]; Program of Shanghai Academic Research Leader [19XD1402500]; Shanghai Municipal Health Commission [2019CXJQ01]; Joint Funds for the Innovation of Science and Technology of Fujian Province of China [2017Y9005]; Collaborative Innovation Center of Hematology; Samuel Waxman Cancer Research Foundation	National Key Research and Development Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Municipal Education Commission Gaofeng Clinical Medicine Grant; Program of Shanghai Academic Research Leader; Shanghai Municipal Health Commission; Joint Funds for the Innovation of Science and Technology of Fujian Province of China; Collaborative Innovation Center of Hematology; Samuel Waxman Cancer Research Foundation	This work was supported by the National Key Research and Development Program of China (2018YFA0107802), the National Natural Science Foundation of China (81973996 and 81570119), the Shanghai Municipal Education Commission Gaofeng Clinical Medicine Grant (20161304), the Program of Shanghai Academic Research Leader (19XD1402500), the Shanghai Municipal Health Commission (2019CXJQ01), the Joint Funds for the Innovation of Science and Technology of Fujian Province of China (No.2017Y9005), the Collaborative Innovation Center of Hematology, and the Samuel Waxman Cancer Research Foundation.	Ahmad K, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.39; Allen MD, 2006, EMBO J, V25, P4503, DOI 10.1038/sj.emboj.7601340; Cao F, 2014, MOL CELL, V53, P247, DOI 10.1016/j.molcel.2013.12.001; Chen YF, 2017, CANCER CELL, V31, P755, DOI 10.1016/j.ccell.2017.05.002; Drexler HG, 2004, LEUKEMIA, V18, P227, DOI 10.1038/sj.leu.2403236; Espinosa JM, 2008, GENE DEV, V22, P2743, DOI 10.1101/gad.1732108; Flavahan WA, 2017, SCIENCE, V357, DOI 10.1126/science.aal2380; Glickman MS, 2012, CELL, V148, P1089, DOI 10.1016/j.cell.2012.02.015; Goldman A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7139; Hideshima T, 2005, P NATL ACAD SCI USA, V102, P8567, DOI 10.1073/pnas.0503221102; Hsieh JJD, 2003, CELL, V115, P293, DOI 10.1016/S0092-8674(03)00816-X; Kaldis P, 2007, CELL, V128, P241, DOI 10.1016/j.cell.2007.01.006; Koss C, 2014, BLOOD, V124, DOI 10.1182/blood.V124.21.972.972; Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253; Lee JS, 2007, CELL, V131, P1084, DOI 10.1016/j.cell.2007.09.046; Li D, 2018, LEUKEMIA, V32, P2012, DOI 10.1038/s41375-018-0212-z; Liang KW, 2017, CELL, V168, P59, DOI 10.1016/j.cell.2016.12.011; Liau BB, 2017, CELL STEM CELL, V20, P233, DOI 10.1016/j.stem.2016.11.003; Liu H, 2014, CANCER CELL, V25, P530, DOI 10.1016/j.ccr.2014.03.008; Liu H, 2010, NATURE, V467, P343, DOI 10.1038/nature09350; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Manasanch EE, 2017, NAT REV CLIN ONCOL, V14, P417, DOI [10.1038/nrclinonc.2016.206, 10.1007/s12079-011-0121-7]; Mazur PK, 2015, NAT MED, V21, P1163, DOI 10.1038/nm.3952; McConkey D, 2010, BLOOD, V116, P308, DOI 10.1182/blood-2010-04-278507; Meyer C, 2018, LEUKEMIA, V32, P273, DOI 10.1038/leu.2017.213; Milne TA, 2005, P NATL ACAD SCI USA, V102, P749, DOI 10.1073/pnas.0408836102; Milne TA, 2010, MOL CELL, V38, P853, DOI 10.1016/j.molcel.2010.05.011; Mishra BP, 2014, CELL REP, V7, P1239, DOI 10.1016/j.celrep.2014.04.015; Moreau P, 2012, BLOOD, V120, P947, DOI 10.1182/blood-2012-04-403733; Mujtaba S, 2007, ONCOGENE, V26, P5521, DOI 10.1038/sj.onc.1210618; Muntean AG, 2012, ANNU REV PATHOL-MECH, V7, P283, DOI 10.1146/annurev-pathol-011811-132434; Nakanishi S, 2008, NAT STRUCT MOL BIOL, V15, P881, DOI 10.1038/nsmb.1454; Pei XY, 2004, CLIN CANCER RES, V10, P3839, DOI 10.1158/1078-0432.CCR-03-0561; Prenzel T, 2011, CANCER RES, V71, P5739, DOI 10.1158/0008-5472.CAN-11-1896; Rao RC, 2015, NAT REV CANCER, V15, P334, DOI 10.1038/nrc3929; Riedel SS, 2016, J CLIN INVEST, V126, P1438, DOI 10.1172/JCI80825; Rushworth SA, 2011, CANCER RES, V71, P1999, DOI 10.1158/0008-5472.CAN-10-3018; Salgia R, 2018, TRENDS CANCER, V4, P110, DOI 10.1016/j.trecan.2018.01.001; San-Miguel JF, 2014, LANCET ONCOL, V15, P1195, DOI 10.1016/S1470-2045(14)70440-1; Shaffer SM, 2017, NATURE, V546, P431, DOI 10.1038/nature22794; Shilatifard A, 2012, ANNU REV BIOCHEM, V81, P65, DOI 10.1146/annurev-biochem-051710-134100; Takeda S, 2006, GENE DEV, V20, P2397, DOI 10.1101/gad.1449406; Thiel AT, 2010, CANCER CELL, V17, P148, DOI 10.1016/j.ccr.2009.12.034; Wainwright EN, 2017, TRENDS CANCER, V3, P372, DOI 10.1016/j.trecan.2017.04.004; Wang E, 2013, P NATL ACAD SCI USA, V110, P3901, DOI 10.1073/pnas.1301045110; Wang ZX, 2010, CELL, V141, P1183, DOI 10.1016/j.cell.2010.05.016; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738; Wu LP, 2013, MOL CELL, V49, P1108, DOI 10.1016/j.molcel.2013.01.033; Xia ZB, 2005, P NATL ACAD SCI USA, V102, P14028, DOI 10.1073/pnas.0506464102; Xu HM, 2016, CANCER CELL, V30, P863, DOI 10.1016/j.ccell.2016.10.019; Zhang QL, 2009, LEUKEMIA, V23, P1507, DOI 10.1038/leu.2009.41; Zhao ZB, 2019, GENE DEV, V33, P61, DOI 10.1101/gad.319830.118	53	4	4	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2020	39	36					5888	5901		10.1038/s41388-020-01408-7	http://dx.doi.org/10.1038/s41388-020-01408-7		JUL 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NJ1HO	32733069	Green Published, hybrid			2022-12-28	WOS:000557084000001
J	Ko, KP; Jeong, SI; Lim, JS; Lee, KW; Lee, MG; Chi, SG				Ko, Kyung-Phil; Jeong, Seong-In; Lim, Ji-Sun; Lee, Kyung-Woo; Lee, Min-Goo; Chi, Sung-Gil			NORE1A directs apoptotic switch of TNF signaling through reciprocal modulation of ITCH-mediated destruction of TNFRI and BAX	ONCOGENE			English	Article							TUMOR-NECROSIS-FACTOR; E3 UBIQUITIN LIGASE; NF-KAPPA-B; SUPPRESSOR GENE; CONFORMATIONAL-CHANGE; RAS; ALPHA; EFFECTOR; RASSF1A; DEATH	NORE1A (RASSF5) is a tumor suppressor of the Ras-association domain family (RASSF) that is commonly inactivated in multiple human cancers. However, the molecular mechanism underlying its growth inhibition function remains largely undefined. Here we report that NORE1A antagonizes tumor necrosis factor receptor I (TNFRI) through the assembly of ITCH-mediated destruction complex to suppress TNF-NF-kappa B signaling and tumorigenesis. Moreover, NORE1A is identified as a transcription target of NF-kappa B, which directs an apoptotic switch of TNF effect by blocking ITCH interaction with and ubiquitination of BAX. Mechanistically, NORE1A binds directly to TNFRI and ITCH via the C1 and PPXY domains, respectively to facilitate the formation of ITCH-mediated destruction complex followed by ubiquitination-mediated lysosomal degradation of TNFRI. Through this function, NORE1A suppresses TNF-induced NF-kappa B-mediated transcription of pro-inflammatory and tumor-promoting genes, epithelial-to-mesenchymal transition, invasion and migration of tumor cells, and also debilitates tumor cell activation of macrophage and fibroblast. While NORE1A suppresses TNF receptor-mediated apoptosis, it activates TNF-induced apoptosis through BAX activation by protecting BAX from ITCH binding and ubiquitination. Cytotoxic response to TNF is substantially attenuated in NORE1A-depleted cells and tumors, and NORE1A-induced tumor regression is highly impeded in BAX-depleted tumors. An inverse correlation is shown between NORE1A and TNFRI expression in both cancer cell lines and primary tumors, and NORE1A effect on survival of cancer patients is strongly associated with expression status of ITCH. Collectively, this study uncovers that NORE1A directs a substrate switch of ITCH favoring TNFRI over BAX to terminate TNF signaling and accelerate apoptosis, illuminating the mechanistic consequence of NORE1A inactivation in tumorigenesis.	[Ko, Kyung-Phil; Jeong, Seong-In; Lim, Ji-Sun; Lee, Kyung-Woo; Lee, Min-Goo; Chi, Sung-Gil] Korea Univ, Dept Life Sci, Seoul 02841, South Korea	Korea University	Chi, SG (corresponding author), Korea Univ, Dept Life Sci, Seoul 02841, South Korea.	chi6302@korea.ac.kr		Chi, Sung-Gil/0000-0003-4643-9003	National Research Foundation of Korea, Republic of Korea [NRF-2018R1A2A1A05020236]; Korea University Grant, Republic of Korea [K1705811]	National Research Foundation of Korea, Republic of Korea(National Research Foundation of Korea); Korea University Grant, Republic of Korea	This work was supported in part by National Research Foundation of Korea (Grant numbers NRF-2018R1A2A1A05020236, SGC) and Korea University Grant (K1705811, SGC), Republic of Korea.	Avruch J, 2009, J BIOL CHEM, V284, P11001, DOI 10.1074/jbc.R800073200; Azakir BA, 2010, FEBS J, V277, P1319, DOI 10.1111/j.1742-4658.2010.07562.x; Baillat G, 2005, BBA-MOL CELL RES, V1745, P101, DOI 10.1016/j.bbamcr.2004.12.005; Baksh S, 2005, MOL CELL, V18, P637, DOI 10.1016/j.molcel.2005.05.010; Balkwill F, 2009, NAT REV CANCER, V9, P361, DOI 10.1038/nrc2628; Benard G, 2010, EMBO J, V29, P1458, DOI 10.1038/emboj.2010.39; Calvisi DF, 2009, CANCER RES, V69, P4629, DOI 10.1158/0008-5472.CAN-08-3672; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Chen JD, 2003, CANCER CELL, V4, P405, DOI 10.1016/S1535-6108(03)00269-1; Choi YB, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00422-16; Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127; D'Alessio A, 2005, AM J PATHOL, V166, P1273, DOI 10.1016/S0002-9440(10)62346-2; Donninger H, 2015, J CELL BIOL, V208, P777, DOI 10.1083/jcb.201408087; Faustman D, 2010, NAT REV DRUG DISCOV, V9, P482, DOI 10.1038/nrd3030; Foley CJ, 2008, MOL CELL BIOL, V28, P4520, DOI 10.1128/MCB.02011-07; Fritsch J, 2014, MOL CELL BIOL, V34, P3214, DOI 10.1128/MCB.00048-14; Guan JJ, 2015, STEM CELL RES THER, V6, DOI 10.1186/scrt539; Hesson L, 2003, ONCOGENE, V22, P947, DOI 10.1038/sj.onc.1206191; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hong IS, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2016.64; Irimia M, 2004, ONCOGENE, V23, P8695, DOI 10.1038/sj.onc.1207914; Johnson BN, 2012, P NATL ACAD SCI USA, V109, P6283, DOI 10.1073/pnas.1113248109; Jones SJ, 1999, J IMMUNOL, V162, P1042; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kim H, 2015, CELL REP, V11, P1151, DOI 10.1016/j.celrep.2015.04.048; Kim S, 2009, NATURE, V457, P102, DOI 10.1038/nature07623; Kraus S, 2009, CURR OPIN PHARMACOL, V9, P405, DOI 10.1016/j.coph.2009.06.006; Lee CK, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-577; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; Martinez-Reza I, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0398-9; Matthews CP, 2007, CURR CANCER DRUG TAR, V7, P317, DOI 10.2174/156800907780809723; Ofengeim D, 2013, NAT REV MOL CELL BIO, V14, P727, DOI 10.1038/nrm3683; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Park J, 2010, J BIOL CHEM, V285, P35029, DOI 10.1074/jbc.M110.165506; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Prando ED, 2011, EPIGENETICS-US, V6, P1413, DOI 10.4161/epi.6.12.18271; Roussos ET, 2011, NAT REV CANCER, V11, P573, DOI 10.1038/nrc3078; Schneider-Brachert W, 2004, IMMUNITY, V21, P415, DOI 10.1016/j.immuni.2004.08.017; Schneider-Brachert W, 2013, INT J MOL SCI, V14, P14475, DOI 10.3390/ijms140714475; Shembade N, 2008, NAT IMMUNOL, V9, P254, DOI 10.1038/ni1563; Stieglitz B, 2008, EMBO J, V27, P1995, DOI 10.1038/emboj.2008.125; Suryaraja R, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.91; TALMADGE JE, 1988, CANCER RES, V48, P544; Tchikov V, 2011, EUR J CELL BIOL, V90, P467, DOI 10.1016/j.ejcb.2010.11.002; Tomita Y, 2004, INT J CANCER, V112, P927, DOI 10.1002/ijc.20493; Tommasi S, 2002, ONCOGENE, V21, P2713, DOI 10.1038/sj.onc.1205365; van der Weyden L, 2007, BBA-REV CANCER, V1776, P58, DOI 10.1016/j.bbcan.2007.06.003; Vos MD, 2003, J BIOL CHEM, V278, P21938, DOI 10.1074/jbc.M211019200; Vucic D, 2011, NAT REV MOL CELL BIO, V12, P439, DOI 10.1038/nrm3143; Wang P, 2009, CELL DEATH DIFFER, V16, P1192, DOI 10.1038/cdd.2009.51; Wertz IE, 2010, CELL DEATH DIFFER, V17, P14, DOI 10.1038/cdd.2009.168; Yau R, 2016, NAT CELL BIOL, V18, P579, DOI 10.1038/ncb3358; Zheng WW, 2016, INT J CLIN EXP MED, V9, P2027	53	4	4	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2020	39	34					5675	5689		10.1038/s41388-020-01392-y	http://dx.doi.org/10.1038/s41388-020-01392-y		JUL 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NE9FK	32690868				2022-12-28	WOS:000550641000001
J	Zhang, XM; Yang, L; Szeto, P; Abali, GK; Zhang, YF; Kulkarni, A; Amarasinghe, K; Li, JS; Vergara, IA; Molania, R; Papenfuss, AT; McLean, C; Shackleton, M; Harvey, KF				Zhang, Xiaomeng; Yang, Lie; Szeto, Pacman; Abali, Gamze Kuser; Zhang, Youfang; Kulkarni, Aishwarya; Amarasinghe, Kaushalya; Li, Jason; Vergara, Ismael A.; Molania, Ramyar; Papenfuss, Anthony T.; McLean, Catriona; Shackleton, Mark; Harvey, Kieran F.			The Hippo pathway oncoprotein YAP promotes melanoma cell invasion and spontaneous metastasis	ONCOGENE			English	Article							SIGNALING PATHWAY; VEMURAFENIB; EXPRESSION; DROSOPHILA; TAZ; DIFFERENTIATION; CLASSIFICATION; FOLLISTATIN; RESISTANCE; PHENOTYPE	Melanoma is a deadly form of skin cancer that accounts for a disproportionally large proportion of cancer-related deaths in younger people. Compared with most other skin cancers, a feature of melanoma is its high metastatic capacity, although the mechanisms that confer this are not well understood. The Hippo pathway is a key regulator of organ growth and cell fate that is deregulated in many cancers. To analyse the Hippo pathway in cutaneous melanoma, we generated a transcriptional signature of melanoma cells that overexpressed YAP, the key downstream Hippo pathway oncoprotein. YAP-mediated transcriptional activity varied in melanoma cell lines but did not cluster with known genetic drivers of melanomagenesis such asBRAFandNRASmutations. Instead, it correlated strongly with published gene expression profiles linked to melanoma cell invasiveness and varied throughout the metastatic cascade in melanoma patient tumours. Consistent with this, YAP was both necessary and sufficient for melanoma cell invasion in vitro. In vivo, YAP promoted spontaneous melanoma metastasis, whilst the growth of YAP-expressing primary tumours was impeded. Finally, we identified the YAP target genesAXL,THBS1andCYR61as key mediators of YAP-induced melanoma cell invasion. These data suggest that YAP is a critical regulator of melanoma metastasis.	[Zhang, Xiaomeng; Yang, Lie; Kulkarni, Aishwarya; Amarasinghe, Kaushalya; Li, Jason; Vergara, Ismael A.; Papenfuss, Anthony T.; Harvey, Kieran F.] Peter MacCallum Canc Ctr, 305 Grattan St, Melbourne, Vic 3000, Australia; [Yang, Lie] Tsinghua Univ, Sch Med, 1 Tsinghua Yuan, Beijing 100084, Peoples R China; [Szeto, Pacman; Abali, Gamze Kuser; Zhang, Youfang; McLean, Catriona; Shackleton, Mark] Monash Univ, Cent Clin Sch, Melbourne, Vic, Australia; [Szeto, Pacman; Abali, Gamze Kuser; Zhang, Youfang; Shackleton, Mark] Alfred Hlth, Melbourne, Vic, Australia; [Kulkarni, Aishwarya; Papenfuss, Anthony T.; Harvey, Kieran F.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic 3010, Australia; [Vergara, Ismael A.; Molania, Ramyar; Papenfuss, Anthony T.] Walter & Eliza Hall Inst Med Res, Bioinformat Div, Parkville, Vic 3052, Australia; [Papenfuss, Anthony T.] Univ Melbourne, Dept Med Biol, Parkville, Vic 3010, Australia; [Harvey, Kieran F.] Monash Univ, Dept Anat & Dev Biol, Clayton, Vic, Australia; [Harvey, Kieran F.] Monash Univ, Biomed Discovery Inst, Clayton, Vic, Australia	Peter Maccallum Cancer Center; Tsinghua University; Monash University; Peter Maccallum Cancer Center; University of Melbourne; Walter & Eliza Hall Institute; University of Melbourne; Monash University; Monash University	Harvey, KF (corresponding author), Peter MacCallum Canc Ctr, 305 Grattan St, Melbourne, Vic 3000, Australia.; Harvey, KF (corresponding author), Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic 3010, Australia.; Harvey, KF (corresponding author), Monash Univ, Dept Anat & Dev Biol, Clayton, Vic, Australia.; Harvey, KF (corresponding author), Monash Univ, Biomed Discovery Inst, Clayton, Vic, Australia.	kieran.harvey@petermac.org	Papenfuss, Anthony T/C-6297-2008; Harvey, Kieran/AAD-5268-2022	Papenfuss, Anthony T/0000-0002-1102-8506; Amarasinghe, Kaushalya C./0000-0001-6024-657X; Vergara, Ismael/0000-0002-2960-2967; Kuser Abali, Gamze/0000-0002-4590-0577; Szeto, Pacman/0000-0002-6159-9913; Yang, Lie/0000-0001-7563-3214; Kulkarni, Aishwarya/0000-0001-5365-214X	Australian Cancer Research Foundation; National Health and Medical Research Council (NHMRC) Senior Research Fellowship [APP1078220, APP1116955]; Pfizer Australia; NHMRC [APP1145166]; veski; VCA Fellowships; Cancer Council of Victoria [APP1080255]; Peter MacCallum Cancer Foundation; Lorenzo and Pamela Galli Charitable Trust; Victorian State Government Operational Infrastructure Support; Australian Government NHMRC Independent Research Institute Infrastructure Support; China Scholarship Council; Australian Government Research Training Programme Scholarship; Rosie Lew Peter MacCallum Cancer Foundation Postgraduate Award	Australian Cancer Research Foundation; National Health and Medical Research Council (NHMRC) Senior Research Fellowship(National Health and Medical Research Council (NHMRC) of Australia); Pfizer Australia(PfizerPfizer Australia); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); veski; VCA Fellowships; Cancer Council of Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); Peter MacCallum Cancer Foundation; Lorenzo and Pamela Galli Charitable Trust; Victorian State Government Operational Infrastructure Support; Australian Government NHMRC Independent Research Institute Infrastructure Support(National Health and Medical Research Council (NHMRC) of Australia); China Scholarship Council(China Scholarship Council); Australian Government Research Training Programme Scholarship(Australian Government); Rosie Lew Peter MacCallum Cancer Foundation Postgraduate Award	We thank the following Peter MacCallum Cancer Centre core facilities: Molecular Genomics, Bioinformatics, Flow Cytometry and the Centre for Advanced Histology and Microscopy, which were in part supported by the Australian Cancer Research Foundation. KFH was supported by a National Health and Medical Research Council (NHMRC) Senior Research Fellowship (APP1078220). MS was supported by Pfizer Australia, NHMRC, veski, and VCA Fellowships. This research was supported by grants from the Cancer Council of Victoria (APP1080255) and NHMRC (APP1145166), and by the Peter MacCallum Cancer Foundation. ATP was supported by a National Health and Medical Research Council (NHMRC) Senior Research Fellowship (APP1116955) and by the Lorenzo and Pamela Galli Charitable Trust. The research benefitted by support from the Victorian State Government Operational Infrastructure Support and Australian Government NHMRC Independent Research Institute Infrastructure Support. LY was supported by the China Scholarship Council. AK was supported by an Australian Government Research Training Programme Scholarship and a Rosie Lew Peter MacCallum Cancer Foundation Postgraduate Award.	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Brastianos PK, 2013, NAT GENET, V45, P285, DOI 10.1038/ng.2526; Bueno R, 2016, NAT GENET; Calses PC, 2019, TRENDS CANCER, V5, P297, DOI 10.1016/j.trecan.2019.04.001; Camargo FD, 2007, CURR BIOL, V17, P2054, DOI 10.1016/j.cub.2007.10.039; Chen Q, 2014, GENE DEV, V28, P432, DOI 10.1101/gad.233676.113; Clark VE, 2013, SCIENCE, V339, P1077, DOI 10.1126/science.1233009; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; Cox AG, 2016, NAT CELL BIOL, V18, P886, DOI 10.1038/ncb3389; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Ege N, 2018, CELL SYST, V6, P692, DOI 10.1016/j.cels.2018.05.006; Elosegui-Artola A, 2017, CELL, V171, P1397, DOI 10.1016/j.cell.2017.10.008; Feng XD, 2014, CANCER CELL, V25, P831, DOI 10.1016/j.ccr.2014.04.016; Halder G, 2011, DEVELOPMENT, V138, P9, DOI 10.1242/dev.045500; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hoek KS, 2006, PIGM CELL RES, V19, P290, DOI 10.1111/j.1600-0749.2006.00322.x; Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491; Hong WJ, 2012, SEMIN CELL DEV BIOL, V23, P785, DOI 10.1016/j.semcdb.2012.05.004; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Jayachandran A, 2014, ONCOTARGET, V5, P5782, DOI 10.18632/oncotarget.2164; Johannessen CM, 2013, NATURE, V504, P138, DOI 10.1038/nature12688; Konieczkowski DJ, 2014, CANCER DISCOV, V4, P816, DOI 10.1158/2159-8290.CD-13-0424; Lamar JM, 2012, P NATL ACAD SCI USA, V109, pE2441, DOI 10.1073/pnas.1212021109; Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868; Larkin J, 2014, LANCET ONCOL, V15, P436, DOI 10.1016/S1470-2045(14)70051-8; Lee CK, 2019, SCIENCE, V363, P644, DOI 10.1126/science.aav0173; Lin LP, 2015, NAT GENET, V47, P250, DOI 10.1038/ng.3218; Manning SA, 2020, DEVELOPMENT, V147, DOI 10.1242/dev.179069; Manning SA, 2018, CURR BIOL, V28, P1651, DOI 10.1016/j.cub.2018.04.018; McArthur GA, 2014, LANCET ONCOL, V15, P323, DOI 10.1016/S1470-2045(14)70012-9; Moroishi T, 2016, CELL, V167, P1525, DOI 10.1016/j.cell.2016.11.005; Muller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6712; Nallet-Staub F, 2014, J INVEST DERMATOL, V134, P123, DOI 10.1038/jid.2013.319; Ogasawara N, 2018, BIOL PHARM BULL, V41, P604, DOI 10.1248/bpb.b17-00990; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Ramsdale R, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aab1111; Seachrist DD, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0857-y; Sensi M, 2011, J INVEST DERMATOL, V131, P2448, DOI 10.1038/jid.2011.218; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Thompson TB, 2005, DEV CELL, V9, P535, DOI 10.1016/j.devcel.2005.09.008; Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501; Titz B, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.28; Verfaillie A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7683; Widmer DS, 2012, PIGM CELL MELANOMA R, V25, P343, DOI 10.1111/j.1755-148X.2012.00986.x; Xu MZ, 2011, ONCOGENE, V30, P1229, DOI 10.1038/onc.2010.504; Yu FX, 2014, CANCER CELL, V25, P822, DOI 10.1016/j.ccr.2014.04.017; Zabkiewicz C, 2017, CANCER GENOM PROTEOM, V14, P241, DOI 10.21873/cgp.20035; Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216; Zeng H, 2015, GROWTH FACTORS, V33, P384, DOI 10.3109/08977194.2015.1119132; Zhang X, 2011, ONCOGENE, V30, P2810, DOI 10.1038/onc.2011.8; Zhang XM, 2019, MOL CANCER RES, V17, P1435, DOI 10.1158/1541-7786.MCR-18-0407; Zhang XM, 2009, CANCER RES, V69, P6033, DOI 10.1158/0008-5472.CAN-08-4592; Zhao B, 2011, GENE DEV, V25, P51, DOI 10.1101/gad.2000111	58	29	30	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 23	2020	39	30					5267	5281		10.1038/s41388-020-1362-9	http://dx.doi.org/10.1038/s41388-020-1362-9		JUN 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MO5BV	32561850	Green Submitted			2022-12-28	WOS:000541308400001
J	Frangez, Z; Fernandez-Marrero, Y; Stojkov, D; Jafari, SMS; Hunger, RE; Djonov, V; Riether, C; Simon, HU				Frangez, Ziva; Fernandez-Marrero, Yuniel; Stojkov, Darko; Jafari, S. Morteza Seyed; Hunger, Robert E.; Djonov, Valentin; Riether, Carsten; Simon, Hans-Uwe			BIF-1 inhibits both mitochondrial and glycolytic ATP production: its downregulation promotes melanoma growth	ONCOGENE			English	Article							INTERACTING FACTOR-I; BAX; METABOLISM; PROTEIN; DOMAIN; EXPRESSION; GENERATION; CURVATURE; MEMBRANES; METFORMIN	Endophilin B1, also known as BAX-interacting protein 1 (BIF-1), is part of the endophilin B protein family, and is a multifunctional protein involved in the regulation of apoptosis, autophagy, and mitochondrial morphology. The role of BIF-1 in cancer is controversial since previous reports indicated to both tumor-promoting and tumor-suppressive roles, perhaps depending on the cancer cell type. In the present study, we report that BIF-1 is significantly downregulated in both primary and metastatic melanomas, and that patients with high levels of BIF-1 expression exhibited a better overall survival. Depleting BIF-1 using CRISPR/Cas9 technology in melanoma cells resulted in higher proliferation rates both in vitro and in vivo, a finding that was associated with increased ATP production, metabolic acidification, and mitochondrial respiration. We also observed mitochondrial hyperpolarization, but no increase in the mitochondrial content of BIF-1-knockout melanoma cells. In contrast, such knockout melanoma cells were equally sensitive to anticancer drug- or UV irradiation-induced cell death, and exhibited similar autophagic activities as compared with control cells. Taken together, it appears that downregulation of BIF-1 contributes to tumorigenesis in cutaneous melanoma by upregulating mitochondrial respiration and metabolism, independent of its effect on apoptosis and autophagy.	[Frangez, Ziva; Fernandez-Marrero, Yuniel; Stojkov, Darko; Simon, Hans-Uwe] Univ Bern, Inst Pharmacol, Bern, Switzerland; [Jafari, S. Morteza Seyed; Hunger, Robert E.] Univ Bern, Bern Univ Hosp, Dept Dermatol, Inselspital, Bern, Switzerland; [Djonov, Valentin] Univ Bern, Inst Anat, Bern, Switzerland; [Riether, Carsten] Univ Bern, Dept Biomed Res, Tumor Immunol, Bern, Switzerland; [Riether, Carsten] Univ Bern, Bern Univ Hosp, Dept Med Oncol, Inselspital, Bern, Switzerland; [Simon, Hans-Uwe] Sechenov Univ, Dept Clin Immunol & Allergol, Moscow, Russia	University of Bern; University of Bern; University Hospital of Bern; University of Bern; University of Bern; University of Bern; University Hospital of Bern; Sechenov First Moscow State Medical University	Simon, HU (corresponding author), Univ Bern, Inst Pharmacol, Bern, Switzerland.; Simon, HU (corresponding author), Sechenov Univ, Dept Clin Immunol & Allergol, Moscow, Russia.	hus@pki.unibe.ch	Jafari, S. Morteza Seyed/AAV-9160-2020; Simon, Hans-Uwe/AAU-7410-2020; Riether, Carsten/ABC-7699-2021; Riether, Carsten/K-8603-2013	Jafari, S. Morteza Seyed/0000-0002-6466-2199; Simon, Hans-Uwe/0000-0002-9404-7736; Riether, Carsten/0000-0001-7512-513X; Riether, Carsten/0000-0001-7512-513X; Frangez, Ziva/0000-0002-9164-7656	Swiss National Science Foundation [310030_184816]; European Union [642295]; Microscopy Imaging Center of the University of Bern	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); European Union(European Commission); Microscopy Imaging Center of the University of Bern	This work was supported by the Swiss National Science Foundation (310030_184816 to H.U.S.) and the European Union Horizon 2020 Research and Innovation Program (Marie Sklodowska-Curie grant No. 642295; MEL-PLEX). Z.F. is a PhD student of the Graduate School of Cellular and Biomedical Sciences of the University of Bern. Images were acquired on equipment supported by the Microscopy Imaging Center of the University of Bern.	Amini P, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05387-y; Bankhead P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17204-5; Coppola D, 2008, CANCER-AM CANCER SOC, V113, P2665, DOI 10.1002/cncr.23892; Cuddeback SM, 2001, J BIOL CHEM, V276, P20559, DOI 10.1074/jbc.M101527200; Diepart C, 2012, CANCER RES, V72, P482, DOI 10.1158/0008-5472.CAN-11-1755; El-Mir MY, 2000, J BIOL CHEM, V275, P223, DOI 10.1074/jbc.275.1.223; Fan RG, 2012, ONCOL LETT, V3, P851, DOI 10.3892/ol.2012.562; Farsad K, 2001, J CELL BIOL, V155, P193, DOI 10.1083/jcb.200107075; Giachino C, 1997, GENOMICS, V41, P427, DOI 10.1006/geno.1997.4645; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huttner WB, 2000, CURR OPIN NEUROBIOL, V10, P543, DOI 10.1016/S0959-4388(00)00126-4; Jiao L, 2018, AUTOPHAGY, V14, P671, DOI 10.1080/15548627.2017.1381804; Karbowski M, 2004, J CELL BIOL, V166, P1027, DOI 10.1083/jcb.200407046; Kim SY, 2008, PATHOLOGY, V40, P553, DOI 10.1080/00313020802320440; Kjaerulff O, 2011, CELL BIOCHEM BIOPHYS, V60, P137, DOI 10.1007/s12013-010-9137-5; Koritzinsky M, 2015, INT J RADIAT ONCOL, V93, P454, DOI 10.1016/j.ijrobp.2015.06.003; Liu H, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005864; Loll PJ, 2008, ACTA CRYSTALLOGR F, V64, P243, DOI 10.1107/S1744309108007574; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Masuda M, 2006, EMBO J, V25, P2889, DOI 10.1038/sj.emboj.7601176; Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314; Mishra P, 2016, J CELL BIOL, V212, P379, DOI 10.1083/jcb.201511036; Moreno-Sanchez R, 2007, FEBS J, V274, P1393, DOI 10.1111/j.1742-4658.2007.05686.x; Pierrat B, 2001, GENOMICS, V71, P222, DOI 10.1006/geno.2000.6378; Rozman S, 2015, CELL DEATH DIFFER, V22, P445, DOI 10.1038/cdd.2014.169; Schlauder SM, 2009, J CUTAN PATHOL, V36, P21, DOI 10.1111/j.1600-0560.2007.00945.x; Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477; Simon N, 1998, FEBS LETT, V435, P25, DOI 10.1016/S0014-5793(98)01033-3; Takahashi Y, 2005, MOL CELL BIOL, V25, P9369, DOI 10.1128/MCB.25.21.9369-9382.2005; Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634; Takahashi Y, 2011, AUTOPHAGY, V7, P61, DOI 10.4161/auto.7.1.14015; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang DB, 2014, J NEUROSCI, V34, P2674, DOI 10.1523/JNEUROSCI.4074-13.2014; Weinberg SE, 2015, NAT CHEM BIOL, V11, P9, DOI 10.1038/nchembio.1712; Wheaton WW, 2014, ELIFE, V3, DOI 10.7554/eLife.02242; Xu L, 2016, ONCOL REP, V36, P3513, DOI 10.3892/or.2016.5172; Yamaguchi H, 2008, J BIOL CHEM, V283, P19112, DOI 10.1074/jbc.M709882200; Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014; Zannella VE, 2013, CLIN CANCER RES, V19, P6741, DOI 10.1158/1078-0432.CCR-13-1787	39	5	6	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 25	2020	39	26					4944	4955		10.1038/s41388-020-1339-8	http://dx.doi.org/10.1038/s41388-020-1339-8		JUN 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MQ2YO	32493957				2022-12-28	WOS:000537926600001
J	Wohlberedt, K; Klusmann, I; Derevyanko, PK; Henningsen, K; Choo, JAMY; Manzini, V; Magerhans, A; Giansanti, C; Eischen, CM; Jochemsen, AG; Dobbelstein, M				Wohlberedt, Kai; Klusmann, Ina; Derevyanko, Polina K.; Henningsen, Kester; Choo, Josephine Ann Mun Yee; Manzini, Valentina; Magerhans, Anna; Giansanti, Celeste; Eischen, Christine M.; Jochemsen, Aart G.; Dobbelstein, Matthias			Mdm4 supports DNA replication in a p53-independent fashion	ONCOGENE			English	Article							TRANSCRIPTION FACTOR; THERAPEUTIC TARGET; P53; TRANSFORMATION; SUPPRESSION; INSTABILITY; REPRESSOR; PATHWAY; COMPLEX; LEADS	The Mdm4 (alias MdmX) oncoprotein, like its paralogue and interaction partner Mdm2, antagonizes the tumor suppressor p53. p53-independent roles of the Mdm proteins are emerging, and we have reported the ability of Mdm2 to modify chromatin and to support DNA replication by suppressing the formation of R-loops (DNA/RNA-hybrids). We show here that the depletion of Mdm4 in p53-deficient cells compromises DNA replication fork progression as well. Among various deletion mutants, only full-length Mdm4 was able to support DNA replication fork progression. Co-depletion of Mdm4 and Mdm2 further impaired DNA replication, and the overexpression of each partially compensated for the other's loss. Despite impairing replication, Mdm4 depletion only marginally hindered cell proliferation, likely due to compensation through increased firing of replication origins. However, depleting Mdm4 sensitized p53-/- cells to the nucleoside analog gemcitabine, raising the future perspective of using Mdm4 inhibitors as chemosensitizers. Mechanistically, Mdm4 interacts with members of the Polycomb Repressor Complexes and supports the ubiquitination of H2A, thereby preventing the accumulation of DNA/RNA-hybrids. Thus, in analogy to previously reported activities of Mdm2, Mdm4 enables unperturbed DNA replication through the avoidance of R-loops.	[Wohlberedt, Kai; Klusmann, Ina; Derevyanko, Polina K.; Henningsen, Kester; Choo, Josephine Ann Mun Yee; Manzini, Valentina; Magerhans, Anna; Giansanti, Celeste; Dobbelstein, Matthias] Univ Med Ctr Gottingen, Gottingen Ctr Mol Biosci GZMB, Inst Mol Oncol, D-37077 Gottingen, Germany; [Eischen, Christine M.] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Dept Canc Biol, Philadelphia, PA 19107 USA; [Jochemsen, Aart G.] Leiden Univ, Med Ctr, Dept Cell & Chem Biol, Leiden, Netherlands	University of Gottingen; Jefferson University; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Dobbelstein, M (corresponding author), Univ Med Ctr Gottingen, Gottingen Ctr Mol Biosci GZMB, Inst Mol Oncol, D-37077 Gottingen, Germany.	mdobbel@uni-goettingen.de		Choo, Josephine Ann Mun Yee/0000-0001-6457-8395; Giansanti, Celeste/0000-0003-3229-8385	Deutsche Krebshilfe; Wilhelm Sander Stiftung; Else Kroner Fresenius Stiftung; Deutsche Jose Carreras Leukamie Stiftung; Deutsche Forschungsgemeinschaft; Boehringer Ingelheim Fonds; German Academic Scholarship Foundation	Deutsche Krebshilfe(Deutsche Krebshilfe); Wilhelm Sander Stiftung; Else Kroner Fresenius Stiftung; Deutsche Jose Carreras Leukamie Stiftung; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Boehringer Ingelheim Fonds(Boehringer Ingelheim); German Academic Scholarship Foundation	We thank Guillermina Lozano for the MEFs with p53/Mdm4/Mdm2 deletions. pCMV-Flag-Mdm4 was a gift from Zhi-Min Yuan. pCMV-MDM2 was a gift from Bert Vogelstein (Addgene plasmid #16441), pCMV-MDM2(C464A) was provided by Tyler Jacks (Addgene plasmid #12086), pICE-RNaseHI-WT-NLS-mCherry (Addgene plasmid #60365) as well as pICE-RNaseHI-D10R-E48R-NLS-mCherry (Addgene plasmid #60367) were obtained from Patrick Calsou. H2A and EZH2 expression plasmids were from Titia Sixma (Addgene plasmids #63561 and #63564) and Kristian Helin (Addgene plasmid #24230), respectively. pLenti6/V5-DEST-RNF2 was a gift from Lynda Chin (Addgene plasmid #31216). This work was supported by the Deutsche Krebshilfe (to MD and KW), the Wilhelm Sander Stiftung, the Else Kroner Fresenius Stiftung, the Deutsche Jose Carreras Leukamie Stiftung, the Deutsche Forschungsgemeinschaft, the Boehringer Ingelheim Fonds (to IK) and the German Academic Scholarship Foundation (to KW). IK, PD, and VM were members of the IMPRS/MSc/PhD program Molecular Biology and IK, VM, CG and JC also of the Gottingen Graduate School GGNB Gottingen.	Aguilera A, 2012, MOL CELL, V46, P115, DOI 10.1016/j.molcel.2012.04.009; Alt JR, 2005, J BIOL CHEM, V280, P18771, DOI 10.1074/jbc.M413387200; Bernal F, 2010, CANCER CELL, V18, P411, DOI 10.1016/j.ccr.2010.10.024; Blow JJ, 2011, TRENDS BIOCHEM SCI, V36, P405, DOI 10.1016/j.tibs.2011.05.002; BOGUSLAWSKI SJ, 1986, J IMMUNOL METHODS, V89, P123, DOI 10.1016/0022-1759(86)90040-2; Bohlman Stephen, 2014, Subcell Biochem, V85, P235, DOI 10.1007/978-94-017-9211-0_13; Bouska A, 2008, MOL CELL BIOL, V28, P4862, DOI 10.1128/MCB.01584-07; Carillo Alexia M, 2015, ONCOGENE, V34, P846; Carvajal LA, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao3003; Danovi D, 2004, MOL CELL BIOL, V24, P5835, DOI 10.1128/MCB.24.13.5835-5843.2004; Dewaele M, 2016, J CLIN INVEST, V126, P68, DOI 10.1172/JCI82534; Dobbelstein M, 2015, NAT REV DRUG DISCOV, V14, P405, DOI 10.1038/nrd4553; El Hage A, 2010, GENE DEV, V24, P1546, DOI 10.1101/gad.573310; Fahraeus R, 2014, ONCOGENE, V33, P4365, DOI 10.1038/onc.2013.410; Fischer M, 2014, CELL CYCLE, V13, P3037, DOI 10.4161/15384101.2014.949083; Gan WJ, 2011, GENE DEV, V25, P2041, DOI 10.1101/gad.17010011; Garcia D, 2011, GENE DEV, V25, P1746, DOI 10.1101/gad.16722111; Gazdar AF, 2010, LUNG CANCER, V68, P309, DOI 10.1016/j.lungcan.2009.12.005; Gembarska A, 2012, NAT MED, V18, P1239, DOI 10.1038/nm.2863; Gradiz R, 2016, SCI REP-UK, V6, DOI 10.1038/srep21648; Han X, 2016, CL LYMPH MYELOM LEUK, V16, pS30, DOI 10.1016/j.clml.2016.03.012; Haupt S, 2019, J MOL CELL BIOL, V11, P231, DOI 10.1093/jmcb/mjz007; Heijkants RC, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0041-y; Jin Y, 2008, MOL CELL BIOL, V28, P1218, DOI 10.1128/MCB.01198-07; Klusmann I, 2018, P NATL ACAD SCI USA, V115, pE11311, DOI 10.1073/pnas.1809592115; Klusmann I, 2016, CELL REP, V17, P1845, DOI 10.1016/j.celrep.2016.10.036; Kuser-Abali G, 2018, P NATL ACAD SCI USA, V115, P3452, DOI 10.1073/pnas.1719532115; Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194; Lee J, 2013, MOL BIOL CELL, V24, P1343, DOI 10.1091/mbc.E13-01-0025; Li YB, 2019, J MED CHEM, V62, P448, DOI 10.1021/acs.jmedchem.8b00909; Linares LK, 2003, P NATL ACAD SCI USA, V100, P12009, DOI 10.1073/pnas.2030930100; Marine JC, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026237; Matijasevic Z, 2008, CELL CYCLE, V7, P2967, DOI 10.4161/cc.7.19.6797; Matijasevic Z, 2008, MOL CELL BIOL, V28, P1265, DOI 10.1128/MCB.01108-07; Meulmeester E, 2003, MOL CELL BIOL, V23, P4929, DOI 10.1128/MCB.23.14.4929-4938.2003; Miranda PJ, 2017, J PATHOL, V241, P661, DOI 10.1002/path.4877; Momand J, 2011, GENE, V486, P23, DOI 10.1016/j.gene.2011.06.030; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Park DE, 2019, P NATL ACAD SCI USA, V116, P1027, DOI 10.1073/pnas.1818798116; Pellegrino M, 2015, CANCER RES, V75, P4560, DOI 10.1158/0008-5472.CAN-15-0439; Plunkett W, 1996, SEMIN ONCOL, V23, P3; Quinet A, 2017, METHOD ENZYMOL, V591, P55, DOI 10.1016/bs.mie.2017.03.019; Riley Maurisa F, 2012, Genes Cancer, V3, P226, DOI 10.1177/1947601912455322; Shvarts A, 1997, GENOMICS, V43, P34, DOI 10.1006/geno.1997.4775; Stad R, 2001, EMBO REP, V2, P1029, DOI 10.1093/embo-reports/kve227; Strachan GD, 2003, J CELL BIOCHEM, V88, P557, DOI 10.1002/jcb.10318; Techer H, 2013, J MOL BIOL, V425, P4845, DOI 10.1016/j.jmb.2013.03.040; Valentin-Vega YA, 2009, DIFFERENTIATION, V77, P442, DOI 10.1016/j.diff.2009.03.001; Wen W, 2014, ONCOGENE, V33, P421, DOI 10.1038/onc.2012.605; Wienken M, 2016, MOL CELL, V61, P68, DOI 10.1016/j.molcel.2015.12.008; Zhang H, 2015, ONCOGENE, V34, P5560, DOI 10.1038/onc.2015.11	51	6	6	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 18	2020	39	25					4828	4843		10.1038/s41388-020-1325-1	http://dx.doi.org/10.1038/s41388-020-1325-1		MAY 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LZ3HT	32427989	Green Accepted, Green Published			2022-12-28	WOS:000534491700002
J	Rao, HY; Li, XF; Liu, M; Liu, J; Li, XX; Xu, J; Li, L; Gao, WQ				Rao, Hanyu; Li, Xuefeng; Liu, Min; Liu, Jing; Li, Xiaoxue; Xu, Jin; Li, Li; Gao, Wei-Qiang			Di-Ras2 promotes renal cell carcinoma formation by activating the mitogen-activated protein kinase pathway in the absence of von Hippel-Lindau protein	ONCOGENE			English	Article							COMPREHENSIVE MOLECULAR CHARACTERIZATION; TUMOR-SUPPRESSOR; SIGNALING PATHWAYS; UBIQUITINATION; RAS; VHL; INHIBITION; LANDSCAPE; NECROSIS; DRIVER	Clear cell renal cell carcinoma (ccRCC) is one of the most common and lethal human urological malignancies in the world. One of the pathological drivers for ccRCC is the Ras family of small GTPases that function as "molecular switches" in many diseases including ccRCC. Among the GTPases in the Di-Ras family, DIRAS2 gene encodes a GTPase that shares 60% homology to Ras and Rap. Yet little is known about the biological function(s) of Di-Ras2 or how its activities are regulated. In this study, we focused on Di-Ras2, and determined its functions and underlying mechanism during formation of ccRCC. We found that Di-Ras2 was upregulated in ccRCC, and promoted the proliferation, migration and invasion of human ccRCC cells in the absence of von Hippel-Lindau protein (pVHL). Mechanistically, Di-Ras2 induces and regulates ccRCC formation by modulating phosphorylation of the downstream effectors and activating the Ras/mitogen-activated protein kinase (MAPK) signaling pathway. Moreover, Di-Ras2 interacts with E3 ubiquitin ligase, pVHL, which facilitates the ubiquitination and degradation of Di-Ras2. Together, these results indicate a potential function of Di-Ras2 as an oncogene in ccRCC, and these data provide a new perspective of the relationship between pVHL and the MAPK pathway in ccRCC tumorigenesis.	[Rao, Hanyu; Li, Xuefeng; Liu, Min; Liu, Jing; Li, Xiaoxue; Li, Li; Gao, Wei-Qiang] Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Renji Med X Clin Stem Cell Res Ctr, Ren Ji Hosp,Sch Med, Shanghai 200127, Peoples R China; [Rao, Hanyu; Li, Xuefeng; Liu, Min; Liu, Jing; Li, Xiaoxue; Xu, Jin; Li, Li; Gao, Wei-Qiang] Shanghai Jiao Tong Univ, Sch Biomed Engn, Shanghai 200127, Peoples R China; [Rao, Hanyu; Liu, Min; Liu, Jing; Li, Xiaoxue; Xu, Jin; Li, Li; Gao, Wei-Qiang] Shanghai Jiao Tong Univ, Med X Res Inst, Shanghai, Peoples R China; [Li, Xuefeng] Univ South China, Affiliated Hosp 1, Dept Med Oncol, Hengyang 421001, Hunan, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; University of South China	Li, L; Gao, WQ (corresponding author), Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Renji Med X Clin Stem Cell Res Ctr, Ren Ji Hosp,Sch Med, Shanghai 200127, Peoples R China.; Li, L; Gao, WQ (corresponding author), Shanghai Jiao Tong Univ, Sch Biomed Engn, Shanghai 200127, Peoples R China.; Li, L; Gao, WQ (corresponding author), Shanghai Jiao Tong Univ, Med X Res Inst, Shanghai, Peoples R China.	lil@sjtu.edu.cn; gao.weiqiang@sjtu.edu.cn	Gao, Wei/GXH-0380-2022	Li, Li/0000-0003-2342-3658				Alonso-Gordoa T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081901; Alt AL, 2011, CANCER-AM CANCER SOC, V117, P2873, DOI 10.1002/cncr.25836; Aoki Y, 2008, HUM MUTAT, V29, P992, DOI 10.1002/humu.20748; Banumathy G, 2010, CANCER BIOL THER, V10, P658, DOI 10.4161/cbt.10.7.13247; Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Brinkmann K, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00098; Brodaczewska KK, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0565-8; Chitalia VC, 2008, NAT CELL BIOL, V10, P1208, DOI 10.1038/ncb1781; Chittiboina Prashant, 2015, Handb Clin Neurol, V132, P139, DOI 10.1016/B978-0-444-62702-5.00010-X; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Davis CF, 2014, CANCER CELL, V26, P319, DOI 10.1016/j.ccr.2014.07.014; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Dushukyan N, 2017, CELL REP, V21, P1883, DOI 10.1016/j.celrep.2017.10.074; Elbanna M, 2020, MOL CANCER THER, V19, P147, DOI 10.1158/1535-7163.MCT-18-1202; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Foster SA, 2016, MOL CELL, V64, P854, DOI 10.1016/j.molcel.2016.11.024; Gasper Raphael, 2010, Small GTPases, V1, P133, DOI 10.4161/sgtp.1.3.14742; Hasanov E, 2017, ONCOGENE, V36, P3450, DOI 10.1038/onc.2016.495; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Hsieh JJ, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.9; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Kontani K, 2002, J BIOL CHEM, V277, P41070, DOI 10.1074/jbc.M202150200; Kulbe H, 2007, CANCER RES, V67, P585, DOI 10.1158/0008-5472.CAN-06-2941; Kuznetsova AV, 2003, P NATL ACAD SCI USA, V100, P2706, DOI 10.1073/pnas.0436037100; Li Q, 2018, IMMUNITY, V48, P258, DOI 10.1016/j.immuni.2017.12.013; Linehan WM, 2016, NEW ENGL J MED, V374, P135, DOI 10.1056/NEJMoa1505917; Maniaci C, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00954-1; Moch H, 2016, EUR UROL, V70, P93, DOI 10.1016/j.eururo.2016.02.029; Morris MR, 2017, NAT REV NEPHROL, V13, P47, DOI 10.1038/nrneph.2016.168; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Ogita Y, 2015, J BIOL CHEM, V290, P20245, DOI 10.1074/jbc.M115.637769; Okuda H, 2001, J BIOL CHEM, V276, P43611, DOI 10.1074/jbc.M107880200; Paik PK, 2011, J CLIN ONCOL, V29, P2046, DOI 10.1200/JCO.2010.33.1280; Rini BI, 2009, LANCET, V373, P1119, DOI 10.1016/S0140-6736(09)60229-4; Ritt DA, 2016, MOL CELL, V64, P875, DOI 10.1016/j.molcel.2016.10.029; Robinson CM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21524-5; Schermer B, 2006, J CELL BIOL, V175, P547, DOI 10.1083/jcb.200605092; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Stadler WM, 2005, CANCER-AM CANCER SOC, V104, P2323, DOI 10.1002/cncr.21453; Tang XH, 2016, CANCER RES, V76, P1892, DOI 10.1158/0008-5472.CAN-15-2328; Tidyman WE, 2009, CURR OPIN GENET DEV, V19, P230, DOI 10.1016/j.gde.2009.04.001; Tu YQ, 2012, INT J CLIN EXP PATHO, V5, P726; Wu XF, 2016, OPEN MED-WARSAW, V11, P226, DOI 10.1515/med-2016-0043; Yang L, 2018, AM J MED SCI, V355, P368, DOI 10.1016/j.amjms.2017.12.012; Zeng LL, 2013, CANCER RES, V73, P5371, DOI 10.1158/0008-5472.CAN-12-4707; Zhang J, 2018, SCIENCE, V361, P290, DOI 10.1126/science.aap8411; Zhang JH, 2012, NATURE, V481, P157, DOI 10.1038/nature10725	48	5	5	2	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	19					3853	3866		10.1038/s41388-020-1247-y	http://dx.doi.org/10.1038/s41388-020-1247-y			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LK4OF	32161311				2022-12-28	WOS:000530841700005
J	Zhou, YH; Zhang, JL; Li, H; Huang, TT; Wong, CC; Wu, F; Wu, M; Weng, NQ; Liu, LP; Cheng, ASL; Yu, J; Wong, N; Lo, KW; Tang, PMK; Kang, W; To, KF				Zhou, Yuhang; Zhang, Jinglin; Li, Hui; Huang, Tingting; Wong, Chi Chun; Wu, Feng; Wu, Man; Weng, Nuoqing; Liu, Liping; Cheng, Alfred S. L.; Yu, Jun; Wong, Nathalie; Lo, Kwok Wai; Tang, Patrick M. K.; Kang, Wei; To, Ka Fai			AMOTL1 enhances YAP1 stability and promotes YAP1-driven gastric oncogenesis	ONCOGENE			English	Article							HIPPO PATHWAY; CANCER PROGRESSION; FAMILY PROTEINS; ANGIOMOTIN; ACTIVATION; REVEALS	Hippo signaling functions to limit cellular growth, but the aberrant nuclear accumulation of its downstream YAP1 leads to carcinogenesis. YAP1/TEAD complex activates the oncogenic downstream transcription, such as CTGF and c-Myc. How YAP1 is protected in the cytoplasm from ubiquitin-mediated degradation remains elusive. In this study, a member of Angiomotin (Motin) family, AMOTL1 (Angiomotin Like 1), was screened out as the only one to promote YAP1 nuclear accumulation by several clinical cohorts, which was further confirmed by the cellular functional assays. The interaction between YAP1 and AMOTL1 was suggested by co-immunoprecipitation and immunofluorescent staining. The clinical significance of the AMOTL1-YAP1-CTGF axis in gastric cancer (GC) was analyzed by multiple clinical cohorts. Moreover, the therapeutic effect of targeting the oncogenic axis was appraised by drug-sensitivity tests and xenograft-formation assays. The upregulation of AMOTL1 is associated with unfavorable clinical outcomes of GC, and knocking down AMOTL1 impairs its oncogenic properties. The cytoplasmic interaction between AMOTL1 and YAP1 protects each other from ubiquitin-mediated degradation. AMOTL1 promotes YAP1 translocation into the nuclei to activate the downstream expression, such as CTGF. Knocking down AMOTL1, YAP1, and CTGF enhances the therapeutic efficacies of the first-line anticancer drugs. Taken together, AMOTL1 plays an oncogenic role in gastric carcinogenesis through interacting with YAP1 and promoting its nuclear accumulation. A combination of AMOTL1, YAP1, and CTGF expression might serve as a surrogate of Hippo activation status. The co-activation of the AMOTL1/YAP1-CTGF axis is associated with poor clinical outcomes of GC patients, and targeting this oncogenic axis may enhance the chemotherapeutic effects.	[Zhou, Yuhang; Zhang, Jinglin; Li, Hui; Huang, Tingting; Wu, Feng; Wu, Man; Wong, Nathalie; Lo, Kwok Wai; Tang, Patrick M. K.; Kang, Wei; To, Ka Fai] Chinese Univ Hong Kong, Prince Wales Hosp, State Key Lab Translat Oncol, Dept Anat & Cellular Pathol, Hong Kong, Peoples R China; [Zhou, Yuhang; Zhang, Jinglin; Huang, Tingting; Wong, Chi Chun; Yu, Jun; Kang, Wei; To, Ka Fai] Chinese Univ Hong Kong, Inst Digest Dis, State Key Lab Digest Dis, Hong Kong, Peoples R China; [Zhou, Yuhang; Zhang, Jinglin; Huang, Tingting; Wong, Nathalie; Lo, Kwok Wai; Kang, Wei; To, Ka Fai] Chinese Univ Hong Kong, Sir YK Pao Canc Ctr, Li Ka Shing Inst Hlth Sci, Hong Kong, Peoples R China; [Weng, Nuoqing; Cheng, Alfred S. L.; Yu, Jun] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Guangdong, Peoples R China; [Liu, Liping] Jinan Univ, Clin Med Coll 2, Shenzhen Peoples Hosp, Dept Hepatobiliary & Pancreat Surg, Shenzhen, Guangdong, Peoples R China; [Cheng, Alfred S. L.] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Peoples R China; [Yu, Jun] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Chinese University of Hong Kong; Sun Yat Sen University; Jinan University; Chinese University of Hong Kong; Chinese University of Hong Kong	Kang, W; To, KF (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, State Key Lab Translat Oncol, Dept Anat & Cellular Pathol, Hong Kong, Peoples R China.; Kang, W; To, KF (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis, State Key Lab Digest Dis, Hong Kong, Peoples R China.; Kang, W; To, KF (corresponding author), Chinese Univ Hong Kong, Sir YK Pao Canc Ctr, Li Ka Shing Inst Hlth Sci, Hong Kong, Peoples R China.	weikang@cuhk.edu.hk; kfto@cuhk.edu.hk	KANG, Wei/C-5451-2016; huang, ting/GRR-3141-2022; Tang, Patrick MK/AAJ-8461-2021	KANG, Wei/0000-0002-4651-677X; Tang, Patrick MK/0000-0002-3194-3736	Research Grants Council of the Hong Kong Special Administrative Region, China [CUHK 14100019, 14118518]; Innovation and Technology Fund of Hong Kong [ITS/068/18, PiH/009/19, PiH/010/19, InP/008/19, InP/009/19]; CUHK Direct Grant for Research from The Chinese University of Hong Kong [2018.002]	Research Grants Council of the Hong Kong Special Administrative Region, China(Hong Kong Research Grants Council); Innovation and Technology Fund of Hong Kong; CUHK Direct Grant for Research from The Chinese University of Hong Kong	The paper is under support of the Research Grants Council of the Hong Kong Special Administrative Region, China [Project No.: CUHK 14100019 and 14118518 (for GRF projects)], Innovation and Technology Fund of Hong Kong (Project No.: (ITS/068/18, PiH/009/19, PiH/010/19, InP/008/19, and InP/009/19)), and CUHK Direct Grant for Research (2018.002) from The Chinese University of Hong Kong.	Aase K, 2007, GENE DEV, V21, P2055, DOI 10.1101/gad.432007; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cheng TY, 2014, WORLD J GASTROENTERO, V20, P1694, DOI 10.3748/wjg.v20.i7.1694; Couderc C, 2016, NEOPLASIA, V18, P10, DOI 10.1016/j.neo.2015.11.010; Deng NT, 2012, GUT, V61, P673, DOI 10.1136/gutjnl-2011-301839; Hong SA, 2017, APMIS, V125, P996, DOI 10.1111/apm.12750; Hsu YL, 2015, ONCOGENE, V34, P4056, DOI 10.1038/onc.2014.333; Huang HZ, 2007, DEVELOPMENT, V134, P979, DOI 10.1242/dev.02782; Huang TT, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1466-y; Hultin S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4743; Jiang CG, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-122; Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161; Kang W, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0134-0; Kang W, 2017, J THORAC DIS, V9, P1748, DOI 10.21037/jtd.2017.06.26; Kang W, 2016, WORLD J GASTROENTERO, V22, P1279, DOI 10.3748/wjg.v22.i3.1279; Kang W, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0323-3; Kang W, 2011, CLIN CANCER RES, V17, P2130, DOI 10.1158/1078-0432.CCR-10-2467; Li ZQ, 2012, J BIOL CHEM, V287, P13005, DOI 10.1074/jbc.M112.347419; Lim B, 2014, CARCINOGENESIS, V35, P1020, DOI 10.1093/carcin/bgt409; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Lu TT, 2018, CANCER LETT, V423, P36, DOI 10.1016/j.canlet.2018.02.015; Paramasivam M, 2011, MOL BIOL CELL, V22, P3725, DOI 10.1091/mbc.E11-04-0300; Perra A, 2014, J HEPATOL, V61, P1088, DOI 10.1016/j.jhep.2014.06.033; Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035; Shi Z, 2017, ONCOGENE, V36, P4362, DOI 10.1038/onc.2017.24; Trautmann M, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201809889; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Wang WQ, 2011, J BIOL CHEM, V286, P4364, DOI 10.1074/jbc.C110.205401; Wang Y, 2017, ONCOGENE, V36, P534, DOI 10.1038/onc.2016.224; Weiler SME, 2017, GASTROENTEROLOGY, V152, P2037, DOI 10.1053/j.gastro.2017.02.018; Yi CL, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004060; Yu MX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0515-z; Zhao B, 2011, GENE DEV, V25, P51, DOI 10.1101/gad.2000111; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810; Zheng YJ, 2009, CIRC RES, V105, P260, DOI 10.1161/CIRCRESAHA.109.195156; Zhou Y, 2017, ONCOGENE, V36, P6518, DOI 10.1038/onc.2017.257; Zhou YH, 2018, CANCER LETT, V426, P73, DOI 10.1016/j.canlet.2018.04.004; Zhou YH, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0647-2; Zhou YH, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010138	40	11	11	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	22					4375	4389		10.1038/s41388-020-1293-5	http://dx.doi.org/10.1038/s41388-020-1293-5		APR 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LR9IT	32313226	hybrid, Green Published			2022-12-28	WOS:000527509300001
J	Ames, S; Andring, JT; McKenna, R; Becker, HM				Ames, Samantha; Andring, Jacob T.; McKenna, Robert; Becker, Holger M.			CAIX forms a transport metabolon with monocarboxylate transporters in human breast cancer cells	ONCOGENE			English	Article							CARBONIC-ANHYDRASE IX; APPARENT DIFFUSION-COEFFICIENT; XENOPUS-LAEVIS OOCYTES; IMMUNOGLOBULIN SUPERFAMILY; TRANSMEMBRANE HELICES; LACTATE TRANSPORTER; ANCILLARY PROTEIN; PLASMA-MEMBRANE; BASIGIN CD147; EXPRESSION	Tumor cells rely on glycolysis to meet their elevated demand for energy. Thereby they produce significant amounts of lactate and protons, which are exported via monocarboxylate transporters (MCTs), supporting the formation of an acidic microenvironment. The present study demonstrates that carbonic anhydrase IX (CAIX), one of the major acid/base regulators in cancer cells, forms a protein complex with MCT1 and MCT4 in tissue samples from human breast cancer patients, but not healthy breast tissue. Formation of this transport metabolon requires binding of CAIX to the Ig1 domain of the MCT1/4 chaperon CD147 and is required for CAIX-mediated facilitation of MCT1/4 activity. Application of an antibody, directed against the CD147-Ig1 domain, displaces CAIX from the transporter and suppresses CAIX-mediated facilitation of proton-coupled lactate transport. In cancer cells, this "metabolon disruption" results in a decrease in lactate transport, reduced glycolysis, and ultimately reduced cell proliferation. Taken together, the study shows that carbonic anhydrases form transport metabolons with acid/base transporters in human tumor tissue and that these interactions can be exploited to interfere with tumor metabolism and proliferation.	[Ames, Samantha; Becker, Holger M.] Univ Kaiserslautern TUK, Dept Biol, Div Gen Zool, D-67653 Kaiserslautern, Germany; [Andring, Jacob T.; McKenna, Robert] Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; [Becker, Holger M.] Univ Vet Med Hannover, Inst Physiol Chem, D-30559 Hannover, Germany	State University System of Florida; University of Florida; University of Veterinary Medicine Hannover, Foundation	Becker, HM (corresponding author), Univ Kaiserslautern TUK, Dept Biol, Div Gen Zool, D-67653 Kaiserslautern, Germany.	Holger.Becker@tiho-hannover.de	Becker, Holger/AAB-4322-2020		Deutsche Forschungsgemeinschaft [BE 4310/6-1]; Research Initiative BioComp; Lotto-Stiftung Rheinland-Pfalz; FAZIT Stiftung	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Research Initiative BioComp; Lotto-Stiftung Rheinland-Pfalz; FAZIT Stiftung	We thank Heike Kanapin, Sandra Pfeiffer, HansPeter Schneider, and Patrick Pattar for technical assistance. The work was funded by the Deutsche Forschungsgemeinschaft (to H.M.B.; BE 4310/6-1), the Research Initiative BioComp (to H.M.B), and by stipends from the Lotto-Stiftung Rheinland-Pfalz and the FAZIT Stiftung (to S.A.).	Adams A, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-538; Adelroth P, 2004, BBA-BIOENERGETICS, V1655, P102, DOI 10.1016/j.bbabio.2003.10.018; Alvarez BV, 2005, EMBO J, V24, P2499, DOI 10.1038/sj.emboj.7600736; Ames Samantha, 2018, Oncotarget, V9, P27940, DOI 10.18632/oncotarget.25371; Bane AL, 2014, ANN ONCOL, V25, P992, DOI 10.1093/annonc/mdu090; Becker HM, 2004, BIOPHYS J, V86, P235, DOI 10.1016/S0006-3495(04)74099-0; Becker HM, 2014, NEUROMETHODS, V90, P25, DOI 10.1007/978-1-4939-1059-5_2; Becker HM, 2011, P NATL ACAD SCI USA, V108, P3071, DOI 10.1073/pnas.1014293108; Beketic-Oreskovic L, 2011, PATHOL ONCOL RES, V17, P593, DOI 10.1007/s12253-010-9355-6; Belli P, 2015, RADIOL MED, V120, P268, DOI 10.1007/s11547-014-0442-8; Benjamin D, 2018, CELL REP, V25, P3047, DOI 10.1016/j.celrep.2018.11.043; Bonen A, 2000, MED SCI SPORT EXER, V32, P778, DOI 10.1097/00005768-200004000-00010; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Broer S, 1997, J BIOL CHEM, V272, P30096, DOI 10.1074/jbc.272.48.30096; Broer S, 1998, BIOCHEM J, V333, P167, DOI 10.1042/bj3330167; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen CL, 2010, VIRCHOWS ARCH, V457, P53, DOI 10.1007/s00428-010-0938-0; Chiche J, 2009, CANCER RES, V69, P358, DOI 10.1158/0008-5472.CAN-08-2470; Choi JH, 2018, ANN NUCL MED, V32, P389, DOI 10.1007/s12149-018-1259-7; Choi J, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3472; Choi J, 2013, PATHOBIOLOGY, V80, P41, DOI 10.1159/000339513; Cipolla V, 2014, EUR J RADIOL, V83, P2144, DOI 10.1016/j.ejrad.2014.09.015; Currie MJ, 2013, HUM PATHOL, V44, P402, DOI 10.1016/j.humpath.2012.06.004; Debernardi R, 2003, J NEUROSCI RES, V73, P141, DOI 10.1002/jnr.10660; Deitmer JW, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00291; DEITMER JW, 1991, J GEN PHYSIOL, V98, P637, DOI 10.1085/jgp.98.3.637; Dimmer KS, 2000, BIOCHEM J, V350, P219, DOI 10.1042/0264-6021:3500219; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Forero-Quintero LS, 2019, J BIOL CHEM, V294, P593, DOI 10.1074/jbc.RA118.005536; FOSSUM S, 1991, EUR J IMMUNOL, V21, P671, DOI 10.1002/eji.1830210320; Friedman R, 2005, BIOPHYS J, V89, P768, DOI 10.1529/biophysj.105.058917; Guan X, 2019, AAPS J, V21, DOI 10.1208/s12248-018-0279-5; Guan XW, 2019, AAPS J, V21, DOI 10.1208/s12248-018-0261-2; Gutman M, 2006, PHOTOCH PHOTOBIO SCI, V5, P531, DOI 10.1039/b515887g; Halestrap AP, 2013, MOL ASPECTS MED, V34, P337, DOI 10.1016/j.mam.2012.05.003; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; Hiremath SA, 2019, MATH BIOSCI ENG, V16, P320, DOI 10.3934/mbe.2019016; Innocenti A, 2009, BIOORG MED CHEM LETT, V19, P5825, DOI 10.1016/j.bmcl.2009.08.088; Jackson VN, 1996, J BIOL CHEM, V271, P861, DOI 10.1074/jbc.271.2.861; Jamali S, 2015, SCI REP-UK, V5, DOI 10.1038/srep13605; Johnson JM, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00027; Kim S, 2013, J BREAST CANCER, V16, P146, DOI 10.4048/jbc.2013.16.2.146; Klier M, 2011, J BIOL CHEM, V286, P27781, DOI 10.1074/jbc.M111.255331; Kuang YH, 2018, HONG KONG MED J, V24, P252, DOI 10.12809/hkmj176865; Kwon JE, 2013, TUMOR BIOL, V34, P115, DOI 10.1007/s13277-012-0518-9; Liu M, 2018, J CLIN PATHOL, V71, P1007, DOI 10.1136/jclinpath-2018-205342; Luz MCD, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040170; Manoharan C, 2006, MOL MEMBR BIOL, V23, P486, DOI 10.1080/09687860600841967; Mboge MY, 2019, BIOCHEM J, V476, P1497, DOI 10.1042/BCJ20190177; Muramatsu T, 2016, J BIOCHEM, V159, P481, DOI 10.1093/jb/mvv127; Nabeshima K, 2006, PATHOL INT, V56, P359, DOI 10.1111/j.1440-1827.2006.01972.x; Noor SI, 2018, ELIFE, V7, DOI 10.7554/eLife.35176; Noor SI, 2017, FEBS J, V284, P149, DOI 10.1111/febs.13964; Noor SI, 2015, J BIOL CHEM, V290, P4476, DOI 10.1074/jbc.M114.624577; Ovens MJ, 2010, BIOCHEM J, V425, P523, DOI 10.1042/BJ20091515; Ozretic P, 2018, INT J BIOL MARKER, V33, P109, DOI 10.5301/ijbm.5000291; Parks SK, 2013, NAT REV CANCER, V13, P611, DOI 10.1038/nrc3579; PASTOREK J, 1994, ONCOGENE, V9, P2877; Pastorek J, 2015, SEMIN CANCER BIOL, V31, P52, DOI 10.1016/j.semcancer.2014.08.002; Pastorekova S, 2004, CANC THER, V2, P245; Pinard MA, 2015, ACTA CRYSTALLOGR F, V71, P1352, DOI 10.1107/S2053230X1501239X; Pinheiro C, 2012, J BIOENERG BIOMEMBR, V44, P127, DOI 10.1007/s10863-012-9428-1; Pinheiro C, 2011, HISTOL HISTOPATHOL, V26, P1279, DOI 10.14670/HH-26.1279; Pinheiro C, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/427694; Pinheiro C, 2010, HISTOPATHOLOGY, V56, P860, DOI 10.1111/j.1365-2559.2010.03560.x; Renner K, 2019, CELL REP, V29, P135, DOI 10.1016/j.celrep.2019.08.068; San Martin A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057712; SRERE PA, 1985, TRENDS BIOCHEM SCI, V10, P109, DOI 10.1016/0968-0004(85)90266-X; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; Stridh MH, 2012, J PHYSIOL-LONDON, V590, P2333, DOI 10.1113/jphysiol.2011.220152; Supuran CT, 2017, METABOLITES, V7, DOI 10.3390/metabo7030048; Swietach P, 2010, ONCOGENE, V29, P6509, DOI 10.1038/onc.2010.455; Swietach P, 2019, CANCER METAST REV, V38, P5, DOI 10.1007/s10555-018-09778-x; Tan EY, 2009, BRIT J CANCER, V100, P405, DOI 10.1038/sj.bjc.6604844; Vermeulen JF, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-240; Walter M, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1078056; Wilson MC, 2005, J BIOL CHEM, V280, P27213, DOI 10.1074/jbc.M411950200; Wilson MC, 2002, J BIOL CHEM, V277, P3666, DOI 10.1074/jbc.M109658200; Wykoff CC, 2000, CANCER RES, V60, P7075; Yu XL, 2008, J BIOL CHEM, V283, P18056, DOI 10.1074/jbc.M802694200; Zat'ovicova M, 2003, J IMMUNOL METHODS, V282, P117, DOI 10.1016/j.jim.2003.08.011	81	21	22	0	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	8					1710	1723		10.1038/s41388-019-1098-6	http://dx.doi.org/10.1038/s41388-019-1098-6			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN6CG	31723238	Green Submitted			2022-12-28	WOS:000514923000007
J	Warren, NJH; Eastman, A				Warren, Nicholas J. H.; Eastman, Alan			Comparison of the different mechanisms of cytotoxicity induced by checkpoint kinase I inhibitors when used as single agents or in combination with DNA damage	ONCOGENE			English	Review							CYCLIN-DEPENDENT KINASES; STRAND BREAK REPAIR; CHK1 INHIBITOR; CELL-CYCLE; PHASE-I; REPLICATION STRESS; SYNTHETIC LETHALITY; DOSE-ESCALATION; CANCER-CELLS; GENOME INTEGRITY	Inhibition of the DNA damage response is an emerging strategy to treat cancer. Understanding how DNA damage response inhibitors cause cytotoxicity in cancer cells is crucial to their further clinical development. This review focuses on three different mechanisms of cell killing by checkpoint kinase I inhibitors (CHK1i). DNA damage induced by chemotherapy drugs, such as topoisomerase I inhibitors, results in S and G2 phase arrest. Addition of CHK1i promotes cell cycle progression before repair is completed resulting in mitotic catastrophe. Ribonucleotide reductase inhibitors such as gemcitabine also arrest cells in S phase by preventing dNTP synthesis. Addition of CHK1i re-activates the DNA helicase to unwind DNA, but in the absence of dNTPs, this leads to excessive single-strand DNA that exceeds the protective capacity of the single-strand-binding protein RPA. Unprotected DNA is subjected to nuclease cleavage, resulting in replication catastrophe. CHK1i alone also kills a subset of cell lines through MRE11 and MUS81-mediated DNA cleavage in S phase cells. The choice of mechanism depends on the activation state of CDK2. Low level activation of CDK2 mediates helicase activation, cell cycle progression, and both replication and mitotic catastrophe. In contrast, high CDK2 activity is required for sensitivity to CHK1i as monotherapy. This high CDK2 activity threshold usually occurs late in the cell cycle to prepare for mitosis, but in CHK1i-sensitive cells, high activity can be attained in early S phase, resulting in DNA cleavage and cell death. This sensitivity to CHK1i has previously been associated with endogenous replication stress, but the dependence on high CDK2 activity, as well as MRE11, contradicts this hypothesis. The major unresolved question is why some cell lines fail to restrain their high CDK2 activity and hence succumb to CHK1i in S phase. Resolving this question will facilitate stratification of patients for treatment with CHK1i as monotherapy.	[Warren, Nicholas J. H.; Eastman, Alan] Geisel Sch Med Dartmouth, Dept Mol & Syst Biol, Lebanon, NH 03756 USA; [Eastman, Alan] Geisel Sch Med Dartmouth, Norris Cotton Canc Ctr, Lebanon, NH 03756 USA	Dartmouth College; Dartmouth College; Norris Cotton Cancer Center	Eastman, A (corresponding author), Geisel Sch Med Dartmouth, Dept Mol & Syst Biol, Lebanon, NH 03756 USA.; Eastman, A (corresponding author), Geisel Sch Med Dartmouth, Norris Cotton Canc Ctr, Lebanon, NH 03756 USA.	Alan.R.Eastman@Dartmouth.edu		Warren, Nicholas/0000-0003-4640-2868	National Cancer Institute [CA117874]; Cancer Center Support Grant [CA23108]	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Center Support Grant	The research of the authors has been supported by a grant from the National Cancer Institute (CA117874), and a Cancer Center Support Grant to the Norris Cotton Cancer Center (CA23108).	Aarts M, 2012, CANCER DISCOV, V2, P524, DOI 10.1158/2159-8290.CD-11-0320; Al-Ahmadie H, 2014, CANCER DISCOV, V4, P1014, DOI 10.1158/2159-8290.CD-14-0380; [Anonymous], 2019, J CLIN ONCOL S; Arooz T, 2000, BIOCHEMISTRY-US, V39, P9494, DOI 10.1021/bi0009643; Bahassi EM, 2008, ONCOGENE, V27, P3977, DOI 10.1038/onc.2008.17; Banerji U, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.3095; Barnard D, 2016, INVEST NEW DRUG, V34, P49, DOI 10.1007/s10637-015-0310-y; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Beck H, 2010, J CELL BIOL, V188, P629, DOI 10.1083/jcb.200905059; Bergman AM, 2005, CANCER RES, V65, P9510, DOI 10.1158/0008-5472.CAN-05-0989; Betous R, 2012, GENE DEV, V26, P151, DOI 10.1101/gad.178459.111; Blackford AN, 2017, MOL CELL, V66, P801, DOI 10.1016/j.molcel.2017.05.015; Brega N, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.3062; Bremmer SC, 2012, J BIOL CHEM, V287, P1662, DOI 10.1074/jbc.M111.281105; Brooks EE, 1997, J BIOL CHEM, V272, P29207, DOI 10.1074/jbc.272.46.29207; Brown JS, 2017, CANCER DISCOV, V7, P20, DOI 10.1158/2159-8290.CD-16-0860; Buis J, 2012, NAT STRUCT MOL BIOL, V19, P246, DOI 10.1038/nsmb.2212; Buisson R, 2015, MOL CELL, V59, P1011, DOI 10.1016/j.molcel.2015.07.029; Bunch RT, 1996, CLIN CANCER RES, V2, P791; Carrassa L, 2011, CELL CYCLE, V10, P2121, DOI 10.4161/cc.10.13.16398; Cicenas J, 2014, CANCERS, V6, P2224, DOI 10.3390/cancers6042224; Coudreuse D, 2010, NATURE, V468, P1074, DOI 10.1038/nature09543; D'Angiolella V, 2012, CELL, V149, P1023, DOI 10.1016/j.cell.2012.03.043; Daud AI, 2015, J CLIN ONCOL, V33, P1060, DOI 10.1200/JCO.2014.57.5027; Davidson JD, 2004, CANCER RES, V64, P3761, DOI 10.1158/0008-5472.CAN-03-3363; Del Nagro CJ, 2014, CELL CYCLE, V13, P303, DOI 10.4161/cc.27055; Dietlein F, 2015, CELL, V162, P146, DOI 10.1016/j.cell.2015.05.053; Duda H, 2016, DEV CELL, V39, P740, DOI 10.1016/j.devcel.2016.11.017; Dungrawala H, 2015, MOL CELL, V59, P998, DOI 10.1016/j.molcel.2015.07.030; Eastman A, 2017, ONCOTARGET, V8, P8854, DOI 10.18632/oncotarget.12673; Esashi F, 2005, NATURE, V434, P598, DOI 10.1038/nature03404; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Ferrao PT, 2012, ONCOGENE, V31, P1661, DOI 10.1038/onc.2011.358; Forment JV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023517; Fugger K, 2015, CELL REP, V10, P1749, DOI 10.1016/j.celrep.2015.02.028; Fugger K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2395; Fukuda T, 2001, CANCER RES, V61, P23; Gadhikar MA, 2018, CANCER RES, V78, P781, DOI 10.1158/0008-5472.CAN-17-2802; Ge XQ, 2010, J CELL BIOL, V191, P1285, DOI 10.1083/jcb.201007074; Giannini G, 2002, EMBO REP, V3, P248, DOI 10.1093/embo-reports/kvf044; Gilad O, 2010, CANCER RES, V70, P9693, DOI 10.1158/0008-5472.CAN-10-2286; Godfrey M, 2017, MOL CELL, V65, P393, DOI 10.1016/j.molcel.2016.12.018; Gong CJ, 2016, BBA-GENE REGUL MECH, V1859, P612, DOI 10.1016/j.bbagrm.2016.02.012; Hashimoto Y, 2010, NAT STRUCT MOL BIOL, V17, P1305, DOI 10.1038/nsmb.1927; He YJ, 2018, NATURE, V563, P522, DOI 10.1038/s41586-018-0670-5; HEINEMANN V, 1990, MOL PHARMACOL, V38, P567; Hong D, 2016, J CLIN ONCOL, V34, P1764, DOI 10.1200/JCO.2015.64.5788; Infante JR, 2017, CLIN CANCER RES, V23, P2423, DOI 10.1158/1078-0432.CCR-16-1782; Italiano A, 2018, ANN ONCOL, V29, P1304, DOI 10.1093/annonc/mdy076; Jorda R, 2018, J MED CHEM, V61, P9105, DOI 10.1021/acs.jmedchem.8b00049; Karp JE, 2012, CLIN CANCER RES, V18, P6723, DOI 10.1158/1078-0432.CCR-12-2442; Kim MK, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1231-z; Kohler C, 2016, CELL CYCLE, V15, P974, DOI 10.1080/15384101.2016.1152424; Koh SB, 2018, CANCER RES, V78, P3054, DOI 10.1158/0008-5472.CAN-17-3932; Koh SB, 2015, CANCER RES, V75, P3583, DOI 10.1158/0008-5472.CAN-14-3347; Kohn EA, 2002, J BIOL CHEM, V277, P26553, DOI 10.1074/jbc.M202040200; Kotsantis P, 2018, CANCER DISCOV, V8, P537, DOI 10.1158/2159-8290.CD-17-1461; Kumagai A, 2011, J CELL BIOL, V193, P995, DOI 10.1083/jcb.201102003; Kumagai A, 2010, CELL, V140, P349, DOI 10.1016/j.cell.2009.12.049; Kwok M, 2016, BLOOD, V127, P582, DOI 10.1182/blood-2015-05-644872; Lee Jeaho, 2016, [Journal of Creative Information Culture, 창의정보문화연구], V2, P1; Lemacon D, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01180-5; Levesque AA, 2008, MOL CANCER THER, V7, P252, DOI 10.1158/1535-7163.MCT-07-2066; Lowery CD, 2019, CLIN CANCER RES, V25, P2278, DOI 10.1158/1078-0432.CCR-18-2728; Lu R, 2004, J BIOL CHEM, V279, P31164, DOI 10.1074/jbc.M404728200; Lu XY, 2009, J BIOL CHEM, V284, P35325, DOI 10.1074/jbc.M109.035949; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Manic G, 2018, GUT, V67, P903, DOI 10.1136/gutjnl-2016-312623; Mei L, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0733-6; Mini E, 2006, ANN ONCOL, V17, pV7, DOI 10.1093/annonc/mdj941; Mohni KN, 2014, CANCER RES, V74, P2835, DOI 10.1158/0008-5472.CAN-13-3229; Montano R, 2017, ONCOTARGET, V8, P67754, DOI 10.18632/oncotarget.18834; Montano R, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-604; Montano R, 2012, MOL CANCER THER, V11, P427, DOI 10.1158/1535-7163.MCT-11-0406; Nagel R, 2019, MOL CANCER THER, V18, P762, DOI 10.1158/1535-7163.MCT-18-0972; Parsels LA, 2016, CELL CYCLE, V15, P730, DOI 10.1080/15384101.2016.1148841; Pefani DE, 2014, NAT CELL BIOL, V16, P962, DOI 10.1038/ncb3035; Petermann E, 2010, MOL CELL, V37, P492, DOI 10.1016/j.molcel.2010.01.021; Pfister SX, 2015, CANCER CELL, V28, P557, DOI 10.1016/j.ccell.2015.09.015; Pommier Y, 2013, ACS CHEM BIOL, V8, P82, DOI 10.1021/cb300648v; Powers BL, 2017, J CELL SCI, V130, P2673, DOI 10.1242/jcs.201012; Puigvert JC, 2016, FEBS J, V283, P232, DOI 10.1111/febs.13574; Rawlinson R, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-483; Reaper PM, 2011, NAT CHEM BIOL, V7, P428, DOI [10.1038/NCHEMBIO.573, 10.1038/nchembio.573]; Rosell R, 2004, CLIN CANCER RES, V10, P1318, DOI 10.1158/1078-0432.CCR-03-0156; Sakurikar N, 2016, CELL CYCLE, V15, P1184, DOI 10.1080/15384101.2016.1160983; Sakurikar N, 2016, ONCOTARGET, V7, P1380, DOI 10.18632/oncotarget.6364; Saldivar JC, 2018, SCIENCE, V361, P806, DOI 10.1126/science.aap9346; Sausville E, 2014, CANCER CHEMOTH PHARM, V73, P539, DOI 10.1007/s00280-014-2380-5; Scagliotti G, 2016, INVEST NEW DRUG, V34, P625, DOI 10.1007/s10637-016-0368-1; Sen T, 2017, CANCER RES, V77, P3870, DOI 10.1158/0008-5472.CAN-16-3409; Seto T, 2013, CANCER CHEMOTH PHARM, V72, P619, DOI 10.1007/s00280-013-2234-6; Sorensen CS, 2010, CELL CYCLE, V9, P450, DOI 10.4161/cc.9.3.10513; Spencer SL, 2013, CELL, V155, P369, DOI 10.1016/j.cell.2013.08.062; Suhasini AN, 2013, MOL CELL BIOL, V33, P2212, DOI 10.1128/MCB.01256-12; Sultana R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057098; Swaffer MP, 2016, CELL, V167, P1750, DOI 10.1016/j.cell.2016.11.034; Syljuasen RG, 2005, MOL CELL BIOL, V25, P3553, DOI 10.1128/MCB.25.9.3553-3562.2005; Thompson R, 2013, BRIT J CLIN PHARMACO, V76, P358, DOI 10.1111/bcp.12139; Thompson R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044021; Toledo L, 2017, MOL CELL, V66, P735, DOI 10.1016/j.molcel.2017.05.001; Toledo LI, 2011, NAT STRUCT MOL BIOL, V18, P721, DOI 10.1038/nsmb.2076; Toledo LI, 2013, CELL, V155, P1088, DOI 10.1016/j.cell.2013.10.043; Tomimatsu N, 2017, J BIOL CHEM, V292, P10779, DOI 10.1074/jbc.M116.772475; Ubhi T, 2019, CANCER RES, V79, P1730, DOI 10.1158/0008-5472.CAN-18-3631; Vassilev LT, 2006, P NATL ACAD SCI USA, V103, P10660, DOI 10.1073/pnas.0600447103; Walton MI, 2016, ONCOTARGET, V7, P2329, DOI 10.18632/oncotarget.4919; Warren NJH, 2019, ACS PHARMACOL TRANSL, V2, P168, DOI 10.1021/acsptsci.9b00001; Warren NJH, 2019, J BIOL CHEM, V294, P1763, DOI 10.1074/jbc.RA118.005231; Wehler T, 2017, LUNG CANCER, V108, P212, DOI 10.1016/j.lungcan.2017.03.001; Welcker M, 2003, MOL CELL, V12, P381, DOI 10.1016/S1097-2765(03)00287-9; Wong PG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017533; Zeman MK, 2014, NAT CELL BIOL, V16, P2, DOI 10.1038/ncb2897; Zhang YW, 2009, J BIOL CHEM, V284, P18085, DOI 10.1074/jbc.M109.003020; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	115	13	14	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	7					1389	1401		10.1038/s41388-019-1079-9	http://dx.doi.org/10.1038/s41388-019-1079-9			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KL2WP	31659257	Green Accepted			2022-12-28	WOS:000513289600001
J	Chen, Y; Xu, L; Lin, RYT; Muschen, M; Koeffler, HP				Chen, Ye; Xu, Liang; Lin, Ruby Yu-Tong; Muschen, Markus; Koeffler, H. Phillip			Core transcriptional regulatory circuitries in cancer	ONCOGENE			English	Review							SUPER-ENHANCERS; TAL1 COMPLEX; NETWORK; IDENTITY; ELEMENTS; AMPLIFICATION; PLURIPOTENCY; ACETYLATION; LANDSCAPE; PROGRAM	Transcription factors (TFs) coordinate the on-and-off states of gene expression typically in a combinatorial fashion. Studies from embryonic stem cells and other cell types have revealed that a clique of self-regulated core TFs control cell identity and cell state. These core TFs form interconnected feed-forward transcriptional loops to establish and reinforce the cell-type-specific gene-expression program; the ensemble of core TFs and their regulatory loops constitutes core transcriptional regulatory circuitry (CRC). Here, we summarize recent progress in computational reconstitution and biologic exploration of CRCs across various human malignancies, and consolidate the strategy and methodology for CRC discovery. We also discuss the genetic basis and therapeutic vulnerability of CRC, and highlight new frontiers and future efforts for the study of CRC in cancer. Knowledge of CRC in cancer is fundamental to understanding cancer-specific transcriptional addiction, and should provide important insight to both pathobiology and therapeutics.	[Chen, Ye; Xu, Liang; Lin, Ruby Yu-Tong; Koeffler, H. Phillip] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117599, Singapore; [Xu, Liang; Muschen, Markus] City Hope Comprehens Canc Ctr, Dept Syst Biol, Monrovia, CA 91016 USA; [Xu, Liang] Zhejiang Univ, Coll Life Sci, Hangzhou 310058, Peoples R China; [Koeffler, H. Phillip] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA; [Koeffler, H. Phillip] Natl Univ Singapore Hosp, Natl Univ Canc Inst, Singapore 119074, Singapore	National University of Singapore; Zhejiang University; Cedars Sinai Medical Center; National University of Singapore	Chen, Y; Xu, L (corresponding author), Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117599, Singapore.; Xu, L (corresponding author), City Hope Comprehens Canc Ctr, Dept Syst Biol, Monrovia, CA 91016 USA.; Xu, L (corresponding author), Zhejiang Univ, Coll Life Sci, Hangzhou 310058, Peoples R China.	csicye@nus.edu.sg; csixl@nus.edu.sg	Xu, Liang/I-9877-2014	Xu, Liang/0000-0002-2700-4840; Lin, Ruby/0000-0003-3229-4659	National Institute of Health [R01-CA200992-03, R35CA197628, R01CA137060, R01CA157644, R01CA172558, R01CA213138]; Howard Hughes Medical Institute [HHMI-55108547]; National Research Foundation Singapore under its Singapore Translational Research (STaR) Investigator Award [NMRC/STaR/0021/2014]; Singapore Ministry of Education Academic Research Fund Tier 2 [MOE2017-T2-1-033]; Singapore Ministry of Health's National Medical Research Council (NMRC) Centre Grant; National Research Foundation Singapore; Singapore Ministry of Education under its Research Centres of Excellence initiatives; NMRC Open Fund Young Individual Research Grant [MOH-OFYIRG18May-0001]; Seed Funding Program within the NCIS Centre Grant; NCIS Yong Siew Yoon Research grant; Wendy Walk Foundation; Wellcome Trust Senior Investigator Award [WT101880]; Leukemia and Lymphoma Scholar award; Norman and Sadie Lee Foundation; Falk Trust through a Falk Medical Research Trust Catalyst Award; Pediatric Cancer Research Foundation; Cancer Research Institute through a Clinic and Laboratory Integration Program grant; California Institute for Regenerative Medicine [DISC2-10061]	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institute(Howard Hughes Medical Institute); National Research Foundation Singapore under its Singapore Translational Research (STaR) Investigator Award(National Research Foundation, Singapore); Singapore Ministry of Education Academic Research Fund Tier 2(Ministry of Education, Singapore); Singapore Ministry of Health's National Medical Research Council (NMRC) Centre Grant(Ministry of Health-SingaporeNational Medical Research Council, Singapore); National Research Foundation Singapore(National Research Foundation, Singapore); Singapore Ministry of Education under its Research Centres of Excellence initiatives(Ministry of Education, Singapore); NMRC Open Fund Young Individual Research Grant; Seed Funding Program within the NCIS Centre Grant; NCIS Yong Siew Yoon Research grant; Wendy Walk Foundation; Wellcome Trust Senior Investigator Award(Wellcome Trust); Leukemia and Lymphoma Scholar award(Leukemia and Lymphoma Society); Norman and Sadie Lee Foundation; Falk Trust through a Falk Medical Research Trust Catalyst Award; Pediatric Cancer Research Foundation; Cancer Research Institute through a Clinic and Laboratory Integration Program grant; California Institute for Regenerative Medicine(California Institute for Regenerative Medicine)	This work is funded by the National Institute of Health (R01-CA200992-03 to HPK; R35CA197628, R01CA137060, R01CA157644, R01CA172558, and R01CA213138 to MM), the Howard Hughes Medical Institute (HHMI-55108547 to MM), National Research Foundation Singapore under its Singapore Translational Research (STaR) Investigator Award (NMRC/STaR/0021/2014 to HPK), the Singapore Ministry of Education Academic Research Fund Tier 2 (MOE2017-T2-1-033 to HPK), the Singapore Ministry of Health's National Medical Research Council (NMRC) Centre Grant awarded to National University Cancer Institute of Singapore (NCIS), the National Research Foundation Singapore and the Singapore Ministry of Education under its Research Centres of Excellence initiatives, and is additionally supported by NMRC Open Fund Young Individual Research Grant (MOH-OFYIRG18May-0001 to LX), a Seed Funding Program within the NCIS Centre Grant, a NCIS Yong Siew Yoon Research grant through donations from the Yong Loo Lin Trust, and the Wendy Walk Foundation. MM is also supported by a Wellcome Trust Senior Investigator Award (WT101880), a Leukemia and Lymphoma Scholar award, the Norman and Sadie Lee Foundation (for Pediatric Cancer), the Falk Trust through a Falk Medical Research Trust Catalyst Award, the Pediatric Cancer Research Foundation, the Cancer Research Institute through a Clinic and Laboratory Integration Program grant, and the California Institute for Regenerative Medicine through DISC2-10061. MM is a Howard Hughes Medical Institute (HHMI) Faculty Scholar.	Adamson DC, 2010, CANCER RES, V70, P181, DOI 10.1158/0008-5472.CAN-09-2331; Aldiri I, 2017, NEURON, V94, P550, DOI 10.1016/j.neuron.2017.04.022; Ang YS, 2011, CELL, V145, P183, DOI 10.1016/j.cell.2011.03.003; Assi SA, 2019, NAT GENET, V51, P151, DOI 10.1038/s41588-018-0270-1; Bailey TL, 2009, NUCLEIC ACIDS RES, V37, pW202, DOI 10.1093/nar/gkp335; Bleu M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11672-1; Boeva V, 2017, NAT GENET, V49, P1408, DOI 10.1038/ng.3921; Boon K, 2005, CANCER RES, V65, P703; Boulay G, 2017, CELL, V171, P163, DOI 10.1016/j.cell.2017.07.036; Boulay G, 2017, CANCER DISCOV, V7, P288, DOI 10.1158/2159-8290.CD-16-0844; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Bradner JE, 2017, CELL, V168, P629, DOI 10.1016/j.cell.2016.12.013; Chen L, 2020, GUT, V69, P630, DOI 10.1136/gutjnl-2019-318325; Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043; Chen Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09257-z; Chia NY, 2015, GUT, V64, P707, DOI 10.1136/gutjnl-2013-306596; Cho WK, 2018, SCIENCE, V361, P412, DOI 10.1126/science.aar4199; Choi A, 2017, BLOOD, V130, P1722, DOI 10.1182/blood-2017-03-775536; Chong SS, 2018, SCIENCE, V361, DOI 10.1126/science.aar2555; Cole MF, 2008, COLD SH Q B, V73, P183, DOI 10.1101/sqb.2008.73.027; Decaesteker B, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06699-9; DRIMAN D, 1994, CANCER, V73, P2231, DOI 10.1002/1097-0142(19940415)73:8<2231::AID-CNCR2820730832>3.0.CO;2-E; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Durbin AD, 2018, NAT GENET, V50, P1240, DOI 10.1038/s41588-018-0191-z; Endoh M, 2008, DEVELOPMENT, V135, P1513, DOI 10.1242/dev.014340; Fournier M, 2016, SCI REP-UK, V6, DOI 10.1038/srep34962; Garancher A, 2018, CANCER CELL, V33, P435, DOI 10.1016/j.ccell.2018.02.006; Garraway LA, 2013, CELL, V153, P17, DOI 10.1016/j.cell.2013.03.002; Gheorghe M, 2019, NUCLEIC ACIDS RES, V47, DOI 10.1093/nar/gky1210; Girardi T, 2017, BLOOD, V129, P1113, DOI 10.1182/blood-2016-10-706465; Grant CE, 2011, BIOINFORMATICS, V27, P1017, DOI 10.1093/bioinformatics/btr064; Gryder BE, 2019, NAT GENET, V51, P1714, DOI 10.1038/s41588-019-0534-4; Gryder BE, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11046-7; Gryder BE, 2017, CANCER DISCOV, V7, P884, DOI 10.1158/2159-8290.CD-16-1297; Guttman M, 2011, NATURE, V477, P295, DOI 10.1038/nature10398; Hemming ML, 2018, P NATL ACAD SCI USA, V115, pE5746, DOI 10.1073/pnas.1802079115; Huang ML, 2018, NUCLEIC ACIDS RES, V46, pD71, DOI 10.1093/nar/gkx796; Jaenisch R, 2008, CELL, V132, P567, DOI 10.1016/j.cell.2008.01.015; Jiang YY, 2020, GASTROENTEROLOGY, V159, P1311, DOI 10.1053/j.gastro.2020.06.050; Jiang Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06081-9; Jin Y, 2018, BLOOD, V131, P2138, DOI 10.1182/blood-2017-09-808063; Joo MS, 2019, EBIOMEDICINE, V40, P488, DOI 10.1016/j.ebiom.2018.12.056; Kunarso G, 2010, NAT GENET, V42, P631, DOI 10.1038/ng.600; Kwiatkowski N, 2014, NATURE, V511, P616, DOI 10.1038/nature13393; Lambert SA, 2018, CELL, V172, P650, DOI 10.1016/j.cell.2018.01.029; Lazar AJ, 2017, CELL, V171, P950, DOI 10.1016/j.cell.2017.10.014; Leong WZ, 2017, GENE DEV, V31, P2343, DOI 10.1101/gad.302646.117; Li XZ, 2012, CELL STEM CELL, V11, P163, DOI 10.1016/j.stem.2012.04.023; Lim CY, 2008, CELL STEM CELL, V3, P543, DOI 10.1016/j.stem.2008.08.004; Lin CY, 2016, NATURE, V530, P57, DOI 10.1038/nature16546; Lin DC, 2018, GUT, V67, P1769, DOI 10.1136/gutjnl-2017-314607; Lin DC, 2014, NAT GENET, V46, P467, DOI 10.1038/ng.2935; Mack SC, 2018, NATURE, V553, P101, DOI 10.1038/nature25169; Mansour MR, 2014, SCIENCE, V346, P1373, DOI 10.1126/science.1259037; Marson A, 2008, CELL, V134, P521, DOI 10.1016/j.cell.2008.07.020; Mercado N, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12559-x; Neph S, 2012, CELL, V150, P1274, DOI 10.1016/j.cell.2012.04.040; Northcott PA, 2011, J CLIN ONCOL, V29, P1408, DOI 10.1200/JCO.2009.27.4324; Odom Duncan T, 2006, Mol Syst Biol, V2; Oldridge DA, 2015, NATURE, V528, P418, DOI 10.1038/nature15540; Olson CM, 2018, NAT CHEM BIOL, V14, P163, DOI [10.1038/nchembio.2538, 10.1038/NCHEMBIO.2538]; Ott CJ, 2018, CANCER CELL, V34, P982, DOI 10.1016/j.ccell.2018.11.001; Pan J, 2020, CANCER RES, V80, P2722, DOI 10.1158/0008-5472.CAN-20-0390; Ngoc PCT, 2018, LEUKEMIA, V32, P2138, DOI 10.1038/s41375-018-0110-4; Pijnappel WWMP, 2013, NATURE, V495, P516, DOI 10.1038/nature11970; Pott S, 2015, NAT GENET, V47, P8, DOI 10.1038/ng.3167; Ramsey SA, 2010, BIOINFORMATICS, V26, P2071, DOI 10.1093/bioinformatics/btq405; Ran LL, 2018, CANCER DISCOV, V8, P234, DOI 10.1158/2159-8290.CD-17-0468; Riddick G, 2017, SCI REP-UK, V7, DOI 10.1038/srep43605; Sabari BR, 2018, SCIENCE, V361, DOI 10.1126/science.aar3958; Saint-Andre V, 2016, GENOME RES, V26, P385, DOI 10.1101/gr.197590.115; Sanda T, 2017, EXP HEMATOL, V53, P7, DOI 10.1016/j.exphem.2017.06.001; Sanda T, 2012, CANCER CELL, V22, P209, DOI 10.1016/j.ccr.2012.06.007; Skapek SX, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-018-0051-2; Tan SH, 2016, LEUKEMIA, V30, P959, DOI 10.1038/leu.2015.195; Tsuzuki S, 2020, BLOOD CANCER DISCOV, V1, P82, DOI 10.1158/2643-3249.BCD-19-0080; van Groningen T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09470-w; Wang L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13515-5; Wang L, 2018, CELL REP, V22, P2601, DOI 10.1016/j.celrep.2018.01.075; Whyte WA, 2013, CELL, V153, P307, DOI 10.1016/j.cell.2013.03.035; Winter GE, 2017, MOL CELL, V67, P5, DOI 10.1016/j.molcel.2017.06.004; Wontakal SN, 2012, P NATL ACAD SCI USA, V109, P3832, DOI 10.1073/pnas.1121019109; Xie W, 2009, MOL CELL, V33, P417, DOI 10.1016/j.molcel.2009.02.004; Yohe ME, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan4470; Zhang SH, 2014, NUCLEIC ACIDS RES, V42, P12380, DOI 10.1093/nar/gku923; Zhang XY, 2018, CANCER DISCOV, V8, P108, DOI 10.1158/2159-8290.CD-17-0532; Zhang XY, 2016, NAT GENET, V48, P176, DOI 10.1038/ng.3470	87	18	18	6	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2020	39	43					6633	6646		10.1038/s41388-020-01459-w	http://dx.doi.org/10.1038/s41388-020-01459-w		SEP 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OF2UT	32943730	hybrid, Green Published			2022-12-28	WOS:000571161500001
J	Yang, B; Feng, XD; Liu, H; Tong, RL; Wu, JB; Li, CB; Yu, HX; Chen, YH; Cheng, QY; Chen, JR; Cai, XL; Wu, WX; Lu, YJ; Hu, JT; Liang, KJ; Lv, Z; Wu, J; Zheng, SS				Yang, Beng; Feng, Xiaode; Liu, Hua; Tong, Rongliang; Wu, Jingbang; Li, Changbiao; Yu, Hanxi; Chen, Yunhao; Cheng, Qiyang; Chen, Junru; Cai, Xianlei; Wu, Wenxuan; Lu, Yuejie; Hu, Jiating; Liang, Kejiong; Lv, Zhen; Wu, Jian; Zheng, Shusen			High-metastatic cancer cells derived exosomal miR92a-3p promotes epithelial-mesenchymal transition and metastasis of low-metastatic cancer cells by regulating PTEN/Akt pathway in hepatocellular carcinoma	ONCOGENE			English	Article							CIRCULATING TUMOR-CELLS; EXTRACELLULAR VESICLES; EVOLUTIONARY; GENETICS; ROLES; EXPRESSION; BIOLOGY	Exosomes play an important role in intercellular communication and metastatic progression of hepatocellular carcinoma (HCC). However, cellular communication between heterogeneous HCC cells with different metastatic potentials and the resultant cancer progression are not fully understood in HCC. Here, HCC cells with high-metastatic capacity (97hm and Huhm) were constructed by continually exerting selective pressure on primary HCC cells (MHCC-97H and Huh7). Through performing exosomal miRNA sequencing in HCC cells with different metastatic potentials (MHCC-97H and 97hm), many significantly different miRNA candidates were found. Among these miRNAs, miR-92a-3p was the most abundant miRNA in the exosomes of highly metastatic HCC cells. Exosomal miR92a-3p was also found enriched in the plasma of HCC patient-derived xenograft mice (PDX) model with high-metastatic potential. Exosomal miR-92a-3p promotes epithelial-mesenchymal transition (EMT) in recipient cancer cells via targeting PTEN and regulating its downstream Akt/Snail signaling. Furthermore, through mRNA sequencing in HCC cells with different metastatic potentials and predicting potential transcription factors of miR92a-3p, upregulated transcript factors E2F1 and c-Myc were found in high-metastatic HCC cells promote the expression of cellular and exosomal miR-92a-3p in HCC by directly binding the promoter of its host gene,miR17HG. Clinical data showed that a high plasma exosomal miR92a-3p level was correlated with shortened overall survival and disease-free survival, indicating poor prognosis in HCC patients. In conclusion, hepatoma-derived exosomal miR92a-3p plays a critical role in the EMT progression and promoting metastasis by inhibiting PTEN and activating Akt/Snail signaling. Exosomal miR92a-3p is a potential predictive biomarker for HCC metastasis, and this may provoke the development of novel therapeutic and preventing strategies against metastasis of HCC.	[Yang, Beng; Feng, Xiaode; Liu, Hua; Tong, Rongliang; Wu, Jingbang; Li, Changbiao; Chen, Yunhao; Cheng, Qiyang; Chen, Junru; Cai, Xianlei; Wu, Wenxuan; Lu, Yuejie; Hu, Jiating; Lv, Zhen; Wu, Jian; Zheng, Shusen] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Div Hepatobiliary & Pancreat Surg,Dept Surg, Hangzhou, Zhejiang, Peoples R China; [Yang, Beng; Liu, Hua; Cheng, Qiyang; Wu, Jian; Zheng, Shusen] NHC Key Lab Combined Multiorgan Transplantat, Hangzhou, Zhejiang, Peoples R China; [Yang, Beng; Chen, Junru; Wu, Jian; Zheng, Shusen] CAMS, Key Lab Diag & Treatment Organ Transplantat, Hangzhou, Zhejiang, Peoples R China; [Yang, Beng; Chen, Yunhao; Wu, Jian; Zheng, Shusen] Key Lab Organ Transplantat, Hangzhou, Zhejiang, Peoples R China; [Yu, Hanxi] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Gynecol & Obstet, Hangzhou, Zhejiang, Peoples R China; [Liang, Kejiong] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Orthoped, Hangzhou, Zhejiang, Peoples R China	Zhejiang University; Chinese Academy of Medical Sciences - Peking Union Medical College; Zhejiang University; Zhejiang University	Wu, J; Zheng, SS (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hosp 1, Div Hepatobiliary & Pancreat Surg,Dept Surg, Hangzhou, Zhejiang, Peoples R China.; Wu, J; Zheng, SS (corresponding author), NHC Key Lab Combined Multiorgan Transplantat, Hangzhou, Zhejiang, Peoples R China.; Wu, J; Zheng, SS (corresponding author), CAMS, Key Lab Diag & Treatment Organ Transplantat, Hangzhou, Zhejiang, Peoples R China.; Wu, J; Zheng, SS (corresponding author), Key Lab Organ Transplantat, Hangzhou, Zhejiang, Peoples R China.	drwujian@zju.edu.cn; shusenzheng@zju.edu.cn	Yang, Beng/GRX-9557-2022; Yang, Beng/HIR-3204-2022		Innovative Research Groups of National Natural Science Foundation of China [81721091]; Major program of National Natural Science Foundation of China [91542205]; National Natural Science Foundation of China [81874228]; National ST Major Project [2017ZX10203205]; Zhejiang International Science and Technology Cooperation Project [2016C04003]; Natural Science Foundation of Zhejiang Province [LQ20H160037, LQ18H160011]	Innovative Research Groups of National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Major program of National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National ST Major Project; Zhejiang International Science and Technology Cooperation Project; Natural Science Foundation of Zhejiang Province(Natural Science Foundation of Zhejiang Province)	This work was supported by Innovative Research Groups of National Natural Science Foundation of China (No. 81721091), Major program of National Natural Science Foundation of China (No. 91542205), the National Natural Science Foundation of China (No. 81874228), National S&T Major Project (No. 2017ZX10203205) and Zhejiang International Science and Technology Cooperation Project (No. 2016C04003), Natural Science Foundation of Zhejiang Province (LQ20H160037, LQ18H160011).	Alix-Panabieres C, 2016, CANCER DISCOV, V6, P479, DOI 10.1158/2159-8290.CD-15-1483; Andela VB, 2003, CLIN ORTHOP RELAT R, pS75, DOI 10.1097/01.blo.0000093048.96273.aa; [Anonymous], 2019, J ASIAN NAT PROD RES; Augsten M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00062; Becker A, 2016, CANCER CELL, V30, P836, DOI 10.1016/j.ccell.2016.10.009; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Casadei L, 2017, CANCER RES, V77, P3846, DOI 10.1158/0008-5472.CAN-16-2984; Chen JA, 2019, HEPATOB PANCREAT DIS, V18, P321, DOI 10.1016/j.hbpd.2018.09.016; Crespi B, 2005, TRENDS ECOL EVOL, V20, P545, DOI 10.1016/j.tree.2005.07.007; Crichton MB, 1996, MOL CELL ENDOCRINOL, V118, P215, DOI 10.1016/0303-7207(96)03761-6; Crowley E, 2013, NAT REV CLIN ONCOL, V10, P472, DOI 10.1038/nrclinonc.2013.110; Dudas J, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00044; Fang JH, 2018, HEPATOLOGY, V68, P1459, DOI 10.1002/hep.29920; Fang T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02583-0; Finn RS, 2018, HEPATOLOGY, V67, P422, DOI 10.1002/hep.29486; Hu JL, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1019-x; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; JOHANSEN JS, 1992, J BONE MINER RES, V7, P501; Lakkaraju A, 2008, TRENDS CELL BIOL, V18, P199, DOI 10.1016/j.tcb.2008.03.002; Lehmann BD, 2008, CANCER RES, V68, P7864, DOI 10.1158/0008-5472.CAN-07-6538; Lynch M, 2016, NAT REV GENET, V17, P704, DOI 10.1038/nrg.2016.104; Makohon-Moore A, 2016, NAT REV CANCER, V16, P553, DOI 10.1038/nrc.2016.66; Martincorena I, 2018, CELL, V173, P1823, DOI 10.1016/j.cell.2018.06.001; Mathieu M, 2019, NAT CELL BIOL, V21, P9, DOI 10.1038/s41556-018-0250-9; Meng SD, 2004, CLIN CANCER RES, V10, P8152, DOI 10.1158/1078-0432.CCR-04-1110; Merlo LMF, 2006, NAT REV CANCER, V6, P924, DOI 10.1038/nrc2013; Mogilyansky E, 2013, CELL DEATH DIFFER, V20, P1603, DOI 10.1038/cdd.2013.125; Moi L, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2086-x; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Reiter JG, 2019, NAT REV CANCER, V19, P639, DOI 10.1038/s41568-019-0185-x; Singal AG, 2015, CLIN GASTROENTEROL H, V13, P2140, DOI 10.1016/j.cgh.2015.08.014; Song H, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111799; Strilic B, 2017, CANCER CELL, V32, P282, DOI 10.1016/j.ccell.2017.07.001; Tang J, 2018, MINERVA MED, V109, P15, DOI 10.23736/S0026-4806.17.05167-9; Tkach M, 2016, CELL, V164, P1226, DOI 10.1016/j.cell.2016.01.043; Turajlic S, 2019, NAT REV GENET, V20, P404, DOI 10.1038/s41576-019-0114-6; Uchino K, 2011, CANCER-AM CANCER SOC, V117, P4475, DOI 10.1002/cncr.25960; Wan ZH, 2019, HEPATOB PANCREAT DIS, V18, P525, DOI 10.1016/j.hbpd.2019.09.005; Wang HW, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/864894; Wang XF, 2018, CANCER RES, V78, P4586, DOI 10.1158/0008-5472.CAN-17-3841; Weng XY, 2019, EBIOMEDICINE, V44, P225, DOI 10.1016/j.ebiom.2019.05.029; Xue XF, 2018, BIOCHEM BIOPH RES CO, V502, P515, DOI 10.1016/j.bbrc.2018.05.208; Yan W, 2018, NAT CELL BIOL, V20, P597, DOI 10.1038/s41556-018-0083-6; Yang B, 2019, J MATER CHEM B, V7, P6476, DOI 10.1039/c9tb01299k; Yang B, 2018, INT J ONCOL, V52, P1235, DOI 10.3892/ijo.2018.4292; Yin ZY, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0782-x; Yuan L, 2015, NAT CELL BIOL, V17, P1169, DOI 10.1038/ncb3218; Zhang G, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0829-6; Zhang HJ, 2011, CANCER RES, V71, P1292, DOI 10.1158/0008-5472.CAN-10-2825; Zhang L, 2015, NATURE, V527, P100, DOI 10.1038/nature15376	50	76	77	2	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 15	2020	39	42					6529	6543		10.1038/s41388-020-01450-5	http://dx.doi.org/10.1038/s41388-020-01450-5		SEP 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OA9HI	32917956	Green Published, hybrid			2022-12-28	WOS:000568475200001
J	Zhang, XJ; Li, F; Tang, Y; Ren, QL; Xiao, B; Wan, Y; Jiang, S				Zhang, Xingju; Li, Fei; Tang, Ying; Ren, Qinglan; Xiao, Bin; Wan, Ying; Jiang, Shan			miR-21a in exosomes from Lewis lung carcinoma cells accelerates tumor growth through targeting PDCD4 to enhance expansion of myeloid-derived suppressor cells	ONCOGENE			English	Article							CLINICAL CANCER STAGE; DENDRITIC CELLS; T-CELLS; MICRORNA-21; EXPRESSION; METASTASIS; INDUCTION; MIGRATION; CORRELATE; PROMOTE	In patients with lung cancer, myeloid-derived suppressor cells (MDSCs) have been reported to be significantly increased. Tumor-derived exosomes (TDEs) from various cancers played a critical role in MDSC induction. However, studies on the molecular mechanism underlying MDSC expansion induced by exosomes from lung cancer cells are still limited. In this study, we demonstrated that LLC-Exo accelerated tumor growth along with a significant accumulation of MDSCs in mouse tumor model. miRNA profiling showed that miR-21a was enriched in LLC-Exo. The depletion of miR-21a in LLC-Exo leads to the loss of their ability to induce MDSC expansion. Further results showed that miR-21a of LLC-Exo induced MDSC expansion via downregulation of the programmed cell death protein 4 (PDCD4) protein. The results of gain-and loss-of-function experiments validated that PDCD4 function as a critical inhibitor to negatively regulate expansion of MDSCs via inhibition Il-6 production in bone marrow cells. In addition, our data showed that exosomes derived from human lung cancer cell lines expressing miR-21a, also induced expansion of MDSCs in human CD14(+)monocytes in vitro. Overall, our results demonstrated that miR-21a enriched in lung carcinoma cell-derived exosomes could promote functional expansion of MDSCs through targeting PDCD4.	[Zhang, Xingju; Tang, Ying] Shenzhen Univ, Coll Optoelect Engn, Key Lab Optoelect Devices & Syst, Minist Educ & Guangdong Prov, Shenzhen 518060, Peoples R China; [Zhang, Xingju; Tang, Ying; Jiang, Shan] Shenzhen Univ, Inst Adv Study, Shenzhen 518060, Peoples R China; [Li, Fei; Wan, Ying] Army Med Univ, Biomed Anal Ctr, Chongqing 400038, Peoples R China; [Ren, Qinglan] Chongqing Med Univ, Affiliated Hosp 1, Dept Oncol, Chongqing 400016, Peoples R China; [Xiao, Bin] Chongqing Med Univ, Coll Pharm, Chongqing 400016, Peoples R China	Shenzhen University; Shenzhen University; Army Medical University; Chongqing Medical University; Chongqing Medical University	Jiang, S (corresponding author), Shenzhen Univ, Inst Adv Study, Shenzhen 518060, Peoples R China.; Wan, Y (corresponding author), Army Med Univ, Biomed Anal Ctr, Chongqing 400038, Peoples R China.; Xiao, B (corresponding author), Chongqing Med Univ, Coll Pharm, Chongqing 400016, Peoples R China.	binxiaotmmu@163.com; wanying516@foxmail.com; shan.jiang1975@szu.edu.cn		Zhang, Xingju/0000-0003-0717-2510; Li, Fei/0000-0002-4695-944X; Wan, Ying/0000-0001-7922-4434	Natural Science Foundation of Shenzhen [KQJSCX20180328094239048]; National Key Research and Development Program of China [2016YFA0502201]; Scientific Research Foundation for Introduced High-level Personnel in Chongqing Medical University [41021300160256]	Natural Science Foundation of Shenzhen; National Key Research and Development Program of China; Scientific Research Foundation for Introduced High-level Personnel in Chongqing Medical University	This work was supported by grants from the Natural Science Foundation of Shenzhen (KQJSCX20180328094239048) of Shan Jiang, National Key Research and Development Program of China (2016YFA0502201) of Ying, Wan and Scientific Research Foundation for Introduced High-level Personnel in Chongqing Medical University of Bin Xiao (41021300160256).	Almand B, 2001, J IMMUNOL, V166, P678, DOI 10.4049/jimmunol.166.1.678; Andre F, 2002, LANCET, V360, P295, DOI 10.1016/S0140-6736(02)09552-1; Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Ashiru O, 2010, CANCER RES, V70, P481, DOI 10.1158/0008-5472.CAN-09-1688; Berrondo C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147236; Brimnes MK, 2010, SCAND J IMMUNOL, V72, P540, DOI 10.1111/j.1365-3083.2010.02463.x; Bronte V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12150; Bunt SK, 2007, CANCER RES, V67, P10019, DOI 10.1158/0008-5472.CAN-07-2354; Chalmin F, 2010, J CLIN INVEST, V120, P457, DOI 10.1172/JCI40483; Chen WZ, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/1073947; Cheng YQ, 2017, DEV COMP IMMUNOL, V77, P200, DOI 10.1016/j.dci.2017.08.011; Chow A, 2014, SCI REP-UK, V4, DOI 10.1038/srep05750; Cohen TS, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003682; Cooks T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03224-w; Cramer Z, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26625-9; Das A, 2014, J IMMUNOL, V192, P1120, DOI 10.4049/jimmunol.1300613; de Goeje PL, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1014242; Diaz-Montero CM, 2009, CANCER IMMUNOL IMMUN, V58, P49, DOI 10.1007/s00262-008-0523-4; Dikshit B, 2013, ONCOGENE, V32, P3798, DOI 10.1038/onc.2012.393; Frydrychowicz M, 2015, SCAND J IMMUNOL, V81, P2, DOI 10.1111/sji.12247; Gabrilovich Dmitry, 1998, Blood, V92, P4150; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Galicia-Vazquez G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087237; Guo XF, 2019, INT J CANCER, V144, P3111, DOI 10.1002/ijc.32052; Guo XF, 2018, ONCOGENE, V37, P4239, DOI 10.1038/s41388-018-0261-9; He LQ, 2019, THERANOSTICS, V9, P8206, DOI 10.7150/thno.37455; Heuvers ME, 2013, LUNG CANCER, V81, P468, DOI 10.1016/j.lungcan.2013.06.005; Hingorani SR, 2015, CANCER CELL, V28, P151, DOI 10.1016/j.ccell.2015.07.015; Hoffmann SHL, 2019, THERANOSTICS, V9, P5869, DOI 10.7150/thno.33275; Huang A, 2013, CANCER IMMUNOL IMMUN, V62, P1439, DOI 10.1007/s00262-013-1450-6; Huber V, 2018, J CLIN INVEST, V128, P5505, DOI 10.1172/JCI98060; Ingenito F, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194687; Jiang S, 2011, BLOOD, V118, P5487, DOI 10.1182/blood-2011-05-355644; Kamran N, 2018, CLIN IMMUNOL, V189, P34, DOI 10.1016/j.clim.2016.10.008; Kannan A, 2016, CLIN CANCER RES, V22, P3348, DOI 10.1158/1078-0432.CCR-15-2456; Kortylewski M, 2005, NAT MED, V11, P1314, DOI 10.1038/nm1325; Kusmartsev S, 2002, CANCER IMMUNOL IMMUN, V51, P293, DOI 10.1007/s00262-002-0280-8; Lankat-Buttgereit B, 2009, BIOL CELL, V101, P309, DOI 10.1042/BC20080191; Li J, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12724; Li LM, 2014, J IMMUNOL, V192, P1034, DOI 10.4049/jimmunol.1301309; Li Y, 2015, CELL BIOCHEM FUNCT, V33, P308, DOI 10.1002/cbf.3115; Liu SL, 2019, BIOMED PHARMACOTHER, V111, P338, DOI 10.1016/j.biopha.2018.12.088; Liu YF, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1027472; Liu YL, 2010, AM J PATHOL, V176, P2490, DOI 10.2353/ajpath.2010.090777; Mao XH, 2017, MOL CARCINOGEN, V56, P886, DOI 10.1002/mc.22542; Menetrier-Caux C, 1998, BLOOD, V92, P4778, DOI 10.1182/blood.V92.12.4778; MULLER L, 2016, SCI REP UK, V6; Nasri M, 2014, CYTOTECHNOLOGY, V66, P1031, DOI 10.1007/s10616-013-9652-5; Niu HQ, 2018, INT IMMUNOPHARMACOL, V61, P45, DOI 10.1016/j.intimp.2018.05.014; Ochoa AC, 2007, CLIN CANCER RES, V13, p721S, DOI 10.1158/1078-0432.CCR-06-2197; Ostrand-Rosenberg S, 2009, J IMMUNOL, V182, P4499, DOI 10.4049/jimmunol.0802740; Ruiz-Martinez M, 2016, ONCOTARGET, V7, P51515, DOI 10.18632/oncotarget.9862; Schulz I, 2014, BBA-MOL CELL RES, V1843, P965, DOI 10.1016/j.bbamcr.2014.01.022; Song XP, 2005, J IMMUNOL, V175, P8200, DOI 10.4049/jimmunol.175.12.8200; Spaggiari GM, 2009, BLOOD, V113, P6576, DOI 10.1182/blood-2009-02-203943; Steinbichler TB, 2017, SEMIN CANCER BIOL, V44, P170, DOI 10.1016/j.semcancer.2017.02.006; Strand-Rosenberg S, 2018, CURR OPIN IMMUNOL, V51, P68, DOI 10.1016/j.coi.2018.03.007; Su Z, 2016, SCAND J IMMUNOL, V84, P255, DOI 10.1111/sji.12473; Sundararajan V, 2018, CELL ONCOL, V41, P223, DOI 10.1007/s13402-018-0378-4; Thery Clotilde, 2011, F1000 Biol Rep, V3, P15, DOI 10.3410/B3-15; Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30; Tian XY, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0772-z; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; van den Bosch MWM, 2014, J BIOL CHEM, V289, P22980, DOI 10.1074/jbc.M114.573089; Vetsika EK, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/659294; Wang Q, 2018, BIOL CELL, V110, P169, DOI 10.1111/boc.201800014; Weber R, 2019, J CLIN INVEST, V129, P4080, DOI 10.1172/JCI131649; Weston WW, 2019, BIODRUGS, V33, P137, DOI 10.1007/s40259-019-00338-5; Whiteside TL, 2017, CLIN EXP IMMUNOL, V189, P259, DOI 10.1111/cei.12974; Wieckowski EU, 2009, J IMMUNOL, V183, P3720, DOI 10.4049/jimmunol.0900970; Wu CT, 2012, J MOL MED, V90, P1343, DOI 10.1007/s00109-012-0916-x; Wu LL, 2017, ONCOTARGET, V8, P76843, DOI 10.18632/oncotarget.20164; Xiang XY, 2009, INT J CANCER, V124, P2621, DOI 10.1002/ijc.24249; Xie Y, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0984-4; Yang Y, 2015, CANCER GENE THER, V22, P23, DOI 10.1038/cgt.2014.66; YOUNG MRI, 1992, CANCER RES, V52, P6335; Yuan XK, 2011, J INT MED RES, V39, P1381, DOI 10.1177/147323001103900424; Zhang KL, 2020, THERANOSTICS, V10, P411, DOI 10.7150/thno.33482; Zhang ZP, 2013, J BIOL CHEM, V288, P37082, DOI 10.1074/jbc.M113.517953; Zhou L, 2017, CANCER LETT, V407, P84, DOI 10.1016/j.canlet.2017.08.003; Zhou M, 2014, CELL IMMUNOL, V292, P65, DOI 10.1016/j.cellimm.2014.09.004; Zhu JM, 2019, THERANOSTICS, V9, P6901, DOI 10.7150/thno.37357	82	9	10	2	23	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2020	39	40					6354	6369		10.1038/s41388-020-01406-9	http://dx.doi.org/10.1038/s41388-020-01406-9		AUG 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NV5JK	32855524				2022-12-28	WOS:000565020000003
J	Li, CC; Zhao, W; Pan, X; Li, XY; Yan, F; Liu, SW; Feng, JF; Lu, JW				Li, Chenchen; Zhao, Wei; Pan, Xuan; Li, Xiaoyou; Yan, Fei; Liu, Siwen; Feng, Jifeng; Lu, Jianwei			LncRNA KTN1-AS1 promotes the progression of non-small cell lung cancer via sponging of miR-130a-5p and activation of PDPK1	ONCOGENE			English	Article							LONG NONCODING RNA; GROWTH; METASTASIS; STATISTICS; AUTOPHAGY; EVOLUTION; INVASION; GENOMICS; PATHWAY; PDK1	Non-small cell lung cancer (NSCLC) is the major cause of cancer-associated death worldwide, but its underlying mechanisms remain to be fully elucidated. Long noncoding RNAs (lncRNAs) are known to play an important role in the aberrant regulation of gene expression in many cancers, including NSCLC. Here, we investigated the involvement of the lncRNA KTN1-AS1 in NSCLC. We found that KTN1-AS1 expression was upregulated in NSCLC tissue and was positively associated with poor prognosis. KTN1-AS1 knockdown inhibited cell growth and proliferation, increased apoptosis, and modulated the expression of cell cycle- and apoptosis-related proteins (cyclin A1, cyclin-dependent kinase 2, Bcl2, and Bax) in NSCLC cell lines and tumour xenografts in nude mice. KTN1-AS1 bound to and directly regulated the expression of miR-130a-5p. Notably, miR-130a-5p overexpression suppressed NSCLC cell proliferation and increased apoptosis in vitro and in vivo, and this effect was reversed by KTN1-AS1 overexpression. Finally, we showed that KTN1-AS1 modulated the expression of 3-phosphoinositide-dependent protein kinase 1 (PDPK1), a miR-130a-5p target and key regulator of autophagy in NSCLC cells. Taken together, our results suggest that the KTN1-AS1/miR-130a-5p/PDPK1 pathway may be a potential therapeutic target for NSCLC.	[Li, Chenchen; Pan, Xuan; Li, Xiaoyou; Yan, Fei; Liu, Siwen; Feng, Jifeng; Lu, Jianwei] Nanjing Med Univ, Affiliated Canc Hosp, Dept Med Oncol, Nanjing, Peoples R China; [Li, Chenchen; Pan, Xuan; Li, Xiaoyou; Yan, Fei; Liu, Siwen; Feng, Jifeng; Lu, Jianwei] Jiangsu Canc Hosp, Nanjing, Peoples R China; [Li, Chenchen; Pan, Xuan; Li, Xiaoyou; Yan, Fei; Liu, Siwen; Feng, Jifeng; Lu, Jianwei] Jiangsu Inst Canc Res, Nanjing, Peoples R China; [Zhao, Wei] Chengdu Med Coll, Sch Lab Med, Sichuan Prov Engn Lab Prevent & Control Technol V, Chengdu, Peoples R China	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Chengdu Medical College	Feng, JF; Lu, JW (corresponding author), Nanjing Med Univ, Affiliated Canc Hosp, Dept Med Oncol, Nanjing, Peoples R China.; Feng, JF; Lu, JW (corresponding author), Jiangsu Canc Hosp, Nanjing, Peoples R China.; Feng, JF; Lu, JW (corresponding author), Jiangsu Inst Canc Res, Nanjing, Peoples R China.	fjifvvip@126.com; lujw@medmail.com.cn	Zhao, Wei/AAC-6849-2020	Zhao, Wei/0000-0003-2421-7311; Pan, Xuan/0000-0001-9161-4267	National Natural Science Foundation of China [81602636]; General Program of Jiangsu Cancer Hospital [ZM201809]; Jiangsu Provincial Medical Youth Talent [QNRC2016645]; Young Talents Program of Jiangsu Cancer Hospital [QL201814]; Nanjing Medical Science and Technology Development Project [ZKX15049]; Key Project of Science of Sichuan Education Department [18ZA0164]; Natural Science Foundation of Chengdu Medical College [CYZ18-04]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); General Program of Jiangsu Cancer Hospital; Jiangsu Provincial Medical Youth Talent; Young Talents Program of Jiangsu Cancer Hospital; Nanjing Medical Science and Technology Development Project; Key Project of Science of Sichuan Education Department; Natural Science Foundation of Chengdu Medical College	This work was supported by the National Natural Science Foundation of China (81602636), General Program of Jiangsu Cancer Hospital (ZM201809), Jiangsu Provincial Medical Youth Talent (QNRC2016645), Young Talents Program of Jiangsu Cancer Hospital (QL201814), Nanjing Medical Science and Technology Development Project (ZKX15049), Key Project of Science of Sichuan Education Department (18ZA0164) and Natural Science Foundation of Chengdu Medical College (CYZ18-04).	Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193; Behan FM, 2019, NATURE, V568, P511, DOI 10.1038/s41586-019-1103-9; Boolell V, 2015, CANCERS, V7, P1815, DOI 10.3390/cancers7030864; Cao W, 2017, ORAL ONCOL, V65, P94, DOI 10.1016/j.oraloncology.2016.12.017; Carrot-Zhang J, 2020, CANCER CELL, V37, P639, DOI 10.1016/j.ccell.2020.04.012; Chang CW, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0250-x; Chang ZW, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0724-4; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Chen ZR, 2016, J CLIN INVEST, V126, P2267, DOI 10.1172/JCI85250; Dan Cao, 2015, EMBO Mol Med, V7, P140, DOI 10.15252/emmm.201404797; Deng J, 2015, BIOMED PHARMACOTHER, V75, P8, DOI 10.1016/j.biopha.2015.07.003; Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606; Gong ZJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110674; Gutschner T, 2013, CANCER RES, V73, P1180, DOI 10.1158/0008-5472.CAN-12-2850; Han J, 2018, AUTOPHAGY, V14, P958, DOI 10.1080/15548627.2018.1434471; Huarte M, 2013, CELL RES, V23, P449, DOI 10.1038/cr.2012.169; Kim T, 2015, JNCI-J NATL CANCER I, V107, P1; Li Y, 2018, P NATL ACAD SCI USA, V115, pE10849, DOI 10.1073/pnas.1803377115; Li Y, 2017, CELL MOL BIOL LETT, V22, P1, DOI 10.1186/s11658-017-0033-5; Lu KH, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-461; Lv JJ, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0352-9; McManus S, 2016, J BONE MINER RES, V31, P1334, DOI 10.1002/jbmr.2806; Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev-biochem-051410-092902; Bautista RR, 2018, CLIN EPIGENETICS, V10, DOI 10.1186/s13148-018-0537-5; Shen WT, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.137; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Tang Q, 2019, J CELL MOL MED, V23, P7749, DOI 10.1111/jcmm.14649; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020; Wang F, 2018, INT J BIOCHEM CELL B, V99, P91, DOI 10.1016/j.biocel.2018.04.005; Wang YF, 2016, TRENDS GENET, V32, P211, DOI 10.1016/j.tig.2016.02.001; Wood SL, 2015, CANCER TREAT REV, V41, P361, DOI 10.1016/j.ctrv.2015.02.008; Xian XS, 2018, ONCOTARGETS THER, V11, P7503, DOI 10.2147/OTT.S181706; Xu CH, 2019, EUR REV MED PHARMACO, V23, P241, DOI 10.26355/eurrev_201901_16770; Yin DD, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0836-7; Zhang L, 2019, BIOMED PHARMACOTHER, V109, P1140, DOI 10.1016/j.biopha.2018.10.105; Zhang L, 2018, GENES DIS, V5, P158, DOI 10.1016/j.gendis.2017.12.003; Zhao W, 2014, EUR REV MED PHARMACO, V18, P1930; Zheng NN, 2015, CELL PHYSIOL BIOCHEM, V36, P1903, DOI 10.1159/000430159; Zhou LK, 2012, HEPATOLOGY, V56, P95, DOI 10.1002/hep.25611	40	29	29	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2020	39	39					6157	6171		10.1038/s41388-020-01427-4	http://dx.doi.org/10.1038/s41388-020-01427-4		AUG 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NS8XO	32820252				2022-12-28	WOS:000561253800001
J	Li, H; Jiang, W; Liu, XN; Yuan, LY; Li, TJ; Li, S; Xu, SS; Zhang, WH; Gao, HL; Han, X; Wang, WQ; Wu, CT; Yu, XJ; Xu, HX; Liu, L				Li, Hao; Jiang, Wang; Liu, Xue-Ni; Yuan, Li-Yun; Li, Tian-Jiao; Li, Shuo; Xu, Shuai-Shuai; Zhang, Wu-Hu; Gao, He-Li; Han, Xuan; Wang, Wen-Quan; Wu, Chun-Tao; Yu, Xian-Jun; Xu, Hua-Xiang; Liu, Liang			TET1 downregulates epithelial-mesenchymal transition and chemoresistance in PDAC by demethylating CHL1 to inhibit the Hedgehog signaling pathway	ONCOGENE			English	Article							GEMCITABINE; METASTASIS; PROMOTER; METHYLATION; GROWTH	Chemoresistance is a major obstacle to prolonging pancreatic ductal adenocarcinoma (PDAC) patient survival. TET1 is identified as the most important epigenetic modification enzyme that facilitates chemoresistance in cancers. However, the chemoresistance mechanism of TET1 in PDAC is unknown. This study aimed to determine the role of TET1 in the chemoresistance of PDAC. TET1-associated chemoresistance in PDAC was investigated in vitro and in vivo. The clinical significance of TET1 was analyzed in 228 PDAC patients by tissue microarray profiling. We identified that TET1 downregulation is caused by its promoter hypermethylation and correlates with poor survival in PDAC patients. In vitro and in vivo functional studies performed by silencing or overexpressing TET1 suggested that TET1 is able to suppress epithelial-mesenchymal transition (EMT) and sensitize PDAC cells to 5FU and gemcitabine. Then RNA-seq, whole genome bisulfite sequencing (WGBS) and ChIP-seq were used to explore the TET1-associated pathway, and showed that TET1 promotes the transcription of CHL1 by binding and demethylating the CHL1 promoter, which consequently inhibits the Hedgehog pathway. Additionally, inhibiting Hedgehog signaling by CHL1 overexpression or the Hedgehog pathway inhibitor, GDC-0449, reversed the chemoresistance induced by TET1 silencing. Regarding clinical significance, we found that high TET1 and high CHL1 expression predicted a better prognosis in resectable PDAC patients. In summary, we demonstrated that TET1 reverses chemoresistance in PDAC by downregulating the CHL1-associated Hedgehog signaling pathway. PDAC patients with a high expression levels of TET1 and CHL1 have a better prognosis.	[Li, Hao; Jiang, Wang; Li, Tian-Jiao; Li, Shuo; Xu, Shuai-Shuai; Zhang, Wu-Hu; Gao, He-Li; Han, Xuan; Wang, Wen-Quan; Wu, Chun-Tao; Yu, Xian-Jun; Xu, Hua-Xiang; Liu, Liang] Fudan Univ, Shanghai Canc Ctr, Dept Pancreat Surg, Shanghai, Peoples R China; [Li, Hao; Jiang, Wang; Li, Tian-Jiao; Li, Shuo; Xu, Shuai-Shuai; Zhang, Wu-Hu; Gao, He-Li; Han, Xuan; Wang, Wen-Quan; Wu, Chun-Tao; Yu, Xian-Jun; Xu, Hua-Xiang; Liu, Liang] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China; [Li, Hao; Jiang, Wang; Li, Tian-Jiao; Li, Shuo; Xu, Shuai-Shuai; Zhang, Wu-Hu; Gao, He-Li; Han, Xuan; Wang, Wen-Quan; Wu, Chun-Tao; Yu, Xian-Jun; Xu, Hua-Xiang; Liu, Liang] Shanghai Pancreat Canc Inst, Shanghai, Peoples R China; [Li, Hao; Jiang, Wang; Li, Tian-Jiao; Li, Shuo; Xu, Shuai-Shuai; Zhang, Wu-Hu; Gao, He-Li; Han, Xuan; Wang, Wen-Quan; Wu, Chun-Tao; Yu, Xian-Jun; Xu, Hua-Xiang; Liu, Liang] Fudan Univ, Pancreat Canc Inst, Shanghai, Peoples R China; [Liu, Xue-Ni] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Gen Surg, Sch Med, Shanghai, Peoples R China; [Yuan, Li-Yun] Chinese Acad Sci, Shanghai Inst Biol Sci, CAS MPG Partner Inst Computat Biol, Biomed Big Data Ctr, Shanghai, Peoples R China	Fudan University; Fudan University; Fudan University; Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Max Planck Society	Yu, XJ; Xu, HX; Liu, L (corresponding author), Fudan Univ, Shanghai Canc Ctr, Dept Pancreat Surg, Shanghai, Peoples R China.; Yu, XJ; Xu, HX; Liu, L (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China.; Yu, XJ; Xu, HX; Liu, L (corresponding author), Shanghai Pancreat Canc Inst, Shanghai, Peoples R China.; Yu, XJ; Xu, HX; Liu, L (corresponding author), Fudan Univ, Pancreat Canc Inst, Shanghai, Peoples R China.	yuxianjun@fudanpci.org; xuhuaxiang@fudanpci.org; liuliang@fudanpci.org	Li, Shuo/GXV-6545-2022	Jiang, Wang/0000-0003-4546-3466; wuhu, Zhang/0000-0002-5182-9850; Liu, Liang/0000-0002-7826-3877	National Science Foundation for Distinguished Young Scholars of China [81625016]; National Natural Science Foundation of China [81871941, 81872366, 81827807, 81802675, 81702341, 81802380]; Outstanding Academic Leader Program of the "Technological Innovation Action Plan" in Shanghai Science and Technology Commission [18XD1401200]; Scientific Innovation Project of Shanghai Education Committee [2019-01-07-00-07-E00057]; Young Talented Specialist Training Program of Shanghai	National Science Foundation for Distinguished Young Scholars of China(National Natural Science Foundation of China (NSFC)National Science Fund for Distinguished Young Scholars); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Outstanding Academic Leader Program of the "Technological Innovation Action Plan" in Shanghai Science and Technology Commission; Scientific Innovation Project of Shanghai Education Committee; Young Talented Specialist Training Program of Shanghai	This work was supported by grants from the National Science Foundation for Distinguished Young Scholars of China [81625016]; the National Natural Science Foundation of China [81871941, 81872366, 81827807, 81802675, 81702341, and 81802380]; the Outstanding Academic Leader Program of the "Technological Innovation Action Plan" in Shanghai Science and Technology Commission [18XD1401200]; Scientific Innovation Project of Shanghai Education Committee (2019-01-07-00-07-E00057) and the Young Talented Specialist Training Program of Shanghai. The funding agencies had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adamska A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071338; Baharudin R, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00047; Bhateja P, 2019, CANCERS, V11, DOI 10.3390/cancers11081126; Chen J, 2019, INT J BIOL SCI, V15, P1802, DOI 10.7150/ijbs.34785; Dahl JA, 2008, NAT PROTOC, V3, P1032, DOI 10.1038/nprot.2008.68; De Jesus-Acosta A, 2020, BRIT J CANCER, V122, P498, DOI 10.1038/s41416-019-0683-3; Eto K, 2013, BRIT J CANCER, V108, P1488, DOI 10.1038/bjc.2013.108; Feng JH, 2015, INT J CLIN EXP MED, V8, P203; Fu HL, 2014, J BIOMED NANOTECHNOL, V10, P1217, DOI 10.1166/jbn.2014.1861; Gaianigo N, 2017, CANCERS, V9, DOI 10.3390/cancers9090122; Han X, 2017, CELL BIOL INT, V41, P405, DOI 10.1002/cbin.10734; Hsu CH, 2012, CELL REP, V2, P568, DOI 10.1016/j.celrep.2012.08.030; Infante P, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.195; Kang KA, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.149; Kumar V, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01942-7; Lei JJ, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-66; Li H, 2017, HEPATOLOGY, V66, P136, DOI 10.1002/hep.29116; Martin-Sanchez E, 2017, ONCOTARGET, V8, P15789, DOI 10.18632/oncotarget.15004; Ognibene Marzia, 2018, Oncotarget, V9, P25903, DOI 10.18632/oncotarget.25403; Pei YF, 2016, ONCOTARGET, V7, P31322, DOI 10.18632/oncotarget.8900; Sun M, 2013, P NATL ACAD SCI USA, V110, P9920, DOI 10.1073/pnas.1305172110; Tang H, 2019, ONCOGENE, V38, P3119, DOI 10.1038/s41388-018-0648-7; Thomson JP, 2016, CANCER RES, V76, P3097, DOI 10.1158/0008-5472.CAN-15-1910; Voutsadakis IA, 2011, WORLD J GASTRO ONCOL, V3, P153, DOI 10.4251/wjgo.v3.i11.153; Wajed SA, 2001, ANN SURG, V234, P10, DOI 10.1097/00000658-200107000-00003; Wang CX, 2019, CANCER MED-US, V8, P990, DOI 10.1002/cam4.1983; Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050; Wu J, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1334-5; Zhang JF, 2018, CELL PHYSIOL BIOCHEM, V45, P692, DOI 10.1159/000487162; Zhang SR, 2019, EJSO-EUR J SURG ONC, V45, P769, DOI 10.1016/j.ejso.2018.10.539; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064; Zhou PT, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0624-9	32	8	9	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2020	39	36					5825	5838		10.1038/s41388-020-01407-8	http://dx.doi.org/10.1038/s41388-020-01407-8		AUG 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NJ1HO	32753651				2022-12-28	WOS:000555747100003
J	Xia, Q; Zhang, HW; Zhang, P; Li, Y; Xu, MC; Li, XB; Li, XJ; Dong, L				Xia, Qin; Zhang, Hanwen; Zhang, Pei; Li, Yang; Xu, Mengchuan; Li, Xiaobo; Li, Xuejun; Dong, Lei			Oncogenic Smurf1 promotes PTEN wild-type glioblastoma growth by mediating PTEN ubiquitylation	ONCOGENE			English	Article							MAMMALIAN TARGET; UBIQUITIN LIGASE; STEM-CELLS; RESISTANCE; RAPAMYCIN; GLIOMA; RECEPTOR; COMPLEX; SMAD7	PI3K/Akt/mTOR signaling pathway activity is highly elevated in glioblastoma (GBM). Although rapamycin is known to inhibit this pathway, GBM patients are resistant to rapamycin monotherapy. This may be related to mutations of tumor suppressor phosphatase and tensin homolog (PTEN). Here, we show that higher expression of E3 ligase Smad ubiquitylation regulatory factor 1 (Smurf1) in GBM is correlated with poor prognosis. Smurf1 promotes cell growth and colony formation by accelerating cell cycle and aberrant signaling pathways. In addition, we show that Smurf1 ubiquitylates and degrades PTEN. We further demonstrate that the oncogenic role of Smurf1 is dependent on PTEN. Upregulated Smurf1 impairs PTEN activity, leading to consistent activation of PI3K/Akt/mTOR signaling pathway; and depletion of Smurf1 dramatically inhibits cell proliferation and tumor growth. Moreover, loss of Smurf1 abolishes the aberrant regulation of PTEN, causing negative feedback on PI3K/Akt/mTOR signaling pathway, and thus leading to rescue of tumor sensitivity to rapamycin in an orthotopic GBM model. Taken together, we show that Smurf1 promotes tumor progression via PTEN, and combined treatment of Smurf1 knockdown with mammalian target of rapamycin (mTOR) inhibition reduces tumor progression. These results identify a unique role of Smurf1 in mTOR inhibitor resistance and provide a strong rationale for combined therapy targeting GBM.	[Xia, Qin; Zhang, Hanwen; Zhang, Pei; Li, Yang; Xu, Mengchuan; Dong, Lei] Beijing Inst Technol, Sch Life Sci, Beijing, Peoples R China; [Li, Xiaobo] Tianjin Med Univ, Tianjin Med Univ Canc Inst & Hosp, Collaborat Innovat Ctr Tianjin Med Epigenet, Tianjin Key Lab Med Epigenet,Dept Immunol, Tianjin, Peoples R China; [Li, Xuejun] Cent South Univ, Xiangya Hosp, Dept Neurosurg, Changsha, Hunan, Peoples R China	Beijing Institute of Technology; Tianjin Medical University; Central South University	Dong, L (corresponding author), Beijing Inst Technol, Sch Life Sci, Beijing, Peoples R China.	ldong@bit.edu.cn	Zhang, Hanwen/AAG-1299-2022; Zhang, Hanwen/AFK-2928-2022; dong, lei/O-9654-2016	Zhang, Hanwen/0000-0001-8955-7494; Zhang, Hanwen/0000-0001-8955-7494; dong, lei/0000-0001-7530-7427	Beijing Natural Science Foundation [Z190018]; Natural Science Foundation of China [81870123]; China Postdoctoral Science Foundation [2018M641206]; National Science Foundation for Young Scientists of China [81902545]	Beijing Natural Science Foundation(Beijing Natural Science Foundation); Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); National Science Foundation for Young Scientists of China	This work was supported by grants from Beijing Natural Science Foundation (Z190018), The Natural Science Foundation of China (81870123), China Postdoctoral Science Foundation Grant (2018M641206), and the National Science Foundation for Young Scientists of China (81902545).	Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Bassi C, 2013, SCIENCE, V341, P395, DOI 10.1126/science.1236188; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; Chang H, 2018, CELL MOL NEUROBIOL, V38, P421, DOI 10.1007/s10571-017-0485-1; Chen A, 2009, MOL CELL BIOL, V29, P5348, DOI 10.1128/MCB.00407-09; Cheng PL, 2011, NEURON, V69, P231, DOI 10.1016/j.neuron.2010.12.021; Cloughesy TF, 2008, PLOS MED, V5, P139, DOI 10.1371/journal.pmed.0050008; Cloughesy TF, 2014, ANNU REV PATHOL-MECH, V9, P1, DOI 10.1146/annurev-pathol-011110-130324; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Edinger AL, 2003, CANCER RES, V63, P8451; Endersby R, 2008, ONCOGENE, V27, P5416, DOI 10.1038/onc.2008.239; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Grunwald V, 2002, CANCER RES, V62, P6141; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; Holmes B, 2019, J NEURO-ONCOL, V145, P11, DOI 10.1007/s11060-019-03274-0; Iwamaru A, 2007, ONCOGENE, V26, P1840, DOI 10.1038/sj.onc.1209992; Iwanami A, 2013, P NATL ACAD SCI USA, V110, P4339, DOI 10.1073/pnas.1217602110; Juric D, 2015, NATURE, V518, P240, DOI 10.1038/nature13948; Khammanivong A, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-260; Knobbe CB, 2002, NEURO-ONCOLOGY, V4, P196; Korkaya H, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000121; Lee JJ, 2011, CELL DEATH DIFFER, V18, P666, DOI 10.1038/cdd.2010.139; Lee MG, 2016, CANCER RES, V76, P1847, DOI 10.1158/0008-5472.CAN-15-1752; Lee YR, 2019, SCIENCE, V364, P651, DOI 10.1126/science.aau0159; Lee YR, 2018, NAT REV MOL CELL BIO, V19, P547, DOI 10.1038/s41580-018-0015-0; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Li H, 2017, ONCOGENE, V36, P5668, DOI 10.1038/onc.2017.166; Lin F, 2014, CLIN CANCER RES, V20, P2703, DOI 10.1158/1078-0432.CCR-14-0084; Maddika S, 2011, NAT CELL BIOL, V13, P728, DOI 10.1038/ncb2240; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Mondal S, 2018, CELL DEATH DISCOV, V4, DOI 10.1038/s41420-018-0126-6; Narimatsu M, 2009, CELL, V137, P295, DOI 10.1016/j.cell.2009.02.025; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Song MS, 2011, CELL, V144, P187, DOI 10.1016/j.cell.2010.12.020; Stichel D, 2018, ACTA NEUROPATHOL, V136, P793, DOI 10.1007/s00401-018-1905-0; Subramanian A, 2007, BIOINFORMATICS, V23, P3251, DOI 10.1093/bioinformatics/btm369; Suzuki C, 2002, J BIOL CHEM, V277, P39919, DOI 10.1074/jbc.M201901200; Wang J, 2019, NAT NEUROSCI, V22, P91, DOI 10.1038/s41593-018-0285-z; Wang XJ, 2007, CELL, V128, P129, DOI 10.1016/j.cell.2006.11.039; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Wiedemeyer R, 2008, CANCER CELL, V13, P355, DOI 10.1016/j.ccr.2008.02.010; Xie P, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4733; Yamashita M, 2005, CELL, V121, P101, DOI 10.1016/j.cell.2005.01.035; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; Yu L, 2015, CANCER RES, V75, P1275, DOI 10.1158/0008-5472.CAN-14-2387; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	48	22	22	4	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2020	39	36					5902	5915		10.1038/s41388-020-01400-1	http://dx.doi.org/10.1038/s41388-020-01400-1		JUL 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NJ1HO	32737433				2022-12-28	WOS:000554333300001
J	Li, JN; Alvero, AB; Nuti, S; Tedja, R; Roberts, CM; Pitruzzello, M; Li, YM; Xiao, Q; Zhang, S; Gan, YQ; Wu, XY; Mor, G; Yin, G				Li, Juanni; Alvero, Ayesha B.; Nuti, Sudhakar; Tedja, Roslyn; Roberts, Cai M.; Pitruzzello, Mary; Li, Yimin; Xiao, Qing; Zhang, Sai; Gan, Yaqi; Wu, Xiaoying; Mor, Gil; Yin, Gang			CBX7 binds the E-box to inhibit TWIST-1 function and inhibit tumorigenicity and metastatic potential	ONCOGENE			English	Article							CANCER STEM-CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; OVARIAN-CANCER; TUMOR-SUPPRESSOR; E-CADHERIN; POLYCOMB; CARCINOMA; GROWTH; CHEMORESISTANCE; EXPRESSION	Deaths from ovarian cancer usually occur when patients succumb to overwhelmingly numerous and widespread micrometastasis. Whereas epithelial-mesenchymal transition is required for epithelial ovarian cancer cells to acquire metastatic potential, the cellular phenotype at secondary sites and the mechanisms required for the establishment of metastatic tumors are not fully determined. Using in vitro and in vivo models we show that secondary epithelial ovarian cancer cells (sEOC) do not fully reacquire the molecular signature of the primary epithelial ovarian cancer cells from which they are derived. Despite displaying an epithelial morphology, sEOC maintains a high expression of the mesenchymal effector, TWIST-1. TWIST-1 is however transcriptionally nonfunctional in these cells as it is precluded from binding its E-box by the PcG protein, CBX7. Deletion of CBX7 in sEOC was sufficient to reactivate TWIST-1-induced transcription, prompt mesenchymal transformation, and enhanced tumorigenicity in vivo. This regulation allows secondary tumors to achieve an epithelial morphology while conferring the advantage of prompt reversal to a mesenchymal phenotype upon perturbation of CBX7. We also describe a subclassification of ovarian tumors based on CBX7 and TWIST-1 expression, which predicts clinical outcomes and patient prognosis.	[Li, Juanni; Li, Yimin; Xiao, Qing; Zhang, Sai; Gan, Yaqi; Wu, Xiaoying; Yin, Gang] Cent South Univ, Sch Basic Med Sci, Xiangya Hosp, Dept Pathol, Changsha, Hunan, Peoples R China; [Alvero, Ayesha B.; Nuti, Sudhakar; Tedja, Roslyn; Roberts, Cai M.; Pitruzzello, Mary; Mor, Gil] Yale Sch Med, Div Reprod Sci, Dept Obstet Gynecol & Reprod Sci, New Haven, CT USA; [Mor, Gil] Wayne State Univ, Dept Obstet & Gynecol, CS Mott Ctr Human Growth & Dev, Detroit, MI USA	Central South University; Yale University; Wayne State University	Yin, G (corresponding author), Cent South Univ, Sch Basic Med Sci, Xiangya Hosp, Dept Pathol, Changsha, Hunan, Peoples R China.; Mor, G (corresponding author), Yale Sch Med, Div Reprod Sci, Dept Obstet Gynecol & Reprod Sci, New Haven, CT USA.	gmor@med.wayne.edu; gang.yin@csu.edu.cn		Alvero, Ayesha/0000-0002-6593-3595; Gan, Yaqi/0000-0001-8097-4603	NIH NCI [R01CA199004]; National Natural Science Foundation of China [81572900]; National Key R&D Program of China; Stem Cell and Translation Research [2016YFA0102000]; Hunan Provincial Natural Science Foundation of China [2018JJ3820]	NIH NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key R&D Program of China; Stem Cell and Translation Research; Hunan Provincial Natural Science Foundation of China(Natural Science Foundation of Hunan Province)	This study is supported in part by grants from NIH NCI R01CA199004 (GM), The National Natural Science Foundation of China No. 81572900 (GY), The National Key R&D Program of China, Stem Cell and Translation Research No. 2016YFA0102000 (GY), and Hunan Provincial Natural Science Foundation of China No. 2018JJ3820 (JL).	Alvero AB, 2006, CANCER-AM CANCER SOC, V106, P599, DOI 10.1002/cncr.21633; Alvero AB, 2017, SCI REP-UK, V7, DOI 10.1038/srep40989; Alvero AB, 2016, MOL CANCER THER, V15, P1279, DOI 10.1158/1535-7163.MCT-16-0005; Alvero AB, 2014, ONCOTARGET, V5, P8703, DOI 10.18632/oncotarget.2367; Alvero AB, 2009, CANCER-AM CANCER SOC, V115, P3204, DOI 10.1002/cncr.24397; Alvero AB, 2009, CELL CYCLE, V8, P158, DOI 10.4161/cc.8.1.7533; Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005; Armstrong DK, 2002, ONCOLOGIST, V7, P20, DOI 10.1634/theoncologist.7-suppl_5-20; Bao ZY, 2017, ONCOTARGET, V8, P39048, DOI 10.18632/oncotarget.16587; Baylies MK, 1996, SCIENCE, V272, P1481, DOI 10.1126/science.272.5267.1481; Bernard D, 2005, ONCOGENE, V24, P5543, DOI 10.1038/sj.onc.1208735; Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534-5807(04)00058-9; Cardenas C, 2017, APOPTOSIS, V22, P558, DOI 10.1007/s10495-016-1339-x; Carmona-Fontaine C, 2011, DEV CELL, V21, P1026, DOI 10.1016/j.devcel.2011.10.012; Chen R, 2008, ONCOGENE, V27, P4712, DOI 10.1038/onc.2008.112; Chen R, 2008, ONCOGENE, V27, P225, DOI 10.1038/sj.onc.1210907; Cheng GZ, 2008, J BIOL CHEM, V283, P14665, DOI 10.1074/jbc.M707429200; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Craveiro V, 2013, CANCER MED-US, V2, P751, DOI 10.1002/cam4.115; Duan RS, 2018, CELL DEATH DIFFER, V25, P1598, DOI 10.1038/s41418-018-0064-0; Fabregat I, 2016, J CLIN MED, V5, DOI 10.3390/jcm5030037; Federico A, 2019, BBA-GENE REGUL MECH, V1862, P509, DOI 10.1016/j.bbagrm.2019.02.006; Forzati F, 2014, BIOL OPEN, V3, P871, DOI 10.1242/bio.20147872; Forzati F, 2012, CELL CYCLE, V11, P1888, DOI 10.4161/cc.20022; Forzati F, 2012, J CLIN INVEST, V122, P612, DOI 10.1172/JCI58620; GLACKIN CA, 1992, BIOCHEM INT, V28, P67; Glackin CA, 2014, MATURITAS, V79, P48, DOI 10.1016/j.maturitas.2014.06.015; Glackin Carlotta A., 1994, Molecular and Cellular Differentiation, V2, P309; Goff Barbara A, 2013, Gynecol Oncol, V130, P9; Heintz APM, 2006, INT J GYNECOL OBSTET, V95, pS161, DOI 10.1016/S0020-7292(06)60033-7; HILDRETH NG, 1981, AM J EPIDEMIOL, V114, P398, DOI 10.1093/oxfordjournals.aje.a113207; Howard TD, 1997, NAT GENET, V15, P36, DOI 10.1038/ng0197-36; Jarboe EA, 2008, HISTOPATHOLOGY, V53, P127, DOI 10.1111/j.1365-2559.2007.02938.x; Jelovac D, 2011, CA-CANCER J CLIN, V61, P183, DOI 10.3322/caac.20113; Jolly MK, 2017, MOL ONCOL, V11, P755, DOI 10.1002/1878-0261.12083; Jordan NV, 2011, CELL CYCLE, V10, P2865, DOI 10.4161/cc.10.17.17188; Kamsteeg M, 2003, ONCOGENE, V22, P2611, DOI 10.1038/sj.onc.1206422; Kelly MG, 2006, CANCER RES, V66, P3859, DOI 10.1158/0008-5472.CAN-05-3948; Kian W, 2018, TRANSL LUNG CANCER R, V7, pS334, DOI 10.21037/tlcr.2018.12.01; Kurman RJ, 2010, AM J SURG PATHOL, V34, P433, DOI 10.1097/PAS.0b013e3181cf3d79; Lee YB, 2009, NUCLEIC ACIDS RES, V37, P123, DOI 10.1093/nar/gkn920; Leeb M, 2010, CELL CYCLE, V9, P2692, DOI 10.4161/cc.9.14.12455; Leeb M, 2010, GENE DEV, V24, P265, DOI 10.1101/gad.544410; Lovisa S, 2015, NAT MED, V21, P998, DOI 10.1038/nm.3902; Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784; Mas G, 2016, CURR OPIN CELL BIOL, V43, P87, DOI 10.1016/j.ceb.2016.09.006; Morey L, 2010, TRENDS BIOCHEM SCI, V35, P323, DOI 10.1016/j.tibs.2010.02.009; Naora H, 2005, NAT REV CANCER, V5, P355, DOI 10.1038/nrc1611; Pallante P, 2015, AM J CANCER RES, V5, P1594; Pallante P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098295; Pizzonia J, 2012, AM J REPROD IMMUNOL, V67, P84, DOI 10.1111/j.1600-0897.2011.01070.x; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Scott CL, 2007, P NATL ACAD SCI USA, V104, P5389, DOI 10.1073/pnas.0608721104; Seto ML, 2001, AM J MED GENET, V104, P323, DOI 10.1002/ajmg.10065; Shen CH, 2011, J BUON, V16, P733; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Tan TZ, 2014, EMBO MOL MED, V6, P1279, DOI 10.15252/emmm.201404208; Tedja R, 2019, J BIOL CHEM, V294, P5082, DOI 10.1074/jbc.RA118.005921; Thrall MM, 2011, GYNECOL ONCOL, V122, P100, DOI 10.1016/j.ygyno.2011.03.022; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Vergara D, 2010, CANCER LETT, V291, P59, DOI 10.1016/j.canlet.2009.09.017; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Wu WN, 2017, AM J CANCER RES, V7, P64; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yang-Hartwich Y, 2015, ONCOGENE, V34, P3605, DOI 10.1038/onc.2014.296; Yang-Hartwich Y, 2019, MOL CANCER RES, V17, P153, DOI 10.1158/1541-7786.MCR-18-0238; Yao DB, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-432; Yao DB, 2011, MOL CANCER RES, V9, P1608, DOI 10.1158/1541-7786.MCR-10-0568; Ye X, 2015, TRENDS CELL BIOL, V25, P675, DOI 10.1016/j.tcb.2015.07.012; Yin G, 2013, ONCOGENE, V32, P39, DOI 10.1038/onc.2012.33; Yin G, 2010, ONCOGENE, V29, P3545, DOI 10.1038/onc.2010.111; Yuen HF, 2007, J CLIN PATHOL, V60, P510, DOI 10.1136/jcp.2006.039099; Zanudo JGT, 2019, PHYS BIOL, V16, DOI 10.1088/1478-3975/aaffa1; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183; Zhang YY, 2018, ONCOL RES, V26, P1327, DOI 10.3727/096504018X15165493852990; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	78	16	16	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	20					3965	3979		10.1038/s41388-020-1269-5	http://dx.doi.org/10.1038/s41388-020-1269-5		MAR 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LN3GC	32205869	Green Accepted			2022-12-28	WOS:000521527500001
J	Diaz-Valdivia, NI; Diaz, J; Contreras, P; Campos, A; Rojas-Celis, V; Burgos-Ravanal, RA; Lobos-Gonzalez, L; Torres, VA; Perez, VI; Frei, B; Leyton, L; Quest, AFG				Diaz-Valdivia, Natalia I.; Diaz, Jorge; Contreras, Pamela; Campos, America; Rojas-Celis, Victoria; Burgos-Ravanal, Renato A.; Lobos-Gonzalez, Lorena; Torres, Vicente A.; Perez, Viviana I.; Frei, Balz; Leyton, Lisette; Quest, Andrew F. G.			The non-receptor tyrosine phosphatase type 14 blocks caveolin-1-enhanced cancer cell metastasis	ONCOGENE			English	Article							FOCAL ADHESION DYNAMICS; MESENCHYMAL TRANSITION; SRC KINASE; PHOSPHORYLATION; GROWTH; MIGRATION; CAVEOLIN; BETA; PEZ; IDENTIFICATION	Caveolin-1 (CAV1) enhanced migration, invasion, and metastasis of cancer cells is inhibited by co-expression of the glycoprotein E-cadherin. Although the two proteins form a multiprotein complex that includes beta-catenin, it remained unclear how this would contribute to blocking the metastasis promoting function of CAV1. Here, we characterized by mass spectrometry the protein composition of CAV1 immunoprecipitates from B16F10 murine melanoma cells expressing or not E-cadherin. The novel protein tyrosine phosphatase PTPN14 was identified by mass spectrometry analysis exclusively in co-immunoprecipitates of CAV1 with E-cadherin. Interestingly, PTPN14 is implicated in controlling metastasis, but only few known PTPN14 substrates exist. We corroborated by western blotting experiments that PTPN14 and CAV1 co-inmunoprecipitated in the presence of E-cadherin in B16F10 melanoma and other cancer cells. Moreover, the CAV1(Y14F) mutant protein was shown to co-immunoprecipitate with PTPN14 even in the absence of E-cadherin, and overexpression of PTPN14 reduced CAV1 phosphorylation on tyrosine-14, as well as suppressed CAV1-enhanced cell migration, invasion and Rac-1 activation in B16F10, metastatic colon [HT29(US)] and breast cancer (MDA-MB-231) cell lines. Finally, PTPN14 overexpression in B16F10 cells reduced the ability of CAV1 to induce metastasis in vivo. In summary, we identify here CAV1 as a novel substrate for PTPN14 and show that overexpression of this phosphatase suffices to reduce CAV1-induced metastasis.	[Diaz-Valdivia, Natalia I.; Diaz, Jorge; Contreras, Pamela; Campos, America; Rojas-Celis, Victoria; Burgos-Ravanal, Renato A.; Lobos-Gonzalez, Lorena; Leyton, Lisette; Quest, Andrew F. G.] Univ Chile, Fac Med, Cellular Commun Lab, Ctr Studies Exercise Metab & Canc CEMC,Adv Ctr Ch, Santiago, Chile; [Diaz, Jorge; Torres, Vicente A.] Univ Chile, Inst Res Dent Sci, Fac Dent, Santiago, Chile; [Campos, America; Lobos-Gonzalez, Lorena] Fdn Ciencia & Vida, Santiago, Chile; [Perez, Viviana I.; Frei, Balz] Oregon State Univ, Dept Biochem & Biophys, Linus Pauling Inst, Corvallis, OR 97331 USA	Universidad de Chile; Universidad de Chile; Oregon State University	Leyton, L; Quest, AFG (corresponding author), Univ Chile, Fac Med, Cellular Commun Lab, Ctr Studies Exercise Metab & Canc CEMC,Adv Ctr Ch, Santiago, Chile.	lleyton@med.uchile.cl; aquest@med.uchile.cl	Díaz-Valdivia, Natalia/Z-1893-2019	Díaz-Valdivia, Natalia/0000-0002-8063-2598; Lobos-Gonzalez, Lorena/0000-0002-4957-9864; Torres, Vicente A/0000-0002-5973-7248	CONICYT-FONDAP [15130011]; FONDECYT [1130250, 1170925, 1150744, 1140907, 11140204]; American federation for Aging Research (AFAR); Faculty Development Funds from Linus Pauling Institute; CONICYT; BASAL CCTE-PFB16 CONICYT;  [Anillo ACT 1111]	CONICYT-FONDAP(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDAP); FONDECYT(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT); American federation for Aging Research (AFAR); Faculty Development Funds from Linus Pauling Institute; CONICYT(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)); BASAL CCTE-PFB16 CONICYT; 	This work was supported by CONICYT-FONDAP 15130011 (AFGQ), FONDECYT 1130250, 1170925 (AFGQ), Anillo ACT 1111 (AFGQ), FONDECYT 1150744 (LL), FONDECYT 1140907 (VAT), American federation for Aging Research (AFAR), Faculty Development Funds from Linus Pauling Institute (VIP) and CONICYT PhD fellowships (NDV, JD, AC), FONDECYT 11140204 (LLG), BASAL CCTE-PFB16 CONICYT (LLG).	Barr AJ, 2009, CELL, V136, P352, DOI 10.1016/j.cell.2008.11.038; Belle L, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005547; Bender FC, 2000, CANCER RES, V60, P5870; Cao HM, 2004, EXP CELL RES, V294, P159, DOI 10.1016/j.yexcr.2003.11.010; Cao HM, 2002, J BIOL CHEM, V277, P8771, DOI 10.1074/jbc.C100661200; Cao XQ, 2008, J BIOL CHEM, V283, P31401, DOI 10.1074/jbc.M804002200; Chiang WF, 2008, ORAL ONCOL, V44, P325, DOI 10.1016/j.oraloncology.2007.03.004; del Pozo MA, 2005, NAT CELL BIOL, V7, P901, DOI 10.1038/ncb1293; Diaz Jorge, 2014, Commun Integr Biol, V7, DOI 10.4161/19420889.2014.972850; Diaz J, 2014, J CELL SCI, V127, P2401, DOI 10.1242/jcs.141689; Diaz-Valdivia N, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1477-5; Diaz-Valdivia NI, 2017, ONCOTARGET, V8, P111943, DOI 10.18632/oncotarget.22955; Galvagni F, 2007, BIOCHEMISTRY-US, V46, P3998, DOI 10.1021/bi061400n; Goetz JG, 2008, J CELL BIOL, V180, P1261, DOI 10.1083/jcb.200709019; Grande-Garcia A, 2007, J CELL BIOL, V177, P683, DOI 10.1083/jcb.200701006; Hu HL, 2005, CURR BIOL, V15, P815, DOI 10.1016/j.cub.2005.03.049; Jo A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091582; Joshi B, 2008, CANCER RES, V68, P8210, DOI 10.1158/0008-5472.CAN-08-0343; Khusial PR, 2010, ONCOTARGET, V1, P198; Kimura A, 2002, J BIOL CHEM, V277, P30153, DOI 10.1074/jbc.M203375200; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Labrecque L, 2004, J BIOL CHEM, V279, P52132, DOI 10.1074/jbc.M409617200; Lee H, 2006, BIOCHEMISTRY-US, V45, P234, DOI 10.1021/bi051560j; Lee H, 2000, MOL ENDOCRINOL, V14, P1750, DOI 10.1210/me.14.11.1750; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Li SW, 1996, J BIOL CHEM, V271, P3863; Liu X, 2013, ONCOGENE, V32, P1266, DOI 10.1038/onc.2012.147; Lobos-Gonzalez L, 2013, PIGM CELL MELANOMA R, V26, DOI 10.1111/pcmr.12085; Mastick CC, 1997, J BIOL CHEM, V272, P20706, DOI 10.1074/jbc.272.33.20706; MASTICK CC, 1995, J CELL BIOL, V129, P1523, DOI 10.1083/jcb.129.6.1523; Ogata M, 1999, J BIOL CHEM, V274, P12905, DOI 10.1074/jbc.274.18.12905; Ogata M, 1999, J BIOL CHEM, V274, P20717, DOI 10.1074/jbc.274.29.20717; Orlichenko L, 2006, J BIOL CHEM, V281, P4570, DOI 10.1074/jbc.M512088200; Ortiz R, 2016, ONCOTARGET, V7, P40571, DOI 10.18632/oncotarget.9738; Parat MO, 2003, MOL BIOL CELL, V14, P3156, DOI 10.1091/mbc.e02-11-0761; Poernbacher I, 2012, CURR BIOL, V22, P389, DOI 10.1016/j.cub.2012.01.019; Radel C, 2005, AM J PHYSIOL-HEART C, V288, pH936, DOI 10.1152/ajpheart.00519.2004; Rizzo V, 2003, AM J PHYSIOL-HEART C, V285, pH1720, DOI 10.1152/ajpheart.00344.2002; Rodriguez DA, 2009, MOL BIOL CELL, V20, P2297, DOI 10.1091/mbc.E08-09-0939; SMITH AL, 1995, BIOCHEM BIOPH RES CO, V209, P959, DOI 10.1006/bbrc.1995.1591; Sun YF, 2014, SCI REP-UK, V4, DOI 10.1038/srep06527; Tomono T, 2017, J PHARM SCI-US, V106, P2642, DOI 10.1016/j.xphs.2017.03.011; Torres VA, 2007, MOL CELL BIOL, V27, P7703, DOI 10.1128/MCB.01991-06; Torres VA, 2006, J CELL SCI, V119, P1812, DOI 10.1242/jcs.02894; Urra H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033085; Vaisar T, 2007, J CLIN INVEST, V117, P746, DOI 10.1172/JCI26206; Volonte D, 2001, J BIOL CHEM, V276, P8094, DOI 10.1074/jbc.M009245200; Wadham C, 2003, MOL BIOL CELL, V14, P2520, DOI 10.1091/mbc.E02-09-0577; Wilson KE, 2014, J BIOL CHEM, V289, P23693, DOI 10.1074/jbc.M113.534701; Wyatt L, 2007, J CELL BIOL, V178, P1223, DOI 10.1083/jcb.200705035; Zhang P, 2013, ONCOGENE, V32, P2087, DOI 10.1038/onc.2012.220	51	11	11	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	18					3693	3709		10.1038/s41388-020-1242-3	http://dx.doi.org/10.1038/s41388-020-1242-3		MAR 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LI5XR	32152405	Green Published, hybrid			2022-12-28	WOS:000518734000001
J	Liu, XC; Cui, JF; Gong, L; Tian, F; Shen, YL; Chen, LP; Wang, Y; Xia, YY; Liu, L; Ye, X; Wang, ML; Liu, GY; Jiang, BC; Shao, CS; Zou, YX; Gong, YQ				Liu, Xiaochen; Cui, Jianfeng; Gong, Li; Tian, Fei; Shen, Yangli; Chen, Lipeng; Wang, Yong; Xia, Yangyang; Liu, Lei; Ye, Xiang; Wang, Molin; Liu, Guangyi; Jiang, Baichun; Shao, Changshun; Zou, Yongxin; Gong, Yaoqin			The CUL4B-miR-372/373-PIK3CA-AKT axis regulates metastasis in bladder cancer	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; PI3K/AKT PATHWAY; CUL4B; MUTATIONS; CELLS; TUMORIGENESIS; EXPRESSION; RESTRICTS; ENCODES; COMPLEX	CUL4B, which acts as a scaffold protein in CUL4B-RING ubiquitin ligase (CRL4B) complexes, participates in a variety of biological processes. Previous studies have shown that CUL4B is often overexpressed and exhibits oncogenic activities in a variety of solid tumors. However, the roles and the underlying mechanisms of CUL4B in bladder cancer (BC) were poorly understood. Here, we showed that CUL4B levels were overexpressed and positively correlated with the malignancy of BC, and CUL4B could confer BC cells increased motility, invasiveness, stemness, and chemoresistance. The PIK3CA/AKT pathway was identified as a critical downstream mediator of CUL4B-driven oncogenicity in BC cells. Furthermore, we demonstrated that CRL4B epigenetically repressed the transcription of miR-372/373, via catalyzing monoubiquitination of H2AK119 at the gene cluster encoding miR-372/373, leading to upregulation of PIK3CA and activation of AKT. Our findings thus establish a critical role for the CUL4B-miR-372/373-PIK3CA/AKT axis in the pathogenesis of BC and have important prognostic and therapeutic implications in BC.	[Liu, Xiaochen; Gong, Li; Tian, Fei; Shen, Yangli; Ye, Xiang; Wang, Molin; Jiang, Baichun; Zou, Yongxin; Gong, Yaoqin] Shandong Univ, Sch Basic Med Sci, Minist Educ, Key Lab Expt Teratol, Jinan, Shandong, Peoples R China; [Liu, Xiaochen; Gong, Li; Tian, Fei; Shen, Yangli; Ye, Xiang; Wang, Molin; Jiang, Baichun; Zou, Yongxin; Gong, Yaoqin] Shandong Univ, Sch Basic Med Sci, Dept Mol Med & Genet, Jinan, Shandong, Peoples R China; [Cui, Jianfeng; Chen, Lipeng; Wang, Yong; Xia, Yangyang; Liu, Lei] Shandong Univ, Qilu Hosp, Dept Urol, Jinan, Shandong, Peoples R China; [Liu, Guangyi] Shandong Univ, Qilu Hosp, Dept Nephrol, Jinan, Shandong, Peoples R China; [Shao, Changshun] Soochow Univ, Inst Translat Med, State Key Lab Radiat Med & Protect, Suzhou, Jiangsu, Peoples R China	Shandong University; Shandong University; Shandong University; Shandong University; Soochow University - China	Zou, YX; Gong, YQ (corresponding author), Shandong Univ, Sch Basic Med Sci, Minist Educ, Key Lab Expt Teratol, Jinan, Shandong, Peoples R China.; Zou, YX; Gong, YQ (corresponding author), Shandong Univ, Sch Basic Med Sci, Dept Mol Med & Genet, Jinan, Shandong, Peoples R China.	zouyongxin@sdu.edu.cn; yxg8@sdu.edu.cn	Shao, Changshun/AAD-8977-2022	Shao, Changshun/0000-0003-2618-9342	National Natural Science Foundation of China [81330050, 81571523, 31671427, 81770660]; Natural Science Foundation of Shandong Province [ZR2016HZ01]; Key Research and Development Program of Shandong Province [2016ZDJS07A08]; Young Scholars Program of Shandong University	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province); Key Research and Development Program of Shandong Province; Young Scholars Program of Shandong University	The authors would like to thank Dr M. Oren for kindly providing psiCHECK2 reporter plasmids containing the 3UTR wide-type and mutant sequences of PIK3CA. This work was supported by the National Natural Science Foundation of China (81330050 and 81571523 to YG, 31671427 to YZ, 81770660 to GL); the Natural Science Foundation of Shandong Province (ZR2016HZ01 to YG); the Key Research and Development Program of Shandong Province (2016ZDJS07A08 to YG); and Young Scholars Program of Shandong University (to YZ).	Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; BUBENIK J, 1973, INT J CANCER, V11, P765, DOI 10.1002/ijc.2910110327; Caino MC, 2015, P NATL ACAD SCI USA, V112, P8638, DOI 10.1073/pnas.1500722112; Carnero A, 2008, CURR CANCER DRUG TAR, V8, P187, DOI 10.2174/156800908784293659; Choi W, 2017, EUR UROL, V72, P354, DOI 10.1016/j.eururo.2017.03.010; Cicenas J, 2008, INT J BIOL MARKER, V23, P1, DOI 10.1177/172460080802300101; Earl J, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1450-3; El-Daly SM, 2016, SCI REP-UK, V6, DOI 10.1038/srep24720; Hannah J, 2015, GENE, V573, P33, DOI 10.1016/j.gene.2015.08.064; Harel SA, 2015, CELL DEATH DIFFER, V22, P1328, DOI 10.1038/cdd.2014.221; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Hu HL, 2012, CANCER CELL, V22, P781, DOI 10.1016/j.ccr.2012.10.024; Ji QH, 2014, J CELL SCI, V127, P4679, DOI 10.1242/jcs.154245; Julien S, 2007, ONCOGENE, V26, P7445, DOI 10.1038/sj.onc.1210546; Knowles MA, 2015, NAT REV CANCER, V15, P25, DOI 10.1038/nrc3817; Kuwada M, 2015, CANCER LETT, V369, P212, DOI 10.1016/j.canlet.2015.08.019; Lang A, 2019, CANCERS, V11, DOI 10.3390/cancers11040481; Lang QB, 2012, BIOCHEM BIOPH RES CO, V426, P247, DOI 10.1016/j.bbrc.2012.08.075; Ler LD, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai8312; Li PS, 2017, DIABETES, V66, P300, DOI 10.2337/db16-0743; Liu J, 2017, AM J CANCER RES, V7, P148; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Mao XW, 2017, ONCOTARGET, V8, P77241, DOI 10.18632/oncotarget.20455; Mayer IA, 2016, ANNU REV MED, V67, P11, DOI 10.1146/annurev-med-062913-051343; Mensah FA, 2018, ONCOTARGETS THER, V11, P4817, DOI 10.2147/OTT.S142264; Mi J, 2017, MOL ONCOL, V11, P305, DOI 10.1002/1878-0261.12038; Paplomata E, 2014, THER ADV MED ONCOL, V6, P154, DOI 10.1177/1758834014530023; Platt FM, 2009, CLIN CANCER RES, V15, P6008, DOI 10.1158/1078-0432.CCR-09-0898; Qi M, 2018, ONCOGENE, V37, P1075, DOI 10.1038/onc.2017.380; Qi M, 2019, ONCOGENESIS, V8, DOI 10.1038/s41389-019-0131-5; Qian YY, 2015, CANCER RES, V75, P5070, DOI 10.1158/0008-5472.CAN-15-0898; Qiao M, 2008, CELL CYCLE, V7, P2991, DOI 10.4161/cc.7.19.6784; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sanli O, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.22; See WA, 1997, J UROLOGY, V157, P1136, DOI 10.1016/S0022-5347(01)65156-5; Segovia C, 2017, ONCOTARGET, V8, P10531, DOI 10.18632/oncotarget.14453; Solomon DA, 2013, NAT GENET, V45, P1428, DOI 10.1038/ng.2800; Tarpey PS, 2007, AM J HUM GENET, V80, P345, DOI 10.1086/511134; Vasudevan KM, 2009, CANCER CELL, V16, P21, DOI 10.1016/j.ccr.2009.04.012; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wei Z, 2015, FREE RADICAL BIO MED, V79, P1, DOI 10.1016/j.freeradbiomed.2014.11.010; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Xu ZL, 2019, ONCOGENE, V38, P5860, DOI 10.1038/s41388-019-0847-x; Yang Y, 2015, ONCOGENE, V34, P104, DOI 10.1038/onc.2013.522; Yu QQ, 2014, BIOMED PHARMACOTHER, V68, P155, DOI 10.1016/j.biopha.2014.01.005; Yuan JP, 2015, J PATHOL, V235, P784, DOI 10.1002/path.4492; Zhang Y, 1997, INT J CANCER, V71, P851; Zhao MF, 2019, PROSTATE, V79, DOI 10.1002/pros.23754; Zou YX, 2007, AM J HUM GENET, V80, P561, DOI 10.1086/512489; Zou YX, 2013, J CELL BIOL, V200, P743, DOI 10.1083/jcb.201206065; Zou YX, 2009, J BIOL CHEM, V284, P33320, DOI 10.1074/jbc.M109.050427	52	12	13	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	17					3588	3603		10.1038/s41388-020-1236-1	http://dx.doi.org/10.1038/s41388-020-1236-1		MAR 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LH1YK	32127645				2022-12-28	WOS:000517861800002
J	Vessoni, AT; Filippi-Chiela, EC; Lenz, G; Batista, LFZ				Vessoni, Alexandre Teixeira; Filippi-Chiela, Eduardo Cremonese; Lenz, Guido; Batista, Luis Francisco Zirnberger			Tumor propagating cells: drivers of tumor plasticity, heterogeneity, and recurrence	ONCOGENE			English	Review							CANCER STEM-CELLS; ACUTE MYELOID-LEUKEMIA; INITIATING CELLS; OXIDATIVE-PHOSPHORYLATION; INTRATUMOR HETEROGENEITY; PHENOTYPIC HETEROGENEITY; MESENCHYMAL TRANSITION; CLONAL EVOLUTION; DRUG-RESISTANCE; MELANOMA-CELLS	Tumorigenesis is associated with the development of a highly variable pattern of cellular diversity, consequence of genetic and epigenetic diversification, followed by clonal selection and expansion. This process is shaped by the microenvironment and leads to intratumoral heterogeneity, which is characterized by differences between cancer cells in terms of gene expression, phenotypic markers, growth dynamics, and resistance to treatment. Another relevant aspect in intratumor heterogeneity is cell plasticity-the ability of a cell to switch to new identities. In this review, we focus on the mechanisms that regulate cancer cell plasticity within a tumor, and explore the concept of tumor propagating cells, or TPCs, a cancer cell able to propagate/phenocopy the parental tumor and recapitulate tumor heterogeneity. We discuss the influence of the microenvironment and driver mutations on TPCs formation and function, the existence of phenotypically distinct TPC clones within a tumor, the evolution of TPCs with disease progression, and their implications for therapy.	[Vessoni, Alexandre Teixeira; Batista, Luis Francisco Zirnberger] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; [Filippi-Chiela, Eduardo Cremonese] Univ Fed Rio Grande do Sul, Dept Ciencias Morfol, Inst Ciencias Basicas Saude, Porto Alegre, RS, Brazil; [Lenz, Guido] Univ Fed Rio Grande do Sul, Dept Biofis, Porto Alegre, RS, Brazil; [Lenz, Guido] Univ Fed Rio Grande do Sul, Ctr Biotecnol, Porto Alegre, RS, Brazil; [Batista, Luis Francisco Zirnberger] Washington Univ, Sch Med, Dept Dev Biol, St Louis, MO 63110 USA; [Batista, Luis Francisco Zirnberger] Washington Univ, Sch Med, Ctr Regenerat Med, St Louis, MO 63110 USA	Washington University (WUSTL); Universidade Federal do Rio Grande do Sul; Universidade Federal do Rio Grande do Sul; Universidade Federal do Rio Grande do Sul; Washington University (WUSTL); Washington University (WUSTL)	Vessoni, AT; Batista, LFZ (corresponding author), Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.; Batista, LFZ (corresponding author), Washington Univ, Sch Med, Dept Dev Biol, St Louis, MO 63110 USA.; Batista, LFZ (corresponding author), Washington Univ, Sch Med, Ctr Regenerat Med, St Louis, MO 63110 USA.	alexandre.vessoni@wustl.edu; lbatista@wustl.edu	Filippi-Chiela, Eduardo/F-1959-2014; Vessoni, Alexandre/L-5754-2013	Filippi-Chiela, Eduardo/0000-0001-8192-3779; Vessoni, Alexandre/0000-0001-9170-5185	Philip Majerus Fellowship Fund; NHLBI [4R00HL114732, 1R01HL137793]; V Foundation for Cancer Research; AA&MDS International Foundation; CONCERN Foundation; Department of Defense Bone Marrow Failure Research Program [BM160054]; American Cancer Society; Edward Mallinckrodt Jr. Foundation	Philip Majerus Fellowship Fund; NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); V Foundation for Cancer Research; AA&MDS International Foundation; CONCERN Foundation; Department of Defense Bone Marrow Failure Research Program; American Cancer Society(American Cancer Society); Edward Mallinckrodt Jr. Foundation	ATV was supported by the Philip Majerus Fellowship Fund. LFZB is supported by the NHLBI (4R00HL114732; 1R01HL137793) and grants from the V Foundation for Cancer Research, the Edward Mallinckrodt Jr. Foundation, the AA&MDS International Foundation, the CONCERN Foundation, the Department of Defense Bone Marrow Failure Research Program (BM160054) and the American Cancer Society. We thank Sapiens Scientific Illustrations for the artistic work on Figs. 1-3.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Anderson K, 2011, NATURE, V469, P356, DOI 10.1038/nature09650; Auffinger B, 2014, CELL DEATH DIFFER, V21, P1119, DOI 10.1038/cdd.2014.31; Baca SC, 2013, CELL, V153, P666, DOI 10.1016/j.cell.2013.03.021; Bai F, 2014, CANCER RES, V74, P6161, DOI 10.1158/0008-5472.CAN-14-1119; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bapat SA, 2005, CANCER RES, V65, P3025, DOI 10.1158/0008-5472.CAN-04-3931; Barrett LE, 2012, CANCER CELL, V21, P11, DOI 10.1016/j.ccr.2011.11.025; Blazek ER, 2007, INT J RADIAT ONCOL, V67, P1, DOI 10.1016/j.ijrobp.2006.09.037; Boiko AD, 2010, NATURE, V466, P133, DOI 10.1038/nature09161; Bridges HR, 2014, BIOCHEM J, V462, P475, DOI 10.1042/BJ20140620; Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020; Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005; Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108; Charles N, 2010, CELL STEM CELL, V6, P141, DOI 10.1016/j.stem.2010.01.001; Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287; Chen RH, 2010, CANCER CELL, V17, P362, DOI 10.1016/j.ccr.2009.12.049; Cheng L, 2013, CELL, V153, P139, DOI 10.1016/j.cell.2013.02.021; Corces MR, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00263; Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; de Bruin EC, 2014, SCIENCE, V346, P251, DOI 10.1126/science.1253462; De Luca A, 2015, ONCOTARGET, V6, P14777, DOI 10.18632/oncotarget.4401; Denise C, 2015, ONCOTARGET, V6, P41706, DOI 10.18632/oncotarget.5991; Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733; Dieter SM, 2011, CELL STEM CELL, V9, P357, DOI 10.1016/j.stem.2011.08.010; Ding L, 2012, NATURE, V481, P506, DOI 10.1038/nature10738; Driessens G, 2012, NATURE, V488, P527, DOI 10.1038/nature11344; Egan JB, 2012, BLOOD, V120, P1060, DOI 10.1182/blood-2012-01-405977; Elinav E, 2013, NAT REV CANCER, V13, P759, DOI 10.1038/nrc3611; Engle EK, 2015, LEUKEMIA, V29, P869, DOI 10.1038/leu.2014.289; Ge YJ, 2017, CELL, V169, P636, DOI 10.1016/j.cell.2017.03.042; Gerlinger M, 2014, NAT GENET, V46, P225, DOI 10.1038/ng.2891; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Giesen C, 2014, NAT METHODS, V11, P417, DOI [10.1038/NMETH.2869, 10.1038/nmeth.2869]; Giessler KM, 2017, J EXP MED, V214, P2073, DOI 10.1084/jem.20162017; Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harbst K, 2016, CANCER RES, V76, P4765, DOI 10.1158/0008-5472.CAN-15-3476; Hicks J, 2006, GENOME RES, V16, P1465, DOI 10.1101/gr.5460106; Hong DL, 2008, SCIENCE, V319, P336, DOI 10.1126/science.1150648; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Hughes AEO, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004462; Ischenko I, 2013, P NATL ACAD SCI USA, V110, P3937, DOI 10.1073/pnas.1219592110; Jacoby MA, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98962; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Jeon HM, 2014, CANCER RES, V74, P4482, DOI 10.1158/0008-5472.CAN-13-1597; Jin LQ, 2006, NAT MED, V12, P1167, DOI 10.1038/nm1483; Jinushi M, 2011, P NATL ACAD SCI USA, V108, P12425, DOI 10.1073/pnas.1106645108; Kelly PN, 2007, SCIENCE, V317, P337, DOI 10.1126/science.1142596; Kim SY, 2016, J CELL BIOCHEM, V117, P2289, DOI 10.1002/jcb.25527; Kim TM, 2015, CLIN CANCER RES, V21, P4461, DOI 10.1158/1078-0432.CCR-14-2413; Klco JM, 2014, CANCER CELL, V25, P379, DOI 10.1016/j.ccr.2014.01.031; Krause DS, 2006, NAT MED, V12, P1175, DOI 10.1038/nm1489; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Kreso A, 2013, SCIENCE, V339, P543, DOI 10.1126/science.1227670; Kurtova AV, 2015, NATURE, V517, P209, DOI 10.1038/nature14034; Lagadec C, 2012, STEM CELLS, V30, P833, DOI 10.1002/stem.1058; Lagadinou ED, 2013, CELL STEM CELL, V12, P329, DOI 10.1016/j.stem.2012.12.013; Lamb R, 2014, ONCOTARGET, V5, P11029, DOI 10.18632/oncotarget.2789; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Lapouge G, 2012, EMBO J, V31, P4563, DOI 10.1038/emboj.2012.312; Ledur PF, 2016, NEURO-ONCOLOGY, V18, P1413, DOI 10.1093/neuonc/now062; Ledur PF, 2017, ONCOTARGET, V8, P69185, DOI 10.18632/oncotarget.20193; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Lee KM, 2017, CELL METAB, V26, P633, DOI 10.1016/j.cmet.2017.09.009; Li S, 2016, NAT MED, V22, P792, DOI 10.1038/nm.4125; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018; Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001; Liu K, 2017, MOL CELL, V68, P281, DOI 10.1016/j.molcel.2017.09.022; Liu XJ, 2017, CELL RES, V27, P764, DOI 10.1038/cr.2017.41; Lotti F, 2013, J EXP MED, V210, P2851, DOI 10.1084/jem.20131195; Lu HH, 2014, NAT CELL BIOL, V16, P1105, DOI 10.1038/ncb3041; Lu R, 2016, CANCER CELL, V30, P92, DOI 10.1016/j.ccell.2016.05.008; Maenhaut C, 2010, CARCINOGENESIS, V31, P149, DOI 10.1093/carcin/bgp259; Majeti R, 2009, CELL, V138, P286, DOI 10.1016/j.cell.2009.05.045; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mazumdar C, 2015, CELL STEM CELL, V17, P1, DOI 10.1016/j.stem.2015.09.017; McClellan JS, 2015, P NATL ACAD SCI USA, V112, P4074, DOI 10.1073/pnas.1413383112; McDonald OG, 2017, NAT GENET, V49, P367, DOI 10.1038/ng.3753; Medyouf H, 2014, CELL STEM CELL, V14, P824, DOI 10.1016/j.stem.2014.02.014; Miller CA, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003665; Neftel C, 2019, CELL, V178, P835, DOI 10.1016/j.cell.2019.06.024; Nik-Zainal S, 2012, CELL, V149, DOI 10.1016/j.cell.2012.04.023; Notta F, 2011, NATURE, V469, P362, DOI 10.1038/nature09733; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Oshimori N, 2015, CELL, V160, P963, DOI 10.1016/j.cell.2015.01.043; Pagotto A, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.327; Park SM, 2015, J CLIN INVEST, V125, P1286, DOI 10.1172/JCI78440; Patrawala L, 2005, CANCER RES, V65, P6207, DOI 10.1158/0008-5472.CAN-05-0592; Piccirillo SGM, 2015, STEM CELL REP, V4, P7, DOI 10.1016/j.stemcr.2014.11.003; Quek L, 2018, NAT MED, V24, P1167, DOI 10.1038/s41591-018-0115-6; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Quintana E, 2010, CANCER CELL, V18, P510, DOI 10.1016/j.ccr.2010.10.012; Read TA, 2009, CANCER CELL, V15, P135, DOI 10.1016/j.ccr.2008.12.016; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Rycaj K, 2015, CANCER RES, V75, P4003, DOI 10.1158/0008-5472.CAN-15-0798; Sancho P, 2015, CELL METAB, V22, P590, DOI 10.1016/j.cmet.2015.08.015; Schapiro D, 2017, NAT METHODS, V14, P873, DOI [10.1038/NMETH.4391, 10.1038/nmeth.4391]; Schepers AG, 2012, SCIENCE, V337, P730, DOI 10.1126/science.1224676; Schober M, 2011, P NATL ACAD SCI USA, V108, P10544, DOI 10.1073/pnas.1107807108; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Shackleton M, 2009, CELL, V138, P822, DOI 10.1016/j.cell.2009.08.017; Shalapour S, 2015, J CLIN INVEST, V125, P3347, DOI 10.1172/JCI80007; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Shi Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15080; Shih AH, 2015, CANCER CELL, V27, P502, DOI 10.1016/j.ccell.2015.03.009; Shimoda M, 2014, NAT CELL BIOL, V16, P889, DOI 10.1038/ncb3021; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Sonveaux P, 2008, J CLIN INVEST, V118, P3930, DOI 10.1172/JCI36843; Sottoriva A, 2015, NAT GENET, V47, P209, DOI 10.1038/ng.3214; Sottoriva A, 2013, P NATL ACAD SCI USA, V110, P4009, DOI 10.1073/pnas.1219747110; Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055; Stewart JM, 2011, P NATL ACAD SCI USA, V108, P6468, DOI 10.1073/pnas.1005529108; Sun YQ, 2018, CANCER CELL, V34, P643, DOI 10.1016/j.ccell.2018.08.018; Taussig DC, 2008, BLOOD, V112, P568, DOI 10.1182/blood-2007-10-118331; Taussig DC, 2010, BLOOD, V115, P1976, DOI 10.1182/blood-2009-02-206565; Tehranchi R, 2010, NEW ENGL J MED, V363, P1025, DOI 10.1056/NEJMoa0912228; Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001; Trissal MC, 2018, CANCER RES, V78, P3510, DOI 10.1158/0008-5472.CAN-17-3592; Van Keymeulen A, 2015, NATURE, V525, P119, DOI 10.1038/nature14665; van Niel G, 2018, NAT REV MOL CELL BIO, V19, P213, DOI 10.1038/nrm.2017.125; Venkataramani V, 2019, NATURE, V573, P532, DOI 10.1038/s41586-019-1564-x; Venkatesh HS, 2019, NATURE, V573, P539, DOI 10.1038/s41586-019-1563-y; Venteicher AS, 2017, SCIENCE, V355, DOI 10.1126/science.aai8478; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Viale A, 2014, NATURE, V514, P628, DOI 10.1038/nature13611; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Vlashi E, 2014, BREAST CANCER RES TR, V146, P525, DOI 10.1007/s10549-014-3051-2; Vlashi E, 2011, P NATL ACAD SCI USA, V108, P16062, DOI 10.1073/pnas.1106704108; Volonte A, 2014, J IMMUNOL, V192, P523, DOI 10.4049/jimmunol.1301342; Walker BA, 2014, LEUKEMIA, V28, P384, DOI 10.1038/leu.2013.199; Wang Y, 2011, CELL STEM CELL, V8, P399, DOI 10.1016/j.stem.2011.02.006; Wei J, 2010, MOL CANCER THER, V9, P67, DOI 10.1158/1535-7163.MCT-09-0734; Weng QJ, 2019, CELL STEM CELL, V24, P707, DOI 10.1016/j.stem.2019.03.006; Wong TN, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02858-0; Wulf GG, 2001, BLOOD, V98, P1166, DOI 10.1182/blood.V98.4.1166; Xu J, 2019, ELIFE, V8, DOI 10.7554/eLife.45105; Xue RD, 2016, GASTROENTEROLOGY, V150, P998, DOI 10.1053/j.gastro.2015.12.033; Yan C, 2017, CANCER LETT, V388, P34, DOI 10.1016/j.canlet.2016.11.018; Yang Y, 2017, INT J ONCOL, V51, P515, DOI 10.3892/ijo.2017.4044; Ye HB, 2016, CELL STEM CELL, V19, P23, DOI 10.1016/j.stem.2016.06.001; You Y, 2018, CLIN EXP IMMUNOL, V191, P60, DOI 10.1111/cei.13044; Zamarron BF, 2011, INT J BIOL SCI, V7, P651, DOI 10.7150/ijbs.7.651; Zeng QQ, 2019, NATURE, V573, P526, DOI 10.1038/s41586-019-1576-6	148	22	22	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	10					2055	2068		10.1038/s41388-019-1128-4	http://dx.doi.org/10.1038/s41388-019-1128-4			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KS8UR	31801972				2022-12-28	WOS:000518584000003
J	Zhang, Q; Fan, H; Liu, HD; Jin, JJ; Zhu, SH; Zhou, L; Liu, HB; Zhang, F; Zhan, P; Lv, TF; Song, Y				Zhang, Qun; Fan, Hang; Liu, Hongda; Jin, Jiajia; Zhu, Suhua; Zhou, Li; Liu, Hongbin; Zhang, Fang; Zhan, Ping; Lv, Tangfeng; Song, Yong			WNT5B exerts oncogenic effects and is negatively regulated by miR-5587-3p in lung adenocarcinoma progression	ONCOGENE			English	Article							WNT/BETA-CATENIN PATHWAY; CANCER; IDENTIFICATION; PROLIFERATION; DISEASE; FAMILY; WNT-5B; CELLS; RISK	WNT5B glycoprotein belongs to the Wnt protein family. Limited investigations revealed a possible role of WNT5B in malignancies, such as triple-negative breast cancer and oral squamous cell carcinoma. However, whether WNT5B contributes to the progression of lung adenocarcinoma (LAD) remains unclear. Here, we initially determine that WNT5B is highly expressed in LAD and is positively correlated with lymph node metastasis and TNM stage. Consistently, clinical analysis reveals WNT5B as an independent prognostic biomarker in LAD. Silencing WNT5B suppresses the proliferation of LAD both in vitro and in vivo by interfering G1/S cell-cycle progression and modulating amino acid metabolism, revealing its remarkable oncogenic role in LAD. Of note, we also identified miR-5587-3p as a negative upstream regulator of WNT5B in LAD, which may help develop therapies targeting LAD patients with high WNT5B expression. Taken together, our results revealed an oncogenic role of WNT5B in LAD, which could be a prognostic biomarker and promising therapeutic target for LAD patients.	[Zhang, Qun; Fan, Hang; Zhu, Suhua; Zhou, Li; Liu, Hongbin; Zhang, Fang; Zhan, Ping; Lv, Tangfeng; Song, Yong] Nanjing Univ, Jinling Hosp, Dept Resp Med, Sch Med, Nanjing 210002, Jiangsu, Peoples R China; [Zhang, Qun] Nanjing Med Univ, Dept Resp Med, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China; [Liu, Hongda] Nanjing Med Univ, Dept Gen Surg, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China; [Jin, Jiajia] Southern Med Univ, Jinling Hosp, Dept Resp Med, Nanjing 210002, Jiangsu, Peoples R China	Nanjing University; Nanjing Medical University; Nanjing Medical University; Southern Medical University - China	Zhan, P; Lv, TF; Song, Y (corresponding author), Nanjing Univ, Jinling Hosp, Dept Resp Med, Sch Med, Nanjing 210002, Jiangsu, Peoples R China.	zhanping207@163.com; bairoushui@163.com; yong_song6310@yahoo.com		Liu, Hongda/0000-0002-5977-9130	National Natural Science Foundation of China [81572937, 81572273, 81772500]; 16th batch "Summit of the Six Top Talents" Program of Jiangsu Province [WSN-154]; China Postdoctoral Science Foundation 12th batch Special fund [45786]; China Postdoctoral Science Foundation [45786]; Jiangsu Provincial Postdoctoral Science Foundation [2018K049A]; Natural Science Foundation of Jiangsu province [BK20180139, BK20161386]; Jiangsu Provincial Medical Youth Talent [QNRC2016125]; Nanjing Medical Science and Technology Development Project [ZKX17044]; Jiangsu Provincial Key Research and Development Program [BE2016721]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 16th batch "Summit of the Six Top Talents" Program of Jiangsu Province; China Postdoctoral Science Foundation 12th batch Special fund; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Jiangsu Provincial Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Natural Science Foundation of Jiangsu province(Natural Science Foundation of Jiangsu Province); Jiangsu Provincial Medical Youth Talent; Nanjing Medical Science and Technology Development Project; Jiangsu Provincial Key Research and Development Program	This work was supported by grants from the National Natural Science Foundation of China (grant numbers 81572937, 81572273, and 81772500); the16th batch "Summit of the Six Top Talents" Program of Jiangsu Province (grant number WSN-154); China Postdoctoral Science Foundation 12th batch Special fund (Postdoctoral number: 45786); China Postdoctoral Science Foundation 64th batch (Postdoctoral number: 45786); Jiangsu Provincial Postdoctoral Science Foundation (grant number 2018K049A); the Natural Science Foundation of Jiangsu province (grant numbers BK20180139 and BK20161386); Jiangsu Provincial Medical Youth Talent (grant number QNRC2016125), and the Nanjing Medical Science and Technology Development Project (No. ZKX17044), the Jiangsu Provincial Key Research and Development Program (No. BE2016721).	Behari J, 2014, AM J PATHOL, V184, P3284, DOI 10.1016/j.ajpath.2014.08.022; Bergethon K, 2012, J CLIN ONCOL, V30, P863, DOI 10.1200/JCO.2011.35.6345; Chen WQ, 2014, ANN TRANSL MED, V2, DOI 10.3978/j.issn.2305-5839.2014.04.05; Cormerais Y, 2018, J BIOL CHEM, V293, P2877, DOI 10.1074/jbc.RA117.001342; Cormerais Y, 2016, CANCER RES, V76, P4481, DOI 10.1158/0008-5472.CAN-15-3376; Dato S, 2019, BIOGERONTOLOGY, V20, P17, DOI 10.1007/s10522-018-9770-8; Dissanayake SK, 2007, J BIOL CHEM, V282, P17259, DOI 10.1074/jbc.M700075200; Ghosh S, 2008, DEV GROWTH DIFFER, V50, P289, DOI [10.1111/j.1440-169x.2008.01000.x, 10.1111/j.1440-169X.2008.01000.x]; Giroux-Leprieur E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092835; Grant SFA, 2006, NAT GENET, V38, P320, DOI 10.1038/ng1732; HABAS R, 2005, J BIOL LONDON, V4; Hou J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010312; Kanazawa A, 2004, AM J HUM GENET, V75, P832, DOI 10.1086/425340; Komiya Yuko, 2008, Organogenesis, V4, P68; Krishnamurthy N, 2018, CANCER TREAT REV, V62, P50, DOI 10.1016/j.ctrv.2017.11.002; Lu TP, 2010, CANCER EPIDEM BIOMAR, V19, P2590, DOI 10.1158/1055-9965.EPI-10-0332; Mani A, 2007, SCIENCE, V315, P1278, DOI 10.1126/science.1136370; Niu XC, 2015, CELL PHYSIOL BIOCHEM, V37, P1527, DOI 10.1159/000438520; Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Ozeki N, 2014, EXP CELL RES, V328, P69, DOI 10.1016/j.yexcr.2014.05.006; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Rapp J, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0650-6; Rydell-Tormanen K, 2016, PHYSIOL REP, V4, DOI 10.14814/phy2.12727; Sherwood V, 2015, MOL CELL BIOL, V35, P2, DOI 10.1128/MCB.00992-14; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Skronska-Wasek W, 2018, PHARMACOL THERAPEUT, V187, P150, DOI 10.1016/j.pharmthera.2018.02.009; Spanjer AIR, 2016, FASEB J, V30, P1823, DOI 10.1096/fj.201500129; Stewart DJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt356; Tian J, 2014, TUMOR BIOL, V35, P9439, DOI 10.1007/s13277-014-2433-8; van Dijk EM, 2016, AM J PHYSIOL-LUNG C, V310, pL1166, DOI 10.1152/ajplung.00226.2015; Wang QY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015479; Wang SH, 2017, ONCOGENE, V36, P1503, DOI 10.1038/onc.2016.317; Watanabe K, 2011, P NATL ACAD SCI USA, V108, P5929, DOI 10.1073/pnas.1103102108; Weyandt Jamie D, 2017, Am Soc Clin Oncol Educ Book, V37, P825, DOI 10.14694/EDBK_175561; Xi SC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013764; Xu XD, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-373; Yuan X, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0087-z; Zhan P, 2017, J CELL MOL MED, V21, P665, DOI 10.1111/jcmm.13010; Zhang Q, 2018, BIOMED PHARMACOTHER, V105, P204, DOI 10.1016/j.biopha.2018.05.074; Zhang Q, 2018, J CELL MOL MED, V22, P3560, DOI 10.1111/jcmm.13634; Zhang Q, 2014, PHARMACOL RES, V84, P32, DOI 10.1016/j.phrs.2014.04.009	42	14	13	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	7					1484	1497		10.1038/s41388-019-1071-4	http://dx.doi.org/10.1038/s41388-019-1071-4			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KL2WP	31666682				2022-12-28	WOS:000513289600007
J	Zhao, J; Hou, YR; Yin, C; Hu, J; Gao, T; Huang, XJ; Zhang, XH; Xing, JL; An, JZ; Wan, SG; Li, JB				Zhao, Jing; Hou, Yiran; Yin, Chun; Hu, Jing; Gao, Tian; Huang, Xiaojun; Zhang, Xiaohong; Xing, Jinliang; An, Jiaze; Wan, Shaogui; Li, Jibin			Upregulation of histamine receptor H1 promotes tumor progression and contributes to poor prognosis in hepatocellular carcinoma	ONCOGENE			English	Article							NERVE GROWTH-FACTOR; H-1 RECEPTOR; MESENCHYMAL TRANSITION; SIGNALING PATHWAY; ACTIVATION; ALLERGIES; CANCER; RISK; IDENTIFICATION; PROLIFERATION	H1 histamine receptor (H1HR) belongs to the family of rhodopsin-like G-protein-coupled receptors. Recent studies have shown that H1HR expression is increased in several types of cancer. However, its functional roles in tumor progression remain largely unknown, especially in hepatocellular carcinoma (HCC). We found that H1HR is frequently unregulated in HCC, which is significantly associated with both recurrence-free survival and overall survival in HCC patients. Functional experiments revealed that H1HR promoted both the growth and metastasis of HCC cells by inducing cell cycle progression, formation of lamellipodia, production of matrix metalloproteinase 2, and suppression of cell apoptosis. Activation of cyclic adenosine monophosphate-dependent protein kinase A was found to be involved in H1HR-mediated HCC cell growth and metastasis. In addition, we found that overexpression of H1HR was mainly due to the downregulation of miR-940 in HCC cells. Moreover, the H1HR inhibitor terfenadine significantly suppressed tumor growth and metastasis in an HCC xenograft nude mice model. Our findings demonstrate that H1HR plays a critical role in the growth and metastasis of HCC cells, which provides experimental evidence supporting H1HR as a potential drug target for the treatment of HCC.	[Zhao, Jing; Wan, Shaogui] Gannan Med Univ, Affiliated Hosp 1, Ctr Mol Pathol, Ganzhou 341000, Jiangxi, Peoples R China; [Zhao, Jing; Yin, Chun; Hu, Jing; Huang, Xiaojun; Xing, Jinliang; Li, Jibin] Fourth Mil Med Univ, State Key Lab Canc Biol, Xian 710032, Peoples R China; [Zhao, Jing; Yin, Chun; Hu, Jing; Huang, Xiaojun; Xing, Jinliang; Li, Jibin] Fourth Mil Med Univ, Expt Teaching Ctr Basic Med, Xian 710032, Peoples R China; [Hou, Yiran] Yanan Univ, Med Coll, Yanan 716000, Shaanxi, Peoples R China; [Gao, Tian; Zhang, Xiaohong] Fourth Mil Med Univ, Xijing Hosp, Dept Gynecol & Obstet, Xian 710032, Peoples R China; [An, Jiaze] Fourth Mil Med Univ, Xijing Hosp, Dept Hepatobiliary Surg, Xian 710032, Peoples R China	Gannan Medical University; Air Force Military Medical University; Air Force Military Medical University; Yanan University; Air Force Military Medical University; Air Force Military Medical University	Wan, SG (corresponding author), Gannan Med Univ, Affiliated Hosp 1, Ctr Mol Pathol, Ganzhou 341000, Jiangxi, Peoples R China.; Li, JB (corresponding author), Fourth Mil Med Univ, State Key Lab Canc Biol, Xian 710032, Peoples R China.; Li, JB (corresponding author), Fourth Mil Med Univ, Expt Teaching Ctr Basic Med, Xian 710032, Peoples R China.	wansg@gmu.edu.cn; lijibin2006@163.com		, Chun Yin/0000-0002-7299-1929	State Key Laboratory of Cancer Biology Project [CBSKL2017Z01]; National Natural Science Foundation of China [81472298, 81502085, U1604167]; Natural Science Basic Research Plan in Shaanxi Province of China [2018JM7018]	State Key Laboratory of Cancer Biology Project; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Basic Research Plan in Shaanxi Province of China	This work was supported by the State Key Laboratory of Cancer Biology Project (CBSKL2017Z01), National Natural Science Foundation of China (grants 81472298, 81502085 and U1604167) and Natural Science Basic Research Plan in Shaanxi Province of China (Program no. 2018JM7018).	Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Beermann S, 2015, BIOCHEM PHARMACOL, V98, P432, DOI 10.1016/j.bcp.2015.09.011; Cai WK, 2014, EUR J CANCER, V50, P1195, DOI 10.1016/j.ejca.2013.12.025; Capurro M, 2003, GASTROENTEROLOGY, V125, P89, DOI 10.1016/S0016-5085(03)00689-9; Cianchi F, 2005, CLIN CANCER RES, V11, P6807, DOI 10.1158/1078-0432.CCR-05-0675; Cotterchio M, 2014, CANCER EPIDEM BIOMAR, V23, P469, DOI 10.1158/1055-9965.EPI-13-0965; Das AK, 2007, J PHARMACOL SCI, V103, P374, DOI 10.1254/jphs.FP0061411; Davio C, 1995, Inflamm Res, V44 Suppl 1, pS70, DOI 10.1007/BF01674401; de Esch IJP, 2005, TRENDS PHARMACOL SCI, V26, P462, DOI 10.1016/j.tips.2005.07.002; Farso M, 2013, NEUROBIOL AGING, V34, P1971, DOI 10.1016/j.neurobiolaging.2013.02.008; Francis H, 2012, GUT, V61, P753, DOI 10.1136/gutjnl-2011-300007; Gandini S, 2005, CANCER EPIDEM BIOMAR, V14, P1908, DOI 10.1158/1055-9965.EPI-05-0119; GARCIACABALLERO M, 1994, SURG ONCOL, V3, P167, DOI 10.1016/0960-7404(94)90046-9; Hernandez-Angeles A, 2001, J NEURO-ONCOL, V55, P81, DOI 10.1023/A:1013338515229; Kim YS, 2016, MOL BRAIN, V9, DOI 10.1186/s13041-016-0227-1; Lieberman P, 2011, ANN ALLERG ASTHMA IM, V106, pS2, DOI 10.1016/j.anai.2010.08.005; Lin JJ, 2015, ONCOTARGET, V6, P17107, DOI 10.18632/oncotarget.3672; Lipnik-Stangelj M, 2006, BIOCHEM PHARMACOL, V72, P1375, DOI 10.1016/j.bcp.2006.06.028; Liu CJ, 2016, ACM T SENSOR NETWORK, V12, DOI 10.1145/2835180; Mahajan UM, 2018, GASTROENTEROLOGY, V155, P1625, DOI 10.1053/j.gastro.2018.08.009; Medina VA, 2010, BRIT J PHARMACOL, V161, P755, DOI 10.1111/j.1476-5381.2010.00961.x; Megson AC, 2001, MOL PHARMACOL, V59, P1012, DOI 10.1124/mol.59.5.1012; Meng FY, 2011, HEPATOLOGY, V54, P1718, DOI 10.1002/hep.24573; Mu H, 2014, WORLD J GASTROENTERO, V20, P5826, DOI 10.3748/wjg.v20.i19.5826; Ohtsu H, 2017, HANDB EXP PHARMACOL, V241, P333, DOI 10.1007/164_2016_9; Pelekanou V, 2018, CANCER RES, V78; Pino-Angeles A, 2012, J CELL MOL MED, V16, P1947, DOI 10.1111/j.1582-4934.2012.01566.x; Procopiou PA, 2017, BIOORG MED CHEM LETT, V27, P4914, DOI 10.1016/j.bmcl.2017.09.020; Rajendiran S, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-250; Reynolds JL, 1996, MELANOMA RES, V6, P95, DOI 10.1097/00008390-199604000-00003; Schneider Elke, 2011, Front Biosci (Schol Ed), V3, P467, DOI 10.2741/s165; Shadman M, 2013, AM J HEMATOL, V88, P1050, DOI 10.1002/ajh.23564; Shirdel EA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017429; Shiroishi M, 2017, HANDB EXP PHARMACOL, V241, P21, DOI 10.1007/164_2016_10; Sieja K, 2005, BREAST, V14, P236, DOI 10.1016/j.breast.2004.06.012; Suzuki Y, 2011, BIOL PHARM BULL, V34, P507, DOI 10.1248/bpb.34.507; Thomas CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031951; Tomita Kazuyoshi, 2005, Inflammopharmacology, V13, P281, DOI 10.1163/156856005774423917; Wang MH, 2014, INT J MOL MED, V33, P1019, DOI 10.3892/ijmm.2014.1649; Wang ZY, 2010, MOL MED REP, V3, P103, DOI 10.3892/mmr_00000225; Wu XY, 2016, BMC PLANT BIOL, V16, DOI 10.1186/s12870-016-0755-y; Xu TY, 2019, AM J CANCER RES, V9, P250; Xue RD, 2019, CANCER CELL, V35, P932, DOI 10.1016/j.ccell.2019.04.007; Yang CG, 2019, INT J BIOL SCI, V15, P984, DOI 10.7150/ijbs.29836; Yuan B, 2015, CANCER SCI, V106, P819, DOI 10.1111/cas.12688	45	24	24	3	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	8					1724	1738		10.1038/s41388-019-1093-y	http://dx.doi.org/10.1038/s41388-019-1093-y			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN6CG	31740780	hybrid, Green Published			2022-12-28	WOS:000514923000008
J	Zhou, Q; Wu, XY; Wang, XF; Yu, ZJ; Pan, T; Li, Z; Chang, XY; Jin, ZJ; Li, JF; Zhu, ZG; Liu, BY; Su, LP				Zhou, Quan; Wu, Xiongyan; Wang, Xiaofeng; Yu, Zhenjia; Pan, Tao; Li, Zhen; Chang, Xinyu; Jin, Zhijian; Li, Jianfang; Zhu, Zhenggang; Liu, Bingya; Su, Liping			The reciprocal interaction between tumor cells and activated fibroblasts mediated by TNF-alpha/IL-33/ST2L signaling promotes gastric cancer metastasis	ONCOGENE			English	Article							STROMAL FIBROBLASTS; INTERLEUKIN-33; RECEPTOR; IL-33; CYTOKINE; EXPRESSION; GROWTH; PROGRESSION; INITIATION; INVASION	Gastric cancer (GC) is characterized by extensive local invasion, distant metastasis and poor prognosis. In most cases, GC progression is associated with aberrant expression of cytokines or activation of signaling cascades mediated by tumor-stroma interactions. However, the mechanisms by which these interactions contribute to GC progression are poorly understood. In this study, we find that IL-33 and its receptor ST2L are upregulated in the human GC and served as prognostic markers for poor survival of GC patients. In a co-culture model with GC cells and cancer-associated fibroblasts (CAFs), we further demonstrate that CAFs-derived IL-33 enhances the migration and invasion of GC cells by inducing the epithelial-mesenchymal transition (EMT) through activation of the ERK1/2-SP1-ZEB2 pathway in a ST2L-dependent manner. Furthermore, the secretion of IL-33 by CAFs can be induced by the proinflammatory cytokines TNF-alpha that is released by GC cells via TNFR2-NF-kappa B-IRF-1 pathway. Additionally, silencing of IL-33 expression in CAFs or ST2L expression in GC cells inhibits the peritoneal dissemination and metastatic potential of GC cells in nude mice. Taken together, these results characterize a critical role of the interaction between epithelial-stroma mediated by the TNF-alpha/IL-33/ST2L signaling in GC progression, and provide a rationale for targeting this pathway to treat GC metastasis.	[Zhou, Quan; Wu, Xiongyan; Yu, Zhenjia; Pan, Tao; Li, Zhen; Chang, Xinyu; Jin, Zhijian; Li, Jianfang; Zhu, Zhenggang; Liu, Bingya; Su, Liping] Shanghai Jiao Tong Univ, Shanghai Key Lab Gastr Neoplasms, Shanghai Inst Digest Surg, Dept Surg,Ruijin Hosp,Sch Med, Shanghai 200025, Peoples R China; [Zhou, Quan] Shanghai Jiao Tong Univ, Ruijin Hosp, Ctr Organ Transplantat, Dept Urol,Sch Med, Shanghai 200025, Peoples R China; [Wang, Xiaofeng] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Gen Surg, Sch Med, Shanghai 200025, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Liu, BY; Su, LP (corresponding author), Shanghai Jiao Tong Univ, Shanghai Key Lab Gastr Neoplasms, Shanghai Inst Digest Surg, Dept Surg,Ruijin Hosp,Sch Med, Shanghai 200025, Peoples R China.	liubingya@sjtu.edu.cn; suliping@shsmu.edu.cn	Liu, Bingya/GMW-5655-2022	Liu, Bingya/0000-0002-4406-3762; su, liping/0000-0003-2401-0265	National Natural Science Foundation of China [81572798, 81871902, 81702385, 81672822, 81772509, 91529302]; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support [20152505]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support	We thank LetPub (www.letpub.com) for its linguistic assistance during the preparation of this manuscript. This work was supported by the National Natural Science Foundation of China (No. 81572798 and No. 81871902 to L.S., No. 81702385 to Q.Z., No. 81672822 to Z.Z., No. 81772509 and No. 91529302 to B.L.), Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (No. 20152505 to L.S.).	Ajani JA, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.36; Akimoto M, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.418; Andersson P, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.122375; Avgustinova A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10305; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Bhowmick NA, 2005, CURR OPIN GENET DEV, V15, P97, DOI 10.1016/j.gde.2004.12.003; Bi S, 2016, SENSORS-BASEL, V16, DOI 10.3390/s16030318; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Carriere V, 2007, P NATL ACAD SCI USA, V104, P282, DOI 10.1073/pnas.0606854104; Cayrol C, 2018, IMMUNOL REV, V281, P154, DOI 10.1111/imr.12619; Chang KW, 2013, BIOCHEM BIOPH RES CO, V434, P854, DOI 10.1016/j.bbrc.2013.04.031; Chen SF, 2013, J PATHOL, V231, P180, DOI 10.1002/path.4226; Chia NY, 2016, ANN ONCOL, V27, P763, DOI 10.1093/annonc/mdw040; Cirri P, 2013, CELL CYCLE, V12, P204, DOI 10.4161/cc.23421; Cirri P, 2012, CANCER METAST REV, V31, P195, DOI 10.1007/s10555-011-9340-x; Coyle AJ, 1999, J EXP MED, V190, P895, DOI 10.1084/jem.190.7.895; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Gascard P, 2016, GENE DEV, V30, P1002, DOI 10.1101/gad.279737.116; Glentis A, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00985-8; Gramatzki D, 2016, ONCOL LETT, V12, P445, DOI 10.3892/ol.2016.4626; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kakkar R, 2012, J BIOL CHEM, V287, P6941, DOI 10.1074/jbc.M111.298703; Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308; Kasagi Y, 2016, CANCER RES, V76, P347, DOI 10.1158/0008-5472.CAN-15-1563; Labernadie A, 2017, NAT CELL BIOL, V19, P224, DOI 10.1038/ncb3478; Larsen KM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092676; Levescot A, 2014, CANCER RES, V74, P2669, DOI 10.1158/0008-5472.CAN-13-2797; Li J, 2014, J CLIN INVEST, V124, P3241, DOI 10.1172/JCI73742; Liew FY, 2016, NAT REV IMMUNOL, V16, P676, DOI 10.1038/nri.2016.95; Lin TT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063966; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Lordick F, 2017, ANN ONCOL, V28, P1767, DOI 10.1093/annonc/mdx051; Lu M, 2013, P NATL ACAD SCI USA, V110, P18144, DOI 10.1073/pnas.1318192110; Maywald RL, 2015, P NATL ACAD SCI USA, V112, pE2487, DOI 10.1073/pnas.1422445112; Nam EH, 2014, CARCINOGENESIS, V35, P302, DOI 10.1093/carcin/bgt340; Oboki Keisuke, 2010, Allergology International, V59, P143, DOI 10.2332/allergolint.10-RAI-0186; Ridge SM, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0597-8; Schauer IG, 2011, NEOPLASIA, V13, P393, DOI 10.1593/neo.101720; Schmieder A, 2012, CYTOKINE, V60, P514, DOI 10.1016/j.cyto.2012.06.286; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Sun PH, 2011, DIGEST DIS SCI, V56, P3596, DOI 10.1007/s10620-011-1760-5; Tong XG, 2016, MOL ONCOL, V10, P113, DOI 10.1016/j.molonc.2015.06.004; Townsend MJ, 2000, J EXP MED, V191, P1069, DOI 10.1084/jem.191.6.1069; Tsujimoto H, 2010, GASTRIC CANCER, V13, P212, DOI 10.1007/s10120-010-0568-x; Wang XF, 2017, INT J CANCER, V141, P998, DOI 10.1002/ijc.30801; Wu XY, 2017, ONCOTARGET, V8, P20741, DOI 10.18632/oncotarget.15119; Wu XY, 2013, CANCER LETT, V335, P128, DOI 10.1016/j.canlet.2013.02.002; Xing F, 2010, FRONT BIOSCI-LANDMRK, V15, P166, DOI 10.2741/3613; Yang SG, 2015, J BIOL CHEM, V290, P861, DOI 10.1074/jbc.M114.586560; Yang YL, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11385; Yang ZP, 2015, DIS MARKERS, V2015, P1, DOI 10.1155/2015/516895; Ye XL, 2015, ONCOL REP, V33, P2746, DOI 10.3892/or.2015.3898; Zhang BG, 2014, ONCOTARGET, V5, P10584, DOI 10.18632/oncotarget.2513	54	45	50	2	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	7					1414	1428		10.1038/s41388-019-1078-x	http://dx.doi.org/10.1038/s41388-019-1078-x			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KL2WP	31659258	Green Published, hybrid			2022-12-28	WOS:000513289600003
J	He, J; Zhou, MX; Li, XY; Gu, SW; Cao, Y; Xing, TF; Chen, W; Chu, CY; Gu, F; Zhou, J; Jin, YT; Ma, J; Ma, D; Zou, Q				He, Jing; Zhou, Mingxia; Li, Xiaoyan; Gu, Siwen; Cao, Yun; Xing, Tengfei; Chen, Wei; Chu, Chengyu; Gu, Fei; Zhou, Jian; Jin, Yiting; Ma, Jing; Ma, Duan; Zou, Qiang			SLC34A2 simultaneously promotes papillary thyroid carcinoma growth and invasion through distinct mechanisms	ONCOGENE			English	Article							NONSMALL CELL LUNG; COLORECTAL-CANCER; PROTEIN-KINASE; PROLIFERATION; PROGRESSION; METASTASIS; FAMILY	Thyroid cancer is the fastest growing cancer among all solid tumors in recent decades. Papillary thyroid carcinoma (PTC) is the most predominant type of thyroid cancer. Around 30% of PTC patients with distant metastases and local invasion receive poor prognosis. Thus, the identification of new druggable biological targets is of great importance. Accumulating evidence indicates that solute carrier family numbers have emerged as obligate effectors during the progression of multiple malignancies. Here, we uncovered the functional significance, molecular mechanisms, and clinical impact of solute carrier family 34 member A2 (SLC34A2) in PTC. SLC34A2 was markedly overexpressed in PTC tissues at both mRNA and protein levels compared with matched adjacent normal tissues due to promoter hypomethylation mediated by the DNA methyltransferase 3 beta (DNMT3B). Furthermore, a series of in vivo and in vitro gain- or loss-of-functional assays elucidated the role of SLC34A2 in boosting cell proliferation, cell cycle progression, migration, invasion, and adhesion of PTC cells. Using immunoprecipitation and mass spectrometry, we discovered that SLC34A2 bound to the actin-binding repeats domain of Cortactin (CTTN), thereby inducing the invadopodia formation of PTC cells to promote the metastasis potential of PTC cells. Besides, our mechanistic studies, as well as gene set enrichment analysis (GSEA), have pinpointed the PTEN/AKT/FOXO3a pathway as a major signaling functioning downstream of SLC34A2 regulated cell growth. Taken together, our results highlighted that SLC34A2 plays a pivotal oncogenic role during carcinogenesis and metastasis through distinct mechanisms in PTC.	[He, Jing; Li, Xiaoyan; Gu, Siwen; Cao, Yun; Xing, Tengfei; Chen, Wei; Chu, Chengyu; Gu, Fei; Zhou, Jian; Jin, Yiting; Zou, Qiang] Fudan Univ, Huashan Hosp, Dept Gen Surg, 12 Urumqi Middle Rd, Shanghai 200040, Peoples R China; [Zhou, Mingxia] Shanghai Jiao Tong Univ, Xinhua Hosp, Sch Med, Dept Gastroenterol, 1665 Kongjiang Rd, Shanghai 200092, Peoples R China; [Ma, Jing; Ma, Duan] Fudan Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Key Lab Metab & Mol Med,Minist Educ, 130 Dongan Rd, Shanghai 200032, Peoples R China; [Ma, Jing; Ma, Duan] Fudan Univ, Inst Biomed Sci, 130 Dongan Rd, Shanghai 200032, Peoples R China	Fudan University; Shanghai Jiao Tong University; Fudan University; Fudan University	Zou, Q (corresponding author), Fudan Univ, Huashan Hosp, Dept Gen Surg, 12 Urumqi Middle Rd, Shanghai 200040, Peoples R China.; Ma, D (corresponding author), Fudan Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Key Lab Metab & Mol Med,Minist Educ, 130 Dongan Rd, Shanghai 200032, Peoples R China.; Ma, D (corresponding author), Fudan Univ, Inst Biomed Sci, 130 Dongan Rd, Shanghai 200032, Peoples R China.	duanma@fudan.edu.cn; zouqiang_hs@163.com		Li, Xiaoyan/0000-0002-1243-3845	Science and Technology Commission of Shanghai Municipality [15411952503]; National Nature Science Foundation of China [81602326, 81741078, 81801501]	Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by Science and Technology Commission of Shanghai Municipality (No. 15411952503) and National Nature Science Foundation of China (Nos. 81602326, 81741078, and 81801501).	Lacerda-Abreu MA, 2018, BBA-REV CANCER, V1870, P291, DOI 10.1016/j.bbcan.2018.05.001; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cabanillas ME, 2016, LANCET, V388, P2783, DOI 10.1016/S0140-6736(16)30172-6; Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21; Cesar-Razquin A, 2015, CELL, V162, P478, DOI 10.1016/j.cell.2015.07.022; Chen DR, 2010, ANTICANCER RES, V30, P4135; Crowell JA, 2007, MOL CANCER THER, V6, P2139, DOI 10.1158/1535-7163.MCT-07-0120; Davies KD, 2012, CLIN CANCER RES, V18, P4570, DOI 10.1158/1078-0432.CCR-12-0550; Eddy RJ, 2017, TRENDS CELL BIOL, V27, P595, DOI 10.1016/j.tcb.2017.03.003; Fisher KE, 2014, MODERN PATHOL, V27, P222, DOI 10.1038/modpathol.2013.140; Gamble LD, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau1099; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He J, 2018, CANCER SCI, V109, P642, DOI 10.1111/cas.13478; He J, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0378-z; Hernando N, 2018, COMPR PHYSIOL, V8, P1065, DOI 10.1002/cphy.c170024; Hirai H, 2010, MOL CANCER THER, V9, P1956, DOI 10.1158/1535-7163.MCT-09-1012; Jarzab B, 2005, CANCER RES, V65, P1587, DOI 10.1158/0008-5472.CAN-04-3078; Jeannot Pauline, 2020, Small GTPases, V11, P256, DOI 10.1080/21541248.2017.1405773; Jin H, 2009, AM J RESP CRIT CARE, V179, P59, DOI 10.1164/rccm.200802-306OC; Kareva I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051844; Kim S, 2018, ONCOGENE, V37, P2982, DOI 10.1038/s41388-018-0124-4; Li YH, 2016, ONCOL RES, V24, P511, DOI 10.3727/096504016X14719078133483; Li YJ, 2018, CANCER RES, V78, P5216, DOI 10.1158/0008-5472.CAN-18-0003; Lin KD, 2015, CLIN CANCER RES, V21, P5139, DOI 10.1158/1078-0432.CCR-14-3383; Liu XZ, 2017, DNA CELL BIOL, V36, P775, DOI 10.1089/dna.2017.3750; Lv P, 2014, INT J MOL SCI, V15, P5774, DOI 10.3390/ijms15045774; Lv SD, 2018, ONCOGENE, V37, P1354, DOI 10.1038/s41388-017-0026-x; Mader CC, 2011, CANCER RES, V71, P1730, DOI 10.1158/0008-5472.CAN-10-1432; Neel DS, 2019, CANCER RES, V79, P546, DOI 10.1158/0008-5472.CAN-18-1492; Ramirez-Moya J, 2018, ONCOGENE, V37, P3369, DOI 10.1038/s41388-017-0088-9; Rangel LBA, 2003, ONCOGENE, V22, P7225, DOI 10.1038/sj.onc.1207008; Ricketts CJ, 2012, EPIGENETICS-US, V7, P278, DOI 10.4161/epi.7.3.19103; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Spina A, 2013, J CELL PHYSIOL, V228, P198, DOI 10.1002/jcp.24124; Wagner CA, 2014, PFLUG ARCH EUR J PHY, V466, P139, DOI 10.1007/s00424-013-1418-6; Wang Y, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929-015-0158-7; Watkins RJ, 2016, J CLIN ENDOCR METAB, V101, P4551, DOI 10.1210/jc.2016-1932; Weisenberger DJ, 2018, ONCOGENE, V37, P566, DOI 10.1038/onc.2017.374; Wong CC, 2017, ONCOGENE, V36, P3359, DOI 10.1038/onc.2016.485; Wong CC, 2016, GASTROENTEROLOGY, V151, P945, DOI 10.1053/j.gastro.2016.07.011; Yousefi M, 2018, CELL ONCOL, V41, P123, DOI 10.1007/s13402-018-0376-6	41	17	17	1	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	13					2658	2675		10.1038/s41388-020-1181-z	http://dx.doi.org/10.1038/s41388-020-1181-z		JAN 2020	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KX4EF	32005974				2022-12-28	WOS:000510346700004
J	Dias, MM; Adamoski, D; dos Reis, LM; Ascencao, CFR; de Oliveira, KRS; Mafra, ACP; Bastos, ACD; Quintero, M; Cassago, CD; Ferreira, IM; Fidelis, CHV; Rocco, SA; Bajgelman, MC; Stine, Z; Berindan-Neagoe, I; Calin, GA; Ambrosio, ALB; Dias, SMG				Dias, Marilia M.; Adamoski, Douglas; dos Reis, Larissa M.; Ascencao, Carolline F. R.; de Oliveira, Krishina R. S.; Paschoalini Mafra, Ana Carolina; da Silva Bastos, Alliny Cristiny; Quintero, Melissa; Cassago, Carolina de G.; Ferreira, Igor M.; Fidelis, Carlos H., V; Rocco, Silvana A.; Bajgelman, Marcio Chaim; Stine, Zachary; Berindan-Neagoe, Ioana; Calin, George A.; Berteli Ambrosio, Andre Luis; Gomes Dias, Sandra Martha			GLS2 is protumorigenic in breast cancers	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; ASPARAGINE SYNTHETASE; GLUTAMINE-METABOLISM; GROWTH; ROLES; ACTIVATION; PATHWAY; CELLS; TRANSFORMATION; CONTRIBUTES	Many types of cancers have a well-established dependence on glutamine metabolism to support survival and growth, a process linked to glutaminase 1 (GLS) isoforms. Conversely, GLS2 variants often have tumor-suppressing activity. Triple-negative (TN) breast cancer (testing negative for estrogen, progesterone, and Her2 receptors) has elevated GLS protein levels and reportedly depends on exogenous glutamine and GLS activity for survival. Despite having high GLS levels, we verified that several breast cancer cells (including TN cells) express endogenous GLS2, defying its role as a bona fide tumor suppressor. Moreover, ectopic GLS2 expression rescued cell proliferation, TCA anaplerosis, redox balance, and mitochondrial function after GLS inhibition by the small molecule currently in clinical trials CB-839 or GLS knockdown of GLS-dependent cell lines. In several cell lines, GLS2 knockdown decreased cell proliferation and glutamine-linked metabolic phenotypes. Strikingly, long-term treatment of TN cells with another GLS-exclusive inhibitor bis-2 '-(5-phenylacetamide-1,3,4-thiadiazol-2-yl)ethyl sulfide (BPTES) selected for a drug-resistant population with increased endogenous GLS2 and restored proliferative capacity. GLS2 was linked to enhanced in vitro cell migration and invasion, mesenchymal markers (through the ERK-ZEB1-vimentin axis under certain conditions) and in vivo lung metastasis. Of concern, GLS2 amplification or overexpression is linked to an overall, disease-free and distant metastasis-free worse survival prognosis in breast cancer. Altogether, these data establish an unforeseen role of GLS2 in sustaining tumor proliferation and underlying metastasis in breast cancer and provide an initial framework for exploring GLS2 as a novel therapeutic target.	[Dias, Marilia M.; Adamoski, Douglas; dos Reis, Larissa M.; Ascencao, Carolline F. R.; de Oliveira, Krishina R. S.; Paschoalini Mafra, Ana Carolina; da Silva Bastos, Alliny Cristiny; Quintero, Melissa; Cassago, Carolina de G.; Ferreira, Igor M.; Rocco, Silvana A.; Bajgelman, Marcio Chaim; Berteli Ambrosio, Andre Luis; Gomes Dias, Sandra Martha] Brazilian Ctr Res Energy & Mat CNPEM, Brazilian Biosci Natl Lab LNBio, BR-13083970 Campinas, SP, Brazil; [Dias, Marilia M.; Adamoski, Douglas; dos Reis, Larissa M.; Ascencao, Carolline F. R.; de Oliveira, Krishina R. S.; Paschoalini Mafra, Ana Carolina; da Silva Bastos, Alliny Cristiny] Univ Estadual Campinas, Grad Program Genet & Mol Biol, Inst Biol, UNICAMP, Campinas, SP, Brazil; [Fidelis, Carlos H., V] Univ Estadual Campinas, Inst Chem, ThoMSon Mass Spectrometry Lab, BR-13083970 Campinas, SP, Brazil; [Stine, Zachary] Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA; [Berindan-Neagoe, Ioana] Univ Med & Pharm Iuliu Hatieganu, Res Ctr Funct Genom Biomed & Translat Med, Cluj Napoca 400337, Romania; [Berindan-Neagoe, Ioana] Univ Med & Pharm Iuliu Hatieganu, MedFuture Res Ctr Adv Med, Cluj Napoca 400349, Romania; [Berindan-Neagoe, Ioana] Oncol Inst Prof Dr Ion Chiricuta, Dept Funct Genom & Expt Pathol, Cluj Napoca 400015, Romania; [Calin, George A.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, 1515 Holcombe Blvd,Unit 1950, Houston, TX 77030 USA; [Calin, George A.] Univ Texas MD Anderson Canc Ctr, Ctr RNA Inference & Noncoding RNAs, 1515 Holcombe Blvd,Unit 1950, Houston, TX 77030 USA; [Berteli Ambrosio, Andre Luis] Univ Sao Paulo, Sao Carlos Inst Phys IFSC, BR-13563120 Sao Carlos, SP, Brazil	Universidade de Sao Paulo; Universidade Estadual de Campinas; Universidade Estadual de Campinas; The Wistar Institute; Iuliu Hatieganu University of Medicine & Pharmacy; Iuliu Hatieganu University of Medicine & Pharmacy; Oncology Institute Prof. Dr. Ion Chiricuta; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Universidade de Sao Paulo	Ambrosio, ALB; Dias, SMG (corresponding author), Brazilian Ctr Res Energy & Mat CNPEM, Brazilian Biosci Natl Lab LNBio, BR-13083970 Campinas, SP, Brazil.; Ambrosio, ALB (corresponding author), Univ Sao Paulo, Sao Carlos Inst Phys IFSC, BR-13563120 Sao Carlos, SP, Brazil.	andre@ifsc.usp.br; sandra.dias@lnbio.cnpem.br	Dias, Marília M/C-3014-2012; Bajgelman, Marcio Chaim/A-8146-2019; Fidelis, Carlos HV/B-9696-2012; Escobar, Melissa Quintero/AAN-8999-2021; Adamoski, Douglas/J-8570-2014; Ambrosio, Andre/AAB-1178-2020; Reis, Larissa Menezes dos/T-9867-2019; Rocco, Silvana Aparecida/H-6300-2014; Rocco, Silvana Aparecida/Q-3828-2019	Bajgelman, Marcio Chaim/0000-0003-3371-1143; Escobar, Melissa Quintero/0000-0002-2645-7418; Adamoski, Douglas/0000-0001-5062-2586; Rocco, Silvana Aparecida/0000-0003-4551-3443; Rocco, Silvana Aparecida/0000-0003-4551-3443; Calin, George/0000-0001-6704-5615; Menezes dos Reis, Larissa/0000-0003-1597-0176; Dias, Marilia/0000-0003-1415-9023; Mafra, Ana Carolina/0000-0002-2547-9033	Sao Paulo State Research Foundation, FAPESP [2012/14298-9, 2014/20673-2, 2014/15968-3, 2015/25832-4, 2013/05668-0, 2013/23510-4, 2012/11577-4, 2014/18061-9, 2014/17820-3, 2016/06625-0, 2014/06512-6, 2011/10127-2, 2012/09452-9]; LNBio; National Institutes of Health (NIH/NCATS) grant through the NIH Common Fund, Office of Strategic Coordination (OSC) [UH3TR00943-01]; NCI [1R01 CA182905-01, 1R01CA222007-01A1]; NIGMS [1R01GM122775-01]; U54 grant UPR/MDACC Partnership for Excellence in Cancer Research 2016 Pilot Project [CA096297/CA096300]; DOD [CA160445P1]; Chronic Lymphocytic Leukemia Moonshot Flagship project; Sister Institution Network Fund (SINF) 2017 grant; Estate of C. G. Johnson, Jr	Sao Paulo State Research Foundation, FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); LNBio; National Institutes of Health (NIH/NCATS) grant through the NIH Common Fund, Office of Strategic Coordination (OSC)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); U54 grant UPR/MDACC Partnership for Excellence in Cancer Research 2016 Pilot Project; DOD(United States Department of Defense); Chronic Lymphocytic Leukemia Moonshot Flagship project; Sister Institution Network Fund (SINF) 2017 grant; Estate of C. G. Johnson, Jr	This work was supported by the Sao Paulo State Research Foundation, FAPESP, under grants 2012/14298-9 (ALBA) and 2014/20673-2 (ALBA), 2014/15968-3 (SMGD), 2015/25832-4 (SMGD) and fellowships 2013/05668-0 (IMF) 2013/23510-4 (CFRA), 2012/11577-4 (MMD), 2014/18061-9 (LMR), 2014/17820-3 (DAM), 2016/06625-0 (ACPM), 2014/06512-6 (KRSO), 2011/10127-2 (CAGC), and 2012/09452-9 (MQE). We thank LNBio for financial support and access to all facilities (PBQT, LCCMI, LPP, LEC, LVV, and LIB). Data used in this publication were generated by the National Cancer Institute Clinical Proteomic Tumor Analysis Consortium (CPTAC). The results published here are in whole or part based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/. We thank Dr Alessandra Girasole for expert technical support. GAC is the Felix L. Haas Endowed Professor in Basic Science. Work in GAC's laboratory is supported by National Institutes of Health (NIH/NCATS) grant UH3TR00943-01 through the NIH Common Fund, Office of Strategic Coordination (OSC), the NCI grants 1R01 CA182905-01 and 1R01CA222007-01A1, an NIGMS 1R01GM122775-01 grant, a U54 grant #CA096297/CA096300 UPR/MDACC Partnership for Excellence in Cancer Research 2016 Pilot Project, a Team DOD (CA160445P1) grant, a Chronic Lymphocytic Leukemia Moonshot Flagship project, a Sister Institution Network Fund (SINF) 2017 grant, and the Estate of C. G. Johnson, Jr.	Bastide C, 2002, PROSTATE CANCER P D, V5, P311, DOI 10.1038/sj.pcan.4500606; Billin AN, 2000, MOL CELL BIOL, V20, P8845, DOI 10.1128/MCB.20.23.8845-8854.2000; Cassago A, 2012, P NATL ACAD SCI USA, V109, P1092, DOI 10.1073/pnas.1112495109; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Davis FM, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-76; de Guzzi Cassago CA, 2018, BIOCHEMISTRY-US; Elgadi KM, 1999, PHYSIOL GENOMICS, V1, P51, DOI 10.1152/physiolgenomics.1999.1.2.51; Gameiro PA, 2013, CELL METAB, V17, P372, DOI 10.1016/j.cmet.2013.02.002; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Gross MI, 2014, MOL CANCER THER, V13, P890, DOI 10.1158/1535-7163.MCT-13-0870; Hollestelle A, 2007, MOL CANCER RES, V5, P195, DOI 10.1158/1541-7786.MCR-06-0263; Hu WW, 2010, P NATL ACAD SCI USA, V107, P7455, DOI 10.1073/pnas.1001006107; Jang MH, 2015, HUM PATHOL, V46, P1267, DOI 10.1016/j.humpath.2015.05.010; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Katt WP, 2017, FUTURE MED CHEM, V9, P223, DOI 10.4155/fmc-2016-0190; Kim J, 2016, ONCOTARGET, V7, P85021, DOI 10.18632/oncotarget.13116; Kim RK, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2014.99; Koh LWH, 2013, ANTIOXID REDOX SIGN, V19, P2261, DOI 10.1089/ars.2012.4999; Kung HN, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002229; Kuo T, 2016, CANC LETT, V383, P1; Lampa M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185092; Lee SY, 2016, ONCOTARGET, V7, P7925, DOI 10.18632/oncotarget.6879; Lee YZ, 2014, ONCOTARGET, V5, P6087, DOI 10.18632/oncotarget.2173; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Liu CY, 2015, ONCOTARGET, V6, P15966, DOI 10.18632/oncotarget.3862; Liu J, 2014, ONCOTARGET, V5, P2635, DOI 10.18632/oncotarget.1862; Liu W, 2012, P NATL ACAD SCI USA, V109, P8983, DOI 10.1073/pnas.1203244109; Lorenzi PL, 2008, MOL CANCER THER, V7, P3123, DOI 10.1158/1535-7163.MCT-08-0589; Martin-Rufian M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038380; McCubrey JA, 2007, BBA-MOL CELL RES, V1773, P1263, DOI 10.1016/j.bbamcr.2006.10.001; Nitta M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010767; Panosyan EH, 2014, MOL CANCER RES, V12, P694, DOI 10.1158/1541-7786.MCR-13-0576; Pavlova NN, 2018, CELL METAB, V27, P428, DOI 10.1016/j.cmet.2017.12.006; Pieter A, 2012, CANCER BIOL THER, V13, P1185, DOI 10.4161/cbt.21348; Sanchez-Tillo E, 2011, AM J CANCER RES, V1, P897; Seltzer MJ, 2010, CANCER RES, V70, P8981, DOI 10.1158/0008-5472.CAN-10-1666; Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020; Shirakihara T, 2007, MOL BIOL CELL, V18, P3533, DOI 10.1091/mbc.E07-03-0249; Sircar K, 2012, AM J PATHOL, V180, P895, DOI 10.1016/j.ajpath.2011.11.030; SOMMERS CL, 1994, BREAST CANCER RES TR, V31, P325, DOI 10.1007/BF00666165; Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040; Suzuki S, 2010, P NATL ACAD SCI USA, V107, P7461, DOI 10.1073/pnas.1002459107; Szeliga M, 2015, NEUROCHEM INT, V88, P6, DOI 10.1016/j.neuint.2014.11.004; Timmerman LA, 2013, CANCER CELL, V24, P450, DOI 10.1016/j.ccr.2013.08.020; UBUKA T, 1971, J NATL CANCER I, V46, P291; Wang BG, 2016, ONCOTARGET, V7, P20357, DOI 10.18632/oncotarget.7952; Wang JB, 2010, CANCER CELL, V18, P207, DOI 10.1016/j.ccr.2010.08.009; Wellen KE, 2010, GENE DEV, V24, P2784, DOI 10.1101/gad.1985910; Xiao DB, 2015, ONCOTARGET, V6, P40655, DOI 10.18632/oncotarget.5821; Xu D, 2011, J CELL BIOL, V193, P409, DOI 10.1083/jcb.201010100; Yuneva MO, 2012, CELL METAB, V15, P157, DOI 10.1016/j.cmet.2011.12.015; Zacharias NM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16327-z; Zhang C.J., 2016, BIOENERG OPEN ACCESS, V5, P1	53	15	17	0	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	3					690	702		10.1038/s41388-019-1007-z	http://dx.doi.org/10.1038/s41388-019-1007-z			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG1RJ	31541193				2022-12-28	WOS:000509718300015
J	Tian, YR; Ma, RR; Sun, YJ; Liu, HT; Zhang, H; Sun, YY; Liu, L; Li, YH; Song, L; Gao, P				Tian, Yaru; Ma, Ranran; Sun, Yujing; Liu, Haiting; Zhang, Hui; Sun, Yiyuan; Liu, Lei; Li, Yuhong; Song, Lin; Gao, Peng			SP1-activated long noncoding RNA lncRNA GCMA functions as a competing endogenous RNA to promote tumor metastasis by sponging miR-124 and miR-34a in gastric cancer	ONCOGENE			English	Article							MESENCHYMAL TRANSITIONS; RESISTANCE; CARCINOMA; INSIGHTS; SNAIL; EMT	Long noncoding RNAs (lncRNAs) were demonstrated to play important roles in gene regulation and cancer progression. However, the functional roles of lncRNAs and the detailed mechanisms underlying gastric cancer (GC) progression remain largely unclear. Here, we identified a novel cancer-related lncRNA, termed lncRNA GCMA (Gastric Cancer metastasis-associated lncRNA), which was upregulated in GC tissues with lymph node metastasis (LNM) compared with tissues without LNM. High expression of GCMA was significantly associated with poor prognosis of patients with GC. Luciferase assays, bioinformatics analyses and chromatin immunoprecipitation (ChIP) assays indicated that SP1 transcription factor directly bound to the GCMA promoter region and activated its transcription. Functionally, upregulation of GCMA dramatically promoted GC cells proliferation, migration and invasion in vitro, whereas knockdown of GCMA elicited the opposite function. Consistently, stable knockdown of GCMA inhibited tumor proliferation, invasion and metastasis in vivo. Mechanistically, by using bioinformatics analyses, RNA binding protein immunoprecipitation (RIP) assays, luciferase assays and western-blot assays, GCMA was demonstrated to function as a competing endogenous RNA (ceRNA) via competitively absorbing miR-124 and miR-34a to upregulate slug and snail, thereby induced epithelial-mesenchymal transition (EMT) and GC cell metastasis in vitro and in vivo. Collectively, these results demonstrate that GCMA functions as an oncogenic lncRNA that may serve as a potential prognostic biomarker for GC and shed new lights on targeted therapy of GC in the future.	[Tian, Yaru; Ma, Ranran; Sun, Yujing; Liu, Haiting; Zhang, Hui; Sun, Yiyuan; Liu, Lei; Li, Yuhong; Song, Lin; Gao, Peng] Shandong Univ, Cheeloo Coll Med, Minist Educ, Key Lab Expt Teratol, Jinan, Peoples R China; [Tian, Yaru; Ma, Ranran; Sun, Yujing; Liu, Haiting; Zhang, Hui; Sun, Yiyuan; Liu, Lei; Li, Yuhong; Song, Lin; Gao, Peng] Shandong Univ, Cheeloo Coll Med, Dept Pathol, Sch Basic Med Sci, Jinan, Peoples R China; [Ma, Ranran; Sun, Yujing; Liu, Haiting; Zhang, Hui; Sun, Yiyuan; Liu, Lei; Gao, Peng] Shandong Univ, Cheeloo Coll Med, Qilu Hosp, Dept Pathol, Jinan, Peoples R China; [Li, Yuhong] Peoples Hosp Liaocheng, Dept Pathol, Liaocheng, Shandong, Peoples R China; [Song, Lin] Shandong Univ, Shandong Prov Hosp, Cheeloo Coll Med, Dept Pathol, Jinan, Peoples R China	Shandong University; Shandong University; Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University	Gao, P (corresponding author), Shandong Univ, Cheeloo Coll Med, Minist Educ, Key Lab Expt Teratol, Jinan, Peoples R China.; Gao, P (corresponding author), Shandong Univ, Cheeloo Coll Med, Dept Pathol, Sch Basic Med Sci, Jinan, Peoples R China.; Gao, P (corresponding author), Shandong Univ, Cheeloo Coll Med, Qilu Hosp, Dept Pathol, Jinan, Peoples R China.	gaopeng@sdu.edu.cn			National Natural Science Foundation of China [81672842, 81872362]; Taishan Scholars Program of Shandong Province [ts201511096]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Taishan Scholars Program of Shandong Province	This study was supported by the National Natural Science Foundation of China (Grant nos. 81672842 and 81872362), the Taishan Scholars Program of Shandong Province (Grant no. ts201511096).	Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chu PC, 2018, ONCOGENE, V37, P3440, DOI 10.1038/s41388-018-0222-3; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Fang XY, 2015, CANCER LETT, V356, P357, DOI 10.1016/j.canlet.2014.11.005; Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606; Gao HY, 2017, ONCOTARGETS THER, V10, P205, DOI 10.2147/OTT.S116178; Gao P, 2009, J PATHOL, V218, P192, DOI 10.1002/path.2523; Gibb EA, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-38; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Gupta PB, 2005, NAT GENET, V37, P1047, DOI 10.1038/ng1634; Hansen BC, 2017, FASEB J, V31, P4216, DOI 10.1096/fj.201601250R; Hu XT, 2020, J CANCER, V11, P229, DOI 10.7150/jca.35537; Jang E, 2016, BIOMATERIALS, V105, P12, DOI 10.1016/j.biomaterials.2016.07.036; Jung HY, 2019, NAT CELL BIOL, V21, P359, DOI 10.1038/s41556-019-0291-8; Kallen AN, 2013, MOL CELL, V52, P101, DOI 10.1016/j.molcel.2013.08.027; Kim WY, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2014.1; Liu HT, 2018, CANCER RES, V78, P5877, DOI 10.1158/0008-5472.CAN-18-1011; Lu YY, 2017, NAT MED, V23, P1331, DOI 10.1038/nm.4424; McLean MIH, 2014, NAT REV GASTRO HEPAT, V11, P664, DOI 10.1038/nrgastro.2014.143; Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521; Murray-Stewart T, 2016, ONCOGENE, V35, P5480, DOI 10.1038/onc.2016.91; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976; Qian YW, 2017, HEPATOLOGY, V66, P1165, DOI 10.1002/hep.29296; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Schirle NT, 2014, SCIENCE, V346, P608, DOI 10.1126/science.1258040; Sheng Y, 2016, GYNECOL ONCOL, V140, P145, DOI 10.1016/j.ygyno.2015.11.017; Shi DB, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1125-z; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Song YX, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00304-1; Thomson DW, 2016, NAT REV GENET, V17, P272, DOI 10.1038/nrg.2016.20; Tsai CY, 2014, CLIN CANCER RES, V20, P2276, DOI 10.1158/1078-0432.CCR-13-1221; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Wapinski O, 2011, TRENDS CELL BIOL, V21, P354, DOI 10.1016/j.tcb.2011.04.001; Wilusz JE, 2009, GENE DEV, V23, P1494, DOI 10.1101/gad.1800909; Xing AY, 2015, J PATHOL, V236, P53, DOI 10.1002/path.4495; Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010; Zhang K, 2014, GENE, V547, P1, DOI 10.1016/j.gene.2014.06.043	39	30	31	1	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 18	2020	39	25					4854	4868		10.1038/s41388-020-1330-4	http://dx.doi.org/10.1038/s41388-020-1330-4		MAY 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LZ3HT	32439864				2022-12-28	WOS:000534735300002
J	Qi, YJ; Ma, YZ; Peng, ZQ; Wang, L; Li, LX; Tang, YL; He, JQ; Zheng, JF				Qi, Yijun; Ma, Yuanzhen; Peng, Zhiqiang; Wang, Lei; Li, Lanxin; Tang, Yilan; He, Junqi; Zheng, Junfang			Long noncoding RNA PENG upregulates PDZK1 expression by sponging miR-15b to suppress clear cell renal cell carcinoma cell proliferation	ONCOGENE			English	Article							COMPETING ENDOGENOUS RNA; ESTROGEN; CANCER; NEPHRECTOMY; HYPOTHESIS; BIOMARKERS; PREDICTS; SURVIVAL; GENE	PDZK1 downregulation was reported to independently predict poor prognosis of clear cell renal cell carcinoma (ccRCC) patients and induce ccRCC development and progression. However, the underlying mechanism of PDZK1 downregulation remains unknown. Competing endogenous RNA (ceRNA) networks are emerging as new players in gene regulation and are associated with cancer development. ceRNAs regulate other RNA transcripts by competing for shared miRNAs. To investigate the role and mechanism of ceRNAs in PDZK1 downregulation and the development of ccRCC, we searched databases for miRNAs and lncRNAs that regulate PDZK1 expression in ccRCC tissues and assessed their effects in ccRCC. We found that miR-15b was expressed at higher levels in ccRCC tissues, and its upregulation was clinically associated with lower PDZK1 level, larger tumor size and shorter survival time of ccRCC patients. Conversely, a novel lncRNA (lncPENG) was expressed at a lower level in ccRCC tissues, and its downregulation was associated with the same effects as upregulation of miR-15b. Downregulation of miR-15b and upregulation of lncPENG resulted in a significant increase in PDZK1 level and inhibition of proliferation in vitro and in vivo. Mechanistically, lncPENG directly bound to miR-15b and effectively functioned as a sponge for miR-15b to modulate the expression of PDZK1. Thus, lncPENG may function as a ceRNA to attenuate miR-15b-dependent PDZK1 downregulation and inhibit cell proliferation, suggesting that it may be clinically valuable as a therapeutic target and a prognostic biomarker of ccRCC.	[Qi, Yijun; Ma, Yuanzhen; Peng, Zhiqiang; Li, Lanxin; Tang, Yilan; He, Junqi; Zheng, Junfang] Capital Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Beijing Key Lab Canc Invas & Metastasis Res, Beijing 100069, Peoples R China; [Wang, Lei] Capital Med Univ, Beijing Friendship Hosp, Dept Urol, Beijing 100050, Peoples R China	Capital Medical University; Capital Medical University	Zheng, JF (corresponding author), Capital Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Beijing Key Lab Canc Invas & Metastasis Res, Beijing 100069, Peoples R China.	zhengjf@ccmu.edu.cn		Zheng, Junfang/0000-0003-4071-4764; He, jq/0000-0002-5921-1297	National Natural Science Foundation of the People's Republic of China [81672521, 81974415, 81372739]; Natural Science Foundation of Beijing [7192021]	National Natural Science Foundation of the People's Republic of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Beijing(Beijing Natural Science Foundation)	This work was supported by grants from the National Natural Science Foundation of the People's Republic of China (Nos. 81672521, 81974415, 81372739) and the Natural Science Foundation of Beijing (No. 7192021).	Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Chen Y, 2015, MED SCI MONITOR, V21, P1864, DOI 10.12659/MSM.893082; Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233; Eggener SE, 2006, J CLIN ONCOL, V24, P3101, DOI 10.1200/JCO.2005.04.8280; Ellinger J, 2015, EXPERT REV MOL DIAGN, V15, P505, DOI 10.1586/14737159.2015.1019477; Flanigan RC, 2004, CLIN CANCER RES, V10, p6335S, DOI 10.1158/1078-0432.CCR-sup-040026; Ghosh MG, 2000, CANCER RES, V60, P6367; Hadoux J, 2010, CLIN MED INSIGHTS-ON, V4, P143, DOI 10.4137/CMO.S4482; Hirata H, 2015, CANCER RES, V75, P1322, DOI 10.1158/0008-5472.CAN-14-2931; Inoue J, 2004, AM J PATHOL, V165, P71, DOI 10.1016/S0002-9440(10)63276-2; Karreth FA, 2015, CELL, V161, P319, DOI 10.1016/j.cell.2015.02.043; Kim H, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0589-7; Kim HY, 2013, MOL MED, V19, P253, DOI 10.2119/molmed.2011.00001; Kocher O, 1998, LAB INVEST, V78, P117; Ling H, 2013, NAT REV DRUG DISCOV, V12, P847, DOI 10.1038/nrd4140; Liu CY, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.114; Ma YZ, 2019, FREE RADICAL BIO MED, V134, P468, DOI 10.1016/j.freeradbiomed.2019.01.030; Miah S, 2012, BRIT J CANCER, V107, P123, DOI 10.1038/bjc.2012.221; MINASIAN LM, 1993, J CLIN ONCOL, V11, P1368, DOI 10.1200/JCO.1993.11.7.1368; Olejniczak M, 2018, CELL MOL LIFE SCI, V75, P177, DOI 10.1007/s00018-017-2591-0; Pantuck AJ, 2001, J UROLOGY, V166, P1611, DOI 10.1016/S0022-5347(05)65640-6; Pennisi E, 2012, SCIENCE, V337, P1159, DOI 10.1126/science.337.6099.1159; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Prestin K, 2017, AM J PHYSIOL-RENAL, V313, pF973, DOI 10.1152/ajprenal.00650.2016; Rashid F, 2016, GENOM PROTEOM BIOINF, V14, P73, DOI 10.1016/j.gpb.2016.03.005; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Satzger I, 2010, INT J CANCER, V126, P2553, DOI 10.1002/ijc.24960; Schmitz U, 2016, BRIEF BIOINFORM, V17, P380, DOI 10.1093/bib/bbv061; Tachibana K, 2008, FEBS LETT, V582, P3884, DOI 10.1016/j.febslet.2008.10.027; Tao T, 2017, ONCOGENE, V36, P6119, DOI 10.1038/onc.2017.199; Walker G, 2007, GYNECOL ONCOL, V106, P461, DOI 10.1016/j.ygyno.2007.05.009; Weirauch U, 2013, NEOPLASIA, V15, P783, DOI 10.1593/neo.13172; Wen LZ, 2018, CANCER RES, V78, P4680, DOI 10.1158/0008-5472.CAN-17-3896; Xia T, 2015, SCI REP-UK, V5, DOI 10.1038/srep13445; Xiao HB, 2015, ONCOTARGET, V6, P38005, DOI 10.18632/oncotarget.5357; Yang C, 2016, ONCOTARGET, V7, P13479, DOI 10.18632/oncotarget.7266; Yu G, 2014, MOL CANCER THER, V13, P3086, DOI 10.1158/1535-7163.MCT-14-0245; Zhao C, 2016, TUMOR BIOL, V37, P177, DOI 10.1007/s13277-015-4269-2; Zheng JF, 2017, EBIOMEDICINE, V15, P62, DOI 10.1016/j.ebiom.2016.12.003; Zhu HX, 2012, CANCER BIOL THER, V13, P401, DOI 10.4161/cbt.19291	40	18	18	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	22					4404	4420		10.1038/s41388-020-1297-1	http://dx.doi.org/10.1038/s41388-020-1297-1		APR 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LR9IT	32341409				2022-12-28	WOS:000528992700001
J	Dong, XS; Chen, RQ				Dong, Xuesen; Chen, Ruiqi			Understanding aberrant RNA splicing to facilitate cancer diagnosis and therapy	ONCOGENE			English	Review							NEUROENDOCRINE PROSTATE-CANCER; CIRCULAR RNA; SR PROTEIN; TRANSCRIPTION; MECHANISMS; RESISTANCE; VARIANTS; TARGET; INSTABILITY; RECOGNITION	Almost all genes in normal cells undergo alternative RNA splicing to generate a greater extent of diversification of gene products for normal cellular functions. RNA splicing is tightly regulated and closely interplays with genetic and epigenetic machinery. While DNA polymorphism and somatic mutations modulate alternative splicing patterns, RNA splicing also controls genomic stability, chromatin organization, and transcriptome. Tumor cells, in turn, often take advantage of aberrant RNA splicing to develop, grow and progress into therapy-resistant tumors. Understanding alternative RNA splicing in tumor cells would, therefore, provide us opportunities to gain further insights into tumor biology, identify diagnostic or prognosis biomarkers, as well as to design effective therapeutic means to control tumor progression. Here, we provide an overview of RNA splicing mechanisms and use prostate cancer as an example to review recent advancements in our understanding of RNA splicing in cancer progression and therapy resistance. We also discuss emerging diagnostic and therapeutic potentials of RNA splicing events or RNA splicing factors.	[Dong, Xuesen] Univ British Columbia, Fac Med, Dept Urol Sci, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada; [Dong, Xuesen] Vancouver Gen Hosp, Vancouver Prostate Ctr, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada; [Chen, Ruiqi] Univ Toronto, Fac Med, 27 Kings Coll Circle 8, Toronto, ON M5S 1A1, Canada	University of British Columbia; University of British Columbia; University of Toronto	Dong, XS (corresponding author), Univ British Columbia, Fac Med, Dept Urol Sci, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.; Dong, XS (corresponding author), Vancouver Gen Hosp, Vancouver Prostate Ctr, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.	xdong@prostatecentre.com	Dong, Xuesen/AGF-9228-2022	Dong, Xuesen/0000-0002-3115-3371	Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada) [MOP-137007, PJT-156150] Funding Source: Medline	Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada)		Aartsma-Rus A, 2017, NUCLEIC ACID THER, V27, P67, DOI 10.1089/nat.2017.0665; Agrawal AA, 2018, CURR OPIN GENET DEV, V48, P67, DOI 10.1016/j.gde.2017.10.010; Aguilera A, 2012, MOL CELL, V46, P115, DOI 10.1016/j.molcel.2012.04.009; Anczukow O, 2012, NAT STRUCT MOL BIOL, V19, P220, DOI 10.1038/nsmb.2207; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Araki S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116929; Ashwal-Fluss R, 2014, MOL CELL, V56, P55, DOI 10.1016/j.molcel.2014.08.019; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; Bonnal S, 2012, NAT REV DRUG DISCOV, V11, P847, DOI 10.1038/nrd3823; Bryzgunova OE, 2015, ACTA NATURAE, V7, P48, DOI 10.32607/20758251-2015-7-3-48-54; Busch A, 2012, WIRES RNA, V3, P1, DOI 10.1002/wrna.100; Calarco JA, 2009, CELL, V138, P898, DOI 10.1016/j.cell.2009.06.012; Cao SB, 2019, ONCOGENE, V38, P7060, DOI 10.1038/s41388-019-0947-7; Cato L, 2019, CANCER CELL, V35, P401, DOI 10.1016/j.ccell.2019.01.008; Chan YA, 2014, TRENDS GENET, V30, P245, DOI 10.1016/j.tig.2014.03.005; Chaudhuri J, 2003, NATURE, V422, P726, DOI 10.1038/nature01574; Chen K, 2017, CLIN CANCER RES, V23, P3428, DOI 10.1158/1078-0432.CCR-16-2020; Chen RQ, 2018, BJU INT, V122, P560, DOI 10.1111/bju.14207; Chen SJ, 2019, CELL, V176, P831, DOI 10.1016/j.cell.2019.01.025; Chen Z, 2018, P NATL ACAD SCI USA, V115, P6810, DOI 10.1073/pnas.1718811115; Corrionero A, 2011, GENE DEV, V25, P445, DOI 10.1101/gad.2014311; Dredge BK, 2005, EMBO J, V24, P1608, DOI 10.1038/sj.emboj.7600630; Dvinge H, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0168-9; Effenberger KA, 2016, RNA, V22, P350, DOI 10.1261/rna.053108.115; Escobar-Hoyos L, 2019, ANNU REV CANC BIOL, V3, P167, DOI 10.1146/annurev-cancerbio-030617-050407; Etxebarria A, 2009, J BIOL CHEM, V284, P4200, DOI 10.1074/jbc.M808050200; Fan L, 2016, ONCOGENE, V35, P2441, DOI 10.1038/onc.2015.309; Fan LL, 2018, P NATL ACAD SCI USA, V115, pE4584, DOI 10.1073/pnas.1802415115; Gan Y, 2018, EBIOMEDICINE, V31, P267, DOI 10.1016/j.ebiom.2018.05.002; Giannakouros T, 2011, FEBS J, V278, P570, DOI 10.1111/j.1742-4658.2010.07987.x; Gonatopoulos-Pournatzis T, 2018, MOL CELL, V72, P510, DOI 10.1016/j.molcel.2018.10.008; Guo JU, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0409-z; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; Helmrich A, 2011, MOL CELL, V44, P966, DOI 10.1016/j.molcel.2011.10.013; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Hua YM, 2008, AM J HUM GENET, V82, P834, DOI 10.1016/j.ajhg.2008.01.014; Ilagan JO, 2015, GENOME RES, V25, P14, DOI 10.1101/gr.181016.114; Irimia M, 2014, CELL, V159, P1511, DOI 10.1016/j.cell.2014.11.035; Jangi M, 2014, GENE DEV, V28, P637, DOI 10.1101/gad.235770.113; Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112; Jensen MA, 2014, NAT STRUCT MOL BIOL, V21, P189, DOI 10.1038/nsmb.2756; Jurica MS, 2003, MOL CELL, V12, P5, DOI 10.1016/S1097-2765(03)00270-3; Kaida D, 2007, NAT CHEM BIOL, V3, P576, DOI 10.1038/nchembio.2007.18; Karni R, 2007, NAT STRUCT MOL BIOL, V14, P185, DOI 10.1038/nsmb1209; Kim J, 2017, ONCOGENE, V36, P4072, DOI 10.1038/onc.2017.50; Kim N, 2012, NAT REV GENET, V13, P204, DOI 10.1038/nrg3152; Kim S, 2011, P NATL ACAD SCI USA, V108, P13564, DOI 10.1073/pnas.1109475108; Kornblihtt AR, 2005, CURR OPIN CELL BIOL, V17, P262, DOI 10.1016/j.ceb.2005.04.014; Kotake Y, 2007, NAT CHEM BIOL, V3, P570, DOI 10.1038/nchembio.2007.16; Krawczak M, 2007, HUM MUTAT, V28, P150, DOI 10.1002/humu.20400; Ku SY, 2017, SCIENCE, V355, P78, DOI 10.1126/science.aah4199; Laugesen A, 2019, MOL CELL, V74, P8, DOI 10.1016/j.molcel.2019.03.011; Laurent B, 2015, MOL CELL, V57, P957, DOI 10.1016/j.molcel.2015.01.010; Lee AR, 2019, CANCER SCI, V110, P245, DOI 10.1111/cas.13869; Lee AR, 2018, EBIOMEDICINE, V35, P167, DOI 10.1016/j.ebiom.2018.08.011; Lee AR, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00093; Lee AR, 2017, ONCOTARGET, V8, P27966, DOI 10.18632/oncotarget.15854; Lee Y, 2015, ANNU REV BIOCHEM, V84, P291, DOI 10.1146/annurev-biochem-060614-034316; Li Y, 2015, CELL RES, V25, P981, DOI 10.1038/cr.2015.82; Li YN, 2019, EUR UROL, V76, P157, DOI 10.1016/j.eururo.2019.03.011; Li YN, 2019, PROSTATE, V79, P96, DOI 10.1002/pros.23715; Li YN, 2017, ONCOTARGET, V8, P66878, DOI 10.18632/oncotarget.19916; Li YA, 2017, EUR UROL, V71, P68, DOI 10.1016/j.eururo.2016.04.028; Lim KH, 2011, P NATL ACAD SCI USA, V108, P11093, DOI 10.1073/pnas.1101135108; Lin D, 2014, CANCER RES, V74, P1272, DOI 10.1158/0008-5472.CAN-13-2921-T; Lippert MJ, 2011, P NATL ACAD SCI USA, V108, P698, DOI 10.1073/pnas.1012363108; Liu LL, 2014, ONCOGENE, V33, P3140, DOI 10.1038/onc.2013.284; Lorson CL, 1999, P NATL ACAD SCI USA, V96, P6307, DOI 10.1073/pnas.96.11.6307; Luco RF, 2011, CELL, V144, P16, DOI 10.1016/j.cell.2010.11.056; Luco RF, 2010, SCIENCE, V327, P996, DOI 10.1126/science.1184208; Luo JD, 2019, MOL THER-NUCL ACIDS, V18, P916, DOI 10.1016/j.omtn.2019.10.015; Luo J, 2018, EUR UROL, V73, P715, DOI 10.1016/j.eururo.2017.11.038; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; Muraki M, 2004, J BIOL CHEM, V279, P24246, DOI 10.1074/jbc.M314298200; Nadiminty N, 2015, MOL CANCER THER, V14, P1884, DOI 10.1158/1535-7163.MCT-14-1057; Ni JZ, 2007, GENE DEV, V21, P708, DOI 10.1101/gad.1525507; Nilsen TW, 2010, NATURE, V463, P457, DOI 10.1038/nature08909; Orban TI, 2003, J CLIN PATHOL-MOL PA, V56, P191, DOI 10.1136/mp.56.4.191; Pan Q, 2008, NAT GENET, V40, P1413, DOI 10.1038/ng.259; Paschalis A, 2018, NAT REV CLIN ONCOL, V15, P663, DOI 10.1038/s41571-018-0085-0; Pradeepa MM, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002717; Prasad J, 1999, MOL CELL BIOL, V19, P6991; Rahman L, 2002, GENOMICS, V80, P245, DOI 10.1006/geno.2002.6826; Raj B, 2011, MOL CELL, V43, P843, DOI 10.1016/j.molcel.2011.08.014; Rickman DS, 2017, NAT MED, V23, P664, DOI 10.1038/nm.4341; Roberts GC, 1998, NUCLEIC ACIDS RES, V26, P5568, DOI 10.1093/nar/26.24.5568; Rostovtseva TK, 2009, J BIOL CHEM, V284, P34390, DOI 10.1074/jbc.M109.021873; Roybal GA, 2010, NUCLEIC ACIDS RES, V38, P6664, DOI 10.1093/nar/gkq494; Salzman J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030733; Scotti MM, 2016, NAT REV GENET, V17, P19, DOI 10.1038/nrg.2015.3; Seiler M, 2018, CELL REP, V23, P282, DOI 10.1016/j.celrep.2018.01.088; Seiler M, 2018, NAT MED, V24, P497, DOI 10.1038/nm.4493; Shepard PJ, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-10-242; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Shimojo M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43100-1; Sollier J, 2014, MOL CELL, V56, P777, DOI 10.1016/j.molcel.2014.10.020; Stockley J, 2015, SCI REP-UK, V5, DOI 10.1038/srep13426; Sun GQ, 2010, MOL CELL BIOL, V30, P1997, DOI 10.1128/MCB.01116-09; Takahashi Y, 2005, MOL CELL BIOL, V25, P9369, DOI 10.1128/MCB.25.21.9369-9382.2005; Tuduri S, 2009, NAT CELL BIOL, V11, P1315, DOI 10.1038/ncb1984; Vo JN, 2019, CELL, V176, P869, DOI 10.1016/j.cell.2018.12.021; Wagener N, 2008, INT J CANCER, V123, P1545, DOI 10.1002/ijc.23683; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Wang ZF, 2008, RNA, V14, P802, DOI 10.1261/rna.876308; Watson PA, 2015, NAT REV CANCER, V15, P701, DOI 10.1038/nrc4016; Xu D, 2015, CANCER RES, V75, P3663, DOI 10.1158/0008-5472.CAN-15-0381; Yang YJ, 2016, CLIN CANCER RES, V22, P1744, DOI 10.1158/1078-0432.CCR-15-1606; Yokoi A, 2011, FEBS J, V278, P4870, DOI 10.1111/j.1742-4658.2011.08387.x; Yu ZY, 2014, CLIN CANCER RES, V20, P1590, DOI 10.1158/1078-0432.CCR-13-1863; Zhang XT, 2015, CLIN CANCER RES, V21, P4698, DOI 10.1158/1078-0432.CCR-15-0157; Zhou W, 2016, J CELL SCI, V129, P1963, DOI 10.1242/jcs.179465; Zibetti C, 2010, J NEUROSCI, V30, P2521, DOI 10.1523/JNEUROSCI.5500-09.2010	113	27	27	3	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	11					2231	2242		10.1038/s41388-019-1138-2	http://dx.doi.org/10.1038/s41388-019-1138-2			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KU0ZS	31819165				2022-12-28	WOS:000519440400001
J	Ripani, P; Delp, J; Bode, K; Delgado, ME; Dietrich, L; Betzler, VM; Yan, N; von Scheven, G; Mayer, TU; Leist, M; Brunner, T				Ripani, P.; Delp, J.; Bode, K.; Delgado, M. E.; Dietrich, L.; Betzler, V. M.; Yan, N.; von Scheven, G.; Mayer, T. U.; Leist, M.; Brunner, T.			Thiazolides promote G1 cell cycle arrest in colorectal cancer cells by targeting the mitochondrial respiratory chain	ONCOGENE			English	Article							HELICOBACTER-PYLORI; DRUG NITAZOXANIDE; VIRUS-REPLICATION; INDUCED APOPTOSIS; INHIBITION; PRAZIQUANTEL; TIZOXANIDE; CHILDREN; CULTURE	Systemic toxicity and tumor cell resistance still limit the efficacy of chemotherapy in colorectal cancer. Therefore, alternative treatments are desperately needed. The thiazolide Nitazoxanide (NTZ) is an FDA-approved drug for the treatment of parasite-mediated infectious diarrhea with a favorable safety profile. Interestingly, NTZ and the thiazolide RM4819-its bromo-derivative lacking antibiotic activity-are also promising candidates for cancer treatment. Yet the exact anticancer mechanism(s) of these compounds still remains unclear. In this study, we systematically investigated RM4819 and NTZ in 2D and 3D colorectal cancer culture systems. Both compounds strongly inhibited proliferation of colon carcinoma cell lines by promoting G1 phase cell cycle arrest. Thiazolide-induced cell cycle arrest was independent of the p53/p21 axis, but was mediated by inhibition of protein translation via the mTOR/c-Myc/p27 pathway, likely caused by inhibition of mitochondrial respiration. While both thiazolides demonstrated mitochondrial uncoupling activity, only RM4819 inhibited the mitochondrial respiratory chain complex III. Interestingly, thiazolides also potently inhibited the growth of murine colonic tumoroids in a comparable manner with cisplatin, while in contrast to cisplatin thiazolides did not affect the growth of primary intestinal organoids. Thus, thiazolides appear to have a tumor-selective antiproliferative activity, which offers new perspectives in the treatment of colorectal cancer.	[Ripani, P.; Bode, K.; Delgado, M. E.; Dietrich, L.; Betzler, V. M.; Brunner, T.] Univ Konstanz, Dept Biol Biochem Pharmacol, Constance, Germany; [Ripani, P.; Delp, J.; Mayer, T. U.; Leist, M.; Brunner, T.] Univ Konstanz, Konstanz Res Sch Chem Biol KORS CB, Constance, Germany; [Delp, J.; Leist, M.] Univ Konstanz, Chair Vitro Toxicol & Biomed, Doerenkamp Zbinden Fdn, Constance, Germany; [Betzler, V. M.] Univ Konstanz, Biotechnol Inst Thurgau, Constance, Germany; [Yan, N.] Peking Univ, Dept Med Chem, Hlth Sci Ctr, Beijing, Peoples R China; [von Scheven, G.] Univ Konstanz, Dept Biol, Mol Toxicol Grp, Constance, Germany; [Mayer, T. U.] Univ Konstanz, Dept Biol, Mol Genet, Constance, Germany	University of Konstanz; University of Konstanz; University of Konstanz; University of Konstanz; Peking University; University of Konstanz; University of Konstanz	Brunner, T (corresponding author), Univ Konstanz, Dept Biol Biochem Pharmacol, Constance, Germany.; Brunner, T (corresponding author), Univ Konstanz, Konstanz Res Sch Chem Biol KORS CB, Constance, Germany.	thomas.brunner@uni-konstanz.de	Leist, Marcel/D-2133-2010; Delgado, M.Eugenia/ABH-3795-2020	Leist, Marcel/0000-0002-3778-8693; Delgado, M.Eugenia/0000-0002-8653-1819; Niu, Yan/0000-0001-9193-8659; Mayer, Thomas/0000-0001-6954-2287; Delp, Johannes/0000-0003-3224-0677				Angelucci F, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1494-4; Ashour DS, 2016, EXP PARASITOL, V170, P28, DOI 10.1016/j.exppara.2016.08.009; Aslam S, 2007, FUTURE MICROBIOL, V2, P583, DOI 10.2217/17460913.2.6.583; Bode KJ, 2019, BIOTECHNIQUES, V67, P23, DOI 10.2144/btn-2019-0023; Brockmann A, 2014, ACS CHEM BIOL, V9, P1520, DOI 10.1021/cb500209a; Castell A, 2015, CANCER DISCOV, V5, P701, DOI 10.1158/2159-8290.CD-15-0660; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Ciardiello D, 2019, CANCER TREAT REV, V76, P22, DOI 10.1016/j.ctrv.2019.04.003; de Carvalho LPS, 2009, J MED CHEM, V52, P5789, DOI 10.1021/jm9010719; de Caryalho LPS, 2011, ACS MED CHEM LETT, V2, P849, DOI 10.1021/ml200157f; Delp J, 2019, ARCH TOXICOL, V93, P1585, DOI 10.1007/s00204-019-02473-y; Delp J, 2018, TOXICOL APPL PHARM, V354, P64, DOI 10.1016/j.taap.2017.12.013; Di Santo N, 2014, MUTAT RES-FUND MOL M, V768, P16, DOI 10.1016/j.mrfmmm.2014.05.005; El-Deiry WS, 2016, CANCER RES, V76, P5189, DOI 10.1158/0008-5472.CAN-16-2055; Fan-Minogue H, 2013, MOL CANCER THER, V12, P1896, DOI 10.1158/1535-7163.MCT-12-1243; Favennec L, 2003, ALIMENT PHARM THER, V17, P265, DOI 10.1046/j.1365-2036.2003.01419.x; Fontaine E, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00753; Fox LM, 2005, CLIN INFECT DIS, V40, P1173, DOI 10.1086/428839; Grabinger T, 2016, METHODS MOL BIOL, V1491, P83, DOI 10.1007/978-1-4939-3581-9_7; Guttner Y, 2003, ANTIMICROB AGENTS CH, V47, P3780, DOI 10.1128/AAC.47.12.3780-3783.2003; Hauck Ludger, 2004, V296, P239; Hickson SE, 2018, VIROLOGY, V518, P398, DOI 10.1016/j.virol.2018.03.023; Hu YJ, 2017, PHARMACOL RES, V119, P219, DOI 10.1016/j.phrs.2017.01.034; Hydbring P, 2017, GENES-BASEL, V8, DOI 10.3390/genes8070174; Kozovska Z, 2014, BIOMED PHARMACOTHER, V68, P911, DOI 10.1016/j.biopha.2014.10.019; Kuipers EJ, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.65; La Frazia S, 2018, ANTIVIR RES, V157, P159, DOI 10.1016/j.antiviral.2018.06.008; Lam KKY, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002691; Lateef M, 2008, INT J INFECT DIS, V12, P80, DOI 10.1016/j.ijid.2007.04.017; Liu Y, 2006, P NATL ACAD SCI USA, V103, P976, DOI 10.1073/pnas.0510146103; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; McVay CS, 2000, ANTIMICROB AGENTS CH, V44, P2254, DOI 10.1128/AAC.44.9.2254-2258.2000; Muller J, 2008, INT J CANCER, V123, P1797, DOI 10.1002/ijc.23755; Neufert C, 2007, NAT PROTOC, V2, P1998, DOI 10.1038/nprot.2007.279; Ortiz JJ, 2002, T ROY SOC TROP MED H, V96, P193, DOI 10.1016/S0035-9203(02)90301-9; Pankuch GA, 2006, ANTIMICROB AGENTS CH, V50, P1112, DOI 10.1128/AAC.50.3.1112-1117.2006; Perelygina L, 2017, ANTIVIR RES, V147, P58, DOI 10.1016/j.antiviral.2017.09.019; Piacentini S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28172-9; Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168; Qu Y, 2018, NAT CHEM BIOL, V14, P94, DOI [10.1038/NCHEMBIO.2510, 10.1038/nchembio.2510]; Rossignol JF, 2014, ANTIVIR RES, V110, P94, DOI 10.1016/j.antiviral.2014.07.014; ROSSIGNOL JF, 1984, AM J TROP MED HYG, V33, P511, DOI 10.4269/ajtmh.1984.33.511; Rossingol JF, 2016, J INFECT PUBLIC HEAL, V9, P227, DOI 10.1016/j.jiph.2016.04.001; Senkowski W, 2015, MOL CANCER THER, V14, P1504, DOI 10.1158/1535-7163.MCT-14-0792; Shakya Anshul, 2018, Curr Drug Discov Technol, V15, P201, DOI 10.2174/1570163814666170727130003; Sidler D, 2012, ONCOGENE, V31, P4095, DOI 10.1038/onc.2011.575; Stachulski AV, 2018, FUTURE MED CHEM, V10, P851, DOI 10.4155/fmc-2017-0217; Stachulski AV, 2017, EUR J MED CHEM, V126, P154, DOI 10.1016/j.ejmech.2016.09.080; Tilmanis D, 2017, ANTIVIR RES, V147, P142, DOI 10.1016/j.antiviral.2017.10.002; Tsou L, 2011, CELL METAB, V13, P476, DOI 10.1016/j.cmet.2011.03.006; Wang X, 2018, SPR GEOL, P9, DOI 10.1007/978-3-319-58325-9_2; Webster PC, 2010, CAN MED ASSOC J, V182, pE141, DOI 10.1503/cmaj.109-3109; Weinberg SE, 2015, NAT CHEM BIOL, V11, P9, DOI 10.1038/nchembio.1712; Xue X, 2013, JOVE-J VIS EXP, DOI 10.3791/50210; Yamamoto Y, 1999, CHEMOTHERAPY, V45, P303, DOI 10.1159/000007200; Yan B, 2016, MITOCHONDRION, V26, P86, DOI 10.1016/j.mito.2015.12.007; Zaman SB, 2017, CUREUS, V9, pe1352; Zhu YM, 2018, J CLIN INVEST, V128, P3682, DOI 10.1172/JCI120844	58	17	17	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	11					2345	2357		10.1038/s41388-019-1142-6	http://dx.doi.org/10.1038/s41388-019-1142-6			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KU0ZS	31844249	Green Submitted			2022-12-28	WOS:000519440400008
J	Luo, SQ; Xiong, DH; Li, J; Li, GD; Wang, YL; Zhang, JM; Bu, XF; Hu, WX; Hu, JP				Luo, Sai-Qun; Xiong, De-Hui; Li, Jiang; Li, Guangdi; Wang, Yali; Zhang, Jia-Ming; Bu, Xiu-Fen; Hu, Wei-Xin; Hu, Jingping			C1orf35 contributes to tumorigenesis by activating c-MYC transcription in multiple myeloma	ONCOGENE			English	Article							BINDING-PROTEIN; CELL-CYCLE; PROGNOSTIC-SIGNIFICANCE; DNA; PROGRESSION; ABNORMALITIES; EXPRESSION; ADDICTION; TRANSLATION; PROMOTER	Multiple myeloma (MM) is a clinically and biologically heterogenous event that accounts for approximately 10% of all hematological malignancies. Chromosome 1 open reading frame 35 (C1orf35) is a gene cloned and identified in our laboratory from a MM cell line (GenBank: AY137773), but little is known about its function. In the current study, we have confirmed that C1orf35 is a candidate oncogene, and it can promote cell cycle progression from G1 to S. Later, we found that C1orf35 is able to affect the cell proliferation by modulating the expression of c-MYC (v-myc myelocytomatosis viral oncogene homolog), and the oncogenic property of C1orf35 can be rescued by c-MYC inhibition. Herein, we found positive association between C1orf35 and c-MYC in MM patients and in MM cell lines. The correlation analysis of the genes coamplified in MM patients from GEO datasets showed a correlation between C1orf35 and c-MYC, and the expression data of different stages of plasma cell neoplasm acquired from GEO datasets showed that the expression of C1orf35 increase with the progression of the disease. This indicates that C1orf35 may play a role in the disease progression. Moreover, C1orf35 can modulate c-MYC expression and rescue c-MYC transcription inhibited by Act D. Finally, we have shown that C1orf35 activates c-MYC transcription by binding to the i-motif of Nuclease hypersensitivity element III1 (NHE III1) in the c-MYC promoter. Not only does our current study advance our knowledge of the pathogenesis and therapeutic landscape of MM, but also of other cancer types and diseases that are initiated with deregulated c-MYC transcription.	[Luo, Sai-Qun; Xiong, De-Hui; Li, Jiang; Zhang, Jia-Ming; Bu, Xiu-Fen; Hu, Wei-Xin; Hu, Jingping] Cent South Univ, Mol Biol Res Ctr, Sch Life Sci, 110 Xiangya Rd, Changsha 410078, Hunan, Peoples R China; [Li, Guangdi; Wang, Yali] Cent South Univ, Xiangya Sch Publ Hlth, Dept Epidemiol & Hlth Stat, 110 Xiangya Rd, Changsha 410078, Hunan, Peoples R China	Central South University; Central South University	Hu, WX; Hu, JP (corresponding author), Cent South Univ, Mol Biol Res Ctr, Sch Life Sci, 110 Xiangya Rd, Changsha 410078, Hunan, Peoples R China.	weixinhu@mail.csu.edu.cn; jingpinghu@csu.edu.cn	Li, Guangdi/AAU-6951-2020	Hu, Jingping/0000-0001-5548-1241; Li, Guangdi/0000-0001-8852-034X	National Natural Science Foundation of China [81372538, 81400819, 81071947, 39880021, 30770906]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported with grants from the National Natural Science Foundation of China (Nos. 81372538, 81400819, 81071947, 39880021 and 30770906).	Agnelli L, 2009, GENE CHROMOSOME CANC, V48, P603, DOI 10.1002/gcc.20668; Arabi A, 2005, NAT CELL BIOL, V7, P303, DOI 10.1038/ncb1225; Armas P, 2008, J CELL BIOCHEM, V103, P1013, DOI 10.1002/jcb.21474; Avet-Loiseau H, 2012, J CLIN ONCOL, V30, P1949, DOI 10.1200/JCO.2011.36.5726; Avet-Loiseau H, 2009, J CLIN ONCOL, V27, P4585, DOI 10.1200/JCO.2008.20.6136; Bretones G, 2015, BBA-GENE REGUL MECH, V1849, P506, DOI 10.1016/j.bbagrm.2014.03.013; Carrasco DR, 2006, CANCER CELL, V9, P313, DOI 10.1016/j.ccr.2006.03.019; Chesi M, 2008, CANCER CELL, V13, P167, DOI 10.1016/j.ccr.2008.01.007; Chng WJ, 2011, LEUKEMIA, V25, P1026, DOI 10.1038/leu.2011.53; Chng WJ, 2007, CANCER RES, V67, P2982, DOI 10.1158/0008-5472.CAN-06-4046; Decaux O, 2008, J CLIN ONCOL, V26, P4798, DOI 10.1200/JCO.2007.13.8545; Dominguez-Sola D, 2007, NATURE, V448, P445, DOI 10.1038/nature05953; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; Eddy J, 2006, NUCLEIC ACIDS RES, V34, P3887, DOI 10.1093/nar/gkl529; Geltinger C, 1996, GENE EXPRESSION, V6, P113; Gonzalez V, 2010, ANNU REV PHARMACOL, V50, P111, DOI 10.1146/annurev.pharmtox.48.113006.094649; Grand CL, 2002, MOL CANCER THER, V1, P565; Hanamura I, 2006, BLOOD, V108, P1724, DOI 10.1182/blood-2006-03-009910; Holien T, 2012, BLOOD, V120, P2450, DOI 10.1182/blood-2011-08-371567; Hu JP, 2018, CANCER LETT, V414, P214, DOI 10.1016/j.canlet.2017.11.020; Jovanovic KK, 2018, LEUKEMIA, V32, P1295, DOI 10.1038/s41375-018-0036-x; Kuehl WM, 2012, BLOOD, V120, P2351, DOI 10.1182/blood-2012-08-445262; Kumar SK, 2018, NAT REV CLIN ONCOL, V15, P409, DOI 10.1038/s41571-018-0018-y; Le Baccon P, 2001, GENE CHROMOSOME CANC, V32, P250, DOI 10.1002/gcc.1189; MAJELLO B, 1995, ONCOGENE, V10, P1841; Manier S, 2017, NAT REV CLIN ONCOL, V14, P100, DOI 10.1038/nrclinonc.2016.122; Marzin Y, 2006, ANTICANCER RES, V26, P953; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Mathur V, 2004, BIOCHEM BIOPH RES CO, V320, P1220, DOI 10.1016/j.bbrc.2004.06.074; Melton PE, 2019, J HYPERTENS, V37, P997, DOI 10.1097/HJH.0000000000002023; Morgan GJ, 2012, NAT REV CANCER, V12, P335, DOI 10.1038/nrc3257; Neben K, 2013, J CLIN ONCOL, V31, P4325, DOI 10.1200/JCO.2012.48.4923; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Pawlyn C, 2017, NAT REV CANCER, V17, P543, DOI 10.1038/nrc.2017.63; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; Rajkumar SV, 2009, CURR PROB CANCER, V33, P7, DOI 10.1016/j.currproblcancer.2009.01.001; Sabo A, 2014, NATURE, V511, P488, DOI 10.1038/nature13537; Sawyer JR, 2011, CANCER GENET-NY, V204, P3, DOI 10.1016/j.cancergencyto.2010.11.002; Shaffer AL, 2008, NATURE, V454, P226, DOI 10.1038/nature07064; Shi YJ, 2008, CANCER RES, V68, P10215, DOI 10.1158/0008-5472.CAN-08-1066; Shou YP, 2000, P NATL ACAD SCI USA, V97, P228, DOI 10.1073/pnas.97.1.228; Snead NM, 2013, NUCLEIC ACIDS RES, V41, P6209, DOI 10.1093/nar/gkt200; SOBELL HM, 1985, P NATL ACAD SCI USA, V82, P5328, DOI 10.1073/pnas.82.16.5328; Stine ZE, 2015, CANCER DISCOV, V5, P1024, DOI 10.1158/2159-8290.CD-15-0507; Tian JY, 2003, ACTA BIOCH BIOPH SIN, V35, P143; Wiegering A, 2015, CANCER DISCOV, V5, P768, DOI 10.1158/2159-8290.CD-14-1040; Zeraati M, 2018, NAT CHEM, V10, P631, DOI 10.1038/s41557-018-0046-3	48	9	9	0	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2020	39	16					3354	3366		10.1038/s41388-020-1222-7	http://dx.doi.org/10.1038/s41388-020-1222-7		FEB 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF9OJ	32103167				2022-12-28	WOS:000516683100001
J	Osei-Amponsa, V; Buckwalter, JM; Shuman, L; Zheng, ZY; Yamashita, H; Walter, V; Wildermuth, T; Ellis-Mohl, J; Liu, C; Warrick, JI; Shantz, LM; Feehan, RP; AI-Ahmadie, H; Mendelsohn, C; Raman, JD; Kaestner, KH; Wu, XR; DeGraff, DJ				Osei-Amponsa, Vasty; Buckwalter, Jenna M.; Shuman, Lauren; Zheng, Zongyu; Yamashita, Hironobu; Walter, Vonn; Wildermuth, Thomas; Ellis-Mohl, Justine; Liu, Chang; Warrick, Joshua, I; Shantz, Lisa M.; Feehan, Robert P.; AI-Ahmadie, Hikmat; Mendelsohn, Cathy; Raman, Jay D.; Kaestner, Klaus H.; Wu, Xue-Ru; DeGraff, David J.			Hypermethylation of FOXA1 and allelic loss of PTEN drive squamous differentiation and promote heterogeneity in bladder cancer	ONCOGENE			English	Article							BREAST-CANCER; CARCINOMAS; EXPRESSION; BASAL; N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE; HETEROZYGOSITY; INACTIVATION; METHYLATION; UROTHELIUM; PHYSIOLOGY	Intratumoral heterogeneity in bladder cancer is a barrier to accurate molecular sub-classification and treatment efficacy. However, individual cellular and mechanistic contributions to tumor heterogeneity are controversial. We examined potential mechanisms of FOXA1 and PTEN inactivation in bladder cancer and their contribution to tumor heterogeneity. These analyses were complemented with inactivation of FOXA1 and PTEN in intermediate and luminal mouse urothelium. We show inactivation and reduced expression of FOXA1 and PTEN is prevalent in human disease, where PTEN and FOXA1 are downregulated by allelic loss and site-specific DNA hypermethylation, respectively. Conditional inactivation of both Foxa1 and Pten in intermediate/luminal cells in mice results in development of bladder cancer exhibiting squamous features as well as enhanced sensitivity to a bladder-specific carcinogen. In addition, FOXA1 is hypermethylated in basal bladder cancer cell lines, and this is reversed by treatment with DNA methyltransferase inhibitors. By integrating human correlative and in vivo studies, we define a critical role for PTEN loss and epigenetic silencing of FOXA1 in heterogeneous human disease and show genetic targeting of luminal/intermediate cells in mice drives squamous differentiation.	[Osei-Amponsa, Vasty; Buckwalter, Jenna M.; Shuman, Lauren; Zheng, Zongyu; Yamashita, Hironobu; Wildermuth, Thomas; Ellis-Mohl, Justine; Warrick, Joshua, I; Raman, Jay D.; DeGraff, David J.] Penn State Univ, Coll Med, Dept Pathol & Lab Med, Hershey, PA 17033 USA; [Buckwalter, Jenna M.; Shuman, Lauren; Yamashita, Hironobu; Wildermuth, Thomas; Ellis-Mohl, Justine; Warrick, Joshua, I; Raman, Jay D.; DeGraff, David J.] Penn State Univ, Coll Med, Dept Surg, Div Urol, Hershey, PA USA; [Walter, Vonn] Penn State Univ, Coll Med, Dept Publ Hlth Sci, Hershey, PA USA; [Liu, Chang; Mendelsohn, Cathy] Columbia Univ, Dept Urol, New York, NY USA; [Shantz, Lisa M.; Feehan, Robert P.] Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA USA; [AI-Ahmadie, Hikmat] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA; [Kaestner, Klaus H.] Univ Penn, Dept Genet, Philadelphia, PA 19104 USA; [Wu, Xue-Ru] NYU, Sch Med, Dept Urol, New York, NY 10003 USA; [Wu, Xue-Ru] NYU, Sch Med, Dept Pathol, New York, NY USA; [Wu, Xue-Ru] Vet Affairs New York Harbor Healthcare Syst, Manhattan Campus, New York, NY USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Columbia University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Memorial Sloan Kettering Cancer Center; University of Pennsylvania; New York University; New York University	DeGraff, DJ (corresponding author), Penn State Univ, Coll Med, Dept Pathol & Lab Med, Hershey, PA 17033 USA.	ddegraff@pennstatehealth.psu.edu		Wu, Xue-Ru/0000-0001-6058-6291; Yamashita, Hironobu/0000-0003-2587-7100; Shuman, Lauren/0000-0003-2383-2240	Departments of Pathology and Surgery at Pennsylvania State University College of Medicine [K99CA172122, R00CA172122]; Ken and Bonnie Shockey Fund for Urologic Research [K99CA172122, R00CA172122]; Bladder Cancer Support Group at Penn State Health [K99CA172122, R00CA172122]	Departments of Pathology and Surgery at Pennsylvania State University College of Medicine; Ken and Bonnie Shockey Fund for Urologic Research; Bladder Cancer Support Group at Penn State Health	Supported by K99CA172122 (DJD), R00CA172122 (DJD), startup funding from the Departments of Pathology and Surgery at Pennsylvania State University College of Medicine (DJD), the Ken and Bonnie Shockey Fund for Urologic Research and the Bladder Cancer Support Group at Penn State Health. The authors wish to additionally acknowledge the expert administrative assistance of Kimberly Walker, and valuable discussions with Gordon Robertson, Mauro Castro and Clarice Groeneveld.	Al-Ahmadie HA, 2016, NAT GENET, V48, P356, DOI 10.1038/ng.3503; Aveyard JS, 1999, BRIT J CANCER, V80, P904, DOI 10.1038/sj.bjc.6690439; BERTRAM JS, 1972, EUR J CANCER, V8, P587, DOI 10.1016/0014-2964(72)90137-5; Bertucci F, 2012, CURR MOL MED, V12, P96, DOI 10.2174/156652412798376134; Cairns P, 1998, ONCOGENE, V16, P3215, DOI 10.1038/sj.onc.1201855; Cappellen D, 1997, ONCOGENE, V14, P3059, DOI 10.1038/sj.onc.1201154; Cheng JC, 2004, MOL CELL BIOL, V24, P1270, DOI 10.1128/MCB.24.3.1270-1278.2004; Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009; Damrauer JS, 2014, P NATL ACAD SCI USA, V111, P3110, DOI 10.1073/pnas.1318376111; DeGraff DJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036669; Drayton RM, 2014, ONCOTARGET, V5, P6375, DOI 10.18632/oncotarget.2221; Espinal AC, 2017, BREAST CANCER RES TR, V166, P559, DOI 10.1007/s10549-017-4418-y; Gao N, 2008, GENE DEV, V22, P3435, DOI 10.1101/gad.1752608; Ghosh S, 2014, BREAST CANCER RES TR, V147, P653, DOI 10.1007/s10549-014-3132-2; Gong C, 2015, ONCOGENE, V34, P5012, DOI 10.1038/onc.2014.421; Gross K, 2016, J DEV BIOL, V4, DOI 10.3390/jdb4010004; Guo CC, 2016, EUR UROL, V70, P611, DOI 10.1016/j.eururo.2016.02.056; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; He F, 2015, CANCER RES, V75, P2017, DOI 10.1158/0008-5472.CAN-14-3067; He ZM, 2012, MUTAT RES-GEN TOX EN, V742, P92, DOI 10.1016/j.mrgentox.2011.11.015; Hedegaard J, 2016, CANCER CELL, V30, P27, DOI 10.1016/j.ccell.2016.05.004; Hoadley KA, 2014, CELL, V158, P929, DOI 10.1016/j.cell.2014.06.049; Hovelson DH, 2018, EUR UROL, V74, P741, DOI 10.1016/j.eururo.2018.06.047; JOST SP, 1989, J ANAT, V167, P103; Karoui M, 2004, BRIT J CANCER, V90, P1230, DOI 10.1038/sj.bjc.6601687; Khandelwal P, 2009, AM J PHYSIOL-RENAL, V297, pF1477, DOI 10.1152/ajprenal.00327.2009; Knobbe CB, 2008, ONCOGENE, V27, P5398, DOI 10.1038/onc.2008.238; Lesche R, 2002, GENESIS, V32, P148, DOI 10.1002/gene.10036; Li Z, 2012, CELL, V148, P72, DOI 10.1016/j.cell.2011.11.026; Mermel CH, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r41; Miyamoto H, 2007, J NATL CANCER I, V99, P558, DOI 10.1093/jnci/djk113; Mo L, 2005, AM J PHYSIOL-RENAL, V289, pF562, DOI 10.1152/ajprenal.00368.2004; Moch H., 2016, WHO CLASSIFICATION T; NAGAO M, 1977, CANCER RES, V37, P399; OHTANI M, 1986, CANCER RES, V46, P2001; Oliveira PA, 2005, J EXP CLIN CANC RES, V24, P609; Puzio-Kuter AM, 2009, GENE DEV, V23, P675, DOI 10.1101/gad.1772909; R Development Core Team, 2009, R LANG ENV STAT COMP; Reddy OL, 2015, AM J PATHOL, V185, P1385, DOI 10.1016/j.ajpath.2015.01.014; Robertson AG, 2017, CELL, V171, P540, DOI 10.1016/j.cell.2017.09.007; Staack A, 2005, DIFFERENTIATION, V73, P121, DOI 10.1111/j.1432-0436.2005.00014.x; Thomsen MBH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11291-0; Thorat MA, 2008, J CLIN PATHOL, V61, P327, DOI 10.1136/jcp.2007.052431; Tsuruta H, 2006, CANCER RES, V66, P8389, DOI 10.1158/0008-5472.CAN-05-4627; Van Batavia J, 2014, NAT CELL BIOL, V16, P982, DOI 10.1038/ncb3038; Varley CL, 2009, CELL DEATH DIFFER, V16, P103, DOI 10.1038/cdd.2008.116; Vasconcelos-Nobrega C, 2012, IN VIVO, V26, P727; Walter V, 2018, CANCER RES, V78, P337533; Warrick JI, 2019, EUR UROL, V75, P18, DOI 10.1016/j.eururo.2018.09.003; Warrick JI, 2016, SCI REP-UK, V6, DOI 10.1038/srep38531; Warrick JI, 2016, INT J SURG PATHOL, V24, P306, DOI 10.1177/1066896916629783; Yoo LI, 2006, CANCER RES, V66, P1929, DOI 10.1158/0008-5472.CAN-05-1986	52	17	17	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	6					1302	1317		10.1038/s41388-019-1063-4	http://dx.doi.org/10.1038/s41388-019-1063-4			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE4UH	31636388				2022-12-28	WOS:000526714600010
J	Cui, KS; Liu, C; Li, X; Zhang, Q; Li, YJ				Cui, Kaisa; Liu, Cheng; Li, Xu; Zhang, Qiang; Li, Youjun			Comprehensive characterization of the rRNA metabolism-related genes in human cancer	ONCOGENE			English	Article							COLON-CANCER; END-POINTS; EXOSOME; BOP1; TUMORIGENESIS; DEFINITIONS; EXPRESSION; SIGNATURES; DATABASE; ONTOLOGY	Although rRNA metabolism-related genes have been reported to be associated with human cancer, a systematic assessment of rRNA metabolism-related genes across human cancers is lacking. Thus, we performed a Pan-cancer analysis of rRNA metabolism-related genes across 20 human cancers. Here, we examined mRNA expression, mutation, DNA methylation, copy number variation (CNV) and clinical landscape of rRNA metabolism-related genes in more than 8600 patients across 20 human cancers from The Cancer Genome Atlas (TCGA) dataset. Besides, ten independent Gene Expression Omnibus (GEO) datasets, Cancer Cell Line Encyclopedia (CCLE) dataset and Project Achilles dataset were used to verify our study. A landscape of rRNA metabolism-related genes was established across 20 human cancers. The results suggest that rRNA metabolism-related genes are upregulated in multiple cancers, particularly in digestive and respiratory system cancers. Most of the upregulated genes were driven by CNV gain rather than mutation or DNA hypomethylation. We systematically identified CNV-driven rRNA metabolism-related genes with clinical relevance, including EXOSC8. Finally, functional experiments confirmed the oncogenic roles of EXOSC8 in colorectal carcinoma. Our study highlights the important roles of rRNA metabolism-related genes in tumorigenesis as prognostic biomarkers.	[Cui, Kaisa; Liu, Cheng; Li, Xu; Zhang, Qiang; Li, Youjun] Wuhan Univ, Coll Life Sci, Hubei Key Lab Cell Homeostasis, Wuhan 430072, Peoples R China; [Cui, Kaisa; Liu, Cheng; Li, Xu; Zhang, Qiang; Li, Youjun] Wuhan Univ, Sch Med, Med Res Inst, Wuhan 430071, Peoples R China	Wuhan University; Wuhan University	Li, YJ (corresponding author), Wuhan Univ, Coll Life Sci, Hubei Key Lab Cell Homeostasis, Wuhan 430072, Peoples R China.; Li, YJ (corresponding author), Wuhan Univ, Sch Med, Med Res Inst, Wuhan 430071, Peoples R China.	liy7@whu.edu.cn	Cui, Kaisa/AAM-6601-2020	Cui, Kaisa/0000-0001-7255-2689	National Key R&D Program of China [2016YFC1302300]; National Nature Science Foundation of China [81772609]; Medical Science Advancement Program (Basic Medical Sciences) of Wuhan University [TFJC2018005]	National Key R&D Program of China; National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Medical Science Advancement Program (Basic Medical Sciences) of Wuhan University	We thank the TCGA, GEO, CCLE and Project Achilles teams. We thank Professor Jinxiang Zhang (Wuhan Union Hospital, Wuhan) for providing the CRC patient samples. This work was supported by grants from the National Key R&D Program of China (2016YFC1302300), National Nature Science Foundation of China (81772609) and Medical Science Advancement Program (Basic Medical Sciences) of Wuhan University (TFJC2018005).	Allmang C, 1999, EMBO J, V18, P5399, DOI 10.1093/emboj/18.19.5399; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bhattacharya C, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-82; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Calo E, 2018, NATURE, V554, P112, DOI 10.1038/nature25449; Carbon S, 2017, NUCLEIC ACIDS RES, V45, pD331, DOI 10.1093/nar/gkw1108; Chestkov IV, 2018, SCHIZOPHR RES, V197, P305, DOI 10.1016/j.schres.2018.01.001; Choudhury P, 2019, RNA BIOL, V16, P54, DOI 10.1080/15476286.2018.1556149; Chung KY, 2011, HEPATOLOGY, V54, P307, DOI 10.1002/hep.24372; Cowling VH, 2014, ONCOGENE, V33, P3519, DOI 10.1038/onc.2013.338; Dolezal JM, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4178-z; Driscoll JJ, 2009, CANCER J, V15, P401, DOI 10.1097/PPO.0b013e3181bdc2e0; Ehrlich M, 2009, EPIGENOMICS-UK, V1, P239, DOI 10.2217/EPI.09.33; Foroutan M, 2018, BMC BIOINFORMATICS, V19, DOI 10.1186/s12859-018-2435-4; Gamazon ER, 2015, BRIEF FUNCT GENOMICS, V14, P352, DOI 10.1093/bfgp/elv017; Gantenbein N, 2018, EUR J CANCER, V101, P165, DOI 10.1016/j.ejca.2018.07.001; Ge ZQ, 2018, CELL REP, V23, P213, DOI 10.1016/j.celrep.2018.03.047; Gong J, 2017, CELL REP, V21, P1968, DOI 10.1016/j.celrep.2017.10.070; Haag S, 2015, RNA, V21, P180, DOI 10.1261/rna.047910.114; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Helleday T, 2014, NAT REV GENET, V15, P585, DOI 10.1038/nrg3729; Henrichsen CN, 2009, HUM MOL GENET, V18, pR1, DOI 10.1093/hmg/ddp011; Hudis CA, 2007, J CLIN ONCOL, V25, P2127, DOI 10.1200/JCO.2006.10.3523; Killian A, 2006, GENE CHROMOSOME CANC, V45, P874, DOI 10.1002/gcc.20351; Kulkarni S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182705; Li WJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0523-z; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Lin TC, 2016, ELIFE, V5, DOI 10.7554/eLife.11288; Liu TZ, 2016, CANCER RES, V76, P572, DOI 10.1158/0008-5472.CAN-15-0671; Maruvka YE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083100; Mayakonda A, 2018, GENOME RES, V28, P1747, DOI 10.1101/gr.239244.118; McIver SC, 2014, BLOOD, V124, P2285, DOI 10.1182/blood-2014-04-571083; Meyers RM, 2017, NAT GENET, V49, P1779, DOI 10.1038/ng.3984; Miluzio A, 2011, CANCER CELL, V19, P765, DOI 10.1016/j.ccr.2011.04.018; Pan Y, 2018, MOL CARCINOGEN, V57, P1780, DOI 10.1002/mc.22896; Prieto JL, 2007, GENE DEV, V21, P2041, DOI 10.1101/gad.436707; Punt CJA, 2007, JNCI-J NATL CANCER I, V99, P998, DOI 10.1093/jnci/djm024; Rohrmoser M, 2007, MOL CELL BIOL, V27, P3682, DOI 10.1128/MCB.00172-07; Ruggero D, 2014, BLOOD, V124, P2784, DOI 10.1182/blood-2014-04-526301; Schaub FX, 2018, CELL SYST, V6, P282, DOI 10.1016/j.cels.2018.03.003; Shen HX, 2017, CELL DEATH DIFFER, V24, P1253, DOI 10.1038/cdd.2017.63; Sloan KE, 2014, RNA, V20, P540, DOI 10.1261/rna.043471.113; Song JL, 2018, J CELL MOL MED, V22, P6304, DOI 10.1111/jcmm.13922; Srivastava L, 2010, MOL CELL BIOL, V30, P2947, DOI 10.1128/MCB.00226-10; Stransky N, 2015, NATURE, V528, P84, DOI 10.1038/nature15736; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tai P, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-48; Tang XL, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00396-9; Tsoi H, 2017, ONCOGENE, V36, P6109, DOI 10.1038/onc.2017.86; Van Dijk EL, 2007, RNA, V13, P1027, DOI 10.1261/rna.575107; Wang YM, 2018, CELL REP, V25, P1304, DOI 10.1016/j.celrep.2018.10.001; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Yan DM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15749-z; Ye YQ, 2019, NAT METAB, V1, P431, DOI 10.1038/s42255-019-0045-8; Zhu YH, 2017, CELL DEATH DIFFER, V24, P2199, DOI 10.1038/cdd.2017.151	57	28	28	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	4					786	800		10.1038/s41388-019-1026-9	http://dx.doi.org/10.1038/s41388-019-1026-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KF4EJ	31548613				2022-12-28	WOS:000509197200004
J	Yang, W; Li, YY; Gao, RL; Xiu, ZH; Sun, T				Yang, Wei; Li, Yanyan; Gao, Ruoling; Xiu, Zenghe; Sun, Ting			MHC class I dysfunction of glioma stem cells escapes from CTL-mediated immune response via activation of Wnt/beta-catenin signaling pathway	ONCOGENE			English	Article							DENDRITIC CELLS; T-CELLS; CANCER; RECOGNITION; EXPRESSION; SENSITIVITY; INHIBITORS; MEMORY; P53	Glioma stem cells (GSCs) decrease T cells cognition and evade systemic immunosurveillance via downregulations or defects of major histocompatibility complex class I (MHC-I) molecule and antigen-processing machinery (APM) components. Improvement of tumor surface antigens of GSCs may be effective strategy to trigger an adaptive immune response and activate cytotoxic T cells (CTLs) to eliminate glioma. In this study, our data indicated that downregulations of MHC-I and APM components expressions were associated with Wnt pathway activation in GSCs. Histone deacetylases (HDAC) inhibition improved MHC-I and APM components expressions, which could be partly reverted by Wnt pathway activation. Blocking CTLs-mediated killing decreased the anti-tumor effect of tumor lysate vaccine. The enhancement of T cells immune response resulting from HDAC inhibition was dependent on CTLs cognition on tumor antigens presented by upregulated MHC-I molecule in GSCs. These data suggest that suppression of stemness pathway may be effective for GSCs-based immunotherapy against immune-escaped tumors.	[Yang, Wei; Gao, Ruoling; Xiu, Zenghe] Soochow Univ, Sch Radiat Med & Protect, State Key Lab Radiat Med & Protect, Suzhou 215123, Jiangsu, Peoples R China; [Yang, Wei; Gao, Ruoling; Xiu, Zenghe] Soochow Univ, Collaborat Innovat Ctr Radiat Med Jiangsu Higher, Suzhou 215123, Jiangsu, Peoples R China; [Li, Yanyan; Sun, Ting] Soochow Univ, Neurosurg & Brain & Nerve Res Lab, Affiliated Hosp 1, Suzhou 215006, Jiangsu, Peoples R China	Soochow University - China; Soochow University - China; Soochow University - China	Yang, W (corresponding author), Soochow Univ, Sch Radiat Med & Protect, State Key Lab Radiat Med & Protect, Suzhou 215123, Jiangsu, Peoples R China.; Yang, W (corresponding author), Soochow Univ, Collaborat Innovat Ctr Radiat Med Jiangsu Higher, Suzhou 215123, Jiangsu, Peoples R China.; Sun, T (corresponding author), Soochow Univ, Neurosurg & Brain & Nerve Res Lab, Affiliated Hosp 1, Suzhou 215006, Jiangsu, Peoples R China.	detachedy@aliyun.com; sunting1979st@aliyun.com			National Natural Science Foundation of China [81874080, 31870844, 31570851]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	This work was supported by the National Natural Science Foundation of China (81874080, 31870844, 31570851) and A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).	Alimonti J, 2000, NAT BIOTECHNOL, V18, P515, DOI 10.1038/75373; Brown SD, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2018.1556080; Cai L, 2019, CLIN CANCER RES, V25, P2644, DOI 10.1158/1078-0432.CCR-18-1401; Carugo A, 2019, CANCER CELL, V35, P204, DOI 10.1016/j.ccell.2019.01.006; Chang CC, 2015, J BIOL CHEM, V290, P26562, DOI 10.1074/jbc.M115.676130; Di Tomaso T, 2010, CLIN CANCER RES, V16, P800, DOI 10.1158/1078-0432.CCR-09-2730; Durgeau A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00014; Falkenberg KJ, 2014, NAT REV DRUG DISCOV, V13, P673, DOI 10.1038/nrd4360; Finocchiaro G, 2016, CANCER IMMUNOL IMMUN, V65, P101, DOI 10.1007/s00262-015-1754-9; GABATHULER R, 1994, J EXP MED, V180, P1415, DOI 10.1084/jem.180.4.1415; JEFFERIES WA, 1993, J IMMUNOL, V151, P2974; Lathia JD, 2015, GENE DEV, V29, P1203, DOI 10.1101/gad.261982.115; Lou YM, 2005, CANCER RES, V65, P7926, DOI 10.1158/0008-5472.CAN-04-3977; Lou YM, 2007, VACCINE, V25, P2331, DOI 10.1016/j.vaccine.2006.11.064; McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490; Morgan MA, 2018, CANCER RES, V78, P6713, DOI 10.1158/0008-5472.CAN-18-2439; Morrison BJ, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4389-3; Pages F, 2005, NEW ENGL J MED, V353, P2654, DOI 10.1056/NEJMoa051424; Sadahiro H, 2014, BRAIN TUMOR PATHOL, V31, P77, DOI 10.1007/s10014-013-0149-x; Setiadi AF, 2007, MOL CELL BIOL, V27, P7886, DOI 10.1128/MCB.01547-07; Setiadi AF, 2008, CANCER RES, V68, P9601, DOI 10.1158/0008-5472.CAN-07-5270; Sun T, 2017, ONCOTARGET, V8, P74451, DOI 10.18632/oncotarget.20165; Szatmari T, 2006, CANCER SCI, V97, P546, DOI 10.1111/j.1349-7006.2006.00208.x; Topper MJ, 2017, CELL, V171, P1284, DOI 10.1016/j.cell.2017.10.022; VERSTEEG R, 1988, EMBO J, V7, P1023, DOI 10.1002/j.1460-2075.1988.tb02909.x; Vik-Mo EO, 2013, CANCER IMMUNOL IMMUN, V62, P1499, DOI 10.1007/s00262-013-1453-3; Wang B, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3359; Woan KV, 2012, IMMUNOL CELL BIOL, V90, P55, DOI 10.1038/icb.2011.96; Wong TS, 2018, ONCOL LETT, V16, P2887, DOI 10.3892/ol.2018.9041; Wu A, 2010, NEURO-ONCOLOGY, V12, P1113, DOI 10.1093/neuonc/noq082; Yang W, 2018, CANCER LETT, V415, P164, DOI 10.1016/j.canlet.2017.12.005; Yang W, 2016, ONCOTARGET, V7, P41505, DOI 10.18632/oncotarget.9214; Yang W, 2014, EXP CELL RES, V326, P22, DOI 10.1016/j.yexcr.2014.05.022; Zhu KC, 1999, ONCOGENE, V18, P7740, DOI 10.1038/sj.onc.1203235	34	41	44	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	5					1098	1111		10.1038/s41388-019-1045-6	http://dx.doi.org/10.1038/s41388-019-1045-6			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KI2VY	31591480				2022-12-28	WOS:000511209700011
J	Guan, XW; Deng, HL; Choi, UL; Li, ZF; Yang, YQ; Zeng, JM; Liu, YZ; Zhang, XJ; Li, G				Guan, Xiaowen; Deng, Houliang; Choi, Un Lam; Li, Zhengfeng; Yang, Yiqi; Zeng, Jianming; Liu, Yunze; Zhang, Xuanjun; Li, Gang			EZH2 overexpression dampens tumor-suppressive signals via anEGR1silencer to drive breast tumorigenesis	ONCOGENE			English	Article							HISTONE METHYLTRANSFERASE EZH2; GROUP PROTEIN EZH2; TRANSCRIPTION FACTOR; DEVELOPMENTAL REGULATORS; CHIP-SEQ; POLYCOMB; EXPRESSION; GENE; CANCER; GROWTH	The mechanism underlying EZH2 overexpression in breast cancer and its involvement in tumorigenesis remain poorly understood. In this study, we developed an approach to systematically identify the trans-acting factors regulating the EZH2 expression, and identified more than 20 such factors. We revealed reciprocal regulation of early growth response 1 (EGR1) and EZH2: EGR1 activates the expression of EZH2, and EZH2 represses EGR1 expression. Using CRISPR-mediated genome/epigenome editing, we demonstrated that EHZ2 represses EGR1 expression through a silencer downstream of theEGR1gene. Deletion of theEGR1silencer resulted in reduced cell growth, invasion, tumorigenicity of breast cancer cells, and extensive changes in gene expression, such as upregulation of GADD45, DDIT3, and RND1; and downregulation of genes encoding cholesterol biosynthesis pathway enzymes. We hypothesize that EZH2/PRC2 acts as a "brake" for EGR1 expression by targeting theEGR1silencer, and EZH2 overexpression dampens tumor-suppressive signals mediated by EGR1 to drive breast tumorigenesis.	[Guan, Xiaowen; Deng, Houliang; Choi, Un Lam; Li, Zhengfeng; Yang, Yiqi; Zeng, Jianming; Liu, Yunze; Zhang, Xuanjun; Li, Gang] Univ Macau, Fac Hlth Sci, Macau, Peoples R China; [Guan, Xiaowen; Deng, Houliang; Choi, Un Lam; Li, Zhengfeng; Yang, Yiqi; Zeng, Jianming; Liu, Yunze; Zhang, Xuanjun; Li, Gang] Univ Macau, Fac Hlth Sci, Ctr Canc, Macau, Peoples R China; [Guan, Xiaowen; Deng, Houliang; Choi, Un Lam; Li, Zhengfeng; Yang, Yiqi; Zeng, Jianming; Liu, Yunze; Zhang, Xuanjun; Li, Gang] Univ Macau, Fac Hlth Sci, Inst Translat Med, Ctr Reprod Dev & Aging, Macau, Peoples R China	University of Macau; University of Macau; University of Macau	Li, G (corresponding author), Univ Macau, Fac Hlth Sci, Macau, Peoples R China.; Li, G (corresponding author), Univ Macau, Fac Hlth Sci, Ctr Canc, Macau, Peoples R China.; Li, G (corresponding author), Univ Macau, Fac Hlth Sci, Inst Translat Med, Ctr Reprod Dev & Aging, Macau, Peoples R China.	gangli@um.edu.mo		deng, houliang/0000-0002-7217-0063; Liu, Yunze/0000-0002-7414-8556	Science and Technology Development Fund, Macau SAR [137/2014/A3, 095/2015/A3]; Science and Technology Program of Guangzhou, China [201807010101]; Research & Development Administration Office of the University of Macau [MYRG201700099, MYRG2018-00022]	Science and Technology Development Fund, Macau SAR; Science and Technology Program of Guangzhou, China; Research & Development Administration Office of the University of Macau	This work was funded by the Science and Technology Development Fund, Macau SAR (File no. 137/2014/A3 and 095/2015/A3), the Science and Technology Program of Guangzhou, China (201807010101), and the Research & Development Administration Office of the University of Macau (MYRG201700099, MYRG2018-00022) awarded to GL.	Alajez NM, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.64; Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180; Bahrami Shahram, 2016, Advances in Biological Regulation, V62, P37, DOI 10.1016/j.jbior.2016.05.001; Barbieri E, 2018, MOL CELL, V71, P103, DOI 10.1016/j.molcel.2018.05.031; Baron V, 2006, CANCER GENE THER, V13, P115, DOI 10.1038/sj.cgt.7700896; Bejar R, 2011, NEW ENGL J MED, V364, P2496, DOI 10.1056/NEJMoa1013343; Bhattacharyya S, 2013, J PATHOL, V229, P286, DOI 10.1002/path.4131; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Breuer RHJ, 2004, NEOPLASIA, V6, P736, DOI 10.1593/neo.04160; Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333; Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035; Ciarapica R, 2009, CELL CYCLE, V8, P172, DOI 10.4161/cc.8.1.7292; Du J, 2012, BREAST CANCER RES TR, V131, P65, DOI 10.1007/s10549-011-1396-3; Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621; Fujii S, 2011, ONCOGENE, V30, P4118, DOI 10.1038/onc.2011.118; Gibbs J, 2008, ONCOGENE, V27, P98, DOI 10.1038/sj.onc.1210627; Gnad F, 2015, BMC GENOMICS, V16, DOI 10.1186/1471-2164-16-S8-S5; Gokey NG, 2011, J BIOL CHEM, V286, P29501, DOI 10.1074/jbc.M111.263509; Hetz C, 2020, NAT REV MOL CELL BIO, V21, P421, DOI 10.1038/s41580-020-0250-z; Kalashnikova EV, 2010, CANCER RES, V70, P9402, DOI 10.1158/0008-5472.CAN-10-1199; Keilwagen J, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-018-1614-y; Khan A, 2018, NUCLEIC ACIDS RES, V46, pD1284, DOI 10.1093/nar/gkx1188; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Koh CM, 2011, ONCOTARGET, V2, P669, DOI 10.18632/oncotarget.327; Koppens M, 2016, ONCOGENE, V35, P1341, DOI 10.1038/onc.2015.195; Kotake Y, 2007, GENE DEV, V21, P49, DOI 10.1101/gad.1499407; Kuzu OF, 2016, CANCER RES, V76, P2063, DOI 10.1158/0008-5472.CAN-15-2613; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Lejard V, 2011, J BIOL CHEM, V286, P5855, DOI 10.1074/jbc.M110.153106; Lin YW, 2013, J PATHOL, V230, P277, DOI 10.1002/path.4179; Liu CT, 1998, CANCER GENE THER, V5, P3; Mahara S, 2016, P NATL ACAD SCI USA, V113, pE3735, DOI 10.1073/pnas.1602079113; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; McCabe MT, 2014, EPIGENOMICS-UK, V6, P341, DOI [10.2217/EPI.14.23, 10.2217/epi.14.23]; Mei SL, 2017, NUCLEIC ACIDS RES, V45, pD658, DOI 10.1093/nar/gkw983; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; Oeggerli M, 2004, ONCOGENE, V23, P5616, DOI 10.1038/sj.onc.1207749; Ohoka N, 2005, EMBO J, V24, P1243, DOI 10.1038/sj.emboj.7600596; Okada T, 2015, NAT CELL BIOL, V17, P81, DOI 10.1038/ncb3082; Pagel JI, 2011, INDIAN J BIOCHEM BIO, V48, P226; Pietrasik S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030870; Salvador JM, 2013, ADV EXP MED BIOL, V793, P1, DOI 10.1007/978-1-4614-8289-5_1; Saramaki OR, 2006, GENE CHROMOSOME CANC, V45, P639, DOI 10.1002/gcc.20327; Shafarenko M, 2005, BLOOD, V106, P871, DOI 10.1182/blood-2004-08-3056; Silvente-Poirot S, 2014, SCIENCE, V343, P1445, DOI 10.1126/science.1252787; Silverman ES, 1998, BIOCHEM J, V336, P183, DOI 10.1042/bj3360183; Spaapen F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058083; Sudo T, 2005, BRIT J CANCER, V92, P1754, DOI 10.1038/sj.bjc.6602531; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Takawa M, 2011, CANCER SCI, V102, P1298, DOI 10.1111/j.1349-7006.2011.01958.x; Tamura RE, 2012, CURR MOL MED, V12, P634; Tanaka S, 2012, BLOOD, V120, P1107, DOI 10.1182/blood-2011-11-394932; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Thyss R, 2005, EMBO J, V24, P128, DOI 10.1038/sj.emboj.7600501; Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395; Wagener N, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-524; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; Wang GG, 2015, BLOOD, V125, P1217, DOI 10.1182/blood-2014-10-606822; Wassef M, 2017, J MOL BIOL, V429, P1978, DOI 10.1016/j.jmb.2016.10.012; Weikert S, 2005, INT J MOL MED, V16, P349; Worringer KA, 2014, CELL STEM CELL, V14, P40, DOI 10.1016/j.stem.2013.11.001; Yamaguchi H, 2014, CANCER RES TREAT, V46, P209, DOI 10.4143/crt.2014.46.3.209; Yu J, 2007, CELL DEATH DIFFER, V14, P436, DOI 10.1038/sj.cdd.4402029; Zeng JM, 2018, INT J BIOL SCI, V14, P1724, DOI 10.7150/ijbs.28850; Zheng RB, 2019, NUCLEIC ACIDS RES, V47, pD729, DOI 10.1093/nar/gky1094	70	8	8	2	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	2020	39	48					7127	7141		10.1038/s41388-020-01484-9	http://dx.doi.org/10.1038/s41388-020-01484-9		OCT 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PE1YE	33009487				2022-12-28	WOS:000574731000002
J	Li, LY; Chen, XS; Wang, KS; Guan, YD; Ren, XC; Cao, DS; Sun, XY; Li, AX; Tao, YG; Zhang, Y; Yin, MZ; Wang, XL; Wu, MH; Yang, JM; Cheng, Y				Li, Lan-Ya; Chen, Xi-Sha; Wang, Kuan-Song; Guan, Yi-Di; Ren, Xing-Cong; Cao, Dong-Sheng; Sun, Xin-Yuan; Li, Ao-Xue; Tao, Yong-Guang; Zhang, Yi; Yin, Ming-Zhu; Wang, Xin-Luan; Wu, Ming-Hua; Yang, Jin-Ming; Cheng, Yan			RSK2 protects human breast cancer cells under endoplasmic reticulum stress through activating AMPK alpha 2-mediated autophagy	ONCOGENE			English	Article							ER STRESS; SIGNALING PATHWAY; INDUCED APOPTOSIS; CARCINOMA-CELLS; INHIBITION; SURVIVAL; KINASE; PROTEINS; PHOSPHORYLATION; SENSITIVITY	Autophagy can protect stressed cancer cell by degradation of damaged proteins and organelles. However, the regulatory mechanisms behind this cellular process remain incompletely understood. Here, we demonstrate that RSK2 (p90 ribosomal S6 kinase 2) plays a critical role in ER stress-induced autophagy in breast cancer cells. We demonstrated that the promotive effect of RSK2 on autophagy resulted from directly binding of AMPK alpha 2 in nucleus and phosphorylating it at Thr172 residue. IRE1 alpha, an ER membrane-associated protein mediating unfolded protein response (UPR), is required for transducing the signal for activation of ERK1/2-RSK2 under ER stress. Suppression of autophagy by knockdown of RSK2 enhanced the sensitivity of breast cancer cells to ER stress both in vitro and in vivo. Furthermore, we demonstrated that inhibition of RSK2-mediated autophagy rendered breast cancer cells more sensitive to paclitaxel, a chemotherapeutic agent that induces ER stress-mediated cell death. This study identifies RSK2 as a novel controller of autophagy in tumor cells and suggests that targeting RSK2 can be exploited as an approach to reinforce the efficacy of ER stress-inducing agents against cancer.	[Li, Lan-Ya; Chen, Xi-Sha; Guan, Yi-Di; Sun, Xin-Yuan; Cheng, Yan] Cent South Univ, Xiangya Hosp 2, Dept Pharm, Changsha 410011, Peoples R China; [Li, Lan-Ya; Cao, Dong-Sheng; Sun, Xin-Yuan; Li, Ao-Xue] Cent South Univ, Xiangya Sch Pharmaceut Sci, Changsha 410008, Peoples R China; [Wang, Kuan-Song] Cent South Univ, Sch Basic Med, Xiangya Hosp, Dept Pathol, Changsha 410078, Peoples R China; [Wang, Kuan-Song] Cent South Univ, Sch Basic Med, Dept Pathol, Changsha 410078, Peoples R China; [Ren, Xing-Cong; Yang, Jin-Ming] Univ Kentucky, Coll Med, Markey Canc Ctr, Dept Pharmacol,Dept Canc Biol & Toxicol, Lexington, KY 40536 USA; [Tao, Yong-Guang; Wu, Ming-Hua] Cent South Univ, Sch Basic Med, Canc Res Inst, Changsha 410078, Peoples R China; [Tao, Yong-Guang; Wu, Ming-Hua] Cent South Univ, Minist Educ, Key Lab Carcinogenesis & Canc Invas, Changsha 410078, Peoples R China; [Zhang, Yi] Soochow Univ, Coll Pharmaceut Sci, Dept Pharmacol, Suzhou 410008, Peoples R China; [Yin, Ming-Zhu] Cent South Univ, Xiangya Hosp, Hunan Engn Res Ctr Skin Hlth & Dis, Dept Dermatol,Hunan Key Lab Skin Canc & Psoriasis, Changsha 410008, Hunan, Peoples R China; [Wang, Xin-Luan] Chinese Acad Sci, Shenzhen Inst Adv Technol, Translat Med R&D Ctr, Inst Biomed & Hlth Engn, Shenzhen 518057, Peoples R China	Central South University; Central South University; Central South University; Central South University; University of Kentucky; Central South University; Central South University; Soochow University - China; Central South University; Chinese Academy of Sciences; Shenzhen Institute of Advanced Technology, CAS	Cheng, Y (corresponding author), Cent South Univ, Xiangya Hosp 2, Dept Pharm, Changsha 410011, Peoples R China.	yancheng@csu.edu.cn		Chen, Xisha/0000-0003-3091-2919; tao, yongguang/0000-0003-2354-5321	National Natural Science Foundation of China [81472593, 81972480]; Postgraduate Research and Innovation Project of Central South University [1053320183910]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Postgraduate Research and Innovation Project of Central South University	This work was supported by the National Natural Science Foundation of China under Grant Nos. 81472593 and 81972480; the Postgraduate Research and Innovation Project of Central South University under Grant No. 1053320183910.	Anjum R, 2008, NAT REV MOL CELL BIO, V9, P747, DOI 10.1038/nrm2509; Bhardwaj M, 2020, SEMIN CANCER BIOL, V66, P116, DOI 10.1016/j.semcancer.2019.11.007; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Cheng Y, 2013, PHARMACOL REV, V65, P1162, DOI 10.1124/pr.112.007120; Cheng Y, 2013, AUTOPHAGY, V9, P208, DOI 10.4161/auto.22801; Cho YY, 2012, CARCINOGENESIS, V33, P2529, DOI 10.1093/carcin/bgs271; Cho YY, 2009, CANCER RES, V69, P4398, DOI 10.1158/0008-5472.CAN-08-4959; Cho YY, 2005, CANCER RES, V65, P3596, DOI 10.1158/0008-5472.CAN-04-3935; Ciechomska IA, 2013, ONCOGENE, V32, P1518, DOI 10.1038/onc.2012.174; Cubillos-Ruiz JR, 2017, CELL, V168, P692, DOI 10.1016/j.cell.2016.12.004; Dey S, 2013, AUTOPHAGY, V9, P612, DOI 10.4161/auto.23486; Eisinger-Mathason TSK, 2008, MOL CELL, V31, P722, DOI 10.1016/j.molcel.2008.06.025; Fujiki K, 2014, ARCH TOXICOL, V88, P403, DOI 10.1007/s00204-013-1129-y; Gao J, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.444; Garcia D, 2017, MOL CELL, V66, P789, DOI 10.1016/j.molcel.2017.05.032; Gawecka JE, 2012, J BIOL CHEM, V287, P43424, DOI 10.1074/jbc.M112.423046; Goncalves RLS, 2019, CELL METAB, V30, P999, DOI 10.1016/j.cmet.2019.11.008; Hart LS, 2012, J CLIN INVEST, V122, P4621, DOI 10.1172/JCI62973; He J, 2015, AUTOPHAGY, V11, P373, DOI 10.1080/15548627.2015.1009781; Hong-Brown LQ, 2017, ALCOHOL CLIN EXP RES, V41, P895, DOI 10.1111/acer.13377; Hospital MA, 2018, LEUKEMIA, V32, P597, DOI 10.1038/leu.2017.284; Houles T, 2018, SEMIN CANCER BIOL, V48, P53, DOI 10.1016/j.semcancer.2017.04.016; Im JY, 2018, ONCOGENE, V37, P1251, DOI 10.1038/s41388-017-0025-y; Janczar S, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.346; Jeon YJ, 2015, CANCER CELL, V27, P354, DOI 10.1016/j.ccell.2015.02.006; Kang SM, 2011, EXPERT OPIN THER TAR, V15, P11, DOI 10.1517/14728222.2010.531013; Lara R, 2013, CANCER RES, V73, P5301, DOI 10.1158/0008-5472.CAN-12-4448; Lei Y, 2015, ONCOGENE, V34, P485, DOI 10.1038/onc.2013.566; Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53; Li N, 2013, ONCOGENE, V32, P1933, DOI 10.1038/onc.2012.212; Li X, 2016, AUTOPHAGY, V12, P1521, DOI 10.1080/15548627.2016.1191722; Lim HC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074334; Liu KD, 2011, J BIOL CHEM, V286, P2057, DOI 10.1074/jbc.M110.147306; Liu SL, 2015, INT J ONCOL, V46, P2399, DOI 10.3892/ijo.2015.2937; Lozy F, 2014, AUTOPHAGY, V10, P662, DOI 10.4161/auto.27867; Luan Q, 2015, AUTOPHAGY, V11, P975, DOI 10.1080/15548627.2015.1049800; Maddalena F, 2013, MOL ONCOL, V7, P895, DOI 10.1016/j.molonc.2013.04.009; Nam HY, 2013, AUTOPHAGY, V9, P1631, DOI 10.4161/auto.25879; Nawrocki ST, 2005, CANCER RES, V65, P11510, DOI 10.1158/0008-5472.CAN-05-2394; Piasecka D, 2016, ONCOTARGET, V7, P86011, DOI 10.18632/oncotarget.13322; Qiang L, 2017, AUTOPHAGY, V13, P2086, DOI 10.1080/15548627.2017.1380757; Rao SV, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3055-5; Russell RC, 2014, CELL RES, V24, P42, DOI 10.1038/cr.2013.166; Salt IP, 2017, CIRC RES, V120, P1825, DOI 10.1161/CIRCRESAHA.117.309633; Schaffer BE, 2015, CELL METAB, V22, P907, DOI 10.1016/j.cmet.2015.09.009; Shang LB, 2011, P NATL ACAD SCI USA, V108, P4788, DOI 10.1073/pnas.1100844108; She QB, 2002, J BIOL CHEM, V277, P24039, DOI 10.1074/jbc.M109907200; Shi YH, 2011, AUTOPHAGY, V7, P1159, DOI 10.4161/auto.7.10.16818; Shin HJR, 2016, NATURE, V534, P553, DOI 10.1038/nature18014; Smith MD, 2018, DEV CELL, V44, P217, DOI 10.1016/j.devcel.2017.11.024; Spaan CN, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1729-4; Stratford AL, 2012, STEM CELLS, V30, P1338, DOI 10.1002/stem.1128; Sulzmaier FJ, 2016, ONCOTARGET, V7, P79855, DOI 10.18632/oncotarget.13084; Tameire F, 2019, NAT CELL BIOL, V21, P889, DOI 10.1038/s41556-019-0347-9; van Jaarsveld MTM, 2013, EUR J CANCER, V49, P345, DOI 10.1016/j.ejca.2012.08.024; Wang M, 2014, NAT REV CANCER, V14, P581, DOI 10.1038/nrc3800; Wang QL, 2017, AUTOPHAGY, V13, P404, DOI 10.1080/15548627.2016.1263776; Wen J, 2015, BREAST CANCER RES TR, V149, P619, DOI 10.1007/s10549-015-3283-9; Xiang XY, 2016, ONCOL REP, V35, P3471, DOI 10.3892/or.2016.4725; Xu L, 2015, CANCER RES TREAT, V47, P313, DOI 10.4143/crt.2013.222; Xu LY, 2012, MOL CANCER THER, V11, P2174, DOI 10.1158/1535-7163.MCT-12-0602; Zaouali MA, 2013, J PINEAL RES, V55, P65, DOI 10.1111/jpi.12051; Zhang DY, 2016, AUTOPHAGY, V12, P1447, DOI 10.1080/15548627.2016.1185576; Zhang SF, 2015, AUTOPHAGY, V11, P225, DOI 10.1080/15548627.2014.998931; Zhao C, 2013, AUTOPHAGY, V9, P196, DOI 10.4161/auto.22805; Zhu YX, 2015, BLOOD, V125, P483, DOI 10.1182/blood-2014-05-577130	66	7	9	0	20	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2020	39	43					6704	6718		10.1038/s41388-020-01447-0	http://dx.doi.org/10.1038/s41388-020-01447-0		SEP 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OF2UT	32958832				2022-12-28	WOS:000571674200001
J	Ren, SL; Gaykalova, DA; Guo, T; Favorov, AV; Fertig, EJ; Tamayo, P; Callejas-Valera, JL; Allevato, M; Gilardi, M; Santos, J; Fukusumi, T; Sakai, A; Ando, M; Sadat, S; Liu, C; Xu, GR; Fisch, KM; Wang, ZY; Molinolo, AA; Gutkind, JS; Ideker, T; Koch, WM; Califano, JA				Ren, Shuling; Gaykalova, Daria A.; Guo, Theresa; Favorov, Alexander, V; Fertig, Elana J.; Tamayo, Pablo; Callejas-Valera, Juan Luis; Allevato, Mike; Gilardi, Mara; Santos, Jessica; Fukusumi, Takahito; Sakai, Akihiro; Ando, Mizuo; Sadat, Sayed; Liu, Chao; Xu, Guorong; Fisch, Kathleen M.; Wang, Zhiyong; Molinolo, Alfredo A.; Gutkind, J. Silvio; Ideker, Trey; Koch, Wayne M.; Califano, Joseph A.			HPV E2, E4, E5 drive alternative carcinogenic pathways in HPV positive cancers	ONCOGENE			English	Article							HUMAN-PAPILLOMAVIRUS; INTEGRATION SITES; GENE-EXPRESSION; PROTEIN; HEAD; INHIBITION; E6; TRANSCRIPTION; REPLICATION; CARCINOMAS	The dominant paradigm for HPV carcinogenesis includes integration into the host genome followed by expression of E6 and E7 (E6/E7). We explored an alternative carcinogenic pathway characterized by episomal E2, E4, and E5 (E2/E4/E5) expression. Half of HPV positive cervical and pharyngeal cancers comprised a subtype with increase in expression of E2/E4/E5, as well as association with lack of integration into the host genome. Models of the E2/E4/E5 carcinogenesis show p53 dependent enhanced proliferation in vitro, as well as increased susceptibility to induction of cancer in vivo. Whole genomic expression analysis of the E2/E4/E5 pharyngeal cancer subtype is defined by activation of the fibroblast growth factor receptor (FGFR) pathway and this subtype is susceptible to combination FGFR and mTOR inhibition, with implications for targeted therapy.	[Ren, Shuling; Callejas-Valera, Juan Luis; Allevato, Mike; Gilardi, Mara; Santos, Jessica; Fukusumi, Takahito; Sakai, Akihiro; Ando, Mizuo; Sadat, Sayed; Liu, Chao; Wang, Zhiyong; Molinolo, Alfredo A.; Gutkind, J. Silvio; Califano, Joseph A.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA; [Ren, Shuling] Capital Med Univ, Beijing Friendship Hosp, Dept Otolaryngol Head & Neck Surg, Beijing, Peoples R China; [Gaykalova, Daria A.; Guo, Theresa; Koch, Wayne M.] Johns Hopkins Med Inst, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA; [Favorov, Alexander, V; Fertig, Elana J.] Johns Hopkins Med Inst, Dept Oncol, Div Oncol Biostat, Baltimore, MD 21205 USA; [Favorov, Alexander, V] Russian Acad Sci, Vavilov Inst Gen Genet, Lab Syst Biol & Computat Genet, Moscow, Russia; [Tamayo, Pablo; Xu, Guorong; Fisch, Kathleen M.; Ideker, Trey] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Callejas-Valera, Juan Luis] Sanford Res, Canc Biol & Immunotherapies Grp, Sioux Falls, SD USA; [Califano, Joseph A.] Univ Calif San Diego, Dept Surg, Div Otolaryngol Head & Neck Surg, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Capital Medical University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Russian Academy of Sciences; Vavilov Institute of General Genetics; University of California System; University of California San Diego; Sanford Health; University of California System; University of California San Diego	Califano, JA (corresponding author), Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA.; Califano, JA (corresponding author), Univ Calif San Diego, Dept Surg, Div Otolaryngol Head & Neck Surg, La Jolla, CA 92093 USA.	jcalifano@ucsd.edu	Favorov, Alexander V/K-2699-2018; Guo, Theresa/AAF-2216-2021; Gutkind, J. Silvio/J-1201-2016; Guo, Theresa/AFU-3555-2022	Favorov, Alexander V/0000-0003-2595-1091; Gutkind, J. Silvio/0000-0002-5150-4482; Tamayo, Pablo/0000-0002-9360-4668; Ideker, Trey/0000-0002-1708-8454; Santos, Jessica/0000-0002-4721-2292; Guo, Theresa/0000-0002-1689-3275; Liu, Chao/0000-0003-2184-9102; Allevato, Michael/0000-0003-1846-7189	National Institute of Dental and Craniofacial Research; NIH [P30 CA006973, R01 DE023347]; UC San Diego Clinical and Translational Research Institute Grant [UL1TR001442]; Russian Basic Research Foundation (RBRF) [17-00-00208]; Russian Academy of Sciences Project [0112-2019-0001]	National Institute of Dental and Craniofacial Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UC San Diego Clinical and Translational Research Institute Grant; Russian Basic Research Foundation (RBRF); Russian Academy of Sciences Project	We would like to thank Dennis Young, Joseph Aguilera for valuable advice and support. This work has been supported by National Institute of Dental and Craniofacial Research and NIH (R01 DE023347, JAC), the UC San Diego Clinical and Translational Research Institute Grant (UL1TR001442, KMF), NIH (P30 CA006973, AVF), Russian Basic Research Foundation (RBRF) (17-00-00208, AVF), and Russian Academy of Sciences Project (0112-2019-0001, AVF).	Akagi K, 2014, GENOME RES, V24, P185, DOI 10.1101/gr.164806.113; Amornphimoltham P, 2008, CLIN CANCER RES, V14, P8094, DOI 10.1158/1078-0432.CCR-08-0703; Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Babina IS, 2017, NAT REV CANCER, V17, P318, DOI 10.1038/nrc.2017.8; Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Boulenouar S, 2010, CARCINOGENESIS, V31, P473, DOI 10.1093/carcin/bgp281; Callejas-Valera JL, 2016, CARCINOGENESIS, V37, P1014, DOI 10.1093/carcin/bgw086; Campo MS, 2010, VIROLOGY, V407, P137, DOI 10.1016/j.virol.2010.07.044; Chen ZG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020183; Chung CH, 2004, CANCER CELL, V5, P489, DOI 10.1016/S1535-6108(04)00112-6; Crow JM, 2012, NATURE, V486, pS12, DOI 10.1038/486S12a; Davy CE, 2002, J VIROL, V76, P9806, DOI 10.1128/JVI.76.19.9806-9818.2002; Davy C, 2009, VIROLOGY, V394, P266, DOI 10.1016/j.virol.2009.08.035; de Martel C, 2017, INT J CANCER, V141, P664, DOI 10.1002/ijc.30716; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Egawa N, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006282; Gammoh N, 2009, ONCOGENE, V28, P2299, DOI 10.1038/onc.2009.78; Gaykalova DA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093102; Gleber-Netto FO, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.124762; Graham SV, 2016, J VIROL, V90, P8384, DOI 10.1128/JVI.00502-16; Graham SV, 2010, FUTURE MICROBIOL, V5, P1493, DOI 10.2217/FMB.10.107; Guo T, 2016, INT J CANCER, V139, P373, DOI 10.1002/ijc.30081; Halavaty KK, 2014, VIROLOGY, V452, P223, DOI 10.1016/j.virol.2014.01.013; Iglesias-Bartolome R, 2013, CANCER DISCOV, V3, P722, DOI 10.1158/2159-8290.CD-13-0239; Iglesias-Bartolome R, 2012, CELL STEM CELL, V11, P401, DOI 10.1016/j.stem.2012.06.007; Jemal A, 2013, JNCI-J NATL CANCER I, V105, P175, DOI 10.1093/jnci/djs491; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Liu Y, 2016, ONCOTARGET, V7, P5852, DOI 10.18632/oncotarget.6809; Martinez-Zapien D, 2016, NATURE, V529, P541, DOI 10.1038/nature16481; Massimi P, 1999, ONCOGENE, V18, P7748, DOI 10.1038/sj.onc.1203208; Moody CA, 2010, NAT REV CANCER, V10, P550, DOI 10.1038/nrc2886; Muller Mandy, 2012, Open Virol J, V6, P173, DOI 10.2174/1874357901206010173; Muller M, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002761; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; Ojesina AI, 2014, NATURE, V506, P371, DOI 10.1038/nature12881; Olthof NC, 2015, INT J CANCER, V136, pE207, DOI 10.1002/ijc.29112; Parfenov M, 2014, P NATL ACAD SCI USA, V111, P15544, DOI 10.1073/pnas.1416074111; Prescott EL, 2014, J VIROL, V88, P12599, DOI 10.1128/JVI.02029-14; Ranieri D, 2015, INT J CANCER, V137, P61, DOI 10.1002/ijc.29373; Rundhaug Joyce E, 2010, Cancers (Basel), V2, P436, DOI 10.3390/cancers2020436; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Schwartz S, 2013, VIROLOGY, V445, P187, DOI 10.1016/j.virol.2013.04.034; Seiwert TY, 2015, CLIN CANCER RES, V21, P632, DOI 10.1158/1078-0432.CCR-13-3310; Tan CL, 2015, CELL CYCLE, V14, P1459, DOI 10.1080/15384101.2015.1021519; Vitale-Cross L, 2004, CANCER RES, V64, P8804, DOI 10.1158/0008-5472.CAN-04-2623; Walter V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056823; Wang K, 2010, NUCLEIC ACIDS RES, V38; Wentzensen N, 2004, CANCER RES, V64, P3878, DOI 10.1158/0008-5472.CAN-04-0009; Wesche J, 2011, BIOCHEM J, V437, P199, DOI 10.1042/BJ20101603; Zhang LF, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0361-x; Zhang YX, 2016, CLIN CANCER RES, V22, P4735, DOI 10.1158/1078-0432.CCR-16-0323	53	28	29	3	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2020	39	40					6327	6339		10.1038/s41388-020-01431-8	http://dx.doi.org/10.1038/s41388-020-01431-8		AUG 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NV5JK	32848210	Green Published, hybrid			2022-12-28	WOS:000563171800002
J	Yan, PP; Liu, J; Zhou, R; Lin, C; Wu, KH; Yang, SB; Yang, S; Zhou, JY; Xu, LJ; Wang, H; Zhao, L				Yan, Pingping; Liu, Jian; Zhou, Rui; Lin, Chuang; Wu, Kunhe; Yang, Shibin; Yang, Shuai; Zhou, Jueyu; Xu, Lijun; Wang, Hui; Zhao, Liang			LASP1 interacts with N-WASP to activate the Arp2/3 complex and facilitate colorectal cancer metastasis by increasing tumour budding and worsening the pattern of invasion	ONCOGENE			English	Article							LIM; PROTEINS; PROLIFERATION; MIGRATION; CELLS	LIM and SH3 protein 1 (LASP1) is a metastasis-related protein reported to enhance tumour progression in colorectal cancer (CRC). However, the underlying mechanism is still elusive. As the major biological and pathological functions of LASP1 are accomplished by its LIM and SH3 domains via protein-protein interactions, a yeast two-hybrid system was employed to screen novel LASP1-interacting proteins. N-WASP, a member of the Wiskott-Aldrich syndrome protein (WASP) family, was screened and identified as a LASP1-interacting protein overexpressed in CRC tissues. N-WASP could stimulate the migration and invasion of CRC cells in vitro and increase the formation of subcutaneous tumours, mesenteric implanted tumours and hepatic metastatic tumours. N-WASP could interact with and activate the Arp2/3 complex to stimulate actin polymerization, thus changing the migratory and invasive capabilities of CRC cells. The interaction of LASP1 with N-WASP did not influence the expression of N-WASP but recovered the reduced actin polymerization induced by N-WASP silencing. High N-WASP expression was detected in most clinical colorectal samples, and it was positively correlated with the expression of LASP1 and ARP3, as well as the tumour budding and pattern of invasion, but negatively correlated with host lymphocytic response. Our study suggests a new mechanism for LASP1-mediated CRC metastasis determined by exploring LASP1-interacting proteins and identifies N-WASP as a potential therapeutic target for CRC.	[Yan, Pingping; Liu, Jian; Zhou, Rui; Lin, Chuang; Xu, Lijun; Zhao, Liang] Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou, Peoples R China; [Yan, Pingping; Liu, Jian; Zhou, Rui; Xu, Lijun; Zhao, Liang] Southern Med Univ, Sch Basic Med Sci, Dept Pathol, Guangzhou, Peoples R China; [Yan, Pingping; Liu, Jian; Zhou, Rui; Xu, Lijun; Zhao, Liang] Southern Med Univ, Guangdong Prov Key Lab Mol Tumor Pathol, Guangzhou, Peoples R China; [Wu, Kunhe] Guangdong Women & Children Hosp, Dept Pathol, Guangzhou 511442, Guangdong, Peoples R China; [Yang, Shibin] Sun Yat Sen Univ, Gastrointestinal Surg Ctr, Affiliated Hosp 1, Guangzhou 510080, Peoples R China; [Yang, Shuai] Sun Yat Sen Univ, Dept Neurosurg, Affiliated Hosp 1, Guangzhou 510080, Peoples R China; [Zhou, Jueyu] Southern Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Guangzhou 510515, Peoples R China; [Wang, Hui] Guangzhou Med Univ, Dept Med Oncol, Affiliated Tumor Hosp, Guangzhou, Peoples R China	Southern Medical University - China; Southern Medical University - China; Southern Medical University - China; Sun Yat Sen University; Sun Yat Sen University; Southern Medical University - China; Guangzhou Medical University	Zhao, L (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou, Peoples R China.; Zhao, L (corresponding author), Southern Med Univ, Sch Basic Med Sci, Dept Pathol, Guangzhou, Peoples R China.; Zhao, L (corresponding author), Southern Med Univ, Guangdong Prov Key Lab Mol Tumor Pathol, Guangzhou, Peoples R China.	liangsmu@foxmail.com	xu, li/GNH-3667-2022		National Natural Science Foundation of China [81773082, 81702903, 81872423, 81972813]; Guangdong Natural Science Foundation [2018B030311036, 2019A1515010974]; Fork Ying Tung Education Foundation [161035]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Natural Science Foundation(National Natural Science Foundation of Guangdong Province); Fork Ying Tung Education Foundation	This work was supported by the National Natural Science Foundation of China (Nos. 81773082, 81702903, 81872423, 81972813), Guangdong Natural Science Foundation (2018B030311036, 2019A1515010974) and Fork Ying Tung Education Foundation (161035).	Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912; Caie PD, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-156; Carlier MF, 2000, J BIOL CHEM, V275, P21946, DOI 10.1074/jbc.M000687200; Chatterjee D, 2019, ENT-EAR NOSE THROAT, V98, pE112, DOI 10.1177/0145561319848669; Co C, 2007, CELL, V128, P901, DOI 10.1016/j.cell.2006.12.049; Cronin KA, 2018, CANCER-AM CANCER SOC, V124, P2785, DOI [10.1002/cncr.32802, 10.1002/cncr.31551]; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; Duvall-Noelle N, 2016, ONCOGENE, V35, P1122, DOI 10.1038/onc.2015.166; Gao QZ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0443-y; Grunewald TGP, 2007, BRIT J CANCER, V96, P296, DOI 10.1038/sj.bjc.6603545; Grunewald TGP, 2006, EXP CELL RES, V312, P974, DOI 10.1016/j.yexcr.2005.12.016; Heerema MGJ, 2016, HISTOPATHOLOGY, V68, P388, DOI 10.1111/his.12754; Kurisu S, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-6-226; Lane J, 2014, CANCER GENOM PROTEOM, V11, P155; Li H, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05280-6; Li YF, 2013, HEAD NECK PATHOL, V7, P211, DOI 10.1007/s12105-012-0412-1; Lugli A, 2017, MODERN PATHOL, V30, P1299, DOI 10.1038/modpathol.2017.46; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Nakagawa H, 2006, FEBS LETT, V580, P3223, DOI 10.1016/j.febslet.2006.04.082; Niu Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep26112; Orth MF, 2015, ONCOTARGET, V6, P26, DOI 10.18632/oncotarget.3083; Panchal SC, 2003, NAT STRUCT BIOL, V10, P591, DOI 10.1038/nsb952; Pollard TD, 2002, CURR OPIN STRUC BIOL, V12, P768, DOI 10.1016/S0959-440X(02)00396-2; Pollard TD, 2007, ANNU REV BIOPH BIOM, V36, P451, DOI 10.1146/annurev.biophys.35.040405.101936; Prall F, 1994, HISTOPATHOLOGY, V78, P635; Rachlin AS, 2006, J CELL SCI, V119, P995, DOI 10.1242/jcs.02825; Rohatgi R, 2001, J BIOL CHEM, V276, P26448, DOI 10.1074/jbc.M103856200; Salvi A, 2015, INT J ONCOL, V46, P1901, DOI 10.3892/ijo.2015.2923; Shao ZY, 2016, SCI REP-UK, V6, DOI 10.1038/srep25631; Sun WD, 2017, ONCOL REP, V37, P341, DOI 10.3892/or.2016.5223; Takano K, 2008, EMBO J, V27, P2817, DOI 10.1038/emboj.2008.216; TOMASETTO C, 1995, FEBS LETT, V373, P245, DOI 10.1016/0014-5793(95)01040-L; van Wyk HC, 2019, ANN SURG ONCOL, V26, P4397, DOI 10.1245/s10434-019-07931-6; Wang H, 2014, CLIN CANCER RES, V20, P5835, DOI 10.1158/1078-0432.CCR-14-0485; Wang WG, 2005, TRENDS CELL BIOL, V15, P138, DOI 10.1016/j.tcb.2005.01.003; Zhao LA, 2010, GUT, V59, P1226, DOI 10.1136/gut.2009.202739; Zhao TS, 2015, CANCER RES, V75, P111, DOI 10.1158/0008-5472.CAN-14-2040; Zhou R, 2018, INT J CANCER, V142, P1853, DOI 10.1002/ijc.31206	38	10	11	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2020	39	35					5743	5755		10.1038/s41388-020-01397-7	http://dx.doi.org/10.1038/s41388-020-01397-7		JUL 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NF2QB	32704133				2022-12-28	WOS:000551792300001
J	Hruschka, N; Kalisz, M; Subijana, M; Grana-Castro, O; Del Cano-Ochoa, F; Brunet, LP; Chernukhin, I; Sagrera, A; De Reynies, A; Kloesch, B; Chin, SF; Burgues, O; Andreu, D; Bermejo, B; Cejalvo, JM; Sutton, J; Caldas, C; Ramon-Maiques, S; Carroll, JS; Prat, A; Real, FX; Martinelli, P				Hruschka, Natascha; Kalisz, Mark; Subijana, Maria; Grana-Castro, Osvaldo; Del Cano-Ochoa, Francisco; Brunet, Laia Pare; Chernukhin, Igor; Sagrera, Ana; De Reynies, Aurelien; Kloesch, Bernhard; Chin, Suet-Feung; Burgues, Octavio; Andreu, David; Bermejo, Begona; Cejalvo, Juan Miguel; Sutton, Joe; Caldas, Carlos; Ramon-Maiques, Santiago; Carroll, Jason S.; Prat, Aleix; Real, Francisco X.; Martinelli, Paola			The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver	ONCOGENE			English	Article							EXPRESSION; DIFFERENTIATION; BINDING	As the catalog of oncogenic driver mutations is expanding, it becomes clear that alterations in a given gene might have different functions and should not be lumped into one class. The transcription factorGATA3is a paradigm of this. We investigated the functions of the most commonGATA3mutation (X308_Splice) and five additional mutations, which converge into a neoprotein that we called "neoGATA3," associated with excellent prognosis in patients. Analysis of available molecular data from >3000 breast cancer patients revealed a dysregulation of the ER-dependent transcriptional response in tumors carrying neoGATA3-generating mutations. Mechanistic studies in vitro showed that neoGATA3 interferes with the transcriptional programs controlled by estrogen and progesterone receptors, without fully abrogating them. ChIP-Seq analysis indicated that ER binding is reduced in neoGATA3-expressing cells, especially at distal regions, suggesting that neoGATA3 interferes with the fine tuning of ER-dependent gene expression. This has opposite outputs in distinct hormonal context, having pro- or anti-proliferative effects, depending on the estrogen/progesterone ratio. Our data call for functional analyses of putative cancer drivers to guide clinical application.	[Hruschka, Natascha; Subijana, Maria; Kloesch, Bernhard; Martinelli, Paola] Med Univ Vienna, Comprehens Canc Ctr, Inst Canc Res, Vienna, Austria; [Kalisz, Mark; Sagrera, Ana; Real, Francisco X.; Martinelli, Paola] CIBERONC, Epithelial Carcinogenesis Grp, Spanish Natl Canc Res Ctr CNIO, Madrid, Spain; [Grana-Castro, Osvaldo] Spanish Natl Canc Res Ctr CNIO, Bioinformat Unit, Madrid, Spain; [Del Cano-Ochoa, Francisco; Ramon-Maiques, Santiago] CSIC UAM, Dept Genome Dynam & Funct, Ctr Biol Mol Severo Ochoa, Madrid, Spain; [Brunet, Laia Pare; Prat, Aleix] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain; [Brunet, Laia Pare; Prat, Aleix] IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Barcelona, Spain; [Chernukhin, Igor; Sutton, Joe; Carroll, Jason S.] Univ Cambridge, Canc Res UK Cambridge Inst, Robinson Way, Cambridge CB2 0RE, England; [De Reynies, Aurelien] Ligue Natl Canc, Programme Cartes Identite Tumeurs, F-75013 Paris, France; [Chin, Suet-Feung; Caldas, Carlos] Univ Cambridge, Canc Res UK Cambridge Inst, Dept Oncol, Cambridge, England; [Burgues, Octavio; Bermejo, Begona; Cejalvo, Juan Miguel] INCLIVA Biomed Res Inst, Valencia, Spain; [Burgues, Octavio] Hosp Clin Univ CIBERONC, Pathol Dept, Valencia, Spain; [Andreu, David] Univ Pompeu Fabra, Lab Prote & Prot Chem, Barcelona, Spain; [Bermejo, Begona; Cejalvo, Juan Miguel] Hosp Clin Univ CIBERONC, Oncol & Hematol Dept, Valencia, Spain; [Real, Francisco X.] Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Barcelona, Spain; [Martinelli, Paola] Boehringer Ingelheim RCV, Canc Cell Signaling Dept, Vienna, Austria	Medical University of Vienna; Centro Nacional de Investigaciones Oncologicas (CNIO); CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Centro Nacional de Investigaciones Oncologicas (CNIO); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; Pompeu Fabra University; Pompeu Fabra University; Boehringer Ingelheim	Martinelli, P (corresponding author), Med Univ Vienna, Comprehens Canc Ctr, Inst Canc Res, Vienna, Austria.; Martinelli, P (corresponding author), CIBERONC, Epithelial Carcinogenesis Grp, Spanish Natl Canc Res Ctr CNIO, Madrid, Spain.; Martinelli, P (corresponding author), Boehringer Ingelheim RCV, Canc Cell Signaling Dept, Vienna, Austria.	paola.martinelli@boehringer-ingelheim.com	Ramon-Maiques, Santiago/R-2533-2019; Burgues, Octavio/ABC-8699-2021; Arribas, Francisco X Real/H-5275-2015; Caldas, Carlos/U-7250-2019	Arribas, Francisco X Real/0000-0001-9501-498X; Caldas, Carlos/0000-0003-3547-1489; Grana-Castro, Osvaldo/0000-0003-1615-4242; Carroll, Jason/0000-0003-3643-0080; Burgues, Octavio/0000-0002-2471-5516; del Cano-Ochoa, Francisco/0000-0003-3093-3103; Ramon-Maiques, Santiago/0000-0001-9674-8088; Kalisz, Mark/0000-0002-8770-2798	Institute of Cancer Research of the Medical University Vienna; Austrian Science Grant (FWF) [P27361-B23]; Ministerio de Economia y Competitividad (Madrid, Spain) [SAF2011-29530, SAF2015-70553-R]; ERDF-EU; Fundacion Cientifica de la Asociacion Espanola Contra el Cancer; Ministerio de Ciencia, Innovacion y Universidades [SEV-2015-0510]; Cancer Research UK; Spanish Ministry of Science, Innovation and Universities (AEI/FEDER, UE) [BFU2016-80570-R]	Institute of Cancer Research of the Medical University Vienna; Austrian Science Grant (FWF)(Austrian Science Fund (FWF)); Ministerio de Economia y Competitividad (Madrid, Spain); ERDF-EU; Fundacion Cientifica de la Asociacion Espanola Contra el Cancer; Ministerio de Ciencia, Innovacion y Universidades; Cancer Research UK(Cancer Research UK); Spanish Ministry of Science, Innovation and Universities (AEI/FEDER, UE)	Work in the lab of PM was supported by the Institute of Cancer Research of the Medical University Vienna and by the grant P27361-B23 from the Austrian Science Grant (FWF), FXR was supported by SAF2011-29530 and SAF2015-70553-R grants from Ministerio de Economia y Competitividad (Madrid, Spain) (co-funded by the ERDF-EU), Fundacion Cientifica de la Asociacion Espanola Contra el Cancer. CNIO is supported by Ministerio de Ciencia, Innovacion y Universidades as a Centro de Excelencia Severo Ochoa SEV-2015-0510. Work in the lab of JSC and CC was supported by Cancer Research UK. Work in the lab of SRM was supported by the Spanish Ministry of Science, Innovation and Universities (BFU2016-80570-R; AEI/FEDER, UE).	Adomas AB, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-278; Becht E, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1070-5; Bruna A, 2016, CELL, V167, P260, DOI 10.1016/j.cell.2016.08.041; Chin L, 2011, GENE DEV, V25, P534, DOI 10.1101/gad.2017311; Cohen H, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0464-0; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746; Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143; Gustin JP, 2017, ONCOTARGET, V8, P103415, DOI 10.18632/oncotarget.21910; Izzo F, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0491-x; Jayasinghe RG, 2018, CELL REP, V23, P270, DOI 10.1016/j.celrep.2018.03.052; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kong SL, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.59; Kouros-Mehr H, 2008, CANCER CELL, V13, P141, DOI 10.1016/j.ccr.2008.01.011; Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048; Mair B, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006279; Mohammed H, 2015, NATURE, V523, P313, DOI 10.1038/nature14583; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Prat A, 2012, ANN ONCOL, V23, P2866, DOI 10.1093/annonc/mds080; Ross-Innes CS, 2012, NATURE, V481, P389, DOI 10.1038/nature10730; Singhal H, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1501924; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Takaku M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03478-4; Takaku M, 2015, GENE EXPRESSION, V16, P163, DOI 10.3727/105221615X14399878166113; Theodorou V, 2013, GENOME RES, V23, P12, DOI 10.1101/gr.139469.112; Thorsson V, 2018, IMMUNITY, V48, P812, DOI [10.1016/j.immuni.2018.03.023, 10.1016/j.immuni.2019.08.004]; Tkocz D, 2012, ONCOGENE, V31, P3667, DOI 10.1038/onc.2011.531; Turajlic S, 2017, LANCET ONCOL, V18, P1009, DOI 10.1016/S1470-2045(17)30516-8; Usary J, 2004, ONCOGENE, V23, P7669, DOI 10.1038/sj.onc.1207966; Yan W, 2010, J BIOL CHEM, V285, P14042, DOI 10.1074/jbc.M110.105262; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333	31	7	7	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2020	39	32					5455	5467		10.1038/s41388-020-1376-3	http://dx.doi.org/10.1038/s41388-020-1376-3		JUN 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW4DS	32587399	hybrid, Green Published, Green Submitted			2022-12-28	WOS:000543299500002
J	Kan, TT; Wang, W; Ip, PP; Zhou, ST; Wong, AS; Wang, X; Yang, MS				Kan, Tongtong; Wang, Wei; Ip, Philip P.; Zhou, Shengtao; Wong, Alice S.; Wang, Xin; Yang, Mengsu			Single-cell EMT-related transcriptional analysis revealed intra-cluster heterogeneity of tumor cell clusters in epithelial ovarian cancer ascites	ONCOGENE			English	Article							FIBROBLASTS; METASTASIS; DISSEMINATION; TUMORIGENESIS; SUBTYPES	Malignant ascites of epithelial ovarian cancer is a metastatic tumor microenvironment in which large amounts of disseminated single cells (DSCs) and disseminated tumor cell clusters (DTCCs) are commonly observed. The tumor cell clusters are known to be more aggressive than individual tumor cells in cancer metastasis; however, little is known about the mechanism. Applying single-cell epithelial-to-mesenchymal transition (EMT)-related transcriptional analysis in 120 DSCs and 195 intra-cluster cells from 27 DTCCs, we demonstrated that DTCCs were heterogeneous cellular units comprised of epithelial tumor cells, leukocytes, and cancer-associated fibroblasts (CAFs). Through the analysis of intra-DTCC heterogeneity, we identified that CAFs induced EMT of tumor cells via TGF beta signaling within the DTCC microenvironment. The activation of EMT program, in particular the upregulation of ZEB2, enabled the acquisition of additional chemoresistance and metastasis abilities of the intra-DTCC tumor cells, which resulted in the aggressiveness of DTCCs.	[Kan, Tongtong; Wang, Wei; Wang, Xin; Yang, Mengsu] City Univ Hong Kong, Dept Biomed Sci, Hong Kong, Peoples R China; [Ip, Philip P.] Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Peoples R China; [Zhou, Shengtao] Sichuan Univ, West China Hosp, Dept Obstet & Gynecol,Key Lab Birth Defects & Rel, Minist Educ,West China Hosp 2, Chengdu, Peoples R China; [Zhou, Shengtao] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Collaborat Innovat Ctr, Chengdu, Peoples R China; [Wong, Alice S.] Univ Hong Kong, Sch Biol Sci, Hong Kong, Peoples R China; [Yang, Mengsu] City Univ Hong Kong, Shenzhen Res Inst, Key Lab Biochip Technol, Shenzhen, Peoples R China	City University of Hong Kong; University of Hong Kong; Sichuan University; Sichuan University; University of Hong Kong; City University of Hong Kong	Yang, MS (corresponding author), City Univ Hong Kong, Dept Biomed Sci, Hong Kong, Peoples R China.; Yang, MS (corresponding author), City Univ Hong Kong, Shenzhen Res Inst, Key Lab Biochip Technol, Shenzhen, Peoples R China.	bhmyang@cityu.edu.hk	Ip, Philip/AAV-5995-2021; Wang, Xin/A-1130-2012; Wong, Alice/AFJ-4595-2022	Ip, Philip/0000-0002-0493-9838; Wang, Xin/0000-0002-5122-2418; Wong, Alice/0000-0002-0676-6475	Hong Kong Research Grant Council [CityU_11303815, CRF/1013-15G]; Guangdong Frontier and Key Technology Development Fund of Guangdong Province, PR China [2017B020226001]; Knowledge Innovation Program of Shenzhen Municipality, PR China [JCYJ20150601102053070]	Hong Kong Research Grant Council(Hong Kong Research Grants Council); Guangdong Frontier and Key Technology Development Fund of Guangdong Province, PR China; Knowledge Innovation Program of Shenzhen Municipality, PR China	We thank Maggie K.S. Tang from the School of Biological Sciences, The University of Hong Kong for assistance in delivering ascites samples and ovarian cancer cell lines. This work was supported by grants from the General Research Fund (CityU_11303815) and the Collaborative Research Fund (CRF/1013-15G) of Hong Kong Research Grant Council, the Guangdong Frontier and Key Technology Development Fund (2017B020226001) of Guangdong Province, PR China, and the Knowledge Innovation Program (JCYJ20150601102053070) of Shenzhen Municipality, PR China.	Aceto N, 2014, CELL, V158, P1110, DOI 10.1016/j.cell.2014.07.013; Ao Z, 2015, CANCER RES, V75, P4681, DOI 10.1158/0008-5472.CAN-15-1633; Au SH, 2016, P NATL ACAD SCI USA, V113, P4947, DOI 10.1073/pnas.1524448113; Ayantunde AA, 2007, ANN ONCOL, V18, P945, DOI 10.1093/annonc/mdl499; Bell DA, 2005, MODERN PATHOL, V18, pS19, DOI 10.1038/modpathol.3800306; Burleson KM, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-6; Calon A, 2014, SEMIN CANCER BIOL, V25, P15, DOI 10.1016/j.semcancer.2013.12.008; Calon A, 2015, NAT GENET, V47, P320, DOI 10.1038/ng.3225; Cheung KJ, 2016, SCIENCE, V352, P167, DOI 10.1126/science.aaf6546; Cheung KJ, 2016, P NATL ACAD SCI USA, V113, pE854, DOI 10.1073/pnas.1508541113; Desoize B, 2000, CRIT REV ONCOL HEMAT, V36, P193, DOI 10.1016/S1040-8428(00)00086-X; Dumont N, 2013, NEOPLASIA, V15, P249, DOI 10.1593/neo.121950; Fang ZD, 2011, BRIEF BIOINFORM, V12, P280, DOI 10.1093/bib/bbr004; FIDLER IJ, 1973, EUR J CANCER, V9, P223, DOI 10.1016/S0014-2964(73)80022-2; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hanley CJ, 2016, ONCOTARGET, V7, P6159, DOI 10.18632/oncotarget.6740; Hendrix ND, 2006, CANCER RES, V66, P1354, DOI 10.1158/0008-5472.CAN-05-3694; Hou JM, 2012, J CLIN ONCOL, V30, P525, DOI 10.1200/JCO.2010.33.3716; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kim S, 2016, CANCER SCI, V107, P1173, DOI 10.1111/cas.12987; Kipps E, 2013, NAT REV CANCER, V13, P273, DOI 10.1038/nrc3432; Krebs MG, 2014, NAT REV CLIN ONCOL, V11, P129, DOI 10.1038/nrclinonc.2013.253; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Maddipati R, 2015, CANCER DISCOV, V5, P1086, DOI 10.1158/2159-8290.CD-15-0120; Massague J, 2016, NATURE, V529, P298, DOI 10.1038/nature17038; Mateescu B, 2011, NAT MED, V17, P1627, DOI 10.1038/nm.2512; McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018; Paoli P, 2013, BBA-MOL CELL RES, V1833, P3481, DOI 10.1016/j.bbamcr.2013.06.026; Puram SV, 2017, CELL, V171, P1611, DOI 10.1016/j.cell.2017.10.044; Rostami P, 2019, J SCI-ADV MATER DEV, V4, P1, DOI 10.1016/j.jsamd.2019.01.006; RUNYON BA, 1988, HEPATOLOGY, V8, P1104, DOI 10.1002/hep.1840080521; Schelker M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02289-3; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shield K, 2009, GYNECOL ONCOL, V113, P143, DOI 10.1016/j.ygyno.2008.11.032; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Tomczak Katarzyna, 2015, Contemp Oncol (Pozn), V19, pA68, DOI 10.5114/wo.2014.47136; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Uehara Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128066; VELLIOS F, 1954, AM J CLIN PATHOL, V24, P676, DOI 10.1093/ajcp/24.6.676; Wang MN, 2017, J CANCER, V8, P761, DOI 10.7150/jca.17648; Winter MJ, 2003, AM J PATHOL, V163, P2139, DOI 10.1016/S0002-9440(10)63570-5; Ye X, 2015, TRENDS CELL BIOL, V25, P675, DOI 10.1016/j.tcb.2015.07.012; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Zhang SZ, 2015, SCI REP-UK, V5, DOI 10.1038/srep16066; Zhuang JL, 2015, SCI REP-UK, V5, DOI 10.1038/srep11924	47	21	21	3	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	21					4227	4240		10.1038/s41388-020-1288-2	http://dx.doi.org/10.1038/s41388-020-1288-2		APR 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LQ2DH	32284541				2022-12-28	WOS:000526276600001
J	Hazawa, M; Sakai, K; Kobayashi, A; Yoshino, H; Iga, Y; Iwashima, Y; Lim, KS; Voon, DCC; Jiang, YY; Horike, S; Lin, DC; Wong, RHW				Hazawa, Masaharu; Sakai, Kie; Kobayashi, Akiko; Yoshino, Hironori; Iga, Yoshihiro; Iwashima, Yuki; Lim, Kee Sing; Voon, Dominic Chih-Cheng; Jiang, Yan-Yi; Horike, Shin-ichi; Lin, De-Chen; Wong, Richard W.			Disease-specific alteration of karyopherin-alpha subtype establishes feed-forward oncogenic signaling in head and neck squamous cell carcinoma	ONCOGENE			English	Article							NUCLEAR-LOCALIZATION SIGNAL; NF-KAPPA-B; PORE COMPLEX; STEM-CELLS; PHOSPHORYLATION; DIFFERENTIATION; MAINTENANCE; INHIBITION; ACTIVATION; CONVERSION	Nuclear import, mediated in part by karyopherin-alpha (KPNA)/importin-alpha subtypes, regulates transcription factor access to the genome and determines cell fate. However, the cancer-specific changes of KPNA subtypes and the relevancy in cancer biology remain largely unknown. Here, we report that KPNA4, encoding karyopherin-alpha 4 (KPNA4), is exclusively amplified and overexpressed in head and neck of squamous cell carcinoma (HNSCC). Depletion of KPNA4 attenuated nuclear localization signal-dependent transport activity and suppressed malignant phenotypes and induced epidermal differentiation. Mechanistically, KPNA4-mediated nuclear transport of Ras-responsive element-binding protein (RREB1), which sustains Ras/ERK pathway signaling through repressing miR-143/145 expression. Notably, MAPK signaling enhanced trafficking activity of KPNA4 via phosphorylation of KPNA4 at Ser60. These data reveal that KPNA4 establishes a feed-forward cascade that potentiates Ras/ERK signaling in HNSCC.	[Hazawa, Masaharu; Sakai, Kie; Horike, Shin-ichi; Wong, Richard W.] Kanazawa Univ, Inst Frontier Sci Initiat, Cell Bionom Res Unit, Kanazawa, Ishikawa, Japan; [Hazawa, Masaharu; Iga, Yoshihiro; Iwashima, Yuki; Wong, Richard W.] Kanazawa Univ, Inst Sci & Engn, Sch Nat Syst, Mol Cell Biol Lab, Kanazawa, Ishikawa, Japan; [Hazawa, Masaharu; Kobayashi, Akiko; Lim, Kee Sing; Wong, Richard W.] Kanazawa Univ, WPI Nano Life Sci Inst, Kanazawa, Ishikawa, Japan; [Yoshino, Hironori] Hirosaki Univ, Dept Radiat Sci, Grad Sch Hlth Sci, 66-1 Hon Cho, Hirosaki, Aomori 0368564, Japan; [Voon, Dominic Chih-Cheng] Kanazawa Univ, Inst Frontier Sci Initiat, Canc Model Res Innovat Unit, Kanazawa, Ishikawa, Japan; [Jiang, Yan-Yi; Lin, De-Chen] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA; [Horike, Shin-ichi] Kanazawa Univ, Inst Gene Res, Adv Sci Res Ctr, Kanazawa, Ishikawa, Japan	Kanazawa University; Kanazawa University; Kanazawa University; Hirosaki University; Kanazawa University; Cedars Sinai Medical Center; Kanazawa University	Hazawa, M; Wong, RHW (corresponding author), Kanazawa Univ, Inst Frontier Sci Initiat, Cell Bionom Res Unit, Kanazawa, Ishikawa, Japan.; Hazawa, M; Wong, RHW (corresponding author), Kanazawa Univ, Inst Sci & Engn, Sch Nat Syst, Mol Cell Biol Lab, Kanazawa, Ishikawa, Japan.; Hazawa, M; Wong, RHW (corresponding author), Kanazawa Univ, WPI Nano Life Sci Inst, Kanazawa, Ishikawa, Japan.	masaharu.akj@gmail.com; rwong@staff.kanazawa-u.ac.jp	HAZAWA, Masaharu/A-6520-2016; Wong, Richard W./E-9155-2011; Hazawa, M/AAA-2712-2021; Yoshino, Hironori/E-7961-2013; Lim, Kee Siang/AAH-1407-2019	Yoshino, Hironori/0000-0003-2705-9929; Voon, Dominic Chih-Cheng/0000-0002-2963-9305; Wong, Richard/0000-0002-2131-6595	Infiniti Grant; Japan Society for Promotion of Science [17K16332, 17H05874, 17K08655]; Ichiro Kanehara Foundation; Hokuriku bank young investigator foundation	Infiniti Grant; Japan Society for Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ichiro Kanehara Foundation; Hokuriku bank young investigator foundation	This work was funded by an Infiniti Grant and in part by Grants-in-Aid for scientific research (JSPS KAKENHI Grant Number 17K16332) and (JSPS KAKENHI Grant Number 17H05874, 17K08655) from the Japan Society for Promotion of Science. This research was supported by the grant provided by The Ichiro Kanehara Foundation as well as Hokuriku bank young investigator foundation. We thank the Edanz Group (www.edanzediting.com/ac) for proof reading of this paper.	Borlido J, 2018, NAT IMMUNOL, V19, P594, DOI 10.1038/s41590-018-0103-5; Brown University, 2017, NATURE, V541, P169, DOI [DOI 10.1038/NATURE20805, 10.1038/nature20805]; Czimmerer Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055168; Fagerlund R, 2005, J BIOL CHEM, V280, P15942, DOI 10.1074/jbc.M500814200; Funasaka T, 2011, CANCER METAST REV, V30, P239, DOI 10.1007/s10555-011-9287-y; Haverty PM, 2004, NUCLEIC ACIDS RES, V32, pW213, DOI 10.1093/nar/gkh402; Hazawa M, 2017, ONCOGENE, V36, P2243, DOI 10.1038/onc.2016.377; Hazawa M, 2018, EMBO REP, V19, P73, DOI 10.15252/embr.201744523; Heist EK, 1998, J BIOL CHEM, V273, P19763, DOI 10.1074/jbc.273.31.19763; Hoelz A, 2016, NAT STRUCT MOL BIOL, V23, P624, DOI 10.1038/nsmb.3244; Jiang Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06081-9; Kent OA, 2013, ONCOGENE, V32, P2576, DOI 10.1038/onc.2012.266; Kent OA, 2010, GENE DEV, V24, P2754, DOI 10.1101/gad.1950610; Kobe B, 1999, NAT STRUCT BIOL, V6, P388, DOI 10.1038/7625; Kosyna FK, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7110221; Lange A, 2007, J BIOL CHEM, V282, P5101, DOI 10.1074/jbc.R600026200; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Lee CS, 2014, NAT GENET, V46, P1060, DOI 10.1038/ng.3091; Liang SH, 1999, ONCOGENE, V18, P2163, DOI 10.1038/sj.onc.1202350; Lin DC, 2014, NAT GENET, V46, P467, DOI 10.1038/ng.2935; Liu ZX, 2019, NEURON, V102, P587, DOI 10.1016/j.neuron.2019.02.018; Loercher A, 2004, CANCER RES, V64, P6511, DOI 10.1158/0008-5472.CAN-04-0852; Ma AH, 2019, ONCOGENE, V38, P2405, DOI 10.1038/s41388-018-0590-8; Masre SF, 2017, ONCOGENE, V36, P2529, DOI 10.1038/onc.2016.402; Mohamed MS, 2017, ACS NANO, V11, P5567, DOI 10.1021/acsnano.7b00906; Noetzel E, 2012, ONCOGENE, V31, P2101, DOI 10.1038/onc.2011.403; Olsen JV, 2006, CELL, V127, P635, DOI 10.1016/j.cell.2006.09.026; Raices M, 2017, DEV CELL, V41, P540, DOI 10.1016/j.devcel.2017.05.007; Rodriguez-Bravo V, 2018, CELL, V174, P1200, DOI 10.1016/j.cell.2018.07.015; Saladi SV, 2017, CANCER CELL, V31, P35, DOI 10.1016/j.ccell.2016.12.001; Tang YW, 2018, CELL REP, V24, P1355, DOI 10.1016/j.celrep.2018.06.116; Toda T, 2017, CELL STEM CELL, V21, P618, DOI 10.1016/j.stem.2017.08.012; Wong RW, 2015, CHEM BIOL, V22, P1285, DOI 10.1016/j.chembiol.2015.10.001; Xiang SS, 2019, ONCOGENE, V38, P1269, DOI 10.1038/s41388-018-0494-7; Xie JJ, 2018, GASTROENTEROLOGY, V154, P2137, DOI 10.1053/j.gastro.2018.02.018; Yang J, 2017, ONCOGENE, V36, P2868, DOI 10.1038/onc.2016.440; Yang J, 2019, ONCOGENE, V38, P4700, DOI 10.1038/s41388-019-0745-2; Yasuhara N, 2007, NAT CELL BIOL, V9, P72, DOI 10.1038/ncb1521; Yasuhara N, 2013, DEV CELL, V26, P123, DOI 10.1016/j.devcel.2013.06.022; Yoneda Y, 1996, ARCH HISTOL CYTOL, V59, P97, DOI 10.1679/aohc.59.97; Zhang F, 2000, P NATL ACAD SCI USA, V97, P12577, DOI 10.1073/pnas.230435597; Zhu JR, 2019, ONCOGENE, V38, P2736, DOI 10.1038/s41388-018-0621-5; Zhu ZC, 2018, ONCOGENE, V37, P2936, DOI 10.1038/s41388-018-0180-9	43	18	18	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	10					2212	2223		10.1038/s41388-019-1137-3	http://dx.doi.org/10.1038/s41388-019-1137-3			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KS8UR	31822798	Green Published, hybrid			2022-12-28	WOS:000518584000014
J	Oshikawa, K; Matsumoto, M; Kodama, M; Shimizu, H; Nakayama, KI				Oshikawa, Kiyotaka; Matsumoto, Masaki; Kodama, Manabu; Shimizu, Hideyuki; Nakayama, Keiichi I.			A fail-safe system to prevent oncogenesis by senescence is targeted by SV40 small T antigen	ONCOGENE			English	Article							CANCER; CELLS; TRANSFORMATION; ONCOPROTEINS; PATHWAY; BTG2; P53; FIBROBLASTS; MIGRATION; VACCINES	Whereas large T antigen (LT) of simian virus 40 (SV40) promotes oncogenesis by inactivating the tumor suppressor proteins p53 and pRb, SV40 small T antigen (ST) has been thought to be dispensable for this process. However, here we show that LT promotes both oncogenic growth and senescence in human cells expressing oncogenic Ras and that this latter effect is antagonized by ST. Inactivation of p53 by LT alone promoted the senescence-associated secretory phenotype (SASP), whereas the additional expression of ST attenuated this phenotype, allowing cells to avoid oncogene-induced senescence (OIS) and thereby promoting efficient oncogenesis. ST interacts with and inhibits the function of heterochromatin protein 1-binding protein 3 (HP1BP3), a positive regulator of global microRNA biogenesis, and it thereby triggers aberrant upregulation of B-cell translocation gene 2 (BTG2), which is essential for prevention of SASP and OIS by ST. Collectively, our results indicate that the HP1BP3-BTG2 axis constitutes a fail-safe system to prevent oncogenesis by means of OIS induction, and that this system is hijacked by ST.	[Oshikawa, Kiyotaka; Kodama, Manabu; Shimizu, Hideyuki; Nakayama, Keiichi I.] Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Fukuoka, Japan; [Matsumoto, Masaki; Nakayama, Keiichi I.] Kyushu Univ, Med Inst Bioregulat, Div Prote, Fukuoka, Japan	Kyushu University; Kyushu University	Nakayama, KI (corresponding author), Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Fukuoka, Japan.; Matsumoto, M; Nakayama, KI (corresponding author), Kyushu Univ, Med Inst Bioregulat, Div Prote, Fukuoka, Japan.	masakim@bioreg.kyushu-u.ac.jp; nakayak1@bioreg.kyushu-u.ac.jp		Matsumoto, Masaki/0000-0002-6987-0288; Shimizu, Hideyuki/0000-0002-0772-2204	KAKENHI grants from Japan Society for the Promotion of Science (JSPS); Ministry of Education, Culture, Sports, Science, and Technology of Japan [18H05215, 17H06301, 25221303, 17K19606, 17H05534, 17H06011]; Project for Cancer Research and Therapeutic Evolution (P-CREATE) of the Japan Agency for Medical Research and Development (AMED); Core Research for Evolutionary Science and Technology (CREST) of the Japan Science and Technology Agency (JST) [JPMJCR15G4]	KAKENHI grants from Japan Society for the Promotion of Science (JSPS); Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Project for Cancer Research and Therapeutic Evolution (P-CREATE) of the Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Core Research for Evolutionary Science and Technology (CREST) of the Japan Science and Technology Agency (JST)(Japan Science & Technology Agency (JST))	We thank T. Akagi for the pCX4 system as well as hTERT, SV40 ER, and H-RasG12V expression vectors; A. Sakiyama and K. Tsunematsu for technical assistance; members of our laboratories for comments on the manuscript; and A. Ohta for help in preparation of the manuscript. This work was supported in part by KAKENHI grants from Japan Society for the Promotion of Science (JSPS) and the Ministry of Education, Culture, Sports, Science, and Technology of Japan to KIN (18H05215, 17H06301, and 25221303) and to MM (17K19606, 17H05534, and 17H06011) as well as by the Project for Cancer Research and Therapeutic Evolution (P-CREATE) of the Japan Agency for Medical Research and Development (AMED). MM is also supported by Core Research for Evolutionary Science and Technology (CREST, JPMJCR15G4) of the Japan Science and Technology Agency (JST).	Akagi T, 2003, P NATL ACAD SCI USA, V100, P13567, DOI 10.1073/pnas.1834876100; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Ben-Porath I, 2005, INT J BIOCHEM CELL B, V37, P961, DOI 10.1016/j.biocel.2004.10.013; Boiko AD, 2006, GENE DEV, V20, P236, DOI 10.1101/gad.1372606; Buganim Y, 2010, CANCER RES, V70, P2274, DOI 10.1158/0008-5472.CAN-09-2661; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Chen W, 2003, HISTOL HISTOPATHOL, V18, P541, DOI 10.14670/HH-18.541; Chien YC, 2011, GENE DEV, V25, P2125, DOI 10.1101/gad.17276711; Choi OR, 2016, CELL SIGNAL, V28, P1172, DOI 10.1016/j.cellsig.2016.05.014; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; de Boer E, 2003, P NATL ACAD SCI USA, V100, P7480, DOI 10.1073/pnas.1332608100; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Nguyen HT, 2014, CELL REP, V8, P707, DOI 10.1016/j.celrep.2014.06.062; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Li WQ, 2015, INT J ONCOL, V46, P1601, DOI 10.3892/ijo.2015.2843; Lim IK, 2017, CELL SIGNAL, V30, P179, DOI 10.1016/j.cellsig.2016.12.001; Liu HM, 2016, MOL CELL, V63, P420, DOI 10.1016/j.molcel.2016.06.014; Mao BJ, 2015, INT J ONCOL, V46, P459, DOI 10.3892/ijo.2014.2765; Matsumoto M, 2017, NAT METHODS, V14, P251, DOI [10.1038/NMETH.4116, 10.1038/nmeth.4116]; Moody CA, 2010, NAT REV CANCER, V10, P550, DOI 10.1038/nrc2886; Olin P, 1998, DEV BIOL STAND, V94, P227; Qi F, 2011, EXPERT REV RESP MED, V5, P683, DOI [10.1586/ERS.11.51, 10.1586/ers.11.51]; Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009; Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Strickler HD, 1998, JAMA-J AM MED ASSOC, V279, P292, DOI 10.1001/jama.279.4.292; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tong ZY, 2015, INT J MOL SCI, V16, P14511, DOI 10.3390/ijms160714511; Uren A, 2005, CANCER RES, V65, P6199, DOI 10.1158/0008-5472.CAN-05-0455; Wagener N, 2013, BRIT J CANCER, V108, P973, DOI 10.1038/bjc.2012.573; Yang G, 2006, P NATL ACAD SCI USA, V103, P16472, DOI 10.1073/pnas.0605752103; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110	36	3	4	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	10					2170	2186		10.1038/s41388-019-1139-1	http://dx.doi.org/10.1038/s41388-019-1139-1			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KS8UR	31819167				2022-12-28	WOS:000518584000011
J	Ayyathan, DM; Koganti, P; Marcu-Malina, V; Litmanovitch, T; Trakhtenbrot, L; Emanuelli, A; Apel-Sarid, L; Blank, M				Manikoth Ayyathan, Dhanoop; Koganti, Praveen; Marcu-Malina, Victoria; Litmanovitch, Talia; Trakhtenbrot, Luba; Emanuelli, Andrea; Apel-Sarid, Liat; Blank, Michael			SMURF2 prevents detrimental changes to chromatin, protecting human dermal fibroblasts from chromosomal instability and tumorigenesis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; E3 UBIQUITIN LIGASE; PROTEIN STABILITY; DEPENDENT DEGRADATION; SENESCENCE; EXPRESSION; COMPLEX; SMAD7; CELLS; ASSAY	E3 ubiquitin ligases (E3s) play essential roles in the maintenance of tissue homeostasis under normal and stress conditions, as well as in disease states, particularly in cancer. However, the role of E3s in the initiation of human tumors is poorly understood. Previously, we reported that genetic ablation of the HECT-type E3 ubiquitin ligase Smurf2 induces carcinogenesis in mice; but whether and how these findings are pertinent to the inception of human cancer remain unknown. Here we show that SMURF2 is essential to protect human dermal fibroblasts (HDFs) from malignant transformation, and its depletion converts HDFs into tumorigenic entity. This phenomenon was associated with the radical changes in chromatin structural and epigenetic landscape, dysregulated gene expression and cell-cycle control, mesenchymal-to-epithelial transition and impaired DNA damage response. Furthermore, we show that SMURF2-mediated tumor suppression is interlinked with SMURF2's ability to regulate the expression of two central chromatin modifiers-an E3 ubiquitin ligase RNF20 and histone methyltransferase EZH2. Silencing these factors significantly reduced the growth and transformation capabilities of SMURF2-depleted cells. Finally, we demonstrate that SMURF2-compromised HDFs are highly tumorigenic in nude mice. These findings suggest the critical role that SMURF2 plays in preventing malignant alterations, chromosomal instability and cancer.	[Manikoth Ayyathan, Dhanoop; Koganti, Praveen; Emanuelli, Andrea; Blank, Michael] Bar Ilan Univ, Azrieli Fac Med, Lab Mol & Cellular Canc Biol, IL-1311502 Safed, Israel; [Marcu-Malina, Victoria; Litmanovitch, Talia; Trakhtenbrot, Luba] Sheba Med Ctr, Canc Res Ctr, Hematol Lab, Ramat Gan, Israel; [Apel-Sarid, Liat] Galilee Med Ctr, Dept Pathol, IL-22100 Nahariyya, Israel	Bar Ilan University; Chaim Sheba Medical Center; Western Galilee Hospital	Blank, M (corresponding author), Bar Ilan Univ, Azrieli Fac Med, Lab Mol & Cellular Canc Biol, IL-1311502 Safed, Israel.	michael.blank@biu.ac.il	Emanuelli, Andrea/AAJ-8175-2020	Koganti, Praveen/0000-0002-9708-0996; Manikoth Ayyathan, Dhanoop/0000-0001-8214-1381	ICRF [00636]; Marie-Curie FP-7 CIG [612816]; Israel Cancer Association [20160073, 20171153, 20200007]; Dayan Family Foundation	ICRF; Marie-Curie FP-7 CIG; Israel Cancer Association; Dayan Family Foundation	We thank Sandy Boutros Suleiman for helping with some data acquisition/analysis, Gal Levy-Cohen for important administrative support, and Meir Shamay for the helpful discussions during the manuscript preparation. This work was supported by the following grants: ICRF (#00636), Marie-Curie FP-7 CIG (#612816), and Israel Cancer Association (#20160073, #20171153, and #20200007) grants awarded to MB. We are very grateful to Dayan Family Foundation for their continued support of our research.	Abdollahi E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082399; Ayyathan DM, 2017, ANAL BIOCHEM, V531, P56, DOI 10.1016/j.ab.2017.05.024; Blank M, 2001, ONCOL RES, V12, P409; Blank M, 2006, J CELL BIOL, V174, P195, DOI 10.1083/jcb.200604022; Blank M, 2012, NAT MED, V18, P227, DOI 10.1038/nm.2596; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Borroni AP, 2018, AGING CELL, V17, DOI 10.1111/acel.12732; Chandhoke AS, 2016, CELL DEATH DIFFER, V23, P876, DOI 10.1038/cdd.2015.152; de Magalhaes JP, 2002, FEBS LETT, V523, P157, DOI 10.1016/S0014-5793(02)02973-3; Du JX, 2011, J BIOL CHEM, V286, P40354, DOI 10.1074/jbc.M111.258707; Emanuelli A, 2019, CANCERS, V11, DOI 10.3390/cancers11040556; Emanuelli A, 2017, CANCER RES, V77, P4217, DOI 10.1158/0008-5472.CAN-16-2828; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Fukuchi M, 2001, MOL BIOL CELL, V12, P1431, DOI 10.1091/mbc.12.5.1431; Genna A, 2018, J CELL BIOL, V217, P375, DOI 10.1083/jcb.201702184; Grade Marian, 2015, Recent Results Cancer Res, V200, P115, DOI 10.1007/978-3-319-20291-4_6; Howe B, 2014, JOVE-J VIS EXP, DOI 10.3791/50203; Huang PS, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051463; Jeong HM, 2014, BBA-MOL CELL RES, V1843, P2005, DOI 10.1016/j.bbamcr.2014.04.023; Johnston ST, 2015, BMC SYST BIOL, V9, DOI 10.1186/s12918-015-0182-y; Jolly MK, 2019, PHARMACOL THERAPEUT, V194, P161, DOI 10.1016/j.pharmthera.2018.09.007; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kim S, 2010, J BIOL CHEM, V285, P36420, DOI 10.1074/jbc.M110.137471; Koganti P, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00295; Kong YH, 2011, AGING CELL, V10, P1038, DOI 10.1111/j.1474-9726.2011.00746.x; Kumaravel TS, 2009, CELL BIOL TOXICOL, V25, P53, DOI 10.1007/s10565-007-9043-9; Li Y, 2014, CANCER RES, V74, P6107, DOI 10.1158/0008-5472.CAN-14-0389; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Liu XP, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-57; McGowan-Jordan J, 2016, INT STANDING COMMITT; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nie J, 2010, J BIOL CHEM, V285, P22816, DOI 10.1074/jbc.M110.126920; Osmundson EC, 2008, J CELL BIOL, V183, P267, DOI 10.1083/jcb.200801049; Padilla-Nash HM, 2006, NAT PROTOC, V1, P3129, DOI 10.1038/nprot.2006.358; Popovic D, 2014, NAT MED, V20, P1242, DOI 10.1038/nm.3739; Ramkumar C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3598; Ramkumar C, 2012, CANCER RES, V72, P2714, DOI 10.1158/0008-5472.CAN-11-3773; Ray D, 2011, NEOPLASIA, V13, P570, DOI 10.1593/neo.11632; Schaeffer D, 2014, MOL CELL BIOL, V34, P3486, DOI 10.1128/MCB.00694-14; Senft D, 2018, NAT REV CANCER, V18, P69, DOI 10.1038/nrc.2017.105; Shechter D, 2007, NAT PROTOC, V2, P1445, DOI 10.1038/nprot.2007.202; Shukla S, 2014, NEOPLASIA, V16, P115, DOI 10.1593/neo.14184; Spagnol ST, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146244; Williams ED, 2019, NAT REV CANCER, V19, P716, DOI 10.1038/s41568-019-0213-x; Wu QQ, 2009, EXP CELL RES, V315, P2386, DOI 10.1016/j.yexcr.2009.05.019; Yu L, 2019, CANCER LETT, V448, P40, DOI 10.1016/j.canlet.2019.01.039; Yu YL, 2013, EMBO MOL MED, V5, P531, DOI 10.1002/emmm.201201783; Yuan B, 2019, EMBO J, V38, DOI 10.15252/embj.201899945; Zhang H, 2004, GENE DEV, V18, P3028, DOI 10.1101/gad.1253004; Zhang WL, 2015, INT J ONCOL, V47, P1043, DOI 10.3892/ijo.2015.3076; Zou X, 2015, BBA-REV CANCER, V1856, P91, DOI 10.1016/j.bbcan.2015.06.005	51	12	12	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2020	39	16					3396	3410		10.1038/s41388-020-1226-3	http://dx.doi.org/10.1038/s41388-020-1226-3		FEB 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF9OJ	32103168				2022-12-28	WOS:000516683200001
J	Chobrutskiy, BI; Yeagley, M; Tipping, P; Zaman, S; Diviney, A; Patel, DN; Falasiri, S; Uversky, VN; Blanck, G				Chobrutskiy, Boris, I; Yeagley, Michelle; Tipping, Price; Zaman, Saif; Diviney, Andrea; Patel, Dhruv N.; Falasiri, Shayan; Uversky, Vladimir N.; Blanck, George			Chemical complementarity between immune receptor CDR3s and IDH1 mutants correlates with increased survival for lower grade glioma	ONCOGENE			English	Article							PERIPHERAL-BLOOD; DISTINCT; SEQUENCE; IDENTIFICATION; LYMPHOCYTES; MECHANISMS; MELANOMA; DATASETS; GENES	Focusing on highly specific aspects of the immune response is likely to answer a number of basic questions, and in some cases even resolve basic contradictions, in cancer immunology. For example, there are many cases, where chronic inflammation is associated with cancer development, and many other cases where an immune response represents an anticancer process. In this study, using bioinformatics algorithms, we examined the chemical relationships between the amino acid sequences of the complementarity-determining region-3 (CDR3) represented by immune receptors associated with lower grade glioma and isocitrate dehydrogenase-1 (IDH1) mutants. In particular, we developed a chemical complementarity scoring approach to classify tumors based on the complementarity of CDR3s and mutant IDH1 amino acids, relying on net charge per residue and hydropathy parameters. There was a strong correlation between the increased survival in low-grade glioma (LGG) and complementarity of IDH1 mutants to the CDR3 domain of the T-cell receptor beta chain (TRB). Similar results were obtained for TRB CDR3s and NRAS mutants in melanoma. Furthermore, the clear connection between increased survival rates and immune receptor-IDH1 mutant complementarities may also, partially, explain the better LGG prognosis for patients with IDH1 mutants.	[Chobrutskiy, Boris, I; Yeagley, Michelle; Tipping, Price; Zaman, Saif; Diviney, Andrea; Patel, Dhruv N.; Falasiri, Shayan; Uversky, Vladimir N.; Blanck, George] Univ S Florida, Morsani Coll Med, Dept Mol Med, Tampa, FL 33612 USA; [Zaman, Saif; Blanck, George] H Lee Moffitt Canc Ctr & Res Inst, Immunol Program, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute	Blanck, G (corresponding author), Univ S Florida, Morsani Coll Med, Dept Mol Med, Tampa, FL 33612 USA.; Blanck, G (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Immunol Program, Tampa, FL 33612 USA.	gblanck@health.usf.edu	Uversky, Vladimir N./F-4515-2011	Uversky, Vladimir N./0000-0002-4037-5857; Patel, Dhruv/0000-0002-9888-7783; Falasiri, Seyed Shayan/0000-0002-8701-5146	USF Morsani College of Medicine RISE fellowships	USF Morsani College of Medicine RISE fellowships	Authors thank USF research computing and the taxpayers of the State of Florida. BIC, SZ, SF, MY and AD were recipients of USF Morsani College of Medicine RISE fellowships.	[Anonymous], 2014, Cancer Discov, V4, pOF13, DOI 10.1158/2159-8290.CD-RW2014-145; Berghoff AS, 2017, NEURO-ONCOLOGY, V19, P1460, DOI 10.1093/neuonc/nox054; Chen G, 2017, CELL REP, V19, P569, DOI 10.1016/j.celrep.2017.03.072; Chen WW, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.28; Chobrutskiy BI, 2019, J CANCER RES CLIN, V145, P615, DOI 10.1007/s00432-018-2815-1; Chobrutskiy BI, 2018, J NEURO-ONCOL, V140, P697, DOI 10.1007/s11060-018-03001-1; Cohen AL, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0345-4; Davidson TB, 2019, CLIN CANCER RES, V25, P1913, DOI 10.1158/1078-0432.CCR-18-1176; Dutoit V, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1391972; Fisler DA, 2018, ONCOL LETT, V16, P2757, DOI 10.3892/ol.2018.8957; Gros A, 2016, NAT MED, V22, P433, DOI 10.1038/nm.4051; Han S, 2014, BRIT J CANCER, V110, P2560, DOI 10.1038/bjc.2014.162; Holehouse AS, 2017, BIOPHYS J, V112, P16, DOI 10.1016/j.bpj.2016.11.3200; KIMURA H, 1988, J IMMUNOL, V140, P1212; Kiviniemi A, 2015, J NEURO-ONCOL, V124, P237, DOI 10.1007/s11060-015-1829-7; Leu S, 2013, NEURO-ONCOLOGY, V15, P469, DOI 10.1093/neuonc/nos317; Mauro JA, 2017, GENE, V614, P37, DOI 10.1016/j.gene.2017.02.026; Mauro JA, 2015, GENE, V554, P50, DOI 10.1016/j.gene.2014.10.021; Mauro JA, 2014, GENE, V536, P398, DOI 10.1016/j.gene.2013.11.013; Metellus P, 2010, ACTA NEUROPATHOL, V120, P719, DOI 10.1007/s00401-010-0777-8; Roca AM, 2019, HUM IMMUNOL, V80, P237, DOI 10.1016/j.humimm.2019.01.005; Schumacher T, 2014, NATURE, V512, P324, DOI 10.1038/nature13387; Sikaria D, 2018, J CANCER RES CLIN, V144, P459, DOI 10.1007/s00432-017-2569-1; Syed P, 2015, SCI REP-UK, V5, DOI 10.1038/srep13895; Thorsson V, 2018, IMMUNITY, V48, P812, DOI [10.1016/j.immuni.2018.03.023, 10.1016/j.immuni.2019.08.004]; Tong WL, 2019, BREAST CANCER RES TR, V173, P167, DOI 10.1007/s10549-018-4961-1; Tsuchiya Y, 2018, IMMUNOLOGY, V153, P466, DOI 10.1111/imm.12849; Yin QS, 2010, HEMATOLOGY, V15, P48, DOI 10.1179/102453310X12583347009694; You ZB, 2006, CANCER RES, V66, P175, DOI 10.1158/0008-5472.CAN-05-1130; Zaman S, 2019, ONCOL REP, V41, P1359, DOI 10.3892/or.2018.6896; Zaman S, 2019, CLIN BIOCHEM, V63, P85, DOI 10.1016/j.clinbiochem.2018.11.004; Zaman S, 2018, BIOCHEM BIOPH RES CO, V503, P2218, DOI 10.1016/j.bbrc.2018.06.141; Zhang J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099255; Zhou CY, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00983	34	16	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	8					1773	1783		10.1038/s41388-019-1101-2	http://dx.doi.org/10.1038/s41388-019-1101-2			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN6CG	31740784				2022-12-28	WOS:000514923000011
J	Ran, R; Harrison, H; Ariffin, NS; Ayubi, R; Pegg, HJ; Deng, WS; Mastro, A; Ottewell, PD; Mason, SM; Blyth, K; Holen, I; Shore, P				Ran, Ran; Harrison, Hannah; Ariffin, Nur Syamimi; Ayubi, Rahna; Pegg, Henry J.; Deng, Wensheng; Mastro, Andrea; Ottewell, Penny D.; Mason, Susan M.; Blyth, Karen; Holen, Ingunn; Shore, Paul			A role for CBF beta in maintaining the metastatic phenotype of breast cancer cells	ONCOGENE			English	Article							RUNX FAMILY; STEM-CELLS; EXPRESSION; PLASTICITY; MORPHOGENESIS; EMT	Epithelial to mesenchymal transition (EMT) is a dynamic process that drives cancer cell plasticity and is thought to play a major role in metastasis. Here we show, using MDA-MB-231 cells as a model, that the plasticity of at least some metastatic breast cancer cells is dependent on the transcriptional co-regulator CBF beta. We demonstrate that CBF beta is essential to maintain the mesenchymal phenotype of triple-negative breast cancer cells and that CBF beta-depleted cells undergo a mesenchymal to epithelial transition (MET) and re-organise into acini-like structures, reminiscent of those formed by epithelial breast cells. We subsequently show, using an inducible CBF beta system, that the MET can be reversed, thus demonstrating the plasticity of CBF beta-mediated EMT. Moreover, the MET can be reversed by expression of the EMT transcription factor Slug whose expression is dependent on CBF beta. Finally, we demonstrate that loss of CBF beta inhibits the ability of metastatic breast cancer cells to invade bone cell cultures and suppresses their ability to form bone metastases in vivo. Together our findings demonstrate that CBF beta can determine the plasticity of the metastatic cancer cell phenotype, suggesting that its regulation in different micro-environments may play a key role in the establishment of metastatic tumours.	[Ran, Ran; Harrison, Hannah; Ariffin, Nur Syamimi; Ayubi, Rahna; Pegg, Henry J.; Shore, Paul] Univ Manchester, Fac Biol Med & Hlth, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England; [Deng, Wensheng] Wuhan Univ Sci & Technol, Jishi Rd, Wuhan 430065, Hubei, Peoples R China; [Mastro, Andrea] Penn State Univ, 428 South Frear Lab,Univ Pk, Philadelphia, PA 16802 USA; [Ottewell, Penny D.; Holen, Ingunn] Univ Sheffield, Dept Oncol & Metab, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England; [Mason, Susan M.; Blyth, Karen] CRUK Beatson Inst, Garscube Estate, Glasgow G61 1BD, Lanark, Scotland; [Blyth, Karen] Univ Glasgow, Inst Canc Sci, Glasgow G61 1QH, Lanark, Scotland	University of Manchester; Wuhan University of Science & Technology; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; University of Sheffield; Beatson Institute; University of Glasgow	Shore, P (corresponding author), Univ Manchester, Fac Biol Med & Hlth, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.; Holen, I (corresponding author), Univ Sheffield, Dept Oncol & Metab, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.	i.holen@sheffield.ac.uk; paul.shore@manchester.ac.uk	Ariffin, Nur Syamimi/AAJ-3580-2020	Ariffin, Nur Syamimi/0000-0002-4183-8147; Ottewell, Penelope/0000-0002-4826-0771; Holen, Ingunn/0000-0002-8759-6913; Shore, Paul/0000-0002-1832-5976	Breast Cancer Now [PR018]; Cancer Research UK PhD Studentship; BBSRC PhD studentship; Manchester Alumni fund	Breast Cancer Now; Cancer Research UK PhD Studentship(Cancer Research UK); BBSRC PhD studentship(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Manchester Alumni fund	The work was funded by Breast Cancer Now (2013 May PR018; PS, IH and HH), a Cancer Research UK PhD Studentship (PS and HP), a BBSRC PhD studentship and the Manchester Alumni fund.	Banerji S, 2012, NATURE, V486, P405, DOI 10.1038/nature11154; Bianchini G, 2016, NAT REV CLIN ONCOL, V13, P674, DOI 10.1038/nrclinonc.2016.66; Browne G, 2016, TUMOR BIOL, V37, P8825, DOI 10.1007/s13277-015-4710-6; Browne G, 2015, J CELL PHYSIOL, V230, P2522, DOI 10.1002/jcp.24989; Chaffer CL, 2016, CANCER METAST REV, V35, P645, DOI 10.1007/s10555-016-9648-7; Chimge NO, 2013, ONCOGENE, V32, P2121, DOI 10.1038/onc.2012.328; Chimge NO, 2017, CELL CYCLE, V16, P312, DOI 10.1080/15384101.2016.1237325; Chimge NO, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3073; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Deng WS, 2012, P NATL ACAD SCI USA, V109, P1524, DOI 10.1073/pnas.1107879109; Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143; Ferrari N, 2015, SCI REP-UK, V5, DOI 10.1038/srep15658; Ferreira NC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084531; Harrison H, 2010, CANCER RES, V70, P709, DOI 10.1158/0008-5472.CAN-09-1681; Holen I, 2016, ONCOTARGET, V7, P75571, DOI 10.18632/oncotarget.12289; Hong D, 2017, ONCOTARGET, V8, P17610, DOI 10.18632/oncotarget.15381; Illendula A, 2016, EBIOMEDICINE, V8, P117, DOI 10.1016/j.ebiom.2016.04.032; Ingthorsson S, 2016, J MAMMARY GLAND BIOL, V21, P139, DOI 10.1007/s10911-016-9366-3; Ito Y, 2015, NAT REV CANCER, V15, P81, DOI 10.1038/nrc3877; Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004; Kim DH, 2018, J CLIN MED, V7, DOI 10.3390/jcm7010001; Kulkarni Madhura, 2018, Oncotarget, V9, P14175, DOI 10.18632/oncotarget.24419; Luo M, 2015, CURR PHARM DESIGN, V21, P1301, DOI 10.2174/1381612821666141211120604; Mastro AM, 2009, CANCER RES, V69, P4097, DOI 10.1158/0008-5472.CAN-08-4437; McDonald L, 2014, DIS MODEL MECH, V7, P525, DOI 10.1242/dmm.015040; Mendoza-Villanueva D, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3048; Mendoza-Villanueva D, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-171; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Pratap J, 2011, BONE, V48, P30, DOI 10.1016/j.bone.2010.05.035; Pratap J, 2009, CANCER RES, V69, P6807, DOI 10.1158/0008-5472.CAN-09-1471; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Rooney N, 2017, ADV EXP MED BIOL, V962, P353, DOI 10.1007/978-981-10-3233-2_22; Shaw FL, 2012, J MAMMARY GLAND BIOL, V17, P111, DOI 10.1007/s10911-012-9255-3; Shore P, 2005, J CELL BIOCHEM, V96, P484, DOI 10.1002/jcb.20557; Shore P, 2002, NUCLEIC ACIDS RES, V30, P1767, DOI 10.1093/nar/30.8.1767; Tahirov TH, 2017, ADV EXP MED BIOL, V962, P21, DOI 10.1007/978-981-10-3233-2_2; van Bragt MPA, 2014, ELIFE, V3, DOI 10.7554/eLife.03881; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897; Zhu YY, 2014, CLIN TRANSL MED, V3, DOI 10.1186/s40169-014-0032-3	39	5	5	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	12					2624	2637		10.1038/s41388-020-1170-2	http://dx.doi.org/10.1038/s41388-020-1170-2		JAN 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KW4HU	32005976	Green Accepted, Green Published, hybrid			2022-12-28	WOS:000510346700003
J	McGinn, O; Ward, AV; Fettig, LM; Riley, D; Ivie, J; Paul, KV; Kabos, P; Finlay-Schultz, J; Sartorius, CA				McGinn, Olivia; Ward, Ashley, V; Fettig, Lynsey M.; Riley, Duncan; Ivie, Joshua; Paul, Kiran, V; Kabos, Peter; Finlay-Schultz, Jessica; Sartorius, Carol A.			Cytokeratin 5 alters beta-catenin dynamics in breast cancer cells	ONCOGENE			English	Article							NEGATIVE RESPONSE ELEMENTS; GROWTH-FACTOR RECEPTOR; STEM-CELLS; KERATIN 17; PROGESTERONE-RECEPTORS; EPITHELIAL PROGENITORS; ESTROGEN-RECEPTOR; MASS-SPECTROMETRY; RETINOIC ACID; CROSS-TALK	Estrogen receptor (ER) positive breast cancers often contain subpopulations of cells that express the intermediate filament protein cytokeratin 5 (CK5). CK5+ cells are enriched in cancer stem cell (CSC) properties, can be induced by progestins, and predict poor prognosis in ER+ breast cancer. We established through CK5 knockout and overexpression in ER+ breast cancer cell lines that CK5 is important for tumorsphere formation, prompting us to speculate that CK5 has regulatory activity in CSCs. To interrogate CK5 interacting proteins that may be functionally cooperative, we performed immunoprecipitation-mass spectrometry for CK5 in ER+ breast cancer cells. Focusing on proteins with signaling activity, we identified beta-catenin, a key transcription factor of the Wnt signaling pathway and cell adhesion molecule, as a CK5 interactor, which we confirmed by co-immunoprecipitation in several breast cancer models. We interrogated the dual functions of beta-catenin in relation to CK5. Knockout or knockdown of CK5 ablated beta-catenin transcriptional activity in response to progestins and Wnt stimuli. Conversely, CK5 induced by progestins or overexpression was sufficient to promote the loss of beta-catenin at the cell membrane and total E-cadherin loss. A breast cancer patient-derived xenograft showed similar loss of membrane beta-catenin and E-cadherin in CK5+ but not intratumoral CK5- cells and single-cell RNA sequencing found the top enriched pathways in the CK5+ cell cluster were cell junction remodeling and signaling. This report highlights that CK5 actively remodels cell morphology and that blockade of CK5-beta-catenin interaction may reverse the detrimental properties of CK5+ breast cancer cells.	[McGinn, Olivia; Ward, Ashley, V; Fettig, Lynsey M.; Riley, Duncan; Ivie, Joshua; Finlay-Schultz, Jessica; Sartorius, Carol A.] Univ Colorado, Dept Pathol, Anschutz Med Campus, Aurora, CO 80045 USA; [Paul, Kiran, V; Kabos, Peter] Univ Colorado, Dept Med, Div Med Oncol, Anschutz Med Campus, Aurora, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Sartorius, CA (corresponding author), Univ Colorado, Dept Pathol, Anschutz Med Campus, Aurora, CO 80045 USA.	Carol.Sartorius@cuanschutz.edu	; McGinn, Olivia/J-8337-2015	Riley, Duncan/0000-0003-1829-7116; Vinod Paul, Kiran/0000-0002-1212-4217; Finlay-Schultz, Jessica/0000-0002-7855-9870; McGinn, Olivia/0000-0003-0769-5581	National Institutes of Health [NIH F31 CA232456, NIH 2R01 CA140985]; Breast Cancer Research Foundation	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Breast Cancer Research Foundation	We thank the University of Colorado School of Medicine Biological Mass Spectrometry Facility and Advanced Light Microscopy Core for their assistance. This work was supported by National Institutes of Health grants NIH F31 CA232456 (OM), NIH 2R01 CA140985 (CAS), and the Breast Cancer Research Foundation (CAS).	Abdelrahman AE, 2017, ANN DIAGN PATHOL, V28, P43, DOI 10.1016/j.anndiagpath.2017.01.009; Axlund SD, 2013, HORM CANCER-US, V4, P36, DOI 10.1007/s12672-012-0127-5; Bocker W, 2002, LAB INVEST, V82, P737, DOI 10.1097/01.LAB.0000017371.72714.C5; Boecker W, 2003, CELL PROLIFERAT, V36, P73, DOI 10.1046/j.1365-2184.36.s.1.7.x; Boudreau A, 2013, P NATL ACAD SCI USA, V110, pE3937, DOI 10.1073/pnas.1315022110; Brisken C, 2000, GENE DEV, V14, P650; Callipo L, 2010, ANAL BIOCHEM, V400, P195, DOI 10.1016/j.ab.2010.01.039; Cheang MCU, 2008, CLIN CANCER RES, V14, P1368, DOI 10.1158/1078-0432.CCR-07-1658; Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Coulombe PA, 2002, CURR OPIN CELL BIOL, V14, P110, DOI 10.1016/S0955-0674(01)00301-5; Melo FDE, 2016, CANCERS, V8, DOI 10.3390/cancers8070060; DePianto D, 2010, NAT GENET, V42, P910, DOI 10.1038/ng.665; Dolled-Filhart M, 2006, CANCER RES, V66, P5487, DOI 10.1158/0008-5472.CAN-06-0100; Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580-018-0080-4; Escobar-Hoyos LF, 2015, CANCER RES, V75, P3650, DOI 10.1158/0008-5472.CAN-15-0293; Faivre EJ, 2007, MOL CELL BIOL, V27, P466, DOI 10.1128/MCB.01539-06; Farahani E, 2014, CARCINOGENESIS, V35, P747, DOI 10.1093/carcin/bgu045; Fettig LM, 2017, ONCOGENE, V36, P6074, DOI 10.1038/onc.2017.204; Finlay-Schultz J, 2017, CANCER RES, V77, P4934, DOI 10.1158/0008-5472.CAN-16-3541; Furthauer M, 2009, MOL ONCOL, V3, P339, DOI 10.1016/j.molonc.2009.05.006; Goodman CR, 2016, ONCOGENE, V35, P1373, DOI 10.1038/onc.2015.193; Gusterson BA, 2005, BREAST CANCER RES, V7, P143, DOI 10.1186/bcr1041; Gusterson B, 2009, NAT REV CANCER, V9, P128, DOI 10.1038/nrc2571; Hammond MEH, 2010, J CLIN ONCOL, V28, P2784, DOI 10.1200/JCO.2009.25.6529; Hartwell KA, 2013, NAT CHEM BIOL, V9, P840, DOI [10.1038/nchembio.1367, 10.1038/NCHEMBIO.1367]; Haughian JM, 2012, P NATL ACAD SCI USA, V109, P2742, DOI 10.1073/pnas.1106509108; Herrmann H, 2009, J CLIN INVEST, V119, P1772, DOI 10.1172/JCI38214; Holland JD, 2013, CURR OPIN CELL BIOL, V25, P254, DOI 10.1016/j.ceb.2013.01.004; Horwitzt KB, 2008, P NATL ACAD SCI USA, V105, P5774, DOI 10.1073/pnas.0706216105; Howard S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023899; Jho SH, 2001, J BIOL CHEM, V276, P45914, DOI 10.1074/jbc.M103144200; Joshi PA, 2010, NATURE, V465, P803, DOI 10.1038/nature09091; Kabos P, 2012, BREAST CANCER RES TR, V135, P415, DOI 10.1007/s10549-012-2164-8; Kabos P, 2011, BREAST CANCER RES TR, V128, P45, DOI 10.1007/s10549-010-1078-6; Kam Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004580; Khanom R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161163; Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125; Kim S, 2006, NATURE, V441, P362, DOI 10.1038/nature04659; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kowalski PJ, 2003, BREAST CANCER RES, V5, pR217, DOI 10.1186/bcr651; Kreplak L, 2004, EXP CELL RES, V301, P77, DOI 10.1016/j.yexcr.2004.08.021; Ku NO, 2004, J CELL BIOL, V166, P479, DOI 10.1083/jcb.200402051; Laakso M, 2006, CLIN CANCER RES, V12, P4185, DOI 10.1158/1078-0432.CCR-06-0353; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Lindstrom LS, 2018, JNCI-J NATL CANCER I, V110, P726, DOI 10.1093/jnci/djx270; Malzahn K, 1998, VIRCHOWS ARCH, V433, P119, DOI 10.1007/s004280050226; Mellacheruvu D, 2013, NAT METHODS, V10, P730, DOI 10.1038/nmeth.2557; Mikami T, 2015, VIRCHOWS ARCH, V466, P559, DOI 10.1007/s00428-015-1735-6; Moll R, 2008, HISTOCHEM CELL BIOL, V129, P705, DOI 10.1007/s00418-008-0435-6; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917; Pan HC, 2017, NEW ENGL J MED, V377, P1836, DOI 10.1056/NEJMoa1701830; Radoja N, 1997, J INVEST DERMATOL, V109, P566, DOI 10.1111/1523-1747.ep12337483; Roarty K, 2010, CURR OPIN PHARMACOL, V10, P643, DOI 10.1016/j.coph.2010.07.004; Sankar S, 2013, MOL CELL BIOL, V33, P4448, DOI 10.1128/MCB.00241-13; Sartorius CA, 2005, CANCER RES, V65, P9779, DOI 10.1158/0008-5472.CAN-05-0505; Sato T, 2014, ONCOGENE, V33, P2215, DOI 10.1038/onc.2013.172; Searle BC, 2010, PROTEOMICS, V10, P1265, DOI 10.1002/pmic.200900437; Siitonen SMKJ, 1995, ANAT PATHOL, V105, P394; Stingl J, 2005, J MAMMARY GLAND BIOL, V10, P49, DOI 10.1007/s10911-005-2540-7; Sutton LM, 2010, AM J CLIN PATHOL, V134, P782, DOI 10.1309/AJCPRMD3ARUO5WPN; Toivola DM, 2010, TRENDS CELL BIOL, V20, P79, DOI 10.1016/j.tcb.2009.11.004; Truong TH, 2019, ENDOCRINOLOGY, V160, P430, DOI 10.1210/en.2018-00990; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; van de Rijn M, 2002, AM J PATHOL, V161, P1991, DOI 10.1016/S0002-9440(10)64476-8; Villadsen R, 2007, J CELL BIOL, V177, P87, DOI 10.1083/jcb.200611114; Wheelock MJ, 2001, J MAMMARY GLAND BIOL, V6, P275, DOI 10.1023/A:1011319507155	71	13	13	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	12					2478	2492		10.1038/s41388-020-1164-0	http://dx.doi.org/10.1038/s41388-020-1164-0		JAN 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KW4HU	31988452	Green Accepted			2022-12-28	WOS:000509655100002
J	O'Connor, CM; Leonard, D; Wiredja, D; Avelar, RA; Wang, ZZ; Schlatzer, D; Bryson, B; Tokala, E; Taylor, SE; Upadhyay, A; Sangodkar, J; Gingras, AC; Westermarck, J; Xu, WQ; DiFeo, A; Brautigan, DL; Haider, S; Jackson, M; Narla, G				O'Connor, Caitlin M.; Leonard, Daniel; Wiredja, Danica; Avelar, Rita A.; Wang, Zhizhi; Schlatzer, Daniela; Bryson, Benjamin; Tokala, Eesha; Taylor, Sarah E.; Upadhyay, Aditya; Sangodkar, Jaya; Gingras, Anne-Claude; Westermarck, Jukka; Xu, Wenqing; DiFeo, Analisa; Brautigan, David L.; Haider, Shozeb; Jackson, Mark; Narla, Goutham			Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors	ONCOGENE			English	Article							PROTEIN PHOSPHATASE 2A; PURIFICATION-MASS SPECTROMETRY; A-ALPHA; SUBUNIT INTERACTION; MOLECULAR-DYNAMICS; COMPLEXES; PPP2R1A; OVARIAN; IDENTIFICATION; SIMULATION	The serine/threonine Protein Phosphatase 2A (PP2A) functions as a tumor suppressor by negatively regulating multiple oncogenic signaling pathways. The canonical PP2A holoenzyme comprises a scaffolding subunit (PP2A A alpha/beta), which serves as the platform for binding of both the catalytic C subunit and one regulatory B subunit. Somatic heterozygous missense mutations in PPP2R1A, the gene encoding the PP2A A alpha scaffolding subunit, have been identified across multiple cancer types, but the effects of the most commonly mutated residue, Arg-183, on PP2A function have yet to be fully elucidated. In this study, we used a series of cellular and in vivo models and discovered that the most frequent A alpha R183W mutation formed alternative holoenzymes by binding of different PP2A regulatory subunits compared with wild-type A alpha, suggesting a rededication of PP2A functions. Unlike wild-type A alpha, which suppressed tumorigenesis, the R183W mutant failed to suppress tumor growth in vivo through activation of the MAPK pathway in RAS-mutant transformed cells. Furthermore, cells expressing R183W were less sensitive to MEK inhibitors. Taken together, our results demonstrate that the R183W mutation in PP2A A alpha scaffold abrogates the tumor suppressive actions of PP2A, thereby potentiating oncogenic signaling and reducing drug sensitivity of RAS-mutant cells.	[O'Connor, Caitlin M.] Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA; [Leonard, Daniel; Taylor, Sarah E.; Jackson, Mark] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA; [Wiredja, Danica; Schlatzer, Daniela] Case Western Reserve Univ, Ctr Prote & Bioinformat, Cleveland, OH 44106 USA; [Avelar, Rita A.; DiFeo, Analisa] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Wang, Zhizhi; Xu, Wenqing] Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA; [Bryson, Benjamin; Tokala, Eesha; Upadhyay, Aditya; Jackson, Mark] Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA; [Sangodkar, Jaya; Narla, Goutham] Univ Michigan, Dept Internal Med Genet Med, Ann Arbor, MI 48109 USA; [Gingras, Anne-Claude] Sinai Hlth Syst, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada; [Gingras, Anne-Claude] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada; [Westermarck, Jukka] Univ Turku, Turku Ctr Biotechnol, Turku, Finland; [Westermarck, Jukka] Abo Akad Univ, Turku, Finland; [DiFeo, Analisa; Narla, Goutham] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA; [DiFeo, Analisa] Univ Michigan, Dept Obstet & Gynecol, Ann Arbor, MI 48109 USA; [Brautigan, David L.] Univ Virginia, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA USA; [Haider, Shozeb] UCL, Dept Pharmaceut & Biol Chem, London, England	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; University of Michigan System; University of Michigan; University of Washington; University of Washington Seattle; Case Western Reserve University; University of Michigan System; University of Michigan; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Turku; Abo Akademi University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Virginia; University of London; University College London	Narla, G (corresponding author), Univ Michigan, Dept Internal Med Genet Med, Ann Arbor, MI 48109 USA.; Narla, G (corresponding author), Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA.	gnarla@med.umich.edu	Westermarck, Jukka/AAL-6464-2020; Gingras, Anne-Claude/E-9982-2010; Narla, Goutham/AAZ-5710-2020; Gingras, Anne-Claude/ABA-8341-2020; Bryson, Benjamin L/D-1070-2014; O'Connor, Caitlin M./AAC-5203-2020; Haider, Shozeb/B-3452-2015	Westermarck, Jukka/0000-0001-7478-3018; Gingras, Anne-Claude/0000-0002-6090-4437; Narla, Goutham/0000-0003-4098-4203; Gingras, Anne-Claude/0000-0002-6090-4437; Bryson, Benjamin L/0000-0003-4131-0200; O'Connor, Caitlin M./0000-0002-7840-6399; Haider, Shozeb/0000-0003-2650-2925; DiFeo, Analisa/0000-0001-8319-6763; Taylor, Sarah/0000-0003-2743-8099	NIH/NCI [R01CA181654, T32GM008803]; National Center for Advancing Translational Sciences (NCATS) component of the National Institutes of Health [4UL1TR000439]; Athymic Animal and Preclinical Therapeutics of the Case Comprehensive Cancer Center at Case Western Reserve University (NIH) [P30 CA043703]; Cytometry and Imaging Microscopy cores of the Case Comprehensive Cancer Center at Case Western Reserve University (NIH) [P30 CA043703]; Pardee-Gerstacker Professorship in Cancer Research	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Center for Advancing Translational Sciences (NCATS) component of the National Institutes of Health; Athymic Animal and Preclinical Therapeutics of the Case Comprehensive Cancer Center at Case Western Reserve University (NIH); Cytometry and Imaging Microscopy cores of the Case Comprehensive Cancer Center at Case Western Reserve University (NIH); Pardee-Gerstacker Professorship in Cancer Research	The authors wish to acknowledge the Young Scientist Foundation and the students who worked on this project through this program, including Aditya Upadhyay. This work was partially supported by the NIH/NCI R01CA181654 (to GN) and T32GM008803 (to CMO). This publication was made possible in part by the Clinical and Translational Science Collaborative of Cleveland, 4UL1TR000439 from the National Center for Advancing Translational Sciences (NCATS) component of the National Institutes of Health and NIH roadmap for Medical Research. This research was supported by the Athymic Animal and Preclinical Therapeutics and Cytometry and Imaging Microscopy cores of the Case Comprehensive Cancer Center at Case Western Reserve University (funded by NIH P30 CA043703). GN is supported by the Pardee-Gerstacker Professorship in Cancer Research.	ABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Bonomi M, 2009, J COMPUT CHEM, V30, P1615, DOI 10.1002/jcc.21305; Calin GA, 2000, ONCOGENE, V19, P1191, DOI 10.1038/sj.onc.1203389; Casado P, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003573; Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290; Caunt CJ, 2015, NAT REV CANCER, V15, P577, DOI 10.1038/nrc4000; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Chen W, 2005, CANCER RES, V65, P8183, DOI 10.1158/0008-5472.CAN-05-1103; Cipriano R, 2011, P NATL ACAD SCI USA, V108, P8668, DOI 10.1073/pnas.1015022108; DeLano WL, 2009, ABSTR PAP AM CHEM S, V238; Doerr S, 2016, J CHEM THEORY COMPUT, V12, P1845, DOI 10.1021/acs.jctc.6b00049; Fabregat A, 2016, NUCLEIC ACIDS RES, V44, pD481, DOI 10.1093/nar/gkv1351; Garbe JC, 2009, CANCER RES, V69, P7557, DOI 10.1158/0008-5472.CAN-09-0270; Grinthal A, 2010, P NATL ACAD SCI USA, V107, P2467, DOI 10.1073/pnas.0914073107; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; Haesen D, 2016, CANCER RES, V76, P5719, DOI 10.1158/0008-5472.CAN-15-3342; Harvey MJ, 2009, J CHEM THEORY COMPUT, V5, P1632, DOI 10.1021/ct9000685; Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q; Hoang LN, 2015, HISTOPATHOLOGY, V66, P664, DOI 10.1111/his.12581; Holt SV, 2012, CANCER RES, V72, P1804, DOI 10.1158/0008-5472.CAN-11-1780; Horn T, 2011, NAT METHODS, V8, P341, DOI 10.1038/NMETH.1581; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Jeong AL, 2016, SCI REP-UK, V6, DOI 10.1038/srep27391; Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333; Junk DJ, 2013, NEOPLASIA, V15, P1086, DOI 10.1593/neo.131114; Kamburov A, 2015, P NATL ACAD SCI USA, V112, pE5486, DOI 10.1073/pnas.1516373112; Kauko O, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aaq1093; Kauko O, 2015, SCI REP-UK, V5, DOI 10.1038/srep13099; Knight JDR, 2017, NAT METHODS, V14, P645, DOI 10.1038/nmeth.4330; Letourneux C, 2006, EMBO J, V33, P3489; McClinch K, 2018, CANCER RES, V78, P2065, DOI 10.1158/0008-5472.CAN-17-0123; Mellacheruvu D, 2013, NAT METHODS, V10, P730, DOI 10.1038/nmeth.2557; Morris JH, 2014, NAT PROTOC, V9, P2539, DOI 10.1038/nprot.2014.164; O'Connor CM, 2019, J BIOL CHEM, V294, P5923, DOI 10.1074/jbc.RA119.007593; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Price DJ, 2004, J CHEM PHYS, V121, P10096, DOI 10.1063/1.1808117; Rahman M, 2013, ANTICANCER RES, V33, P113; Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009; Roberts PJ, 2012, CLIN CANCER RES, V18, P5290, DOI 10.1158/1078-0432.CCR-12-0563; Ruediger R, 2001, ONCOGENE, V20, P1892, DOI 10.1038/sj.onc.1204279; Ruediger R, 2011, MOL CELL BIOL, V31, P3832, DOI 10.1128/MCB.05744-11; Sablina AA, 2007, CELL, V129, P969, DOI 10.1016/j.cell.2007.03.047; Sablina AA, 2010, CANCER RES, V70, P10474, DOI 10.1158/0008-5472.CAN-10-2855; Sangodkar J, 2017, J CLIN INVEST, V127, P2081, DOI 10.1172/JCI89548; Sangodkar J, 2016, FEBS J, V283, P1004, DOI 10.1111/febs.13573; Schlatzer D, 2017, ANAL CHEM, V89, P5325, DOI 10.1021/acs.analchem.6b05070; Seshacharyulu P, 2013, CANCER LETT, V335, P9, DOI 10.1016/j.canlet.2013.02.036; Shi YG, 2009, CELL, V139, P468, DOI 10.1016/j.cell.2009.10.006; Shih IM, 2011, AM J PATHOL, V178, P1442, DOI 10.1016/j.ajpath.2011.01.009; Skliros A, 2012, PHYS BIOL, V9, DOI 10.1088/1478-3975/9/1/014001; Strack S, 2004, J BIOL CHEM, V279, P47732, DOI 10.1074/jbc.M408015200; Taylor SE, 2019, CANCER RES, V79, P4242, DOI 10.1158/0008-5472.CAN-19-0218; Tsytlonok M, 2013, STRUCTURE, V21, P1954, DOI 10.1016/j.str.2013.08.028; Walter G, 2012, CELL CYCLE, V11, P451, DOI 10.4161/cc.11.3.19057; Wiemann S, 2016, NAT METHODS, V13, P191, DOI 10.1038/nmeth.3776; Wiredja DD, 2017, BIOINFORMATICS; Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/nmeth.1322, 10.1038/NMETH.1322]; Zhou J, 2003, BIOCHEM J, V369, P387, DOI 10.1042/BJ20021244	59	18	19	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	3					703	717		10.1038/s41388-019-1012-2	http://dx.doi.org/10.1038/s41388-019-1012-2			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG1RJ	31541192	Green Accepted, Green Submitted			2022-12-28	WOS:000509718300016
J	Smeester, BA; Slipek, NJ; Pomeroy, EJ; Bomberger, HE; Shamsan, GA; Peterson, JJ; Crosby, MR; Draper, GM; Becklin, KL; Rahrmann, EP; McCarthy, JB; Odde, DJ; Wood, DK; Largaespada, DA; Moriarity, BS				Smeester, Branden A.; Slipek, Nicholas J.; Pomeroy, Emily J.; Bomberger, Heather E.; Shamsan, Ghaidan A.; Peterson, Joseph J.; Crosby, Margaret R.; Draper, Garrett M.; Becklin, Kelsie L.; Rahrmann, Eric P.; McCarthy, James B.; Odde, David J.; Wood, David K.; Largaespada, David A.; Moriarity, Branden S.			SEMA4C is a novel target to limit osteosarcoma growth, progression, and metastasis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; GENETIC SCREEN; CELL-GROWTH; TUMOR; SEMAPHORINS; EXPRESSION; PLEXIN-B2	Semaphorins, specifically type IV, are important regulators of axonal guidance and have been increasingly implicated in poor prognoses in a number of different solid cancers. In conjunction with their cognate PLXNB family receptors, type IV members have been increasingly shown to mediate oncogenic functions necessary for tumor development and malignant spread. In this study, we investigated the role of semaphorin 4C (SEMA4C) in osteosarcoma growth, progression, and metastasis. We investigated the expression and localization of SEMA4C in primary osteosarcoma patient tissues and its tumorigenic functions in these malignancies. We demonstrate that overexpression of SEMA4C promotes properties of cellular transformation, while RNAi knockdown of SEMA4C promotes adhesion and reduces cellular proliferation, colony formation, migration, wound healing, tumor growth, and lung metastasis. These phenotypic changes were accompanied by reductions in activated AKT signaling, G1 cell cycle delay, and decreases in expression of mesenchymal marker genes SNAI1, SNAI2, and TWIST1. Lastly, monoclonal antibody blockade of SEMA4C in vitro mirrored that of the genetic studies. Together, our results indicate a multi-dimensional oncogenic role for SEMA4C in metastatic osteosarcoma and more importantly that SEMA4C has actionable clinical potential.	[Smeester, Branden A.; Slipek, Nicholas J.; Pomeroy, Emily J.; Peterson, Joseph J.; Crosby, Margaret R.; Draper, Garrett M.; Becklin, Kelsie L.; Largaespada, David A.; Moriarity, Branden S.] Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA; [Smeester, Branden A.; Slipek, Nicholas J.; Pomeroy, Emily J.; Peterson, Joseph J.; Crosby, Margaret R.; Draper, Garrett M.; Becklin, Kelsie L.; Largaespada, David A.; Moriarity, Branden S.] Univ Minnesota, Ctr Genome Engn, Minneapolis, MN 55455 USA; [Smeester, Branden A.; Slipek, Nicholas J.; Pomeroy, Emily J.; Shamsan, Ghaidan A.; Peterson, Joseph J.; Crosby, Margaret R.; Draper, Garrett M.; Becklin, Kelsie L.; McCarthy, James B.; Odde, David J.; Largaespada, David A.; Moriarity, Branden S.] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA; [Bomberger, Heather E.; Shamsan, Ghaidan A.; Odde, David J.; Wood, David K.] Univ Minnesota, Dept Biomed Engn, Minneapolis, MN USA; [Rahrmann, Eric P.] Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge, England; [McCarthy, James B.] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; University of Minnesota System; University of Minnesota Twin Cities	Moriarity, BS (corresponding author), Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA.; Moriarity, BS (corresponding author), Univ Minnesota, Ctr Genome Engn, Minneapolis, MN 55455 USA.; Moriarity, BS (corresponding author), Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA.	mori0164@umn.edu	Shamsan, Ghaidan A./X-3338-2019; Smeester, Branden A/E-7655-2013; Odde, David/AAY-1720-2020	Shamsan, Ghaidan A./0000-0003-0884-7540; Smeester, Branden A/0000-0001-9421-1711; Odde, David/0000-0001-7731-2799; Pomeroy, Emily/0000-0001-7690-3570	NIH NIAMS [T32 AR050938]; NIH NIAID [T32 AI997313]; Sobiech Osteosarcoma Fund Award; Randy Shaver Cancer and Community Fund; University of Minnesota Foundation; Rein in Sarcoma Foundation; Aflac-AACR Career Development Award; Children's Cancer Research Fund; National Science Foundation through the National Nano Coordinated Infrastructure Network (NNCI) [ECCS-1542202]	NIH NIAMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIH NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Sobiech Osteosarcoma Fund Award; Randy Shaver Cancer and Community Fund; University of Minnesota Foundation(University of Minnesota System); Rein in Sarcoma Foundation; Aflac-AACR Career Development Award; Children's Cancer Research Fund; National Science Foundation through the National Nano Coordinated Infrastructure Network (NNCI)	The authors would like to thank Dr. Kyle Williams for helpful discussion throughout the study, Dr. Sterbs for her intoxicating enthusiasm during the preparation of this paper, Dr. Juan Abrahante for statistical advice, and the Clinical and Translational Science Institute (CSTI) Histology and Research Laboratory team members Dr. Colleen Forester and Lori Holm for tissue preparation and histology services. Author BAS is supported by an NIH NIAMS T32 AR050938 Musculoskeletal Training Grant. Author EJP is supported by an NIH NIAID T32 AI997313 Immunology Training Grant. This work was made possible through funding from the Sobiech Osteosarcoma Fund Award, Randy Shaver Cancer and Community Fund, University of Minnesota Foundation, Rein in Sarcoma Foundation, Aflac-AACR Career Development Award, and the Children's Cancer Research Fund to author BSM Portions of this work were conducted in the Minnesota Nano Center, which is supported by the National Science Foundation through the National Nano Coordinated Infrastructure Network (NNCI) under Award Number ECCS-1542202. SEMA4C RNA expression results in data set #2 were in whole or part based upon data generated by the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) initiative, phs000218, managed by the NCI. The data used are available (dbGaP accession phs000218.v21.p7). Information about TARGET can be found at http://ocg.cancer.gov/programs/target.	Abarrategi A, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/3631764; Alto LT, 2017, METHODS MOL BIOL, V1493, P1, DOI 10.1007/978-1-4939-6448-2_1; Brett ME, 2018, INTEGR BIOL-UK, V10, P242, DOI 10.1039/c7ib00173h; Butti R, 2018, BREAST CANCER-TARGET, V10, P79, DOI 10.2147/BCTT.S135753; Chan CKF, 2018, CELL, V175, P43, DOI 10.1016/j.cell.2018.07.029; Choo S, 2018, PEDIATR BLOOD CANCER, V65, DOI 10.1002/pbc.26721; Clavijo PE, 2019, CANCER IMMUNOL RES, V7, P282, DOI 10.1158/2326-6066.CIR-18-0156; Deng SH, 2007, J NEUROSCI, V27, P6333, DOI 10.1523/JNEUROSCI.5381-06.2007; Evans EE, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1054599; Evans EE, 2015, CANCER IMMUNOL RES, V3, P689, DOI 10.1158/2326-6066.CIR-14-0171; Faustino-Rocha A, 2013, LAB ANIMAL, V42, P217, DOI 10.1038/laban.254; Garcia Z, 2006, EMBO J, V25, P655, DOI 10.1038/sj.emboj.7600967; Gianferante DM, 2017, NAT REV ENDOCRINOL, V13, P480, DOI 10.1038/nrendo.2017.16; Gurrapu S, 2018, CELL DEATH DIFFER, V25, P1259, DOI 10.1038/s41418-018-0097-4; Horvai AE, 2012, MODERN PATHOL, V25, P1452, DOI 10.1038/modpathol.2012.110; Jiang WG, 2015, SEMIN CANCER BIOL, V35, pS244, DOI 10.1016/j.semcancer.2015.03.008; Khanna C, 2000, CLIN EXP METASTAS, V18, P261, DOI 10.1023/A:1006767007547; Kumar S, 2014, MOL BIOSYST, V10, P838, DOI 10.1039/c3mb70431a; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Le AP, 2015, ONCOTARGET, V6, P7293, DOI 10.18632/oncotarget.3421; Leder K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014366; Lee KW, 2014, CANCER LETT, V343, P62, DOI 10.1016/j.canlet.2013.09.013; Lu J, 2018, FASEB J, V32, pfj201800113R; Marko TA, 2016, SCI REP-UK, V6, DOI 10.1038/srep39059; Meazza C, 2016, EXPERT REV ANTICANC, V16, P543, DOI 10.1586/14737140.2016.1168697; Meyer LAT, 2016, CELL ADHES MIGR, V10, P700, DOI 10.1080/19336918.2016.1261785; Mirabello L, 2009, CANCER-AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121; Mori S, 2009, ONCOGENE, V28, P2796, DOI 10.1038/onc.2009.139; Moriarity BS, 2015, NAT GENET, V47, P615, DOI 10.1038/ng.3293; Moriarity BS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096114; Morrow James J., 2015, Critical Reviews in Oncogenesis, V20, P173, DOI 10.1615/CritRevOncog.2015013713; Negishi-Koga T, 2011, NAT MED, V17, P1473, DOI 10.1038/nm.2489; Paldy E, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00341-w; Poleszczuk J, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/3923527; Rahrmann EP, 2013, NAT GENET, V45, P756, DOI 10.1038/ng.2641; Rickel K, 2017, BONE, V102, P69, DOI 10.1016/j.bone.2016.10.017; Roche J, 2018, CANCERS, V10, DOI 10.3390/cancers10020052; Smeester BA, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/387169; Smeester BA, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/671386; Swiercz JM, 2008, J BIOL CHEM, V283, P1893, DOI 10.1074/jbc.M706822200; Tamagnone L, 2012, CANCER CELL, V22, P145, DOI 10.1016/j.ccr.2012.06.031; Wei JC, 2017, CLIN CANCER RES, V23, P214, DOI 10.1158/1078-0432.CCR-16-0741; Worzfeld T, 2014, NAT REV DRUG DISCOV, V13, P603, DOI 10.1038/nrd4337; Xue D, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00558; Yan GN, 2016, CANCER LETT, V370, P268, DOI 10.1016/j.canlet.2015.11.003; Yang QL, 2015, ONCOTARGET, V6, P3268, DOI 10.18632/oncotarget.3065; Ye X, 2015, TRENDS CELL BIOL, V25, P675, DOI 10.1016/j.tcb.2015.07.012; Yin K, 2012, MED ONCOL, V29, P3449, DOI 10.1007/s12032-012-0317-6; Zhou QD, 2013, J HUAZHONG U SCI-MED, V33, P672, DOI 10.1007/s11596-013-1179-7	49	3	4	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	5					1049	1062		10.1038/s41388-019-1041-x	http://dx.doi.org/10.1038/s41388-019-1041-x			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KI2VY	31582836	Green Submitted			2022-12-28	WOS:000511209700008
J	Yousefi, H; Maheronnaghsh, M; Molaei, F; Mashouri, L; Aref, AR; Momeny, M; Alahari, SK				Yousefi, Hassan; Maheronnaghsh, Maryam; Molaei, Fatemeh; Mashouri, Ladan; Aref, Amir Reza; Momeny, Majid; Alahari, Suresh K.			Long noncoding RNAs and exosomal lncRNAs: classification, and mechanisms in breast cancer metastasis and drug resistance	ONCOGENE			English	Review							ENHANCES TAMOXIFEN RESISTANCE; CELL-PROLIFERATION; STEM-CELLS; DOWN-REGULATION; POOR-PROGNOSIS; MESENCHYMAL TRANSITION; MEDIATED TRANSFER; EMERGING ROLES; UP-REGULATION; INACTIVE-X	Breast cancer is the most common cancer, and the second cause of cancer-related deaths (after lung cancer) among women. Developing tumor metastasis and invasion is the most important cause of death in breast cancer patients. Several key factors participate in breast cancer metastasis including long noncoding RNAs (lncRNAs). lncRNAs are a category of cellular RNAs that are longer than 200 nucleotides in length. Accumulating evidence suggests that lncRNAs have the potential to be promising diagnostic, prognostic biomarkers and therapeutic targets in breast cancer. Understanding the role of lncRNAs and their mechanisms of functions might help to further discovery of breast cancer biological characteristics. In this review, we discuss physiological functions, epigenetic regulation, transcriptional regulation of lncRNAs, and their important role in tumor progression and metastasis. Some lncRNAs function as oncogenes and some function as tumor suppressors. Interestingly, recent reports depict that hypomethylation of promoters of lncRNAs play a pivotal role in cancer progression, suggesting the importance of epigenetic regulation. Furthermore, we discuss the role of lncRNAs in exosomes and their function in drug resistance, and therapeutic importance of exosomal lncRNAs in cancer biology. In summary, lncRNAs have a great potential to consider them as novel prognostic biomarkers as well as new therapeutic targets in breast cancer	[Yousefi, Hassan; Alahari, Suresh K.] LSUHSC, Sch Med, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; [Maheronnaghsh, Maryam] Univ Tehran Med Sci, Dept Med Genet, Tehran, Iran; [Molaei, Fatemeh] Mashhad Univ Med Sci, Med Genet Res Ctr, Mashhad, Razavi Khorasan, Iran; [Mashouri, Ladan] Shahrekord Univ, Fac Sci, Dept Genet, Shahrekord, Iran; [Aref, Amir Reza] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Momeny, Majid] Univ Turku, Turku Ctr Biotechnol, Turku, Finland; [Momeny, Majid] Abo Akad Univ, Turku, Finland	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Tehran University of Medical Sciences; Mashhad University Medical Science; Shahrekord University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Turku; Abo Akademi University	Alahari, SK (corresponding author), LSUHSC, Sch Med, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA.	salaha@lsuhsc.edu	Momeny, Majid/AAR-3398-2020					Alipoor FJ, 2018, J CELL BIOCHEM, V119, P6470, DOI 10.1002/jcb.26678; Amodio N, 2018, LEUKEMIA, V32, P1948, DOI 10.1038/s41375-018-0067-3; Angrand PO, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00165; Aram R, 2017, ONCOTARGET, V8, P67538, DOI 10.18632/oncotarget.18733; Arun G, 2016, GENE DEV, V30, P34, DOI 10.1101/gad.270959.115; Augoff K, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-5; Ayers D, 2013, J CANC RES TREATMENT, V1, P31; Bai Y, 2018, EXP THER MED, V16, P2235, DOI 10.3892/etm.2018.6461; Berrondo C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147236; Bester AC, 2018, CELL, V173, P649, DOI 10.1016/j.cell.2018.03.052; Bian EB, 2019, INT J ONCOL, V54, P713, DOI 10.3892/ijo.2018.4644; Brabletz T, 2018, NAT REV CANCER, V18, P128, DOI 10.1038/nrc.2017.118; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; Carrieri C, 2012, NATURE, V491, P454, DOI 10.1038/nature11508; Chang L, 2018, CELL PHYSIOL BIOCHEM, V48, P16, DOI 10.1159/000491659; Chen DQ, 2017, EUR REV MED PHARMACO, V21, P275; Chen S, 2017, CELL DEATH DIS, V8, pe2710; Cojoc M, 2015, SEMIN CANCER BIOL, V31, P16, DOI 10.1016/j.semcancer.2014.06.004; Cooper C, 2009, NUCLEIC ACIDS RES, V37, P4518, DOI 10.1093/nar/gkp441; Dong HY, 2018, INT J ONCOL, V53, P1013, DOI 10.3892/ijo.2018.4467; Dykes IM, 2017, GENOM PROTEOM BIOINF, V15, P177, DOI 10.1016/j.gpb.2016.12.005; Eastlack SC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198945; Evans JR, 2016, J CLIN INVEST, V126, P2775, DOI 10.1172/JCI84421; Fan SL, 2017, BIOMED PHARMACOTHER, V95, P1636, DOI 10.1016/j.biopha.2017.09.076; Fazil MHUT, 2016, SCI REP-UK, V6, DOI 10.1038/srep37721; Ferreira HJ, 2018, CANCER METAST REV, V37, P55, DOI 10.1007/s10555-017-9715-8; Geisler S, 2013, NAT REV MOL CELL BIO, V14, P699, DOI 10.1038/nrm3679; Godinho MFE, 2010, BRIT J CANCER, V103, P1284, DOI 10.1038/sj.bjc.6605884; Godinho M, 2011, J CELL PHYSIOL, V226, P1741, DOI 10.1002/jcp.22503; Gradia Daniela F., 2017, Non-Coding RNA, V3, P26, DOI 10.3390/ncrna3040026; Gu J, 2018, CELL PHYSIOL BIOCHEM, V48, P194, DOI 10.1159/000491718; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Gutschner T, 2013, J MOL MED, V91, P791, DOI 10.1007/s00109-013-1028-y; Guttman M, 2012, NATURE, V482, P339, DOI 10.1038/nature10887; Hanly DJ, 2018, PHILOS T R SOC B, V373, DOI 10.1098/rstb.2017.0074; Hessvik NP, 2018, CELL MOL LIFE SCI, V75, P193, DOI 10.1007/s00018-017-2595-9; Hood JL, 2016, NANOMEDICINE-UK, V11, P1745, DOI 10.2217/nnm-2016-0102; Hou P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.249; Hu HB, 2018, EUR REV MED PHARMACO, V22, P1987, DOI 10.26355/eurrev_201804_14726; Hu XW, 2014, CANCER CELL, V26, P344, DOI 10.1016/j.ccr.2014.07.009; Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040; Hung T, 2011, NAT GENET, V43, P621, DOI 10.1038/ng.848; Janakiraman H, 2018, MOL CANCER RES, V16, P567, DOI 10.1158/1541-7786.MCR-17-0547; Jiang J, 2018, ONCOL LETT, V15, P9543, DOI 10.3892/ol.2018.8513; Jiang ZY, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0853-2; Kaikkonen MU, 2018, TRENDS BIOCHEM SCI, V43, P654, DOI 10.1016/j.tibs.2018.06.002; Kawakami T, 2004, ONCOGENE, V23, P6163, DOI 10.1038/sj.onc.1207808; Keshavarz M, 2019, J CELL BIOCHEM, V120, P18398, DOI 10.1002/jcb.29152; Keshavarz M, 2019, FEBS J, V286, P2611, DOI 10.1111/febs.14825; Kojima R, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03733-8; Koldemir O, 2017, BIOMED REP, V6, P358, DOI 10.3892/br.2017.848; Kong QL, 2018, BIOCHEM BIOPH RES CO, V495, P1594, DOI 10.1016/j.bbrc.2017.12.013; Kooijmans SAA, 2013, J CONTROL RELEASE, V172, P229, DOI 10.1016/j.jconrel.2013.08.014; Kopp F, 2018, CELL, V172, P393, DOI 10.1016/j.cell.2018.01.011; Kotake Y, 2011, ONCOGENE, V30, P1956, DOI 10.1038/onc.2010.568; Krichevsky AM, 2019, NEUROTHERAPEUTICS, V16, P319, DOI 10.1007/s13311-018-00702-3; Lang HL, 2017, EUR REV MED PHARMACO, V21, P959; Li BZ, 2018, ONCOGENE, V37, P5508, DOI 10.1038/s41388-018-0359-0; Li CL, 2019, J CELL PHYSIOL, V234, P20721, DOI 10.1002/jcp.28678; Li CL, 2017, NAT CELL BIOL, V19, P106, DOI 10.1038/ncb3464; Li J, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0707-8; Li JT, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0454-2; Li PC, 2018, INT J MED SCI, V15, P1227, DOI 10.7150/ijms.25662; Li SQ, 2018, BIOMED PHARMACOTHER, V104, P451, DOI 10.1016/j.biopha.2018.05.056; Li SP, 2018, ACTA PHARMACOL SIN, V39, P542, DOI 10.1038/aps.2017.178; Li WX, 2017, EUR REV MED PHARMACO, V21, P3397; Li WT, 2016, ONCOTARGET, V7, P27778, DOI 10.18632/oncotarget.8413; Li XC, 2016, TUMOR BIOL, V37, P7599, DOI 10.1007/s13277-015-4655-9; Li Y, 2018, BIOMED PHARMACOTHER, V103, P939, DOI 10.1016/j.biopha.2018.04.087; Li ZH, 2018, ONCOGENE, V37, P3822, DOI 10.1038/s41388-018-0237-9; Li ZW, 2017, CELL DEATH DIFFER, V24, P59, DOI 10.1038/cdd.2016.95; Liang  Y., 2018, ADV MATER INTERFACES, V5, P1, DOI DOI 10.1017/S0266466617000317; Liang YR, 2018, CANCER BIOL THER, V19, P120, DOI 10.1080/15384047.2017.1394543; Lin AF, 2016, NAT CELL BIOL, V18, P213, DOI 10.1038/ncb3295; Lin YH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123742; Ling H, 2013, NAT REV DRUG DISCOV, V12, P847, DOI 10.1038/nrd4140; Liu CY, 2019, THERANOSTICS, V9, P1015, DOI 10.7150/thno.30853; Liu J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0246-6; Liu Q, 2013, NUCLEIC ACIDS RES, V41, P4976, DOI 10.1093/nar/gkt182; Liu T, 2016, ONCOTARGET, V7, P85551, DOI 10.18632/oncotarget.13465; Liu Yin, 2015, Front Biosci (Schol Ed), V7, P94; Lo PK, 2016, ONCOTARGET, V7, P65067, DOI 10.18632/oncotarget.11364; Long YC, 2017, SCI ADV, V3, DOI 10.1126/sciadv.aao2110; Lu GM, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0945-6; Luan T, 2017, ONCOTARGET, V8, P76153, DOI 10.18632/oncotarget.19190; Luo LY, 2018, ONCOGENE, V37, P6166, DOI 10.1038/s41388-018-0396-8; Ma F, 2019, CANCER LETT, V450, P63, DOI 10.1016/j.canlet.2019.02.008; Marchese FP, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1348-2; Marin-Bejar O, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1331-y; Mashouri L, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0991-5; Mathias C, 2019, CLIN GENET, V95, P558, DOI 10.1111/cge.13502; Maziveyi M, 2019, CANCER RES, V79, P2152, DOI 10.1158/0008-5472.CAN-18-0842; Morlando M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020570; Naderi-Meshkin H, 2018, J BIOINFORM, V35, P352; Niknafs YS, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12791; Niu YY, 2014, INT J CLIN EXP PATHO, V7, P5144; Ozes AR, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00966-3; Pan L, 2017, J CANCER RES CLIN, V143, P991, DOI 10.1007/s00432-017-2361-2; Peng F, 2018, ONCOGENE, V37, P1062, DOI 10.1038/onc.2017.368; Peng F, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.438; Pickard MR, 2015, GENES-BASEL, V6, P484, DOI 10.3390/genes6030484; Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209; Qiu JJ, 2018, INT J BIOL SCI, V14, P1960, DOI 10.7150/ijbs.28048; Qu L, 2016, CANCER CELL, V29, P653, DOI 10.1016/j.ccell.2016.03.004; Richard John Lalith Charles, 2018, Oncotarget, V9, P20179, DOI 10.18632/oncotarget.24591; Rinaldi C, 2018, NAT REV NEUROL, V14, P9, DOI 10.1038/nrneurol.2017.148; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Shi F, 2016, ARCH MED RES, V47, P446, DOI 10.1016/j.arcmed.2016.11.001; Shi SJ, 2015, ONCOTARGET, V6, P11652, DOI 10.18632/oncotarget.3457; Shin VY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1513-5; Si XX, 2016, ONCOTARGET, V7, P81452, DOI 10.18632/oncotarget.13263; Skalska L, 2017, NAT REV MOL CELL BIO, V18, P1, DOI 10.1038/nrm.2017.12; Soifer Harris S., 2011, METHOD MOL BIOL, P333; Su JC, 2017, MOL MED REP, V16, P4887, DOI 10.3892/mmr.2017.7163; Sun H, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0648-7; Sun SJ, 2017, EUR REV MED PHARMACO, V21, P504; Sun W, 2019, INT J CANCER, V145, P842, DOI 10.1002/ijc.32185; Taherian-Esfahani Z, 2019, J CELL PHYSIOL, V234, P22044, DOI 10.1002/jcp.28767; Teng Y, 2019, GENET TEST MOL BIOMA, V23, P235, DOI 10.1089/gtmb.2018.0103; Tu ZB, 2019, STEM CELLS, V37, P1281, DOI 10.1002/stem.3055; Usman WM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04791-8; Vidovic D, 2020, CELL DEATH DIFFER, V27, P363, DOI 10.1038/s41418-019-0362-1; Wang DN, 2016, CELL PHYSIOL BIOCHEM, V40, P644, DOI 10.1159/000452577; Wang FW, 2019, J CLIN INVEST, V129, P727, DOI 10.1172/JCI122478; Wang HH, 2017, ONCOTARGET, V8, P64638, DOI 10.18632/oncotarget.18344; Wang J, 2017, ARCH GYNECOL OBSTET, V295, P1469, DOI 10.1007/s00404-017-4365-1; Wang JS, 2018, MED SCI MONITOR, V24, P9307, DOI 10.12659/MSM.912018; Wang Jin-Peng, 2018, Oncotarget, V9, P12487, DOI 10.18632/oncotarget.23552; Wang M, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12534; Wang MZ, 2018, CANCER SCI, V109, P1764, DOI 10.1111/cas.13592; Wang OC, 2017, AM J TRANSL RES, V9, P533; Wang RM, 2018, J CELL MOL MED, V22, P4068, DOI 10.1111/jcmm.13679; Wang Y, 2017, BIOCHEM BIOPH RES CO, V493, P429, DOI 10.1016/j.bbrc.2017.09.005; Wang YH, 2018, CELL PHYSIOL BIOCHEM, V46, P532, DOI 10.1159/000488620; Wang YL, 2019, BREAST, V46, P64, DOI 10.1016/j.breast.2019.05.003; Wu CH, 2016, MED SCI MONITOR, V22, P3860, DOI 10.12659/MSM.900689; Wu WJ, 2013, GASTROENTEROLOGY, V144, P956, DOI 10.1053/j.gastro.2013.01.019; Wu ZJ, 2017, EUR REV MED PHARMACO, V21, P706; Xia EJ, 2018, AM J CANCER RES, V8, P1273; Xing Z, 2018, CANCER RES, V78, P4524, DOI 10.1158/0008-5472.CAN-17-0385; Xu CG, 2016, EUR REV MED PHARMACO, V20, P4362; Xu J, 2017, CELL PHYSIOL BIOCHEM, V41, P635, DOI 10.1159/000457938; Xu SP, 2015, TUMOR BIOL, V36, P9807, DOI 10.1007/s13277-015-3746-y; Xu SP, 2015, INT J CLIN EXP PATHO, V8, P4881; Xue M, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0714-8; Xue X, 2016, ONCOGENE, V35, P2746, DOI 10.1038/onc.2015.340; Yan MD, 2017, BIOTECHNOL APPL BIOC, V64, P5, DOI 10.1002/bab.1461; Yang F, 2016, BIOCHEM BIOPH RES CO, V470, P479, DOI 10.1016/j.bbrc.2016.01.147; Yang L, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0990-6; Yang QL, 2015, ONCOTARGET, V6, P3268, DOI 10.18632/oncotarget.3065; Yuan ZX, 2016, INT J ONCOL, V48, P2675, DOI 10.3892/ijo.2016.3447; Zeng ZY, 2016, TUMOR BIOL, V37, P729, DOI 10.1007/s13277-015-3860-x; Zhang CY, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317701311; Zhang HY, 2014, STEM CELLS, V32, P2858, DOI 10.1002/stem.1795; Zhang H, 2017, CANCER CHEMOTH PHARM, V79, P49, DOI 10.1007/s00280-016-3194-4; Zhang JY, 2016, INT J ONCOL, V48, P1590, DOI 10.3892/ijo.2016.3385; Zhang M, 2017, EUR REV MED PHARMACO, V21, P1020; Zhang P, 2018, ONCOTARGETS THER, V11, P291, DOI 10.2147/OTT.S155134; Zhang R, 2017, BIOCHEM BIOPH RES CO, V490, P406, DOI 10.1016/j.bbrc.2017.06.055; Zhang XF, 2015, INT J CLIN EXP PATHO, V8, P9440; Zhang ZX, 2015, BIOCHEM BIOPH RES CO, V465, P225, DOI 10.1016/j.bbrc.2015.07.158; Zhang ZR, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1139-6; Zhao Dan, 2018, Non-Coding RNA, V4, P39, DOI 10.3390/ncrna4040039; Zheng A, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1315-8; Zheng R, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0880-3; Zheng RN, 2018, BIOCHEM BIOPH RES CO, V498, P1002, DOI 10.1016/j.bbrc.2018.03.104; Zheng ZQ, 2019, MED SCI MONITOR, V25, P2211, DOI 10.12659/MSM.915419; Zhou ML, 2016, STEM CELLS, V34, P55, DOI 10.1002/stem.2219; Zhou SY, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20180772; Zou QY, 2018, J CELL BIOCHEM, V119, P2189, DOI 10.1002/jcb.26380	170	95	96	1	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	5					953	974		10.1038/s41388-019-1040-y	http://dx.doi.org/10.1038/s41388-019-1040-y			22	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KI2VY	31601996				2022-12-28	WOS:000511209700001
J	Mu, ML; Niu, WX; Zhang, XM; Hu, SS; Niu, CS				Mu, Maolin; Niu, Wanxiang; Zhang, Xiaoming; Hu, Shanshan; Niu, Chaoshi			LncRNA BCYRN1 inhibits glioma tumorigenesis by competitively binding with miR-619-5p to regulate CUEDC2 expression and the PTEN/AKT/p21 pathway	ONCOGENE			English	Article							LONG NONCODING RNA; CANCER; CELLS; PROLIFERATION; DYSREGULATION; RESISTANCE; RECEPTOR; HOTAIR; LEADS	Glioma is the most common malignant tumor in the central nervous system. Altered long noncoding RNAs (lncRNAs) are playing regulatory roles in physiological and pathogenic processes in cancer. Here, we uncovered a differentially expressed lncRNA called brain cytoplasmic RNA 1 (BCYRN1), and elucidated its function and molecular mechanism in the progression and development of glioma. Three fresh tumor tissues from glioma patients and three normal brain tissues from craniocerebral trauma patients were prepared for high-throughput RNA sequencing. Differential RNA transcripts and BCYRN1 were identified by RT-qPCR in glioma samples and controls. CCK-8, colony formation assays, flow cytometry, TUNEL assays, cell migration assays, wound-healing assays, and xenograft model were established to investigate the biological function of BCYRN1 both in vitro and in vivo. Various bioinformatics analysis, dual-luciferase reporter assays, biotinylated RNA pulldown assays, and rescue experiments were conducted to reveal the underlying mechanisms of competitive endogenous RNAs (ceRNAs). 183 lncRNAs were identified with significant dysregulation in glioma and randomly selected differential RNAs were further confirmed by RT-qPCR. Among them, BCYRN1 was the most downregulated lncRNA, and its low expression positively correlated with glioma progression. Functionally, BCYRN1 overexpression inhibited cell proliferation, migration in glioma cell lines, whereas BCYRN1 depletion resulted in the opposite way. MiR-619-5p was further confirmed as the direct target of BCYRN1. Mechanistically, miR-619-5p specifically targeted the CUE domain containing protein 2 (CUEDC2), and BCYRN1/miR-619-5p suppressed glioma tumorigenesis by inactivating PTEN/AKT/p21 pathway in a CUEDC2-dependent manner. Overall, our data presented that the reduced expression of BCYRN1 was associated with poor patient outcome in glioma. BCYRN1 functioned as a ceRNA to inhibit glioma progression by sponging miR-619-5p to regulate CUEDC2 expression and PTEN/AKT/p21 pathway. Our results indicated that BCYRN1 exerted tumor suppressor potential and might be a candidate in the diagnosis and treatment of glioma.	[Mu, Maolin; Niu, Wanxiang; Zhang, Xiaoming; Hu, Shanshan; Niu, Chaoshi] Univ Sci & Technol China, Affiliated Hosp USTC 1, Div Life Sci & Med, Dept Neurosurg, Hefei 230001, Anhui, Peoples R China; [Mu, Maolin; Niu, Wanxiang; Zhang, Xiaoming; Hu, Shanshan; Niu, Chaoshi] Anhui Key Lab Brain Funct & Dis, Hefei 230001, Anhui, Peoples R China; [Hu, Shanshan; Niu, Chaoshi] Anhui Prov Stereotact Neurosurg Inst, Hefei 230001, Anhui, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS	Hu, SS; Niu, CS (corresponding author), Univ Sci & Technol China, Affiliated Hosp USTC 1, Div Life Sci & Med, Dept Neurosurg, Hefei 230001, Anhui, Peoples R China.; Hu, SS; Niu, CS (corresponding author), Anhui Key Lab Brain Funct & Dis, Hefei 230001, Anhui, Peoples R China.; Hu, SS; Niu, CS (corresponding author), Anhui Prov Stereotact Neurosurg Inst, Hefei 230001, Anhui, Peoples R China.	hss923@ustc.edu.cn; niuchaoshi@ustc.edu.cn			National Natural Science Foundation of China [:81902525]; Natural Science Foundation of Anhui Province [1908085QH336]; USTC Research Funds of the Double First-Class Initiative [YD9100002002]; Fundamental Research Funds for the Central Universities [WK9110000033]; Special Fund Project for Guiding Local Science and Technology Development by the Central Government [2017070802D144]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Anhui Province(Natural Science Foundation of Anhui Province); USTC Research Funds of the Double First-Class Initiative; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Special Fund Project for Guiding Local Science and Technology Development by the Central Government	This study was support by the National Natural Science Foundation of China (No:81902525), Natural Science Foundation of Anhui Province (No: 1908085QH336), USTC Research Funds of the Double First-Class Initiative (No: YD9100002002), the Fundamental Research Funds for the Central Universities (No: WK9110000033) and Special Fund Project for Guiding Local Science and Technology Development by the Central Government (No: 2017070802D144).	Ahir BK, 2019, CELL SIGNAL, V53, P22, DOI 10.1016/j.cellsig.2018.09.014; Balci T, 2016, GENE, V590, P120, DOI 10.1016/j.gene.2016.06.024; Bartel DP, 2018, CELL, V173, P20, DOI 10.1016/j.cell.2018.03.006; Booy EP, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0679-7; Bossi L, 2016, NAT REV MICROBIOL, V14, P775, DOI 10.1038/nrmicro.2016.129; Casamassimi A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081652; Chen G, 2019, J CELL PHYSIOL, V234, P18688, DOI 10.1002/jcp.28509; Chen Y, 2014, CELL REP, V7, P1982, DOI 10.1016/j.celrep.2014.05.007; D'Amico RS, 2017, WORLD NEUROSURG, V103, P538, DOI 10.1016/j.wneu.2017.04.041; Deguchi S, 2017, ONCOGENE, V36, P4629, DOI 10.1038/onc.2017.88; Dhir A, 2015, NAT STRUCT MOL BIOL, V22, P319, DOI 10.1038/nsmb.2982; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Ge XL, 2019, ONCOGENE, V38, P3061, DOI 10.1038/s41388-018-0645-x; Han MZ, 2020, BRAIN, V143, P512, DOI 10.1093/brain/awz406; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Hu L, 2017, ONCOGENE, V36, P1145, DOI 10.1038/onc.2016.281; Hu SS, 2016, NAT STRUCT MOL BIOL, V23, P1011, DOI 10.1038/nsmb.3302; Hu SS, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/2681925; Hu T, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0183-3; Hua JJ, 2019, TRENDS GENET, V35, P840, DOI 10.1016/j.tig.2019.08.004; Huang TZ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12885; Iyer MK, 2015, NAT GENET, V47, P199, DOI 10.1038/ng.3192; Jia P, 2016, CANCER LETT, V381, P359, DOI 10.1016/j.canlet.2016.08.009; Karreth FA, 2013, CANCER DISCOV, V3, P1113, DOI 10.1158/2159-8290.CD-13-0202; Katsushima K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13616; Kopp F, 2018, CELL, V172, P393, DOI 10.1016/j.cell.2018.01.011; Kung JTY, 2013, GENETICS, V193, P651, DOI 10.1534/genetics.112.146704; Lauria A, 2020, NUCLEIC ACIDS RES, V48, P1730, DOI 10.1093/nar/gkz1208; Lee JT, 2013, CELL, V152, P1308, DOI 10.1016/j.cell.2013.02.016; Li F, 2017, INT J ONCOL, V51, P115, DOI 10.3892/ijo.2017.4009; Li HY, 2008, NAT IMMUNOL, V9, P533, DOI 10.1038/ni.1600; Li LL, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00849-7; Li ZY, 2015, NAT STRUCT MOL BIOL, V22, P256, DOI 10.1038/nsmb.2959; Lien EC, 2017, CURR OPIN CELL BIOL, V45, P62, DOI 10.1016/j.ceb.2017.02.007; Liu K, 2020, ONCOGENE, V39, P3075, DOI 10.1038/s41388-020-1213-8; Luo S, 2016, CELL STEM CELL, V18, P637, DOI 10.1016/j.stem.2016.01.024; McDonel P, 2019, CSH PERSPECT BIOL, V11, DOI 10.1101/cshperspect.a032151; Pan X, 2011, NAT MED, V17, P708, DOI 10.1038/nm.2369; Pastori C, 2015, P NATL ACAD SCI USA, V112, P8326, DOI 10.1073/pnas.1424220112; Peng J, 2018, ONCOL LETT, V15, P5809, DOI 10.3892/ol.2018.8015; Qiu G, 2016, ONCOL LETT, V12, P5036, DOI 10.3892/ol.2016.5312; Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246; Shao M, 2018, CANCER GENET-NY, V226, P23, DOI 10.1016/j.cancergen.2018.05.001; Singh R, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.168; Slack FJ, 2019, CELL, V179, P1033, DOI 10.1016/j.cell.2019.10.017; Sun B, 2019, ONCOGENE, V38, P6142, DOI 10.1038/s41388-019-0867-6; Sun QY, 2018, TRENDS GENET, V34, P142, DOI 10.1016/j.tig.2017.11.005; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; Thomas C, 2011, NAT MED, V17, P658, DOI 10.1038/nm0611-658; Thomson DW, 2016, NAT REV GENET, V17, P272, DOI 10.1038/nrg.2016.20; Tripathi V, 2010, MOL CELL, V39, P925, DOI 10.1016/j.molcel.2010.08.011; Van Meir EG, 2010, CA-CANCER J CLIN, V60, P166, DOI 10.3322/caac.20069; Wang AC, 2019, J CANCER, V10, P1800, DOI 10.7150/jca.29889; Wang RJ, 2018, CANCER RES, V78, P4812, DOI 10.1158/0008-5472.CAN-18-0532; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Westphal M, 2011, NAT REV NEUROSCI, V12, P495, DOI 10.1038/nrn3060; Wu D, 2016, ONCOL LETT, V11, P1189, DOI 10.3892/ol.2015.3983; Wu PF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10025-2; Wu QY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0812-6; Yu W, 2020, CANCER MANAG RES, V12, P1151, DOI 10.2147/CMAR.S227327; Zhai HB, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20190505; Zhang JX, 2013, NEURO-ONCOLOGY, V15, P1595, DOI 10.1093/neuonc/not131; Zhang PJ, 2007, EMBO J, V26, P1831, DOI 10.1038/sj.emboj.7601602; Zhang SC, 2017, CANCER CELL, V31, P591, DOI 10.1016/j.ccell.2017.02.013; Zhang XY, 2016, AM J TRANSL RES, V8, P3409	66	46	46	3	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 5	2020	39	45					6879	6892		10.1038/s41388-020-01466-x	http://dx.doi.org/10.1038/s41388-020-01466-x		SEP 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ON7IM	32978519	hybrid, Green Published			2022-12-28	WOS:000572714000002
J	Lian, EY; Hyndman, BD; Moodley, S; Maritan, SM; Mulligan, LM				Lian, Eric Y.; Hyndman, Brandy D.; Moodley, Serisha; Maritan, Sarah M.; Mulligan, Lois M.			RET isoforms contribute differentially to invasive processes in pancreatic ductal adenocarcinoma	ONCOGENE			English	Article							CANCER CELL INVASION; NEUROTROPHIC FACTOR; PERINEURAL INVASION; UP-REGULATION; RHO-GTPASES; RECEPTOR; INVADOPODIA; GDNF; FILOPODIA; TKS5	Pancreatic ductal adenocarcinoma (PDAC) is a therapeutically challenging disease with poor survival rates, owing to late diagnosis and early dissemination. These tumors frequently undergo perineural invasion, spreading along nerves regionally and to distant sites. The RET receptor tyrosine kinase is implicated in increased aggressiveness, local invasion, and metastasis in multiple cancers, including PDAC. RET mediates directional motility and invasion towards sources of its neurotrophic factor ligands, suggesting that it may enhance perineural invasion of tumor cells towards nerves. RET is expressed as two main isoforms, RET9 and RET51, which differ in their protein interactions and oncogenic potentials, however, the contributions of RET isoforms to neural invasion have not been investigated. In this study, we generated total RET and isoform-specific knockdown PDAC cell lines and assessed the contributions of RET isoforms to PDAC invasive spread. Our data show that RET activity induces cell polarization and actin remodeling through activation of CDC42 and RHOA GTPases to promote directional motility in PDAC cells. Further, we show that RET interacts with the adaptor protein TKS5 to induce invadopodia formation, enhance matrix degradation and promote tumor cell invasion through a SRC and GRB2-dependent mechanism. Finally, we show that RET51 is the predominant isoform contributing to these RET-mediated invasive processes in PDAC. Together, our work suggests that RET expression in pancreatic cancers may enhance tumor aggressiveness by promoting perineural invasion, and that RET expression may be a valuable marker of invasiveness, and a potential therapeutic target in the treatment of these cancers.	[Lian, Eric Y.; Hyndman, Brandy D.; Moodley, Serisha; Maritan, Sarah M.; Mulligan, Lois M.] Queens Univ, Div Canc Biol & Genet, Canc Res Inst, Kingston, ON K7L 3N6, Canada; [Lian, Eric Y.; Hyndman, Brandy D.; Moodley, Serisha; Maritan, Sarah M.; Mulligan, Lois M.] Queens Univ, Dept Pathol & Mol Med, Kingston, ON K7L 3N6, Canada	Queens University - Canada; McMaster University; Queens University - Canada	Mulligan, LM (corresponding author), Queens Univ, Div Canc Biol & Genet, Canc Res Inst, Kingston, ON K7L 3N6, Canada.; Mulligan, LM (corresponding author), Queens Univ, Dept Pathol & Mol Med, Kingston, ON K7L 3N6, Canada.	mulligal@queensu.ca	Mulligan, Lois/D-1893-2010	Maritan, Sarah/0000-0002-9703-7429; Lian, Eric/0000-0002-2147-5422; Mulligan, Lois/0000-0002-9308-8245; /0000-0003-4096-0922	Cancer Research Society of Canada [19439]; Canadian Institutes for Health Research [MOP-142303, 398979]; Canadian Graduate Scholarship; Terry Fox Research Institute Training Program in Transdisciplinary Cancer Research	Cancer Research Society of Canada; Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Graduate Scholarship; Terry Fox Research Institute Training Program in Transdisciplinary Cancer Research	This work was supported by an operating grant from the Cancer Research Society of Canada (19439) and a Canadian Institutes for Health Research operating grant (MOP-142303 (LMM)) and postdoctoral fellowship (398979 (SM)), and Canadian Graduate Scholarship (SMM) and by Ontario Graduate Scholarships and studentships from the Terry Fox Research Institute Training Program in Transdisciplinary Cancer Research (EYL, SMM).	Abella JV, 2010, J BIOL CHEM, V285, P24956, DOI 10.1074/jbc.M110.127985; Amit M, 2017, ONCOGENE, V36, P3232, DOI 10.1038/onc.2016.483; Amit M, 2019, INT J CANCER, V144, P3014, DOI 10.1002/ijc.32040; Arjonen A, 2011, CELL ADHES MIGR, V5, P421, DOI 10.4161/cam.5.5.17723; Bakst RL, 2016, J NEUROL SURG PART B, V77, P96, DOI 10.1055/s-0036-1571835; Beaty BT, 2014, EUR J CELL BIOL, V93, P438, DOI 10.1016/j.ejcb.2014.07.003; Ben-Chetrit N, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005537; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Bhinge K, 2017, ONCOTARGET, V8, P27155, DOI 10.18632/oncotarget.15676; Boulay A, 2008, CANCER RES, V68, P3743, DOI 10.1158/0008-5472.CAN-07-5100; Burger KL, 2014, PROSTATE, V74, P134, DOI 10.1002/pros.22735; Cavel O, 2012, CANCER RES, V72, P5733, DOI 10.1158/0008-5472.CAN-12-0764; Ceyhan GO, 2008, BIOCHEM BIOPH RES CO, V374, P442, DOI 10.1016/j.bbrc.2008.07.035; Ceyhan GO, 2006, ANN SURG, V244, P274, DOI 10.1097/01.sla.0000217642.68697.55; Chermenina M, 2014, NEUROSCIENCE, V270, P1, DOI 10.1016/j.neuroscience.2014.04.008; Condeelis JS, 2001, SEMIN CANCER BIOL, V11, P119, DOI 10.1006/scbi.2000.0363; Courtneidge SA, 2005, COLD SH Q B, V70, P167, DOI 10.1101/sqb.2005.70.014; Crupi MJF, 2020, ONCOGENE, V39, P1361, DOI 10.1038/s41388-019-1068-z; Crupi MJF, 2015, TRAFFIC, V16, P1155, DOI 10.1111/tra.12315; Di Martino J, 2014, CELL ADHES MIGR, V8, P280, DOI 10.4161/cam.28833; Drinkut A, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.263; Eddy RJ, 2017, TRENDS CELL BIOL, V27, P595, DOI 10.1016/j.tcb.2017.03.003; Encinas M, 2004, J BIOL CHEM, V279, P18262, DOI 10.1074/jbc.M400505200; Esseghir S, 2007, CANCER RES, V67, P11732, DOI 10.1158/0008-5472.CAN-07-2343; Fischer RS, 2019, DEV BIOL, V451, P86, DOI 10.1016/j.ydbio.2018.08.015; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; Gil Z, 2010, J NATL CANCER I, V102, P107, DOI 10.1093/jnci/djp456; Gorelik R, 2014, NAT PROTOC, V9, P1931, DOI 10.1038/nprot.2014.131; Griseri P, 2016, ONCOTARGET, V7, P26465, DOI 10.18632/oncotarget.8417; Gujral TS, 2008, CANCER RES, V68, P1338, DOI 10.1158/0008-5472.CAN-07-6052; Gupton Stephanie L, 2007, Sci STKE, V2007, pre5, DOI 10.1126/stke.4002007re5; He SB, 2014, P NATL ACAD SCI USA, V111, pE2008, DOI 10.1073/pnas.1402944111; Hickey JG, 2009, GENE CHROMOSOME CANC, V48, P429, DOI 10.1002/gcc.20653; Hirai I, 2002, PANCREAS, V24, P15, DOI 10.1097/00006676-200201000-00003; Honma Y, 2002, NEURON, V35, P267, DOI 10.1016/S0896-6273(02)00774-2; Hoshino D, 2013, J CELL SCI, V126, P2979, DOI 10.1242/jcs.079475; Huang L, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1120-9; Hyndman BD, 2017, J CELL SCI, V130, P3282, DOI 10.1242/jcs.203885; Ibanez CF, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a009134; Ilic M, 2016, WORLD J GASTROENTERO, V22, P9694, DOI 10.3748/wjg.v22.i44.9694; Ito Y, 2005, SURGERY, V138, P788, DOI 10.1016/j.surg.2005.07.007; Itoh Y, 2015, MATRIX BIOL, V44-46, P207, DOI 10.1016/j.matbio.2015.03.004; Jacquemet G, 2015, CURR OPIN CELL BIOL, V36, P23, DOI 10.1016/j.ceb.2015.06.007; Kohno T, 2012, NAT MED, V18, P375, DOI 10.1038/nm.2644; Kramer ER, 2015, FEBS LETT, V589, P3760, DOI 10.1016/j.febslet.2015.11.006; Lamorte L, 2002, MOL BIOL CELL, V13, P1449, DOI 10.1091/mbc.01-10-0477; Leong HS, 2014, CELL REP, V8, P1558, DOI 10.1016/j.celrep.2014.07.050; Lian EY, 2017, ENDOCR-RELAT CANCER, V24, P53, DOI 10.1530/ERC-16-0393; Liang DK, 2016, BBA-REV CANCER, V1865, P111, DOI 10.1016/j.bbcan.2016.01.002; Liebig C, 2009, CANCER-AM CANCER SOC, V115, P3379, DOI 10.1002/cncr.24396; Marchesi F, 2010, CYTOKINE GROWTH F R, V21, P77, DOI 10.1016/j.cytogfr.2009.11.001; Maritan SM, 2017, JOVE-J VIS EXP, DOI 10.3791/55544; Mattila PK, 2008, NAT REV MOL CELL BIO, V9, P446, DOI 10.1038/nrm2406; Mayor R, 2010, TRENDS CELL BIOL, V20, P319, DOI 10.1016/j.tcb.2010.03.005; Meka DP, 2015, J CLIN INVEST, V125, P1873, DOI 10.1172/JCI79300; Menard L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4907; Moodley S, 2020, LUNG CANCER, V142, P123, DOI 10.1016/j.lungcan.2020.02.004; Morandi A, 2011, TRENDS MOL MED, V17, P149, DOI 10.1016/j.molmed.2010.12.007; Mulligan LM, 2019, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01873; Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141; Murphy DM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021436; MYERS SM, 1995, ONCOGENE, V11, P2039; Nevalainen N, 2010, NEUROSCIENCE, V171, P1357, DOI 10.1016/j.neuroscience.2010.10.010; Oikawa T, 2008, J CELL BIOL, V182, P157, DOI 10.1083/jcb.200801042; Parachoniak CA, 2012, TRENDS CELL BIOL, V22, P231, DOI 10.1016/j.tcb.2012.02.002; Parachoniak CA, 2011, DEV CELL, V20, P751, DOI 10.1016/j.devcel.2011.05.007; Partridge MA, 2006, MOL BIOL CELL, V17, P4237, DOI 10.1091/mbc.E06-06-0496; Paz H, 2014, ONCOGENE, V33, P4193, DOI 10.1038/onc.2013.393; Poteryaev D, 1999, FEBS LETT, V463, P63, DOI 10.1016/S0014-5793(99)01590-2; Radhakrishna H, 1999, J CELL SCI, V112, P855; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Rajadurai CV, 2012, J CELL SCI, V125, P2940, DOI 10.1242/jcs.100834; Richardson DS, 2006, ONCOGENE, V25, P3206, DOI 10.1038/sj.onc.1209349; Richardson DS, 2012, MOL BIOL CELL, V23, P3838, DOI 10.1091/mbc.E12-02-0114; Rodrigues DM, 2011, NEUROGASTROENT MOTIL, V23, pe44, DOI 10.1111/j.1365-2982.2010.01626.x; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Saad AM, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4610-4; Sawai H, 2005, CANCER RES, V65, P11536, DOI 10.1158/0008-5472.CAN-05-2843; Sharma VP, 2013, CURR BIOL, V23, P2079, DOI 10.1016/j.cub.2013.08.044; Sit ST, 2011, J CELL SCI, V124, P679, DOI 10.1242/jcs.064964; Stylli SS, 2009, J CELL SCI, V122, P2727, DOI 10.1242/jcs.046680; SUTERCRAZZOLARA C, 1994, NEUROREPORT, V5, P2486, DOI 10.1097/00001756-199412000-00020; TAHIRA T, 1990, ONCOGENE, V5, P97; Tsui-Pierchala BA, 2002, J BIOL CHEM, V277, P34618, DOI 10.1074/jbc.M203580200; Vincent A, 2011, LANCET, V378, P607, DOI 10.1016/S0140-6736(10)62307-0; Williams KC, 2019, ONCOGENE, V38, P3598, DOI 10.1038/s41388-018-0667-4; Yang CS, 2011, CELL ADHES MIGR, V5, P402, DOI 10.4161/cam.5.5.16971; Zeng Q, 2008, J INT MED RES, V36, P656, DOI 10.1177/147323000803600406	88	9	9	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2020	39	41					6493	6510		10.1038/s41388-020-01448-z	http://dx.doi.org/10.1038/s41388-020-01448-z		SEP 2020	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OA1JL	32884116				2022-12-28	WOS:000565829600001
J	Shah, K; Gagliano, T; Garland, L; O'Hanlon, T; Bortolotti, D; Gentili, V; Rizzo, R; Giamas, G; Dean, M				Shah, Kalpit; Gagliano, Teresa; Garland, Lisa; O'Hanlon, Timothy; Bortolotti, Daria; Gentili, Valentina; Rizzo, Roberta; Giamas, Georgios; Dean, Michael			Androgen receptor signaling regulates the transcriptome of prostate cancer cells by modulating global alternative splicing	ONCOGENE			English	Article							INTRON RETENTION; DNA-BINDING; ANTIANDROGEN; MECHANISM; EXPRESSION; REPRESSION; RESISTANCE; THERAPY; NETWORK	Androgen receptor (AR), is a transcription factor and a member of a hormone receptor superfamily. AR plays a vital role in the progression of prostate cancer and is a crucial target for therapeutic interventions. While the majority of advanced-stage prostate cancer patients will initially respond to the androgen deprivation, the disease often progresses to castrate-resistant prostate cancer (CRPC). Interestingly, CRPC tumors continue to depend on hyperactive AR signaling and will respond to potent second-line antiandrogen therapies, including bicalutamide (CASODEX(R)) and enzalutamide (XTANDI(R)). However, the progression-free survival rate for the CRPC patients on antiandrogen therapies is only 8-19 months. Hence, there is a need to understand the mechanisms underlying CRPC progression and eventual treatment resistance. Here, we have leveraged next-generation sequencing and newly developed analytical methodologies to evaluate the role of AR signaling in regulating the transcriptome of prostate cancer cells. The genomic and pharmacologic stimulation and inhibition of AR activity demonstrates that AR regulates alternative splicing within cancer-relevant genes. Furthermore, by integrating transcriptomic data from in vitro experiments and in prostate cancer patients, we found that a significant number of AR-regulated splicing events are associated with tumor progression. For example, we found evidence for an inadvertent AR-antagonist-mediated switch inIDH1andPL2G2Aisoform expression, which is associated with a decrease in overall survival of patients. Mechanistically, we discovered that the epithelial-specific splicing regulators (ESRP1 and ESRP2), flank many AR-regulated alternatively spliced exons. And, using 2D invasion assays, we show that the inhibition of ESRPs can suppress AR-antagonist-driven tumor invasion. Our work provides evidence for a new mechanism by which AR alters the transcriptome of prostate cancer cells by modulating alternative splicing. As such, our work has important implications for CRPC progression and development of resistance to treatment with bicalutamide and enzalutamide.	[Shah, Kalpit; Garland, Lisa; Dean, Michael] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA; [Gagliano, Teresa] Univ Udine, Dept Med Sci, Udine, Italy; [O'Hanlon, Timothy] Frederick Natl Lab Canc Res, Canc Genom Res Lab, Bethesda, MD 20892 USA; [Bortolotti, Daria; Gentili, Valentina; Rizzo, Roberta] Univ Ferrara, Dept Chem & Pharmaceut Sci, Ferrara, Italy; [Giamas, Georgios] Univ Sussex, Sch Life Sci, Dept Biochem & Biomed, Brighton BN1 9QG, E Sussex, England; [Shah, Kalpit] Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Udine; University of Ferrara; University of Sussex; Roche Holding; Genentech	Shah, K; Dean, M (corresponding author), NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.; Shah, K (corresponding author), Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.	kalpit.shah2016@gmail.com; michael.dean@nih.gov	Gentili, Valentina/AAC-1028-2022; Gagliano, Teresa/G-1645-2015; Dean, Michael C/G-8172-2012; Giamas, Georgios/AAP-3487-2021; Bortolotti, Daria/K-5125-2016	Gentili, Valentina/0000-0003-4572-5497; Gagliano, Teresa/0000-0002-4877-6292; Dean, Michael C/0000-0003-2234-0631; Bortolotti, Daria/0000-0003-4496-9561; O'Hanlon, Timothy/0000-0003-2759-733X	intramural research program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health	intramural research program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health	This work was supported by grants from the intramural research program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health. This work utilized the computational resources of the NIH HPC Biowulf cluster and DCEG CCAD cluster (http://hpc.nih.gov).	Auboeuf D, 2002, SCIENCE, V298, P416, DOI 10.1126/science.1073734; Azad AA, 2015, NAT REV UROL, V12, P26, DOI 10.1038/nrurol.2014.320; Baniwal SK, 2009, MOL ENDOCRINOL, V23, P1203, DOI 10.1210/me.2008-0470; Braunschweig U, 2014, GENOME RES, V24, P1774, DOI 10.1101/gr.177790.114; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen SY, 2006, P NATL ACAD SCI USA, V103, P15969, DOI 10.1073/pnas.0604193103; David CJ, 2010, GENE DEV, V24, P2343, DOI 10.1101/gad.1973010; Di CX, 2019, CELL DEATH DIFFER, V26, P1181, DOI 10.1038/s41418-018-0231-3; Dutertre M, 2010, CANCER RES, V70, P3760, DOI 10.1158/0008-5472.CAN-09-3988; Dvinge H, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0168-9; Fizazi K, 2012, LANCET ONCOL, V13, P983, DOI 10.1016/S1470-2045(12)70379-0; FURR BJA, 1987, J ENDOCRINOL, V113, pR7, DOI 10.1677/joe.0.113R007; Ganesan K, 2008, CANCER RES, V68, P4277, DOI 10.1158/0008-5472.CAN-07-6517; Georget V, 1997, MOL CELL ENDOCRINOL, V129, P17, DOI 10.1016/S0303-7207(97)04034-3; Georget V, 2002, BIOCHEMISTRY-US, V41, P11824, DOI 10.1021/bi0259150; Gregory CW, 2005, CLIN CANCER RES, V11, P1704, DOI 10.1158/1078-0432.CCR-04-1158; Gregory CW, 2004, J BIOL CHEM, V279, P7119, DOI 10.1074/jbc.M307649200; Grosse A, 2012, MOL CELL ENDOCRINOL, V352, P46, DOI 10.1016/j.mce.2011.06.032; Hammes A, 2005, CELL, V122, P751, DOI 10.1016/j.cell.2005.06.032; Huang H, 2002, CRIT REV EUKAR GENE, V12, P193, DOI 10.1615/CritRevEukaryotGeneExpr.v12.i3.30; HUGGINS C, 1946, JAMA-J AM MED ASSOC, V131, P576, DOI 10.1001/jama.1946.02870240008003; Iwasaki K, 2018, CANCER SCI, V109, P3159, DOI 10.1111/cas.13754; Jung- H, 2015, NAT GENET, V47, P1242, DOI 10.1038/ng.3414; Kahles A, 2018, CANCER CELL, V34, P211, DOI 10.1016/j.ccell.2018.07.001; Lee Y, 2015, ANNU REV BIOCHEM, V84, P291, DOI 10.1146/annurev-biochem-060614-034316; Lin TH, 2013, J BIOL CHEM, V288, P19359, DOI 10.1074/jbc.M113.477216; Liu WW, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0743-1; Liu YN, 2008, MOL CELL BIOL, V28, P7096, DOI 10.1128/MCB.00449-08; Lu-Yao GL, 2014, JAMA INTERN MED, V174, P1460, DOI 10.1001/jamainternmed.2014.3028; Mellinghoff IK, 2004, CANCER CELL, V6, P517, DOI 10.1016/j.ccr.2004.09.031; Miao L, 2017, CANCER RES, V77, P3101, DOI 10.1158/0008-5472.CAN-16-2169; Molenaar RJ, 2018, ONCOGENE, V37, P1949, DOI 10.1038/s41388-017-0077-z; Munkley J, 2019, ELIFE, V8, DOI 10.7554/eLife.47678; Nilsen TW, 2010, NATURE, V463, P457, DOI 10.1038/nature08909; OLIVIER JL, 1994, BIOCHEMISTRY-US, V33, P7134, DOI 10.1021/bi00189a017; Paradon M, 1998, EUR J BIOCHEM, V258, P113, DOI 10.1046/j.1432-1327.1998.2580113.x; Park JW, 2016, NUCLEIC ACIDS RES, V44, pW333, DOI 10.1093/nar/gkw410; Penson DF, 2016, J CLIN ONCOL, V34, P2098, DOI 10.1200/JCO.2015.64.9285; Prescott J, 2007, PROSTATE, V67, P1371, DOI 10.1002/pros.20623; Rasmussen KD, 2016, GENE DEV, V30, P733, DOI 10.1101/gad.276568.115; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Sirotnak FM, 2004, MOL CARCINOGEN, V41, P150, DOI 10.1002/mc.20051; Smart AC, 2018, NAT BIOTECHNOL, V36, P1056, DOI 10.1038/nbt.4239; Stebbing J, 2018, ONCOGENE, V37, P3113, DOI 10.1038/s41388-018-0197-0; Stylianou N, 2019, ONCOGENE, V38, P913, DOI 10.1038/s41388-018-0488-5; Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175; Verras M, 2007, CANCER RES, V67, P967, DOI 10.1158/0008-5472.CAN-06-3552; Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041; Warzecha CC, 2010, EMBO J, V29, P3286, DOI 10.1038/emboj.2010.195; Watson PA, 2015, NAT REV CANCER, V15, P701, DOI 10.1038/nrc4016; Weber MJ, 2004, J CELL BIOCHEM, V91, P13, DOI 10.1002/jcb.10683; WONG CI, 1993, J BIOL CHEM, V268, P19004; Wong YNS, 2014, NAT REV CLIN ONCOL, V11, P365, DOI 10.1038/nrclinonc.2014.72; Yang YQ, 2016, MOL CELL BIOL, V36, P1704, DOI 10.1128/MCB.00019-16; Yun SJ, 2017, ONCOTARGET, V8, P114845, DOI 10.18632/oncotarget.22296; Zhang YJ, 2018, NAT GENET, V50, P814, DOI 10.1038/s41588-018-0120-1	56	14	14	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2020	39	39					6172	6189		10.1038/s41388-020-01429-2	http://dx.doi.org/10.1038/s41388-020-01429-2		AUG 2020	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NS8XO	32820253	Green Published, hybrid, Green Submitted			2022-12-28	WOS:000561253800004
J	Ruan, HL; Li, S; Bao, L; Zhang, XP				Ruan, Hailong; Li, Sen; Bao, Lin; Zhang, Xiaoping			Enhanced YB1/EphA2 axis signaling promotes acquired resistance to sunitinib and metastatic potential in renal cell carcinoma	ONCOGENE			English	Article							YB-1 PROMOTES; TRANSLATIONAL ACTIVATION; THERAPEUTIC TARGET; CANCER METASTASIS; INTERFERON-ALPHA; POOR-PROGNOSIS; EPHA2; EXPRESSION; OVEREXPRESSION; PROLIFERATION	VHL mutations are the most common tumorigenic lesions in clear cell renal cell carcinoma (ccRCC) and result in continued activation of the HIF/VEGF pathway and uncontrolled cancer progression. Receptor tyrosine kinase (RTK) inhibitors such as sunitinib have been demonstrated to target tumorigenic signaling pathways, delay tumor progression, and improve patient prognosis in metastatic renal cell carcinoma (mRCC). Although several mechanisms of sunitinib resistance have been reported, the solutions to overcome this resistance remain unclear. In our study, we found that increased expression of Y-box binding protein 1 (YB1, a multidrug resistance associated protein) and EphA2 (a member of the erythropoietin-producing hepatocellular (Eph) receptor family, belonging to the RTK family) mediated sunitinib resistance and mRCC exhibited a large phenotypic dependence on YB1 and EphA2. In addition, our findings confirm that YB1 promotes the invasion, metastasis and sunitinib resistance of ccRCC by regulating the EphA2 signaling pathway. Furthermore, pharmacological inhibition of EphA2 through the small molecule inhibitor ALW-II-41-27 reduced the proliferation of sunitinib-resistant tumor cells, suppressed tumor growth in vivo, and restored the sensitivity of sunitinib-resistant tumor cells to sunitinib in vitro and in vivo. Mechanistically, YB1 increases the protein levels of EphA2 by maintaining the protein stability of EphA2 through inhibition of the proteasomal degradation pathway. Collectively, our findings provide the theoretical rationale that ccRCC metastasis and RTK-directed therapeutic resistance could be prospectively and purposefully targeted.	[Ruan, Hailong; Li, Sen; Bao, Lin; Zhang, Xiaoping] Huazhong Univ Sci & Technol, Dept Urol, Union Hosp, Tongji Med Coll, Wuhan 430022, Peoples R China; [Ruan, Hailong; Li, Sen; Bao, Lin; Zhang, Xiaoping] Huazhong Univ Sci & Technol, Inst Urol, Union Hosp, Tongji Med Coll, Wuhan 430022, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology	Ruan, HL; Bao, L; Zhang, XP (corresponding author), Huazhong Univ Sci & Technol, Dept Urol, Union Hosp, Tongji Med Coll, Wuhan 430022, Peoples R China.; Ruan, HL; Bao, L; Zhang, XP (corresponding author), Huazhong Univ Sci & Technol, Inst Urol, Union Hosp, Tongji Med Coll, Wuhan 430022, Peoples R China.	hlruan2018@hust.edu.cn; 2417221775@qq.com; xzhang@hust.edu.cn			National Natural Science Foundation of China [81874090]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the National Natural Science Foundation of China (Grant No. 81874090). We thank the members of the Zhang Lab for helpful discussions and suggestions. We are grateful to Huazhong University of Science and Technology for providing a good experimental platform.	Amato KR, 2016, CANCER RES, V76, P305, DOI 10.1158/0008-5472.CAN-15-0717; Chen XY, 2014, CLIN CANCER RES, V20, P2617, DOI 10.1158/1078-0432.CCR-13-3224; Chu PC, 2018, ONCOGENE, V37, P3440, DOI 10.1038/s41388-018-0222-3; Cutz JC, 2006, CLIN CANCER RES, V12, P4043, DOI 10.1158/1078-0432.CCR-06-0252; D'Costa NM, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-1527-y; El-Naggar AM, 2015, CANCER CELL, V27, P682, DOI 10.1016/j.ccell.2015.04.003; Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655; Evdokimova V, 2009, CANCER CELL, V15, P402, DOI 10.1016/j.ccr.2009.03.017; Gotink KJ, 2011, CLIN CANCER RES, V17, P7337, DOI 10.1158/1078-0432.CCR-11-1667; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Herrem CJ, 2005, CLIN CANCER RES, V11, P226; Joosten SC, 2015, BBA-REV CANCER, V1855, P1, DOI 10.1016/j.bbcan.2014.11.002; Jurchott K, 2003, J BIOL CHEM, V278, P27988, DOI 10.1074/jbc.M212966200; Kosnopfel C, 2018, MOL CANCER RES, V16, P1149, DOI 10.1158/1541-7786.MCR-17-0528; Kuwano M, 2019, CANCER SCI, V110, P1536, DOI 10.1111/cas.14006; Lim JP, 2019, CANCER LETT, V452, P119, DOI 10.1016/j.canlet.2019.03.014; Liu FH, 2006, CANCER RES, V66, P10815, DOI 10.1158/0008-5472.CAN-06-1408; Miao BC, 2015, CANCER DISCOV, V5, P274, DOI 10.1158/2159-8290.CD-14-0295; Miao XB, 2016, EXP CELL RES, V346, P157, DOI 10.1016/j.yexcr.2016.07.003; Miyazaki T, 2003, INT J CANCER, V103, P657, DOI 10.1002/ijc.10860; Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044; Motzer RJ, 2009, J CLIN ONCOL, V27, P3584, DOI 10.1200/JCO.2008.20.1293; Park K, 2012, MED ONCOL, V29, P3291, DOI 10.1007/s12032-012-0227-7; Ruan HL, 2020, MOL THER, V28, P1299, DOI 10.1016/j.ymthe.2020.03.001; Ruan HL, 2017, EXP CELL RES, V358, P269, DOI 10.1016/j.yexcr.2017.07.004; Ruan HL, 2017, INT J ONCOL, V51, P336, DOI 10.3892/ijo.2017.4010; Shi HC, 2020, ONCOGENE, V39, P530, DOI 10.1038/s41388-019-0962-8; Shibao K, 1999, INT J CANCER, V83, P732; Shiota M, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djw005; Tao Z, 2019, CANCER IMMUNOL RES, V7, P1135, DOI 10.1158/2326-6066.CIR-18-0648; Wang Y, 2015, TUMOR BIOL, V36, P7159, DOI 10.1007/s13277-015-3417-z; Yamashita T, 2017, INT J ONCOL, V51, P579, DOI 10.3892/ijo.2017.4031; Yang Y, 2019, ENDOCRINE, V65, P683, DOI 10.1007/s12020-019-02022-8	33	11	12	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2020	39	38					6113	6128		10.1038/s41388-020-01409-6	http://dx.doi.org/10.1038/s41388-020-01409-6		AUG 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NQ9JF	32814829	Green Published, hybrid			2022-12-28	WOS:000561008600001
J	Bajaj, R; Kundu, ST; Grzeskowiak, CL; Fradette, JJ; Scott, KL; Creighton, CJ; Gibbons, DL				Bajaj, Rakhee; Kundu, Samrat T.; Grzeskowiak, Caitlin L.; Fradette, Jared J.; Scott, Kenneth L.; Creighton, Chad J.; Gibbons, Don L.			IMPAD1 and KDELR2 drive invasion and metastasis by enhancing Golgi-mediated secretion	ONCOGENE			English	Article							LIGASE CBL-B; MIR-200 FAMILY; ORGANIZATION; TRAFFICKING; PATHWAY; TARGET; BREAST	Non-small cell lung cancer (NSCLC) is the deadliest form of cancer worldwide, due in part to its proclivity to metastasize. Identifying novel drivers of invasion and metastasis holds therapeutic potential for the disease. We conducted a gain-of-function invasion screen, which identified two separate hits, IMPAD1 and KDELR2, as robust, independent drivers of lung cancer invasion and metastasis. Given that IMPAD1 and KDELR2 are known to be localized to the ER-Golgi pathway, we studied their common mechanism of driving in vitro invasion and in vivo metastasis and demonstrated that they enhance Golgi-mediated function and secretion. Therapeutically inhibiting matrix metalloproteases (MMPs) suppressed both IMPAD1- and KDELR2-mediated invasion. The hits from this unbiased screen and the mechanistic validation highlight Golgi function as one of the key cellular features altered during invasion and metastasis.	[Bajaj, Rakhee; Kundu, Samrat T.; Fradette, Jared J.; Gibbons, Don L.] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA; [Grzeskowiak, Caitlin L.] Baylor Coll Med, Dan L Duncan Canc Ctr, Dept Mol & Human Genet, Houston, TX 77030 USA; [Grzeskowiak, Caitlin L.; Scott, Kenneth L.; Creighton, Chad J.] Baylor Coll Med, Dan L Duncan Canc Ctr, Dept Med, Houston, TX 77030 USA; [Gibbons, Don L.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Kundu, ST; Gibbons, DL (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.; Gibbons, DL (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	skundu@mdanderson.org; dlgibbon@mdanderson.org		Fradette, Jared/0000-0001-6712-2860; Kundu, Samrat/0000-0002-0117-6986; Bajaj, Rakhee/0000-0002-9990-1655	DoD CDMRP Lung cancer [W81XWH-12-16294]; NIH/NCI [K08 CA151651]; NIH [R37CA214609]; MD Anderson Physician-Scientist Program; Rexanna's Foundation for Fighting Lung Cancer; Jeane F. Shelby Scholarship Fund; generous philanthropic contributions to The University of Texas MD Anderson Lung Cancer Moon Shots Program	DoD CDMRP Lung cancer; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MD Anderson Physician-Scientist Program; Rexanna's Foundation for Fighting Lung Cancer; Jeane F. Shelby Scholarship Fund; generous philanthropic contributions to The University of Texas MD Anderson Lung Cancer Moon Shots Program	This work was supported by the DoD CDMRP Lung cancer research award W81XWH-12-16294 (DLG and KLS), NIH/NCI K08 CA151651, NIH R37CA214609, the MD Anderson Physician-Scientist Program and Rexanna's Foundation for Fighting Lung Cancer (DLG). DLG is an R. Lee Clark Fellow of the University of Texas MD Anderson Cancer Center, supported by the Jeane F. Shelby Scholarship Fund. The work was also supported by the generous philanthropic contributions to The University of Texas MD Anderson Lung Cancer Moon Shots Program. We would like to thank the UTMDACC Department of Veterinary Medicine Facility.	Ahn YH, 2012, J CLIN INVEST, V122, P3170, DOI 10.1172/JCI63608; BERSHADSKY AD, 1994, P NATL ACAD SCI USA, V91, P5686, DOI 10.1073/pnas.91.12.5686; Bogdanov Alexey, 2017, F1000Res, V6, P10, DOI 10.12688/f1000research.10481.1; Brandizzi F, 2013, NAT REV MOL CELL BIO, V14, P382, DOI 10.1038/nrm3588; Cancino J, 2013, HISTOCHEM CELL BIOL, V140, P395, DOI 10.1007/s00418-013-1130-9; Capitani M, 2009, FEBS LETT, V583, P3863, DOI 10.1016/j.febslet.2009.10.053; Feizi A, 2017, NPJ SYST BIOL APPL, V3, DOI 10.1038/s41540-017-0021-4; Frederick JP, 2008, P NATL ACAD SCI USA, V105, P11605, DOI 10.1073/pnas.0801182105; Friedl P, 2012, NAT CELL BIOL, V14, P777, DOI 10.1038/ncb2548; Gibbons DL, 2009, GENE DEV, V23, P2140, DOI 10.1101/gad.1820209; Gibbons DL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005401; Grzeskowiak CL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04572-3; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Halberg N, 2016, CANCER CELL, V29, P339, DOI 10.1016/j.ccell.2016.02.013; HANDLER JS, 1989, ANNU REV PHYSIOL, V51, P729, DOI 10.1146/annurev.ph.51.030189.003501; Justus CR, 2014, JOVE-J VIS EXP, DOI 10.3791/51046; Khajah MA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193779; Kundu ST, 2016, ONCOGENE, V35, P173, DOI 10.1038/onc.2015.71; Kundu ST, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05013-x; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Martinotti S, 2020, METHODS MOL BIOL, V2109, P225, DOI 10.1007/7651_2019_259; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Ochieng JK, 2020, ONCOGENE; Pangon L, 2016, ONCOGENE, V35, P2834, DOI 10.1038/onc.2015.347; Paolino M, 2014, NATURE, V507, P508, DOI 10.1038/nature12998; Parris TZ, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.8; Plasterer C, 2019, G3-GENES GENOM GENET, V9, P1739, DOI 10.1534/g3.118.200873; Rodriguez-Boulan E, 2014, NAT REV MOL CELL BIO, V15, P225, DOI 10.1038/nrm3775; Ruggiero Carmen, 2018, Oncotarget, V9, P10228, DOI 10.18632/oncotarget.23421; Ruggiero C, 2015, ONCOTARGET, V6, P3375, DOI 10.18632/oncotarget.3270; Sbai O, 2008, MOL CELL NEUROSCI, V39, P549, DOI 10.1016/j.mcn.2008.08.004; Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI [10.3322/caac.21601, 10.3322/caac.21590]; Sohaskey ML, 2008, DEVELOPMENT, V135, P2215, DOI 10.1242/dev.019950; Steeg PS, 2008, NAT CLIN PRACT ONCOL, V5, P206, DOI 10.1038/ncponc1066; Tan XC, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aax3772; Tan XC, 2017, J CLIN INVEST, V127, P117, DOI 10.1172/JCI88736; Tang CH, 2009, PROSTATE, V69, P1781, DOI 10.1002/pros.21029; Taylor A, 2016, J VIROL, V90, P4150, DOI 10.1128/JVI.03192-15; Uhlen M, 2017, SCIENCE, V357, P660, DOI 10.1126/science.aan2507; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Viotti C, 2016, METHODS MOL BIOL, V1459, P3, DOI 10.1007/978-1-4939-3804-9_1; Vissers LELM, 2011, AM J HUM GENET, V88, P608, DOI 10.1016/j.ajhg.2011.04.002; Wiersma VR, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00007; Wu XM, 2012, ONCOL REP, V27, P1488, DOI 10.3892/or.2012.1670; Xu L, 2017, NEOPLASIA, V19, P374, DOI 10.1016/j.neo.2017.01.011	45	13	13	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2020	39	37					5979	5994		10.1038/s41388-020-01410-z	http://dx.doi.org/10.1038/s41388-020-01410-z		AUG 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NM2OY	32753652	Green Accepted			2022-12-28	WOS:000555747100001
J	Yang, H; Geng, YH; Wang, P; Yang, H; Zhou, YT; Zhang, HQ; He, HY; Fang, WG; Tian, XX				Yang, Hui; Geng, Yue-Hang; Wang, Peng; Yang, Han; Zhou, Yan-Ting; Zhang, Hong-Quan; He, Hui-Ying; Fang, Wei-Gang; Tian, Xin-Xia			Extracellular ATP promotes breast cancer invasion and chemoresistance via SOX9 signaling	ONCOGENE			English	Article							TO-MESENCHYMAL TRANSITION; PURINERGIC RECEPTORS; CELL INVASION; LEADING ROLE; METASTASIS; ACTIVATION; INFLAMMATION; EPITHELIUM; IMMUNITY; FAMILY	Our previous research demonstrated that extracellular adenosine 5 '-triphosphate (ATP) could promote breast cancer cell invasion. However, the impact of extracellular ATP on chemoresistance and the mechanisms behind ATP pro-invasion and pro-chemoresistance remain unclear. Here we aimed to determine the molecules or signaling pathways involved. cDNA microarray was performed to identify the differentially expressed genes before and after ATP treatment. As a result, Sex-determining region Y-box 9 (SOX9) was up-regulated after ATP treatment in breast cancer cells. In vitro invasion and migration assays demonstrated that knocking down SOX9 attenuated ATP-driven invasive capability. Mass spectrometry and co-IP revealed that SOX9 interacted with Janus kinase 1 (JAK1). Afterward, IL-6-JAK1-STAT3 signaling was demonstrated to promote SOX9 expression and invasion following ATP treatment. Notably, ATP-IL-6-SOX9 signaling was shown to stimulate chemoresistance in breast cancer cells. ChIP assays identified some potential SOX9 target genes, among which carcinoembryonic antigen-related cell adhesion molecule 5/6 (CEACAM5/6) was demonstrated to mediate ATP pro-invasive function, while ATP-binding cassette subfamily B member 1 (ABCB1) and ATP-binding cassette subfamily G member 2 (ABCG2) mediated ATP-driven chemoresistance. In addition, SOX9-knockdown and apyrase (an ATP hydrolase)-treated MDA-MB-231 cells illustrated decreased tumor growth and enhanced drug sensitivity in nude mice. In vitro spheroid formation assays also proved the significance of ATP-SOX9 in mediating chemoresistance. Moreover, molecules involved in ATP-SOX9 signaling were up-regulated in human breast carcinoma specimens and were associated with poor prognosis. Altogether, SOX9 signaling is vital in ATP-driven invasion and chemoresistance, which may serve as a potential target for breast cancer therapies.	[Yang, Hui; Geng, Yue-Hang; Yang, Han; Zhou, Yan-Ting; He, Hui-Ying; Fang, Wei-Gang; Tian, Xin-Xia] Peking Univ, Dept Pathol, Key Lab Carcinogenesis & Translat Res, Minist Educ,Sch Basic Med Sci,Hosp 3,Hlth Sci Ctr, Beijing 100191, Peoples R China; [Wang, Peng; Zhang, Hong-Quan] Peking Univ, Hlth Sci Ctr, Dept Anat Histol & Embryol, Beijing 100191, Peoples R China	Peking University; Peking University	Fang, WG; Tian, XX (corresponding author), Peking Univ, Dept Pathol, Key Lab Carcinogenesis & Translat Res, Minist Educ,Sch Basic Med Sci,Hosp 3,Hlth Sci Ctr, Beijing 100191, Peoples R China.	wgfang@bjmu.edu.cn; tianxinxia@bjmu.edu.cn		Wang, Peng/0000-0002-2558-292X; Tian, Xin-Xia/0000-0002-1593-4987; Yang, Hui/0000-0002-9138-1325	National Natural Science Foundation of China [81872382, 81621063]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants to XXT and WGF from the National Natural Science Foundation of China (No 81872382 and 81621063).	Abbosh C, 2017, NATURE, V545, P446, DOI 10.1038/nature22364; Antonioli L, 2013, NAT REV CANCER, V13, P842, DOI 10.1038/nrc3613; Atarashi K, 2008, NATURE, V455, P808, DOI 10.1038/nature07240; Auger R, 2005, J BIOL CHEM, V280, P28142, DOI 10.1074/jbc.M501290200; Cai CM, 2013, J CLIN INVEST, V123, P1109, DOI 10.1172/JCI66666; Chen H, 2017, CLIN CANCER RES, V23, P5176, DOI 10.1158/1078-0432.CCR-17-0177; Chen L, 2004, CANCER LETT, V215, P239, DOI 10.1016/j.canlet.2004.05.023; Crystal AS, 2014, SCIENCE, V346, P1480, DOI 10.1126/science.1254721; Di Virgilio F, 2017, ONCOGENE, V36, P293, DOI 10.1038/onc.2016.206; Di Virgilio F, 2016, CURR OPIN PHARMACOL, V29, P17, DOI 10.1016/j.coph.2016.05.001; Di Virgilio F, 2012, CANCER RES, V72, P5441, DOI 10.1158/0008-5472.CAN-12-1600; Eguchi Y, 1997, CANCER RES, V57, P1835; FANG WG, 1992, J CLIN INVEST, V89, P191, DOI 10.1172/JCI115562; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Galluzzi L, 2015, CELL REP, V11, P1501, DOI 10.1016/j.celrep.2015.05.041; Ghiringhelli F, 2009, NAT MED, V15, P1170, DOI 10.1038/nm.2028; Gilbert SM, 2019, ONCOGENE, V38, P194, DOI 10.1038/s41388-018-0426-6; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Johnson DE, 2018, NAT REV CLIN ONCOL, V15, P234, DOI 10.1038/nrclinonc.2018.8; Kumar S, 2015, CELL REP, V12, P1325, DOI 10.1016/j.celrep.2015.07.034; Larsimont JC, 2015, CELL STEM CELL, V17, P60, DOI 10.1016/j.stem.2015.05.008; Leung CON, 2016, ONCOTARGET, V7, P29371, DOI 10.18632/oncotarget.8835; Li WH, 2013, BRIT J CANCER, V109, P1666, DOI 10.1038/bjc.2013.484; Li WH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133165; Liu Y, 2018, CANCER LETT, V430, P1, DOI 10.1016/j.canlet.2018.04.043; McKenney RJ, 2014, SCIENCE, V345, P337, DOI 10.1126/science.1254198; Nagy A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27521-y; Patel A, 2017, SCIENCE, V356, P753, DOI 10.1126/science.aaf6846; Pearson RA, 2005, NEURON, V46, P731, DOI 10.1016/j.neuron.2005.04.024; Prevostel C, 2017, EUR J CANCER, V86, P150, DOI 10.1016/j.ejca.2017.08.037; Putoczki T, 2010, J LEUKOCYTE BIOL, V88, P1109, DOI 10.1189/jlb.0410226; Qiu ML, 2020, EXP CELL RES, V392, DOI 10.1016/j.yexcr.2020.112002; Qiu Y, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.011437, DOI 10.1371/JOURNAL.PONE.011437]; Qiu Y, 2018, ONCOL REP, V39, P138, DOI 10.3892/or.2017.6081; Roger S, 2011, EXPERT OPIN INV DRUG, V20, P875, DOI 10.1517/13543784.2011.583918; Santos JC, 2016, CANCER RES, V76, P6735, DOI 10.1158/0008-5472.CAN-16-1120; Shan L, 2016, CANCER CELL, V30, P708, DOI 10.1016/j.ccell.2016.09.010; Solini A, 1999, J CELL SCI, V112, P297; Verhalen B, 2017, NATURE, V543, P738, DOI 10.1038/nature21414; Wang H, 2015, CANCER CELL, V27, P193, DOI 10.1016/j.ccell.2014.11.017; Wang H, 2008, CANCER RES, V68, P1625, DOI 10.1158/0008-5472.CAN-07-5915; Wang X, 2017, ONCOTARGET, V8, P87860, DOI 10.18632/oncotarget.21231; Wilson M, 2002, CURR OPIN GENET DEV, V12, P441, DOI 10.1016/S0959-437X(02)00323-4; Xia MS, 2015, J MOL NEUROSCI, V55, P131, DOI 10.1007/s12031-014-0393-5; Yang H, 2019, CANCER SCI, V110, P2456, DOI 10.1111/cas.14086; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zalzali H, 2008, ONCOGENE, V27, P7131, DOI 10.1038/onc.2008.331; Zeng HL, 2016, CANCER CELL, V30, P459, DOI 10.1016/j.ccell.2016.08.001; Zhang JL, 2017, CANCER SCI, V108, P1318, DOI 10.1111/cas.13273; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	50	23	23	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2020	39	35					5795	5810		10.1038/s41388-020-01402-z	http://dx.doi.org/10.1038/s41388-020-01402-z		JUL 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NF2QB	32724162				2022-12-28	WOS:000553333400001
J	Anderson, KJ; Osvaldsdottir, AB; Atzinger, B; Traustadottir, GA; Jensen, KN; Larusdottir, AE; Bergthorsson, JT; Hardardottir, I; Magnusdottir, E				Anderson, Kimberley Jade; Osvaldsdottir, Arny Bjorg; Atzinger, Birgit; Traustadottir, Gunnhildur Asta; Jensen, Kirstine Nolling; Larusdottir, Adalheidur Elin; Bergthorsson, Jon Thor; Hardardottir, Ingibjorg; Magnusdottir, Erna			The BLIMP1-EZH2 nexus in a non-Hodgkin lymphoma	ONCOGENE			English	Article							PLASMA-CELL DIFFERENTIATION; CLASS-II TRANSACTIVATOR; WALDENSTROM MACROGLOBULINEMIA; B-CELLS; TRANSCRIPTIONAL REPRESSION; METHYLTRANSFERASE ACTIVITY; SOMATIC MUTATIONS; MYD88 L265P; BLIMP-1; EXPRESSION	Waldenstrom's macroglobulinemia (WM) is a non-Hodgkin lymphoma, resulting in antibody-secreting lymphoplasmacytic cells in the bone marrow and pathologies resulting from high levels of monoclonal immunoglobulin M (IgM) in the blood. Despite the key role for BLIMP1 in plasma cell maturation and antibody secretion, its potential effect on WM cell biology has not yet been explored. Here we provide evidence of a crucial role for BLIMP1 in the survival of cells from WM cell line models and further demonstrate that BLIMP1 is necessary for the expression of the histone methyltransferase EZH2 in both WM and multiple myeloma cell lines. The effect of BLIMP1 on EZH2 levels is post-translational, at least partially through the regulation of proteasomal targeting of EZH2. Chromatin immunoprecipitation analysis and transcriptome profiling suggest that the two factors co-operate in regulating genes involved in cancer cell immune evasion. Co-cultures of natural killer cells and cells from a WM cell line further suggest that both factors participate in immune evasion by promoting escape from natural killer cell-mediated cytotoxicity. Together, the interplay of BLIMP1 and EZH2 plays a vital role in promoting the survival of WM cell lines, suggesting a role for the two factors in Waldenstrom's macroglobulinaemia.	[Anderson, Kimberley Jade; Osvaldsdottir, Arny Bjorg; Atzinger, Birgit; Traustadottir, Gunnhildur Asta; Larusdottir, Adalheidur Elin; Magnusdottir, Erna] Univ Iceland, Fac Med, Dept Anat, Vatnsmyrarvegur 16, IS-101 Reykjavik, Iceland; [Anderson, Kimberley Jade; Osvaldsdottir, Arny Bjorg; Atzinger, Birgit; Larusdottir, Adalheidur Elin; Bergthorsson, Jon Thor; Magnusdottir, Erna] Univ Iceland, Fac Med, Dept Biomed Sci, Vatnsmyrarvegur 16, IS-101 Reykjavik, Iceland; [Anderson, Kimberley Jade; Osvaldsdottir, Arny Bjorg; Atzinger, Birgit; Traustadottir, Gunnhildur Asta; Jensen, Kirstine Nolling; Larusdottir, Adalheidur Elin; Bergthorsson, Jon Thor; Hardardottir, Ingibjorg; Magnusdottir, Erna] Univ Iceland, Biomed Ctr, Vatnsmyrarvegur 16, IS-101 Reykjavik, Iceland; [Jensen, Kirstine Nolling; Hardardottir, Ingibjorg] Univ Iceland, Fac Med, Dept Biochem & Mol Biol, Vatnsmyrarvegur 16, IS-101 Reykjavik, Iceland; [Jensen, Kirstine Nolling; Hardardottir, Ingibjorg] Landspitali Natl Univ Hosp Iceland, Dept Immunol, IS-101 Reykjavik, Iceland; [Bergthorsson, Jon Thor] Landspitali Natl Univ Hosp Iceland, Dept Lab Haematol, IS-101 Reykjavik, Iceland	University of Iceland; University of Iceland; University of Iceland; University of Iceland	Magnusdottir, E (corresponding author), Univ Iceland, Fac Med, Dept Anat, Vatnsmyrarvegur 16, IS-101 Reykjavik, Iceland.; Magnusdottir, E (corresponding author), Univ Iceland, Fac Med, Dept Biomed Sci, Vatnsmyrarvegur 16, IS-101 Reykjavik, Iceland.; Magnusdottir, E (corresponding author), Univ Iceland, Biomed Ctr, Vatnsmyrarvegur 16, IS-101 Reykjavik, Iceland.	erna@hi.is	Magnusdottir, Erna/H-5181-2013	Magnusdottir, Erna/0000-0002-3369-4390; Hardardottir, Ingibjorg/0000-0003-0178-7047; Anderson, Kimberley/0000-0003-0629-6343; Nolling Jensen, Kirstine/0000-0002-7625-7529; Traustadottir, Gunnhildur Asta/0000-0001-6044-0989; Bergthorsson, Jon Thor/0000-0002-0560-2639				Anderson AC, 2016, IMMUNITY, V44, P989, DOI 10.1016/j.immuni.2016.05.001; Barakat FH, 2011, AM J CLIN PATHOL, V135, P365, DOI 10.1309/AJCP15YFULCZHZVH; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Calado DP, 2010, CANCER CELL, V18, P580, DOI 10.1016/j.ccr.2010.11.024; Cartron G, 2004, BLOOD, V104, P2635, DOI 10.1182/blood-2004-03-1110; Chen H, 2007, MOL IMMUNOL, V44, P1461, DOI 10.1016/j.molimm.2006.04.026; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; de Charette M, 2018, HAEMATOLOGICA, V103, P1256, DOI 10.3324/haematol.2017.184192; de Tute RM, 2013, CL LYMPH MYELOM LEUK, V13, P211, DOI 10.1016/j.clml.2013.02.018; Doody GM, 2007, J IMMUNOL, V179, P7614, DOI 10.4049/jimmunol.179.11.7614; El-Ayoubi A, 2017, PATHOLOGY, V49, P337, DOI 10.1016/j.pathol.2017.02.004; Elias S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18652-9; Garcia JF, 2006, HAEMATOLOGICA, V91, P467; Gavriatopoulou M, 2018, LEUKEMIA, V32, P1883, DOI 10.1038/s41375-018-0209-7; Ghobrial IM, 2004, CANCER-AM CANCER SOC, V101, P2593, DOI 10.1002/cncr.20658; Guo M, 2018, J IMMUNOL, V200, P1039, DOI 10.4049/jimmunol.1701470; Gyory I, 2004, NAT IMMUNOL, V5, P299, DOI 10.1038/ni1046; Hackett JA, 2013, SCIENCE, V339, P448, DOI 10.1126/science.1229277; Hernando H, 2016, MOL CANCER THER, V15, P287, DOI 10.1158/1535-7163.MCT-15-0486; Herviou L, 2019, LEUKEMIA, V33, P2047, DOI 10.1038/s41375-019-0392-1; Hung KH, 2016, CELL DEATH DIFFER, V23, P1175, DOI 10.1038/cdd.2015.167; Hunter ZR, 2016, BLOOD, V128, P827, DOI 10.1182/blood-2016-03-708263; Iwanaga M, 2014, INT J CANCER, V134, P174, DOI 10.1002/ijc.28343; Jalali S, 2018, BLOOD ADV, V2, P1985, DOI 10.1182/bloodadvances.2018021113; Kallies A, 2004, J EXP MED, V200, P967, DOI 10.1084/jem.20040973; Kallies A, 2007, IMMUNITY, V26, P555, DOI 10.1016/j.immuni.2007.04.007; Kriangkum J, 2004, BLOOD, V104, P2134, DOI 10.1182/blood-2003-11-4024; Kuo TC, 2004, J IMMUNOL, V173, P5556, DOI 10.4049/jimmunol.173.9.5556; Kurimoto K, 2015, CELL STEM CELL, V16, P517, DOI 10.1016/j.stem.2015.03.002; Kyle RA, 2018, MAYO CLIN PROC, V93, P739, DOI 10.1016/j.mayocp.2018.02.011; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Lin FR, 2007, CANCER RES, V67, P11914, DOI 10.1158/0008-5472.CAN-07-1868; Lin KI, 2002, MOL CELL BIOL, V22, P4771, DOI 10.1128/MCB.22.13.4771-4780.2002; Lin Y, 1997, SCIENCE, V276, P596, DOI 10.1126/science.276.5312.596; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Lozano E, 2018, J IMMUNOL, V200, P2581, DOI 10.4049/jimmunol.1701622; Magnusdottir E, 2007, P NATL ACAD SCI USA, V104, P14988, DOI 10.1073/pnas.0707323104; Magnusdottir E, 2013, NAT CELL BIOL, V15, P905, DOI 10.1038/ncb2798; Mandelbaum J, 2010, CANCER CELL, V18, P568, DOI 10.1016/j.ccr.2010.10.030; Minnich M, 2016, NAT IMMUNOL, V17, P331, DOI 10.1038/ni.3349; Morgan MAJ, 2009, MOL CELL BIOL, V29, P5813, DOI 10.1128/MCB.00670-09; Morice WG, 2009, MODERN PATHOL, V22, P807, DOI 10.1038/modpathol.2009.34; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Mould AW, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005375; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Murakami K, 2016, NATURE, V529, P403, DOI 10.1038/nature16480; O'Carroll D, 2001, MOL CELL BIOL, V21, P4330, DOI 10.1128/MCB.21.13.4330-4336.2001; Pasare C, 2005, NATURE, V438, P364, DOI 10.1038/nature04267; Pasqualucci L, 2006, J EXP MED, V203, P311, DOI 10.1084/jem.20052204; Pasricha SR, 2011, J CLIN PATHOL, V64, P520, DOI 10.1136/jcp.2010.088591; Paulus A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122338; Pawlyn C, 2017, BLOOD CANCER J, V7, DOI 10.1038/bcj.2017.27; Petermann F, 2019, MOL CELL, V75, P1229, DOI 10.1016/j.molcel.2019.06.025; Piskurich JF, 2000, NAT IMMUNOL, V1, P526, DOI 10.1038/82788; Ren B, 1999, GENE DEV, V13, P125, DOI 10.1101/gad.13.1.125; Roberts MJ, 2013, AM J CLIN PATHOL, V139, P210, DOI 10.1309/AJCP0YGM8BLFYHJY; Roccaro AM, 2010, BLOOD; Savitsky D, 2006, J EXP MED, V203, P2305, DOI 10.1084/jem.20060411; Schop RFJ, 2002, BLOOD, V100, P2996, DOI 10.1182/blood.V100.8.2996; Shaffer AL, 2002, IMMUNITY, V17, P51, DOI 10.1016/S1074-7613(02)00335-7; Shaffer AL, 2008, NATURE, V454, P226, DOI 10.1038/nature07064; Shapiro-Shelef M, 2003, IMMUNITY, V19, P607, DOI 10.1016/S1074-7613(03)00267-X; Steinberg MW, 2011, IMMUNOL REV, V244, P169, DOI 10.1111/j.1600-065X.2011.01064.x; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tellier J, 2016, NAT IMMUNOL, V17, P323, DOI 10.1038/ni.3348; Tooze RM, 2006, J IMMUNOL, V177, P4584, DOI 10.4049/jimmunol.177.7.4584; Treon SP, 2014, BLOOD, V123, P2791, DOI 10.1182/blood-2014-01-550905; Treon SP, 2012, NEW ENGL J MED, V367, P826, DOI 10.1056/NEJMoa1200710; Treon SP, 2009, BLOOD, V114, P2375, DOI 10.1182/blood-2009-05-174359; Varghese AM, 2009, CLIN LYMPHOMA MYELOM, V9, P53, DOI 10.3816/CLM.2009.n.013; Vijay A, 2007, BLOOD, V109, P5096, DOI 10.1182/blood-2006-11-055012; Wang HJ, 2012, CANCER-AM CANCER SOC, V118, P3793, DOI 10.1002/cncr.26627; Xu L, 2014, LEUKEMIA, V28, P1698, DOI 10.1038/leu.2014.65; Yu J, 2000, MOL CELL BIOL, V20, P2592, DOI 10.1128/MCB.20.7.2592-2603.2000; Yu XF, 2018, CANCER RES, V78, P2457, DOI 10.1158/0008-5472.CAN-18-0215; Zhou YS, 2014, BRIT J HAEMATOL, V166, P677, DOI 10.1111/bjh.12936; Zingg D, 2017, CELL REP, V20, P854, DOI 10.1016/j.celrep.2017.07.007	77	2	2	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	2020	39	28					5138	5151		10.1038/s41388-020-1347-8	http://dx.doi.org/10.1038/s41388-020-1347-8			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MH4RK	32533097	Green Submitted, Green Published			2022-12-28	WOS:000546718100005
J	Lin, CC; Yao, CY; Hsu, YW; Hou, HA; Yuan, CS; Li, YH; Kao, HJ; Chuang, PH; Chiu, YC; Chen, YD; Chou, WC; Tien, WF				Lin, Chien-Chin; Yao, Chi-Yuan; Hsu, Yueh-Chwen; Hou, Hsin-An; Yuan, Chang-Tsu; Li, Yi-Hung; Kao, Chein-Jun; Chuang, Po-Han; Chiu, Yu-Chiao; Chen, Yidong; Chou, Wen-Chien; Tien, Hwei-Fang			Knock-out ofHopxdisrupts stemness and quiescence of hematopoietic stem cells in mice	ONCOGENE			English	Article							LABEL-RETAINING CELLS; HOMEOBOX GENE; HOPX EXPRESSION; CXCR4; PROLIFERATION; METHYLATION; POPULATION; SUBSET; CANCER	HOPX is a stem cell marker in hair follicles and intestines. It was shown critical for primitive hematopoiesis. We previously showed an association between higherHOPXexpression and clinical characteristics related to stemness and quiescence of leukemic cells in acute myeloid leukemia (AML) patients. To further explore its physiologic functions in hematopoietic system, we generated a mouse model with hematopoietic cell-specific knockout ofHopx(Hopx(-/-)). In youngHopx(-/-)mice, the hematopoietic stem cells (HSC) showed decreased reconstitution ability after serial transplantation. Further transcriptomic study revealed decreased HSC signatures in long-term HSCs from theHopx(-/-)mice. At 18 months of age, half of theHopx(-/-)mice developed cytopenia and splenomegaly. Bone marrow (BM) from the sick mice showed myeloid hyperplasia with predominant mature neutrophils, and decreased progenitor cells and lymphocytes. These phenotypes suggested critical functions of Hopx in maintaining HSC quiescence. Transcriptomic study of theHopx(-/-)marrow cells showed significant downregulation of theCxcl12-Cxcr4axis, which is critical for maintenance of HSC quiescence. We next examined the role of Hopx in AML by using theMN1overexpression murine leukemia model. Mice transplanted withMN1-overexpressedHopx(-/-)BM cells developed AML with more aggressive phenotypes compared with those transplanted withMN1-overexpressedHopx-wild cells.Hopx(-/-)MN1-overexpressed leukemia cells showed higher proliferation rate and downregulation ofCxcl12andCxcr4. Furthermore, in human AML, BM plasma CXCL12 levels were lower in patients with lowerHOPXexpression. In conclusion, our study highlights the roles of Hopx in maintenance of quiescence of the hematopoietic stem cells through CXCL12 pathway in vivo and provides implication of this protein in normal and malignant hematopoiesis.	[Lin, Chien-Chin; Yao, Chi-Yuan; Hsu, Yueh-Chwen; Chou, Wen-Chien] Natl Taiwan Univ Hosp, Dept Lab Med, Taipei, Taiwan; [Lin, Chien-Chin; Yao, Chi-Yuan; Hou, Hsin-An; Kao, Chein-Jun; Chuang, Po-Han; Chou, Wen-Chien; Tien, Hwei-Fang] Natl Taiwan Univ Hosp, Dept Internal Med, Div Hematol, Taipei, Taiwan; [Lin, Chien-Chin; Yuan, Chang-Tsu] Natl Taiwan Univ, Grad Inst Clin Med, Taipei, Taiwan; [Yuan, Chang-Tsu] Natl Taiwan Univ, Coll Med, Grad Inst Oncol, Dept Pathol, Taipei, Taiwan; [Li, Yi-Hung] Chinese Culture Univ, Dept Anim Sci, Taipei, Taiwan; [Chiu, Yu-Chiao; Chen, Yidong] Univ Texas Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, San Antonio, TX 78229 USA	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; Chinese Culture University; University of Texas System; University of Texas Health San Antonio	Chou, WC (corresponding author), Natl Taiwan Univ Hosp, Dept Lab Med, Taipei, Taiwan.; Chou, WC; Tien, WF (corresponding author), Natl Taiwan Univ Hosp, Dept Internal Med, Div Hematol, Taipei, Taiwan.	wchou@ntu.edu.tw; hftien@ntu.edu.tw		HOU, HSIN-AN/0000-0003-2780-4845; Yuan, Chang-Tsu/0000-0003-1438-9187; Chiu, Yu-Chiao/0000-0003-1647-8634; LIN, CHIEN-CHIN/0000-0001-7160-2285; Yao, Chi-Yuan/0000-0001-5052-9445; TIEN, HWEI-FANG/0000-0002-1384-5593; CHOU, WEN-CHIEN/0000-0003-2967-698X				Agarwal P, 2019, CELL STEM CELL, V24, P769, DOI 10.1016/j.stem.2019.02.018; Basak O, 2017, CELL STEM CELL, V20, P177, DOI 10.1016/j.stem.2016.11.001; Beck TC, 2014, J EXP MED, V211, P2567, DOI 10.1084/jem.20140457; Berg DA, 2019, CELL, V177, P654, DOI 10.1016/j.cell.2019.02.010; Buczacki SJA, 2013, NATURE, V495, P65, DOI 10.1038/nature11965; Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood-2005-08-3182; Chakkalakal JV, 2012, NATURE, V490, P355, DOI 10.1038/nature11438; Chen F, 2002, CELL, V110, P713, DOI 10.1016/S0092-8674(02)00932-7; Chen Y, 2007, INT J CANCER, V121, P1021, DOI 10.1002/ijc.22753; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Codega P, 2014, NEURON, V82, P545, DOI 10.1016/j.neuron.2014.02.039; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; Greenbaum A, 2013, NATURE, V495, P227, DOI 10.1038/nature11926; Harada Y, 2011, ANTICANCER RES, V31, P2889; Heuser M, 2011, CANCER CELL, V20, P39, DOI 10.1016/j.ccr.2011.06.020; Hock H, 2004, NATURE, V431, P1002, DOI 10.1038/nature02994; Hsu YC, 2019, BLOOD ADV, V3, P2355, DOI 10.1182/bloodadvances.2019000391; Jain R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7727; Katoh H, 2012, NEOPLASIA, V14, P559, DOI 10.1593/neo.12330; Kook H, 2006, BIOCHEMISTRY-US, V45, P10584, DOI 10.1021/bi060641s; Lin CC, 2017, HAEMATOLOGICA, V102, P1044, DOI 10.3324/haematol.2016.161257; Mendelson A, 2014, NAT MED, V20, P833, DOI 10.1038/nm.3647; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; Munoz J, 2012, EMBO J, V31, P3079, DOI 10.1038/emboj.2012.166; Ni F, 2019, CELL STEM CELL, V24, P608, DOI 10.1016/j.stem.2019.02.009; Nie YC, 2008, J EXP MED, V205, P777, DOI 10.1084/jem.20072513; Ooki A, 2010, ONCOGENE, V29, P3263, DOI 10.1038/onc.2010.76; Palpant NJ, 2017, CELL REP, V20, P1597, DOI 10.1016/j.celrep.2017.07.067; Pitt LA, 2015, CANCER CELL, V27, P755, DOI 10.1016/j.ccell.2015.05.002; Ren XY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14053; Scadden DT, 2014, CELL, V157, P41, DOI 10.1016/j.cell.2014.02.013; Shin CH, 2002, CELL, V110, P725, DOI 10.1016/S0092-8674(02)00933-9; Takeda N, 2013, DEVELOPMENT, V140, P1655, DOI 10.1242/dev.093005; Takeda N, 2011, SCIENCE, V334, P1420, DOI 10.1126/science.1213214; Tian H, 2011, NATURE, V478, P255, DOI 10.1038/nature10408; Tumpel S, 2019, TRENDS CELL BIOL, V29, P672, DOI 10.1016/j.tcb.2019.05.002; Tzeng YS, 2011, BLOOD, V117, P429, DOI 10.1182/blood-2010-01-266833; Waraya M, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-397; Yamaguchi S, 2009, INT J CANCER, V124, P2577, DOI 10.1002/ijc.24217; Yamashita K, 2008, MOL CANCER RES, V6, P31, DOI 10.1158/1541-7786.MCR-07-0213; Zhou XY, 2015, STEM CELL REP, V5, P125, DOI 10.1016/j.stemcr.2015.05.008	41	8	8	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	2020	39	28					5112	5123		10.1038/s41388-020-1340-2	http://dx.doi.org/10.1038/s41388-020-1340-2			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MH4RK	32533098				2022-12-28	WOS:000546718100003
J	Suo, DQ; Wang, ZF; Li, L; Chen, QY; Zeng, TT; Liu, RY; Yun, JP; Guan, XY; Li, Y				Suo, Daqin; Wang, Zifeng; Li, Lei; Chen, Qingyun; Zeng, Tingting; Liu, Ranyi; Yun, Jingping; Guan, Xin-Yuan; Li, Yan			HOXC10 upregulation confers resistance to chemoradiotherapy in ESCC tumor cells and predicts poor prognosis	ONCOGENE			English	Article							GENE-EXPRESSION; DNA-REPAIR; CANCER; ACTIVATION; OVEREXPRESSION; CHEMOTHERAPY; INHIBITION; INVASION	Esophageal squamous cell carcinoma (ESCC) is a malignant disease and is a common cause of death in China. By performing an integrative study investigating public databases and clinical samples collected by our group, we found that HOXC10 (homeobox C10) is upregulated in ESCC tumor tissues compared with nontumor tissues and that the upregulation of HOXC10 is correlated with the poor prognosis of patients with ESCC. The enforced expression of HOXC10 promoted ESCC cell proliferation in vitro and in vivo. Our study revealed that HOXC10 could bind the promoter region of human Erb-b2 receptor tyrosine kinase 3 (ERBB3/HER3) and activate the PI3K/AKT pathway. In addition, by immunoprecipitation and mass spectrometry analysis, we found that HOXC10 could bind X-ray repair cross complementing 6 (Ku70) and accelerate the DNA repair mechanism via the nonhomologous end-joining (NHEJ) pathway. We further evaluated HOXC10 expression in ESCC patients receiving adjuvant radiotherapy or platinum-based chemotherapy. The results demonstrate that HOXC10 upregulation predicts the poor prognosis of ESCC patients receiving adjuvant radiotherapy or chemotherapy. Our study reveals that HOXC10 upregulation reflects the poor prognosis of ESCC patients and directs the selection of postoperative therapy regimens.	[Suo, Daqin; Wang, Zifeng; Li, Lei; Chen, Qingyun; Zeng, Tingting; Liu, Ranyi; Yun, Jingping; Guan, Xin-Yuan; Li, Yan] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Ctr Canc, Guangzhou, Peoples R China; [Li, Lei; Guan, Xin-Yuan] Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; University of Hong Kong	Guan, XY; Li, Y (corresponding author), Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Ctr Canc, Guangzhou, Peoples R China.; Guan, XY (corresponding author), Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China.	xyguan@hku.hk; liy6@mail.sysu.edu.cn		Li, Yan/0000-0002-8856-4083	National Key R&D Program of China [2017YFC1309000]; NSFC [81672357, 81871903, 81772554]; Open funds of State Key Laboratory of Oncology in South China [HN2019-06]	National Key R&D Program of China; NSFC(National Natural Science Foundation of China (NSFC)); Open funds of State Key Laboratory of Oncology in South China	This work was supported by National Key R&D Program of China (2017YFC1309000), NSFC (81672357, 81871903, and 81772554), and Open funds of State Key Laboratory of Oncology in South China (HN2019-06).	Akbas GE, 2004, BIOL REPROD, V70, P39, DOI 10.1095/biolreprod.102.014969; Bedenne L, 2007, J CLIN ONCOL, V25, P1160, DOI 10.1200/JCO.2005.04.7118; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cantile M, 2003, ONCOGENE, V22, P6462, DOI 10.1038/sj.onc.1206808; Cao MF, 2019, CANCER BIOL MED, V16, P595, DOI 10.20892/j.issn.2095-3941.2018.0277; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Chu MC, 2004, CANCER BIOL THER, V3, P568, DOI 10.4161/cbt.3.6.848; CILLO C, 1992, INT J CANCER, V51, P892, DOI 10.1002/ijc.2910510610; Dai BW, 2019, J CANCER, V10, P4540, DOI 10.7150/jca.30645; Damia G, 2019, CANCERS, V11, DOI 10.3390/cancers11010119; de Stanchina E, 2000, J MOL BIOL, V299, P667, DOI 10.1006/jmbi.2000.3782; DEVITA G, 1993, EUR J CANCER, V29A, P887, DOI 10.1016/S0959-8049(05)80432-0; FAIELLA A, 1994, P NATL ACAD SCI USA, V91, P5335, DOI 10.1073/pnas.91.12.5335; Feng XY, 2015, MOL BIOSYST, V11, P2946, DOI 10.1039/c5mb00253b; Finn RS, 2019, CLIN CANCER RES, V19, P751; Hafner A, 2019, NAT REV MOL CELL BIO, V20, P199, DOI 10.1038/s41580-019-0110-x; Hostikka SL, 2009, INT J BIOL SCI, V5, P397; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Jain AK, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.158360; Koyama FC, 2018, BRIT J SURG, V105, pE192, DOI 10.1002/bjs.10695; Lagergren J, 2017, LANCET, V390, P2383, DOI 10.1016/S0140-6736(17)31462-9; Leng X, 2019, ANN SURG, V12, P4932; Li JF, 2019, J WATER REUSE DESAL, V9, P1, DOI 10.2166/wrd.2017.019; Li S, 2017, ONCOTARGET, V8, P88974, DOI 10.18632/oncotarget.21634; Li Y, 2011, CANCER RES, V71, P6106, DOI 10.1158/0008-5472.CAN-10-4291; Lieber MR, 2010, ANNU REV BIOCHEM, V79, P181, DOI 10.1146/annurev.biochem.052308.093131; Lin DC, 2018, GASTROENTEROLOGY, V154, P374, DOI 10.1053/j.gastro.2017.06.066; Ma J, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-105; Ma M, 2020, MOL CELL PROBE, V49, DOI 10.1016/j.mcp.2019.101491; Miwa T, 2019, ANN SURG ONCOL, V26, P1535, DOI 10.1245/s10434-019-07166-5; Nemoz C, 2018, NAT STRUCT MOL BIOL, V25, P971, DOI 10.1038/s41594-018-0133-6; Ohashi S, 2015, GASTROENTEROLOGY, V149, P1700, DOI 10.1053/j.gastro.2015.08.054; Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6; Ponz-Sarvise M, 2019, CLIN CANCER RES, V25, P11; Sadik H, 2016, CANCER RES, V76, P4443, DOI 10.1158/0008-5472.CAN-16-0774; Shah N, 2010, NAT REV CANCER, V10, P361, DOI 10.1038/nrc2826; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Takahashi O, 2007, ONCOL REP, V17, P753; Tan ZY, 2018, THERANOSTICS, V8, P5143, DOI 10.7150/thno.27310; Tang XL, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00557; Tang ZF, 2019, NUCLEIC ACIDS RES, V47, pW556, DOI 10.1093/nar/gkz430; Waltregny D, 2002, PROSTATE, V50, P162, DOI 10.1002/pros.10045; Wang C, 2013, INT J RADIAT ONCOL, V86, P440, DOI 10.1016/j.ijrobp.2013.01.011; Wang XC, 2019, CLIN CANCER RES, V25, P4567, DOI 10.1158/1078-0432.CCR-18-3735; Yan T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09255-1; Yang G, 2018, NUCLEIC ACIDS RES, V46, P3446, DOI 10.1093/nar/gky088; Yang H, 2018, J CLIN ONCOL, V36, P2796, DOI 10.1200/JCO.2018.79.1483; Yao S, 2018, BIOCHEM BIOPH RES CO, V501, P628, DOI 10.1016/j.bbrc.2018.05.019; Zhang LZ, 2017, CHINESE J CANCER RES, V29, P149, DOI 10.21147/j.issn.1000-9604.2017.02.08	50	20	20	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2020	39	32					5441	5454		10.1038/s41388-020-1375-4	http://dx.doi.org/10.1038/s41388-020-1375-4		JUN 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW4DS	32587398				2022-12-28	WOS:000543299500001
J	El-Khoury, M; Cabagnols, X; Mosca, M; Vertenoeil, G; Marzac, C; Favale, F; Bluteau, O; Lorre, F; Tisserand, A; Moraes, GR; Ugo, V; Ianotto, JC; Rey, J; Solary, E; Roy, L; Rameau, P; Debili, N; Pasquier, F; Casadevall, N; Marty, C; Constantinescu, SN; Raslova, H; Vainchenker, W; Plo, I				El-Khoury, Mira; Cabagnols, Xenia; Mosca, Matthieu; Vertenoeil, Gaelle; Marzac, Christophe; Favale, Fabrizia; Bluteau, Olivier; Lorre, Florence; Tisserand, Amandine; Moraes, Graciela Rabadan; Ugo, Valerie; Ianotto, Jean-Christophe; Rey, Jerome; Solary, Eric; Roy, Lydia; Rameau, Philippe; Debili, Najet; Pasquier, Florence; Casadevall, Nicole; Marty, Caroline; Constantinescu, Stefan N.; Raslova, Hana; Vainchenker, William; Plo, Isabelle			Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms	ONCOGENE			English	Article							ESSENTIAL THROMBOCYTHEMIA; THROMBOPOIETIN RECEPTOR; MUTANT CALRETICULIN; POLYCYTHEMIA-VERA; CALR MUTATIONS; SOMATIC MUTATIONS; JAK2 MUTATION; STEM-CELLS; MPL; MYELOFIBROSIS	Mutations of calreticulin (CALRm) define a subtype of myeloproliferative neoplasms (MPN). We studied the biological and genetic features ofCALR-mutated essential thrombocythemia and myelofibrosis patients. In most cases,CALRmwere found in granulocytes, monocytes, B and NK cells, but also in T cells. However, the type 1CALRmspreads more easily than the type 2CALRmin lymphoid cells. TheCALRmwere also associated with an early clonal dominance at the level of hematopoietic stem and progenitor cells (HSPC) with no significant increase during granulo/monocytic differentiation in most cases. Moreover, we found that half of type 2CALRmpatients harbors some homozygous progenitors. Those patients were associated with a higher clonal dominance during granulo/monocytic differentiation than patients with only heterozygous type 2CALRmprogenitors. When associated mutations were present,CALRmwere the first genetic event suggesting that they are both the initiating and phenotypic event. In blood, type 1CALRmled to a greater increased number of all types of progenitors compared with the type 2CALRm. However, both types ofCALRminduced an increase in megakaryocytic progenitors associated with a ruxolitinib-sensitive independent growth and with a mild constitutive signaling in megakaryocytes. At the transcriptional level, type 1CALRmseems to deregulate more pathways than the type 2CALRmin megakaryocytes. Altogether, our results show thatCALRmmodify both the HSPC and megakaryocyte biology with a stronger effect for type 1 than for type 2CALRm.	[El-Khoury, Mira; Cabagnols, Xenia; Mosca, Matthieu; Bluteau, Olivier; Tisserand, Amandine; Moraes, Graciela Rabadan; Solary, Eric; Debili, Najet; Pasquier, Florence; Casadevall, Nicole; Marty, Caroline; Raslova, Hana; Vainchenker, William; Plo, Isabelle] INSERM, UMR1287, Villejuif, France; [El-Khoury, Mira; Cabagnols, Xenia; Mosca, Matthieu; Bluteau, Olivier; Tisserand, Amandine; Moraes, Graciela Rabadan; Solary, Eric; Rameau, Philippe; Debili, Najet; Pasquier, Florence; Casadevall, Nicole; Marty, Caroline; Raslova, Hana; Vainchenker, William; Plo, Isabelle] Gustave Roussy, Villejuif, France; [El-Khoury, Mira; Cabagnols, Xenia; Tisserand, Amandine; Moraes, Graciela Rabadan] Univ Paris Diderot Paris 7, Gustave Roussy, UMR1287, Villejuif, France; [Mosca, Matthieu; Bluteau, Olivier; Solary, Eric; Debili, Najet; Pasquier, Florence; Marty, Caroline; Raslova, Hana; Vainchenker, William; Plo, Isabelle] Univ Paris XI, UMR1287, Gustave Roussy, Villejuif, France; [Vertenoeil, Gaelle; Constantinescu, Stefan N.] Ludwig Inst Canc Res Brussels, Brussels, Belgium; [Vertenoeil, Gaelle; Constantinescu, Stefan N.] Catholic Univ Louvain, Brussels, Belgium; [Vertenoeil, Gaelle; Constantinescu, Stefan N.] Duve Inst, Brussels, Belgium; [Marzac, Christophe; Solary, Eric; Pasquier, Florence] Gustave Roussy, Dept Hematol, Villejuif, France; [Favale, Fabrizia; Lorre, Florence] Sorbonne Univ, INSERM, Ctr Rech St Antoine, CRSA,UMR S 938, Paris, France; [Ugo, Valerie] CHU Angers, Lab Hematol, Angers, France; [Ianotto, Jean-Christophe] CHRU Brest, Serv Hematol, Brest, France; [Rey, Jerome] Inst Paoli Calmettes, Dept Hematol, Serv Hematol, Marseille, France; [Roy, Lydia] CHU Henri Mondor, Assistance Publ Hop Paris, Serv Hematol, Creteil, France; [Casadevall, Nicole] Hop St Antoine, Assistance Publ Hop Paris, Lab Hematol, Paris, France; [Constantinescu, Stefan N.] WELBIO Walloon Excellence Life Sci & Biotechnol, Brussels, Belgium	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Cite; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Universite Catholique Louvain; UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; CHU Brest; Universite de Bretagne Occidentale; UNICANCER; Institut Paoli-Calmette (IPC); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; WELBIO	Vainchenker, W; Plo, I (corresponding author), INSERM, UMR1287, Villejuif, France.; Vainchenker, W; Plo, I (corresponding author), Gustave Roussy, Villejuif, France.; Vainchenker, W; Plo, I (corresponding author), Univ Paris XI, UMR1287, Gustave Roussy, Villejuif, France.	william.vainchenker@gustaveroussy.fr; isabelle.plo@gustaveroussy.fr	Plo, Isabelle/AAT-6742-2021; Plo, Isabelle/C-9056-2017; Raslova, Hana/N-3562-2018	Plo, Isabelle/0000-0002-5915-6910; Raslova, Hana/0000-0001-8846-5299; Bluteau, Olivier/0000-0002-6943-8858; Ugo, Valerie/0000-0002-4678-2138; Solary, Eric/0000-0002-8629-1341; Ianotto, Jean-Christophe/0000-0001-9074-7287	Agence Nationale pour la Recherche; Ligue Nationale contre le Cancer; Fondation Laurette Fugain; INCA PLBIO 2016; grant "Taxe d'apprentissage" Gustave Roussy-2016; INSERM; program "Investissements d'avenir"; Salus Sanguinis Action de recherche concertee (ARC) [16/21-073]; WelBio [F 44/8/5-MCF/UIG-10955]; SFH (Societe francaise d'hematologie); university Paris-Diderot (MENRT grant); Gustave Roussy Foundation; SFH; Fonds Nationals de la Recherche Scientifique, Belgium; Fondation contre le cancer; la Ligue Nationale contre le Cancer	Agence Nationale pour la Recherche(French National Research Agency (ANR)); Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Fondation Laurette Fugain; INCA PLBIO 2016; grant "Taxe d'apprentissage" Gustave Roussy-2016; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); program "Investissements d'avenir"(French National Research Agency (ANR)); Salus Sanguinis Action de recherche concertee (ARC); WelBio(WELBIO); SFH (Societe francaise d'hematologie); university Paris-Diderot (MENRT grant); Gustave Roussy Foundation; SFH; Fonds Nationals de la Recherche Scientifique, Belgium; Fondation contre le cancer; la Ligue Nationale contre le Cancer(Ligue nationale contre le cancer)	This work was funded by grants from the Agence Nationale pour la Recherche (Thrombocytosis, WV), the Ligue Nationale contre le Cancer (equipe labellelisee HR 2016, 2019), the Fondation Laurette Fugain (WV, IP), INCA PLBIO 2016 (IP), by grant "Taxe d'apprentissage" Gustave Roussy-2016 (LS and MEK) and from the INSERM. Labex GR-Ex (IP, WV) is funded by the program "Investissements d'avenir." Support to SNC was from Fondation contre le cancer, Salus Sanguinis Action de recherche concertee (ARC) 16/21-073 and WelBio F 44/8/5-MCF/UIG-10955. MEK was supported by the SFH (Societe francaise d'hematologie), XC and AT were supported by the university Paris-Diderot (MENRT grant), MM by la Ligue Nationale contre le Cancer, Gustave Roussy Foundation and SFH. GRM was a recipient from allocations doctorales sur domaines cibles (ARDoc, Ile-de-France region). GV was supported by a PhD aspirant fellowship of the Fonds Nationals de la Recherche Scientifique, Belgium. We want to thank the platforms of bioinformatic (Khadija M Diop, Guillaume Meurice and Marc Deloger) and flow cytometry and Edwige Leclercq, Marie-Helene Courtier for CALR sizing analysis.	Allen C, 2014, BLOOD, V124, P2091, DOI 10.1182/blood-2014-06-580183; Anand S, 2011, BLOOD, V118, P177, DOI 10.1182/blood-2010-12-327593; Andrikovics H, 2014, HAEMATOLOGICA, V99, P1184, DOI 10.3324/haematol.2014.107482; Araki M, 2016, BLOOD, V127, P1307, DOI 10.1182/blood-2015-09-671172; Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Balligand T, 2020, LEUKEMIA, V34, P510, DOI 10.1038/s41375-019-0538-1; Barosi G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035631; Cabagnols X, 2015, LEUKEMIA, V29, P249, DOI 10.1038/leu.2014.270; Cabagnols X, 2016, BLOOD, V127, P333, DOI 10.1182/blood-2015-07-661983; Campbell PJ, 2005, LANCET, V366, P1945, DOI 10.1016/S0140-6736(05)67785-9; Chachoua I, 2016, BLOOD, V127, P1325, DOI 10.1182/blood-2015-11-681932; Chagraoui H, 2002, BLOOD, V100, P3495, DOI 10.1182/blood-2002-04-1133; Debili N, 1996, BLOOD, V88, P1284, DOI 10.1182/blood.V88.4.1284.bloodjournal8841284; Delhommeau F, 2007, BLOOD, V109, P71, DOI 10.1182/blood-2006-03-007146; Delhommeau F, 2009, NEW ENGL J MED, V360, P2289, DOI 10.1056/NEJMoa0810069; Di Buduo CA, 2020, BLOOD, V135, P133, DOI 10.1182/blood.2019001103; Dupont S, 2007, BLOOD, V110, P1013, DOI 10.1182/blood-2006-10-054940; Eder-Azanza L, 2014, LEUKEMIA, V28, P2106, DOI 10.1038/leu.2014.190; Elf S, 2018, BLOOD, V131, P782, DOI 10.1182/blood-2017-08-800896; Elf S, 2016, CANCER DISCOV, V6, P368, DOI 10.1158/2159-8290.CD-15-1434; Feenstra JDM, 2016, BLOOD, V127, P325, DOI 10.1182/blood-2015-07-661835; Gekas C, 2013, BLOOD, V121, P4463, DOI 10.1182/blood-2012-09-457929; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; James C, 2008, BLOOD, V112, P2429, DOI 10.1182/blood-2008-02-137877; Kent DG, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001576; Kjaer L, 2018, LEUKEMIA LYMPHOMA, V59, P973, DOI 10.1080/10428194.2017.1359743; Kjaer L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165336; Klampfl T, 2013, NEW ENGL J MED, V369, P2379, DOI 10.1056/NEJMoa1311347; Kollmann K, 2017, LEUKEMIA, V31, P934, DOI 10.1038/leu.2016.280; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Lau WWY, 2015, BLOOD, V125, P1679, DOI 10.1182/blood-2014-12-618074; Li J, 2018, BLOOD, V131, P649, DOI 10.1182/blood-2017-09-806356; Lundberg P, 2014, BLOOD, V123, P2220, DOI 10.1182/blood-2013-11-537167; Marty C, 2016, BLOOD, V127, P1317, DOI 10.1182/blood-2015-11-679571; Mondet J, 2015, HAEMATOLOGICA, V100, DOI 10.3324/haematol.2014.118927; Nam AS, 2019, NATURE, V571, P355, DOI 10.1038/s41586-019-1367-0; Nangalia J, 2013, NEW ENGL J MED, V369, P2391, DOI 10.1056/NEJMoa1312542; Ortmann CA, 2015, NEW ENGL J MED, V372, P601, DOI 10.1056/NEJMoa1412098; Passamonti F, 2010, LEUKEMIA, V24, P1574, DOI 10.1038/leu.2010.148; Pietra D, 2016, LEUKEMIA, V30, P431, DOI 10.1038/leu.2015.277; Pikman Y, 2006, PLOS MED, V3, P1140, DOI 10.1371/journal.pmed.0030270; Pronier E, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.122703; Rodriguez-Meira A, 2019, MOL CELL, V73, P1292, DOI 10.1016/j.molcel.2019.01.009; Rotunno G, 2014, BLOOD, V123, P1552, DOI 10.1182/blood-2013-11-538983; Rumi E, 2014, BLOOD, V123, P1544, DOI 10.1182/blood-2013-11-539098; Rumi E, 2013, BLOOD, V121, P4388, DOI 10.1182/blood-2013-02-486050; Saint-Martin C, 2009, BLOOD, V114, P1628, DOI 10.1182/blood-2009-01-197525; Sanjuan-Pla A, 2013, NATURE, V502, P232, DOI 10.1038/nature12495; Scott LM, 2006, BLOOD, V108, P2435, DOI 10.1182/blood-2006-04-018259; Shide K, 2017, LEUKEMIA, V31, P1136, DOI 10.1038/leu.2016.308; Tefferi A, 2014, LEUKEMIA, V28, P1568, DOI 10.1038/leu.2014.83; Tefferi A, 2014, LEUKEMIA, V28, P1407, DOI 10.1038/leu.2014.35; Tefferi A, 2014, AM J HEMATOL, V89, pE121, DOI 10.1002/ajh.23743; Vainchenker W, 2011, BLOOD, V118, P1723, DOI 10.1182/blood-2011-02-292102	54	6	6	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 30	2020	39	31					5323	5337		10.1038/s41388-020-1368-3	http://dx.doi.org/10.1038/s41388-020-1368-3		JUN 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MT1TS	32572159	Green Published			2022-12-28	WOS:000542723000001
J	Haider, N; Dutt, P; van de Kooij, B; Ho, JS; Palomero, L; Pujana, MA; Yaffe, M; Stambolic, V				Haider, Nasir; Dutt, Previn; van de Kooij, Bert; Ho, Jason; Palomero, Luis; Pujana, Miquel Angel; Yaffe, Michael; Stambolic, Vuk			NEK10tyrosine phosphorylates p53 and controls its transcriptional activity	ONCOGENE			English	Article							DNA-DAMAGE RESPONSE; CELL-CYCLE ARREST; REPLICATION; STRESS; MULTIPLE; ACETYLATION; SENSITIVITY; EXPRESSION; MORTALITY; PATTERNS	In response to genotoxic stress, multiple kinase signaling cascades are activated, many of them directed towards the tumor suppressor p53, which coordinates the DNA damage response (DDR). Defects in DDR pathways lead to an accumulation of mutations that can promote tumorigenesis. Emerging evidence implicates multiple members of the NimA-related kinase (NEK) family (NEK1,NEK10, andNEK11) in the DDR. Here, we describe a function forNEK10in the regulation of p53 transcriptional activity through tyrosine phosphorylation.NEK10loss increases cellular proliferation by modulating the p53-dependent transcriptional output.NEK10directly phosphorylates p53 on Y327, revealingNEK10'sunexpected substrate specificity. A p53 mutant at this site (Y327F) acts as a hypomorph, causing an attenuated p53-mediated transcriptional response. Consistently,NEK10-deficient cells display heightened sensitivity to DNA-damaging agents. Further, a combinatorial score ofNEK10andTP53-target gene expression is an independent predictor of a favorable outcome in breast cancers.	[Haider, Nasir; Stambolic, Vuk] Univ Toronto, Dept Med Biophys, Princess Margaret Canc Res Tower, Toronto, ON M5G 1L7, Canada; [Haider, Nasir; Dutt, Previn; Ho, Jason; Stambolic, Vuk] Univ Hlth Network, Princess Margaret Canc Ctr, Princess Margaret Canc Res Tower, Toronto, ON M5G 1L7, Canada; [van de Kooij, Bert; Yaffe, Michael] MIT, David H Koch Inst Integrat Canc Res, Ctr Precis Canc Med, Cambridge, MA 02142 USA; [Palomero, Luis; Pujana, Miquel Angel] Bellvitge Inst Biomed Res IDIBELL, Catalan Inst Oncol, ProCURE, Gran Via 199, Barcelona 08908, Spain; [Yaffe, Michael] MIT, Dept Biol & Biol Engn, Cambridge, MA 02142 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Massachusetts Institute of Technology (MIT); Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Massachusetts Institute of Technology (MIT)	Stambolic, V (corresponding author), Univ Toronto, Dept Med Biophys, Princess Margaret Canc Res Tower, Toronto, ON M5G 1L7, Canada.; Stambolic, V (corresponding author), Univ Hlth Network, Princess Margaret Canc Ctr, Princess Margaret Canc Res Tower, Toronto, ON M5G 1L7, Canada.	vuks@uhnresearch.ca	Pujana, Miquel Angel/N-3127-2014; Pujana, Miguel Angel/ABF-9055-2021; Palomero, Luis/K-1058-2017	Pujana, Miquel Angel/0000-0003-3222-4044; Pujana, Miguel Angel/0000-0003-3222-4044; Stambolic, Vuk/0000-0001-8853-3239; Palomero, Luis/0000-0002-9144-1017; Yaffe, Michael/0000-0002-9547-3251	Princess Margaret Hospital Foundation; CIHR strategic training fellowship of the EIRR 21st Program	Princess Margaret Hospital Foundation; CIHR strategic training fellowship of the EIRR 21st Program(Canadian Institutes of Health Research (CIHR))	We thank Ryan Dowling and members of the Stambolic group (Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada) for their helpful discussion and advice. We thank Anne van Vlimmeren for technical assistance. This work was supported by the Princess Margaret Hospital Foundation and by the CIHR strategic training fellowship of the EIRR 21st Program (Awarded to NH). The results published here are in whole or part based upon data generated by the TCGA Research Network: https://www.cancer.gov/tcga.	Abeyta A, 2017, CELL CYCLE, V16, P335, DOI 10.1080/15384101.2016.1259038; Ahmed S, 2009, NAT GENET, V41, P585, DOI 10.1038/ng.354; Bai Y, 2012, CANCER RES, V72, P2501, DOI 10.1158/0008-5472.CAN-11-3015; Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devcel.2008.01.013; Burstein MD, 2015, CLIN CANCER RES, V21, P1688, DOI 10.1158/1078-0432.CCR-14-0432; Cazzalini O, 2010, MUTAT RES-REV MUTAT, V704, P12, DOI 10.1016/j.mrrev.2010.01.009; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chao C, 2006, MOL CELL BIOL, V26, P6859, DOI 10.1128/MCB.00062-06; Chen YM, 2008, CELL CYCLE, V7, P3194, DOI 10.4161/cc.7.20.6815; Chen YM, 2011, CELL CYCLE, V10, P655, DOI 10.4161/cc.10.4.14814; Choi HJC, 2013, MOL CELL, V51, P423, DOI 10.1016/j.molcel.2013.08.006; Chong LT, 2006, J MOL BIOL, V357, P1039, DOI 10.1016/j.jmb.2005.12.083; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Davies H, 2005, CANCER RES, V65, P7591, DOI 10.1158/0008-5472.CAN-05-1855; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; Early Breast Canc Trialists Collab, 2011, LANCET, V378, P1707, DOI 10.1016/S0140-6736(11)61629-2; Fischer M, 2017, ONCOGENE, V36, P3943, DOI 10.1038/onc.2016.502; Fletcher L, 2004, RADIAT RES, V162, P128, DOI 10.1667/RR3211; Forbes SA, 2017, NUCLEIC ACIDS RES, V45, pD777, DOI 10.1093/nar/gkw1121; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; GAO J, 2013, SCI SIGNAL, V6, ppp11; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Giono LE, 2006, J CELL PHYSIOL, V209, P13, DOI 10.1002/jcp.20689; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Hafner A, 2019, NAT REV MOL CELL BIO, V20, P199, DOI 10.1038/s41580-019-0110-x; Horn HF, 2007, ONCOGENE, V26, P1306, DOI 10.1038/sj.onc.1210263; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; Huang YF, 2014, ONCOTARGET, V5, P5808, DOI 10.18632/oncotarget.2199; HUDSON JM, 1995, DNA CELL BIOL, V14, P759, DOI 10.1089/dna.1995.14.759; Jee HJ, 2010, CELL CYCLE, V9, P4703, DOI 10.4161/cc.9.23.14059; Jin SQ, 2002, ONCOGENE, V21, P8696, DOI 10.1038/sj.onc.1206034; Junttila MR, 2009, NAT REV CANCER, V9, P821, DOI 10.1038/nrc2728; Kastenhuber ER, 2017, CELL, V170, P1062, DOI 10.1016/j.cell.2017.08.028; Kawaguchi T, 2005, ONCOGENE, V24, P6976, DOI 10.1038/sj.onc.1208839; Knights CD, 2006, J CELL BIOL, V173, P533, DOI 10.1083/jcb.200512059; Kumari R, 2014, MOL CELL ONCOL, V1; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lee MY, 2008, CELL CYCLE, V7, P2705, DOI 10.4161/cc.7.17.6551; Liu JF, 2018, CELL, V173, P400, DOI 10.1016/j.cell.2018.02.052; Liu L, 1999, MOL CELL BIOL, V19, P1202; Lord CJ, 2016, NAT REV CANCER, V16, P110, DOI 10.1038/nrc.2015.21; Malkin D., 2011, GENES CANC, V2, P475, DOI DOI 10.1177/1947601911413466; McGale P, 2014, LANCET, V383, P2127, DOI 10.1016/S0140-6736(14)60488-8; McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018; Meek DW, 2004, DNA REPAIR, V3, P1049, DOI 10.1016/j.dnarep.2004.03.027; Melixetian M, 2009, NAT CELL BIOL, V11, P1247, DOI 10.1038/ncb1969; Menendez D, 2009, NAT REV CANCER, V9, P724, DOI 10.1038/nrc2730; Mi J, 2007, CANCER RES, V67, P1082, DOI 10.1158/0008-5472.CAN-06-3071; Moniz L, 2011, CELL DIV, V6, DOI 10.1186/1747-1028-6-18; Moniz LS, 2011, MOL CELL BIOL, V31, P30, DOI 10.1128/MCB.00648-10; Moniz LS, 2010, CHARACTERIZATION NIM; Noguchi K, 2002, J BIOL CHEM, V277, P39655, DOI 10.1074/jbc.M204599200; Pappas K, 2017, MOL CANCER RES, V15, P1051, DOI 10.1158/1541-7786.MCR-17-0089; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Sabir SR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140975; Salem H, 2010, ONCOGENE, V29, P4046, DOI 10.1038/onc.2010.162; Salic A, 2008, P NATL ACAD SCI USA, V105, P2415, DOI 10.1073/pnas.0712168105; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933; Smith SC, 2014, NUCLEIC ACIDS RES, V42, P11517, DOI 10.1093/nar/gku840; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Tsai CF, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7622; Tutt A, 2018, NAT MED, V24, P628, DOI 10.1038/s41591-018-0009-7; van de Kooij B, 2019, ELIFE, V8, DOI 10.7554/eLife.44635; Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179; Wang SL, 2006, CANCER RES, V66, P6982, DOI 10.1158/0008-5472.CAN-06-0511; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Yakovlev VA, 2010, BIOCHEMISTRY-US, V49, P5331, DOI 10.1021/bi100564w	70	7	8	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 23	2020	39	30					5252	5266		10.1038/s41388-020-1361-x	http://dx.doi.org/10.1038/s41388-020-1361-x		JUN 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MO5BV	32561851	Green Submitted			2022-12-28	WOS:000541308400003
J	Li, QL; Karim, RM; Cheng, M; Das, M; Chen, LH; Zhang, C; Lawrence, HR; Daughdrill, GW; Schonbrunn, E; Ji, HT; Chen, JD				Li, Qingliang; Karim, Rezaul M.; Cheng, Mo; Das, Mousumi; Chen, Lihong; Zhang, Chen; Lawrence, Harshani R.; Daughdrill, Gary W.; Schonbrunn, Ernst; Ji, Haitao; Chen, Jiandong			Inhibition of p53 DNA binding by a small molecule protects mice from radiation toxicity	ONCOGENE			English	Article							PARADOXICAL ACTIVATION; PROLIFERATING CELLS; INVOLVEMENT; EXPRESSION; STABILITY; PROMOTES; DAMAGE; ALPHA; RAF	Transcription factors are attractive therapeutic targets that are considered non-druggable because they do not have binding sites for small drug-like ligands. We established a cell-free high-throughput screening assay to search for small molecule inhibitors of DNA binding by transcription factors. A screen was performed using p53 as a target, resulting in the identification of NSC194598 that inhibits p53 sequence-specific DNA binding in vitro (IC50 = 180 nm) and in vivo. NSC194598 selectively inhibited DNA binding by p53 and homologs p63/p73, but did not affect E2F1, TCF1, and c-Myc. Treatment of cells with NSC194598 alone paradoxically led to p53 accumulation and modest increase of transcriptional output owing to disruption of the MDM2-negative feedback loop. When p53 was stabilized and activated by irradiation or chemotherapy drug treatment, NSC194598 inhibited p53 DNA binding and induction of target genes. A single dose of NSC194598 increased the survival of mice after irradiation. The results suggest DNA binding by p53 can be targeted using small molecules to reduce acute toxicity to normal tissues by radiation and chemotherapy.	[Li, Qingliang; Das, Mousumi; Chen, Lihong; Chen, Jiandong] H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL 33612 USA; [Karim, Rezaul M.; Cheng, Mo; Lawrence, Harshani R.; Schonbrunn, Ernst; Ji, Haitao] H Lee Moffitt Canc Ctr & Res Inst, Dept Drug Discovery, Tampa, FL USA; [Karim, Rezaul M.] Univ S Florida, Morsani Coll Med, Dept Mol Med, Tampa, FL 33620 USA; [Zhang, Chen] Univ Illinois, High Throughput Screening Facil, Urbana, IL USA; [Daughdrill, Gary W.] Univ S Florida, Dept Cell Biol Microbiol & Mol Biol, Tampa, FL 33620 USA	H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; University of Illinois System; University of Illinois Urbana-Champaign; State University System of Florida; University of South Florida	Chen, JD (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL 33612 USA.	Jiandong.chen@moffitt.org	Karim, Rezaul M./H-7930-2016; Ji, Haitao/P-6441-2015	Karim, Rezaul M./0000-0002-0424-127X; Ji, Haitao/0000-0001-5526-4503; Schonbrunn, Ernst/0000-0002-3589-3510	National Institutes of Health [CA141244, CA186917, CA208363, GM115556, R50CA211447]; H. Lee Moffitt Cancer Center & Research Institute [P30-CA076292]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); H. Lee Moffitt Cancer Center & Research Institute	The authors wish to thank the National Cancer Institute Developmental Therapeutics Program for providing key compounds. This work is supported in part by grants from the National Institutes of Health (CA141244, CA186917, CA208363 to J.C. GM115556 to D.G. R50CA211447 to H. R. L.). H. Lee Moffitt Cancer Center & Research Institute is an NCI designated Comprehensive Cancer Center (P30-CA076292).	Berg T, 2011, CURR TOP MICROBIOL, V348, P139, DOI 10.1007/82_2010_90; Bushweller JH, 2019, NAT REV CANCER, V19, P611, DOI 10.1038/s41568-019-0196-7; Carvajal D, 2005, CANCER RES, V65, P1918, DOI 10.1158/0008-5472.CAN-04-3576; Checler F, 2014, PHARMACOL THERAPEUT, V142, P99, DOI 10.1016/j.pharmthera.2013.11.009; CRUMRINE RC, 1994, J CEREBR BLOOD F MET, V14, P887, DOI 10.1038/jcbfm.1994.119; Goh AM, 2015, ONCOTARGET, V6, P17968, DOI 10.18632/oncotarget.4956; Gudkov AV, 2005, BIOCHEM BIOPH RES CO, V331, P726, DOI 10.1016/j.bbrc.2005.03.153; Hall-Jackson CA, 1999, CHEM BIOL, V6, P559, DOI 10.1016/S1074-5521(99)80088-X; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; He F, 2019, P NATL ACAD SCI USA, V116, P8859, DOI 10.1073/pnas.1903077116; Hoe KK, 2014, NAT REV DRUG DISCOV, V13, P217, DOI 10.1038/nrd4236; Hoggard LR, 2015, J AM CHEM SOC, V137, P12249, DOI 10.1021/jacs.5b04988; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Jiang M, 2006, ONCOGENE, V25, P4056, DOI 10.1038/sj.onc.1209440; Khoo KH, 2009, J MOL BIOL, V393, P161, DOI 10.1016/j.jmb.2009.08.013; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Komarova EA, 2004, ONCOGENE, V23, P3265, DOI 10.1038/sj.onc.1207494; Komarova EA, 2003, J BIOL CHEM, V278, P15465, DOI 10.1074/jbc.C300011200; Lilyestrom W, 2006, GENE DEV, V20, P2373, DOI 10.1101/gad.1456306; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Luker KE, 2004, P NATL ACAD SCI USA, V101, P12288, DOI 10.1073/pnas.0404041101; Mandell JG, 2006, NUCLEIC ACIDS RES, V34, pW516, DOI 10.1093/nar/gkl209; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; Pant V, 2013, GENE DEV, V27, P1857, DOI 10.1101/gad.227249.113; Pochampally R, 2000, BIOCHEM BIOPH RES CO, V279, P1001, DOI 10.1006/bbrc.2000.4056; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Retzlaff M, 2013, J MOL BIOL, V425, P144, DOI 10.1016/j.jmb.2012.10.015; Ross FA, 2017, CELL CHEM BIOL, V24, P813, DOI 10.1016/j.chembiol.2017.05.021; Segal DJ, 2006, J MOL BIOL, V363, P405, DOI 10.1016/j.jmb.2006.08.016; Shin YJ, 2015, ONCOGENE, V34, P1292, DOI 10.1038/onc.2014.65; Tisato V, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0500-5; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Walton MI, 2005, MOL CANCER THER, V4, P1369, DOI 10.1158/1535-7163.MCT-04-0341; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wassman CD, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2361; Wei QQ, 2007, AM J PHYSIOL-RENAL, V293, pF1282, DOI 10.1152/ajprenal.00230.2007; Westphal CH, 1998, CANCER RES, V58, P5637; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhang XL, 2012, P NATL ACAD SCI USA, V109, P9623, DOI 10.1073/pnas.1121606109; Zhu JW, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58051-1	41	6	6	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 16	2020	39	29					5187	5200		10.1038/s41388-020-1344-y	http://dx.doi.org/10.1038/s41388-020-1344-y		JUN 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ML6WO	32555331	Green Accepted			2022-12-28	WOS:000545371000002
J	Zhu, ZH; Song, JLE; Guo, YG; Huang, ZY; Chen, XJ; Dang, XN; Huang, YJ; Wang, YH; Ou, WJ; Yang, YL; Yu, W; Liu, CY; Cui, L				Zhu, Zhehui; Song, Jinglue; Guo, Yuegui; Huang, Zhenyu; Chen, Xiaojian; Dang, Xuening; Huang, Yuji; Wang, Yuhan; Ou, Weijun; Yang, Yili; Yu, Wei; Liu, Chen-Ying; Cui, Long			LAMB3 promotes tumour progression through the AKT-FOXO3/4 axis and is transcriptionally regulated by the BRD2/acetylated ELK4 complex in colorectal cancer	ONCOGENE			English	Article							LAMININ GAMMA-2; ACTIVATION; CARCINOMAS; EXPRESSION; BRD4; SUPPRESSES; ADHESION; INVASION; FAMILY; TARGET	Aberrant expression of laminin-332 promotes tumour growth and metastasis in multiple cancers. However, the dysregulated expression and mechanism of action of LAMB3, which encodes the beta 3 subunit of laminin-332, and the mechanism underlying dysregulated LAMB3 expression in CRC remain obscure. Here, we show that LAMB3 is overexpressed in CRC and that this overexpression is correlated with tumour metastasis and poor prognosis. Overexpression of LAMB3 promoted cell proliferation and cell migration in vitro and tumour growth and metastasis in vivo, while knockdown of LAMB3 elicited opposing effects. LAMB3 inhibited the tumour suppressive function of FOXO3/4 by activating AKT in CRC. Both the BET inhibitor JQ1 and the MEK inhibitor U0126 decreased the mRNA level of LAMB3 in multiple CRC cells. Mechanistically, ELK4 cooperated with BRD2 to regulate the transcription of LAMB3 in CRC by directly binding to the ETS binding motifs in the LAMB3 promoter. ELK4 was as acetylated at K125, which enhanced the interaction between ELK4 and BRD2. JQ1 disrupted the interaction between ELK4 and BRD2, resulting in decreased binding of BRD2 to the LAMB3 promoter and downregulation of LAMB3 transcription. Both ELK4 and BRD2 expression was associated with LAMB3 expression in CRC. LAMB3 expression was also negatively correlated with FOXO3/4 in CRC. Our study reveals the pro-tumorigenic role of LAMB3 through the AKT-FOXO3/4 axis and the transcriptional mechanism of LAMB3 in CRC, demonstrating that LAMB3 is a potential therapeutic target that can be targeted by BET inhibitors and MEK inhibitors.	[Zhu, Zhehui; Song, Jinglue; Guo, Yuegui; Wang, Yuhan; Ou, Weijun; Liu, Chen-Ying; Cui, Long] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Colorectal & Anal Surg, Shanghai 200092, Peoples R China; [Zhu, Zhehui; Huang, Zhenyu; Chen, Xiaojian; Dang, Xuening; Huang, Yuji; Liu, Chen-Ying; Cui, Long] Shanghai Colorectal Canc Res Ctr, Shanghai 200092, Peoples R China; [Yang, Yili] Chinese Acad Med Sci, Ctr Syst Med Res, Suzhou Inst Syst Med, Suzhou 215123, Jiangsu, Peoples R China; [Yu, Wei] Fudan Univ, State Key Lab Genet Engn, Shanghai 200438, Peoples R China; [Yu, Wei] Fudan Univ, Collaborat Innovat Ctr Genet & Dev, Sch Life Sci, Shanghai 200438, Peoples R China; [Yu, Wei] Fudan Univ, Zhongshan Hosp, Shanghai 200438, Peoples R China	Shanghai Jiao Tong University; Chinese Academy of Medical Sciences - Peking Union Medical College; Fudan University; Fudan University; Fudan University	Liu, CY; Cui, L (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Colorectal & Anal Surg, Shanghai 200092, Peoples R China.; Liu, CY; Cui, L (corresponding author), Shanghai Colorectal Canc Res Ctr, Shanghai 200092, Peoples R China.; Yu, W (corresponding author), Fudan Univ, State Key Lab Genet Engn, Shanghai 200438, Peoples R China.; Yu, W (corresponding author), Fudan Univ, Collaborat Innovat Ctr Genet & Dev, Sch Life Sci, Shanghai 200438, Peoples R China.; Yu, W (corresponding author), Fudan Univ, Zhongshan Hosp, Shanghai 200438, Peoples R China.	yuw@fudan.edu.cn; liuchenying@xinhuamed.com.cn; cuilong@xinhuamed.com.cn		YU, WEI/0000-0001-9898-4607; Liu, Chen-Ying/0000-0002-8930-6182; Zhu, Zhehui/0000-0002-3676-5254	National Natural Science Foundation of China [81974060, 81874177, 81672517, 31771545, 91749120]; National High Technology Research and Development Program of China (863 Program) [2014AA020801]; National Key R&D Program of China [2019YFC1316002]; Program for Professor of Special Appointment (Young Eastern Scholar) at Shanghai Institutions of Higher Learning; Shanghai Pujiang Program [18PJ1407400]; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant [20171918]; Innovative research team of high-level local universities in Shanghai; Innovation Program for Ph.D. students in Shanghai Jiao Tong University School of Medicine [BXJ201827]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National High Technology Research and Development Program of China (863 Program)(National High Technology Research and Development Program of China); National Key R&D Program of China; Program for Professor of Special Appointment (Young Eastern Scholar) at Shanghai Institutions of Higher Learning; Shanghai Pujiang Program(Shanghai Pujiang Program); Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant; Innovative research team of high-level local universities in Shanghai; Innovation Program for Ph.D. students in Shanghai Jiao Tong University School of Medicine	This work was supported by the National Natural Science Foundation of China (81974060, 81874177, 81672517, 31771545, and 91749120), the National High Technology Research and Development Program of China (863 Program) (Grant No. 2014AA020801), the National Key R&D Program of China (2019YFC1316002), The Program for Professor of Special Appointment (Young Eastern Scholar) at Shanghai Institutions of Higher Learning (to C-YL), Shanghai Pujiang Program (18PJ1407400), Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant (20171918), Innovative research team of high-level local universities in Shanghai and the Innovation Program for Ph.D. students in Shanghai Jiao Tong University School of Medicine (BXJ201827).	Baeza J, 2016, TRENDS BIOCHEM SCI, V41, P231, DOI 10.1016/j.tibs.2015.12.006; Barber MF, 2012, NATURE, V487, P114, DOI 10.1038/nature11043; Blee AM, 2016, ONCOTARGET, V7, P38319, DOI 10.18632/oncotarget.9513; Chen JH, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00405-x; Chen XB, 2016, ONCOTARGET, V7, P86695, DOI 10.18632/oncotarget.13435; Choma DP, 2007, J INVEST DERMATOL, V127, P31, DOI 10.1038/sj.jid.5700505; Domogatskaya A, 2012, ANNU REV CELL DEV BI, V28, P523, DOI 10.1146/annurev-cellbio-101011-155750; Feng MB, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0564-9; Fukushima Y, 1998, INT J CANCER, V76, P63, DOI 10.1002/(SICI)1097-0215(19980330)76:1<63::AID-IJC11>3.0.CO;2-H; Gollavilli PN, 2018, CANCER RES, V78, P4760, DOI 10.1158/0008-5472.CAN-18-0484; Hlubek F, 2001, CANCER RES, V61, P8089; Huang ZM, 2018, NAT CHEM BIOL, V14, P1118, DOI 10.1038/s41589-018-0150-0; Irifune H, 2005, CANCER BIOL THER, V4, P449; Jedlicka P, 2008, HISTOL HISTOPATHOL, V23, P1417, DOI 10.14670/HH-23.1417; Jung SN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21216-0; Kai F, 2019, DEV CELL, V49, P332, DOI 10.1016/j.devcel.2019.03.026; Keum N, 2019, NAT REV GASTRO HEPAT, V16, P713, DOI 10.1038/s41575-019-0189-8; Kwon OH, 2011, BIOCHEM BIOPH RES CO, V406, P539, DOI 10.1016/j.bbrc.2011.02.082; Lamonica JM, 2011, P NATL ACAD SCI USA, V108, pE159, DOI 10.1073/pnas.1102140108; Le Rolle AF, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0555-4; Li QJ, 2003, EMBO J, V22, P281, DOI 10.1093/emboj/cdg028; Lohi J, 2000, APMIS, V108, P161, DOI 10.1034/j.1600-0463.2000.d01-40.x; Ma YF, 2017, CLIN CANCER RES, V23, P2027, DOI 10.1158/1078-0432.CCR-16-0453; Manfredi S, 2006, ANN SURG, V244, P254, DOI 10.1097/01.sla.0000217629.94941.cf; Manohar A, 2004, J CELL SCI, V117, P4043, DOI 10.1242/jcs.01277; McCleland ML, 2016, J CLIN INVEST, V126, P639, DOI 10.1172/JCI83265; Moriya Y, 2001, CANCER, V91, P1129, DOI 10.1002/1097-0142(20010315)91:6<1129::AID-CNCR1109>3.0.CO;2-C; Nguyen BP, 2000, J BIOL CHEM, V275, P31896, DOI 10.1074/jbc.M006379200; Olsen J, 2003, BIOCHEM J, V371, P211, DOI 10.1042/BJ20021454; Peng C, 2016, ONCOGENE, V35, P1170, DOI 10.1038/onc.2015.175; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; PYKE C, 1994, AM J PATHOL, V145, P782; Roe JS, 2015, MOL CELL, V58, P1028, DOI 10.1016/j.molcel.2015.04.011; Shi J, 2014, CANCER CELL, V25, P210, DOI 10.1016/j.ccr.2014.01.028; Sizemore GM, 2017, NAT REV CANCER, V17, P337, DOI 10.1038/nrc.2017.20; Stathis A, 2018, CANCER DISCOV, V8, P24, DOI 10.1158/2159-8290.CD-17-0605; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tani T, 1997, AM J PATHOL, V151, P1289; Tsuruta D, 2008, CURR MED CHEM, V15, P1968, DOI 10.2174/092986708785132834; Wang XL, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0053938, 10.1371/journal.pone.0050627]; Wu TY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0354-y; Young B, 2017, CANCER LETT, V387, P114, DOI 10.1016/j.canlet.2016.01.048; Zhang F, 2018, ONCOGENE, V37, P363, DOI 10.1038/onc.2017.334; Zhang H, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1320-z; Zhou Y, 2016, CANCER RES, V76, P5777, DOI 10.1158/0008-5472.CAN-15-2936; Zou Z, 2014, ONCOGENE, V33, P2395, DOI 10.1038/onc.2013.179	46	19	19	5	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	24					4666	4680		10.1038/s41388-020-1321-5	http://dx.doi.org/10.1038/s41388-020-1321-5		MAY 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LY0HO	32398865				2022-12-28	WOS:000532103100003
J	Yu, L; Dong, L; Li, H; Liu, ZJ; Luo, Z; Duan, GJ; Dai, XT; Lin, ZH				Yu, Le; Dong, Ling; Li, Hui; Liu, Zhaojian; Luo, Zhong; Duan, Guangjie; Dai, Xiaotian; Lin, Zhenghong			Ubiquitination-mediated degradation of SIRT1 by SMURF2 suppresses CRC cell proliferation and tumorigenesis	ONCOGENE			English	Article							DEPENDENT DEGRADATION; DEACETYLASE ACTIVITY; CANCER STATISTICS; PROTEIN SIR2; LIGASE; TRANSCRIPTION; ACTIVATION; REPRESSION; REGULATOR; INTERACTS	The NAD-dependent deacetylase sirtuin 1 (SIRT1), a member of the mammalian sirtuin family, plays a pivotal role in deacetylating histone and nonhistone proteins. Recently, it has been reported that SIRT1 is upregulated in various kinds of tumors and is associated with cell growth and metastasis. However, the factors and molecular mechanism regulating its cellular levels remain to be clarified. Here, we reported that the E3 ubiquitin ligase SMURF2 interacts with SIRT1 and mediates its ubiquitination and degradation. Depletion of SMURF2 leads to SIRT1 upregulation and induces the tumor formation and growth of colorectal cancer in vitro and in vivo. Furthermore, we show a negative correlation between SIRT1 and SMURF2 expression in human colorectal cancer. Thus, we propose a novel mechanism of colorectal tumorigenesis via SIRT1 regulation by SMURF2, which could potentially give rise to a new strategy for the treatment of colorectal cancer.	[Yu, Le; Dong, Ling; Li, Hui; Luo, Zhong; Lin, Zhenghong] Chongqing Univ, Sch Life Sci, Chongqing 401331, Peoples R China; [Liu, Zhaojian] Shandong Univ, Dept Cell Biol, Sch Med, Jinan 250012, Peoples R China; [Duan, Guangjie; Dai, Xiaotian] Third Mil Med Univ, Dept Pulmonol, Southwest Hosp, Chongqing 400038, Peoples R China	Chongqing University; Shandong University; Army Medical University	Lin, ZH (corresponding author), Chongqing Univ, Sch Life Sci, Chongqing 401331, Peoples R China.; Dai, XT (corresponding author), Third Mil Med Univ, Dept Pulmonol, Southwest Hosp, Chongqing 400038, Peoples R China.	daixt1973@163.com; zhenghonglin@cqu.edu.cn	Luo, Zhong/AAU-2225-2020; , Owen/AHE-6976-2022	Luo, Zhong/0000-0002-9019-3314; Lin, Zhenghong/0000-0002-6354-0042	National Natural Science Foundation of China [31571454, 31801181]; 61st Batch of China Postdoctoral Science Fund [2017M610588]; Special Fund for Postdoctoral Research Projects of Chongqing City [Xm2017080]; Fundamental Research Funds for the Central Universities [106112017CDJQJ298833]; Key Laboratory for Experimental Teratology of the Ministry of Education of Shandong University	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 61st Batch of China Postdoctoral Science Fund; Special Fund for Postdoctoral Research Projects of Chongqing City; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Key Laboratory for Experimental Teratology of the Ministry of Education of Shandong University	The National Natural Science Foundation of China (Grant Nos. 31571454 and 31801181), the 61st Batch of China Postdoctoral Science Fund (Grant No. 2017M610588), the Special Fund for Postdoctoral Research Projects of Chongqing City (Grant No. Xm2017080), the Fundamental Research Funds for the Central Universities (Project No. 106112017CDJQJ298833), and the funding from Key Laboratory for Experimental Teratology of the Ministry of Education of Shandong University supported this study. We also thank the Analytical and Testing Center of Chongqing University for confocal fluorescence microscopy assistance.	Behrouzfar K, 2017, CELL BIOCHEM FUNCT, V35, P327, DOI 10.1002/cbf.3279; Blank M, 2012, NAT MED, V18, P227, DOI 10.1038/nm.2596; Bouras T, 2005, J BIOL CHEM, V280, P10264, DOI 10.1074/jbc.M408748200; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brooks CL, 2009, NAT REV CANCER, V9, P123, DOI 10.1038/nrc2562; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Cha B, 2015, MOL CELLS, V38, P723, DOI 10.14348/molcells.2015.0113; Chen J, 2011, CANCER RES, V71, P4138, DOI 10.1158/0008-5472.CAN-10-4274; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Cheng FF, 2016, CANCER LETT, V375, P274, DOI 10.1016/j.canlet.2016.03.010; Dong L, 2018, ONCOGENE, V37, P2702, DOI 10.1038/s41388-018-0137-z; Elangovan S, 2011, CANCER RES, V71, P6654, DOI 10.1158/0008-5472.CAN-11-1446; Elias D, 2015, ANN SURG, V261, P157, DOI 10.1097/SLA.0000000000000582; Fukunaga E, 2008, J BIOL CHEM, V283, P35660, DOI 10.1074/jbc.M710496200; Haigis MC, 2010, ANNU REV PATHOL-MECH, V5, P253, DOI 10.1146/annurev.pathol.4.110807.092250; Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jeong HM, 2014, BBA-MOL CELL RES, V1843, P2005, DOI 10.1016/j.bbamcr.2014.04.023; Jeong J, 2007, EXP MOL MED, V39, P8, DOI 10.1038/emm.2007.2; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kim EJ, 2007, MOL CELL, V28, P277, DOI 10.1016/j.molcel.2007.08.030; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Lee IH, 2008, P NATL ACAD SCI USA, V105, P3374, DOI 10.1073/pnas.0712145105; Lee YS, 2019, ASTROPHYS SPACE SCI, V364, DOI 10.1007/s10509-019-3691-0; Li LS, 2013, CLIN EXP MED, V13, P109, DOI 10.1007/s10238-012-0186-5; Li Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00299-9; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Lin ZH, 2012, MOL CELL, V46, P484, DOI 10.1016/j.molcel.2012.03.024; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; Menssen A, 2012, P NATL ACAD SCI USA, V109, pE187, DOI 10.1073/pnas.1105304109; Mertins P, 2013, NAT METHODS, V10, P634, DOI 10.1038/nmeth.2518; Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349; Nemoto S, 2005, J BIOL CHEM, V280, P16456, DOI 10.1074/jbc.M501485200; Olmos Y, 2011, DRUG RESIST UPDATE, V14, P35, DOI 10.1016/j.drup.2010.12.001; Ramkumar C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3598; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wang CG, 2006, NAT CELL BIOL, V8, P1025, DOI 10.1038/ncb1468; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Wiesner S, 2007, CELL, V130, P651, DOI 10.1016/j.cell.2007.06.050; Wilking MJ, 2014, ARCH BIOCHEM BIOPHYS, V563, P94, DOI 10.1016/j.abb.2014.04.001; Wong S, 2007, BIOCHEM J, V407, P451, DOI 10.1042/BJ20070151; Yamakuchi M, 2008, P NATL ACAD SCI USA, V105, P13421, DOI 10.1073/pnas.0801613105; Yang YH, 2007, NAT CELL BIOL, V9, P1253, DOI 10.1038/ncb1645; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Yu L, 2019, CANCER LETT, V448, P40, DOI 10.1016/j.canlet.2019.01.039; Zhang R, 2010, J BIOL CHEM, V285, P7097, DOI 10.1074/jbc.M109.038604; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhang Y, 2009, ONCOGENE, V28, P445, DOI 10.1038/onc.2008.388	51	32	32	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	22					4450	4464		10.1038/s41388-020-1298-0	http://dx.doi.org/10.1038/s41388-020-1298-0		MAY 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LR9IT	32361710				2022-12-28	WOS:000530258200001
J	Pellarin, I; Dall'Acqua, A; Gambelli, A; Pellizzari, I; D'Andrea, S; Sonego, M; Lorenzon, I; Schiappacassi, M; Belletti, B; Baldassarre, G				Pellarin, Ilenia; Dall'Acqua, Alessandra; Gambelli, Alice; Pellizzari, Ilenia; D'Andrea, Sara; Sonego, Maura; Lorenzon, Ilaria; Schiappacassi, Monica; Belletti, Barbara; Baldassarre, Gustavo			Splicing factor proline- and glutamine-rich (SFPQ) protein regulates platinum response in ovarian cancer-modulating SRSF2 activity	ONCOGENE			English	Article							RNA-BINDING PROTEIN; REPAIR; PSF; EXPRESSION; APOPTOSIS; NONO; RESISTANCE; VARIANT; DOMAIN; ERCC1	In epithelial ovarian cancer (EOC), response to platinum (PT)-based chemotherapy dictates subsequent treatments and predicts patients' prognosis. Alternative splicing is often deregulated in human cancers and can be altered by chemotherapy. Whether and how changes in alternative splicing regulation could impact on the response of EOC to PT-based chemotherapy is still not clarified. We identified the splicing factor proline and glutamine rich (SFPQ) as a critical mediator of response to PT in an unbiased functional genomic screening in EOC cells and, using a large cohort of primary and recurrent EOC samples, we observed that it is frequently overexpressed in recurrent PT-treated samples and that its overexpression correlates with PT resistance. At mechanistic level, we show that, under PT treatment, SFPQ, in complex with p54(nrb), binds and regulates the activity of the splicing factor SRSF2. SFPQ/p54(nrb) complex decreases SRSF2 binding to caspase-9 RNA, favoring the expression of its alternative spliced antiapoptotic form. As a consequence, SFPQ/p54(nrb) protects cells from PT-induced death, eventually contributing to chemoresistance. Overall, our work unveils a previously unreported SFPQ/p54(nrb)/SRSF2 pathway that in EOC cells plays a central role in regulating alternative splicing and PT-induced apoptosis and that could result in the design of new possible ways of intervention to overcome PT resistance.	[Pellarin, Ilenia; Dall'Acqua, Alessandra; Gambelli, Alice; Pellizzari, Ilenia; D'Andrea, Sara; Sonego, Maura; Lorenzon, Ilaria; Schiappacassi, Monica; Belletti, Barbara; Baldassarre, Gustavo] NCI, IRCCS, Ctr Riferimento Oncol Aviano CRO, Div Mol Oncol, I-33081 Aviano, PN, Italy	IRCCS Aviano (CRO)	Baldassarre, G (corresponding author), NCI, IRCCS, Ctr Riferimento Oncol Aviano CRO, Div Mol Oncol, I-33081 Aviano, PN, Italy.	gbaldassarre@cro.it	Schiappacassi, Monica/AAX-5505-2020; Pellarin, Ilenia/AAY-2238-2020; Lorenzon, Ilaria/AAY-6372-2020; Belletti, Barbara/J-2028-2018; Dall'Acqua, Alessandra/ABF-8020-2020; Sonego, Maura/AAX-5529-2020; GAMBELLI, ALICE/ABD-4280-2020; Baldassarre, Gustavo/K-1350-2016	Schiappacassi, Monica/0000-0003-4804-4291; Pellarin, Ilenia/0000-0002-1041-1722; Lorenzon, Ilaria/0000-0001-6336-4678; Belletti, Barbara/0000-0003-2249-0285; Dall'Acqua, Alessandra/0000-0003-2297-1361; Sonego, Maura/0000-0002-9505-9771; GAMBELLI, ALICE/0000-0003-0223-9798; Baldassarre, Gustavo/0000-0002-9750-8825	Ministero della Salute [RCR-2019-23669115, RF-2016-02361040, GR-2016-02361041]; Ministero degli Affari Esteri e Cooperazione Internazionale [PGR01036]; CRO-Ricerca Corrente core grant (linea 1); 5x1000 CRO Intramural; Regione Friuli Venezia Giulia (POR-FERS TICHEP grant)	Ministero della Salute(Ministry of Health, Italy); Ministero degli Affari Esteri e Cooperazione Internazionale; CRO-Ricerca Corrente core grant (linea 1); 5x1000 CRO Intramural; Regione Friuli Venezia Giulia (POR-FERS TICHEP grant)	We are grateful to the patients who consented to donating their samples. We thank Dr Benjamin Blencowe for providing the p54<SUP>nrb</SUP> and the SFPQ wild type and mutant expression vectors (through Addgene) and Dr Beatrice Eymin for providing the SRSF2 vector. We like to thank all members of the SCICC lab for fruitful scientific discussion, Dr Riccardo Bomben for helping us with the analysis of gene expression profiles and Dr Francesca Rossi for FACS analyses. This work was supported by grants from Ministero della Salute (RCR-2019-23669115 and RF-2016-02361040 to GB and GR-2016-02361041 to MS); Ministero degli Affari Esteri e Cooperazione Internazionale (PGR01036 to GB), CRO-Ricerca Corrente core grant (linea 1); 5x1000 CRO Intramural to GB and Regione Friuli Venezia Giulia (POR-FERS TICHEP grant to GB).	Dall'Acqua A, 2017, EMBO MOL MED, V9, P1415, DOI 10.15252/emmm.201607012; Edmond V, 2011, EMBO J, V30, P510, DOI 10.1038/emboj.2010.333; Fischer DC, 2004, ONCOL REP, V11, P1085; Freimund AE, 2018, HEMATOL ONCOL CLIN N, V32, P983, DOI 10.1016/j.hoc.2018.07.007; Gabriel M, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1259-0; Heyd F, 2010, MOL CELL, V40, P126, DOI 10.1016/j.molcel.2010.09.013; Jaafar L, 2017, NUCLEIC ACIDS RES, V45, P1848, DOI 10.1093/nar/gkw1209; Jayson GC, 2014, LANCET, V384, P1376, DOI 10.1016/S0140-6736(13)62146-7; Kedzierska H, 2017, CANCER LETT, V396, P53, DOI 10.1016/j.canlet.2017.03.013; Knott GJ, 2016, NUCLEIC ACIDS RES, V44, P3989, DOI 10.1093/nar/gkw271; Konstantinopoulos PA, 2018, HEMATOL ONCOL CLIN N, V32, P997, DOI 10.1016/j.hoc.2018.07.006; Lambert CA, 2017, INT J BIOCHEM CELL B, V91, P84, DOI 10.1016/j.biocel.2017.04.006; Lee SCW, 2016, NAT MED, V22, P976, DOI 10.1038/nm.4165; Lee SCW, 2016, NAT MED, V22, P672, DOI 10.1038/nm.4097; Lheureux S, 2019, LANCET, V393, P1240, DOI 10.1016/S0140-6736(18)32552-2; Li SY, 2017, DNA REPAIR, V51, P70, DOI 10.1016/j.dnarep.2017.02.002; Lorenzon I, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010036; Marzec M, 2008, P NATL ACAD SCI USA, V105, P20852, DOI 10.1073/pnas.0810958105; Merdzhanova G, 2008, CELL DEATH DIFFER, V15, P1815, DOI 10.1038/cdd.2008.135; Meyer S, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.264; Nicoloso MS, 2017, CANC BREAK NEWS, P25, DOI DOI 10.19156/CBN.2017.0056; Rosonina E, 2005, MOL CELL BIOL, V25, P6734, DOI 10.1128/MCB.25.15.6734-6746.2005; Segatto I, 2019, CANCER RES, V79, P397, DOI 10.1158/0008-5472.CAN-18-2488; Seiler M, 2018, NAT MED, V24, P497, DOI 10.1038/nm.4493; Sevcik J, 2013, CELL SIGNAL, V25, P1186, DOI 10.1016/j.cellsig.2013.02.008; Sevcik J, 2012, CELL SIGNAL, V24, P1023, DOI 10.1016/j.cellsig.2011.12.023; Shav-Tal Y, 2002, FEBS LETT, V531, P109, DOI 10.1016/S0014-5793(02)03447-6; Shav-Tal Y, 2001, MOL BIOL CELL, V12, P2328, DOI 10.1091/mbc.12.8.2328; Sonego M, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav3235; Sonego M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07005-1; Sonego M, 2013, EMBO MOL MED, V5, P707, DOI 10.1002/emmm.201201504; Sun YH, 2009, CANCER INVEST, V27, P891, DOI 10.3109/07357900902744536; Takayama K, 2017, P NATL ACAD SCI USA, V114, P10461, DOI 10.1073/pnas.1706076114; Tsukahara T, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/204973; Wu W, 2010, MUTAT RES-FUND MOL M, V691, P1, DOI 10.1016/j.mrfmmm.2010.06.002; Yarosh CA, 2015, WIRES RNA, V6, P351, DOI 10.1002/wrna.1280; Yu JJ, 1998, INT J MOL MED, V1, P617; Zhang GL, 2012, MUTAT RES-GEN TOX EN, V746, P66, DOI 10.1016/j.mrgentox.2012.03.004; Zhu JY, 2018, GYNECOL ONCOL, V148, P368, DOI 10.1016/j.ygyno.2017.11.028	39	23	24	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	22					4390	4403		10.1038/s41388-020-1292-6	http://dx.doi.org/10.1038/s41388-020-1292-6		APR 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LR9IT	32332923	hybrid, Green Published			2022-12-28	WOS:000528417800001
J	Grassi, ES; Pantazopoulou, V; Pietras, A				Grassi, Elisa Stellaria; Pantazopoulou, Vasiliki; Pietras, Alexander			Hypoxia-induced release, nuclear translocation, and signaling activity of a DLK1 intracellular fragment in glioma	ONCOGENE			English	Article							STEM-CELLS; TUMOR; INTERACTS; PREF-1; AKT; HIF-2-ALPHA; INHIBITION; ACTIVATION; EXPRESSION; PHENOTYPE	Glioblastoma multiforme is characterized in part by severe hypoxia associated with tumor necrosis. The cellular response to hypoxia can influence several properties of tumor cells associated with aggressive tumor growth, including metabolic adaptations and tumor cell migration and invasion. Here, we found that Delta Like Non-Canonical Notch Ligand 1 (DLK1) expression was elevated as compared with normal brain in a genetically engineered mouse model of glioma, and that DLK1 expression increased with tumor grade in human glioma samples. DLK1 expression was highest in hypoxic and perivascular tumor areas, and we found that hypoxia induced the release and nuclear translocation of an intracellular fragment of DLK1 in murine glioma as well as in human glioma cultures. Release of the intracellular fragment was dependent on ADAM17 and Hypoxia-inducible Factor 1alpha and 2alpha (HIF-1alpha/HIF-2alpha), as ADAM17 inhibitors and HIF1A/HIF2A siRNA blocked DLK1 cleavage. Expression of a cleavable form of DLK1 amplified several hypoxia-induced traits of glioma cells such as colony formation, stem cell marker gene expression, a PI3K-pathway-mediated metabolic shift, and enhanced invasiveness. Effects of DLK1 were dependent on DLK1-cleavage by ADAM17, as expression of non-cleavable DLK1 could not replicate the DLK1-induced hypoxic phenotype. Finally, forced expression of DLK1 resulted in more invasive tumor growth in a PDGFB-induced glioma mouse model without affecting overall survival. Together, our findings suggest a previously undescribed role for DLK1 as an intracellular signaling molecule.	[Grassi, Elisa Stellaria; Pantazopoulou, Vasiliki; Pietras, Alexander] Lund Univ, Div Translat Canc Res, Dept Lab Med, Lund, Sweden; [Grassi, Elisa Stellaria] Univ Milan, Dept Clin Sci & Community Hlth DISCCO, Milan, Italy	Lund University; University of Milan	Pietras, A (corresponding author), Lund Univ, Div Translat Canc Res, Dept Lab Med, Lund, Sweden.	Alexander.Pietras@med.lu.se	Grassi, Elisa Stellaria/K-4402-2016	Grassi, Elisa Stellaria/0000-0002-0410-1277; Pietras, Alexander/0000-0002-5783-9347; Pantazopoulou, Vasiliki/0000-0002-5965-5795	Ragnar Soderberg Foundation; Swedish Cancer Society; Swedish Research Council; Swedish Childhood Cancer Fund; Ollie & Elof Ericssons foundation; Jeanssons stiftelser; Crafoord foundation; Gosta Miltons donationsfond; Stiftelsen Cancera	Ragnar Soderberg Foundation; Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Childhood Cancer Fund; Ollie & Elof Ericssons foundation; Jeanssons stiftelser; Crafoord foundation; Gosta Miltons donationsfond; Stiftelsen Cancera	The authors thank Christina Moller for skillful technical assistance and A HGCC (www.hgcc.se) (Lene Uhrbom, Bengt Westermark, Karin Forsberg Nilsson and Sven Nelander, Uppsala University, Sweden) for human GBM cultures. This work was supported by grants from the Ragnar Soderberg Foundation, the Swedish Cancer Society, the Swedish Research Council, the Swedish Childhood Cancer Fund, Ollie & Elof Ericssons foundation, Jeanssons stiftelser, the Crafoord foundation, Gosta Miltons donationsfond, and Stiftelsen Cancera.	Baladron V, 2005, EXP CELL RES, V303, P343, DOI 10.1016/j.yexcr.2004.10.001; Bernstock JD, 2020, J NEUROSURG, V133, P655, DOI 10.3171/2019.5.JNS19364; Bleau AM, 2009, CELL STEM CELL, V4, P226, DOI 10.1016/j.stem.2009.01.007; Bowman RL, 2017, NEURO-ONCOLOGY, V19, P139, DOI 10.1093/neuonc/now247; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Ceccarelli M, 2016, CELL, V164, P550, DOI 10.1016/j.cell.2015.12.028; Ceder JA, 2008, EUR UROL, V54, P1344, DOI 10.1016/j.eururo.2008.03.006; Cho SJ, 2008, MOL MED REP, V1, P83; Dekel B, 2006, CANCER RES, V66, P6040, DOI 10.1158/0008-5472.CAN-05-4528; Dyczynska E, 2007, J BIOL CHEM, V282, P436, DOI 10.1074/jbc.M605451200; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Falix FA, 2012, BBA-MOL BASIS DIS, V1822, P988, DOI 10.1016/j.bbadis.2012.02.003; Ferron SR, 2011, NATURE, V475, P381, DOI 10.1038/nature10229; Gulyaeva O, 2018, CELL REP, V25, P1002, DOI 10.1016/j.celrep.2018.09.086; Hambardzumyan D, 2015, TRENDS CANCER, V1, P252, DOI 10.1016/j.trecan.2015.10.009; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; Huang CC, 2019, ONCOGENE, V38, P3201, DOI 10.1038/s41388-018-0658-5; Hudak Carolyn S, 2013, Front Endocrinol (Lausanne), V4, P79, DOI 10.3389/fendo.2013.00079; Huse JT, 2010, NAT REV CANCER, V10, P319, DOI 10.1038/nrc2818; Jawhari S, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.318; Johansson E, 2017, CELL REP, V20, P1641, DOI 10.1016/j.celrep.2017.07.049; Kim Y, 2009, CANCER RES, V69, P9271, DOI 10.1158/0008-5472.CAN-09-1605; Li L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099222; Ma JC, 2009, MOL CELL BIOCHEM, V331, P161, DOI 10.1007/s11010-009-0154-x; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Masui K, 2015, BRAIN PATHOL, V25, P755, DOI 10.1111/bpa.12307; Nagano O, 2004, J CELL BIOL, V165, P893, DOI 10.1083/jcb.200310024; Pelullo M, 2019, CANCER RES, V79, P5575, DOI 10.1158/0008-5472.CAN-19-0145; Pietras A, 2008, J PATHOL, V214, P482, DOI 10.1002/path.2304; Pietras A, 2014, CELL STEM CELL, V14, P357, DOI 10.1016/j.stem.2014.01.005; Puchalski RB, 2018, SCIENCE, V360, P660, DOI 10.1126/science.aaf2666; Strickland M, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00043; Tong B, 2018, EXP CELL RES, V371, P122, DOI 10.1016/j.yexcr.2018.08.002; Traustadottir GA, 2019, CYTOKINE GROWTH F R, V46, P17, DOI 10.1016/j.cytogfr.2019.03.006; Traustadottir GA, 2017, INT J BIOL MACROMOL, V97, P460, DOI 10.1016/j.ijbiomac.2017.01.067; Villanueva C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036134; Wang YH, 2006, MOL CELL BIOL, V26, P5421, DOI 10.1128/MCB.02437-05; Wang YH, 2010, MOL CELL BIOL, V30, P3480, DOI 10.1128/MCB.00057-10; Wang YH, 2009, CELL METAB, V9, P287, DOI 10.1016/j.cmet.2009.01.013; Weskamp G, 2004, J BIOL CHEM, V279, P4241, DOI 10.1074/jbc.M307974200; Xie Y, 2015, EBIOMEDICINE, V2, P1351, DOI 10.1016/j.ebiom.2015.08.026; Yin D, 2006, ONCOGENE, V25, P1852, DOI 10.1038/sj.onc.1209219; Yun Z, 2015, J CLIN INVEST, V125, P2264, DOI 10.1172/JCI82058; Zhang Z, 2018, MOL MED REP, V18, P3547, DOI 10.3892/mmr.2018.9375; Zhao Z, 2020, BIORXIV, DOI [10.1101/2020.01.20.911982, DOI 10.1101/2020.01.20.911982]; Zheng XG, 2007, CANCER SCI, V98, P674, DOI 10.1111/j.1349-7006.2007.00440.x	47	15	15	3	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	20					4028	4044		10.1038/s41388-020-1273-9	http://dx.doi.org/10.1038/s41388-020-1273-9		MAR 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LN3GC	32205867	hybrid, Green Published			2022-12-28	WOS:000521527400001
J	Green, AL; DeSisto, J; Flannery, P; Lemma, R; Knox, A; Lemieux, M; Sanford, B; O'Rourke, R; Ramkissoon, S; Jones, K; Perry, J; Hui, X; Moroze, E; Balakrishnan, I; O'Neill, AF; Dunn, K; DeRyckere, D; Danis, E; Safadi, A; Gilani, A; Hubbell-Engler, B; Nuss, Z; Levy, JMM; Serkova, N; Venkataraman, S; Graham, DK; Foreman, N; Ligon, K; Jones, K; Kung, AL; Vibhakar, R				Green, Adam L.; DeSisto, John; Flannery, Patrick; Lemma, Rakeb; Knox, Aaron; Lemieux, Madeleine; Sanford, Bridget; O'Rourke, Rebecca; Ramkissoon, Shakti; Jones, Kristen; Perry, Jennifer; Hui, Xu; Moroze, Erin; Balakrishnan, Ilango; O'Neill, Allison F.; Dunn, Katherine; DeRyckere, Deborah; Danis, Etienne; Safadi, Aaron; Gilani, Ahmed; Hubbell-Engler, Benjamin; Nuss, Zachary; Levy, Jean M. Mulcahy; Serkova, Natalie; Venkataraman, Sujatha; Graham, Douglas K.; Foreman, Nicholas; Ligon, Keith; Jones, Ken; Kung, Andrew L.; Vibhakar, Rajeev			BPTF regulates growth of adult and pediatric high-grade glioma through the MYC pathway	ONCOGENE			English	Article							HISTONE DEACETYLASE INHIBITORS; SELF-RENEWAL; PHD-FINGER; GLIOBLASTOMA; CANCER; RNA; MUTATIONS; PROGNOSIS; FAMILY; CELLS	High-grade gliomas (HGG) afflict both children and adults and respond poorly to current therapies. Epigenetic regulators have a role in gliomagenesis, but a broad, functional investigation of the impact and role of specific epigenetic targets has not been undertaken. Using a two-step, in vitro/in vivo epigenomic shRNA inhibition screen, we determine the chromatin remodeler BPTF to be a key regulator of adult HGG growth. We then demonstrate that BPTF knockdown decreases HGG growth in multiple pediatric HGG models as well. BPTF appears to regulate tumor growth through cell self-renewal maintenance, and BPTF knockdown leads these glial tumors toward more neuronal characteristics. BPTF's impact on growth is mediated through positive effects on expression of MYC and MYC pathway targets. HDAC inhibitors synergize with BPTF knockdown against HGG growth. BPTF inhibition is a promising strategy to combat HGG through epigenetic regulation of the MYC oncogenic pathway.	[Green, Adam L.; DeSisto, John; Flannery, Patrick; Lemma, Rakeb; Knox, Aaron; Sanford, Bridget; O'Rourke, Rebecca; Moroze, Erin; Balakrishnan, Ilango; Danis, Etienne; Nuss, Zachary; Levy, Jean M. Mulcahy; Venkataraman, Sujatha; Foreman, Nicholas; Jones, Ken; Vibhakar, Rajeev] Univ Colorado, Morgan Adams Fdn Pediat Brain Tumor Res Program, Dept Pediat, Sch Med, Anschutz Med Campus,RC1-N,Mail Stop 8302, Aurora, CO 80045 USA; [Green, Adam L.; Levy, Jean M. Mulcahy; Foreman, Nicholas; Vibhakar, Rajeev] Childrens Hosp Colorado, Ctr Canc & Blood Disorders, Aurora, CO 80045 USA; [Lemieux, Madeleine] Bioinfo, Ottawa, ON, Canada; [Ramkissoon, Shakti; Jones, Kristen; Perry, Jennifer; O'Neill, Allison F.; Dunn, Katherine; Hubbell-Engler, Benjamin; Ligon, Keith] Dana Farber Canc Inst, Boston, MA 02115 USA; [Hui, Xu] Mem Sloan Kettering Canc Ctr, Dept Pediat, 1275 York Ave, New York, NY 10021 USA; [DeRyckere, Deborah; Graham, Douglas K.] Emory Univ, Aflac Canc & Blood Disorders Ctr, Childrens Healthcare Atlanta, Atlanta, GA 30322 USA; [Safadi, Aaron; Serkova, Natalie] Univ Colorado, Dept Radiol, Sch Med, Aurora, CO USA; [Gilani, Ahmed] Univ Colorado, Dept Pathol, Sch Med, Aurora, CO USA; [Kung, Andrew L.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; Harvard University; Dana-Farber Cancer Institute; Memorial Sloan Kettering Cancer Center; Children's Healthcare of Atlanta (CHOA); Emory University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; Memorial Sloan Kettering Cancer Center	Green, AL (corresponding author), Univ Colorado, Morgan Adams Fdn Pediat Brain Tumor Res Program, Dept Pediat, Sch Med, Anschutz Med Campus,RC1-N,Mail Stop 8302, Aurora, CO 80045 USA.; Green, AL (corresponding author), Childrens Hosp Colorado, Ctr Canc & Blood Disorders, Aurora, CO 80045 USA.	adam.green@cuanschutz.edu	Gilani, Ahmed/GYJ-5201-2022; Kung, Andrew/AAL-2384-2020; Kung, Andrew L/AEU-0826-2022	Kung, Andrew L/0000-0002-9091-488X; Knox, Aaron/0000-0002-2179-9961; Lemieux, Madeleine/0000-0001-6355-8691	NCI NIH HHS [P30 CA008748, P30 CA046934] Funding Source: Medline; NICHD NIH HHS [K12 HD068372] Funding Source: Medline; NINDS NIH HHS [P30 NS048154, R01 NS086839, L40 NS098453] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andrade JM, 2014, ANAL CHIM ACTA, V838, P1, DOI 10.1016/j.aca.2014.04.057; Arrigoni L, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv1495; Baird NL, 2014, J VIROL, V88, P5877, DOI 10.1128/JVI.00476-14; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bekpen C, 2012, GENOME RES, V22, P1050, DOI 10.1101/gr.134098.111; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Bramanti Vincenzo, 2010, Front Biosci (Schol Ed), V2, P558; Broad D, 2019, DEPMAP ACHILLES 19Q1; Buganim Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009657; Clarke J, 2013, EPIGENETICS-US, V8, P785, DOI 10.4161/epi.25440; Dai M, 2015, ONCOTARGET, V6, P33878, DOI 10.18632/oncotarget.5302; Dar AA, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv034; Fangusaro J, 2009, J CHILD NEUROL, V24, P1409, DOI 10.1177/0883073809338960; Frey WD, 2017, STEM CELL REP, V9, P23, DOI 10.1016/j.stemcr.2017.04.031; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; Ghantous A, 2015, MUTAGENESIS, V30, P733, DOI 10.1093/mutage/gev010; Gong YC, 2017, EUR REV MED PHARMACO, V21, P102; Grasso CS, 2015, NAT MED, V21, P827, DOI 10.1038/nm0715-827a; Green AL, 2015, NEURO-ONCOLOGY, V17, P697, DOI 10.1093/neuonc/nou303; Herms JW, 1999, SURG NEUROL, V51, P536, DOI 10.1016/S0090-3019(98)00028-7; Kerosuo L, 2008, J CELL SCI, V121, P3941, DOI 10.1242/jcs.024802; Kim J, 2003, NEURON, V38, P17, DOI 10.1016/S0896-6273(03)00163-6; Landry J, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000241; Lapin DH, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00057; Lee JH, 2016, APMIS, V124, P425, DOI 10.1111/apm.12512; Lee P, 2015, ANTICANCER RES, V35, P615; Li HT, 2006, NATURE, V442, P91, DOI 10.1038/nature04802; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Lulla RR, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1501354; Ma YQ, 2015, J NEUROSCI, V35, P8493, DOI 10.1523/JNEUROSCI.0377-15.2015; Maleszewska Marta, 2013, Cancers (Basel), V5, P1120, DOI 10.3390/cancers5031120; Meyers RM, 2017, NAT GENET, V49, P1779, DOI 10.1038/ng.3984; Miozzo M, 2015, FUTURE ONCOL, V11, P333, DOI [10.2217/fon.14.237, 10.2217/FON.14.237]; La Madrid AM, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00148; Mottamal M, 2015, MOLECULES, V20, P3898, DOI 10.3390/molecules20033898; Nebbioso A, 2017, CLIN CANCER RES, V23, P2542, DOI 10.1158/1078-0432.CCR-15-2388; Person F, 2017, TUMOR BIOL, V39, DOI [DOI 10.1177/1010428317712166, 10.1177/1010428317712166]; Ramirez F, 2016, NUCLEIC ACIDS RES, V44, pW160, DOI 10.1093/nar/gkw257; Richart L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10153; Rodriguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305; Ross-Innes CS, 2012, NATURE, V481, P389, DOI 10.1038/nature10730; Schwartzentruber J, 2012, NATURE, V482, P226, DOI [10.1038/nature10833, 10.1007/s13311-012-0137-6]; Ferreira WAS, 2016, EPIGENOMICS-UK, V8, P1289, DOI 10.2217/epi-2016-0040; Stankiewicz P, 2017, AM J HUM GENET, V101, P503, DOI 10.1016/j.ajhg.2017.08.014; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Su ZD, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4338; Touat M, 2017, ANN ONCOL, V28, P1457, DOI 10.1093/annonc/mdx106; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Urick AK, 2015, ACS CHEM BIOL, V10, P2246, DOI 10.1021/acschembio.5b00483; Wang JL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003769; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Wu TD, 2005, BIOINFORMATICS, V21, P1859, DOI 10.1093/bioinformatics/bti310; Wu TD, 2010, BIOINFORMATICS, V26, P873, DOI 10.1093/bioinformatics/btq057; Xiao SA, 2015, J CANCER RES CLIN, V141, P1465, DOI 10.1007/s00432-015-1937-y; Xiao S, 2015, DIGEST DIS SCI, V60, P910, DOI 10.1007/s10620-014-3411-0; Xie Q, 2016, J CLIN INVEST, V126, P2757, DOI 10.1172/JCI86114	58	16	17	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	11					2305	2327		10.1038/s41388-019-1125-7	http://dx.doi.org/10.1038/s41388-019-1125-7			23	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KU0ZS	31844250	Green Accepted			2022-12-28	WOS:000519440400006
J	Du, F; Li, XW; Feng, WB; Qiao, CY; Chen, J; Jiang, MZ; Qiu, ZY; Qian, MR; Tian, D; Nie, YZ; Fan, DM; Wu, KC; Xia, LM				Du, Feng; Li, Xiaowei; Feng, Weibo; Qiao, Chenyang; Chen, Jie; Jiang, Mingzuo; Qiu, Zhaoyan; Qian, Meirui; Tian, Dean; Nie, Yongzhan; Fan, Daiming; Wu, Kaichun; Xia, Limin			SOX13 promotes colorectal cancer metastasis by transactivating SNAI2 and c-MET	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR-SUPPRESSOR; PANCREATIC-CANCER; EXPRESSION; STEM; CHEMOTHERAPY; PRINCIPLES; CRIZOTINIB; RESISTANCE; REGULATORS	Metastasis is a major cause of high recurrence and poor survival of patients with colorectal cancer (CRC), although the mechanisms associated with this process remain poorly understood. In this study, we report a novel mechanism by which SOX13 promotes CRC metastasis by transactivating SNAI2 and c-MET. SOX13 overexpression was significantly correlated with more aggressive clinicopathological features of CRC and indicated poor prognosis in two independent cohorts of CRC patients (cohort I, n = 363; cohort II, n = 390). Overexpression of SOX13-promoted CRC migration, invasion, and metastasis, whereas SOX13 downregulation caused the opposite effects. Further mechanistic investigation identified SNAI2 and MET as important target genes of SOX13 using serial deletion and site-directed mutagenesis luciferase reporter and chromatin immunoprecipitation (ChIP) assays, as well as functional complementation analyses. In addition, SOX13 was shown to be a direct target of HGF/STAT3 signaling, and the c-MET inhibitor crizotinib blocked the HGF/STAT3/SOX13/c-MET axis, significantly inhibiting SOX13-mediated CRC migration, invasion and metastasis. Moreover, in clinical CRC tissues, SOX13 expression was positively correlated with the expression of SNAI2, c-MET, and HGF. CRC patients with positive coexpression of SOX13/SNAI2, SOX13/c-MET, or HGF/SOX13 exhibited a worse prognosis. In summary, SOX13 is a promising prognostic biomarker in patients with CRC, and blocking the HGF/STAT3/SOX13/c-MET axis with crizotinib could be a new therapeutic strategy to prevent SOX13-mediated CRC metastasis.	[Du, Feng; Tian, Dean; Xia, Limin] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Gastroenterol, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China; [Du, Feng; Feng, Weibo; Qiao, Chenyang; Chen, Jie; Jiang, Mingzuo; Qian, Meirui; Nie, Yongzhan; Fan, Daiming; Wu, Kaichun; Xia, Limin] Fourth Mil Med Univ, State Key Lab Canc Biol, Natl Clin Res Ctr Digest Dis, Xian 710032, Shaanxi, Peoples R China; [Du, Feng; Feng, Weibo; Qiao, Chenyang; Chen, Jie; Jiang, Mingzuo; Qian, Meirui; Nie, Yongzhan; Fan, Daiming; Wu, Kaichun; Xia, Limin] Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xian 710032, Shaanxi, Peoples R China; [Du, Feng] Chinese People Liberat Army 306th Hosp, Dept Gastroenterol, Beijing, Peoples R China; [Li, Xiaowei] Navy Gen Hosp, Dept Gastroenterol, Beijing 100048, Peoples R China; [Qiu, Zhaoyan] Chinese Peoples Liberat Army Gen Hosp, Dept Gen Surg, Fuxing Rd 28, Beijing 100853, Peoples R China; [Tian, Dean; Xia, Limin] Huazhong Univ Sci & Technol, Tongji Hosp, Inst Liver & Gastrointestinal Dis, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China	Huazhong University of Science & Technology; Air Force Military Medical University; Air Force Military Medical University; Sixth Medical Center of Chinese PLA General Hospital; Chinese People's Liberation Army General Hospital; Huazhong University of Science & Technology	Xia, LM (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Dept Gastroenterol, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China.; Xia, LM (corresponding author), Fourth Mil Med Univ, State Key Lab Canc Biol, Natl Clin Res Ctr Digest Dis, Xian 710032, Shaanxi, Peoples R China.; Xia, LM (corresponding author), Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xian 710032, Shaanxi, Peoples R China.; Xia, LM (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Inst Liver & Gastrointestinal Dis, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China.	xialimin@fmmu.edu.cn			National Key Research and Development Program of China [SQ2017YFSF090132, 2018YFC1312103]; National Natural Science Foundation of China [81972237, 81772623, 81627807, 81430072, 81421003]; National Center for Clinical Research of Digestive Diseases [2015BAI13B07]	National Key Research and Development Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Center for Clinical Research of Digestive Diseases	Research was supported by grants from the National Key Research and Development Program of China 2018YFC1312103 (LX), National Natural Science Foundation of China No. 81972237 (LX), No. 81772623 (LX), No. 81627807 (KW), No.81430072 (DF) and No. 81421003 (KW), National Key Research and Development Program of China SQ2017YFSF090132 (KW), and National Center for Clinical Research of Digestive Diseases 2015BAI13B07 (DF). We also would like to thank Qingling An and Jianhua Dou from the Fourth Military Medical University for providing excellent technical assistance.	Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Balsas P, 2017, BLOOD, V130, P501, DOI 10.1182/blood-2017-04-776740; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Boumahdi S, 2014, NATURE, V511, P246, DOI 10.1038/nature13305; Du F, 2019, CANCER LETT, V452, P103, DOI 10.1016/j.canlet.2019.03.035; Du F, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1481-9; Emaduddin M, 2008, P NATL ACAD SCI USA, V105, P2358, DOI 10.1073/pnas.0712176105; Fakih MG, 2015, J CLIN ONCOL, V33, P1809, DOI 10.1200/JCO.2014.59.7633; Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Hu Y, 2018, CLIN EPIGENETICS, V10, DOI 10.1186/s13148-018-0592-y; Huang WJ, 2015, HEPATOLOGY, V61, P1920, DOI 10.1002/hep.27756; Kamachi Y, 2013, DEVELOPMENT, V140, P4129, DOI 10.1242/dev.091793; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Larsimont JC, 2015, CELL STEM CELL, V17, P60, DOI 10.1016/j.stem.2015.05.008; Lee SJ, 2018, CLIN COLORECTAL CANC, V17, P165, DOI 10.1016/j.clcc.2018.02.013; Li CW, 2011, GASTROENTEROLOGY, V141, P2218, DOI 10.1053/j.gastro.2011.08.009; Li CX, 2017, P NATL ACAD SCI USA, V114, pE2852, DOI 10.1073/pnas.1618297114; Man CH, 2015, BLOOD, V125, P3928, DOI 10.1182/blood-2014-06-580993; McQuade RM, 2017, CURR MED CHEM, V24, P1537, DOI 10.2174/0929867324666170111152436; Moore AE, 2009, CARCINOGENESIS, V30, P1796, DOI 10.1093/carcin/bgp183; Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307; Peters S, 2017, NEW ENGL J MED, V377, P829, DOI 10.1056/NEJMoa1704795; Pietrantonio F, 2016, CANCER DISCOV, V6, P963, DOI 10.1158/2159-8290.CD-16-0297; Prior HM, 1996, MOL MED, V2, P405, DOI 10.1007/BF03401900; Sarkar A, 2013, CELL STEM CELL, V12, P15, DOI 10.1016/j.stem.2012.12.007; Shakhova O, 2012, NAT CELL BIOL, V14, P882, DOI 10.1038/ncb2535; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Solomon BJ, 2014, NEW ENGL J MED, V371, P2167, DOI [10.1056/NEJMoa1408440, 10.1056/NEJMx150034]; Tchougounova E, 2009, ONCOGENE, V28, P1537, DOI 10.1038/onc.2009.9; Thu KL, 2014, ONCOGENE, V33, P279, DOI 10.1038/onc.2012.595; Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020; Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012; Tsao CM, 2012, HEPATOLOGY, V56, P2277, DOI 10.1002/hep.25933; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; Zarour LR, 2017, CELL MOL GASTROENTER, V3, P163, DOI 10.1016/j.jcmgh.2017.01.006; Zeng ZS, 2008, CANCER LETT, V265, P258, DOI 10.1016/j.canlet.2008.02.049; Zhang R, 2018, EUR REV MED PHARMACO, V22, P6801, DOI 10.26355/eurrev_201810_16146	38	22	22	2	23	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	17					3522	3540		10.1038/s41388-020-1233-4	http://dx.doi.org/10.1038/s41388-020-1233-4		FEB 2020	19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LH1YK	32111984				2022-12-28	WOS:000517049100003
J	Kasiri, S; Chen, BZ; Wilson, AN; Reczek, A; Mazambani, S; Gadhvi, J; Noel, E; Marriam, U; Mino, B; Lu, W; Girard, L; Solis, LM; Luby-Phelps, K; Bishop, J; Kim, JW; Kim, J				Kasiri, Sahba; Chen, Baozhi; Wilson, Alexandra N.; Reczek, Annika; Mazambani, Simbarashe; Gadhvi, Jashkaran; Noel, Evan; Marriam, Ummay; Mino, Barbara; Lu, Wei; Girard, Luc; Solis, Luisa M.; Luby-Phelps, Katherine; Bishop, Justin; Kim, Jung-Whan; Kim, James			Stromal Hedgehog pathway activation by IHH suppresses lung adenocarcinoma growth and metastasis by limiting reactive oxygen species	ONCOGENE			English	Article							MITOCHONDRIAL COMPLEX-III; MOTOR-NEURON INDUCTION; SONIC-HEDGEHOG; OXIDATIVE STRESS; FLOOR PLATE; MOUSE MODEL; CANCER; ANGIOGENESIS; PROGRESSION; MUTATIONS	Activation of the Hedgehog (Hh) signaling pathway by mutations within its components drives the growth of several cancers. However, the role of Hh pathway activation in lung cancers has been controversial. Here, we demonstrate that the canonical Hh signaling pathway is activated in lung stroma by Hh ligands secreted from transformed lung epithelia. Genetic deletion of Shh, the primary Hh ligand expressed in the lung, in Kras(G12D/+);Trp53(fl/fl) autochthonous murine lung adenocarcinoma had no effect on survival. Early abrogation of the pathway by an anti-SHH/IHH antibody 5E1 led to significantly worse survival with increased tumor and metastatic burden. Loss of IHH, another Hh ligand, by in vivo CRISPR led to more aggressive tumor growth suggesting that IHH, rather than SHH, activates the pathway in stroma to drive its tumor suppressive effects-a novel role for IHH in the lung. Tumors from mice treated with 5E1 had decreased blood vessel density and increased DNA damage suggestive of reactive oxygen species (ROS) activity. Treatment of Kras(G12D/+);Trp53(fl/fl) mice with 5E1 and N-acetylcysteine, as a ROS scavenger, decreased tumor DNA damage, inhibited tumor growth and prolonged mouse survival. Thus, IHH induces stromal activation of the canonical Hh signaling pathway to suppress tumor growth and metastases, in part, by limiting ROS activity.	[Kasiri, Sahba; Chen, Baozhi; Wilson, Alexandra N.; Reczek, Annika; Noel, Evan; Marriam, Ummay; Girard, Luc; Kim, James] Nancy B & Jake L Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; [Kasiri, Sahba; Chen, Baozhi; Wilson, Alexandra N.; Reczek, Annika; Noel, Evan; Marriam, Ummay; Girard, Luc; Kim, James] Harold C Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA; [Mazambani, Simbarashe; Gadhvi, Jashkaran; Kim, Jung-Whan] Univ Texas Dallas, Dept Biol Sci, Richardson, TX 75080 USA; [Mino, Barbara; Lu, Wei; Solis, Luisa M.] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [Luby-Phelps, Katherine] Univ Texas Southwestern Med Ctr Dallas, Dept Cell Biol, Dallas, TX 75390 USA; [Bishop, Justin] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA; [Kim, James] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Kim, J (corresponding author), Nancy B & Jake L Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA.; Kim, J (corresponding author), Harold C Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA.; Kim, J (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA.	james.kim@utsouthwestern.edu		Luby-Phelps, Katherine/0000-0002-8378-1409; Mazambani, Simbarashe/0000-0002-6554-7889; Gadhvi, Jashkaran/0000-0002-9522-8053	National Cancer Institute [P50CA70907, R01CA196851, R21 CA208746]; National Heart, Lung, and Blood Institute [5T32HL098040]; American Cancer Society [RSG-16-090-01-TBG]; American Lung Association [LCD-400239]; Sidney Kimmel Foundation for Cancer Research [SKF-14-057]; Lung Cancer Research Foundation; Bonnie J. Addario Lung Cancer Foundation	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); American Cancer Society(American Cancer Society); American Lung Association; Sidney Kimmel Foundation for Cancer Research; Lung Cancer Research Foundation; Bonnie J. Addario Lung Cancer Foundation	We thank Dr John D. Minna for valuable discussions, Drs Rolf Brekken and David Wang for their helpful comments on the manuscript, Nicolas Loof, Kim Nguyen, and Terry Shih of the Moody Foundation Flow Cytometry Core Facility for assistance with FACS, and Denise Ramirez of the Whole Brain Microscopy Facility. We also thank John Shelton at UTSW HistoPathology Core and Dr Cheryl Lewis at UTSW Tissue Management Core for assistance with tissue processing and embedding. This work was supported in part by the National Cancer Institute (P50CA70907: JK; R01CA196851: JK; R21 CA208746: J-WK), National Heart, Lung, and Blood Institute (5T32HL098040 to SK), American Cancer Society (RSG-16-090-01-TBG: JK), American Lung Association (LCD-400239: J-WK), Sidney Kimmel Foundation for Cancer Research (SKF-14-057: JK), Lung Cancer Research Foundation (JK) and Bonnie J. Addario Lung Cancer Foundation (J.K.).	Aavikko M, 2012, AM J HUM GENET, V91, P520, DOI 10.1016/j.ajhg.2012.07.015; Administration USFaD, 2015, SON; Administration USFaD, 2018, FDA APPR NEW TREATM; Axelson M, 2013, CLIN CANCER RES, V19, P2289, DOI 10.1158/1078-0432.CCR-12-1956; Bai CB, 2002, DEVELOPMENT, V129, P4753; Barreto DC, 2000, J DENT RES, V79, P1418, DOI 10.1177/00220345000790061101; Belani CP, 2013, J CLIN ONCOL S, V31, P7508, DOI DOI 10.1200/JCO.2013.31.15_SUPPL.7508; Bell EL, 2007, J CELL BIOL, V177, P1029, DOI 10.1083/jcb.200609074; Bermudez O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063226; Brastianos PK, 2013, NAT GENET, V45, P285, DOI 10.1038/ng.2526; Buglino JA, 2008, J BIOL CHEM, V283, P22076, DOI 10.1074/jbc.M803901200; Byrd N, 2002, DEVELOPMENT, V129, P361; Cancer Genome Atlas Research Network, 2014, Nature, V511, P543, DOI [10.1038/s41586-018-0228-6, 10.1038/nature13385]; Cha YJ, 2017, TRANSL LUNG CANCER R, V6, P508, DOI 10.21037/tlcr.2017.06.10; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Clark VE, 2013, SCIENCE, V339, P1077, DOI 10.1126/science.1233009; Colnot C, 2005, DEVELOPMENT, V132, P1057, DOI 10.1242/dev.01649; Di Mauro C, 2017, BRIT J CANCER, V116, P1425, DOI 10.1038/bjc.2017.116; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; Epstein EH, 2008, NAT REV CANCER, V8, P743, DOI 10.1038/nrc2503; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; Eser S, 2013, CANCER CELL, V23, P406, DOI 10.1016/j.ccr.2013.01.023; Gerling M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12321; Guzy RD, 2005, CELL METAB, V1, P401, DOI 10.1016/j.cmet.2005.05.001; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Justilien V, 2014, CANCER CELL, V25, P139, DOI 10.1016/j.ccr.2014.01.008; Kasiri S, 2017, CANCER RES, V77, P4448, DOI 10.1158/0008-5472.CAN-16-3315; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kugler MC, 2015, AM J RESP CELL MOL, V52, P1, DOI 10.1165/rcmb.2014-0132TR; Lauth M, 2010, NAT STRUCT MOL BIOL, V17, P718, DOI 10.1038/nsmb.1833; Lee JJ, 2016, P NATL ACAD SCI USA, V113, pE7545, DOI 10.1073/pnas.1616447113; Lee JJ, 2014, P NATL ACAD SCI USA, V111, pE3091, DOI 10.1073/pnas.1411679111; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Lewis PM, 2001, CELL, V105, P599, DOI 10.1016/S0092-8674(01)00369-5; Li W, 2016, CANCER INVEST, V34, P424, DOI 10.1080/07357907.2016.1227442; Li ZX, 2006, FEBS LETT, V580, P6161, DOI 10.1016/j.febslet.2006.10.016; Liou GY, 2016, CELL REP, V14, P2325, DOI 10.1016/j.celrep.2016.02.029; Maity T, 2005, P NATL ACAD SCI USA, V102, P17026, DOI 10.1073/pnas.0507848102; MARTI E, 1995, DEVELOPMENT, V121, P2537; Mathew E, 2014, CELL REP, V9, P484, DOI 10.1016/j.celrep.2014.09.010; Maun HR, 2010, J BIOL CHEM, V285, P26570, DOI 10.1074/jbc.M110.112284; Morrisey EE, 2010, DEV CELL, V18, P8, DOI 10.1016/j.devcel.2009.12.010; Munchhof MJ, 2012, ACS MED CHEM LETT, V3, P106, DOI 10.1021/ml2002423; Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335; National Cancer Institute Surveillance E and End Results Program, CANC STAT FACTS LUNG; Paladini RD, 2005, J INVEST DERMATOL, V125, P638, DOI 10.1111/j.0022-202X.2005.23867.x; Pan SF, 2010, ACS MED CHEM LETT, V1, P130, DOI 10.1021/ml1000307; Park KS, 2011, NAT MED, V17, P1504, DOI 10.1038/nm.2473; Po A, 2017, ONCOGENE, V36, P4641, DOI 10.1038/onc.2017.91; Pola R, 2001, NAT MED, V7, P706, DOI 10.1038/89083; Reczek CR, 2017, ANNU REV CANC BIOL, V1, P79, DOI 10.1146/annurev-cancerbio-041916-065808; Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021; Robarge KD, 2009, BIOORG MED CHEM LETT, V19, P5576, DOI 10.1016/j.bmcl.2009.08.049; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; Sabharwal SS, 2014, NAT REV CANCER, V14, P709, DOI 10.1038/nrc3803; SAFFORD SE, 1994, CANCER RES, V54, P4261; Samudrala P, 2017, PROC SPIE, V10147, DOI 10.1117/12.2258137; Sanchez-Rivera FJ, 2014, NATURE, V516, P428, DOI 10.1038/nature13906; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Shimada Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070995; Shin K, 2014, CANCER CELL, V26, P521, DOI 10.1016/j.ccell.2014.09.001; Shin K, 2014, NAT CELL BIOL, V16, P469, DOI 10.1038/ncb2956; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; STCLAIR DK, 1992, MOL CARCINOGEN, V6, P238, DOI 10.1002/mc.2940060404; Sweeney RT, 2014, NAT GENET, V46, P722, DOI 10.1038/ng.2986; Szczepny A, 2017, ONCOGENE, V36, P5544, DOI 10.1038/onc.2017.173; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Tanaka T, 2006, CELL CYCLE, V5, P2671, DOI 10.4161/cc.5.22.3472; Theunissen JW, 2009, CANCER RES, V69, P6007, DOI 10.1158/0008-5472.CAN-09-0756; Toftgard R, 2000, CELL MOL LIFE SCI, V57, P1720, DOI 10.1007/PL00000654; Varjosalo M, 2008, GENE DEV, V22, P2454, DOI 10.1101/gad.1693608; Wang LC, 2000, J INVEST DERMATOL, V114, P901, DOI 10.1046/j.1523-1747.2000.00951.x; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Wiel C, 2019, CELL, V178, P330, DOI 10.1016/j.cell.2019.06.005; Yang ZH, 2017, DIS MODEL MECH, V10, P39, DOI 10.1242/dmm.027417	83	8	8	2	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2020	39	16					3258	3275		10.1038/s41388-020-1224-5	http://dx.doi.org/10.1038/s41388-020-1224-5		FEB 2020	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF9OJ	32108165	Green Accepted, hybrid, Green Submitted, Green Published			2022-12-28	WOS:000516891300002
J	Zhuo, MH; Chen, WB; Shang, SH; Guo, P; Peng, KS; Li, M; Mo, PL; Zhang, YY; Qiu, XF; Li, WG; Yu, CD				Zhuo, Minghui; Chen, Wenbo; Shang, Shaohui; Guo, Peng; Peng, Kesong; Li, Ming; Mo, Pingli; Zhang, Yongyou; Qiu, Xingfeng; Li, Wengang; Yu, Chundong			Inflammation-induced JMJD2D promotes colitis recovery and colon tumorigenesis by activating Hedgehog signaling	ONCOGENE			English	Article							INTESTINAL INFLAMMATION; KAPPA-B; EPITHELIAL-CELLS; RANDOMIZED-TRIAL; ASPIRIN; METASTASIS; INHIBITION; SALICYLATE; VISMODEGIB; DEFICIENT	Histone demethylase JMJD2D can promote gene expression by specifically demethylating H3K9me2/3. The role of JMJD2D in colitis and colitis-associated colorectal cancer (CRC) progression remains unclear. Here, we show that colonic JMJD2D is induced by TNF alpha during dextran sulfate sodium-induced colitis. JMJD2D-deficient mice exhibit more severe colon damage and defective colon regeneration due to impaired Hedgehog signaling activation after colitis. JMJD2D knockdown in CRC cells suppresses Hedgehog signaling, resulting in reduced CRC growth and metastasis. Mechanistically, JMJD2D promotes Hedgehog target gene expression through interacting with Gli2 to reduce H3K9me3 levels at the promoter. Clinically, JMJD2D expression is upregulated and positively correlated with Gli2 expression in human inflammatory bowel disease specimens and CRC specimens. The JMJD2D inhibitor 5-c-8HQ or aspirin synergizes with Hedgehog inhibitor vismodegib to inhibit CRC cell proliferation and tumorigenesis. Collectively, our findings unveil an essential role of JMJD2D in activating the processes of colonic protection, regeneration, and tumorigenesis.	[Zhuo, Minghui; Shang, Shaohui; Guo, Peng; Peng, Kesong; Mo, Pingli; Zhang, Yongyou; Yu, Chundong] Xiamen Univ, Sch Life Sci, Innovat Ctr Cell Biol, State Key Lab Cellular Stress Biol, Xiamen, Peoples R China; [Chen, Wenbo] Xiamen Univ, Dept Cardiol, Affiliated Hosp 1, Xiamen, Peoples R China; [Peng, Kesong] Fudan Univ, Sch Basic Med Sci, Dept Cellular & Genet Med, Shanghai, Peoples R China; [Li, Ming; Li, Wengang] Xiamen Univ, Sch Med, Xiangan Hosp, Dept Hepatobiliary & Pancreat & Organ Transplanta, Xiamen, Peoples R China; [Qiu, Xingfeng] Xiamen Univ, Zhongshan Hosp, Dept Gastrointestinal Surg, Xiamen, Peoples R China	Xiamen University; Xiamen University; Fudan University; Xiamen University; Xiamen University	Yu, CD (corresponding author), Xiamen Univ, Sch Life Sci, Innovat Ctr Cell Biol, State Key Lab Cellular Stress Biol, Xiamen, Peoples R China.; Li, WG (corresponding author), Xiamen Univ, Sch Med, Xiangan Hosp, Dept Hepatobiliary & Pancreat & Organ Transplanta, Xiamen, Peoples R China.; Qiu, XF (corresponding author), Xiamen Univ, Zhongshan Hosp, Dept Gastrointestinal Surg, Xiamen, Peoples R China.	dr.qxf@xmu.edu.cn; lwg11861@163.com; cdyu@xmu.edu.cn		zhang, yongyou/0000-0003-2413-9106	National Natural Science Foundation of China [81970485, 81772942, 81901597]; National Basic Research Program of China (973 Program) [2015CB553800]; National Science and Technology Major Project of China [2017ZX10203206]; Scientific Research Foundation for Advanced Talents, Xiang'an Hospital of Xiamen University [PM20180917008]; Natural Science Foundation of Fujian Province [2017J01268]; National Health and Family Planning Commission's Scientific Research Foundation-Health and Education cooperation foundation [WKJ2016-2-17]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Science and Technology Major Project of China; Scientific Research Foundation for Advanced Talents, Xiang'an Hospital of Xiamen University; Natural Science Foundation of Fujian Province(Natural Science Foundation of Fujian Province); National Health and Family Planning Commission's Scientific Research Foundation-Health and Education cooperation foundation	We thank Shiwen Luo (Nanchang University) for providing Gli2 expression plasmid and Hedgehog signaling reporter 8xGBS, Chenglin Bian for TCGA data analysis, and Lei Huang for technical support. This study was supported by grants from the National Natural Science Foundation of China (no. 81970485 to CY), the National Natural Science Foundation of China (no. 81772942 to CY), the National Basic Research Program of China (973 Program, no. 2015CB553800 to CY), the National Natural Science Foundation of China (no. 81901597 to WC), the National Science and Technology Major Project of China (2017ZX10203206 to WL), the Scientific Research Foundation for Advanced Talents, Xiang'an Hospital of Xiamen University (no. PM20180917008 to WL), the Natural Science Foundation of Fujian Province (2017J01268 to XQ), and the National Health and Family Planning Commission's Scientific Research Foundation-Health and Education cooperation foundation (WKJ2016-2-17 to XQ).	Accari SL, 2015, INT REV CEL MOL BIO, V319, P165, DOI 10.1016/bs.ircmb.2015.07.003; Baron JA, 2003, NEW ENGL J MED, V348, P891, DOI 10.1056/NEJMoa021735; Berlin J, 2013, CLIN CANCER RES, V19, P258, DOI 10.1158/1078-0432.CCR-12-1800; Berry WL, 2013, CANCER RES, V73, P2936, DOI 10.1158/0008-5472.CAN-12-4300; Buller NVJA, 2012, PHYSIOLOGY, V27, P148, DOI 10.1152/physiol.00003.2012; Catenacci DVT, 2015, J CLIN ONCOL, V33, P4284, DOI 10.1200/JCO.2015.62.8719; Chen WB, 2018, INT J BIOL SCI, V14, P2051, DOI 10.7150/ijbs.28576; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Das S, 2016, ONCOGENE, V35, P2645, DOI 10.1038/onc.2015.327; Elinav E, 2013, NAT REV CANCER, V13, P759, DOI 10.1038/nrc3611; Fattahi S, 2018, J CELL PHYSIOL, V233, P5726, DOI 10.1002/jcp.26506; Feagins LA, 2009, NAT REV GASTRO HEPAT, V6, P297, DOI 10.1038/nrgastro.2009.44; Geng H, 2018, GASTROENTEROLOGY, V155, P144, DOI 10.1053/j.gastro.2018.03.058; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Ikram MS, 2004, J INVEST DERMATOL, V122, P1503, DOI 10.1111/j.0022-202X.2004.22612.x; Jiang J, 2008, DEV CELL, V15, P801, DOI 10.1016/j.devcel.2008.11.010; Kasper M, 2006, EUR J CANCER, V42, P437, DOI 10.1016/j.ejca.2005.08.039; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Lees CW, 2008, PLOS MED, V5, P1761, DOI 10.1371/journal.pmed.0050239; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Mizushima T, 2013, AM J PATHOL, V183, P1936, DOI 10.1016/j.ajpath.2013.08.012; Naito Y, 2003, J GASTROEN HEPATOL, V18, P560, DOI 10.1046/j.1440-1746.2003.03034.x; Onizawa M, 2009, AM J PHYSIOL-GASTR L, V296, pG850, DOI 10.1152/ajpgi.00071.2008; Peng KS, 2019, GASTROENTEROLOGY, V156, P1112, DOI 10.1053/j.gastro.2018.11.036; Pugliese D, 2017, EXPERT REV CLIN IMMU, V13, P223, DOI 10.1080/1744666X.2017.1243468; Ranganathan P, 2013, AM J PHYSIOL-RENAL, V305, pF1422, DOI 10.1152/ajprenal.00319.2013; Regl G, 2004, CANCER RES, V64, P7724, DOI 10.1158/0008-5472.CAN-04-1085; Rominger CM, 2009, J PHARMACOL EXP THER, V329, P995, DOI 10.1124/jpet.109.152090; Sandler RS, 2003, NEW ENGL J MED, V348, P883, DOI 10.1056/NEJMoa021633; Schwitalla S, 2013, CANCER CELL, V23, P93, DOI 10.1016/j.ccr.2012.11.014; Sekulic A, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3286-5; Sekulic A, 2012, NEW ENGL J MED, V366, P2171, DOI 10.1056/NEJMoa1113713; Sipos Ferenc, 2002, Orv Hetil, V143, P2485; Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058; Tong ZW, 2015, J BIOL CHEM, V290, P18596, DOI 10.1074/jbc.M115.640490; Ullman TA, 2011, GASTROENTEROLOGY, V140, P1807, DOI 10.1053/j.gastro.2011.01.057; Varnat F, 2009, EMBO MOL MED, V1, P338, DOI 10.1002/emmm.200900039; Wang Y, 2013, LAB INVEST, V93, P1024, DOI 10.1038/labinvest.2013.89; Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028; Wirtz S, 2017, NAT PROTOC, V12, P1295, DOI 10.1038/nprot.2017.044; Xiao YT, 2016, CYTOKINE, V83, P189, DOI 10.1016/j.cyto.2016.04.012; Xu YH, 2007, IMMUNOL CELL BIOL, V85, P633, DOI 10.1038/sj.icb.7100112; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zhao B, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8166	44	18	17	9	23	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2020	39	16					3336	3353		10.1038/s41388-020-1219-2	http://dx.doi.org/10.1038/s41388-020-1219-2		FEB 2020	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF9OJ	32094404				2022-12-28	WOS:000515475800001
J	Hillert, LK; Ivanisenko, NV; Espe, J; Konig, C; Ivanisenko, VA; Kahne, T; Lavrik, IN				Hillert, Laura K.; Ivanisenko, Nikita, V; Espe, Johannes; Koenig, Corinna; Ivanisenko, Vladimir A.; Kaehne, Thilo; Lavrik, Inna N.			Long and short isoforms of c-FLIP act as control checkpoints of DED filament assembly	ONCOGENE			English	Article							KAPPA-B ACTIVATION; CELL-DEATH; CASPASE-8; REVEALS; PROCASPASE-8; MECHANISM; QUANTIFICATION; REGULATOR; APOPTOSIS; SKYLINE	The assembly of the death-inducing signaling complex (DISC) and death effector domain (DED) filaments at CD95/Fas initiates extrinsic apoptosis. Procaspase-8 activation at the DED filaments is controlled by short and long c-FLIP isoforms. Despite apparent progress in understanding the assembly of CD95-activated platforms and DED filaments, the detailed molecular mechanism of c-FLIP action remains elusive. Here, we further addressed the mechanisms of c-FLIP action at the DISC using biochemical assays, quantitative mass spectrometry, and structural modeling. Our data strongly indicate that c-FLIP can bind to both FADD and procaspase-8 at the DED filament. Moreover, the constructed in silico model shows that c-FLIP proteins can lead to the formation of the DISCs comprising short DED filaments as well as serve as bridging motifs for building a cooperative DISC network, in which adjacent CD95 DISCs are connected by DED filaments. This network is based on selective interactions of FADD with both c-FLIP and procaspase-8. Hence, c-FLIP proteins at the DISC control initiation, elongation, and composition of DED filaments, playing the role of control checkpoints. These findings provide new insights into DISC and DED filament regulation and open innovative possibilities for targeting the extrinsic apoptosis pathway.	[Hillert, Laura K.; Espe, Johannes; Koenig, Corinna; Lavrik, Inna N.] Otto von Guericke Univ, Ctr Dynam Syst, Med Fac, Translat Inflammat Res, D-39106 Magdeburg, Germany; [Ivanisenko, Nikita, V; Ivanisenko, Vladimir A.] SB RAS, Inst Cytol & Genet, Fed Res Ctr, Novosibirsk 630090, Russia; [Kaehne, Thilo] Otto von Guericke Univ, Med Fac, Inst Internal Expt Med, D-39120 Magdeburg, Germany	Otto von Guericke University; Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB RAS; Otto von Guericke University	Lavrik, IN (corresponding author), Otto von Guericke Univ, Ctr Dynam Syst, Med Fac, Translat Inflammat Res, D-39106 Magdeburg, Germany.	inna.lavrik@med.ovgu.de	Lavrik, Inna N/C-1700-2009; Ivanisenko, Vladimir/J-7832-2018; Ivanisenko, Nikita/AAO-1621-2020	Lavrik, Inna N/0000-0002-9324-309X; Ivanisenko, Vladimir/0000-0002-1859-4631	Volkswagen Foundation [VW 90315]; Wilhelm Sander-Stiftung [2017.008.01]; Center of dynamic systems (CDS) - EU-program ERDF (European Regional Development Fund); DFG [LA 2386]	Volkswagen Foundation(Volkswagen); Wilhelm Sander-Stiftung; Center of dynamic systems (CDS) - EU-program ERDF (European Regional Development Fund); DFG(German Research Foundation (DFG))	We acknowledge Volkswagen Foundation (VW 90315), Wilhelm Sander-Stiftung (2017.008.01), Center of dynamic systems (CDS), funded by the EU-program ERDF (European Regional Development Fund) and DFG (LA 2386) for supporting our work.	Algeciras-Schimnich A, 2002, MOL CELL BIOL, V22, P207, DOI 10.1128/MCB.22.1.207-220.2002; Algeciras-Schimnich A, 2003, FEBS LETT, V546, P185, DOI 10.1016/S0014-5793(03)00558-1; Bentele M, 2004, J CELL BIOL, V166, P839, DOI 10.1083/jcb.200404158; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; Chaudhury S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022477; Dickens LS, 2012, MOL CELL, V47, P291, DOI 10.1016/j.molcel.2012.05.004; Fricker N, 2010, J CELL BIOL, V190, P377, DOI 10.1083/jcb.201002060; Fu TM, 2016, MOL CELL, V64, P236, DOI 10.1016/j.molcel.2016.09.009; Golks A, 2006, CELL DEATH DIFFER, V13, P489, DOI 10.1038/sj.cdd.4401766; Golks A, 2005, J BIOL CHEM, V280, P14507, DOI 10.1074/jbc.M414425200; Hoffmann JC, 2009, MOL CELL BIOL, V29, P4431, DOI 10.1128/MCB.02261-07; Horn S, 2017, CELL REP, V19, P785, DOI 10.1016/j.celrep.2017.04.010; Hughes MA, 2016, MOL CELL, V61, P834, DOI 10.1016/j.molcel.2016.02.023; Hwang EY, 2014, BMB REP, V47, P488, DOI 10.5483/BMBRep.2014.47.9.239; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Krammer PH, 2007, NAT REV IMMUNOL, V7, P532, DOI 10.1038/nri2115; Lavrik I, 2005, J CELL SCI, V118, P265, DOI 10.1242/jcs.01610; Lavrik IN, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.160; Lavrik IN, 2012, CELL DEATH DIFFER, V19, P36, DOI 10.1038/cdd.2011.155; MacLean B, 2010, BIOINFORMATICS, V26, P966, DOI 10.1093/bioinformatics/btq054; Majkut J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4350; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Neumann L, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.6; Ozturk S, 2012, EXP CELL RES, V318, P1324, DOI 10.1016/j.yexcr.2012.01.019; Peter Marcus E, 2004, Biochem J, V382, pe1; Pietkiewicz S, 2015, EXP CELL RES, V339, P1, DOI 10.1016/j.yexcr.2015.10.005; Pietkiewicz S, 2015, J IMMUNOL METHODS, V423, P99, DOI 10.1016/j.jim.2015.04.025; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Schilling B, 2012, MOL CELL PROTEOMICS, V11, P202, DOI 10.1074/mcp.M112.017707; Schleich K, 2016, CELL DEATH DIFFER, V23, P681, DOI 10.1038/cdd.2015.137; Schleich K, 2012, MOL CELL, V47, P306, DOI 10.1016/j.molcel.2012.05.006; Schmidt JH, 2015, J IMMUNOL METHODS, V423, P12, DOI 10.1016/j.jim.2015.04.026; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Ueffing N, 2008, CELL DEATH DIFFER, V15, P773, DOI 10.1038/sj.cdd.4402314; Warnken Uwe, 2013, Cells, V2, P476, DOI 10.3390/cells2030476; Yu JW, 2009, P NATL ACAD SCI USA, V106, P8169, DOI 10.1073/pnas.0812453106	37	16	18	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	8					1756	1772		10.1038/s41388-019-1100-3	http://dx.doi.org/10.1038/s41388-019-1100-3			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN6CG	31740779				2022-12-28	WOS:000514923000010
J	Manoranjan, B; Chokshi, C; Venugopal, C; Subapanditha, M; Savage, N; Tatari, N; Provias, JP; Murty, NK; Moffat, J; Doble, BW; Singh, SK				Manoranjan, Branavan; Chokshi, Chirayu; Venugopal, Chitra; Subapanditha, Minomi; Savage, Neil; Tatari, Nazanin; Provias, John P.; Murty, Naresh K.; Moffat, Jason; Doble, Bradley W.; Singh, Sheila K.			A CD133-AKT-Wnt signaling axis drives glioblastoma brain tumor-initiating cells	ONCOGENE			English	Article							CANCER STEM-CELLS; BETA-CATENIN; NEURAL PROGENITORS; ACTIVATION; CD133; EXPRESSION; AKT; TRANSACTIVATION; DIFFERENTIATION; IDENTIFICATION	Mechanistic insight into signaling pathways downstream of surface receptors has been revolutionized with integrated cancer genomics. This has fostered current treatment modalities, namely immunotherapy, to capitalize on targeting key oncogenic signaling nodes downstream of a limited number of surface markers. Unfortunately, rudimentary mechanistic understanding of most other cell surface proteins has reduced the clinical utility of these markers. CD133 has reproducibly been shown to correlate with disease progression, recurrence, and poor overall survivorship in the malignant adult brain tumor, glioblastoma (GBM). Using several patient-derived CD133(high) and CD133(low) GBMs we describe intrinsic differences in determinants of stemness, which we owe to a CD133-AKT-Wnt signaling axis in which CD133 functions as a putative cell surface receptor for AKT-dependent Wnt activation. These findings may have implications for personalized oncology trials targeting PI3K/AKT or Wnt as both pathways may be activated independent of their canonical drivers, leading to treatment resistance and disease relapse.	[Manoranjan, Branavan] McMaster Univ, Michael G DeGroote Sch Med, Hamilton, ON L8S 4K1, Canada; [Manoranjan, Branavan; Chokshi, Chirayu; Venugopal, Chitra; Subapanditha, Minomi; Savage, Neil; Tatari, Nazanin; Doble, Bradley W.; Singh, Sheila K.] McMaster Univ, McMaster Stem Cell & Canc Res Inst, Hamilton, ON L8S 4K1, Canada; [Manoranjan, Branavan; Chokshi, Chirayu; Tatari, Nazanin; Doble, Bradley W.; Singh, Sheila K.] McMaster Univ, Dept Biochem & Biomed Sci, 1200 Main St West, Hamilton, ON L8N 3Z5, Canada; [Provias, John P.] McMaster Univ, Dept Pathol, 1200 Main St West, Hamilton, ON L8N 3Z5, Canada; [Murty, Naresh K.; Singh, Sheila K.] McMaster Univ, Fac Hlth Sci, Surg, 1200 Main St West, Hamilton, ON L8N 3Z5, Canada; [Moffat, Jason] Univ Toronto, Donnelly Ctr, Toronto, ON M5S 3E1, Canada	McMaster University; McMaster University; McMaster University; McMaster University; McMaster University; University of Toronto	Singh, SK (corresponding author), McMaster Univ, McMaster Stem Cell & Canc Res Inst, Hamilton, ON L8S 4K1, Canada.; Singh, SK (corresponding author), McMaster Univ, Dept Biochem & Biomed Sci, 1200 Main St West, Hamilton, ON L8N 3Z5, Canada.; Singh, SK (corresponding author), McMaster Univ, Fac Hlth Sci, Surg, 1200 Main St West, Hamilton, ON L8N 3Z5, Canada.	ssingh@mcmaster.ca	Moffat, Jason/AAC-1110-2020; Singh, Sheila K/W-2799-2018; Doble, Bradley/L-7551-2016	Moffat, Jason/0000-0002-5663-8586; Singh, Sheila K/0000-0003-1272-5300; Doble, Bradley/0000-0002-0260-2983; Tatari, Nazanin/0000-0002-0003-6121	Canadian Institutes of Health Research Vanier Canada Graduate Scholarship; Neurosurgical Research and Education Foundation; American Association of Neurological surgeons, Pediatric Section; Ontario Institute for Cancer Research; McMaster University Department of Surgery	Canadian Institutes of Health Research Vanier Canada Graduate Scholarship(Canadian Institutes of Health Research (CIHR)); Neurosurgical Research and Education Foundation; American Association of Neurological surgeons, Pediatric Section; Ontario Institute for Cancer Research; McMaster University Department of Surgery	B.M. is supported by a Canadian Institutes of Health Research Vanier Canada Graduate Scholarship. S.K.S. is supported by the Neurosurgical Research and Education Foundation and American Association of Neurological surgeons, Pediatric Section, the Ontario Institute for Cancer Research, and McMaster University Department of Surgery.	Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Chenn A, 2002, SCIENCE, V297, P365, DOI 10.1126/science.1074192; Cox CV, 2009, BLOOD, V113, P3287, DOI 10.1182/blood-2008-04-154187; Fuerer C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009370; Fukumoto S, 2001, J BIOL CHEM, V276, P17479, DOI 10.1074/jbc.C000880200; Hambardzumyan D, 2008, STEM CELL REV, V4, P203, DOI 10.1007/s12015-008-9021-5; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Hu BL, 2016, CELL, V167, P1281, DOI 10.1016/j.cell.2016.10.039; Ji HT, 2009, MOL CELL, V36, P547, DOI 10.1016/j.molcel.2009.09.034; Kim WY, 2009, NAT NEUROSCI, V12, P1390, DOI 10.1038/nn.2408; Lan XY, 2017, NATURE, V549, P227, DOI 10.1038/nature23666; Mak AB, 2012, CELL REP, V2, P951, DOI 10.1016/j.celrep.2012.09.016; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Maw MA, 2000, HUM MOL GENET, V9, P27, DOI 10.1093/hmg/9.1.27; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Morris LGT, 2013, NAT GENET, V45, P253, DOI 10.1038/ng.2538; Ng SW, 2009, J BIOL CHEM, V284, P24767, DOI 10.1074/jbc.M109.011692; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; Pulvirenti T, 2011, CANCER RES, V71, P7280, DOI 10.1158/0008-5472.CAN-11-1531; Rheinbay E, 2013, CELL REP, V3, P1567, DOI 10.1016/j.celrep.2013.04.021; Rossi M, 2011, CANCER BIOL THER, V11, P753, DOI 10.4161/cbt.11.8.14894; Sastre-Perona A, 2016, ONCOTARGET, V7, P49435, DOI 10.18632/oncotarget.10356; Shibahara I, 2013, NEURO-ONCOLOGY, V15, P1151, DOI 10.1093/neuonc/not066; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Taal W, 2014, LANCET ONCOL, V15, P943, DOI 10.1016/S1470-2045(14)70314-6; ter Haar E, 2001, NAT STRUCT BIOL, V8, P593, DOI 10.1038/89624; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Uhrbom L, 2002, CANCER RES, V62, P5551; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wei W, 2016, CANCER CELL, V29, P563, DOI 10.1016/j.ccell.2016.03.012; Wei YY, 2013, P NATL ACAD SCI USA, V110, P6829, DOI 10.1073/pnas.1217002110; Weller M, 2017, LANCET ONCOL, V18, P1373, DOI 10.1016/S1470-2045(17)30517-X; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Yin AH, 1997, BLOOD, V90, P5002, DOI 10.1182/blood.V90.12.5002.5002_5002_5012; Zeppernick F, 2008, CLIN CANCER RES, V14, P123, DOI 10.1158/1078-0432.CCR-07-0932; Zhang LY, 2010, PATHOL ONCOL RES, V16, P253, DOI 10.1007/s12253-009-9219-0; Zhang N, 2011, CANCER CELL, V20, P427, DOI 10.1016/j.ccr.2011.08.016; Zheng HW, 2010, CANCER CELL, V17, P497, DOI 10.1016/j.ccr.2010.03.020	41	21	21	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	7					1590	1599		10.1038/s41388-019-1086-x	http://dx.doi.org/10.1038/s41388-019-1086-x			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KL2WP	31695152				2022-12-28	WOS:000513289600014
J	Yu, SR; Sha, HH; Qin, XB; Chen, Y; Li, XY; Shi, MQ; Feng, JF				Yu, Shaorong; Sha, Huanhuan; Qin, Xiaobing; Chen, Yan; Li, Xiaoyou; Shi, Meiqi; Feng, Jifeng			EGFR E746-A750 deletion in lung cancer represses antitumor immunity through the exosome-mediated inhibition of dendritic cells	ONCOGENE			English	Article							TUMOR-DERIVED EXOSOMES; CHECKPOINT INHIBITORS; DOCETAXEL; CARCINOMA; BLOCKADE; PATHWAY; ALTERS	EGFR-mutant lung cancer (LC) patients display a poor response to PD-1/PD-L1 blockade. In the absence of independent genetic validation, whether EGFR mutation distorts host antitumor immunity is unknown. Here, we showed that in the clinic, LC with the E746-A750 deletion mutation (EGFR-19del) displayed a temporal association with the loss of intratumoral CD8+ T cells. In a xenograft model, EGFR-19del-expressing Lewis lung cancer (LLC) tumors had a low T cell density at the early stage of tumor development, along with dendritic cells (DCs) exhibiting variant phenotypes in the tumors and draining lymph nodes (LNs). Importantly, EGFR-19del DCs were observed in the LNs of tumor-bearing mice and LC patients. The proliferative activity of T cells within the LN was significantly dampened. In vitro experiments indicated that the function of DCs was repressed by EGFR-19del LLC cells through exosome uptake in which exosomes derived from the EGFR-19del LLC cells could efficiently transfer active EGFR-19del to the surface of the DCs. Injection of EGFR-19del tumor-derived exosomes promoted LLC tumor progression and induced immunosuppression. The combination of gefitinib and GM-CSF treatment recovered tumor T cell infiltration in EGFR-19del tumors by rescuing the function of DCs and increasing the efficacy of anti-PD-L1 treatment. Together, these results indicated that LC with the EGFR E746-A750 deletion mutation induced anergic DCs to repress antitumor immunity through exosomes.	[Yu, Shaorong; Sha, Huanhuan; Qin, Xiaobing; Li, Xiaoyou; Shi, Meiqi; Feng, Jifeng] Nanjing Med Univ, Affiliated Canc Hosp, Dept Med Oncol, Nanjing, Jiangsu, Peoples R China; [Yu, Shaorong; Sha, Huanhuan; Qin, Xiaobing; Chen, Yan; Li, Xiaoyou; Shi, Meiqi; Feng, Jifeng] Jiangsu Canc Hosp, Nanjing, Jiangsu, Peoples R China; [Yu, Shaorong; Sha, Huanhuan; Qin, Xiaobing; Chen, Yan; Li, Xiaoyou; Shi, Meiqi; Feng, Jifeng] Jiangsu Inst Canc Res, Nanjing, Jiangsu, Peoples R China; [Qin, Xiaobing] Xuzhou Med Univ, Affiliated Hosp, Dept Med Oncol, Xuzhou, Jiangsu, Peoples R China; [Chen, Yan] Nanjing Med Univ, Affiliated Canc Hosp, Dept Pathol, Nanjing, Jiangsu, Peoples R China	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Xuzhou Medical University; Nanjing Medical University	Feng, JF (corresponding author), Nanjing Med Univ, Affiliated Canc Hosp, Dept Med Oncol, Nanjing, Jiangsu, Peoples R China.; Feng, JF (corresponding author), Jiangsu Canc Hosp, Nanjing, Jiangsu, Peoples R China.; Feng, JF (corresponding author), Jiangsu Inst Canc Res, Nanjing, Jiangsu, Peoples R China.	fjif@vip.sina.com			National Natural Science Foundation of China [81871873]; Project of Invigorating Health Care through Science, Technology and Education, Jiangsu Provincial Medical Youth Talent [QNRC2016646]; China Postdoctoral Science Foundation [2017M621680]; Six talent peaks project in Jiangsu Province [WSN-039]; talents program of Jiangsu Cancer Hospital [YC201807]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Project of Invigorating Health Care through Science, Technology and Education, Jiangsu Provincial Medical Youth Talent; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Six talent peaks project in Jiangsu Province; talents program of Jiangsu Cancer Hospital	This work was supported by grants from the National Natural Science Foundation of China (81871873); the Project of Invigorating Health Care through Science, Technology and Education, Jiangsu Provincial Medical Youth Talent (QNRC2016646); the China Postdoctoral Science Foundation (2017M621680); the Six talent peaks project in Jiangsu Province (WSN-039); and the talents program of Jiangsu Cancer Hospital (YC201807).	Al-Nedawi K, 2008, NAT CELL BIOL, V10, P619, DOI 10.1038/ncb1725; Anguille S, 2015, PHARMACOL REV, V67, P731, DOI 10.1124/pr.114.009456; Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Chalmin F, 2010, J CLIN INVEST, V120, P457, DOI 10.1172/JCI40483; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Choi D, 2018, MOL CELL PROTEOMICS, V17, P1948, DOI 10.1074/mcp.RA118.000644; Conejo-Garcia JR, 2016, PHARMACOL THERAPEUT, V164, P97, DOI 10.1016/j.pharmthera.2016.04.003; Cristescu R, 2018, SCIENCE, V362, P197, DOI 10.1126/science.aar3593; Dong ZY, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1356145; Donnem T, 2015, CLIN CANCER RES, V21, P2635, DOI 10.1158/1078-0432.CCR-14-1905; Dresch C, 2012, TRENDS IMMUNOL, V33, P381, DOI 10.1016/j.it.2012.04.009; Eisenbarth SC, 2019, NAT REV IMMUNOL, V19, P89, DOI 10.1038/s41577-018-0088-1; Enamorado M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16073; Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175; Gainor JF, 2016, CLIN CANCER RES, V22, P4585, DOI 10.1158/1078-0432.CCR-15-3101; Jameson SC, 2018, IMMUNITY, V48, P214, DOI 10.1016/j.immuni.2018.02.010; Lee CK, 2018, JAMA ONCOL, V4, P210, DOI 10.1001/jamaoncol.2017.4427; Lee CK, 2017, J THORAC ONCOL, V12, P403, DOI 10.1016/j.jtho.2016.10.007; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Mascia F, 2016, INT J CANCER, V139, P2593, DOI 10.1002/ijc.30376; Mondanelli G, 2017, IMMUNITY, V46, P233, DOI 10.1016/j.immuni.2017.01.005; Park SL, 2018, NAT IMMUNOL, V19, P183, DOI 10.1038/s41590-017-0027-5; Qin XB, 2017, INT J NANOMED, V12, P3721, DOI 10.2147/IJN.S131516; Raulf N, 2018, EUR J CANCER, V102, P52, DOI 10.1016/j.ejca.2018.07.123; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Sanderson MP, 2008, J CELL BIOCHEM, V103, P1783, DOI 10.1002/jcb.21569; van de Laar L, 2012, BLOOD, V119, P3383, DOI 10.1182/blood-2011-11-370130; Wang SH, 2016, J BIOL CHEM, V291, P21085, DOI 10.1074/jbc.M116.717892; Zhang HY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15016; Zhang LL, 2019, THERANOSTICS, V9, P2541, DOI 10.7150/thno.32655; Zhang ZF, 2010, CARCINOGENESIS, V31, P577, DOI 10.1093/carcin/bgq020	33	22	22	2	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	13					2643	2657		10.1038/s41388-020-1182-y	http://dx.doi.org/10.1038/s41388-020-1182-y		JAN 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KX4EF	32001818				2022-12-28	WOS:000510328400002
J	Adler, AJ; Mittal, P; Hagymasi, AT; Menoret, A; Shen, C; Agliano, F; Wright, KT; Grady, JJ; Kuo, CL; Ballesteros, E; Claffey, KP; Vella, AT				Adler, Adam J.; Mittal, Payal; Hagymasi, Adam T.; Menoret, Antoine; Shen, Chen; Agliano, Federica; Wright, Kyle T.; Grady, James J.; Kuo, Chia-Ling; Ballesteros, Enrique; Claffey, Kevin P.; Vella, Anthony T.			GRK2 enforces androgen receptor dependence in the prostate and prostate tumors	ONCOGENE			English	Article							PROTEIN-COUPLED RECEPTOR; RAF KINASE INHIBITOR; MOUSE MODEL; NEUROENDOCRINE DIFFERENTIATION; REGULATED EXPRESSION; CANCER; PTEN; GENE; ADENOCARCINOMA; METASTASIS	Metastatic tumors that have become resistant to androgen deprivation therapy represent the major challenge in treating prostate cancer. Although these recurrent tumors typically remain dependent on the androgen receptor (AR), non-AR-driven tumors that also emerge are particularly deadly and becoming more prevalent. Here, we present a new genetically engineered mouse model for non-AR-driven prostate cancer that centers on a negative regulator of G protein-coupled receptors that is downregulated in aggressive human prostate tumors. Thus, prostate-specific expression of a dominant-negative G protein-coupled receptor kinase 2 (GRK2-DN) transgene diminishes AR and AR target gene expression in the prostate, and confers resistance to castration-induced involution. Further, the GRK2-DN transgene dramatically accelerates oncogene-initiated prostate tumorigenesis by increasing primary tumor size, potentiating visceral organ metastasis, suppressing AR, and inducing neuroendocrine marker mRNAs. In summary, GRK2 enforces AR-dependence in the prostate, and the loss of GRK2 function in prostate tumors accelerates disease progression toward the deadliest stage.	[Adler, Adam J.; Mittal, Payal; Hagymasi, Adam T.; Menoret, Antoine; Shen, Chen; Agliano, Federica; Wright, Kyle T.; Vella, Anthony T.] UConn Hlth, Dept Immunol, Sch Med, Farmington, CT 06030 USA; [Grady, James J.; Kuo, Chia-Ling] UConn Hlth, Sch Med, Dept Community Med & Hlth Care, Farmington, CT USA; [Ballesteros, Enrique] UConn Hlth, Sch Med, Dept Pathol & Lab Med, Farmington, CT USA; [Claffey, Kevin P.] UConn Hlth, Sch Med, Dept Cell Biol, Farmington, CT USA; [Mittal, Payal] Merck Res Labs, Oncol Dept, Boston, MA 02115 USA; [Hagymasi, Adam T.] Univ Connecticut, Sch Med, Carole & Ray Neag Comprehens Canc Ctr, Farmington, CT USA	Merck & Company; University of Connecticut	Adler, AJ; Vella, AT (corresponding author), UConn Hlth, Dept Immunol, Sch Med, Farmington, CT 06030 USA.	aadler@uchc.edu; vella@uchc.edu		Agliano, Federica/0000-0002-1093-171X	National Institutes of Health [R01CA109339, R01AI094640]; Carole and Ray Neag Comprehensive Cancer Center	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Carole and Ray Neag Comprehensive Cancer Center	This work was supported by National Institutes of Health Grants R01CA109339 and R01AI094640 (to AJA and ATV) and by the Carole and Ray Neag Comprehensive Cancer Center. The authors thank Dr. Jeffrey Benovic for providing the GRK2-DN (beta ARK-K220R) construct, Dr. Robert Matusik for providing the ARR<INF>2</INF>PB construct as well as helpful discussions and critical reading of the paper, Dr. Stefan Brocke for advice regarding in vitro forskolin stimulations, and Dr. Christopher Bonin for editing the paper.	Abate-Shen C, 2003, CANCER RES, V63, P3886; Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Aggarwal R, 2018, J CLIN ONCOL, V36, P2492, DOI 10.1200/JCO.2017.77.6880; Alanee S, 2015, ANTICANCER RES, V35, P4145; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; Bethel CR, 2006, CANCER RES, V66, P10683, DOI 10.1158/0008-5472.CAN-06-0963; Bishop JL, 2017, CANCER DISCOV, V7, P54, DOI 10.1158/2159-8290.CD-15-1263; Bluemn EG, 2017, CANCER CELL, V32, P474, DOI 10.1016/j.ccell.2017.09.003; Bookout AL, 2003, J BIOL CHEM, V278, P37569, DOI 10.1074/jbc.M306276200; Cai JA, 2010, TRANSL ONCOL, V3, P195, DOI 10.1593/tlo.09328; Carver BS, 2016, CANCER CELL, V29, P431, DOI 10.1016/j.ccell.2016.03.023; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Chang KH, 2013, CELL, V154, P1074, DOI 10.1016/j.cell.2013.07.029; Chang KH, 2011, P NATL ACAD SCI USA, V108, P13728, DOI 10.1073/pnas.1107898108; Chiaverotti T, 2008, AM J PATHOL, V172, P236, DOI 10.2353/ajpath.2008.070602; Daaka Y., 2004, SCI STKE, V2004, pre2, DOI [10.1126/stke.2162004re2, DOI 10.1126/STKE.2162004RE2]; Dehm SM, 2008, CANCER RES, V68, P5469, DOI 10.1158/0008-5472.CAN-08-0594; Denmeade SR, 2002, NAT REV CANCER, V2, P389, DOI 10.1038/nrc801; Ding ZH, 2012, CELL, V148, P896, DOI 10.1016/j.cell.2012.01.039; Ding ZH, 2011, NATURE, V470, P269, DOI 10.1038/nature09677; Drake CG, 2005, CANCER CELL, V7, P239, DOI 10.1016/j.ccr.2005.01.027; Drake CG, 2014, ONCOLOGY-NY, V28, P974; Escara-Wilke J, 2015, PROSTATE, V75, P292, DOI 10.1002/pros.22915; Fu XB, 2013, J BIOL CHEM, V288, P7738, DOI 10.1074/jbc.M112.428078; Fu Z, 2003, J NATL CANCER I, V95, P878, DOI 10.1093/jnci/95.12.878; Furusato B, 2010, PATHOL INT, V60, P497, DOI 10.1111/j.1440-1827.2010.02548.x; Gandaglia G, 2015, EUR UROL, V68, P325, DOI 10.1016/j.eururo.2014.07.020; Gingrich J, 1999, PROSTATE CANCER P D, V6, P1; Gingrich JR, 1996, CANCER RES, V56, P4096; Gingrich JR, 1997, CANCER RES, V57, P4687; Grabowska MM, 2014, CANCER METAST REV, V33, P377, DOI 10.1007/s10555-013-9487-8; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; GREENBERG NM, 1994, MOL ENDOCRINOL, V8, P230, DOI 10.1210/me.8.2.230; Han GZ, 2001, J BIOL CHEM, V276, P11204, DOI 10.1074/jbc.M008207200; He WW, 1997, GENOMICS, V43, P69, DOI 10.1006/geno.1997.4715; Hirano D, 2004, EUR UROL, V45, P586, DOI 10.1016/j.eururo.2003.11.032; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hu MM, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005171; Hurwitz AA, 2000, CANCER RES, V60, P2444; Kaplan-Lefko PJ, 2003, PROSTATE, V55, P219, DOI 10.1002/pros.10215; Kasbohm EA, 2005, J BIOL CHEM, V280, P11583, DOI 10.1074/jbc.M414423200; Khasnavis S, 2013, J BIOL CHEM, V288, P20843, DOI 10.1074/jbc.M112.443556; Komolov KE, 2017, CELL SIGNAL, V41, P17, DOI 10.1016/j.cellsig.2017.07.004; KONG GH, 1994, J BIOL CHEM, V269, P13084; Kwon ED, 2014, LANCET ONCOL, V15, P700, DOI 10.1016/S1470-2045(14)70189-5; Lee H, 2010, NAT MED, V16, P1421, DOI 10.1038/nm.2250; Lee JK, 2016, CANCER CELL, V29, P536, DOI 10.1016/j.ccell.2016.03.001; Lin BY, 1999, CANCER RES, V59, P4180; Lonergan Peter E, 2011, J Carcinog, V10, P20, DOI 10.4103/1477-3163.83937; Lorenz K, 2003, NATURE, V426, P574, DOI 10.1038/nature02158; Malchow S, 2013, SCIENCE, V339, P1219, DOI 10.1126/science.1233913; Metaye T, 2008, J ENDOCRINOL, V198, P101, DOI 10.1677/JOE-07-0562; Mulholland DJ, 2012, CANCER RES, V72, P1878, DOI 10.1158/0008-5472.CAN-11-3132; Mulholland DJ, 2011, CANCER CELL, V19, P792, DOI 10.1016/j.ccr.2011.05.006; Nogues L, 2017, MOL PHARMACOL, V91, P220, DOI 10.1124/mol.116.107185; Palmgren JS, 2007, SEMIN ONCOL, V34, P22, DOI 10.1053/j.seminoncol.2006.10.026; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Prowatke I, 2007, BRIT J CANCER, V96, P82, DOI 10.1038/sj.bjc.6603490; Purayil HT, 2015, ONCOGENE, V34, P3144, DOI 10.1038/onc.2014.252; Qiao JB, 2016, ONCOTARGET, V7, P61955, DOI 10.18632/oncotarget.11326; Savage PA, 2008, SCIENCE, V319, P215, DOI 10.1126/science.1148886; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; SUGIMURA Y, 1986, BIOL REPROD, V34, P973, DOI 10.1095/biolreprod34.5.973; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tsurutani N, 2016, J IMMUNOL, V196, P124, DOI 10.4049/jimmunol.1501217; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wang ZQ, 2017, CANCER LETT, V408, P10, DOI 10.1016/j.canlet.2017.08.013; Watson PA, 2015, NAT REV CANCER, V15, P701, DOI 10.1038/nrc4016; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Wright KT, 2013, J IMMUNOL, V191, P708, DOI 10.4049/jimmunol.1203486; Xu LL, 2000, CANCER RES, V60, P6568; Xu ZW, 2017, CANCER CHEMOTH PHARM, V79, P747, DOI 10.1007/s00280-017-3267-z; Yowell Charles W, 2002, Clin Prostate Cancer, V1, P177, DOI 10.3816/CGC.2002.n.020; Zhang JF, 2000, ENDOCRINOLOGY, V141, P4698, DOI 10.1210/en.141.12.4698; Zhou ZX, 2006, CANCER RES, V66, P7889, DOI 10.1158/0008-5472.CAN-06-0486; Zou M, 2017, CANCER DISCOV, V7, P736, DOI 10.1158/2159-8290.CD-16-1174	77	3	3	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	11					2424	2436		10.1038/s41388-020-1159-x	http://dx.doi.org/10.1038/s41388-020-1159-x		JAN 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KU0ZS	31959897	Green Accepted			2022-12-28	WOS:000508322900002
J	Lopez, I; Chalatsi, E; Ellenbroek, SIJ; Andrieux, A; Roux, PF; Cerapio, JP; Jouvion, G; van Rheenen, J; Seeler, JS; Dejean, A				Lopez, Ignacio; Chalatsi, Eleftheria; Ellenbroek, Saskia I. J.; Andrieux, Alexandra; Roux, Pierre-Francois; Cerapio, Juan P.; Jouvion, Gregory; van Rheenen, Jacco; Seeler, Jacob-S.; Dejean, Anne			An unanticipated tumor-suppressive role of the SUMO pathway in the intestine unveiled by Ubc9 haploinsufficiency	ONCOGENE			English	Article							CRYPT STEM-CELLS; ENRICHMENT ANALYSIS; CONJUGATING ENZYME; DNA-DAMAGE; SUMOYLATION; EXPRESSION; INFLAMMATION; CANCER; UBIQUITIN; COLON	Sumoylation is an essential posttranslational modification in eukaryotes that has emerged as an important pathway in oncogenic processes. Most human cancers display hyperactivated sumoylation and many cancer cells are remarkably sensitive to its inhibition, thus supporting application of chemical sumoylation inhibitors in cancer treatment. Here we show, first, that transformed embryonic fibroblasts derived from mice haploinsufficient for Ubc9, the essential and unique gene encoding the SUMO E2 conjugating enzyme, exhibit enhanced proliferation and transformed phenotypes in vitro and as xenografts ex vivo. To then evaluate the possible impact of loss of oneUbc9allele in vivo, we used a mouse model of intestinal tumorigenesis. We crossedUbc9(+/-)mice with mice harboring a conditional ablation of Apc either all along the crypt-villus axis or only in Lgr5(+)crypt-based columnar (CBC) cells, the cell compartment that includes the intestinal stem cells proposed as cells-of-origin of intestinal cancer. WhileUbc9(+/-)mice display no overt phenotypes and no globally visible hyposumoylation in cells of the small intestine, we found, strikingly, that, upon loss of Apc in both models,Ubc9(+/-)mice develop more (>2-fold) intestinal adenomas and show significantly shortened survival. This is accompanied by reduced global sumoylation levels in the polyps, indicating that Ubc9 levels become critical upon oncogenic stress. Moreover, we found that, in normal conditions,Ubc9(+/-)mice show a moderate but robust (15%) increase in the number of Lgr5(+)CBC cells when compared to their wild-type littermates, and further, that these cells display higher degree of stemness and cancer-related and inflammatory gene expression signatures that, altogether, may contribute to enhanced intestinal tumorigenesis. The phenotypes of Ubc9 haploinsufficiency discovered here indicate an unanticipated tumor-suppressive role of sumoylation, one that may have important implications for optimal use of sumoylation inhibitors in the clinic.	[Lopez, Ignacio; Chalatsi, Eleftheria; Andrieux, Alexandra; Roux, Pierre-Francois; Cerapio, Juan P.; Seeler, Jacob-S.; Dejean, Anne] Inst Pasteur, Equipe Labellisee Ligue Natl Canc, INSERM, Nucl Org & Oncogenesis Unit,U993, F-75015 Paris, France; [Chalatsi, Eleftheria] Sorbonne Univ, Coll Doctoral, F-75005 Paris, France; [Ellenbroek, Saskia I. J.; van Rheenen, Jacco] Netherlands Canc Inst, Oncode Inst, Div Mol Pathol, Amsterdam, Netherlands; [Jouvion, Gregory] Inst Pasteur, Expt Neuropathol Unit, F-75015 Paris, France; [Chalatsi, Eleftheria] Biorad Labs, Marnes La Coquette, France; [Cerapio, Juan P.] Univ Toulouse, Ctr Rech Cancerol Toulouse, Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Sorbonne Universite; Netherlands Cancer Institute; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Seeler, JS; Dejean, A (corresponding author), Inst Pasteur, Equipe Labellisee Ligue Natl Canc, INSERM, Nucl Org & Oncogenesis Unit,U993, F-75015 Paris, France.	jacob.seeler@pasteur.fr; anne.dejean@pasteur.fr	Dejean, Anne/L-5145-2018; Roux, Pierre-François/J-8875-2019; Jouvion, Grégory/AAL-2620-2021	Roux, Pierre-François/0000-0002-0695-4206; Lopez, Ignacio/0000-0001-9669-8906; Cerapio Arroyo, Juan Pablo/0000-0002-3032-3180; Ellenbroek, Saskia/0000-0001-8007-2634; Chalatsi, Eleftheria/0000-0003-2447-5572	INCa; ANR; ERC-AdG "SUMOSTRESS"; Josef Steiner Cancer Foundation; ERC-CoG "Cancer Recurrence"; Fondation ARC [PDF20170505624]; LNCC (Equipe labellisee); Odyssey; ERC-AdG "SUMiDENTITY"	INCa(Institut National du Cancer (INCA) France); ANR(French National Research Agency (ANR)); ERC-AdG "SUMOSTRESS"; Josef Steiner Cancer Foundation; ERC-CoG "Cancer Recurrence"; Fondation ARC; LNCC (Equipe labellisee); Odyssey; ERC-AdG "SUMiDENTITY"	This work was supported by grants from INCa, LNCC (Equipe labellisee), Odyssey, ANR and ERC-AdG "SUMOSTRESS" and "SUMiDENTITY" to AD, and by the Josef Steiner Cancer Foundation and ERC-CoG "Cancer Recurrence" to JvR. IL was supported by Fondation ARC (PDF20170505624). We thank Dr. Giulia Nigro and the Institut Pasteur UTechS facility for technical input and Drs. Bob Weinberg, Maria Jasin, and Sergio F. de Almeida for providing reagents.	Alvarez A, 2014, JOVE-J VIS EXP, DOI 10.3791/51742; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Basak O, 2014, EMBO J, V33, P2057, DOI 10.15252/embj.201488017; Bettermann K, 2012, CANCER LETT, V316, P113, DOI 10.1016/j.canlet.2011.10.036; Borowicz S, 2014, JOVE-J VIS EXP, DOI 10.3791/51998; Bu PC, 2016, CELL STEM CELL, V18, P189, DOI 10.1016/j.stem.2016.01.006; Buczacki SJA, 2013, NATURE, V495, P65, DOI 10.1038/nature11965; Carbon S, 2019, NUCLEIC ACIDS RES, V47, pD330, DOI 10.1093/nar/gky1055; Carvalho BS, 2010, BIOINFORMATICS, V26, P2363, DOI 10.1093/bioinformatics/btq431; Cheloufi S, 2015, NATURE, V528, P218, DOI 10.1038/nature15749; Chen J, 2009, NUCLEIC ACIDS RES, V37, pW305, DOI 10.1093/nar/gkp427; Clevers H, 2013, CELL, V154, P274, DOI 10.1016/j.cell.2013.07.004; Colnot S, 2004, P NATL ACAD SCI USA, V101, P17216, DOI 10.1073/pnas.0404761101; Cossec JC, 2018, CELL STEM CELL, V23, P742, DOI 10.1016/j.stem.2018.10.001; Croft D, 2014, NUCLEIC ACIDS RES, V42, pD472, DOI 10.1093/nar/gkt1102; Decque A, 2016, NAT IMMUNOL, V17, P140, DOI 10.1038/ni.3342; Demarque MD, 2011, GASTROENTEROLOGY, V140, P286, DOI 10.1053/j.gastro.2010.10.002; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; Fevr T, 2007, MOL CELL BIOL, V27, P7551, DOI 10.1128/MCB.01034-07; Flotho A, 2013, ANNU REV BIOCHEM, V82, P357, DOI 10.1146/annurev-biochem-061909-093311; Golebiowski F, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000282; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Hayashi T, 2002, EXP CELL RES, V280, P212, DOI 10.1006/excr.2002.5634; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He XY, 2017, NAT CHEM BIOL, V13, P1164, DOI [10.1038/nchembio.2463, 10.1038/NCHEMBIO.2463]; Hendriks IA, 2016, NAT REV MOL CELL BIO, V17, P581, DOI 10.1038/nrm.2016.81; Jackson SP, 2013, MOL CELL, V49, P795, DOI 10.1016/j.molcel.2013.01.017; Jackstadt R, 2016, J PATHOL, V238, P141, DOI 10.1002/path.4645; Kanehisa M, 2017, NUCLEIC ACIDS RES, V45, pD353, DOI 10.1093/nar/gkw1092; Karin M, 2016, NATURE, V529, P307, DOI 10.1038/nature17039; Kessler JD, 2012, SCIENCE, V335, P348, DOI 10.1126/science.1212728; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Lindemans CA, 2015, NATURE, V528, P560, DOI 10.1038/nature16460; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; MOLL R, 1993, DIFFERENTIATION, V53, P75, DOI 10.1111/j.1432-0436.1993.tb00648.x; Moschos SJ, 2010, HUM PATHOL, V41, P1286, DOI 10.1016/j.humpath.2010.02.007; Munoz J, 2012, EMBO J, V31, P3079, DOI 10.1038/emboj.2012.166; Mustfa SA, 2017, OPEN BIOL, V7, DOI 10.1098/rsob.170024; Nacerddine K, 2005, DEV CELL, V9, P769, DOI 10.1016/j.devcel.2005.10.007; Nagel R, 2016, EMBO REP, V17, P1516, DOI 10.15252/embr.201643030; Neyret-Kahn H, 2013, GENOME RES, V23, P1563, DOI 10.1101/gr.154872.113; Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29; Ordonez-Moran P, 2015, CANCER CELL, V28, P815, DOI 10.1016/j.ccell.2015.11.001; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Pino MS, 2010, GASTROENTEROLOGY, V138, P2059, DOI 10.1053/j.gastro.2009.12.065; Rafehi H, 2011, JOVE-J VIS EXP, DOI 10.3791/2573; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Seeler JS, 2017, NAT REV CANCER, V17, P184, DOI 10.1038/nrc.2016.143; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Stankovic-Valentin N, 2018, MOL ASPECTS MED, V63, P3, DOI 10.1016/j.mam.2018.07.002; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Suhail A, 2019, CELL REP, V29, P3522, DOI 10.1016/j.celrep.2019.11.028; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tetteh PW, 2016, CELL STEM CELL, V18, P203, DOI 10.1016/j.stem.2016.01.001; Tian H, 2011, NATURE, V478, P255, DOI 10.1038/nature10408; van Es JH, 2012, NAT CELL BIOL, V14, P1099, DOI 10.1038/ncb2581; Yu B, 2015, P NATL ACAD SCI USA, V112, pE1724, DOI 10.1073/pnas.1415569112	61	4	4	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2020	39	43					6692	6703		10.1038/s41388-020-01457-y	http://dx.doi.org/10.1038/s41388-020-01457-y		SEP 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OF2UT	32948837	Green Published, hybrid			2022-12-28	WOS:000570855500001
J	Wen, SM; He, YD; Wang, LW; Zhang, J; Quan, CY; Niu, YJ; Huang, HJ				Wen, Simeng; He, Yundong; Wang, Liewei; Zhang, Jun; Quan, Changyi; Niu, Yuanjie; Huang, Haojie			Aberrant activation of super enhancer and choline metabolism drive antiandrogen therapy resistance in prostate cancer	ONCOGENE			English	Article							INTEGRATIVE CLINICAL GENOMICS; PHOSPHOLIPID-METABOLISM; CELL IDENTITY; SELECTIVE-INHIBITION; ENZALUTAMIDE; TRANSCRIPTION; DEPENDENCIES; BICALUTAMIDE; STIMULATION; MECHANISMS	Next generation antiandrogens such as enzalutamide (Enz) are effective initially for the treatment of castration-resistant prostate cancer (CRPC). However, the disease often relapses and the underlying mechanisms remain elusive. By performing H3-lysine-27 acetylation (H3K27ac) ChIP-seq in Enz-resistant CRPC cells, we identified a group of super enhancers (SEs) that are abnormally activated in Enz-resistant CRPC cells and associated with enhanced transcription of a subset of tumor promoting genes such asCHPT1, which catalyzes phosphatidylcholine (PtdCho) synthesis and regulates choline metabolism. Increased CHPT1 conferred CRPC resistance to Enz in vitro and in mice. While androgen receptor (AR) primarily binds to a putativeCHPT1enhancer and mediates androgen-dependent expression ofCHPT1gene in Enz-sensitive prostate cancer cells, AR binds to a different enhancer within theCHPT1SE locus and facilities androgen-independent expression ofCHPT1in Enz-resistant cells. We further identified a long-non coding RNA transcribed atCHPT1enhancer (also known as enhancer RNA) that binds to the H3K27ac reader BRD4 and participates in regulatingCHPT1SE activity andCHPT1gene expression. Our findings demonstrate that aberrantly activated SE upregulates CHPT1 expression and confers Enz resistance in CRPC, suggesting that SE-mediated expression of downstream effectors such as CHPT1 can be viable targets to overcome Enz resistance in PCa.	[Wen, Simeng; Quan, Changyi; Niu, Yuanjie] Tianjin Med Univ, Tianjin Inst Urol, Hosp 2, Dept Urol, Tianjin, Peoples R China; [Wen, Simeng; He, Yundong; Huang, Haojie] Mayo Clin, Dept Biochem & Mol Biol, Coll Med & Sci, Rochester, MN 55905 USA; [Wang, Liewei] Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Coll Med & Sci, Rochester, MN USA; [Zhang, Jun] Mayo Clin, Dept Lab Med & Pathol, Coll Med & Sci, Scottsdale, AZ USA; [Huang, Haojie] Mayo Clin, Dept Urol, Coll Med & Sci, Rochester, MN 55905 USA; [Huang, Haojie] Mayo Clin, Ctr Canc, Coll Med & Sci, Rochester, MN 55905 USA	Tianjin Medical University; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic	Quan, CY; Niu, YJ (corresponding author), Tianjin Med Univ, Tianjin Inst Urol, Hosp 2, Dept Urol, Tianjin, Peoples R China.; Huang, HJ (corresponding author), Mayo Clin, Dept Biochem & Mol Biol, Coll Med & Sci, Rochester, MN 55905 USA.; Huang, HJ (corresponding author), Mayo Clin, Dept Urol, Coll Med & Sci, Rochester, MN 55905 USA.; Huang, HJ (corresponding author), Mayo Clin, Ctr Canc, Coll Med & Sci, Rochester, MN 55905 USA.	quancy98@163.com; niuyuanjie9317@163.com; huang.haojie@mayo.edu			Mayo Clinic Foundation; National Natural Science Foundation of China [81972654]; Tianjin International Student Science and Technology Activities Launched Project [20160014]; Tianjin science and technology commission [18JCZDJC34800]	Mayo Clinic Foundation; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Tianjin International Student Science and Technology Activities Launched Project; Tianjin science and technology commission	This work was supported in part by the Mayo Clinic Foundation (to HH) and the National Natural Science Foundation of China (81972654 to SW), Tianjin International Student Science and Technology Activities Launched Project (20160014 to SW), and Tianjin science and technology commission (18JCZDJC34800 to CQ).	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Abida W, 2019, P NATL ACAD SCI USA, V116, P11428, DOI 10.1073/pnas.1902651116; Ackerstaff E, 2003, J CELL BIOCHEM, V90, P525, DOI 10.1002/jcb.10659; Anthony ML, 1999, J BIOL CHEM, V274, P19686, DOI 10.1074/jbc.274.28.19686; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229; Beagrie RA, 2016, BIOESSAYS, V38, P881, DOI 10.1002/bies.201600032; Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Chapuy B, 2013, CANCER CELL, V24, P777, DOI 10.1016/j.ccr.2013.11.003; Chatterjee D, 2001, BIOCHEM BIOPH RES CO, V282, P861, DOI 10.1006/bbrc.2001.4662; Cho WK, 2018, SCIENCE, V361, P412, DOI 10.1126/science.aar4199; Core LJ, 2008, SCIENCE, V322, P1845, DOI 10.1126/science.1162228; Di Micco R, 2014, CELL REP, V9, P234, DOI 10.1016/j.celrep.2014.08.055; Donati B, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0915-9; Doroshow DB, 2017, ANN ONCOL, V28, P1776, DOI 10.1093/annonc/mdx157; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Glunde K, 2004, CANCER RES, V64, P4270, DOI 10.1158/0008-5472.CAN-03-3829; Glunde K, 2011, NAT REV CANCER, V11, P835, DOI 10.1038/nrc3162; Hah N, 2015, P NATL ACAD SCI USA, V112, pE297, DOI 10.1073/pnas.1424028112; Hajmirza A, 2018, BIOMEDICINES, V6, DOI 10.3390/biomedicines6010016; He Y, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00361; Heidenreich A, 2017, EUR UROL, V71, P534, DOI 10.1016/j.eururo.2016.07.027; Hentze MW, 2018, NAT REV MOL CELL BIO, V19, P327, DOI 10.1038/nrm.2017.130; Hnisz D, 2013, CELL, V155, P934, DOI 10.1016/j.cell.2013.09.053; Jia M, 2016, CANCER RES, V76, P5634, DOI 10.1158/0008-5472.CAN-15-2910; Katz-Brull R, 2001, MAGNET RESON MED, V46, P31, DOI 10.1002/mrm.1157; Khan A, 2018, EPIGENETICS-US, V13, P910, DOI 10.1080/15592294.2018.1514231; Kim TK, 2010, NATURE, V465, P182, DOI 10.1038/nature09033; Ko JY, 2017, MOL CELLS, V40, P169, DOI 10.14348/molcells.2017.0033; Kohli M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145176; Kvaratskhelia M, 2014, NUCLEIC ACIDS RES, V42, P10209, DOI 10.1093/nar/gku769; Larue RC, 2014, NUCLEIC ACIDS RES, V42, P4868, DOI 10.1093/nar/gku135; Lee TI, 2013, CELL, V152, P1237, DOI 10.1016/j.cell.2013.02.014; Li YM, 2013, CANCER RES, V73, P483, DOI 10.1158/0008-5472.CAN-12-3630; Lin D, 2014, CANCER RES, V74, P1272, DOI 10.1158/0008-5472.CAN-13-2921-T; Loven J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036; Lunde BM, 2007, NAT REV MOL CELL BIO, V8, P479, DOI 10.1038/nrm2178; Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521; Miquel K, 1998, J BIOL CHEM, V273, P26179, DOI 10.1074/jbc.273.40.26179; Mousavi K, 2013, MOL CELL, V51, P606, DOI 10.1016/j.molcel.2013.07.022; Niu Y, 2010, ONCOGENE, V29, P3593, DOI 10.1038/onc.2010.121; Ramos B, 2002, MOL PHARMACOL, V62, P1068, DOI 10.1124/mol.62.5.1068; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Robinson DR, 2017, NATURE, V548, P297, DOI 10.1038/nature23306; ROHRSCHNEIDER LR, 1973, CANCER RES, V33, P1945; Sabari BR, 2018, SCIENCE, V361, DOI 10.1126/science.aar3958; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Sen P, 2019, MOL CELL, V73, P684, DOI 10.1016/j.molcel.2019.01.021; Sengupta S, 2017, TRENDS CANCER, V3, P269, DOI 10.1016/j.trecan.2017.03.006; Sharp A, 2019, J CLIN INVEST, V129, P192, DOI 10.1172/JCI122819; Shore ND, 2016, LANCET ONCOL, V17, P153, DOI 10.1016/S1470-2045(15)00518-5; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Stelloo S, 2019, ENDOCR-RELAT CANCER, V26, pR267, DOI 10.1530/ERC-19-0032; Ting YLT, 1996, ANTICANCER RES, V16, P1381; Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175; Wang D, 2011, NATURE, V474, P390, DOI 10.1038/nature10006; WERTZ PW, 1978, CANCER RES, V38, P2900; Whyte WA, 2013, CELL, V153, P307, DOI 10.1016/j.cell.2013.03.035; Xie JJ, 2018, GASTROENTEROLOGY, V154, P2137, DOI 10.1053/j.gastro.2018.02.018; Zanconato F, 2018, NAT MED, V24, P1599, DOI 10.1038/s41591-018-0158-8; Zhao Y, 2016, CELL REP, V15, P599, DOI 10.1016/j.celrep.2016.03.038; Zuber V, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3620-y	63	19	20	3	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 15	2020	39	42					6556	6571		10.1038/s41388-020-01456-z	http://dx.doi.org/10.1038/s41388-020-01456-z		SEP 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OA9HI	32917955				2022-12-28	WOS:000568475200002
J	Vernier, M; McGuirk, S; Dufour, CR; Wan, LXY; Audet-Walsh, E; St-Pierre, J; Giguere, V				Vernier, Mathieu; McGuirk, Shawn; Dufour, Catherine R.; Wan, Liangxinyi; Audet-Walsh, Etienne; St-Pierre, Julie; Giguere, Vincent			Inhibition of DNMT1 and ERR alpha crosstalk suppresses breast cancer via derepression ofIRF4	ONCOGENE			English	Article							ESTROGEN-RELATED RECEPTORS; ONE-CARBON METABOLISM; DNA METHYLATION; TUMOR-SUPPRESSOR; ADIPOSE-TISSUE; GENES; TARGET; DECITABINE; SERINE; CONVERSION	DNA methylation is implicated in the acquisition of malignant phenotypes, and the use of epigenetic modulating drugs is a promising anti-cancer therapeutic strategy. 5-aza-2'deoxycytidine (decitabine, 5-azadC) is an FDA-approved DNA methyltransferase (DNMT) inhibitor with proven effectiveness against hematological malignancies and more recently triple-negative breast cancer (BC). Herein, genetic or pharmacological studies uncovered a hitherto unknown feedforward molecular link between DNMT1 and the estrogen related receptor alpha (ERR alpha), a key transcriptional regulator of cellular metabolism. Mechanistically, DNMT1 promotes ERR alpha stability which in turn couples DNMT1 transcription with that of the methionine cycle and S-adenosylmethionine synthesis to drive DNA methylation. In vitro and in vivo investigation using a pre-clinical mouse model of BC demonstrated a clear therapeutic advantage for combined administration of the ERR alpha inhibitor C29 with 5-azadC. A large-scale bisulfite genomic sequencing analysis revealed specific methylation perturbations fostering the discovery that reversal of promoter hypermethylation and consequently derepression of the tumor suppressor gene,IRF4, is a factor underlying the observed BC suppressive effects. This work thus uncovers a critical role of ERR alpha in the crosstalk between transcriptional control of metabolism and epigenetics and illustrates the potential for targeting ERR alpha in combination with DNMT inhibitors for BC treatment and other epigenetics-driven malignancies.	[Vernier, Mathieu; McGuirk, Shawn; Dufour, Catherine R.; Wan, Liangxinyi; Audet-Walsh, Etienne; St-Pierre, Julie; Giguere, Vincent] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada; [St-Pierre, Julie; Giguere, Vincent] McGill Univ, Fac Med, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; [St-Pierre, Julie; Giguere, Vincent] McGill Univ, Fac Med, Dept Med, Montreal, PQ H3G 1Y6, Canada; [St-Pierre, Julie; Giguere, Vincent] McGill Univ, Fac Med, Dept Oncol, Montreal, PQ H3G 1Y6, Canada; [Audet-Walsh, Etienne] Univ Laval, Dept Med Mol, Fac Med, Ctr Rech,CHU Quebec, Quebec City, PQ G1V 4G2, Canada; [St-Pierre, Julie] Univ Ottawa, Ottawa Inst Syst Biol, Fac Med, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada	McGill University; McGill University; McGill University; McGill University; Laval University; University of Ottawa	Vernier, M; Giguere, V (corresponding author), McGill Univ, Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada.; Giguere, V (corresponding author), McGill Univ, Fac Med, Dept Biochem, Montreal, PQ H3G 1Y6, Canada.; Giguere, V (corresponding author), McGill Univ, Fac Med, Dept Med, Montreal, PQ H3G 1Y6, Canada.; Giguere, V (corresponding author), McGill Univ, Fac Med, Dept Oncol, Montreal, PQ H3G 1Y6, Canada.	mathieu.vernier@mail.mcgill.ca; vincent.giguere@mcgill.ca	St-Pierre, Julie/AGB-3651-2022	St-Pierre, Julie/0000-0002-2815-7099; Dufour, Catherine Rosa/0000-0001-7324-3458; Vernier, Mathieu/0000-0001-9356-7353; Giguere, Vincent/0000-0001-9567-3694	Terry Fox Research Institute Program Project Team Grant on Oncometabolism; Canadian Institutes of Health Research (CIHR); CIHR [MOP-106603]; Vanier Canada Graduate Scholarship-CIHR; CIHR	Terry Fox Research Institute Program Project Team Grant on Oncometabolism; Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); CIHR(Canadian Institutes of Health Research (CIHR)); Vanier Canada Graduate Scholarship-CIHR(Canadian Institutes of Health Research (CIHR)); CIHR(Canadian Institutes of Health Research (CIHR))	We acknowledge contributions from the Metabolomics Core Facility (MCF) of the GCRC, as well as technical assistance from Dr. Daina Avizonis, Mariana De Sa Tavares Russo, Gaelle Bridon, and Luc Choiniere. We thank all members of the V.G. laboratory for discussions, Xiaojing Li for technical assistance and Dr. David J. Papadopoli for guidance with metabolic studies. This work was supported by a Terry Fox Research Institute Program Project Team Grant on Oncometabolism (VG and JS-P), a Foundation Grant from the Canadian Institutes of Health Research (CIHR) to VG, and an operating grant from CIHR to JS-P (MOP-106603). MV was a recipient of a post-doctoral fellowship from CIHR. SM was supported by a Vanier Canada Graduate Scholarship-CIHR. EAW was a recipient of a post-doctoral fellowship from CIHR.	Acquaviva J, 2008, BLOOD, V112, P3798, DOI 10.1182/blood-2007-10-117838; Ariazi EA, 2002, CANCER RES, V62, P6510; Audet-Walsh E, 2016, CELL REP, V14, P920, DOI 10.1016/j.celrep.2015.12.086; Audet-Walsh E, 2015, ACTA PHARMACOL SIN, V36, P51, DOI 10.1038/aps.2014.121; Barcena C, 2018, CELL REP, V24, P2392, DOI 10.1016/j.celrep.2018.07.089; Barry JB, 2005, CANCER RES, V65, P6120, DOI 10.1158/0008-5472.CAN-05-0922; Bauerle MR, 2015, J BIOL CHEM, V290, P3995, DOI 10.1074/jbc.R114.607044; Cao S, 2017, CANCER RES, V77, P4185, DOI 10.1158/0008-5472.CAN-17-0262; Castellano-Castillo D, 2019, J CLIN MED, V8, DOI 10.3390/jcm8010087; Chang CY, 2011, CANCER CELL, V20, P500, DOI 10.1016/j.ccr.2011.08.023; Chen MY, 2011, CANCER-AM CANCER SOC, V117, P4424, DOI 10.1002/cncr.26073; Cowan LA, 2010, EPIGENOMICS-UK, V2, P71, DOI 10.2217/EPI.09.44; de la Rosa J, 2017, NAT GENET, V49, P730, DOI 10.1038/ng.3817; Deblois G, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12156; Deblois G, 2013, NAT REV CANCER, V13, P27, DOI 10.1038/nrc3396; Deblois G, 2009, CANCER RES, V69, P6149, DOI 10.1158/0008-5472.CAN-09-1251; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Fan J, 2014, NATURE, V510, P298, DOI 10.1038/nature13236; Farlik M, 2016, CELL STEM CELL, V19, P808, DOI 10.1016/j.stem.2016.10.019; Gao X, 2019, NATURE, V572, P397, DOI 10.1038/s41586-019-1437-3; Gentles AJ, 2015, NAT MED, V21, P938, DOI 10.1038/nm.3909; Giguere V, 2008, ENDOCR REV, V29, P677, DOI 10.1210/er.2008-0017; Heimes AS, 2017, J CANCER RES CLIN, V143, P1123, DOI 10.1007/s00432-017-2377-7; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hermann A, 2004, J BIOL CHEM, V279, P48350, DOI 10.1074/jbc.M403427200; Huss L, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1169-1; Issa Jean-Pierre, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS24, DOI 10.1038/ncponc0355; Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303; Jeon H, 2016, ONCOTARGET, V7, P67223, DOI 10.18632/oncotarget.11615; Komninou D, 2006, NUTR CANCER, V54, P202, DOI 10.1207/s15327914nc5402_6; Labuschagne CF, 2014, CELL REP, V7, P1248, DOI 10.1016/j.celrep.2014.04.045; Lambert SA, 2018, CELL, V175, P598, DOI 10.1016/j.cell.2018.09.045; Lee BC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4592; Li Y, 2019, EPIGENET CHROMATIN, V12, DOI 10.1186/s13072-019-0316-3; Lindqvist BM, 2014, EPIGENETICS-US, V9, P1149, DOI 10.4161/epi.29632; Lu SC, 2013, BBA-GEN SUBJECTS, V1830, P3143, DOI 10.1016/j.bbagen.2012.09.008; Luo CY, 2018, SCIENCE, V361, P1336, DOI 10.1126/science.aat6806; Maddocks ODK, 2016, MOL CELL, V61, P210, DOI 10.1016/j.molcel.2015.12.014; Martin EM, 2018, ANNU REV PUBL HEALTH, V39, P309, DOI 10.1146/annurev-publhealth-040617-014629; McGuirk S, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-22; Mehrmohamadi M, 2014, CELL REP, V9, P1507, DOI 10.1016/j.celrep.2014.10.026; Meissner A, 2005, NUCLEIC ACIDS RES, V33, P5868, DOI 10.1093/nar/gki901; Momparler RL, 1997, ANTI-CANCER DRUG, V8, P358, DOI 10.1097/00001813-199704000-00008; Phan NLC, 2016, ONCOTARGETS THER, V9, DOI 10.2147/OTT.S96291; Nilsson E, 2014, DIABETES, V63, P2962, DOI 10.2337/db13-1459; Oh S, 2012, BBA-REV CANCER, V1826, P1, DOI 10.1016/j.bbcan.2012.02.002; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Park S, 2019, CELL REP, V27, P3587, DOI 10.1016/j.celrep.2019.05.066; Patch RJ, 2011, J MED CHEM, V54, P788, DOI 10.1021/jm101063h; Putiri EL, 2011, CLIN EPIGENETICS, V2, P299, DOI 10.1007/s13148-010-0017-z; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; Sanchez-Mut JV, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2015.214; Sanderson SM, 2019, NAT REV CANCER, V19, P625, DOI 10.1038/s41568-019-0187-8; Schade B, 2009, J BIOL CHEM, V284, P19018, DOI 10.1074/jbc.M109.018937; Shaffer AL, 2009, CLIN CANCER RES, V15, P2954, DOI 10.1158/1078-0432.CCR-08-1845; Shlomi T, 2014, ANAL CHEM, V86, P1583, DOI 10.1021/ac4032093; Smith ZD, 2013, NAT REV GENET, V14, P204, DOI 10.1038/nrg3354; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Vernier M, 2020, GENE DEV, V34, P544, DOI 10.1101/gad.330746.119; Yu J, 2018, J CLIN INVEST, V128, P2376, DOI 10.1172/JCI97924; Zdzisinska B, 2017, ARCH IMMUNOL THER EX, V65, P21, DOI 10.1007/s00005-016-0406-x	62	12	12	4	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2020	39	41					6406	6420		10.1038/s41388-020-01438-1	http://dx.doi.org/10.1038/s41388-020-01438-1		AUG 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OA1JL	32855526	hybrid, Green Published			2022-12-28	WOS:000565020000002
J	Maeda, T; Kitamura, S; Nishihara, H; Yanagi, T				Maeda, Takuya; Kitamura, Shinya; Nishihara, Hiroshi; Yanagi, Teruki			Extramammary Paget's disease patient-derived xenografts harboring ERBB2 S310F mutation show sensitivity to HER2-targeted therapies	ONCOGENE			English	Article							COMBINATION CHEMOTHERAPY; ANTITUMOR-ACTIVITY; BREAST-CANCER; DOCETAXEL; EFFICACY; ERIBULIN; OUTCOMES; PROTEIN; GROWTH; TUMOR	Although the prognosis of advanced extramammary Paget's disease (EMPD) is poor, there have been no preclinical research models for the development of novel therapeutics. This study aims to establish a preclinical research model for EMPD. We transplanted EMPD tissue into immunodeficient NOD/Scid mice. Histopathological and genetic analyses using a comprehensive cancer panel were performed. For in vivo preclinical treatments, trastuzumab, lapatinib, docetaxel, or eribulin were administered to patient-derived xenograft (PDX) models. Tissue transplanted from the EMPD patient was enlarged in NOD/Scid mice and was transplanted into further generations. Both the transplantation of PDX intonu/numice and the reanimation of the cryopreserved xenografted tumors in NOD/Scid mice were successful. We also established an EMPD-PDX-derived primary cell culture. Histopathologically, the xenografted tumors were positive for CK7, which was consistent with the patient's tumors. Genetically, the pathogenic mutationERBB2S310F was detected in the patient's tumors (primary intraepidermal lesion, metastatic lymph node) and was observed in the xenografted tumors even after continued passages. The xenografted tumors responded well to trastuzumab and lapatinib therapy. Also, cytotoxic agents (docetaxel and eribulin) were effective against the xenografted tumors. This PDX model (EMPD-PDX-H1) could be a powerful tool for the research and development of EMPD treatments.	[Maeda, Takuya; Kitamura, Shinya; Yanagi, Teruki] Hokkaido Univ, Fac Med, Dept Dermatol, Sapporo, Hokkaido, Japan; [Maeda, Takuya; Kitamura, Shinya; Yanagi, Teruki] Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan; [Nishihara, Hiroshi] Keio Univ, Sch Med, Keio Canc Ctr, Genom Unit, Tokyo, Japan	Hokkaido University; Hokkaido University; Keio University	Yanagi, T (corresponding author), Hokkaido Univ, Fac Med, Dept Dermatol, Sapporo, Hokkaido, Japan.; Yanagi, T (corresponding author), Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan.	yanagi@med.hokudai.ac.jp	Yanagi, Teruki/D-4222-2017	Yanagi, Teruki/0000-0003-2196-7600	KAKENHI from the Ministry of Education, Culture, Sports, Science and Technology in Japan [18K08259]	KAKENHI from the Ministry of Education, Culture, Sports, Science and Technology in Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Ms. Yuko Tateda for her technical assistance. This work was supported in part by KAKENHI grant #18K08259 to TY from the Ministry of Education, Culture, Sports, Science and Technology in Japan.	Bertotti A, 2011, CANCER DISCOV, V1, P508, DOI 10.1158/2159-8290.CD-11-0109; Greulich H, 2012, P NATL ACAD SCI USA, V109, P14476, DOI 10.1073/pnas.1203201109; Hatta N, 2008, BRIT J DERMATOL, V158, P313, DOI 10.1111/j.1365-2133.2007.08314.x; Hendrikx JJMA, 2016, INT J CANCER, V138, P758, DOI 10.1002/ijc.29812; Herrel LA, 2015, ANN SURG ONCOL, V22, P1625, DOI 10.1245/s10434-014-4139-y; Hidalgo M, 2014, CANCER DISCOV, V4, P998, DOI 10.1158/2159-8290.CD-14-0001; Hirai I, 2019, ONCOLOGIST, V24, pE394, DOI 10.1634/theoncologist.2018-0856; Hirakawa S, 2009, AM J PATHOL, V175, P2235, DOI 10.2353/ajpath.2009.090420; Hyman DM, 2018, NATURE, V554, P189, DOI 10.1038/nature25475; Ivanics T, 2018, LAB INVEST, V98, P947, DOI 10.1038/s41374-018-0042-7; Kanitakis J, 2007, J EUR ACAD DERMATOL, V21, P1450, DOI 10.1111/j.1468-3083.2007.02438.x; Karam A, 2012, GYNECOL ONCOL, V125, P346, DOI 10.1016/j.ygyno.2012.01.032; Karam A, 2008, GYNECOL ONCOL, V111, P568, DOI 10.1016/j.ygyno.2007.12.014; Kato M, 2019, BRIT J DERMATOL, V181, P831, DOI 10.1111/bjd.17922; Kavuri SM, 2015, CANCER DISCOV, V5, P832, DOI 10.1158/2159-8290.CD-14-1211; Kiniwa Y, 2019, J DERMATOL SCI, V94, P229, DOI 10.1016/j.jdermsci.2019.03.006; Koga Y, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050418; Ma CX, 2017, CLIN CANCER RES, V23, P5687, DOI 10.1158/1078-0432.CCR-17-0900; NISHI M, 1992, J NATL CANCER I, V84, P519, DOI 10.1093/jnci/84.7.519; Nonagase Y, 2016, ONCOTARGET, V7, P84860, DOI 10.18632/oncotarget.12743; Oashi K, 2014, BRIT J DERMATOL, V170, P1354, DOI 10.1111/bjd.12788; Ohara K, 2016, J DERMATOL SCI, V83, P234, DOI 10.1016/j.jdermsci.2016.06.004; Paget J., 1874, ST BARTHOLOMEWS HOSP, V10, P87; Richter CE, 2010, J CLIN PATHOL, V63, P544, DOI 10.1136/jcp.2010.077446; Takahagi S, 2009, J DERMATOL, V36, P457, DOI 10.1111/j.1346-8138.2009.00676.x; Takeichi T, 2020, CANCERS, V12, DOI 10.3390/cancers12040820; Tanaka R, 2013, BRIT J DERMATOL, V168, P1259, DOI 10.1111/bjd.12249; Tanaka R, 2016, CLIN EXP METASTAS, V33, P687, DOI 10.1007/s10585-016-9804-z; Tate JG, 2019, NUCLEIC ACIDS RES, V47, pD941, DOI 10.1093/nar/gky1015; Tokuda Y, 2015, INT J CLIN ONCOL, V20, P194, DOI 10.1007/s10147-014-0686-2; Towle MJ, 2012, ANTICANCER RES, V32, P1611; Twelves C, 2014, BREAST CANCER RES TR, V148, P553, DOI 10.1007/s10549-014-3144-y; Vornicova O, 2014, ONCOLOGIST, V19, P1006, DOI 10.1634/theoncologist.2014-0054; Wainberg ZA, 2010, CLIN CANCER RES, V16, P1509, DOI 10.1158/1078-0432.CCR-09-1112; Wolff AC, 2018, J CLIN ONCOL, V36, P2105, DOI 10.1200/JCO.2018.77.8738; Yanagi T, 2018, CANCER RES, V78, P6795, DOI 10.1158/0008-5472.CAN-18-1495; Yanagi T, 2014, CANCER RES, V74, P5795, DOI 10.1158/0008-5472.CAN-14-0872; Yoshino K, 2016, J DERMATOL, V43, P633, DOI 10.1111/1346-8138.13200; Zhang GH, 2019, J INVEST DERMATOL, V139, P789, DOI 10.1016/j.jid.2018.08.030	39	9	9	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2020	39	36					5867	5875		10.1038/s41388-020-01404-x	http://dx.doi.org/10.1038/s41388-020-01404-x		JUL 2020	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NJ1HO	32724160	Green Submitted			2022-12-28	WOS:000553333400002
J	Lee, N; Spears, ME; Carlisle, AE; Kim, D				Lee, Namgyu; Spears, Meghan E.; Carlisle, Anne E.; Kim, Dohoon			Endogenous toxic metabolites and implications in cancer therapy	ONCOGENE			English	Review							MITOCHONDRIAL RESPIRATORY-CHAIN; S-ADENOSYLHOMOCYSTEINE; HEREDITARY TYROSINEMIA; MOLECULAR-MECHANISMS; SALVAGE PATHWAY; QUINOLINIC ACID; DNA-SYNTHESIS; T-CELLS; DEHYDROEPIANDROSTERONE; GANGLIOSIDE	It is well recognized that many metabolic enzymes play essential roles in cancer cells in producing building blocks such as nucleotides, which are required in greater amounts due to their increased proliferation. On the other hand, the significance of enzymes in preventing the accumulation of their substrates is less recognized. Here, we outline the evidence and underlying mechanisms for how many metabolites normally produced in cells are highly toxic, such as metabolites containing reactive groups (e.g., methylglyoxal, 4-hydroxynonenal, and glutaconyl-CoA), or metabolites that act as competitive analogs against other metabolites (e.g., deoxyuridine triphosphate and l-2-hydroxyglutarate). Thus, if a metabolic pathway contains a toxic intermediate, then we may be able to induce accumulation and poison a cancer cell by targeting the downstream enzyme. Furthermore, this poisoning may be cancer cell selective if this pathway is overactive in a cancer cell relative to a nontransformed cell. We describe this concept as illustrated in selenocysteine metabolism and other pathways and discuss future directions in exploiting toxic metabolites to kill cancer cells.	[Lee, Namgyu; Spears, Meghan E.; Carlisle, Anne E.; Kim, Dohoon] Univ Massachusetts, Sch Med, Dept Mol Cell & Canc Biol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Kim, D (corresponding author), Univ Massachusetts, Sch Med, Dept Mol Cell & Canc Biol, Worcester, MA 01605 USA.	Dohoon.Kim@umassmed.edu		Lee, Namgyu/0000-0002-2980-2758; Spears, Meghan/0000-0001-6427-0614	Suh Kyungbae Foundation (SUHF) Young Investigator Award	Suh Kyungbae Foundation (SUHF) Young Investigator Award	We sincerely apologize for not being able to add numerous important studies in our review due to space limitations. We thank Christopher Cervantes and David Sabatini for helpful discussions. All authors are supported by the Suh Kyungbae Foundation (SUHF) Young Investigator Award.	Anso E, 2017, NAT CELL BIOL, V19, P614, DOI 10.1038/ncb3529; Banerjee BD, 1997, HUM EXP TOXICOL, V16, P276, DOI 10.1177/096032719701600508; Baumann T, 2020, NAT IMMUNOL, V21, P555, DOI 10.1038/s41590-020-0666-9; Blackburn PR, 2017, APPL CLIN GENET, V10, P57, DOI 10.2147/TACG.S125962; Blau N, 2010, LANCET, V376, P1417, DOI 10.1016/S0140-6736(10)60961-0; Bleich S, 2004, PROG NEURO-PSYCHOPH, V28, P453, DOI 10.1016/j.pnpbp.2003.11.019; Braidy N, 2009, NEUROTOX RES, V16, P77, DOI 10.1007/s12640-009-9051-z; Breiden B, 2018, METHODS MOL BIOL, V1804, P97, DOI 10.1007/978-1-4939-8552-4_5; Brown AJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08866-y; BROWN GK, 1982, PEDIATRICS, V70, P532; BRUNTON VG, 1990, BIOCHEM PHARMACOL, V40, P1893, DOI 10.1016/0006-2952(90)90371-Q; Burgos-Barragan G, 2017, NATURE, V548, P549, DOI 10.1038/nature23481; Cantor JR, 2017, CELL, V169, P258, DOI 10.1016/j.cell.2017.03.023; Carlisle AE, 2020, NAT METAB, V2, P603, DOI 10.1038/s42255-020-0224-7; Cesaratto L, 2007, J MOL MED, V85, P1099, DOI 10.1007/s00109-007-0204-3; Cheng ML, 2011, BIOCHEM PHARMACOL, V82, P1549, DOI 10.1016/j.bcp.2011.07.104; Choi HJ, 2006, GLYCOBIOLOGY, V16, P573, DOI 10.1093/glycob/cwj105; Choudhury S, 2015, MED HYPOTHESES, V85, P64, DOI 10.1016/j.mehy.2015.03.027; Commisso C, 2013, NATURE, V497, P633, DOI 10.1038/nature12138; Copley SD, 2017, CURR OPIN STRUC BIOL, V47, P167, DOI 10.1016/j.sbi.2017.11.001; Csaky Z, 2020, YEAST, V37, P45, DOI 10.1002/yea.3454; Currie E, 2013, CELL METAB, V18, P153, DOI 10.1016/j.cmet.2013.05.017; CURTIN NJ, 1991, CANCER RES, V51, P2346; Dean Erin, 2016, Nurs Stand, V30, P15, DOI 10.7748/ns.30.44.15.s17; DeBerardinis RJ, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600200; Del Rio D, 2005, NUTR METAB CARDIOVAS, V15, P316, DOI 10.1016/j.numecd.2005.05.003; DEWEY DL, 1979, CANCER LETT, V6, P247, DOI 10.1016/S0304-3835(79)80041-5; DYKENS JA, 1987, BIOCHEM PHARMACOL, V36, P211, DOI 10.1016/0006-2952(87)90691-5; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; FARBER S, 1948, NEW ENGL J MED, V238, P787, DOI 10.1056/NEJM194806032382301; Fauman EB, 2011, CURR OPIN CHEM BIOL, V15, P463, DOI 10.1016/j.cbpa.2011.05.020; Flavin R, 2010, FUTURE ONCOL, V6, P551, DOI [10.2217/fon.10.11, 10.2217/FON.10.11]; Fujisawa T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034437; Fujiwara R, 2018, HEPATOLOGY, V67, P1609, DOI 10.1002/hep.29599; Galmarini CM, 2002, LANCET ONCOL, V3, P415, DOI 10.1016/S1470-2045(02)00788-X; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; Gil-ad I, 2001, ISRAEL MED ASSOC J, V3, P639; Guillemin GJ, 2012, FEBS J, V279, P1356, DOI 10.1111/j.1742-4658.2012.08485.x; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hiramatsu R, 2008, J CELL BIOCHEM, V103, P42, DOI 10.1002/jcb.21384; HUBER M, 1995, CANCER RES, V55, P934; Hunt RJ, 2019, J CELL BIOL, V218, P4007, DOI 10.1083/jcb.201904148; Hyman SE, 2005, CURR BIOL, V15, pR154, DOI 10.1016/j.cub.2005.02.037; INGRAHAM HA, 1982, MOL PHARMACOL, V21, P211; Intlekofer AM, 2015, CELL METAB, V22, P304, DOI 10.1016/j.cmet.2015.06.023; IWATA K, 1984, TOXICOL LETT, V22, P75, DOI 10.1016/0378-4274(84)90048-1; Jeffryes J, 2019, METHODS MOL BIOL, V1927, P11, DOI 10.1007/978-1-4939-9142-6_2; Jeitner TM, 1996, CANCER LETT, V103, P85, DOI 10.1016/0304-3835(96)04200-0; Jeitner TM, 2001, TOXICOL SCI, V63, P57, DOI 10.1093/toxsci/63.1.57; Jiang SH, 2020, ONCOGENE, V39, P503, DOI 10.1038/s41388-019-1006-0; Jorquera R, 2001, HUM MOL GENET, V10, P1741, DOI 10.1093/hmg/10.17.1741; KALAPOS MP, 1994, TOXICOL LETT, V73, P3, DOI 10.1016/0378-4274(94)90184-8; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kang Y, 2006, GLYCOBIOLOGY, V16, P375, DOI 10.1093/glycob/cwj087; Kennedy BP, 2004, J NEURAL TRANSM, V111, P547, DOI 10.1007/s00702-003-0096-5; Kennedy EM, 2011, J BIOL CHEM, V286, P25047, DOI 10.1074/jbc.M111.234047; Kim D, 2015, NATURE, V520, P363, DOI 10.1038/nature14363; Kim S, 2016, NUCLEIC ACIDS RES, V44, pD1202, DOI 10.1093/nar/gkv951; Kitatani K, 2008, CELL SIGNAL, V20, P1010, DOI 10.1016/j.cellsig.2007.12.006; Kolker S, 2004, ANN NEUROL, V55, P7, DOI 10.1002/ana.10784; Kranendijk M, 2012, J INHERIT METAB DIS, V35, P571, DOI 10.1007/s10545-012-9462-5; KREDICH NM, 1977, CELL, V12, P931, DOI 10.1016/0092-8674(77)90157-X; KREDICH NM, 1979, P NATL ACAD SCI USA, V76, P2450, DOI 10.1073/pnas.76.5.2450; Kubo S, 1998, P NATL ACAD SCI USA, V95, P9552, DOI 10.1073/pnas.95.16.9552; Latini A, 2002, BRAIN RES, V956, P367, DOI 10.1016/S0006-8993(02)03573-4; LEE SE, 2013, OXID MED CELL LONGEV, V2013, DOI DOI 10.1155/2013/629028; Lehnert W, 2005, MED HYPOTHESES, V65, P330, DOI 10.1016/j.mehy.2005.02.021; Li L, 2017, J BIOL CHEM, V292, P4755, DOI 10.1074/jbc.M116.764787; Locasale JW, 2011, NAT GENET, V43, P869, DOI 10.1038/ng.890; LoPachin RM, 2014, CHEM RES TOXICOL, V27, P1081, DOI 10.1021/tx5001046; Lopez-Marure R, 2011, EUR J PHARMACOL, V660, P268, DOI 10.1016/j.ejphar.2011.03.040; Luengo A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13419-4; Luengo A, 2017, CELL CHEM BIOL, V24, P1161, DOI 10.1016/j.chembiol.2017.08.028; Mahoney CE, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07959-4; Malina HZ, 1999, BIOCHEM BIOPH RES CO, V265, P600, DOI 10.1006/bbrc.1999.1716; Malina HZ, 2001, BMC PHYSL, V1, P34606; Malisan F, 2002, BBA-MOL CELL BIOL L, V1585, P179, DOI 10.1016/S1388-1981(02)00339-6; Mayeur C, 2005, BBA-MOL CELL RES, V1745, P111, DOI 10.1016/j.bbamcr.2004.12.004; Mexas LM, 2011, NEUROTOXICOLOGY, V32, P471, DOI 10.1016/j.neuro.2011.03.013; Moghe A, 2015, TOXICOL SCI, V143, P242, DOI 10.1093/toxsci/kfu233; NaveenKumar SK, 2015, SCI REP-UK, V5, DOI 10.1038/srep15045; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Pegg AE, 2013, CHEM RES TOXICOL, V26, P1782, DOI 10.1021/tx400316s; Perla-Kajan J, 2007, AMINO ACIDS, V32, P561, DOI 10.1007/s00726-006-0432-9; Peyroche G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036343; Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350; QUASH G, 1995, BIOCHEM J, V305, P1017, DOI 10.1042/bj3051017; Rao MS, 1997, CELL PROLIFERAT, V30, P1; Rawat V, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/1801243; Regier DS, 2016, PEDIATR ENDOCR REV P, V13, P663; Richon VM, 2011, CHEM BIOL DRUG DES, V78, P199, DOI 10.1111/j.1747-0285.2011.01135.x; Robinson AD, 2020, CANCER LETT, V470, P134, DOI 10.1016/j.canlet.2019.11.013; RUSSO P, 1990, AM J HUM GENET, V47, P317; Ryu HM, 2016, J CELL MOL MED, V20, P2160, DOI 10.1111/jcmm.12916; Rzem R, 2004, P NATL ACAD SCI USA, V101, P16849, DOI 10.1073/pnas.0404840101; Rzem R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119540; Safiulina D, 2006, TOXICOL SCI, V93, P348, DOI 10.1093/toxsci/kfl064; Sarkar C, 2008, CLIN CANCER RES, V14, P2502, DOI 10.1158/1078-0432.CCR-07-1778; Sarniak A, 2016, POSTEP HIG MED DOSW, V70, P1150, DOI 10.5604/17322693.1224259; Schalkwijk CG, 2020, PHYSIOL REV, V100, P407, DOI 10.1152/physrev.00001.2019; SCHECTER A, 1980, CHEST, V77, P554, DOI 10.1378/chest.77.4.554; Shoeb M, 2014, CURR MED CHEM, V21, P230; Sies H, 2017, ANNU REV BIOCHEM, V86, P715, DOI 10.1146/annurev-biochem-061516-045037; Sorice M, 2012, ANTI-CANCER AGENT ME, V12, P376, DOI 10.2174/187152012800228670; Stewart BJ, 2007, CHEM RES TOXICOL, V20, P1111, DOI 10.1021/tx700106v; Swinnen JV, 2006, CURR OPIN CLIN NUTR, V9, P358, DOI 10.1097/01.mco.0000232894.28674.30; Tang BQ, 2006, BIOCHEM PHARMACOL, V72, P806, DOI 10.1016/j.bcp.2006.06.018; Taniguchi K, 1996, HEPATOLOGY, V24, P1395, DOI 10.1002/hep.510240614; Tulpule K, 2013, J NEUROCHEM, V127, P7, DOI 10.1111/jnc.12356; Ueda N, 2015, INT J MOL SCI, V16, P5076, DOI 10.3390/ijms16035076; Valachovic M, 2016, BIOCHEM BIOPH RES CO, V469, P1123, DOI 10.1016/j.bbrc.2015.12.050; Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Weinberg SE, 2019, NATURE, V565, P495, DOI 10.1038/s41586-018-0846-z; Wexler P, 2001, TOXICOLOGY, V157, P3, DOI 10.1016/S0300-483X(00)00337-1; Wolf C, 2007, MOL PHARMACOL, V71, P276, DOI 10.1124/mol.106.028449; Xu D, 2016, MOL BIOSYST, V12, P3067, DOI 10.1039/c6mb00231e; Yang LF, 2017, ANNU REV BIOMED ENG, V19, P163, DOI 10.1146/annurev-bioeng-071516-044546; Ye D, 2018, TRENDS CANCER, V4, P151, DOI 10.1016/j.trecan.2017.12.005; Yoshinaga A, 2016, EUR J PHARMACOL, V782, P21, DOI 10.1016/j.ejphar.2016.04.035; Zhang DS, 2014, CANCER LETT, V355, P176, DOI 10.1016/j.canlet.2014.09.003; Zhao Hui-Ying, 2018, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V26, P1022, DOI 10.7534/j.issn.1009-2137.2018.04.013	122	7	9	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2020	39	35					5709	5720		10.1038/s41388-020-01395-9	http://dx.doi.org/10.1038/s41388-020-01395-9		JUL 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NF2QB	32709924	hybrid, Green Published			2022-12-28	WOS:000552155200002
J	Boissinot, M; King, H; Adams, M; Higgins, J; Shaw, G; Ward, TA; Steele, LP; Tams, D; Morton, R; Polson, E; da Silva, B; Droop, A; Hayes, JL; Martin, H; Laslo, P; Morrison, E; Tomlinson, DC; Wurdak, H; Bond, J; Lawler, SE; Short, SC				Boissinot, M.; King, H.; Adams, M.; Higgins, J.; Shaw, G.; Ward, T. A.; Steele, L. P.; Tams, D.; Morton, R.; Polson, E.; da Silva, B.; Droop, A.; Hayes, J. L.; Martin, H.; Laslo, P.; Morrison, E.; Tomlinson, D. C.; Wurdak, H.; Bond, J.; Lawler, S. E.; Short, S. C.			Profiling cytotoxic microRNAs in pediatric and adult glioblastoma cells by high-content screening, identification, and validation of miR-1300	ONCOGENE			English	Article							CLEAVAGE FURROW FORMATION; EXCHANGE FACTORS; ECT2; TARGETS; POLYPLOIDIZATION; PATHWAYS; MIRBASE; MEDIATE; TRIO	MicroRNAs play an important role in the regulation of mRNA translation and have therapeutic potential in cancer and other diseases. To profile the landscape of microRNAs with significant cytotoxicity in the context of glioblastoma (GBM), we performed a high-throughput screen in adult and pediatric GBM cells using a synthetic oligonucleotide library representing all known human microRNAs. Bioinformatics analysis was used to refine this list and the top seven microRNAs were validated in a larger panel of GBM cells using state-of-the-art in vitro assays. The cytotoxic effect of our most relevant candidate was assessed in a preclinical model. Our screen identified similar to 100 significantly cytotoxic microRNAs with 70% concordance between cell lines. MicroRNA-1300 (miR-1300) was the most potent and robust candidate. We observed a striking binucleated phenotype in miR-1300 transfected cells due to cytokinesis failure followed by apoptosis. This was also observed in two stem-like patient-derived cultures. We identified the physiological role of miR-1300 as a regulator of endomitosis in megakaryocyte differentiation where blockade of cytokinesis is an essential step. In GBM cells, where miR-1300 is normally not expressed, the oncogene Epithelial Cell Transforming 2 (ECT2) was validated as a direct key target. ECT2 siRNA phenocopied the effects of miR-1300, and ECT2 overexpression led to rescue of miR-1300 induced binucleation. We showed that ectopic expression of miR-1300 led to decreased tumor growth in an orthotopic GBM model. Our screen provides a resource for the neuro-oncology community and identified miR-1300 as a novel regulator of endomitosis with translatable potential for therapeutic application.	[Boissinot, M.; Higgins, J.; Shaw, G.; Ward, T. A.; Steele, L. P.; Tams, D.; Hayes, J. L.; Lawler, S. E.; Short, S. C.] Univ Leeds, St Jamess Hosp, Leeds Inst Med Res, Radiat Biol & Therapy Grp, Leeds LS9 7TF, W Yorkshire, England; [King, H.; Adams, M.; Tomlinson, D. C.; Bond, J.] Univ Leeds, St Jamess Hosp, BioScreening Technol Grp, Leeds LS9 7TF, W Yorkshire, England; [Tams, D.] Babraham, Roslin Cell Sci, Cambridge CB22 3AT, England; [Morton, R.; Polson, E.; da Silva, B.; Wurdak, H.] Univ Leeds, St Jamess Hosp, Leeds Inst Med Res, Stem Cells & Brain Tumour Res Grp, Leeds LS9 7TF, W Yorkshire, England; [Droop, A.] Univ Leeds, MRC Med Bioinformat Ctr, Clarendon Way, Leeds LS2 9NL, W Yorkshire, England; [Hayes, J. L.] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA; [Martin, H.; Tomlinson, D. C.] Univ Leeds, Fac Biol Sci, Sch Mol & Cellular Biol, Leeds LS2 9JT, W Yorkshire, England; [Laslo, P.] Univ Leeds, St Jamess Hosp, Leeds Inst Med Res, Myeloid Differentiat Grp, Leeds LS9 7TF, W Yorkshire, England; [Morrison, E.] Univ Leeds, St Jamess Hosp, Leeds Inst Med Res, Cell Biol Res Grp, Leeds LS9 7TF, W Yorkshire, England; [Bond, J.] Univ Leeds, St Jamess Hosp, Leeds Inst Med Res, Microcephaly & Neurogenesis Res Grp, Leeds LS9 7TF, W Yorkshire, England; [Lawler, S. E.] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Harvey Cushing Neurooncol Labs, Boston, MA 02115 USA; [Short, S. C.] Univ Leeds, St Jamess Hosp, St Jamess Inst Oncol, Leeds LS9 7TF, W Yorkshire, England; [Short, S. C.] Univ Leeds, St Jamess Hosp, Leeds Inst Med Res, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital; University of Leeds; Saint James's University Hospital; University of Leeds; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Saint James's University Hospital; University of Leeds; University of Leeds; University of California System; University of California Berkeley; University of Leeds; Saint James's University Hospital; University of Leeds; Saint James's University Hospital; University of Leeds; Saint James's University Hospital; University of Leeds; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Saint James's University Hospital; University of Leeds; Saint James's University Hospital; University of Leeds	Lawler, SE; Short, SC (corresponding author), Univ Leeds, St Jamess Hosp, Leeds Inst Med Res, Radiat Biol & Therapy Grp, Leeds LS9 7TF, W Yorkshire, England.; Lawler, SE (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Harvey Cushing Neurooncol Labs, Boston, MA 02115 USA.; Short, SC (corresponding author), Univ Leeds, St Jamess Hosp, St Jamess Inst Oncol, Leeds LS9 7TF, W Yorkshire, England.; Short, SC (corresponding author), Univ Leeds, St Jamess Hosp, Leeds Inst Med Res, Leeds LS9 7TF, W Yorkshire, England.	SLAWLER@bwh.harvard.edu; S.C.Short@leeds.ac.uk		Ward, Thomas/0000-0003-0937-4554; Boissinot, Marjorie/0000-0002-5241-2520; Wurdak, Heiko/0000-0003-4385-4324; Martin, Heather/0000-0002-5455-4434; Short, Susan/0000-0003-4423-7256	UK-based charities Yorkshire Cancer Research [L369]; Brain Tumor Charity [13/192]; Brain Tumor Research and Support Yorkshire; Candle-lighters; MRC [MR/J001171/1] Funding Source: UKRI	UK-based charities Yorkshire Cancer Research; Brain Tumor Charity; Brain Tumor Research and Support Yorkshire; Candle-lighters; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This project was supported by the UK-based charities Yorkshire Cancer Research (award L369 SEL, DCT), The Brain Tumor Charity (Program reference number 13/192 SCS), Candle-lighters and Brain Tumor Research and Support Yorkshire (SEL).	Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005; Ahir BK, 2017, CRIT REV ONCOL HEMAT, V120, P22, DOI 10.1016/j.critrevonc.2017.10.003; Alexander BM, 2017, J CLIN ONCOL, V35, P2402, DOI 10.1200/JCO.2017.73.0119; Banelli B, 2017, INT J GENOMICS, V2017, DOI 10.1155/2017/7639084; Bastos RN, 2012, J CELL BIOL, V198, P865, DOI 10.1083/jcb.201204107; Bhaskaran V, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08390-z; Brower JV, 2014, NEUROCHEM INT, V77, P68, DOI 10.1016/j.neuint.2014.06.002; Carbon S, 2009, BIOINFORMATICS, V25, P288, DOI 10.1093/bioinformatics/btn615; Castoreno AB, 2010, NAT CHEM BIOL, V6, P457, DOI 10.1038/nchembio.363; Chalamalasetty RB, 2006, J CELL SCI, V119, P3008, DOI 10.1242/jcs.03032; Chen LY, 2015, ONCOTARGET, V6, P38628, DOI 10.18632/oncotarget.5926; Eulalio A, 2015, J BIOMOL SCREEN, V20, P1003, DOI 10.1177/1087057115578837; Fields AP, 2010, ADV ENZYME REGUL, V50, P190, DOI 10.1016/j.advenzreg.2009.10.010; Fortin SP, 2012, MOL CANCER RES, V10, P958, DOI 10.1158/1541-7786.MCR-11-0616; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Gao Y, 2012, DEV CELL, V22, P573, DOI 10.1016/j.devcel.2011.12.019; Garcia DM, 2011, NAT STRUCT MOL BIOL, V18, P1139, DOI 10.1038/nsmb.2115; Godlewski J, 2010, CELL DEATH DIFFER, V17, P221, DOI 10.1038/cdd.2009.71; Griffiths-Jones S, 2004, NUCLEIC ACIDS RES, V32, pD109, DOI 10.1093/nar/gkh023; Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Hayes J, 2014, TRENDS MOL MED, V20, P460, DOI 10.1016/j.molmed.2014.06.005; Katsushima K, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00014; King HO, 2017, STEM CELL REP, V8, P125, DOI 10.1016/j.stemcr.2016.12.005; Kozomara A, 2014, NUCLEIC ACIDS RES, V42, pD68, DOI 10.1093/nar/gkt1181; Kozomara A, 2011, NUCLEIC ACIDS RES, V39, pD152, DOI 10.1093/nar/gkq1027; Krichevsky AM, 2019, NEUROTHERAPEUTICS, V16, P319, DOI 10.1007/s13311-018-00702-3; Lannutti BJ, 2005, BLOOD, V105, P3875, DOI 10.1182/blood-2004-10-3934; LeBlanc VC, 2015, J CLIN MED, V4, P1612, DOI 10.3390/jcm4081612; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li ZH, 2014, NAT REV DRUG DISCOV, V13, P622, DOI 10.1038/nrd4359; Mercatelli N, 2017, INT REV CEL MOL BIO, V333, P269, DOI 10.1016/bs.ircmb.2017.03.002; Moskwa P, 2014, MOL CANCER RES, V12, P1767, DOI 10.1158/1541-7786.MCR-14-0268; Nagalla S, 2011, BLOOD, V117, P5189, DOI 10.1182/blood-2010-09-299719; Nam JW, 2014, MOL CELL, V53, P1031, DOI 10.1016/j.molcel.2014.02.013; Normand G, 2010, ADV EXP MED BIOL, V676, P27; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Polson ES, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aar2718; Salhia B, 2008, AM J PATHOL, V173, P1828, DOI 10.2353/ajpath.2008.080043; Sana J, 2011, J CELL MOL MED, V15, P1636, DOI 10.1111/j.1582-4934.2011.01317.x; Sano M, 2006, ONCOL REP, V16, P1093; Shin C, 2010, MOL CELL, V38, P789, DOI 10.1016/j.molcel.2010.06.005; Su KC, 2011, DEV CELL, V21, P1104, DOI 10.1016/j.devcel.2011.11.003; Suva ML, 2014, CELL, V157, P580, DOI 10.1016/j.cell.2014.02.030; Wen Q, 2012, CELL, V150, P575, DOI 10.1016/j.cell.2012.06.032; Westphal M, 2015, NAT REV NEUROL, V11, P556, DOI 10.1038/nrneurol.2015.171; Wurdak H, 2010, CELL STEM CELL, V6, P37, DOI 10.1016/j.stem.2009.11.002	48	2	2	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 23	2020	39	30					5292	5306		10.1038/s41388-020-1360-y	http://dx.doi.org/10.1038/s41388-020-1360-y		JUN 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MO5BV	32555332	Green Published, hybrid			2022-12-28	WOS:000545371000004
J	Feng, JB; Zhang, Y; Ren, X; Li, D; Fu, HJ; Liu, CH; Zhou, W; Liu, Q; Liu, Q; Wu, MH				Feng, Jianbo; Zhang, Yan; Ren, Xing; Li, Di; Fu, Haijuan; Liu, Changhong; Zhou, Wen; Liu, Qing; Liu, Qiang; Wu, Minghua			Leucine-rich repeat containing 4 act as an autophagy inhibitor that restores sensitivity of glioblastoma to temozolomide	ONCOGENE			English	Article							COLORECTAL-CANCER; GLIOMA-CELLS; BETA-TRCP; RESISTANCE; MTOR; CHEMORESISTANCE; PROLIFERATION; EXPRESSION; APOPTOSIS; CYTOKINE	Temozolomide (TMZ) insensitivity and resistance are major causes of treatment failure and poor prognosis for GBM patients. Here, we identify LRRC4 as a novel autophagy inhibitor that restores the sensitivity of GBMs to TMZ. LRRC4 was associated with the DEPTOR/mTOR complex, and this interaction resulted in autophagy inhibition. Further investigation demonstrated that the PDZ binding domain of LRRC4 binds to the PDZ domain of DEPTOR. This binding decreases the half-life of DEPTOR via ubiquitination, thus inhibiting GBM cell autophagy and increasing the TMZ treatment response of GBM. Combined LRRC4 expression and TMZ treatment prolonged the survival of mice with tumour xenografts. Furthermore, the levels of LRRC4, DEPTOR and autophagy are clinically relevant for GBM, indicating that LRRC4 is likely to have significant potential as a therapeutic marker and target for TMZ treatment in glioma patients.	[Feng, Jianbo; Zhang, Yan; Ren, Xing; Li, Di; Fu, Haijuan; Liu, Changhong; Wu, Minghua] Cent South Univ, Hunan Prov Tumor Hosp, Changsha 410006, Hunan, Peoples R China; [Feng, Jianbo; Zhang, Yan; Ren, Xing; Li, Di; Fu, Haijuan; Liu, Changhong; Wu, Minghua] Cent South Univ, Xiangya Med Sch, Affiliated Tumor Hosp, Changsha 410006, Hunan, Peoples R China; [Feng, Jianbo; Zhang, Yan; Ren, Xing; Li, Di; Fu, Haijuan; Liu, Changhong; Zhou, Wen; Wu, Minghua] Cent South Univ, Canc Res Inst, Sch Basic Med Sci, Changsha 410078, Hunan, Peoples R China; [Feng, Jianbo; Zhang, Yan; Ren, Xing; Li, Di; Fu, Haijuan; Liu, Changhong; Zhou, Wen; Wu, Minghua] Minist Educ, Key Lab Carcinogenesis & Canc Invas, Changsha 410078, Hunan, Peoples R China; [Feng, Jianbo; Zhang, Yan; Ren, Xing; Li, Di; Fu, Haijuan; Liu, Changhong; Zhou, Wen; Wu, Minghua] Minist Hlth, Key Lab Carcinogenesis, Changsha 410078, Hunan, Peoples R China; [Liu, Changhong] Shandong Univ, Hosp 2, Inst Med Sci, Jinan 250033, Shandong, Peoples R China; [Liu, Qing] Cent South Univ, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China; [Liu, Qiang] Cent South Univ, Xiangya Hosp 3, Changsha 410013, Hunan, Peoples R China	Central South University; Central South University; Central South University; Shandong University; Central South University; Central South University	Wu, MH (corresponding author), Cent South Univ, Hunan Prov Tumor Hosp, Changsha 410006, Hunan, Peoples R China.; Wu, MH (corresponding author), Cent South Univ, Xiangya Med Sch, Affiliated Tumor Hosp, Changsha 410006, Hunan, Peoples R China.; Wu, MH (corresponding author), Cent South Univ, Canc Res Inst, Sch Basic Med Sci, Changsha 410078, Hunan, Peoples R China.; Wu, MH (corresponding author), Minist Educ, Key Lab Carcinogenesis & Canc Invas, Changsha 410078, Hunan, Peoples R China.; Wu, MH (corresponding author), Minist Hlth, Key Lab Carcinogenesis, Changsha 410078, Hunan, Peoples R China.	wuminghua554@aliyun.com			National Natural Science Foundation of China [81874150]; Graduate Student Research Innovation Project in Hunan Province [2019zzts084]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Graduate Student Research Innovation Project in Hunan Province	This works was supported by the National Natural Science Foundation of China (Grant No. 81874150) and Graduate Student Research Innovation Project in Hunan Province (2019zzts084).	Catena V, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-016-0484-y; Chin SF, 2007, ONCOGENE, V26, P1959, DOI 10.1038/sj.onc.1209985; Cosin-Roger J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00213-3; Duan SS, 2011, MOL CELL, V44, P317, DOI 10.1016/j.molcel.2011.09.005; Dunlop EA, 2014, SEMIN CELL DEV BIOL, V36, P121, DOI 10.1016/j.semcdb.2014.08.006; Dunn GP, 2012, GENE DEV, V26, P756, DOI 10.1101/gad.187922.112; Efeyan A, 2010, CURR OPIN CELL BIOL, V22, P169, DOI 10.1016/j.ceb.2009.10.007; Ghavami S, 2014, PROG NEUROBIOL, V112, P24, DOI 10.1016/j.pneurobio.2013.10.004; Guo JY, 2013, CELL, V155, P1216, DOI 10.1016/j.cell.2013.11.019; Hale AN, 2013, AUTOPHAGY, V9, P951, DOI 10.4161/auto.24273; Hombach-Klonisch S, 2018, PHARMACOL THERAPEUT, V184, P13, DOI 10.1016/j.pharmthera.2017.10.017; Hori YS, 2015, J NEURO-ONCOL, V122, P11, DOI 10.1007/s11060-014-1686-9; Huang J, 2011, ANTIOXID REDOX SIGN, V14, P2215, DOI 10.1089/ars.2010.3554; Jiang PD, 2014, CELL RES, V24, P69, DOI 10.1038/cr.2013.161; Johansen T, 2011, AUTOPHAGY, V7, P279, DOI 10.4161/auto.7.3.14487; Kim S, 2006, NAT NEUROSCI, V9, P1294, DOI 10.1038/nn1763; Li PY, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01748; Li PY, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-266; Masui K, 2012, NEUROPATH APPL NEURO, V38, P271, DOI 10.1111/j.1365-2990.2011.01238.x; Menzies FM, 2017, NEURON, V93, P1015, DOI 10.1016/j.neuron.2017.01.022; Minghua W, 2010, J CELL BIOCHEM, V103, P245; Mokarram P, 2017, AUTOPHAGY, V13, P781, DOI 10.1080/15548627.2017.1290751; Murat A, 2008, J CLIN ONCOL, V26, P3015, DOI 10.1200/JCO.2007.15.7164; Nanegrungsunk D, 2015, NEUROL RES, V37, P167, DOI 10.1179/1743132814Y.0000000423; Nixon RA, 2013, NAT MED, V19, P983, DOI 10.1038/nm.3232; Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06; Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P1, DOI 10.1093/neuonc/nou223; Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046; Soto F, 2018, ELIFE, V7, DOI 10.7554/eLife.30388; Um SM, 2018, CELL REP, V23, P3839, DOI 10.1016/j.celrep.2018.05.087; Wang JR, 2002, PROG BIOCHEM BIOPHYS, V29, P233; Wang QD, 2018, CANCER RES, V78, P3163, DOI 10.1158/0008-5472.CAN-17-3107; Wang ZY, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0355-1; Wang ZW, 2012, NEOPLASIA, V14, P368, DOI 10.1593/neo.12542; White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262; Wick W, 2014, CANCER DISCOV, V4, P1120, DOI 10.1158/2159-8290.CD-14-0918; Woo J, 2009, NAT NEUROSCI, V12, P428, DOI 10.1038/nn.2279; Wu MH, 2008, J CELL PHYSIOL, V214, P65, DOI 10.1002/jcp.21163; Wu MH, 2006, MOL BIOL CELL, V17, P3534, DOI 10.1091/mbc.E05-11-1082; Xu G, 2015, J NEUROSCI, V35, P7153, DOI 10.1523/JNEUROSCI.4726-14.2015; Yan YL, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0303-5; Yang ZNJ, 2011, CANCER BIOL THER, V11, P169, DOI 10.4161/cbt.11.2.14663; Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008; Yu TF, 2018, CANCER LETT, V433, P210, DOI 10.1016/j.canlet.2018.06.041; Zanotto-Filho A, 2015, CANCER LETT, V358, P220, DOI 10.1016/j.canlet.2014.12.044; Zhang W, 2008, GENES BRAIN BEHAV, V7, P385, DOI 10.1111/j.1601-183X.2007.00361.x; Zhao YC, 2011, MOL CELL, V44, P304, DOI 10.1016/j.molcel.2011.08.029; Zhou WC, 2017, CELL STEM CELL, V21, P591, DOI 10.1016/j.stem.2017.10.002	48	5	5	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	23					4551	4566		10.1038/s41388-020-1312-6	http://dx.doi.org/10.1038/s41388-020-1312-6		MAY 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LU5ZF	32372061	Green Published, hybrid			2022-12-28	WOS:000530617200002
J	Simon, T; Jackson, E; Giamas, G				Simon, Thomas; Jackson, Ellen; Giamas, Georgios			Breaking through the glioblastoma micro-environment via extracellular vesicles	ONCOGENE			English	Review							GLIOMA-CELLS; ENDOTHELIAL-CELLS; TUMOR-GROWTH; EXOSOMES; BRAIN; RNA; ANGIOGENESIS; SURVIVAL; DELIVERY; PROMOTE	Glioblastoma (GBM) is the most common and most aggressive brain tumour. Prognosis remains poor, despite the combined treatment of radio- and chemotherapy following surgical removal. GBM cells coexist with normal non-neoplastic cells, including endothelial cells, astrocytes and immune cells, constituting a complex and dynamic tumour micro-environment (TME). Extracellular vesicles (EVs) provide a critical means of bidirectional inter-cellular communication in the TME. Through delivery of a diverse range of genomic, lipidomic and proteomic cargo to neighbouring and distant cells, EVs can alter the phenotype and function of the recipient cell. As such, EVs have demonstrated their role in promoting angiogenesis, immune suppression, invasion, migration, drug resistance and GBM recurrence. Moreover, EVs can reflect the phenotype of the cells within the TME. Thus, in conjunction with their accessibility in biofluids, they can potentially serve as a biomarker reservoir for patient prognosis, diagnosis and predictive therapeutic response as well as treatment follow-up. Furthermore, together with the ability of EVs to cross the blood-brain barrier undeterred and through the exploitation of their cargo, EVs may provide an effective mean of drug delivery to the target site. Unveiling the mechanisms by which EVs within the GBM TME are secreted and target recipient cells may offer an indispensable understanding of GBM that holds the potential to provide a better prognosis and overall quality of life for GBM patients.	[Simon, Thomas; Jackson, Ellen; Giamas, Georgios] Univ Sussex, Sch Life Sci, Dept Biochem & Biomed, Brighton BN1 9QG, E Sussex, England	University of Sussex	Simon, T; Giamas, G (corresponding author), Univ Sussex, Sch Life Sci, Dept Biochem & Biomed, Brighton BN1 9QG, E Sussex, England.	t.simon@sussex.ac.uk; g.giamas@sussex.ac.uk	Giamas, Georgios/AAP-3487-2021	Simon, Thomas/0000-0002-3280-2716	Action Against Cancer; Rothschild Foundation; Searle Memorial Charitable Trust; Colin McDavid Family Trust; Bernard Sunley Foundation	Action Against Cancer; Rothschild Foundation; Searle Memorial Charitable Trust; Colin McDavid Family Trust; Bernard Sunley Foundation	This work was supported by Action Against Cancer, The Colin McDavid Family Trust, The Rothschild Foundation, The Bernard Sunley Foundation, The Searle Memorial Charitable Trust, Mr. Alessandro Dusi, and Mr. Milan Markovic.	Abels ER, 2019, CELL REP, V28, P3105, DOI 10.1016/j.celrep.2019.08.036; Andre-Gregoire G, 2017, CELL ADHES MIGR, V11, P164, DOI 10.1080/19336918.2016.1247145; [Anonymous], [No title captured]; Azam Zulfikar, 2019, Acta Oncol, V58, P353, DOI 10.1080/0284186X.2018.1551621; Balachandran B., 2019, COGENT MED, V6, DOI [10.1080/2331205X.2019.1635806, DOI 10.1080/2331205X.2019.1635806]; Banelli B, 2017, INT J GENOMICS, V2017, DOI 10.1155/2017/7639084; Baulch JE, 2016, ENVIRON MOL MUTAGEN, V57, P405, DOI 10.1002/em.21988; Behnan J, 2019, BRAIN, V142, P847, DOI 10.1093/brain/awz044; Benito-Jardon M, 2017, ELIFE, V6, DOI 10.7554/eLife.22264; Berenguer J, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1446660; Brandao M, 2019, GLIA, V67, P779, DOI 10.1002/glia.23520; Bronisz A, 2014, CANCER RES, V74, P738, DOI 10.1158/0008-5472.CAN-13-2650; Brown NF, 2018, BRIT J CANCER, V119, P1171, DOI 10.1038/s41416-018-0258-8; Chandran VI, 2019, J NEURO-ONCOL, V144, P477, DOI 10.1007/s11060-019-03262-4; Chen JWE, 2018, FRONT MATER, V5, DOI 10.3389/fmats.2018.00039; Chetty C, 2012, CELL SIGNAL, V24, P549, DOI 10.1016/j.cellsig.2011.10.008; Cuperlovic-Culf M, ANAL SIMULATION GLIO, pE88, DOI [10.3390/metabo10030088, DOI 10.3390/METAB010030088]; Davis CN, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007191; Davis ME, 2016, CLIN J ONCOL NURS, V20, P2, DOI 10.1188/16.CJON.S1.2-8; De Vleeschouwer S, 2017, GLIOBLASTOMA, P315, DOI 10.15586/codon.glioblastoma.2017.ch16; Domenis R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169932; Erkan EP, 2017, CANCER GENE THER, V24, P38, DOI 10.1038/cgt.2016.78; Fidoamore A, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/6809105; Gabrusiewicz K, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1412909; Gao XF, 2020, CELL REP, V30, P2489, DOI 10.1016/j.celrep.2020.01.089; Garofalo M, 2019, THERANOSTICS, V9, P5681, DOI 10.7150/thno.34824; Greene C, 2019, FLUIDS BARRIERS CNS, V16, DOI 10.1186/s12987-019-0123-z; Grimaldi A, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00041; Guo XF, 2019, INT J CANCER, V144, P3111, DOI 10.1002/ijc.32052; Guo YW, 2019, FRONT MOL NEUROSCI, V12, DOI 10.3389/fnmol.2019.00125; Gupta K, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00503; Hallal S, 2019, MOL NEUROBIOL, V56, P4566, DOI 10.1007/s12035-018-1385-1; Harder BG, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00462; Heffernan JM, 2018, FRONT MATER, V5, DOI 10.3389/fmats.2018.00007; Hellwinkel JE, 2015, IMMUNE MODULATION TU, P329; Jena L, 2019, TRANSL RES, V10, P304; Jovanovic N, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55020034; Kesanakurti D, 2013, ONCOGENE, V32, P327, DOI 10.1038/onc.2012.52; Kim Y, 2014, MOL CANCER RES, V12, P1416, DOI 10.1158/1541-7786.MCR-13-0629; Kucharzewska P, 2013, P NATL ACAD SCI USA, V110, P7312, DOI 10.1073/pnas.1220998110; Lam D, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40128-1; Lane R, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0560-x; Lang HL, 2017, EUR REV MED PHARMACO, V21, P959; Lang HL, 2017, ONCOL REP, V38, P785, DOI 10.3892/or.2017.5742; Lim EJ, 2017, ONCOTARGET, V8, P1438, DOI 10.18632/oncotarget.13638; Loo HK, 2019, BIOMARK MED, V13, P161, DOI 10.2217/bmm-2018-0463; Lucero R, 2020, CELL REP, V30, P2065, DOI 10.1016/j.celrep.2020.01.073; Ma X, 2017, AM J TRANSL RES, V9, P5012; Mallawaaratchy DM, 2017, J NEURO-ONCOL, V131, P233, DOI 10.1007/s11060-016-2298-3; Margolis L, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000363; Misra S, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00201; Mondal A, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00144; Monteiro AR, 2017, CELLS-BASEL, V6, DOI 10.3390/cells6040045; Morad G, 2019, ACS NANO, V13, P13853, DOI 10.1021/acsnano.9b04397; Munoz JL, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00134; Munoz JL, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.60; Nareshkumar RN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28745-8; Neftel C, 2019, CELL, V178, P835, DOI 10.1016/j.cell.2019.06.024; Ning XF, 2018, MED SCI MONITOR, V24, P2350, DOI 10.12659/MSM.906641; Osti D, 2019, CLIN CANCER RES, V25, P266, DOI 10.1158/1078-0432.CCR-18-1941; Oushy S, 2018, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0477; Parker NR, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00055; Parodi A, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11050245; Qian MY, 2020, ONCOGENE, V39, P428, DOI 10.1038/s41388-019-0996-y; Rackov G, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00651; Ramachandran RK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172234; Rempe RG, 2016, J CEREBR BLOOD F MET, V36, P1481, DOI 10.1177/0271678X16655551; Ricklefs F, 2016, CANCER RES, V76, P2876, DOI 10.1158/0008-5472.CAN-15-3432; Ricklefs FL, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aar2766; Saint-Pol JAO, TARGETING CROSSING B, pE851, DOI [10.3390/cells9040851, DOI 10.3390/CELLS9040851]; Schiffer D, 2019, CANCERS, V11, DOI 10.3390/cancers11010005; Serlin Y, 2015, SEMIN CELL DEV BIOL, V38, P2, DOI 10.1016/j.semcdb.2015.01.002; Shao HL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7999; Sharma A, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00146; Si WG, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-018-0587-8; Simon T, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0878-x; Simon T, 2017, TRENDS MOL MED, V23, P282, DOI 10.1016/j.molmed.2017.01.002; Simon T, 2014, NEUROMOL MED, V16, P752, DOI 10.1007/s12017-014-8324-8; Simon Thomas, 2020, INT J MOL SCI, V21, P3071; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; Spinelli C, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1490144; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Sullivan R, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00194; Sun X, 2017, ONCOTARGET, V8, P36137, DOI 10.18632/oncotarget.16661; Svensson KJ, 2011, P NATL ACAD SCI USA, V108, P13147, DOI 10.1073/pnas.1104261108; Thery C, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1535750; Todorova D, 2017, CIRC RES, V120, P1658, DOI 10.1161/CIRCRESAHA.117.309681; Treps L, 2016, ONCOGENE, V35, P2615, DOI 10.1038/onc.2015.317; Treps L, 2017, J EXTRACELL VESICLES, V6, DOI 10.1080/20013078.2017.1359479; van der Vlis TAMB, 2018, ACTA NEUROPATHOL COM, V6, DOI 10.1186/s40478-018-0591-4; van der Vos KE, 2016, NEURO-ONCOLOGY, V18, P58, DOI 10.1093/neuonc/nov244; Venkatesh HS, 2017, NATURE, V549, P533, DOI 10.1038/nature24014; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Walker S, 2019, THERANOSTICS, V9, P8001, DOI 10.7150/thno.37097; Wang FF, 2018, EBIOMEDICINE, V37, P68, DOI 10.1016/j.ebiom.2018.10.024; Wang ZF, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1181-4; Watkins S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5196; Wendler F, 2017, ONCOGENE, V36, P877, DOI 10.1038/onc.2016.253; Xue Q, 2017, ONCOL LETT, V13, P1325, DOI 10.3892/ol.2017.5567; Yi Y, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00477; Yin JX, 2019, EBIOMEDICINE, V42, P238, DOI 10.1016/j.ebiom.2019.03.016; Yu TF, 2018, CANCER LETT, V433, P210, DOI 10.1016/j.canlet.2018.06.041; Zeng AL, 2018, CANCER LETT, V436, P10, DOI 10.1016/j.canlet.2018.08.004; Zhang L, 2015, NATURE, V527, P100, DOI 10.1038/nature15376; Zhao C, 2018, BIOCHEM BIOPH RES CO, V502, P324, DOI 10.1016/j.bbrc.2018.05.140; Zhao X, 2017, ACTA PHARM SIN B, V7, P541, DOI [10.1016/j.apsh.2017.07.002, 10.1016/j.apsb.2017.07.002]	106	47	47	4	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	23					4477	4490		10.1038/s41388-020-1308-2	http://dx.doi.org/10.1038/s41388-020-1308-2		MAY 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LU5ZF	32366909	Green Accepted, Green Published, hybrid			2022-12-28	WOS:000530271400003
J	Wang, Y; Ma, RN; Liu, B; Kong, JY; Lin, HY; Yu, X; Wang, RY; Li, L; Gao, M; Zhou, BS; Mohan, M; Yu, H; Hou, ZY; Shen, HB; Qian, BY				Wang, Yu; Ma, Rongna; Liu, Ben; Kong, Jinyu; Lin, Hongyan; Yu, Xiao; Wang, Ruoyang; Li, Lei; Gao, Ming; Zhou, Baosen; Mohan, Man; Yu, Herbert; Hou, Zhaoyuan; Shen, Hongbin; Qian, Biyun			SNP rs17079281 decreases lung cancer risk through creating an YY1-binding site to suppress DCBLD1 expression	ONCOGENE			English	Article							GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY LOCI; GENETIC SUSCEPTIBILITY; IDENTIFICATION; TUMORS	Genome-wide association studies (GWAS) have identified numerous genetic variants that are associated with lung cancer risk, but the biological mechanisms underlying these associations remain largely unknown. Here we investigated the functional relevance of a genetic region in 6q22.2 which was identified to be associated with lung cancer risk in our previous GWAS. We performed linkage disequilibrium (LD) analysis and bioinformatic prediction to screen functional SNPs linked to a tagSNP in 6q22.2 loci, followed by two case-control studies and a meta-analysis with 4403 cases and 5336 controls to identify if these functional SNPs were associated with lung cancer risk. A novel SNP rs17079281 in the DCBLD1 promoter was identified to be associated with lung cancer risk in Chinese populations. Compared with those with C allele, patients with T allele had lower risk of adenocarcinoma (adjusted OR = 0.86; 95% CI: 0.80-0.92), but not squamous cell carcinoma (adjusted OR = 0.99; 95% CI: 0.91-1.10), and patients with the C/T or T/T genotype had lower levels of DCBLD1 expression than those with C/C genotype in lung adenocarcinoma tissues. We performed functional assays to characterize its biological relevance. The results showed that the T allele of rs17079281 had higher binding affinity to transcription factor YY1 than the C allele, which suppressed DCBLD1 expression. DCBLD1 behaved like an oncogene, promoting tumor growth by influencing cell cycle progression. These findings suggest that the functional variant rs17079281C>T decreased lung adenocarcinoma risk by creating an YY1-binding site to suppress DCBLD1 expression, which may serve as a biomarker for assessing lung cancer susceptibility.	[Wang, Yu; Ma, Rongna; Lin, Hongyan; Yu, Xiao; Wang, Ruoyang; Li, Lei; Qian, Biyun] Shanghai Jiao Tong Univ, Sch Med, Shanghai Tongren Hosp, Hongqiao Int Inst Med, Shanghai 200025, Peoples R China; [Wang, Yu; Ma, Rongna; Lin, Hongyan; Yu, Xiao; Wang, Ruoyang; Li, Lei; Qian, Biyun] Shanghai Jiao Tong Univ, Sch Med, Fac Publ Hlth, Shanghai 200025, Peoples R China; [Liu, Ben; Kong, Jinyu; Gao, Ming] Tianjin Med Univ, Dept Canc Epidemiol & Biostat, Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjin 300060, Peoples R China; [Zhou, Baosen] China Med Univ, Sch Publ Hlth, Dept Epidemiol, Shenyang 110001, Liaoning, Peoples R China; [Mohan, Man] Shanghai Jiao Tong Univ, Shanghai Key Lab Tumor Microenvironm & Inflammat, Sch Med, Dept Biochem & Mol Cell Biol, Shanghai 200025, Peoples R China; [Yu, Herbert] Univ Hawaii, Canc Epidemiol Program, Canc Ctr, Honolulu, HI 96813 USA; [Hou, Zhaoyuan] Shanghai Jiao Tong Univ, Fac Basic Med, Sch Med, Hongqiao Inst Med,Shanghai Tongren Hosp, Shanghai 200025, Peoples R China; [Shen, Hongbin] Nanjing Med Univ, Canc Ctr, Sect Clin Epidemiol, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing 211166, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Tianjin Medical University; China Medical University; Shanghai Jiao Tong University; Cancer Research Center of Hawaii; University of Hawaii System; Shanghai Jiao Tong University; Nanjing Medical University	Qian, BY (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Tongren Hosp, Hongqiao Int Inst Med, Shanghai 200025, Peoples R China.; Qian, BY (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Fac Publ Hlth, Shanghai 200025, Peoples R China.	qianbiyun@sjtu.edu.cn	Liu, Ben/AAZ-4649-2021	Liu, Ben/0000-0001-8452-5397; Mohan, Man/0000-0002-8811-8542	National Natural Science Foundation of China [81573231]; Natural Science Foundation of Shanghai [15ZR1424400]; National Human Genetic Resources Sharing Service Platform [2005DKA21300]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shanghai(Natural Science Foundation of Shanghai); National Human Genetic Resources Sharing Service Platform	This work was supported by the National Natural Science Foundation of China (Grant no. 81573231), Natural Science Foundation of Shanghai (Grant no.15ZR1424400), National Human Genetic Resources Sharing Service Platform(2005DKA21300). We thank Cancer Biobank of Tianjin Medical University Cancer Institute and Hospital for providing the biological samples. We thank Cancer Biobank of Tianjin Medical University Cancer Institute and Hospital for providing the biological samples.	Boyle AP, 2012, GENOME RES, V22, P1790, DOI 10.1101/gr.137323.112; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Donnelly P, 2008, NATURE, V456, P728, DOI 10.1038/nature07631; Fu JY, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002431; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; Han JY, 2014, PHARMACOGENOMICS J, V14, P20, DOI 10.1038/tpj.2013.7; Hirschhorn JN, 2005, NAT REV GENET, V6, P95, DOI 10.1038/nrg1521; Hong QY, 2015, CANCER-AM CANCER SOC, V121, P3080, DOI 10.1002/cncr.29584; Hu ZB, 2011, NAT GENET, V43, P792, DOI 10.1038/ng.875; Koshikawa K, 2002, ONCOGENE, V21, P2822, DOI 10.1038/sj.onc.1205405; Lan Q, 2012, NAT GENET, V44, P1330, DOI 10.1038/ng.2456; Liu B, 2015, ONCOTARGET, V6, P9445, DOI 10.18632/oncotarget.3255; Liu SG, 2015, GENET MOL RES, V14, P4469, DOI 10.4238/2015.May.4.4; Maurano MT, 2012, SCIENCE, V337, P1190, DOI 10.1126/science.1222794; McCarthy MI, 2008, NAT REV GENET, V9, P356, DOI 10.1038/nrg2344; McKay JD, 2017, NAT GENET, V49, P1126, DOI 10.1038/ng.3892; Pashos EE, 2017, CELL STEM CELL, V20, P558, DOI 10.1016/j.stem.2017.03.017; Peters U, 2013, GASTROENTEROLOGY, V144, P799, DOI 10.1053/j.gastro.2012.12.020; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Rimkunas VM, 2012, CLIN CANCER RES, V18, P4449, DOI 10.1158/1078-0432.CCR-11-3351; Ryan BM, 2015, CANCER RES, V75, P566, DOI 10.1158/0008-5472.CAN-14-2101; Wang K, 2010, AM J HUM GENET, V86, P730, DOI 10.1016/j.ajhg.2010.04.003; Xie D, 2013, CELL, V155, P713, DOI 10.1016/j.cell.2013.09.043; YANT SR, 1995, NUCLEIC ACIDS RES, V23, P4353, DOI 10.1093/nar/23.21.4353; Zhang XL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041930	25	17	18	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	20					4092	4102		10.1038/s41388-020-1278-4	http://dx.doi.org/10.1038/s41388-020-1278-4		MAR 2020	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LN3GC	32231272	Green Published, hybrid			2022-12-28	WOS:000522380700001
J	Yin, HJ; Jiang, ZY; Feng, X; Ji, ZD; Jin, W				Yin, Huijing; Jiang, Zhengyu; Feng, Xu; Ji, Zhaodong; Jin, Wei			Identification of Sca-1(+)Abcg1(+) bronchioalveolar epithelial cells as the origin of lung adenocarcinoma in Gprc5a-knockout mouse model through the interaction between lung progenitor AT2 and Lgr5 cells	ONCOGENE			English	Article							TUMOR-SUPPRESSOR GPRC5A; STEM-CELLS; EXTRACELLULAR-MATRIX; CHOLESTEROL EFFLUX; CANCER; GENE; ACTIVATION; EXPRESSION; POPULATION; PROMOTES	The reason for the reduced efficacy of lung cancer therapy is the existence of lung cancer stem cells (CSCs). Targeting CSCs results in evolved phenotypes with increased malignancy, leading to therapy failure. Here, we propose a new therapeutic strategy: investigating the "transitional" cells that represent the stage between normal lung stem cells and lung CSCs. Identifying and targeting the key molecule that drives carcinogenesis to inhibit or reverse this process would thus provide new perspectives for early diagnosis and intervention in lung cancer. We used Gprc5a-knockout (KO) mice, the first animal model of spontaneous lung adenocarcinoma established by the deletion of a single lung tumor suppressor gene. We investigated the interaction of lung progenitor cells AT2 with Lgr5 cells in the generation of CSCs and related signaling mechanism. In the present study, using Gprc5a-KO mice, we found the initiator Sca-1(+)Abcg1(+) subset with a CSC-like phenotype within the lung progenitor AT2 cell population in mice that had not yet developed tumors. We confirmed the self-renewal and tumor initiation capacities of this subset in vitro, in vivo, and clinical samples. Mechanistically, we found that the generation of Sca-1(+)Abcg1(+) cells was associated with an interaction between AT2 and Lgr5 cells and the subsequent activation of the ECM1-alpha 6 beta 4-ABCG1 axis. Importantly, Sca-1(+)Abcg1(+) and SPA(+)ABCG1(+) cells specifically existed in the small bronchioles of Gprc5a-KO mice and patients with pneumonia, respectively. Thus, the present study unveiled a new kind of lung cancer-initiating cells (LCICs) and provided potential markers for the early diagnosis of lung cancer.	[Yin, Huijing; Feng, Xu; Ji, Zhaodong] Fudan Univ, Inst Canc, Shanghai Canc Ctr, Shanghai 200032, Peoples R China; [Yin, Huijing; Feng, Xu; Ji, Zhaodong] Fudan Univ, Shanghai Med Sch, Dept Oncol, Shanghai 200032, Peoples R China; [Jiang, Zhengyu] Second Mil Med Univ, PLA, Dept Anesthesiol, Naval Med Ctr,Naval Med Univ, Shanghai 200052, Peoples R China; [Jiang, Zhengyu] Second Mil Med Univ, Changhai Hosp, Fac Anesthesiol, Naval Med Univ,PLA, Shanghai 200433, Peoples R China; [Jin, Wei] Shanghai Jiao Tong Univ, Dept Immunol & Microbiol, Sch Med,Chinese Minist Educ, Shanghai Inst Immunol,Key Lab Cell Differentiat &, Shanghai 200025, Peoples R China	Fudan University; Fudan University; Naval Medical University; Naval Medical University; Chinese Academy of Sciences; Shanghai Jiao Tong University	Yin, HJ (corresponding author), Fudan Univ, Inst Canc, Shanghai Canc Ctr, Shanghai 200032, Peoples R China.; Yin, HJ (corresponding author), Fudan Univ, Shanghai Med Sch, Dept Oncol, Shanghai 200032, Peoples R China.	yinhuijing@fudan.edu.cn			National Natural Science Foundation of China [81601985]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by grants from the National Natural Science Foundation of China (No. 81601985 for HY). We appreciate all the members in our lab and co-authors' contribution in encouraging discussion and suggestions.	Adorno-Cruz V, 2015, CANCER RES, V75, P924, DOI 10.1158/0008-5472.CAN-14-3225; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Cabezas-Wallscheid N, 2017, CELL, V169, P807, DOI 10.1016/j.cell.2017.04.018; Chapman HA, 2011, J CLIN INVEST, V121, P2855, DOI 10.1172/JCI57673; Cheng YJ, 1998, J BIOL CHEM, V273, P35008, DOI 10.1074/jbc.273.52.35008; Clevers H, 2014, SCIENCE, V346, P54, DOI 10.1126/science.1248012; COSTANTINI RM, 1990, CANCER RES, V50, P6107; Deng JO, 2010, CANCER PREV RES, V3, P424, DOI 10.1158/1940-6207.CAPR-10-0032; El Roz A, 2012, ANTICANCER RES, V32, P3007; Eramo A, 2010, ONCOGENE, V29, P4625, DOI 10.1038/onc.2010.207; Fujimoto J, 2012, J THORAC ONCOL, V7, P1747, DOI 10.1097/JTO.0b013e31826bb1ff; Grepmeier U, 2005, INT J ONCOL, V27, P481; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hantgan RR, 2003, J BIOL CHEM, V278, P3417, DOI 10.1074/jbc.M208869200; Hoye AM, 2016, AM J PHYSIOL-CELL PH, V310, pC955, DOI 10.1152/ajpcell.00326.2015; Hu L, 2010, BRIT J CANCER, V102, P1276, DOI 10.1038/sj.bjc.6605626; Huch M, 2013, NATURE, V494, P247, DOI 10.1038/nature11826; Hynes RO, 2009, SCIENCE, V326, P1216, DOI 10.1126/science.1176009; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jaks V, 2008, NAT GENET, V40, P1291, DOI 10.1038/ng.239; Kennedy MA, 2005, CELL METAB, V1, P121, DOI 10.1016/j.cmet.2005.01.002; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Kobayashi Y, 2011, GYNECOL ONCOL, V121, P390, DOI 10.1016/j.ygyno.2010.12.366; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Lee JH, 2017, CELL, V170, P1149, DOI 10.1016/j.cell.2017.07.028; Lee KM, 2015, ONCOGENE, V34, P6055, DOI 10.1038/onc.2015.54; Lee KM, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0479-6; Lee KM, 2015, CELL SIGNAL, V27, P228, DOI 10.1016/j.cellsig.2014.11.004; Leeman KT, 2014, CURR TOP DEV BIOL, V107, P207, DOI 10.1016/B978-0-12-416022-4.00008-1; Lin CW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053817; Lipscomb EA, 2005, CANCER METAST REV, V24, P413, DOI 10.1007/s10555-005-5133-4; Love Michael I, 2018, F1000Res, V7, P952, DOI 10.12688/f1000research.15398.1; Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147; Matsuura F, 2006, J CLIN INVEST, V116, P1435, DOI 10.1172/JCI27602; Morrison BJ, 2013, TARGET ONCOL, V8, P159, DOI 10.1007/s11523-012-0247-4; Roberts A, 2013, NAT METHODS, V10, P71, DOI [10.1038/NMETH.2251, 10.1038/nmeth.2251]; Roberts A, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-3-r22; Song JH, 2007, CANCER RES, V67, P6946, DOI 10.1158/0008-5472.CAN-06-3896; Sturek JM, 2010, J CLIN INVEST, V120, P2575, DOI 10.1172/JCI41280; Szotek PP, 2006, P NATL ACAD SCI USA, V103, P11154, DOI 10.1073/pnas.0603672103; Takeuchi S, 1996, CANCER RES, V56, P738; Tammela T, 2017, NATURE, V545, P355, DOI 10.1038/nature22334; Tao QG, 2007, JNCI-J NATL CANCER I, V99, P1668, DOI 10.1093/jnci/djm208; Wang X, 2007, J CLIN INVEST, V117, P2216, DOI 10.1172/JCI32057; Yang Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002220; Ye XF, 2009, CANCER BIOL THER, V8, P951, DOI 10.4161/cbt.8.10.8244; Ye Xiaofeng, 2008, Briefings in Functional Genomics & Proteomics, V7, P322, DOI 10.1093/bfgp/eln021; Zhong SS, 2015, CANCER RES, V75, P1801, DOI 10.1158/0008-5472.CAN-14-2005	52	3	3	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	18					3754	3773		10.1038/s41388-020-1251-2	http://dx.doi.org/10.1038/s41388-020-1251-2		MAR 2020	20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LI5XR	32157214	Green Published, hybrid			2022-12-28	WOS:000518886000006
J	He, ZS; Thorrez, L; Siegfried, G; Meulemans, S; Evrard, S; Tejpar, S; Khatib, AM; Creemers, JWM				He, Zongsheng; Thorrez, Lieven; Siegfried, Geraldine; Meulemans, Sandra; Evrard, Serge; Tejpar, Sabine; Khatib, Abdel-Majid; Creemers, John W. M.			The proprotein convertase furin is a pro-oncogenic driver in KRAS and BRAF driven colorectal cancer	ONCOGENE			English	Article							HUMAN COLON; TUMOR PROGRESSION; GROWTH; EXPRESSION; CELLS; PROLIFERATION; ACTIVATION; RESISTANCE; INHIBITORS; MUTATIONS	Mutations in KRAS and/or BRAF that activate the ERK kinase are frequently found in colorectal cancer (CRC) and drive resistance to targeted therapies. Therefore, the identification of therapeutic targets that affect multiple signaling pathways simultaneously is crucial for improving the treatment of patients with KRAS or BRAF mutations. The proprotein convertase furin activates several oncogenic protein precursors involved in the ERK-MAPK pathway by endoproteolytic cleavage. Here we show that genetic inactivation of furin suppresses tumorigenic growth, proliferation, and migration in KRAS or BRAF mutant CRC cell lines but not in wild-type KRAS and BRAF cells. In a mouse xenograft model, these KRAS or BRAF mutant cells lacking furin displayed reduced growth and angiogenesis, and increased apoptosis. Mechanistically, furin inactivation prevents the processing of various protein pecursors including proIGF1R, proIR, proc-MET, proTGF-beta 1 and NOTCH1 leading to potent and durable ERK-MAPK pathway suppression in KRAS or BRAF mutant cells. Furthermore, we identified genes involved in activating the ERK-MAPK pathway, such as PTGS2, which are downregulated in the KRAS or BRAF mutant cells after furin inactivation but upregulated in wild-type KRAS and BRAF cells. Analysis of human colorectal tumor samples reveals a positive correlation between enhanced furin expression and KRAS or BRAF expression. These results indicate that furin plays an important role in KRAS or BRAF-associated ERK-MAPK pathway activation and tumorigenesis, providing a potential target for personalized treatment.	[He, Zongsheng; Meulemans, Sandra; Creemers, John W. M.] Katholieke Univ Leuven, Dept Human Genet, Lab Biochem Neuroendocrinol, Leuven, Belgium; [Thorrez, Lieven] Katholieke Univ Leuven, Dept Dev & Regenerat, Interdisciplinary Res Facil, Campus Kulak Kortrijk, Kortrijk, Belgium; [Siegfried, Geraldine; Evrard, Serge; Khatib, Abdel-Majid] INSERM, UMR, LAMC, Allee Geoffroy St Hilaire 1029, Pessac, France; [Evrard, Serge] Inst Bergonie, Bordeaux, France; [Tejpar, Sabine] Univ Hosp Leuven, Dept Oncol, Digest Oncol Unit, Leuven, Belgium	KU Leuven; KU Leuven; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Bergonie; KU Leuven; University Hospital Leuven	Creemers, JWM (corresponding author), Katholieke Univ Leuven, Dept Human Genet, Lab Biochem Neuroendocrinol, Leuven, Belgium.	john.creemers@kuleuven.be	Thorrez, Lieven/A-2583-2011; KHATIB, Abdel-Majid/A-9948-2015	Thorrez, Lieven/0000-0002-5896-6823; KHATIB, Abdel-Majid/0000-0001-6957-0384; siegfried, geraldine/0000-0002-6346-5206	SIRIC BRIO, France; La Ligue Contre le Cancer, France; FWO Vlaanderen [G.0738.15]; Chinese Government Scholarship [201409110101]	SIRIC BRIO, France; La Ligue Contre le Cancer, France; FWO Vlaanderen(FWO); Chinese Government Scholarship	We would like to thank Maria Francesca Baietti for providing help with the soft agar assay, and Rudra Kashyap for providing help with the wound healing migration assay. We would also like to thank Alvaro Cortes Calabuig for the RNA-seq data analysis. This work was supported in part by SIRIC BRIO and La Ligue Contre le Cancer to AMK, France. We acknowledge grant support from FWO Vlaanderen (Grant nr. G.0738.15) to JC. ZH was supported by a Chinese Government Scholarship (Nr. 201409110101).	Artenstein AW, 2011, NEW ENGL J MED, V365, P2507, DOI 10.1056/NEJMra1106700; Bardelli A, 2013, CANCER DISCOV, V3, P658, DOI 10.1158/2159-8290.CD-12-0558; Bassi DE, 2001, MOL CARCINOGEN, V31, P224, DOI 10.1002/mc.1057; Batlle E, 2019, IMMUNITY, V50, P924, DOI 10.1016/j.immuni.2019.03.024; Benvenuti S, 2007, CANCER RES, V67, P2643, DOI 10.1158/0008-5472.CAN-06-4158; Blommaert E, 2019, P NATL ACAD SCI USA, V116, P9865, DOI 10.1073/pnas.1817815116; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Buck E, 2010, MOL CANCER THER, V9, P2652, DOI 10.1158/1535-7163.MCT-10-0318; Chisanga D, 2016, NUCLEIC ACIDS RES, V44, pD969, DOI 10.1093/nar/gkv1097; Cordova ZM, 2016, ONCOTARGET, V7, P54392, DOI 10.18632/oncotarget.11106; Couture F, 2015, EXPERT OPIN THER PAT, V25, P379, DOI 10.1517/13543776.2014.1000303; Creemers JWM, 2008, FRONT BIOSCI-LANDMRK, V13, P4960, DOI 10.2741/3055; Dahms SO, 2016, SCI REP-UK, V6, DOI 10.1038/srep34303; De Roock W, 2011, LANCET ONCOL, V12, P594, DOI 10.1016/S1470-2045(10)70209-6; Declercq J, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/148651; Duguay SJ, 1998, J BIOL CHEM, V273, P18443, DOI 10.1074/jbc.273.29.18443; Duguay SJ, 1997, J BIOL CHEM, V272, P6663, DOI 10.1074/jbc.272.10.6663; Erdogan B, 2017, BIOCHEM SOC T, V45, P229, DOI 10.1042/BST20160387; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Ghisoli M, 2016, MOL THER, V24, P1478, DOI 10.1038/mt.2016.86; Ginefra P, 2018, CELL REP, V22, P2176, DOI 10.1016/j.celrep.2018.02.005; Grabocka E, 2016, CELL, V167, P1803, DOI 10.1016/j.cell.2016.11.035; Guo SC, 2011, BBA-REV CANCER, V1815, P197, DOI 10.1016/j.bbcan.2010.12.002; Hardes K, 2015, CHEMMEDCHEM, V10, P1218, DOI 10.1002/cmdc.201500103; Henrich S, 2005, J MOL BIOL, V345, P211, DOI 10.1016/j.jmb.2004.10.050; Holderfield M, 2014, NAT REV CANCER, V14, P455, DOI 10.1038/nrc3760; Huang YY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030638; Jaaks P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161396; Jin M, 2018, PATHOL ONCOL RES, V24, P45, DOI 10.1007/s12253-017-0195-5; Khatib AM, 2001, J BIOL CHEM, V276, P30686, DOI 10.1074/jbc.M101725200; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Kosumi K, 2019, EUR J CANCER, V111, P82, DOI 10.1016/j.ejca.2019.01.022; Krysan K, 2005, CANCER RES, V65, P6275, DOI 10.1158/0008-5472.CAN-05-0216; Liu DX, 2007, J CLIN ENDOCR METAB, V92, P2264, DOI 10.1210/jc.2006-1613; Liu XL, 2011, AM J CLIN PATHOL, V135, P245, DOI 10.1309/AJCP7FO2VAXIVSTP; Low K, 2019, FEBS J, V286, P4597, DOI 10.1111/febs.14979; Lopez de Cicco R, 2002, Acta Odontol Latinoam, V15, P29; Louagie E, 2008, P NATL ACAD SCI USA, V105, P12319, DOI 10.1073/pnas.0800340105; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Oh J, 2016, GYNECOL ONCOL, V143, P504, DOI 10.1016/j.ygyno.2016.09.018; Page RE, 2007, CELL ONCOL, V29, P289; Ramirez C, 2019, NATURE, V576, P477, DOI 10.1038/s41586-019-1831-x; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Roebroek AJM, 2004, J BIOL CHEM, V279, P53442, DOI 10.1074/jbc.M407152200; Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035; Sarac MS, 2002, INFECT IMMUN, V70, P7136, DOI 10.1128/IAI.70.12.7136-7139.2002; Scamuffa N, 2008, J CLIN INVEST, V118, P352, DOI 10.1172/JCI32040; Scamuffa N, 2014, CARCINOGENESIS, V35, P528, DOI 10.1093/carcin/bgt345; Shimura T, 2020, CARCINOGENESIS, V41, P751, DOI 10.1093/carcin/bgz195; Siegfried G, 2005, ONCOGENE, V24, P6925, DOI 10.1038/sj.onc.1208838; Siegfried G, 2003, J CLIN INVEST, V111, P1723, DOI 10.1172/JCI200317220; Siegfried G, 2020, CANCER LETT, V473, P50, DOI 10.1016/j.canlet.2019.12.027; Susan-Resiga D, 2011, J BIOL CHEM, V286, P22785, DOI 10.1074/jbc.M111.233577; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tome M, 2019, CANCER RES, V79, P5008, DOI 10.1158/0008-5472.CAN-19-0086; Tripathi S, 2015, CELL HOST MICROBE, V18, P723, DOI 10.1016/j.chom.2015.11.002; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Ulanet DB, 2010, P NATL ACAD SCI USA, V107, P10791, DOI 10.1073/pnas.0914076107; Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019; Van Schaeybroeck S, 2014, CELL REP, V7, P1940, DOI 10.1016/j.celrep.2014.05.032; Vartanian S, 2013, J BIOL CHEM, V288, P2403, DOI 10.1074/jbc.M112.394130; Wang D, 2010, ONCOGENE, V29, P781, DOI 10.1038/onc.2009.421; Wang DZ, 2010, NAT REV CANCER, V10, P181, DOI 10.1038/nrc2809; Zhang DX, 2015, CELL REP, V10, P1335, DOI 10.1016/j.celrep.2015.02.006; Zhang YL, 2017, INT J ONCOL, V50, P1352, DOI 10.3892/ijo.2017.3896	65	23	23	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	17					3571	3587		10.1038/s41388-020-1238-z	http://dx.doi.org/10.1038/s41388-020-1238-z		MAR 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LH1YK	32139876	Green Published			2022-12-28	WOS:000518240400001
J	Olou, AA; King, RJ; Yu, F; Singh, PK				Olou, Appolinaire A.; King, Ryan J.; Yu, Fang; Singh, Pankaj K.			MUC1 oncoprotein mitigates ER stress via CDA-mediated reprogramming of pyrimidine metabolism	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; CYTIDINE DEAMINASE; OXIDATIVE STRESS; GLUCOSE DEPRIVATION; GEMCITABINE RESISTANCE; TUMOR-CELLS; APOPTOSIS; ACTIVATION; CALCIUM	The Mucin 1 (MUC1) protein is overexpressed in various cancers and mediates chemotherapy resistance. However, the mechanism is not fully understood. Given that most chemotherapeutic drugs disrupt ER homeostasis as part of their toxicity, and MUC1 expression is regulated by proteins involved in ER homeostasis, we investigated the link between MUC1 and ER homeostasis. MUC1 knockdown in pancreatic cancer cells enhanced unfolded protein response (UPR) signaling and cell death upon ER stress induction. Transcriptomic analysis revealed alterations in the pyrimidine metabolic pathway and cytidine deaminase (CDA). ChIP and CDA activity assays showed that MUC1 occupied CDA gene promoter upon ER stress induction correlating with increased CDA expression and activity in MUC1-expressing cells as compared with MUC1 knockdown cells. Inhibition of either the CDA or pyrimidine metabolic pathway diminished survival in MUC1-expressing cancer cells upon ER stress induction. Metabolomic analysis demonstrated that MUC1-mediated CDA activity corresponded to deoxycytidine to deoxyuridine metabolic reprogramming upon ER stress induction. The resulting increase in deoxyuridine mitigated ER stress-induced cytotoxicity. In addition, given (1) the established roles of MUC1 in protecting cells against reactive oxygen species (ROS) insults, (2) ER stress-generated ROS further promote ER stress and (3) the emerging anti-oxidant property of deoxyuridine, we further investigated if MUC1 regulated ER stress by a deoxyuridine-mediated modulation of ROS levels. We observed that deoxyuridine could abrogate ROS-induced ER stress to promote cancer cell survival. Taken together, our findings demonstrate a novel MUC1-CDA axis of the adaptive UPR that provides survival advantage upon ER stress induction.	[Olou, Appolinaire A.; King, Ryan J.; Singh, Pankaj K.] Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; [Yu, Fang; Singh, Pankaj K.] Univ Nebraska Med Ctr, Dept Biostat, Omaha, NE 68198 USA; [Singh, Pankaj K.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Singh, Pankaj K.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; [Singh, Pankaj K.] Univ Nebraska Med Ctr, Dept Genet Cell Biol & Anat, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Singh, PK (corresponding author), Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA.; Singh, PK (corresponding author), Univ Nebraska Med Ctr, Dept Biostat, Omaha, NE 68198 USA.; Singh, PK (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.; Singh, PK (corresponding author), Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA.; Singh, PK (corresponding author), Univ Nebraska Med Ctr, Dept Genet Cell Biol & Anat, Omaha, NE 68198 USA.	pankaj.singh@unmc.edu		Singh, Pankaj/0000-0001-8903-0131	National Institutes of Health (NCI) [R01 CA216853, CA163649, CA210439]; Specialized Programs of Research Excellence (SPORE, NCI) [2P50 CA127297]; NCI [P01 CA2117798]; Fred & Pamela Buffett Cancer Center Support Grant (NCI) [P30CA036727];  [R01CA216853-01]	National Institutes of Health (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Specialized Programs of Research Excellence (SPORE, NCI); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Fred & Pamela Buffett Cancer Center Support Grant (NCI); 	This work was supported in part by funding from the National Institutes of Health (R01 CA216853, CA163649, CA210439, NCI) to PKS, the Specialized Programs of Research Excellence (SPORE, 2P50 CA127297, NCI) to PKS, P01 CA2117798 (NCI) to PKS, and a supplement to NIH grant (R01CA216853-01) to AAO. We would also like to acknowledge the Fred & Pamela Buffett Cancer Center Support Grant (P30CA036727, NCI) for supporting shared resources.	Agata N, 2008, CANCER RES, V68, P6136, DOI 10.1158/0008-5472.CAN-08-0464; Alejandro EU, 2015, CELL REP, V13, P2527, DOI 10.1016/j.celrep.2015.11.020; Behrens ME, 2010, ONCOGENE, V29, P5667, DOI 10.1038/onc.2010.327; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Blackburn RV, 1999, FREE RADICAL BIO MED, V26, P419, DOI 10.1016/S0891-5849(98)00217-2; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Castellvi A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39722-0; Chabosseau P, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1363; Chaika NV, 2012, P NATL ACAD SCI USA, V109, P13787, DOI 10.1073/pnas.1203339109; Chang QS, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-64; Chevet E, 2013, ONCOGENE, V32, P2499, DOI 10.1038/onc.2012.346; Chung SJ, 2005, J MED CHEM, V48, P658, DOI 10.1021/jm0496279; COHEN RM, 1971, J BIOL CHEM, V246, P7561; Denzel MS, 2014, CELL, V156, P1167, DOI 10.1016/j.cell.2014.01.061; Dickinson DA, 2002, ANN NY ACAD SCI, V973, P488, DOI 10.1111/j.1749-6632.2002.tb04690.x; Dumartin L, 2017, ONCOGENE, V36, P3094, DOI 10.1038/onc.2016.459; Eletto D, 2014, J CELL SCI, V127, P3649, DOI 10.1242/jcs.153643; Fagone P, 2009, J LIPID RES, V50, pS311, DOI 10.1194/jlr.R800049-JLR200; Farooqi AA, 2015, TUMOR BIOL, V36, P5743, DOI 10.1007/s13277-015-3797-0; Feno S, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9324018; Ferrer CM, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723548.2014.961809; Gebregiworgis T, 2017, J PROTEOME RES, V16, P3536, DOI 10.1021/acs.jproteome.7b00246; Gemble S, 2016, J CELL SCI, V129, P3167, DOI 10.1242/jcs.187781; Goode G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176820; Guang W, 2009, INT J BIOCHEM CELL B, V41, P1354, DOI 10.1016/j.biocel.2008.12.004; Gunda V, 2017, CLIN CANCER RES, V23, P5881, DOI 10.1158/1078-0432.CCR-17-1151; Hauser J, 2008, P NATL ACAD SCI USA, V105, P1267, DOI 10.1073/pnas.0708220105; Hayakawa Y, 2011, P NATL ACAD SCI USA, V108, P780, DOI 10.1073/pnas.1011418108; Hiraki M, 2016, SCI REP-UK, V6, DOI 10.1038/srep26643; Hui LJ, 2008, J CLIN INVEST, V118, P3943, DOI 10.1172/JCI37156; Ikonen E, 2008, NAT REV MOL CELL BIO, V9, P125, DOI 10.1038/nrm2336; Jing X, 2019, ONCOL REP, V41, P801, DOI 10.3892/or.2018.6887; Juin P, 1998, J BIOL CHEM, V273, P17559, DOI 10.1074/jbc.273.28.17559; Jun HS, 2010, BLOOD, V116, P2783, DOI 10.1182/blood-2009-12-258491; Kannan N, 2014, P NATL ACAD SCI USA, V111, P7789, DOI 10.1073/pnas.1403813111; Kriss CL, 2012, BLOOD, V120, P1027, DOI 10.1182/blood-2011-11-394346; Lau SK, 2004, AM J CLIN PATHOL, V122, P61, DOI 10.1309/9R6673QEC06D86Y4; Lebrecht D, 2008, ARTHRITIS RHEUM-US, V58, P318, DOI 10.1002/art.23235; Lebrecht D, 2007, HEPATOLOGY, V45, P72, DOI 10.1002/hep.21490; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lee YJ, 1998, J BIOL CHEM, V273, P5294, DOI 10.1074/jbc.273.9.5294; Li G, 2009, J CELL BIOL, V186, P783, DOI 10.1083/jcb.200904060; Vu LT, 2017, BIOSCI TRENDS, V11, P243, DOI 10.5582/bst.2017.01049; Ma Q, 2013, ANNU REV PHARMACOL, V53, P401, DOI 10.1146/annurev-pharmtox-011112-140320; Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6; Rodriguez-Vargas JM, 2012, CELL RES, V22, P1181, DOI 10.1038/cr.2012.70; Marini C, 2016, SCI REP-UK, V6, DOI 10.1038/srep25092; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Mehla K, 2014, BBA-REV CANCER, V1845, P126, DOI 10.1016/j.bbcan.2014.01.001; Menendez D, 2017, MOL CANCER RES, V15, P735, DOI 10.1158/1541-7786.MCR-17-0019; Nath S, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.16; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Norris AM, 2013, ONCOGENE, V32, P3867, DOI 10.1038/onc.2012.394; Oslowski CM, 2011, METHOD ENZYMOL, V490, P71, DOI 10.1016/B978-0-12-385114-7.00004-0; Rahn JJ, 2004, J BIOL CHEM, V279, P29386, DOI 10.1074/jbc.C400010200; Raina D, 2004, J BIOL CHEM, V279, P20607, DOI 10.1074/jbc.M310538200; Rajabi H, 2016, ONCOGENE, V35, P6439, DOI 10.1038/onc.2016.180; Rajabi H, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07850-0; Ren Z, 2017, TOXICOLOGY, V392, P11, DOI 10.1016/j.tox.2017.10.002; Ron D, 2004, J CELL BIOL, V167, P23, DOI 10.1083/jcb.200408117; Ruckemann K, 1998, J BIOL CHEM, V273, P21682, DOI 10.1074/jbc.273.34.21682; Serdjebi C, 2015, EXPERT OPIN DRUG MET, V11, P665, DOI 10.1517/17425255.2015.985648; Sharma AK, 2004, J BIOL CHEM, V279, P35564, DOI 10.1074/jbc.M401037200; Sharma S, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1651-1; Shukla SK, 2017, CANCER CELL, V32, P71, DOI 10.1016/j.ccell.2017.06.004; Singh PK, 2008, J BIOL CHEM, V283, P26985, DOI 10.1074/jbc.M805036200; Singh PK, 2007, CANCER RES, V67, P5201, DOI 10.1158/0008-5472.CAN-06-4647; Singh PK, 2006, TRENDS CELL BIOL, V16, P467, DOI 10.1016/j.tcb.2006.07.006; Song BB, 2008, J CLIN INVEST, V118, P3378, DOI 10.1172/JCI34587; Song M, 2018, NATURE, V562, P423, DOI 10.1038/s41586-018-0597-x; Spitz DR, 2000, ANN NY ACAD SCI, V899, P349, DOI 10.1111/j.1749-6632.2000.tb06199.x; Srinivas US, 2019, REDOX BIOL, V25, DOI 10.1016/j.redox.2018.101084; STOLLER RG, 1978, BIOCHEM PHARMACOL, V27, P53, DOI 10.1016/0006-2952(78)90256-3; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tadros S, 2017, CANCER RES, V77, P5503, DOI 10.1158/0008-5472.CAN-16-3062; Tagde A, 2016, ONCOTARGET, V7, P38974, DOI 10.18632/oncotarget.9777; Thorp E, 2009, CELL METAB, V9, P474, DOI 10.1016/j.cmet.2009.03.003; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Wang L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184110; Wang MX, 2018, CRIT REV ONCOL HEMAT, V127, P66, DOI 10.1016/j.critrevonc.2018.05.003; Wang M, 2014, NAT REV CANCER, V14, P581, DOI 10.1038/nrc3800; Wei XL, 2005, CANCER CELL, V7, P167, DOI 10.1016/j.ccr.2005.01.008; Weizman N, 2014, ONCOGENE, V33, P3812, DOI 10.1038/onc.2013.357; Yamamori T, 2013, FEBS LETT, V587, P3348, DOI 10.1016/j.febslet.2013.08.030; Yamamoto M, 2019, CANCER RES, V79, P2031, DOI 10.1158/0008-5472.CAN-18-3259; Ye FG, 2015, CANCER RES, V75, P1504, DOI 10.1158/0008-5472.CAN-14-2341; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yin L, 2003, J BIOL CHEM, V278, P35458, DOI 10.1074/jbc.M301987200; Zeeshan HMA, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030327; Zeng T, 2015, BIOCHEM BIOPH RES CO, V460, P530, DOI 10.1016/j.bbrc.2015.03.064; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982; Zweitzig DR, 2007, MOL CELL BIOCHEM, V306, P255, DOI 10.1007/s11010-007-9562-y	93	14	15	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2020	39	16					3381	3395		10.1038/s41388-020-1225-4	http://dx.doi.org/10.1038/s41388-020-1225-4		FEB 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF9OJ	32103170	Green Accepted			2022-12-28	WOS:000516683200002
J	Luiken, S; Fraas, A; Bieg, M; Sugiyanto, R; Goeppert, B; Singer, S; Ploeger, C; Warsow, G; Marquardt, JU; Sticht, C; De La Torre, C; Pusch, S; Mehrabi, A; Gretz, N; Schlesner, M; Eils, R; Schirmacher, P; Longerich, T; Roessler, S				Luiken, Sarah; Fraas, Angelika; Bieg, Matthias; Sugiyanto, Raisatun; Goeppert, Benjamin; Singer, Stephan; Ploeger, Carolin; Warsow, Gregor; Marquardt, Jens U.; Sticht, Carsten; De La Torre, Carolina; Pusch, Stefan; Mehrabi, Arianeb; Gretz, Norbert; Schlesner, Matthias; Eils, Roland; Schirmacher, Peter; Longerich, Thomas; Roessler, Stephanie			NOTCH target gene HES5 mediates oncogenic and tumor suppressive functions in hepatocarcinogenesis	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; ORNITHINE-DECARBOXYLASE; MYC; SURVEILLANCE; HEPATOCYTES; MUTATIONS; PATHWAY; ROLES; FATE; SOX2	NOTCH receptor signaling plays a pivotal role in liver homeostasis and hepatocarcinogenesis. However, the role of NOTCH pathway mutations and the NOTCH target gene HES5 in liver tumorigenesis are poorly understood. Here we performed whole-exome sequencing of 54 human HCC specimens and compared the prevalence of NOTCH pathway component mutations with the TCGA-LIHC cohort (N = 364). In addition, we functionally characterized the NOTCH target HES5 and the patient-derived HES5-R31G mutation in vitro and in an orthotopic mouse model applying different oncogenic backgrounds, to dissect the role of HES5 in different tumor subgroups in vivo. We identified nonsynonymous mutations in 14 immediate NOTCH pathway genes affecting 24.1% and 16.8% of HCC patients in the two independent cohorts, respectively. Among these, the HES5-R31G mutation was predicted in silico to have high biological relevance. Functional analyses in cell culture showed that HES5 reduced cell migration and clonogenicity. Further analyses revealed that the patient-derived HES5-R31G mutant protein was non-functional due to loss of DNA binding and greatly reduced nuclear localization. Furthermore, HES5 exhibited a negative feedback loop by directly inhibiting the NOTCH target HES1 and downregulated the pro-proliferative MYC targets ODC1 and LDHA. Interestingly, HES5 inhibited MYC-dependent hepatocarcinogenesis, whereas it promoted AKT-dependent liver tumor formation and stem cell features in a murine model. Thus, NOTCH pathway component mutations are commonly observed in HCC. Furthermore, the NOTCH target gene HES5 has both pro- and anti-tumorigenic functions in liver cancer proposing a driver gene dependency and it promotes tumorigenesis with its interaction partner AKT.	[Luiken, Sarah; Fraas, Angelika; Sugiyanto, Raisatun; Goeppert, Benjamin; Singer, Stephan; Ploeger, Carolin; Schirmacher, Peter; Longerich, Thomas; Roessler, Stephanie] Univ Hosp Heidelberg, Inst Pathol, Heidelberg, Germany; [Bieg, Matthias; Eils, Roland] Berlin Inst Hlth, Ctr Digital Hlth, Berlin, Germany; [Bieg, Matthias; Eils, Roland] Charite Univ Med Berlin, Berlin, Germany; [Bieg, Matthias; Eils, Roland] Heidelberg Ctr Personalized Oncol DKFZ HIPO, Heidelberg, Germany; [Warsow, Gregor; Schlesner, Matthias] German Canc Res Ctr, Bioinformat & Omics Data Analyt, Heidelberg, Germany; [Marquardt, Jens U.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Med 1, Mainz, Germany; [Sticht, Carsten; De La Torre, Carolina; Gretz, Norbert] Heidelberg Univ, Med Res Ctr, Mannheim, Germany; [Pusch, Stefan] Univ Hosp Heidelberg, Dept Neuropathol, Heidelberg, Germany; [Pusch, Stefan] German Canc Res Ctr, Clin Cooperat Unit Neuropathol, Heidelberg, Germany; [Mehrabi, Arianeb] Univ Hosp Heidelberg, Dept Gen Visceral & Transplantat Surg, Heidelberg, Germany; [Eils, Roland] Univ Hosp Heidelberg, Hlth Data Sci Unit, Heidelberg, Germany; [Eils, Roland] Heidelberg Univ, German Ctr Lung Res DZL, Translat Lung Res Ctr Heidelberg TLRC, Heidelberg, Germany	Ruprecht Karls University Heidelberg; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; German Cancer Research Center (DKFZ); Johannes Gutenberg University of Mainz; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Roessler, S (corresponding author), Univ Hosp Heidelberg, Inst Pathol, Heidelberg, Germany.	Stephanie.Roessler@med.uni-heidelberg.de	Goeppert, Benjamin/AAC-2303-2022; Eils, Roland/B-6121-2009; Roessler, Stephanie/J-8432-2019	Eils, Roland/0000-0002-0034-4036; Roessler, Stephanie/0000-0002-5333-5942; Fritzsche, Sarah/0000-0003-4621-1391	German Research Foundation (DFG) CRC SFB/TR 209 Liver Cancer; European Union [667273]; HIPO project [H014]; Projekt DEAL	German Research Foundation (DFG) CRC SFB/TR 209 Liver Cancer(German Research Foundation (DFG)); European Union(European Commission); HIPO project; Projekt DEAL	We thank Darjus F. Tschaharganeh (University Hospital Heidelberg) for providing vectors used for hydrodynamic tail vein injection. Tissue samples were provided by the tissue bank of the National Center for Tumor Diseases (NCT; Heidelberg, Germany) in accordance with the regulations of the tissue bank and the approval of the Ethics Committee of Heidelberg University. We thank Veronika Geissler (NCT tissue bank, Heidelberg), the Center for Model System and Comparative Pathology (CMCP) of the Institute of Pathology Heidelberg and Leon Schwab for technical assistance. We thank the Nikon Imaging Center Heidelberg for help with image acquisition and Dr Carlo Beretta from MATH-Clinic (University Heidelberg) for help with Fiji Macro. This work was supported by German Research Foundation (DFG) CRC SFB/TR 209 Liver Cancer (B01 to SR, B04 to SS, B08 to TL and Z01 to PS) and the European Union's Horizon 2020 research and innovation program under grant agreement number 667273 (HEP-CAR) to PS and SR. We thank the Genomics and Proteomics Core Facility (GPCF) of DKFZ for Whole Genome Sequencing and the DKFZ-Heidelberg Center for Personalized Oncology (DKFZ-HIPO) for technical support and funding through HIPO project H014. Open access funding provided by Projekt DEAL.	Abitbol S, 2018, J HEPATOL, V68, P1203, DOI 10.1016/j.jhep.2017.12.018; Ally A, 2017, CELL, V169, P1327, DOI 10.1016/j.cell.2017.05.046; Aster JC, 2017, ANNU REV PATHOL-MECH, V12, P245, DOI 10.1146/annurev-pathol-052016-100127; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Boulter L, 2012, NAT MED, V18, P572, DOI 10.1038/nm.2667; Braccioli L, 2018, STEM CELL RES, V33, P110, DOI 10.1016/j.scr.2018.10.005; Bray SJ, 2016, NAT REV MOL CELL BIO, V17, P722, DOI 10.1038/nrm.2016.94; Calvisi DF, 2011, GASTROENTEROLOGY, V140, P1071, DOI 10.1053/j.gastro.2010.12.006; Chen X, 2014, AM J PATHOL, V184, P912, DOI 10.1016/j.ajpath.2013.12.002; Chen ZZ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12598; Dill MT, 2013, HEPATOLOGY, V57, P1607, DOI 10.1002/hep.26165; Ding L, 2018, CELL, V173, P305, DOI 10.1016/j.cell.2018.03.033; Dugger SA, 2018, NAT REV DRUG DISCOV, V17, P183, DOI 10.1038/nrd.2017.226; Eggert T, 2016, CANCER CELL, V30, P533, DOI 10.1016/j.ccell.2016.09.003; Evert M, 2013, HEPATOLOGY, V58, P1857, DOI 10.1002/hep.26411; Fan B, 2012, J CLIN INVEST, V122, P2911, DOI 10.1172/JCI63212; Fu WY, 2019, CLIN CANCER RES, V25, P2835, DOI 10.1158/1078-0432.CCR-18-2732; Fujimoto A, 2012, NAT GENET, V44, P760, DOI 10.1038/ng.2291; Geisler F, 2015, HEPATOLOGY, V61, P382, DOI 10.1002/hep.27268; Giachino C, 2015, CANCER CELL, V28, P730, DOI 10.1016/j.ccell.2015.10.008; Gramantieri L, 2007, LIVER INT, V27, P997, DOI 10.1111/j.1478-3231.2007.01544.x; Guichard C, 2012, NAT GENET, V44, P694, DOI 10.1038/ng.2256; Hoare M, 2016, NAT CELL BIOL, V18, P979, DOI 10.1038/ncb3397; Huang J, 2012, NAT GENET, V44, P1117, DOI 10.1038/ng.2391; Imayoshi I, 2013, SCIENCE, V342, P1203, DOI 10.1126/science.1242366; Jiang WD, 2010, INT J CANCER, V127, P1011, DOI 10.1002/ijc.25118; Kageyama R, 2007, DEVELOPMENT, V134, P1243, DOI 10.1242/dev.000786; Kang TW, 2011, NATURE, V479, P547, DOI 10.1038/nature10599; Kim JW, 2004, MOL CELL BIOL, V24, P5923, DOI 10.1128/MCB.24.13.5923-5936.2004; Kuang SQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061807; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Lachenmayer A, 2012, CLIN CANCER RES, V18, P4997, DOI 10.1158/1078-0432.CCR-11-2322; Le A, 2010, P NATL ACAD SCI USA, V107, P2037, DOI 10.1073/pnas.0914433107; Liu HY, 2015, NAT CELL BIOL, V17, P1036, DOI 10.1038/ncb3210; Liu LM, 2016, HEPATOLOGY, V64, P814, DOI 10.1002/hep.28690; Llovet JM, 2015, NAT REV CLIN ONCOL, V12, P408, DOI [10.1038/nrclinonc.2015.103, 10.1038/nrclinonc.2015.121]; Mittal S, 2013, J CLIN GASTROENTEROL, V47, pS2, DOI 10.1097/MCG.0b013e3182872f29; Morell CM, 2014, J HEPATOL, V60, P885, DOI 10.1016/j.jhep.2013.11.028; Nilsson JA, 2005, CANCER CELL, V7, P433, DOI 10.1016/j.ccr.2005.03.036; Ploeger C, 2016, HEPATOLOGY, V64, P828, DOI 10.1002/hep.28684; Roessler S, 2012, GASTROENTEROLOGY, V142, P957, DOI 10.1053/j.gastro.2011.12.039; Rudin CM, 2012, NAT GENET, V44, P1111, DOI 10.1038/ng.2405; Schulze K, 2015, NAT GENET, V47, P505, DOI 10.1038/ng.3252; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Sun LC, 2015, ANTI-CANCER AGENT ME, V15, P809, DOI 10.2174/1871520615666150202102809; Totoki Y, 2014, NAT GENET, V46, P1267, DOI 10.1038/ng.3126; Tschaharganeh DF, 2014, CELL, V158, P579, DOI 10.1016/j.cell.2014.05.051; Tschaharganeh DF, 2013, GASTROENTEROLOGY, V144, P1530, DOI 10.1053/j.gastro.2013.02.009; Viatour P, 2011, J EXP MED, V208, P1963, DOI 10.1084/jem.20110198; Villanueva A, 2012, GASTROENTEROLOGY, V143, P1660, DOI 10.1053/j.gastro.2012.09.002; Zender S, 2013, CANCER CELL, V23, P784, DOI 10.1016/j.ccr.2013.04.019; Zhou L, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0057382, 10.1371/journal.pone.0073724]	52	15	15	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	15					3128	3144		10.1038/s41388-020-1198-3	http://dx.doi.org/10.1038/s41388-020-1198-3		FEB 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LB8NS	32055024	hybrid, Green Published			2022-12-28	WOS:000513314100002
J	Lazarian, G; Friedrich, C; Quinquenel, A; Tran, J; Ouriemmi, S; Dondi, E; Martin, A; Mihoub, I; Chiron, D; Bellanger, C; Fleury, C; Gelebart, P; McCormack, E; Ledoux, D; Thieblemont, C; Marzec, J; Gribben, JG; Cymbalista, F; Varin-Blank, N; Gardano, L; Baran-Marszak, F				Lazarian, Gregory; Friedrich, Chloe; Quinquenel, Anne; Tran, Julie; Ouriemmi, Souhail; Dondi, Elisabetta; Martin, Antoine; Mihoub, Imane; Chiron, David; Bellanger, Celine; Fleury, Carole; Gelebart, Pascal; McCormack, Emmet; Ledoux, Dominique; Thieblemont, Catherine; Marzec, Jacek; Gribben, John G.; Cymbalista, Florence; Varin-Blank, Nadine; Gardano, Laura; Baran-Marszak, Fanny			Stabilization of beta-catenin upon B-cell receptor signaling promotes NF-kB target genes transcription in mantle cell lymphoma	ONCOGENE			English	Article							KAPPA-B; WNT/BETA-CATENIN; SYNTHASE KINASE-3; CYCLIN D1; CONSTITUTIVE ACTIVATION; PATHWAY; WNT; INHIBITION; EXPRESSION; AKT	B-cell receptor (BCR) signaling pathways and interactions with the tumor microenvironment account for mantle cell lymphoma (MCL) cells survival in lymphoid organs. In several MCL cases, the WNT/beta-catenin canonical pathway is activated and beta-catenin accumulates into the nucleus. As both BCR and beta-catenin are important mediators of cell survival and interaction with the microenvironment, we investigated the crosstalk between BCR and WNT/beta-catenin signaling and analyzed their impact on cellular homeostasis as well as their targeting by specific inhibitors. beta-catenin was detected in all leukemic MCL samples and its level of expression rapidly increased upon BCR stimulation. This stabilization was hampered by the BCR-pathway inhibitor Ibrutinib, supporting beta-catenin as an effector of the BCR signaling. In parallel, MCL cells as compared with normal B cells expressed elevated levels of WNT16, a NF-kappa B target gene. Its expression increased further upon BCR stimulation to participate to the stabilization of beta-catenin. Upon BCR stimulation, beta-catenin translocated into the nucleus but did not induce a Wnt-like transcriptional response, i.e., TCF/LEF dependent. beta-catenin rather participated to the regulation of NF-kappa B transcriptional targets, such as IL6, IL8, and IL1. Oligo pull down and chromatin immunoprecipitation experiments demonstrated that beta-catenin is part of a protein complex that binds the NF-kappa B DNA consensus sequence, strengthening the idea of an association between the two proteins. An inhibitor targeting beta-catenin transcriptional interactions hindered both NF-kappa B DNA recruitment and induced primary MCL cells apoptosis. Thus, beta-catenin likely represents another player through which BCR signaling impacts on MCL cell survival.	[Lazarian, Gregory; Friedrich, Chloe; Quinquenel, Anne; Tran, Julie; Ouriemmi, Souhail; Dondi, Elisabetta; Martin, Antoine; Mihoub, Imane; Fleury, Carole; Ledoux, Dominique; Cymbalista, Florence; Varin-Blank, Nadine; Gardano, Laura; Baran-Marszak, Fanny] INSERM, U978, Bobigny, France; [Lazarian, Gregory; Friedrich, Chloe; Quinquenel, Anne; Tran, Julie; Ouriemmi, Souhail; Dondi, Elisabetta; Martin, Antoine; Mihoub, Imane; Fleury, Carole; Ledoux, Dominique; Cymbalista, Florence; Varin-Blank, Nadine; Gardano, Laura; Baran-Marszak, Fanny] Univ Paris 13, Sorbonne Paris Cite, Labex Inflamex, Bobigny, France; [Lazarian, Gregory; Fleury, Carole; Cymbalista, Florence; Baran-Marszak, Fanny] Hop Avicenne, Assistance Publ Hop Paris, Serv Hematol Biol, Bobigny, France; [Martin, Antoine] Hop Avicenne, Assistance Publ Hop Paris, Serv Anatomopathol, Bobigny, France; [Chiron, David; Bellanger, Celine] Univ Nantes, CNRS, U1232 INSERM, Ctr Rech Cancerol & Immunol Nantes Angers,ERL6001, Nantes, France; [Gelebart, Pascal; McCormack, Emmet] Univ Bergen, Dept Clin Sci, Bergen, Norway; [Thieblemont, Catherine] Hop St Louis, Assistance Publ Hop Paris, Hematol, Paris, France; [Marzec, Jacek] Univ Melbourne, Dept Clin Pathol, Melbourne, Vic, Australia; [Gribben, John G.] Queen Mary Univ London, Barts Canc Inst, London, England	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris 13; Centre National de la Recherche Scientifique (CNRS); Nantes Universite; University of Bergen; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; University of Melbourne; University of London; Queen Mary University London	Varin-Blank, N; Baran-Marszak, F (corresponding author), INSERM, U978, Bobigny, France.; Varin-Blank, N; Baran-Marszak, F (corresponding author), Univ Paris 13, Sorbonne Paris Cite, Labex Inflamex, Bobigny, France.; Baran-Marszak, F (corresponding author), Hop Avicenne, Assistance Publ Hop Paris, Serv Hematol Biol, Bobigny, France.	nadine.varin@inserm.fr; fanny.baran-marszak@aphp.fr	Cormack, Emmet Mc/D-2922-2012; Gelebart, Pascal/AAI-1439-2020; Thieblemont, Catherine/AAZ-8423-2020	Cormack, Emmet Mc/0000-0002-7621-4625; Gelebart, Pascal/0000-0003-2434-8987; Thieblemont, Catherine/0000-0002-9941-2448; VARIN-BLANK, Nadine/0000-0003-2769-018X; Dondi, Elisabetta/0000-0003-0975-459X; Lazarian, Gregory/0000-0002-4315-3440; LEDOUX, DOMINIQUE/0000-0002-5886-2266; Marzec, Jacek/0000-0001-6577-8866	APHP; Jansen fellowship; INSERM; Labex INFLAMEX [ANR11 IDEX00502]; University Paris 13	APHP; Jansen fellowship; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Labex INFLAMEX; University Paris 13	CF was the recipient of a "Annee Recherche" support from APHP. AQ was the recipient of a Jansen fellowship. This project was funded by a "Bonus Qualite Recherche" grant from University Paris 13 and benefited from the financial support of INSERM, University Paris 13 and the Labex INFLAMEX, contract ANR11 IDEX00502. We thank Dr C. Leroy for reading the manuscript, Dr L. Guittat for helpful discussion during the experimental work and Dr B. Papp for initiating collaboration with Dr P. Gelebart.	Argatoff LH, 1997, BLOOD, V89, P2067, DOI 10.1182/blood.V89.6.2067; Baran-Marszak F, 2010, HAEMATOL-HEMATOL J, V95, P1865, DOI 10.3324/haematol.2009.019745; Bernard S, 2015, INT J CANCER, V136, P2761, DOI 10.1002/ijc.29326; Bognar MK, 2016, ONCOGENE, V35, P4269, DOI 10.1038/onc.2015.493; BOSCH F, 1994, BLOOD, V84, P2726; Boukhiar MA, 2013, EXP HEMATOL ONCOL, V2, DOI 10.1186/2162-3619-2-4; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Christian SL, 2002, J IMMUNOL, V169, P758, DOI 10.4049/jimmunol.169.2.758; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dal Col J, 2008, CELL CYCLE, V7, P2813, DOI 10.4161/cc.7.18.6733; de Rooij MFM, 2015, BLOOD, V125, P2306, DOI 10.1182/blood-2014-12-619163; Gandhirajan RK, 2010, CURR CANCER DRUG TAR, V10, P716; Gelebart P, 2008, BLOOD, V112, P5171, DOI 10.1182/blood-2008-02-139212; Gold MR, 1999, J IMMUNOL, V163, P1894; Gold MR, 2000, IMMUNOL REV, V176, P47; GOODE N, 1992, J BIOL CHEM, V267, P16878; Hadzidimitriou A, 2011, BLOOD, V118, P3088, DOI 10.1182/blood-2011-03-343434; Hallett RM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033976; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Jares P, 2012, J CLIN INVEST, V122, P3416, DOI 10.1172/JCI61272; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Khan NI, 2007, BRIT J HAEMATOL, V138, P338, DOI 10.1111/j.1365-2141.2007.06667.x; Kimura Y, 2013, INT J ONCOL, V43, P457, DOI 10.3892/ijo.2013.1982; Koopmans T, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01086; Lepourcelet M, 2004, CANCER CELL, V5, P91, DOI 10.1016/S1535-6108(03)00334-9; Lindvall J, 2002, BIOCHEM BIOPH RES CO, V293, P1319, DOI 10.1016/S0006-291X(02)00382-0; Lovatt M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012794; Ma B, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00378; Mathur R, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0161-1; Mazieres J, 2005, ONCOGENE, V24, P5396, DOI 10.1038/sj.onc.1208568; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Orchard J, 2003, BLOOD, V101, P4975, DOI 10.1182/blood-2002-06-1864; Perez-Galan P, 2011, BLOOD, V117, P26, DOI 10.1182/blood-2010-04-189977; Raskatov JA, 2012, P NATL ACAD SCI USA, V109, P1023, DOI 10.1073/pnas.1118506109; Rizzatti EG, 2005, BRIT J HAEMATOL, V130, P516, DOI 10.1111/j.1365-2141.2005.05630.x; Saba NS, 2016, BLOOD, V128, P82, DOI 10.1182/blood-2015-11-681460; Spaargaren M, 2015, ONCOGENE, V34, P2426, DOI 10.1038/onc.2014.181; Stamos JL, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a007898; Sun Y, 2016, ONCOGENE, V35, P4321, DOI 10.1038/onc.2015.494; Sun Y, 2012, NAT MED, V18, P1359, DOI 10.1038/nm.2890; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; Zhang XQ, 2015, AM J CANCER RES, V5, P2344	45	7	8	4	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	14					2934	2947		10.1038/s41388-020-1183-x	http://dx.doi.org/10.1038/s41388-020-1183-x		FEB 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KZ2VB	32034308				2022-12-28	WOS:000511752600004
J	Tong, X; Wang, SJ; Lei, Z; Li, C; Zhang, CJ; Su, ZY; Liu, X; Zhao, J; Zhang, HT				Tong, Xin; Wang, Shengjie; Lei, Zhe; Li, Chang; Zhang, Cuijuan; Su, Zhiyue; Liu, Xia; Zhao, Jun; Zhang, Hong-Tao			MYOCD and SMAD3/SMAD4 form a positive feedback loop and drive TGF-beta-induced epithelial-mesenchymal transition in non-small cell lung cancer	ONCOGENE			English	Article							GENE-EXPRESSION; MYOCARDIN FAMILY; DIFFERENTIATION; TRANSCRIPTION; ACTIVATION; SNAIL; TRANSFORMATION; INDUCTION; PROTEINS; BINDING	Myocardin (MYOCD) promotes Smad3-mediated transforming growth factor-beta (TGF-beta) signaling in mouse fibroblast cells. Our previous studies show that TGF-beta/SMADs signaling activation enhances epithelial-mesenchymal transition (EMT) in human non-small cell lung cancer (NSCLC) cells. However, whether and how MYOCD contributes to TGF-beta-induced EMT of NSCLC cells are poorly elucidated. Here, we found that TGF-beta-induced EMT was accompanied by increased MYOCD expression. Interestingly, MYOCD overexpression augmented EMT and invasion of NSCLC cells induced by TGF-beta, whereas knockdown of MYOCD expression attenuated these effects. Overexpression and knockdown of MYOCD resulted in the upregulation and downregulation of TGF-beta-induced Snail mRNA, respectively. Moreover, MYOCD overexpression promoted TGF-beta-stimulated NSCLC cell metastasis in vivo. MYOCD was highly expressed and positively correlated with Snail in metastatic NSCLC tissues. Mechanistically, MYOCD directly interacted with SMAD3 and sustained the formation of TGF-beta-induced nuclear SMAD3/SMAD4 complex, facilitating TGF-beta/SMAD3-induced transactivation of Snail. Importantly, MYOCD was transcriptionally activated by TGF-beta-induced SMAD3/SMAD4 complex and CRISPR/Cas9-mediated silencing of SMAD3/SMAD4 led to a reduction in MYOCD mRNA expression. Taken together, our findings indicate that MYOCD promotes TGF-beta-induced EMT and metastasis of NSCLC and identify a positive feedback loop between MYOCD and SMAD3/SMAD4 driving TGF-beta-induced EMT.	[Tong, Xin; Wang, Shengjie; Lei, Zhe; Zhang, Cuijuan; Su, Zhiyue; Liu, Xia; Zhang, Hong-Tao] Soochow Univ, Med Coll, Lab Canc Mol Genet, Suzhou 215123, Jiangsu, Peoples R China; [Tong, Xin; Wang, Shengjie; Lei, Zhe; Zhang, Cuijuan; Su, Zhiyue; Liu, Xia; Zhang, Hong-Tao] Soochow Univ, Med Coll, Sch Biol & Basic Med Sci, Dept Genet, Suzhou 215123, Jiangsu, Peoples R China; [Wang, Shengjie] Nanjing Med Univ, Kangda Coll, Dept Basic Med, Lianyungang 222000, Peoples R China; [Li, Chang; Zhao, Jun] Soochow Univ, Med Coll, Affiliated Hosp 1, Dept Thorac Surg, Suzhou 215006, Jiangsu, Peoples R China; [Zhang, Hong-Tao] Suzhou Key Lab Mol Canc Genet, Suzhou 215123, Jiangsu, Peoples R China	Soochow University - China; Soochow University - China; Nanjing Medical University; Soochow University - China	Zhang, HT (corresponding author), Soochow Univ, Med Coll, Lab Canc Mol Genet, Suzhou 215123, Jiangsu, Peoples R China.; Zhang, HT (corresponding author), Soochow Univ, Med Coll, Sch Biol & Basic Med Sci, Dept Genet, Suzhou 215123, Jiangsu, Peoples R China.; Zhang, HT (corresponding author), Suzhou Key Lab Mol Canc Genet, Suzhou 215123, Jiangsu, Peoples R China.	htzhang@suda.edu.cn	Zhang, Hong-Tao/P-9661-2017; Lei, Zhe/AGZ-4963-2022	Zhang, Hong-Tao/0000-0003-4182-421X; 	National Natural Science Foundation of China [81872343, 81672277]; Suzhou Key Laboratory for Molecular Cancer Genetics [SZS201209]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Suzhou Key Laboratory for Molecular Cancer Genetics; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	We are grateful for participation and cooperation from the patients with NSCLC. Funding was provided by grants from National Natural Science Foundation of China (81872343, 81672277), and Suzhou Key Laboratory for Molecular Cancer Genetics (SZS201209), and A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).	Ackers-Johnson M, 2015, ARTERIOSCL THROM VAS, V35, P817, DOI 10.1161/ATVBAHA.114.305218; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bunn PA, 2008, ONCOLOGIST, V13, P1, DOI 10.1634/theoncologist.13-S1-1; Chen J, 2011, ARTERIOSCL THROM VAS, V31, P368, DOI 10.1161/ATVBAHA.110.218149; Chen Z, 2014, NAT REV CANCER, V14, P535, DOI 10.1038/nrc3775; Deheuninck J, 2009, CELL RES, V19, P47, DOI 10.1038/cr.2008.324; Donatelli SS, 2014, P NATL ACAD SCI USA, V111, P4203, DOI 10.1073/pnas.1319269111; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; He W, 2006, CELL, V125, P929, DOI 10.1016/j.cell.2006.03.045; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Kimura Y, 2010, CANCER RES, V70, P501, DOI 10.1158/0008-5472.CAN-09-1469; Kurpinski K, 2010, STEM CELLS, V28, P734, DOI 10.1002/stem.319; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Liu RY, 2014, INT J ONCOL, V44, P1643, DOI 10.3892/ijo.2014.2310; Macias MJ, 2015, TRENDS BIOCHEM SCI, V40, P296, DOI 10.1016/j.tibs.2015.03.012; Marwitz S, 2016, CANCER RES, V76, P3785, DOI 10.1158/0008-5472.CAN-15-1326; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; McDonald OG, 2006, J CLIN INVEST, V116, P36, DOI 10.1172/JCI26505; Milyavsky M, 2007, CANCER CELL, V11, P133, DOI 10.1016/j.ccr.2006.11.022; Mitra P, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7080097; Molchadsky A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003707; Morita T, 2007, J CELL BIOL, V179, P1027, DOI 10.1083/jcb.200708174; Morita T, 2018, MOL CANCER RES, V16, P880, DOI 10.1158/1541-7786.MCR-17-0715; O'Connor JW, 2015, J CELL PHYSIOL, V230, P1829, DOI 10.1002/jcp.24895; Perot G, 2009, CANCER RES, V69, P2269, DOI 10.1158/0008-5472.CAN-08-1443; Ponten F, 2008, J PATHOL, V216, P387, DOI 10.1002/path.2440; Qiu P, 2005, CIRC RES, V97, P983, DOI 10.1161/01.RES.0000190604.90049.71; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Sartor MA, 2010, BIOINFORMATICS, V26, P456, DOI 10.1093/bioinformatics/btp683; Schmierer B, 2007, NAT REV MOL CELL BIO, V8, P970, DOI 10.1038/nrm2297; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Smith AP, 2009, ONCOGENE, V28, P422, DOI 10.1038/onc.2008.395; Sward K, 2016, J PHYSIOL-LONDON, V594, P4741, DOI 10.1113/JP271913; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Wang DZ, 2004, CURR OPIN GENET DEV, V14, P558, DOI 10.1016/j.gde.2004.08.003; Wang L, 2016, ONCOGENE, V35, P867, DOI 10.1038/onc.2015.141; Wang LQ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0889-7; Wang YF, 2013, CURR CANCER DRUG TAR, V13, P963, DOI 10.2174/15680096113136660102; Wu JY, 2017, CANCER LETT, V400, P18, DOI 10.1016/j.canlet.2017.04.021; Xia XD, 2017, ATHEROSCLEROSIS, V257, P266, DOI 10.1016/j.atherosclerosis.2016.12.002; Xie WB, 2011, J BIOL CHEM, V286, P15050, DOI 10.1074/jbc.M110.202747; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Xue JF, 2014, J CLIN INVEST, V124, P564, DOI 10.1172/JCI71104; Yang HP, 2015, LUNG CANCER, V87, P249, DOI 10.1016/j.lungcan.2014.12.015	50	22	24	3	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	14					2890	2904		10.1038/s41388-020-1189-4	http://dx.doi.org/10.1038/s41388-020-1189-4		FEB 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KZ2VB	32029901				2022-12-28	WOS:000511540800005
J	Kilinc, AN; Sugiyama, N; Kalathur, RKR; Antoniadis, H; Birogul, H; Ishay-Ronen, D; George, JT; Levine, H; Jolly, MK; Christofori, G				Kilinc, Ayse Nihan; Sugiyama, Nami; Kalathur, Ravi Kiran Reddy; Antoniadis, Helena; Birogul, Huseyin; Ishay-Ronen, Dana; George, Jason T.; Levine, Herbert; Jolly, Mohit Kumar; Christofori, Gerhard			Histone deacetylases, Mbd3/NuRD, and Tet2 hydroxylase are crucial regulators of epithelial-mesenchymal plasticity and tumor metastasis	ONCOGENE			English	Article							TRANSCRIPTION FACTOR SNAIL; CADHERIN GENE-EXPRESSION; MI-2/NURD COMPLEX; MASTER REGULATOR; CANCER-CELLS; TRANSITION; NURD; EMT; REPRESSOR; METHYLATION	An epithelial-mesenchymal transition (EMT) represents a basic morphogenetic process of high cell plasticity underlying embryogenesis, wound healing, cancer metastasis and drug resistance. It involves a profound transcriptional and epigenetic reprogramming of cells. A critical role of epigenetic modifiers and their specific chromatin modifications has been demonstrated during EMT. However, it has remained elusive whether epigenetic control differs between the dynamic cell state transitions of reversible EMT and the fixed differentiation status of irreversible EMT. We have employed varying EMT models of murine breast cancer cells to identify the key players establishing epithelial-mesenchymal cell plasticity during reversible and irreversible EMT. We demonstrate that the Mbd3/NuRD complex and the activities of histone deacetylases (HDACs), and Tet2 hydroxylase play a critical role in keeping cancer cells in a highly metastatic mesenchymal state. Combinatorial interference with their functions leads to mesenchymal-epithelial transition (MET) and efficiently represses metastasis formation by invasive murine and human breast cancer cells in vivo.	[Kilinc, Ayse Nihan; Sugiyama, Nami; Kalathur, Ravi Kiran Reddy; Antoniadis, Helena; Birogul, Huseyin; Ishay-Ronen, Dana; Christofori, Gerhard] Univ Basel, Dept Biomed, CH-4058 Basel, Switzerland; [Kilinc, Ayse Nihan] Princeton Univ, Dept Chem & Biol Engn, 303 Hoyt Lab,William St, Princeton, NJ 08544 USA; [George, Jason T.; Levine, Herbert] Rice Univ, Ctr Theoret Biol Phys, Houston, TX USA; [George, Jason T.] Baylor Coll Med, Med Sci Training Program, Houston, TX 77030 USA; [Levine, Herbert] Northeastern Univ, Dept Bioengn, Boston, MA 02115 USA; [Levine, Herbert] Northeastern Univ, Dept Phys, Boston, MA 02115 USA; [Jolly, Mohit Kumar] Indian Inst Sci, Ctr BioSyst Sci & Engn, Bangalore 560012, Karnataka, India	University of Basel; Princeton University; Rice University; Baylor College of Medicine; Northeastern University; Northeastern University; Indian Institute of Science (IISC) - Bangalore	Christofori, G (corresponding author), Univ Basel, Dept Biomed, CH-4058 Basel, Switzerland.	gerhard.christofori@unibas.ch	Ishay-Ronen, Dana/AAZ-2396-2021; Levine, Herbert/C-1704-2008; Jolly, Mohit Kumar/A-1826-2014	Levine, Herbert/0000-0002-8819-9055; Jolly, Mohit Kumar/0000-0002-6631-2109; Sugiyama, Nami/0000-0003-0788-2934; George, Jason/0000-0002-8248-2888; Ishay-Ronen, Dana/0000-0003-0425-1408	SystemsX.ch RTD project Cellplasticity; SystemsX.ch MTD project MetastasiX; Swiss National Science Foundation; Swiss Cancer League; Gulf Coast Consortia on the Computational Cancer Biology Training Program (CPRIT) [RP170593]	SystemsX.ch RTD project Cellplasticity; SystemsX.ch MTD project MetastasiX; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Swiss Cancer League; Gulf Coast Consortia on the Computational Cancer Biology Training Program (CPRIT)	This work was supported by the SystemsX.ch RTD project Cellplasticity, the SystemsX.ch MTD project MetastasiX, the Swiss National Science Foundation, and the Swiss Cancer League. MKJ was also supported by a training fellowship from the Gulf Coast Consortia on the Computational Cancer Biology Training Program (CPRIT Grant No. RP170593).	Aiello NM, 2018, DEV CELL, V45, P681, DOI 10.1016/j.devcel.2018.05.027; Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Nieto MA, 2011, ANNU REV CELL DEV BI, V27, P347, DOI 10.1146/annurev-cellbio-092910-154036; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Baubec T, 2013, CELL, V153, P480, DOI 10.1016/j.cell.2013.03.011; Beckers T, 2007, INT J CANCER, V121, P1138, DOI 10.1002/ijc.22751; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cimmino L, 2011, CELL STEM CELL, V9, P193, DOI 10.1016/j.stem.2011.08.007; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Crea F, 2012, CRIT REV ONCOL HEMAT, V83, P184, DOI 10.1016/j.critrevonc.2011.10.007; Denslow SA, 2007, ONCOGENE, V26, P5433, DOI 10.1038/sj.onc.1210611; Diepenbruck M, 2016, CURR OPIN CELL BIOL, V43, P7, DOI 10.1016/j.ceb.2016.06.002; Dumont N, 2008, P NATL ACAD SCI USA, V105, P14867, DOI 10.1073/pnas.0807146105; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; Fantozzi A, 2014, CANCER RES, V74, P1566, DOI 10.1158/0008-5472.CAN-13-1641; Fraga MF, 2003, NUCLEIC ACIDS RES, V31, P1765, DOI 10.1093/nar/gkg249; Fu JJ, 2011, CELL RES, V21, P275, DOI 10.1038/cr.2010.118; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; George JT, 2017, CANCER RES, V77, P6415, DOI 10.1158/0008-5472.CAN-16-3521; Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610; Grozinger CM, 2002, CHEM BIOL, V9, P3, DOI 10.1016/S1074-5521(02)00092-3; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hayakawa T, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/129383; Hu X, 2014, CELL STEM CELL, V14, P512, DOI 10.1016/j.stem.2014.01.001; Jiang GM, 2013, BBA-MOL CELL RES, V1833, P663, DOI 10.1016/j.bbamcr.2012.12.002; Jolly MK, 2016, ONCOTARGET, V7, P27067, DOI 10.18632/oncotarget.8166; Jolly MK, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00155; Kaji K, 2006, NAT CELL BIOL, V8, P285, DOI 10.1038/ncb1372; Kaji K, 2007, DEVELOPMENT, V134, P1123, DOI 10.1242/dev.02802; Knutson SK, 2012, NAT CHEM BIOL, V8, P890, DOI [10.1038/NCHEMBIO.1084, 10.1038/nchembio.1084]; Lai AY, 2011, NAT REV CANCER, V11, P588, DOI 10.1038/nrc3091; Li RH, 2010, CELL STEM CELL, V7, P51, DOI 10.1016/j.stem.2010.04.014; Li WY, 2016, TRENDS CANCER, V2, P65, DOI 10.1016/j.trecan.2016.01.001; Lorizio W, 2011, GENOME MED, V3, DOI 10.1186/gm280; McDonald OG, 2011, NAT STRUCT MOL BIOL, V18, P867, DOI 10.1038/nsmb.2084; Meidhof S, 2015, EMBO MOL MED, V7, P831, DOI 10.15252/emmm.201404396; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586-018-0040-3; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Peng L, 2016, J CELL SCI, V129, P1059, DOI 10.1242/jcs.179044; Rais Y, 2013, NATURE, V502, P65, DOI 10.1038/nature12587; Saito M, 2002, J BIOL CHEM, V277, P35434, DOI 10.1074/jbc.M203455200; Shirakihara T, 2007, MOL BIOL CELL, V18, P3533, DOI 10.1091/mbc.E07-03-0249; Srivastava RK, 2010, MOL CANCER THER, V9, P3254, DOI 10.1158/1535-7163.MCT-10-0582; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Tang HM, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.41; Tate CR, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3192; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020; Verstappen G, 2008, HUM MOL GENET, V17, P1175, DOI 10.1093/hmg/ddn007; Vesuna F, 2008, BIOCHEM BIOPH RES CO, V367, P235, DOI 10.1016/j.bbrc.2007.11.151; Waldmeier L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048651; Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yang Y, 2018, J MOL CELL BIOL, V10, P285, DOI 10.1093/jmcb/mjy021; Yildirim O, 2011, CELL, V147, P1498, DOI 10.1016/j.cell.2011.11.054; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zhang N, 2017, DRUG DES DEV THER, V11, P969, DOI 10.2147/DDDT.S129305; Zhang WY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031450	61	12	12	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	7					1498	1513		10.1038/s41388-019-1081-2	http://dx.doi.org/10.1038/s41388-019-1081-2			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KL2WP	31666683				2022-12-28	WOS:000513289600008
J	Thomsen, MK; Skouboe, MK; Boularan, C; Vernejoul, F; Lioux, T; Leknes, SL; Berthelsen, MF; Riedel, M; Cai, HQ; Joseph, JV; Perouzel, E; Tiraby, M; Vendelbo, MH; Paludan, SR				Thomsen, Martin K.; Skouboe, Morten K.; Boularan, Cedric; Vernejoul, Fabienne; Lioux, Thierry; Leknes, Siv L.; Berthelsen, Martin F.; Riedel, Maria; Cai, Huiqiang; Joseph, Justin, V; Perouzel, Eric; Tiraby, Michele; Vendelbo, Mikkel H.; Paludan, Soren R.			The cGAS-STING pathway is a therapeutic target in a preclinical model of hepatocellular carcinoma	ONCOGENE			English	Article							INTERFERON-ALPHA; CANCER; DNA; ACTIVATION; INFLAMMATION; IMMUNITY; CELLS; HEPATOCYTES; CONTRIBUTES; REGRESSION	Hepatocellular carcinoma (HCC) is the most common primary liver cancer, and the incidence of HCC is increasing. Recently, cancer immunotherapy has emerged as an efficient treatment against some cancers. Here we have used a mouse model of mutagen-induced HCC to explore the therapeutic usefulness of targeting the DNA-activated STING pathway in HCC. STING-deficient mice exhibited unaltered initial development of HCC, but had higher number of large tumors at late stages of disease. In the liver of STING-deficient HCC mice, we observed reduced levels of phospho-STAT1, autophagy, and cleaved caspase3. These responses were activated in the liver by treatment with a cyclic dinucleotide (CDN) STING agonist. Importantly, CDN treatment of mice after HCC development efficiently reduced tumor size. Initiation of CDN treatment at an even later stage of disease to allow HCC detection by MR scanning revealed that the majority of tumors regressed in response to CDN, but new tumors were also detected, which were unresponsive to CDN treatment. Overall, the modulation of the STING pathway affects the development of HCC, and holds promise for a use as a treatment of this disease, most likely in combination with other immunomodulatory treatments such as PD1 inhibitors or with standard of care.	[Thomsen, Martin K.; Skouboe, Morten K.; Vendelbo, Mikkel H.; Paludan, Soren R.] Univ Aarhus, Dept Biomed, Hoegh Guldberg Gade 10, Aarhus C, Denmark; [Thomsen, Martin K.; Leknes, Siv L.; Berthelsen, Martin F.; Riedel, Maria; Cai, Huiqiang; Joseph, Justin, V] Univ Aarhus, Dept Clin Med, Palle Juul Jensens Blvd 82, DK-8200 Aarhus N, Denmark; [Boularan, Cedric; Vernejoul, Fabienne; Lioux, Thierry; Perouzel, Eric; Tiraby, Michele] InvivoGen, Toulouse, France; [Vendelbo, Mikkel H.] Aarhus Univ Hosp, Dept Nucl Med, Aarhus, Denmark; [Vendelbo, Mikkel H.] Aarhus Univ Hosp, PET Ctr, Aarhus, Denmark	Aarhus University; Aarhus University; Aarhus University; Aarhus University	Thomsen, MK; Paludan, SR (corresponding author), Univ Aarhus, Dept Biomed, Hoegh Guldberg Gade 10, Aarhus C, Denmark.; Thomsen, MK (corresponding author), Univ Aarhus, Dept Clin Med, Palle Juul Jensens Blvd 82, DK-8200 Aarhus N, Denmark.	mkt@clin.au.dk; srp@biomed.au.dk	Thomsen, Martin/AAU-5014-2021	Thomsen, Martin/0000-0002-5055-7531; Riedel, Maria/0000-0002-6545-0243; Skouboe, Morten Kelder/0000-0001-9358-5500; Vendelbo, Mikkel Holm/0000-0003-0431-2522	Danish Medical Research Council [12-124330, DFF-6110-00068]; Lundbeck Foundation [R198-2015-171]; InvivoGen; Danish Cancer Society [R146-A9394-16-S2, R204-A12490]; Ministry of health [4-1612-236/7]; AUFF NOVA [E-2o15-FLS-9-8]	Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Lundbeck Foundation(Lundbeckfonden); InvivoGen; Danish Cancer Society(Danish Cancer Society); Ministry of health; AUFF NOVA	We thank Mette Simonsen for assistant with scanning, Latifa Bakiri for thoroughly reading and comments on the manuscript, and Kirsten S Petersen for technical assistance. This work was funded by the Danish Medical Research Council (grants nos: 12-124330 and DFF-6110-00068), the Lundbeck Foundation (grant no R198-2015-171), and an unrestricted research grant from InvivoGen (all to SRP). MKT was funded by a fellowship sponsored by InvivoGen, Danish Cancer Society (R146-A9394-16-S2 and R204-A12490), Ministry of health (4-1612-236/7), and AUFF NOVA (E-2o15-FLS-9-8).	Ahn J, 2015, ONCOGENE, V34, P5302, DOI 10.1038/onc.2014.457; Ahn J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4723; Ariff B, 2009, WORLD J GASTROENTERO, V15, P1289, DOI 10.3748/wjg.15.1289; Bakiri L, 2013, MOL ONCOL, V7, P206, DOI 10.1016/j.molonc.2013.01.005; Chen DS, 2018, P NATL ACAD SCI USA, V115, P3930, DOI 10.1073/pnas.1717190115; Cheon H, 2014, SEMIN ONCOL, V41, P156, DOI 10.1053/j.seminoncol.2014.02.002; Corrales L, 2015, CLIN CANCER RES, V21, P4774, DOI 10.1158/1078-0432.CCR-15-1362; Corrales L, 2015, CELL REP, V11, P1018, DOI 10.1016/j.celrep.2015.04.031; Diner EJ, 2013, CELL REP, V3, P1355, DOI 10.1016/j.celrep.2013.05.009; Gao P, 2014, CELL REP, V8, P1668, DOI 10.1016/j.celrep.2014.08.010; Gulen MF, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00573-w; Haanen JBAG, 2015, PROG TUMOR RES, V42, P55, DOI 10.1159/000437178; Hou J, 2014, CANCER CELL, V25, P49, DOI 10.1016/j.ccr.2013.11.011; Iurescia S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00711; Jessy Thomas, 2011, J Nat Sci Biol Med, V2, P43, DOI 10.4103/0976-9668.82318; Larkin B, 2017, J IMMUNOL, V199, P397, DOI 10.4049/jimmunol.1601999; Lau L, 2015, SCIENCE, V350, P568, DOI 10.1126/science.aab3291; Li K, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020404; Li T, 2018, J EXP MED, V215, P1287, DOI 10.1084/jem.20180139; Lucas ED, 2018, J IMMUNOL, V45, P520; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Muhlbauer M, 2006, J HEPATOL, V45, P520, DOI 10.1016/j.jhep.2006.05.007; Ohkuri T, 2014, CANCER IMMUNOL RES, V2, P1199, DOI 10.1158/2326-6066.CIR-14-0099; Paludan SR, 2019, NAT REV IMMUNOL, V19, P141, DOI 10.1038/s41577-018-0117-0; Paludan SR, 2015, MICROBIOL MOL BIOL R, V79, P225, DOI 10.1128/MMBR.00061-14; Parker BS, 2016, NAT REV CANCER, V16, P131, DOI 10.1038/nrc.2016.14; Prabakaran T, 2018, EMBO J, V37, DOI 10.15252/embj.201797858; Rasmussen SB, 2011, J IMMUNOL, V187, P5268, DOI 10.4049/jimmunol.1100949; Sakamaki A, 2017, WORLD J GASTROENTERO, V23, P3797, DOI 10.3748/wjg.v23.i21.3797; Schlageter M, 2014, WORLD J GASTROENTERO, V20, P15955, DOI 10.3748/wjg.v20.i43.15955; Schoggins JW, 2014, NATURE, V505, P691, DOI 10.1038/nature12862; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Skouboe MK, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006976; Sokolowska O, 2018, ARCH IMMUNOL THER EX, V66, P125, DOI 10.1007/s00005-017-0481-7; Sze A, 2013, CELL HOST MICROBE, V14, P422, DOI 10.1016/j.chom.2013.09.009; Takahashi A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03555-8; Thomsen MK, 2016, HEPATOLOGY, V64, P746, DOI 10.1002/hep.28685; vanRooijen N, 1996, J IMMUNOL METHODS, V193, P93, DOI 10.1016/0022-1759(96)00056-7; Wang H, 2017, P NATL ACAD SCI USA, V114, P1637, DOI 10.1073/pnas.1621363114; Wherry EJ, 2011, NAT IMMUNOL, V12, P492, DOI 10.1038/ni.2035; Yeung JT, 2013, CLIN CANCER RES, V19, P1816, DOI 10.1158/1078-0432.CCR-12-2861; Young A, 2018, CANCER IMMUNOL RES, V6, P1445, DOI 10.1158/2326-6066.CIR-18-0487; Yu YS, 2019, J CLIN INVEST, V129, P546, DOI 10.1172/JCI121842; Zaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958; Zhang CX, 2019, CELL DEATH DIFFER, V26, P2314, DOI 10.1038/s41418-019-0302-0; Zhong ZY, 2016, CELL, V166, P288, DOI 10.1016/j.cell.2016.05.051; Zhu QF, 2014, J IMMUNOL, V193, P4779, DOI 10.4049/jimmunol.1402051	47	27	27	3	31	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	8					1652	1664		10.1038/s41388-019-1108-8	http://dx.doi.org/10.1038/s41388-019-1108-8			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN6CG	31740782				2022-12-28	WOS:000514923000003
J	Mani, C; Tripathi, K; Luan, S; Clark, DW; Andrews, JF; Vindigni, A; Thomas, G; Palle, K				Mani, Chinnadurai; Tripathi, Kaushlendra; Luan, Shan; Clark, David W.; Andrews, Joel F.; Vindigni, Alessandro; Thomas, Gary; Palle, Komaraiah			The multifunctional protein PACS-1 is required for HDAC2-and HDAC3-dependent chromatin maturation and genomic stability	ONCOGENE			English	Article							HISTONE DEACETYLASE 3; REPLICATION STRESS; DNA-REPLICATION; DELETION; HDAC3; CELLS; 11Q13; ROLES; ACETYLATION; TRAFFICKING	Phosphofurin acidic cluster sorting protein-1 (PACS-1) is a multifunctional membrane traffic regulator that plays important roles in organ homeostasis and disease. In this study, we elucidate a novel nuclear function for PACS-1 in maintaining chromosomal integrity. PACS-1 progressively accumulates in the nucleus during cell cycle progression, where it interacts with class I histone deacetylases 2 and 3 (HDAC2 and HDAC3) to regulate chromatin dynamics by maintaining the acetylation status of histones. PACS-1 knockdown results in the proteasome-mediated degradation of HDAC2 and HDAC3, compromised chromatin maturation, as indicated by elevated levels of histones H3K9 and H4K16 acetylation, and, consequently, increased replication stress-induced DNA damage and genomic instability.	[Mani, Chinnadurai; Palle, Komaraiah] Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Biochem, Lubbock, TX 79430 USA; [Mani, Chinnadurai; Tripathi, Kaushlendra; Clark, David W.; Andrews, Joel F.; Palle, Komaraiah] Univ S Alabama, Mitchell Canc Inst, Dept Oncol Sci, Mobile, AL 36604 USA; [Luan, Shan; Thomas, Gary] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA 15219 USA; [Luan, Shan; Thomas, Gary] Univ Pittsburgh, Canc Inst, Pittsburgh, PA 15239 USA; [Luan, Shan; Thomas, Gary] Univ Pittsburgh, Sch Med, 5117 Ctr Ave, Pittsburgh, PA 15213 USA; [Vindigni, Alessandro] St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA; [Palle, Komaraiah] Texas Tech Univ, Hlth Sci Ctr, Dept Surg, Lubbock, TX 79430 USA	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; University of South Alabama; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Saint Louis University; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center	Palle, K (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Biochem, Lubbock, TX 79430 USA.; Palle, K (corresponding author), Univ S Alabama, Mitchell Canc Inst, Dept Oncol Sci, Mobile, AL 36604 USA.; Palle, K (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Surg, Lubbock, TX 79430 USA.	komaraiah.palle@ttuhsc.edu			Abraham Mitchell Cancer Research Scholar Endowment grant; NIH [DK114855, DK112844, R01GM108648, R01GM098956, R01CA219187]; DOD BRCP [BC151728]	Abraham Mitchell Cancer Research Scholar Endowment grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD BRCP(United States Department of Defense)	We thank Steve McClellan, Mitchell Cancer Institute for flow cytometry. This work is supported by grants from Abraham Mitchell Cancer Research Scholar Endowment grant, and partly by NIH grants R01GM098956 and R01CA219187 to KP, the NIH grants DK114855 and DK112844 to GT, the NIH grant R01GM108648 and DOD BRCP Breakthrough Award BC151728 to AV.	Atkins KM, 2014, CELL REP, V8, P1545, DOI 10.1016/j.celrep.2014.07.049; Bhaskara S, 2008, MOL CELL, V30, P61, DOI 10.1016/j.molcel.2008.02.030; Bhaskara S, 2013, EPIGENET CHROMATIN, V6, DOI 10.1186/1756-8935-6-27; Bhaskara S, 2010, CANCER CELL, V18, P436, DOI 10.1016/j.ccr.2010.10.022; Blagoveshchenskaya AD, 2002, CELL, V111, P853, DOI 10.1016/S0092-8674(02)01162-5; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Clark DW, 2015, ONCOTARGET, V6, P28816, DOI 10.18632/oncotarget.5006; Conti C, 2010, CANCER RES, V70, P4470, DOI 10.1158/0008-5472.CAN-09-3028; Crump CM, 2001, EMBO J, V20, P2191, DOI 10.1093/emboj/20.9.2191; Crump CM, 2003, J VIROL, V77, P11105, DOI 10.1128/JVI.77.20.11105-11113.2003; De Souza C, 2015, RECENT PAT ANTI-CANC, V10, P145; Feng D, 2011, SCIENCE, V331, P1315, DOI 10.1126/science.1198125; Gaillard H, 2015, NAT REV CANCER, V15, P276, DOI 10.1038/nrc3916; Gilbert N, 2005, INT REV CYTOL, V242, P283; Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610; Godman CA, 2008, CANCER BIOL THER, V7, P1570, DOI 10.4161/cbt.7.10.6561; Hagelkruys A, 2014, DEVELOPMENT, V141, P604, DOI 10.1242/dev.100487; Hayakawa T, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/129383; Hinners I, 2003, EMBO REP, V4, P1182, DOI 10.1038/sj.embor.7400018; Jenkins PM, 2009, J NEUROSCI, V29, P10541, DOI 10.1523/JNEUROSCI.1590-09.2009; Johnson CA, 2002, J BIOL CHEM, V277, P9590, DOI 10.1074/jbc.M107942200; Khurana S, 2015, GENES-BASEL, V6, P858, DOI 10.3390/genes6030858; Lande-Diner L, 2009, MOL CELL, V34, P767, DOI 10.1016/j.molcel.2009.05.027; Leman AR, 2013, GENES-BASEL, V4, P1, DOI 10.3390/genes4010001; Ma PP, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003377; Mendonca MS, 2004, GENE CHROMOSOME CANC, V39, P277, DOI 10.1002/gcc.20007; Mullican SE, 2011, GENE DEV, V25, P2480, DOI 10.1101/gad.175950.111; Peterson CL, 2004, CURR BIOL, V14, pR546, DOI 10.1016/j.cub.2004.07.007; Piguet V, 2000, NAT CELL BIOL, V2, P163, DOI 10.1038/35004038; Pommier Y, 2006, NAT REV CANCER, V6, P789, DOI 10.1038/nrc1977; Schmidt V, 2007, J BIOL CHEM, V282, P32956, DOI 10.1074/jbc.M705073200; Scott GK, 2003, EMBO J, V22, P6234, DOI 10.1093/emboj/cdg596; Scott GK, 2006, EMBO J, V25, P4423, DOI 10.1038/sj.emboj.7601336; Senese S, 2007, MOL CELL BIOL, V27, P4784, DOI 10.1128/MCB.00494-07; Seto E, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a018713; Sirbu BM, 2011, GENE DEV, V25, P1320, DOI 10.1101/gad.2053211; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; Srivatsan ES, 2002, ONCOGENE, V21, P5631, DOI 10.1038/sj.onc.1205698; Srivatsan ES, 2000, GENE CHROMOSOME CANC, V29, P157, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1024>3.0.CO;2-P; Stengel KR, 2015, ANTIOXID REDOX SIGN, V23, P51, DOI 10.1089/ars.2014.5915; Stern D, 2017, CLIN GENET, V92, P221, DOI 10.1111/cge.12956; Summers AR, 2013, J CLIN INVEST, V123, P3112, DOI 10.1172/JCI60806; Thomas G, 2017, J CELL SCI, V130, P1865, DOI 10.1242/jcs.199463; Tripathi K, 2016, ONCOTARGET, V7, P12537, DOI 10.18632/oncotarget.7247; Tripathi K, 2015, ONCOTARGET, V6, P5237, DOI 10.18632/oncotarget.3026; Tripathi K, 2014, J BIOL CHEM, V289, P31513, DOI 10.1074/jbc.M114.606483; Wagner FF, 2015, CHEM SCI, V6, P804, DOI 10.1039/c4sc02130d; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; Wang ZB, 2009, CELL, V138, P1019, DOI 10.1016/j.cell.2009.06.049; Wells CE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068915; Yoon HG, 2003, EMBO J, V22, P1336, DOI 10.1093/emboj/cdg120; Zainabadi K, 2014, GENOMICS, V103, P276, DOI 10.1016/j.ygeno.2014.01.001; Zhang XH, 2004, MOL CELL BIOL, V24, P5106, DOI 10.1128/MCB.24.12.5106-5118.2004	53	11	11	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	12					2583	2596		10.1038/s41388-020-1167-x	http://dx.doi.org/10.1038/s41388-020-1167-x		JAN 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KW4HU	31988453	Green Accepted			2022-12-28	WOS:000509655100006
J	Taniue, K; Hayashi, T; Kamoshida, Y; Kurimoto, A; Takeda, Y; Negishi, L; Iwasaki, K; Kawamura, Y; Goshima, N; Akiyama, T				Taniue, Kenzui; Hayashi, Tomoatsu; Kamoshida, Yuki; Kurimoto, Akiko; Takeda, Yasuko; Negishi, Lumi; Iwasaki, Kei; Kawamura, Yoshifumi; Goshima, Naoki; Akiyama, Tetsu			UHRF1-KAT7-mediated regulation of TUSC3 expression via histone methylation/acetylation is critical for the proliferation of colon cancer cells	ONCOGENE			English	Article							DNA METHYLATION; PROMOTES PROLIFERATION; BURKITT-LYMPHOMA; STRUCTURAL BASIS; GENE-REGULATION; MYST FAMILY; STEM-CELLS; SRA DOMAIN; UHRF1; PROTEIN	The epigenetic factor UHRF1 regulates transcription by modulating DNA methylation and histone modification, and plays critical roles in proliferation, development, and tumorigenesis. Here, we show that Wnt/c-Myc signaling upregulates UHRF1, which in turn downregulates TUSC3, a candidate tumor suppressor gene that is frequently deleted or downregulated in several cancers. We also show that UHRF1-mediated downregulation of TUSC3 is required for the proliferation of colon cancer cells. Furthermore, we demonstrate that UHRF1 suppresses TUSC3 expression by interacting with methylated H3K14 and thereby suppressing the acetylation of H3K14 by the histone acetyltransferase KAT7. Our study provides evidence for the significance of UHRF1-KAT7-mediated regulation of histone methylation/acetylation in the proliferation of tumor cells and in a diverse set of biological processes controlled by Wnt/c-Myc signaling.	[Taniue, Kenzui; Hayashi, Tomoatsu; Kamoshida, Yuki; Kurimoto, Akiko; Takeda, Yasuko; Negishi, Lumi; Iwasaki, Kei; Akiyama, Tetsu] Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, Tokyo, Japan; [Kurimoto, Akiko] Daiichi Sankyo Co Ltd, Oncol Res Labs, Shinagawa Ku, Tokyo, Japan; [Kawamura, Yoshifumi] Japan Biol Informat Consortium, Koto Ku, Tokyo, Japan; [Goshima, Naoki] Natl Inst Adv Ind Sci & Technol, Mol Profiling Res Ctr Drug Discovery, Koto Ku, Tokyo, Japan	University of Tokyo; Daiichi Sankyo Company Limited; National Institute of Advanced Industrial Science & Technology (AIST)	Akiyama, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, Tokyo, Japan.	akiyama@iam.u-tokyo.ac.jp		Negishi, Lumi/0000-0002-7297-0634	MEXT, Japan [17H06325, 15H01464]; Project for Cancer Research and Therapeutic Evolution (P-CREATE) from the Japan Agency for Medical Research and Development [17cm0106103h0002]	MEXT, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Project for Cancer Research and Therapeutic Evolution (P-CREATE) from the Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED))	This work was supported by Grants-in-Aid for Scientific Research on Innovative Areas (Integrative Analysis and Regulation of Cellular Diversity, no. 17H06325 and Non-coding RNA neo-taxonomy, no. 15H01464) from MEXT, Japan, and Project for Cancer Research and Therapeutic Evolution (P-CREATE, no. 17cm0106103h0002) from the Japan Agency for Medical Research and Development.	Ahuja N, 1998, CANCER RES, V58, P5489; Arbieva ZH, 2000, GENOME RES, V10, P244, DOI 10.1101/gr.10.2.244; Arita K, 2012, P NATL ACAD SCI USA, V109, P12950, DOI 10.1073/pnas.1203701109; Avvakumov GV, 2008, NATURE, V455, P822, DOI 10.1038/nature07273; Avvakumov N, 2007, ONCOGENE, V26, P5395, DOI 10.1038/sj.onc.1210608; Babbio F, 2012, ONCOGENE, V31, P4878, DOI 10.1038/onc.2011.641; Bashyam MD, 2005, NEOPLASIA, V7, P556, DOI 10.1593/neo.04586; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Birnbaum DJ, 2011, GENE CHROMOSOME CANC, V50, P456, DOI 10.1002/gcc.20870; Bookstein R, 1997, BRIT J UROL, V79, P28, DOI 10.1111/j.1464-410X.1997.tb00798.x; Bostick M, 2007, SCIENCE, V317, P1760, DOI 10.1126/science.1147939; Citterio E, 2004, MOL CELL BIOL, V24, P2526, DOI 10.1128/MCB.24.6.2526-2535.2004; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Cooke SL, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-288; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; De Vos M, 2014, J BIOL CHEM, V289, P16223, DOI 10.1074/jbc.M113.527424; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Du ZW, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001462; Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408; Fan XQ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149028; Feng YP, 2016, EMBO J, V35, P176, DOI 10.15252/embj.201591293; Ferraro A, 2013, J CLIN ENDOCR METAB, V98, P2834, DOI 10.1210/jc.2012-2926; Gelato KA, 2014, MOL CELL, V54, P905, DOI 10.1016/j.molcel.2014.04.004; Georgiakaki M, 2006, MOL ENDOCRINOL, V20, P2122, DOI 10.1210/me.2005-0149; Goshima N, 2008, NAT METHODS, V5, P1011, DOI 10.1038/nmeth.1273; Hashimoto H, 2008, NATURE, V455, P826, DOI 10.1038/nature07280; Iizuka M, 2006, MOL CELL BIOL, V26, P1098, DOI 10.1128/MCB.26.3.1098-1108.2006; Jenkins Y, 2005, MOL BIOL CELL, V16, P5621, DOI 10.1091/mbc.E05-03-0194; Jiang ZF, 2016, TUMOR BIOL, V37, P12039, DOI 10.1007/s13277-016-5072-4; Kelleher DJ, 2003, MOL CELL, V12, P101, DOI 10.1016/S1097-2765(03)00243-0; Kress TR, 2015, NAT REV CANCER, V15, P593, DOI 10.1038/nrc3984; Kueh AJ, 2011, MOL CELL BIOL, V31, P845, DOI 10.1128/MCB.00159-10; Lalonde ME, 2014, GENE DEV, V28, P1029, DOI 10.1101/gad.236331.113; Lalonde ME, 2013, GENE DEV, V27, P2009, DOI 10.1101/gad.223396.113; Latham JA, 2007, NAT STRUCT MOL BIOL, V14, P1017, DOI 10.1038/nsmb1307; Li XL, 2012, ONCOL REP, V28, P375, DOI 10.3892/or.2012.1792; Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005; Maruyama Y, 2012, NUCLEIC ACIDS RES, V40, pD924, DOI 10.1093/nar/gkr1188; Matys V, 2006, NUCLEIC ACIDS RES, V34, pD108, DOI 10.1093/nar/gkj143; Miotto B, 2008, GENE DEV, V22, P2633, DOI 10.1101/gad.1674108; Miotto B, 2006, MOL CELL BIOL, V26, P5969, DOI 10.1128/MCB.00696-06; Miotto B, 2010, MOL CELL, V37, P57, DOI 10.1016/j.molcel.2009.12.012; Mishima Y, 2011, BLOOD, V118, P2443, DOI 10.1182/blood-2011-01-331892; Mohorko E, 2014, STRUCTURE, V22, P590, DOI 10.1016/j.str.2014.02.013; Mohorko E, 2011, J INHERIT METAB DIS, V34, P869, DOI 10.1007/s10545-011-9337-1; Nishiyama A, 2013, NATURE, V502, P249, DOI 10.1038/nature12488; Pils D, 2005, CANCER-AM CANCER SOC, V104, P2417, DOI 10.1002/cncr.21538; Pils D, 2013, CANCER-AM CANCER SOC, V119, P946, DOI 10.1002/cncr.27850; Pronobis MI, 2012, CURR BIOL, V22, pR137, DOI 10.1016/j.cub.2012.01.002; Qin WH, 2011, J CELL BIOCHEM, V112, P439, DOI 10.1002/jcb.22998; Quenneville S, 2011, MOL CELL, V44, P361, DOI 10.1016/j.molcel.2011.08.032; Rolando M, 2013, CELL HOST MICROBE, V13, P395, DOI 10.1016/j.chom.2013.03.004; Sabatino L, 2012, ONCOGENE, V31, P5061, DOI 10.1038/onc.2012.3; Saksouk N, 2009, MOL CELL, V33, P257, DOI 10.1016/j.molcel.2009.01.007; Sapountzi V, 2011, CELL MOL LIFE SCI, V68, P1147, DOI 10.1007/s00018-010-0599-9; Sharif J, 2007, NATURE, V450, P908, DOI 10.1038/nature06397; Shou YP, 2000, P NATL ACAD SCI USA, V97, P228, DOI 10.1073/pnas.97.1.228; Taniue K, 2016, P NATL ACAD SCI USA, V113, P12739, DOI 10.1073/pnas.1605938113; Taniue K, 2016, P NATL ACAD SCI USA, V113, P1273, DOI 10.1073/pnas.1500992113; Taniue K, 2011, EMBO REP, V12, P682, DOI 10.1038/embor.2011.81; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; Unoki M, 2010, BRIT J CANCER, V103, P217, DOI 10.1038/sj.bjc.6605717; Unoki M, 2009, BRIT J CANCER, V101, P98, DOI 10.1038/sj.bjc.6605123; Vanhara P, 2013, INT J ONCOL, V42, P1383, DOI 10.3892/ijo.2013.1824; Voss AK, 2009, BIOESSAYS, V31, P1050, DOI 10.1002/bies.200900051; Walczak EM, 2014, MOL ENDOCRINOL, V28, P1471, DOI 10.1210/me.2014-1060; Zhang Y, 2014, CANCER EPIDEM BIOMAR, V23, P2019, DOI 10.1158/1055-9965.EPI-13-0994; Zong HL, 2005, FEBS LETT, V579, P3579, DOI 10.1016/j.febslet.2005.05.039	69	10	10	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	5					1018	1030		10.1038/s41388-019-1032-y	http://dx.doi.org/10.1038/s41388-019-1032-y			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KI2VY	31582837				2022-12-28	WOS:000511209700005
J	Wang, XY; Wendel, JRH; Emerson, RE; Broaddus, RR; Creighton, CJ; Rusch, DB; Buechlein, A; DeMayo, FJ; Lydon, JP; Hawkins, SM				Wang, Xiyin; Wendel, Jillian R. H.; Emerson, Robert E.; Broaddus, Russell R.; Creighton, Chad J.; Rusch, Douglas B.; Buechlein, Aaron; DeMayo, Francesco J.; Lydon, John P.; Hawkins, Shannon M.			PtenandDicer1loss in the mouse uterus causes poorly differentiated endometrial adenocarcinoma	ONCOGENE			English	Article							DICER1 HOTSPOT MUTATIONS; EPHA2 OVEREXPRESSION; OVARIAN-CANCER; CARCINOMA; EXPRESSION; PTEN; TUMORS; RECOMMENDATIONS; IDENTIFICATION; RECURRENCE	Endometrial cancer remains the most common gynecological malignancy in the United States. While the loss of the tumor suppressor,PTEN(phosphatase and tensin homolog), is well studied in endometrial cancer, recent studies suggest thatDICER1, the endoribonuclease responsible for miRNA genesis, also plays a significant role in endometrial adenocarcinoma. Conditional uterine deletion ofDicer1andPtenin mice resulted in poorly differentiated endometrial adenocarcinomas, which expressed Napsin A and HNF1B (hepatocyte nuclear factor 1 homeobox B), markers of clear-cell adenocarcinoma. Adenocarcinomas were hormone-independent. Treatment with progesterone did not mitigate poorly differentiated adenocarcinoma, nor did it affect adnexal metastasis. Transcriptomic analyses ofDICER1deleted uteri or Ishikawa cells revealed unique transcriptomic profiles and global miRNA downregulation. Computational integration of miRNA with mRNA targets revealed deregulated let-7 and miR-16 target genes, similar to published humanDICER1-mutant endometrial cancers from TCGA (The Cancer Genome Atlas). Similar to human endometrial cancers, tumors exhibited dysregulation of ephrin-receptor signaling and transforming growth factor-beta signaling pathways. LIM kinase 2 (LIMK2), an essential molecule in p21 signal transduction, was significantly upregulated and represents a novel mechanism for hormone-independent pathogenesis of endometrial adenocarcinoma. This preclinical mouse model represents the first genetically engineered mouse model of poorly differentiated endometrial adenocarcinoma.	[Wang, Xiyin; Wendel, Jillian R. H.; Hawkins, Shannon M.] Indiana Univ Sch Med, Dept Obstet & Gynecol, Indianapolis, IN 46202 USA; [Emerson, Robert E.] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA; [Broaddus, Russell R.] Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Chapel Hill, NC 27515 USA; [Creighton, Chad J.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Rusch, Douglas B.; Buechlein, Aaron] Indiana Univ, Ctr Genom & Bioinformat, Bloomington, IN USA; [DeMayo, Francesco J.] Natl Inst Environm Hlth Sci, Res Triangle Pk, NC USA; [Lydon, John P.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Baylor College of Medicine; Indiana University System; Indiana University Bloomington; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Baylor College of Medicine	Hawkins, SM (corresponding author), Indiana Univ Sch Med, Dept Obstet & Gynecol, Indianapolis, IN 46202 USA.	shhawkin@iu.edu	; Hawkins, Shannon/B-7095-2015	Wang, Xiyin/0000-0002-3642-9373; Hawkins, Shannon/0000-0002-0727-3971	Indiana Clinical Translational Sciences Institute - National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award [UL1TR002529]; Uterine SPORE Career Development Award from MD Anderson Cancer Center [P50-CA098258]; Intramural Research Program of the National Institute of Environmental Health Sciences [Z1AES103311-01]	Indiana Clinical Translational Sciences Institute - National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award; Uterine SPORE Career Development Award from MD Anderson Cancer Center; Intramural Research Program of the National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We acknowledge the Indiana Center for Musculoskeletal Health Histology Core at Indiana University School of Medicine and the Human Tissue and Acquisition and Pathology Core at the Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine for histology services; the Center for Genomics and Bioinformatics for RNA sequencing, and the Center for Medical Genomics for RNA quality control analysis. We appreciate Dr. Ken Nephew for thoughtful review and comments. These studies were supported by the Indiana Clinical Translational Sciences Institute funded, in part, by Award Number UL1TR002529 from the National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. These studies were supported by a Uterine SPORE Career Development Award from MD Anderson Cancer Center P50-CA098258 (to SMH) and the Intramural Research Program of the National Institute of Environmental Health Sciences supported FJD: Project Z1AES103311-01.	Aghajanova L, 2009, ENDOCRINOLOGY, V150, P3863, DOI 10.1210/en.2009-0008; Al-Maghrabi JA, 2017, APPL IMMUNOHISTO M M, V25, P632, DOI 10.1097/PAI.0000000000000350; Dosil MA, 2017, J PATHOL, V242, P152, DOI 10.1002/path.4896; Anglesio MS, 2013, J PATHOL, V229, P400, DOI 10.1002/path.4135; Bailey MH, 2018, CELL, V174, P1034, DOI 10.1016/j.cell.2018.07.034; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bean GR, 2019, MODERN PATHOL, V32, P280, DOI 10.1038/s41379-018-0132-5; Bian Y, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010236; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen JM, 2015, J PATHOL, V237, P215, DOI 10.1002/path.4569; Chou CH, 2018, NUCLEIC ACIDS RES, V46, pD296, DOI 10.1093/nar/gkx1067; Clarke MA, 2019, J CLIN ONCOL, V37, P1895, DOI 10.1200/JCO.19.00151; Creasman WT, 2006, INT J GYNECOL OBSTET, V95, pS105, DOI 10.1016/S0020-7292(06)60031-3; Creighton CJ, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-4-r28; Creutzberg CL, 2000, LANCET, V355, P1404, DOI 10.1016/S0140-6736(00)02139-5; Daikoku T, 2008, CANCER RES, V68, P5619, DOI 10.1158/0008-5472.CAN-08-1274; de Kock L, 2020, MODERN PATHOL, V33, P1207, DOI 10.1038/s41379-019-0436-0; DeLair DF, 2017, J PATHOL, V243, P230, DOI 10.1002/path.4947; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gennarino VA, 2009, GENOME RES, V19, P481, DOI 10.1101/gr.084129.108; Gordon LB., 1993, GENEREVIEWS; Gurtan AM, 2012, RNA, V18, P1116, DOI 10.1261/rna.032680.112; Han GM, 2013, MODERN PATHOL, V26, P1594, DOI 10.1038/modpathol.2013.102; Hawkins SM, 2012, MOL ENDOCRINOL, V26, P1552, DOI 10.1210/me.2012-1042; Hawkins SM, 2011, MOL ENDOCRINOL, V25, P821, DOI 10.1210/me.2010-0371; Heravi-Moussavi A, 2012, NEW ENGL J MED, V366, P234, DOI 10.1056/NEJMoa1102903; Hoadley KA, 2018, CELL, V173, P291, DOI 10.1016/j.cell.2018.03.022; Hsu SD, 2011, NUCLEIC ACIDS RES, V39, pD163, DOI 10.1093/nar/gkq1107; Huang EY, 2015, FUTURE ONCOL, V11, P2351, DOI 10.2217/fon.15.101; Huang HY, 2020, NUCLEIC ACIDS RES, V48, pD148, DOI 10.1093/nar/gkz896; Hussain NK, 2015, P NATL ACAD SCI USA, V112, pE5883, DOI 10.1073/pnas.1518382112; Ihira K, 2017, ONCOTARGET, V8, P13509, DOI 10.18632/oncotarget.14586; Ikeda Y, 2015, BRIT J CANCER, V113, P1477, DOI 10.1038/bjc.2015.369; Jeong JW, 2005, ENDOCRINOLOGY, V146, P3490, DOI 10.1210/en.2005-0016; Ji H, 2011, PROTEOMICS, V11, P4029, DOI 10.1002/pmic.201100102; Kamat AA, 2009, CANCER-AM CANCER SOC, V115, P2684, DOI 10.1002/cncr.24335; Kim J, 2012, P NATL ACAD SCI USA, V109, P3921, DOI 10.1073/pnas.1117135109; Kriseman M, 2019, P NATL ACAD SCI USA, V116, P3873, DOI 10.1073/pnas.1806862116; Kumar MS, 2009, GENE DEV, V23, P2700, DOI 10.1101/gad.1848209; KURMAN RJ, 1982, CANCER, V49, P2547, DOI 10.1002/1097-0142(19820615)49:12<2547::AID-CNCR2820491224>3.0.CO;2-0; Le Gallo M, 2017, CANCER-AM CANCER SOC, V123, P3261, DOI 10.1002/cncr.30745; Lim D, 2015, AM J SURG PATHOL, V39, P1061, DOI 10.1097/PAS.0000000000000436; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Mashiach-Farkash E, 2012, ONCOTARGET, V3, P629; Merritt WM, 2010, CANCER BIOL THER, V10, P1306, DOI 10.4161/cbt.10.12.13582; Monsivais D, 2019, P NATL ACAD SCI USA, V116, P3883, DOI 10.1073/pnas.1806838116; MORROW CP, 1991, GYNECOL ONCOL, V40, P55, DOI 10.1016/0090-8258(91)90086-K; Munson PB, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48133-0; Murali R, 2019, INT J GYNECOL PATHOL, V38, pS40, DOI 10.1097/PGP.0000000000000491; Nikhil K, 2019, CANCER LETT, V448, P182, DOI 10.1016/j.canlet.2019.01.035; Pandita P, 2019, CANCERS, V11, DOI 10.3390/cancers11111665; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Schultz KAP, 2017, CLIN CANCER RES, V23, pE76, DOI 10.1158/1078-0432.CCR-17-0629; Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI [10.3322/caac.21601, 10.3322/caac.21590]; Soslow RA, 2019, INT J GYNECOL PATHOL, V38, pS64, DOI 10.1097/PGP.0000000000000518; Soyal SM, 2005, GENESIS, V41, P58, DOI 10.1002/gene.20098; Tashiro H, 1997, CANCER RES, V57, P3935; Torres A, 2011, TUMOR BIOL, V32, P769, DOI 10.1007/s13277-011-0179-0; Ullman-Cullere MH, 1999, LAB ANIM SCI, V49, P319; van der Horst PH, 2014, INT J CANCER, V135, P1028, DOI 10.1002/ijc.28746; Vedanayagam J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11610-1; Versluis MA, 2015, BRIT J CANCER, V113, P786, DOI 10.1038/bjc.2015.268; Vogel TJ, 2015, J GYNECOL ONCOL, V26, P25, DOI 10.3802/jgo.2015.26.1.25; Wang J, 2017, NUCLEIC ACIDS RES, V45, pW130, DOI 10.1093/nar/gkx356; Wang XJ, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317695967; Wang XY, 2017, GYNECOL ONCOL, V147, P481, DOI 10.1016/j.ygyno.2017.08.027; Wang XY, 2016, BIOL REPROD, V94, DOI 10.1095/biolreprod.115.133637; Wang YM, 2015, NEOPLASIA, V17, P650, DOI 10.1016/j.neo.2015.08.003; Wang YM, 2010, TECHNOL CANCER RES T, V9, P179, DOI 10.1177/153303461000900207; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333; Zhang B, 2014, ONCOGENE, V33, P3099, DOI 10.1038/onc.2013.281; Zighelboim I, 2011, CANCER-AM CANCER SOC, V117, P1446, DOI 10.1002/cncr.25665; Zorn KK, 2005, CLIN CANCER RES, V11, P6422, DOI 10.1158/1078-0432.CCR-05-0508	75	5	5	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2020	39	40					6286	6299		10.1038/s41388-020-01434-5	http://dx.doi.org/10.1038/s41388-020-01434-5		AUG 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NV5JK	32843721	Green Accepted, Green Submitted			2022-12-28	WOS:000562669100002
J	Nair, J; Huang, TT; Murai, J; Haynes, B; Steeg, PS; Pommier, Y; Lee, JM				Nair, Jayakumar; Huang, Tzu-Ting; Murai, Junko; Haynes, Brittany; Steeg, Patricia S.; Pommier, Yves; Lee, Jung-Min			Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer	ONCOGENE			English	Article							CHECKPOINT KINASE 1; CYCLIN B1; DNA-DAMAGE; PHOSPHORYLATION; REPLICATION; GEMCITABINE; ACTIVATION; PATHWAYS; PROTEINS; CELLS	High grade serous ovarian cancer (HGSOC) is a fatal gynecologic malignancy in the U.S. with limited treatment options. New therapeutic strategies include targeting of the cell cycle checkpoints, e.g., ATR and CHK1. We recently reported a promising clinical activity of the CHK1 inhibitor (CHK1i) prexasertib monotherapy inBRCAwild-type (BRCAwt) HGSOC patients. In this study, biopsies of treated patients and cell line models were used to investigate possible mechanisms of resistance to CHK1i. We report that BRCAwt HGSOC develops resistance to prexasertib monotherapy via a prolonged G2 delay induced by lower CDK1/CyclinB1 activity, thus preventing cells from mitotic catastrophe and cell death. On the other hand, we noted CHK1's regulation on RAD51-mediated homologous recombination (HR) repair was not altered in CHK1i-resistant cells. Therefore, CHK1i sensitizes CHK1i-resistant cells to DNA damaging agents such as gemcitabine or hydroxyurea by inhibition of HR. In summary, our results demonstrate new mechanistic insights of functionally distinct CHK1 activities and highlight a potential combination treatment approach to overcome CHK1i resistance in BRCAwt HGSOC.	[Nair, Jayakumar; Huang, Tzu-Ting; Haynes, Brittany; Steeg, Patricia S.; Lee, Jung-Min] NIH, Womens Malignancies Branch, Bldg 10, Bethesda, MD 20892 USA; [Murai, Junko; Pommier, Yves] NCI, Dev Therapeut Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Murai, Junko; Pommier, Yves] NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Nair, J (corresponding author), NIH, Womens Malignancies Branch, Bldg 10, Bethesda, MD 20892 USA.	jayakumar.nair@nih.gov	Murai, Junko/AAU-9516-2021	Nair, Jayakumar/0000-0002-4478-4607	Intramural Research Program of NCI, CCR [ZIA BC011525, Z01 BC01006150]	Intramural Research Program of NCI, CCR	We thank Dr. Chen X, Mrs. Bao T, and Mrs. Shetty J at the Sequencing Facility, National Cancer Institute (NCI) at Frederick; Dr. Cam M, Lack J, and Abdalla A, at the Center for Cancer Research (CCR) Collaborative Bioinformatics Resource, NCI for their expertise in generating the RNA-seq datasets and help with data analysis. This research was supported by the Intramural Research Program of NCI, CCR (JML, #ZIA BC011525 and JM, YP Z01 BC01006150).	Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Barnard D, 2016, INVEST NEW DRUG, V34, P49, DOI 10.1007/s10637-015-0310-y; Belanger F, 2018, CANCER RES, V78, P5561, DOI 10.1158/0008-5472.CAN-18-0618; Biswas K, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03020-6; Booth L, 2013, CANCER BIOL THER, V14, P458, DOI 10.4161/cbt.24424; Brill E, 2017, ONCOTARGET, V8, P111026, DOI 10.18632/oncotarget.22195; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; DARZYNKIEWICZ Z, 2001, CURRENT PROTOCOLS CY, V7, P7; Edelman MJ, 2007, CLIN CANCER RES, V13, P2667, DOI 10.1158/1078-0432.CCR-06-1832; Gatei M, 2003, J BIOL CHEM, V278, P14806, DOI 10.1074/jbc.M210862200; Gomez LA, 2007, MOL CANCER THER, V6, P1534, DOI 10.1158/1535-7163.MCT-06-0727; Hagting A, 1999, CURR BIOL, V9, P680, DOI 10.1016/S0960-9822(99)80308-X; Haynes B, 2018, CANCER TREAT REV, V71, P1, DOI 10.1016/j.ctrv.2018.09.003; Kao GD, 1997, CANCER RES, V57, P753; Kim H, 2017, CLIN CANCER RES, V23, P3097, DOI 10.1158/1078-0432.CCR-16-2273; King C, 2015, MOL CANCER THER, V14, P2004, DOI 10.1158/1535-7163.MCT-14-1037; Kurman RJ, 2008, INT J GYNECOL PATHOL, V27, P151, DOI 10.1097/PGP.0b013e318161e4f5; Lee JM, 2014, ANN ONCOL, V25, P32, DOI 10.1093/annonc/mdt384; Lee JM, 2018, LANCET ONCOL, V19, P207, DOI 10.1016/S1470-2045(18)30009-3; Lowery CD, 2019, CLIN CANCER RES, V25, P2278, DOI 10.1158/1078-0432.CCR-18-2728; Ma CX, 2011, TRENDS MOL MED, V17, P88, DOI 10.1016/j.molmed.2010.10.009; MCKENNA WG, 1991, RADIAT RES, V125, P283, DOI 10.2307/3578111; Mimitou EP, 2009, DNA REPAIR, V8, P983, DOI 10.1016/j.dnarep.2009.04.017; Montano R, 2012, MOL CANCER THER, V11, P427, DOI 10.1158/1535-7163.MCT-11-0406; Murai J, 2018, MOL CELL, V69, P371, DOI 10.1016/j.molcel.2018.01.012; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Parsels LA, 2009, MOL CANCER THER, V8, P45, DOI 10.1158/1535-7163.MCT-08-0662; Patch AM, 2015, NATURE, V521, P489, DOI 10.1038/nature14410; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; ROEHM NW, 1991, J IMMUNOL METHODS, V142, P257, DOI 10.1016/0022-1759(91)90114-U; Ruff P, 2016, CELL REP, V17, P3359, DOI 10.1016/j.celrep.2016.12.003; Ruiz S, 2016, MOL CELL, V62, P307, DOI 10.1016/j.molcel.2016.03.006; Sabbaghi MA, 2017, CLIN CANCER RES, V23, P7006, DOI 10.1158/1078-0432.CCR-17-0696; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Smith J, 2010, ADV CANCER RES, V108, P73, DOI [10.1016/B978-0-12-380888-2.00003-0, 10.1016/S0065.230X(10)08002.4]; Sorensen CS, 2005, NAT CELL BIOL, V7, P195, DOI 10.1038/ncb1212; Syljuasen RG, 2005, MOL CELL BIOL, V25, P3553, DOI 10.1128/MCB.25.9.3553-3562.2005; Van Horn RD, 2010, J BIOL CHEM, V285, P21849, DOI 10.1074/jbc.M110.141010; Wang Y, 2000, GENE DEV, V14, P927; Young LA, 2019, CANCER RES, V79, P3762, DOI 10.1158/0008-5472.CAN-18-2480; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	41	15	16	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2020	39	33					5520	5535		10.1038/s41388-020-1383-4	http://dx.doi.org/10.1038/s41388-020-1383-4		JUL 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NB0QV	32647134	Green Published, hybrid			2022-12-28	WOS:000546858900001
J	Boedicker, C; Hussong, M; Grimm, C; Dolgikh, N; Meister, MT; Enssle, JC; Wanior, M; Knapp, S; Schweiger, MR; Fulda, S				Boedicker, Cathinka; Hussong, Michelle; Grimm, Christina; Dolgikh, Nadezda; Meister, Michael T.; Enssle, Julius C.; Wanior, Marek; Knapp, Stefan; Schweiger, Michal R.; Fulda, Simone			Co-inhibition of BET proteins and PI3K alpha triggers mitochondrial apoptosis in rhabdomyosarcoma cells	ONCOGENE			English	Article							HEMATOLOGICAL MALIGNANCIES; BROMODOMAIN INHIBITORS; SYNTHETIC LETHALITY; GENE-EXPRESSION; IDENTIFICATION; HEDGEHOG; PATHWAY; RESISTANCE; KINASE; ACTIVATION	Remodeling transcription by targeting bromodomain and extraterminal (BET) proteins has emerged as promising anticancer strategy. Here, we identify a novel synergistic interaction of the BET inhibitor JQ1 with the PI3K alpha-specific inhibitor BYL719 to trigger mitochondrial apoptosis and to suppress tumor growth in models of rhabdomyosarcoma (RMS). RNA-Seq revealed that JQ1/BYL719 co-treatment shifts the overall balance of BCL-2 family gene expression towards apoptosis and upregulates expression of BMF, BCL2L11 (BIM), and PMAIP1 (NOXA) while downregulating BCL2L1 (BCL-x(L)). These changes were confirmed by qRT-PCR and western blot analysis. Ingenuity pathway analysis (IPA) of RNA-Seq data followed by validation qRT-PCR and western blot identified MYC and FOXO3a as potential transcription factors (TFs) upstream of the observed gene expression pattern. Immunoprecipitation (IP) studies showed that JQ1/BYL719-stimulated increase in BIM expression enhances the neutralization of antiapoptotic BCL-2, BCL-x(L), and MCL-1. This promotes the activation of BAK and BAX and caspase-dependent apoptosis, as (1) individual silencing of BMF, BIM, NOXA, BAK, or BAX, (2) overexpression of BCL-2 or MCL-1 or (3) the caspase inhibitor N-Benzyloxycarbonyl-Val-Ala-Asp(O-Me) fluoromethylketone (zVAD.fmk) all rescue JQ1/BYL719-induced cell death. In conclusion, co-inhibition of BET proteins and PI3K alpha cooperatively induces mitochondrial apoptosis by proapoptotic re-balancing of BCL-2 family proteins. This discovery opens exciting perspectives for therapeutic exploitation of BET inhibitors in RMS.	[Boedicker, Cathinka; Dolgikh, Nadezda; Meister, Michael T.; Enssle, Julius C.; Fulda, Simone] Goethe Univ, Inst Expt Canc Res Pediat, Frankfurt, Germany; [Boedicker, Cathinka; Meister, Michael T.; Knapp, Stefan; Fulda, Simone] German Canc Consortium DKTK, Partner Site, Frankfurt, Germany; [Boedicker, Cathinka; Meister, Michael T.; Fulda, Simone] German Canc Res Ctr, Heidelberg, Germany; [Hussong, Michelle; Grimm, Christina; Schweiger, Michal R.] Univ Hosp Cologne, Lab Epigen & Tumor genet, Cologne, Germany; [Hussong, Michelle; Schweiger, Michal R.] Univ Cologne, Ctr Mol Med Cologne, Cologne, Germany; [Meister, Michael T.] Univ Hosp Frankfurt, Dept Pediat Hematol & Oncol, Frankfurt, Germany; [Wanior, Marek; Knapp, Stefan] Inst Pharmaceut Chem, Frankfurt, Germany; [Wanior, Marek; Knapp, Stefan] BMLS SGC, Frankfurt, Germany	Goethe University Frankfurt; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); University of Cologne; University of Cologne; Goethe University Frankfurt; Goethe University Frankfurt Hospital	Fulda, S (corresponding author), Goethe Univ, Inst Expt Canc Res Pediat, Frankfurt, Germany.; Fulda, S (corresponding author), German Canc Consortium DKTK, Partner Site, Frankfurt, Germany.; Fulda, S (corresponding author), German Canc Res Ctr, Heidelberg, Germany.	simone.fulda@kgu.de	Grimm, Christina/Z-6172-2019; Knapp, Stefan/AAG-2347-2019; Meister, Michael Torsten/AAV-2291-2021; Dolgikh, Nadezda/AAE-2893-2022	Grimm, Christina/0000-0002-4676-8870; Knapp, Stefan/0000-0001-5995-6494; Dolgikh, Nadezda/0000-0001-6186-007X; Meister, Michael Torsten/0000-0001-8311-721X; Fulda, Simone/0000-0002-0459-6417				Adams JM, 2007, CURR OPIN IMMUNOL, V19, P488, DOI 10.1016/j.coi.2007.05.004; Bid HK, 2016, MOL CANCER THER, V15, P1018, DOI 10.1158/1535-7163.MCT-15-0567; Chou TC, 1991, SYNERGISM ANTAGONISM, P61; Ciceri P, 2014, NAT CHEM BIOL, V10, P305, DOI 10.1038/nchembio.1471; Costa C, 2015, CANCER CELL, V27, P97, DOI 10.1016/j.ccell.2014.11.007; Czymai T, 2010, J BIOL CHEM, V285, P10163, DOI 10.1074/jbc.M109.056663; Da Costa D, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.24; Dagher R, 1999, Oncologist, V4, P34; Dantonello TM, 2013, PEDIATR BLOOD CANCER, V60, P224, DOI 10.1002/pbc.24174; Dittmann A, 2014, ACS CHEM BIOL, V9, P495, DOI 10.1021/cb400789e; Eijkelenboom A, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2012.74; Filippakopoulos P, 2014, NAT REV DRUG DISCOV, V13, P339, DOI 10.1038/nrd4286; Fiskus W, 2014, MOL CANCER THER, V13, P2315, DOI 10.1158/1535-7163.MCT-14-0258; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 2010, NAT REV DRUG DISCOV, V9, P447, DOI 10.1038/nrd3137; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Graab U, 2015, ONCOTARGET, V6, P8722, DOI 10.18632/oncotarget.2726; Gryder BE, 2017, CANCER DISCOV, V7, P884, DOI 10.1158/2159-8290.CD-16-1297; Haydn T, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.239; Hayes-Jordan A, 2009, CURR OPIN PEDIATR, V21, P373, DOI 10.1097/MOP.0b013e32832b4171; Heinicke U, 2015, ONCOTARGET, V6, P37836, DOI 10.18632/oncotarget.6097; Heinicke U, 2014, CANCER LETT, V351, P50, DOI 10.1016/j.canlet.2014.04.021; Hensel T, 2016, ONCOTARGET, V7, P1451, DOI 10.18632/oncotarget.6385; Hornsveld M, 2016, CELL DEATH DIFFER, V23, P1483, DOI 10.1038/cdd.2016.33; Hugle M, 2015, CELL DEATH DIFFER, V22, P1946, DOI 10.1038/cdd.2015.59; Ianevski A, 2017, BIOINFORMATICS, V33, P2413, DOI 10.1093/bioinformatics/btx162; Kuang WH, 2018, KAOHSIUNG J MED SCI, V34, P370, DOI 10.1016/j.kjms.2018.02.004; Lee DH, 2015, INT J CANCER, V136, P2055, DOI 10.1002/ijc.29269; Li GQ, 2016, ONCOTARGET, V7, P2462, DOI 10.18632/oncotarget.6275; Loven J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036; Ma YF, 2017, CLIN CANCER RES, V23, P2027, DOI 10.1158/1078-0432.CCR-16-0453; Mujtaba S, 2007, ONCOGENE, V26, P5521, DOI 10.1038/sj.onc.1210618; Packer LM, 2017, MOL CANCER THER, V16, P637, DOI 10.1158/1535-7163.MCT-16-0415; Satheesha S, 2016, ONCOGENE, V35, P2020, DOI 10.1038/onc.2015.267; Schaffer M, 2018, LEUKEMIA LYMPHOMA, V59, P931, DOI 10.1080/10428194.2017.1349899; Seal J, 2012, BIOORG MED CHEM LETT, V22, P2968, DOI 10.1016/j.bmcl.2012.02.041; Stratikopoulos EE, 2015, CANCER CELL, V27, P837, DOI 10.1016/j.ccell.2015.05.006; Tang YJ, 2014, NAT MED, V20, P732, DOI 10.1038/nm.3613; Tinsley S, 2015, BRIT J HAEMATOL, V170, P275, DOI 10.1111/bjh.13283; Toren P, 2015, EUR UROL, V67, P986, DOI 10.1016/j.eururo.2014.08.006; Wu SY, 2007, J BIOL CHEM, V282, P13141, DOI 10.1074/jbc.R700001200; Yohe ME, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan4470; Zibat A, 2010, ONCOGENE, V29, P6323, DOI 10.1038/onc.2010.368; Zuber V, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3620-y	45	7	7	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	19					3837	3852		10.1038/s41388-020-1229-0	http://dx.doi.org/10.1038/s41388-020-1229-0			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LK4OF	32161312				2022-12-28	WOS:000530841700004
J	Huang, M; Feng, X; Su, D; Wang, G; Wang, C; Tang, MF; Paulucci-Holthauzen, A; Hart, T; Chen, JJ				Huang, Min; Feng, Xu; Su, Dan; Wang, Gang; Wang, Chao; Tang, Mengfan; Paulucci-Holthauzen, Adriana; Hart, Traver; Chen, Junjie			Genome-wide CRISPR screen uncovers a synergistic effect of combining Haspin and Aurora kinase B inhibition	ONCOGENE			English	Article							SMALL-MOLECULE INHIBITOR; PHOSPHORYLATED HISTONE H3; THR-3 PHOSPHORYLATION; STRUCTURAL BASIS; FEEDBACK LOOP; OVEREXPRESSION; RECOGNITION; CARCINOMA; MLN8054; POTENT	Aurora kinases are a family of serine/threonine kinases vital for cell division. Because of the overexpression of Aurora kinases in a broad range of cancers and their important roles in mitosis, inhibitors targeting Aurora kinases have attracted attention in cancer therapy. VX-680 is an effective pan-Aurora kinase inhibitor; however, its clinical efficacy was not satisfying. In this study, we performed CRISPR/Cas9 screens to identify genes whose depletion shows synthetic lethality with VX-680. The top hit from these screens was GSG2 (also known as Haspin), a serine/threonine kinase that phosphorylates histone H3 at Thr-3 during mitosis. Moreover, both Haspin knockout and Haspin inhibitor-treated HCT116 cells were hypersensitive to VX-680. Furthermore, we showed that the synthetic lethal interaction between Haspin depletion and VX-680 was mediated by the inhibition of Haspin with Aurora kinase B (AURKB), but not with Aurora kinase A (AURKA). Strikingly, combined inhibition of Haspin and AURKB had a better efficacy than single-agent treatment in both head and neck squamous cell carcinoma and non-small cell lung cancer. Taken together, our findings have uncovered a synthetic lethal interaction between AURKB and Haspin, which provides a strong rationale for this combination therapy for cancer patients.	[Huang, Min; Feng, Xu; Su, Dan; Wang, Chao; Tang, Mengfan; Chen, Junjie] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; [Wang, Gang; Hart, Traver] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Paulucci-Holthauzen, Adriana] Univ Texas MD Anderson Canc Ctr, Dept Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Chen, JJ (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA.	jchen8@mdanderson.org		Wang, Andy/0000-0001-6798-1032; Feng, Xu/0000-0003-1603-7070	NCI NIH HHS [P30 CA016672, R01 CA210929] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amoussou NG, 2018, DRUG DISCOV TODAY, V23, P409, DOI 10.1016/j.drudis.2017.10.005; Araki K, 2004, J NEURO-ONCOL, V67, P53, DOI 10.1023/B:NEON.0000021784.33421.05; Balzano D, 2011, CHEM BIOL, V18, P966, DOI 10.1016/j.chembiol.2011.04.013; Bavetsias V, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00278; Bebbington D, 2009, BIOORG MED CHEM LETT, V19, P3586, DOI 10.1016/j.bmcl.2009.04.136; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Borisa AC, 2017, EUR J MED CHEM, V140, P1, DOI 10.1016/j.ejmech.2017.08.045; Boss DS, 2009, ONCOLOGIST, V14, P780, DOI 10.1634/theoncologist.2009-0019; Burdova K, 2019, EMBO J, V38, DOI 10.15252/embj.2018101443; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Chieffi P, 2004, J ENDOCRINOL, V181, P263, DOI 10.1677/joe.0.1810263; Dai J, 2005, GENE DEV, V19, P472, DOI 10.1101/gad.1267105; dos Santos EO, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0494-6; Du JM, 2012, STRUCTURE, V20, P185, DOI 10.1016/j.str.2011.12.001; Eswaran J, 2009, P NATL ACAD SCI USA, V106, P20198, DOI 10.1073/pnas.0901989106; Fu JY, 2007, MOL CANCER RES, V5, P1, DOI 10.1158/1541-7786.MCR-06-0208; Ghenoiu C, 2013, MOL CELL, V52, P734, DOI 10.1016/j.molcel.2013.10.002; Gritsko TM, 2003, CLIN CANCER RES, V9, P1420; Harrington EA, 2004, NAT MED, V10, P262, DOI 10.1038/nm1003; Hart T, 2015, CELL, V163, DOI 10.1016/j.cell.2015.11.015; Helfrich BA, 2016, MOL CANCER THER, V15, P2314, DOI 10.1158/1535-7163.MCT-16-0298; Herbst RS, 2018, NATURE, V553, P446, DOI 10.1038/nature25183; Hoar K, 2007, MOL CELL BIOL, V27, P4513, DOI 10.1128/MCB.02364-06; Jeyaprakash AA, 2011, STRUCTURE, V19, P1625, DOI 10.1016/j.str.2011.09.002; Katayama H, 2010, BBA-GENE REGUL MECH, V1799, P829, DOI 10.1016/j.bbagrm.2010.09.004; Kelly AE, 2010, SCIENCE, V330, P235, DOI 10.1126/science.1189505; Kestav K, 2017, CURR MED CHEM, V24, P2276, DOI 10.2174/0929867324666170414155520; Li Y, 2010, AM J TRANSL RES, V2, P296; Manfredi MG, 2007, P NATL ACAD SCI USA, V104, P4106, DOI 10.1073/pnas.0608798104; Marur S, 2016, MAYO CLIN PROC, V91, P386, DOI 10.1016/j.mayocp.2015.12.017; Mehra R, 2013, LANCET ONCOL, V14, pE425, DOI 10.1016/S1470-2045(13)70128-1; Niedzialkowska E, 2012, MOL BIOL CELL, V23, P1457, DOI 10.1091/mbc.E11-11-0904; Potting C, 2018, P NATL ACAD SCI USA, V115, pE180, DOI 10.1073/pnas.1711023115; Reichardt W, 2003, ONCOL REP, V10, P1275; Sells TB, 2015, ACS MED CHEM LETT, V6, P630, DOI 10.1021/ml500409n; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Shimada M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12059; Sorrentino R, 2005, J CLIN ENDOCR METAB, V90, P928, DOI 10.1210/jc.2004-1518; Takeshita M, 2013, LUNG CANCER, V80, P85, DOI 10.1016/j.lungcan.2012.12.018; Tanaka T, 1999, CANCER RES, V59, P2041; Tang AQ, 2017, ONCOTARGET, V8, P23937, DOI 10.18632/oncotarget.14893; Wang C, 2019, ONCOGENE, V38, P2451, DOI 10.1038/s41388-018-0606-4; Wang FW, 2012, J CELL BIOL, V199, P251, DOI 10.1083/jcb.201205106; Wang FW, 2011, CURR BIOL, V21, P1061, DOI 10.1016/j.cub.2011.05.016; Wang FW, 2010, SCIENCE, V330, P231, DOI 10.1126/science.1189435; Willems E, 2018, CELL DIV, V13, DOI 10.1186/s13008-018-0040-6; Yamagishi Y, 2010, SCIENCE, V330, P239, DOI 10.1126/science.1194498; Yu FZ, 2017, CELL DISCOV, V3, DOI 10.1038/celldisc.2016.49; Zappa C, 2016, TRANSL LUNG CANCER R, V5, P288, DOI 10.21037/tlcr.2016.06.07; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496; Zhou LL, 2014, EMBO REP, V15, P273, DOI 10.1002/embr.201338080	51	9	9	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	21					4312	4322		10.1038/s41388-020-1296-2	http://dx.doi.org/10.1038/s41388-020-1296-2			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LQ2DH	32300176	Green Accepted			2022-12-28	WOS:000534819000012
J	Rajan, SS; Amin, AD; Li, LX; Rolland, DC; Li, HQ; Kwon, D; Kweh, MF; Arumov, A; Roberts, ER; Yan, AM; Basrur, V; Elenitoba-Johnson, KSJ; Chen, XS; Puvvada, SD; Lussier, YA; Bilbao, D; Lim, MS; Schatz, JH				Rajan, Soumya S.; Amin, Amit Dipak; Li, Lingxiao; Rolland, Delphine C.; Li, Haiquan; Kwon, Deukwoo; Kweh, Mercedes F.; Arumov, Artavazd; Roberts, Evan R.; Yan, Aimin; Basrur, Venkatesha; Elenitoba-Johnson, Kojo S. J.; Chen, Xi Steven; Puvvada, Soham D.; Lussier, Yves A.; Bilbao, Daniel; Lim, Megan S.; Schatz, Jonathan H.			The mechanism of cancer drug addiction in ALK-positive T-Cell lymphoma	ONCOGENE			English	Article							NPM-ALK; ANAPLASTIC LYMPHOMA; TYROSINE PHOSPHORYLATION; KINASE INHIBITORS; APOPTOSIS; TUMOR; GENE; RESISTANCE; REVEALS; TARGET	Rational new strategies are needed to treat tumors resistant to kinase inhibitors. Mechanistic studies of resistance provide fertile ground for development of new approaches. Cancer drug addiction is a paradoxical resistance phenomenon, well-described in MEK-ERK-driven solid tumors, in which drug-target overexpression promotes resistance but a toxic overdose of signaling if the inhibitor is withdrawn. This can permit prolonged control of tumors through intermittent dosing. We and others showed previously that cancer drug addiction arises also in the hematologic malignancy ALK-positive anaplastic large-cell lymphoma (ALCL) resistant to ALK-specific tyrosine kinase inhibitors (TKIs). This is driven by the overexpression of the fusion kinase NPM1-ALK, but the mechanism by which ALK overactivity drives toxicity upon TKI withdrawal remained obscure. Here we reveal the mechanism of ALK-TKI addiction in ALCL. We interrogated the well-described mechanism of MEK/ERK pathway inhibitor addiction in solid tumors and found it does not apply to ALCL. Instead, phosphoproteomics and confirmatory functional studies revealed that the STAT1 overactivation is the key mechanism of ALK-TKI addiction in ALCL. The withdrawal of TKI from addicted tumors in vitro and in vivo leads to overwhelming phospho-STAT1 activation, turning on its tumor-suppressive gene-expression program and turning off STAT3's oncogenic program. Moreover, a novel NPM1-ALK-positive ALCL PDX model showed a significant survival benefit from intermittent compared with continuous TKI dosing. In sum, we reveal for the first time the mechanism of cancer drug addiction in ALK-positive ALCL and the benefit of scheduled intermittent dosing in high-risk patient-derived tumors in vivo.	[Rajan, Soumya S.; Arumov, Artavazd] Univ Miami, Miller Sch Med, Sheila & David Fuente Grad Program Canc Biol, Miami, FL 33136 USA; [Rajan, Soumya S.; Amin, Amit Dipak; Li, Lingxiao; Kwon, Deukwoo; Kweh, Mercedes F.; Arumov, Artavazd; Roberts, Evan R.; Yan, Aimin; Chen, Xi Steven; Bilbao, Daniel; Schatz, Jonathan H.] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA; [Amin, Amit Dipak; Li, Lingxiao; Kweh, Mercedes F.; Schatz, Jonathan H.] Univ Miami, Miller Sch Med, Dept Med, Div Hematol, Miami, FL 33136 USA; [Rolland, Delphine C.; Elenitoba-Johnson, Kojo S. J.; Lim, Megan S.] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA USA; [Li, Haiquan] Univ Arizona, Dept Biosyst Engn, Tucson, AZ USA; [Kwon, Deukwoo; Chen, Xi Steven] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA; [Basrur, Venkatesha] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Puvvada, Soham D.; Lussier, Yves A.] UA Canc Ctr, Bio5 Inst, Dept Med, Ann Arbor, MI USA; [Lussier, Yves A.] Univ Arizona, Interdisciplinary Program Stat, Tucson, AZ USA	University of Miami; University of Miami; University of Miami; University of Pennsylvania; Pennsylvania Medicine; University of Arizona; University of Miami; University of Michigan System; University of Michigan; University of Arizona	Schatz, JH (corresponding author), Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA.; Schatz, JH (corresponding author), Univ Miami, Miller Sch Med, Dept Med, Div Hematol, Miami, FL 33136 USA.	jschatz@med.maimi.edu	Sundara Rajan, Soumya/GYJ-3752-2022; Rolland, Delphine/ABG-2497-2021	Amin, Amit Dipak/0000-0002-2613-2082; Li, Haiquan/0000-0002-8049-0278; Elenitoba-Johnson, Kojo/0000-0002-1082-1545; Arumov, Artavazd/0000-0002-9520-2777; Rolland, Delphine/0000-0002-7801-6534; Bilbao Cortes, Daniel/0000-0003-1630-8811; Lim, Megan/0000-0002-0415-2867; Schatz, Jonathan/0000-0003-1842-228X; Sundara Rajan, Soumya/0000-0001-8346-9741	National Institutes of Health/National Cancer Institute [1R01CA190696-01, 5R01CA190696-05]	National Institutes of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a grant from National Institutes of Health/National Cancer Institute, 1R01CA190696-01 (JHS) and 5R01CA190696-05. We would also like to acknowledge the Sheila and David Fuente Graduate Program in Cancer Biology at University of Miami. SSR is a PhD candidate at University of Miami. This work is submitted in partial fulfillment of the requirement of the PhD. We would also like to thank Dr Izidore Lossos, University of Miami, for his input and suggestions in writing the manuscript.	Adam P, 2003, AM J SURG PATHOL, V27, P1473, DOI 10.1097/00000478-200311000-00012; Amin AD, 2015, CANCER RES, V75, P2916, DOI 10.1158/0008-5472.CAN-14-3437; Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Beebe JD, 2018, PHARMACOL THERAPEUT, V191, P74, DOI 10.1016/j.pharmthera.2018.06.006; Bonvini P, 2004, CANCER RES, V64, P3256, DOI 10.1158/0008-5472.CAN-03-3531; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; BRUNET A, 1994, ONCOGENE, V9, P3379; Carpenter RL, 2014, CANCERS, V6, P897, DOI 10.3390/cancers6020897; Ceccon M, 2016, ONCOGENE, V35, P3854, DOI 10.1038/onc.2015.456; Chiarle R, 2005, NAT MED, V11, P623, DOI 10.1038/nm1249; Crockett DK, 2004, ONCOGENE, V23, P2617, DOI 10.1038/sj.onc.1207398; Croucher DR, 2013, CANCER RES, V73, P1969, DOI 10.1158/0008-5472.CAN-12-1472; Cui YX, 2009, BLOOD, V113, P5217, DOI 10.1182/blood-2008-06-160168; Das Thakur M, 2013, NATURE, V494, P251, DOI 10.1038/nature11814; Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053; Ferguson FM, 2018, NAT REV DRUG DISCOV, V17, P353, DOI 10.1038/nrd.2018.21; Gainor JF, 2016, CANCER DISCOV, V6, P1118, DOI 10.1158/2159-8290.CD-16-0596; Gambacorti-Passerini C, 2011, NEW ENGL J MED, V364, P775, DOI 10.1056/NEJMc1013224; Gardeux V, 2014, J AM MED INFORM ASSN, V21, P1015, DOI 10.1136/amiajnl-2013-002519; Haan S, 2005, CELL SIGNAL, V17, P1542, DOI 10.1016/j.cellsig.2005.03.010; Hong A, 2018, CANCER DISCOV, V8, P74, DOI 10.1158/2159-8290.CD-17-0682; Houghton PJ, 2014, PEDIATR BLOOD CANCER, V61, P1972, DOI 10.1002/pbc.25175; Johnson TW, 2014, J MED CHEM, V57, P4720, DOI 10.1021/jm500261q; Kameda H, 2009, BIOCHEM BIOPH RES CO, V378, P744, DOI 10.1016/j.bbrc.2008.11.102; Kodama T, 2014, CANCER LETT, V351, P215, DOI 10.1016/j.canlet.2014.05.020; Kong XJ, 2017, NATURE, V550, P270, DOI 10.1038/nature24037; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Lim MS, 2009, BLOOD, V114, P1585, DOI 10.1182/blood-2009-02-204735; Marzec M, 2007, ONCOGENE, V26, P813, DOI 10.1038/sj.onc.1209843; McDonnell SRP, 2012, ONCOGENE, V31, P3733, DOI 10.1038/onc.2011.542; McDonnell SRP, 2013, BLOOD, V122, P958, DOI 10.1182/blood-2013-01-482026; Moriceau G, 2015, CANCER CELL, V27, P240, DOI 10.1016/j.ccell.2014.11.018; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Mosse YP, 2017, J CLIN ONCOL, V35, P3215, DOI 10.1200/JCO.2017.73.4830; Onciu M, 2003, BLOOD, V102, P2642, DOI 10.1182/blood-2003-04-1095; Passerini CG, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt378; Pearson Joel D, 2012, J Signal Transduct, V2012, P123253, DOI 10.1155/2012/123253; Pensa S, 2013, MADAME CURIE BIOSCIE; Piva R, 2010, J CLIN ONCOL, V28, P1583, DOI 10.1200/JCO.2008.20.9759; Prutsch N, 2019, LEUKEMIA, V33, P696, DOI 10.1038/s41375-018-0239-1; Redaelli S, 2018, CANCER RES, V78, P6866, DOI 10.1158/0008-5472.CAN-18-1867; Rickert KW, 2011, J BIOL CHEM, V286, P11218, DOI 10.1074/jbc.M110.204404; Satoh JI, 2013, GENE REGUL SYST BIO, V7, P41, DOI 10.4137/GRSB.S11433; Sattu K, 2013, FEBS J, V280, P5269, DOI 10.1111/febs.12453; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; Sironi JJ, 2004, J BIOL CHEM, V279, P4066, DOI 10.1074/jbc.M307774200; Suda K, 2012, LUNG CANCER, V76, P292, DOI 10.1016/j.lungcan.2011.11.007; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Wu CS, 2015, BLOOD, V126, P336, DOI 10.1182/blood-2014-10-603738; Xiao Y, 2015, J IMMUNOL, V195, P4218, DOI 10.4049/jimmunol.1501200; Yokoyama K, 2011, EMBO J, V30, P4739, DOI 10.1038/emboj.2011.348	55	4	4	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	10					2103	2117		10.1038/s41388-019-1136-4	http://dx.doi.org/10.1038/s41388-019-1136-4			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KS8UR	31804622	Green Accepted			2022-12-28	WOS:000518584000006
J	Zhou, QQ; Huang, TT; Jiang, ZY; Ge, C; Chen, XX; Zhang, LL; Zhao, FY; Zhu, MX; Chen, TY; Cui, Y; Li, H; Yao, M; Li, JJ; Tian, H				Zhou, Qingqing; Huang, Tingting; Jiang, Zhiyuan; Ge, Chao; Chen, Xiaoxia; Zhang, Lili; Zhao, Fangyu; Zhu, Miaoxin; Chen, Taoyang; Cui, Ying; Li, Hong; Yao, Ming; Li, Jinjun; Tian, Hua			Upregulation of SNX5 predicts poor prognosis and promotes hepatocellular carcinoma progression by modulating the EGFR-ERK1/2 signaling pathway	ONCOGENE			English	Article							SORTING NEXIN 5; TARGETED THERAPIES; CANCER; EGFR; ENDOCYTOSIS; DEGRADATION; PROTEINS; DOMAINS	Endocytosis is an essential component of cell motility, which facilitates the malignant behavior of cancer. Sorting nexin (SNX) family members are associated with tumor progression. However, the role and mechanism of SNX5 in hepatocellular carcinoma (HCC) progression remain largely unknown. In this study, we investigated the clinical significance and possible involvement of SNX5 in the progression of HCC. Here, we showed that SNX5 was upregulated in tumors compared with adjacent nontumorous tissues in HCC patients. The upregulation of SNX5 in HCC was associated with vascular invasion, intrahepatic metastasis, and poor prognosis. The overexpression of SNX5 promoted HCC cell proliferation, migration, invasion, and metastasis, whereas silencing SNX5 expression resulted in decreased cell proliferation, migration, and invasion. Knockdown of SNX5 significantly inhibited HCC cell proliferation by inducing G1/S transition arrest. Mechanistically, we demonstrated that SNX5 promoted cell proliferation, migration, and invasion via the activation of the EGFR-ERK1/2 pathway by blocking EGF-mediated EGFR internalization. We found that SNX5 interacted with EGFR in HCC cells. Moreover, SNX5-induced cell proliferation, migration, and invasion were partially reversed by the knockdown of EGFR or by ERK1/2 inhibitors. In addition, we demonstrated that SNX5 knockdown sensitized HCC cells to tyrosine kinase inhibitors, including erlotinib and sorafenib. Taken together, our results indicate that SNX5 promotes HCC cell proliferation and metastasis via inhibiting the endocytosis and degradation of EGFR, thereby activating the ERK1/2 signaling pathway. Our work also suggests that SNX5 is a potential therapeutic target for HCC.	[Zhou, Qingqing; Huang, Tingting; Jiang, Zhiyuan; Ge, Chao; Chen, Xiaoxia; Zhang, Lili; Zhao, Fangyu; Zhu, Miaoxin; Li, Hong; Yao, Ming; Li, Jinjun; Tian, Hua] Shanghai Jiao Tong Univ, Sch Med, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst,Renji Hosp, Shanghai, Peoples R China; [Chen, Taoyang] Qi Dong Liver Canc Inst, Qi Dong, Jiangsu, Peoples R China; [Cui, Ying] Canc Inst Guangxi, Nanning, Peoples R China	Shanghai Jiao Tong University	Tian, H (corresponding author), Shanghai Jiao Tong Univ, Sch Med, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst,Renji Hosp, Shanghai, Peoples R China.	htian@shsci.org	huang, ting/GRR-3141-2022		National Natural Science Foundation of China [81972581, 81472570]; National Key Sci-Tech Special Project of China [2018ZX10723204-006]; Natural Science Foundation of Shanghai [19ZR1452800]; Foundation of Shanghai Municipal Health Commission [201940429]; SKLORG Research Foundation [91-17-29]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Sci-Tech Special Project of China; Natural Science Foundation of Shanghai(Natural Science Foundation of Shanghai); Foundation of Shanghai Municipal Health Commission; SKLORG Research Foundation	This work was supported by grants from the National Natural Science Foundation of China (81972581, 81472570), the National Key Sci-Tech Special Project of China (2018ZX10723204-006), Natural Science Foundation of Shanghai (19ZR1452800), Foundation of Shanghai Municipal Health Commission (201940429) and the SKLORG Research Foundation (91-17-29).	Ara S, 2012, CANCER SCI, V103, P1356, DOI 10.1111/j.1349-7006.2012.02296.x; Bendris N, 2016, J CELL SCI, V129, P2804, DOI 10.1242/jcs.188045; Bokel C, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a017020; Brunt L, 2018, CELL MOL LIFE SCI, V75, P785, DOI 10.1007/s00018-017-2654-2; Choi E, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09318-3; Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Cullen PJ, 2012, NAT CELL BIOL, V14, P29, DOI 10.1038/ncb2374; Fu J, 2018, CANCER LETT, V412, P283, DOI 10.1016/j.canlet.2017.10.008; Fuchs BC, 2014, HEPATOLOGY, V59, P1577, DOI 10.1002/hep.26898; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heucken N, 2018, J CELL SCI, V131, DOI 10.1242/jcs.203695; Hirsch FR, 2009, ONCOGENE, V28, pS32, DOI 10.1038/onc.2009.199; Hou HL, 2018, CANCER SCI, V109, P1088, DOI 10.1111/cas.13518; Hu PF, 2018, ACTA BIOCH BIOPH SIN, V50, P1075, DOI 10.1093/abbs/gmy110; Jiang ZY, 2019, CANCER LETT, V447, P1, DOI 10.1016/j.canlet.2019.01.020; Jitsukawa S, 2017, J PATHOL, V243, P342, DOI 10.1002/path.4951; Joffre C, 2011, NAT CELL BIOL, V13, P827, DOI 10.1038/ncb2257; Kaksonen M, 2018, NAT REV MOL CELL BIO, V19, P313, DOI 10.1038/nrm.2017.132; Kim N, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08533-2; Lanaya H, 2014, NAT CELL BIOL, V16, P972, DOI 10.1038/ncb3031; Liu H, 2006, BIOCHEM BIOPH RES CO, V342, P537, DOI 10.1016/j.bbrc.2006.01.179; Liu ZC, 2018, J CELL BIOCHEM, V119, P4170, DOI 10.1002/jcb.26625; Llovet JM, 2008, HEPATOLOGY, V48, P1312, DOI 10.1002/hep.22506; Menard JA, 2016, CANCER RES, V76, P4828, DOI 10.1158/0008-5472.CAN-15-2831; Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521; Mygind KJ, 2018, J BIOL CHEM, V293, P8077, DOI 10.1074/jbc.RA117.001077; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; Nothwehr SF, 2000, J CELL BIOL, V151, P297, DOI 10.1083/jcb.151.2.297; Nothwehr SF, 1999, MOL BIOL CELL, V10, P875, DOI 10.1091/mbc.10.4.875; Roskoski R, 2019, PHARMACOL RES, V144, P19, DOI 10.1016/j.phrs.2019.03.006; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sigismund S, 2018, MOL ONCOL, V12, P3, DOI 10.1002/1878-0261.12155; Sun Y, 2013, DEV CELL, V25, P144, DOI 10.1016/j.devcel.2013.03.010; Tanigawa K, 2019, J CELL PHYSIOL, V234, P17280, DOI 10.1002/jcp.28346; Villanueva A, 2019, NEW ENGL J MED, V380, P1450, DOI 10.1056/NEJMra1713263; Villanueva A, 2011, GASTROENTEROLOGY, V140, P1410, DOI 10.1053/j.gastro.2011.03.006; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107; Xu MJ, 2017, CANCER METAST REV, V36, P463, DOI 10.1007/s10555-017-9687-8; Zhang SL, 2018, CANCER LETT, V419, P116, DOI 10.1016/j.canlet.2018.01.045; Zhu AX, 2015, J CLIN ONCOL, V33, P559, DOI 10.1200/JCO.2013.53.7746	41	23	23	6	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	10					2140	2155		10.1038/s41388-019-1131-9	http://dx.doi.org/10.1038/s41388-019-1131-9			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KS8UR	31819169				2022-12-28	WOS:000518584000009
J	Orsolic, I; Bursac, S; Jurada, D; Hofman, ID; Dembic, Z; Bartek, J; Mihalek, I; Volarevic, S				Orsolic, Ines; Bursac, Sladana; Jurada, Deana; Drmic Hofman, Irena; Dembic, Zlatko; Bartek, Jiri; Mihalek, Ivana; Volarevic, Sinisa			Cancer-associated mutations in the ribosomal protein L5 gene dysregulate the HDM2/p53-mediated ribosome biogenesis checkpoint	ONCOGENE			English	Article							DIAMOND-BLACKFAN ANEMIA; RPL11 GENES; P53; L11; RNA; INHIBITION; IDENTIFICATION; CONSERVATION; DEGRADATION; ACTIVATION	Perturbations in ribosome biogenesis have been associated with cancer. Such aberrations activate p53 through the RPL5/RPL11/5S rRNA complex-mediated inhibition of HDM2. Studies using animal models have suggested that this signaling pathway might constitute an important anticancer barrier. To gain a deeper insight into this issue in humans, here we analyze somatic mutations in RPL5 and RPL11 coding regions, reported in The Cancer Genome Atlas and International Cancer Genome Consortium databases. Using a combined computational and statistical approach, complemented by a range of biochemical and functional analyses in human cancer cell models, we demonstrate the existence of several mechanisms by which RPL5 mutations may impair wild-type p53 upregulation and ribosome biogenesis. Unexpectedly, the same approach provides only modest evidence for a similar role of RPL11, suggesting that RPL5 represents a preferred target during human tumorigenesis in cancers with wild-type p53. Furthermore, we find that several functional cancer-associated RPL5 somatic mutations occur as rare germline variants in general population. Our results shed light on the so-far enigmatic role of cancer-associated mutations in genes encoding ribosomal proteins, with implications for our understanding of the tumor suppressive role of the RPL5/RPL11/5S rRNA complex in human malignancies.	[Orsolic, Ines; Bursac, Sladana; Jurada, Deana; Mihalek, Ivana; Volarevic, Sinisa] Univ Rijeka, Fac Med, Dept Mol Med & Biotechnol, Rijeka 51000, Croatia; [Drmic Hofman, Irena] Univ Split, Sch Med, Dept Med Chem & Biochem, Split 21000, Croatia; [Dembic, Zlatko] Univ Oslo, Fac Dent, Inst Oral Biol, PB 1052 Blindern, N-0316 Oslo, Norway; [Bartek, Jiri] Karolinska Inst, Dept Med Biochem & Biophys, Div Genome Biol, S-17176 Stockholm, Sweden; [Bartek, Jiri] Danish Canc Soc Res, DK-2100 Copenhagen, Denmark	University of Rijeka; University of Split; University of Oslo; Karolinska Institutet; Danish Cancer Society	Mihalek, I; Volarevic, S (corresponding author), Univ Rijeka, Fac Med, Dept Mol Med & Biotechnol, Rijeka 51000, Croatia.; Bartek, J (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Genome Biol, S-17176 Stockholm, Sweden.; Bartek, J (corresponding author), Danish Canc Soc Res, DK-2100 Copenhagen, Denmark.	jb@cancer.dk; ivana.mihalek@medri.uniri.hr; sinisa.volarevic@medri.uniri.hr	Volarevic, Sinisa/O-4349-2018; Bursać, Slađana/Q-7894-2018; Oršolić, Ines/AGE-5929-2022; Dembic, Zlatko/A-1833-2008	Volarevic, Sinisa/0000-0003-4893-389X; Bursać, Slađana/0000-0002-6478-3409; Oršolić, Ines/0000-0003-4517-7187; Dembic, Zlatko/0000-0002-9970-6497	Croatian Science Foundation [09.01/220, 2079]; Scientific Center of Excellence for Reproductive and Regenerative Medicine [KK.01.1.1.01.0008]; University of Rijeka [uniri-biomed-18-206]; Swedish Cancer Society [170176]; Swedish Research Council [VR-MH 2014-46602-117891-30]; Novo Nordisk Foundation [16854]; Danish National Research Foundation (project CARD) [DNRF125]; Danish Cancer Society [R204-A12617]; Lundbeck Foundation	Croatian Science Foundation; Scientific Center of Excellence for Reproductive and Regenerative Medicine; University of Rijeka; Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Danish National Research Foundation (project CARD); Danish Cancer Society(Danish Cancer Society); Lundbeck Foundation(Lundbeckfonden)	We are grateful to Drs George Thomas and Jonathan Ashwell for critical review of the manuscript and helpful suggestions. We would also like to thank Davor Mihalek for his expert assistance in preparing the supplementary movie as well as Miljana Uzelac and Ivana Matui for their technical help. The authors sincerely thank Dr. Moshe Oren (Weizmann Institute of Science) for providing the pCMV-HA3-HDM1B expression plasmid. The pCHDM1A-HDM2 expression plasmid was kindly provided by Dr. Karen Vousden (Francis Crick Institute). SV laboratory was supported with grants from the Croatian Science Foundation (09.01/220 and 2079 to SV), the Scientific Center of Excellence for Reproductive and Regenerative Medicine (KK.01.1.1.01.0008 to SV), the University of Rijeka (uniri-biomed-18-206 to SV). JB laboratory is funded by grants from the Swedish Cancer Society (grant number: 170176) and the Swedish Research Council (VR-MH 2014-46602-117891-30), the Novo Nordisk Foundation (no. 16854), the Danish National Research Foundation (project CARD: no. DNRF125), the Danish Cancer Society (R204-A12617), and the Lundbeck Foundation.	Ajore R, 2017, EMBO MOL MED, V9, P498, DOI 10.15252/emmm.201606660; ANDERSON DE, 1990, BIOCHEMISTRY-US, V29, P2403, DOI 10.1021/bi00461a025; Anslyn E.V., 2006, MODERN PHYS ORGANIC; Arena G, 2018, CELL DEATH DIFFER, V25, P1533, DOI 10.1038/s41418-018-0156-x; Aspesi A, 2019, NAT REV CANCER, V19, P228, DOI 10.1038/s41568-019-0105-0; Badertscher L, 2015, CELL REP, V13, P2879, DOI 10.1016/j.celrep.2015.11.061; Ben-Shem A, 2011, SCIENCE, V334, P1524, DOI 10.1126/science.1212642; Berman H. M., 2006, INT TABLES CRYSTALLO, P675, DOI DOI 10.1107/97809553602060000722; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Bohlman Stephen, 2014, Subcell Biochem, V85, P235, DOI 10.1007/978-94-017-9211-0_13; Boria I, 2010, HUM MUTAT, V31, P1269, DOI 10.1002/humu.21383; Bursac S, 2012, P NATL ACAD SCI USA, V109, P20467, DOI 10.1073/pnas.1218535109; Bywater MJ, 2012, CANCER CELL, V22, P51, DOI 10.1016/j.ccr.2012.05.019; Cancer Genome Atlas Research Network, 2013, Nat Genet, V45, P1113, DOI 10.1038/ng.2764; Cmejla R, 2009, HUM MUTAT, V30, P321, DOI 10.1002/humu.20874; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; De Keersmaecker K, 2013, NAT GENET, V45, P186, DOI 10.1038/ng.2508; Delaporta P, 2014, PEDIATR BLOOD CANCER, V61, P2249, DOI 10.1002/pbc.25183; Donati G, 2013, CELL REP, V4, P87, DOI 10.1016/j.celrep.2013.05.045; Ebert BL, 2008, NATURE, V451, P335, DOI 10.1038/nature06494; Errichiello E, 2017, BLOOD CELL MOL DIS, V64, P38, DOI 10.1016/j.bcmd.2017.03.002; Fancello L, 2017, ONCOTARGET, V8, P14462, DOI 10.18632/oncotarget.14895; Fersht AR, 2002, CELL, V108, P573, DOI 10.1016/S0092-8674(02)00620-7; Ballester EF, 2015, CLIN CASE REP, V3, P392, DOI 10.1002/ccr3.240; Gao J, 2017, RETHINK ASIA INT REL, P1; Gazda HT, 2008, AM J HUM GENET, V83, P769, DOI 10.1016/j.ajhg.2008.11.004; Golomb L, 2014, FEBS LETT, V588, P2571, DOI 10.1016/j.febslet.2014.04.014; Greenman C, 2006, GENETICS, V173, P2187, DOI 10.1534/genetics.105.044677; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hofman IJF, 2017, LEUKEMIA, V31, P1706, DOI 10.1038/leu.2016.370; Hofman IJF, 2017, HAEMATOLOGICA, V102, pE317, DOI 10.3324/haematol.2016.162198; Horn HF, 2008, ONCOGENE, V27, P5774, DOI 10.1038/onc.2008.189; Hunter JD, 2007, COMPUT SCI ENG, V9, P90, DOI 10.1109/MCSE.2007.55; Irving JA, 2000, GENOME RES, V10, P1845, DOI 10.1101/gr.GR-1478R; Kamburov A, 2015, P NATL ACAD SCI USA, V112, pE5486, DOI 10.1073/pnas.1516373112; Karlin S, 1996, J BACTERIOL, V178, P1881, DOI 10.1128/jb.178.7.1881-1894.1996; Kazerounian S, 2016, J CANCER, V7, P32, DOI 10.7150/jca.13292; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057; Lindstrom MS, 2018, ONCOGENE, V37, P2351, DOI 10.1038/s41388-017-0121-z; Liu S, 2017, ONCOGENE, V36, P1374, DOI 10.1038/onc.2016.301; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Lykke-Andersen S, 2015, NAT REV MOL CELL BIO, V16, P665, DOI 10.1038/nrm4063; Macias E, 2010, CANCER CELL, V18, P231, DOI 10.1016/j.ccr.2010.08.007; Mihalek I, 2003, J MOL BIOL, V331, P263, DOI 10.1016/S0022-2836(03)00663-6; Morgado-Palacin L, 2015, CELL REP, V13, P712, DOI 10.1016/j.celrep.2015.09.038; Narla A, 2010, BLOOD, V115, P3196, DOI 10.1182/blood-2009-10-178129; Nicolas E, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11390; Nishimura K, 2015, CELL REP, V10, P1310, DOI 10.1016/j.celrep.2015.01.055; Noller HF, 2012, CSH PERSPECT BIOL, V4, P1, DOI 10.1101/cshperspect.a003681; Orsolic I, 2016, SEMIN CANCER BIOL, V37-38, P36, DOI 10.1016/j.semcancer.2015.12.004; Pelletier J, 2018, NAT REV CANCER, V18, P51, DOI 10.1038/nrc.2017.104; Pon JR, 2015, ANNU REV PATHOL-MECH, V10, P25, DOI 10.1146/annurev-pathol-012414-040312; Quarello P, 2010, HAEMATOL-HEMATOL J, V95, P206, DOI 10.3324/haematol.2009.011783; Rahman N, 2014, NATURE, V505, P302, DOI 10.1038/nature12981; Sivley RM, 2018, AM J HUM GENET, V102, P415, DOI 10.1016/j.ajhg.2018.01.017; Sloan KE, 2013, CELL REP, V5, P237, DOI 10.1016/j.celrep.2013.08.049; Tafforeau L, 2013, MOL CELL, V51, P539, DOI 10.1016/j.molcel.2013.08.011; Tahmasebi S, 2018, NAT REV MOL CELL BIO, V19, P791, DOI 10.1038/s41580-018-0034-x; Tzoneva G, 2013, NAT MED, V19, P368, DOI 10.1038/nm.3078; Velimezi G, 2013, NAT CELL BIOL, V15, P967, DOI 10.1038/ncb2795; Vlachos A, 2012, BLOOD, V119, P3815, DOI 10.1182/blood-2011-08-375972; Voorhees RM, 2014, CELL, V157, P1632, DOI 10.1016/j.cell.2014.05.024; Zhang J, 2011, DISCRETE DYN NAT SOC, V2011, DOI [10.1155/2011/958381, 10.1093/database/bar026]; Zhang JY, 2007, GENE DEV, V21, P2580, DOI 10.1101/gad.1569307; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zheng JG, 2015, GENE DEV, V29, P1524, DOI 10.1101/gad.261792.115	67	15	15	2	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	17					3443	3457		10.1038/s41388-020-1231-6	http://dx.doi.org/10.1038/s41388-020-1231-6		FEB 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LH1YK	32108164				2022-12-28	WOS:000516891300004
J	Tarullo, SE; Hill, RC; Hansen, KC; Behbod, F; Borges, VF; Nelson, AC; Lyons, TR				Tarullo, Sarah E.; Hill, Ryan C.; Hansen, Kirk C.; Behbod, Fariba; Borges, Virginia F.; Nelson, Andrew C.; Lyons, Traci R.			Postpartum breast cancer progression is driven by semaphorin 7a-mediated invasion and survival	ONCOGENE			English	Article							HUMAN OVARIAN-CANCER; X-LINKED INHIBITOR; CARCINOMA IN-SITU; MOLECULAR-MECHANISMS; 7A; RESISTANCE; FIBRONECTIN; APOPTOSIS; GROWTH; CELLS	Young women diagnosed with breast cancer (BC) have poor prognosis due to increased rates of metastasis. In addition, women diagnosed within 10 years of most recent childbirth are approximately three times more likely to develop metastasis than age- and stage-matched nulliparous women. We define these cases as postpartum BC (PPBC) and propose that the unique biology of the postpartum mammary gland drives tumor progression. Our published results revealed roles for SEMA7A in breast tumor cell growth, motility, invasion, and tumor-associated lymphangiogenesis, all of which are also increased in preclinical models of PPBC. However, whether SEMA7A drives progression in PPBC remains largely unexplored. Our results presented herein show that silencing of SEMA7A decreases tumor growth in a model of PPBC, while overexpression is sufficient to increase growth in nulliparous hosts. Further, we show that SEMA7A promotes multiple known drivers of PPBC progression including tumor-associated COX-2 expression and fibroblast-mediated collagen deposition in the tumor microenvironment. In addition, we show for the first time that SEMA7A-expressing cells deposit fibronectin to promote tumor cell survival. Finally, we show that co-expression of SEMA7A/COX-2/FN predicts for poor prognosis in breast cancer patient cohorts. These studies suggest SEMA7A as a key mediator of BC progression, and that targeting SEMA7A may open avenues for novel therapeutic strategies.	[Tarullo, Sarah E.; Borges, Virginia F.; Lyons, Traci R.] CU, Dept Med, Div Med Oncol, Anschutz Med Campus, Aurora, CO 80045 USA; [Tarullo, Sarah E.; Borges, Virginia F.; Lyons, Traci R.] CU, Young Womens BC Translat Program, Anschutz Med Campus, Aurora, CO 80045 USA; [Hill, Ryan C.; Hansen, Kirk C.] CU, Dept Biochem & Mol Genet, Anschutz Med Campus, Aurora, CO 80045 USA; [Behbod, Fariba] Univ Kansas, Med Ctr, Div Canc & Dev Biol, Kansas City, KS 66160 USA; [Borges, Virginia F.; Lyons, Traci R.] Univ Colorado, Ctr Canc, Aurora, CO 80045 USA; [Nelson, Andrew C.] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Kansas; University of Kansas Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Minnesota System; University of Minnesota Twin Cities	Lyons, TR (corresponding author), CU, Dept Med, Div Med Oncol, Anschutz Med Campus, Aurora, CO 80045 USA.; Lyons, TR (corresponding author), CU, Young Womens BC Translat Program, Anschutz Med Campus, Aurora, CO 80045 USA.; Lyons, TR (corresponding author), Univ Colorado, Ctr Canc, Aurora, CO 80045 USA.	traci.lyons@cuanschutz.edu		Tarullo, Sarah/0000-0002-7551-5733	American Cancer Society [RSG 16-171-01-CSM]; NIH/NCI [R01CA211696-01A1]; NIH/CCTSI/CTSA [TL1 TR001081]	American Cancer Society(American Cancer Society); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/CCTSI/CTSA	MCF10DCIS cells were obtained from K. Polyak and A. Marusyk (Harvard University, Cambridge, MA). MDA-MB-231 cells were obtained from P. Schedin (Oregon Heath and Sciences University, Portland OR). HLF-1 cells were gifted from M. Fini (CU Anschutz Medical Campus, Denver, CO). We thank H. Ford for the pcDNA3.1 vector (CU Anschutz Medical Campus, Denver, CO) and R. Medzhitov (Yale University, New Haven, CT) for the SEMA7A-Fc overexpression vector. We also acknowledge V. Wessells, A. Elder, L. Crump, T. Wallace, C. Young, A. Stoller, M. Kobritz, and C. Hoang for technical support and advice. This work was supported by the American Cancer Society (RSG 16-171-01-CSM) and NIH/NCI (R01CA211696-01A1) to TRL and NIH/CCTSI/CTSA (TL1 TR001081) to SET.	Albrektsen G, 2005, BRIT J CANCER, V92, P167, DOI 10.1038/sj.bjc.6602302; Allegra M, 2012, MOL BIOL CELL, V23, P3873, DOI 10.1091/mbc.E12-04-0276; Asztalos S, 2010, CANCER PREV RES, V3, P301, DOI 10.1158/1940-6207.CAPR-09-0069; Balmanno K, 2009, CELL DEATH DIFFER, V16, P368, DOI 10.1038/cdd.2008.148; Baritaki S, 2009, CANCER RES, V69, P8376, DOI 10.1158/0008-5472.CAN-09-1069; Barrett AS, 2017, J PROTEOME RES, V16, P4177, DOI 10.1021/acs.jproteome.7b00527; Black SA, 2016, ONCOGENE, V35, P5170, DOI 10.1038/onc.2016.49; Callihan EB, 2013, BREAST CANCER RES TR, V138, P549, DOI 10.1007/s10549-013-2437-x; Cerny J, 1996, EUR J IMMUNOL, V26, P2335, DOI 10.1002/eji.1830261010; Chao Y, 2012, CANCER MICROENVIRON, V5, P19, DOI 10.1007/s12307-011-0085-4; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; Cheng JQ, 2002, DRUG RESIST UPDATE, V5, P131, DOI 10.1016/S1368-7646(02)00003-1; Chong J, 2018, BIOINFORMATICS, V34, P4313, DOI 10.1093/bioinformatics/bty528; Crump LS, 2019, HORMONAL REGULATION; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dean JL, 2012, CELL CYCLE, V11, P2756, DOI 10.4161/cc.21195; Deep G, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-37; Denkert C, 2003, CANCER-AM CANCER SOC, V97, P2978, DOI 10.1002/cncr.11437; Eke I, 2013, CANCER RES, V73, P5869, DOI 10.1158/0008-5472.CAN-13-0344; Elder AM, 2018, CANCER RES, V78, P6473, DOI 10.1158/0008-5472.CAN-18-1642; Fong KP, 2011, BLOOD, V117, pE15, DOI 10.1182/blood-2010-05-283838; Fraser M, 2003, CANCER RES, V63, P7081; Gan Y, 2011, ARTHRITIS RHEUM-US, V63, P2484, DOI 10.1002/art.30386; Garcia-Areas R, 2017, INT J ONCOL, V51, P1395, DOI 10.3892/ijo.2017.4144; Garcia-Areas R, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00017; Gilmore AP, 2009, CURR OPIN CELL BIOL, V21, P654, DOI 10.1016/j.ceb.2009.05.009; Goddard ET, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2018.6997; Goddard ET, 2018, JAMA NETWORK; Guo QC, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.89206; Gupta PB, 2007, CANCER RES, V67, P2062, DOI 10.1158/0008-5472.CAN-06-3895; Gurrapu S, 2018, CELL DEATH DIFFER, V25, P1259, DOI 10.1038/s41418-018-0097-4; Han SW, 2006, ONCOGENE, V25, P4341, DOI 10.1038/sj.onc.1209460; Hattar R, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2220; Hua M, 2009, P NATL ACAD SCI USA, V106, P3372, DOI 10.1073/pnas.0813306106; Jacob A, 2013, J CELL SCI, V126, P4647, DOI 10.1242/jcs.126573; Jaimes Y, 2012, J THROMB HAEMOST, V10, P1100, DOI 10.1111/j.1538-7836.2012.04708.x; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kang HR, 2007, J EXP MED, V204, P1083, DOI 10.1084/jem.20061273; Kinehara Y, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.123093; Knowles LM, 2013, CANCER RES, V73, P6175, DOI 10.1158/0008-5472.CAN-13-0602; Knuefermann C, 2003, ONCOGENE, V22, P3205, DOI 10.1038/sj.onc.1206394; Kopp MA, 2010, GLIA, V58, P1748, DOI 10.1002/glia.21045; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Li JL, 2001, ENDOCRINOLOGY, V142, P370, DOI 10.1210/en.142.1.370; Liu HL, 2010, CELL, V142, P749, DOI 10.1016/j.cell.2010.07.040; Lyons TR, 2014, J CLIN INVEST, V124, P3901, DOI 10.1172/JCI73777; Lyons TR, 2011, NAT MED, V17, P1109, DOI 10.1038/nm.2416; Ma B, 2015, CANCER RES, V75, P487, DOI 10.1158/0008-5472.CAN-13-3339; Maller O, 2013, J CELL SCI, V126, P4108, DOI 10.1242/jcs.121590; McKeithen D, 2010, PROSTATE, V70, P982, DOI 10.1002/pros.21132; Mi HY, 2019, NUCLEIC ACIDS RES, V47, pD419, DOI 10.1093/nar/gky1038; Miller FR, 2000, J NATL CANCER I, V92, P1185, DOI 10.1093/jnci/92.14.1185A; Nagy A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27521-y; Nichols HB, 2019, ANN INTERN MED, V170, P22, DOI 10.7326/M18-1323; Nurwidya F, 2012, CANCER RES TREAT, V44, P151, DOI 10.4143/crt.2012.44.3.151; Nurwidya Fariz, 2012, Cancer Biology Medicine, V9, P18, DOI 10.3969/j.issn.2095-3941.2012.01.003; Parkash J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7385; Pasterkamp RJ, 2003, NATURE, V424, P398, DOI 10.1038/nature01790; Pontiggia O, 2012, BREAST CANCER RES TR, V133, P459, DOI 10.1007/s10549-011-1766-x; Provenzano PP, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-11; Provenzano PP, 2006, BMC MED, V4, DOI 10.1186/1741-7015-4-38; Reddig PJ, 2005, CANCER METAST REV, V24, P425, DOI 10.1007/s10555-005-5134-3; Rehman M, 2013, SEMIN CELL DEV BIOL, V24, P179, DOI 10.1016/j.semcdb.2012.10.005; Reilkoff RA, 2013, AM J RESP CRIT CARE, V187, P180, DOI 10.1164/rccm.201206-1109OC; Reisz JA, 2018, TRANSFUSION, V58, P2978, DOI 10.1111/trf.14936; Ristimaki A, 2002, CANCER RES, V62, P632; Saito T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118432; Schedin P, 2006, NAT REV CANCER, V6, P281, DOI 10.1038/nrc1839; Scott GA, 2009, J INVEST DERMATOL, V129, P954, DOI 10.1038/jid.2008.329; Slepicka PF, 2019, TRENDS MOL MED, V25, P866, DOI 10.1016/j.molmed.2019.06.003; Slocum E, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1142-z; Smith BN, 2016, J CLIN MED, V5, DOI 10.3390/jcm5020017; St-Germain ME, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-7; Tiwari N, 2012, SEMIN CANCER BIOL, V22, P194, DOI 10.1016/j.semcancer.2012.02.013; Uchikado Y, 2011, GASTRIC CANCER, V14, P41, DOI 10.1007/s10120-011-0004-x; Valdez KE, 2011, J PATHOL, V225, P565, DOI 10.1002/path.2969; Vesuna F, 2012, ONCOGENE, V31, P3223, DOI 10.1038/onc.2011.483; Welch DR, 2019, CANCER RES, V79, P3011, DOI 10.1158/0008-5472.CAN-19-0458; Xie JM, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-016-1217-5; Zhou YP, 2008, TRENDS BIOCHEM SCI, V33, P161, DOI 10.1016/j.tibs.2008.01.006	80	13	13	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	13					2772	2785		10.1038/s41388-020-1192-9	http://dx.doi.org/10.1038/s41388-020-1192-9		FEB 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KX4EF	32020054	Green Accepted, Green Submitted			2022-12-28	WOS:000511084200002
J	Lopez-Guerra, M; Xargay-Torrent, S; Fuentes, P; Roldan, J; Gonzalez-Farre, B; Rosich, L; Silkenstedt, E; Garcia-Leon, MJ; Lee-Verges, E; Gimenez, N; Giro, A; Aymerich, M; Villamor, N; Delgado, J; Lopez-Guillermo, A; Puente, XS; Campo, E; Toribio, ML; Colomer, D				Lopez-Guerra, Monica; Xargay-Torrent, Silvia; Fuentes, Patricia; Roldan, Jocabed; Gonzalez-Farre, Blanca; Rosich, Laia; Silkenstedt, Elisabeth; Garcia-Leon, Maria J.; Lee-Verges, Eriong; Gimenez, Neus; Giro, Ariadna; Aymerich, Marta; Villamor, Neus; Delgado, Julio; Lopez-Guillermo, Armando; Puente, Xose S.; Campo, Elias; Toribio, Maria L.; Colomer, Dolors			Specific NOTCH1 antibody targets DLL4-induced proliferation, migration, and angiogenesis in NOTCH1-mutated CLL cells	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; RECURRENT MUTATIONS; ACTIVATION; PROMOTES; SURVIVAL; LIGAND; OVEREXPRESSION; TRANSFORMATION; MECHANISMS; INHIBITION	Targeting Notch signaling has emerged as a promising therapeutic strategy for chronic lymphocytic leukemia (CLL), particularly in NOTCH1-mutated patients. We provide first evidence that the Notch ligand DLL4 is a potent stimulator of Notch signaling in NOTCH1-mutated CLL cells while increases cell proliferation. Importantly, DLL4 is expressed in histiocytes from the lymph node, both in NOTCH1-mutated and -unmutated cases. We also show that the DLL4-induced activation of the Notch signaling pathway can be efficiently blocked with the specific anti-Notch1 antibody OMP-52M51. Accordingly, OMP-52M51 also reverses Notch-induced MYC, CCND1, and NPM1 gene expression as well as cell proliferation in NOTCH1-mutated CLL cells. In addition, DLL4 stimulation triggers the expression of protumor target genes, such as CXCR4, NRARP, and VEGFA, together with an increase in cell migration and angiogenesis. All these events can be antagonized by OMP-52M51. Collectively, our results emphasize the role of DLL4 stimulation in NOTCH1-mutated CLL and confirm the specific therapeutic targeting of Notch1 as a promising approach for this group of poor prognosis CLL patients.	[Lopez-Guerra, Monica; Xargay-Torrent, Silvia; Roldan, Jocabed; Rosich, Laia; Silkenstedt, Elisabeth; Lee-Verges, Eriong; Gimenez, Neus; Giro, Ariadna; Aymerich, Marta; Colomer, Dolors] IDIBAPS, Expt Therapeut Lymphoid Malignancies Grp, Barcelona, Spain; [Lopez-Guerra, Monica; Roldan, Jocabed; Gonzalez-Farre, Blanca; Aymerich, Marta; Villamor, Neus; Campo, Elias; Colomer, Dolors] IDIBAPS, Hosp Clin, Hematopathol Sect, Barcelona, Spain; [Lopez-Guerra, Monica; Roldan, Jocabed; Gonzalez-Farre, Blanca; Rosich, Laia; Lee-Verges, Eriong; Gimenez, Neus; Giro, Ariadna; Aymerich, Marta; Villamor, Neus; Delgado, Julio; Lopez-Guillermo, Armando; Puente, Xose S.; Campo, Elias; Colomer, Dolors] Ctr Invest Biomed Red Canc CIBERONC, Barcelona, Spain; [Fuentes, Patricia; Toribio, Maria L.] Univ Autonoma Madrid, Consejo Super Invest Cient, Ctr Biol Mol Severo Ochoa, Madrid, Spain; [Gonzalez-Farre, Blanca; Lopez-Guillermo, Armando; Campo, Elias; Colomer, Dolors] Univ Barcelona, Barcelona, Spain; [Silkenstedt, Elisabeth] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Internal Med 3, Munich, Germany; [Garcia-Leon, Maria J.] INSERM U1109, Inst Hematol Immunol, Strasbourg, France; [Delgado, Julio; Lopez-Guillermo, Armando] IDIBAPS, Hematol Dept, Hosp Clin, Barcelona, Spain; [Puente, Xose S.] Univ Oviedo, Dept Bioquim & Biol, Mol Inst Univ Oncol, Oviedo, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); University of Barcelona; University of Munich; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Oviedo	Colomer, D (corresponding author), IDIBAPS, Expt Therapeut Lymphoid Malignancies Grp, Barcelona, Spain.; Colomer, D (corresponding author), IDIBAPS, Hosp Clin, Hematopathol Sect, Barcelona, Spain.; Colomer, D (corresponding author), Ctr Invest Biomed Red Canc CIBERONC, Barcelona, Spain.; Colomer, D (corresponding author), Univ Barcelona, Barcelona, Spain.	dcolomer@clinic.cat	Gonzalez-Farre, Blanca/AAD-9467-2019; COLOMER, DOLORS/ABG-6894-2020; Puente, Xosé S./ADB-0672-2022; Toribio, Maria L/C-2039-2017	Gonzalez-Farre, Blanca/0000-0002-1796-7248; Puente, Xosé S./0000-0001-9525-1483; Fuentes, Patricia/0000-0003-4597-1022; Toribio, Maria L/0000-0002-8637-0373; Garcia-Leon, Maria Jesus/0000-0001-9790-808X	Ministerio de Ciencia e Innovacion [SAF2015-31242-R, RTI2018-094584-B-I00, SAF2016-75442-R]; Departament de Salut [SLT002-16-00350]; ISCII-Sub-Directorate General for Evaluation [PM15/00007]; European Regional Development Fund (FEDER-"Una manera de hacer Europa"); Generalitat de Catalunya [2014SGR967, 2017SGR1009]; CIBERONC [CB16/12/00334, CB16/12/00225, CB16/12/00236]; Ministerio de Ciencia e Innovacion (FPI program); Agaur, Generalitat de Catalunya	Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Departament de Salut; ISCII-Sub-Directorate General for Evaluation; European Regional Development Fund (FEDER-"Una manera de hacer Europa"); Generalitat de Catalunya(Generalitat de Catalunya); CIBERONC; Ministerio de Ciencia e Innovacion (FPI program); Agaur, Generalitat de Catalunya(Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR)Generalitat de Catalunya)	The authors would like to thank Sandra Cabezas and Laura Jimenez for their technical support. We also thank Dr Maria C Cid for providing HUVEC cells. We are very grateful to the CLL Genome Consortium and all CLL patients who have participated in this study. This work was carried out at the Centre Esther Koplowitz, Barcelona. This study was supported by research funding from Ministerio de Ciencia e Innovacion (SAF2015-31242-R and RTI2018-094584-B-I00 to DC and SAF2016-75442-R to MLT), Departament de Salut (SLT002-16-00350) to DC, the ISCII-Sub-Directorate General for Evaluation (PM15/00007), which are part of Plan Nacional de I+D+I and are co-financed by and the European Regional Development Fund (FEDER-"Una manera de hacer Europa"), Generalitat de Catalunya (2014SGR967 and 2017SGR1009) and CIBERONC (CB16/12/00334, CB16/12/00225 and CB16/12/00236). ELV and NG are recipients of predoctoral fellowships from Ministerio de Ciencia e Innovacion (FPI program), and from Agaur, Generalitat de Catalunya, respectively.	Agnusdei V, 2014, LEUKEMIA, V28, P278, DOI 10.1038/leu.2013.183; Andersson ER, 2014, NAT REV DRUG DISCOV, V13, P359, DOI 10.1038/nrd4252; Andrawes MB, 2013, J BIOL CHEM, V288, P25477, DOI 10.1074/jbc.M113.454850; Arruga F, 2017, LEUKEMIA, V31, P1882, DOI 10.1038/leu.2016.383; Arruga F, 2014, LEUKEMIA, V28, P1060, DOI 10.1038/leu.2013.319; Arruga F, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00550; Aste-Amezaga M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009094; Ayllon V, 2015, LEUKEMIA, V29, P1741, DOI 10.1038/leu.2015.74; Beckstead BL, 2006, J BIOMED MATER RES A, V79A, P94, DOI 10.1002/jbm.a.30760; Belver L, 2016, NAT REV CANCER, V16, P494, DOI 10.1038/nrc.2016.63; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Burkle A, 2007, BLOOD, V110, P3316, DOI 10.1182/blood-2007-05-089409; Calissano C, 2009, BLOOD, V114, P4832, DOI 10.1182/blood-2009-05-219634; Fabbri G, 2017, P NATL ACAD SCI USA, V114, pE2911, DOI 10.1073/pnas.1702564114; Fabbri G, 2013, J EXP MED, V210, P2273, DOI 10.1084/jem.20131448; Fabbri G, 2011, J EXP MED, V208, P1389, DOI 10.1084/jem.20110921; Galletti G, 2016, LEUKEMIA, V30, P2293, DOI 10.1038/leu.2016.261; Galletti G, 2016, CELL REP, V14, P1748, DOI 10.1016/j.celrep.2016.01.042; Guo DM, 2009, LEUKEMIA RES, V33, P678, DOI 10.1016/j.leukres.2008.10.026; Hanna BS, 2016, LEUKEMIA, V30, P570, DOI 10.1038/leu.2015.305; Herishanu Y, 2011, BLOOD, V117, P563, DOI 10.1182/blood-2010-05-284984; Kangsamaksin T, 2015, CANCER DISCOV, V5, P182, DOI 10.1158/2159-8290.CD-14-0650; Krebs LT, 2001, DEV BIOL, V238, P110, DOI 10.1006/dbio.2001.0408; Lamar E, 2001, GENE DEV, V15, P1885, DOI 10.1101/gad.908101; Lopez-Guerra M, 2015, LEUKEMIA, V29, P96, DOI 10.1038/leu.2014.143; Mirandola L, 2013, LEUKEMIA, V27, P1558, DOI 10.1038/leu.2013.27; Mongini PKA, 2015, J IMMUNOL, V195, P901, DOI 10.4049/jimmunol.1403189; Palomero T, 2006, P NATL ACAD SCI USA, V103, P18261, DOI 10.1073/pnas.0606108103; Patel NS, 2005, CANCER RES, V65, P8690, DOI 10.1158/0008-5472.CAN-05-1208; Phng LK, 2009, DEV CELL, V16, P196, DOI 10.1016/j.devcel.2009.01.015; Pozzo F, 2017, LEUKEMIA, V31, P2407, DOI 10.1038/leu.2017.90; Puente XS, 2015, NATURE, V526, P519, DOI 10.1038/nature14666; Puente XS, 2011, NATURE, V475, P101, DOI 10.1038/nature10113; Quesada V, 2012, NAT GENET, V44, P47, DOI 10.1038/ng.1032; Rosati E, 2009, BLOOD, V113, P856, DOI 10.1182/blood-2008-02-139725; Rosich L, 2014, ONCOTARGET, V5, P6788, DOI 10.18632/oncotarget.2253; Rossi D, 2012, BLOOD, V119, P521, DOI 10.1182/blood-2011-09-379966; Scehnet JS, 2007, BLOOD, V109, P4753, DOI 10.1182/blood-2006-12-063933; Thurston G, 2008, BRIT J CANCER, V99, P1204, DOI 10.1038/sj.bjc.6604484; Varnum-Finney B, 2000, J CELL SCI, V113, P4313; Villamor N, 2013, LEUKEMIA, V27, P1100, DOI 10.1038/leu.2012.357; Wu Y, 2010, NATURE, V464, P1052, DOI 10.1038/nature08878; Xargay-Torrent S, 2015, ONCOTARGET, V6, P22734, DOI 10.18632/oncotarget.4212; Zhang JR, 2013, CARCINOGENESIS, V34, P667, DOI 10.1093/carcin/bgs386	44	16	16	4	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	6					1185	1197		10.1038/s41388-019-1053-6	http://dx.doi.org/10.1038/s41388-019-1053-6			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE4UH	31616059	Green Published, hybrid			2022-12-28	WOS:000526714600002
J	Lempiainen, JK; Manjur, ABMK; Malinen, M; Ketola, K; Niskanen, EA; Palvimo, JJ				Lempiainen, Joanna K.; Manjur, A. B. M. Kaiser; Malinen, Marjo; Ketola, Kirsi; Niskanen, Einari A.; Palvimo, Jorma J.			BCOR-coupled H2A monoubiquitination represses a subset of androgen receptor target genes regulating prostate cancer proliferation	ONCOGENE			English	Article							LENZ MICROPHTHALMIA SYNDROMES; GROUP PROTEIN EZH2; BCL6 BTB DOMAIN; TRANSCRIPTION FACTORS; HOMEOBOX GENE; HOX GENES; POLYCOMB; COMPLEX; CELLS; EXPRESSION	We have identified BCL6 corepressor (BCOR) as a hormone-dependent interaction partner of androgen receptor (AR), a key transcription factor in the development of normal and cancerous prostate. BCOR is often mutated in cancers and hematological diseases and as a component of a non-canonical polycomb repressive complex 1 (ncPRC1.1) required for arranging many facets of cellular differentiation. However, its role in androgen signaling or prostate cancer cells remains unknown. Here, our genome-wide analyses reveal that BCOR is recruited in an androgen-dependent fashion to majority of AR-binding chromatin sites in castration-resistant prostate cancer (CRPC) cells. Interestingly, depletion of BCOR has a significant effect on the expression of androgen-repressed genes linked to regulation of cell proliferation, differentiation and development. At many of these genes, such as HOX genes, the depletion leads to a decrease in H2A K119 monoubiquitination and an increase in mRNA expression. Consistently, BCOR depletion impairs the proliferation and viability of CRPC cells, inducing their apoptosis. Collectively, our data indicate a key role for the BCOR-ncPRC1.1 complex in the corepression of an important subset of AR target genes and the regulation of prostate cancer cell proliferation.	[Lempiainen, Joanna K.; Manjur, A. B. M. Kaiser; Malinen, Marjo; Ketola, Kirsi; Niskanen, Einari A.; Palvimo, Jorma J.] Univ Eastern Finland, Inst Biomed, Kuopio, Finland; [Malinen, Marjo] Univ Eastern Finland, Dept Environm & Biol Sci, Joensuu, Finland	University of Eastern Finland; University of Eastern Finland	Palvimo, JJ (corresponding author), Univ Eastern Finland, Inst Biomed, Kuopio, Finland.	jorma.palvimo@uef.fi	Ketola, Kirsi/O-1071-2016; Niskanen, Einari/F-2883-2017; Lempiainen, Joanna/M-8833-2017	Ketola, Kirsi/0000-0001-6484-9861; Manjur, Kaiser/0000-0001-8260-1915; Niskanen, Einari/0000-0001-9471-7026; Palvimo, Jorma/0000-0003-2373-0578; Lempiainen, Joanna/0000-0001-6100-5815	Academy of Finland; Cancer Foundation Finland; Sigrid Juselius Foundation; UEF Doctoral Programme in Molecular Medicine; Jalmari and Rauha Ahokas Foundation; Instrumentarium Foundation; Orion Research Foundation; Ida Montini Foundation; Kuopio University Foundation	Academy of Finland(Academy of Finland); Cancer Foundation Finland; Sigrid Juselius Foundation(Sigrid Juselius Foundation); UEF Doctoral Programme in Molecular Medicine; Jalmari and Rauha Ahokas Foundation; Instrumentarium Foundation; Orion Research Foundation; Ida Montini Foundation; Kuopio University Foundation	This work was supported by the Academy of Finland, the Cancer Foundation Finland, the Sigrid Juselius Foundation, the UEF Doctoral Programme in Molecular Medicine, the Jalmari and Rauha Ahokas Foundation, the Instrumentarium Foundation, the Orion Research Foundation, the Ida Montini Foundation and the Kuopio University Foundation.	Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Astolfi A, 2019, EPIGENOMICS-UK, V11, P835, DOI 10.2217/epi-2018-0195; Axlund SD, 2010, MOL CANCER RES, V8, P1643, DOI 10.1158/1541-7786.MCR-10-0111; Banerjee PP, 2018, AM J CLIN EXP UROL, V6, P62; Beguelin W, 2016, CANCER CELL, V30, P197, DOI 10.1016/j.ccell.2016.07.006; Bhatlekar S, 2014, J MOL MED, V92, P811, DOI 10.1007/s00109-014-1181-y; Blackledge NP, 2015, NAT REV MOL CELL BIO, V16, P643, DOI 10.1038/nrm4067; Blackledge NP, 2014, CELL, V157, P1445, DOI 10.1016/j.cell.2014.05.004; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Cao Q, 2016, LEUKEMIA, V30, P1155, DOI 10.1038/leu.2016.2; Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333; Chatr-aryamontri A, 2017, NUCLEIC ACIDS RES, V45, pD369, DOI 10.1093/nar/gkw1102; Chng KR, 2012, EMBO J, V31, P2810, DOI 10.1038/emboj.2012.112; Cohen I, 2018, CELL STEM CELL, V22, P726, DOI 10.1016/j.stem.2018.04.005; Connelly ZM, 2018, AM J CLIN EXP UROL, V6, P172; Cooper S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13661; Cooper S, 2014, CELL REP, V7, P1456, DOI 10.1016/j.celrep.2014.04.012; Di Croce L, 2013, NAT STRUCT MOL BIOL, V20, P1147, DOI 10.1038/nsmb.2669; Dickson BC, 2018, GENE CHROMOSOME CANC, V57, P598, DOI 10.1002/gcc.22649; Dobashi A, 2016, GENE CHROMOSOME CANC, V55, P460, DOI 10.1002/gcc.22348; Foley C, 2016, HORM CANCER-US, V7, P84, DOI 10.1007/s12672-015-0239-9; Fursova NA, 2019, MOL CELL, V74, P1020, DOI 10.1016/j.molcel.2019.03.024; Gao ZH, 2012, MOL CELL, V45, P344, DOI 10.1016/j.molcel.2012.01.002; Ghetu AF, 2008, MOL CELL, V29, P384, DOI 10.1016/j.molcel.2007.12.026; Granadino-Roldan JM, 2014, J MOL GRAPH MODEL, V50, P142, DOI 10.1016/j.jmgm.2014.04.003; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Han SJ, 2016, MOL PHARMACOL, V89, P14, DOI 10.1124/mol.115.100925; Hatzi K, 2013, CELL REP, V4, P578, DOI 10.1016/j.celrep.2013.06.016; Heemers HV, 2010, PROSTATE, V70, P959, DOI 10.1002/pros.21130; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Helsen C, 2014, ENDOCR-RELAT CANCER, V21, pT105, DOI 10.1530/ERC-13-0545; Hilton E, 2009, EUR J HUM GENET, V17, P1325, DOI 10.1038/ejhg.2009.52; Hsiao JJ, 2016, J BIOL CHEM, V291, P18818, DOI 10.1074/jbc.M116.732313; Hsiao JJ, 2015, MOL ENDOCRINOL, V29, P1195, DOI 10.1210/me.2015-1021; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Huynh KD, 2000, GENE DEV, V14, P1810; Javed S, 2014, BJU INT, V113, P535, DOI 10.1111/bju.12269; Junco SE, 2013, STRUCTURE, V21, P665, DOI 10.1016/j.str.2013.02.013; Karvonen U, 1997, J BIOL CHEM, V272, P15973, DOI 10.1074/jbc.272.25.15973; Kelly MJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09250-6; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Lempiainen JK, 2017, MOL CELL PROTEOMICS, V16, P1462, DOI 10.1074/mcp.M117.067488; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Linke T, 2011, METHODS MOL BIOL, V776, P225, DOI 10.1007/978-1-61779-243-4_14; Liu QP, 2019, INT J CANCER, V145, P415, DOI 10.1002/ijc.32118; Liu S, 2017, ELIFE, V6, DOI 10.7554/eLife.28482.001; Lukacs RU, 2010, CELL STEM CELL, V7, P682, DOI 10.1016/j.stem.2010.11.013; Malinen M, 2017, NUCLEIC ACIDS RES, V45, P619, DOI 10.1093/nar/gkw855; Manjur ABMK, 2019, J STEROID BIOCHEM, V192, DOI 10.1016/j.jsbmb.2019.105382; Meier K, 2014, EPIGENETICS-US, V9, P1485, DOI 10.4161/15592294.2014.971580; Millard CJ, 2013, J MOL ENDOCRINOL, V51, pT23, DOI 10.1530/JME-13-0227; Miller GJ, 2003, CANCER RES, V63, P5879; Minner S, 2019, PROSTATE, V79, P302, DOI 10.1002/pros.23736; Mostaghel EA, 2014, CLIN CANCER RES, V20, P791, DOI 10.1158/1078-0432.CCR-12-3601; Ng D, 2004, NAT GENET, V36, P411, DOI 10.1038/ng1321; Oliviero G, 2015, SCI REP-UK, V5, DOI 10.1038/srep18388; Panagopoulos I, 2013, GENE CHROMOSOME CANC, V52, P733, DOI 10.1002/gcc.22068; Pretorius E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159867; Reiter F, 2017, CURR OPIN GENET DEV, V43, P73, DOI 10.1016/j.gde.2016.12.007; Ren CY, 2016, ACS MED CHEM LETT, V7, P601, DOI 10.1021/acsmedchemlett.6b00042; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rytinki MM, 2011, METHODS MOL BIOL, V776, P183, DOI 10.1007/978-1-61779-243-4_12; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schuettengruber B, 2017, CELL, V171, P34, DOI 10.1016/j.cell.2017.08.002; Shah N, 2017, ELIFE, V6, DOI 10.7554/eLife.27861; Skowron KJ, 2019, MOL CELL ENDOCRINOL, V493, DOI 10.1016/j.mce.2019.110471; Stark C, 2006, NUCLEIC ACIDS RES, V34, pD535, DOI 10.1093/nar/gkj109; Stelloo S, 2018, ONCOGENE, V37, P313, DOI 10.1038/onc.2017.330; Su WJ, 2019, CANCER CELL, V36, P139, DOI 10.1016/j.ccell.2019.06.009; Tavares L, 2012, CELL, V148, P664, DOI 10.1016/j.cell.2011.12.029; Tiberi L, 2014, CANCER CELL, V26, P797, DOI 10.1016/j.ccell.2014.10.021; Tilki D, 2016, EUR UROL FOCUS, V2, P499, DOI 10.1016/j.euf.2016.11.013; Toropainen S, 2016, SCI REP-UK, V6, DOI 10.1038/srep33510; Toropainen S, 2015, NUCLEIC ACIDS RES, V43, P848, DOI 10.1093/nar/gku1375; van den Boom V, 2016, CELL REP, V14, P332, DOI 10.1016/j.celrep.2015.12.034; van Leenders GJLH, 2007, EUR UROL, V52, P455, DOI 10.1016/j.eururo.2006.11.020; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Wang Z, 2018, CELL STEM CELL, V22, P235, DOI 10.1016/j.stem.2017.12.002; Wei M, 2017, ONCOTARGET, V8, P5323, DOI 10.18632/oncotarget.14142; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Yamamoto Y, 2014, MOL CANCER RES, V12, P479, DOI 10.1158/1541-7786.MCR-13-0596; Yamamoto Y, 2010, BLOOD, V116, P4274, DOI 10.1182/blood-2010-01-264432; Yao JQ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46064-4; Zhang X, 2016, ONCOL REP, V36, P2349, DOI 10.3892/or.2016.5018; Zhu S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02863-3	88	6	6	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	11					2391	2407		10.1038/s41388-020-1153-3	http://dx.doi.org/10.1038/s41388-020-1153-3		JAN 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KU0ZS	31925334				2022-12-28	WOS:000508151400001
J	Tung, CH; Kuo, LW; Huang, MF; Wu, YY; Tsai, YT; Wu, JE; Hsu, KF; Chen, YL; Hong, TM				Tung, Chia-Hao; Kuo, Li-Wei; Huang, Meng-Fan; Wu, Yi-Ying; Tsai, Yao-Tsung; Wu, Jia-En; Hsu, Keng-Fu; Chen, Yuh-Ling; Hong, Tse-Ming			MicroRNA-150-5p promotes cell motility by inhibiting c-Myb-mediated Slug suppression and is a prognostic biomarker for recurrent ovarian cancer	ONCOGENE			English	Article							MESENCHYMAL TRANSITION; MONOCLONAL-ANTIBODY; COLORECTAL-CANCER; EARLY RELAPSE; MIR-150; EXPRESSION; METASTASIS; INVASION; ACTIVATION; SIGNATURES	Treatment of ovarian cancer (OvCa) remains challenging owing to its high recurrence rates. Detachment of cancer cells into the peritoneal fluid plays a key role in OvCa relapse, but how this occurs remains incompletely understood. Here we examined global miRNA expression profiles of paired primary/recurrent OvCa specimens and identified a novel biomarker, microRNA-150-5p (miR-150-5p), that was significantly upregulated in 16 recurrent OvCa tissues compared with their matched primary specimens. Analyses of cohorts from two other groups confirmed that expression of miR-150-5p was associated with early relapse and poor survival of OvCa patients. Inhibition of miR-150-5p significantly inhibited the migration and invasion of OvCa cells and induced a mesenchymal-epithelial transition (MET) phenotype. We demonstrated that the proto-oncogene, MYB, is an miR-150-5p target in OvCa cells and that the miR-150-5p/c-Myb/Slug axis plays important roles in regulating epithelial-mesenchymal transition (EMT) in OvCa cells. Expression of MYB was significantly correlated with good clinical outcome in OvCa and was negatively correlated with Slug expression in late-stage clinical specimens. These results suggest that miR-150-5p upregulation mediates the progression of recurrent OvCa by targeting the c-Myb/Slug pathway. Inhibition of miR-150-5p may serve as a new therapeutic strategy for preventing recurrence of OvCa.	[Tung, Chia-Hao; Tsai, Yao-Tsung; Wu, Jia-En] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan, Taiwan; [Kuo, Li-Wei; Huang, Meng-Fan; Hsu, Keng-Fu; Hong, Tse-Ming] Natl Cheng Kung Univ, Coll Med, Inst Clin Med, Tainan, Taiwan; [Wu, Yi-Ying; Hong, Tse-Ming] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Clin Med Res Ctr, Tainan, Taiwan; [Hsu, Keng-Fu] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Obstet & Gynecol, Tainan, Taiwan; [Chen, Yuh-Ling] Natl Cheng Kung Univ, Coll Med, Inst Oral Med, Tainan, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University	Hong, TM (corresponding author), Natl Cheng Kung Univ, Coll Med, Inst Clin Med, Tainan, Taiwan.; Hong, TM (corresponding author), Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Clin Med Res Ctr, Tainan, Taiwan.; Chen, YL (corresponding author), Natl Cheng Kung Univ, Coll Med, Inst Oral Med, Tainan, Taiwan.	yuhling@mail.ncku.edu.tw; tmhong@mail.ncku.edu.tw	Tung, Chia-Hao/AAI-7923-2020; Chen, Yuh-Ling/AAS-7957-2021	Huang, Meng-Fan/0000-0001-5113-1746; Tung, Chia-Hao/0000-0001-5638-4216; Kuo, Li-Wei/0000-0002-1135-8740	Ministry of Science and Technology, Taiwan [MOST 107-2314-B-006-068-MY3, MOST 108-2314-B-006-004, MOST 108-2321-B-006-010, MOST 106-2314-B-006-015-MY2]	Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan)	We are grateful for providing the services from the RNAi Core Lab, Research Center of Clinical Medicine, National Cheng Kung University Hospital, Taiwan. RNAi reagents were obtained from the National RNAi Core Facility located at the Institute of Molecular Biology/Genomic Research Center, Academia Sinica, Taiwan. This study was supported by grants MOST 107-2314-B-006-068-MY3, MOST 108-2314-B-006-004, MOST 108-2321-B-006-010, and MOST 106-2314-B-006-015-MY2 from the Ministry of Science and Technology, Taiwan.	Bagnoli M, 2016, LANCET ONCOL, V17, P1137, DOI 10.1016/S1470-2045(16)30108-5; Bagnoli M, 2011, ONCOTARGET, V2, P1265, DOI 10.18632/oncotarget.401; BAST RC, 1983, NEW ENGL J MED, V309, P883, DOI 10.1056/NEJM198310133091503; BENARD J, 1985, CANCER RES, V45, P4970; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Bureau of Health Promotion DoH, 2018, CANC REG ANN REP 201; CAMP RL, 2004, CLIN CANCER RES, V10, P7252, DOI [10.1158/1078-0432.CCR-04-0713, DOI 10.1158/1078-0432.CCR-04-0713]; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Chan CK, 2016, OPEN BIOL, V6, DOI 10.1098/rsob.160275; Cordero Alexis B, 2010, J Vis Exp, DOI 10.3791/2125; Cormio G, 2003, INT J GYNECOL CANCER, V13, P125, DOI 10.1046/j.1525-1438.2003.13054.x; Davidson B, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00033; Dong Peixin, 2018, Oncotarget, V9, P23253, DOI 10.18632/oncotarget.25298; Feng JL, 2014, J CELL MOL MED, V18, P2125, DOI 10.1111/jcmm.12398; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; Goonewardene TI, 2007, LANCET ONCOL, V8, P813, DOI 10.1016/S1470-2045(07)70273-5; Gunaje JJ, 2011, AM J PHYSIOL-CELL PH, V301, pC478, DOI 10.1152/ajpcell.00348.2010; Guo YH, 2016, ONCOTARGET, V7, P42513, DOI 10.18632/oncotarget.9893; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hsu IL, 2016, ONCOTARGET, V7, P62925, DOI 10.18632/oncotarget.7497; Huntzinger E, 2011, NAT REV GENET, V12, P99, DOI 10.1038/nrg2936; Jayson GC, 2014, LANCET, V384, P1376, DOI 10.1016/S0140-6736(13)62146-7; Jia LY, 2016, ONCOTARGET, V7, P36743, DOI 10.18632/oncotarget.9163; Junttila MR, 2013, NATURE, V501, P346, DOI 10.1038/nature12626; Karlan BY, 2014, GYNECOL ONCOL, V132, P334, DOI 10.1016/j.ygyno.2013.12.021; Konecny GE, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju249; Kurrey NK, 2005, GYNECOL ONCOL, V97, P155, DOI 10.1016/j.ygyno.2004.12.043; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Li GM, 2008, CELL RES, V18, P1, DOI 10.1038/cr.2008.9; Li H, 2016, SCI REP-UK, V6, DOI 10.1038/srep39001; Lin YC, 2008, MOL BIOL EVOL, V25, P2189, DOI 10.1093/molbev/msn165; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lujambio A, 2012, NATURE, V482, P347, DOI 10.1038/nature10888; MAINGUENE C, 1986, J NUCL MED ALLIED S, V30, P19; Mateescu B, 2011, NAT MED, V17, P1627, DOI 10.1038/nm.2512; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Naora H, 2005, NAT REV CANCER, V5, P355, DOI 10.1038/nrc1611; Narod S, 2016, NAT REV CLIN ONCOL, V13, P255, DOI 10.1038/nrclinonc.2015.224; NOSEDA A, 1987, LIPIDS, V22, P878, DOI 10.1007/BF02535548; Peng Y, 2016, SIGNAL TRANSDUCT TAR, V1, DOI 10.1038/sigtrans.2015.4; Pradeep S, 2014, CANCER CELL, V26, P77, DOI 10.1016/j.ccr.2014.05.002; Shih KK, 2011, GYNECOL ONCOL, V121, P444, DOI 10.1016/j.ygyno.2011.01.025; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Smith BN, 2016, J CLIN MED, V5, DOI 10.3390/jcm5020017; Smolle E, 2014, ANTICANCER RES, V34, P1553; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun Y, 2015, J PATHOL, V235, P25, DOI 10.1002/path.4443; Theriault BL, 2007, CARCINOGENESIS, V28, P1153, DOI 10.1093/carcin/bgm015; Torre LA, 2018, CA-CANCER J CLIN, V68, P284, DOI 10.3322/caac.21456; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Vang S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058226; Vergara D, 2010, CANCER LETT, V291, P59, DOI 10.1016/j.canlet.2009.09.017; Verhaak RGW, 2013, J CLIN INVEST, V123, P517, DOI 10.1172/JCI65833; Wang F, 2015, ONCOL LETT, V10, P11, DOI 10.3892/ol.2015.3170; Wang F, 2018, PEERJ, V6, DOI 10.7717/peerj.5912; Wang WH, 2014, ASIAN PAC J CANCER P, V15, P6269, DOI 10.7314/APJCP.2014.15.15.6269; Wang Y, 2012, ONCOGENE, V31, P2512, DOI 10.1038/onc.2011.435; Xiao CC, 2007, CELL, V131, P146, DOI 10.1016/j.cell.2007.07.021; Xu L, 2017, NEOPLASIA, V19, P374, DOI 10.1016/j.neo.2017.01.011; Yang D, 2013, CANCER CELL, V23, P186, DOI 10.1016/j.ccr.2012.12.020; Zhang HY, 2017, GENE, V633, P61, DOI 10.1016/j.gene.2017.08.009; Zhang J, 2012, INT J ONCOL, V40, P747, DOI 10.3892/ijo.2011.1242; Zhang YJ, 2010, MOL CELL, V39, P133, DOI 10.1016/j.molcel.2010.06.010; Zhao LJ, 2019, ONCOGENE, V38, P2305, DOI 10.1038/s41388-018-0577-5	66	14	15	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	4					862	876		10.1038/s41388-019-1025-x	http://dx.doi.org/10.1038/s41388-019-1025-x			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KF4EJ	31570789				2022-12-28	WOS:000509197200009
J	Gupta, R; Janostiak, R; Wajapeyee, N				Gupta, Romi; Janostiak, Radoslav; Wajapeyee, Narendra			Transcriptional regulators and alterations that drive melanoma initiation and progression	ONCOGENE			English	Review							TERT PROMOTER MUTATIONS; MALIGNANT-MELANOMA; MITF; EXPRESSION; LANDSCAPE; GENE; PROTEIN; BRN-2; BRAF; P53	Although melanoma is the least frequent type of skin cancer, it accounts for the majority of skin cancer-related deaths. Large-scale sequencing efforts have led to the classification of melanoma into four major subtypes (i.e., BRAF-mutant, NRAS-mutant, NF1-deficient, and triple wild-type). These sequencing studies have also revealed that melanoma genomes are some of the most mutated genomes of all cancers and therefore have a high neoantigen load. These findings have resulted in the development and clinical use of targeted therapies against the oncogenic BRAF -> MEK -> ERK pathway and immune checkpoint inhibitors for the treatment of metastatic melanoma. Although some patients with metastatic melanoma benefit immensely from these transformative therapies, others either become resistant or do not respond at all. These clinical challenges have intensified the search for new drug targets and drugs that can benefit patients who are either intrinsically resistant or have acquired resistance to targeted therapies and immunotherapies. Numerous signaling pathways and oncogenic drivers can cause changes in mRNA transcription that in turn drive melanoma initiation and progression. Transcriptional regulation of mRNA expression is necessary to maintain cell identity and cellular plasticity via the regulation of transcription factor expression and function, promoter/enhancer activities, chromatin regulators, and three-dimensional genome organization. Transcriptional deregulation can arise due to genetic and/or non-genetic alterations in the genome. Specifically, these deregulated transcriptional programs can become liabilities for melanoma cells due to their acquired dependencies on these programs for survival, which can be harnessed to develop new therapies for melanoma. In this article, we present an overview of the mechanisms that result in the transcriptional deregulation of mRNA expression in melanoma cells and assess how these changes facilitate melanoma initiation and progression. We also describe how these deregulated transcriptional pathways represent new opportunities for the development of unconventional and potentially impactful treatments for metastatic melanoma.	[Gupta, Romi; Wajapeyee, Narendra] Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; [Janostiak, Radoslav] Barcelona Inst Sci & Technol, Inst Res Biomed IRB Barcelona, Barcelona 08028, Spain	University of Alabama System; University of Alabama Birmingham; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona	Gupta, R; Wajapeyee, N (corresponding author), Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA.	romigup@uab.edu; nwajapey@uab.edu	Janostiak, Radoslav/ABE-5349-2020	Janostiak, Radoslav/0000-0002-6602-9389; Wajapeyee, Narendra/0000-0003-3306-349X; Gupta, Romi/0000-0001-5108-5962	NCI NIH HHS [R01 CA200919, R01 CA196566, R21 CA191364] Funding Source: Medline; U.S. Department of Health &amp; Human Services | NIH | Office of Extramural Research, National Institutes of Health (OER) [R01CA200919, R01CA196566, R03CA221926] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); U.S. Department of Health &amp; Human Services | NIH | Office of Extramural Research, National Institutes of Health (OER)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Akdemir KC, 2020, NAT GENET, V52, P294, DOI 10.1038/s41588-019-0564-y; Ally A, 2017, CELL, V169, P1327, DOI 10.1016/j.cell.2017.05.046; ANGUS J, 1995, ONCOGENE, V11, P691; Arrowsmith CH, 2019, NAT STRUCT MOL BIOL, V26, P863, DOI 10.1038/s41594-019-0290-2; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Chaoui A, 2015, HUM MOL GENET, V24, P4933, DOI 10.1093/hmg/ddv215; Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876; Corces MR, 2018, SCIENCE, V362, P420, DOI 10.1126/science.aav1898; Dai C, 2010, TRENDS MOL MED, V16, P528, DOI 10.1016/j.molmed.2010.09.002; Dekker J, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a019356; Dixon JR, 2012, NATURE, V485, P376, DOI 10.1038/nature11082; Donaldson-Collier MC, 2019, NAT GENET, V51, P517, DOI 10.1038/s41588-018-0338-y; EISEN T, 1995, ONCOGENE, V11, P2157; Ernst J, 2017, NAT PROTOC, V12, P2478, DOI 10.1038/nprot.2017.124; Freed-Pastor WA, 2012, GENE DEV, V26, P1268, DOI 10.1101/gad.190678.112; Fujimoto A, 2016, NAT GENET, V48, P500, DOI 10.1038/ng.3547; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Goodall J, 2004, MOL CELL BIOL, V24, P2923, DOI 10.1128/MCB.24.7.2923-2931.2004; Greenberg MVC, 2019, NAT REV MOL CELL BIO, V20, P590, DOI 10.1038/s41580-019-0159-6; Han SJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02354-x; Haqq C, 2005, P NATL ACAD SCI USA, V102, P6092, DOI 10.1073/pnas.0501564102; Helin K, 2013, NATURE, V502, P480, DOI 10.1038/nature12751; Herbert K, 2019, GENE DEV, V33, P310, DOI 10.1101/gad.314633.118; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Horn S, 2013, SCIENCE, V339, P959, DOI 10.1126/science.1230062; Huang FW, 2013, SCIENCE, V339, P957, DOI 10.1126/science.1229259; Italiano A, 2018, LANCET ONCOL, V19, P649, DOI 10.1016/S1470-2045(18)30145-1; Jain AK, 2017, J MOL BIOL, V429, P2003, DOI 10.1016/j.jmb.2016.11.020; Johannessen CM, 2013, NATURE, V504, P138, DOI 10.1038/nature12688; Kato S, 2020, CANCER DISCOV, V10, P980, DOI 10.1158/2159-8290.CD-19-0532; Kinsler VA, 2017, BRIT J DERMATOL, V176, P1131, DOI 10.1111/bjd.15301; Kundaje A, 2015, NATURE, V518, P317, DOI 10.1038/nature14248; Levy C, 2006, TRENDS MOL MED, V12, P406, DOI 10.1016/j.molmed.2006.07.008; Li YH, 2016, P NATL ACAD SCI USA, V113, P14402, DOI 10.1073/pnas.1611106113; Lian CG, 2012, CELL, V150, P1135, DOI 10.1016/j.cell.2012.07.033; Lopez-Bergami P, 2007, CANCER CELL, V11, P447, DOI 10.1016/j.ccr.2007.03.009; Lu C, 2012, NATURE, V483, P474, DOI 10.1038/nature10860; Mansky KC, 2002, J BIOL CHEM, V277, P11077, DOI 10.1074/jbc.M111696200; Maric H, 2019, MELANOMA RES, V29, P596, DOI 10.1097/CMR.0000000000000612; Micevic G, 2016, CELL REP, V14, P2180, DOI 10.1016/j.celrep.2016.02.010; Miller AJ, 2005, J BIOL CHEM, V280, P146, DOI 10.1074/jbc.M411757200; Misteli T, 2007, CELL, V128, P787, DOI 10.1016/j.cell.2007.01.028; Murakami H, 2005, PIGM CELL RES, V18, P265, DOI 10.1111/j.1600-0749.2005.00234.x; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Musselman CA, 2012, NAT STRUCT MOL BIOL, V19, P1218, DOI 10.1038/nsmb.2436; Nacev BA, 2019, NATURE, V567, P473, DOI 10.1038/s41586-019-1038-1; Nora EP, 2012, NATURE, V485, P381, DOI 10.1038/nature11049; Pan W, 2017, IMMUNITY, V47, P284, DOI 10.1016/j.immuni.2017.07.020; Pavey S, 2004, ONCOGENE, V23, P4060, DOI 10.1038/sj.onc.1207563; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Phillips JE, 2009, CELL, V137, P1194, DOI 10.1016/j.cell.2009.06.001; Pierce CJ, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-00247-1; Polak P, 2015, NATURE, V518, P360, DOI 10.1038/nature14221; Pusch C, 1998, HUM GENET, V103, P115, DOI 10.1007/s004390050793; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sen N, 2011, MOL CELL, V44, P621, DOI 10.1016/j.molcel.2011.08.044; Shah S., 2019, ONCOTARGET, V10, P3745, DOI [10.18632/oncotarget.26959, DOI 10.18632/ONCOTARGET.26959]; Shakhova O, 2012, NAT CELL BIOL, V14, P882, DOI 10.1038/ncb2535; Simmons JL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11366-y; Souroullas GP, 2016, NAT MED, V22, P632, DOI 10.1038/nm.4092; Taberlay PC, 2016, GENOME RES, V26, P719, DOI 10.1101/gr.201517.115; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Takeda K, 2000, HUM MOL GENET, V9, P125, DOI 10.1093/hmg/9.1.125; Talantov D, 2005, CLIN CANCER RES, V11, P7234, DOI 10.1158/1078-0432.CCR-05-0683; Turcan S, 2012, NATURE, V483, P479, DOI 10.1038/nature10866; Villicana C, 2014, CANCER CELL INT, V14, DOI 10.1186/1475-2867-14-18; Weinhold N, 2014, NAT GENET, V46, P1160, DOI 10.1038/ng.3101; Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028; Wu H, 2011, GENE DEV, V25, P2436, DOI 10.1101/gad.179184.111; Wu M, 2000, GENE DEV, V14, P301; Yan ZJ, 2005, GENE DEV, V19, P1662, DOI 10.1101/gad.1323805; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Yang JY, 2010, CANCER RES, V70, P4709, DOI 10.1158/0008-5472.CAN-09-4524; Yokoyama S, 2011, NATURE, V480, P99, DOI 10.1038/nature10630; Zingg D, 2018, CANCER CELL, V34, P69, DOI 10.1016/j.ccell.2018.06.001; Zingg D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7051	77	11	12	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	2020	39	48					7093	7105		10.1038/s41388-020-01490-x	http://dx.doi.org/10.1038/s41388-020-01490-x		OCT 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PE1YE	33024276	Green Published, hybrid			2022-12-28	WOS:000575700700002
J	Broggini, T; Piffko, A; Hoffmann, CJ; Ghori, A; Harms, C; Adams, RH; Vajkoczy, P; Czabanka, M				Broggini, Thomas; Piffko, Andras; Hoffmann, Christian J.; Ghori, Adnan; Harms, Christoph; Adams, Ralf H.; Vajkoczy, Peter; Czabanka, Marcus			Ephrin-B2-EphB4 communication mediates tumor-endothelial cell interactions during hematogenous spread to spinal bone in a melanoma metastasis model	ONCOGENE			English	Article							EPHB4 RECEPTOR; IN-VIVO; EPHRIN; PROLIFERATION; ANGIOGENESIS; ENDOCYTOSIS; MECHANISMS; MIGRATION; PROMOTES; ADHESION	Metastases account for the majority of cancer deaths. Bone represents one of the most common sites of distant metastases, and spinal bone metastasis is the most common source of neurological morbidity in cancer patients. During metastatic seeding of cancer cells, endothelial-tumor cell interactions govern extravasation to the bone and potentially represent one of the first points of action for antimetastatic treatment. The ephrin-B2-EphB4 pathway controls cellular interactions by inducing repulsive or adhesive properties, depending on forward or reverse signaling. Here, we report that in an in vivo metastatic melanoma model, ephrin-B2-mediated activation of EphB4 induces tumor cell repulsion from bone endothelium, translating in reduced spinal bone metastatic loci and improved neurological function. Selective ephrin-B2 depletion in endothelial cells or EphB4 inhibition increases bone metastasis and shortens the time window to hind-limb locomotion deficit from spinal cord compression. EphB4 overexpression in melanoma cells ameliorates the metastatic phenotype and improves neurological outcome. Timely harvesting of bone tissue after tumor cell injection and intravital bone microscopy revealed less tumor cells attached to ephrin-B2-positive endothelial cells. These results suggest that ephrin-B2-EphB4 communication influences bone metastasis formation by altering melanoma cell repulsion/adhesion to bone endothelial cells, and represents a molecular target for therapeutic intervention.	[Broggini, Thomas; Piffko, Andras; Ghori, Adnan; Vajkoczy, Peter; Czabanka, Marcus] Univ Med Charite, Dept Neurosurg, D-10117 Berlin, Germany; [Broggini, Thomas] Univ Calif San Diego, Dept Phys, 9500 Gilman Dr, La Jolla, CA 92093 USA; [Piffko, Andras] Univ Med Ctr Hamburg Eppendorf, Dept Neurosurg, Martinistr 52, D-20246 Hamburg, Germany; [Hoffmann, Christian J.; Harms, Christoph] Univ Med Charite, Ctr Stroke Res Berlin, Dept Expt Neurol, D-10117 Berlin, Germany; [Adams, Ralf H.] Max Planck Inst Mol Biomed, Dept Tissue Morphogenesis, D-48149 Munster, Germany; [Adams, Ralf H.] Univ Munster, Fac Med, D-48149 Munster, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of California System; University of California San Diego; University of Hamburg; University Medical Center Hamburg-Eppendorf; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Max Planck Society; University of Munster	Czabanka, M (corresponding author), Univ Med Charite, Dept Neurosurg, D-10117 Berlin, Germany.	marcus.czabanka@charite.de	Harms, Christoph/HIK-2989-2022; Harms, Christoph/AAD-7895-2021	Harms, Christoph/0000-0002-2063-2860; Adams, Ralf/0000-0003-3031-7677; Piffko, Andras/0000-0001-5300-6594; Ghori, Adnan/0000-0003-0921-1683; Hoffmann, Christian Johannes/0000-0003-0861-2418	German research foundation [DFG GEPRIS: 267716524]; DFG Forschergruppe [FOR2325]; Berliner Krebsgesellschaft e.V.; Early/Advanced Postdoc Mobility fellowship from the Swiss National Science Foundation; Volkswagen Foundation; Charite Foundation; Clinical Fellow Program of the Berlin Institue of Health	German research foundation(German Research Foundation (DFG)); DFG Forschergruppe(German Research Foundation (DFG)); Berliner Krebsgesellschaft e.V.; Early/Advanced Postdoc Mobility fellowship from the Swiss National Science Foundation(Swiss National Science Foundation (SNSF)); Volkswagen Foundation(Volkswagen); Charite Foundation; Clinical Fellow Program of the Berlin Institue of Health	Basic components of the cartoon are provided by Servier Medical Art. This work was supported by the German research foundation (DFG GEPRIS: 267716524) and the FOR2325 DFG Forschergruppe. TB was a doctoral student of the Charite Medical Neuroscience, NeuroCure cluster of excellence graduate school, received the Ernst von Leyden fellowship from the "Berliner Krebsgesellschaft e.V.," and the Early/Advanced Postdoc Mobility fellowship from the Swiss National Science Foundation. MC was part of the Friedrich C. Luft Clinical Scientist Pilot Program funded by the Volkswagen Foundation and the Charite Foundation and the Clinical Fellow Program of the Berlin Institue of Health. The funding sources had no involvement in study design; in the collection, analysis, and interpretation of the data; in the writing of the report; in the decision to submit the paper for publication.	Adams RH, 2000, TRENDS CARDIOVAS MED, V10, P183, DOI 10.1016/S1050-1738(00)00046-3; ARGUELLO F, 1988, CANCER RES, V48, P6876; Azab F, 2012, CLIN CANCER RES, V18, P91, DOI 10.1158/1078-0432.CCR-11-0111; Bayerl SH, 2016, GLIA, V64, P1210, DOI 10.1002/glia.22994; Bochenek ML, 2010, J CELL SCI, V123, P1235, DOI 10.1242/jcs.061903; Broggini T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162540; Broggini T, 2016, CANCER LETT, V380, P568, DOI 10.1016/j.canlet.2015.06.026; Broggini T, 2015, EUR SPINE J, V24, P2173, DOI 10.1007/s00586-015-3811-7; Chen YN, 2019, SEMIN CANCER BIOL, V56, P37, DOI 10.1016/j.semcancer.2017.10.002; Erber R, 2006, EMBO J, V25, P628, DOI 10.1038/sj.emboj.7600949; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; Foster KE, 2010, P NATL ACAD SCI USA, V107, P13414, DOI 10.1073/pnas.1003747107; Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304; Heroult M, 2006, EXP CELL RES, V312, P642, DOI 10.1016/j.yexcr.2005.10.028; Heroult M, 2010, MOL CANCER RES, V8, P1297, DOI 10.1158/1541-7786.MCR-09-0453; Holmberg J, 2006, CELL, V125, P1151, DOI 10.1016/j.cell.2006.04.030; Huehnchen P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076772; Kania A, 2016, NAT REV MOL CELL BIO, V17, P240, DOI 10.1038/nrm.2015.16; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Kusumbe AP, 2015, NAT PROTOC, V10, P1904, DOI 10.1038/nprot.2015.125; Kwak H, 2016, J CLIN INVEST, V126, P4554, DOI 10.1172/JCI87848; Laurent C, 2011, CANCER RES, V71, P666, DOI 10.1158/0008-5472.CAN-10-0605; Lin SC, 2017, DEV CELL, V41, P467, DOI 10.1016/j.devcel.2017.05.005; Macedo F, 2017, ONCOL REV, V11, P43, DOI 10.4081/oncol.2017.321; Marston DJ, 2003, NAT CELL BIOL, V5, P879, DOI 10.1038/ncb1044; Martiny-Baron G, 2010, ANGIOGENESIS, V13, P259, DOI 10.1007/s10456-010-9183-z; Matsuo K, 2012, CELL ADHES MIGR, V6, P148, DOI 10.4161/cam.20888; Noren NK, 2007, CANCER RES, V67, P3994, DOI 10.1158/0008-5472.CAN-07-0525; Nunan R, 2015, CELL REP, V13, P1380, DOI 10.1016/j.celrep.2015.09.085; Onken J, 2016, ONCOTARGET, V7, P9876, DOI 10.18632/oncotarget.7130; Patchell RA, 2005, LANCET, V366, P643, DOI 10.1016/S0140-6736(05)66954-1; Pennisi A, 2009, BLOOD, V114, P1803, DOI 10.1182/blood-2009-01-201954; Pitulescu ME, 2010, GENE DEV, V24, P2480, DOI 10.1101/gad.1973910; Sawamiphak S, 2010, NATURE, V465, P487, DOI 10.1038/nature08995; Schott AF, 2016, BREAST CANCER RES TR, V159, P87, DOI 10.1007/s10549-016-3911-z; Wang YD, 2010, NATURE, V465, P483, DOI 10.1038/nature09002; Weichselbaum RR, 2011, NAT REV CLIN ONCOL, V8, P378, DOI 10.1038/nrclinonc.2011.44; Xu R, 2018, NAT MED, V24, P823, DOI 10.1038/s41591-018-0020-z; Yang NY, 2010, PIGM CELL MELANOMA R, V23, P684, DOI 10.1111/j.1755-148X.2010.00745.x; Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012; Zimmer M, 2003, NAT CELL BIOL, V5, P869, DOI 10.1038/ncb1045	41	5	5	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	2020	39	47					7063	7075		10.1038/s41388-020-01473-y	http://dx.doi.org/10.1038/s41388-020-01473-y		SEP 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OT7KA	32989254				2022-12-28	WOS:000573446900006
J	Kanamori, A; Matsubara, D; Saitoh, Y; Fukui, Y; Gotoh, N; Kaneko, S; Seiki, M; Murakami, Y; Inoue, J; Sakamoto, T				Kanamori, Akane; Matsubara, Daisuke; Saitoh, Yurika; Fukui, Yuya; Gotoh, Noriko; Kaneko, Shuichi; Seiki, Motoharu; Murakami, Yoshinori; Inoue, Jun-ichiro; Sakamoto, Takeharu			Mint3 depletion restricts tumor malignancy of pancreatic cancer cells by decreasing SKP2 expression via HIF-1	ONCOGENE			English	Article							HYPOXIA-INDUCIBLE FACTOR-1; UBIQUITIN LIGASE; PROSTATE-CANCER; DEGRADATION; RESISTANCE; PROTEINS; BIOLOGY; P21; EMT	Pancreatic cancer is one of the most fatal cancers without druggable molecular targets. Hypoxia inducible factor-1 (HIF-1) is a heterodimeric transcriptional factor that promotes malignancy in various cancers including pancreatic cancer. Herein, we found that HIF-1 is accumulated in normoxic or moderate hypoxic areas of pancreatic cancer xenografts in vivo and is active even during normoxia in pancreatic cancer cells in vitro. This prompted us to analyze whether the HIF-1 activator Mint3 contributes to malignant features of pancreatic cancer. Mint3 depletion by shRNAs attenuated HIF-1 activity during normoxia and cell proliferation concomitantly with accumulated p21 and p27 protein in pancreatic cancer cells. Further analyses revealed that Mint3 increased transcription of the oncogenic ubiquitin ligase SKP2 in pancreatic cancer cells via HIF-1. This Mint3-HIF-1-SKP2 axis also promoted partial epithelial-mesenchymal transition, stemness features, and chemoresistance in pancreatic cancer cells. Even in vivo, Mint3 depletion attenuated tumor growth of orthotopically inoculated human pancreatic cancer AsPC-1 cells. Database and tissue microarray analyses showed that Mint3 expression is correlated with SKP2 expression in human pancreatic cancer specimens and high Mint3 expression is correlated with poor prognosis of pancreatic cancer patients. Thus, targeting Mint3 may be useful for attenuating the malignant features of pancreatic cancer.	[Kanamori, Akane; Saitoh, Yurika; Fukui, Yuya; Inoue, Jun-ichiro] Univ Tokyo, Inst Med Sci, Div Cellular & Mol Biol, Minato Ku, Tokyo, Japan; [Matsubara, Daisuke] Jichi Med Univ, Dept Pathol, Shimotsuke, Tochigi, Japan; [Saitoh, Yurika] Teikyo Univ Sci, Ctr Med Educ, Adachi Ku, Tokyo, Japan; [Gotoh, Noriko] Kanazawa Univ, Canc Res Inst, Div Canc Cell Biol, Kakuma Machi, Kanazawa, Ishikawa, Japan; [Kaneko, Shuichi] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Dept Gastroenterol, Takaramachi, Kanazawa, Ishikawa, Japan; [Seiki, Motoharu] Univ Tokyo, Inst Med Sci, Div Canc Cell Res, Minato Ku, Tokyo, Japan; [Murakami, Yoshinori] Univ Tokyo, Inst Med Sci, Div Mol Pathol, Minato Ku, Tokyo, Japan; [Sakamoto, Takeharu] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Dept Syst Biol, Takaramachi, Kanazawa, Ishikawa, Japan	University of Tokyo; Jichi Medical University; Kanazawa University; Kanazawa University; University of Tokyo; University of Tokyo; Kanazawa University	Sakamoto, T (corresponding author), Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Dept Syst Biol, Takaramachi, Kanazawa, Ishikawa, Japan.	t-saka@staff.kanazawa-u.ac.jp		Sakamoto, Takeharu/0000-0002-1225-1902; Inoue, Jun-ichiro/0000-0001-6389-7036	MEXT [19K07659]; P-CREATE (Project for Cancer Research and Therapeutic Evolution) grant from The Japan Agency for Medical Research and Development [16770655]; Kobayashi Foundation for Cancer Research; Extramural Collaborative Research Grant of the Cancer Research Institute, Kanazawa University	MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); P-CREATE (Project for Cancer Research and Therapeutic Evolution) grant from The Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED)); Kobayashi Foundation for Cancer Research(Kobayashi Foundation for Cancer Research); Extramural Collaborative Research Grant of the Cancer Research Institute, Kanazawa University	This work was supported by a Grant-in-Aid for Scientific Research (C) (19K07659) from MEXT; a P-CREATE (Project for Cancer Research and Therapeutic Evolution) grant (16770655) from The Japan Agency for Medical Research and Development; the Kobayashi Foundation for Cancer Research; and partly by the Extramural Collaborative Research Grant of the Cancer Research Institute, Kanazawa University (to TS).	Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Bhattacharya S, 2003, ONCOGENE, V22, P2443, DOI 10.1038/sj.onc.1206339; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chan CH, 2013, CELL, V154, P556, DOI 10.1016/j.cell.2013.06.048; Chan CH, 2012, CELL, V149, P1098, DOI 10.1016/j.cell.2012.02.065; Ciliberto D, 2013, EUR J CANCER, V49, P593, DOI 10.1016/j.ejca.2012.08.019; Einama T, 2006, PANCREAS, V32, P376, DOI 10.1097/01.mpa.0000220862.78248.c4; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Gartel AL, 2002, MOL CANCER THER, V1, P639; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Hara T, 2017, P NATL ACAD SCI USA, V114, pE4416, DOI 10.1073/pnas.1703171114; Hara T, 2011, J BIOL CHEM, V286, P32542, DOI 10.1074/jbc.M111.271726; Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557; Hiromura K, 1999, J CLIN INVEST, V103, P597, DOI 10.1172/JCI5461; Ho A, 2006, J NEUROSCI, V26, P13089, DOI 10.1523/JNEUROSCI.2855-06.2006; Huang H, 2005, P NATL ACAD SCI USA, V102, P1649, DOI 10.1073/pnas.0406789102; Huang TH, 2017, ONCOTARGETS THER, V10, P439, DOI 10.2147/OTT.S125789; Jung YS, 2010, CELL SIGNAL, V22, P1003, DOI 10.1016/j.cellsig.2010.01.013; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Nakaoka HJ, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.27; Raleigh JA, 1999, RADIAT RES, V151, P580, DOI 10.2307/3580034; Rius J, 2008, NATURE, V453, P807, DOI 10.1038/nature06905; Ruan D, 2017, ONCOGENE, V36, P4299, DOI 10.1038/onc.2017.64; Sakamoto T, 2017, CANCER SCI, V108, P1095, DOI 10.1111/cas.13231; Sakamoto T, 2014, MOL CELL BIOL, V34, P30, DOI 10.1128/MCB.01169-13; Sakamoto T, 2011, J BIOL CHEM, V286, P14691, DOI 10.1074/jbc.M110.188714; Sakamoto T, 2010, J BIOL CHEM, V285, P29951, DOI 10.1074/jbc.M110.132704; Sakamoto T, 2009, J BIOL CHEM, V284, P30350, DOI 10.1074/jbc.M109.019216; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sobhanifar S, 2005, CANCER RES, V65, P7259, DOI 10.1158/0008-5472.CAN-04-4480; Solomon S, 2007, AR4 CLIMATE CHANGE 2007: THE PHYSICAL SCIENCE BASIS, P1; Vaupel P, 2007, CANCER METAST REV, V26, P225, DOI 10.1007/s10555-007-9055-1; Vervoorts J, 2008, CELL MOL LIFE SCI, V65, P3255, DOI 10.1007/s00018-008-8296-7; Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691; Yang YG, 2016, ONCOL REP, V36, P559, DOI 10.3892/or.2016.4809; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; Zhang HM, 2015, P NATL ACAD SCI USA, V112, pE6215, DOI 10.1073/pnas.1520032112	45	9	9	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2020	39	39					6218	6230		10.1038/s41388-020-01423-8	http://dx.doi.org/10.1038/s41388-020-01423-8		AUG 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NS8XO	32826949	hybrid, Green Published			2022-12-28	WOS:000561519300003
J	Fong, WN; Li, Q; Yu, J				Fong, Winnie; Li, Qing; Yu, Jun			Gut microbiota modulation: a novel strategy for prevention and treatment of colorectal cancer	ONCOGENE			English	Review							LACTOBACILLUS-RHAMNOSUS GG; LACTIC-ACID BACTERIA; COLON-CANCER; PROBIOTIC LACTOBACILLUS; INTESTINAL MICROBIOTA; DOUBLE-BLIND; ACIDOPHILUS DEFICIENT; ESCHERICHIA-COLI; BARRIER FUNCTION; POTENTIAL ROLE	Research about the role of gut microbiome in colorectal cancer (CRC) is a newly emerging field of study. Gut microbiota modulation, with the aim to reverse established microbial dysbiosis, is a novel strategy for prevention and treatment of CRC. Different strategies including probiotics, prebiotics, postbiotics, antibiotics, and fecal microbiota transplantation (FMT) have been employed. Although these strategies show promising results, mechanistically by correcting microbiota composition, modulating innate immune system, enhancing gut barrier function, preventing pathogen colonization and exerting selective cytotoxicity against tumor cells, it should be noted that they are accompanied by risks and controversies that can potentially introduce clinical complications. During bench-to-bedside translation, evaluation of risk-and-benefit ratio, as well as patient selection, should be carefully performed. In view of the individualized host response to gut microbiome intervention, developing personalized microbiome therapy may be the key to successful clinical treatment.	[Fong, Winnie; Li, Qing; Yu, Jun] Chinese Univ Hong Kong, Inst Digest Dis & Dept Med & Therapeut, State Key Lab Digest Dis,Li Ka Shing Inst Hlth Sc, CUHK Shenzhen Res Inst, Hong Kong, Peoples R China; [Fong, Winnie] Chinese Univ Hong Kong, Sch Pharm, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong	Yu, J (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis & Dept Med & Therapeut, State Key Lab Digest Dis,Li Ka Shing Inst Hlth Sc, CUHK Shenzhen Res Inst, Hong Kong, Peoples R China.	junyu@cuhk.edu.hk	Li, Qing/ABC-4649-2020; Jun, Yu/D-8569-2015	Li, Qing/0000-0002-0169-8098; Jun, Yu/0000-0001-5008-2153	National Natural Science Foundation of China (National Science Foundation of China) [81972576] Funding Source: Medline	National Natural Science Foundation of China (National Science Foundation of China)(National Natural Science Foundation of China (NSFC))		Ahmad R, 2017, ONCOGENE, V36, P6592, DOI 10.1038/onc.2017.259; Alang N, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofv004; Alvarez CS, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01981; Ambalam P, 2016, BEST PRACT RES CL GA, V30, P119, DOI 10.1016/j.bpg.2016.02.009; Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912; Azcarate-Peril MA, 2017, P NATL ACAD SCI USA, V114, pE367, DOI 10.1073/pnas.1606722113; Belcheva A, 2014, CELL, V158, P288, DOI 10.1016/j.cell.2014.04.051; Bermudez-Brito M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059370; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bullman S, 2017, SCIENCE, V358, P1443, DOI 10.1126/science.aal5240; Bultman SJ, 2014, CELL HOST MICROBE, V16, P143, DOI 10.1016/j.chom.2014.07.011; Campana R, 2017, GUT PATHOG, V9, DOI 10.1186/s13099-017-0162-4; Canani RB, 2011, WORLD J GASTROENTERO, V17, P1519, DOI [10.3748/wjg.v17.i12.1519, 10.3748/wjg.v17.i12. 1519]; Cannon JP, 2005, EUR J CLIN MICROBIOL, V24, P31, DOI 10.1007/s10096-004-1253-y; Cao HL, 2017, INT J CANCER, V140, P2545, DOI 10.1002/ijc.30643; Cao Y, 2018, GUT, V67, P672, DOI 10.1136/gutjnl-2016-313413; Chang CW, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00983; Chen CC, 2012, BRIT J NUTR, V107, P1623, DOI 10.1017/S0007114511004934; Chen LL, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/909514; Chen ZF, 2015, FUTURE MICROBIOL, V10, P1433, DOI 10.2217/fmb.15.66; Chen ZY, 2017, MOLECULES, V22, DOI 10.3390/molecules22010107; Chung L, 2018, CELL HOST MICROBE, V23, P421, DOI 10.1016/j.chom.2018.02.004; Crook N, 2019, CELL HOST MICROBE, V25, P499, DOI 10.1016/j.chom.2019.02.005; Cui M, 2017, EMBO MOL MED, V9, P448, DOI 10.15252/emmm.201606932; Dai ZW, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0451-2; Daillere R, 2016, IMMUNITY, V45, P931, DOI 10.1016/j.immuni.2016.09.009; De Marco S, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/1756308; Delia P, 2007, WORLD J GASTROENTERO, V13, P912, DOI 10.3748/wjg.v13.i6.912; Demers M, 2014, CLIN NUTR, V33, P761, DOI 10.1016/j.clnu.2013.10.015; Derosa L, 2018, ANN ONCOL, V29, P1437, DOI 10.1093/annonc/mdy103; Dewulf EM, 2013, GUT, V62, P1112, DOI 10.1136/gutjnl-2012-303304; Dik VK, 2016, DIGEST DIS SCI, V61, P255, DOI 10.1007/s10620-015-3828-0; Doron S, 2015, CLIN INFECT DIS, V60, pS129, DOI 10.1093/cid/civ085; Escamilla J, 2012, NUTR CANCER, V64, P871, DOI 10.1080/01635581.2012.700758; Fayol-Messaoudi D, 2005, APPL ENVIRON MICROB, V71, P6008, DOI 10.1128/AEM.71.10.6008-6013.2005; Feng Q, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7528; Food and Drug Administration, 2019, IMP SAF AL REG US FE; Forchielli ML, 2005, BRIT J NUTR, V93, pS41, DOI 10.1079/BJN20041356; Fukuda S, 2011, NATURE, V469, P543, DOI 10.1038/nature09646; Gamallat Y, 2016, BIOMED PHARMACOTHER, V83, P536, DOI 10.1016/j.biopha.2016.07.001; Gao J, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00477; Geier MS, 2006, CANCER BIOL THER, V5, P1265, DOI 10.4161/cbt.5.10.3296; Geller LT, 2017, SCIENCE, V357, P1156, DOI 10.1126/science.aah5043; Ghadimi D, 2012, J LEUKOCYTE BIOL, V92, P895, DOI 10.1189/jlb.0611286; Gibson GR, 2017, NAT REV GASTRO HEPAT, V14, P491, DOI 10.1038/nrgastro.2017.75; Gibson GR, 2000, J NUTR, V130, p391S, DOI 10.1093/jn/130.2.391S; GIBSON GR, 1995, J NUTR, V125, P1401, DOI 10.1093/jn/125.6.1401; Gill SR, 2006, SCIENCE, V312, P1355, DOI 10.1126/science.1124234; Gillor O, 2008, APPL MICROBIOL BIOT, V81, P591, DOI 10.1007/s00253-008-1726-5; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Gregory JC, 2015, J BIOL CHEM, V290, P5647, DOI 10.1074/jbc.M114.618249; Gueimonde M, 2013, FRONT MICROBIOL, V4, DOI 10.3389/fmicb.2013.00202; Hassan H, 2018, SUPPORT CARE CANCER, V26, P2503, DOI 10.1007/s00520-018-4216-z; Hattori N, 2019, CANCER SCI, V110, P147, DOI 10.1111/cas.13880; Hohmann EL, 2014, NEW ENGL J MED, V371, P668, DOI 10.1056/NEJMcpc1400842; Hu YF, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3151; Iida N, 2013, SCIENCE, V342, P967, DOI 10.1126/science.1240527; Ijssennagger N, 2015, P NATL ACAD SCI USA, V112, P10038, DOI 10.1073/pnas.1507645112; Ishikawa H, 2005, INT J CANCER, V116, P762, DOI 10.1002/ijc.21115; Ito H, 2011, J AGR FOOD CHEM, V59, P5771, DOI 10.1021/jf200859z; Jacobsen L, 2007, FEMS MICROBIOL ECOL, V59, P158, DOI 10.1111/j.1574-6941.2006.00212.x; Jacouton E, 2019, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.03281; Jeon Seong Gyu, 2012, PLoS Pathog, V8, pe1002714, DOI 10.1371/journal.ppat.1002714; Kamada N, 2012, SCIENCE, V336, P1325, DOI 10.1126/science.1222195; Khazaie K, 2012, P NATL ACAD SCI USA, V109, P10462, DOI 10.1073/pnas.1207230109; Kilkkinen A, 2008, INT J CANCER, V123, P2152, DOI 10.1002/ijc.23622; Klaenhammer TR, 2012, NAT REV IMMUNOL, V12, P728, DOI 10.1038/nri3312; Konieczna P, 2012, GUT, V61, P354, DOI 10.1136/gutjnl-2011-300936; Konishi H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12365; Konstantinov SR, 2013, NAT REV GASTRO HEPAT, V10, P741, DOI 10.1038/nrgastro.2013.178; Kotzampassi K, 2015, WORLD J SURG, V39, P2776, DOI 10.1007/s00268-015-3071-z; Kroemer G, 2018, NAT REV IMMUNOL, V18, P87, DOI 10.1038/nri.2018.4; Kumar M, 2017, AM J PHYSIOL-GASTR L, V312, pG34, DOI 10.1152/ajpgi.00298.2016; Kuugbee ED, 2016, DIGEST DIS SCI, V61, P2908, DOI 10.1007/s10620-016-4238-7; Kyriacou DN, 2016, JAMA-J AM MED ASSOC, V316, P1818, DOI 10.1001/jama.2016.16435; Lenoir M, 2016, J GASTROENTEROL, V51, P862, DOI 10.1007/s00535-015-1158-9; Li HL, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00455; Lin XXB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083644; Lindsay JO, 2006, GUT, V55, P348, DOI 10.1136/gut.2005.074971; Liu C, 2009, BIOMED ENVIRON SCI, V22, P401, DOI 10.1016/S0895-3988(10)60018-9; Liu Z, 2011, ALIMENT PHARM THER, V33, P50, DOI 10.1111/j.1365-2036.2010.04492.x; Liu ZH, 2013, AM J CLIN NUTR, V97, P117, DOI 10.3945/ajcn.112.040949; Long XH, 2019, NAT MICROBIOL, V4, P2319, DOI 10.1038/s41564-019-0541-3; Mackowiak Philip A, 2013, Front Public Health, V1, P52, DOI 10.3389/fpubh.2013.00052; Maier TV, 2017, MBIO, V8, DOI [10.1128/mbio.01343-17, 10.1128/mBio.01343-17]; Martin R, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41738-5; Mego M, 2015, COMPLEMENT THER MED, V23, P356, DOI 10.1016/j.ctim.2015.03.008; Mi H, 2017, CELL PHYSIOL BIOCHEM, V42, P2330, DOI 10.1159/000480005; Miller LE, 2017, NUTRIENTS, V9, DOI 10.3390/nu9030191; Mills JP, 2018, CURR OPIN GASTROEN, V34, P3, DOI 10.1097/MOG.0000000000000410; Mima K, 2016, GUT, V65, P1973, DOI 10.1136/gutjnl-2015-310101; Mohamadzadeh M, 2011, P NATL ACAD SCI USA, V108, P4623, DOI 10.1073/pnas.1005066107; Monteagudo-Mera A, 2019, APPL MICROBIOL BIOT, V103, P6463, DOI 10.1007/s00253-019-09978-7; Osterlund P, 2007, BRIT J CANCER, V97, P1028, DOI 10.1038/sj.bjc.6603990; Parkin DM, 2011, BRIT J CANCER, V105, pS77, DOI 10.1038/bjc.2011.489; Piewngam P, 2018, NATURE, V562, P532, DOI 10.1038/s41586-018-0616-y; Puppa MJ, 2011, BBA-MOL BASIS DIS, V1812, P1601, DOI 10.1016/j.bbadis.2011.08.010; Quera R, 2014, J CROHNS COLITIS, V8, P252, DOI 10.1016/j.crohns.2013.10.002; Rafter J, 2007, AM J CLIN NUTR, V85, P488, DOI 10.1093/ajcn/85.2.488; Ridaura VK, 2013, SCIENCE, V341, P1079, DOI 10.1126/science.1241214; Rocha-Ramirez LM, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/4607491; Rosshart SP, 2017, CELL, V171, P1015, DOI 10.1016/j.cell.2017.09.016; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Rubinstein MR, 2013, CELL HOST MICROBE, V14, P195, DOI 10.1016/j.chom.2013.07.012; Salva S, 2014, INT IMMUNOPHARMACOL, V22, P209, DOI 10.1016/j.intimp.2014.06.017; Sanders ME, 2018, CURR OPIN BIOTECH, V49, P207, DOI 10.1016/j.copbio.2017.09.007; Sanders ME, 2010, GUT MICROBES, V1, P164, DOI 10.4161/gmic.1.3.12127; Sangild PT, 2018, AM J PHYSIOL-GASTR L, V314, pG231, DOI 10.1152/ajpgi.00204.2017; Schwartz M, 2013, AM J GASTROENTEROL, V108, P1367, DOI 10.1038/ajg.2013.164; Scott AJ, 2019, GUT, V68, P1624, DOI 10.1136/gutjnl-2019-318556; Sekirov I, 2010, PHYSIOL REV, V90, P859, DOI 10.1152/physrev.00045.2009; Sethi V, 2018, GASTROENTEROLOGY, V155, P33, DOI 10.1053/j.gastro.2018.04.001; Shields CED, 2016, J INFECT DIS, V214, P122, DOI 10.1093/infdis/jiw069; Shin W, 2018, P NATL ACAD SCI USA, V115, pE10539, DOI 10.1073/pnas.1810819115; Shoaf K, 2006, INFECT IMMUN, V74, P6920, DOI 10.1128/IAI.01030-06; Sichetti M, 2018, NUTRITION, V53, P95, DOI 10.1016/j.nut.2018.02.005; Singh V, 2018, CELL, V175, P679, DOI 10.1016/j.cell.2018.09.004; Sitaraman R, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0551-z; Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255; Skye SM, 2018, CIRC RES, V123, P1164, DOI 10.1161/CIRCRESAHA.118.313142; Smits LP, 2013, GASTROENTEROLOGY, V145, P946, DOI 10.1053/j.gastro.2013.08.058; Soler AP, 1999, CARCINOGENESIS, V20, P1425, DOI 10.1093/carcin/20.8.1425; Southcott E, 2008, DIGEST DIS SCI, V53, P1837, DOI 10.1007/s10620-008-0275-1; Taper HS, 2005, IN VIVO, V19, P201; Tong LC, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00253; Toomey N, 2009, FOODBORNE PATHOG DIS, V6, P925, DOI 10.1089/fpd.2009.0278; Triner D, 2019, GASTROENTEROLOGY, V156, P1467, DOI 10.1053/j.gastro.2018.12.003; Tuomola EM, 1999, FEMS IMMUNOL MED MIC, V26, P137, DOI 10.1111/j.1574-695X.1999.tb01381.x; Vetizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329; Viaud S, 2013, SCIENCE, V342, P971, DOI 10.1126/science.1240537; Wang F, 2018, P NATL ACAD SCI USA, V115, P157, DOI 10.1073/pnas.1712901115; Wang LH, 2014, J BIOL CHEM, V289, P20234, DOI 10.1074/jbc.M114.553800; Wang Y, 2017, MUCOSAL IMMUNOL, V10, P373, DOI 10.1038/mi.2016.57; Wang ZK, 2014, WORLD J GASTROENTERO, V20, P14805, DOI 10.3748/wjg.v20.i40.14805; Weingarden AR, 2017, GUT MICROBES, V8, P238, DOI 10.1080/19490976.2017.1290757; Willing BP, 2011, NAT REV MICROBIOL, V9, P233, DOI 10.1038/nrmicro2536; Wong JMW, 2006, J CLIN GASTROENTEROL, V40, P235, DOI 10.1097/00004836-200603000-00015; Yan F, 2012, GUT MICROBES, V3, P25, DOI 10.4161/gmic.19245; Yang YZ, 2017, GASTROENTEROLOGY, V152, P851, DOI 10.1053/j.gastro.2016.11.018; Yang YZ, 2016, ONCOTARGET, V7, P8432, DOI 10.18632/oncotarget.7045; Yeung CY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138746; Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008; Zackular JP, 2016, MSPHERE, V1, DOI 10.1128/mSphere.00001-15; Zackular JP, 2013, MBIO, V4, DOI 10.1128/mBio.00692-13; Zaharuddin L, 2019, BMC GASTROENTEROL, V19, DOI 10.1186/s12876-019-1047-4; Zhao S, 2019, LUNG CANCER, V130, P10, DOI 10.1016/j.lungcan.2019.01.017; Zyrek AA, 2007, CELL MICROBIOL, V9, P804, DOI 10.1111/j.1462-5822.2006.00836.x	147	164	165	24	98	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 25	2020	39	26					4925	4943		10.1038/s41388-020-1341-1	http://dx.doi.org/10.1038/s41388-020-1341-1		JUN 2020	19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MQ2YO	32514151	hybrid, Green Published			2022-12-28	WOS:000538969800002
J	Federico, MB; Siri, SO; Calzetta, NL; Paviolo, NS; de la Vega, MB; Martino, J; Campana, MC; Wiesmuller, L; Gottifredi, V				Federico, Maria Belen; Siri, Sebastian Omar; Calzetta, Nicolas Luis; Paviolo, Natalia Soledad; de la Vega, Maria Belen; Martino, Julieta; Campana, Maria Carolina; Wiesmueller, Lisa; Gottifredi, Vanesa			Unscheduled MRE11 activity triggers cell death but not chromosome instability in polymerase eta-depleted cells subjected to UV irradiation	ONCOGENE			English	Article							XERODERMA-PIGMENTOSUM VARIANT; STALLED REPLICATION FORKS; TRANSLESION DNA-SYNTHESIS; DAMAGE TOLERANCE; STRUCTURAL BASIS; REPAIR; CISPLATIN; BREAK; SURVIVAL; PATHWAY	The elimination of DNA polymerase eta (pol eta) causes discontinuous DNA elongation and fork stalling in UV-irradiated cells. Such alterations in DNA replication are followed by S-phase arrest, DNA double-strand break (DSB) accumulation, and cell death. However, their molecular triggers and the relative timing of these events have not been fully elucidated. Here, we report that DSBs accumulate relatively early after UV irradiation in pol eta-depleted cells. Despite the availability of repair pathways, DSBs persist and chromosome instability (CIN) is not detectable. Later on cells with pan-nuclear gamma H2AX and massive exposure of template single-stranded DNA (ssDNA), which indicate severe replication stress, accumulate and such events are followed by cell death. Reinforcing the causal link between the accumulation of pan-nuclear ssDNA/gamma H2AX signals and cell death, downregulation of RPA increased both replication stress and the cell death of pol eta-deficient cells. Remarkably, DSBs, pan-nuclear ssDNA/gamma H2AX, S-phase arrest, and cell death are all attenuated by MRE11 nuclease knockdown. Such results suggest that unscheduled MRE11-dependent activities at replicating DNA selectively trigger cell death, but not CIN. Together these results show that pol eta-depletion promotes a type of cell death that may be attractive as a therapeutic tool because of the lack of CIN.	[Federico, Maria Belen; Siri, Sebastian Omar; Calzetta, Nicolas Luis; Paviolo, Natalia Soledad; de la Vega, Maria Belen; Martino, Julieta; Campana, Maria Carolina; Gottifredi, Vanesa] Consejo Nacl Invest Cient & Tecn, Cell Cycle & Genom Stabil Lab, Fdn Inst Leloir, Ave Patricias Argentinas 435, Buenos Aires, DF, Argentina; [Wiesmueller, Lisa] Ulm Univ, Dept Obstet & Gynecol, D-89075 Ulm, Germany	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Leloir Institute; Ulm University	Gottifredi, V (corresponding author), Consejo Nacl Invest Cient & Tecn, Cell Cycle & Genom Stabil Lab, Fdn Inst Leloir, Ave Patricias Argentinas 435, Buenos Aires, DF, Argentina.	vgottifredi@leloir.org.ar		Gottifredi, Vanesa/0000-0001-9656-5951; Calzetta, Nicolas Luis/0000-0002-5790-0515; Martino, Julieta/0000-0001-9880-2682	Agencia Nacional de Promocion Cientifica y Tecnologica (ANPCyT) [PICT 2015-1217]; Instituto Nacional del Cancer (INC)-"Asistencia Financiera a proyectos de investigacion de cancer de origen nacional III; German Cancer Aid, Priority Program "Translational Oncology" [70112504]; Deutsche Forschungsgemeinschaft (DFG); CONICET; ANPCyT; Alexander von Humboldt Foundation	Agencia Nacional de Promocion Cientifica y Tecnologica (ANPCyT)(ANPCyT); Instituto Nacional del Cancer (INC)-"Asistencia Financiera a proyectos de investigacion de cancer de origen nacional III; German Cancer Aid, Priority Program "Translational Oncology"; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); CONICET(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); ANPCyT(ANPCyT); Alexander von Humboldt Foundation(Alexander von Humboldt Foundation)	We would like to thank Professors AR Lehmann (University of Sussex), for the gift of XPV cells. We also thank Carlos Menck at the University of Sao Paolo and all the members of the Gottifredi laboratory for fruitful discussions. The excellent support of Andres H. Rossi and Anabel Alvarez Julia in the microscopy and tissue cultures facilities is acknowledged. This work was supported by grants from the Agencia Nacional de Promocion Cientifica y Tecnologica (ANPCyT) grant number PICT 2015-1217, Instituto Nacional del Cancer (INC)-"Asistencia Financiera a proyectos de investigacion de cancer de origen nacional III to VG and the German Cancer Aid, Priority Program "Translational Oncology" 70112504 and by the Deutsche Forschungsgemeinschaft (DFG, Research Training Group 2544) to LW. MBF, SOS, NLC, NSP, JM, and MBdlV were supported by fellowships from CONICET and ANPCyT. VG is a researcher from CONICET and was supported by the Friedrich Wilhelm Bessel from Alexander von Humboldt Foundation.	Albertella MR, 2005, CANCER RES, V65, P9799, DOI 10.1158/0008-5472.CAN-05-1095; Alt A, 2007, SCIENCE, V318, P967, DOI 10.1126/science.1148242; Ashworth A, 2018, NAT REV CLIN ONCOL, V15, P564, DOI 10.1038/s41571-018-0055-6; Barnes RP, 2018, CANCER RES, V78, P6549, DOI 10.1158/0008-5472.CAN-17-3931; Federico MB, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005792; Vallerga MB, 2015, P NATL ACAD SCI USA, V112, pE6624, DOI 10.1073/pnas.1508543112; Bertolin AP, 2015, DNA REPAIR, V32, P158, DOI 10.1016/j.dnarep.2015.04.027; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Bryant PE, 2004, RADIOTHER ONCOL, V72, P251, DOI 10.1016/j.radonc.2004.07.005; Buisson R, 2015, MOL CELL, V59, P1011, DOI 10.1016/j.molcel.2015.07.029; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Ceppi P, 2009, CLIN CANCER RES, V15, P1039, DOI 10.1158/1078-0432.CCR-08-1227; Chen YW, 2006, MOL CANCER RES, V4, P257, DOI 10.1158/1541-7786.MCR-05-0118; Cleaver JE, 1999, CANCER RES, V59, P1102; Cruet-Hennequart S, 2006, DNA REPAIR, V5, P491, DOI 10.1016/j.dnarep.2006.01.008; Cruet-Hennequart S, 2010, SUBCELL BIOCHEM, V50, P189, DOI 10.1007/978-90-481-3471-7_10; Deniz M, 2013, MUTAT RES-FUND MOL M, V743, P132, DOI 10.1016/j.mrfmmm.2013.03.009; Despras E, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13326; Despras E, 2010, HUM MOL GENET, V19, P1690, DOI 10.1093/hmg/ddq046; Eckert Kristin A, 2019, Oncotarget, V10, P620, DOI 10.18632/oncotarget.26572; Elvers I, 2011, NUCLEIC ACIDS RES, V39, P7049, DOI 10.1093/nar/gkr420; EVENO E, 1995, CANCER RES, V55, P4325; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Gonzalez Besteiro MA, 2019, EMBO J, V38, DOI 10.15252/embj.2018101284; Gueranger Q, 2008, DNA REPAIR, V7, P1551, DOI 10.1016/j.dnarep.2008.05.012; Gursoy-Yuzugullu O, 2016, J MOL BIOL, V428, P1846, DOI 10.1016/j.jmb.2015.11.021; Hamppa S, 2016, P NATL ACAD SCI USA, V113, pE4311, DOI 10.1073/pnas.1605828113; Hashimoto Y, 2012, NAT STRUCT MOL BIOL, V19, P17, DOI 10.1038/nsmb.2177; Helleday T, 2011, MOL ONCOL, V5, P387, DOI 10.1016/j.molonc.2011.07.001; Hendel A, 2008, DNA REPAIR, V7, P1636, DOI 10.1016/j.dnarep.2008.06.008; Ireno IC, 2014, CARCINOGENESIS, V35, P2273, DOI 10.1093/carcin/bgu160; Jansen JG, 2014, NUCLEIC ACIDS RES, V42, P11071, DOI 10.1093/nar/gku779; Jeggo PA, 2014, EXP CELL RES, V329, P69, DOI 10.1016/j.yexcr.2014.09.023; Kannouche P, 2001, GENE DEV, V15, P158, DOI 10.1101/gad.187501; Kannouche P, 2003, BIOCHIMIE, V85, P1123, DOI 10.1016/j.biochi.2003.10.009; Lemacon D, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01180-5; Lerner LK, 2017, NUCLEIC ACIDS RES, V45, P1270, DOI 10.1093/nar/gkw1196; Limoli CL, 2002, P NATL ACAD SCI USA, V99, P233, DOI 10.1073/pnas.231611798; Limoli CL, 2000, P NATL ACAD SCI USA, V97, P7939, DOI 10.1073/pnas.130182897; Mah LJ, 2010, LEUKEMIA, V24, P679, DOI 10.1038/leu.2010.6; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; McIlwraith MJ, 2005, MOL CELL, V20, P783, DOI 10.1016/j.molcel.2005.10.001; Mouron S, 2013, NAT STRUCT MOL BIOL, V20, P1383, DOI 10.1038/nsmb.2719; Murfuni I, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003910; Ochs F, 2016, NAT STRUCT MOL BIOL, V23, P714, DOI 10.1038/nsmb.3251; Panier S, 2014, NAT REV MOL CELL BIO, V15, P7, DOI 10.1038/nrm3719; Paull TT, 2018, MOL CELL, V71, P419, DOI 10.1016/j.molcel.2018.06.033; Pellegrino S, 2017, CELL REP, V19, P1819, DOI 10.1016/j.celrep.2017.05.016; Petermann E, 2010, MOL CELL, V37, P492, DOI 10.1016/j.molcel.2010.01.021; Quinet A, 2016, NUCLEIC ACIDS RES, V44, P5717, DOI 10.1093/nar/gkw280; Quinet A, 2014, DNA REPAIR, V14, P27, DOI 10.1016/j.dnarep.2013.12.005; Roerink SF, 2014, GENOME RES, V24, P954, DOI 10.1101/gr.170431.113; Schlacher K, 2012, CANCER CELL, V22, P106, DOI 10.1016/j.ccr.2012.05.015; Schlacher K, 2011, CELL, V145, P529, DOI 10.1016/j.cell.2011.03.041; Paviolo NS, 2020, GENET MOL BIOL, V43, DOI [10.1590/1678-4685-GMB-2019-0070, 10.1590/1678-4685-gmb-2019-0070]; Spivak G, 2015, DNA REPAIR, V36, P13, DOI 10.1016/j.dnarep.2015.09.003; Stary A, 2003, J BIOL CHEM, V278, P18767, DOI 10.1074/jbc.M211838200; Syed A, 2018, ANNU REV BIOCHEM, V87, P263, DOI 10.1146/annurev-biochem-062917-012415; Teng KY, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-126; Toledo LI, 2013, CELL, V155, P1088, DOI 10.1016/j.cell.2013.10.043; Ummat A, 2012, NAT STRUCT MOL BIOL, V19, P628, DOI 10.1038/nsmb.2295; Villafanez F, 2019, ONCOGENE, V38, P4310, DOI 10.1038/s41388-019-0724-7; Xu XY, 2013, P NATL ACAD SCI USA, V110, P18638, DOI 10.1073/pnas.1303958110; Yang Y, 2018, CELL CYCLE, V17, P833, DOI 10.1080/15384101.2018.1456296; Yoon JH, 2019, CELL, V176, P1295, DOI 10.1016/j.cell.2019.01.023; Zellweger R, 2015, J CELL BIOL, V208, P563, DOI 10.1083/jcb.201406099; Zhang F, 2009, ANNU REV GENOM HUM G, V10, P451, DOI 10.1146/annurev.genom.9.081307.164217; Zhao Y, 2012, P NATL ACAD SCI USA, V109, P7269, DOI 10.1073/pnas.1202681109; Ziv O, 2009, P NATL ACAD SCI USA, V106, P11552, DOI 10.1073/pnas.0812548106	70	5	5	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	19					3952	3964		10.1038/s41388-020-1265-9	http://dx.doi.org/10.1038/s41388-020-1265-9		MAR 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LK4OF	32203168				2022-12-28	WOS:000521527500003
J	Williams, M; Liu, XH; Zhang, YQ; Reske, J; Bahal, D; Gohl, TG; Hollern, D; Ensink, E; Kiupel, M; Luo, RC; Das, R; Xiao, H				Williams, Mark; Liu, Xinhui; Zhang, Yueqi; Reske, Jake; Bahal, Devika; Gohl, Trevor G.; Hollern, Daniel; Ensink, Elliot; Kiupel, Matti; Luo, Rongcheng; Das, Rupali; Xiao, Hua			NCOA5 deficiency promotes a unique liver protumorigenic microenvironment through p21(WAF1/CIP1) overexpression, which is reversed by metformin	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; NONALCOHOLIC STEATOHEPATITIS; DIABETIC-PATIENTS; GENE-EXPRESSION; T-CELLS; CANCER; TUMORIGENESIS; IL-6; P21; INFLAMMATION	Prevention and treatment options for hepatocellular carcinoma (HCC) are presently limited, underscoring the necessity for further elucidating molecular mechanisms underlying HCC development and identifying new prevention and therapeutic targets. Here, we demonstrate a unique protumorigenic niche in the livers of Ncoa5(+/)(-) mouse model of HCC, which is characterized by altered expression of a subset of genes including p21(WAF1/CIP1) and proinflammatory cytokine genes, increased putative hepatic progenitors, and expansions of activated and tissue-resident memory (TRM) CD8+ T lymphocytes, myeloid-derived suppressor cells (MDSCs), and alternatively activated M2 macrophages. Importantly, prophylactic metformin treatment reversed these characteristics including aberrant p21(WAF1/CIP1) expression and subsequently reduced HCC incidence in Ncoa5(+/-) male mice. Heterozygous deletion of the p21(WAF1/CIP1) gene alleviated the key features associated with the protumorigenic niche in the livers of Ncoa5(+/-) male mice. Moreover, transcriptomic analysis reveals that preneoplastic livers of Ncoa5(+/-) mice are similar to the livers of nonalcoholic steatohepatitis patients as well as the adjacent noncancerous liver tissues of a subset of HCC patients with a relatively poor prognosis. Together, our results suggest that p21(WAF1/CIP1) overexpression is essential in the development of protumorigenic microenvironment induced by NCOA5 deficiency and metformin prevents HCC development via alleviating p21(WAF1/CIP1) overexpression and protumorigenic microenvironment.	[Williams, Mark; Liu, Xinhui; Zhang, Yueqi; Reske, Jake; Gohl, Trevor G.; Ensink, Elliot; Das, Rupali; Xiao, Hua] Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA; [Williams, Mark; Zhang, Yueqi] Michigan State Univ, Cellular & Mol Biol Program, E Lansing, MI 48824 USA; [Liu, Xinhui; Luo, Rongcheng] Southern Med Univ, Canc Ctr, Guangzhou 510315, Guangdong, Peoples R China; [Liu, Xinhui] Southern Med Univ, Integrated Hosp Tradit Chinese Med, Guangzhou 510315, Guangdong, Peoples R China; [Bahal, Devika] Michigan State Univ, Comparat Med & Integrat Biol Program, E Lansing, MI 48824 USA; [Hollern, Daniel] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Kiupel, Matti] Michigan State Univ, Dept Pathobiol & Diagnost Invest, Lansing, MI 48910 USA; [Gohl, Trevor G.] Michigan State Univ, Coll Osteopath Med, E Lansing, MI 48824 USA	Michigan State University; Michigan State University; Southern Medical University - China; Southern Medical University - China; Michigan State University; University of North Carolina; University of North Carolina Chapel Hill; Michigan State University; Michigan State University; Michigan State University College of Osteopathic Medicine	Xiao, H (corresponding author), Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA.	xiaoh@msu.edu		Bahal, Devika/0000-0002-4423-6387	National Cancer Institute [R01 CA188305, R21 CA185021]; NIH-NCI K22 award [5K22CA18814802]; NIH F32 student training fellowship [5 T32 GM 92715-3]; Integrated Hospital of Traditional Chinese Medicine, Southern Medical University	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH-NCI K22 award; NIH F32 student training fellowship(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Integrated Hospital of Traditional Chinese Medicine, Southern Medical University	This work was supported by the grants (R01 CA188305 and R21 CA185021) of National Cancer Institute to HX and a NIH-NCI K22 award (5K22CA18814802) to RD. MW was supported by a NIH F32 student training fellowship (5 T32 GM 92715-3). XL was partially supported by a fellowship from Integrated Hospital of Traditional Chinese Medicine, Southern Medical University. The authors thank J. Rennhack and E. Andrechek for sharing expertise in RNA-seq data analysis; E. Andrechek for manuscript comments; and members of the HX lab for helpful discussions. The results reported here are partially based on data generated by the TCGA Research Network: http://cancergenome.nih.gov, which we also gratefully acknowledge.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Algire C, 2012, CANCER PREV RES, V5, P536, DOI 10.1158/1940-6207.CAPR-11-0536; Arendt BM, 2015, HEPATOLOGY, V61, P1565, DOI 10.1002/hep.27695; Bhalla K, 2012, CANCER PREV RES, V5, P544, DOI 10.1158/1940-6207.CAPR-11-0228; Cmielova J, 2011, J CELL BIOCHEM, V112, P3502, DOI 10.1002/jcb.23296; DePeralta DK, 2016, CANCER-AM CANCER SOC, V122, P1216, DOI 10.1002/cncr.29912; Dhar D, 2014, CELL METAB, V19, P6, DOI 10.1016/j.cmet.2013.12.010; Donadon V, 2010, LIVER INT, V30, P750, DOI 10.1111/j.1478-3231.2010.02223.x; Ehedego H, 2015, CANCER RES, V75, P1144, DOI 10.1158/0008-5472.CAN-14-1356; Eikawa S, 2015, P NATL ACAD SCI USA, V112, P1809, DOI 10.1073/pnas.1417636112; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Finkin S, 2015, NAT IMMUNOL, V16, P1235, DOI 10.1038/ni.3290; Fujita K, 2016, WORLD J GASTROENTERO, V22, P6100, DOI 10.3748/wjg.v22.i27.6100; Gao SL, 2013, CANCER CELL, V24, P725, DOI 10.1016/j.ccr.2013.11.005; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gentles AJ, 2010, JAMA-J AM MED ASSOC, V304, P2706, DOI 10.1001/jama.2010.1862; Gerbes A, 2018, GUT, V67, P594, DOI 10.1136/gutjnl-2017-315068corr1; Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666; He GB, 2013, CELL, V155, P384, DOI 10.1016/j.cell.2013.09.031; Hirsch HA, 2013, P NATL ACAD SCI USA, V110, P972, DOI 10.1073/pnas.1221055110; Kalender A, 2010, CELL METAB, V11, P390, DOI 10.1016/j.cmet.2010.03.014; Lee SY, 2015, PLOS ONE, V10, DOI [10.1371/journal.pone.0136385, 10.1371/journal.pone.0128448]; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Liu XH, 2017, CANCER LETT, V391, P152, DOI 10.1016/j.canlet.2017.01.028; Llovet JM, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.18, 10.1038/nrdp.2016.19]; Luo XL, 2016, CELL REP, V17, P2979, DOI 10.1016/j.celrep.2016.11.048; Marhenke S, 2014, GUT, V63, P1501, DOI 10.1136/gutjnl-2013-304829; Molnar Z, 2014, INT J CHRONIC DIS, V2014, P327640; Nakagawa H, 2012, WORLD J GASTROENTERO, V18, P4071, DOI 10.3748/wjg.v18.i31.4071; Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485; Nicolae CM, 2018, ONCOGENE, V37, P3647, DOI 10.1038/s41388-018-0219-y; Noren Hooten N, 2016, AGING CELL, V15, P572, DOI 10.1111/acel.12469; Park EJ, 2010, CELL, V140, P197, DOI 10.1016/j.cell.2009.12.052; Pauken KE, 2016, SCIENCE, V354, P1160, DOI 10.1126/science.aaf2807; Nguyen P, 2018, CELL REP, V24, P1597, DOI 10.1016/j.celrep.2018.07.014; Roessler S, 2010, CANCER RES, V70, P10202, DOI 10.1158/0008-5472.CAN-10-2607; Rohr-Udilova N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24437-5; Schulte L, 2019, LIVER INT, V39, P714, DOI 10.1111/liv.14048; Shalapour S, 2017, NATURE, V551, P340, DOI 10.1038/nature24302; Sia D, 2017, GASTROENTEROLOGY, V153, P812, DOI 10.1053/j.gastro.2017.06.007; Tajima K, 2013, AM J PHYSIOL-ENDOC M, V305, pE987, DOI 10.1152/ajpendo.00133.2013; Tan XL, 2015, PANCREAS, V44, P636, DOI 10.1097/MPA.0000000000000308; Tomita K, 2012, J HEPATOL, V57, P837, DOI 10.1016/j.jhep.2012.05.013; Torre LA, 2016, CANCER EPIDEM BIOMAR, V25, P16, DOI 10.1158/1055-9965.EPI-15-0578; Verdura S, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1633235; Villanueva A, 2015, HEPATOLOGY, V61, P1945, DOI 10.1002/hep.27732; Warfel NA, 2013, CURR OPIN ONCOL, V25, P52, DOI 10.1097/CCO.0b013e32835b639e; Wherry EJ, 2007, IMMUNITY, V27, P670, DOI 10.1016/j.immuni.2007.09.006; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; Yano M, 2013, LIVER INT, V33, P1218, DOI 10.1111/liv.12176; Yu LX, 2018, NPJ PRECIS ONCOL, V2, DOI 10.1038/s41698-018-0048-z; Zheng CH, 2017, CELL, V169, P1342, DOI 10.1016/j.cell.2017.05.035	52	8	8	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	19					3821	3836		10.1038/s41388-020-1256-x	http://dx.doi.org/10.1038/s41388-020-1256-x		MAR 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LK4OF	32203160	Green Accepted			2022-12-28	WOS:000520614000002
J	Arnal-Estape, A; Cai, WLL; Albert, AE; Zhao, MH; Stevens, LE; Lopez-Giraldez, F; Patel, KD; Tyagi, S; Schmitt, EM; Westbrook, TF; Nguyen, DX				Arnal-Estape, Anna; Cai, Wesley L.; Albert, Alexandra E.; Zhao, Minghui; Stevens, Laura E.; Lopez-Giraldez, Francesc; Patel, Kiran D.; Tyagi, Siddhartha; Schmitt, Earlene M.; Westbrook, Thomas F.; Nguyen, Don X.			Tumor progression and chromatin landscape of lung cancer are regulated by the lineage factor GATA6	ONCOGENE			English	Article							STEM-CELLS; ADENOCARCINOMA; DIFFERENTIATION; SUPPRESSION; EXPRESSION; ORIGIN; NKX2-1; MICE	Lineage selective transcription factors (TFs) are important regulators of tumorigenesis, but their biological functions are often context dependent with undefined epigenetic mechanisms of action. In this study, we uncover a conditional role for the endodermal and pulmonary specifying TF GATA6 in lung adenocarcinoma (LUAD) progression. Impairing Gata6 in genetically engineered mouse models reduces the proliferation and increases the differentiation of Kras mutant LUAD tumors. These effects are influenced by the epithelial cell type that is targeted for transformation and genetic context of Kras-mediated tumor initiation. In LUAD cells derived from surfactant protein C expressing progenitors, we identify multiple genomic loci that are bound by GATA6. Moreover, suppression of Gata6 in these cells significantly alters chromatin accessibility, particularly at distal enhancer elements. Analogous to its paradoxical activity in lung development, GATA6 expression fluctuates during different stages of LUAD progression and can epigenetically control diverse transcriptional programs associated with bone morphogenetic protein signaling, alveolar specification, and tumor suppression. These findings reveal how GATA6 can modulate the chromatin landscape of lung cancer cells to control their proliferation and divergent lineage dependencies during tumor progression.	[Arnal-Estape, Anna; Cai, Wesley L.; Zhao, Minghui; Stevens, Laura E.; Patel, Kiran D.; Nguyen, Don X.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; [Arnal-Estape, Anna; Nguyen, Don X.] Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT 06510 USA; [Albert, Alexandra E.] Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; [Lopez-Giraldez, Francesc] Yale Univ, Sch Med, Yale Ctr Genome Anal, New Haven, CT USA; [Tyagi, Siddhartha; Schmitt, Earlene M.; Westbrook, Thomas F.] Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Tyagi, Siddhartha; Schmitt, Earlene M.; Westbrook, Thomas F.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Westbrook, Thomas F.] Baylor Coll Med, Therapeut Innovat Ctr THINC, Houston, TX 77030 USA; [Nguyen, Don X.] Yale Univ, Sch Med, Dept Med Med Oncol, New Haven, CT 06510 USA; [Stevens, Laura E.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA	Yale University; Yale University; Yale University; Yale University; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Yale University; Harvard University; Dana-Farber Cancer Institute	Nguyen, DX (corresponding author), Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA.; Nguyen, DX (corresponding author), Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT 06510 USA.; Nguyen, DX (corresponding author), Yale Univ, Sch Med, Dept Med Med Oncol, New Haven, CT 06510 USA.	don.nguyen@yale.edu	López-Giráldez, Francesc/A-5251-2011	López-Giráldez, Francesc/0000-0001-7476-9822; Cai, Wesley L/0000-0002-3871-5509; , SIDDHARTHA/0000-0001-5543-4787	Lung Cancer Research Foundation; McNair Medical Institute [R01CA178039]; Cancer Research UK Grand Challenge; Mark Foundation for Cancer Research [R01CA166376, R01CA191489];  [DGE-1122492];  [T32GM007205];  [T32CA193200]	Lung Cancer Research Foundation; McNair Medical Institute; Cancer Research UK Grand Challenge(Cancer Research UK); Mark Foundation for Cancer Research; ; ; 	We thank Qin Yan for discussion. This work was funded by the Lung Cancer Research Foundation (AA-E), the McNair Medical Institute (TFW), R01CA178039 (TFW), Cancer Research UK Grand Challenge (TFW), Mark Foundation for Cancer Research (TFW), R01CA166376 (DXN), and R01CA191489 (DXN). WLC was supported by DGE-1122492, AEA by T32GM007205, and KDP by T32CA193200.	Atlasi Y, 2017, NAT REV GENET, V18, DOI 10.1038/nrg.2017.57; Barkauskas CE, 2013, J CLIN INVEST, V123, P3025, DOI 10.1172/JCI68782; Borczuk AC, 2003, AM J PATHOL, V163, P1949, DOI 10.1016/S0002-9440(10)63553-5; Chen TP, 2014, NAT REV GENET, V15, P93, DOI 10.1038/nrg3607; Chen Z, 2014, NAT REV CANCER, V14, P535, DOI 10.1038/nrc3775; Cheung WKC, 2015, ONCOGENE, V34, P5771, DOI 10.1038/onc.2015.85; Cheung WKC, 2013, CANCER CELL, V23, P725, DOI 10.1016/j.ccr.2013.04.009; Chung MI, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.163014; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Corces MR, 2017, NAT METHODS, V14, P959, DOI [10.1038/NMETH.4396, 10.1038/nmeth.4396]; David CJ, 2016, CELL, V164, P1015, DOI 10.1016/j.cell.2016.01.009; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Hirsch HA, 2010, CANCER CELL, V17, P348, DOI 10.1016/j.ccr.2010.01.022; Hu HC, 2016, J THORAC ONCOL, V11, P2161, DOI 10.1016/j.jtho.2016.07.016; IKEDA K, 1995, J BIOL CHEM, V270, P8108, DOI 10.1074/jbc.270.14.8108; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Kimura H, 2013, J HUM GENET, V58, P439, DOI 10.1038/jhg.2013.66; Kwei KA, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000081; Li CMC, 2015, GENE DEV, V29, P1850, DOI 10.1101/gad.267393.115; Liao CM, 2018, J CLIN INVEST, V128, P2944, DOI 10.1172/JCI96539; Lin L, 2012, P NATL ACAD SCI USA, V109, P4251, DOI 10.1073/pnas.1011989109; Liu C, 2002, AM J PHYSIOL-LUNG C, V283, pL468, DOI 10.1152/ajplung.00044.2002; Marino S, 2000, GENE DEV, V14, P994; Martinelli P, 2017, GUT, V66, P1665, DOI 10.1136/gutjnl-2015-311256; Martinelli P, 2016, GUT, V65, P476, DOI 10.1136/gutjnl-2014-308042; McCormack N, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-36; Mehta A, 2016, EMBO MOL MED, V8, P1380, DOI 10.15252/emmm.201606382; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Nakajima N, 2018, HISTOPATHOLOGY, V73, P38, DOI 10.1111/his.13500; Quinlan MP, 2008, CELL CYCLE, V7, P1332, DOI 10.4161/cc.7.10.5927; Sodhi CP, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471-213X-6-19; Stevens LE, 2017, CANCER RES, V77, P1905, DOI 10.1158/0008-5472.CAN-16-1978; Sutherland KD, 2014, P NATL ACAD SCI USA, V111, P4952, DOI 10.1073/pnas.1319963111; Whissell G, 2014, NAT CELL BIOL, V16, P695, DOI 10.1038/ncb2992; Whitsett JA, 2011, AM J RESP CRIT CARE, V184, P401, DOI 10.1164/rccm.201103-0495PP; Winslow MM, 2011, NATURE, V473, P101, DOI 10.1038/nature09881; Xu X, 2012, P NATL ACAD SCI USA, V109, P4910, DOI 10.1073/pnas.1112499109; Yang HH, 2002, DEVELOPMENT, V129, P2233; Yang YA, 2014, J CLIN INVEST, V124, P2696, DOI 10.1172/JCI72171; Zaret KS, 2011, GENE DEV, V25, P2227, DOI 10.1101/gad.176826.111; Zhang Y, 2008, NAT GENET, V40, P862, DOI 10.1038/ng.157	42	4	4	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	18					3726	3737		10.1038/s41388-020-1246-z	http://dx.doi.org/10.1038/s41388-020-1246-z		MAR 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LI5XR	32157212	Green Accepted, hybrid, Green Published			2022-12-28	WOS:000518886000003
J	Hutchinson, MKND; Mierzwa, M; D'Silva, NJ				Hutchinson, Marsha-Kay N. D.; Mierzwa, Michelle; D'Silva, Nisha J.			Radiation resistance in head and neck squamous cell carcinoma: dire need for an appropriate sensitizer	ONCOGENE			English	Review							GROWTH-FACTOR RECEPTOR; STRAND BREAK REPAIR; DEPENDENT PROTEIN-KINASE; DNA-DAMAGE-RESPONSE; IONIZING-RADIATION; LIGASE-IV; HUMAN-PAPILLOMAVIRUS; SALVAGE SURGERY; XRCC4 PROTEIN; P53	Radiation is a significant treatment for patients with head and neck cancer. Despite advances to improve treatment, many tumors acquire radiation resistance resulting in poor survival. Radiation kills cancer cells by inducing DNA double-strand breaks. Therefore, radiation resistance is enhanced by efficient repair of damaged DNA. Head and neck cancers overexpress EGFR and have a high frequency of p53 mutations, both of which enhance DNA repair. This review discusses the clinical criteria for radiation resistance in patients with head and neck cancer and summarizes how cancer cells evade radiation-mediated apoptosis by p53- and epidermal growth factor receptor (EGFR)-mediated DNA repair. In addition, we explore the role of cancer stem cells in promoting radiation resistance, and how the abscopal effect provides rationale for combination strategies with immunotherapy.	[Hutchinson, Marsha-Kay N. D.; D'Silva, Nisha J.] Univ Michigan, Sch Dent, Dept Periodont & Oral Med, 1011 North Univ Ave, Ann Arbor, MI 48109 USA; [Mierzwa, Michelle] Univ Michigan, Sch Med, Dept Radiat Oncol, Ann Arbor, MI USA; [D'Silva, Nisha J.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	D'Silva, NJ (corresponding author), Univ Michigan, Sch Dent, Dept Periodont & Oral Med, 1011 North Univ Ave, Ann Arbor, MI 48109 USA.	njdsilva@umich.edu		Hutchinson, Marsha-Kay/0000-0002-1461-5810; D'Silva, Nisha/0000-0001-7030-3187	NIH/NIDCR [DE027551, DE007057-43]	NIH/NIDCR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This work was supported by grants from NIH/NIDCR DE027551 and DE007057-43.	Ang KK, 2014, J CLIN ONCOL, V32, P2940, DOI 10.1200/JCO.2013.53.5633; Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Ang KK, 2002, CANCER RES, V62, P7350; [Anonymous], 2019, 1 IN HUM STUD SAF TO; Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; Banerjee R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5527; Bensaad K, 2007, TRENDS CELL BIOL, V17, P286, DOI 10.1016/j.tcb.2007.04.004; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Cadet J, 2008, ACCOUNTS CHEM RES, V41, P1075, DOI 10.1021/ar700245e; Chan TA, 2000, GENE DEV, V14, P1584; Chang HW, 2006, ORAL ONCOL, V42, P979, DOI 10.1016/j.oraloncology.2005.12.016; Chen BPC, 2007, J BIOL CHEM, V282, P6582, DOI 10.1074/jbc.M611605200; Chen X, 2008, CANCER RES, V68, P3169, DOI 10.1158/0008-5472.CAN-07-6636; Chung CH, 2014, J CLIN ONCOL, V32, P3930, DOI 10.1200/JCO.2013.54.5228; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Collis SJ, 2005, ONCOGENE, V24, P949, DOI 10.1038/sj.onc.1208332; Das AK, 2007, CANCER RES, V67, P5267, DOI 10.1158/0008-5472.CAN-07-0242; Davidson D, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00005; Davis AJ, 2013, TRANSL CANCER RES, V2, P130, DOI 10.3978/j.issn.2218-676X.2013.04.02; De Crevoisier R, 2001, CANCER-AM CANCER SOC, V91, P2071, DOI 10.1002/1097-0142(20010601)91:11<2071::AID-CNCR1234>3.0.CO;2-Z; De Felice F, 2015, ORAL ONCOL, V51, P1051, DOI 10.1016/j.oraloncology.2015.08.004; Deckbar D, 2010, CANCER RES, V70, P4412, DOI 10.1158/0008-5472.CAN-09-3198; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dittmann K, 2005, J BIOL CHEM, V280, P31182, DOI 10.1074/jbc.M506591200; Downs JA, 2004, NAT REV MOL CELL BIO, V5, P367, DOI 10.1038/nrm1367; Dynan W, 2008, NANOMEDICINE-UK, V3, P93, DOI 10.2217/17435889.3.1.93; Emerson CH, 2016, BIOCHEM CELL BIOL, V94, P396, DOI 10.1139/bcb-2016-0001; Eriksson D, 2010, TUMOR BIOL, V31, P363, DOI 10.1007/s13277-010-0042-8; Fakhry C, 2019, CANCER-AM CANCER SOC, V125, P2027, DOI 10.1002/cncr.32025; Fei PW, 2003, ONCOGENE, V22, P5774, DOI 10.1038/sj.onc.1206677; Ferlay J, 2018, INT J CANCER, V144, P31937, DOI [10.1002/ijc.31937.ijc, DOI 10.1002/IJC.31937.IJC]; Freschauf GK, 2009, CANCER RES, V69, P7739, DOI 10.1158/0008-5472.CAN-09-1805; Fu KK PT, 2000, INT J RADIAT ONCOL, V48, P7, DOI DOI 10.1016/S0360-3016(00)00663-5; Furness S, 2011, COCHRANE DB SYST REV, V2011, P1; Gatz SA, 2006, CELL DEATH DIFFER, V13, P1003, DOI 10.1038/sj.cdd.4401903; Ghisolfi L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043628; Gillison ML, 2019, LANCET, V393, P40, DOI 10.1016/S0140-6736(18)32779-X; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Grundy GJ, 2013, EMBO J, V32, P112, DOI 10.1038/emboj.2012.304; Gu JF, 2007, EMBO J, V26, P1010, DOI 10.1038/sj.emboj.7601559; Gunn GB, 2016, INT J RADIAT ONCOL, V95, P360, DOI 10.1016/j.ijrobp.2016.02.021; Haimovitz-Friedman, 1996, Semin Radiat Oncol, V6, P273, DOI 10.1016/S1053-4296(96)80023-3; HALDAR S, 1994, CANCER RES, V54, P2095; Hammel M, 2010, J BIOL CHEM, V285, P1414, DOI 10.1074/jbc.M109.065615; Hanai R, 1998, INT J RADIAT BIOL, V73, P475, DOI 10.1080/095530098142013; Harari PM, 2009, SEMIN RADIAT ONCOL, V19, P63, DOI 10.1016/j.semradonc.2008.09.009; HARPER JW, 1993, CELL, V75, P805; Helton ES, 2007, J CELL BIOCHEM, V100, P883, DOI 10.1002/jcb.21091; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Huang SM, 2000, CLIN CANCER RES, V6, P2166; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Janot F, 2008, J CLIN ONCOL, V26, P5518, DOI 10.1200/JCO.2007.15.0102; Karimi-Busheri F, 2007, CANCER RES, V67, P6619, DOI 10.1158/0008-5472.CAN-07-0480; Khan Atif J, 2018, Oncotarget, V9, P25833, DOI 10.18632/oncotarget.25383; Korzeniewski N, 2011, CANCER LETT, V305, P113, DOI 10.1016/j.canlet.2010.10.013; Lafarga V, 2009, MOL CELL BIOL, V29, P4341, DOI 10.1128/MCB.00210-09; Lee N, 2020, STUDY PROTON VERSUS; Li YH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039588; Liccardi G, 2011, CANCER RES, V71, P1103, DOI 10.1158/0008-5472.CAN-10-2384; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Lobrich M, 2007, NAT REV CANCER, V7, P861, DOI 10.1038/nrc2248; Lomax ME, 2013, CLIN ONCOL-UK, V25, P578, DOI 10.1016/j.clon.2013.06.007; Lucero H, 2003, J BIOL CHEM, V278, P22136, DOI 10.1074/jbc.M301579200; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Mansour WY, 2013, RADIOTHER ONCOL, V106, P147, DOI 10.1016/j.radonc.2012.10.020; Mari PO, 2006, P NATL ACAD SCI USA, V103, P18597, DOI 10.1073/pnas.0609061103; McCulloch HD, 1908, BRIT MED J, V1908, P1146, DOI 10.1136/bmj.2.2494.1146; Mehanna H, 2019, LANCET, V393, P51, DOI 10.1016/S0140-6736(18)32752-1; Michalak EM, 2008, CELL DEATH DIFFER, V15, P1019, DOI 10.1038/cdd.2008.16; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; Modesti M, 1999, EMBO J, V18, P2008, DOI 10.1093/emboj/18.7.2008; Moeller BJ, 2011, CLIN CANCER RES, V17, P2035, DOI 10.1158/1078-0432.CCR-10-2641; Nagasawa H, 2010, MUTAT RES-GEN TOX EN, V701, P12, DOI 10.1016/j.mrgentox.2010.03.003; Ngwa W, 2018, NAT REV CANCER, V18, P313, DOI 10.1038/nrc.2018.6; Nutley BP, 2005, BRIT J CANCER, V93, P1011, DOI 10.1038/sj.bjc.6602823; Oksuz DC, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-54; Patel SH, 2014, LANCET ONCOL, V15, P1027, DOI 10.1016/S1470-2045(14)70268-2; Postow L, 2008, J CELL BIOL, V182, P467, DOI 10.1083/jcb.200802146; RADFORD IR, 1994, INT J RADIAT BIOL, V65, P217, DOI 10.1080/09553009414550251; Reynolds P, 2012, NUCLEIC ACIDS RES, V40, P10821, DOI 10.1093/nar/gks879; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; SchmidtUllrich RK, 1997, ONCOGENE, V15, P1191, DOI 10.1038/sj.onc.1201275; Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI [10.3322/caac.21601, 10.3322/caac.21590]; Skinner HD, 2012, CLIN CANCER RES, V18, P290, DOI 10.1158/1078-0432.CCR-11-2260; Spence T, 2016, CANCERS, V8, DOI 10.3390/cancers8080075; Srivastava M, 2012, CELL, V151, P1474, DOI 10.1016/j.cell.2012.11.054; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Stucki M, 2006, DNA REPAIR, V5, P534, DOI 10.1016/j.dnarep.2006.01.012; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Timme CR, 2018, MOL CANCER THER, V17, P1207, DOI 10.1158/1535-7163.MCT-17-1267; Tsai CJ, 2007, P NATL ACAD SCI USA, V104, P7851, DOI 10.1073/pnas.0702620104; Valente LJ, 2013, CELL REP, V3, P1339, DOI 10.1016/j.celrep.2013.04.012; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Weinberg RL, 2005, J MOL BIOL, V348, P589, DOI 10.1016/j.jmb.2005.03.014; Weisz L, 2007, ONCOGENE, V26, P2202, DOI 10.1038/sj.onc.1210294; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Zhao X, 2017, ACTA BIOCH BIOPH SIN, V49, P655, DOI 10.1093/abbs/gmx055; Zhou G, 2016, J CELL BIOCHEM, V117, P2682, DOI 10.1002/jcb.25592; Zhou X, 2019, J MOL CELL BIOL, V11, P293, DOI 10.1093/jmcb/mjy072	100	42	43	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	18					3638	3649		10.1038/s41388-020-1250-3	http://dx.doi.org/10.1038/s41388-020-1250-3		MAR 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LI5XR	32157215	Green Published, hybrid, Green Accepted			2022-12-28	WOS:000518886000007
J	Khan, A; Valli, E; Lam, H; Scott, DA; Murray, J; Hanssen, KM; Eden, G; Gamble, LD; Pandher, R; Flemming, CL; Allan, S; Osterman, AL; Haber, M; Norris, MD; Fletcher, JI; Yu, DMT				Khan, Aaminah; Valli, Emanuele; Lam, Hayley; Scott, David A.; Murray, Jayne; Hanssen, Kimberley M.; Eden, Georgina; Gamble, Laura D.; Pandher, Rupinder; Flemming, Claudia L.; Allan, Sophie; Osterman, Andrei L.; Haber, Michelle; Norris, Murray D.; Fletcher, Jamie, I; Yu, Denise M. T.			Targeting metabolic activity in high-risk neuroblastoma through Monocarboxylate Transporter 1 (MCT1) inhibition	ONCOGENE			English	Article							CANCER-CELLS; N-MYC; GLYCOLYSIS; HYPOXIA; GROWTH; ACTIVATION; PYRUVATE; GLUTAMINOLYSIS; COMBINATION; METASTASIS	Amplification of the MYCN oncogene occurs in similar to 25% of primary neuroblastomas and is the single most powerful biological marker of poor prognosis in this disease. MYCN transcriptionally regulates a range of biological processes important for cancer, including cell metabolism. The MYCN-regulated metabolic gene SLC16A1, encoding the lactate transporter monocarboxylate transporter 1 (MCT1), is a potential therapeutic target. Treatment of neuroblastoma cells with the MCT1 inhibitor SR13800 increased intracellular lactate levels, disrupted the nicotinamide adenine dinucleotide (NADH/NAD(+)) ratio, and decreased intracellular glutathione levels. Metabolite tracing with 13C-glucose and 13C-glutamine following MCT1 inhibitor treatment revealed increased quantities of tricarboxylic acid (TCA) cycle intermediates and increased oxygen consumption rate. MCT1 inhibition was highly synergistic with vincristine and LDHA inhibition under cell culture conditions, but this combination was ineffective against neuroblastoma xenografts. Posttreatment xenograft tumors had increased synthesis of the MCT1 homolog MCT4/SLC16A, a known resistance factor to MCT1 inhibition. We found that MCT4 was negatively regulated by MYCN in luciferase reporter assays and its synthesis in neuroblastoma cells was increased under hypoxic conditions and following hypoxia-inducible factor (HIF1) induction, suggesting that MCT4 may contribute to resistance to MCT1 inhibitor treatment in hypoxic neuroblastoma tumors. Co-treatment of neuroblastoma cells with inhibitors of MCT1 and LDHA, the enzyme responsible for lactate production, resulted in a large increase in intracellular pyruvate and was highly synergistic in decreasing neuroblastoma cell viability. These results highlight the potential of targeting MCT1 in neuroblastoma in conjunction with strategies that involve disruption of pyruvate homeostasis and indicate possible resistance mechanisms.	[Khan, Aaminah; Valli, Emanuele; Lam, Hayley; Murray, Jayne; Hanssen, Kimberley M.; Eden, Georgina; Gamble, Laura D.; Pandher, Rupinder; Flemming, Claudia L.; Allan, Sophie; Haber, Michelle; Norris, Murray D.; Fletcher, Jamie, I; Yu, Denise M. T.] UNSW Sydney, Childrens Canc Inst, Lowy Canc Res Ctr, Sydney, NSW 2052, Australia; [Khan, Aaminah; Lam, Hayley] UNSW Sydney, Sch Med Sci, Sydney, NSW 2052, Australia; [Valli, Emanuele; Hanssen, Kimberley M.; Fletcher, Jamie, I; Yu, Denise M. T.] UNSW Sydney, Sch Womens & Childrens Hlth, Sydney, NSW 2052, Australia; [Scott, David A.; Osterman, Andrei L.] Sanford Burnham Prebys Med Discovery Inst, Canc Metab Core, La Jolla, CA 92037 USA; [Norris, Murray D.] Univ New South Wales, Ctr Childhood Canc Res, Sydney, NSW, Australia	Children's Cancer Institute; University of New South Wales Sydney; University of New South Wales Sydney; University of New South Wales Sydney; Sanford Burnham Prebys Medical Discovery Institute; University of New South Wales Sydney	Fletcher, JI; Yu, DMT (corresponding author), UNSW Sydney, Childrens Canc Inst, Lowy Canc Res Ctr, Sydney, NSW 2052, Australia.; Fletcher, JI; Yu, DMT (corresponding author), UNSW Sydney, Sch Womens & Childrens Hlth, Sydney, NSW 2052, Australia.	JFletcher@ccia.unsw.edu.au; DYu@ccia.unsw.edu.au	Murray, Jayne/AAM-8115-2021; Valli, Emanuele/ABD-7213-2020	Valli, Emanuele/0000-0002-0928-8624; Fletcher, Jamie/0000-0003-2949-9469; Hanssen, Kimberley/0000-0002-2919-3104; Haber, Michelle/0000-0003-2036-8817; Gamble, Laura D./0000-0001-8496-9705; Murray, Jayne/0000-0002-1861-6570; Scott, David/0000-0002-8668-2449	Balnaves Foundation Young Investigator Grant; National Health and Medical Research Council [APP1016699]; SBP NCI Cancer Center Support Grant [P30 CA030199]	Balnaves Foundation Young Investigator Grant; National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); SBP NCI Cancer Center Support Grant	We thank Donna Lai and Sheng Hua from the Bosch Molecular Biology Facility, University of Sydney for support with Seahorse Analyses, and Alan Truong for technical support. This work was supported by a Balnaves Foundation Young Investigator Grant (DMTY), a National Health and Medical Research Council Program Grant APP1016699 (MH, MDN), and a SBP NCI Cancer Center Support Grant P30 CA030199 (DS, AO).	Benjamin D, 2018, CELL REP, V25, P3047, DOI 10.1016/j.celrep.2018.11.043; Birsoy K, 2013, NAT GENET, V45, P104, DOI 10.1038/ng.2471; Bonuccelli G, 2010, CELL CYCLE, V9, P3506, DOI 10.4161/cc.9.17.12731; Cohn SL, 2009, J CLIN ONCOL, V27, P289, DOI 10.1200/JCO.2008.16.6785; Curtis NJ, 2017, ONCOTARGET, V8, P69219, DOI 10.18632/oncotarget.18215; Doherty JR, 2014, CANCER RES, V74, P908, DOI 10.1158/0008-5472.CAN-13-2034; Fang J, 2006, MOL PHARMACOL, V70, P2108, DOI 10.1124/mol.106.026245; Faubert B, 2017, CELL, V171, P358, DOI 10.1016/j.cell.2017.09.019; Fiaschi T, 2012, CANCER RES, V72, P5130, DOI 10.1158/0008-5472.CAN-12-1949; Fotsis T, 1999, EUR J BIOCHEM, V263, P757, DOI 10.1046/j.1432-1327.1999.00575.x; Galluzzi L, 2013, NAT REV DRUG DISCOV, V12, P829, DOI 10.1038/nrd4145; Gan L, 2016, ONCOGENE, V35, P3037, DOI 10.1038/onc.2015.360; Gherardi S, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00042; Groninger E, 2002, INT J ONCOL, V21, P1339; Halestrap AP, 2012, IUBMB LIFE, V64, P109, DOI 10.1002/iub.572; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Henderson MJ, 2011, J NATL CANCER I, V103, P1236, DOI 10.1093/jnci/djr256; Hong CS, 2016, CELL REP, V14, P1590, DOI 10.1016/j.celrep.2016.01.057; Huang M, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014415; Jin L, 2016, ONCOGENE, V35, P3619, DOI 10.1038/onc.2015.447; Kocak H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.84; Le Floch R, 2011, P NATL ACAD SCI USA, V108, P16663, DOI 10.1073/pnas.1106123108; Levy AG, 2012, INVEST NEW DRUG, V30, P191, DOI 10.1007/s10637-010-9551-y; Lin RY, 1998, J BIOL CHEM, V273, P28959, DOI 10.1074/jbc.273.44.28959; Matthay KK, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.78; Noble RA, 2017, HAEMATOLOGICA, V102, P1247, DOI 10.3324/haematol.2016.163030; Obre E, 2015, INT J BIOCHEM CELL B, V59, P167, DOI 10.1016/j.biocel.2014.12.008; Park JR, 2010, HEMATOL ONCOL CLIN N, V24, P65, DOI 10.1016/j.hoc.2009.11.011; Pelicano H, 2006, ONCOGENE, V25, P4633, DOI 10.1038/sj.onc.1209597; Pertega-Gomes N, 2015, ONCOTARGET, V6, P21675, DOI 10.18632/oncotarget.4328; Polanski R, 2014, CLIN CANCER RES, V20, P926, DOI 10.1158/1078-0432.CCR-13-2270; Qing GL, 2012, CANCER CELL, V22, P631, DOI 10.1016/j.ccr.2012.09.021; Qing GL, 2010, CANCER RES, V70, P10351, DOI 10.1158/0008-5472.CAN-10-0740; Quanz M, 2018, MOL CANCER THER, V17, P2285, DOI 10.1158/1535-7163.MCT-17-1253; Ratnikov B, 2015, ONCOTARGET, V6, P7379, DOI 10.18632/oncotarget.3132; Ren P, 2015, J PATHOL, V235, P90, DOI 10.1002/path.4429; Scott DA, 2011, J BIOL CHEM, V286, P42626, DOI 10.1074/jbc.M111.282046; Sonveaux P, 2008, J CLIN INVEST, V118, P3930, DOI 10.1172/JCI36843; Sounni NE, 2014, CELL METAB, V20, P280, DOI 10.1016/j.cmet.2014.05.022; Sullivan LB, 2016, NAT REV CANCER, V16, P680, DOI 10.1038/nrc.2016.85; Thangaraju M, 2009, BIOCHEM J, V417, P379, DOI 10.1042/BJ20081132; Tu Y, 2013, INT J MOL MED, V31, P113, DOI 10.3892/ijmm.2012.1167; Ullah MS, 2006, J BIOL CHEM, V281, P9030, DOI 10.1074/jbc.M511397200; Valli E, 2012, BBA-GENE REGUL MECH, V1819, P1173, DOI 10.1016/j.bbagrm.2012.08.001; Wagner W, 2015, CELL COMMUN SIGNAL, V13, DOI 10.1186/s12964-015-0114-x; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Xiao DB, 2015, ONCOTARGET, V6, P40655, DOI 10.18632/oncotarget.5821; Xu RH, 2005, CANCER RES, V65, P613; Zhang XL, 2011, MOL CELL BIOCHEM, V358, P287, DOI 10.1007/s11010-011-0979-y; Zhao L, 2004, CLIN CANCER RES, V10, P7994, DOI 10.1158/1078-0432.CCR-04-1087; Zhao YX, 2011, J CEREBR BLOOD F MET, V31, P1412, DOI 10.1038/jcbfm.2010.230	51	14	14	3	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	17					3555	3570		10.1038/s41388-020-1235-2	http://dx.doi.org/10.1038/s41388-020-1235-2		MAR 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LH1YK	32123312	Green Accepted			2022-12-28	WOS:000517738400001
J	Tamura, R; Yoshihara, K; Nakaoka, H; Yachida, N; Yamaguchi, M; Suda, K; Ishiguro, T; Nishino, K; Ichikawa, H; Homma, K; Kikuchi, A; Ueda, Y; Takei, Y; Fujiwara, H; Motoyama, T; Okuda, S; Wakai, T; Inoue, I; Enomoto, T				Tamura, Ryo; Yoshihara, Kosuke; Nakaoka, Hirofumi; Yachida, Nozomi; Yamaguchi, Manako; Suda, Kazuaki; Ishiguro, Tatsuya; Nishino, Koji; Ichikawa, Hiroshi; Homma, Keiichi; Kikuchi, Akira; Ueda, Yutaka; Takei, Yuji; Fujiwara, Hiroyuki; Motoyama, Teiichi; Okuda, Shujiro; Wakai, Toshifumi; Inoue, Ituro; Enomoto, Takayuki			XCL1 expression correlates with CD8-positive T cells infiltration and PD-L1 expression in squamous cell carcinoma arising from mature cystic teratoma of the ovary	ONCOGENE			English	Article							GENOMIC CHARACTERIZATION; HEAD; LYMPHOTACTIN; NIVOLUMAB; RECEPTOR; NUMBER; XCR1	Molecular characteristics of carcinoma arising from mature cystic teratoma of the ovary (MCT) remain unclear due to its rarity. We analyzed RNA-sequencing data of 2322 pan-cancer [1378 squamous cell carcinomas (SCC), 6 adenosquamous carcinomas (ASC), and 938 adenocarcinomas (AC)] including six carcinomas arising from MCT (four SCCs, one ASC, and one AC). Hierarchical clustering and principal component analysis showed that gene expression profiles of carcinomas arising from MCT were different between each histological type and that gene expression profiles of SCCs arising MCT (MCT-SCCs) was apparently similar to those of lung SCCs. By epidermis-associated pathways activity based on gene set enrichment analysis, 1030 SCCs were divided into two groups: epidermis-signature high (head and neck, esophagus, and skin) and low (cervix, lung, and MCT). In addition to pan-SCC transcriptome analysis, cytokeratin profiling based on immunohistochemistry in the independent samples of 21 MCT-SCCs clarified that MCT-SCC dominantly expressed CK18, suggesting the origin of MCT-SCC was columnar epithelium. Subsequently, we investigated differentially expressed genes in MCT-SCCs compared with different SCCs and identified XCL1 was specifically overexpressed in MCT-SCCs. Through immunohistochemistry analysis, we identified XCL1 expression on tumor cells in 13/24 (54%) of MCT-SCCs but not in MCTs. XCL1 expression was also significantly associated with the number of tumor-infiltrating CD8-positive T cells and PD-L1 expression on tumor cells. XCL1 produced by tumor cells may induce PD1/PD-L1 interaction and dysfunction of CD8-positive T cells in tumor microenvironment. XCL1 expression may be a novel biomarker for malignant transformation of MCT into SCC and a biomarker candidate for therapeutic response to an anti-PD1/PD-L1 therapy.	[Tamura, Ryo; Yoshihara, Kosuke; Yachida, Nozomi; Yamaguchi, Manako; Suda, Kazuaki; Ishiguro, Tatsuya; Nishino, Koji; Enomoto, Takayuki] Niigata Univ, Dept Obstet & Gynecol, Grad Sch Med & Dent Sci, Niigata 9518510, Japan; [Nakaoka, Hirofumi; Inoue, Ituro] Natl Inst Genet, Human Genet Lab, Mishima, Shizuoka 4118540, Japan; [Ichikawa, Hiroshi; Wakai, Toshifumi] Niigata Univ, Div Digest & Gen Surg, Grad Sch Med & Dent Sci, Niigata 9518510, Japan; [Homma, Keiichi] Niigata Canc Ctr Hosp, Dept Pathol, Niigata 9518133, Japan; [Kikuchi, Akira] Niigata Canc Ctr Hosp, Dept Gynecol, Niigata 9518133, Japan; [Ueda, Yutaka] Osaka Univ, Dept Obstet & Gynecol, Sch Med, Suita, Osaka 5650871, Japan; [Takei, Yuji; Fujiwara, Hiroyuki] Jichi Med Univ, Dept Obstet & Gynecol, Shimotsuke, Tochigi 3290498, Japan; [Motoyama, Teiichi] Niigata Univ, Dept Mol & Diagnost Pathol, Grad Sch Med & Dent Sci, Niigata 9518510, Japan; [Okuda, Shujiro] Niigata Univ, Div Bioinformat, Grad Sch Med & Dent Sci, Niigata 9518510, Japan	Niigata University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Niigata University; Osaka University; Jichi Medical University; Niigata University; Niigata University	Yoshihara, K (corresponding author), Niigata Univ, Dept Obstet & Gynecol, Grad Sch Med & Dent Sci, Niigata 9518510, Japan.	yoshikou@med.niigata-u.ac.jp	Takei, Yuji/ABD-2485-2020; Yoshihara, Kosuke/AAU-9874-2020	Takei, Yuji/0000-0002-1744-5570; Yoshihara, Kosuke/0000-0002-2254-3378; Enomoto, Takayuki/0000-0003-4538-5541; Ueda, Yutaka/0000-0001-8760-6379; Ishiguro, Tatsuya/0000-0002-6445-4066; Nakaoka, Hirofumi/0000-0002-8454-1159	JSPS KAKENHI [18K16760, JP16H06267, JP16H06279]; Mochida Grant; Tsukada Grant for Niigata University Medical Research; ROIS (Research Organization of Information and Systems)	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Mochida Grant; Tsukada Grant for Niigata University Medical Research; ROIS (Research Organization of Information and Systems)	We are grateful to Anna Ishida, Junko Kajiwara, Junko Kitayama, and Yumiko Sato for their technical assistance. We also grateful to Yusuke Tanaka, Reisa Kakubari, Mariko Kayamori, and Taeko Hyuga for sample collections. This work was supported in part by JSPS KAKENHI grant number 18K16760 (Grant-in-Aid for Young Scientists for RT), JP16H06267 (Grant-in-Aid for Young Scientists A for KY), JP16H06279 (Grant-in-Aid for Scientific Research on Innovative Areas-Platforms for Advanced Technologies and Research Resources for HN and KY), the Mochida Grant for KY, the Tsukada Grant for Niigata University Medical Research for RT, and "Challenging Exploratory Research Projects for the Future" grant from ROIS (Research Organization of Information and Systems) for HN.	Akazawa M, 2018, INT J GYNECOL CANCER, V28, P1650, DOI 10.1097/IGC.0000000000001375; AMERIGO J, 1979, GYNECOL ONCOL, V8, P277, DOI 10.1016/0090-8258(79)90035-0; Bray NL, 2016, NAT BIOTECHNOL, V34, P888, DOI 10.1038/nbt0816-888d; Burk RD, 2017, NATURE, V543, P378, DOI 10.1038/nature21386; Calinski R.B., 1974, COMMUNICATIONS STAT, V3, P1, DOI [10.1080/03610927408827101, DOI 10.1080/03610927408827101]; Campbell JD, 2018, CELL REP, V23, P194, DOI 10.1016/j.celrep.2018.03.063; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chakravarty D, 2017, JCO PRECIS ONCOL, V1; Chiang AJ, 2017, J GYNECOL ONCOL, V28, DOI 10.3802/jgo.2017.28.e69; Chitsazzadeh V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12601; Chung HC, 2019, J CLIN ONCOL, V37, P1470, DOI 10.1200/JCO.18.01265; Cooke SL, 2017, CLIN CANCER RES, V23, P7633, DOI 10.1158/1078-0432.CCR-17-1789; Cristescu R, 2018, SCIENCE, V362, P197, DOI 10.1126/science.aar3593; Ding HY, 2019, CELL REP, V27, P3331, DOI 10.1016/j.celrep.2019.05.043; Dorner BG, 2009, IMMUNITY, V31, P823, DOI 10.1016/j.immuni.2009.08.027; Eifert C, 2017, PERS MED, V14, P309, DOI 10.2217/pme-2017-0011; Ferris RL, 2016, NEW ENGL J MED, V375, P1856, DOI 10.1056/NEJMoa1602252; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Fruman DA, 2017, CELL, V170, P605, DOI 10.1016/j.cell.2017.07.029; Hackethal A, 2008, LANCET ONCOL, V9, P1173, DOI 10.1016/S1470-2045(08)70306-1; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; HIRAKAWA T, 1989, AM J SURG PATHOL, V13, P397, DOI 10.1097/00000478-198905000-00007; Hoadley KA, 2018, CELL, V173, P291, DOI 10.1016/j.cell.2018.03.022; Ichikawa H, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0484-3; Iwasa A, 2007, HISTOPATHOLOGY, V51, P98, DOI 10.1111/j.1365-2559.2007.02727.x; John T, 2009, ONCOGENE, V28, pS14, DOI 10.1038/onc.2009.197; Keck MK, 2015, CLIN CANCER RES, V21, P870, DOI 10.1158/1078-0432.CCR-14-2481; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; Khurram SA, 2010, J PATHOL, V221, P153, DOI 10.1002/path.2695; Kim J, 2017, NATURE, V541, P169, DOI 10.1038/nature20805; Kim M, 2012, MOL CANCER RES, V10, P1419, DOI 10.1158/1541-7786.MCR-12-0361; KRZANOWSKI WJ, 1988, BIOMETRICS, V44, P23, DOI 10.2307/2531893; Kudo T, 2017, LANCET ONCOL, V18, P631, DOI 10.1016/S1470-2045(17)30181-X; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Lei Y, 2012, MICROBES INFECT, V14, P262, DOI 10.1016/j.micinf.2011.10.003; Li BL, 2019, CLIN CANCER RES, V25, P3528, DOI 10.1158/1078-0432.CCR-18-4085; Li F, 2013, CELL, V153, P590, DOI 10.1016/j.cell.2013.03.025; MARCIALROJAS RA, 1958, ARCH PATHOL, V66, P577; Migden MR, 2018, NEW ENGL J MED, V379, P341, DOI 10.1056/NEJMoa1805131; Mori Y, 2003, GYNECOL ONCOL, V90, P338, DOI 10.1016/S0090-8258(03)00259-2; Nicorici, 2014, BIORXIV, DOI [10.1101/011650, DOI 10.1101/011650V1]; Nishiwaki M, 2008, J CLIN MICROBIOL, V46, P1161, DOI 10.1128/JCM.00793-07; O'Malley DP, 2019, MODERN PATHOL, V32, P929, DOI 10.1038/s41379-019-0210-3; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Suda K, 2018, CELL REP, V24, P1777, DOI 10.1016/j.celrep.2018.07.037; Sun JQ, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-219; Tamura R, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-017-0018-2; Teng MWL, 2015, CANCER RES, V75, P2139, DOI 10.1158/0008-5472.CAN-15-0255; Torres-Garcia W, 2014, BIOINFORMATICS, V30, P2224, DOI 10.1093/bioinformatics/btu169; Yarchoan M, 2017, NEW ENGL J MED, V377, P2500, DOI 10.1056/NEJMc1713444; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177	51	16	17	7	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	17					3541	3554		10.1038/s41388-020-1237-0	http://dx.doi.org/10.1038/s41388-020-1237-0		MAR 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LH1YK	32115573	hybrid, Green Published			2022-12-28	WOS:000517359700002
J	Herrmann, A; Lahtz, C; Song, J; Aftabizadeh, M; Cherryholmes, GA; Xin, H; Adamus, T; Lee, HY; Grunert, D; Armstrong, B; Chu, PG; Brown, C; Lim, M; Forman, S; Yu, H				Herrmann, Andreas; Lahtz, Christoph; Song, Jieun; Aftabizadeh, Maryam; Cherryholmes, Gregory A.; Xin, Hong; Adamus, Tomasz; Lee, Heehyoung; Grunert, David; Armstrong, Brian; Chu, Peiguo; Brown, Christine; Lim, Michael; Forman, Stephen; Yu, Hua			Integrin alpha 6 signaling induces STAT3-TET3-mediated hydroxymethylation of genes critical for maintenance of glioma stem cells	ONCOGENE			English	Article							EXTRACELLULAR-MATRIX; TET PROTEINS; CANCER; 5-HYDROXYMETHYLCYTOSINE; DNA; 5-METHYLCYTOSINE; GLIOBLASTOMA; PLURIPOTENT; EPIGENETICS; RESISTANCE	Both the extracellular matrix (ECM) and DNA epigenetic regulation are critical for maintaining stem cell phenotype and cancer progression. Whether and how ECM regulates epigenetic alterations to influence cancer stem cells (CSCs) remain to be explored. Here we report that ECM through laminin-integrin alpha 6 upregulates ten-eleven translocation enzyme 3 (TET3) dioxygenase. TET3 in turn mediates DNA cytosine 5 '-hydroxymethylation (5hmC) and upregulates genes critical for maintenance of glioma stem cells (GSCs). Activating integrin alpha 6-FAK pathway increases STAT3 activity, TET3 expression and 5hmC levels in GSCs. Moreover, targeting STAT3 disrupts integrin alpha 6-FAK signaling and inhibits TET3(+) GSC maturation in vivo. STAT3 directly regulates TET3 expression and the two proteins are co-localized with 5hmC in GSC clusters. 5hmC is upregulated by STAT3 at the promoters of several tumorigenic genes, including c-Myc, known to be critical for GSCs. In vivo silencing of TET3 in GSC-enriched tumors reduces 5hmC accumulation and expression of the GSC critical genes, leading to tumor growth inhibition. TET3 expression and 5hmC accumulation also co-segregate with integrin alpha 6 in patient malignant glioma. Thus, ECM- integrin alpha 6-STAT3-TET3 axis regulates hydroxymethylation of genes important for GSCs, thereby increasing GSC tumorigenicity and resistance to therapies.	[Herrmann, Andreas; Lahtz, Christoph; Song, Jieun; Aftabizadeh, Maryam; Cherryholmes, Gregory A.; Xin, Hong; Adamus, Tomasz; Lee, Heehyoung; Grunert, David; Yu, Hua] City Hope Comprehens Canc Ctr, Dept Immunooncol, Beckman Res Inst, Duarte, CA 91010 USA; [Herrmann, Andreas; Lahtz, Christoph; Adamus, Tomasz] Sorrento Therapeut, San Diego, CA 92121 USA; [Armstrong, Brian] City Hope Comprehens Canc Ctr, Dept Neurosci, Beckman Res Inst, Duarte, CA 91010 USA; [Chu, Peiguo] City Hope Comprehens Canc Ctr, Dept Pathol, Duarte, CA 91010 USA; [Brown, Christine; Forman, Stephen] City Hope Comprehens Canc Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA 91010 USA; [Lim, Michael] Johns Hopkins Univ, Dept Neurosurg, Baltimore, MD 21287 USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; City of Hope; City of Hope; Johns Hopkins University	Herrmann, A; Yu, H (corresponding author), City Hope Comprehens Canc Ctr, Dept Immunooncol, Beckman Res Inst, Duarte, CA 91010 USA.; Herrmann, A (corresponding author), Sorrento Therapeut, San Diego, CA 92121 USA.	aherrmann@sorrentotherapeutics.com; hyu@coh.org	; Song, Ji Eun/A-3567-2013	YU, Hua/0000-0003-0931-1000; Song, Ji Eun/0000-0001-7886-1765; Lim, Michael/0000-0003-0523-3076	Billy and Audrey Wilder Endowment; National Cancer Institute of the National Institutes of Health [P30CA033572];  [R01CA122976];  [R01CA146092]	Billy and Audrey Wilder Endowment; National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ; 	This work is funded in part by R01CA122976 and R01CA146092 (to HY), as well as the Billy and Audrey Wilder Endowment (to HY). Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under grant number P30CA033572 (to City of Hope Comprehensive Cancer Center). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Acerbi I, 2015, INTEGR BIOL-UK, V7, P1120, DOI 10.1039/c5ib00040h; Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Baylin SB, 2011, NAT MED, V17, P288, DOI 10.1038/nm0311-288; Branco MR, 2012, NAT REV GENET, V13, P7, DOI 10.1038/nrg3080; Brown CE, 2012, CLIN CANCER RES, V18, P2199, DOI 10.1158/1078-0432.CCR-11-1669; Brown CE, 2009, CANCER RES, V69, P8886, DOI 10.1158/0008-5472.CAN-09-2687; Cimmino L, 2015, NAT IMMUNOL, V16, P653, DOI 10.1038/ni.3148; Cui Q, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10637; Frantz C, 2010, J CELL SCI, V123, P4195, DOI 10.1242/jcs.023820; Guo JU, 2011, CELL, V145, P423, DOI 10.1016/j.cell.2011.03.022; Herrmann A, 2015, J CLIN INVEST, V125, P2547, DOI 10.1172/JCI82555; Herrmann A, 2014, CANCER RES, V74, P5218, DOI 10.1158/0008-5472.CAN-14-1151; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Huang H, 2013, P NATL ACAD SCI USA, V110, P11994, DOI 10.1073/pnas.1310656110; Huang Y, 2014, P NATL ACAD SCI USA, V111, P1361, DOI 10.1073/pnas.1322921111; Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303; Jiang X, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02290-w; Jin F, 2008, NEUROSCIENCE, V154, P541, DOI 10.1016/j.neuroscience.2008.03.054; Johnson KC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13177; Koh KP, 2011, CELL STEM CELL, V8, P200, DOI 10.1016/j.stem.2011.01.008; Lathia JD, 2010, CELL STEM CELL, V6, P421, DOI 10.1016/j.stem.2010.02.018; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147; Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003; Mathieu J, 2011, CANCER RES, V71, P4640, DOI 10.1158/0008-5472.CAN-10-3320; Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107; Meissner A, 2010, NAT BIOTECHNOL, V28, P1079, DOI 10.1038/nbt.1684; Pickup MW, 2014, EMBO REP, V15, P1243, DOI 10.15252/embr.201439246; Prasad P, 2017, STEM CELLS, V35, P1468, DOI 10.1002/stem.2621; Schroeder A, 2014, CANCER RES, V74, P1227, DOI 10.1158/0008-5472.CAN-13-0594; Singh SK, 2003, CANCER RES, V63, P5821; Sun YB, 2012, ANNU REV BIOPHYS, V41, P519, DOI 10.1146/annurev-biophys-042910-155306; Tagscherer KE, 2008, ONCOGENE, V27, P6646, DOI 10.1038/onc.2008.259; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Takai H, 2014, CELL REP, V9, P48, DOI 10.1016/j.celrep.2014.08.071; Veron N, 2011, NATURE, V473, P293, DOI 10.1038/473293a; Wang JL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003769; Weaver VM, 1997, TRENDS CELL BIOL, V7, P40, DOI 10.1016/S0962-8924(97)30078-6; Wu MZ, 2015, CANCER RES, V75, P3912, DOI 10.1158/0008-5472.CAN-14-3208; Yang L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133896; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Zhang F, 2016, SCI REP-UK, V6, DOI 10.1038/srep20882	42	15	17	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	10					2156	2169		10.1038/s41388-019-1134-6	http://dx.doi.org/10.1038/s41388-019-1134-6			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KS8UR	31819166	Green Accepted			2022-12-28	WOS:000518584000010
J	Shen, JJ; Zhai, J; You, Q; Zhang, GX; He, MF; Yao, XQ; Shen, LZ				Shen, Jiajia; Zhai, Jing; You, Qiang; Zhang, Guoxin; He, Mingfang; Yao, Xuequan; Shen, Lizong			Cancer-associated fibroblasts-derived VCAM1 induced by H. pylori infection facilitates tumor invasion in gastric cancer	ONCOGENE			English	Article							CELL-ADHESION MOLECULE-1; HELICOBACTER-PYLORI; EXPRESSION; PROGNOSIS	Cancer-associated fibroblasts (CAFs) play a major role in the progression of stomach cancer, but the related mechanisms are not fully understood. H. pylori infection is recognized as one of the strongest risk factors for gastric carcinoma, but its effects on CAFs remain unknown. We aimed to determine the causative relationship between H. pylori infection in fibroblasts and the promoted cancer pathogenesis and progression in gastric cancer. Primary CAFs and normal activated fibroblasts (NAFs) were generated from gastric cancer patients. Gene signature of H. pylori-infected human stomach fibroblasts was performed using the RNA-seq analysis. Spheroid cell invasion assay and zebrafish cell line-derived xenograft (zCDX) model were introduced to evaluate tumor invasion induced by CAFs. The molecule interactions were determined using the kinetic binding analysis with the Biolayer Interferometry (BLI). Clinical significance and relevance were also assessed using the database analyses. H. pylori infection activated stomach fibroblasts and caused multiple gene alterations, including vascular adhesion molecule 1 (VCAM1). H. pylori infection increased VCAM1 expression in CAFs in gastric carcinoma via activation of JAK/STAT1 signaling pathway, and VCAM1 levels were positively associated with tumor progression and dismal prognosis in stomach cancer patients. Furthermore, CAFs-derived VCAM1 molecularly interacted with integrin alpha v beta 1/5 in gastric cancer cells facilitated tumor invasion in vitro and in vivo. Our results identify a novel mechanism underlying CAFs to promote tumor invasion during H. pylori infection. These studies facilitate us for a better understanding of the molecular process of gastric carcinoma progression, and provide the potential strategies for gastric cancer therapy.	[Shen, Jiajia; Shen, Lizong] Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Div Gastrointestinal Surg, Nanjing 210029, Peoples R China; [Zhai, Jing; Yao, Xuequan] Nanjing Univ Chinese Med, Affiliated Hosp, Jiangsu Prov Hosp Chinese Med, Dept Surg Oncol, Nanjing 210029, Peoples R China; [You, Qiang] Nanjing Med Univ, Affiliated Hosp 2, Dept Geriatr, Nanjing 210003, Peoples R China; [Zhang, Guoxin] Nanjing Med Univ, Affiliated Hosp 1, Dept Gastroenterol, Nanjing 210029, Peoples R China; [He, Mingfang] Nanjing Tech Univ, Coll Biotechnol & Pharmaceut Engn, Inst Translat Med, Nanjing 211800, Peoples R China	Nanjing Medical University; Nanjing University of Chinese Medicine; Nanjing Medical University; Nanjing Medical University; Nanjing Tech University	Shen, LZ (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Div Gastrointestinal Surg, Nanjing 210029, Peoples R China.	shenlz@njmu.edu.cn		You, Qiang/0000-0003-3308-4127	National Natural Science Foundation of China [81272711, 81871959]; Priority Academic Program Development of Jiangsu Higher Education Institutions [JX10231801]; Key Medical Talents Program of Jiangsu Province [ZDRCA2016014]; Key R&D Program of Jiangsu Province (Social Development) [BE2018758]; Programs of Jiangsu Province Hospital of Chinese Medicine [Y2018RC14, Y2018CX71]; Jiangsu Graduate Research Innovation Program [KYCX18_1479]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development of Jiangsu Higher Education Institutions; Key Medical Talents Program of Jiangsu Province; Key R&D Program of Jiangsu Province (Social Development); Programs of Jiangsu Province Hospital of Chinese Medicine; Jiangsu Graduate Research Innovation Program	This work was supported by the National Natural Science Foundation of China (Grant Nos. 81272711 and 81871959 to LS), the Priority Academic Program Development of Jiangsu Higher Education Institutions (JX10231801 to LS), the Key Medical Talents Program of Jiangsu Province (ZDRCA2016014 to LS), the Key R&D Program of Jiangsu Province (Social Development, BE2018758 to LS), the Programs of Jiangsu Province Hospital of Chinese Medicine (Y2018RC14 to LS and Y2018CX71 to JZ), and the Jiangsu Graduate Research Innovation Program (KYCX18_1479 to JS).	Attieh Y, 2017, J CELL BIOL, V216, P3509, DOI 10.1083/jcb.201702033; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cerutti C, 2017, EXP CELL RES, V358, P31, DOI 10.1016/j.yexcr.2017.06.003; Chen Q, 2011, CANCER CELL, V20, P538, DOI 10.1016/j.ccr.2011.08.025; Coburn N, 2018, CANCER TREAT REV, V63, P104, DOI 10.1016/j.ctrv.2017.12.006; Crowe SE, 2019, NEW ENGL J MED, V380, P1158, DOI 10.1056/NEJMcp1710945; Fujii S, 2015, CANCER MED-US, V4, P1667, DOI 10.1002/cam4.515; Galamb O, 2008, HELICOBACTER, V13, P112, DOI 10.1111/j.1523-5378.2008.00584.x; Horvat A, 2018, ONCOGENE, V37, P5054, DOI 10.1038/s41388-018-0343-8; Huelsken J, 2018, CELL, V172, P643, DOI 10.1016/j.cell.2018.01.028; Ishimoto T, 2017, GASTROENTEROLOGY, V153, P191, DOI 10.1053/j.gastro.2017.03.046; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Karakasheva TA, 2018, CANCER RES, V78, P4957, DOI 10.1158/0008-5472.CAN-17-2268; Kiga K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5497; Kong DH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041057; Krzysiek-Maczka G, 2013, J PHYSIOL PHARMACOL, V64, P77; Krzysiek-Maczka G, 2018, HELICOBACTER, V23, DOI 10.1111/hel.12538; LeBleu VS, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.029447; Liu CJ, 2018, CANCERS, V10, DOI 10.3390/cancers10120479; Liu YS, 2017, ONCOGENE, V36, P5006, DOI 10.1038/onc.2017.129; Maeda M, 2020, GUT, V69, P243, DOI 10.1136/gutjnl-2018-317645; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; Plummer M, 2015, INT J CANCER, V136, P487, DOI 10.1002/ijc.28999; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; Satoyoshi R, 2015, ONCOGENE, V34, P650, DOI 10.1038/onc.2013.584; Scalici JM, 2017, CANCER-AM CANCER SOC, V123, P977, DOI 10.1002/cncr.30415; Schlesinger M, 2015, INT J CANCER, V136, P2504, DOI 10.1002/ijc.28927; Sharma R, 2017, CELL ONCOL, V40, P199, DOI 10.1007/s13402-017-0324-x; Sigal M, 2017, NATURE, V548, P451, DOI 10.1038/nature23642; Su SC, 2018, CELL, V172, P841, DOI 10.1016/j.cell.2018.01.009; Terai S, 2015, GASTRIC CANCER, V18, P306, DOI 10.1007/s10120-014-0380-0; Tichet M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7993; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Van Cutsem E, 2016, LANCET, V388, P2654, DOI 10.1016/S0140-6736(16)30354-3; Velikova G, 1997, BRIT J CANCER, V76, P1398, DOI 10.1038/bjc.1997.569; Wadhwa R, 2013, NAT REV CLIN ONCOL, V10, P643, DOI 10.1038/nrclinonc.2013.170; Wang XF, 2017, INT J CANCER, V141, P998, DOI 10.1002/ijc.30801; Wen JF, 2018, ONCOGENE, V37, P3549, DOI 10.1038/s41388-018-0208-1; Wu JQ, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0631-0; Yang L, 2018, CHINESE J CANCER RES, V30, P291, DOI 10.21147/j.issn.1000-9604.2018.03.01; Zhai J, 2019, CANCER LETT, V454, P37, DOI 10.1016/j.canlet.2019.04.002	42	27	29	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	14					2961	2974		10.1038/s41388-020-1197-4	http://dx.doi.org/10.1038/s41388-020-1197-4		FEB 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KZ2VB	32034307				2022-12-28	WOS:000511752600001
J	Waisertreiger, I; Popovich, K; Block, M; Anderson, KR; Barlow, JH				Waisertreiger, Irina; Popovich, Katherine; Block, Maya; Anderson, Krista R.; Barlow, Jacqueline H.			Visualizing locus-specific sister chromatid exchange reveals differential patterns of replication stress-induced fragile site breakage	ONCOGENE			English	Article							DNA SECONDARY STRUCTURES; HOMOLOGOUS RECOMBINATION; REPAIR PATHWAYS; COMMON; INSTABILITY; GENE; APHIDICOLIN; CANCER; CHROMOSOMES; INHIBITION	Chromosomal fragile sites are genomic loci sensitive to replication stress which accumulate high levels of DNA damage, and are frequently mutated in cancers. Fragile site damage is thought to arise from the aberrant repair of spontaneous replication stress, however successful fragile site repair cannot be calculated using existing techniques. Here, we report a new assay measuring recombination-mediated repair at endogenous genomic loci by combining a sister chromatid exchange (SCE) assay with fluorescent in situ hybridization (SCE-FISH). Using SCE-FISH, we find that endogenous and exogenous replication stress generated unrepaired breaks and SCEs at fragile sites. We also find that distinct sources of replication stress induce distinct patterns of breakage: ATR inhibition induces more breaks at early replicating fragile sites (ERFS), while ERFS and late-replicating common fragile sites (CFS) are equally fragile in response to aphidicolin. Furthermore, SCEs were suppressed at fragile sites near centromeres in response to replication stress, suggesting that genomic location influences DNA repair pathway choice. SCE-FISH also measured successful recombination in human primary lymphocytes, and identificed the proto-oncogene BCL2 as a replication stress-induced fragile site. These findings demonstrate that SCE-FISH frequency at fragile sites is a sensitive indicator of replication stress, and that large-scale genome organization influences DNA repair pathway choice.	[Waisertreiger, Irina; Popovich, Katherine; Block, Maya; Anderson, Krista R.; Barlow, Jacqueline H.] Univ Calif Davis, Dept Microbiol & Mol Genet, Davis, CA 95616 USA; [Barlow, Jacqueline H.] Univ Calif Davis, Genome Ctr, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Barlow, JH (corresponding author), Univ Calif Davis, Dept Microbiol & Mol Genet, Davis, CA 95616 USA.; Barlow, JH (corresponding author), Univ Calif Davis, Genome Ctr, Davis, CA 95616 USA.	jhbarlow@ucdavis.edu			NIHK22 grant from the NCI [K22CA188106]; NIH [S100D018223]	NIHK22 grant from the NCI; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Dr. Neil Hunter, Jack McTiernan, and all members of the Barlow and Hunter labs for helpful discussions and suggestions. This work was supported by a NIHK22 grant to JHB from the NCI (K22CA188106) and NIH S100D018223.	Alzu A, 2012, CELL, V151, P835, DOI 10.1016/j.cell.2012.09.041; Arlt MF, 2004, MOL CELL BIOL, V24, P6701, DOI 10.1128/mcb.24.15.6701-6709.2004; Baranovskiy AG, 2014, NUCLEIC ACIDS RES, V42, P14013, DOI 10.1093/nar/gku1209; Barlow JH, 2013, CELL, V152, P620, DOI 10.1016/j.cell.2013.01.006; Berti M, 2016, NAT STRUCT MOL BIOL, V23, P103, DOI 10.1038/nsmb.3163; Cimprich KA, 2008, NAT REV MOL CELL BIO, V9, P616, DOI 10.1038/nrm2450; Deans B, 2003, CANCER RES, V63, P8181; Dillon LW, 2013, HUM MOL GENET, V22, P1443, DOI 10.1093/hmg/dds561; Durkin SG, 2007, ANNU REV GENET, V41, P169, DOI 10.1146/annurev.genet.41.042007.165900; Flynn RL, 2011, TRENDS BIOCHEM SCI, V36, P133, DOI 10.1016/j.tibs.2010.09.005; Gaillard H, 2015, NAT REV CANCER, V15, P276, DOI 10.1038/nrc3916; Garsed DW, 2014, CANCER CELL, V26, P653, DOI 10.1016/j.ccell.2014.09.010; Gascoigne KE, 2013, CHROMOSOME RES, V21, P407, DOI 10.1007/s10577-013-9368-6; Gisselsson D, 2000, P NATL ACAD SCI USA, V97, P5357, DOI 10.1073/pnas.090013497; Glover TW, 2017, NAT REV CANCER, V17, P489, DOI 10.1038/nrc.2017.52; GLOVER TW, 1984, HUM GENET, V67, P136, DOI 10.1007/BF00272988; Helmrich A, 2006, GENOME RES, V16, P1222, DOI 10.1101/gr.5335506; Helmrich A, 2011, MOL CELL, V44, P966, DOI 10.1016/j.molcel.2011.10.013; Jaco I, 2008, J CELL BIOL, V181, P885, DOI 10.1083/jcb.200803042; Jiang YW, 2009, HUM MOL GENET, V18, P4501, DOI 10.1093/hmg/ddp410; LAMBIE EJ, 1988, CELL, V52, P863, DOI 10.1016/0092-8674(88)90428-X; Leon-Ortiz AM, 2014, DNA REPAIR, V19, P152, DOI 10.1016/j.dnarep.2014.03.016; Letessier A, 2011, NATURE, V470, P120, DOI 10.1038/nature09745; Lopez-Contreras AJ, 2015, GENE DEV, V29, P690, DOI 10.1101/gad.256958.114; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; Marotta M, 2017, SCI REP-UK, V7, DOI 10.1038/srep41921; McClintock B, 1941, GENETICS, V26, P234; Mortusewicz O, 2013, EMBO J, V32, P493, DOI 10.1038/emboj.2013.20; Nagaraju G, 2009, MOL CELL BIOL, V29, P4283, DOI 10.1128/MCB.01406-08; Orii KE, 2006, P NATL ACAD SCI USA, V103, P10017, DOI 10.1073/pnas.0602436103; Ozeri-Galai E, 2011, MOL CELL, V43, P122, DOI 10.1016/j.molcel.2011.05.019; Paeschke K, 2011, CELL, V145, P678, DOI 10.1016/j.cell.2011.04.015; PORFIRIO B, 1985, MUTAT RES, V144, P257, DOI 10.1016/0165-7992(85)90061-2; Richardson C, 1998, GENE DEV, V12, P3831, DOI 10.1101/gad.12.24.3831; Rickert RC, 1997, NUCLEIC ACIDS RES, V25, P1317, DOI 10.1093/nar/25.6.1317; Robbiani DF, 2008, CELL, V135, P1028, DOI 10.1016/j.cell.2008.09.062; Rozier L, 2004, ONCOGENE, V23, P6872, DOI 10.1038/sj.onc.1207809; Schwartz M, 2005, GENE DEV, V19, P2715, DOI 10.1101/gad.340905; Serra H, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003971; Shiraishi T, 2001, P NATL ACAD SCI USA, V98, P5722, DOI 10.1073/pnas.091095898; Somyajit K, 2015, NUCLEIC ACIDS RES, V43, P9835, DOI 10.1093/nar/gkv880; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Takata M, 2001, MOL CELL BIOL, V21, P2858, DOI 10.1128/MCB.21.8.2858-2866.2001; Talbert PB, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000326; Termolino P, 2016, CHROMOSOMA, V125, P301, DOI 10.1007/s00412-016-0574-9; Vincenten N, 2015, ELIFE, V4, DOI 10.7554/eLife.10850; Ying SM, 2013, NAT CELL BIOL, V15, P1001, DOI 10.1038/ncb2773; Yonetani Y, 2005, NUCLEIC ACIDS RES, V33, P4544, DOI 10.1093/nar/gki766; Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760; Zeman MK, 2014, NAT CELL BIOL, V16, P2, DOI 10.1038/ncb2897; Zhou Y, 2015, ANAL BIOCHEM, V479, P48, DOI 10.1016/j.ab.2015.03.025; Zlotorynski E, 2003, MOL CELL BIOL, V23, P7143, DOI 10.1128/MCB.23.20.7143-7151.2003	52	11	11	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	6					1260	1272		10.1038/s41388-019-1054-5	http://dx.doi.org/10.1038/s41388-019-1054-5			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE4UH	31636383	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000526714600007
J	Li, B; Chen, YY; Wang, F; Guo, J; Fu, W; Li, M; Zheng, QC; Liu, Y; Fan, LL; Li, L; Xu, CR				Li, Bin; Chen, Yuyuan; Wang, Fei; Guo, Jun; Fu, Wen; Li, Min; Zheng, Qichang; Liu, Yong; Fan, Lingling; Li, Lei; Xu, Chuanrui			Bmi1 drives hepatocarcinogenesis by repressing the TGF beta 2/SMAD signalling axis	ONCOGENE			English	Article							CELL SELF-RENEWAL; TGF-BETA; C-MYC; IN-VIVO; H-RAS; GROWTH; RECEPTOR; PROTEIN; TUMORIGENESIS; ONCOPROTEIN	Bmi1 is overexpressed in one-third of hepatocellular carcinoma (HCC) patients and acts as an oncogene in hepatocarcinogenesis. However, the underlying mechanism is unclear. The role of TGF beta signalling in HCC is not well defined as well. Here, we report that TGF beta 2 is a target of Bmi1 in HCC and has a tumour-suppressing role. In Bmi1-knockout mouse livers and HCC cell lines, TGF beta 2/SMAD cascade proteins were upregulated. TGF beta 2 expression was inversely correlated with Bmi1 expression in human and mouse HCC tissues. In vitro, Bmi1 knockdown activated TGF beta 2/SMAD signalling and led to cell apoptosis via upregulation of p15 and p21. TGF beta 2 inhibition rescued the inhibitory effect of Bmi1 knockdown on HCC cell survival, proliferation, and cell-cycle progression. In vivo, restoration of TGF beta 2 expression blocked Bmi1/Ras-driven hepatocarcinogenesis in mice. Chromatin immunoprecipitation and luciferase reporter assays revealed that Bmi1 repressed TGF beta 2 expression by binding to its promoter as a co-factor of polycomb repressor complex 1. Our findings elucidate the molecular mechanism underlying hepatic Bmi1-driven carcinogenesis and highlight the importance of TGF beta 2 as a tumour suppressor in HCC development.	[Li, Bin; Chen, Yuyuan; Guo, Jun; Fu, Wen; Liu, Yong; Li, Lei; Xu, Chuanrui] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Pharm, Wuhan 430030, Peoples R China; [Wang, Fei] Huazhong Univ Sci & Technol, Sch Basic Med, Dept Biochem & Mol Biol, Wuhan 430030, Peoples R China; [Li, Min; Zheng, Qichang] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Hepatobiliary Surg, Wuhan 430022, Peoples R China; [Fan, Lingling] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Stem Cell Ctr, Wuhan 430022, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Xu, CR (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Pharm, Wuhan 430030, Peoples R China.	xcr@hust.edu.cn			National Science Foundation of China [81572723, 81872253]; Innovation Foundation of Higher Education of China [2016JCTD109]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Innovation Foundation of Higher Education of China	This study was supported by the National Science Foundation of China (81572723 and 81872253) and the Innovation Foundation of Higher Education of China (2016JCTD109).	Batlle E, 2019, IMMUNITY, V50, P924, DOI 10.1016/j.immuni.2019.03.024; Becker M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004230; Bentley ML, 2011, EMBO J, V30, P3285, DOI 10.1038/emboj.2011.243; Blackledge NP, 2014, CELL, V157, P1445, DOI 10.1016/j.cell.2014.05.004; Bruggeman SWM, 2007, CANCER CELL, V12, P328, DOI 10.1016/j.ccr.2007.08.032; Charan J, 2013, J PHARMACOL PHARMACO, V4, P303, DOI 10.4103/0976-500X.119726; Chiba T, 2008, CANCER RES, V68, P7742, DOI 10.1158/0008-5472.CAN-07-5882; Chiba T, 2010, HEPATOLOGY, V52, P1111, DOI 10.1002/hep.23793; Coulouarn C, 2008, HEPATOLOGY, V47, P2059, DOI 10.1002/hep.22283; Datta S, 2007, CANCER RES, V67, P10286, DOI 10.1158/0008-5472.CAN-07-1636; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; del Re E, 2004, J BIOL CHEM, V279, P22765, DOI 10.1074/jbc.M401350200; Dhawan S, 2009, GENE DEV, V23, P906, DOI 10.1101/gad.1742609; Douglas D, 2008, CANCER RES, V68, P6507, DOI 10.1158/0008-5472.CAN-07-6152; Dovey JS, 2008, P NATL ACAD SCI USA, V105, P11857, DOI 10.1073/pnas.0803574105; Dropmann A, 2016, ONCOTARGET, V7, P19499, DOI 10.18632/oncotarget.6967; Fan C, 2008, BBA-MOL BASIS DIS, V1782, P642, DOI 10.1016/j.bbadis.2008.08.009; Fan LL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046472; Gargiulo G, 2013, CANCER CELL, V23, P660, DOI 10.1016/j.ccr.2013.03.030; Goel HL, 2012, CANCER DISCOV, V2, P906, DOI 10.1158/2159-8290.CD-12-0085; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Ho C, 2012, HEPATOLOGY, V55, P833, DOI 10.1002/hep.24736; Hoenerhoff MJ, 2009, ONCOGENE, V28, P3022, DOI 10.1038/onc.2009.165; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Jagani Z, 2010, CANCER RES, V70, P5528, DOI 10.1158/0008-5472.CAN-09-4229; Jiang Y, 2015, ONCOGENE, V34, P6079, DOI 10.1038/onc.2015.53; Karla N, 2004, J BIOL CHEM, V279, P25313, DOI 10.1074/jbc.M400932200; Kim JH, 2004, CANCER LETT, V203, P217, DOI 10.1016/j.canlet.2003.07.009; Kim RH, 2010, EXP CELL RES, V316, P2600, DOI 10.1016/j.yexcr.2010.04.013; Kreso A, 2014, NAT MED, V20, P29, DOI 10.1038/nm.3418; Levy L, 2002, ANN NY ACAD SCI, V963, P21; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; McGinty RK, 2014, NATURE, V514, P591, DOI 10.1038/nature13890; MITCHELL EJ, 1992, MOL BIOL CELL, V3, P1295, DOI 10.1091/mbc.3.11.1295; Molofsky AV, 2005, GENE DEV, V19, P1432, DOI 10.1101/gad.1299505; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Noma T, 1991, GROWTH FACTORS, V4, P247, DOI 10.3109/08977199109043910; Oh S, 2013, CANCER GENE THER, V20, P94, DOI 10.1038/cgt.2012.90; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Park IK, 2004, J CLIN INVEST, V113, P175, DOI 10.1172/JCI200420800; Pietersen AM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2214; Qi SB, 2014, INT J MOL SCI, V15, P20004, DOI 10.3390/ijms151120004; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; RODRIGUEZ C, 1995, J BIOL CHEM, V270, P15919, DOI 10.1074/jbc.270.27.15919; Rotzer D, 2001, EMBO J, V20, P480, DOI 10.1093/emboj/20.3.480; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; Sangiorgi E, 2008, NAT GENET, V40, P915, DOI 10.1038/ng.165; Shi Y, 2012, CARCINOGENESIS, V33, P1468, DOI 10.1093/carcin/bgs171; Silva J, 2006, CLIN CANCER RES, V12, P6929, DOI 10.1158/1078-0432.CCR-06-0788; Tward AD, 2007, P NATL ACAD SCI USA, V104, P14771, DOI 10.1073/pnas.0706578104; Vonlanthen S, 2001, BRIT J CANCER, V84, P1372, DOI 10.1054/bjoc.2001.1791; Wojtowicz JM, 2006, NAT PROTOC, V1, P1399, DOI 10.1038/nprot.2006.224; Xu CR, 2009, MOL CANCER RES, V7, P1937, DOI 10.1158/1541-7786.MCR-09-0333; Yang T, 2014, THERANOSTICS, V4, P1096, DOI 10.7150/thno.9423	56	13	13	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	5					1063	1079		10.1038/s41388-019-1043-8	http://dx.doi.org/10.1038/s41388-019-1043-8			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KI2VY	31591477				2022-12-28	WOS:000511209700009
J	Leng, XJ; Wang, JF; An, N; Wang, X; Sun, YL; Chen, ZW				Leng, Xuejiao; Wang, Jianfeng; An, Na; Wang, Xue; Sun, Yile; Chen, Zhiwei			Histone 3 lysine-27 demethylase KDM6A coordinates with KMT2B to play an oncogenic role in NSCLC by regulating H3K4me3	ONCOGENE			English	Article							UTX; CANCER; METHYLATION; ACTIVATION; EZH2; MUTATIONS; PATHWAY; GENES; H3	Aberrations in epigenetic modulation dysregulate transcription, playing a critical role in the developmental process of tumors, including lung cancer. Aberrant levels of the histone 3 lysine-27 demethylase KDM6A have been found in cancer and are either positively or negatively associated with tumorigenesis and prognosis. However, the clinical relevance and functional role of KDM6A in lung cancer is largely unknown. We found that KDM6A protein expression was higher in NSCLC tissues than in the corresponding paracancer tissues and that high KDM6A expression was associated with poor patient prognosis. Furthermore, KDM6A knockdown in NSCLC cell lines markedly inhibited the tumorigenic phenotype both in vitro and in vivo. Mechanistically, KDM6A colocalized and cooperated with KMT2B to reprogram the transcriptional network via regulating the cancer pathway, in which abnormal activation of the Wnt pathway is the dominant factor. Interestingly, in NSCLC cell lines, H3K4me3 but not H3K27me2/3 or H3K4me1/2 was markedly altered upon KDM6A or KMT2B knockdown, indicating that KDM6A may act independently of H3K27 demethylases in NSCLC. Taken together, these results indicated that KDM6A or KMT2B may be a prognostic biomarker and promising therapeutic target in NSCLC.	[Leng, Xuejiao; An, Na; Wang, Xue; Sun, Yile; Chen, Zhiwei] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Tumor Clin Med Ctr, Shanghai, Peoples R China; [Wang, Jianfeng] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Urol, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University	Chen, ZW (corresponding author), Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Tumor Clin Med Ctr, Shanghai, Peoples R China.	drchenzhiwei@163.com		chen, zhiwei/0000-0002-6027-3575	National Natural Science Foundation of China [81572250]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This research was supported by National Natural Science Foundation of China (Grant no. 81572250).	Ahuja N, 2016, ANNU REV MED, V67, P73, DOI 10.1146/annurev-med-111314-035900; Akiri G, 2009, ONCOGENE, V28, P2163, DOI 10.1038/onc.2009.82; Audia JE, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a019521; Berger SL, 2009, GENE DEV, V23, P781, DOI 10.1101/gad.1787609; Bienz M, 2005, CURR BIOL, V15, pR64, DOI 10.1016/j.cub.2004.12.058; Chen YC, 2018, COMPUT STRUCT BIOTEC, V16, P211, DOI 10.1016/j.csbj.2018.06.001; Cho Ju Hwan, 2017, Curr Pharmacol Rep, V3, P360; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Ezponda T, 2017, CELL REP, V21, P628, DOI 10.1016/j.celrep.2017.09.078; Fan L, 2016, ONCOGENE, V35, P2441, DOI 10.1038/onc.2015.309; Gridelli C, 2015, NAT REV DIS PRIMERS, V1, DOI [10.1038/nrdp.2015.9, 10.1038/nrdp.2015.48]; Hardy TM, 2011, EPIGENOMICS-UK, V3, P503, DOI [10.2217/EPI.11.71, 10.2217/epi.11.71]; Herz HM, 2012, GENE DEV, V26, P2604, DOI 10.1101/gad.201327.112; Hong SH, 2007, P NATL ACAD SCI USA, V104, P18439, DOI 10.1073/pnas.0707292104; Issaeva I, 2007, MOL CELL BIOL, V27, P1889, DOI 10.1128/MCB.01506-06; Jankowska AM, 2011, BLOOD, V118, P3932, DOI 10.1182/blood-2010-10-311019; Kalkat M, 2017, GENES-BASEL, V8, DOI 10.3390/genes8060151; Kim JH, 2014, CANCER RES, V74, P1705, DOI 10.1158/0008-5472.CAN-13-1896; Lan F, 2007, NATURE, V449, P689, DOI 10.1038/nature06192; Li SH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010297; Li X, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04769-6; Liao LL, 2015, CANCER GENET-NY, V208, P206, DOI 10.1016/j.cancergen.2015.02.008; Mansour AA, 2012, NATURE, V488, P409, DOI 10.1038/nature11272; Montgomery ND, 2005, CURR BIOL, V15, P942, DOI 10.1016/j.cub.2005.04.051; Ng L, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080826; Rao RC, 2015, NAT REV CANCER, V15, P334, DOI 10.1038/nrc3929; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Shpargel KB, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002964; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Sierra J, 2006, GENE DEV, V20, P586, DOI 10.1101/gad.1385806; Sun LC, 2015, CELL RES, V25, P429, DOI 10.1038/cr.2015.33; Tang X, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0841-y; Toh TB, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0596-9; Van der Meulen J, 2015, BLOOD, V125, P13, DOI 10.1182/blood-2014-05-577270; Van der Meulen J, 2014, EPIGENETICS-US, V9, P658, DOI 10.4161/epi.28298; van Haaften G, 2009, NAT GENET, V41, P521, DOI 10.1038/ng.349; Wang CC, 2012, P NATL ACAD SCI USA, V109, P15324, DOI 10.1073/pnas.1204166109; Wang L, 2019, CANCER CELL, V35, P168, DOI 10.1016/j.ccell.2019.01.001; Xu BW, 2015, EXP HEMATOL, V43, P698, DOI 10.1016/j.exphem.2015.05.001; Zhang C, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0731-8	40	13	13	0	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2020	39	41					6468	6479		10.1038/s41388-020-01449-y	http://dx.doi.org/10.1038/s41388-020-01449-y		SEP 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OA1JL	32879445				2022-12-28	WOS:000565482600003
J	Su, Y; Wang, XY; Guo, Z; Wang, J				Su, Yao; Wang, Xueying; Guo, Zhen; Wang, Jun			Aberrant JmjC domain-containing protein 8 (JMJD8) expression promotes activation of AKT and tumor epithelial-mesenchymal transition	ONCOGENE			English	Article							BETA-CATENIN; CELL-MIGRATION; KINASE; PHOSPHORYLATION; EPIGENOMICS; METHYLATION; METASTASIS; INHIBITION; PATHWAY; FAMILY	Posttranslational modifications of histone and nonhistone proteins greatly influence numerous molecular events in multiple diseases. Jumonji domain-containing proteins are a family functioning as histone demethylase. Jumonji domain-containing protein 8 (JMJD8) is Jumonji C (JmjC) domain-only member of this family, and its physiological functions remain largely unknown. In this study, we investigated the mechanism by which aberrant JMJD8 stimulates phosphorylation of AKT and activate AKT/GSK3 beta/beta-catenin signaling pathway thereby promotes tumor cell epithelial-mesenchymal transition (EMT). We demonstrated that knockdown of JMJD8 increased the interaction of SETDB1 and phosphoinositide-dependent kinase 1 (PDK1) with AKT1 and resulted in enhanced trimethylation of AKT1 at lysine 142 (K142), which is crucial for cell membrane recruitment, phosphorylation, and activation of AKT. Moreover, the mutation of histidine 200 of JMJD8 (JMJD8-H200Q) disrupted its binding with AKT1 and increased interaction of SETDB1 and PDK1 with AKT1. Furthermore, histone demethylase jumonji domain-containing protein 2B functioned as an adapter to recruit beta-catenin to the methylated AKT1 upon JMJD8 depression, which facilitated the phosphorylation of beta-catenin at Ser552 and its accumulation in cell nucleus where the activated beta-catenin transcriptionally stimulated the expression of genes involved in EMT. In conclusion, our data unraveled a novel role of JMJD8 in regulating the migration and invasion of tumor via modulating AKT methylation and activation. In addition, this study showed that JMJD8 is a potential biomarker and drug design target for tumor EMT.	[Su, Yao; Wang, Jun] Chinese Acad Sci, HFIPS, Key Lab High Magnet Field & Ion Beam Phys Biol, Hefei 230031, Peoples R China; [Wang, Xueying; Guo, Zhen] Univ Sci & Technol China, Sch Life Sci, Anhui Key Lab Cellular Dynam & Chem Biol, Hefei 230027, Peoples R China	Chinese Academy of Sciences; Hefei Institutes of Physical Science, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Wang, J (corresponding author), Chinese Acad Sci, HFIPS, Key Lab High Magnet Field & Ion Beam Phys Biol, Hefei 230031, Peoples R China.; Guo, Z (corresponding author), Univ Sci & Technol China, Sch Life Sci, Anhui Key Lab Cellular Dynam & Chem Biol, Hefei 230027, Peoples R China.	zhenguo@ustc.edu.cn; wangjun0457@ipp.ac.cn			National Natural Science Foundation [11575232, 31471268]; National Key Research and Development Program of China (Stem Cell and Translational Research) [2016YFA0101202]; International Partnership Program of Chinese Academy of Sciences [116134KYSB20160084]; Innovative Program of Development Foundation of Hefei Center for Physical Science and Technology [2016FXCX005]	National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program of China (Stem Cell and Translational Research); International Partnership Program of Chinese Academy of Sciences; Innovative Program of Development Foundation of Hefei Center for Physical Science and Technology	This study was supported by the National Natural Science Foundation (11575232, 31471268), the National Key Research and Development Program of China (Stem Cell and Translational Research) 2016YFA0101202, the International Partnership Program of Chinese Academy of Sciences (116134KYSB20160084), and the Innovative Program of Development Foundation of Hefei Center for Physical Science and Technology (2016FXCX005).	Alam H, 2015, CELL MOL LIFE SCI, V72, P4577, DOI 10.1007/s00018-015-2023-y; Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Boeckel JN, 2016, ARTERIOSCL THROM VAS, V36, P1425, DOI 10.1161/ATVBAHA.116.307695; Chu N, 2018, CELL, V174, P897, DOI 10.1016/j.cell.2018.07.003; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; De Santis MC, 2019, BBA-REV CANCER, V1871, P361, DOI 10.1016/j.bbcan.2019.03.003; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200; Gao CX, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-13; Ghahhari NM, 2015, EUR J CANCER, V51, P1638, DOI 10.1016/j.ejca.2015.04.021; Guo JP, 2019, CELL CYCLE, V18, P917, DOI 10.1080/15384101.2019.1609832; Guo JP, 2019, NAT CELL BIOL, V21, P226, DOI 10.1038/s41556-018-0261-6; Hamamoto R, 2015, NAT REV CANCER, V15, P110, DOI 10.1038/nrc3884; Henderson V, 2015, CELL ADHES MIGR, V9, P255, DOI 10.1080/19336918.2015.1013383; Hermida Miguel A., 2017, Advances in Biological Regulation, V65, P5, DOI 10.1016/j.jbior.2017.06.003; Hino S, 2005, MOL CELL BIOL, V25, P9063, DOI 10.1128/MCB.25.20.9063-9072.2005; Jamieson C, 2012, INT J BIOCHEM CELL B, V44, P847, DOI 10.1016/j.biocel.2012.03.001; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kelly AD, 2017, CURR OPIN GENET DEV, V42, P68, DOI 10.1016/j.gde.2017.03.015; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Li Q, 2015, INT J CLIN EXP PATHO, V8, P6334; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Mayer IA, 2016, ANNU REV MED, V67, P11, DOI 10.1146/annurev-med-062913-051343; Oh S, 2019, BBA-REV CANCER, V1871, P406, DOI 10.1016/j.bbcan.2019.04.002; Revathidevi S, 2019, SEMIN CANCER BIOL, V59, P80, DOI 10.1016/j.semcancer.2019.06.002; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sechler M, 2017, ONCOGENE, V36, P4150, DOI 10.1038/onc.2017.44; Serrano-Gomez SJ, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0502-x; Shin S, 2007, BIOCHEM BIOPH RES CO, V353, P973, DOI 10.1016/j.bbrc.2006.12.147; Skrypek N, 2017, TRENDS GENET, V33, P943, DOI 10.1016/j.tig.2017.08.004; Song Y, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317712617; Su Y, 2019, BBA-MOL CELL RES, V1866, DOI 10.1016/j.bbamcr.2019.118541; Sun LD, 2016, CELL MOL LIFE SCI, V73, P4493, DOI 10.1007/s00018-016-2303-1; Suva ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184; Tang B, 2016, CANCER RES, V76, P6520, DOI 10.1158/0008-5472.CAN-15-3029; Tang B, 2015, ONCOTARGET, V6, P12723, DOI 10.18632/oncotarget.3713; Tzivion G, 2011, BBA-MOL CELL RES, V1813, P1938, DOI 10.1016/j.bbamcr.2011.06.002; Wang GH, 2019, NAT CELL BIOL, V21, P214, DOI 10.1038/s41556-018-0266-1; Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028; Yang F, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09289-5; Yang Q, 2019, SEMIN CANCER BIOL, V59, P112, DOI 10.1016/j.semcancer.2019.04.001; Yeo KS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15676-z; Yeo KS, 2016, SCI REP-UK, V6, DOI 10.1038/srep34125; Zhang HH, 2006, MOL CELL, V24, P185, DOI 10.1016/j.molcel.2006.09.019; Zhang J, 2019, MOL MED REP, V19, P3963, DOI 10.3892/mmr.2019.10111; Zhao L, 2013, CLIN CANCER RES, V19, P6419, DOI 10.1158/1078-0432.CCR-13-0254	47	2	3	3	33	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2020	39	41					6451	6467		10.1038/s41388-020-01446-1	http://dx.doi.org/10.1038/s41388-020-01446-1		SEP 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OA1JL	32879443				2022-12-28	WOS:000565482600004
J	Wang, SX; Somisetty, VS; Bai, BY; Chernukhin, I; Niskanen, H; Kaikkonen, MU; Bellet, M; Carroll, JS; Hurtado, A				Wang, Shixiong; Somisetty, Venkata S.; Bai, Baoyan; Chernukhin, Igor; Niskanen, Henri; Kaikkonen, Minna U.; Bellet, Meritxell; Carroll, Jason S.; Hurtado, Antoni			The proapoptotic gene interferon regulatory factor-1 mediates the antiproliferative outcome of paired box 2 gene and tamoxifen	ONCOGENE			English	Article							BREAST-CANCER; EXPRESSION; PAX2; ACETYLATION	Tamoxifen is the most prescribed selective estrogen receptor (ER) modulator in patients with ER-positive breast cancers. Tamoxifen requires the transcription factor paired box 2 protein (PAX2) to repress the transcription of ERBB2/HER2. Now, we identified that PAX2 inhibits cell growth of ER+/HER2- tumor cells in a dose-dependent manner. Moreover, we have identified that cell growth inhibition can be achieved by expressing moderate levels of PAX2 in combination with tamoxifen treatment. Global run-on sequencing of cells overexpressing PAX2, when coupled with PAX2 ChIP-seq, identified common targets regulated by both PAX2 and tamoxifen. The data revealed that PAX2 can inhibit estrogen-induced gene transcription and this effect is enhanced by tamoxifen, suggesting that they converge on repression of the same targets. Moreover, PAX2 and tamoxifen have an additive effect and both induce coding genes and enhancer RNAs (eRNAs). PAX2-tamoxifen upregulated genes are also enriched with PAX2 eRNAs. The enrichment of eRNAs is associated with the highest expression of genes that positivity regulate apoptotic processes. In luminal tumors, the expression of a subset of these proapoptotic genes predicts good outcome and their expression are significantly reduced in tumors of patients with relapse to tamoxifen treatment. Mechanistically, PAX2 and tamoxifen coexert an antitumoral effect by maintaining high levels of transcription of tumor suppressors that promote cell death. The apoptotic effect is mediated in large part by the gene interferon regulatory factor 1. Altogether, we conclude that PAX2 contributes to better clinical outcome in tamoxifen treated ER-positive breast cancer patients by repressing estrogen signaling and inducing cell death related pathways.	[Wang, Shixiong; Somisetty, Venkata S.; Bai, Baoyan] Univ Oslo, Ctr Mol Med Norway NCMM, Cell Cycle Regulat Grp, Nord EMBL Partnership, PO 1137, N-0318 Oslo, Norway; [Chernukhin, Igor; Carroll, Jason S.] Univ Cambridge, Canc Res UK Cambridge Inst, Robinson Way, Cambridge CB2 0RE, England; [Niskanen, Henri; Kaikkonen, Minna U.] Univ Eastern Finland, AI Virtanen Inst Mol Sci, POB 1627, Kuopio 70211, Finland; [Bellet, Meritxell] Vall Hebron Inst Oncol, Barcelona, Spain; [Bellet, Meritxell] Vall Hebron Univ Hosp, Barcelona, Spain; [Hurtado, Antoni] Univ Barcelona, Dept Biomed Sci, Canc Genom & Prote Grp, Casanova,143, Barcelona 08014, Spain; [Hurtado, Antoni] August Pi & Sunyer Res Ctr IDIBAPS, C Rossello 149-153, Barcelona 08036, Spain	University of Oslo; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; University of Eastern Finland; Vall d'Hebron Institut d'Oncologia (VHIO); Hospital Universitari Vall d'Hebron; University of Barcelona	Hurtado, A (corresponding author), Univ Barcelona, Dept Biomed Sci, Canc Genom & Prote Grp, Casanova,143, Barcelona 08014, Spain.; Hurtado, A (corresponding author), August Pi & Sunyer Res Ctr IDIBAPS, C Rossello 149-153, Barcelona 08036, Spain.	toni.hurtado@ub.edu		Carroll, Jason/0000-0003-3643-0080; Kaikkonen, Minna/0000-0001-6294-0979; Hurtado, Antoni/0000-0002-0145-4763				Beauchemin D, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-148; Cai Y, 2003, EMBO J, V22, P5522, DOI 10.1093/emboj/cdg536; Dai CH, 1999, BLOOD, V93, P3309, DOI 10.1182/blood.V93.10.3309.410k04_3309_3316; Daniel JA, 2010, SCIENCE, V329, P917, DOI 10.1126/science.1187942; Dornan D, 2004, MOL CELL BIOL, V24, P10083, DOI 10.1128/MCB.24.22.10083-10098.2004; Eberhard D, 2000, EMBO J, V19, P2292, DOI 10.1093/emboj/19.10.2292; Hurtado A, 2008, NATURE, V456, P663, DOI 10.1038/nature07483; Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Jahangiri R, 2018, TISSUE CELL, V52, P135, DOI 10.1016/j.tice.2018.05.005; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Martinez-Outschoorn UE, 2012, CELL CYCLE, V11, P3964, DOI 10.4161/cc.22137; Patel SR, 2007, DEV CELL, V13, P580, DOI 10.1016/j.devcel.2007.09.004; Pistelli M, 2018, CURR ONCOL, V25, pE168, DOI 10.3747/co.25.3735; Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Ramirez F, 2014, NUCLEIC ACIDS RES, V42, pW187, DOI 10.1093/nar/gku365; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Sane S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020442; Schmidt D, 2009, METHODS, V48, P240, DOI 10.1016/j.ymeth.2009.03.001; Schwartz JL, 2011, INT J BREAST CANCER, V2011, DOI 10.4061/2011/912102; Sharma R, 2015, SEMIN CELL DEV BIOL, V44, P97, DOI 10.1016/j.semcdb.2015.09.016; Silberstein GB, 2002, ONCOGENE, V21, P1009, DOI 10.1038/sj.onc.1205172; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Wang D, 2011, NATURE, V474, P390, DOI 10.1038/nature10006; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6	29	2	2	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2020	39	40					6300	6312		10.1038/s41388-020-01435-4	http://dx.doi.org/10.1038/s41388-020-01435-4		AUG 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NV5JK	32843722	Green Published, hybrid			2022-12-28	WOS:000562669100001
J	Buschhaus, JM; Humphries, BA; Eckley, SS; Robison, TH; Cutter, AC; Rajendran, S; Haley, HR; Bevoor, AS; Luker, KE; Luker, GD				Buschhaus, Johanna M.; Humphries, Brock A.; Eckley, Samantha S.; Robison, Tanner H.; Cutter, Alyssa C.; Rajendran, Shrila; Haley, Henry R.; Bevoor, Avinash S.; Luker, Kathryn E.; Luker, Gary D.			Targeting disseminated estrogen-receptor-positive breast cancer cells in bone marrow	ONCOGENE			English	Article							SIGNALING PATHWAY; AKT INHIBITOR; IN-VITRO; THIOREDOXIN; METASTASIS; CYCLE; OPPORTUNITIES; SENSITIVITY; SURVIVAL; FACILE	Estrogen receptor-positive (ER+) breast cancer can recur up to 20 years after initial diagnosis. Delayed recurrences arise from disseminated tumors cells (DTCs) in sites such as bone marrow that remain quiescent during endocrine therapy and subsequently proliferate to produce clinically detectable metastases. Identifying therapies that eliminate DTCs and/or effectively target cells transitioning to proliferation promises to reduce risk of recurrence. To tackle this problem, we utilized a 3D co-culture model incorporating ER+ breast cancer cells and bone marrow mesenchymal stem cells to represent DTCs in a bone marrow niche. 3D co-cultures maintained cancer cells in a quiescent, viable state as measured by both single-cell and population-scale imaging. Single-cell imaging methods for metabolism by fluorescence lifetime (FLIM) of NADH and signaling by kinases Akt and ERK revealed that breast cancer cells utilized oxidative phosphorylation and signaling by Akt to a greater extent both in 3D co-cultures and a mouse model of ER+ breast cancer cells in bone marrow. Using our 3D co-culture model, we discovered that combination therapies targeting oxidative phosphorylation via the thioredoxin reductase (TrxR) inhibitor, D9, and the Akt inhibitor, MK-2206, preferentially eliminated breast cancer cells without altering viability of bone marrow stromal cells. Treatment of mice with disseminated ER+ human breast cancer showed that D9 plus MK-2206 blocked formation of new metastases more effectively than tamoxifen. These data establish an integrated experimental system to investigate DTCs in bone marrow and identify combination therapy against metabolic and kinase targets as a promising approach to effectively target these cells and reduce risk of recurrence in breast cancer.	[Buschhaus, Johanna M.; Robison, Tanner H.; Luker, Gary D.] Univ Michigan, Dept Biomed Engn, 2200 Bonisteel Blvd, Ann Arbor, MI 48109 USA; [Buschhaus, Johanna M.; Humphries, Brock A.; Robison, Tanner H.; Cutter, Alyssa C.; Rajendran, Shrila; Haley, Henry R.; Bevoor, Avinash S.; Luker, Kathryn E.; Luker, Gary D.] Univ Michigan, Dept Radiol, Ctr Mol Imaging, 109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA; [Eckley, Samantha S.] Univ Michigan, Unit Lab Anim Med, 412 Victor Vaughan, Ann Arbor, MI 48109 USA; [Luker, Gary D.] Univ Michigan, Dept Microbiol & Immunol, 109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA; [Eckley, Samantha S.] Univ Iowa, Off Anim Resources, Iowa City, IA USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Iowa	Luker, GD (corresponding author), Univ Michigan, Dept Biomed Engn, 2200 Bonisteel Blvd, Ann Arbor, MI 48109 USA.; Luker, GD (corresponding author), Univ Michigan, Dept Radiol, Ctr Mol Imaging, 109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.; Luker, GD (corresponding author), Univ Michigan, Dept Microbiol & Immunol, 109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	gluker@med.umich.edu		luker, gary/0000-0001-6832-2581; Humphries, Brock/0000-0002-6992-3394; Robison, Tanner/0000-0001-6407-6475; Buschhaus, Johanna/0000-0002-4181-0953	United States National Institutes of Health [R01CA238042, R01CA196018, U01CA210152, R01CA238023, R33CA225549, R50CA221807, R37CA222563]; American Cancer Society - Michigan Cancer Research Fund Postdoctoral Fellowship [PF-18-236-01-CCG]; University of Michigan Rogel Cancer Center through National Institutes of Health [P30CA046592]; National Science Foundation Graduate Research Fellowship [DGE 1256260]	United States National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society - Michigan Cancer Research Fund Postdoctoral Fellowship; University of Michigan Rogel Cancer Center through National Institutes of Health; National Science Foundation Graduate Research Fellowship(National Science Foundation (NSF))	We thank Aye J. Muniz and Max Wicha for paper feedback. We thank Michael Pihalja for assistance with flow cytometry. We acknowledge funding from United States National Institutes of Health grants R01CA238042, R01CA196018, U01CA210152, R01CA238023, R33CA225549, R50CA221807, and R37CA222563. Brock Humphries, Ph.D., was supported by an American Cancer Society - Michigan Cancer Research Fund Postdoctoral Fellowship, PF-18-236-01-CCG. We acknowledge support to the University of Michigan Rogel Cancer Center through National Institutes of Health grant P30CA046592 for flow cytometry and animal imaging studies. This material is based upon work supported by the National Science Foundation Graduate Research Fellowship under Grant No. DGE 1256260 to Johanna Buschhaus.	Abu-Eid R, 2014, CANCER IMMUNOL RES, V2, P1080, DOI 10.1158/2326-6066.CIR-14-0095; Aka JA, 2012, PLOS ONE, P7; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Bartkowiak K, 2012, CANCER MICROENVIRON, V5, P59, DOI 10.1007/s12307-011-0067-6; Buschhaus JM, 2018, METHODS MOL BIOL, V1686, P201, DOI 10.1007/978-1-4939-7371-2_15; Cavnar SP, 2016, TOMOGRAPHY, V2, P146, DOI 10.18383/j.tom.2016.00157; Cavnar SP, 2015, NEOPLASIA, V17, P625, DOI 10.1016/j.neo.2015.08.001; Cavnar SP, 2014, JALA-J LAB AUTOM, V19, P208, DOI 10.1177/2211068213504296; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Ding W, 2014, BRIT J HAEMATOL, V164, P146, DOI 10.1111/bjh.12564; Eckley SS, 2019, TOMOGRAPHY, V5, P346, DOI 10.18383/j.tom.2019.00019; Grabinski N, 2011, CELL SIGNAL, V23, P1952, DOI 10.1016/j.cellsig.2011.07.003; Gross S, 2015, J CLIN INVEST, V125, P1780, DOI 10.1172/JCI76094; Haley HR, 2018, TOMOGRAPHY, V4, P84, DOI 10.18383/j.tom.2018.00010; Heinz S, 2017, SCI REP-UK, V7, DOI 10.1038/srep45465; Hirai H, 2010, MOL CANCER THER, V9, P1956, DOI 10.1158/1535-7163.MCT-09-1012; Holen I, 2016, CLIN EXP METASTAS, V33, P211, DOI 10.1007/s10585-015-9770-x; Humphries BA, 2019, MOL CANCER RES, V17, P1142, DOI 10.1158/1541-7786.MCR-18-0836; Iwata M, 2014, STEM CELLS DEV, V23, P729, DOI 10.1089/scd.2013.0300; Kaboli PJ, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.10480; Kennecke H, 2010, J CLIN ONCOL, V28, P3271, DOI 10.1200/JCO.2009.25.9820; Kohno M, 2006, ANN MED, V38, P200, DOI 10.1080/07853890600551037; LeBleu VS, 2014, NAT CELL BIOL, V16, P992, DOI 10.1038/ncb3039; Lu X, 2011, CANCER CELL, V20, P701, DOI 10.1016/j.ccr.2011.11.002; Luengo A, 2017, CELL CHEM BIOL, V24, P1161, DOI 10.1016/j.chembiol.2017.08.028; Luo M, 2018, CELL METAB, V28, P69, DOI 10.1016/j.cmet.2018.06.006; Ma G, 2015, INT J BIOL SCI, V11, P618, DOI 10.7150/ijbs.11380; Martini M, 2014, ANN MED, V46, P372, DOI 10.3109/07853890.2014.912836; Maryu G, 2016, CELL STRUCT FUNCT, V41, P81, DOI 10.1247/csf.16007; Mehta G, 2012, J CONTROL RELEASE, V164, P192, DOI 10.1016/j.jconrel.2012.04.045; Melzer C, 2016, CELL COMMUN SIGNAL, V14, DOI 10.1186/s12964-016-0143-0; Mustacich D, 2000, BIOCHEM J, V346, P1, DOI 10.1042/0264-6021:3460001; Ogba N, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0489-4; Ottewell PD, 2014, CLIN CANCER RES, V20, P2922, DOI 10.1158/1078-0432.CCR-13-1246; Ozdemir B, 2018, ENDOCR RELAT CANC, V25; Pan HC, 2017, NEW ENGL J MED, V377, P1836, DOI 10.1056/NEJMoa1701830; Pantel Klaus, 2014, Bonekey Rep, V3, P584, DOI 10.1038/bonekey.2014.79; Patel CH, 2019, NAT REV DRUG DISCOV, V18, P669, DOI 10.1038/s41573-019-0032-5; Phansalkar Neerad, 2011, 2011 International Conference on Communications and Signal Processing (ICCSP), P218, DOI 10.1109/ICCSP.2011.5739305; Plava J, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0960-z; Pozarowski Piotr, 2004, Methods Mol Biol, V281, P301; Pradhan S, 2018, J BIOL ENG, V12, DOI 10.1186/s13036-018-0120-9; Regot S, 2014, CELL, V157, P1724, DOI 10.1016/j.cell.2014.04.039; Sakaue-Sawano A, 2008, CELL, V132, P487, DOI 10.1016/j.cell.2007.12.033; Scalcon V, 2018, FREE RADICAL BIO MED, V127, P62, DOI 10.1016/j.freeradbiomed.2018.03.043; Shi Junlin, 2018, Oncotarget, V9, P9206, DOI 10.18632/oncotarget.24104; Sosa MS, 2011, CLIN CANCER RES, V17, P5850, DOI 10.1158/1078-0432.CCR-10-2574; Spinosa PC, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aaw4204; Stringari C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048014; Thakur S, 2018, CLIN CANCER RES, V24, P4030, DOI 10.1158/1078-0432.CCR-17-3167; TRIPATHY D, 2015, J CLIN ONCOL S, V33; Vallabhaneni KC, 2015, ONCOTARGET, V6, P4953, DOI 10.18632/oncotarget.3211; Walsh AJ, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.11.116015; Wang H, 2015, CANCER CELL, V27, P193, DOI 10.1016/j.ccell.2014.11.017; Weinberg SE, 2015, NAT CHEM BIOL, V11, P9, DOI 10.1038/nchembio.1712; Widner DB, 2018, CURR OSTEOPOROS REP, V16, P596, DOI 10.1007/s11914-018-0471-7; Xue G., 2015, JNCI-J NATL CANCER I, V107, P171; Yarosz EL, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e14; Yin ZP, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1409-3; Zhang D, 2014, J MED CHEM, V57, P8132, DOI 10.1021/jm5012098; Zhang XHF, 2013, CLIN CANCER RES, DOI [10.1158/078-0432.CCR-13-838, DOI 10.1158/078-0432.CCR-13-838]; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017; Zhang Y, 2013, CLIN CANCER RES, V19, P4196, DOI 10.1158/1078-0432.CCR-13-0804; Zhong W, 2017, ONCOTARGET, V8, P73693, DOI 10.18632/oncotarget.17793	64	15	16	3	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2020	39	34					5649	5662		10.1038/s41388-020-01391-z	http://dx.doi.org/10.1038/s41388-020-01391-z		JUL 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NE9FK	32678295	Green Accepted			2022-12-28	WOS:000557627400001
J	Lloyd, RL; Wijnhoven, PWG; Ramos-Montoya, A; Wilson, Z; Illuzzi, G; Falenta, K; Jones, GN; James, N; Chabbert, CD; Stott, J; Dean, E; Lau, A; Young, LA				Lloyd, Rebecca L.; Wijnhoven, Paul W. G.; Ramos-Montoya, Antonio; Wilson, Zena; Illuzzi, Giuditta; Falenta, Katarzyna; Jones, Gemma N.; James, Neil; Chabbert, Christophe D.; Stott, Jonathan; Dean, Emma; Lau, Alan; Young, Lucy A.			Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells	ONCOGENE			English	Article							DNA-DAMAGE RESPONSE; HOMOLOGOUS RECOMBINATION; SYNTHETIC LETHALITY; GASTRIC-CANCER; OLAPARIB; SENSITIVITY; MUTATIONS; THERAPY; PHOSPHORYLATION; REGULATOR	The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib is FDA approved for the treatment of BRCA-mutated breast, ovarian and pancreatic cancers. Olaparib inhibits PARP1/2 enzymatic activity and traps PARP1 on DNA at single-strand breaks, leading to replication-induced DNA damage that requires BRCA1/2-dependent homologous recombination repair. Moreover, DNA damage response pathways mediated by the ataxia-telangiectasia mutated (ATM) and ataxia-telangiectasia mutated and Rad3-related (ATR) kinases are hypothesised to be important survival pathways in response to PARP-inhibitor treatment. Here, we show that olaparib combines synergistically with the ATR-inhibitor AZD6738 (ceralasertib), in vitro, leading to selective cell death in ATM-deficient cells. We observe that 24 h olaparib treatment causes cells to accumulate in G2-M of the cell cycle, however, co-administration with AZD6738 releases the olaparib-treated cells from G2 arrest. Selectively in ATM-knockout cells, we show that combined olaparib/AZD6738 treatment induces more chromosomal aberrations and achieves this at lower concentrations and earlier treatment time-points than either monotherapy. Furthermore, single-agent olaparib efficacy in vitro requires PARP inhibition throughout multiple rounds of replication. Here, we demonstrate in several ATM-deficient cell lines that the olaparib and AZD6738 combination induces cell death within 1-2 cell divisions, suggesting that combined treatment could circumvent the need for prolonged drug exposure. Finally, we demonstrate in vivo combination activity of olaparib and AZD6738 in xenograft and PDX mouse models with complete ATM loss. Collectively, these data provide a mechanistic understanding of combined PARP and ATR inhibition in ATM-deficient models, and support the clinical development of AZD6738 in combination with olaparib.	[Lloyd, Rebecca L.; Wijnhoven, Paul W. G.; Ramos-Montoya, Antonio; Illuzzi, Giuditta; Falenta, Katarzyna; Chabbert, Christophe D.; Lau, Alan; Young, Lucy A.] AstraZeneca, Oncol R&D, Biosci, Cambridge, England; [Lloyd, Rebecca L.] Univ Cambridge, Wellcome Trust, Cambridge, England; [Lloyd, Rebecca L.] Univ Cambridge, CRUK Gurdon Inst, Cambridge, England; [Lloyd, Rebecca L.] Univ Cambridge, Dept Biochem, Cambridge, England; [Wilson, Zena; James, Neil] AstraZeneca, Oncol R&D, Biosci, Alderley Pk, England; [Jones, Gemma N.] AstraZeneca, Oncol R&D, Translat Med, Cambridge, England; [Stott, Jonathan] AstraZeneca, Oncol R&D, Discovery Sci, Quantitat Biol, Cambridge, England; [Dean, Emma] AstraZeneca, Oncol R&D, Res & Early Dev, Cambridge, England	AstraZeneca; University of Cambridge; Wellcome Trust Sanger Institute; University of Cambridge; University of Cambridge; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca	Young, LA (corresponding author), AstraZeneca, Oncol R&D, Biosci, Cambridge, England.	Lucy.Young@astrazeneca.com	Kumar, Sushil/AAF-1312-2019	Kumar, Sushil/0000-0003-0547-745X; Lau, Alan/0000-0003-1055-9812; Young/Press, Lucy/0000-0001-9368-6213	AstraZeneca	AstraZeneca(AstraZeneca)	This study was funded by AstraZeneca. We are grateful to Sarah Ross for critical reading of the manuscript. We thank Anna Ramne and John W. Wiseman for providing the FaDu ATM-KO cell line and Jenni Nikkila for the A549 ATM-KO cell line. We thank the AstraZeneca Laboratory Animal Sciences and Oncology in vivo teams for their expert technical assistance. We thank Champions Oncology for their assistance with PDX studies.	[Anonymous], 2019, ANN ONCOL S5; Audeh MW, 2010, LANCET, V376, P245, DOI 10.1016/S0140-6736(10)60893-8; Balmus G, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07729-2; Bang YJ, 2017, LANCET ONCOL, V18, P1637, DOI 10.1016/S1470-2045(17)30682-4; Berges A, 2018, AM ASS CANC RES, V78; Blackford AN, 2017, MOL CELL, V66, P801, DOI 10.1016/j.molcel.2017.05.015; Boussios S, 2020, DRUGS R&D, V20, P55, DOI 10.1007/s40268-020-00301-8; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Buisson R, 2017, MOL CELL, V65, P336, DOI 10.1016/j.molcel.2016.12.007; Burgess BT, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10020121; Capoluongo E, 2017, SEMIN ONCOL, V44, P187, DOI 10.1053/j.seminoncol.2017.08.004; Choi M, 2016, MOL CANCER THER, V15, P1781, DOI 10.1158/1535-7163.MCT-15-0945; Cimprich KA, 2008, NAT REV MOL CELL BIO, V9, P616, DOI 10.1038/nrm2450; Crafter C, 2015, INT J ONCOL, V47, P446, DOI 10.3892/ijo.2015.3062; DEBONO JS, 2019, J CLIN ONCOL, V37; Dillon M, 2019, ANN ONCOL, V30, P165; Durant ST, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aat1719; Fang Y, 2019, CANCER CELL, V35, P851, DOI 10.1016/j.ccell.2019.05.001; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fok JHL, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12836-9; Foote KM, 2018, J MED CHEM, V61, P9889, DOI 10.1021/acs.jmedchem.8b01187; Forment JV, 2018, PHARMACOL THERAPEUT, V188, P155, DOI 10.1016/j.pharmthera.2018.03.005; Golan T, 2019, NEW ENGL J MED, V381, P317, DOI 10.1056/NEJMoa1903387; Illuzzi G, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.AM2019-2077; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Jette NR, 2019, BRIT J CANCER, V121, P600, DOI 10.1038/s41416-019-0565-8; Jones GN, 2018, BRIT J CANCER, V119, P1233, DOI 10.1038/s41416-018-0286-4; Kim H, 2017, CLIN CANCER RES, V23, P3097, DOI 10.1158/1078-0432.CCR-16-2273; Krebs MG, 2018, CANCER RES, V78, DOI 10.1158/1538-7445.AM2018-CT026; Kwok M, 2016, BLOOD, V127, P582, DOI 10.1182/blood-2015-05-644872; Laufer C, 2013, NAT METHODS, V10, P427, DOI [10.1038/NMETH.2436, 10.1038/nmeth.2436]; Loewe S, 1926, N-S ARCH EX PATH PH, V114, P313; Lord CJ, 2017, SCIENCE, V355, P1152, DOI 10.1126/science.aam7344; Lord CJ, 2015, ANNU REV MED, V66, P455, DOI 10.1146/annurev-med-050913-022545; Mateo J, 2015, NEW ENGL J MED, V373, P1697, DOI 10.1056/NEJMoa1506859; Mateo J, 2020, LANCET ONCOL, V21, P162, DOI 10.1016/S1470-2045(19)30684-9; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Middleton FK, 2018, CANCERS, V10, DOI 10.3390/cancers10080275; Min A, 2017, MOL CANCER THER, V16, P566, DOI 10.1158/1535-7163.MCT-16-0378; Mu JJ, 2007, J BIOL CHEM, V282, P17330, DOI 10.1074/jbc.C700079200; Murai J, 2019, ANNU REV CANC BIOL, V3, P131, DOI 10.1146/annurev-cancerbio-030518-055914; Murai J, 2012, CANCER RES, V72, P5588, DOI 10.1158/0008-5472.CAN-12-2753; Nadeu F, 2016, BLOOD, V127, P2122, DOI 10.1182/blood-2015-07-659144; O'Connor MJ, 2015, MOL CELL, V60, P547, DOI 10.1016/j.molcel.2015.10.040; Ozeri-Galai E, 2008, ONCOGENE, V27, P2109, DOI 10.1038/sj.onc.1210849; Reaper PM, 2011, NAT CHEM BIOL, V7, P428, DOI [10.1038/NCHEMBIO.573, 10.1038/nchembio.573]; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Ruiz S, 2016, MOL CELL, V62, P307, DOI 10.1016/j.molcel.2016.03.006; Schmitt A, 2017, CANCER RES, V77, P3040, DOI 10.1158/0008-5472.CAN-16-3398; Stankovic T, 2014, LEUKEMIA LYMPHOMA, V55, P1227, DOI 10.3109/10428194.2013.829919; Stiff T, 2006, EMBO J, V25, P5775, DOI 10.1038/sj.emboj.7601446; Stokes MP, 2007, P NATL ACAD SCI USA, V104, P19855, DOI 10.1073/pnas.0707579104; Trenz K, 2006, EMBO J, V25, P1764, DOI 10.1038/sj.emboj.7601045; Villaruz LC, 2016, ONCOTARGET, V7, P57714, DOI 10.18632/oncotarget.9757; Wang C, 2017, TRANSL ONCOL, V10, P190, DOI 10.1016/j.tranon.2017.01.007; Weber AM, 2016, ONCOTARGET, V7, P60807, DOI 10.18632/oncotarget.11845; Wengner AM, 2020, MOL CANCER THER, V19, P26, DOI 10.1158/1535-7163.MCT-19-0019; Weston VJ, 2010, BLOOD, V116, P4578, DOI 10.1182/blood-2010-01-265769; Yazinski SA, 2017, GENE DEV, V31, P318, DOI 10.1101/gad.290957.116; Young LA, 2019, CANCER RES, V79, P3762, DOI 10.1158/0008-5472.CAN-18-2480; Zhou DS, 2019, CLIN PHARMACOKINET, V58, P615, DOI 10.1007/s40262-018-0714-x	61	63	63	6	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 18	2020	39	25					4869	4883		10.1038/s41388-020-1328-y	http://dx.doi.org/10.1038/s41388-020-1328-y		MAY 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LZ3HT	32444694	Green Published, hybrid			2022-12-28	WOS:000534868800001
J	Samsa, WE; Mamidi, MK; Bashur, LA; Elliott, R; Miron, A; Chen, YQ; Lees, B; Greenfield, EM; Chan, R; Danielpour, D; Zhou, G				Samsa, William E.; Mamidi, Murali K.; Bashur, Lindsay A.; Elliott, Robin; Miron, Alexander; Chen, Yuqing; Lees, Brendan; Greenfield, Edward M.; Chan, Ricky; Danielpour, David; Zhou, Guang			The crucial p53-dependent oncogenic role of JAB1 in osteosarcoma in vivo	ONCOGENE			English	Article							NEDD8-ACTIVATING ENZYME; COP9 SIGNALOSOME; CELL-LINES; P53; RB; INACTIVATION; ACTIVATION; INHIBITOR; CARCINOMA; TOOLS	Osteosarcoma (OS) is the most common primary bone cancer and ranks amongst the leading causes of cancer mortality in young adults. Jun activation domain-binding protein 1 (JAB1) is overexpressed in many cancers and has recently emerged as a novel target for cancer treatment. However, the role of JAB1 in osteosarcoma was virtually unknown. In this study, we demonstrate that JAB1-knockdown in malignant osteosarcoma cell lines significantly reduced their oncogenic properties, including proliferation, colony formation, and motility. We also performed RNA-sequencing analysis in JAB1-knockdown OS cells and identified 4110 genes that are significantly differentially expressed. This demonstrated for the first time that JAB1 regulates a large and specific transcriptome in cancer. We also found that JAB1 is overexpressed in human OS and correlates with a poor prognosis. Moreover, we generated a novel mouse model that overexpresses Jab1 specifically in osteoblasts upon a TP53 heterozygous sensitizing background. Interestingly, by 13 months of age, a significant proportion of these mice spontaneously developed conventional OS. Finally, we demonstrate that a novel, highly specific small molecule inhibitor of JAB1, CSN5i-3, reduces osteosarcoma cell viability, and has specific effects on the ubiquitin-proteasome system in OS. Thus, we show for the first time that the overexpression of JAB1 in vivo can result in accelerated spontaneous tumor formation in a p53-dependent manner. In summary, JAB1 might be a unique target for the treatment of osteosarcoma and other cancers.	[Samsa, William E.; Mamidi, Murali K.; Bashur, Lindsay A.; Zhou, Guang] Case Western Reserve Univ, Dept Orthopaed, Cleveland, OH 44106 USA; [Samsa, William E.; Mamidi, Murali K.; Miron, Alexander; Danielpour, David; Zhou, Guang] Case Comprehens Canc Ctr, Cleveland, OH 44106 USA; [Elliott, Robin] Dept Pathol, Cleveland, OH USA; [Miron, Alexander; Zhou, Guang] Dept Genet & Genome Sci, Cleveland, OH 44106 USA; [Chen, Yuqing; Lees, Brendan] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Greenfield, Edward M.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA; [Chan, Ricky] Case Comprehens Canc Ctr, Inst Computat Biol, Cleveland, OH USA; [Danielpour, David] Div Gen Med Sci, Cleveland, OH USA	Case Western Reserve University; Case Western Reserve University; Baylor College of Medicine; Indiana University System; Indiana University Bloomington; Case Western Reserve University	Zhou, G (corresponding author), Case Western Reserve Univ, Dept Orthopaed, Cleveland, OH 44106 USA.; Zhou, G (corresponding author), Case Comprehens Canc Ctr, Cleveland, OH 44106 USA.; Zhou, G (corresponding author), Dept Genet & Genome Sci, Cleveland, OH 44106 USA.	gxz27@case.edu	Mamidi, Murali/ABD-1676-2021		NCI [R03 CA175874]; NIAMS [R01 AR068361, T32 AR7505-30]; Rally Foundation for Childhood Cancer Research and Open Hands Overflowing Hearts Fellowship [CON221575]; ACS [119999-IRG-91-022-18IRG]	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Rally Foundation for Childhood Cancer Research and Open Hands Overflowing Hearts Fellowship; ACS(American Cancer Society)	NCI R03 CA175874 to GZ, ACS #119999-IRG-91-022-18IRG to GZ, NIAMS R01 AR068361 to GZ, NIAMS T32 AR7505-30 to WES and LAB, and the Rally Foundation for Childhood Cancer Research and Open Hands Overflowing Hearts Fellowship CON221575 to WES.	Ballatori SE, 2016, SIGNAL TRANSDUCT TAR, V1, DOI 10.1038/sigtrans.2016.1; Bashur LA, 2014, J CELL PHYSIOL, V229, P1607, DOI 10.1002/jcp.24602; Behjati S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15936; Berman SD, 2008, P NATL ACAD SCI USA, V105, P11851, DOI 10.1073/pnas.0805462105; Chen DX, 2013, J CELL SCI, V126, P234, DOI 10.1242/jcs.113795; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Collier CD, 2018, CLIN ORTHOP RELAT R, V476, P1400, DOI 10.1007/s11999.0000000000000059; Crone SG, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-71; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Enchev RI, 2015, NAT REV MOL CELL BIO, V16, P30, DOI 10.1038/nrm3919; Gavet O, 2010, DEV CELL, V18, P533, DOI 10.1016/j.devcel.2010.02.013; Gianferante DM, 2017, NAT REV ENDOCRINOL, V13, P480, DOI 10.1038/nrendo.2017.16; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Johmura Y, 2018, J CLIN INVEST, V128, P5603, DOI 10.1172/JCI121679; Kato JY, 2009, GENES CELLS, V14, P1209, DOI 10.1111/j.1365-2443.2009.01349.x; Lauvrak SU, 2013, BRIT J CANCER, V109, P2228, DOI 10.1038/bjc.2013.549; Lee YH, 2011, ONCOGENE, V30, P4175, DOI 10.1038/onc.2011.126; Liang BJ, 2012, CALCIFIED TISSUE INT, V90, P76, DOI 10.1007/s00223-011-9550-9; Lin PP, 2009, CARCINOGENESIS, V30, P1789, DOI 10.1093/carcin/bgp180; Liu GH, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00135; Loukil Abdelhalim, 2015, World J Biol Chem, V6, P346, DOI 10.4331/wjbc.v6.i4.346; Lu RQ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12044; Malhab LJB, 2016, SCI REP-UK, V6, DOI 10.1038/srep37775; Manasanch EE, 2017, NAT REV CLIN ONCOL, V14, P417, DOI [10.1038/nrclinonc.2016.206, 10.1007/s12079-011-0121-7]; Mirabello L, 2009, CANCER-AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121; Mori M, 2008, J BIOL CHEM, V283, P29011, DOI 10.1074/jbc.M804539200; Oh W, 2006, J BIOL CHEM, V281, P17457, DOI 10.1074/jbc.M601857200; Ottaviano L, 2010, GENE CHROMOSOME CANC, V49, P40, DOI 10.1002/gcc.20717; Pan Y, 2017, ONCOGENE, V36, P1069, DOI 10.1038/onc.2016.271; Pan Y, 2013, ONCOGENE, V32, P2756, DOI 10.1038/onc.2012.294; Panattoni M, 2008, J EXP MED, V205, P465, DOI 10.1084/jem.20070725; Perry JA, 2014, P NATL ACAD SCI USA, V111, pE5564, DOI 10.1073/pnas.1419260111; Schlierf A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13166; Sitte S, 2012, J IMMUNOL, V188, P2677, DOI 10.4049/jimmunol.1101455; Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884; Sun R, 2018, CANCER RES, V78, P5274, DOI 10.1158/0008-5472.CAN-17-3647; Swords RT, 2017, BLOOD CANCER J, V7, DOI 10.1038/bcj.2017.1; Tao JN, 2014, CANCER CELL, V26, P390, DOI 10.1016/j.ccr.2014.07.023; Tian L, 2010, ONCOGENE, V29, P6125, DOI 10.1038/onc.2010.345; Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808; Wang ZW, 2014, NAT REV CANCER, V14, P233, DOI 10.1038/nrc3700; Wei N, 2008, TRENDS BIOCHEM SCI, V33, P592, DOI 10.1016/j.tibs.2008.09.004; Zhang F, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0791-6; Zhang YD, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32428-9; Zhou G, 2006, P NATL ACAD SCI USA, V103, P19004, DOI 10.1073/pnas.0605170103; Zhou LS, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0979-1	48	16	16	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	23					4581	4591		10.1038/s41388-020-1320-6	http://dx.doi.org/10.1038/s41388-020-1320-6		MAY 2020	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LU5ZF	32390003	Green Submitted, Green Accepted			2022-12-28	WOS:000531697700001
J	Zhou, S; Liu, SL; Lin, CY; Li, Y; Ye, LP; Wu, XQ; Jian, YT; Dai, YH; Ouyang, Y; Zhao, L; Liu, MZ; Song, LB; Xi, M				Zhou, Sha; Liu, Shiliang; Lin, Chuyong; Li, Yue; Ye, Liping; Wu, Xianqiu; Jian, Yunting; Dai, Yuhu; Ouyang, Ying; Zhao, Lei; Liu, Mengzhong; Song, Libing; Xi, Mian			TRIB3 confers radiotherapy resistance in esophageal squamous cell carcinoma by stabilizing TAZ	ONCOGENE			English	Article							CANCER STATISTICS; TRB3 INTERACTS; C/EBP-ALPHA; STEM-CELLS; PROLIFERATION; PROGRESSION; ACTIVATION; EXPRESSION; DROSOPHILA; MIGRATION	Radioresistance becomes the major obstacle to reduce tumor recurrence and improve prognosis in the treatment of esophageal squamous cell carcinoma (ESCC). Thus new strategies for radioresistant ESCC are urgently needed. Herein, we reported that tribbles pseudokinase 3 (TRIB3) serves as a key regulator of radioresistance in ESCC. TRIB3 is overexpressed in ESCC tissues and cell lines. High expression of TRIB3 significantly correlates with poor radiotherapy response and prognosis in ESCC patients. Upregulation of TRIB3 in ESCC cells conferred radioresistance in vitro and in vivo by interacting with TAZ thus impeding beta-TrCP-mediated TAZ ubiquitination and degradation. Conversely, silencing TRIB3 sensitized ESCC cells to ionizing radiation. More importantly, TRIB3 was significantly correlated with TAZ activation in ESCC biopsies, and patients with high expression of both TRIB3 and TAZ suffered the worst radiotherapy response and survival. Our study uncovers the critical mechanism of ESCC resistance to radiotherapy, and provides a new pharmacological opportunity for developing a mechanism-based strategy to eliminate radioresistant ESCC in clinical practice.	[Zhou, Sha; Liu, Shiliang; Zhao, Lei; Liu, Mengzhong; Xi, Mian] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Radiat Oncol, Canc Ctr,State Key Lab Oncol South China, Guangzhou 510060, Peoples R China; [Lin, Chuyong; Li, Yue; Ye, Liping; Wu, Xianqiu; Jian, Yunting; Ouyang, Ying; Song, Libing] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Expt Res, Canc Ctr,State Key Lab Oncol South China, Guangzhou 510060, Peoples R China; [Dai, Yuhu] Sun Yat Sen Univ, Dept Orthpaed Surg, Affiliated Hosp 1, Guangzhou 510080, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University	Xi, M (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Radiat Oncol, Canc Ctr,State Key Lab Oncol South China, Guangzhou 510060, Peoples R China.; Song, LB (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Expt Res, Canc Ctr,State Key Lab Oncol South China, Guangzhou 510060, Peoples R China.	songlb@sysucc.org.cn; ximian@sysucc.org.cn	Lin, Chuyong/AAA-9931-2020; Song, LB/AAL-1968-2020	Lin, Chuyong/0000-0003-4887-5386; 	Natural Science Foundation of China [81272487, 81874220, 81530082, 81672854, 81773106, 91740118]; Science and Technology of Guangdong Province [2016A030308002, 2017A030306019, 2018B030311060]; Guangdong Esophageal Cancer Institute Science and Technology Program [M201715]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology of Guangdong Province; Guangdong Esophageal Cancer Institute Science and Technology Program	This work was supported by Natural Science Foundation of China (Nos. 81272487, 81874220, 81530082, 81672854, 81773106, 91740118); The Science and Technology of Guangdong Province (Nos. 2016A030308002, 2017A030306019, 2018B030311060); Guangdong Esophageal Cancer Institute Science and Technology Program (M201715).	Alison MR, 2012, CANCER TREAT REV, V38, P589, DOI 10.1016/j.ctrv.2012.03.003; Andl CD, 2003, J BIOL CHEM, V278, P1824, DOI 10.1074/jbc.M209148200; Ando T, 2018, ONCOGENE, V37, P263, DOI 10.1038/onc.2017.321; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bartucci M, 2015, ONCOGENE, V34, P681, DOI 10.1038/onc.2014.5; Bhat KPL, 2011, GENE DEV, V25, P2594, DOI 10.1101/gad.176800.111; Bowers AJ, 2003, ONCOGENE, V22, P2823, DOI 10.1038/sj.onc.1206367; Che SM, 2011, DIS ESOPHAGUS, V24, P265, DOI 10.1111/j.1442-2050.2010.01138.x; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Chen YA, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00060; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; Cui CB, 2003, MOL CELL BIOL, V23, P1004, DOI 10.1128/MCB.23.3.1004-1013.2003; Eyers PA, 2017, TRENDS CELL BIOL, V27, P284, DOI 10.1016/j.tcb.2016.11.002; Fernandez A, 2012, ONCOGENE, V31, P1923, DOI 10.1038/onc.2011.379; Hou ZL, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0922-x; Hua F, 2019, GASTROENTEROLOGY, V156, P708, DOI 10.1053/j.gastro.2018.10.031; Hua F, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8951; Hua F, 2011, J CELL SCI, V124, P3235, DOI 10.1242/jcs.082875; Hwang CC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105676; Jin GA, 2007, BLOOD, V109, P3998, DOI 10.1182/blood-2006-08-041202; Kim MH, 2017, CELL MOL LIFE SCI, V74, P1457, DOI 10.1007/s00018-016-2412-x; Lai D, 2011, CANCER RES, V71, P2728, DOI 10.1158/0008-5472.CAN-10-2711; Lee YC, 2019, CANCERS, V11, DOI 10.3390/cancers11020127; Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874-07; Li J, 2008, CLIN CANCER RES, V14, P6996, DOI 10.1158/1078-0432.CCR-08-0754; Li K, 2018, ONCOGENE, V37, P2967, DOI 10.1038/s41388-018-0172-9; Li K, 2017, CANCER CELL, V31, P697, DOI 10.1016/j.ccell.2017.04.006; Liu CY, 2010, J BIOL CHEM, V285, P37159, DOI 10.1074/jbc.M110.152942; MANDARD AM, 1994, CANCER, V73, P2680, DOI 10.1002/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C; Mata J, 2000, CELL, V101, P511, DOI 10.1016/S0092-8674(00)80861-2; Miyoshi N, 2009, BRIT J CANCER, V101, P1664, DOI 10.1038/sj.bjc.6605361; O'Connor C, 2016, ONCOGENE, V35, P5272, DOI 10.1038/onc.2016.66; Phillips TM, 2006, JNCI-J NATL CANCER I, V98, P1777, DOI 10.1093/jnci/djj495; Salome M, 2018, EXP HEMATOL, V66, P63, DOI 10.1016/j.exphem.2018.07.005; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Tian T, 2015, BIOCHEM BIOPH RES CO, V463, P638, DOI 10.1016/j.bbrc.2015.05.115; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Varelas X, 2010, DEV CELL, V19, P831, DOI 10.1016/j.devcel.2010.11.012; Wang JY, 2013, MOL CELL, V51, P211, DOI 10.1016/j.molcel.2013.05.013; Wennemers M, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2934; Wu M, 2003, J BIOL CHEM, V278, P27072, DOI 10.1074/jbc.M209814200; Xi M, 2019, ANN SURG, V269, P663, DOI 10.1097/SLA.0000000000002670; Xu JM, 2007, BBA-GEN SUBJECTS, V1770, P273, DOI 10.1016/j.bbagen.2006.09.025; Xu W, 2015, CELL BIOSCI, V5, DOI 10.1186/2045-3701-5-7; Yang H, 2018, J CLIN ONCOL, V36, P2796, DOI 10.1200/JCO.2018.79.1483; Zhang H, 2009, J BIOL CHEM, V284, P13355, DOI 10.1074/jbc.M900843200; Zhang J, 2011, ORAL ONCOL, V47, P934, DOI 10.1016/j.oraloncology.2011.06.512; Zhang L, 2019, ONCOGENE, V38, P2788, DOI 10.1038/s41388-018-0626-0; Zhang XC, 2008, CLIN CANCER RES, V14, P2813, DOI 10.1158/1078-0432.CCR-07-1528; Zhang ZK, 2019, MOL CELL, V73, P7, DOI 10.1016/j.molcel.2018.10.030; Zhao YY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0466-4; Zhou S, 2018, ANN SURG ONCOL, V25, P3639, DOI 10.1245/s10434-018-6736-7	52	8	10	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	18					3710	3725		10.1038/s41388-020-1245-0	http://dx.doi.org/10.1038/s41388-020-1245-0		MAR 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LI5XR	32157210				2022-12-28	WOS:000518886000004
J	Li, F; Li, ZM; Han, Q; Cheng, YR; Ji, WX; Yang, Y; Lu, S; Xia, WL				Li, Fan; Li, Ziming; Han, Qing; Cheng, Yirui; Ji, Wenxiang; Yang, Ying; Lu, Shun; Xia, Weiliang			Enhanced autocrine FGF19/FGFR4 signaling drives the progression of lung squamous cell carcinoma, which responds to mTOR inhibitor AZD2104	ONCOGENE			English	Article							TUMOR PROGRESSION; FGF19 CONTRIBUTES; BETA-KLOTHO; CANCER; GROWTH; FGFR4; PROMOTES; TARGET; IDENTIFICATION; EXPRESSION	Lung cancer occurrence and associated mortality ranks top in all countries. Despite the rapid development of targeted and immune therapies, many patients experience relapse within a few years. It is urgent to uncover the mechanisms that drive lung cancer progression and identify novel molecular targets. Our group has previously identified FGF19 as a prognostic marker and potential driver gene of lung squamous cell carcinomas (LSQ) in Chinese smoking patients. However, the underlying mechanism of how FGF19 promotes the progression of LSQ remains unclear. In this study, we characterized and confirmed that FGF19 serves as an oncogenic driver in LSQ development and progression, and reported that the amplification and high expression of FGF19 in LSQ was significantly associated with poor overall and progression-free survival. A higher serum level of FGF19 was found in lung cancer patients, which could also serve as a novel diagnostic index to screen lung cancer. Overproduction of FGF19 in LSQ cells markedly promoted cell growth, progression and metastasis, while downregulating FGF19 effectively inhibited LSQ progression in vitro and in vivo. Moreover, downregulating the receptor FGFR4 was also effective to suppress the growth and migration of LSQ cells. Since FGF19 could be induced by smoking or endoplasmic reticulum stress, to tackle the more malignant FGF19-overproducing LSQ, we reported for the first time that inhibiting mTOR pathway by using AZD2014 was effective and feasible. These findings have offered a new strategy by using anti-FGF19/FGFR4 therapy or mTOR-based therapy in FGF19-driven LSQ.	[Li, Fan; Han, Qing; Cheng, Yirui; Xia, Weiliang] Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Renji Med Clin Stem Cell Res Ctr 10, Ren Ji Hosp,Sch Med, Shanghai, Peoples R China; [Li, Fan; Han, Qing; Cheng, Yirui; Xia, Weiliang] Shanghai Jiao Tong Univ, Sch Biomed Engn, Shanghai, Peoples R China; [Li, Ziming; Ji, Wenxiang; Yang, Ying; Lu, Shun] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Xia, WL (corresponding author), Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Renji Med Clin Stem Cell Res Ctr 10, Ren Ji Hosp,Sch Med, Shanghai, Peoples R China.; Xia, WL (corresponding author), Shanghai Jiao Tong Univ, Sch Biomed Engn, Shanghai, Peoples R China.	wlxia@sjtu.edu.cn	XIA, WEILIANG/AEA-0835-2022; li, fan/AAY-5915-2020; Lu, Shun/ABF-8341-2021; Li, Fan/GRX-7461-2022	XIA, WEILIANG/0000-0002-0256-4219; 	National Natural Science Foundation of China [81773115]; National Key Grant of China [2016YFC0906400]; Medical-Engineering Joint Funds from Shanghai Jiao Tong University [YG2017MS52, YG2017MS81]; Shanghai Science and Technology Commission guidance projects [18411968200]; Shanghai Chest Hospital Project of Collaborative Innovation [YJXT20190209]; Shanghai Youth Top Talent Project	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Grant of China; Medical-Engineering Joint Funds from Shanghai Jiao Tong University; Shanghai Science and Technology Commission guidance projects; Shanghai Chest Hospital Project of Collaborative Innovation; Shanghai Youth Top Talent Project	This work is financially supported, in whole or in part, by National Natural Science Foundation of China (81773115), National Key Grant of China (2016YFC0906400) and Medical-Engineering Joint Funds from Shanghai Jiao Tong University (YG2017MS52, YG2017MS81), Shanghai Science and Technology Commission guidance projects (18411968200), Shanghai Chest Hospital Project of Collaborative Innovation (YJXT20190209) and Shanghai Youth Top Talent Project.	Aldhahrani Adil, 2017, ERJ Open Res, V3, DOI 10.1183/23120541.00107-2016; Beck JT, 2014, CANCER TREAT REV, V40, P980, DOI 10.1016/j.ctrv.2014.06.006; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Desnoyers L, 2008, ONCOGENE, V27, P85, DOI 10.1038/sj.onc.1210623; Feng S, 2013, CANCER RES, V73, P2551, DOI 10.1158/0008-5472.CAN-12-4108; Gao LX, 2019, ONCOGENE, V38, P2394, DOI 10.1038/s41388-018-0591-7; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Guichard SM, 2015, MOL CANCER THER, V14, P2508, DOI 10.1158/1535-7163.MCT-15-0365; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hagel M, 2015, CANCER DISCOV, V5, P424, DOI 10.1158/2159-8290.CD-14-1029; Ji WX, 2016, ONCOTARGET, V7, P15118, DOI 10.18632/oncotarget.7701; Joshi JJ, 2017, CANCER RES, V77, P6999, DOI 10.1158/0008-5472.CAN-17-1865; Koole K, 2015, PATHOBIOLOGY, V82, P280, DOI 10.1159/000439536; Lang LW, 2019, CURR CANCER DRUG TAR, V19, P17, DOI 10.2174/1568009618666180319091731; Lewis DR, 2014, CANCER-AM CANCER SOC, V120, P2883, DOI 10.1002/cncr.28749; Li F, 2019, THERANOSTICS, V9, P7474, DOI 10.7150/thno.35582; Lin BC, 2007, J BIOL CHEM, V282, P27277, DOI 10.1074/jbc.M704244200; Lin YN, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109249; Luo YD, 2010, J BIOL CHEM, V285, P30069, DOI 10.1074/jbc.M110.148288; Massafra V, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171185; Nagamatsu H, 2015, PROSTATE, V75, P1092, DOI 10.1002/pros.22994; Pelaez-Garcia A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063695; Piotrowska Z, 2018, CANCER DISCOV, V8, P1529, DOI 10.1158/2159-8290.CD-18-1022; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Raja A, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8060536; Sawey ET, 2011, CANCER CELL, V19, P347, DOI 10.1016/j.ccr.2011.01.040; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Singleton KR, 2015, CANCER RES, V75, P4398, DOI 10.1158/0008-5472.CAN-15-0509; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tan Q, 2016, ONCOTARGET, V7, P18394, DOI 10.18632/oncotarget.7817; Teng Y, 2017, CANCER RES, V77, P6215, DOI 10.1158/0008-5472.CAN-17-2039; Tiong KH, 2016, ONCOTARGET, V7, P57633, DOI 10.18632/oncotarget.9328; Turunen SP, 2019, CELL DEATH DIFFER, V26, P2577, DOI 10.1038/s41418-019-0321-x; Wan ZY, 2016, HEPATOLOGY, V64, P1289, DOI 10.1002/hep.28639; Wang S, 2016, ONCOL RES, V23, P197, DOI 10.3727/096504016X14537290676919; Yoo C, 2017, ONCOTARGET, V8, P38592, DOI 10.18632/oncotarget.16951; Zhang XC, 2017, THORAC CANCER, V8, P655, DOI 10.1111/1759-7714.12504; Zhang XL, 2016, OTOLARYNG HEAD NECK, V154, P52, DOI 10.1177/0194599815609534; Zhao HK, 2016, ONCOTARGET, V7, P13575, DOI 10.18632/oncotarget.6185; Zhou M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15433	40	15	15	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	17					3507	3521		10.1038/s41388-020-1227-2	http://dx.doi.org/10.1038/s41388-020-1227-2		FEB 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LH1YK	32111983	Green Published, hybrid			2022-12-28	WOS:000517049100002
J	Wang, T; Jing, B; Xu, DL; Liao, YL; Song, HY; Sun, BB; Guo, WZ; Xu, JH; Li, KM; Hu, M; Liu, SL; Ling, J; Kuang, YB; Zhang, T; Zhang, SW; Yao, F; Zhou, BHP; Deng, J				Wang, Tong; Jing, Bo; Xu, Dongliang; Liao, Yueling; Song, Hongyong; Sun, Beibei; Guo, Wenzheng; Xu, Jianhua; Li, Kaimi; Hu, Min; Liu, Shuli; Ling, Jing; Kuang, Yanbin; Zhang, Tuo; Zhang, Siwei; Yao, Feng; Zhou, Binhua P.; Deng, Jiong			PTGES/PGE(2) signaling links immunosuppression and lung metastasis in Gprc5a-knockout mouse model	ONCOGENE			English	Article							TUMOR-ASSOCIATED MACROPHAGES; CANCER METASTASIS; SUPPRESSOR-CELLS; INDUCED EMT; GM-CSF; GPRC5A; IMMUNOTHERAPY; SYNTHASE-1; EXPRESSION; EPITHELIUM	Chronic inflammation has been linked to promotion of tumorigenesis and metastasis in lung. However, due to lack of a relevant animal model for characterization, the underlying mechanism remains elusive. Lung tumor suppressor gene Gprc5a-knockout (ko) mice are susceptible to lung inflammation, tumorigenesis and metastasis, which resembles the pathological features in human patients. Here, we showed that PTGES/PGE(2) signaling was highly associated with lung tumorigenesis and metastasis in Gprc5a-ko mice. Interestingly, Ptges-knockout in mouse lung tumor cells, although reduced their stemness and EMT-like features, still formed tumors and lung metastasis in immune-deficient nude mice, but not in immune-competent mice. This suggests that the major role of PTGES/PGE(2) signaling in tumorigenicity and lung metastasis is through immunosuppression. Mechanistically, PTGES/PGE(2) signaling intrinsically endows tumor cells resistant to T-cell cytotoxicity, and induces cytokines extrinsically for MDSC recruitment, which is crucial for suppression of T-cell immunity. Importantly, targeting PGE(2) signaling in Gprc5a-ko mice by PTGES inhibitor suppressed MDSC recruitment, restored T cells, and significantly repressed lung metastasis. Thus, PTGES/PGE(2) signaling links immunosuppression and metastasis in an inflammatory lung microenvironment of Gprc5a-ko mouse model.	[Wang, Tong; Jing, Bo; Xu, Dongliang; Liao, Yueling; Song, Hongyong; Guo, Wenzheng; Li, Kaimi; Hu, Min; Zhang, Siwei; Deng, Jiong] Shanghai Jiao Tong Univ, Key Lab Cell Differentiat & Apoptosis, Chinese Minister Educ, Sch Med, Shanghai, Peoples R China; [Wang, Tong; Jing, Bo; Xu, Dongliang; Liao, Yueling; Song, Hongyong; Li, Kaimi; Hu, Min; Zhang, Siwei; Deng, Jiong] Shanghai Jiao Tong Univ, Shanghai Key Lab Tumor Microenvironm & Inflammat, Sch Med, Shanghai, Peoples R China; [Sun, Beibei; Deng, Jiong] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Translat Med Res Ctr, Shanghai, Peoples R China; [Xu, Jianhua] Kunming Med Univ, Dept Pathol, Kunming, Yunnan, Peoples R China; [Liu, Shuli] Shanghai Jiao Tong Univ, Peoples Hosp 9, Dept Oral & Maxillofacial Head & Neck Oncol, Coll Stomatol,Sch Med, Shanghai, Peoples R China; [Ling, Jing] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Oncol, Sch Med, Shanghai, Peoples R China; [Kuang, Yanbin] Dalian Med Univ, Affiliated Hosp 2, Dept Resp Med, Dalian, Peoples R China; [Zhang, Tuo; Yao, Feng] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Thorac Surg, Shanghai, Peoples R China; [Zhou, Binhua P.] Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Markey Canc Ctr, Lexington, KY 40506 USA	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Kunming Medical University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Dalian Medical University; Shanghai Jiao Tong University; University of Kentucky	Deng, J (corresponding author), Shanghai Jiao Tong Univ, Key Lab Cell Differentiat & Apoptosis, Chinese Minister Educ, Sch Med, Shanghai, Peoples R China.; Deng, J (corresponding author), Shanghai Jiao Tong Univ, Shanghai Key Lab Tumor Microenvironm & Inflammat, Sch Med, Shanghai, Peoples R China.; Deng, J (corresponding author), Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Translat Med Res Ctr, Shanghai, Peoples R China.; Yao, F (corresponding author), Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Thorac Surg, Shanghai, Peoples R China.; Zhou, BHP (corresponding author), Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Markey Canc Ctr, Lexington, KY 40506 USA.	yaofeng6796678@126.com; peter.zhou@uky.edu; jiongdeng@shsmu.edu.cn		Yao, Feng/0000-0002-9635-9581; Shuli, Liu/0000-0002-8988-8899; Kuang, Yanbin/0000-0003-3041-7854	National Natural Science Foundation of China [81620108022, 91129303, 91729302, 81572759, 81572693]; Shenzhen Municipal Government of China [KQTD20170810160226082]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shenzhen Municipal Government of China	This study was supported by grants from National Natural Science Foundation of China (81620108022, 91129303, 91729302 and 81572759 to JD, 81572693 to FY) and Shenzhen Municipal Government of China (KQTD20170810160226082).	Bottcher JP, 2018, CELL, V172, P1022, DOI 10.1016/j.cell.2018.01.004; Cheng YJ, 1998, J BIOL CHEM, V273, P35008, DOI 10.1074/jbc.273.52.35008; Cortes M, 2017, EMBO J, V36, P3336, DOI 10.15252/embj.201797345; Coulombe F, 2014, IMMUNITY, V40, P554, DOI 10.1016/j.immuni.2014.02.013; Coward JIG, 2012, LUNG CANCER, V75, P133, DOI 10.1016/j.lungcan.2011.11.001; Daley-Bauer LP, 2012, IMMUNITY, V37, P122, DOI 10.1016/j.immuni.2012.04.014; Deng JO, 2010, CANCER PREV RES, V3, P424, DOI 10.1158/1940-6207.CAPR-10-0032; Guo WZ, 2019, BIOMED PHARMACOTHER, V114, DOI 10.1016/j.biopha.2019.108791; Herbst RS, 2018, NATURE, V553, P446, DOI 10.1038/nature25183; Hu M, 2019, AM J CANCER RES, V9, P134; Hutchison S, 2019, VET IMMUNOL IMMUNOP, V216, DOI 10.1016/j.vetimm.2019.109912; Isono M, 2011, LIFE SCI, V88, P693, DOI 10.1016/j.lfs.2011.02.008; Katoh H, 2013, CANCER CELL, V24, P631, DOI 10.1016/j.ccr.2013.10.009; Kawahara K, 2015, BBA-MOL CELL BIOL L, V1851, P414, DOI 10.1016/j.bbalip.2014.07.008; Ke YB, 2017, AM J PHYSIOL-LUNG C, V313, pL710, DOI 10.1152/ajplung.00519.2016; Kim SH, 2016, PIGM CELL MELANOMA R, V29, P297, DOI 10.1111/pcmr.12455; Kudo-Saito C, 2009, CANCER CELL, V15, P195, DOI 10.1016/j.ccr.2009.01.023; Kurtova AV, 2015, NATURE, V517, P209, DOI 10.1038/nature14034; Li KM, 2019, NEOPLASIA, V21, P602, DOI 10.1016/j.neo.2019.03.008; Li W, 2018, CELL METAB, V28, P87, DOI 10.1016/j.cmet.2018.04.022; Liao YL, 2015, CELL CYCLE, V14, P1403, DOI 10.1080/15384101.2015.1006006; Lin Y, 2017, ONCOGENE, V36, P3599, DOI 10.1038/onc.2016.516; Lin YW, 2010, EMBO J, V29, P1803, DOI 10.1038/emboj.2010.63; Liu SL, 2015, ONCOTARGET, V6, P6887, DOI 10.18632/oncotarget.3159; Majumder M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041019; Mak MP, 2016, CLIN CANCER RES, V22, P609, DOI 10.1158/1078-0432.CCR-15-0876; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Mondanelli G, 2017, IMMUNITY, V46, P233, DOI 10.1016/j.immuni.2017.01.005; Nandi P, 2017, BMC CANCER, V17, DOI 10.1186/s12885-016-3018-2; Ong HS, 2017, HEAD NECK-J SCI SPEC, V39, P2450, DOI 10.1002/hed.24914; Paff M, 2014, HUM VACC IMMUNOTHER, V10, P3322, DOI 10.4161/21645515.2014.983002; Palizgir MT, 2018, IMMUNOPHARM IMMUNOT, V40, P297, DOI 10.1080/08923973.2018.1474921; Prima V, 2017, P NATL ACAD SCI USA, V114, P1117, DOI 10.1073/pnas.1612920114; Quail DF, 2017, NAT CELL BIOL, V19, P974, DOI 10.1038/ncb3578; Roussel M, 2017, J LEUKOCYTE BIOL, V102, P437, DOI 10.1189/jlb.5MA1116-457R; Samuelsson B, 2007, PHARMACOL REV, V59, P207, DOI 10.1124/pr.59.3.1; Schumacher Y, 2016, ONCOGENE, V35, P2602, DOI 10.1038/onc.2015.283; Song HY, 2019, INT J CANCER, V144, P777, DOI 10.1002/ijc.31726; Steele CW, 2016, CANCER CELL, V29, P832, DOI 10.1016/j.ccell.2016.04.014; Tao QG, 2007, JNCI-J NATL CANCER I, V99, P1668, DOI 10.1093/jnci/djm208; Tian XY, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4564-6; Tong DL, 2017, CANCER LETT, V389, P23, DOI 10.1016/j.canlet.2016.12.031; Waghray M, 2016, CANCER DISCOV, V6, P886, DOI 10.1158/2159-8290.CD-15-0947; Wang T, 2019, AM J CANCER RES, V9, P1145; Wang T, 2019, BIOCHEM BIOPH RES CO, V513, P319, DOI [10.1016/j.bbrc.2019.03.198, 10.1016/ibbrc.2019.03.198]; Wu AA, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1016700; Xu JS, 2005, AM J RESP CELL MOL, V32, P381, DOI 10.1165/rcmb.2004-0343OC; Zelenay S, 2015, CELL, V162, P1257, DOI 10.1016/j.cell.2015.08.015; Zhong SS, 2015, CANCER RES, V75, P1801, DOI 10.1158/0008-5472.CAN-14-2005	49	19	20	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	15					3179	3194		10.1038/s41388-020-1207-6	http://dx.doi.org/10.1038/s41388-020-1207-6		FEB 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LB8NS	32060421	hybrid, Green Published			2022-12-28	WOS:000513384600001
J	Ito, H; Tsunoda, T; Riku, M; Inaguma, S; Inoko, A; Murakami, H; Ikeda, H; Matsuda, M; Kasai, K				Ito, Hideaki; Tsunoda, Takumi; Riku, Miho; Inaguma, Shingo; Inoko, Akihito; Murakami, Hideki; Ikeda, Hiroshi; Matsuda, Michiyuki; Kasai, Kenji			Indispensable role of STIL in the regulation of cancer cell motility through the lamellipodial accumulation of ARHGEF7-PAK1 complex	ONCOGENE			English	Article							CENTRIOLE DUPLICATION; PAK; MEMBRANE; MIGRATION; CDC42; PROMOTES; RAC1; PLK4; CENTROSOME; ACTIVATION	Cell motility is a tightly regulated phenomenon that supports the accurate formation of organ structure during development and homeostasis, including wound healing and inflammation. Meanwhile, cancer cells exhibit dysregulated motility, which causes spreading and invasion. The Dbl family RhoGEF ARHGEF7/beta-PIX and its binding partner p21-activated kinase PAK1 are overexpressed in a variety of cancers and have been shown to be responsible for cancer cell migration. A key step in motility is the intracellular transport of ARHGEF7-PAK1 complex to the migrating front of cells, where lamellipodia protrusion and cytoskeletal remodeling efficiently occur. However, the molecular mechanisms of the intracellular transport of this complex are not fully understood. Here we revealed that SCL/TAL1-interrupting locus (STIL) is indispensable for the efficient migration of cancer cells. STIL forms a ternary complex with ARHGEF7 and PAK1 and accumulates with those proteins at the lamellipodia protrusion of motile cells. Knockdown of STIL impedes the accumulation of ARHGEF7-PAK1 complex within membrane ruffles and attenuates the phosphorylation of PAK1 substrates and cortical actin remodeling at the migrating front. Intriguingly, ARHGEF7 knockdown also diminishes STIL and PAK1 accumulation in membrane ruffles. Either STIL or ARHGEF7 knockdown impedes cell migration and Rac1 activity at the migrating front of cells. These results indicate that STIL is involved in the ARHGEF7-mediated positive-feedback activation of cytoskeletal remodeling through accumulating the ARHGEF7-PAK1 complex in lamellipodia. We conclude that its involvement is crucial for the polarized formation of Rac1-mediated leading edge, which supports the efficient migration of cancer cells.	[Ito, Hideaki; Tsunoda, Takumi; Riku, Miho; Inaguma, Shingo; Inoko, Akihito; Murakami, Hideki; Ikeda, Hiroshi; Kasai, Kenji] Aichi Med Univ, Dept Pathol, Sch Med, Nagakute, Aichi, Japan; [Matsuda, Michiyuki] Kyoto Univ, Dept Pathol & Biol Dis, Grad Sch Med, Kyoto, Japan	Aichi Medical University; Kyoto University	Kasai, K (corresponding author), Aichi Med Univ, Dept Pathol, Sch Med, Nagakute, Aichi, Japan.	kkasai@aichi-med-u.ac.jp	Riku, Miho/GPP-3435-2022	Riku, Miho/0000-0002-1799-5839; Kasai, Kenji/0000-0001-6566-9483	JSPS KAKENHI [16K19091, 17K08706, 19K06671, 18K07031, 16H06280, 15H05949, 24590456, 19K07449]; Pancreas Research Foundation of Japan	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Pancreas Research Foundation of Japan(Pancreas Research Foundation of Japan)	We thank Norika Yamada, Kazuko Tanimizu, and Minako Suzuki for their excellent technical assistance and Tatsuhito Miyake and Yuji Nakagomi for laser confocal microscope. We also thank Yukiko Kuru (Faculty of Foreign Languages, Aichi Medical University School of Medicine) for English editing. This study was supported in part by JSPS KAKENHI Grant Number 16K19091 (HI), 17K08706 (SI), 19K06671 (AI), 18K07031 (HM), 16H06280 "ABiS" (MM), 15H05949 "Resonance Bio" (MM), 24590456 and 19K07449 (KK); Pancreas Research Foundation of Japan (HI).	APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; Arquint C, 2012, J CELL SCI, V125, P1342, DOI 10.1242/jcs.099887; Bryce NS, 2005, CURR BIOL, V15, P1276, DOI 10.1016/j.cub.2005.06.043; Bustelo Xose R, 2012, Small GTPases, V3, P60, DOI 10.4161/sgtp.19111; Byrne KM, 2016, CELL SYST, V2, P38, DOI 10.1016/j.cels.2016.01.003; Castro-Castro A, 2011, EMBO J, V30, P3913, DOI 10.1038/emboj.2011.310; Delattre M, 2004, NAT CELL BIOL, V6, P656, DOI 10.1038/ncb1146; Erez A, 2004, ONCOGENE, V23, P5371, DOI 10.1038/sj.onc.1207685; Itoh RE, 2002, MOL CELL BIOL, V22, P6582, DOI 10.1128/MCB.22.18.6582-6591.2002; Izraeli S, 1999, NATURE, V399, P691, DOI 10.1038/21429; Jorissen RN, 2009, CLIN CANCER RES, V15, P7642, DOI 10.1158/1078-0432.CCR-09-1431; Kasai K, 2008, CANCER RES, V68, P7723, DOI 10.1158/0008-5472.CAN-07-6661; Kazazian K, 2017, CANCER RES, V77, P434, DOI 10.1158/0008-5472.CAN-16-2060; Koh CG, 2001, J CELL SCI, V114, P4239; Krause M, 2014, NAT REV MOL CELL BIO, V15, P577, DOI 10.1038/nrm3861; Kumar R, 2017, GENE, V605, P20, DOI 10.1016/j.gene.2016.12.014; Kunida K, 2012, J CELL SCI, V125, P2381, DOI 10.1242/jcs.096859; Kurokawa K, 2004, MOL BIOL CELL, V15, P1003, DOI 10.1091/mbc.E03-08-0609; Lawson CD, 2018, J CELL BIOL, V217, P447, DOI 10.1083/jcb.201612069; Li F, 2002, EMBO REP, V3, P767, DOI 10.1093/embo-reports/kvf157; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Nigg EA, 2018, NAT REV MOL CELL BIO, V19, P297, DOI 10.1038/nrm.2017.127; Nola S, 2008, HUM MOL GENET, V17, P3552, DOI 10.1093/hmg/ddn248; Ohta M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6267; Omelchenko T, 2014, GENE DEV, V28, P2764, DOI 10.1101/gad.251371.114; Parrini MC, 2002, MOL CELL, V9, P73, DOI 10.1016/S1097-2765(01)00428-2; Patwardhan D, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0101-9; Pei HD, 2009, CANCER CELL, V16, P259, DOI 10.1016/j.ccr.2009.07.016; Rabinowicz N, 2017, ONCOTARGET, V8, P27380, DOI 10.18632/oncotarget.16068; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Rane CK, 2019, SEMIN CANCER BIOL, V54, P40, DOI 10.1016/j.semcancer.2018.01.006; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rosario CO, 2015, ONCOGENE, V34, P3441, DOI 10.1038/onc.2014.275; Schmidt M, 2008, CANCER RES, V68, P5405, DOI 10.1158/0008-5472.CAN-07-5206; Schnoor M, 2018, TRENDS CELL BIOL, V28, P79, DOI 10.1016/j.tcb.2017.10.009; Skrzypczak M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013091; Stevens NR, 2010, J CELL BIOL, V188, P313, DOI 10.1083/jcb.200910016; Vadlamudi RK, 2002, NAT CELL BIOL, V4, P681, DOI 10.1038/ncb838; Vulprecht J, 2012, J CELL SCI, V125, P1353, DOI 10.1242/jcs.104109; Wu XC, 2019, GENE, V686, P220, DOI 10.1016/j.gene.2018.11.048; Yamao M, 2015, SCI REP-UK, V5, DOI 10.1038/srep17527; Zhao ZS, 2005, MOL CELL, V20, P237, DOI 10.1016/j.molcel.2005.08.035	44	9	9	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	9					1931	1943		10.1038/s41388-019-1115-9	http://dx.doi.org/10.1038/s41388-019-1115-9			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KP9VM	31754215				2022-12-28	WOS:000516579800008
J	Zhang, JC; Lin, XX; Wu, LF; Huang, JJ; Jiang, WQ; Kipps, TJ; Zhang, SP				Zhang, Jianchao; Lin, Xinxin; Wu, Liufeng; Huang, Jia-Jia; Jiang, Wen-Qi; Kipps, Thomas J.; Zhang, Suping			Aurora B induces epithelial-mesenchymal transition by stabilizing Snail1 to promote basal-like breast cancer metastasis	ONCOGENE			English	Article							OCT4 INTERACTION; POOR-PROGNOSIS; STEM-CELLS; EXPRESSION; PHOSPHORYLATION; OVEREXPRESSION; EMT; TRANSCRIPTION; REPRESSION; PLASTICITY	Aurora B is a serine/threonine kinase that has been implicated in regulating cell proliferation in distinct cancers, including breast cancer. Here we show that Aurora B expression is elevated in basal-like breast cancer (BLBC) compared with other breast cancer subtypes. This high level of expression seems to correlate with poor metastasis-free survival and relapse-free survival in affected patients. Mechanistically, we show that elevated Aurora B expression in breast cancer cells activates AKT/GSK3 beta to stabilize Snail1 protein, a master regulator of epithelial-mesenchymal transition (EMT), leading to EMT induction in a kinase-dependent manner. Conversely, Aurora B knock down by short-hairpin RNAs (shRNAs) suppresses AKT/GSK3 beta/Snail1 signaling, reverses EMT and reduces breast cancer metastatic potential in vitro and in vivo. Finally, we identified a specific OCT4 phosphorylation site (T343) responsible for mediating Aurora B-induced AKT/GSK3 beta/Snail1 signaling and EMT that could be attenuated by Aurora B kinase inhibitor treatment. These findings support that Aurora B induces EMT to promote breast cancer metastasis via OCT4/AKT/GSK3 beta/Snail1 signaling. Pharmacologic Aurora B inhibition might be a potential effective treatment for breast cancer patients with metastatic disease.	[Zhang, Jianchao; Lin, Xinxin; Wu, Liufeng; Zhang, Suping] Shenzhen Univ, Hlth Sci Ctr, Int Canc Ctr,Dept Pharmacol,Guangdong Key Lab Gen, Base Int Sci & Technol Cooperat Carson Canc Stem, Shenzhen 518055, Peoples R China; [Huang, Jia-Jia; Jiang, Wen-Qi] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Med Oncol,State Key Lab Oncol South China, Guangzhou 510060, Peoples R China; [Kipps, Thomas J.; Zhang, Suping] Univ Calif San Diego, Moores UCSD Canc Ctr, 9310 Athena Circle, San Diego, CA 92093 USA	Shenzhen University; State Key Lab Oncology South China; Sun Yat Sen University; University of California System; University of California San Diego	Zhang, SP (corresponding author), Shenzhen Univ, Hlth Sci Ctr, Int Canc Ctr,Dept Pharmacol,Guangdong Key Lab Gen, Base Int Sci & Technol Cooperat Carson Canc Stem, Shenzhen 518055, Peoples R China.; Zhang, SP (corresponding author), Univ Calif San Diego, Moores UCSD Canc Ctr, 9310 Athena Circle, San Diego, CA 92093 USA.	s9zhang@szu.edu.cn	jiang, wen/GYI-9662-2022		National Natural Science Foundation of China [81672912, 81972753, 81502537]; Science and Technology Program of Guangdong Province, China [2017B030301016, 2016A030310128]; Shenzhen Basic Research Program [JCYJ20170818143630465, JCYJ20170818101638620, JCYJ20180507182203049]; Shenzhen Peacock Innovation Team Project [KQTD20140630100658078]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Program of Guangdong Province, China; Shenzhen Basic Research Program; Shenzhen Peacock Innovation Team Project	This study was supported by the National Natural Science Foundation of China (81672912, 81972753, and 81502537), the Science and Technology Program of Guangdong Province, China (2017B030301016 and 2016A030310128), the Shenzhen Basic Research Program (JCYJ20170818143630465, JCYJ20170818101638620, and JCYJ20180507182203049) and the Shenzhen Peacock Innovation Team Project (KQTD20140630100658078). The authors would like to thank Dr Jessica Tamanini (Shenzhen University, ETediting) for editing the paper prior to submission. We acknowledge the help of the Instrumental Analysis Center of Shenzhen University (Xili Campus) for technical assistance.	Abulaiti X, 2017, STEM CELL REP, V9, P1630, DOI 10.1016/j.stemcr.2017.09.001; Brabletz T, 2018, NAT REV CANCER, V18, P128, DOI 10.1038/nrc.2017.118; Brumbaugh J, 2012, P NATL ACAD SCI USA, V109, P7162, DOI 10.1073/pnas.1203874109; Calabro A, 2009, BREAST CANCER RES TR, V116, P69, DOI 10.1007/s10549-008-0105-3; Campbell PA, 2013, STEM CELLS, V31, P1107, DOI 10.1002/stem.1365; Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005; Chieffi P, 2006, PROSTATE, V66, P326, DOI 10.1002/pros.20345; Chin SF, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r215; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022; Fernandez-Miranda G, 2011, DEVELOPMENT, V138, P2661, DOI 10.1242/dev.066381; Goldenson B, 2015, ONCOGENE, V34, P537, DOI 10.1038/onc.2014.14; Gonzalez-Loyola A, 2015, MOL CELL BIOL, V35, P3566, DOI 10.1128/MCB.01286-14; Guise AJ, 2012, MOL CELL PROTEOMICS, V11, P1220, DOI 10.1074/mcp.M112.021030; Gully CP, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-42; Jezequel P, 2012, BREAST CANCER RES TR, V131, P765, DOI 10.1007/s10549-011-1457-7; Jin Y, 2015, CANCER LETT, V362, P70, DOI 10.1016/j.canlet.2015.03.037; Kai K, 2015, MOL CANCER THER, V14, P2687, DOI 10.1158/1535-7163.MCT-15-0096; Krenn V, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00225; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Lin YJ, 2012, MOL CELL, V48, P627, DOI 10.1016/j.molcel.2012.08.030; Liu ZC, 2014, BBA-GEN SUBJECTS, V1840, P3096, DOI 10.1016/j.bbagen.2014.07.018; Ma YX, 2015, J MOL MED, V93, P427, DOI 10.1007/s00109-014-1228-0; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mittal V, 2018, ANNU REV PATHOL-MECH, V13, P395, DOI 10.1146/annurev-pathol-020117-043854; Nadler Y, 2008, CLIN CANCER RES, V14, P4455, DOI 10.1158/1078-0432.CCR-07-5268; Pattabiraman DR, 2016, COLD SH Q B, V81, P11, DOI 10.1101/sqb.2016.81.030957; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Porcelli L, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0385-4; Portella G, 2011, CURR MED CHEM, V18, P482, DOI 10.2174/092986711794480203; Rakha EA, 2008, J CLIN ONCOL, V26, P2568, DOI 10.1200/JCO.2007.13.1748; Riaz M, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3415; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029; Schmidt JM, 2015, CELL REP, V10, P131, DOI 10.1016/j.celrep.2014.12.032; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; Shin J, 2016, ELIFE, V5, DOI 10.7554/eLife.10877; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sorrentino R, 2005, J CLIN ENDOCR METAB, V90, P928, DOI 10.1210/jc.2004-1518; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Vargo-Gogola T, 2007, NAT REV CANCER, V7, P659, DOI 10.1038/nrc2193; Vinas-Castells R, 2010, J BIOL CHEM, V285, P3794, DOI 10.1074/jbc.M109.065995; Vischioni B, 2006, MOL CANCER THER, V5, P2905, DOI 10.1158/1535-7163.MCT-06-0301; Wang C, 2016, EUR J PHARMACOL, V779, P1, DOI 10.1016/j.ejphar.2015.11.049; Wang D, 2014, ONCOTARGET, V5, P10803, DOI 10.18632/oncotarget.2506; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522; Zeng QQ, 2012, P NATL ACAD SCI USA, V109, P1127, DOI 10.1073/pnas.1111053108; Zeng WFF, 2007, J CLIN PATHOL, V60, P218, DOI 10.1136/jcp.2006.036806; Zhang A, 2013, ONCOL LETT, V6, P339, DOI 10.3892/ol.2013.1385; Zhang YQ, 2015, INT J CLIN EXP PATHO, V8, P751; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173; Zhu XP, 2014, EXP THER MED, V7, P560, DOI 10.3892/etm.2014.1491	56	20	19	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	12					2550	2567		10.1038/s41388-020-1165-z	http://dx.doi.org/10.1038/s41388-020-1165-z		JAN 2020	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KW4HU	31996785				2022-12-28	WOS:000510136400002
J	Xia, X; Wang, SC; Ni, B; Xing, SP; Cao, H; Zhang, ZZ; Yu, FR; Zhao, EH; Zhao, G				Xia, Xiang; Wang, Shuchang; Ni, Bo; Xing, Shunpeng; Cao, Hui; Zhang, Zizhen; Yu, Fengrong; Zhao, Enhao; Zhao, Gang			Hypoxic gastric cancer-derived exosomes promote progression and metastasis via MiR-301a-3p/PHD3/HIF-1 alpha positive feedback loop	ONCOGENE			English	Article							CELL-PROLIFERATION; INDUCIBLE FACTORS; INVASION; VESICLES; PLASMA; RNAS	Hypoxic tumor microenvironment(TME) is a universal feature in solid carcinoma and is associated with unfavorable prognosis. Tumor-derived exosomes are now significantly implicating in mediating cellular communication and interactions in TME. The aim of this study was to identify exosomal miR-301a-3p involved in gastric cancer(GC) progression and metastasis. Here, we found hypoxia promote GC exosomes release and miR-301a-3p expression in an HIF-1 alpha-dependent manner. In hypoxic TME, enriched miR-301a-3p could be transmitted between GC cells via exosomes and then contributed to inhibit HIF-1 alpha degradation through targeting PHD3, that were capable to hydroxylate HIF-1 alpha subunits to ubiquitinate degradation. This synergistical positive feedback loop between HIF-1 alpha and miR-301a-3p facilitated GC proliferation, invasion, migration, and epithelial-mesenchymal transition. In clinical samples, we further discovered circulating exosomal miR-301a-3p in serum was positively related with peritoneal metastasis. Collectively, these data indicate that GC cells could generate miR-301a-3p-rich exosomes in the hypoxic TME, which then help to HIF-1 alpha accumulation and promote GC malignant behaviors and metastasis. Exosomal miR-301a-3p/HIF-1 alpha signaling axis may serve as a promising predictor and potential therapeutic target of GC with metastasis.	[Xia, Xiang; Wang, Shuchang; Ni, Bo; Cao, Hui; Zhang, Zizhen; Yu, Fengrong; Zhao, Enhao; Zhao, Gang] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Gastrointestinal Surg, Shanghai, Peoples R China; [Xing, Shunpeng] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Crit Care, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University	Yu, FR; Zhao, EH; Zhao, G (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Gastrointestinal Surg, Shanghai, Peoples R China.	yufengrongrj@163.com; zhaoenhao@renji.com; zhaogangrj@163.com			National Natural Science Foundation of China [81802313, 81972206]; Shanghai Sailing Program [17YF1415700]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Sailing Program	The National Natural Science Foundation of China (grant numbers: 81802313 and 81972206). Shanghai Sailing Program (Grant No. 17YF1415700). The funding bodies had no role in the design of the study and collection, analysis, and interpretation of data and in the writing of the manuscript.	Ajani JA, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.36; Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200; Binenbaum Y, 2018, CANCER RES, V78, P5287, DOI 10.1158/0008-5472.CAN-18-0124; Brahimi-Horn MC, 2007, J MOL MED-JMM, V85, P1301, DOI 10.1007/s00109-007-0281-3; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bristow RG, 2008, NAT REV CANCER, V8, P180, DOI 10.1038/nrc2344; Dassler-Plenker J, 2020, BBA-REV CANCER, V1873, DOI 10.1016/j.bbcan.2020.188340; Fan Q, 2018, CANCER LETT, V414, P107, DOI 10.1016/j.canlet.2017.10.040; Ge XX, 2016, ONCOTARGET, V7, P24466, DOI 10.18632/oncotarget.8228; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hsu YL, 2017, ONCOGENE, V36, P4929, DOI 10.1038/onc.2017.105; Hu JH, 2018, PATHOL RES PRACT, V214, P2039, DOI 10.1016/j.prp.2018.09.008; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Jain RK, 2014, CANCER CELL, V26, P605, DOI 10.1016/j.ccell.2014.10.006; JOHNSTONE RM, 1987, J BIOL CHEM, V262, P9412; Khan MI, 2018, SEMIN CANCER BIOL, V49, P75, DOI 10.1016/j.semcancer.2017.05.008; King HW, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-421; Kroh EM, 2010, METHODS, V50, P298, DOI 10.1016/j.ymeth.2010.01.032; Li L, 2016, CANCER RES, V76, P1770, DOI 10.1158/0008-5472.CAN-15-1625; Li XJ, 2018, CANCER LETT, V418, P211, DOI 10.1016/j.canlet.2018.01.031; Lordick F, 2017, ANN ONCOL, V28, P1767, DOI 10.1093/annonc/mdx051; Meng WR, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0982-6; Palazon A, 2014, IMMUNITY, V41, P518, DOI 10.1016/j.immuni.2014.09.008; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Rankin EB, 2016, SCIENCE, V352, P175, DOI 10.1126/science.aaf4405; Schito L, 2016, TRENDS CANCER, V2, P758, DOI 10.1016/j.trecan.2016.10.016; Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021; Shao CC, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0869-y; Strowitzki MJ, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050384; Swartz MA, 2012, CANCER RES, V72, P2473, DOI 10.1158/0008-5472.CAN-12-0122; Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30; Thomassen I, 2014, INT J CANCER, V134, P622, DOI 10.1002/ijc.28373; Trajkovic K, 2008, SCIENCE, V319, P1244, DOI 10.1126/science.1153124; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Wang M, 2013, J GASTROENTEROL, V48, P1023, DOI 10.1007/s00535-012-0733-6; Wang T, 2014, P NATL ACAD SCI USA, V111, pE3234, DOI 10.1073/pnas.1410041111; Wang XF, 2018, CANCER RES, V78, P4586, DOI 10.1158/0008-5472.CAN-17-3841; Wang Z, 2019, WORLD J SURG ONCOL, V17, DOI 10.1186/s12957-019-1761-y; Wortzel I, 2019, DEV CELL, V49, P347, DOI 10.1016/j.devcel.2019.04.011; Xia X, 2017, AM J TRANSL RES, V9, P1886; Xia X, 2015, ONCOTARGET, V6, P21046, DOI 10.18632/oncotarget.4124; Xie F, 2019, ADV SCI, V6, DOI 10.1002/advs.201901779; Yin J, 2019, J CANCER, V10, P5964, DOI 10.7150/jca.35704; Yue X, 2019, MOL THER, V27, P1939, DOI 10.1016/j.ymthe.2019.07.011; Zong L, 2016, LANCET, V388, P2606, DOI 10.1016/S0140-6736(16)32226-7	46	51	55	1	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2020	39	39					6231	6244		10.1038/s41388-020-01425-6	http://dx.doi.org/10.1038/s41388-020-01425-6		AUG 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NS8XO	32826951				2022-12-28	WOS:000561519300002
J	El Jamal, SM; Alamodi, A; Wahl, RU; Grada, Z; Shareef, MA; Hassan, SY; Murad, F; Hassan, SL; Santourlidis, S; Gomez, CR; Haikel, Y; Megahed, M; Hassan, M				Jamal, Siraj M. El; Alamodi, Abdulhadi; Wahl, Renate U.; Grada, Zakaria; Shareef, Mohammad Abrar; Hassan, Sofie-Yasmin; Murad, Fadi; Hassan, Sarah-Lilly; Santourlidis, Simeon; Gomez, Christian R.; Haikel, Youssef; Megahed, Mosaad; Hassan, Mohamed			Melanoma stem cell maintenance and chemo-resistance are mediated by CD133 signal to PI3K-dependent pathways	ONCOGENE			English	Article							KINASE C-YES; METASTATIC MELANOMA; ACQUIRED-RESISTANCE; ELEVATED EXPRESSION; INDUCED APOPTOSIS; THERAPEUTIC TARGET; PHASE-III; ACTIVATION; MULTICENTER; INHIBITOR	Melanoma stem cells (MSCs) are characterized by their unique cell surface proteins and aberrant signaling pathways. These stemness properties are either in a causal or consequential relationship to melanoma progression, treatment resistance and recurrence. The functional analysis of CD133(+)and CD133(-)cells in vitro and in vivo revealed that melanoma progression and treatment resistance are the consequences of CD133 signal to PI3K pathway. CD133 signal to PI3K pathway drives two downstream pathways, the PI3K/Akt/MDM2 and the PI3K/Akt/MKP-1 pathways. Activation of PI3K/Akt/MDM2 pathway results in the destabilization of p53 protein, while the activation of PI3K/Akt/MKP-1 pathway results in the inhibition of mitogen-activated protein kinases (MAPKs) JNK and p38. Activation of both pathways leads to the inhibition of fotemustine-induced apoptosis. Thus, the disruption of CD133 signal to PI3K pathway is essential to overcome Melanoma resistance to fotemustine. The pre-clinical verification of in vitro data using xenograft mouse model of MSCs confirmed the clinical relevance of CD133 signal as a therapeutic target for melanoma treatment. In conclusion, our study provides an insight into the mechanisms regulating MSCs growth and chemo-resistance and suggested a clinically relevant approach for melanoma treatment.	[Jamal, Siraj M. El] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA; [Alamodi, Abdulhadi] Jackson State Univ, Sch Publ Hlth, Jackson, MS USA; [Wahl, Renate U.; Hassan, Sofie-Yasmin; Hassan, Sarah-Lilly; Megahed, Mosaad] Univ Hosp Aachen, Clin Dermatol, Aachen, Germany; [Grada, Zakaria] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02115 USA; [Shareef, Mohammad Abrar] Eastern Maine Med Ctr, Dept Internal Med, Bangor, ME USA; [Murad, Fadi] Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; [Santourlidis, Simeon] Heinrich Heine Univ Duesseldorf, Inst Transplantat Diagnost & Cell Therapeut, Epigenet Core Lab, Med Fac, Dusseldorf, Germany; [Gomez, Christian R.] Univ Mississippi, Med Ctr, Dept Pathol, Jackson, MS 39216 USA; [Haikel, Youssef; Hassan, Mohamed] INSERM, Strasbourg, France; [Haikel, Youssef] Univ Strasbourg, Dept Operat Dent & Endodont, Dent Fac, Strasbourg, France; [Hassan, Mohamed] Tulane Univ, Sch Med, Dept Surg, New Orleans, LA 70112 USA	Icahn School of Medicine at Mount Sinai; Jackson State University; RWTH Aachen University; RWTH Aachen University Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Eastern Maine Medical Center; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Heinrich Heine University Dusseldorf; University of Mississippi; University of Mississippi Medical Center; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Tulane University	Hassan, M (corresponding author), INSERM, Strasbourg, France.; Hassan, M (corresponding author), Tulane Univ, Sch Med, Dept Surg, New Orleans, LA 70112 USA.	dr.hassan@gmx.de	Jamal, Siraj M El/J-2603-2013; Hassan, Mohamed/AHE-7565-2022; Jamal, Siraj El/AAJ-1728-2021	Jamal, Siraj M El/0000-0001-6299-1071; Jamal, Siraj El/0000-0001-6299-1071; Santourlidis, Simeon/0000-0002-0743-5336	German Research Foundation [HA 5081/3-1]; L' Alsace contre le cancer, France; German cancer research foundation [10-2202-Ha 1]	German Research Foundation(German Research Foundation (DFG)); L' Alsace contre le cancer, France; German cancer research foundation	This work was supported by grants from German Research Foundation (HA 5081/3-1), from L' Alsace contre le cancer, France, German cancer research foundation (10-2202-Ha 1) to MH.	Assouline SE, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2014.71; Aveic S, 2016, CANCER CELL INT, V16, DOI 10.1186/s12935-016-0341-2; Bagrodia S, 2012, PIGM CELL MELANOMA R, V25, P819, DOI 10.1111/pcmr.12007; Beasley GM, 2015, ANN SURG ONCOL, V22, P287, DOI 10.1245/s10434-014-3887-z; Bright R, 2017, J IMMUNOTHER, V40, P21, DOI 10.1097/CJI.0000000000000149; de Polo A, 2017, J MOL CELL BIOL, V9, P154, DOI 10.1093/jmcb/mjw045; Desvignes C, 2017, MELANOMA RES, V27, P281, DOI 10.1097/CMR.0000000000000350; Dong CY, 2016, ONCOTARGET, V7, P8850, DOI 10.18632/oncotarget.7091; Easty DJ, 2011, PIGM CELL MELANOMA R, V24, P446, DOI 10.1111/j.1755-148X.2011.00836.x; El Jamal SM, 2016, CELL DIV, V11, DOI 10.1186/s13008-016-0023-4; El-Khattouti A, 2016, J CELL MOL MED, V20, P266, DOI 10.1111/jcmm.12718; El-Khattouti A, 2015, CANCER LETT, V357, P83, DOI 10.1016/j.canlet.2014.10.043; El-Khattouti Abdelouahid, 2013, J Cell Death, V6, P37, DOI 10.4137/JCD.S11034; El-Khattouti A, 2014, CANCER LETT, V343, P123, DOI 10.1016/j.canlet.2013.09.024; Fenouille N, 2011, ONCOGENE, V30, P4887, DOI 10.1038/onc.2011.198; Fujii Y, 2018, INTERNAL MED, V57, P1173, DOI 10.2169/internalmedicine.8910-17; Ganesh S, 2018, MOL CANCER THER, V17, P544, DOI 10.1158/1535-7163.MCT-17-0605; Gembarska A, 2012, NAT MED, V18, P1239, DOI 10.1038/nm.2863; Gen Y, 2013, CANCER SCI, V104, P810, DOI 10.1111/cas.12155; del Alba AG, 2017, CRIT REV ONCOL HEMAT, V113, P171, DOI 10.1016/j.critrevonc.2017.03.010; Gowrishankar K, 2012, J INVEST DERMATOL, V132, P1850, DOI 10.1038/jid.2012.63; Hassan M, 2008, ONCOGENE, V27, P4557, DOI 10.1038/onc.2008.90; Hassan M, 2016, J CELL BIOCHEM, V117, P1308, DOI 10.1002/jcb.25419; Hays JL, 2003, J BIOL CHEM, V278, P27456, DOI 10.1074/jbc.M210648200; Ichimura K, 2000, CANCER RES, V60, P417; Jang JW, 2017, LIFE SCI, V184, P25, DOI 10.1016/j.lfs.2017.07.008; Jazirehi AR, 2014, AM J CLIN EXP IMMUNO, V3, P43; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Johnson DB, 2015, EUR J CANCER, V51, P2792, DOI 10.1016/j.ejca.2015.08.022; Kakavand H, 2017, MODERN PATHOL, V30, P1666, DOI 10.1038/modpathol.2017.89; Kaufmann R, 2005, J CLIN ONCOL, V23, P9001, DOI 10.1200/JCO.2005.01.1551; Kawaguchi K, 2018, ONCOTARGET, V9, P915, DOI [10.18632/oncotarget.23185, 10.18632/oncotarget.24996]; Ko A, 2018, MOL CELLS, V41, P381, DOI 10.14348/molcells.2018.0100; Ko HM, 2018, BIOCHEM BIOPH RES CO, V495, P1214, DOI 10.1016/j.bbrc.2017.11.143; Kumar D, 2016, J INVEST DERMATOL, V136, P2462, DOI 10.1016/j.jid.2016.07.024; Lee J, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317695534; Lee WR, 2016, MOL CARCINOGEN, V55, P1542, DOI 10.1002/mc.22407; Li H, 2018, ACTA PHARMACOL SIN, V39, P1787, DOI 10.1038/s41401-018-0034-6; Li ZH, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006436; Liu FR, 2018, ONCOL REP, V39, P1523, DOI 10.3892/or.2018.6188; Liu MX, 2014, BIOL REPROD, V90, DOI 10.1095/biolreprod.114.117754; LOGANZO F, 1993, ONCOGENE, V8, P2637; Ma LJ, 2016, TUMOR BIOL, V37, P12889, DOI 10.1007/s13277-016-5209-5; Maio M, 2018, LANCET ONCOL, V19, P510, DOI 10.1016/S1470-2045(18)30106-2; Manzano JL, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.06.07; Marchetti D, 1998, ONCOGENE, V16, P3253, DOI 10.1038/sj.onc.1201877; Meng Y, 2018, EUR J HEALTH ECON, V19, P1163, DOI 10.1007/s10198-018-0964-4; Michaelis M, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.129; Munugalavadla V, 2007, BLOOD, V110, P1612, DOI 10.1182/blood-2006-10-053058; Nadel G, 2018, CELL PHYSIOL BIOCHEM, V50, P121, DOI 10.1159/000493963; Nikolic N, 2015, ARCH ORAL BIOL, V60, P1662, DOI 10.1016/j.archoralbio.2015.08.011; Oo AKK, 2018, TRANSL ONCOL, V11, P653, DOI 10.1016/j.tranon.2018.03.001; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Prahallad A, 2015, CELL REP, V12, P1978, DOI 10.1016/j.celrep.2015.08.037; Pulluri B, 2017, PHARMACOL RES, V123, P95, DOI 10.1016/j.phrs.2017.07.006; Roesch A, 2016, EUR J CANCER, V59, P109, DOI 10.1016/j.ejca.2016.02.023; Schadendorf D, 2015, EUR J CANCER, V51, P833, DOI 10.1016/j.ejca.2015.03.004; Segrelles C, 2014, STEM CELLS, V32, P1917, DOI 10.1002/stem.1669; Selimovic D, 2013, CELL SIGNAL, V25, P308, DOI 10.1016/j.cellsig.2012.10.004; Selimovic D, 2012, J CELL MOL MED, V16, P349, DOI 10.1111/j.1582-4934.2011.01304.x; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Sun HY, 2011, EXP BIOL MED, V236, P352, DOI 10.1258/ebm.2010.010106; Tanaka K, 2009, P JPN ACAD B-PHYS, V85, P12, DOI [10.2183/pjab.85.12, 10.2183/pjab/85.12]; van den Hurk K, 2012, BBA-REV CANCER, V1826, P89, DOI 10.1016/j.bbcan.2012.03.011; Verstraete K, 2012, NAT REV CANCER, V12, P753, DOI 10.1038/nrc3371; Wang Haibin, 2018, Oncotarget, V9, P35512, DOI 10.18632/oncotarget.26283; Wang YH, 2018, J PATHOL, V246, P508, DOI 10.1002/path.5164; Wang Z, 2018, CELL SIGNAL, V52, P137, DOI 10.1016/j.cellsig.2018.09.007; Wei YY, 2013, P NATL ACAD SCI USA, V110, P6829, DOI 10.1073/pnas.1217002110; Yadav V, 2012, J BIOL CHEM, V287, P28087, DOI 10.1074/jbc.M112.377218; Yang H, 2017, ONCOGENE, V36, P3842, DOI 10.1038/onc.2016.526; Yao DY, 2013, HUM PATHOL, V44, P844, DOI 10.1016/j.humpath.2012.08.009; Yoshimoto N, 2017, METHODS MOL BIOL, V1487, P35, DOI 10.1007/978-1-4939-6424-6_3; Zhao Y, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0288-x	74	12	13	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2020	39	32					5468	5478		10.1038/s41388-020-1373-6	http://dx.doi.org/10.1038/s41388-020-1373-6		JUL 2020	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW4DS	32616888				2022-12-28	WOS:000545059900001
J	Chai, TF; Manu, KA; Casey, PJ; Wang, M				Chai, Tin Fan; Manu, Kanjoormana Aryan; Casey, Patrick J.; Wang, Mei			Isoprenylcysteine carboxylmethyltransferase is required for the impact of mutant KRAS on TAZ protein level and cancer cell self-renewal	ONCOGENE			English	Article							SMALL-MOLECULE INHIBITOR; STEM-CELLS; K-RAS; HIPPO PATHWAY; CARBOXYL METHYLTRANSFERASE; CONDITIONAL EXPRESSION; TUMOR-GROWTH; YAP; PROMOTES; RESISTANCE	Cancer stem cells possess the capacity for self-renewal and resistance to chemotherapy. It is therefore crucial to understand the molecular regulators of stemness in the quest to develop effective cancer therapies. TAZ is a transcription activator that promotes stem cell functions in post-development mammalian cells; suppression of TAZ activity reduces or eliminates cancer stemness in select cancers. Isoprenylcysteine carboxylmethyltransferase (ICMT) is the unique enzyme of the last step of posttranslational prenylation processing pathway that modifies several oncogenic proteins, including RAS. We found that suppression of ICMT results in reduced self-renewal/stemness in KRAS-driven pancreatic and breast cancer cells. Silencing of ICMT led to significant reduction of TAZ protein levels and loss of self-renewal ability, which could be reversed by overexpressing mutant KRAS, demonstrating the functional impact of ICMT modification on the ability of KRAS to control TAZ stability and function. Contrary to expectation, YAP protein levels appear to be much less susceptible than TAZ to the regulation by ICMT and KRAS, and YAP is less consequential in regulating stemness characteristics in these cells. Further, we found that the ICMT-dependent KRAS regulation of TAZ was mediated through RAF, but not PI3K, signaling. Functionally, we demonstrate that a signaling cascade from ICMT modification of KRAS to TAZ protein stability supports cancer cell self-renewal abilities in both in vitro and in vivo settings. In addition, studies using the proof-of-concept small molecule inhibitors of ICMT confirmed its role in regulating TAZ and self-renewal, demonstrating the potential utility of targeting ICMT to control aggressive KRAS-driven cancers.	[Chai, Tin Fan; Manu, Kanjoormana Aryan; Casey, Patrick J.; Wang, Mei] Duke NUS Med Sch, Program Canc & Stem Cell Biol, Singapore 169857, Singapore; [Chai, Tin Fan; Wang, Mei] Natl Univ Singapore, Dept Biochem, Singapore 117596, Singapore; [Casey, Patrick J.] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	National University of Singapore; National University of Singapore; Duke University	Wang, M (corresponding author), Duke NUS Med Sch, Program Canc & Stem Cell Biol, Singapore 169857, Singapore.; Wang, M (corresponding author), Natl Univ Singapore, Dept Biochem, Singapore 117596, Singapore.	mei.wang@duke-nus.edu.sg		Casey, Patrick/0000-0002-7366-9309; Kanjoormana Aryan, Manu/0000-0002-4437-6486; Wang, Mei/0000-0001-6887-6840	Ministry of Education [MOE2017-T2-1-039]; National Medical Research Council [NMRC/CIRG/1486/2018]	Ministry of Education; National Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The work is supported by Ministry of Education (MOE2017-T2-1-039) and National Medical Research Council (NMRC/CIRG/1486/2018) Singapore.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Awasthi N, 2013, CARCINOGENESIS, V34, P2361, DOI 10.1093/carcin/bgt227; Bahmad HF, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00347; Bartucci M, 2015, ONCOGENE, V34, P681, DOI 10.1038/onc.2014.5; Bender RHF, 2015, STEM CELLS, V33, P1998, DOI 10.1002/stem.1990; Bergo MO, 2000, J BIOL CHEM, V275, P17605, DOI 10.1074/jbc.C000079200; Bhat KPL, 2011, GENE DEV, V25, P2594, DOI 10.1101/gad.176800.111; Bisson I, 2009, CELL RES, V19, P683, DOI 10.1038/cr.2009.43; Boehm JS, 2007, CELL, V129, P1065, DOI 10.1016/j.cell.2007.03.052; Boggiano JC, 2011, DEV CELL, V21, P888, DOI 10.1016/j.devcel.2011.08.028; Calcagno AM, 2010, JNCI-J NATL CANCER I, V102, P1637, DOI 10.1093/jnci/djq361; Caruso C, 2019, CANCER DISCOV, V9, P988, DOI 10.1158/2159-8290.CD-NB2019-073; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; Chan SW, 2008, CANCER RES, V68, P2592, DOI 10.1158/0008-5472.CAN-07-2696; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Cushman I, 2009, J BIOL CHEM, V284, P27964, DOI 10.1074/jbc.M109.025296; Do MT, 2017, ONCOGENE, V36, P5757, DOI 10.1038/onc.2017.183; Garcia-Rendueles MER, 2015, CANCER DISCOV, V5, P1178, DOI 10.1158/2159-8290.CD-15-0330; Gierut JJ, 2015, STEM CELL RES, V15, P165, DOI 10.1016/j.scr.2015.06.003; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hirschhaeuser F, 2010, J BIOTECHNOL, V148, P3, DOI 10.1016/j.jbiotec.2010.01.012; Hong X, 2014, EMBO J, V33, P2447, DOI 10.15252/embj.201489385; Huang W, 2012, J BIOL CHEM, V287, P26245, DOI 10.1074/jbc.M112.382036; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Janes MR, 2018, CELL, V172, P578, DOI 10.1016/j.cell.2018.01.006; Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161; Kapoor A, 2014, CELL, V158, P185, DOI 10.1016/j.cell.2014.06.003; Kutner RH, 2009, NAT PROTOC, V4, P495, DOI 10.1038/nprot.2009.22; Lai D, 2011, CANCER RES, V71, P2728, DOI 10.1158/0008-5472.CAN-10-2711; Lau HY, 2017, ONCOGENE, V36, P3934, DOI 10.1038/onc.2016.508; Lau HY, 2014, CANCER BIOL THER, V15, P1280, DOI 10.4161/cbt.29692; Lau HK, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06477-7; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Lin LP, 2015, NAT GENET, V47, P250, DOI 10.1038/ng.3218; Manu KA, 2017, MOL CANCER THER, V16, P914, DOI 10.1158/1535-7163.MCT-16-0703; McFall A, 2001, MOL CELL BIOL, V21, P5488, DOI 10.1128/MCB.21.16.5488-5499.2001; Meng ZP, 2016, GENE DEV, V30, P1, DOI 10.1101/gad.274027.115; Mo JS, 2014, EMBO REP, V15, P642, DOI 10.15252/embr.201438638; Moon BS, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt373; Pattabiraman DR, 2014, NAT REV DRUG DISCOV, V13, P497, DOI 10.1038/nrd4253; Pichot CS, 2009, BRIT J CANCER, V101, P38, DOI 10.1038/sj.bjc.6605101; Plouffe SW, 2018, J BIOL CHEM, V293, P11230, DOI 10.1074/jbc.RA118.002715; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Poon CLC, 2011, DEV CELL, V21, P896, DOI 10.1016/j.devcel.2011.09.012; Prieto-Vila M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122574; Reddy BVVG, 2013, DEV CELL, V24, P459, DOI 10.1016/j.devcel.2013.01.020; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Shaheen S, 2016, STEM CELL REV REP, V12, P492, DOI 10.1007/s12015-016-9664-6; Shao DD, 2014, CELL, V158, P171, DOI 10.1016/j.cell.2014.06.004; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; Teh JT, 2015, ONCOGENE, V34, P3296, DOI 10.1038/onc.2014.260; Teh JT, 2019, MOL CANCER THER, V18, P693, DOI 10.1158/1535-7163.MCT-18-0766; Touil Y, 2014, CLIN CANCER RES, V20, P837, DOI 10.1158/1078-0432.CCR-13-1854; Valent P, 2012, NAT REV CANCER, V12, P767, DOI 10.1038/nrc3368; Van den Broeck A, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-354; Varelas X, 2014, DEVELOPMENT, V141, P1614, DOI 10.1242/dev.102376; Vitale-Cross L, 2004, CANCER RES, V64, P8804, DOI 10.1158/0008-5472.CAN-04-2623; Wang M, 2010, ONCOGENE, V29, P4959, DOI 10.1038/onc.2010.247; Wang M, 2008, J BIOL CHEM, V283, P18678, DOI 10.1074/jbc.M801855200; Wang M, 2016, NAT REV MOL CELL BIO, V17, P110, DOI 10.1038/nrm.2015.11; Winter-Vann AM, 2005, NAT REV CANCER, V5, P405, DOI 10.1038/nrc1612; Winter-Vann AM, 2005, P NATL ACAD SCI USA, V102, P4336, DOI 10.1073/pnas.0408107102; Yuan XP, 2004, ONCOGENE, V23, P9392, DOI 10.1038/sj.onc.1208311; Yuan YL, 2016, MOL MED REP, V13, P237, DOI 10.3892/mmr.2015.4550; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zanconato F, 2016, EMBO J, V35, P459, DOI 10.15252/embj.201593584; Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zhang WY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005049; Zhang ZK, 2019, MOL CELL, V73, P7, DOI 10.1016/j.molcel.2018.10.030; Zhao X, 2017, CANCER LETT, V402, P61, DOI 10.1016/j.canlet.2017.05.015; Zhao YL, 2018, MOL CANCER RES, V16, P1046, DOI 10.1158/1541-7786.MCR-17-0593; Zhou Z, 2011, ONCOGENE, V30, P2181, DOI 10.1038/onc.2010.606; Zhu WL, 2011, J BIOL CHEM, V286, P35291, DOI 10.1074/jbc.M111.280990	78	7	7	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 30	2020	39	31					5373	5389		10.1038/s41388-020-1364-7	http://dx.doi.org/10.1038/s41388-020-1364-7		JUN 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MT1TS	32561852	hybrid, Green Published			2022-12-28	WOS:000541308400004
J	Richart, L; Felipe, I; Delgado, P; de Andres, MP; Prieto, J; del Pozo, N; Garcia, JF; Piris, MA; Ramiro, A; Real, FX				Richart, Laia; Felipe, Irene; Delgado, Pilar; de Andres, Monica P.; Prieto, Jaime; del Pozo, Natalia; Garcia, Juan F.; Piris, Miguel A.; Ramiro, Almudena; Real, Francisco X.			Bptf determines oncogenic addiction in aggressive B-cell lymphomas	ONCOGENE			English	Article							BURKITTS-LYMPHOMA; DISTINCT TYPES; MYC; CANCER; MODEL; PATHWAY; DRIVEN; GENES; MOUSE	Chromatin remodeling factors contribute to establish aberrant gene expression programs in cancer cells and therefore represent valuable targets for therapeutic intervention. BPTF (Bromodomain PhD Transcription Factor), a core subunit of the nucleosome remodeling factor (NURF), modulates c-MYC oncogenic activity in pancreatic cancer. Here, we analyze the role of BPTF in c-MYC-driven B-cell lymphomagenesis using the E mu-Myc transgenic mouse model of aggressive B-cell lymphoma. We find that BPTF is required for normal B-cell differentiation without evidence of haploinsufficiency. In contrast, deletion of one Bptf allele is sufficient to delay lymphomagenesis in E mu-Myc mice. Tumors arising in a Bptf heterozygous background display decreased c-MYC levels and pathway activity, together with increased activation of the NF-kappa B pathway, a molecular signature characteristic of human diffuse large B-cell lymphoma (DLBCL). In human B-cell lymphoma samples, we find a strong correlation between BPTF and c-MYC mRNA and protein levels, together with an anti-correlation between BPTF and NF-kappa B pathway activity. Our results indicate that BPTF is a relevant therapeutic target in B-cell lymphomas and that, upon its inhibition, cells acquire distinct oncogenic dependencies.	[Richart, Laia; Felipe, Irene; de Andres, Monica P.; Prieto, Jaime; del Pozo, Natalia; Real, Francisco X.] CNIO, Spanish Natl Canc Res Ctr, Mol Oncol Programme, Epithelial Carcinogenesis Grp, Madrid 28029, Spain; [Delgado, Pilar; Ramiro, Almudena] CNIC, B Lymphocyte Biol Lab, Madrid 28029, Spain; [del Pozo, Natalia; Piris, Miguel A.; Real, Francisco X.] Ctr Invest Biomed Red Canc CIBERONC, Madrid 28029, Spain; [Garcia, Juan F.] MD Anderson Canc Ctr, Dept Pathol, Madrid 28033, Spain; [Piris, Miguel A.] Fdn Jimenez Diaz, Dept Pathol, Madrid 28040, Spain; [Piris, Miguel A.] Hosp Univ Marques de Valdecilla, Dept Pathol, Santander 39008, Spain; [Real, Francisco X.] Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Barcelona 08003, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Cardiovasculares (CNIC); CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; University of Texas System; UTMD Anderson Cancer Center; Hospital Universitario Marques de Valdecilla (HUMV); Pompeu Fabra University	Real, FX (corresponding author), CNIO, Spanish Natl Canc Res Ctr, Mol Oncol Programme, Epithelial Carcinogenesis Grp, Madrid 28029, Spain.; Real, FX (corresponding author), Ctr Invest Biomed Red Canc CIBERONC, Madrid 28029, Spain.; Real, FX (corresponding author), Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Barcelona 08003, Spain.	preal@cnio.es	Delgado, Pilar/F-3365-2016; Arribas, Francisco X Real/H-5275-2015; FELIPE, IRENE/ABF-9743-2021; Ramiro, Almudena R/H-6037-2015	Delgado, Pilar/0000-0002-8431-8002; Arribas, Francisco X Real/0000-0001-9501-498X; FELIPE, IRENE/0000-0001-7781-1459; Ramiro, Almudena R/0000-0002-7539-3844	(Ministerio de Ciencia, Innovacion y Universidades, Madrid, Spain) (ERDF-EU) [SAF2011-29530, SAF2015-70553-R, RTI2018-101071-B-I00]; RTICC [RD12/0036/0034, RD12/0036/0050]; ERC [StG BCLYM-207844, SAF2013-42767-R, SAF2016-75511-R]; Fondo Europeo de Desarrollo Regional (FEDER); Ministerio de Ciencia, Innovacion y Universidades as a Centro de Excelencia Severo Ochoa [SEV-2015-0510]; Ministerio de Ciencia, Innovacion y Universidades (MCNU); Pro CNIC Foundation; Asociacion Espanola Contra el Cancer; Amigos del CNIO/Juegaterapia; Ministerio de Ciencia, Innovacion y Universidades, Spain	(Ministerio de Ciencia, Innovacion y Universidades, Madrid, Spain) (ERDF-EU); RTICC(Instituto de Salud Carlos III); ERC(European Research Council (ERC)European Commission); Fondo Europeo de Desarrollo Regional (FEDER)(European CommissionSpanish Government); Ministerio de Ciencia, Innovacion y Universidades as a Centro de Excelencia Severo Ochoa; Ministerio de Ciencia, Innovacion y Universidades (MCNU)(Spanish Government); Pro CNIC Foundation; Asociacion Espanola Contra el Cancer; Amigos del CNIO/Juegaterapia; Ministerio de Ciencia, Innovacion y Universidades, Spain(Spanish Government)	We thank the CNIO Core facilities and ECG members for support, V. J. Sanchez-Arevalo for valuable discussions, E. Carrillo-de-Santa Pau for discussion on bioinformatics analyses, and V. de Yebenes for critical comments to a previous version of the manuscript. We thank M. Reth and C. Blanco for providing Mb1-Cre and E mu-Myc mice, respectively. FXR was supported, in part, by grants SAF2011-29530, SAF2015-70553-R, RTI2018-101071-B-I00, and RTI2018-101071-B-I00 (Ministerio de Ciencia, Innovacion y Universidades, Madrid, Spain) (co-funded by the ERDF-EU) and RTICC (RD12/0036/0034, RD12/0036/0050, Instituto de Salud Carlos III). AR was supported by ERC StG BCLYM-207844, SAF2013-42767-R, and SAF2016-75511-R grants and co-funding by Fondo Europeo de Desarrollo Regional (FEDER). CNIO is supported by Ministerio de Ciencia, Innovacion y Universidades as a Centro de Excelencia Severo Ochoa SEV-2015-0510. The CNIC is supported by the Ministerio de Ciencia, Innovacion y Universidades (MCNU) and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (SEV-2015-0505). Personal grants: PD and JP, Asociacion Espanola Contra el Cancer; IF, Amigos del CNIO/Juegaterapia; MPA, Ministerio de Ciencia, Innovacion y Universidades, Spain. FXR acknowledges the support of Asociacion Espanola Contra el Cancer.	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Balbas-Martinez C, 2013, NAT GENET, V45, P1464, DOI 10.1038/ng.2799; Bishop PC, 2000, CANCER INVEST, V18, P574, DOI 10.3109/07357900009012197; Dar AA, 2016, P NATL ACAD SCI USA, V113, P6254, DOI 10.1073/pnas.1606027113; Dave SS, 2006, NEW ENGL J MED, V354, P2431, DOI 10.1056/NEJMoa055759; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Frey WD, 2017, STEM CELL REP, V9, P23, DOI 10.1016/j.stemcr.2017.04.031; Gonzalez-Perez A., 2013, GENOME BIOL, V14, pr106; Grana O, 2018, CURR BIOINFORM, V13, P583, DOI 10.2174/1574893612666170810153850; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; Hobeika E, 2006, P NATL ACAD SCI USA, V103, P13789, DOI 10.1073/pnas.0605944103; Hummel M, 2006, NEW ENGL J MED, V354, P2419, DOI 10.1056/NEJMoa055351; Iritani BM, 1997, EMBO J, V16, P7019, DOI 10.1093/emboj/16.23.7019; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Keller U, 2005, ONCOGENE, V24, P6231, DOI 10.1038/sj.onc.1208779; Klapper W, 2008, BLOOD, V112, P1374, DOI 10.1182/blood-2008-01-136465; Klapproth K, 2009, BLOOD, V114, P2448, DOI 10.1182/blood-2008-09-181008; Landry J, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000241; Landry JW, 2011, GENE DEV, V25, P275, DOI 10.1101/gad.2007311; Lee SCW, 2013, BLOOD, V122, P2654, DOI 10.1182/blood-2013-02-484055; Li HT, 2006, NATURE, V442, P91, DOI 10.1038/nature04802; Lunning MA, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.89; Malysheva V, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0310-3; Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108; Michalak EM, 2009, CELL DEATH DIFFER, V16, P684, DOI 10.1038/cdd.2008.195; Mori S, 2008, CANCER RES, V68, P8525, DOI 10.1158/0008-5472.CAN-08-1329; Morin RD, 2011, NATURE, V476, P298, DOI 10.1038/nature10351; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Oeckinghaus A, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000034; Pasqualucci L, 2008, NAT GENET, V40, P108, DOI 10.1038/ng.2007.35; Pfister SX, 2017, NAT REV DRUG DISCOV, V16, P241, DOI 10.1038/nrd.2016.256; Pujana MA, 2007, NAT GENET, V39, P1338, DOI 10.1038/ng.2007.2; Rempel RE, 2014, MOL CANCER THER, V13, P3219, DOI 10.1158/1535-7163.MCT-13-0044; Richart L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10153; Ruthenburg AJ, 2011, CELL, V145, P692, DOI 10.1016/j.cell.2011.03.053; Sabo A, 2014, NATURE, V511, P488, DOI 10.1038/nature13537; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Xu BW, 2018, STEM CELL REP, V10, P675, DOI 10.1016/j.stemcr.2018.01.020; Yang YB, 2012, CANCER CELL, V21, P723, DOI 10.1016/j.ccr.2012.05.024; Yang ZH, 2018, J CLIN INVEST, V128, P3605, DOI 10.1172/JCI97072; Yu DN, 2005, ANN NY ACAD SCI, V1059, P145, DOI 10.1196/annals.1339.047	42	2	3	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 18	2020	39	25					4884	4895		10.1038/s41388-020-1331-3	http://dx.doi.org/10.1038/s41388-020-1331-3		MAY 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LZ3HT	32451433				2022-12-28	WOS:000535403900001
J	Dellle Cave, D; Di Guida, M; Costa, V; Sevillano, M; Ferrante, L; Heeschen, C; Corona, M; Cucciardi, A; Lonardo, E				Dellle Cave, Donatella; Di Guida, Martina; Costa, Valerio; Sevillano, Marta; Ferrante, Luigi; Heeschen, Christopher; Corona, Marco; Cucciardi, Antonio; Lonardo, Enza			TGF-beta 1 secreted by pancreatic stellate cells promotes stemness and tumourigenicity in pancreatic cancer cells through L1CAM downregulation	ONCOGENE			English	Article							DUCTAL ADENOCARCINOMA; ADHESION MOLECULE; PROGNOSTIC VALUE; UP-REGULATION; SELF-RENEWAL; EXPRESSION; L1; PROTEIN; PROVIDES; BINDING	Pancreatic stellate cells (PSCs) secrete high levels of transforming growth factor-beta 1 (TGF-beta 1) that contributes to the development of pancreatic ductal adenocarcinoma (PDAC). TGF-beta 1 modulates the expression of L1 cell adhesion molecule (L1CAM), but its role in tumour progression still remains controversial. To clarify L1 function in PDAC and cellular phenotypes, we performed L1CAM cell sorting, silencing and overexpression in several primary pancreatic cancer cells. PSCs silenced for TGF-beta 1 were used for crosstalk experiments. We found that TGF-beta 1 secreted by PSCs negatively regulates L1CAM expression, through canonical TGF-beta-Smad2/3 signalling, leading to a more aggressive PDAC phenotype. Cells with reduced expression of L1CAM harboured enhanced stemness potential and tumourigenicity. Inactivation of TGF-beta 1 signalling in PSCs strongly reduced the aggressiveness of PDAC cells. Our data provide functional proof and mechanistic insights for the tumour-suppressive function of L1CAM via reducing stemness. Rescuing L1CAM expression in cancer cells through targeting of TGF-beta 1 reverses stemness and bears the potential to improve the still miserable prognosis of PDAC patients.	[Dellle Cave, Donatella; Di Guida, Martina; Costa, Valerio; Ferrante, Luigi; Corona, Marco; Cucciardi, Antonio; Lonardo, Enza] CNR, Inst Genet & Biophys Adriano Buzzati Traverso IGB, Via Pietro Castellino 111, I-80131 Naples, Italy; [Sevillano, Marta] Barcelona Inst Sci & Technol, IRB, Barcelona, Spain; [Heeschen, Christopher; Lonardo, Enza] CNIO, Spanish Natl Canc Res Ctr, Madrid, Spain	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; Centro Nacional de Investigaciones Oncologicas (CNIO)	Lonardo, E (corresponding author), CNR, Inst Genet & Biophys Adriano Buzzati Traverso IGB, Via Pietro Castellino 111, I-80131 Naples, Italy.; Lonardo, E (corresponding author), CNIO, Spanish Natl Canc Res Ctr, Madrid, Spain.	enza.lonardo@igb.cnr.it	Costa, Valerio/K-4505-2016; Delle Cave, Donatella/AAM-2941-2021	Costa, Valerio/0000-0002-7294-6933; Delle Cave, Donatella/0000-0002-4019-2778; Lonardo, Enza/0000-0001-6654-1043; corona, marco/0000-0002-3727-6444; SEVILLANO, MARTA/0000-0001-5761-0879	Marie Curie IF (H2020MSCA-IF-2015) [703753]; my first AIRC grant (MFAG-2017) [20206]; POR Campania FESR 2014/2020 (Project SATIN)	Marie Curie IF (H2020MSCA-IF-2015); my first AIRC grant (MFAG-2017); POR Campania FESR 2014/2020 (Project SATIN)	This work was supported by the: Marie Curie IF (H2020MSCA-IF-2015, #703753) to EL, my first AIRC grant (MFAG-2017, #20206) to EL and POR Campania FESR 2014/2020 (Project SATIN) to EL and VC.	Altevogt P, 2016, INT J CANCER, V138, P1565, DOI 10.1002/ijc.29658; Aponte PM, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/5619472; Apte MV, 2004, PANCREAS, V29, P179, DOI 10.1097/00006676-200410000-00002; Bachem MG, 2008, LANGENBECK ARCH SURG, V393, P891, DOI 10.1007/s00423-008-0279-5; Ben QW, 2010, ANN SURG ONCOL, V17, P2213, DOI 10.1245/s10434-010-0955-x; Bergmann F, 2010, ONCOL REP, V24, P909, DOI 10.3892/or_00000936; Er EE, 2019, NAT CELL BIOL, V21, P408, DOI 10.1038/s41556-018-0257-2; Feig C, 2012, CLIN CANCER RES, V18, P4266, DOI 10.1158/1078-0432.CCR-11-3114; Foucher ED, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01044; Geismann C, 2011, INT J ONCOL, V38, P257, DOI 10.3892/ijo_00000846; Geismann C, 2009, CANCER RES, V69, P4517, DOI 10.1158/0008-5472.CAN-08-3493; Haspel J, 2003, FRONT BIOSCI-LANDMRK, V8, pS1210, DOI 10.2741/1108; He J, 2018, ONCOTARGET, V9, P1326, DOI 10.18632/oncotarget.19847; Hwang RF, 2008, CANCER RES, V68, P918, DOI 10.1158/0008-5472.CAN-07-5714; Javle M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085942; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kaifi JT, 2006, ANTICANCER RES, V26, P1167; Kaifi JT, 2006, WORLD J GASTROENTERO, V12, P94, DOI 10.3748/wjg.v12.i1.94; Kiefel H, 2012, CARCINOGENESIS, V33, P1919, DOI 10.1093/carcin/bgs220; Kim HS, 2012, INT J CLIN EXP PATHO, V5, P754; KOWITZ A, 1993, CLIN EXP METASTAS, V11, P419, DOI 10.1007/BF00132985; Phi LTH, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/5416923; Li XP, 2015, INT J CLIN EXP PATHO, V8, P12084; Locke M, 2005, CANCER RES, V65, P8944, DOI 10.1158/0008-5472.CAN-05-0931; Lonardo E, 2015, JOVE-J VIS EXP, DOI 10.3791/52801; Lonardo E, 2012, CELL CYCLE, V11, P1282, DOI 10.4161/cc.19679; Lonardo E, 2011, CELL STEM CELL, V9, P433, DOI 10.1016/j.stem.2011.10.001; Garcia-Heredia JM, 2017, CLIN CANCER RES, V23, P3871, DOI 10.1158/1078-0432.CCR-16-2358; Marzoq AJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41740-x; Miranda-Lorenzo I, 2014, NAT METHODS, V11, P1161, DOI [10.1038/NMETH.3112, 10.1038/nmeth.3112]; Mizukami T, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-687; Moulla A, 2013, POL J PATHOL, V64, P180, DOI 10.5114/PJP.2013.38135; Na'ara S, 2019, ONCOGENE, V38, P596, DOI 10.1038/s41388-018-0458-y; Pechriggl EJ, 2017, J HISTOCHEM CYTOCHEM, V65, P21, DOI 10.1369/0022155416677241; Roa-Pena L, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47519-4; Rubio-Viqueira B, 2006, CLIN CANCER RES, V12, P4652, DOI 10.1158/1078-0432.CCR-06-0113; Schirmer U, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4928-y; Schroder C, 2009, ONCOL REP, V22, P1109, DOI 10.3892/or_00000543; Shen W, 2017, CELL BIOSCI, V7, DOI 10.1186/s13578-017-0168-0; Soovares P, 2017, GYNECOL ONCOL, V146, P615, DOI 10.1016/j.ygyno.2017.06.010; Tang DY, 2015, EXP CELL RES, V330, P336, DOI [10.1016/j.yexcr.10.021, 10.1016/j.yexcr.2014.10.021]; Tsutsumi S, 2011, J SURG ONCOL, V103, P669, DOI 10.1002/jso.21880; Uhlen M, 2010, NAT BIOTECHNOL, V28, P1248, DOI 10.1038/nbt1210-1248; Valiente M, 2014, CELL, V156, P1002, DOI 10.1016/j.cell.2014.01.040; Valle S, 2018, CANCERS, V10, DOI 10.3390/cancers10020033; Wachowiak R, 2007, ANN SURG ONCOL, V14, P3575, DOI 10.1245/s10434-007-9608-0	46	31	32	3	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	21					4271	4285		10.1038/s41388-020-1289-1	http://dx.doi.org/10.1038/s41388-020-1289-1		APR 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LQ2DH	32291413	Green Published, hybrid			2022-12-28	WOS:000526237900002
J	Ramirez-Moya, J; Baker, AR; Slack, FJ; Santisteban, P				Ramirez-Moya, Julia; Baker, Allison R.; Slack, Frank J.; Santisteban, Pilar			ADAR1-mediated RNA editing is a novel oncogenic process in thyroid cancer and regulates miR-200 activity	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; E-CADHERIN; ADAR1 PROMOTES; ZEB1; MICRORNAS; FAMILY; PHENOTYPE; CELLS; PATHOGENESIS; METASTASIS	Adenosine deaminases acting on RNA (ADARs) convert adenosine to inosine in double-stranded RNA. A-to-I editing of RNA is a widespread posttranscriptional process that has recently emerged as an important mechanism in cancer biology. A-to-I editing levels are high in several human cancers, including thyroid cancer, but ADAR1 editase-dependent mechanisms governing thyroid cancer progression are unexplored. To address the importance of RNA A-to-I editing in thyroid cancer, we examined the role of ADAR1. Loss-of-function analysis showed that ADAR1 suppression profoundly repressed proliferation, invasion, and migration in thyroid tumor cell models. These observations were validated in an in vivo xenograft model, which showed that ADAR1-silenced cells had a diminished ability to form tumors. RNA editing of miRNAs has the potential to markedly alter target recognition. According to TCGA data, the tumor suppressor miR-200b is overedited in thyroid tumors, and its levels of editing correlate with a worse progression-free survival and disease stage. We confirmed miR-200b overediting in thyroid tumors and we showed that edited miR-200b has weakened activity against its target gene ZEB1 in thyroid cancer cells, likely explaining the reduced aggressiveness of ADAR1-silenced cells. We also found that RAS, but not BRAF, modulates ADAR1 levels, an effect mediated predominantly by PI3K and in part by MAPK. Lastly, pharmacological inhibition of ADAR1 activity with the editing inhibitor 8-azaadenosine reduced cancer cell aggressiveness. Overall, our data implicate ADAR1-mediated A-to-I editing as an important pathway in thyroid cancer progression, and highlight RNA editing as a potential therapeutic target in thyroid cancer.	[Ramirez-Moya, Julia; Santisteban, Pilar] Univ Autonoma Madrid, Inst Invest Biomed Alberto Sols, Madrid, Spain; [Ramirez-Moya, Julia; Santisteban, Pilar] Univ Autonoma Madrid, Consejo Super Invest Cient, Madrid, Spain; [Ramirez-Moya, Julia; Baker, Allison R.; Slack, Frank J.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Pathol, Harvard Med Sch Initiat RNA Med, Boston, MA 02115 USA; [Ramirez-Moya, Julia; Santisteban, Pilar] Inst Salud Carlos III ISCII, Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC	Santisteban, P (corresponding author), Univ Autonoma Madrid, Inst Invest Biomed Alberto Sols, Madrid, Spain.; Santisteban, P (corresponding author), Univ Autonoma Madrid, Consejo Super Invest Cient, Madrid, Spain.; Santisteban, P (corresponding author), Inst Salud Carlos III ISCII, Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain.	psantisteban@iib.uam.es	Ramírez-Moya, Julia/B-9104-2018	Ramírez-Moya, Julia/0000-0002-2458-2186; Slack, Frank/0000-0001-8263-0409; Baker, Allison/0000-0003-2030-7379	Ministerio de Ciencia e Innovacion (MICIN), Spain [SAF2016-75531-R]; Comunidad de Madrid [B2017/BMD-3724]; Fundacion Espanola contra el Cancer (AECC) [GCB14142311CRES]; Ludwig Center at Harvard; MECD (Spain); Fondo Europeo de Desarrollo Regional FEDER	Ministerio de Ciencia e Innovacion (MICIN), Spain(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Comunidad de Madrid(Comunidad de Madrid); Fundacion Espanola contra el Cancer (AECC); Ludwig Center at Harvard; MECD (Spain)(Spanish Government); Fondo Europeo de Desarrollo Regional FEDER(European CommissionSpanish Government)	This work was supported by grants SAF2016-75531-R from Ministerio de Ciencia e Innovacion (MICIN), Spain, Fondo Europeo de Desarrollo Regional FEDER, B2017/BMD-3724 from Comunidad de Madrid, and GCB14142311CRES from Fundacion Espanola contra el Cancer (AECC) (To PS), and by the Ludwig Center at Harvard (To FJS). JR-M hold a FPU fellowship from MECD (Spain).	Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; Antoni D, 2015, INT J MOL SCI, V16, P5517, DOI 10.3390/ijms16035517; Bass BL, 2002, ANNU REV BIOCHEM, V71, P817, DOI 10.1146/annurev.biochem.71.110601.135501; Baysal BE, 2017, CANCER RES, V77, P3733, DOI 10.1158/0008-5472.CAN-17-0520; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Braun J, 2010, ONCOGENE, V29, P4237, DOI 10.1038/onc.2010.169; Butz Henriett, 2019, EJIFCC, V30, P146; Cho CJ, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040799; Crews LA, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-014-0370-3; Feng B, 2012, BIOMED PHARMACOTHER, V66, P397, DOI 10.1016/j.biopha.2012.06.002; Feng XL, 2014, CANCER LETT, V344, P166, DOI 10.1016/j.canlet.2013.11.004; Fritzell K, 2018, SEMIN CELL DEV BIOL, V79, P123, DOI 10.1016/j.semcdb.2017.11.018; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Gannon HS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07824-4; Gregory PA, 2008, CELL CYCLE, V7, P3112, DOI 10.4161/cc.7.20.6851; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Han L, 2015, CANCER CELL, V28, DOI 10.1016/j.ccell.2015.08.013; Ishizuka JJ, 2019, NATURE, V565, P43, DOI 10.1038/s41586-018-0768-9; Jia BQ, 2012, MOL CELL BIOCHEM, V366, P223, DOI 10.1007/s11010-012-1299-6; Jiang QF, 2013, P NATL ACAD SCI USA, V110, P1041, DOI 10.1073/pnas.1213021110; Keegan LP, 2001, NAT REV GENET, V2, P869, DOI 10.1038/35098584; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; Lehmann KA, 1999, J MOL BIOL, V291, P1, DOI 10.1006/jmbi.1999.2914; Lim H, 2017, JAMA-J AM MED ASSOC, V317, P1338, DOI 10.1001/jama.2017.2719; Lin SB, 2015, NAT REV CANCER, V15, P321, DOI 10.1038/nrc3932; Liu HY, 2019, NAT MED, V25, P95, DOI 10.1038/s41591-018-0302-5; Liu X, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1300-2; Mitsutake N, 2005, CANCER RES, V65, P2465, DOI 10.1158/0008-5472.CAN-04-3314; Montemayor-Garcia C, 2013, ENDOCR PATHOL, V24, P206, DOI 10.1007/s12022-013-9272-9; Nemlich Y, 2013, J CLIN INVEST, V123, P2703, DOI 10.1172/JCI62980; Nishikura K, 2016, NAT REV MOL CELL BIO, V17, P83, DOI 10.1038/nrm.2015.4; Pallante P, 2014, NAT REV ENDOCRINOL, V10, P88, DOI 10.1038/nrendo.2013.223; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Paterson EL, 2008, THESCIENTIFICWORLDJO, V8, P901, DOI 10.1100/tsw.2008.115; Paz-Yaacov N, 2015, CELL REP, V13, P267, DOI 10.1016/j.celrep.2015.08.080; Qi LH, 2014, CANCER RES, V74, P1301, DOI 10.1158/0008-5472.CAN-13-3485; Qin YR, 2014, CANCER RES, V74, P840, DOI 10.1158/0008-5472.CAN-13-2545; Ramirez-Moya J, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00430; Ramirez-Moya J, 2019, ONCOGENE, V38, P5486, DOI 10.1038/s41388-019-0804-8; Ramirez-Moya J, 2018, ONCOGENE, V37, P3369, DOI 10.1038/s41388-017-0088-9; Riesco-Eizaguirre G, 2015, CANCER RES, V75, P4119, DOI 10.1158/0008-5472.CAN-14-3547; Sanchez-Tillo E, 2010, ONCOGENE, V29, P3490, DOI 10.1038/onc.2010.102; Sastre-Perona A, 2016, ONCOTARGET, V7, P49435, DOI 10.18632/oncotarget.10356; Shen AD, 2012, J SURG ONCOL, V105, P830, DOI 10.1002/jso.23012; Shirokawa JM, 2000, MOL ENDOCRINOL, V14, P1725, DOI 10.1210/me.14.11.1725; Shoshan E, 2015, NAT CELL BIOL, V17, P311, DOI 10.1038/ncb3110; Song C, 2016, GENES-BASEL, V7, DOI 10.3390/genes7120129; SPREMULLI EN, 1983, J NATL CANCER I, V70, P499; Wahlstedt H, 2009, GENOME RES, V19, P978, DOI 10.1101/gr.089409.108; Walkley CR, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1347-3; Wang HF, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-282; Wang YM, 2017, GENOME RES, V27, P1112, DOI 10.1101/gr.219741.116; Xing MZ, 2013, NAT REV CANCER, V13, P184, DOI 10.1038/nrc3431; Xu L., 2018, SUSTAINABILITY, V10, P1, DOI [10.3390/su10020001, DOI 10.3390/genes10010012]; Zaballos MA, 2017, J ENDOCRINOL, V235, pR43, DOI 10.1530/JOE-17-0266; Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028; Zhang JX, 2013, MOL BIOL REP, V40, P949, DOI 10.1007/s11033-012-2136-4; Zhang PJ, 2015, CELL CYCLE, V14, P481, DOI 10.1080/15384101.2015.1006048; Zhang XP, 2019, INT J NONLIN SCI NUM, V20, P1, DOI 10.1515/ijnsns-2017-0166; Zhang YC, 2016, INT J FUTUR GENER CO, V9, P1, DOI 10.14257/ijfgcn.2016.9.10.01; Zipeto MA, 2016, CELL STEM CELL, V19, P177, DOI 10.1016/j.stem.2016.05.004	61	38	39	4	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	18					3738	3753		10.1038/s41388-020-1248-x	http://dx.doi.org/10.1038/s41388-020-1248-x		MAR 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LI5XR	32157211	hybrid, Green Published			2022-12-28	WOS:000518886000002
J	Zhang, ML; Lin, X; Zhang, JP; Su, L; Ma, MM; Ea, VL; Liu, X; Wang, LM; Chang, J; Li, XR; Zhang, XM				Zhang, Mingliang; Lin, Xiao; Zhang, Jinping; Su, Lin; Ma, Mingming; Ea, Vicki L.; Liu, Xun; Wang, Liming; Chang, Jin; Li, Xiaorong; Zhang, Xiaomin			Blue light-triggered optogenetic system for treating uveal melanoma	ONCOGENE			English	Article							PHOTODYNAMIC THERAPY; EXPRESSION	Uveal melanoma is the most common intraocular primary malignancy in adults and has been considered a fatal disease for decades. Optogenetics is an emerging technique that can control the activation of signaling components via irradiation with visible light. The clinical translation of optogenetics has been limited because of the need for surgical implantation of electrodes and relatively shallow tissue penetration. As visible light easily penetrates the eyes, we hypothesized that an optogenetics approach can be an effective treatment of uveal melanoma without surgery. In this study, we evaluated the feasibility of this strategy by using a genetically encoded optogenetic system based on reversible blue light-induced binding pairs between Fas-CIB1-EGFP and CRY2-mCherry-FADD. Subretinal injection of B16 cells was performed to create a uveal melanoma model. Plasmids pairs were co-transfected into B16 cells. We found that blue light irradiation dynamically controlled the translocation of FADD to Fas on the plasma membrane and induced the apoptosis of B16 cells transfected with the optogenetic nanosystem in vitro. Moreover, the blue light-controlled optogenetic nanosystem suppressed the growth of uveal melanoma in vivo by inducing apoptosis. These results suggest that light-controlled optogenetic therapy can be used as a potential novel therapeutic strategy for uveal melanoma.	[Zhang, Mingliang; Lin, Xiao; Zhang, Jinping; Su, Lin; Ma, Mingming; Ea, Vicki L.; Liu, Xun; Wang, Liming; Li, Xiaorong; Zhang, Xiaomin] Tianjin Med Univ, Tianjin Key Lab Retinal Funct & Dis, Inst Eye, Hosp Eye, 251 Fukang Rd, Tianjin 300384, Peoples R China; [Zhang, Mingliang; Lin, Xiao; Zhang, Jinping; Su, Lin; Ma, Mingming; Ea, Vicki L.; Liu, Xun; Wang, Liming; Li, Xiaorong; Zhang, Xiaomin] Tianjin Med Univ, Sch Optometry, Hosp Eye, 251 Fukang Rd, Tianjin 300384, Peoples R China; [Chang, Jin] Tianjin Univ, Sch Life Sci, 92 Weijin Rd, Tianjin 300072, Peoples R China	Tianjin Medical University; Tianjin Medical University; Tianjin University	Li, XR; Zhang, XM (corresponding author), Tianjin Med Univ, Tianjin Key Lab Retinal Funct & Dis, Inst Eye, Hosp Eye, 251 Fukang Rd, Tianjin 300384, Peoples R China.; Li, XR; Zhang, XM (corresponding author), Tianjin Med Univ, Sch Optometry, Hosp Eye, 251 Fukang Rd, Tianjin 300384, Peoples R China.	lixiaorong@tmu.edu.cn; xzhang08@tmu.edu.cn	Chang, Jin/B-1413-2016; zhang, jin/GXV-9154-2022	Zhang, Mingliang/0000-0003-2285-3592; Ea, Vicki/0000-0002-5450-6264; Zhang, Xiaomin/0000-0003-4898-4152	National Natural Science Foundation of China [81900894, 81671642, 81870651]; Natural Science Foundation of Tianjin [18JCQNJC11300]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Tianjin(Natural Science Foundation of Tianjin)	We thank Prof. Colin J. Barnstable for his contribution in revising this manuscript. This work was supported by grants from the National Natural Science Foundation of China (81900894, 81671642, 81870651) and Natural Science Foundation of Tianjin (18JCQNJC11300).	Alvarez-Rodriguez B, 2017, MED RES REV, V37, P1350, DOI 10.1002/med.21460; Amaro A, 2017, CANCER METAST REV, V36, P109, DOI 10.1007/s10555-017-9663-3; Blasi MA, 2018, BIOMEDICINES, V6, DOI 10.3390/biomedicines6010017; Canal-Fontcuberta I, 2012, RETINA-J RET VIT DIS, V32, P942, DOI 10.1097/IAE.0b013e31825097c1; Chen LX, 2009, ONCOL REP, V21, P917, DOI 10.3892/or_00000304; Chen S, 2018, SCIENCE, V359, P679, DOI 10.1126/science.aaq1144; Chen XY, 2013, INVEST OPHTH VIS SCI, V54, P2248, DOI 10.1167/iovs.12-10977; Damato BE, 2012, DEV OPHTHALMOL, V49, P16, DOI 10.1159/000328251; Deisseroth K, 2011, NAT METHODS, V8, P26, DOI 10.1038/NMETH.F.324; He L, 2015, ELIFE, V4, DOI 10.7554/eLife.10024; Jiang C, 2018, EUROPACE, V20, P1741, DOI 10.1093/europace/eux345; Jmor F, 2017, PHOTODIAGN PHOTODYN, V20, P175, DOI 10.1016/j.pdpdt.2017.10.018; Kennedy MJ, 2010, NAT METHODS, V7, P973, DOI 10.1038/NMETH.1524; Kim CK, 2017, NAT REV NEUROSCI, V18, P222, DOI 10.1038/nrn.2017.15; Konermann S, 2013, NATURE, V500, P472, DOI 10.1038/nature12466; Konig K, 1996, OPT LETT, V21, P1090, DOI 10.1364/OL.21.001090; Luo C, 2017, CANCER LETT, V397, P120, DOI 10.1016/j.canlet.2017.03.037; Moore AR, 2016, NAT GENET, V48, P675, DOI 10.1038/ng.3549; Oliva M, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.05.04; Sagoo MS, 2014, ONCOGENE, V33, P4722, DOI 10.1038/onc.2013.555; Shain AH, 2019, NAT GENET, V51, P1123, DOI 10.1038/s41588-019-0440-9; Shao JW, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal2298; Tanaka, 2012, WORLD J DERMATOL, V1, P30, DOI DOI 10.5314/WJD.V1.I3.30; Venza I, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0156-3; Xu YX, 2014, P NATL ACAD SCI USA, V111, P6371, DOI 10.1073/pnas.1319296111; Ye HF, 2019, CSH PERSPECT MED, V9, DOI 10.1101/cshperspect.a034371; Yu FX, 2014, CANCER CELL, V25, P822, DOI 10.1016/j.ccr.2014.04.017; Yu LL, 2017, J AM COLL CARDIOL, V70, P2778, DOI 10.1016/j.jacc.2017.09.1107; Zhang K, 2015, TRENDS BIOTECHNOL, V33, P92, DOI 10.1016/j.tibtech.2014.11.007; Zhang KW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098215; Zhang Y, 2009, J NEUROSCI, V29, P9186, DOI 10.1523/JNEUROSCI.0184-09.2009; Zheng B, 2018, BIOMATER SCI-UK, V6, P1379, DOI 10.1039/c8bm00218e; Zheng B, 2017, ACS NANO, V11, P11898, DOI 10.1021/acsnano.7b06395; Zhou YS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116095	34	8	8	2	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	10					2118	2124		10.1038/s41388-019-1119-5	http://dx.doi.org/10.1038/s41388-019-1119-5			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KS8UR	31811271				2022-12-28	WOS:000518584000007
J	He, YF; Mi, JQ; Olson, A; Aldahl, J; Hooker, E; Yu, EJ; Le, V; Lee, DH; Kim, WK; Robins, DM; Geradts, J; Sun, ZJ				He, Yongfeng; Mi, Jiaqi; Olson, Adam; Aldahl, Joseph; Hooker, Erika; Yu, Eun-Jeong; Le, Vien; Lee, Dong-Hoon; Kim, Won Kyung; Robins, Diane M.; Geradts, Joseph; Sun, Zijie			Androgen receptor with short polyglutamine tract preferably enhances Wnt/beta-catenin-mediated prostatic tumorigenesis	ONCOGENE			English	Article							BETA-CATENIN; CANCER; GENE; CAG; ACTIVATION; EXPRESSION; TRANSCRIPTION; PROGRESSION; POLYPOSIS; REPEATS	Polyglutamine (polyQ) tract polymorphism within the human androgen receptor (AR) shows population heterogeneity. African American men possess short polyQ tracts significantly more frequently than Caucasian American men. The length of polyQ tracts is inversely correlated with the risk of prostate cancer, age of onset, and aggressiveness at diagnosis. Aberrant activation of Wnt signaling also reveals frequently in advanced prostate cancer, and an enrichment of androgen and Wnt signaling activation has been observed in African American patients. Here, we assessed aberrant expression of AR bearing different polyQ tracts and stabilized beta-catenin in prostate tumorigenesis using newly generated mouse models. We observed an early onset oncogenic transformation, accelerated tumor cell growth, and aggressive tumor phenotypes in the compound mice bearing short polyQ tract AR and stabilized beta-catenin. RNA sequencing analysis showed a robust enrichment of Myc-regulated downstream genes in tumor samples bearing short polyQ AR versus those with longer polyQ tract AR. Upstream regulator analysis further identified Myc as the top candidate of transcriptional regulators in tumor cells from the above mouse samples with short polyQ tract AR and beta-catenin. Chromatin immunoprecipitation analyses revealed increased recruitment of beta-catenin and AR on the c-Myc gene regulatory locus in the tumor tissues expressing stabilized beta-catenin and shorter polyQ tract AR. These data demonstrate a promotional role of aberrant activation of Wnt/beta-catenin in combination with short polyQ AR expression in prostate tumorigenesis and suggest a potential mechanism underlying aggressive prostatic tumor development, which has been frequently observed in African American patients.	[He, Yongfeng; Mi, Jiaqi; Olson, Adam; Aldahl, Joseph; Hooker, Erika; Yu, Eun-Jeong; Le, Vien; Lee, Dong-Hoon; Kim, Won Kyung; Sun, Zijie] City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Biol, Duarte, CA 91010 USA; [Robins, Diane M.] Univ Michigan, Dept Human Genet, Sch Med, Ann Arbor, MI 48109 USA; [Geradts, Joseph] City Hope Natl Med Ctr, Beckman Res Inst, Dept Populat Sci, Duarte, CA 91010 USA; [Geradts, Joseph] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA	City of Hope; Beckman Research Institute of City of Hope; University of Michigan System; University of Michigan; City of Hope; Beckman Research Institute of City of Hope; Duke University	Sun, ZJ (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Biol, Duarte, CA 91010 USA.	zjsun@coh.org	Mi, Jiaqi/GVU-4732-2022; le, vien/GWV-7308-2022; He, Yongfeng/AAR-8257-2020	Mi, Jiaqi/0000-0002-6537-7795; Olson, Adam W./0000-0003-3118-0393; Hooker, Erika/0000-0002-4515-4041; Robins, Diane M./0000-0001-6727-6309	Public Health Service [R01CA070297, R01CA166894, R21CA190021, R01DK104941]	Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service)	This work was supported by Public Health Service grants R01CA070297, R01CA166894, R21CA190021, and R01DK104941.	Albertelli MA, 2006, MOL ENDOCRINOL, V20, P1248, DOI 10.1210/me.2006-0021; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bennett CL, 2002, J CLIN ONCOL, V20, P3599, DOI 10.1200/JCO.2002.11.085; Bierie B, 2003, ONCOGENE, V22, P3875, DOI 10.1038/sj.onc.1206426; Chesire DR, 2002, ONCOGENE, V21, P8453, DOI 10.1038/sj.onc.1206049; Choong CS, 1998, J MOL ENDOCRINOL, V21, P235, DOI 10.1677/jme.0.0210235; Clark Peter E, 2003, Methods Mol Med, V81, P255; Culig Z, 2003, UROLOGY, V62, P21, DOI 10.1016/S0090-4295(03)00698-8; DeSantis CE, 2019, CA-CANCER J CLIN, V69, P211, DOI 10.3322/caac.21555; Dess RT, 2019, JAMA ONCOL, V5, P975, DOI 10.1001/jamaoncol.2019.0826; Drost J, 2016, NAT PROTOC, V11, P347, DOI 10.1038/nprot.2016.006; FLEMING WH, 1986, CANCER RES, V46, P1535; Gann PH, 1996, J NATL CANCER I, V88, P1118, DOI 10.1093/jnci/88.16.1118; Gounari F, 2002, ONCOGENE, V21, P4099, DOI 10.1038/sj.onc.1205562; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Hsu F, 2006, BIOINFORMATICS, V22, P1036, DOI 10.1093/bioinformatics/btl048; IRVINE RA, 1995, CANCER RES, V55, P1937; Ittmann M, 2013, CANCER RES, V73, P2718, DOI 10.1158/0008-5472.CAN-12-4213; Jenster G, 1999, SEMIN ONCOL, V26, P407; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Koh Cheryl M, 2010, Genes Cancer, V1, P617, DOI 10.1177/1947601910379132; Kumar R, 2019, CANCER RES, V79, P1353, DOI 10.1158/0008-5472.CAN-18-2383; KYPRIANOU N, 1988, ENDOCRINOLOGY, V122, P552, DOI 10.1210/endo-122-2-552; Lawrence M, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003118; Lee J, 2007, NUCLEIC ACIDS RES, V35, P4523, DOI 10.1093/nar/gkm476; Lee SH, 2016, ONCOGENE, V35, P702, DOI 10.1038/onc.2015.117; Mahmoudi T, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000539; McNamara MA, 2019, PROSTATE, V79, P1106, DOI 10.1002/pros.23822; MHATRE AN, 1993, NAT GENET, V5, P184, DOI 10.1038/ng1093-184; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; Mulholland DJ, 2002, J BIOL CHEM, V277, P17933, DOI 10.1074/jbc.M200135200; Pan HF, 2018, WORLD J SURG ONCOL, V16, DOI 10.1186/s12957-018-1352-3; Rennoll Sherri, 2015, World J Biol Chem, V6, P290, DOI 10.4331/wjbc.v6.i4.290; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Sartor O, 1999, UROLOGY, V53, P378, DOI 10.1016/S0090-4295(98)00481-6; Shukla S, 2013, PROSTATE, V73, P1507, DOI 10.1002/pros.22698; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Spratt DE, 2016, EUR UROL FOCUS, V2, P532, DOI 10.1016/j.euf.2016.03.010; Stanford JL, 1997, CANCER RES, V57, P1194; SUGIMURA Y, 1986, BIOL REPROD, V34, P973, DOI 10.1095/biolreprod34.5.973; Truica CI, 2000, CANCER RES, V60, P4709; Verras M, 2006, CANCER LETT, V237, P22, DOI 10.1016/j.canlet.2005.06.004; Wang BD, 2013, PROSTATE CANCER, V2013, DOI 10.1155/2013/763569; Wang J, 2010, CANCER RES, V70, P10182, DOI 10.1158/0008-5472.CAN-10-2414; Weischenfeldt J, 2013, CANCER CELL, V23, P159, DOI 10.1016/j.ccr.2013.01.002; Wu XT, 2001, MECH DEVELOP, V101, P61, DOI 10.1016/S0925-4773(00)00551-7; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200; Yu ZG, 2006, AM J PATHOL, V168, P195, DOI 10.2353/ajpath.2006.050619; Zhang L, 2012, TRANSGENIC RES, V21, P1117, DOI 10.1007/s11248-012-9598-y; Zheng CG, 2009, CANCER RES, V69, P2324, DOI 10.1158/0008-5472.CAN-08-4113; ZHOU ZX, 1994, RECENT PROG HORM RES, V49, P249; Zhu CF, 2011, J BIOL CHEM, V286, P33478, DOI 10.1074/jbc.M111.269894	54	7	7	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2020	39	16					3276	3291		10.1038/s41388-020-1214-7	http://dx.doi.org/10.1038/s41388-020-1214-7		FEB 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF9OJ	32089544	Green Accepted			2022-12-28	WOS:000515215100001
J	Chen, CL; Gupta, P; Parashar, D; Nair, GG; George, J; Geethadevi, A; Wang, W; Tsaih, SW; Bradley, W; Ramchandran, R; Rader, JS; Chaluvally-Raghavan, P; Pradeep, S				Chen, Changliang; Gupta, Prachi; Parashar, Deepak; Nair, Gopakumar G.; George, Jasmine; Geethadevi, Anjali; Wang, Wei; Tsaih, Shirng-Wern; Bradley, William; Ramchandran, Ramani; Rader, Janet S.; Chaluvally-Raghavan, Pradeep; Pradeep, Sunila			ERBB3-induced furin promotes the progression and metastasis of ovarian cancer via the IGF1R/STAT3 signaling axis	ONCOGENE			English	Article							STAT3; MUTATIONS; SURVIVAL; PATHWAY; TARGET; GROWTH; HEAD	High-grade serous carcinoma, accounts for up to 70% of all ovarian cases. Furin, a proprotein convertase, is highly expressed in high-grade serous carcinoma of ovarian cancer patients, and its expression is even higher in tumor omentum than in normal omentum, the preferred site of ovarian cancer metastasis. The proteolytic actions of this cellular endoprotease help the maturation of several important precursors of protein substrates and its levels increase the risk of several cancer. We show that furin activates the IGF1R/STAT3 signaling axis in ovarian cancer cells. Conversely, furin knockdown downregulated IGF1R-beta and p-STAT3 (Tyr705) expression. Further, silencing furin reduced tumor cell migration and invasion in vitro and tumor growth and metastasis in vivo. Collectively, our findings show that furin can be an effective therapeutic target for ovarian cancer prevention or treatment.	[Chen, Changliang; Gupta, Prachi; Parashar, Deepak; Nair, Gopakumar G.; George, Jasmine; Geethadevi, Anjali; Tsaih, Shirng-Wern; Bradley, William; Ramchandran, Ramani; Rader, Janet S.; Chaluvally-Raghavan, Pradeep; Pradeep, Sunila] Med Coll Wisconsin, Dept Obstet & Gynecol, Milwaukee, WI 53226 USA; [Wang, Wei] Case Western Reserve Univ, Metrohlth Med Res Ctr, Cleveland, OH 44106 USA; [Ramchandran, Ramani] Med Coll Wisconsin, Dept Pediat, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA; [Rader, Janet S.; Chaluvally-Raghavan, Pradeep; Pradeep, Sunila] Med Coll Wisconsin, Canc Ctr, Milwaukee, WI 53226 USA; [Chaluvally-Raghavan, Pradeep; Pradeep, Sunila] Med Coll Wisconsin, Dept Physiol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Case Western Reserve University; Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin	Pradeep, S (corresponding author), Med Coll Wisconsin, Dept Obstet & Gynecol, Milwaukee, WI 53226 USA.; Pradeep, S (corresponding author), Med Coll Wisconsin, Canc Ctr, Milwaukee, WI 53226 USA.; Pradeep, S (corresponding author), Med Coll Wisconsin, Dept Physiol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	spradeep@mcw.edu	GEETHADEVI, ANJALI/AAI-3798-2020; GOPINADHAN NAIR, GOPA KUMAR/J-6473-2014; Chen, Chang-Liang/AAO-6738-2021; Parashar, Deepak/T-8609-2017	GEETHADEVI, ANJALI/0000-0001-5486-7919; GOPINADHAN NAIR, GOPA KUMAR/0000-0002-2694-8401; Parashar, Deepak/0000-0002-5062-8950	Ovarian Cancer Research Fund Alliance (OCRFA); Women's Health Research Program (WHRP) in the Department of Obstetrics and Gynecology at the Medical College of Wisconsin (MCW); OCRFA; WHRP; DoD Breast Cancer Research Program [W81XWH-18-1-0024]; Children's Research Institute; NIH grants; Department of OBGYN; Department of Pediatrics;  [1R01CA229907]	Ovarian Cancer Research Fund Alliance (OCRFA); Women's Health Research Program (WHRP) in the Department of Obstetrics and Gynecology at the Medical College of Wisconsin (MCW); OCRFA; WHRP; DoD Breast Cancer Research Program(United States Department of Defense); Children's Research Institute; NIH grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of OBGYN; Department of Pediatrics; 	SP is supported by the Ovarian Cancer Research Fund Alliance (OCRFA) and by research funds from the Women's Health Research Program (WHRP) in the Department of Obstetrics and Gynecology at the Medical College of Wisconsin (MCW). PCR is supported by the 1R01CA229907, OCRFA, and WHRP as well as by the DoD Breast Cancer Research Program (W81XWH-18-1-0024). RR is supported by Children's Research Institute, Department of Pediatrics, Department of OBGYN and funds from NIH grants. Authors acknowledge Dr Anil Sood for providing tissue slides collected from the nude mice, treated with NRG1 siRNA-encapsulated nanoparticle.	Bassi DE, 2003, AM J PATHOL, V162, P439, DOI 10.1016/S0002-9440(10)63838-2; Bassi DE, 2001, P NATL ACAD SCI USA, V98, P10326, DOI 10.1073/pnas.191199198; Baumann J, 2019, EXP CELL RES, V383, DOI 10.1016/j.yexcr.2019.111503; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Chaluvally-Raghavan P, 2016, CELL REP, V15, P1493, DOI 10.1016/j.celrep.2016.04.034; Chaluvally-Raghavan P, 2014, CANCER CELL, V26, P863, DOI 10.1016/j.ccell.2014.10.010; Chen CL, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0902-4; Coleman RL, 2013, NAT REV CLIN ONCOL, V10, P211, DOI 10.1038/nrclinonc.2013.5; Coppola J, 2008, NEOPLASIA, V10, P363, DOI 10.1593/neo.08166; Devarajan E, 2009, CURR MOL MED, V9, P626, DOI 10.2174/156652409788488720; Elster N, 2018, THER ADV MED ONCOL, V10, DOI 10.1177/1758835918778297; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Fang D, 2017, ONCOGENE, V36, P1546, DOI 10.1038/onc.2016.323; Furtek SL, 2016, ACS CHEM BIOL, V11, P308, DOI 10.1021/acschembio.5b00945; Gaitskell K, 2018, INT J CANCER, V142, P281, DOI 10.1002/ijc.31063; Geethadevi Anjali, 2017, Genes Cancer, V8, P746, DOI 10.18632/genesandcancer.162; Geiger JL, 2016, ORAL ONCOL, V56, P84, DOI 10.1016/j.oraloncology.2015.11.022; Gyorffy B, 2012, ENDOCR-RELAT CANCER, V19, P197, DOI 10.1530/ERC-11-0329; Hassan R, 2004, CLIN CANCER RES, V10, P3937, DOI 10.1158/1078-0432.CCR-03-0801; HORIMOTO T, 1994, J VIROL, V68, P6074, DOI 10.1128/JVI.68.9.6074-6078.1994; Huang GY, 2014, STEM CELLS, V32, P1149, DOI 10.1002/stem.1609; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Jaaks P, 2017, INT J CANCER, V141, P654, DOI 10.1002/ijc.30714; Junttila TT, 2005, CANCER RES, V65, P1384, DOI 10.1158/0008-5472.CAN-04-3150; Lee JH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29142-x; Linardou H, 2009, NAT REV CLIN ONCOL, V6, P352, DOI 10.1038/nrclinonc.2009.62; Ma YC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033414; Page RE, 2007, CELL ONCOL, V29, P289; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Pradeep S, 2015, CANCER CELL, V28, P610, DOI 10.1016/j.ccell.2015.09.008; Pradeep S, 2014, CANCER CELL, V26, P77, DOI 10.1016/j.ccr.2014.05.002; Siveen KS, 2014, BBA-REV CANCER, V1845, P136, DOI 10.1016/j.bbcan.2013.12.005; Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137; Stephens P, 2004, NATURE, V431, P525, DOI 10.1038/431525b; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Torre LA, 2018, CA-CANCER J CLIN, V68, P284, DOI 10.3322/caac.21456; Wang T, 2007, CANCER RES, V67, P11830, DOI 10.1158/0008-5472.CAN-07-1160; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	40	21	21	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	14					2921	2933		10.1038/s41388-020-1194-7	http://dx.doi.org/10.1038/s41388-020-1194-7		FEB 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KZ2VB	32029900	Green Accepted			2022-12-28	WOS:000511540800004
J	Zhou, BJ; Zong, SM; Zhong, WL; Tian, YX; Wang, LM; Zhang, Q; Zhang, RY; Li, L; Wang, W; Zhao, JM; Chen, X; Feng, YJ; Zhai, BH; Sun, T; Liu, YR				Zhou, Bijiao; Zong, Shumin; Zhong, Weilong; Tian, Yixuan; Wang, Lumeng; Zhang, Qian; Zhang, Renya; Li, Lei; Wang, Wei; Zhao, Jianmin; Chen, Xin; Feng, Yaju; Zhai, Binghui; Sun, Tao; Liu, Yanrong			Interaction between laminin-5 gamma 2 and integrin beta 1 promotes the tumor budding of colorectal cancer via the activation of Yes-associated proteins	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; POOR-PROGNOSIS; THERAPEUTIC TARGET; CELL-ADHESION; INVASION; SURVIVAL; LAMININ; METASTASIS; EXPRESSION; MIGRATION	Colorectal cancer (CRC) is a common cancer type and a threat to human health. Tumor budding (TB) is the presence of a single cancer cell or clusters of up to five cancer cells prior to the invasive front of an aggressive carcinoma and is an independent prognosis factor for CRC. The molecular mechanism of TB is still unclear, and drugs that inhibit this process are still in the blank stage. This study found that TBs exhibit characteristics of partial EMT with a decreased expression of E-cadherin and no substantial differences in the expression of N-cadherin and vimentin. We also observed the interaction of integrin with extracellular matrix components, laminin-5 gamma 2 (LN-5 gamma 2), play essential roles in the TB of CRC. We then verified that the interaction between LN-5 gamma 2 and integrin beta 1 promotes the TB of CRC via the activation of FAK and Yes-associated proteins (YAP). A natural drug monomer, cucurbitacin B, was screened using virtual screening methods for the interaction interface of proteins. We found that this monomer could block the interaction interface between LN-5 gamma 2 and integrin beta 1 and substantially inhibit the TB of CRC cells via inactivation of YAP. This study provides new insights into the mechanism of TB mechanism and the development of drugs targeting the TB of CRC.	[Zhou, Bijiao; Zhang, Renya; Li, Lei; Wang, Wei; Liu, Yanrong] Jining Med Univ, Mol Pathol Inst Gastrointestinal Tumors, Affiliated Hosp, Jining 272029, Shandong, Peoples R China; [Zhou, Bijiao; Zong, Shumin; Tian, Yixuan; Wang, Lumeng; Zhang, Qian; Chen, Xin; Feng, Yaju; Zhai, Binghui; Sun, Tao; Liu, Yanrong] Nankai Univ, State Key Lab Med Chem Biol, Tianjin 300350, Peoples R China; [Zhou, Bijiao; Zong, Shumin; Tian, Yixuan; Wang, Lumeng; Zhang, Qian; Chen, Xin; Feng, Yaju; Zhai, Binghui; Sun, Tao; Liu, Yanrong] Nankai Univ, Coll Pharm, Tianjin 300350, Peoples R China; [Zhou, Bijiao; Zong, Shumin; Tian, Yixuan; Wang, Lumeng; Zhang, Qian; Chen, Xin; Feng, Yaju; Zhai, Binghui; Sun, Tao; Liu, Yanrong] Tianjin Int Joint Acad Biomed, Tianjin Key Lab Early Druggabil Evaluat Innovat D, Tianjin 300457, Peoples R China; [Zhou, Bijiao; Zong, Shumin; Tian, Yixuan; Wang, Lumeng; Zhang, Qian; Chen, Xin; Feng, Yaju; Zhai, Binghui; Sun, Tao; Liu, Yanrong] Tianjin Int Joint Acad Biomed, Tianjin Key Lab Mol Drug Res, Tianjin 300457, Peoples R China; [Zhong, Weilong] Tianjin Med Univ, Dept Gastroenterol & Hepatol, Gen Hosp, Tianjin 300052, Peoples R China; [Zhao, Jianmin] Hosp Shun Yi Dist, Dept Pathol, Beijing, Peoples R China	Jining Medical University; Nankai University; Nankai University; Tianjin International Joint Academy of Biomedicine; Tianjin International Joint Academy of Biomedicine; Tianjin Medical University	Liu, YR (corresponding author), Jining Med Univ, Mol Pathol Inst Gastrointestinal Tumors, Affiliated Hosp, Jining 272029, Shandong, Peoples R China.; Sun, T; Liu, YR (corresponding author), Nankai Univ, State Key Lab Med Chem Biol, Tianjin 300350, Peoples R China.; Sun, T; Liu, YR (corresponding author), Nankai Univ, Coll Pharm, Tianjin 300350, Peoples R China.; Sun, T; Liu, YR (corresponding author), Tianjin Int Joint Acad Biomed, Tianjin Key Lab Early Druggabil Evaluat Innovat D, Tianjin 300457, Peoples R China.; Sun, T; Liu, YR (corresponding author), Tianjin Int Joint Acad Biomed, Tianjin Key Lab Mol Drug Res, Tianjin 300457, Peoples R China.	sunrockmia@hotmail.com; liuyanrong1984@163.com			National Natural Science Funds of China [81972629, 81802945, 81872374, 81572838]; Taishan Scholar Project Special Funding; National Science and Technology Major Project [2018ZX09736-005]	National Natural Science Funds of China(National Natural Science Foundation of China (NSFC)); Taishan Scholar Project Special Funding; National Science and Technology Major Project	This work was funded by the following: National Natural Science Funds of China (81972629, 81802945, 81872374, and 81572838), the Taishan Scholar Project Special Funding and the National Science and Technology Major Project (2018ZX09736-005).	Almangush A, 2014, HISTOPATHOLOGY, V65, P587, DOI 10.1111/his.12471; Attramadal CG, 2015, ANTICANCER RES, V35, P6111; Belkin AM, 2015, MICROSC RES TECHNIQ, V51, P280; Bolos V, 2010, ONCOTARGETS THER, V3, P83; Bronsert P, 2014, J PATHOL, V234, P410, DOI 10.1002/path.4416; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; Chai YT, 2018, MED SCI MONITOR, V24, P9251, DOI 10.12659/MSM.911594; Cheng DT, 2016, ONCOTARGET, V7, P45199, DOI 10.18632/oncotarget.9900; Decline F, 2001, J CELL SCI, V114, P811; GABBERT HE, 1992, INT J CANCER, V50, P202, DOI 10.1002/ijc.2910500208; Graves ML, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-015-0670-4; Grigore AD, 2016, J CLIN MED, V5, P51, DOI 10.3390/jcm5050051; Haggar Fatima A, 2009, Clin Colon Rectal Surg, V22, P191, DOI 10.1055/s-0029-1242458; Han JX, 2019, CANCER RES, V79, P1451, DOI 10.1158/0008-5472.CAN-18-2238; Hillig T, 2012, APMIS, V120, P1000, DOI 10.1111/j.1600-0463.2012.02929.x; Jensen DH, 2015, J PATHOL, V236, P505, DOI 10.1002/path.4550; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Khan N, 2017, CARCINOGENESIS, V38, P184, DOI 10.1093/carcin/bgw124; KIKKAWA Y, 1994, J BIOCHEM-TOKYO, V116, P862, DOI 10.1093/oxfordjournals.jbchem.a124608; Kim NG, 2015, J CELL BIOL, V210, P503, DOI 10.1083/jcb.201501025; Koelzer VH, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1106677; Koelzer VH, 2015, HUM PATHOL, V46, P1573, DOI 10.1016/j.humpath.2015.07.010; Kohler I, 2015, J GASTROEN HEPATOL, V30, P78, DOI 10.1111/jgh.12752; Lachowski D, 2018, FASEB J, V32, P1099, DOI 10.1096/fj.201700721R; Landau MS, 2014, MODERN PATHOL, V27, P1578, DOI 10.1038/modpathol.2014.66; Lenander C, 2008, INT J CLIN EXP PATHO, V1, P254; Li J, 2019, J CELL MOL MED, V23, P6283, DOI 10.1111/jcmm.14514; Liang FL, 2013, PATHOL RES PRACT, V209, P269, DOI 10.1016/j.prp.2013.01.009; Liang J, 2019, PHYTOTHER RES, V33, P618, DOI 10.1002/ptr.6250; Lugli A, 2017, MODERN PATHOL, V30, P1299, DOI 10.1038/modpathol.2017.46; Masugi Y, 2010, HUM PATHOL, V41, P1061, DOI 10.1016/j.humpath.2010.01.016; MIYAZAKI K, 1993, P NATL ACAD SCI USA, V90, P11767, DOI 10.1073/pnas.90.24.11767; Moon YW, 2015, CELL DEATH DIFFER, V22, P1341, DOI 10.1038/cdd.2014.228; NIESSEN CM, 1994, EXP CELL RES, V211, P360, DOI 10.1006/excr.1994.1099; Nishiuchi R, 2006, MATRIX BIOL, V25, P189, DOI 10.1016/j.matbio.2005.12.001; Niwa Y, 2014, J SURG ONCOL, V110, P764, DOI 10.1002/jso.23694; Oh BY, 2018, ANN SURG ONCOL, V25, P204, DOI 10.1245/s10434-017-6135-5; Ohike N, 2010, AM J SURG PATHOL, V34, P1417, DOI 10.1097/PAS.0b013e3181f0b05a; Rogers AC, 2014, MODERN PATHOL, V27, P156, DOI 10.1038/modpathol.2013.124; Roh MS, 2004, DIS ESOPHAGUS, V17, P333, DOI 10.1111/j.1442-2050.2004.00436.x; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; Scott RW, 2011, JOVE-J VIS EXP, V58, P3525; Shen J, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0850-z; Shukla S, 2016, SCI REP-UK, V6, DOI 10.1038/srep21860; Shukla S, 2015, CANCER PREV RES, V8, P552, DOI 10.1158/1940-6207.CAPR-14-0286; Song JM, 2015, ONCOL REP, V33, P1867, DOI 10.3892/or.2015.3749; Sy J, 2010, DIS COLON RECTUM, V53, P301, DOI 10.1007/DCR.0b013e3181c3ed05; Tiwari N, 2012, SEMIN CANCER BIOL, V22, P194, DOI 10.1016/j.semcancer.2012.02.013; Ueno H, 2002, HISTOPATHOLOGY, V40, P127, DOI 10.1046/j.1365-2559.2002.01324.x; van Wyk HC, 2015, CANCER TREAT REV, V41, P151, DOI 10.1016/j.ctrv.2014.12.007; Venderbosch S, 2012, PROGNOSTIC VALUE RES, P3252; Wang C, 2011, J ORAL PATHOL MED, V40, P545, DOI 10.1111/j.1600-0714.2011.01041.x; Wang LM, 2009, AM J SURG PATHOL, V33, P134, DOI 10.1097/PAS.0b013e318184cd55; Wu JI, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37443-4; Xiang XY, 2018, NPJ PRECIS ONCOL, V2, DOI 10.1038/s41698-017-0045-7; Yamada N, 2017, HUM PATHOL, V60, P151, DOI 10.1016/j.humpath.2016.10.007; Yamaguchi Y, 2010, J THORAC ONCOL, V5, P1361, DOI 10.1097/JTO.0b013e3181eaf2f3; Yang T, 2017, ONCOTARGET, V8, P5800, DOI 10.18632/oncotarget.10584; Yasuda S, 2010, MOL NUTR FOOD RES, V54, P559, DOI 10.1002/mnfr.200900165; Zhang Q, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-018-1282-6; Zhong WL, 2018, EBIOMEDICINE, V37, P246, DOI 10.1016/j.ebiom.2018.10.041	61	20	20	2	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	7					1527	1542		10.1038/s41388-019-1082-1	http://dx.doi.org/10.1038/s41388-019-1082-1			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KL2WP	31676872				2022-12-28	WOS:000513289600010
J	Qi, M; Dai, D; Liu, J; Li, ZQ; Liang, PP; Wang, Y; Cheng, L; Zhan, YH; An, ZF; Song, YY; Yang, YN; Yan, XH; Xiao, H; Shao, HJ				Qi, Miao; Dai, Dan; Liu, Jin; Li, Zhongqi; Liang, Panpan; Wang, Yue; Cheng, Lu; Zhan, Yihong; An, Zhifeng; Song, Yaoyao; Yang, Yana; Yan, Xiaohui; Xiao, Hui; Shao, Huanjie			AIM2 promotes the development of non-small cell lung cancer by modulating mitochondrial dynamics	ONCOGENE			English	Article							NF-KAPPA-B; DNA SENSOR; FISSION; INFLAMMASOME; FUSION; PHOSPHORYLATION; PROLIFERATION; TUMORIGENESIS; PROGRESSION; EXPRESSION	Mitochondrial fusion and fission dynamics fine-tune cellular calcium homeostasis, ATP production capacity and ROS production and play important roles in cell proliferation and migration. Dysregulated mitochondrial dynamics is closely related to tumor development, but the mechanism of mitochondrial dynamics dysregulation and its role in the development of lung cancer remains unclear. Here, we demonstrate that the DNA sensor protein absent in melanoma 2 (AIM2) is highly expressed in non-small cell lung cancer (NSCLC) cells and that high AIM2 expression is associated with poor prognosis in patients with NSCLC. High expression of AIM2 contributes to tumor cell growth and proliferation independent of inflammasome activation in vitro and in vivo. Further studies have shown that AIM2 colocalizes with mitochondria in NSCLC cells and that AIM2 knockdown leads to enhanced mitochondrial fusion and decreased cell proliferation. Mechanistic studies have shown that AIM2 downregulation promotes MFN2 upregulation, thereby enhancing mitochondrial fusion. Moreover, we found that mitochondrial fusion driven by AIM2 knockdown leads to a decrease of cellular reactive oxygen species (ROS) production, which further causes inactivation of the MAPK/ERK signaling pathway. Together, we discovered a novel function of AIM2 in promoting NSCLC development by regulating mitochondrial dynamics and revealed its underlying mechanism. Our work provides new intervention targets for the treatment of NSCLC.	[Qi, Miao; Dai, Dan; Liu, Jin; Li, Zhongqi; Liang, Panpan; Wang, Yue; Cheng, Lu; Zhan, Yihong; An, Zhifeng; Song, Yaoyao; Yang, Yana; Yan, Xiaohui; Xiao, Hui; Shao, Huanjie] Shaanxi Normal Univ, Coll Life Sci, Natl Engn Lab Resource Developing Endangered Chin, Key Lab,Minist Educ Med Resources & Nat Pharmaceu, Xian 710119, Shaanxi, Peoples R China	Shaanxi Normal University	Shao, HJ (corresponding author), Shaanxi Normal Univ, Coll Life Sci, Natl Engn Lab Resource Developing Endangered Chin, Key Lab,Minist Educ Med Resources & Nat Pharmaceu, Xian 710119, Shaanxi, Peoples R China.	hshao@snnu.edu.cn			National Natural Science Foundation of China [81872250]; Natural Science Foundation of Shaanxi Province, China [2016JM8102]; key industrial chain projects of Shaanxi Province [2019TD-033]; program of Innovative Research Team for the Central Universities [GK201701005]; Student Innovation Training Program, Shaanxi Normal University [201810718056, 201910718048]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shaanxi Province, China(Natural Science Foundation of Shaanxi Province); key industrial chain projects of Shaanxi Province; program of Innovative Research Team for the Central Universities; Student Innovation Training Program, Shaanxi Normal University	We are thankful for financial support of National Natural Science Foundation of China (81872250), the Natural Science Foundation of Shaanxi Province, China (2016JM8102), the key industrial chain projects of Shaanxi Province (2019TD-033), the program of Innovative Research Team for the Central Universities (GK201701005), and the Student Innovation Training Program (201810718056, 201910718048), Shaanxi Normal University. The authors like to thank Dr Ling Guo and Yaohui Ren for assistance with TEM.	Arciuch VGA, 2012, ANTIOXID REDOX SIGN, V16, P1150, DOI 10.1089/ars.2011.4085; Archer SL, 2013, NEW ENGL J MED, V369, P2236, DOI 10.1056/NEJMra1215233; Azim HA, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0538-7; Berman SB, 2008, CELL DEATH DIFFER, V15, P1147, DOI 10.1038/cdd.2008.57; Brown AP, 2007, CANCER CHEMOTH PHARM, V59, P671, DOI 10.1007/s00280-006-0323-5; Broz P, 2016, NAT REV IMMUNOL, V16, P407, DOI 10.1038/nri.2016.58; Cai JY, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.370; Che TF, 2015, ONCOTARGET, V6, P37349, DOI 10.18632/oncotarget.5736; Chen HC, 2007, CELL, V130, P548, DOI 10.1016/j.cell.2007.06.026; Chen HC, 2017, CELL METAB, V26, P39, DOI 10.1016/j.cmet.2017.05.016; Chen IF, 2006, MOL CANCER THER, V5, P1, DOI 10.1158/1535-7163.MCT-05-0310; Chen KH, 2004, NAT CELL BIOL, V6, P872, DOI 10.1038/ncb1161; Chen Y, 2013, SCIENCE, V340, P471, DOI 10.1126/science.1231031; Deheshi S, 2015, J NEUROCHEM, V133, P684, DOI 10.1111/jnc.13090; DeYoung KL, 1997, ONCOGENE, V15, P453, DOI 10.1038/sj.onc.1201206; Farshchian M, 2017, ONCOTARGET, V8, P45825, DOI 10.18632/oncotarget.17573; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hornung V, 2009, NATURE, V458, P514, DOI 10.1038/nature07725; Inoue-Yamauchi A, 2012, BIOCHEM BIOPH RES CO, V421, P81, DOI 10.1016/j.bbrc.2012.03.118; Kashatus JA, 2015, MOL CELL, V57, P537, DOI 10.1016/j.molcel.2015.01.002; Kondo Y, 2012, CANCER SCI, V103, P782, DOI 10.1111/j.1349-7006.2012.02211.x; Kong H, 2015, TUMOR BIOL, V36, P7501, DOI 10.1007/s13277-015-3473-4; Lei H, 2009, J BIOL CHEM, V284, P6329, DOI 10.1074/jbc.M808426200; Lennon FE, 2014, EXPERT OPIN INV DRUG, V23, P675, DOI 10.1517/13543784.2014.899350; Li J, 2017, ONCOGENE, V36, P4901, DOI 10.1038/onc.2017.98; Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23; Loson OC, 2013, MOL BIOL CELL, V24, P659, DOI 10.1091/mbc.E12-10-0721; Lugrin J, 2018, IMMUNOL REV, V281, P99, DOI 10.1111/imr.12618; Ma LM, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1447-y; Ma XM, 2016, ONCOTARGET, V7, P36185, DOI 10.18632/oncotarget.9154; Ponomareva L, 2013, MOL CANCER RES, V11, P1193, DOI 10.1158/1541-7786.MCR-13-0145; Rehman J, 2012, FASEB J, V26, P2175, DOI 10.1096/fj.11-196543; Reynaert NL, 2006, P NATL ACAD SCI USA, V103, P13086, DOI 10.1073/pnas.0603290103; Serasinghe MN, 2015, MOL CELL, V57, P521, DOI 10.1016/j.molcel.2015.01.003; Shao HJ, 2013, MOL CANCER THER, V12, P2640, DOI 10.1158/1535-7163.MCT-13-0066; Simula L, 2017, SEMIN CANCER BIOL, V47, P29, DOI 10.1016/j.semcancer.2017.06.007; Stack JH, 2005, J IMMUNOL, V175, P2630, DOI 10.4049/jimmunol.175.4.2630; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Trotta AP, 2017, CELL MOL LIFE SCI, V74, P1999, DOI 10.1007/s00018-016-2451-3; Vyas S, 2016, CELL, V166, P555, DOI 10.1016/j.cell.2016.07.002; Willems PHGM, 2015, CELL METAB, V22, P207, DOI 10.1016/j.cmet.2015.06.006; Wilson JE, 2015, NAT MED, V21, P906, DOI 10.1038/nm.3908; Xia MH, 2014, INT J ONCOL, V45, P2341, DOI 10.3892/ijo.2014.2669; Yan XH, 2018, BIOCHEM PHARMACOL, V150, P72, DOI 10.1016/j.bcp.2018.01.031; Yeo W, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1334-6; Zhang JH, 2019, REDOX BIOL, V22, DOI 10.1016/j.redox.2019.101116; Zhang MD, 2019, J CELL PHYSIOL, V234, P20161, DOI 10.1002/jcp.28617; Zhao J, 2013, ONCOGENE, V32, P4814, DOI 10.1038/onc.2012.494	48	27	28	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	13					2707	2723		10.1038/s41388-020-1176-9	http://dx.doi.org/10.1038/s41388-020-1176-9		JAN 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KX4EF	32005973				2022-12-28	WOS:000510346700001
J	Chen, H; Libring, S; Ruddraraju, KV; Miao, JM; Solorio, L; Zhang, ZY; Wendt, MK				Chen, Hao; Libring, Sarah; Ruddraraju, Kasi Viswanatharaju; Miao, Jinmin; Solorio, Luis; Zhang, Zhong-Yin; Wendt, Michael K.			SHP2 is a multifunctional therapeutic target in drug resistant metastatic breast cancer	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE-PHOSPHATASE; ANTITUMOR IMMUNITY; KINASE INHIBITOR; ACTIVATION; CELLS; NERATINIB; PHOSPHORYLATION; MECHANISM; SUBSETS	Metastatic breast cancer (MBC) is an extremely recalcitrant disease capable of bypassing current targeted therapies via engagement of several growth promoting pathways. SH2 containing protein tyrosine phosphatase-2 (SHP2) is an oncogenic phosphatase known to facilitate growth and survival signaling downstream of numerous receptor inputs. Herein, we used inducible genetic depletion and two distinct pharmacological inhibitors to investigate the therapeutic potential of targeting SHP2 in MBC. Cells that acquired resistance to the ErbB kinase inhibitor, neratinib, displayed increased phosphorylation of SHP2 at the Y542 activation site. In addition, higher levels of SHP2 phosphorylation, but not expression, were associated with decreased survival of breast cancer patients. Pharmacological inhibition of SHP2 activity blocked ERK1/2 and AKT signaling generated from exogenous stimulation with FGF2, PDGF, and hGF and readily prevented MBC cell growth induced by these factors. SHP2 was also phosphorylated upon engagement of the extracellular matrix (ECM) via focal adhesion kinase. Consistent with the potential of SHP2-targeted compounds as therapeutic agents, the growth inhibitory property of SHP2 blockade was enhanced in ECM-rich 3D culture environments. In vivo blockade of SHP2 in the adjuvant setting decreased pulmonary metastasis and extended the survival of systemic tumor-bearing mice. Finally, inhibition of SHP2 in combination with FGFR-targeted kinase inhibitors synergistically blocked the growth of MBC cells. Overall, our findings support the conclusion that SHP2 constitutes a shared signaling node allowing MBC cells to simultaneously engage a diversity of growth and survival pathways, including those derived from the ECM.	[Chen, Hao; Ruddraraju, Kasi Viswanatharaju; Miao, Jinmin; Zhang, Zhong-Yin; Wendt, Michael K.] Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA; [Libring, Sarah; Solorio, Luis] Purdue Univ, Dept Biomed Engn, W Lafayette, IN 47907 USA; [Solorio, Luis; Zhang, Zhong-Yin; Wendt, Michael K.] Purdue Univ, Ctr Canc Res, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Wendt, MK (corresponding author), Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA.; Wendt, MK (corresponding author), Purdue Univ, Ctr Canc Res, W Lafayette, IN 47907 USA.	mwendt@purdue.edu	Ruddraraju, Kasi Viswanatharaju/D-2384-2016; Miao, Jinmin/AAU-8461-2021	Ruddraraju, Kasi Viswanatharaju/0000-0002-5614-720X; Libring, Sarah/0000-0001-8336-5862; Wendt, Mike/0000-0002-3665-7413; Chen, Hao/0000-0002-2070-5062	National Cancer Institute [R01CA207751, RO1CA207288]; Metavivor Foundation Translation Research Award; American Cancer Society Research Scholar Grant [RSG-CSM-130259]; SIRG Graduate Research Assistantships Award [P30CA023168]; Purdue University Center for Cancer Research	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Metavivor Foundation Translation Research Award; American Cancer Society Research Scholar Grant(American Cancer Society); SIRG Graduate Research Assistantships Award; Purdue University Center for Cancer Research	This work was supported by National Cancer Institute (R01CA207751), Metavivor Foundation Translation Research Award, and American Cancer Society Research Scholar Grant (RSG-CSM-130259) to MKW and National Cancer Institute (RO1CA207288) to ZYZ. We gratefully acknowledge the SIRG Graduate Research Assistantships Award (P30CA023168) and the support from the Purdue University Center for Cancer Research. We thank Dr. Jill E. Hutchcroft, Dr. Wen-Hung Wang, and Flow Cytometry and Cell Separation Core Facility at Bindley Bioscience Center, Purdue University for technical support. We also thank Saeed Salehin Akhand, Hang Lin, Juan Sebastian Paez and other members at Wendt Lab for technical support.	Aceto N, 2012, NAT MED, V18, P529, DOI 10.1038/nm.2645; Agazie YM, 2003, MOL CELL BIOL, V23, P7875, DOI 10.1128/MCB.23.21.7875-7886.2003; Ahmed TA, 2019, CELL REP, V26, P65, DOI 10.1016/j.celrep.2018.12.013; Alexander PB, 2017, J BIOL CHEM, V292, P748, DOI 10.1074/jbc.M116.754960; ALI R, 2018, CELL DEATH DIS, V9, P1, DOI DOI 10.1038/s41419-017-0012-9; Araki T, 2003, J BIOL CHEM, V278, P41677, DOI 10.1074/jbc.M306461200; Barkan D, 2010, CANCER RES, V70, P5706, DOI 10.1158/0008-5472.CAN-09-2356; Brown WS, 2016, ONCOTARGET, V7, P83424, DOI 10.18632/oncotarget.13117; Brown WS, 2016, MOL CANCER THER, V15, P2096, DOI 10.1158/1535-7163.MCT-16-0136; Bunda S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9859; Burstein HJ, 2010, J CLIN ONCOL, V28, P1301, DOI 10.1200/JCO.2009.25.8707; Chen YNP, 2016, NATURE, V535, P148, DOI 10.1038/nature18621; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Cunnick JM, 2000, J BIOL CHEM, V275, P13842, DOI 10.1074/jbc.275.18.13842; Dance M, 2008, CELL SIGNAL, V20, P453, DOI 10.1016/j.cellsig.2007.10.002; Fedele C, 2018, CANCER DISCOV, V8, P1237, DOI 10.1158/2159-8290.CD-18-0444; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Gotoh N, 2004, P NATL ACAD SCI USA, V101, P17144, DOI 10.1073/pnas.0407577101; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hanker AB, 2017, CANCER DISCOV, V7, P575, DOI 10.1158/2159-8290.CD-16-1431; Helsten T, 2016, CLIN CANCER RES, V22, P259, DOI 10.1158/1078-0432.CCR-14-3212; Jechlinger M, 2006, J CLIN INVEST, V116, P1561, DOI 10.1172/JCI24652; Konecny GE, 2006, CANCER RES, V66, P1630, DOI 10.1158/0008-5472.CAN-05-1182; Koyama T, 2008, J BIOL CHEM, V283, P24234, DOI 10.1074/jbc.M803907200; Lan LX, 2015, EMBO J, V34, P1493, DOI 10.15252/embj.201489004; Li DM, 2011, BREAST CANCER RES TR, V128, P7, DOI 10.1007/s10549-011-1499-x; Liu W, 2017, LEUKEMIA, V31, P1415, DOI 10.1038/leu.2016.326; Mariotto AB, 2017, CANCER EPIDEM BIOMAR, V26, P809, DOI [10.1158/1055-9965.EPI-16-0889, 10.1158/1055-9965.epi-16-0889]; Martin M, 2017, LANCET ONCOL, V18, P1688, DOI 10.1016/S1470-2045(17)30717-9; Minuti G, 2012, BRIT J CANCER, V107, P793, DOI 10.1038/bjc.2012.335; Montagner A, 2005, J BIOL CHEM, V280, P5350, DOI 10.1074/jbc.M410012200; Palakurthi S, 2019, CANCER IMMUNOL RES, V7, P1457, DOI 10.1158/2326-6066.CIR-18-0595; Pulaski BA, 2000, CURR PROTOC IMMUNOL, V39, P20; Ran H, 2016, CANCER CELL, V30, P194, DOI 10.1016/j.ccell.2016.07.010; Ritter CA, 2007, CLIN CANCER RES, V13, P4909, DOI 10.1158/1078-0432.CCR-07-0701; Shattuck DL, 2008, CANCER RES, V68, P1471, DOI 10.1158/0008-5472.CAN-07-5962; Shibue T, 2009, P NATL ACAD SCI USA, V106, P10290, DOI 10.1073/pnas.0904227106; Shinde A, 2018, MOL CANCER RES, V16, P1579, DOI 10.1158/1541-7786.MCR-18-0151; Stuhlmiller TJ, 2015, CELL REP, V11, P390, DOI 10.1016/j.celrep.2015.03.037; Sun J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3037; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Wei T., 2017, STATISTICIAN, V56, pe24; Wendt MK, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3623; Wendt MK, 2011, MOL BIOL CELL, V22, P2423, DOI 10.1091/mbc.E11-04-0306; Wendt MK, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2360; Ye TH, 2014, BREAST CANCER RES TR, V143, P435, DOI 10.1007/s10549-013-2829-y; Yokosuka T, 2012, J EXP MED, V209, P1201, DOI 10.1084/jem.20112741; Zeng LF, 2014, J MED CHEM, V57, P6594, DOI 10.1021/jm5006176; Zhang RY, 2016, ONCOTARGET, V7, P73817, DOI 10.18632/oncotarget.12074; Zhang SQ, 2002, MOL CELL BIOL, V22, P4062, DOI 10.1128/MCB.22.12.4062-4072.2002; Zhao H, 2019, ONCOGENE, V38, P2275, DOI 10.1038/s41388-018-0574-8; Zhao MX, 2019, ACTA PHARM SIN B, V9, P304, DOI 10.1016/j.apsb.2018.08.009; Zhou B, 2014, MOL CANCER RES, V12, P143, DOI 10.1158/1541-7786.MCR-13-0184	53	12	12	2	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2020	39	49					7166	7180		10.1038/s41388-020-01488-5	http://dx.doi.org/10.1038/s41388-020-01488-5		OCT 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PB0GA	33033382	hybrid, Green Published			2022-12-28	WOS:000576873200001
J	Peng, KS; Zhuo, MH; Li, M; Chen, Q; Mo, PL; Yu, CD				Peng, Kesong; Zhuo, Minghui; Li, Ming; Chen, Qiang; Mo, Pingli; Yu, Chundong			Histone demethylase JMJD2D activates HIF1 signaling pathway via multiple mechanisms to promote colorectal cancer glycolysis and progression	ONCOGENE			English	Article							HYPOXIA; MTOR; HIF-1-ALPHA; ALPHA	Hypoxia-inducible factor 1 (HIF1) signaling pathway plays a key role in cancer progression by enhancing glycolysis through activating the transcription of glycolytic genes. JMJD2D, a histone demethylase that specifically demethylates H3K9me2/3, can promote colorectal cancer (CRC) progression. However, it is unknown whether JMJD2D could promote CRC progression by enhancing glycolysis through activating HIF1 signaling pathway. In this study, we found that downregulation of JMJD2D inhibited the glycolysis in CRC cells through suppressing HIF1 signaling pathway to downregulate glycolytic gene expression. Restoring HIF1 signaling by enforced expression of HIF1 alpha in JMJD2D-knockdown CRC cells partially recovered CRC cell glycolysis, proliferation, migration, invasion, xenograft growth, and metastasis, suggesting that JMJD2D promotes CRC progression by enhancing glycolysis through activating HIF1 signaling pathway. JMJD2D activated HIF1 signaling pathway through three different mechanisms: JMJD2D cooperated with the transcription factor SOX9 to enhance mTOR expression and then to promote HIF1 alpha translation; JMJD2D cooperated with the transcription factor c-Fos to enhance HIF1 beta transcription; JMJD2D interacted and cooperated with HIF1 alpha to enhance the expression of glycolytic gene. The demethylase-defective mutant of JMJD2D could not induce the expression of mTOR, HIF1 alpha, HIF1 beta, and glycolytic genes, suggesting that the demethylase activity of JMJD2D is important for glycolysis through activating HIF1 signaling. Clinically, a highly positive correlation between the expression of JMJD2D and mTOR, HIF1 beta, and several glycolytic genes in human CRC specimens was identified. Collectively, our study reveals an important role of JMJD2D in CRC progression by enhancing glycolysis through activating HIF1 signaling pathway.	[Peng, Kesong; Zhuo, Minghui; Chen, Qiang; Mo, Pingli; Yu, Chundong] Xiamen Univ, Sch Life Sci, Innovat Ctr Cell Biol, State Key Lab Cellular Stress Biol, Xiamen, Peoples R China; [Peng, Kesong] Fudan Univ, Sch Basic Med Sci, Dept Cellular & Genet Med, Shanghai, Peoples R China; [Li, Ming] Xiamen Univ, Sch Med, Xiangan Hosp, Dept Hepatobiliary Surg, Xiamen, Peoples R China	Xiamen University; Fudan University; Xiamen University	Mo, PL; Yu, CD (corresponding author), Xiamen Univ, Sch Life Sci, Innovat Ctr Cell Biol, State Key Lab Cellular Stress Biol, Xiamen, Peoples R China.	mop@xmu.edu.cn; cdyu@xmu.edu.cn		Peng, Kesong/0000-0001-9035-3421; Li, Ming/0000-0002-9700-1282	National Natural Science Foundation of China [81970485, 81772942]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by grants from the National Natural Science Foundation of China (No. 81970485 and No. 81772942 to CY). We thank Dr Mingxia Zhu and Shuhai Lin (Xiamen University) for the technical support and reagents.	Berry WL, 2013, CANCER RES, V73, P2936, DOI 10.1158/0008-5472.CAN-12-4300; Dancey J, 2010, NAT REV CLIN ONCOL, V7, P209, DOI 10.1038/nrclinonc.2010.21; Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468; Dong FY, 2019, EBIOMEDICINE, V39, P472, DOI 10.1016/j.ebiom.2018.11.055; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hu FQ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0861-6; Iadevaia V, 2012, METHODS MOL BIOL, V821, P171, DOI 10.1007/978-1-61779-430-8_10; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Kim AL, 2018, J INVEST DERMATOL, V138, P1716, DOI 10.1016/j.jid.2018.01.040; Koh MY, 2008, TRENDS BIOCHEM SCI, V33, P526, DOI 10.1016/j.tibs.2008.08.002; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Masoud GN, 2015, ACTA PHARM SIN B, V5, P378, DOI 10.1016/j.apsb.2015.05.007; Mi CL, 2017, J ETHNOPHARMACOL, V203, P27, DOI 10.1016/j.jep.2017.03.033; Peng KS, 2019, GASTROENTEROLOGY, V156, P1112, DOI 10.1053/j.gastro.2018.11.036; San-Millan I, 2017, CARCINOGENESIS, V38, P119, DOI 10.1093/carcin/bgw127; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; Wan W, 2017, ONCOGENE, V36, P3868, DOI 10.1038/onc.2017.13; Wouters BG, 2008, NAT REV CANCER, V8, P851, DOI 10.1038/nrc2501; Zhong H, 1999, CANCER RES, V59, P5830; Zhuo MH, 2020, ONCOGENE, V39, P3336, DOI 10.1038/s41388-020-1219-2	25	15	15	7	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	2020	39	47					7076	7091		10.1038/s41388-020-01483-w	http://dx.doi.org/10.1038/s41388-020-01483-w		SEP 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OT7KA	32989255				2022-12-28	WOS:000573446900001
J	Zhu, YZ; Dalrymple, SL; Coleman, I; Zheng, SL; Xu, JF; Hooper, JE; Antonarakis, ES; De Marzo, AM; Meeker, AK; Nelson, PS; Isaacs, WB; Denmeade, SR; Luo, J; Brennen, WN; Isaacs, JT				Zhu, Yezi; Dalrymple, Susan L.; Coleman, Ilsa; Zheng, S. Lilly; Xu, Jianfeng; Hooper, Jody E.; Antonarakis, Emmanuel S.; De Marzo, Angelo M.; Meeker, Alan K.; Nelson, Peter S.; Isaacs, William B.; Denmeade, Samuel R.; Luo, Jun; Brennen, W. Nathaniel; Isaacs, John T.			Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors	ONCOGENE			English	Article							ABIRATERONE; THERAPY; GROWTH; GENE; ENZALUTAMIDE; ANTIANDROGEN; PROGRESSION; EXPRESSION; APOPTOSIS; INDUCE	The role of truncated androgen receptor splice variant-7 (AR-V7) in prostate cancer biology is an unresolved question. Is it simply a marker of resistance to 2nd-generation androgen receptor signaling inhibitors (ARSi) like abiraterone acetate (Abi) and enzalutamide (Enza) or a functional driver of lethal resistance via its ligand-independent transcriptional activity? To resolve this question, the correlation between resistance to ARSi and genetic chances and expression of full length AR (AR-FL) vs. AR-V7 were evaluated in a series of independent patient-derived xenografts (PDXs). While all PDXs lack PTEN expression, there is no consistent requirement for mutation inTP53, RB1, BRCA2, PIK3CA, or MSH2, or expression of SOX2 or ERG and ARSi resistance. Elevated expression of AR-FL alone is sufficient for Abi but not Enza resistance, even if AR-FL is gain-of-function (GOF) mutated. Enza resistance is consistently correlated with enhanced AR-V7 expression. In vitro and in vivo growth responses of Abi-/Enza-resistant LNCaP-95 cells in which CRISPR-Cas9 was used to knockout AR-FL or AR-V7 alone or in combination were evaluated. Combining these growth responses with RNAseq analysis demonstrates that both AR-FL- and AR-V7-dependent transcriptional complementation are needed for Abi/Enza resistance.	[Zhu, Yezi; Antonarakis, Emmanuel S.; De Marzo, Angelo M.; Meeker, Alan K.; Isaacs, William B.; Denmeade, Samuel R.; Luo, Jun; Brennen, W. Nathaniel; Isaacs, John T.] Johns Hopkins Univ, Sch Med, James Buchanan Brady Urol Inst, Dept Urol, Baltimore, MD 21205 USA; [Dalrymple, Susan L.; Antonarakis, Emmanuel S.; De Marzo, Angelo M.; Meeker, Alan K.; Isaacs, William B.; Denmeade, Samuel R.; Luo, Jun; Brennen, W. Nathaniel; Isaacs, John T.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr SKCCC, Dept Oncol, Baltimore, MD 21205 USA; [Coleman, Ilsa] Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA; [Zheng, S. Lilly; Xu, Jianfeng] North Shore Univ Hlth Syst, Program Personalized Canc Care, Evanston, IL USA; [Hooper, Jody E.; De Marzo, Angelo M.; Meeker, Alan K.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Nelson, Peter S.] Univ Washington, Dept Med & Urol, Seattle, WA 98195 USA	Johns Hopkins University; Johns Hopkins University; Fred Hutchinson Cancer Center; Johns Hopkins University; University of Washington; University of Washington Seattle	Isaacs, JT (corresponding author), Johns Hopkins Univ, Sch Med, James Buchanan Brady Urol Inst, Dept Urol, Baltimore, MD 21205 USA.; Isaacs, JT (corresponding author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr SKCCC, Dept Oncol, Baltimore, MD 21205 USA.	isaacjo@jhmi.edu		, Jody/0000-0002-8209-3559; Antonarakis, Emmanuel Stylianos/0000-0003-3531-3851	Department of Defense Prostate Cancer Research Program [W81XWH1810349, W81XWH-17-1-0528, W81XWH-18-2-0015]; NIH Prostate SPOREs [P50 CA058236]; Pathology Core from the Prostate SPORE [P50 CA058236, P50 CA097186, W81XWH-18-1-0347, P01 CA163227]; Emerson Collective Cancer Research Fund [643396]; Allegheny Health Network-Johns Hopkins University Cancer Research Fund [R01 CA185297]; SKCCC CCSG [P30 CA006973]	Department of Defense Prostate Cancer Research Program(United States Department of Defense); NIH Prostate SPOREs(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pathology Core from the Prostate SPORE; Emerson Collective Cancer Research Fund; Allegheny Health Network-Johns Hopkins University Cancer Research Fund; SKCCC CCSG	We are grateful to the patients and their families who participated in the Legacy Gift Rapid Autopsy program at Hopkins. We would like to acknowledge the Department of Defense Prostate Cancer Research Program W81XWH1810349 (JTI), W81XWH-17-1-0528 (WNB), W81XWH-18-2-0015 (AMM) and NIH Prostate SPOREs P50 CA058236 (JTI), Pathology Core from the Prostate SPORE P50 CA058236 (AMM) and P50 CA097186 (PSN), W81XWH-18-1-0347 (PSN), P01 CA163227 (PSN), Emerson Collective Cancer Research Fund [643396, (WNB)], Allegheny Health Network-Johns Hopkins University Cancer Research Fund (WNB), R01 CA185297 (JL and ESA). Also, we wish to thank the Cell Imaging Facility, Animal Core Facility, Tissue Histology Core, Genetic Resource Core, Cytogenetics Core Facility, and the Autopsy Core from the CCSG Grant supported by the SKCCC CCSG (P30 CA006973) for their services and assistance.	Ajiboye AS, 2017, PROSTATE, V77, P829, DOI 10.1002/pros.23323; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Bellur S, 2019, HUM PATHOL, V85, P313, DOI 10.1016/j.humpath.2018.11.016; BERCHEM GJ, 1995, CANCER RES, V55, P735; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen EJ, 2015, CLIN CANCER RES, V21, P1273, DOI 10.1158/1078-0432.CCR-14-1220; Dehm SM, 2008, CANCER RES, V68, P5469, DOI 10.1158/0008-5472.CAN-08-0594; Esquenet M, 1997, J STEROID BIOCHEM, V62, P391, DOI 10.1016/S0960-0760(97)00054-X; Guo YP, 1999, CANCER RES, V59, P1366; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Hu R, 2012, CANCER RES, V72, P3457, DOI 10.1158/0008-5472.CAN-11-3892; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Huang YT, 2021, ASIAN J CONTROL, V23, P1693, DOI 10.1002/asjc.2326; Isaacs JT, 2018, AM J CLIN EXP UROL, V6, P55; Isaacs JT, 2012, PROSTATE, V72, P1491, DOI 10.1002/pros.22504; JENSTER G, 1993, BIOCHEM J, V293, P761, DOI 10.1042/bj2930761; Karan D, 2001, CLIN CANCER RES, V7, P3472; Kurita T, 2001, CELL DEATH DIFFER, V8, P192, DOI 10.1038/sj.cdd.4400797; KYPRIANOU N, 1990, CANCER RES, V50, P3748; Lam HM, 2017, CLIN CANCER RES, V23, P2301, DOI 10.1158/1078-0432.CCR-16-2054; Leach FS, 2000, J UROLOGY, V164, P1830, DOI 10.1016/S0022-5347(05)67115-7; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li YM, 2013, CANCER RES, V73, P483, DOI 10.1158/0008-5472.CAN-12-3630; Lin XH, 2001, AM J PATHOL, V159, P1815, DOI 10.1016/S0002-9440(10)63028-3; Litvinov IV, 2003, J CLIN ENDOCR METAB, V88, P2972, DOI 10.1210/jc.2002-022038; Liu LL, 2014, ONCOGENE, V33, P3140, DOI 10.1038/onc.2013.284; Lu CX, 2020, PROSTATE CANCER P D, V23, P381, DOI 10.1038/s41391-020-0217-3; Moll JM, 2019, PROSTATE, V79, P937, DOI 10.1002/pros.23799; Mostaghel EA, 2019, CLIN CANCER RES, V25, P426, DOI 10.1158/1078-0432.CCR-18-1431; Mostaghel EA, 2017, CLIN CANCER RES, V23, P4592, DOI 10.1158/1078-0432.CCR-16-2245; Naidu C Kumaraswamy, 2016, Asian Pac J Cancer Prev, V17, P2199; Pflug BR, 1999, PROSTATE, V40, P269, DOI 10.1002/(SICI)1097-0045(19990901)40:4<269::AID-PROS9>3.0.CO;2-6; Quigley DA, 2018, CELL, V174, P758, DOI 10.1016/j.cell.2018.06.039; Sedelaar JPM, 2009, PROSTATE, V69, P1724, DOI 10.1002/pros.21028; Sharp A, 2016, CLIN CANCER RES, V22, P4280, DOI 10.1158/1078-0432.CCR-16-1137; Takeda DY, 2018, CELL, V174, P422, DOI 10.1016/j.cell.2018.05.037; Tan J, 1997, MOL ENDOCRINOL, V11, P450, DOI 10.1210/me.11.4.450; Teply BA, 2018, LANCET ONCOL, V19, P76, DOI 10.1016/S1470-2045(17)30906-3; Tombal B, 2002, CELL DEATH DIFFER, V9, P561, DOI 10.1038/sj.cdd.4400999; Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175; Vander Griend DJ, 2010, PROSTATE, V70, P90, DOI 10.1002/pros.21043; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Viswanathan SR, 2018, CELL, V174, P433, DOI 10.1016/j.cell.2018.05.036; Yang YC, 2016, CLIN CANCER RES, V22, P4466, DOI 10.1158/1078-0432.CCR-15-2901; Zhang Q, 2005, MOL ENDOCRINOL, V19, P2390, DOI 10.1210/me.2005-0096	47	31	31	2	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 5	2020	39	45					6935	6949		10.1038/s41388-020-01479-6	http://dx.doi.org/10.1038/s41388-020-01479-6		SEP 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ON7IM	32989253	Green Accepted			2022-12-28	WOS:000573446900002
J	Ray, U; Raghavan, SC				Ray, Ujjayinee; Raghavan, Sathees C.			Modulation of DNA double-strand break repair as a strategy to improve precise genome editing	ONCOGENE			English	Review							HOMOLOGY-DIRECTED REPAIR; ONE-STEP GENERATION; KNOCK-IN; EFFICIENT GENERATION; RESTRICTION ENZYMES; ENCAPSULATED SCR7; HUMAN-CELLS; CRISPR-CAS9; PROTEIN; MICE	In the present day, it is possible to incorporate targeted mutations or replace a gene using genome editing techniques such as customisable CRISPR/Cas9 system. Although induction of DNA double-strand breaks (DSBs) by genome editing tools can be repaired by both non-homologous end joining (NHEJ) and homologous recombination (HR), the skewness of the former pathway in human and other mammals normally result in imprecise repair. Scientists working at the crossroads of DNA repair and genome editing have devised new strategies for using a specific pathway to their advantage. Refinement in the efficiency of precise gene editing was witnessed upon downregulation of NHEJ by knockdown or using small molecule inhibitors on one hand, and upregulation of HR proteins and addition of HR stimulators, other hand. The exploitation of cell cycle phase differences together with appropriate donor DNA length/sequence and small molecules has provided further improvement in precise genome editing. The present article reviews the mechanisms of improving the efficiency of precise genome editing in several model organisms and in clinics.	[Ray, Ujjayinee; Raghavan, Sathees C.] Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Raghavan, SC (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.	sathees@iisc.ac.in			CEFIPRA [IFC/52034/2015/131]; DAE [21/01/2016-BRNS/35074]; DBT Glue-Grant [BT/PR23078/MED/29/1253/2017]; IISc-DBT partnership programme [BT/PR27952-INF/22/212/2018]; CSIR, India	CEFIPRA; DAE(Department of Atomic Energy (DAE)); DBT Glue-Grant; IISc-DBT partnership programme(Indian Institute of Science (IISC) - Bangalore); CSIR, India(Council of Scientific & Industrial Research (CSIR) - India)	We thank Urbi Roy, Dipayan Ghosh and other members of SCR laboratory for critical reading and comments on the paper. This work was supported by grants from CEFIPRA (IFC/52034/2015/131), DAE (21/01/2016-BRNS/35074), DBT Glue-Grant (BT/PR23078/MED/29/1253/2017), IISc-DBT partnership programme (BT/PR27952-INF/22/212/2018) to SCR. UR is supported by Senior Research Fellowship (SRF) from CSIR, India.	Aird EJ, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003-018-0054-2; Allen AG, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02940; Aslan Y, 2017, DEVELOPMENT, V144, P2852, DOI 10.1242/dev.152967; Auer TO, 2014, GENOME RES, V24, P142, DOI 10.1101/gr.161638.113; Barrangou R, 2016, NAT BIOTECHNOL, V34, P933, DOI 10.1038/nbt.3659; Beumer KJ, 2008, P NATL ACAD SCI USA, V105, P19821, DOI 10.1073/pnas.0810475105; Bhargava R, 2016, TRENDS GENET, V32, P566, DOI 10.1016/j.tig.2016.06.007; Boboila C, 2010, P NATL ACAD SCI USA, V107, P3034, DOI 10.1073/pnas.0915067107; Boch J, 2009, SCIENCE, V326, P1509, DOI 10.1126/science.1178811; Boel A, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.035352; Brinkman EK, 2018, MOL CELL, V70, P801, DOI 10.1016/j.molcel.2018.04.016; Canny MD, 2018, NAT BIOTECHNOL, V36, P95, DOI 10.1038/nbt.4021; Carlson-Stevermer J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01875-9; Ceccaldi R, 2016, TRENDS CELL BIOL, V26, P52, DOI 10.1016/j.tcb.2015.07.009; Chandrasegaran S, 2016, J MOL BIOL, V428, P963, DOI 10.1016/j.jmb.2015.10.014; Charpentier M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03475-7; Chen SA, 2019, CELL REP, V27, P3780, DOI 10.1016/j.celrep.2019.05.103; Christian M, 2010, GENETICS, V186, P757, DOI 10.1534/genetics.110.120717; Davis AJ, 2013, TRANSL CANCER RES, V2, P130, DOI 10.3978/j.issn.2218-676X.2013.04.02; Davis KM, 2015, NAT CHEM BIOL, V11, P316, DOI [10.1038/NCHEMBIO.1793, 10.1038/nchembio.1793]; Davis L, 2016, CELL REP, V17, P1872, DOI 10.1016/j.celrep.2016.10.049; Di Primio C, 2005, NUCLEIC ACIDS RES, V33, P4639, DOI 10.1093/nar/gki778; Du J, 2018, MOL CANCER THER, V17, P419, DOI 10.1158/1535-7163.MCT-17-0090; Dungl DA, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00240; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Gaj T, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a023754; Greco GE, 2016, DNA REPAIR, V43, P18, DOI 10.1016/j.dnarep.2016.04.004; Grundy GJ, 2013, EMBO J, V32, P112, DOI 10.1038/emboj.2012.304; Gutschner T, 2016, CELL REP, V14, P1555, DOI 10.1016/j.celrep.2016.01.019; Haber JE, 2016, ANNU REV GENET, V50, P1, DOI 10.1146/annurev-genet-120215-035043; Harper JW, 2007, MOL CELL, V28, P739, DOI 10.1016/j.molcel.2007.11.015; Hart T, 2015, CELL, V163, DOI 10.1016/j.cell.2015.11.015; Heyer WD, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a016501; Holt N, 2010, NAT BIOTECHNOL, V28, P839, DOI 10.1038/nbt.1663; Hsu PD, 2014, CELL, V157, P1262, DOI 10.1016/j.cell.2014.05.010; Hu Z, 2018, CELL BIOSCI, V8, DOI 10.1186/s13578-018-0200-z; Huang XS, 2015, STEM CELLS, V33, P1470, DOI 10.1002/stem.1969; Hung PJ, 2018, MOL CELL, V71, P332, DOI 10.1016/j.molcel.2018.06.018; Hyodo T, 2020, CELL REP, V30, P1195, DOI 10.1016/j.celrep.2019.12.064; Jasin M, 2016, DNA REPAIR, V44, P6, DOI 10.1016/j.dnarep.2016.05.001; Javadekar SM, 2015, FEBS J, V282, P2627, DOI 10.1111/febs.13311; Jayavaradhan R, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10735-7; Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829; John F, 2015, FARADAY DISCUSS, V177, P155, DOI 10.1039/c4fd00176a; John F, 2015, MACROMOL BIOSCI, V15, P521, DOI 10.1002/mabi.201400480; Kent T, 2015, NAT STRUCT MOL BIOL, V22, P230, DOI 10.1038/nsmb.2961; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Killian T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15206-x; Kim YG, 1996, P NATL ACAD SCI USA, V93, P1156, DOI 10.1073/pnas.93.3.1156; Kostyushev D, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38526-6; Kulashreshtha M, 2016, NUCLEIC ACIDS RES, V44, P8272, DOI 10.1093/nar/gkw573; Lackner DH, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10237; Leahy JJJ, 2004, BIOORG MED CHEM LETT, V14, P6083, DOI 10.1016/j.bmcl.2004.09.060; Li GL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09306-x; Li HY, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-019-0089-y; Lieber MR, 2010, ANNU REV BIOCHEM, V79, P181, DOI 10.1146/annurev.biochem.052308.093131; Lin S, 2014, ELIFE, V3, DOI 10.7554/eLife.04766; Liu YF, 2016, SCI REP-UK, V6, DOI 10.1038/srep24014; Lok BH, 2013, ONCOGENE, V32, P3552, DOI 10.1038/onc.2012.391; Ma M, 2017, CELL RES, V27, P578, DOI 10.1038/cr.2017.29; Ma YW, 2016, RNA BIOL, V13, P605, DOI 10.1080/15476286.2016.1185591; Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033; Mao ZY, 2008, DNA REPAIR, V7, P1765, DOI 10.1016/j.dnarep.2008.06.018; Maruyama T, 2015, NAT BIOTECHNOL, V33, P538, DOI 10.1038/nbt.3190; Mikuni T, 2016, CELL, V165, P1803, DOI 10.1016/j.cell.2016.04.044; Miura H, 2018, NAT PROTOC, V13, P195, DOI 10.1038/nprot.2017.153; Moreno-Mateos MA, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01836-2; Moscou MJ, 2009, SCIENCE, V326, P1501, DOI 10.1126/science.1178817; Nambiar M, 2011, NUCLEIC ACIDS RES, V39, P5813, DOI 10.1093/nar/gkr223; Nambiar TS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11105-z; Tran NT, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00365; Ochi T, 2015, SCIENCE, V347, P185, DOI 10.1126/science.1261971; Ochs F, 2016, NAT STRUCT MOL BIOL, V23, P714, DOI 10.1038/nsmb.3251; Orthwein A, 2015, NATURE, V528, P422, DOI 10.1038/nature16142; Pandey M., 2019, J RAD CANC RES, V10, P27, DOI 10.4103/jrcr.jrcr_24_18; Pandey M., 2017, J RADIAT CANCER RES, V8, P93, DOI [10.4103/jrcr.jrcr_18_17, DOI 10.4103/JRCR.JRCR_18_17]; Paulsen BS, 2017, NAT BIOMED ENG, V1, P878, DOI 10.1038/s41551-017-0145-2; Pawelczak KS, 2018, ACS CHEM BIOL, V13, P389, DOI 10.1021/acschembio.7b00777; Pinder J, 2015, NUCLEIC ACIDS RES, V43, P9379, DOI 10.1093/nar/gkv993; Ran FA, 2013, CELL, V154, P1380, DOI 10.1016/j.cell.2013.08.021; Ray U., 2020, CLIN ONCOL RES, V3, P2; Ray U, 2020, MOL CARCINOGEN, V59, P618, DOI 10.1002/mc.23186; Reid DA, 2017, NUCLEIC ACIDS RES, V45, P1872, DOI 10.1093/nar/gkw1221; Reid DA, 2015, P NATL ACAD SCI USA, V112, pE2575, DOI 10.1073/pnas.1420115112; Reyes AP, 2018, CELL STEM CELL, V23, P155, DOI 10.1016/j.stem.2018.07.008; Richardson CD, 2018, NAT GENET, V50, P1132, DOI 10.1038/s41588-018-0174-0; Riesenberg S, 2019, NUCLEIC ACIDS RES, V47, pE116, DOI 10.1093/nar/gkz669; Riesenberg S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04609-7; Robert F, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0215-6; Saito S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16112; Savic N, 2018, ELIFE, V7, DOI 10.7554/eLife.33761; Savic N, 2016, TRANSL RES, V168, P15, DOI 10.1016/j.trsl.2015.09.008; Shao SM, 2017, INT J BIOCHEM CELL B, V92, P43, DOI 10.1016/j.biocel.2017.09.012; Sharma S, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.58; Shen B, 2014, NAT METHODS, V11, P399, DOI [10.1038/NMETH.2857, 10.1038/nmeth.2857]; Shim G, 2017, ACTA PHARMACOL SIN, V38, P738, DOI 10.1038/aps.2017.2; Singh P, 2015, GENETICS, V199, P1, DOI 10.1534/genetics.114.169771; Smith CE, 2007, NATURE, V447, P102, DOI 10.1038/nature05723; Smith C, 2015, MOL THER, V23, P570, DOI 10.1038/mt.2014.226; Smith J, 2000, NUCLEIC ACIDS RES, V28, P3361, DOI 10.1093/nar/28.17.3361; Song B, 2015, STEM CELLS DEV, V24, P1053, DOI 10.1089/scd.2014.0347; Song F, 2017, MOL THER-NUCL ACIDS, V7, P53, DOI 10.1016/j.omtn.2017.02.006; Song J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10548; Srivastava M, 2015, CHEM BIOL, V22, P17, DOI 10.1016/j.chembiol.2014.11.013; Srivastava M, 2012, CELL, V151, P1474, DOI 10.1016/j.cell.2012.11.054; Suzuki K, 2016, NATURE, V540, P144, DOI 10.1038/nature20565; Tanenbaum ME, 2014, CELL, V159, P635, DOI 10.1016/j.cell.2014.09.039; Tomimatsu N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4561; Tripathi V, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03393-8; Chu VT, 2015, NAT BIOTECHNOL, V33, P543, DOI 10.1038/nbt.3198; Vartak SV, 2018, FEBS J, V285, P3959, DOI 10.1111/febs.14661; Wang HY, 2013, CELL, V153, P910, DOI 10.1016/j.cell.2013.04.025; Wienert B, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15845-1; Wu Y, 2008, J BIOL CHEM, V283, P14883, DOI 10.1074/jbc.M801097200; Wyman C, 2006, ANNU REV GENET, V40, P363, DOI 10.1146/annurev.genet.40.110405.090451; Xu SX, 2020, PROTEIN CELL, V11, P352, DOI 10.1007/s13238-020-00699-6; Yang D, 2016, SCI REP-UK, V6, DOI 10.1038/srep21264; Yang H, 2013, CELL, V154, P1370, DOI 10.1016/j.cell.2013.08.022; Ye LP, 2018, CELL DISCOV, V4, DOI 10.1038/s41421-018-0049-7; Yu C, 2015, CELL STEM CELL, V16, P142, DOI 10.1016/j.stem.2015.01.003; Yu SL, 2011, J BIOTECHNOL, V154, P21, DOI 10.1016/j.jbiotec.2011.03.023; Zelensky AN, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00124-3	122	17	17	0	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2020	39	41					6393	6405		10.1038/s41388-020-01445-2	http://dx.doi.org/10.1038/s41388-020-01445-2		SEP 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OA1JL	32884115				2022-12-28	WOS:000565829600002
J	Liang, ER; Lu, YS; Shi, YQ; Zhou, Q; Zhi, FC				Liang, Erbo; Lu, Yishi; Shi, Yanqiang; Zhou, Qian; Zhi, Fachao			MYEOV increases HES1 expression and promotes pancreatic cancer progression by enhancing SOX9 transactivity	ONCOGENE			English	Article							DNA METHYLATION; GENE-EXPRESSION; CELL; METASTASIS; EPIDEMIOLOGY; ACTIVATION; SUBSET; 11Q13; KRAS; SRY	Emerging evidence indicates that myeloma overexpressed (MYEOV) is an oncogene and plays crucial roles in multiple human cancers. However, its roles in the development of pancreatic ductal adenocarcinoma (PDAC) remain elusive. Here, we provide evidence of essential roles of MYEOV in the development and progression of PDAC. In tumor specimens derived from pancreatic cancer patients, MYEOV was overexpressed and associated with poor prognosis. In addition, MYEOV expression in PDAC was upregulated through promoter hypomethylation. MYEOV depletion impaired metastatic ability and proliferation of PDAC cells both in vitro and in vivo, whereas its overexpression had the opposite effect. Mechanistic investigations revealed that MYEOV interacted with SRY-Box Transcription Factor 9 (SOX9), a well-known oncogenic transcription factor in PDAC. This interaction occurred mainly in the nuclei of PDAC cells and increased transcriptional activity of SOX9. Furthermore, MYEOV promoted the expression ofHairy and enhancer of split homolog-1 (HES1), a SOX9 target gene, by enhancing SOX9 DNA-binding ability to theHES1enhancer without affecting the protein level and subcellular localization of SOX9. HES1 knockdown partly abrogated the oncogenic effect of MYEOV. Our findings suggest that MYEOV could be a potential prognostic biomarker and therapeutic target for PDAC.	[Liang, Erbo; Lu, Yishi; Shi, Yanqiang; Zhou, Qian; Zhi, Fachao] Guangdong Prov Key Lab Gastroenterol, Guangzhou 510515, Peoples R China; [Liang, Erbo; Lu, Yishi; Shi, Yanqiang; Zhou, Qian; Zhi, Fachao] Inst Gastroenterol Guangdong Prov, Guangzhou 510515, Peoples R China; [Liang, Erbo; Lu, Yishi; Shi, Yanqiang; Zhou, Qian; Zhi, Fachao] Southern Med Univ, Nanfang Hosp, Dept Gastroenterol, Guangzhou 510515, Peoples R China	Southern Medical University - China	Zhi, FC (corresponding author), Guangdong Prov Key Lab Gastroenterol, Guangzhou 510515, Peoples R China.; Zhi, FC (corresponding author), Inst Gastroenterol Guangdong Prov, Guangzhou 510515, Peoples R China.; Zhi, FC (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Gastroenterol, Guangzhou 510515, Peoples R China.	zhifc41532@163.com		Zhi, Fachao/0000-0001-8674-4737; Shi, Yanqiang/0000-0003-0814-6322				Abel EV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091983; Coccaro N, 2016, ONCOL LETT, V12, P1460, DOI 10.3892/ol.2016.4759; Deng FH, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0244-8; Fang LS, 2019, ONCOGENE, V38, P896, DOI 10.1038/s41388-018-0484-9; Fukuda Akihisa, 2013, Gastroenterology, V145, P904, DOI 10.1053/j.gastro.2013.08.028; Grimm D, 2020, SEMIN CANCER BIOL, V67, P122, DOI 10.1016/j.semcancer.2019.03.004; Grimont A, 2015, GUT, V64, P1790, DOI 10.1136/gutjnl-2014-307075; Harley VR, 2003, ENDOCR REV, V24, P466, DOI 10.1210/er.2002-0025; Horie M, 2017, MOL CANCER RES, V15, P1354, DOI 10.1158/1541-7786.MCR-17-0191; Huang L, 2015, NAT MED, V21, P1364, DOI 10.1038/nm.3973; Huang WY, 2015, NUCLEIC ACIDS RES, V43, pD856, DOI 10.1093/nar/gku1151; Ilic M, 2016, WORLD J GASTROENTERO, V22, P9694, DOI 10.3748/wjg.v22.i44.9694; Janssen JWG, 2000, BLOOD, V95, P2691; Janssen JWG, 2002, J HUM GENET, V47, P460, DOI 10.1007/s100380200065; Janssen JWG, 2002, INT J CANCER, V102, P608, DOI 10.1002/ijc.10765; Kawaguchi Y, 2013, J CLIN INVEST, V123, P1881, DOI 10.1172/JCI66022; Kopp JL, 2012, CANCER CELL, V22, P737, DOI 10.1016/j.ccr.2012.10.025; Lawlor G, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-81; Lee JY, 2014, PANCREATOLOGY, V14, P48, DOI 10.1016/j.pan.2013.11.011; Leung CON, 2016, ONCOTARGET, V7, P29371, DOI 10.18632/oncotarget.8835; Leyden J, 2006, BRIT J CANCER, V94, P1204, DOI 10.1038/sj.bjc.6603054; Li TT, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0877-2; Liu ZH, 2015, CANCER BIOL THER, V16, P353, DOI 10.1080/15384047.2015.1016662; McGuigan A, 2018, WORLD J GASTROENTERO, V24, P4846, DOI 10.3748/wjg.v24.i43.4846; Mertin S, 1999, NUCLEIC ACIDS RES, V27, P1359, DOI 10.1093/nar/27.5.1359; Mishra NK, 2017, ONCOTARGET, V8, P28990, DOI 10.18632/oncotarget.15993; Moreaux J, 2010, EXP HEMATOL, V38, P1189, DOI 10.1016/j.exphem.2010.09.002; Moss AC, 2006, BIOCHEM BIOPH RES CO, V345, P216, DOI 10.1016/j.bbrc.2006.04.094; Muller P, 2010, BREAST CANCER RES TR, V120, P317, DOI 10.1007/s10549-009-0381-6; Nevala-Plagemann C, 2020, NAT REV CLIN ONCOL, V17, P108, DOI 10.1038/s41571-019-0281-6; Nishikawa Y, 2019, ONCOGENE, V38, P4283, DOI 10.1038/s41388-019-0718-5; Rani A, 2016, CYTOKINE GROWTH F R, V30, P113, DOI 10.1016/j.cytogfr.2016.03.010; Royo JL, 2007, NAT PROTOC, V2, P1734, DOI 10.1038/nprot.2007.244; Ruan HH, 2017, ONCOTARGET, V8, P113163, DOI 10.18632/oncotarget.22635; Sato N, 2003, CANCER RES, V63, P4158; Seymour PA, 2007, P NATL ACAD SCI USA, V104, P1865, DOI 10.1073/pnas.0609217104; Shen ZY, 2015, ONCOTARGET, V6, P20672, DOI 10.18632/oncotarget.3967; Shi JG, 2018, INT J ONCOL, V52, P179, DOI 10.3892/ijo.2017.4201; Sim H, 2008, TRENDS ENDOCRIN MET, V19, P213, DOI 10.1016/j.tem.2008.04.002; Sun L, 2013, STEM CELLS, V31, P1454, DOI 10.1002/stem.1394; Takita J, 2011, CANCER SCI, V102, P1645, DOI 10.1111/j.1349-7006.2011.01995.x; Xie VK, 2017, CLIN CANCER RES, V23, P5585, DOI 10.1158/1078-0432.CCR-17-0387; Yen WC, 2015, CLIN CANCER RES, V21, P2084, DOI 10.1158/1078-0432.CCR-14-2808; Zhao TS, 2017, CANCER RES, V77, P874, DOI 10.1158/0008-5472.CAN-16-2170; Zhou H, 2018, ONCOGENE, V37, P912, DOI 10.1038/onc.2017.393	45	17	17	4	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2020	39	41					6437	6450		10.1038/s41388-020-01443-4	http://dx.doi.org/10.1038/s41388-020-01443-4		SEP 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OA1JL	32879444				2022-12-28	WOS:000565482600002
J	Burgess, M; Chen, UCE; Mapp, S; Blumenthal, A; Mollee, P; Gill, D; Saunders, NA				Burgess, M.; Chen, U. C. E.; Mapp, S.; Blumenthal, A.; Mollee, P.; Gill, D.; Saunders, N. A.			HDAC7 is an actionable driver of therapeutic antibody resistance by macrophages from CLL patients	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; SKIN-CANCER; CELLS; INHIBITION; PHAGOCYTOSIS; SELECTIVITY; SURVIVAL	Resistance, to therapeutic antibodies used to treat chronic lymphocytic leukemia (CLL) patients is common. Monocyte-derived macrophages (MDMs) are a major effector of antitumour responses to therapeutic antibodies and we have previously reported that resistance to therapeutic antibodies, by MDMs, increases as CLL disease progresses. In this study, we examine the effect of a Class IIa-selective HDAC inhibitor (TMP195) on the phagocytic response to opsonised tumor cells or non-opsonised targets by MDMs derived from CLL patients. We report that TMP195 enhances phagocytic responses to antibody-opsonised CLL cells andE. coliwithin 30 min of treatment. The enhanced response is phenocopied by knockdown of the Class IIa HDAC, HDAC7, or by low concentrations of the pan-HDAC inhibitor, vorinostat. HDAC7 knockdown and inhibition induces hyperacetylation and hyperphosphorylation of Bruton's tyrosine kinase (BTK). Moreover, BTK inhibitors abrogated the enhanced response to HDAC7 inhibition. Our data show that HDAC7 is an actionable driver of resistance to therapeutic antibodies by MDMs derived from CLL patients.	[Burgess, M.; Chen, U. C. E.; Saunders, N. A.] Univ Queensland, Woolloongabba, Qld, Australia; [Burgess, M.; Mapp, S.; Mollee, P.; Gill, D.] Princess Alexandra Hosp, Dept Haematol, Canc Serv Unit, Woolloongabba, Qld, Australia; [Mapp, S.] Univ Queensland, Translat Res Inst, Sch Med, Woolloongabba, Qld, Australia; [Blumenthal, A.] Univ Queensland, Translat Res Inst, Diamantina Inst, Woolloongabba, Qld, Australia	University of Queensland; University of Queensland; University of Queensland	Saunders, NA (corresponding author), Univ Queensland, Woolloongabba, Qld, Australia.	nsaunders@uq.edu.au	saunders, nicholas/E-1544-2014	saunders, nicholas/0000-0002-2478-3420; Chen, Yu Chen Enya/0000-0003-4223-5054	Queensland Health, Princess Alexandra Hospital	Queensland Health, Princess Alexandra Hospital	The authors acknowledge the generosity of the patients who donated their time and blood for this study. This work was supported by a generous donation from Jeff and Fran Maclean and a research support package to DG from Queensland Health, Princess Alexandra Hospital.	Ackerman ME, 2011, J IMMUNOL METHODS, V366, P8, DOI 10.1016/j.jim.2010.12.016; Barkal AA, 2019, NATURE, V572, P392, DOI 10.1038/s41586-019-1456-0; Bobrowicz M, 2017, BLOOD, V130, P1628, DOI [10.1182/blood-2016-08-736066, 10.1182/blood-2016-08736066]; Boissard F, 2015, LEUKEMIA LYMPHOMA, V56, P1570, DOI 10.3109/10428194.2014.991731; Bosch F, 2019, NAT REV CLIN ONCOL, V16, P684, DOI 10.1038/s41571-019-0239-8; Burgess M, 2017, ONCOGENE, V36, P2366, DOI 10.1038/onc.2016.387; Burgess M, 2013, CLIN CANCER RES, V19, P5675, DOI 10.1158/1078-0432.CCR-13-1037; Burgess M, 2012, LEUKEMIA LYMPHOMA, V53, P1988, DOI 10.3109/10428194.2012.672735; Chen YCE, 2017, BBA-REV CANCER, V1868, P176, DOI 10.1016/j.bbcan.2017.03.006; Chen YCE, 2020, LEUKEMIA, V34, P451, DOI 10.1038/s41375-019-0556-z; Church AK, 2016, CLIN EXP IMMUNOL, V183, P90, DOI 10.1111/cei.12697; Galletti G, 2016, CELL REP, V14, P1748, DOI 10.1016/j.celrep.2016.01.042; Ginhoux F, 2016, NAT IMMUNOL, V17, P34, DOI 10.1038/ni.3324; Guerriero JL, 2017, NATURE, V543, P428, DOI 10.1038/nature21409; Gul N, 2014, J CLIN INVEST, V124, P812, DOI 10.1172/JCI66776; Hallek M, 2008, BLOOD, V111, P5446, DOI 10.1182/blood-2007-06-093906; Hanna BS, 2016, LEUKEMIA, V30, P570, DOI 10.1038/leu.2015.305; Jung JW, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1479627; Khan N, 2008, BIOCHEM J, V409, P581, DOI 10.1042/BJ20070779; Kimbrough D, 2018, J MOL CELL CARDIOL, V119, P51, DOI 10.1016/j.yjmcc.2018.04.011; Lindelof B, 2000, BRIT J DERMATOL, V143, P513, DOI 10.1046/j.1365-2133.2000.03703.x; Liu ZJ, 2010, J IMMUNOL, V184, P244, DOI 10.4049/jimmunol.0902324; Lobera M, 2013, NAT CHEM BIOL, V9, P319, DOI [10.1038/nchembio.1223, 10.1038/NCHEMBIO.1223]; Marek L, 2013, J MED CHEM, V56, P427, DOI 10.1021/jm301254q; Murray PJ, 2017, ANNU REV PHYSIOL, V79, P541, DOI 10.1146/annurev-physiol-022516-034339; Qi XB, 2018, J CELL BIOCHEM, V119, P3081, DOI 10.1002/jcb.26446; Ramsay HM, 2002, BRIT J DERMATOL, V147, P950, DOI 10.1046/j.1365-2133.2002.04976.x; Ribes S, 2010, INFECT IMMUN, V78, P865, DOI 10.1128/IAI.01110-09; Rogers KA, 2019, LEUKEMIA, V33, P2527, DOI 10.1038/s41375-019-0481-1; Roghanian A, 2015, CANCER CELL, V27, P473, DOI 10.1016/j.ccell.2015.03.005; Salvagno C, 2019, NAT CELL BIOL, V21, P511, DOI 10.1038/s41556-019-0298-1; Uribe-Querol E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01368; Van Damme M, 2014, EPIGENETICS-US, V9, P1374, DOI 10.4161/15592294.2014.969628; VanDerMeid KR, 2018, CANCER IMMUNOL RES, V6, P1150, DOI 10.1158/2326-6066.CIR-18-0319; Varughese T, 2018, CLIN INFECT DIS, V67, P687, DOI 10.1093/cid/ciy175; Veillette A, 2018, TRENDS IMMUNOL, V39, P173, DOI 10.1016/j.it.2017.12.005; Weiskopf K, 2017, EUR J CANCER, V76, P100, DOI 10.1016/j.ejca.2017.02.013	37	7	7	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2020	39	35					5756	5767		10.1038/s41388-020-01394-w	http://dx.doi.org/10.1038/s41388-020-01394-w		JUL 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NF2QB	32709923				2022-12-28	WOS:000552155200001
J	Feng, H; Liu, J; Qiu, YY; Liu, Y; Saiyin, H; Liang, X; Zheng, F; Wang, Y; Jiang, DK; Wang, Y; Yu, L; Su, W; Shen, SQ; Wu, JX				Feng, Huan; Liu, Juan; Qiu, Yangyang; Liu, Yao; Saiyin, Hexig; Liang, Xiao; Zheng, Fen; Wang, Ying; Jiang, Deke; Wang, Ying; Yu, Long; Su, Wei; Shen, Suqin; Wu, Jiaxue			RNA-binding motif protein 43 (RBM43) suppresses hepatocellular carcinoma progression through modulation of cyclin B1 expression	ONCOGENE			English	Article							CELL-CYCLE; MESSENGER-RNA; PROLIFERATION; APOPTOSIS	RNA-binding proteins play key roles in the posttranscriptional regulation of mRNA during cancer progression. Here, we show that RNA-binding motif protein 43 (RBM43) is significantly downregulated in human tumors, and its low expression is correlated with poor prognosis in patients with HCC. Overexpression of RBM43 suppressed cell proliferation in culture and resulted in the growth arrest of tumor xenografts, whereas downregulating RBM43 played an opposite role. We have also demonstrated that overexpression or knockdown of RBM43 affects the cell-cycle progression of liver cancer cells. Mechanistically, RBM43 directly associated with the 3 ' UTR of Cyclin B1 mRNA and regulated its expression. Moreover, loss ofRbm43in mice promoted liver carcinogenesis and HCC development after diethylnitrosamine (DEN)-carbon tetrachloride (CCl4) treatment. Taken together, our data indicate that RBM43 is a tumor suppressor that controls the cell cycle through modulation of Cyclin B1 expression, providing evidence that RBM43 is particularly important in HCC.	[Feng, Huan; Liu, Juan; Qiu, Yangyang; Liu, Yao; Saiyin, Hexig; Liang, Xiao; Zheng, Fen; Wang, Ying; Yu, Long; Su, Wei; Shen, Suqin; Wu, Jiaxue] Fudan Univ, Zhongshan Hosp, State Key Lab Genet Engn, Shanghai, Peoples R China; [Feng, Huan; Liu, Juan; Qiu, Yangyang; Liu, Yao; Saiyin, Hexig; Liang, Xiao; Zheng, Fen; Wang, Ying; Yu, Long; Su, Wei; Shen, Suqin; Wu, Jiaxue] Fudan Univ, Sch Life Sci, Shanghai, Peoples R China; [Jiang, Deke] Southern Med Univ, Nanfang Hosp, Dept Infect Dis, Guangzhou, Peoples R China; [Jiang, Deke] Southern Med Univ, Nanfang Hosp, Hepatol Unit, Guangzhou, Peoples R China; [Wang, Ying] Second Mil Med Univ, Changhai Hosp, Dept Oncol, Shanghai, Peoples R China	Fudan University; Fudan University; Southern Medical University - China; Southern Medical University - China; Naval Medical University	Shen, SQ; Wu, JX (corresponding author), Fudan Univ, Zhongshan Hosp, State Key Lab Genet Engn, Shanghai, Peoples R China.; Shen, SQ; Wu, JX (corresponding author), Fudan Univ, Sch Life Sci, Shanghai, Peoples R China.	shensq@fudan.edu.cn; jiaxue@fudan.edu.cn		Saiyin, Hexige/0000-0003-2993-6817; Jiang, Deke/0000-0002-7888-2344	National Natural Science Foundation of China [81702742, 81972712]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (81702742 to SS and 81972712 to JW).	Aaltonen K, 2009, BRIT J CANCER, V100, P1055, DOI 10.1038/sj.bjc.6604874; Albertsen HM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058257; Castello A, 2012, CELL, V149, P1393, DOI 10.1016/j.cell.2012.04.031; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Covini G, 1997, HEPATOLOGY, V25, P75; Dang H, 2017, CANCER CELL, V32, P101, DOI 10.1016/j.ccell.2017.06.002; Dapito DH, 2012, CANCER CELL, V21, P504, DOI 10.1016/j.ccr.2012.02.007; Denicourt C, 2004, GENE DEV, V18, P851, DOI 10.1101/gad.1205304; Dong J, 2018, CLIN GASTROENTEROL H, V16, P1598, DOI 10.1016/j.cgh.2018.03.007; Egloff AM, 2005, ANN NY ACAD SCI, V1062, P29, DOI 10.1196/annals.1358.005; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Gerstberger S, 2014, NAT REV GENET, V15, P829, DOI 10.1038/nrg3813; Glisovic T, 2008, FEBS LETT, V582, P1977, DOI 10.1016/j.febslet.2008.03.004; Guan MJ, 2019, HUM GENOMICS, V13, DOI 10.1186/s40246-019-0205-7; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hentze MW, 2018, NAT REV MOL CELL BIO, V19, P327, DOI 10.1038/nrm.2017.130; Jiang DK, 2013, NAT GENET, V45, P72, DOI 10.1038/ng.2483; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Nakahata S, 2003, MECH DEVELOP, V120, P865, DOI 10.1016/S0925-4773(03)00160-6; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Sakurai T, 2016, ONCOGENE, V35, P5000, DOI 10.1038/onc.2016.35; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Takahashi K, 2018, BIOCHEM BIOPH RES CO, V503, P2778, DOI 10.1016/j.bbrc.2018.08.039; Van Assche E, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00141; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Wang Y, 2014, CANCER CELL, V26, P374, DOI 10.1016/j.ccr.2014.07.010; Wang ZQ, 2014, DEV CELL, V29, P217, DOI 10.1016/j.devcel.2014.03.012; Zhang H, 2019, J CELL PHYSIOL, V234, P619, DOI 10.1002/jcp.26816; Zhao LJ, 2019, NUCLEIC ACIDS RES, V47, P2011, DOI 10.1093/nar/gky1209	30	13	14	3	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2020	39	33					5495	5506		10.1038/s41388-020-1380-7	http://dx.doi.org/10.1038/s41388-020-1380-7		JUL 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NB0QV	32632220				2022-12-28	WOS:000546748200001
J	Aubry, A; Pearson, JD; Huang, K; Livne-Bar, I; Ahmad, M; Jagadeesan, M; Khetan, V; Ketela, T; Brown, KR; Yu, T; Lu, SY; Wrana, JL; Moffat, J; Bremner, R				Aubry, Arthur; Pearson, Joel D.; Huang, Katherine; Livne-Bar, Izhar; Ahmad, Mohammad; Jagadeesan, Madhavan; Khetan, Vikas; Ketela, Troy; Brown, Kevin R.; Yu, Tao; Lu, Suying; Wrana, Jeffrey L.; Moffat, Jason; Bremner, Rod			Functional genomics identifies new synergistic therapies for retinoblastoma	ONCOGENE			English	Article							DNA-REPAIR; TUMOR-SUPPRESSOR; INTRAVITREAL CHEMOTHERAPY; HOMOLOGOUS RECOMBINATION; BRCA1 INTERACTS; RB INACTIVATION; VITREOUS SEEDS; CELL-DEATH; PATHWAY; PROTEIN	Local intravitreal or intra-arterial chemotherapy has improved therapeutic success for the pediatric cancer retinoblastoma (RB), but toxicity remains a major caveat. RB initiates primarily withRB1loss or, rarely,MYCNamplification, but the critical downstream networks are incompletely understood. We set out to uncover perturbed molecular hubs, identify synergistic drug combinations to target these vulnerabilities, and expose and overcome drug resistance. We applied dynamic transcriptomic analysis to identify network hubs perturbed in RB versus normal fetal retina, and performed in vivo RNAi screens inRB1(null)andRB1(wt);MYCN(amp)orthotopic xenografts to pinpoint essential hubs. We employed in vitro and in vivo studies to validate hits, define mechanism, develop new therapeutic modalities, and understand drug resistance. We identified BRCA1 and RAD51 as essential for RB cell survival. Their oncogenic activity was independent of BRCA1 functions in centrosome, heterochromatin, or ROS regulation, and instead linked to DNA repair. RAD51 depletion or inhibition with the small molecule inhibitor, B02, killed RB cells in a Chk1/Chk2/p53-dependent manner. B02 further synergized with clinically relevant topotecan (TPT) to engage this pathway, activating p53-BAX mediated killing of RB but not human retinal progenitor cells. Paradoxically, a B02/TPT-resistant tumor exhibited more DNA damage than sensitive RB cells. Resistance reflected dominance of the p53-p21 axis, which mediated cell cycle arrest instead of death. Deleting p21 or applying the BCL2/BCL2L1 inhibitor Navitoclax re-engaged the p53-BAX axis, and synergized with B02, TPT or both to override resistance. These data expose new synergistic therapies to trigger p53-induced killing in diverse RB subtypes.	[Aubry, Arthur; Pearson, Joel D.; Huang, Katherine; Ahmad, Mohammad; Yu, Tao; Lu, Suying; Wrana, Jeffrey L.; Bremner, Rod] Sinai Hlth, Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada; [Aubry, Arthur; Pearson, Joel D.; Bremner, Rod] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Pearson, Joel D.; Livne-Bar, Izhar; Bremner, Rod] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada; [Livne-Bar, Izhar] Univ Hlth Network, Krembil Res Inst, Toronto, ON, Canada; [Jagadeesan, Madhavan] Sankara Nethralaya, Vis Res Fdn, Chennai, Tamil Nadu, India; [Khetan, Vikas] Sankara Nethralaya, Dept Vitroretina & Ocular Oncol, Chennai, Tamil Nadu, India; [Ketela, Troy; Brown, Kevin R.; Moffat, Jason] Univ Toronto, Donnelly Ctr, Toronto, ON, Canada; [Wrana, Jeffrey L.; Moffat, Jason] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada; [Jagadeesan, Madhavan] Dualhelix Genet Diagnost, Chennai, Tamil Nadu, India	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; Krembil Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto	Bremner, R (corresponding author), Sinai Hlth, Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada.; Bremner, R (corresponding author), Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.	bremner@lunenfeld.ca	Pearson, Joel/AFK-9248-2022; Bremner, Rod/I-6490-2012; Moffat, Jason/AAC-1110-2020	Bremner, Rod/0000-0001-9184-7212; Moffat, Jason/0000-0002-5663-8586; Aubry, Arthur/0000-0002-4344-1194; Khetan, Vikas/0000-0003-4396-9877	Canadian Institutes for Health Research (CIHR) [153128]; Cancer Research Society; Krembil Foundation	Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Cancer Research Society; Krembil Foundation	This work was funded by grants to RB from the Canadian Institutes for Health Research (CIHR) Grant #153128, The Cancer Research Society, and the Krembil Foundation.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Abramson DH, 2015, JAMA OPHTHALMOL, V133, P1341, DOI 10.1001/jamaophthalmol.2015.3108; Anderson SN, 2007, J BIOMOL SCREEN, V12, P938, DOI 10.1177/1087057107306130; Aubry A, 2020, CELL DEATH DISCOV, V6, DOI 10.1038/s41420-020-0237-8; Banerjee R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5527; Blackshaw S, 2004, PLOS BIOL, V2, P1411, DOI 10.1371/journal.pbio.0020247; Bouwman P, 2012, NAT REV CANCER, V12, P587, DOI 10.1038/nrc3342; Camp DA, 2019, J AAPOS, V23, P241, DOI 10.1016/j.jaapos.2019.03.002; Ceccaldi R, 2016, TRENDS CELL BIOL, V26, P52, DOI 10.1016/j.tcb.2015.07.009; Chen D, 2004, CANCER CELL, V5, P539, DOI 10.1016/j.ccr.2004.05.025; Chen DN, 2009, NATURE, V462, P925, DOI 10.1038/nature08544; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; Chu WK, 2016, P NATL ACAD SCI USA, V113, P14396, DOI 10.1073/pnas.1617427113; Clairmont CS, 2020, NAT CELL BIOL, V22, P87, DOI 10.1038/s41556-019-0442-y; Cook R, 2015, CELL REP, V10, P2006, DOI 10.1016/j.celrep.2015.02.059; Corella AN, 2020, CLIN CANCER RES, V26, P1667, DOI 10.1158/1078-0432.CCR-19-0775; Corson TW, 2007, GENE CHROMOSOME CANC, V46, P617, DOI 10.1002/gcc.20457; De Francesco S, 2015, INT OPHTHALMOL, V35, P887, DOI 10.1007/s10792-015-0129-8; Deng CX, 2002, ONCOGENE, V21, P6222, DOI 10.1038/sj.onc.1205713; Dimaras H, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.21; Dizin E, 2006, J BIOL CHEM, V281, P24236, DOI 10.1074/jbc.M602176200; Donzelli M, 2003, EMBO REP, V4, P671, DOI 10.1038/sj.embor.embor887; Downward J, 2004, ONCOGENE, V23, P8376, DOI 10.1038/sj.onc.1208073; Elison JR, 2006, ARCH OPHTHALMOL-CHIC, V124, P1269, DOI 10.1001/archopht.124.9.1269; Etemadmoghadam D, 2013, P NATL ACAD SCI USA, V110, P19489, DOI 10.1073/pnas.1314302110; FITZSIMMONS J, 1994, EARLY HUM DEV, V38, P121, DOI 10.1016/0378-3782(94)90223-2; Foucquier J, 2015, PHARMACOL RES PERSPE, V3, DOI 10.1002/prp2.149; Francis JH, 2017, OPHTHALMOLOGY, V124, P1548, DOI 10.1016/j.ophtha.2017.04.010; Francis JH, 2015, OPHTHALMOLOGY, V122, P1173, DOI 10.1016/j.ophtha.2015.01.017; Garsed DW, 2018, CLIN CANCER RES, V24, P569, DOI 10.1158/1078-0432.CCR-17-1621; Gavande NS, 2016, PHARMACOL THERAPEUT, V160, P65, DOI 10.1016/j.pharmthera.2016.02.003; Gong XQ, 2019, CANCER DISCOV, V9, P248, DOI 10.1158/2159-8290.CD-18-0469; Gorrini C, 2013, J EXP MED, V210, P1529, DOI 10.1084/jem.20121337; Helleday T, 2008, NAT REV CANCER, V8, P193, DOI 10.1038/nrc2342; Huang F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100993; Huang F, 2011, ACS CHEM BIOL, V6, P628, DOI 10.1021/cb100428c; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Knudsen ES, 2006, CURR MOL MED, V6, P749; Landreville S, 2010, CURR EYE RES, V35, P435, DOI 10.3109/02713680903509428; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 2005, MOL CELL BIOL, V25, P3563, DOI 10.1128/MCB.25.9.3563-3574.2005; Lasorella A, 2002, CANCER RES, V62, P301; Laurie NA, 2007, CURR CANCER DRUG TAR, V7, P689, DOI 10.2174/156800907782418266; Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194; Lemaitre S, 2020, CLIN EXP OPHTHALMOL, V48, P500, DOI 10.1111/ceo.13711; Liang TY, 2020, INT J OPHTHALMOL-CHI, V13, P257, DOI 10.18240/ijo.2020.02.09; Liu JC, 2018, CELL REP, V23, P112, DOI 10.1016/j.celrep.2018.03.039; Lochmann TL, 2018, CLIN CANCER RES, V24, P360, DOI 10.1158/1078-0432.CCR-17-1606; Maclay T, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.AM2019-363; MacPherson D, 2004, GENE DEV, V18, P1681, DOI 10.1101/gad.1203304; Marshall AE, 2019, MOL CELL BIOL, V39, DOI 10.1128/MCB.00105-19; MIYASHITA T, 1995, CELL, V80, P293; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Munier FL, 2012, BRIT J OPHTHALMOL, V96, P1078, DOI 10.1136/bjophthalmol-2011-301450; Nam C, 2010, HISTOL HISTOPATHOL, V25, P485, DOI 10.14670/HH-25.485; Oser MG, 2019, CANCER DISCOV, V9, P230, DOI 10.1158/2159-8290.CD-18-0389; Pajovic S, 2011, INVEST OPHTH VIS SCI, V52, P7618, DOI 10.1167/iovs.11-7989; Pickering MT, 2006, ONCOGENE, V25, P746, DOI 10.1038/sj.onc.1209103; Qi DL, 2017, ONCOGENE, V36, P1760, DOI 10.1038/onc.2016.350; Rasmussen RD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13398; Rudin CM, 2012, CLIN CANCER RES, V18, P3163, DOI 10.1158/1078-0432.CCR-11-3090; Rushlow DE, 2013, LANCET ONCOL, V14, P327, DOI 10.1016/S1470-2045(13)70045-7; Sangwan M, 2012, ONCOGENE, V31, P5019, DOI 10.1038/onc.2011.654; Schuster A, 2019, TRENDS BIOTECHNOL, V37, P38, DOI 10.1016/j.tibtech.2018.08.002; Shepard T.H., 1975, GROWTH DEV HUMAN EMB; Shields CL, 2014, JAMA OPHTHALMOL, V132, P319, DOI 10.1001/jamaophthalmol.2013.7666; Sims D, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-10-r104; Suvarna V, 2019, EUR J PHARMACOL, V862, DOI 10.1016/j.ejphar.2019.172655; Suzuki A, 1999, MOL CELL BIOL, V19, P3842; Taylor IW, 2009, NAT BIOTECHNOL, V27, P199, DOI 10.1038/nbt.1522; Thangavel C, 2014, CLIN CANCER RES, V20, P5468, DOI 10.1158/1078-0432.CCR-14-0326; To KH, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-69; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; Tsui JY, 2008, INVEST OPHTH VIS SCI, V49, P490, DOI 10.1167/iovs.07-0653; Velez-Cruz R, 2016, GENE DEV, V30, P2500, DOI 10.1101/gad.288282.116; Wang HB, 2010, NAT GENET, V42, P83, DOI 10.1038/ng.498; WINDLE JJ, 1990, NATURE, V343, P665, DOI 10.1038/343665a0; Xu XLL, 2009, CELL, V137, P1018, DOI 10.1016/j.cell.2009.03.051; Yang Y, 2013, INT J MOL MED, V32, P137, DOI 10.3892/ijmm.2013.1374; Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296; Zhu Q, 2011, NATURE, V477, P179, DOI 10.1038/nature10371	81	12	12	4	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 30	2020	39	31					5338	5357		10.1038/s41388-020-1372-7	http://dx.doi.org/10.1038/s41388-020-1372-7		JUN 2020	20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MT1TS	32572160	Green Published, hybrid			2022-12-28	WOS:000542723000002
J	Kwon, OS; Lee, H; Kong, HJ; Kwon, EJ; Park, JE; Lee, W; Kang, S; Kim, M; Kim, W; Cha, HJ				Kwon, Ok-Seon; Lee, Haeseung; Kong, Hyeon-Joon; Kwon, Eun-Ji; Park, Ji Eun; Lee, Wooin; Kang, Seungmin; Kim, Mirang; Kim, Wankyu; Cha, Hyuk-Jin			Connectivity map-based drug repositioning of bortezomib to reverse the metastatic effect of GALNT14 in lung cancer	ONCOGENE			English	Article							TGF-BETA; EXPRESSION; INHIBITORS; GENE; GLYCOSYLATION; CANDIDATES; PROTEASOME; DULANERMIN; GALNAC-T14; MIGRATION	Despite the continual discovery of promising new cancer targets, drug discovery is often hampered by the poor druggability of these targets. As such, repurposing FDA-approved drugs based on cancer signatures is a useful alternative to cancer precision medicine. Here, we adopted an in silico approach based on large-scale gene expression signatures to identify drug candidates for lung cancer metastasis. Our clinicogenomic analysis identified GALNT14 as a putative driver of lung cancer metastasis, leading to poor survival. To overcome the poor druggability of GALNT14 in the control of metastasis, we utilized the Connectivity Map and identified bortezomib (BTZ) as a potent metastatic inhibitor, bypassing the direct inhibition of the enzymatic activity of GALNT14. The antimetastatic effect of BTZ was verified both in vitro and in vivo. Notably, both BTZ treatment and GALNT14 knockdown attenuated TGF beta-mediated gene expression and suppressed TGF beta-dependent metastatic genes. These results demonstrate that our in silico approach is a viable strategy for the use of undruggable targets in cancer therapies and for revealing the underlying mechanisms of these targets.	[Kwon, Ok-Seon; Kwon, Eun-Ji; Park, Ji Eun; Lee, Wooin; Cha, Hyuk-Jin] Seoul Natl Univ, Coll Pharm, Seoul 08826, South Korea; [Kwon, Ok-Seon; Cha, Hyuk-Jin] Seoul Natl Univ, Pharmaceut Sci Res Inst, Seoul 08826, South Korea; [Lee, Haeseung; Kim, Wankyu] Ewha Womans Univ, Dept Life Sci, Coll Nat Sci, Seoul 03760, South Korea; [Kong, Hyeon-Joon] Sogang Univ, Dept Life Sci, Coll Nat Sci, Seoul 04107, South Korea; [Kang, Seungmin] Ewha Womans Univ, KaiPharm, Seoul 03760, South Korea; [Kim, Mirang] Korea Res Inst Biosci & Biotechnol KRIBB, Personalized Genom Med Res Ctr, Daejeon 34141, South Korea; [Kwon, Ok-Seon] Korea Res Inst Biosci & Biotechnol KRIBB, Stem Cell Convergence Res Ctr, Daejeon 34141, South Korea; [Lee, Haeseung] Korea Inst Oriental Med, Future Med Div, Intellectual Informat Team, Daejeon 34054, South Korea	Seoul National University (SNU); Seoul National University (SNU); Ewha Womans University; Sogang University; Ewha Womans University; Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Institute of Oriental Medicine (KIOM)	Cha, HJ (corresponding author), Seoul Natl Univ, Coll Pharm, Seoul 08826, South Korea.; Cha, HJ (corresponding author), Seoul Natl Univ, Pharmaceut Sci Res Inst, Seoul 08826, South Korea.; Kim, W (corresponding author), Ewha Womans Univ, Dept Life Sci, Coll Nat Sci, Seoul 03760, South Korea.	wkim@ewha.ac.kr; hjcha93@snu.ac.kr	Lee, Wooin/K-7789-2012	Lee, Wooin/0000-0001-7805-869X; Lee, Haeseung/0000-0002-9947-4032; Cha, Hyuk-Jin/0000-0001-9277-2662	National Research Foundation of Korea [NRF-2017M3C9A5028691, NRF-2019R1C1C1008710, NRF-2017M3A9B3061843]	National Research Foundation of Korea(National Research Foundation of Korea)	We appreciate Jeong-Hwan Kim, Seon-Young Kim and Dong-Uk Kim at Korea Research Institute of Bioscience and Biotechnology (KRIBB) for helpful discussions. This work was supported by a grant from the National Research Foundation of Korea (NRF-2017M3C9A5028691 from HJ.C, NRF-2019R1C1C1008710 from OS.K and NRF-2017M3A9B3061843 from W.K).	Argyriou AA, 2008, BLOOD, V112, P1593, DOI 10.1182/blood-2008-04-149385; Ashburn TT, 2004, NAT REV DRUG DISCOV, V3, P673, DOI 10.1038/nrd1468; Bertolini F, 2015, NAT REV CLIN ONCOL, V12, P732, DOI 10.1038/nrclinonc.2015.169; Chang TP, 2015, J IMMUNOL, V194, P2942, DOI 10.4049/jimmunol.1402610; Chen B, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16022; Dang CV, 2017, NAT REV CANCER, V17, P502, DOI 10.1038/nrc.2017.36; De Mariano M, 2015, ONCOTARGET, V6, P26335, DOI 10.18632/oncotarget.4501; Gandolfi S, 2017, CANCER METAST REV, V36, P561, DOI 10.1007/s10555-017-9707-8; Gayvert KM, 2016, CELL REP, V15, P2348, DOI 10.1016/j.celrep.2016.05.037; Groll M, 2006, STRUCTURE, V14, P451, DOI 10.1016/j.str.2005.11.019; Gross BJ, 2008, J AM CHEM SOC, V130, P440, DOI 10.1021/ja078125s; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hang HC, 2004, CHEM BIOL, V11, P337, DOI 10.1016/j.chembiol.2004.02.023; Huang DD, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317705849; Iorio F, 2013, DRUG DISCOV TODAY, V18, P350, DOI 10.1016/j.drudis.2012.07.014; Jahchan NS, 2013, CANCER DISCOV, V3, P1364, DOI 10.1158/2159-8290.CD-13-0183; Kim ES, 2011, CANCER DISCOV, V1, P44, DOI 10.1158/2159-8274.CD-10-0010; Kwon OS, 2019, ARCH PHARM RES, V42, P879, DOI 10.1007/s12272-019-01176-3; Kwon OS, 2015, ONCOTARGET, V6, P41916, DOI 10.18632/oncotarget.6019; Lazo JS, 2016, ANNU REV PHARMACOL, V56, P23, DOI 10.1146/annurev-pharmtox-010715-103440; Lee H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150460; Lee JS, 2015, NEURO-ONCOLOGY, V17, P95, DOI 10.1093/neuonc/nou145; Levy L, 2005, MOL CELL BIOL, V25, P8108, DOI 10.1128/MCB.25.18.8108-8125.2005; Li AM, 2013, BIOCHEM BIOPH RES CO, V436, P486, DOI 10.1016/j.bbrc.2013.05.131; Liang KH, 2016, PHARMACOGENOMICS, V17, P353, DOI 10.2217/pgs.15.179; Maggiora G, 2014, J MED CHEM, V57, P3186, DOI 10.1021/jm401411z; Marquart J, 2018, JAMA ONCOL, V4, P1093, DOI 10.1001/jamaoncol.2018.1660; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Moon YW, 2015, CELL DEATH DIFFER, V22, P1341, DOI 10.1038/cdd.2014.228; Nagaraj AB, 2018, ONCOGENE, V37, P403, DOI 10.1038/onc.2017.328; Olsen D, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00105; Oprea TI, 2015, ASSAY DRUG DEV TECHN, V13, P299, DOI 10.1089/adt.2015.29011.tiodrrr; Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046; Padua D, 2009, CELL RES, V19, P89, DOI 10.1038/cr.2008.316; Shan JS, 2018, TRANSL ONCOL, V11, P786, DOI 10.1016/j.tranon.2018.04.003; Sleire L, 2017, PHARMACOL RES, V124, P74, DOI 10.1016/j.phrs.2017.07.013; Song KH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13796; Soria JC, 2011, J CLIN ONCOL, V29, P4442, DOI 10.1200/JCO.2011.37.2623; Spear BB, 2001, TRENDS MOL MED, V7, P201, DOI 10.1016/S1471-4914(01)01986-4; Stern HM, 2010, CLIN CANCER RES, V16, P1587, DOI 10.1158/1078-0432.CCR-09-3108; Subramanian A, 2017, CELL, V171, P1437, DOI 10.1016/j.cell.2017.10.049; Ten Hagen KG, 2003, GLYCOBIOLOGY, V13, p1R, DOI 10.1093/glycob/cwg007; Tian HN, 2015, MOL CARCINOGEN, V54, P1159, DOI 10.1002/mc.22186; Tsherniak A, 2017, CELL, V170, P564, DOI 10.1016/j.cell.2017.06.010; van Noort V, 2014, CANCER RES, V74, P5690, DOI 10.1158/0008-5472.CAN-13-3540; van 't Veer LJ, 2008, NATURE, V452, P564, DOI 10.1038/nature06915; Wagle MC, 2018, NPJ PRECIS ONCOL, V2, DOI 10.1038/s41698-018-0051-4; Wagner KW, 2007, NAT MED, V13, P1070, DOI 10.1038/nm1627; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wang ZQ, 2014, ONCOTARGET, V5, P544, DOI 10.18632/oncotarget.1652; Wu C, 2009, J BIOSCIENCES, V34, P389, DOI 10.1007/s12038-009-0045-z; Yeh CT, 2014, INT J CANCER, V134, P1214, DOI 10.1002/ijc.28439; Zeniya M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13486-x; Zhou X, 2017, J THORAC ONCOL, V12, pS1542, DOI 10.1016/j.jtho.2017.06.044	54	17	17	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	23					4567	4580		10.1038/s41388-020-1316-2	http://dx.doi.org/10.1038/s41388-020-1316-2		MAY 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LU5ZF	32388539				2022-12-28	WOS:000531196000001
J	Choi, PW; So, WW; Yang, JZ; Liu, SB; Tong, KK; Kwan, KM; Kwok, JSL; Tsui, SKW; Ng, SK; Hales, KH; Hales, DB; Welch, WR; Crum, CP; Fong, WP; Berkowitz, RS; Ng, SW				Choi, Pui-Wah; So, Wai Wing; Yang, Junzheng; Liu, Shubai; Tong, Ka Kui; Kwan, Kin Ming; Kwok, Jamie S. -L.; Tsui, Stephen K. W.; Ng, Shu-Kay; Hales, Karen H.; Hales, Dale B.; Welch, William R.; Crum, Christopher P.; Fong, Wing-Ping; Berkowitz, Ross S.; Ng, Shu-Wing			MicroRNA-200 family governs ovarian inclusion cyst formation and mode of ovarian cancer spread	ONCOGENE			English	Article							E-CADHERIN; SEROUS CARCINOMAS; MIR-200 FAMILY; FALLOPIAN-TUBE; CELL; RISK; SRC; PHENOTYPE; INVASION; INTEGRIN	Epidemiologic and histopathologic findings and the laying hen model support the long-standing incessant ovulation hypothesis and cortical inclusion cyst involvement in sporadic ovarian cancer development. MicroRNA-200 (miR-200) family is highly expressed in ovarian cancer. Herewith, we show that ovarian surface epithelial (OSE) cells with ectopic miR-200 expression formed stabilized cysts in three-dimensional (3D) organotypic culture with E-cadherin fragment expression and steroid hormone pathway activation, whereas ovarian cancer 3D cultures with miR-200 knockdown showed elevated TGF-beta expression, mitotic spindle disorientation, increased lumenization, disruption of ROCK-mediated myosin II phosphorylation, and SRC signaling, which led to histotype-dependent loss of collective movement in tumor spread. Gene expression profiling revealed that epithelial-mesenchymal transition and hypoxia were the top enriched gene sets regulated by miR-200 in both OSE and ovarian cancer cells. The molecular changes uncovered by the in vitro studies were verified in both human and laying hen ovarian cysts and tumor specimens. As miR-200 is also essential for ovulation, our results of estrogen pathway activation in miR-200-expressing OSE cells add another intriguing link between incessant ovulation and ovarian carcinogenesis.	[Choi, Pui-Wah; Yang, Junzheng; Liu, Shubai; Berkowitz, Ross S.; Ng, Shu-Wing] Harvard Med Sch, Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA; [Choi, Pui-Wah; So, Wai Wing; Tong, Ka Kui; Kwan, Kin Ming; Fong, Wing-Ping] Chinese Univ Hong Kong, Sch Life Sci, Hong Kong, Peoples R China; [Kwan, Kin Ming] Chinese Univ Hong Kong, Ctr Cell & Dev Biol, Hong Kong, Peoples R China; [Kwan, Kin Ming] Chinese Univ Hong Kong, State Key Lab Agrobiotechnol, Hong Kong, Peoples R China; [Kwok, Jamie S. -L.; Tsui, Stephen K. W.] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Peoples R China; [Ng, Shu-Kay] Griffith Univ, Sch Med, Nathan, Qld 4111, Australia; [Ng, Shu-Kay] Griffith Univ, Menzies Hlth Inst Queensland, Nathan, Qld 4111, Australia; [Hales, Karen H.; Hales, Dale B.] Southern Illinois Sch Med, Dept Obstet Gynecol, Carbondale, IL 62901 USA; [Hales, Dale B.] Southern Illinois Sch Med, Dept Physiol Biochem & Mol Biol, Carbondale, IL 62901 USA; [Welch, William R.; Crum, Christopher P.] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Ng, Shu-Wing] Tufts Med Ctr, Mother Infant Res Inst, Dept Obstet & Gynecol, 800 Washington St, Boston, MA 02111 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Griffith University; Griffith University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Tufts Medical Center	Fong, WP (corresponding author), Chinese Univ Hong Kong, Sch Life Sci, Hong Kong, Peoples R China.	wpfong@cuhk.edu.hk; sng1@tuftsmedicalcenter.org	; Tsui, Stephen Kwok-Wing/E-4385-2015	liu, shubai/0000-0001-8929-4209; Ng, Shu Kay/0000-0002-6865-9384; Tsui, Stephen Kwok-Wing/0000-0003-0686-4259	Robert and Deborah First Fund; Sperling Family Fund Foundation; Ruth N. White Gynecologic Oncology Research Fund; Women's Cancer Program; Gillette Center for Women's Cancer from Dana-Farber Cancer Institute; Ovarian Cancer Research Foundation; Adler Foundation, Inc.; Friends of Dana-Farber Cancer Institute; CNOOC	Robert and Deborah First Fund; Sperling Family Fund Foundation; Ruth N. White Gynecologic Oncology Research Fund; Women's Cancer Program; Gillette Center for Women's Cancer from Dana-Farber Cancer Institute; Ovarian Cancer Research Foundation; Adler Foundation, Inc.; Friends of Dana-Farber Cancer Institute; CNOOC	We acknowledge Dr. Gregory Goodall for the provision of lentiviral miR-200 expression constructs and control, Mr. Shi-Kin Ma for the help of constructing the polar graphs, the support of the CNOOC Grants to the first author, and the Robert and Deborah First Fund, the Sperling Family Fund Foundation, Ruth N. White Gynecologic Oncology Research Fund, Women's Cancer Program and Gillette Center for Women's Cancer from Dana-Farber Cancer Institute, Ovarian Cancer Research Foundation, Adler Foundation, Inc., and Friends of Dana-Farber Cancer Institute to The Laboratory of Gynecologic Oncology at Brigham and Women's Hospital.	Aguilar-Rojas A, 2016, INT J ONCOL, V48, P861, DOI 10.3892/ijo.2016.3346; Ansenberger K, 2009, GYNECOL ONCOL, V113, P362, DOI 10.1016/j.ygyno.2009.02.011; ATFI A, 1994, J BIOL CHEM, V269, P30688; Avizienyte E, 2004, MOL BIOL CELL, V15, P2794, DOI 10.1091/mbc.E03-12-0879; Avizienyte E, 2002, NAT CELL BIOL, V4, P632, DOI 10.1038/ncb829; Barnes MN, 2002, GYNECOL ONCOL, V87, P57, DOI 10.1006/gyno.2002.6806; Bryant DM, 2010, NAT CELL BIOL, V12, P1035, DOI 10.1038/ncb2106; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Canel M, 2013, J CELL SCI, V126, P393, DOI 10.1242/jcs.100115; Choi PW, 2016, ONCOTARGET, V7, P4110, DOI 10.18632/oncotarget.6588; Cochrane DR, 2017, J PATHOL, V243, P26, DOI 10.1002/path.4934; CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P711; David JM, 2012, CANCER RES, V72, P2917, DOI 10.1158/0008-5472.CAN-11-3498; Drapkin R, 2004, HUM PATHOL, V35, P1014, DOI 10.1016/j.humpath.2004.04.014; Esselen KM, 2014, GYNECOL ONCOL, V132, P316, DOI 10.1016/j.ygyno.2013.12.007; FATHALLA MF, 1971, LANCET, V2, P163; Friedl P, 2012, NAT CELL BIOL, V14, P777, DOI 10.1038/ncb2548; Giampieri S, 2009, NAT CELL BIOL, V11, P1287, DOI 10.1038/ncb1973; Giles JR, 2010, INT J GYNECOL CANCER, V20, P738, DOI 10.1111/IGC.0b013e3181da2c49; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Gruessner C, 2014, AM J CANCER RES, V4, P61; HANKINSON SE, 1993, JAMA-J AM MED ASSOC, V270, P2813, DOI 10.1001/jama.270.23.2813; Hasuwa H, 2013, SCIENCE, V341, P71, DOI 10.1126/science.1237999; Ho Shuk-Mei, 2003, Reprod Biol Endocrinol, V1, P73, DOI 10.1186/1477-7827-1-73; Howitt BE, 2015, AM J SURG PATHOL, V39, P287, DOI 10.1097/PAS.0000000000000369; Hua YY, 2016, ONCOTARGET, V7, P66077, DOI 10.18632/oncotarget.11808; Johnson PA, 2013, NAT REV CANCER, V13, P432, DOI 10.1038/nrc3535; Kim J, 2015, ENDOCRINOLOGY, V156, P1975, DOI 10.1210/en.2014-1977; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kolin DL, 2018, J PATHOL, V244, P131, DOI 10.1002/path.5009; Kommoss F, 2017, AM J SURG PATHOL, V41, P161, DOI 10.1097/PAS.0000000000000757; Konecny GE, 2009, BRIT J CANCER, V101, P1699, DOI 10.1038/sj.bjc.6605381; Konze SA, 2014, MOL CELL PROTEOMICS, V13, P990, DOI 10.1074/mcp.M113.033423; Kurman RJ, 2011, HUM PATHOL, V42, P918, DOI 10.1016/j.humpath.2011.03.003; Lee Y, 2007, J PATHOL, V211, P26, DOI 10.1002/path.2091; Matsumura N, 2011, GENOME RES, V21, P74, DOI 10.1101/gr.108803.110; McDaniel AS, 2015, JAMA ONCOL, V1, P1128, DOI 10.1001/jamaoncol.2015.1618; Mertens-Walker I, 2012, CANCER LETT, V324, P152, DOI 10.1016/j.canlet.2012.05.017; Messina A, 2016, NAT NEUROSCI, V19, P835, DOI 10.1038/nn.4298; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Parsons JT, 2010, NAT REV MOL CELL BIO, V11, P633, DOI 10.1038/nrm2957; Perets R, 2013, CANCER CELL, V24, P751, DOI 10.1016/j.ccr.2013.10.013; Przybycin CG, 2010, AM J SURG PATHOL, V34, P1407, DOI 10.1097/PAS.0b013e3181ef7b16; Rauh-Hain Jose A, 2011, Rev Obstet Gynecol, V4, P15; Rodriguez-Fraticelli AE, 2011, CURR OPIN CELL BIOL, V23, P638, DOI 10.1016/j.ceb.2011.07.002; Ryniers F, 2002, BIOL CHEM, V383, P159, DOI 10.1515/BC.2002.016; Sampson JA, 1927, AM J PATHOL, V3, P93; Scully RE, 1995, J CELL BIOCHEM, P208; Seidman JD, 2003, AM J SURG PATHOL, V27, P985, DOI 10.1097/00000478-200307000-00014; Steinhusen U, 2001, J BIOL CHEM, V276, P4972, DOI 10.1074/jbc.M006102200; Whiteman DC, 2000, JNCI-J NATL CANCER I, V92, P1172, DOI 10.1093/jnci/92.14.1172; Worley MJ, 2013, INT J MOL SCI, V14, P5367, DOI 10.3390/ijms14035367; Wu R, 2013, AM J PATHOL, V182, P1391, DOI 10.1016/j.ajpath.2012.12.031; Wyckoff JB, 2006, CURR BIOL, V16, P1515, DOI 10.1016/j.cub.2006.05.065; Yang JZ, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3417-z; Zhao S, 2015, INT J CLIN EXP PATHO, V8, P10412	56	9	9	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	20					4045	4060		10.1038/s41388-020-1264-x	http://dx.doi.org/10.1038/s41388-020-1264-x		MAR 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LN3GC	32214198				2022-12-28	WOS:000521526300003
J	Floren, M; Cruz, SR; Termini, CM; Marjon, KD; Lidke, KA; Gillette, JM				Floren, Muskan; Cruz, Sebastian; Termini, Christina M.; Marjon, Kristopher D.; Lidke, Keith A.; Gillette, Jennifer M.			Tetraspanin CD82 drives acute myeloid leukemia chemoresistance by modulating protein kinase C alpha and beta 1 integrin activation	ONCOGENE			English	Article							INTEGRIN PROMOTES CHEMORESISTANCE; P38 MAPK; PROGENITOR CELLS; DUAL INHIBITOR; PHASE-II; SURVIVAL; STEM; CLASSIFICATION; RESISTANCE; PKC	A principal challenge in treating acute myeloid leukemia (AML) is chemotherapy refractory disease. As such, there remains a critical need to identify key regulators of chemotherapy resistance in AML. In this study, we demonstrate that the membrane scaffold, CD82, contributes to the chemoresistant phenotype of AML. Using an RNA-seq approach, we identified the increased expression of the tetraspanin family member, CD82, in response to the chemotherapeutic, daunorubicin. Analysis of the TARGET and BEAT AML databases identifies a correlation between CD82 expression and overall survival of AML patients. Moreover, using a combination of cell lines and patient samples, we find that CD82 overexpression results in significantly reduced cell death in response to chemotherapy. Investigation of the mechanism by which CD82 promotes AML survival in response to chemotherapy identified a crucial role for enhanced protein kinase c alpha (PKC alpha) signaling and downstream activation of the beta 1 integrin. In addition, analysis of beta 1 integrin clustering by super-resolution imaging demonstrates that CD82 expression promotes the formation of dense beta 1 integrin membrane clusters. Lastly, evaluation of survival signaling following daunorubicin treatment identified robust activation of p38 mitogen-activated protein kinase (MAPK) downstream of PKC alpha and beta 1 integrin signaling when CD82 is overexpressed. Together, these data propose a mechanism where CD82 promotes chemoresistance by increasing PKC alpha activation and downstream activation/clustering of beta 1 integrin, leading to AML cell survival via activation of p38 MAPK. These observations suggest that the CD82-PKC alpha signaling axis may be a potential therapeutic target for attenuating chemoresistance signaling in AML.	[Floren, Muskan; Cruz, Sebastian; Termini, Christina M.; Marjon, Kristopher D.; Gillette, Jennifer M.] Univ New Mexico, Hlth Sci Ctr, Dept Pathol, Albuquerque, NM 87131 USA; [Lidke, Keith A.] Univ New Mexico, Dept Phys & Astron, Albuquerque, NM 87131 USA; [Lidke, Keith A.; Gillette, Jennifer M.] Univ New Mexico, Ctr Comprehens Canc, Albuquerque, NM 87131 USA	University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico	Gillette, JM (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Pathol, Albuquerque, NM 87131 USA.; Gillette, JM (corresponding author), Univ New Mexico, Ctr Comprehens Canc, Albuquerque, NM 87131 USA.	jgillette@salud.unm.edu		Termini, Christina/0000-0002-1831-1347	NHLBI investigator grant [F31CA232480, F31HL124977, T32HL007736, RO1HL122483]; American Cancer Society Research Scholar Grant [130675]; UNM Spatiotemporal Modeling Center [P50GM085273]; UNM Comprehensive Cancer Center Support Grant [P30CA118100]	NHLBI investigator grant; American Cancer Society Research Scholar Grant(American Cancer Society); UNM Spatiotemporal Modeling Center; UNM Comprehensive Cancer Center Support Grant	This work was supported by fellowships: F31CA232480 to MF, F31HL124977 to CMT, and T32HL007736 to KDM, and an NHLBI investigator grant (RO1HL122483 to JMG), and an American Cancer Society Research Scholar Grant (130675 to JMG). This work was partially supported by the UNM Spatiotemporal Modeling Center (P50GM085273) and the UNM Comprehensive Cancer Center Support Grant (P30CA118100) through the following shared resources: Analytical and Translational Genomics, Human Tissue Repository, Fluorescence Microscopy, Flow Cytometry and Biostatistics. We also acknowledge Victoria Balise for critical manuscript review and the experimental assistance of Christian Doyle.	American Cancer Society, CANC FACTS FIG 2015, P2105; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Aoudjit Fawzi, 2012, Chemother Res Pract, V2012, P283181, DOI 10.1155/2012/283181; Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Bachegowda L, 2016, CANCER RES, V76, P4841, DOI 10.1158/0008-5472.CAN-15-3062; Beckwith KA, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00091; Berrazouane S, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1593-2; Bonardi F, 2013, MOL CELL PROTEOMICS, V12, P626, DOI 10.1074/mcp.M112.021931; Bosman MCJ, 2016, CRIT REV ONCOL HEMAT, V98, P35, DOI 10.1016/j.critrevonc.2015.10.001; Boyer T, 2016, ONCOTARGET, V7, P62377, DOI 10.18632/oncotarget.11481; Brayer KJ, 2016, CANCER DISCOV, V6, P176, DOI 10.1158/2159-8290.CD-15-0859; Brockstein B, 2001, INVEST NEW DRUG, V19, P249, DOI 10.1023/A:1010628903248; Brown RB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176675; Burchert A, 1999, BRIT J HAEMATOL, V107, P494, DOI 10.1046/j.1365-2141.1999.01741.x; Byun JM, 2016, ANN HEMATOL, V95, P1223, DOI 10.1007/s00277-016-2691-1; Cloos J, 2006, LEUKEMIA, V20, P1217, DOI 10.1038/sj.leu.2404246; Cook AM, 2014, BLOOD, V123, P2826, DOI 10.1182/blood-2013-05-505735; Crump M, 2016, J CLIN ONCOL, V34, P2484, DOI 10.1200/JCO.2015.65.7171; Davoudi Z, 2014, ASIAN PAC J CANCER P, V15, P4353, DOI 10.7314/APJCP.2014.15.10.4353; Eftmova T, 2002, J BIOL CHEM, V277, P31753, DOI 10.1074/jbc.M205098200; El Fakih R, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7010004; Ester M., 1996, KDD-96 Proceedings. Second International Conference on Knowledge Discovery and Data Mining, P226; Frerich Candace A, 2018, Oncotarget, V9, P7341, DOI 10.18632/oncotarget.23641; Garcia-Manero G, 2015, CLIN CANCER RES, V21, P985, DOI 10.1158/1078-0432.CCR-14-1765; Gupta J, 2015, ONCOTARGET, V6, P8539, DOI 10.18632/oncotarget.3816; Hemler ME, 2014, NAT REV CANCER, V14, P49, DOI 10.1038/nrc3640; Hemler ME, 2005, NAT REV MOL CELL BIO, V6, P801, DOI 10.1038/nrm1736; HOCEVAR BA, 1992, J CELL SCI, V101, P671; Huang F, 2011, BIOMED OPT EXPRESS, V2, P1377, DOI 10.1364/BOE.2.001377; Hwang S, 2019, CELL MOL LIFE SCI, V76, P1595, DOI 10.1007/s00018-019-03014-7; Ji HY, 2019, PEDIATR RES, V85, P1024, DOI 10.1038/s41390-019-0370-3; Jin JK, 2015, ONCOGENE, V34, P1811, DOI 10.1038/onc.2014.116; Kohmo S, 2010, CANCER RES, V70, P8025, DOI 10.1158/0008-5472.CAN-10-0996; Kolanus W, 1997, CURR OPIN CELL BIOL, V9, P725, DOI 10.1016/S0955-0674(97)80127-5; Kurinna S, 2006, LEUKEMIA, V20, P1316, DOI 10.1038/sj.leu.2404248; Kwon HY, 2015, CELL STEM CELL, V17, P152, DOI 10.1016/j.stem.2015.06.006; Marjon KD, 2016, ONCOGENE, V35, P4132, DOI 10.1038/onc.2015.449; McCubrey JA, 2008, LEUKEMIA, V22, P708, DOI 10.1038/leu.2008.27; Miranti CK, 2009, CELL SIGNAL, V21, P196, DOI 10.1016/j.cellsig.2008.08.023; Myklebust JH, 2000, BLOOD, V95, P510, DOI 10.1182/blood.V95.2.510; Naci D, 2014, CELL SIGNAL, V26, P2008, DOI 10.1016/j.cellsig.2014.05.016; Naci D, 2012, J BIOL CHEM, V287, P17065, DOI 10.1074/jbc.M112.349365; Nair MG, 2016, EXP CELL RES, V346, P137, DOI 10.1016/j.yexcr.2016.05.015; Nasir SS, 2017, CL LYMPH MYELOM LEUK, V17, P126, DOI 10.1016/j.clml.2016.09.011; Nishioka C, 2015, LEUKEMIA, V29, P2296, DOI 10.1038/leu.2015.219; Nishioka C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125017; Nishioka C, 2014, INT J CANCER, V134, P55, DOI 10.1002/ijc.28348; Nishioka C, 2013, INT J CANCER, V132, P2006, DOI 10.1002/ijc.27904; Okamoto Y, 2019, BONE MARROW TRANSPL, V54, P1489, DOI 10.1038/s41409-019-0461-0; Ramirez P, 2009, BLOOD, V114, P1340, DOI 10.1182/blood-2008-10-184721; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Ruvolo PP, 2011, J CELL BIOCHEM, V112, P1696, DOI 10.1002/jcb.23090; Saito-Reis CA, 2018, MOL BIOL CELL, V29, P2946, DOI 10.1091/mbc.E18-05-0305; Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349; Sansing HA, 2011, BIOCHEM BIOPH RES CO, V406, P171, DOI 10.1016/j.bbrc.2011.01.109; Scott MJ, 2008, J BIOL CHEM, V283, P29433, DOI 10.1074/jbc.M803905200; Seguin L, 2015, TRENDS CELL BIOL, V25, P234, DOI 10.1016/j.tcb.2014.12.006; Takami M, 2018, BIOCHEM BIOPH RES CO, V503, P1364, DOI 10.1016/j.bbrc.2018.07.049; Termini CM, 2016, SCI REP-UK, V6, DOI 10.1038/srep29859; TERMINI CM, 2012, MOL BIOL CELL, V23, P1545; Thornton TM, 2009, INT J BIOL SCI, V5, P44, DOI 10.7150/ijbs.5.44; Tonoli H, 2005, TRENDS MOL MED, V11, P563, DOI 10.1016/j.molmed.2005.10.002; Tsai YC, 2011, FEBS LETT, V585, P3166, DOI 10.1016/j.febslet.2011.08.031; Tyner JW, 2018, NATURE, V562, P526, DOI 10.1038/s41586-018-0623-z; Ullah Mujib, 2019, Oncotarget, V10, P3435, DOI 10.18632/oncotarget.26952; Valley CC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123941; van Kooyk Y, 2000, CURR OPIN CELL BIOL, V12, P542, DOI 10.1016/S0955-0674(00)00129-0; Varet H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157022; Varterasian ML, 2000, CLIN CANCER RES, V6, P825; Veuger M, 2001, LEUKEMIA, V15, P503; Wakui M, 2008, INT J HEMATOL, V87, P144, DOI 10.1007/s12185-008-0025-3; Walter RB, 2013, BLOOD, V121, P2424, DOI 10.1182/blood-2012-10-462440; Wood CD, 2009, INT J BIOL SCI, V5, P428; Ye MT, 2017, BIOCHEM BIOPH RES CO, V486, P349, DOI 10.1016/j.bbrc.2017.03.044; Zhang J, 2019, ONCOTARGETS THER, V12, P1937, DOI 10.2147/OTT.S191621; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200; Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6	77	6	7	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	19					3910	3925		10.1038/s41388-020-1261-0	http://dx.doi.org/10.1038/s41388-020-1261-0		MAR 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LK4OF	32203165	Green Accepted			2022-12-28	WOS:000520614100001
J	Brummer, G; Fang, W; Smart, C; Zinda, B; Alissa, N; Berkland, C; Miller, D; Cheng, N				Brummer, Gage; Fang, Wei; Smart, Curtis; Zinda, Brandon; Alissa, Nadia; Berkland, Cory; Miller, David; Cheng, Nikki			CCR2 signaling in breast carcinoma cells promotes tumor growth and invasion by promoting CCL2 and suppressing CD154 effects on the angiogenic and immune microenvironments	ONCOGENE			English	Article							NF-KAPPA-B; MONOCYTE CHEMOATTRACTANT PROTEIN-1; CANCER PROGRESSION; NUCLEAR FACTOR; CYCLOSPORINE-A; ACTIVATION; EXPRESSION; CHEMOKINE; RECEPTOR; IMMUNOTHERAPY	Breast cancer is the second leading cause of cancer-related deaths for women, due mainly to metastatic disease. Invasive tumors exhibit aberrations in recruitment and activity of immune cells, including decreased cytotoxic T cells. Restoring the levels and activity of cytotoxic T cells is a promising anticancer strategy; but its success is tumor type dependent. The mechanisms that coordinate recruitment and activity of immune cells and other stromal cells in breast cancer remain poorly understood. Using the MMTV-PyVmT/FVB mammary tumor model, we demonstrate a novel role for CCL2/CCR2 chemokine signaling in tumor progression by altering the microenvironment. Selective targeting of CCR2 in the PyVmT mammary epithelium inhibited tumor growth and invasion, elevated CD8+ T cells, decreased M2 macrophages and decreased angiogenesis. Co-culture models demonstrated these stromal cell responses were mediated by tumor-derived CCL2 and CCR2-mediated suppression of the T-cell activating cytokine, CD154. Coculture analysis indicated that CCR2-induced stromal reactivity was important for tumor cell proliferation and invasion. In breast tumor tissues, CD154 expression inversely correlated with CCR2 expression and correlated with relapse free survival. Targeting the CCL2/CCR2 signaling pathway may reprogram the immune angiogenic and microenvironments and enhance effectiveness of targeted and immunotherapies.	[Brummer, Gage; Fang, Wei; Smart, Curtis; Zinda, Brandon; Cheng, Nikki] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66160 USA; [Alissa, Nadia; Cheng, Nikki] Univ Kansas, Dept Canc Biol, Med Ctr, Kansas City, KS 66160 USA; [Berkland, Cory] Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66045 USA; [Miller, David] Pittsburg State Univ, Dept Engn Technol, Pittsburg, KS 66762 USA	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; Pittsburg State University	Cheng, N (corresponding author), Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66160 USA.; Cheng, N (corresponding author), Univ Kansas, Dept Canc Biol, Med Ctr, Kansas City, KS 66160 USA.	ncheng@kumc.edu			NCI NIH HHS [R01 CA207445, R01 CA172764] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Saleh K, 2017, ONCOL LETT, V14, P337, DOI 10.3892/ol.2017.6144; Aras S, 2017, BRIT J CANCER, V117, P1583, DOI 10.1038/bjc.2017.356; Arasanz H, 2017, MELANOMA MANAG, V4, P39, DOI 10.2217/mmt-2016-0019; Artym Vira V, 2010, Curr Protoc Cell Biol, VChapter 10, DOI 10.1002/0471143030.cb1018s48; Balkwill FR, 2012, J PATHOL, V226, P148, DOI 10.1002/path.3029; Baoum A, 2009, PHARM RES-DORDR, V26, P2619, DOI 10.1007/s11095-009-9976-1; Barnhart B, 2000, J IMMUNOL, V165, P4478, DOI 10.4049/jimmunol.165.8.4478; Behbod F, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2358; Blum S, 2017, LEUKEMIA RES, V60, P63, DOI 10.1016/j.leukres.2017.06.011; Borsig L, 2014, ONCOGENE, V33, P3217, DOI 10.1038/onc.2013.272; Boss V, 1998, J BIOL CHEM, V273, P19664, DOI 10.1074/jbc.273.31.19664; Brandvold KR, 2012, ACS CHEM BIOL, V7, P1393, DOI 10.1021/cb300172e; Brantley-Sieders DM, 2011, CANCER RES, V71, P976, DOI 10.1158/0008-5472.CAN-10-3396; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brodmerkel CM, 2005, J IMMUNOL, V175, P5370, DOI 10.4049/jimmunol.175.8.5370; Brummer G, 2018, MOL CANCER RES, V16, P296, DOI 10.1158/1541-7786.MCR-17-0308; Clawson GA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134320; Connor CS, 2015, J SURG ONCOL, V111, P198, DOI 10.1002/jso.23790; Crist SA, 2008, BLOOD, V111, P3553, DOI 10.1182/blood-2007-05-088161; Du LL, 2017, HEMATOL ONCOL CLIN N, V31, P131, DOI 10.1016/j.hoc.2016.08.004; Dusaban SS, 2013, P NATL ACAD SCI USA, V110, P3609, DOI 10.1073/pnas.1217355110; Fang WB, 2016, ONCOTARGET, V7, P49349, DOI 10.18632/oncotarget.9885; Fang WB, 2015, BREAST CANCER RES TR, V150, P309, DOI 10.1007/s10549-015-3324-4; Fang WB, 2012, J BIOL CHEM, V287, P36593, DOI 10.1074/jbc.M112.365999; Fang WB, 2011, CLIN EXP METASTAS, V28, P351, DOI 10.1007/s10585-011-9373-0; Ford GS, 1999, J IMMUNOL, V162, P4037; Franca TT, 2019, EXPERT REV CLIN IMMU, V15, P529, DOI 10.1080/1744666X.2019.1573674; Georganaki M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03081; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hamilton BJ, 2003, MOL CELL BIOL, V23, P510, DOI 10.1128/MCB.23.2.510-525.2003; Hassan GS, 2015, CANCER TREAT REV, V41, P431, DOI 10.1016/j.ctrv.2015.03.007; Hembruff SL, 2010, NEOPLASIA, V12, P425, DOI 10.1593/neo.10200; Hida K, 2016, INT J CLIN ONCOL, V21, P206, DOI 10.1007/s10147-016-0957-1; Huang DR, 2001, J EXP MED, V193, P713, DOI 10.1084/jem.193.6.713; Khondee S, 2011, MOL PHARMACEUT, V8, P788, DOI 10.1021/mp100393j; Kim JH, 2010, J BIOL CHEM, V285, P5224, DOI 10.1074/jbc.M109.042812; Kurihara T, 1996, J BIOL CHEM, V271, P11603, DOI 10.1074/jbc.271.20.11603; Law AMK, 2017, ENDOCR-RELAT CANCER, V24, pR123, DOI [10.1530/ERC-16-0404, 10.1530/ERC-16-0404e]; Lee EG, 2013, J IMMUNOTOXICOL, V10, P192, DOI 10.3109/1547691X.2012.707700; Lefebvre E, 2016, CTS-CLIN TRANSL SCI, V9, P139, DOI 10.1111/cts.12397; Li TL, 2018, ONCOL LETT, V16, P687, DOI 10.3892/ol.2018.8733; Lim SY, 2016, ONCOTARGET, V7, P28697, DOI 10.18632/oncotarget.7376; Linehan D, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.5_suppl.92; Liu SZ, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3148; MartinezMartinez S, 1997, MOL CELL BIOL, V17, P6437, DOI 10.1128/MCB.17.11.6437; Meyer S, 1997, FEBS LETT, V413, P354, DOI 10.1016/S0014-5793(97)00930-7; Mori N, 2002, BLOOD, V100, P1828, DOI 10.1182/blood-2002-01-0151; Moscat J, 2003, EMBO REP, V4, P31, DOI 10.1038/sj.embor.embor704; Pearson LL, 2001, INT IMMUNOL, V13, P273, DOI 10.1093/intimm/13.3.273; Pfeifhofer C, 2003, J EXP MED, V197, P1525, DOI 10.1084/jem.20020234; Pickel L, 2010, CANCER BIOL THER, V9, P277, DOI 10.4161/cbt.9.4.10643; Qian YC, 2002, P NATL ACAD SCI USA, V99, P9386, DOI 10.1073/pnas.142294499; Rakhmilevich AL, 2012, INT REV IMMUNOL, V31, P267, DOI 10.3109/08830185.2012.698337; Ribatti D, 2017, ONCOTARGET, V8, P7175, DOI 10.18632/oncotarget.12739; Richardsen E, 2015, ANTICANCER RES, V35, P865; Ridiandries A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103217; ROLLINS BJ, 1990, AM J PATHOL, V136, P1229; Schaaf MB, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0061-0; Scribner KC, 2013, ONCOGENE, V32, P2631, DOI 10.1038/onc.2012.286; Seo AN, 2013, BRIT J CANCER, V109, P2705, DOI 10.1038/bjc.2013.634; Slone S, 2016, CELL SIGNAL, V28, P1735, DOI 10.1016/j.cellsig.2016.08.005; Srahna M, 2001, CLIN EXP IMMUNOL, V125, P229, DOI 10.1046/j.1365-2249.2001.01601.x; Stuelten CH, 2018, NAT REV CANCER, V18, P296, DOI 10.1038/nrc.2018.15; Palomino DCT, 2015, EINSTEIN-SAO PAULO, V13, P469, DOI 10.1590/S1679-45082015RB3438; Tylaska LA, 2002, CYTOKINE, V18, P184, DOI 10.1006/cyto.2002.1031; Valdez KE, 2011, J PATHOL, V225, P565, DOI 10.1002/path.2969; Vonderheide RH, 2010, CLIN CANCER RES, V16, P3485, DOI 10.1158/1078-0432.CCR-10-0505; Wyckoff JB, 2007, CANCER RES, V67, P2649, DOI 10.1158/0008-5472.CAN-06-1823; Xue CB, 2011, ACS MED CHEM LETT, V2, P450, DOI 10.1021/ml200030q; Yang M, 2009, BIOCHEM J, V417, P287, DOI 10.1042/BJ20081561; Yao M, 2016, ADV CANCER RES, V132, P265, DOI 10.1016/bs.acr.2016.05.005; Yao M, 2019, MOL CANCER RES, V17, P604, DOI 10.1158/1541-7786.MCR-18-0750; Yao M, 2017, TRANSL ONCOL, V10, P734, DOI 10.1016/j.tranon.2017.06.009; Yao M, 2016, MODERN PATHOL, V29, P810, DOI 10.1038/modpathol.2016.78; Yoshimura T, 2017, CYTOKINE, V98, P71, DOI 10.1016/j.cyto.2017.02.001; Youngblood V, 2015, MOL CANCER RES, V13, P524, DOI 10.1158/1541-7786.MCR-14-0142; Zhao XX, 2017, ONCOTARGET, V8, P30576, DOI 10.18632/oncotarget.15736	79	15	15	3	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	11					2275	2289		10.1038/s41388-019-1141-7	http://dx.doi.org/10.1038/s41388-019-1141-7			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KU0ZS	31827233	Green Accepted			2022-12-28	WOS:000519440400004
J	Richter, AM; Woods, ML; Kuster, MM; Walesch, SK; Braun, T; Boettger, T; Dammann, RH				Richter, Antje M.; Woods, Michelle L.; Kuester, Miriam M.; Walesch, Sara K.; Braun, Thomas; Boettger, Thomas; Dammann, Reinhard H.			RASSF10 is frequently epigenetically inactivated in kidney cancer and its knockout promotes neoplasia in cancer prone mice	ONCOGENE			English	Article							TUMOR-SUPPRESSOR GENES; DNA METHYLATION; P53; MOUSE; EXPRESSION; FAMILY; HYPERMETHYLATION; SUSCEPTIBILITY; APOPTOSIS; MODEL	Kidney cancer incidences are rising globally, thereby fueling the demand for targeted therapies and precision medicine. In our previous work, we have identified and characterized the Ras-Association Domain Family encoding ten members that are often aberrantly expressed in human cancers. In this study, we created and analyzed the Rassf10 knockout mice. Here we show that Rassf10 haploinsufficiency promotes neoplasia formation in two established mouse cancer models (Rassf1A(-/-) and p53(-/-)). Haploinsufficient Rassf10 knockout mice were significantly prone to various diseases including lymphoma (Rassf1A(-/-) background) and thymoma (p53(-/-) background). Especially Rassf10(-/-) and p53-deficient mice exhibited threefold increased rates of kidney cysts compared with p53(-/-) controls. Moreover, we observed that in human kidney cancer, RASSF10 is frequently epigenetically inactivated by its CpG island promoter hypermethylation. Primary tumors of renal clear cell and papillary cell carcinoma confirmed that RASSF10 methylation is associated with decreased expression in comparison to normal kidney tissue. In independent data sets, we could validate that RASSF10 inactivation clinically correlated with decreased survival and with progressed disease state of kidney cancer patients and polycystic kidney size. Functionally, we revealed that the loss of Rassf10 was significantly associated with upregulation of KRAS signaling and MYC expression. In summary, we could show that Rassf10 functions as a haploinsufficient tumor suppressor. In combination with other markers, RASSF10 silencing can serve as diagnostic and prognostic cancer biomarker in kidney diseases.	[Richter, Antje M.; Woods, Michelle L.; Kuester, Miriam M.; Walesch, Sara K.; Dammann, Reinhard H.] Univ Giessen, Inst Genet, D-35392 Giessen, Germany; [Richter, Antje M.; Braun, Thomas; Boettger, Thomas] Max Planck Inst Heart & Lung Res, Bad Nauheim, Germany; [Braun, Thomas; Dammann, Reinhard H.] Univ Giessen & Marburg Lung Ctr, German Ctr Lung Res DZL, D-35392 Giessen, Germany	Justus Liebig University Giessen; Max Planck Society	Richter, AM; Dammann, RH (corresponding author), Univ Giessen, Inst Genet, D-35392 Giessen, Germany.; Richter, AM (corresponding author), Max Planck Inst Heart & Lung Res, Bad Nauheim, Germany.; Dammann, RH (corresponding author), Univ Giessen & Marburg Lung Ctr, German Ctr Lung Res DZL, D-35392 Giessen, Germany.	antje.m.richter@gen.bio.uni-giessen.de; reinhard.dammann@gen.bio.uni-giessen.de	Braun, Thomas/B-2310-2008; Boettger, Thomas/E-3406-2012	Boettger, Thomas/0000-0003-4280-8449; Braun, Thomas/0000-0002-6165-4804	Projekt DEAL	Projekt DEAL	We thank Sylvia Thomas at the MPI for performing the microarrays analysis, Richard Volckmann for his help with R2 data at AMC and Julia Weber and Helga Linder for cloning of the Rassf10 mouse knockout vector. Open access funding provided by Projekt DEAL.	Baylin S, 2002, CANCER CELL, V1, P299, DOI 10.1016/S1535-6108(02)00061-2; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen YJ, 2005, WORLD J GASTROENTERO, V11, P1333, DOI 10.3748/wjg.v11.i9.1333; Cheng YY, 2018, DIS MARKERS, V2018, DOI 10.1155/2018/4987103; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Diez-Villanueva A, 2015, EPIGENET CHROMATIN, V8, DOI 10.1186/s13072-015-0014-8; Doetschman Thomas, 2009, V530, P423, DOI 10.1007/978-1-59745-471-1_23; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donehower LA, 1996, SEMIN CANCER BIOL, V7, P269, DOI 10.1006/scbi.1996.0035; Dudgeon C, 2014, GENE DEV, V28, P2613, DOI 10.1101/gad.252148.114; Eden E, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-48; Fan C, 2017, CELL PHYSIOL BIOCHEM, V41, P1229, DOI 10.1159/000464386; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Goossens N, 2015, TRANSL CANCER RES, V4, P256, DOI 10.3978/j.issn.2218-676X.2015.06.04; Gostissa M, 2013, P NATL ACAD SCI USA, V110, P2934, DOI 10.1073/pnas.1222570110; GRANTHAM JJ, 1990, AM J KIDNEY DIS, V15, P110, DOI 10.1016/S0272-6386(12)80507-5; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Haag T, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2087-6; Haag Tanja, 2014, Genes Cancer, V5, P365; Han SM, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37101-9; Helmbold P, 2012, J INVEST DERMATOL, V132, P687, DOI 10.1038/jid.2011.380; Henry NL, 2012, MOL ONCOL, V6, P140, DOI 10.1016/j.molonc.2012.01.010; Herman JG, 1999, SEMIN CANCER BIOL, V9, P359, DOI 10.1006/scbi.1999.0138; Hesson LB, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-42; Hill VK, 2011, ONCOGENE, V30, P978, DOI 10.1038/onc.2010.471; Hornbeck PV, 2015, NUCLEIC ACIDS RES, V43, pD512, DOI 10.1093/nar/gku1267; Inoue Kazushi, 2017, Adv Med Biol, V118, P83; Issa IA, 2017, WORLD J GASTROENTERO, V23, P5086, DOI 10.3748/wjg.v23.i28.5086; Jimenez AP, 2017, ONCOTARGET, V8, P88437, DOI 10.18632/oncotarget.18177; Johansson J, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00003; Kiehl S, 2014, SCI REP-UK, V4, DOI 10.1038/srep06899; Kirwan A, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/490531; Klopstock N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005025; Kornberg Z, 2018, TRANSL ANDROL UROL, V7, P459, DOI 10.21037/tau.2018.06.02; Kuperwasser C, 2000, AM J PATHOL, V157, P2151, DOI 10.1016/S0002-9440(10)64853-5; Li X, 2016, ONCOGENE, V35, P2453, DOI 10.1038/onc.2015.300; Liu W, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.24; Loeb LA, 2016, CANCER RES, V76, P2057, DOI 10.1158/0008-5472.CAN-16-0794; Modhukur V, 2018, EPIGENOMICS-UK, V10, P277, DOI 10.2217/epi-2017-0118; Molenaar JJ, 2012, NATURE, V483, P589, DOI 10.1038/nature10910; Morales JK, 2010, GENES IMMUN, V11, P599, DOI 10.1038/gene.2010.35; Nagy A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27521-y; Partin AW, 2014, J UROLOGY, V192, P1081, DOI 10.1016/j.juro.2014.04.013; Puccini J, 2013, CELL DEATH DIFFER, V20, P964, DOI 10.1038/cdd.2013.35; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Richter AM, 2012, ONCOGENESIS, V1, DOI 10.1038/oncsis.2012.18; Richter AM, 2019, CANCERS, V11, DOI 10.3390/cancers11121976; Richter AM, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148-017-0360-4; Richter AM, 2016, CANCERS, V8, DOI 10.3390/cancers8030026; Richter AM, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00021; Richter Antje M, 2013, Cancers (Basel), V5, P1566, DOI 10.3390/cancers5041566; Richter AM, 2009, BBA-REV CANCER, V1796, P114, DOI 10.1016/j.bbcan.2009.03.004; Rivera J, 2008, IMMUNITY, V28, P1, DOI 10.1016/j.immuni.2007.12.008; Santarosa M, 2004, BBA-REV CANCER, V1654, P105, DOI 10.1016/j.bbcan.2004.01.001; Sauter ER, 2017, EUR J BREAST HEALTH, V13, P162, DOI 10.5152/ejbh.2017.3635; Schagdarsurengin U, 2007, ONCOGENE, V26, P3089, DOI 10.1038/sj.onc.1210107; Schagdarsurengin U, 2009, EPIGENETICS-US, V4, P571, DOI 10.4161/epi.4.8.10056; Schonenberger D, 2016, CANCER RES, V76, P2025, DOI 10.1158/0008-5472.CAN-15-1859; Seeger-Nukpezah T, 2015, NAT REV NEPHROL, V11, P515, DOI 10.1038/nrneph.2015.46; Selleck MJ, 2017, BIOMARK INSIGHTS, V12, DOI 10.1177/1177271917715236; Sherwood V, 2010, BIOCHEM J, V425, P303, DOI 10.1042/BJ20091318; Steinmann Katrin, 2011, Genes Cancer, V2, P65, DOI 10.1177/1947601911405043; Stewart GD, 2013, J UROLOGY, V189, P1110, DOI 10.1016/j.juro.2012.08.219; Sweetman D, 2006, DEV DYNAM, V235, P2185, DOI 10.1002/dvdy.20881; Szasz AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337; Tommasi S, 2005, CANCER RES, V65, P92; Van Bodegom D, 2006, J BIOL CHEM, V281, P31234, DOI 10.1074/jbc.M606510200; van der Weyden L, 2009, INT J EXP PATHOL, V90, P101, DOI 10.1111/j.1365-2613.2008.00635.x; Vaseva AV, 2018, CANCER CELL, V34, P807, DOI 10.1016/j.ccell.2018.10.001; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Vogelmann R, 2005, J CELL SCI, V118, P4901, DOI 10.1242/jcs.02594; Volodko N, 2014, FEBS LETT, V588, P2671, DOI 10.1016/j.febslet.2014.02.041; Wang YF, 2014, BIOMED PHARMACOTHER, V68, P321, DOI 10.1016/j.biopha.2013.12.005; Wei ZR, 2013, BIOCHEM BIOPH RES CO, V432, P632, DOI 10.1016/j.bbrc.2013.02.033; Wystub K, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003793; Xie NN, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/7834175; Xu Q, 2005, ONCOGENE, V24, P5552, DOI 10.1038/sj.onc.1208719; Zamay TN, 2017, CANCERS, V9, DOI 10.3390/cancers9110155	79	10	10	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	15					3114	3127		10.1038/s41388-020-1195-6	http://dx.doi.org/10.1038/s41388-020-1195-6		FEB 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LB8NS	32047266	Green Published, hybrid			2022-12-28	WOS:000512843500001
J	Kouzi, F; Zibara, K; Bourgeais, J; Picou, F; Gallay, N; Brossaud, J; Dakik, H; Roux, B; Hamard, S; Le Nail, LR; Hleihel, R; Foucault, A; Ravalet, N; Rouleux-Bonnin, F; Gouilleux, F; Mazurier, F; Bene, MC; Akl, H; Gyan, E; Domenech, J; El-Sabban, M; Herault, O				Kouzi, Farah; Zibara, Kazem; Bourgeais, Jerome; Picou, Frederic; Gallay, Nathalie; Brossaud, Julie; Dakik, Hassan; Roux, Benjamin; Hamard, Sophie; Le Nail, Louis-Romee; Hleihel, Rita; Foucault, Amelie; Ravalet, Noemie; Rouleux-Bonnin, Florence; Gouilleux, Fabrice; Mazurier, Frederic; Bene, Marie C.; Akl, Haidar; Gyan, Emmanuel; Domenech, Jorge; El-Sabban, Marwan; Herault, Olivier			Disruption of gap junctions attenuates acute myeloid leukemia chemoresistance induced by bone marrow mesenchymal stromal cells	ONCOGENE			English	Article							AML CELLS; STEM-CELLS; INCREASE PROLIFERATION; CARBENOXOLONE SODIUM; INHIBIT APOPTOSIS; UP-REGULATION; CONNEXIN-43; EXPRESSION; PROTEIN; IDENTIFICATION	The bone marrow (BM) niche impacts the progression of acute myeloid leukemia (AML) by favoring the chemoresistance of AML cells. Intimate interactions between leukemic cells and BM mesenchymal stromal cells (BM-MSCs) play key roles in this process. Direct intercellular communications between hematopoietic cells and BM-MSCs involve connexins, components of gap junctions. We postulated that blocking gap junction assembly could modify cell-cell interactions in the leukemic niche and consequently the chemoresistance. The comparison of BM-MSCs from AML patients and healthy donors revealed a specific profile of connexins in BM-MSCs of the leukemic niche and the effects of carbenoxolone (CBX), a gap junction disruptor, were evaluated on AML cells. CBX presents an antileukemic effect without affecting normal BM-CD34(+) progenitor cells. The proapoptotic effect of CBX on AML cells is in line with the extinction of energy metabolism. CBX acts synergistically with cytarabine (Ara-C) in vitro and in vivo. Coculture experiments of AML cells with BM-MSCs revealed that CBX neutralizes the protective effect of the niche against the Ara-C-induced apoptosis of leukemic cells. Altogether, these results suggest that CBX could be of therapeutic interest to reduce the chemoresistance favored by the leukemic niche, by targeting gap junctions, without affecting normal hematopoiesis.	[Kouzi, Farah; Bourgeais, Jerome; Picou, Frederic; Gallay, Nathalie; Dakik, Hassan; Roux, Benjamin; Hamard, Sophie; Foucault, Amelie; Ravalet, Noemie; Rouleux-Bonnin, Florence; Gouilleux, Fabrice; Mazurier, Frederic; Gyan, Emmanuel; Domenech, Jorge; Herault, Olivier] CNRS, ERL7001, LNOx Leukem Niche & Redox Metab, Tours, France; [Kouzi, Farah; Bourgeais, Jerome; Picou, Frederic; Gallay, Nathalie; Dakik, Hassan; Roux, Benjamin; Hamard, Sophie; Foucault, Amelie; Ravalet, Noemie; Rouleux-Bonnin, Florence; Gouilleux, Fabrice; Mazurier, Frederic; Gyan, Emmanuel; Domenech, Jorge; Herault, Olivier] Univ Tours, Fac Med, EA7501, GICC, Tours, France; [Kouzi, Farah; Zibara, Kazem; Akl, Haidar] Lebanese Univ, DSST, PRASE, Beirut, Lebanon; [Zibara, Kazem; Akl, Haidar] Lebanese Univ, Fac Sci, Biol Dept, Beirut, Lebanon; [Bourgeais, Jerome; Picou, Frederic; Gallay, Nathalie; Roux, Benjamin; Foucault, Amelie; Ravalet, Noemie; Domenech, Jorge; Herault, Olivier] Tours Univ Hosp, Dept Biol Hematol, Tours, France; [Brossaud, Julie] Bordeaux Univ Hosp, Dept Nucl Med, Pessac, France; [Le Nail, Louis-Romee] Tours Univ Hosp, Dept Surg Orthopedia, Tours, France; [Hleihel, Rita; El-Sabban, Marwan] Amer Univ Beirut, Fac Med, Dept Anat Cell Biol & Physiol Sci, Beirut, Lebanon; [Hleihel, Rita] Amer Univ Beirut, Fac Med, Dept Internal Med, Beirut, Lebanon; [Bene, Marie C.] CRCINA, Nantes Univ Hosp, Dept Biol Hematol, Nantes, France; [Gyan, Emmanuel] Tours Univ Hosp, Dept Hematol & Cell Therapy, Tours, France	Centre National de la Recherche Scientifique (CNRS); Universite de Tours; Lebanese University; Lebanese University; CHU Tours; CHU Bordeaux; CHU Tours; American University of Beirut; American University of Beirut; Nantes Universite; CHU de Nantes; CHU Tours	Herault, O (corresponding author), CNRS, ERL7001, LNOx Leukem Niche & Redox Metab, Tours, France.; Herault, O (corresponding author), Univ Tours, Fac Med, EA7501, GICC, Tours, France.; Herault, O (corresponding author), Tours Univ Hosp, Dept Biol Hematol, Tours, France.	olivier.herault@univ-tours.fr	PICOU, FREDERIC/AAC-4695-2022; Hleihel, Rita/GON-7341-2022; Ravalet, Noémie/AAC-7874-2022; DAKIK, Hassan/E-3153-2015; Rouleux, Florence/AFT-8675-2022; Le Nail, Louis-Romée/CAH-0851-2022	PICOU, FREDERIC/0000-0002-2066-2146; Ravalet, Noémie/0000-0001-5779-337X; DAKIK, Hassan/0000-0003-0270-8195; Herault, Olivier/0000-0002-7419-1124; Gouilleux, Fabrice/0000-0001-6047-1718; Mazurier, Frederic/0000-0002-6984-7096; Bourgeais, Jerome/0000-0002-2557-9624; Foucault, Amelie/0000-0003-4225-2006; , Nathalie GALLAY/0000-0002-4236-4780; Le Nail, Louis-Romee/0000-0003-1642-4935; Hamard, Sophie/0000-0002-8537-2713; Zibara, Kazem/0000-0002-9887-072X; Roux, Benjamin/0000-0002-0400-5672	Association of Specialization and Scientific Orientation (Lebanon); Ligue Nationale Contre le Cancer (France); International Rotary Club of Blois; les Sapins de l'Espoir Contre le Cancer; CANCEN; Tours-Autogreffe; AHB associations; UL; L-CNRS	Association of Specialization and Scientific Orientation (Lebanon); Ligue Nationale Contre le Cancer (France)(Ligue nationale contre le cancer); International Rotary Club of Blois; les Sapins de l'Espoir Contre le Cancer; CANCEN; Tours-Autogreffe; AHB associations; UL; L-CNRS	The authors acknowledge Philippe Rosset for the collect of healthy donors' samples, Lamya Haddaoui, and all the participants to the FILOtheque. This work is supported by grants awarded to FK from the Association of Specialization and Scientific Orientation (Lebanon) and the Ligue Nationale Contre le Cancer (France). The research program was supported by the International Rotary Club of Blois, les Sapins de l'Espoir Contre le Cancer, CANCEN, Tours-Autogreffe, and AHB associations. The authors would particularly like to thank Prof. Philippe Rosset for having provided the BM samples as well as Elfi Ducrocq, Jorge Khamis, from LNOx (CNRS ERL 7001), and Marie-Therese Georget from the Department of Hematology Biology (Tours University Hospital) for their technical help. This research was also supported by grants to KZ (UL and L-CNRS).	Aasen T, 2016, NAT REV CANCER, V16, P775, DOI 10.1038/nrc.2016.105; ARCHAMBAULT A, 1977, CAN MED ASSOC J, V117, P1155; BENDALL LJ, 1994, EXP HEMATOL, V22, P1252; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; Bruserud O, 2004, HAEMATOLOGICA, V89, P391; Bruserud O, 1998, CYTOKINES CELL MOL T, V4, P187; Cairns RA, 2011, COLD SH Q B, V76, P299, DOI 10.1101/sqb.2011.76.012856; Chapuis N, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00405; Chen WL, 2014, BLOOD, V124, P1645, DOI 10.1182/blood-2014-02-554204; Chen Z, 2007, J BIOENERG BIOMEMBR, V39, P267, DOI 10.1007/s10863-007-9086-x; Colmone A, 2008, SCIENCE, V322, P1861, DOI 10.1126/science.1164390; Delorme Bruno, 2007, V140, P67; Desbourdes L, 2017, STEM CELLS DEV, V26, P709, DOI 10.1089/scd.2016.0295; Dhanesha N, 2012, CLIN EXP PHARMACOL P, V39, P69, DOI 10.1111/j.1440-1681.2011.05640.x; Fares I, 2017, BLOOD, V129, P3344, DOI 10.1182/blood-2016-11-750729; Gao FH, 2007, BIOCHEM BIOPH RES CO, V356, P505, DOI 10.1016/j.bbrc.2007.03.009; Hatfield K, 2006, INT J CANCER, V119, P2313, DOI 10.1002/ijc.22180; HAUSMANN W, 1966, BRIT J PHARM CHEMOTH, V26, P412, DOI 10.1111/j.1476-5381.1966.tb01921.x; Herault O, 1999, BRIT J HAEMATOL, V104, P530, DOI 10.1046/j.1365-2141.1999.01203.x; Herault O, 2012, J EXP MED, V209, P895, DOI 10.1084/jem.20102386; Hundertmark S, 1997, J ENDOCRINOL, V155, P171, DOI 10.1677/joe.0.1550171; Ishikawa ET, 2012, P NATL ACAD SCI USA, V109, P9071, DOI 10.1073/pnas.1120358109; Jensen K, 2011, ENDOCR-RELAT CANCER, V18, P613, DOI 10.1530/ERC-10-0289; Kaushik AK, 2014, J PROTEOME RES, V13, P1088, DOI 10.1021/pr401106h; Konopleva M, 2002, LEUKEMIA, V16, P1713, DOI 10.1038/sj.leu.2402608; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Kotini M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06368-x; Lagadinou ED, 2013, CELL STEM CELL, V12, P329, DOI 10.1016/j.stem.2012.12.013; Li HC, 2007, J CELL BIOCHEM, V101, P805, DOI 10.1002/jcb.21159; Li X, 2006, J CELL PHYSIOL, V208, P594, DOI 10.1002/jcp.20695; Liu Y, 2010, LEUKEMIA RES, V34, P631, DOI 10.1016/j.leukres.2009.10.013; Lowenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407; Mason EF, 2011, BBA-MOL CELL RES, V1813, P645, DOI 10.1016/j.bbamcr.2010.08.011; Mesnil M, 2002, BIOL CELL, V94, P493, DOI 10.1016/S0248-4900(02)00025-4; MONTGOMERY RD, 1968, GUT, V9, P704, DOI 10.1136/gut.9.6.704; Moschoi R, 2016, BLOOD, V128, P253, DOI 10.1182/blood-2015-07-655860; Pabst C, 2014, NAT METHODS, V11, P436, DOI 10.1038/nmeth.2847; Paraguassu-Braga FH, 2003, CELL DEATH DIFFER, V10, P1101, DOI 10.1038/sj.cdd.4401279; Picou F, 2018, PHARMACOL RES, V136, P45, DOI 10.1016/j.phrs.2018.08.015; Raza A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08058-y; Reikvam H, 2015, INT J MOL MED, V35, P645, DOI 10.3892/ijmm.2014.2045; Rozental R, 2001, METH MOL B, V154, P447; Ryningen A, 2005, LEUKEMIA RES, V29, P185, DOI 10.1016/j.leukres.2004.06.008; Samudio I, 2008, CANCER RES, V68, P5198, DOI 10.1158/0008-5472.CAN-08-0555; Shiozawa Y, 2008, LEUKEMIA, V22, P941, DOI 10.1038/leu.2008.48; Sinyuk M, 2015, ONCOTARGET, V6, P31508, DOI 10.18632/oncotarget.5226; Skrtic M, 2011, CANCER CELL, V20, P674, DOI 10.1016/j.ccr.2011.10.015; Sriskanthadevan S, 2015, BLOOD, V125, P2120, DOI 10.1182/blood-2014-08-594408; Stolzel F, 2016, BLOOD CANCER J, V6, DOI 10.1038/bcj.2015.114; Thuma F, 2014, SEMIN CANCER BIOL, V28, P39, DOI 10.1016/j.semcancer.2014.02.011; Traub RD, 2017, NETWORK FUNCTIONS AND PLASTICITY: PERSPECTIVES FROM STUDYING NEURONAL ELECTRICAL COUPLING IN MICROCIRCUITS, P301, DOI 10.1016/B978-0-12-803471-2.00013-8; Trovato-Salinaro A, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-122; Vignon C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068425; Wang AD, 2018, HEMATOLOGY, V23, P729, DOI 10.1080/10245332.2018.1486064; WEBER MC, 1994, BLOOD, V83, P2221; Ye HB, 2016, CELL STEM CELL, V19, P23, DOI 10.1016/j.stem.2016.06.001; Yeung SJ, 2008, CELL MOL LIFE SCI, V65, P3981, DOI 10.1007/s00018-008-8224-x; Yi S, 2012, ONCOL LETT, V4, P1003, DOI 10.3892/ol.2012.884; Yulyana Y, 2013, STEM CELLS DEV, V22, P1870, DOI 10.1089/scd.2012.0529; Zeng ZH, 2012, BLOOD, V120, P2679, DOI 10.1182/blood-2011-11-393934; Zhang X, 2012, LEUKEMIA RES, V36, P198, DOI 10.1016/j.leukres.2011.10.001; Zhou HS, 2016, CANCER BIOL MED, V13, P248, DOI 10.20892/j.issn.2095-3941.2016.0023	62	23	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	6					1198	1212		10.1038/s41388-019-1069-y	http://dx.doi.org/10.1038/s41388-019-1069-y			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE4UH	31649334	Green Published, hybrid			2022-12-28	WOS:000526714600003
J	Pinto, I; Duque, M; Goncalves, J; Akkapeddi, P; Oliveira, ML; Cabrita, R; Yunes, JA; Durum, SK; Barata, JT; Fragoso, R				Pinto, Ines; Duque, Mafalda; Goncalves, Joana; Akkapeddi, Padma; Oliveira, Mariana L.; Cabrita, Rita; Yunes, J. Andres; Durum, Scott K.; Barata, Joao T.; Fragoso, Rita			NRARP displays either pro- or anti-tumoral roles in T-cell acute lymphoblastic leukemia depending on Notch and Wnt signaling	ONCOGENE			English	Article							ANKYRIN-REPEAT PROTEIN; ENHANCER FACTOR-I; ACTIVATING MUTATIONS; DIFFERENTIATION; NOTCH1/NICD; INHIBITOR; ISOFORM; ENCODES; LEF1	T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy with a dismal prognosis in patients with resistant or relapsed disease. Although NOTCH is a known driver in T-ALL, its clinical inhibition has significant limitations. Our previous studies suggested that NRARP, a negative regulator of Notch signaling, could have a suppressive role in T-ALL. Here, we report that NRARP levels are significantly increased in primary T-ALL cells suggesting that NRARP is not sufficient to block NOTCH oncogenic signals. Interestingly, although NRARP overexpression blocks NOTCH1 signaling and delays the proliferation of T-ALL cells that display high levels of Notch1 signaling, it promotes the expansion of T-ALL cells with lower levels of Notch1 activity. We found that NRARP interacts with lymphoid enhancer-binding factor 1 (LEF1) and potentiates Wnt signaling in T-ALL cells with low levels of Notch. Together these results indicate that NRARP plays a dual role in T-ALL pathogenesis, regulating both Notch and Wnt pathways, with opposite functional effects depending on Notch activity. Consistent with this hypothesis, mice transplanted with T-cells co-expressing NOTCH1 and NRARP develop leukemia later than mice transplanted with T-NOTCH1 cells. Importantly, mice transplanted with T-cells overexpressing NRARP alone developed leukemia with similar kinetics to those transplanted with T-NOTCH1 cells. Our findings uncover a role for NRARP in T-ALL pathogenesis and indicate that Notch inhibition may be detrimental for patients with low levels of Notch signaling, which would likely benefit from the use of Wnt signaling inhibitors. Importantly, our findings may extend to other cancers where Notch and Wnt play a role.	[Pinto, Ines; Duque, Mafalda; Goncalves, Joana; Akkapeddi, Padma; Oliveira, Mariana L.; Cabrita, Rita; Barata, Joao T.; Fragoso, Rita] Univ Lisbon, Fac Med, Inst Med Mol Joao Lobo Antunes, Lisbon, Portugal; [Yunes, J. Andres] Ctr Infantil Boldrini, Campinas, SP, Brazil; [Yunes, J. Andres] Univ Estadual Campinas, Fac Med Sci, Dept Med Genet, Campinas, SP, Brazil; [Durum, Scott K.] NCI, Canc & Inflammat Program, Ctr Canc Res, NIH, Frederick, MD 21701 USA	Universidade de Lisboa; Universidade Estadual de Campinas; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Fragoso, R (corresponding author), Univ Lisbon, Fac Med, Inst Med Mol Joao Lobo Antunes, Lisbon, Portugal.	arfragoso@medicina.ulisboa.pt	Pinto, Inês/GVT-4690-2022; Fragoso, Rita/ABH-3528-2020; Akkapeddi, Ph.D., Padma/AAX-9406-2021; Fragoso, Rita/O-7164-2019; Gonçalves, Joana/AAL-5516-2020; Barata, Joao/D-9181-2015	Fragoso, Rita/0000-0002-9206-1964; durum, scott/0000-0003-1307-9582; Goncalves, Joana/0000-0003-1997-9514; dos Santos Dias Duque, Mafalda/0000-0002-1459-161X; Oliveira, Mariana/0000-0001-8669-7627; Barata, Joao/0000-0002-4826-8976; Yunes, Jose Andres/0000-0002-1316-3525	Fundacao para a Ciencia e a Tecnologia (FCT) [IF/00788/2013]; European Research Council [ERC CoG-648455]; Marie Curie Protein Conjugates ITN; FCT [PD/BD/114102/2015]; Fundacao para a Ciencia e a Tecnologia (FCT)/Ministerio da Ciencia, Tecnologia e Ensino Superior (MCTES) through Fundos do Orcamento de Estado [UID/BIM/50005/2019]	Fundacao para a Ciencia e a Tecnologia (FCT)(Portuguese Foundation for Science and TechnologyEuropean Commission); European Research Council(European Research Council (ERC)European Commission); Marie Curie Protein Conjugates ITN; FCT(Portuguese Foundation for Science and TechnologyEuropean Commission); Fundacao para a Ciencia e a Tecnologia (FCT)/Ministerio da Ciencia, Tecnologia e Ensino Superior (MCTES) through Fundos do Orcamento de Estado	The authors thank the members of the JBarata laboratory for comments and discussions, and Sergio Almeida e Joao Sabino for the valuable help with PLA assays. The authors especially thank the generosity of patients and their families for providing primary samples, and the health care professionals (Service directors, physicians, and nurses) from IPO Lisboa and Centro Infantil Boldrini involved in the collection of those samples. This work was supported by the grant IF/00788/2013 from Fundacao para a Ciencia e a Tecnologia (FCT) awarded to RF and by the consolidator grant ERC CoG-648455 from the European Research Council awarded to JTB. PA is a Marie Curie ITN PhD student, supported by Marie Curie Protein Conjugates ITNand. MLO is a LisbonBioMed student supported by an FCT PhD fellowship (PD/BD/114102/2015). RF and JTB are FCT starting and consolidator investigators, respectively. Publication costs of this work were supported by UID/BIM/50005/2019, project funded by Fundacao para a Ciencia e a Tecnologia (FCT)/Ministerio da Ciencia, Tecnologia e Ensino Superior (MCTES) through Fundos do Orcamento de Estado.	Andersson ER, 2014, NAT REV DRUG DISCOV, V13, P359, DOI 10.1038/nrd4252; Arensman MD, 2014, MOL CANCER THER, V13, P2303, DOI 10.1158/1535-7163.MCT-13-1005; Bernasconi-Elias P, 2016, ONCOGENE, V35, P6077, DOI 10.1038/onc.2016.133; Correia NC, 2016, SCI REP-UK, V6, DOI 10.1038/srep31894; Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101; Fragoso R, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002855; Fullmer Amber, 2009, Curr Hematol Malig Rep, V4, P148, DOI 10.1007/s11899-009-0021-6; Guo X, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125429; Gutierrez A, 2010, BLOOD, V115, P2845, DOI 10.1182/blood-2009-07-234377; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264; Ishitani T, 2005, NAT CELL BIOL, V7, P1106, DOI 10.1038/ncb1311; Jin YH, 2009, MOL CELLS, V27, P15, DOI 10.1007/s10059-009-0001-7; Jin YH, 2009, BBA-MOL CELL RES, V1793, P290, DOI 10.1016/j.bbamcr.2008.10.002; Kobielak A, 2001, ACTA BIOCHIM POL, V48, P221; Krebs LT, 2001, DEV BIOL, V238, P110, DOI 10.1006/dbio.2001.0408; Kwon C, 2011, NAT CELL BIOL, V13, P1244, DOI 10.1038/ncb2313; Lahaye K, 2002, MECH DEVELOP, V110, P113, DOI 10.1016/S0925-4773(01)00570-6; Lamar E, 2001, GENE DEV, V15, P1885, DOI 10.1101/gad.908101; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Papayannidis C, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.80; Phng LK, 2009, DEV CELL, V16, P70, DOI 10.1016/j.devcel.2008.12.009; Pui C, 2004, NEW ENGL J MED, V350, P1535, DOI 10.1056/NEJMra023001; Roti G, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00170; Shang S, 2017, ONCOTARGET, V8, P33972, DOI 10.18632/oncotarget.15687; Silva A, 2010, HAEMATOL-HEMATOL J, V95, P674, DOI 10.3324/haematol.2009.011999; Smith Malcolm A, 2009, Curr Hematol Malig Rep, V4, P175, DOI 10.1007/s11899-009-0024-3; Spaulding C, 2007, BLOOD, V110, P2650, DOI 10.1182/blood-2007-04-084202; Squiban B, 2017, LEUKEMIA LYMPHOMA, V58, P2728, DOI 10.1080/10428194.2017.1300896; Van de Walle I, 2009, BLOOD, V113, P2988, DOI 10.1182/blood-2008-06-164871; van Noort M, 2002, DEV BIOL, V244, P1, DOI 10.1006/dbio.2001.0566; Wang WB, 2005, ACTA BIOCH BIOPH SIN, V37, P173, DOI 10.1111/j.1745-7270.2005.00023.x; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Yun TJ, 2003, J IMMUNOL, V170, P5834, DOI 10.4049/jimmunol.170.12.5834; Zenatti PP, 2011, NAT GENET, V43, P932, DOI 10.1038/ng.924	35	6	7	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	5					975	986		10.1038/s41388-019-1042-9	http://dx.doi.org/10.1038/s41388-019-1042-9			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KI2VY	31586130	hybrid, Green Accepted, Green Published			2022-12-28	WOS:000511209700002
J	Santoni, MJ; Kashyap, R; Camoin, L; Borg, JP				Santoni, Marie-Josee; Kashyap, Rudra; Camoin, Luc; Borg, Jean-Paul			The Scribble family in cancer: twentieth anniversary	ONCOGENE			English	Review							UBIQUITIN-MEDIATED DEGRADATION; PROMOTES MAMMARY TUMORIGENESIS; TUMOR-SUPPRESSOR SCRIBBLE; BASOLATERAL PDZ PROTEIN; CELL-CELL JUNCTIONS; LEUCINE-RICH REPEAT; RISK HPV E6; INTERACTING PROTEIN; S-PALMITOYLATION; DOWN-REGULATION	Among the more than 160 PDZ containing proteins described in humans, the cytoplasmic scaffold Scribble stands out because of its essential role in many steps of cancer development and dissemination. Its fame has somehow blurred the importance of homologous proteins, Erbin and Lano, all belonging to the LRR and PDZ (LAP) protein family first described twenty years ago. In this review, we will retrace the history of LAP family protein research and draw attention to their contribution in cancer by detailing the features of its members at the structural and functional levels, and highlighting their shared-but also different-implication in the tumoral process.	[Santoni, Marie-Josee; Kashyap, Rudra; Borg, Jean-Paul] Aix Marseille Univ, Ctr Rech Cancerol Marseille, Equipe Labellisee Ligue Cell Polar Cell Signaling, CRCM,INSERM,CNRS,Inst Paoli Calmettes, F-13009 Marseille, France; [Kashyap, Rudra] Katholisch Univ Leuven, Cellular & Mol Med, Leuven, Belgium; [Camoin, Luc; Borg, Jean-Paul] Aix Marseille Univ, CNRS, Inst Paoli Calmettes, INSERM,CRCM,Marseille Proteom, Marseille, France; [Borg, Jean-Paul] Inst Univ France IUF, Paris, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); Institut Universitaire de France	Santoni, MJ; Borg, JP (corresponding author), Aix Marseille Univ, Ctr Rech Cancerol Marseille, Equipe Labellisee Ligue Cell Polar Cell Signaling, CRCM,INSERM,CNRS,Inst Paoli Calmettes, F-13009 Marseille, France.; Borg, JP (corresponding author), Aix Marseille Univ, CNRS, Inst Paoli Calmettes, INSERM,CRCM,Marseille Proteom, Marseille, France.; Borg, JP (corresponding author), Inst Univ France IUF, Paris, France.	marie-josee.santoni@inserm.fr; jean-paul.borg@inserm.fr	Kashyap, Rudra/ABD-3316-2020; Borg, Jean-Paul/AAX-8096-2020	Borg, Jean-Paul/0000-0001-8418-3382; Santoni, Marie-Josee/0000-0002-2619-7257; Camoin, Luc/0000-0002-1230-4787	La Ligue Nationale Contre le Cancer (Label Ligue Equipe labellisee 2019); Fondation de France; European PDZnet consortium (EU Horizon 2020 RIA under the Marie Skodowska-Curie grant) [675341]; Excellence Initiative of Aix-Marseille University-A*Midex, "Investissement d'avenir" (CapoStromEx)	La Ligue Nationale Contre le Cancer (Label Ligue Equipe labellisee 2019); Fondation de France(Fondation de France); European PDZnet consortium (EU Horizon 2020 RIA under the Marie Skodowska-Curie grant); Excellence Initiative of Aix-Marseille University-A*Midex, "Investissement d'avenir" (CapoStromEx)(French National Research Agency (ANR))	We thank Philippe Roche and the Phyre2 web portal for the generation of images, and Valerie Depraetere for careful reading of the manuscript. J-PB's lab is funded by La Ligue Nationale Contre le Cancer (Label Ligue Equipe labellisee 2019), Fondation de France (fellowship to RK), the European PDZnet consortium (EU Horizon 2020 RIA under the Marie Skodowska-Curie grant agreement no. 675341), and by Excellence Initiative of Aix-Marseille University-A*Midex, "Investissement d'avenir" (CapoStromEx). J-PB is a scholar of Institut Universitaire de France.	Almeida LL, 2018, STEM CELL REP, V11, P1040, DOI 10.1016/j.stemcr.2018.09.008; Althoff M, BLOOD, DOI [10.1182/blood.2019004113, DOI 10.1182/BL00D.2019004113]; Anastas JN, 2012, ONCOGENE, V31, P3696, DOI 10.1038/onc.2011.528; Apperson ML, 1996, J NEUROSCI, V16, P6839; Appleton BA, 2006, J BIOL CHEM, V281, P22312, DOI 10.1074/jbc.M602901200; Arnaud C, 2009, FEBS LETT, V583, P2326, DOI 10.1016/j.febslet.2009.06.034; Aster JC, 2017, ANNU REV PATHOL-MECH, V12, P245, DOI 10.1146/annurev-pathol-052016-100127; Audebert S, 2004, CURR BIOL, V14, P987, DOI 10.1016/j.cub.2004.05.051; Awadia S, 2019, J CELL BIOL, V218, P2699, DOI 10.1083/jcb.201811114; Baker L, 2016, J CELL SCI, V129, P2307, DOI 10.1242/jcs.185413; Bilder D, 2000, NAT CELL BIOL, V2, pE114, DOI 10.1038/35017119; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Birrane G, 2003, J BIOL CHEM, V278, P1399, DOI 10.1074/jbc.C200571200; Boisguerin P, 2004, CHEM BIOL, V11, P449, DOI 10.1016/j.chembiol.2004.03.010; Bonello TT, 2019, J CELL BIOL, V218, P742, DOI 10.1083/jcb.201810103; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; Chastney M, 2020, PREPRINT, DOI [10.1101/2020.01.24.918458v1.full, DOI 10.1101/2020.01.24.918458V1.FULL]; Chen BE, 2016, NAT CHEM BIOL, V12, P686, DOI 10.1038/nchembio.2119; Choi J, 2019, J CELL BIOL, V218, P2277, DOI 10.1083/jcb.201804201; Chong CH, 2019, TRANSL PSYCHIAT, V9, DOI 10.1038/s41398-019-0580-9; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; Dai FY, 2007, MOL CELL BIOL, V27, P6183, DOI 10.1128/MCB.00132-07; Dai PG, 2006, J BIOL CHEM, V281, P927, DOI 10.1074/jbc.M507360200; Daulat AM, 2019, PROTEOMICS, V19, DOI 10.1002/pmic.201800487; Daulat AM, 2017, TRENDS CANCER, V3, P113, DOI 10.1016/j.trecan.2017.01.001; Dow LE, 2007, ONCOGENE, V26, P2272, DOI 10.1038/sj.onc.1210016; Dow LE, 2003, ONCOGENE, V22, P9225, DOI 10.1038/sj.onc.1207154; Elsum IA, 2014, ONCOGENE, V33, P5523, DOI 10.1038/onc.2013.498; Elsum IA, 2013, J CELL SCI, V126, P3990, DOI 10.1242/jcs.129387; Favre B, 2001, J BIOL CHEM, V276, P32427, DOI 10.1074/jbc.M011005200; Feigin ME, 2014, CANCER RES, V74, P3180, DOI 10.1158/0008-5472.CAN-13-3415; Godde NJ, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004323; Harmon RM, 2013, J CLIN INVEST, V123, P1556, DOI 10.1172/JCI65220; Hawkins ED, 2016, ONCOGENE, V35, P1193, DOI 10.1038/onc.2015.167; Hernandez JL, 2017, CELL CHEM BIOL, V24, P87, DOI 10.1016/j.chembiol.2016.12.007; Horton ER, 2015, NAT CELL BIOL, V17, P1577, DOI 10.1038/ncb3257; How JY, 2019, FEBS LETT, V593, P533, DOI 10.1002/1873-3468.13329; HRDLICKOVA R, 1995, J VIROL, V69, P403; Hu Y, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.18; Hua SN, 2020, AGING-US, V12, P5439, DOI 10.18632/aging.102969; Huang H, 2015, BIOCHEM BIOPH RES CO, V463, P370, DOI 10.1016/j.bbrc.2015.05.071; Huang YZ, 2003, J BIOL CHEM, V278, P1108, DOI 10.1074/jbc.M205413200; Huang YZ, 2001, J BIOL CHEM, V276, P19318, DOI 10.1074/jbc.M100494200; Ivanov AI, 2010, AM J PATHOL, V176, P134, DOI 10.2353/ajpath.2010.090220; Ivarsson Y, 2014, P NATL ACAD SCI USA, V111, P2542, DOI 10.1073/pnas.1312296111; Izawa I, 2002, GENES CELLS, V7, P475, DOI 10.1046/j.1365-2443.2002.00533.x; Izawa I, 2008, GENES CELLS, V13, P691, DOI 10.1111/j.1365-2443.2008.01198.x; Jarjour AA, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002107; Jaulin-Bastard F, 2002, J BIOL CHEM, V277, P2869, DOI 10.1074/jbc.M109652200; Jaulin-Bastard F, 2001, J BIOL CHEM, V276, P15256, DOI 10.1074/jbc.M010032200; Kallay LM, 2006, J CELL BIOCHEM, V99, P647, DOI 10.1002/jcb.20992; Kelley LA, 2015, NAT PROTOC, V10, P845, DOI 10.1038/nprot.2015.053; Khoury MJ, 2020, P NATL ACAD SCI USA, V117, P11531, DOI 10.1073/pnas.1918462117; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; Kranjec C, 2016, PAPILLOMAVIRUS RES, V2, P70, DOI 10.1016/j.pvr.2016.04.001; Laura RP, 2002, J BIOL CHEM, V277, P12906, DOI 10.1074/jbc.M200818200; Lebeau S, 2005, BRIT J DERMATOL, V152, P1248, DOI 10.1111/j.1365-2133.2005.06687.x; Legouis R, 2000, NAT CELL BIOL, V2, P415, DOI 10.1038/35017046; Legouis R, 2003, EMBO REP, V4, P1096, DOI 10.1038/sj.embor.7400006; Li H, 2017, NEOPLASIA, V19, P509, DOI 10.1016/j.neo.2017.04.003; Li X, 2011, EMBO REP, V12, P818, DOI 10.1038/embor.2011.106; Li YD, 2013, MOL BIOL REP, V40, P4543, DOI 10.1007/s11033-013-2549-8; Lim KYB, 2017, J BIOL CHEM, V292, P20425, DOI 10.1074/jbc.M117.799452; Liu D, 2013, MOL IMMUNOL, V56, P104, DOI 10.1016/j.molimm.2013.04.007; Liu H, 2018, J CELL BIOL, V217, P299, DOI 10.1083/jcb.201705136; Liu HB, 2010, J VIROL, V84, P11164, DOI 10.1128/JVI.01278-10; Liu N, 2008, J BIOCHEM, V143, P793, DOI 10.1093/jb/mvn032; Liu X, 2019, INT REV CEL MOL BIO, V343, P129, DOI 10.1016/bs.ircmb.2018.05.013; Ludford-Menting MJ, 2005, IMMUNITY, V22, P737, DOI 10.1016/j.immuni.2005.04.009; Lyons JJ, 2017, J EXP MED, V214, P669, DOI 10.1084/jem.20161435; McDonald C, 2005, J BIOL CHEM, V280, P40301, DOI 10.1074/jbc.M508538200; Metais JY, 2005, FEBS LETT, V579, P3725, DOI 10.1016/j.febslet.2005.05.062; Montcouquiol M, 2006, J NEUROSCI, V26, P5265, DOI 10.1523/JNEUROSCI.4680-05.2006; Moreau MM, 2010, J NEUROSCI, V30, P9738, DOI 10.1523/JNEUROSCI.6007-09.2010; Murdoch JN, 2001, GENOMICS, V78, P55, DOI 10.1006/geno.2001.6638; Nagasaka K, 2010, ONCOGENE, V29, P5311, DOI 10.1038/onc.2010.265; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nakagawa S, 2004, BRIT J CANCER, V90, P194, DOI 10.1038/sj.bjc.6601465; Navarro C, 2005, ONCOGENE, V24, P4330, DOI 10.1038/sj.onc.1208632; Nola S, 2008, HUM MOL GENET, V17, P3552, DOI 10.1093/hmg/ddn248; Nolan ME, 2008, CANCER RES, V68, P8201, DOI 10.1158/0008-5472.CAN-07-6567; Nourry Claire, 2003, Sci STKE, V2003, pRE7; Okajima M, 2008, VIRUS GENES, V37, P231, DOI 10.1007/s11262-008-0259-4; Ono Y, 2015, CELL REP, V10, P1135, DOI 10.1016/j.celrep.2015.01.045; Osmani N, 2006, CURR BIOL, V16, P2395, DOI 10.1016/j.cub.2006.10.026; Pearson HB, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0440-z; Pearson HB, 2011, J CLIN INVEST, V121, P4257, DOI 10.1172/JCI58509; Peres E, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006933; Phua DCY, 2009, MOL BIOL CELL, V20, P2841, DOI 10.1091/mbc.E08-02-0199; PRINTEN JA, 1994, GENETICS, V138, P609; Rachmin I, 2014, P NATL ACAD SCI USA, V111, P5902, DOI 10.1073/pnas.1320350111; Rangwala R, 2005, J BIOL CHEM, V280, P11790, DOI 10.1074/jbc.M414154200; Ress A, 2008, EUR SURG RES, V41, P284, DOI 10.1159/000148241; Ress A, 2006, PROTEIN PEPTIDE LETT, V13, P877, DOI 10.2174/092986606778256126; Robertson J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7265; Rubin I, 2001, ANN ONCOL, V12, P3, DOI 10.1023/A:1011195320446; Saito H, 2001, J BIOL CHEM, V276, P32051, DOI 10.1074/jbc.C100330200; Santoni MJ, 2002, TRENDS GENET, V18, P494, DOI 10.1016/S0168-9525(02)02738-5; Schurmann C, 2019, CARDIOVASC RES, V115, P1963, DOI 10.1093/cvr/cvz093; Sflomos G, 2011, J CELL SCI, V124, P3209, DOI 10.1242/jcs.062307; Shen LB, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0034-x; Simeone L, 2010, J NEUROSCI, V30, P6620, DOI 10.1523/JNEUROSCI.5778-09.2010; Skouloudaki K, 2009, P NATL ACAD SCI USA, V106, P8579, DOI 10.1073/pnas.0811691106; Song CJ, 2009, IUBMB LIFE, V61, P685, DOI 10.1002/iub.221; Stephens R, 2018, J MOL BIOL, V430, P3585, DOI 10.1016/j.jmb.2018.01.011; Stevens PD, 2018, CANCER RES, V78, P4839, DOI 10.1158/0008-5472.CAN-17-3629; Strassburger K, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0198149; Sundell GN, 2018, MOL SYST BIOL, V14, DOI 10.15252/msb.20178129; Takizawa S, 2006, GENES CELLS, V11, P453, DOI 10.1111/j.1365-2443.2006.00954.x; Tao YM, 2014, P NATL ACAD SCI USA, V111, pE4429, DOI 10.1073/pnas.1407139111; Tao YM, 2009, P NATL ACAD SCI USA, V106, P9477, DOI 10.1073/pnas.0901844106; Thomas M, 2005, ONCOGENE, V24, P6222, DOI 10.1038/sj.onc.1208757; Thomas M, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005766; Tran E, 2014, SCIENCE, V344, P641, DOI 10.1126/science.1251102; Valenzuela-Iglesias A, 2019, MOL CANCER RES, V17, P1195, DOI 10.1158/1541-7786.MCR-18-0048; Wan S, 2018, HEPATOLOGY, V67, P1842, DOI 10.1002/hep.29669; Warner DR, 2003, FEBS LETT, V539, P167, DOI 10.1016/S0014-5793(03)00155-8; Wilkes MC, 2009, DEV CELL, V16, P433, DOI 10.1016/j.devcel.2009.01.009; Wu H, 2017, J HEPATOL, V66, P1193, DOI 10.1016/j.jhep.2017.01.030; Yao S, 2015, J PATHOL, V236, P65, DOI 10.1002/path.4502; Yoshihara K, 2011, EXP CELL RES, V317, P413, DOI 10.1016/j.yexcr.2010.12.004; Young LC, 2013, MOL CELL, V52, P679, DOI 10.1016/j.molcel.2013.10.004; Yuan J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13489-4; Zeitler J, 2004, J CELL BIOL, V167, P1137, DOI 10.1083/jcb.200407158; Zhan LX, 2008, CELL, V135, P865, DOI 10.1016/j.cell.2008.09.045; Zheng WY, 2016, NAT CELL BIOL, V18, P1244, DOI 10.1038/ncb3413; Zheng ZJ, 2019, MOL THER, V27, P542, DOI 10.1016/j.ymthe.2019.01.016	127	16	16	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	2020	39	47					7019	7033		10.1038/s41388-020-01478-7	http://dx.doi.org/10.1038/s41388-020-01478-7		SEP 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OT7KA	32999444	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000574076200001
J	Peng, H; Wang, YF; Luo, WB				Peng, Hui; Wang, Yingfei; Luo, Weibo			Multifaceted role of branched-chain amino acid metabolism in cancer	ONCOGENE			English	Review							PROMOTES CELL-PROLIFERATION; HEPATOCELLULAR-CARCINOMA; BCAT1 PROMOTES; RADIOFREQUENCY ABLATION; ONCOMETABOLITE 2-HYDROXYGLUTARATE; ORAL SUPPLEMENTATION; ALPHA-KETOGLUTARATE; CATABOLISM; SURVIVAL; LEUCINE	Metabolic reprogramming fulfils increased nutrient demands and regulates numerous oncogenic processes in tumors, leading to tumor malignancy. Branched-chain amino acids (BCAAs, i.e., valine, leucine, and isoleucine) function as nitrogen donors to generate macromolecules such as nucleotides and are indispensable for human cancer cell growth. The cell-autonomous and non-autonomous roles of altered BCAA metabolism have been implicated in cancer progression and the key proteins in the BCAA metabolic pathway serve as possible prognostic and diagnostic biomarkers in human cancers. Here we summarize how BCAA metabolic reprogramming is regulated in cancer cells and how it influences cancer progression.	[Peng, Hui; Wang, Yingfei; Luo, Weibo] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Wang, Yingfei] Univ Texas Southwestern Med Ctr Dallas, Dept Neurol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Luo, Weibo] Univ Texas Southwestern Med Ctr Dallas, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Wang, YF; Luo, WB (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.; Wang, YF (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Neurol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.; Luo, WB (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Yingfei.Wang@UTSouthwestern.edu; Weibo.Luo@UTSouthwestern.edu		Luo, Weibo/0000-0002-1992-0320; wang, yingfei/0000-0002-8723-252X	NIH [R01AG066166, R35GM124693, R01CA222393]; CPRIT [RP190358]; Mary Kay Foundation [08-19]; Welch Foundation [I-1903-20190330]; UTSW startup funds	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CPRIT; Mary Kay Foundation; Welch Foundation(The Welch Foundation); UTSW startup funds	Work in authors' laboratories was supported by grants from NIH (R01CA222393), CPRIT (RP190358), Mary Kay Foundation (08-19), and Welch Foundation (I-1903-20190330) to WL; and NIH (R01AG066166, R35GM124693) and UTSW startup funds to YW. WL is a CPRIT Scholar in Cancer Research.	Abla H, 2020, SEMIN CELL DEV BIOL, V98, P26, DOI 10.1016/j.semcdb.2019.05.031; Ananieva EA, 2018, CURR OPIN CLIN NUTR, V21, P64, DOI 10.1097/MCO.0000000000000430; Ananieva EA, 2014, J BIOL CHEM, V289, P18793, DOI 10.1074/jbc.M114.554113; Arakawa M, 2011, ENDOCR J, V58, P161, DOI 10.1507/endocrj.K10E-221; Baracos VE, 2006, J NUTR, V136, p237S, DOI 10.1093/jn/136.1.237S; Biswas D, 2019, FASEB J, V33, P8711, DOI 10.1096/fj.201802842RR; Cha JH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077899; Chowdhury R, 2011, EMBO REP, V12, P463, DOI 10.1038/embor.2011.43; Cluntun AA, 2017, TRENDS CANCER, V3, P169, DOI 10.1016/j.trecan.2017.01.005; DeBerardinis RJ, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600200; Dey P, 2017, NATURE, V542, P119, DOI 10.1038/nature21052; Elorza A, 2012, MOL CELL, V48, P681, DOI 10.1016/j.molcel.2012.09.017; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Ericksen RE, 2019, CELL METAB, V29, P1151, DOI 10.1016/j.cmet.2018.12.020; Faubert B, 2020, SCIENCE, V368, P152, DOI 10.1126/science.aaw5473; Gu ZM, 2019, CANCER DISCOV, V9, P1228, DOI 10.1158/2159-8290.CD-19-0152; HALL TR, 1993, J BIOL CHEM, V268, P3092; Hatazawa Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091006; Hattori A, 2017, NATURE, V545, P500, DOI 10.1038/nature22314; Hayaishi S, 2011, DIGEST DIS, V29, P326, DOI 10.1159/000327571; Holecek M, 2018, NUTR METAB, V15, DOI 10.1186/s12986-018-0271-1; Ikeda K, 2017, CELL REP, V21, P1824, DOI 10.1016/j.celrep.2017.10.082; Imanaka K, 2016, HEPATOL RES, V46, P1002, DOI 10.1111/hepr.12640; Ivan M, 2017, MOL CELL, V66, P772, DOI 10.1016/j.molcel.2017.06.002; Iwasa M, 2015, J NUTR SCI VITAMINOL, V61, P433, DOI 10.3177/jnsv.61.433; Iwasa M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070309; Kaelin WG, 2013, CELL, V153, P56, DOI 10.1016/j.cell.2013.03.004; Kawaguchi T, 2014, CLIN GASTROENTEROL H, V12, P1012, DOI 10.1016/j.cgh.2013.08.050; Kim DK, 2004, NEUROSCI RES, V50, P437, DOI 10.1016/j.neures.2004.08.003; Kuroda H, 2010, J GASTROEN HEPATOL, V25, P1550, DOI 10.1111/j.1440-1746.2010.06306.x; Lee IJ, 2011, CANCER RES TREAT, V43, P24, DOI 10.4143/crt.2011.43.1.24; Lee JH, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0350-z; Li JT, 2020, NAT CELL BIOL, V22, P167, DOI 10.1038/s41556-019-0455-6; Liu XY, 2018, CELL REP, V23, P1461, DOI 10.1016/j.celrep.2018.03.140; Loenarz C, 2008, NAT CHEM BIOL, V4, P152, DOI 10.1038/nchembio0308-152; Luo WB, 2019, ADV EXP MED BIOL, V1136, P1, DOI 10.1007/978-3-030-12734-3_1; Luo WB, 2018, CELL MOL LIFE SCI, V75, P1043, DOI 10.1007/s00018-017-2684-9; Martin SB, 2020, BIOCHEM J, V477, P1579, DOI 10.1042/BCJ20190754; Mayers JR, 2016, SCIENCE, V353, P1161, DOI 10.1126/science.aaf5171; Mayers JR, 2014, NAT MED, V20, P1193, DOI 10.1038/nm.3686; McBrayer SK, 2018, CELL, V175, P101, DOI 10.1016/j.cell.2018.08.038; Morihara D, 2012, HEPATOL RES, V42, P658, DOI 10.1111/j.1872-034X.2012.00969.x; Mossmann D, 2018, NAT REV CANCER, V18, P744, DOI 10.1038/s41568-018-0074-8; Nojiri S, 2017, NUTRITION, V33, P20, DOI 10.1016/j.nut.2016.07.013; Qu YY, 2020, CANCER RES, V80, P319, DOI 10.1158/0008-5472.CAN-19-1023; Raffel S, 2017, NATURE, V551, P384, DOI 10.1038/nature24294; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Shennan DB, 2004, BBA-BIOMEMBRANES, V1664, P206, DOI 10.1016/j.bbamem.2004.05.008; Shimizu N, 2011, CELL METAB, V13, P170, DOI 10.1016/j.cmet.2011.01.001; Shimomura Y, 2004, J NUTR, V134, p1583S, DOI 10.1093/jn/134.6.1583S; Silva LS, 2017, EMBO REP, V18, P2172, DOI 10.15252/embr.201744154; Sivanand S, 2020, CANCER CELL, V37, P147, DOI 10.1016/j.ccell.2019.12.011; Tada T, 2014, HEPATOL RES, V44, P288, DOI 10.1111/hepr.12120; Takami T, 2016, WORLD J GASTROENTERO, V22, P7252, DOI 10.3748/wjg.v22.i32.7252; Takegoshi K, 2017, ONCOTARGET, V8, P18191, DOI 10.18632/oncotarget.15304; Terakura D, 2012, CARCINOGENESIS, V33, P2499, DOI 10.1093/carcin/bgs303; Tian Q, 2020, ONCOGENE, V39, P3980, DOI 10.1038/s41388-020-1262-z; Tian T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030755; Tonjes M, 2013, NAT MED, V19, P901, DOI 10.1038/nm.3217; Wang P, 2018, INT J CLIN EXP PATHO, V11, P5536; Wang YT, 2019, CELL REP, V28, P512, DOI 10.1016/j.celrep.2019.06.026; Wang ZQ, 2015, ONCOTARGET, V6, P31522, DOI 10.18632/oncotarget.5159; Wolfson RL, 2016, SCIENCE, V351, P43, DOI 10.1126/science.aab2674; Xu M, 2016, ONCOL LETT, V12, P2648, DOI 10.3892/ol.2016.4969; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Xue PP, 2017, EBIOMEDICINE, V20, P50, DOI 10.1016/j.ebiom.2017.05.001; Yoneshiro T, 2019, NATURE, V572, P614, DOI 10.1038/s41586-019-1503-x; Zdzisinska B, 2017, ARCH IMMUNOL THER EX, V65, P21, DOI 10.1007/s00005-016-0406-x; Zhang B, 2021, CELL MOL LIFE SCI, V78, P195, DOI 10.1007/s00018-020-03483-1; Zhang L, 2017, BIOCHEM BIOPH RES CO, V486, P224, DOI 10.1016/j.bbrc.2017.02.101; Zheng YH, 2016, LIVER INT, V36, P1836, DOI 10.1111/liv.13178; Zhenyukh O, 2017, FREE RADICAL BIO MED, V104, P165, DOI 10.1016/j.freeradbiomed.2017.01.009; Zhou W, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-53; Zhu ZW, 2020, NAT METAB, V2, P775, DOI 10.1038/s42255-020-0226-5; Zou HF, 2019, ONCOL LETT, V18, P5879, DOI 10.3892/ol.2019.10932	75	45	45	6	28	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2020	39	44					6747	6756		10.1038/s41388-020-01480-z	http://dx.doi.org/10.1038/s41388-020-01480-z		SEP 2020	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OH9QS	32978521	Green Accepted			2022-12-28	WOS:000572714000007
J	Wu, DH; Wang, Y; Yang, GC; Zhang, SG; Liu, Y; Zhou, S; Guo, HR; Liang, SH; Cui, YF; Zhang, B; Ma, K; Zhang, CY; Liu, YF; Sun, LM; Wang, JB; Liu, LX				Wu, Dehai; Wang, Yan; Yang, Guangchao; Zhang, Shugeng; Liu, Yao; Zhou, Shuo; Guo, Hongrui; Liang, Shuhang; Cui, Yifeng; Zhang, Bo; Ma, Kun; Zhang, Congyi; Liu, Yufeng; Sun, Linmao; Wang, Jiabei; Liu, Lianxin			A novel mitochondrial amidoxime reducing component 2 is a favorable indicator of cancer and suppresses the progression of hepatocellular carcinoma by regulating the expression of p27	ONCOGENE			English	Article							CYTOCHROME B(5); PATHWAY; P27(KIP1); REDUCTASE	Hepatocellular carcinoma (HCC) is the fifth leading cause of cancer-related mortality in the United States. Exploring the mechanism of HCC and identifying ideal targets is critical. In the present study, we demonstrated metabolism dysfunction might be a key diver for the development of HCC. The mitochondrial amidoxime reducing component 2 (MARC2) as a newly discovered molybdenum enzyme was downregulated in human HCC tissues and HCC cells. Downregulated MARC2 was significantly associated with clinicopathological characteristics of HCC, such as tumor size, AFP levels, and tumor grade and was an independent risk factor of poor prognosis. Both in vitro and in vivo studies suggested that MARC2 suppressed the progression of HCC by regulating the protein expression level of p27. The Hippo signaling pathway and RNF123 were required for this process. Moreover, MARC2 regulated expression of HNF4A via the Hippo signaling pathway. HNF4A was recruited to the promoter of MARC2 forming a feedback loop. MARC2 levels were downregulated by methylation. We demonstrated the prognostic value of MARC2 in HCC and determined the mechanism by which MARC2 suppressed the progression of HCC in this study. These findings may lead to new therapeutic targets for HCC.	[Wu, Dehai; Yang, Guangchao; Zhang, Shugeng; Zhou, Shuo; Guo, Hongrui; Liang, Shuhang; Cui, Yifeng; Zhang, Bo; Ma, Kun; Zhang, Congyi; Liu, Yufeng; Sun, Linmao; Liu, Lianxin] Harbin Med Univ, Affiliated Hosp 1, Minist Educ, Dept Hepat Surg,Key Lab Hepatosplen Surg, Harbin 150001, Heilongjiang, Peoples R China; [Wang, Yan] Harbin Med Univ, Canc Hosp, Dept Colorectal Surg, Harbin 150001, Heilongjiang, Peoples R China; [Liu, Yao; Wang, Jiabei] Univ Sci & Technol China, Affiliated Hosp 1, Anhui Prov Key Lab Hepatopancreatobiliary Surg, Div Life Sci & Med,Dept Hepatobiliary Surg, Hefei 230001, Anhui, Peoples R China	Harbin Medical University; Harbin Medical University; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Liu, LX (corresponding author), Harbin Med Univ, Affiliated Hosp 1, Minist Educ, Dept Hepat Surg,Key Lab Hepatosplen Surg, Harbin 150001, Heilongjiang, Peoples R China.; Wang, JB (corresponding author), Univ Sci & Technol China, Affiliated Hosp 1, Anhui Prov Key Lab Hepatopancreatobiliary Surg, Div Life Sci & Med,Dept Hepatobiliary Surg, Hefei 230001, Anhui, Peoples R China.	jbwang16@ustc.edu.cn; liulx@ems.hrbmu.edu.cn						Dobashi Y, 2017, HUM PATHOL, V66, P67, DOI 10.1016/j.humpath.2017.05.022; Fitamant J, 2015, CELL REP, V10, P1692, DOI 10.1016/j.celrep.2015.02.027; Ganem NJ, 2014, CELL, V158, P833, DOI 10.1016/j.cell.2014.06.029; Guichard C, 2012, NAT GENET, V44, P694, DOI 10.1038/ng.2256; Hnit SST, 2015, INT J BIOCHEM CELL B, V68, P9, DOI 10.1016/j.biocel.2015.08.005; Jang W, 2017, EMBO J, V36, P2510, DOI 10.15252/embj.201696089; Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194; Khanna R, 2018, FEBS J, V285, P2243, DOI 10.1111/febs.14477; Kotthaus J, 2011, BIOCHEM J, V433, P383, DOI 10.1042/BJ20100960; Li Z, 2019, J CELL BIOCHEM, V120, P6046, DOI 10.1002/jcb.27891; Liu Y, 2019, CLIN CANCER RES, V25, P5407, DOI 10.1158/1078-0432.CCR-18-4113; Massarweh NN, 2017, CANCER CONTROL, V24, DOI 10.1177/1073274817729245; Mikula M, 2011, FUNCT INTEGR GENOMIC, V11, P215, DOI 10.1007/s10142-010-0200-5; Mo JS, 2014, EMBO REP, V15, P642, DOI 10.15252/embr.201438638; Neve EPA, 2012, J BIOL CHEM, V287, P6307, DOI 10.1074/jbc.M111.328237; Plitzko B, 2013, J BIOL CHEM, V288, P20228, DOI 10.1074/jbc.M113.474916; Rixen S, 2019, J BIOL CHEM, V294, P17593, DOI 10.1074/jbc.RA119.007606; Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sparacino-Watkins CE, 2014, J BIOL CHEM, V289, P10345, DOI 10.1074/jbc.M114.555177; Wahl B, 2010, J BIOL CHEM, V285, P37847, DOI 10.1074/jbc.M110.169532; Wang XD, 2020, ACAD RADIOL, V27, P1720, DOI 10.1016/j.acra.2018.04.021; Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112	23	7	7	3	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2020	39	38					6099	6112		10.1038/s41388-020-01417-6	http://dx.doi.org/10.1038/s41388-020-01417-6		AUG 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NQ9JF	32811980	Green Published, hybrid			2022-12-28	WOS:000561911600001
J	Lin, BY; Li, YX; Wang, TP; Qiu, YM; Chen, ZZ; Zhao, K; Lu, N				Lin, Binyan; Li, Yongxu; Wang, Tiepeng; Qiu, Yangmin; Chen, Zhenzhong; Zhao, Kai; Lu, Na			CRMP2 is a therapeutic target that suppresses the aggressiveness of breast cancer cells by stabilizing RECK	ONCOGENE			English	Article							NF-KAPPA-B; METASTASIS; VARIANCE; EMT	Metastatic breast cancer is characterized by high mortality and limited therapeutic target. During tumor metastasis, cytoskeletal reorganization is one of the key steps in the migration and invasion of breast cancer cells. Collapsin response mediator protein 2 (CRMP2) is a cytosolic phosphoprotein that plays an important role in regulating cytoskeletal dynamics. Previous researches have reported that altered CRMP2 expression is associated with breast cancer progression, but the underlying mechanism remains poorly understood. Here, we show that CRMP2 expression is reduced in various subtypes of breast cancers and negatively correlated with lymphatic metastasis. Overexpression of CRMP2 significantly inhibits invasion and stemness in breast cancer cells, while downregulation of CRMP2 promotes cell invasion, which is not required for tubulin polymerization. Mechanistic studies demonstrate that CRMP2 interacts with RECK, prevents RECK degradation, which, in turn, blocks NF-kappa B and Wnt signaling pathways. Furthermore, we find that phosphorylation of CRMP2 at T514 and S522 remarkably abolishes its functions to bind with RECK and to inhibit cell invasion. Pharmacologic rescue of CRMP2 expression suppressed breast cancer metastasis in vitro and in vivo and stimulated a synergetic effect with FN-1501 that induces CRMP2 dephosphorylation. Collectively, this study highlights the potential of CRMP2 as a therapeutic target in breast cancer metastasis and reveals a distinct mechanism of CRMP2.	[Lin, Binyan; Li, Yongxu; Wang, Tiepeng; Qiu, Yangmin; Chen, Zhenzhong; Zhao, Kai; Lu, Na] China Pharmaceut Univ, State Key Lab Nat Med, Jiangsu Key Lab Carcinogenesis & Intervent, Dept Physiol,Sch Basic Med & Clin Pharm, 24 Tongjiaxiang, Nanjing 210009, Peoples R China; [Lin, Binyan] Nanjing Univ Chinese Med, Sch Pharm, Xianlin Ave 138, Nanjing 210023, Peoples R China	China Pharmaceutical University; Nanjing University of Chinese Medicine	Zhao, K; Lu, N (corresponding author), China Pharmaceut Univ, State Key Lab Nat Med, Jiangsu Key Lab Carcinogenesis & Intervent, Dept Physiol,Sch Basic Med & Clin Pharm, 24 Tongjiaxiang, Nanjing 210009, Peoples R China.	cpuzhaokai@163.com; nalu@cpu.edu.com		Qiu, Yangmin/0000-0001-6039-7909; Wang, Tiepeng/0000-0002-0691-2882; Zhao, Kai/0000-0002-4492-6185	National Natural Science Foundation of China [81872899, 81903625]; National Science & Technology Major Project [2017ZX09101003-005023, 2017ZX09301014, 2018ZX09711001-003-007]; Social Development Project of Jiangsu Provincial Science and Technology Department [BE2018711]; Natural Science Foundation of Jiangsu Province [BK20190563]; "Double First-Class" University project [CPU2018GY17]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science & Technology Major Project; Social Development Project of Jiangsu Provincial Science and Technology Department; Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); "Double First-Class" University project	This work was supported by the National Natural Science Foundation of China (Nos. 81872899 and 81903625), the National Science & Technology Major Project (Nos. 2017ZX09101003-005023, 2017ZX09301014, and 2018ZX09711001-003-007), Social Development Project of Jiangsu Provincial Science and Technology Department (BE2018711), Natural Science Foundation of Jiangsu Province (BK20190563), and the "Double First-Class" University project (CPU2018GY17).	Abe H, 2018, SCIENCE, V360, P50, DOI 10.1126/science.aao2300; Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Armstrong RA, 2002, OPHTHAL PHYSL OPT, V22, P248, DOI 10.1046/j.1475-1313.2002.00020.x; Brabletz T, 2012, NAT REV CANCER, V12, P425, DOI 10.1038/nrc3265; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Deng J, 2004, MOL CARCINOGEN, V39, P139, DOI 10.1002/mc.10169; DiDonato JA, 2012, IMMUNOL REV, V246, P379, DOI 10.1111/j.1600-065X.2012.01099.x; Duciel L, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39643-y; Farago M, 2005, CANCER RES, V65, P5792, DOI 10.1158/0008-5472.CAN-05-1021; Fife CM, 2014, BRIT J PHARMACOL, V171, P5507, DOI 10.1111/bph.12704; Geng SQ, 2014, CANCER LETT, V349, P1, DOI 10.1016/j.canlet.2014.03.036; Grant NJ, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1691-1; Huang RYJ, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.442; Kawai T, 2008, ANN NY ACAD SCI, V1143, P1, DOI 10.1196/annals.1443.020; Ma B, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00378; Matsunuma R, 2018, P NATL ACAD SCI USA, V115, pE11978, DOI 10.1073/pnas.1810598115; Matsuzaki T, 2018, BIOL OPEN, V7, DOI 10.1242/bio.033985; McDonald ES, 2016, J NUCL MED, V57, p9S, DOI 10.2967/jnumed.115.157834; Mishra P, 2019, ANN CARD ANAESTH, V22, P407, DOI 10.4103/aca.ACA_94_19; Moutal A, 2019, MOL NEUROBIOL, V56, P6736, DOI 10.1007/s12035-019-1568-4; Moutal A, 2018, MOL NEUROBIOL, V55, P4403, DOI 10.1007/s12035-017-0653-9; Oliemuller E, 2013, INT J CANCER, V132, P1986, DOI 10.1002/ijc.27881; Pastushenko I, 2019, TRENDS CELL BIOL, V29, P212, DOI 10.1016/j.tcb.2018.12.001; Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586-018-0040-3; Quach TT, 2015, MOL PSYCHIATR, V20, P1037, DOI 10.1038/mp.2015.77; Schlenker E, 2016, METHODS MOL BIOL, V1366, P271, DOI 10.1007/978-1-4939-3127-9_21; Schmidt EF, 2007, ADV EXP MED BIOL, V600, P1; Shih JY, 2001, JNCI-J NATL CANCER I, V93, P1392, DOI 10.1093/jnci/93.18.1392; Shih YW, 2010, CELL BIOCHEM BIOPHYS, V58, P31, DOI 10.1007/s12013-010-9091-2; Shimada K, 2014, BREAST CANCER-TOKYO, V21, P715, DOI 10.1007/s12282-013-0447-5; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Walsh LA, 2015, ONCOGENE, V34, P2189, DOI 10.1038/onc.2014.175; Wang Y, 2018, J MED CHEM, V61, P1499, DOI 10.1021/acs.jmedchem.7b01261; Wilson SM, 2012, NEUROSCIENCE, V210, P451, DOI 10.1016/j.neuroscience.2012.02.038; Wu YY, 2012, MOL CANCER RES, V10, P1597, DOI 10.1158/1541-7786.MCR-12-0155-T; Yan W, 2018, CELL PHYSIOL BIOCHEM, V47, P489, DOI 10.1159/000489983; Zardavas D, 2013, NAT REV CLIN ONCOL, V10, P191, DOI 10.1038/nrclinonc.2013.29; Zheng YR, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04954-7	39	6	6	1	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2020	39	37					6024	6040		10.1038/s41388-020-01412-x	http://dx.doi.org/10.1038/s41388-020-01412-x		AUG 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NM2OY	32778769				2022-12-28	WOS:000558201400001
J	de Krijger, I; van der Torre, J; Peuscher, MH; Eder, M; Jacobs, JJL				de Krijger, Inge; van der Torre, Jaco; Peuscher, Marieke H.; Eder, Mathias; Jacobs, Jacqueline J. L.			H3K36 dimethylation by MMSET promotes classical non-homologous end-joining at unprotected telomeres	ONCOGENE			English	Article							DNA-DAMAGE RESPONSE; HISTONE H3; HOMOLOGOUS RECOMBINATION; LYSINE 36; DYSFUNCTIONAL TELOMERES; MAMMALIAN TELOMERES; REPAIR; 53BP1; CHROMATIN; METHYLATION	The epigenetic environment plays an important role in DNA damage recognition and repair, both at DNA double-strand breaks and at deprotected telomeres. To increase understanding on how DNA damage responses (DDR) at deprotected telomeres are regulated by modification and remodeling of telomeric chromatin we screened 38 methyltransferases for their ability to promote telomere dysfunction-induced genomic instability. As top hit we identified MMSET, a histone methyltransferase (HMT) causally linked to multiple myeloma and Wolf-Hirschhorn syndrome. We show that MMSET promotes non-homologous end-joining (NHEJ) at deprotected telomeres through Ligase4-dependent classical NHEJ, and does not contribute to Ligase3-dependent alternative NHEJ. Moreover, we show that this is dependent on the catalytic activity of MMSET, enabled by its SET-domain. Indeed, in absence of MMSET H3K36-dimethylation (H3K36me2) decreases, both globally and at subtelomeric regions. Interestingly, the level of MMSET-dependent H3K36me2 directly correlates with NHEJ-efficiency. We show that MMSET depletion does not impact on recognition of deprotected telomeres by the DDR-machinery or on subsequent recruitment of DDR-factors acting upstream or at the level of DNA repair pathway choice. Our data are most consistent with an important role for H3K36me2 in more downstream steps of the DNA repair process. Moreover, we find additional H3K36me2-specific HMTs to contribute to NHEJ at deprotected telomeres, further emphasizing the importance of H3K36me2 in DNA repair.	[de Krijger, Inge; van der Torre, Jaco; Peuscher, Marieke H.; Eder, Mathias; Jacobs, Jacqueline J. L.] Netherlands Canc Inst, Div Oncogen, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Jacobs, JJL (corresponding author), Netherlands Canc Inst, Div Oncogen, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	j.jacobs@nki.nl	Jacobs, Jacqueline/ABA-5652-2020	Jacobs, Jacqueline/0000-0002-7704-4795; Peuscher, Marieke/0000-0001-9410-4350; van der Torre, Jaco/0000-0002-5405-3824				Arnoult N, 2015, NAT STRUCT MOL BIOL, V22, P859, DOI 10.1038/nsmb.3092; Aymard F, 2014, NAT STRUCT MOL BIOL, V21, P366, DOI 10.1038/nsmb.2796; Bartocci C, 2014, CELL REP, V7, P1320, DOI 10.1016/j.celrep.2014.04.002; Benetti R, 2007, NAT GENET, V39, P243, DOI 10.1038/ng1952; Bennett RL, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a026708; Bergemann AD, 2005, TRENDS GENET, V21, P188, DOI 10.1016/j.tig.2005.01.008; Blackford AN, 2017, MOL CELL, V66, P801, DOI 10.1016/j.molcel.2017.05.015; Blasco MA, 2007, NAT REV GENET, V8, P299, DOI 10.1038/nrg2047; Boersma V, 2015, NATURE, V521, P537, DOI 10.1038/nature14216; Botuyan MV, 2006, CELL, V127, P1361, DOI 10.1016/j.cell.2006.10.043; Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012; Cao LL, 2016, ONCOGENE, V35, P301, DOI 10.1038/onc.2015.81; Carvalho S, 2014, ELIFE, V3, DOI 10.7554/eLife.02482; Celli GB, 2005, NAT CELL BIOL, V7, P712, DOI 10.1038/ncb1275; Celli GB, 2006, NAT CELL BIOL, V8, P885, DOI 10.1038/ncb1444; Chapman JR, 2013, MOL CELL, V49, P858, DOI 10.1016/j.molcel.2013.01.002; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Clouaire T, 2015, NUCLEUS-PHILA, V6, P107, DOI 10.1080/19491034.2015.1010946; Clouaire T, 2018, MOL CELL, V72, P250, DOI 10.1016/j.molcel.2018.08.020; Coussens NP, 2018, J BIOL CHEM, V293, P13750, DOI 10.1074/jbc.RA118.004274; de Lange T, 2010, COLD SH Q B, V75, P167, DOI 10.1101/sqb.2010.75.017; de Lange T, 2009, SCIENCE, V326, P948, DOI 10.1126/science.1170633; Di Virgilio M, 2013, SCIENCE, V339, P711, DOI 10.1126/science.1230624; Dimitrova N, 2009, MOL CELL BIOL, V29, P5552, DOI 10.1128/MCB.00476-09; Edmunds JW, 2008, EMBO J, V27, P406, DOI 10.1038/sj.emboj.7601967; Escribano-Diaz C, 2013, MOL CELL, V49, P872, DOI 10.1016/j.molcel.2013.01.001; Fnu S, 2011, P NATL ACAD SCI USA, V108, P540, DOI 10.1073/pnas.1013571108; Fortuny A, 2018, CHROMOSOMA, V127, P291, DOI 10.1007/s00412-018-0669-6; Fradet-Turcotte A, 2013, NATURE, V499, P50, DOI 10.1038/nature12318; Nguyen HV, 2017, P NATL ACAD SCI USA, V114, pE10560, DOI 10.1073/pnas.1701366114; Hajdu I, 2011, P NATL ACAD SCI USA, V108, P13130, DOI 10.1073/pnas.1110081108; Hartlerode AJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049211; Hsiao KY, 2013, J MOL CELL BIOL, V5, P157, DOI 10.1093/jmcb/mjs066; Hsu HL, 2000, GENE DEV, V14, P2807, DOI 10.1101/gad.844000; Hudlebusch HR, 2011, CLIN CANCER RES, V17, P2919, DOI 10.1158/1078-0432.CCR-10-1302; Jacquet K, 2016, MOL CELL, V62, P409, DOI 10.1016/j.molcel.2016.03.031; Jha DK, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4965; Jiang WX, 2015, MOL CELL, V58, P172, DOI 10.1016/j.molcel.2015.02.024; Kassambara A, 2009, BIOCHEM BIOPH RES CO, V379, P840, DOI 10.1016/j.bbrc.2008.12.093; Kim JY, 2008, MOL CELL BIOL, V28, P2023, DOI 10.1128/MCB.02130-07; Konishi A, 2008, GENE DEV, V22, P1221, DOI 10.1101/gad.1634008; Kuo AJ, 2011, MOL CELL, V44, P609, DOI 10.1016/j.molcel.2011.08.042; Lauring J, 2008, BLOOD, V111, P856, DOI 10.1182/blood-2007-05-088674; Li Y, 2009, J BIOL CHEM, V284, P34283, DOI 10.1074/jbc.M109.034462; Luijsterburg MS, 2016, MOL CELL, V61, P547, DOI 10.1016/j.molcel.2016.01.019; Lukas J, 2011, NAT CELL BIOL, V13, P1161, DOI 10.1038/ncb2344; Marango J, 2008, BLOOD, V111, P3145, DOI 10.1182/blood-2007-06-092122; Martinez-Garcia E, 2011, BLOOD, V117, P211, DOI 10.1182/blood-2010-07-298349; Miller KM, 2010, NAT STRUCT MOL BIOL, V17, P1144, DOI 10.1038/nsmb.1899; Nimura K, 2009, NATURE, V460, P287, DOI 10.1038/nature08086; O'Sullivan RJ, 2010, NAT REV MOL CELL BIO, V11, P171, DOI 10.1038/nrm2848; Pai CC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5091; Pei HD, 2013, J IMMUNOL, V190, P756, DOI 10.4049/jimmunol.1201811; Pei HD, 2011, NATURE, V470, P124, DOI 10.1038/nature09658; Peuscher MH, 2011, NAT CELL BIOL, V13, P1139, DOI 10.1038/ncb2326; Pfister SX, 2014, CELL REP, V7, P2006, DOI 10.1016/j.celrep.2014.05.026; Popovic R, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004566; Porro A, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6379; Ribes-Zamora A, 2013, CELL REP, V5, P194, DOI 10.1016/j.celrep.2013.08.040; Sallmyr A, 2018, J BIOL CHEM, V293, P10536, DOI 10.1074/jbc.TM117.000375; Sfeir A, 2012, SCIENCE, V336, P593, DOI 10.1126/science.1218498; Shah MY, 2016, ONCOGENE, V35, P5905, DOI 10.1038/onc.2016.116; Smogorzewska A, 2002, CURR BIOL, V12, P1635, DOI 10.1016/S0960-9822(02)01179-X; Stec I, 1998, HUM MOL GENET, V7, P1071, DOI 10.1093/hmg/7.7.1071; Symington LS, 2016, CRIT REV BIOCHEM MOL, V51, P195, DOI 10.3109/10409238.2016.1172552; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Tang JB, 2013, NAT STRUCT MOL BIOL, V20, P317, DOI 10.1038/nsmb.2499; Todoerti K, 2005, BRIT J HAEMATOL, V131, P214, DOI 10.1111/j.1365-2141.2005.05741.x; Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433; Tuzon CT, 2014, CELL REP, V8, P429, DOI 10.1016/j.celrep.2014.06.013; Wagner EJ, 2012, NAT REV MOL CELL BIO, V13, P115, DOI 10.1038/nrm3274; Zhang JF, 2019, CANCER DISCOV, V9, P1306, DOI 10.1158/2159-8290.CD-18-0083; Zimmermann M, 2013, SCIENCE, V339, P700, DOI 10.1126/science.1231573	73	9	9	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 18	2020	39	25					4814	4827		10.1038/s41388-020-1334-0	http://dx.doi.org/10.1038/s41388-020-1334-0			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LZ3HT	32472076	Green Published, hybrid			2022-12-28	WOS:000541119400003
J	Yi, HY; Li, GP; Long, YK; Liang, WZ; Cui, HN; Zhang, B; Tan, Y; Li, YF; Shen, LC; Deng, DQ; Tang, YS; Mao, CY; Tian, SY; Cai, YT; Zhu, QH; Hu, YH; Chen, W; Fang, L				Yi, Hongyang; Li, Guipeng; Long, Yongkang; Liang, Weizheng; Cui, Huanhuan; Zhang, Bin; Tan, Ying; Li, Yunfei; Shen, Luochen; Deng, Daqi; Tang, Yisen; Mao, Chenyu; Tian, Shuye; Cai, Yunting; Zhu, Qionghua; Hu, Yuhui; Chen, Wei; Fang, Liang			Integrative multi-omics analysis of a colon cancer cell line with heterogeneous Wnt activity revealed RUNX2 as an epigenetic regulator of EMT	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CONSENSUS MOLECULAR SUBTYPES; TRANSCRIPTION FACTOR RUNX2; STEM-CELLS; TGF-BETA; OSTEOBLAST DIFFERENTIATION; INTRATUMOR HETEROGENEITY; EXPRESSION; GENERATION; PLASTICITY	Epithelial-mesenchymal transition (EMT) program, which facilitates tumor metastasis, stemness and therapy resistance, is a reversible biological process that is largely orchestrated at the epigenetic level under the regulation of different cell signaling pathways. EMT state is often heterogeneous within individual tumors, though the epigenetic drivers underlying such heterogeneity remain elusive. In colon cancer, hyperactivation of the Wnt/beta-catenin signaling not only drives tumor initiation, but also promotes metastasis in late stage by promoting EMT program. However, it is unknown whether the intratumorally heterogeneous Wnt activity could directly drive EMT heterogeneity, and, if so, what are the underlying epigenetic driver(s). Here, by analyzing a phenotypically and molecularly heterogeneous colon cancer cell line using single-cell RNA sequencing, we identified two distinct cell populations with positively correlated Wnt activity and EMT state. Integrative multi-omics analysis of these two cell populations revealed RUNX2 as a critical transcription factor epigenetically driving the EMT heterogeneity. Both in vitro and in vivo genetic perturbation assays validated the EMT-enhancing effect of RUNX2, which remodeled chromatin landscape and activated a panel of EMT-associated genes through binding to their promoters and/or potential enhancers. Finally, by exploring the clinical data, we showed that RUNX2 expression is positively correlated with metastasis development and poor survival of colon cancer patients, as well as patients afflicted with other types of cancer. Taken together, our work revealed RUNX2 as a new EMT-promoting epigenetic regulator in colon cancer, which may potentially serve as a prognostic marker for tumor metastasis.	[Yi, Hongyang; Liang, Weizheng] Harbin Inst Technol, Harbin, Peoples R China; [Yi, Hongyang; Li, Guipeng; Long, Yongkang; Liang, Weizheng; Cui, Huanhuan; Tan, Ying; Li, Yunfei; Shen, Luochen; Deng, Daqi; Tang, Yisen; Mao, Chenyu; Tian, Shuye; Cai, Yunting; Zhu, Qionghua; Hu, Yuhui; Chen, Wei; Fang, Liang] Southern Univ Sci & Technol, Dept Biol, Shenzhen, Peoples R China; [Li, Guipeng; Cui, Huanhuan; Hu, Yuhui; Chen, Wei; Fang, Liang] Southern Univ Sci & Technol, Acad Adv Interdisciplinary Studies, Shenzhen, Peoples R China; [Zhang, Bin] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore	Harbin Institute of Technology; Southern University of Science & Technology; Southern University of Science & Technology; National University of Singapore	Hu, YH; Chen, W; Fang, L (corresponding author), Southern Univ Sci & Technol, Dept Biol, Shenzhen, Peoples R China.; Hu, YH; Chen, W; Fang, L (corresponding author), Southern Univ Sci & Technol, Acad Adv Interdisciplinary Studies, Shenzhen, Peoples R China.	huyh@sustech.edu.cn; chenw@sustech.edu.cn; fangl@sustech.edu.cn	chen, wei/AFV-4999-2022; Fang, Liang/V-5019-2018	Fang, Liang/0000-0003-4502-1756; Cui, Huanhuan/0000-0002-6190-6135; Long, Yongkang/0000-0003-0953-7325; Li, Guipeng/0000-0002-3244-5499	National Natural Science Foundation of China [31701237]; Shenzhen Science and Technology Program [JCYJ20170817110925887, KQTD20180411143432337, GJHZ20170310161947503]; Center for Computational Science and Engineering of Southern University of Science and Technology; Laboratory Animal Center of Southern University of Science and Technology	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shenzhen Science and Technology Program; Center for Computational Science and Engineering of Southern University of Science and Technology; Laboratory Animal Center of Southern University of Science and Technology	This work was supported by the National Natural Science Foundation of China (Grant No. 31701237) and the Shenzhen Science and Technology Program (Grant No. JCYJ20170817110925887, KQTD20180411143432337, and GJHZ20170310161947503). Bioinformatic analysis was supported by the Center for Computational Science and Engineering of Southern University of Science and Technology. Animal experiments were supported by the Laboratory Animal Center of Southern University of Science and Technology.	Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Nieto MA, 2009, INT J DEV BIOL, V53, P1541, DOI 10.1387/ijdb.072410mn; Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912; Baniwal SK, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-258; Barnes GL, 2004, CANCER RES, V64, P4506, DOI 10.1158/0008-5472.CAN-03-3851; Barnes GL, 2003, CANCER RES, V63, P2631; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bedard PL, 2013, NATURE, V501, P355, DOI 10.1038/nature12627; Bian SH, 2018, SCIENCE, V362, P1060, DOI 10.1126/science.aao3791; Blois SM, 2014, MUCOSAL IMMUNOL, V7, P348, DOI 10.1038/mi.2013.53; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Buenrostro Jason D, 2015, Curr Protoc Mol Biol, V109, DOI 10.1002/0471142727.mb2129s109; Chimge NO, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3073; Melo FDE, 2017, NATURE, V543, P676, DOI 10.1038/nature21713; Derynck R, 2014, CURR OPIN CELL BIOL, V31, P56, DOI 10.1016/j.ceb.2014.09.001; Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580-018-0080-4; Driessens G, 2012, NATURE, V488, P527, DOI 10.1038/nature11344; Fang L, 2016, CANCER RES, V76, P891, DOI 10.1158/0008-5472.CAN-15-1519; Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660; Hinohara K, 2018, CANCER CELL, V34, P939, DOI 10.1016/j.ccell.2018.10.014; Hu Y, 2018, GENE CHROMOSOME CANC, V57, P140, DOI 10.1002/gcc.22512; Inman CK, 2003, J BIOL CHEM, V278, P48684, DOI 10.1074/jbc.M308001200; Jagan I, 2013, ONCOGENE, V32, P1305, DOI 10.1038/onc.2012.140; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Komori T, 2008, FRONT BIOSCI-LANDMRK, V13, P898, DOI 10.2741/2730; Krebs AM, 2017, NAT CELL BIOL, V19, P518, DOI 10.1038/ncb3513; Lee JW, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09810-w; Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200; Li HP, 2017, NAT GENET, V49, P708, DOI 10.1038/ng.3818; Ligorio M, 2019, CELL, V178, P160, DOI 10.1016/j.cell.2019.05.012; Lin CW, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13867; Magnani L, 2011, TRENDS GENET, V27, P465, DOI 10.1016/j.tig.2011.07.002; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; McGranahan N, 2015, CANCER CELL, V27, P15, DOI 10.1016/j.ccell.2014.12.001; Navin N, 2011, NATURE, V472, P90, DOI 10.1038/nature09807; Niu DF, 2012, LAB INVEST, V92, P1181, DOI 10.1038/labinvest.2012.84; Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586-018-0040-3; Pistore C, 2017, ONCOGENE, V36, P5551, DOI 10.1038/onc.2017.159; Pratap J, 2005, MOL CELL BIOL, V25, P8581, DOI 10.1128/MCB.25.19.8581-8591.2005; Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976; Puram SV, 2017, CELL, V171, P1611, DOI 10.1016/j.cell.2017.10.044; Rahman MS, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.5; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Sanchez-Tillo E, 2011, P NATL ACAD SCI USA, V108, P19204, DOI 10.1073/pnas.1108977108; Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035; Selvamurugan N, 2004, J BIOL CHEM, V279, P27764, DOI 10.1074/jbc.M312870200; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Soares Kevin C, 2014, J Vis Exp, P51677, DOI 10.3791/51677; Stark AL, 2010, AM J HUM GENET, V87, P829, DOI 10.1016/j.ajhg.2010.10.018; Sveen A, 2018, CLIN CANCER RES, V24, P794, DOI 10.1158/1078-0432.CCR-17-1234; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; van Staalduinen J, 2018, ONCOGENE, V37, P6195, DOI 10.1038/s41388-018-0378-x; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9; Yang J, 2001, CANCER RES, V61, P5652; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897; Yeung F, 2002, J BIOL CHEM, V277, P2468, DOI 10.1074/jbc.M105947200; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304	67	14	14	0	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	2020	39	28					5152	5164		10.1038/s41388-020-1351-z	http://dx.doi.org/10.1038/s41388-020-1351-z		JUN 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MH4RK	32535615				2022-12-28	WOS:000539953300003
J	Awah, CU; Chen, L; Bansal, M; Mahajan, A; Winter, J; Lad, M; Warnke, L; Gonzalez-Buendia, E; Park, C; Zhang, D; Feldstein, E; Yu, D; Zannikou, M; Balyasnikova, IV; Martuscello, R; Konerman, S; Gyorffy, B; Burdett, KB; Scholtens, DM; Stupp, R; Ahmed, A; Hsu, P; Sonabend, AM				Awah, Chidiebere U.; Chen, Li; Bansal, Mukesh; Mahajan, Aayushi; Winter, Jan; Lad, Meeki; Warnke, Louisa; Gonzalez-Buendia, Edgar; Park, Cheol; Zhang, Daniel; Feldstein, Eric; Yu, Dou; Zannikou, Markella; Balyasnikova, Irina, V; Martuscello, Regina; Konerman, Silvana; Gyorffy, Balazs; Burdett, Kirsten B.; Scholtens, Denise M.; Stupp, Roger; Ahmed, Atique; Hsu, Patrick; Sonabend, Adam M.			Ribosomal protein S11 influences glioma response to TOP2 poisons	ONCOGENE			English	Article							SCALE CRISPR-CAS9 KNOCKOUT; BRAIN-BARRIER DISRUPTION; DNA TOPOISOMERASE-II; METRONOMIC CHEMOTHERAPY; ORAL ETOPOSIDE; PHASE-II; GLIOBLASTOMA; DOXORUBICIN; ACTIVATION; ULTRASOUND	Topoisomerase II poisons are one of the most common class of chemotherapeutics used in cancer. We and others had shown that a subset of glioblastomas, the most malignant of all primary brain tumors in adults, is responsive to TOP2 poisons. To identify genes that confer susceptibility to this drug in gliomas, we performed a genome-scale CRISPR knockout screen with etoposide. Genes involved in protein synthesis and DNA damage were implicated in etoposide susceptibility. To define potential biomarkers for TOP2 poisons, CRISPR hits were overlapped with genes whose expression correlates with susceptibility to this drug across glioma cell lines, revealing ribosomal protein subunit RPS11, 16, and 18 as putative biomarkers for response to TOP2 poisons. Loss of RPS11 led to resistance to etoposide and doxorubicin and impaired the induction of proapoptotic gene APAF1 following treatment. The expression of these ribosomal subunits was also associated with susceptibility to TOP2 poisons across cell lines from gliomas and multiple other cancers.	[Awah, Chidiebere U.; Chen, Li; Warnke, Louisa; Gonzalez-Buendia, Edgar; Park, Cheol; Zhang, Daniel; Feldstein, Eric; Yu, Dou; Zannikou, Markella; Balyasnikova, Irina, V; Scholtens, Denise M.; Stupp, Roger; Ahmed, Atique; Sonabend, Adam M.] Northwestern Univ, Dept Neurol Surg, Feinberg Sch Med, Chicago, IL 60611 USA; [Bansal, Mukesh] Psychogen Inc, Paramus, NJ USA; [Mahajan, Aayushi] Columbia Univ, Dept Neurol Surg, Med Ctr, New York, NY USA; [Winter, Jan] German Ctr Canc Res, Funct Genom & Signaling, Heidelberg, Germany; [Lad, Meeki] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA; [Martuscello, Regina] Columbia Univ, Dept Pathol, Med Ctr, New York, NY USA; [Konerman, Silvana; Hsu, Patrick] Salk Inst Biol Studies, Mol & Cell Biol, La Jolla, CA USA; [Gyorffy, Balazs] Hungarian Acad Sci, MTA TTK Lendulet Canc Biomarker Res Grp, Inst Enzymol, Budapest, Hungary; [Gyorffy, Balazs] Semmelweis Univ, Dept Pediat 2, Budapest, Hungary; [Burdett, Kirsten B.] Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Columbia University; Columbia University; Columbia University; Salk Institute; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Research Centre for Natural Sciences; Semmelweis University; Northwestern University	Sonabend, AM (corresponding author), Northwestern Univ, Dept Neurol Surg, Feinberg Sch Med, Chicago, IL 60611 USA.	adam.sonabend@nm.org	Hsu, Patrick/ABD-5749-2021; Feldstein, Eric/GLS-1215-2022; Mahajan, Aayushi/ABC-1481-2021; Gyorffy, Balazs/AAA-9135-2021	Mahajan, Aayushi/0000-0003-3966-2936; Gyorffy, Balazs/0000-0002-5772-3766; Feldstein, Eric/0000-0002-1952-4555; Zhang, Daniel Yang/0000-0001-9962-9295	SPORE for Translational Approaches to Brain Cancer [5DP5OD021356-05, P50CA221747]; Robert H. Lurie NCI Cancer Center Support Grant [P30CA060553]; NCI CCSG [P30 CA060553]; NVKP [16-1-2016-0037]	SPORE for Translational Approaches to Brain Cancer; Robert H. Lurie NCI Cancer Center Support Grant; NCI CCSG; NVKP	This work was funded by 5DP5OD021356-05 (AMS), P50CA221747 SPORE for Translational Approaches to Brain Cancer (AMS), and Developmental funds from The Robert H. Lurie NCI Cancer Center Support Grant #P30CA060553 (AMS), and generous philanthropic support from Dan and Sharon Moceri. We thank Dr. Ichiro Nakano (University of Alabama), Dr. Charles David James (Northwestern University), and Dr. Shi-Yuan Cheng (Northwestern University) for the kind gift of the GBM xenografts. We thank Dr. Peng Zhang (Northwestern University) for technical support with culture of GBM PDX. We thank Synthego, CA, USA, for the gifts of RPS11 sgRNA guides. Immunofluorescence imaging work was performed at the Center for Advanced Microscopy/Nikon Imaging Center and RHLCCC - Flow Cytometry Core, Northwestern University supported by NCI CCSG P30 CA060553 awarded to the Robert H. Lurie Comprehensive Cancer Center. BG was supported by the NVKP 16-1-2016-0037 grant.	Alli S, 2018, J CONTROL RELEASE, V281, P29, DOI 10.1016/j.jconrel.2018.05.005; Barnoud D, 2018, PEDIATR BLOOD CANCER, V65, DOI 10.1002/pbc.27038; Carpentier A, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf6086; Ceccaldi R, 2016, NAT REV MOL CELL BIO, V17, P337, DOI 10.1038/nrm.2016.48; Ceccarelli M, 2016, CELL, V164, P550, DOI 10.1016/j.cell.2015.12.028; Dennis G, 2003, GENOME BIOL, V4; Doench JG, 2016, NAT BIOTECHNOL, V34, P184, DOI 10.1038/nbt.3437; Forbes S A, 2016, Curr Protoc Hum Genet, V91, DOI 10.1002/cphg.21; Forester CM, 2018, P NATL ACAD SCI USA, V115, P2353, DOI 10.1073/pnas.1707514115; Franceschi E, 2004, BRIT J CANCER, V91, P1038, DOI 10.1038/sj.bjc.6602105; Girling DJ, 1996, LANCET, V348, P563, DOI 10.1016/S0140-6736(96)02005-3; Guschin DY, 2010, METHODS MOL BIOL, V649, P247, DOI 10.1007/978-1-60761-753-2_15; Haapaniemi E, 2018, NAT MED, V24, P927, DOI 10.1038/s41591-018-0049-z; Hsu PD, 2014, CELL, V157, P1262, DOI 10.1016/j.cell.2014.05.010; Idbaih A, 2019, CLIN CANCER RES, V25, P3793, DOI 10.1158/1078-0432.CCR-18-3643; Joung J, 2017, NAT PROTOC, V12, P828, DOI 10.1038/nprot.2017.016; Kesari S, 2007, NEURO-ONCOLOGY, V9, P354, DOI 10.1215/15228517-2007-006; Koschmann C, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aac8228; Krisp C, 2018, BR J CANC; Leonard A, 2013, ANTICANCER RES, V33, P3307; Lin YL, 2018, J PHARMACEUT BIOMED, V149, P482, DOI 10.1016/j.jpba.2017.11.047; Lu CR, 2006, MOL CELL, V23, P121, DOI 10.1016/j.molcel.2006.05.023; Mainprize T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36340-0; Mehta A, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00459; Michlits G, 2017, NAT METHODS, V14, P1191, DOI [10.1038/NMETH.4466, 10.1038/nmeth.4466]; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; Mjelle R, 2015, DNA REPAIR, V30, P53, DOI 10.1016/j.dnarep.2015.03.007; Moreno P, 2018, MOL ONCOL, V12, P1778, DOI 10.1002/1878-0261.12369; Nitiss JL, 2009, NAT REV CANCER, V9, P338, DOI 10.1038/nrc2607; Nitiss JL, 2009, NAT REV CANCER, V9, P327, DOI 10.1038/nrc2608; Pitz MW, 2011, J NEURO-ONCOL, V104, P629, DOI 10.1007/s11060-011-0564-y; Pop C, 2006, MOL CELL, V22, P269, DOI 10.1016/j.molcel.2006.03.009; Pop C, 2005, CELL, V123, P192, DOI 10.1016/j.cell.2005.10.010; Reardon DA, 2009, BRIT J CANCER, V101, P1986, DOI 10.1038/sj.bjc.6605412; Sapio RT, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09002-w; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Sonabend AM, 2019, CLIN CANCER RES, V25, P3750, DOI 10.1158/1078-0432.CCR-19-0932; Sonabend AM, 2014, NEURO-ONCOLOGY, V16, P1210, DOI 10.1093/neuonc/nou026; STEWART DJ, 1984, J NEURO-ONCOL, V2, P133; Stransky N, 2015, NATURE, V528, P84, DOI 10.1038/nature15736; Stupp R, 2017, JAMA-J AM MED ASSOC, V318, P2306, DOI 10.1001/jama.2017.18718; Sturm D, 2012, CANCER CELL, V22, P425, DOI 10.1016/j.ccr.2012.08.024; Subramanian A, 2007, BIOINFORMATICS, V23, P3251, DOI 10.1093/bioinformatics/btm369; Sun T, 2017, P NATL ACAD SCI USA, V114, pE10281, DOI 10.1073/pnas.1713328114; Tsai Cheng-Han, 2018, Oncotarget, V9, P30731, DOI 10.18632/oncotarget.24578; Uuskula-Reimand L, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1043-8; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wang T, 2014, SCIENCE, V343, P80, DOI 10.1126/science.1246981; Wijdeven RH, 2015, CANCER RES, V75, P4176, DOI 10.1158/0008-5472.CAN-15-0380; Winter J, 2017, CRIS PRANALYZER INTE; Zinkel SS, 2005, CELL, V122, P579, DOI 10.1016/j.cell.2005.06.022; ZUCCHETTI M, 1991, ANN ONCOL, V2, P63, DOI 10.1093/oxfordjournals.annonc.a057826	52	10	10	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 2	2020	39	27					5068	5081		10.1038/s41388-020-1342-0	http://dx.doi.org/10.1038/s41388-020-1342-0		JUN 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ME5NL	32528131	Green Submitted, Green Accepted			2022-12-28	WOS:000539817600002
J	Yu, SY; Yu, XT; Sun, LL; Zheng, YW; Chen, LL; Xu, H; Jin, J; Lan, Q; Chen, CC; Li, M				Yu, Shuye; Yu, Xiaoting; Sun, Lili; Zheng, Yanwen; Chen, Lili; Xu, Hui; Jin, Jing; Lan, Qing; Chen, Clark C.; Li, Ming			GBP2 enhances glioblastoma invasion through Stat3/fibronectin pathway	ONCOGENE			English	Article							BINDING PROTEIN-1; CELL-ADHESION; GENOMIC ANALYSIS; DRUG-RESISTANCE; BREAST-CANCER; FIBRONECTIN; PROLIFERATION; PROMOTES; GROWTH; LANDSCAPE	Guanylate-binding protein 2 (GBP2) is an interferon-inducible large GTPase which is crucial to the protective immunity against microorganisms. However, its biological function in cancer remains largely unknown. Glioblastoma multiforme (GBM) is the most common and deadly brain tumor in adults. Here we show that GBP2 expression is highly elevated in GBM tumor and cell lines, particularly in those of the mesenchymal subtype. High GBP2 expression is associated with poor prognosis. GBP2 overexpression significantly promotes GBM cell migration and invasion in vitro, and GBP2 silencing by RNA interference exhibits opposite effects. We further show that fibronectin (FN1) is dramatically induced by GBP2 expression at both mRNA and protein levels, and FN1 is essential for GBP2-promoted GBM invasiveness. Inhibition of Stat3 pathway prevents GBP2-promoted FN1 induction and cell invasion. Consistently, GBP2 dramatically promotes GBM tumor growth and invasion in mice and significantly reduces the survival time of the mice with tumor. Taken together, these findings establish the role of GBP2/Stat3/FN1 signaling cascade in GBM invasion and suggest GBP2 may serve as a potential therapeutic target for inhibiting GBM invasion.	[Yu, Shuye; Sun, Lili; Zheng, Yanwen; Chen, Lili; Li, Ming] Soochow Univ, Affiliated Hosp 2, Cent Lab, Suzhou, Jiangsu, Peoples R China; [Xu, Hui; Jin, Jing; Lan, Qing; Li, Ming] Soochow Univ, Affiliated Hosp 2, Dept Neurosurg, Suzhou, Jiangsu, Peoples R China; [Yu, Xiaoting] Soochow Univ, Affiliated Hosp 2, Dept Oncol, Suzhou, Jiangsu, Peoples R China; [Chen, Clark C.; Li, Ming] Univ Minnesota, Sch Med, Dept Neurosurg, Minneapolis, MN 55455 USA; [Yu, Shuye] Songlingzhen Hlth Ctr, Suzhou, Jiangsu, Peoples R China	Soochow University - China; Soochow University - China; Soochow University - China; University of Minnesota System; University of Minnesota Twin Cities	Li, M (corresponding author), Soochow Univ, Affiliated Hosp 2, Cent Lab, Suzhou, Jiangsu, Peoples R China.; Li, M (corresponding author), Soochow Univ, Affiliated Hosp 2, Dept Neurosurg, Suzhou, Jiangsu, Peoples R China.; Li, M (corresponding author), Univ Minnesota, Sch Med, Dept Neurosurg, Minneapolis, MN 55455 USA.	li001705@umn.edu	Sun, lili/GQH-2057-2022	Li, Ming/0000-0002-2540-1738	National Natural Sciences Foundation of China [81572480]	National Natural Sciences Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported with a grant from the National Natural Sciences Foundation of China (81572480). We thank Drs. Frank Furnari and Benjamin Purow for the gift of cell lines.	Behnan J, 2019, BRAIN, V142, P847, DOI 10.1093/brain/awz044; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Britzen-Laurent N, 2013, CARCINOGENESIS, V34, P153, DOI 10.1093/carcin/bgs310; Caffo M, 2004, ACTA NEUROCHIR, V146, P1113, DOI 10.1007/s00701-004-0344-y; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Fei M, 2013, INT J HEMATOL, V98, P446, DOI 10.1007/s12185-013-1435-4; Fukumoto M, 2014, CANCER SCI, V105, P1351, DOI 10.1111/cas.12489; Godoy P, 2014, BREAST CANCER-TOKYO, V21, P491, DOI 10.1007/s12282-012-0404-8; Gong J, 2017, MOL MED REP, V16, P143, DOI 10.3892/mmr.2017.6610; Guenzi E, 2001, EMBO J, V20, P5568, DOI 10.1093/emboj/20.20.5568; Guimaraes DP, 2009, INT J CANCER, V124, P272, DOI 10.1002/ijc.23944; Han SW, 2006, CANCER RES, V66, P315, DOI 10.1158/0008-5472.CAN-05-2367; Hazlehurst LA, 2006, CANCER RES, V66, P2338, DOI 10.1158/0008-5472.CAN-05-3256; Iwamaru A, 2007, ONCOGENE, V26, P2435, DOI 10.1038/sj.onc.1210031; Lan Q, 2016, ONCOTARGET, V7, P9680, DOI 10.18632/oncotarget.7109; Lau J, 2015, CANCER RES, V75, P4302, DOI 10.1158/0008-5472.CAN-14-3331; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Li L, 2015, DISCOV MED, V20, P369; Li M, 2011, J EXP MED, V208, P2657, DOI 10.1084/jem.20111102; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Nakagawa Y, 2014, INT J ONCOL, V44, P1376, DOI 10.3892/ijo.2014.2265; Natesh K, 2015, NEOPLASIA, V17, P225, DOI 10.1016/j.neo.2015.01.001; Olszewski MA, 2006, J INTERF CYTOK RES, V26, P328, DOI 10.1089/jir.2006.26.328; Pankov R, 2002, J CELL SCI, V115, P3861, DOI 10.1242/jcs.00059; Quintero M, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3726-2; SAWAYA R, 1985, NEUROSURGERY, V16, P161, DOI 10.1227/00006123-198502000-00006; Sengupta S, 2010, NEOPLASIA, V12, P837, DOI 10.1593/neo.10662; Tipton AR, 2016, BIOCHEM BIOPH RES CO, V478, P1617, DOI 10.1016/j.bbrc.2016.08.169; Tretina K, 2019, J EXP MED, V216, P482, DOI 10.1084/jem.20182031; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vestal DJ, 2011, J INTERF CYTOK RES, V31, P89, DOI 10.1089/jir.2010.0102; Weinlander K, 2008, FASEB J, V22, P4168, DOI 10.1096/fj.08-107524; Xu H, 2018, BIOCHEM BIOPH RES CO, V495, P446, DOI 10.1016/j.bbrc.2017.11.050; Yu Q, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00130; Zhang J, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.559	35	30	30	3	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 2	2020	39	27					5042	5055		10.1038/s41388-020-1348-7	http://dx.doi.org/10.1038/s41388-020-1348-7		JUN 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ME5NL	32518375				2022-12-28	WOS:000539201700002
J	Goto, Y; Ando, T; Izumi, H; Feng, XD; Arang, N; Gilardi, M; Wang, ZY; Ando, K; Gutkind, JS				Goto, Yusuke; Ando, Toshinori; Izumi, Hiroki; Feng, Xiaodong; Arang, Nadia; Gilardi, Mara; Wang, Zhiyong; Ando, Kazuyo; Gutkind, J. Silvio			Muscarinic receptors promote castration-resistant growth of prostate cancer through a FAK-YAP signaling axis	ONCOGENE			English	Article							PROTEIN-COUPLED RECEPTORS; ANDROGEN RECEPTOR; VERTEPORFIN; PROGRESSION; ACTIVATION; EXPRESSION; THERAPY	Prostate cancer (PCa) innervation contributes to the progression of PCa. However, the precise impact of innervation on PCa cells is still poorly understood. By focusing on muscarinic receptors, which are activated by the nerve-derived neurotransmitter acetylcholine, we show that muscarinic receptors 1 and 3 (m1 and m3) are highly expressed in PCa clinical specimens compared with all other cancer types, and that amplification or gain of their corresponding encoding genes (CHRM1 and CHRM3, respectively) represent a worse prognostic factor for PCa progression free survival. Moreover, m1 and m3 gene gain or amplification is frequent in castration-resistant PCa (CRPC) compared with hormone-sensitive PCa (HSPC) specimens. This was reflected in HSPC-derived cells, which show aberrantly high expression of m1 and m3 under androgen deprivation mimicking castration and androgen receptor inhibition. We also show that pharmacological activation of m1 and m3 signaling is sufficient to induce the castration-resistant growth of PCa cells. Mechanistically, we found that m1 and m3 stimulation induces YAP activation through FAK, whose encoding gene, PTK2 is frequently amplified in CRPC cases. Pharmacological inhibition of FAK and knockdown of YAP abolished m1 and m3-induced castration-resistant growth of PCa cells. Our findings provide novel therapeutic opportunities for muscarinic-signal-driven CRPC progression by targeting the FAK-YAP signaling axis.	[Goto, Yusuke; Ando, Toshinori; Izumi, Hiroki; Feng, Xiaodong; Arang, Nadia; Gilardi, Mara; Wang, Zhiyong; Ando, Kazuyo; Gutkind, J. Silvio] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92093 USA; [Ando, Toshinori] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Hiroshima, Japan; [Feng, Xiaodong] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, State Key Lab Oral Dis, Chengdu 610041, Peoples R China; [Ando, Kazuyo] Hiroshima Univ, Inst Biomed & Hlth Sci, Appl Life Sci, Dept Orthodont, Hiroshima, Japan	University of California System; University of California San Diego; Hiroshima University; Sichuan University; Hiroshima University	Gutkind, JS (corresponding author), Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92093 USA.	sgutkind@health.ucsd.edu	Gutkind, J. Silvio/J-1201-2016; Ando, Toshinori/AAG-4033-2021; Ando, Toshinori/AAA-6401-2021; Gilardi, Mara/AAP-4387-2020	Gutkind, J. Silvio/0000-0002-5150-4482; Ando, Toshinori/0000-0002-3141-8173; Ando, Toshinori/0000-0002-3141-8173; Arang, Nadia/0000-0002-8167-2188	JSPS Overseas Research Fellowships; Uehara Memorial Foundation Research Fellowship; 111 Project of MOE China [B14038]; National Natural Science Foundation China [81402230, 81672677]; FIRC-AIRC fellowship for abroad (Italian Foundation for cancer research);  [S10OD021831]	JSPS Overseas Research Fellowships; Uehara Memorial Foundation Research Fellowship(Uehara Memorial Foundation); 111 Project of MOE China; National Natural Science Foundation China(National Natural Science Foundation of China (NSFC)); FIRC-AIRC fellowship for abroad (Italian Foundation for cancer research); 	YG is supported by the JSPS Overseas Research Fellowships and the Uehara Memorial Foundation Research Fellowship. XF is supported by 111 Project of MOE (B14038) China, the National Natural Science Foundation (81402230, 81672677) China. MG is supported by FIRC-AIRC fellowship for abroad (Italian Foundation for cancer research). We thank La Jolla Institute Microscopy Core Facility for professional advice and guidance, in particular Zbigniew Mikulski. This work was supported by S10OD021831. YG initiated the study; YG and JSG designed the study and experiments; YG performed the genomic analyses; YG, TA, HI, NA, KA performed in vitro experiments, YG and MG performed immunofluorescence experiments, YG, NA and JSG prepared the manuscript, XF, ZW, NA and JSG provided advice and supervised the project. All authors discussed the results and reviewed the manuscript.	Armbruster BN, 2007, P NATL ACAD SCI USA, V104, P5163, DOI 10.1073/pnas.0700293104; Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059; Arora VK, 2013, CELL, V155, P1309, DOI 10.1016/j.cell.2013.11.012; Baig AM, 2017, ANTI-CANCER DRUG, V28, P75, DOI 10.1097/CAD.0000000000000432; Bankhead P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17204-5; Bluemn EG, 2017, CANCER CELL, V32, P474, DOI 10.1016/j.ccell.2017.09.003; Cao X, 2006, ONCOGENE, V25, P3719, DOI 10.1038/sj.onc.1209408; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chlenski A, 2001, PROSTATE, V47, P66; Crawford ED, 2015, J UROLOGY, V194, P1537, DOI 10.1016/j.juro.2015.06.106; Daaka Y., 2004, SCI STKE, V2004, pre2, DOI [10.1126/stke.2162004re2, DOI 10.1126/STKE.2162004RE2]; Drake JM, 2013, P NATL ACAD SCI USA, V110, pE4762, DOI 10.1073/pnas.1319948110; Feng XD, 2019, CANCER CELL, V35, P457, DOI 10.1016/j.ccell.2019.01.009; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gibault F, 2016, CURR MED CHEM, V23, P1171, DOI 10.2174/0929867323666160316125048; Grytli HH, 2014, EUR UROL, V65, P635, DOI 10.1016/j.eururo.2013.01.007; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; Inoue A, 2019, CELL, V177, P1933, DOI 10.1016/j.cell.2019.04.044; Kaye JA, 2017, PHARMACOTHERAPY, V37, P673, DOI 10.1002/phar.1932; Konstantinou EK, 2017, SCI REP-UK, V7, DOI 10.1038/srep46581; Kuser-Abali G, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9126; Lee WY, 2014, UROL ONCOL-SEMIN ORI, V32, DOI 10.1016/j.urolonc.2013.07.019; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Luthin GR, 1997, LIFE SCI, V60, P963, DOI 10.1016/S0024-3205(97)00035-0; Magnon C, 2013, SCIENCE, V341, P143, DOI 10.1126/science.1236361; Mauffrey P, 2019, NATURE, V569, P672, DOI 10.1038/s41586-019-1219-y; Mendiratta P, 2009, J CLIN ONCOL, V27, P2022, DOI 10.1200/JCO.2008.17.2882; Navone NM, 1997, CLIN CANCER RES, V3, P2493; O'Hayre M, 2013, NAT REV CANCER, V13, P412, DOI 10.1038/nrc3521; Patel N, 2011, PM&R, V3, P633, DOI 10.1016/j.pmrj.2011.04.024; Rayford W, 1997, PROSTATE, V30, P160, DOI 10.1002/(SICI)1097-0045(19970215)30:3<160::AID-PROS3>3.0.CO;2-Q; Roberts WG, 2008, CANCER RES, V68, P1935, DOI 10.1158/0008-5472.CAN-07-5155; Schultze A, 2010, EXPERT OPIN INV DRUG, V19, P777, DOI 10.1517/13543784.2010.489548; Schwartz S, 2015, CANCER CELL, V27, P109, DOI 10.1016/j.ccell.2014.11.008; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Slack-Davis JK, 2009, MOL CANCER THER, V8, P2470, DOI 10.1158/1535-7163.MCT-09-0262; Sulzmaier FJ, 2014, NAT REV CANCER, V14, P598, DOI 10.1038/nrc3792; Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175; Wang NT, 2015, CLIN CANCER RES, V21, P4676, DOI 10.1158/1078-0432.CCR-14-3163; Wu V, 2019, J BIOL CHEM, V294, P11062, DOI 10.1074/jbc.REV119.005601; Zahalka AH, 2017, SCIENCE, V358, P321, DOI 10.1126/science.aah5072; Zhang HB, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aac5418; Zhang L, 2015, MOL CELL BIOL, V35, P1350, DOI 10.1128/MCB.00102-15	44	13	14	2	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	20					4014	4027		10.1038/s41388-020-1272-x	http://dx.doi.org/10.1038/s41388-020-1272-x		MAR 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LN3GC	32205868	Green Accepted			2022-12-28	WOS:000521527500002
J	Lee, TH; Choi, JY; Park, JM; Kang, TH				Lee, Tae-Hee; Choi, Ji Ye; Park, Jeong-Min; Kang, Tae-Hong			Posttranscriptional control of the replication stress response via TTP-mediated Claspin mRNA stabilization	ONCOGENE			English	Article							DNA-DAMAGE CHECKPOINT; FORK STABILITY; CELL-CYCLE; TNF-ALPHA; TRISTETRAPROLIN; ATR; CHK1; EXPRESSION; DEGRADATION; ACTIVATION	ATR and CHK1 play key roles in the protection and recovery of the stalled replication forks. Claspin, an adaptor for CHK1 activation, is essential for DNA damage signaling and efficient replication fork progression. Here, we show that tristetraprolin (TTP), an mRNA-binding protein, can modulate the replication stress response via stabilization of Claspin mRNA. TTP depletion compromised specifically in the phosphorylation of CHK1, but not p53 or H2AX among other ATR substrates, and produced CHK1-defective replication phenotypes including accumulation of stalled replication forks. Importantly, the expression of siRNA-resistant TTP in TTP-deficient cells restored CHK1 phosphorylation and reduced the number of stalled replication forks as close to the control cells. Besides, we found that TTP was required for efficient replication fork progression even in the absence of exogenous DNA damage in a Claspin-dependent manner. Mechanistically, TTP was able to bind to the 3 '-untranslated region of Claspin mRNA to increase the stability of Claspin mRNA which eventually contributed to the subsequent ATR-CHK1 activation upon DNA damage. Taken together, our results revealed an intimate link between TTP-dependent Claspin mRNA stability and ATR-CHK1-dependent replication fork stability to maintain replication fork integrity and chromosomal stability.	[Lee, Tae-Hee; Choi, Ji Ye; Park, Jeong-Min; Kang, Tae-Hong] Dong A Univ, Dept Biol Sci, Busan 49315, South Korea	Dong A University	Kang, TH (corresponding author), Dong A Univ, Dept Biol Sci, Busan 49315, South Korea.	thkang@dau.ac.kr	Kang, Tae-Hong/Y-8294-2019	Kang, Tae-Hong/0000-0002-6013-900X; Lee, Tae-Hee/0000-0002-6263-6499	Basic Science Research Program through the National Research Foundation of Korea - Ministry of Education [NRF-2018R1D1A3B07043817, NRF-2015R1D1A1A01056994]	Basic Science Research Program through the National Research Foundation of Korea - Ministry of Education	We would like to thank Dr Sang-Eun Lee (UT Health San Antonio) for the insightful discussion and comments. We also thank JWP (University of Ulsan) for generous sharing of reagents. This research was supported by Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education (NRF-2018R1D1A3B07043817 and NRF-2015R1D1A1A01056994).	Berglund AE, 2016, ONCOTARGET, V7, P83462, DOI 10.18632/oncotarget.13128; Bertoli C, 2016, CELL REP, V15, P1412, DOI 10.1016/j.celrep.2016.04.036; Bevilacqua A, 2003, J CELL PHYSIOL, V195, P356, DOI 10.1002/jcp.10272; Bianco JN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08886-8; Brennan SE, 2009, CANCER RES, V69, P5168, DOI 10.1158/0008-5472.CAN-08-4238; Brooks SA, 2013, BBA-GENE REGUL MECH, V1829, P666, DOI 10.1016/j.bbagrm.2013.02.003; Bye-A-Jee H, 2018, SKELET MUSCLE, V8, DOI 10.1186/s13395-018-0183-9; Carrick DM, 2007, ARCH BIOCHEM BIOPHYS, V462, P278, DOI 10.1016/j.abb.2007.04.011; Choi JY, 2016, ONCOTARGET, V7, P32980, DOI 10.18632/oncotarget.9087; Choi JY, 2015, ONCOTARGET, V6, P22575, DOI 10.18632/oncotarget.4610; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Ciais D, 2013, CELL MOL LIFE SCI, V70, P2031, DOI 10.1007/s00018-012-1150-y; Faustrup H, 2009, J CELL BIOL, V184, P13, DOI 10.1083/jcb.200807137; Freire R, 2006, CELL CYCLE, V5, P2831, DOI 10.4161/cc.5.24.3559; Gao DM, 2009, MOL BIOL CELL, V20, P3305, DOI 10.1091/mbc.E09-01-0092; Izawa N, 2011, CANCER RES, V71, P5621, DOI 10.1158/0008-5472.CAN-11-0385; Jeong SY, 2003, J BIOL CHEM, V278, P46782, DOI 10.1074/jbc.M304551200; Kang TH, 2014, NUCLEIC ACIDS RES, V42, P4427, DOI 10.1093/nar/gku094; Keene JD, 2006, NAT PROTOC, V1, P302, DOI 10.1038/nprot.2006.47; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Lee JM, 2016, BMB REP, V49, P566, DOI 10.5483/BMBRep.2016.49.10.097; Lee JY, 2013, NUCLEIC ACIDS RES, V41, P5614, DOI 10.1093/nar/gkt222; Lee TH, 2014, ONCOGENE, V33, P19, DOI 10.1038/onc.2012.539; Lin SY, 2004, P NATL ACAD SCI USA, V101, P6484, DOI 10.1073/pnas.0401847101; Lindsey-Boltz LA, 2009, J BIOL CHEM, V284, P33107, DOI 10.1074/jbc.M109.064485; Ma XL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179852; Macheret M, 2015, ANNU REV PATHOL-MECH, V10, P425, DOI 10.1146/annurev-pathol-012414-040424; Martin Y, 2015, ONCOGENE, V34, P1058, DOI 10.1038/onc.2014.38; McGarry E, 2016, CANCER RES, V76, P2384, DOI 10.1158/0008-5472.CAN-15-2890; Oakes V, 2014, CELL CYCLE, V13, P3302, DOI 10.4161/15384101.2014.949111; Osborn AJ, 2002, TRENDS CELL BIOL, V12, P509, DOI 10.1016/S0962-8924(02)02380-2; Park JM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113384; Park JM, 2015, BIOCHEM BIOPH RES CO, V461, P543, DOI 10.1016/j.bbrc.2015.04.071; Peschiaroli A, 2006, MOL CELL, V23, P319, DOI 10.1016/j.molcel.2006.06.013; Petermann E, 2008, MOL BIOL CELL, V19, P2373, DOI 10.1091/mbc.E07-10-1035; Pfeiffer JR, 2012, J IMMUNOL, V188, P1828, DOI 10.4049/jimmunol.1102837; Rounbehler RJ, 2012, CELL, V150, P563, DOI 10.1016/j.cell.2012.06.033; Scorah J, 2009, CELL CYCLE, V8, P1036, DOI 10.4161/cc.8.7.8040; Seiler JA, 2007, MOL CELL BIOL, V27, P5806, DOI 10.1128/MCB.02278-06; Sercin O, 2011, CELL CYCLE, V10, P1599, DOI 10.4161/cc.10.10.15562; Shaltiel IA, 2015, J CELL SCI, V128, P607, DOI 10.1242/jcs.163766; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; Toledo LI, 2013, CELL, V155, P1088, DOI 10.1016/j.cell.2013.10.043; Vesela E, 2017, BIOMOLECULES, V7, DOI 10.3390/biom7010019; Wei ZR, 2016, ONCOTARGET, V7, P17737, DOI 10.18632/oncotarget.7397; Yang CC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12135; Yazinski SA, 2016, ANNU REV GENET, V50, P155, DOI 10.1146/annurev-genet-121415-121658; Yuan J, 2014, NUCLEIC ACIDS RES, V42, P13110, DOI 10.1093/nar/gku1034; Zeman MK, 2014, NAT CELL BIOL, V16, P2, DOI 10.1038/ncb2897; Zhu M, 2014, NUCLEIC ACIDS RES, V42, P13074, DOI 10.1093/nar/gku978	50	7	7	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2020	39	16					3245	3257		10.1038/s41388-020-1220-9	http://dx.doi.org/10.1038/s41388-020-1220-9		FEB 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF9OJ	32086441				2022-12-28	WOS:000514942300001
J	Seifert, AM; Reiche, C; Heiduk, M; Tannert, A; Meinecke, AC; Baier, S; von Renesse, J; Kahlert, C; Distler, M; Welsch, T; Reissfelder, C; Aust, DE; Miller, G; Weitz, J; Seifert, L				Seifert, Adrian M.; Reiche, Charlotte; Heiduk, Max; Tannert, Anna; Meinecke, Ann-Christin; Baier, Stephanie; von Renesse, Janusz; Kahlert, Christoph; Distler, Marius; Welsch, Thilo; Reissfelder, Christoph; Aust, Daniela E.; Miller, George; Weitz, Juergen; Seifert, Lena			Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels	ONCOGENE			English	Article							T-CELLS; CANCER; EXPRESSION; ONCOGENESIS; SURVIVAL; IMMUNITY	Pancreatic ductal adenocarcinoma (PDAC) responds poorly to checkpoint blockade, such as anti-CTLA-4 and anti-PD-1. Galectin-9, a beta-galactoside-binding lectin, promotes immune suppression through T-cell inhibition, and programming of tolerogenic macrophages. Of all cancers tested, PDAC showed the highest expression of LGALS9 (galectin-9) mRNA. We analyzed formalin-fixed and paraffin-embedded specimens from 83 patients with PDAC stained for galectin-9. Using flow cytometry, we determined galectin-9 expression on immune cells from tumor and matched blood samples from 12 patients with resectable PDAC. Furthermore, we analyzed galectin-9 serum levels by enzyme-linked immunosorbent assay using serum samples from 70 patients with PDAC, from 36 individuals with benign pancreatic disease, and from 28 healthy controls. Galectin-9 was highly expressed in human PDAC compared with normal pancreas and present on both tumor and immune cells. Tumor-infiltrating immune cells, especially CD3(+) T cells, showed upregulation of galectin-9 compared with immune cells from matched blood. Blood gamma delta T cells from PDAC patients had higher galectin-9 expression than gamma delta T cells from healthy individuals. Galectin-9 polarized macrophages toward a protumoral M2 phenotype leading to suppressed T-cell cytokine secretion. Furthermore, serum concentration of galectin-9 was able to discriminate PDAC from benign pancreatic disease and healthy individuals, and was prognostic for stage IV patients. Galectin-9 is a new biomarker for the detection of PDAC.	[Seifert, Adrian M.; Reiche, Charlotte; Heiduk, Max; Tannert, Anna; Meinecke, Ann-Christin; Baier, Stephanie; von Renesse, Janusz; Kahlert, Christoph; Distler, Marius; Welsch, Thilo; Weitz, Juergen; Seifert, Lena] Univ Dresden, Fac Med, Univ Hosp Carl Gustav Carus, Dept Visceral Thorac & Vasc Surg, Dresden, Germany; [Seifert, Adrian M.; Heiduk, Max; Kahlert, Christoph; Welsch, Thilo; Weitz, Juergen; Seifert, Lena] German Canc Consortium DKTK, Partner Site Dresden, Heidelberg, Germany; [Seifert, Adrian M.; Heiduk, Max; Kahlert, Christoph; Welsch, Thilo; Weitz, Juergen; Seifert, Lena] German Canc Res Ctr, Heidelberg, Germany; [Heiduk, Max] Natl Ctr Tumor Dis NCT, Partner Site Dresden, Dresden, Germany; [Reissfelder, Christoph] Heidelberg Univ, Univ Med Mannheim, Med Fac Mannheim, Dept Surg, Mannheim, Germany; [Aust, Daniela E.] Univ Dresden, Univ Hosp Carl Gustav Carus, Fac Med, Dept Pathol, Dresden, Germany; [Aust, Daniela E.] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, NCT Biobank Dresden, Dresden, Germany; [Miller, George] NYU, Sch Med, Dept Surg, SA Localio Lab, New York, NY USA; [Miller, George] NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA	Technische Universitat Dresden; Carl Gustav Carus University Hospital; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Technische Universitat Dresden; Carl Gustav Carus University Hospital; New York University; New York University	Seifert, L (corresponding author), Univ Dresden, Fac Med, Univ Hosp Carl Gustav Carus, Dept Visceral Thorac & Vasc Surg, Dresden, Germany.; Seifert, L (corresponding author), German Canc Consortium DKTK, Partner Site Dresden, Heidelberg, Germany.; Seifert, L (corresponding author), German Canc Res Ctr, Heidelberg, Germany.	lena.seifert@ukdd.de	Seifert, Adrian M./AAL-3453-2021	Seifert, Adrian M./0000-0002-5329-3164; Reissfelder, Christoph/0000-0003-4591-1046; Heiduk, Max/0000-0002-7907-4162; Seifert, Lena/0000-0003-4763-8127	Ernst-Jung Stiftung; Monika Kutzner Stiftung; German Research Foundation (DFG); German Cancer Consortium (DKTK); Medical Faculty Carl Gustav Carus TU Dresden; CMCB Light Microscopy Facility of TU Dresden; Projekt DEAL	Ernst-Jung Stiftung; Monika Kutzner Stiftung; German Research Foundation (DFG)(German Research Foundation (DFG)); German Cancer Consortium (DKTK); Medical Faculty Carl Gustav Carus TU Dresden; CMCB Light Microscopy Facility of TU Dresden; Projekt DEAL	This work was supported by the Ernst-Jung Stiftung (LS), the Monika Kutzner Stiftung (LS), the German Research Foundation (DFG; LS), the German Cancer Consortium (DKTK; AMS) and the Medical Faculty Carl Gustav Carus TU Dresden (AMS, LS). We thank the CMCB Light Microscopy Facility of TU Dresden for their support. Open access funding provided by Projekt DEAL.	Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Balli D, 2017, CLIN CANCER RES, V23, P3129, DOI 10.1158/1078-0432.CCR-16-2128; Belo AI, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065957; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chan A, 2014, CLIN CANCER RES, V20, P5787, DOI 10.1158/1078-0432.CCR-14-0289; Clark CE, 2007, CANCER RES, V67, P9518, DOI 10.1158/0008-5472.CAN-07-0175; Daley D, 2017, NAT MED, V23, P556, DOI 10.1038/nm.4314; Daley D, 2016, CELL, V166, P1485, DOI 10.1016/j.cell.2016.07.046; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Irie A, 2005, CLIN CANCER RES, V11, P2962, DOI 10.1158/1078-0432.CCR-04-0861; Jiang J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081799; Kim J, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah5583; Li H, 2012, HEPATOLOGY, V56, P1342, DOI 10.1002/hep.25777; Liu FT, 2005, NAT REV CANCER, V5, P29, DOI 10.1038/nrc1527; Madireddi S, 2014, J EXP MED, V211, P1425, DOI 10.1084/jem.20132687; Maftouh M, 2014, ONCOTARGET, V5, P5335, DOI 10.18632/oncotarget.2104; Martinez-Bosch Neus, 2018, Oncotarget, V9, P32984, DOI 10.18632/oncotarget.26034; Nagahara K, 2008, J IMMUNOL, V181, P7660, DOI 10.4049/jimmunol.181.11.7660; Ohue Y, 2016, CANCER IMMUNOL RES, V4, P1049, DOI 10.1158/2326-6066.CIR-15-0266; Okura R, 2018, ONCOL LETT, V15, P407, DOI 10.3892/ol.2017.7316; Rabinovich GA, 2009, NAT REV IMMUNOL, V9, P338, DOI 10.1038/nri2536; Radon TP, 2015, CLIN CANCER RES, V21, P3512, DOI 10.1158/1078-0432.CCR-14-2467; Roda O, 2009, GASTROENTEROLOGY, V136, P1379, DOI 10.1053/j.gastro.2008.12.039; Royal RE, 2010, J IMMUNOTHER, V33, P828, DOI 10.1097/CJI.0b013e3181eec14c; Seifert AM, 2017, CLIN CANCER RES, V23, P454, DOI 10.1158/1078-0432.CCR-16-1163; Seifert L, 2016, NATURE, V532, P245, DOI 10.1038/nature17403; Shimamura T, 2002, CLIN CANCER RES, V8, P2570; Sideras K, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1273309; Song SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042699; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Wang Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152599; Wu C, 2014, IMMUNITY, V41, P270, DOI 10.1016/j.immuni.2014.06.011; Yadav D, 2013, GASTROENTEROLOGY, V144, P1252, DOI 10.1053/j.gastro.2013.01.068; Yang KS, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3226; Zhu C, 2005, NAT IMMUNOL, V6, P1245, DOI 10.1038/ni1271	36	32	33	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	15					3102	3113		10.1038/s41388-020-1186-7	http://dx.doi.org/10.1038/s41388-020-1186-7		FEB 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LB8NS	32055023	Green Published, hybrid			2022-12-28	WOS:000513314100001
J	Ali, S; Zhang, YL; Zhou, M; Li, HZ; Jin, WW; Zheng, L; Yu, XC; Stark, JM; Weitzel, JN; Shen, BH				Ali, Shafat; Zhang, Yilan; Zhou, Mian; Li, Hongzhi; Jin, Weiwei; Zheng, Li; Yu, Xiaochun; Stark, Jeremy M.; Weitzel, Jeffrey N.; Shen, Binghui			Functional deficiency of DNA repair gene EXO5 results in androgen-induced genomic instability and prostate tumorigenesis	ONCOGENE			English	Article							DOUBLE-STRAND BREAKS; HOMOLOGOUS RECOMBINATION; DELETERIOUS MUTATIONS; SUSCEPTIBILITY LOCI; WIDE ASSOCIATION; END RESECTION; CANCER; MRE11; RISK; IDENTIFICATION	Germline mutations of DNA double-strand break (DSB) response and repair genes that drive tumorigenesis could be a major cause of prostate cancer (PCa) heritability. In this study, we demonstrated the role of novel exonuclease 5 (EXO5) gene in androgen-induced double strand breaks repair via homology-directed repair pathway and prostate tumorigenesis. Using whole-exome sequencing of samples from 20 PCa families, with three or more siblings diagnosed with metastatic PCa, we identified mutations in 31 genes involved in DSB response and repair. Among them, the L151P mutation in the exonuclease 5 (EXO5) gene was present in all affected siblings in three PCa families. We found two other EXO5 SNPs significantly associated with risk of PCa in cases-controls study from databases of genotype and phenotype (dbGaP), which are in linkage disequilibrium (D ' = 1) with Exo5 L151P found in PCa family. The L151 residue is conserved across diverse species and its mutation is deleterious for protein functions, as demonstrated by our bioinformatics analyses. The L151P mutation impairs the DNA repair function of EXO5 due to loss of nuclease activity, as well as failure of nuclear localization. CRISPR elimination of EXO5 in a PCa cell line impaired homology-directed recombination repair (HDR) and caused androgen-induced genomic instability, as indicated by frequent occurrence of the oncogenic fusion transcript TMPRSS2-ERG. Genetic and functional validation of the EXO5 mutations indicated that EXO5 is a risk gene for prostate tumorigenesis, likely due to its functions in HDR.	[Ali, Shafat; Zhang, Yilan; Zhou, Mian; Jin, Weiwei; Zheng, Li; Yu, Xiaochun; Stark, Jeremy M.; Shen, Binghui] City Hope Natl Med Ctr, Dept Canc Genet & Epigenet, Beckman Res Inst, Duarte, CA 91010 USA; [Li, Hongzhi] City Hope Natl Med Ctr, Dept Mol Med, Beckman Res Inst, Duarte, CA USA; [Weitzel, Jeffrey N.] City Hope Natl Med Ctr, Dept Populat Sci, Beckman Res Inst, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope	Shen, BH (corresponding author), City Hope Natl Med Ctr, Dept Canc Genet & Epigenet, Beckman Res Inst, Duarte, CA 91010 USA.	bshen@coh.org		Shen, Binghui/0000-0002-4408-407X	National Cancer Institute of the National Institutes of Health [P30CA033572]; City of Hope institutional Excellence Award	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); City of Hope institutional Excellence Award	We acknowledge Dr. Theodore Krontiris and Dr. Ching Ouyang in City of Hope for providing the genomic DNA samples of prostate cancer families. We thank Charles Warden and Dr. Xiwei Wu for their help in genomic data deposition. Drs. Keely Walker and Kerin K. Higa for proofreading the manuscript. Research reported in this publication included work performed in the Computational Therapeutics and Integrative Genomics core facilities, which are supported by the National Cancer Institute of the National Institutes of Health under award number P30CA033572. The work was partially supported by City of Hope institutional Excellence Award to B.H.S.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Al Olama AA, 2014, NAT GENET, V46, P1103, DOI 10.1038/ng.3094; Al Olama AA, 2013, HUM MOL GENET, V22, P408, DOI 10.1093/hmg/dds425; Alvarez-Quilon A, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4347; Andres-Leon E, 2016, DATABASE-OXFORD, DOI 10.1093/database/baw123; Bennardo N, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000110; Bienert S, 2017, NUCLEIC ACIDS RES, V45, pD313, DOI 10.1093/nar/gkw1132; Broderick R, 2016, NAT CELL BIOL, V18, P271, DOI 10.1038/ncb3303; CARTER BS, 1992, P NATL ACAD SCI USA, V89, P3367, DOI 10.1073/pnas.89.8.3367; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; Cejka P, 2015, J BIOL CHEM, V290, P22931, DOI 10.1074/jbc.R115.675942; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen CC, 2017, DNA REPAIR, V57, P98, DOI 10.1016/j.dnarep.2017.07.003; Chun S, 2009, GENOME RES, V19, P1553, DOI 10.1101/gr.092619.109; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Eeles RA, 2008, NAT GENET, V40, P316, DOI 10.1038/ng.90; Forment JV, 2012, CYTOM PART A, V81A, P922, DOI 10.1002/cyto.a.22155; Garcia V, 2011, NATURE, V479, P241, DOI 10.1038/nature10515; Gudmundsson J, 2012, NAT GENET, V44, P1326, DOI 10.1038/ng.2437; Gunn Amanda, 2012, Methods Mol Biol, V920, P379, DOI 10.1007/978-1-61779-998-3_27; Haffner MC, 2010, NAT GENET, V42, P668, DOI 10.1038/ng.613; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Howard SM, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1004943; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Kircher M, 2014, NAT GENET, V46, P310, DOI 10.1038/ng.2892; la Cour T, 2004, PROTEIN ENG DES SEL, V17, P527, DOI 10.1093/protein/gzh062; Leongamornlert D, 2014, BRIT J CANCER, V110, P1663, DOI 10.1038/bjc.2014.30; Liao SR, 2016, NUCLEIC ACIDS RES, V44, P5689, DOI 10.1093/nar/gkw274; Lin CR, 2009, CELL, V139, P1069, DOI 10.1016/j.cell.2009.11.030; Merajver SD, 1995, CLIN CANCER RES, V1, P539; Milanowska K, 2011, NUCLEIC ACIDS RES, V39, pD788, DOI 10.1093/nar/gkq1087; Mimitou EP, 2008, NATURE, V455, P770, DOI 10.1038/nature07312; Mucci LA, 2016, JAMA-J AM MED ASSOC, V315, P68, DOI 10.1001/jama.2015.17703; Ng PC, 2003, NUCLEIC ACIDS RES, V31, P3812, DOI 10.1093/nar/gkg509; Hoa NN, 2016, MOL CELL, V64, P580, DOI 10.1016/j.molcel.2016.10.011; Nussenzweig A, 2010, CELL, V141, P27, DOI 10.1016/j.cell.2010.03.016; Pritchard CC, 2016, NEW ENGL J MED, V375, P443, DOI 10.1056/NEJMoa1603144; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Reva B, 2011, NUCL ACIDS RES, V39, pe118; Santarosa M, 2004, BBA-REV CANCER, V1654, P105, DOI 10.1016/j.bbcan.2004.01.001; Schumacher FR, 2011, HUM MOL GENET, V20, P3867, DOI 10.1093/hmg/ddr295; Schwarz JM, 2010, NAT METHODS, V7, P575, DOI 10.1038/nmeth0810-575; Sishc BJ, 2017, CANCERS, V9, DOI 10.3390/cancers9070081; Sparks JL, 2012, J BIOL CHEM, V287, P42773, DOI 10.1074/jbc.M112.422444; St John Jason, 2012, J Cancer Sci Ther, V4, P94; Stanford JL, 2001, EPIDEMIOL REV, V23, P19, DOI 10.1093/oxfordjournals.epirev.a000789; STEINBERG GD, 1990, PROSTATE, V17, P337, DOI 10.1002/pros.2990170409; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Wang JH, 2006, CANCER RES, V66, P8347, DOI 10.1158/0008-5472.CAN-06-1966; Wilson S, 2016, SCI REP-UK, V6, DOI 10.1038/srep32611; Wood RD, 2005, MUTAT RES-FUND MOL M, V577, P275, DOI 10.1016/j.mrfmmm.2005.03.007; Yeager M, 2009, NAT GENET, V41, P1055, DOI 10.1038/ng.444; Zheng SL, 2006, PROSTATE, V66, P1556, DOI 10.1002/pros.20496; Zhu Z, 2008, CELL, V134, P981, DOI 10.1016/j.cell.2008.08.037	57	7	7	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	6					1246	1259		10.1038/s41388-019-1061-6	http://dx.doi.org/10.1038/s41388-019-1061-6			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE4UH	31616062	Green Accepted			2022-12-28	WOS:000526714600006
J	Asare-Werehene, M; Nakka, K; Reunov, A; Chiu, CT; Lee, WT; Abedini, MR; Wang, PW; Shieh, DB; Dilworth, FJ; Carmona, E; Le, T; Mes-Masson, AM; Burger, D; Tsang, BK				Asare-Werehene, Meshach; Nakka, Kiran; Reunov, Arkadiy; Chiu, Chen-Tzu; Lee, Wei-Ting; Abedini, Mohammad R.; Wang, Pei-Wen; Shieh, Dar-Bin; Dilworth, F. Jeffrey; Carmona, Euridice; Le, Tien; Mes-Masson, Anne-Marie; Burger, Dylan; Tsang, Benjamin K.			The exosome-mediated autocrine and paracrine actions of plasma gelsolin in ovarian cancer chemoresistance	ONCOGENE			English	Article							PROTEIN-KINASE B; CISPLATIN RESISTANCE; AKT; ACTIVATION; CELLS; PROGRESSION; HYPOXIA; P53; EXPRESSION; APOPTOSIS	Ovarian cancer (OVCA) is the most lethal gynecological cancer, due predominantly to late presentation, high recurrence rate and common chemoresistance development. The expression of the actin-associated protein cytosolic gelsolin (GSN) regulates the gynecological cancer cell fate resulting in dysregulation in chemosensitivity. In this study, we report that elevated expression of plasma gelsolin (pGSN), a secreted isoform of GSN and expressed from the same GSN gene, correlates with poorer overall survival and relapse-free survival in patients with OVCA. In addition, it is highly expressed and secreted in chemoresistant OVCA cells than its chemosensitive counterparts. pGSN, secreted and transported via exosomes (Ex-pGSN), upregulates HIF1 alpha-mediated pGSN expression in chemoresistant OVCA cells in an autocrine manner as well as confers cisplatin resistance in otherwise chemosensitive OVCA cells. These findings support our hypothesis that exosomal pGSN promotes OVCA cell survival through both autocrine and paracrine mechanisms that transform chemosensitive cells to resistant counterparts. Specifically, pGSN transported via exosomes is a determinant of chemoresistance in OVCA.	[Asare-Werehene, Meshach; Le, Tien; Tsang, Benjamin K.] Univ Ottawa, Dept Obstet & Gynecol, Ottawa, ON, Canada; [Asare-Werehene, Meshach; Nakka, Kiran; Dilworth, F. Jeffrey; Le, Tien; Burger, Dylan; Tsang, Benjamin K.] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada; [Asare-Werehene, Meshach; Nakka, Kiran; Abedini, Mohammad R.; Dilworth, F. Jeffrey; Le, Tien; Burger, Dylan; Tsang, Benjamin K.] Ottawa Hosp Res Inst, Chron Dis Program, Ottawa, ON K1H 8L6, Canada; [Asare-Werehene, Meshach; Nakka, Kiran; Abedini, Mohammad R.; Dilworth, F. Jeffrey; Le, Tien; Burger, Dylan; Tsang, Benjamin K.] Ottawa Hosp Res Inst, Regenerat Med Program, Ottawa, ON K1H 8L6, Canada; [Nakka, Kiran; Dilworth, F. Jeffrey; Burger, Dylan; Tsang, Benjamin K.] Univ Ottawa, Dept Med, Ottawa, ON, Canada; [Reunov, Arkadiy] St Francis Xavier Univ, Dept Biol, 2320 Notre Dame Ave, Antigonish, NS B2G 2W5, Canada; [Chiu, Chen-Tzu; Lee, Wei-Ting; Wang, Pei-Wen; Shieh, Dar-Bin] Natl Cheng Kung Univ, Inst Basic Med Sci, Inst Oral Med, Natl Cheng Kung Univ Hosp, Tainan 704, Taiwan; [Chiu, Chen-Tzu; Lee, Wei-Ting; Wang, Pei-Wen; Shieh, Dar-Bin] Natl Cheng Kung Univ, Dept Stomatol, Natl Cheng Kung Univ Hosp, Tainan 704, Taiwan; [Abedini, Mohammad R.] Birjand Univ Med Sci, Cellular & Mol Med Res Ctr, Dept Pharmacol, Birjand 97178, Iran; [Shieh, Dar-Bin] Natl Cheng Kung Univ, Adv Optoelect Technol Ctr, Tainan 701, Taiwan; [Shieh, Dar-Bin] Natl Cheng Kung Univ, Ctr Micro Nano Sci & Technol, Tainan 701, Taiwan; [Carmona, Euridice; Mes-Masson, Anne-Marie] Ctr Rech CHUM, Montreal, PQ H2X 0A9, Canada; [Carmona, Euridice; Mes-Masson, Anne-Marie] Inst Canc Montreal, Montreal, PQ H2X 0A9, Canada; [Carmona, Euridice; Mes-Masson, Anne-Marie] Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada	University of Ottawa; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Saint Francis Xavier University - Canada; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University; Universite de Montreal; Universite de Montreal; Universite de Montreal	Tsang, BK (corresponding author), Univ Ottawa, Dept Obstet & Gynecol, Ottawa, ON, Canada.; Tsang, BK (corresponding author), Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada.; Tsang, BK (corresponding author), Ottawa Hosp Res Inst, Chron Dis Program, Ottawa, ON K1H 8L6, Canada.; Tsang, BK (corresponding author), Ottawa Hosp Res Inst, Regenerat Med Program, Ottawa, ON K1H 8L6, Canada.; Tsang, BK (corresponding author), Univ Ottawa, Dept Med, Ottawa, ON, Canada.	btsang@ohri.ca	Burger, Dylan/ABD-2727-2020; Nakka, Kiran/CAJ-3374-2022	Burger, Dylan/0000-0003-3951-2911; Dilworth, F. Jeffrey/0000-0002-6265-8102; Wang, Pei-Wen/0000-0002-1863-3661; Nakka, Kiran/0000-0002-8418-9343	Canadian Institutes of Health Research [MOP-15691]; Taiwan Ministry of Science and Technology [MOST 104-2314-B-006-063-MY3, 106-2627-M-006-001, 107-2321-B-006-019, 107-2314-B-006-029]; Center of Applied Nanomedicine, National Cheng Kung University; Dragon Gate Program [MOST 105-2911-I-006-529]; Taiwan Ministry of Education	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Taiwan Ministry of Science and Technology; Center of Applied Nanomedicine, National Cheng Kung University; Dragon Gate Program; Taiwan Ministry of Education(Ministry of Education, Taiwan)	This work was supported by the Canadian Institutes of Health Research (MOP-15691), the Dragon Gate Program (MOST 105-2911-I-006-529), and research grants (MOST 104-2314-B-006-063-MY3, 106-2627-M-006-001, 107-2321-B-006-019, and 107-2314-B-006-029) from the Taiwan Ministry of Science and Technology, the Center of Applied Nanomedicine, National Cheng Kung University, The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project, the Taiwan Ministry of Education.	Abedini MR, 2010, ONCOGENE, V29, P11, DOI 10.1038/onc.2009.300; Abedini MR, 2014, P NATL ACAD SCI USA, V111, P14442, DOI 10.1073/pnas.1401166111; Abedini MR, 2004, ONCOGENE, V23, P6997, DOI 10.1038/sj.onc.1207925; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Ali AY, 2012, ONCOGENE, V31, P2175, DOI 10.1038/onc.2011.399; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Armstrong DK, 2006, NEW ENGL J MED, V354, P34, DOI 10.1056/NEJMoa052985; Ata R, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010189; Bohgaki M, 2011, J CELL MOL MED, V15, P141, DOI 10.1111/j.1582-4934.2009.00940.x; Bruney L, 2016, ONCOTARGET, V7, P21968, DOI 10.18632/oncotarget.7880; Budnik V, 2016, NAT REV NEUROSCI, V17, P160, DOI 10.1038/nrn.2015.29; Burger D, 2015, AM J PATHOL, V185, P2309, DOI 10.1016/j.ajpath.2015.04.010; Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824; Chen CC, 2017, ONCOTARGET, V8, P77152, DOI 10.18632/oncotarget.20414; Chen WX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095240; Crow J, 2017, ONCOTARGET, V8, P11917, DOI 10.18632/oncotarget.14440; Dai CL, 2013, J BIOL CHEM, V288, P23875, DOI 10.1074/jbc.M112.445148; Daponte A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-335; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Dengler VL, 2014, CRIT REV BIOCHEM MOL, V49, P1, DOI 10.3109/10409238.2013.838205; Elattar A, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD007565.pub2, 10.1002/14651858.CD007565]; Faridi J, 2003, AM J PHYSIOL-ENDOC M, V285, pE964, DOI 10.1152/ajpendo.00239.2003; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fraser M, 2003, CANCER RES, V63, P7081; Fu LJ, 2013, J OVARIAN RES, V6, DOI 10.1186/1757-2215-6-92; Gomez-Roman N, 2016, ONCOTARGET, V7, P22650, DOI 10.18632/oncotarget.7998; Greijer AE, 2005, J PATHOL, V206, P291, DOI 10.1002/path.1778; Gyorffy B, 2012, ENDOCR-RELAT CANCER, V19, P197, DOI 10.1530/ERC-11-0329; Krieg T, 2003, CARDIOVASC RES, V58, P196, DOI 10.1016/S0008-6363(02)00861-1; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; Lee PS, 2006, AM J RESP CRIT CARE, V173, P685, DOI 10.1164/ajrccm.173.6.685; Liu PD, 2014, NATURE, V508, P541, DOI 10.1038/nature13079; Lofberg M, 1998, J NEUROL SCI, V157, P187, DOI 10.1016/S0022-510X(98)00056-2; Meng XD, 2016, ONCOTARGET, V7, P16923, DOI 10.18632/oncotarget.7850; Nakka KK, 2015, P NATL ACAD SCI USA, V112, pE3374, DOI 10.1073/pnas.1418603112; Nitulescu GM, 2016, INT J ONCOL, V48, P869, DOI 10.3892/ijo.2015.3306; Pal SK, 2010, EXPERT OPIN INV DRUG, V19, P1355, DOI 10.1517/13543784.2010.520701; Pink RC, 2015, GYNECOL ONCOL, V137, P143, DOI 10.1016/j.ygyno.2014.12.042; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Reunov A, 2018, GENE, V658, P1, DOI 10.1016/j.gene.2018.03.012; Roma-Rodrigues C, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/179486; Safaei R, 2005, MOL CANCER THER, V4, P1595, DOI 10.1158/1535-7163.MCT-05-0102; SMITH DB, 1987, J LAB CLIN MED, V110, P189; Spinardi L., 2007, V45, P55; Stefanou DT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117654; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179; Tsai MH, 2012, J MOL MED, V90, P187, DOI 10.1007/s00109-011-0817-4; Vinas JL, 2016, KIDNEY INT, V90, P1238, DOI 10.1016/j.kint.2016.07.015; Wang PW, 2014, INT J CANCER, V135, P2760, DOI 10.1002/ijc.28928; Wefers C, 2015, GYNECOL ONCOL, V137, P335, DOI 10.1016/j.ygyno.2015.02.019; Wei YF, 2014, BREAST CANCER RES TR, V147, P423, DOI 10.1007/s10549-014-3037-0; Yang XK, 2006, CANCER RES, V66, P3126, DOI 10.1158/0008-5472.CAN-05-0425; Yang ZY, 2015, SCI REP-UK, V5, DOI 10.1038/srep07758; Yeung CLA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11150; YIN HL, 1984, J BIOL CHEM, V259, P5271; Yin J, 2012, J CELL MOL MED, V16, P337, DOI 10.1111/j.1582-4934.2011.01316.x; Ying X, 2016, ONCOTARGET, V7, P43076, DOI 10.18632/oncotarget.9246; Yu TC, 2017, YONSEI MED J, V58, P489, DOI 10.3349/ymj.2017.58.3.489; Zeng B, 2018, ONCOTARGETS THER, V11, P1333, DOI 10.2147/OTT.S154215	59	43	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	7					1600	1616		10.1038/s41388-019-1087-9	http://dx.doi.org/10.1038/s41388-019-1087-9			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KL2WP	31700155	Green Published, hybrid			2022-12-28	WOS:000513289600015
J	Bommi, PV; Chand, V; Mukhopadhyay, NK; Raychaudhuri, P; Bagchi, S				Bommi, Prashant, V; Chand, Vaibhav; Mukhopadhyay, Nishit K.; Raychaudhuri, Pradip; Bagchi, Srilata			NER-factor DDB2 regulates HIF1 alpha and hypoxia-response genes in HNSCC	ONCOGENE			English	Article							TO-MESENCHYMAL TRANSITION; NF-KAPPA-B; LYSYL OXIDASE; NECK-CANCER; HEAD; PROTEIN; EXPRESSION; CARCINOMA; THROMBOSPONDIN-1; METASTASIS	Cancers in the oral/head & neck region (HNSCC) are aggressive due to high incidence of recurrence and distant metastasis. One prominent feature of aggressive HNSCC is the presence of severely hypoxic regions in tumors and activation of hypoxia-inducible factors (HIFs). In this study, we report that the XPE gene product DDB2 (damaged DNA binding protein 2), a nucleotide excision repair protein, is upregulated by hypoxia. Moreover, DDB2 inhibits HIF1 alpha in HNSCC cells. It inhibits HIF1 alpha in both normoxia and hypoxia by reducing mRNA expression. Knockdown of DDB2 enhances the expression of angiogenic markers and promotes tumor growth in a xenograft model. We show that DDB2 binds to an upstream promoter element in the HIF1 Alpha gene and promotes histone H3K9 trimethylation around the binding site by recruiting Suv39h1. Also, we provide evidence that DDB2 has a significant suppressive effect on expression of the endogenous markers of hypoxia that are also prognostic indicators in HNSCC. Together, these results describe a new mechanism of hypoxia regulation that opposes expression of HIF1 Alpha mRNA and the hypoxia-response genes.	[Bommi, Prashant, V; Bagchi, Srilata] Univ Illinois, Coll Dent, Dept Oral Biol, 801 S Paulina St, Chicago, IL 60612 USA; [Chand, Vaibhav; Mukhopadhyay, Nishit K.; Raychaudhuri, Pradip] Univ Illinois, Dept Biochem & Mol Genet, 900 S Ashland Ave, Chicago, IL 60607 USA; [Bommi, Prashant, V] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Biol Sci Res Bldg,6767 Bertner Ave, Houston, TX 77030 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Texas System; UTMD Anderson Cancer Center	Bagchi, S (corresponding author), Univ Illinois, Coll Dent, Dept Oral Biol, 801 S Paulina St, Chicago, IL 60612 USA.; Raychaudhuri, P (corresponding author), Univ Illinois, Dept Biochem & Mol Genet, 900 S Ashland Ave, Chicago, IL 60607 USA.	pradip@uic.edu; sbagchi@uic.edu		Bommi, Prashant/0000-0002-9457-1730	National Cancer Institute (NCI) [R01CA156164]	National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the grants from National Cancer Institute (NCI) to SB (R03CA227308) and the multi-PI grant from the National Cancer Institute (NCI) to PR and SB (R01CA156164).	Albinger-Hegyi A, 2010, INT J CANCER, V126, P2653, DOI 10.1002/ijc.24948; Bae SH, 2004, BIOCHEM BIOPH RES CO, V324, P394, DOI 10.1016/j.bbrc.2004.09.068; BelAiba RS, 2007, MOL BIOL CELL, V18, P4691, DOI 10.1091/mbc.E07-04-0391; Berra E, 2001, FEBS LETT, V491, P85, DOI 10.1016/S0014-5793(01)02159-7; Bommi Prashant V, 2018, Oncotarget, V9, P34708, DOI 10.18632/oncotarget.26168; Brizel DM, 1997, INT J RADIAT ONCOL, V38, P285, DOI 10.1016/S0360-3016(97)00101-6; Cam H, 2010, MOL CELL, V40, P509, DOI 10.1016/j.molcel.2010.10.030; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Cheng J, 2007, CELL, V131, P584, DOI 10.1016/j.cell.2007.08.045; Cheung KJ, 2016, P NATL ACAD SCI USA, V113, pE854, DOI 10.1073/pnas.1508541113; Dames SA, 2002, P NATL ACAD SCI USA, V99, P5271, DOI 10.1073/pnas.082121399; Ennen M, 2013, CANCER RES, V73, P5040, DOI 10.1158/0008-5472.CAN-12-3655; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Firlej V, 2011, CANCER RES, V71, P7649, DOI 10.1158/0008-5472.CAN-11-0833; Gandini NA, 2012, EXP MOL PATHOL, V93, P237, DOI 10.1016/j.yexmp.2012.05.001; Guzy RD, 2005, CELL METAB, V1, P401, DOI 10.1016/j.cmet.2005.05.001; Han CH, 2014, MOL CANCER RES, V12, P784, DOI 10.1158/1541-7786.MCR-13-0638; Hayashido Y, 2003, INT J MOL MED, V12, P447; Horiguchi Hidehisa, 2013, J Med Invest, V60, P91; Hoskin PJ, 2003, BRIT J CANCER, V89, P1290, DOI 10.1038/sj.bjc.6601260; Huang S, 2017, CANCER RES, V77, P6562, DOI 10.1158/0008-5472.CAN-17-1570; Iyer AK, 2013, ADV DRUG DELIVER REV, V65, P1784, DOI 10.1016/j.addr.2013.07.012; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jayachandran A, 2014, ONCOTARGET, V5, P5782, DOI 10.18632/oncotarget.2164; Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019; Koumenis C, 2014, ADV EXP MED BIOL, V772, pV; Le QT, 2009, J CLIN ONCOL, V27, P4281, DOI 10.1200/JCO.2008.20.6003; Li F, 2007, MOL CELL, V26, P63, DOI 10.1016/j.molcel.2007.02.024; Lim JH, 2010, MOL CELL, V38, P864, DOI 10.1016/j.molcel.2010.05.023; McDonald PC, 2014, SUBCELL BIOCHEM, V75, P255, DOI 10.1007/978-94-007-7359-2_13; Minig V, 2009, J BIOL CHEM, V284, P14165, DOI 10.1074/jbc.M808208200; Nowrousian MR, 2008, RECOMBINANT HUMAN ER; Overgaard J, 2005, LANCET ONCOL, V6, P757, DOI 10.1016/S1470-2045(05)70292-8; Pal SK, 2016, J ORAL PATHOL MED, V45, P730, DOI 10.1111/jop.12430; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Perez-Sayans M, 2013, J ORAL PATHOL MED, V42, P1, DOI 10.1111/j.1600-0714.2012.01144.x; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Rius J, 2008, NATURE, V453, P807, DOI 10.1038/nature06905; Roy N, 2013, CANCER RES, V73, P3771, DOI 10.1158/0008-5472.CAN-12-4069; Roy N, 2013, CANCER BIOL THER, V14, P108, DOI 10.4161/cbt.22631; Roy N, 2012, INT J MOL SCI, V13, P11012, DOI 10.3390/ijms130911012; Ryu JH, 2011, J BIOL CHEM, V286, P6963, DOI 10.1074/jbc.M110.188706; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186; Simon MC, 2008, NAT REV MOL CELL BIO, V9, P285, DOI 10.1038/nrm2354; Sorensen BS, 2015, RADIOTHER ONCOL, V116, P346, DOI 10.1016/j.radonc.2015.06.028; Stoyanova T, 2012, J BIOL CHEM, V287, P3019, DOI 10.1074/jbc.M111.295816; Stoyanova T, 2009, CELL CYCLE, V8, P4067, DOI 10.4161/cc.8.24.10109; Sui H, 2014, ONCOL RES TREAT, V37, P584, DOI 10.1159/000367802; Toustrup K, 2016, ACTA ONCOL, V55, P1091, DOI 10.3109/0284186X.2016.1167959; Toustrup K, 2011, CANCER RES, V71, P5923, DOI 10.1158/0008-5472.CAN-11-1182; Vaupel P, 2001, MED ONCOL, V18, P243, DOI 10.1385/MO:18:4:243; Vaupel P, 2002, Wien Med Wochenschr, V152, P334; Vaupel P, 2001, SEMIN ONCOL, V28, P29, DOI 10.1016/S0093-7754(01)90210-6; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Waypa GB, 2016, MOL ASPECTS MED, V47-48, P76, DOI 10.1016/j.mam.2016.01.002; Wittschieben BO, 2005, J BIOL CHEM, V280, P39982, DOI 10.1074/jbc.M507854200; Wittschieben BO, 2003, DNA REPAIR, V2, P1065, DOI 10.1016/S1568-7864(03)00113-7; Wykoff CC, 2000, CANCER RES, V60, P7075; Yoo YG, 2006, EMBO J, V25, P1231, DOI 10.1038/sj.emboj.7601025; Zhang S, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2408-9; Zhao R, 2015, NUCLEIC ACIDS RES, V43, P7838, DOI 10.1093/nar/gkv667; Zhao R, 2014, MOL CANCER RES, V12, P370, DOI 10.1158/1541-7786.MCR-13-0281	64	6	6	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	8					1784	1796		10.1038/s41388-019-1105-y	http://dx.doi.org/10.1038/s41388-019-1105-y			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN6CG	31740787				2022-12-28	WOS:000514923000012
J	Chen, XY; Xiong, XF; Cui, DR; Yang, F; Wei, DP; Li, HM; Shu, JF; Bi, YL; Dai, XQ; Gong, LY; Sun, Y; Zhao, YC				Chen, Xiaoyu; Xiong, Xiufang; Cui, Danrui; Yang, Fei; Wei, Dongping; Li, Haomin; Shu, Jianfeng; Bi, Yanli; Dai, Xiaoqing; Gong, Longyuan; Sun, Yi; Zhao, Yongchao			DEPTOR is an in vivo tumor suppressor that inhibits prostate tumorigenesis via the inactivation of mTORC1/2 signals	ONCOGENE			English	Article							BETA-TRCP; CANCER; PTEN; PROGRESSION; ACTIVATION; GROWTH; RADIOTHERAPY; DEGRADATION; METABOLISM; TRANSITION	The DEPTOR-mTORC1/2 axis has been shown to play an important, but a context dependent role in the regulation of proliferation and the survival of various cancer cells in cell culture settings. The in vivo role of DEPTOR in tumorigenesis remains elusive. Here we showed that the levels of both DEPTOR protein and mRNA were substantially decreased in human prostate cancer tissues, which positively correlated with disease progression. DEPTOR depletion accelerated proliferation and survival, migration, and invasion in human prostate cancer cells. Mechanistically, DEPTOR depletion not only activated both mTORC1 and mTORC2 signals to promote cell proliferation and survival, but also induced an AKT-dependent epithelial-mesenchymal transition (EMT) and beta-catenin nuclear translocation to promote cell migration and invasion. Abrogation of mTOR or AKT activation rescued the biological consequences of DEPTOR depletion. Importantly, in a Deptor-KO mouse model, Deptor knockout accelerated prostate tumorigenesis triggered by Pten loss via the activation of mTOR signaling. Collectively, our study demonstrates that DEPTOR is a tumor suppressor in the prostate, and its depletion promotes tumorigenesis via the activation of mTORC1 and mTORC2 signals. Thus, DEPTOR reactivation via a variety of means would have therapeutic potential for the treatment of prostate cancer.	[Chen, Xiaoyu; Cui, Danrui; Shu, Jianfeng; Bi, Yanli; Dai, Xiaoqing; Gong, Longyuan; Zhao, Yongchao] Zhejiang Univ, Affiliated Hosp 1, Key Lab Combined Multiorgan Transplantat, Minist Publ Hlth,Sch Med, Hangzhou, Peoples R China; [Chen, Xiaoyu; Xiong, Xiufang; Cui, Danrui; Yang, Fei; Li, Haomin; Shu, Jianfeng; Bi, Yanli; Dai, Xiaoqing; Gong, Longyuan; Sun, Yi; Zhao, Yongchao] Zhejiang Univ, Inst Translat Med, Sch Med, Hangzhou, Peoples R China; [Xiong, Xiufang; Sun, Yi] Zhejiang Univ, Affiliated Hosp 2, Canc Inst, Sch Med, Hangzhou, Peoples R China; [Wei, Dongping] Nanjing Med Univ, Nanjing Hosp 1, Dept Oncol, Nanjing, Peoples R China; [Li, Haomin] Zhejiang Univ, Childrens Hosp, Sch Med, Hangzhou, Zhejiang, Peoples R China; [Sun, Yi] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA	Zhejiang University; Zhejiang University; Zhejiang University; Nanjing Medical University; Zhejiang University; University of Michigan System; University of Michigan	Zhao, YC (corresponding author), Zhejiang Univ, Affiliated Hosp 1, Key Lab Combined Multiorgan Transplantat, Minist Publ Hlth,Sch Med, Hangzhou, Peoples R China.; Zhao, YC (corresponding author), Zhejiang Univ, Inst Translat Med, Sch Med, Hangzhou, Peoples R China.	yongchao@zju.edu.cn	Li, Haomin/AAY-5044-2021; Sun, Yi/K-1025-2014	Li, Haomin/0000-0002-6420-7719; Sun, Yi/0000-0002-5841-4287; Xiong, Xiufang/0000-0001-6842-3673	National Key R&D Program of China [2016YFA0501800]; National Natural Science Foundation of China [81672728, 81972591, 81721091, 81572708, 31501129, 81974429, 81572718, 81630076, 81672895]; Natural Science Foundation of Zhejiang Province [LR16C050001]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Zhejiang Province(Natural Science Foundation of Zhejiang Province)	This work was supported by the National Key R&D Program of China (2016YFA0501800 to YZ, XX, and YS), the National Natural Science Foundation of China (81672728, 81972591, and 81721091 to YZ, 81572708, 31501129, and 81974429 to XX, 81572718 and 81630076 to YS, and 81672895 to DW), and the Natural Science Foundation of Zhejiang Province (LR16C050001 to YZ).	Beer TM, 2017, EUR UROL, V71, P151, DOI 10.1016/j.eururo.2016.07.032; Blando J, 2009, AM J PATHOL, V174, P1869, DOI 10.2353/ajpath.2009.080055; Brand D, 2018, EUR UROL, V73, P521, DOI 10.1016/j.eururo.2017.12.021; Caron A, 2018, PHYSIOL REV, V98, P1765, DOI 10.1152/physrev.00064.2017; Caron A, 2017, MOL METAB, V6, P447, DOI 10.1016/j.molmet.2017.02.005; Chiarini F, 2015, TRENDS PHARMACOL SCI, V36, P124, DOI 10.1016/j.tips.2014.11.004; Crabb SJ, 2017, INVEST NEW DRUG, V35, P599, DOI 10.1007/s10637-017-0433-4; Duan SS, 2011, MOL CELL, V44, P317, DOI 10.1016/j.molcel.2011.09.005; Edlind MP, 2014, ASIAN J ANDROL, V16, P378, DOI 10.4103/1008-682X.122876; El Sheikh SS, 2008, NEOPLASIA, V10, P949, DOI 10.1593/neo.08582; Ferraldeschi R, 2015, EUR UROL, V67, P795, DOI 10.1016/j.eururo.2014.10.027; Fraser M, 2012, CLIN CANCER RES, V18, P1015, DOI 10.1158/1078-0432.CCR-11-2189; Gao DM, 2011, MOL CELL, V44, P290, DOI 10.1016/j.molcel.2011.08.030; Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189; Goodall J, 2017, CANCER DISCOV, V7, P1006, DOI 10.1158/2159-8290.CD-17-0261; Henderson V, 2015, CELL ADHES MIGR, V9, P255, DOI 10.1080/19336918.2015.1013383; Huang W, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-1; Jamaspishvili T, 2018, NAT REV UROL, V15, P222, DOI 10.1038/nrurol.2018.9; Janku F, 2018, NAT REV CLIN ONCOL, V15, P273, DOI 10.1038/nrclinonc.2018.28; Ji YM, 2016, ONCOTARGET, V7, P14188, DOI 10.18632/oncotarget.7420; Julien S, 2007, ONCOGENE, V26, P7445, DOI 10.1038/sj.onc.1210546; Khamis ZI, 2012, MED RES REV, V32, P1026, DOI 10.1002/med.20232; Lai EY, 2014, ASIAN PAC J CANCER P, V15, P4589, DOI 10.7314/APJCP.2014.15.11.4589; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lamouille S, 2012, J CELL SCI, V125, P1259, DOI 10.1242/jcs.095299; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Lee YR, 2018, NAT REV MOL CELL BIO, V19, P547, DOI 10.1038/s41580-018-0015-0; Li H, 2014, ONCOTARGET, V5, P12811, DOI 10.18632/oncotarget.2659; Liu QS, 2010, J MED CHEM, V53, P7146, DOI 10.1021/jm101144f; Lynch JT, 2018, MOL CANCER THER, V17, P2309, DOI 10.1158/1535-7163.MCT-18-0183; Mahal BA, 2018, EUR UROL, V74, P146, DOI 10.1016/j.eururo.2018.01.043; Obara A, 2015, BIOCHEM BIOPH RES CO, V460, P1047, DOI 10.1016/j.bbrc.2015.03.148; Pei L, 2011, MOL MED REP, V4, P817, DOI 10.3892/mmr.2011.503; Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Reid AHM, 2010, BRIT J CANCER, V102, P678, DOI 10.1038/sj.bjc.6605554; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.03.035, 10.1016/j.cell.2017.02.004]; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Sole CV, 2013, EUR J NUCL MED MOL I, V40, P1635, DOI 10.1007/s00259-013-2479-7; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; Wang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056664; Wang JC, 2018, BBA-MOL CELL RES, V1865, P1105, DOI 10.1016/j.bbamcr.2018.05.007; Yen CH, 2012, MOL MED, V18, P546, DOI 10.2119/molmed.2012.00003.erratum; Zhang S, 2019, CANCER RES, V79, P3725, DOI 10.1158/0008-5472.CAN-19-0180; Zhao Y, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.125; Zhao YC, 2012, NEOPLASIA, V14, P360, DOI 10.1593/neo.12532; Zhao YC, 2011, MOL CELL, V44, P304, DOI 10.1016/j.molcel.2011.08.029; Zhou XF, 2016, MOL CANCER RES, V14, P448, DOI 10.1158/1541-7786.MCR-15-0480; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	50	17	17	2	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	7					1557	1571		10.1038/s41388-019-1085-y	http://dx.doi.org/10.1038/s41388-019-1085-y			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KL2WP	31685947	Green Published, hybrid			2022-12-28	WOS:000513289600012
J	Hu, LY; Sun, Y; Luo, J; He, X; Ye, MH; Li, GH; Zhang, Y; Bai, J; Zhang, DH; Chang, CS				Hu, Linyi; Sun, Yin; Luo, Jie; He, Xiang; Ye, Meihua; Li, Gonghui; Zhang, Yong; Bai, Jian; Zhang, Dahong; Chang, Chawnshang			Targeting TR4 nuclear receptor with antagonist bexarotene increases docetaxel sensitivity to better suppress the metastatic castration-resistant prostate cancer progression	ONCOGENE			English	Article							LINCRNA-P21; MECHANISMS; APOPTOSIS; ROLES; CELLS	Prostate cancer (PCa) is the second leading cause of cancer death in men in America, and there are no curative options for metastatic castration-resistant prostate cancer (mCRPC). Docetaxel (DTX) has been used as a standard chemotherapy for the mCRPC. However, resistance to DTX is a significant clinical problem as half of patients fail to respond to therapy. The TR4 nuclear receptor has been reported to play an important role in PCa progression, however, its linkage to the DTX resistance remains unclear. Here we found that TR4 was upregulated after DTX chemotherapy in the mCRPC cells and patients, and TR4 expression is correlated with DTX sensitivity with a higher level conferring chemo-resistance. Targeting TR4 with an antagonist bexarotene (Bex, a derivative of retinoid) suppressed the TR4 transactivation with increased DTX chemo-sensitivity. Mechanism dissection studies revealed that TR4 might alter the DTX chemo-sensitivity via modulating the TR4/lincRNA-p21/HIF-1 alpha/VEGF-A signaling. Together, these results suggest that targeting this newly identified TR4/lincRNA-p21/HIF-1 alpha/VEGF-A signaling with Bex, an FDA-approved drug, may increase the DTX chemo-sensitivity to better suppress the mCRPC progression.	[Hu, Linyi; He, Xiang; Ye, Meihua; Zhang, Dahong] Zhejiang Prov Peoples Hosp, Dept Urol, Hangzhou 310014, Peoples R China; [Hu, Linyi; Sun, Yin; Luo, Jie; Li, Gonghui; Bai, Jian; Chang, Chawnshang] Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Urol, Rochester, NY 14642 USA; [Hu, Linyi; Sun, Yin; Luo, Jie; Li, Gonghui; Bai, Jian; Chang, Chawnshang] Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, Rochester, NY 14642 USA; [Hu, Linyi; Sun, Yin; Luo, Jie; Li, Gonghui; Bai, Jian; Chang, Chawnshang] Univ Rochester, Med Ctr, Wilmot Canc Inst, Rochester, NY 14642 USA; [Zhang, Yong] Hebei Med Univ, Hosp 2, Dept Urol, Shijiazhuang 050000, Hebei, Peoples R China; [Chang, Chawnshang] China Med Univ & Hosp, Dept Urol, Sex Hormone Res Ctr, Taichung 404, Taiwan	Zhejiang Provincial People's Hospital; University of Rochester; University of Rochester; University of Rochester; Hebei Medical University; China Medical University Taiwan; China Medical University Hospital - Taiwan	Zhang, DH (corresponding author), Zhejiang Prov Peoples Hosp, Dept Urol, Hangzhou 310014, Peoples R China.; Chang, CS (corresponding author), Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Urol, Rochester, NY 14642 USA.; Chang, CS (corresponding author), Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, Rochester, NY 14642 USA.; Chang, CS (corresponding author), Univ Rochester, Med Ctr, Wilmot Canc Inst, Rochester, NY 14642 USA.; Chang, CS (corresponding author), China Med Univ & Hosp, Dept Urol, Sex Hormone Res Ctr, Taichung 404, Taiwan.	zhangdahongzhj@163.co; chang@urmc.rochester.edu	Luo, Jie/AAG-3091-2019	Chang, Chawnshang/0000-0001-8510-3516	NIH [CA155477, CA156700]; George Whipple Professorship Endowment; Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence [MOHW104-TDU-B-212-113002]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); George Whipple Professorship Endowment; Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence	This work was supported by NIH grants (CA155477 and CA156700), George Whipple Professorship Endowment and Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW104-TDU-B-212-113002). We thank Karen Wolf for help preparing the manuscript.	Bos TJ, 2009, CURR GENE THER, V9, P192, DOI 10.2174/156652309788488578; CHANG CS, 1994, P NATL ACAD SCI USA, V91, P6040, DOI 10.1073/pnas.91.13.6040; Chen B, 2014, CANCER GENE THER, V21, P411, DOI 10.1038/cgt.2014.41; Chen SY, 2017, MED ONCOL, V34, DOI 10.1007/s12032-017-0959-5; Chen S, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0048747, 10.1371/journal.pone.0046703, 10.1371/journal.pone.0029579, 10.1371/journal.pone.0050850]; Chen YC, 2016, SCI REP-UK, V6, DOI 10.1038/srep27301; Corcoran C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050999; Ding XF, 2015, MOL CANCER, V14, DOI 10.1186/s12943-014-0281-1; Ding XF, 2015, INT J CANCER, V136, P955, DOI 10.1002/ijc.29049; Fayda M, 2016, TUMOR BIOL, V37, P3969, DOI 10.1007/s13277-015-4189-1; Fenner Annette, 2015, Nat Rev Urol, V12, P361, DOI 10.1038/nrurol.2015.135; Galletti G, 2017, CANCER TREAT REV, V57, P16, DOI 10.1016/j.ctrv.2017.04.008; Isin M, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00168; Lee YF, 2004, BIOCHEM BIOPH RES CO, V323, P876, DOI 10.1016/j.bbrc.2004.08.176; Lin SJ, 2012, REPROD BIOL ENDOCRIN, V10, DOI 10.1186/1477-7827-10-43; Liu S, 2014, ENDOCR-RELAT CANCER, V21, pR279, DOI 10.1530/ERC-13-0529; O'Neill AJ, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-126; Obasaju C, 2001, HEMATOL ONCOL CLIN N, V15, P525, DOI 10.1016/S0889-8588(05)70230-6; Pan Y, 2016, CELL PHYSIOL BIOCHEM, V40, P219, DOI 10.1159/000452539; Pileri A, 2013, IMMUNOTHERAPY-UK, V5, P427, DOI [10.2217/IMT.13.15, 10.2217/imt.13.15]; Qiu XF, 2015, ONCOTARGET, V6, P15397, DOI 10.18632/oncotarget.3778; Saad F, 2018, CUAJ-CAN UROL ASSOC, V12, pE415, DOI 10.5489/cuaj.5154; Sakuma T, 2016, NAT PROTOC, V11, P118, DOI 10.1038/nprot.2015.140; Seruga B, 2011, NAT REV CLIN ONCOL, V8, P12, DOI 10.1038/nrclinonc.2010.136; Shen YM, 2017, EXP CELL RES, V358, P188, DOI 10.1016/j.yexcr.2017.06.016; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Wang GY, 2014, ONCOL REP, V31, P1839, DOI 10.3892/or.2014.3047; Wang XH, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12395; Wang XH, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12318; Wu GZ, 2014, CIRCULATION, V130, P1452, DOI 10.1161/CIRCULATIONAHA.114.011675; Yang DR, 2013, J BIOL CHEM, V288, P16476, DOI 10.1074/jbc.M112.448142; Yang F, 2014, MOL CELL, V53, P88, DOI 10.1016/j.molcel.2013.11.004; Yoon JH, 2012, MOL CELL, V47, P648, DOI 10.1016/j.molcel.2012.06.027; Yu SC, 2015, PROSTATE, V75, P1632, DOI 10.1002/pros.23044; Zhou XE, 2011, J BIOL CHEM, V286, P2877, DOI 10.1074/jbc.M110.168740	35	6	6	2	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	9					1891	1903		10.1038/s41388-019-1070-5	http://dx.doi.org/10.1038/s41388-019-1070-5			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KP9VM	31748715	Green Published, hybrid			2022-12-28	WOS:000516579800005
J	Lefort, S; Tan, S; Balani, S; Rafn, B; Pellacani, D; Hirst, M; Sorensen, PH; Eaves, CJ				Lefort, Sylvain; Tan, Susanna; Balani, Sneha; Rafn, Bo; Pellacani, Davide; Hirst, Martin; Sorensen, Poul H.; Eaves, Connie J.			Initiation of human mammary cell tumorigenesis by mutant KRAS requires YAP inactivation	ONCOGENE			English	Article							COMPREHENSIVE MOLECULAR PORTRAITS; HIPPO PATHWAY; BREAST; GROWTH; YAP/TAZ; DIFFERENTIATION; LOCALIZATION; CROSSTALK; MUTATION; COMPLEX	High YAP activity is associated with poor prognosis human breast cancers, but its role during the initial stage of mammary cell transformation is unknown. To address this question, we designed experiments that exploit the ability of KRAS(G12D)-transduced subsets of freshly isolated normal human mammary cells to form invasive tumors rapidly and efficiently when transplanted into immunodeficient mice. Initial examination of the newly developing tumors thus generated revealed a consistent marked loss of nuclear YAP, independent of the initial primary human mammary cell type transduced. Conversely, co-transduction of the same subsets of primary human mammary cells with KRAS(G12D) plus the constitutively active YAP(S127A) prevented tumor formation. These findings contrast with the enhanced display of transformed properties obtained when the immortalized, but non-tumorigenic MCF10A cells are transduced just with YAP(S127A). In addition, we show that YAP(S127A)-transduction of the human MDA-MB-231 breast cancer cell line (that carry a similar KRAS mutation) enhances their metastatic activity in vivo. We also discover that the KRAS(G12D)-induced early loss of YAP in primary human mammary cells is associated with their induced secretion of amphiregulin. Collectively, these findings suggest that YAP can differentially affect the acquisition of malignant properties by human mammary cells at different stages of their transformation.	[Lefort, Sylvain; Tan, Susanna; Balani, Sneha; Pellacani, Davide; Eaves, Connie J.] British Columbia Canc Agcy, Terry Fox Lab, 675 West 10th Ave, Vancouver, BC V5Z 1L3, Canada; [Rafn, Bo; Sorensen, Poul H.] British Columbia Canc Agcy, Dept Mol Oncol, 675 West 10th Ave, Vancouver, BC V5Z 1L3, Canada; [Hirst, Martin] British Columbia Canc Agcy, Canadas Michael Smith Genome Sci Ctr, Vancouver, BC V5Z 1L3, Canada; [Hirst, Martin] Univ British Columbia, Dept Microbiol & Immunol, Michael Smith Labs, Vancouver, BC V6T 1Z4, Canada	British Columbia Cancer Agency; British Columbia Cancer Agency; British Columbia Cancer Agency; University of British Columbia	Lefort, S (corresponding author), British Columbia Canc Agcy, Terry Fox Lab, 675 West 10th Ave, Vancouver, BC V5Z 1L3, Canada.	sylvain.lefort@lyon.unicancer.fr		Lefort, Sylvain/0000-0001-7320-4256; Eaves, Connie/0000-0002-3452-1926	Canadian Cancer Society Research Institute; Cancer Research Society; Cancer Institute for Health Research [CRP-154482]; University of British Columbia Graduate Studentship; Canadian Institute of Health Research Banting and Best Studentship	Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); Cancer Research Society; Cancer Institute for Health Research; University of British Columbia Graduate Studentship; Canadian Institute of Health Research Banting and Best Studentship(Canadian Institutes of Health Research (CIHR))	The authors thank D. Wilkinson, G. Edin, and M. Hale for excellent technical support; Drs J. Cheng and P. Hoodless for their help with data interpretation; and Drs E. Bovill, J. Boyle, S. Bristol, P. Gdalevitch, A. Seal, J. Sproul, and N. van Laeken for access to discarded reduction human mammoplasty tissue. This work was supported by grants from the Canadian Cancer Society Research Institute, the Cancer Research Society, and the Cancer Institute for Health Research (grant CRP-154482). The authors declare no conflict of interest. SB was a recipient of a University of British Columbia Graduate Studentship and ST was a recipient of a Canadian Institute of Health Research Banting and Best Studentship.	Aragon E, 2011, GENE DEV, V25, P1275, DOI 10.1101/gad.2060811; Aragona M, 2013, CELL, V154, P1047, DOI 10.1016/j.cell.2013.07.042; Balani S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15422; Bartucci M, 2015, ONCOGENE, V34, P681, DOI 10.1038/onc.2014.5; Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Britschgi A, 2017, NATURE, V541, P541, DOI 10.1038/nature20829; Chen Q, 2014, GENE DEV, V28, P432, DOI 10.1101/gad.233676.113; Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Eirew P, 2008, NAT MED, V14, P1384, DOI 10.1038/nm.1791; Grannas K, 2015, J MOL BIOL, V427, P3407, DOI 10.1016/j.jmb.2015.04.015; Ikediobi ON, 2006, MOL CANCER THER, V5, P2606, DOI 10.1158/1535-7163.MCT-06-0433; Kannan N, 2014, P NATL ACAD SCI USA, V111, P7789, DOI 10.1073/pnas.1403813111; Kapoor A, 2014, CELL, V158, P185, DOI 10.1016/j.cell.2014.06.003; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; KOZMA SC, 1987, NUCLEIC ACIDS RES, V15, P5963; Lamar JM, 2012, P NATL ACAD SCI USA, V109, pE2441, DOI 10.1073/pnas.1212021109; Li Z, 2010, GENE DEV, V24, P235, DOI 10.1101/gad.1865810; Marella NV, 2009, CANCER RES, V69, P5946, DOI 10.1158/0008-5472.CAN-09-0420; Morel AP, 2017, NAT MED, V23, P568, DOI 10.1038/nm.4323; Nguyen LV, 2015, NATURE, V528, P267, DOI 10.1038/nature15742; Nguyen LV, 2014, CELL STEM CELL, V14, P253, DOI 10.1016/j.stem.2013.12.011; Pellacani D, 2016, CELL REP, V17, P2060, DOI 10.1016/j.celrep.2016.10.058; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014; Shao DD, 2014, CELL, V158, P171, DOI 10.1016/j.cell.2014.06.004; Skibinski A, 2014, CELL REP, V6, P1059, DOI 10.1016/j.celrep.2014.02.038; Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601; Vlug EJ, 2013, CELL ONCOL, V36, P375, DOI 10.1007/s13402-013-0143-7; Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216; Zhang JM, 2009, NAT CELL BIOL, V11, P1444, DOI 10.1038/ncb1993; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907	34	12	12	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	9					1957	1968		10.1038/s41388-019-1111-0	http://dx.doi.org/10.1038/s41388-019-1111-0			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KP9VM	31772328	Green Published, hybrid			2022-12-28	WOS:000516579800010
J	Sorolla, A; Wang, E; Golden, E; Duffy, C; Henriques, ST; Redfern, AD; Blancafort, P				Sorolla, Anabel; Wang, Edina; Golden, Emily; Duffy, Ciara; Henriques, Sonia T.; Redfern, Andrew D.; Blancafort, Pilar			Precision medicine by designer interference peptides: applications in oncology and molecular therapeutics	ONCOGENE			English	Review							CELL-PENETRATING PEPTIDES; VIVO HALF-LIFE; TRANSCRIPTION-FACTOR; IN-VIVO; BREAST-CANCER; HOX GENES; LUNG-CANCER; MYC; INHIBITION; PROTEINS	In molecular cancer therapeutics only 10% of known cancer gene products are targetable with current pharmacological agents. Major oncogenic drivers, such as MYC and KRAS proteins are frequently highly overexpressed or mutated in multiple human malignancies. However, despite their key role in oncogenesis, these proteins are hard to target with traditional small molecule drugs due to their large, featureless protein interfaces and lack of deep pockets. In addition, they are inaccessible to large biologicals, which are unable to cross cell membranes. Designer interference peptides (iPeps) represent emerging pharmacological agents created to block selective interactions between protein partners that are difficult to target with conventional small molecule chemicals or with large biologicals. iPeps have demonstrated successful inhibition of multiple oncogenic drivers with some now entering clinical settings. However, the clinical translation of iPeps has been hampered by certain intrinsic limitations including intracellular localization, targeting tissue specificity and pharmacological potency. Herein, we outline recent advances for the selective inhibition of major cancer oncoproteins via iPep approaches and discuss the development of multimodal peptides to overcome limitations of the first generations of iPeps. Since many protein-protein interfaces are cell-type specific, this approach opens the door to novel programmable, precision medicine tools in cancer research and treatment for selective manipulation and reprogramming of the cancer cell oncoproteome.	[Sorolla, Anabel; Wang, Edina; Golden, Emily; Duffy, Ciara; Blancafort, Pilar] Univ Western Australia, QEII Med Ctr, Harry Perkins Inst Med Res, Nedlands, WA 6009, Australia; [Sorolla, Anabel; Wang, Edina; Golden, Emily; Duffy, Ciara; Blancafort, Pilar] Univ Western Australia, Ctr Med Res, Nedlands, WA 6009, Australia; [Henriques, Sonia T.] Queensland Univ Technol, Translat Res Inst, Inst Hlth & Biomed Innovat, Sch Biomed Sci,Fac Hlth, Brisbane, Qld 4102, Australia; [Redfern, Andrew D.] Univ Western Australia, Sch Med, Crawley, WA 6009, Australia	Harry Perkins Institute of Medical Research; University of Western Australia; University of Western Australia; Queensland University of Technology (QUT); University of Western Australia	Sorolla, A; Blancafort, P (corresponding author), Univ Western Australia, QEII Med Ctr, Harry Perkins Inst Med Res, Nedlands, WA 6009, Australia.; Sorolla, A; Blancafort, P (corresponding author), Univ Western Australia, Ctr Med Res, Nedlands, WA 6009, Australia.	anabel.sorollabardaji@perkins.uwa.edu.au; pilar.blancafort@uwa.edu.au	Redfern, Andrew/ABA-4597-2020; Troeira Henriques, Sonia/J-3500-2016	Redfern, Andrew/0000-0001-6728-8713; Troeira Henriques, Sonia/0000-0001-9564-9651; Wang, Edina/0000-0002-9652-3513; Golden, Emily/0000-0001-6386-201X; Blancafort, Pilar/0000-0002-3881-7396; Sorolla, Anabel/0000-0001-8238-8763	Australian Research Council (ARC) [FT130101767]; Cancer Council of Western Australia (CCWA) Research Fellowship; National Health and Medical Research Council (NHMRC) [APP1069308, APP1147528, APP1165208]; NBCF [PF-15-001]; Raine Medical Research Foundation; Australian Government Research Training Program (RTP) Scholarship; Cancer Council of Western Australia PhD Top-Up Scholarship; ARC [FT150100398]; NHMRC [APP1084965]; Australian Government; CCWA [APP1083745, APP1147435]	Australian Research Council (ARC)(Australian Research Council); Cancer Council of Western Australia (CCWA) Research Fellowship; National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); NBCF; Raine Medical Research Foundation; Australian Government Research Training Program (RTP) Scholarship(Australian GovernmentDepartment of Industry, Innovation and Science); Cancer Council of Western Australia PhD Top-Up Scholarship; ARC(Australian Research Council); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Australian Government(Australian GovernmentCGIAR); CCWA(Cancer Council Western Australia)	This work was supported by the following grants awarded to PB: the Australian Research Council (ARC) Future Fellowship FT130101767, the Cancer Council of Western Australia (CCWA) Research Fellowship and CCWA project grants APP1083745 and APP1147435, and National Health and Medical Research Council (NHMRC) grants APP1069308, APP1147528, and APP1165208. AS acknowledges the postdoctoral fellowship from the NBCF, PF-15-001 and the research funds from the Raine Medical Research Foundation. CD acknowledges the Australian Government Research Training Program (RTP) Scholarship and the Cancer Council of Western Australia PhD Top-Up Scholarship. STH acknowledges ARC Future Fellowship FT150100398 and NHMRC project grant APP1084965. The Translational Research Institute is supported by a grant from the Australian Government. The authors would like to acknowledge Dr. Kade Roberts for critical reading and review of the paper.	Alharbi RA, 2013, LEUKEMIA, V27, P1000, DOI 10.1038/leu.2012.356; Alvarez-Fischer D, 2011, NAT NEUROSCI, V14, P1260, DOI 10.1038/nn.2916; Annibali D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5632; Avramis VI, 2002, BLOOD, V99, P1986, DOI 10.1182/blood.V99.6.1986; Bale SS, 2010, ACS NANO, V4, P1493, DOI 10.1021/nn901586e; Beaulieu ME, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aar5012; Beltran AS, 2014, ONCOGENE, V33, P4767, DOI 10.1038/onc.2013.422; Benayed R, 2005, AM J HUM GENET, V77, P851, DOI 10.1086/497705; Bernal F, 2010, CANCER CELL, V18, P411, DOI 10.1016/j.ccr.2010.10.024; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bhatlekar S, 2018, J CELL PHYSIOL, V233, P727, DOI 10.1002/jcp.25981; Bidwell GL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055104; Bidwell GL, 2005, MOL CANCER THER, V4, P1076, DOI 10.1158/1535-7163.MCT-04-0253; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Blundell TL, 2000, BIOL CHEM, V381, P955, DOI 10.1515/BC.2000.117; BOS JL, 1989, CANCER RES, V49, P4682; Brown RV, 2011, J BIOL CHEM, V286, P41018, DOI 10.1074/jbc.M111.274720; Bruno BJ, 2013, THER DELIV, V4, P1443, DOI [10.4155/TDE.13.104, 10.4155/tde.13.104]; Buckton LK, 2018, ORG LETT, V20, P506, DOI 10.1021/acs.orglett.7b03363; Caruso C, 2019, CANCER DISCOV, V9, P988, DOI 10.1158/2159-8290.CD-NB2019-073; Carvajal LA, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao3003; Chang YS, 2013, P NATL ACAD SCI USA, V110, pE3445, DOI 10.1073/pnas.1303002110; Clark RJ, 2005, P NATL ACAD SCI USA, V102, P13767, DOI 10.1073/pnas.0504613102; Craik DJ, 2013, CHEM BIOL DRUG DES, V81, P136, DOI 10.1111/cbdd.12055; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; dos Santos MTMA, 2011, NEURAL DEV, V6, DOI 10.1186/1749-8104-6-23; Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275; Farkhani SM, 2014, PEPTIDES, V57, P78, DOI 10.1016/j.peptides.2014.04.015; Fosgerau K, 2015, DRUG DISCOV TODAY, V20, P122, DOI 10.1016/j.drudis.2014.10.003; Fukazawa T, 2010, ANTICANCER RES, V30, P4193; Gandhi Neha S, 2018, Oncotarget, V9, P22383, DOI 10.18632/oncotarget.25025; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; Giorello L, 1998, CANCER RES, V58, P3654; GREEN M, 1989, CELL, V58, P215, DOI 10.1016/0092-8674(89)90417-0; Gu Z, 2011, CHEM SOC REV, V40, P3638, DOI 10.1039/c0cs00227e; Han G, 2012, ONCOL RES, V20, P149, DOI 10.3727/096504012X13522227232237; Hao XY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138911; Harbour JW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1341, DOI 10.1001/archopht.120.10.1341; Hoffmann K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30790-2; Hopkins AL, 2002, NAT REV DRUG DISCOV, V1, P727, DOI 10.1038/nrd892; Janes MR, 2018, CELL, V172, P578, DOI 10.1016/j.cell.2018.01.006; Kater AP, 2019, J CLIN ONCOL, V37, P269, DOI 10.1200/JCO.18.01580; Khan I, 2019, ONCOGENE, V38, P2984, DOI 10.1038/s41388-018-0636-y; Kretzmann JA, 2019, CHEM SCI, V10, P7718, DOI 10.1039/c9sc01432b; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Leshchiner ES, 2015, P NATL ACAD SCI USA, V112, P1761, DOI 10.1073/pnas.1413185112; Li L, 2016, J CONTROL RELEASE, V232, P62, DOI 10.1016/j.jconrel.2016.04.021; Li ZG, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.187; Liu M, 2010, P NATL ACAD SCI USA, V107, P14321, DOI 10.1073/pnas.1008930107; Liu Y, 2011, ANGEW CHEM INT EDIT, V50, P3058, DOI 10.1002/anie.201005740; Luo M, 2017, NAT NANOTECHNOL, V12, P648, DOI [10.1038/nnano.2017.52, 10.1038/NNANO.2017.52]; Marier JF, 2008, J CLIN PHARMACOL, V48, P1289, DOI 10.1177/0091270008320605; Mas-Moruno C, 2010, ANTI-CANCER AGENT ME, V10, P753, DOI 10.2174/187152010794728639; Mathur D, 2016, SCI REP, V6; Morgan R, 2007, CANCER RES, V67, P5806, DOI 10.1158/0008-5472.CAN-06-4231; Morgan R, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.AM2019-5215; Morgan R, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2106-7; Morgan R, 2014, BMC UROL, V14, DOI 10.1186/1471-2490-14-17; Morgan R, 2012, BREAST CANCER RES TR, V136, P389, DOI 10.1007/s10549-012-2259-2; Morgan R, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-89; Morris MC, 2008, BIOL CELL, V100, P201, DOI 10.1042/BC20070116; Mundargi RC, 2008, J CONTROL RELEASE, V125, P193, DOI 10.1016/j.jconrel.2007.09.013; Neuteboom STC, 1997, MOL CELL BIOL, V17, P4696, DOI 10.1128/MCB.17.8.4696; Oliva R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27231-5; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Pandha H, 2012, BJU INT, V110, pE287, DOI 10.1111/j.1464-410X.2012.11208.x; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; Patel S, 2014, ACS NANO, V8, P8959, DOI 10.1021/nn501589f; Peltenburg LTC, 1996, EMBO J, V15, P3385, DOI 10.1002/j.1460-2075.1996.tb00704.x; Penchala SC, 2015, NAT CHEM BIOL, V11, P793, DOI [10.1038/NCHEMBIO.1907, 10.1038/nchembio.1907]; Plowright L, 2009, BRIT J CANCER, V100, P470, DOI 10.1038/sj.bjc.6604857; Schellenberger V, 2009, NAT BIOTECHNOL, V27, P1186, DOI 10.1038/nbt.1588; Shears L, 2008, J UROLOGY, V180, P2196, DOI 10.1016/j.juro.2008.07.018; SHEINESS D, 1978, J VIROL, V28, P600, DOI 10.1128/JVI.28.2.600-610.1978; Shen LL, 2015, P NATL ACAD SCI USA, V112, P5425, DOI 10.1073/pnas.1501555112; Sodir NM, 2011, GENE DEV, V25, P907, DOI 10.1101/gad.2038411; Sorolla A, 2016, NANOSCALE, V8, P9343, DOI 10.1039/c5nr08331a; Sorolla A, 2019, NANOMED-NANOTECHNOL, V20, DOI 10.1016/j.nano.2019.04.006; Sorolla A, 2012, MOL ONCOL, V6, P530, DOI 10.1016/j.molonc.2012.06.006; Soucek L, 2004, CELL DEATH DIFFER, V11, P1038, DOI 10.1038/sj.cdd.4401443; Soucek L, 2002, CANCER RES, V62, P3507; Soucek L, 1998, ONCOGENE, V17, P2463, DOI 10.1038/sj.onc.1202199; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048; Spencer-Smith R, 2017, NAT CHEM BIOL, V13, P62, DOI [10.1038/nchembio.2231, 10.1038/NCHEMBIO.2231]; Tang R, 2013, ACS NANO, V7, P6667, DOI 10.1021/nn402753y; Trinh TB, 2016, ACS COMB SCI, V18, P75, DOI 10.1021/acscombsci.5b00164; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; Verdine GL, 2007, CLIN CANCER RES, V13, P7264, DOI 10.1158/1078-0432.CCR-07-2184; Vogler M, 2009, BLOOD, V113, P4403, DOI 10.1182/blood-2008-08-173310; Walensky LD, 2004, SCIENCE, V305, P1466, DOI 10.1126/science.1099191; Wang E, 2019, ONCOGENE, V38, P140, DOI 10.1038/s41388-018-0421-y; Wang S, 2013, CLIN CANCER RES, V19, P128, DOI 10.1158/1078-0432.CCR-12-2654; Warren CFA, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1407-6; Wells JA, 2007, NATURE, V450, P1001, DOI 10.1038/nature06526; Wu XH, 2013, MEDCHEMCOMM, V4, P378, DOI 10.1039/c2md20329d	100	40	40	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	6					1167	1184		10.1038/s41388-019-1056-3	http://dx.doi.org/10.1038/s41388-019-1056-3			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE4UH	31636382	Green Published, hybrid			2022-12-28	WOS:000526714600001
J	Ouahoud, S; Voorneveld, PW; van der Burg, LRA; de Jonge-Muller, ESM; Schoonderwoerd, MJA; Paauwe, M; de Vos, T; de Wit, S; van Pelt, GW; Mesker, WE; Hawinkels, LJAC; Hardwick, JCH				Ouahoud, Sarah; Voorneveld, Philip W.; van der Burg, Lennart R. A.; de Jonge-Muller, Eveline S. M.; Schoonderwoerd, Mark J. A.; Paauwe, Madelon; de Vos, Thijs; de Wit, Sophie; van Pelt, Gabi W.; Mesker, Wilma E.; Hawinkels, Lukas J. A. C.; Hardwick, James C. H.			Bidirectional tumor/stroma crosstalk promotes metastasis in mesenchymal colorectal cancer	ONCOGENE			English	Article							BONE MORPHOGENETIC PROTEIN; APOPTOSIS-INDUCING LIGAND; TUMOR-STROMA RATIO; CONSENSUS MOLECULAR SUBTYPES; INDEPENDENT PREDICTOR; PANCREATIC-CANCER; POOR-PROGNOSIS; CELLS; SMAD4; SURVIVAL	Patients with the mesenchymal subtype colorectal cancer (CRC) have a poor prognosis, in particular patients with stroma-rich tumors and aberrant SMAD4 expression. We hypothesized that interactions between SMAD4-deficient CRC cells and cancer-associated fibroblasts provide a biological explanation. In transwell invasion assays, fibroblasts increased the invasive capacity of SMAD4-deficient HT29 CRC cells, but not isogenic SMAD4-proficient HT29 cells. A TGF-beta/BMP-specific array showed BMP2 upregulation by fibroblasts upon stimulation with conditioned medium from SMAD4-deficient CRC cells, while also stimulating their invasion. In a mouse model for experimental liver metastasis, the co-injection of fibroblasts increased metastasis formation of SMAD4-deficient CRC cells (p = 0.02) but not that of SMAD4-proficient CRC cells. Significantly less metastases were seen in mice co-injected with BMP2 knocked-down fibroblasts. Fibroblast BMP2 expression seemed to be regulated by TRAIL, a factor overexpressed in SMAD4-deficient CRC cells. In a cohort of 146 stage III CRC patients, we showed that patients with a combination of high stromal BMP2 expression and the loss of tumor SMAD4 expression had a significantly poorer overall survival (HR 2.88, p = 0.04). Our results suggest the existence of a reciprocal loop in which TRAIL from SMAD4-deficient CRC cells induces BMP2 in fibroblasts, which enhances CRC invasiveness and metastasis.	[Ouahoud, Sarah; Voorneveld, Philip W.; van der Burg, Lennart R. A.; de Jonge-Muller, Eveline S. M.; Schoonderwoerd, Mark J. A.; Paauwe, Madelon; de Vos, Thijs; de Wit, Sophie; Hawinkels, Lukas J. A. C.; Hardwick, James C. H.] Leiden Univ, Dept Gastroenterol & Hepatol, Med Ctr, Leiden, Netherlands; [van Pelt, Gabi W.; Mesker, Wilma E.] Leiden Univ, Dept Surg, Med Ctr, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Hardwick, JCH (corresponding author), Leiden Univ, Dept Gastroenterol & Hepatol, Med Ctr, Leiden, Netherlands.	J.C.H.Hardwick@LUMC.nl	Hawinkels, Lukas/Q-5098-2019; Hardwick, James/J-4862-2013	Hawinkels, Lukas/0000-0002-2274-9325; Hardwick, James/0000-0002-9575-5099; Voorneveld, Philip/0000-0002-3881-4435				Alazzouzi H, 2005, CLIN CANCER RES, V11, P2606, DOI 10.1158/1078-0432.CCR-04-1458; Alhopuro P, 2005, CLIN CANCER RES, V11, P6311, DOI 10.1158/1078-0432.CCR-05-0244; Calon A, 2015, NAT GENET, V47, P320, DOI 10.1038/ng.3225; Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013; Chen SX, 2014, J PROTEOMICS, V110, P155, DOI 10.1016/j.jprot.2014.07.031; Cortez VS, 2017, NAT IMMUNOL, V18, P995, DOI 10.1038/ni.3809; Dekker TJA, 2013, BREAST CANCER RES TR, V139, P371, DOI 10.1007/s10549-013-2571-5; Dienstmann R, 2017, NAT REV CANCER, V17, P79, DOI 10.1038/nrc.2016.126; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Hardwick JC, 2008, NAT REV CANCER, V8, P806, DOI 10.1038/nrc2467; Hardwick JCH, 2004, GASTROENTEROLOGY, V126, P111, DOI 10.1053/j.gastro.2003.10.067; Hawinkels LJAC, 2011, GROWTH FACTORS, V29, P140, DOI 10.3109/08977194.2011.595411; Herzer K, 2008, MOL CANCER RES, V6, P1169, DOI 10.1158/1541-7786.MCR-08-0073; Huijbers A, 2013, ANN ONCOL, V24, P179, DOI 10.1093/annonc/mds246; Irshad S, 2017, J PATHOL, V242, P178, DOI 10.1002/path.4891; Jin H, 2012, APPL MICROBIOL BIOT, V93, P1715, DOI 10.1007/s00253-011-3865-3; Jiramongkolchai P, 2016, BIOCHEM SOC T, V44, P1117, DOI 10.1042/BST20160069; Johnstone RW, 2008, NAT REV CANCER, V8, P782, DOI 10.1038/nrc2465; Kang MH, 2011, EXP CELL RES, V317, P1746, DOI 10.1016/j.yexcr.2011.04.006; Karagiannis GS, 2013, MOL ONCOL, V7, P826, DOI 10.1016/j.molonc.2013.04.002; Katsuno Y, 2008, ONCOGENE, V27, P6322, DOI 10.1038/onc.2008.232; Kleeff J, 1999, GASTROENTEROLOGY, V116, P1202, DOI 10.1016/S0016-5085(99)70024-7; Koch PS, 2017, BLOOD, V129, P415, DOI 10.1182/blood-2016-07-729822; Kodach LL, 2008, GASTROENTEROLOGY, V134, P1332, DOI 10.1053/j.gastro.2008.02.059; Kodach LL, 2008, CANCER, V112, P300, DOI 10.1002/cncr.23160; Koornstra JJ, 2003, J PATHOL, V200, P327, DOI 10.1002/path.1364; Lane D, 2004, GYNECOL ONCOL, V93, P594, DOI 10.1016/j.ygyno.2004.03.029; Lee TJ, 2006, BIOCHEM BIOPH RES CO, V351, P1024, DOI 10.1016/j.bbrc.2006.10.163; Lemke J, 2014, CELL DEATH DIFFER, V21, P1350, DOI 10.1038/cdd.2014.81; Liu J, 2014, GYNECOL ONCOL, V132, P81, DOI 10.1016/j.ygyno.2013.11.003; Lv Z, 2015, SURGERY, V158, P142, DOI 10.1016/j.surg.2015.02.013; Mesker WE, 2007, CELL ONCOL, V29, P387; Mesker WE, 2009, CELL ONCOL, V31, P169, DOI 10.3233/CLO-2009-0478; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Paauwe M, 2018, CLIN CANCER RES, V24, P6331, DOI 10.1158/1078-0432.CCR-18-0329; Papageorgis P, 2011, CANCER RES, V71, P998, DOI 10.1158/0008-5472.CAN-09-3269; Song JH, 2007, CANCER RES, V67, P6946, DOI 10.1158/0008-5472.CAN-06-3896; Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492; Voorneveld PW, 2015, BRIT J CANCER, V112, P122, DOI 10.1038/bjc.2014.560; Voorneveld PW, 2013, BRIT J CANCER, V109, P1805, DOI 10.1038/bjc.2013.486; Voorneveld PW, 2014, GASTROENTEROLOGY, V147, P196, DOI 10.1053/j.gastro.2014.03.052; Wakefield LM, 2013, NAT REV CANCER, V13, P328, DOI 10.1038/nrc3500; Wang K, 2012, J THORAC ONCOL, V7, P1457, DOI 10.1097/JTO.0b013e318260dfe8; Wenger T, 2006, CELL DEATH DIFFER, V13, P1740, DOI 10.1038/sj.cdd.4401867; Zhang LD, 2005, CANCER GENE THER, V12, P228, DOI 10.1038/sj.cgt.7700792	45	15	15	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	12					2453	2466		10.1038/s41388-020-1157-z	http://dx.doi.org/10.1038/s41388-020-1157-z		JAN 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KW4HU	31974473	Green Published			2022-12-28	WOS:000509037000001
J	Hsu, YL; Huang, MS; Hung, JY; Chang, WA; Tsai, YM; Pan, YC; Lin, YS; Tsai, HP; Kuo, PL				Hsu, Ya-Ling; Huang, Ming-Shyan; Hung, Jen-Yu; Chang, Wei-An; Tsai, Ying-Ming; Pan, Yi-Chung; Lin, Yi-Shiuan; Tsai, Hung-Pei; Kuo, Po-Lin			Bone-marrow-derived cell-released extracellular vesicle miR-92a regulates hepatic pre-metastatic niche in lung cancer	ONCOGENE			English	Article							BREAST-CANCER; LIVER METASTASIS; STELLATE CELLS; MICROENVIRONMENT; HEMATOPOIESIS; ACTIVATION; EXPRESSION; FIBROSIS; INITIATE	Metastatic tumors have been shown to establish a supportive pre-metastatic niche (PMN) in distant organs, which in turn determines disseminated tumor cells' targeting of such organs. PMN is formed through the recruitment of bone-marrow-derived cells (BMDCs); however, the role of BMDCs in PMN formation is not fully understood. On the basis of RNA-seq data and bioinformatic analysis, secretion of extracellular vesicle (EV) miR-92a by BMDCs of lung cancer-bearing mice contributes to the establishment of liver PMN. Both BMDC-derived EVs and miR-92a mimics potentiate the activation of hepatic stellate cells (HSCs), subsequently increasing extracellular matrix (ECM) deposition in mice. Consequently, remodeling of the liver microenvironment enhanced immunosuppressive cell accumulation and cancer cell attachment. EVs miR-92a directly suppressed its target SMAD7, leading to the enhancement of transforming growth factor-beta signaling in HSC. Elevated levels of circulating miR-92a are found in the sera of lung cancer patients, and EVs isolated from these patients have a similar ability to increase HSCs activation and ECM protein expression. Our study reveals the sequential steps of liver PMN formation in lung cancer, providing critical mediators that prepare PMN in the liver, and identifies new targets that offer valuable options for diagnosis and therapeutic intervention.	[Hsu, Ya-Ling; Tsai, Ying-Ming] Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung 807, Taiwan; [Huang, Ming-Shyan] E DA Canc Hosp, Dept Internal Med, Kaohsiung 840, Taiwan; [Huang, Ming-Shyan] I Shou Univ, Sch Med, Kaohsiung 840, Taiwan; [Hung, Jen-Yu; Chang, Wei-An; Tsai, Ying-Ming] Kaohsiung Med Univ Hosp, Div Pulm & Crit Care Med, Kaohsiung 807, Taiwan; [Hung, Jen-Yu; Chang, Wei-An; Tsai, Ying-Ming] Kaohsiung Med Univ, Sch Med, Coll Med, Kaohsiung 807, Taiwan; [Chang, Wei-An; Pan, Yi-Chung; Lin, Yi-Shiuan; Kuo, Po-Lin] Kaohsiung Med Univ, Grad Inst Clin Med, Coll Med, Kaohsiung 807, Taiwan; [Tsai, Hung-Pei] Kaohsiung Med Univ Hosp, Div Neurosurg, Dept Surg, Kaohsiung 807, Taiwan; [Kuo, Po-Lin] Kaohsiung Med Univ, Ctr Canc Res, Kaohsiung 807, Taiwan; [Kuo, Po-Lin] Natl Sun Yat Sen Univ, Inst Med Sci & Technol, Kaohsiung 804, Taiwan	Kaohsiung Medical University; E-Da Hospital; I Shou University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; National Sun Yat Sen University	Kuo, PL (corresponding author), Kaohsiung Med Univ, Grad Inst Clin Med, Coll Med, Kaohsiung 807, Taiwan.; Kuo, PL (corresponding author), Kaohsiung Med Univ, Ctr Canc Res, Kaohsiung 807, Taiwan.; Kuo, PL (corresponding author), Natl Sun Yat Sen Univ, Inst Med Sci & Technol, Kaohsiung 804, Taiwan.	kuopolin@seed.net.tw			Ministry of Science and Technology [MOST 107-2320-B-037-011-MY3, MOST 104-2314-B-037-053-MY4]; Kaohsiung Medical University Hospital [KMUHS10701, KMUHS10712]; Kaohsiung Medical University [KMU-DK108003, KMU-DK108008, KMU-TC108A04]; E-DA Cancer Hospital Research Foundation [EDCHI107001]	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Kaohsiung Medical University Hospital; Kaohsiung Medical University; E-DA Cancer Hospital Research Foundation	The authors gratefully acknowledge the support of research grants from the Ministry of Science and Technology (MOST 107-2320-B-037-011-MY3; MOST 104-2314-B-037-053-MY4), the Kaohsiung Medical University Hospital (KMUHS10701; KMUHS10712), the Kaohsiung Medical University (KMU-DK108003; KMU-DK108008; KMU-TC108A04), and the E-DA Cancer Hospital Research Foundation (EDCHI107001). The authors thank the Center for Research Resources and Development of Kaohsiung Medical University.	Adler BJ, 2014, NAT REV ENDOCRINOL, V10, P737, DOI 10.1038/nrendo.2014.169; Barbazan J, 2017, CANCER RES, V77, P3431, DOI 10.1158/0008-5472.CAN-16-1917; Bian EB, 2014, TOXICOL LETT, V224, P175, DOI 10.1016/j.toxlet.2013.10.038; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brodt P, 2016, CLIN CANCER RES, V22, P5971, DOI 10.1158/1078-0432.CCR-16-0460; Burnier JV, 2011, ONCOGENE, V30, P3766, DOI 10.1038/onc.2011.89; Chang YP, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178676; Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169; Coulouarn C, 2008, HEPATOLOGY, V47, P2059, DOI 10.1002/hep.22283; Deng Z, 2017, ONCOGENE, V36, P639, DOI 10.1038/onc.2016.229; Dooley S, 2003, GASTROENTEROLOGY, V125, P178, DOI 10.1016/S0016-5085(03)00666-8; Engblom C, 2017, SCIENCE, V358, DOI 10.1126/science.aal5081; Fong MY, 2015, NAT CELL BIOL, V17, P183, DOI 10.1038/ncb3094; Grange C, 2011, CANCER RES, V71, P5346, DOI 10.1158/0008-5472.CAN-11-0241; Hara T, 2017, BIOCHEM BIOPH RES CO, V490, P688, DOI 10.1016/j.bbrc.2017.06.102; Hashimoto M, 2016, INT J CANCER, V139, P812, DOI 10.1002/ijc.30118; Houg DS, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0842-9; Huang AL, 2014, ASIAN PAC J CANCER P, V15, P8143, DOI 10.7314/APJCP.2014.15.19.8143; Jiang T, 2017, CLIN LUNG CANCER, V18, P631, DOI 10.1016/j.cllc.2017.04.015; Kang NL, 2011, HEPATOLOGY, V54, P707, DOI 10.1002/hep.24384; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Kim KW, 2017, CANCER RES TREAT, V49, P1, DOI 10.4143/crt.2016.606; Lin LY, 2016, ONCOGENE, V35, P6038, DOI 10.1038/onc.2016.131; Liu YF, 2016, CANCER CELL, V30, P243, DOI 10.1016/j.ccell.2016.06.021; Liu Y, 2016, CANCER CELL, V30, P668, DOI 10.1016/j.ccell.2016.09.011; Mederacke I, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3823; Nielsen SR, 2016, NAT CELL BIOL, V18, P549, DOI 10.1038/ncb3340; Peinado H, 2017, NAT REV CANCER, V17, P302, DOI 10.1038/nrc.2017.6; Rana S, 2013, NEOPLASIA, V15, P281, DOI 10.1593/neo.122010; Redig AJ, 2013, J INTERN MED, V274, P113, DOI 10.1111/joim.12084; Ren YJ, 2016, ONCOTARGET, V7, P53245, DOI 10.18632/oncotarget.10644; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Taylor D, 2011, J IMMUNOL, V186, P5956, DOI 10.4049/jimmunol.1003558; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Tsao AS, 2016, J THORAC ONCOL, V11, P613, DOI 10.1016/j.jtho.2016.03.012; Tsuchida T, 2017, NAT REV GASTRO HEPAT, V14, P397, DOI 10.1038/nrgastro.2017.38; Xu R, 2018, NAT REV CLIN ONCOL, V15, P617, DOI 10.1038/s41571-018-0036-9; Xu WW, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14399; Zhang L, 2015, NATURE, V527, P100, DOI 10.1038/nature15376	39	22	23	2	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	4					739	753		10.1038/s41388-019-1024-y	http://dx.doi.org/10.1038/s41388-019-1024-y			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KQ3JF	31558801				2022-12-28	WOS:000516822100001
J	Nicolai, S; Mahen, R; Raschella, G; Marini, A; Pieraccioli, M; Malewicz, M; Venkitaraman, AR; Melino, G				Nicolai, Sara; Mahen, Robert; Raschella, Giuseppe; Marini, Alberto; Pieraccioli, Marco; Malewicz, Michal; Venkitaraman, Ashok R.; Melino, Gerry			ZNF281 is recruited on DNA breaks to facilitate DNA repair by non-homologous end joining	ONCOGENE			English	Article							DOUBLE-STRAND BREAKS; DAMAGE RESPONSE; HOMOLOGOUS-RECOMBINATION; ATM; PLURIPOTENCY; KU	Efficient repair of DNA double-strand breaks (DSBs) is of critical importance for cell survival. Although non-homologous end joining (NHEJ) is the most used DSBs repair pathway in the cells, how NHEJ factors are sequentially recruited to damaged chromatin remains unclear. Here, we identify a novel role for the zinc-finger protein ZNF281 in participating in the ordered recruitment of the NHEJ repair factor XRCC4 at damage sites. ZNF281 is recruited to DNA lesions within seconds after DNA damage through a mechanism dependent on its DNA binding domain and, at least in part, on poly-ADP ribose polymerase (PARP) activity. ZNF281 binds XRCC4 through its zinc-finger domain and facilitates its recruitment to damaged sites. Consequently, depletion of ZNF281 impairs the efficiency of the NHEJ repair pathway and decreases cell viability upon DNA damage. Survival analyses from datasets of commonly occurring human cancers show that higher levels of ZNF281 correlate with poor prognosis of patients treated with DNA-damaging therapies. Thus, our results define a late ZNF281-dependent regulatory step of NHEJ complex assembly at DNA lesions and suggest additional possibilities for cancer patients' stratification and for the development of personalised therapeutic strategies.	[Nicolai, Sara; Marini, Alberto; Malewicz, Michal; Melino, Gerry] Univ Cambridge, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England; [Mahen, Robert; Venkitaraman, Ashok R.] Univ Cambridge, MRC, Canc Unit, Cambridge CB2 0XZ, England; [Raschella, Giuseppe] ENEA, Lab Biosafety & Risk Assessment, I-00123 Rome, Italy; [Pieraccioli, Marco; Melino, Gerry] Univ Roma Tor Vergata, Dept Expt Med, I-00133 Rome, Italy	University of Cambridge; University of Leicester; University of Cambridge; Italian National Agency New Technical Energy & Sustainable Economics Development; University of Rome Tor Vergata	Melino, G (corresponding author), Univ Cambridge, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England.	gm614@mrc-tox.cam.ac.uk	Marini, Alberto/AIA-5808-2022; Marini, Alberto/AAA-7802-2022; Pieraccioli, Marco/K-4294-2018	Marini, Alberto/0000-0001-7222-9056; Pieraccioli, Marco/0000-0003-3995-535X; Mahen, Robert/0000-0002-4748-3690; Nicolai, Sara/0000-0001-8776-1440; MELINO, GERRY/0000-0001-9428-5972	Medical Research Council, UK; Associazione Italiana per la Ricerca contro il Cancro (AIRC) [20473]; EMBO Fellowship [ASTF 572-2015]; Wellcome Trust Henry Wellcome Fellowship [100090/12/Z]; MRC [MC_UU_12022/1, MC_UU_00025/2, MC_U132670600] Funding Source: UKRI	Medical Research Council, UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Associazione Italiana per la Ricerca contro il Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); EMBO Fellowship(European Molecular Biology Organization (EMBO)); Wellcome Trust Henry Wellcome Fellowship; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We wish to thank D.J. Read for his expert assistance in confocal microscopy and G. Legube and M. Bushell for providing the DIvA and the NHEJ and HR reporter cell lines, respectively. This work was supported by the Medical Research Council, UK; grants from Associazione Italiana per la Ricerca contro il Cancro (AIRC) to GM IG#20473 (2018-2022). SN was supported by an EMBO Fellowship (ASTF 572-2015). RM was supported by a Wellcome Trust Henry Wellcome Fellowship (grant number 100090/12/Z).	Aymard F, 2014, NAT STRUCT MOL BIOL, V21, P366, DOI 10.1038/nsmb.2796; Ayoub N, 2008, NATURE, V453, P682, DOI 10.1038/nature06875; Begg AC, 2011, NAT REV CANCER, V11, P239, DOI 10.1038/nrc3007; Berkovich E, 2008, NAT PROTOC, V3, P915, DOI 10.1038/nprot.2008.54; Berkovich E, 2007, NAT CELL BIOL, V9, P683, DOI 10.1038/ncb1599; Britton S, 2013, J CELL BIOL, V202, P579, DOI 10.1083/jcb.201303073; Chapman JR, 2012, MOL CELL, V47, P497, DOI 10.1016/j.molcel.2012.07.029; Chen G, 2018, NUCLEIC ACIDS RES, V46, P1266, DOI 10.1093/nar/gkx1258; Chou DM, 2010, P NATL ACAD SCI USA, V107, P18475, DOI 10.1073/pnas.1012946107; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Cohen S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02894-w; Craxton A, 2015, CELL DEATH DIFFER, V22, P890, DOI 10.1038/cdd.2015.22; Fidalgo M, 2016, CELL STEM CELL, V19, P355, DOI 10.1016/j.stem.2016.05.025; Fidalgo M, 2012, P NATL ACAD SCI USA, V109, P16202, DOI 10.1073/pnas.1208533109; Fidalgo M, 2011, STEM CELLS, V29, P1705, DOI 10.1002/stem.736; Goldstein M, 2015, ANNU REV MED, V66, P129, DOI 10.1146/annurev-med-081313-121208; Goldstein M, 2013, P NATL ACAD SCI USA, V110, P16874, DOI 10.1073/pnas.1306160110; Hahn S, 2013, EMBO J, V32, P3079, DOI 10.1038/emboj.2013.236; Izhar L, 2015, CELL REP, V11, P1486, DOI 10.1016/j.celrep.2015.04.053; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Jungmichel S, 2013, MOL CELL, V52, P272, DOI 10.1016/j.molcel.2013.08.026; Law DJ, 1999, BIOCHEM BIOPH RES CO, V262, P113, DOI 10.1006/bbrc.1999.1180; Liu C, 2017, NUCLEIC ACIDS RES, V45, P8129, DOI 10.1093/nar/gkx565; Lord CJ, 2012, NATURE, V481, P287, DOI 10.1038/nature10760; Lukas J, 2011, NAT CELL BIOL, V13, P1161, DOI 10.1038/ncb2344; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Miller KM, 2010, NAT STRUCT MOL BIOL, V17, P1144, DOI 10.1038/nsmb.1899; Nowsheen S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05161-0; O'Connor MJ, 2015, MOL CELL, V60, P547, DOI 10.1016/j.molcel.2015.10.040; Ochi T, 2015, SCIENCE, V347, P185, DOI 10.1126/science.1261971; Pieraccioli M, 2016, ONCOGENE, V35, P2592, DOI 10.1038/onc.2015.320; Pieraccioli M, 2018, P NATL ACAD SCI USA, V115, P7356, DOI 10.1073/pnas.1801435115; Raschell G, 2017, ONCOGENE, V36, P4673, DOI 10.1038/onc.2017.60; Srivastava M, 2015, CHEM BIOL, V22, P17, DOI 10.1016/j.chembiol.2014.11.013; Wang JL, 2006, NATURE, V444, P364, DOI 10.1038/nature05284; Wei HT, 2016, GENOM PROTEOM BIOINF, V14, P131, DOI 10.1016/j.gpb.2016.05.001; Xiao X, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06771-4; Ziv Y, 2006, NAT CELL BIOL, V8, P870, DOI 10.1038/ncb1446	38	16	16	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	4					754	766		10.1038/s41388-019-1028-7	http://dx.doi.org/10.1038/s41388-019-1028-7			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KF4EJ	31570788	Green Published, hybrid			2022-12-28	WOS:000509197200002
J	Shin, SB; Jang, HR; Xu, R; Won, JY; Yim, H				Shin, Sol-Bi; Jang, Hay-Ran; Xu, Rong; Won, Jae-Yeon; Yim, Hyungshin			Active PLK1-driven metastasis is amplified by TGF-beta signaling that forms a positive feedback loop in non-small cell lung cancer	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; POLO-LIKE KINASES; PLK1; EXPRESSION; CARCINOMA; MIGRATION; INVASION; TSG-6; PHOSPHORYLATION; SURVIVAL	Early findings that PLK1 is highly expressed in cancer have driven an exploration of its functions in metastasis. However, whether PLK1 induces metastasis in vivo and its underlying mechanisms in NSCLC have not yet been determined. Here, we show that the expression of active PLK1 phosphorylated at T210, abundant in TGF-beta-treated lung cells, potently induced metastasis in a tail-vein injection model. Active PLK1 with intact polo-box and ATP-binding domains accelerated cell motility and invasiveness by triggering EMT reprogramming, whereas a phosphomimetic version of p-S137-PLK1 did not, indicating that the phosphorylation status of PLK1 may determine the cell traits. Active PLK1-driven invasiveness upregulated TGF-beta signaling and TSG6 encoded by TNFAIP6. Loss of TNFAIP6 disturbed the metastatic activity induced by active PLK1 or TGF-beta. Clinical relevance shows that PLK1 and TNFAIP6 are strong predictors of poor survival rates in metastatic NSCLC patients. Therefore, we suggest that active PLK1 promotes metastasis by upregulating TGF-beta signaling, which amplifies its metastatic properties by forming a positive feedback loop and that the PLK1/TGF-beta-driven metastasis is effectively blocked by targeting PLK1 and TSG6, providing PLK1 and TSG6 as negative markers for prognostics and therapeutic targets in metastatic NSCLC.	[Shin, Sol-Bi; Jang, Hay-Ran; Xu, Rong; Won, Jae-Yeon; Yim, Hyungshin] Hanyang Univ, Coll Pharm, Inst Pharmaceut Sci & Technol, Dept Pharm, Ansan, Gyeonggi Do, South Korea	Hanyang University	Yim, H (corresponding author), Hanyang Univ, Coll Pharm, Inst Pharmaceut Sci & Technol, Dept Pharm, Ansan, Gyeonggi Do, South Korea.	hsyim@hanyang.ac.kr			National Research Foundation of Korea (NRF) - Ministry of Science and ICT [NRF- 2014R1A2A1A11049701, NRF-2017R1A2B2012301]	National Research Foundation of Korea (NRF) - Ministry of Science and ICT	We thank Dr. Raymond L. Erikson (Harvard University, MA, USA) for his generous support for experimental materials. We also thank Dr. Jadranka Loncarek (National Cancer Institute, MD, USA) and Dr. Young-Joo Jang (Dankook University, Korea) for help with plasmid pLVX-TRE3G-RFP-PLK1-T210D and pCMV-PLK1-S137D, respectively. We appreciate the helpful discussions about the manuscript by Dr. Chang K. Sung (Texas A&M University, USA) and the technical support by Dr. Gyeoung-Jin Kang (Dongguk University, Korea) for big data analysis. This work was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT (NRF- 2014R1A2A1A11049701, NRF-2017R1A2B2012301) to H. Y.	Acharya PS, 2008, J CELL SCI, V121, P1393, DOI 10.1242/jcs.021683; Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005; Ali A, 2013, CURR ONCOL, V20, pE300, DOI 10.3747/co.20.1481; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Bednarz-Knoll N, 2012, CANCER METAST REV, V31, P673, DOI 10.1007/s10555-012-9370-z; Bommaya G, 2011, INT J BIOCHEM CELL B, V43, P1739, DOI 10.1016/j.biocel.2011.08.009; Cai XP, 2016, AM J TRANSL RES, V8, P4172; Chen QY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108528; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fransvea E, 2008, HEPATOLOGY, V47, P1557, DOI 10.1002/hep.22201; Gordian Edna, 2019, Oncotarget, V10, P810, DOI 10.18632/oncotarget.26574; Grosse-Wilde A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126522; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Han DP, 2012, MED SCI MONITOR, V18, pBR237, DOI 10.12659/MSM.882900; Jang YJ, 2002, J BIOL CHEM, V277, P44115, DOI 10.1074/jbc.M202172200; Jang YJ, 2002, P NATL ACAD SCI USA, V99, P1984, DOI 10.1073/pnas.042689299; Kong D, 2014, J CELL BIOL, V206, P855, DOI 10.1083/jcb.201407087; Kothe M, 2007, CHEM BIOL DRUG DES, V70, P540, DOI 10.1111/j.1747-0285.2007.00594.x; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Larsen JE, 2011, CLIN CHEST MED, V32, P703, DOI 10.1016/j.ccm.2011.08.003; LEE TH, 1992, J CELL BIOL, V116, P545, DOI 10.1083/jcb.116.2.545; Liu XQ, 2006, MOL CELL BIOL, V26, P2093, DOI 10.1128/MCB.26.6.2093-2108.2006; Maier R, 1996, ARTHRITIS RHEUM, V39, P552, DOI 10.1002/art.1780390403; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Milner CM, 2003, J CELL SCI, V116, P1863, DOI 10.1242/jcs.00407; Mittal M, 2016, P NATL ACAD SCI USA, V113, pE8151, DOI 10.1073/pnas.1614935113; Pickup M, 2013, NAT REV CANCER, V13, P788, DOI 10.1038/nrc3603; Rizki A, 2007, CANCER RES, V67, P11106, DOI 10.1158/0008-5472.CAN-07-2348; Sancisi V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075489; Steeg PS, 2016, NAT REV CANCER, V16, P201, DOI 10.1038/nrc.2016.25; Su J, 2016, MOL CARCINOGEN, V55, P1962, DOI 10.1002/mc.22443; Takai N, 2005, ONCOGENE, V24, P287, DOI 10.1038/sj.onc.1208272; Tamura T, 2015, MOL CLIN ONCOL, V3, P217, DOI 10.3892/mco.2014.410; Tsvetkov L, 2005, CELL CYCLE, V4, P166, DOI 10.4161/cc.4.1.1348; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Wu JG, 2016, ELIFE, V5, DOI 10.7554/eLife.10734; Yim H, 2014, MUTAT RES-REV MUTAT, V761, P31, DOI 10.1016/j.mrrev.2014.02.005; Yim HS, 2009, MOL CELL BIOL, V29, P2609, DOI 10.1128/MCB.01277-08; Yoo HY, 2004, CELL, V117, P575, DOI 10.1016/S0092-8674(04)00417-9; Zhang Z, 2013, UROL ONCOL-SEMIN ORI, V31, P1222, DOI 10.1016/j.urolonc.2011.11.028; Zheng H, 2014, ONCOGENE, V33, P1755, DOI 10.1038/onc.2013.128	42	38	39	3	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	4					767	785		10.1038/s41388-019-1023-z	http://dx.doi.org/10.1038/s41388-019-1023-z			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KF4EJ	31548612	Green Published, hybrid			2022-12-28	WOS:000509197200003
J	Reischmann, N; Andrieux, G; Griffin, R; Reinheckel, T; Boerries, M; Brummer, T				Reischmann, Nadine; Andrieux, Geoffroy; Griffin, Ricarda; Reinheckel, Thomas; Boerries, Melanie; Brummer, Tilman			BRAF(V600E) drives dedifferentiation in small intestinal and colonic organoids and cooperates with mutant p53 and Apc loss in transformation	ONCOGENE			English	Article							COLORECTAL-CANCER; STEM-CELLS; MOLECULAR SUBTYPES; ECTOPIC EXPRESSION; BRAF MUTATION; MOUSE MODELS; GENE; DIFFERENTIATION; PROGRESSION; CAVEOLIN-1	BRAF(V600E)confers poor prognosis and is associated with a distinct subtype of colorectal cancer (CRC). Little is known, however, about the genetic events driving the initiation and progression of BRAF(V600E)mutant CRCs. Recent genetic analyses of CRCs indicate that BRAF(V600E)often coexists with alterations in the WNT- and p53 pathways, but their cooperation remains ill-defined. Therefore, we systematically compared small and large intestinal organoids from mice harboring conditionalBraf(floxV600E),Trp53(LSL-R172H), and/orApc(flox/flox)alleles. Using these isogenic models, we observe tissue-specific differences toward sudden BRAF(V600E)expression, which can be attributed to different ERK-pathway ground states in small and large intestinal crypts. BRAF(V600E)alone causes transient proliferation and suppresses epithelial organization, followed by organoid disintegration. Moreover, BRAF(V600E)induces a fetal-like dedifferentiation transcriptional program in colonic organoids, which resembles human BRAF(V600E)-driven CRC. Co-expression of p53(R172H)delays organoid disintegration, confers anchorage-independent growth, and induces invasive properties. Interestingly, p53(R172H)cooperates with BRAF(V600E)to modulate the abundance of transcripts linked to carcinogenesis, in particular within colonic organoids. Remarkably, WNT-pathway activation byApcdeletion fully protects organoids against BRAF(V600E)-induced disintegration and confers growth/niche factor independence. Still,Apc-deficient BRAF(V600E)-mutant organoids remain sensitive toward the MEK inhibitor trametinib, albeit p53(R172H)confers partial resistance against this clinically relevant compound. In summary, our systematic comparison of the response of small and large intestinal organoids to oncogenic alterations suggests colonic organoids to be better suited to model the human situation. In addition, our work on BRAF-, p53-, and WNT-pathway mutations provides new insights into their cooperation and for the design of targeted therapies.	[Reischmann, Nadine; Griffin, Ricarda; Reinheckel, Thomas; Brummer, Tilman] Univ Freiburg, Inst Mol Med & Cell Res IMMZ, Freiburg, Germany; [Reischmann, Nadine] Univ Freiburg, Spemann Grad Sch Biol & Med SGBM, Freiburg, Germany; [Reischmann, Nadine] Univ Freiburg, Fac Biol, Freiburg, Germany; [Andrieux, Geoffroy; Boerries, Melanie] Univ Freiburg, Med Ctr, Inst Med Bioinformat & Syst Med, Freiburg, Germany; [Andrieux, Geoffroy; Reinheckel, Thomas; Boerries, Melanie; Brummer, Tilman] German Canc Consortium DKTK, Partner Site Freiburg, Heidelberg, Germany; [Andrieux, Geoffroy; Reinheckel, Thomas; Boerries, Melanie; Brummer, Tilman] German Canc Res Ctr, Heidelberg, Germany; [Reinheckel, Thomas; Boerries, Melanie; Brummer, Tilman] Univ Freiburg, Univ Med Ctr Freiburg, Comprehens Canc Ctr Freiburg CCCF, Freiburg, Germany; [Reinheckel, Thomas; Brummer, Tilman] Univ Freiburg, Ctr Biol Signalling Studies BIOSS, Freiburg, Germany	University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); University of Freiburg; University of Freiburg	Brummer, T (corresponding author), Univ Freiburg, Inst Mol Med & Cell Res IMMZ, Freiburg, Germany.; Brummer, T (corresponding author), German Canc Consortium DKTK, Partner Site Freiburg, Heidelberg, Germany.; Brummer, T (corresponding author), German Canc Res Ctr, Heidelberg, Germany.; Brummer, T (corresponding author), Univ Freiburg, Univ Med Ctr Freiburg, Comprehens Canc Ctr Freiburg CCCF, Freiburg, Germany.; Brummer, T (corresponding author), Univ Freiburg, Ctr Biol Signalling Studies BIOSS, Freiburg, Germany.	tilman.brummer@mol-med.uni-freiburg.de	Brummer, Tilman/B-6218-2016; Boerries, Melanie/AAM-2602-2021; Reinheckel, Thomas/AAL-9761-2021; Brummer, Tilman/AAA-9428-2020	Brummer, Tilman/0000-0003-4387-7905; Reinheckel, Thomas/0000-0001-9866-9105; Brummer, Tilman/0000-0003-4387-7905; Griffin, Ricarda/0000-0003-1368-2832; ANDRIEUX, GEOFFROY/0000-0002-5389-9481	German Research Foundation (DFG) [SFB 850, BR 3662/5-1, EXC 294 BIOSS]; German Cancer Consortium DKTK [L627]; DFG [GSC-4]; German Federal Ministry of Education and Research (BMBF) [FKZ 01ZX1708F]; MIRACUM within the Medical Informatics Funding Scheme [FKZ 01ZZ1801B]; Projekt DEAL	German Research Foundation (DFG)(German Research Foundation (DFG)); German Cancer Consortium DKTK; DFG(German Research Foundation (DFG)); German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); MIRACUM within the Medical Informatics Funding Scheme; Projekt DEAL	We thank the Genomics and Proteomics Core Facility team, German Cancer Research Center/DKFZ, for its sequencing service. This work was supported by the German Research Foundation (DFG) through SFB 850, projects B4 (TB), B7 (TR), and Z1 (MB), a Heisenberg professorship to TB (BR 3662/5-1) and EXC 294 BIOSS, and the German Cancer Consortium DKTK (L627 to TR, MB, and TB). NR was supported in part by the DFG funded SGBM (GSC-4). MB is supported by the German Federal Ministry of Education and Research (BMBF) within the framework of the e:Med research and funding concept to CoNfirm (FKZ 01ZX1708F) and by MIRACUM within the Medical Informatics Funding Scheme (FKZ 01ZZ1801B). Open access funding provided by Projekt DEAL.	Aguirre-Portoles C, 2018, MOL ONCOL, V12, P1735, DOI 10.1002/1878-0261.12367; Bender FC, 2000, CANCER RES, V60, P5870; Bond CE, 2018, GASTROENT RES PRACT, V2018, DOI 10.1155/2018/9250757; Bond CE, 2018, EPIGENETICS-US, V13, P40, DOI 10.1080/15592294.2017.1411446; Boudreau F, 2002, J BIOL CHEM, V277, P31909, DOI 10.1074/jbc.M204622200; Brandt R, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10954-y; Campos A, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9080314; Carragher LAS, 2010, EMBO MOL MED, V2, P458, DOI 10.1002/emmm.201000099; Caruso M, 2009, VIRCHOWS ARCH, V454, P291, DOI 10.1007/s00428-009-0731-0; Chanvorachote P, 2015, MOL CELL BIOCHEM, V399, P291, DOI 10.1007/s11010-014-2255-4; Clarke CN, 2015, J GASTROINTEST ONCOL, V6, P660, DOI 10.3978/j.issn.2078-6891.2015.077; Dankort D, 2007, GENE DEV, V21, P379, DOI 10.1101/gad.1516407; Datta J, 2020, CLIN CANCER RES, V26, P1077, DOI 10.1158/1078-0432.CCR-19-2390; Dawson H, 2014, INT J CANCER, V134, P2342, DOI 10.1002/ijc.28564; Melo FDE, 2017, NATURE, V543, P676, DOI 10.1038/nature21713; Delker DA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088367; Dienstmann R, 2017, NAT REV CANCER, V17, P79, DOI 10.1038/nrc.2016.126; Dorard C, 2017, BIOCHEM SOC T, V45, P27, DOI 10.1042/BST20160135; Dow LE, 2015, CELL, V161, P1539, DOI 10.1016/j.cell.2015.05.033; DUDA P, 2020, CELLS-BASEL, V9, DOI DOI 10.3390/CELLS9051110; Dunne PD, 2016, CLIN CANCER RES, V22, P230, DOI 10.1158/1078-0432.CCR-15-0603; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fennell LJ, 2020, CANCERS, V12, DOI 10.3390/cancers12051171; Gillies TE, 2017, CELL SYST, V5, P549, DOI 10.1016/j.cels.2017.10.019; Halim H, 2012, CELL BIOL INT, V36, P1055, DOI 10.1042/CBI20120111; Han T, 2020, CANCER DISCOV, V10, P1590, DOI 10.1158/2159-8290.CD-19-1536; Hashimoto T, 2019, AM J SURG PATHOL, V43, P132, DOI 10.1097/PAS.0000000000001149; Herr R, 2018, ONCOGENE, V37, P1576, DOI 10.1038/s41388-017-0063-5; Herr R, 2015, MOL CELL ONCOL, V2, DOI 10.1080/23723556.2014.1002709; Herr R, 2015, CANCER RES, V75, P216, DOI 10.1158/0008-5472.CAN-13-3686; Ireton RC, 2005, CURR CANCER DRUG TAR, V5, P149, DOI 10.2174/1568009053765780; Jackstadt R, 2016, J PATHOL, V238, P141, DOI 10.1002/path.4645; Kane AM, 2020, NEOPLASIA, V22, P120, DOI 10.1016/j.neo.2019.12.002; Kastenhuber ER, 2017, CELL, V170, P1062, DOI 10.1016/j.cell.2017.08.028; Kawasaki K, 2020, GASTROENTEROLOGY, V158, P638, DOI 10.1053/j.gastro.2019.10.009; Kawazoe T, 2019, CANCER SCI, V110, P1525, DOI 10.1111/cas.13999; Khanal T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11106-2; Kidger AM, 2016, SEMIN CELL DEV BIOL, V50, P125, DOI 10.1016/j.semcdb.2016.01.009; Kitowska A, 2015, J SURG ONCOL, V112, P408, DOI 10.1002/jso.23995; Laforest A, 2014, EUR J CANCER, V50, P1740, DOI 10.1016/j.ejca.2014.04.007; Lannagan TRM, 2019, GUT, V68, P684, DOI 10.1136/gutjnl-2017-315920; Lavoie H, 2018, NATURE, V554, P549, DOI 10.1038/nature25478; Li S, 2019, J CELL PHYSIOL, V234, P3730, DOI 10.1002/jcp.27149; Liu QZ, 2015, INT J CLIN EXP PATHO, V8, P12802; Macrae M, 2005, CANCER CELL, V8, P111, DOI 10.1016/j.ccr.2005.07.005; Matsuda M, 2010, PATHOL INT, V60, P673, DOI 10.1111/j.1440-1827.2010.02587.x; Merlos-Suarez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020; Mi L, 2017, ONCOGENE, V36, P4323, DOI 10.1038/onc.2017.74; Morkel M, 2015, ONCOTARGET, V6, P20785, DOI 10.18632/oncotarget.4750; Munoz J, 2012, EMBO J, V31, P3079, DOI 10.1038/emboj.2012.166; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Mustata RC, 2013, CELL REP, V5, P421, DOI 10.1016/j.celrep.2013.09.005; Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Paoli P, 2013, BBA-MOL CELL RES, V1833, P3481, DOI 10.1016/j.bbamcr.2013.06.026; Park YY, 2012, EMBO MOL MED, V4, P52, DOI 10.1002/emmm.201100187; Phipps AI, 2015, GASTROENTEROLOGY, V148, P77, DOI 10.1053/j.gastro.2014.09.038; Popovici V, 2012, J CLIN ONCOL, V30, P1288, DOI 10.1200/JCO.2011.39.5814; Rad R, 2013, CANCER CELL, V24, P15, DOI 10.1016/j.ccr.2013.05.014; Rademaker G, 2019, ONCOGENESIS, V8, DOI 10.1038/s41389-019-0130-6; Riemer P, 2015, ONCOGENE, V34, P3164, DOI 10.1038/onc.2014.247; Riemer P, 2017, J CELL BIOL, V216, P1567, DOI 10.1083/jcb.201610058; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; Sakamoto N, 2017, ELIFE, V6, DOI 10.7554/eLife.20331; Sato Toshiro, 2013, Methods Mol Biol, V945, P319, DOI 10.1007/978-1-62703-125-7_19; Sekine S, 2020, J GASTROENTEROL, V55, P418, DOI 10.1007/s00535-020-01673-z; Sentani K, 2013, HISTOPATHOLOGY, V62, P1018, DOI 10.1111/his.12099; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Silberg DG, 2002, GASTROENTEROLOGY, V122, P689, DOI 10.1053/gast.2002.31902; Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052; Sundar R, 2017, CANCER DISCOV, V7, P558, DOI 10.1158/2159-8290.CD-17-0087; Tan BS, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.191; Tao Y, 2019, CANCER CELL, V35, P315, DOI 10.1016/j.ccell.2019.01.005; Tong K, 2017, CELL REP, V21, P3833, DOI 10.1016/j.celrep.2017.11.104; Torrejon B, 2017, WORLD J SURG, V41, P2625, DOI 10.1007/s00268-017-4065-9; Verzi MP, 2011, MOL CELL BIOL, V31, P2026, DOI 10.1128/MCB.01250-10; Wang DY, 2019, DIGEST DIS, V37, P214, DOI 10.1159/000494454; Wang YM, 2018, CELL REP, V25, P1304, DOI 10.1016/j.celrep.2018.10.001; Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009; Yang G, 1998, CLIN CANCER RES, V4, P1873; Yui SR, 2012, NAT MED, V18, P618, DOI 10.1038/nm.2695; Zhou X, 2019, J MOL CELL BIOL, V11, P293, DOI 10.1093/jmcb/mjy072	83	8	8	5	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2020	39	38					6053	6070		10.1038/s41388-020-01414-9	http://dx.doi.org/10.1038/s41388-020-01414-9		AUG 2020	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NQ9JF	32792685	Green Published, hybrid			2022-12-28	WOS:000559422800001
J	Totani, H; Shinjo, K; Suzuki, M; Katsushima, K; Mase, S; Masaki, A; Ito, A; Ri, M; Kusumoto, S; Komatsu, H; Ishida, T; Inagaki, H; Iida, S; Kondo, Y				Totani, Haruhito; Shinjo, Keiko; Suzuki, Miho; Katsushima, Keisuke; Mase, Shoko; Masaki, Ayako; Ito, Asahi; Ri, Masaki; Kusumoto, Shigeru; Komatsu, Hirokazu; Ishida, Takashi; Inagaki, Hiroshi; Iida, Shinsuke; Kondo, Yutaka			Autocrine HGF/c-Met signaling pathway confers aggressiveness in lymph node adult T-cell leukemia/lymphoma	ONCOGENE			English	Article							LEUKEMIA-LYMPHOMA; EXPRESSION; GROWTH; LINE; IDENTIFICATION; MOGAMULIZUMAB; INVOLVEMENT; TAX	Adult T-cell leukemia/lymphoma (ATL) is an aggressive T-cell neoplasm. While ATL cells in peripheral blood (PB-ATL) are sensitive to anti-CC chemokine receptor 4 treatment, non-PB-ATLs, including lymph node ATLs (LN-ATLs), are more aggressive and resistant. We examined characteristic cytokines and growth factors that allow non-PB-ATLs to proliferate and invade compared with PB-ATLs. Protein array analysis revealed hepatocyte growth factor (HGF) and C-C motif chemokine 2 (CCL2) were significantly upregulated in non-PB-ATLs compared with PB-ATLs. The HGF membrane receptor, c-Met, was expressed in PB-ATL and non-PB-ATL cell lines, but CCR2, a CCL2 receptor, was not. Immunohistochemical analysis in clinical ATLs revealed high HGF expression in LNs, pharynx, bone marrow, and tonsils. The HGF/c-Met signaling pathway was active downstream in non-PB-ATLs. Downregulation of HGF/c-Met by siRNA or chemical inhibitors decreased in vitro and in vivo proliferation and invasion by non-PB-ATLs. Treatment with bromodomain and extra-terminal motif inhibitor suppressed HGF expression and decreased levels of histone H3 lysine 27 acetylation (H3K27Ac) and bromodomain-containing protein 4 (BRD4) binding promoter and enhancer regions, suppressing non-PB-ATL cellular growth. Our data indicate H3K27Ac/BRD4 epigenetics regulates the HGF/c-MET pathway in ATLs; targeting this pathway may improve treatment of aggressive non-PB-ATLs.	[Totani, Haruhito; Shinjo, Keiko; Suzuki, Miho; Katsushima, Keisuke; Mase, Shoko; Kondo, Yutaka] Nagoya Univ, Grad Sch Med, Div Canc Biol, Nagoya, Aichi, Japan; [Totani, Haruhito; Masaki, Ayako; Ito, Asahi; Ri, Masaki; Kusumoto, Shigeru; Komatsu, Hirokazu; Iida, Shinsuke] Nagoya City Univ, Grad Sch Med Sci, Dept Hematol & Oncol, Nagoya, Aichi, Japan; [Masaki, Ayako; Inagaki, Hiroshi] Nagoya City Univ, Grad Sch Med Sci, Dept Pathol & Mol Diagnost, Nagoya, Aichi, Japan; [Ri, Masaki] Nagoya City Univ Hosp, Dept Blood Transfus & Cell Therapy, Nagoya, Aichi, Japan; [Ishida, Takashi] Nagoya Univ, Grad Sch Med, Dept Immunol, Nagoya, Aichi, Japan	Nagoya University; Nagoya City University; Nagoya City University; Nagoya City University; Nagoya University	Kondo, Y (corresponding author), Nagoya Univ, Grad Sch Med, Div Canc Biol, Nagoya, Aichi, Japan.	ykondo@med.nagoya-u.ac.jp	katsushima, keisuke/AAD-5945-2019; 石田, 高司/GRS-3184-2022	katsushima, keisuke/0000-0001-7770-432X; 石田, 高司/0000-0002-1060-0777	Japan Society for the Promotion of Science [25290048, 19K16752]; National Cancer Center Research and Development Fund [29-A-3]	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); National Cancer Center Research and Development Fund(National Cancer Center - Japan)	This study was performed as research program with a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (25290048, YK; 19K16752, HT) and the National Cancer Center Research and Development Fund (29-A-3, SI).	Bonanno G, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-247; Choi YL, 2007, ONCOGENE, V26, P1245, DOI 10.1038/sj.onc.1209898; Ding XS, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0922-1; Fujikawa D, 2016, BLOOD, V127, P1790, DOI 10.1182/blood-2015-08-662593; Hartmann S, 2016, CLIN CANCER RES, V22, P4005, DOI 10.1158/1078-0432.CCR-16-0951; Hieshima K, 2008, J IMMUNOL, V180, P931, DOI 10.4049/jimmunol.180.2.931; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; Imaizumi Y, 2003, CLIN CANCER RES, V9, P181; Ishida T, 2017, CANCER SCI, V108, P2022, DOI 10.1111/cas.13343; Ishida T, 2015, BRIT J HAEMATOL, V169, P672, DOI 10.1111/bjh.13338; Ishida T, 2012, J CLIN ONCOL, V30, P837, DOI 10.1200/JCO.2011.37.3472; Kataoka K, 2015, NAT GENET, V47, P1304, DOI 10.1038/ng.3415; Katsuya H, 2015, BLOOD, V126, P2570, DOI 10.1182/blood-2015-03-632489; Kwon Y, 2015, ONCOGENE, V34, P144, DOI 10.1038/onc.2013.539; Masaki A, 2015, CLIN CANCER RES, V21, P2830, DOI 10.1158/1078-0432.CCR-14-2275; MIYOSHI I, 1980, GANN, V71, P155; Murashima A, 2019, J BIOCHEM, V166, P41, DOI 10.1093/jb/mvz007; Nakagawa M, 2018, CANCER CELL, V34, P286, DOI 10.1016/j.ccell.2018.06.014; NAOE T, 1988, CANCER GENET CYTOGEN, V34, P77, DOI 10.1016/0165-4608(88)90171-9; Oki S, 2018, EMBO REP, V19, DOI 10.15252/embr.201846255; Olsen EA, 2007, J CLIN ONCOL, V25, P3109, DOI 10.1200/JCO.2006.10.2434; Onimaru Y, 2008, INT J ONCOL, V33, P697, DOI 10.3892/ijo_00000055; Oshiro A, 2006, BLOOD, V107, P4500, DOI 10.1182/blood-2005-09-3801; Piekarz RL, 2011, BLOOD, V117, P5827, DOI 10.1182/blood-2010-10-312603; Piekarz RL, 2009, J CLIN ONCOL, V27, P5410, DOI 10.1200/JCO.2008.21.6150; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Rutella S, 2006, BLOOD, V108, P218, DOI 10.1182/blood-2005-08-3141; SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111/j.1365-2141.1991.tb08051.x; Skibinski G, 2001, EUR J CANCER, V37, P1562, DOI 10.1016/S0959-8049(01)00164-2; SUGAMURA K, 1984, INT J CANCER, V34, P221, DOI 10.1002/ijc.2910340213; Suzuki S, 2012, CANCER SCI, V103, P1764, DOI 10.1111/j.1349-7006.2012.02371.x; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; Umino A, 2011, BLOOD, V117, P5473, DOI 10.1182/blood-2010-12-327791; Xu CH, 2012, HAEMATOL-HEMATOL J, V97, P572, DOI 10.3324/haematol.2011.056101; Yamada Y, 1997, LEUKEMIA LYMPHOMA, V26, P327, DOI 10.3109/10428199709051782; Yamagishi M, 2019, CELL REP, V29, P2321, DOI 10.1016/j.celrep.2019.10.083; Yamagishi M, 2012, CANCER CELL, V21, P121, DOI 10.1016/j.ccr.2011.12.015; Yoshie O, 2002, BLOOD, V99, P1505, DOI 10.1182/blood.V99.5.1505	38	1	1	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2020	39	35					5782	5794		10.1038/s41388-020-01393-x	http://dx.doi.org/10.1038/s41388-020-01393-x		AUG 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NF2QB	32747750				2022-12-28	WOS:000555362200001
J	Braggio, D; Zewdu, A; Londhe, P; Yu, P; Lopez, G; Batte, K; Koller, D; de Faria, FCC; Casadei, L; Strohecker, AM; Lev, D; Pollock, RE				Braggio, Danielle; Zewdu, Abeba; Londhe, Priya; Yu, Peter; Lopez, Gonzalo; Batte, Kara; Koller, David; de Faria, Fernanda Costas Casal; Casadei, Lucia; Strohecker, Anne M.; Lev, Dina; Pollock, Raphael E.			beta-catenin S45F mutation results in apoptotic resistance	ONCOGENE			English	Article							GASTRIC-CANCER; TUMOR-SUPPRESSOR; BREAST-CANCER; DESMOID TUMOR; EXON 3; EXPRESSION; CTNNB1; RUNX3; ACTIVATION; GENE	Wnt/beta-catenin signaling is one of the key cascades regulating embryogenesis and tissue homeostasis; it has also been intimately associated with carcinogenesis. This pathway is deregulated in several tumors, including colorectal cancer, breast cancer, and desmoid tumors. It has been shown thatCTNNB1exon 3 mutations are associated with an aggressive phenotype in several of these tumor types and may be associated with therapeutic tolerance. Desmoid tumors typically have a stable genome with beta-catenin mutations as a main feature, making these tumors an ideal model to study the changes associated with different types of beta-catenin mutations. Here, we show that the apoptosis mechanism is deregulated in beta-catenin S45F mutants, resulting in decreased induction of apoptosis in these cells. Our findings also demonstrate thatRUNX3plays a pivotal role in the inhibition of apoptosis found in the beta-catenin S45F mutants. Restoration ofRUNX3overcomes this inhibition in the S45F mutants, highlighting it as a potential therapeutic target for malignancies harboring this specificCTNNB1mutation. While the regulatory effect of RUNX3 in beta-catenin is already known, our results suggest the possibility of a feedback loop involving these two genes, with theCTNNB1S45F mutation downregulating expression ofRUNX3, thus providing additional possible novel therapeutic targets for tumors having deregulated Wnt/beta-catenin signaling induced by this mutation.	[Braggio, Danielle; Zewdu, Abeba; Lopez, Gonzalo; Batte, Kara; Koller, David; de Faria, Fernanda Costas Casal; Casadei, Lucia; Pollock, Raphael E.] Ohio State Univ, James Comprehens Canc Ctr, Program Translat Therapeut, Columbus, OH 43210 USA; [Braggio, Danielle; Zewdu, Abeba; Lopez, Gonzalo; Batte, Kara; Koller, David; de Faria, Fernanda Costas Casal; Casadei, Lucia; Strohecker, Anne M.; Pollock, Raphael E.] Ohio State Univ, Dept Surg, Columbus, OH 43210 USA; [Londhe, Priya] Millipore Sigma, Burlington, MA 01803 USA; [Yu, Peter] Ohio State Univ, Med Student Res Program, Columbus, OH 43210 USA; [Strohecker, Anne M.] Ohio State Univ, James Comprehens Canc Ctr, Program Mol Biol & Canc Genet, Columbus, OH 43210 USA; [Strohecker, Anne M.] Ohio State Univ, Coll Med, Dept Canc Biol & Genet, Columbus, OH 43210 USA; [Lev, Dina] Sheba Med Ctr, Surg B, Tel Aviv, Israel; [Lev, Dina] Tel Aviv Univ, Tel Aviv, Israel	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Merck KGaA; MilliporeSigma; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Chaim Sheba Medical Center; Tel Aviv University	Braggio, D; Pollock, RE (corresponding author), Ohio State Univ, James Comprehens Canc Ctr, Program Translat Therapeut, Columbus, OH 43210 USA.; Braggio, D; Pollock, RE (corresponding author), Ohio State Univ, Dept Surg, Columbus, OH 43210 USA.	dabraggio@gmail.com; raphael.pollock@osumc.edu		CASADEI, Lucia/0000-0002-5731-8197	Desmoid Tumor Research Foundation Seed Grant; National Cancer Institute of the National Institutes of Health [U54CA168512, 1K22CA187931]; National Institutes of Health [P30 CA016058]	Desmoid Tumor Research Foundation Seed Grant; National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported in part by a Desmoid Tumor Research Foundation Seed Grant, and the following grants from the National Cancer Institute of the National Institutes of Health: U54CA168512 (REP), 1K22CA187931 (AMS) and a grant from the National Institutes of Health to The OSU Comprehensive Cancer Center (P30 CA016058).	Aitken SJ, 2015, VIRCHOWS ARCH, V467, P203, DOI 10.1007/s00428-015-1765-0; Bhattacharya B, 2005, AM J SURG PATHOL, V29, P653, DOI 10.1097/01.pas.0000157938.95785.da; Braggio D, 2019, CANCER-AM CANCER SOC, V125, P2693, DOI 10.1002/cncr.32120; Bui N, 2017, ONCOTARGET, V8, P90608, DOI 10.18632/oncotarget.21293; Chilov D, 2011, DEV BIOL, V357, P259, DOI 10.1016/j.ydbio.2011.06.029; Cieply B, 2009, HEPATOLOGY, V49, P821, DOI 10.1002/hep.22695; Colombo C, 2013, CANCER-AM CANCER SOC, V119, P3696, DOI 10.1002/cncr.28271; Crago AM, 2015, GENE CHROMOSOME CANC, V54, P606, DOI 10.1002/gcc.22272; Debatin KM, 2004, ONCOGENE, V23, P2950, DOI 10.1038/sj.onc.1207558; Fodde R, 2007, CURR OPIN CELL BIOL, V19, P150, DOI 10.1016/j.ceb.2007.02.007; Garcia-Rostan G, 2001, AM J PATHOL, V158, P987, DOI 10.1016/S0002-9440(10)64045-X; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Hamada S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096391; Ito K, 2005, CANCER RES, V65, P7743, DOI 10.1158/0008-5472.CAN-05-0743; Ito K, 2008, CANCER CELL, V14, P226, DOI 10.1016/j.ccr.2008.08.004; Iwao K, 1998, CANCER RES, V58, P1021; Jamora C, 2002, NAT CELL BIOL, V4, pE101, DOI 10.1038/ncb0402-e101; Ju XL, 2014, CANCER SCI, V105, P418, DOI 10.1111/cas.12356; Kasper B, 2016, ANN SURG ONCOL, V23, P1924, DOI 10.1245/s10434-016-5132-4; Kotiligam D, 2008, HISTOL HISTOPATHOL, V23, P117, DOI 10.14670/HH-23.117; Kurnit KC, 2017, MODERN PATHOL, V30, P1032, DOI 10.1038/modpathol.2017.15; Lau QC, 2006, CANCER RES, V66, P6512, DOI 10.1158/0008-5472.CAN-06-0369; Lazar AJF, 2008, AM J PATHOL, V173, P1518, DOI 10.2353/ajpath.2008.080475; Lecarpentier Y, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01248; Lento W, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008011; Leung JY, 2002, J BIOL CHEM, V277, P21657, DOI 10.1074/jbc.M200139200; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Liu YX, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju245; McCarty Mark F, 2004, Integr Cancer Ther, V3, P349, DOI 10.1177/1534735404270757; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Mullen JT, 2013, ONCOLOGIST, V18, P1043, DOI 10.1634/theoncologist.2012-0449; Nejak-Bowen KN, 2010, HEPATOLOGY, V51, P1603, DOI 10.1002/hep.23538; Nelson WJ, 2008, BIOCHEM SOC T, V36, P149, DOI 10.1042/BST0360149; Nishio M, 2010, ANTICANCER RES, V30, P2673; Polakis P, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008052; Rebouissou S, 2016, HEPATOLOGY, V64, P2047, DOI 10.1002/hep.28638; Salas S, 2010, GENE CHROMOSOME CANC, V49, P560, DOI 10.1002/gcc.20766; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sun JK, 2018, J NEURO-ONCOL, V140, P15, DOI 10.1007/s11060-018-2927-0; Tornesello ML, 2013, GENOMICS, V102, P74, DOI 10.1016/j.ygeno.2013.04.001; Wei DY, 2005, CANCER RES, V65, P4809, DOI 10.1158/0008-5472.CAN-04-3741; Xu JH, 2016, MOL CARCINOGEN, V55, P431, DOI 10.1002/mc.22292; Yamamura Y, 2005, RUNX3 COOPERATES FOX, DOI [10.1074/jbc.M512151200, DOI 10.1074/JBC.M512151200]; Zeng G, 2006, NEOPLASIA, V8, P279, DOI 10.1593/neo.05607; Zhu QS, 2008, CANCER RES, V68, P2895, DOI 10.1158/0008-5472.CAN-07-6268	45	9	9	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2020	39	34					5589	5600		10.1038/s41388-020-1382-5	http://dx.doi.org/10.1038/s41388-020-1382-5		JUL 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NE9FK	32651460	hybrid, Green Published			2022-12-28	WOS:000547254200001
J	Nollet, EA; Cardo-Vila, M; Ganguly, SS; Tran, JD; Schulz, VV; Cress, A; Corey, E; Miranti, CK				Nollet, Eric A.; Cardo-Vila, Marina; Ganguly, Sourik S.; Tran, Jack D.; Schulz, Veronique V.; Cress, Anne; Corey, Eva; Miranti, Cindy K.			Androgen receptor-induced integrin alpha 6 beta 1 and Bnip3 promote survival and resistance to PI3K inhibitors in castration-resistant prostate cancer	ONCOGENE			English	Article							PLASMINOGEN-ACTIVATOR; GROWTH-FACTOR; AUTOPHAGY; INDUCTION; TRANSCRIPTION; EXPRESSION; PROTEIN; MITOPHAGY; PATHWAYS; CLEAVAGE	The androgen receptor (AR) is the major driver of prostate cancer growth and survival. However, almost all patients relapse with castration-resistant disease (CRPC) when treated with anti-androgen therapy. In CRPC, AR is often aberrantly activated independent of androgen. Targeting survival pathways downstream of AR could be a viable strategy to overcome CRPC. Surprisingly, little is known about how AR drives prostate cancer survival. Furthermore, CRPC tumors in which Pten is lost are also resistant to eradication by PI3K inhibitors. We sought to identify the mechanism by which AR drives tumor survival in CRPC to identify ways to overcome resistance to PI3K inhibition. We found that integrins alpha 6 beta 1 and Bnip3 are selectively elevated in CRPC downstream of AR. While integrin alpha 6 promotes survival and is a direct transcriptional target of AR, the ability of AR to induce Bnip3 is dependent on adhesion to laminin and integrin alpha 6 beta 1-dependent nuclear translocation of HIF1 alpha. Integrins alpha 6 beta 1 and Bnip3 were found to promote survival of CRPC cells selectively on laminin through the induction of autophagy and mitophagy. Furthermore, blocking Bnip3 or integrin alpha 6 beta 1 restored sensitivity to PI3K inhibitors in Pten-negative CRPC. We identified an AR driven pathway that cooperates with laminin and hypoxia to drive resistance to PI3K inhibitors. These findings can help explain in part why PI3K inhibitors have failed in clinical trials to overcome AR-dependent CRPC.	[Nollet, Eric A.; Schulz, Veronique V.; Miranti, Cindy K.] Van Andel Res Inst, Grand Rapids, MI 49503 USA; [Cardo-Vila, Marina; Ganguly, Sourik S.; Tran, Jack D.; Cress, Anne; Miranti, Cindy K.] Univ Arizona, Ctr Canc, Dept Cellular & Mol Med, Tucson, AZ 85721 USA; [Cardo-Vila, Marina; Ganguly, Sourik S.; Tran, Jack D.; Cress, Anne; Miranti, Cindy K.] Univ Arizona, Ctr Canc, Prostate Canc Res Program, Tucson, AZ 85721 USA; [Corey, Eva] Univ Washington, Dept Urol, Seattle, WA 98195 USA	Van Andel Institute; University of Arizona; University of Arizona; University of Washington; University of Washington Seattle	Miranti, CK (corresponding author), Van Andel Res Inst, Grand Rapids, MI 49503 USA.; Miranti, CK (corresponding author), Univ Arizona, Ctr Canc, Dept Cellular & Mol Med, Tucson, AZ 85721 USA.; Miranti, CK (corresponding author), Univ Arizona, Ctr Canc, Prostate Canc Res Program, Tucson, AZ 85721 USA.	cmiranti@email.arizona.edu		Corey, Eva/0000-0002-9244-3807	NIH/NCI [CA159406]; Van Andel Research Institute	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Van Andel Research Institute	We would like to thank Drs. Sander Frank and Don Tindall for feedback and constructive suggestions and Penny Berger for technical expertise. Special thanks to Scott Peterson for supplying the PX-866. These studies were supported by funding from NIH/NCI R01CA154835, P30CA023074 (CKM, SSG, EAN, and VVS), and the Van Andel Research Institute. Additional support was provided by NIH/NCI CA159406 (AC).	Alers S, 2012, MOL CELL BIOL, V32, P2, DOI 10.1128/MCB.06159-11; Anastasiadis Aristotelis G, 2002, Curr Urol Rep, V3, P222, DOI 10.1007/s11934-002-0068-6; Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09; Berger PL, 2014, CANCER RES, V74, P3357, DOI 10.1158/0008-5472.CAN-13-3076; Boddy JL, 2005, CLIN CANCER RES, V11, P7658, DOI 10.1158/1078-0432.CCR-05-0460; Brooks DLP, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0510-x; Campeau E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006529; Chen Q, 2006, CANCER LETT, V244, P274, DOI 10.1016/j.canlet.2005.12.027; Chen XQ, 2010, CANCER RES, V70, P2728, DOI 10.1158/0008-5472.CAN-09-3718; CRESS AE, 1995, CANCER METAST REV, V14, P219, DOI 10.1007/BF00690293; Crumbaker M, 2017, CANCERS, V9, DOI 10.3390/cancers9040034; Demetriou MC, 2004, EXP CELL RES, V294, P550, DOI 10.1016/j.yexcr.2003.11.023; Feng Q, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00858; Frank SB, 2017, BMC BIOTECHNOL, V17, DOI 10.1186/s12896-017-0341-x; Fung C, 2008, MOL BIOL CELL, V19, P797, DOI 10.1091/mbc.E07-10-1092; Galletti G, 2017, CANCER TREAT REV, V57, P16, DOI 10.1016/j.ctrv.2017.04.008; Glick D, 2012, MOL CELL BIOL, V32, P2570, DOI 10.1128/MCB.00167-12; Gu YC, 2003, BLOOD, V101, P877, DOI 10.1182/blood-2002-03-0796; Guo K, 2001, CELL DEATH DIFFER, V8, P367, DOI 10.1038/sj.cdd.4400810; Hanna RA, 2012, J BIOL CHEM, V287, P19094, DOI 10.1074/jbc.M111.322933; Harryman WL, 2016, BBA-REV CANCER, V1866, P221, DOI 10.1016/j.bbcan.2016.09.005; Hiraga T, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113523; Hong DS, 2012, CLIN CANCER RES, V18, P4173, DOI 10.1158/1078-0432.CCR-12-0714; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; Ihle NT, 2005, MOL CANCER THER, V4, P1349, DOI 10.1158/1535-7163.MCT-05-0149; Jung SN, 2008, CARCINOGENESIS, V29, P713, DOI 10.1093/carcin/bgn032; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Lamb LE, 2011, CANCER RES, V71, P2739, DOI 10.1158/0008-5472.CAN-10-2745; Lee SH, 2015, J BIOL CHEM, V290, P2759, DOI 10.1074/jbc.M114.607846; Majumder PK, 2005, ONCOGENE, V24, P7465, DOI 10.1038/sj.onc.1209096; Mazure NM, 2009, AUTOPHAGY, V5, P868, DOI 10.4161/auto.9042; Neri P, 2012, CURR CANCER DRUG TAR, V12, P776, DOI 10.2174/156800912802429337; Pietrocola F, 2013, SEMIN CANCER BIOL, V23, P310, DOI 10.1016/j.semcancer.2013.05.008; Pontes-Junior Jose, 2009, J Carcinog, V8, P3; Ports MO, 2009, CANCER RES, V69, P5007, DOI 10.1158/0008-5472.CAN-09-0354; Qi WQ, 2015, ONCOTARGET, V6, P41976, DOI 10.18632/oncotarget.5659; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Rual JF, 2004, GENOME RES, V14, P2128, DOI 10.1101/gr.2973604; Shabsigh A, 2001, J CELL BIOCHEM, V81, P437, DOI 10.1002/1097-4644(20010601)81:3<437::AID-JCB1057>3.3.CO;2-Y; Shaw J, 2008, P NATL ACAD SCI USA, V105, P20734, DOI 10.1073/pnas.0807735105; Sinha RA, 2015, AUTOPHAGY, V11, P1341, DOI 10.1080/15548627.2015.1061849; Sobocinski GP, 2010, BMC IMMUNOL, V11, DOI 10.1186/1471-2172-11-42; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Tang D, 2017, SCI REP-UK, V7, DOI 10.1038/srep43926; Thomas C, 2013, MOL CANCER THER, V12, P2342, DOI 10.1158/1535-7163.MCT-13-0032; Toth RK, 2019, AM J CLIN EXP UROL, V7, P297; Tracy K, 2007, MOL CELL BIOL, V27, P6229, DOI 10.1128/MCB.02246-06; van Uden P, 2008, BIOCHEM J, V412, P477, DOI 10.1042/BJ20080476; Veeramani S, 2008, ONCOGENE, V27, P5057, DOI 10.1038/onc.2008.143; VELDSCHOLTE J, 1992, BIOCHEMISTRY-US, V31, P2393, DOI 10.1021/bi00123a026; Wang DP, 2011, METHODS MOL BIOL, V776, P25, DOI 10.1007/978-1-61779-243-4_2; White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941; WU HC, 1994, INT J CANCER, V57, P406, DOI 10.1002/ijc.2910570319; Yoo NJ, 2010, TUMORI J, V96, P138, DOI 10.1177/030089161009600122; Zhang J, 2009, CELL DEATH DIFFER, V16, P939, DOI 10.1038/cdd.2009.16; Zhang J, 2012, AUTOPHAGY, V8, P1325, DOI 10.4161/auto.20764; Zhu YY, 2013, J BIOL CHEM, V288, P1099, DOI 10.1074/jbc.M112.399345	57	10	10	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 30	2020	39	31					5390	5404		10.1038/s41388-020-1370-9	http://dx.doi.org/10.1038/s41388-020-1370-9		JUN 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MT1TS	32565538	Green Accepted			2022-12-28	WOS:000541695700001
J	Zhang, CZ; Huang, SZ; Zhuang, HK; Ruan, SY; Zhou, ZX; Huang, KJ; Ji, F; Ma, ZY; Hou, BH; He, XS				Zhang, Chuanzhao; Huang, Shanzhou; Zhuang, Hongkai; Ruan, Shiye; Zhou, Zixuan; Huang, Kaijun; Ji, Fei; Ma, Zuyi; Hou, Baohua; He, Xiaoshun			YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation	ONCOGENE			English	Article							MICRORNAS	N-6-methyladenosine (m6A) RNA methylation contributes to the cancer stem cell (CSC) phenotype through regulating gene expression. YTHDF2, an m6A reader, was shown to be associated with hepatocellular carcinoma (HCC) patient prognosis. However, the effect of YTHDF2 on liver CSC and cancer metastasis and the molecular mechanism of this effect have not been documented. Here, we show that YTHDF2 expression is negatively correlated with HCC patient survival in both data from the Cancer Genome Atlas (TCGA) database and clinical data from our center. By detecting CD133(+) cells and carrying out sphere culture assays, we found that knockdown of YTHDF2 led to impaired stemness in Hep3B and Huh7 cells. In contrast, overexpression of YTHDF2 increased the CSC phenotype. Mechanistically, the knockdown and overexpression of YTHDF2 in liver cancer cells resulted in decreased and increased m6A levels in the 5 '-untranslated region (UTR) of OCT4 mRNA, respectively, leading to decreased and increased OCT4 protein expression, respectively. A luciferase activity assay showed that mutation of the corresponding m6A methylation sequence in the 5 '-UTR of OCT4 mRNA caused significantly decreased gene expression, suggesting a role for YTHDF2-dependent m6A methylation in protein translation. Polysome profiling results also indicated the knockdown and overexpression of YTHDF2 could decrease and increase OCT4 translation, respectively. In particular, overexpression of OCT4 rescued the impaired stemness caused by YTHDF2 depletion, which confirmed the effect of YTHDF2 on CSC phenotype is dependent on OCT4. In vivo, the loss of YTHDF2 reduced tumor burden and inhibited lung metastasis following orthotopic transplantation in nude mice. Last, we demonstrated that YTHDF2 expression is positively correlated with OCT4 expression and m6A levels in the 5 '-UTR of OCT4 mRNA in clinical HCC specimens. In conclusion, YTHDF2 promotes the CSC liver phenotype and cancer metastasis by modulating the m6A methylation of OCT4 mRNA.	[Zhang, Chuanzhao; Huang, Shanzhou; Zhuang, Hongkai; Ruan, Shiye; Zhou, Zixuan; Huang, Kaijun; Ji, Fei; Ma, Zuyi; Hou, Baohua] South China Univ Technol, Sch Med, Guangdong Acad Med Sci, Dept Gen Surg,Guangdong Prov Peoples Hosp, Guangzhou 510080, Peoples R China; [Zhuang, Hongkai; Ma, Zuyi] Shantou Univ Med Coll, Shantou 515000, Guangdong, Peoples R China; [He, Xiaoshun] Sun Yat Sen Univ, Affiliated Hosp 1, Organ Transplant Ctr, Guangzhou 510080, Peoples R China	Guangdong Academy of Medical Sciences & Guangdong General Hospital; South China University of Technology; Sun Yat Sen University	Zhang, CZ; Hou, BH (corresponding author), South China Univ Technol, Sch Med, Guangdong Acad Med Sci, Dept Gen Surg,Guangdong Prov Peoples Hosp, Guangzhou 510080, Peoples R China.; He, XS (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Organ Transplant Ctr, Guangzhou 510080, Peoples R China.	641703837@qq.com; 15917919681@163.com; 13922171191@163.com	zhang, chuanzhao/K-8624-2019		National Natural Science Foundation of China [81702783, 81672475]; Natural Science Foundation of Guangdong Province [2017A030310574]; Guangdong Medical Science and Technology Research Fund [A2019494, A2019252]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Guangdong Medical Science and Technology Research Fund	This study was supported by the National Natural Science Foundation of China (project Nos.: 81702783 and 81672475), the Natural Science Foundation of Guangdong Province (project No.: 2017A030310574), and Guangdong Medical Science and Technology Research Fund (A2019494 and A2019252).	Alarcon CR, 2015, NATURE, V519, P482, DOI 10.1038/nature14281; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cao GC, 2016, OPEN BIOL, V6, DOI 10.1098/rsob.160003; Chen MN, 2018, HEPATOLOGY, V67, P2254, DOI 10.1002/hep.29683; Chen T, 2015, CELL STEM CELL, V16, P289, DOI 10.1016/j.stem.2015.01.016; Faye MD, 2014, JOVE-J VIS EXP, DOI 10.3791/52295; Fu Y, 2014, NAT REV GENET, V15, P293, DOI 10.1038/nrg3724; Han DL, 2019, NATURE, V566, P270, DOI 10.1038/s41586-019-0916-x; Li MM, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1436-y; Plaks V, 2015, CELL STEM CELL, V16, P225, DOI 10.1016/j.stem.2015.02.015; Shi HL, 2017, CELL RES, V27, P315, DOI 10.1038/cr.2017.15; Song YY, 2015, GASTROENTEROLOGY, V149, P1068, DOI 10.1053/j.gastro.2015.06.010; Villanueva A, 2019, NEW ENGL J MED, V380, P1450, DOI 10.1056/NEJMra1713263; Villanueva A, 2013, NAT REV GASTRO HEPAT, V10, P34, DOI 10.1038/nrgastro.2012.199; Wang X, 2014, NATURE, V505, P117, DOI 10.1038/nature12730; Wen J, 2018, MOL CELL, V69, P1028, DOI 10.1016/j.molcel.2018.02.015; Yang Z, 2017, J BIOL CHEM, V292, P3614, DOI 10.1074/jbc.M116.749689; Zhang CZ, 2016, ONCOTARGET, V7, P64527, DOI 10.18632/oncotarget.11743; Zhang CZ, 2016, P NATL ACAD SCI USA, V113, pE2047, DOI 10.1073/pnas.1602883113; Zhang SC, 2017, CANCER CELL, V31, P591, DOI 10.1016/j.ccell.2017.02.013; Zhao BS, 2018, RNA, V24, P268, DOI 10.1261/rna.064295.117; Zhong L, 2019, CANCER LETT, V442, P252, DOI 10.1016/j.canlet.2018.11.006; Zhou J, 2015, NATURE, V526, P591, DOI 10.1038/nature15377; Zhu PP, 2015, J CLIN INVEST, V125, P3795, DOI 10.1172/JCI81979	24	148	155	11	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	23					4507	4518		10.1038/s41388-020-1303-7	http://dx.doi.org/10.1038/s41388-020-1303-7		MAY 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LU5ZF	32366907				2022-12-28	WOS:000530271400004
J	Brummer, T; McInnes, C				Brummer, Tilman; McInnes, Campbell			RAF kinase dimerization: implications for drug discovery and clinical outcomes	ONCOGENE			English	Review							ALLOSTERIC ACTIVATION; INHIBITOR RESISTANCE; GENE FUSIONS; BRAF MUTANTS; PHOSPHORYLATION; PROTEIN; MECHANISM; MUTATION; PATHWAY; DIMERS	The RAF kinases activated by RAS GTPases regulate cell growth and division by signal transduction through the ERK cascade and mutations leading to constitutive activity are key drivers of human tumors, as are upstream activators including RAS and receptor tyrosine kinases. The development of first-generation RAF inhibitors, including vemurafenib (VEM) and dabrafenib led to initial excitement due to high response rates and profound regression of malignant melanomas carrying BRAF(V600E) mutations. The excitement about these unprecedented response rates, however, was tempered by tumor unresponsiveness through both intrinsic and acquired drug-resistance mechanisms. In recent years much insight into the complexity of the RAS-RAF axis has been obtained and inactivation and signal transduction mechanisms indicate that RAF dimerization is a critical step in multiple cellular contexts and plays a key role in resistance. Both homo- and hetero-dimerization of BRAF and CRAF can modulate therapeutic response and disease progression in patients treated with ATP-competitive inhibitors and are therefore highly clinically significant. Ten years after the definition of the RAF dimer interface (DIF) by crystallography, this review focuses on the implications of RAF kinase dimerization in signal transduction and for drug development, both from a classical ATP-competitive standpoint and from the perspective of new therapeutic strategies including inhibiting dimer formation. A structural perspective of the DIF, how dimerization impacts inhibitor activation and the structure-based design of next-generation RAF kinase inhibitors with unique mechanisms of action is presented. We also discuss potential fields of application for DIF inhibitors, ranging from non-V600E oncoproteins and BRAF fusions to tumors driven by aberrant receptor tyrosine kinase or RAS signaling.	[Brummer, Tilman] Univ Freiburg, Fac Med, Inst Mol Med & Cell Res, Stefan Meier Str 17, D-79104 Freiburg, Germany; [Brummer, Tilman] German Canc Res Ctr, Partner Site Freiburg, German Canc Consortium DKTK, Heidelberg, Germany; [Brummer, Tilman] Univ Freiburg, Comprehens Canc Ctr Freiburg, Freiburg, Germany; [McInnes, Campbell] Univ South Carolina, Drug Discovery & Biomed Sci, Columbia, SC 29208 USA	University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ); University of Freiburg; University of South Carolina System; University of South Carolina Columbia	McInnes, C (corresponding author), Univ South Carolina, Drug Discovery & Biomed Sci, Columbia, SC 29208 USA.	mcinnes@cop.sc.edu	Brummer, Tilman/AAA-9428-2020; Brummer, Tilman/B-6218-2016	Brummer, Tilman/0000-0003-4387-7905; Brummer, Tilman/0000-0003-4387-7905				Agianian B, 2018, J MED CHEM, V61, P5775, DOI 10.1021/acs.jmedchem.7b01306; Baljuls A, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.194167; Beneker CM, 2019, J MED CHEM, V62, P3886, DOI 10.1021/acs.jmedchem.8b01288; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Botton T, 2019, CELL REP, V29, P573, DOI 10.1016/j.celrep.2019.09.009; Chen SH, 2016, CANCER DISCOV, V6, P300, DOI 10.1158/2159-8290.CD-15-0896; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; Cope NJ, 2020, J BIOL CHEM, V295, P2407, DOI 10.1074/jbc.RA119.011536; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; Dankner M, 2018, ONCOGENE, V37, P3183, DOI 10.1038/s41388-018-0171-x; Diamond EL, 2016, CANCER DISCOV, V6, P154, DOI [10.1158/2159-8290.CD-15-0913, 10.1158/2159-8290.CD-NB2016-001]; Diedrich B, 2017, EMBO J, V36, P646, DOI 10.15252/embj.201694732; Dietrich S, 2016, BLOOD, V127, P2847, DOI 10.1182/blood-2015-11-680074; Dorard C, 2017, BIOCHEM SOC T, V45, P27, DOI 10.1042/BST20160135; Douziech M, 2006, GENE DEV, V20, P807, DOI 10.1101/gad.1390406; Eide CA, 2019, CANCER CELL, V36, P431, DOI 10.1016/j.ccell.2019.08.004; Eisenhardt AE, 2016, ONCOTARGET, V7, P26628, DOI 10.18632/oncotarget.8427; Foster SA, 2016, CANCER CELL, V29, P477, DOI 10.1016/j.ccell.2016.02.010; Freeman AK, 2013, MOL CELL, V49, P751, DOI 10.1016/j.molcel.2012.12.018; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Gunderwala AY, 2019, ACS CHEM BIOL, V14, P1471, DOI 10.1021/acschembio.9b00191; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Hernandez MA, 2016, CELL SIGNAL, V28, P561, DOI 10.1016/j.cellsig.2016.02.009; Herr R, 2018, ONCOGENE, V37, P1576, DOI 10.1038/s41388-017-0063-5; Hu J, 2015, MOL CELL BIOL, V35, P264, DOI 10.1128/MCB.00943-14; Hu JC, 2013, CELL, V154, P1036, DOI 10.1016/j.cell.2013.07.046; Hu JC, 2011, P NATL ACAD SCI USA, V108, P6067, DOI 10.1073/pnas.1102554108; Jain P, 2017, ONCOGENE, V36, P6348, DOI 10.1038/onc.2017.276; Jambrina PG, 2016, ANGEW CHEM INT EDIT, V55, P983, DOI 10.1002/anie.201509272; Jambrina PG, 2014, BIOCHEM SOC T, V42, P784, DOI 10.1042/BST20140025; Jones DTW, 2013, NAT GENET, V45, P927, DOI 10.1038/ng.2682; Karoulia Z, 2017, NAT REV CANCER, V17, P676, DOI 10.1038/nrc.2017.79; Karoulia Z, 2016, CANCER CELL, V30, P485, DOI 10.1016/j.ccell.2016.06.024; Kholodenko BN, 2015, CELL REP, V12, P1939, DOI 10.1016/j.celrep.2015.08.014; Kohler M, 2016, EMBO J, V35, P143, DOI 10.15252/embj.201592097; Kondo Y, 2019, SCIENCE, V366, P109, DOI 10.1126/science.aay0543; Kordes M, 2016, LEUKEMIA, V30, P937, DOI 10.1038/leu.2015.319; Lavoie H, 2018, NATURE, V554, P549, DOI 10.1038/nature25478; Lavoie H, 2015, NAT REV MOL CELL BIO, V16, P281, DOI 10.1038/nrm3979; Li D, 2019, NAT MED, V25, P1116, DOI 10.1038/s41591-019-0479-2; Lin LP, 2014, P NATL ACAD SCI USA, V111, pE748, DOI 10.1073/pnas.1320956111; Little AS, 2013, ONCOGENE, V32, P1207, DOI 10.1038/onc.2012.160; Mai TT, 2018, NAT MED, V24, P902, DOI 10.1038/s41591-018-0111-x; Marino KA, 2015, J AM CHEM SOC, V137, P5280, DOI 10.1021/jacs.5b01421; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Matallanas David, 2011, Genes Cancer, V2, P232, DOI 10.1177/1947601911407323; Mooz J, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005484; Nielsen DS, 2017, CHEM REV, V117, P8094, DOI 10.1021/acs.chemrev.6b00838; Park E, 2019, NATURE, V575, P545, DOI 10.1038/s41586-019-1660-y; Peng SB, 2015, CANCER CELL, V28, P384, DOI 10.1016/j.ccell.2015.08.002; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Rajakulendran T, 2009, NATURE, V461, P542, DOI 10.1038/nature08314; Rauen KA, 2018, AM J MED GENET A, V176, P2924, DOI 10.1002/ajmg.a.40632; Roring M, 2012, EMBO J, V31, P2629, DOI 10.1038/emboj.2012.100; Ross JS, 2016, INT J CANCER, V138, P881, DOI 10.1002/ijc.29825; Rukhlenko OS, 2018, CELL SYST, V7, P161, DOI 10.1016/j.cels.2018.06.002; Rushworth LK, 2006, MOL CELL BIOL, V26, P2262, DOI 10.1128/MCB.26.6.2262-2272.2006; Sievert AJ, 2013, P NATL ACAD SCI USA, V110, P5957, DOI 10.1073/pnas.1219232110; Sun Y, 2017, NEURO-ONCOLOGY, V19, P774, DOI 10.1093/neuonc/now261; Takahashi M, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00132-17; Terrell EM, 2019, MOL CELL, V76, P872, DOI 10.1016/j.molcel.2019.09.004; Terrell Elizabeth M., 2018, COLD SPRING HARB PER, V9, pa033746; Thevakumaran N, 2015, NAT STRUCT MOL BIOL, V22, P37, DOI 10.1038/nsmb.2924; Tsai CJ, 2018, CURR OPIN STRUC BIOL, V53, P100, DOI 10.1016/j.sbi.2018.07.007; Unal EB, 2017, FEBS LETT, V591, P2607, DOI 10.1002/1873-3468.12740; Weber CK, 2001, CANCER RES, V61, P3595; Weinberg F, 2020, ONCOGENE, V39, P814, DOI 10.1038/s41388-019-1021-1; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Wu X, 2012, MOL CELL BIOL, V32, P3872, DOI 10.1128/MCB.00751-12; Yao Z, 2019, NAT MED, V25, P284, DOI 10.1038/s41591-018-0274-5; Yao Z, 2017, NATURE, V548, P234, DOI 10.1038/nature23291; Yao Z, 2015, CANCER CELL, V28, P370, DOI 10.1016/j.ccell.2015.08.001; Yuan JM, 2018, ONCOGENE, V37, P5719, DOI 10.1038/s41388-018-0365-2; Zang MW, 2008, J BIOL CHEM, V283, P31429, DOI 10.1074/jbc.M802855200; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429	77	28	28	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	21					4155	4169		10.1038/s41388-020-1263-y	http://dx.doi.org/10.1038/s41388-020-1263-y			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LQ2DH	32269299				2022-12-28	WOS:000534819000001
J	Ricciardiello, F; Gang, Y; Palorini, R; Li, QX; Giampa, M; Zhao, FY; You, L; La Ferla, B; De Vitto, H; Guan, WF; Gu, J; Zhang, TP; Zhao, YP; Chiaradonna, F				Ricciardiello, Francesca; Gang, Yang; Palorini, Roberta; Li, Quanxiao; Giampa, Marco; Zhao, Fangyu; You, Lei; La Ferla, Barbara; De Vitto, Humberto; Guan, Wenfang; Gu, Jin; Zhang, Taiping; Zhao, Yupei; Chiaradonna, Ferdinando			Hexosamine pathway inhibition overcomes pancreatic cancer resistance to gemcitabine through unfolded protein response and EGFR-Akt pathway modulation	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; O-GLCNAC; GLCNACYLATION; CELLS	Different evidence has indicated metabolic rewiring as a necessity for pancreatic cancer (PC) growth, invasion, and chemotherapy resistance. A relevant role has been assigned to glucose metabolism. In particular, an enhanced flux through the Hexosamine Biosynthetic Pathway (HBP) has been tightly linked to PC development. Here, we show that enhancement of the HBP, through the upregulation of the enzyme Phosphoacetylglucosamine Mutase 3 (PGM3), is associated with the onset of gemcitabine (GEM) resistance in PC. Indeed, mRNA profiles of GEM sensitive and resistant patient-derived tumor xenografts (PDXs) indicate that PGM3 expression is specifically increased in GEM-resistant PDXs. Of note, PGM3 results also overexpressed in human PC tissues as compared to paired adjacent normal tissues and its higher expression in PC patients is associated with worse median overall survival (OS). Strikingly, genetic or pharmacological PGM3 inhibition reduces PC cell growth, migration, invasion, in vivo tumor growth and enhances GEM sensitivity. Thus, combined treatment between a specific inhibitor of PGM3, named FR054, and GEM results in a potent reduction of xenograft tumor growth without any obvious side effects in normal tissues. Mechanistically, PGM3 inhibition, reducing protein glycosylation, causes a sustained Unfolded Protein Response (UPR), a significant attenuation of the pro-tumorigenic Epidermal Growth Factor Receptor (EGFR)-Akt axis, and finally cell death. In conclusion this study identifies the HBP as a metabolic pathway involved in GEM resistance and provides a strong rationale for a PC therapy addressing the combined treatment with the PGM3 inhibitor and GEM.	[Ricciardiello, Francesca; Palorini, Roberta; Giampa, Marco; La Ferla, Barbara; De Vitto, Humberto; Chiaradonna, Ferdinando] Univ Milano Bicocca, Dept Biotechnol & Biosci, I-20126 Milan, Italy; [Gang, Yang; Li, Quanxiao; Zhao, Fangyu; You, Lei; Zhang, Taiping; Zhao, Yupei] Chinese Acad Med Sci & Peking Union Med Coll, Dept Gen Surg, Peking Union Med Coll Hosp, Beijing 100730, Peoples R China; [Guan, Wenfang; Gu, Jin] Tsinghua Univ, MOE Key Lab Bioinformat, Beijing 100084, Peoples R China; [Guan, Wenfang; Gu, Jin] Tsinghua Univ, Bioinformat Div, Ctr Synthet & Syst Biol, BNRist, Beijing 100084, Peoples R China; [Guan, Wenfang; Gu, Jin] Tsinghua Univ, Dept Automat, Beijing 100084, Peoples R China; [De Vitto, Humberto] Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA	University of Milano-Bicocca; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital; Tsinghua University; Tsinghua University; Tsinghua University; University of Minnesota System	Chiaradonna, F (corresponding author), Univ Milano Bicocca, Dept Biotechnol & Biosci, I-20126 Milan, Italy.; Zhang, TP; Zhao, YP (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Dept Gen Surg, Peking Union Med Coll Hosp, Beijing 100730, Peoples R China.	tpingzhang@yahoo.com; zhao8028@263.net; ferdinando.chiaradonna@unimib.it	ricciardiello, francesca/AAO-3804-2020; CHIARADONNA, Ferdinando/K-4959-2016; La Ferla, Barbara/AAM-3452-2020	CHIARADONNA, Ferdinando/0000-0001-8529-2732; La Ferla, Barbara/0000-0002-4340-9717	MAECI (Executive Programme of Scientific and Technological Cooperation Italy-China) [CN19GR03]; Associazione Italiana per la Ricerca sul Cancro [15364]; Fondo individuale FFABBR_NAT 2017 (MIUR, Italy); Chinese Government [2018YFE0118600]; National Natural Science Foundation of China [81772639]; Natural Science Foundation of Beijing [7192157]; CAMS Innovation Fund for Medical Sciences (CIFMS) [2016-I2M-1-001]; Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences [2018PT32014]; MIUR; National Brazilian Institution of Science (CAPES) [9281-13-4]; Italian Government [2018YFE0118600]	MAECI (Executive Programme of Scientific and Technological Cooperation Italy-China); Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); Fondo individuale FFABBR_NAT 2017 (MIUR, Italy); Chinese Government; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Beijing(Beijing Natural Science Foundation); CAMS Innovation Fund for Medical Sciences (CIFMS); Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences; MIUR(Ministry of Education, Universities and Research (MIUR)); National Brazilian Institution of Science (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Italian Government	FC was supported by grants from MAECI (Executive Programme of Scientific and Technological Cooperation Italy-China 2019-2021, #CN19GR03), from Associazione Italiana per la Ricerca sul Cancro (A.I.R.C., IG2014 Id.15364) and Fondo individuale FFABBR_NAT 2017 (MIUR, Italy). TZ was supported by grants from Key Projects of International Scientific and Technological Innovation Cooperation Between Chinese and Italian Governments (2018YFE0118600), from the National Natural Science Foundation of China (No. 81772639), from Natural Science Foundation of Beijing (No. 7192157) and CAMS Innovation Fund for Medical Sciences (CIFMS) (No. 2016-I2M-1-001). YZ was supported by grants from Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (No. 2018PT32014). FR is supported by fellowship from MIUR. RP and HDV were supported by fellowship from MIUR and National Brazilian Institution of Science (CAPES 9281-13-4), respectively. We thank Neil Campbell for English editing.	ABBRUZZESE JL, 1991, J CLIN ONCOL, V9, P491, DOI 10.1200/JCO.1991.9.3.491; Akella NM, 2019, BMC BIOL, V17, DOI 10.1186/s12915-019-0671-3; Amrutkar M, 2017, CANCERS, V9, DOI 10.3390/cancers9110157; Ardito CM, 2012, CANCER CELL, V22, P304, DOI 10.1016/j.ccr.2012.07.024; Avril T, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.72; Binenbaum Y, 2015, DRUG RESIST UPDATE, V23, P55, DOI 10.1016/j.drup.2015.10.002; Cavalcante LD, 2014, EUR J PHARMACOL, V741, P8, DOI [10.1016/j.ejphar.2014.07.041, 10.1010/j.ejphar.2014.07.041]; Chatham JC, 2010, CURR SIGNAL TRANSD T, V5, P49, DOI 10.2174/157436210790226492; Chen RR, 2017, SCI REP-UK, V7, DOI 10.1038/srep41463; Chiaradonna F, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7060053; Dauer P, 2018, MOL ONCOL, V12, P1498, DOI 10.1002/1878-0261.12322; de Queiroz RM, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00116; Du YX, 2017, CANCER RES, V77, P2661, DOI 10.1158/0008-5472.CAN-16-2339; Fang B, 2001, EXP CELL RES, V263, P243, DOI 10.1006/excr.2000.5110; Feng MY, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0947-4; Gao H, 2015, NAT MED, V21, P1318, DOI 10.1038/nm.3954; Guillaumond F, 2013, P NATL ACAD SCI USA, V110, P3919, DOI 10.1073/pnas.1219555110; Itkonen HM, 2013, CANCER RES, V73, P5277, DOI 10.1158/0008-5472.CAN-13-0549; Liu CF, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00415; Liu XF, 2012, AM J PATHOL, V180, P599, DOI 10.1016/j.ajpath.2011.10.036; Liu YC, 2011, P NATL ACAD SCI USA, V108, P11332, DOI 10.1073/pnas.1107385108; Lopez-Sambrooks C, 2016, NAT CHEM BIOL, V12, P1023, DOI 10.1038/nchembio.2194; Luo WH, 2019, CANCER MED-US, V8, P6403, DOI 10.1002/cam4.2384; Ma ZY, 2013, J BIOL CHEM, V288, P15121, DOI 10.1074/jbc.M113.470047; Munkley J, 2019, ONCOL LETT, V17, P2569, DOI 10.3892/ol.2019.9885; Nagaraj NS, 2011, CLIN CANCER RES, V17, P483, DOI 10.1158/1078-0432.CCR-10-1670; Namba T, 2015, MAR DRUGS, V13, P2376, DOI 10.3390/md13042376; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Paiotta A, 2018, EUR J ORG CHEM, V2018, P1946, DOI 10.1002/ejoc.201800183; Palam LR, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.264; Qian WK, 2018, LIFE SCI, V208, P253, DOI 10.1016/j.lfs.2018.07.046; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Ricciardiello F, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0405-4; Rodrigues JG, 2018, CELL IMMUNOL, V333, P46, DOI 10.1016/j.cellimm.2018.03.007; Shukla SK, 2017, CANCER CELL, V32, P392, DOI 10.1016/j.ccell.2017.08.008; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Stichelen SOV, 2012, AM J PHYSIOL-ENDOC M, V302, pE417, DOI 10.1152/ajpendo.00390.2011; Tadros S, 2017, CANCER RES, V77, P5503, DOI 10.1158/0008-5472.CAN-16-3062; Thakur PC, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1562-z; Uhlen M, 2017, SCIENCE, V357, P660, DOI 10.1126/science.aan2507; Vaziri-Gohar A, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00617; Wellen KE, 2012, NAT REV MOL CELL BIO, V13, P270, DOI 10.1038/nrm3305; Yang G, 2019, SCI CHINA LIFE SCI, V62, P791, DOI 10.1007/s11427-018-9495-2; Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	45	22	23	3	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	20					4103	4117		10.1038/s41388-020-1260-1	http://dx.doi.org/10.1038/s41388-020-1260-1		MAR 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LN3GC	32235891	Green Submitted			2022-12-28	WOS:000522606000001
J	Shibata, N; Ohoka, N; Tsuji, G; Demizu, Y; Miyawaza, K; Ui-Tei, K; Akiyama, T; Naito, M				Shibata, Norihito; Ohoka, Nobumichi; Tsuji, Genichiro; Demizu, Yosuke; Miyawaza, Keiji; Ui-Tei, Kumiko; Akiyama, Tetsu; Naito, Mikihiko			Deubiquitylase USP25 prevents degradation of BCR-ABL protein and ensures proliferation of Ph-positive leukemia cells	ONCOGENE			English	Article							IDENTIFICATION; INHIBITORS; TANKYRASE; FUSIONS; TARGET; GENES; HEAT-SHOCK-PROTEIN-90; BIOTINYLATION; OMACETAXINE; LINE	Fusion genes resulting from chromosomal rearrangements are frequently found in a variety of cancer cells. Some of these are known to be driver oncogenes, such as BCR-ABL in chronic myelogenous leukemia (CML). The products of such fusion genes are abnormal proteins that are ordinarily degraded in cells by a mechanism known as protein quality control. This suggests that the degradation of BCR-ABL protein is suppressed in CML cells to ensure their proliferative activity. Here, we show that ubiquitin-specific protease 25 (USP25) suppresses the degradation of BCR-ABL protein in cells harboring Philadelphia chromosome (Ph). USP25 was found proximal to BCR-ABL protein in cells. Depletion of USP25 using shRNA-mediated gene silencing increased the ubiquitylated BCR-ABL, and reduced the level of BCR-ABL protein. Accordingly, BCR-ABL-mediated signaling and cell proliferation were suppressed in BCR-ABL-positive leukemia cells by the depletion of USP25. We further found that pharmacological inhibition of USP25 induced rapid degradation of BCR-ABL protein in Ph-positive leukemia cells, regardless of their sensitivity to tyrosine kinase inhibitors. These results indicate that USP25 is a novel target for inducing the degradation of oncogenic BCR-ABL protein in Ph-positive leukemia cells. This could be an effective approach to overcome resistance to kinase inhibitors.	[Shibata, Norihito; Ohoka, Nobumichi; Naito, Mikihiko] Natl Inst Hlth Sci, Div Mol Target & Gene Therapy Prod, Kawasaki, Kanagawa 2109501, Japan; [Tsuji, Genichiro; Demizu, Yosuke] Natl Inst Hlth Sci, Div Organ Chem, Kawasaki, Kanagawa 2109501, Japan; [Miyawaza, Keiji] Univ Yamanashi, Grad Sch Med, Dept Biochem, Yamanashi 4093898, Japan; [Ui-Tei, Kumiko] Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Tokyo 1130033, Japan; [Ui-Tei, Kumiko] Univ Tokyo, Grad Sch Frontier Sci, Dept Computat Biol & Med Sci, Chiba 2778561, Japan; [Akiyama, Tetsu] Univ Tokyo, Inst Quantitat Biosci, Lab Mol & Genet Informat, Tokyo 1130032, Japan	National Institute of Health Sciences - Japan; National Institute of Health Sciences - Japan; University of Yamanashi; University of Tokyo; University of Tokyo; University of Tokyo	Naito, M (corresponding author), Natl Inst Hlth Sci, Div Mol Target & Gene Therapy Prod, Kawasaki, Kanagawa 2109501, Japan.	miki-naito@nihs.go.jp	Demizu, Yosuke/AAE-2839-2022	Demizu, Yosuke/0000-0001-7521-4861; Ui-Tei, Kumiko/0000-0001-8695-9025; SHIBATA, NORIHITO/0000-0001-5792-8510	Japan Society for the Promotion of Science (KAKENHI) [18K07311, 16H05090, 18H05502]; Project for Cancer Research and Therapeutic Evolution (P-CREATE) from the Japan Agency for Medical Research and Development (AMED) [JP17cm0106522j0002]; Takeda Science Foundation	Japan Society for the Promotion of Science (KAKENHI)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Project for Cancer Research and Therapeutic Evolution (P-CREATE) from the Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Takeda Science Foundation(Takeda Science Foundation (TSF))	This study was supported, in part, by the Japan Society for the Promotion of Science (KAKENHI Grant Numbers 18K07311 to NS, 16H05090 and 18H05502 to MN), by the Project for Cancer Research and Therapeutic Evolution (P-CREATE) (JP17cm0106522j0002 to NS) from the Japan Agency for Medical Research and Development (AMED), and by the Takeda Science Foundation (to NS).	Altun M, 2011, CHEM BIOL, V18, P1401, DOI 10.1016/j.chembiol.2011.08.018; Alvandi F, 2014, ONCOLOGIST, V19, P94, DOI 10.1634/theoncologist.2013-0077; Choi-Rhee E, 2004, PROTEIN SCI, V13, P3043, DOI 10.1110/ps.04911804; Cronan JE, 2005, J NUTR BIOCHEM, V16, P416, DOI 10.1016/j.jnutbio.2005.03.017; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; Demizu Y, 2016, BIOORG MED CHEM LETT, V26, P4865, DOI 10.1016/j.bmcl.2016.09.041; Deng SS, 2007, BREAST CANCER RES TR, V104, P21, DOI 10.1007/s10549-006-9393-7; Denuc A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005571; Gandhi V, 2014, CLIN CANCER RES, V20, P1735, DOI 10.1158/1078-0432.CCR-13-1283; Gelmini S, 2004, CANCER LETT, V216, P81, DOI 10.1016/j.canlet.2004.05.010; Gersch M, 2019, MOL CELL, V74, P436, DOI 10.1016/j.molcel.2019.02.030; Harrigan JA, 2018, NAT REV DRUG DISCOV, V17, P57, DOI 10.1038/nrd.2017.152; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; Hjerpe R, 2009, EMBO REP, V10, P1250, DOI 10.1038/embor.2009.192; Hochhaus A, 2017, NEW ENGL J MED, V376, P917, DOI 10.1056/NEJMoa1609324; Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356; Kawaguchi K, 2017, SCI REP-UK, V7, DOI 10.1038/srep45037; KISHI K, 1985, LEUKEMIA RES, V9, P381, DOI 10.1016/0145-2126(85)90060-8; Klejman A, 2002, EMBO J, V21, P5766, DOI 10.1093/emboj/cdf562; Kohno T, 2012, NAT MED, V18, P375, DOI 10.1038/nm.2644; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; Lai AC, 2016, ANGEW CHEM INT EDIT, V55, P807, DOI 10.1002/anie.201507634; Lawson AP, 2015, CANCER RES, V75, P5130, DOI 10.1158/0008-5472.CAN-15-1544; Li J, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-166; Lipson D, 2012, NAT MED, V18, P382, DOI 10.1038/nm.2673; Liu B, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07510-5; Massimino M, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0805-1; Okabe S, 2010, EXP HEMATOL, V38, P765, DOI 10.1016/j.exphem.2010.04.017; Pal A, 2014, CANCER RES, V74, P4955, DOI 10.1158/0008-5472.CAN-14-1211; Peng C, 2007, CELL CYCLE, V6, P2227, DOI 10.4161/cc.6.18.4722; Peng C, 2007, BLOOD, V110, P678, DOI 10.1182/blood-2006-10-054098; Popov N, 2007, NAT CELL BIOL, V9, P765, DOI 10.1038/ncb1601; Reckel S, 2017, LEUKEMIA, V31, P1502, DOI 10.1038/leu.2017.36; Roux KJ, 2012, J CELL BIOL, V196, P801, DOI 10.1083/jcb.201112098; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; RUDKIN GT, 1964, SCIENCE, V144, P1229, DOI 10.1126/science.144.3623.1229; Sauer F, 2019, MOL CELL, V74, P421, DOI 10.1016/j.molcel.2019.02.029; Shibata N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31913-5; Shibata N, 2017, CANCER SCI, V108, P1657, DOI 10.1111/cas.13284; Shimokawa K, 2017, ACS MED CHEM LETT, V8, P1042, DOI 10.1021/acsmedchemlett.7b00247; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Takeuchi K, 2012, NAT MED, V18, P378, DOI 10.1038/nm.2658; Tanno H, 2014, J BIOL CHEM, V289, P2415, DOI 10.1074/jbc.M113.528372; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tsukahara F, 2010, BLOOD, V116, P3582, DOI 10.1182/blood-2009-10-249623; Ui-Tei K, 2004, NUCLEIC ACIDS RES, V32, P936, DOI 10.1093/nar/gkh247; Wang WQ, 2015, CELL REP, V13, P524, DOI 10.1016/j.celrep.2015.09.014; Wrigley JD, 2017, ACS CHEM BIOL, V12, P3113, DOI 10.1021/acschembio.7b00334; Xu DC, 2017, GENE DEV, V31, P1024, DOI 10.1101/gad.300889.117	50	15	15	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	19					3867	3878		10.1038/s41388-020-1253-0	http://dx.doi.org/10.1038/s41388-020-1253-0		MAR 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LK4OF	32203161				2022-12-28	WOS:000519342000001
J	Park, SM; Hwang, CY; Choi, J; Joung, CY; Cho, KH				Park, Sang-Min; Hwang, Chae Young; Choi, Jihye; Joung, Chang Young; Cho, Kwang-Hyun			Feedback analysis identifies a combination target for overcoming adaptive resistance to targeted cancer therapy	ONCOGENE			English	Article							MEK INHIBITION; SYSTEMS BIOLOGY; NETWORKS; DYNAMICS; BRAF; PATHWAY; SRC; KINOME; ENCYCLOPEDIA; ACTIVATION	Targeted drugs aim to treat cancer by directly inhibiting oncogene activity or oncogenic pathways, but drug resistance frequently emerges. Due to the intricate dynamics of cancer signaling networks, which contain complex feedback regulations, cancer cells can rewire these networks to adapt to and counter the cytotoxic effects of a drug, thereby limiting the efficacy of targeted therapies. To identify a combinatorial drug target that can overcome such a limitation, we developed a Boolean network simulation and analysis framework and applied this approach to a large-scale signaling network of colorectal cancer with integrated genomic information. We discovered Src as a critical combination drug target that can overcome the adaptive resistance to the targeted inhibition of mitogen-activated protein kinase pathway by blocking the essential feedback regulation responsible for resistance. The proposed framework is generic and can be widely used to identify drug targets that can overcome adaptive resistance to targeted therapies.	[Park, Sang-Min; Hwang, Chae Young; Choi, Jihye; Joung, Chang Young; Cho, Kwang-Hyun] Korea Adv Inst Sci & Technol, Dept Bio & Brain Engn, Lab Syst Biol & Bioinspired Engn, Daejeon 34141, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Cho, KH (corresponding author), Korea Adv Inst Sci & Technol, Dept Bio & Brain Engn, Lab Syst Biol & Bioinspired Engn, Daejeon 34141, South Korea.	ckh@kaist.ac.kr	Cho, Kwang-Hyun/C-1684-2011	Park, Sang-Min/0000-0003-2915-0742	National Research Foundation of Korea (NRF) - Korea Government; Ministry of Science and ICT [2017R1A2A1A17069642, 2015M3A9A7067220]	National Research Foundation of Korea (NRF) - Korea Government(National Research Foundation of Korea); Ministry of Science and ICT(Ministry of Science, ICT & Future Planning, Republic of Korea)	We thank Dr Ki-Sun Kwon (Korea Research Institute of Bioscience and Biotechnology) for the rabbit polyclonal anti-GAPDH antibody, Nancy R. Gough (BioSerendipity, LLC) for editorial assistance, and Sea Choi for her editorial assistance during revision. This work was supported by the National Research Foundation of Korea (NRF) grants funded by the Korea Government, the Ministry of Science and ICT (2017R1A2A1A17069642 and 2015M3A9A7067220).	Abdi A, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.2000008; Aldridge BB, 2006, NAT CELL BIOL, V8, P1195, DOI 10.1038/ncb1497; Anderson GR, 2017, CELL REP, V20, P999, DOI 10.1016/j.celrep.2017.07.006; Assmus HE, 2006, EXPERT REV MOL DIAGN, V6, P891, DOI 10.1586/14737159.6.6.891; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Chakravarty Debyani, 2017, JCO Precis Oncol, V2017, DOI 10.1200/PO.17.00011; Chen SH, 2016, CURR OPIN STRUC BIOL, V41, P145, DOI 10.1016/j.sbi.2016.07.020; Cho SH, 2016, BMC SYST BIOL, V10, DOI 10.1186/s12918-016-0341-9; Choi M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02160-5; Corcoran RB, 2015, J CLIN ONCOL, V33, P4023, DOI 10.1200/JCO.2015.63.2471; Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341; Courtney KD, 2010, J CLIN ONCOL, V28, P1075, DOI 10.1200/JCO.2009.25.3641; Creixell P, 2015, CELL, V163, P202, DOI 10.1016/j.cell.2015.08.056; Danielsen SA, 2015, BBA-REV CANCER, V1855, P104, DOI 10.1016/j.bbcan.2014.09.008; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053; Dunn EF, 2011, ONCOGENE, V30, P561, DOI 10.1038/onc.2010.430; Eshaghi M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011620; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; Gargalionis AN, 2014, INT J CANCER, V134, P2019, DOI 10.1002/ijc.28299; Garraway LA, 2012, CANCER DISCOV, V2, P214, DOI 10.1158/2159-8290.CD-12-0012; Girotti MR, 2013, CANCER DISCOV, V3, P158, DOI 10.1158/2159-8290.CD-12-0386; Girotti MR, 2015, CANCER CELL, V27, P85, DOI 10.1016/j.ccell.2014.11.006; He GG, 2005, ONCOGENE, V24, P2929, DOI 10.1038/sj.onc.1208474; Helikar T, 2008, P NATL ACAD SCI USA, V105, P1913, DOI 10.1073/pnas.0705088105; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Imperial R, 2019, SEMIN CANCER BIOL, V54, P14, DOI 10.1016/j.semcancer.2017.11.016; Jeong WJ, 2018, NPJ PRECIS ONCOL, V2, DOI 10.1038/s41698-018-0049-y; Johnson GL, 2014, CLIN CANCER RES, V20, P2516, DOI 10.1158/1078-0432.CCR-13-1081; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kim JR, 2006, COMPUT BIOL CHEM, V30, P438, DOI 10.1016/j.compbiolchem.2006.09.004; Kim JR, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001390; Kim J, 2013, SCI REP-UK, V3, DOI 10.1038/srep02223; Kim S, 2007, COMPUT BIOL CHEM, V31, P239, DOI 10.1016/j.compbiolchem.2007.03.013; Kirouac DC, 2017, NPJ SYST BIOL APPL, V3, DOI 10.1038/s41540-017-0016-1; Klinger B, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.29; Kolch W, 2015, NAT REV CANCER, V15, P515, DOI 10.1038/nrc3983; Konieczkowski DJ, 2018, CANCER CELL, V33, P801, DOI 10.1016/j.ccell.2018.03.025; Kopetz S, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.3534; Kwon YK, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-430; Kwon YK, 2007, BIOPHYS J, V92, P2975, DOI 10.1529/biophysj.106.097097; Lamba S, 2014, CELL REP, V8, P1475, DOI 10.1016/j.celrep.2014.07.033; Lee HS, 2015, SCI REP-UK, V5, DOI 10.1038/srep10305; Lito P, 2013, NAT MED, V19, P1401, DOI 10.1038/nm.3392; Murray PJ, 2010, BIOPHYS J, V99, P716, DOI 10.1016/j.bpj.2010.05.016; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Ornes S, 2016, P NATL ACAD SCI USA, V113, P7007, DOI 10.1073/pnas.1608277113; Park D, 2018, J MOL CELL BIOL, V10, P180, DOI 10.1093/jmcb/mjy019; Park SM, 2019, FEBS J, V286, P1305, DOI 10.1111/febs.14773; Park SG, 2006, FEBS LETT, V580, P822, DOI 10.1016/j.febslet.2006.01.004; Parseghian CM, 2017, CLIN CANCER RES, V23, P4146, DOI 10.1158/1078-0432.CCR-16-3138; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Saez-Rodriguez J, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.87; Sawyers C, 2004, NATURE, V432, P294, DOI 10.1038/nature03095; Scaltriti J, 2017, CANC CONVERG, V1, P5, DOI DOI 10.1186/s41236-017-0007-6; Schaefer CF, 2009, NUCLEIC ACIDS RES, V37, pD674, DOI 10.1093/nar/gkn653; Schmidt H, 2005, FEBS J, V272, P2141, DOI 10.1111/j.1742-4658.2005.04605.x; Sharma SV, 2007, GENE DEV, V21, P3214, DOI 10.1101/gad.1609907; Shin D, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01171-6; Shmulevich I, 2002, BIOINFORMATICS, V18, P261, DOI 10.1093/bioinformatics/18.2.261; Sontag ED, 2008, ESSAYS BIOCHEM, V45, P161, DOI 10.1042/BSE0450161; Sreenath SN, 2008, ESSAYS BIOCHEM, V45, P1, DOI 10.1042/BSE0450001; Sturm OE, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001212; Sun C, 2014, TRENDS BIOCHEM SCI, V39, P465, DOI 10.1016/j.tibs.2014.08.010; Thieffry D, 1999, BIOSYSTEMS, V50, P49, DOI 10.1016/S0303-2647(98)00087-2; Turke AB, 2012, CANCER RES, V72, P3228, DOI 10.1158/0008-5472.CAN-11-3747; Wee P, 2017, CANCERS, V9, DOI 10.3390/cancers9050052; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366	68	8	8	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	19					3803	3820		10.1038/s41388-020-1255-y	http://dx.doi.org/10.1038/s41388-020-1255-y		MAR 2020	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LK4OF	32157217				2022-12-28	WOS:000518886000008
J	Bessou, M; Lopez, J; Gadet, R; Deygas, M; Popgeorgiev, N; Poncet, D; Nougarede, A; Billard, P; Mikaelian, I; Gonzalo, P; Rimokh, R; Gillet, G				Bessou, Margaux; Lopez, Jonathan; Gadet, Rudy; Deygas, Mathieu; Popgeorgiev, Nikolay; Poncet, Delphine; Nougarede, Adrien; Billard, Pauline; Mikaelian, Ivan; Gonzalo, Philippe; Rimokh, Ruth; Gillet, Germain			The apoptosis inhibitor Bcl-xL controls breast cancer cell migration through mitochondria-dependent reactive oxygen species production	ONCOGENE			English	Article							ANION CHANNEL; ENDOPLASMIC-RETICULUM; CYTOCHROME-C; BH4 DOMAIN; BCL-X(L); FAMILY; CALCIUM; VDAC; METASTASIS; RELEASE	The Bcl-xL apoptosis inhibitor plays a major role in vertebrate development. In addition to its effect on apoptosis, Bcl-xL is also involved in cell migration and mitochondrial metabolism. These effects may favour the onset and dissemination of metastasis. However, the underlying molecular mechanisms remain to be fully understood. Here we focus on the control of cell migration by Bcl-xL in the context of breast cancer cells. We show that Bcl-xL silencing led to migration defects in Hs578T and MDA-MB231 cells. These defects were rescued by re-expressing mitochondria-addressed, but not endoplasmic reticulum-addressed, Bcl-xL. The use of BH3 mimetics, such as ABT-737 and WEHI-539 confirmed that the effect of Bcl-xL on migration did not depend on interactions with BH3-containing death accelerators such as Bax or BH3-only proteins. In contrast, the use of a BH4 peptide that disrupts the Bcl-xL/VDAC1 complex supports that Bcl-xL by acting on VDAC1 permeability contributes to cell migration through the promotion of reactive oxygen species production by the electron transport chain. Collectively our data highlight the key role of Bcl-xL at the interface between cell metabolism, cell death, and cell migration, thus exposing the VDAC1/Bcl-xL interaction as a promising target for anti-tumour therapy in the context of metastatic breast cancer.	[Bessou, Margaux; Lopez, Jonathan; Gadet, Rudy; Deygas, Mathieu; Popgeorgiev, Nikolay; Poncet, Delphine; Nougarede, Adrien; Billard, Pauline; Mikaelian, Ivan; Gonzalo, Philippe; Rimokh, Ruth; Gillet, Germain] Univ Claude Bernard Lyon 1, Univ Lyon, Ctr Rech Cancerol Lyon, Ctr Leon Berard,INSERM 1052,CNRS 5286, F-69008 Lyon, France; [Lopez, Jonathan; Poncet, Delphine] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Ctr Biol Sud, Chemin Grand Revoyet, F-69495 Pierre Benite, France; [Gonzalo, Philippe] CHU St Etienne, Lab Biochim, F-42000 St Etienne, France; [Gillet, Germain] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Lab Anat & Cytol Pathol, Chemin Grand Revoyet, F-69495 Pierre Benite, France; [Deygas, Mathieu] Inst Curie, CNRS, UMR144, 6 Rue Jean Calvin, F-75005 Paris, France; [Nougarede, Adrien] CEA LETI, 17 Ave Martyrs, F-38000 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UNICANCER; Centre Leon Berard; CHU Lyon; CHU de St Etienne; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; CEA	Rimokh, R; Gillet, G (corresponding author), Univ Claude Bernard Lyon 1, Univ Lyon, Ctr Rech Cancerol Lyon, Ctr Leon Berard,INSERM 1052,CNRS 5286, F-69008 Lyon, France.; Gillet, G (corresponding author), Hosp Civils Lyon, Ctr Hosp Lyon Sud, Lab Anat & Cytol Pathol, Chemin Grand Revoyet, F-69495 Pierre Benite, France.	ruth.rimokh@inserm.fr; germain.gillet@univ-lyon1.fr	gillet, germain/A-9095-2013; Billard, Pauline/AAS-5731-2020; Poncet, Delphine A/A-7190-2016	Billard, Pauline/0000-0002-3255-0192; Poncet, Delphine A/0000-0003-0446-5262; LOPEZ, Jonathan/0000-0003-3768-2378; Popgeorgiev, Nikolay/0000-0002-4835-5201; GILLET, Germain/0000-0002-1514-327X	AFM telethon [20269]; Fondation ARC [PGA1 RF20180206799, PJA 20161204606]	AFM telethon(Association Francaise contre les Myopathies); Fondation ARC	We would like to thank Stephane Borel for technical assistance, Julien Prudent for critical reading of the manuscript, Brigitte Manship for manuscript editing, Isabelle Goddard for skilful technical assistance regarding studies in mice (LMT, Lyon), and CIQLE core facility (SFR Sante Lyon-Est) for videomicroscopy. This work was supported by AFM telethon (to GG, grant #20269) and Fondation ARC to GG (grant #PGA1 RF20180206799) and JL (grant #PJA 20161204606).	Angelova PR, 2016, FREE RADICAL BIO MED, V100, P81, DOI 10.1016/j.freeradbiomed.2016.06.005; Banaszynski LA, 2006, CELL, V126, P995, DOI 10.1016/j.cell.2006.07.025; Ben-Hail D, 2016, BBA-MOL CELL RES, V1863, P1612, DOI 10.1016/j.bbamcr.2016.04.002; Bonneau B, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004480; Bonneau B, 2013, BBA-MOL CELL RES, V1833, P1755, DOI 10.1016/j.bbamcr.2013.01.021; Chen YB, 2011, J CELL BIOL, V195, P263, DOI 10.1083/jcb.201108059; Choi SY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10384; Dogterom M, 2019, NAT REV MOL CELL BIO, V20, P38, DOI 10.1038/s41580-018-0067-1; Du YCN, 2007, PLOS BIOL, V5, P2255, DOI 10.1371/journal.pbio.0050276; Eno CO, 2012, MOL BIOL CELL, V23, P2605, DOI 10.1091/mbc.E12-02-0090; Fernandez Y, 2000, CELL DEATH DIFFER, V7, P350, DOI 10.1038/sj.cdd.4400662; Fouque A, 2016, CELL DEATH DIFFER, V23, P1702, DOI 10.1038/cdd.2016.61; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; Griffiths EJ, 2009, BBA-BIOENERGETICS, V1787, P1324, DOI 10.1016/j.bbabio.2009.01.019; Hager JH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004455; Hardwick JM, 2012, TRENDS CELL BIOL, V22, P318, DOI 10.1016/j.tcb.2012.03.005; Heiden MGV, 2001, J BIOL CHEM, V276, P19414, DOI 10.1074/jbc.M101590200; Huang HY, 2013, J BIOL CHEM, V288, P19870, DOI 10.1074/jbc.M112.448290; Hwang KT, 2012, INT J CANCER, V131, pE1109, DOI 10.1002/ijc.27539; Johnson BW, 2000, J BIOL CHEM, V275, P31546, DOI 10.1074/jbc.M001363200; Karczmarek-Borowska B, 2006, LUNG CANCER, V51, P61, DOI 10.1016/j.lungcan.2005.08.010; Kastl L, 2014, FEBS LETT, V588, P175, DOI 10.1016/j.febslet.2013.11.033; Keitel U, 2014, ONCOTARGET, V5, P11778, DOI 10.18632/oncotarget.2634; Lessene G, 2013, NAT CHEM BIOL, V9, P390, DOI [10.1038/NCHEMBIO.1246, 10.1038/nchembio.1246]; Li C, 2007, P NATL ACAD SCI USA, V104, P12565, DOI 10.1073/pnas.0702489104; Lim SK, 2012, CLIN EXP METASTAS, V29, P901, DOI 10.1007/s10585-012-9479-z; Lopez J, 2015, BRIT J CANCER, V112, P957, DOI 10.1038/bjc.2015.85; Ludin A, 2014, ANTIOXID REDOX SIGN, V21, P1605, DOI 10.1089/ars.2014.5941; Martin SS, 2004, ONCOGENE, V23, P4641, DOI 10.1038/sj.onc.1207595; Monaco G, 2015, J BIOL CHEM, V290, P9150, DOI 10.1074/jbc.M114.622514; Mookerjee SA, 2017, J BIOL CHEM, V292, P7189, DOI 10.1074/jbc.M116.774471; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Nguyen MHT, 2005, ANN NY ACAD SCI, V1047, P127, DOI 10.1196/annals.1341.012; Olopade OI, 1997, CANCER J SCI AM, V3, P230; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Paupe V, 2018, BIOCHEM BIOPH RES CO, V500, P75, DOI 10.1016/j.bbrc.2017.05.039; Popgeorgiev N, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00013; Popgeorgiev N, 2011, DEV CELL, V20, P663, DOI 10.1016/j.devcel.2011.03.016; Prevarskaya N, 2011, NAT REV CANCER, V11, P609, DOI 10.1038/nrc3105; Prudent J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3330; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Rostovtseva TK, 2005, J BIOENERG BIOMEMBR, V37, P129, DOI 10.1007/s10863-005-6566-8; Schmitt E, 2007, ONCOGENE, V26, P5851, DOI 10.1038/sj.onc.1210396; Senju Y, 2019, CURR OPIN CELL BIOL, V56, P7, DOI 10.1016/j.ceb.2018.08.003; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Suzuki J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5153; Tan WZ, 2007, BBA-BIOMEMBRANES, V1768, P2510, DOI 10.1016/j.bbamem.2007.06.002; Teng Y, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-453; Tsujimoto Y, 2000, CELL DEATH DIFFER, V7, P1174, DOI 10.1038/sj.cdd.4400780; Vander Heiden MG, 1999, MOL CELL, V3, P159; Vervliet T, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00075; Vogler M, 2011, BLOOD, V117, P7145, DOI 10.1182/blood-2011-03-344812; Watanabe J, 2002, INT J ONCOL, V21, P515; White C, 2005, NAT CELL BIOL, V7, P1021, DOI 10.1038/ncb1302; Yang J, 2016, P NATL ACAD SCI USA, V113, pE1953, DOI 10.1073/pnas.1517935113; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308	58	26	26	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	15					3056	3074		10.1038/s41388-020-1212-9	http://dx.doi.org/10.1038/s41388-020-1212-9		FEB 2020	19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LB8NS	32066881	Green Submitted			2022-12-28	WOS:000514052700002
J	Mukhopadhyay, H; Lee, NY				Mukhopadhyay, Himadri; Lee, Nam Y.			Multifaceted roles of TAK1 signaling in cancer	ONCOGENE			English	Review							NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; TGF-BETA; IKK ACTIVATION; CELL-SURVIVAL; PATHWAY; GROWTH; STRESS; EXPRESSION; PHOSPHORYLATION	Context-specific signaling is a prevalent theme in cancer biology wherein individual molecules and pathways can have multiple or even opposite effects depending on the tumor type. TAK1 represents a particularly notable example of such signaling diversity in cancer progression. Originally discovered as a TGF-beta-activated kinase, over the years it has been shown to respond to numerous other stimuli to phosphorylate a wide range of downstream targets and elicit distinct cellular responses across cell and tissue types. Here we present a comprehensive review of TAK1 signaling and provide important therapeutic perspectives related to its function in different cancers.	[Mukhopadhyay, Himadri; Lee, Nam Y.] Univ Arizona, Coll Med, Deparment Pharmacol, Tucson, AZ 85721 USA; [Lee, Nam Y.] Univ Arizona, Dept Chem & Biochem, Tucson, AZ 85721 USA; [Lee, Nam Y.] Univ Arizona, Canc Ctr, Tucson, AZ 85721 USA	University of Arizona; University of Arizona; University of Arizona	Lee, NY (corresponding author), Univ Arizona, Coll Med, Deparment Pharmacol, Tucson, AZ 85721 USA.; Lee, NY (corresponding author), Univ Arizona, Dept Chem & Biochem, Tucson, AZ 85721 USA.; Lee, NY (corresponding author), Univ Arizona, Canc Ctr, Tucson, AZ 85721 USA.	namlee@email.arizona.edu			NIGMS NIH HHS [R01 GM128055] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmed N, 2011, NAT IMMUNOL, V12, P1176, DOI 10.1038/ni.2157; Ajibade AA, 2012, IMMUNITY, V36, P43, DOI 10.1016/j.immuni.2011.12.010; Augeri DJ, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0511-9; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Besse A, 2007, J BIOL CHEM, V282, P3918, DOI 10.1074/jbc.M608867200; Bettermann K, 2010, CANCER CELL, V17, P481, DOI 10.1016/j.ccr.2010.03.021; Blanco S, 2007, MOL CELL BIOL, V27, P7273, DOI 10.1128/MCB.00025-07; Buglio D, 2012, BLOOD, V120, P347, DOI 10.1182/blood-2011-07-369397; Burotto M, 2014, CANCER-AM CANCER SOC, V120, P3446, DOI 10.1002/cncr.28864; Cai PCH, 2014, ONCOTARGET, V5, P7549, DOI 10.18632/oncotarget.2273; Cheung PCF, 2004, BIOCHEM J, V378, P27, DOI 10.1042/BJ20031794; Choo MK, 2006, MOL CANCER THER, V5, P2970, DOI 10.1158/1535-7163.MCT-06-0379; Chowdhury SM, 2017, ULTRASONOGRAPHY, V36, P171, DOI 10.14366/usg.17021; Dai L, 2012, IUBMB LIFE, V64, P825, DOI 10.1002/iub.1078; Dasgupta B, 2016, TRENDS PHARMACOL SCI, V37, P192, DOI 10.1016/j.tips.2015.11.007; dos Santos DMC, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4525-0; Ear T, 2010, J IMMUNOL, V184, P3897, DOI 10.4049/jimmunol.0902958; Freudlsperger C, 2013, ONCOGENE, V32, P1549, DOI 10.1038/onc.2012.171; Gonzalez H, 2018, GENE DEV, V32, P1267, DOI 10.1101/gad.314617.118; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hamidi A, 2012, J BIOL CHEM, V287, P123, DOI 10.1074/jbc.M111.285122; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hashimoto K, 2016, ANTIOXID REDOX SIGN, V25, P953, DOI 10.1089/ars.2016.6663; Hinz M, 2010, MOL CELL, V40, P63, DOI 10.1016/j.molcel.2010.09.008; Hirata Y, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010205; Hoffmann A, 2005, J BIOL CHEM, V280, P27271, DOI 10.1074/jbc.M503368200; Huang HL, 2015, ONCOTARGET, V6, P995, DOI 10.18632/oncotarget.2739; HuangFu WC, 2006, J BIOL CHEM, V281, P28802, DOI 10.1074/jbc.M603627200; Inagaki M, 2008, J BIOL CHEM, V283, P33080, DOI 10.1074/jbc.M807574200; Inokuchi S, 2010, P NATL ACAD SCI USA, V107, P844, DOI 10.1073/pnas.0909781107; Inokuchi-Shimizu S, 2014, J CLIN INVEST, V124, P3566, DOI 10.1172/JCI74068; Iriondo O, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04460-w; Ishitani T, 2003, MOL CELL BIOL, V23, P131, DOI 10.1128/MCB.23.1.131-139.2003; Jeon SM, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2016.81; Jiang LL, 2016, CANCER RES, V76, P1101, DOI 10.1158/0008-5472.CAN-15-1770; Kajino-Sakamoto R, 2010, J IMMUNOL, V185, P4729, DOI 10.4049/jimmunol.0903587; Kansanen E, 2013, REDOX BIOL, V1, P45, DOI 10.1016/j.redox.2012.10.001; Kim SI, 2012, KIDNEY RES CLIN PRAC, V31, P94, DOI 10.1016/j.krcp.2012.04.322; Lam CRI, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.339; Lam CRI, 2011, CELL DEATH DIFFER, V18, P1120, DOI 10.1038/cdd.2010.182; Lamothe B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051228; Lin PF, 2015, INT J CLIN EXP PATHO, V8, P14449; Liu W, 2007, CLIN CANCER RES, V13, P5028, DOI 10.1158/1078-0432.CCR-07-0300; Marsin AS, 2000, CURR BIOL, V10, P1247, DOI 10.1016/S0960-9822(00)00742-9; Marsin AS, 2002, J BIOL CHEM, V277, P30778, DOI 10.1074/jbc.M205213200; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; McNew KL, 2016, MOL CANCER RES, V14, P1204, DOI 10.1158/1541-7786.MCR-16-0173; Melisi D, 2011, JNCI-J NATL CANCER I, V103, P1190, DOI 10.1093/jnci/djr243; Melvin A, 2011, CELL CYCLE, V10, P879, DOI 10.4161/cc.10.6.14910; Mihaly SR, 2014, CELL DEATH DIFFER, V21, P1667, DOI 10.1038/cdd.2014.123; Morioka S, 2012, BLOOD, V120, P3846, DOI 10.1182/blood-2012-03-416198; Naito H, 2019, DEV CELL, V48, P151, DOI 10.1016/j.devcel.2018.12.002; Neuzillet C, 2015, PHARMACOL THERAPEUT, V147, P22, DOI 10.1016/j.pharmthera.2014.11.001; Ogura Y, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10123; Ohkawara B, 2004, GENE DEV, V18, P381, DOI 10.1101/gad.1166904; Omori E, 2008, J BIOL CHEM, V283, P26161, DOI 10.1074/jbc.M804513200; Park MH, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5020015; Ray DM, 2012, BRIT J CANCER, V107, P129, DOI 10.1038/bjc.2012.214; Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006; Roh YS, 2014, J GASTROENTEROL, V49, P185, DOI 10.1007/s00535-013-0931-x; Safina A, 2008, ONCOGENE, V27, P1198, DOI 10.1038/sj.onc.1210768; Safina A, 2011, MOL CANCER RES, V9, P1042, DOI 10.1158/1541-7786.MCR-10-0196; Sakurai H, 2000, FEBS LETT, V474, P141, DOI 10.1016/S0014-5793(00)01588-X; Sakurai H, 2012, TRENDS PHARMACOL SCI, V33, P522, DOI 10.1016/j.tips.2012.06.007; Santoro R, 2017, DRUG RESIST UPDATE, V33-35, P36, DOI 10.1016/j.drup.2017.10.004; Sato S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255; Shah N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04121-y; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shinohara H, 2005, J EXP MED, V202, P1423, DOI 10.1084/jem.20051591; Singh A, 2012, CELL, V148, P639, DOI 10.1016/j.cell.2011.12.033; Singhirunnusorn P, 2005, J BIOL CHEM, V280, P7359, DOI 10.1074/jbc.M407537200; Smit L, 2004, J BIOL CHEM, V279, P17232, DOI 10.1074/jbc.M307801200; Sorrentino A, 2008, NAT CELL BIOL, V10, P1199, DOI 10.1038/ncb1780; Stoppani J, 2002, AM J PHYSIOL-ENDOC M, V283, pE1239, DOI 10.1152/ajpendo.00278.2002; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Syed V, 2016, J CELL BIOCHEM, V117, P1279, DOI 10.1002/jcb.25496; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Taylor EB, 2008, J BIOL CHEM, V283, P9787, DOI 10.1074/jbc.M708839200; Terada Y, 1999, KIDNEY INT, V56, P1258, DOI 10.1046/j.1523-1755.1999.00704.x; Totzke J, 2017, CELL CHEM BIOL, V24, P1029, DOI 10.1016/j.chembiol.2017.07.011; Vallet-Regi M, 2018, MOLECULES, V23, DOI 10.3390/molecules23010047; Wei YX, 2016, INT J CLIN EXP MED, V9, P10891; Wen J, 2013, ANN THORAC SURG, V95, P285, DOI 10.1016/j.athoracsur.2012.09.050; Wu M, 2012, CANCER RES, V72, P2833, DOI 10.1158/0008-5472.CAN-11-2724; Wu N, 2013, MOL CELL, V49, P1167, DOI 10.1016/j.molcel.2013.01.035; Wu ZH, 2010, MOL CELL, V40, P75, DOI 10.1016/j.molcel.2010.09.010; Xie M, 2006, P NATL ACAD SCI USA, V103, P17378, DOI 10.1073/pnas.0604708103; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Yamashita M, 2008, MOL CELL, V31, P918, DOI 10.1016/j.molcel.2008.09.002; Yang L, 2013, GASTROENTEROLOGY, V144, P1042, DOI 10.1053/j.gastro.2013.01.056; Yang YB, 2011, MOL CELL BIOL, V31, P2774, DOI 10.1128/MCB.01139-10; Yang Y, 2017, MOL MED REP, V16, P3103, DOI 10.3892/mmr.2017.6998; Yu Y, 2008, J BIOL CHEM, V283, P24497, DOI 10.1074/jbc.M802825200; Zhang DM, 2016, CELL SIGNAL, V28, P1742, DOI 10.1016/j.cellsig.2016.08.008; Zheng DH, 2001, J APPL PHYSIOL, V91, P1073, DOI 10.1152/jappl.2001.91.3.1073	97	27	29	3	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	7					1402	1413		10.1038/s41388-019-1088-8	http://dx.doi.org/10.1038/s41388-019-1088-8			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KL2WP	31695153	Green Accepted			2022-12-28	WOS:000513289600002
J	Guan, YF; Huang, QL; Ai, YL; Chen, QT; Zhao, WX; Wang, XM; Wu, Q; Chen, HZ				Guan, Yun-feng; Huang, Qiao-ling; Ai, Yuan-li; Chen, Qi-tao; Zhao, Wen-xiu; Wang, Xiao-min; Wu, Qiao; Chen, Hang-zi			Nur77-activated lncRNA WFDC21P attenuates hepatocarcinogenesis via modulating glycolysis	ONCOGENE			English	Article							LONG NONCODING RNAS; NUCLEAR RECEPTOR TR3; PYRUVATE-KINASE M2; HEPATOCELLULAR-CARCINOMA; GLUCOSE-METABOLISM; CANCER; PHOSPHOFRUCTOKINASE; EXPRESSION; ISOFORM	Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. Orphan nuclear receptor Nur77, which is low expressed in HCC, functions as a tumor suppressor to suppress HCC. However, the detailed mechanism is still not well understood. Here, we demonstrate that Nur77 could inhibit HCC development via transcriptional activation of the lncRNA WAP four-disulfide core domain 21 pseudogene (WFDC21P). Nur77 binds to its response elements on the WFDC21P promoter to directly induce WFDC21P transcription, which inhibits HCC cell proliferation, tumor growth, and tumor metastasis both in vitro and in vivo. In clinical HCC samples, WFDC21P expression positively correlated with that of Nur77, and the loss of WFDC21P is associated with worse prognosis. Mechanistically, WFDC21P could inhibit glycolysis by simultaneously interacting with PFKP and PKM2, two key enzymes in glycolysis. These interactions not only abrogate the tetramer formation of PFKP to impede its catalytic activity but also prevent the nuclear translocation of PKM2 to suppress its function as a transcriptional coactivator. Cytosporone-B (Csn-B), an agonist for Nur77, could stimulate WFDC21P expression and suppress HCC in a WFDC21P-dependent manner. Therefore, our study reveals a new HCC suppressor and connects the glycolytic remodeling of HCC with the Nur77-WFDC21P-PFKP/PKM2 axis.	[Guan, Yun-feng; Huang, Qiao-ling; Ai, Yuan-li; Chen, Qi-tao; Wu, Qiao; Chen, Hang-zi] Xiamen Univ, Innovat Ctr Cell Signaling Network, Sch Life Sci, State Key Lab Cellular Stress Biol, Xiamen 361102, Fujian, Peoples R China; [Zhao, Wen-xiu; Wang, Xiao-min] Xiamen Univ, Zhong Shan Hosp, Fujian Prov Key Lab Chron Liver Dis & Hepatocellu, Xiamen 361005, Fujian, Peoples R China	Xiamen University; Xiamen University	Chen, HZ (corresponding author), Xiamen Univ, Innovat Ctr Cell Signaling Network, Sch Life Sci, State Key Lab Cellular Stress Biol, Xiamen 361102, Fujian, Peoples R China.	Chenhz@xmu.edu.cn		Chen, Hang-zi/0000-0002-4827-2182	National Natural Science Fund of China; Ministry of Science and Technology of China [31822013, 31871434, U1405224, 81672695, 2017YFA0504502]; Fundamental Research Funds for the Central Universities of China [20720190083]	National Natural Science Fund of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China); Fundamental Research Funds for the Central Universities of China(Fundamental Research Funds for the Central Universities)	We thank Dr Hui-ying Huang for her assistance with the metabolites detection using NMR magnet system. This work was supported by grants from the National Natural Science Fund of China and the Ministry of Science and Technology of China (31822013, 31871434, U1405224, 81672695, and 2017YFA0504502), the Fundamental Research Funds for the Central Universities of China (20720190083).	Allen AE, 2018, CANCER CELL, V33, P337, DOI 10.1016/j.ccell.2018.02.008; Anastasiou D, 2011, SCIENCE, V334, P1278, DOI 10.1126/science.1211485; Atianand MK, 2017, ANNU REV IMMUNOL, V35, P177, DOI 10.1146/annurev-immunol-041015-055459; Beard JA, 2015, CELL SIGNAL, V27, P257, DOI 10.1016/j.cellsig.2014.11.009; Beyoglu D, 2013, J HEPATOL, V59, P842, DOI 10.1016/j.jhep.2013.05.030; Bian XL, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14420; Chen HZ, 2012, ONCOGENE, V31, P2876, DOI 10.1038/onc.2011.463; Chen HZ, 2012, GUT, V61, P714, DOI 10.1136/gutjnl-2011-300783; Chen X, 2016, CELL RES, V26, P1007, DOI 10.1038/cr.2016.100; Cho SD, 2007, CANCER RES, V67, P674, DOI 10.1158/0008-5472.CAN-06-2907; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; DUNAWAY GA, 1988, BIOCHEM J, V251, P677, DOI 10.1042/bj2510677; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fu WM, 2015, J HEPATOL, V63, P886, DOI 10.1016/j.jhep.2015.05.016; Han YH, 2006, ONCOGENE, V25, P2974, DOI 10.1038/sj.onc.1209358; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hay N, 2016, NAT REV CANCER, V16, P635, DOI 10.1038/nrc.2016.77; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; Hung CL, 2014, P NATL ACAD SCI USA, V111, P18697, DOI 10.1073/pnas.1415669112; Jiang SH, 2017, NATURE, V544, P460, DOI 10.1038/nature22032; Klingenberg M, 2017, J HEPATOL, V67, P603, DOI 10.1016/j.jhep.2017.04.009; Kong L, 2007, NUCLEIC ACIDS RES, V35, pW345, DOI 10.1093/nar/gkm391; Kopp F, 2018, CELL, V172, P393, DOI 10.1016/j.cell.2018.01.011; Li XX, 2018, MOL CELL, V69, P480, DOI 10.1016/j.molcel.2018.01.001; Lin MF, 2011, BIOINFORMATICS, V27, pI275, DOI 10.1093/bioinformatics/btr209; Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054; Mazurek S, 2011, INT J BIOCHEM CELL B, V43, P969, DOI 10.1016/j.biocel.2010.02.005; Mor I, 2011, COLD SH Q B, V76, P211, DOI 10.1101/sqb.2011.76.010868; Morita M, 2018, CANCER CELL, V33, P355, DOI 10.1016/j.ccell.2018.02.004; Orom UA, 2010, CELL, V143, P46, DOI 10.1016/j.cell.2010.09.001; Park YY, 2013, HEPATOLOGY, V58, P182, DOI 10.1002/hep.26310; Pawlak A, 2015, STEROIDS, V95, P1, DOI 10.1016/j.steroids.2014.12.020; Safe S, 2016, J STEROID BIOCHEM, V157, P48, DOI 10.1016/j.jsbmb.2015.04.016; Safe S, 2014, MOL ENDOCRINOL, V28, P157, DOI 10.1210/me.2013-1291; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Takahashi K, 2014, HEPATOLOGY, V60, P744, DOI 10.1002/hep.27043; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002; VORA S, 1983, HUM GENET, V63, P374, DOI 10.1007/BF00274765; Wang HJ, 2014, P NATL ACAD SCI USA, V111, P279, DOI 10.1073/pnas.1311249111; Wang WJ, 2014, NAT CHEM BIOL, V10, P133, DOI [10.1038/nchembio.1406, 10.1038/NCHEMBIO.1406]; Webb BA, 2015, NATURE, V523, P111, DOI 10.1038/nature14405; Wong N, 2015, CANCER LETT, V356, P184, DOI 10.1016/j.canlet.2014.01.031; Yang F, 2014, MOL CELL, V53, P88, DOI 10.1016/j.molcel.2013.11.004; Yang H, 2011, HEPATOLOGY, V53, P865, DOI 10.1002/hep.24101; Yang JD, 2010, NAT REV GASTRO HEPAT, V7, P448, DOI 10.1038/nrgastro.2010.100; Yao LM, 2012, CARCINOGENESIS, V33, P301, DOI 10.1093/carcin/bgr287; Yi W, 2012, SCIENCE, V337, P975, DOI 10.1126/science.1222278; Yoon JH, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3939; Yuan JH, 2017, NAT CELL BIOL, V19, P820, DOI 10.1038/ncb3538; Zhan YP, 2008, NAT CHEM BIOL, V4, P548, DOI 10.1038/nchembio.106; Zhao XY, 2015, TRENDS BIOCHEM SCI, V40, P586, DOI 10.1016/j.tibs.2015.08.002	52	32	33	5	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	11					2408	2423		10.1038/s41388-020-1158-y	http://dx.doi.org/10.1038/s41388-020-1158-y		JAN 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KU0ZS	31959898	Green Published, hybrid			2022-12-28	WOS:000508322900001
J	Ji, JX; Ding, KK; Luo, T; Xu, R; Zhang, X; Huang, B; Chen, AJ; Zhang, D; Miletic, H; Bjerkvig, R; Thorsen, F; Wang, J; Li, XG				Ji, Jianxiong; Ding, Kaikai; Luo, Tao; Xu, Ran; Zhang, Xin; Huang, Bin; Chen, Anjing; Zhang, Di; Miletic, Hrvoje; Bjerkvig, Rolf; Thorsen, Frits; Wang, Jian; Li, Xingang			PMEPA1 isoform a drives progression of glioblastoma by promoting protein degradation of the Hippo pathway kinase LATS1	ONCOGENE			English	Article							NEDD4-BINDING PROTEIN; DECREASED EXPRESSION; TGF-BETA; INVASION; GENE; YAP; PHOSPHORYLATION; HOMEOSTASIS; SUPPRESSES; CELLS	The Hippo signaling pathway controls organ development and is also known, in cancer, to have a tumor suppressing role. Within the Hippo pathway, we here demonstrate, in human gliomas, a functional interaction of a transmembrane protein, prostate transmembrane protein, androgen induced 1 (PMEPA1) with large tumor suppressor kinase 1 (LATS1). We show that PMEPA1 is upregulated in primary human gliomas. The PMEPA1 isoform PMEPA1a was predominantly expressed in glioma specimens and cell lines, and ectopic expression of the protein promoted glioma growth and invasion in vitro and in an orthotopic xenograft model in nude mice. In co-immunoprecipitation experiments, PMEPA1a associated with the Hippo tumor suppressor kinase LATS1. This interaction led to a proteasomal degradation of LATS1 through recruitment of the ubiquitin ligase, neural precursor cell expressed, developmentally downregulated 4 (NEDD4), which led to silencing of Hippo signaling. Alanine substitution in PMEPA1a at PY motifs resulted in failed LATS1 degradation. Targeting of a downstream component in the Hippo signaling pathway, YAP, with shRNA, interfered with the growth promoting activities of PMEPA1a in vitro and in vivo. In conclusion, the presented work shows that PMEPA1a contributes to glioma progression by a dysregulation of the Hippo signaling pathway and thus represents a promising target for the treatment of gliomas.	[Ji, Jianxiong; Ding, Kaikai; Luo, Tao; Xu, Ran; Zhang, Xin; Huang, Bin; Chen, Anjing; Zhang, Di; Thorsen, Frits; Wang, Jian; Li, Xingang] Shandong Univ, Qilu Hosp, Dept Neurosurg, Jinan, Peoples R China; [Ji, Jianxiong; Ding, Kaikai; Luo, Tao; Xu, Ran; Zhang, Xin; Huang, Bin; Chen, Anjing; Zhang, Di; Thorsen, Frits; Wang, Jian; Li, Xingang] Shandong Univ, Inst Brain & Brain Inspired Sci, Jinan, Peoples R China; [Ji, Jianxiong; Ding, Kaikai; Luo, Tao; Xu, Ran; Zhang, Xin; Huang, Bin; Chen, Anjing; Zhang, Di; Thorsen, Frits; Wang, Jian; Li, Xingang] Shandong Key Lab Brain Funct Remodeling, Jinan, Peoples R China; [Chen, Anjing] Shandong Univ, Sch Med, Jinan, Peoples R China; [Miletic, Hrvoje; Bjerkvig, Rolf; Thorsen, Frits; Wang, Jian] Univ Bergen, Dept Biomed, Jonas Lies Vei 91, N-5009 Bergen, Norway; [Miletic, Hrvoje] Haukeland Hosp, Dept Pathol, Jonas Lies Vei 65, N-5021 Bergen, Norway; [Bjerkvig, Rolf] Luxembourg Inst Hlth, Dept Oncol, 84 Val Fleuri, L-1526 Luxembourg, Luxembourg; [Thorsen, Frits] Univ Bergen, Mol Imaging Ctr, Dept Biomed, Jonas Lies Vei 91, N-5009 Bergen, Norway	Shandong University; Shandong University; Shandong University; University of Bergen; University of Bergen; Haukeland University Hospital; Luxembourg Institute of Health; University of Bergen	Wang, J; Li, XG (corresponding author), Shandong Univ, Qilu Hosp, Dept Neurosurg, Jinan, Peoples R China.; Wang, J; Li, XG (corresponding author), Shandong Univ, Inst Brain & Brain Inspired Sci, Jinan, Peoples R China.; Wang, J; Li, XG (corresponding author), Shandong Key Lab Brain Funct Remodeling, Jinan, Peoples R China.; Wang, J (corresponding author), Univ Bergen, Dept Biomed, Jonas Lies Vei 91, N-5009 Bergen, Norway.	jian.wang@uib.no; lixg@sdu.edu.cn	Huang, Bin/AAT-4514-2021; Chen, Anjing/GYE-2355-2022	Thorsen, Frits/0000-0002-7762-3703	National Natural Science Foundation of China [81701329, 81702474]; Department of Science & Technology of Shandong Province [2017CXGC1502, 2017CXGC1504, 2018GSF118082]; Special Foundation for Taishan Scholars [ts20110814, tshw201502056, tsqn20161067]; Shandong Provincial Natural Science Foundation [ZR2017MH116, ZR2017MH015]; China Postdoctoral Science Foundation [2018M642666]; Jinan Science and Technology Bureau of Shandong Province [201704096]; Norwegian Research Council; Nowegian Cancer Society; Helse-Vest, Haukeland University Hospital	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Department of Science & Technology of Shandong Province; Special Foundation for Taishan Scholars; Shandong Provincial Natural Science Foundation(Natural Science Foundation of Shandong Province); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Jinan Science and Technology Bureau of Shandong Province; Norwegian Research Council(Research Council of NorwayEuropean Commission); Nowegian Cancer Society; Helse-Vest, Haukeland University Hospital	We thank Dr Mengmeng Jin for helping edit the paper. This work was supported by the National Natural Science Foundation of China (81701329 and 81702474), the Department of Science & Technology of Shandong Province (2017CXGC1502, 2017CXGC1504 and 2018GSF118082), the Special Foundation for Taishan Scholars (ts20110814, tshw201502056 and tsqn20161067), the Shandong Provincial Natural Science Foundation (ZR2017MH116 and ZR2017MH015), the China Postdoctoral Science Foundation (2018M642666), the Jinan Science and Technology Bureau of Shandong Province (201704096), and the Norwegian Research Council, The Nowegian Cancer Society and Helse-Vest, Haukeland University Hospital.	Anazawa Y, 2004, ONCOGENE, V23, P7621, DOI 10.1038/sj.onc.1207270; Arif T, 2017, NEURO-ONCOLOGY, V19, P951, DOI 10.1093/neuonc/now297; Bae SJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7314; Brunschwig EB, 2003, CANCER RES, V63, P1568; Cheng CY, 2014, J NEURO-ONCOL, V120, P273, DOI 10.1007/s11060-014-1558-3; Du YY, 2018, J BIOL CHEM, V293, P5847, DOI 10.1074/jbc.RA117.000972; Fournier PGJ, 2015, CANCER CELL, V27, P809, DOI 10.1016/j.ccell.2015.04.009; Giannini G, 2003, MOL CARCINOGEN, V38, P188, DOI 10.1002/mc.10162; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Ho KC, 2016, P NATL ACAD SCI USA, V113, pE5776, DOI 10.1073/pnas.1613909113; Hu Y, 2013, CARCINOGENESIS, V34, P1764, DOI 10.1093/carcin/bgt132; Ji JX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0548-3; Ji TH, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-67; Jiang Z, 2006, NEUROSCI RES, V56, P450, DOI 10.1016/j.neures.2006.09.006; Keunen O, 2011, P NATL ACAD SCI USA, V108, P3749, DOI 10.1073/pnas.1014480108; Koido M, 2016, BIOCHEM BIOPH RES CO, V479, P615, DOI 10.1016/j.bbrc.2016.09.166; Li HY, 2008, J BIOL CHEM, V283, P28988, DOI 10.1074/jbc.M710528200; Liu CY, 2010, J BIOL CHEM, V285, P37159, DOI 10.1074/jbc.M110.152942; Ma B, 2015, NAT CELL BIOL, V17, P95, DOI 10.1038/ncb3073; Meng ZP, 2016, GENE DEV, V30, P1, DOI 10.1101/gad.274027.115; Oh H, 2009, ONCOGENE, V28, P1916, DOI 10.1038/onc.2009.43; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Persaud A, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005290; Rae FK, 2001, MOL CARCINOGEN, V32, P44, DOI 10.1002/mc.1063; Salah Z, 2013, CELL CYCLE, V12, P3817, DOI 10.4161/cc.26672; Singha Prajjal K, 2014, Genes Cancer, V5, P320; Varelas X, 2014, DEVELOPMENT, V141, P1614, DOI 10.1242/dev.102376; Wang CJ, 2012, BIOCHEM J, V444, P279, DOI 10.1042/BJ20111983; Xu LL, 2003, CANCER RES, V63, P4299; Xu LL, 2000, GENOMICS, V70, P407, DOI 10.1006/geno.2000.6458; Xu R, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0665-3; Yeung B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061027; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zhang H, 2016, TUMOR BIOL, V37, P11321, DOI 10.1007/s13277-016-4995-0; Zhang X, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1451-5; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810	37	14	15	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	5					1125	1139		10.1038/s41388-019-1050-9	http://dx.doi.org/10.1038/s41388-019-1050-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KI2VY	31605013	Green Published, hybrid			2022-12-28	WOS:000511209700013
J	Ko, TY; Sharma, R; Li, SS				Ko, Tengyu; Sharma, Rahul; Li, Shisheng			Genome-wide screening identifies novel genes implicated in cellular sensitivity to BRAF(V600E) expression	ONCOGENE			English	Article							ONCOGENE-INDUCED SENESCENCE; SYRUP-URINE-DISEASE; RECEPTOR SIGNALS; PROTEIN; P53; ACTIVATION; GPR4; BRAF; MECHANISMS; MUTATIONS	The V600E mutation of BRAF (BRAF(V600E)), which constitutively activates the ERK/MAPK signaling pathway, is frequently found in melanoma and other cancers. Like most other oncogenes, BRAF(V600E) causes oncogenic stress to normal cells, leading to growth arrest (senescence) or apoptosis. Through genome-wide screening, we identified genes implicated in sensitivity of human skin melanocytes and fibroblasts to BRAF(V600E) overexpression. Among the identified genes shared by the two cell types are proto-oncogenes ERK2, a component of the ERK/MAPK pathway, and VAV1, a guanine nucleotide exchange factor for Rho family GTPases that also activates the ERK/MAPK pathway. CDKN1A, which has been known to promote senescence of fibroblasts but not melanocytes, is implicated in sensitivity of the fibroblasts but not the melanocytes to BRAF(V600E) overexpression. Disruptions of GPR4, a pH-sensing G-protein coupled receptor, and DBT, a subunit of the branched chain alpha-keto acid dehydrogenase that is required for the second and rate-limiting step of branched amino acid catabolism and implicated in maple syrup urine disease, are the most highly selected in the melanocytes upon BRAF(V600E) overexpression. Disruption of DBT severely attenuates ERK/MAPK signaling, p53 activation, and apoptosis in melanocytes, at least in part due to accumulation of branched chain alpha-keto acids. The expression level of BRAF positively correlates with that of DBT in all cancer types and with that of GPR4 in most cancer types. Overexpression of DBT kills all four melanoma cell lines tested regardless of the presence of BRAF(V600E) mutation. Our findings shed new lights on regulations of oncogenic stress signaling and may be informative for development of novel cancer treatment strategies.	[Ko, Tengyu; Li, Shisheng] Louisiana State Univ, Sch Vet Med, Dept Comparat Biomed Sci, Baton Rouge, LA 70803 USA; [Sharma, Rahul] Louisiana State Univ, Lab Res Branch, Natl Hansens Dis Program, 3519E Sch Vet Med, Baton Rouge, LA 70803 USA; [Sharma, Rahul] NuProbe Inc, Cambridge, MA 02140 USA	Louisiana State University School of Veterinary Medicine; Louisiana State University System; Louisiana State University; Louisiana State University System; Louisiana State University	Li, SS (corresponding author), Louisiana State Univ, Sch Vet Med, Dept Comparat Biomed Sci, Baton Rouge, LA 70803 USA.	shli@lsu.edu			National Science Foundation [MCB-1615550]	National Science Foundation(National Science Foundation (NSF))	We are deeply in debt to Elena Sviderskaya and Philip Goff at Wellcome Trust Functional Genomics Cell Bank for supplying human melanocyte and melanoma cell lines. We also thank Mary Price at the Cell Analysis Core Facility, Louisiana Cancer Research Center for flow cytometry analysis, cell sorting and single cell deposition, and Dr Luan Vu at our department for analysis and graphic preparation of flow cytometry data. This study was supported by the National Science Foundation (MCB-1615550 to SL).	Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Bandyopadhyay D, 2000, ANN NY ACAD SCI, V908, P71; Bansal R, 2010, CELL CYCLE, V9, P2782, DOI 10.4161/cc.9.14.12251; Bektas M, 2003, BIOCHEMISTRY-US, V42, P12181, DOI 10.1021/bi035051y; Blackburn PR, 2017, APPL CLIN GENET, V10, P57, DOI 10.2147/TACG.S125962; Brennan DF, 2011, NATURE, V472, P366, DOI 10.1038/nature09860; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Caloca MJ, 2003, EMBO J, V22, P3326, DOI 10.1093/emboj/cdg316; Carpenter K, 2015, NUTR HEALTH SER, P145, DOI 10.1007/978-1-4939-1923-9_12; Castellone RD, 2011, CANCER LETT, V312, P197, DOI 10.1016/j.canlet.2011.08.013; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; Childs BG, 2014, EMBO REP, V15, P1139, DOI 10.15252/embr.201439245; Cole JT, 2015, NUTR HEALTH SER, P13, DOI 10.1007/978-1-4939-1923-9_2; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; Dankner M, 2018, ONCOGENE, V37, P3183, DOI 10.1038/s41388-018-0171-x; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Deschenes-Simard X, 2013, GENE DEV, V27, P900, DOI 10.1101/gad.203984.112; Dhanasekaran DN, 2007, ONCOGENE, V26, P3185, DOI 10.1038/sj.onc.1210411; Dong B, 2017, BIOCHEM J, V474, P4065, DOI 10.1042/BCJ20170676; Dong L, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020278; Fukuda H, 2016, ACS MED CHEM LETT, V7, P493, DOI 10.1021/acsmedchemlett.6b00014; Galanos P, 2016, NAT CELL BIOL, V18, P777, DOI 10.1038/ncb3378; Georgakilas AG, 2017, TRENDS MOL MED, V23, P310, DOI 10.1016/j.molmed.2017.02.001; Goldman M., 2019, UCSC XENA PLATFORM P; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Gray-Schopfer VC, 2006, BRIT J CANCER, V95, P496, DOI 10.1038/sj.bjc.6603283; Hedman AC, 2015, EMBO REP, V16, P427, DOI 10.15252/embr.201439834; Hernandez B, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020394; Hernandez-Segura A, 2018, TRENDS CELL BIOL, V28, P436, DOI 10.1016/j.tcb.2018.02.001; Holecek M, 2018, NUTR METAB, V15, DOI 10.1186/s12986-018-0271-1; Kakadia S, 2018, ONCOTARGETS THER, V11, P7095, DOI 10.2147/OTT.S182721; Kidger AM, 2016, SEMIN CELL DEV BIOL, V50, P125, DOI 10.1016/j.semcdb.2016.01.009; Kong BY, 2016, MELANOMA MANAG, V3, P33, DOI 10.2217/mmt.15.38; Kotsantis P, 2018, CANCER DISCOV, V8, P537, DOI 10.1158/2159-8290.CD-17-1461; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Labazi M, 2003, ESSAYS BIOCHEM, V39, P89, DOI 10.1042/bse0390089; Lake D, 2016, CELL MOL LIFE SCI, V73, P4397, DOI 10.1007/s00018-016-2297-8; Lee EYHP, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003236; Li W, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0843-6; Li W, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0554-4; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; McDuff FKE, 2011, CELL SIGNAL, V23, P6, DOI 10.1016/j.cellsig.2010.07.004; Melnikova VO, 2003, ONCOGENE, V22, P5958, DOI 10.1038/sj.onc.1206595; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Reynolds LF, 2004, J BIOL CHEM, V279, P18239, DOI 10.1074/jbc.M400257200; Sambrook J, 2006, CSH PROTOC, V1, P3871; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Scott MC, 2002, J CELL SCI, V115, P2349; Shamma A, 2009, CANCER CELL, V15, P255, DOI 10.1016/j.ccr.2009.03.001; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Shortt J, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a009829; Sin WC, 2004, ONCOGENE, V23, P6299, DOI 10.1038/sj.onc.1207838; SURH CD, 1989, HEPATOLOGY, V9, P63, DOI 10.1002/hep.1840090110; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tomczak Katarzyna, 2015, Contemp Oncol (Pozn), V19, pA68, DOI 10.5114/wo.2014.47136; Tsuruta M, 1998, J HUM GENET, V43, P91, DOI 10.1007/s100380050047; Vredeveld LCW, 2012, GENE DEV, V26, P1055, DOI 10.1101/gad.187252.112; Wellbrock C, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00033; Wilsbacher JL, 2006, CELL COMMUN SIGNAL, V4; Wyder L, 2011, ANGIOGENESIS, V14, P533, DOI 10.1007/s10456-011-9238-9; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	66	5	6	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	4					723	738		10.1038/s41388-019-1022-0	http://dx.doi.org/10.1038/s41388-019-1022-0			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KF4EJ	31548614				2022-12-28	WOS:000509197200001
J	Toda, J; Ichii, M; Oritani, K; Shibayama, H; Tanimura, A; Saito, H; Yokota, T; Motooka, D; Okuzaki, D; Kitai, Y; Muromoto, R; Kashiwakura, J; Matsuda, T; Hosen, N; Kanakura, Y				Toda, Jun; Ichii, Michiko; Oritani, Kenji; Shibayama, Hirohiko; Tanimura, Akira; Saito, Hideaki; Yokota, Takafumi; Motooka, Daisuke; Okuzaki, Daisuke; Kitai, Yuichi; Muromoto, Ryuta; Kashiwakura, Jun-ichi; Matsuda, Tadashi; Hosen, Naoki; Kanakura, Yuzuru			Signal-transducing adapter protein-1 is required for maintenance of leukemic stem cells in CML	ONCOGENE			English	Article							CHRONIC MYELOID-LEUKEMIA; BCR-ABL; MOLECULAR RESPONSE; TYROSINE KINASE; IN-VITRO; IMATINIB; CONTRIBUTES; ACTIVATION; NILOTINIB; SURVIVAL	The family of signal-transducing adapter proteins (STAPs) has been reported to be involved in a variety of intracellular signaling pathways and implicated as transcriptional factors. We previously cloned STAP-2 as a c-Fms interacting protein and explored its effects on chronic myeloid leukemia (CML) leukemogenesis. STAP-2 binds to BCR-ABL, upregulates BCR-ABL phosphorylation, and activates its downstream molecules. In this study, we evaluated the role of STAP-1, another member of the STAP family, in CML pathogenesis. We found that the expression of STAP-1 is aberrantly upregulated in CML stem cells (LSCs) in patients' bone marrow. Using experimental model mice, deletion of STAP-1 prolonged the survival of CML mice with inducing apoptosis of LSCs. The impaired phosphorylation status of STAT5 by STAP-1 ablation leads to downregulation of antiapoptotic genes, Bcl-2 and Bcl-xL. Interestingly, transcriptome analyses indicated that STAP-1 affects several signaling pathways related to BCR-ABL, JAK2, and PPAR gamma. This adapter protein directly binds to not only BCR-ABL, but also STAT5 proteins, showing synergistic effects of STAP-1 inhibition and BCR-ABL or JAK2 tyrosine kinase inhibition. Our results identified STAP-1 as a regulator of CML LSCs and suggested it to be a potential therapeutic target for CML.	[Toda, Jun; Ichii, Michiko; Oritani, Kenji; Shibayama, Hirohiko; Tanimura, Akira; Saito, Hideaki; Yokota, Takafumi; Hosen, Naoki; Kanakura, Yuzuru] Osaka Univ, Dept Hematol & Oncol, Grad Sch Med, Suita, Osaka, Japan; [Oritani, Kenji] Int Univ Hlth & Welf, Grad Sch Med Sci, Dept Hematol, Narita, Japan; [Motooka, Daisuke; Okuzaki, Daisuke] Osaka Univ, Genome Informat Res Ctr, Res Inst Microbial Dis, Suita, Osaka, Japan; [Kitai, Yuichi; Muromoto, Ryuta; Kashiwakura, Jun-ichi; Matsuda, Tadashi] Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Sapporo, Hokkaido, Japan; [Kanakura, Yuzuru] Sumitomo Hosp, Osaka, Japan	Osaka University; International University of Health & Welfare; Osaka University; Hokkaido University; Sumitomo Hospital	Ichii, M (corresponding author), Osaka Univ, Dept Hematol & Oncol, Grad Sch Med, Suita, Osaka, Japan.	michii@bldon.med.osaka-u.ac.jp	Muromoto, Ryuta/E-4203-2012; Matsuda, Tadashi/A-3835-2012; Okuzaki, Daisuke/AAN-5641-2020	Muromoto, Ryuta/0000-0002-7474-493X; Matsuda, Tadashi/0000-0002-3089-3757; Okuzaki, Daisuke/0000-0002-4552-783X; /0000-0002-0297-5640; Shibayama, Hirohiko/0000-0003-4014-2815; ichii, michiko/0000-0002-0018-6656	Japan Society for the Promotion of Science KAKENHI [16K09872, 19K17829]	Japan Society for the Promotion of Science KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The authors would like to thank the courageous patients for participation and contribution to this study. We are also grateful to Ms. Habuchi, Ms. Shih, and Mr. Takashima (Osaka University) for technical support. This work was supported in part by Japan Society for the Promotion of Science KAKENHI (Grant Nos 16K09872 and 19K17829).	Abraham SA, 2016, NATURE, V534, P341, DOI 10.1038/nature18288; Agarwal P, 2019, CELL STEM CELL, V24, P769, DOI 10.1016/j.stem.2019.02.018; Agerstam H, 2016, BLOOD, V128, P2683, DOI 10.1182/blood-2015-11-679985; Chomel JC, 2016, ONCOTARGET, V7, P35293, DOI 10.18632/oncotarget.9182; Chu S, 2011, BLOOD, V118, P5565, DOI 10.1182/blood-2010-12-327437; Copland M, 2006, BLOOD, V107, P4532, DOI 10.1182/blood-2005-07-2947; Corbin AS, 2011, J CLIN INVEST, V121, P396, DOI 10.1172/JCI35721; Diaz-Blanco E, 2007, LEUKEMIA, V21, P494, DOI 10.1038/sj.leu.2404549; Fujita N, 2014, EUR J IMMUNOL, V44, P1791, DOI 10.1002/eji.201344239; Gallipoli P, 2014, BLOOD, V124, P1492, DOI 10.1182/blood-2013-12-545640; Gallipoli P, 2013, BLOOD, V122, P3335, DOI 10.1182/blood-2013-02-485607; Giustacchini A, 2017, NAT MED, V23, P692, DOI 10.1038/nm.4336; Graham SM, 2002, BLOOD, V99, P319, DOI 10.1182/blood.V99.1.319; Hamilton A, 2012, BLOOD, V119, P1501, DOI 10.1182/blood-2010-12-326843; Hoelbl A, 2010, EMBO MOL MED, V2, P98, DOI 10.1002/emmm.201000062; Hurtz C, 2011, J EXP MED, V208, P2163, DOI 10.1084/jem.20110304; Ikeda O, 2011, CANCER SCI, V102, P756, DOI 10.1111/j.1349-7006.2010.01842.x; Jiang XY, 2002, BLOOD, V100, P3731, DOI 10.1182/blood-2002-05-1324; Lemoli RM, 2009, BLOOD, V114, P5191, DOI 10.1182/blood-2008-08-176016; Liu X, 2017, LEUKEMIA, V31, P2376, DOI 10.1038/leu.2017.108; Mahon FX, 2010, LANCET ONCOL, V11, P1029, DOI 10.1016/S1470-2045(10)70233-3; Masuhara M, 2000, BIOCHEM BIOPH RES CO, V268, P697, DOI 10.1006/bbrc.2000.2223; Minoguchi M, 2003, J BIOL CHEM, V278, P11182, DOI 10.1074/jbc.M211230200; Mitchell PJ, 2000, ONCOGENE, V19, P4273, DOI 10.1038/sj.onc.1203775; Naka K, 2010, NATURE, V463, P676, DOI 10.1038/nature08734; Nelson EA, 2011, BLOOD, V117, P3421, DOI 10.1182/blood-2009-11-255232; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Ohya K, 1999, P NATL ACAD SCI USA, V96, P11976, DOI 10.1073/pnas.96.21.11976; Prost S, 2015, NATURE, V525, P380, DOI 10.1038/nature15248; Quintas-Cardama A, 2009, BLOOD, V113, P1619, DOI 10.1182/blood-2008-03-144790; Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567; Reynaud D, 2011, CANCER CELL, V20, P661, DOI 10.1016/j.ccr.2011.10.012; Ross DM, 2010, LEUKEMIA, V24, P1719, DOI 10.1038/leu.2010.185; Ross DM, 2013, BLOOD, V122, P515, DOI 10.1182/blood-2013-02-483750; Saussele S, 2018, LANCET ONCOL, V19, P747, DOI 10.1016/S1470-2045(18)30192-X; Sekine Y, 2005, J BIOL CHEM, V280, P8188, DOI 10.1074/jbc.M411692200; Sekine Y, 2012, ONCOGENE, V31, P4384, DOI 10.1038/onc.2011.604; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; Steeghs EMP, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-17704-4; Stoecker K, 2009, BIOCHEM BIOPH RES CO, V379, P121, DOI 10.1016/j.bbrc.2008.12.021; Sweet K, 2018, LEUKEMIA RES, V74, P89, DOI 10.1016/j.leukres.2018.10.002; Tokunaga M, 2010, J BIOL CHEM, V285, P31774, DOI 10.1074/jbc.M110.118653; Uchida N, 2019, MOL THER-METH CLIN D, V13, P187, DOI 10.1016/j.omtm.2019.01.005; Wang Y, 2007, BLOOD, V109, P2147, DOI 10.1182/blood-2006-08-040022; Warfvinge R, 2017, BLOOD, V129, P2384, DOI 10.1182/blood-2016-07-728873; Warsch W, 2012, ONCOTARGET, V3, P1669; Zhang B, 2012, CANCER CELL, V21, P577, DOI 10.1016/j.ccr.2012.02.018; Zhang HJ, 2012, BLOOD, V119, P2595, DOI 10.1182/blood-2011-10-387381; Zhao C, 2007, CANCER CELL, V12, P528, DOI 10.1016/j.ccr.2007.11.003; Zhao C, 2009, NATURE, V458, P776, DOI 10.1038/nature07737	50	4	4	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2020	39	34					5601	5615		10.1038/s41388-020-01387-9	http://dx.doi.org/10.1038/s41388-020-01387-9		JUL 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NE9FK	32661325	hybrid, Green Published			2022-12-28	WOS:000548100200003
J	Shrestha, S; Adhikary, G; Xu, W; Kandasamy, S; Eckert, RL				Shrestha, Suruchi; Adhikary, Gautam; Xu, Wen; Kandasamy, Sivaveera; Eckert, Richard L.			ACTL6A suppresses p21(Cip1)expression to enhance the epidermal squamous cell carcinoma phenotype	ONCOGENE			English	Article							CHROMATIN REMODELING COMPLEX; BAF53A SUBUNIT; STEM-CELLS; PKC-DELTA; P53; TRANSGLUTAMINASE; PROLIFERATION; INVASION; SURVIVAL; PROTEIN	Epidermal squamous cell carcinoma (SCC) is a common and highly invasive form of cancer. SCC arises due to ultraviolet light exposure and is associated with increased expression of pro-cancer genes and reduced expression of cancer suppressors. Actin-Like Protein 6A (ACTL6A, BAF53a) is an important protein subunit of the SWI/SNF epigenetic chromatin regulatory complex. ACTL6A is elevated in cancer cells and has been implicated as a driver of cancer cell proliferation and tumor growth. In the present study, we show that ACTL6A drives SCC cell proliferation, spheroid formation, invasion and migration, and that these activities are markedly reduced by ACTL6A knockdown. We further show that ACTL6A expression is associated with reduced levels of the p21(Cip1)cyclin-dependent kinase inhibitor and tumor suppressor protein. Molecular studies show that ACTL6A interacts with p53 DNA response elements in the p21(Cip1)gene promoter to suppress p21(Cip1)promoter activity and mRNA and protein level. Additional studies show that an increase in p21(Cip1)expression in ACTL6A knockdown cells is required for suppression of the SCC cell phenotype, suggesting that p21(Cip1)is a mediator of ACTL6A action. We further show that this regulation is p53 independent. These findings suggest that ACTL6A suppresses p21(Cip1)promoter activity to reduce p21(Cip1)protein as a mechanism to maintain the aggressive epidermal SCC phenotype.	[Shrestha, Suruchi; Adhikary, Gautam; Xu, Wen; Eckert, Richard L.] Dept Biochem & Mol Biol, Baltimore, MD 21205 USA; [Kandasamy, Sivaveera] Univ Maryland, Sch Med, Baltimore, MD 21201 USA; [Kandasamy, Sivaveera] Rutgers Robert Wood Johnson Med Sch, Dept Surg, New Brunswick, NJ USA; [Eckert, Richard L.] Dept Dermatol, Baltimore, MD 21201 USA; [Eckert, Richard L.] Dept Reprod Biol, Baltimore, MD 21205 USA; [Eckert, Richard L.] Marlene & Stewart Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; Rutgers State University New Brunswick; Rutgers State University Medical Center	Eckert, RL (corresponding author), Dept Biochem & Mol Biol, Baltimore, MD 21205 USA.; Eckert, RL (corresponding author), Dept Dermatol, Baltimore, MD 21201 USA.; Eckert, RL (corresponding author), Dept Reprod Biol, Baltimore, MD 21205 USA.; Eckert, RL (corresponding author), Marlene & Stewart Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA.	reckert@umaryland.edu			National Institutes of Health [CA184027, CA211909]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by National Institutes of Health R01 grants CA184027 and CA211909 awarded to RLE, Ph.D.	Adhikary Gautam, 2018, Oncotarget, V9, P34495, DOI 10.18632/oncotarget.26130; Adhikary G, 2015, CARCINOGENESIS, V36, P800, DOI 10.1093/carcin/bgv064; Adhikary G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084324; Adhikary G, 2010, J INVEST DERMATOL, V130, P2017, DOI 10.1038/jid.2010.108; Bao XM, 2013, CELL STEM CELL, V12, P193, DOI 10.1016/j.stem.2012.12.014; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BURNS JE, 1993, BRIT J CANCER, V67, P1274, DOI 10.1038/bjc.1993.238; Chew YC, 2012, J BIOL CHEM, V287, P16168, DOI 10.1074/jbc.M111.305292; Chew YC, 2011, J BIOL CHEM, V286, P28772, DOI 10.1074/jbc.M110.205245; Christenson LJ, 2005, JAMA-J AM MED ASSOC, V294, P681, DOI 10.1001/jama.294.6.681; Cranmer LD, 2010, ONCOLOGIST, V15, P1320, DOI 10.1634/theoncologist.2009-0210; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fisher ML, 2017, ONCOTARGET, V8, P110257, DOI 10.18632/oncotarget.22628; Fisher ML, 2016, CANCER RES, V76, P7265, DOI 10.1158/0008-5472.CAN-16-2032; Fisher ML, 2015, ONCOTARGET, V6, P20525, DOI 10.18632/oncotarget.3890; Fisher ML, 2015, MOL CANCER RES, V13, P1083, DOI 10.1158/1541-7786.MCR-14-0685-T; Grun D, 2016, ONCOGENE, V35, P4379, DOI 10.1038/onc.2015.507; Ji JX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0548-3; Kadoch C, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500447; Kerr C, 2018, MOL CARCINOGEN, V57, P3, DOI 10.1002/mc.22714; Krasteva V, 2012, BLOOD, V120, P4720, DOI 10.1182/blood-2012-04-427047; Le Borgne R, 1998, BBA-MOL CELL RES, V1404, P195, DOI 10.1016/S0167-4889(98)00057-3; Lee JH, 2005, MOL CELLS, V19, P289; Lee JH, 2003, MOL CELLS, V16, P78; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Lessard J, 2007, NEURON, V55, P201, DOI 10.1016/j.neuron.2007.06.019; Lu WS, 2015, STEM CELLS, V33, P1782, DOI 10.1002/stem.2000; Meng L, 2017, ONCOL REP, V38, P3327, DOI 10.3892/or.2017.6019; MOLLER R, 1979, ARCH DERMATOL, V115, P703, DOI 10.1001/archderm.115.6.703; Park J, 2002, MOL CELL BIOL, V22, P1307, DOI 10.1128/MCB.22.5.1307-1316.2002; Reisman DN, 2002, ONCOGENE, V21, P1196, DOI 10.1038/sj.onc.1205188; RHEINWALD JG, 1981, CANCER RES, V41, P1657; Ronan JL, 2013, NAT REV GENET, V14, P347, DOI 10.1038/nrg3413; Saha K, 2014, J BIOL CHEM, V289, P11443, DOI 10.1074/jbc.M113.543165; Saladi SV, 2017, CANCER CELL, V31, P35, DOI 10.1016/j.ccell.2016.12.001; St Pierre R, 2017, CURR OPIN GENET DEV, V42, P56, DOI 10.1016/j.gde.2017.02.004; Sun W, 2017, ONCOL REP, V37, P2405, DOI 10.3892/or.2017.5473; Taulli R, 2014, ONCOGENE, V33, P2354, DOI 10.1038/onc.2013.188; Wang M, 2007, J BIOCHEM, V142, P613, DOI 10.1093/jb/mvm176; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Xiao S, 2016, HEPATOLOGY, V63, P1256, DOI 10.1002/hep.28417; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5; Zhu B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14362-4; ZIRVI KA, 1993, CANCER BIOCHEM BIOPH, V13, P283	44	9	9	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2020	39	36					5855	5866		10.1038/s41388-020-1371-8	http://dx.doi.org/10.1038/s41388-020-1371-8		JUL 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NJ1HO	32616890	Green Accepted			2022-12-28	WOS:000545059900003
J	Du, RJ; Huang, CT; Chen, HY; Liu, KD; Xiang, P; Yao, N; Yang, L; Zhou, LT; Wu, Q; Zheng, YQ; Xin, MX; Dong, ZG; Li, X				Du, Ruijuan; Huang, Chuntian; Chen, Hanyong; Liu, Kangdong; Xiang, Pu; Yao, Ning; Yang, Lu; Zhou, Liting; Wu, Qiong; Zheng, Yaqiu; Xin, Mingxia; Dong, Zigang; Li, Xiang			SDCBP/MDA-9/syntenin phosphorylation by AURKA promotes esophageal squamous cell carcinoma progression through the EGFR-PI3K-Akt signaling pathway	ONCOGENE			English	Article							AURORA-A; MDA-9/SYNTENIN; PROTEIN; SYNTENIN; OVEREXPRESSION; PROLIFERATION; ACTIVATION; MIGRATION; SPECIFICITY; INHIBITION	SDCBP is an adapter protein containing two tandem PDZ domains mediating cell adhesion. The role and underlying molecular mechanism of SDCBP in ESCC remain obscure. Here, we report that SDCBP is frequently overexpressed in ESCC tissues and cells compared to normal controls and that its overexpression is correlated with late clinical stage and predicts poor prognosis in ESCC patients. Functionally, high expression of SDCBP is positively related to ESCC progression both in vitro and in vivo. Furthermore, mechanistic studies show that SDCBP activates the EGFR-PI3K-Akt signaling pathway by binding to EGFR and preventing EGFR internalization. Moreover, we provide evidence that AURKA binds to SDCBP and phosphorylates it at the Ser131 and Thr200 sites to inhibit ubiquitination-mediated SDCBP degradation. More importantly, the sites at which AURKA phosphorylates SDCBP are crucial for the EGFR signaling-mediated oncogenic function of SDCBP. Taken together, we propose that SDCBP phosphorylation by AURKA prevents SDCBP degradation and promotes ESCC tumor growth through the EGFR-PI3K-Akt signaling pathway. Our findings unveil a new AURKA-SDCBP-EGFR axis that is involved in ESCC progression and provide a promising therapeutic target for ESCC treatment in the clinic.	[Du, Ruijuan; Huang, Chuntian; Liu, Kangdong; Zhou, Liting; Wu, Qiong; Dong, Zigang; Li, Xiang] Zhengzhou Univ, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou 450001, Henan, Peoples R China; [Du, Ruijuan; Huang, Chuntian; Liu, Kangdong; Yao, Ning; Yang, Lu; Zhou, Liting; Wu, Qiong; Zheng, Yaqiu; Xin, Mingxia; Dong, Zigang; Li, Xiang] China US Henan Hormel Canc Inst, 127 Dongming Rd, Zhengzhou 450008, Henan, Peoples R China; [Chen, Hanyong] Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; [Liu, Kangdong; Dong, Zigang; Li, Xiang] Collaborat Innovat Ctr Henan Prov Canc Chemopreve, Zhengzhou, Peoples R China; [Liu, Kangdong; Dong, Zigang; Li, Xiang] Zhengzhou Univ, State Key Lab Esophageal Canc Prevent & Treatment, Zhengzhou, Henan, Peoples R China; [Xiang, Pu] Zhengzhou Univ, Dept Hematol, Affiliated Canc Hosp, Zhengzhou 450008, Henan, Peoples R China; [Xiang, Pu] Henan Canc Hosp, Zhengzhou 450008, Henan, Peoples R China	Zhengzhou University; University of Minnesota System; Zhengzhou University; Zhengzhou University; Zhengzhou University	Dong, ZG; Li, X (corresponding author), Zhengzhou Univ, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou 450001, Henan, Peoples R China.; Dong, ZG; Li, X (corresponding author), China US Henan Hormel Canc Inst, 127 Dongming Rd, Zhengzhou 450008, Henan, Peoples R China.; Dong, ZG; Li, X (corresponding author), Collaborat Innovat Ctr Henan Prov Canc Chemopreve, Zhengzhou, Peoples R China.; Dong, ZG; Li, X (corresponding author), Zhengzhou Univ, State Key Lab Esophageal Canc Prevent & Treatment, Zhengzhou, Henan, Peoples R China.	dongzg@zzu.edu.cn; lixiang@zzu.edu.cn			National Natural Science Foundation of China [81802795, 31301144]; Key Scientific Research Project Plan of Colleges and Universities in Henan Province [18A310034]; Science and Technology Project of Henan Province [182102310324, 202102310206]; Training plan for Young Backbone Teachers of Zhengzhou University [2018ZDGGJS037]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Scientific Research Project Plan of Colleges and Universities in Henan Province; Science and Technology Project of Henan Province; Training plan for Young Backbone Teachers of Zhengzhou University	This study was supported by the National Natural Science Foundation of China (Nos. 81802795 and 31301144); the Key Scientific Research Project Plan of Colleges and Universities in Henan Province (No. 18A310034); the Science and Technology Project of Henan Province (Nos. 182102310324 and 202102310206); and the Training plan for Young Backbone Teachers of Zhengzhou University (No. 2018ZDGGJS037).	Baietti MF, 2012, NAT CELL BIOL, V14, P677, DOI 10.1038/ncb2502; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Boukerche H, 2005, CANCER RES, V65, P10901, DOI 10.1158/0008-5472.CAN-05-1614; Boukerche H, 2010, ONCOGENE, V29, P3054, DOI 10.1038/onc.2010.65; Boukerche H, 2008, P NATL ACAD SCI USA, V105, P15914, DOI 10.1073/pnas.0808171105; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Choi Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep36818; Cui L, 2016, ONCOTARGET, V7, P82634, DOI 10.18632/oncotarget.13020; Das SK, 2012, FRONT BIOSCI-LANDMRK, V17, P1, DOI 10.2741/3911; Dasgupta S, 2013, CLIN CANCER RES, V19, P4621, DOI 10.1158/1078-0432.CCR-13-0585; Dutertre S, 2002, ONCOGENE, V21, P6175, DOI 10.1038/sj.onc.1205775; Egea-Jimenez AL, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12101; Fancelli D, 2006, J MED CHEM, V49, P7247, DOI 10.1021/jm060897w; Ferrari S, 2005, BIOCHEM J, V390, P293, DOI 10.1042/BJ20050343; Gangemi R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029989; Gao YB, 2014, NAT GENET, V46, P1097, DOI 10.1038/ng.3076; Guan Z, 2007, CANCER RES, V67, P10436, DOI 10.1158/0008-5472.CAN-07-1379; Humphrey SJ, 2015, TRENDS ENDOCRIN MET, V26, P676, DOI 10.1016/j.tem.2015.09.013; Kamran M, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2016.80; Kang BS, 2003, STRUCTURE, V11, P845, DOI 10.1016/S0969-2126(03)00125-4; Kang BS, 2003, STRUCTURE, V11, P459, DOI 10.1016/S0969-2126(03)00052-2; Kegelman TP, 2017, P NATL ACAD SCI USA, V114, P370, DOI 10.1073/pnas.1616100114; Kegelman TP, 2014, NEURO-ONCOLOGY, V16, P50, DOI 10.1093/neuonc/not157; Koo TH, 2002, ONCOGENE, V21, P4080, DOI 10.1038/sj.onc.1205514; Liu JH, 2018, EUR J MED CHEM, V154, P354, DOI 10.1016/j.ejmech.2018.05.015; Lopez-Saez JF, 1998, HISTOL HISTOPATHOL, V13, P1197, DOI 10.14670/HH-13.1197; Luyten A, 2008, MOL BIOL CELL, V19, P1594, DOI 10.1091/mbc.E07-08-0832; Macindoe G, 2010, NUCLEIC ACIDS RES, V38, pW445, DOI 10.1093/nar/gkq311; Melhado Rachel E, 2010, Cancers (Basel), V2, P1379, DOI 10.3390/cancers2031379; Mori H, 1999, MUTAT RES-FUND MOL M, V428, P291, DOI 10.1016/S1383-5742(99)00055-1; Ohno K, 2004, MOL CELL NEUROSCI, V26, P518, DOI 10.1016/j.mcn.2004.04.007; Otto T, 2009, CANCER CELL, V15, P67, DOI 10.1016/j.ccr.2008.12.005; Oyesanya Regina A, 2014, Oncoscience, V1, P725; Qian XL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060046; Qina L, 2009, CANCER LETT, V275, P77, DOI 10.1016/j.canlet.2008.10.011; Radivojac P, 2008, BIOINFORMATICS, V24, pI241, DOI 10.1093/bioinformatics/btn267; Rajesh S, 2011, J BIOL CHEM, V286, P39606, DOI 10.1074/jbc.M111.262402; Sala-Valdes M, 2012, J CELL SCI, V125, P1235, DOI 10.1242/jcs.094912; Talukdar S, 2018, P NATL ACAD SCI USA, V115, P5768, DOI 10.1073/pnas.1721650115; Tanaka E, 2005, CLIN CANCER RES, V11, P1827, DOI 10.1158/1078-0432.CCR-04-1627; Tong T, 2004, CLIN CANCER RES, V10, P7304, DOI 10.1158/1078-0432.CCR-04-0806; Wang J, 2017, J CELL SCI, V130, P1078, DOI 10.1242/jcs.196790; Wang J, 2017, BMC BIOL, V15, DOI 10.1186/s12915-016-0335-5; Wang LK, 2016, ONCOTARGET, V7, P386, DOI 10.18632/oncotarget.6299; Wang XX, 2012, MOL CANCER RES, V10, P588, DOI 10.1158/1541-7786.MCR-11-0416; Yang H, 2006, INT J CANCER, V119, P2304, DOI 10.1002/ijc.22154; Yang SB, 2007, ONCOL REP, V17, P1083; Yao JE, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-95; Yoshida GJ, 2018, P NATL ACAD SCI USA, V115, pE7652, DOI 10.1073/pnas.1810152115; Zeng HM, 2018, LANCET GLOB HEALTH, V6, pE555, DOI 10.1016/S2214-109X(18)30127-X; Zhong D, 2012, ASIAN PAC J CANCER P, V13, P2897, DOI 10.7314/APJCP.2012.13.6.2897; Zimmermann P, 2001, MOL BIOL CELL, V12, P339, DOI 10.1091/mbc.12.2.339	52	12	12	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 30	2020	39	31					5405	5419		10.1038/s41388-020-1369-2	http://dx.doi.org/10.1038/s41388-020-1369-2		JUN 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MT1TS	32572158				2022-12-28	WOS:000542723000003
J	Koyen, AE; Madden, MZ; Park, D; Minten, EV; Kapoor-Vazirani, P; Werner, E; Pfister, NT; Haji-Seyed-Javadi, R; Zhang, H; Xu, J; Deng, N; Duong, DM; Pecen, TJ; Frazier, Z; Nagel, ZD; Lazaro, JB; Mouw, KW; Seyfried, NT; Moreno, CS; Owonikoko, TK; Deng, XM; Yu, DS				Koyen, Allyson E.; Madden, Matthew Z.; Park, Dongkyoo; Minten, Elizabeth, V; Kapoor-Vazirani, Priya; Werner, Erica; Pfister, Neil T.; Haji-Seyed-Javadi, Ramona; Zhang, Hui; Xu, Jie; Deng, Nikita; Duong, Duc M.; Pecen, Turner J.; Frazier, Zoe; Nagel, Zachary D.; Lazaro, Jean-Bernard; Mouw, Kent W.; Seyfried, Nicholas T.; Moreno, Carlos S.; Owonikoko, Taofeek K.; Deng, Xingming; Yu, David S.			EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repair	ONCOGENE			English	Article							OVARIAN-CANCER CELLS; GROUP PROTEIN EZH2; LUNG-CANCER; IN-VIVO; NONCANONICAL FUNCTION; SELECTIVE-INHIBITION; GENE-EXPRESSION; DNA-REPAIR; POLYCOMB; METHYLATION	Small cell lung cancer (SCLC) is a highly aggressive malignancy with poor outcomes associated with resistance to cisplatin-based chemotherapy. Enhancer of zeste homolog 2 (EZH2) is the catalytic subunit of polycomb repressive complex 2 (PRC2), which silences transcription through trimethylation of histone H3 lysine 27 (H3K27me3) and has emerged as an important therapeutic target with inhibitors targeting its methyltransferase activity under clinical investigation. Here, we show that EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repair (NER) and govern cisplatin resistance in SCLC. Using a synthetic lethality screen, we identified important regulators of cisplatin resistance in SCLC cells, including EZH2. EZH2 depletion causes cellular cisplatin and UV hypersensitivity in an epistatic manner with DDB1-DDB2. EZH2 complexes with DDB1-DDB2 and promotes DDB2 stability by impairing its ubiquitination independent of methyltransferase activity or PRC2, thereby facilitating DDB2 localization to cyclobutane pyrimidine dimer crosslinks to govern their repair. Furthermore, targeting EZH2 for depletion with DZNep strongly sensitizes SCLC cells and tumors to cisplatin. Our findings reveal a non-catalytic and PRC2-independent function for EZH2 in promoting NER through DDB2 stabilization, suggesting a rationale for targeting EZH2 beyond its catalytic activity for overcoming cisplatin resistance in SCLC.	[Koyen, Allyson E.; Madden, Matthew Z.; Park, Dongkyoo; Minten, Elizabeth, V; Kapoor-Vazirani, Priya; Werner, Erica; Pfister, Neil T.; Haji-Seyed-Javadi, Ramona; Zhang, Hui; Xu, Jie; Deng, Nikita; Deng, Xingming; Yu, David S.] Emory Univ, Dept Radiat Oncol, Sch Med, Atlanta, GA 30322 USA; [Duong, Duc M.; Seyfried, Nicholas T.] Emory Univ, Dept Biochem, Sch Med, Atlanta, GA 30322 USA; [Pecen, Turner J.; Nagel, Zachary D.] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; [Frazier, Zoe; Lazaro, Jean-Bernard; Mouw, Kent W.] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA; [Moreno, Carlos S.] Emory Univ, Dept Pathol & Lab Med, Sch Med, Atlanta, GA 30322 USA; [Owonikoko, Taofeek K.] Emory Univ, Dept Hematol & Med Oncol, Sch Med, Atlanta, GA 30322 USA	Emory University; Emory University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Emory University; Emory University	Yu, DS (corresponding author), Emory Univ, Dept Radiat Oncol, Sch Med, Atlanta, GA 30322 USA.	dsyu@emory.edu	Classen, Scott/AAY-8176-2020; Moreno, Carlos S/B-3863-2009	Moreno, Carlos S/0000-0002-5582-0028; Mouw, Kent/0000-0001-7939-7343; Madden, Matthew/0000-0003-4062-4427; Werner, Erica/0000-0002-8183-1601	NCI NIH HHS [P01 CA092584, R01 CA193828, R01 CA178999, F31 CA225119] Funding Source: Medline; NIEHS NIH HHS [U01 ES029520] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Barakat BM, 2010, INT J CANCER, V127, P977, DOI 10.1002/ijc.25112; Barckhausen C, 2014, ONCOGENE, V33, P1964, DOI 10.1038/onc.2013.141; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Byers LA, 2012, CANCER DISCOV, V2, P798, DOI 10.1158/2159-8290.CD-12-0112; Byrski T, 2008, BREAST CANCER RES TR, V108, P289, DOI 10.1007/s10549-007-9600-1; Byrski T, 2014, BREAST CANCER RES TR, V147, P401, DOI 10.1007/s10549-014-3100-x; Campbell S, 2013, CELL CYCLE, V12, P2675, DOI 10.4161/cc.25795; Ceccaldi R, 2015, NATURE, V518, P258, DOI 10.1038/nature14184; Chang JW, 2016, ORAL ONCOL, V52, P66, DOI 10.1016/j.oraloncology.2015.11.002; Chen XA, 2001, J BIOL CHEM, V276, P48175, DOI 10.1074/jbc.M106808200; Chen YT, 2016, CANCER CHEMOTH PHARM, V77, P757, DOI 10.1007/s00280-016-2990-1; Chou DM, 2010, P NATL ACAD SCI USA, V107, P18475, DOI 10.1073/pnas.1012946107; Chute JP, 1999, J CLIN ONCOL, V17, P1794, DOI 10.1200/JCO.1999.17.6.1794; Coe BP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071670; Colbert LE, 2014, CANCER RES, V74, P2677, DOI 10.1158/0008-5472.CAN-13-1996; Crea F, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-40; El-Mahdy MA, 2006, J BIOL CHEM, V281, P13404, DOI 10.1074/jbc.M511834200; Fei J, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001183; Fischer ES, 2011, CELL, V147, P1024, DOI 10.1016/j.cell.2011.10.035; Fitch ME, 2003, J BIOL CHEM, V278, P46906, DOI 10.1074/jbc.M307254200; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Gardner EE, 2017, CANCER CELL, V31, P286, DOI 10.1016/j.ccell.2017.01.006; Groisman R, 2003, CELL, V113, P357, DOI 10.1016/S0092-8674(03)00316-7; He AB, 2012, GENE DEV, V26, P37, DOI 10.1101/gad.173930.111; Horita N, 2015, SCI REP-UK, V5, DOI 10.1038/srep18113; Hu S, 2010, CANCER BIOL THER, V10, P788, DOI 10.4161/cbt.10.8.12913; Huang S, 2017, CANCER RES, V77, P6562, DOI 10.1158/0008-5472.CAN-17-1570; Huang YX, 2017, MOL CARCINOGEN, V56, P447, DOI 10.1002/mc.22507; Hubaux R, 2013, J THORAC ONCOL, V8, P1102, DOI 10.1097/JTO.0b013e318298762f; Jansson M, 2008, NAT CELL BIOL, V10, P1431, DOI 10.1038/ncb1802; Jiang FZ, 2015, ONCOTARGET, V6, P44660, DOI 10.18632/oncotarget.6350; KEENEY S, 1993, J BIOL CHEM, V268, P21293; Kim E, 2013, CANCER CELL, V23, P839, DOI 10.1016/j.ccr.2013.04.008; Kim J, 2018, CELL REP, V25, P2808, DOI 10.1016/j.celrep.2018.11.035; Knutson SK, 2014, MOL CANCER THER, V13, P842, DOI 10.1158/1535-7163.MCT-13-0773; Lee JM, 2012, MOL CELL, V48, P572, DOI 10.1016/j.molcel.2012.09.004; Lei AH, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00422; Li H, 2010, MOL CANCER RES, V8, P1610, DOI 10.1158/1541-7786.MCR-10-0398; Li ZW, 2013, ONCOTARGET, V4, P2532, DOI 10.18632/oncotarget.1503; Liu HD, 2016, ONCOTARGET, V7, P56338, DOI 10.18632/oncotarget.10841; Marteijn JA, 2014, NAT REV MOL CELL BIO, V15, P465, DOI 10.1038/nrm3822; Matsumoto S, 2015, NUCLEIC ACIDS RES, V43, P1700, DOI 10.1093/nar/gkv038; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; Miranda TB, 2009, MOL CANCER THER, V8, P1579, DOI 10.1158/1535-7163.MCT-09-0013; Murai F, 2015, CELL DISCOV, V1, DOI 10.1038/celldisc.2015.26; Nagel ZD, 2014, P NATL ACAD SCI USA, V111, pE1823, DOI 10.1073/pnas.1401182111; Nienstedt JC, 2018, J ORAL PATHOL MED, V47, P240, DOI 10.1111/jop.12673; Owonikoko TK, 2014, CANCER MED-US, V3, P1579, DOI 10.1002/cam4.317; Pines A, 2012, J CELL BIOL, V199, P235, DOI 10.1083/jcb.201112132; Puppe J, 2019, CLIN CANCER RES, V25, P4351, DOI 10.1158/1078-0432.CCR-18-4024; Qi W, 2012, P NATL ACAD SCI USA, V109, P21360, DOI 10.1073/pnas.1210371110; Rao ZY, 2010, CARCINOGENESIS, V31, P1576, DOI 10.1093/carcin/bgq150; Rondinelli B, 2017, NAT CELL BIOL, V19, P1371, DOI 10.1038/ncb3626; Sanulli S, 2015, MOL CELL, V57, P769, DOI 10.1016/j.molcel.2014.12.020; Sato T, 2013, SCI REP-UK, V3, DOI 10.1038/srep01911; Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI [10.3322/caac.21601, 10.3322/caac.21590]; Smith SC, 2014, NUCLEIC ACIDS RES, V42, P11517, DOI 10.1093/nar/gku840; Stefansson OA, 2012, EPIGENETICS-US, V7, P1225, DOI 10.4161/epi.22561; Stoyanova T, 2008, MOL CELL BIOL, V28, P177, DOI 10.1128/MCB.00880-07; Stoyanova T, 2009, P NATL ACAD SCI USA, V106, P10690, DOI 10.1073/pnas.0812254106; Sun S, 2018, CANCER SCI, V109, P1853, DOI 10.1111/cas.13599; Takedachi A, 2010, MOL CELL BIOL, V30, P2708, DOI 10.1128/MCB.01460-09; Vasanthakumar A, 2017, EMBO REP, V18, P619, DOI 10.15252/embr.201643237; Vaswani RG, 2016, J MED CHEM, V59, P9928, DOI 10.1021/acs.jmedchem.6b01315; Wan LX, 2018, MOL CELL, V69, P279, DOI 10.1016/j.molcel.2017.12.024; Wang QE, 2007, NUCLEIC ACIDS RES, V35, P5338, DOI 10.1093/nar/gkm550; Wu Z, 2011, CELL DEATH DIFFER, V18, P1771, DOI 10.1038/cdd.2011.48; Xa H, 2012, ONCOL LETT, V4, P135, DOI 10.3892/ol.2012.696; Xie HF, 2016, CANCER DISCOV, V6, P1237, DOI 10.1158/2159-8290.CD-15-1439; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Xu L, 2019, MOL MED REP, V19, P4249, DOI 10.3892/mmr.2019.10075; Yamaguchi H, 2018, ONCOGENE, V37, P208, DOI 10.1038/onc.2017.311; Yan JL, 2016, BLOOD, V128, P948, DOI 10.1182/blood-2016-01-690701; Yap DB, 2011, BLOOD, V117, P2451, DOI 10.1182/blood-2010-11-321208; Zeidler M, 2005, NEOPLASIA, V7, P1011, DOI 10.1593/neo.05472; Zhang L, 2012, CELL CYCLE, V11, P4378, DOI 10.4161/cc.22688; Zhao R, 2015, NUCLEIC ACIDS RES, V43, P7838, DOI 10.1093/nar/gkv667	77	20	20	3	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 18	2020	39	25					4798	4813		10.1038/s41388-020-1332-2	http://dx.doi.org/10.1038/s41388-020-1332-2			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LZ3HT	32457468	Green Accepted			2022-12-28	WOS:000541119400002
J	Lin, RR; Zhan, M; Yang, LH; Wang, H; Shen, H; Huang, S; Huang, XC; Xu, SW; Zhang, ZJ; Li, WJ; Liu, Q; Shi, YS; Chen, W; Yu, JX; Wang, J				Lin, Ruirong; Zhan, Ming; Yang, Linhua; Wang, Hui; Shen, Hui; Huang, Shuai; Huang, Xince; Xu, Sunwang; Zhang, Zijie; Li, Weijian; Liu, Qiang; Shi, Yongsheng; Chen, Wei; Yu, Jianxiu; Wang, Jian			Deoxycholic acid modulates the progression of gallbladder cancer through N-6-methyladenosine-dependent microRNA maturation	ONCOGENE			English	Article							BILE-ACIDS; CHOLANGIOCYTE PROLIFERATION; NUCLEAR-RNA; MESSENGER; METABOLISM; APOPTOSIS; N6-METHYLADENOSINE; INFLAMMATION; ACTIVATION; ENDOCRINE	Bile acids (BAs), well-defined signaling molecules with diverse metabolic functions, play important roles in cellular processes associated with many cancers. As one of the most common BAs, deoxycholic acid (DCA) is originally synthesized in the liver, stored in the gallbladder, and processed in the gut. DCA plays crucial roles in various tumors; however, functions and molecular mechanisms of DCA in gallbladder cancer (GBC) still remain poorly characterized. Here, we analyzed human GBC samples and found that DCA was significantly downregulated in GBC, and reduced levels of DCA was associated with poor clinical outcome in patients with GBC. DCA treatment impeded tumor progression by halting cell proliferation. DCA decreased miR-92b-3p expression in an m(6)A-dependent posttranscriptional modification manner by facilitating dissociation of METTL3 from METTL3-METTL14-WTAP complex, which increased the protein level of the phosphatase and tensin homolog, a newly identified target of miR-92b-3p, and subsequently inactivated the PI3K/AKT signaling pathway. Our findings revealed that DCA might function as a tumor suppressive factor in GBC at least by interfering with miR-92b-3p maturation, and suggested that DCA treatment could provide a new therapeutic strategy for GBC.	[Lin, Ruirong; Zhan, Ming; Yang, Linhua; Wang, Hui; Shen, Hui; Huang, Shuai; Huang, Xince; Xu, Sunwang; Zhang, Zijie; Li, Weijian; Chen, Wei; Wang, Jian] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Biliary Pancreat Surg, Shanghai 200127, Peoples R China; [Liu, Qiang; Shi, Yongsheng] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Pathol, Shanghai 200127, Peoples R China; [Yu, Jianxiu] Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Tumor Microenvironm & Inflammat, Dept Biochem & Mol Cell Biol, Shanghai 200025, Peoples R China; [Yu, Jianxiu; Wang, Jian] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Basic Clin Res Ctr, Shanghai 200127, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Wang, J (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Biliary Pancreat Surg, Shanghai 200127, Peoples R China.; Yu, JX (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Tumor Microenvironm & Inflammat, Dept Biochem & Mol Cell Biol, Shanghai 200025, Peoples R China.; Yu, JX; Wang, J (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Basic Clin Res Ctr, Shanghai 200127, Peoples R China.	Jianxiu.Yu@gmail.com; dr_wangjian@126.com	Liu, Qiang/HHZ-3181-2022	Zhang, ZiJie/0000-0002-2513-3091; Wang, Jian/0000-0002-5335-8845; Lin, Ruirong/0000-0003-1675-8724	National Natural Science Foundation of China [81974370, 81773184, 81472240]; Shanghai Outstanding Academic Leaders Plan (2016); High-Level Collaborative Innovation Team Incentive Program of Shanghai Municipal Education Commission (2018)	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Outstanding Academic Leaders Plan (2016); High-Level Collaborative Innovation Team Incentive Program of Shanghai Municipal Education Commission (2018)	The authors acknowledge the grants from National Natural Science Foundation of China (81974370, 81773184, and 81472240 to JW), Shanghai Outstanding Academic Leaders Plan (2016 to JW), and High-Level Collaborative Innovation Team Incentive Program of Shanghai Municipal Education Commission (2018 to JW).	Alarcon CR, 2015, NATURE, V519, P482, DOI 10.1038/nature14281; Alpini G, 1997, AM J PHYSIOL-GASTR L, V273, pG518, DOI 10.1152/ajpgi.1997.273.2.G518; Alpini G, 1999, GASTROENTEROLOGY, V116, P179, DOI 10.1016/S0016-5085(99)70242-8; Batista PJ, 2014, CELL STEM CELL, V15, P707, DOI 10.1016/j.stem.2014.09.019; Bokar JA, 1997, RNA, V3, P1233; Broeders EPM, 2015, CELL METAB, V22, P418, DOI 10.1016/j.cmet.2015.07.002; Chavez-Talavera O, 2017, GASTROENTEROLOGY, V152, P1679, DOI 10.1053/j.gastro.2017.01.055; Chen MN, 2018, HEPATOLOGY, V67, P2254, DOI 10.1002/hep.29683; Cheng L, 2019, J CELL BIOCHEM, V120, P17405, DOI 10.1002/jcb.29005; Devkota S, 2012, NATURE, V487, P104, DOI 10.1038/nature11225; Dominissini D, 2012, NATURE, V485, P201, DOI 10.1038/nature11112; Du YZ, 2018, NUCLEIC ACIDS RES, V46, P5195, DOI 10.1093/nar/gky156; Gafar AA, 2016, PEERJ, V4, DOI 10.7717/peerj.2445; Geula S, 2015, SCIENCE, V347, P1002, DOI 10.1126/science.1261417; Goldberg AA, 2011, ONCOTARGET, V2, P761; Graf D, 2002, GASTROENTEROLOGY, V122, P1411, DOI 10.1053/gast.2002.32976; Hohenester S, 2010, J HEPATOL, V53, P918, DOI 10.1016/j.jhep.2010.05.015; Horowitz NS, 2007, GYNECOL ONCOL, V107, P344, DOI 10.1016/j.ygyno.2007.07.072; Hou JJ, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1082-3; Houten SM, 2006, EMBO J, V25, P1419, DOI 10.1038/sj.emboj.7601049; Huang J, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1919; Huang WD, 2006, SCIENCE, V312, P233, DOI 10.1126/science.1121435; Hundal R, 2014, CLIN EPIDEMIOL, V6, P99, DOI 10.2147/CLEP.S37357; Jia GF, 2011, NAT CHEM BIOL, V7, P885, DOI [10.1038/NCHEMBIO.687, 10.1038/nchembio.687]; Jonsson AL, 2017, NAT REV CARDIOL, V14, P79, DOI 10.1038/nrcardio.2016.183; Keitel V, 2008, WORLD J GASTROENTERO, V14, P5620, DOI 10.3748/wjg.14.5620; Kim DH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12179; Konig A, 2014, J HEPATOL, V61, P867, DOI 10.1016/j.jhep.2014.05.018; Kong YW, 2012, LANCET ONCOL, V13, pE249, DOI 10.1016/S1470-2045(12)70073-6; Kovacs P, 2019, CANCERS, V11, DOI 10.3390/cancers11091255; Lefebvre P, 2009, PHYSIOL REV, V89, P147, DOI 10.1152/physrev.00010.2008; Li K, 2019, FLOW MEAS INSTRUM, V69, DOI 10.1016/j.flowmeasinst.2019.101590; Li TG, 2014, PHARMACOL REV, V66, P948, DOI 10.1124/pr.113.008201; Lin SB, 2015, NAT REV CANCER, V15, P321, DOI 10.1038/nrc3932; Liu JZ, 2014, NAT CHEM BIOL, V10, P93, DOI 10.1038/nchembio.1432; Liu RP, 2014, HEPATOLOGY, V60, P908, DOI 10.1002/hep.27085; Meyer KD, 2012, CELL, V149, P1635, DOI 10.1016/j.cell.2012.05.003; Miko E, 2018, BBA-BIOENERGETICS, V1859, P958, DOI 10.1016/j.bbabio.2018.04.002; Neuschwander-Tetri BA, 2015, LANCET, V385, P956, DOI 10.1016/S0140-6736(14)61933-4; Pan T, 2013, TRENDS BIOCHEM SCI, V38, P204, DOI 10.1016/j.tibs.2012.12.006; Ping XL, 2014, CELL RES, V24, P177, DOI 10.1038/cr.2014.3; Pols TWH, 2011, CELL METAB, V14, P747, DOI 10.1016/j.cmet.2011.11.006; Pols TWH, 2011, J HEPATOL, V54, P1263, DOI 10.1016/j.jhep.2010.12.004; Rolo AP, 2004, TOXICOL SCI, V79, P196, DOI 10.1093/toxsci/kfh078; Shapiro H, 2018, J EXP MED, V215, P383, DOI 10.1084/jem.20171965; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Stinton LM, 2012, GUT LIVER, V6, P172, DOI 10.5009/gnl.2012.6.2.172; Sun Y, 2019, THER ADV MED ONCOL, V11, DOI 10.1177/1758835919855859; Tang W, 2019, CLIN CANCER RES, V25, P5972, DOI 10.1158/1078-0432.CCR-19-0094; Valle J, 2010, NEW ENGL J MED, V362, P1273, DOI 10.1056/NEJMoa0908721; Wang X, 2016, NATURE, V534, P575, DOI 10.1038/nature18298; Wang X, 2014, NATURE, V505, P117, DOI 10.1038/nature12730; Wang XD, 2015, 2015 5TH INTERNATIONAL CONFERENCE ON ELECTRIC UTILITY DEREGULATION AND RESTRUCTURING AND POWER TECHNOLOGIES (DRPT 2015), P161, DOI 10.1109/DRPT.2015.7432219; Wang YQ, 2017, HEPATOLOGY, V65, P2005, DOI 10.1002/hep.29076; Wistuba II, 2004, NAT REV CANCER, V4, P695, DOI 10.1038/nrc1429; Wolpin BM, 2010, NEW ENGL J MED, V362, P1335, DOI 10.1056/NEJMe1001183; Xiao W, 2016, MOL CELL, V61, P507, DOI 10.1016/j.molcel.2016.01.012; Xu SW, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13420-x; Zhang JL, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09712-x; Zhang W, 2020, J CELL BIOCHEM, V121, P1998, DOI 10.1002/jcb.29434; Zhao X, 2014, CELL RES, V24, P1403, DOI 10.1038/cr.2014.151; Zheng GQ, 2013, MOL CELL, V49, P18, DOI 10.1016/j.molcel.2012.10.015	62	27	27	4	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 25	2020	39	26					4983	5000		10.1038/s41388-020-1349-6	http://dx.doi.org/10.1038/s41388-020-1349-6		JUN 2020	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MQ2YO	32514152	hybrid, Green Published			2022-12-28	WOS:000538969800001
J	Huang, WJ; Tian, XP; Bi, SX; Zhang, SR; He, TS; Song, LY; Yun, JP; Zhou, ZG; Yu, RM; Li, M				Huang, Wei-Juan; Tian, Xiao-Peng; Bi, Si-Xue; Zhang, Si-Rui; He, Ting-Sha; Song, Li-Yan; Yun, Jing-Ping; Zhou, Zhong-Guo; Yu, Rong-Min; Li, Mei			The beta-catenin/TCF-4-LINC01278-miR-1258-Smad2/3 axis promotes hepatocellular carcinoma metastasis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; WNT/BETA-CATENIN PATHWAY; LONG NONCODING RNAS; CELL-PROLIFERATION; ACTIVATION; CROSSTALK; NETWORKS; CERNA	Hepatocellular carcinoma (HCC) metastasis is largely responsible for HCC-associated recurrence and mortality. We aimed to identify metastasis-related long non-coding RNAs (lncRNAs) to understand the molecular mechanism of HCC metastasis. We first identified that miR-1258 was downregulated in HCC tissues both in The Cancer Genome Atlas (TCGA) and Sun Yat-sen University Cancer Center (SYSUCC) dataset. MiR-1258 expression negatively correlated with recurrence-free survival and overall survival of HCC patients. MiR-1258 overexpression inhibited migration and invasion of HCC cells both in vitro and in vivo, whereas miR-1258 downregulation promoted cell metastasis. Luciferase assays verified direct binding of miR-1258 to Smad2 and Smad3, thereby attenuating TGF-beta/Smad signaling. We further established that lncRNA LINC01278 was a negative regulator of miR-1258. In vivo and in vitro assays demonstrated that LINC01278-mediated HCC metastasis was dependent on miR-1258 expression. Furthermore, miR-1258 downregulation in turn increased LINC01278 expression. We also observed that TCF-4 could bind to the LINC01278 promoter site. In addition, LINC01278 downregulation decreased migration and invasion of HCC cells induced by beta-catenin and TGF-beta 1 both in vitro and in vivo. We uncovered a novel mechanism for beta-catenin/TCF-4-LINC01278-miR-1258-Smad2/3 feedback loop activation in HCC metastasis, and the study indicated that LINC01278 could serve as a therapeutic target for HCC metastasis.	[Huang, Wei-Juan; Bi, Si-Xue; Zhang, Si-Rui; He, Ting-Sha; Song, Li-Yan; Yu, Rong-Min] Jinan Univ, Coll Pharm, Dept Pharmacol, Guangzhou, Peoples R China; [Huang, Wei-Juan; Yu, Rong-Min] Jinan Univ, Integrated Chinese & Western Med Postdoctoral Res, Guangzhou, Peoples R China; [Huang, Wei-Juan; Yu, Rong-Min] Jinan Univ, Biotechnol Inst Chinese Mat Med, Guangzhou, Peoples R China; [Tian, Xiao-Peng; Yun, Jing-Ping; Li, Mei] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Ctr Canc, Guangzhou, Peoples R China; [Yun, Jing-Ping; Li, Mei] Sun Yat Sen Univ, Ctr Canc, Dept Pathol, Guangzhou, Peoples R China; [Zhou, Zhong-Guo] Sun Yat Sen Univ, Ctr Canc, Dept Hepatol, Guangzhou, Peoples R China	Jinan University; Jinan University; Jinan University; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Li, M (corresponding author), Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Ctr Canc, Guangzhou, Peoples R China.; Li, M (corresponding author), Sun Yat Sen Univ, Ctr Canc, Dept Pathol, Guangzhou, Peoples R China.	limei@sysucc.org.cn			National Natural Science Foundation of China [81973384]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from National Natural Science Foundation of China (81973384).	Ally A, 2017, CELL, V169, P1327, DOI 10.1016/j.cell.2017.05.046; Anastasiadou E, 2018, NAT REV CANCER, V18, P5, DOI 10.1038/nrc.2017.99; Arun G, 2018, TRENDS MOL MED, V24, P257, DOI 10.1016/j.molmed.2018.01.001; Chen DL, 2017, THERANOSTICS, V7, P4836, DOI 10.7150/thno.20942; Clarke DC, 2008, TRENDS CELL BIOL, V18, P430, DOI 10.1016/j.tcb.2008.06.006; Ding N, 2013, CELL, V153, P601, DOI 10.1016/j.cell.2013.03.028; DiRenzo DM, 2016, CELL SIGNAL, V28, P498, DOI 10.1016/j.cellsig.2016.02.011; Farre D, 2003, NUCLEIC ACIDS RES, V31, P3651, DOI 10.1093/nar/gkg605; Forner A, 2018, LANCET, V391, P1301, DOI 10.1016/S0140-6736(18)30010-2; Gagliardi M, 2016, METHODS MOL BIOL, V1480, P73, DOI 10.1007/978-1-4939-6380-5_7; Joliat GR, 2018, EUR J GASTROEN HEPAT, V30, P792, DOI 10.1097/MEG.0000000000001115; Li GY, 2018, THERANOSTICS, V8, P2846, DOI 10.7150/thno.23463; Lin SJ, 2019, CANCER MANAG RES, V11, P8557, DOI 10.2147/CMAR.S217886; Liu W, 2019, BIOCHEM BIOPH RES CO, V510, P479, DOI 10.1016/j.bbrc.2019.01.139; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; Paraskevopoulou MD, 2016, NUCLEIC ACIDS RES, V44, pD231, DOI 10.1093/nar/gkv1270; Ceballos MP, 2011, BIOCHEM PHARMACOL, V82, P1682, DOI 10.1016/j.bcp.2011.08.001; Qiu JL, 2017, J CLIN ONCOL, V35, P734, DOI [10.1200/JCO.2016.68.2153, 10.1200/jco.2016.68.2153]; Song YX, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00304-1; Su XQ, 2013, CHINESE J CANCER RES, V25, P235, DOI 10.3978/j.issn.1000-9604.2013.03.08; Taiyab A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092078; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; Tian XP, 2019, THERANOSTICS, V9, P1965, DOI 10.7150/thno.30958; Ueno M, 2015, J HEPATOL, V63, P1352, DOI 10.1016/j.jhep.2015.07.013; Vilchez V, 2016, WORLD J GASTROENTERO, V22, P823, DOI 10.3748/wjg.v22.i2.823; Wallace MC, 2015, EXPERT REV GASTROENT, V9, P765, DOI 10.1586/17474124.2015.1028363; Wang LQ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0889-7; Xiao FF, 2009, NUCLEIC ACIDS RES, V37, pD105, DOI 10.1093/nar/gkn851; Xu L, 2017, J CELL MOL MED, V21, P1545, DOI 10.1111/jcmm.13085; Yang Y, 2018, CARCINOGENESIS, V39, P900, DOI 10.1093/carcin/bgy010; Yeh HW, 2018, NAT CELL BIOL, V20, P479, DOI 10.1038/s41556-018-0062-y; Zhang LX, 2011, CANCER RES, V71, P645, DOI 10.1158/0008-5472.CAN-10-1910; Zhang ZY, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12505	34	26	26	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	23					4538	4550		10.1038/s41388-020-1307-3	http://dx.doi.org/10.1038/s41388-020-1307-3		MAY 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LU5ZF	32372060	Green Published, hybrid			2022-12-28	WOS:000530617200001
J	Liu, JH; He, DH; Cheng, LJ; Huang, CK; Zhang, YQ; Rao, XJ; Kong, YF; Li, CH; Zhang, ZZ; Liu, JP; Jones, K; Napier, D; Lee, EY; Wang, C; Liu, XQ				Liu, Jinghui; He, Daheng; Cheng, Lijun; Huang, Changkun; Zhang, Yanquan; Rao, Xiongjian; Kong, Yifan; Li, Chaohao; Zhang, Zhuangzhuang; Liu, Jinpeng; Jones, Karrie; Napier, Dana; Lee, Eun Y.; Wang, Chi; Liu, Xiaoqi			p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer	ONCOGENE			English	Article							ANTITUMOR IMMUNITY; ANDROGEN RECEPTOR; PD-L1; EXPRESSION; MECHANISMS; DOCETAXEL	Blockade of programmed death-ligand 1 (PD-L1) by therapeutic antibodies has shown to be a promising strategy in cancer therapy, yet clinical response in many types of cancer, including prostate cancer (PCa), is limited. Tumor cells secrete PD-L1 through exosomes or splice variants, which has been described as a new mechanism for the resistance to PD-L1 blockade therapy in multiple cancers, including PCa. This suggests that cutting off the secretion or expression of PD-L1 might improve the response rate of PD-L1 blockade therapy in PCa treatment. Here we report that p300/CBP inhibition by a small molecule p300/CBP inhibitor dramatically enhanced the efficacy of PD-L1 blockade treatment in a syngeneic model of PCa by blocking both the intrinsic and IFN-gamma-induced PD-L1 expression. Mechanistically, p300/CBP could be recruited to the promoter of CD274 (encoding PD-L1) by the transcription factor IRF-1, which induced the acetylation of Histone H3 at CD274 promoter followed by the transcription of CD274. A485, a p300/CBP inhibitor, abrogated this process and cut off the secretion of exosomal PD-L1 by blocking the transcription of CD274, which combined with the anti-PD-L1 antibody to reactivate T cells function for tumor attack. This finding reports a new mechanism of how cancer cells regulate PD-L1 expression through epigenetic factors and provides a novel therapeutic approach to enhance the efficacy of immune checkpoint inhibitors treatment.	[Liu, Jinghui; Huang, Changkun; Zhang, Yanquan; Rao, Xiongjian; Kong, Yifan; Li, Chaohao; Zhang, Zhuangzhuang; Liu, Xiaoqi] Univ Kentucky, Dept Toxicol & Canc Biol, Lexington, KY 40536 USA; [He, Daheng; Liu, Jinpeng; Wang, Chi] Univ Kentucky, Dept Biostat, Lexington, KY 40536 USA; [Cheng, Lijun] Ohio State Univ, Dept Biomed Informat, Columbus, OH 43210 USA; [Jones, Karrie; Napier, Dana; Lee, Eun Y.; Wang, Chi; Liu, Xiaoqi] Univ Kentucky, Markey Canc Ctr, Lexington, KY 40536 USA; [Lee, Eun Y.] Univ Kentucky, Dept Pathol & Lab Med, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University System of Ohio; Ohio State University; University of Kentucky; University of Kentucky	Liu, XQ (corresponding author), Univ Kentucky, Dept Toxicol & Canc Biol, Lexington, KY 40536 USA.; Liu, XQ (corresponding author), Univ Kentucky, Markey Canc Ctr, Lexington, KY 40536 USA.	Xiaoqi.Liu@uky.edu	He, Daheng/AAR-1813-2021; Zhang, Yanquan/D-5615-2017	Zhang, Zhuangzhuang/0000-0003-2578-7375; Zhang, Yanquan/0000-0003-3527-9972	NIH [R01 CA157429, R01 CA192894, R01 CA196835, R01 CA196634]; Biospecimen Procurement and Translational Pathology, Biostatistics and Bioinformatics, Flow Cytometry and Immune Monitoring Shared Resources of the University of Kentucky Markey Cancer Center [P30CA177558]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Biospecimen Procurement and Translational Pathology, Biostatistics and Bioinformatics, Flow Cytometry and Immune Monitoring Shared Resources of the University of Kentucky Markey Cancer Center	This work was supported by NIH grants R01 CA157429 (XL), R01 CA192894 (XL), R01 CA196835 (XL), and R01 CA196634 (XL). The work was also supported by Biospecimen Procurement and Translational Pathology, Biostatistics and Bioinformatics, Flow Cytometry and Immune Monitoring Shared Resources of the University of Kentucky Markey Cancer Center (P30CA177558). We thank Heather Russell-Simmons at Research Communications Office of Markey Cancer Center for proof-reading of the paper.	Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Calagua C, 2017, CLIN CANCER RES, V23, P6812, DOI 10.1158/1078-0432.CCR-17-0807; Chen G, 2018, NATURE, V560, P382, DOI 10.1038/s41586-018-0392-8; Chen LP, 2015, J CLIN INVEST, V125, P3384, DOI 10.1172/JCI80011; Claessens F, 2014, NAT REV UROL, V11, P712, DOI 10.1038/nrurol.2014.243; Coelho MA, 2017, IMMUNITY, V47, P1083, DOI 10.1016/j.immuni.2017.11.016; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; Drazic A, 2016, BBA-PROTEINS PROTEOM, V1864, P1372, DOI 10.1016/j.bbapap.2016.06.007; Eckschlager T, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071414; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; Garcia-Diaz A, 2017, CELL REP, V19, P1189, DOI 10.1016/j.celrep.2017.04.031; Gevensleben H, 2016, CLIN CANCER RES, V22, P1969, DOI 10.1158/1078-0432.CCR-15-2042; Gong B, 2019, J EXP MED, V216, P982, DOI 10.1084/jem.20180870; Haeussler M, 2019, NUCLEIC ACIDS RES, V47, pD853, DOI 10.1093/nar/gky1095; Jin LY, 2017, CANCER RES, V77, P5564, DOI 10.1158/0008-5472.CAN-17-0314; Kaushik D, 2015, THER ADV UROL, V7, P388, DOI 10.1177/1756287215597637; Lasko LM, 2017, NATURE, V550, P128, DOI 10.1038/nature24028; Li TW, 2017, CANCER RES, V77, pE108, DOI 10.1158/0008-5472.CAN-17-0307; Li Y, 2016, COLD SPRING HARB PER, V6, P1; Liu JH, 2016, CHEMOSPHERE, V163, P14, DOI 10.1016/j.chemosphere.2016.08.002; Mahoney KM, 2019, CANCER IMMUNOL IMMUN, V68, P421, DOI 10.1007/s00262-018-2282-1; Martin AM, 2015, PROSTATE CANCER P D, V18, P325, DOI 10.1038/pcan.2015.39; Massari F, 2016, TARGET ONCOL, V11, P345, DOI 10.1007/s11523-015-0396-3; Michaelis M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019705; Nebbioso A, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007362; Poggio M, 2019, CELL, V177, P414, DOI 10.1016/j.cell.2019.02.016; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Seruga B, 2011, NAT REV CLIN ONCOL, V8, P12, DOI 10.1038/nrclinonc.2010.136; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Smithy JW, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0229-2; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Zhong J, 2014, CANCER RES, V74, P1870, DOI 10.1158/0008-5472.CAN-13-2485; Zhu HR, 2016, CELL REP, V16, P2829, DOI 10.1016/j.celrep.2016.08.032	35	44	44	2	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	19					3939	3951		10.1038/s41388-020-1270-z	http://dx.doi.org/10.1038/s41388-020-1270-z		MAR 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LK4OF	32203167	Green Accepted			2022-12-28	WOS:000520950900001
J	Sarac, H; Morova, T; Pires, E; McCullagh, J; Kaplan, A; Cingoz, A; Bagci-Onder, T; Onder, T; Kawamura, A; Lack, NA				Sarac, Hilal; Morova, Tunc; Pires, Elisabete; McCullagh, James; Kaplan, Anil; Cingoz, Ahmet; Bagci-Onder, Tugba; onder, Tamer; Kawamura, Akane; Lack, Nathan A.			Systematic characterization of chromatin modifying enzymes identifies KDM3B as a critical regulator in castration resistant prostate cancer	ONCOGENE			English	Article							CARCINOMA-CELL LINE; ANDROGEN-RECEPTOR; H3K9 METHYLATION; TUMOR-GROWTH; DEMETHYLASE; PROGRESSION; PROLIFERATION; TRANSCRIPTION; EXPRESSION; PROTEIN	Androgen deprivation therapy (ADT) is the standard care for prostate cancer (PCa) patients who fail surgery or radiotherapy. While initially effective, the cancer almost always recurs as a more aggressive castration resistant prostate cancer (CRPC). Previous studies have demonstrated that chromatin modifying enzymes can play a critical role in the conversion to CRPC. However, only a handful of these potential pharmacological targets have been tested. Therefore, in this study, we conducted a focused shRNA screen of chromatin modifying enzymes previously shown to be involved in cellular differentiation. We found that altering the balance between histone methylation and demethylation impacted growth and proliferation. Of all genes tested, KDM3B, a histone H3K9 demethylase, was found to have the most antiproliferative effect. These results were phenocopied with a KDM3B CRISPR/Cas9 knockout. When tested in several PCa cell lines, the decrease in proliferation was remarkably specific to androgen-independent cells. Genetic rescue experiments showed that only the enzymatically active KDM3B could recover the phenotype. Surprisingly, despite the decreased proliferation of androgen-independent cell no alterations in the cell cycle distribution were observed following KDM3B knockdown. Whole transcriptome analyses revealed changes in the gene expression profile following loss of KDM3B, including downregulation of metabolic enzymes such as ARG2 and RDH11. Metabolomic analysis of KDM3B knockout showed a decrease in several critical amino acids. Overall, our work reveals, for the first time, the specificity and the dependence of KDM3B in CRPC proliferation.	[Sarac, Hilal; Morova, Tunc; Kaplan, Anil; Cingoz, Ahmet; Bagci-Onder, Tugba; onder, Tamer; Lack, Nathan A.] Koc Univ, Sch Med, TR-34450 Istanbul, Turkey; [Sarac, Hilal; Pires, Elisabete; McCullagh, James; Kawamura, Akane] Univ Oxford, Dept Chem, Chem Res Lab, Oxford OX1 3TA, England; [Sarac, Hilal; Kawamura, Akane] Univ Oxford, Wellcome Ctr Human Genet, Radcliffe Dept Med, Oxford OX3 7BN, England; [Morova, Tunc; Lack, Nathan A.] Univ British Columbia, Vancouver Prostate Ctr, Vancouver, BC V6H 3Z6, Canada	Koc University; University of Oxford; University of Oxford; Wellcome Centre for Human Genetics; University of British Columbia	Lack, NA (corresponding author), Koc Univ, Sch Med, TR-34450 Istanbul, Turkey.	nlack@ku.edu.tr	Onder, Tamer T/H-3330-2013; Onder, Tamer/O-3669-2019; Cingoz, Ahmet/AAG-4228-2019; McCullagh, James/AAD-2669-2022; KAPLAN, ANIL/AAT-2829-2020; Onder, Tugba Bagci/AAN-1392-2021; Kawamura, Akane/I-4047-2018	Onder, Tamer T/0000-0002-2372-9158; Onder, Tamer/0000-0002-2372-9158; Cingoz, Ahmet/0000-0002-1111-7752; McCullagh, James/0000-0003-4733-1205; Bagci Onder, Tugba/0000-0003-3646-2613; Pires, Elisabete/0000-0001-8646-062X; Kawamura, Akane/0000-0003-1169-5082	TUBITAK 1001 [114Z997]; Royal Society Newton Advanced Fellowship [NA150165]; Wellcome Trust [203141/Z/16/Z]; Royal Society Dorothy Hodgkin Fellowship [DH120028]; Cancer Research UK Programme Grant [C8717/A18245]; BBSRC [BB/R013829/1] Funding Source: UKRI; EPSRC [EP/L003376/1] Funding Source: UKRI	TUBITAK 1001(Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)); Royal Society Newton Advanced Fellowship; Wellcome Trust(Wellcome Trust); Royal Society Dorothy Hodgkin Fellowship(Royal Society of London); Cancer Research UK Programme Grant(Cancer Research UK); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))	This work was primarily supported by TUBITAK 1001 (114Z997) and the Royal Society Newton Advanced Fellowship (NA150165 to NAL and AK). We thank Zeynep Kahya for helping with shRNA library packaging. We also gratefully acknowledge the services and facilities of the Koc University Research Centre for Translational Medicine and Wellcome Trust Core Award Grant number 203141/Z/16/Z. AK gratefully acknowledges the Royal Society Dorothy Hodgkin Fellowship (DH120028), the Cancer Research UK Programme Grant (C8717/A18245).	Acar O, 2013, SCI WORLD J, DOI 10.1155/2013/379641; Albany C, 2011, PROSTATE CANCER, V2011, DOI 10.1155/2011/580318; [Anonymous], P NATL ACAD SCI US, V102, P15545, DOI [10.1073/pnas.0506580102, DOI 10.1073/PNAS.0506580102, DOI 10.1073/pnas.0506580102]; Bello D, 1997, CARCINOGENESIS, V18, P1215, DOI 10.1093/carcin/18.6.1215; Braadland PR, 2019, ENDOCR-RELAT CANCER, V26, pR211, DOI 10.1530/ERC-18-0579; Brauchle M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060549; Caldwell RB, 2015, TRENDS PHARMACOL SCI, V36, P395, DOI 10.1016/j.tips.2015.03.006; Carlberg C., 2018, HUMAN EPIGENOMICS, DOI DOI 10.4330/wjc.v8.i9.504; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen Y, 2008, CURR OPIN PHARMACOL, V8, P440, DOI 10.1016/j.coph.2008.07.005; Coffey K, 2013, NUCLEIC ACIDS RES, V41, P4433, DOI 10.1093/nar/gkt106; Cohet N, 2010, J CELL PHYSIOL, V223, P667, DOI 10.1002/jcp.22072; Crea F, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-52; Culig Z, 1999, BRIT J CANCER, V81, P242, DOI 10.1038/sj.bjc.6690684; Duan LL, 2015, CHEM BIOL, V22, P1185, DOI 10.1016/j.chembiol.2015.08.007; Fagerberg L, 2014, MOL CELL PROTEOMICS, V13, P397, DOI 10.1074/mcp.M113.035600; Gannon PO, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012107; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Giskeodegard GF, 2015, BRIT J CANCER, V113, P1712, DOI 10.1038/bjc.2015.411; Goda S, 2013, J BIOL CHEM, V288, P36948, DOI 10.1074/jbc.M113.492595; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; Gravina GL, 2013, ONCOL REP, V29, P1189, DOI 10.3892/or.2012.2192; Han A, 2015, BMB REP, V48, P401, DOI 10.5483/BMBRep.2015.48.7.188; Hatch SB, 2017, EPIGENET CHROMATIN, V10, DOI 10.1186/s13072-017-0116-6; Hausinger R, 2015, SERIES RSCM 2 OXOGLU, DOI [10.1039/9781782621959, DOI 10.1039/9781782621959]; Heck D, 2014, NAT BIOTECHNOL, V32, P941, DOI 10.1038/nbt.2951; Helsen C, 2014, ENDOCR-RELAT CANCER, V21, pT105, DOI 10.1530/ERC-13-0545; Hopkinson RJ, 2013, CHEM SCI, V4, P3110, DOI [10.1039/c3sc51122g, 10.1039/C3SC51122G]; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Hu ZB, 2001, ONCOGENE, V20, P6946, DOI 10.1038/sj.onc.1204850; Kanehisa M, 2017, NUCLEIC ACIDS RES, V45, pD353, DOI 10.1093/nar/gkw1092; Karantanos T, 2013, ONCOGENE, V32, P5501, DOI 10.1038/onc.2013.206; Kim JY, 2012, MOL CELL BIOL, V32, P2917, DOI 10.1128/MCB.00133-12; Kim TD, 2016, J CLIN INVEST, V126, P706, DOI 10.1172/JCI78132; King ONF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015535; Korenchuk S, 2001, IN VIVO, V15, P163; Kummalue T, 2015, EXP HEMATOL, V43, P414, DOI 10.1016/j.exphem.2015.01.006; Kurien BT, 2006, METHODS, V38, P283, DOI 10.1016/j.ymeth.2005.11.007; Kurt IC, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.288; Li J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15146; Li SH, 2018, CELL REP, V23, P389, DOI 10.1016/j.celrep.2018.03.051; Liu YX, 2013, GUT, V62, P571, DOI 10.1136/gutjnl-2011-301059; Liu ZL, 2015, INT J BIOL SCI, V11, P1447, DOI 10.7150/ijbs.13795; MacKinnon RN, 2011, CANCER GENET-NY, V204, P187, DOI 10.1016/j.cancergen.2011.02.001; Maina PK, 2016, ONCOTARGET, V7, P75585, DOI 10.18632/oncotarget.12310; McAllister TE, 2016, J MED CHEM, V59, P1308, DOI 10.1021/acs.jmedchem.5b01758; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Montgomery RB, 2008, CANCER RES, V68, P4447, DOI 10.1158/0008-5472.CAN-08-0249; Okada Y, 2007, NATURE, V450, P119, DOI 10.1038/nature06236; Onder TT, 2012, NATURE, V483, P598, DOI 10.1038/nature10953; Paolicchi E, 2013, CRIT REV ONCOL HEMAT, V86, P97, DOI 10.1016/j.critrevonc.2012.11.008; Papp B, 2013, CELL, V152, P1324, DOI 10.1016/j.cell.2013.02.043; Pauler FM, 2009, GENOME RES, V19, P221, DOI 10.1101/gr.080861.108; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Rotili D, 2014, J MED CHEM, V57, P42, DOI 10.1021/jm4012802; Shen Y, 2017, COATINGS, V7, DOI 10.3390/coatings7120212; SHEPPARD D, 1994, AM J RESP CELL MOL, V11, P1; Sramkoski RM, 1999, IN VITRO CELL DEV-AN, V35, P403; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; Sun SH, 2010, J CLIN INVEST, V120, P2715, DOI 10.1172/JCI41824; Tai S, 2011, PROSTATE, V71, P1668, DOI 10.1002/pros.21383; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Teng T, 2013, MOL CELL BIOL, V33, P4660, DOI 10.1128/MCB.01174-13; Tong D, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.74; Urbanucci A, 2017, CELL REP, V19, P2045, DOI 10.1016/j.celrep.2017.05.049; Waddington CH, 2012, INT J EPIDEMIOL, V41, P10, DOI 10.1093/ije/dyr184; Wang L, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3035; Wei CG, 2018, MOL MED REP, V17, P2901, DOI 10.3892/mmr.2017.8257; Wilson S, 2017, ONCOTARGET, V8, P30328, DOI 10.18632/oncotarget.15681; Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546; Wu LZ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153556; Xiang Y, 2007, P NATL ACAD SCI USA, V104, P19226, DOI 10.1073/pnas.0700735104; Xin L, 2006, P NATL ACAD SCI USA, V103, P7789, DOI 10.1073/pnas.0602567103; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Yamane K, 2006, CELL, V125, P483, DOI 10.1016/j.cell.2006.03.027; Zhang JW, 2016, EXP CELL RES, V349, P77, DOI 10.1016/j.yexcr.2016.09.023; Zhang QJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07173-2; Zong Y, 2013, NAT REV UROL, V10, P90, DOI [10.1038/nruro1.2012.237, 10.1038/nrurol.2012.237]	79	15	15	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	10					2187	2201		10.1038/s41388-019-1116-8	http://dx.doi.org/10.1038/s41388-019-1116-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KS8UR	31822799	Green Published, hybrid			2022-12-28	WOS:000518584000012
J	NavaneethaKrishnan, S; Rosales, JL; Lee, KY				NavaneethaKrishnan, Saranya; Rosales, Jesusa L.; Lee, Ki-Young			mPTP opening caused by Cdk5 loss is due to increased mitochondrial Ca2+ uptake	ONCOGENE			English	Article							CYCLIN-DEPENDENT KINASE-5; PERMEABILITY TRANSITION PORE; ENDOPLASMIC-RETICULUM; CELL-DEATH; CALCIUM; ER; INHIBITION; MEMBRANES; CONTACTS; COMPLEX	We previously demonstrated that loss of Cdk5 in breast cancer cells promotes ROS-mediated cell death by inducing mitochondrial permeability transition pore (mPTP) opening (Oncogene 37, 1788-1804). However, the molecular mechanism by which Cdk5 loss causes mPTP opening remains to be investigated. Using primary mouse embryonic fibroblasts (MEFs) isolated from Cdk5(-/-) mouse embryos, we show that absence of Cdk5 causes a significant increase in both mPTP opening and mitochondrial Ca2+ level. Analysis of subcellular fractions of MEFs demonstrates that Cdk5 localizes in the mitochondria-associated endoplasmic reticulum (ER) membrane (MAM) and Cdk5 loss in MAMs causes increased ER-mitochondria tethering, a process required for Ca2+ transfer from the ER to the mitochondria. Loss of Cdk5 also causes increased ATP-mediated mitochondrial Ca2+ uptake from the ER. Inhibition of ER Ca2+ release or mitochondrial Ca2+ uptake in Cdk5(-/-) MEFs prevents mPTP opening, indicating that mPTP opening in Cdk5(-/-) MEFs is due to increased Ca2+ transfer from the ER to the mitochondria. Altogether, our findings suggest that Cdk5 in MAMs regulates mitochondrial Ca2+ homeostasis that is disturbed upon Cdk5 loss, which leads to mPTP opening.	[NavaneethaKrishnan, Saranya; Rosales, Jesusa L.; Lee, Ki-Young] Univ Calgary, Dept Cell Biol & Anat, Arnie Charbonneau Canc Inst, Calgary, AB, Canada; [NavaneethaKrishnan, Saranya; Rosales, Jesusa L.; Lee, Ki-Young] Univ Calgary, Alberta Childrens Hosp, Res Inst, Cumming Sch Med, Calgary, AB, Canada	University of Calgary; Alberta Childrens Hospital; University of Calgary	Lee, KY (corresponding author), Univ Calgary, Dept Cell Biol & Anat, Arnie Charbonneau Canc Inst, Calgary, AB, Canada.; Lee, KY (corresponding author), Univ Calgary, Alberta Childrens Hosp, Res Inst, Cumming Sch Med, Calgary, AB, Canada.	kylee@ucalgary.ca			CIHR [MOP-123400]; NSERC [RGPIN/06270-2019]; Alberta Cancer Foundation	CIHR(Canadian Institutes of Health Research (CIHR)); NSERC(Natural Sciences and Engineering Research Council of Canada (NSERC)); Alberta Cancer Foundation	We thank Novartis Pharma AG for providing SfA. This work was supported in part by grants from the CIHR (MOP-123400) and NSERC (RGPIN/06270-2019) to KYL and an Alberta Cancer Foundation graduate studentship to SN.	ALTSCHULD RA, 1992, AM J PHYSIOL, V262, pH1699, DOI 10.1152/ajpheart.1992.262.6.H1699; Batandier C, 2004, J BIOL CHEM, V279, P17197, DOI 10.1074/jbc.M310329200; Bravo-Sagua R, 2013, CURR MOL MED, V13, P317, DOI 10.2174/156652413804810781; Clarke SJ, 2002, J BIOL CHEM, V277, P34793, DOI 10.1074/jbc.M202191200; Coats S, 1999, CURR BIOL, V9, P163, DOI 10.1016/S0960-9822(99)80086-4; Contreras L, 2010, BBA-BIOENERGETICS, V1797, P607, DOI 10.1016/j.bbabio.2010.05.005; CROMPTON M, 1988, BIOCHEM J, V255, P357; Csordas G, 2010, MOL CELL, V39, P121, DOI 10.1016/j.molcel.2010.06.029; Csordas G, 2006, J CELL BIOL, V174, P915, DOI 10.1083/jcb.200604016; Decuypere, 2011, J AGING RES, V2011, P920178, DOI [10.4061/2011/920178, DOI 10.4061/2011/920178]; Duchen MR, 2000, J PHYSIOL-LONDON, V529, P57, DOI 10.1111/j.1469-7793.2000.00057.x; Durkin M.E., 2013, BIOPROTOC, V3, pE908, DOI DOI 10.21769/BioProtoc.908; Finkel T, 2015, CIRC RES, V116, P1810, DOI 10.1161/CIRCRESAHA.116.305484; Fitzgerald JC, 2012, CELL DEATH DIFFER, V19, P257, DOI 10.1038/cdd.2011.90; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; Giacomello M, 2016, CELL DEATH DIFFER, V23, P1417, DOI 10.1038/cdd.2016.52; Giaime E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040501; Giorgi C, 2018, NAT REV MOL CELL BIO, V19, P713, DOI 10.1038/s41580-018-0052-8; Gomez-Suaga P, 2017, CURR BIOL, V27, P371, DOI 10.1016/j.cub.2016.12.038; Grimm S, 2012, BBA-MOL CELL RES, V1823, P327, DOI 10.1016/j.bbamcr.2011.11.018; Halestrap AP, 2009, J MOL CELL CARDIOL, V46, P821, DOI 10.1016/j.yjmcc.2009.02.021; Hayashi T, 2009, TRENDS CELL BIOL, V19, P81, DOI 10.1016/j.tcb.2008.12.002; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; Kaczmarek-Hajek K, 2012, PURINERG SIGNAL, V8, P375, DOI 10.1007/s11302-012-9314-7; Kinnally KW, 2011, BBA-MOL CELL RES, V1813, P616, DOI 10.1016/j.bbamcr.2010.09.013; Lemasters JJ, 2002, ANTIOXID REDOX SIGN, V4, P769, DOI 10.1089/152308602760598918; Lemasters JJ, 2009, BBA-BIOENERGETICS, V1787, P1395, DOI 10.1016/j.bbabio.2009.06.009; Liu Y, 2017, TRANSL NEURODEGENER, V6, DOI 10.1186/s40035-017-0092-6; Ma JHJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02213-1; Meuer K, 2007, CELL DEATH DIFFER, V14, P651, DOI 10.1038/sj.cdd.4402087; Michel AH, 2012, BIOCHEM SOC T, V40, P445, DOI 10.1042/BST20110758; MOORE CL, 1971, BIOCHEM BIOPH RES CO, V42, P298, DOI 10.1016/0006-291X(71)90102-1; Naon D, 2014, BBA-MOL CELL RES, V1843, P2184, DOI 10.1016/j.bbamcr.2014.05.011; NavaneethaKrishnan S, 2018, ONCOGENE, V37, P1788, DOI 10.1038/s41388-017-0103-1; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Ortiz-Sandoval C. G., 2014, CELL LOGIST, P2799, DOI [10.4161/21592799.2014.986399, DOI 10.4161/21592799.2014.986399]; Patergnani S, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00173; Patergnani S, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-19; Paupe V, 2018, BIOCHEM BIOPH RES CO, V500, P75, DOI 10.1016/j.bbrc.2017.05.039; Petronilli V, 1998, BIOFACTORS, V8, P263, DOI 10.1002/biof.5520080314; Poston CN, 2013, J PROTEOMICS, V79, P219, DOI 10.1016/j.jprot.2012.12.018; Pozzan T, 2009, BBA-BIOENERGETICS, V1787, P1317, DOI 10.1016/j.bbabio.2008.11.012; Qu D, 2007, NEURON, V55, P37, DOI 10.1016/j.neuron.2007.05.033; Raffaello A, 2016, TRENDS BIOCHEM SCI, V41, P1035, DOI 10.1016/j.tibs.2016.09.001; Rieusset J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0416-1; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Rizzuto R, 2012, NAT REV MOL CELL BIO, V13, P566, DOI 10.1038/nrm3412; Rizzuto R, 2009, BBA-BIOENERGETICS, V1787, P1342, DOI 10.1016/j.bbabio.2009.03.015; Rowland AA, 2012, NAT REV MOL CELL BIO, V13, P607, DOI 10.1038/nrm3440; Shoshan-Barmatz V, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00060; SMITH JB, 1985, J BIOL CHEM, V260, P4413; Solanes P, 2015, EMBO J, V34, P798, DOI 10.15252/embj.201489056; Sun KH, 2008, J NEUROCHEM, V107, P265, DOI 10.1111/j.1471-4159.2008.05616.x; Tagaya M, 2017, ADV EXP MED BIOL, V997, P33, DOI 10.1007/978-981-10-4567-7_3; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Vance JE, 2014, BBA-MOL CELL BIOL L, V1841, P595, DOI 10.1016/j.bbalip.2013.11.014; Weishaupt JH, 2003, MOL CELL NEUROSCI, V24, P489, DOI 10.1016/S1044-7431(03)00221-5; Wieckowski MR, 2009, NAT PROTOC, V4, P1582, DOI 10.1038/nprot.2009.151; Wiedemann N, 2009, SCIENCE, V325, P403, DOI 10.1126/science.1178016	60	12	12	3	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	13					2797	2806		10.1038/s41388-020-1188-5	http://dx.doi.org/10.1038/s41388-020-1188-5		FEB 2020	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KX4EF	32024968	hybrid, Green Published			2022-12-28	WOS:000511273600002
J	Jin, Y; Bao, H; Le, XN; Fan, XJ; Tang, M; Shi, X; Zhao, J; Yan, JR; Xu, Y; Quek, K; Elamin, YY; Zhang, J; Futreal, PA; Wistuba, II; Heymach, JV; Lou, GY; Shao, L; He, Q; Lin, C; Wu, X; Shao, YW; Wang, XN; He, JC; Chen, YM; Stebbing, J; Chen, M; Zhang, JJ; Yu, XM				Jin, Ying; Bao, Hua; Le, Xiuning; Fan, Xiaojun; Tang, Ming; Shi, Xun; Zhao, Jun; Yan, Junrong; Xu, Yang; Quek, Kelly; Elamin, Yasir Y.; Zhang, Jianhua; Futreal, P. Andrew; Wistuba, Ignacio I.; Heymach, John, V; Lou, Guangyuan; Shao, Lan; He, Qiong; Lin, Chen; Wu, Xue; Shao, Yang W.; Wang, Xiaonan; He, Jiachen; Chen, Yamei; Stebbing, Justin; Chen, Ming; Zhang, Jianjun; Yu, Xinmin			Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITORS; INTRATUMOR GENETIC-HETEROGENEITY; 1ST-LINE TREATMENT; CLINICAL IMPACT; OPEN-LABEL; RESISTANCE; PIK3CA; ADENOCARCINOMAS; DIVERSITY	EGFR-mutant non-small-cell lung cancer (NSCLC) patients inevitably develop drug resistance when treated with EGFR tyrosine kinase inhibitors (TKIs). Systematic genetic analysis is important to understand drug-resistant mechanisms; however, the clinical significance of co-occurring genetic alterations at baseline, co-acquired mutations at progressive disease (PD), and the clonal evolution remain underinvestigated. We performed targeted sequencing of pre-treatment and PD tumor samples from 54 EGFR-mutant NSCLC patients. Ten additional patients were sequenced using whole-exome sequencing to infer the clonal evolution patterns. We observed a domain-dependent effect of PIK3CA mutation at baseline on patient progression-free survival (PFS). In addition, at baseline, 9q34.3/19p13.3 (NOTCH1/STK11/GNA11) showed a co-deletion pattern, which was associated with a significantly worse PFS (p = 0.00079). T790M-postive patients with other concurrent acquired oncogenic mutations had a significantly shorter PFS (p = 0.005). Besides acquired T790M mutation, chromosomal instability (CIN) related genes, including AURKA and TP53 alterations, were the most frequently acquired events. CIN significantly increased during TKI treatment in T790M-negative patients and is a candidate resistance mechanism to the first-generation TKIs. Clonal evolution analyses suggest that the composition and relationship among resistant subclones, particularly relationship with T790M subclone, affect patients' outcomes. Overall, our findings of novel co-occurring alterations and clonal evolution patterns can be served as predictive biomarkers to stratify patients and help to better understand the drug-resistant mechanism to TKIs.	[Jin, Ying; Shi, Xun; Zhao, Jun; Lou, Guangyuan; Shao, Lan; He, Qiong; Lin, Chen; Chen, Yamei; Chen, Ming; Yu, Xinmin] Chinese Acad Sci, Inst Canc & Basic Med, Hangzhou, Zhejiang, Peoples R China; [Jin, Ying; Shi, Xun; Zhao, Jun; Lou, Guangyuan; Shao, Lan; He, Qiong; Lin, Chen; Yu, Xinmin] Univ Chinese Acad Sci, Canc Hosp, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China; [Jin, Ying; Shi, Xun; Zhao, Jun; Lou, Guangyuan; Shao, Lan; He, Qiong; Lin, Chen; Yu, Xinmin] Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China; [Jin, Ying; Chen, Yamei; Chen, Ming] Zhejiang Key Lab Radiat Oncol, Hangzhou, Zhejiang, Peoples R China; [Bao, Hua; Fan, Xiaojun; Xu, Yang; Wu, Xue] Geneseeq Technol Inc, Translat Med Res Ctr, Toronto, ON, Canada; [Le, Xiuning; Tang, Ming; Quek, Kelly; Elamin, Yasir Y.; Heymach, John, V; Zhang, Jianjun] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; [Yan, Junrong; Shao, Yang W.; Wang, Xiaonan; He, Jiachen] Nanjing Geneseeq Technol Inc, Nanjing, Jiangsu, Peoples R China; [Zhang, Jianhua; Futreal, P. Andrew; Zhang, Jianjun] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA; [Wistuba, Ignacio I.] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [Stebbing, Justin] Imperial Coll London, ICTEM, Div Canc, Dept Surg & Canc, London W12 0NN, England	Chinese Academy of Sciences; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Zhejiang Cancer Hospital; Geneseeq Technology Inc.; University of Texas System; UTMD Anderson Cancer Center; Geneseeq Technology Inc.; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Imperial College London	Chen, M; Yu, XM (corresponding author), Chinese Acad Sci, Inst Canc & Basic Med, Hangzhou, Zhejiang, Peoples R China.; Yu, XM (corresponding author), Univ Chinese Acad Sci, Canc Hosp, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China.; Yu, XM (corresponding author), Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China.; Chen, M (corresponding author), Zhejiang Key Lab Radiat Oncol, Hangzhou, Zhejiang, Peoples R China.; Zhang, JJ (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA.; Zhang, JJ (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA.	chenming@zjcc.org.cn; jzhang20@mdanderson.org; yuxm@zjcc.org.cn	Xu, Yang/CAG-8877-2022; Chen, Ming/GYE-1379-2022	Xu, Yang/0000-0003-1670-6131; Chen, Ming/0000-0001-5041-9342; Stebbing, Justin/0000-0002-1117-6947; Bao, Hua/0000-0001-5774-8755	National Natural Science Foundation of China [81702248, 81672972]; Zhejiang Medical and Health Science and Technology Project [2018KY309, 2017KY239]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Zhejiang Medical and Health Science and Technology Project	Professor Stebbing sits on SABs for Celltrion, Singapore Biotech, Vor Biopharma, TLC Biopharmaceuticals and Benevolent AI, has consulted with Lansdowne partners, Vitruvian and Social Impact Capital and Chairs the Board of Directors for BB Biotech Healthcare Trust and Xerion Healthcare. This study was supported by the National Natural Science Foundation of China (Grant nos. 81702248, 81672972), and Zhejiang Medical and Health Science and Technology Project (Grant nos. 2018KY309, 2017KY239).	Andor N, 2016, NAT MED, V22, P105, DOI 10.1038/nm.3984; Balak MN, 2006, CLIN CANCER RES, V12, P6494, DOI 10.1158/1078-0432.CCR-06-1570; Birkbak NJ, 2011, CANCER RES, V71, P3447, DOI 10.1158/0008-5472.CAN-10-3667; Bivona TG, 2016, NAT MED, V22, P472, DOI 10.1038/nm.4091; Blakely CM, 2017, NAT GENET, V49, P1693, DOI 10.1038/ng.3990; Boolell V, 2015, CANCERS, V7, P1815, DOI 10.3390/cancers7030864; Buermans HPJ, 2014, BBA-MOL BASIS DIS, V1842, P1932, DOI 10.1016/j.bbadis.2014.06.015; Canale M, 2017, CLIN CANCER RES, V23, P2195, DOI 10.1158/1078-0432.CCR-16-0966; Carter SL, 2012, NAT BIOTECHNOL, V30, P413, DOI 10.1038/nbt.2203; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; de Bruin EC, 2014, SCIENCE, V346, P251, DOI 10.1126/science.1253462; Eng J, 2015, J THORAC ONCOL, V10, P1713, DOI 10.1097/JTO.0000000000000671; Fu JY, 2007, MOL CANCER RES, V5, P1, DOI 10.1158/1541-7786.MCR-06-0208; Gill RK, 2011, ONCOGENE, V30, P3784, DOI 10.1038/onc.2011.98; Guo LX, 2015, DIS MARKERS, V2015, DOI 10.1155/2015/520590; Ikenoue T, 2005, CANCER RES, V65, P4562, DOI 10.1158/0008-5472.CAN-04-4114; Jackman D, 2010, J CLIN ONCOL, V28, P357, DOI 10.1200/JCO.2009.24.7049; Jin Y, 2016, ONCOTARGET, V7, P61755, DOI 10.18632/oncotarget.11237; Kim HR, 2014, LUNG CANCER, V83, P374, DOI 10.1016/j.lungcan.2013.12.011; Kohno T, 1999, CARCINOGENESIS, V20, P1403, DOI 10.1093/carcin/20.8.1403; Lee AJX, 2011, CANCER RES, V71, P1858, DOI 10.1158/0008-5472.CAN-10-3604; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Liang HR, 2018, J THORAC DIS, V10, P2311, DOI 10.21037/jtd.2018.03.150; Ma GZ, 2017, ONCOTARGET, V8, P99429, DOI 10.18632/oncotarget.19681; Majem M, 2013, TRANSL LUNG CANCER R, V2, P226, DOI 10.3978/j.issn.2218-6751.2013.03.09; Maley CC, 2006, NAT GENET, V38, P468, DOI 10.1038/ng1768; McGranahan N, 2012, EMBO REP, V13, P528, DOI 10.1038/embor.2012.61; McNeill RS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200014; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Mroz EA, 2013, CANCER-AM CANCER SOC, V119, P3034, DOI 10.1002/cncr.28150; Mroz EA, 2013, ORAL ONCOL, V49, P211, DOI 10.1016/j.oraloncology.2012.09.007; Nadeu F, 2018, LEUKEMIA, V32, P645, DOI 10.1038/leu.2017.291; Nagano T, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7110212; Niknafs N, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004416; Nowell CS, 2017, NAT REV CANCER, V17, P145, DOI 10.1038/nrc.2016.145; Oda K, 2008, CANCER RES, V68, P8127, DOI 10.1158/0008-5472.CAN-08-0755; Ohgaki H, 2004, CANCER LETT, V207, P197, DOI 10.1016/j.canlet.2003.10.020; Pao W., 2005, PLOS MED, V2; Pfarr N, 2016, GENE CHROMOSOME CANC, V55, P821, DOI 10.1002/gcc.22378; Remon J, 2014, CANCER TREAT REV, V40, P93, DOI 10.1016/j.ctrv.2013.06.002; Rosell R, 2013, LANCET, V382, P720, DOI 10.1016/S0140-6736(13)61715-8; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Rosell R, 2009, NEW ENGL J MED, V361, P958, DOI 10.1056/NEJMoa0904554; Roth A, 2014, NAT METHODS, V11, P396, DOI [10.1038/nmeth.2883, 10.1038/NMETH.2883]; Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Shah KN, 2019, NAT MED, V25, P111, DOI 10.1038/s41591-018-0264-7; Shigemitsu K, 2001, ONCOGENE, V20, P4249, DOI 10.1038/sj.onc.1204557; Skoulidis F, 2018, CANCER DISCOV, V8, P822, DOI 10.1158/2159-8290.CD-18-0099; Talevich E, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004873; Toth LN, 2018, HUM PATHOL, V78, P138, DOI 10.1016/j.humpath.2018.04.014; Turajlic S, 2019, NAT REV GENET, V20, P404, DOI 10.1038/s41576-019-0114-6; VanderLaan PA, 2017, LUNG CANCER, V106, P17, DOI 10.1016/j.lungcan.2017.01.011; Wang J, 2016, ONCOTARGETS THER, V9, P3711, DOI 10.2147/OTT.S106399; Westover D, 2018, ANN ONCOL, V29, pI10, DOI 10.1093/annonc/mdx703; Wu SY, 2016, BIOMOLECULES, V6, DOI 10.3390/biom6030038; Wu YL, 2014, LANCET ONCOL, V15, P213, DOI 10.1016/S1470-2045(13)70604-1; Xie M, 2013, EUR J CANCER, V49, P3559, DOI 10.1016/j.ejca.2013.07.007; Yard BD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11428; Yu HA, 2013, CLIN CANCER RES, V19, P2240, DOI 10.1158/1078-0432.CCR-12-2246; Zhang JJ, 2014, SCIENCE, V346, P256, DOI 10.1126/science.1256930; Zhao JJ, 2005, P NATL ACAD SCI USA, V102, P18443, DOI 10.1073/pnas.0508988102; Zhao RX, 2014, CURR DRUG TARGETS, V15, P32, DOI 10.2174/1389450114666140106095811	64	19	19	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	9					1846	1859		10.1038/s41388-019-1104-z	http://dx.doi.org/10.1038/s41388-019-1104-z			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KP9VM	31754213				2022-12-28	WOS:000516579800002
J	Liu, F; Zhang, H; Xie, F; Tao, D; Xiao, XY; Huang, C; Wang, M; Gu, CH; Zhang, XP; Jiang, GS				Liu, Feng; Zhang, Hui; Xie, Fei; Tao, Dan; Xiao, Xingyuan; Huang, Chao; Wang, Miao; Gu, Chaohui; Zhang, Xiaoping; Jiang, Guosong			Hsa_circ_0001361 promotes bladder cancer invasion and metastasis through miR-491-5p/MMP9 axis	ONCOGENE			English	Article							MATRIX-METALLOPROTEINASE POLYMORPHISMS; CIRCULAR RNAS; TUMOR-SUPPRESSOR; EXPRESSION; ABUNDANT	Circular RNAs (circRNAs) have been increasingly indicated to be important participants in the development and progression of various malignant tumors. Our previous studies found that hundreds of circRNAs were aberrantly expressed in bladder cancer (BC) by high-throughput sequencing and we have confirmed that the downregulated circRNAs circHIPK3, circRNA BCRC-3, and circNR3C1 played inhibitory roles in BC progression. In this study, we focused on the upregulated circRNAs and identified a novel circular RNA, hsa_circ_0001361 (circ0001361), was expressed at high levels in BC tissues and cell lines based on RNA-Seq data and qRT-PCR analysis, and it was positively corelated with pathologic grade and muscle invasion. Moreover, Kaplan-Meier survival analysis implied that BC patients with high circ0001361 expression level had a poor overall survival. Functionally, circ0001361 promoted BC cell invasion and metastasis both in vitro and in vivo, but had no effect on cell cycle and proliferation. Mechanistically, RNA sequencing analysis indicated that MMP9 was upregulated in circ0001361-overexpressed BC cells, and MMP9 was verified to mediate circ0001361-induced cell migration and invasion. Furthermore, we demonstrated that circ0001361 could directly interact with miR-491-5p to upregulate MMP9 expression. Collectively, our findings indicate that circ0001361 plays oncogenic role in BC invasion and metastasis through targeting the miR-491-5p/MMP9 axis, and it might be a potential novel target for BC therapy.	[Liu, Feng; Zhang, Hui; Xie, Fei; Xiao, Xingyuan; Huang, Chao; Wang, Miao; Zhang, Xiaoping; Jiang, Guosong] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Urol, Wuhan 430022, Peoples R China; [Xie, Fei] Qingdao Univ, Affiliated Hosp, Dept Urol, Qingdao 266013, Peoples R China; [Tao, Dan] Fifth Hosp Wuhan, Dept Oncol, Wuhan 430050, Peoples R China; [Gu, Chaohui] Zhengzhou Univ, Affiliated Hosp 1, Dept Urol, Zhengzhou 450052, Henan, Peoples R China	Huazhong University of Science & Technology; Qingdao University; Zhengzhou University	Zhang, XP; Jiang, GS (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Urol, Wuhan 430022, Peoples R China.	xzhang@hust.edu.cn; jiangguosongdoc@hotmail.com			National Natural Science Foundation of China [81672529, 81772724, 81874091, 81602234, 81702524]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (Nos. 81672529, 81772724, 81874091, 81602234, 81702524).	Abdelmohsen K, 2017, RNA BIOL, V14, P361, DOI 10.1080/15476286.2017.1279788; Antoni S, 2017, EUR UROL, V71, P96, DOI 10.1016/j.eururo.2016.06.010; Arnaiz E, 2019, SEMIN CANCER BIOL, V58, P90, DOI 10.1016/j.semcancer.2018.12.002; Ashwal-Fluss R, 2014, MOL CELL, V56, P55, DOI 10.1016/j.molcel.2014.08.019; Barrett SP, 2016, DEVELOPMENT, V143, P1838, DOI 10.1242/dev.128074; Berindan-Neagoe I, 2014, CA-CANCER J CLIN, V64, P311, DOI 10.3322/caac.21244; Bracken CP, 2016, NAT REV GENET, V17, P719, DOI 10.1038/nrg.2016.134; Bray F, 2018, CA-CANCER J CLIN, V68, P5; Brockschmidt A, 2012, BRAIN, V135, P1027, DOI 10.1093/brain/aws045; Burd CE, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001233; Chen X, 2018, CLIN CANCER RES, V24, P6319, DOI 10.1158/1078-0432.CCR-18-1270; Chen ZL, 2019, ONCOGENE, V38, P6017, DOI 10.1038/s41388-019-0857-8; Cheng ZX, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11129-5; Du WW, 2017, CELL DEATH DIFFER, V24, P357, DOI 10.1038/cdd.2016.133; Errichelli L, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14741; Gu CH, 2018, MOL THER-NUCL ACIDS, V13, P633, DOI 10.1016/j.omtn.2018.10.008; Guo JU, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0409-z; Ha M, 2014, NAT REV MOL CELL BIO, V15, P509, DOI 10.1038/nrm3838; Han D, 2017, HEPATOLOGY, V66, P1151, DOI 10.1002/hep.29270; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; HSU MT, 1979, NATURE, V280, P339, DOI 10.1038/280339a0; Huang WC, 2014, CANCER RES, V74, P751, DOI 10.1158/0008-5472.CAN-13-1297; Hui Zeng, 2015, FEBS Lett, V589, P812, DOI 10.1016/j.febslet.2015.02.014; Jeck WR, 2014, NAT BIOTECHNOL, V32, P453, DOI 10.1038/nbt.2890; Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112; Kader AK, 2007, CLIN CANCER RES, V13, P2614, DOI 10.1158/1078-0432.CCR-06-1187; Kader AK, 2006, CANCER RES, V66, P11644, DOI 10.1158/0008-5472.CAN-06-1212; Kamat AM, 2016, LANCET, V388, P2796, DOI 10.1016/S0140-6736(16)30512-8; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kristensen LS, 2018, ONCOGENE, V37, P555, DOI 10.1038/onc.2017.361; Li Y, 2015, CELL RES, V25, P981, DOI 10.1038/cr.2015.82; Li YW, 2017, EMBO REP, V18, P1646, DOI 10.15252/embr.201643581; Li ZY, 2015, NAT STRUCT MOL BIOL, V22, P256, DOI 10.1038/nsmb.2959; Liu HW, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0908-8; Liu HW, 2018, AGING-US, V10, P2606, DOI 10.18632/aging.101573; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Nelson KM, 2008, MOL CANCER THER, V7, P3655, DOI 10.1158/1535-7163.MCT-08-0586; NIGRO JM, 1991, CELL, V64, P607, DOI 10.1016/0092-8674(91)90244-S; Pirooz HJ, 2018, J CELL BIOCHEM, V119, P5126, DOI 10.1002/jcb.26471; Qu SB, 2015, CANCER LETT, V365, P141, DOI 10.1016/j.canlet.2015.06.003; Rybak-Wolf A, 2015, MOL CELL, V58, P870, DOI 10.1016/j.molcel.2015.03.027; Sun RF, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.134; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; Vo JN, 2019, CELL, V176, P869, DOI 10.1016/j.cell.2018.12.021; Wang K, 2016, EUR HEART J, V37, P2602, DOI 10.1093/eurheartj/ehv713; Weren RDA, 2015, J PATHOL, V236, P155, DOI 10.1002/path.4520; Witjes JA, 2017, EUR UROL, V71, P462, DOI 10.1016/j.eururo.2016.06.020; Wu J, 2018, CANCER LETT, V430, P179, DOI 10.1016/j.canlet.2018.05.033; Xie F, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0892-z; Xu YJ, 2017, AM J CANCER RES, V7, P2545; Yang CD, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0771-7; Yang YB, 2018, JNCI-J NATL CANCER I, V110, DOI 10.1093/jnci/djx166; Zheng FX, 2019, CANCER LETT, V460, P139, DOI 10.1016/j.canlet.2019.06.018; Zhong YX, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0827-8; Zhong ZY, 2017, CANCER LETT, V403, P305, DOI 10.1016/j.canlet.2017.06.027; Zhong ZL, 2016, SCI REP-UK, V6, DOI 10.1038/srep37840	56	61	62	6	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	8					1696	1709		10.1038/s41388-019-1092-z	http://dx.doi.org/10.1038/s41388-019-1092-z			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN6CG	31705065				2022-12-28	WOS:000514923000006
J	Sun, CY; Li, X; Guo, ES; Li, N; Zhou, B; Lu, H; Huang, J; Xia, M; Shan, WY; Wang, BB; Li, KZ; Weng, DH; Xu, XY; Gao, QL; Wang, SX; Hu, JB; Lu, YL; Mills, GB; Chen, G				Sun, Chaoyang; Li, Xi; Guo, Ensong; Li, Na; Zhou, Bo; Lu, Hao; Huang, Jia; Xia, Meng; Shan, Wanying; Wang, Beibei; Li, Kezhen; Weng, Danhui; Xu, Xiaoyan; Gao, Qinglei; Wang, Shixuan; Hu, Junbo; Lu, Yiling; Mills, Gordon B.; Chen, Gang			MCP-1/CCR-2 axis in adipocytes and cancer cell respectively facilitates ovarian cancer peritoneal metastasis	ONCOGENE			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; CHEMOTACTIC PROTEIN-1; GENE-EXPRESSION; LIGAND 2; METFORMIN; RECEPTOR; GROWTH; OBESITY; CCL2; IDENTIFICATION	Ovarian cancer selective metastasizes to the omentum contributing to the poor prognosis associated with ovarian cancer. However, the mechanism underlining this propensity and therapeutic approaches to counter this process has not been fully elucidated. Here, we show that MCP-1 produced by omental adipocytes binding to its cognate receptor CCR-2 on ovarian cancer cells facilitates migration and omental metastasis by activating the PI3K/AKT/mTOR pathway and its downstream effectors HIF-1 alpha and VEGF-A in cell lines, xenografts, and transgenic murine models. MCP-1 antibody significantly decreased tumor burden and increased survival of mice in vivo. Interestingly, metformin decreased omental metastasis at least partially by inhibiting MCP-1 secretion from adipocytes independent of direct effects on cancer cells. Together this suggests a novel target of MCP-1/CCR-2 axis that could benefit ovarian cancer patients.	[Sun, Chaoyang; Li, Xi; Guo, Ensong; Li, Na; Zhou, Bo; Lu, Hao; Huang, Jia; Xia, Meng; Shan, Wanying; Wang, Beibei; Li, Kezhen; Weng, Danhui; Xu, Xiaoyan; Gao, Qinglei; Wang, Shixuan; Hu, Junbo; Chen, Gang] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Gynecol & Obstet, Wuhan 430030, Hubei, Peoples R China; [Li, Na] Peter MacCallum Canc Ctr, Canc Genet Lab, Melbourne, Vic 3000, Australia; [Zhou, Bo] Wuhan Univ, Dept Gynecol Oncol, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China; [Lu, Hao; Xia, Meng] Cent Hosp Wuhan, Dept Gynecol & Obstet, Wuhan 430030, Hubei, Peoples R China; [Hu, Junbo] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Gastrointestinal Surg, Wuhan 430030, Hubei, Peoples R China; [Lu, Yiling; Mills, Gordon B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA	Huazhong University of Science & Technology; Peter Maccallum Cancer Center; Wuhan University; Huazhong University of Science & Technology; University of Texas System; UTMD Anderson Cancer Center	Chen, G (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Gynecol & Obstet, Wuhan 430030, Hubei, Peoples R China.	gumpc@126.com	chaoyang, sun/HCH-0905-2022	Chen, Gang/0000-0002-8320-6594; Sun, Chaoyang/0000-0003-2469-1638; Mills, Gordon/0000-0002-0144-9614	National Key R&D Program of China [2016YFC1303100]; National Basic Research Program of China (973 Program) [2015CB553903]; Nature and Science Foundation of China [81272859, 81572569, 81402163, 81402164, 81501530, 81671394, 81370469]; International S&T Cooperation Program of China [2013DFA31400]; NIH [P50CA217685]; Ovarian Cancer Research Foundation	National Key R&D Program of China; National Basic Research Program of China (973 Program)(National Basic Research Program of China); Nature and Science Foundation of China(National Natural Science Foundation of China (NSFC)); International S&T Cooperation Program of China; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ovarian Cancer Research Foundation	This study was supported by the National Key R&D Program of China (2016YFC1303100), the National Basic Research Program of China (973 Program, 2015CB553903), Nature and Science Foundation of China (81272859, 81572569, 81402163, 81402164, 81501530, 81671394, and 81370469), the International S&T Cooperation Program of China (No. 2013DFA31400). GBM has support from NIH P50CA217685, Ovarian Cancer Research Foundation, and a kind gift from the Adelson Medical Research Fund.	Al-Wahab Z, 2015, ONCOTARGET, V6, P10908, DOI 10.18632/oncotarget.3434; Algire C, 2012, CANCER PREV RES, V5, P536, DOI 10.1158/1940-6207.CAPR-11-0536; Amano SU, 2014, CELL METAB, V19, P162, DOI 10.1016/j.cmet.2013.11.017; Bae HS, 2014, J OVARIAN RES, V7, DOI 10.1186/1757-2215-7-41; Baldan V, 2015, BRIT J CANCER, V112, P1510, DOI 10.1038/bjc.2015.96; Banerjee S, 2013, CLIN CANCER RES, V19, P961, DOI 10.1158/1078-0432.CCR-12-2243; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Broek IV, 2003, BRIT J CANCER, V88, P855, DOI 10.1038/sj.bjc.6600833; Castadot P, 2005, Cancer Radiother, V9, P183, DOI 10.1016/j.canrad.2005.03.001; Fang WB, 2012, J BIOL CHEM, V287, P36593, DOI 10.1074/jbc.M112.365999; Furukawa S, 2013, ANTICANCER RES, V33, P4785; Giuliani M, 2017, MINERVA GINECOL, V8; Guru SK, 2015, CANCER RES, V75, P2886, DOI 10.1158/0008-5472.CAN-14-2312; He YY, 2007, HUM REPROD, V22, P2733, DOI 10.1093/humrep/dem208; Hoy AJ, 2017, TRENDS MOL MED, V23, P381, DOI 10.1016/j.molmed.2017.02.009; Kojima R, 2010, J IMMUNOL, V184, P5253, DOI 10.4049/jimmunol.0901298; Li XG, 2017, GUT, V66, P157, DOI 10.1136/gutjnl-2015-310514; Lim MC, 2009, GYNECOL ONCOL, V112, P28, DOI 10.1016/j.ygyno.2008.09.046; Liu GX, 2013, TUMOR BIOL, V34, P2741, DOI 10.1007/s13277-013-0827-7; Lu CH, 2016, EUR J PHARMACOL, V789, P60, DOI 10.1016/j.ejphar.2016.07.012; MANOME Y, 1995, CANCER IMMUNOL IMMUN, V41, P227; Milliken D, 2002, CLIN CANCER RES, V8, P1108; Mizutani K, 2009, ANTICANCER RES, V29, P3109; Naora H, 2005, NAT REV CANCER, V5, P355, DOI 10.1038/nrc1611; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Pequeux C, 2012, CANCER RES, V72, P3010, DOI 10.1158/0008-5472.CAN-11-3768; Pienta KJ, 2013, INVEST NEW DRUG, V31, P760, DOI 10.1007/s10637-012-9869-8; Rattan R, 2011, NEOPLASIA, V13, P483, DOI 10.1593/neo.11148; Robinson E, 2014, BIOCHEM SOC T, V42, P125, DOI 10.1042/BST20130203; Rodriguez GM, 2018, CANCERS, V10, DOI 10.3390/cancers10080242; Romero IL, 2015, CLIN CANCER RES, V21, P680, DOI 10.1158/1078-0432.CCR-14-2198; Shen H, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1250-8; Sica A, 2000, J IMMUNOL, V164, P733, DOI 10.4049/jimmunol.164.2.733; Sierra-Filardi E, 2014, J IMMUNOL, V192, P3858, DOI 10.4049/jimmunol.1302821; Sikka A, 2012, CELL CYCLE, V11, P1374, DOI 10.4161/cc.19798; Tabuso M, 2017, WORLD J GASTROENTERO, V23, P5829, DOI 10.3748/wjg.v23.i32.5829; TARIN D, 1984, CANCER RES, V44, P3584; Teng PN, 2014, BRIT J CANCER, V110, P123, DOI 10.1038/bjc.2013.687; Torre LA, 2018, CA-CANCER J CLIN, V68, P284, DOI 10.3322/caac.21456; Tsuyada A, 2012, CANCER RES, V72, P2768, DOI 10.1158/0008-5472.CAN-11-3567; Visser M, 1999, JAMA-J AM MED ASSOC, V282, P2131, DOI 10.1001/jama.282.22.2131; Wang Y, 2018, CAN RESPIR J, V2018, DOI 10.1155/2018/8354892; Wang YX, 2019, J CELL PHYSL, P8; Wojnarowicz P, 2012, ONCOGENESIS, V1, DOI 10.1038/oncsis.2012.25; Xu TP, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0063-7; Xu XJ, 2012, J LIPID RES, V53, P792, DOI 10.1194/jlr.P022905; Yang HS, 2011, INT J GYNECOL CANCER, V21, P1525, DOI 10.1097/IGC.0b013e31822eb5f8; Yu HD, 2019, J CLIN INVEST, V129, P2485, DOI 10.1172/JCI125646; Yumimoto K, 2019, CANCER SCI, V110, P2090, DOI 10.1111/cas.14075; Zhang J, 2010, JNCI-J NATL CANCER I, V102, P522, DOI 10.1093/jnci/djq044	50	30	31	3	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	8					1681	1695		10.1038/s41388-019-1090-1	http://dx.doi.org/10.1038/s41388-019-1090-1			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN6CG	31705064	Green Accepted			2022-12-28	WOS:000514923000005
J	Wu, HJ; Hao, MG; Yeo, SK; Guan, JL				Wu, Hsin-Jung; Hao, Mingang; Yeo, Syn Kok; Guan, Jun-Lin			FAK signaling in cancer-associated fibroblasts promotes breast cancer cell migration and metastasis by exosomal miRNAs-mediated intercellular communication	ONCOGENE			English	Article							FOCAL-ADHESION KINASE; EPITHELIAL-SPECIFIC DISRUPTION; STEM-CELLS; HETEROGENEITY; SURVIVAL; BIOLOGY; GENES	Cancer-associated fibroblasts (CAFs) are activated fibroblasts that constitute the major components of tumor microenvironment (TME) and play crucial roles in tumor development and metastasis. Here, we generated fibroblast-specific inducible focal adhesion kinase (FAK) knockout (cKO) mice in a breast cancer model to study potential role and mechanisms of FAK signaling in CAF to promote breast cancer metastasis in vivo. While not affecting primary tumor development and growth, FAK deletion significantly suppressed breast cancer metastasis in vivo. Analyses of CAFs derived from cKO mice as well as human CAFs showed that FAK is required for their activity to promote mammary tumor cell migration. We further showed that FAK ablation in CAFs decreased exosome functions to promote tumor cell migration and other activities, which could contribute to the reduced metastasis observed in cKO mice. Lastly, profiling of miRs from CAF exosomes showed alterations of several exosomal miRs in FAK-null CAFs, and further analysis suggested that miR-16 and miR-148a enriched in exosomes from FAK-null CAFs contribute to the reduced tumor cell activities and metastasis. Together, these results identify a new role for FAK signaling in CAFs that regulate their intercellular communication with tumor cells to promote breast cancer metastasis.	[Wu, Hsin-Jung; Hao, Mingang; Yeo, Syn Kok; Guan, Jun-Lin] Univ Cincinnati, Coll Med, Dept Canc Biol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Guan, JL (corresponding author), Univ Cincinnati, Coll Med, Dept Canc Biol, Cincinnati, OH 45267 USA.	guanjl@uc.edu	Hao, Mingang/AAL-7254-2020; Hao, Mingang/X-2317-2018; Yeo, Syn/I-1617-2019	Hao, Mingang/0000-0001-6456-1710; Yeo, Syn/0000-0002-4333-2510	NIH [R01CA163493, R01NS094144, R01HL073394]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We would like to thank Glenn Doerman for his help in the preparation of figures. We are grateful to members of our laboratory for their critical comments and suggestions for the manuscript. The work in this study is funded by NIH grants R01CA163493, R01NS094144, and R01HL073394 to J-LG.	Augsten M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00062; BouGharios G, 1996, J CELL BIOL, V134, P1333, DOI 10.1083/jcb.134.5.1333; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Costa A, 2018, CANCER CELL, V33, P463, DOI 10.1016/j.ccell.2018.01.011; Costea DE, 2013, CANCER RES, V73, P3888, DOI 10.1158/0008-5472.CAN-12-4150; Dalerba P, 2007, ANNU REV MED, V58, P267, DOI 10.1146/annurev.med.58.062105.204854; Donnarumma E, 2017, ONCOTARGET, V8, P19592, DOI 10.18632/oncotarget.14752; Duran A, 2016, CANCER CELL, V30, P595, DOI 10.1016/j.ccell.2016.09.004; Fan HP, 2013, J BIOL CHEM, V288, P3322, DOI 10.1074/jbc.M112.420497; Golubovskaya VM, 2007, INT REV CYTOL, V263, P103, DOI 10.1016/S0074-7696(07)63003-4; Greening DW, 2015, METHODS MOL BIOL, V1295, P179, DOI 10.1007/978-1-4939-2550-6_15; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hannafon BN, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0400-7; Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756; Hu BA, 2012, AM J PATHOL, V180, P2257, DOI 10.1016/j.ajpath.2012.02.010; Jiang H, 2016, NAT MED, V22, P851, DOI 10.1038/nm.4123; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Lahlou H, 2007, P NATL ACAD SCI USA, V104, P20302, DOI 10.1073/pnas.0710091104; Li Y, 2016, J CANCER, V7, P1233, DOI 10.7150/jca.14616; Luga V, 2012, CELL, V151, P1542, DOI 10.1016/j.cell.2012.11.024; Luo M, 2013, CANCER RES, V73, P5591, DOI 10.1158/0008-5472.CAN-13-1351; Luo M, 2009, CANCER RES, V69, P466, DOI 10.1158/0008-5472.CAN-08-3078; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Orimo A, 2006, CELL CYCLE, V5, P1597, DOI 10.4161/cc.5.15.3112; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Provenzano PP, 2008, AM J PATHOL, V173, P1551, DOI 10.2353/ajpath.2008.080308; Pylayeva Y, 2009, J CLIN INVEST, V119, P252, DOI 10.1172/JCI37160; Rivas MA, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3187; Rosen JM, 2009, SCIENCE, V324, P1670, DOI 10.1126/science.1171837; Ruivo CF, 2017, CANCER RES, V77, P6480, DOI 10.1158/0008-5472.CAN-17-0994; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; Serrels A, 2015, CELL, V163, P160, DOI 10.1016/j.cell.2015.09.001; Serrels B, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aan8355; Shiga K, 2015, CANCERS, V7, P2443, DOI 10.3390/cancers7040902; Shimoda M, 2014, NAT CELL BIOL, V16, P889, DOI 10.1038/ncb3021; Siesser PMF, 2006, CLIN CANCER RES, V12, P3233, DOI 10.1158/1078-0432.CCR-06-0456; Simons M, 2009, CURR OPIN CELL BIOL, V21, P575, DOI 10.1016/j.ceb.2009.03.007; Stingl J, 2007, NAT REV CANCER, V7, P791, DOI 10.1038/nrc2212; Su SC, 2018, CELL, V172, P841, DOI 10.1016/j.cell.2018.01.009; Sun SG, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20930-z; Symeonides SN, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0217-6; Tavora B, 2014, NATURE, V514, P112, DOI 10.1038/nature13541; Tavora B, 2010, EMBO MOL MED, V2, P516, DOI 10.1002/emmm.201000106; Tkach M, 2016, CELL, V164, P1226, DOI 10.1016/j.cell.2016.01.043; Umemura A, 2016, CANCER CELL, V29, P935, DOI 10.1016/j.ccell.2016.04.006; Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153; Zhao J, 2009, CANCER METAST REV, V28, P35, DOI 10.1007/s10555-008-9165-4; Zhao XF, 2010, J CELL BIOL, V189, P955, DOI 10.1083/jcb.200912094; Zheng B, 2002, AM J PATHOL, V160, P1609, DOI 10.1016/S0002-9440(10)61108-X	50	67	71	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	12					2539	2549		10.1038/s41388-020-1162-2	http://dx.doi.org/10.1038/s41388-020-1162-2		JAN 2020	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KW4HU	31988451	Green Accepted			2022-12-28	WOS:000509655100003
J	Zhang, JQ; Bosbach, B; Loo, JK; Vitiello, GA; Zeng, S; Seifert, AM; Medina, BD; Param, NJ; Maltbaek, JH; Rossi, F; Antonescu, CR; Besmer, P; DeMatteo, RP				Zhang, Jennifer Q.; Bosbach, Benedikt; Loo, Jennifer K.; Vitiello, Gerardo A.; Zeng, Shan; Seifert, Adrian M.; Medina, Benjamin D.; Param, Nesteene J.; Maltbaek, Joanna H.; Rossi, Ferdinand; Antonescu, Cristina R.; Besmer, Peter; DeMatteo, Ronald P.			The V654A second-site KIT mutation increases tumor oncogenesis and STAT activation in a mouse model of gastrointestinal stromal tumor	ONCOGENE			English	Article							C-KIT; IMATINIB MESYLATE; SIGNAL-TRANSDUCTION; INTERSTITIAL-CELLS; TARGETED MUTATION; DRUG-RESISTANCE; TYROSINE KINASE; INHIBITION; MECHANISMS; EFFICACY	Gastrointestinal stromal tumor (GIST) is the most common human sarcoma and arises in the gastrointestinal tract. Most GISTs are caused by activating mutations in the KIT receptor tyrosine kinase, such as the exon 11KITV559 Delta mutation. The small molecule imatinib inhibits KIT and has been a mainstay of therapy in GIST. Unfortunately, imatinib-treated patients typically relapse, most often due to clonal emergence of the resistance-associatedKITV654A mutation. To determine the biologic impact of this second-site mutation in vivo, we created a mouse model with the corresponding V558 Delta;V653AKitdouble mutation restricted (a) spatially to ETV1(+)cells, which include the interstitial cells of Cajal (ICCs) from which GISTs presumably originate, and (b) temporally through tamoxifen treatment after birth. This resulted in the first in vivo model of the most common second-site mutation associated with imatinib resistance in GIST and the first in vivo demonstration that cell-autonomous expression of mutant KIT in the ICC lineage leads to GIST. GISTs driven by the V558 Delta;V653AKitdouble mutation were resistant to imatinib, while cabozantinib was more effective in overcoming resistance than sunitinib. Compared to control mice with a single V558 Delta Kitmutation, mice with a double V558 Delta; V653AKitmutation had increased tumor oncogenesis and associated KIT-dependent STAT activation. Our findings demonstrate that the biologic consequences of a second-site mutation in an oncogenic driver may include not only a mechanism for drug resistance, but changes in tumor oncogenic potential and differential activation of signaling pathways.	[Zhang, Jennifer Q.; Loo, Jennifer K.; Vitiello, Gerardo A.; Zeng, Shan; Seifert, Adrian M.; Medina, Benjamin D.; Param, Nesteene J.; Maltbaek, Joanna H.; Rossi, Ferdinand; DeMatteo, Ronald P.] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA; [Bosbach, Benedikt; Besmer, Peter] Mem Sloan Kettering Canc Ctr, Dev Biol, New York, NY 10021 USA; [Bosbach, Benedikt] Mem Sloan Kettering Canc Ctr, Dept Canc Biol & Genet, New York, NY 10021 USA; [Rossi, Ferdinand; DeMatteo, Ronald P.] Hosp Univ Penn, Dept Surg, 3400 Spruce St, Philadelphia, PA 19104 USA; [Antonescu, Cristina R.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Pennsylvania; Pennsylvania Medicine; Memorial Sloan Kettering Cancer Center	DeMatteo, RP (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA.; DeMatteo, RP (corresponding author), Hosp Univ Penn, Dept Surg, 3400 Spruce St, Philadelphia, PA 19104 USA.	ronald.dematteo@pennmedicine.upenn.edu	Seifert, Adrian M./AAL-3453-2021	Seifert, Adrian M./0000-0002-5329-3164; Maltbaek, Joanna/0000-0003-3225-1843; Vitiello, Gerardo/0000-0002-7452-8903	NIH [R01 CA102613, T32 CA09501]; GIST Cancer Research Fund; Starr Cancer Consortium; Cancer Center Support Grant [P30 CA008748];  [F32 CA186534];  [P50 CA140146-01];  [R01 HL55748];  [CA102774]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); GIST Cancer Research Fund; Starr Cancer Consortium; Cancer Center Support Grant; ; ; ; 	The investigators were supported by NIH grants R01 CA102613 and T32 CA09501, and Betsy Levine-Brown and Marc Brown (RPD); GIST Cancer Research Fund (RPD and CRA); F32 CA186534 (JQZ); P50 CA140146-01 and the Starr Cancer Consortium (CRA and PB); and R01 HL55748 and CA102774 (PB). The Flow Cytometry and Molecular Cytology Core Facilities were supported by Cancer Center Support Grant P30 CA008748.	Antonescu CR, 2005, CLIN CANCER RES, V11, P4182, DOI 10.1158/1078-0432.CCR-04-2245; Bahlawane C, 2015, CELL COMMUN SIGNAL, V13, DOI 10.1186/s12964-015-0096-8; Balachandran VP, 2011, NAT MED, V17, P1094, DOI 10.1038/nm.2438; Beckett EAH, 2007, DEV DYNAM, V236, P60, DOI 10.1002/dvdy.20929; Blanke CD, 2008, J CLIN ONCOL, V26, P626, DOI 10.1200/JCO.2007.13.4452; Bosbach B, 2017, P NATL ACAD SCI USA, V114, pE8448, DOI 10.1073/pnas.1711449114; Bosbach B, 2012, P NATL ACAD SCI USA, V109, pE2276, DOI 10.1073/pnas.1115240109; Casteran N, 2003, ONCOGENE, V22, P4710, DOI 10.1038/sj.onc.1206587; Cavnar MJ, 2013, J EXP MED, V210, P2873, DOI 10.1084/jem.20130875; Chaix A, 2014, ONCOGENE, V33, P872, DOI 10.1038/onc.2013.12; Chaix A, 2011, J BIOL CHEM, V286, P5956, DOI 10.1074/jbc.M110.182642; Chi P, 2010, NATURE, V467, P849, DOI 10.1038/nature09409; Choudhary C, 2009, MOL CELL, V36, P326, DOI 10.1016/j.molcel.2009.09.019; Cohen NA, 2015, CANCER RES, V75, P2061, DOI 10.1158/0008-5472.CAN-14-2564; Debiec-Rychter M, 2005, GASTROENTEROLOGY, V128, P270, DOI 10.1053/j.gastro.2004.11.020; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Duensing A, 2004, ONCOGENE, V23, P3999, DOI 10.1038/sj.onc.1207525; Gajiwala KS, 2009, P NATL ACAD SCI USA, V106, P1542, DOI 10.1073/pnas.0812413106; Georgiades P, 2002, GENESIS, V34, P251, DOI 10.1002/gene.10161; Guo TH, 2009, CLIN CANCER RES, V15, P6862, DOI 10.1158/1078-0432.CCR-09-1315; Heinrich MC, 2008, J CLIN ONCOL, V26, P5360, DOI 10.1200/JCO.2008.17.4284; Heinrich MC, 2008, J CLIN ONCOL, V26, P5352, DOI 10.1200/JCO.2007.15.7461; Heydt C, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1311-0; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Joensuu H, 2012, ANNU REV MED, V63, P247, DOI 10.1146/annurev-med-043010-091813; Kim TS, 2014, CLIN CANCER RES, V20, P2350, DOI 10.1158/1078-0432.CCR-13-3033; Kluppel M, 1998, DEV DYNAM, V211, P60; Kwon JG, 2009, GASTROENTEROLOGY, V136, P630, DOI 10.1053/j.gastro.2008.10.031; Lorincz A, 2008, GASTROENTEROLOGY, V134, P1083, DOI 10.1053/j.gastro.2008.01.036; Miller CL, 1996, EXP HEMATOL, V24, P185; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; Prenen H, 2006, CLIN CANCER RES, V12, P2622, DOI 10.1158/1078-0432.CCR-05-2275; Ran LL, 2015, CANCER DISCOV, V5, P304, DOI 10.1158/2159-8290.CD-14-0985; Regales L, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000810; Roberts KG, 2007, MOL CANCER THER, V6, P1159, DOI 10.1158/1535-7163.MCT-06-0641; Schoffski P, 2020, EUR J CANCER, V134, P62, DOI 10.1016/j.ejca.2020.04.021; Seifert AM, 2017, CLIN CANCER RES, V23, P454, DOI 10.1158/1078-0432.CCR-16-1163; Sommer G, 2003, P NATL ACAD SCI USA, V100, P6706, DOI 10.1073/pnas.1037763100; Spector MS, 2012, LEUKEMIA, V26, P1422, DOI 10.1038/leu.2011.354; Stadtfeld M, 2005, DEVELOPMENT, V132, P203, DOI 10.1242/dev.01558; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; Tamborini E, 2006, ONCOGENE, V25, P6140, DOI 10.1038/sj.onc.1209639; Torihashi S, 1997, GASTROENTEROLOGY, V112, P144, DOI 10.1016/S0016-5085(97)70229-4; Verweij J, 2004, LANCET, V364, P1127, DOI 10.1016/S0140-6736(04)17098-0; West RB, 2004, AM J PATHOL, V165, P107, DOI 10.1016/S0002-9440(10)63279-8; YEE NS, 1994, J EXP MED, V179, P1777, DOI 10.1084/jem.179.6.1777; Zhang JQ, 2018, CANCER IMMUNOL RES, V6, P434, DOI 10.1158/2326-6066.CIR-17-0345; Zhao J, 2014, CANCER SCI, V105, P117, DOI 10.1111/cas.12320; Zhu MJ, 2007, ONCOGENE, V26, P6386, DOI 10.1038/sj.onc.1210464	49	4	4	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2020	39	49					7153	7165		10.1038/s41388-020-01489-4	http://dx.doi.org/10.1038/s41388-020-01489-4		OCT 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PB0GA	33024275	Green Accepted			2022-12-28	WOS:000575700700003
J	Wagner, V; Gil, J				Wagner, Verena; Gil, Jesus			Senescence as a therapeutically relevant response to CDK4/6 inhibitors	ONCOGENE			English	Review							DEPENDENT KINASE 4/6; CELLULAR SENESCENCE; BREAST-CANCER; TUMOR-CELLS; STROMAL SENESCENCE; LUNG-CANCER; GROWTH; CDK6; P53; PROLIFERATION	Cyclin-dependent kinases 4 and 6 (CDK4/6) phosphorylate and inhibit retinoblastoma (RB) family proteins. Hyperphosphorylated RB releases E2F transcription factors, activating a transcriptional program that initiates S phase. Due to the critical role that this pathway has in regulating cell cycle progression, inhibiting CDK4/6 is an attractive therapeutic strategy. Indeed, CDK4/6 inhibitors in combination with antiestrogens produce a significant benefit in patients with ER+/HER2(-)breast cancer. Clinical trials are currently investigating if the use of CDK4/6 inhibitors alone or in combination can be extended to other cancer types. Inhibition of CDK4/6 can result in different cell fates such as quiescence, senescence, or apoptosis. Senescence is a stress response that can be induced by stimuli that include oncogenic activation, chemotherapy, irradiation, and targeted therapies such as CDK4/6 inhibitors. Senescent cells undergo a stable cell cycle arrest and produce a bioactive secretome that remodels their microenvironment and engages the immune system. In this review, we analyze the therapeutic relevance of senescence induction by CDK4/6 inhibitors. We also discuss how different therapies, including checkpoint inhibitors and drugs targeting MEK or PI3K, can be used in combination with CDK4/6 inhibitors to reinforce or exploit senescence. Recently, a lot of effort has been put into identifying compounds that selectively kill senescent cells (termed senolytics). Thus, sequential treatment with senolytics might be an additional strategy to potentiate the antitumor effects of CDK4/6 inhibitors.	[Wagner, Verena; Gil, Jesus] MRC, London Inst Med Sci LMS, Du Cane Rd, London W12 0NN, England; [Wagner, Verena; Gil, Jesus] Imperial Coll London, Inst Clin Sci ICS, Fac Med, Du Cane Rd, London W12 0NN, England	Imperial College London	Gil, J (corresponding author), MRC, London Inst Med Sci LMS, Du Cane Rd, London W12 0NN, England.; Gil, J (corresponding author), Imperial Coll London, Inst Clin Sci ICS, Fac Med, Du Cane Rd, London W12 0NN, England.	jesus.gil@imperial.ac.uk		Wagner, Verena/0000-0003-2604-0759; Gil, Jesus/0000-0002-4303-6260	CRUK [C15075/A28647]; MRC [MC_U120085810]; German Cancer Aid Mildred-Scheel Postdoc Program	CRUK(Cancer Research UK); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); German Cancer Aid Mildred-Scheel Postdoc Program	Grants from CRUK (C15075/A28647) and core support from MRC (MC_U120085810) funded this research in J. Gil's Laboratory. VW was funded by the German Cancer Aid Mildred-Scheel Postdoc Program.	Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Acosta JC, 2013, NAT CELL BIOL, V15, P978, DOI 10.1038/ncb2784; Alvarez-Fernandez M, 2020, CANCER CELL, V37, P514, DOI 10.1016/j.ccell.2020.03.010; Anders L, 2011, CANCER CELL, V20, P620, DOI 10.1016/j.ccr.2011.10.001; Andre F, 2019, NEW ENGL J MED, V380, P1929, DOI 10.1056/NEJMoa1813904; Asghar U, 2015, NAT REV DRUG DISCOV, V14, P130, DOI 10.1038/nrd4504; Asghar US, 2017, CLIN CANCER RES, V23, P5561, DOI 10.1158/1078-0432.CCR-17-0369; Baker DJ, 2011, NATURE, V479, P232, DOI 10.1038/nature10600; Basisty N, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000599; Bellutti F, 2018, CANCER DISCOV, V8, P884, DOI 10.1158/2159-8290.CD-17-0912; Bollard J, 2017, GUT, V66, P1286, DOI 10.1136/gutjnl-2016-312268; Chang BD, 1999, CANCER RES, V59, P3761; Chang JH, 2016, NAT MED, V22, P78, DOI 10.1038/nm.4010; Chen L, 2017, BRIT J PHARMACOL, V174, P2427, DOI 10.1111/bph.13836; Choi YJ, 2012, CANCER CELL, V22, P438, DOI 10.1016/j.ccr.2012.09.015; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Condorelli R, 2018, ANN ONCOL, V29, P640, DOI 10.1093/annonc/mdx784; Coppe JP, 2006, J BIOL CHEM, V281, P29568, DOI 10.1074/jbc.M603307200; Coppe JP, 2011, J BIOL CHEM, V286, P36396, DOI 10.1074/jbc.M111.257071; Dall'Acqua A, 2017, EMBO MOL MED, V9, P1415, DOI 10.15252/emmm.201607012; Damsky W, 2015, CANCER CELL, V27, P41, DOI 10.1016/j.ccell.2014.11.014; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Demaria M, 2017, CANCER DISCOV, V7, P165, DOI 10.1158/2159-8290.CD-16-0241; Deng JH, 2018, CANCER DISCOV, V8, P216, DOI 10.1158/2159-8290.CD-17-0915; Dorr JR, 2013, NATURE, V501, P421, DOI 10.1038/nature12437; Eggert T, 2016, CANCER CELL, V30, P533, DOI 10.1016/j.ccell.2016.09.003; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Finn RS, 2015, LANCET ONCOL, V16, P25, DOI 10.1016/S1470-2045(14)71159-3; Franco J, 2016, CELL REP, V14, P979, DOI 10.1016/j.celrep.2015.12.094; Fry DW, 2004, MOL CANCER THER, V3, P1427; Gelbert LM, 2014, INVEST NEW DRUG, V32, P825, DOI 10.1007/s10637-014-0120-7; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Goel S, 2017, NATURE, V548, P471, DOI 10.1038/nature23465; Gong XQ, 2017, CANCER CELL, V32, P761, DOI 10.1016/j.ccell.2017.11.006; Gorgoulis V, 2019, CELL, V179, P813, DOI 10.1016/j.cell.2019.10.005; Guan XN, 2017, MOL CANCER RES, V15, P237, DOI 10.1158/1541-7786.MCR-16-0319; Guerrero A, 2019, NAT METAB, V1, P1074, DOI 10.1038/s42255-019-0122-z; Hafner M, 2019, CELL CHEM BIOL, V26, P1067, DOI 10.1016/j.chembiol.2019.05.005; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Haugstetter AM, 2010, BRIT J CANCER, V103, P505, DOI 10.1038/sj.bjc.6605784; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; He SH, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3986; Herrera-Abreu MT, 2016, CANCER RES, V76, P2301, DOI 10.1158/0008-5472.CAN-15-0728; Iannello A, 2013, J EXP MED, V210, P2057, DOI 10.1084/jem.20130783; Jerby-Arnon L, 2018, CELL, V175, P984, DOI 10.1016/j.cell.2018.09.006; Jiang SH, 2017, NATURE, V544, P460, DOI 10.1038/nature22032; Kang TW, 2011, NATURE, V479, P547, DOI 10.1038/nature10599; Kim S., 2013, MOL CANCER THER, V12, pPR02, DOI DOI 10.1158/1535-7163.TARG-13-PR02; Kim YH, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15208; Klein ME, 2018, CANCER CELL, V34, P9, DOI 10.1016/j.ccell.2018.03.023; Kollmann K, 2016, CANCER CELL, V30, P359, DOI 10.1016/j.ccell.2016.07.003; Kovatcheva M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00540-5; Kovatcheva M, 2015, ONCOTARGET, V6, P8226, DOI 10.18632/oncotarget.3364; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Kumarasamy V, 2020, ONCOGENE, V39, P1831, DOI 10.1038/s41388-019-1102-1; Kwong LN, 2012, NAT MED, V18, P1503, DOI 10.1038/nm.2941; Li J, 2010, CANCER INVEST, V28, P350, DOI 10.3109/07357900903286966; Martini M, 2014, ANN MED, V46, P372, DOI 10.3109/07853890.2014.912836; McHugh D, 2018, J CELL BIOL, V217, P65, DOI 10.1083/jcb.201708092; Miettinen TP, 2018, EMBO J, V37, DOI 10.15252/embj.201798359; Milanovic M, 2018, NATURE, V553, P96, DOI 10.1038/nature25167; Munoz-Espin D, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201809355; Patnaik A, 2016, CANCER DISCOV, V6, P740, DOI 10.1158/2159-8290.CD-16-0095; Petrova NV, 2016, AGING CELL, V15, P999, DOI 10.1111/acel.12518; Puyol M, 2010, CANCER CELL, V18, P63, DOI 10.1016/j.ccr.2010.05.025; Rader J, 2013, CLIN CANCER RES, V19, P6173, DOI 10.1158/1078-0432.CCR-13-1675; Reddy HKDL, 2005, CANCER RES, V65, P10174, DOI 10.1158/0008-5472.CAN-05-2639; Roberson RS, 2005, CANCER RES, V65, P2795, DOI 10.1158/0008-5472.CAN-04-1270; Roberts PJ, 2012, JNCI-J NATL CANCER I, V104, P476, DOI 10.1093/jnci/djs002; Ruhland MK, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11762; Ruscetti M, 2020, CELL, V181, P424, DOI 10.1016/j.cell.2020.03.008; Ruscetti M, 2018, SCIENCE, V362, P1416, DOI 10.1126/science.aas9090; Salvador-Barbero B, 2020, CANCER CELL, V37, P340, DOI 10.1016/j.ccell.2020.01.007; Sawai CM, 2012, CANCER CELL, V22, P452, DOI 10.1016/j.ccr.2012.09.016; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Schuler MH, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.9519; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Sherr CJ, 2016, CANCER DISCOV, V6, P353, DOI 10.1158/2159-8290.CD-15-0894; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Simanshu DK, 2017, CELL, V170, P17, DOI 10.1016/j.cell.2017.06.009; Tao YF, 2017, CANCER CELL INT, V17, DOI 10.1186/s12935-017-0405-y; te Poele RH, 2002, CANCER RES, V62, P1876; Teo ZL, 2017, CANCER RES, V77, P6340, DOI 10.1158/0008-5472.CAN-17-2210; Toogood PL, 2005, J MED CHEM, V48, P2388, DOI 10.1021/jm049354h; Torres-Guzman R, 2017, ONCOTARGET, V8, P69493, DOI 10.18632/oncotarget.17778; Turner NC, 2019, J CLIN ONCOL, V37, P1169, DOI 10.1200/JCO.18.00925; Valenzuela CA, 2017, EXP CELL RES, V360, P390, DOI 10.1016/j.yexcr.2017.09.031; Vijayaraghavan S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15916; Vora SR, 2014, CANCER CELL, V26, P136, DOI 10.1016/j.ccr.2014.05.020; Walter DM, 2019, NATURE, V569, P423, DOI 10.1038/s41586-019-1172-9; Wander SA, 2020, CANCER DISCOV; Wang C, 2019, NATURE, V574, P268, DOI 10.1038/s41586-019-1607-3; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yoshida A, 2016, CANCER RES, V76, P2990, DOI 10.1158/0008-5472.CAN-15-2931; Yu QY, 2006, CANCER CELL, V9, P23, DOI 10.1016/j.ccr.2005.12.012; Zhang JF, 2018, NATURE, V553, P91, DOI 10.1038/nature25015; Zou XH, 2002, GENE DEV, V16, P2923, DOI 10.1101/gad.1033002	100	35	36	3	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 16	2020	39	29					5165	5176		10.1038/s41388-020-1354-9	http://dx.doi.org/10.1038/s41388-020-1354-9		JUN 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ML6WO	32541838	Green Accepted			2022-12-28	WOS:000540391900002
J	Jiang, K; Liu, P; Xu, HZ; Liang, DP; Fang, K; Du, S; Cheng, W; Ye, LG; Liu, T; Zhang, XH; Gong, P; Shao, SJ; Wang, YF; Meng, SS				Jiang, Ke; Liu, Peng; Xu, Huizhe; Liang, Dapeng; Fang, Kun; Du, Sha; Cheng, Wei; Ye, Leiguang; Liu, Tong; Zhang, Xiaohong; Gong, Peng; Shao, Shujuan; Wang, Yifei; Meng, Songshu			SASH1 suppresses triple-negative breast cancer cell invasion through YAP-ARHGAP42-actin axis	ONCOGENE			English	Article							HIPPO PATHWAY; ACTIN CYTOSKELETON; YAP; GENE; COMPLEX; GROWTH; PHOSPHORYLATION; METASTASIS; INHIBITION; EXPRESSION	Triple-negative breast cancer (TNBC) is extremely aggressive and lacks effective therapy. SAM and SH3 domain containing1 (SASH1) has been implicated in TNBC as a candidate tumor suppressor; however, the mechanisms of action of SASH1 in TNBC remain underexplored. Here, we show that SASH1 was significantly downregulated in TNBC patients samples compared with other subtypes of breast cancer. Ectopic SASH1 expression inhibited, while depletion of SASH1 enhanced, the invasive phenotype of TNBC cells, accompanied by deregulated expression of MMP2 and MMP9. The functional effects of SASH1 depletion were confirmed in the chicken chorioallantoic membrane and mouse xenograft models. Mechanistically, SASH1 knockdown downregulated the phosphorylation levels of the Hippo kinase LATS1 and its effector YAP (Yes associated protein), thereby upregulating YAP accumulation together with its downstream target CYR61. Consistently, forced SASH1 expression exhibited opposite effects. Pharmacological inhibition of YAP or knockdown of YAP reversed the enhanced cell invasion of TNBC cells following SASH1 depletion. Furthermore, SASH1-induced YAP signaling was LATS1-dependent, which in reverse enhanced phosphorylation of SASH1. The SASH1 S407A mutant (phosphorylation deficient) failed to rescue the altered YAP signaling by SASH1 knockdown. Notably, SASH1 depletion upregulated ARHGAP42 levels via YAP-TEAD and the YAP-ARHGAP42-actin axis contributed to SASH1-regulated TNBC cell invasion. Therefore, our findings uncover a new mechanism for the tumor-suppressive activity of SASH1 in TNBC, which may serve as a novel target for therapeutic intervention.	[Jiang, Ke; Xu, Huizhe; Liang, Dapeng; Fang, Kun; Du, Sha; Cheng, Wei; Zhang, Xiaohong; Meng, Songshu] Dalian Med Univ, Inst Canc Stem Cell, Canc Ctr, Dalian 116044, Peoples R China; [Liu, Peng; Gong, Peng] Shenzhen Univ, Gen Hosp, Dept Gen Surg, Shenzhen 518055, Peoples R China; [Liu, Peng; Gong, Peng] Shenzhen Univ, Sch Med, Carson Int Canc Res Ctr, Shenzhen 518055, Peoples R China; [Ye, Leiguang] Harbin Med Univ, Canc Hosp, Dept Oncol, Harbin 150000, Peoples R China; [Liu, Tong] Harbin Med Univ, Canc Hosp, Dept Breast Surg, Harbin 150000, Peoples R China; [Shao, Shujuan] Dalian Med Univ, Key Lab Prote, Dalian 116044, Peoples R China; [Wang, Yifei] Dalian Med Univ, Affiliated Hosp 2, Dept Obstet & Gynecol, Dalian 116027, Peoples R China	Dalian Medical University; Shenzhen University; Shenzhen University; Harbin Medical University; Harbin Medical University; Dalian Medical University; Dalian Medical University	Meng, SS (corresponding author), Dalian Med Univ, Inst Canc Stem Cell, Canc Ctr, Dalian 116044, Peoples R China.; Shao, SJ (corresponding author), Dalian Med Univ, Key Lab Prote, Dalian 116044, Peoples R China.; Wang, YF (corresponding author), Dalian Med Univ, Affiliated Hosp 2, Dept Obstet & Gynecol, Dalian 116027, Peoples R China.	shaoshujuan2006@126.com; yly2000.312@163.com; ssmeng@dmu.edu.cn	chegn, maizy/GVU-3127-2022	Jiang, Ke/0000-0001-7959-7716	National Natural Science Foundation of China [81572707, 81772973, 81973646, 81402071]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank professors Bin Zhao, Huadong Pei, Shian Wu, Zengqiang Yuan and Alexander Hergovich for providing plasmids. The authors gratefully acknowledge the financial support from the National Natural Science Foundation of China (81572707 and 81772973 to SM, 81973646 to PG, 81402071 to DL).	BUBB MR, 1994, J BIOL CHEM, V269, P14869; Burgess JT, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.364; Burgess JT, 2016, ONCOTARGET, V7, P72807, DOI 10.18632/oncotarget.12020; Calses PC, 2019, TRENDS CANCER, V5, P297, DOI 10.1016/j.trecan.2019.04.001; Citron F, 2017, CLIN CANCER RES, V23, P3769, DOI 10.1158/1078-0432.CCR-16-2814; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; Coumans Joelle V F, 2018, Biophys Rev, V10, P1323, DOI 10.1007/s12551-018-0445-0; Das Thakur M, 2010, CURR BIOL, V20, P657, DOI 10.1016/j.cub.2010.02.035; Fang Q, 2018, ONCOTARGET, V9, P2475, DOI 10.18632/oncotarget.23504; Franke FC, 2019, CELL MOL GASTROENTER, V7, P33, DOI 10.1016/j.jcmgh.2018.08.007; Gong XC, 2017, ONCOTARGETS THER, V10, P271, DOI 10.2147/OTT.S119244; Hiemer SE, 2014, J BIOL CHEM, V289, P13461, DOI 10.1074/jbc.M113.529115; Jagannathan R, 2016, MOL CELL BIOL, V36, P2526, DOI 10.1128/MCB.00136-16; Jiang K, 2016, ONCOTARGET, V7, P25652, DOI 10.18632/oncotarget.8357; Kim T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10186; Kumar MA, 2018, MOL CELL BIOCHEM, V442, P1, DOI 10.1007/s11010-017-3187-6; Lin SY, 2013, J BUON, V18, P891; Liu M, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0806-3; Liu X, 2018, CELL SIGNAL, V51, P243, DOI 10.1016/j.cellsig.2018.08.011; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Luo WF, 2017, J CELL SCI, V130, P2382, DOI 10.1242/jcs.197434; Ma SH, 2019, ANNU REV BIOCHEM, V88, P577, DOI 10.1146/annurev-biochem-013118-111829; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Martini M, 2011, INT J BIOCHEM CELL B, V43, P1630, DOI 10.1016/j.biocel.2011.07.012; Meng ZP, 2016, GENE DEV, V30, P1, DOI 10.1101/gad.274027.115; Porazinski S, 2015, NATURE, V521, P217, DOI 10.1038/nature14215; Qiao YT, 2017, CELL REP, V19, P1495, DOI 10.1016/j.celrep.2017.04.075; Rimkus C, 2006, BRIT J CANCER, V95, P1419, DOI 10.1038/sj.bjc.6603452; Shi PG, 2015, ACTA BIOCH BIOPH SIN, V47, P53, DOI 10.1093/abbs/gmu114; Shoji K, 2012, BIOCHEM BIOPH RES CO, V424, P52, DOI 10.1016/j.bbrc.2012.06.063; Stubblefield K, 2017, EXP CELL RES, V359, P384, DOI 10.1016/j.yexcr.2017.08.022; Sulaiman A, 2018, MOL ONCOL, V12, P423, DOI 10.1002/1878-0261.12167; Sumi T, 1999, J CELL BIOL, V147, P1519, DOI 10.1083/jcb.147.7.1519; Sun CY, 2017, INT J BIOCHEM CELL B, V89, P95, DOI 10.1016/j.biocel.2017.06.006; Yao Chuanbo, 2017, Yichuan, V39, P617, DOI 10.16288/j.yczz.17-100; Yu FX, 2014, EMBO J, V33, P942, DOI 10.1002/embj.201488329; Zeller C, 2003, ONCOGENE, V22, P2972, DOI 10.1038/sj.onc.1206474; Zhang ZZ, 2014, ACS MED CHEM LETT, V5, P993, DOI 10.1021/ml500160m; Zheng YG, 2019, DEV CELL, V50, P264, DOI 10.1016/j.devcel.2019.06.003; Zhou X, 2015, J CLIN INVEST, V125, P2123, DOI 10.1172/JCI79573	40	11	11	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 2	2020	39	27					5015	5030		10.1038/s41388-020-1356-7	http://dx.doi.org/10.1038/s41388-020-1356-7		JUN 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ME5NL	32523092				2022-12-28	WOS:000539515400002
J	Portney, BA; Arad, M; Gupta, A; Brown, RA; Khatri, R; Lin, PN; Hebert, AM; Angster, KH; Silipino, LE; Meltzer, WA; Taylor, RJ; Zalzman, M				Portney, Benjamin A.; Arad, Michal; Gupta, Aditi; Brown, Robert A.; Khatri, Raju; Lin, Phyo Nay; Hebert, Andrea M.; Angster, Kristen H.; Silipino, Lorna E.; Meltzer, W. Alex; Taylor, Rodney J.; Zalzman, Michal			ZSCAN4 facilitates chromatin remodeling and promotes the cancer stem cell phenotype	ONCOGENE			English	Article							DEVELOPMENTAL REGULATORS; TELOMERE ELONGATION; GENOMIC STABILITY; NECK-CANCER; HEAD; PLURIPOTENCY; NANOG; EXPRESSION; CARCINOMA; POLYCOMB	Cancer stem cells (CSCs) are cells within tumors that maintain the ability to self-renew, drive tumor growth, and contribute to therapeutic resistance and cancer recurrence. In this study, we investigate the role of Zinc finger and SCAN domain containing 4 (ZSCAN4) in human head and neck squamous cell carcinoma (HNSCC). The murine Zscan4 is involved in telomere maintenance and genomic stability of mouse embryonic stem cells. Our data indicate that the human ZSCAN4 is enriched for, marks and is co-expressed with CSC markers in HNSCC. We show that transient ZSCAN4 induction for just 2 days increases CSC frequency both in vitro and in vivo and leads to upregulation of pluripotency and CSC factors. Importantly, we define for the first time the role of ZSCAN4 in altering the epigenetic profile and regulating the chromatin state. Our data show that ZSCAN4 leads to a functional histone 3 hyperacetylation at the promoters of OCT3/4 and NANOG, leading to an upregulation of CSC factors. Consistently, ZSCAN4 depletion leads to downregulation of CSC markers, decreased ability to form tumorspheres and severely affects tumor growth. Our study suggests that ZSCAN4 plays an important role in the maintenance of the CSC phenotype, indicating it is a potential therapeutic target in HNSCC.	[Portney, Benjamin A.; Arad, Michal; Gupta, Aditi; Brown, Robert A.; Khatri, Raju; Lin, Phyo Nay; Hebert, Andrea M.; Angster, Kristen H.; Meltzer, W. Alex; Zalzman, Michal] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; [Hebert, Andrea M.; Angster, Kristen H.; Silipino, Lorna E.; Taylor, Rodney J.; Zalzman, Michal] Univ Maryland, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Baltimore, MD 21201 USA; [Taylor, Rodney J.; Zalzman, Michal] Univ Maryland, Sch Med, Marlene & Stewart Greenbaum Canc Ctr, Baltimore, MD 21201 USA; [Zalzman, Michal] Univ Maryland, Sch Med, Ctr Stem Cell Biol & Regenerat Med, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Zalzman, M (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA.; Zalzman, M (corresponding author), Univ Maryland, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Baltimore, MD 21201 USA.; Zalzman, M (corresponding author), Univ Maryland, Sch Med, Marlene & Stewart Greenbaum Canc Ctr, Baltimore, MD 21201 USA.; Zalzman, M (corresponding author), Univ Maryland, Sch Med, Ctr Stem Cell Biol & Regenerat Med, Baltimore, MD 21201 USA.	MZalzman@som.umaryland.edu	Gupta, Aditi/HGD-9632-2022	Khatri, Raju/0000-0002-1381-8560; Zalzman, Michal/0000-0002-4689-2951; Lin, Phyo Nay/0000-0003-4041-629X	National Institutes of Health/NINDS grant [1R21 NS095088-01A1]; NIH/NIAMS [R01 AR070819]; National Institutes of Health/NIH/NIAMS grant [R01 AR070819]	National Institutes of Health/NINDS grant; NIH/NIAMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); National Institutes of Health/NIH/NIAMS grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The molecular studies of ZSCAN4 were partially supported by the National Institutes of Health/NINDS grant number 1R21 NS095088-01A1 and NIH/NIAMS grant number R01 AR070819. MZ, RJT, BAP, were partially supported by the National Institutes of Health/NIH/NIAMS grant number R01 AR070819.	Adhikary G, 2015, CARCINOGENESIS, V36, P800, DOI 10.1093/carcin/bgv064; Adhikary G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084324; Ailles L, 2009, METHODS MOL BIOL, V568, P175, DOI 10.1007/978-1-59745-280-9_11; Akiyama T, 2015, DNA RES, V22, P307, DOI 10.1093/dnares/dsv013; Allegra E, 2014, ONCOLOGY-BASEL, V86, P199, DOI 10.1159/000358598; Allegra E, 2012, ONCOTARGETS THER, V5, P375, DOI 10.2147/OTT.S38694; Amano T, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2966; Azuara V, 2006, NAT CELL BIOL, V8, P532, DOI 10.1038/ncb1403; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bibikova M, 2008, CELL STEM CELL, V2, P123, DOI 10.1016/j.stem.2008.01.005; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Carew JS, 2008, CANCER LETT, V269, P7, DOI 10.1016/j.canlet.2008.03.037; Chinn SB, 2015, HEAD NECK-J SCI SPEC, V37, P317, DOI 10.1002/hed.23600; Chiou SH, 2008, CLIN CANCER RES, V14, P4085, DOI 10.1158/1078-0432.CCR-07-4404; Chiou SH, 2010, CANCER RES, V70, P10433, DOI 10.1158/0008-5472.CAN-10-2638; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Dan JM, 2017, CELL REP, V20, P1936, DOI 10.1016/j.celrep.2017.07.070; Falco G, 2007, DEV BIOL, V307, P539, DOI 10.1016/j.ydbio.2007.05.003; Gaspar-Maia A, 2011, NAT REV MOL CELL BIO, V12, P36, DOI 10.1038/nrm3036; Hirata T, 2012, SCI REP-UK, V2, DOI 10.1038/srep00208; Jiang J, 2013, CELL RES, V23, P92, DOI 10.1038/cr.2012.157; Joshi P, 2014, RAMBAM MAIMONIDES ME, V5, DOI 10.5041/RMMJ.10143; Joshua B, 2012, HEAD NECK-J SCI SPEC, V34, P42, DOI 10.1002/hed.21699; Lee K, 2014, CANCER BIOL THER, V15, P1094, DOI 10.4161/cbt.29220; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338; Liu AF, 2013, CHIN J CANCER, V32, P483, DOI 10.5732/cjc.012.10282; Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760; Lu YH, 2013, CANCER LETT, V340, P113, DOI 10.1016/j.canlet.2013.07.009; Marur S, 2016, MAYO CLIN PROC, V91, P386, DOI 10.1016/j.mayocp.2015.12.017; Marur S, 2010, LANCET ONCOL, V11, P781, DOI 10.1016/S1470-2045(10)70017-6; Meshorer E, 2006, NAT REV MOL CELL BIO, V7, P540, DOI 10.1038/nrm1938; Nakai-Futatsugi Y, 2016, STEM CELL REP, V6, P483, DOI 10.1016/j.stemcr.2016.02.010; Ohbo K, 1996, BLOOD, V87, P956, DOI 10.1182/blood.V87.3.956.bloodjournal873956; Okamoto A, 2009, ORAL ONCOL, V45, P633, DOI 10.1016/j.oraloncology.2008.10.003; Orkin SH, 2011, CELL, V145, P835, DOI 10.1016/j.cell.2011.05.019; Plimack ER, 2007, J CLIN ONCOL, V25, P4519, DOI 10.1200/JCO.2007.12.6029; Portney BA, 2018, BIOCHEM BIOPH RES CO, V498, P72, DOI 10.1016/j.bbrc.2018.02.155; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Prince MEP, 2008, J CLIN ONCOL, V26, P2871, DOI 10.1200/JCO.2007.15.1613; Proctor E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055820; Sano D, 2007, CANCER METAST REV, V26, P645, DOI 10.1007/s10555-007-9082-y; Seiwert TY, 2005, BRIT J CANCER, V92, P1341, DOI 10.1038/sj.bjc.6602510; Sharov AA, 2003, PLOS BIOL, V1, P410, DOI 10.1371/journal.pbio.0000074; Siddique HR, 2012, STEM CELLS, V30, P372, DOI 10.1002/stem.1035; Spafford MF, 1996, ARCH OTOLARYNGOL, V122, P627; Su YJ, 2011, EMBO J, V30, P3186, DOI 10.1038/emboj.2011.211; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; van Vlerken LE, 2013, STEM CELL TRANSL MED, V2, P43, DOI 10.5966/sctm.2012-0036; Zalzman M, 2010, NATURE, V464, P858, DOI 10.1038/nature08882	51	8	8	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 25	2020	39	26					4970	4982		10.1038/s41388-020-1333-1	http://dx.doi.org/10.1038/s41388-020-1333-1		JUN 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MQ2YO	32507861	Green Accepted, Green Published, hybrid			2022-12-28	WOS:000538701900001
J	Yang, CL; Yong, L; Liang, C; Li, Y; Ma, YL; Wei, F; Jiang, L; Zhou, H; He, GP; Pan, XY; Hai, B; Wu, J; Xu, YL; Liu, ZJ; Liu, XG				Yang, Chenlong; Yong, Lei; Liang, Chen; Li, Yan; Ma, Yunlong; Wei, Feng; Jiang, Liang; Zhou, Hua; He, Guanping; Pan, Xiaoyu; Hai, Bao; Wu, Jian; Xu, Yulun; Liu, Zhongjun; Liu, Xiaoguang			Genetic landscape and ligand-dependent activation of sonic hedgehog-Gli1 signaling in chordomas: a novel therapeutic target	ONCOGENE			English	Article							PATHWAY; GROWTH; CANCER; EXPRESSION; CARCINOMA; MUTATIONS; BIOLOGY; BCL-2; PTCH; GLI1	Chordoma, a rare neoplasm derived from intraosseous notochordal remnants, is unresponsive to conventional chemotherapy and radiotherapy. Sonic Hedgehog (Shh) is a crucial fetal notochord-secreted morphogen that directs notochordal development. The aim of this study was to determine the functional roles and therapeutic potential of Shh-Gli1 signaling in chordomas. Tissue samples and clinical profiles were collected from 42 patients with chordoma. The chordoma cell lines U-CH1 and MUG-Chor1 were used for functional experiments. Shh-Gli1 signaling pathway genetic alterations were screened, and the functions of the identified novel variants were analyzed using in silico analyses, real-time quantitative PCR, and minigene assays. Ligand-dependent Shh-Gli1 signaling activation was assessed using single- and dual-label immunostaining, western blot analysis, and a Shh-responsive Gli-luciferase reporter assay. The small-molecule inhibitor vismodegib was used to target Shh-Gli1 signaling in vitro and in vivo. Overall, 44 genetic alterations were identified, including four novel variants (c.67_69dupCTG in SMO, c.-6_-4dupGGC and c.3306 + 83_3306 + 84insG in PTCH1, and c.183-67_183-66delinsA in SUFU). Shh, PTCH1, SMO, SUFU, and Gli1 were extensively expressed in chordomas, and higher Gli1 expression correlated with poorer prognosis. A luciferase reporter assay and dual-label immunostaining indicated the occurrence of juxtacrine ligand-dependent Shh-Gli1 signaling activation. Vismodegib significantly inhibited cell proliferation and induced apoptosis and G1/S cell cycle arrest. In vivo investigation demonstrated that vismodegib effectively inhibited chordoma xenograft growth. This current preclinical evidence elucidates the therapeutic potential of Shh-Gli1 signaling pathway targeting for chordoma treatment. Vismodegib may be a promising targeted agent, and further clinical trials are warranted.	[Yang, Chenlong; Yong, Lei; Liang, Chen; Ma, Yunlong; Wei, Feng; Jiang, Liang; Zhou, Hua; He, Guanping; Pan, Xiaoyu; Hai, Bao; Liu, Zhongjun; Liu, Xiaoguang] Peking Univ, Hosp 3, Dept Orthoped, Beijing, Peoples R China; [Li, Yan] Peking Univ, Hlth Sci Ctr, Sch Basic Med Sci, Dept Pathol, Beijing, Peoples R China; [Wu, Jian] Capital Med Univ, Sch Clin Med, Beijing, Peoples R China; [Xu, Yulun] Capital Med Univ, Beijing Tiantan Hosp, China Natl Clin Res Ctr Neurol Dis, Dept Neurosurg, Beijing, Peoples R China	Peking University; Peking University; Capital Medical University; Capital Medical University	Liu, XG (corresponding author), Peking Univ, Hosp 3, Dept Orthoped, Beijing, Peoples R China.	liuxg.puth@hotmail.com	Zhou, Hua/HGC-9504-2022; Pan, Xiaoyu/ABE-1764-2021	Pan, Xiaoyu/0000-0002-5184-222X; Wu, Jian/0000-0003-3199-0492; Zhou, hua/0000-0002-2718-4108; Yang, Chenlong/0000-0001-8102-8811; Yang, Jun/0000-0002-7460-2800	National Natural Science Foundation of China [81641103, 81901202]; Postdoctoral Science Foundation of China [2018M630047]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Postdoctoral Science Foundation of China(China Postdoctoral Science Foundation)	This work was supported by the National Natural Science Foundation of China (81641103 to XL; 81901202 to CY) and the Postdoctoral Science Foundation of China (2018M630047 to CY).	Ahmed AT, 2018, SPINE, V43, pE1157, DOI 10.1097/BRS.0000000000002638; Akhavan-Sigari R, 2019, J CLIN MED, V8, DOI 10.3390/jcm8020248; Amini P, 2017, BMC MOL BIOL, V18, DOI 10.1186/s12867-017-0099-7; Armas-Lopez L, 2017, ONCOTARGET, V8, P60684, DOI 10.18632/oncotarget.19527; Bari R, 2015, SCI REP-UK, V5, DOI 10.1038/srep11098; Begnini A, 2010, BRIT J DERMATOL, V163, P364, DOI 10.1111/j.1365-2133.2010.09776.x; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Bigelow RLH, 2004, J BIOL CHEM, V279, P1197, DOI 10.1074/jbc.M310589200; Cates JMM, 2010, HISTOPATHOLOGY, V56, P978, DOI 10.1111/j.1365-2559.2010.03572.x; Charan J, 2013, J PHARMACOL PHARMACO, V4, P303, DOI 10.4103/0976-500X.119726; Chen H, 2017, CLIN CANCER RES, V23, P5176, DOI 10.1158/1078-0432.CCR-17-0177; Choi KS, 2008, DEV DYNAM, V237, P3953, DOI 10.1002/dvdy.21805; Cortes JE, 2019, CANCER TREAT REV, V76, P41, DOI 10.1016/j.ctrv.2019.04.005; Duman-Scheel M, 2002, NATURE, V417, P299, DOI 10.1038/417299a; FREIREICH EMIL J., 1966, CANCER CHEMOTHERAP REP, V50, P219; GOTZ W, 1995, CELL TISSUE RES, V280, P455; Hancock DB, 2010, NAT GENET, V42, P45, DOI 10.1038/ng.500; Incardona JP, 2000, CELL MOL LIFE SCI, V57, P1709, DOI 10.1007/PL00000653; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kitamura Y, 2017, BRAIN TUMOR PATHOL, V34, P78, DOI 10.1007/s10014-017-0283-y; Kubo M, 2004, CANCER RES, V64, P6071, DOI 10.1158/0008-5472.CAN-04-0416; Lee IJ, 2017, WORLD NEUROSURG, V104, P346, DOI 10.1016/j.wneu.2017.04.118; Magic M, 2019, CLIN ORAL INVEST, V23, P2675, DOI 10.1007/s00784-018-2686-5; Otani R, 2018, J NEUROSURG, V128, P1428, DOI 10.3171/2016.12.JNS161444; Raffel C, 1997, CANCER RES, V57, P842; Regl G, 2002, ONCOGENE, V21, P5529, DOI 10.1038/sj.onc.1205748; Reifenberger J, 2005, BRIT J DERMATOL, V152, P43, DOI 10.1111/J.1365-2133.2005.06353.X; Sari IN, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7110208; Scheil-Bertram S, 2014, INT J ONCOL, V44, P1041, DOI 10.3892/ijo.2014.2268; Sebaugh JL, 2011, PHARM STAT, V10, P128, DOI 10.1002/pst.426; Sekulic A, 2012, NEW ENGL J MED, V366, P2171, DOI 10.1056/NEJMoa1113713; SINICROPE FA, 1995, CANCER RES, V55, P237; Skoda AM, 2018, BOSNIAN J BASIC MED, V18, P8, DOI 10.17305/bjbms.2018.2756; Sun X, 2015, CURR REV MUSCULOSKE, V8, P344, DOI 10.1007/s12178-015-9311-x; Szkandera J, 2014, CLIN CANCER RES, V20, P1687, DOI 10.1158/1078-0432.CCR-13-1517; Taylor MD, 2002, NAT GENET, V31, P306, DOI 10.1038/ng916; Theunissen JW, 2009, CANCER RES, V69, P6007, DOI 10.1158/0008-5472.CAN-09-0756; Tian H, 2009, P NATL ACAD SCI USA, V106, P4254, DOI 10.1073/pnas.0813203106; Vinall RL, 2007, CLIN CANCER RES, V13, P6204, DOI 10.1158/1078-0432.CCR-07-0600; Wang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075407; Williams S, 2019, CURR TOP DEV BIOL, V133, P49, DOI 10.1016/bs.ctdb.2018.11.018; Wu FJ, 2017, CELL CHEM BIOL, V24, P252, DOI 10.1016/j.chembiol.2017.02.010; Yakldoui Y, 2014, BBA-REV CANCER, V1846, P655, DOI 10.1016/j.bbcan.2014.07.012; Zhu JJ, 2016, P NATL ACAD SCI USA, V113, P3820, DOI 10.1073/pnas.1601252113	44	6	6	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	24					4711	4727		10.1038/s41388-020-1324-2	http://dx.doi.org/10.1038/s41388-020-1324-2		MAY 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LY0HO	32404987				2022-12-28	WOS:000532807900002
J	Shmulevich, R; Nissim, TBK; Wolf, I; Merenbakh-Lamin, K; Fishman, D; Sekler, I; Rubinek, T				Shmulevich, Riva; Nissim, Tsipi Ben-Kasus; Wolf, Ido; Merenbakh-Lamin, Keren; Fishman, Daniel; Sekler, Israel; Rubinek, Tami			Klotho rewires cellular metabolism of breast cancer cells through alteration of calcium shuttling and mitochondrial activity	ONCOGENE			English	Article							OPERATED CA2+ ENTRY; TUMOR-SUPPRESSOR; PROTEIN-KINASE; TCA CYCLE; GROWTH; AMPK; ACTIVATION; PATHWAY; PROLIFERATION; LIVER	Klotho is a transmembrane protein, which can be shed and act as a circulating hormone and is involved in regulating cellular calcium levels and inhibition of the PI3K/AKT pathway. As a longevity hormone, it protects normal cells from oxidative stress, and as a tumor suppressor it inhibits growth of cancer cells. Mechanisms governing these differential activities have not been addressed. Altered cellular metabolism is a hallmark of cancer and dysregulation of mitochondrial activity is a hallmark of aging. We hypothesized that klotho exerts its differential effects through regulation of these two hallmarks. Treatment with klotho inhibited glycolysis, reduced mitochondrial activity and membrane potential only in cancer cells. Accordingly, global metabolic screen revealed that klotho altered pivotal metabolic pathways, amongst them glycolysis and tricarboxylic acid cycle in breast cancer cells. Alteration of metabolic activity and increased AMP/ATP ratio lead to LKB1-dependent AMPK activation. Indeed, klotho induced AMPK phosphorylation; furthermore, inhibition of LKB1 partially abolished klotho's tumor suppressor activity. By diminishing deltapsi (Delta psi) klotho also inhibited mitochondria Ca2+ shuttling thereby impairing mitochondria communication with SOCE leading to reduced Ca2+ influx by SOCE channels. The reduced SOCE was followed by ER Ca2+ depletion and stress. These data delineate mechanisms mediating the differential effects of klotho toward cancer versus normal cells, and indicate klotho as a potent regulator of metabolic activity.	[Shmulevich, Riva; Wolf, Ido; Merenbakh-Lamin, Keren; Rubinek, Tami] Tel Aviv Sourasky Med Ctr, Inst Oncol, Tel Aviv, Israel; [Shmulevich, Riva; Wolf, Ido; Rubinek, Tami] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel; [Nissim, Tsipi Ben-Kasus; Fishman, Daniel; Sekler, Israel] Ben Gurion Univ Negev, Fac Hlth Sci, Dept Physiol & Cell Biol, Beer Sheva, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Ben Gurion University	Rubinek, T (corresponding author), Tel Aviv Sourasky Med Ctr, Inst Oncol, Tel Aviv, Israel.; Rubinek, T (corresponding author), Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.; Sekler, I (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Dept Physiol & Cell Biol, Beer Sheva, Israel.	sekler@bgu.ac.il; rubinekt@gmail.com						Abramovitz L, 2011, CLIN CANCER RES, V17, P4254, DOI 10.1158/1078-0432.CCR-10-2749; Brown KA, 2013, MOL CELL ENDOCRINOL, V366, P170, DOI 10.1016/j.mce.2012.06.016; Cantor JR, 2012, CANCER DISCOV, V2, P881, DOI 10.1158/2159-8290.CD-12-0345; Cha SK, 2008, P NATL ACAD SCI USA, V105, P9805, DOI 10.1073/pnas.0803223105; Chang Q, 2005, SCIENCE, V310, P490, DOI 10.1126/science.1114245; Chen B, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-99; Chen CD, 2007, P NATL ACAD SCI USA, V104, P19796, DOI 10.1073/pnas.0709805104; Corbet C, 2017, BBA-REV CANCER, V1868, P7, DOI 10.1016/j.bbcan.2017.01.002; Cui CC, 2017, ACTA PHARM SIN B, V7, P3, DOI 10.1016/j.apsb.2016.11.001; Delcroix V, 2018, CANCERS, V10, DOI 10.3390/cancers10110439; Demaurex N, 2009, BBA-BIOENERGETICS, V1787, P1383, DOI 10.1016/j.bbabio.2008.12.012; Doi S, 2011, J BIOL CHEM, V286, P8655, DOI 10.1074/jbc.M110.174037; Fedida-Metula S, 2012, CARCINOGENESIS, V33, P740, DOI 10.1093/carcin/bgs021; Fox Melissa M, 2013, Genes Cancer, V4, P3, DOI 10.1177/1947601913486346; Hadad SM, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-307; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hardie DG, 2014, PHYSIOLOGY, V29, P99, DOI 10.1152/physiol.00050.2013; Hardie DG, 2002, BIOCHEM SOC T, V30, P1064, DOI 10.1042/BST0301064; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Kato Y, 2000, BIOCHEM BIOPH RES CO, V267, P597, DOI 10.1006/bbrc.1999.2009; Kim Hak-Su, 2014, Genes Cancer, V5, P175; Krishnan S, 2019, FASEB J, V33; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Kurosu H, 2006, J BIOL CHEM, V281, P6120, DOI 10.1074/jbc.C500457200; Kurosu H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766; Lee J, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-109; Lee Minjong, 2015, World J Biol Chem, V6, P148, DOI 10.4331/wjbc.v6.i3.148; Lewis RS, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a003970; Ligumsky H, 2015, MOL CANCER RES, V13, P1398, DOI 10.1158/1541-7786.MCR-15-0141; Lim K, 2015, J CLIN ENDOCR METAB, V100, P1308, DOI DOI 10.1210/jc.2015-1800; Liu HJ, 2007, SCIENCE, V317, P803, DOI 10.1126/science.1143578; Lojkin I, 2015, CANCER LETT, V362, P149, DOI 10.1016/j.canlet.2015.03.035; Lopez-Otin C, 2016, CELL, V166, P802, DOI 10.1016/j.cell.2016.07.031; Luengo A, 2017, CELL CHEM BIOL, V24, P1161, DOI 10.1016/j.chembiol.2017.08.028; Luo ZJ, 2010, FUTURE ONCOL, V6, P457, DOI 10.2217/FON.09.174; Manjarres IM, 2011, CELL CALCIUM, V49, P153, DOI 10.1016/j.ceca.2011.01.007; Martinez-Reyes I, 2016, MOL CELL, V61, P199, DOI 10.1016/j.molcel.2015.12.002; Mignen O, 2005, J CELL SCI, V118, P5615, DOI 10.1242/jcs.02663; Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329; Nabeshima Y, 2002, AGEING RES REV, V1, P627, DOI 10.1016/S1568-1637(02)00027-2; Palty R, 2012, J BIOL CHEM, V287, P31650, DOI 10.1074/jbc.R112.355867; Palty R, 2010, P NATL ACAD SCI USA, V107, P436, DOI 10.1073/pnas.0908099107; Pesakhov S, 2016, ONCOTARGET, V7, P31847, DOI 10.18632/oncotarget.7240; Putney JW, 2017, BBA-MOL CELL RES, V1864, P900, DOI 10.1016/j.bbamcr.2016.11.028; Raffaello A, 2016, TRENDS BIOCHEM SCI, V41, P1035, DOI 10.1016/j.tibs.2016.09.001; Rios M, 2013, CANCER RES, V73, P2628, DOI 10.1158/0008-5472.CAN-12-0861; Rubinek T, 2016, VITAM HORM, V101, P197, DOI 10.1016/bs.vh.2016.03.001; Rubinek T, 2012, BREAST CANCER RES TR, V133, P649, DOI 10.1007/s10549-011-1824-4; Rubinstein TA, 2019, ONCOGENE, V38, P794, DOI 10.1038/s41388-018-0489-4; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Spat A, 2017, ADV EXP MED BIOL, V993, P257, DOI 10.1007/978-3-319-57732-6_14; To MS, 2010, ARCH BIOCHEM BIOPHYS, V495, P152, DOI 10.1016/j.abb.2010.01.004; Urakawa I, 2006, NATURE, V444, P770, DOI 10.1038/nature05315; Vashisht A, 2015, AM J PHYSIOL-CELL PH, V309, pC457, DOI 10.1152/ajpcell.00064.2015; Viollet B, 2006, J PHYSIOL-LONDON, V574, P41, DOI 10.1113/jphysiol.2006.108506; Wolf I, 2008, ONCOGENE, V27, P7094, DOI 10.1038/onc.2008.292; Xie B, 2013, PATHOL ONCOL RES, V19, P611, DOI 10.1007/s12253-013-9663-8; Xie B, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-18; Zinger L, 2019, CLIN CANCER RES, V25, P2900, DOI 10.1158/1078-0432.CCR-18-1505; Zong WX, 2016, MOL CELL, V61, P667, DOI 10.1016/j.molcel.2016.02.011	61	7	7	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	24					4636	4649		10.1038/s41388-020-1313-5	http://dx.doi.org/10.1038/s41388-020-1313-5		MAY 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LY0HO	32398866				2022-12-28	WOS:000532103100001
J	Tabatabaeian, H; Rao, A; Ramos, A; Chu, T; Sudol, M; Lim, YP				Tabatabaeian, Hossein; Rao, Angad; Ramos, Alisha; Chu, Tinghine; Sudol, Marius; Lim, Yoon Pin			The emerging roles of WBP2 oncogene in human cancers	ONCOGENE			English	Review							DOMAIN BINDING PROTEIN-2; WW-DOMAIN; BREAST-CANCER; SIGNALING PATHWAY; HIPPO PATHWAY; TUMOR-SUPPRESSOR; ESTROGEN; COACTIVATOR; TARGET; MECHANISMS	WW domain-binding protein 2 (WBP2) is an emerging oncoprotein. Over the past decade, WBP2 surfaced as a key node connecting key signaling pathways associated with ER/PR, EGFR, PI3K, Hippo, and Wnt in cancer. In addition to the oncogenic functions of WBP2, this review discusses the latest research regarding the multilevel regulation and modes of action of WBP2 and how they can be exploited for molecular medicine. In translational research, evidence supports the role of WBP2 as a biomarker for early detection, prognosis, and companion diagnostics in breast cancer. Finally, we envision new trends in WBP2 research in the space of molecular etiology of cancer, targeted therapeutics, and precision medicine.	[Tabatabaeian, Hossein] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117599, Singapore; [Tabatabaeian, Hossein; Rao, Angad; Ramos, Alisha; Chu, Tinghine; Lim, Yoon Pin] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore 117545, Singapore; [Chu, Tinghine; Lim, Yoon Pin] Natl Univ Singapore, NUS Grad Sch Integrat Sci & Engn, Singapore 117456, Singapore; [Sudol, Marius] Natl Univ Singapore, Mechanobiol Inst, Dept Physiol, Singapore 117597, Singapore; [Sudol, Marius] ASTAR, IMCB, Singapore 138673, Singapore; [Sudol, Marius] Icahn Sch Med Mt Sinai, New York, NY 10029 USA; [Lim, Yoon Pin] Natl Univ Canc Inst, Singapore 119082, Singapore	National University of Singapore; National University of Singapore; National University of Singapore; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Icahn School of Medicine at Mount Sinai; National University of Singapore	Lim, YP (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore 117545, Singapore.; Lim, YP (corresponding author), Natl Univ Singapore, NUS Grad Sch Integrat Sci & Engn, Singapore 117456, Singapore.; Lim, YP (corresponding author), Natl Univ Canc Inst, Singapore 119082, Singapore.	bchlyp@nus.edu.sg	Tabatabaeian, Hossein/I-2235-2019	Tabatabaeian, Hossein/0000-0001-9757-6150	Ministry of Education, Singapore [MOE2016-T2-2-007]; National Medical Research Council, Ministry of Health, Singapore [NMRC/OFIRG/0034/2017]; National University of Singapore [R-185-000-2710-133-733]; Mechanobiology Institute [R-714-018-006-271]; Institute of Molecular and Cell Biology [M-R02010]	Ministry of Education, Singapore(Ministry of Education, Singapore); National Medical Research Council, Ministry of Health, Singapore(National Medical Research Council, Singapore); National University of Singapore(National University of Singapore); Mechanobiology Institute; Institute of Molecular and Cell Biology	This work is supported by funding from the Ministry of Education, Singapore (MOE2016-T2-2-007), the National Medical Research Council, Ministry of Health, Singapore (NMRC/OFIRG/0034/2017), the National University of Singapore (R-185-000-2710-133-733), Mechanobiology Institute (R-714-018-006-271), and the Institute of Molecular and Cell Biology (M-R02010). The figures were created using BioRender.	Aoudjit Fawzi, 2012, Chemother Res Pract, V2012, P283181, DOI 10.1155/2012/283181; ATKINSON MA, 1994, NEW ENGL J MED, V331, P1428; Bidwell GL, 2009, EXPERT OPIN DRUG DEL, V6, P1033, DOI 10.1517/17425240903143745; Bradley CA, 2019, NAT REV CLIN ONCOL, V16, P465, DOI 10.1038/s41571-019-0215-3; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brown SDM, 2012, MAMM GENOME, V23, P632, DOI 10.1007/s00335-012-9427-x; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Buffa L, 2013, IUBMB LIFE, V65, P76, DOI 10.1002/iub.1105; Buniello A, 2016, EMBO MOL MED, V8, P191, DOI 10.15252/emmm.201505523; Chan SW, 2011, ONCOGENE, V30, P600, DOI 10.1038/onc.2010.438; Chen DG, 2000, J BIOL CHEM, V275, P40810, DOI 10.1074/jbc.M005459200; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; CHEN S, 2018, CELL DEATH DIS, V9, P1, DOI DOI 10.1038/s41419-017-0012-9; Chen S, 2018, BRIT J CANCER, V119, P182, DOI 10.1038/s41416-018-0119-5; Chen S, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0376-5; Chen S, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0693-9; Chen YH, 2007, MOL CELL PROTEOMICS, V6, P2072, DOI 10.1074/mcp.M700395-MCP200; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dai YX, 2020, EUR J MED CHEM, V187, DOI 10.1016/j.ejmech.2019.111967; Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987; Dey N, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-537; Dhananjayan SC, 2006, MOL ENDOCRINOL, V20, P2343, DOI 10.1210/me.2005-0533; Dolcet X, 2005, VIRCHOWS ARCH, V446, P475, DOI 10.1007/s00428-005-1264-9; Doroshow JH, 2014, NAT REV CLIN ONCOL, V11, P649, DOI 10.1038/nrclinonc.2014.158; Druker BJ, 2002, TRENDS MOL MED, V8, pS14, DOI 10.1016/S1471-4914(02)02305-5; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Fisher SL, 2018, CURR OPIN CHEM BIOL, V44, P47, DOI 10.1016/j.cbpa.2018.05.004; Gao J, 2020, CELL SIGNAL, V66, DOI 10.1016/j.cellsig.2019.109466; Glisovic T, 2008, FEBS LETT, V582, P1977, DOI 10.1016/j.febslet.2008.03.004; Hamilton LE, 2018, BIOL REPROD, V99, P1171, DOI 10.1093/biolre/ioy156; Harvey K, 2007, NAT REV CANCER, V7, P182, DOI 10.1038/nrc2070; Howlader N, 2018, CANCER EPIDEM BIOMAR, V27, P619, DOI 10.1158/1055-9965.EPI-17-0627; Huang XD, 2016, CELL RES, V26, P484, DOI 10.1038/cr.2016.31; Isfort I, 2019, HIPPO PATHWAY TRANSC; Iyer VV, 2016, CURR MED CHEM, V23, P3025, DOI 10.2174/0929867323666160627103134; Jackson Richard J, 2007, Sci STKE, V2007, pre1, DOI 10.1126/stke.3672007re1; Jiang ZF, 2019, LANCET ONCOL, V20, P806, DOI 10.1016/S1470-2045(19)30164-0; Jolliffe CN, 2000, BIOCHEM J, V351, P557, DOI 10.1042/0264-6021:3510557; Kang SA, 2019, CLIN CANCER RES, V25, P2588, DOI 10.1158/1078-0432.CCR-18-3228; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Khosrow-Khavar F, 2017, ANN ONCOL, V28, P487, DOI 10.1093/annonc/mdw673; Kim Y, 2018, BMB REP, V51, P143, DOI 10.5483/BMBRep.2018.51.3.017; Li SS, 2007, CELL SIGNAL, V19, P1101, DOI 10.1016/j.cellsig.2007.02.002; Li XB, 2016, AM J CLIN PATHOL, V145, P871, DOI 10.1093/ajcp/aqw045; Li ZL, 2018, J BIOL CHEM, V293, P20014, DOI 10.1074/jbc.RA118.005796; Lim SK, 2016, CANCER RES, V76, P6278, DOI 10.1158/0008-5472.CAN-15-3537; Lim SK, 2011, FASEB J, V25, P3004, DOI 10.1096/fj.10-169136; Mann MJ, 2000, J CLIN INVEST, V106, P1071, DOI 10.1172/JCI11459; Marqus S, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0328-x; Martini M, 2014, ANN MED, V46, P372, DOI 10.3109/07853890.2014.912836; Mazzoni SM, 2014, CANCER LETT, V355, P1, DOI 10.1016/j.canlet.2014.09.018; McDonald CB, 2012, J MOL BIOL, V422, P58, DOI 10.1016/j.jmb.2012.05.015; Meng ZP, 2016, GENE DEV, V30, P1, DOI 10.1101/gad.274027.115; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Mori M, 2014, CELL, V156, P893, DOI 10.1016/j.cell.2013.12.043; Munoz-Fuentes V, 2018, CONSERV GENET, V19, P995, DOI 10.1007/s10592-018-1072-9; Nitsch R, 2004, BIOCHEM J, V377, P553, DOI 10.1042/BJ20031233; Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353; Parbin S, 2014, J HISTOCHEM CYTOCHEM, V62, P11, DOI 10.1369/0022155413506582; Patel HK, 2018, PHARMACOL THERAPEUT, V186, P1, DOI 10.1016/j.pharmthera.2017.12.012; Pereira B, 2016, NAT COMMUN, V7, P1; Pisamai S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200619; Poulard C, 2017, EMBO REP, V18, P1442, DOI 10.15252/embr.201744060; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; Ramos A, 2018, FASEB J, V32, P6982, DOI 10.1096/fj.201801167RR; Ren YQ, 2017, CANCER CHEMOTH PHARM, V79, P1003, DOI 10.1007/s00280-017-3302-0; Richer JK, 2002, J BIOL CHEM, V277, P5209, DOI 10.1074/jbc.M110090200; Rimawi MF, 2015, ANNU REV MED, V66, P111, DOI 10.1146/annurev-med-042513-015127; Roche J, 2016, EUR J MED CHEM, V121, P451, DOI 10.1016/j.ejmech.2016.05.047; Rubio-Somoza I, 2011, CELL, V147, P1431, DOI 10.1016/j.cell.2011.12.003; Sakamoto KM, 2001, P NATL ACAD SCI USA, V98, P8554, DOI 10.1073/pnas.141230798; Saucedo LJ, 2007, NAT REV MOL CELL BIO, V8, P613, DOI 10.1038/nrm2221; Schneikert J, 2007, GUT, V56, P417, DOI 10.1136/gut.2006.093310; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Song HM, 2018, CELL PHYSIOL BIOCHEM, V48, P1968, DOI 10.1159/000492520; Song XZ, 2016, P NATL ACAD SCI USA, V113, P4970, DOI 10.1073/pnas.1604274113; Spoel SH, 2010, NEW PHYTOL, V186, P333, DOI 10.1111/j.1469-8137.2009.03125.x; Stamos JL, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a007898; Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403; Tokunaga Eriko, 2006, Breast Cancer, V13, P137, DOI 10.2325/jbcs.13.137; Tomczak Katarzyna, 2015, Contemp Oncol (Pozn), V19, pA68, DOI 10.5114/wo.2014.47136; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Vandghanooni S, 2018, J MOL MED, V96, P885, DOI 10.1007/s00109-018-1669-y; Vogel C, 1998, BREAST CANC RES TREA, V;50, P232; Volmar C.H., 2015, NEUROEPIGENETICS, V1, P20, DOI [10.1016/j.nepig.2014.10.002, DOI 10.1016/J.NEPIG.2014.10.002]; Vorobyeva NE, 2009, P NATL ACAD SCI USA, V106, P11049, DOI 10.1073/pnas.0901801106; Walko G, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14744; Wei YY, 2013, P NATL ACAD SCI USA, V110, P6829, DOI 10.1073/pnas.1217002110; Welboren WJ, 2007, MOL ONCOL, V1, P138, DOI 10.1016/j.molonc.2007.04.001; Willert K, 2006, GENE DEV, V20, P1394, DOI 10.1101/gad.1424006; Yang J, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0954-x; Zeng Q, 2008, CANCER CELL, V13, P188, DOI 10.1016/j.ccr.2008.02.011; Zhang SH, 2019, CURR OPIN CELL BIOL, V61, P64, DOI 10.1016/j.ceb.2019.07.006; Zhang X, 2011, CELL DEATH DIFFER, V18, P1346, DOI 10.1038/cdd.2011.6	96	9	9	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	24					4621	4635		10.1038/s41388-020-1318-0	http://dx.doi.org/10.1038/s41388-020-1318-0		MAY 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LY0HO	32393834	hybrid, Green Published			2022-12-28	WOS:000531752500001
J	Yoneda, A; Minomi, K; Tamura, Y				Yoneda, Akihiro; Minomi, Kenjiro; Tamura, Yasuaki			HSP47 promotes metastasis of breast cancer by interacting with myosin IIA via the unfolded protein response transducer IRE1 alpha	ONCOGENE			English	Article							MATRIX METALLOPROTEINASES; CHAPERONE HSP47; ENDOPLASMIC-RETICULUM; IV COLLAGEN; EXPRESSION; INHIBITORS; INDUCTION; PROGNOSIS; PODOSOMES; APOPTOSIS	Breast cancer (BC) is an aggressive cancer that is a leading cause of cancer-associated death in women worldwide. Although increased expression of heat shock protein 47 (HSP47), a collagen-specific chaperone, is associated with the high malignancy of BC, its role in BC remains largely unclear. Here we show that a small population of high-invasive BC cells expresses HSP47 and that HSP47-positive high-invasive BC cells have a high metastatic potential that is completely abolished by disruption of HSP47. HSP47 interacts with non-muscle myosin IIA (NMIIA) via the unfolded protein response transducer IRE1 alpha, resulting in enhancement of the metastatic potential of high-invasive BC cells by augmenting the contractile force of actin filaments. Ablation of NMIIA abrogates the metastatic potential of HSP47-positive high-invasive BC cells. We further show that forced expression of NMIIA confers a high metastatic potential on low-invasive BC cells in which HSP47 but not NMIIA is expressed. Overall, our study indicates that HSP47 acts as a stimulator for metastasis of BC cells and suggest that HSP47 may be a candidate for a therapeutic target against BC.	[Yoneda, Akihiro; Minomi, Kenjiro; Tamura, Yasuaki] Hokkaido Univ, Ctr Food & Med Innovat, Inst Promot Business Reg Collaborat, Dept Mol Therapeut, Sapporo, Hokkaido 0010021, Japan; [Minomi, Kenjiro] Nitto Denko Corp, Nucle Acid Med Business Div, Res & Dev Dept, Sapporo, Hokkaido 0010021, Japan	Hokkaido University; Nitto Denko Corporation	Yoneda, A (corresponding author), Hokkaido Univ, Ctr Food & Med Innovat, Inst Promot Business Reg Collaborat, Dept Mol Therapeut, Sapporo, Hokkaido 0010021, Japan.	ayoneda@fmi.hokuida.ac.jp						Albiges-Rizo C, 2009, J CELL SCI, V122, P3037, DOI 10.1242/jcs.052704; Bachmeier BE, 2001, ANTICANCER RES, V21, P3821; Carey L, 2010, NAT REV CLIN ONCOL, V7, P683, DOI 10.1038/nrclinonc.2010.154; Chen X, 2014, NATURE, V508, P103, DOI 10.1038/nature13119; Conti MA, 2008, J CELL SCI, V121, P11, DOI 10.1242/jcs.007112; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Derycke L, 2011, INT J DEV BIOL, V55, P835, DOI 10.1387/ijdb.113336ld; Duarte BD, 2018, J CANCER RES CLIN, V144, P2319, DOI 10.1007/s00432-018-2739-9; Even-Ram S, 2007, NAT CELL BIOL, V9, P299, DOI 10.1038/ncb1540; Gimona M, 2008, CURR OPIN CELL BIOL, V20, P235, DOI 10.1016/j.ceb.2008.01.005; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; He Y, 2012, DEV CELL, V23, P1141, DOI 10.1016/j.devcel.2012.11.006; Honzawa Y, 2014, GUT, V63, P1902, DOI 10.1136/gutjnl-2013-305632; Ishida Y, 2006, MOL BIOL CELL, V17, P2346, DOI 10.1091/mbc.E05-11-1065; Ishiwata-Kimata Y, 2013, CELL STRUCT FUNCT, V38, P135, DOI 10.1247/csf.12033; Ito S, 2019, J BIOL CHEM, V294, P2133, DOI 10.1074/jbc.TM118.002812; Ito S, 2017, SEMIN CELL DEV BIOL, V62, P142, DOI 10.1016/j.semcdb.2016.11.005; Kawasaki K, 2015, J BIOL CHEM, V290, P3639, DOI 10.1074/jbc.M114.592139; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kohrmann A, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-188; Kumar A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10740-0; Kumar A, 2015, PEERJ, V3, DOI 10.7717/peerj.1026; Li XX, 2017, ONCOGENE, V36, P6738, DOI 10.1038/onc.2017.284; Liu RG, 2017, INT J CLIN EXP PATHO, V10, P5498; Logue SE, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05763-8; Marusyk A, 2012, NAT REV CANCER, V12, P323, DOI 10.1038/nrc3261; Marutani T, 2004, J CELL SCI, V117, P5913, DOI 10.1242/jcs.01514; Matsuoka Y, 2004, MOL BIOL CELL, V15, P4467, DOI 10.1091/mbc.E04-01-0050; Mori K, 2017, INT J CANCER, V140, P1425, DOI 10.1002/ijc.30557; Newell-Litwa KA, 2015, DIS MODEL MECH, V8, P1495, DOI 10.1242/dmm.022103; Parveen A, 2019, GENOMICS, VS0888-7543, P30671; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Poschmann G, 2009, MOL CELL PROTEOMICS, V8, P1105, DOI 10.1074/mcp.M800422-MCP200; Ren FH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135544; Santagata S, 2012, ACS CHEM BIOL, V7, P339, DOI 10.1021/cb200353m; Sasaki H, 2002, J IMMUNOL, V168, P5178, DOI 10.4049/jimmunol.168.10.5178; Sepulveda D, 2018, MOL CELL, V69, P238, DOI 10.1016/j.molcel.2017.12.028; Tojkander S, 2012, J CELL SCI, V125, P1855, DOI 10.1242/jcs.098087; Vizoso FJ, 2007, BRIT J CANCER, V96, P903, DOI 10.1038/sj.bjc.6603666; Volinia S, 2012, P NATL ACAD SCI USA, V109, P3024, DOI 10.1073/pnas.1200010109; Winer A, 2018, MOL CANCER THER, V17, P1147, DOI 10.1158/1535-7163.MCT-17-0646; Xiong GF, 2020, P NATL ACAD SCI USA, V117, P3748, DOI 10.1073/pnas.1911951117; Yeo SK, 2017, TRENDS CANCER, V3, P753, DOI 10.1016/j.trecan.2017.09.001; Zhang X, 2010, INT J ONCOL, V36, P405, DOI 10.3892/ijo_00000513; Zhao D, 2014, J NEURO-ONCOL, V118, P39, DOI 10.1007/s11060-014-1412-7; Zhou PT, 2019, ONCOGENE, V38, P5500, DOI 10.1038/s41388-019-0806-6; Zhu JQ, 2015, CANCER RES, V75, P1580, DOI 10.1158/0008-5472.CAN-14-1027	47	7	7	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	23					4519	4537		10.1038/s41388-020-1311-7	http://dx.doi.org/10.1038/s41388-020-1311-7		MAY 2020	19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LU5ZF	32366908				2022-12-28	WOS:000530271400002
J	Uka, R; Britschgi, C; Krattli, A; Matter, C; Mihic, D; Okoniewski, MJ; Gualandi, M; Stupp, R; Cinelli, P; Dummer, R; Levesque, MP; Shakhova, O				Uka, Rexhep; Britschgi, Christian; Krattli, Anja; Matter, Claudia; Mihic, Daniela; Okoniewski, Michal J.; Gualandi, Marco; Stupp, Roger; Cinelli, Paolo; Dummer, Reinhard; Levesque, Mitchell P.; Shakhova, Olga			Temporal activation of WNT/beta-catenin signaling is sufficient to inhibit SOX10 expression and block melanoma growth	ONCOGENE			English	Article							BETA-CATENIN; TRANSCRIPTION FACTOR; CUTANEOUS MELANOMA; MITF; CELL; PROGRESSION; IPILIMUMAB; IDENTIFICATION; MONOTHERAPY; VEMURAFENIB	Despite advances in the systemic treatment of patients with metastatic melanoma using immune checkpoint and tyrosine kinase inhibitors (TKI), the majority of stage IV melanoma patients eventually succumb to the disease. We have previously identified the transcription factor Sox10 as a crucial player in melanoma, yet the underlying molecular mechanisms mediating Sox10-dependent tumorigenesis remain largely uncharacterized. Here, we show that MEK and RAF inhibitors do not suppress levels of SOX10 protein in patient-derived cells in vitro, as well as in melanoma patients in vivo. In a search for pharmacological inhibitors of SOX10, we performed a mass spectrometry-based screen in human melanoma cells. Subsequent analysis revealed that SOX10 directly interacts with beta-catenin, which is a key mediator of canonical Wnt/beta-catenin signaling. We demonstrate that inhibitors of glycogen synthase kinase 3 alpha/beta (GSK3 alpha/beta) efficiently abrogate SOX10 protein in human melanoma cells in vitro and in melanoma mouse models in vivo. The mechanism of action of GSK3-mediated SOX10 suppression is transcription-independent and relies on the presence of a proteasome degradable form of beta-catenin. Taken together, we provide evidence that activation of canonical Wnt signaling has a profound effect on melanoma growth and is able to counteract Sox10-dependent melanoma maintenance both in vitro and in vivo.	[Uka, Rexhep; Britschgi, Christian; Krattli, Anja; Matter, Claudia; Gualandi, Marco; Stupp, Roger; Shakhova, Olga] Univ Zurich, Univ Hosp Zurich, Dept Med Oncol & Hematol, Wagistr 14, CH-8952 Schlieren, Switzerland; [Mihic, Daniela] Univ Zurich, Univ Hosp Zurich, Dept Surg Pathol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland; [Okoniewski, Michal J.] Swiss Fed Inst Technol, Sci IT Serv ETH Zurich, Weinbergstr 11, CH-8092 Zurich, Switzerland; [Cinelli, Paolo] Univ Zurich, Univ Zurich Hosp, Dept Trauma Surg, Sternwartstr 1, CH-8091 Zurich, Switzerland; [Dummer, Reinhard; Levesque, Mitchell P.] Univ Zurich, Univ Zurich Hosp, Dept Dermatol, Wagistrasse 14, CH-8952 Schlieren, Switzerland; [Stupp, Roger] Northwestern Univ, Feinberg Sch Med, Ken & Ruth Davee Dept Neurol, Chicago, IL 60611 USA; [Stupp, Roger] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Lou & Jean Malnati Brain Tumor Inst, Chicago, IL 60611 USA	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center	Shakhova, O (corresponding author), Univ Zurich, Univ Hosp Zurich, Dept Med Oncol & Hematol, Wagistr 14, CH-8952 Schlieren, Switzerland.	olga.shakhova@usz.ch		Britschgi, Christian/0000-0001-8831-1564	Oncosuisse; Promedica UBS Stiftung; Krebsliga Zurich; Novartis Research Foundation	Oncosuisse; Promedica UBS Stiftung; Krebsliga Zurich; Novartis Research Foundation	This work was supported by Oncosuisse, Promedica UBS Stiftung, Krebsliga Zurich, and Novartis Research Foundation to OS. We thank A. Serra-Roma, C-L Yang, O. Engeler for helpful suggestions and scientific discussions. We thank Dr Lorenza Penengo (Institute of Molecular Cancer Research University of Zurich) for technical support and suggestions. We thank Dr Jelena Kuhn-Georgijevic from Functional Genomic Center Zurich for her support in RNA sequencing. We thank Dr Daniel Zingg from Institute of Anatomy University of Zurich for kindly providing with Mel888 and Mel501 human melanoma cell lines. We thank Axel Zani and Redi Leraj for helping drawing the cartoons. We thank Cindy Lee for helpful discussion and critically reading of the manuscript. Finally, we would like to thank the University Research Priority Program (URPP) in translational cancer research biobank for the melanoma cell lines that were generated from surplus biopsy material from consenting patients at the University of Zurich Hospital (EK.647/800).	Ackermann J, 2005, CANCER RES, V65, P4005, DOI 10.1158/0008-5472.CAN-04-2970; Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Anastas JN, 2014, J CLIN INVEST, V124, P2877, DOI 10.1172/JCI70156; Atkinson JM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125028; Bachmann IM, 2005, CLIN CANCER RES, V11, P8606, DOI 10.1158/1078-0432.CCR-05-0011; Bastidas F, 2004, DEV DYNAM, V229, P109, DOI 10.1002/dvdy.10486; Biechele TL, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002274; Biechele TL, 2010, CHEM BIOL, V17, P1177, DOI 10.1016/j.chembiol.2010.08.012; Bondurand N, 2000, HUM MOL GENET, V9, P1907, DOI 10.1093/hmg/9.13.1907; Chien AJ, 2009, P NATL ACAD SCI USA, V106, P1193, DOI 10.1073/pnas.0811902106; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Damsky WE, 2011, CANCER CELL, V20, P741, DOI 10.1016/j.ccr.2011.10.030; Demunter A, 2002, MODERN PATHOL, V15, P454, DOI 10.1038/modpathol.3880546; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dorsky RI, 1998, NATURE, V396, P370, DOI 10.1038/24620; Dorsky RI, 2000, GENE DEV, V14, P158; Dummer R, 2015, ANN ONCOL, V26, pV126, DOI 10.1093/annonc/mdv297; Forbes SA, 2010, NUCLEIC ACIDS RES, V38, pD652, DOI 10.1093/nar/gkp995; Garcia-Castro MI, 2002, SCIENCE, V297, P848, DOI 10.1126/science.1070824; Grob JJ, 2015, LANCET ONCOL, V16, P1389, DOI 10.1016/S1470-2045(15)00087-X; Grossmann AH, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003398; Kageshita T, 2001, BRIT J DERMATOL, V145, P210, DOI 10.1046/j.1365-2133.2001.04336.x; Kaur A, 2016, BRIT J CANCER, V115, P1273, DOI 10.1038/bjc.2016.332; Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868; Le S, 2008, J STAT SOFTW, V25, P1, DOI 10.18637/jss.v025.i01; Lee M, 2000, J BIOL CHEM, V275, P37978, DOI 10.1074/jbc.M003816200; Leung AW, 2016, DEVELOPMENT, V143, P398, DOI 10.1242/dev.130849; Liao Y, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt214; Long GV, 2018, J CLIN ONCOL, V36, P667, DOI 10.1200/JCO.2017.74.1025; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Maelandsmo GM, 2003, CLIN CANCER RES, V9, P3383; Nonaka D, 2008, AM J SURG PATHOL, V32, P1291, DOI 10.1097/PAS.0b013e3181658c14; Omholt K, 2001, INT J CANCER, V92, P839, DOI 10.1002/ijc.1270; Potterf SB, 2000, HUM GENET, V107, P1, DOI 10.1007/s004390050001; Rehberg S, 2002, MOL CELL BIOL, V22, P5826, DOI 10.1128/MCB.22.16.5826-5834.2002; Reifenberger J, 2002, INT J CANCER, V100, P549, DOI 10.1002/ijc.10512; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Robertson AG, 2017, CANCER CELL, V32, P204, DOI 10.1016/j.ccell.2017.07.003; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Schepsky A, 2006, MOL CELL BIOL, V26, P8914, DOI 10.1128/MCB.02299-05; Shakhova O, 2012, NAT CELL BIOL, V14, P882, DOI 10.1038/ncb2535; Tacha D, 2015, ARCH PATHOL LAB MED, V139, P530, DOI 10.5858/arpa.2014-0077-OA; Vasilescu J, 2004, PROTEOMICS, V4, P3845, DOI 10.1002/pmic.200400856; Webster MR, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004114; Wellbrock C, 2015, PIGM CELL MELANOMA R, V28, P390, DOI 10.1111/pcmr.12370; Widlund HR, 2002, J CELL BIOL, V158, P1079, DOI 10.1083/jcb.200202049; Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304; Zhou DJ, 2014, TUMOR BIOL, V35, P9935, DOI 10.1007/s13277-014-1893-1; Zimmerman ZF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069593	52	12	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	20					4132	4154		10.1038/s41388-020-1267-7	http://dx.doi.org/10.1038/s41388-020-1267-7		APR 2020	23	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LN3GC	32238882	Green Published, hybrid, Green Accepted			2022-12-28	WOS:000522804800002
J	Francart, ME; Vanwynsberghe, AM; Lambert, J; Bourcy, M; Genna, A; Ancel, J; Perez-Boza, J; Noel, A; Birembaut, P; Struman, I; Polette, M; Gilles, C				Francart, Marie-Emilie; Vanwynsberghe, Aline M.; Lambert, Justine; Bourcy, Morgane; Genna, Anthony; Ancel, Julien; Perez-Boza, Jennifer; Noel, Agnes; Birembaut, Philippe; Struman, Ingrid; Polette, Myriam; Gilles, Christine			Vimentin prevents a miR-dependent negative regulation of tissue factor mRNA during epithelial-mesenchymal transitions and facilitates early metastasis	ONCOGENE			English	Article							CIRCULATING TUMOR-CELLS; FACTOR EXPRESSION; CANCER-CELLS; COAGULATION; PATHWAY; BINDING; IDENTIFICATION; CONTRIBUTES; ACTIVATION; MECHANISMS	Epithelial-mesenchymal transitions (EMTs) are high-profile in the field of circulating tumor cells (CTCs). EMT-shifted CTCs are considered to encompass pre-metastatic subpopulations though underlying molecular mechanisms remain elusive. Our previous work identified tissue factor (TF) as an EMT-induced gene providing tumor cells with coagulant properties and supporting metastatic colonization by CTCs. We here report that vimentin, the type III intermediate filament considered a canonical EMT marker, contributes to TF regulation and positively supports coagulant properties and early metastasis. Different evidence further pointed to a new post-transcriptional regulatory mechanism of TF mRNA by vimentin: (1) vimentin silencing accelerated TF mRNA decay after actinomycin D treatment, reflecting TF mRNA stabilization, (2) RNA immunoprecipitation revealed enriched levels of TF mRNA in vimentin immunoprecipitate, (3) TF 3 '-UTR-luciferase reporter vector assays implicated the 3 '-UTR of TF mRNA in vimentin-dependent TF regulation, and (4) using different TF 3 ' UTR-luciferase reporter vectors mutated for potential miR binding sites and specific Target Site Blockers identified a key miR binding site in vimentin-dependent TF mRNA regulation. All together, these data support a novel mechanism by which vimentin interferes with a miR-dependent negative regulation of TF mRNA, thereby promoting coagulant activity and early metastasis of vimentin-expressing CTCs.	[Francart, Marie-Emilie; Vanwynsberghe, Aline M.; Lambert, Justine; Bourcy, Morgane; Genna, Anthony; Noel, Agnes; Gilles, Christine] Univ Liege, GIGA Canc, Lab Tumor & Dev Biol, Liege, Belgium; [Ancel, Julien] CHU Reims, Hop Maison Blanche, Serv Pneumol, F-51092 Reims, France; [Ancel, Julien; Birembaut, Philippe; Polette, Myriam] Univ Reims, INSERM, P3Cell UMRS 1250, SFR CAP SANTE, F-51097 Reims, France; [Perez-Boza, Jennifer; Struman, Ingrid] Univ Liege, GIGA Canc, Mol Angiogenesis Lab, Liege, Belgium; [Polette, Myriam] CHU Reims, Hop Maison Blanche, Lab Pathol, F-51092 Reims, France	University of Liege; CHU de Reims; Universite de Reims Champagne-Ardenne; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Reims Champagne-Ardenne; University of Liege; CHU de Reims; Universite de Reims Champagne-Ardenne	Gilles, C (corresponding author), Univ Liege, GIGA Canc, Lab Tumor & Dev Biol, Liege, Belgium.	cgilles@uliege.be	Boza, Jennifer Perez/AAA-7061-2021; ANCEL, Julien/AAD-7228-2022; ancel, julien/AAM-8908-2020	Boza, Jennifer Perez/0000-0003-3843-494X; ancel, julien/0000-0003-3128-9348; struman, ingrid/0000-0003-2550-3707	"Fonds de la Recherche Scientifique" FNRS (F.R.S.-FNRS, Belgium); "Fonds Speciaux de la Recherche" (University of Liege, Belgium); "Fondation contre le Cancer" (foundation of public interest, Belgium); Fondation Hospitalo Universitaire Leon Fredericq (FHULF, University of Liege); Programme Hubert-Curien (WBI); Televie grants	"Fonds de la Recherche Scientifique" FNRS (F.R.S.-FNRS, Belgium)(Fonds de la Recherche Scientifique - FNRS); "Fonds Speciaux de la Recherche" (University of Liege, Belgium); "Fondation contre le Cancer" (foundation of public interest, Belgium); Fondation Hospitalo Universitaire Leon Fredericq (FHULF, University of Liege); Programme Hubert-Curien (WBI); Televie grants	We thank Erika Konradowski, Nathalie Lefin, Emilie Feyereisen, Isabelle Dasoul, Laetitia Montero-Ruiz, and Marie Dehuy for technical assistance. We thank Pr. Silvia Blacher and Thomas Louis for their help with statistical analyses. We thank the following technical platforms from the University of Liege (Belgium): the GIGA-imaging and flow cytometry platform for providing access to FACSCanto II (BD), and the GIGA-Animal Facility. This work was supported by grants from the "Fonds de la Recherche Scientifique" FNRS (F.R.S.-FNRS, Belgium), the "Fonds Speciaux de la Recherche" (University of Liege, Belgium), the "Fondation contre le Cancer" (foundation of public interest, Belgium), the Fondation Hospitalo Universitaire Leon Fredericq (FHULF, University of Liege), and the "Programme Hubert-Curien (WBI)". CG and IS are Senior Research Associates at the F.R.S-FNRS. M-EF, AMV, JL, AG, MB, JP-B are/were supported by Televie grants.	Aberg M, 2013, J THROMB HAEMOST, V11, P817, DOI 10.1111/jth.12156; Ackland ML, 2003, LAB INVEST, V83, P435, DOI 10.1097/01.LAB.0000059927.97515.FD; Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005; Alix-Panabieres C, 2017, J MOL MED, V95, P133, DOI 10.1007/s00109-016-1500-6; Alix-Panabieres C, 2016, CANCER DISCOV, V6, P479, DOI 10.1158/2159-8290.CD-15-1483; Beinse G, 2017, J THROMB HAEMOST, V15, P1981, DOI 10.1111/jth.13792; Biggerstaff JP, 2008, CLIN APPL THROMB-HEM, V14, P193, DOI 10.1177/1076029607305619; Bonnomet A, 2012, ONCOGENE, V31, P3741, DOI 10.1038/onc.2011.540; Bourcy M, 2016, CANCER RES, V76, P4270, DOI 10.1158/0008-5472.CAN-15-2263; Breij ECW, 2014, CANCER RES, V74, P1214, DOI 10.1158/0008-5472.CAN-13-2440; Bystricky B, 2017, CRIT REV ONCOL HEMAT, V114, P33, DOI 10.1016/j.critrevonc.2017.04.003; Cabel L, 2017, INT J CLIN ONCOL, V22, P421, DOI 10.1007/s10147-017-1105-2; Challa AA, 2011, MOL CELL BIOL, V31, P3773, DOI 10.1128/MCB.05263-11; Chatterjee S, 2013, FEBS LETT, V587, P474, DOI 10.1016/j.febslet.2013.01.013; D'Asti E, 2016, THROMB RES, V140, pS37, DOI 10.1016/S0049-3848(16)30096-2; D'Asti E, 2016, AM J PATHOL, V186, P446, DOI 10.1016/j.ajpath.2015.10.020; Dauphin M, 2013, LUNG CANCER, V81, P117, DOI 10.1016/j.lungcan.2013.03.011; de Bono JS, 2019, LANCET ONCOL, V20, P383, DOI 10.1016/S1470-2045(18)30859-3; Dmello C, 2016, INT J BIOCHEM CELL B, V70, P161, DOI 10.1016/j.biocel.2015.11.015; Eisenreich A, 2014, TRENDS CARDIOVAS MED, V24, P128, DOI 10.1016/j.tcm.2013.09.005; Francart ME, 2018, DEV DYNAM, V247, P432, DOI 10.1002/dvdy.24506; Garnier D, 2010, THROMB RES, V125, pS44, DOI 10.1016/S0049-3848(10)70012-8; Gil-Bernabe AM, 2013, BRIT J HAEMATOL, V162, P433, DOI 10.1111/bjh.12381; Gilles C, 1999, J CELL SCI, V112, P4615; Hisada Y, 2019, SEMIN THROMB HEMOST, V45, P385, DOI 10.1055/s-0039-1687894; Hu ZW, 2017, ONCOTARGET, V8, P1481, DOI 10.18632/oncotarget.13644; Ivaska Johanna, 2011, Small GTPases, V2, P51; Jolly MK, 2019, PHARMACOL THERAPEUT, V194, P161, DOI 10.1016/j.pharmthera.2018.09.007; Li SF, 2014, ATHEROSCLEROSIS, V237, P514, DOI 10.1016/j.atherosclerosis.2014.09.033; Liu SL, 2019, NANO LETT, V19, P4721, DOI 10.1021/acs.nanolett.9b01785; Lowery J, 2015, J BIOL CHEM, V290, P17145, DOI 10.1074/jbc.R115.640359; Magnus N, 2014, THROMB RES, V133, pS1, DOI 10.1016/S0049-3848(14)50001-1; Markiewicz A, 2017, PATHOBIOLOGY, V84, P264, DOI 10.1159/000477812; Matrone MA, 2010, CANCER RES, V70, P7737, DOI 10.1158/0008-5472.CAN-10-1569; Mego M, 2009, BRIT J CANCER, V101, P1813, DOI 10.1038/sj.bjc.6605413; Milsom C, 2009, ARTERIOSCL THROM VAS, V29, P2005, DOI 10.1161/ATVBAHA.108.177444; Milsom CC, 2008, CANCER RES, V68, P10068, DOI 10.1158/0008-5472.CAN-08-2067; Mitrugno A, 2016, BLOOD REV, V30, P11, DOI 10.1016/j.blre.2015.07.001; Palumbo JS, 2008, SEMIN THROMB HEMOST, V34, P154, DOI 10.1055/s-2008-1079255; Palumbo JS, 2007, BLOOD, V110, P133, DOI 10.1182/blood-2007-01-065995; Pastushenko I, 2019, TRENDS CELL BIOL, V29, P212, DOI 10.1016/j.tcb.2018.12.001; Perlson E, 2006, J MOL BIOL, V364, P938, DOI 10.1016/j.jmb.2006.09.056; Phua DCY, 2009, MOL BIOL CELL, V20, P2841, DOI 10.1091/mbc.E08-02-0199; Provencal M, 2009, CARCINOGENESIS, V30, P1089, DOI 10.1093/carcin/bgp085; Rothmeier AS, 2018, BLOOD, V131, P674, DOI 10.1182/blood-2017-02-768218; Ruf W.R.M., 2013, MADAME CURIE BIOSCIE; Ruf W, 2016, THROMB RES, V140, pS1, DOI 10.1016/S0049-3848(16)30090-1; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Satelli A, 2016, J CANCER, V7, P1824, DOI 10.7150/jca.15622; Satelli A, 2016, SCI REP-UK, V6, DOI 10.1038/srep28910; Satelli A, 2011, CELL MOL LIFE SCI, V68, P3033, DOI 10.1007/s00018-011-0735-1; Schmidt Y, 2015, BIOL CHEM, V396, P253, DOI 10.1515/hsz-2014-0274; Song KY, 2013, RNA BIOL, V10, P256, DOI 10.4161/rna.23022; Sun B, 2015, BIOMED REP, V3, P603, DOI 10.3892/br.2015.494; Teruel R, 2011, J THROMB HAEMOST, V9, P1985, DOI 10.1111/j.1538-7836.2011.04451.x; Theunissen JW, 2018, MOL CANCER THER, V17, P2412, DOI 10.1158/1535-7163.MCT-18-0471; Ueno T, 2000, BRIT J CANCER, V83, P164; Unlu B, 2018, RES PRACT THROMB HAE, V2, P622, DOI 10.1002/rth2.12143; Virtakoivu R, 2015, CANCER RES, V75, P2349, DOI 10.1158/0008-5472.CAN-14-2842; Wang HX, 2017, ONCOTARGET, V8, P1884, DOI 10.18632/oncotarget.12242; Wang W, 2018, MOL CELL BIOCHEM, V438, P47, DOI 10.1007/s11010-017-3112-z; Witkowski M, 2018, CARDIOVASC DIABETOL, V17, DOI 10.1186/s12933-018-0678-z; Witkowski M, 2016, ARTERIOSCL THROM VAS, V36, P1263, DOI 10.1161/ATVBAHA.115.306094; Wong N, 2015, NUCLEIC ACIDS RES, V43, pD146, DOI 10.1093/nar/gku1104; Yamashita N, 2013, J CANCER RES CLIN, V139, P739, DOI 10.1007/s00432-013-1376-6; Yoneyama MS, 2014, EUR J CELL BIOL, V93, P157, DOI 10.1016/j.ejcb.2014.03.002; Yu G, 2013, MOL CELL BIOCHEM, V380, P239, DOI 10.1007/s11010-013-1679-6; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522; Yu YH, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt332; Zhang XX, 2011, J BIOL CHEM, V286, P1429, DOI 10.1074/jbc.M110.146530; Zhang XS, 2017, ONCOTARGET, V8, P59086, DOI 10.18632/oncotarget.19175; Zhao XT, 2018, EXP THER MED, V16, P4075, DOI 10.3892/etm.2018.6723	72	16	17	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	18					3680	3692		10.1038/s41388-020-1244-1	http://dx.doi.org/10.1038/s41388-020-1244-1		MAR 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LI5XR	32152404	Green Published, hybrid			2022-12-28	WOS:000518734100001
J	Li, K; Zhang, JW; Tian, YH; He, YQ; Xu, XL; Pan, WT; Gao, Y; Chen, FF; Wei, L				Li, Kai; Zhang, Jingwei; Tian, Yihao; He, Yanqi; Xu, Xiaolong; Pan, Wenting; Gao, Yang; Chen, Fangfang; Wei, Lei			The Wnt/beta-catenin/VASP positive feedback loop drives cell proliferation and migration in breast cancer	ONCOGENE			English	Article							VASODILATOR-STIMULATED PHOSPHOPROTEIN; BETA-CATENIN; DIFFERENTIAL EXPRESSION; ENA/VASP PROTEINS; RNA-SEQ; VASP; INVASION; ADHESION; PATHWAY; RAC1	Previous studies have shown that the main function of VASP is to regulate the cytoskeleton and play an important role in promoting tumor cell metastasis. In this study, we first reveal that VASP is located in the nucleus of breast cancer cells and elucidate a Wnt/beta-catenin/VASP positive feedback loop. We identify that VASP is a target gene of Wnt/beta-catenin signaling pathway, and activation of Wnt/beta-catenin signaling pathway can significantly upregulate VASP protein expression, while upregulated VASP protein can in turn promote translocation of beta-catenin and DVL3 proteins into the nucleus. In the nucleus, VASP, DVL3, beta-catenin, and TCF4 can form VASP/DVL3/beta-catenin/TCF4 protein complex, activating Wnt/beta-catenin signaling pathway, and promoting the expression of target genes VASP, c-myc, and cyclin D1. Thus, our study reveals that there is a Wnt/beta-catenin/VASP malignant positive feedback loop in breast cancer, which promotes the proliferation and migration of breast cancer cells, and breaking this positive feedback loop may provide new strategy for breast cancer treatment.	[Li, Kai; He, Yanqi; Xu, Xiaolong; Pan, Wenting; Gao, Yang; Wei, Lei] Wuhan Univ, Sch Basic Med Sci, Dept Pathol & Pathophysiol, Hubei Prov Key Lab Developmentally Originated Dis, 185 Donghu Rd, Wuhan 430071, Hubei, Peoples R China; [Li, Kai] Nanyang Inst Technol, Zhang Zhongjing Coll Chinese Med, Henan Key Lab Zhang Zhongjing Formulae & Herbs Im, Nanyang 473004, Henan, Peoples R China; [Zhang, Jingwei; Chen, Fangfang] Wuhan Univ, Zhongnan Hosp, Hubei Canc Clin Study Ctr, Dept Breast & Thyroid Surg,Hubei Key Lab Tumor Bi, Wuhan 430071, Hubei, Peoples R China; [Tian, Yihao] Wuhan Univ, Sch Basic Med Sci, Dept Anat, Wuhan 430071, Hubei, Peoples R China	Wuhan University; Nanyang Institute of Technology; Wuhan University; Wuhan University	Wei, L (corresponding author), Wuhan Univ, Sch Basic Med Sci, Dept Pathol & Pathophysiol, Hubei Prov Key Lab Developmentally Originated Dis, 185 Donghu Rd, Wuhan 430071, Hubei, Peoples R China.	leiwei@whu.edu.cn	Li, Kai/ABD-6377-2020	Li, Kai/0000-0002-0318-7064				Arend RC, 2013, GYNECOL ONCOL, V131, P772, DOI 10.1016/j.ygyno.2013.09.034; Arques O, 2016, CLIN CANCER RES, V22, P644, DOI 10.1158/1078-0432.CCR-14-3081; Ball LJ, 2000, EMBO J, V19, P4903, DOI 10.1093/emboj/19.18.4903; Bauer A, 1998, P NATL ACAD SCI USA, V95, P14787, DOI 10.1073/pnas.95.25.14787; Bruhmann S, 2017, P NATL ACAD SCI USA, V114, pE5815, DOI 10.1073/pnas.1703145114; Chen XJ, 2014, DEV CELL, V30, P569, DOI 10.1016/j.devcel.2014.08.001; Chen YH, 2016, EMBO J, V35, P668, DOI 10.15252/embj.201592810; Daniels DL, 2005, NAT STRUCT MOL BIOL, V12, P364, DOI 10.1038/nsmb912; Dertsiz L, 2005, THORAX, V60, P576, DOI 10.1136/thx.2004.037622; Gan XQ, 2008, J CELL BIOL, V180, P1087, DOI 10.1083/jcb.200710050; Gkretsi V, 2017, EXP CELL RES, V352, P281, DOI 10.1016/j.yexcr.2017.02.019; Grabherr MG, 2011, NAT BIOTECHNOL, V29, P644, DOI 10.1038/nbt.1883; Han G, 2008, ONCOL REP, V20, P929, DOI 10.3892/or_00000093; Hansen SD, 2015, ELIFE, V4, DOI 10.7554/eLife.06585; Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017; Kanehisa M, 2008, NUCLEIC ACIDS RES, V36, pD480, DOI 10.1093/nar/gkm882; Kramps T, 2002, CELL, V109, P47, DOI 10.1016/S0092-8674(02)00679-7; Krause M, 2002, J CELL SCI, V115, P4721, DOI 10.1242/jcs.00218; Krause M, 2003, ANNU REV CELL DEV BI, V19, P541, DOI 10.1146/annurev.cellbio.19.050103.103356; Kuang CC, 2017, ONCOL LETT, V13, P3253, DOI 10.3892/ol.2017.5825; Li K, 2018, CANCER MED-US, V7, P3875, DOI 10.1002/cam4.1568; Li K, 2018, J CANCER, V9, P1821, DOI 10.7150/jca.24934; Liu AB, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0669-9; Liu ZK, 2018, THERANOSTICS, V8, P4649, DOI 10.7150/thno.26789; Lu Y, 2017, CELL RES, V27, P1422, DOI 10.1038/cr.2017.107; Ma F, 2016, J CLIN INVEST, V126, P1745, DOI 10.1172/JCI78815; Marioni JC, 2008, GENOME RES, V18, P1509, DOI 10.1101/gr.079558.108; Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016; Renfranz PJ, 2002, CURR OPIN CELL BIOL, V14, P88, DOI 10.1016/S0955-0674(01)00299-X; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Runowicz CD, 2016, CA-CANCER J CLIN, V66, P44, DOI 10.3322/caac.21319; Stewart DJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt356; Su K, 2016, ONCOTARGET, V7, P45849, DOI 10.18632/oncotarget.9968; Su K, 2012, DNA CELL BIOL, V31, P1078, DOI 10.1089/dna.2011.1563; Sun SM, 2019, FISH SHELLFISH IMMUN, V86, P832, DOI 10.1016/j.fsi.2018.12.028; Tago K, 2000, GENE DEV, V14, P1741; Takemaru KI, 2003, NATURE, V422, P905, DOI 10.1038/nature01570; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; Tian YH, 2018, ONCOL LETT, V16, P2151, DOI 10.3892/ol.2018.8930; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Townsley FM, 2004, NAT CELL BIOL, V6, P626, DOI 10.1038/ncb1141; Varghese F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096801; Wang GZ, 2017, CLIN CANCER RES, V23, P6640, DOI 10.1158/1078-0432.CCR-17-0774; Wang J, 2012, EUR J CANCER, V48, P1904, DOI 10.1016/j.ejca.2011.11.026; Wang WQ, 2015, DEV CELL, V32, P707, DOI 10.1016/j.devcel.2015.01.031; Wang YP, 2010, EUR J PHARMACOL, V635, P40, DOI 10.1016/j.ejphar.2010.03.017; Wang ZY, 2016, P NATL ACAD SCI USA, V113, P13150, DOI 10.1073/pnas.1616336113; Xue GD, 2016, CANCER TREAT REV, V49, P1, DOI 10.1016/j.ctrv.2016.06.009; Zhang JW, 2013, ACTA PHARMACOL SIN, V34, P1084, DOI 10.1038/aps.2013.15; Zhang LJ, 2007, EUR J PHARMACOL, V563, P69, DOI 10.1016/j.ejphar.2007.01.073	50	20	22	3	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	11					2258	2274		10.1038/s41388-019-1145-3	http://dx.doi.org/10.1038/s41388-019-1145-3			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KU0ZS	31831834				2022-12-28	WOS:000519440400003
J	Brown, TP; Bhattacharjee, P; Ramachandran, S; Sivaprakasam, S; Ristic, B; Sikder, MOF; Ganapathy, V				Brown, Timothy P.; Bhattacharjee, Pushpak; Ramachandran, Sabarish; Sivaprakasam, Sathish; Ristic, Bojana; Sikder, Mohd Omar F.; Ganapathy, Vadivel			The lactate receptor GPR81 promotes breast cancer growth via a paracrine mechanism involving antigen-presenting cells in the tumor microenvironment	ONCOGENE			English	Article							MURINE DENDRITIC CELLS; UP-REGULATION; LACTIC-ACID; METABOLISM; INFLAMMATION; GENERATION; EXPRESSION; GPR109A; PROTEIN; ACTIVATION	GPR81 is a G-protein-coupled receptor for lactate, which is upregulated in breast cancer and plays an autocrine role to promote tumor growth by tumor cell-derived lactate. Here we asked whether lactate has any paracrine role via activation of GPR81 in cells present in tumor microenvironment to help tumor growth. First, we showed that deletion of Gpr81 suppresses breast cancer growth in a constitutive breast cancer mouse model (MMTV-PyMT-Tg). We then used a syngeneic transplant model by monitoring tumor growth from a mouse breast cancer cell line (AT-3, Gpr81-negative) implanted in mammary fat pad of wild-type mice and Gpr81-null mice. Tumor growth was suppressed in Gpr81-null mice compared with wild-type mice. There were more tumor-infiltrating T cells and MHCIIhi-immune cells in tumors from Gpr81-null mice compared with tumors from wild-type mice. RNA-seq analysis of tumors indicated involvement of immune cells and antigen presentation in Gpr81-dependent tumor growth. Antigen-presenting dendritic cells expressed Gpr81 and activation of this receptor by lactate suppressed cell-surface presentation of MHCII. Activation of Gpr81 in dendritic cells was associated with decreased cAMP, IL-6 and IL-12. These findings suggest that tumor cell-derived lactate activates GPR81 in dendritic cells and prevents presentation of tumor-specific antigens to other immune cells. This paracrine mechanism is complementary to the recently discovered autocrine mechanism in which lactate induces PD-L1 in tumor cells via activation of GPR81 in tumor cells, thus providing an effective means for tumor cells to evade immune system. As such, blockade of GPR81 signaling could boost cancer immunotherapy.	[Brown, Timothy P.; Bhattacharjee, Pushpak; Ramachandran, Sabarish; Sivaprakasam, Sathish; Ristic, Bojana; Sikder, Mohd Omar F.; Ganapathy, Vadivel] Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Biochem, Lubbock, TX 79430 USA	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center	Ganapathy, V (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Biochem, Lubbock, TX 79430 USA.	vadivel.ganapathy@ttuhsc.edu	Bhattacharjee, Pushpak/AFV-4590-2022; Sivaprakasam, Sathish/E-9367-2018	Sivaprakasam, Sathish/0000-0002-9230-0144	Welch Endowed Chair in Biochemistry at Texas Tech University Health Sciences Center [BI-0028]; South Plains Foundation	Welch Endowed Chair in Biochemistry at Texas Tech University Health Sciences Center; South Plains Foundation	This work was supported by the Welch Endowed Chair in Biochemistry, Grant no. BI-0028, at Texas Tech University Health Sciences Center (VG) and a grant from the South Plains Foundation (SR).	Ahmed K, 2010, CELL METAB, V11, P311, DOI 10.1016/j.cmet.2010.02.012; Brasel K, 2000, BLOOD, V96, P3029, DOI 10.1182/blood.V96.9.3029.h8003029_3029_3039; Brown AJ, 2003, J BIOL CHEM, V278, P11312, DOI 10.1074/jbc.M211609200; Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; Doherty JR, 2013, J CLIN INVEST, V123, P3685, DOI 10.1172/JCI69741; Dvorak CA, 2012, ACS MED CHEM LETT, V3, P637, DOI 10.1021/ml3000676; Elangovan S, 2014, CANCER RES, V74, P1166, DOI 10.1158/0008-5472.CAN-13-1451; Feng J, 2017, ONCOGENE, V36, P5829, DOI 10.1038/onc.2017.188; Fischer K, 2007, BLOOD, V109, P3812, DOI 10.1182/blood-2006-07-035972; Fisel P, 2018, CTS-CLIN TRANSL SCI, V11, P352, DOI 10.1111/cts.12551; Frauwirth KA, 2004, J IMMUNOL, V172, P4661, DOI 10.4049/jimmunol.172.8.4661; Ganapathy V, 2009, PHARMACOL THERAPEUT, V121, P29, DOI 10.1016/j.pharmthera.2008.09.005; Ge H, 2008, J LIPID RES, V49, P797, DOI 10.1194/jlr.M700513-JLR200; GOLDMAN RD, 1964, CANCER RES, V24, P389; Gottfried E, 2006, BLOOD, V107, P2013, DOI 10.1182/blood-2005-05-1795; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Halestrap AP, 2013, MOL ASPECTS MED, V34, P337, DOI 10.1016/j.mam.2012.05.003; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hoque R, 2014, GASTROENTEROLOGY, V146, P1763, DOI 10.1053/j.gastro.2014.03.014; Husain Z, 2013, J IMMUNOL, V191, P1486, DOI 10.4049/jimmunol.1202702; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Krawczyk CM, 2010, BLOOD, V115, P4742, DOI 10.1182/blood-2009-10-249540; Lee YJ, 2016, ONCOTARGET, V7, P70898, DOI 10.18632/oncotarget.12286; Liu CL, 2009, J BIOL CHEM, V284, P2811, DOI 10.1074/jbc.M806409200; Naik SH, 2005, J IMMUNOL, V174, P6592, DOI 10.4049/jimmunol.174.11.6592; Offermanns S, 2017, TRENDS ENDOCRIN MET, V28, P227, DOI [10.1016/J.tem.2016.11.007, 10.1016/j.tem.2016.11.007]; Ranganathan P, 2018, J IMMUNOL, V200, P1781, DOI 10.4049/jimmunol.1700604; Raychaudhuri D, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01878; Roland CL, 2014, CANCER RES, V74, P5301, DOI 10.1158/0008-5472.CAN-14-0319; Romero-Garcia S, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00052; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Singh N, 2014, IMMUNITY, V40, P128, DOI 10.1016/j.immuni.2013.12.007; STANISLAUS D, 1994, ENDOCRINOLOGY, V135, P2220, DOI 10.1210/en.135.5.2220; Stewart TJ, 2009, J IMMUNOL, V183, P117, DOI 10.4049/jimmunol.0804132; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thangaraju M, 2009, CANCER RES, V69, P2826, DOI 10.1158/0008-5472.CAN-08-4466; Vegran F, 2011, CANCER RES, V71, P2550, DOI 10.1158/0008-5472.CAN-10-2828; Wagner W, 2017, J PHYSIOL PHARMACOL, V68, P555; Wagner W, 2017, DNA REPAIR, V52, P49, DOI 10.1016/j.dnarep.2017.02.007; Wagner W, 2015, CELL COMMUN SIGNAL, V13, DOI 10.1186/s12964-015-0114-x; Walenta S, 2000, CANCER RES, V60, P916; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; WIKEHOOLEY JL, 1984, RADIOTHER ONCOL, V2, P343, DOI 10.1016/S0167-8140(84)80077-8; Xu YK, 2007, J IMMUNOL, V179, P7577, DOI 10.4049/jimmunol.179.11.7577	47	74	77	4	31	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2020	39	16					3292	3304		10.1038/s41388-020-1216-5	http://dx.doi.org/10.1038/s41388-020-1216-5		FEB 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF9OJ	32071396				2022-12-28	WOS:000514262700001
J	Li, JJ; Pu, TJ; Yin, LJ; Li, QL; Liao, CP; Wu, BJ				Li, Jingjing; Pu, Tianjie; Yin, Lijuan; Li, Qinlong; Liao, Chun-Peng; Wu, Boyang Jason			MAOA-mediated reprogramming of stromal fibroblasts promotes prostate tumorigenesis and cancer stemness	ONCOGENE			English	Article							MONOAMINE-OXIDASE; TUMOR PROGRESSION; SIGNALING PATHWAY; OXIDATIVE STRESS; CELLS; STAT3; INTERLEUKIN-6; INFLAMMATION; METASTASIS; MICROENVIRONMENT	The tumor microenvironment plays a critical role in prostate cancer (PC) development and progression. Inappropriate activation of the stroma potentiates the growth and transformation of epithelial tumor cells. Here, we show that upregulation of monoamine oxidase A (MAOA), a mitochondrial enzyme that degrades monoamine neurotransmitters and dietary amines, in stromal cells elevates production of reactive oxygen species, triggers an inflammatory response including activation of IL-6, and promotes tumorigenesis in vitro and in vivo. Mechanistically, MAOA enhances IL-6 transcription through direct Twist1 binding to a conserved E-box element at the IL-6 promoter. MAOA in stromal fibroblasts provides tumor cell growth advantages through paracrine IL-6/STAT3 signaling. Tissue microarray analysis revealed co-expression correlations between individual pairs of proteins of the stromal MAOA-induced Twist1/IL-6/STAT3 pathway in clinical specimens. Downstream of stromal MAOA, STAT3 also promotes cell stemness and transcriptionally activates expression of cancer stem cell marker CD44 in PC cells. MAOA inhibitor treatment effectively suppressed prostate tumor growth in mice in a stroma-specific targeted manner. Collectively, these findings characterize the contribution of MAOA to stromal activation in PC pathogenesis and provide a rationale for targeting MAOA in stromal cells to treat PC.	[Li, Jingjing; Pu, Tianjie; Wu, Boyang Jason] Washington State Univ, Coll Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, 205 E Spokane Falls Blvd,PBS 421, Spokane, WA 99202 USA; [Li, Jingjing] Shanghai Jiao Tong Univ, Sch Pharm, Lab Regener, Shanghai 200240, Peoples R China; [Pu, Tianjie; Yin, Lijuan] Sichuan Univ, West China Hosp, Dept Pathol, Chengdu 610041, Sichuan, Peoples R China; [Yin, Lijuan] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Dept Med, Urooncol Res Program, Los Angeles, CA 90048 USA; [Li, Qinlong] Med Univ Air Force, Xijing Hosp, Dept Pathol, Xian 710032, Shaanxi, Peoples R China; [Liao, Chun-Peng] Univ Southern Calif, Keck Sch Med, Lawrence J Ellison Inst Transformat Med, Los Angeles, CA 90089 USA	Washington State University; Shanghai Jiao Tong University; Sichuan University; Cedars Sinai Medical Center; Air Force Military Medical University; University of Southern California	Wu, BJ (corresponding author), Washington State Univ, Coll Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, 205 E Spokane Falls Blvd,PBS 421, Spokane, WA 99202 USA.	boyang.wu@wsu.edu	Li, Jing/GYU-5036-2022; Pu, Tianjie/AAE-9454-2022; Pu, Tianjie/AFD-8574-2022	Liao, Chun-Peng/0000-0001-8920-4322	Concern Foundation CONquer canCER Now Award; Department of Defense Prostate Cancer Research Program [W81XWH-15-1-0493]; NIH/NCI [R37CA233658]; WSU start-up fund	Concern Foundation CONquer canCER Now Award; Department of Defense Prostate Cancer Research Program(United States Department of Defense); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); WSU start-up fund	We thank Yang Li (University of Southern California), Yanping Wang (CSMC), and Yidi Xu (Washington State University) for technical help, Leland W.K. Chung (CSMC) for comprehensive support of this study, and Gary Mawyer for editorial assistance. This work was supported by a Concern Foundation CONquer canCER Now Award, the Department of Defense Prostate Cancer Research Program grant W81XWH-15-1-0493, the NIH/NCI grant R37CA233658, and the WSU start-up fund to B.J.W.	Acharya A, 2010, OXID MED CELL LONGEV, V3, P23, DOI 10.4161/oxim.3.1.10095; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Azevedo A, 2011, WORLD J CLIN ONCOL, V2, P384, DOI 10.5306/wjco.v2.i12.384; Barron DA, 2012, ENDOCR-RELAT CANCER, V19, pR187, DOI 10.1530/ERC-12-0085; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bromberg J, 2009, CANCER CELL, V15, P79, DOI 10.1016/j.ccr.2009.01.009; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Cheng N, 2011, JOVE-J VIS EXP, DOI 10.3791/2716; Culig Z, 2018, MOL CELL ENDOCRINOL, V462, P25, DOI 10.1016/j.mce.2017.03.012; De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090; Dobrian Anca D, 2012, Front Endocrinol (Lausanne), V3, P108, DOI 10.3389/fendo.2012.00108; Dumont N, 2013, NEOPLASIA, V15, P249, DOI 10.1593/neo.121950; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Flamand V, 2010, J CANCER RES CLIN, V136, P1761, DOI 10.1007/s00432-010-0835-6; Franco OE, 2012, ADV PHARMACOL, V65, P267, DOI 10.1016/B978-0-12-397927-8.00009-9; Galoczova M, 2018, CELL MOL BIOL LETT, V23, DOI 10.1186/s11658-018-0078-0; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Hodge DR, 2005, EUR J CANCER, V41, P2502, DOI 10.1016/j.ejca.2005.08.016; Ishihara K, 2002, BBA-MOL CELL RES, V1592, P281, DOI 10.1016/S0167-4889(02)00321-X; Kawada M, 2006, CANCER RES, V66, P4419, DOI 10.1158/0008-5472.CAN-05-4239; Kumari N, 2016, TUMOR BIOL, V37, P11553, DOI 10.1007/s13277-016-5098-7; Policastro LL, 2013, ANTIOXID REDOX SIGN, V19, P854, DOI 10.1089/ars.2011.4367; Leach DA, 2017, CANCERS, V9, DOI 10.3390/cancers9010010; Lee JL, 2009, J CELL BIOL, V185, P949, DOI 10.1083/jcb.200812060; Lee KW, 2015, CANCER RES, V75, P73, DOI 10.1158/0008-5472.CAN-14-0350; Li Y, 2013, J BIOL CHEM, V288, P25007, DOI 10.1074/jbc.M113.450353; Lin L, 2016, INT J ONCOL, V49, P2265, DOI 10.3892/ijo.2016.3728; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745; Mathy-Hartert M, 2008, OSTEOARTHR CARTILAGE, V16, P756, DOI 10.1016/j.joca.2007.10.009; Meng E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107142; Moreira MP, 2018, EXP CELL RES, V363, P283, DOI 10.1016/j.yexcr.2018.01.018; Olumi AF, 1999, CANCER RES, V59, P5002; Patrawala L, 2006, ONCOGENE, V25, P1696, DOI 10.1038/sj.onc.1209327; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Shih JC, 1999, ANNU REV NEUROSCI, V22, P197, DOI 10.1146/annurev.neuro.22.1.197; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Studebaker AW, 2008, CANCER RES, V68, P9087, DOI 10.1158/0008-5472.CAN-08-0400; Sun XJ, 2010, IN VITRO CELL DEV-AN, V46, P538, DOI 10.1007/s11626-010-9309-z; Sun Y, 2012, NAT MED, V18, P1359, DOI 10.1038/nm.2890; Tanner MJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016027; THALMANN GN, 1994, CANCER RES, V54, P2577; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; True L, 2006, P NATL ACAD SCI USA, V103, P10991, DOI 10.1073/pnas.0603678103; Valencia T, 2014, CANCER CELL, V26, P121, DOI 10.1016/j.ccr.2014.05.004; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wassmann S, 2004, CIRC RES, V94, P534, DOI 10.1161/01.RES.0000115557.25127.8D; Wu JB, 2009, J BIOL CHEM, V284, P16723, DOI 10.1074/jbc.M901779200; Wu JB, 2017, CANCER CELL, V31, P368, DOI 10.1016/j.ccell.2017.02.003; Wu JB, 2014, J CLIN INVEST, V124, P2891, DOI 10.1172/JCI70982; Yan YM, 2015, STEM CELL TRANSL MED, V4, P1033, DOI 10.5966/sctm.2015-0048; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Zhang G, 2013, GASTROENT RES PRACT, V2013, DOI 10.1155/2013/782581; Zhau HYE, 1996, P NATL ACAD SCI USA, V93, P15152, DOI 10.1073/pnas.93.26.15152; Zhu YZ, 2014, PROSTATE, V74, P1086, DOI 10.1002/pros.22819	56	13	13	5	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2020	39	16					3305	3321		10.1038/s41388-020-1217-4	http://dx.doi.org/10.1038/s41388-020-1217-4		FEB 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF9OJ	32066880				2022-12-28	WOS:000514052700004
J	Jeannot, E; Darrigues, L; Michel, M; Stern, MH; Pierga, JY; Rampanou, A; Melaabi, S; Benoist, C; Bieche, I; Vincent-Salomon, A; El Ayachy, R; Noret, A; Epaillard, N; Cabel, L; Bidard, FC; Proudhon, C				Jeannot, Emmanuelle; Darrigues, Lauren; Michel, Marc; Stern, Marc-Henri; Pierga, Jean-Yves; Rampanou, Aurore; Melaabi, Samia; Benoist, Camille; Bieche, Ivan; Vincent-Salomon, Anne; El Ayachy, Radouane; Noret, Aurelien; Epaillard, Nicolas; Cabel, Luc; Bidard, Francois-Clement; Proudhon, Charlotte			A single droplet digital PCR for ESR1 activating mutations detection in plasma	ONCOGENE			English	Article							ESTROGEN-RECEPTOR-ALPHA; CELL-FREE DNA; BREAST-CANCER; RESISTANCE	Activating mutations in the estrogen receptor 1 (ESR1) gene confer resistance to aromatase inhibitors (AI), and may be targeted by selective estrogen receptor downregulators. We designed a multiplex droplet digital PCR (ddPCR), which combines a drop-off assay, targeting the clustered hotspot mutations found in exon 8, with an unconventional assay interrogating the E380Q mutation in exon 5. We assessed its sensitivity in vitro using synthetic oligonucleotides, harboring E380Q, L536R, Y537C, Y537N, Y537S, or D538G mutations. Further validation was performed on plasma samples from a prospective study and compared with next generation sequencing (NGS) data. The multiplex ESR1-ddPCR showed a high sensitivity with a limit of detection ranging from 0.07 to 0.19% in mutant allele frequency. The screening of plasma samples from patients with AI-resistant metastatic breast cancer identified ESR1 mutations in 29% of them, all mutations being confirmed by NGS. In addition, this test identifies patients harboring polyclonal alterations. Furthermore, the monitoring of circulating tumor DNA using this technique during treatment follow-up predicts the clinical benefit of palbociclib-fulvestrant. The multiplex ESR1-ddPCR detects, in a single reaction, the most frequent ESR1 activating mutations with good sensitivity. This method allows real-time liquid biopsy for ESR1 mutation monitoring in large cohorts of patients.	[Jeannot, Emmanuelle; Darrigues, Lauren; Michel, Marc; Pierga, Jean-Yves; Rampanou, Aurore; Bidard, Francois-Clement; Proudhon, Charlotte] PSL Res Univ, Inst Curie, Circulating Tumor Biomarkers Lab, Inserm CIC 1428, Paris, France; [Jeannot, Emmanuelle; Melaabi, Samia; Benoist, Camille; Bieche, Ivan; Vincent-Salomon, Anne] PSL Res Univ, Inst Curie, Dept Biopathol & Genet, Paris, France; [Stern, Marc-Henri] PSL Res Univ, Inst Curie, INSERM U830, Paris, France; [Pierga, Jean-Yves; El Ayachy, Radouane; Noret, Aurelien; Epaillard, Nicolas; Cabel, Luc; Bidard, Francois-Clement] PSL Res Univ, Inst Curie, Dept Med Oncol, Paris, France; [Pierga, Jean-Yves; El Ayachy, Radouane; Noret, Aurelien; Epaillard, Nicolas; Cabel, Luc; Bidard, Francois-Clement] PSL Res Univ, Inst Curie, Dept Med Oncol, St Cloud, France; [Pierga, Jean-Yves] Univ Paris, Paris, France; [Pierga, Jean-Yves] Dept Inst Curie, Med Oncol, Paris, France; [Cabel, Luc; Bidard, Francois-Clement] Versailles St Quentin Univ, Paris Saclay Univ, St Cloud, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Saclay	Proudhon, C (corresponding author), PSL Res Univ, Inst Curie, Circulating Tumor Biomarkers Lab, Inserm CIC 1428, Paris, France.	charlotte.proudhon@curie.fr	Stern, Marc-Henri/A-2728-2011	Stern, Marc-Henri/0000-0002-8100-2272; Proudhon, Charlotte/0000-0002-4649-4574; Michel, Marc/0000-0001-6613-8027	Innovative Medicines Initiative Joint Undertaking [115749]; SIRIC 2 Curie [INCa-DGOS-Inserm_12554]	Innovative Medicines Initiative Joint Undertaking; SIRIC 2 Curie	SIRIC 2 Curie (grant INCa-DGOS-Inserm_12554) and the Innovative Medicines Initiative Joint Undertaking under grant agreement no. 115749 (project Cancer-ID). The funding sources of the study had no role in the design of the study, collection, analysis, or interpretation of the data or in the writing of this report.	Bidard FC, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.SABCS18-PD2-06; Bidard FC, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006305; Bidshahri R, 2016, J MOL DIAGN, V18, P190, DOI 10.1016/j.jmoldx.2015.09.003; Carausu M, 2019, EXPERT REV MOL DIAGN, V19, P599, DOI 10.1080/14737159.2019.1631799; Chandarlapaty S, 2016, JAMA ONCOL, V2, P1310, DOI 10.1001/jamaoncol.2016.1279; Chu D, 2016, CLIN CANCER RES, V22, P993, DOI 10.1158/1078-0432.CCR-15-0943; Chung JH, 2017, ANN ONCOL, V28, P2866, DOI 10.1093/annonc/mdx490; Clatot F, 2016, ONCOTARGET, V7, P74448, DOI 10.18632/oncotarget.12950; Decraene C, 2018, JOVE-J VIS EXP, V139, P1; Decraene C, 2018, CLIN CHEM, V64, P317, DOI 10.1373/clinchem.2017.272518; Fribbens C, 2016, J CLIN ONCOL, V34, P2961, DOI 10.1200/JCO.2016.67.3061; Garcia-Murillas I, 2015, SCI TRANSL MED, V7, DOI [10.1126/scitranslmed.aab0021, 10.1126/scitranslmed.aac7551]; Gyanchandani R, 2017, ONCOTARGET, V8, P66901, DOI 10.18632/oncotarget.11383; Jeselsohn R, 2014, CLIN CANCER RES, V20, P1757, DOI 10.1158/1078-0432.CCR-13-2332; Li SQ, 2013, CELL REP, V4, P1116, DOI 10.1016/j.celrep.2013.08.022; Lupini L, 2018, SCI REP, V8, P1; Merenbakh-Lamin K, 2013, CANCER RES, V73, P6856, DOI 10.1158/0008-5472.CAN-13-1197; Niu JX, 2015, ONCOTARGETS THER, V8, P3323, DOI 10.2147/OTT.S92443; O'Leary B, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03215-x; Robinson DR, 2013, NAT GENET, V45, P1446, DOI 10.1038/ng.2823; Seki Y, 2016, ONCOLOGIST, V21, P156, DOI 10.1634/theoncologist.2015-0288; Takeshita T, 2017, ONCOTARGET, V8, P52142, DOI 10.18632/oncotarget.18479; Takeshita T, 2015, TRANSL RES, V166, P540, DOI 10.1016/j.trsl.2015.09.003; Toy W, 2017, CANCER DISCOV, V7, P277, DOI 10.1158/2159-8290.CD-15-1523; Toy W, 2013, NAT GENET, V45, P1439, DOI 10.1038/ng.2822; Wang PL, 2016, CLIN CANCER RES, V22, P1130, DOI 10.1158/1078-0432.CCR-15-1534	26	21	21	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	14					2987	2995		10.1038/s41388-020-1174-y	http://dx.doi.org/10.1038/s41388-020-1174-y		FEB 2020	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KZ2VB	32042112	Green Submitted			2022-12-28	WOS:000512528200003
J	Koch, JP; Aebersold, DM; Zimmer, Y; Medova, M				Koch, Jonas P.; Aebersold, Daniel M.; Zimmer, Yitzhak; Medova, Michaela			MET targeting: time for a rematch	ONCOGENE			English	Review							HEPATOCYTE GROWTH-FACTOR; CELL LUNG-CANCER; RECEPTOR-TYROSINE KINASE; MODIFIED T-CELLS; DURABLE COMPLETE RESPONSE; PRIMARY COLON-CANCER; EXON 14 MUTATIONS; C-MET; SCATTER FACTOR; ONCOGENE ADDICTION	MET, the receptor tyrosine kinase (RTK) for hepatocyte growth factor, is a proto-oncogene involved in embryonic development and throughout life in homeostasis and tissue regeneration. Deregulation of MET signaling has been reported in numerous malignancies, prompting great interest in MET targeting for cancer therapy. The present review offers a summary of the biology of MET and its known functions in normal physiology and carcinogenesis, followed by an overview of the most relevant MET-targeting strategies and corresponding clinical trials, highlighting both past setbacks and promising future prospects. By placing their efforts on a more precise stratification strategy through the genetic analysis of tumors, modern trials such as the NCI-MATCH trial could revive the past enthusiasm for MET-targeted therapy.	[Koch, Jonas P.; Aebersold, Daniel M.; Zimmer, Yitzhak; Medova, Michaela] Bern Univ Hosp, Inselspital, Dept BioMed Res, CH-3008 Bern, Switzerland; [Koch, Jonas P.; Aebersold, Daniel M.; Zimmer, Yitzhak; Medova, Michaela] Univ Bern, CH-3008 Bern, Switzerland; [Koch, Jonas P.; Aebersold, Daniel M.; Zimmer, Yitzhak; Medova, Michaela] Bern Univ Hosp, Inselspital, Dept Radiat Oncol, CH-3010 Bern, Switzerland; [Koch, Jonas P.; Aebersold, Daniel M.; Zimmer, Yitzhak; Medova, Michaela] Univ Bern, CH-3010 Bern, Switzerland	University of Bern; University Hospital of Bern; University of Bern; University of Bern; University Hospital of Bern; University of Bern	Medova, M (corresponding author), Bern Univ Hosp, Inselspital, Dept BioMed Res, CH-3008 Bern, Switzerland.; Medova, M (corresponding author), Univ Bern, CH-3008 Bern, Switzerland.; Medova, M (corresponding author), Bern Univ Hosp, Inselspital, Dept Radiat Oncol, CH-3010 Bern, Switzerland.; Medova, M (corresponding author), Univ Bern, CH-3010 Bern, Switzerland.	michaela.medova@dbmr.unibe.ch	Aebersold, Daniel Matthias/C-2946-2013	Aebersold, Daniel Matthias/0000-0002-9493-3834; Medova, Michaela/0000-0003-0649-469X	Werner und Hedy Berger-Janser Stiftung	Werner und Hedy Berger-Janser Stiftung	This work has been supported by the Werner und Hedy Berger-Janser Stiftung (grant to MM).	Abou-Alfa GK, 2018, NEW ENGL J MED, V379, P54, DOI 10.1056/NEJMoa1717002; Abounader R, 2001, FASEB J, V15, P108, DOI 10.1096/fj.01-0421fje; Ahmed N, 2015, J CLIN ONCOL, V33, P1688, DOI 10.1200/JCO.2014.58.0225; Ahmed N, 2009, MOL THER, V17, P1779, DOI 10.1038/mt.2009.133; Al-Saad S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181527; Androulla MN, 2018, CURR PHARM BIOTECHNO, V19, P5, DOI 10.2174/1389201019666180418095526; Ariyawutyakorn W, 2016, J CANCER, V7, P633, DOI 10.7150/jca.12663; Atabey N, 2001, J BIOL CHEM, V276, P14308, DOI 10.1074/jbc.M010202200; Awad MM, 2016, J CLIN ONCOL, V34, P721, DOI 10.1200/JCO.2015.63.4600; Bahcall M, 2016, CANCER DISCOV, V6, P1334, DOI 10.1158/2159-8290.CD-16-0686; Bardelli A, 2013, CANCER DISCOV, V3, P658, DOI 10.1158/2159-8290.CD-12-0558; Basilico C, 2008, J BIOL CHEM, V283, P21267, DOI 10.1074/jbc.M800727200; Basilico C, 2013, CLIN CANCER RES, V19, P2381, DOI 10.1158/1078-0432.CCR-12-3459; Bauer TW, 2006, MOL CANCER THER, V5, P1676, DOI 10.1158/1535-7163.MCT-05-0175; Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Borowiak M, 2004, P NATL ACAD SCI USA, V101, P10608, DOI 10.1073/pnas.0403412101; Bradley CA, 2017, NAT REV CLIN ONCOL, V14, P562, DOI 10.1038/nrclinonc.2017.40; Breindel JL, 2013, CANCER RES, V73, P5053, DOI 10.1158/0008-5472.CAN-12-3775; Burgess TL, 2010, MOL CANCER THER, V9, P400, DOI 10.1158/1535-7163.MCT-09-0824; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Cabometyx, CAB; Camidge DR, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.8001; Carter S, 2004, J BIOL CHEM, V279, P52835, DOI 10.1074/jbc.M407769200; Catenacci DVT, 2017, LANCET ONCOL, V18, P1467, DOI 10.1016/S1470-2045(17)30566-1; Catenacci DVT, 2011, CANCER DISCOV, V1, P573, DOI 10.1158/2159-8290.CD-11-0175; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Choueiri TK, 2017, ANN ONCOL, V28, pv605, DOI 10.1093/annonc/; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; COLOMER R, 1994, BRIT J CANCER, V70, P819, DOI 10.1038/bjc.1994.405; Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530; Comoglio PM, 2018, NAT REV CANCER, V18, P341, DOI 10.1038/s41568-018-0002-y; Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; D'Arcangelo M, 2013, BIOL-TARGETS THER, V7, P61, DOI 10.2147/BTT.S28908; De Bacco F, 2011, J NATL CANCER I, V103, P645, DOI 10.1093/jnci/djr093; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; Di Renzo MF, 2000, ONCOGENE, V19, P1547, DOI 10.1038/sj.onc.1203455; DIRENZO MF, 1995, J ENDOCRINOL INVEST, V18, P134, DOI 10.1007/BF03349722; DIRENZO MF, 1995, CANCER RES, V55, P1129; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; Doi T, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.3_suppl.tps226; Du J, 2017, ONCOTARGET, V8, P26281, DOI 10.18632/oncotarget.15457; El-Deiry WS, 2015, CANCER BIOL THER, V16, P1726, DOI 10.1080/15384047.2015.1113356; Engstrom LD, 2017, CLIN CANCER RES, V23, P6661, DOI 10.1158/1078-0432.CCR-17-1192; European Medicines Agency, COM; Falchook GS, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.2521; Fan QW, 2003, CANCER RES, V63, P8930; Fan SJ, 2005, ONCOGENE, V24, P1749, DOI 10.1038/sj.onc.1208327; Feng KC, 2016, SCI CHINA LIFE SCI, V59, P468, DOI 10.1007/s11427-016-5023-8; Feng Y, 2011, CANCER DISCOV, V1, P550, DOI 10.1158/2159-8290.CD-11-0289; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Follenzi A, 2000, ONCOGENE, V19, P3041, DOI 10.1038/sj.onc.1203620; de Jesus VHF, 2018, J HEPATOCELL CARCINO, V5, P87, DOI 10.2147/JHC.S171396; Foveau B, 2009, MOL BIOL CELL, V20, P2495, DOI 10.1091/mbc.E08-09-0969; Frampton GM, 2015, CANCER DISCOV, V5, P850, DOI 10.1158/2159-8290.CD-15-0285; FURUKAWA T, 1995, AM J PATHOL, V147, P889; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Garber K, 2014, NAT REV DRUG DISCOV, V13, P563, DOI 10.1038/nrd4406; Gherardi E, 2003, P NATL ACAD SCI USA, V100, P12039, DOI 10.1073/pnas.2034936100; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GIORDANO S, 1989, ONCOGENE, V4, P1383; Giordano S, 2002, NAT CELL BIOL, V4, P720, DOI 10.1038/ncb843; Grano M, 1996, P NATL ACAD SCI USA, V93, P7644, DOI 10.1073/pnas.93.15.7644; Hara T, 1998, LAB INVEST, V78, P1143; Hashigasako A, 2004, J BIOL CHEM, V279, P26445, DOI 10.1074/jbc.M314254200; Herter S, 2005, BIOCHEM J, V390, P125, DOI 10.1042/BJ20041955; Hochhaus A, 2017, NEW ENGL J MED, V376, P917, DOI 10.1056/NEJMoa1609324; Hong DS, 2019, CLIN CANCER RES, V25, P2403, DOI 10.1158/1078-0432.CCR-18-1341; HOULDSWORTH J, 1990, CANCER RES, V50, P6417; Huang FJ, 2016, J PATHOL CLIN RES, V2, P210, DOI 10.1002/cjp2.49; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; Hui AY, 2009, J CELL BIOCHEM, V107, P1168, DOI 10.1002/jcb.22219; Ignatius SH, 2017, J THORAC ONCOL, V12, P137, DOI 10.1016/j.jtho.2016.09.119; Ivan M, 1997, ONCOGENE, V14, P2417, DOI 10.1038/sj.onc.1201083; Janne PA, 2015, NEW ENGL J MED, V372, P1689, DOI 10.1056/NEJMoa1411817; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kammula US, 2007, CANCER LETT, V248, P219, DOI 10.1016/j.canlet.2006.07.007; Kim K, 2007, BIOCHEM BIOPH RES CO, V354, P115, DOI 10.1016/j.bbrc.2006.12.164; Kim TY, 2016, LIVER CANCER, V5, P74; Kitajima Y, 2008, CANCER SCI, V99, P1341, DOI 10.1111/j.1349-7006.2008.00828.x; Kobayashi T, 2016, J THORAC DIS, V8, pE1381, DOI 10.21037/jtd.2016.10.62; Koeppen H, 2014, CLIN CANCER RES, V20, P4488, DOI 10.1158/1078-0432.CCR-13-1836; Koeppen H, 2014, J PATHOL, V232, P210, DOI 10.1002/path.4268; Kohno T, 2015, TRANSL LUNG CANCER R, V4, P156, DOI 10.3978/j.issn.2218-6751.2014.11.11; Kong-Beltran M, 2006, CANCER RES, V66, P283, DOI 10.1158/0008-5472.CAN-05-2749; Kong-Beltran M, 2004, CANCER CELL, V6, P75, DOI 10.1016/j.ccr.2004.06.013; Kozlov G, 2004, BIOCHEM BIOPH RES CO, V321, P234, DOI 10.1016/j.bbrc.2004.06.132; Kuba K, 2000, CANCER RES, V60, P6737; Kwak EL, 2015, CANCER DISCOV, V5, P1271, DOI 10.1158/2159-8290.CD-15-0748; Lassus P, 2006, BIOL NEONATE, V90, P28, DOI 10.1159/000091663; Lee JM, 2014, ONCOGENE, V33, P34, DOI 10.1038/onc.2012.551; Lee JH, 2000, ONCOGENE, V19, P4947, DOI 10.1038/sj.onc.1203874; Lengyel E, 2005, INT J CANCER, V113, P678, DOI 10.1002/ijc.20598; Lennerz JK, 2011, J CLIN ONCOL, V29, P4803, DOI 10.1200/JCO.2011.35.4928; Li N, 2018, TRANSL ONCOL, V11, P11, DOI 10.1016/j.tranon.2017.10.009; Lim WA, 2017, CELL, V168, P724, DOI 10.1016/j.cell.2017.01.016; Liu L, 2014, CLIN CANCER RES, V20, P6059, DOI 10.1158/1078-0432.CCR-14-0543; Liu Y, 2015, WORLD J GASTROENTERO, V21, P3706, DOI 10.3748/wjg.v21.i12.3706; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; Lu KV, 2012, CANCER CELL, V22, P21, DOI 10.1016/j.ccr.2012.05.037; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Maina F, 1998, NEURON, V20, P835, DOI 10.1016/S0896-6273(00)80466-3; Martens T, 2006, CLIN CANCER RES, V12, P6144, DOI 10.1158/1078-0432.CCR-05-1418; Matsumoto K, 2001, KIDNEY INT, V59, P2023, DOI 10.1046/j.1523-1755.2001.00717.x; MATSUMOTO K, 1991, J GASTROEN HEPATOL, V6, P509, DOI 10.1111/j.1440-1746.1991.tb00897.x; Matsumoto K, 2006, INT J CANCER, V119, P477, DOI 10.1002/ijc.21808; McNeil C, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv193; Medova M, 2013, MOL CANCER THER, V12, P2415, DOI 10.1158/1535-7163.MCT-13-0151; Michieli P, 2004, CANCER CELL, V6, P61, DOI 10.1016/j.ccr.2004.05.032; Mignot F, 2017, RADIOTHER ONCOL, V124, P190, DOI 10.1016/j.radonc.2017.07.006; Mitchell CJ, 2016, MOL ONCOL, V10, P910, DOI 10.1016/j.molonc.2016.03.003; Mitsudomi T, 2010, LANCET ONCOL, V11, P121, DOI 10.1016/S1470-2045(09)70364-X; Miyata Y, 2006, CLIN CANCER RES, V12, P4876, DOI 10.1158/1078-0432.CCR-06-0362; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Mujtaba G, 2015, J MED GENET, V52, P548, DOI 10.1136/jmedgenet-2015-103023; Mullard A, 2015, NAT REV DRUG DISCOV, V14, P513, DOI 10.1038/nrd4694; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Nakamura T, 2000, J CLIN INVEST, V106, P1511, DOI 10.1172/JCI10226; Nakamura Y, 2008, CANCER SCI, V99, P14, DOI 10.1111/j.1349-7006.2007.00640.x; Nakamura Y, 2007, CANCER SCI, V98, P1006, DOI 10.1111/j.1349-7006.2007.00493.x; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NISHINO T, 1995, BLOOD, V85, P3093, DOI 10.1182/blood.V85.11.3093.bloodjournal85113093; Okamoto W, 2010, MOL CANCER THER, V9, P2785, DOI 10.1158/1535-7163.MCT-10-0481; Orian-Rousseau W, 2007, MOL BIOL CELL, V18, P76, DOI 10.1091/mbc.E06-08-0674; Pacchiana G, 2010, J BIOL CHEM, V285, P36149, DOI 10.1074/jbc.M110.134031; Pagliarini R, 2015, EMBO REP, V16, P280, DOI 10.15252/embr.201439949; Paik PK, 2015, CANCER DISCOV, V5, P842, DOI 10.1158/2159-8290.CD-14-1467; Palka HL, 2003, J BIOL CHEM, V278, P5728, DOI 10.1074/jbc.M210656200; Park M, 2005, EXP MOL MED, V37, P213, DOI 10.1038/emm.2005.29; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Park WS, 2000, APMIS, V108, P195, DOI 10.1034/j.1600-0463.2000.d01-44.x; Pasquini G, 2018, EXPERT OPIN INV DRUG, V27, P363, DOI 10.1080/13543784.2018.1462336; Personeni Nicola, 2018, Drugs Context, V7, P212533, DOI 10.7573/dic.212533; Peschard P, 2004, J BIOL CHEM, V279, P29565, DOI 10.1074/jbc.M403954200; Petrini I, 2015, ANN TRANSL MED, V82, P3; Pilotto S, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2016.12.33; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; Qin S, 2015, EUR J CANCER, V51, pS452, DOI 10.1016/S0959-8049(16)31269-2; Qin S, 2015, LIVER CANCER, V4, P219; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Rosen PJ, 2010, CLIN CANCER RES, V16, P2677, DOI 10.1158/1078-0432.CCR-09-2862; Rusciano D, 1996, J BIOL CHEM, V271, P20763, DOI 10.1074/jbc.271.34.20763; Sacher AG, 2014, CANCER-AM CANCER SOC, V120, P2289, DOI 10.1002/cncr.28723; Salian-Mehta S, 2013, MOL CELL ENDOCRINOL, V374, P92, DOI 10.1016/j.mce.2013.04.018; Sangwan V, 2008, J BIOL CHEM, V283, P34374, DOI 10.1074/jbc.M805916200; Santini FC, 2017, TRANSL LUNG CANCER R, V6, P393, DOI 10.21037/tlcr.2017.04.06; Sawyers C, 2004, NATURE, V432, P294, DOI 10.1038/nature03095; Schelter F, 2010, J BIOL CHEM, V285, P26335, DOI 10.1074/jbc.M110.106435; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1999, ONCOGENE, V18, P2343, DOI 10.1038/sj.onc.1202547; Schuler MH, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.9067; Shah MA, 2017, JAMA ONCOL, V3, P620, DOI 10.1001/jamaoncol.2016.5580; Sharma SV, 2007, GENE DEV, V21, P3214, DOI 10.1101/gad.1609907; Shaw A., 2016, ANN ONCOL, DOI [10.1093/annonc/mdw383.07, DOI 10.1093/ANNONC/MDW383.07]; Shaw AT, 2014, NEW ENGL J MED, V371, P1963, DOI 10.1056/NEJMoa1406766; Smolen GA, 2006, P NATL ACAD SCI USA, V103, P2316, DOI 10.1073/pnas.0508776103; SOMAN NR, 1991, P NATL ACAD SCI USA, V88, P4892, DOI 10.1073/pnas.88.11.4892; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; Spigel DR, 2017, J CLIN ONCOL, V35, P412, DOI 10.1200/JCO.2016.69.2160; Spigel DR, 2013, J CLIN ONCOL, V31, P4105, DOI 10.1200/JCO.2012.47.4189; Srivastava AK, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2016.12.78; Stamos J, 2004, EMBO J, V23, P2325, DOI 10.1038/sj.emboj.7600243; Sun YL, 2013, INT J MED SCI, V10, P548, DOI 10.7150/ijms.5191; Suryavanshi M, 2017, ONCOL RES TREAT, V40, P198, DOI 10.1159/000457801; Taher TEI, 2002, J IMMUNOL, V169, P3793, DOI 10.4049/jimmunol.169.7.3793; Takeuchi H, 2003, CLIN CANCER RES, V9, P1480; Tamagnone Luca, 1997, Cytokine and Growth Factor Reviews, V8, P129, DOI 10.1016/S1359-6101(97)00007-5; Tchou J, 2017, CANCER IMMUNOL RES, V5, P1152, DOI 10.1158/2326-6066.CIR-17-0189; Thayaparan T, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1363137; Toiyama Y, 2012, INT J CANCER, V130, P2912, DOI 10.1002/ijc.26330; Tong CYK, 2004, J NEUROSURG, V100, P187, DOI 10.3171/ped.2004.100.2.0187; Tong JH, 2016, CLIN CANCER RES, V22, P3048, DOI 10.1158/1078-0432.CCR-15-2061; Tretiakova M, 2011, J ENVIRON PATHOL TOX, V30, P341, DOI 10.1615/JEnvironPatholToxicolOncol.v30.i4.70; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012; Turke AB, 2010, CANCER CELL, V17, P77, DOI 10.1016/j.ccr.2009.11.022; van der Horst E, 2009, NEOPLASIA, V11, P355, DOI 10.1593/neo.81536; Van Schaeybroeck S, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.tps3632; Vigna E, 2015, ONCOGENE, V34, P1883, DOI 10.1038/onc.2014.142; Vigna E, 2014, J MOL MED, V92, P65, DOI 10.1007/s00109-013-1079-0; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719; Vosjan MJWD, 2012, MOL CANCER THER, V11, P1017, DOI 10.1158/1535-7163.MCT-11-0891; Wang JY, 2017, CLIN CANCER RES, V23, P992, DOI 10.1158/1078-0432.CCR-16-1568; Wang JY, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2138-z; Wang WY, 2015, INT J CARDIOL, V181, P180, DOI 10.1016/j.ijcard.2014.10.148; Wang X, 2002, MOL CELL, V9, P411, DOI 10.1016/S1097-2765(02)00439-2; Watanabe K, 2015, J IMMUNOL, V194, P911, DOI 10.4049/jimmunol.1402346; Watermann I, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0362-5; Weinstein IB, 2006, NAT CLIN PRACT ONCOL, V3, P448, DOI 10.1038/ncponc0558; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Wu YL, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.9020; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; Xu YR, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.212597; Yi S, 2000, NEOPLASIA, V2, P226, DOI 10.1038/sj.neo.7900080; Zarnegar R, 1995, EXS, V74, P33; Zhang J, 2016, CARCINOGENESIS, V37, P345, DOI 10.1093/carcin/bgw015; Zhang YW, 2003, P NATL ACAD SCI USA, V100, P12718, DOI 10.1073/pnas.2135113100; Zhang YW, 2002, ONCOGENE, V21, P217, DOI 10.1038/sj/onc/1205004; Zhao J, 2011, HISTOL HISTOPATHOL, V26, P1111, DOI 10.14670/HH-26.1111; Zou HY, 2007, CANCER RES, V67, P4408, DOI 10.1158/0008-5472.CAN-06-4443	210	30	30	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	14					2845	2862		10.1038/s41388-020-1193-8	http://dx.doi.org/10.1038/s41388-020-1193-8		FEB 2020	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KZ2VB	32034310				2022-12-28	WOS:000511752600005
J	Barak, AF; Lewinsky, H; Perpinial, M; Huber, V; Radomir, L; Kramer, MP; Sever, L; Wolf, Y; Shapiro, M; Herishanu, Y; Jung, S; Becker-Herman, S; Shachar, I				Barak, Avital F.; Lewinsky, Hadas; Perpinial, Michal; Huber, Victoria; Radomir, Lihi; Kramer, Mattias P.; Sever, Lital; Wolf, Yochai; Shapiro, Mika; Herishanu, Yair; Jung, Steffen; Becker-Herman, Shirly; Shachar, Idit			Bone marrow dendritic cells support the survival of chronic lymphocytic leukemia cells in a CD84 dependent manner	ONCOGENE			English	Article							IMMUNE SUPPRESSION; B-CELLS; RECEPTOR; MICROENVIRONMENT; MONOCYTES; MOUSE; CLL; PATHOGENESIS; APOPTOSIS; DEPLETION	Chronic lymphocytic leukemia (CLL) is a malignancy of mature B lymphocytes. The microenvironment of the CLL cells is a vital element in the regulation of the survival of these malignant cells. CLL cell longevity is dependent on external signals, originating from cells in their microenvironment including secreted and surface-bound factors. Dendritic cells (DCs) play an important part in tumor microenvironment, but their role in the CLL bone marrow (BM) niche has not been studied. We show here that CLL cells induce accumulation of bone marrow dendritic cells (BMDCs). Depletion of this population attenuates disease expansion. Our results show that the support of the microenvironment is partly dependent on CD84, a cell surface molecule belonging to the Signaling Lymphocyte Activating Molecule (SLAM) family of immunoreceptors. Our results suggest a novel therapeutic strategy whereby eliminating BMDCs or blocking the CD84 expressed on these cells may reduce the tumor load.	[Barak, Avital F.; Lewinsky, Hadas; Perpinial, Michal; Huber, Victoria; Radomir, Lihi; Kramer, Mattias P.; Sever, Lital; Wolf, Yochai; Jung, Steffen; Becker-Herman, Shirly; Shachar, Idit] Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; [Shapiro, Mika; Herishanu, Yair] Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Dept Hematol, Tel Aviv, Israel	Weizmann Institute of Science; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center	Shachar, I (corresponding author), Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel.	idit.shachar@weizmann.ac.il	Jung, Steffen/K-1409-2012	Jung, Steffen/0000-0003-4290-5716; Wolf, Yochai/0000-0003-0270-2025; Kramer, Matthias P/0000-0002-0289-5261	DKFZ-MOST cooperation in cancer research; ERA-NET TRANSCAN-2 program JTC 2014-project FIRE-CLL; Binational Science Foundation (BSF) [711979]; Israel Science Foundation	DKFZ-MOST cooperation in cancer research; ERA-NET TRANSCAN-2 program JTC 2014-project FIRE-CLL; Binational Science Foundation (BSF)(US-Israel Binational Science Foundation); Israel Science Foundation(Israel Science Foundation)	The authors wish to thank members of the Shachar lab for fruitful discussion and support. IS is the incumbent of the Dr Morton and Ann Kleiman Professorial Chair. This research was supported by the DKFZ-MOST cooperation in cancer research, ERA-NET TRANSCAN-2 program JTC 2014-project FIRE-CLL and the Binational Science Foundation (BSF) grant no 711979. This research was performed without the support of the Israel Science Foundation.	Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Bichi R, 2002, P NATL ACAD SCI USA, V99, P6955, DOI 10.1073/pnas.102181599; BINET JL, 1977, CANCER-AM CANCER SOC, V40, P855, DOI 10.1002/1097-0142(197708)40:2<855::AID-CNCR2820400239>3.0.CO;2-1; Binsky-Ehrenreich I, 2014, ONCOGENE, V33, P1006, DOI 10.1038/onc.2013.31; Birnberg T, 2008, IMMUNITY, V29, P986, DOI 10.1016/j.immuni.2008.10.012; Brockschniedier D, 2006, GENESIS, V44, P322, DOI 10.1002/dvg.20218; Burger JA, 2007, LEUKEMIA RES, V31, P887, DOI 10.1016/j.leukres.2006.12.004; Cabanas C, 1999, J BIOL REG HOMEOS AG, V13, P134; Caligaris-Cappio F, 1999, J CLIN ONCOL, V17, P399, DOI 10.1200/JCO.1999.17.1.399; Calpe S, 2008, ADV IMMUNOL, V97, P177, DOI 10.1016/S0065-2776(08)00004-7; Cannons JL, 2010, IMMUNITY, V32, P253, DOI 10.1016/j.immuni.2010.01.010; de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Engelhardt JJ, 2012, CANCER CELL, V21, P402, DOI 10.1016/j.ccr.2012.01.008; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; GALE RP, 1994, LEUKEMIA, V8, P1610; Galletti G, 2016, CELL REP, V14, P1748, DOI 10.1016/j.celrep.2016.01.042; Ghiringhelli F, 2005, J EXP MED, V202, P919, DOI 10.1084/jem.20050463; Ginhoux F, 2014, NAT REV IMMUNOL, V14, P392, DOI 10.1038/nri3671; Greaves P, 2013, BLOOD, V121, P734, DOI 10.1182/blood-2012-10-385591; Hanna BS, 2016, LEUKEMIA, V30, P570, DOI 10.1038/leu.2015.305; Hofbauer JP, 2011, LEUKEMIA, V25, P1452, DOI 10.1038/leu.2011.111; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Jung S, 2002, IMMUNITY, V17, P211, DOI 10.1016/S1074-7613(02)00365-5; Karthaus N, 2012, AM J PATHOL, V181, P733, DOI 10.1016/j.ajpath.2012.05.012; Kipps T J, 1998, Curr Opin Hematol, V5, P244; Klein U, 2010, SEMIN CANCER BIOL, V20, P377, DOI 10.1016/j.semcancer.2010.10.012; Krempski J, 2011, J IMMUNOL, V186, P6905, DOI 10.4049/jimmunol.1100274; Kuziel WA, 1997, P NATL ACAD SCI USA, V94, P12053, DOI 10.1073/pnas.94.22.12053; Lagneaux L, 1998, BLOOD, V91, P2387, DOI 10.1182/blood.V91.7.2387.2387_2387_2396; Lewinsky H, 2018, J CLIN INVEST, V128, P5465, DOI 10.1172/JCI96610; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Marom A, 2017, ONCOGENE, V36, P628, DOI 10.1038/onc.2016.238; Martin M, 2001, J IMMUNOL, V167, P3668, DOI 10.4049/jimmunol.167.7.3668; Mildner A, 2014, IMMUNITY, V40, P642, DOI 10.1016/j.immuni.2014.04.016; Montserrat E, 2008, ANN ONCOL, V19, P320, DOI 10.1093/annonc/mdn460; Nicholas NS, 2016, BBA-MOL CELL RES, V1863, P471, DOI 10.1016/j.bbamcr.2015.11.003; RAI KR, 1975, BLOOD, V46, P219, DOI 10.1182/blood.V46.2.219.219; Ramsay AD, 2013, BRIT J HAEMATOL, V162, P15, DOI 10.1111/bjh.12344; Romero X, 2005, J IMMUNOL, V174, P7033, DOI 10.4049/jimmunol.174.11.7033; Sapoznikov A, 2008, IMMUNOL CELL BIOL, V86, P409, DOI 10.1038/icb.2008.23; Sapoznikov A, 2008, NAT IMMUNOL, V9, P388, DOI 10.1038/ni1571; Saulep-Easton D, 2014, LEUKEMIA, V28, P2005, DOI 10.1038/leu.2014.105; Serbina NV, 2006, NAT IMMUNOL, V7, P311, DOI 10.1038/ni1309; Varol C, 2007, J EXP MED, V204, P171, DOI 10.1084/jem.20061011; Yan QR, 2007, P NATL ACAD SCI USA, V104, P10583, DOI 10.1073/pnas.0703893104; Yang JY, 2014, BIOMARK RES, V2, DOI 10.1186/2050-7771-2-1; Zlotnikov-Klionsky Y, 2015, IMMUNITY, V43, P776, DOI 10.1016/j.immuni.2015.08.015	48	1	1	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	9					1997	2008		10.1038/s41388-019-1121-y	http://dx.doi.org/10.1038/s41388-019-1121-y			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KP9VM	31772329				2022-12-28	WOS:000516579800013
J	Clements, ME; Johnson, RW				Clements, Miranda E.; Johnson, Rachelle W.			PREX1 drives spontaneous bone dissemination of ER plus breast cancer cells	ONCOGENE			English	Article							RAC-GEF; RECEPTOR; METASTASIS; P-REX1; PHOSPHORYLATION; ACTIVATION; COMPLEXES; DORMANCY; PROGRAM; GTPASE	A significant proportion of breast cancer patients develop bone metastases, but the mechanisms regulating tumor cell dissemination from the primary site to the skeleton remain largely unknown. Using a novel model of spontaneous bone metastasis derived from human ER+ MCF7 cells, molecular profiling revealed increased PREX1 expression in a cell line established from bone-disseminated MCF7 cells (MCF7b), which were more migratory, invasive, and adhesive in vitro compared with parental MCF7 cells, and this phenotype was mediated by PREX1. MCF7b cells grew poorly in the primary tumor site when reinoculated in vivo, suggesting that these cells are primed to grow in the bone, and were enriched in skeletal sites of metastasis over soft tissue sites. Skeletal dissemination from the primary tumor was reversed with PREX1 knockdown, indicating that PREX1 is a key driver of spontaneous dissemination of tumor cells from the primary site to the bone marrow. In breast cancer patients, PREX1 levels are significantly increased in ER+ tumors and associated with invasive disease and distant metastasis. Together, these findings implicate PREX1 in spontaneous bone dissemination and provide a significant advance to the molecular mechanisms by which breast cancer cells disseminate from the primary tumor site to bone.	[Clements, Miranda E.; Johnson, Rachelle W.] Vanderbilt Univ, Program Canc Biol, Nashville, TN 37232 USA; [Clements, Miranda E.; Johnson, Rachelle W.] Vanderbilt Univ, Med Ctr, Dept Med, Vanderbilt Ctr Bone Biol,Div Clin Pharmacol, Nashville, TN 37232 USA; [Johnson, Rachelle W.] Vanderbilt Univ, Med Ctr, Dept Med, Div Clin Pharmacol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Johnson, RW (corresponding author), Vanderbilt Univ, Program Canc Biol, Nashville, TN 37232 USA.; Johnson, RW (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Vanderbilt Ctr Bone Biol,Div Clin Pharmacol, Nashville, TN 37232 USA.; Johnson, RW (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Div Clin Pharmacol, Nashville, TN 37232 USA.	rachelle.johnson@vumc.org	Clements, Miranda/AAE-6427-2019; Clements, Miranda/AAE-4756-2019	Johnson, Rachelle/0000-0003-2755-9851	Vanderbilt-Ingram Cancer Center [P30 CA68485]; Vanderbilt Digestive Disease Research Center [DK058404]; RPPA Core facility at MD Anderson Cancer Center (NCI) [CA16672]; NIH [R00CA194198, P30CA068485]	Vanderbilt-Ingram Cancer Center; Vanderbilt Digestive Disease Research Center; RPPA Core facility at MD Anderson Cancer Center (NCI); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors wish to acknowledge Mr. Joshua Johnson for histological processing and sectioning of tibiae. Flow Cytometry experiments were performed in the VMC Flow Cytometry Shared Resource, which is supported by the Vanderbilt-Ingram Cancer Center (P30 CA68485) and the Vanderbilt Digestive Disease Research Center (DK058404). The authors wish to acknowledge the expert technical support of the VANGARD core facilities. RPPA data were generated by the RPPA Core facility at MD Anderson Cancer Center (NCI #CA16672). RWJ and MEC are supported in part by and funding for experiments was provided by NIH award R00CA194198 (RWJ). Experiments performed at Vanderbilt were supported in part by scholarship funds from NIH award P30CA068485 Vanderbilt-Ingram Cancer Center Support Grant.	Albain K, 2012, LANCET, V379, P432, DOI 10.1016/S0140-6736(11)61625-5; ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; Barkan D, 2008, CANCER RES, V68, P6241, DOI 10.1158/0008-5472.CAN-07-6849; Barrio-Real Laura, 2018, Oncotarget, V9, P28612, DOI 10.18632/oncotarget.25584; Bidwell BN, 2012, NAT MED, V18, P1224, DOI 10.1038/nm.2830; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cheng WY, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005974; Colak D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063204; Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210; Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078-0432.CCR-06-0931; Dillon LM, 2015, ONCOGENE, V34, P3968, DOI 10.1038/onc.2014.328; Duplessis TT, 2011, ENDOCRINOLOGY, V152, P2517, DOI 10.1210/en.2010-1281; Ganapathy V, 2012, CLIN EXP METASTAS, V29, P493, DOI 10.1007/s10585-012-9466-4; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gawrzak S, 2018, NAT CELL BIOL, V20, P211, DOI 10.1038/s41556-017-0021-z; Gont A, 2017, ONCOTARGET, V8, P8559, DOI 10.18632/oncotarget.14348; Guo X, 2009, CELL RES, V19, P71, DOI 10.1038/cr.2008.302; Gustafsson KL, 2016, SCI REP-UK, V6, DOI 10.1038/srep29473; Han HH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002909; Johnson RW, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00241; Johnson RW, 2016, NAT CELL BIOL, V18, P1078, DOI 10.1038/ncb3408; Johnson RW, 2015, PHARMACOL THERAPEUT, V150, P169, DOI 10.1016/j.pharmthera.2015.02.002; Johnson RW, 2011, CANCER RES, V71, P822, DOI 10.1158/0008-5472.CAN-10-2993; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kazanietz MG, 2017, CANCER RES, V77, P5445, DOI 10.1158/0008-5472.CAN-17-1456; Kimbung S, 2014, MOL ONCOL, V8, P119, DOI 10.1016/j.molonc.2013.10.002; Kremer KN, 2017, BLOOD, V130, P982, DOI 10.1182/blood-2017-03-770982; La Rosa P, 2012, MOL ENDOCRINOL, V26, P762, DOI 10.1210/me.2011-1208; Lawson CD, 2018, J CELL BIOL, V217, P447, DOI 10.1083/jcb.201612069; Lawson DA, 2015, NATURE, V526, P131, DOI 10.1038/nature15260; Lindsay CR, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1560; Liu HJ, 2016, J BIOL CHEM, V291, P17258, DOI 10.1074/jbc.M116.743401; Ma XJ, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2222; Marotti JD, 2017, INT J BREAST CANCER, V2017, DOI 10.1155/2017/4537532; Montero JC, 2011, ONCOGENE, V30, P1059, DOI 10.1038/onc.2010.489; Neuzillet C, 2015, PHARMACOL THERAPEUT, V147, P22, DOI 10.1016/j.pharmthera.2014.11.001; Porter Andrew P, 2016, Small GTPases, V7, P123, DOI 10.1080/21541248.2016.1173767; Qin J, 2009, ONCOGENE, V28, P1853, DOI 10.1038/onc.2009.30; Rahman MS, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.5; Ryan MB, 2016, MOL CANCER RES, V14, P1009, DOI 10.1158/1541-7786.MCR-16-0184; Savci-Heijink CD, 2015, BREAST CANCER RES TR, V150, P547, DOI 10.1007/s10549-015-3352-0; Schroder J, 2017, EUR J CANCER, V79, P139, DOI 10.1016/j.ejca.2017.03.031; Sosa MS, 2010, MOL CELL, V40, P877, DOI 10.1016/j.molcel.2010.11.029; Sowder ME, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32653-2; Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451; Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017	47	10	10	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	6					1318	1334		10.1038/s41388-019-1064-3	http://dx.doi.org/10.1038/s41388-019-1064-3			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE4UH	31636389	Green Accepted			2022-12-28	WOS:000526714600011
J	Njeru, SN; Kraus, J; Meena, JK; Lechel, A; Katz, SF; Kumar, M; Knippschild, U; Azoitei, A; Wezel, F; Bolenz, C; Leithauser, F; Gollowitzer, A; Omrani, O; Hoischen, C; Koeberle, A; Kestler, HA; Gunes, C; Rudolph, KL				Njeru, Sospeter N.; Kraus, Johann; Meena, Jitendra K.; Lechel, Andre; Katz, Sarah-Fee; Kumar, Mukesh; Knippschild, Uwe; Azoitei, Anca; Wezel, Felix; Bolenz, Christian; Leithaeuser, Frank; Gollowitzer, Andre; Omrani, Omid; Hoischen, Christian; Koeberle, Andreas; Kestler, Hans A.; Guenes, Cagatay; Rudolph, K. Lenhard			Aneuploidy-inducing gene knockdowns overlap with cancer mutations and identify Orp3 as a B-cell lymphoma suppressor	ONCOGENE			English	Article							FATTY-ACIDS; STEM-CELLS; EXPRESSION; IMMORTALIZATION; PROLIFERATION; TUMORIGENESIS; CONTRIBUTE	Aneuploidy can instigate tumorigenesis. However, mutations in genes that control chromosome segregation are rare in human tumors as these mutations reduce cell fitness. Screening experiments indicate that the knockdown of multiple classes of genes that are not directly involved in chromosome segregation can lead to aneuploidy induction. The possible contribution of these genes to cancer formation remains yet to be defined. Here we identified gene knockdowns that lead to an increase in aneuploidy in checkpoint-deficient human cancer cells. Computational analysis revealed that the identified genes overlap with recurrent mutations in human cancers. The knockdown of the three strongest selected candidate genes (ORP3, GJB3, and RXFP1) enhances the malignant transformation of human fibroblasts in culture. Furthermore, the knockout of Orp3 results in an aberrant expansion of lymphoid progenitor cells and a high penetrance formation of chromosomal instable, pauci-clonal B-cell lymphoma in aging mice. At pre-tumorous stages, lymphoid cells from the animals exhibit deregulated phospholipid metabolism and an aberrant induction of proliferation regulating pathways associating with increased aneuploidy in hematopoietic progenitor cells. Together, these results support the concept that aneuploidy-inducing gene deficiencies contribute to cellular transformation and carcinogenesis involving the deregulation of various molecular processes such as lipid metabolism, proliferation, and cell survival.	[Njeru, Sospeter N.; Meena, Jitendra K.; Omrani, Omid; Hoischen, Christian; Rudolph, K. Lenhard] Fritz Lipmann Inst eV, Leibniz Inst Aging, D-07745 Jena, Germany; [Kraus, Johann; Kestler, Hans A.] Ulm Univ, Inst Med Syst Biol, D-89081 Ulm, Germany; [Lechel, Andre; Katz, Sarah-Fee] Ulm Univ Hosp, Dept Internal Med 1, D-89081 Ulm, Germany; [Kumar, Mukesh; Azoitei, Anca; Wezel, Felix; Bolenz, Christian; Guenes, Cagatay] Ulm Univ Hosp, Dept Urol, D-89081 Ulm, Germany; [Knippschild, Uwe] Ulm Univ Hosp, Dept Gen & Visceral Surg, D-89081 Ulm, Germany; [Leithaeuser, Frank] Ulm Univ, Inst Pathol, D-89075 Ulm, Germany; [Gollowitzer, Andre; Koeberle, Andreas] Friedrich Schiller Univ Jena, Inst Pharm, D-07743 Jena, Germany; [Njeru, Sospeter N.] Paul Ehrlich Inst, Div Immunol, D-63225 Langen, Germany; [Meena, Jitendra K.] Baylor Coll Med, Houston, TX 77030 USA; [Koeberle, Andreas] Univ Innsbruck, Michael Popp Res Inst, Innsbruck, Austria	Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI); Ulm University; Ulm University; Ulm University; Ulm University; Ulm University; Friedrich Schiller University of Jena; Paul Ehrlich Institute; Baylor College of Medicine; University of Innsbruck	Rudolph, KL (corresponding author), Fritz Lipmann Inst eV, Leibniz Inst Aging, D-07745 Jena, Germany.; Kestler, HA (corresponding author), Ulm Univ, Inst Med Syst Biol, D-89081 Ulm, Germany.; Gunes, C (corresponding author), Ulm Univ Hosp, Dept Urol, D-89081 Ulm, Germany.	hans.kestler@uni-ulm.de; cagatay.guenes@uniklinik-ulm.de; lenhard.rudolph@leibniz-fli.de	Koeberle, Andreas/ABB-2356-2020; Wezel, Felix/AAO-8761-2021; Kestler, Hans A./D-5799-2012; Lechel, André/AAQ-2041-2021; Gollowitzer, André/AAH-7653-2020; Meena, Jitendra Kumar/C-7444-2016	Koeberle, Andreas/0000-0001-6269-5088; Kestler, Hans A./0000-0002-4759-5254; Lechel, André/0000-0003-0221-6959; Njeru, Sospeter/0000-0003-1154-0777; Meena, Jitendra Kumar/0000-0003-0199-9357; Gollowitzer, Andre/0000-0003-1524-8298	Erich und Gertrud Roggenbuck Stiftung; Deutsche Krebshilfe [10-2086-Gu 2]; European Union (advanced ERC grant) [323136]; German Science Foundation (DFG) [SFB 1074, GRK 2254 HEIST]; Free State of Thuringia [41-5507-2016]; Leibniz ScienceCampus InfectoOptics (SAS-2015-HKI-LWC); Leibniz Graduate School on Ageing and Age-Related Diseases (LGSA), the government of Kenya; Federal Government of Germany through DAAD/NACOSTI scholarship; NRF	Erich und Gertrud Roggenbuck Stiftung; Deutsche Krebshilfe(Deutsche Krebshilfe); European Union (advanced ERC grant); German Science Foundation (DFG)(German Research Foundation (DFG)); Free State of Thuringia(European Commission); Leibniz ScienceCampus InfectoOptics (SAS-2015-HKI-LWC); Leibniz Graduate School on Ageing and Age-Related Diseases (LGSA), the government of Kenya; Federal Government of Germany through DAAD/NACOSTI scholarship; NRF	This work was supported by the Erich und Gertrud Roggenbuck Stiftung and Deutsche Krebshilfe (C. Gunes, grant 10-2086-Gu 2), the European Union (advanced ERC grant to K. L. Rudolph, grant 323136), and the German Science Foundation (DFG, grants: SFB 1074 Projekt Z1 and GRK 2254 HEIST to H.A. Kestler). A.K. was supported by a Strategy and Innovation Grant from the Free State of Thuringia (41-5507-2016) and the Leibniz ScienceCampus InfectoOptics (SAS-2015-HKI-LWC). The FLI Core Facilities; Flow Cytometry, Histology, S2 laboratory, and Mouse facilities are gratefully acknowledged. We would like to thank the members of the K.L. Rudolph laboratory for helpful support. We thank Lars Zender and Torsten Wustefeld for the cooperation in providing the lentiviral shRNA library targeting human cells and deep sequencing expertize. We also thank Sabrina Eichwald and Michaela Eggel for technical support and Lucien Frappart for his help with the histological evaluation of the xenograft mouse tumors. We acknowledge the Leibniz Graduate School on Ageing and Age-Related Diseases (LGSA), the government of Kenya and the Federal Government of Germany for financing S.N.N. through DAAD/NACOSTI (present NRF) scholarship	Abdelbaset-Ismail A, 2019, STEM CELL REV REP, V15, P139, DOI 10.1007/s12015-018-9853-6; Baker DJ, 2009, CANCER CELL, V16, P475, DOI 10.1016/j.ccr.2009.10.023; Barth TFE, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05116-3; Begus-Nahrmann Y, 2009, NAT GENET, V41, P1138, DOI 10.1038/ng.426; Bejarano E, 2014, NAT CELL BIOL, V16, P401, DOI 10.1038/ncb2934; Carneiro MC, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005798; Carricaburu V, 2001, EUR J BIOCHEM, V268, P1238, DOI 10.1046/j.1432-1327.2001.01984.x; Cattoretti G, 2005, CANCER CELL, V7, P445, DOI 10.1016/j.ccr.2005.03.037; Conery AR, 2010, P NATL ACAD SCI USA, V107, P15455, DOI 10.1073/pnas.1010627107; Davoli T, 2013, CELL, V155, P948, DOI 10.1016/j.cell.2013.10.011; Deshpande I, 2019, NATURE, V571, P284, DOI 10.1038/s41586-019-1355-4; Du XM, 2018, SEMIN CELL DEV BIOL, V81, P149, DOI 10.1016/j.semcdb.2017.07.017; Duijf PHG, 2013, ONCOGENE, V32, P4727, DOI 10.1038/onc.2012.616; Ema H, 2006, NAT PROTOC, V1, P2979, DOI 10.1038/nprot.2006.447; Fujimura S, 2005, CANCER RES, V65, P5925, DOI 10.1158/0008-5472.CAN-04-3259; Gordon DJ, 2012, NAT REV GENET, V13, P189, DOI 10.1038/nrg3123; Gunes C, 2018, NAT REV UROL, V15, P386, DOI 10.1038/s41585-018-0001-5; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Harris H, 2008, J CELL SCI, V121, P3, DOI 10.1242/jcs.025742; Hell MP, 2014, CANCER RES, V74, P2422, DOI 10.1158/0008-5472.CAN-13-2040; Holubcova Z, 2015, SCIENCE, V348, P1143, DOI 10.1126/science.aaa9529; Kaftanovskaya EM, 2015, BIOL REPROD, V92, DOI 10.1095/biolreprod.114.127209; Koeberle A, 2013, P NATL ACAD SCI USA, V110, P2546, DOI 10.1073/pnas.1216182110; Koeberle A, 2010, FASEB J, V24, P4929, DOI 10.1096/fj.10-162818; Lehto M, 2004, CELL TISSUE RES, V315, P39, DOI 10.1007/s00441-003-0817-y; Lehto M, 2008, J CELL SCI, V121, P695, DOI 10.1242/jcs.016964; Li M, 2010, P NATL ACAD SCI USA, V107, P14188, DOI 10.1073/pnas.1005960107; Li M, 2009, J CELL BIOL, V185, P983, DOI 10.1083/jcb.200904020; MAGNUSON T, 1985, J EXP ZOOL, V236, P353, DOI 10.1002/jez.1402360313; Martins VC, 2014, NATURE, V509, P465, DOI 10.1038/nature13317; Meena JK, 2015, EMBO J, V34, P1371, DOI 10.15252/embj.201490070; Orr B, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00164; Passerini V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10754; Patel D, 2017, OXID MED CELL LONGEV, V2017, P1, DOI 10.1155/2017/4829180; Petzoldt JL, 1995, UROL RES, V23, P377, DOI 10.1007/BF00698738; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Raychaudhuri S, 2010, ANNU REV CELL DEV BI, V26, P157, DOI 10.1146/annurev.cellbio.042308.113334; Richard G, 1998, NAT GENET, V20, P366, DOI 10.1038/3840; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; SEGAL DJ, 1974, J CELL PHYSIOL, V83, P85, DOI 10.1002/jcp.1040830112; Shen KC, 2005, CANCER RES, V65, P8747, DOI 10.1158/0008-5472.CAN-05-1471; Skarnes WC, 2011, NATURE, V474, P337, DOI 10.1038/nature10163; Tang YC, 2013, CELL, V152, P394, DOI 10.1016/j.cell.2012.11.043; Thapa N, 2016, TRENDS CANCER, V2, P378, DOI 10.1016/j.trecan.2016.05.009; Wang PY, 2005, SCIENCE, V307, P1472, DOI 10.1126/science.1107710; Weber-Boyvat M, 2015, EXP CELL RES, V331, P278, DOI 10.1016/j.yexcr.2014.10.019; Williams BR, 2008, SCIENCE, V322, P703, DOI 10.1126/science.1160058; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	49	6	6	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	7					1445	1465		10.1038/s41388-019-1073-2	http://dx.doi.org/10.1038/s41388-019-1073-2			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KL2WP	31659255				2022-12-28	WOS:000513289600005
J	Qian, MY; Geng, JW; Luo, KL; Huang, Z; Zhang, QK; Zhang, JA; Ji, LY; Wu, JM				Qian, Mengyao; Geng, Jingwen; Luo, Kaili; Huang, Zheng; Zhang, Qinkai; Zhang, Jian-an; Ji, Liying; Wu, Jianmin			BCL11B regulates MICA/B-mediated immune response by acting as a competitive endogenous RNA	ONCOGENE			English	Article							NATURAL-KILLER-CELLS; HUMAN NKG2D; TUMOR; LIGANDS; CANCER; CYTOTOXICITY; RECEPTOR; EXPRESSION; MICB; IMMUNOBIOLOGY	Cancer immune surveillance is an important host protection process that inhibits carcinogenesis and maintains cellular homeostasis. The major histocompatibility complex class I-related molecules A and B (MICA and MICB) are NKG2D ligands that play important roles in tumor immune surveillance. In the present study, by a combined bioinformatics prediction and experimental approach, we identify BCL11B 3 '-UTR as a putative MICA and MICB ceRNA. We demonstrate in several human cell lines of different origins that the knockdown of BCL11B downregulates surface expression of MICA and MICB. Furthermore, we demonstrate miRNA dependency of BCL11B-mediated MICA and MICB regulation in Dicer knockdown HCT116 cells. In addition, MICA/B-targeting miRNAs (miR-17, miR-93, miR-20a, miR-20b, miR-106a, and miR-106b) repressed the expression of BCL11B by targeting its 3 '-UTR. Moreover, we showed that the BCL11B knockdown-mediated downregulation of MICA/B resulted in reduced NK cell elimination in vitro and in vivo through reduced recognition of NKG2D. Of particular significance, BCL11B displays tumor-suppressive properties. The expression of BCL11B is downregulated in colon cancer tissues and associated with a reduced median survival of colon cancer patients. Taken together, our study revealed a new mechanism of BCL11B that prevents immune evasion of cancerous cells by upregulation of the NKG2D ligands MICA and MICB in a ceRNA manner.	[Qian, Mengyao; Geng, Jingwen; Luo, Kaili; Huang, Zheng; Zhang, Qinkai; Ji, Liying; Wu, Jianmin] Wenzhou Med Univ, Inst Genom Med, Wenzhou 325000, Zhejiang, Peoples R China; [Zhang, Jian-an] Wenzhou Med Univ, Dept Obstet & Gynecol, Affiliated Hosp 2, Wenzhou 325027, Zhejiang, Peoples R China; [Zhang, Jian-an] Wenzhou Med Univ, Yuying Children, Wenzhou 325027, Zhejiang, Peoples R China	Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical University	Wu, JM (corresponding author), Wenzhou Med Univ, Inst Genom Med, Wenzhou 325000, Zhejiang, Peoples R China.	Jianminwu81@hotmail.com		Zhang, Qinkai/0000-0002-3709-2362; Wu, Jianmin/0000-0002-8223-1667	National Natural Sciences Foundation of China [NSFC-81472651, 81201589]	National Natural Sciences Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by National Natural Sciences Foundation of China (grant NSFC-81472651, 81201589).	Abel AM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01869; Aragon-Sanabria V, 2018, ADV EXP MED BIOL, V1092, P113, DOI 10.1007/978-3-319-95294-9_7; Arnon TI, 2006, SEMIN CANCER BIOL, V16, P348, DOI 10.1016/j.semcancer.2006.07.005; Breunig C, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.364; Bugide S, 2018, P NATL ACAD SCI USA, V115, pE3509, DOI 10.1073/pnas.1802691115; Cai S, 2017, CELL STEM CELL, V20, P247, DOI 10.1016/j.stem.2016.11.007; Cerwenka A, 2018, SCIENCE, V359, P1460, DOI 10.1126/science.aat2184; Chitadze G, 2013, SCAND J IMMUNOL, V78, P120, DOI 10.1111/sji.12072; Chitadze G, 2013, INT J CANCER, V133, P1557, DOI 10.1002/ijc.28174; Connell C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032442; de Andrade LF, 2018, SCIENCE, V359, P1537, DOI 10.1126/science.aao0505; Dhar P, 2018, CURR OPIN IMMUNOL, V51, P55, DOI 10.1016/j.coi.2018.02.004; Eichmuller SB, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx034; El-Gazzar A, 2013, J IMMUNOL, V191, P1509, DOI 10.4049/jimmunol.1301071; Fernandez-Messina L, 2010, J BIOL CHEM, V285, P8543, DOI 10.1074/jbc.M109.045906; Fu WJ, 2017, J INVEST DERMATOL, V137, P1523, DOI 10.1016/j.jid.2017.02.980; Gasser S, 2005, NATURE, V436, P1186, DOI 10.1038/nature03884; Gonzalez S, 2006, CURR TOP MICROBIOL, V298, P121; Guerra N, 2008, IMMUNITY, V28, P571, DOI 10.1016/j.immuni.2008.02.016; Halfteck GG, 2009, J IMMUNOL, V182, P2221, DOI 10.4049/jimmunol.0801878; Kaiser BK, 2007, NATURE, V447, P482, DOI 10.1038/nature05768; Kato N, 2007, LEUKEMIA, V21, P2103, DOI 10.1038/sj.leu.2404862; Kloess S, 2010, EUR J IMMUNOL, V40, P3255, DOI 10.1002/eji.201040568; Koch J, 2013, TRENDS IMMUNOL, V34, P182, DOI 10.1016/j.it.2013.01.003; Kumar MS, 2014, NATURE, V505, P212, DOI 10.1038/nature12785; Kumar S, 2018, IMMUNOLOGY, V154, P383, DOI 10.1111/imm.12921; Lanier LL, 2008, NAT IMMUNOL, V9, P495, DOI 10.1038/ni1581; Lennon MJ, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00089; Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248; Lopez-Soto A, 2009, ONCOGENE, V28, P2370, DOI 10.1038/onc.2009.117; Lopez-Soto A, 2015, INT J CANCER, V136, P1741, DOI 10.1002/ijc.28775; Lopez-Soto A, 2013, J IMMUNOL, V190, P4408, DOI 10.4049/jimmunol.1202950; Lowry LE, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01061; Min-Oo G, 2013, TRENDS IMMUNOL, V34, P251, DOI 10.1016/j.it.2013.02.005; Nachmani D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5186; Nishiguchi Y, 2016, DEV BIOL, V416, P98, DOI 10.1016/j.ydbio.2016.06.001; Punwani D, 2016, NEW ENGL J MED, V375, P2165, DOI 10.1056/NEJMoa1509164; Raulet DH, 2013, ANNU REV IMMUNOL, V31, P413, DOI 10.1146/annurev-immunol-032712-095951; Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246; Sakamaki A, 2015, CARCINOGENESIS, V36, P622, DOI 10.1093/carcin/bgv044; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Schmiedel D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02040; Schmiedel D, 2016, ELIFE, V5, DOI 10.7554/eLife.13426; Seidel E, 2012, CELL MOL LIFE SCI, V69, P3911, DOI 10.1007/s00018-012-1001-x; Shen JY, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.158; Simon R, 2016, GENES BRAIN BEHAV, V15, P405, DOI 10.1111/gbb.12287; Smyth MJ, 2005, J EXP MED, V202, P583, DOI 10.1084/jem.20050994; Stern-Ginossar N, 2008, NAT IMMUNOL, V9, P1065, DOI 10.1038/ni.1642; Sumazin P, 2011, CELL, V147, P370, DOI 10.1016/j.cell.2011.09.041; Tam YK, 1999, HUM GENE THER, V10, P1359, DOI 10.1089/10430349950018030; Tay Y, 2014, CELL RES, V24, P259, DOI 10.1038/cr.2014.21; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; Tay Y, 2011, CELL, V147, P344, DOI 10.1016/j.cell.2011.09.029; Toledano T, 2018, J IMMUNOL, V200, P2819, DOI 10.4049/jimmunol.1700968; Tsukerman P, 2012, CANCER RES, V72, P5463, DOI 10.1158/0008-5472.CAN-11-2671; Vesely MD, 2013, ANN NY ACAD SCI, V1284, P1, DOI 10.1111/nyas.12105; Vyas M, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1339854; Wu JM, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.289; Wu JM, 2014, CARCINOGENESIS, V35, P155, DOI 10.1093/carcin/bgt268	59	4	4	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	7					1514	1526		10.1038/s41388-019-1083-0	http://dx.doi.org/10.1038/s41388-019-1083-0			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KL2WP	31673069				2022-12-28	WOS:000513289600009
J	Li, T; Forbes, ME; Fuller, GN; Li, JB; Yang, XJ; Zhang, W				Li, Tao; Forbes, M. Elizabeth; Fuller, Gregory N.; Li, Jiabo; Yang, Xuejun; Zhang, Wei			IGFBP2: integrative hub of developmental and oncogenic signaling network	ONCOGENE			English	Review							GROWTH-FACTOR-BINDING; NF-KAPPA-B; NEUROBLASTOMA-CELL PROLIFERATION; DISTINCT EXPRESSION PATTERNS; ACUTE LYMPHOBLASTIC-LEUKEMIA; EX-VIVO EXPANSION; PROSTATE-CANCER; GENE-EXPRESSION; FACTOR-II; PROTEIN-2 IGFBP-2	Insulin-like growth factor (IGF) binding protein 2 (IGFBP2) was discovered and identified as an IGF system regulator, controlling the distribution, function, and activity of IGFs in the pericellular space. IGFBP2 is a developmentally regulated gene that is highly expressed in embryonic and fetal tissues and markedly decreases after birth. Studies over the last decades have shown that in solid tumors, IGFBP2 is upregulated and promotes several key oncogenic processes, such as epithelial-to-mesenchymal transition, cellular migration, invasion, angiogenesis, stemness, transcriptional activation, and epigenetic programming via signaling that is often independent of IGFs. Growing evidence indicates that aberrant expression of IGFBP2 in cancer acts as a hub of an oncogenic network, integrating multiple cancer signaling pathways and serving as a potential therapeutic target for cancer treatment.	[Li, Tao; Forbes, M. Elizabeth; Zhang, Wei] Wake Forest Sch Med, Dept Canc Biol, Winston Salem, NC 27101 USA; [Li, Tao; Li, Jiabo; Yang, Xuejun] Tianjin Med Univ, Gen Hosp, Tianjin, Peoples R China; [Li, Tao; Li, Jiabo; Yang, Xuejun] Tianjin Neurol Inst, Lab Neurooncol, Tianjin, Peoples R China; [Fuller, Gregory N.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	Wake Forest University; Tianjin Medical University; University of Texas System; UTMD Anderson Cancer Center	Zhang, W (corresponding author), Wake Forest Sch Med, Dept Canc Biol, Winston Salem, NC 27101 USA.; Yang, XJ (corresponding author), Tianjin Med Univ, Gen Hosp, Tianjin, Peoples R China.; Yang, XJ (corresponding author), Tianjin Neurol Inst, Lab Neurooncol, Tianjin, Peoples R China.	ydenny@126.com; wezhang@wakehealth.edu		Forbes, Elizabeth/0000-0003-3300-5476; Li, Jiabo/0000-0002-9288-9673	NCI Cancer Center Support Grant [P30CA012197]; Hanes and Willis Professorship in Cancer; National Foundation for Cancer Research; National Natural Science Foundation of China [81872063]	NCI Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Hanes and Willis Professorship in Cancer; National Foundation for Cancer Research; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We would like to thank all of the investigators who have contributed to the study of IGFBP2 in cancer that inspired this review article. This work was supported in part by the NCI Cancer Center Support Grant to the Comprehensive Cancer Center of Wake Forest University Health Sciences (P30CA012197). WZ is supported by the Hanes and Willis Professorship in Cancer and a Fellowship from the National Foundation for Cancer Research. XY and TL are supported by the National Natural Science Foundation of China (No. 81872063).	ADASHI EY, 1993, ANN NY ACAD SCI, V687, P10; AKMAL SN, 1995, HUM PATHOL, V26, P846, DOI 10.1016/0046-8177(95)90005-5; Allander SV, 2002, AM J PATHOL, V161, P1587, DOI 10.1016/S0002-9440(10)64437-9; Arai T, 1996, ENDOCRINOLOGY, V137, P4571, DOI 10.1210/en.137.11.4571; Arguelles B, 2000, J CLIN ENDOCR METAB, V85, P4087, DOI 10.1210/jc.85.11.4087; Azar WJ, 2014, ONCOGENE, V33, P578, DOI 10.1038/onc.2012.630; Azar WJ, 2011, ENDOCRINOLOGY, V152, P3332, DOI 10.1210/en.2011-1121; Bach LA, 2005, TRENDS ENDOCRIN MET, V16, P228, DOI 10.1016/j.tem.2005.05.005; Baron-Hay S, 2004, CLIN CANCER RES, V10, P1796, DOI 10.1158/1078-0432.CCR-0672-2; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Ben-Shmuel A, 2013, ONCOGENE, V32, P3220, DOI 10.1038/onc.2012.340; Biernacka KM, 2013, ENDOCR-RELAT CANCER, V20, P741, DOI 10.1530/ERC-13-0077; BINKERT C, 1989, EMBO J, V8, P2497, DOI 10.1002/j.1460-2075.1989.tb08386.x; Blank U, 2008, BLOOD, V111, P492, DOI 10.1182/blood-2007-07-075168; Boulle N, 1998, J CLIN ENDOCR METAB, V83, P1713, DOI 10.1210/jc.83.5.1713; Boulle N, 2001, EUR J ENDOCRINOL, V144, P29, DOI 10.1530/eje.0.1440029; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Bubendorf L, 1999, J NATL CANCER I, V91, P1758, DOI 10.1093/jnci/91.20.1758; Bunn RC, 2003, TRENDS ENDOCRIN MET, V14, P176, DOI 10.1016/S1043-2760(03)00049-3; Busund LT, 2005, J CLIN PATHOL, V58, P361, DOI 10.1136/jcp.2004.020834; Cai JQ, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1426516; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Carrick FE, 2005, J MOL ENDOCRINOL, V34, P685, DOI 10.1677/jme.1.01756; Carrick FE, 2001, J BIOL CHEM, V276, P27120, DOI 10.1074/jbc.M101317200; Cecil DL, 2014, CANCER RES, V74, P2710, DOI 10.1158/0008-5472.CAN-13-3286; Chen R, 2007, MOL CELL PROTEOMICS, V6, P1331, DOI 10.1074/mcp.M700072-MCP200; Chen R, 2006, PROTEOMICS, V6, P3871, DOI 10.1002/pmic.200500702; Chesik D, 2004, NEUROSCI LETT, V362, P14, DOI 10.1016/j.neulet.2004.01.039; Chua CY, 2016, ONCOGENE, V35, P738, DOI 10.1038/onc.2015.131; COHEN P, 1993, J CLIN ENDOCR METAB, V76, P1031, DOI 10.1210/jc.76.4.1031; Colman H, 2010, NEURO-ONCOLOGY, V12, P49, DOI 10.1093/neuonc/nop007; Coverley JA, 1997, MOL CELL ENDOCRINOL, V128, P1, DOI 10.1016/S0303-7207(97)04032-X; Crofton PM, 2000, PEDIATR RES, V48, P490, DOI 10.1203/00006450-200010000-00012; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; Das SK, 2013, CANCER RES, V73, P844, DOI 10.1158/0008-5472.CAN-12-1681; Dawczynski K, 2003, BONE MARROW TRANSPL, V32, P411, DOI 10.1038/sj.bmt.1704149; Dawczynski K, 2008, PEDIATR BLOOD CANCER, V50, P24, DOI 10.1002/pbc.21294; Dean SJR, 2014, AM J CLIN PATHOL, V141, P323, DOI 10.1309/AJCPR11DEAYPTUSL; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Dunlap SM, 2007, P NATL ACAD SCI USA, V104, P11736, DOI 10.1073/pnas.0703145104; ELATIQ F, 1994, INT J CANCER, V57, P491, DOI 10.1002/ijc.2910570409; Elmlinger MW, 2001, ENDOCRINOLOGY, V142, P1652, DOI 10.1210/en.142.4.1652; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Flyvbjerg A, 1997, J CLIN ENDOCR METAB, V82, P2308, DOI 10.1210/jc.82.7.2308; Forbes BE, 1998, J BIOL CHEM, V273, P4647, DOI 10.1074/jbc.273.8.4647; Fottner C, 2008, EUR J ENDOCRINOL, V159, P317, DOI 10.1530/EJE-08-0033; Foulstone EJ, 2013, ENDOCRINOLOGY, V154, P1780, DOI 10.1210/en.2012-1970; Frommer KW, 2006, J MOL ENDOCRINOL, V37, P13, DOI 10.1677/jme.1.01955; Fuller GN, 1999, CANCER RES, V59, P4228; Galea CA, 2012, BIOCHIMIE, V94, P608, DOI 10.1016/j.biochi.2011.09.012; Perez-Larraya JG, 2014, CANCER-AM CANCER SOC, V120, P3972, DOI 10.1002/cncr.28949; Gao S, 2016, CANCER RES, V76, P6543, DOI 10.1158/0008-5472.CAN-16-0438; Godard S, 2003, CANCER RES, V63, P6613; GREEN BN, 1994, ENDOCRINOLOGY, V134, P954, DOI 10.1210/en.134.2.954; Guo CC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074973; Han S, 2014, BRIT J CANCER, V111, P1400, DOI 10.1038/bjc.2014.435; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Higgins RJ, 2010, J NEURO-ONCOL, V98, P49, DOI 10.1007/s11060-009-0072-5; Ho PJ, 1997, ENDOCRINOLOGY, V138, P3811, DOI 10.1210/en.138.9.3811; Hobba GD, 1998, J BIOL CHEM, V273, P19691, DOI 10.1074/jbc.273.31.19691; Hoeflich A, 2000, CANCER RES, V60, P834; Hoeflich A, 2004, BIOCHEM BIOPH RES CO, V324, P705, DOI 10.1016/j.bbrc.2004.09.111; Holland EC, 2000, AM J PATHOL, V157, P1031, DOI 10.1016/S0002-9440(10)64615-9; Holmes KM, 2012, P NATL ACAD SCI USA, V109, P3475, DOI 10.1073/pnas.1120375109; Hsieh D, 2010, BIOCHEM BIOPH RES CO, V397, P367, DOI 10.1016/j.bbrc.2010.05.145; Huynh HD, 2008, STEM CELLS, V26, P1628, DOI 10.1634/stemcells.2008-0064; Huynh H, 2011, BLOOD, V118, P3236, DOI 10.1182/blood-2011-01-331876; Hwa V, 1999, ENDOCR REV, V20, P761, DOI 10.1210/er.20.6.761; JAQUES G, 1992, EUR J CANCER, V28A, P1899, DOI 10.1016/0959-8049(92)90032-W; JONES JI, 1993, P NATL ACAD SCI USA, V90, P10553, DOI 10.1073/pnas.90.22.10553; Kanety H, 1996, BRIT J CANCER, V73, P1069, DOI 10.1038/bjc.1996.206; KANETY H, 1993, J CLIN ENDOCR METAB, V77, P229, DOI 10.1210/jc.77.1.229; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kendrick ZW, 2014, HPB, V16, P670, DOI 10.1111/hpb.12199; Kim YW, 2013, INT J ONCOL, V43, P539, DOI 10.3892/ijo.2013.1961; Kuang ZH, 2006, J MOL BIOL, V364, P690, DOI 10.1016/j.jmb.2006.09.006; Kuhnl A, 2011, LEUKEMIA RES, V35, P1585, DOI 10.1016/j.leukres.2011.08.006; Ladd JJ, 2012, CANCER PREV RES, V5, P655, DOI 10.1158/1940-6207.CAPR-11-0412; Laffaire J, 2011, NEURO-ONCOLOGY, V13, P84, DOI 10.1093/neuonc/noq110; Lamalice L, 2007, CIRC RES, V100, P782, DOI 10.1161/01.RES.0000259593.07661.1e; Lancaster JM, 2004, J SOC GYNECOL INVEST, V11, P51, DOI 10.1016/j.jsgi.2003.07.004; Lee CF, 2008, WORLD J GASTROENTERO, V14, P6072, DOI 10.3748/wjg.14.6072; Lee DY, 1999, J KOREAN MED SCI, V14, P401, DOI 10.3346/jkms.1999.14.4.401; Lee EJ, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-7; LEE WH, 1993, NEUROSCIENCE, V53, P251, DOI 10.1016/0306-4522(93)90303-W; Levitt RJ, 2005, BIOCHEM BIOPH RES CO, V336, P1056, DOI 10.1016/j.bbrc.2005.08.229; Li X, 2015, ONCOGENE, V34, P1619, DOI 10.1038/onc.2014.98; Lin Y, 2009, NEURO-ONCOLOGY, V11, P468, DOI 10.1215/15228517-2008-114; Liou JM, 2010, J CLIN ENDOCR METAB, V95, P1717, DOI 10.1210/jc.2009-2668; Liu Y, 2019, ONCOGENE, V38, P1815, DOI 10.1038/s41388-018-0525-4; Lu HB, 2013, MOL CANCER THER, V12, P2864, DOI 10.1158/1535-7163.MCT-13-0233; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Marucci G, 2008, VIRCHOWS ARCH, V453, P599, DOI 10.1007/s00428-008-0685-7; Matuschek C, 2011, EUR J MED RES, V16, P451; McDonald KL, 2007, J NEUROPATH EXP NEUR, V66, P405, DOI 10.1097/nen.0b013e31804567d7; Mehrian-Shai R, 2007, P NATL ACAD SCI USA, V104, P5563, DOI 10.1073/pnas.0609139104; Menouny M, 1997, ENDOCRINOLOGY, V138, P683, DOI 10.1210/en.138.2.683; Migita T, 2010, AM J PATHOL, V176, P1756, DOI 10.2353/ajpath.2010.090500; Miyake H, 2005, ONCOL REP, V13, P341; Miyake H, 2000, CANCER RES, V60, P3058; Moore MG, 2003, INT J CANCER, V105, P14, DOI 10.1002/ijc.11015; Moorehead RA, 2003, J BIOL CHEM, V278, P50422, DOI 10.1074/jbc.M306894200; MULLER HL, 1994, J CLIN ENDOCR METAB, V79, P428, DOI 10.1210/jc.79.2.428; Myers AL, 2015, ONCOTARGET, V6, P25897, DOI 10.18632/oncotarget.4532; Nakano H, 2010, INT J CANCER, V127, P1072, DOI 10.1002/ijc.25143; Neuhouser ML, 2013, CANCER PREV RES, V6, P91, DOI 10.1158/1940-6207.CAPR-12-0250; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; OLNEY RC, 1995, MOL CELL ENDOCRINOL, V110, P213, DOI 10.1016/0303-7207(95)03536-G; Park KH, 2008, CANCER RES, V68, P8400, DOI 10.1158/0008-5472.CAN-07-5891; Patil SS, 2016, NEURO-ONCOLOGY, V18, P1487, DOI 10.1093/neuonc/now053; Patil SS, 2015, J NEURO-ONCOL, V123, P225, DOI 10.1007/s11060-015-1800-7; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Pereira JJ, 2004, CANCER RES, V64, P977, DOI 10.1158/0008-5472.CAN-03-3056; Perks CM, 2007, ONCOGENE, V26, P5966, DOI 10.1038/sj.onc.1210397; Phillips LM, 2016, J PATHOL, V239, P355, DOI 10.1002/path.4734; PINTAR JE, 1991, ADV EXP MED BIOL, V293, P325; Planque C, 2009, MOL CELL PROTEOMICS, V8, P2746, DOI 10.1074/mcp.M900134-MCP200; Png KJ, 2012, NATURE, V481, P190, DOI 10.1038/nature10661; Probst-Hensch NM, 2010, CLIN CANCER RES, V16, P1025, DOI 10.1158/1078-0432.CCR-09-0957; Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976; Quail DF, 2017, CANCER CELL, V31, P326, DOI 10.1016/j.ccell.2017.02.009; Ranke MB, 2003, HORM RES, V60, P174, DOI 10.1159/000073229; Renehan AG, 2000, J CLIN ENDOCR METAB, V85, P3402, DOI 10.1210/jc.85.9.3402; Renehan AG, 2000, BRIT J CANCER, V83, P1344, DOI 10.1054/bjoc.2000.1462; Rickman DS, 2001, CANCER RES, V61, P6885; Rorive S, 2008, GLIA, V56, P1679, DOI 10.1002/glia.20719; Rosenbluh J, 2012, CELL, V151, P1457, DOI 10.1016/j.cell.2012.11.026; Russo VC, 2015, CYTOKINE GROWTH F R, V26, P329, DOI 10.1016/j.cytogfr.2014.12.001; Russo VC, 1999, ENDOCRINOLOGY, V140, P3082, DOI 10.1210/en.140.7.3082; Russo VC, 1997, ENDOCRINOLOGY, V138, P4858, DOI 10.1210/en.138.11.4858; Russo VC, 2005, ENDOCRINOLOGY, V146, P4445, DOI 10.1210/en.2005-0467; Santarius T, 2010, NAT REV CANCER, V10, P59, DOI 10.1038/nrc2771; Schutt BS, 2004, J MOL ENDOCRINOL, V32, P859, DOI 10.1677/jme.0.0320859; Scrideli CA, 2007, J NEURO-ONCOL, V83, P233, DOI 10.1007/s11060-007-9328-0; Sehgal P, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-63; Shariat SF, 2002, J CLIN ONCOL, V20, P833, DOI 10.1200/JCO.20.3.833; Shen XC, 2012, MOL CELL BIOL, V32, P4116, DOI 10.1128/MCB.01011-12; Shi LH, 2006, WORLD J GASTROENTERO, V12, P6285, DOI 10.3748/wjg.v12.i39.6285; So AI, 2008, CLIN CANCER RES, V14, P6944, DOI 10.1158/1078-0432.CCR-08-0408; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Song SW, 2003, P NATL ACAD SCI USA, V100, P13970, DOI 10.1073/pnas.2332186100; STRECK RD, 1992, ENDOCRINOLOGY, V131, P2030, DOI 10.1210/en.131.4.2030; Tombolan L, 2011, AM J PATHOL, V179, P2611, DOI 10.1016/j.ajpath.2011.07.018; Uzoh CC, 2011, BRIT J CANCER, V104, P1587, DOI 10.1038/bjc.2011.127; van Kleffens M, 1998, MOL CELL ENDOCRINOL, V140, P129, DOI 10.1016/S0303-7207(98)00041-0; Villani RM, 2010, CANCER PREV RES, V3, P1222, DOI 10.1158/1940-6207.CAPR-10-0082; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Vorwerk P, 2005, J CLIN ENDOCR METAB, V90, P3022, DOI 10.1210/jc.2004-0461; Wang HM, 2003, J CUTAN PATHOL, V30, P599, DOI 10.1034/j.1600-0560.2003.00120.x; Wang HM, 2002, BRAIN PATHOL, V12, P95; Wang HM, 2008, BREAST J, V14, P261, DOI 10.1111/j.1524-4741.2008.00572.x; Wang HM, 2006, MODERN PATHOL, V19, P1149, DOI 10.1038/modpathol.3800637; WANG JF, 1988, BIOCHEM BIOPH RES CO, V157, P718, DOI 10.1016/S0006-291X(88)80309-7; WOOD TL, 1992, DEVELOPMENT, V114, P59; Yao XF, 2018, CANCER LETT, V432, P38, DOI 10.1016/j.canlet.2018.06.008; Yi HK, 2001, EUR J CANCER, V37, P2257, DOI 10.1016/S0959-8049(01)00269-6; Yoneyama T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161009; Yu CJ, 2011, J PROTEOME RES, V10, P4671, DOI 10.1021/pr2004743; Zhai HY, 2011, GLIA, V59, P472, DOI 10.1002/glia.21117; Zhang CC, 2008, BLOOD, V111, P3415, DOI 10.1182/blood-2007-11-122119; Zhang LH, 2007, DIGEST DIS SCI, V52, P248, DOI 10.1007/s10620-006-9358-z; Zhang Y, 2013, INT J ONCOL, V42, P93, DOI 10.3892/ijo.2012.1699; Zhao Y, 2017, CANCER LETT, V408, P102, DOI 10.1016/j.canlet.2017.08.027; Zheng SC, 2011, NEURO-ONCOLOGY, V13, P280, DOI 10.1093/neuonc/noq190; Zhou Q, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046851; ZUMKELLER W, 1993, EUR J CANCER, V29A, P1973, DOI 10.1016/0959-8049(93)90455-O	170	33	34	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	11					2243	2257		10.1038/s41388-020-1154-2	http://dx.doi.org/10.1038/s41388-020-1154-2		JAN 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KU0ZS	31925333	Green Accepted			2022-12-28	WOS:000508151400002
J	Dubrez, L; Causse, S; Bonan, NB; Dumetier, B; Garrido, C				Dubrez, Laurence; Causse, Sebastien; Bonan, Natalia Borges; Dumetier, Baptiste; Garrido, Carmen			Heat-shock proteins: chaperoning DNA repair	ONCOGENE			English	Review							BASE EXCISION-REPAIR; HEAT-SHOCK-PROTEIN-70 HSP70 INHIBITOR; SMALL-MOLECULE INHIBITOR; SENSITIZES CANCER-CELLS; STRAND-BREAK REPAIR; HSP90 INHIBITOR; COLORECTAL-CANCER; TUMOR-CELLS; HOMOLOGOUS RECOMBINATION; 90-ALPHA HSP90-ALPHA	Cells are repeatedly exposed to environmental or endogenous stresses that can alter normal cell behavior and increase cell vulnerability. In order to ensure tissue integrity and function, cells cope with cellular injuries by adapting their metabolism, protecting essential intracellular constituents, inhibiting cell death signaling pathways and activating those devoted to damage repair. The molecular chaperones of the heat-shock protein (HSP) family are critical effectors of this adaptive response. They protect intracellular proteins from misfolding or aggregation, inhibit cell death signaling cascades and preserve the intracellular signaling pathways that are essential for cell survival. Most HSPs are rapidly overexpressed in response to cellular injuries including genotoxic stress. DNA damage can dramatically alter cell behavior and contribute to a number of diseases including developmental defects, neurodegenerative disorders, and cancer. Thus, the ability of cells to repair DNA damage is essential for preserving cell integrity. DNA damage activates a coordinated response that includes detecting DNA lesions before their transmission to daughter cells, blocking cell cycle progression and DNA replication and repairing the damage. Although the role of HSPs in proteins homeostasis and cell death, especially apoptosis has been widely reported, much less is known about their function in DNA repair. This review aims to present the role of HSPs in DNA repair signaling pathways.	[Dubrez, Laurence; Causse, Sebastien; Bonan, Natalia Borges; Dumetier, Baptiste; Garrido, Carmen] INSERM UMR 1231, Equipe Labellisee, Ligue Natl Canc, Dijon, France; [Dubrez, Laurence; Causse, Sebastien; Bonan, Natalia Borges; Dumetier, Baptiste; Garrido, Carmen] Lab Excellence LipSTIC, Dijon, France; [Dubrez, Laurence; Causse, Sebastien; Bonan, Natalia Borges; Dumetier, Baptiste; Garrido, Carmen] Univ Bourgogne Franche Comte, Dijon, France; [Garrido, Carmen] Anticanc Ctr Georges Francois Leclerc Unicancer, Dijon, France	Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne	Dubrez, L; Garrido, C (corresponding author), INSERM UMR 1231, Equipe Labellisee, Ligue Natl Canc, Dijon, France.; Dubrez, L; Garrido, C (corresponding author), Lab Excellence LipSTIC, Dijon, France.; Dubrez, L; Garrido, C (corresponding author), Univ Bourgogne Franche Comte, Dijon, France.; Garrido, C (corresponding author), Anticanc Ctr Georges Francois Leclerc Unicancer, Dijon, France.	ldubrez@u-bourgogne.fr; cgarrido@u-bourgogne.fr	Laurence, Dubrez/P-9472-2019; Causse, Sebastien Zwe/AAZ-7365-2021; Garrido, Carmen/G-1633-2018	Laurence, Dubrez/0000-0002-7030-2181; DUMETIER, Baptiste/0000-0001-9087-2344; Garrido, Carmen/0000-0003-1368-1493; Causse, Sebastien/0000-0003-3246-3491	Institut National du Cancer; Ligue Nationale Contre le Cancer; Conseil Regional de Bourgogne; French Government [ANR-11-LABX-0021, ANR-15-IDEX-0003]	Institut National du Cancer(Institut National du Cancer (INCA) France); Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Conseil Regional de Bourgogne(Region Bourgogne-Franche-Comte); French Government	Our work was supported by grants from the Institut National du Cancer, Ligue Nationale Contre le Cancer, the Conseil Regional de Bourgogne, a French Government grants managed by the French National Research Agency under the program"Investissements d'Avenir" with reference ANR-11-LABX-0021 (LabEX LipSTIC) and ANR-15-IDEX-0003 (I-SITE-UBFC). We thank the "Fondation de France" (SC) and the European Union program FEDER.	ABE T, 1995, BIOCHEM BIOPH RES CO, V206, P548, DOI 10.1006/bbrc.1995.1078; Abu-Farha M, 2008, MOL CELL PROTEOMICS, V7, P560, DOI 10.1074/mcp.M700271-MCP200; Arlander SJH, 2006, J BIOL CHEM, V281, P2989, DOI 10.1074/jbc.M508687200; Arlander SJH, 2003, J BIOL CHEM, V278, P52572, DOI 10.1074/jbc.M309054200; Arrigo AP, 2017, CELL STRESS CHAPERON, V22, P517, DOI 10.1007/s12192-017-0765-1; Baretti M, 2018, PHARMACOL THERAPEUT, V189, P45, DOI 10.1016/j.pharmthera.2018.04.004; Bases R, 2006, CELL STRESS CHAPERON, V11, P240, DOI 10.1379/CSC-185R.1; Blackford AN, 2017, MOL CELL, V66, P801, DOI 10.1016/j.molcel.2017.05.015; Boudesco C, 2018, BLOOD, V132, P510, DOI 10.1182/blood-2017-12-819706; Bracher A, 2015, FRONT MOL BIOSCI, V2, DOI 10.3389/fmolb.2015.00010; Brown MA, 2015, ONCOTARGET, V6, P4005, DOI 10.18632/oncotarget.2970; Calderwood SK, 2006, TRENDS BIOCHEM SCI, V31, P164, DOI 10.1016/j.tibs.2006.01.006; Calderwood SK, 2019, CELL STRESS CHAPERON, V24, P1, DOI 10.1007/s12192-018-00966-w; Calini V, 2003, TOXICOL IN VITRO, V17, P561, DOI 10.1016/S0887-2333(03)00116-4; Campos EI, 2010, NAT STRUCT MOL BIOL, V17, P1343, DOI 10.1038/nsmb.1911; Causse SZ, 2019, ONCOGENE, V38, P2767, DOI 10.1038/s41388-018-0616-2; Chatterjee S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091978; Cheng AN, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17126-2; Cho W, 2019, MOL CELL BIOL, V39, DOI 10.1128/MCB.00391-18; Choi EJ, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-17; Clerico EM, 2019, BIOCHEM J, V476, P1653, DOI 10.1042/BCJ20170380; Coban N, 2019, EXCLI J, V18, P195, DOI 10.17179/excli2018-1807; Collura A, 2014, GASTROENTEROLOGY, V146, P401, DOI 10.1053/j.gastro.2013.10.054; Condelli V, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8060532; Dahiya V, 2019, ADV PROTEIN CHEM STR, V114, P1, DOI 10.1016/bs.apcsb.2018.10.001; de Toda IM, 2015, BIOGERONTOLOGY, V16, P709, DOI 10.1007/s10522-015-9607-7; Dicks N, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00011; Dorard C, 2011, NAT MED, V17, P1283, DOI 10.1038/nm.2457; Dote H, 2006, CANCER RES, V66, P9211, DOI 10.1158/0008-5472.CAN-06-2181; Duan YY, 2014, CELL STRESS CHAPERON, V19, P271, DOI 10.1007/s12192-013-0454-7; Dungey FA, 2009, MOL CANCER THER, V8, P2243, DOI 10.1158/1535-7163.MCT-09-0201; Echtenkamp FJ, 2016, MOL CELL, V64, P888, DOI 10.1016/j.molcel.2016.09.040; Elaimy AL, 2016, ONCOTARGET, V7, P82450, DOI 10.18632/oncotarget.12557; Ernst A, 2015, CANCER LETT, V365, P211, DOI 10.1016/j.canlet.2015.05.024; Fang QR, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5503; Fewell SW, 2004, J BIOL CHEM, V279, P51131, DOI 10.1074/jbc.M404857200; Fu WM, 2014, CELL BIOL INT, V38, P272, DOI 10.1002/cbin.10193; Garrido C, 2012, M S-MED SCI, V28, P9, DOI 10.1051/medsci/2012281002; Gibert B, 2011, ONCOGENE, V30, P3672, DOI 10.1038/onc.2011.73; Goldfless SJ, 2006, MOL CELL, V21, P595, DOI 10.1016/j.molcel.2006.01.025; Gozzi G, 2019, CELL DEATH DIFFER; Gupta SD, 2019, EUR J MED CHEM, V178, P48, DOI 10.1016/j.ejmech.2019.05.073; Guttmann DM, 2013, INT J RADIAT ONCOL, V87, P168, DOI 10.1016/j.ijrobp.2013.05.028; Gvozdenov Z, 2019, COLD SPRING HARB PER; Ha K, 2011, MOL CANCER THER, V10, P1194, DOI 10.1158/1535-7163.MCT-11-0094; Heidinger-Pauli JM, 2008, MOL CELL, V31, P47, DOI 10.1016/j.molcel.2008.06.005; Heinrich JC, 2011, J CANCER RES CLIN, V137, P1349, DOI 10.1007/s00432-011-1005-1; Her J, 2018, J BIOL CHEM, V293, P10502, DOI 10.1074/jbc.TM118.000371; Huang KH, 2009, J MED CHEM, V52, P4288, DOI 10.1021/jm900230j; Huang QR, 2017, BLOOD, V129, P2737, DOI 10.1182/blood-2016-08-735886; Hunt CR, 2004, MOL CELL BIOL, V24, P899, DOI 10.1128/MCB.24.2.899-911.2004; Imahori T, 2017, NEUROSCIENCE, V349, P1, DOI 10.1016/j.neuroscience.2017.02.036; Isaacs JS, 2016, ADV CANCER RES, V129, P107, DOI 10.1016/bs.acr.2015.09.003; Jang WJ, 2014, CANCER SCI, V105, P1245, DOI 10.1111/cas.12497; Jego G, 2013, CANCER LETT, V332, P275, DOI 10.1016/j.canlet.2010.10.014; Jez JM, 2003, CHEM BIOL, V10, P361, DOI 10.1016/S1074-5521(03)00075-9; Jiricny J, 2006, NAT REV MOL CELL BIO, V7, P335, DOI 10.1038/nrm1907; Kai M, 2003, ONCOL REP, V10, P1777; Kasioulis I, 2014, MOL BIOL CELL, V25, P1216, DOI 10.1091/mbc.E13-08-0471; Katsogiannou M, 2014, MOL CELL PROTEOMICS, V13, P3585, DOI 10.1074/mcp.M114.041228; Kenny GP, 1997, EUR J APPL PHYSIOL O, V76, P109, DOI 10.1007/s004210050221; Kenny MK, 2001, J BIOL CHEM, V276, P9532, DOI 10.1074/jbc.M009297200; Khuran N, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00225-18; Kim SH, 2012, J MED CHEM, V55, P7480, DOI 10.1021/jm3004619; Kim W, 2019, NEUROCHEM INT, V129, DOI 10.1016/j.neuint.2019.104477; Kimura A, 2016, ONCOTARGET, V7, P18415, DOI 10.18632/oncotarget.7821; Ko JC, 2012, REGUL TOXICOL PHARM, V64, P415, DOI 10.1016/j.yrtph.2012.10.003; Koll TT, 2008, MOL CANCER THER, V7, P1985, DOI 10.1158/1535-7163.MCT-07-2104; Kotoglou P, 2009, CELL STRESS CHAPERON, V14, P391, DOI 10.1007/s12192-008-0093-6; Lee Y, 2016, RADIOTHER ONCOL, V121, P162, DOI 10.1016/j.radonc.2016.08.029; Leu JIJ, 2009, MOL CELL, V36, P15, DOI 10.1016/j.molcel.2009.09.023; Li Q, 2011, RADIAT RES, V176, P17, DOI 10.1667/RR2393.1; Li QQ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00143-6; Li XK, 2013, ACS MED CHEM LETT, V4, P1042, DOI 10.1021/ml400204n; Litwin I, 2018, GENES-BASEL, V9, DOI 10.3390/genes9120581; Liu YJ, 2019, CANCER RES, V79, P2923, DOI 10.1158/0008-5472.CAN-18-2540; Liu YH, 2016, ARCH BIOCHEM BIOPHYS, V594, P18, DOI 10.1016/j.abb.2016.02.018; Luengo TM, 2019, TRENDS CELL BIOL, V29, P164, DOI 10.1016/j.tcb.2018.10.004; Massey AJ, 2010, CANCER CHEMOTH PHARM, V66, P535, DOI 10.1007/s00280-009-1194-3; Mattoo RUH, 2013, J BIOL CHEM, V288, P21399, DOI 10.1074/jbc.M113.479253; Mendez F, 2003, CELL STRESS CHAPERON, V8, P153, DOI 10.1379/1466-1268(2003)008<0153:HSPSOT>2.0.CO;2; Mittelman D, 2010, CELL STRESS CHAPERON, V15, P753, DOI 10.1007/s12192-010-0191-0; Miyata Y, 2013, ACS CHEM NEUROSCI, V4, P930, DOI 10.1021/cn300210g; NADEAU K, 1994, BIOCHEMISTRY-US, V33, P2561, DOI 10.1021/bi00175a027; Nadin SB, 2007, CANCER LETT, V252, P131, DOI 10.1016/j.canlet.2006.12.028; Naim V, 2009, CELL CYCLE, V8, P2907, DOI 10.4161/cc.8.18.9538; Castro GN, 2015, CELL STRESS CHAPERON, V20, P253, DOI 10.1007/s12192-014-0537-0; Neckers L, 1999, INVEST NEW DRUG, V17, P361, DOI 10.1023/A:1006382320697; Noguchi M, 2006, BIOCHEM BIOPH RES CO, V351, P658, DOI 10.1016/j.bbrc.2006.10.094; Nomura M, 2005, BIOCHEM BIOPH RES CO, V335, P900, DOI 10.1016/j.bbrc.2005.07.160; Obermann WMJ, 2018, J BIOL CHEM, V293, P16479, DOI 10.1074/jbc.RA118.003578; Oda T, 2007, BLOOD, V109, P5016, DOI 10.1182/blood-2006-08-038638; Olotu F, 2018, EXPERT OPIN DRUG DIS, V13, P903, DOI 10.1080/17460441.2018.1516035; Pannunzio NR, 2018, J BIOL CHEM, V293, P10512, DOI 10.1074/jbc.TM117.000374; Park C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7823; Park KC, 2000, ARCH DERMATOL RES, V292, P482, DOI 10.1007/s004030000173; PETIT MA, 1994, J BIOL CHEM, V269, P23824; Quanz M, 2012, J BIOL CHEM, V287, P8803, DOI 10.1074/jbc.M111.320887; Rampelt H, 2012, EMBO J, V31, P4221, DOI 10.1038/emboj.2012.264; Rauch JN, 2014, J BIOL CHEM, V289, P1402, DOI 10.1074/jbc.M113.521997; Rerole AL, 2011, CANCER RES, V71, P484, DOI 10.1158/0008-5472.CAN-10-1443; Rocchi P, 2006, BJU INT, V98, P1082, DOI 10.1111/j.1464-410X.2006.06425.x; Rosenzweig R, 2019, NAT REV MOL CELL BIO; Rousaki A, 2011, J MOL BIOL, V411, P614, DOI 10.1016/j.jmb.2011.06.003; Sallmyr A, 2018, J BIOL CHEM, V293, P10536, DOI 10.1074/jbc.TM117.000375; Scaltriti M, 2011, MOL CANCER THER, V10, P817, DOI 10.1158/1535-7163.MCT-10-0966; Scharer OD, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a012609; Schmitt E, 2003, CANCER RES, V63, P8233; Schrank B, 2019, J CELL BIOL, V218, P2444, DOI 10.1083/jcb.201904202; Sekimoto T, 2010, MOL CELL, V37, P79, DOI 10.1016/j.molcel.2009.12.015; Soga S, 2003, CURR CANCER DRUG TAR, V3, P359, DOI 10.2174/1568009033481859; Solier S, 2012, P NATL ACAD SCI USA, V109, P12866, DOI 10.1073/pnas.1203617109; Sollars V, 2003, NAT GENET, V33, P70, DOI 10.1038/ng1067; Sottile ML, 2018, CELL STRESS CHAPERON, V23, P303, DOI 10.1007/s12192-017-0843-4; Sottile ML, 2015, INT J HYPERTHER, V31, P464, DOI 10.3109/02656736.2015.1026848; Stangl S, 2011, P NATL ACAD SCI USA, V108, P733, DOI 10.1073/pnas.1016065108; Stecklein SR, 2012, P NATL ACAD SCI USA, V109, P13650, DOI 10.1073/pnas.1203326109; Suhane T, 2015, EUKARYOT CELL, V14, P64, DOI 10.1128/EC.00159-14; Sydor JR, 2006, P NATL ACAD SCI USA, V103, P17408, DOI 10.1073/pnas.0608372103; Taherian A, 2008, BIOCHEM CELL BIOL, V86, P37, DOI [10.1139/O07-154, 10.1139/o07-154]; Thomas X, 2005, LEUKEMIA RES, V29, P1049, DOI 10.1016/j.leukres.2005.02.010; Wallace SS, 2014, DNA REPAIR, V19, P14, DOI 10.1016/j.dnarep.2014.03.030; Wang X, 2010, CANCER INVEST, V28, P635, DOI 10.3109/07357901003630983; Wang YS, 2010, CURR OPIN INVEST DR, V11, P1466; Wano C, 2004, EXP CELL RES, V298, P584, DOI 10.1016/j.yexcr.2004.04.048; Weatherbee JL, 2016, ONCOTARGET, V7, P43820, DOI 10.18632/oncotarget.9907; Whitaker AM, 2017, FRONT BIOSCI-LANDMRK, V22, P1493, DOI 10.2741/4555; Woodhead AJ, 2010, J MED CHEM, V53, P5956, DOI 10.1021/jm100060b; Wright WD, 2018, J BIOL CHEM, V293, P10524, DOI 10.1074/jbc.TM118.000372; Xu YM, 2013, CELL SIGNAL, V25, P1176, DOI 10.1016/j.cellsig.2013.01.017; Yamamori T, 2013, FEBS LETT, V587, P3348, DOI 10.1016/j.febslet.2013.08.030; Yamamoto Y, 2018, BRAIN RES, V1687, P82, DOI 10.1016/j.brainres.2018.03.001; Yamashita T, 2007, CELL CYCLE, V6, P2232, DOI 10.4161/cc.6.18.4653; Yang J, 2009, TOXICOLOGY, V265, P10, DOI 10.1016/j.tox.2009.09.001; Yang YH, 2019, CELL MOL LIFE SCI, V76, P381, DOI 10.1007/s00018-018-2957-y; Zabinsky RA, 2019, SEMIN CELL DEV BIOL, V88, P21, DOI 10.1016/j.semcdb.2018.05.015; Zaidi S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035436; Zemanovic S, 2018, CELL REP, V25, P2605, DOI 10.1016/j.celrep.2018.11.015; Zhou X, 2015, HUM MOL GENET, V24, P3982, DOI 10.1093/hmg/ddv136	139	50	52	4	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	3					516	529		10.1038/s41388-019-1016-y	http://dx.doi.org/10.1038/s41388-019-1016-y			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG1RJ	31541194				2022-12-28	WOS:000509718300003
J	Kwon, OJ; Zhang, L; Jia, DY; Zhou, ZC; Li, ZYH; Haffner, M; Lee, JK; True, L; Morrissey, C; Xin, L				Kwon, Oh-Joon; Zhang, Li; Jia, Deyong; Zhou, Zhicheng; Li, Zhouyihan; Haffner, Michael; Lee, John K.; True, Lawrence; Morrissey, Colm; Xin, Li			De novo induction of lineage plasticity from human prostate luminal epithelial cells by activated AKT1 and c-Myc	ONCOGENE			English	Article							NEUROENDOCRINE PHENOTYPE; PROGENITOR CELLS; CANCER; IDENTIFICATION; DIFFERENTIATION; ORIGIN; MOUSE; BASAL; RESISTANCE; MECHANISM	Neuroendocrine prostate cancer (NEPC) is an aggressive variant of prostate cancer that either develops de novo or arises from prostate adenocarcinoma as a result of treatment resistance. Although the prostate basal cells have been shown to directly generate tumor cells with neuroendocrine features when transduced with oncogenic signaling, the identity of the cell-of-origin for de novo NEPC remains unclear. We show that the TACSTD2(high)human prostate luminal epithelia cells highly express SOX2 and are relatively enriched in the transition zone prostate. Both TACSTD2(high)and TACSTD2(low)luminal cells transduced by constitutively activated AKT1 (caAKT1), and c-Myc can form organoids containing versatile clinically relevant tumor cell lineages with regard to the expression of AR and the neuroendocrine cell markers Synaptophysin and Chromogranin A. Tumor organoid cells derived from the TACSTD2(high)luminal cells are more predisposed to neuroendocrine differentiation along passaging and are relatively more castration-resistant. Knocking downTACSTD2andSOX2both attenuate neuroendocrine differentiation of tumor organoid cells. This study demonstrates de novo neuroendocrine differentiation of the human prostate luminal epithelial cells induced by caAKT1 and c-Myc and reveals an impact of cellular status on initiation of lineage plasticity.	[Kwon, Oh-Joon; Zhang, Li; Jia, Deyong; Zhou, Zhicheng; Morrissey, Colm; Xin, Li] Univ Washington, Dept Urol, Seattle, WA 98109 USA; [Li, Zhouyihan] Univ Washington, Dept Chem & Biochem, Seattle, WA 98109 USA; [Haffner, Michael; Lee, John K.] Fred Hutch Canc Res Ctr, Human Biol Div, Seattle, WA 98109 USA; [True, Lawrence] Univ Washington, Dept Pathol, Seattle, WA 98109 USA; [Xin, Li] Univ Washington, Inst Stem Cell & Regenerat Med, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Xin, L (corresponding author), Univ Washington, Dept Urol, Seattle, WA 98109 USA.; Xin, L (corresponding author), Univ Washington, Inst Stem Cell & Regenerat Med, Seattle, WA 98109 USA.	xin18@uw.edu	Jia, Deyong/GSJ-0327-2022; Zhou, Zhicheng/AAM-8685-2020; Jia, Deyong/GQP-9611-2022	Jia, Deyong/0000-0003-2034-0363; Kwon, Oh-Joon/0000-0001-9067-0240; Xin, Li/0000-0002-7138-0042	 [R01CA190378];  [R01DK092202];  [R01DK107436]	; ; 	This work was supported by R01CA190378, R01DK092202, and R01DK107436 (L.X.).	Beltran H, 2019, CLIN CANCER RES, V25, P43, DOI 10.1158/1078-0432.CCR-18-1912; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; Bishop JL, 2017, CANCER DISCOV, V7, P54, DOI 10.1158/2159-8290.CD-15-1263; Choi N, 2012, CANCER CELL, V21, P253, DOI 10.1016/j.ccr.2012.01.005; Collins AT, 2001, J CELL SCI, V114, P3865; Conteduca V, 2019, EUR J CANCER, V121, P7, DOI 10.1016/j.ejca.2019.08.011; Crowell PD, 2019, CELL REP, V28, P1499, DOI 10.1016/j.celrep.2019.07.007; Dardenne E, 2016, CANCER CELL, V30, P563, DOI 10.1016/j.ccell.2016.09.005; Davies AH, 2018, NAT REV UROL, V15, P271, DOI 10.1038/nrurol.2018.22; Fine SW, 2012, ADV ANAT PATHOL, V19, P204, DOI 10.1097/PAP.0b013e31825c6b92; Goldstein AS, 2010, SCIENCE, V329, P568, DOI 10.1126/science.1189992; Guo HY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08133-6; Hsu EC, 2020, P NATL ACAD SCI USA, V117, P2032, DOI 10.1073/pnas.1905384117; Joseph DB, 2020, PROSTATE, V80, P872, DOI 10.1002/pros.24020; Karthaus WR, 2020, SCIENCE, V368, P497, DOI 10.1126/science.aay0267; Karthaus WR, 2014, CELL, V159, P163, DOI 10.1016/j.cell.2014.08.017; Ku SY, 2017, SCIENCE, V355, P78, DOI 10.1126/science.aah4199; Kwon OJ, 2020, STEM CELLS, V38, P1479, DOI 10.1002/stem.3253; Kwon OJ, 2016, STEM CELLS, V34, P191, DOI 10.1002/stem.2217; Labrecque MP, 2019, J CLIN INVEST, V129, P4492, DOI 10.1172/JCI128212; Lapuk AV, 2012, J PATHOL, V227, P286, DOI 10.1002/path.4047; Lawson DA, 2007, P NATL ACAD SCI USA, V104, P181, DOI 10.1073/pnas.0609684104; Lee JK, 2016, CANCER CELL, V29, P536, DOI 10.1016/j.ccell.2016.03.001; Leong KG, 2008, NATURE, V456, P804, DOI 10.1038/nature07427; Lin D, 2014, CANCER RES, V74, P1272, DOI 10.1158/0008-5472.CAN-13-2921-T; Liu J, 2011, MOL ENDOCRINOL, V25, P1849, DOI 10.1210/me.2011-1081; Lu TL, 2013, AM J PATHOL, V182, P975, DOI 10.1016/j.ajpath.2012.11.025; MCNEAL JE, 1988, AM J SURG PATHOL, V12, P897, DOI 10.1097/00000478-198812000-00001; Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307; Park JW, 2018, SCIENCE, V362, P91, DOI 10.1126/science.aat5749; Park JW, 2016, P NATL ACAD SCI USA, V113, P4482, DOI 10.1073/pnas.1603645113; Rotinen M, 2018, NAT MED, V24, P1887, DOI 10.1038/s41591-018-0241-1; Wang ZA, 2013, NAT CELL BIOL, V15, P274, DOI 10.1038/ncb2697; Xin L, 2006, P NATL ACAD SCI USA, V103, P7789, DOI 10.1073/pnas.0602567103; Yao JL, 2006, AM J SURG PATHOL, V30, P705, DOI 10.1097/00000478-200606000-00005; Zou M, 2017, CANCER DISCOV, V7, P736, DOI 10.1158/2159-8290.CD-16-1174	37	16	17	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	2020	39	48					7142	7151		10.1038/s41388-020-01487-6	http://dx.doi.org/10.1038/s41388-020-01487-6		OCT 2020	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PE1YE	33009488	Green Accepted			2022-12-28	WOS:000574731000001
J	Rose, M; Maurer, A; Wirtz, J; Bleilevens, A; Waldmann, T; Wenz, M; Eyll, M; Geelvink, M; Gereitzig, M; Ruchel, N; Denecke, B; Eltze, E; Herrmann, E; Toma, M; Horst, D; Grimm, T; Denzinger, S; Ecke, T; Vogeli, TA; Knuechel, R; Maurer, J; Gaisa, NT				Rose, Michael; Maurer, Angela; Wirtz, Julia; Bleilevens, Andreas; Waldmann, Tanja; Wenz, Maximilian; Eyll, Marie; Geelvink, Mirja; Gereitzig, Melanie; Ruechel, Nadine; Denecke, Bernd; Eltze, Elke; Herrmann, Edwin; Toma, Marieta; Horst, David; Grimm, Tobias; Denzinger, Stefan; Ecke, Thorsten; Voegeli, Thomas Alexander; Knuechel, Ruth; Maurer, Jochen; Gaisa, Nadine T.			EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer	ONCOGENE			English	Article							TRANSITIONAL-CELL CARCINOMA; COMPREHENSIVE MOLECULAR CHARACTERIZATION; PHASE-II; UROTHELIAL CARCINOMA; LUNG-CANCER; 1ST-LINE TREATMENT; MASS-ACTION; FAMILY; CHEMOTHERAPY; EXPRESSION	Recent findings suggested a benefit of anti-EGFR therapy for basal-like muscle-invasive bladder cancer (MIBC). However, the impact on bladder cancer with substantial squamous differentiation (Sq-BLCA) and especially pure squamous cell carcinoma (SCC) remains unknown. Therefore, we comprehensively characterized pure and mixed Sq-BLCA (n = 125) on genetic and protein expression level, and performed functional pathway and drug-response analyses with cell line models and isolated primary SCC (p-SCC) cells of the human urinary bladder. We identified abundant EGFR expression in 95% of Sq-BLCA without evidence for activatingEGFRmutations. Both SCaBER and p-SCC cells were sensitive to EGFR tyrosine kinase inhibitors (TKIs: erlotinib and gefitinib). Combined treatment with anti-EGFR TKIs and varying chemotherapeutics led to a concentration-dependent synergism in SCC cells according to the Chou-Talalay method. In addition, the siRNA knockdown of EGFR impaired SCaBER viability suggesting a putative "Achilles heel" of Sq-BLCA. The observed effects seem Sq-BLCA-specific since non-basal urothelial cancer cells were characterized by poor TKI sensitivity associated with a short-term feedback response potentially attenuating anti-tumor activity. Hence, our findings give further insights into a crucial, Sq-BLCA-specific role of the ERBB signaling pathway proposing improved effectiveness of anti-EGFR based regimens in combination with chemotherapeutics in squamous bladder cancers with wild-type EGFR-overexpression.	[Rose, Michael; Maurer, Angela; Wirtz, Julia; Wenz, Maximilian; Eyll, Marie; Geelvink, Mirja; Gereitzig, Melanie; Ruechel, Nadine; Knuechel, Ruth; Gaisa, Nadine T.] Rhein Westfal TH Aachen, Inst Pathol, Aachen, Germany; [Bleilevens, Andreas; Waldmann, Tanja; Maurer, Jochen] Univ Clin RWTH, Dept Gynecol, Aachen, Germany; [Denecke, Bernd] Rhein Westfal TH Aachen, Med Fac, IZKF Aachen, Aachen, Germany; [Eltze, Elke] Saarbrucken Rastpfuhl, Inst Pathol, Saarbrucken, Germany; [Herrmann, Edwin] Univ Hosp Munster, Dept Urol, Munster, Germany; [Toma, Marieta] Tech Univ Dresden, Inst Pathol, Univ Hosp Gustav Carus, Dresden, Germany; [Horst, David] Charite Univ Med Berlin, Inst Pathol, Berlin, Germany; [Grimm, Tobias] Ludwig Maximilians Univ Munchen, Dept Urol, Munich, Germany; [Denzinger, Stefan] Univ Regensburg, Dept Urol, Regensburg, Germany; [Ecke, Thorsten] Helios Hosp Bad Saarow, Dept Urol, Bad Saarow Pieskow, Germany; [Voegeli, Thomas Alexander] Rhein Westfal TH Aachen, Dept Urol, Aachen, Germany; [Toma, Marieta] Univ Hosp Bonn, Inst Pathol, Bonn, Germany	RWTH Aachen University; RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; University of Munster; Technische Universitat Dresden; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Munich; University of Regensburg; RWTH Aachen University; University of Bonn	Gaisa, NT (corresponding author), Rhein Westfal TH Aachen, Inst Pathol, Aachen, Germany.	ngaisa@ukaachen.de	Maurer, Jochen/G-4832-2018; Toma, Marieta/AAI-8022-2021	Maurer, Jochen/0000-0003-3962-3128; Ruchel, Nadine/0000-0001-9657-8787; Wirtz, Julia/0000-0003-0220-6312	Medical Faculty of the RWTH Aachen University [42/13]	Medical Faculty of the RWTH Aachen University	The authors appreciate the contributions of all pathologists and urologists sending cases for study material, the German Study Group of Bladder Cancers (DFBK e.V.), as well as the excellent technical support of Uschi Schneider, Patrick Kuhl and Anja Steinle. We thank Timon Heide for his great support in analyzing TCGA data sets and are grateful for the publicly available TCGA research Network data sets (http://cancergenome.nih.gov). We further thank Dr. Kathrin Scheckenbach (Dusseldorf University Hospital, Germany), Prof. Wolfgang Schulz (Dusseldorf University Hospital, Germany) and Dr. Alexander Buchner (LMU Munchen, Germany) for providing cell lines. We also thank Pia Dinger and Franziska Lammert for proofreading the manuscript. Furthermore, we thank Dr. Olbrich for supporting our study. This project was partly funded by START-funds of the Medical Faculty of the RWTH Aachen University (NTG grant number: 42/13).	Ahsan A, 2010, CANCER RES, V70, P2862, DOI 10.1158/0008-5472.CAN-09-4294; Baldia PH, 2016, ONCOTARGET, V7, P71429, DOI 10.18632/oncotarget.12198; Benhar M, 2002, ONCOGENE, V21, P8723, DOI 10.1038/sj.onc.1205980; Bergman AM, 1996, CLIN CANCER RES, V2, P521; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Casalini P, 2004, J CELL PHYSIOL, V200, P343, DOI 10.1002/jcp.20007; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen LF, 2010, CLIN CANCER RES, V16, P2489, DOI 10.1158/1078-0432.CCR-09-2318; Chin TM, 2008, CLIN CANCER RES, V14, P6867, DOI 10.1158/1078-0432.CCR-08-0093; Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Chow NH, 1997, VIRCHOWS ARCH, V430, P461, DOI 10.1007/s004280050056; Chow NH, 2001, CLIN CANCER RES, V7, P1957; Eriksson P, 2017, ONCOTARGET, V8, P48905, DOI 10.18632/oncotarget.16554; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Ferner RE, 2016, BRIT J CLIN PHARMACO, V81, P52, DOI 10.1111/bcp.12721; Freed DM, 2017, CELL, V171, P683, DOI 10.1016/j.cell.2017.09.017; Gaisa NT, 2011, J PATHOL, V225, P172, DOI 10.1002/path.2959; Gaisa NT, 2011, VIRCHOWS ARCH, V458, P301, DOI 10.1007/s00428-010-1017-2; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Hasinoff BB, 2010, TOXICOL APPL PHARM, V249, P132, DOI 10.1016/j.taap.2010.08.026; Herbst RS, 2007, J CLIN ONCOL, V25, P4743, DOI 10.1200/JCO.2007.12.3026; Humphrey PA, 2016, EUR UROL, V70, P106, DOI 10.1016/j.eururo.2016.02.028; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Kamoun A, 2019, EUR UROL; Kenakin T, 2016, BRIT J CLIN PHARMACO, V81, P41, DOI 10.1111/bcp.12810; Knowles MA, 2015, NAT REV CANCER, V15, P25, DOI 10.1038/nrc3817; Kramer C, 2007, CANCER-AM CANCER SOC, V109, P2016, DOI 10.1002/cncr.22627; Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191; Ling SZ, 2011, CANCER RES, V71, P3812, DOI 10.1158/0008-5472.CAN-10-3072; Longton E, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00432; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Metzger E, 2017, CANCER RES, V77, P5900, DOI 10.1158/0008-5472.CAN-17-1754; Minato A, 2018, CANCER CONTROL, V25, DOI 10.1177/1073274818800269; Minato A, 2017, CLIN GENITOURIN CANC, V15, pE1063, DOI 10.1016/j.clgc.2017.07.008; Miyabayashi K, 2013, CANCER RES, V73, P2221, DOI 10.1158/0008-5472.CAN-12-1453; Moody SE, 2002, CANCER CELL, V2, P451, DOI 10.1016/S1535-6108(02)00212-X; Mooso BA, 2015, J UROLOGY, V193, P19, DOI 10.1016/j.juro.2014.07.121; O-Charoenrat P, 2000, INT J CANCER, V88, P759, DOI 10.1002/1097-0215(20001201)88:5<759::AID-IJC12>3.0.CO;2-0; Petrylak DP, 2010, BJU INT, V105, P317, DOI 10.1111/j.1464-410X.2009.08799.x; Pirker Robert, 2010, J Thorac Oncol, V5, P1706, DOI 10.1097/JTO.0b013e3181f1c8de; Pruthi RS, 2010, BJU INT, V106, P349, DOI 10.1111/j.1464-410X.2009.09101.x; Rebouissou S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008970; Robertson AG, 2017, CELL, V171, P540, DOI 10.1016/j.cell.2017.09.007; Rose M, 2018, METHODS MOL BIOL, V1655, P43, DOI 10.1007/978-1-4939-7234-0_4; Rose M, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0610-2; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Seiler R, 2017, EUR UROL, V72, P544, DOI 10.1016/j.eururo.2017.03.030; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Tebbutt N, 2013, NAT REV CANCER, V13, P663, DOI 10.1038/nrc3559; Tsai CM, 2011, J THORAC ONCOL, V6, P559, DOI 10.1097/JTO.0b013e3182021ff5; Weickhardt AJ, 2012, J CLIN ONCOL, V30, P1505, DOI 10.1200/JCO.2011.38.6599; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Wilson KJ, 2012, GROWTH FACTORS, V30, P107, DOI 10.3109/08977194.2011.649918; Wirth LJ, 2016, ORAL ONCOL, V61, P31, DOI 10.1016/j.oraloncology.2016.07.005; Yan XT, 2019, LUNG CANCER, V128, P6, DOI 10.1016/j.lungcan.2018.12.007; Yarden Y, 2012, NAT REV CANCER, V12, P553, DOI 10.1038/nrc3309	59	22	22	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2020	39	44					6856	6870		10.1038/s41388-020-01465-y	http://dx.doi.org/10.1038/s41388-020-01465-y		SEP 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OH9QS	32978523	hybrid, Green Published			2022-12-28	WOS:000572714000004
J	Li, YL; Wu, LW; Zeng, LH; Zhang, ZY; Wang, W; Zhang, C; Lin, NM				Li, Yang-ling; Wu, Lin-wen; Zeng, Ling-hui; Zhang, Zuo-yan; Wang, Wei; Zhang, Chong; Lin, Neng-ming			ApoC1 promotes the metastasis of clear cell renal cell carcinoma via activation of STAT3	ONCOGENE			English	Article							APOLIPOPROTEIN C1 APOC1; SH2 DOMAIN; CANCER; SURVIVAL; PROGRESSION; EXPRESSION; THERAPY	Clear cell renal cell carcinoma (ccRCC) is the most common renal cancer and frequently diagnosed at an advanced stage. It is prone to develop unpredictable metastases even with proper treatment. Antiangiogenic therapy is the most effective medical treatment for metastatic ccRCC. Thus, exploration of novel approaches to inhibit angiogenesis and metastasis may potentially lead to a better therapeutic option for ccRCC. Among all the types of cancer, renal cancer samples exhibited the maximum upregulation of ApoC1 as referred to in the Oncomine database. The expression of ApoC1 was increased accompanied by ccRCC progression. A high level of ApoC1 was closely related to poor survival time in ccRCC patients. Furthermore, ApoC1 was over-expressed in the highly invasive ccRCC cells as compared to that in the low-invasive ccRCC cells. Besides, ApoC1 promoted metastasis of ccRCC cells via EMT pathway, whereas depletion of ApoC1 alleviated these effects. ApoC1 as a novel pro-metastatic factor facilitates the activation of STAT3 and enhances the metastasis of ccRCC cells. Meanwhile, ApoC1 in the exosomes were transferred from the ccRCC cells to the vascular endothelial cells and promoted metastasis of the ccRCC cells via activating STAT3. Finally, the metastatic potential of the ccRCC cells driven by ApoC1 was suppressed by DPP-4 inhibition. Our study not only identifies a novel ApoC1-STAT3 pathway in ccRCC metastasis but also provides direction for the exploration of novel strategies to predict and treat metastatic ccRCC in the future.	[Li, Yang-ling; Lin, Neng-ming] Zhejiang Univ, Dept Clin Pharmacol, Key Lab Clin Canc Pharmacol & Toxicol Res Zhejian, Affiliated Hangzhou Peoples Hosp 1,Sch Med, Hangzhou 310006, Zhejiang, Peoples R China; [Wu, Lin-wen; Zeng, Ling-hui; Zhang, Zuo-yan; Zhang, Chong] Zhejiang Univ City Coll, Sch Med, Hangzhou 310015, Zhejiang, Peoples R China; [Wu, Lin-wen; Zhang, Zuo-yan] Zhejiang Univ, Coll Pharmaceut Sci, Hangzhou 310058, Zhejiang, Peoples R China; [Wang, Wei] Zhejiang Univ, Sch Med, Affiliated Hangzhou Peoples Hosp 1, Dept Pathol, Hangzhou 310058, Zhejiang, Peoples R China; [Lin, Neng-ming] Zhejiang Univ, Key Lab Clin Canc Pharmacol & Toxicol Res Zhejian, Hangzhou Translat Med Res Ctr, Affiliated Hangzhou Peoples Hosp 1,Sch Med, Hangzhou 310058, Zhejiang, Peoples R China	Zhejiang University; Zhejiang University City College; Zhejiang University; Zhejiang University; Zhejiang University	Lin, NM (corresponding author), Zhejiang Univ, Dept Clin Pharmacol, Key Lab Clin Canc Pharmacol & Toxicol Res Zhejian, Affiliated Hangzhou Peoples Hosp 1,Sch Med, Hangzhou 310006, Zhejiang, Peoples R China.; Zhang, C (corresponding author), Zhejiang Univ City Coll, Sch Med, Hangzhou 310015, Zhejiang, Peoples R China.; Lin, NM (corresponding author), Zhejiang Univ, Key Lab Clin Canc Pharmacol & Toxicol Res Zhejian, Hangzhou Translat Med Res Ctr, Affiliated Hangzhou Peoples Hosp 1,Sch Med, Hangzhou 310058, Zhejiang, Peoples R China.	zhangchong@zucc.edu.cn; lnm1013@zju.edu.cn		wang, Wei/0000-0001-6060-8665; Zhang, Chong/0000-0002-8113-5585; ZUOYAN, ZHANG/0000-0003-0883-6016	National Natural Science Foundation of China [81702887, 81272473]; Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province [2020E10021]; Key Medical Discipline of Zhejiang Province [2018-2-3]; Key Medical Discipline of Hangzhou City [2017-51-07]; Zhejiang Provincial Foundation of Natural Science [LY19H310004]; Hangzhou Major Science and Technology Project [20172016A01]; High-level Talents Coming Back from Abroad Innovation and Entrepreneurship Program in Hangzhou, Scientific and Technological Developing Scheme of Hangzhou City [20191203B49]; Science Research Foundation of Zhejiang Health Bureau [2020RC026]; Teachers Research Fund of Zhejiang University City College [J-19006]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province; Key Medical Discipline of Zhejiang Province; Key Medical Discipline of Hangzhou City; Zhejiang Provincial Foundation of Natural Science(Natural Science Foundation of Zhejiang Province); Hangzhou Major Science and Technology Project; High-level Talents Coming Back from Abroad Innovation and Entrepreneurship Program in Hangzhou, Scientific and Technological Developing Scheme of Hangzhou City; Science Research Foundation of Zhejiang Health Bureau; Teachers Research Fund of Zhejiang University City College	This study was funded by National Natural Science Foundation of China (81702887, 81272473), Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province (2020E10021), Key Medical Discipline of Zhejiang Province (2018-2-3), Key Medical Discipline of Hangzhou City (2017-51-07), Zhejiang Provincial Foundation of Natural Science (LY19H310004), Hangzhou Major Science and Technology Project (20172016A01), High-level Talents Coming Back from Abroad Innovation and Entrepreneurship Program in Hangzhou, Scientific and Technological Developing Scheme of Hangzhou City (20191203B49), Science Research Foundation of Zhejiang Health Bureau (2020RC026), and Teachers Research Fund of Zhejiang University City College (J-19006).	Aguirre-Gamboa R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074250; Barata PC, 2017, CA-CANCER J CLIN, V67, P507, DOI 10.3322/caac.21411; Beebe JD, 2018, PHARMACOL THERAPEUT, V191, P74, DOI 10.1016/j.pharmthera.2018.06.006; Bielecka Zofia F, 2014, Curr Signal Transduct Ther, V8, P218; Bouillet B, 2016, DIABETES METAB, V42, P263, DOI 10.1016/j.diabet.2016.01.003; Bouillet B, 2014, DIABETES CARE, V37, P1148, DOI 10.2337/dc13-1467; Bus P, 2017, J PATHOL, V241, P589, DOI 10.1002/path.4859; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Choueiri TK, 2017, NEW ENGL J MED, V376, P354, DOI 10.1056/NEJMra1601333; de Palma M, 2017, NAT REV CANCER, V17, P457, DOI 10.1038/nrc.2017.51; Desroses M, 2018, J PHARMACEUT BIOMED, V160, P80, DOI 10.1016/j.jpba.2018.07.018; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Harshman LC, 2012, LANCET ONCOL, V13, P927, DOI 10.1016/S1470-2045(12)70285-1; Horiguchi A, 2002, J UROLOGY, V168, P762, DOI 10.1016/S0022-5347(05)64741-6; Hsieh JJ, 2018, J CLIN ONCOL, V36, P3533, DOI 10.1200/JCO.2018.79.2549; Hsieh JJ, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.9; Huang YP, 2012, EUR J OBSTET GYN R B, V165, P96, DOI 10.1016/j.ejogrb.2012.06.031; Huynh J, 2019, NAT REV CANCER, V19, P82, DOI 10.1038/s41568-018-0090-8; Ko HL, 2014, THORAC CANCER, V5, P500, DOI 10.1111/1759-7714.12117; Li X, 2018, ONCOGENE, V37, P2469, DOI 10.1038/s41388-017-0076-0; Mathieu M, 2019, NAT CELL BIOL, V21, P9, DOI 10.1038/s41556-018-0250-9; McPherson A, 2019, J LIPID RES, V60, P400, DOI 10.1194/jlr.M089441; Patard JJ, 2009, BRIT J CANCER, V101, P1417, DOI 10.1038/sj.bjc.6605298; Ren H, 2019, CANCER MANAG RES, V11, P4917, DOI 10.2147/CMAR.S192529; Sanchez-Gastaldo A, 2017, CANCER TREAT REV, V60, P77, DOI 10.1016/j.ctrv.2017.08.010; Schokrpur S, 2016, SCI REP-UK, V6, DOI 10.1038/srep29032; Shen C, 2013, SEMIN CANCER BIOL, V23, P18, DOI 10.1016/j.semcancer.2012.06.001; Sirkisoon SR, 2018, ONCOGENE, V37, P2502, DOI 10.1038/s41388-018-0132-4; Skinner NEB, 2015, DIABETES THER, V6, P395, DOI 10.1007/s13300-015-0123-1; Srivastava J, 2016, MOL CARCINOGEN, V55, P1889, DOI 10.1002/mc.22438; Su WP, 2018, J BIOCHEM MOL TOXIC, V32, DOI 10.1002/jbt.22158; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Wang XK, 2019, J CELL BIOCHEM, V120, P18246, DOI 10.1002/jcb.29131; Wang XG, 2019, J CELL BIOCHEM, V120, P1492, DOI 10.1002/jcb.27347; Wu LW, 2019, BIOCHEM BIOPH RES CO, V512, P852, DOI 10.1016/j.bbrc.2019.03.154; Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995; Yusenko MV, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-152; Zhang RJ, 2018, LIPIDS HEALTH DIS, V17, DOI 10.1186/s12944-018-0725-5; Zhao W, 2010, J BIOL CHEM, V285, P35855, DOI 10.1074/jbc.M110.154088; Zheng PM, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0465-5; Zhou Q, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087017	42	25	25	4	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2020	39	39					6203	6217		10.1038/s41388-020-01428-3	http://dx.doi.org/10.1038/s41388-020-01428-3		AUG 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NS8XO	32826950				2022-12-28	WOS:000561519300001
J	Liu, HP; Gruber, CW; Alewood, PF; Moller, A; Muttenthaler, M				Liu, Huiping; Gruber, Christian W.; Alewood, Paul F.; Moller, Andreas; Muttenthaler, Markus			The oxytocin receptor signalling system and breast cancer: a critical review	ONCOGENE			English	Review							PROTEIN-COUPLED RECEPTORS; MAMMARY-GLAND; GENE-EXPRESSION; CELL-GROWTH; PHYSICAL-EXERCISE; CARCINOMA CELLS; BLOOD-PRESSURE; RESEARCH TOOLS; REDUCED RISK; TUMOR-GROWTH	Breast cancer is making up one-quarter of all new female cancer cases diagnosed worldwide. Breast cancer surgeries, radiation therapies, cytotoxic chemotherapies and targeted therapies have made significant progress and play a dominant role in breast cancer patient management. However, many challenges remain, including resistance to systemic therapies, tumour recurrence and metastasis. The cyclic neuropeptide oxytocin (OT) elicits a plethora of biological responses via the oxytocin receptor (OTR) in both the central and peripheral nervous system, including social bonding, stress, maternal behaviour, sexual activity, uterus contraction, milk ejection and cancer. As a typical member of the G protein-coupled receptor family, OTR represents also an intriguing target for cancer therapy. There is emerging evidence that OTR plays a role in breast cancer development and progression, and several breast cancer cell lines express OTR. However, despite supporting evidence that OT lowers breast cancer risks, its mechanistic role in breast cancer development and the related signalling pathways are not fully understood. Here, we review the current knowledge of the OT/OTR signalling system in healthy breast tissue as well as in breast cancer, and discuss OTR as a potential therapeutic target for breast cancer management.	[Liu, Huiping; Alewood, Paul F.; Muttenthaler, Markus] Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; [Gruber, Christian W.] Med Univ Vienna, Ctr Physiol & Pharmacol, A-1090 Vienna, Austria; [Moller, Andreas] QIMR Berghofer Med Res Inst, Tumour Microenvironm Lab, Herston, Qld 4006, Australia; [Muttenthaler, Markus] Univ Vienna, Fac Chem, Inst Biol Chem, A-1090 Vienna, Austria	University of Queensland; Medical University of Vienna; QIMR Berghofer Medical Research Institute; University of Vienna	Muttenthaler, M (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.; Muttenthaler, M (corresponding author), Univ Vienna, Fac Chem, Inst Biol Chem, A-1090 Vienna, Austria.	markus.muttenthaler@univie.ac.at	Muttenthaler, Markus/AAF-5944-2021; Liu, Huiping/C-3428-2018	Muttenthaler, Markus/0000-0003-1996-4646; Gruber, Christian/0000-0001-6060-7048; Liu, Huiping/0000-0003-0317-9029	European Research Council under the European Union [714366]; Australian Research Council [DP190101667]; Cancer Australia; Cancer Council Queensland [1146504]; National Breast Cancer Foundation Australia [IIRS-18-159]; Austrian Science Fund (FWF) [I3243, P32109]; Research Training Scholarship of The University of Queensland	European Research Council under the European Union(European Research Council (ERC)); Australian Research Council(Australian Research Council); Cancer Australia; Cancer Council Queensland(Cancer Council Queensland); National Breast Cancer Foundation Australia; Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Research Training Scholarship of The University of Queensland	Funding supporting the studies are listed as follows: MM was supported by the European Research Council under the European Union's Horizon 2020 research and innovation program (714366) and by the Australian Research Council (DP190101667). MM, PFA and AM were supported by grants from Cancer Australia and Cancer Council Queensland (1146504). AM was supported by a grant from the National Breast Cancer Foundation Australia (IIRS-18-159). CWG has been supported by the Austrian Science Fund (FWF) through projects I3243 and P32109. HL is supported by the Research Training Scholarship of The University of Queensland.	Alizadeh AM, 2018, EXP PHYSIOL, V103, P222, DOI 10.1113/EP086463; Amico JA, 2002, ENDOCRINE, V18, P79, DOI 10.1385/ENDO:18:1:79; Benavente MA, 2016, FRONT VET SCI, V3, DOI 10.3389/fvets.2016.00119; Aoyagi T, 2009, KIDNEY INT, V76, P1035, DOI 10.1038/ki.2009.319; Ariana M, 2019, PERS MED, V16, P25, DOI 10.2217/pme-2018-0009; Bankir L, 2017, J INTERN MED, V282, P284, DOI 10.1111/joim.12645; Benavente MA, 2019, J COMP PATHOL, V170, P26, DOI 10.1016/j.jcpa.2019.05.005; BENSON GK, 1957, J ENDOCRINOL, V16, P189, DOI 10.1677/joe.0.0160189; Beral V, 2002, LANCET, V360, P187, DOI 10.1016/S0140-6736(02)09454-0; BERNSTEIN L, 1994, J NATL CANCER I, V86, P1403, DOI 10.1093/jnci/86.18.1403; Berryhill GE, 2016, J DAIRY SCI, V99, P875, DOI 10.3168/jds.2015-10105; Biyikli NK, 2006, PEPTIDES, V27, P2249, DOI 10.1016/j.peptides.2006.03.029; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Breton C, 2001, J MOL ENDOCRINOL, V27, P175, DOI 10.1677/jme.0.0270175; Brisken C, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003178; Busnelli M, 2016, J MED CHEM, V59, P7152, DOI 10.1021/acs.jmedchem.6b00564; Busnelli M, 2012, J BIOL CHEM, V287, P3617, DOI 10.1074/jbc.M111.277178; Busnelli M, 2010, FERTIL STERIL, V94, P1869, DOI 10.1016/j.fertnstert.2009.10.064; Bussolati G, 1996, AM J PATHOL, V148, P1895; Bussolati G, 2001, CANCER RES, V61, P4393; CARMICHAEL MS, 1987, J CLIN ENDOCR METAB, V64, P27, DOI 10.1210/jcem-64-1-27; Cassoni P, 2006, INT J ONCOL, V28, P1263; Cassoni P, 2002, INT J ONCOL, V21, P375; Cassoni P, 2002, CANCER RES, V62, P2406; Cassoni P, 2001, ANN ONCOL, V12, pS37, DOI 10.1093/annonc/12.suppl_2.S37; Cassoni P, 2001, ENDOCRINOLOGY, V142, P1130, DOI 10.1210/en.142.3.1130; Cassoni P, 1997, INT J CANCER, V72, P340, DOI 10.1002/(SICI)1097-0215(19970717)72:2<340::AID-IJC23>3.0.CO;2-I; CASSONI P, 1994, VIRCHOWS ARCH, V425, P467; Cassoni P, 1996, INT J CANCER, V66, P817, DOI 10.1002/(SICI)1097-0215(19960611)66:6<817::AID-IJC18>3.0.CO;2-#; Cassoni P, 1998, INT J CANCER, V77, P695, DOI 10.1002/(SICI)1097-0215(19980831)77:5<695::AID-IJC6>3.0.CO;2-Q; Cassoni P, 2000, J PATHOL, V190, P470, DOI 10.1002/(SICI)1096-9896(200003)190:4<470::AID-PATH550>3.0.CO;2-G; Cassoni P, 2006, MOL CANCER RES, V4, P351, DOI 10.1158/1541-7786.MCR-06-0024; Cavallaro G, 2007, EUR J PHARM BIOPHARM, V66, P182, DOI 10.1016/j.ejpb.2006.10.013; Chini B, 2003, BRIT J CANCER, V89, P930, DOI 10.1038/sj.bjc.6601189; Chini B, 1996, FEBS LETT, V397, P201, DOI 10.1016/S0014-5793(96)01135-0; Conti F, 2009, AM J PHYSIOL-ENDOC M, V296, pE532, DOI 10.1152/ajpendo.90590.2008; Copland JA, 1999, ENDOCRINOLOGY, V140, P2258, DOI 10.1210/en.140.5.2258; de Araujo AD, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4165; de Jong TR, 2015, PSYCHONEUROENDOCRINO, V62, P381, DOI 10.1016/j.psyneuen.2015.08.027; De Silva M, 2010, CANCER EPIDEMIOL, V34, P267, DOI 10.1016/j.canep.2010.02.012; DEMBINSKI TC, 1985, CANCER RES, V45, P3083; Desprez PY, 1998, MOL CELL BIOL, V18, P4577, DOI 10.1128/MCB.18.8.4577; DHONDT G, 1977, PROSTAGLANDINS, V13, P1185, DOI 10.1016/0090-6980(77)90144-7; Di Giglio MG, 2017, SCI REP-UK, V7, DOI 10.1038/srep41002; Donaldson ZR, 2008, SCIENCE, V322, P900, DOI 10.1126/science.1158668; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; Duerrauer L, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55675-w; Dutertre S, 2008, J BIOL CHEM, V283, P7100, DOI 10.1074/jbc.M706477200; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Fay MJ, 1999, RES COMMUN MOL PATH, V103, P115; Friedenreich CM, 2011, RECENT RESULTS CANC, V188, P125, DOI 10.1007/978-3-642-10858-7_11; Garona J, 2016, CLIN EXP METASTAS, V33, P589, DOI 10.1007/s10585-016-9799-5; GAZIS D, 1978, P SOC EXP BIOL MED, V158, P663; Gimpl G, 2001, PHYSIOL REV, V81, P629, DOI 10.1152/physrev.2001.81.2.629; Gimpl G, 2008, EXPERT OPIN THER PAT, V18, P1239, DOI 10.1517/13543776.18.11.1239; Graf C, 2010, BREAST CARE, V5, P389, DOI 10.1159/000322650; Grotegut CA, 2011, AM J PHYSIOL-ENDOC M, V300, pE468, DOI 10.1152/ajpendo.00390.2010; Gruber CW, 2012, FUTURE MED CHEM, V4, P1791, DOI [10.4155/FMC.12.108, 10.4155/fmc.12.108]; Gruber CW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032559; Guzzi F, 2002, ONCOGENE, V21, P1658, DOI 10.1038/sj.onc.1205219; Hassiotou F, 2013, CLIN ANAT, V26, P29, DOI 10.1002/ca.22165; Imanieh MH, 2014, EUR J PHARMACOL, V741, P112, DOI 10.1016/j.ejphar.2014.07.053; Iseri SO, 2005, J SURG RES, V126, P73, DOI 10.1016/j.jss.2005.01.021; Ito Y, 1996, ENDOCRINOLOGY, V137, P773, DOI 10.1210/en.137.2.773; Ivell R, 2001, EXP PHYSIOL, V86, P289, DOI 10.1113/eph8602185; Jean-Charles PY, 2017, J CARDIOVASC PHARM, V70, P142, DOI 10.1097/FJC.0000000000000482; Jurek B, 2018, PHYSIOL REV, V98, P1805, DOI 10.1152/physrev.00031.2017; Katritch V, 2012, TRENDS PHARMACOL SCI, V33, P17, DOI 10.1016/j.tips.2011.09.003; Keegan BP, 2006, BREAST CANCER RES TR, V95, P265, DOI 10.1007/s10549-005-9024-8; Khori V, 2018, PEPTIDES, V107, P54, DOI 10.1016/j.peptides.2018.07.007; KIMURA T, 1994, EUR J ENDOCRINOL, V131, P385, DOI 10.1530/eje.0.1310385; Klein BY, 2011, J CELL BIOCHEM, V112, P3216, DOI 10.1002/jcb.23243; Knols R, 2005, J CLIN ONCOL, V23, P3830, DOI 10.1200/JCO.2005.02.148; Koehbach J, 2013, P NATL ACAD SCI USA, V110, P21183, DOI 10.1073/pnas.1311183110; Koehbach J, 2013, BIOCHEM SOC T, V41, P197, DOI 10.1042/BST20120256; Kovtun O, 2015, J CELL SCI, V128, P1269, DOI 10.1242/jcs.167866; KU CY, 1995, ENDOCRINOLOGY, V136, P1509, DOI 10.1210/en.136.4.1509; LANDGRAF R, 1982, ENDOKRINOLOGIE, V79, P281; LE MG, 1989, J CLIN EPIDEMIOL, V42, P1227, DOI 10.1016/0895-4356(89)90121-2; Lerman B, 2018, WORLD J CLIN ONCOL, V9, P74, DOI 10.5306/wjco.v9.i5.74; Li D, 2018, J ENDOCRINOL, V239, P121, DOI [10.1530/JOE-18-0356, 10.1530/joe-18-0356]; Li T, 2017, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00693; Macias H, 2012, WIRES DEV BIOL, V1, P533, DOI 10.1002/wdev.35; Manning M, 2012, J NEUROENDOCRINOL, V24, P609, DOI 10.1111/j.1365-2826.2012.02303.x; Manning M, 2008, PROG BRAIN RES, V170, P473, DOI 10.1016/S0079-6123(08)00437-8; Martinez JM, 1999, CLIN CHEM, V45, P1797; MCCANN SM, 1959, ENDOCRINOLOGY, V64, P870, DOI 10.1210/endo-64-6-870; Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349; Morita T, 2004, INT J CANCER, V109, P525, DOI 10.1002/ijc.20017; MURRELL TGC, 1995, BREAST CANCER RES TR, V35, P225, DOI 10.1007/BF00668213; MUSTACCHI P, 1961, ARCH INTERN MED, V108, P639, DOI 10.1001/archinte.1961.03620100131018; Muttenthaler M, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aan3398; Muttenthaler M, 2010, J MED CHEM, V53, P8585, DOI 10.1021/jm100989w; Nakano H, 2001, PFLUG ARCH EUR J PHY, V442, P57, DOI 10.1007/s004240100521; Nation DA, 2010, PSYCHOSOM MED, V72, P376, DOI 10.1097/PSY.0b013e3181d74c48; Neves SR, 2002, SCIENCE, V296, P1636, DOI 10.1126/science.1071550; Neville MC, 2002, J MAMMARY GLAND BIOL, V7, P49, DOI 10.1023/A:1015770423167; NEWCOMB PA, 1994, NEW ENGL J MED, V330, P81, DOI 10.1056/NEJM199401133300201; Nishimori K, 1996, P NATL ACAD SCI USA, V93, P11699, DOI 10.1073/pnas.93.21.11699; NISSENSON R, 1978, P NATL ACAD SCI USA, V75, P2044, DOI 10.1073/pnas.75.4.2044; OTA K, 1962, NATURE, V195, P77, DOI 10.1038/195077b0; Pandy-Szekeres G, 2018, NUCLEIC ACIDS RES, V46, pD440, DOI 10.1093/nar/gkx1109; Passoni I, 2016, J NEUROENDOCRINOL, V28, DOI 10.1111/jne.12363; Patel AV, 2003, CANCER CAUSE CONTROL, V14, P519, DOI 10.1023/A:1024895613663; PDQ Screening and Prevention Editorial Board, 2002, PDQ CANC INFORM SUMM; Pequeux C, 2004, ENDOCR-RELAT CANCER, V11, P871, DOI 10.1677/erc.1.00803; Petersson M, 2002, PEPTIDES, V23, P1121, DOI 10.1016/S0196-9781(02)00041-4; Petersson M, 2008, REGUL PEPTIDES, V150, P50, DOI 10.1016/j.regpep.2008.02.007; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Carrera-Gonzalez MP, 2011, TUMOR BIOL, V32, P543, DOI 10.1007/s13277-010-0149-y; Plested CP, 2001, EXP PHYSIOL, V86, P303, DOI 10.1113/eph8602187; Prevost M, 2014, FRONT PUBLIC HEALTH, V2, DOI 10.3389/fpubh.2014.00001; Purwanto H, 2000, Gan To Kagaku Ryoho, V27 Suppl 2, P474; Renoir JM, 2013, BIOCHEM PHARMACOL, V85, P449, DOI 10.1016/j.bcp.2012.10.018; Reversi A, 2005, J BIOL CHEM, V280, P16311, DOI 10.1074/jbc.M409945200; Rimoldi V, 2003, ONCOGENE, V22, P6054, DOI 10.1038/sj.onc.1206612; Rivenbark AG, 2013, AM J PATHOL, V183, P1113, DOI 10.1016/j.ajpath.2013.08.002; Robinson VC, 2015, MED HYPOTHESES, V85, P976, DOI 10.1016/j.mehy.2015.09.002; Sanborn BM, 2005, J SOC GYNECOL INVEST, V12, P479, DOI 10.1016/j.jsgi.2005.07.002; Sapino A, 1998, ANTICANCER RES, V18, P2181; SAPINO A, 1993, ENDOCRINOLOGY, V133, P838, DOI 10.1210/en.133.2.838; Seyedabadi M, 2019, PHARMACOL THERAPEUT, V200, P148, DOI 10.1016/j.pharmthera.2019.05.006; Shukla AK, 2011, TRENDS BIOCHEM SCI, V36, P457, DOI 10.1016/j.tibs.2011.06.003; Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI [10.3322/caac.21601, 10.3322/caac.21590]; Smith JS, 2018, NAT REV DRUG DISCOV, V17, P243, DOI 10.1038/nrd.2017.229; Smith MP, 2006, MOL ENDOCRINOL, V20, P379, DOI 10.1210/me.2005-0031; Strakova Z, 1997, AM J PHYSIOL-ENDOC M, V272, pE870, DOI 10.1152/ajpendo.1997.272.5.E870; Strunecka A, 2009, FOLIA BIOL-PRAGUE, V55, P159; Sugawara Y, 2013, EUR J CANCER PREV, V22, P187, DOI 10.1097/CEJ.0b013e3283564610; Svennersten-Sjaunja K, 2005, DOMEST ANIM ENDOCRIN, V29, P241, DOI 10.1016/j.domaniend.2005.03.006; Szeto A, 2013, PSYCHONEUROENDOCRINO, V38, P685, DOI 10.1016/j.psyneuen.2012.08.009; Szeto A, 2008, AM J PHYSIOL-ENDOC M, V295, pE1495, DOI 10.1152/ajpendo.90718.2008; Tahara M, 2002, ENDOCRINOLOGY, V143, P920, DOI 10.1210/en.143.3.920; Takayanagi Y, 2005, P NATL ACAD SCI USA, V102, P16096, DOI 10.1073/pnas.0505312102; Takeda S, 1989, Nihon Naibunpi Gakkai Zasshi, V65, P182; Tang ZR, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8101123; TAYLOR AH, 1990, CANCER RES, V50, P7882; Turton NJ, 2001, ONCOGENE, V20, P1300, DOI 10.1038/sj.onc.1204235; Uvnas-Moberg K, 1990, ACTA OBSTET GYN SCAN, V69, P301, DOI 10.3109/00016349009036151; Vargo-Gogola T, 2007, NAT REV CANCER, V7, P659, DOI 10.1038/nrc2193; Viero C, 2010, CNS NEUROSCI THER, V16, pe138, DOI 10.1111/j.1755-5949.2010.00185.x; Vrachnis N, 2011, INT J ENDOCRINOL, V2011, DOI 10.1155/2011/350546; Wagner Kay-Uwe, 1997, Genes and Function, V1, P233; Wang P, 2015, J NEUROIMMUNOL, V289, P152, DOI 10.1016/j.jneuroim.2015.11.001; Wang YF, 2007, J NEUROSCI, V27, P1902, DOI 10.1523/JNEUROSCI.5346-06.2007; Wheatley M, 1997, BIOCHEM SOC T, V25, P1046, DOI 10.1042/bst0251046; Whittington K, 2007, PROSTATE, V67, P1132, DOI 10.1002/pros.20612; Xu H, 2017, ONCOTARGET, V8, P31215, DOI 10.18632/oncotarget.16107; Yip CH, 2014, FUTURE ONCOL, V10, P2293, DOI 10.2217/fon.14.110; YOKOYAMA AKIRA, 1959, ENDOCRINOL JAPON, V6, P268; Zhong M, 2003, ENDOCRINOLOGY, V144, P2947, DOI 10.1210/en.2002-221039; Zhou XB, 2007, MOL ENDOCRINOL, V21, P740, DOI 10.1210/me.2006-0220; Zingg HH, 2003, TRENDS ENDOCRIN MET, V14, P222, DOI 10.1016/S1043-2760(03)00080-8	153	13	14	4	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2020	39	37					5917	5932		10.1038/s41388-020-01415-8	http://dx.doi.org/10.1038/s41388-020-01415-8		AUG 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NM2OY	32782397	Green Published, hybrid			2022-12-28	WOS:000558632600001
J	Misawa, K; Mai, A; Matsui, H; Kanai, A; Misawa, Y; Mochizuki, D; Mima, M; Yamada, S; Kurokawa, T; Nakagawa, T; Mineta, H				Misawa, Kiyoshi; Mai, Atsushi; Matsui, Hirotaka; Kanai, Akinori; Misawa, Yuki; Mochizuki, Daiki; Mima, Masato; Yamada, Satoshi; Kurokawa, Tomoya; Nakagawa, Takuya; Mineta, Hiroyuki			Identification of novel methylation markers in HPV-associated oropharyngeal cancer: genome-wide discovery, tissue verification and validation testing in ctDNA	ONCOGENE			English	Article							CALMODULIN-LIKE PROTEIN; HUMAN-PAPILLOMAVIRUS; CLINICAL-SIGNIFICANCE; DNA METHYLATION; NECK-CANCER; HEAD; SURVIVAL; SERUM; STAGE	Human papilloma virus (HPV)-associated oropharyngeal cancer (OPC) is an independent tumour type with regard to cellular, biological, and clinical features. The use of non-invasive biomarkers such as circulating tumour DNA (ctDNA) may be relevant in early diagnosis and eventually improve the outcomes of patients with head and neck squamous cell carcinoma (HNSCC). Genome-wide discovery using RNA sequencing and reduced representation bisulfite sequencing yielded 21 candidates for methylation-targeted genes. A verification study (252 HNSCC patients) using quantitative methylation-specific PCR (Q-MSP) identified 10 genes (ATP2A1, CALML5, DNAJC5G, GNMT, GPT, LY6D, LYNX1, MAL, MGC16275, and MRGPRF) that showed a significant increase recurrence in methylation groups with OPC. Further study on ctDNA using Q-MSP in HPV-associated OPC showed that three genes (CALML5, DNAJC5G, and LY6D) had a high predictive ability as emerging biomarkers for a validation set, each capable of discriminating between the plasma of the patients from healthy individuals. Among the 42 ctDNA samples, methylated CALML5, DNAJC5G, and LY6D were observed in 31 (73.8%), 19 (45.2%), and 19 (45.2%) samples, respectively. Among pre-treatment ctDNA samples, methylated CALML5, DNAJC5G, and LY6D were observed in 8/8 (100%), 7/8 (87.5%), and 7/8 (87.5%) samples, respectively. Methylated CALML5, DNAJC5G, and LY6D were found in 2/8 (25.0%), 0/8 (0%), and 1/8 (12.5%) of the final samples in the series, respectively. Here, we present the relationship between the methylation status of three specific genes and cancer recurrence for risk classification of HPV-associated OPC cases. In conclusion, ctDNA analysis has the potential to aid in determining patient prognosis and real-time surveillance for disease recurrences and serves as an alternative method of screening for HPV-associated OPC.	[Misawa, Kiyoshi; Mai, Atsushi; Misawa, Yuki; Mochizuki, Daiki; Mima, Masato; Yamada, Satoshi; Mineta, Hiroyuki] Hamamatsu Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Shizuoka, Japan; [Matsui, Hirotaka] Kumamoto Univ, Grad Sch Med Sci, Dept Mol Lab Med, Kumamoto, Japan; [Kanai, Akinori] Hiroshima Univ, Res Inst Radiat Biol & Med, Hiroshima, Japan; [Kurokawa, Tomoya; Nakagawa, Takuya] Chiba Univ, Grad Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Chiba, Japan	Hamamatsu University School of Medicine; Kumamoto University; Hiroshima University; Chiba University	Misawa, K (corresponding author), Hamamatsu Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Shizuoka, Japan.	kiyoshim@hama-med.ac.jp	Yamada, Satohi/HHY-9909-2022; Matsui, Hirotaka/AED-6669-2022	Matsui, Hirotaka/0000-0002-6266-3227	Ministry of Education, Culture, Sports, Science, and Technology of Japan [16K11228, 16K20239, 17K16904, 17K16903, 19K09866, 19K09906, 19K18728]	Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This study was funded by a Grant-in-Aid for Scientific Research (No. 16K11228, No. 16K20239, 17K16904, 17K16903, 19K09866, 19K09906 and 19K18728) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.	Akalin A, 2012, GENOME BIOL, V13, DOI [10.1186/gb-2012-13-10-R87, 10.1186/gb-2012-13-10-r87]; Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Barros-Silva JD, 2018, CELL REP, V25, P3504, DOI 10.1016/j.celrep.2018.11.069; Berman TA, 2017, CANCER-AM CANCER SOC, V123, P2219, DOI 10.1002/cncr.30588; Bose P, 2013, INT J CANCER, V133, P2013, DOI 10.1002/ijc.28112; Chera BS, 2020, J CLIN ONCOL, V38, P1050, DOI 10.1200/JCO.19.02444; Chera BS, 2019, CLIN CANCER RES, V25, P4682, DOI 10.1158/1078-0432.CCR-19-0211; Cree IA, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3693-7; Damerla RR, 2019, JCO PRECIS ONCOL, V3, DOI 10.1200/PO.18.00276; Debald M, 2013, J CANCER RES CLIN, V139, P2125, DOI 10.1007/s00432-013-1541-y; Fakhry C, 2019, CANCER-AM CANCER SOC, V125, P2027, DOI 10.1002/cncr.32025; Fici P, 2019, METHODS MOL BIOL, V1909, P47, DOI 10.1007/978-1-4939-8973-7_4; Garnaes E, 2016, INT J CANCER, V139, P2598, DOI 10.1002/ijc.30389; Golusinski P, 2019, ORAL ONCOL, V88, P145, DOI 10.1016/j.oraloncology.2018.11.020; Gonda TA, 2012, GASTROENTEROLOGY, V142, P824, DOI 10.1053/j.gastro.2011.12.058; Granata R, 2012, ANN ONCOL, V23, P1832, DOI 10.1093/annonc/mdr544; IJzerman MJ, 2018, EXPERT REV PHARM OUT, V18, P593, DOI 10.1080/14737167.2018.1505505; Jeannot E, 2016, J PATHOL CLIN RES, V2, P201, DOI 10.1002/cjp2.47; Kong HK, 2012, BMB REP, V45, P595, DOI 10.5483/BMBRep.2012.45.11.210; Krueger F, 2011, BIOINFORMATICS, V27, P1571, DOI 10.1093/bioinformatics/btr167; Kurokawa T, 2020, CANCER SCI, V111, P1407, DOI 10.1111/cas.14338; Ludwig ML, 2018, ORAL ONCOL, V87, P144, DOI 10.1016/j.oraloncology.2018.10.031; Mayama A, 2018, CANCER SCI, V109, P3350, DOI 10.1111/cas.13770; Mazurek AM, 2019, HEAD NECK-J SCI SPEC, V41, P632, DOI 10.1002/hed.25368; Mehul B, 2000, J BIOL CHEM, V275, P12841, DOI 10.1074/jbc.275.17.12841; Misawa K, 2020, SCI REP, V10; Misawa K, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148-017-0363-1; Misawa K, 2016, ONCOTARGET, V7, P26087, DOI 10.18632/oncotarget.8317; Moss J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07466-6; Mydlarz WK, 2016, HEAD NECK-J SCI SPEC, V38, P9, DOI 10.1002/hed.23842; Nakagawa T, 2020, INT J CANCER, V146, P2460, DOI 10.1002/ijc.32890; Nieuwenhuis EJC, 2003, LAB INVEST, V83, P1233, DOI 10.1097/01.LAB.0000083532.46536.56; Ossandon MR, 2018, JNCI-J NATL CANCER I, V110, P929, DOI 10.1093/jnci/djy105; Ribeiro IP, 2019, MOL CYTOGENET, V12, DOI 10.1186/s13039-019-0447-z; Schilling B, 1998, VIROLOGY, V247, P74, DOI 10.1006/viro.1998.9220; Schmidt H, 2018, DIAGNOSTICS, V8, DOI 10.3390/diagnostics8040079; Schrock A, 2017, CLIN CHEM, V63, P1288, DOI 10.1373/clinchem.2016.270207; Seyhan AA, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1864-9; Shen SY, 2018, NATURE, V563, P579, DOI 10.1038/s41586-018-0703-0; Sullivan CS, 2001, VIROLOGY, V287, P1, DOI 10.1006/viro.2001.1038; Sun BK, 2015, GENE DEV, V29, P2225, DOI 10.1101/gad.267708.115; Swiecicki PL, 2019, LARYNGOSCOPE, V129, P1836, DOI 10.1002/lary.27725; Terai H, 2015, INT J ONCOL, V46, P430, DOI 10.3892/ijo.2014.2733; Urano E, 2013, JAIDS-J ACQ IMM DEF, V64, P154, DOI 10.1097/QAI.0b013e31829a2ef8; van Ginkel JH, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3424-0; Volik S, 2016, MOL CANCER RES, V14, P898, DOI 10.1158/1541-7786.MCR-16-0044	46	20	20	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	24					4741	4755		10.1038/s41388-020-1327-z	http://dx.doi.org/10.1038/s41388-020-1327-z		MAY 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LY0HO	32415241	Green Published, hybrid			2022-12-28	WOS:000533041900001
J	Chao, HH; Karagounis, IV; Thomas, C; Francois, NB; Facciabene, A; Koumenis, C; Maity, A				Chao, Hann-Hsiang; Karagounis, Ilias, V; Thomas, Christoforos; Francois, Noeulle B.; Facciabene, Andrea; Koumenis, Constantinos; Maity, Amit			Combination of CHEK1/2 inhibition and ionizing radiation results in abscopal tumor response through increased micronuclei formation	ONCOGENE			English	Article							INTERFERON REGULATORY FACTOR-3; CYTOSOLIC DNA SENSOR; KINASE INHIBITOR; MITOTIC ENTRY; STING PATHWAY; S-PHASE; CHECKPOINT; CELLS; PEMBROLIZUMAB; CANCER	We explore a novel strategy of activating immune signaling through increased micronuclei formation utilizing a cell cycle checkpoint inhibitor to drive cell cycle progression following ionizing radiation. The Chk1/2 inhibitor AZD7762 is used to abrogate radiation therapy (RT)-induced G2/M cell cycle arrest in multiple cell lines and, we find that this therapeutic combination promotes increased micronuclei formation in vitro and subsequently drives increased type I interferon signaling and cytotoxic T-cell activation. In vivo studies using B16-F10 melanoma cancer cells implanted in C57/BL6 mice demonstrate improved rates of tumor control at the abscopal (unirradiated) site, located outside of the radiation field, only in the AZD7762 + RT group, with a corresponding reduction in mean tumor volume, increase in the CD8 T-cell population, and immune activated gene signaling. Our results demonstrate that targeted inhibition of cell cycle checkpoint activation following ionizing radiation drives increased production of immunogenic micronuclei, leading to systemic tumor response with potential future clinical benefit.	[Chao, Hann-Hsiang; Karagounis, Ilias, V; Thomas, Christoforos; Francois, Noeulle B.; Facciabene, Andrea; Koumenis, Constantinos; Maity, Amit] Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA; [Chao, Hann-Hsiang] McGuire VA Med Ctr, Dept Radiat Oncol, Richmond, VA USA	University of Pennsylvania; Hunter Holmes McGuire Veterinary Affairs Medical Center	Maity, A (corresponding author), Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA.	Amit.Maity@uphs.upenn.edu	Karagounis, Ilias V/A-6497-2013	Karagounis, Ilias V/0000-0003-1642-1996; Koumenis, Costas/0000-0001-5945-4726; Maity, Amit/0000-0001-7151-2845	NIH/NCI grant [1R01CA182747]; University of Pennsylvania Radiation Oncology Resident Research Award	NIH/NCI grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Pennsylvania Radiation Oncology Resident Research Award	This study was supported by NIH/NCI grant (1R01CA182747 (PI: AM, CK) and the University of Pennsylvania Radiation Oncology Resident Research Award (to H-HC). The authors thank Roger Greenberg group for contribution of cGAS constructs.	Aarts M, 2012, CANCER DISCOV, V2, P524, DOI 10.1158/2159-8290.CD-11-0320; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chen Q, 2016, NAT IMMUNOL, V17, P1142, DOI 10.1038/ni.3558; Cuneo KC, 2019, J CLIN ONCOL, V37, P2643, DOI 10.1200/JCO.19.00730; Deng LF, 2014, IMMUNITY, V41, P843, DOI 10.1016/j.immuni.2014.10.019; Dillon MT, 2017, MOL CANCER THER, V16, P25, DOI 10.1158/1535-7163.MCT-16-0239; Diner EJ, 2013, CELL REP, V3, P1355, DOI 10.1016/j.celrep.2013.05.009; Dou ZX, 2017, NATURE, V550, P402, DOI 10.1038/nature24050; Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005; Grandvaux N, 2002, J VIROL, V76, P5532, DOI 10.1128/JVI.76.11.5532-5539.2002; Guzi TJ, 2011, MOL CANCER THER, V10, P591, DOI 10.1158/1535-7163.MCT-10-0928; Hamilton DH, 2014, CANCER RES, V74, P2510, DOI 10.1158/0008-5472.CAN-13-1894; Harding SM, 2017, NATURE, V548, P466, DOI 10.1038/nature23470; Hartlova A, 2015, IMMUNITY, V42, P332, DOI 10.1016/j.immuni.2015.01.012; Ishikawa H, 2009, NATURE, V461, P788, DOI 10.1038/nature08476; Karpova AY, 2002, P NATL ACAD SCI USA, V99, P2818, DOI 10.1073/pnas.052713899; KASTAN MB, 1991, CANCER RES, V51, P6304; Lu Hsu-Fung, 2007, Cancer Genomics & Proteomics, V4, P93; Ma CX, 2011, TRENDS MOL MED, V17, P88, DOI 10.1016/j.molmed.2010.10.009; Mackenzie KJ, 2017, NATURE, V548, P461, DOI 10.1038/nature23449; Maity A, 2018, BRIT J CANCER, V119, P1200, DOI 10.1038/s41416-018-0281-9; Melms JC, 2020, CANCER RES, V80, P798, DOI 10.1158/0008-5472.CAN-19-2330; Moran DM, 2008, ONCOGENE, V27, P5567, DOI 10.1038/onc.2008.172; Morgan MA, 2010, CANCER RES, V70, P4972, DOI 10.1158/0008-5472.CAN-09-3573; Postow MA, 2012, NEW ENGL J MED, V366, P925, DOI 10.1056/NEJMoa1112824; Reck M, 2018, IMMUNOTHERAPY-UK, V10, P93, DOI 10.2217/imt-2017-0121; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Schoonen PM, 2019, MOL ONCOL, V13, P2422, DOI 10.1002/1878-0261.12573; Shaverdian N, 2017, LANCET ONCOL, V18, P895, DOI 10.1016/S1470-2045(17)30380-7; Sun LJ, 2013, SCIENCE, V339, P786, DOI 10.1126/science.1232458; Tao YG, 2009, CELL CYCLE, V8, P3172, DOI 10.4161/cc.8.19.9729; Thomas C, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3358; Twyman-Saint Victor C, 2015, NATURE, V520, P373, DOI 10.1038/nature14292; Vendetti FP, 2018, J CLIN INVEST, V128, P3926, DOI 10.1172/JCI96519; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Woo SR, 2015, TRENDS IMMUNOL, V36, P250, DOI 10.1016/j.it.2015.02.003; Woo SR, 2014, IMMUNITY, V41, P830, DOI 10.1016/j.immuni.2014.10.017; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Zabludoff SD, 2008, MOL CANCER THER, V7, P2955, DOI 10.1158/1535-7163.MCT-08-0492; Zeng L, 2017, MOL CANCER THER, V16, P591, DOI 10.1158/1535-7163.MCT-16-0352; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299	45	12	13	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	22					4344	4357		10.1038/s41388-020-1300-x	http://dx.doi.org/10.1038/s41388-020-1300-x		APR 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LR9IT	32335582	Green Accepted			2022-12-28	WOS:000528824400001
J	He, JC; McLaughlin, RP; van der Beek, L; Canisius, S; Wessels, L; Smid, M; Martens, JWM; Foekens, JA; Zhang, YH; van de Water, B				He, Jichao; McLaughlin, Ronan P.; van der Beek, Lambert; Canisius, Sander; Wessels, Lodewyk; Smid, Marcel; Martens, John W. M.; Foekens, John A.; Zhang, Yinghui; van de Water, Bob			Integrative analysis of genomic amplification-dependent expression and loss-of-function screen identifies ASAP1 as a driver gene in triple-negative breast cancer progression	ONCOGENE			English	Article							GTPASE-ACTIVATING PROTEIN; COPY NUMBER VARIATION; SURVIVAL; MYC; LANDSCAPE; IMPACT; REGION	The genetically heterogeneous triple-negative breast cancer (TNBC) continues to be an intractable disease, due to lack of effective targeted therapies. Gene amplification is a major event in tumorigenesis. Genes with amplification-dependent expression are being explored as therapeutic targets for cancer treatment. In this study, we have applied Analytical Multi-scale Identification of Recurring Events analysis and transcript quantification in the TNBC genome across 222 TNBC tumors and identified 138 candidate genes with positive correlation in copy number gain (CNG) and gene expression. siRNA-based loss-of-function screen of the candidate genes has validated EGFR, MYC, ASAP1, IRF2BP2, and CCT5 genes as drivers promoting proliferation in different TNBC cells. MYC, ASAP1, IRF2BP2, and CCT5 display frequent CNG and concurrent expression over 2173 breast cancer tumors (cBioPortal dataset). More frequently are MYC and ASAP1 amplified in TNBC tumors (>30%, n = 320). In particular, high expression of ASAP1, the ADP-ribosylation factor GTPase-activating protein, is significantly related to poor metastatic relapse-free survival of TNBC patients (n = 257, bc-GenExMiner). Furthermore, we have revealed that silencing of ASAP1 modulates numerous cytokine and apoptosis signaling components, such as IL1B, TRAF1, AIFM2, and MAP3K11 that are clinically relevant to survival outcomes of TNBC patients. ASAP1 has been reported to promote invasion and metastasis in various cancer cells. Our findings that ASAP1 is an amplification-dependent TNBC driver gene promoting TNBC cell proliferation, functioning upstream apoptosis components, and correlating to clinical outcomes of TNBC patients, support ASAP1 as a potential actionable target for TNBC treatment.	[He, Jichao; McLaughlin, Ronan P.; van der Beek, Lambert; Zhang, Yinghui; van de Water, Bob] Leiden Univ, Div Drug Discovery & Safety, Leiden Acad Ctr Drug Res, NL-2300 RA Leiden, Netherlands; [Canisius, Sander; Wessels, Lodewyk] Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; [Smid, Marcel; Martens, John W. M.; Foekens, John A.] Erasmus MC, Dept Med Oncol & Canc Genom Netherlands, Erasmus MC Canc Inst, NL-3000 CA Rotterdam, Netherlands	Leiden University; Leiden University - Excl LUMC; Netherlands Cancer Institute; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute	van de Water, B (corresponding author), Leiden Univ, Div Drug Discovery & Safety, Leiden Acad Ctr Drug Res, NL-2300 RA Leiden, Netherlands.	b.water@lacdr.leidenuniv.nl		Martens, John/0000-0002-3428-3366; Zhang, Yinghui/0000-0003-1635-0278	ERC Advanced grant Triple-BC [322737]; China Scholarship Council	ERC Advanced grant Triple-BC; China Scholarship Council(China Scholarship Council)	This work was supported by the ERC Advanced grant Triple-BC (grant no. 322737). JH was financially supported by the China Scholarship Council.	Andreopoulou E, 2017, BREAST CARE, V12, P21, DOI 10.1159/000455821; Bianchini G, 2016, NAT REV CLIN ONCOL, V13, P674, DOI 10.1038/nrclinonc.2016.66; Brown MT, 1998, MOL CELL BIOL, V18, P7038, DOI 10.1128/MCB.18.12.7038; Chaignat E, 2011, GENOME RES, V21, P106, DOI 10.1101/gr.112748.110; Chiu AM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29992-5; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Ehlers JP, 2005, CLIN CANCER RES, V11, P3609, DOI 10.1158/1078-0432.CCR-04-1941; Fallah Y, 2017, BIOMOLECULES, V7, DOI 10.3390/biom7030053; Gamazon ER, 2015, BRIEF FUNCT GENOMICS, V14, P352, DOI 10.1093/bfgp/elv017; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; He JC, 2019, BREAST CANCER RES TR, V178, P263, DOI 10.1007/s10549-019-05380-z; Horiuchi D, 2012, J EXP MED, V209, P679, DOI 10.1084/jem.20111512; Hou T, 2014, INT J CLIN EXP PATHO, V7, P280; Jandu H, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2071-1; Jezequel P, 2012, BREAST CANCER RES TR, V131, P765, DOI 10.1007/s10549-011-1457-7; Jolly C, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1476-3; Kim MH, 2013, J CLIN INVEST, V123, P3211, DOI 10.1172/JCI65521; Kim Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13027-2; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Krepischi ACV, 2012, EUR J CANCER, V48, pS134, DOI 10.1016/S0959-8049(12)71222-4; Kwok HF, 2015, AM J CANCER RES, V5, P52; Lanczky A, 2016, BREAST CANCER RES TR, V160, P439, DOI 10.1007/s10549-016-4013-7; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Liang L, 2016, ONCOGENE, V35, P1475, DOI 10.1038/onc.2015.209; Lin D, 2008, CANCER RES, V68, P4352, DOI 10.1158/0008-5472.CAN-07-5237; Liu YH, 2002, MOL BIOL CELL, V13, P2147, DOI 10.1091/mbc.E02-01-0018; Long J, 2018, AM J CANCER RES, V8, P778; Mazaki Y, 2001, MOL BIOL CELL, V12, P645, DOI 10.1091/mbc.12.3.645; Metzger O, 2012, J CLIN ONCOL, V30, P1879, DOI 10.1200/JCO.2011.38.2010; Muller T, 2010, ONCOGENE, V29, P2393, DOI 10.1038/onc.2010.6; Onodera Y, 2005, EMBO J, V24, P963, DOI 10.1038/sj.emboj.7600588; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Rimawi MF, 2013, J CLIN ONCOL, V31, P1726, DOI 10.1200/JCO.2012.44.8027; Riquelme E, 2014, J THORAC ONCOL, V9, P998, DOI 10.1097/JTO.0000000000000202; Robertson AG, 2018, CANCER CELL, V33, P151, DOI 10.1016/j.ccell.2017.12.013; Sabe H, 2009, TRAFFIC, V10, P982, DOI 10.1111/j.1600-0854.2009.00917.x; Sandhu V, 2016, CANCER RES, V76, P5092, DOI 10.1158/0008-5472.CAN-16-0658; Santarius T, 2010, NAT REV CANCER, V10, P59, DOI 10.1038/nrc2771; Schaub FX, 2018, CELL SYST, V6, P282, DOI 10.1016/j.cels.2018.03.003; Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933; Shi YQ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0850-9; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Stranger BE, 2007, SCIENCE, V315, P848, DOI 10.1126/science.1136678; van Dyk E, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12159; van Dyk E, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt155; Ventura Elisa, 2018, Oncoscience, V5, P278, DOI 10.18632/oncoscience.467; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wang K, 2013, HEPATOLOGY, V58, P706, DOI 10.1002/hep.26402; Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036; Weisman PS, 2016, MODERN PATHOL, V29, P476, DOI 10.1038/modpathol.2016.39; Zhang T, 2018, ONCOL LETT, V15, P4432, DOI 10.3892/ol.2018.7834; Zhang YH, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2883; Zhao ZM, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5290-4; Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6	54	12	14	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	20					4118	4131		10.1038/s41388-020-1279-3	http://dx.doi.org/10.1038/s41388-020-1279-3		MAR 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LN3GC	32235890	Green Published, hybrid			2022-12-28	WOS:000522606000002
J	Monte, ER; Wilding, A; Leubolt, G; Kerbs, P; Bagnoli, JW; Hartmann, L; Hiddemann, W; Chen-Wichmann, L; Krebs, S; Blum, H; Cusan, M; Vick, B; Jeremias, I; Enard, W; Theurich, S; Wichmann, C; Greif, PA				Redondo Monte, Enric; Wilding, Anja; Leubolt, Georg; Kerbs, Paul; Bagnoli, Johannes W.; Hartmann, Luise; Hiddemann, Wolfgang; Chen-Wichmann, Linping; Krebs, Stefan; Blum, Helmut; Cusan, Monica; Vick, Binje; Jeremias, Irmela; Enard, Wolfgang; Theurich, Sebastian; Wichmann, Christian; Greif, Philipp A.			ZBTB7A prevents RUNX1-RUNX1T1-dependent clonal expansion of human hematopoietic stem and progenitor cells	ONCOGENE			English	Article							AML1-ETO; MUTATIONS; LEUKEMIA; FATE; REPRESSION; LRF	ZBTB7A is frequently mutated in acute myeloid leukemia (AML) with t(8;21) translocation. However, the oncogenic collaboration between mutated ZBTB7A and the RUNX1-RUNX1T1 fusion gene in AML t(8;21) remains unclear. Here, we investigate the role of ZBTB7A and its mutations in the context of normal and malignant hematopoiesis. We demonstrate that clinically relevant ZBTB7A mutations in AML t(8;21) lead to loss of function and result in perturbed myeloid differentiation with block of the granulocytic lineage in favor of monocytic commitment. In addition, loss of ZBTB7A increases glycolysis and hence sensitizes leukemic blasts to metabolic inhibition with 2-deoxy-d-glucose. We observed that ectopic expression of wild-type ZBTB7A prevents RUNX1-RUNX1T1-mediated clonal expansion of human CD34+ cells, whereas the outgrowth of progenitors is enabled by ZBTB7A mutation. Finally, ZBTB7A expression in t(8;21) cells lead to a cell cycle arrest that could be mimicked by inhibition of glycolysis. Our findings suggest that loss of ZBTB7A may facilitate the onset of AML t(8;21), and that RUNX1-RUNX1T1-rearranged leukemia might be treated with glycolytic inhibitors.	[Redondo Monte, Enric; Wilding, Anja; Leubolt, Georg; Kerbs, Paul; Hartmann, Luise; Hiddemann, Wolfgang; Cusan, Monica; Theurich, Sebastian; Greif, Philipp A.] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Med 3, D-81377 Munich, Germany; [Redondo Monte, Enric; Wilding, Anja; Leubolt, Georg; Kerbs, Paul; Hartmann, Luise; Hiddemann, Wolfgang; Greif, Philipp A.] German Canc Consortium DKTK, Partner Site Munich, D-81377 Munich, Germany; [Redondo Monte, Enric; Wilding, Anja; Leubolt, Georg; Kerbs, Paul; Hartmann, Luise; Hiddemann, Wolfgang; Greif, Philipp A.] German Canc Res Ctr, D-69121 Heidelberg, Germany; [Bagnoli, Johannes W.; Enard, Wolfgang] Ludwig Maximilians Univ Munchen, Dept Biol 2, Anthropol & Human Genom, D-82152 Martinsried, Germany; [Chen-Wichmann, Linping; Wichmann, Christian] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Transfus Med Cell Therapeut & Hemostasis, D-81377 Munich, Germany; [Krebs, Stefan; Blum, Helmut] Ludwig Maximilians Univ Munchen, Lab Funct Genome Anal, Gene Ctr, D-81377 Munich, Germany; [Vick, Binje; Jeremias, Irmela] Helmholtz Ctr Munich, Res Unit Apoptosis Hematopoiet Stem Cells, D-81377 Munich, Germany; [Theurich, Sebastian] Ludwig Maximilians Univ Munchen, Gene Ctr, Canc & Immunometab Res Grp, D-81377 Munich, Germany	University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); University of Munich; University of Munich; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich	Greif, PA (corresponding author), Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Med 3, D-81377 Munich, Germany.; Greif, PA (corresponding author), German Canc Consortium DKTK, Partner Site Munich, D-81377 Munich, Germany.; Greif, PA (corresponding author), German Canc Res Ctr, D-69121 Heidelberg, Germany.	pgreif@med.lmu.de	Theurich, Sebastian/C-9995-2018; Wichmann, Christian/H-2491-2017; Theurich, Sebastian/AAB-2855-2022; Jeremias, Irmela/Q-5934-2019	Theurich, Sebastian/0000-0001-5706-8258; Jeremias, Irmela/0000-0003-1773-7677; Vick, Binje/0000-0003-1956-2778; Bagnoli, Johannes/0000-0003-0393-6157; Redondo Monte, Enric/0000-0002-3588-223X; Kerbs, Paul/0000-0001-5525-1374	German Research Foundation (DFG) within the Collaborative Research Centre [(SFB) 1243]; Wilhelm Sander-Stiftung [2014.162.2]; Munich Clinician Scientist Program (MCSP) Advanced Track; Projekt DEAL	German Research Foundation (DFG) within the Collaborative Research Centre(German Research Foundation (DFG)); Wilhelm Sander-Stiftung; Munich Clinician Scientist Program (MCSP) Advanced Track; Projekt DEAL	This study was supported by the German Research Foundation (DFG) within the Collaborative Research Centre (SFB) 1243 "Cancer Evolution" (Projects A05, A08, A14, and Z02). PAG and CW acknowledge support by the Wilhelm Sander-Stiftung (Forderantrag Nr. 2014.162.2). PAG received funds from the Munich Clinician Scientist Program (MCSP) Advanced Track. Open access funding provided by Projekt DEAL.	BENZ EJ, 1980, P NATL ACAD SCI-BIOL, V77, P3509, DOI 10.1073/pnas.77.6.3509; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; Christen F, 2019, BLOOD, V133, P1140, DOI 10.1182/blood-2018-05-852822; COLLINS SJ, 1987, BLOOD, V70, P1233; de Guzman CG, 2002, MOL CELL BIOL, V22, P5506, DOI 10.1128/MCB.22.15.5506-5517.2002; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Faber ZJ, 2016, NAT GENET, V48, P1551, DOI 10.1038/ng.3709; Hartmann L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11733; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Isa A, 2018, KLIN PADIATR, V230, P165; Kawashima N, 2019, ANN HEMATOL, V98, P83, DOI 10.1007/s00277-018-3492-5; Lavallee VP, 2016, BLOOD, V127, P2498, DOI 10.1182/blood-2016-03-703868; Lee SU, 2013, BLOOD, V121, P918, DOI 10.1182/blood-2012-03-418103; Liu XS, 2016, ONCOGENE, V35, P3071, DOI 10.1038/onc.2015.371; Liu XS, 2014, GENE DEV, V28, P1917, DOI 10.1101/gad.245910.114; Lunardi A, 2013, BLOOD, V121, P2845, DOI 10.1182/blood-2012-11-292037; Maeda T, 2007, SCIENCE, V316, P860, DOI 10.1126/science.1140881; Maeda T, 2009, DEV CELL, V17, P527, DOI 10.1016/j.devcel.2009.09.005; MARTIN SJ, 1990, CLIN EXP IMMUNOL, V79, P448; Mulloy JC, 2002, BLOOD, V99, P15, DOI 10.1182/blood.V99.1.15; Opatz S, 2020, LEUKEMIA, V34, P1553, DOI 10.1038/s41375-019-0697-0; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Rhoades KL, 2000, BLOOD, V96, P2108; ROWLEY JD, 1973, ANN GENET-PARIS, V16, P109; Schwieger M, 2002, J EXP MED, V196, P1227, DOI 10.1084/jem.20020824; Suganuma K, 2010, LEUKEMIA LYMPHOMA, V51, P2112, DOI 10.3109/10428194.2010.512966; Vick B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120925; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Wichmann C, 2015, LEUKEMIA, V29, P279, DOI 10.1038/leu.2014.179; Yan JS, 2017, LEUKEMIA LYMPHOMA, V58, P1985, DOI 10.1080/10428194.2016.1272690; Yeh JRJ, 2008, DEVELOPMENT, V135, P401, DOI 10.1242/dev.008904; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298	32	10	10	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	15					3195	3205		10.1038/s41388-020-1209-4	http://dx.doi.org/10.1038/s41388-020-1209-4		MAR 2020	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LB8NS	32115572	Green Published, hybrid			2022-12-28	WOS:000517359700001
J	Li, S; Lavrijsen, M; Bakker, A; Magierowski, M; Magierowska, K; Liu, PY; Wang, WH; Peppelenbosch, MP; Smits, R				Li, Shan; Lavrijsen, Marla; Bakker, Aron; Magierowski, Marcin; Magierowska, Katarzyna; Liu, Pengyu; Wang, Wenhui; Peppelenbosch, Maikel P.; Smits, Ron			Commonly observed RNF43 mutations retain functionality in attenuating Wnt/beta-catenin signaling and unlikely confer Wnt-dependency onto colorectal cancers	ONCOGENE			English	Article							COMPREHENSIVE MOLECULAR CHARACTERIZATION; TUMOR-SUPPRESSOR RNF43; FINGER PROTEIN 43; RECURRENT MUTATIONS; RECEPTOR TURNOVER; GENOMIC LANDSCAPE; CARCINOMA; NEOPLASMS; SUBTYPES; PROMOTES	Cancer-associated RNF43 mutations lead to activation of beta-catenin signaling through aberrantly increasing Wnt-receptor levels at the membrane. Importantly, inactivating RNF43 mutations have been suggested to render cancer cells sensitive to Wnt-based therapeutics. However, the extent to which RNF43 mutations lead to impaired regulation of Wnt/beta-catenin signaling has been poorly investigated. Here, we observed that tumors with a functional mismatch repair system show a predominant 5 '-location of truncating RNF43 mutations, suggesting C-terminal truncations such as the most commonly reported p.G659fs mutation, do not affect beta-catenin signaling. In accordance, expressing C-terminal truncation mutants and wild-type RNF43, showed equal effects on beta-catenin signaling, Wnt-receptor turnover, and DVL-binding. We confirmed these observations at endogenous levels by CRISPR-Cas9-mediated knockout of G659fs RNF43 expression in KM12 cells and generating comparable mutations in HEK293T cells. We could not confirm previous reports linking RNF43 to p53 and E-cadherin breakdown. Our data also suggest that only colorectal cancer cells harboring N-terminal mutations of RNF43 convey Wnt-dependency onto the tumor cells. Results of this study have potentially important clinical implications indicating that Wnt-based therapeutics should be applied cautiously in cancer patients harboring RNF43 mutations.	[Li, Shan; Lavrijsen, Marla; Bakker, Aron; Magierowski, Marcin; Magierowska, Katarzyna; Liu, Pengyu; Wang, Wenhui; Peppelenbosch, Maikel P.; Smits, Ron] Erasmus MC, Univ Med Ctr, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands; [Li, Shan] Army Med Univ, Daping Hosp, Dept Hepatobiliary Surg, Chongqing, Peoples R China; [Magierowski, Marcin; Magierowska, Katarzyna] Jagiellonian Univ, Med Coll, Dept Physiol, Krakow, Poland; [Wang, Wenhui] China Pharmaceut Univ, Dept Pharmacol, State Key Lab Nat Med, Nanjing, Peoples R China	Erasmus University Rotterdam; Erasmus MC; Army Medical University; Jagiellonian University; Collegium Medicum Jagiellonian University; China Pharmaceutical University	Smits, R (corresponding author), Erasmus MC, Univ Med Ctr, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands.	m.j.m.smits@erasmusmc.nl	; Li, Shan/GSN-4678-2022	Magierowski, Marcin/0000-0003-0175-5600; liu, pengyu/0000-0001-6600-6139; Peppelenbosch, Maikel/0000-0001-9112-6028; Li, Shan/0000-0003-4446-2218	China Scholarship Council [201408060053, 201408220029]; Erasmus MC Grant; National Science Center Poland [UMO-2015/16/T/NZ4/00176]	China Scholarship Council(China Scholarship Council); Erasmus MC Grant; National Science Center Poland(National Science Centre, Poland)	We wish to thank Dr Louis Vermeulen (AMC, Amsterdam, The Netherlands) for providing us with several of the cell lines used in this study. We are grateful to Dr Erik A.C. Wiemer and Dr Robbert J. Rottier (Erasmus MC, Rotterdam, The Netherlands) for providing us, respectively with H1299 and A549 cell lines. We gratefully acknowledge Dr Aart G. Jochemsen (LUMC, Leiden, The Netherlands) for helpful discussion on p53-related works and providing us the p53-related plasmids. We thank Dr Markus Gerhard (Technische Universitat Munchen, Munich, Germany) for kindly providing HA-tagged RNF43 plasmid. We thank Natascha Nieuwenhuijze (Erasmus MC, Rotterdam, The Netherlands) for help with confocal microscopy. We would like to thank Dr Feng Cong (Novartis Institutes for Biomedical Research, Cambridge, MA, USA) for kindly giving us positive responses and the detailed protocol of surface SNAP-labeling experiments. This work was supported by the China Scholarship Council PhD fellowship (grant numbers 201408060053 to SL and 201408220029 to PL); and an Erasmus MC Grant; MM received financial support from National Science Center Poland (UMO-2015/16/T/NZ4/00176).	Ashkenazy H, 2016, NUCLEIC ACIDS RES, V44, pW344, DOI 10.1093/nar/gkw408; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Behm-Ansmant I, 2007, FEBS LETT, V581, P2845, DOI 10.1016/j.febslet.2007.05.027; Carmon KS, 2014, P NATL ACAD SCI USA, V111, pE1221, DOI 10.1073/pnas.1323106111; Carmon KS, 2011, P NATL ACAD SCI USA, V108, P11452, DOI 10.1073/pnas.1106083108; Eto T, 2018, J PATHOL, V245, P445, DOI 10.1002/path.5098; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Fujii M, 2016, CELL STEM CELL, V18, P827, DOI 10.1016/j.stem.2016.04.003; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Giannakis M, 2016, CELL REP, V15, P857, DOI 10.1016/j.celrep.2016.03.075; Giannakis M, 2014, NAT GENET, V46, P1264, DOI 10.1038/ng.3127; Gibson WJ, 2016, NAT GENET, V48, P848, DOI 10.1038/ng.3602; Gonzalez-Sancho JM, 2004, MOL CELL BIOL, V24, P4757, DOI 10.1128/MCB.24.11.4757-4768.2004; Hao HX, 2016, CANCERS, V8, DOI 10.3390/cancers8060054; Hao HX, 2012, NATURE, V485, P195, DOI 10.1038/nature11019; Hashimoto T, 2017, AM J SURG PATHOL, V41, P1188, DOI 10.1097/PAS.0000000000000877; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Jiang XM, 2015, MOL CELL, V58, P522, DOI 10.1016/j.molcel.2015.03.015; Jiang XM, 2013, P NATL ACAD SCI USA, V110, P12649, DOI 10.1073/pnas.1307218110; Jiao YC, 2014, J PATHOL, V232, P428, DOI 10.1002/path.4310; Koo BK, 2015, P NATL ACAD SCI USA, V112, P7548, DOI 10.1073/pnas.1508113112; Koo BK, 2012, NATURE, V488, P665, DOI 10.1038/nature11308; Lee HJ, 2015, ELIFE, V4, DOI 10.7554/eLife.08142; Loregger A, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aac6757; Madan B, 2016, ONCOGENE, V35, P2197, DOI 10.1038/onc.2015.280; Mazzoni SM, 2014, CANCER LETT, V355, P1, DOI 10.1016/j.canlet.2014.09.018; Min BH, 2016, J PATHOL, V240, P304, DOI 10.1002/path.4777; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nailwal H, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.131; Neumeyer V, 2019, CARCINOGENESIS, V40, P551, DOI 10.1093/carcin/bgy152; Niu L, 2015, CELL PHYSIOL BIOCHEM, V36, P1835, DOI 10.1159/000430154; Picco G, 2017, EMBO MOL MED, V9, P293, DOI 10.15252/emmm.201606773; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Ryland GL, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0210-y; Ryland GL, 2013, J PATHOL, V229, P469, DOI 10.1002/path.4134; Sakamoto H, 2015, MODERN PATHOL, V28, P261, DOI 10.1038/modpathol.2014.98; Sekine S, 2016, J PATHOL, V239, P133, DOI 10.1002/path.4709; Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282; Shinada K, 2011, BIOCHEM BIOPH RES CO, V404, P143, DOI 10.1016/j.bbrc.2010.11.082; Soumerai TE, 2018, CLIN CANCER RES, V24, P5939, DOI 10.1158/1078-0432.CCR-18-0412; Steinhart Z, 2017, NAT MED, V23, P60, DOI 10.1038/nm.4219; Tsai JH, 2017, HISTOPATHOLOGY, V70, P756, DOI 10.1111/his.13125; Tsukiyama T, 2015, MOL CELL BIOL, V35, P2007, DOI 10.1128/MCB.00159-15; van de Wetering M, 2015, CELL, V161, P933, DOI 10.1016/j.cell.2015.03.053; Vanderwalde A, 2018, CANCER MED-US, V7, P746, DOI 10.1002/cam4.1372; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Wang K, 2014, NAT GENET, V46, P573, DOI 10.1038/ng.2983; Wang K, 2011, NAT GENET, V43, P1219, DOI 10.1038/ng.982; Wang WH, 2016, NEOPLASIA, V18, P711, DOI 10.1016/j.neo.2016.10.004; Witkiewicz AK, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7744; Wu J, 2011, P NATL ACAD SCI USA, V108, P21188, DOI 10.1073/pnas.1118046108; Xie HY, 2015, INT J CLIN EXP PATHO, V8, P14995; Xie Y, 2013, EMBO REP, V14, P1120, DOI 10.1038/embor.2013.167; Xing CY, 2013, MOL CANCER THER, V12, P94, DOI 10.1158/1535-7163.MCT-12-0672; Yaeger R, 2018, CANCER CELL, V33, P125, DOI 10.1016/j.ccell.2017.12.004; Yan HHN, 2017, GUT, V66, P1645, DOI 10.1136/gutjnl-2016-311849; Zebisch M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3787; Zhang YF, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5880-1; Zou Y, 2013, GENE, V531, P112, DOI 10.1016/j.gene.2013.08.054	60	19	20	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	17					3458	3472		10.1038/s41388-020-1232-5	http://dx.doi.org/10.1038/s41388-020-1232-5		FEB 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LH1YK	32103169	Green Submitted			2022-12-28	WOS:000516683200003
J	Viallard, C; Audiger, C; Popovic, N; Akla, N; Lanthier, K; Legault-Navarrete, I; Melichar, H; Costantino, S; Lesage, S; Larrivee, B				Viallard, Claire; Audiger, Cindy; Popovic, Natalija; Akla, Naoufal; Lanthier, Kevin; Legault-Navarrete, Isaac; Melichar, Heather; Costantino, Santiago; Lesage, Sylvie; Larrivee, Bruno			BMP9 signaling promotes the normalization of tumor blood vessels	ONCOGENE			English	Article							BONE MORPHOGENETIC PROTEIN-9; ENDOTHELIAL-CELL-ADHESION; RECEPTOR-LIKE KINASE-1; VASCULAR NORMALIZATION; ANTIANGIOGENIC THERAPY; INHIBITS ANGIOGENESIS; IN-VIVO; CANCER; HYPOXIA; GROWTH	The presence of an immature tumor vascular network contributes to cancer dissemination and the development of resistance to therapies. Strategies to normalize the tumor vasculature are therefore of significant therapeutic interest for cancer treatments. VEGF inhibitors are used clinically to normalize tumor blood vessels. However, the time frame and dosage of these inhibitors required to achieve normalization is rather narrow, and there is a need to identify additional signaling targets to attain vascular normalization. In addition to VEGF, the endothelial-specific receptor Alk1 plays a critical role in vascular development and promotes vascular remodeling and maturation. Therefore, we sought to evaluate the effects of the Alk1 ligand BMP9 on tumor vascular formation. BMP9 overexpression in Lewis Lung Carcinoma (LLC) tumors significantly delayed tumor growth. Blood vessels in BMP9-overexpressing LLC tumors displayed markers of vascular maturation and were characterized by increased perivascular cell coverage. Tumor vasculature normalization was associated with decreased permeability and increased perfusion. These changes in vascular function in BMP9-overexpressing LLC tumors resulted in significant alterations of the tumor microenvironment, characterized by a decrease in hypoxia and an increase in immune infiltration. In conclusion, we show that BMP9 promotes vascular normalization in LLC tumors that leads to changes in the microenvironment.	[Viallard, Claire; Audiger, Cindy; Popovic, Natalija; Akla, Naoufal; Lanthier, Kevin; Legault-Navarrete, Isaac; Melichar, Heather; Costantino, Santiago; Lesage, Sylvie; Larrivee, Bruno] Ctr Rech Hop Maisonneuve Rosemt, Montreal, PQ, Canada; [Viallard, Claire; Popovic, Natalija; Lanthier, Kevin; Larrivee, Bruno] Univ Montreal, Dept Biol Mol, Montreal, PQ, Canada; [Audiger, Cindy; Lesage, Sylvie] Univ Montreal, Dept Microbiol Infectiol & Immunol, Montreal, PQ, Canada; [Akla, Naoufal] Univ Montreal, Dept Biochim, Montreal, PQ, Canada; [Melichar, Heather] Univ Montreal, Dept Med, Montreal, PQ, Canada; [Costantino, Santiago; Larrivee, Bruno] Univ Montreal, Dept Ophtalmol, Montreal, PQ, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal	Larrivee, B (corresponding author), Ctr Rech Hop Maisonneuve Rosemt, Montreal, PQ, Canada.; Larrivee, B (corresponding author), Univ Montreal, Dept Biol Mol, Montreal, PQ, Canada.; Larrivee, B (corresponding author), Univ Montreal, Dept Ophtalmol, Montreal, PQ, Canada.	bruno.larrivee@umontreal.ca	Costantino, Santiago/ABD-5472-2020	Costantino, Santiago/0000-0002-2454-2635; Popovic, Natalija/0000-0002-8324-4099; Larrivee, Bruno/0000-0003-1388-3108; Lesage, Sylvie/0000-0002-0968-2795	Cancer Research Society; Canadian Institutes of Health Research [363450]; Fonds de recherche -Sante (FRQS); Department of Ophthalmology of Universite de Montreal Research Fund Award (FROUM); Suzanne-Veronneau-Troutmann Award (SVT); FRQS scholarship; Montreal Diabetes Research Center PhD Award; Heart and Stroke Foundation of Canada	Cancer Research Society; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Fonds de recherche -Sante (FRQS); Department of Ophthalmology of Universite de Montreal Research Fund Award (FROUM); Suzanne-Veronneau-Troutmann Award (SVT); FRQS scholarship; Montreal Diabetes Research Center PhD Award; Heart and Stroke Foundation of Canada(Heart & Stroke Foundation of Canada)	We thank Dr. Paul S. Oh for kindly providing the Alk1.EC mice and Manuel Buscarlet for assistance with data analysis. This work was supported by an operating grant from the Cancer Research Society, and an operating grant from the Canadian Institutes of Health Research (363450). CV was supported by a post-doctoral research award from Fonds de recherche -Sante (FRQS). NA was supported by the Department of Ophthalmology of Universite de Montreal Research Fund Award (FROUM), Suzanne-Veronneau-Troutmann Award (SVT) and a FRQS scholarship. CA is recipient of a Montreal Diabetes Research Center PhD Award. SL is an FRQS Research Scholar Emeritus. BL is recipient of a New Investigator Award from the Heart and Stroke Foundation of Canada.	Abou-Alfa GK, 2019, ONCOLOGIST, V24, P161, DOI 10.1634/theoncologist.2018-0654; Akla N, 2018, ARTERIOSCL THROM VAS, V38, P1821, DOI 10.1161/ATVBAHA.118.310733; Appleby SL, 2016, J IMMUNOL, V197, P3302, DOI 10.4049/jimmunol.1601219; Arndt H, 1996, GUT, V38, P911, DOI 10.1136/gut.38.6.911; Azzi S, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00211; Baeyens N, 2016, J CELL BIOL, V214, P807, DOI 10.1083/jcb.201603106; Batchelor TT, 2007, CANCER CELL, V11, P83, DOI 10.1016/j.ccr.2006.11.021; Benn A, 2016, J CELL SCI, V129, P206, DOI 10.1242/jcs.179960; Berman ME, 1996, J IMMUNOL, V156, P1515; Brand V, 2016, MOL ONCOL, V10, P1603, DOI 10.1016/j.molonc.2016.10.002; Carmeliet P, 2011, NAT REV DRUG DISCOV, V10, P417, DOI 10.1038/nrd3455; Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144; Cerani A, 2013, CELL METAB, V18, P505, DOI 10.1016/j.cmet.2013.09.003; Chabot C, 2009, MOL CELL BIOL, V29, P241, DOI 10.1128/MCB.01374-08; David L, 2008, CIRC RES, V102, P914, DOI 10.1161/CIRCRESAHA.107.165530; David L, 2007, BLOOD, V109, P1953, DOI 10.1182/blood-2006-07-034124; de Vinuesa AG, 2016, BIOCHEM SOC T, V44, P1142, DOI 10.1042/BST20160093; del Toro R, 2010, BLOOD, V116, P4025, DOI 10.1182/blood-2010-02-270819; Douaisi M, 2017, J IMMUNOL, V198, P2310, DOI 10.4049/jimmunol.1500350; Duriez PJ, 2000, J BIOL CHEM, V275, P18099, DOI 10.1074/jbc.M908925199; Eales KL, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.50; Ebos JML, 2011, NAT REV CLIN ONCOL, V8, P210, DOI 10.1038/nrclinonc.2011.21; Friedl J, 2002, BLOOD, V100, P1334, DOI 10.1182/blood.V100.4.1334.h81602001334_1334_1339; Goel S, 2011, PHYSIOL REV, V91, P1071, DOI 10.1152/physrev.00038.2010; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Greenberg JI, 2009, EXPERT OPIN BIOL TH, V9, P1347, DOI 10.1517/14712590903208883; Gupta S, 2015, CURR ONCOL REP, V17, DOI 10.1007/s11912-015-0441-5; Hawinkels LJAC, 2016, CLIN CANCER RES, V22, P96, DOI 10.1158/1078-0432.CCR-15-0743; Hawinkels LJAC, 2013, EXPERT OPIN INV DRUG, V22, P1371, DOI 10.1517/13543784.2013.837884; Hu-Lowe DD, 2011, CANCER RES, V71, P1362, DOI 10.1158/0008-5472.CAN-10-1451; Huang YH, 2013, CANCER RES, V73, P2943, DOI 10.1158/0008-5472.CAN-12-4354; Huang YH, 2012, P NATL ACAD SCI USA, V109, P17561, DOI 10.1073/pnas.1215397109; Inai T, 2004, AM J PATHOL, V165, P35, DOI 10.1016/S0002-9440(10)63273-7; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Jayson GC, 2016, LANCET, V388, P518, DOI 10.1016/S0140-6736(15)01088-0; Jerkic M, 2015, FASEB J, V29, P3678, DOI 10.1096/fj.14-269258; Keane MP, 2004, J IMMUNOL, V172, P2853, DOI 10.4049/jimmunol.172.5.2853; Kim JH, 2012, ANGIOGENESIS, V15, P497, DOI 10.1007/s10456-012-9277-x; Kim R, 2007, IMMUNOLOGY, V121, P1, DOI 10.1111/j.1365-2567.2007.02587.x; Koch AW, 2011, DEV CELL, V20, P33, DOI 10.1016/j.devcel.2010.12.001; Kumar V, 2014, IMMUNOLOGY, V143, P512, DOI 10.1111/imm.12380; Lamouille S, 2002, BLOOD, V100, P4495, DOI 10.1182/blood.V100.13.4495; Larrivee B, 2012, DEV CELL, V22, P489, DOI 10.1016/j.devcel.2012.02.005; Lechner MG, 2013, J IMMUNOTHER, V36, P477, DOI 10.1097/01.cji.0000436722.46675.4a; Liu T, 2014, SCI REP-UK, V4, DOI 10.1038/srep04833; Long L, 2015, NAT MED, V21, P777, DOI 10.1038/nm.3877; Lu TY, 2011, J CLIN INVEST, V121, P4015, DOI 10.1172/JCI45862; McKenney JK, 2001, AM J SURG PATHOL, V25, P1167, DOI 10.1097/00000478-200109000-00007; Mitchell D, 2010, MOL CANCER THER, V9, P379, DOI 10.1158/1535-7163.MCT-09-0650; Mitrofan CG, 2017, J BIOL CHEM, V292, P13714, DOI 10.1074/jbc.M117.778506; Moya IM, 2012, DEV CELL, V22, P501, DOI 10.1016/j.devcel.2012.01.007; Murakami T, 2009, J BIOL CHEM, V284, P21036, DOI 10.1074/jbc.M109.016766; Nakahara T, 2006, CANCER RES, V66, P1434, DOI 10.1158/0008-5472.CAN-05-0923; Noman MZ, 2015, AM J PHYSIOL-CELL PH, V309, pC569, DOI 10.1152/ajpcell.00207.2015; Nouvion AL, 2010, J CELL SCI, V123, P4221, DOI 10.1242/jcs.073635; Ntumba K, 2016, ONCOTARGET, V7, P55957, DOI 10.18632/oncotarget.11182; Ochoa-Callejero L, 2016, SCI REP-UK, V6, DOI 10.1038/srep33495; Ola R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13650; Oladipupo SS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33037-2; Ouarne M, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0885-1; Oubaha M, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf9440; Park JS, 2016, CANCER CELL, V30, P953, DOI 10.1016/j.ccell.2016.10.018; Qin RS, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4738-2; Renier N, 2016, CELL, V165, P1789, DOI 10.1016/j.cell.2016.05.007; Ricard N, 2012, BLOOD, V119, P6162, DOI 10.1182/blood-2012-01-407593; Rostama B, 2015, ARTERIOSCL THROM VAS, V35, P2626, DOI 10.1161/ATVBAHA.115.306541; Sceneay J, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.22355; Scharpfenecker M, 2007, J CELL SCI, V120, P964, DOI 10.1242/jcs.002949; Shrimali RK, 2010, CANCER RES, V70, P6171, DOI 10.1158/0008-5472.CAN-10-0153; Sitkovsky MV, 2008, CLIN CANCER RES, V14, P5947, DOI 10.1158/1078-0432.CCR-08-0229; Stacchini A, 2003, J BIOL REG HOMEOS AG, V17, P308; Sun ZY, 2012, J EXP MED, V209, P1363, DOI 10.1084/jem.20111343; Taguchi K, 2019, J IMMUNOL METHODS, V464, P105, DOI 10.1016/j.jim.2018.11.005; Tian HY, 2018, FASEB J, V32, P2934, DOI 10.1096/fj.201700867RR; Tolaney SM, 2015, P NATL ACAD SCI USA, V112, P14325, DOI 10.1073/pnas.1518808112; Upton PD, 2009, J BIOL CHEM, V284, P15794, DOI 10.1074/jbc.M109.002881; Varadaraj A, 2015, NEOPLASIA, V17, P826, DOI 10.1016/j.neo.2015.11.003; Vaupel P, 2004, ONCOLOGIST, V9, P10, DOI 10.1634/theoncologist.9-90005-10; Viallard C, 2017, ANGIOGENESIS, V20, P409, DOI 10.1007/s10456-017-9562-9; Voss MH, 2019, CANCER-AM CANCER SOC, V125, P2400, DOI 10.1002/cncr.32061; Wang XE, 2016, ONCOTARGET, V7, P41857, DOI 10.18632/oncotarget.9621; Ye L, 2008, MOL CANCER RES, V6, P1594, DOI 10.1158/1541-7786.MCR-08-0171; Yi M, 2009, P NATL ACAD SCI USA, V106, P17886, DOI 10.1073/pnas.0901324106; Yoong KF, 1998, J IMMUNOL, V160, P3978	84	17	18	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	14					2996	3014		10.1038/s41388-020-1200-0	http://dx.doi.org/10.1038/s41388-020-1200-0		FEB 2020	19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KZ2VB	32042114				2022-12-28	WOS:000512528200004
J	Huang, J; Lan, XW; Wang, T; Lu, HL; Cao, MR; Yan, S; Cui, Y; Jia, DX; Cai, L; Xing, Y				Huang, Jian; Lan, Xiuwen; Wang, Ting; Lu, Hailing; Cao, Mengru; Yan, Shi; Cui, Yue; Jia, Dexin; Cai, Li; Xing, Ying			Targeting the IL-1 beta/EHD1/TUBB3 axis overcomes resistance to EGFR-TKI in NSCLC	ONCOGENE			English	Article							CELL LUNG-CANCER; DOMAIN 1 PROMOTES; III BETA-TUBULIN; BINDING PROTEIN; FOCAL ADHESIONS; STRESS FIBERS; KAPPA-B; INHIBITORS; SENSITIVITY; MICROTUBULES	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) significantly prolong the survival time of non-small-cell lung cancer (NSCLC) patients with EGFR-activating mutations, but resistance develops universally. Activation of the phosphatidyl inositol-3 kinase (PI3K)/AKT signaling pathway and phenotypic alterations in epithelial-mesenchymal transition (EMT) are both mechanisms of acquired resistance to EGFR-TKIs. However, the mechanisms underlying this resistance remain unclear. In this study, EHD1 depletion significantly increased NSCLC cell sensitivity to EGFR-TKI, which was accompanied by EMT reversal. Microarray analysis showed that the PTEN/PI3K/AKT signaling pathway is a crucial pathway regulated by EHD1. Moreover, a PTEN inhibitor abolished EHD1 shRNA regulation of EGFR-TKI sensitivity, EMT, and cancer progression. Mass spectrometry showed that TUBB3 is a novel EHD1-interacting protein. EHD1 modulated microtubule stability by interacting with TUBB3. Furthermore, TUBB3 depletion significantly attenuated EHD1-induced EGFR-TKI resistance and EMT. Bioinformatics analysis revealed that EHD1 is significantly associated with the gene set, "Cellular Response to Interleukin-1 beta (IL-1 beta)". As expected, treatment with IL-1 beta led to increased expression of EHD1, activation of PTEN/PI3K/AKT signaling, and induction of EMT in NSCLC cells. In patient specimens, EHD1 was highly expressed in EGFR-TKI-refractory specimens. EHD1 was positively associated with TUBB3 and IL-1R1 but negatively associated with PTEN. In addition, targeting the IL-1 beta/EHD1/TUBB3 axis mitigated cancer progression by inhibiting cell proliferation and metastasis and promoting apoptosis. Our study demonstrates the involvement of the IL-1 beta/EHD1/TUBB3 axis in EGFR-TKI resistance and provides a potential therapeutic approach for treating patients with NSCLC that has acquired EGFR-TKI resistance.	[Huang, Jian; Wang, Ting; Lu, Hailing; Cao, Mengru; Yan, Shi; Cui, Yue; Jia, Dexin; Cai, Li; Xing, Ying] Harbin Med Univ, Dept Med Oncol 4, Canc Hosp, 150 Haping Rd, Harbin 150040, Peoples R China; [Lan, Xiuwen] Harbin Med Univ, Dept Crit Care Med, Canc Hosp, 150 Haping Rd, Harbin 150040, Peoples R China	Harbin Medical University; Harbin Medical University	Cai, L; Xing, Y (corresponding author), Harbin Med Univ, Dept Med Oncol 4, Canc Hosp, 150 Haping Rd, Harbin 150040, Peoples R China.	caili@ems.hrbmu.edu.cn; xingying0618@163.com		Huang, Jian/0000-0002-2409-0878	Certificate of China Postdoctoral Science Foundation [2015M581477, 2017M621307]; Hei Long Jiang Postdoctoral Foundation [LBH-Z15145, LBH-Z17182]; Natural Science and Technology Foundation of Heilongjiang Province [LC2016037]; Fundamental Research Funds for the Provincial Universities; Hai Yan Youth Fund from Harbin Medical University Cancer Hospital [JJQN2018-11, JJQN2018-02, BJQN2019-07]; Top-Notch Youth Fund from Harbin Medical University Cancer Hospital [JJQN2018-11, JJQN2018-02, BJQN2019-07]; NSFC [81772474, 81572276, 81803023, 81602717]	Certificate of China Postdoctoral Science Foundation; Hei Long Jiang Postdoctoral Foundation; Natural Science and Technology Foundation of Heilongjiang Province; Fundamental Research Funds for the Provincial Universities; Hai Yan Youth Fund from Harbin Medical University Cancer Hospital; Top-Notch Youth Fund from Harbin Medical University Cancer Hospital; NSFC(National Natural Science Foundation of China (NSFC))	This study was supported in part by grants from the Certificate of China Postdoctoral Science Foundation Grant (2015M581477, 2017M621307), the Hei Long Jiang Postdoctoral Foundation (LBH-Z15145, LBH-Z17182), the Natural Science and Technology Foundation of Heilongjiang Province (LC2016037), the Fundamental Research Funds for the Provincial Universities, the Hai Yan Youth Fund and Top-Notch Youth Fund from Harbin Medical University Cancer Hospital (JJQN2018-11, JJQN2018-02 and BJQN2019-07), and the NSFC (Grant Nos. 81772474, 81572276, 81803023 and 81602717).	Amann J, 2005, CANCER RES, V65, P226; Apte RN, 2006, EUR J CANCER, V42, P751, DOI 10.1016/j.ejca.2006.01.010; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Burke SJ, 2015, AM J PHYSIOL-ENDOC M, V309, pE715, DOI 10.1152/ajpendo.00153.2015; Chan JK, 2014, GYNECOL ONCOL, V133, P568, DOI 10.1016/j.ygyno.2014.03.564; Daumke O, 2007, NATURE, V449, P923, DOI 10.1038/nature06173; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Du JT, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1553-x; Duran GE, 2017, BRIT J CANCER, V116, P1318, DOI 10.1038/bjc.2017.102; Edgar KA, 2010, CANCER RES, V70, P1164, DOI 10.1158/0008-5472.CAN-09-2525; Engelman JA, 2005, P NATL ACAD SCI USA, V102, P3788, DOI 10.1073/pnas.0409773102; Enomoto T, 1996, CELL STRUCT FUNCT, V21, P317, DOI 10.1247/csf.21.317; Etienne-Manneville S, 2004, TRAFFIC, V5, P470, DOI 10.1111/j.1600-0854.2004.00196.x; Fernando RI, 2016, ONCOTARGET, V7, P42031, DOI 10.18632/oncotarget.9662; Franco-Barraza J, 2010, ARCH MED RES, V41, P170, DOI 10.1016/j.arcmed.2010.04.010; Gan PP, 2007, CANCER RES, V67, P9356, DOI 10.1158/0008-5472.CAN-07-0509; Gelfo V, 2018, CANCERS, V10, DOI 10.3390/cancers10100355; George M, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471-2121-8-3; Hehnly H, 2014, DEV CELL, V28, P497, DOI 10.1016/j.devcel.2014.01.014; Hinsch A, 2017, HUM PATHOL, V61, P210, DOI 10.1016/j.humpath.2016.11.005; Hyman DM, 2015, CANCER CHEMOTH PHARM, V75, P747, DOI 10.1007/s00280-015-2693-z; Jackman D, 2010, J CLIN ONCOL, V28, P357, DOI 10.1200/JCO.2009.24.7049; Jacobsen K, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00450-6; Jean A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172358; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Juric D, 2015, NATURE, V518, P240, DOI 10.1038/nature13948; Kavallaris M, 2010, NAT REV CANCER, V10, P194, DOI 10.1038/nrc2803; Kim SM, 2012, MOL CANCER THER, V11, P2254, DOI 10.1158/1535-7163.MCT-12-0311; Kim SB, 2017, LANCET ONCOL, V18, P1360, DOI 10.1016/S1470-2045(17)30450-3; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Lebok P, 2016, ONCOL LETT, V11, P1987, DOI 10.3892/ol.2016.4206; Lee DH, 2017, PHARMACOL THERAPEUT, V174, P1, DOI 10.1016/j.pharmthera.2017.02.001; Li YJ, 2005, WORLD J GASTROENTERO, V11, P2117, DOI 10.3748/wjg.v11.i14.2117; Liu BP, 1998, CELL ADHES COMMUN, V5, P249, DOI 10.3109/15419069809040295; Liu Y, 2018, ONCOL LETT, V16, P4263, DOI 10.3892/ol.2018.9200; LUDUENA RF, 1993, MOL BIOL CELL, V4, P445, DOI 10.1091/mbc.4.5.445; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Mantovani A, 2018, IMMUNOL REV, V281, P57, DOI 10.1111/imr.12614; Mariani M, 2012, CLIN CANCER RES, V18, P2964, DOI 10.1158/1078-0432.CCR-11-2318; McCarroll JA, 2015, CANCER RES, V75, P415, DOI 10.1158/0008-5472.CAN-14-2740; Meng QW, 2017, ONCOTARGET, V8, P22433, DOI 10.18632/oncotarget.11220; Nakaya Y, 2008, NAT CELL BIOL, V10, P765, DOI 10.1038/ncb1739; Nickoloff BJ, 2005, J INVEST DERMATOL, V124, pX, DOI 10.1111/j.0022-202X.2005.23724.x; Ono M, 2004, MOL CANCER THER, V3, P465; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Parker AL, 2016, CARCINOGENESIS, V37, P787, DOI 10.1093/carcin/bgw058; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Powell S, 2014, ONCOL LETT, V7, P405, DOI 10.3892/ol.2013.1734; Reiman T, 2012, ANN ONCOL, V23, P86, DOI 10.1093/annonc/mdr033; Reinecke JB, 2015, TRAFFIC, V16, P48, DOI 10.1111/tra.12234; Riihimaki M, 2014, LUNG CANCER, V86, P78, DOI 10.1016/j.lungcan.2014.07.020; SATIR P, 1990, CANCER INVEST, V8, P685, DOI 10.3109/07357909009018945; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Sobierajska K, 2016, BBA-MOL CELL RES, V1863, P2221, DOI 10.1016/j.bbamcr.2016.05.008; Solinas G, 2010, CANCER METAST REV, V29, P243, DOI 10.1007/s10555-010-9227-2; Soucheray M, 2015, CANCER RES, V75, P4372, DOI 10.1158/0008-5472.CAN-15-0377; Steel JL, 2018, PSYCHOSOM MED, V80, P483, DOI 10.1097/PSY.0000000000000579; Suda K, 2018, MOL CANCER THER, V17, P2257, DOI 10.1158/1535-7163.MCT-17-1279; Sullivan I, 2016, THER ADV RESPIR DIS, V10, P549, DOI 10.1177/1753465816670498; Sun XO, 2011, CELL CYCLE, V10, P3929, DOI 10.4161/cc.10.22.18106; Tong DD, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317691010; Walczak CE, 2010, NAT REV MOL CELL BIO, V11, P91, DOI 10.1038/nrm2832; Wang DY, 2015, INFLAMMATION, V38, P2235, DOI 10.1007/s10753-015-0206-1; Wang XF, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0208-z; Weng CH, 2019, ONCOGENE, V38, P455, DOI 10.1038/s41388-018-0454-2; Yao Z, 2010, P NATL ACAD SCI USA, V107, P15535, DOI 10.1073/pnas.1009472107; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245	68	17	19	1	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	8					1739	1755		10.1038/s41388-019-1099-5	http://dx.doi.org/10.1038/s41388-019-1099-5			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN6CG	31740781				2022-12-28	WOS:000514923000009
J	Zhong, R; Tian, JB; Fu, MP; Ma, SM; Liu, L; Li, JY; Shen, N; Ke, JT; Yang, Y; Gong, YJ; Zhu, Y; Wang, Y; Gong, J; Chang, J; Lei, P; Cheng, X; Huang, K; Shen, GX; Miao, XP				Zhong, Rong; Tian, Jianbo; Fu, Mingpeng; Ma, Simin; Liu, Li; Li, Jiaoyuan; Shen, Na; Ke, Juntao; Yang, Yang; Gong, Yajie; Zhu, Ying; Wang, Ying; Gong, Jing; Chang, Jiang; Lei, Ping; Cheng, Xiang; Huang, Kun; Shen, Guanxin; Miao, Xiaoping			LINC01149 variant modulates MICA expression that facilitates hepatitis B virus spontaneous recovery but increases hepatocellular carcinoma risk	ONCOGENE			English	Article							GENOME-WIDE ASSOCIATION; GENETIC-VARIATIONS; LNCRNAS; CANCER; SUSCEPTIBILITY; SEQUENCE; DATABASE; LIGANDS; CATALOG; ASTHMA	Interpreting disease-causing variants, especially in noncoding regions by genome-wide association studies (GWAS), has become one of the most challenging and demanding tasks. We hypothesized that functional lncRNAs variants in GWAS-identified loci might alter expression level of genes associated with persistent HBV infection and hepatocellular carcinoma (HCC). Integrated bioinformatics approaches were used to prioritize potentially functional variants and a two-stage case-control study (2473 HBV positive HCC patients, 2248 persistent HBV carriers and 2294 spontaneously recovered subjects) was performed to assess the roles of these variants. The rs2844512 G > C variant in LINC01149 was identified to facilitate HBV spontaneous recovery (OR = 0.84, 95% CI = 0.77-0.92) but increase the risk of HCC (OR = 1.21, 95% CI = 1.11-1.32) in combined samples. Subsequent biological assays indicated this variant created a binding site for miR-128-3p and upregulated MICA expression by serving as a miRNA sponge, which might recruit NK-cells to lyse infected cells, but release highly soluble MICA by shedding to induce NK-cells exhaustion and tumor immune evasion. These findings highlight a regulatory circuit between LINC01149 and MICA, mediating by miR-128-3p, and the important role of upregulated MICA in conferring susceptibility to persistent HBV infection and HCC.	[Zhong, Rong; Tian, Jianbo; Li, Jiaoyuan; Ke, Juntao; Yang, Yang; Gong, Yajie; Zhu, Ying; Gong, Jing; Chang, Jiang; Miao, Xiaoping] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Dept Epidemiol & Biostat, Wuhan, Peoples R China; [Zhong, Rong; Tian, Jianbo; Li, Jiaoyuan; Ke, Juntao; Yang, Yang; Gong, Yajie; Zhu, Ying; Gong, Jing; Chang, Jiang; Miao, Xiaoping] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Minist Educ,Key Lab Environm & Hlth, Wuhan, Peoples R China; [Fu, Mingpeng; Ma, Simin; Lei, Ping; Shen, Guanxin] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Immunol, Wuhan, Peoples R China; [Liu, Li] Guangdong Pharmaceut Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Guangzhou, Peoples R China; [Shen, Na] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Lab Med, Wuhan, Peoples R China; [Wang, Ying] Wuhan Ctr Dis Prevent & Control, Dept Virol, Wuhan, Peoples R China; [Cheng, Xiang] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Hepatobiliary Surg, Wuhan, Peoples R China; [Huang, Kun] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Pharm, Wuhan, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Guangdong Pharmaceutical University; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Miao, XP (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Dept Epidemiol & Biostat, Wuhan, Peoples R China.; Miao, XP (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Minist Educ,Key Lab Environm & Hlth, Wuhan, Peoples R China.	miaoxp@mail.hust.edu.cn	李, 娇元/GVS-6952-2022; miao, xiaoping/C-4336-2011; Chang, Jiang/AAP-6156-2020	miao, xiaoping/0000-0002-6818-9722; Zhong, Rong/0000-0002-5060-895X; Tian, Jianbo/0000-0001-9493-694X; Ma, Simin/0000-0002-0218-2261	National Natural Science Foundation of China [NSFC-81874278, NSFC-81601839]; Wuhan Innovation Development Program of Young Professionals; National Program for Support of Top-notch Young Professionals	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Wuhan Innovation Development Program of Young Professionals; National Program for Support of Top-notch Young Professionals	We thank all the people who help us accomplish this research. This work was supported by National Natural Science Foundation of China (NSFC-81874278, NSFC-81601839), Wuhan Innovation Development Program of Young Professionals for YW and National Program for Support of Top-notch Young Professionals for XM.	Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; Clifford RJ, 2010, HEPATOLOGY, V52, P2034, DOI 10.1002/hep.23943; Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111; Du Z, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10982; Dweep H, 2015, NAT METHODS, V12, P697, DOI 10.1038/nmeth.3485; El-Gazzar A, 2013, J IMMUNOL, V191, P1509, DOI 10.4049/jimmunol.1301071; Engreitz JM, 2016, NATURE, V539, P452, DOI 10.1038/nature20149; Freedman ML, 2011, NAT GENET, V43, P513, DOI 10.1038/ng.840; Gong J, 2018, ANN ONCOL, V29, P632, DOI 10.1093/annonc/mdx789; Gong J, 2015, NUCLEIC ACIDS RES, V43, pD181, DOI 10.1093/nar/gku1000; Groh V, 2002, NATURE, V419, P734, DOI 10.1038/nature01112; Hofacker IL, 2003, NUCLEIC ACIDS RES, V31, P3429, DOI 10.1093/nar/gkg599; Holdenrieder S, 2006, INT J CANCER, V118, P684, DOI 10.1002/ijc.21382; Hu LM, 2012, HEPATOLOGY, V55, P1426, DOI 10.1002/hep.24799; Hu ZB, 2013, NAT GENET, V45, P1499, DOI 10.1038/ng.2809; Huang QY, 2015, J GENET GENOMICS, V42, P87, DOI 10.1016/j.jgg.2015.02.001; Ioannidis JPA, 2009, NAT REV GENET, V10, P318, DOI 10.1038/nrg2544; Jiang DK, 2015, HEPATOLOGY, V62, P118, DOI 10.1002/hep.27794; Jinushi M, 2008, P NATL ACAD SCI USA, V105, P1285, DOI 10.1073/pnas.0711293105; Joung J, 2017, NATURE, V548, P343, DOI 10.1038/nature23451; Khurana E, 2016, NAT REV GENET, V17, P93, DOI 10.1038/nrg.2015.17; Koguchi Y, 2015, CANCER RES, V75, P5084, DOI 10.1158/0008-5472.CAN-15-2303; Kumar V, 2011, NAT GENET, V43, P455, DOI 10.1038/ng.809; Li JY, 2018, CANCER EPIDEM BIOMAR, V27, P1029, DOI [10.1158/1055-9965.EPI-18-0099, 10.1158/1055-9965.epi-18-0099]; Liang TJ, 2009, HEPATOLOGY, V49, pS13, DOI 10.1002/hep.22881; Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031; Nguyen VTT, 2009, J VIRAL HEPATITIS, V16, P453, DOI 10.1111/j.1365-2893.2009.01117.x; Paralkar VR, 2016, MOL CELL, V62, P104, DOI 10.1016/j.molcel.2016.02.029; Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209; Quinn JJ, 2016, NAT REV GENET, V17, P47, DOI 10.1038/nrg.2015.10; Takagi A, 2017, BIOCHEM BIOPH RES CO, V492, P27, DOI 10.1016/j.bbrc.2017.08.045; Tan JY, 2015, GENOME RES, V25, P655, DOI 10.1101/gr.181974.114; Te Helen S, 2010, Clin Liver Dis, V14, P1, DOI 10.1016/j.cld.2009.11.009; Thakkinstian A, 2005, AM J EPIDEMIOL, V162, P201, DOI 10.1093/aje/kwi184; Thomson DW, 2016, NAT REV GENET, V17, P272, DOI 10.1038/nrg.2016.20; Tokar T, 2018, NUCLEIC ACIDS RES, V46, pD360, DOI 10.1093/nar/gkx1144; Trepo C, 2014, LANCET, V384, P2053, DOI 10.1016/S0140-6736(14)60220-8; Volders PJ, 2015, NUCLEIC ACIDS RES, V43, P4363, DOI 10.1093/nar/gkv295; Welter D, 2014, NUCLEIC ACIDS RES, V42, pD1001, DOI 10.1093/nar/gkt1229; Wu JD, 2004, J CLIN INVEST, V114, P560, DOI 10.1172/JCI200422206; Yang FQ, 2014, ACTAS UROL ESP, V38, P172, DOI 10.1016/j.acuro.2013.09.015; Zaritskaya L, 2010, EXPERT REV VACCINES, V9, P601, DOI [10.1586/erv.10.49, 10.1586/ERV.10.49]; Zhang F, 2015, INT IMMUNOPHARMACOL, V24, P110, DOI 10.1016/j.intimp.2014.11.005; Zhong R, 2013, CARCINOGENESIS, V34, P936, DOI 10.1093/carcin/bgs395; Zhu M, 2016, HUM MOL GENET, V25, P1225, DOI 10.1093/hmg/ddw003	46	11	12	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	9					1944	1956		10.1038/s41388-019-1117-7	http://dx.doi.org/10.1038/s41388-019-1117-7			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KP9VM	31754211				2022-12-28	WOS:000516579800009
J	Chen, CJ; Yang, CJ; Yang, SF; Huang, MS; Liu, YP				Chen, Chao-Ju; Yang, Chih-Jen; Yang, Sheau-Fang; Huang, Ming-Shyang; Liu, Yu-Peng			The MyoD family inhibitor domain-containing protein enhances the chemoresistance of cancer stem cells in the epithelial state by increasing beta-catenin activity	ONCOGENE			English	Article							MESENCHYMAL TRANSITION; LUNG ADENOCARCINOMA; TUMOR-CELLS; MECHANISM; RESPONSES; INTERACT; SELECTS	Cancer cells with mesenchymal attributes potentially display chemoresistance. Cancer stem cells (CSCs), which are intrinsically resistant to most chemotherapy agents, exhibit considerable phenotypic heterogeneity in their epithelial versus mesenchymal states. However, the drug response of CSCs in the epithelial and mesenchymal states has not been completely investigated. In this study, we found that epithelial-type (E-cadherin(high)/CD133(high)) CSCs displayed a higher sphere formation ability and chemoresistance than mesenchymal-type (E-cadherin(low)CD133(high)) CSCs. Gene expression profiling of the CSC and non-CSC subpopulations with distinct epithelial-to-mesenchymal transition (EMT) states showed that MyoD family inhibitor domain-containing (MDFIC) was selectively upregulated in epithelial-type CSCs. Knockdown of MDFIC sensitized epithelial-type CSCs to chemotherapy agents. Ectopic expression of MDFIC increased the chemoresistance of mesenchymal-type CSCs. In a tissue microarray, high MDFIC expression was associated with poor prognosis of non-small cell lung cancer (NSCLC) patients. A mechanistic study showed that the MDFIC p32 isoform, which is located in the cytoplasm, interacted with the destruction complex, Axin/GSK-3/beta-catenin. This interaction stabilized beta-catenin by inhibiting beta-catenin phosphorylation at S33/37 and increased the nuclear translocation and transcriptional activity of beta-catenin. Knockdown of beta-catenin decreased MDFIC-enhanced chemoresistance. These results suggested that the upregulation of MDFIC enhanced the chemoresistance of epithelial-type CSCs by elevating beta-catenin activity. Thus, targeting MDFIC-regulated beta-catenin signaling of epithelial-type CSCs may be a potential strategy to overcome chemoresistance in NSCLC.	[Chen, Chao-Ju] Kaohsiung Med Univ, Coll Med, Grad Inst Med, Kaohsiung, Taiwan; [Chen, Chao-Ju] Kaohsiung Med Univ Hosp, Dept Lab Med, Kaohsiung, Taiwan; [Yang, Chih-Jen] Kaohsiung Med Univ, Coll Med, Sch Med, Dept Internal Med, Kaohsiung, Taiwan; [Yang, Chih-Jen] Kaohsiung Med Univ Hosp, Dept Internal Med, Div Pulm & Crit Care Med, Kaohsiung, Taiwan; [Yang, Sheau-Fang] Kaohsiung Med Univ, Coll Med, Sch Med, Dept Pathol, Kaohsiung, Taiwan; [Huang, Ming-Shyang] E DA Canc Hosp, Dept Internal Med, Div Pulm & Crit Care Med, Kaohsiung, Taiwan; [Huang, Ming-Shyang] I Shou Univ, Coll Med, Sch Med, Kaohsiung, Taiwan; [Liu, Yu-Peng] Kaohsiung Med Univ, Coll Med, Grad Inst Clin Med, Kaohsiung, Taiwan; [Liu, Yu-Peng] Kaohsiung Med Univ, Res Ctr Environm Med, Kaohsiung, Taiwan; [Liu, Yu-Peng] Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; E-Da Hospital; I Shou University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital	Liu, YP (corresponding author), Kaohsiung Med Univ, Coll Med, Grad Inst Clin Med, Kaohsiung, Taiwan.; Liu, YP (corresponding author), Kaohsiung Med Univ, Res Ctr Environm Med, Kaohsiung, Taiwan.; Liu, YP (corresponding author), Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung, Taiwan.	ypliu@kmu.edu.tw		Liu, Yu-Peng/0000-0002-2716-0050	Ministry of Science and Technology of Taiwan [MOST 107-2320-B-037-025-]; Kaohsiung Medical University Hospital [KMUH106-6M63]; Research Center for Environmental Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project, Ministry of Education (MOE) in Taiwan	Ministry of Science and Technology of Taiwan(Ministry of Science and Technology, Taiwan); Kaohsiung Medical University Hospital; Research Center for Environmental Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project, Ministry of Education (MOE) in Taiwan	This study was financially supported by the Ministry of Science and Technology of Taiwan (MOST 107-2320-B-037-025-) and Kaohsiung Medical University Hospital (KMUH106-6M63). This work was also financially supported by the Research Center for Environmental Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan. We thank Dr Michael Hsiao for providing the tissue microarray chips. We thank the assistance of the Department of Pathology and the Biobank in Kaohsiung Medical University Hospital, Kaohsiung, Taiwan for the clinical sample collection. We thank the Center for Research Resources and Development in Kaohsiung Medical University for the instrumental support for the confocal microscope and TissueFAX system. The authors thank the Immunobiology core facility of Clinical Medicine Research Center in National Cheng Kung University Hospital for assisting with the fluorescence-activated cell sorting.	Beck TN, 2016, CELL REP, V16, P657, DOI 10.1016/j.celrep.2016.06.043; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chang YW, 2015, CANCER RES, V75, P3398, DOI 10.1158/0008-5472.CAN-14-3265; Chen CMA, 1996, CELL, V86, P731, DOI 10.1016/S0092-8674(00)80148-8; Collisson EA, 2011, NAT MED, V17, P500, DOI 10.1038/nm.2344; Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580-018-0080-4; Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005; Gupta PB, 2019, CELL STEM CELL, V24, P65, DOI 10.1016/j.stem.2018.11.011; Huang XJ, 2018, J BIOL CHEM, V293, P6693, DOI 10.1074/jbc.RA118.001689; Kusano S, 2002, MOL CELL BIOL, V22, P6393, DOI 10.1128/MCB.22.18.6393-6405.2002; Li GM, 2018, INT J BIOL SCI, V14, P280, DOI 10.7150/ijbs.23756; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu YP, 2013, CANCER RES, V73, P406, DOI 10.1158/0008-5472.CAN-12-1733; Luo M, 2018, CELL METAB, V28, P69, DOI 10.1016/j.cmet.2018.06.006; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mittal V, 2016, ADV EXP MED BIOL, V890, P37, DOI 10.1007/978-3-319-24932-2_3; Novak A, 1999, CELL MOL LIFE SCI, V56, P523, DOI 10.1007/s000180050449; Oakley RH, 2017, J BIOL CHEM, V292, P5825, DOI 10.1074/jbc.M116.758888; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Pore M, 2016, CLIN LUNG CANCER, V17, P535, DOI 10.1016/j.cllc.2016.05.015; Reck M, 2017, NEW ENGL J MED, V377, P849, DOI 10.1056/NEJMra1703413; Sculier JP, 2008, J THORAC ONCOL, V3, P457, DOI 10.1097/JTO.0b013e31816de2b8; Sen Heng W, 2019, BIOCHEM PHARMACOL, V160, P121, DOI 10.1016/j.bcp.2018.12.010; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Snider L, 2001, MOL CELL BIOL, V21, P1866, DOI 10.1128/MCB.21.5.1866-1873.2001; Song C, 2009, BIOL CHEM, V390, P215, DOI 10.1515/BC.2009.028; Sullivan JP, 2010, CANCER RES, V70, P9937, DOI 10.1158/0008-5472.CAN-10-0881; Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131; Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937; Thebault S, 2001, CURR PROTEIN PEPT SC, V2, P155, DOI 10.2174/1389203013381143; Thebault S, 2000, J BIOL CHEM, V275, P4848, DOI 10.1074/jbc.275.7.4848; Thu Kelsie L, 2014, Oncoscience, V1, P326; Tiran V, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09929-0; Tsoukalas N, 2017, ANTICANCER RES, V37, P1773, DOI 10.21873/anticanres.11510; Vijay GV, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1125-0; Wang D, 2018, CANCER BIOMARK, V22, P385, DOI 10.3233/CBM-170835; Wang Q, 2007, J MOL BIOL, V367, P630, DOI 10.1016/j.jmb.2007.01.020; Wu DM, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1591-4; Xu YR, 2017, SEMIN CELL DEV BIOL, V63, P23, DOI 10.1016/j.semcdb.2016.07.028; Yadav AK, 2019, STEM CELL REV REP, V15, P331, DOI 10.1007/s12015-019-09887-2; Yakisich JS, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317694310; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522; Zhang M, 2019, CURR MOL MED, V19, P349, DOI 10.2174/1566524019666190405121139	44	2	2	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	11					2377	2390		10.1038/s41388-019-1152-4	http://dx.doi.org/10.1038/s41388-019-1152-4		JAN 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KU0ZS	31911618				2022-12-28	WOS:000508154600002
